Medicines information services
Information on any aspect of drug therapy can be obtained from Regional and District Medicines Information Services. Details regarding the local services provided within your Region can be obtained by telephoning the following numbers.

**England**
- Birmingham (0121) 424 7298
- Bristol (0117) 342 2867
- Ipswich (01473) 704 431
- Leeds (0113) 206 5377
- Leicester (0116) 255 5779
- Liverpool (0151) 794 8113/4/5/7 (0151) 794 8206

**London**
- Guy's Hospital (020) 7188 8750
- Northwick Park Hospital (020) 8869 2761 (020) 8869 3973
- Newcastle (0191) 282 4631
- Southampton (023) 8079 6908/9

**Wales**
- Cardiff (029) 2074 2979 (029) 2074 2251

**Scotland**
- Aberdeen (01224) 552 316
- Dundee (01382) 632 351 (01382) 660 111 Extn 32351
- Edinburgh (0131) 242 2920
- Glasgow (0141) 211 4407

**Northern Ireland**
- Belfast (028) 9063 2032 (028) 9063 3847

**Republic of Ireland**
- Dublin Dublin 473 0589 Dublin 453 7941 Extn 2348

**United Kingdom Medicines Information Pharmacists Group (UKMIPG) website**
[www.ukmi.nhs.uk](http://www.ukmi.nhs.uk)

**Information on drug therapy relating to dental treatment** can be obtained by telephoning Liverpool (0151) 794 8206

**Driver and Vehicle Licensing Agency (DVLA)**
Information on the national medical guidelines of fitness to drive is available from:
[www.dvla.gov.uk/medical.aspx](http://www.dvla.gov.uk/medical.aspx)

**Patient Information Lines**
NHS Direct 0845 4647

**Poisons Information Services**
UK National Poisons Information Service 0844 892 0111

**Sport**
Information on substances currently permitted or prohibited is provided in a card supplied by UK Anti-doping.
Further information regarding medicines in sport is available from: [www.ukad.org.uk](http://www.ukad.org.uk)
Tel: (020) 7766 7350 information@ukad.org.uk

**Travel Immunisation**
Up-to-date information on travel immunisation requirements may be obtained from:
- National Travel Health Network and Centre (for healthcare professionals only) 0845 602 6712 (09.00–12.00 and 14.00–16.30 hours weekdays)
- Travel Medicine Team, Health Protection Scotland (0141) 300 1130 (14.00–16.00 hours weekdays) [www.travax.nhs.uk](http://www.travax.nhs.uk) (for registered users of the NHS website Travax only)
- Welsh Assembly Government (029) 2082 5397 (09.00–17.30 hours weekdays)
- Department of Health and Social Services (Belfast) (028) 9052 2118 (weekdays)

**List of Registered Medical Practitioners**
Details on whether doctors are registered and hold a licence to practise medicine in the UK can be obtained from the General Medical Council.
Tel: (0161) 923 6602
[www.gmc-uk.org/register](http://www.gmc-uk.org/register)
The BNF is designed as a digest for rapid reference and it may not always include all the information necessary for prescribing and dispensing. Also, less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services (see inside front cover).
Preface

The BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is published biannually under the authority of a Joint Formulary Committee which comprises representatives of the two professional bodies and of the UK Health Departments. The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the Group includes representatives of the British Dental Association. The Nurse Prescribers' Advisory Group advises on the content relevant to nurses.

The BNF aims to provide prescribers, pharmacists and other healthcare professionals with sound up-to-date information about the use of medicines.

The BNF includes key information on the selection, prescribing, dispensing and administration of medicines. Medicines generally prescribed in the UK are covered and those considered less suitable for prescribing are clearly identified. Little or no information is included on medicines promoted for purchase by the public.

Information on drugs is drawn from the manufacturers' product literature, medical and pharmaceutical literature, UK health departments, regulatory authorities, and professional bodies. Advice is constructed from clinical literature and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the editorial team receives advice on all therapeutic areas from expert clinicians; this ensures that the BNF's recommendations are relevant to practice.

The BNF is designed as a digest for rapid reference and it may not always include all the information necessary for prescribing and dispensing. Also, less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services (see inside front cover).

It is vital to use the most recent edition of the BNF for making clinical decisions. The more important changes for this edition are listed on p. xvi.

The website (bnf.org) includes additional information of relevance to healthcare professionals. Other digital formats of the BNF—including intranet and versions for mobile devices—are produced in parallel with the printed version.

The BNF welcomes comments from healthcare professionals. Comments and constructive criticism should be sent to:
British National Formulary,
Royal Pharmaceutical Society,
1 Lambeth High Street, London SE1 7JN.
editor@bnf.org

Contents

Preface iii
Acknowledgements iv
How the BNF is constructed viii
How to use the BNF x
Changes for this edition xvi
Significant changes xvi
Dose changes xvii
Classification changes xvii
New names xvii
Deleted preparations xvii
New preparations included in this edition xviii
Guidance on prescribing 1
General guidance 1
Prescription writing 5
Emergency supply of medicines 7
Controlled Drugs and drug dependence 8
Adverse reactions to drugs 12
Prescribing for children 15
Prescribing in hepatic impairment 17
Prescribing in renal impairment 17
Prescribing in pregnancy 19
Prescribing in breast-feeding 19
Prescribing in palliative care 20
Prescribing for the elderly 24
Prescribing in dental practice 26
Drugs and sport 31
Emergency treatment of poisoning 32

Notes on drugs and Preparations
1: Gastro-intestinal system 43
2: Cardiovascular system 81
3: Respiratory system 170
4: Central nervous system 207
5: Infections 320
6: Endocrine system 418
7: Obstetrics, gynaecology, and urinary-tract disorders 485
8: Malignant disease and immunosuppression 518
9: Nutrition and blood 576
10: Musculoskeletal and joint diseases 629
11: Eye 666
12: Ear, nose, and oropharynx 685
13: Skin 700
14: Immunological products and vaccines 746
15: Anaesthesia 775

Appendices and indices
Appendix 1: Interactions 800
Appendix 2: Liver disease 17
Appendix 3: Renal impairment 17
Appendix 4: Pregnancy 19
Appendix 5: Breast-feeding 19
Appendix 6: Intravenous additives 892
Appendix 7: Borderline substances 903
Appendix 8: Wound management products and elasticated garments 935

Appendix 9: Cautionary and advisory labels for dispensed medicines 957

Dental Practitioners’ Formulary 972
Nurse Prescribers’ Formulary 974
Non-medical prescribing 978
Index of manufacturers 979
Index 990
Acknowledgements

The Joint Formulary Committee is grateful to individuals and organisations that have provided advice and information to the BNF.

The principal contributors for this edition were:


Expert advice on the management of oral and dental conditions was kindly provided by M. Addy, P. Coulthard, A. Crighton, M.A.O. Lewis, J.G. Meechan, N.D. Robb, R.A. Seymour, R. Welbury, and M.J. Zakrzewska. S. Kaur provided valuable advice on dental prescribing policy.

Members of the British Association of Dermatologists’ Therapy & Guidelines Subcommittee, D.A. Buckley, L.C. Fuller, J. Hughes, S.E. Hulley, J. Lear, A.J. McDo- nghag, J. McLelland, N. Morar, I. Nasr, S. Punjabi, M.J. Tidman, S.E. Haveron (Secretariat), and M.F. Mohd Mustapa (Secretariat) have provided valuable advice.

Members of the Advisory Committee on Malaria Prevention, R.H. Behrens, P.L. Chiodini, F. Genasi, L. Good- yer, A. Green, D. Hill, G. Kassianos, D.G. Lalico, G. Pas- vol, S. Patel, M. Powell, D.V. Shingadia, C.J.M. Whitby, M. Blaze (Secretariat), and V. Smith (Secretariat) have provided valuable advice.

Members of the UK Ophthalmic Pharmacy Group have also provided valuable advice.

The Joint British Societies’ Coronary Risk Prediction Charts have been reproduced with the kind permission of P.N. Durrington who has also provided the BNF with access to the computer program for assessing coronary and stroke risk.

R. Suvarna and colleagues at the MHRA have provided valuable assistance.

Correspondents in the pharmaceutical industry have provided information on new products and commented on products in the BNF. NHS Prescription Services has supplied the prices of products in the BNF.

Numerous doctors, pharmacists, nurses and others have sent comments and suggestions.
BNF Staff

Managing Editor: Knowledge Creation
John Martin BPharm, PhD, MRPharmS

Assistant Editors
Leigh Anne Claase BSc, PhD, MRPharmS
Bryony Jordan BSc, DipPharmPract, MRPharmS
Colin R. Macfarlane BPharm, MSc, MRPharmS
Paul S. Maycock MPharm, DipPharmPract, MRPharmS
Rachel S. M. Ryan BPharm, MRPharmS
Shana M. S. Wagle BPharm, DipPharmPract, MRPharmS

Staff Editors
Sejal Amin BPharm, MSc, MRPharmS
Angela K. Bennett MPharm, DipPharmPract, MRPharmS
Shena S. Chauhan BPharm, MRPharmS
Susan E. Clarke BPharm, DipClinPharm, MRPharmS
Belén Granell Villen BSc, PGDipClinPharm, MRPharmS
Manjula Halai BScChem, MPharm, MRPharmS
Emma E. Harris MPharm, DipPharmPract, MRPharmS
Amy E. Harvey MPharm, PGDipCommPharm
Amber F. Lauder BPharm, PGCertPharm, MRPharmS
Angela M. G. McFarlane BSc, DipClinPharm, MRPharmS
Sarah Mohamad MPharm, MRPharmS
Elizabeth Nix DipPharm(NZ), MRPharmS
Sanjay Patel BPharm, MRPharmS
Claire L. Preston BPharm, PGDipMedMan, MRPharmS
Nirvashi Ramgoolam BPharm, MRPharmS
Vinaya K. Sharma BPharm, MSc, PGDipPIM, MRPharmS

Editorial Assistants
Rebecca S. Bastable BA, BTEC
Cristina Lopez-Bueno BA

Senior BNF Administrator
Heidi Homar BA

Administrative Assistant
Zoe Daniel

Managing Editor: Digital Development and Delivery
Cornelia Schnelle MPhil

Digital Development Editor
Philip D. Lee BSc, PhD

Digital Development Assistants
Robert C. Buckingham BSc
Michelle Cartwright
Jennifer L. Palmer FdSc

Terminologist
Sarah Peck BSc

Head of Publishing Services
John Wilson

BNF Publishing Director
Duncan S. T. Enright MA, PGCE, MInstP, FIDM

Managing Director, Pharmaceutical Press
Robert Bolick BA, MA

Senior Medical Adviser
Martin J. Kendall OBE, MB, ChB, MD, FRCP, FFPM
Joint Formulary Committee 2010–2011

Chair
Derek G. Waller
BSc, MB, BS, DM, FRCP

Deputy Chair
Alison Blenkinsopp
OBE, PhD, BPharm, FRPharmS

Committee Members
Jeffrey K. Aronson
MA, MB ChB, DPhil, FRCP, FBPharmacolS, FFPM
Anthony J. Avery
BMedSci, MB ChB, DM, FRCPG
Tom S.J. Elliott
BMedSci, BTech, BM, BS, MRCP, FRCPath, PhD, DSc
Sue Faulding (from December 2010)
BPharm, MSc, FRPharmS
Beth Hird
BPharm, MSc, MRPharmS, SP, IP
W. Moira Kinnear
BSc, MSc, MRPharmS
Donal O’Donoghue
BSc, MB, ChB, FRCP
Guil Root (to September 2010)
BSc(Pharm), MRPharmS, DMS
Michael J. Stewart
MB ChB, MD, FRCP(Ed), FRCP
Rafe Suvarna
MBBS, BSc, FFPM, DA Med, DipIMC
Mark G. Timoney
BPharm, MSc, PhD, MPSNI

Executive Secretary
Heidi Homar
BA

Dental Advisory Group 2010–2011

Chair
David Wray
MD, BDS, MB ChB, FDSRCPS, FDSRCS Ed, F MedSci

Committee Members
Christine Arnold
BDS, DDPHRCPS, MCDH
Barry Cockcroft
BDS, FDSRCS (Eng)
Duncan S.T. Enright
MA, PGCE, MnstP, FIDM
Amy E. Harvey
MPPharm, PGDipCommPharm, MRPharmS
Martin J. Kendall
OBE, MB, ChB, MD, FRCP, FFPM
Lesley P. Longman
BSc, BDS, FDSRCS Ed, PhD
Sarah Manton
BDS, FDSRCS Ed, FHEA, PhD
John Martin
BPharm, PhD, MRPharmS
Michelle Moffat
BDS, MFDS RCS Ed, M Paed Dent RCPS, FDS (Paed Dent) RCS Ed
Rachel S.M. Ryan
BPharm, MRPharmS

Secretary
Ariane J. Matlin
MA, MSc, PhD

Executive Secretary
Heidi Homar
BA

Advice on dental practice
The British Dental Association has contributed to the advice on medicines for dental practice through its representatives on the Dental Advisory Group.
Nurses Prescribers’ Advisory Group 2010–2011

Chair
Nicky A. Cullum (until November 2010)
PhD, RGN
Molly Courtenay (from December 2010)
PhD, MSc, Cert Ed, BSc, RGN

Committee Members
Shena S. Chauhan
BPharm, MRPharmS
Fiona Culley (from July 2010)
LLM, RN, BSc, Cert Ed
Duncan S.T. Enright
MA, PGCE, MinstP, FIDM
Michael Fanning (from November 2010)
Penny M. Franklin
RN, RCN, RSCPHN(HV), MA, PGCE
Margaret F. Helliwell
MB, BS, BSc, MFPHM, FRCP (Edin)
Bryony Jordan
BSc, DipPharmPract, MRPharmS
Martin J. Kendall
OBE, MB, ChB, MD, FRCP, FFPM
Fiona Lynch
BSc, MSc, RGN, RSCN
John Martin
BPharm, PhD, MRPharmS
Elizabeth J. Plastow
RMN, RGN, RSCPHN(HV), MSc, PGDipEd
Jill M. Shearer
BSc, RGN, RM
Rabina Tindale
RGN, RSCN, BSc, DipAEN, PGCE
Vicky Vidler
MA, RGN, RSCN
John Wright (from November 2010)

Executive Secretary
Heidi Homar
BA
How the BNF is constructed

The BNF is unique in bringing together authoritative, independent guidance on best practice with clinically validated drug information, enabling healthcare professionals to select safe and effective medicines for individual patients.

Information in the BNF has been validated against emerging evidence, best-practice guidelines, and advice from a network of clinical experts.

Hundreds of changes are made between editions, and the most clinically significant changes are listed at the front of each edition (pp. xvi–xviii).

Joint Formulary Committee

The Joint Formulary Committee (JFC) is responsible for the content of the BNF. The JFC includes doctors appointed by the BMJ Publishing Group, pharmacists appointed by the Royal Pharmaceutical Society, and representatives from the Medicines and Healthcare products Regulatory Agency (MHRA) and the UK health departments. The JFC decides on matters of policy and reviews amendments to the BNF in the light of new evidence and expert advice. The Committee meets quarterly and each member also receives proofs of all BNF chapters for review before publication.

Editorial team

BNF staff editors are pharmacists with a sound understanding of how drugs are used in clinical practice. Each staff editor is responsible for editing, maintaining, and updating specific chapters of the BNF. During the publication cycle the staff editors review information in the BNF against a variety of sources (see below).

Amendments to the text are drafted when the editors are satisfied that any new information is reliable and relevant. The draft amendments are passed to expert advisers for comment and for assimilation into the BNF. Additionally, for each edition, sections are chosen from every chapter for thorough review. These planned reviews aim to verify all the information in the selected sections and to draft any amendments to reflect the current best practice.

Staff editors prepare the text for publication and undertake a number of checks on the knowledge at various stages of the production.

Expert advisers

The BNF uses about 60 expert clinical advisers (including doctors, pharmacists, nurses, and dentists) throughout the UK to help with the production of each edition. The role of these expert advisers is to review existing text and to comment on amendments drafted by the staff editors. These clinical experts help to ensure that the BNF remains reliable by:

- checking draft amendments for appropriate interpretation of any new evidence;
- providing expert opinion in areas of controversy or when reliable evidence is lacking;
- advising on areas where the BNF diverges from summaries of product characteristics;
- providing independent advice on drug interactions, prescribing in hepatic impairment, renal impairment, pregnancy, breast-feeding, children, the elderly, palliative care, and the emergency treatment of poisoning.

In addition to consulting with regular advisers, the BNF calls on other clinical specialists for specific developments when particular expertise is required.

The BNF also works closely with a number of expert bodies that produce clinical guidelines. Drafts or pre-publication copies of guidelines are routinely received for comment and for assimilation into the BNF.

Sources of BNF information

The BNF uses a variety of sources for its information; the main ones are shown below.

Summaries of product characteristics The BNF receives summaries of product characteristics (SPCs) of all new products as well as revised SPCs for existing products. The SPCs are the principal source of product information and are carefully processed, despite the ever-increasing volume of information being issued by the pharmaceutical industry. Such processing involves:

- verifying the approved names of all relevant ingredients including ‘non-active’ ingredients (the BNF is committed to using approved names and descriptions as laid down by the Medicines Act);
- comparing the indications, cautions, contra-indications, and side-effects with similar existing drugs.

Where these are different from the expected pattern, justification is sought for their inclusion or exclusion;

- seeking independent data on the use of drugs in pregnancy and breast-feeding;
- incorporating the information into the BNF using established criteria for the presentation and inclusion of the data;
- checking interpretation of the information by two staff editors before submitting to a senior editor; changes relating to doses receive an extra check;
- identifying potential clinical problems or omissions and seeking further information from manufacturers or from expert advisers;
- careful validation of any areas of divergence of the BNF from the SPC before discussion by the Committee (in the light of supporting evidence);

- constructing, with the help of expert advisers, a comment on the role of the drug in the context of similar drugs. Much of this processing is applicable to the following sources as well.

Expert advisers The role of expert clinical advisers in providing the appropriate clinical context for all BNF information is discussed above.
Literature  Staff editors monitor core medical and pharmaceutical journals. Research papers and reviews relating to drug therapy are carefully processed. When a difference between the advice in the BNF and the paper is noted, the new information is assessed for reliability and relevance to UK clinical practice. If necessary, new text is drafted and discussed with expert advisers and the Joint Formulary Committee. The BNF enjoys a close working relationship with a number of national information providers.

Systematic reviews The BNF has access to various databases of systematic reviews (including the Cochrane Library and various web-based resources). These are used for answering specific queries, for reviewing existing text and for constructing new text. Staff editors receive training in critical appraisal, literature evaluation, and search strategies. Reviews published in Clinical Evidence are used to validate BNF advice.

Consensus guidelines The advice in the BNF is checked against consensus guidelines produced by expert bodies. A number of bodies make drafts or pre-publication copies of the guidelines available to the BNF; it is therefore possible to ensure that a consistent message is disseminated. The BNF routinely processes guidelines from the National Institute for Health and Clinical Excellence (NICE), the Scottish Medicines Consortium (SMC), and the Scottish Intercollegiate Guidelines Network (SIGN).

Reference sources Textbooks and reference sources are used to provide background information for the review of existing text or for the construction of new text. The BNF team works closely with the editorial team that produces Martindale: The Complete Drug Reference. The BNF has access to Martindale information resources and each team keeps the other informed of significant developments and shifts in the trends of drug usage.

Statutory information The BNF routinely processes relevant information from various Government bodies including Statutory Instruments and regulations affecting the Prescription only Medicines Order. Official compendia such as the British Pharmacopoeia and its addenda are processed routinely to ensure that the BNF complies with the relevant sections of the Medicines Act. The BNF itself is named as an official compendium in the Medicines Act.

The BNF maintains close links with the Home Office (in relation to controlled drug regulations) and the Medicines and Healthcare products Regulatory Agency (including the British Pharmacopoeia Commission). Safety warnings issued by the Commission on Human Medicines (CHM) and guidelines on drug use issued by the UK health departments are processed as a matter of routine.

Relevant professional statements issued by the Royal Pharmaceutical Society are included in the BNF as are guidelines from bodies such as the Royal College of General Practitioners.

The BNF reflects information from the Drug Tariff, the Scottish Drug Tariff, and the Northern Ireland Drug Tariff.

Pricing information NHS Prescription Services (from the NHS Business Services Authority) provides information on prices of medicinal products and appliances in the BNF.

Comments from readers Readers of the BNF are invited to send in comments. Numerous letters and emails are received during the preparation of each edition. Such feedback helps to ensure that the BNF provides practical and clinically relevant information. Many changes in the presentation and scope of the BNF have resulted from comments sent in by users.

Comments from industry Close scrutiny of the BNF by the manufacturers provides an additional check and allows them an opportunity to raise issues about the BNF’s presentation of the role of various drugs; this is yet another check on the balance of the BNF’s advice. All comments are looked at with care and, where necessary, additional information and expert advice are sought.

Virtual user groups The BNF has set up virtual user groups across various healthcare professions (e.g. doctors, pharmacists, nurses, dentists). The aim of these groups will be to provide feedback to the editors and publishers to ensure that BNF publications continue to serve the needs of its users.

Market research Market research is conducted at regular intervals to gather feedback on specific areas of development, such as drug interactions or changes to the way information is presented in digital formats.

The BNF is an independent professional publication that is kept up-to-date and addresses the day-to-day prescribing information needs of healthcare professionals. Use of this resource throughout the health service helps to ensure that medicines are used safely, effectively, and appropriately.
How to Use the BNF

In order to achieve the safe, effective, and appropriate use of medicines, healthcare professionals must be able to use the BNF effectively, and keep up to date with significant changes in each new edition of the BNF that are relevant to their clinical practice. How to Use the BNF is aimed as a quick refresher for all healthcare professionals involved with prescribing, monitoring, supplying, and administering medicines, and as a learning aid for students training to join these professions. While How to Use the BNF is linked to the main elements of rational prescribing, the generic structure of this section means that it can be adapted for teaching and learning in different clinical settings.

Structure of the BNF

The Contents list (on p. iii) shows that information in the BNF is divided into:

- How the BNF is Constructed (p. vii);
- Changes for this Edition (p. xvi);
- Guidance on Prescribing (p. 1), which provides practical information on many aspects of prescribing from writing a prescription to prescribing in palliative care;
- Emergency Treatment of Poisoning (p. 52), which provides an overview on the management of acute poisoning;
- Classified notes on clinical conditions, drugs, and preparations; these notes are divided into 15 chapters, each of which is related to a particular system of the body (e.g. chapter 2, Cardiovascular System) or to an aspect of medical care (e.g. chapter 5, Infections). Each chapter is further divided into classified sections. Each section usually begins with prescribing notes followed by relevant drug monographs and preparations (see fig. 1). Drugs are classified in a section according to their pharmacology and therapeutic use;
- Appendices and Indices, includes 5 Appendices (providing information on drug interactions, intravenous additives, Borderline substances, wound management, and cautionary and advisory labels for dispensed medicines), the Dental Practitioners’ Formulary, the Nurse Prescribers’ Formulary, Non-medical Prescribing, Index of Manufacturers, and the main Index. The information in the Appendices should be used in conjunction with relevant information in the chapters.

Finding information in the BNF

The BNF includes a number of aids to help access relevant information:

- Index (p. 990), where entries are included in alphabetical order of non-proprietary drug names, proprietary drug names, clinical conditions, and prescribing topics. A specific entry for ‘Dental Prescribing’ brings together topics of relevance to dental surgeons. The page reference to the drug monograph is shown in bold type. References to drugs in Appendices 1 and 9 are not included in the main Index;
- Contents (p. iii), provides a hierarchy of how information in the BNF is organised;
- The beginning of each chapter includes a classified hierarchy of how information is organised in that chapter;
- Running heads, located next to the page number on the top of each page, show the section of the BNF that is being used;
- Thumbnails, on the outer edge of each page, show the chapter of the BNF that is being used;
- Cross-references, lead to additional relevant information in other parts of the BNF.

Finding dental information in the BNF

Extra signposts have been added to help access dental information in the BNF:

- Prescribing in Dental Practice (p. 26), includes a contents list dedicated to drugs and topics of relevance to dentists, together with cross-references to the prescribing notes in the appropriate sections of the BNF. For example, a review of this list shows that information on the local treatment of oral infections is located in chapter 12 (Ear, Nose, and Oropharynx) while information on the systemic treatment of these infections is found in chapter 5 (Infections). This section also includes advice on Medical Emergencies in Dental Practice (p. 26) and Medical Problems in Dental Practice (p. 28). Guidance on the prevention of endocarditis and advice on the management of anticoagulated patients undergoing dental surgery can also be found here;
- Side-headings, in the prescribing notes, side-headings facilitate the identification of advice on oral conditions (e.g. Dental and Orofacial Pain, p. 257);
- Dental prescribing on NHS, in the body of the BNF, preparations that can be prescribed using NHS form FP10D (GP14 in Scotland, WP10D in Wales) can be identified by means of a note headed ‘Dental prescribing on NHS’ (e.g. Aciclovir Tablets, p. 593).

Identifying effective drug treatments

The prescribing notes in the BNF provide an overview of the drug management of common conditions and facilitate rapid appraisal of treatment options (e.g. hypertension, p. 104). For ease of use, information on the management of certain conditions has been tabulated (e.g. acute asthma, p. 173). Information is also provided on the prevention of disease (e.g. malaria prophylaxis for travellers, p. 404). Cardiovascular risk prediction charts for the primary prevention of cardiovascular disease can be found in the glossy pages at the back of the BNF.

Advice issued by the National Institute for Health and Clinical Excellence (NICE) is integrated within the BNF prescribing notes if appropriate. Summaries of NICE technology appraisals, and relevant short guidelines, are included in blue panels. The BNF also includes advice issued by the Scottish Medicines Consortium (SMC) when a medicine is restricted or not recommended for use within NHS Scotland.

In order to select safe and effective medicines for individual patients, information in the prescribing notes must be used in conjunction with other pre-
scribing details about the drugs and knowledge of the patient's medical and drug history.

A brief description of the clinical uses of a drug can usually be found in the Indications section of its monograph (e.g. bendroflumethiazide, p. 84); a cross-reference is provided to any indications for that drug that are covered in other sections of the BNF.

The symbol is used to denote preparations that are considered by the Joint Formulary Committee to be less suitable for prescribing. Although such preparations may not be considered as drugs of first choice, their use may nevertheless be justifiable in certain circumstances.

Figure 1 Illustrates the typical layout of a drug monograph and preparation records within these pages.

**Drug management of medical emergencies**

Guidance on the drug management of medical emergencies can be found in the relevant BNF chapters (e.g. treatment of anaphylaxis is included in section 3.4.3); advice on the management of medical emergencies in dental practice can be found in Prescribing in Dental Practice, p. 26. A summary of drug doses used for Medical Emergencies in the Community can be found in the glossy pages at the back of the BNF. An algorithm for Adult Advanced Life Support can also be found within these pages.
Minimising harm in patients with co-morbidities

The drug chosen to treat a particular condition should have minimal detrimental effects on the patient's other diseases and minimise the patient's susceptibility to adverse effects. To achieve this, the Cautions, Contra-indications, and Side-effects of the relevant drug should be reviewed, and can usually be found in the drug monograph. However, if a class of drugs (e.g. tetracyclines, p. 346) share the same cautions, contra-indications, and side-effects, these are amalgamated in the prescribing notes while those unique to a particular drug in that class are included in its individual drug monograph. Occasionally, the cautions, contra-indications, and side-effects may be included within a preparation record if they are specific to that preparation or if the preparation is not accompanied by a monograph.

The information under Cautions can be used to assess the risks of using a drug in a patient who has co-morbidities that are also included in the Cautions for that drug—if a safer alternative cannot be found, the drug may be prescribed while monitoring the patient for adverse-effects or deterioration in the co-morbidity. Contra-indications are far more restrictive than Cautions and mean that the drug should be avoided in a patient with a condition that is contra-indicated.

The impact that potential side-effects may have on a patient's quality of life should also be assessed. For instance, in a patient who has difficulty sleeping, it may be preferable to avoid a drug that frequently causes insomnia. The prescribing notes in the BNF may highlight important safety concerns and differences between drugs in their ability to cause certain side-effects.

Prescribing for patients with hepatic or renal impairment

Drug selection should aim to minimise the potential for drug accumulation, adverse drug reactions, and exacerbation of pre-existing hepatic or renal disease. If it is necessary to prescribe drugs whose effect is altered by hepatic or renal disease, appropriate drug dose adjustments should be made, and patients should be monitored adequately. The general principles for prescribing are outlined under Prescribing in Hepatic Impairment (p. 17) and Prescribing in Renal Impairment (p. 17). Information about drugs that should be avoided or used with caution in hepatic disease or renal impairment can be found in drug monographs under Hepatic Impairment and Renal Impairment (e.g. fluconazole, p. 374). However, if a class of drugs (e.g. tetracyclines, p. 346) share the same recommendations for use in hepatic disease or renal impairment, this advice is presented in the prescribing notes under Hepatic Impairment and Renal Impairment and any advice that is unique to a particular drug in that class is included in its individual drug monograph.

Prescribing for patients who are pregnant or breast-feeding

Drug selection should aim to minimise harm to the fetus, nursing infant, and mother. The infant should be monitored for potential side-effects of drugs used by the mother during pregnancy or breast-feeding. The general principles for prescribing are outlined under Prescribing in Pregnancy (p. 19) and Prescribing in Breast-feeding (p. 19). The prescribing notes in the BNF chapters provide guidance on the drug treatment of common conditions that can occur during pregnancy and breast-feeding (e.g. asthma, p. 170). Information about the use of specific drugs during pregnancy and breast-feeding can be found in their drug monographs under Pregnancy and Breast-feeding (e.g. fluconazole, p. 374). However, if a class of drugs (e.g. tetracyclines, p. 346) share the same recommendations for use during pregnancy or breast-feeding, this advice is amalgamated in the prescribing notes under Pregnancy and Breast-feeding while any advice that is unique to a particular drug in that class is included in its individual drug monograph.

Minimising drug interactions

Drug selection should aim to minimise drug interactions. If it is necessary to prescribe a potentially serious combination of drugs, patients should be monitored appropriately. The mechanisms underlying drug interactions are explained in Appendix 1 (p. 800). Details of drug interactions can be found in Appendix 1 of the BNF (p. 801). Drugs and their interactions are listed in alphabetical order of the non-proprietary drug name, and cross-references to drug classes are provided where appropriate. Each drug or drug class is listed twice: in the alphabetical list and also against the drug or class with which it interacts. The symbol ● is placed against interactions that are potentially serious and where combined administration of drugs should be avoided (or only undertaken with caution and appropriate monitoring). Interactions that have no symbol do not usually have serious consequences.

If a drug or drug class has interactions, a cross reference to where these can be found in Appendix 1 is provided under the Cautions of the drug monograph or prescribing notes.

Prescribing for the elderly

General guidance on prescribing for the elderly can be found on p. 24.

Prescribing for children

General guidance on prescribing for children can be found on p. 15. For detailed advice on medicines used in children, consult BNF for Children.

Selecting the dose

The drug dose is usually located in the Dose section of the drug monograph or preparation record. The dose of a drug may vary according to different indications and routes of administration. If no indication is given by the dose, then that dose can be used for the conditions specified in the Indications section of that drug monograph, but not for the conditions cross-referring to other sections of the BNF. The dose is located within the preparation record when the dose varies according to different formulations of that drug (e.g. amphotericin, p. 378) or when a preparation has a dose different to that in its monograph (e.g. Sporanox® liquid, p. 376). Occasionally, drug doses may be included in the prescribing notes for practical reasons (e.g. doses of drugs in Helicobacter pylori eradication regimens, p. 50). The right dose should be selected for the right indication, route of administration, and preparation.
Doses are either expressed in terms of a definite frequency (e.g. 1 g 4 times daily) or in the total daily dose format (e.g. 6 g daily in 3 divided doses); the total daily dose should be divided into individual doses (in the second example, the patient should receive 2 g 3 times daily).

The doses of some drugs may need to be adjusted if their effects are altered by concomitant use with other drugs, or in patients with hepatic or renal impairment (see Minimising Drug Interactions, and Prescribing for Patients with Hepatic or Renal Impairment).

Doses for specific patient groups (e.g. the elderly) may be included if they are different to the standard dose. Doses for children can be identified by the terms NEO-NATE, INFANT, and CHILD, and will vary according to their age or body-weight.

Conversions for imperial to metric measures can be found in the glossy pages at the back of the BNF.

Selecting a suitable preparation

Patients should be prescribed a preparation that complements their daily routine, and that provides the right dose of drug for the right indication and route of administration.

In the BNF, preparations usually follow immediately after the monograph for the drug which is their main ingredient. The preparation record (see fig. 1) provides information on the type of formulation (e.g. tablet), the amount of active drug in a solid dosage form, and the concentration of active drug in a liquid dosage form. The legal status is shown for prescription only medicines and controlled drugs; any exception to the legal status is shown by a Note immediately after the preparation record or a footnote. If a proprietary preparation has a distinct colour, coating, scoring, or flavour, this is shown in the preparation record. If a proprietary preparation includes excipients usually specified in the BNF (see p. 2), these are shown in the Excipients statement, and if it contains clinically significant quantities of electrolytes, these are usually shown in the Electrolytes statement.

Branded oral liquid preparations that do not contain fructose, glucose, or sucrose are described as ‘sugar-free’ in the BNF. Preparations containing hydrogenated glucose syrup, mannitol, maltitol, sorbitol, or xylitol are also marked ‘sugar-free’ since there is evidence that they do not cause dental caries. Patients receiving medicines containing cariogenic sugars should be advised of appropriate dental hygiene measures to prevent caries. Sugar-free preparations should be used whenever possible.

Where a drug has several preparations, those of a similar type may be grouped together under a heading (e.g. 'Modified-release' for theophylline preparations, p. 181). Where there is good evidence to show that the preparations for a particular drug are not interchangeable, this is stated in a Note either in the Dose section of the monograph or by the group of preparations affected. When the dose of a drug varies according to different formulations of that drug, the right dose should be prescribed for the preparation selected.

In the case of compound preparations, the prescribing information of all constituents should be taken into account for prescribing.

Writing prescriptions

Guidance is provided on writing prescriptions that will help to reduce medication errors, see p. 5. Prescription requirements for controlled drugs are also specified on p. 8.

Administering drugs

If a drug can be given parenterally or by more than one route, the Dose section in the monograph or preparation record provides basic information on the route of administration. Further information on administration may be found in the monograph or preparation record, often as a Note or Counselling advice. If a class of drugs (e.g. topical corticosteroids, p. 708) share the same administration advice, this may be presented in the prescribing notes.

Appendix 6 (p. 892) provides practical information on the preparation of intravenous drug infusions, including compatibility of drugs with standard intravenous infusion fluids, method of dilution or reconstitution, and administration rates.

Advising patients

The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (see Taking Medicines to Best Effect, p. 1). Taking the time to explain to the patient (and carers) the rationale and the potential adverse effects of treatment may improve adherence. For some medicines there is a special need for counselling (e.g. appropriate posture during administration of doxycycline); this is shown in Counselling statements, usually in the Cautions or Dose section of a monograph, or within a preparation record if it is specific to that preparation.

Patients should be advised if treatment is likely to affect their ability to drive or operate machinery. Cautionary and advisory labels that pharmacists are recommended to add when dispensing are included in the preparation record (see fig. 1). Details of these labels can be found in Appendix 9 (p. 957), a list of products and their labels is included in alphabetical order of the non-proprietary and proprietary drug names.

Monitoring drug treatment

Patients should be monitored to ensure they are achieving the expected benefits from drug treatment without any unwanted side-effects. The prescribing notes or the Cautions in the drug monograph specify any special monitoring requirements. Further information on monitoring the plasma concentration of drugs with a narrow therapeutic index can be found as a Note under the Dose section of the drug monograph.

Identifying and reporting adverse drug reactions

Clinically relevant Side-effects for most drugs are included in the monographs. However, if a class of drugs (e.g. tetracyclines, p. 346) share the same side-effects, these are presented in the prescribing notes while those unique to a particular drug in that class are included in its individual drug monograph. Occa-
nationally, side-effects may be included within a preparation record if they are specific to that preparation or if the preparation is not accompanied by a monograph.

Side-effects are generally listed in order of frequency and arranged broadly by body systems. Occasionally a rare side-effect might be listed first if it is considered to be particularly important because of its seriousness. The frequency of side-effects is described in fig. 1.

An exhaustive list of side-effects is not included for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is generally not listed, unless the drug carries an increased risk of such reactions. The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes).

The prescribing notes in the BNF may highlight important safety concerns and differences between drugs in their ability to cause certain side-effects. Safety warnings issued by the Commission on Human Medicines (CHM) or Medicines and Healthcare products Regulatory Agency (MHRA) can also be found here or in the drug monographs.

Adverse Reactions to Drugs (p. 12) provides advice on preventing adverse drug reactions, and guidance on reporting adverse drug reactions to the MHRA. The black triangle symbol \( \blacktriangle \) identifies those preparations in the BNF that are monitored intensively by the MHRA.

Finding significant changes in a new edition

The BNF is published in March and September each year and includes lists of changes in a new edition that are relevant to clinical practice:

- The print version includes an Insert that summarises the background to several key changes. A copy of the Insert can also be found at bnf.org in the section on Updates under ‘What’s new in BNF?’;
- Changes for this edition (p. xvi), provides a list of significant changes, dose changes, classification changes, new names, and new preparations that have been incorporated into a new edition, as well as a list of preparations that have been discontinued since the last edition. For ease of identification, the margins of these pages are marked in blue;
- Changes to the Dental Practitioners’ Formulary (p. 973), these are located at the end of the Dental List;
- Changes to the Appendices, drug entries that have been amended or introduced since the previous edition in Appendix 1 (Drug Interactions) or Appendix 9 (Cautionary and Advisory Labels for Dispensed Medicines) are underlined in the print versions;
- E-newsletter, the BNF & BNFC e-newsletter service is available free of charge. It alerts healthcare professionals to details of significant changes in the clinical content of these publications and to the way that this information is delivered. Newsletters also review clinical case studies and provide tips on using these publications effectively. To sign up for e-newsletters go to bnf.org/newsletter. To visit the e-newsletter archive, go to bnf.org/bnf/extras/current/450066.htm
- BNF Update, an e-learning programme developed in collaboration with the Centre for Pharmacy Postgraduate Education (CPPE), enables pharmacists to identify and assess how significant changes in the BNF affect their clinical practice. Separate modules for primary and secondary care can be found at www.cppe.ac.uk.

So many changes are made to each new edition of the BNF, that not all of them can be accommodated in the Insert and the Changes section. We encourage healthcare professionals to review regularly the prescribing information on drugs that they encounter frequently.

Nutrition

Appendix 7 (p. 903) includes tables of ACBS-approved enteral feeds and nutritional supplements based on their energy and protein content. There are separate tables for specialised formulae for specific clinical conditions. Classified sections on foods for special diets and nutritional supplements for metabolic diseases are also included.

Wound dressings

A table on wound dressings in Appendix 8 (p. 935) allows an appropriate dressing to be selected based on the appearance and condition of the wound. Further information about the dressing can be found by following the cross-reference to the relevant classified section in the Appendix. In section (A8.2) advanced wound contact dressings have been classified in order of increasing absorancy.

Unlicensed medicines

The BNF includes unlicensed use of medicines when the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience. When the BNF recommends an unlicensed medicine or the ‘off-label’ use of a licensed medicine, this is shown in the appropriate place by ‘[unlicensed]’.

Prices in the BNF

Basic net prices are given in the BNF to provide an indication of relative cost. Where there is a choice of suitable preparations for a particular disease or condition the relative cost may be used in making a selection. Cost-effective prescribing must, however, take into account other factors (such as dose frequency and duration of treatment) that affect the total cost. The use of more expensive drugs is justified if it will result in better treatment of the patient, or a reduction of the length of an illness, or the time spent in hospital. Prices have generally been calculated from the net cost used in pricing NHS prescriptions in October 2010. Prices generally reflect whole dispensing packs; prices for injections are stated per ampoule, vial, or syringe. The price for an extemporaneously prepared preparation has been omitted where the net cost of the ingredients used to make it would give a misleadingly low impression of the final price. In Appendix 8 prices stated are per dressing or bandage.

BNF prices are not suitable for quoting to patients seeking private prescriptions or contemplating over-
the-counter purchases because they do not take into account VAT, professional fees, and other overheads.

A fuller explanation of costs to the NHS may be obtained from the Drug Tariff. Separate drug tariffs are applicable to England and Wales, Scotland, and Northern Ireland; prices in the different tariffs may vary.

Extra resources on the BNF website
While the BNF website (bnf.org) hosts the digital content of the BNF proper, it also provides additional resources such as Frequently Asked Questions and online calculators.

BNF prescribing practice for medical students
This online revision aid, produced in collaboration with Onexamination, provides clinical case studies to help medical students improve their knowledge of safe and effective prescribing while using the BNF. Further details about this module can be found at bnf.org/bnf/extra/current/450048.htm

Using other sources for medicines information
The BNF is designed as a digest for rapid reference. Less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services (see inside front cover).
Changes for this edition

Significant changes

The BNF is revised twice yearly and numerous changes are made between issues. All copies of BNF No. 60 (September 2010) should therefore be withdrawn and replaced by BNF No. 61 (March 2011). Significant changes have been made in the following sections for BNF No. 61:

- Bowel cleansing preparations, section 1.6.5
- Atrial fibrillation and atrial arrhythmia, section 2.3.1
- Dronedarone [NICE guidance], section 2.3.2
- Hypertension in pregnancy, section 2.5
- Hypertensive crises [title ‘Accelerated or very severe hypertension’ amended to ‘Hypertensive crises’ and advice updated], section 2.5
- Sitaxentan (Thelin) [to be withdrawn from the market due to hepatotoxicity], section 2.5.1
- Heart failure, section 2.5.5
- Management of stroke [new prescribing notes on the management of transient ischaemic attack, ischaemic stroke, and intracerebral haemorrhage], section 2.9
- Clopidogrel and modified-release dipyridamole [NICE guidance], section 2.9
- Familial hypercholesterolaemia, section 2.12
- Formoterol dose in children [MHRA/CHM advice], section 3.1.1.1
- Fentanyl [counselling for the use of patches], section 4.7.2
- Epilepsy in pregnancy, section 4.8.1
- Alcohol dependence, section 4.10.1
- Nicotine dependence, section 4.10.2
- Opioid dependence, section 4.10.3
- Missed maintenance doses in opioid dependence, section 4.10.3
- Summary of antibacterial therapy [advice reformatted], section 5.1, Table 1
- Meningitis, section 5.1, Table 1
- Urinary-tract infections [culture and sensitivity testing], section 5.1.13
- Treatment of fungal infections: aspergillosis, section 5.2
- Treatment of fungal infections: invasive or disseminated candidiasis, section 5.2
- Indinavir [application of ‘less suitable for prescribing’ symbol], section 5.3.1
- Saquinavir [changes to cautions and contra-indications], section 5.3.1
- Peginterferon alfa, interferon alfa, and ribavirin for chronic hepatitis C [NICE guidance], section 5.3.3
- Palivizumab [updated advice], section 5.3.5
- Prophylaxis against malaria [recommendations for Morocco and Turkmenistan removed], section 5.4.1
- Rosiglitazone [marketing authorisation suspended], section 6.1.2.3
- Liraglutide for the treatment of type 2 diabetes mellitus [NICE guidance], section 6.1.2.3
- Diabetic ketoacidosis, section 6.1.3
- Treatment of hypoglycaemia, section 6.1.4
- Denosumab for the prevention of osteoporotic fractures in postmenopausal women [NICE guidance], section 6.6.2
- Recurrent vulvovaginal candidiasis [updated treatment regimens], section 7.2.2
- Combined hormonal contraceptive interactions, section 7.3.1
- Combined oral contraceptives [preparations tabulated], section 7.3.1
- Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours [NICE guidance], section 8.1.5
- Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours [NICE guidance], section 8.1.5
- Trastuzumab for the treatment of HER2-positive metastatic gastric cancer [NICE guidance], section 8.1.5
- Bevacizumab and sunitinib: risk of osteonecrosis of the jaw [MHRA/CHM advice], section 8.1.5
- Caution when dispensing mycophenolate mofetil [new brand available], section 8.2.1
- Rapamune® tablets [0.5 mg tablet not bioequivalent to other strengths], section 8.2.2
- Etorbropag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura [NICE guidance], section 9.1.4
- G6FD deficiency [rasburicase and risk of haemolysis], section 9.1.5
- Calcium gluconate injection [MHRA advice], section 9.5.1
- Drugs unsafe for use in acute porphyrias, section 9.8.2
- Etanercept, infliximab, and adalimumab for psoriatic arthritis [NICE guidance], section 10.1.3
- Adalimumab, etanercept, infliximab, rituximab, and abatacept for rheumatoid arthritis after the failure of a TNF inhibitor [NICE guidance], section 10.1.3
- Tocilizumab for rheumatoid arthritis [NICE guidance], section 10.1.3
- Distigmine [removal of monograph for use in myasthenia gravis], section 10.2.1
- Aqueous cream [skin reactions when used as a leave-on emollient], section 13.2.1
- Immunisation schedule, section 14.1
- Haemophilus type B conjugate vaccine in complement deficiency, section 14.4
- Influenza vaccines, section 14.4
- Meningococcal vaccines in complement deficiency, section 14.4
- Adult advanced life support algorithm [Resuscitation Council (UK) updated algorithm 2010], inside back cover
Dose changes
Changes in dose statements introduced into BNF No. 61:
Aciclovir [herpes simplex treatment and suppression], p. 393
AmBisome®, p. 378
Atazanavir [paediatric dose], p. 386
Benzylpenicillin, p. 333
Bisacodyl, p. 69
Cefadroxil, p. 341
Cervarix®, p. 757
Cetirizine [dose in renal impairment], p. 192
Cetirizine [paediatric dose], p. 192
Co-amoxiclav [intravenous dose], p. 337
Cyproterone acetate [prevention of flare with initial gonadorelin analogue therapy], p. 573
Daptomycin [dose in renal impairment], p. 357
Ethosuximide [paediatric dose], p. 283
Famciclovir, p. 394
Fersamal®, p. 578
Fluoxetine [obsessive compulsive disorder], p. 241
Foradi® [dose for children under 12 years], p. 177
Fulvestrant, p. 570
Galantamine [dose in hepatic impairment], p. 318
Hyoscine butylbromide [by continuous infusion device for bowel colic and excessive respiratory secretions], p. 23
Hyoscine hydrobromide [by continuous infusion device for bowel colic and excessive respiratory secretions], p. 23
Ipratropium [dose frequency for severe acute asthma in adults], p. 171 and p. 173
Itraconazole [histoplasmosis], p. 375
Melatonin, p. 212
Methoxy polyethylene glycol-epoetin beta, p. 586
Metronidazole, p. 367
Methyldopa, p. 177
Phosphodiesterase type-3 inhibitors [title change]
Phosphodiesterase type-4 inhibitors [new sub-section]
Non-opioid analgesics and compound analgesic preparations [title change]
Alcohol dependence [new section]
Nicotine dependence [new section]
Opioid dependence [new section]
Opioid substitution therapy [new sub-section]
Adjunctive therapy and symptomatic treatment [new sub-section]
Opioid-receptor antagonists [new sub-section]
Drugs for the relief of soft-tissue inflammation and topical pain relief [title change]
Rubefacients, topical NSAIDs, capsaicin, and poultices [title change]
Anxiolytics [title change]
Hydrocortisone mucoadhesive buccal tablets [formerly Corlan®], p. 694
Laxido® Orange [formerly Laxido®], p. 71
Oiatum® Junior bath additive [formerly Oiatum® Junior emollient bath additive], p. 704
Actinac®
Andropatch®
Avandamet®
Avandia®
Baxan®
Clonidine injection
Dexedrine®
Digitoxin
Dimercaprol
Flixotide® Diskhaler
Imuderm®
Vagifem®, p. 491
Valaciclovir, p. 394
Xylometazoline [nasal spray], p. 692

Classification changes
Classification changes have been made in the following sections for BNF No. 61:
Section 2.1.2 Phosphodiesterase type-3 inhibitors [title change]
Section 3.3.3 Phosphodiesterase type-4 inhibitors [new sub-section]
Section 4.7.1 Non-opioid analgesics and compound analgesic preparations [title change]
Section 4.10.1 Alcohol dependence [new section]
Section 4.10.2 Nicotine dependence [new section]
Section 4.10.3 Opioid dependence [new section]
Section 4.10.3 Opioid substitution therapy [new sub-section]
Section 4.10.3 Adjunctive therapy and symptomatic treatment [new sub-section]
Section 4.10.3 Opioid-receptor antagonists [new sub-section]
Section 10.3 Drugs for the relief of soft-tissue inflammation and topical pain relief [title change]
Section 10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices [title change]
Section 15.1.4.1 Anxiolytics [title change]

New names
Name changes introduced into BNF No. 61:
Hydrocortisone mucoadhesive buccal tablets [formerly Corlan®], p. 694
Laxido® Orange [formerly Laxido®], p. 71
Oiatum® Junior bath additive [formerly Oiatum® Junior emollient bath additive], p. 704

Deleted preparations
Preparations listed below have been discontinued during the compilation of BNF No. 61, or are still available but are not considered suitable for inclusion by the Joint Formulary Committee (see footnote).
Actinac®
Andropatch®
Avandamet®
Avandia®
Baxan®
Clonidine injection
Dexedrine®
Digitoxin
Dimercaprol
Flixotide® Diskhaler
Imuderm®

1 Not considered suitable for inclusion by the Joint Formulary Committee
New preparations included in this edition

Preparations included in the relevant sections of BNF No. 61:

Adoport® [tacrolimus], p. 558
Aquamol®, p. 702
Arzip® [mycophenolate mofetil], p. 555
Bocouture® [botulinum toxin type A], p. 309
Calcichew-D® 500 mg/400 unit caplets [calcium carbonate with colecalciferol], p. 619
Capimune® [ciclosporin], p. 557
Catacrom® [sodium cromoglycate], p. 673
Clinis Gel® [carbomers], p. 680
Cyanokit® [hydroxocobalamin], p. 39
Dexa® [dexamethasone], p. 191
Dermatonics Heel Balm®, p. 703
Dovobet® gel [betametasone with calcipotriol], p. 717
Dovonex® ointment [calcipotriol], p. 717
Genotropin GoQuick® [somatropin], p. 465
Glusart® [glucosamine sulphate], p. 657
Gynoxin® [fenticonazole], p. 493
Humulin I KwikPen® [isophane insulin], p. 424
Humulin M3 KwikPen® [biphasic isophane insulin], p. 426
Hyabak® [sodium hyaluronate], p. 681
Hylo-Care® [sodium hyaluronate], p. 681
Insuman Comb 25 SoloStar® [biphasic isophane insulin], p. 426
Levact® [bendamustine], p. 524
Lodotra® [prednisone], p. 448
Lumecare® Long Lasting Tear Gel [carbomers], p. 680
Lumecare® Preservative Free Tear Drops [hypromellose], p. 680
Marol® [tramadol m/r], p. 272
Mipilet® [acetylcholine chloride], p. 682
Monofer® [iron isomaltoside 1000], p. 579
Moxivig® [moxifloxacin], p. 668
Neokay® [phytomenadione], p. 621
Nexplanor® [etoricoxib], p. 502
Nivestim® [filgrastim], p. 592
NuTRIflex® Omega plus, p. 605
NuTRIflex® Omega special, p. 605
Onbrez Breezhaler® [indacaterol], p. 177
Ozurdex® [dexamethasone], p. 671
PecFent® [pentanyl], p. 266
Rebif® (Rebif®) injection [interferon beta-1a], p. 562
Renvela® [sevelamer carbonate], p. 613
Sativex® [Cannabis sativa extract], p. 661
Simpont® [golimumab], p. 653
Tears Naturale® Single Dose [hypromellose], p. 680
Tevagranstim® [filgrastim], p. 593
Tobramycin® [tobramycin], p. 669
Tructial® , p. 607
Vimovo® [naproxen with esomeprazole], p. 639
Votrient® [pazopanib], p. 548
VPRI® [velaglucerase alfa], p. 624
Zutectra® [hepatitis B-specific immunoglobulin], p. 771
Taking medicines to best effect  

Difficulties in adherence to drug treatment occur regardless of age. Factors contributing to poor compliance with prescribed medicines include:

- prescription not collected or not dispensed;
- purpose of medicine not clear;
- perceived lack of efficacy;
- real or perceived adverse effects;
- patients’ perception of the risk and severity of side-effects may differ from that of the prescriber;
- instructions for administration not clear;
- physical difficulty in taking medicines (e.g. swallowing the medicine, handling small tablets, or opening medicine containers);
- unattractive formulation (e.g. unpleasant taste);
- complicated regimen.

The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (‘concordance’). The prescriber should be sensitive to religious, cultural, and personal beliefs that can affect a patient’s acceptance of medicines.

Taking the time to explain to the patient (and relatives) the rationale and the potential adverse effects of treatment may improve adherence. Reinforcement and elaboration of the physician’s instructions by the pharmacist and other members of the healthcare team also helps. Advising the patient of the possibility of alternative treatments may encourage the patient to seek advice rather than merely abandon unacceptable treatment.

Simplifying the drug regimen may help; the need for frequent administration may reduce adherence, although there appears to be little difference in adherence between once-daily and twice-daily administration. Combination products reduce the number of drugs taken but at the expense of the ability to titrate individual doses.

Biosimilar medicines  

A biosimilar medicine is a new biological product that is similar to a medicine that has already been authorised to be marketed (the biological reference medicine) in the European Union. The active substance of a biosimilar medicine is similar, but not identical, to the biological reference medicine. Biological products are different from standard chemical products in terms of their complexity and although theoretically there should be no important differences between the biosimilar and the biological reference medicine in terms of safety or efficacy, when prescribing biological products, it is good practice to use the brand name. This will ensure that substitution of a biosimilar medicine does not occur when the medicine is dispensed.

Biosimilar medicines have black triangle status (/lists, see p. 12) at the time of initial marketing. It is important to report suspected adverse reactions to biosimilar medicines using the Yellow Card Scheme (p. 12). For biosimilar medicines, adverse reaction reports should clearly state the brand name of the suspected medicine.

Complementary and alternative medicine  

An increasing amount of information on complementary and alternative medicine is becoming available. The scope of the BNF is restricted to the discussion of conventional medicines but reference is made to complementary treatments if they affect conventional therapy (e.g. interactions with St John’s wort—see Appendix 1). Further information on herbal medicines is available at www.mhra.gov.uk.

Abbreviation of titles  

In general, titles of drugs and preparations should be written in full. Unofficial abbreviations should not be used as they may be misinterpreted.

Non-proprietary titles  

Where non-proprietary (‘generic’) titles are given, they should be used in prescribing. This will enable any suitable product to be dispensed, thereby saving delay to the patient and sometimes expense to the health service. The only exception is where there is a demonstrable difference in clinical effect between each manufacturer’s version of the formulation, making it important that the patient should always receive the same brand; in such cases, the brand name or the manufacturer should be stated. Non-proprietary titles should not be invented for the purposes of prescribing generically since this can lead to confusion, particularly in the case of compound and modified-release preparations.

Titles used as headings for monographs may be used freely in the United Kingdom but in other countries may be subject to restriction.

Many of the non-proprietary titles used in this book are titles of monographs in the European Pharmacopoeia, British Pharmacopoeia, or British Pharmaceutical Codex 1973. In such cases the preparations must comply with the standard (if any) in the appropriate publication, as required by the Medicines Act (Section 65).

Proprietary titles  

Names followed by the symbol® are or have been used as proprietary names in the United Kingdom. These names may in general be applied only to products supplied by the owners of the trade marks.
2 General guidance

Marketing authorisation and BNF advice In general the doses, indications, cautions, contra-indications, and side-effects in the BNF reflect those in the manufacturers’ data sheets or Summaries of Product Characteristics (SPCs) which, in turn, reflect those in the corresponding marketing authorisations (formerly known as Product Licences). The BNF does not generally include proprietary medicines that are not supported by a valid Summary of Product Characteristics or when the marketing authorisation holder has not been able to supply essential information. When a preparation is available from more than one manufacturer, the BNF reflects advice that is the most clinically relevant regardless of any variation in the marketing authorisations. Unlicensed products can be obtained from ‘special-order’ manufacturers or specialist importing companies, see p. 988.

Where an unlicensed drug is included in the BNF, this is indicated in square brackets after the entry. When the BNF suggests a use (or route) that is outside the licensed indication of a product (‘off-label’ use), this too is indicated. Unlicensed use of medicines becomes necessary if the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience.

The doses stated in the BNF are intended for general guidance and represent, unless otherwise stated, the usual range of doses that are generally regarded as being suitable for adults.

Excipients Branded oral liquid preparations that do not contain fructose, glucose, or sucrose are described as ‘sugar-free’ in the BNF. Preparations containing hydrogenated glucose syrup, mannitol, maltitol, sorbitol, or xylitol are also marked ‘sugar-free’ since there is evidence that they do not cause dental caries. Patients receiving medicines containing cariogenic sugars should be advised of appropriate dental hygiene measures to prevent caries. Sugar-free preparations should be used whenever possible.

Where information on the presence of aspartame, gluten, sulphites, tartrazine, arachis (peanut) oil or sesame oil is available, this is indicated in the BNF against the relevant preparation.

Information is provided on selected excipients in skin preparations (section 13.1.3), in vaccines (section 14.1), and on selected preservatives and excipients in eye drops and injections.

The presence of benzyl alcohol and polyoxyl castor oil (polyethoxylated castor oil) in injections is indicated in the BNF. Benzyl alcohol has been associated with a fatal

1 These recommendations are acceptable for prescription-only medicines (POM). For items marked (R) see also Controlled Drugs and Drug Dependence, p. 8.
toxic syndrome in preterm neonates, and therefore, parenteral preparations containing the preservative should not be used in neonates. Polyoxyxyl castor oils, used as vehicles in intravenous injections, have been associated with severe anaphylactoid reactions.

The presence of propylene glycol in oral or parenteral medicines is indicated in the BNF; it can cause adverse effects if its elimination is impaired, e.g., in renal failure, in neonates and young children, and in slow metabolizers of the substance. It may interact with disulfiram and metronidazole.

The lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However, in severe lactose intolerance, the lactose content should be determined before prescribing. The amount of lactose varies according to manufacturer, product, formulation, and strength. However, in severe lactose intolerance, the lactose content should be determined before prescribing. The amount of lactose varies according to manufacturer, product, formulation, and strength.

Extemporaneous preparation A product should be dispensed extemporaneously only when no product with a marketing authorisation is available.

The BP direction that a preparation must be freshly prepared indicates that it must be made not more than 24 hours before it is issued for use. The direction that a preparation should be recently prepared indicates that deterioration is likely if the preparation is stored for longer than about 4 weeks at 15–25°C.

The term water used without qualification means either potable water freshly drawn direct from the public supply and suitable for drinking or freshly boiled and cooled purified water. The latter should be used if the public supply is from a local storage tank or if the potable water is unsuitable for a particular preparation (Water for injections, section 9.2.2).

Drugs and driving Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g., driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

Patents In the BNF, certain drugs have been included notwithstanding the existence of actual or potential patent rights. In so far as such substances are protected by Letters Patent, their inclusion in this Formulary neither conveys, nor implies, licence to manufacture.

Health and safety When handling chemical or biological materials particular attention should be given to the possibility of allergy, fire, explosion, radiation, or poisoning. Substances such as corticosteroids, some antimicrobials, phenothiazines, and many cytotoxics, are irritant or very potent and should be handled with caution. Contact with the skin and inhalation of dust should be avoided.

Safety in the home Patients must be warned to keep all medicines out of the reach of children. All solid dose and all oral and external liquid preparations must be dispensed in a reclosable child-resistant container unless:

- the medicine is in an original pack or patient pack such as to make this inadvisable;
- the patient will have difficulty in opening a child-resistant container;
- a specific request is made that the product shall not be dispensed in a child-resistant container;
- no suitable child-resistant container exists for a particular liquid preparation.

All patients should be advised to dispose of unwanted medicines by returning them to a supplier for destruction.

Name of medicine The name of the medicine should appear on the label unless the prescriber indicates otherwise.

(a) The strength is also stated on the label in the case of tablets, capsules, and similar preparations that are available in different strengths.

(b) If it is the wish of the prescriber that a description such as ‘The Sedative Tablets’ should appear on the label, the prescriber should write the desired description on the prescription form.

(c) The arrangement will extend to approved names, proprietary names or titles given in the BP, BPC, BNF, DPF, or NPF.

(d) The name written on the label is that used by the prescriber on the prescription.

(e) When a prescription is written other than on an NHS prescription form the name of the prescribed preparation will be stated on the label of the dispensed medicine unless the prescriber indicates otherwise.

(f) The Council of the Royal Pharmaceutical Society advises that the labels of dispensed medicines should indicate the total quantity of the product dispensed in the container to which the label refers. This requirement applies equally to solid, liquid, internal, and external preparations. If a product is dispensed in more than one container, the reference should be to the amount in each container.

Non-proprietary names of compound preparations which appear in the BNF are those that have been compiled by the British Pharmacopoeia Commission or another recognised body; whenever possible they reflect the names of the active ingredients. Prescribers should avoid creating their own compound names for the purposes of generic prescribing; such names do not have an approved definition and can be misinterpreted. Special care should be taken to avoid errors when prescribing compound preparations; in particular the hyphen in the prefix ‘co-’ should be retained. Special care should also be taken to avoid creating generic names for modified-release preparations where the use of these names could lead to confusion between formulations with different lengths of action.
EEA and Swiss prescriptions. Pharmacists can dispense prescriptions issued by doctors and dentists from the European Economic Area (EEA) or Switzerland (except prescriptions for controlled drugs in Schedules 1 to 5 or for drugs without a UK marketing authorisation). Prescriptions should be written in ink or otherwise so as to be indelible, should be dated, should state the name of the patient, should state the address of the prescriber, should contain particulars indicating whether the prescriber is a doctor or dentist, and should be signed by the prescriber.

Security and validity of prescriptions. The Councils of the British Medical Association and the Royal Pharmaceutical Society have issued a joint statement on the security and validity of prescriptions. In particular, prescription forms should:
- not be left unattended at reception desks;
- not be left in a car where they may be visible; and
- when not in use, be kept in a locked drawer within the surgery and at home.

Where there is any doubt about the authenticity of a prescription, the pharmacist should contact the prescriber. If this is done by telephone, the number should be obtained from the directory rather than relying on the information on the prescription form, which may be false.

Patient group direction (PGD). In most cases, the most appropriate clinical care will be provided on an individual basis by a prescriber to a specific individual patient. However, a Patient Group Direction for supply and administration of medicines by other healthcare professionals can be used where it would benefit patient care without compromising safety.

A Patient Group Direction is a written direction relating to the supply and administration (or administration only) of a licensed prescription-only medicine by certain classes of healthcare professionals; the Direction is signed by a doctor (or dentist) and by a pharmacist. Further information on Patient Group Directions is available in Health Service Circular HSC 2000/026 (England), HDL (2001) 7 (Scotland), and WHC (2000) 116 (Wales) and at www.nelm.nhs.uk/en/Communities/NeLM/PGDs.

NICE and Scottish Medicines Consortium. Advice issued by the National Institute for Health and Clinical Excellence (NICE) is included in the BNF when relevant. The BNF also includes advice issued by the Scottish Medicines Consortium (SMC) when a medicine is restricted or not recommended for use within NHS Scotland. If advice within a NICE Single Technology Appraisal differs from SMC advice, the Scottish Executive expects NHS Boards within NHS Scotland to comply with the SMC advice. Details of the advice together with updates can be obtained from www.nice.org.uk and from www.scottishmedicines.org.uk.
Prescription writing

Shared care
In its guidelines on responsibility for prescribing (circular EL (91) 127) between hospitals and general practitioners, the Department of Health has advised that legal responsibility for prescribing lies with the doctor who signs the prescription.

Prescriptions should be written legibly in ink or otherwise so as to be indelible, should be dated, should state the name and address of the patient, and should be signed in ink by the prescriber. The age and the date of birth of the patient should preferably be stated, and it is a legal requirement in the case of prescription-only medicines to state the age for children under 12 years.

The following should be noted:

(a) The unnecessary use of decimal points should be avoided, e.g. 3 mg, not 3.0 mg.
Quantities of 1 gram or more should be written in milligrams, e.g. 500 mg, not 0.5 g.
Quantities less than 1 mg should be written in micrograms, e.g. 100 micrograms, not 0.1 mg.
When decimals are unavoidable a zero should be written in front of the decimal point where there is no other figure, e.g. 0.5 mL, not .5 mL.
Use of the decimal point is acceptable to express a range, e.g. 0.5 to 1 g.

(b) ‘Micrograms’ and ‘nanograms’ should not be abbreviated. Similarly ‘units’ should not be abbreviated.

(c) The term ‘millilitre’ (ml or mL) is used in medicine and pharmacy, and cubic centimetre, c.c., or cm³ should not be used.

(d) Dose and dose frequency should be stated; in the case of preparations to be taken as required a minimum dose interval should be specified.
When doses other than multiples of 5 mL are prescribed for oral liquid preparations the dose-volume will be provided by means of an oral syringe, see p. 2 (except for preparations intended to be measured with a pipette).
Suitable quantities:

- Elixirs, Linctuses, and Paediatric Mixtures (5-mL dose), 50, 100, or 150 mL
- Adult Mixtures (10-mL dose), 200 or 300 mL
- Ear Drops, Eye drops, and Nasal Drops, 10 mL (or the manufacturer’s pack)
- Eye Lotions, Gargles, and Mouthwashes, 200 mL

(e) For suitable quantities of dermatological preparations, see section 13.1.2.

(f) The names of drugs and preparations should be written clearly and not abbreviated, using approved titles only (see also advice in box on p. 3 to avoid creating generic titles for modified-release preparations).

(g) The quantity to be supplied may be stated by indicating the number of days of treatment required in the box provided on NHS forms. In most cases the exact amount will be supplied. This does not apply to items directed to be used as required—if the dose and frequency are not given then the quantity to be supplied needs to be stated.
When several items are ordered on one form the box can be marked with the number of days of treatment provided the quantity is added for any item for which the amount cannot be calculated.

(h) Although directions should preferably be in English without abbreviation, it is recognised that some Latin abbreviations are used (for details see Inside Back Cover).

(i) Medical and dental practitioners may prescribe unlicensed medicines (i.e. those without marketing authorisation) or withdrawn medicines. The prescriber should inform the patient or the patient’s carer that the product does not have a marketing authorisation.

For a sample prescription, see below.
Prescribing by dental surgeons Until new prescribing arrangements are in place for NHS prescriptions, dental surgeons should use form FP10D (GP14 in Scotland, WP10D in Wales) to prescribe only those items listed in the Dental Practitioners’ Formulary. The Act and Regulations do not set any limitations upon the number and variety of substances which the dental surgeon may administer to patients in the surgery or may order by private prescription—provided the relevant legal requirements are observed the dental surgeon may use or order whatever is required for the clinical situation. There is no statutory requirement for the dental surgeon to communicate with a patient’s medical practitioner when prescribing for dental use. There are, however, occasions when this would be in the patient’s interest and such communication is to be encouraged. For legal requirements relating to prescriptions for Controlled Drugs, see p. 8.

Computer-issued prescriptions For computer-issued prescriptions the following advice, based on the recommendations of the Joint GP Information Technology Committee, should also be noted:

1. The computer must print out the date, the patient’s surname, one forename, other initials, and address, and may also print out the patient’s title and date of birth. The age of children under 12 years and of adults over 60 years must be printed in the box available; the age of children under 5 years should be printed in years and months. A facility may also exist to print out the age of patients between 12 and 60 years.

2. The doctor’s name must be printed at the bottom of the prescription form; this will be the name of the doctor responsible for the prescription (who will normally sign it). The doctor’s surgery address, reference number, and Primary Care Trust (PCT) are also necessary. In addition, the surgery telephone number should be printed.

3. When prescriptions are to be signed by general practitioner registrars, assistants, locums, or depu- tising doctors, the name of the doctor printed at the bottom of the form must still be that of the responsible principal.

4. Names of medicines must come from a dictionary held in the computer memory, to provide a check on the spelling and to ensure that the name is written in full. The computer can be programmed to recognise both the non-proprietary and the proprietary name of a particular drug and to print out the preferred choice, but must not print out both names. For medicines not in the dictionary, separate checks are required—the user must be warned that no check was possible and the entire prescription must be entered in the lexicon.

5. The dictionary may contain information on the usual doses, formulations, and pack sizes to produce standard predetermined prescriptions for common preparations, and to provide a check on the validity of an individual prescription on entry.

6. The prescription must be printed in English without abbreviation; information may be entered or stored in abbreviated form. The dose must be in numbers, the frequency in words, and the quantity in numbers in brackets, thus: 40 mg four times daily (112). It must also be possible to prescribe by indicating the length of treatment required, see (h) above.

7. The BNF recommendations should be followed as in (a), (b), (c), (d), and (e) above.

8. Checks may be incorporated to ensure that all the information required for dispensing a particular drug has been filled in. For instructions such as ‘as directed’ and ‘when required’, the maximum daily dose should normally be specified.

9. Numbers and codes used in the system for organising and retrieving data must never appear on the form.

10. Supplementary warnings or advice should be written in full, should not interfere with the clarity of the prescription itself, and should be in line with any warnings or advice in the BNF; numerical codes should not be used.

11. A mechanism (such as printing a series of non-specific characters) should be incorporated to cancel out unused space, or wording such as ‘no more items on this prescription’ may be added after the last item. Otherwise the doctor should delete the space manually.

12. To avoid forgery the computer may print on the form the number of items to be dispensed (some- where separate from the box for the pharmacist). The number of items per form need be limited only by the ability of the printer to produce clear and well-demarcated instructions with sufficient space for each item and a spacer line before each fresh item.

13. Handwritten alterations should only be made in exceptional circumstances—it is preferable to print out a new prescription. Any alterations must be made in the doctor’s own handwriting and countersigned; computer records should be updated to fully reflect any alteration. Prescriptions for drugs used for contraceptive purposes (but which are not promoted as contraceptives) may need to be marked in handwriting with the symbol " (or endorsed in another way to indicate that the item is prescribed for contraceptive purposes).

14. Prescriptions for controlled drugs can be printed from the computer, but the prescriber’s signature must be handwritten.*

15. The strip of paper on the side of the FP10SS may be used for various purposes but care should be taken to avoid including confidential information. It may be advisable for the patient’s name to appear at the top, but this should be preceded by ‘confiden- tial’.

16. In rural dispensing practices prescription requests (or details of medicines dispensed) will normally be entered in one surgery. The prescriptions (or dispensed medicines) may then need to be delivered to another surgery or location; if possible the computer should hold up to 10 alternatives.

17. Prescription forms that are reprinted or issued as a duplicate should be labelled clearly as such.

---

1. Health Board in Scotland, Local Health Board in Wales.
2. See Controlled Drugs and Drug Dependence p. 8; the prescriber may use a date stamp.
3. GP10SS in Scotland, WP10SS in Wales.
Emergency supply of medicines

Emergency supply requested by member of the public

Pharmacists are sometimes called upon by members of the public to make an emergency supply of medicines. The Prescription Only Medicines (Human Use) Order 1997 allows exemptions from the Prescription Only requirements for emergency supply to be made by a person lawfully conducting a retail pharmacy business provided:

(a) that the pharmacist has interviewed the person requesting the prescription-only medicine and is satisfied:

(i) that there is immediate need for the prescription-only medicine and that it is impracticable in the circumstances to obtain a prescription without undue delay;
(ii) that treatment with the prescription-only medicine has on a previous occasion been prescribed for the person requesting it;
(iii) as to the dose that it would be appropriate for the person to take;

(b) that no greater quantity shall be supplied than will provide 5 days’ treatment of phenobarbital, phenobarbital sodium, or Controlled Drugs in Schedules 4 or 5, or 30 days’ treatment for other prescription-only medicines, except when the prescription-only medicine is:

(i) insulin, an ointment or cream, or a preparation for the relief of asthma in an aerosol dispenser when the smallest pack can be supplied;
(ii) an oral contraceptive when a full cycle may be supplied;
(iii) an antibiotic in liquid form for oral administration when the smallest quantity that will provide a full course of treatment can be supplied;

(c) that an entry shall be made by the pharmacist in the prescription book stating:

(i) the date of supply;
(ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
(iii) the name and address of the patient;
(iv) the nature of the emergency;

(d) that the container or package must be labelled to show:

(i) the date of supply;
(ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
(iii) the name of the patient;
(iv) the name and address of the pharmacy;
(v) the words ‘Emergency supply’;
(vi) the words ‘Keep out of the reach of children’ (or similar warning);

(e) that the prescription-only medicine is not a substance specifically excluded from the emergency supply provision, and does not contain a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital or phenobarbital sodium for the treatment of epilepsy; for details see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available).

Emergency supply requested by prescriber

Emergency supply of a prescription-only medicine may also be made at the request of a doctor, a dentist, a supplementary prescriber, a community practitioner nurse prescriber, a nurse, pharmacist, or optometrist independent prescriber, or a doctor or dentist from the European Economic Area or Switzerland, provided:

(a) that the pharmacist is satisfied that the prescriber by reason of some emergency is unable to furnish a prescription immediately;
(b) that the prescriber has undertaken to furnish a prescription within 72 hours;
(c) that the medicine is supplied in accordance with the directions of the prescriber requesting it;
(d) that the medicine is not a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital or phenobarbital sodium for the treatment of epilepsy; for details see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available);

(e) that an entry shall be made in the prescription book stating:

(i) the date of supply;
(ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
(iii) the name and address of the practitioner requesting the emergency supply;
(iv) the name and address of the patient;
(v) the date on the prescription;
(vi) when the prescription is received the entry should be amended to include the date on which it is received.

Royal Pharmaceutical Society’s guidelines

1. The pharmacist should consider the medical consequences of not supplying a medicine in an emergency.
2. If the pharmacist is unable to make an emergency supply of a medicine the pharmacist should advise the patient how to obtain essential medical care.

For conditions that apply to supplies made at the request of a patient see Medicines, Ethics and Practice, No. 34, London Pharmaceutical Press, 2010 (and subsequent editions).

1. Doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs, or drugs that do not have a UK marketing authorisation.
Controlled Drugs and drug dependence

The Misuse of Drugs Act, 1971 prohibits certain activities in relation to ‘Controlled Drugs’, in particular their manufacture, supply, and possession. The penalties applicable to offences involving the different drugs are graded broadly according to the harmfulness attributable to a drug when it is misused and for this purpose the drugs are defined in the following three classes:

**Class A** includes: afillin, cocaine, diamorphine (heroin), dipipanone, lysergide (LSD), methadone, methylatedxoxymethamphetamine (MDMA), ‘ecstasy’), morphine, opium, pethidine, phenacyldine, remifentanil, and class B substances when prepared for injection

**Class B** includes: oral amphetamines, barbiturates, cannabis, cannabis resin, codeine, ethylmorphine, glutethimide, nabilone, pentazocine, phenmetrazine, and pholcodine

**Class C** includes: certain drugs related to the amphetamines such as benzphetamine and chlorphentermine, buprenorphine, diethylpropion, mazindol, meprobamate, pemoline, pipradrol, most benzodiazepines, zolpidem, and androgenic and anabolic steroids, clenbuterol, chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, somatotropin, somatrem, and somatropin

The Misuse of Drugs Regulations 2001 define the classes of person who are authorised to supply and possess controlled drugs while acting in their professional capacities and lay down the conditions under which these activities may be carried out. In the regulations drugs are divided into five schedules each specifying the requirements governing such activities as import, export, production, supply, possession, prescribing, and record keeping which apply to them.

**Schedule 1** includes drugs such as cannabis and lysergide which are not used medicinally. Possession and supply are prohibited except in accordance with Home Office authority.

**Schedule 2** includes drugs such as diamorphine (heroin), morphine, nabilone, remifentanil, pethidine, secobarbital, glutethimide, amfetamine, and cocaine and are subject to the full controlled drug requirements relating to prescriptions, safe custody (except for secobarbital), the need to keep registers, etc. (unless exempted in Schedule 5).

**Schedule 3** includes the barbiturates (except seco- barbital, now Schedule 2), buprenorphine, diethylpropion, mazindol, meprobamate, midazolam, pentazocine, phentermine, and temazepam. They are subject to the special prescription requirements (except for temazepam) and to the safe custody requirements (except for any 5,5 disubstituted barbituric acid (e.g. phenobarbital), mazindol, meprobamate, midazolam, pentazocine, phentermine, or any stereoisomeric form or salts of the above).

Records in registers do not need to be kept (although there are requirements for the retention of invoices for 2 years).

**Schedule 4** includes in Part I benzodiazepines (except temazepam and midazolam, which are in Schedule 3) and zolpidem, which are subject to minimal control. Part II includes androgenic and anabolic steroids, clenbuterol, chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, somatotropin, somatrem, and somatropin. Controlled drug prescription requirements do not apply and Schedule 4 Controlled Drugs are not subject to safe custody requirements.

**Schedule 5** includes those preparations which, because of their strength, are exempt from virtually all Controlled Drug requirements other than retention of invoices for two years.

**Prescriptions** Preparations in Schedules 2 and 3 of the Misuse of Drugs Regulations 2001 (and subsequent amendments) are identified throughout the BNF by the symbol [C] (Controlled Drug). The principal legal requirements relating to medical prescriptions are listed below (see also Department of Health Guidance, p. 9).

**Prescription requirements** Prescriptions for Controlled Drugs that are subject to prescription requirements must be indelible, and must be signed by the prescriber, be dated, and specify the prescriber’s address. The prescription must always state:

- the name and address of the patient;
- in the case of a preparation, the form and where appropriate the strength of the preparation;
- either the total quantity (in both words and figures) of the preparation, or the number (in both words and figures) of dosage units, as appropriate, to be supplied; in any other case, the total quantity (in both words and figures) of the Controlled Drug to be supplied;
- the dose;
- the words ‘for dental treatment only’ if issued by a dentist.

A pharmacist is not allowed to dispense a Controlled Drug unless all the information required by law is given on the prescription. In the case of a prescription for a Controlled Drug in Schedule 2 or 3, a pharmacist can amend the prescription if it specifies the total quantity only in words or in figures or if it contains minor typographical errors, provided that such amendments are indelible and clearly attributable to the pharmacist. Failure to comply with the regulations concerning the writing of prescriptions will result in inconvenience to patients and delay in supplying the necessary medicine. A prescription for a Controlled Drug in Schedules 2, 3, or 4 is valid for 28 days from the date stated thereon.7

1. All preparations in Schedules 2 and 3, except temazepam.
2. A machine-written prescription is acceptable. The prescriber’s signature must be handwritten.
3. The dosage form (e.g. tablets) must be included on a Controlled Drugs prescription irrespective of whether it is implicit in the proprietary name (e.g. MST ‘Continus’) or whether only one form is available.
4. When more than one strength of a preparation exists the strength required must be specified.
5. The Home Office has advised that quantities of liquid preparations, such as methadone oral solution, should be written in millilitres.
6. The instruction ‘one as directed’ constitutes a dose but ‘as directed’ does not.
7. The prescriber may forward-date the prescription; the start date may also be specified in the body of the prescription.
Instalments and ‘repeats’ A prescription may order a Controlled Drug to be dispensed by instalments; the amount of instalments and the intervals to be observed must be specified.1

Instalment prescriptions must be dispensed in accordance with the directions in the prescription. However, the Home Office has approved specific wording which may be included in an instalment prescription, to cover certain situations; for example, if a pharmacy is closed on the day when an instalment is due. For details, see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available) or see Drug Misuse and Dependence: UK Guidelines on Clinical Management (2007), available at www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf.

Prescriptions ordering ‘repeats’ on the same form are not permitted for Controlled Drugs in Schedules 2 or 3.

Private prescriptions Private prescriptions for Controlled Drugs in Schedules 2 and 3 must be written on specially designated forms provided by Primary Care Trusts in England, Health Boards in Scotland, Local Health Boards in Wales, or the Northern Ireland Central Services Agency; in addition, prescriptions must specify the prescriber’s identification number. Prescriptions to be supplied by a pharmacist in hospital are exempt from the requirements for private prescriptions.

1 A total of 14 days’ treatment by instalment of any drug listed in Schedule 2 of the Misuse of Drugs Regulations, bupropion, and diazepam may be prescribed in England. In England, forms FP10(MDA) (blue) and FP10H(MDA) (blue) should be used. In Scotland, forms GP10 (peach), HPB (blue), or HBPA (pink) should be used. In Wales a total of 14 days’ treatment by instalment of any drug listed in Schedules 2–5 of the Misuse of Drugs Regulations may be prescribed. In Wales, form WP10(MDA) or form WP10HP(AD) should be used.

Department of Health guidance Guidance (June 2006) issued by the Department of Health in England on prescribing and dispensing of Controlled Drugs requires:

- in general, prescriptions for Controlled Drugs in Schedules 2, 3, and 4 to be limited to a supply of up to 30 days’ treatment; exceptionally, to cover a justifiable clinical need and after consideration of any risk, a prescription can be issued for a longer period, but the reasons for the decision should be recorded on the patient’s notes;
- the patient’s identifier to be shown on NHS and private prescriptions for Controlled Drugs in Schedules 2 and 3.

Further information is available at www.dh.gov.uk. For a sample prescription, see above.

Dependence and misuse The most serious drugs of addiction are cocaine, diamorphine (heroin), morphine, and the synthetic opioids. For arrangements for prescribing of diamorphine, dipipanone, or cocaine for addicts, see p. 11.

Despite marked reduction in the prescribing of amphetamines, there is concern that abuse of illicit amphetamine and related compounds is widespread.

Benzodiazepines are commonly misused. However, the misuse of barbiturates is now uncommon, in line with declining medicinal use and consequent availability.

Cannabis (Indian hemp) has no approved medicinal use and cannot be prescribed by doctors. Its use is illegal but widespread. Cannabis is a mild hallucinogen seldom accompanied by a desire to increase the dose; withdrawal symptoms are unusual. Lysergide (lysergic acid diethylamide, LSD) is a much more potent hallucinogen; its use can lead to severe psychotic states which can be life-threatening.

There are concerns over increases in the availability and misuse of other drugs with variously combined hallucinogenic, anaesthetic, or sedative properties. These include ketamine and gamma-hydroxybutyrate (sodium oxybate, GHB).

Supervised consumption Individuals prescribed opioid substitution therapy (section 4.10.3) can take their daily dose under the supervision of a doctor, nurse, or pharmacist during the dose stabilisation phase (usually the first 3 months of treatment), after a relapse or period of instability, or if there is a significant increase in the dose of methadone. Supervised consumption should continue (in accordance with local protocols) until the prescriber is confident that the patient is compliant with their treatment.

Prescribing drugs likely to cause dependence or misuse The prescriber has three main responsibilities:

- To avoid creating dependence by introducing drugs to patients without sufficient reason. In this context, the proper use of the morphine-like drugs is well understood. The dangers of other Controlled Drugs are less clear because recognition of dependence is not easy and its effects, and those of withdrawal, are less obvious.
- To see that the patient does not gradually increase the dose of a drug, given for good medical reasons, to the point where dependence becomes more
likely. This tendency is seen especially with hypnotics and anxiolytics (for CSM advice see section 4.1). The prescriber should keep a close eye on the amount prescribed to prevent patients from accumulating stocks. A minimal amount should be prescribed in the first instance, or when seeing a new patient for the first time.

- To avoid being used as an unwitting source of supply for addicts. Methods include visiting more than one doctor, fabricating stories, and forging prescriptions.

Patients under temporary care should be given only small supplies of drugs unless they present an unequivocal letter from their own doctor. Doctors should also remember that their own patients may be attempting to collect prescriptions from other prescribers, especially in hospitals. It is sensible to reduce dosages steadily or to issue weekly or even daily prescriptions for small amounts if it is apparent that dependence is occurring.

The stealing and misuse of prescription forms could be minimised by the following precautions:

- do not leave unattended if called away from the consulting room or at reception desks; do not leave in a car where they may be visible; when not in use, keep in a locked drawer within the surgery and at home;
- draw a diagonal line across the blank part of the form under the prescription;
- write the quantity in words and figures when prescribing drugs prone to abuse; this is obligatory for prescribed in the first instance, or when seeing a new patient for the first time.

Patients travelling for less than 3 months do not require a personal export/import licence for carrying Controlled Drugs, but are advised to carry a letter from the prescribing doctor. Those travelling for more than 3 months are advised to make arrangements to have their medication prescribed by a practitioner in the country they are visiting.

Doctors who want to take Controlled Drugs abroad while accompanying patients may similarly be issued with licences. Licences are not normally issued to doctors who want to take Controlled Drugs abroad solely in case a family emergency should arise.

Personal export/import licences do not have any legal status outside the UK and are issued only to comply with the Misuse of Drugs Act and to facilitate passage through UK Customs and Excise control. For clearance in the country to be visited it is necessary to approach that country’s consulate in the UK.

### Notification of drug misusers

Doctors should report cases of drug misuse to their regional or national drug misuse database or centre—see below for contact telephone numbers. The National Drugs Treatment Monitoring System (NDTMS) was introduced in England in April 2001; regional (NDTMS) centres replace the Regional Drug Misuse Databases. A similar system has been introduced in Wales.

Notification to regional (NDTMS) or national centre should be made when a patient starts treatment for drug misuse. All types of problem drug misuse should be reported including opioid, benzodiazepine, and CNS stimulant.

The regional (NDTMS) or national centres are now the only national and local source of epidemiological data on people presenting with problem drug misuse; they provide valuable information to those working with drug misusers and those planning services for them. The databases cannot, however be used as a check on misusers and those planning services for them. The regional (NDTMS) centres replace the Regional Drug Misuse Databases. A similar system has been introduced in Wales.

Enquiries about the regional (NDTMS) or national centres (including information on how to submit data) can be made to one of the centres listed below:

**ENGLAND**

<table>
<thead>
<tr>
<th>Region</th>
<th>Tel</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eastern</td>
<td>(01223) 767904</td>
<td>(01223) 330 345</td>
</tr>
<tr>
<td>South East</td>
<td>(01865) 334734</td>
<td>(01865) 334 964</td>
</tr>
<tr>
<td>London</td>
<td>(020) 7972 1986</td>
<td>(020) 7972 1998</td>
</tr>
<tr>
<td>North West</td>
<td>(0151) 231 4533</td>
<td>(0151) 231 4515</td>
</tr>
<tr>
<td>North East</td>
<td>(0191) 334 0372</td>
<td>(0191) 334 0391</td>
</tr>
<tr>
<td>Yorkshire and the Humber</td>
<td>(0113) 341 2923</td>
<td>(0113) 341 3082</td>
</tr>
</tbody>
</table>

**Travelling abroad**

Prescribed drugs listed in Schedule 4 Part II (CD Anab) and Schedule 5 of the Misuse of Drugs Regulations 2001 are not subject to export or import licensing. However, patients intending to travel abroad for more than 3 months carrying any amount of drugs listed in Schedules 2, 3, or 4 Part I (CD Benz) will require a personal export/import licence. Further details can be obtained at www.homeoffice.gov.uk/drugs/licensing/personal, or from the Home Office by contacting licensing_enquiry.aadu@homeoffice.gsi.gov.uk (in cases of emergency, telephone (020) 7035 0484).

Applications must be supported by a covering letter from the prescriber and should give details of:

- the patient’s name and address;
- the quantities of drugs to be carried;
- the strength and form in which the drugs will be dispensed;
- the dates of travel to and from the United Kingdom.

Applications for licences should be sent to the Home Office, Drugs Licensing, Peel Building, 2 Marsham Street, London, SW1P 4DF. Alternatively, completed application forms can be emailed to licensing_enquiry.aadu@homeoffice.gsi.gov.uk with a scanned copy of the covering letter from the prescriber. A minimum of two weeks should be allowed for processing the application.
In **Northern Ireland**, the Misuse of Drugs (Notification of and Supply to Addicts) (Northern Ireland) Regulations 1973 require doctors to send particulars of persons whom they consider to be addicted to certain controlled drugs to the Chief Medical Officer of the Department of Health and Social Services. The Northern Ireland contacts are:

**Medical contact:**
Dr Ian McMaster  
C3 Castle Buildings  
Belfast, BT4 3FQ  
Tel: (028) 9052 2421  
Fax: (028) 9052 0718  
ian.mcmaster@dhsspsni.gov.uk

**Administrative contact:**
Public Health Information & Research Branch  
Annex 2  
Castle Building  
Belfast, BT4 3SQ  
Tel: (028) 9052 2520

Public Health Information & Research Branch also maintains the Northern Ireland Drug Misuse Database (NIDMD) which collects detailed information on those presenting for treatment, on drugs misused and injecting behaviour; participation is not a statutory requirement.

---

**Prescribing of diamorphine (heroin), dipipanone, and cocaine for addicts**

The Misuse of Drugs (Supply to Addicts) Regulations 1997 require that only medical practitioners who hold a special licence issued by the Home Secretary may prescribe, administer, or supply diamorphine, dipipanone (Diconal®), or cocaine in the treatment of drug addiction; other practitioners must refer any addict who requires these drugs to a treatment centre. Whenever possible the addict will be introduced by a member of staff from the treatment centre to a pharmacist whose agreement has been obtained and whose pharmacy is conveniently sited for the patient. Prescriptions for weekly supplies will be sent to the pharmacy by post and will be dispensed on a daily basis as indicated by the doctor. If any alterations of the arrangements are requested by the addict, the portion of the prescription affected must be represcribed and not merely altered.

General practitioners and other doctors do not require a special licence for prescribing diamorphine, dipipanone,
Adverse reactions to drugs

Any drug may produce unwanted or unexpected adverse reactions. Rapid detection and recording of adverse drug reactions is of vital importance so that unrecognised hazards are identified promptly and appropriate regulatory action is taken to ensure that medicines are used safely. Healthcare professionals and coroners (see also Self-reporting below) are urged to report suspected adverse drug reactions directly to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme using the electronic form at www.yellowcard.gov.uk. Alternatively, prepaid Yellow Cards for reporting are available from the address below and are also bound in this book (inside back cover).

Send Yellow Cards to:
FREEPOST YELLOW CARD
(No other address details required)
Tel: 0800 731 6789

Suspected adverse drug reactions to any therapeutic agent should be reported, including drugs (self-medication as well as those prescribed), blood products, vaccines, radiographic contrast media, complementary and herbal products.

A 24-hour Freephone service is available to all parts of the UK for advice and information on suspected adverse drug reactions; contact the National Yellow Card Information Service at the MHRA on 0800 731 6789. Outside office hours a telephone-answering machine will take messages.

The following Yellow Card Centres can be contacted for further information:

Yellow Card Centre
Northwest
Freepost SW2991
70 Pembroke Place
Liverpool L69 3GF
Tel: (0151) 794 8122

Yellow Card Centre
Northern & Yorkshire
Freepost SW2991
Wolfson Unit
Claremont Place
Newcastle upon Tyne NE2 4HH
Tel: (0191) 280 6181

Yellow Card Centre Scotland
Freepost NAT3271
CARDS, Royal Infirmary of Edinburgh
Edinburgh EH16 4SA
Tel: (0131) 242 2919

The MHRA’s database facilitates the monitoring of adverse drug reactions.

More detailed information on reporting and a list of products currently under intensive monitoring can be found on the MHRA website: www.mhra.gov.uk.

Self-reporting

Patients and their carers can also report suspected adverse drug reactions to the MHRA. Reports can be submitted directly to the MHRA through the Yellow Card Scheme using the electronic form at www.yellowcard.gov.uk, by telephone on 0808 100 3352, or by downloading the Yellow Card form from www.mhra.gov.uk. Alternatively, patient Yellow Cards are available from pharmacies and GP surgeries. Information for patients about the Yellow Card Scheme is available in other languages at www.yellowcard.gov.uk.

Prescription-event monitoring

In addition to the MHRA’s Yellow Card Scheme, an independent scheme monitors the safety of new medicines using a different approach. The Drug Safety Research Unit identifies patients who have been prescribed selected new medicines and collects data on clinical events in these patients. The data are submitted on a voluntary basis by general practitioners on green forms. More information about the scheme and the Unit’s educational material is available from www.dsrpu.org.

Newer drugs and vaccines

Only limited information is available from clinical trials on the safety of new medicines. Further understanding about the safety of medicines depends on the availability of information from routine clinical practice.

The black triangle symbol (▼) identifies newly licensed medicines that are monitored intensively by the MHRA. Such medicines include new active substances, biosimilar medicines, medicines that have been licensed for administration by a new route or drug delivery system, or for significant new indications which may alter the established risks and benefits of that drug, or that contain a new combination of active substances. There is no standard time for which products retain a black triangle; safety data are usually reviewed after 2 years.

Spontaneous reporting is particularly valuable for recognising possible new hazards rapidly. For medicines showing the black triangle symbol, the MHRA asks that all suspected reactions (including those considered not to be serious) are reported through the Yellow Card Scheme. An adverse reaction should be reported even if it is not certain that the drug has caused it, or if the reaction is well recognised, or if other drugs have been given at the same time.

Established drugs and vaccines

Healthcare professionals and coroners are asked to report all serious suspected reactions to established drugs (including over-the-counter, herbal, and unlicensed medicines and medicines used off-label) and vaccines. Serious reactions include those that are fatal, life-threatening, disabling, incapacitating, or which result in or prolong hospitalisation; they should be reported even if the effect is well recognised. Examples include anaphylaxis, blood disorders, endocrine disturbances, effects on fertility, haemorrhage from any site, renal impairment, jaundice, ophthalmic disorders, severe CNS effects, severe skin reactions, reactions in pregnant women, and any drug interactions. Reports of serious adverse reactions are required to enable comparison with other drugs of a similar class. Reports of overdoses (deliberate or accidental) can complicate the assessment of adverse drug reactions, but provide important information on the potential toxicity of drugs.
For established drugs there is no need to report well-known, relatively minor side-effects, such as dry mouth with tricyclic antidepressants or constipation with opioids.

Adverse reactions to medical devices Suspected adverse reactions to medical devices including dental or surgical materials, intra-uterine devices, and contact lens fluids should be reported. Information on reporting these can be found at: www.mhra.gov.uk.

Side-effects in the BNF The BNF includes clinically relevant side-effects for most drugs; an exhaustive list is not included for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). Where causality has not been established, side-effects in the manufacturers’ literature may be omitted from the BNF.

Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is not generally listed, unless the drug carries an increased risk of such reactions. The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes).

Side-effects are generally listed in order of frequency and arranged broadly by body systems. Occasionally a rare side-effect might be listed first if it is considered to be particularly important because of its seriousness.

In the product literature the frequency of side-effects is generally described as follows:

- Very common: greater than 1 in 10
- Common: 1 in 100 to 1 in 10
- Uncommon ['less commonly' in BNF]: 1 in 1000 to 1 in 100
- Rare: 1 in 10 000 to 1 in 1000
- Very rare: less than 1 in 10 000

Special problems

Delayed drug effects Some reactions (e.g. cancers, chloroquine retinopathy, and retroperitoneal fibrosis) may become manifest months or years after exposure. Any suspicion of such an association should be reported directly to the MHRA through the Yellow Card Scheme.

The elderly Particular vigilance is required to identify adverse reactions in the elderly.

Congenital abnormalities When an infant is born with a congenital abnormality or there is a malformed aborted fetus doctors are asked to consider whether this might be an adverse reaction to a drug and to report all drugs (including self-medication) taken during pregnancy.

Children Particular vigilance is required to identify and report adverse reactions in children, including those resulting from the unlicensed use of medicines; all suspected reactions should be reported directly to the MHRA through the Yellow Card Scheme (see also Adverse Drug Reactions in Children, p. 15).

Prevention of adverse reactions

Adverse reactions may be prevented as follows:

- never use any drug unless there is a good indication. If the patient is pregnant do not use a drug unless the need for it is imperative;
- allergy and idiosyncrasy are important causes of adverse drug reactions. Ask if the patient had previous reactions;
- ask if the patient is already taking other drugs including self-medication drugs, health supplements, complementary and alternative therapies; interactions may occur;
- age and hepatic or renal disease may alter the metabolism or excretion of drugs, so that much smaller doses may be needed. Genetic factors may also be responsible for variations in metabolism, notably of isoniazid and the tricyclic antidepressants;
- prescribe as few drugs as possible and give very clear instructions to the elderly or any patient likely to misunderstand complicated instructions;
- whenever possible use a familiar drug; with a new drug, be particularly alert for adverse reactions or unexpected events;
- warn the patient if serious adverse reactions are liable to occur.

Oral side-effects of drugs

Drug-induced disorders of the mouth may be due to a local action on the mouth or to a systemic effect manifested by oral changes. In the latter case urgent referral to the patient’s medical practitioner may be necessary.

Oral mucosa

Medicaments left in contact with or applied directly to the oral mucosa can lead to inflammation or ulceration; the possibility of allergy should also be borne in mind. Aspirin tablets allowed to dissolve in the sulcus for the treatment of toothache can lead to a white patch followed by ulceration. Flavouring agents, particularly essential oils, may sensitise the skin, but mucosal swelling is not usually prominent.

The oral mucosa is particularly vulnerable to ulceration in patients treated with cytotoxic drugs, e.g. methotrexate. Other drugs capable of causing oral ulceration include captopril (and other ACE inhibitors), gold, nicorandil, NSAI Ds, pancreatin, penicillamine, proguanil, and protease inhibitors.

Erythema multiforme or Stevens-Johnson syndrome may follow the use of a wide range of drugs including antibacterials, antiretrovirals, sulfonamide derivatives, and anticonvulsants; the oral mucosa may be extensively ulcerated, with characteristic target lesions on the skin. Oral lesions of toxic epidermal necrolysis have been reported with a similar range of drugs.

Lichenoid eruptions are associated with ACE inhibitors, NSAIDs, methyldopa, chloroquine, oral antidiabetics, thiazide diuretics, and gold.

Candidiasis can complicate treatment with antibacterials and immunosuppressants and is an occasional side-effect of corticosteroid inhalers, see also p. 185.
Adverse reactions to drugs

Teeth and jaw

Brown staining of the teeth frequently follows the use of chlorhexidine mouthwash, spray or gel, and can readily be removed by polishing. Iron salts in liquid form can stain the enamel black. Superficial staining has been reported rarely with co-amoxiclav suspension.

Intrinsic staining of the teeth is most commonly caused by tetracyclines. They will affect the teeth if given at any time from about the fourth month in utero until the age of twelve years; they are contra-indicated during pregnancy, in breast-feeding women, and in children under 12 years. All tetracyclines can cause permanent, unsightly staining in children, the colour varying from yellow to grey.

Excessive ingestion of fluoride leads to dental fluorosis with mottling of the enamel and areas of hypoplasia or pitting; fluoride supplements occasionally cause mild mottling (white patches) if the dose is too large for the child’s age (taking into account the fluoride content of the local drinking water and of toothpaste).

The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease. All patients receiving bisphosphonates for cancer should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment. However, urgent bisphosphonate treatment should not be delayed, and a dental check-up should be carried out as soon as possible in these patients. All other patients who are prescribed bisphosphonates should have a dental examination only if they have poor dental health, see also MHRA/CHM advice (Bisphosphonates: osteonecrosis of the jaw), p. 537.

Gingival overgrowth (gingival hyperplasia) is a side-effect of phenytoin and sometimes of ciclosporin or of nifedipine (and some other calcium-channel blockers).

Thrombocytopenia may be drug related and may cause bleeding at the gingival margins, which may be spontaneous or may follow mild trauma (such as toothbrushing).

Salivary glands

The most common effect that drugs have on the salivary glands is to reduce flow (xerostomia). Patients with a persistently dry mouth may have poor oral hygiene; they are at an increased risk of dental caries and oral infections (particularly candidiasis). Many drugs have been implicated in xerostomia, particularly antimuscarinics (anticholinergics), antidepressants (including tricyclic antidepressants, and selective serotonin re-uptake inhibitors), alpha-blockers, antihistamines, antipsychotics, bactefen, bupropion, clonidine, 5HT, agonists, opioids, and tizanidine. Excessive use of diuretics can also result in xerostomia.

Some drugs (e.g. clozapine, neostigmine) can increase saliva production but this is rarely a problem unless the patient has associated difficulty in swallowing.

Defective medicines

During the manufacture or distribution of a medicine an error or accident may occur whereby the finished product does not conform to its specification. While such a defect may impair the therapeutic effect of the product and could adversely affect the health of a patient, it should not be confused with an Adverse Drug Reaction where the product conforms to its specification. The Defective Medicines Report Centre assists with the investigation of problems arising from licensed medicinal products thought to be defective and coordinates any necessary protective action. Reports on suspect defective medicinal products should include the brand or the non-proprietary name, the name of the manufacturer or supplier, the strength and dosage form of the product, the product licence number, the batch number or numbers of the product, the nature of the defect, and an account of any action already taken in consequence. The Centre can be contacted at:

The Defective Medicines Report Centre
Medicines and Healthcare products Regulatory Agency
151 Buckingham Palace Road
London, SW1W 9SZ
Tel: (020) 3080 6588
info@mhra.gsi.gov.uk
Prescribing for children

For detailed advice on medicines used for children, consult BNF for Children

Children, and particularly neonates, differ from adults in their response to drugs. Special care is needed in the neonatal period (first 28 days of life) and doses should always be calculated with care. At this age, the risk of toxicity is increased by reduced drug clearance and differing target organ sensitivity.

Whenever possible, intramuscular injections should be avoided in children because they are painful.

Where possible, medicines for children should be prescribed within the terms of the marketing authorisation (product licence). However, many children may require medicines not specifically licensed for paediatric use.

Although medicines cannot be promoted outside the limits of the licence, the Medicines Act does not prohibit the use of unlicensed medicines. It is recognised that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications ('off-label' use) is often necessary in paediatric practice.

Adverse drug reactions in children

The reporting of all suspected adverse drug reactions, no matter how minor, in children under 18 years is strongly encouraged through the Yellow Card Scheme (see p. 12) even if the intensive monitoring symbol (◇) has been removed. This is because experience in children may still be limited.

The identification and reporting of adverse reactions to drugs in children is particularly important because:

- the action of the drug and its pharmacokinetics in children (especially in the very young) may be different from that in adults;
- drugs are not extensively tested in children;
- many drugs are not specifically licensed for use in children and are used 'off-label';
- suitable formulations may not be available to allow precise dosing in children;
- the nature and course of illnesses and adverse drug reactions may differ between adults and children.

Dose calculation

Many children’s doses are standardised by weight (and therefore require multiplying by the body-weight in kilograms to determine the child’s dose); occasionally, the doses have been standardised by body surface area (in m²). These methods should be used rather than attempting to calculate a child’s dose on the basis of doses used in adults.

For most drugs the adult maximum dose should not be exceeded. For example if the dose is stated as 8 mg/kg (max. 300 mg), a child weighing 10 kg should receive 80 mg but a child weighing 40 kg should receive 300 mg (rather than 320 mg).

Young children may require a higher dose per kilogram than adults because of their higher metabolic rates. Other problems need to be considered. For example, calculation by body-weight in the overweight child may result in much higher doses being administered than necessary; in such cases, dose should be calculated from

Rare paediatric conditions

Information on substances such as biotin and sodium benzoate used in rare metabolic conditions is included in BNF for Children; further information can be obtained from:

Alder Hey Children’s Hospital
Drug Information Centre
Liverpool L12 2AP
Tel: (0151) 252 5381

Great Ormond Street Hospital for Children
Pharmacy
Great Ormond St
London WC1N 3JH
Tel: (020) 7405 9200

Dosage in children

Children’s doses in the BNF are stated in the individual drug entries as far as possible, except where paediatric use is not recommended, information is not available, or there are special hazards.

Doses are generally based on body-weight (in kilograms) or the following age ranges:

- first month (neonate) up to 1 year (infant)
- 1–5 years
- 6–12 years

Unless the age is specified, the term ‘child’ in the BNF includes persons aged 12 years and younger.

Parents should be advised not to add any medicines to the infant’s feed, since the drug may interact with the milk or other liquid in it; moreover the ingested dosage may be reduced if the child does not drink all the contents.

Parents must be warned to keep all medicines out of reach of children, see Safety in the Home, p. 3.

Prescription writing

Prescriptions should be written according to the guidelines in Prescription Writing (p. 5)

Inclusion of age is a legal requirement in the case of prescription-only medicines for children under 12 years of age, but it is preferable to state the age for all prescriptions for children.

It is particularly important to state the strengths of capsules or tablets. Although liquid preparations are particularly suitable for children, they may contain sugar which encourages dental decay. Sugar-free medicines are preferred for long-term treatment.

Many children are able to swallow tablets or capsules and may prefer a solid dose form; involving the child and parents in choosing the formulation is helpful.

When a prescription for a liquid oral preparation is written and the dose ordered is smaller than 5 mL an oral syringe will be supplied (for details, see p. 2).
an ideal weight, related to height and age (see inside back cover).

**Body surface area (BSA) estimates** are sometimes preferable to body-weight for calculation of paediatric doses since many physiological phenomena correlate better with body surface area. Body surface area can be estimated from weight. For more information, refer to *BNF for Children*.

Where the dose for children is not stated, prescribers should consult *BNF for Children* or seek advice from a medicines information centre.

**Dose frequency** Antibacterials are generally given at regular intervals throughout the day. Some flexibility should be allowed in children to avoid waking them during the night. For example, the night-time dose may be given at the child’s bedtime.

Where new or potentially toxic drugs are used, the manufacturers’ recommended doses should be carefully followed.
Prescribing in hepatic impairment

Liver disease may alter the response to drugs in several ways as indicated below, and drug prescribing should be kept to a minimum in all patients with severe liver disease. The main problems occur in patients with jaundice, ascites, or evidence of encephalopathy.

**Impaired drug metabolism** Metabolism by the liver is the main route of elimination for many drugs, but hepatic reserve is large and liver disease has to be severe before important changes in drug metabolism occur. Routine liver-function tests are a poor guide to the capacity of the liver to metabolise drugs, and in the individual patient it is not possible to predict the extent to which the metabolism of a particular drug may be impaired.

A few drugs, e.g. rifampicin and fusidic acid, are excreted in the bile unchanged and can accumulate in patients with intrahepatic or extrahepatic obstructive jaundice.

**Hypoproteinaemia** The hypoalbuminaemia in severe liver disease is associated with reduced protein binding and increased toxicity of some highly protein-bound drugs such as phenytoin and prednisolone.

**Reduced clotting** Reduced hepatic synthesis of blood-clotting factors, indicated by a prolonged prothrombin time, increases the sensitivity to oral anticoagulants such as warfarin and phenindione.

**Hepatic encephalopathy** In severe liver disease many drugs can further impair cerebral function and may precipitate hepatic encephalopathy. These include all sedative drugs, opioid analgesics, those diuretics that produce hypokalaemia, and drugs that cause constipation.

**Fluid overload** Oedema and ascites in chronic liver disease can be exacerbated by drugs that give rise to fluid retention, e.g. NSAIDs and corticosteroids.

**Hepatotoxic drugs** Hepatotoxicity is either dose-related or unpredictable (idiosyncratic). Drugs that cause dose-related toxicity may do so at lower doses in the presence of hepatic impairment than in individuals with normal liver function, and some drugs that produce reactions of the idiosyncratic kind do so more frequently in patients with liver disease. These drugs should be avoided or used very carefully in patients with liver disease.

Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

---

Prescribing in renal impairment

The use of drugs in patients with reduced renal function can give rise to problems for several reasons:

- reduced renal excretion of a drug or its metabolites may cause toxicity;
- sensitivity to some drugs is increased even if elimination is unimpaired;
- many side-effects are tolerated poorly by patients with renal impairment;
- some drugs are not effective when renal function is reduced.

Many of these problems can be avoided by reducing the dose or by using alternative drugs.

**Principles of dose adjustment in renal impairment**

The level of renal function below which the dose of a drug must be reduced depends on the proportion of the drug eliminated by renal excretion and its toxicity.

For many drugs with only minor or no dose-related side-effects very precise modification of the dose regimen is unnecessary and a simple scheme for dose reduction is sufficient.

For more toxic drugs with a small safety margin or patients at extremes of weight, dose regimens based on creatinine clearance (see below for details) should be used. When both efficacy and toxicity are closely related to plasma-drug concentration, recommended regimens should be regarded only as a guide to initial treatment; subsequent doses must be adjusted according to clinical response and plasma-drug concentration.

Renal function declines with age; many elderly patients have renal impairment but, because of reduced muscle mass, this may not be indicated by a raised serum creatinine. It is wise to assume at least mild impairment of renal function when prescribing for the elderly.

The total daily maintenance dose of a drug can be reduced either by reducing the size of the individual doses or by increasing the interval between doses. For some drugs, although the size of the maintenance dose is reduced it is important to give a loading dose if an immediate effect is required. This is because it takes about five times the half-life of the drug to achieve steady-state plasma concentrations. Because the plasma half-life of drugs excreted by the kidney is prolonged in renal impairment it can take many doses for the reduced dosage to achieve a therapeutic plasma concentration. The loading dose should usually be the same size as the initial dose for a patient with normal renal function.

**Nephrotoxic drugs** should, if possible, be avoided in patients with renal disease because the consequences of nephrotoxicity are likely to be more serious when renal reserve is already reduced.

Dose recommendations are based on the severity of renal impairment.
Renal function is measured either in terms of estimated glomerular filtration rate (eGFR) calculated from a formula derived from the Modification of Diet in Renal Disease study (‘MDRD formula’ that uses serum creatinine, age, sex, and race (for Afro-Caribbean patients)) or it can be expressed as creatinine clearance (best derived from a 24-hour urine collection but often calculated from the Cockcroft and Gault formula (CG)).

Cockcroft and Gault formula

\[
\text{Estimated Creatinine Clearance in mL/minute} = \frac{(140 - \text{Age}) \times \text{Weight} \times \text{Constant}}{\text{Serum creatinine}}
\]

- Age in years
- Weight in kilograms; use ideal body-weight
- Serum creatinine in micromol/litre
- Constant = 1.23 for men; 1.04 for women

The serum-creatinine concentration is sometimes used instead as a measure of renal function but it is only a rough guide to drug dosing.

Important

Renal function in adults is increasingly being reported on the basis of estimated glomerular filtration rate (eGFR) normalised to a body surface area of 1.73 m² and derived from the Modification of Diet in Renal Disease (MDRD) formula. However, published information on the effects of renal impairment on drug elimination is usually stated in terms of creatinine clearance as a surrogate for glomerular filtration rate (GFR).

The information on dosage adjustment in the BNF is expressed in terms of eGFR, rather than creatinine clearance, for most drugs (see exceptions below: Toxic Drugs and Patients at Extremes of Weight). Although the two measures of renal function are not interchangeable, in practice, for most drugs and for most patients (over 18 years) of average build and height, eGFR (MDRD ‘formula’) can be used to determine dosage adjustments in place of creatinine clearance. An individual’s absolute glomerular filtration rate can be calculated from the eGFR as follows:

\[
\text{GFR Absolute} = \frac{\text{eGFR}}{\text{Body surface area}/1.73}
\]

Toxic drugs

For potentially toxic drugs with a small safety margin, creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages in addition to plasma-drug concentration and clinical response.

Patients at extremes of weight

In patients at both extremes of weight (BMI of less than 18.5 kg/m² or greater than 30 kg/m²) the absolute glomerular filtration rate or creatinine clearance (calculated from the Cockcroft and Gault formula) should be used to adjust drug dosages.

In the BNF, values for eGFR, creatinine clearance (for toxic drugs), or another measure of renal function are included where possible. However, where such values are not available, the BNF reflects the terms used in the published information.

Chronic kidney disease in adults: UK guidelines for identification, management and referral (March 2006) define renal function as follows:

<table>
<thead>
<tr>
<th>Degree of impairment</th>
<th>eGFR mL/minute/1.73 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal - Stage 1</td>
<td>More than 90 (with other evidence of kidney damage)</td>
</tr>
<tr>
<td>Mild - Stage 2</td>
<td>60–89 (with other evidence of kidney damage)</td>
</tr>
<tr>
<td>Moderate - Stage 3</td>
<td>30–59</td>
</tr>
<tr>
<td>Severe - Stage 4</td>
<td>15–29</td>
</tr>
<tr>
<td>Established renal failure - Stage 5</td>
<td>Less than 15</td>
</tr>
</tbody>
</table>

1. NICE clinical guideline 73 (September 2008)—Chronic kidney disease: Stage 3A eGFR 45–59, Stage 3B eGFR 30–44

Dialysis

For prescribing in patients on continuous ambulatory peritoneal dialysis (CAPD) or haemodialysis, consult specialist literature.

Drug prescribing should be kept to the minimum in all patients with severe renal disease. If even mild renal impairment is considered likely on clinical grounds, renal function should be checked before prescribing any drug which requires dose modification.

Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.
Prescribing in pregnancy

Drugs can have harmful effects on the embryo or fetus at any time during pregnancy. It is important to bear this in mind when prescribing for a woman of childbearing age or for men trying to father a child.

During the first trimester drugs can produce congenital malformations (teratogenesis), and the period of greatest risk is from the third to the eleventh week of pregnancy.

During the second and third trimesters drugs can affect the growth or functional development of the fetus, or they can have toxic effects on fetal tissues.

Drugs given shortly before term or during labour can have adverse effects on labour or on the neonate after delivery.

Not all the damaging effects of intrauterine exposure to drugs are obvious at birth, some may only manifest later in life. Such late-onset effects include malignancy, e.g. adenocarcinoma of the vagina after puberty in females exposed to diethylstilbestrol in the womb, and adverse effects on intellectual, social, and functional development.

The BNF identifies drugs which:
1. may have harmful effects in pregnancy and indicates the trimester of risk
2. are not known to be harmful in pregnancy

The information is based on human data, but information from animal studies has been included for some drugs when its omission might be misleading.

Where care is needed when prescribing in pregnancy, this is indicated under the relevant drug in the BNF.

Prescribing in breast-feeding

Breast-feeding is beneficial; the immunological and nutritional value of breast milk to the infant is greater than that of formula feeds.

Although there is concern that drugs taken by the mother might affect the infant, there is very little information on this. In the absence of evidence of an effect, the potential for harm to the infant can be inferred from:

1. the amount of drug or active metabolite of the drug delivered to the infant (dependent on the pharmacokinetic characteristics of the drug in the mother);
2. the efficiency of absorption, distribution, and elimination of the drug by the infant (infant pharmacokinetics);
3. the nature of the effect of the drug on the infant (pharmacodynamic properties of the drug in the infant).

The amount of drug transferred in breast milk is rarely sufficient to produce a discernible effect on the infant. This applies particularly to drugs that are poorly absorbed and need to be given parenterally. However, there is a theoretical possibility that a small amount of drug present in breast milk can induce a hypersensitivity reaction.

A clinical effect can occur in the infant if a pharmacologically significant quantity of the drug is present in milk. For some drugs (e.g. fluvastatin), the ratio between the concentration in milk and that in maternal plasma may be high enough to expose the infant to adverse effects. Some infants, such as those born prematurely or who have jaundice, are at a slightly higher risk of toxicity.

Some drugs inhibit the infant’s sucking reflex (e.g. phenobarbital) while others can affect lactation (e.g. bromocriptine).

The BNF identifies drugs:
1. that should be used with caution or are contraindicated in breast-feeding;
2. that can be given to the mother during breast-feeding because they are present in milk in amounts which are too small to be harmful to the infant;
3. that might be present in milk in significant amount but are not known to be harmful.

Where care is needed when prescribing in breast-feeding, this is indicated under the relevant drug in the BNF.

For many drugs insufficient evidence is available to provide guidance and it is advisable to administer only essential drugs to a mother during breast-feeding. Because of the inadequacy of information on drugs in breast-feeding, absence of information does not imply safety.
Prescribing in palliative care

Palliative care is the active total care of patients whose disease is not responsive to curative treatment. Control of pain, of other symptoms, and of psychological, social and spiritual problems, is paramount to provide the best quality of life for patients and their families. Careful assessment of symptoms and needs of the patient should be undertaken by a multidisciplinary team.

Specialist palliative care is available in most areas as day hospice care, home-care teams (often known as Macmillan teams), in-patient hospice care, and hospital teams. Many acute hospitals and teaching centres now have consultative, hospital-based teams.

Hospice care of terminally ill patients has shown the importance of symptom control and psychosocial support of the patient and family. Families should be included in the care of the patient if they wish.

Many patients wish to remain at home with their families. Although some families may at first be afraid of caring for the patient at home, support can be provided by community nursing services, social services, voluntary agencies and hospices together with the general practitioner. The family may be reassured by the knowledge that the patient will be admitted to a hospital or hospice if the family cannot cope.

Drug treatment

The number of drugs should be as few as possible, for even the taking of medicine may be an effort. Oral medication is usually satisfactory unless there is severe nausea and vomiting, dysphagia, weakness, or coma, when parenteral medication may be necessary.

Pain

Analgesics are more effective in preventing pain than in the relief of established pain; it is important that they are given regularly.

Paracetamol (p. 259) or a NSAID (section 10.1.1) given regularly will often make the use of opioid analgesics unnecessary. A NSAID may also control the pain of bone secondaries; if necessary, flurbiprofen or indometacin can be given rectally. Radiotherapy, bisphosphonates (section 6.6.2), and radioactive isotopes of strontium (Metastron®, available from GE Healthcare) may also be useful for pain due to bone metastases.

An opioid analgesic (section 4.7.2) such as codeine (p. 264), alone or in combination with a non-opioid analgesic at adequate dosage, may be helpful in the control of moderate pain if non-opioid analgesics alone are not sufficient. Alternatively, tramadol (p. 271) can be considered for moderate pain. If these preparations do not control the pain, morphine (p. 268) is the most useful opioid analgesic. Alternatives to morphine, including hydromorphone (p. 267), methadone (p. 267), oxycodone (p. 269), and transdermal fentanyl (see below and p. 265) are best initiated by those with experience in palliative care. Initiation of an opioid analgesic should not be delayed by concern over a theoretical likelihood of psychological dependence (addiction).

Equivalent single doses of opioid analgesics

These equivalences are intended only as an approximate guide; patients should be carefully monitored after any change in medication and dose titration may be required.

<table>
<thead>
<tr>
<th>Analgesic</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine sulphate (oral)</td>
<td>10 mg</td>
</tr>
<tr>
<td>Diamorphine hydrochloride</td>
<td>3 mg</td>
</tr>
<tr>
<td>Hydromorphone hydrochloride</td>
<td>1.3 mg</td>
</tr>
<tr>
<td>Oxycodone (oral)</td>
<td>5 mg</td>
</tr>
</tbody>
</table>

Oral route

Morphine (p. 268) is given by mouth as an oral solution or as standard (‘immediate release’) tablets regularly every 4 hours, the initial dose depending largely on the patient’s previous treatment. A dose of 5–10 mg is enough to replace a weaker analgesic (such as paracetamol), but 10–20 mg or more is required to replace a strong one (comparable to morphine itself). If the first dose of morphine is no more effective than the previous analgesic, the next dose should be increased by 30–50%, the aim being to choose the lowest dose that prevents pain. The dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics (such as NSAIDs) should also be considered.

Although morphine in a dose of 5–20 mg is usually adequate there should be no hesitation in increasing it stepwise according to response to 100 mg or occasionally up to 500 mg or higher if necessary. It may be possible to omit the overnight dose if double the usual dose is given at bedtime.

When the pain is controlled and the patient’s 24-hour morphine requirement is established, the daily dose can be given as a modified-release preparation in a single dose or in two divided doses.

Preparations suitable for twice-daily administration include Morphgesic® tablets or suspension (p. 268), MST Continus® tablets or suspension (p. 269), and Zomorph® capsules (p. 269). MXL® capsules (p. 269) allow administration of the total daily morphine requirement as a single dose.

The starting dose of modified-release morphine preparations designed for twice daily administration is usually 10–20 mg every 12 hours if no other analgesic (or only paracetamol) has been taken previously, but to replace a weaker opioid analgesic (such as co-codamol) the starting dose is usually 20–30 mg every 12 hours. Increments should be made to the dose, not to the frequency of administration, which should remain at every 12 hours.

The effective dose of modified-release preparations can alternatively be determined by giving the oral solution of morphine every 4 hours in increasing doses until the pain has been controlled, and then transferring the patient to the same total 24-hour dose of morphine given as the modified-release preparation (divided into two portions for 12-hourly administration). The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the oral solution. The patient should be monitored closely for treatment efficacy and side-effects.

If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) should be given. An additional dose should also
be given 30 minutes before an activity that causes pain (e.g. wound dressing). Morphine, as oral solution or standard formulation tablets, should be prescribed for breakthrough pain. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24 hour total daily dose, repeated every 4 hours if necessary (review pain management if analgesic required more frequently). Each patient should be assessed on an individual basis. Fentanyl lozenges are also licensed for breakthrough pain.

**Oxycodone** (p. 269) can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone should be started at a dose equivalent to the current analgesic (see Equivalent Single Doses of Opioid Analgesics table, p. 20).

**Levomepromazine** (p. 220) is licensed to treat pain in palliative care, and may be of benefit in some patients. It should be reserved for use in conjunction with strong opioid analgesics in distressed patients with severe pain unresponsive to other measures.

**Parenteral route** If the patient becomes unable to swallow, the equivalent intramuscular dose of morphine is half the oral solution dose; in the case of the modified-release tablets it is half the total 24-hour dose (which is then divided into 6 portions to be given every 4 hours). **Diamorphine** (p. 264) is preferred for injection because, being more soluble, it can be given in a smaller volume. The equivalent intramuscular (or subcutaneous) dose is approximately a third of the oral dose of morphine. **Subcutaneous infusion of diamorphine via continuous infusion device** can be useful (for details, see p. 23). If the patient can resume taking medicines by mouth, then oral morphine may be substituted for subcutaneous infusion of diamorphine. See table of approximate equivalent doses of morphine and diamorphine, p. 24.

**Rectal route** Morphine (p. 269) is also available for rectal administration as suppositories; alternatively oxycodone (p. 269) suppositories can be obtained on special order.

**Transdermal route** Transdermal preparations of fentanyl and buprenorphine are available (section 4.7.2); they are not suitable for acute pain or in patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Prescribers should ensure that they are familiar with the correct use of transdermal preparations (see under Fentanyl, p. 265) because inappropriate use has caused fatalities. The following 24-hour doses of morphine by mouth are considered to be approximately equivalent to the fentanyl patches shown:

<table>
<thead>
<tr>
<th>Morphine salt 45 mg daily</th>
<th>fentanyl '12' patch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine salt 90 mg daily</td>
<td>fentanyl '25' patch</td>
</tr>
<tr>
<td>Morphine salt 180 mg daily</td>
<td>fentanyl '50' patch</td>
</tr>
<tr>
<td>Morphine salt 270 mg daily</td>
<td>fentanyl '75' patch</td>
</tr>
<tr>
<td>Morphine salt 360 mg daily</td>
<td>fentanyl '100' patch</td>
</tr>
</tbody>
</table>

Morphine (as oral solution or standard formulation tablets) is given for breakthrough pain.

**Gastro-intestinal pain** The pain of bowel colic may be reduced by loperamide 2–4 mg 4 times daily. Hyoscine hydrobromide (section 4.6) may also be helpful, given sublingually at a dose of 300 micrograms 3 times daily as Kwells® tablets. For the dose by subcutaneous infusion, see p. 23.

Gastric distension pain due to pressure on the stomach may be helped by a preparation incorporating an antacid with an antiflatulent (section 1.1.1) and a prokinetic such as domperidone 10 mg 3 times daily before meals.

**Muscle spasm** The pain of muscle spasm can be helped by a muscle relaxant such as diazepam 5–10 mg daily or baci lene 5–10 mg 3 times daily.

**Neuropathic pain** Patients with neuropathic pain (section 4.7.3) may benefit from a trial of a tricyclic antidepressant for several weeks. An anticonvulsant may be added or substituted if pain persists; gabapentin and pregabalin (both section 4.8.1) are licensed for neuropathic pain. Ketamine is sometimes used under specialist supervision for neuropathic pain that responds poorly to opioid analgesics.

Pain due to nerve compression may be reduced by a corticosteroid such as dexamethasone 6 mg daily, which reduces oedema around the tumour, thus reducing compression.

**Nerve blocks** can be considered when pain is localised to a specific area. **Transcutaneous electrical nerve stimulation** (TENS) may also help.

### Miscellaneous conditions

**Anorexia** Anorexia may be helped by prednisolone 15–30 mg daily or dexamethasone 2–4 mg daily.

**Bowel colic and excessive respiratory secretions** Bowel colic and excessive respiratory secretions may be reduced by a subcutaneous injection of hyoscine hydrobromide 400 micrograms, hyoscine butylbromide 20 mg, or glycopyrronium 200 micrograms. These antimuscarinics are generally given every 4 hours when required, but hourly use is occasionally necessary, particularly in excessive respiratory secretions. If symptoms persist, they can be given regularly via a continuous infusion device, see p. 23. Care is required to avoid the discomfort of dry mouth.

**Capillary bleeding** Capillary bleeding can be treated with tranexamic acid (section 2.11) by mouth; treatment is usually discontinued one week after the bleeding has stopped, or, if necessary, it can be continued at a reduced dose. Alternatively, gauze soaked in tranexamic acid 100 mg/mL or adrenaline (epinephrine) solution 1 mg/mL (1 in 1000) can be applied to the affected area. Vitamin K may be useful for the treatment and prevention of bleeding associated with prolonged clotting in liver disease. In severe chronic cholestasis, absorption of vitamin K may be impaired; either parenteral or water-soluble oral vitamin K should be considered (section 9.6.6).
Constipation
Constipation is a very common cause of distress and is almost invariable after administration of an opioid analgesic. It should be prevented if possible by the regular administration of laxatives; a faecal softener with a peristaltic stimulant (e.g. co-danthramer) or lactulose solution with a senna preparation should be used (section 1.6.2 and section 1.6.3). Methylnaltrexone (section 1.6.6) is licensed for the treatment of opioid-induced constipation.

Convulsions
Patients with cerebral tumours or uraemia may be susceptible to convulsions. Prophylactic treatment with phenytoin or carbamazepine (section 4.8.1) should be considered. When oral medication is no longer possible, diazepam as suppositories 10–20 mg every 4 to 8 hours, or phenobarbital by injection 50–200 mg twice daily is continued as prophylaxis. For the use of midazolam by subcutaneous infusion using a continuous infusion device, see below.

Dry mouth
Dry mouth may be relieved by good mouth care and measures such as chewing sugar-free gum, sucking ice or pineapple chunks, or the use of artificial saliva (section 12.3.5); dry mouth associated with candidiasis can be treated by oral preparations of nystatin or micronazole (section 12.3.2); alternatively, fluconazole can be given by mouth (section 5.2.1). Dry mouth may be caused by certain medications including opioids, antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiemetics; if possible, an alternative preparation should be considered.

Dysphagia
A corticosteroid such as dexamethasone 8 mg daily may help, temporarily, if there is an obstruction due to tumour. See also Dry Mouth, above.

Dyspnoea
Breathlessness at rest may be relieved by regular oral morphine in carefully titrated doses, starting at 5 mg every 4 hours. Diazepam 5–10 mg daily may be helpful for dryness associated with anxiety. A corticosteroid, such as dexamethasone 4–8 mg daily, may also be helpful if there is bronchospasim or partial obstruction.

Fungating tumours
Fungating tumours can be treated by regular dressing and antibacterial drugs; systemic treatment with metronidazole (section 5.1.1) is often required to reduce malodour but topical metronidazole can be given by mouth (section 5.2.1). Dry mouth may be alleviated by antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiemetics; if possible, an alternative preparation should be considered.

Hiccup
Hiccup due to gastric distension may be helped by moist inhalations or by regular administration of oral morphine in an initial dose of 5 mg every 4 hours. Methadone linctus should be avoided because it has a long duration of action and tends to accumulate.

Nausea and vomiting
Nausea and vomiting are common in patients with advanced cancer. Ideally, the cause should be determined before treatment with an antiemetic (section 4.6) is started.

Nausea and vomiting may occur with opioid therapy particularly in the initial stages but can be prevented by giving an antiemetic such as haloperidol or metoclopramide. An antiemetic is usually necessary only for the first 4 or 5 days and therefore combined preparations containing an opioid with an antiemetic are not recommended because they lead to unnecessary antiemetic therapy (and associated side-effects when used long-term).

Metoclopramide has a prokinetic action and is used in a dose of 10 mg 3 times daily by mouth for nausea and vomiting associated with gastritis, gastric stasis, and functional bowel obstruction. Drugs with antimuscarinic effects antagonise prokinetic drugs and, if possible, should not be used concurrently.

Haloperidol is used by mouth in an initial dose of 1.5 mg once or twice daily (can be increased if necessary to 5–10 mg daily in divided doses) for most metabolic causes of vomiting (e.g. hypercalcaemia, renal failure). Cyclizine is given in a dose of 50 mg up to 3 times daily by mouth. It is used for nausea and vomiting due to mechanical bowel obstruction, raised intracranial pressure, and motion sickness.

Antiemetic therapy should be reviewed every 24 hours; it may be necessary to substitute the antiemetic or to add another one.

Levomepromazine can be used if first-line antiemetics are inadequate; it is given by mouth in a dose of 6–50 mg daily (6-mg tablets available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) in 1–2 divided doses. For the dose by subcutaneous infusion, see p. 23. Dexamethasone 8–16 mg daily by mouth can be used as an adjunct.

For the administration of antiemetics by subcutaneous infusion using a continuous infusion device, see below.

For the treatment of nausea and vomiting associated with cancer chemotherapy, see section 8.1.

Pruritus
Pruritus, even when associated with obstructive jaundice, often responds to simple measures such as application of emollients (section 13.2.1). In the case of obstructive jaundice, further measures include administration of cholestyramine (section 1.9.2).

Raised intracranial pressure
Headache due to raised intracranial pressure often responds to a high dose of a corticosteroid, such as dexamethasone 16 mg daily for 4 to 5 days, subsequently reduced to 4–6 mg daily if possible; dexamethasone should be given before 6 p.m. to reduce the risk of insomnia.

Restlessness and confusion
Restlessness and confusion may require treatment with haloperidol 1–3 mg by mouth every 8 hours. Levomepromazine is also used occasionally for restlessness. For the dose by subcutaneous infusion using a continuous infusion device, see p. 23.
Continuous infusion devices

Although drugs can usually be administered by mouth to control the symptoms of advanced cancer, the parenteral route may sometimes be necessary. Repeated administration of intramuscular injections can be difficult in a cachectic patient. This has led to the use of portable continuous infusion devices, such as syringe drivers, to give a continuous subcutaneous infusion, which can provide good control of symptoms with little discomfort or inconvenience to the patient.

Syringe driver rate settings

Staff using syringe drivers should be adequately trained and different rate settings should be clearly identified and differentiated; incorrect use of syringe drivers is a common cause of medication errors.

Indications for the parenteral route are:

1. the patient is unable to take medicines by mouth owing to nausea and vomiting, dysphagia, severe weakness, or coma;
2. there is malignant bowel obstruction in patients for whom further surgery is inappropriate (avoiding the need for an intravenous infusion or for insertion of a nasogastric tube);
3. occasionally when the patient does not wish to take regular medication by mouth.

Bowel colic and excessive respiratory secretions

Hyoscine hydrobromide effectively reduces respiratory secretions and is sedative (but occasionally causes paradoxical agitation); it is given in a subcutaneous infusion dose of 1.2–2.4 mg/24 hours.

Hyoscine butylbromide is used for bowel colic and for excessive respiratory secretions, and is less sedative than hyoscine hydrobromide. Hyoscine butylbromide is given in a subcutaneous infusion dose of 60–300 mg/24 hours for bowel colic and 20–120 mg/24 hours for excessive respiratory secretions (important: these doses of hyoscine butylbromide must not be confused with the much lower dose of hyoscine hydrobromide, above).

Glycopyrronium 0.6–1.2 mg/24 hours by subcutaneous infusion may also be used.

Convolusions

If a patient has previously been receiving an antiepileptic drug or has a primary or secondary cerebral tumour or is at risk of convulsion (e.g. owing to uraemia) antiepileptic medication should not be stopped. Midazolam is the benzodiazepine antiepileptic of choice for continuous subcutaneous infusion, and it is given initially in a dose of 20–40 mg/24 hours.

Nausea and vomiting

Haloperidol is given in a subcutaneous infusion dose of 2.5–10 mg/24 hours. Levomepromazine is given in a subcutaneous infusion dose of 5–25 mg/24 hours but sedation can limit the dose.

Cyclizine is particularly likely to precipitate if mixed with diamorphine or other drugs (see under Mixing and compatibility, below); it is given in a subcutaneous infusion dose of 30–100 mg/24 hours.

Metoclopramide can cause skin reactions; it is given in a subcutaneous infusion dose of 30–100 mg/24 hours.

Octreotide (section 8.3.4.3), which stimulates water and electrolyte absorption and inhibits water secretion in the small bowel, can be used by subcutaneous infusion in a dose of 250–500 micrograms/24 hours to reduce intestinal secretions and to reduce vomiting due to bowel obstruction. Doses of 750 micrograms/24 hours, and occasionally higher, are sometimes required.

Pain control

Diamorphine is the preferred opioid since its high solubility permits a large dose to be given in a small volume (see under Mixing and compatibility, below). The table on p. 24 shows approximate equivalent doses of morphine and diamorphine.

Restlessness and confusion

Haloperidol has little sedative effect; it is given in a subcutaneous infusion dose of 5–15 mg/24 hours.

Levomepromazine has a sedative effect; it is given in a subcutaneous infusion dose of 12.5–200 mg/24 hours. Midazolam is a sedative and an antiepileptic that may be used in addition to an antipsychotic drug in a very restless patient; it is given in a subcutaneous infusion dose of 20–100 mg/24 hours.

Mixing and compatibility

The general principle that injections should be given into separate sites (and should not be mixed) does not apply to the use of syringe drivers in palliative care. Provided that there is evidence of compatibility, selected injections can be mixed in syringe drivers. Not all types of medication can be used in a subcutaneous infusion. In particular, chlorpromazine, prochlorperazine, and diazepam are contra-indicated as they cause skin reactions at the injection site; to a lesser extent cyclizine and levomepromazine also sometimes cause local irritation.

In theory injections dissolved in water for injections are more likely to be associated with pain (possibly owing to their hypotonicity). The use of physiological saline (sodium chloride 0.9%) however increases the likelihood of precipitation when more than one drug is used; moreover subcutaneous infusion rates are slow (0.1–0.3 mL/hour) that pain is not usually a problem when water is used as a diluent.

Diamorphine can be given by subcutaneous infusion in a strength of up to 250 mg/mL; up to a strength of 40 mg/mL either water for injections or physiological saline (sodium chloride 0.9%) is a suitable diluent—above that strength only water for injections is used (to avoid precipitation).

The following can be mixed with diamorphine:

- Cyclizine
- Dexamethasone
- Haloperidol
- Hyoscine butylbromide
- Hyoscine hydrobromide
- Levomepromazine
- Metoclopramide
- Midazolam

1. Cyclizine may precipitate at concentrations above 10 mg/mL, or in the presence of sodium chloride 0.9% or as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.
2. Special care is needed to avoid precipitation of dexamethasone when preparing it.
3. Mixtures of haloperidol and diamorphine are likely to precipitate after 24 hours if haloperidol concentration is above 2 mg/mL.
4. Under some conditions infusions containing metoclopramide become discoloured; such solutions should be discarded.
Subcutaneous infusion solution should be monitored regularly both to check for precipitation (and discoloration) and to ensure that the infusion is running at the correct rate.

Problems encountered with syringe drivers. The following are problems that may be encountered with syringe drivers and the action that should be taken:

- if the subcutaneous infusion runs too quickly check the rate setting and the calculation;
- if the subcutaneous infusion runs too slowly check the start button, the battery, the syringe driver, the cannula, and make sure that the injection site is not inflamed;
- if there is an injection site reaction make sure that the site does not need to be changed—firmness or swelling at the site of injection is not in itself an indication for change, but pain or obvious inflammation is.

Equivalent doses of morphine sulphate and diamorphine hydrochloride given over 24 hours

These equivalences are approximate only and should be adjusted according to response

<table>
<thead>
<tr>
<th>MORPHINE</th>
<th>PARENTERAL DIAMORPHINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral morphine sulphate</td>
<td>Subcutaneous infusion of morphine sulphate</td>
</tr>
<tr>
<td>over 24 hours</td>
<td>over 24 hours</td>
</tr>
<tr>
<td>30 mg</td>
<td>15 mg</td>
</tr>
<tr>
<td>60 mg</td>
<td>30 mg</td>
</tr>
<tr>
<td>90 mg</td>
<td>45 mg</td>
</tr>
<tr>
<td>120 mg</td>
<td>60 mg</td>
</tr>
<tr>
<td>180 mg</td>
<td>90 mg</td>
</tr>
<tr>
<td>240 mg</td>
<td>120 mg</td>
</tr>
<tr>
<td>360 mg</td>
<td>180 mg</td>
</tr>
<tr>
<td>480 mg</td>
<td>240 mg</td>
</tr>
<tr>
<td>600 mg</td>
<td>300 mg</td>
</tr>
<tr>
<td>780 mg</td>
<td>390 mg</td>
</tr>
<tr>
<td>960 mg</td>
<td>480 mg</td>
</tr>
<tr>
<td>1200 mg</td>
<td>600 mg</td>
</tr>
</tbody>
</table>

If breakthrough pain occurs give a subcutaneous (preferable) or intramuscular injection equivalent to one-tenth to one-sixth of the total 24-hour subcutaneous infusion dose. It is kinder to give an intermittent bolus injection subcutaneously—absorption is smoother so that the risk of adverse effects at peak absorption is avoided (an even better method is to use a subcutaneous butterfly needle). To minimise the risk of infection no individual subcutaneous infusion solution should be used for longer than 24 hours.

Prescribing for the elderly

Old people, especially the very old, require special care and consideration from prescribers. Medicines for Older People, a component document of the National Service Framework for Older People, describes how to maximise the benefits of medicines and how to avoid excessive, inappropriate, or inadequate consumption of medicines by older people.

Appropriate prescribing. Elderly patients often receive multiple drugs for their multiple diseases. This greatly increases the risk of drug interactions as well as adverse reactions, and may affect compliance (see Taking medicines to best effect under General guidance). The balance of benefit and harm of some medicines may be altered in the elderly. Therefore, elderly patients’ medicines should be reviewed regularly and medicines which are not of benefit should be stopped.

Non-pharmacological measures may be more appropriate for symptoms such as headache, sleeplessness, and lightheadedness when associated with social stress as in widowhood, loneliness, and family dispersal. In some cases prophylactic drugs are inappropriate if they are likely to complicate existing treatment or introduce unnecessary side-effects, especially in elderly patients with poor prognosis or with poor overall health. However, elderly patients should not be denied medicines which may help them, such as anticoagulants or antithrombotic drugs for atrial fibrillation, antihypertensives, statins, and drugs for osteoporosis.

Form of medicine. Frail elderly patients may have difficulty swallowing tablets; if left in the mouth, ulceration may develop. They should always be encouraged to take their tablets or capsules with enough fluid, and whilst in an upright position to avoid the possibility of oesophageal ulceration. It can be helpful to discuss with the patient the possibility of taking the drug as a liquid if available.

Manifestations of ageing. In the very old, manifestations of normal ageing may be mistaken for disease and lead to inappropriate prescribing. In addition, age-related muscle weakness and difficulty in maintaining balance should not be confused with neurological disease. Disorders such as lightheadedness not associated with postural or postprandial hypotension are unlikely to be helped by drugs.

Sensitivity. The nervous system of elderly patients is more sensitive to many commonly used drugs, such as...
opioid analgesics, benzodiazepines, antipsychotics, and antiparkinsonian drugs, all of which must be used with caution. Similarly, other organs may also be more susceptible to the effects of drugs such as antihypertensives and NSAIDs.

Pharmacokinetics
Pharmacokinetic changes can markedly increase the tissue concentration of a drug in the elderly, especially in debilitated patients.

The most important effect of age is reduced renal clearance. Many aged patients thus excrete drugs slowly, and are highly susceptible to nephrotoxic drugs. Acute illness can lead to rapid reduction in renal clearance, especially if accompanied by dehydration. Hence, a patient stabilised on a drug with a narrow margin between the therapeutic and the toxic dose (e.g. digoxin) can rapidly develop adverse effects in the aftermath of a myocardial infarction or a respiratory-tract infection. The hepatic metabolism of lipid soluble drugs is reduced in elderly patients because there is a reduction in liver volume. This is important for drugs with a narrow therapeutic window.

Adverse reactions
Adverse reactions often present in the elderly in a vague and non-specific fashion. Confusion is often the presenting symptom (caused by almost any of the commonly used drugs). Other common manifestations are constipation (with antimuscarinics and many tranquilisers) and postural hypotension and falls (with diuretics and many psychotropics).

Hypnotics Many hypnotics with long half-lives have serious hangover effects, including drowsiness, unsteady gait, slurred speech, and confusion. Hypnotics with short half-lives should be used but they too can present problems (section 4.1.1). Short courses of hypnotics are occasionally useful for helping a patient through an acute illness or some other crisis but every effort must be made to avoid dependence. Benzodiazepines impair balance, which can result in falls.

Diuretics Diuretics are overprescribed in old age and should not be used on a long-term basis to treat simple gravitational oedema which will usually respond to increased movement, raising the legs, and support stockings. A few days of diuretic treatment may speed the clearing of the oedema but it should never continue in perpetuity.

NSAIDs Bleeding associated with aspirin and other NSAIDs is more common in the elderly who are more likely to have a fatal or serious outcome. NSAIDs are also a special hazard in patients with cardiac disease or renal impairment which may again place older patients at particular risk.

Owing to the increased susceptibility of the elderly to the side-effects of NSAIDs the following recommendations are made:

- alternatively, a low-dose NSAID (e.g. ibuprofen up to 1.2 g daily) may be given;
- for pain relief when either drug is inadequate, paracetamol in a full dose plus a low-dose NSAID may be given;
- if necessary, the NSAID dose can be increased or an opioid analgesic given with paracetamol;
- do not give two NSAIDs at the same time.

For advice on prophylaxis of NSAID-induced peptic ulcers if continued NSAID treatment is necessary, see section 1.3.

Other drugs Other drugs which commonly cause adverse reactions are antiparkinsonian drugs, antihypertensives, psychotropics, and digoxin. The usual maintenance dose of digoxin in very old patients is 125 micrograms daily (62.5 micrograms in those with renal disease); lower doses are often inadequate but toxicity is common in those given 250 micrograms daily. Drug-induced blood disorders are much more common in the elderly. Therefore drugs with a tendency to cause bone marrow depression (e.g. co-trimoxazole, mianserin) should be avoided unless there is no acceptable alternative.

The elderly generally require a lower maintenance dose of warfarin than younger adults; once again, the outcome of bleeding tends to be more serious.

Guidelines
Always consider whether a drug is indicated at all.

Limit range It is a sensible policy to prescribe from a limited range of drugs and to be thoroughly familiar with their effects in the elderly.

Reduce dose Dosage should generally be substantially lower than for younger patients and it is common to start with about 50% of the adult dose. Some drugs (e.g. long-acting antidiabetic drugs such as glibenclamide) should be avoided altogether.

Review regularly Review repeat prescriptions regularly. In many patients it may be possible to stop some drugs, provided that clinical progress is monitored. It may be necessary to reduce the dose of some drugs as renal function declines.

Simplify regimens Elderly patients benefit from simple treatment regimens. Only drugs with a clear indication should be prescribed and whenever possible given once or twice daily. In particular, regimens which call for a confusing array of dosage intervals should be avoided.

Explain clearly Write full instructions on every prescription (including repeat prescriptions) so that containers can be properly labelled with full directions. Avoid imprecisions like ‘as directed’. Child-resistant containers may be unsuitable.

Repeats and disposal Instruct patients what to do when drugs run out, and also how to dispose of any that are no longer necessary. Try to prescribe matching quantities.

If these guidelines are followed most elderly people will cope adequately with their own medicines. If not then it is essential to enrol the help of a third party, usually a relative or a friend.
Prescribing in dental practice

The following is a list of topics of particular relevance to dental surgeons.

Advice on the drug management of dental and oral conditions has been integrated into the BNF. For ease of access, guidance on such conditions is usually identified by means of a relevant heading (e.g. Dental and Orofacial Pain) in the appropriate sections of the BNF.

General guidance
Prescribing by dental surgeons, p. 6
Oral side-effects of drugs, p. 13
Medical emergencies in dental practice, below
Medical problems in dental practice, p. 28

Drug management of dental and oral conditions
Dental and orofacial pain, p. 257
Neuropathic pain, p. 272
Non-opioid analgesics and compound analgesic preparations, p. 257
Opioid analgesics, p. 263
Non-steroidal anti-inflammatory drugs, p. 631

Oral infections
Bacterial infections, p. 321
Phenoxymethylpenicillin, p. 333
Broad-spectrum penicillins (amoxicillin and ampicillin), p. 336
Cephalosporins (cefalexin and cefradine), p. 341
Tetracyclines, p. 347
Macrolides (clarithromycin, erythromycin and azithromycin), p. 352
Clindamycin, p. 354
Metronidazole, p. 367
Pusidic acid, p. 735
Fungal infections, p. 695
Local treatment, p. 695
Systemic treatment, p. 373

Viral infections
Herpetic gingivostomatitis, local treatment, p. 696
Herpetic gingivostomatitis, systemic treatment, p. 392 and p. 696
Herpes labialis, p. 739

Anaesthetics, anxiolytics and hypnotics
Anaesthesia, sedation, and resuscitation in dental practice, p. 776
Hypnotics, p. 208
Peri-operative anxiolytics, p. 783
Local anaesthesia, p. 794

Oral ulceration and inflammation, p. 693
Mouthwashes, gargles and dentifrices, p. 697
Dry mouth, p. 698

Minerals
Fluorides, p. 613
Aromatic inhalations, p. 203
Nasal decongestants, p. 691

Dental Practitioners’ Formulary, p. 972
Changes to Dental Practitioners’ Formulary, p. 973

Medical emergencies in dental practice
This section provides guidelines on the management of the more common medical emergencies which may arise in dental practice. Dental surgeons and their staff should be familiar with standard resuscitation procedures, but in all circumstances it is advisable to summon medical assistance as soon as possible. For an algorithm of the procedure for cardiopulmonary resuscitation, see inside back cover.

The drugs referred to in this section include:
- Adrenaline Injection (Epinephrine Injection), adrenaline 1 in 1000, (adrenaline 1 mg/mL as acid tartrate), 1-mL amps
- Aspirin Dispersible Tablets 300 mg
- Glucagon Injection, glucagon (as hydrochloride), 1-unit vial (with solvent)
- Glucose (for administration by mouth)
- Glyceryl Trinitrate Spray
- Midazolam Buccal Liquid, midazolam 10 mg/mL or Midazolam Injection, midazolam (as hydrochloride) 2 mg/mL, 5-mL amps, or 5 mg/mL, 2-mL amps
- Oxygen
- Salbutamol Aerosol Inhalation, salbutamol 100 micrograms/metered inhalation

Adrenal insufficiency
Adrenal insufficiency may follow prolonged therapy with corticosteroids and can persist for years after stopping. A patient with adrenal insufficiency may become hypotensive under the stress of a dental visit (important: see also p. 444 for details of corticosteroid cover before dental surgical procedures under general anaesthesia).

Management
- Lay the patient flat
- Give oxygen (see section 3.6)
- Transfer patient urgently to hospital

Anaphylaxis
A severe allergic reaction may follow oral or parenteral administration of a drug. Anaphylactic reactions in dentistry may follow the administration of a drug or contact with substances such as latex in surgical gloves. In general, the more rapid the onset of the reaction the more profound it tends to be. Symptoms may develop within minutes and rapid treatment is essential.

Anaphylactic reactions may also be associated with additives and excipients in foods and medicines (see Excipients, p. 2). Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergenic fats or oils (including those for topical application, particularly if they are intended for use in the mouth or for application to the nasal mucosa).
Asthma

Patients with asthma may have an attack while at the dental surgery, and most attacks will respond to 2 puffs of the patient’s short-acting beta, agonist inhaler such as salbutamol 100 micrograms/puff. Further puffs are required if the patient does not respond rapidly. If the patient is unable to use the inhaler effectively, further puffs should be given through a large-volume spacer device (or, if not available, through a plastic or paper cup with a hole in the bottom for the inhaler mouthpiece). If the response remains unsatisfactory, or if further deterioration occurs, then the patient should be transferred urgently to hospital. Whilst awaiting transfer, oxygen may be administered (see section 3.6). Arrangements should be made to transfer the patient to hospital urgently.

For further details on the management of anaphylaxis including details of paediatric doses of adrenaline, see p. 197

Management

First-line treatment includes securing the airway, restoration of blood pressure (laying the patient flat and raising the feet, or in the recovery position if unconscious or nauseous and at risk of vomiting), and administration of adrenaline (epinephrine) injection (section 3.4.3). This is given intramuscularly in a dose of 0.5 mL adrenaline injection 1 in 1000; a dose of 0.3 mL adrenaline injection 1 in 1000 may be appropriate for immediate self-administration. The dose is repeated if necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function. Oxygen administration is also of primary importance (see section 3.6). Arrangements should be made to transfer the patient to hospital urgently.

For further details on the management of anaphylaxis including details of paediatric doses of adrenaline, see p. 197

Epileptic seizures

Patients with epilepsy must continue with their normal dosage of anticonvulsant drugs when attending for dental treatment. It is not uncommon for epileptic patients not to volunteer the information that they are epileptic but there should be little difficulty in recognising a tonic-clonic (grand mal) seizure.

Symptoms and signs

- There may be a brief warning (but variable)
- Sudden loss of consciousness, the patient becomes rigid, falls, may give a cry, and becomes cyanotic (tonic phase)
- After 30 seconds, there are jerking movements of the limbs; the tongue may be bitten (clonic phase)
- There may be frothing from mouth and urinary incontinence
- The seizure typically lasts a few minutes; the patient may then become flaccid but remain unconscious. After a variable time the patient regains consciousness but may remain confused for a while

Arrhythmias may lead to a sudden reduction in cardiac output with loss of consciousness. Medical assistance should be summoned. For advice on pacemaker interference, see also Pacemakers, p. 29.

The pain of myocardial infarction is similar to that of angina but generally more severe and more prolonged. For general advice see also Coronary Artery Disease on p. 29.

Symptoms and signs of myocardial infarction

- Progressive onset of severe, crushing pain across front of chest; pain may radiate towards the shoulder and down arm, or into neck and jaw
- Skin becomes pale and clammy
- Nausea and vomiting are common
- Pulse may be weak and blood pressure may fall
- Breathlessness

Initial management of myocardial infarction

Call immediately for medical assistance and an ambulance, as appropriate. Allow the patient to rest in the position that feels most comfortable; in the presence of breathlessness this is likely to be sitting position, whereas the syncopal patient should be laid flat; often an intermediate position (dictated by the patient) will be most appropriate. Oxygen may be administered (see section 3.6). Sublingual glyceryl trinitrate may relieve pain. Intramuscular injection of drugs should be avoided because absorption may be too slow (particularly when cardiac output is reduced) and pain relief is inadequate. Intramuscular injection also increases the risk of local bleeding into the muscle if the patient is given a thrombolytic drug.

Reassure the patient as much as possible to relieve further anxiety. If available, aspirin in a single dose of 300 mg should be given. A note (to say that aspirin has been given) should be sent with the patient to the hospital. For further details on the initial management of myocardial infarction, see p. 156.

If the patient collapses and loses consciousness attempt standard resuscitation measures. For an algorithm of the procedure for cardiopulmonary resuscitation, see inside back cover.

Cardiac emergencies

If there is a history of angina the patient will probably carry glyceryl trinitrate spray or tablets (or isosorbide dinitrate tablets) and should be allowed to use them. Hospital admission is not necessary if symptoms are mild and resolve rapidly with the patient’s own medication. See also Coronary Artery Disease on p. 29.
Prescribing in dental practice

Management
During a convulsion try to ensure that the patient is not at risk from injury but make no attempt to put anything in the mouth or between the teeth (in mistaken belief that this will protect the tongue). Give oxygen (section 3.6) to support respiration if necessary.

Do not attempt to restrain convulsive movements.

After convulsive movements have subsided place the patient in the coma (recovery) position and check the airway. After the convulsion the patient may be confused (‘post-ictal confusion’) and may need reassurance and sympathetically. The patient should not be sent home until fully recovered. Seek medical attention or transfer the patient to hospital if it was the first episode of epilepsy, or if the convulsion was atypical, prolonged (or repeated), or if injury occurred.

Medication should only be given if convulsive seizures are prolonged (convulsive movements lasting 5 minutes or longer) or repeated rapidly.

Either midazolam buccal liquid or midazolam injection solution can be given by the buccal route [unlicensed use] in a single dose of 10 mg. For further details on the management of status epilepticus, including details of paediatric doses of midazolam, see p. 296.

Focal seizures similarly need very little active management (in an automatism only a minimum amount of restraint should be applied to prevent injury). Again, the patient should be observed until post-ictal confusion has completely resolved.

Hypoglycaemia
Insulin-treated diabetic patients attending for dental treatment under local anaesthesia should inject insulin and eat meals as normal. If food is omitted the blood glucose will fall to an abnormally low level (hypoglycaemia). Patients can often recognise the symptoms themselves and this state responds to sugar in water or a few lumps of sugar. Children may not have such prominent changes but may appear unduly lethargic.

Symptoms and signs
- Shaking and trembling
- Sweating
- ‘Pins and needles’ in lips and tongue
- Hunger
- Palpitation
- Headache (occasionally)
- Double vision
- Difficulty in concentration
- Slurring of speech
- Confusion
- Change of behaviour; truculence
- Convulsions
- Unconsciousness

Management
Initially glucose 10–20 g is given by mouth either in liquid form or as granulated sugar or sugar lumps. Approximately 10 g of glucose is available from non-diet versions of Lucozade® Energy Original 55 mL, Coca-Cola® 100 mL, Ribena® Blackcurrant 18 mL (to be diluted), 2 teaspoons sugar, and also from 3 sugar lumps. If necessary this may be repeated in 10–15 minutes.

If glucose cannot be given by mouth, if it is ineffective, or if the hypoglycaemia causes unconsciousness, glucagon 1 mg (1 unit) should be given by intramuscular (or subcutaneous) injection; a child under 8 years or of body-weight under 25 kg should be given 500 micrograms. Once the patient regains consciousness oral glucose should be administered as above. If glucagon is ineffective or contra-indicated, the patient should be transferred urgently to hospital. The patient must also be admitted to hospital if hypoglycaemia is caused by an oral antidiabetic drug.

Syncope
Insufficient blood supply to the brain results in loss of consciousness. The commonest cause is a vasovagal attack or simple faint (syncope) due to emotional stress.

Symptoms and signs
- Patient feels faint
- Low blood pressure
- Pallor and sweating
- Yawning and slow pulse
- Nausea and vomiting
- Dilated pupils
- Muscular twitching

Management
- Lay the patient as flat as is reasonably comfortable and, in the absence of associated breathlessness, raise the legs to improve cerebral circulation
- Loosen any tight clothing around the neck
- Once consciousness is regained, give sugar in water or a cup of sweet tea

Other possible causes
Postural hypotension can be a consequence of rising abruptly or of standing upright for too long; antihypertensive drugs predispose to this. When rising, susceptible patients should take their time. Management is as for a vasovagal attack.

Under stressful circumstances, some patients hyperventilate. This gives rise to feelings of faintness but does not usually result in syncope. In most cases reassurance is all that is necessary; rebreathing from cupped hands or a bag may be helpful but calls for careful supervision.

Adrenal insufficiency or arrhythmias are other possible causes of syncope, see p. 26 and p. 29.

Medical problems in dental practice

Individuals presenting at the dental surgery may also suffer from an unrelated medical condition; this may require modification to the management of their dental condition. If the patient has systemic disease or is taking other medication, the matter may need to be discussed with the patient’s general practitioner or hospital consultant.

For advice on adrenal insufficiency, anaphylaxis, asthma, cardiac emergencies, epileptic seizures, hypoglycaemia and syncope see under Medical Emergencies in Dental Practice.

1. Proprietary products of quick-acting carbohydrate (e.g. GlucoGel®, Dextrogel®, Hypo-Fit®) are available on prescription for the patient to keep to hand in case of hypoglycaemia.
Allergy
Patients should be asked about any history of allergy; those with a history of atopic allergy (asthma, eczema, hay fever, etc.) are at special risk. Those with a history of a severe allergy or of anaphylactic reactions are at high risk—it is essential to confirm that they are not allergic to any medication, or to any dental materials or equipment (including latex gloves). See also Anaphylaxis on p. 26.

Arrhythmias
Patients, especially those who suffer from heart failure or who have sustained a myocardial infarction, may have irregular cardiac rhythm. Atrial fibrillation is a common arrhythmia even in patients with normal hearts and is of little concern except that dental surgeons should be aware that such patients may be receiving anticoagulant therapy. The patient’s medical practitioner should be asked whether any special precautions are necessary. Premedication (e.g. with temazepam) may be useful in some instances for very anxious patients.
See also Cardiac emergencies, p. 27 and Dental Anaesthesia, p. 794.

Cardiac prostheses
For an account of the risk of infective endocarditis in patients with prosthetic heart valves, see Infective Endocarditis, below. For advice on patients receiving anticoagulants, see Thromboembolic disease, below.

Coronary artery disease
Patients are vulnerable for at least 4 weeks following a myocardial infarction or following any sudden increase in the symptoms of angina. It would be advisable to check with the patient’s medical practitioner before commencing treatment. See also Cardiac Emergencies on p. 27.

Treatment with low-dose aspirin (75 mg daily), clopidogrel, or dipyridamole should not be stopped routinely nor should the dose be altered before dental procedures.

A Working Party of the British Society for Antimicrobial Chemotherapy has not recommended antibiotic prophylaxis for patients following coronary artery bypass surgery.

Cyanotic heart disease
Patients with cyanotic heart disease are at risk in the dental chair, particularly if they have pulmonary hypertension. In such patients a syncopal reaction increases the shunt away from the lungs, causing more hypoxia which worsens the syncopal reaction—a vicious circle that may prove fatal. The advice of the cardiologist should be sought on any patient with congenital cyanotic heart disease. Treatment in hospital is more appropriate for some patients with this condition.

Hypertension
Patients with hypertension are likely to be receiving antihypertensive drugs such as those described in section 2.5. Their blood pressure may fall dangerously low under general anaesthesia, see also under Dental Anaesthesia on p. 794.

Immunosuppression and indwelling intraperitoneal catheters
See Table 2, section 5.1

Infective endocarditis
While almost any dental procedure can cause bacteremia, there is no clear association with the development of infective endocarditis. Routine daily activities such as tooth brushing also produce a bacteremia and may present a greater risk of infective endocarditis than a single dental procedure.

Antibacterial prophylaxis and chlorhexidine mouthwash are not recommended for the prevention of endocarditis in patients undergoing dental procedures. Such prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

Reduction of oral bacteremia
Patients at risk of endocarditis should be advised to maintain the highest possible standards of oral hygiene in order to reduce the:
- need for dental extractions or other surgery;
- chances of severe bacteremia if dental surgery is needed;
- possibility of ‘spontaneous’ bacteremia.

Postoperative care
Patients at risk of endocarditis should be warned to report to the doctor or dental surgeon any unexplained illness that develops after dental treatment. Any infection in patients at risk of endocarditis should be investigated promptly and treated appropriately to reduce the risk of endocarditis.

Patients on anticoagulant therapy
For general advice on dental surgery in patients receiving oral anticoagulant therapy see Thromboembolic Disease, below.

Joint prostheses
See Table 2, section 5.1

Pacemakers
Pacemakers prevent asystole or severe bradycardia. Some ultrasonic scalers, electronic apex locators, electro-analgesic devices, and electrocautery devices interfere with the normal function of pacemakers (including shielded pacemakers) and should not be used. The manufacturer’s literature should be consulted whenever possible. If severe bradycardia occurs in a patient fitted with a pacemaker, electrical equipment should be switched off and the patient placed supine with the legs elevated. If the patient loses consciousness and the pulse remains slow or is absent, cardiopulmonary resuscitation (see inside back cover) may be needed. Call immediately for medical assistance and an ambulance, as appropriate.

1. Patients at risk of endocarditis include those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endoatralised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis.
Prescribing in dental practice

30


Thromboembolic disease

Patients receiving a heparin or an oral anticoagulant such as warfarin, acenocoumarol (nicoumalone), phenindione, dabigatran etexilate, or rivaroxaban may be liable to excessive bleeding after extraction of teeth or other dental surgery. Often dental surgery can be delayed until the anticoagulant therapy has been completed.

For a patient requiring long-term therapy with warfarin, the patient’s medical practitioner should be consulted and the International Normalised Ratio (INR) should be assessed 72 hours before the dental procedure. This allows sufficient time for dose modification if necessary. In those with an unstable INR (including those who require weekly monitoring of their INR, or those who have had some INR measurements greater than 4.0 in the last 2 months), the INR should be assessed within 24 hours of the dental procedure. Patients requiring minor dental procedures (including extractions) who have an INR below 4.0 may continue warfarin without dose adjustment. There is no need to check the INR for a patient requiring a non-invasive dental procedure.

If possible, a single extraction should be done first; if this goes well further teeth may be extracted at subsequent visits (two or three at a time). Measures should be taken to minimise bleeding during and after the procedure. This includes the use of sutures and a haemostatic such as oxidised cellulose, collagen sponge or resorbable gelatin sponge. Scaling and root planing should initially be restricted to a limited area to assess the potential for bleeding.

For a patient on long-term warfarin, the advice of the clinician responsible for the patient’s anticoagulation should be sought if:

- the INR is unstable, or if the INR is greater than 4.0;
- the patient has thrombocytoenia, haemophilia, or other disorders of haemostasis, or suffers from liver impairment, alcoholism, or renal failure;
- the patient is receiving antiplatelet drugs, cytotoxic drugs or radiotherapy.

Intramuscular injections are contra-indicated in patients on anticoagulant therapy, and in those with any disorder of haemostasis.

A local anaesthetic containing a vasoconstrictor should be given by infiltration, or by intraligamentary or mental nerve injection if possible. If regional nerve blocks cannot be avoided the local anaesthetic should be given cautiously using an aspirating syringe.

Drugs which have potentially serious interactions with anticoagulants include aspirin and other NSAIDs, carbamazepine, imidazole and triazole antifungals (including miconazole), erythromycin, clarithromycin, and metronidazole; for details of these and other interactions with anticoagulants, see Appendix 1 (dabigatran etexilate, heparins, phenindione, rivaroxaban, and coumarins). Although studies have failed to demonstrate an interaction, common experience in anticoagulant clinics is that the INR can be altered following a course of an oral broad-spectrum antibiotic, such as ampicillin or amoxicillin.

Information on the treatment of patients who take anticoagulants is available at www.npsa.nhs.uk/patientsafety/alerts-and-directives/alerts/anticoagulant

Liver disease

Liver disease may alter the response to drugs and drug prescribing should be kept to a minimum in patients with severe liver disease. Problems are likely mainly in patients with jaundice, ascites, or evidence of encephalopathy.

For guidance on prescribing for patients with hepatic impairment, see p. 17. Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

Renal impairment

The use of drugs in patients with reduced renal function can give rise to many problems. Many of these problems can be avoided by reducing the dose or by using alternative drugs.

Special care is required in renal transplantation and immunosuppressed patients; if necessary such patients should be referred to specialists.

For guidance on prescribing in patients with renal impairment, see p. 17. Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.

Pregnancy

Drugs taken during pregnancy can be harmful to the fetus and should be prescribed only if the expected benefit to the mother is thought to be greater than the risk to the fetus; all drugs should be avoided if possible during the first trimester.

For guidance on prescribing in pregnancy, see p. 19. Where care is needed when prescribing in pregnancy, this is indicated under the relevant drug in the BNF.

Breast-feeding

Some drugs taken by the mother whilst breast-feeding can be transferred to the breast milk, and may affect the infant.

For guidance on prescribing in breast-feeding, see p. 19. Where care is needed when prescribing in breast-feeding, this is indicated under the relevant drug in the BNF.
UK Anti-Doping advises that athletes are personally responsible should a prohibited substance be detected in their body. An advice card listing examples of permitted and prohibited substances is available from:

UK Anti-Doping
Oceanic House
1a Cockspur Street
London SW1Y 5BG
Tel: (020) 7766 7350
information@ukad.org.uk
www.ukad.org.uk

A similar card detailing classes of drugs and doping methods prohibited in football is available from the Football Association. This contains information specific to the Football Association Doping Control Regulations including the Football Association’s policy on social drugs. Further information is available at www.thefa.com.

**General Medical Council’s advice**

Doctors who prescribe or collude in the provision of drugs or treatment with the intention of improperly enhancing an individual’s performance in sport contravene the GMC’s guidance, and such actions would usually raise a question of a doctor’s continued registration. This does not preclude the provision of any care or treatment where the doctor’s intention is to protect or improve the patient’s health.
Emergency treatment of poisoning

These notes provide only an overview of the treatment of poisoning, and it is strongly recommended that either TOXBASE or the UK National Poisons Information Service (see below) be consulted when there is doubt about the degree of risk or about management.

Hospital admission  Patients who have features of poisoning should generally be admitted to hospital. Patients who have taken poisons with delayed action should also be admitted, even if they appear well. Delayed-action poisons include aspirin, iron, paracetamol, tricyclic antidepressants, and co-phenotrope (diphenoxylate with atropine, Lomotil®); the effects of modified-release preparations are also delayed. A note of all relevant information, including what treatment has been given, should accompany the patient to hospital.

Further information and advice

TOXBASE, the primary clinical toxicology database of the National Poisons Information Service, is available on the internet to registered users at www.toxbase.org (a backup site is available at www.toxbasebackup.org if the main site cannot be accessed). It provides information about routine diagnosis, treatment, and management of patients exposed to drugs, household products, and industrial and agricultural chemicals.

Advice on laboratory analytical services can be obtained from TOXBASE or from the National Poisons Information Service.

Help with identifying capsules or tablets may be available from a regional medicines information centre (see inside front cover) or (out of hours) from the National Poisons Information Service. Specialist information and advice on the treatment of poisoning is available day and night from the UK National Poisons Information Service on the following number:

Tel: 0844 892 0111

National Poisons Information Service should be consulted when there is doubt about any aspect of suspected poisoning.

Respiration

Respiration is often impaired in unconscious patients. An obstructed airway requires immediate attention. In the absence of trauma, the airway should be opened with simple measures such as chin lift or jaw thrust. An oropharyngeal or nasopharyngeal airway may be useful in patients with reduced consciousness to prevent obstruction, provided ventilation is adequate. Intubation and ventilation should be considered in patients whose airway cannot be protected or who have respiratory acidosis because of inadequate ventilation; such patients should be monitored in a critical care area.

Most poisons that impair consciousness also depress respiration. Assisted ventilation (either mouth-to-mouth or using a bag-valve-mask device) may be needed. Oxygen is not a substitute for adequate ventilation, although it should be given in the highest concentration possible in poisoning with carbon monoxide and irritant gases.

Blood pressure

Hypotension is common in severe poisoning with central nervous system depressants. A systolic blood pressure of less than 70 mmHg may lead to irreversible brain damage or renal tubular necrosis. Hypotension should be corrected initially by tilting down the head of the bed and administration of either sodium chloride intravenous infusion or a colloidal infusion. Vasoconstrictor sympathomimetics (section 2.7.2) are rarely required and their use may be discussed with the National Poisons Information Service.

Fluid depletion without hypotension is common after prolonged coma and after aspirin poisoning due to vomiting, sweating, and hyperpnoea.

Hypertension, often transient, occurs less frequently than hypotension in poisoning; it may be associated with sympathomimetic drugs such as amfetamines, phenycyclidine, and cocaine.

Heart

Cardiac conduction defects and arrhythmias can occur in acute poisoning, notably with tricyclic antidepressants, some antipsychotics, and some antihistamines. Arrhythmias often respond to correction of underlying hypoxia, acidosis, or other biochemical abnormalities, but ventricular arrhythmias that cause serious hypotension require treatment (section 2.3.1). If the QT interval is prolonged, specialist advice should be sought because the use of some anti-arrhythmic drugs may be inappropriate. Supraventricular arrhythmias are seldom life-threatening and drug treatment is best withheld until the patient reaches hospital.
Emergency treatment of poisoning

Body temperature

Hypothermia may develop in patients of any age who have been deeply unconscious for some hours, particularly following overdose with barbiturates or phenothiazines. It may be missed unless core temperature is measured using a low-reading rectal thermometer or by some other means. Hypothermia should be managed by prevention of further heat loss and appropriate re-warming as clinically indicated.

Hypothermia can develop in patients taking CNS stimulants; children and the elderly are also at risk when taking therapeutic doses of drugs with antimuscarinic properties. Hyperthermia is initially managed by removing all unnecessary clothing and using a fan. Sponging with tepid water will promote evaporation. Advice should be sought from the National Poisons Information Service on the management of severe hyperthermia resulting from conditions such as the serotonin syndrome.

Both hypothermia and hyperthermia require urgent hospitalisation for assessment and supportive treatment.

Convulsions

Single short-lived convulsions do not require treatment. If convulsions are protracted or recur frequently, lorazepam 4 mg or diazepam (preferably as emulsion) 10 mg should be given by slow intravenous injection into a large vein (section 4.8.2). Benzodiazepines should not be given by the intramuscular route for convulsions. If the intravenous route is not readily available, diazepam can be administered as a rectal solution or midazolam [unlicensed use] can be given by the buccal route (section 4.8.2).

Removal and elimination

Prevention of absorption

Given by mouth, activated charcoal can bind many poisons in the gastro-intestinal system, thereby reducing their absorption. The sooner it is given the more effective it is, but it may still be effective up to 1 hour after ingestion of the poison—longer in the case of modified-release preparations or of drugs with antimuscarinic (anticholinergic) properties. It is particularly useful for the prevention of absorption of poisons that are toxic in small amounts, such as antidepressants.

For the use of charcoal in active elimination techniques, see below.

Active elimination techniques

Repeated doses of activated charcoal by mouth enhance the elimination of some drugs after they have been absorbed; repeated doses are given after overdosage with:

- Carbamazepine
- Dapsone
- Phenobarbital
- Quinine
- Theophylline

The usual dose of activated charcoal in adults and children over 12 years of age is 50 g initially then 50 g every 4 hours. Vomiting should be treated (e.g. with an antiemetic drug) since it may reduce the efficacy of charcoal treatment. In cases of intolerance, the dose may be reduced and the frequency increased (e.g. 25 g every 2 hours or 12.5 g every hour) but this may compromise efficacy.

In children under 12 years of age, activated charcoal is given in a dose of 1 g/kg (max. 50 g) every 4 hours; the dose may be reduced and the frequency increased if not tolerated.

Other techniques intended to enhance the elimination of poisons after absorption are only practicable in hospital and are only suitable for a small number of severely poisoned patients. Moreover, they only apply to a limited number of poisons. Examples include:

- haemodialysis for ethylene glycol, lithium, methanol, phenobarbital, salicylates, and sodium valproate;
- alkalinisation of the urine for salicylates.

Removal from the gastro-intestinal tract

Gastric lavage is rarely required; for substances that cannot be removed effectively by other means (e.g. iron), it should be considered only if a life-threatening amount has been ingested within the previous hour. It should be carried out only if the airway can be protected adequately. Gastric lavage is contra-indicated if a corrosive substance or a petroleum distillate has been ingested, but it may occasionally be considered in patients who have ingested drugs that are not adsorbed by charcoal, such as iron or lithium. Induction of emesis (e.g. with ipecacuanha) is not recommended because there is no evidence that it affects absorption and it may increase the risk of aspiration.

Whole bowel irrigation (by means of a bowel cleansing preparation) has been used in poisoning with certain modified-release or enteric-coated formulations, in severe poisoning with iron and lithium salts, and if illicit drugs are carried in the gastro-intestinal tract (‘body-packing’). However, it is not clear that the procedure improves outcome and advice should be sought from the National Poisons Information Service.

**CHARGOAL, ACTIVATED**

**Indications** reduction of absorption of poisons in the gastro-intestinal system; see also active elimination techniques, above

**Cautions** drowsy or comatose patient (risk of aspiration, ensure airway protected); reduced gastro-intestinal motility (risk of obstruction); not for poisoning with petroleum distillates, corrosive substances, alcohols, malathion, and metal salts including iron and lithium salts

**Side-effects** black stools

**Dose**

- Reduction of absorption. ADULT and CHILD over 12 years, 50 g; CHILD under 12 years, 1 g/kg (max. 50 g)
- Active elimination, see notes above

**Note** Activated charcoal doses in BNF may differ from those in product literature. Suspension or reconstituted powder may be mixed with soft drinks (e.g. caffeine-free diet cola) or fruit juices to mask the taste

**Actidose-Aqua® Advance** (Alliance)

**Oral suspension**, activated charcoal 1.04 g/5 mL, net price 50-g pack (240 mL) = £8.69
Emergency treatment of poisoning

Aspirin

The main features of salicylate poisoning are analgesics (non-opioid) is measured and glucose given if indicated. Maintaining a clear airway and measures to reduce the risk of aspiration of gastric contents. The blood glucose measured and glucose given if indicated.

Plasma-potassium concentration should be corrected if paracetamol in excess of 150 mg/kg or 12 g, whichever is the smaller (or in excess of 75 mg/kg for those considered to be at high risk; see below), is thought to have been ingested within the previous hour. Acetylcysteine protects the liver if infused up to, and possibly beyond, 24 hours of ingesting paracetamol. It is most effective if given within 8 hours of ingestion, after which effectiveness declines. In patients who present 8–36 hours after a potentially toxic ingestion, acetylcysteine treatment should commence immediately even if plasma-paracetamol concentrations are not yet available; if more than 24 hours have elapsed since ingestion advice should be sought from the National Poisons Information Service. Giving acetylcysteine by mouth [unlicensed route] is an alternative if intravenous access is not possible—contact the National Poisons Information Service for advice on risk assessment and management.

Paracetamol

In cases of intravenous paracetamol poisoning contact the National Poisons Information Service for advice on risk assessment and management.

Specific drugs

Alcohol

Acute intoxication with alcohol (ethanol) is common in adults but also occurs in children. The features include ataxia, dysarthria, nystagmus, and drowsiness, which may progress to coma, with hypotension and acidosis. Aspiration of vomit is a special hazard and hypoglycaemia may occur in children and some adults. Patients are managed supportively, with particular attention to maintaining a clear airway and measures to reduce the risk of aspiration of gastric contents. The blood glucose measured and glucose given if indicated.

Anaesthesia are an important cause of death, additional features are may complicate alkalisation of the urine. Haemodialysis is the treatment of choice for severe salicylate poisoning and should be considered when the plasma-salicylate concentration exceeds 700 mg/litre (5.1 mmol/litre) or in the presence of severe metabolic acidosis.

NSAIDs

Mefenamic acid has important consequences in overdose because it can cause convulsions, which if prolonged or recurrent require treatment, see p. 33. Overdose with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. Activated charcoal followed by symptomatic measures are indicated if more than 400 mg/kg has been ingested within the preceding hour.

Carbomix® (Beacon)

Powder, activated charcoal, net price 25-g pack = £8.50, 50-g pack = £11.90

Charcodote® (TEVA UK)

Oral suspension, activated charcoal 1 g/5 mL, net price 50-g pack = £11.88

The National Poisons Information Service (Tel: 0844 892 0111) will provide specialist advice on all aspects of poisoning day and night
Patients at high-risk of liver damage include those:
- taking liver enzyme-inducing drugs (e.g. carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, alcohol, St John’s wort);
- who are malnourished (e.g. in anorexia or bulimia, cystic fibrosis, hepatitis C, in alcoholism, or those who are HIV-positive);
- who have not eaten for a few days.

These patients can develop toxicity at lower plasma-paracetamol concentration and should be treated if the concentration is above the high-risk treatment line (which joins plots that are at 50% of the plasma-paracetamol concentrations of the normal treatment line).

The prognostic accuracy of plasma-paracetamol concentration taken after 15 hours is uncertain, but a concentration above the relevant treatment line should be regarded as carrying a serious risk of liver damage.

Patients whose plasma-paracetamol concentrations are above the normal treatment line should be treated with acetylcysteine by intravenous infusion (or, if acetylcysteine cannot be used, with methionine by mouth, provided the overdose has been taken within 10–12 hours and the patient is not vomiting).

Patients at high-risk of liver damage include those:
- taking liver enzyme-inducing drugs (e.g. carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, alcohol, St John’s wort);
- who are malnourished (e.g. in anorexia or bulimia, cystic fibrosis, hepatitis C, in alcoholism, or those who are HIV-positive);
- who have not eaten for a few days.

These patients should be treated if their plasma-paracetamol concentration is above the high-risk treatment line.

The prognostic accuracy after 15 hours is uncertain but a plasma-paracetamol concentration above the relevant treatment line should be regarded as carrying a serious risk of liver damage.

Graph reproduced courtesy of University of Wales College of Medicine Therapeutics and Toxicology Centre

Patients at high-risk of liver damage include those:
- taking liver enzyme-inducing drugs (e.g. carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, alcohol and St John’s wort);
- who are malnourished (e.g. in anorexia or bulimia, cystic fibrosis, hepatitis C, in alcoholism, or those who are HIV-positive);
- who have not eaten for a few days.

These patients can develop toxicity at lower plasma-paracetamol concentration and should be treated if the concentration is above the high-risk treatment line (which joins plots that are at 50% of the plasma-paracetamol concentrations of the normal treatment line).

The prognostic accuracy of plasma-paracetamol concentration taken after 15 hours is uncertain, but a concentration above the relevant treatment line should be regarded as carrying a serious risk of liver damage.
Emergency treatment of poisoning

The plasma-paracetamol concentration may be difficult to interpret when paracetamol has been ingested over several hours. If there is doubt about timing or the need for treatment then the patient should be treated with an antidote.

**AcETYLCYSTEINE**

**Indications** paracetamol overdosage, see notes above

**Cautions** asthma (see side-effects below but do not delay acetylcysteine treatment)

**Side-effects** hypersensitivity-like reactions managed by reducing infusion rate or suspending until reaction settled (rash also managed by giving antihistamine; acute asthma managed by giving nebulised short-acting beta, agonist)—contact the National Poisons Information Service if reaction severe

**Dose**

- By intravenous infusion, ADULT and CHILD, initially 150 mg/kg (max. 16.5 g) over 15 minutes, then 50 mg/kg (max. 5.5 g) over 4 hours then 100 mg/kg (max. 11 g) over 16 hours

**Administration** Dilute requisite dose in glucose intravenous infusion 5% as follows: ADULT and CHILD over 12 years, initially 200 mL given over 15 minutes, then 500 mL over 4 hours, then 1 litre over 16 hours; CHILD under 12 years, body-weight over 20 kg, initially 100 mL given over 15 minutes, then 250 mL over 4 hours, then 500 mL over 16 hours; CHILD body-weight under 20 kg, initially 3 mL/kg given over 15 minutes, then 7 mL/kg over 4 hours, then 14 mL/kg over 16 hours

**Note** Manufacturer also recommends other infusion fluids, but glucose 5% is preferable

**Acetylcysteine** (Non-proprietary) [PH]

**Injection**, acetylcysteine 200 mg/mL, net price 10-mL amp = £1.96

**Parvolex** (UCB Pharma) [PH]

**Injection**, acetylcysteine 200 mg/mL, net price 10-mL amp = £2.25

**METHIONINE**

**Indications** paracetamol overdosage, see notes above

**Hepatic impairment** may precipitate coma

**Side-effects** nausea, vomiting, drowsiness, irritability

**Dose**

- ADULT and CHILD over 6 years initially 2.5 g, followed by 3 further doses of 2.5 g every 4 hours; CHILD under 6 years initially 1 g, followed by 3 further doses of 1 g every 4 hours

**Methionine** (Pharma Nord)

Tablets, f/c, methionine 500 mg, net price 20-tab pack = £9.95

**With paracetamol (co-methiamol)**

Section 4.7.1

**Analgesics (opioid)**

Opioids (narcotic analgesics) cause coma, respiratory depression, and pinpoint pupils. The specific antidote naloxone is indicated if there is coma or bradypnoea. Since naloxone has a shorter duration of action than many opioids, close monitoring and repeated injections are necessary according to the respiratory rate and depth of coma. When repeated administration of naloxone is required, it can be given by continuous intravenous infusion instead and the rate of infusion adjusted according to vital signs. The effects of some opioids, such as buprenorphine, are only partially reversed by naloxone. Dextropropoxyphene and methadone have very long durations of action; patients may need to be monitored for long periods following large overdoses. Naloxone reverses the opioid effects of dextropropoxyphene; the long duration of action of dextropropoxyphene calls for prolonged monitoring and further doses of naloxone may be required. Norpropoxyphene, a metabolite of dextropropoxyphene, also has cardiotoxic effects which may require treatment with sodium bicarbonate, or magnesium sulphate, or both; arrhythmias may occur for up to 12 hours.

**Naloxone Hydrochloride**

**Indications** overdosage with opioids; reversal of opioid-induced respiratory depression and reversal of neonatal respiratory depression resulting from opioid administration to mother during labour (section 15.1.7)

**Cautions** physical dependence on opioids; cardiac irritability; naloxone is short-acting, see notes above

**Pregnancy** section 15.1.7

**Breast-feeding** section 15.1.7

**Dose**

- By intravenous injection, 0.4–2 mg; if no response repeat at intervals of 2–3 minutes to a max. of 10 mg (then review diagnosis); further doses may be required if respiratory function deteriorates; CHILD 10 micrograms/kg; if no response give subsequent dose of 100 micrograms/kg (then review diagnosis); further doses may be required if respiratory function deteriorates

- By subcutaneous or intramuscular injection, ADULT and CHILD dose as for intravenous injection but use only if intravenous route not feasible (onset of action slower)

- By continuous intravenous infusion using an infusion pump, rate adjusted according to response (initial rate may be set at 60% of initial intravenous injection dose (see above) and infused over 1 hour)

**Important** Doses used in acute opioid overdose may not be appropriate for the management of opioid-induced respiratory depression and sedation in those receiving palliative care and in chronic opioid use; see also section 15.1.7 for management of postoperative respiratory depression

1. Naloxone (Non-proprietary) [PH]

**Injection**, naloxone hydrochloride 20 micrograms/mL, net price 2-mL amp = £5.50; 400 micrograms/mL, 1-mL amp = £4.10; 1 mg/mL, 2-mL prefilled syringe = £8.36

2. Minijet® Naloxone (UCB Pharma) [PH]

**Injection**, naloxone hydrochloride 400 micrograms/mL, net price 1-mL disposable syringe = £20.40, 2-mL disposable syringe = £12.96, 5-mL disposable syringe = £12.68

1. **PH** restriction does not apply where administration is for saving life in emergency
Antidepressants

Tricyclic and related antidepressants Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. Metabolic acidosis may complicate severe poisoning; delirium with confusion, agitation, and visual and auditory hallucinations are common during recovery.

Assessment in hospital is strongly advised in case of poisoning by tricyclic and related antidepressants but symptomatic treatment can be given before transfer. Supportive measures to ensure a clear airway and adequate ventilation during transfer are mandatory. Intravenous lorazepam or intravenous diazepam (preferably in emulsion form) may be required to treat convulsions. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Although arrhythmias are worrying, some will respond to correction of hypoxia and acidosis. The use of anti-arrhythmic drugs is best avoided, but intravenous infusion of sodium bicarbonate can arrest arrhythmias or prevent them in those with an extended QRS duration. Diazepam given by mouth is usually adequate to sedate delirious patients but large doses may be required.

Selective serotonin re-uptake inhibitors (SSRIs) Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, nystagmus, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.

Management of SSRI poisoning is supportive. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Convulsions can be treated with lorazepam, diazepam, or buccal midazolam [unlicensed use] (see p. 33). Contact the National Poisons Information Service for the management of hyperthermia or the serotonin syndrome.

Antimalarials

Overdosage with quinine, chloroquine, or hydroxychloroquine is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

Calcium-channel blockers

Features of calcium-channel blocker poisoning include nausea, vomiting, dizziness, agitation, confusion, and coma in severe poisoning. Metabolic acidosis and hyperglycaemia may occur. Verapamil and diltiazem have a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole. The dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

Activated charcoal should be considered if the patient presents within 1 hour of overdosage with a calcium-channel blocker; repeated doses of activated charcoal are considered if a modified-release preparation is involved. In patients with significant features of poisoning, calcium chloride or calcium gluconate (section 9.5.1.1) is given by injection; atropine is given to correct symptomatic bradycardia. In severe cases, an insulin and glucose infusion may be required in the management of hypotension and myocardial failure. For the management of hypotension, the choice of inotropic sympathomimetic depends on whether hypotension is secondary to vasodilatation or to myocardial depression—advice should be sought from the National Poisons Information Service.

Hypnotics and anxiolytics

Benzzodiazepines Benzodiazepines taken alone cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression, and coma. Activated charcoal can be given within 1 hour of ingesting a significant quantity of benzodiazepine, provided the patient is awake and the airway is protected. Benzodiazepines potentiate the effects of other central nervous system depressants taken concomitantly. Use of the benzodiazepine antagonist flumazenil [unlicensed indication] can be hazardous, particularly in mixed overdoses involving tricyclic antidepressants or in benzodiazepine-dependent patients. Flumazenil may prevent the need for ventilation, particularly in patients with severe respiratory disorders; it should be used on expert advice only and not as a diagnostic test in patients with a reduced level of consciousness.

to another; propranolol overdosage in particular may cause coma and convulsions.

Acute massive overdosage must be managed in hospital and expert advice should be obtained. Maintenance of a clear airway and adequate ventilation is mandatory. An intravenous injection of atropine is required to treat bradycardia (3 mg for an adult, 40 micrograms/kg (max. 3 mg) for a child). Cardiogenic shock unresponsive to atropine is probably best treated with an intravenous injection of glucagon 2–10 mg (child 50–150 micrograms/kg, max. 10 mg [unlicensed indication and dose] in glucose 5% [with precautions to protect the airway in case of vomiting] followed by an intravenous infusion of 50 micrograms/kg/hour. If glucagon is not available, intravenous isoprenaline [available from 'special-order' manufacturers or specialist importing companies, see p. 988] is an alternative. A cardiac pacemaker can be used to increase the heart rate.
Iron salts

Iron poisoning in childhood is usually accidental. The symptoms are nausea, vomiting, abdominal pain, diarrhoea, haematemesis, and rectal bleeding. Hypotension and hepato cellular necrosis can occur later. Coma, shock, and metabolic acidosis indicate severe poisoning.

Advice should be sought from the National Poisons Information Service if a significant quantity of iron has been ingested within the previous hour.

Mortality is reduced by intensive and specific therapy with desferrioxamine, which chelates iron. The serum-iron concentration is measured as an emergency and intravenous desferrioxamine given to chelate absorbed iron in excess of the expected iron binding capacity. In severe toxicity intravenous desferrioxamine should be given immediately without waiting for the result of the serum-iron measurement.

DESFERRIOXAMINE MESILATE
(Dexferoxamine Mesilate)

Indications iron poisoning; chronic iron overload (section 9.1.3)
Cautions section 9.1.3
Renal impairment section 9.1.3
Pregnancy section 9.1.3
Breast-feeding section 9.1.3
Side-effects section 9.1.3
Dose
- By continuous intravenous infusion, ADULT and CHILD up to 15 mg/kg/hour, reduced after 4–6 hours; max. 80 mg/kg in 24 hours (in severe cases, higher doses on advice from the National Poisons Information Service)

Preparations Section 9.1.3

Lithium

Most cases of lithium intoxication occur as a complication of long-term therapy and are caused by reduced excretion of the drug because of a variety of factors including dehydration, deterioration of renal function, infections, and co-administration of diuretics or NSAIDs (or other drugs that interact). Acute deliberate overdoses may also occur with delayed onset of symptoms (12 hours or more) owing to slow entry of lithium into the tissues and continuing absorption from modified-release formulations.

The early clinical features are non-specific and may include apathy and restlessness which could be confused with mental changes arising from the patient’s depressive illness. Vomiting, diarrhoea, ataxia, weakness, dysarthria, muscle twitching, and tremor may follow. Severe poisoning is associated with convulsions, coma, renal failure, electrolyte imbalance, dehydration, and hypotension.

Therapeutic serum-lithium concentrations are within the range of 0.4–1 mmol/litre; concentrations in excess of 2 mmol/litre are usually associated with serious toxicity and such cases may need treatment with haemodialysis if neurological symptoms or renal failure are present. In acute overdosage much higher serum-lithium concentrations may be present without features of toxicity and all that is usually necessary is to take measures to increase urine output (e.g. by increasing fluid intake but avoiding diuretics). Otherwise, treatment is supportive with special regard to electrolyte balance, renal function, and control of convulsions. Gastric lavage may be considered if it can be performed within 1 hour of ingesting significant quantities of lithium. Whole-bowel irrigation should be considered for significant ingestion, but advice should be sought from the National Poisons Information Service, p. 32.

Phenothiazines and related drugs

Phenothiazines cause less depression of consciousness and respiration than other sedatives. Hypotension, hypothermia, sinus tachycardia, and arrhythmias may complicate poisoning. Dystonic reactions can occur with therapeutic doses (particularly with prochlorperazine and trifluoperazine), and convulsions may occur in severe cases. Arrhythmias may respond to correction of hypoxia, acidosis, and other biochemical abnormalities, but specialist advice should be sought if arrhythmias result from a prolonged QT interval; the use of some anti-arrhythmic drugs can worsen such arrhythmias. Dystonic reactions are rapidly abolished by injection of drugs such as procyazine (section 4.9.2) or diazepam (section 4.8.2, emulsion preferred).

Atypical antipsychotic drugs

Features of poisoning by atypical antipsychotic drugs (section 4.2.1) include drowsiness, convulsions, extrapyramidal symptoms, hypotension, and ECG abnormalities (including prolongation of the QT interval). Management is supportive. Activated charcoal can be given within 1 hour of ingesting a significant quantity of an atypical antipsychotic drug.

Stimulants

Amphetamines Amphetamines cause wakefulness, excessive activity, paranoia, hallucinations, and hypertension followed by exhaustion, convulsions, hyperthermia, and coma. The early stages can be controlled by diazepam or lorazepam; advice should be sought from the National Poisons Information Service (p. 32) on the management of hypertension. Later, tepid sponging, anticonvulsants, and artificial respiration may be needed.

Cocaine Cocaine stimulates the central nervous system, causing agitation, dilated pupils, tachycardia, hypertension, hallucinations, hyperthermia, hypertonia, and hyperreflexia; cardiac effects include chest pain, myocardial infarction, and arrhythmias.

Initial treatment of cocaine poisoning involves intravenous administration of diazepam to control agitation and cooling measures for hyperthermia (see Body temperature, p. 33); hypertension and cardiac effects require specific treatment and expert advice should be sought.
Ecstasy  Ecstasy (methyleneoxydemethamine, MDMA) may cause severe reactions, even at doses that were previously tolerated. The most serious effects are delirium, coma, convulsions, ventricular arrhythmias, hyperthermia, rhabdomyolysis, acute renal failure, acute hepatitis, disseminated intravascular coagulation, adult respiratory distress syndrome, hyperreflexia, hypotension and intracerebral haemorrhage; hypernatremia has also been associated with ecstasy use.

Treatment of methyleneoxydemethamine poisoning is supportive, with diazepam to control severe agitation or persistent convulsions and close monitoring including ECG. Self-induced water intoxication should be considered in patients with ecstasy poisoning.

‘Liquid ecstasy’ is a term used for sodium oxybate (gamma-hydroxybutyrate, GHB), which is a sedative.

Theophylline

Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restless, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.

Repeated doses of activated charcoal can be used to eliminate theophylline even if more than 1 hour has elapsed after ingestion and especially if a modified-release preparation has been taken (see also under Active Elimination Techniques, p. 33). Ondansetron (section 4.6) may be effective for severe vomiting that is resistant to other antiemetics [unlicensed indication]. Hypokalaemia is corrected by intravenous infusion of potassium chloride and may be so severe as to require 60 mmol/hour (high doses require ECG monitoring). Convulsions should be controlled by intravenous administration of lorazepam or diazepam (see Convulsions, p. 33). Sedation with diazepam may be necessary in agitated patients.

Provided the patient does not suffer from asthma, a short-acting beta-blocker (section 2.4) can be administered intravenously to reverse severe tachycardia, hypokalaemia, and hyperglycaemia.

Other poisons

Consult either the National Poisons Information Service day and night or TOXBASE, see p. 32.

The National Poisons Information Service (Tel: 0844 892 0111) will provide specialist advice on all aspects of poisoning day and night.

Cyanides

Oxygen should be administered to patients with cyanide poisoning. The choice of antidote depends on the severity of poisoning, certainty of diagnosis, and the cause. Dicobalt edetate is the antidote of choice when there is a strong clinical suspicion of severe cyanide poisoning. Dicobalt edetate itself is toxic, associated with anaphylactoid reactions, and is potentially fatal if administered in the absence of cyanide poisoning. A regimen of sodium nitrite followed by sodium thiosulphate is an alternative if dicobalt edetate is not available.

Hydroxocobalamin (Cyanokit®—no other preparation of hydroxocobalamin is suitable) can be considered for use in victims of smoke inhalation who show signs of significant cyanide poisoning.

**DICOBALT EDETATE**

**Indications** severe poisoning with cyanides

**Cautions** owing to toxicity it should be used only for definite cyanide poisoning when patient tending to lose, or has lost, consciousness; not to be used as a precautionary measure

**Side-effects** hypotension, tachycardia, and vomiting; anaphylactoid reactions including facial and laryngeal oedema and cardiac abnormalities

**Dose**

- By intravenous injection, ADULT 300 mg over 1 minute (5 minutes if condition less serious) followed immediately by 50 mL of glucose intravenous infusion 50%; if response inadequate a second dose of both may be given, but risk of cobalt toxicity; CHILD consult the National Poisons Information Service

**HYDROXOCOBALAMIN**

**Indications** see notes above

**Side-effects** gastro-intestinal disturbances, transient hypertension, peripheral oedema, dyspnœa, throat disorders, hot flush, dizziness, headache, restlessness, memory impairment, red coloration of urine, lymphocytopenia, eye disorders, pustular rashes, pruritus, reversible red coloration of skin and mucous membranes

**Dose**

- By intravenous infusion, ADULT 5 g over 15 minutes; a second dose of 5 g can be given over 15 minutes–2 hours depending on severity of poisoning and patient stability; CHILD 70 mg/kg (max. 5 g) over 15 minutes; a second dose of 70 mg/kg (max. 5 g) can be given over 15 minutes–2 hours depending on severity of poisoning and patient stability

**Cyanokit®** (Swedish Orphan) •

Intravenous infusion, powder for reconstitution, hydroxocobalamin, net price 2 x 2.5-g vials = £772.00

Note: Deep red colour of hydroxocobalamin may interfere with laboratory tests (see Side-effects, above)
Emergency treatment of poisoning

Dose

- By intravenous injection over 5–20 minutes (as sodium nitrite injection 30 mg/mL), 300 mg; CHILD 4–10 mg/kg (max. 300 mg)

1 Sodium Nitrite (Patentin)
Injection, sodium nitrite 3% (30 mg/mL) in water for injections
Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

SODIUM THIOSULPHATE

Indications in conjunction with sodium nitrite for cyanide poisoning

Dose

- By intravenous injection over 10 minutes (as sodium thioulsulphate injection 500 mg/mL), 12.5 g; dose may be repeated in severe cyanide poisoning if dicobalt edetate not available

1 Sodium Thiosulphate (Patentin)
Injection, sodium thioulsulphate 50% (500 mg/mL) in water for injections
Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

Ethylene glycol and methanol

Fomepizole (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is the treatment of choice for ethylene glycol and methanol (methyl alcohol) poisoning. If necessary, ethanol (by mouth or by intravenous infusion) can be used, but with caution. Advice on the treatment of ethylene glycol and methanol poisoning should be obtained from the National Poisons Information Service. It is important to start antidote treatment promptly in cases of suspected poisoning with these agents.

Heavy metals

Heavy metal antidotes include succimer (DMSA) [unlicensed], unithiol (DMPS) [unlicensed], sodium calcium edetate, and dimercaprol. Dimercaprol in the management of heavy metal poisoning has been superseded by other chelating agents. In all cases of heavy metal poisoning, the advice of the National Poisons Information Service should be sought.

SODIUM CALCIUM EDETATE
(Sodium Calciumedetate)

Indications lead poisoning
Renal impairment use with caution in mild impairment: avoid in moderate to severe impairment—contact the National Poisons Information Service for advice
Side-effects nausea, diarrhoea, abdominal pain, pain at site of injection, thrombophlebitis if given too

1. *Patent restriction does not apply where administration is for saving life in emergency*

rapidly, renal damage particularly in overdosage; hypotension, lacrimation, myalgia, nasal congestion, sneezing, malaise, thirst, fever, chills, headache, and zinc depletion also reported

Dose

- By intravenous infusion, ADULT and CHILD 40 mg/kg twice daily for up to 5 days; if necessary, a second course can be given at least 7 days after the first course, a third course can be given at least 7 days after the second course

Ledclair® (Durbin) (Patentin)
Injection, sodium calcium edetate 200 mg/mL, net price 5-mL amp = £7.29

Noxious gases

Carbon monoxide Carbon monoxide poisoning is usually due to inhalation of smoke, car exhaust, or fumes caused by blocked flues or incomplete combustion of fuel gases in confined spaces. Immediate treatment of carbon monoxide poisoning is essential. The person should be moved to fresh air, the airway cleared, and high-flow oxygen 100% administered through a tight-fitting mask with an inflated face seal. Artificial respiration should be given as necessary and continued until adequate spontaneous breathing starts, or stopped only after persistent and efficient treatment of cardiac arrest has failed. The patient should be admitted to hospital because complications may arise after a delay of hours or days. Cerebral oedema may occur in severe poisoning and is treated with an intravenous infusion of mannitol (section 2.2.5). Referral for hyperbaric oxygen treatment should be discussed with the National Poisons Information Service if the patient is pregnant or in cases of severe poisoning, such as if the patient is or has been unconscious, or has psychiatric or neurological features other than a headache, or has myocardial ischaemia or an arrhythmia, or has a blood carboxyhaemoglobin concentration of more than 20%.

Sulphur dioxide, chlorine, phosgene, ammonia All of these gases can cause upper respiratory tract and conjunctival irritation. Pulmonary oedema, with severe breathlessness and cyanosis may develop suddenly up to 36 hours after exposure. Death may occur. Patients are kept under observation and those who develop pulmonary oedema are given oxygen. Assisted ventilation may be necessary in the most serious cases.

CS Spray

CS spray, which is used for riot control, irritates the eyes (hence ‘tear gas’) and the respiratory tract; symptoms normally settle spontaneously within 15 minutes. If symptoms persist, the patient should be removed to a well-ventilated area, and the exposed skin washed with soap and water after removal of contaminated clothing. Contact lenses should be removed and rigid ones washed (soft ones should be discarded). Eye symptoms should be treated by irrigating the eyes with physiological saline (or water if saline is not available) and advice sought from an ophthalmologist. Patients with
Organophosphorus insecticides are usually supplied as powders or dissolved in organic solvents. All are absorbed through the skin. In severe poisoning, particularly respiratory complications, should be admitted to hospital for symptomatic treatment.

Nerve agents

Treatment of nerve agent poisoning is similar to organophosphorus insecticide poisoning (see below), but advice must be sought from the National Poisons Information Service. The risk of cross-contamination is significant; adequate decontamination and protective clothing for healthcare personnel are essential. In emergencies involving the release of nerve agents, kits (‘NAAS pods’) containing pralidoxime can be obtained through the Ambulance Service from the National Blood Service (or the Welsh Blood Service in South Wales or designated hospital pharmacies in Northern Ireland and Scotland—see TOXBASE for list of designated centres).

Snake bites and animal stings

Snake bites. Envenoming from snake bite is uncommon in the UK. Many exotic snakes are kept, some illegally, but the only indigenous venomous snake is the adder (Vipera berus). The bite may cause local and systemic effects. Local effects include pain, swelling, bruising, and tender enlargement of regional lymph nodes. Systemic effects include early anaphylactic symptoms (transient hypotension with syncope, angioedema, urticaria, abdominal colic, diarrhoea, and vomiting), with later persistent or recurrent hypotension, ECG abnormalities, spontaneous systemic bleeding, coagulopathy, adult respiratory distress syndrome, and acute renal failure. Fatal envenoming is rare but the potential for severe envenoming must not be underestimated.

Early anaphylactic symptoms should be treated with adrenaline (epinephrine) (section 3.4.3). Indications for antivenom treatment include systemic envenoming, especially hypotension (see above). ECG abnormalities, vomiting, haemostatic abnormalities, and marked local envenoming such that after bites on the hand or foot, swelling extends beyond the wrist or ankle within 4 hours of the bite. For both adults and children, the contents of one vial (10 mL) of European viper venom antiserum (available from Movianto) is given by intravenous injection over 10–15 minutes or by intravenous infusion over 30 minutes after diluting in sodium chloride intravenous infusion 0.9% (use 5 mL diluent/kg body-weight). The dose can be repeated after 1–2 hours if symptoms of systemic envenoming persist. However, for those patients who present with clinical features of severe envenoming (e.g. shock, ECG abnormalities, or local swelling that has advanced from the foot features of systemic envenoming persist. However, for those patients who present with clinical features of severe envenoming (e.g. shock, ECG abnormalities, or local swelling that has advanced from the foot
to above the knee or from the hand to above the elbow within 2 hours of the bite), an initial dose of 2 vials (20 mL) of the antiserum is recommended; if symptoms of systemic envenoming persist contact the National Poisons Information Service. Adrenaline (epinephrine) injection must be immediately to hand for treatment of anaphylactic reactions to the antivenom (for the management of anaphylaxis, see section 3.4.3). Antivenom is available for bites by certain foreign snakes and spiders, stings by scorpions and fish. For information on identification, management, and for supply in an emergency, telephone the National Poisons Information Service. Whenever possible the TOXBASE entry should be read, and relevant information collected, before telephoning the National Poisons Information Service (see p. 32).

**Insect stings** Stings from ants, wasps, hornets, and bees cause local pain and swelling but seldom cause severe direct toxicity unless many stings are inflicted at the same time. If the sting is in the mouth or on the tongue local swelling may threaten the upper airway. The stings from these insects are usually treated by cleaning the area with a topical antiseptic. Bee stings should be removed as quickly as possible. Anaphylactic reactions require immediate treatment with intramuscular adrenaline (epinephrine); self-administered intramuscular adrenaline (e.g. EpiPen®) is the best first-aid treatment for patients with severe hypersensitivity. An inhaled bronchodilator should be used for asthmatic reactions. For the management of anaphylaxis, see section 3.4.3. A short course of an oral antihistamine or a topical corticosteroid may help to reduce inflammation and relieve itching. A vaccine containing extracts of bee and wasp venom can be used to reduce the risk of anaphylaxis and systemic reactions in patients with systemic hypersensitivity to bee or wasp stings (section 3.4.2).

**Marine stings** The severe pain of weeverfish (Trachinus vipera) and Portuguese man-o’-war stings can be relieved by immersing the stung area immediately in uncomfortably hot, but not scalding, water (not more than 45°C). People stung by jellyfish and Portuguese man-o’-war around the UK coast should be removed from the sea as soon as possible. Adherent tentacles should be lifted off carefully (wearing gloves or using tweezers) or washed off with seawater. Alcoholic solutions, including suntan lotions, should not be applied because they can cause further discharge of stinging hairs. Ice packs will reduce pain and a slurry of baking soda (sodium bicarbonate), but not vinegar, may be useful for treating stings from UK species.
1 Gastro-intestinal system

1.1 Dyspepsia and gastro-oesophageal reflux disease 43
  1.1.1 Antacids and simeticone 44
  1.1.2 Compound alginates and proprietary indigestion preparations 46

1.2 Antispasmodics and other drugs altering gut motility 47

1.3 Antisecretory drugs and mucosal protectants 49
  1.3.1 H2-receptor antagonists 51
  1.3.2 Selective antimuscarinics 53
  1.3.3 Chelates and complexes 53
  1.3.4 Prostaglandin analogues 54
  1.3.5 Proton pump inhibitors 54

1.4 Acute diarrhoea 57
  1.4.1 Adsorbents and bulk-forming drugs 58
  1.4.2 Antimotility drugs 58

1.5 Chronic bowel disorders 59
  1.5.1 Aminosalicylates 61
  1.5.2 Corticosteroids 64
  1.5.3 Drugs affecting the immune response 65
  1.5.4 Food allergy 66

1.6 Laxatives 67
  1.6.1 Bulk-forming laxatives 67
  1.6.2 Stimulant laxatives 68
  1.6.3 Faecal softeners 70
  1.6.4 Osmotic laxatives 71
  1.6.5 Bowel cleansing preparations 73
  1.6.6 Peripheral opioid-receptor antagonists 74
  1.6.7 5HT4-receptor agonists 75

1.7 Local preparations for anal and rectal disorders 75
  1.7.1 Soothing haemorrhoidal preparations 75
  1.7.2 Compound haemorrhoidal preparations with corticosteroids 76
  1.7.3 Rectal sclerosants 77
  1.7.4 Management of anal fissures 77
  1.8 Stoma care 78
  1.9 Drugs affecting intestinal secretions 78
  1.9.1 Drugs affecting biliary composition and flow 78

1.9.2 Bile acid sequestrants 78
1.9.3 Aprotinin 79
1.9.4 Pancreatin 79

This chapter also includes advice on the drug management of the following:
- *Clostridium difficile* infection, p. 60
- constipation, p. 67
- Crohn’s disease, p. 59
- diverticular disease, p. 61
- food allergy, p. 66
- *Helicobacter pylori* infection, p. 49
- irritable bowel syndrome, p. 61
- NSAID-associated ulcers, p. 50
- ulcerative colitis, p. 59

Dyspepsia

Dyspepsia covers upper abdominal pain, fullness, early satiety, bloating, and nausea. It can occur with gastric and duodenal ulceration (section 1.3) and gastric cancer but most commonly it is of uncertain origin.

Urgent endoscopic investigation is required if dyspepsia is accompanied by ‘alarm features’ (e.g. bleeding, dysphagia, recurrent vomiting, or weight loss). Urgent investigation should also be considered for patients over 55 years with unexplained, recent-onset dyspepsia that has not responded to treatment.

Patients with dyspepsia should be advised about lifestyle changes (see Gastro-oesophageal reflux disease, below). Some medications may cause dyspepsia—these should be stopped, if possible. Antacids may provide some symptomatic relief.

If symptoms persist in uninvestigated dyspepsia, treatment involves a proton pump inhibitor (section 1.3.5) for 4 weeks. A proton pump inhibitor can be used intermittently to control symptoms long term. Patients with uninvestigated dyspepsia, who do not respond to an initial trial with a proton pump inhibitor, should be tested for *Helicobacter pylori* and given eradication therapy (section 1.3) if *H. pylori* is present. Alternatively, particularly in populations where *H. pylori* infection is more likely, the ‘test and treat’ strategy for *H. pylori* can be used before a trial with a proton pump inhibitor.
If H. pylori is present in patients with functional (investigated, non-ulcer) dyspepsia, eradication therapy should be provided. If symptoms persist, treatment with either a proton pump inhibitor (section 1.3.5) or a histamine H2-receptor antagonist (section 1.3.1) can be given for 4 weeks. These antisecretory drugs can be used intermittently to control symptoms long term. However, most patients with functional dyspepsia do not benefit symptomatically from H. pylori eradication therapy or antisecretory drugs.

### Gastro-oesophageal reflux disease

Gastro-oesophageal reflux disease (including non-erosive gastro-oesophageal reflux and erosive oesophagitis) is associated with heartburn, acid regurgitation, and sometimes, difficulty in swallowing (dysphagia); oesophageal inflammation (oesophagitis), ulceration, and stricture formation may occur and there is an association with asthma.

The management of gastro-oesophageal reflux disease includes drug treatment, lifestyle changes and, in some cases, surgery. Initial treatment is guided by the severity of symptoms and treatment is then adjusted according to response. The extent of healing depends on the severity of the disease, the treatment chosen, and the duration of therapy.

Patients with gastro-oesophageal reflux disease should be advised about lifestyle changes (avoidance of excess alcohol and of aggravating foods such as fats); other measures include weight reduction, smoking cessation, and raising the head of the bed.

For mild symptoms of gastro-oesophageal reflux disease, initial management may include the use of antacids and alginates. Alginate-containing antacids can form a ‘raft’ that floats on the surface of the stomach contents to reduce reflux and protect the oesophageal mucosa. Histamine H2-receptor antagonists (section 1.3.1) may relieve symptoms and permit reduction in antacid consumption. However, proton pump inhibitors (section 1.3.5) provide more effective relief of symptoms than H2-receptor antagonists. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by giving treatment intermittently).

For severe symptoms of gastro-oesophageal reflux disease or for patients with a proven or severe pathology (e.g. oesophagitis, oesophageal ulceration, oesophagopharyngeal reflux, Barrett’s oesophagus), initial management involves the use of a proton pump inhibitor (section 1.3.5); patients need to be reassessed if symptoms persist despite treatment for 4–6 weeks with a proton pump inhibitor. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by reducing the dose of the proton pump inhibitor or by giving it intermittently, or by substituting treatment with a histamine H2-receptor antagonist). However, for endoscopically confirmed erosive, ulcerative, or strictureing disease, or Barrett’s oesophagus, treatment with a proton pump inhibitor usually needs to be maintained at the minimum effective dose.

A prokinetic drug such as metoclopramide (section 4.6) may improve gastro-oesophageal sphincter function and accelerate gastric emptying.

### Antacids and simeticone

**Children** Gastro-oesophageal reflux disease is common in infancy but most symptoms resolve without treatment between 12 and 18 months of age. In infants, mild or moderate reflux without complications can be managed initially by changing the frequency and volume of feed; a feed thickener or thickened formula feed can be used (with advice of a dietitian—see Appendix 7 for suitable products). If necessary, a suitable alginate-containing preparation can be used instead of thickened feeds. For older children, lifestyle changes similar to those for adults (see above) may be helpful followed if necessary by treatment with an alginate-containing preparation.

Children who do not respond to these measures or who have problems such as respiratory disorders or suspected oesophagitis need to be referred to hospital; an H2-receptor antagonist (section 1.3.1) may be needed to reduce acid secretion. If the oesophagitis is resistant to H2-receptor blockade, the proton pump inhibitor omeprazole (section 1.3.5) can be tried.

**Antacids (usually containing aluminium or magnesium compounds)** can often relieve symptoms in ulcer dyspepsia and in non-erosive gastro-oesophageal reflux (see also section 1.1); they are also sometimes used in functional (non-ulcer) dyspepsia but the evidence of benefit is uncertain. Antacids are best given when symptoms occur or are expected, usually between meals and at bedtime, 4 or more times daily; additional doses may be required up to once an hour. Conventional doses e.g. 10 mL 3 or 4 times daily of liquid magnesium–aluminium antacids promote ulcer healing, but less well than antisecretory drugs (section 1.3); proof of a relationship between healing and neutralising capacity is lacking. Liquid preparations are more effective than tablet preparations.

Aluminium- and magnesium-containing antacids (e.g. aluminium hydroxide, and magnesium carbonate, hydroxide and trisilicate), being relatively insoluble in water, are long-acting if retained in the stomach. They are suitable for most antacid purposes. Magnesium-containing antacids tend to be laxative whereas aluminium-containing antacids may be constipating; antacids containing both magnesium and aluminium may reduce these colonic side-effects. Aluminium accumulation does not appear to be a risk if renal function is normal.

The acid-neutralising capacity of preparations that contain more than one antacid may be the same as simpler preparations. Complexes such as hydrotalcite confer no special advantage.

**Sodium bicarbonate** should no longer be prescribed alone for the relief of dyspepsia but it is present as an ingredient in many indigestion remedies. However, it retains a place in the management of urinary-tract disorders (section 7.4.3) and acidosis (section 9.2.1.3 and section 9.2.2). Sodium bicarbonate should be avoided in patients on salt-restricted diets.

**Bismuth-containing** antacids (unless chelates) are not recommended because absorbed bismuth can be neurotoxic, causing encephalopathy; they tend to be constipating. **Calcium-containing** antacids (section 1.1.2)
can induce rebound acid secretion: with modest doses the clinical significance is doubtful, but prolonged high doses also cause hypercalcaemia and alkalosis, and can precipitate the milk-alkali syndrome.

**Simeticone** (activated dimeticone) is added to an antacid as an antifoaming agent to relieve flatulence. These preparations may be useful for the relief of hiccup in palliative care. **Alginates**, added as protectants, may be useful in gastro-oesophageal reflux disease (section 1.1 and section 1.1.2). The amount of additional ingredient or antacid in individual preparations varies widely, as does their sodium content, so that preparations may not be freely interchangeable.

See also section 1.3 for drugs used in the treatment of peptic ulceration.

**Hepatic impairment** In patients with fluid retention, avoid antacids containing large amounts of sodium. Avoid antacids that cause constipation because this can precipitate coma. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.

**Renal impairment** In patients with fluid retention, avoid antacids containing large amounts of sodium. There is a risk of accumulation and aluminium toxicity with antacids containing aluminium salts. Absorption of aluminium from aluminium salts is increased by citrates, with antacids containing aluminium salts. Absorption of aluminium and magnesium hydroxide in hepatic coma if there is a risk of renal failure.

**Interactions** Antacids should preferably not be taken at the same time as other drugs since they may impair absorption. Antacids may also damage enteric coatings (such as effervescent analgesics). Antacids containing magnesium salts should be avoided or used at a reduced dose because there is an increased risk of toxicity.

**Side-effects**

- **Diarrhoea**
- **Belching due to liberated carbon dioxide**
- **Rebound acid secretion**
- **Hypercalcaemia**
- **Alkalosis**

**Magnesium carbonate** (activated as an antifoaming agent to relieve flatulence. These preparations may be useful for the relief of hiccup in palliative care. **Alginates**, added as protectants, may be useful in gastro-oesophageal reflux disease (section 1.1 and section 1.1.2). The amount of additional ingredient or antacid in individual preparations varies widely, as does their sodium content, so that preparations may not be freely interchangeable.

See also section 1.3 for drugs used in the treatment of peptic ulceration.

**Hepatic impairment** In patients with fluid retention, avoid antacids containing large amounts of sodium. Avoid antacids that cause constipation because this can precipitate coma. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.

**Renal impairment** In patients with fluid retention, avoid antacids containing large amounts of sodium. There is a risk of accumulation and aluminium toxicity with antacids containing aluminium salts. Absorption of aluminium from aluminium salts is increased by citrates, with antacids containing aluminium salts. Absorption of aluminium and magnesium hydroxide in hepatic coma if there is a risk of renal failure.

**Interactions** Antacids should preferably not be taken at the same time as other drugs since they may impair absorption. Antacids may also damage enteric coatings (such as effervescent analgesics). Antacids containing magnesium salts should be avoided or used at a reduced dose because there is an increased risk of toxicity.

**Side-effects**

- **Diarrhoea**
- **Belching due to liberated carbon dioxide**
- **Rebound acid secretion**
- **Hypercalcaemia**
- **Alkalosis**

**Magnesium carbonate**

- **Indications** dyspepsia
- **Cautions** see notes above; **interactions**: Appendix 1 (antacids)
- **Contra-indications** hypophosphataemia
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium carbonate mixture has a high sodium content
- **Side-effects** diarrhoea; belching due to liberated carbon dioxide

**Aromatic Magnesium Carbonate Mixture, BP**

- **Indications** dyspepsia
- **Cautions** see under Magnesium Carbonate
- **Contra-indications** see under Magnesium Carbonate
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium trisilicate mixture has a high sodium content
- **Side-effects** diarrhoea, belching due to liberated carbon dioxide; silica-based renal stones reported on long-term treatment

**Magnesium Trisilicate Tablets, Compound, BP**

- **Indications** dyspepsia
- **Cautions** see under Magnesium Carbonate
- **Contra-indications** see under Magnesium Carbonate
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium trisilicate mixture has a high sodium content
- **Side-effects** diarrhoea, belching due to liberated carbon dioxide; silica-based renal stones reported on long-term treatment

**Aluminium and magnesium-containing antacids**

**Aluminium hydroxide**

- **Indications** dyspepsia; hyperphosphataemia (section 9.5.2.2)
- **Cautions** see notes above; **interactions**: Appendix 1 (antacids)
- **Contra-indications** hypophosphataemia; neonates and infants
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above
- **Side-effects** see notes above

**Aluminium-only preparations**

- **Alu-Cap®** (Meda)
  - **Capsules**, green/red, dried aluminium hydroxide 475 mg (low Na+). Net price 120-cap pack = £3.75
  - **Dose** antacid, 1 capsule 4 times daily and at bedtime; **CHILD** not recommended for antacid therapy

**Antacids and simeticone**

**Co-magaldrox**

- **Co-magaldrox** is a mixture of aluminium hydroxide and magnesium hydroxide; the proportions are expressed in the form x/y where x and y are the strengths in milligrams per unit dose of magnesium hydroxide and aluminium hydroxide respectively

**Maalox®** (Sanofi-Aventis)

- **Suspension**, sugar-free, co-magaldrox 195/220 (magnesium hydroxide 195 mg, dried aluminium hydroxide 220 mg/5 mL (low Na+)). Net price 500 mL = £2.79
  - **Dose** ADULT and CHILD over 14 years, 10–20 mL 20–60 minutes after meals and at bedtime or when required

**Mucogel®** (Chemidex)

- **Suspension**, sugar-free, co-magaldrox 195/220 (magnesium hydroxide 195 mg, dried aluminium hydroxide 220 mg/5 mL (low Na+)). Net price 500 mL = £1.71
  - **Dose** ADULT and CHILD over 12 years, 10–20 mL 3 times daily, 20–60 minutes after meals, and at bedtime or when required

**MAGNESIUM CARBONATE**

- **Indications** dyspepsia
- **Cautions** see notes above; **interactions**: Appendix 1 (antacids)
- **Contra-indications** hypophosphataemia
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium carbonate mixture has a high sodium content
- **Side-effects** diarrhoea; belching due to liberated carbon dioxide

**Aromatic Magnesium Carbonate Mixture, BP**

- **Indications** dyspepsia
- **Cautions** see under Magnesium Carbonate
- **Contra-indications** see under Magnesium Carbonate
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium trisilicate mixture has a high sodium content
- **Side-effects** diarrhoea, belching due to liberated carbon dioxide; silica-based renal stones reported on long-term treatment

**Magnesium Trisilicate Tablets, Compound, BP**

- **Indications** dyspepsia
- **Cautions** see under Magnesium Carbonate
- **Contra-indications** see under Magnesium Carbonate
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium trisilicate mixture has a high sodium content
- **Side-effects** diarrhoea, belching due to liberated carbon dioxide; silica-based renal stones reported on long-term treatment

**Magnesium Trisilicate**

- **Indications** dyspepsia
- **Cautions** see under Magnesium Carbonate
- **Contra-indications** see under Magnesium Carbonate
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above; magnesium trisilicate mixture has a high sodium content
- **Side-effects** diarrhoea, belching due to liberated carbon dioxide; silica-based renal stones reported on long-term treatment

**Aluminium hydroxide**

- **Indications** dyspepsia; hyperphosphataemia (section 9.5.2.2)
- **Cautions** see notes above; **interactions**: Appendix 1 (antacids)
- **Contra-indications** hypophosphataemia; neonates and infants
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above
- **Side-effects** see notes above

**Aluminium-only preparations**

- **Alu-Cap®** (Meda)
  - **Capsules**, green/red, dried aluminium hydroxide 475 mg (low Na+). Net price 120-cap pack = £3.75
  - **Dose** antacid, 1 capsule 4 times daily and at bedtime; **CHILD** not recommended for antacid therapy
**1.1.2 Compound alginates and proprietary indigestion preparations**

**Aluminium-magnesium complexes**

**HYDROTALCITE**
Aluminium magnesium carbonate hydroxide hydrate

**Indications** dyspepsia

**Cautions** see notes above; interactions: Appendix 1 (antacids)

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Side-effects** see notes above

*With simeticone*

**Altacite Plus** (Peckforton)

**Suspension**, sugar-free, co-simalcite 125/500 (simeticone 125 mg, hydroxyaluminate 500 mg)/5 mL (low Na⁺).

Net price 500 mL = £2.79

Dose 10 mL between meals and at bedtime when required; CHILD 8–12 years 5 mL between meals and at bedtime when required

**Asilone** (Thornton & Ross)

**Suspension**, sugar-free, dried aluminium hydroxide 420 mg, simeticone 135 mg, light magnesium oxide 70 mg/5 mL (low Na⁺). Net price 500 mL = £1.95

Dose ADULT and CHILD over 12 years, 5–10 mL after meals and at bedtime or when required up to 4 times daily

**Maalox Plus** (Sanofi-Aventis)

**Suspension**, sugar-free, dried aluminium hydroxide 220 mg, simeticone 25 mg, magnesium hydroxide 195 mg/5 mL (low Na⁺). Net price 500 mL = £2.79

Dose 5–10 mL 4 times daily (after meals and at bedtime) or when required; CHILD under 12 years see BNF for Children

**Simeticone alone**

Simeticone (activated dimeticone) is an antifoaming agent. It is licensed for infantile colic but evidence of benefit is uncertain.

**Dentinox** (DDO)

**Colic drops** (= emulsion), simeticone 21 mg/2.5-mL dose. Net price 100 mL = £1.73

Dose colic or wind pains, NEONATE and INFANT 2.5 mL with or after each feed (max. 6 doses in 24 hours); may be added to bottle feeds

*Note* The brand name Dentinox® is also used for other preparations including teething gel

**Infacol** (Forest)

**Liquid**, sugar-free, simeticone 40 mg/mL (low Na⁺). Net price 50 mL = £2.26. Counselling, use of dropper

Dose colic or wind pains, NEONATE and INFANT 0.5–1 mL before feeds

**Altacite Plus** see below

**Antacid preparations containing simeticone**

**Altacite Plus**® (Thornton & Ross)

**Suspension**, sugar-free, dried aluminium hydroxide 195 mg/5 mL (low Na⁺). Net price 500 mL = £1.95

Dose 10–20 mL after meals and at bedtime; CHILD 6–12 years 5–10 mL after meals and at bedtime

**Peptac**® (IVAX)

**Suspension**, sugar-free, sodium bicarbonate 133.5 mg, calcium carbonate 80 mg/5 mL. Contains about 3 mmol Na⁺/5 mL. Net price 500 mL (aniseed- or peppermint-flavoured) = £2.30

Dose 10–20 mL after meals and at bedtime; CHILD 6–12 years 5–10 mL after meals and at bedtime

**Other compound alginate preparations**

**Gaviscon**® (Actavis)

**Tablets**, alginic acid 200 mg, dried aluminium hydroxide 80 mg, magnesium trisilicate 40 mg, sodium bicarbonate 70 mg. Contains about 1 mmol Na⁺/tablet. Net price 100-tab pack = £3.51

*Cautions* diabetes mellitus (high sugar content)

Dose ADULT and CHILD over 6 years, 1–2 tablets chewed 4 times daily (after meals and at bedtime)

**Liquid**, sugar-free, peach-coloured, dried aluminium hydroxide 80 mg, magnesium trisilicate 40 mg, sodium alginate 220 mg, sodium bicarbonate 70 mg/5 mL. Contains 2.13 mmol Na⁺/5 mL. Net price 500 mL = £2.67

Dose 5–15 mL 4 times daily (after meals and at bedtime); CHILD 6–12 years, 5–10 mL 4 times daily (after meals and at bedtime)

**Gaviscon® Advance** (Reckitt Benckiser)

**Tablets**, sugar-free, sodium alginate 500 mg, potassium bicarbonate 100 mg. Contains 2.25 mmol Na⁺, 1 mmol K⁺/tablet. Net price 60-tab pack (peppermint-flavoured) = £3.07

*Excipients* include aspartame (section 9.4.1)

Dose ADULT and CHILD over 12 years, 1–2 tablets to be chewed after meals and at bedtime; CHILD 6–12 years, 1 tablet to be chewed after meals and at bedtime (under medical advice only)

**Suspension**, sugar-free, aniseed- or peppermint flavour, sodium alginate 500 mg, potassium bicarbonate
Dicycloverine hydrochloride has a much less marked antimuscarinic action than atropine and may also have some direct action on smooth muscle. Hyoscine butylbromide is advocated as a gastro-intestinal antispasmodic, but it is poorly absorbed; the injection is useful in endoscopy and radiology. Atropine and the belladonna alkaloids are outmoded treatments, any clinical virtues being outweighed by atropinic side-effects.

Cautions Antimuscarinics should be used with caution in Down's syndrome, in children and in the elderly; they should also be used with caution in gastro-oesophageal reflux disease, diarrhoea, ulcerative colitis, autonomic neuropathy, acute myocardial infarction, hypertension, conditions characterised by tachycardia (including hyperthyroidism, cardiac insufficiency, cardiac surgery), pyrexia, and in individuals susceptible to angle-closure glaucoma. Interactions: Appendix 1 (antimuscarinics).

Contra-indications Antimuscarinics are contra-indicated in myasthenia gravis (but may be used to decrease muscarnic side-effects of anticholinesterases—section 10.2.1), paralytic ileus, pyloric stenosis, toxic megacolon, and prostatic enlargement.

Side-effects Side-effects of antimuscarinics include constipation, transient bradycardia (followed by tachycardia, palpitation and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. Side-effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting, and giddiness; very rarely, angle-closure glaucoma may occur.

**ATROPINE SULPHATE**

Indications symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm; mydriasis and cycloplegia (section 11.5); premedication (section 15.1.3); see also notes above

Cautions see notes above

Contra-indications see notes above

Pregnancy not known to be harmful; manufacturer advises caution

Breast-feeding small amount present in milk—manufacturer advises caution

Side-effects see notes above

**Dose**

- 0.6–1.2 mg at night

**Atropine** (Non-proprietary) 

Tablets, atropine sulphate 600 micrograms. Net price 28-tab pack = £17.59

**DICYCLOVERINE HYDROCHLORIDE**

(Dicyclomine hydrochloride)

Indications symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm

Cautions see notes above

1.2 Antispasmodics and other drugs altering gut motility

Drugs in this section include antimuscarinic compounds and drugs believed to be direct relaxants of intestinal smooth muscle. The smooth muscle relaxant properties of antimuscarinic and other antispasmodic drugs may be useful in irritable bowel syndrome and in diverticular disease.

The dopamine-receptor antagonists metoclopramide and domperidone (section 4.6) stimulate transit in the gut.

**Antimuscarinics**

Antimuscarinics (formerly termed ‘anticholinergics’) reduce intestinal motility. They are used for the management of irritable bowel syndrome and diverticular disease. However, their value has not been established and response varies. Other indications for antimuscarinic drugs include arrhythmias (section 2.3.1), asthma and airways disease (section 3.1.2), motion sickness (section 4.6), parkinsonism (section 4.9.2), urinary incontinence (section 7.4.2), mydriasis and cycloplegia (section 11.5), premedication (section 15.1.3) and as an antidote to organophosphorus poisoning (p. 41).

Antimuscarinics that are used for gastro-intestinal smooth muscle spasm include the tertiary amines atropine sulphate and dicycloverine hydrochloride and the quaternary ammonium compounds propantheline bromide and hyoscine butylbromide. The quaternary ammonium compounds are less lipid soluble than atropine and are less likely to cross the blood–brain barrier; they are also less well absorbed from the gastro-intestinal tract.

100 mg/5 mL. Contains 2.3 mmol Na+, 1 mmol K+/5 mL, net price 250 mL = £2.56, 500 mL = £5.12

**Dose**

**ADULT** and **CHILD** over 12 years, 5–10 mL after meals and at bedtime; **CHILD** 2–12 years, 2.5–5 mL after meals and at bedtime (under medical advice only)

**Gaviscon Infant®** (Reckitt Benckiser)

**Oral powder**; sugar-free, sodium alginate 225 mg, magnesium alginate 87.5 mg, with colloidal silica and mannitol/dose. Contains 0.92 mmol Na+/dose. Net price 30 doses = £2.46

**Dose**

**INFANT** body-weight under 4.5 kg, 1 ‘dose’ mixed with feeds (or water in breast-fed infants) when required (max. 6 times in 24 hours); body-weight over 4.5 kg, 2 ‘doses’ mixed with feeds (or water in breast-fed infants) when required (max. 6 times in 24 hours); **CHILD** 2 ‘doses’ in water after each meal (max. 6 times in 24 hours)

**Note** Not to be used in preterm neonates, or where excessive water loss likely (e.g. fever, diarrhoea, vomiting, high room temperature), or if intestinal obstruction. Not to be used with other preparations containing thickening agents.

**Important** Each half of the dual-sachet is identified as ‘one dose’.

‘To avoid errors prescribe with directions in terms of ‘dose’

**Topal®** (Fabre)

**Tablets**; alginic acid 200 mg, dried aluminium hydroxide 30 mg, light magnesium carbonate 40 mg with lactose 220 mg, sucrose 880 mg, sodium bicarbonate 40 mg (low Na+). Net price 42-tab pack = £1.67

Cautions diabetes mellitus (high sugar content)

**Indications** symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm and in diverticular disease.
### HYOSCINE BUTYLBROMIDE

**Indications**  
Symptomatic relief of gastro-intestinal or genito-urinary disorders characterised by smooth muscle spasm; bowel colic and excessive respiratory secretions (see Prescribing in Palliative Care, p. 23)

**Cautions**  
See notes above

**Pregnancy**  
Not known to be harmful; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding**  
Avoid—limited information available

**Side-effects**  
Nausea; headache, dizziness; pruritus, rash; hepatitis also reported

**Dose**
- **Adult** and **Child** over 12 years, 60–120 mg 1–3 times daily

**Other antispasmodics**

Alverine, mebeverine, and peppermint oil are believed to be direct relaxants of intestinal smooth muscle and may relieve pain in irritable bowel syndrome and diverticular disease. They have no serious adverse effects but, like all antispasmodics, should be avoided in paralytic ileus. Peppermint oil occasionally causes heartburn.

### PROPSARTHALINE HYDROCHLORIDE

**Indications**  
Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm; urinary frequency (section 7.4.2); gustatory sweating (section 6.1.5)

**Cautions**  
See notes above

**Contra-indications**  
See notes above

**Hepatic impairment**  
Manufacturer advises caution

**Renal impairment**  
Manufacturer advises caution

**Pregnancy**  
Manufacturer advises avoid unless essential

**Breast-feeding**  
May suppress lactation

**Side-effects**  
See notes above

**Dose**
- **Adult** and **Child** over 12 years, 15 mg 3 times daily at least 1 hour before meals and 30 mg at night, max. 120 mg daily

**Pro-Banthine**  
(Archimedes)

**Tablets**, pink, s/c, propantheline bromide 15 mg, net price 112-tab pack = £14.40. Label: 23

### MEBEVERINE HYDROCHLORIDE

**Indications**  
Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm; dysmenorrhoea

**Contra-indications**  
Paralytic ileus

**Pregnancy**  
Use with caution

**Breast-feeding**  
Manufacturer advises avoid—limited information available

**Side-effects**  
Nausea; headache; dizziness; pruritus, rash; hepatitis also reported

**Dose**
- **Adult** and **Child** over 12 years, 60–120 mg 1–3 times daily

**Spasmonal**  
(Norgine)

**Capsules**, alverine citrate 60 mg (blue/grey), net price 100-cap pack = £9.47; 120 mg (Spasmonal Forte, blue/grey), 60-cap pack = £10.94

### ALVERINE CITRATE

**Indications**  
Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm; dysmenorrhoea

**Contra-indications**  
Paralytic ileus

**Pregnancy**  
Use with caution

**Breast-feeding**  
Manufacturer advises avoid—limited information available

**Side-effects**  
Nausea; headache; dizziness; pruritus, rash; hepatitis also reported

**Dose**
- **Adult** and **Child** over 12 years, 60–120 mg 1–3 times daily

**Spasmonal**  
(Norgine)

**Capsules**, alverine citrate 60 mg (blue/grey), net price 100-cap pack = £9.47; 120 mg (Spasmonal Forte, blue/grey), 60-cap pack = £10.94

### MEBEVERINE HYDROCHLORIDE

**Indications**  
Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm

**Cautions**  
Avoid in acute porphyria (section 9.8.2.)

**Contra-indications**  
Paralytic ileus

**Pregnancy**  
Not known to be harmful; manufacturer advises caution

**Breast-feeding**  
May suppress lactation

**Side-effects**  
Allergic reactions (including rash, urticaria, angioedema) reported

### Compound preparations

**Kolanticon**  
(Boehringer Ingelheim)

**Gel**, sugar-free, dicycloverine hydrochloride 2.5 mg, dried aluminium hydroxide 200 mg, light magnesium oxide 100 mg, simeticone 20 mg/5 mL, net price 200 mL = £2.21, 500 mL = £3.35

**Dose**
- **Adult** and **Child** over 12 years, 10–20 mL every 4 hours when required

**Kolanticon**  
(Boehringer Ingelheim)

**Tablets**, dicycloverine hydrochloride 10 mg, net price 100-tab pack = £4.84; 20 mg (Merbentyl 20%), 84-tab pack = £8.14

**Dose**
- **Child** 2–12 years 10 mg 3 times daily
- **Over 12 years** 20 mg 4 times daily; **Infant** 6–24 months 5–10 mg 3–4 times daily, 15 minutes before feeds; **Child** 2–12 years 3 mg 3 times daily

**Merbentyl**  
(Sanofi-Aventis)

**Tablets**, dicycloverine hydrochloride 10 mg, net price 100-tab pack = £4.84; 20 mg (Merbentyl 20%), 84-tab pack = £8.14

**Dose**
- **Adult** and **Child** over 12 years, 15 mg 3 times daily at least 1 hour before meals and 30 mg at night, max. 120 mg daily

**Pro-Banthine**  
(Archimedes)

**Tablets**, pink, s/c, propantheline bromide 15 mg, net price 112-tab pack = £14.40. Label: 23

**Compound preparations**

**Kolanticon**  
(Boehringer Ingelheim)

**Gel**, sugar-free, dicycloverine hydrochloride 2.5 mg, dried aluminium hydroxide 200 mg, light magnesium oxide 100 mg, simeticone 20 mg/5 mL, net price 200 mL = £2.21, 500 mL = £3.35

**Dose**
- **Adult** and **Child** over 12 years, 10–20 mL every 4 hours when required

**Kolanticon**  
(Boehringer Ingelheim)

**Tablets**, dicycloverine hydrochloride 10 mg, net price 100-tab pack = £4.84; 20 mg (Merbentyl 20%), 84-tab pack = £8.14

**Dose**
- **Adult** and **Child** over 12 years, 15 mg 3 times daily at least 1 hour before meals and 30 mg at night, max. 120 mg daily

**Pro-Banthine**  
(Archimedes)

**Tablets**, pink, s/c, propantheline bromide 15 mg, net price 112-tab pack = £14.40. Label: 23

### Other antispasmodics

Alverine, mebeverine, and peppermint oil are believed to be direct relaxants of intestinal smooth muscle and may relieve pain in irritable bowel syndrome and diverticular disease. They have no serious adverse effects but, like all antispasmodics, should be avoided in paralytic ileus. Peppermint oil occasionally causes heartburn.
1.3 Antisecretory drugs and mucosal protectants

**Mintec® (Almirall)**
Capsules, e/c, green/ivory, peppermint oil 0.2 mL.
Net price 84-cap pack = £7.04. Label: 5, 22, 25
Dose Adult over 18 years, 1–2 capsules swallowed whole with water, 3 times daily before meals for up to 2–3 months if necessary

**Motility stimulants**
Metoclopramide and domperidone (section 4.6) are dopamine receptor antagonists which stimulate gastric emptying and small intestinal transit, and enhance the strength of oesophageal sphincter contraction. They are used in some patients with functional dyspepsia that has not responded to a proton pump inhibitor or a H2-receptor antagonist. Metoclopramide is also used to speed the transit of barium during intestinal follow-through examination, and as accessory treatment for gastro-oesophageal reflux disease. For the management of gastroparesis in patients with diabetes, see section 6.1.5. Metoclopramide and domperidone are useful in non-specific and in cytotoxic-induced nausea and vomiting. Metoclopramide and occasionally domperidone can cause acute dystonic reactions, particularly in young women and children—for further details of this and other side-effects, see section 4.6.

**1.3 Antisecretory drugs and mucosal protectants**

### 1.3.1 H2-receptor antagonists

### 1.3.2 Selective antimuscarinics

### 1.3.3 Chelates and complexes

### 1.3.4 Prostaglandin analogues

### 1.3.5 Proton pump inhibitors

Peptic ulceration commonly involves the stomach, duodenum, and lower oesophagus; after gastric surgery it involves the gastro-enterostomy stoma.

Healing can be promoted by general measures, stopping smoking and taking antacids and by antisecretory drug treatment, but relapse is common when treatment ceases. Nearly all duodenal ulcers and most gastric ulcers not associated with NSAIDs are caused by *Helicobacter pylori*.

The management of *H. pylori* infection and of NSAID-associated ulcers is discussed below.

**Helicobacter pylori infection**

Eradication of *Helicobacter pylori* reduces recurrence of gastric and duodenal ulcers and the risk of rebleeding. It also causes regression of most localised gastric mucosa-associated lymphoid-tissue (MALT) lymphomas. The presence of *H. pylori* should be confirmed before starting eradication treatment. Acid inhibition combined with antibacterial treatment is highly effective in the eradication of *H. pylori*; reinfection is rare. Antibiotic-associated colitis is an uncommon risk.

For initial treatment, a one-week triple-therapy regimen that comprises a proton pump inhibitor, clarithromycin, 

---

**Peppermint Oil**

**Indications** relief of abdominal colic and distension, particularly in irritable bowel syndrome

**Cautions** sensitivity to menthol

**Pregnancy** not known to be harmful

**Breast-feeding** significant levels of menthol in breast milk unlikely

**Side-effects** heartburn, perianal irritation; rarely, allergic reactions (including rash, headache, bradycardia, muscle tremor, ataxia)

**Local irritation** Capsules should not be broken or chewed because peppermint oil may irritate mouth or oesophagus

**Dose** See preparations

**Colpermin® (McNeil)**
Capsules, m/r, e/c, light blue/dark blue, blue band, peppermint oil 0.2 mL. Net price 100-cap pack = £12.05. Label: 5, 22, 25
Excipients include arachis (peanut) oil
Dose Adult over 15 years, 1–2 capsules swallowed whole with water, 3 times daily for up to 3 months if necessary
and either amoxicillin or metronidazole can be used. However, if a patient has been treated with metronidazole for other infections, a regimen containing a proton pump inhibitor, amoxicillin and clarithromycin is preferred for initial therapy. If a patient has been treated with a macrolide for other infections, a regimen containing a proton pump inhibitor, amoxicillin and metronidazole is preferred for initial therapy. These regimens eradicate *H. pylori* in about 85% of cases. There is usually no need to continue antisecretory treatment (with a proton pump inhibitor or H2-receptor antagonist), however, if the ulcer is large, or complicated by haemorrhage or perforation, then antisecretory treatment is continued for a further 3 weeks. Treatment failure usually indicates antibacterial resistance or poor compliance. Resistance to amoxicillin is rare. However, resistance to clarithromycin and metronidazole is common and can develop during treatment.

Two-week triple-therapy regimens offer the possibility of higher eradication rates compared to one-week regimens, but adverse effects are common and poor compliance is likely to offset any possible gain.

Two-week dual-therapy regimens using a proton pump inhibitor and a single antibacterial are licensed, but produce low rates of *H. pylori* eradication and are not recommended.

Tinidazole is also used occasionally for *H. pylori* eradication as an alternative to metronidazole; tinidazole should be combined with antisecretory drugs and other antibacterials.

A two-week regimen comprising a proton pump inhibitor (e.g. omeprazole 20 mg twice daily) plus tripotassium dicitratobismuthate 120 mg four times daily, plus tetracycline 500 mg four times daily, plus metronidazole 400–500 mg three times daily can be used for eradication failure. Alternatively, the patient can be referred for endoscopy and treatment based on the results of culture and sensitivity testing.

For the role of *H. pylori* eradication therapy in patients starting or taking a NSAID, see NSAID-associated Ulcers, below. For *H. pylori* eradication in patients with dyspepsia, see also section 1.1.

### Test for *Helicobacter pylori*

13C-Urea breath test kits are available for the diagnosis of gastro-duodenal infection with *Helicobacter pylori*. The test involves collection of breath samples before and after ingestion of an oral solution of 13C-urea; the samples are sent for analysis by an appropriate laboratory. The test should not be performed within 4 weeks of treatment with an antibacterial or within 2 weeks of treatment with an antisecretory drug. A specific 13C-urea breath test kit for children is available (*Helicobacter Test INFAI for children of the age 3–11*®). However, the appropriateness of testing for *H. pylori* infection in children has not been established.

#### diabact UBT® (Mod) (Infai)

| Tablets, 13C-urea 50 mg, net price 1 kit (including 1 tablet, 4 breath-sample containers, straws) = £21.25 (analysis included), 10-kit pack (hosp. only) = £74.50 (analysis not included) |
| Oral powder, 13C-urea 75 mg, net price 1 kit (including 4 breath-sample containers, straws) = £19.20 (spectrometric analysis included), 1 kit (including 2 breath bags) = £14.20 (spectrometric analysis not included), 50-test set = £855.00 (spectrometric analysis included); 45 mg (*Helicobacter Test INFAI for children of the age 3–11*®), 1 kit (including 4 breath-sample containers, straws) = £19.20 (spectrometric analysis included) |
| Pylobactell® (Torbet) (MDE) |

### NSAID-associated ulcers

Gastro-intestinal bleeding and ulceration can occur with NSAID use (section 10.1.1). The risk of serious upper gastro-intestinal side-effects varies between individual NSAIDs (see CSM advice, p. 632). Whenever possible, the NSAID should be withdrawn if an ulcer occurs.

---

**Recommended regimens for *Helicobacter pylori* eradication in adults**

<table>
<thead>
<tr>
<th>Acid suppressant</th>
<th>Antibacterial</th>
<th>Price for 7-day course</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lansoprazole 20 mg twice daily</td>
<td>1 g twice daily 500 mg twice daily —</td>
<td>£15.10</td>
</tr>
<tr>
<td>—</td>
<td>250 mg twice daily 400 mg twice daily</td>
<td>£13.32</td>
</tr>
<tr>
<td>Omeprazole 20 mg twice daily</td>
<td>1 g twice daily 500 mg twice daily —</td>
<td>£6.97</td>
</tr>
<tr>
<td>—</td>
<td>250 mg twice daily 400 mg twice daily</td>
<td>£3.77</td>
</tr>
<tr>
<td>Pantoprazole 40 mg twice daily</td>
<td>1 g twice daily 500 mg twice daily —</td>
<td>£5.19</td>
</tr>
<tr>
<td>—</td>
<td>250 mg twice daily 400 mg twice daily</td>
<td>£5.03</td>
</tr>
<tr>
<td>Rabeprazole 20 mg twice daily</td>
<td>1 g twice daily 500 mg twice daily —</td>
<td>£13.85</td>
</tr>
<tr>
<td>—</td>
<td>250 mg twice daily 400 mg twice daily</td>
<td>£15.63</td>
</tr>
</tbody>
</table>
Patients at high risk of developing gastro-intestinal complications with a NSAID include those aged over 65 years, those with a history of peptic ulcer disease or serious gastro-intestinal complication, those taking other medicines that increase the risk of gastro-intestinal side-effects, or those with serious co-morbidity. In those at risk of ulceration, a proton pump inhibitor can be considered for protection against gastric and duodenal ulcers associated with non-selective NSAIDs; a H$_2$-receptor antagonist such as ranitidine given at twice the usual dose or misoprostol are alternatives. Colic and diarrhoea may limit the dose of misoprostol. A combination of a cyclo-oxygenase-2 selective inhibitor with a proton pump inhibitor may be more appropriate for those with a history of upper gastro-intestinal bleeding or 3 or more risk factors for gastro-intestinal ulceration, but see NSAIDs and Cardiovascular Events, p. 631. NSAID use and $H$. pylori infection are independent risk factors for gastro-intestinal bleeding and ulceration. In patients already taking a NSAID, eradication of $H$. pylori is unlikely to reduce the risk of NSAID-induced bleeding or ulceration. However, in patients with dyspepsia or a history of gastric or duodenal ulcer, who are $H$. pylori positive, and who are about to start long-term treatment with a non-selective NSAID, eradication of $H$. pylori may reduce the overall risk of ulceration.

If the NSAID can be discontinued in a patient who has developed an ulcer, a proton pump inhibitor usually produces the most rapid healing; alternatively, the ulcer can be treated with a H$_2$-receptor antagonist or misoprostol.

If treatment with a non-selective NSAID needs to continue, the following options are suitable:

- Treat ulcer with a proton pump inhibitor and on healing continue the proton pump inhibitor (dose not normally reduced because asymptomatic ulcer recurrence may occur);
- Treat ulcer with a proton pump inhibitor and on healing switch to misoprostol for maintenance therapy (colic and diarrhoea may limit the dose of misoprostol);
- Treat ulcer with a proton pump inhibitor and switch non-selective NSAID to a cyclo-oxygenase-2 selective inhibitor, but see NSAIDs and Cardiovascular Events, p. 631; on healing, continuation of the proton pump inhibitor in patients with a history of upper gastro-intestinal bleeding may provide further protection against recurrence.

If treatment with a cyclo-oxygenase-2 selective inhibitor needs to continue, treat ulcer with a proton pump inhibitor; on healing continuation of the proton pump inhibitor in patients with a history of upper gastrointestinal bleeding may provide further protection against recurrence.

Maintenance treatment with low doses for the prevention of peptic ulcer disease has largely been replaced in *Helicobacter pylori* positive patients by eradication regimens (section 1.3).

H$_2$-receptor antagonists are used for the treatment of functional dyspepsia (section 1.1). H$_2$-receptor antagonists may be used for the treatment of uninvestigated dyspepsia in patients without alarm features.

H$_2$-receptor antagonist therapy can promote healing of NSAID-associated ulcers (particularly duodenal) (section 1.3).

Treatment with a H$_2$-receptor antagonist has not been shown to be beneficial in haematemesis and melaena, but prophylactic use reduces the frequency of bleeding from gastro-duodenal erosions in hepatic coma, and possibly in other conditions requiring intensive care. H$_2$-receptor antagonists also reduce the risk of acid aspiration in obstetric patients at delivery (Mendelson's syndrome).

Cautions H$_2$-receptor antagonists might mask symptoms of gastric cancer; particular care is required in patients presenting with ‘alarm features’ (see p. 43), in such cases gastric malignancy should be ruled out before treatment.

Side-effects Side-effects of the H$_2$-receptor antagonists include diarrhoea, headache, and dizziness. Rash (including erythema multiforme and toxic epidermal necrolysis) occurs less frequently. Other side-effects reported rarely or very rarely include hepatitis, cholestatic jaundice, bradycardia, psychiatric reactions (including confusion, depression, and hallucinations) particularly in the elderly or the very ill, blood disorders (including leucopenia, thrombocytopenia, and pancytopenia), arthralgia, and myalgia. Gynaecomastia and impotence occur occasionally with cimetidine and there are isolated reports with the other H$_2$-receptor antagonists.

Interactions Cimetidine retards oxidative hepatic drug metabolism by binding to microsomal cytochrome P450. It should be avoided in patients stabilised on warfarin, phenytoin, and theophylline (or aminophylline), but other interactions (see Appendix 1) may be of less clinical relevance. Famotidine, nizatidine, and ranitidine do not share the drug metabolism inhibitory properties of cimetidine.

1.3.1 H$_2$-receptor antagonists

Histamine H$_2$-receptor antagonists heal gastric and duodenal ulceration, benign gastric and duodenal ulceration, postsurgical ulceration, functional dyspepsia (section 1.1). H$_2$-receptor antagonists should not normally be used for Zollinger-Ellison syndrome because proton pump inhibitors (section 1.3.5) are more effective.
1.3.1 H₂-receptor antagonists

**Side-effects** see notes above; also malaise; less commonly tachycardia; rarely interstitial nephritis; very rarely pancreatitis, galactorrhoea, vasculitis, alopecia

**Dose**
- 400 mg twice daily (with breakfast and at night) or 800 mg at night (benign gastric and duodenal ulceration) for at least 4 weeks (6 weeks in gastric ulceration, 8 weeks in NSAID-associated ulceration); when necessary the dose may be increased to 400 mg 4 times daily; **INFANT** under 1 year 20 mg/kg daily in divided doses has been used; **CHILD** 1–12 years, 25–30 mg/kg daily in divided doses; max. 400 mg 4 times daily.
- Maintenance, 400 mg at night or 400 mg morning and night.
- Prophylaxis of stress ulceration, 200–400 mg every 4–6 hours.
- Gastric acid reduction (prophylaxis of acid aspiration; do not use syrup), obstetrics 400 mg at start of labour, then up to 400 mg every 4 hours if required (max. 2.4 g daily); surgical procedures 400 mg 90–120 minutes before induction of general anaesthesia.
- Short-bowel syndrome, 400 mg twice daily (with breakfast and at bedtime) adjusted according to response.
- To reduce degradation of pancreatic enzyme supplements, 0.8–1.6 g daily in 4 divided doses 1–1½ hours before meals.

**Famotidine** (Non-proprietary)

**Tables**, cimetidine 200 mg, net price 60-tab pack = £9.08; 400 mg, 60-tab pack = £7.61; 800 mg, 30-tab pack = £2.86.

**Oral solution**, cimetidine 200 mg/5 mL, net price 300 mL = £14.56.

**Excipients** may include propylene glycol (see Excipients, p. 2).

**Tagamet** (Chemidex)

**Tables**, all green, f/c, cimetidine 200 mg, net price 120-tab pack = £19.58; 400 mg, 60-tab pack = £22.62; 800 mg, 30-tab pack = £22.62.

**Syrup**, orange, cimetidine 200 mg/5 mL. Net price 600 mL = £28.49.

**Excipients** include propylene glycol 10% (see Excipients, p. 2).

**Nizatidine**

**Indications** see under Dose.

**Cautions** see notes above; avoid severe anemia; known or suspected aplastic anaemia; or severe or lifethreatening infection.

**Renal impairment** use normal dose every 36–48 hours or use half normal dose if eGFR less than 50 mL/minute/1.73 m²; seizures reported very rarely.

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk.

**Breast-feeding** present in milk—not known to be harmful but manufacturer advises avoid.

**Side-effects** see notes above; also constipation; less commonly dry mouth, nausea, vomiting, flatulence, taste disorders, anorexia, fatigue; very rarely chest tightness, interstitial pneumonia, seizures, paraesthesia.

**Dose**
- **Cimetidine**
  - 400 mg twice daily (with breakfast and at night)
  - **INFANT** under 1 year 20 mg/kg daily in divided doses; **CHILD** 1–12 years, 25–30 mg/kg daily in divided doses; max. 400 mg 4 times daily.

**Famotidine** (Non-proprietary)

**Tables**, famotidine 20 mg, net price 28-tab pack = £4.47; 40 mg, 28-tab pack = £5.64.

- Famotidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks' supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink including when they cause sleep disturbance (max. single dose 10 mg, max. daily dose 20 mg).

**Pepcid** (MSD)

**Tables**, f/c, famotidine 20 mg (beige), net price 28-tab pack = £13.37; 40 mg (brown), 28-tab pack = £25.40

**Famotidine**

**Indications** see under Dose.

**Cautions** see notes above; also avoid rapid intravenous injection (risk of arrhythmias and postural hypotension); **interactions:** Appendix 1 (histamine H₂-antagonists) and notes above.

**Hepatic impairment** manufacturer advises caution.

**Renal impairment** use half normal dose if eGFR 20–50 mL/minute/1.73 m²; use one-quarter normal dose if eGFR less than 20 mL/minute/1.73 m².

**Pregnancy** manufacturer advises avoid unless essential.

**Breast-feeding** amount too small to be harmful.

**Side-effects** see notes above; also sweating; rarely nausea, fever, vasculitis, hyperuricaemia.

**Dose**
- **By mouth**, benign gastric, duodenal or NSAID-associated ulceration, treatment, 300 mg in the evening or 150 mg twice daily for 4–8 weeks; maintenance, 150 mg at night.
- **Gastro-oesophageal reflux disease**, 150–300 mg twice daily for up to 12 weeks.
- **By intravenous infusion**, for short-term use in peptic ulcer as alternative to oral route (for hospital inpatients), by intermittent intravenous infusion over 15 minutes, 100 mg 3 times daily, or by continuous intravenous infusion, 10 mg/hour; max. 480 mg daily.
- **CHILD** not recommended.

**Nizatidine** (Non-proprietary)

**Capsules**, nizatidine 150 mg, net price 30-cap pack = £12.04; 300 mg, 30-cap pack = £14.28.

- Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years: max. single dose 75 mg, max. daily dose 150 mg for max. 14 days.

**Axid** (Flynn)

**Capsules**, nizatidine 150 mg (pale yellow/dark yellow), net price 28-cap pack (hosp. only) = £6.87; 30-cap pack = £7.97; 300 mg (pale yellow/brown), 30-cap pack = £15.80.

**Injection**, nizatidine 25 mg/mL. For dilution and use as an intravenous infusion. Net price 4-mL amp = £1.14.
RANITIDINE

Indications see under Dose, other conditions where reduction of gastric acidity is beneficial (see notes above and section 1.9.4)

Cautions see notes above; also acute porphyria; see Appendix 1 (histamine H2-antagonists) and notes above

Renal impairment use half normal dose if eGFR less than 50 mL/minute/1.73 m2

Pregnancy manufacturer advises avoid unless essential

Breast-feeding significant amount present in milk, but not known to be harmful

Side-effects see notes above; less commonly blurred vision; also reported pancreatitis, involuntary movement disorders, interstitial nephritis, alopecia

Dose

- By mouth, benign gastric and duodenal ulceration, chronic episodic dyspepsia, ADULT and CHILD over 12 years, 150 mg twice daily or 300 mg at night for 4–8 weeks in benign gastric and duodenal ulceration, up to 6 weeks in chronic episodic dyspepsia, and up to 8 weeks in NSAID-associated ulceration (in duodenal ulcer 300 mg can be given twice daily for 4 weeks to achieve a higher healing rate); CHILD 3–12 years, (benign gastric and duodenal ulceration) 2–4 mg/kg (max. 150 mg) twice daily for 4–8 weeks

- Prophylaxis of NSAID-associated gastric or duodenal ulcer [unlicensed dose], ADULT and CHILD over 12 years, 300 mg twice daily

- Gastro-oesophageal reflux disease, ADULT and CHILD over 12 years, 150 mg twice daily or 300 mg at night for up to 8 weeks or if necessary 12 weeks (moderate to severe, 600 mg daily in 2–4 divided doses for up to 12 weeks); long-term treatment of healed gastro-oesophageal reflux disease, 150 mg twice daily; CHILD 3–12 years, 2.5–5 mg/kg (max. 300 mg) twice daily

- Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics, ADULT and CHILD over 12 years, by mouth, 150 mg at onset of labour, then every 6 hours; surgical procedures, by intramuscular or slow intravenous injection, 50 mg 45–60 minutes before induction of anaesthesia (intravenous injection diluted to 20 mL and given over at least 2 minutes), or by mouth, 150 mg 2 hours before induction of anaesthesia and also when possible on the preceding evening

- By intramuscular injection, 50 mg every 6–8 hours

- By slow intravenous injection, ADULT and CHILD over 12 years, 50 mg diluted to 20 mL and given over at least 2 minutes; may be repeated every 6–8 hours

- Prophylaxis of stress ulceration [unlicensed dose], ADULT and CHILD over 12 years, by slow intravenous injection over at least 2 minutes, 50 mg diluted to 20 mL every 8 hours (may be changed to 150 mg twice daily by mouth when oral feeding commences)

Ranitidine (Non-proprietary) Tablets, ranitidine (as hydrochloride) 150 mg, net price 60-tab pack = £1.97; 300 mg, 30-tab pack = £2.17

Brands include Zantac®

Effervescent tablets, ranitidine (as hydrochloride) 150 mg, net price 60-tab pack = £18.04; 300 mg, 30-tab pack = £17.03. Label: 13

Excipients may include sodium (check with supplier)

1.3.2 Selective antimuscarinics

Oral solution, ranitidine (as hydrochloride) 75 mg/5 mL, net price 100 mL = £7.44, 300 mL = £19.61

Excipients may include alcohol (check with supplier)

Note Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks’ supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75 mg, max. daily dose 300 mg)

Injection, ranitidine (as hydrochloride) 25 mg/mL, net price 2-mL amp = 54p

Zantac® (GSK) Tablets, f/c, ranitidine (as hydrochloride) 150 mg, net price 60-tab pack = £1.30; 300 mg, 30-tab pack = £1.30

Syrup, sugar-free, ranitidine (as hydrochloride) 75 mg/5 mL, net price 300 mL = £20.76

Excipients include alcohol 8%

Injection, ranitidine (as hydrochloride) 25 mg/mL, net price 2-mL amp = 57p

1.3.3 Chelates and complexes

Tripotassium dicitratobismuthate is a bismuth chelate effective in healing gastric and duodenal ulcers. For the role of tripotassium dicitratobismuthate in a Helicobacter pylori eradication regimen for those who have not responded to first-line regimens, see section 1.3.

The bismuth content of tripotassium dicitratobismuthate is low but absorption has been reported; encephalopathy (described with older high-dose bismuth preparations) has not been reported.

Sucralfate may act by protecting the mucosa from pepsin attack in gastric and duodenal ulcers. It is a complex of aluminium hydroxide and sulphated sucrose but has minimal antiacid properties. It should be used with caution in patients under intensive care (important: reports of bezoar formation, see Bezoar Formation below)

TRIPOTASSIUM DICTRATOBISMUTHATE

Indications benign gastric and duodenal ulceration; see also Helicobacter pylori infection, section 1.3

Cautions see notes above; interactions: Appendix 1 (tripotassium dicitratobismuthate)

Renal impairment avoid in severe impairment

Pregnancy manufacturer advises avoid on theoretical grounds

Breast-feeding no information available

Side-effects may darken tongue and blacken faeces; less commonly nausea, vomiting, diarrhoea, constipation, rash, and pruritus reported
Misoprostol, a synthetic prostaglandin analogue has antisecretory and protective properties, promoting healing of gastric and duodenal ulcers. It can prevent NSAID-associated ulcers, its use being most appropriate for the frail or very elderly from whom NSAIDs cannot be withdrawn.

For comment on the use of misoprostol to induce abortion or labour [unlicensed indications], see section 7.1.1.

**MISOPROSTOL**

**Indications** see notes above and under Dose

**Cautions** conditions where hypotension might precipitate severe complications (e.g. cerebrovascular disease, cardiovascular disease)

**Contra-indications** planning pregnancy [important: see Women of Childbearing Age, and also Pregnancy, below]

Women of childbearing age Manufacturer advises that misoprostol should not be used in women of childbearing age unless the patient requires non-steroidal anti-inflammatory (NSAID) therapy and is at high risk of complications from NSAID-induced ulceration. In such patients it is advised that misoprostol should only be used if the patient takes effective contraceptive measures and has been advised of the risks of taking misoprostol if pregnant.

**Pregnancy** avoid—potent uterine stimulant (has been used to induce abortion) and may be teratogenic; important: see also Women of Childbearing Age, above

**Breast-feeding** no information available—manufacturer advises avoid

**Side-effects** diarrhoea (may occasionally be severe and require withdrawal, reduced by giving single doses not exceeding 200 micrograms and by avoiding magnesium-containing antacids); also reported: abdominal pain, dyspepsia, flatulence, nausea and vomiting, abnormal vaginal bleeding (including intermenstrual bleeding, menorrhagia, and postmenopausal bleeding), rashes, dizziness

**Dose**

- **Benign gastric and duodenal ulceration and NSAID-associated ulceration, ADULT over 18 years, 800 micrograms daily (in 2–4 divided doses) with breakfast (or main meals) and at bedtime; treatment should be continued for at least 4 weeks and may be continued for up to 8 weeks if required**

- **Prophylaxis of NSAID-induced gastric and duodenal ulcer, ADULT over 18 years, 200 micrograms 4 times daily (if not tolerated, reduced to 200 micrograms 2–3 times daily, but less effective)**

**Cytotec®** (Pharmacia) Tablets, scored, misoprostol 200 micrograms, net price 60-tab pack = £10.03. Label: 21

With diclofenac or naproxen

Section 10.1.1

**1.3.4 Prostaglandin analogues**

**De-Noltab®** (Astellas) Tablets, f/c, tripotassium dicitratobismuthate 120 mg, net price 112-tab pack = £5.09. Counselling, see below Electrolytes K+ 2 mmol/tablet

Dose 2 tablets twice daily or 1 tablet 4 times daily; taken for 28 days followed by further 28 days if necessary; maintenance not indicated but course may be repeated after interval of 1 month; CHILD not recommended

Counselling To be swallowed with half a glass of water; twice-daily dosage to be taken 30 minutes before breakfast and main evening meal; four-times-daily dosage to be taken as follows: one dose 30 minutes before breakfast, midday meal and main evening meal, and one dose 2 hours after main evening meal; milk should not be drunk by itself during treatment but small quantities may be taken in tea or coffee or on cereal; antacids, fruit, or fruit juice should not be taken half an hour before or after a dose; may darken tongue and blacken faces

**Sucralfate**

**Indications** see under Dose

**Cautions** administration of sucralfate and enteral feeds should be separated by 1 hour; interactions: Appendix 1 (sucralfate)

**Bezoar formation** Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying

**Renal impairment** use with caution; aluminium is absorbed and may accumulate

**Pregnancy** no evidence of harm; absorption from gastro-intestinal tract negligible

**Breast-feeding** amount probably too small to be harmful

**Side-effects** constipation; less frequently diarrhoea, nausea, indigestion, flatulence, gastric discomfort, back pain, dizziness, headache, drowsiness, bezoar formation (see above), dry mouth and rash

**Dose**

- **Benign gastric and duodenal ulceration and chronic gastritis, ADULT and CHILD over 15 years, 2 g twice daily (on rising and at bedtime) or 1 g 4 times daily 1 hour before meals and at bedtime, taken for 4–6 weeks or in resistant cases up to 12 weeks; max. 8 g daily**

- **Prophylaxis of stress ulceration, ADULT and CHILD over 15 years, 1 g 6 times daily; max. 8 g daily**

- **CHILD under 15 years see BNF for Children**

**Antepsin®** (Chugai) Tablets, scored, sucralfate 1 g, net price 50-tab pack = £5.77. Label: 5

**Note** Crushed tablets may be dispersed in water

**Suspension**, sucralfate, 1 g/5 mL, net price 250 mL (aniseed- and caramel-flavoured) = £5.77. Label: 5

**1.3.5 Proton pump inhibitors**

Proton pump inhibitors inhibit gastric acid secretion by blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the ‘proton pump’) of the gastric parietal cell. Proton pump inhibitors are effective short-term treatments for gastric and duodenal ulcers; they are also used in combination with antibacterials for the eradication of Helicobacter pylori (see p. 50 for specific regimens). Following endoscopic treatment of severe peptic ulcer bleeding, an intravenous, high-dose proton pump inhibitor reduces the risk of rebleeding and the need for surgery. Proton pump inhibitors can be used for the treatment of dyspepsia and gastro-oesophageal reflux disease (section 1.1).

Proton pump inhibitors are also used for the prevention and treatment of NSAID-associated ulcers (see p. 50). In patients who need to continue NSAID treatment after an
ulcer has healed, the dose of proton pump inhibitor should normally not be reduced because asymptomatic ulcer deterioration may occur.

A proton pump inhibitor can be used to reduce the degradation of pancreatic enzyme supplements (section 1.9.4) in patients with cystic fibrosis. They can also be used to control excessive secretion of gastric acid in Zollinger–Ellison syndrome; high doses are often required.

**Cautions** Proton pump inhibitors may mask the symptoms of gastric cancer; particular care is required in such situations; gastric malignancy should be ruled out before treatment.

**Side-effects** Side-effects of the proton pump inhibitors include gastro-intestinal disturbances (including nausea, vomiting, abdominal pain, flatulence, diarrhoea, constipation), and headache. Less frequent side-effects include dry mouth, peripheral oedema, dizziness, sleep disturbances, fatigue, paraesthesia, arthralgia, myalgia, rash, and pruritus. Other side-effects reported rarely or very rarely include taste disturbance, stomatitis, hepatitis, jaundice, hypersensitivity reactions (including anaphylaxis, bronchospasm), fever, depression, hallucinations, confusion, gynaecomastia, interstitial nephritis, hyponatraemia, blood disorders (including leucopenia, leucocytosis, pancytopenia, thrombocytopenia), visual disturbances, sweating, photosensitivity, alopecia, Stevens-Johnson syndrome, and toxic epidermal necrolysis. By decreasing gastric acidity, proton pump inhibitors may increase the risk of gastro-intestinal infections (including *Clostridium difficile* infection).

**ESOMEPRAZOLE**

**Indications** see under Dose

**Cautions** see notes above; **interactions:** Appendix 1 (proton pump inhibitors)

**Hepatic impairment** in severe hepatic impairment max. 20 mg daily (ADULT 1–12 years max. 10 mg daily); for severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80 mg, then by continuous intravenous infusion, 4 mg/hour for 72 hours

**Renal impairment** manufacturer advises caution in severe renal insufficiency

**Pregnancy** manufacturer advises caution—no information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** see notes above

**Dose**

- **By mouth**
  - Duodenal ulcer associated with *Helicobacter pylori*, see eradication regimens on p. 50
  - NSAID-associated gastric ulcer, **ADULT** over 18 years, 20 mg once daily for 4–8 weeks; prophylaxis in patients with an increased risk of gastrointestinal complications who require continued NSAID treatment, 20 mg daily
  - Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis), **ADULT** and **CHILD** over 12 years, 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily; **CHILD** 1–12 years, body-weight 10–20 kg, 10 mg once daily for 8 weeks; body-weight over 20 kg, 10–20 mg once daily for 8 weeks

**BNF 61 1.3.5 Proton pump inhibitors 55**

Symptomatic treatment of gastro-oesophageal reflux disease (in the absence of oesophagitis), **ADULT** and **CHILD** over 12 years, 20 mg once daily for up to 4 weeks, then 20 mg daily when required; **CHILD** 1–12 years, body-weight over 10 kg, 10 mg once daily for up to 8 weeks

Zollinger–Ellison syndrome, **ADULT** over 18 years, initially 40 mg twice daily, adjusted according to response; usual range 80–160 mg daily (above 80 mg in 2 divided doses)

- By **intravenous injection** over at least 3 minutes or by **intravenous infusion**, **ADULT** over 18 years, gastro-oesophageal reflux disease, 40 mg once daily; symptomatic reflux disease without oesophagitis, treatment of NSAID-associated gastric ulcer, prevention of NSAID-associated gastric or duodenal ulcer, 20 mg daily; continue until oral administration possible

- Severe peptic ulcer bleeding (following endoscopic treatment), **ADULT** over 18 years, initial **intravenous infusion** of 80 mg over 30 minutes, then by continual **intravenous infusion** 8 mg/hour for 72 hours, then by **mouth** 40 mg once daily for 4 weeks

**Nexium®** (AstraZeneca) (HF)

**Tablets**

- f/c, esomeprazole (as magnesium trihydrate) 20 mg (light pink), net price 28-tab pack = £18.50; 40 mg (pink), 28-tab pack = £25.19. Counselling, administration

- **Counselling** Do not chew or crush tablets, swallow whole or disperse in water

**Granules**

- yellow, e/c, esomeprazole (as magnesium trihydrate) 10 mg/sachet, net price 28-sachet pack = £25.19. Label: 25, counselling, administration

- **Counselling** Disperse the contents of each sachet in approx. 15 mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15 mL water to obtain full dose; can be administered through nasogastric or gastric tube

**Injection** powder for reconstitution, esomeprazole (as sodium salt), net price 40-mg vial = £3.13

- **With naproxen**

  Section 10.1.1

**LANSPROZOLE**

**Indications** see under Dose

**Cautions** see notes above; **interactions:** Appendix 1 (proton pump inhibitors)

**Hepatic impairment** use half normal dose in moderate to severe liver disease

**Pregnancy** manufacturer advises avoid

**Breast-feeding** avoid unless essential—present in milk in animal studies

**Side-effects** see notes above; also glossitis, pancreatitis, anorexia, restlessless, tremor, impotence, petechiae, and purpura; very rarely colitis, raised serum cholesterol or triglycerides

**Dose**

- Benign gastric ulcer, 30 mg daily in the morning for 8 weeks

- Duodenal ulcer, 30 mg daily in the morning for 4 weeks; maintenance 15 mg daily

- NSAID-associated duodenal or gastric ulcer, 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; prophylaxis, 15–30 mg once daily

- Eradication of *Helicobacter pylori* associated with duodenal ulcer or ulcer-like dyspepsia, see eradication regimens on p. 50
1.3.5 Proton pump inhibitors

- Zollinger-Ellison syndrome (and other hypersecretory conditions), initially 60 mg once daily adjusted according to response; daily doses of 120 mg or more given in two divided doses
- Gastro-oesophageal reflux disease, 30 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 15–30 mg daily
- Acid-related dyspepsia, 15–30 mg daily in the morning for 4–8 weeks
- CHILD under 18 years see BNF for Children

Note Lansoprazole doses in BNF may differ from those in product literature

Lansoprazole (Non-proprietary) *(P)*

Capsules, enclosing e/c granules, lansoprazole 15 mg, net price 28-cap pack = £1.44; 30 mg, 28-cap pack = £2.23. Label: 5, 22, 25

Dental prescribing on NHS Lansoprazole capsules may be prescribed

Zoton® *(Wyeth)* *(P)*

Capsules, enclosing e/c granules, lansoprazole 15 mg, net price 28-cap pack = £2.99; 30 mg, 28-tab pack = £5.50. Label: 5, 22, counselling, administration Excipients include aspartame (section 9.4.1)

Counselling Tablets should be placed on the tongue, allowed to disperse and swallowed, or may be swallowed whole with a glass of water. Alternatively, tablets can be dispersed in a small amount of water and administered by an oral syringe or nasogastric tube

OMEPRAZOLE

Indications see under Dose

Cautions see notes above; Interactions: Appendix 1 (proton pump inhibitors)

Hepatic impairment not more than 20 mg daily should be needed

Pregnancy not known to be harmful

Breast-feeding present in milk but not known to be harmful

Side-effects see notes above; also agitation and impotence

Dose
- By mouth, benign gastric and duodenal ulcers, 20 mg once daily for 4 weeks in duodenal ulceration or 8 weeks in gastric ulceration; in severe or recurrent cases increase to 40 mg daily; maintenance for recurrent duodenal ulcer, 20 mg once daily; prevention of relapse in duodenal ulcer, 10 mg daily increasing to 20 mg once daily if symptoms return NSAIĐ-associated duodenal or gastric ulcer and gastroduodenal erosions, 20 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; prophylaxis in patients with a history of NSAIĐ-associated duodenal or gastric ulcers, gastroduodenal lesions, or dyspeptic symptoms who require continued NSAIĐ treatment, 20 mg once daily
- Duodenal or benign gastric ulcer associated with Helicobacter pylori, see eradication regimens on p. 50
- Zollinger–Ellison syndrome, initially 60 mg once daily; usual range 20–120 mg daily (above 80 mg in 2 divided doses)
- Gastric acid reduction during general anaesthesia (prophylaxis of acid aspiration), 40 mg on the preceding evening then 40 mg 2–6 hours before surgery
- Gastro-oesophageal reflux disease, 20 mg once daily for 4 weeks, continued for further 4–8 weeks if not fully healed; 40 mg once daily has been given for 8 weeks in gastro-oesophageal reflux disease refractory to other treatment; maintenance 20 mg once daily

Acid reflux disease (long-term management), 10 mg daily increasing to 20 mg once daily if symptoms return
- Acid-related dyspepsia, 10–20 mg once daily for 2–4 weeks according to response
- Severe ulcerating reflux oesophagitis, CHILD over 1 year, body-weight 10–20 kg, 10 mg once daily increased if necessary to 20 mg once daily for 4–12 weeks; body-weight over 20 kg, 20 mg once daily increased if necessary to 40 mg once daily for 4–12 weeks; to be initiated by hospital paediatrician
- By intravenous injection over 5 minutes or by intravenous infusion over 20–30 minutes, prophylaxis of acid aspiration, 40 mg completed 1 hour before surgery
- Benign gastric ulcer, duodenal ulcer and gastro-oesophageal reflux, 40 mg once daily until oral administration possible
- Major peptic ulcer bleeding (following endoscopic treatment) [unlicensed indication], initial intravenous infusion of 80 mg over 40–60 minutes, then by continuous intravenous infusion, 8 mg/hour for 72 hours (then change to oral therapy)

Counselling Swallow whole, or disperse MUPS® tablets in water, or mix capsule contents or MUPS® tablets with fruit juice or yoghurt. Preparations consisting of an e/c tablet within a capsule should not be opened

Omeprazole (Non-proprietary) *(P)*

Capsules, enclosing e/c granules, omeprazole 10 mg, net price 28-cap pack = £1.81; 20 mg, 28-cap pack = £1.92; 40 mg, 7-cap pack = £1.95, 28-cap pack = £21.65. Counselling, administration

Capsules, enclosing e/c tablet, omeprazole 10 mg, net price 28-cap pack = £1.81; 20 mg, 28-cap pack = £1.92. Counselling, administration

Brands include Mepradec®

Dental prescribing on NHS Gastro-resistant omeprazole capsules may be prescribed

1. Omeprazole 10 mg tablets can be sold to the public for the short-term relief of reflux-like symptoms (e.g. heartburn) in adults over 18 years, max. daily dose 20 mg for max. 4 weeks, and a pack size of 28 tablets

Losec® *(AstraZeneca)* *(P)*

MUPS® (multiple-unit pellet system = dispersible tablets), f/c, omeprazole 10 mg (light pink), net price 28-tab pack = £7.75; 20 mg (pink), 28-tab pack = £11.60; 40 mg (red-brown), 7-tab pack = £5.80. Counselling, administration

Capsules, enclosing e/c granules, omeprazole 10 mg (pink), net price 28-cap pack = £7.75; 20 mg (pink/brown), 28-cap pack = £11.60; 40 mg (brown), 7-cap pack = £5.80. Counselling, administration

Intravenous infusion, powder for reconstitution, omeprazole (as sodium salt), net price 40-mg vial = £5.18

With ketoprofen

Section 10.1.1
**PANTOPRAZOLE**

**Indications** see under Dose

**Cautions** see notes above; **interactions:** Appendix 1 (proton pump inhibitors)

**Hepatic impairment** max. 20 mg daily in severe impairment and cirrhosis—monitor liver function (discontinue if deterioration)

**Renal impairment** max. oral dose 40 mg daily

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk—fetal toxic in **animals**

**Breast-feeding** manufacturer advises avoid unless potential benefit outweighs risk—small amount present in milk in **animal** studies

**Side-effects** see notes above; also hyperlipidaemia, weight changes

**Dose**

- By mouth, benign gastric ulcer, **ADULT** over 18 years, 40–80 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed
- Gastro-oesophageal reflux disease, **ADULT** and **CHILD** over 12 years, 20–80 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 20 mg daily, increased to 40 mg daily if symptoms return
- Duodenal ulcer, **ADULT** over 18 years, 40–80 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed
- Duodenal ulcer associated with *Helicobacter pylori*, see eradication regimens on p. 50
- Prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment, **ADULT** over 18 years, 20 mg daily
- Zollinger–Ellison syndrome (and other hypersecretory conditions), **ADULT** over 18 years, initially 80 mg once daily adjusted according to response (ELDERLY max. 40 mg daily); daily doses above 80 mg given in 2 divided doses
- By intravenous **injection** over at least 2 minutes or by intravenous **infusion**, **ADULT** over 18 years, duodenal ulcer, gastric ulcer, and gastro-oesophageal reflux, 40 mg daily until oral administration can be resumed
- Zollinger–Ellison syndrome (and other hypersecretory conditions), **ADULT** over 18 years, initially 80 mg (160 mg if rapid acid control required) then 80 mg once daily adjusted according to response; daily doses above 80 mg given in 2 divided doses

**Pantoprazole** (Non-proprietary)

Tables, e/c, pantoprazole 20 mg, net price 28-tab pack = £1.79; 40 mg, 28-tab pack = £2.82. Label: 25

**Note** Pantoprazole 20 mg tablets can be sold to the public for the short-term treatment of reflux symptoms (e.g. heartburn) in adults over 18 years, max. daily dose 20 mg for max. 4 weeks

**Protiul**® (Nycomed)

**Injection**, powder for reconstitution, pantoprazole (as sodium salt), net price 40-mg vial = £5.11

**RABEPRAZOLE SODIUM**

**Indications** see under Dose

**Cautions** see notes above; **interactions:** Appendix 1 (proton pump inhibitors)

**Hepatic impairment** manufacturer advises caution in severe hepatic dysfunction

**Pregnancy** manufacturer advises avoid—no information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** see notes above; also cough, influenza-like syndrome, and rhinitis; less commonly chest pain and nervousness; rarely anorexia and weight gain

**Dose**

- Benign gastric ulcer, 20 mg daily in the morning for 6 weeks, continued for further 6 weeks if not fully healed
- Duodenal ulcer, 20 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed
- Gastro-oesophageal reflux disease, 20 mg once daily for 4–8 weeks; maintenance 10–20 mg daily; symptomatic treatment in the absence of esophagitis, 10 mg daily for up to 4 weeks, then 10 mg daily when required
- Duodenal and benign gastric ulcer associated with *Helicobacter pylori*, see eradication regimens on p. 50
- Zollinger–Ellison syndrome, initially 60 mg once daily adjusted according to response (max. 120 mg daily); doses above 100 mg daily given in 2 divided doses
- **CHILD** not recommended

**Pariet**® (Janssen-Cilag, Eisai)

Tablets, e/c, rabeprazole sodium 10 mg (pink), net price 28-tab pack = £11.56; 20 mg (yellow), 28-tab pack = £19.55. Label: 25

## 1.4 Acute diarrhoea

### 1.4.1 Adsorbents and bulk-forming drugs

### 1.4.2 Antimotility drugs

The priority in acute diarrhoea, as in gastro-enteritis, is the prevention or reversal of fluid and electrolyte depletion. This is particularly important in infants and in frail and elderly patients. For details of oral rehydration preparations, see section 9.2.1.2. Severe depletion of fluid and electrolytes requires immediate admission to hospital and urgent replacement.

**Antimotility drugs** (section 1.4.2) relieve symptoms of acute diarrhoea. They are used in the management of uncomplicated acute diarrhoea in adults; fluid and electrolyte replacement may be necessary in case of dehydration. However, antimotility drugs are not recommended for acute diarrhoea in young children. Antispasmodics (section 1.2) are occasionally of value in treating abdominal cramp associated with diarrhoea but they should not be used for primary treatment. Antispasmodics and antiemetics should be avoided in young children with gastro-enteritis because they are rarely effective and have troublesome side-effects. Antibacterial drugs are generally unnecessary in simple gastro-enteritis because the complaint usually resolves quickly without them, and infective diarrhoeas in the UK often have a viral cause. Systemic bacterial infection does, however, need appropriate systemic treatment; for drugs used in campylobacter enteritis, shigellosis, and salmonellosis, see Table 1, section 5.1. *Ciprofloxacin* is occasionally used for prophylaxis against travellers’ diarrhoea, but routine use is not recommended. Lactobacillus preparations have not been shown to be effective.
Gastro-intestinal system

Acute diarrhoea

Dose

Section 4.7.2

Side-effects

Breast-feeding

Section 4.7.2

Pregnancy

Section 4.7.2

Renal impairment

Section 4.7.2

section 4.7.2; also conditions resulting from reduced bowel tone

Contra-indications

section 4.7.2; also young children are particularly susceptible to overdosage (section 1.2);

Interactions:

Appendix 1 (antimuscarinics, opioid analgesics)

Contra-indications

section 4.7.2 and also see under Antimuscarinics (section 1.2)

Hepatic impairment

section 4.7.2; also avoid in jaundice

Renal impairment

section 4.7.2

Pregnancy

section 4.7.2 and also see under Atropine Sulphate (section 1.2)

Breast-feeding

may be present in milk

Side-effects

section 4.7.2 and also see under Antimuscarinics (section 1.2); also abdominal pain, anaesthesia, and fever

Dose

● See preparations

Co-phenotrope (Non-proprietary)

Tablets, co-phenotrope 2.5/0.025 (diphenoxylate hydrochloride 2.5 mg, atropine sulphate 25 micrograms), net price 100 = £8.95

Brands include Lomotil®

Dose

initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled; CHILD under 4 years see BNF for Children; 4–9 years 1 tablet 3 times daily, 9–12 years 1 tablet 4 times daily, 12–16 years 2 tablets 3 times daily, but see also notes above

Note

Co-phenotrope 2.5/0.025 can be sold to the public for adults and children over 16 years (provided packs do not contain more than 20 tablets) as an adjunct to rehydration in acute diarrhoea (max. daily dose 10 tablets)

CO-PHENOTROPE

A mixture of diphenoxylate hydrochloride and atropine sulphate in the mass proportions 100 parts to 1 part respectively

Indications

adjunct to rehydration in acute diarrhoea (but see notes above); control of faecal consistency after colostomy or ileostomy (section 1.8)

Cautions

section 4.7.2; also young children are particularly susceptible to overdosage and symptoms may be delayed and observation is needed for at least 48 hours after ingestion; presence of subclinical doses of atropine may give rise to atropine side-effects in susceptible individuals or in overdosage (section 1.2); interactions: Appendix 1 (antimuscarinics, opioid analgesics)

Contra-indications

section 4.7.2 and also see under Antimuscarinics (section 1.2)

Hepatic impairment

section 4.7.2; also avoid in jaundice

Renal impairment

section 4.7.2

Pregnancy

section 4.7.2 and also see under Atropine Sulphate (section 1.2)

Breast-feeding

may be present in milk

Side-effects

section 4.7.2 and also see under Antimuscarinics (section 1.2); also abdominal pain, anaesthesia, and fever

Dose

● See preparations

Co-phenotrope (Non-proprietary)

Tablets, co-phenotrope 2.5/0.025 (diphenoxylate hydrochloride 2.5 mg, atropine sulphate 25 micrograms), net price 100 = £8.95

Brands include Lomotil®

Dose

initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled; CHILD under 4 years see BNF for Children; 4–9 years 1 tablet 3 times daily, 9–12 years 1 tablet 4 times daily, 12–16 years 2 tablets 3 times daily, but see also notes above

Note

Co-phenotrope 2.5/0.025 can be sold to the public for adults and children over 16 years (provided packs do not contain more than 20 tablets) as an adjunct to rehydration in acute diarrhoea (max. daily dose 10 tablets)

LOPERAMIDE HYDROCHLORIDE

Indications

symptomatic treatment of acute diarrhoea; adjunct to rehydration in acute diarrhoea in adults and children over 4 years (but see notes above); chronic diarrhoea in adults only

Cautions

see notes above; interactions: Appendix 1 (loperamide)

Contra-indications

conditions where inhibition of peristalsis should be avoided, where abdominal distension develops, or in acute diarrhoeal conditions such as acute ulcerative colitis or antibiotic-associated colitis

Hepatic impairment

risk of accumulation—manufacturer advises caution

Pregnancy

manufacturers advise avoid—no information available

Breast-feeding

amount probably too small to be harmful

Side-effects

abdominal cramps, dizziness, drowsiness, and skin reactions including urticaria; paralytic ileus and abdominal bloating also reported

Dose

● Acute diarrhoea, 4 mg initially followed by 2 mg after each loose stool for up to 5 days; usual dose 6–8 mg daily; max. 16 mg daily; CHILD under 4 years not

LoPeraMide Hydrochloride

Indications

symptomatic treatment of acute diarrhoea; adjunct to rehydration in acute diarrhoea in adults and children over 4 years (but see notes above); chronic diarrhoea in adults only

Cautions

see notes above; interactions: Appendix 1 (loperamide)

Contra-indications

conditions where inhibition of peristalsis should be avoided, where abdominal distension develops, or in conditions such as active ulcerative colitis or antibiotic-associated colitis

Hepatic impairment

risk of accumulation—manufacturer advises caution

Pregnancy

manufacturers advise avoid—no information available

Breast-feeding

amount probably too small to be harmful

Side-effects

abdominal cramps, dizziness, drowsiness, and skin reactions including urticaria; paralytic ileus and abdominal bloating also reported

Dose

● Acute diarrhoea, 4 mg initially followed by 2 mg after each loose stool for up to 5 days; usual dose 6–8 mg daily; max. 16 mg daily; CHILD under 4 years not

Loperamide Hydrochloride

Indications

symptomatic treatment of acute diarrhoea; adjunct to rehydration in acute diarrhoea in adults and children over 4 years (but see notes above); chronic diarrhoea in adults only

Cautions

see notes above; interactions: Appendix 1 (loperamide)

Contra-indications

conditions where inhibition of peristalsis should be avoided, where abdominal distension develops, or in conditions such as active ulcerative colitis or antibiotic-associated colitis

Hepatic impairment

risk of accumulation—manufacturer advises caution

Pregnancy

manufacturers advise avoid—no information available

Breast-feeding

amount probably too small to be harmful

Side-effects

abdominal cramps, dizziness, drowsiness, and skin reactions including urticaria; paralytic ileus and abdominal bloating also reported

Dose

● Acute diarrhoea, 4 mg initially followed by 2 mg after each loose stool for up to 5 days; usual dose 6–8 mg daily; max. 16 mg daily; CHILD under 4 years not
Loperamide (Non-proprietary) 

Capsules, loperamide hydrochloride 2 mg, net price 30-cap pack = £1.07

Tablets, loperamide hydrochloride 2 mg, net price 30-tab pack = £2.15

Brands include Normode®

Note Loperamide can be sold to the public, provided it is licensed and labelled for the treatment of acute diarrhoea in adults and children over 12 years of age, or for acute diarrhoea associated with irritable bowel syndrome (after initial diagnosis by a doctor) in adults and labelled for the treatment of acute diarrhoea in adults and children over 12 years of age, or for acute diarrhoea associated with irritable bowel syndrome (after initial diagnosis by a doctor) in adults and children over 12 years of age.

Imodium® (Janssen-Cilag) 

Capsules, green/grey, loperamide hydrochloride 2 mg. Net price 30-cap pack = £1.09

Syrup, sugar free, red, loperamide hydrochloride 1 mg/5 mL. Net price 100 mL = £1.17

Compound preparations

Imodium® Plus (McNeil)

Caplets (= tablets), loperamide hydrochloride 2 mg, simeticone 125 mg, net price 6-tab pack = £2.27, 12-tab pack = £3.58

Dose acute diarrhoea with abdominal colic, initially 2 caplets (CHILD 12–18 years 1 caplet) then 1 caplet after each loose stool; max. 4 caplets daily for up to 2 days. CHILD under 12 years not recommended

Breast-feeding see notes above and under Morphine Salts (section 4.7.2)

Contra-indications see notes above and under Morphine Salts (section 4.7.2)

Hepatic impairment section 4.7.2

Renal impairment section 4.7.2

Pregnancy section 4.7.2

Breast-feeding see under Morphine Salts (section 4.7.2)

Side-effects see notes above and under Morphine Salts (section 4.7.2); sedation and the risk of dependence are greater

Dose

• See preparation

Kaolin and Morphine Mixture, BP (Kaolin and Morphine Oral Suspension)

Oral suspension, light kaolin or light kaolin (natural) 20%, sodium bicarbonate 5%, and chloroform and morphine tincture 4% in a suitable vehicle. Contains anhydrous morphine 550–800 micrograms/10 mL

Dose ADULT and CHILD over 12 years, 10 mL every 6 hours in water

MORPHINE

Indications see notes above; cough in terminal disease (section 3.9.1); pain (section 4.7.2)

Cautions see notes above and under Morphine Salts (section 4.7.2)

Contra-indications see notes above and under Morphine Salts (section 4.7.2)

Hepatic impairment section 4.7.2

Renal impairment section 4.7.2

Pregnancy section 4.7.2

Breast-feeding see under Morphine Salts (section 4.7.2)

Side-effects see notes above and under Morphine Salts (section 4.7.2); sedation and the risk of dependence are greater

Dose

• See preparation

Kaolin and Morphine Mixture, BP (Kaolin and Morphine Oral Suspension)

Oral suspension, light kaolin or light kaolin (natural) 20%, sodium bicarbonate 5%, and chloroform and morphine tincture 4% in a suitable vehicle. Contains anhydrous morphine 550–800 micrograms/10 mL

Dose ADULT and CHILD over 12 years, 10 mL every 6 hours in water

Inflammatory bowel disease

Chronic inflammatory bowel diseases include ulcerative colitis and Crohn’s disease. Effective management requires drug therapy, attention to nutrition, and in severe or chronic active disease, surgery.

Aminosalicylates (balsalazide, mesalazine, olsalazine, and sulfasalazine), corticosteroids (hydrocortisone, beclometasone, budesonide, and prednisolone), and drugs that affect the immune response are used in the treatment of inflammatory bowel disease.

Treatment of acute ulcerative colitis and Crohn’s disease

Acute mild to moderate disease affecting the rectum (proctitis) or the recto-sigmoid is treated initially with local application of an aminosalicylate (section 1.5.1); alternatively, a local corticosteroid can be used but it is less effective. A combination of a local aminosalicylate and a local corticosteroid can be used for proctitis that does not respond to a local aminosalicylate alone. Foam preparations and suppositories are especially useful when patients have difficulty retaining liquid enemas.

Diffuse inflammatory bowel disease or disease that does not respond to local therapy requires oral treatment. Mild disease affecting the proximal colon can be treated with an oral aminosalicylate alone; a combination of a local and an oral aminosalicylate can be used in proctitis or distal colitis. Refractory or moderate inflammatory bowel disease usually requires adjunctive use of an oral corticosteroid such as prednisolone (section 1.5.2) for 4–8 weeks. Modified-release budesonide is licensed for Crohn’s disease affecting the ileum and the ascending colon; it causes fewer systemic side-effects than oral prednisolone but may be less effective. Beclometasone dipropionate by mouth is licensed as an adjunct to mesalazine for mild to moderate ulcerative colitis, but it is not known whether it is as effective as other corticosteroids.

Severe inflammatory bowel disease or disease that is not responding to an oral corticosteroid requires hospital admission and treatment with an intravenous corticosteroid (such as hydrocortisone or methylprednisolone, section 6.3.2); other therapy may include intravenous fluid and electrolyte replacement, and possibly parenteral nutrition. Specialist supervision is required for patients who fail to respond adequately to these measures. Patients with severe ulcerative colitis that has not responded to intravenous corticosteroids, may benefit from a short course of intravenous ciclosporin [unlicensed indication] (section 1.5.3). Patients with unresponsive or chronically active Crohn’s disease may benefit from azathioprine (section 1.5.3), mercaptopurine (section 1.5.3), or once-weekly methotrexate (section 1.5.3) [all unlicensed indications]; these drugs have a slower onset of action.

Infliximab (section 1.5.3) is licensed for the management of severe active Crohn’s disease and severe ulcerative colitis in patients whose condition has not
responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them.

NICE guidance
Infliximab and adalimumab for Crohn’s disease (May 2010)
Infliximab or adalimumab is recommended for the treatment of severe active Crohn’s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn’s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications. Infliximab or adalimumab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease—in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, adalimumab or infliximab can be restarted (but see Hypersensitivity Reactions under Infliximab, p. 66).

NICE guidance
Infliximab for subacute manifestations of ulcerative colitis (April 2008)
Infliximab is not recommended for the treatment of subacute manifestations of moderate to severe active ulcerative colitis that would normally be managed in an outpatient setting.

Adalimumab (section 1.5.3) is licensed for the treatment of severe active Crohn’s disease in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them. For inducing remission, adalimumab should be used in combination with a corticosteroid, but it may be given alone if a corticosteroid is inappropriate or is not tolerated. Adalimumab may also be used for Crohn’s disease in patients who have relapsed while taking infliximab or who cannot tolerate infliximab because of hypersensitivity reactions.

Maintenance of remission of acute ulcerative colitis and Crohn’s disease
Smoking cessation (section 4.10.2) reduces the risk of relapse in Crohn’s disease and should be encouraged. Aminosalicylates are efficacious in the maintenance of remission of ulcerative colitis, but there is no evidence of efficacy in the maintenance of remission of Crohn’s disease. Corticosteroids are not suitable for maintenance treatment because of their side-effects. In resistant or frequently relapsing cases either azathioprine (section 1.5.3) [unlicensed indication] or mercaptopurine (section 1.5.3) [unlicensed indication], given under close supervision may be helpful. Methotrexate (section 1.5.3) is tried in Crohn’s disease if azathioprine or mercaptopurine cannot be used [unlicensed indication]. Maintenance therapy with infliximab should be considered for patients with Crohn’s disease or ulcerative colitis who respond to the initial induction course of infliximab; fixed-interval dosing is superior to intermittent dosing. Adalimumab is licensed for maintenance therapy in Crohn’s disease.

Fistulating Crohn’s disease
Treatment may not be necessary for simple, asymptomatic perianal fistulas. Metronidazole (section 5.1.11) or ciprofloxacin (section 5.1.12) can improve symptoms of fistulating Crohn’s disease but complete healing occurs rarely [unlicensed indication]. Metronidazole by mouth is used at a dose of 10–20 mg/kg daily in divided doses (usual dose 500 mg 3 times daily); it is usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy. Ciprofloxacin by mouth is given at a dose of 500 mg twice daily. Other antibacterials should be given if specifically indicated (e.g. sepsis associated with fistulas and perianal disease) and for managing bacterial overgrowth in the small bowel. Fistulas may also require surgical exploration and local drainage.

Either azathioprine or mercaptopurine is used as a second-line treatment for fistulating Crohn’s disease and continued for maintenance [unlicensed indication]. Infliximab is used for fistulating Crohn’s disease refractory to conventional treatments; fixed-interval dosing is superior to intermittent dosing. Maintenance therapy with infliximab should be considered for patients who respond to the initial induction course of infliximab. Adalimumab can be used if there is intolerance to infliximab [unlicensed indication].

Adjunctive treatment of inflammatory bowel disease
Due attention should be paid to diet; high-fibre or low-residue diets should be used as appropriate. Antimotility drugs such as codeine and loperamide, and antispasmodics drugs may precipitate paralytic ileus and megacolon in active ulcerative colitis; treatment of the inflammation is more logical. Laxatives may be required in proctitis. Diarrhoea resulting from the loss of bile-salt absorption (e.g. in terminal ileal disease or bowel resection) may improve with colestyramine (section 1.9.2), which binds bile salts.

Clostridium difficile infection
Clostridium difficile infection is caused by colonisation of the colon with Clostridium difficile and production of toxin. It often follows antibiotic therapy and is usually of acute onset, but may become chronic. It is a particular hazard of ampicillin, amoxicillin, co-amoxiclav, second- and third-generation cephalosporins, clindamycin, and quinolones, but few antibiotics are free of this side-effect. Oral metronidazole (see section 5.1.11) or oral vancomycin (see section 5.1.7) are used as specific treatment; vancomycin may be preferred for very sick patients. Metronidazole can be given by intravenous infusion if oral treatment is inappropriate.
Diverticular disease

Diverticular disease is treated with a high-fibre diet, bran supplements, and bulk-forming drugs (section 1.6.1). Antispasmodics may provide symptomatic relief when colic is a problem (section 1.2). Antibacterials are used only when the diverticula in the intestinal wall become infected. Antimotility drugs which slow intestinal motility, e.g. codeine, diphenoxylate, and loperamide could possibly exacerbate the symptoms of diverticular disease and are contra-indicated.

Irritable bowel syndrome

Irritable bowel syndrome can present with pain, constipation, or diarrhoea. In some patients there may be important psychological aggravating factors which respond to reassurance and possibly specific treatment e.g. with an antidepressant.

The fibre intake of patients with irritable bowel syndrome should be reviewed. If an increase in dietary fibre is required, soluble fibre (e.g. ispaghula husk, sterculia, or oats) is recommended; insoluble fibre (e.g. bran) may exacerbate symptoms and its use should be discouraged. A laxative (section 1.6) can be used to treat constipation. An osmotic laxative, such as a macrogol, is preferred; lactulose may cause bloating. Stimulant laxatives should be avoided or used only occasionally. Loperamide (section 1.4.2) may relieve diarrhoea and antispasmodic drugs (section 1.2) may relieve pain. Opioids with a central action, such as codeine, are better avoided because of the risk of dependence.

A tricyclic antidepressant (section 4.3.1) can be used for abdominal pain or discomfort [unlicensed indication] in patients who have not responded to laxatives, loperamide, or antispasmodics. Low doses of a tricyclic antidepressant are used (e.g. amitriptyline, initially 5–10 mg each night, increased if necessary in steps of 10 mg at intervals of at least 2 weeks to max. 30 mg each night). A selective serotonin reuptake inhibitor (section 4.3.3) may be considered in those who do not respond to a tricyclic antidepressant [unlicensed indication].

Malabsorption syndromes

Individual conditions need specific management and also general nutritional consideration. Coeliac disease (gluten enteropathy) usually needs a gluten-free diet and pancreatic insufficiency needs pancreatic supplements (section 1.9.4). For further information on foods for special diets (ACBS), see Appendix 7.

For notes above; also history of asthma; interactions: Appendix 1 (aminosalicylates)

Contra-indications Aminosalicylates should be avoided in salicylate hypersensitivity.

Side-effects Side-effects of the aminosalicylates include diarrhoea, nausea, vomiting, abdominal pain, exacerbation of symptoms of colitis, headache, hypersensitivity reactions (including rash and urticaria); side-effects that occur rarely include acne pancreatitis, hepatitis, myocardiitis, pericarditis, lung disorders (including eosinophilia and fibrosing alveolitis), peripheral neuropathy, blood disorders (including agranulocytosis, aplastic anaemia, leucopenia, methaemoglobinemia, neutropenia, and thrombocytopenia—see also recommendation above), renal dysfunction (interstitial nephritis, nephrotic syndrome), myalgia, arthralgia, skin reactions (including lupus erythematosus-like syndrome, Stevens-Johnson syndrome), alopecia.

Balsalazide sodium

Indications treatment of mild to moderate ulcerative colitis and maintenance of remission

Contra-indications see notes above

Hepatic impairment avoid in severe impairment

Renal impairment manufacturer advises avoid in moderate to severe impairment

Pregnancy manufacturer advises avoid

Breast-feeding monitor infant for diarrhoea

Side-effects see notes above; also cholelithiasis

Dose
- Acute attack, 2.25 g 3 times daily until remission occurs or for up to max. 12 weeks
- Maintenance, 1.5 g twice daily, adjusted according to response (max. 6 g daily)
- Child under 18 years see BNF for Children

Colazide® (Almirall) Capsules, beige, balsalazide sodium 750 mg. Net price 130-cap pack = £30.42. Label: 21, 25, counseling, blood disorder symptoms (see recommendation above)
1.5.1 Aminosalicylates

MESALAZINE

**Indications** treatment of mild to moderate ulcerative colitis and maintenance of remission; see also under preparations

**Cautions** see notes above; elderly; interactions: Appendix 1 (aminosalicylates)

**Blood disorders** see recommendation above

**Contra-indications** see notes above

**Hepatic impairment** avoid in severe impairment

**Renal impairment** use with caution; avoid if eGFR less than 20 mL/minute/1.73 m²

**Pregnancy** negligible quantities cross placenta

**Breast-feeding** diarrhoea reported but negligible amounts detected in breast milk; monitor infant for diarrhoea

**Side-effects** see notes above

**Dose**

- Note The delivery characteristics of oral mesalazine preparations may vary; these preparations should not be considered interchangeable

Asacol® (Warner Chilcott) (BNF 61)

**Foam enema** mesalazine 1 g/metered application, net price £26.72. Counselling, blood disorder symptoms (see recommendation above)

- Excipients include disodium edetate, hydroxybenzoates (parabens), polysorbate 20, sodium metabisulphite

**Dose** acute attack affecting the rectosigmoid region, 1 metered application (mesalazine 1 g) into the rectum daily for 4–6 weeks; acute attack affecting the descending colon, 2 metered applications (mesalazine 2 g) once daily for 4–6 weeks; CHILD 12–18 years, see BNF for Children

**Suppositories**, mesalazine 250 mg, net price £20.20. Label: 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** acute attack or maintenance, by rectum 0.75–1.5 g daily in divided doses, with last dose at bedtime; CHILD 12–18 years, see BNF for Children

Asacol® MR (Warner Chilcott) (BNF 61)

**Tablets**, red, e/c, mesalazine 400 mg, net price £29.41; 120-tab pack = £39.21. Label: 5, 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** ulcerative colitis, acute attack, 2 g daily in divided doses; maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis, 1.2–2.4 g daily in divided doses; CHILD 12–18 years, see BNF for Children

**Tablets**, red-brown, e/c, mesalazine 800 mg, net price £17.62. Label: 5, 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** acute attack, 2.4 g daily in divided doses; maintenance, 1.2–2.4 g daily in divided doses; CHILD 12–18 years, see BNF for Children

**Note** Preparations that lower stool pH (e.g. lactulose) may prevent release of mesalazine

Ipocol® (Sandoz) (BNF 61)

**Tablets**, e/c, mesalazine 400 mg, net price £41.62. Label: 5, 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** acute attack, 2.4 g daily in divided doses; maintenance, 1.2–2.4 g daily in divided doses; CHILD 12–18 years, see BNF for Children

**Note** Preparations that lower stool pH (e.g. lactulose) may prevent release of mesalazine

Mesren® MR (IVAX) (BNF 61)

**Tablets**, red-brown, e/c, mesalazine 400 mg, net price 90-tab pack = £19.50; 120-tab pack = £26.00. Label: 5, 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** ADULT and CHILD over 12 years, ulcerative colitis, acute attack, 2.4 g daily in divided doses; maintenance of remission of ulcerative colitis and Crohn’s ileo-colitis, 1.2–2.4 g daily in divided doses

Mezavant® XL (Shire) (BNF 61)

**Tablets**, m/r, red-brown, e/c, mesalazine 1.2 g, net price 60-tab pack = £62.44. Label: 21, 25, counselling, blood disorder symptoms (see recommendations above)

**Dose** ADULT over 18 years, acute attack, 2.4 g once daily, if necessary to 4.8 g once daily (review treatment at 8 weeks); maintenance, 2.4 g once daily

Pentasa® (Ferring) (BNF 61)

**Tablets**, m/r, scored, mesalazine 500 mg (grey), net price 100-tab pack = £24.21. Counselling, administration, see dose, blood disorder symptoms (see recommendation above)

**Dose** ADULT and CHILD over 15 years, acute attack, up to 4 g daily in 2–3 divided doses; maintenance, 2 g once daily; tablets may be dispersed in water, but should not be chewed; CHILD 5–15 years see BNF for Children

**Granules**, m/r, pale grey-brown, mesalazine 1 g/sachet, net price 50-sachet pack = £28.82; 2 g/sachet, 60-sachet pack = £72.05. Counselling, administration, see dose, blood disorder symptoms (see recommendation above)

**Dose** acute attack, up to 4 g daily in 2–4 divided doses; maintenance, 2 g once daily; granules should be placed on tongue and washed down with water or orange juice without chewing; CHILD 5–15 years see BNF for Children

**Retention enema**, mesalazine 1 g in 100-mL pack. Net price 7 enemas = £17.73. Counselling, administration, see dose, blood disorder symptoms (see recommendation above)

**Dose** by rectum ADULT and CHILD over 12 years, 1 enema at bedtime

**Suppositories**, mesalazine 1 g. Net price 28-suppos pack = £40.01. Counselling, blood disorder symptoms (see recommendation above)

**Dose** by rectum ulcerative proctitis, ADULT and CHILD over 15 years, acute attack, 1 g daily for 2–4 weeks; maintenance, 1 g daily, CHILD 12–15 years see BNF for Children

Salofalk® (Dr Falk) (BNF 61)

**Tablets**, e/c, yellow, mesalazine 250 mg. Net price 100-tab pack = £16.19. Label: 5, 25, counselling, blood disorder symptoms (see recommendation above)

**Dose** acute attack, 0.5–1 g 3 times daily; maintenance, 500 mg three times daily; CHILD 12–18 years see BNF for Children

**Granules**, m/r, grey, e/c, vanillia-flavoured, mesalazine 500 mg/sachet, net price 100-sachet pack = £28.74; 1 g/sachet, 50-sachet pack = £28.74; 1.5 g/sachet, 60-sachet pack = £48.85. Label: 25, counselling, administration, see dose, blood disorder symptoms (see recommendation above)

- Excipients include aspartame (section 9.4.1)

**Dose** acute attack, 1.5–3 g once daily (preferably in the morning) or 0.5–1.5 g 3 times daily; maintenance, 500 mg 3 times daily; CHILD 6–18 years see BNF for Children

**Counselling** granules should be placed on tongue and washed down with water without chewing

**Note** Preparations that lower stool pH (e.g. lactulose) may prevent release of mesalazine

BNF 61
Suppositories, mesalazine 500 mg. Net price 30-suppos pack = £14.81. Counselling, blood disorder symptoms (see recommendation above)

**Dose**
- **ADULT** and **CHILD** over 15 years, acute attack, by rectum, 0.5–1 g 2–3 times daily adjusted according to response; **CHILD** 12–15 years see **BNF for Children**
- **Enema**, mesalazine 2 g in 59-mL pack. Net price 7 enemas = £29.92. Counselling, blood disorder symptoms (see recommendation above)

**Rectal foam**, mesalazine 1 g metered application, net price 4–14-application canister with disposable applicators and plastic bags = £30.17. Counselling, blood disorder symptoms (see recommendation above)

**Excipients** include crocetin, polyethylene glycol, sodium metabisulphite.

**Dose** mild ulcerative colitis affecting sigmoid colon and rectum, **ADULT** and **CHILD** over 12 years, 2 metered applications (mesalazine 2 g) into the rectum at bedtime or in 2 divided doses

---

**OLSALAZINE SODIUM**

**Indications** treatment of mild ulcerative colitis and maintenance of remission

**Cautions** see notes above; **Interactions**: Appendix 1 (aminsalicylates)

**Blood disorders** See recommendation above

**Contra-indications** see notes above

**Renal impairment** use with caution; manufacturer advises avoid in significant impairment

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk

**Breast-feeding** monitor infant for diarrhoea

**Side-effects** see notes above; watery diarrhoea common over 4 g daily;

**Interactions:**
- **Acute porphyria** (section 9.8.2); methotrexate, rifampicin, isoniazid
- **Hepatic impairment** use with caution
- **Renal impairment** risk of toxicity, including crystaluria, in moderate impairment
- **Blood disorders** (section 10.1.3)

**Dose**
- **ADULT** and **CHILD** over 12 years, acute attack, 1 g daily in divided doses after meals increased if necessary over 1 week to max. 3 g daily (max. single dose 1 g); maintenance, 500 mg twice daily after meals
- **CHILD** under 12 years see **BNF for Children**

**Dipentum** (UCB Pharma)

**Capsules**, brown, olsalazine sodium 250 mg. Net price 112-cap pack = £19.77. Label: 21, counselling, blood disorder symptoms (see recommendation above)

**Tablets**, yellow, scored, olsalazine sodium 500 mg. Net price 60-tab pack = £21.18. Label: 21, counselling, blood disorder symptoms (see recommendation above)

---

**SULFASALAZINE** (Sulphasalazine)

**Indications** treatment of mild to moderate and severe ulcerative colitis and maintenance of remission; active Crohn's disease; rheumatoid arthritis (section 10.1.3)

**Cautions** see notes above; also history of allergy or asthma; G6PD deficiency (section 9.1.5); slow acetylator status; risk of haematological and hepatic toxicity (differential white cell, red cell, and platelet counts initially and at monthly intervals for first 3 months; liver function tests at monthly intervals for first 3 months); maintain adequate fluid intake; upper gastro-intestinal side-effects common over 4 g daily; acute porphyria (section 9.8.2); **Interactions**: Appendix 1 (aminsalicylates)

**Blood disorders** See recommendation above

**Contra-indications** see notes above; also sulphonamide hypersensitivity; child under 2 years of age

**Hepatic impairment** use with caution

**Renal impairment** risk of toxicity, including crystaluria, in moderate impairment—ensure high fluid intake; avoid in severe impairment

**Pregnancy** theoretical risk of neonatal haemolysis in third trimester; adequate folate supplements should be given to mother

**Breast-feeding** small amounts in milk (1 report of bloody diarrhoea); theoretical risk of neonatal haemolysis especially in G6PD-deficient infants

**Side-effects** see notes above; also cough, insomnia, dizziness, fever, blood disorders (including Heinz body anaemia, megaloblastic anaemia), proteinuria, tinnitus, stomatitis, taste disturbances, and pruritus; less commonly dyspnoea, depression, convulsions, vasculitis, and alopecia; also reported loss of appetite, hypersensitivity reactions (including exfoliative dermatitis, epidermal necrolysis, photosensitivity, anaphylaxis, serum sickness), ataxia, hallucinations, aseptic meningitis, oligospermia, crystalluria, disturbances of smell, and parotitis; yellow-orange discoloration of skin, urine, and other body fluids; some soft contact lenses may be stained

**Dose**
- **By mouth**, acute attack 1–2 g 4 times daily but see precautions until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance dose of 500 mg 4 times daily; **CHILD** 2–12 years see **BNF for Children**
- **By rectum**, in suppositories, alone or in conjunction with oral treatment 0.5–1 g morning and night after a bowel movement; **CHILD** 5–12 years see **BNF for Children**

**Sulfasalazine** (Non-proprietary)

**Tablets**, sulfasalazine 500 mg, net price 112 = £6.74. Label: 14, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

**Tablets**, e/c, sulfasalazine 500 mg. Net price 112-tab pack = £14.46. Label: 5, 14, 25, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

**Brands include Sulazine EC**

**Suspension**, sulfasalazine 250 mg/5 mL, net price 500 mL = £29.50. Label: 14, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

**Excipients** include alcohol

**Salazopyrin** (Pharmacia)

**Tablets**, yellow, scored, sulfasalazine 500 mg, net price 112-tab pack = £6.97. Label: 14, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

**EN-Tabs** (= tablets e/c), yellow, I/c, sulfasalazine 500 mg, net price 112-tab pack = £8.43. Label: 5, 14, 25, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

**Suppositories**, yellow, sulfasalazine 500 mg, net price 10 = £3.30. Label: 14, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained
1.5.2 Corticosteroids

For the role of corticosteroids in acute ulcerative colitis and Crohn’s disease, see Inflammatory Bowel Disease, p. 59.

BECLOMETASONE DIPROPIONATE

**Indications**
adjunct to aminosalicylates in acute mild to moderate ulcerative colitis; asthma (section 3.2); allergic and vasomotor rhinitis (section 12.2.1); oral ulceration (unlicensed indication) (section 12.3.1)

**Cautions** section 6.3.2; interactions: Appendix 1 (corticosteroids)

**Contra-indications** section 6.3.2

**Hepatic impairment** manufacturer advises avoid in severe impairment—no information available

**Pregnancy** section 6.3.2

**Breast-feeding** section 6.3.2

**Side-effects** section 6.3.2; also nausea, constipation, headache, and drowsiness

**Dose**

- 5 mg in the morning; max. duration of treatment 4 weeks; CHILD safety and efficacy not established
- CHILD, 3 mg 3 times daily; maintenance, 3 mg twice daily
- ADULT, 2 mg) once daily for up to 8 weeks

**Clipper** (Chiesi) (c)

Tablets, m/r, ivory, beclometasone dipropionate 5 mg, net price 30-tab pack = £56.56. Label: 25

**BUDESONIDE**

**Indications** see preparations

**Cautions** section 6.3.2; for autoimmune hepatitis, monitor liver function tests every 2 weeks and at least every 3 months; interactions: Appendix 1 (corticosteroids)

**Contra-indications** section 6.3.2

**Hepatic impairment** section 6.3.2

**Pregnancy** section 6.3.2

**Breast-feeding** section 6.3.2

**Side-effects** section 6.3.2

**Dose**

- See preparations

**Budenofalk** (Dr Falk) (c)

Tablets, pink, enclosing e/c granules, budesonide 3 mg, net price 100-cap pack = £75.05. Label: 5, 10, steroid card, 25

**Dose** mild to moderate Crohn’s disease affecting ileum or ascending colon, chronic diarrhoea due to collagenous colitis, CHILD over 18 years, 3 mg 3 times daily for up to 8 weeks; reduce dose for the last 2–4 weeks of treatment (see also section 6.3.2); CHILD 12–18 years see BNF for Children

Autoimmune hepatitis, ADULT over 18 years, induction of remission, 3 mg 3 times daily; maintenance, 3 mg twice daily

Rectal foam, budesonide 2 mg/metered application, net price 14-application canister with applicator = £33.00

Dose ulcerative colitis affecting sigmoid colon and rectum, by rectum, ADULT over 18 years, 1 metered application (budesonide 2 mg) once daily for up to 8 weeks

**HYDROCORTISONE**

**Indications** ulcerative colitis, proctitis, proctosigmoiditis

**Cautions** section 6.3.2; systemic absorption may occur; prolonged use should be avoided

**Contra-indications** intestinal obstruction, bowel perforation, recent intestinal anastomoses, extensive fistulas; untreated infection

**Side-effects** section 6.3.2; also local irritation

**Dose**

- By rectum see preparations

**Coliflaxone** (Meda) (c)

Foam in aerosol pack, hydrocortisone acetate 10%, net price 14-application canister with applicator = £9.28

Excipients include cetly alcohol, hydroxybenzoates (parabens), propylene glycol
dose initially 1 metered application (125 mg hydrocortisone acetate) inserted into the rectum once or twice daily for 3-3 weeks, then once on alternate days; CHILD 2–18 years see BNF for Children

**PREDNISOLONE**

**Indications** ulcerative colitis, and Crohn’s disease; other indications, see section 6.3.2, see also preparations

**Cautions** section 6.3.2; systemic absorption may occur with rectal preparations; prolonged use should be avoided

**Contra-indications** section 6.3.2; intestinal obstruction, bowel perforation, recent intestinal anastomoses, extensive fistulas; untreated infection

**Hepatic impairment** section 6.3.2

**Renal impairment** section 6.3.2

**Pregnancy** section 6.3.2

**Breast-feeding** section 6.3.2

**Side-effects** section 6.3.2

**Dose**

- By mouth, initially 20–40 mg daily (up to 60 mg daily in some cases), preferably taken in the morning after breakfast; continued until remission occurs, followed by reducing doses
- By rectum, see preparations

**Oral preparations**

Section 6.3.2

**Entocort** (AstraZeneca) (c)

CR Capsules, grey/pink, enclosing e/c, m/r granules, budesonide 3 mg, net price 100-cap pack = £99.00. Label: 5, 10, steroid card, 25

Note Dispense in original container (contains desiccant)

Dose mild to moderate Crohn’s disease affecting the ileum or ascending colon, 9 mg once daily in the morning for up to 8 weeks; reduce dose for the last 2–4 weeks of treatment (see also section 6.3.2); CHILD 12–18 years see BNF for Children

Enema, budesonide 2 mg/100 mL when dispersible tablet reconstituted in isotonic saline vehicle, net price pack of 7 dispersible tablets and bottles of vehicle = £33.00

Dose ulcerative colitis involving rectal and recto-sigmoid disease, by rectum, 1 enema at bedtime for 4 weeks; CHILD 12–18 years see BNF for Children
1.5.3 Drugs affecting the immune response

For the role of azathioprine, ciclosporin, mercaptopurine, and methotrexate in the treatment of inflammatory bowel disease, see p. 59.

Folic acid (section 9.1.2) should be given to reduce the possibility of methotrexate toxicity [unlicensed indication]. Folic acid is usually given at a dose of 5 mg once weekly on a different day to the methotrexate; alternative regimens may be used in some settings.

AZATHIOPRINE

Indications see under Inflammatory Bowel Disease, p. 59; autoimmune conditions and prophylaxis of transplant rejection (section 8.2.1); rheumatoid arthritis (section 10.1.3); severe refractory eczema (section 13.5.3)

Cautions section 8.2.1

Contra-indications section 8.2.1

Hepatic impairment section 8.2.1

Renal impairment section 8.2.1

Pregnancy section 8.1.3

Breast-feeding section 8.1.3

Side-effects section 8.2.1

Dose
- Severe acute Crohn’s disease, maintenance of remission of Crohn’s disease or ulcerative colitis [unlicensed indications], ADULT over 18 years, by mouth, 2–2.5 mg/kg daily; some patients may respond to lower doses

Preparations Section 8.1.3

METHOTREXATE

Indications see under Inflammatory Bowel Disease, p. 59; malignant disease (section 8.1.3); rheumatoid arthritis (section 10.1.3); psoriasis (section 13.5.5)

Cautions section 10.1.3

Contra-indications section 10.1.3

Hepatic impairment section 10.1.3

Renal impairment section 10.1.3

Pregnancy section 10.1.3

Breast-feeding section 10.1.3

Side-effects section 10.1.3
Cytokine modulators

Infliximab and adalimumab are monoclonal antibodies which inhibit the pro-inflammatory cytokine, tumour necrosis factor alpha. They should be used under specialist supervision. Adequate resuscitation facilities must be available when infliximab is used.

**Infliximab**

Indications see under Inflammatory Bowel Disease, p. 200 mg 4 times daily before meals; may be increased if necessary after 2–13 weeks to a max. of 40 mg/kg daily and then reduced according to response; discontinue if no response 14 weeks after initial dose. Allergy with classical symptoms of vomiting, colic and diarrhoea caused by specific foods such as shellfish should be managed by strict avoidance. The condition should be distinguished from symptoms of occasional food intolerance in those with irritable bowel syndrome. Sodium cromoglicate may be helpful as an adjunct to dietary avoidance.

Preparations

Section 10.1.3

**SODIUM CROMOGLICATE**

(Sodium cromoglicate)

Indications food allergy (in conjunction with dietary restriction); asthma (section 3.3.1); allergic conjunctivitis (section 11.4.2); allergic rhinitis (section 12.2.1)

Pregnancy not known to be harmful

Breast-feeding unlikely to be present in milk

Side-effects occasional nausea, rashes, and joint pain

Dose

● 200 mg 4 times daily before meals; may be increased if necessary after 2–3 weeks to a max. of 40 mg/kg daily and then reduced according to response; CHILD 2–14 years 100 mg 4 times daily before meals; may be increased if necessary after 2–3 weeks to a max. of 40 mg/kg daily and then reduced according to response

Counselling Capsules may be swallowed whole or the contents dissolved in hot water and diluted with cold water before taking

Nalcrom® (Sanofi-Aventis)

Capsules, sodium cromoglicate 100 mg. Net price 100-cap pack = £59.75. Label: 22, counselling, see dose above
1.6 Laxatives

### 1.6.1 Bulk-forming laxatives

Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis; patients should be advised that the full effect may take some days to develop. Bulk-forming laxatives are of particular value in those with small hard stools, but should not be required unless fibre cannot be increased in the diet. A balanced diet, including adequate fluid intake and fibre is of value in preventing constipation.

Bulk-forming laxatives are useful in the management of patients with colostomy, ileostomy, haemorrhoids, anal fissure, chronic diarrhoea associated with diverticular disease, irritable bowel syndrome, and as adjuncts in ulcerative colitis (section 1.5). Adequate fluid intake must be maintained to avoid intestinal obstruction. Unprocessed wheat bran, taken with food or fruit juice, is a most effective bulk-forming preparation.

### 1.6.2 Stimulant laxatives

For the role of laxatives in the treatment of irritable bowel syndrome, see p. 61. For the prevention of opioid-induced constipation in palliative care, see p. 22. For children with chronic constipation, it may be necessary to exceed the licensed doses of some laxatives. Parents and carers of children should be advised to adjust the dose of laxative in order to establish a regular pattern of bowel movements in which stools are soft, well-formed, and passed without discomfort. Laxatives should be administered at a time that produces an effect that is likely to fit in with the child’s toilet routine.

### 1.6.3 Faecal softeners

Macrogols (section 1.6.4) is used to clear faecal mass and to establish and maintain soft well-formed stools. If disimpaction does not occur after 2 weeks, a stimulant laxative (section 1.6.2) can be added. If the impacted mass is not expelled following treatment with macrogols and a stimulant laxative, a sodium citrate enema can be administered. Although rectal administration of laxatives may be effective, this route is frequently distressing for the child and may lead to persistence of withholding. A phosphate enema may be administered under specialist supervision if disimpaction does not occur after a sodium citrate enema; a bowel cleansing preparation (section 1.6.5) is an alternative. Manual evacuation under anaesthetic may be necessary if disimpaction does not occur after oral and rectal treatment, or if the child is afraid.

### 1.6.4 Osmotic laxatives

Long-term regular use of laxatives is essential to maintain well-formed stools and prevent recurrence of faecal impaction; intermittent use may provoke relapses.

### 1.6.5 Bowel cleansing preparations

Pregnancy If dietary and lifestyle changes fail to control constipation in pregnancy, moderate doses of poorly absorbed laxatives may be used. A bulk-forming laxative should be tried first. An osmotic laxative, such as lactulose, can also be used. Bisacodyl or senna may be suitable, if a stimulant effect is necessary.

The laxatives that follow have been divided into 5 main groups (sections 1.6.1–1.6.5). This simple classification disguises the fact that some laxatives have a complex action.

### 1.6.6 Peripheral opioid-receptor antagonists

Before prescribing laxatives it is important to be sure that the patient is constipated and that the constipation is not secondary to an underlying undiagnosed complaint.

It is also important for those who complain of constipation to understand that bowel habit can vary considerably in frequency without doing harm. Some people tend to consider themselves constipated if they do not have a bowel movement each day. A useful definition of constipation is the passage of hard stools less frequently than the patient’s own normal pattern and this can be explained to the patient.

Misconceptions about bowel habits have led to excessive laxative use. Abuse may lead to hypokalaemia.

Thus, laxatives should generally be avoided except where straining will exacerbate a condition (such as angina) or increase the risk of rectal bleeding as in haemorrhoids. Laxatives are also of value in drug-induced constipation, for the expulsion of parasites after anthelmintic treatment, and to clear the alimentary tract before surgery and radiological procedures. Prolonged treatment of constipation is sometimes necessary.

For the role of laxatives in the treatment of irritable bowel syndrome, see p. 61. For the prevention of opioid-induced constipation in palliative care, see p. 22.

**Children** Laxatives should be prescribed by a healthcare professional experienced in the management of constipation in children. Delays of greater than 3 days between stools may increase the likelihood of pain on passing hard stools leading to anal fissure, anal spasm and eventually to a learned response to avoid defaecation.

In infants, increased intake of fluids, particularly fruit juice containing sorbitol (e.g. prune, pear, or apple), may be sufficient to soften the stool. In infants under 1 year of age with mild constipation, lactulose (section 1.6.4) can be used to soften the stool, either an oral preparation containing macrogols or, rarely, glycerol suppositories can be used to clear faecal impaction. The infant should be referred to a hospital paediatric specialist if these measures fail.

The diet of children over 1 year of age should be reviewed to ensure that it includes an adequate intake of fibre and fluid. An osmotic laxative containing macrogols (section 1.6.4) can also be used, particularly in children with chronic constipation; lactulose is an alternative in children who cannot tolerate a macrogol. If there is an inadequate response to the osmotic laxative, a stimulant laxative (section 1.6.2) can be added.

Treatment of faecal impaction may initially increase symptoms of soiling and abdominal pain. In children over 1 year of age with faecal impaction, an oral preparation containing macrogols (section 1.6.4) is used to clear faecal mass and to establish and maintain soft well-formed stools. If disimpaction does not occur after 2 weeks, a stimulant laxative (section 1.6.2) can be added. If the impacted mass is not expelled following treatment with macrogols and a stimulant laxative, a sodium citrate enema can be administered. Although rectal administration of laxatives may be effective, this route is frequently distressing for the child and may lead to persistence of withholding. A phosphate enema may be administered under specialist supervision if disimpaction does not occur after a sodium citrate enema; a bowel cleansing preparation (section 1.6.5) is an alternative. Manual evacuation under anaesthetic may be necessary if disimpaction does not occur after oral and rectal treatment, or if the child is afraid.

Long-term regular use of laxatives is essential to maintain well-formed stools and prevent recurrence of faecal impaction; intermittent use may provoke relapses.

**For children with chronic constipation,** it may be necessary to exceed the licensed doses of some laxatives. Parents and carers of children should be advised to adjust the dose of laxative in order to establish a regular pattern of bowel movements in which stools are soft, well-formed, and passed without discomfort. Laxatives should be administered at a time that produces an effect that is likely to fit in with the child’s toilet routine.

**Pregnancy** If dietary and lifestyle changes fail to control constipation in pregnancy, moderate doses of poorly absorbed laxatives may be used. A bulk-forming laxative should be tried first. An osmotic laxative, such as lactulose, can also be used. Bisacodyl or senna may be suitable, if a stimulant effect is necessary.

The laxatives that follow have been divided into 5 main groups (sections 1.6.1–1.6.5). This simple classification disguises the fact that some laxatives have a complex action.
1.6.2 Stimulant laxatives

Finely ground bran, though more palatable, has poorer water-retaining properties, but can be taken as bran bread or biscuits in appropriately increased quantities. Oat bran is also used.

Methylcellulose, ispaghula, and sterculia are useful in patients who cannot tolerate bran. Methylcellulose also acts as a faecal softener.

**ISPAGHULA HUSK**

**Indications** see notes above

**Cautions** adequate fluid intake should be maintained to avoid intestinal obstruction—it may be necessary to supervise elderly or debilitated patients or those with intestinal narrowing or decreased motility

**Contra-indications** difficulty in swallowing, intestinal obstruction, colonic atony, faecal impaction

**Side-effects** flatulence, abdominal distension, gastrointestinal obstruction or impaction; hypersensitivity reported

**Dose**
- See preparations below

**Counselling** Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed

**Fibrelife** (Manx)

Granules, sugar- and gluten-free, ispaghula husk 3.5 g/sachet (natural or orange flavour), net price 10 sachets = £1.23, 30 sachets = £2.07. Label: 13, counselling, see above

Excipients include aspartame (section 9.4.1)

**Dose**
- Adult and Child over 12 years, 1-6 sachets daily in water in 1-3 divided doses, preferably after meals

**Fybogel** (Reckitt Benckiser)

Granules, buff, effervescent, sugar- and gluten-free, ispaghula husk 3.5 g/sachet (low Na+), net price 30 sachets (plain, lemon, or orange flavour) = £1.84. Label: 13, counselling, see above

Excipients include aspartame 16 mg/sachet (see section 9.4.1)

**Dose**
- 1 sachet or 2 level 5-mL spoonfuls in water twice daily preferably after meals; *Child* (but see section 1.6) 2-12 years ½-1 level 5-mL spoonful in water, twice daily preferably after meals (*Child* 2-6 years on specialist practitioner’s advice only)

**Isogel** (Potters)

Granules, brown, sugar- and gluten-free, ispaghula husk 90%. Net price 200 g = £2.67. Label: 13, counselling, see above

**Dose**
- Constipation, 2 level 5-mL spoonfuls in water once or twice daily, preferably at mealtimes; *Child* (but see section 1.6) 2-12 years, 1 level 5-mL spoonful in water once or twice daily, preferably at mealtimes

Diarrhoea (section 1.4.1), 1 level 5-mL spoonful 3 times daily

**Note** May be difficult to obtain

**Ispagel Orange** (LPJ)

Granules, beige, effervescent, sugar- and gluten-free, ispaghula husk 3.5 g/sachet, net price 30 sachets = £2.10. Label: 13, counselling, see above

Excipients include aspartame [section 9.4.1]

**Dose**
- 1 sachet in water 1-3 times daily, preferably after meals; *Child* (but see section 1.6) 2-6 years, see BNF for Children, 6-12 years 2.5-5 mL in water 1-3 times daily, preferably after meals

**Regulan** (Procter & Gamble)

Powder, beige, sugar- and gluten-free, ispaghula husk 3.4 g/5.85-g sachet (orange or lemon/lime flavour). Net price 30 sachets = £2.44. Label: 13, counselling, see above

Excipients include aspartame [section 9.4.1]

**Dose**
- 1 sachet in 150 mL water 1-3 times daily, preferably after meals; *Child* (but see section 1.6) 2-6 years, see BNF for Children, 6-12 years 2.5-5 mL in water 1-3 times daily, preferably after meals

**METHYLCHELLOSE**

**Indications** see notes above

**Cautions** see under Ispaghula Husk

**Contra-indications** see under Ispaghula Husk; also infective bowel disease

**Side-effects** see under Ispaghula Husk

**Dose**
- See preparations below

**Counselling** Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed

**Celevac** (Amdipharm)

Tablets, pink, scored, methylcellulose ‘450’ 500 mg, net price 112-tab pack = £3.22. Counselling, see above and dose

**Dose**
- Constipation and diarrhoea, 3-6 tablets twice daily; in constipation the dose should be taken with at least 300 mL liquid, in diarrhoea, ileostomy, and colostomy control, avoid liquid intake for 30 minutes before and after dose; *Child* 7-12 years see BNF for Children

**STERCULIA**

**Indications** see notes above

**Cautions** see under Ispaghula Husk

**Contra-indications** see under Ispaghula Husk

**Side-effects** see under Ispaghula Husk

**Dose**
- See under preparations below

**Counselling** Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed

**Normacol** (Norgine)

Granules, coated, gluten-free, sterculia 62%. Net price 500 g = £5.94; 60 × 7-g sachets = £4.99.

Label: 25, 27, counselling, see above

**Dose**
- 1-2 heaped 5-mL spoonfuls, or the contents of 1-2 sachets, washed down without chewing with plenty of liquid once or twice daily after meals; *Child* (but see section 1.6) 6-12 years half adult dose

**Normacol Plus** (Norgine)

Granules, brown, coated, gluten-free, sterculia 62%, frangula (standardised) 8%. Net price 500 g = £6.34; 60 × 7-g sachets = £5.34. Label: 25, 27, counselling, see above

**Dose**
- Constipation and after haemorrhoidectomy, 1-2 heaped 5-mL spoonfuls or the contents of 1-2 sachets washed down without chewing with plenty of liquid once or twice daily after meals; *Child* 6-12 years see BNF for Children

**1.6.2 Stimulant laxatives**

Stimulant laxatives include bisacodyl, sodium picosulphate, and members of the *anthraquinone* group, *senna* and *dantron*. The indications for dantron are limited (see below) by its potential carcinogenicity (based on rodent carcinogenicity studies) and evidence of genotoxicity. Powerful stimulants such as *cascara* (an anthraquinone) and *castor oil* are obsolete. *Docusate sodium* probably acts both as a stimulant and as a softening agent.

Stimulant laxatives increase intestinal motility and often cause abdominal cramp; they should be avoided in intestinal obstruction. Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia; however, prolonged use may be justifiable in some circumstances (see section 1.6.8 for the use of stimulant laxatives in children).
Glycerol suppositories act as a rectal stimulant by virtue of the mildly irritating action of glycerol.

The parasympathomimetics bethanechol, distigmine, neostigmine, and pyridostigmine (see section 7.4.1 and section 10.2.1) enhance parasympathetic activity in the gut and increase intestinal motility. They are rarely used for their gastro-intestinal effects. Organic obstruction of the gut must first be excluded and they should not be used shortly after bowel anastomosis.

### BISACODYL

**Indications** see under Dose  
**Cautions** see notes above  
**Contra-indications** see notes above, acute surgical abdominal conditions, acute inflammatory bowel disease, severe dehydration  
**Pregnancy** see Pregnancy, p. 67  
**Side-effects** see notes above; nausea and vomiting; colitis also reported; suppositories, local irritation  
**Dose**  
- Constipation, by mouth, 5–10 mg at night, increased if necessary to max. 20 mg at night; **CHILD** (but see section 1.6) 4–18 years 5–20 mg once daily, adjusted according to response  
- By rectum in suppositories, 10 mg in the morning; **CHILD** (but see section 1.6) 2–18 years 5–10 mg once daily, adjusted according to response  
- Before radiological procedures and surgery, by mouth, 10 mg in the morning and 10 mg in the evening on the day before procedure, and by rectum in suppositories, 10 mg 1–2 hours before procedure the following day; **CHILD** 4–18 years see BNF for Children  
**Note** tablets act in 10–12 hours; suppositories act in 20–60 minutes

Bisacodyl (Non-proprietary)  
**Tablets**, e/c, bisacodyl 5 mg. Net price 100 = £15.87. Label: 14, (urine red)  
**Suppositories**, bisacodyl 10 mg. Net price 12 = £1.11  
**Paediatric suppositories**, bisacodyl 5 mg. Net price 5 = £0.94  

*Note* The brand name Dulcolax® (Boehringer Ingelheim) is used for bisacodyl tablets, net price 10-tab pack = £4.09; suppositories (10 mg), 10 = £1.57; paediatric suppositories (5 mg), 5 = £0.94  
*The brand names Dulcolax®, Pico Liquid and Dulcolax® Pico Perles are used for sodium picosulfate preparations*

### DANTRON

(Danthron)  
**Indications** only for constipation in terminally ill patients of all ages  
**Cautions** see notes above; *rodent* studies indicate potential carcinogenic risk; avoid prolonged contact with skin (as in incontinent patients or infants wearing nappies)—risk of irritation and excoriation  
**Contra-indications** see notes above  
**Pregnancy** manufacturers of co-danthramer and co-danthrusate advise avoid—no information available  
**Breast-feeding** manufacturers of co-danthramer and co-danthrusate advise avoid—limited information available  
**Side-effects** see notes above; urine may be coloured red  
**Dose**  
- See under preparations

#### With poloxamer ‘188’ (as co-danthramer)  
**Note** Co-danthramer suspension 5 mL = one co-danthramer capsule, but strong co-danthramer suspension 5 mL = two strong co-danthramer capsules

**Co-danthramer** (Non-proprietary)  
**Capsules**, co-danthramer 25/200 (dantron 25 mg, poloxamer ‘188’ 200 mg). Net price 60-cap pack = £12.86. Label: 14, (urine red)  
**Dose** 1–2 capsules at bedtime; **CHILD** 1 capsule at bedtime (restricted indications, see notes above)  
**Strong capsules**, co-danthramer 37.5/500 (dantron 37.5 mg, poloxamer ‘188’ 500 mg). Net price 60-cap pack = £15.55. Label: 14, (urine red)  
**Dose** ADULT and **CHILD** over 12 years, 1–2 capsules at bedtime (restricted indications, see notes above)  
**Suspension**, co-danthramer 25/200 in 5 mL (dantron 25 mg, poloxamer ‘188’ 200 mg/5 mL). Net price 300 mL = £11.27. 1 litre = £37.57. Label: 14, (urine red)  
**Dose** 5–10 mL at night; **CHILD** 2.5–5 mL at night (restricted indications, see notes above)  
**Brands include** Codolax®, Danlux®

**Strong suspension**, co-danthramer 75/1000 in 5 mL (dantron 75 mg, poloxamer ‘188’ 1 g/5 mL). Net price 300 mL = £30.13. Label: 14, (urine red)  
**Dose** ADULT and **CHILD** over 12 years, 5 mL at night (restricted indications, see notes above)  
**Brands include** Codolax Forte®, Ducolax®

#### With docusate sodium (as co-danthrusate)

**Co-danthrusate** (Non-proprietary)  
**Capsules**, co-danthrusate 50/60 (dantron 50 mg, docusate sodium 60 mg). Net price 63-cap pack = £15.87. Label: 14, (urine red)  
**Dose** 1–3 capsules at night; **CHILD** 6–12 years 1 capsule at night (restricted indications, see notes above)  
**Brands include** Normax®

**Suspension**, yellow, co-danthrusate 50/60 (dantron 50 mg, docusate sodium 60 mg/5 mL). Net price 200 mL = £8.75. Label: 14, (urine red)  
**Dose** 5–15 mL at night; **CHILD** 6–12 years 5 mL at night (restricted indications, see notes above)  
**Brands include** Doralax®, Codolax®, Danlux®, Danlax®, Danlax®, Normax®

### DOCUSATE SODIUM

(Dioctyl sodium sulphosuccinate)  
**Indications** constipation, adjunct in abdominal radiological procedures  
**Cautions** see notes above; do not give with liquid paraffin; rectal preparations not indicated if haemorrhoids or anal fissure  
**Contra-indications** see notes above  
**Pregnancy** not known to be harmful—manufacturer advises caution  
**Breast-feeding** present in milk following oral administration—manufacturer advises caution; rectal administration not known to be harmful  
**Side-effects** see notes above  
**Dose**  
- By mouth, chronic constipation, up to 500 mg daily in divided doses; **CHILD** (but see section 1.6) 6 months–2 years 12.5 mg 3 times daily, adjusted according to response (use paediatric solution); 2–12 years 12.5–25 mg 3 times daily, adjusted according to response (use paediatric oral solution)  
**Note** Oral preparations act within 1–2 days  
With barium meal, **ADULT** and **CHILD** over 12 years, 400 mg
70 1.6.3 Faecal softeners

Dioctyl® (UCB Pharma)
Capsules, yellow/white, docusate sodium 100 mg, net price 30-cap pack = £1.92, 100-cap pack = £6.40

Docusol® (Typharm)
Adult oral solution, sugar-free, docusate sodium 50 mg/5 mL, net price 300 mL = £5.49
Paediatric oral solution, sugar-free, docusate sodium 12.5 mg/5 mL, net price 300 mL = £5.29

Rectal preparations
Norgalax Micro-enema® (Norgine)
Enema, docusate sodium 120 mg in 10-g single-dose disposable packs. Net price 10-g unit = 57p
Dose ADULT and CHILD (but see section 1.6) over 12 years, 10-g unit

Glycerol (Glycerin)
Indications constipation
Dose

Glycerol Suppositories, BP
(Glycerin Suppositories)
Suppositories, gelatin 140 mg, glycerol 700 mg, purified water to 1 g, net price 12 = £1.27 (1 g), £1.29 (2 g), £1.49 (4 g)
Dose 1 suppository moistened with water before use, when required. The usual sizes are for INFANT under 1 year, small (1-g mould), CHILD 1–12 years medium (2-g mould), ADULT and CHILD over 12 years, large (4-g mould)

Senna
Indications constipation
Cautions see notes above
Contra-indications see notes above
Pregnancy see Pregnancy, p. 67
Breast-feeding not known to be harmful
Side-effects see notes above
Dose

Sodium Picosulfate
(Sodium picosulphate)
Indications constipation; bowel evacuation before abdominal radiological and endoscopic procedures on the colon, and surgery (section 1.6.5); acts within 6–12 hours
Cautions see notes above; active inflammatory bowel disease (avoid if fulminant)
Contra-indications see notes above; severe dehydration
Pregnancy see Pregnancy, p. 67
Breast-feeding not known to be present in milk but manufacturer advises avoid unless potential benefit outweighs risk
Side-effects see notes above
Dose

Bowel cleansing preparations
Section 1.6.5

Other stimulant laxatives
Unstandardised preparations of cascara, frangula, rhubarb, and senna should be avoided as their laxative action is unpredictable. Aloe, colocynth, and jalap should be avoided as they have a drastic purgative action.

1.6.3 Faecal softeners

Liquid paraffin, the traditional lubricant, has disadvantages (see below). Bulk laxatives (section 1.6.1) and non-ionic surfactant ‘wetting’ agents e.g. docusate sodium (section 1.6.2) also have softening properties. Such drugs are useful for oral administration in the management of haemorrhoids and anal fissure; glycerol (section 1.6.2) is useful for rectal use. Enemas containing arachis oil (ground-nut oil, peanut oil) lubricate and soften impacted faeces and promote a bowel movement.
### 1.6.4 Osmotic laxatives

**Arachis Oil Enema** (Non-proprietary)

**Enema**, arachis (peanut) oil in 130-mL single-dose disposable packs. Net price 130 mL = £7.98

**Dose** to soften impacted faeces, 130 mL; the enema should be warmed before use; **CHILD** (but see section 1.6) under 3 years not recommended; over 3 years reduce adult dose in proportion to body-weight (medical supervision only), see **BNF for Children**

**Liquid Paraffin Oral Emulsion, BP**

**Indications** constipation

**Cautions** avoid prolonged use; contra-indicated in children under 3 years

**Side-effects** anal seepage of paraffin and consequent anal irritation after prolonged use, granulomatous reactions caused by absorption of small quantities of liquid paraffin (especially from the emulsion), lipid pneumonia, and interference with the absorption of fat-soluble vitamins

**Dose**

- See under preparation

**Liquid Paraffin Oral Emulsion, BP**

**Oral emulsion**, liquid paraffin 5 mL, vanillin 5 mg, chloroform 0.025 mL, benzoic acid solution 0.2 mL, methylcellulose-20 200 mg, saccharin sodium 500 micrograms, water to 10 mL

**Dose** **ADULT** over 18 years, 10–30 mL at night when required

**Counselling** Should not be taken immediately before going to bed

**Side-effects** nausea (can be reduced by administration with water, fruit juice or with meals), vomiting, flatulence, cramps, and abdominal discomfort

**Dose**

- See under preparations below

**Lactulose** (Non-proprietary)

**Solution**, lactulose 3.1–3.7 g/5 mL with other ketoses. Net price 300-mL pack = £2.10, 500-mL pack = £2.59

**Dose** constipation, initially 15 mL twice daily, adjusted according to response; **CHILD** (but see section 1.6) under 1 year 2.5 mL twice daily, adjusted according to response; 1–5 years 2.5–10 mL twice daily, adjusted according to response; 5–18 years 5–20 mL twice daily, adjusted according to response

**Hepatic encephalopathy**, 30–50 mL 3 times daily, subsequently adjusted to produce 2–3 soft stools daily; **CHILD** 12–18 years see **BNF for Children**

**Note** Lactulose doses in **BNF** may differ from those in product literature

**Brands Include** *Duphalac*, *Lactugol*, *Regulose*

**MACROGOLS**

**Polyethylene glycols**

**Indications** see preparations below

**Cautions** discontinue if symptoms of fluid and electrolyte disturbance; see also preparations below

**Contra-indications** intestinal perforation or obstruction, paralytic ileus, severe inflammatory conditions of the intestinal tract (such as Crohn’s disease, ulcerative colitis, and toxic megacolon), see also preparations below

**Pregnancy** manufacturers advice use only if essential—no information available

**Breast-feeding** manufacturers advice use only if essential—no information available

**Side-effects** abdominal distension and pain, nausea, flatulence

**Dose**

- See preparations below

**Macrogol Oral Powder, Compound** (Non-proprietary)

**Oral powder**, macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/sachet, net price 20-sachet pack = £4.45, 30-sachet pack = £6.68. Label: 13

**Brands Include** *Laxidex*, *Lactugal*, *Movicol*, *Molaxole*

**Cautions** patients with cardiovascular impairment should not take more than 2 sachets in any 1 hour

**Dose** chronic constipation, **ADULT** and **CHILD** over 12 years, 1–3 sachets daily in divided doses usually for up to 2 weeks; contents of each sachet dissolved in half a glass (approx. 125 mL) of water; maintenance, 1–2 sachets daily

**Faecal impaction**, **ADULT** and **CHILD** over 12 years, 8 sachets daily dissolved in 1 litre of water and drunk within 6 hours, usually for max. 3 days

After reconstitution the solution should be kept in a refrigerator and discarded if unused after 6 hours

**Movicol** (Norgine)**

**Oral powder**, macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/sachet, net price 20-sachet pack (lime and lemon flavour) = £4.45, 30-sachet pack (lime- and lemon- or chocolate- or plain-flavoured) = £6.68, 50–sachet pack (lime- and lemon- or plain-flavoured) = £11.13. Label: 13

**Note** Amount of potassium chloride varies according to flavour of **Movicol** as follows: plain-flavour (sugar-free) = 50.2 mg/sachet; lime and lemon flavour = 50.2 mg/sachet;

**LACTULOSE**

**Indications** constipation (may take up to 48 hours to act), hepatic encephalopathy (portal systemic encephalopathy)

**Cautions** lactose intolerance; **interactions**: Appendix 1 (lactulose)

**Contra-indications** galactosaemia, intestinal obstruction

**Pregnancy** not known to be harmful; see also **Pregnancy**, p. 67
1.6.4 Osmotic laxatives

**BNF 61**

MAGNESIUM SALTS

**Indications** see under preparations below

**Cautions** elderly and debilitated; see also notes above; **Interactions**: Appendix 1 (antacids)

**Contra-indications** acute gastro-intestinal conditions

**Hepatic impairment** avoid in hepatic coma if risk of renal failure

**Renal impairment** avoid or reduce dose; increased risk of toxicity

**Side-effects** colic

- See preparations

- **Magnesium hydroxide**

  **Magnesium Hydroxide Mixture, BP**

  Aqueous suspension containing about 8% hydrated magnesium oxide. Do not store in cold place

  **Dose** constipation, 30–45 mL with water at bedtime when required; **CHILD** 3–12 years, 5–10 mL with water at bedtime when required

  **Magnesium hydroxide with liquid paraffin**

  **Liquid Paraffin and Magnesium Hydroxide Oral Emulsion, BP**

  Oral emulsion, 25% liquid paraffin in aqueous suspension containing 6% hydrated magnesium oxide

  **Dose** constipation, 5–20 mL when required

  **Note** Liquid paraffin and magnesium hydroxide preparations on sale to the public include: Milpar® *rexef.*

  **Magnesium sulphate**

  **Magnesium Sulphate**

  **Label**: 13, 23

  **Dose** rapid bowel evacuation (acts in 2–4 hours) 5–10 g in a glass of water preferably before breakfast

  **Note** Magnesium sulphate is on sale to the public as Epsom Salts

  **Bowel cleansing preparations**

  **Section 1.6.5**

  **PHOSPHATES (RECTAL)**

  **Indications** rectal use in constipation; bowel evacuation before abdominal radiological procedures, endoscopy, and surgery

  **Cautions** elderly and debilitated; with enema, electrolyte disturbances, congestive heart failure, ascites, uncontrolled hypertension, maintain adequate hydration

  **Contra-indications** acute gastro-intestinal conditions (including gastro-intestinal obstruction, inflammatory bowel disease, and conditions associated with increased colonic absorption)

  **Renal impairment** use enema with caution

  **Side-effects** local irritation; with enema, electrolyte disturbances

  **Dose**

  - See under preparations

  **Carbalax®** (Chemidex)

  **Suppositories**, sodium acid phosphate (anhydrous) 1.3 g, sodium bicarbonate 1.08 g, net price £2.01

  **Dose** constipation, **ADULT** and **CHILD** over 12 years, 1 suppository, inserted 30 minutes before evacuation required; moisten with water before use

  **Fleet® Ready-to-use Enema** (Casen-Fleet)

  **Enema**, sodium acid phosphate 21.4 g, sodium phosphate 9.4 g/118 mL; net price £0.67 (delivers 118 mL dose) with standard tube = £5p

  **Dose** **ADULT** and **CHILD** (but see section 1.6) over 12 years, 118 mL; **CHILD** 3–12 years, on doctor’s advice only (under 3 years not recommended)

  **Phosphates Enema BP Formula B**

  **Enema**, sodium dihydrogen phosphate dihydrate 12.8 g, disodium phosphate dodecahydrate 10.24 g, purified water, freshly boiled and cooled, to 128 mL. Net price £0.98 (with long rectal tube = £3.98)

  **Note** Enema BP Formula B with 118 mL of water required

  **Dose** 128 mL; **CHILD** (but see section 1.6) over 3 years, reduced according to body weight see **BNF** for **Children**

  **SODIUM CITRATE (RECTAL)**

  **Indications** rectal use in constipation

  **Cautions** elderly and debilitated; see also notes above

  **Contra-indications** acute gastro-intestinal conditions

  **Dose**

  - See under preparations

  **Micoletz Micro-enema®** (Pinewood)

  **Enema**, sodium citrate 450 mg, sodium lauryl sulphocetate 45 mg, glycerol 625 mg, together with potassium sorbate and sorbitol in a viscous solution,
in 5-mL single-dose disposable packs with nozzle. Net price 5 mL = £3.98.

**Dose**

- **ADULT** and **CHILD** over 3 years, 5–10 mL (see section 1.6).

**Micralax Micro-enema®** (UCB Pharma)

**Enema**, sodium citrate 450 mg, sodium alkylphosphatase 45 mg, sorbic acid 5 mg, together with glycerol and sorbitol in a viscous solution in 5-mL single-dose disposable packs with nozzle. Net price 5 mL = £4.1p.

**Dose**

- **ADULT** and **CHILD** over 3 years, 5 mL (see section 1.6).

**Relaxit Micro-enema®** (Crawford)

**Enema**, sodium citrate 450 mg, sodium laureyl sulphate 75 mg, sorbic acid 5 mg, together with glycerol and sorbitol in a viscous solution in 5-mL single-dose disposable packs with nozzle. Net price 5 mL = £3.2p.

**Dose**

- **ADULT** and **CHILD** (but see section 1.6) 5 mL (insert only half nozzle length in child under 3 years).

### 1.6.5 Bowel cleansing preparations

Bowel cleansing preparations are used before colonic surgery, colonoscopy, or radiological examination to ensure the bowel is free of solid contents. They are not treatments for constipation.

**Caution**: Renal function should be measured before starting. Bowel cleansing preparations should be used with caution in patients with fluid and electrolyte disturbances. Hypovolaemia should be corrected before administration of bowel cleansing preparations. Adequate hydration should be maintained during treatment. Bowel cleansing preparations should be used with caution in patients with an impaired gag reflex, reduced levels of consciousness, or debilitation. They should also be used with caution in patients with an impaired gag reflex, reduced levels of consciousness, or possibility of regurgitation or aspiration. Other oral drugs should not be taken one hour before or after administration of bowel cleansing preparations because absorption may be impaired.

**Contra-indications**: Bowel cleansing preparations are contra-indicated in patients with gastro-intestinal obstruction or perforation, gastric retention, acute severe colitis, or toxic megacolon.

**Side-effects**: Side-effects of bowel cleansing preparations include nausea, vomiting, abdominal pain (usually transient—reduced by taking more slowly), and abdominal distention. Less frequent side-effects include headache, dizziness, dehydration, and electrolyte disturbances.

**MAGNESIUM CITRATE**

-Reconstitution of a sachet containing 11.57 g magnesium carbonate and 17.79 g anhydrous citric acid produces a solution containing magnesium citrate.

**Indications**: see preparations

**Cautions**: see notes above

**Contra-indications**: see notes above

**Hepatic impairment**: avoid in hepatic coma if risk of renal failure

**Renal impairment**: avoid if eGFR less than 30 mL/minute/1.73 m²—risk of hypermagnesaemia

**Pregnancy**: caution

**Breast-feeding**: caution

**Side-effects**: see notes above

**Dose**: see preparations

---

**BNF 61**

**1.6.5 Bowel cleansing preparations**

Bowel cleansing preparations are used before colonic surgery, colonoscopy, or radiological examination to ensure the bowel is free of solid contents. They are not treatments for constipation.

**Caution**: Renal function should be measured before starting. Bowel cleansing preparations should be used with caution in patients with fluid and electrolyte disturbances. Hypovolaemia should be corrected before administration of bowel cleansing preparations. Adequate hydration should be maintained during treatment. Bowel cleansing preparations should be used with caution in patients with an impaired gag reflex, reduced levels of consciousness, or debilitation. They should also be used with caution in patients with an impaired gag reflex, reduced levels of consciousness, or possibility of regurgitation or aspiration. Other oral drugs should not be taken one hour before or after administration of bowel cleansing preparations because absorption may be impaired.

**Contra-indications**: Bowel cleansing preparations are contra-indicated in patients with gastro-intestinal obstruction or perforation, gastric retention, acute severe colitis, or toxic megacolon.

**Side-effects**: Side-effects of bowel cleansing preparations include nausea, vomiting, abdominal pain (usually transient—reduced by taking more slowly), and abdominal distention. Less frequent side-effects include headache, dizziness, dehydration, and electrolyte disturbances.

**MACROGOLS**

- **Indications**: see notes above
- **Cautions**: see notes above; also heart failure; acute inflammatory bowel disease
- **Contra-indications**: see notes above
- **Pregnancy**: manufacturers advise use only if essential—no information available
- **Breast-feeding**: manufacturers advise use only if essential—no information available
- **Side-effects**: see notes above; also fatigue, sleep disturbances, and anal discomfort

---

**Klean-Prep®** (Norgine)

**Oral powder**, sugar-free, macrocol ‘3350’ (polyethylene glycol ‘3350’) 59 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 743 mg/sachet, net price 4 sachets = £8.23. Label: 10, patient information leaflet, 13, counselling.

**Exipients**: include aspartame (section 9.4.1) 1 sachet when reconstituted with 1 litre of water provides Na⁺ 125 mmol, K⁺ 10 mmol, Cl⁻ 35 mmol, HCO₃⁻ 20 mmol.

**Dose**: bowel evacuation before surgery, colonoscopy, or radiological examination, a glass (approx. 250 mL) of reconstituted solution every 10–15 minutes, or by nasogastric tube 20–30 mL/minute, starting on the day before procedure until 4 litres have been consumed; alternatively, administration may be divided into two (2 litres of reconstituted solution taken on the evening before procedure and 2 litres of reconstituted solution taken on the morning of procedure). Treatment can be stopped if bowel motions become watery and clear. To facilitate gastric emptying, domperidone or metoclopramide may be given 30 minutes before starting; **CHILD** 12–18 years see BNF for Children.

**Counselling**: 1 sachet should be reconstituted with 1 litre of water. Flavouring such as clear fruit cordials may be added if required. Solid food should not be taken for at least 2 hours before starting treatment. After reconstitution the solution should be kept in a refrigerator and discarded if unused after 24 hours.

**Moviprep®** (Norgine)

**Oral powder**, lemon- or orange-flavoured, Sachet A (containing macrocol ‘3350’ (polyethylene glycol ‘3350’) 100 g, anhydrous sodium sulphate 7.5 g, sodium chloride 2.691 g, potassium chloride 1.015 g) and Sachet B (containing ascorbic acid 4.7 g, sodium ascorbate 5.9 g), net price 4-sachet pack (2 each of sachet A and B) = £9.87. Label: 10, patient information leaflet, 13, counselling, see below.

**Exipients**: include aspartame (section 9.4.1) 1 pair of sachets (A+B) when reconstituted with 1 litre of water provides Na⁺ 181.6 mmol (Na⁺ 56.2 mmol absorbable), K⁺ 14.2 mmol, Cl⁻ 59.8 mmol.

**Contra-indications**: G6PD deficiency.

**Renal impairment**: caution if eGFR less than 30 mL/minute.

**Dose**: bowel evacuation for surgery, colonoscopy or radiological examination, **ADULT** over 18 years, 2 litres of reconstituted solution on the evening before procedure or 1 litre of reconstituted solution on the evening before procedure and 1 litre of reconstituted solution early on the morning of procedure; treatment should be completed at least 1 hour before colonoscopy. **Counselling**: One pair of sachets (A and B) should be reconstituted in 1 litre of water and taken over 1–2 hours. Solid food should not be taken during treatment until procedure completed. 1 litre of other clear fluid should also be taken during treatment. Treatment can be stopped if bowel motions become watery and clear.

---

**BNF 61 1.6.5 Bowel cleansing preparations 73**
1.6.6 Peripheral opioid-receptor antagonists

Methylnaltrexone is a peripherally acting opioid-receptor antagonist that is licensed for the treatment of opioid-induced constipation in patients receiving palliative care, when response to other laxatives is inade-
1.6.7 5HT₄-receptor agonists

Prucalopride is a selective serotonin 5HT₄-receptor agonist with prokinetic properties. It is licensed for the treatment of chronic constipation in women, when other laxatives have failed to provide an adequate response. Headache and gastro-intestinal symptoms (including abdominal pain, nausea, and diarrhoea) are the most frequent side-effects. The side-effects generally occur at the start of treatment and are usually transient.

1.7 Local preparations for anal and rectal disorders

1.7.1 Soothing haemorrhoidal preparations

Soothing preparations containing mild astringents such as bismuth subgallate, zinc oxide, and hamamelis may give symptomatic relief in haemorrhoids. Many proprietary preparations also contain lubricants, vasoconstrictors, or mild antiseptics.

Local anaesthetics are used to relieve pain associated with haemorrhoids and pruritus ani but good evidence...
is lacking. Lidocaine ointment (section 15.2) is used before emptying the bowel to relieve pain associated with anal fissure. Alternative local anaesthetics include tetracaine, cinchocaine (dibucaine), and pramocaine (pramoxine), but they are more irritant. Local anaesthetic ointments can be absorbed through the rectal mucosa therefore excessive application should be avoided, particularly in infants and children. Preparations containing local anaesthetics should be used for short periods only (no longer than a few days) since they may cause sensitisation of the anal skin.

1.7.2 Compound haemorrhoidal preparations with corticosteroids

Corticosteroids are often combined with local anaesthetics and soothing agents in preparations for haemorrhoids. They are suitable for occasional short-term use after exclusion of infections, such as herpes simplex; prolonged use can cause atrophy of the anal skin. See section 13.4 for general comments on topical corticosteroids and section 1.7.1 for comment on local anaesthetics.

Children

Haemorrhoids in children are rare. Treatment is usually symptomatic and the use of a locally applied cream is appropriate for short periods; however, local anaesthetics can cause stinging initially and this applied cream is appropriate for short periods; however, children may aggravate the child’s fear of defaecation.

Anugescic-HC® (Pfizer) (Full)

Cream, benzyl benzoate 1.2%, bismuth oxide 0.875%, hydrocortisone acetate 0.5%, Peru balsam 1.85%, pramocaine hydrochloride 1%, zinc oxide 12.35%. Net price 30 g (with rectal nozzle) = £3.71

Dose apply night and morning and after a bowel movement; do not use for longer than 7 days; CHILD not recommended

Suppositories, buff, benzyl benzoate 33 mg, bismuth oxide 24 mg, bismuth subgallate 59 mg, hydrocortisone acetate 5 mg, Peru balsam 49 mg, pramocaine hydrochloride 27 mg, zinc oxide 296 mg, net price 12 = £2.69

Dose insert 1 suppository night and morning and after a bowel movement; do not use for longer than 7 days; CHILD not recommended

Anusol-HC® (McNeil) (Full)

Ointment, benzyl benzoate 1.25%, bismuth oxide 0.875%, bismuth subgallate 2.25%, hydrocortisone acetate 0.25%, Peru balsam 1.875%, zinc oxide 10.75%. Net price 30 g (with rectal nozzle) = £3.29

Dose apply night and morning and after a bowel movement; do not use for longer than 7 days; CHILD not recommended

Note A proprietary brand (Anusol Plus HC® ointment) is on sale to the public

Suppositories, benzyl benzoate 33 mg, bismuth oxide 24 mg, bismuth subgallate 59 mg, hydrocortisone acetate 10 mg, Peru balsam 49 mg, zinc oxide 296 mg. Net price 12 = £2.31

Dose insert 1 suppository night and morning and after a bowel movement; do not use for longer than 7 days; CHILD not recommended

Note A proprietary brand (Anusol Plus HC® suppositories) is on sale to the public

Perinal® (Dermal)

Spray application, hydrocortisone 0.2%, lidocaine hydrochloride 1%. Net price 30-ML pack = £6.11

Dose ADULT and CHILD over 14 years, spray once over the affected area up to 3 times daily; do not use for longer than 7 days without medical advice; CHILD under 14 years on medical advice only

Proctofoam HC® (Meda) (Full)

Foam in aerosol pack, hydrocortisone acetate 1%, pramocaine hydrochloride 1%. Net price 21.2-g pack (approx. 40 applications) with applicator = £5.06

Dose haemorrhoids and proctitis, 1 applicatorful (4-6 mg hydrocortisone acetate, 4-6 mg pramocaine hydrochloride) by rectum 2–3 times daily and after each bowel movement (max. 4 times daily), do not use for longer than 7 days; CHILD not recommended

Proctosedyl® (Sanofi-Aventis) (Full)

Ointment, cinchocaine (dibucaine) hydrochloride 0.5%, hydrocortisone 0.5%. Net price 30 g = £10.34 (with cannula)

Dose apply morning and night and after a bowel movement, externally or by rectum; do not use for longer than 7 days

Suppositories, cinchocaine (dibucaine) hydrochloride 5 mg, hydrocortisone 5 mg. Net price 12 = £4.66

Dose insert 1 suppository night and morning and after a bowel movement, do not use for longer than 7 days

Scheriproct® (Bayer Schering) (Full)

Ointment, cinchocaine (dibucaine) hydrochloride 0.5%, prednisolone hexanoate 0.19%. Net price 30 g = £2.94

Dose apply twice daily for 5–7 days (3–4 times daily on 1st day if necessary), then once daily for a few days after symptoms have cleared

Suppositories, cinchocaine (dibucaine) hydrochloride 1 mg, prednisolone hexanoate 1.3 mg. Net price 12 = £1.38

Dose insert 1 suppository daily after a bowel movement, for 5–7 days (in severe cases initially 2–3 times daily)

Ultraproct® (Meadow) (Full)

Ointment, cinchocaine (dibucaine) hydrochloride 0.5%, fluocortolone caproate 0.095%, fluocortolone pivalate 0.092%, net price 30 g (with rectal nozzle) = £4.57

Dose apply twice daily for 5–7 days (3–4 times daily on 1st day if necessary), then once daily for a few days after symptoms have cleared

Suppositories, cinchocaine (dibucaine) hydrochloride 1 mg, fluocortolone caproate 630 micrograms, fluocortolone pivalate 610 micrograms, net price 12 = £2.15

Dose insert 1 suppository daily after a bowel movement, for 5–7 days (in severe cases initially 2–3 times daily) then 1 suppository every other day for 1 week

Uniorid-HC® (Chemidex) (Full)

Ointment, cinchocaine (dibucaine) hydrochloride 0.5%, hydrocortisone 0.5%. Net price 30 g (with applicator) = £4.23

Dose ADULT and CHILD over 12 years, apply twice daily and after a bowel movement, externally or by rectum; do not use for longer than 7 days; CHILD under 12 years on medical advice only

Suppositories, cinchocaine (dibucaine) hydrochloride 5 mg, hydrocortisone 5 mg. Net price 12 = £1.91

Dose ADULT and CHILD over 12 years, insert 1 suppository twice daily and after a bowel movement; do not use for longer than 7 days
XYLOPROCT® (Astra Zeneca) (p. 1G)
Ointment (water-miscible), aluminium acetate 3.5%, hydrocortisone acetate 0.275%, lidocaine 5%, zinc oxide 18%, net price £20.0 (with applicator) = £2.26
Dose apply several times daily; short-term use only

### 1.7.3 Rectal sclerosants

Oily phenol injection is used to inject haemorrhoids particularly when unprolapsed.

**PHENOL**

**Indications** see notes above

**Side-effects** irritation, tissue necrosis

**Oily Phenol Injection, BP** (p. 30
phenol 5% in a suitable fixed oil. Net price 5-mL amp = £4.65
Dose 2–3 mL into the submucosal layer at the base of the pile; several injections may be given at different sites, max. total injected 10 mL at any one time

### 1.7.4 Management of anal fissures

The management of anal fissures requires stool softening by increasing dietary fibre in the form of bran or by using a bulk-forming laxative. Short-term use of local anaesthetic preparations may help (section 1.7.1). If these measures are inadequate, the patient should be referred for specialist treatment in hospital. The use of a topical nitrate (e.g. glyceryl trinitrate 0.4% ointment) may be considered. Before considering surgery, topical diltiazem 2% may be used twice daily [unlicensed indication] in patients with chronic anal fissures unresponsive to topical nitrate.

The Scottish Medicines Consortium (p. 4) has advised (January 2008) that glyceryl trinitrate 0.4% ointment (Rectogesic®) is not recommended for use within NHS Scotland for the relief of pain associated with chronic anal fissure.

**GLYCERYL TRINITRATE**

**Indications** anal fissure; angina, left ventricular failure (section 2.6.1); extravasation (section 10.3)

**Cautions** section 2.6.1

**Contra-indications** section 2.6.1

**Hepatic impairment** section 2.6.1

**Renal impairment** section 2.6.1

**Pregnancy** section 2.6.1

**Breast-feeding** section 2.6.1

**Side-effects** section 2.6.1; also diarrhoea, burning, itching, and rectal bleeding

**Dose**

- see preparations

**Rectogesic®** (ProStrakan) (p. 1G)

**Rectal ointment**, glyceryl trinitrate 0.4%, net price 30 g = £34.80

Excipients include lanolin, propylene glycol

**Dose** ADULT over 18 years, apply 2.5 cm of ointment to anal canal every 12 hours until pain stops; max. duration of use 8 weeks

**Note** 2.5 cm of ointment contains glyceryl trinitrate 1.5 mg; discard tube 8 weeks after first opening

---

**1.8 Stoma care**

Prescribing for patients with stoma calls for special care. The following is a brief account of some of the main points to be borne in mind.

**Enteric-coated and modified-release preparations are unsuitable**, particularly in patients with an ileostomy, as there may not be sufficient release of the active ingredient.

**Laxatives** Enemas and washouts should not be prescribed for patients with an ileostomy as they may cause rapid and severe loss of water and electrolytes.

Colostomy patients may suffer from constipation and whenever possible should be treated by increasing fluid intake or dietary fibre. Bulk-forming drugs (section 1.6.1) may be tried. If they are insufficient, as small a dose as possible of senna (section 1.6.2) should be used.

**Antidiarrhoeals** Drugs such as loperamide, codeine phosphate, or co-phenotrope (diphenoxylate with atropine) are effective. Bulk-forming drugs (section 1.6.1) may be tried but it is often difficult to adjust the dose appropriately.

**Antibacterials** should not be given for an episode of acute diarrhoea.

**Antacids** The tendency to diarrhoea from magnesium salts or constipation from aluminium salts may be increased in these patients.

**Diuretics** Diuretics should be used with caution in patients with an ileostomy as they may become excessively dehydrated and potassium depletion may easily occur. It is usually advisable to use a potassium-sparing diuretic (see section 2.2.3).

**Digoxin** Patients with a stoma are particularly susceptible to hypokalaemia if on digoxin therapy and potassium supplements or a potassium-sparing diuretic may be advisable (for comment see section 9.2.1.1).

**Potassium supplements** Liquid formulations are preferred to modified-release formulations (see above).

**Analgesics** Opioid analgesics (see section 4.7.2) may cause troublesome constipation in colostomy patients. When a non-opioid analgesic is required paracetamol is usually suitable but anti-inflammatory analgesics may cause gastric irritation and bleeding.

**Iron preparations** Iron preparations may cause loose stools and sore skin in these patients. If this is troublesome and if iron is definitely indicated a modified-release preparation should be used. Modified-release preparations are unsuitable for the reasons given above.

**Care of stoma** Patients are usually given advice about the use of cleansing agents, protective creams, lotions, deodorants, or sealants whilst in hospital, either by the surgeon or by stoma care nurses. Voluntary organisations offer help and support to patients with stoma.
1.9 Drugs affecting intestinal secretions

1.9.1 Drugs affecting biliary composition and flow

The use of laparoscopic cholecystectomy and of endoscopic biliary techniques has limited the place of the bile acid ursodeoxycholic acid in gallstone disease. Ursodeoxycholic acid is suitable for patients with unimpaired gall bladder function, small or medium-sized radiolucent stones, and whose mild symptoms are not amenable to other treatment; it should be used cautiously in those with liver disease (but see below). Patients should be given dietary advice (including avoidance of excessive cholesterol and calories) and they require radiological monitoring. Long-term prophylaxis may be needed after complete dissolution of the gallstones has been confirmed because they may recur in up to 25% of patients within one year of stopping treatment.

Ursodeoxycholic acid is also used in primary biliary cirrhosis; liver tests improve in most patients but the effect on overall survival is uncertain.

**URSODEOXYCHOLIC ACID**

**Indications** see under Dose and under preparations

**Cautions** see notes above; **Interactions:** Appendix 1 (ursodeoxycholic acid)

**Contra-indications** radio-opaque stones, non-functioning gall bladder, inflammatory diseases and other conditions of the small intestine, colon and liver which interfere with entero-hepatic circulation of bile salts

**Hepatic impairment** avoid in chronic liver disease (but used in primary biliary cirrhosis)

**Pregnancy** no evidence of harm but manufacturer advises avoid

**Breast-feeding** not known to be harmful but manufacturer advises avoid

**Side-effects** nausea, vomiting, diarrhoea; gallstone calcification; pruritus

**Dose**

- Dissolution of gallstones, 8–12 mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
- Primary biliary cirrhosis, see under Ursofalk®

**Ursodeoxycholic Acid (Non-proprietary)** [BNF]

- **Tablets**, ursodeoxycholic acid 150 mg, net price 60-tab pack = £20.48. Label: 21
- **Capsules**, ursodeoxycholic acid 250 mg, net price 60-cap pack = £38.86. Label: 21

**Destolit®** (Norgine) [BNF]

- **Tablets**, scored, ursodeoxycholic acid 150 mg, net price 60-tab pack = £17.67. Label: 21

**Urdox®** (Wockhardt) [BNF]

- **Tablets**, f/c, ursodeoxycholic acid 300 mg, net price 60-tab pack = £26.50. Label: 21

**Ursofalk®** (Dr Falk) [BNF]

- **Capsules**, ursodeoxycholic acid 250 mg, net price 60-cap pack = £30.17, 100-cap pack = £31.88. Label: 21

- **Suspension**, sugar-free, ursodeoxycholic acid 250 mg/5 mL, net price 250 mL = £26.98. Label: 21

**Dose**

- Primary biliary cirrhosis, 10–15 mg/kg daily as a single daily dose or in 2–4 divided doses
- Dissolution of gallstones, see Dose, above

**Ursogal®** (Galen) [BNF]

- **Tablets**, scored, ursodeoxycholic acid 150 mg, net price 60-tab pack = £17.05. Label: 21

**Other preparations for biliary disorders**

**A terpene mixture** (Rowacho®) raises biliary cholesterol solubility. It is not considered to be a useful adjunct.

**Rowachol®** (Rowa) [BNF]

- **Capsules**, green, e/c, borneol 5 mg, camphene 5 mg, cineole 2 mg, menthol 32 mg, menthone 6 mg, pinene 17 mg in olive oil. Net price 50-cap pack = £7.35. Label: 22

**Dose** 1–2 capsules 3 times daily before food (but see notes above)

**Interactions:** Appendix 1 (Rowacho®)

1.9.2 Bile acid sequestrants

Colestyramine is an anion-exchange resin that is not absorbed from the gastro-intestinal tract. It relieves diarrhoea and pruritus by forming an insoluble complex with bile acids in the intestine. Colestyramine can interfere with the absorption of a number of drugs. Colestyramine is also used in hypercholesterolaemia (section 2.12).

**COLESTYRAMINE** (Cholestyramine)

**Indications** pruritus associated with partial biliary obstruction and primary biliary cirrhosis; diarrhoea associated with Crohn’s disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation; hypercholesterolaemia (section 2.12)

**Cautions** section 2.12

**Contra-indications** section 2.12

**Pregnancy** section 2.12

**Breast-feeding** section 2.12

**Side-effects** section 2.12

**Dose**

- Pruritus, 4–8 g daily in a suitable liquid; **CHILD** 1–18 years see BNF for Children
- Diarrhoea, initially 4 g daily increased by 4 g at weekly intervals to 12–24 g daily in a suitable liquid in 1–4
1.9.3 Aprotinin

Aprotinin is no longer used for the treatment of acute pancreatitis.

1.9.4 Pancreatin

Supplements of pancreatin are given by mouth to compensate for reduced or absent exocrine secretion in cystic fibrosis, and following pancreatectomy, gatroctomy, or chronic pancreatitis. They assist the digestion of starch, fat, and protein. Pancreatin may also be necessary if a tumour (e.g. pancreatic cancer) obstructs outflow from the pancreas.

Pancreatin is inactivated by gastric acid therefore pancreatin preparations are best taken with food (or immediately before or after food). Gastric acid secretion may be reduced by giving cinmetidine or ranitidine an hour beforehand (section 1.3). Concurrent use of antacids also reduces gastric acidity. Enteric-coated preparations deliver a higher enzyme concentration in the duodenum (provided the capsule contents are swallowed whole without chewing). Higher-strength preparations are also available [important: see CSM advice below].

Since pancreatin is also inactivated by heat, excessive heat should be avoided if preparations are mixed with liquids or food; the resulting mixtures should not be kept for more than one hour.

Dosage is adjusted according to size, number, and consistency of stools, so that the patient thrives; extra allowance will be needed if snacks are taken between meals.

Pancreatin can irritate the perioral skin and buccal mucosa if retained in the mouth, and excessive doses can cause perianal irritation. The most frequent side-effects are gastro-intestinal, including nausea, vomiting, and abdominal discomfort; hyperuricaemia and hyperuricosuria have been associated with very high doses. Hypersensitivity reactions occur occasionally and may affect those handling the powder.

**PANCREATIN**

**Indications** see above

**Cautions** see above and (for higher-strength preparations) see below

**Pregnancy** not known to be harmful

**Side-effects** see above and (for higher-strength preparations) see below

**Dose**

- See preparations

**Creon® 10 000 (Solvay)**

**Capsules**, brown/clear, enclosing buff-coloured e/c granules of pancreatin (pork), providing: protease 1400 units, lipase 10 000 units, amylase 8000 units. Net price 100-cap pack = £12.93. Counselling, see dose

**Dose**

- **ADULT** and **CHILD** initially 1–2 capsules with each meal either taken whole or mixed with fluid or soft food (then swallowed immediately without chewing)

**Creon® Micro (Solvay)**

**Gastro-resistant granules**, brown, pancreatin (pork), providing: protease 200 units, lipase 3000 units, amylase 3600 units per 100 mg, net price 20 g = £13.50

Counselling, see dose

**Dose**

- **ADULT** and **CHILD** initially 100 mg with each meal either taken whole or mixed with acidic fluid or soft food (then swallowed immediately without chewing)

**Nutrizym 10® (Merck Serono)**

**Capsules**, red/yellow, enclosing e/c minitablets of pancreatin (pork), providing minimum of: protease 500 units, lipase 10 000 units, amylase 9000 units. Net price 100 = £14.47. Counselling, see dose

**Dose**

- **ADULT** and **CHILD** 1–2 capsules with meals and 1 capsule with snacks, swallowed whole or contents taken with water or mixed with soft food (then swallowed immediately without chewing); higher doses may be required according to response

**Pancrex® (Paines & Byrne)**

**Granules**, pancreatin (pork), providing minimum of: protease 300 units, lipase 5000 units, amylase 4000 units/g. Net price 300 g = £20.39. Label: 25, counselling, see dose

**Dose**

- **ADULT** and **CHILD** 5–10 g just before meals washed down or mixed with a little milk or water

**Pancrex V® (Paines & Byrne)**

**Capsules**, pancreatin (pork), providing minimum of: protease 430 units, lipase 8000 units, amylase 9000 units. Net price 300-cap pack = £15.80. Counselling, see dose

**Dose**

- **ADULT** and **CHILD** over 1 year 2–6 capsules with each meal, swallowed whole or sprinkled on food; **INFANT** up to 1 year contents of 1–2 capsules mixed with feeds

**Capsules ‘125’,** pancreatin (pork), providing minimum of: protease 160 units, lipase 2950 units, amylase 3300 units, net price 300-cap pack = £9.72. Counselling, see dose

**Dose**

- **NEONATE** contents of 1–2 capsules mixed with feeds

**Tablets**, e/c, pancreatin (pork), providing minimum of: protease 110 units, lipase 1900 units, amylase 1700 units. Net price 300-tab pack = £4.51. Label: 5, 25, counselling, see dose

**Dose**

- **ADULT** and **CHILD** 5–15 tablets before each meal

**Tablets forte, e/c, pancreatin (pork), providing minimum of: protease 330 units, lipase 5600 units, amylase 5500 units. Net price 300-tab pack = £13.74. Label: 5, 25, counselling, see dose

**Dose**

- **ADULT** and **CHILD** 6–10 tablets before each meal

**Powder**, pancreatin (pork), providing minimum of: protease 1400 units, lipase 25 000 units, amylase 30 000 units/g. Net price 300 g = £24.28. Counselling, see dose

**Dose**

- **ADULT** and **CHILD** over 1 month, 0.5–2 g before each meal, washed down or mixed with liquid; **NEONATE** 250–500 mg with each feed
Higher-strength preparations

The high-strength pancreatin preparations Nutrizym 22® and Pancrease HL® have been associated with the development of large bowel strictures (fibrosing colonopathy) in children with cystic fibrosis aged between 2 and 13 years. No association was found with Creon® 25 000 and Creon® 40 000. The following is recommended:

- Pancrease HL® and Nutrizym 22® should not be used in children aged 15 years or less with cystic fibrosis;
- the total dose of pancreatic enzyme supplements used in patients with cystic fibrosis should not usually exceed 10 000 units of lipase per kg body-weight daily;
- if a patient on any pancreatin preparation develops new abdominal symptoms (or any change in existing abdominal symptoms) the patient should be reviewed to exclude the possibility of colonic damage.

Possible risk factors are gender (boys at greater risk than girls), more severe cystic fibrosis, and concomitant use of laxatives. The peak age for developing fibrosing colonopathy is between 2 and 8 years. Counselling It is important to ensure adequate hydration at all times in patients receiving higher-strength pancreatin preparations.

Creon® 25 000 (Solvay)
Capsules, orange/clear, enclosing brown-coloured e/c pellets of pancreatin (pork), providing: protease (total) 1000 units, lipase 25 000 units, amylase 18 000 units, net price 100-cap pack = £28.25. Counselling, see above and under dose

Dose
ADULT and CHILD initially 1 capsule with meals either taken whole or contents mixed with fluid or soft food (then swallowed immediately without chewing)

Creon® 40 000 (Solvay)
Capsules, brown/clear, enclosing brown-coloured e/c granules of pancreatin (pork), providing: protease (total) 1600 units, lipase 40 000 units, amylase 25 000 units, net price 100-cap pack = £60.00. Counselling, see above and under dose

Dose
ADULT and CHILD initially 1–2 capsules with meals either taken whole or contents mixed with fluid or soft food (then swallowed immediately without chewing)

Nutrizym 22® (Merck Serono)
Capsules, red/yellow, enclosing e/c minitablets of pancreatin (pork), providing minimum of: protease 1100 units, lipase 22 000 units, amylase 19 800 units. Net price 100-cap pack = £33.33. Counselling, see above and under dose

Dose
ADULT and CHILD over 15 years, 1–2 capsules with meals and 1 capsule with snacks, swallowed whole or contents mixed with water or soft food (then swallowed immediately without chewing)

Pancrease HL® (Janssen-Cilag)
Capsules, enclosing light brown e/c minitablets of pancreatin (pork), providing minimum of: protease 1250 units, lipase 25 000 units, amylase 22 500 units. Net price 100 = £31.70. Counselling, see above and under dose

Dose
ADULT and CHILD over 15 years, 1–2 capsules during each meal and 1 capsule with snacks swallowed whole or contents mixed with slightly acidic liquid or soft food (then swallowed immediately without chewing)
2 Cardiovascular system

2.1 Positive inotropic drugs 81
2.1.1 Cardiac glycosides 81
2.1.2 Phosphodiesterase type-3 inhibitors 83

2.2 Diuretics 83
2.2.1 Thiazides and related diuretics 84
2.2.2 Loop diuretics 86
2.2.3 Potassium-sparing diuretics and aldosterone antagonists 87
2.2.4 Potassium-sparing diuretics with other diuretics 89
2.2.5 Osmotic diuretics 89
2.2.6 Mercurl diuretics 90
2.2.7 Carbonic anhydrase inhibitors 90
2.2.8 Diuretics with potassium 90

2.3 Anti-arrhythmic drugs 90
2.3.1 Management of arrhythmias 90
2.3.2 Drugs for arrhythmias 92

2.4 Beta-adrenoceptor blocking drugs 97

2.5 Hypertension and heart failure 104
2.5.1 Vasodilator antihypertensive drugs 107
2.5.2 Centrally acting antihypertensive drugs 110
2.5.3 Adrenergic neurone blocking drugs 111
2.5.4 Alpha-adrenoceptor blocking drugs 112
2.5.5 Drugs affecting the renin-angiotensin system 114
2.5.5.1 Angiotensin-converting enzyme inhibitors 115
2.5.5.2 Angiotensin-II receptor antagonists 121
2.5.5.3 Renin inhibitors 124

2.6 Nitrates, calcium-channel blockers, and other antianginal drugs 124
2.6.1 Nitrates 125
2.6.2 Calcium-channel blockers 128
2.6.3 Other antianginal drugs 134
2.6.4 Peripheral vasodilators and related drugs 135

2.7 Sympathomimetics 137
2.7.1 Inotropic sympathomimetics 137

2.7.2 Vasoconstrictor sympathomimetics 138
2.7.3 Cardiopulmonary resuscitation 139
2.8 Anticoagulants and protamine 139
2.8.1 Parenteral anticoagulants 140
2.8.2 Oral anticoagulants 146
2.8.3 Protamine sulphate 149

2.9 Antiplatelet drugs 149
2.10 Stable angina, acute coronary syndromes, and fibrinolysis 154
2.10.1 Management of stable angina and acute coronary syndromes 154
2.10.2 Fibrinolytic drugs 157
2.11 Antifibrinolytic drugs and haemostatics 159
2.12 Lipid-regulating drugs 161
2.13 Local sclerosants 169

This chapter also includes advice on the drug management of the following:
- angina, p. 154
- arrhythmias, p. 90
- cardiovascular disease risk, p. 104 and p. 161
- heart failure, p. 114
- hypertension, p. 104
- myocardial infarction, p. 154
- phaeochromocytoma, p. 113
- stroke, p. 150

2.1 Positive inotropic drugs

2.1.1 Cardiac glycosides 124

2.1.1 Cardiac glycosides

Digoxin is a cardiac glycoside that increases the force of myocardial contraction and reduces conductivity within the atrioventricular (AV) node.

Digoxin is most useful for controlling ventricular response in persistent and permanent atrial fibrillation and atrial flutter (section 2.3.1). For reference to the role of digoxin in heart failure, see section 2.5.5.
2 Cardiovascular system

For management of atrial fibrillation the maintenance dose of digoxin can usually be determined by the ventricular rate at rest, which should not usually be allowed to fall persistently below 60 beats per minute.

Digoxin is now rarely used for rapid control of heart rate (see section 2.3 for the management of supraventricular arrhythmias). Even with intravenous administration, response may take many hours; persistence of tachycardia is therefore not an indication for exceeding the recommended dose. The intramuscular route is not recommended.

In patients with heart failure who are in sinus rhythm a loading dose is not required, and a satisfactory plasma-digoxin concentration can be achieved over a period of about a week.

Digoxin has a long half-life and maintenance doses need to be given only once daily (although higher doses may be divided to avoid nausea); renal function is the most important determinant of digoxin dosage.

Unwanted effects depend both on the concentration of digoxin in the plasma and on the sensitivity of the conducting system or of the myocardium, which is often increased in heart disease. It can sometimes be difficult to distinguish between toxic effects and clinical deterioration because symptoms of both are similar. The plasma concentration alone cannot indicate toxicity reliably, but the likelihood of toxicity increases progressively through the range 1.5 to 3 micrograms/litre for digoxin. Digoxin should be used with special care in the elderly, who may be particularly susceptible to digitalis toxicity.

Regular monitoring of plasma-digoxin concentration during maintenance treatment is not necessary unless problems are suspected. Hypokalaemia predisposes the patient to digitalis toxicity; it is managed by giving a potassium-sparring diuretic or, if necessary, potassium supplementation.

If toxicity occurs, digoxin should be withdrawn; serious manifestations require urgent specialist management.

Digoxin-specific antibody fragments are available for reversal of life-threatening overdosage (see below).

### Digoxin

**Indications** heart failure (see also section 2.5.5), supraventricular arrhythmias (particularly atrial fibrillation and atrial flutter; see also section 2.3.2)

**Cautions** recent myocardial infarction; sick sinus syndrome; thyroid disease; reduce dose in the elderly; severe respiratory disease; hypokalaemia, hypomagnesaemia, hypercalcemia, and hypoxia (risk of digitalis toxicity); monitor serum electrolytes and renal function; avoid rapid intravenous administration (risk of hypertension and reduced coronary flow); interactions: Appendix 1 (cardiac glycosides)

**Contra-indications** intermittent complete heart block, second degree AV block; supraventricular arrhythmias associated with accessory conducting pathways e.g. Wolff-Parkinson-White syndrome; ventricular tachycardia or fibrillation; hypertrophic cardiomyopathy (unless concomitant atrial fibrillation and heart failure—but use with caution); myocarditis; constrictive pericarditis (unless to control atrial fibrillation or improve systolic dysfunction—but use with caution)

**Renal impairment** reduce dose and monitor plasma-digoxin concentration; toxicity increased by electrolyte disturbances

**Pregnancy** may need dosage adjustment

**Breast-feeding** amount too small to be harmful

**Side-effects** see notes above; also nausea, vomiting, diarrhoea; arrhythmias, conduction disturbances; dizziness; blurred or yellow vision; rash, eosinophilia; less commonly depression; very rarely anorexia, intestinal ischaemia and necrosis, psychosis, apathy, confusion, headache, fatigue, weakness, gynaecomastia on long-term use, and thrombocytopenia

**Dose**
- Rapid digitalisation, for atrial fibrillation or flutter, by mouth, 0.75–1.5 mg over 24 hours in divided doses
- Maintenance, for atrial fibrillation or flutter, by mouth, according to renal function and initial loading dose; usual range 125–250 micrograms daily
- Heart failure (for patients in sinus rhythm), by mouth, 62.5–125 micrograms once daily
- Emergency loading dose, for atrial fibrillation or flutter, by intravenous infusion (but rarely necessary), 0.75–1 mg over at least 2 hours (see also Cautions) then maintenance dose by mouth on the following day

**Note** The above doses may need to be reduced if digoxin (or another cardiac glycoside) has been given in the preceding 2 weeks. Digoxin doses in the BNF may differ from those in product literature. For plasma concentration monitoring, blood should ideally be taken at least 6 hours after a dose

### Digoxin

**Digoxin (Non-proprietary)**
- **Tablets**, digoxin 62.5 micrograms, net price 28-tab pack = £2.03; 125 micrograms, 28-tab pack = £1.12; 250 micrograms, 28-tab pack = £1.13
- **Injection**, digoxin 250 micrograms/mL, net price 2-mL amp = 70p
- **Paediatric injection**, digoxin 100 micrograms/mL
  - Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

**Lanoxin® (Aspen)**
- **Tablets**, digoxin 62.5 micrograms, net price 500-tab pack = £8.09; 250 micrograms (scored), 500-tab pack = £8.09
- **Injection**, digoxin 250 micrograms/mL, net price 2-mL amp = 66p

**Lanoxin-PG® (Aspen)**
- **Tablets**, blue, digoxin 62.5 micrograms, net price 500-tab pack = £8.09
- **Elixir**, yellow, digoxin 50 micrograms/mL. Do not dilute, measure with pipette. Net price 60 mL = £5.35. Counselling, use of pipette

### Digoxin-specific antibody

Digoxin-specific antibody fragments are indicated for the treatment of known or strongly suspected digoxin or other cardiac glycoside overdosage when measures beyond the withdrawal of the cardiac glycoside and correction of any electrolyte abnormalities are felt to be necessary (see also notes above).

**Digibind® (GSK)**
- **Injection**, powder for preparation of infusion, digoxin-specific antibody fragments (Fab) 36 mg, net price per vial = £93.97 (hosp. and poisons centres only)
- **Dose** consult product literature
2.1.2 Phosphodiesterase type-3 inhibitors

Enoximone and milrinone are phosphodiesterase type-3 inhibitors that exert most of their effect on the myocardium. Sustained haemodynamic benefit has been observed after administration, but there is no evidence of any beneficial effect on survival.

**Enoximone**

**Indications** congestive heart failure where cardiac output reduced and filling pressures increased

**Cautions** heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction; monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count, hepatic enzymes; avoid extravasation; **interactions:** Appendix 1 (phosphodiesterase type-3 inhibitors)

**Hepatic impairment** dose reduction may be required

**Renal impairment** consider dose reduction

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** ectopic beats; less frequently ventricular tachycardia, supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias); hypotension; also headache, insomnia, nausea and vomiting, diarrhea; occasionally, chills, oliguria, fever, urinary retention; upper and lower limb pain

**Dose**
- By slow intravenous injection (rate not exceeding 12.5 mg/minute), diluted before use, initially 0.5–1 mg/kg, then 500 micrograms/kg every 30 minutes until satisfactory response or total of 3 mg/kg given; maintenance, initial dose of up to 3 mg/kg may be repeated every 3–6 hours as required
- By intravenous infusion, initially 90 micrograms/kg/minute over 10–30 minutes, followed by continuous or intermittent infusion of 5–20 micrograms/kg/minute Total dose over 24 hours should not usually exceed 24 mg/kg

**Perfan** (INCA-Pharm) Injection, enoximone 5 mg/mL. For dilution before use. Net price 20-mL amp = £15.02

**Note** Plastic apparatus should be used; crystal formation if glass used

**Milrinone**

**Indications** short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction); acute heart failure, including low output states following heart surgery

**Cautions** see under Enoximone; also correct hypokalaemia; **interactions:** Appendix 1 (phosphodiesterase type-3 inhibitors)

**Renal impairment** reduce dose and monitor response if eGFR less than 50 mL/minute/1.73 m²—consult product literature for details

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** ectopic beats, ventricular tachycardia, supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias), hypotension; headache; less commonly ventricular fibrillation, chest pain, tremor, hypokalaemia, thrombocytopenia; very rarely bronchospasm, anaphylaxis, and rash

**Dose**
- By intravenous injection over 10 minutes, either undiluted or diluted before use, 50 micrograms/kg followed by intravenous infusion at a rate of 375–750 nanograms/kg/minute, usually for up to 12 hours following surgery or for 48–72 hours in congestive heart failure; max. daily dose 1.13 mg/kg

**Primacor** (Sanofi-Aventis) Injection, milrinone (as lactate) 1 mg/mL, net price 10-mL amp = £16.61

2.2 Diuretics

2.2.1 Thiazides and related diuretics

2.2.2 Loop diuretics

2.2.3 Potassium-sparing diuretics and aldosterone antagonists

2.2.4 Potassium-sparing diuretics with other diuretics

2.2.5 Osmotic diuretics

2.2.6 Mercurial diuretics

2.2.7 Carbonic anhydrase inhibitors

2.2.8 Diuretics with potassium

Thiazides (section 2.2.1) are used to relieve oedema due to chronic heart failure (section 2.5.5) and, in lower doses, to reduce blood pressure.

Loop diuretics (section 2.2.2) are used in pulmonary oedema due to left ventricular failure and in patients with chronic heart failure (section 2.5.5).

Combination diuretic therapy may be effective in patients with oedema resistant to treatment with one diuretic. Vigorous diuresis, particularly with loop diuretics, may induce acute hypotension; rapid reduction of plasma volume should be avoided.

Elderly Lower initial doses of diuretics should be used in the elderly because they are particularly susceptible to the side-effects. The dose should then be adjusted according to renal function. Diuretics should not be used continuously on a long-term basis to treat simple gravitational oedema (which will usually respond to increased movement, raising the legs, and support stockings).

**Potassium loss** Hypokalaemia can occur with both thiazide and loop diuretics. The risk of hypokalaemia depends on the duration of action as well as the potency and is thus greater with thiazides than with an equipotent dose of a loop diuretic.

Hypokalaemia is dangerous in severe cardiovascular disease and in patients also being treated with cardiac glycosides. Often the use of potassium-sparing diuretics (section 2.2.5) avoids the need to take potassium supplements.

In hepatic failure, hypokalaemia caused by diuretics can precipitate encephalopathy, particularly in alcoholic
Thiazides and related diuretics are moderately potent diuretics; they inhibit sodium reabsorption at the beginning of the distal convoluted tubule. They act within 1 to 2 hours of oral administration and most have a duration of action of 12 to 24 hours; they are usually administered early in the day so that the diuresis does not interfere with sleep.

In the management of hypertension a low dose of a thiazide, e.g. bendroflumethiazide 2.5 mg daily, produces a maximal or near-maximal blood pressure lowering effect, with very little biochemical disturbance. Higher doses cause more marked changes in plasma potassium, sodium, uric acid, glucose, and lipids, with little advantage in blood pressure control. For reference to the use of thiazides in chronic heart failure see section 2.5.5.

**Bendroflumethiazide** is widely used for mild or moderate heart failure and for hypertension—alone in the treatment of mild hypertension or with other drugs in more severe hypertension.

**Chlortalidone**, a thiazide-related compound, has a longer duration of action than the thiazides and may be given on alternate days to control oedema. It is also useful if acute retention is liable to be precipitated by a more rapid diuresis or if patients dislike the altered pattern of micturition caused by other diuretics.

Other thiazide diuretics (including benzthiazide, clopamide, cyclopenthiazide, hydrochlorothiazide, and hydroflumethiazide) do not offer any significant advantage over bendroflumethiazide or chlortalidone.

**Metolazone** is particularly effective when combined with a loop diuretic (even in renal failure); profound diuresis can occur and the patient should therefore be monitored carefully.

**Xipamide** and indapamide are chemically related to chlortalidone. Indapamide is claimed to lower blood pressure with less metabolic disturbance, particularly less aggravation of diabetes mellitus.

**Cautions** See also section 2.2. Thiazides and related diuretics can exacerbate diabetes, gout, and systemic lupus erythematosus. Electrolytes should be monitored, particularly with high doses, long-term use, or in renal impairment. Thiazides and related diuretics should also be used with caution in nephrotic syndrome, hyperaldosteronism, and malnourishment; *interactions*: Appendix 1 (diuretics)

**Contra-indications** Thiazides and related diuretics should be avoided in refractory hypokalaemia, hypernatraemia and hypercalcaemia, symptomatic hyperuricaemia, and Addison’s disease.

**Hepatic impairment** Thiazides and related diuretics should be used with caution in mild to moderate impairment and avoided in severe liver disease. Hypokalaemia may precipitate coma, although hypokalaemia can be prevented by using a potassium-sparing diuretic. There is an increased risk of hypermagnesaemia in alcoholic cirrhosis.

**Renal impairment** Thiazides and related diuretics are ineffective if eGFR is less than 30 mL/minute/1.73 m² and should be avoided; metolazone remains effective but with a risk of excessive diuresis.

**Pregnancy** Thiazides and related diuretics should not be used to treat gestational hypertension. They may cause neonatal thrombocytopenia, bone marrow suppression, jaundice, electrolyte disturbances, and hypoglycaemia; placental perfusion may also be reduced. Stimulation of labour, uterine inertia, and meconium staining have also been reported.

**Breast-feeding** The amount of bendroflumethiazide, chlortalidone, cyclopenthiazide, and metolazone present in milk is too small to be harmful; large doses may suppress lactation. For indapamide and xipamide see individual drugs.

**Side-effects** Side-effects of thiazides and related diuretics include mild gastro-intestinal disturbances, postural hypotension, altered plasma-lipid concentrations, metabolic and electrolyte disturbances including hypokalaemia (see also notes above), hyperonatraemia, hypomagnesaemia, hypercalcaemia, hyperglycaemia, hyperchloroemic alkalosis, hyperuricaemia, and gout. Less common side-effects include blood disorders such as agranulocytosis, leucopenia, and thrombocytopenia, and impotence. Pancreatitis, intrahepatic cholestasis, cardiac arrhythmias, headache, dizziness, paraesthesia, visual disturbances, and hypersensitivity reactions (including pneumonitis, pulmonary oedema, photosensitivity, and severe skin reactions) have also been reported.

**BENDROFLUMETHIAZIDE**

**Indications** oedema, hypertension (see also notes above)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**

- Oedema, initially 5–10 mg daily in the morning or on alternate days; maintenance 5–10 mg 1–3 times weekly
- Hypertension, 2.5 mg daily in the morning; higher doses rarely necessary (see notes above)

**Bendroflumethiazide** (Non-proprietary)

**Tablets**, bendroflumethiazide 2.5 mg, net price 28 = 79p; 5 mg, 28 = 86p

*Brands include Aprono®*
CHLORTALIDONE
(Chlorthalidone)
Indications ascites due to cirrhosis in stable patients (under close supervision), oedema due to nephrotic syndrome, hypertension (see also notes above), mild to moderate chronic heart failure; diabetes insipidus (see section 6.5.2)
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see notes above; also rarely jaundice and allergic interstitial nephritis
Dose
• Oedema, up to 50 mg daily
• Hypertension, 25 mg daily in the morning, increased to 50 mg daily if necessary (but see notes above)
• Heart failure, 25–50 mg daily in the morning, increased if necessary to 100–200 mg daily (reduce to lowest effective dose for maintenance)

Hygroton® (Alliance) Tablets, yellow, scored, chlortalidone 50 mg, net price 28-tab pack = £1.64

CYCLOPENTHIAZIDE
Indications oedema, hypertension (see also notes above); heart failure
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see notes above; also rarely depression
Dose
• Oedema, 5–10 mg daily in the morning, increased if necessary to 20 mg daily in resistant oedema, max. 80 mg daily
• Hypertension, initially 5 mg daily in the morning; maintenance 5 mg on alternate days

Navidrex® (Goldshield) Tablets, scored, cyclopenthiazide 500 micrograms, net price 28-tab pack = £1.27
Excipients include gluten
Note May be difficult to obtain

INDAPAMIDE
Indications essential hypertension
Cautions see notes above; also acute porphyria (section 9.8.2)
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding present in milk—manufacturer advises avoid

Side-effects see notes above; also palpitation, diuresis with doses above 2.5 mg daily
Dose
• 2.5 mg daily in the morning

Indapamide (Non-proprietary) Tablets, s/c, indapamide 2.5 mg, net price 28-tab pack = £1.27, 56-tab pack = £2.01

Nafrilix® (Servier) Tablets, f/c, indapamide 2.5 mg. Net price 30-tab pack = £3.40, 60-tab pack = £6.80

XIPAMIDE
Indications oedema, hypertension (see also notes above)
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding no information available
Side-effects see notes above
Dose
• Oedema, initially 40 mg daily in the morning, increased to 80 mg in resistant oedema, max. 20 mg daily in the morning
• Hypertension, 20 mg daily in the morning

Diurexan® (Meda) Tablets, scored, xipamide 20 mg, net price 140-tab pack = £19.46
2.2.2 Loop diuretics

Loop diuretics are used in pulmonary oedema due to left ventricular failure; intravenous administration produces relief of breathlessness and reduces pre-load sooner than would be expected from the time of onset of diuresis. Loop diuretics are also used in patients with chronic heart failure. Diuretic-resistant oedema (except lymphoedema and oedema due to peripheral venous stasis or calcium-channel blockers) can be treated with a loop diuretic combined with a thiazide or related diuretic (e.g. bendroflumethiazide 5–10 mg daily or metolazone 5–20 mg daily).

If necessary, a loop diuretic can be added to anti-hypertensive treatment to achieve better control of blood pressure in those with resistant hypertension, or in patients with impaired renal function or heart failure.

Loop diuretics inhibit reabsorption from the ascending limb of the loop of Henle in the renal tubule and are powerful diuretics. Furosemide and bumetanide are similar in activity; both act within 1 hour of oral administration and diuresis is complete within 6 hours so that, if necessary, they can be given twice in one day without interfering with sleep. Following intravenous administration they have a peak effect within 30 minutes. The diuresis associated with these drugs is dose related.

Torasemide has properties similar to those of furosemide and bumetanide, and is indicated for oedema and for hypertension.

Cautions Hypovolaemia and hypotension should be corrected before initiation of treatment with loop diuretics; electrolytes should be monitored during treatment (see also Potassium Loss, section 2.2). Loop diuretics can exacerbate diabetes (but hyperglycaemia is less likely than with thiazides) and goit. If there is an enlarged prostate, urinary retention can occur, although this is less likely if small doses and less potent diuretics are used initially; an adequate urinary output should be established before initiating treatment; interactions: Appendix 1 (diuretics).

Contra-indications Loop diuretics should be avoided in severe hypokalaemia, severe hyponatraemia, anuria, comatose and precomatose states associated with liver cirrhosis, and in renal failure due to nephrotic or hepatotoxic drugs.

Hepatic impairment Hypokalaemia induced by loop diuretics may precipitate hepatic encephalopathy and coma—potassium-sparing diuretics can be used to prevent this.

Renal impairment High doses of loop diuretics may occasionally be needed; high doses or rapid intravenous administration can cause tinnitus and deafness; high doses of bumetanide can also cause musculoskeletal pain.

Pregnancy Furosemide and bumetanide should not be used to treat gestational hypertension because of the maternal hypovolaemia associated with this condition.

Side-effects Side-effects of loop diuretics include mild gastrointestinal disturbances, pancreatitis, hepatic encephalopathy, postural hypotension, temporary increase in serum-cholesterol and triglyceride concentration, hyperglycaemia (less common than with thiazides), acute urinary retention, electrolyte disturbances (including hypokalaemia, hypokalaemia (see section 2.2), hypocalcaemia, hypochloraemia, and hypomagnesaemia), metabolic alkalosis, blood disorders (including bone-marrow depression, thrombocytopenia, and leucopenia), hyperuricaemia, visual disturbances, tinnitus and deafness (usually with high parenteral doses and rapid administration, and in renal impairment), and hypersensitivity reactions (including rash, photosensitivity, and pruritus).

Furosemide (frusemide)

Indications oedema (see notes above); resistant hypertension (see notes above)

Cautions see notes above; also hypoprotenaemia may reduce diuretic effect and increase risk of side-effects; hepatorenal syndrome; intravenous administration rate should not usually exceed 4 mg/minute, however single doses of up to 80 mg may be administered more rapidly

Contra-indications see notes above

Hepatic impairment see notes above

Renal impairment see notes above; also lower rate of infusion may be necessary

Pregnancy see notes above

Breast-feeding amount too small to be harmful; may inhibit lactation

Side-effects see notes above; also intrahepatic cholestasis and gout

Dose
- By mouth, oedema, initially 40 mg in the morning; maintenance 20–40 mg daily; Child under 18 years see BNF for Children
- Resistant oedema, 80–120 mg daily
- Resistant hypertension, 40–80 mg daily
- By intramuscular injection or slow intravenous injection (rate of administration, see Cautions above), initially 20–50 mg, increased if necessary in steps of 20 mg not less than every 2 hours; doses greater than 50 mg by intravenous infusion only; max. 1.5 g daily; Child under 18 years see BNF for Children

Furosemide (Non-proprietary)

Tablets, furosemide 20 mg, net price 28 = £1.85; 40 mg, 28 = £1.35; 80 mg, 28 = £2.60
Brands include Lyside®
Oral solution, sugar-free, furosemide, net price 20 mg/5 mL, 150 ml = £13.97; 40 mg/5 mL, 150 mL = £18.19; 50 mg/5 mL, 150 mL = £19.35
Brands include Prusol® (contains alcohol 10%)
Injection, furosemide 10 mg/mL, net price 2-mL amp = 30p, 5-mL amp = 38p, 25-mL amp = £2.50
Lasix® (Sanofi-Aventis)®
Injection, furosemide 10 mg/mL, net price 2-mL amp = 75p
Note Large-volume furosemide injections also available; brands include Minijet®

Bumetanide

Indications oedema (see notes above)

Cautions see notes above

Contra-indications see notes above
Potassium-sparing diuretics and aldosterone antagonists

2.2.3

Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding no information available; may inhibit lactation

Side-effects see notes above; also gynaecomastia, breast pain, musculoskeletal pain (associated with high doses in renal failure)

Dose
- By mouth, 1 mg in the morning, repeated after 6–8 hours if necessary; severe cases, 5 mg daily increased by 5 mg every 12–24 hours according to response; ELDERLY, 500 micrograms daily may be sufficient
- By intravenous injection, 1–2 mg, repeated after 20 minutes if necessary; ELDERLY, 500 micrograms daily may be sufficient
- By intravenous infusion, 2–5 mg over 30–60 minutes; ELDERLY, 500 micrograms daily may be sufficient
- By intramuscular injection, 1 mg initially then adjusted according to response; ELDERLY, 500 micrograms daily may be sufficient

Bumetanide (Non-proprietary)
Tablets, bumetanide 1 mg, net price 28-tab pack = £1.12; 5 mg, 28-tab pack = £4.33
Oral liquid, bumetanide 1 mg/5 mL, net price 150 mL = £128.00
Injection, bumetanide 500 micrograms/mL, net price 4-mL amp = £1.79

Burinex® (LEO)
Tablets, scored, bumetanide 1 mg, net price 28-tab pack = £1.52; 5 mg, 28 = £9.67

TORASEMIDE

Indications oedema (see notes above), hypertension
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy manufacturer advises avoid—no information available
Breast-feeding manufacturer advises avoid—no information available
Side-effects see notes above; also dry mouth; rarely limb paraesthesia

Dose
- Oedema, 5 mg once daily, preferably in the morning, increased if required to 20 mg once daily; usual max. 40 mg daily
- Hypertension, 2.5 mg daily, increased if necessary to 5 mg once daily

Torasemide (Non-proprietary)
Tablets, torasemide 2.5 mg, net price 28-tab pack = £3.78; 5 mg (scored), 28-tab pack = £5.53; 10 mg (scored), 28-tab pack = £8.14

AMILORITE HYDROCHLORIDE

Indications oedema; potassium conservation when used as an adjunct to thiazide or loop diuretics for hypertension, congestive heart failure, or hepatic cirrhosis with ascites
Cautions monitor electrolytes; diabetes mellitus; elderly; interactions: Appendix 1 (diuretics)
Contra-indications hyperkalaemia; anuria; Addison’s disease
Renal impairment monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment); manufacturers advise avoid in severe impairment
Pregnancy not used to treat gestational hypertension
Breast-feeding manufacturer advises avoid—no information available
Side-effects include gastro-intestinal disturbances, dry mouth, rashes, confusion, postural hypotension, hyperkalaemia, hyponatraemia

Dose
- Used alone, initially 10 mg daily or 5 mg twice daily, adjusted according to response; max. 20 mg daily
- With other diuretics, congestive heart failure and hypertension, initially 5–10 mg daily; cirrhosis with ascites, initially 5 mg daily

Amiloride (Non-proprietary)
Tablets, amiloride hydrochloride 5 mg, net price 28-tab pack = 96p
Oral solution, sugar-free, amiloride hydrochloride 5 mg/5 mL, net price 150 mL = £39.73
Brands include Amilamont® (Excipients include propylene glycol, see Excipients, p. 2)

Compound preparations with thiazide or loop diuretics
Section 2.2.4

TRIAMTERENE

Indications oedema, potassium conservation with thiazide and loop diuretics
Cautions see under Amilroide Hydrochloride; may cause blue fluorescence of urine
Contra-indications see under Amilroide Hydrochloride
Renal impairment monitor plasma-potassium concentration (high risk of hyperkalaemia in renal
Potassium-sparing diuretics and aldosterone antagonists

**Aldosterone antagonists**

Spironolactone potentiates thiazide or loop diuretics by antagonising aldosterone; it is a potassium-sparing diuretic. Spironolactone is of value in the treatment of oedema and ascites caused by cirrhosis of the liver; furosemide (section 2.2.2) can be used as an adjunct. Low doses of spironolactone are beneficial in moderate to severe heart failure, see section 2.5.5.

Spironolactone is also used in primary hyperaldosteronism (Conn’s syndrome). It is given before surgery to enable a better perioperative course. Spironolactone is of value in the treatment of oedema and ascites caused by cirrhosis of the liver; furosemide (section 2.2.2) can be used as an adjunct. Low doses of spironolactone are beneficial in moderate to severe heart failure, see section 2.5.5.

Potassium supplements must not be given with aldosterone antagonists.

**EPLERENONE**

**Indications**

adjunct in stable patients with left ventricular dysfunction with evidence of heart failure, following myocardial infarction (start therapy within 3–14 days of event)

**Cautions**

measure plasma-potassium concentration before treatment, during initiation, and when dose changed; elderly; interactions: Appendix 1 (diuretics)

**Contra-indications**

hyperkalaemia; concomitant use of potassium-sparing diuretics or potassium supplements

**Hepatic impairment**

avoid in severe liver disease

**Renal impairment**

increased risk of hyperkalaemia—close monitoring required; avoid if eGFR less than 50 mL/minute/1.73 m²

**Pregnancy**

manufacturer advises caution—no information available

**Breast-feeding**

manufacturer advises use only if potential benefit outweighs risk

**Side-effects**

diarrhoea, nausea, hypotension; dizziness; hyperkalaemia; rash; less commonly: Fatigue, vomiting, atrial fibrillation, postural hypotension, arterial thrombosis, dyslipidaemia, pharyngitis, headache, insomnia, gynaecomastia, pyelonephritis, hyponatraemia, dehydration, eosinophilia, asthenia, malaise, back pain, leg cramps, impaired renal function, azotaemia, sweating and pruritus

**Dose**

● Initially 25 mg once daily, increased within 4 weeks to 50 mg once daily; CHILD not recommended

**Inspir®** (Pfizer) (BNM)

Tablets, yellow, f/c, eplerenone 25 mg, net price 28-tab pack = £42.72; 50 mg, 28-tab pack = £42.72

**SPIRONOLACTONE**

**Indications**

oedema and ascites in cirrhosis of the liver; malignant ascites, nephrotic syndrome, congestive heart failure (section 2.5.5); primary hyperaldosteronism

**Cautions**

potential metabolic products carcinogenic in rodents; elderly; monitor electrolytes (discontinue if hyperkalaemia); acute porphyria (section 9.8.2); interactions: Appendix 1 (diuretics)

**Contra-indications**

hyperkalaemia, hyponatraemia; anuria; Addison’s disease

**Renal impairment**

monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment); avoid if rapidly deteriorating or severe impairment

**Pregnancy**

feminisation of male fetus in animal studies

**Breast-feeding**

metabolites present in milk, but amount probably too small to be harmful

**Side-effects**

gastro-intestinal disturbances, hepatotoxicity; malaise, headache, confusion, drowsiness, dizziness; gynaecomastia, benign breast tumour, breast pain, menstrual disturbances, changes in libido, breast pain, menstrual disturbances, changes in libido; hypertrichosis, hyperkalaemia (discontinue), hyponatraemia, acute renal failure, hyperuricaemia, leucopenia, agranulocytosis, thrombocytopenia; leg cramps; alopecia, hirsutism, rash, and Stevens-Johnson syndrome

**Dose**

● 100–200 mg daily, increased to 400 mg if required; CHILD under 18 years, see BNF for Children

**Heart failure, see section 2.5.5**

**Spironolactone**

(Non-proprietary) (BNM)

**Tablets**, spironolactone 25 mg, net price 28 = £1.50; 50 mg, 28 = £2.11; 100 mg, 28 = £2.46. Label: 21

**Oral suspensions**, spironolactone 5 mg/5 mL, 10 mg/5 mL, 25 mg/5 mL, 50 mg/5 mL, and 100 mg/5 mL. Label: 21

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

**Aldactone®** (Pharmacia) (BNM)

**Tablets**, f/c, spironolactone 25 mg (buff), net price 100-tab pack = £8.89; 50 mg (white), 100-tab pack = £17.78; 100 mg (buff), 28-tab pack = £9.96. Label: 21

**With thiazides or loop diuretics**

Section 2.2.4
Potassium-sparing diuretics with other diuretics

Although it is preferable to prescribe thiazides (section 2.2.1) and potassium-sparing diuretics (section 2.2.3) separately, the use of fixed combinations may be justified if compliance is a problem. Potassium-sparing diuretics are not usually necessary in the routine treatment of hypertension, unless hypokalaemia develops. For interactions, see Appendix 1 (diuretics).

Amiloride with thiazides

Co-amilozide (Non-proprietary)
Tablets, co-amilozide 2.5/25 (amiloride hydrochloride 2.5 mg, hydrochlorothiazide 25 mg), net price 28-tab pack = £3.73
Brands include Moduret 25®
Dose hypertension, initially 1 tablet daily, increased if necessary to max. 2 tablets daily
Congestive heart failure, initially 1 tablet daily, increased if necessary to max. 4 tablets daily
Oedema and ascites in cirrhosis of the liver, initially 2 tablets daily, increased if necessary to max. 4 tablets daily
Oedema and ascites in cirrhosis of the liver, initially ½ tablet daily, increased if necessary to max. 2 tablets daily

Amiloride with loop diuretics

Co-amilofruse (Non-proprietary)
Tablets, co-amilofruse 2.5/25 (amiloride hydrochloride 2.5 mg, hydrochlorothiazide 25 mg), net price 28-tab pack = £3.73
Brands include Moduret 25®
Dose hypertension, initially 1 tablet daily, increased if necessary to max. 2 tablets daily
Congestive heart failure, initially 1 tablet daily, increased if necessary to max. 4 tablets daily
Oedema and ascites in cirrhosis of the liver, initially 2 tablets daily, increased if necessary to max. 4 tablets daily
Oedema and ascites in cirrhosis of the liver, initially ½ tablet daily, increased if necessary to max. 2 tablets daily

Amiloride with bumetanide

Co-amilofruse (Non-proprietary)
Tablets, co-amilofruse 10/20 (amiloride hydrochloride 10 mg, furosemide 20 mg), net price 28-tab pack = £1.18, 56-tab pack = £1.83
Brands include Frumil LS®
Dose oedema, 1 tablet in the morning
Tablets, co-amilofruse 5/40 (amiloride hydrochloride 5 mg, furosemide 40 mg), net price 28-tab pack = £1.17, 56-tab pack = £1.42
Brands include Frumil®
Dose oedema, 1–2 tablets in the morning
Tablets, co-amilofruse 10/80 (amiloride hydrochloride 10 mg, furosemide 80 mg), net price 28-tab pack = £11.51
Dose oedema, 1 tablet in the morning

Spironolactone with thiazides

Triamterene with thiazides
Counselling Urine may look slightly blue in some lights

Spironolactone with loop diuretics

Triamterene with loop diuretics
Counselling Urine may look slightly blue in some lights

Osmotic diuretics

Mannitol is an osmotic diuretic that can be used to treat cerebral oedema and raised intra-ocular pressure.
2.2.6 Mercurial diuretics

MANNITOL

Indications  see notes above; glaucoma (section 11.6)
Cautions  extravasation causes inflammation and thrombophlebitis; monitor fluid and electrolyte balance, serum osmolality, and pulmonary and renal function; assess cardiac function before and during treatment; interactions: Appendix 1 (mannitol)
Contra-indications  severe cardiac failure; severe pulmonary oedema; intracranial bleeding (except during craniotomy); anuria; severe dehydration
Renal impairment  use with caution in severe impairment
Pregnancy  manufacturer advises avoid unless essential—no information available
Breast-feeding  manufacturer advises avoid unless essential—no information available
Side-effects  less commonly hypotension, thrombophlebitis, fluid and electrolyte imbalance; rarely dry mouth, thirst, nausea, vomiting, oedema, raised intracranial pressure, arrhythmia, hypertension, pulmonary oedema, chest pain, headache, convulsions, dizziness, chills, fever, urinary retention, focal osmotic nephrosis, dehydration, cramp, blurred vision, rhinitis, skin necrosis, and hypersensitivity reactions (including urticaria and anaphylaxis); very rarely congestive heart failure and acute renal failure

Dose  • Cerebral oedema and raised intraocular pressure, by intravenous infusion over 30–60 minutes, 0.25–2 g/kg repeated if necessary 1–2 times after 4–8 hours
Note  For mannitol 20%, an in-line filter is recommended (15-micron filters have been used)

Mannitol (Baxter)  
Intravenous infusion, mannitol 10%, net price 500-mL Viaflex® bag = £2.26, 500-mL Viaflora® bag = £2.15; 20%, net price 250-mL Viaflex® bag = £3.27, 250-mL Viaflora® bag = £3.27, 500-mL Viaflex® bag = £3.29, 500-mL Viaflora® bag = £3.12

2.2.6 Mercurial diuretics

Mercurial diuretics are effective but are now almost never used because of their nephrotoxicity.

2.2.7 Carbonic anhydrase inhibitors

The carbonic anhydrase inhibitor acetazolamide is a weak diuretic and is little used for its diuretic effect. It is used for prophylaxis against mountain sickness [unlicensed indication] but is not a substitute for acclimatisation.

Acetazolamide and eye drops of dorzolamide and brinzolamide inhibit the formation of aqueous humour and are used in glaucoma (section 11.6).

2.2.8 Diuretics with potassium

Many patients on diuretics do not need potassium supplements (section 9.2.1.1). For many of those who do, the amount of potassium in combined preparations may not be enough, and for this reason their use is to be discouraged.

Diuretics with potassium and potassium-sparing diuretics should not usually be given together.

Counselling  Modified-release potassium tablets should be swallowed whole with plenty of fluid during meals while sitting or standing

Diurete K Continus® (Teofarma)  Tablets, white/orange, f/c, furosemide 40 mg, potassium 8 mmol for modified release, net price 30-tab pack = £3.00. Label: 25, 27, counselling, see above

Neo-NeClex-K® (Goldshield)  Tablets, pink/white, f/c, bendrofluamide 2.5 mg, potassium 8.4 mmol for modified release, net price 100 tab-pack = £8.99. Label: 25, 27, counselling, see above

2.3 Anti-arrhythmic drugs

2.3.1 Management of arrhythmias

Management of an arrhythmia requires precise diagnosis of the type of arrhythmia, and electrocardiography is essential; underlying causes such as heart failure require appropriate treatment.

Ectopic beats  If ectopic beats are spontaneous and the patient has a normal heart, treatment is rarely required and reassurance to the patient will often suffice. If they are particularly troublesome, beta-blockers are sometimes effective and may be safer than other suppressant drugs.

Atrial fibrillation  All patients with atrial fibrillation should be assessed for their risk of stroke and thromboembolism, and thromboprophylaxis given if necessary (see below). Atrial fibrillation can be managed by either controlling the ventricular rate or by attempting to restore and maintain sinus rhythm.

All haemodynamically unstable patients with acute-onset atrial fibrillation should undergo electrical cardioversion. Intravenous amiodarone, or alternatively flecainide, can be used in non-life-threatening cases when electrical cardioversion is delayed. If urgent ventricular rate control is required, a beta-blocker, verapamil, or amiodarone can be given intravenously.

In haemodynamically stable patients, a rhythm-control treatment strategy is preferred for patients with paroxysmal atrial fibrillation; rate-control is preferred for those with permanent atrial fibrillation. For patients with persistent atrial fibrillation, the treatment strategy should be based on criteria such as age, co-morbidities, presence of symptoms, and the relative advantages and disadvantages of each treatment.

Ventricular rate can be controlled with a beta-blocker (section 2.4), or diltiazem [unlicensed indication], or verapamil. Digoxin is usually only effective for controlling the ventricular rate at rest, and should therefore
Like atrial fibrillation, treatment options depend on whether there are risk factors for stroke, or if warfarin is contraindicated at preventing emboli, but may be appropriate if the patient with atrial fibrillation is a candidate for cardioversion procedures (see section 2.8.1). Aspirin (section 2.9) is less effective than warfarin for stroke prevention in patients with atrial fibrillation. Anticoagulants are indicated during cardioversion procedures (see section 2.8.1). In selected patients with infrequent episodes of symptomatic paroxysmal atrial fibrillation, sinus rhythm can be restored by electrical cardioversion (see section 2.8.2) for at least 3 weeks; if this is not possible, parenteral anticoagulation (section 2.8.1) should be commenced and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks. For atrial fibrillation of over 48 hours duration, electrical cardioversion is preferred to pharmacological cardioversion. If treatment is required to maintain sinus rhythm, a beta-blocker is used. If a standard beta-blocker is not appropriate or is ineffective, an oral anti-arrhythmic drug such as sotalol (section 2.4), flecainide, propafenone, or amiodarone, is required.

In symptomatic paroxysmal atrial fibrillation, ventricular rhythm is controlled with a beta-blocker. Alternatively, if symptoms persist or a beta-blocker is not appropriate, an oral anti-arrhythmic drug such as sotalol, flecainide, propafenone, or amiodarone can be given (see also Paroxysmal Supraventricular Tachycardia below, and Supraventricular Arrhythmias). In selected patients with infrequent episodes of symptomatic paroxysmal atrial fibrillation, sinus rhythm can be restored using the 'pill-in-the-pocket' approach; this involves the patient taking oral flecainide or propafenone to self-treat an episode of atrial fibrillation when it occurs. All patients with atrial fibrillation should be assessed for their risk of stroke and the need for thromboprophylaxis. Anticoagulants (section 2.8) are indicated for those with cardiovascular disease, diabetes, hypertension, or impaired left ventricular function; anticoagulants should be considered for those with atrial fibrillation and who are at high risk of stroke. Warfarin (section 2.6.2) or intravenous anti-arrhythmic drug such as sotalol, flecainide, propafenone, or amiodarone, is preferred if symptoms persist or a beta-blocker is not effective, and may be particularly useful in those with heart failure. Conversion to sinus rhythm can be achieved by electrical cardioversion (by cardiac pacing or direct current), pharmacological cardioversion, or catheter ablation. If the duration of atrial flutter is unknown, or it has lasted for over 48 hours, cardioversion should not be attempted until the patient has been fully anticoagulated (see section 2.8.2) for at least 3 weeks; if this is not possible, parenteral anticoagulation (section 2.8.1) should be commenced and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks. Direct current cardioversion is usually the treatment of choice when rapid conversion to sinus rhythm is necessary (e.g. when atrial flutter is associated with haemodynamic compromise); catheter ablation is preferred for the treatment of recurrent atrial flutter. There is a limited role for anti-arrhythmic drugs as their use is not always successful. Flecainide or propafenone can slow atrial flutter, resulting in 1:1 conduction to the ventricles, and should therefore be prescribed in conjunction with a ventricular rate controlling drug such as a beta-blocker, diltiazem [unlicensed indication], or verapamil. Amiodarone can be used when other drug treatments are contra-indicated or ineffective. All patients should be assessed for their risk of stroke and the need for thromboprophylaxis; the choice of anticoagulant is based on the same criteria as for atrial fibrillation (see notes above).

**Paroxysmal supraventricular tachycardia** This will often terminate spontaneously or with reflex vagal stimulation such as a Valsalva manoeuvre, immersing the face in ice-cold water, or carotid sinus massage; such manoeuvres should be performed with ECG monitoring. If the effects of reflex vagal stimulation are transient or ineffective, or if the arrhythmia is causing severe symptoms, intravenous adenosine (section 2.3.2) should be given. If adenosine is ineffective or contra-indicated, intravenous verapamil (section 2.6.2) is an alternative, but it should be avoided in patients recently treated with beta-blockers (see p. 133).

Failure to terminate paroxysmal supraventricular tachycardia with reflex vagal stimulation or drug treatment may suggest an arrhythmia of atrial origin, such as focal atrial tachycardia or atrial flutter.

Treatment with direct current cardioversion is needed in haemodynamically unstable patients or when the above measures have failed to restore sinus rhythm (and an alternative diagnosis has not been found). Recurrent episodes of paroxysmal supraventricular tachycardia can be treated by catheter ablation, or prevented with drugs such as diltiazem, verapamil, beta-blockers including sotalol (section 2.4), flecainide, or propafenone (section 2.3.2).

**Arrhythmias after myocardial infarction** In patients with a paroxysmal tachycardia or rapid irregularity of the pulse it is best not to administer an anti-arrhythmic until an ECG record has been obtained. Bradycardia, particularly if complicated by hypotension,
2.3.2 Drugs for arrhythmias

Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity (the Vaughan Williams classification) although this classification is of less clinical significance:

- **Class I**: membrane stabilising drugs (e.g. lidocaine, flecaïnine)
- **Class II**: beta-blockers
- **Class III**: amiodarone; sotalol (also Class II)
- **Class IV**: calcium-channel blockers (includes verapamil but not dihydropyridines)

**Cautions** The negative inotropic effects of anti-arrhythmic drugs tend to be additive. Therefore special care should be taken if two or more are used, especially if myocardial function is impaired. Most drugs that are effective in countering arrhythmias can also provoke them in some circumstances; moreover, hypokalaemia enhances the arrhythmogenic (pro-arrhythmic) effect of many drugs.

---

**Supraventricular arrhythmias**

**Adenosine** is usually the treatment of choice for terminating paroxysmal supraventricular tachycardia. As it has a very short duration of action (half-life only about 8 to 10 seconds, but prolonged in those taking dipyridamole), most side-effects are short lived. Unlike verapamil, adenosine can be used after a beta-blocker. Verapamil may be preferable to adenosine in asthma.

**Dronedarone** is a multi-channel blocking anti-arrhythmic drug; it is licensed for use in clinically stable patients with previous or current non-permanent atrial fibrillation, to prevent recurrence or to lower the ventricular rate.

The **Scottish Medicines Consortium (p. 4)** has advised (August 2010) that dronedarone (Multaq<sup>®</sup>) is accepted for restricted use within NHS Scotland for the prevention of recurrence of atrial fibrillation in patients in whom conventional first-line anti-arrhythmic drugs are ineffective, contra-indicated, or not tolerated; treatment should be initiated on specialist advice only.

---

**Dronedarone for the treatment of non-permanent atrial fibrillation (August 2010)**

Dronedarone is an option for the treatment of non-permanent atrial fibrillation only in patients who:

- are not controlled on first-line therapy (usually including beta-blockers), and
- do not have unstable New York Heart Association class III or IV heart failure, and
- have at least one cardiovascular risk factor from the following:
  - hypertension managed by at least two different drug classes
  - diabetes mellitus
  - previous transient ischaemic attack, stroke, or systemic embolism
  - left atrial diameter ≥50 mm
  - left ventricular ejection fraction <40%
  - age ≥70 years

---

**NICE guidance**

**Dronedarone for the treatment of non-permanent atrial fibrillation (August 2010)**

Dronedarone is an option for the treatment of non-permanent atrial fibrillation only in patients who:

- are not controlled on first-line therapy (usually including beta-blockers), and
- do not have unstable New York Heart Association class III or IV heart failure, and
- have at least one cardiovascular risk factor from the following:
  - hypertension managed by at least two different drug classes
  - diabetes mellitus
  - previous transient ischaemic attack, stroke, or systemic embolism
  - left atrial diameter ≥50 mm
  - left ventricular ejection fraction <40%
  - age ≥70 years

---

2.3.2 Drugs for arrhythmias

Anti-arrhythmic drugs can be classified clinically into those that act on supraventricular arrhythmias (e.g. verapamil), those that act on both supraventricular and ventricular arrhythmias (e.g. amiodarone), and those that act on ventricular arrhythmias (e.g. lidocaine).

---

2 Cardiovascular system

Ventricular tachycardia

Pulseless ventricular tachycardia or ventricular fibrillation should be treated with immediate defibrillation (see Cardiopulmonary Resuscitation, section 2.7.3).

Patients with unstable sustained ventricular tachycardia, who continue to deteriorate with signs of hypotension or reduced cardiac output, should receive direct current cardioversion to restore sinus rhythm. If this fails, intravenous amiodarone (section 2.3.2) should be administered and direct current cardioversion repeated.

Patients with sustained ventricular tachycardia who are haemodynamically stable can be treated with intravenous anti-arrhythmic drugs. Amiodarone is the preferred drug. Flecaïnine, propafenone (section 2.3.2), and, although less effective, lidocaine (section 2.3.2) have all been used. If sinus rhythm is not restored, direct current cardioversion or pacing should be considered.

Catheter ablation is an alternative if cessation of the arrhythmia is not urgent. Non-sustained ventricular tachycardia can be treated with a beta-blocker (section 2.4).

All patients presenting with ventricular tachycardia should be referred to a specialist. Following restoration of sinus rhythm, patients who remain at high risk of cardiac arrest will require maintenance therapy. Most patients will be treated with an implantable cardioverter defibrillator. Beta-blockers or sotalol (in place of a standard beta-blocker), or amiodarone (in combination with a standard beta-blocker), can be used in addition to the device in some patients; alternatively, they can be used alone when use of an implantable cardioverter defibrillator is not appropriate.

**Torsade de pointes** is a form of ventricular tachycardia associated with a long QT syndrome (usually drug-induced, but other factors including hypokalaemia, severe bradycardia, and genetic predisposition are also implicated). Episodes are usually self-limiting, but are frequently recurrent and can cause impairment or loss of consciousness. If not controlled, the arrhythmia can progress to ventricular fibrillation and sometimes death. Intravenous infusion of magnesium sulphate (section 9.5.1.3) is usually effective. A beta-blocker (but not sotalol) and atrial (or ventricular) pacing can be considered. Anti-arrhythmics can further prolong the QT interval, thus worsening the condition.
Oral administration of a cardiac glycoside (such as digoxin, section 2.1.1) slows the ventricular response in cases of atrial fibrillation and atrial flutter. However, intravenous infusion of digoxin is rarely effective for rapid control of ventricular rate. Cardiac glycosides are contra-indicated in supraventricular arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome).

Verapamil (section 2.6.2) is usually effective for supraventricular tachycardias. An initial intravenous dose (important: serious beta-blocker interaction hazard, see p. 133) may be followed by oral treatment; hypotension may occur with large doses. It should not be used for tachyarrhythmias where the QRS complex is wide (i.e. broad complex) unless a supraventricular origin has been established beyond reasonable doubt. It is also contra-indicated in atrial fibrillation or atrial flutter associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome). It should not be used in children with arrhythmias without specialist advice; some supraventricular arrhythmias in childhood can be accelerated by verapamil with dangerous consequences.

Intravenous administration of a beta-blocker (section 2.4) such as esmolol or propranolol, can achieve rapid control of the ventricular rate.

Drugs for both supraventricular and ventricular arrhythmias include amiodarone, beta-blockers (see p. 98), disopyramide, flecainide, procainamide (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988), and propafenone, see below under Supraventricular and Ventricular Arrhythmias.

### ADENOSINE

**Indications** rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome); aid to diagnosis of broad or narrow complex supraventricular tachycardias

**Cautions** monitor ECG and have resuscitation facilities available; atrial fibrillation or flutter with accessory pathway (conduction down anomalous pathway may increase); first-degree AV block; bundle branch block; left main coronary artery stenosis; uncorrected hypovolaemia; stenotic valvular heart disease; left to right shunt; pericarditis; pericardial effusion; autonomic dysfunction; stenotic carotid artery disease with cerebrovascular insufficiency; recent myocardial infarction; heart failure; heart transplant (see below);

**Contra-indications** second- or third-degree AV block and sick sinus syndrome (unless pacemaker fitted); bradycardia; prolonged QT interval; haemodynamically unstable patients (including those with moderate or severe heart failure).

**Hepatic impairment** avoid in severe impairment

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid—毒性 in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** gastro-intestinal disturbances; QT-interval prolongation, bradycardia; fatigue, asthenia; rash, pruritus; raised serum creatinine; less commonly taste disturbance; erythema, eczema, dermatitis, photosensitivity

**Dose**

- **By mouth**, 400 mg twice daily

**Multaq** (Sanofi-Aventis) ▼

| Tablets, f/c, dronedarone (as hydrochloride) 400 mg, net price 20-tab pack = £22.50, 60-tab pack = £87.50. | Label: 21 |

### DRONEDARONE

**Indications** see notes above

**Cautions** heart failure (avoid in patients with a recent history of moderate heart failure, or with a significantly reduced left ventricular function); correct hypokalaemia and hypomagnesaemia before starting and during treatment; measure serum creatinine 7 days after initiation; **interactions:** Appendix 1 (dronedarone)

**Contra-indications** second- or third-degree AV block and sick sinus syndrome (unless pacemaker fitted); bradycardia; prolonged QT interval; haemodynamically unstable patients (including those with moderate or severe heart failure).

**Hepatic impairment** avoid in severe impairment

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid—毒性 in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** gastro-intestinal disturbances; QT-interval prolongation, bradycardia; fatigue, asthenia; rash, pruritus; raised serum creatinine; less commonly taste disturbance; erythema, eczema, dermatitis, photosensitivity

**Dose**

- **By mouth**, 400 mg twice daily

**Multaq** (Sanofi-Aventis) ▼

| Tablets, f/c, dronedarone (as hydrochloride) 400 mg, net price 20-tab pack = £22.50, 60-tab pack = £87.50. | Label: 21 |

### Supraventricular and ventricular arrhythmias

Amiodarone is used in the treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated. It can be used for paroxysmal supraventricu-
larr, nodal and ventricular tachycardias, atrial fibrillation and flutter, and ventricular fibrillation. It can also be used for tachyarrhythmias associated with Wolf-Parkinson-White syndrome. It should be initiated only under hospital or specialist supervision. Amiodarone may be given by intravenous infusion as well as by mouth, and has the advantage of causing little or no myocardial depression. Unlike oral amiodarone, intravenous amiodarone acts relatively rapidly.

Intravenous injection of amiodarone can be used in cardiopulmonary resuscitation for ventricular fibrillation or pulseless tachycardia unresponsive to other interventions (section 2.7.3).

Amiodarone has a very long half-life (extending to several weeks) and only needs to be given once daily (but high doses can cause nausea unless divided). Many weeks or months may be required to achieve steady-state plasma-amiodarone concentration; this is particularly important when drug interactions are likely (see also Appendix 1).

Most patients taking amiodarone develop corneal microdeposits (reversible on withdrawal of treatment); these rarely interfere with vision, but drivers may be dazzled by headlights at night. However, if vision is impaired or if optic neuritis or optic neuropathy occur, amiodarone must be stopped to prevent blindness and expert advice sought. Because of the possibility of phototoxic reactions, patients should be advised to shield the skin from light during treatment and for several months after discontinuing amiodarone; a wide-spectrum sunscreen (section 13.8.1) to protect against both long-wave ultraviolet and visible light should be used.

Amiodarone contains iodine and can cause disorders of thyroid function; both hypothyroidism and hyperthyroidism may occur. Clinical assessment alone is unreliable, and laboratory tests should be performed before treatment and every 6 months. Thyroxine (T4) may be raised in the absence of hyperthyroidism; therefore tri-iodothyronine (T3), T4, and thyroid-stimulating hormone (thyrotrophin, TSH) should all be measured. A raised T3 and T4 with a very low or undetectable TSH concentration suggests the development of thyrotoxicosis. The thyrotoxicosis may be very refractory, and amiodarone should usually be withdrawn at least temporarily to help achieve control; treatment with carbimazole may be required. Hyperthyroidism can be treated with replacement therapy without withdrawing amiodarone if it is essential; careful supervision is required.

Pneumonitis should always be suspected if new or progressive shortness of breath or cough develops in a patient taking amiodarone. Fresh neurological symptoms should raise the possibility of peripheral neuropathy.

Amiodarone is also associated with hepatotoxicity and treatment should be discontinued if severe liver function abnormalities or clinical signs of liver disease develop.

Beta-blockers act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on cardiac contractility. Oral administration of disopyramide is useful, but it has an antimuscarnic effect which limits its use in patients susceptible to angle-closure glaucoma or with prostatic hyperplasia.

Flecainide belongs to the same general class as lidocaine and may be of value for serious symptomatic ventricular arrhythmias. It may also be indicated for functional re-entry tachycardias and for paroxysmal atrial fibrillation. However, it can precipitate serious arrhythmias in a small minority of patients (including those with otherwise normal hearts).

Propafenone is used for the prophylaxis and treatment of ventricular arrhythmias and also for some supraventricular arrhythmias. It has complex mechanisms of action, including weak beta-blocking activity (therefore caution is needed in obstructive airways disease—contra-indicated if severe).

Drugs for supraventricular arrhythmias include adenosine, cardiac glycosides, and verapamil; see above under Supraventricular Arrhythmias. Drugs for ventricular arrhythmias include lidocaine; see under Ventricular Arrhythmias, p. 96.

Mexiletine and procainamide are both available from ‘special-order’ manufacturers or specialist importing companies, see p. 98. Mexiletine can be used for life-threatening ventricular arrhythmias; procainamide is given by intravenous injection to control ventricular arrhythmias.

### AMIODARONE HYDROCHLORIDE

**Indications** see notes above (should be initiated in hospital or under specialist supervision)

**Cautions** liver-function and thyroid-function tests required before treatment and then every 6 months (see notes above for tests of thyroid function); hypokalaemia (measure serum-potassium concentration before treatment); chest x-ray required before treatment; heart failure; elderly; severe bradycardia and conduction disturbances in excessive dosage; intravenous use may cause moderate and transient fall in blood pressure (circulatory collapse precipitated by rapid administration or overdosage) or severe hepatocellular toxicity (monitor transaminases closely); administration by central venous catheter recommended if repeated or continuous infusion required—infusion via peripheral veins may cause pain and inflammation; ECG monitoring and resuscitation facilities must be available during intravenous use; acute porphyria (section 9.8.2), interactions: Appendix 1 (amiodarone)

**Contra-indications** (except in cardiac arrest) sinus bradycardia, sino-atrial heart block; unless pacemaker fitted avoid in severe conduction disturbances or sinus node disease; thyroid dysfunction; iodine sensitivity; avoid intravenous use in severe respiratory failure, circulatory collapse, or severe arterial hypertension; avoid bolus injection in congestive heart failure or cardiomyopathy

**Pregnancy** possible risk of neonatal goitre; use only if no alternative

**Breast-feeding** avoid; present in milk in significant amounts; theoretical risk of neonatal hypothyroidism from release of iodine

**Side-effects** nausea, vomiting, taste disturbances, raised serum transaminases (may require dose reduction or withdrawal if accompanied by acute liver disorders), jaundice; bradycardia (see Cautions):
2.3.2 Drugs for arrhythmias

BNF 61

Flecainide Acetate

Indications
- Ventricular arrhythmias, especially after myocardial infarction, supraventricular arrhythmias

Cautions
- Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur); atrial flutter or atrial tachycardia with partial block, bundle branch block, heart failure (avoid if severe); prostatic enlargement; susceptibility to angle-closure glaucoma; avoid in acute porphyria (section 9.8.2);

Contra-indications
- Second- and third-degree heart block and sinus node dysfunction (unless pacemaker fitted); cardiogenic shock; severe uncompensated heart failure

Hepatic impairment
- Half-life prolonged—may need dose reduction

Renal impairment
- Reduce dose by increasing dose interval; adjust according to response; avoid sustained-release preparation

Pregnancy
- May induce labour if used in third trimester

Breast-feeding
- Present in milk—use only if essential and monitor infant for antimuscarinic effects

Side-effects
- Ventricular tachycardia, ventricular fibrillation or torsade de pointes (usually associated with prolongation of QRS complex or QT interval—see Cautions above), myoccardial depression, hypotension, AV block; antimuscarinic effects include dry mouth, blurred vision, urinary retention, and very rarely angle-closure glaucoma; gastro-intestinal irritation; psychosis, cholestatic jaundice, hypoglycaemia also reported (see Cautions above)

Dose
- By mouth, 300–800 mg daily in divided doses
- By slow intravenous injection, 2 mg/kg over at least 5 minutes to a max. of 150 mg, with ECG monitoring, followed immediately either by 200 mg by mouth, then 200 mg every 8 hours for 24 hours or 400 micrograms/kg/hour by intravenous infusion; max. 300 mg in first hour and 800 mg daily

Disopyramide (Non-proprietary)
- Capsules, disopyramide (as phosphate) 100 mg, net price 84 = £24.38; 150 mg, 84 = £32.57

Rythmodan® (Sanofi-Aventis)
- Capsules, disopyramide 100 mg (green/beige), net price 84-cap pack = £14.14; 150 mg, 84-cap pack = £18.76

Injection, disopyramide (as phosphate) 10 mg/mL, net price 5-ml amp = £2.61

Modified release
- Rythmodan Retard® (Sanofi-Aventis)
- Tablets, m/r, scored, f/c, disopyramide (as phosphate) 250 mg, net price 60-cap pack = £27.72.

Label: 25
Dose
- 250-375 mg every 12 hours

Flecainide Acetate

Indications
- Capsules, tablets, and injection: AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g., Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily)

Immediate-release tablets only: symptomatic sustained ventricular tachycardia, disabling symptoms of premature ventricular contractions or non-sustained ventricular tachycardia in patients resistant to or intolerant of other therapy

Injection only: ventricular tachycarryrhythmias resistant to other treatment

Cautions
- Patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably); atrial fibrillation following heart surgery; elderly (accumulation may occur); ECG monitoring and resuscitation facilities

Disopyramide

Indications
- Ventricular arrhythmias, especially after myocardial infarction, supraventricular arrhythmias

Cautions
- Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur); atrial flutter or atrial tachycardia with partial block, bundle branch block, heart failure (avoid if severe); prostatic enlargement; susceptibility to angle-closure glaucoma; avoid in acute porphyria (section 9.8.2); Interactions: Appendix 1 (disopyramide)

Contra-indications
- Second- and third-degree heart block and sinus node dysfunction (unless pacemaker fitted); cardiogenic shock; severe uncompensated heart failure

Hepatic impairment
- Half-life prolonged—may need dose reduction

Renal impairment
- Reduce dose by increasing dose interval; adjust according to response; avoid sustained-release preparation

Pregnancy
- May induce labour if used in third trimester

Breast-feeding
- Present in milk—use only if essential and monitor infant for antimuscarinic effects

Side-effects
- Ventricular tachycardia, ventricular fibrillation or torsade de pointes (usually associated with prolongation of QRS complex or QT interval—see Cautions above), myoccardial depression, hypotension, AV block; antimuscarinic effects include dry mouth, blurred vision, urinary retention, and very rarely angle-closure glaucoma; gastro-intestinal irritation; psychosis, cholestatic jaundice, hypoglycaemia also reported (see Cautions above)

Dose
- By mouth, 200 mg 3 times daily for 1 week reduced to 200 mg twice daily for a further week; maintenance, usually 200 mg daily or the minimum required to control the arrhythmia
- By intravenous infusion (see Cautions above), initially 5 mg/kg over 20–120 minutes with ECG monitoring; subsequent infusion given if necessary according to response up to max. 1.2 g in 24 hours
- Ventricular fibrillation or pulseless ventricular tachycardia refractory to defibrillation, section 2.7.3

Amiodarone (Non-proprietary)
- Tablets, amiodarone hydrochloride 100 mg, net price 28-tab pack = £1.75; 200 mg, 28-tab pack = £2.22. Label: 11
- Injection, amiodarone hydrochloride 30 mg/mL, net price 10-mL prefilled syringe = £19.60

Sterile concentrate, amiodarone hydrochloride 50 mg/mL, net price 3-ml amp = £1.33, 6-ml amp = £2.86. For dilution and use as an infusion
- Excipients may include benzyl alcohol (avoid in neonates unless no safer alternative available, see Excipients, p. 2)

Cordarone X® (Sanofi-Aventis)
- Tablets, scored, amiodarone hydrochloride 100 mg, net price 28-tab pack = £4.28; 200 mg, 28-tab pack = £6.99. Label: 11
- Sterile concentrate, amiodarone hydrochloride 50 mg/mL, net price 3-ml amp = £1.33. For dilution and use as an infusion
- Excipients may include benzyl alcohol (avoid in neonates unless no safer alternative available, see Excipients, p. 2)

pulmonary toxicity (including pneumonitis and fibrosis); tremor, sleep disorders; hypothyroidism, hyperthyroidism; reversible corneal microdeposits (sometimes with night glare); phototoxicity, persistent slate-grey skin discoloration (see also notes above), injection-site reactions, less commonly onset or worsening of arrhythmia, conduction disturbances (see Cautions), peripheral neuropathy and myopathy (usually reversible on withdrawal); very rarely chronic liver disease including cirrhosis, sinus arrest, bronchospasm (in patients with severe respiratory failure), ataxia, benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash (including exfoliative dermatitis), hypersensitivity including vasculitis, alopecia, impaired vision due to optic neuritis or optic neuropathy (including blindness), anaphylaxis on rapid injection, also hypotension, respiratory distress syndrome, sweating, and hot flushes
must be available during intravenous use; interactions: Appendix 1 (flecainide)

**Contra-indications** heart failure; abnormal left ventricular function; history of myocardial infarction and either asymptomatic ventricular ectopics or asymptomatic non-sustained ventricular tachycardia; long-standing atrial fibrillation where conversion to sinus rhythm not attempted; haemodynamically significant valvular heart disease; avoid in sinus node dysfunction, atrial conduction defects, second-degree or greater AV block, bundle branch block or distal block unless pacing rescue available

**Hepatic impairment** avoid (or reduce dose) in severe liver disease

**Renal impairment** reduce initial oral dose to max. 100 mg daily or reduce intravenous dose by 50%, if eGFR less than 35 mL/minute/1.73 m$^2$

**Pregnancy** used in pregnancy to treat maternal and fetal arrhythmias in specialist centres; toxicity reported in animal studies; infant hyperbilirubinemia also reported

**Breast-feeding** significant amount present in milk but not known to be harmful

**Side-effects** oedema, pro-arrhythmic effects; dizziness, asthenia, fatigue, fever; visual disturbances; rarely pneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia, convulsions, peripheral neuropathy; also reported gastrointestinal disturbances, anorexia, hepatic dysfunction, flushing, syncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia, ataxia, paraesthesia, anaesthesia, leucopenia, thrombocytopenia, corneal deposits, flushing, syncope, dizziness, hypotension, tinnitus, increased antinuclear antibodies, hypersensitivity reactions (including rash, urticaria, and photosensitivity), increased sweating

**Dose**

- **By mouth** (initiated under direction of hospital consultant), ventricular arrhythmias, initially 100 mg twice daily (max. 400 mg daily usually reserved for rapid control or in heavily built patients); reduced after 3–5 days to the lowest dose that controls arrhythmia

Supraventricular arrhythmias, 50 mg twice daily, increased if required to max. 300 mg daily

- **By slow intravenous injection** (in hospital), 2 mg/kg over 10–30 minutes, max. 150 mg, with ECG monitoring; followed if required by infusion at a rate of 1.5 mg/kg/hour for 1 hour, subsequently reduced to 100–250 micrograms/kg/hour for up to 24 hours; max. cumulative dose in first 24 hours, 600 mg; transfer to **oral** treatment, as above

**Flecainide** (Non-proproprietary) [A]

- **Tablets**, flecainide acetate 50 mg, net price 60-tab pack = £6.04; 100 mg, 60-tab pack = £8.95

- **Tambocor** [A] [C]
  - **Tablets**, flecainide acetate 50 mg, net price 60-tab pack = £11.57; 100 mg (scored), 60-tab pack = £16.53
  - **Injection**, flecainide acetate 10 mg/mL, net price 15-mL amp = £4.40

**Modified release**

**Tambocor** [A] [C]

- **Capsules**, m/c, grey/pink, flecainide acetate 200 mg, net price 30-cap pack = £14.77. Label: 25

**Ventricular arrhythmias** Intravenous lidocaine can be used for the treatment of ventricular tachycardia in haemodynamically stable patients (section 2.3.1), and ventricular fibrillation and pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation (section 2.7.3), however it is no longer the anti-arrhythmic drug of first choice.

Drugs for both supraventricular and ventricular arrhythmias include amiodarone, beta-blockers, disopyramide, flecainide, procainamide (available from ‘special-order’ manufacturers or specialist importing
companies, see p. 988), and propafenone, see above under Supraventricular and Ventricular Arrhythmias.

Mexiletine is available from ‘special-order’ manufacturers or specialist importing companies (see p. 988) for treatment of life-threatening ventricular arrhythmias.

**LIDOCAINE HYDROCHLORIDE** (Lignocaine hydrochloride)

**Indications** ventricular arrhythmias, especially after myocardial infarction; eye (section 11.7); local anaesthesia (section 15.2)

**Cautions** lower doses in congestive cardiac failure and following cardiac surgery; monitor ECG and have resuscitation facilities available; elderly; **interactions:** Appendix 1 (lidocaine)

**Contra-indications** sino-atrial disorders, all grades of atrioventricular block, severe myocardial depression; acute porphyria (section 9.8.2)

**Hepatic impairment** caution—increased risk of side-effects

**Renal impairment** possible accumulation of lidocaine and active metabolite; caution in severe impairment

**Pregnancy** crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk

**Breast-feeding** present in milk but amount too small to be harmful

**Side-effects** dizziness, paraesthesia, or drowsiness (particularly if injection too rapid); other CNS effects include confusion, respiratory depression and convulsions; hypotension and bradycardia (may lead to cardiac arrest); rarely hypersensitivity reactions including anaphylaxis

**Dose**

- By intravenous injection, in patients without gross circulatory impairment, 100 mg as a bolus over a few minutes (50 mg in lighter patients or those whose circulation is severely impaired), followed immediately by infusion of 4 mg/minute for 30 minutes, 2 mg/minute for 2 hours, then 1 mg/minute; reduce concentration further if infusion continued beyond 24 hours (ECG monitoring and specialist advice for infusion)

**Note** Following intravenous injection lidocaine has a short duration of action (lasting for 15–20 minutes). If an intravenous infusion is not immediately available the initial intravenous injection of 50–100 mg can be repeated if necessary once or twice at intervals of not less than 10 minutes

**Lidocaine (Non-proprietary)**

- **Injection 1%**, lidocaine hydrochloride 10 mg/mL, net price 2-mL amp = 21p; 5-mL amp = 26p; 10-mL amp = 39p; 20-mL amp = 78p
- **Injection 2%**, lidocaine hydrochloride 20 mg/mL, net price 2-mL amp = 32p; 5-mL amp = 31p; 10-mL amp = 60p; 20-mL amp = 80p
- **Infusion**, lidocaine hydrochloride 0.1% (1 mg/mL) and 0.2% (2 mg/mL) in glucose intravenous infusion 5%, 500-ml containers

**Minijet® Lignocaine** (UCB Pharma)

- **Injection**, lidocaine hydrochloride 1% (10 mg/mL), net price 10-mL disposable syringe = £8.48; 2% (20 mg/mL), 5-mL disposable syringe = £8.18

**2.4 Beta-adrenoceptor blocking drugs**

Beta-adrenoceptor blocking drugs (beta-blockers) block the beta-adrenoceptors in the heart, peripheral vasculature, bronchi, pancreas, and liver.

Many beta-blockers are now available and in general they are all equally effective. There are, however, differences between them, which may affect choice in treating particular diseases or individual patients.

Intrinsic sympathomimetic activity (ISA, partial agonist activity) represents the capacity of beta-blockers to stimulate as well as to block adrenergic receptors. Oxrenolol, pindolol, acebutolol, and celiprolol have intrinsic sympathomimetic activity; they tend to cause less bradycardia than the other beta-blockers and may also cause less coldness of the extremities.

Some beta-blockers are lipid soluble and some are water soluble. Atenolol, celiprolol, nadolol, and sotalol are the most water-soluble; they are less likely to enter the brain, and may therefore cause less sleep disturbance and nightmares. Water-soluble beta-blockers are excreted by the kidneys and dosage reduction is often necessary in renal impairment.

Beta-blockers with a relatively short duration of action have to be given two or three times daily. Many of these are, however, available in modified-release formulations so that administration once daily is adequate for hypertension. For angina twice-daily treatment may sometimes be needed even with a modified-release formulation. Some beta-blockers, such as atenolol, bisoprolol, carvedilol, celiprolol, and nadolol, have an intrinsically longer duration of action and need to be given only once daily.

Beta-blockers slow the heart and can depress the myocardium; they are contra-indicated in patients with second- or third-degree heart block. Beta-blockers should also be avoided in patients with worsening unstable heart failure; care is required when initiating a beta-blocker in those with stable heart failure (see also section 2.5.5). Sotalol may prolong the QT interval, and it occasionally causes life-threatening ventricular arrhythmias (important: particular care is required to avoid hypokalaemia in patients taking sotalol).

Labetalol, celiprolol, carvedilol, and nebivolol are beta-blockers that have, in addition, an arteriolar vasodilating action, by diverse mechanisms, and thus lower peripheral resistance. There is no evidence that these drugs have important advantages over other beta-blockers in the treatment of hypertension.

Beta-blockers can precipitate bronchospasm and should therefore usually be avoided in patients with a history of asthma. When there is no suitable alternative, it may be necessary for a patient with well-controlled asthma, or chronic obstructive pulmonary disease (without significant reversible airways obstruction), to receive treatment with a beta-blocker for a co-existing condition (e.g. heart failure or following myocardial infarction). In this situation, a cardioselective beta-blocker should be selected and initiated at a low dose by a specialist; the patient should be closely monitored for adverse effects. Atenolol, bisoprolol, metoprolol, nebivolol, and (to a lesser extent) acebutolol, have less effect on the beta, (bronchial) receptors and are, therefore, relatively car-
dioselective, but they are not cardioselective. They have a lesser effect on airways resistance but are not free of this side-effect.

Beta-blockers are also associated with fatigue, coldness of the extremities (may be less common with those with ISA, see above), and sleep disturbances with nightmares (may be less common with the water-soluble beta-blockers, see above).

Beta-blockers can affect carbohydrate metabolism, causing hypoglycaemia or hyperglycaemia in patients with or without diabetes; they can also interfere with metabolic and autonomic responses to hypoglycaemia, thereby masking symptoms such as tachycardia. However, beta-blockers are not contra-indicated in diabetes, although the cardioselective beta-blockers (see above) may be preferred. Beta-blockers should be avoided altogether in those with frequent episodes of hypoglycaemia. Beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or in those at high risk of developing diabetes.

Pregnancy Beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia; the risk is greater in severe hypertension. The use of labetalol in maternal hypertension is not understood, but they reduce cardiac output, alter baroreceptor reflex sensitivity, and block peripheral adrenoceptors. Some beta-blockers depress plasma renin secretion. It is possible that a central effect is also partly explained by their mode of action.

Pregnancy should be monitored as there is a risk of possible toxicity due to beta-blockade (and alpha-blockade with labetalol or carve-dilol), but the amount of most beta-blockers present in milk is too small to affect infants. Acebutolol, atenolol, nadolol, and sotalol are present in milk in greater amounts than other beta-blockers. The manufacturers of celiprolol, esmolol, and nebivolol advise avoidance if breast-feeding.

Hypertension The mode of action of beta-blockers in hypertension is not understood, but they reduce cardiac output, alter baroreceptor reflex sensitivity, and block peripheral adrenoceptors. Some beta-blockers depress plasma renin secretion. It is possible that a central effect may also partly explain their mode of action.

Beta-blockers are effective for reducing blood pressure but more effective for reducing the incidence of stroke, myocardial infarction, and cardiovascular mortality, especially in the elderly. Other antihypertensives are therefore preferred for routine initial treatment of uncomplicated hypertension.

In general, the dose of a beta-blocker does not have to be high; for example, atenolol is given in a dose of 25–50 mg daily and it is rarely necessary to increase the dose to 100 mg.

Beta-blockers can be used to control the pulse rate in patients with *pseudochromocytoma* (section 2.5.4). However, they should never be used alone as beta-blockade without concurrent alpha-blockade may lead to a hypertensive crisis. For this reason phenoxybenzamidine should always be used together with the beta-blocker.

Angina By reducing cardiac work beta-blockers improve exercise tolerance and relieve symptoms in patients with *angina* (for further details on the management of stable angina and acute coronary syndromes, see section 2.10.1). As with hypertension there is no good evidence of the superiority of any one drug, although occasionally a patient will respond better to one beta-blocker than to another. There is some evidence that sudden withdrawal may cause an exacerbation of angina and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped. There is a risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischaemic heart disease (important: see p. 133).

Myocardial infarction For advice on the management of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, see section 2.10.1. Several studies have shown that some beta-blockers can reduce the recurrence rate of myocardial infarction. However, among patients with previous failure, hypotension, bradycardia, and obstructive airways disease render beta-blockers unsuitable in some patients following a myocardial infarction. Atenolol and metoprolol may reduce early mortality after intravenous and subsequent oral administration in the acute phase, while acebutolol, metoprolol, propranolol, and timolol have protective value when started in the early convalescent phase. The evidence relating to other beta-blockers is less convincing; some have not been tested in trials of secondary prevention. Sudden cessation of a beta-blocker can cause a rebound worsening of myocardial ischaemia.

Arrhythmias Beta-blockers act as *anti-arrhythmic drugs* principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. They can be used in conjunction with digoxin to control the ventricular response to atrial fibrillation, especially in patients with thyrotoxicosis. Beta-blockers are also useful in the management of supraventricular tachyarrhythmias, and are used to control those following myocardial infarction (see above).

Esmolol is a relatively cardioselective beta-blocker with a very short duration of action, used intravenously for the short-term treatment of supraventricular arrhythmias, sinus tachycardia, or hypertension, particularly in the peri-operative period. It may also be used in other situations, such as acute myocardial infarction, when sustained beta-blockade might be hazardous.

Sotalol, a non-cardioselective beta-blocker with additional class III anti-arrhythmic activity, is used for prophylaxis in paroxysmal supraventricular arrhythmias. It also suppresses ventricular ectopic beats and non-sustained ventricular tachycardia. It has been shown to be more effective than lidocaine in the termination of spontaneous sustained ventricular tachycardia due to coronary disease or cardiomyopathy. However, it may induce torsade de pointes in susceptible patients.

Heart failure Beta-blockers may produce benefit in heart failure by blocking sympathtic activity. Bisoprolol and carvedilol reduce mortality in any grade of stable heart failure, while nebivolol is licensed for stable mild to moderate heart failure in patients over 70
years. Treatment should be initiated by those experienced in the management of heart failure (section 2.5.5).

Thyrotoxicosis Beta-blockers are used in pre-operative preparation for thyroidectomy. Administration of propranolol can reverse clinical symptoms of thyrotoxicosis within 4 days. Routine tests of increased thyroid function remain unaltered. The thyroid gland is rendered less vascular thus making surgery easier (section 6.2.2).

Other uses Beta-blockers have been used to alleviate some symptoms of anxiety, probably patients with palpitation, tremor, and tachycardia respond best (see also section 4.1.2 and section 4.9.3). Beta-blockers are also used in the prophylaxis of migraine (section 4.7.4.2). Betaxolol, carteolol, levobunolol, metipranolol, and timolol are used topically in glaucoma (section 11.6).

**PROPRANOLOL HYDROCHLORIDE**

**Indications** see under Dose

**Cautions** see notes above; also avoid abrupt withdrawal especially in ischaemic heart disease; first-degree AV block; portal hypertension (risk of deterioration in liver function); diabetes; history of obstructive airways disease (introduce cautiously and monitor lung function—see notes above); myasthenia gravis; symptoms of hypeoglycaemia and thyrotoxicosis may be masked (also see notes above); pororrhea; history of hypersensitivity—may increase sensitivity to allergens and result in more serious hypersensitivity reaction, also may reduce response to adrenergic (epinephrine) (see also section 3.4.3); interactions: Appendix 1 (beta-blockers), important: verapamil interaction, see also p. 133

**Contra-indications** asthma (but see notes above), uncontrolled heart failure, Prinzmetal's angina, marked bradycardia, hypotension, sick sinus syndrome, second- or third-degree AV block, cardiogenic shock, metabolic acidosis, severe peripheral arterial disease; phaeochromocytoma (apart from specific use with alpha-blockers, see also notes above)

**Bronchospasm** Beta-blockers, including those considered to be cardioselective, should usually be avoided in patients with a history of asthma or bronchospasm. However, when there is no alternative, a cardioselective beta-blocker can be given to these patients with caution and under specialist supervision.

**Hepatic impairment** reduce oral dose

**Renal impairment** manufacturer advises caution—dose reduction may be required

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also gastro-intestinal disturbances; bradycardia, heart failure, hypotension, conduction disorders, peripheral vasaconstriction (including exacerbation of intermittent claudication and Raynaud’s phenomenon); bronchospasm (see above), dyspnoea; headache, fatigue, sleep disturbances, paraesthesia, dizziness, vertigo, psychoses; sexual dysfunction; purpura, thrombocytopenia; visual disturbances; exacerbation of psoriasis, alopecia; rarely rash and dry eyes (reversible on withdrawal); over dosage: see Emergency Treatment of Poisoning, p. 37

**Dose**

- **By mouth,** hypertension, initially 80 mg twice daily, increased at weekly intervals as required; maintenance 160–320 mg daily
- Prophylaxis of variceal bleeding in portal hypertension, initially 40 mg twice daily, increased to 80 mg twice daily according to heart rate; max. 160 mg twice daily
- Phaeochromocytoma (only with an alpha-blocker), 60 mg daily for 3 days before surgery or 30 mg daily in patients unsuitable for surgery
- Angina, initially 40 mg 2–3 times daily; maintenance 120–240 mg daily
- Arrhythmias, hypertrophic cardiomyopathy, anxiety tachycardia, and thyrotoxicosis (adjunct), 10–40 mg 3–4 times daily
- Anxiety with symptoms such as palpitation, sweating, tremor, 40 mg once daily, increased to 40 mg 3 times daily if necessary
- Prophylaxis after myocardial infarction, 40 mg 4 times daily for 2–3 days, then 80 mg twice daily, beginning 5 to 21 days after infarction
- Essential tremor, initially 40 mg 2–3 times daily; maintenance 80–160 mg daily
- Migraine prophylaxis, 80–240 mg daily in divided doses

- **By intravenous injection,** arrhythmias and thyrotoxic crisis, 1 mg over 1 minute; if necessary repeat at 2-minute intervals; max. total dose 10 mg (5 mg in anaesthesia)

**Note** Excessive bradycardia can be countered with intravenous injection of atropine sulphate 0.6–2.4 mg in divided doses of 600 micrograms, for over dosage see Emergency Treatment of Poisoning, p. 37

**Propranolol** (Non-proprietary)

- **Tablets,** propranolol hydrochloride 10 mg, net price 28 = 92p; 40 mg, 28 = 93p; 80 mg, 56 = £1.54; 160 mg, 56 = £4.02. Label: 8

**Brands include**

- **Angles**

- **Injection,** propranolol hydrochloride 1 mg/mL, net price 1-mL amp = 21p

**Modified release**

**Note** Modified-release preparations can be used for once daily administration

**Half-**<BR>**Inderal LA<sup>®</sup> (AstraZeneca)**

- **Tablets,** m/r, lavender/pink, propranolol hydrochloride 80 mg, net price 28-cap pack = £5.40. Label: 8, 25

**Note** Modified-release capsules containing propranolol hydrochloride 80 mg also available; brands include Bedrolol SR<sup>®</sup>, Half Beta Prograne<sup>®</sup>

**Inderal LA<sup>®</sup> (AstraZeneca)**

- **Tablets,** m/r, lavender/pink, propranolol hydrochloride 160 mg, net price 28-cap pack = £1.91. Label: 8, 25

**Note** Modified-release capsules containing propranolol hydrochloride 160 mg also available; brands include Bedrolon SR<sup>®</sup>, Beta Prograne<sup>®</sup>, Slo-Pro<sup>®</sup>
100 2.4 Beta-adrenoceptor blocking drugs

**ACEBUTOLOL**

**Indications** see under Dose

**Cautions** see under Propranolol Hydrochloride

**Contra-indications** see under Propranolol Hydrochloride

**Renal impairment** halve dose if eGFR 25–50 mL/minute/1.73 m²; use quarter dose if eGFR less than 25 mL/minute/1.73 m²; do not administer more than once daily

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Propranolol Hydrochloride

**Dose**

- Hypertension, initially 400 mg once daily or 200 mg twice daily, increased after 2 weeks to 400 mg twice daily if necessary
- Angina, initially 400 mg once daily or 200 mg twice daily; 300 mg 3 times daily in severe angina; up to 1.2 g daily has been used
- Arrhythmias, 0.4–1.2 g daily in 2–3 divided doses

**Sectral** (Sanofi-Aventis)

**Capsules**, acebutolol (as hydrochloride) 100 mg (buff/white), net price 84-cap pack = £14.97; 200 mg (buff/pink), 56-cap pack = £19.18. Label: 8

**Tablets**, f/c, acebutolol 400 mg (as hydrochloride), net price 28-tab pack = £18.62. Label: 8

**ATENOLOL**

**Indications** see under Dose

**Cautions** see under Propranolol Hydrochloride

**Contra-indications** see under Propranolol Hydrochloride

**Renal impairment** max. 50 mg daily (10 mg on alternate days intravenously) if eGFR 15–35 mL/minute/1.73 m²; max. 25 mg daily or 50 mg on alternate days (10 mg every 4 days intravenously) if eGFR less than 15 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Propranolol Hydrochloride

**Dose**

- By mouth, hypertension, 25–50 mg daily (higher doses rarely necessary)
- Angina, 100 mg daily in 1 or 2 doses
- Arrhythmias, 50–100 mg daily

Migraine prophylaxis [unlicensed], 50–200 mg daily in divided doses

- By intravenous injection, arrhythmias, 2.5 mg at a rate of 1 mg/minute, repeated at 5-minute intervals to a max. of 10 mg

**Note** Excessive bradycardia can be countered with intravenous injection of atropine sulphate 0.6–2.4 mg in divided doses of 600 micrograms; for overdosage see Emergency Treatment of Poisoning, p 37

- By intravenous infusion, arrhythmias, 150 micrograms/kg over 20 minutes, repeated every 12 hours if required

Early intervention within 12 hours of myocardial infarction (section 2.10.1), by intravenous injection over 5 minutes, 5 mg, then by mouth, 50 mg after 15 minutes, 50 mg after 12 hours, then 100 mg daily

**Atenolol** (Non-proprietary) 

**Tablets**, atenolol 25 mg, net price 28-tab pack = 83p; 50 mg, 28-tab pack = 86p; 100 mg, 28-tab pack = 91p. Label: 8

**Tenormin** (AstraZeneca) 

‘25’ tablets, f/c, atenolol 25 mg, net price 28-tab pack = £1.16. Label: 8

**TS tablets**, orange, f/c, scored, atenolol 50 mg, net price 28-tab pack = £2.94. Label: 8

**Tablets**, orange, f/c, scored, atenolol 100 mg, net price 28-tab pack = £3.46. Label: 8

**Syrup**, sugar-free, atenolol 25 mg/5 mL, net price 300 mL = £8.55. Label: 8

**Injection**, atenolol 500 micrograms/mL, net price 10-mL amp = 96p (hosp. only)

**With diuretic**

**Co-tenidone** (Non-proprietary)

**Tablets**, co-tenidone 50/12.5 (atenolol 50 mg, chlorothalidone 12.5 mg), net price 28-tab pack = £1.77; co-tenidone 100/25 (atenolol 100 mg, chlorothalidone 25 mg), 28-tab pack = £1.57. Label: 8

**Dose** hypertension, 1 tablet daily (but see also under Dose above)

**Kalten** (BPC 100)

**Capsules**, red/ivory, atenolol 50 mg, co-amiloide 2.5/25 (anhydrous amiloride hydrochloride 2.5 mg, hydrochlorothiazide 25 mg), net price 28-cap pack = £12.17. Label: 8

**Dose** hypertension, 1 capsule daily

**Tenoret 50** (AstraZeneca)

**Tablets**, brown, f/c, co-tenidone 50/12.5 (atenolol 50 mg, chlorothalidone 12.5 mg), net price 28-tab pack = £1.15. Label: 8

**Dose** hypertension, 1 tablet daily

**Tenoretic** (AstraZeneca)

**Tablets**, brown, f/c, co-tenidone 100/25 (atenolol 100 mg, chlorothalidone 25 mg), net price 28-tab pack = £1.25. Label: 8

**Dose** hypertension, 1 tablet daily (but see also under Dose above)

**With calcium-channel blocker**

**Note** Only indicated when calcium-channel blocker or beta-blocker alone proves inadequate. For prescribing information on nifedipine see section 2.6.2

**Beta-Adalat** (Bayer Schering)

**Capsules**, reddish-brown, atenolol 50 mg, nifedipine 20 mg (m/r), net price 28-cap pack = £9.00. Label: 8, 25

**Dose** hypertension, 1 capsule daily, increased if necessary to twice daily. **ELDERLY**: 1 daily

**Angina**, 1 capsule twice daily

**Tenif** (AstraZeneca)

**Capsules**, reddish-brown, atenolol 50 mg, nifedipine 20 mg (m/r), net price 28-cap pack = £10.63. Label: 8, 25

**Dose** hypertension, 1 capsule daily, increased if necessary to twice daily. **ELDERLY**: 1 daily

**Angina**, 1 capsule twice daily
Bisoprolol Fumarate

Indications see under Dose

Cautions see under Propranolol Hydrochloride; ensure heart failure not worsening before increasing dose

Contra-indications see under Propranolol Hydrochloride; also acute or decompensated heart failure requiring intravenous inotrope; sino-atrial block

Hepatic impairment max. 10 mg daily in severe impairment

Renal impairment reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 10 mg daily)

Pregnancy see notes above

Breast-feeding see notes above

Side-effects postural hypotension, dizziness, headache; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms; rarely angina, AV block, exacerbation of intermittent claudication or Raynaud’s phenomenon; allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paraesthesia, heart failure, changes in liver enzymes, thrombocytopenia, leucopenia also reported

Dose

- Hypertension, initially 12.5 mg once daily, increased after 2 days to usual dose of 25 mg once daily; if necessary may be further increased at intervals of at least 2 weeks to max. 50 mg daily in single or divided doses

- Angina, initially 12.5 mg twice daily, increased after 2 days to 25 mg twice daily

- Adjunct in heart failure (section 2.5.5) initially 3.125 mg twice daily (with food), dose increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily; increase to highest dose tolerated, max. 25 mg twice daily in patients with severe heart failure or body-weight less than 85 kg and 50 mg twice daily in patients over 85 kg

Carvedilol (Non-proprietary)

Tablets, carvedilol 3.125 mg, net price 28-tab pack = £1.10; 6.25 mg, 28-tab pack = £1.25; 12.5 mg, 28-tab pack = £1.37; 25 mg, 28-tab pack = £1.84. Label: 8

Eucardic® (Roche)

Tablets, scored, carvedilol 3.125 mg (pink), net price 28-tab pack = £7.13; 6.25 mg (yellow), 28-tab pack = £7.92; 12.5 mg (peach), 28-tab pack = £8.81; 25 mg, 28-tab pack = £11.00. Label: 8

Celliprolol Hydrochloride

Indications mild to moderate hypertension

Cautions see under Propranolol Hydrochloride

Contra-indications see under Propranolol Hydrochloride

Renal impairment reduce dose by half if eGFR 15–40 mL/minute/1.73 m²; avoid if eGFR less than 15 mL/minute/1.73 m²

Pregnancy see notes above

Breast-feeding see notes above

Side-effects headache, dizziness, fatigue, nausea and somnolence; also bradycardia, bronchospasm; depression and pneumonitis reported rarely

Dose

- 200 mg once daily in the morning, increased to 400 mg once daily if necessary

Celiprolol (Non-proprietary)

Tablets, celiprolol hydrochloride 200 mg, net price 28-tab pack = £4.53; 400 mg, 28-tab pack = £7.13; 600 mg, 28-tab pack = £12.83. Label: 8

Celectol® (Winthrop)

Tablets, scored, celiprolol hydrochloride 200 mg (yellow), net price 28-tab pack = £19.83; 400 mg, 28-tab pack = £39.65. Label: 8, 22
2.4 Beta-adrenoceptor blocking drugs

**ESMOLOL HYDROCHLORIDE**

**Indications** short-term treatment of supraventricular arrhythmias (including atrial fibrillation, atrial flutter, sinus tachycardia); tachycardia and hypertension in peri-operative period.

**Cautions** see under Propranolol Hydrochloride

**Contra-indications** see under Propranolol Hydrochloride

**Renal impairment** manufacturer advises caution

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Propranolol Hydrochloride; also on infusion venous irritation and thrombophlebitis

**Dose**
- By intravenous infusion, usually within range 50–200 micrograms/kg/minute (consult product literature for details of dose titration and doses during peri-operative period)

**Brevibloc® (Baxter)**

Injection, esmolol hydrochloride 10 mg/mL, net price 10-mL vial = £7.79, 250-mL infusion bag = £89.69

**Labetalol Hydrochloride**

**Indications** hypertension (including hypertension in pregnancy; hypertension with angina, and hypertension following acute myocardial infarction); hypertensive crises (see section 2.5); controlled hypotension in anaesthesia

**Cautions** see under Propranolol Hydrochloride; interferes with laboratory tests for catecholamines; liver damage (see below)

**Liver damage** Severe hepatic cellular damage reported after both short-term and long-term treatment. Appropriate laboratory testing needed at first symptom of liver dysfunction and if laboratory evidence of damage (or if jaundice) labetalol should be stopped and not restarted

**Contra-indications** see under Propranolol Hydrochloride

**Hepatic impairment** avoid—severe hepatic cellular injury reported

**Renal impairment** dose reduction may be required

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Propranolol Hydrochloride

**Dose**
- By mouth, hypertension, initially 100 mg daily, increased if necessary to 200 mg daily in 1–2 divided doses; max. 400 mg daily (but high doses rarely necessary)
- Angina, 50–100 mg 2–3 times daily
- Arrhythmias, usually 50 mg 2–3 times daily; up to 300 mg daily in divided doses if necessary
- Migraine prophylaxis, 100–200 mg daily in divided doses
- Hyperthyroidism (adjunct), 50 mg 4 times daily
- By intravenous injection, arrhythmias, up to 5 mg at rate 1–2 mg/minute, repeated after 5 minutes if necessary, total dose 10–15 mg

**Note** Excessive bradycardia can be countered with intravenous injection of atropine sulphate 0.6–2.4 mg in divided doses of 600 micrograms; for overdosage see Emergency Treatment of Poisoning, p. 37

In surgery, by slow intravenous injection 2–4 mg at induction or to control arrhythmias developing during anaesthesia; 2-mg doses may be repeated to a max. of 10 mg

Early intervention within 12 hours of infarction, by intravenous injection 5 mg every 2 minutes to a max. of 15 mg, followed after 15 minutes by 50 mg by mouth every 6 hours for 48 hours; maintenance 200 mg daily in divided doses

**Metoprolol Tartrate**

**Indications** see under Dose

**Cautions** see under Propranolol Hydrochloride

**Contra-indications** see under Propranolol Hydrochloride

**Hepatic impairment** reduce dose in severe impairment

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Propranolol Hydrochloride

**Dose**
- By mouth, hypertension, initially 100 mg daily, increased if necessary to 200 mg daily in 1–2 divided doses; max. 400 mg daily (but high doses rarely necessary)
- Angina, 50–100 mg 2–3 times daily
- Arrhythmias, usually 50 mg 2–3 times daily; up to 300 mg daily in divided doses if necessary
- Migraine prophylaxis, 100–200 mg daily in divided doses
- Hyperthyroidism (adjunct), 50 mg 4 times daily
- By intravenous injection, arrhythmias, up to 5 mg at rate 1–2 mg/minute, repeated after 5 minutes if necessary, total dose 10–15 mg

**Note** Excessive bradycardia can be countered with intravenous injection of atropine sulphate 0.6–2.4 mg in divided doses of 600 micrograms; for overdosage see Emergency Treatment of Poisoning, p. 37

In surgery, by slow intravenous injection 2–4 mg at induction or to control arrhythmias developing during anaesthesia; 2-mg doses may be repeated to a max. of 10 mg

Early intervention within 12 hours of infarction, by intravenous injection 5 mg every 2 minutes to a max. of 15 mg, followed after 15 minutes by 50 mg by mouth every 6 hours for 48 hours; maintenance 200 mg daily in divided doses

**Metoprolol Tartrate** (Non-proprietary)

Tablets, metoprolol tartrate 50 mg, net price 28 = £1.31, 56 = £1.74; 100 mg, 28 = £1.59, 56 = £2.51. Label: 8

**Betaloc® (AstraZeneca)**

Injection, metoprolol tartrate 1 mg/mL, net price 5-mL amp = £4.2p

**Lopresor® (Novartis)**

Tablets, f/c, scored, metoprolol tartrate 50 mg (pink), net price 56-tab pack = £2.57; 100 mg (blue), 56-tab pack = £6.68. Label: 8
2.4 Beta-adrenoceptor blocking drugs

NADOLOL

Indications see under Dose
Cautions see under Propranolol Hydrochloride
Contra-indications see under Propranolol Hydrochloride
Hepatic impairment manufacturer advises caution
Renal impairment increase dosage interval if eGFR less than 50 mL/minute/1.73 m²
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see under Propranolol Hydrochloride
Dose
- Hypertension, initially 80 mg once daily, increased in increments of up to 80 mg at weekly intervals if required; max. 240 mg daily (higher doses rarely necessary)
- Angina, initially 40 mg once daily, increased at weekly intervals if required; usual max. 160 mg daily (rarely up to 240 mg may be required)
- Arrhythmias, initially 40 mg once daily, increased at weekly intervals up to 160 mg if required; reduce to 40 mg if bradycardia occurs
- Migraine prophylaxis, initially 40 mg once daily, increased in 40 mg increments at weekly intervals according to response; usual maintenance dose 80–160 mg once daily
- Thyrotoxicosis (adjunct), 80–160 mg once daily
Corgard® (Sanofi-Aventis) Tablets, blue, scored, nadolol 80 mg, net price 28-tab pack = £5.00. Label: 8.

NEBIVOLOL

Indications essential hypertension; adjunct in stable mild to moderate heart failure in patients over 70 years
Cautions see under Propranolol Hydrochloride
Contra-indications see under Propranolol Hydrochloride; also acute or decompensated heart failure requiring intravenous inotropes
Hepatic impairment no information available—manufacturer advises avoid
Renal impairment for hypertension, initially 2.5 mg once daily, increased to 5 mg once daily if required; for heart failure, manufacturer advises avoid if serum creatinine greater than 250 micromol/litre
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see under Propranolol Hydrochloride; also oedema and depression
Dose
- Hypertension, 5 mg daily; ELDERLY initially 2.5 mg daily, increased if necessary to 5 mg daily
- Adjunct in heart failure (section 2.5.5), initially 1.25 mg once daily, then if tolerated increased at intervals of 1–2 weeks to 2.5 mg once daily, then to 5 mg once daily, then to max. 10 mg once daily

Nebivolol (Non-proprietary) Tablets, nebivolol (as hydrochloride) 5 mg, net price 28-tab pack = £3.98. Label: 8.
Nebilet® (Menarini) Tablets, scored, nebivolol (as hydrochloride) 5 mg, net price 28-tab pack = £9.23. Label: 8.
Note Also available as Hypoloc™.

OXPRENOLOL HYDROCHLORIDE

Indications see under Dose
Cautions see under Propranolol Hydrochloride
Contra-indications see under Propranolol Hydrochloride
Hepatic impairment reduce dose
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see under Propranolol Hydrochloride
Dose
- Hypertension, 80–160 mg daily in 2–3 divided doses, increased as required; max. 320 mg daily
- Angina, 80–160 mg daily in 2–3 divided doses; max. 320 mg daily
- Arrhythmias, 40–240 mg daily in 2–3 divided doses; max. 240 mg daily
- Anxiety symptoms (short-term use), 40–80 mg daily in 1–2 divided doses

Oxproprenol (Non-proprietary) Tablets, coated, oxproprenol hydrochloride 20 mg, net price 56-tab pack = £1.86; 40 mg, 56-tab pack = £3.73; 80 mg, 56-tab pack = £6.20; 160 mg, 20-tab pack = £2.36. Label: 8.
Trasicor® (Amdipharm) Tablets, f/c, oxproprenol hydrochloride 20 mg (contain gluten), net price 56-tab pack = £1.86; 40 mg (contain gluten), 56-tab pack = £3.73; 80 mg (yellow), 56-tab pack = £6.20. Label: 8.

Note See also pindolol.

PINDOLOL

Indications see under Dose
Cautions see under Propranolol Hydrochloride
Contra-indications see under Propranolol Hydrochloride
Renal impairment may adversely affect renal function in severe impairment—manufacturer advises avoid
Pregnancy see notes above
Breast-feeding see notes above
Side-effects see under Propranolol Hydrochloride

Nebilet (Menarini) Tablets, m/r, oxprenolol hydrochloride 160 mg, net price 56-tab pack = £1.86; 200 mg, 56-tab pack = £3.73; 400 mg, 56-tab pack = £6.20. Label: 8.

Modified release

Lopresor SR® (Recordati) Tablets, m/r, yellow, f/c, metoprolol tartrate 200 mg, net price 28-tab pack = £9.80. Label: 8, 25
Dose hypertension, 200 mg daily; angina, 200–400 mg daily; migraine prophylaxis, 200 mg daily
### Hypertension and heart failure

#### Dose
- **Hypertension**, initially 5 mg 2–3 times daily or 15 mg once daily, increased as required at weekly intervals; usual maintenance 15–30 mg daily; max. 45 mg daily
- **Angina**, 2.5–5 mg up to 3 times daily

**Pindolol** (Non-proprietary)  
**Tablets**, pindolol 5 mg, net price 100-tab pack = £7.81. Label: 8

**Visken** (Amdipharm)  
**Tablets**, scored, pindolol 5 mg, net price 56-tab pack = £5.85; 15 mg, 28-tab pack = £8.79. Label: 8

### TIMOLOL MALEATE

#### Indications
- see under Dose; glaucoma (section 11.6)

#### Cautions
- see under Propranolol Hydrochloride

#### Contra-indications
- see under Propranolol Hydrochloride

#### Hepatic impairment
- dose reduction may be necessary

#### Renal impairment
- manufacturer advises caution—dose reduction may be required

#### Pregnancy
- see notes above

#### Breast-feeding
- see notes above

#### Side-effects
- see under Propranolol Hydrochloride

### SOTALOL HYDROCHLORIDE

#### Indications
- life-threatening arrhythmias including ventricular tachyarrhythmias; symptomatic non-sustained ventricular tachyarrhythmias; prophylaxis of paroxysmal atrial tachycardia or fibrillation; paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery; maintenance of sinus rhythm following cardioversion of atrial fibrillation or flutter

#### Cautions
- see under Propranolol Hydrochloride; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances; severe or prolonged diarrhoea; interactions: Appendix 1 (beta-blockers), important: verapamil interaction see also p. 133

#### Contra-indications
- see under Propranolol Hydrochloride; congenital or acquired long QT syndrome; tonsade de pointes; renal failure

#### Renal impairment
- use half normal dose if eGFR 30–60 mL/minute/1.73 m²; use one-quarter normal dose if eGFR 10–30 mL/minute/1.73 m²; avoid if eGFR less than 10 mL/minute/1.73 m²

#### Pregnancy
- see notes above

#### Breast-feeding
- see notes above

#### Side-effects
- see under Propranolol Hydrochloride; arrhythmogenic (pro-arrhythmic) effect (tonsade de pointes—increased risk in women)

#### Dose
- **By mouth** with ECG monitoring and measurement of corrected QT interval, arrhythmias, initially 80 mg daily in 1–2 divided doses increased gradually at intervals of 2–3 days to usual dose of 160–320 mg daily in 2 divided doses; higher doses of 480–640 mg daily for life-threatening ventricular arrhythmias under specialist supervision

**Sotalol** (Non-proprietary)  
**Tablets**, sotalol hydrochloride 40 mg, net price 56 = £1.29; 80 mg, 56 = £1.91; 160 mg, 28 = £2.32. Label: 8

**Beta-Cardone** (UCB Pharma)  
**Tablets**, scored, sotalol hydrochloride 40 mg (green), net price 56-tab pack = £1.29; 80 mg (pink), 56-tab pack = £1.91; 200 mg, 28-tab pack = £2.40. Label: 8

**Sotacor** (Bristol-Myers Squibb)  
**Tablets**, scored, sotalol hydrochloride 80 mg, net price 28-tab pack = £3.06. Label: 8

### 2.5 Hypertension and heart failure

#### Hypertension
- Lowering raised blood pressure decreases the risk of stroke, coronary events, heart failure, and renal impairment. Advice on antihypertensive therapy in this section takes into account the recommendations of the Joint British Societies (JBS2: British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl V): v1–v52).
- Possible causes of hypertension (e.g. renal disease, endocrine causes), contributory factors, risk factors, and the presence of any complications of hypertension, such as left ventricular hypertrophy, should be established. Patients should be given advice on lifestyle
2. Cardiovascular system

2.5 Hypertension and heart failure

Changes to reduce blood pressure or cardiovascular risk; these include smoking cessation, weight reduction, reduction of excessive intake of alcohol, reduction of dietary salt, reduction of total and saturated fat, increasing exercise, and increasing fruit and vegetable intake.

Thresholds and targets for treatment The following thresholds for treatment are recommended:

- Severe hypertension with acute target-organ damage causes prompt treatment (systolic blood pressure ≥180 mmHg or diastolic ≥110 mmHg) without acute target-organ damage, treat promptly (see Hypertensive crises, p. 106).
- When the initial blood pressure is systolic 160–179 mmHg or diastolic 100–109 mmHg, and the patient has cardiovascular complications, target-organ damage (e.g. left ventricular hypertrophy, renal impairment) or diabetes mellitus (type 1 or 2), confirm over 3–4 weeks then treat if these values are sustained;
- When the initial blood pressure is systolic 160–179 mmHg or diastolic 100–109 mmHg, but the patient has no cardiovascular complications, no target-organ damage, or no diabetes, advise lifestyle changes, reassess weekly initially and treat if these values are sustained on repeat measurements over 4–12 weeks;
- When the initial blood pressure is systolic 140–159 mmHg or diastolic 90–99 mmHg and the patient has cardiovascular complications, target-organ damage or diabetes, confirm within 12 weeks and treat if these values are sustained;
- When the initial blood pressure is systolic 140–159 mmHg or diastolic 90–99 mmHg and no cardiovascular complications, no target-organ damage, or no diabetes, advise lifestyle changes and reassess monthly; treat persistent mild hypertension if the 10-year cardiovascular disease risk is 20% or more.  

A target systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg is suggested. A lower target systolic blood pressure < 130 mmHg and diastolic blood pressure < 80 mmHg should be considered for those with established atherosclerotic cardiovascular disease, diabetes, or chronic renal failure. In some individuals it may not be possible to reduce blood pressure below the suggested targets despite the use of appropriate therapy.

Drug treatment of hypertension Response to drug treatment for hypertension may be affected by the patient’s age and ethnic background. An ACE inhibitor (section 2.5.5.1) or an angiotensin-II receptor antagonist (section 2.5.5.2) may be the most appropriate initial drug in younger Caucasians; however a beta-blocker may be considered if an ACE inhibitor or an angiotensin-II receptor antagonist is not tolerated or is contraindicated (see also Hypertension in Pregnancy).

1. Thresholds and targets for treatment based on blood pressure measured in clinic may not apply to ambulatory or home blood-pressure monitoring, which usually give lower values.

2. Cardiovascular disease risk may be determined from the chart issued by the Joint British Societies (Heart 2005; 91 Suppl V: v1–v52)—see inside back cover. The Joint British Societies’ ‘Cardiac Risk Assessor’ computer program may also be used to determine cardiovascular disease risk.

P. 106). Afro-Caribbean patients and those aged over 55 years respond less well to ACE inhibitors and angiotensin-II receptor antagonists, therefore a thiazide (section 2.2.1) or a calcium-channel blocker (section 2.6.2) may be chosen for initial treatment.

Beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or in those at high risk of developing diabetes. A single antihypertensive drug is often not adequate and other antihypertensive drugs are usually added in a step-wise manner until control is achieved. Unless it is necessary to lower the blood pressure urgently, an interval of at least 4 weeks should be allowed to determine response.

When two antihypertensive drugs are needed, an ACE inhibitor or an angiotensin-II receptor antagonist can be combined with either a thiazide or a calcium-channel blocker.

If control is inadequate with 2 drugs, a thiazide and a calcium-channel blocker can be added. The addition of an alpha-blocker (section 2.5.4), spironolactone, another diuretic, or a beta-blocker should be considered in resistant hypertension. In patients with primary hyperaldosteronism, spironolactone (section 2.2.3) is effective.

Other measures to reduce cardiovascular risk

Aspirin (section 2.9) in a dose of 75 mg daily reduces the risk of cardiovascular events and myocardial infarction. Unduly high blood pressure must be controlled before aspirin is given. Unless contra-indicated, aspirin is recommended for all patients with established cardiovascular disease. Use of aspirin in primary prevention, in those with or without diabetes, is of unproven benefit (see also section 2.9).

Lipid-regulating drugs can also be of benefit in cardiovascular disease or in those who are at high risk of developing cardiovascular disease (section 2.12).

Hypertension in the elderly Benefit from antihypertensive therapy is evident up to at least 80 years of age, but it is probably inappropriate to apply a strict age limit when deciding on drug therapy. Patients who reach 80 years of age while taking antihypertensive drugs should continue treatment, provided that it continues to be of benefit and does not cause significant side-effects. The thresholds for treatment are diastolic pressure averaging ≥ 90 mmHg or systolic pressure averaging ≥ 160 mmHg over 3 to 6 months’ observation (despite appropriate lifestyle interventions). Treatment with a low dose of a thiazide or a dihydropyridine calcium-channel blocker is effective. An ACE inhibitor (or an angiotensin-II receptor antagonist) (section 2.5.5) can be added if necessary.

Isolated systolic hypertension Isolated systolic hypertension (systolic pressure ≥ 160 mmHg, diastolic pressure < 90 mmHg) is associated with an increased cardiovascular disease risk, particularly in those aged over 60 years. Systolic blood pressure averaging 160 mmHg or higher over 3 to 6 months (despite appropriate lifestyle interventions) should be lowered in those over 60 years, even if diastolic hypertension is absent. Treatment with a low dose of a thiazide or a dihydropyridine calcium-channel blocker is effective. An ACE inhibitor (or an angiotensin-II receptor antagonist) (sec-
Hypertension in diabetes

For patients with diabetes, the aim should be to maintain systolic pressure < 130 mmHg and diastolic pressure < 80 mmHg. However, in some individuals, it may not be possible to achieve this level of control despite appropriate therapy. Most patients require a combination of antihypertensive drugs.

Hypertension is common in type 2 diabetes, and antihypertensive treatment prevents macrovascular and microvascular complications. In type 1 diabetes, hypertension usually indicates the presence of diabetic nephropathy. An ACE inhibitor (or an angiotensin-II receptor antagonist) may have a specific role in the management of diabetic nephropathy (section 6.1.5); in patients with type 2 diabetes, an ACE inhibitor (or an angiotensin-II receptor antagonist) can delay progression of microalbuminuria to nephropathy.

Hypertension in renal disease

The threshold for antihypertensive treatment in patients with renal impairment or persistent proteinuria is a systolic blood pressure > 140 mmHg or a diastolic blood pressure > 90 mmHg. Optimal blood pressure is a systolic blood pressure < 130 mmHg and a diastolic pressure < 80 mmHg, or lower if proteinuria exceeds 1 g in 24 hours. An ACE inhibitor (or an angiotensin-II receptor antagonist) should be considered for patients with proteinuria; however, ACE inhibitors should be used with caution in renal impairment, see section 2.5.5.1. Thiazide diuretics may be ineffective and high doses of loop diuretics may be required. A dihydropyridine calcium channel blocker can be added.

Hypertension in pregnancy

Hypertensive complications in pregnancy can be hazardous for both the mother and the fetus, and are associated with a significant risk of morbidity and mortality; complications can occur in pregnant women with pre-existing chronic hypertension, or in those who develop hypertension in the latter half of pregnancy.

Labetalol (section 2.4) is widely used for treating hypertension in pregnancy. Methyldopa (section 2.5.2) is considered safe for use in pregnancy. Modified-release preparations of nifedipine [unlicensed] are also used, but see section 2.6.2 (p. 132) for warnings on use during pregnancy.

The following advice takes into account the recommendations of NICE Clinical Guideline 107 (August 2010), Hypertension in Pregnancy.

Pregnant women with chronic hypertension who are already receiving antihypertensive treatment should have their drug therapy reviewed. In uncomplicated chronic hypertension, a target blood pressure of <150/100 mmHg is recommended; women with target-organ damage as a result of chronic hypertension, and in women with chronic hypertension who have given birth, a target blood pressure of <140/90 mmHg is advised. Long-term antihypertensive treatment should be reviewed 2 weeks following the birth. Women managed with methyldopa during pregnancy should discontinue treatment and restart their original antihypertensive medication within 2 days of the birth.

Pregnant women are at high risk of developing pre-eclampsia if they have chronic kidney disease, diabetes mellitus, autoimmune disease, chronic hypertension, or if they have had hypertension during a previous pregnancy; these women are advised to take aspirin (section 2.9) in a dose of 75 mg once daily [unlicensed indication] from week 12 of pregnancy until the baby is born. Women with more than one moderate risk factor (first pregnancy, aged ≥40 years, pregnancy interval >10 years, BMI ≥35 kg/m² at first visit, multiple pregnancy, or family history of pre-eclampsia) for developing pre-eclampsia are also advised to take aspirin 75 mg once daily [unlicensed indication] from week 12 of pregnancy until the baby is born.

Women with pre-eclampsia or gestational hypertension who present with a blood pressure over 150/100 mmHg should receive initial treatment with oral labetalol to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg. If labetalol is unsuitable, methyldopa or modified-release nifedipine may be considered. Women with gestational hypertension or pre-eclampsia who have been managed with methyldopa during pregnancy should discontinue treatment within 2 days of the birth. Women with a blood pressure of ≥160/110 mmHg who require critical care during pregnancy or after birth should receive immediate treatment with either oral or intravenous labetalol, intravenous hydralazine (section 2.5.1), or oral modified-release nifedipine to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg.

For use of magnesium sulphate in pre-eclampsia and eclampsia, see section 9.5.1.3.

Hypertensive crises

If blood pressure is reduced too quickly in the management of hypertensive crises, there is a risk of reduced organ perfusion leading to cerebral infarction, blindness, deterioration in renal function, and myocardial ischaemia.

A hypertensive emergency is defined as severe hypertension with acute damage to the target organs (e.g. signs of papilloedema or retinal haemorrhage, or the presence of clinical conditions such as acute coronary syndromes, acute aortic dissection, acute pulmonary oedema, hypertensive encephalopathy, acute cerebral infarction, intracerebral or subarachnoid haemorrhage, eclampsia, or rapidly progressing renal failure); prompt treatment with intravenous antihypertensive therapy is generally required. Over the first few minutes or within 2 hours, blood pressure should be reduced by 20–25%.

When intravenous therapy is indicated, treatment options include sodium nitroprusside [unlicensed] (section 2.5.1), labetalol (section 2.4), glyceryl trinitrate (section 2.6.1), phentolamine (section 2.5.4), hydralazine (section 2.5.1), or esmolol (section 2.4); choice of drug is dependent on concomitant conditions and clinical status of the patient.

Severe hypertension (blood pressure ≥180/110 mmHg) without acute target-organ damage is defined as a hypertensive urgency; blood pressure should be reduced gradually over 24–48 hours with oral antihypertensive therapy, such as labetalol, or the calcium-channel block-
2.5.1 Vasodilator antihypertensive drugs

Vasodilators have a potent hypotensive effect, especially when used in combination with a beta-blocker and a thiazide. Important: for a warning on the hazards of a very rapid fall in blood pressure, see Hypertensive crises, p. 106.

Diazoxide has been used by intravenous injection in hypertensive emergencies, however alternative treatments are preferred (see section 2.5).

Hydralazine is given by mouth as an adjunct to other antihypertensives for the treatment of resistant hypertension but is rarely used; when used alone it causes tachycardia and fluid retention. The incidence of side-effects is lower if the dose is kept below 100 mg daily, but systemic lupus erythematosus should be suspected if there is unexplained weight loss, arthritis, or any other unexplained ill health.

Sodium nitroprusside [unlicensed] is given by intravenous infusion to control severe hypertensive emergencies when parenteral treatment is necessary.

Minoxidil should be reserved for the treatment of severe hypertension resistant to other drugs. Vasodilation is accompanied by increased cardiac output and tachycardia and the patients develop fluid retention. For this reason the addition of a beta-blocker and a diuretic (usually furosemide, in high dosage) are mandatory. Hypertrichosis is troublesome and renders this drug unsuitable for women.

Prazosin, doxazosin, and terazosin (section 2.5.4) have alpha-blocking and vasodilator properties.

Ambrisentan, bosentan, iloprost, sildenafil, sitaxentan, and tadalafil are licensed for the treatment of pulmonary arterial hypertension and should be used under specialist supervision. Epoprostenol (section 2.8.1) can be used in patients with primary pulmonary hypertension resistant to other treatments. Bosentan is also licensed to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

The Scottish Medicines Consortium (p. 4) has advised (November 2005) that iloprost (Ventavis®) is accepted for restricted use within NHS Scotland in patients in whom bosentan is ineffective or not tolerated, and should only be prescribed by specialists in the Scottish Pulmonary Vascular Unit.

The Scottish Medicines Consortium (p. 4) has advised (October 2008) that ambrisentan (Volibris®) should be prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.

The Scottish Medicines Consortium (p. 4) has advised (January 2010) that sildenafil (Revatio®) should be prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.

Sitaxentan

Sitaxentan (Thelin®) is to be withdrawn from worldwide markets due to severe, sometimes fatal, hepatotoxicity; the benefits of treatment with sitaxentan no longer outweigh the risks. Patients currently taking sitaxentan are advised not to stop until their treatment has been reviewed by their prescriber; patients should be switched to a suitable alternative as soon as possible. Patients with abnormal liver function tests at the time of sitaxentan discontinuation should be monitored regularly until liver enzymes return to within the normal range.

**AMBRISENTAN**

Indications pulmonary arterial hypertension

Cautions not to be initiated in significant anaemia; monitor haemoglobin concentration or haematocrit after 1 month and 3 months of starting treatment, and periodically thereafter (reduce dose or discontinue treatment if significant decrease in haemoglobin concentration or haematocrit observed); monitor liver function before treatment, and monthly thereafter—discontinue if liver enzymes raised significantly or if symptoms of liver impairment develop

Hepatic impairment avoid in severe impairment

Renal impairment use with caution if eGFR less than 30 mL/minute/1.73 m²

Pregnancy avoid (teratogenic in animal studies); exclude pregnancy before treatment and ensure effective contraception during treatment; monthly pregnancy tests advised

Breast-feeding manufacturer advises avoid—no information available

Side-effects abdominal pain, constipation; palpitation, flushing, peripheral oedema; upper respiratory-tract disorders; headache; anaemia; less commonly hypersensitivity reactions (including angioedema and rash)

Dose

- **ADULT** over 18 years, 5 mg once daily, increased if necessary to 10 mg once daily

Volibris® (GSK) ▼ Tablet, f/c, ambrisentan 5 mg (pale pink), net price 30-tab pack = £1618.08; 10 mg (dark pink), 30-tab pack = £1618.08

**BOSENTAN**

Indications pulmonary arterial hypertension; systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers)

Cautions not to be initiated if systemic systolic blood pressure is below 85 mmHg; monitor haemoglobin before and during treatment (monthly for first 4 months, then 3-monthly); avoid abrupt withdrawal; monitor liver function before treatment, at monthly intervals during treatment, and 2 weeks after dose increase (reduce dose or suspend treatment if liver enzymes raised significantly)—discontinue if symptoms of liver impairment; interactions: Appendix 1 (bosentan)

Contra-indications acute porphyria (section 9.8.2)

Hepatic impairment avoid in moderate and severe impairment
Pregnancy avoid (teratogenic in animal studies); effective contraception required during and for at least 3 months after administration (hormonal contraception not considered effective); monthly pregnancy tests advised

Breast-feeding manufacturer advises avoid—no information available

Side-effects gastrointestinal disturbances, dry mouth, rectal haemorrhage, hepatic impairment (see Cautions; above); flushing, hypotension, palpitation, oedema, chest pain; dyspnoea; headache, dizziness, fatigue; back pain and pain in extremities; anaemia; hypersensitivity reactions (including rash, pruritus, and anaphylaxis)

Dose
- Pulmonary arterial hypertension, initially 62.5 mg twice daily increased after 4 weeks to 125 mg twice daily; CHILD under 12 twice daily
- Systemic sclerosis with ongoing digital ulcer disease, initially 62.5 mg twice daily increased after 4 weeks to 125 mg twice daily

Tracleer® (Actelion) ▼ ▽
- Tablets, 2.5 mg/mL, yellow, s/c, diazoxide 15 mg/mL, net price 20-mL amp = £8.26
- Injection, diazoxide 15 mg/mL, net price 20-mL amp = £20.00

HYDRAZINE HYDROCHLORIDE

Indications moderate to severe hypertension (adjunct); heart failure (with long-acting nitrate, but see section 2.5.5); hypertensive emergencies (including during pregnancy) (see section 2.5)

Cautions coronary artery disease (may provoke angina, avoid after myocardial infarction until stabilised); cerebrovascular disease; occasionally blood pressure reduction too rapid even with low parental doses; manufacturer advises test for antinuclear factor and for proteinuria every 6 months and check acetylator status before increasing dose above 100 mg daily, but evidence of clinical value unsatisfactory; interactions: Appendix 1 (hydralazine)

Contra-indications idiopathic systemic lupus erythematosus, severe tachycardia, high output heart failure, myocardial insufficiency due to mechanical obstruction, cor pulmonale, dissecting aortic aneurysm; acute porphyria (section 9.8.2)

Hepatic impairment reduce dose

Renal impairment reduce dose if eGFR less than 30 mL/minute/1.73 m²

Pregnancy neonatal thrombocytopenia reported, but risk should be balanced against risk of uncontrolled maternal hypertension; manufacturer advises avoid before third trimester

Breast-feeding present in milk but not known to be harmful; monitor infant

Side-effects tachycardia, palpitation, flushing, hypotension, fluid retention, gastro-intestinal disturbances; headache, dizziness; systemic lupus erythematosus-like syndrome after long-term therapy with over 100 mg daily (or less in women and in slow acetylator individuals) (see also notes above); rarely rashes, fever, peripheral neuritis, polynuertitis, paraesthesia, arthralgia, myalgia, increased lacrimation, nasal congestion, dyspnoea, agitation, anxiety, anorexia; blood disorders (including leucopenia, thrombocytopenia, haemolytic anaemia), abnormal liver function, jaundice, raised plasma creatinine, proteinuria and haematuria reported

Dose
- By mouth, hypertension, 25 mg twice daily, increased to usual max. 50 mg twice daily (see notes above)
  - Heart failure (initiated in hospital) 25 mg 3–4 times daily, increased every 2 days if necessary; usual maintenance dose 50–75 mg 4 times daily
  - By slow intravenous injection, hypertensive emergencies and hypertension with renal complications, 5–10 mg diluted with 10 mL sodium chloride 0.9%; may be repeated after 20–30 minutes (see Cautions)
  - By intravenous infusion, hypertensive emergencies and hypertension with renal complications, initially 200–300 micrograms/minute; maintenance usually 50–150 micrograms/minute

Hydralazine (Non-proprietary) ▽
- Tablets, hydralazine hydrochloride 25 mg, net price 56 = £9.32; 50 mg, 56 = £16.84
- Apresoline® (Amidipharm) ▽
  - Tablets, yellow, s/c, hydralazine hydrochloride 25 mg, net price 84-tab pack = £3.38
  - Excipients include gluten

Injection, powder for reconstitution, hydralazine hydrochloride, net price 20-mg amp = £2.22

ILOPROST

Indications idiopathic or familial pulmonary arterial hypertension

Cautions unstable pulmonary hypertension with advanced right heart failure; hypotension (do not initiate if systolic blood pressure below 85 mmHg); acute pulmonary infection; chronic obstructive pulmonary disease; severe asthma; interactions: Appendix 1 (iloprost)

Contra-indications unstable angina; within 6 months of myocardial infarction; decompensated cardiac failure (unless under close medical supervision);
severe arrhythmias; congenital or acquired heart-valve defects; within 3 months of cerebrovascular events; pulmonary veno-occlusive disease; conditions which increase risk of bleeding

**Hepatic impairment** elimination reduced—initially 2.5 micrograms no more frequently than every 3 hours (max. 6 times daily), adjusted according to response (consult product literature)

**Pregnancy** manufacturer advises avoid (toxicity in animal studies); effective contraception must be used during treatment

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** vasodilatation, hypotension, syncope, cough, headache, throat or jaw pain; nausea, vomiting, diarrhoea, chest pain, dyspnoea, bronchospasm, and wheezing also reported

**Dose**
- By inhalation of nebulised solution, initial dose 2.5 micrograms increased to 5 micrograms for second dose, if tolerated maintain at 5 micrograms 6–9 times daily according to response; reduce to 2.5 micrograms 6–9 times daily if higher dose not tolerated; CHILD 8–18 years see **BNF for Children**

**Ventavis®** (Bayer Schering) \( ^{TM} \)
**Nebuliser solution**, iloprost (as trometamol)
10 micrograms/mL, net price 30 \( \times \) 1-mL (10-microgram unit-dose vials = £400.19, 168 \( \times \) 1-mL = £2241.08. For use with **Prodose** or **Venta-Neb** nebuliser

---

**MINOXIDIL**

**Indications** severe hypertension, in addition to a diuretic and a beta-blocker

**Cautions** see notes above: angina; after myocardial infarction (until stabilised); lower doses in dialysis patients; acute porphyria (section 9.8.2); interactions: Appendix 1 (vasodilator antihypertensives)

**Contra-indications** phaeochromocytoma

**Renal impairment** use with caution in significant impairment

**Pregnancy** avoid—possible toxicity including reduced placental perfusion; neonatal hirsutism reported

**Breast-feeding** present in milk but not known to be harmful

**Side-effects** sodium and water retention; weight gain, peripheral oedema, tachycardia, hypertrichosis; reversible rise in creatinine and blood urea nitrogen; occasionally, gastro-intestinal disturbances, breast tenderness, rashes

**Dose**
- Initially 5 mg (ELDERLY, 2.5 mg) daily, in 1–2 divided doses, increased in steps of 5–10 mg at intervals of at least 3 days; max. 100 mg daily (seldom necessary to exceed 50 mg daily)

**Loniten®** (Pharmacia) \( ^{TM} \)
**Tablets**, scored, minoxidil 2.5 mg, net price 60-tab pack = £8.88; 5 mg, 60-tab pack = £15.83; 10 mg, 60-tab pack = £30.68

---

**SILDENAFIL**

**Indications** pulmonary arterial hypertension; erectile dysfunction (section 7.4.5)

**Cautions** hypotension (avoid if systolic blood pressure below 90 mmHg); intravascular volume depletion; left ventricular outflow obstruction; cardiovascular disease; autonomic dysfunction; pulmonary veno-occlusive disease; anatomical deformation of the penis, predisposition to priapism; bleeding disorders or active peptic ulceration; consider gradual withdrawal; interactions: Appendix 1 (sildenafil)

**Contra-indications** recent history of stroke or myocardial infarction, history of non-arteritic anterior ischaemic optic neuropathy; hereditary degenerative retinal disorders; avoid concomitant use of nitrates

**Hepatic impairment** for pulmonary hypertension, if usual dose not tolerated, reduce oral dose to 20 mg twice daily, or reduce intravenous dose to 10 mg twice daily; manufacturer advises avoid in severe impairment

**Renal impairment** for pulmonary hypertension, if usual dose not tolerated, reduce oral dose to 20 mg twice daily, or reduce intravenous dose to 10 mg twice daily

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—no evidence of harm in animal studies

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances, dry mouth; flushing, oedema; bronchitis; cough; headache, migraine, night sweats, paraesthesia, insomnia; anxiety, tremor, vertigo; fever, influenza-like symptoms; anaemia; back and limb pain, myalgia; visual disturbances, retinal haemorrhage, photophobia, painful red eyes; nasal congestion, epistaxis; cellulitis, alopecia; less commonly gynaecomastia, priapism; also reported rash, retinal vascular occlusion and non-arteritic anterior ischaemic optic neuropathy (discontinue if sudden visual impairment), and sudden hearing loss (advise patient to seek medical help)

**Dose**
- By mouth, 20 mg 3 times daily; CHILD under 18 years see **BNF for Children**
- By intravenous injection, when oral route not appropriate, 10 mg three times daily

**Revatio®** (Pfizer) \( ^{TM} \)
**Tablets**, f/c, sildenafil (as citrate), 20 mg, net price 90-tab pack = £373.50
**Injection**, sildenafil (as citrate), 800 micrograms/mL, net price 50-mL vial = £45.28

**Viagra®** (Pfizer) \( ^{TM} \)
Section 7.4.5 (erectile dysfunction)

---

**SITAXENTAN SODIUM**

**Indications** pulmonary arterial hypertension (but see notes above)

**Cautions** test liver function before treatment and monitor monthly during treatment (discontinue treatment if liver enzymes significantly raised); measure haemoglobin concentration before treatment, after 1–3 months, then every 3 months; interactions: Appendix 1 (sitaxentan)

**Hepatic impairment** avoid

**Pregnancy** avoid unless essential—toxicity in animal studies; manufacturer advises effective contraception during treatment

---
2.5.2 Centrally acting antihypertensive drugs

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects gastro-intestinal disturbances; peripheral oedema, flushing; headache, insomnia, fatigue, dizziness; decreased haemoglobin, prolonged prothrombin time, increased INR; muscle cramp; nasal congestion, epistaxis

Dose
  • ADULT over 18 years 100 mg once daily

Thelin® (Encysive) ▼ (BNF)

Tablets, f/c, yellow-orange, sitaxentan sodium 100 mg, net price 28-tab pack = £1540.00

Note All orders of Thelin should be based on a prescription from a specialist in Pulmonary Arterial Hypertension, who has received appropriate training as part of the Programmed Access to Sitaxentan Sodium (PASS) scheme. Orders should be placed with Polarspeed at 01525 217211

Sodium Nitroprusside

Indications hypertensive emergencies (see section 2.5); controlled hypotension in anaesthesia; acute or chronic heart failure

Cautions hypothyroidism, hyponaetraemia, ischaemic heart disease, impaired cerebral circulation, elderly; hypothermia; monitor blood pressure and blood-cyanide concentration and if treatment exceeds 3 days, also blood-thiocyanate concentration; avoid sudden withdrawal—terminate infusion over 15–30 minutes; protect infusion from light; interactions: Appendix 1 (sodium nitroprusside)

Contra-indications severe vitamin B12 deficiency; Leber’s optic atrophy; compensatory hypertension

Hepatic impairment use with caution; avoid in hepatic failure—cyanide or thiocyanate metabolites may accumulate

Renal impairment avoid prolonged use—cyanide or thiocyanate metabolites may accumulate

Pregnancy avoid prolonged use—potential for accumulation of cyanide in fetus

Breast-feeding no information available; caution advised due to thiocyanate metabolite

Side-effects associated with rapid reduction in blood pressure (reduce infusion rate): headache, dizziness, nausea, retching, abdominal pain, perspiration, palpitation, anxiety, retrosternal discomfort; occasionally reduced platelet count, acute transient phlebitis

Cyanide Side-effects caused by excessive plasma concentration of the cyanide metabolite include tachycardia, hypertension, seizures, myalgia, back and limb pain, increased uterine bleeding, blurred vision, facial oedema, rash; less commonly tachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis; also reported unstable angina, arrhythmia, myocardial infarction, stroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy, visual field defect, Stevens-Johnson syndrome

Dose
  • ADULT over 18 years 40 mg once daily

Adcirca® (Lilly) ▼ (BNF)

Tablets, f/c, tadalafil 20 mg (orange), net price 56-tab pack = £491.22

Tadalafil

Indications pulmonary arterial hypertension; erectile dysfunction (section 7.4.5)

Cautions hypotension (avoid if systolic blood pressure below 90 mmHg); aortic and mitral valve disease; pericardial constriction; congestive cardiomyopathy; left ventricular dysfunction; life-threatening arrhythmias; coronary artery disease; uncontrolled hypertension; pulmonary veno-occlusive disease; predisposition to priapism; anatomical deformation of the penis; hereditary degenerative retinal disorders; interactions: Appendix 1 (tadalafil)

Contra-indications acute myocardial infarction in past 90 days; history of non-arteritic anterior ischaemic optic neuropathy; avoid concomitant use of nitrates

Hepatic impairment initially 20 mg once daily in mild to moderate impairment; avoid in severe impairment

Renal impairment initially 20 mg once daily in mild to moderate impairment, increased to 40 mg once daily if tolerated; avoid in severe impairment

Pregnancy manufacturer advises avoid

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects nausea, vomiting, dyspepsia, gastrooesophageal reflux, chest pain, palpitation, flushing, hypotension, nasopharyngitis, epistaxis, headache, myalgia, back and limb pain, increased uterine bleeding, blurred vision, facial oedema, rash; less commonly tachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis; also reported unstable angina, arrhythmia, myocardial infarction, stroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy, retinal vascular occlusion, visual field defect, Stevens-Johnson syndrome

Dose
  • ADULT over 18 years 100 mg once daily

Methyl Dopamine 100 mg, net price 28-tab pack = £1540.00

Note All orders of Thelin should be based on a prescription from a specialist in Pulmonary Arterial Hypertension, who has received appropriate training as part of the Programmed Access to Sitaxentan Sodium (PASS) scheme. Orders should be placed with Polarspeed at 01525 217211

SODIUM NITROPRUSSIDE

Indications hypertensive emergencies (see section 2.5); controlled hypotension in anaesthesia; acute or chronic heart failure

Cautions hypothyroidism, hyponaetraemia, ischaemic heart disease, impaired cerebral circulation, elderly; hypothermia; monitor blood pressure and blood-cyanide concentration and if treatment exceeds 3 days, also blood-thiocyanate concentration; avoid sudden withdrawal—terminate infusion over 15–30 minutes; protect infusion from light; interactions: Appendix 1 (sodium nitroprusside)

Contra-indications severe vitamin B12 deficiency; Leber’s optic atrophy; compensatory hypertension

Hepatic impairment use with caution; avoid in hepatic failure—cyanide or thiocyanate metabolites may accumulate

Renal impairment avoid prolonged use—cyanide or thiocyanate metabolites may accumulate

Pregnancy avoid prolonged use—potential for accumulation of cyanide in fetus

Breast-feeding no information available; caution advised due to thiocyanate metabolite

Side-effects associated with rapid reduction in blood pressure (reduce infusion rate): headache, dizziness, nausea, retching, abdominal pain, perspiration, palpitation, anxiety, retrosternal discomfort; occasionally reduced platelet count, acute transient phlebitis

Cyanide Side-effects caused by excessive plasma concentration of the cyanide metabolite include tachycardia, hypertension, seizures, myalgia, back and limb pain, increased uterine bleeding, blurred vision, facial oedema, rash; less commonly tachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis; also reported unstable angina, arrhythmia, myocardial infarction, stroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy, visual field defect, Stevens-Johnson syndrome

Dose
  • ADULT over 18 years 40 mg once daily

Adcirca® (Lilly) ▼ (BNF)

Tablets, f/c, tadalafil 20 mg (orange), net price 56-tab pack = £491.22

Tadalafil

Indications pulmonary arterial hypertension; erectile dysfunction (section 7.4.5)

Cautions hypotension (avoid if systolic blood pressure below 90 mmHg); aortic and mitral valve disease; pericardial constriction; congestive cardiomyopathy; left ventricular dysfunction; life-threatening arrhythmias; coronary artery disease; uncontrolled hypertension; pulmonary veno-occlusive disease; predisposition to priapism; anatomical deformation of the penis; hereditary degenerative retinal disorders; interactions: Appendix 1 (tadalafil)

Contra-indications acute myocardial infarction in past 90 days; history of non-arteritic anterior ischaemic optic neuropathy; avoid concomitant use of nitrates

Hepatic impairment initially 20 mg once daily in mild to moderate impairment; avoid in severe impairment

Renal impairment initially 20 mg once daily in mild to moderate impairment, increased to 40 mg once daily if tolerated; avoid in severe impairment

Pregnancy manufacturer advises avoid

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects nausea, vomiting, dyspepsia, gastro-oesophageal reflux, chest pain, palpitation, flushing, hypotension, nasopharyngitis, epistaxis, headache, myalgia, back and limb pain, increased uterine bleeding, blurred vision, facial oedema, rash; less commonly tachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis; also reported unstable angina, arrhythmia, myocardial infarction, stroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy, retinal vascular occlusion, visual field defect, Stevens-Johnson syndrome

Dose
  • ADULT over 18 years 100 mg once daily

Methyl Dopamine 100 mg, net price 28-tab pack = £1540.00

Note All orders of Thelin should be based on a prescription from a specialist in Pulmonary Arterial Hypertension, who has received appropriate training as part of the Programmed Access to Sitaxentan Sodium (PASS) scheme. Orders should be placed with Polarspeed at 01525 217211

SODIUM NITROPRUSSIDE

Indications hypertensive emergencies (see section 2.5); controlled hypotension in anaesthesia; acute or chronic heart failure

Cautions hypothyroidism, hyponaetraemia, ischaemic heart disease, impaired cerebral circulation, elderly; hypothermia; monitor blood pressure and blood-cyanide concentration and if treatment exceeds 3 days, also blood-thiocyanate concentration; avoid sudden withdrawal—terminate infusion over 15–30 minutes; protect infusion from light; interactions: Appendix 1 (sodium nitroprusside)

Contra-indications severe vitamin B12 deficiency; Leber’s optic atrophy; compensatory hypertension

Hepatic impairment use with caution; avoid in hepatic failure—cyanide or thiocyanate metabolites may accumulate

Renal impairment avoid prolonged use—cyanide or thiocyanate metabolites may accumulate

Pregnancy avoid prolonged use—potential for accumulation of cyanide in fetus

Breast-feeding no information available; caution advised due to thiocyanate metabolite

Side-effects associated with rapid reduction in blood pressure (reduce infusion rate): headache, dizziness, nausea, retching, abdominal pain, perspiration, palpitation, anxiety, retrosternal discomfort; occasionally reduced platelet count, acute transient phlebitis

Cyanide Side-effects caused by excessive plasma concentration of the cyanide metabolite include tachycardia, sweating, hyperventilation, arrhythmias, marked metabolic acidosis (discontinue and give antidote, see p. 39)

Dose
  • Hypertensive emergencies, by intravenous infusion, initially 0.5–1.5 micrograms/kg/minute, then increased in steps of 500 nanograms/kg/minute every 5 minutes within range 0.5–8 micrograms/kg/minute (lower doses if already receiving other anti-hypertensives); stop if response unsatisfactory with max. dose in 10 minutes
  • Maintenance of blood pressure at 30–40% lower than pretreatment diastolic blood pressure, 20–400 micrograms/minute (lower doses for patients being treated with other antihypertensives)

Methyldopa

Methyldopa is a centrally acting antihypertensive; it may be used for the management of hypertension in pregnancy. Side-effects are minimised if the daily dose is kept below 1 g.

Clonidine has the disadvantage that sudden withdrawal of treatment may cause severe rebound hypertension.

Moxonidine, a centrally acting drug, is licensed for mild to moderate essential hypertension. It may have a role when thiazides, calcium-channel blockers, ACE inhibitors, and beta-blockers are not appropriate or have failed to control blood pressure.
### CLONIDINE HYDROCHLORIDE

**Indications**  
Hypertension; migraine (section 4.7.4.2); menopausal flushing (section 6.4.1.1)

**Cautions**  
Must be withdrawn gradually to avoid severe rebound hypertension; Raynaud’s syndrome or other occlusive peripheral vascular disease; history of depression; interactions: Appendix 1 (clonidine)

**Driving**  
Drowsiness may affect performance of skilled tasks (e.g., driving); effects of alcohol may be enhanced

**Pregnancy**  
May lower fetal heart rate, but risk should be balanced against risk of uncontrolled maternal hypertension; avoid intravenous injection

**Breast-feeding**  
Manufacturer advises avoid—present in milk

**Side-effects**  
Dry mouth, sedation, depression, fluid retention, bradycardia, Raynaud’s phenomenon, headache, dizziness, euphoria, nocturnal unrest, rash, nausea, constipation, rarely impotence

**Dose**  
- By mouth, 50–100 micrograms 3 times daily, increased every second or third day; usual max. dose 1.2 mg daily

**Catapres® (Boehringer Ingelheim)**  
Tablets, scored, clonidine hydrochloride 100 micrograms, net price 100-tab pack = £5.32; 300 micrograms, 100-tab pack = £12.39. Label: 3, 8

**Dixart® **  
Section 4.7.4.2

### METHYLDOPA

**Indications**  
Hypertension

**Cautions**  
Monitor blood counts and liver-function before treatment and at intervals during first 6–12 weeks or if unexplained fever occurs; history of depression; positive direct Coombs’ test in up to 20% of patients (may affect blood cross-matching); interference with laboratory tests; interactions: Appendix 1 (methyldopa)

**Driving**  
Drowsiness may affect performance of skilled tasks (e.g., driving); effects of alcohol may be enhanced

**Contra-indications**  
Depression, phaeochromocytoma; acute porphyria (section 9.8.2)

**Hepatic impairment**  
Manufacturer advises caution in hepatic function tests; avoid in active liver disease

**Renal impairment**  
Start with small dose; increased sensitivity to hypotensive and sedative effect

**Pregnancy**  
Not known to be harmful

**Breast-feeding**  
Amount too small to be harmful

**Side-effects**  
Gastro-intestinal disturbances, dry mouth, stomatitis, sialadenitis; bradycardia, exacerbation of angina, postural hypotension, oedema; sedation, headache, dizziness, asthenia, myalgia, arthralgia, paraesthesia, nightmares, mild psychosis, depression, impaired mental acuity; Parkinsonism, Bell’s palsy; hepatitis, jaundice; pancreatitis; haemolytic anaemia; bone-marrow depression, leucopenia, thrombocytopenia, eosinophilia; hypersensitivity reactions including lupus erythematosus-like syndrome, drug fever, myocarditis, pericarditis; rashes (including toxic epidermal necrolysis); nasal congestion, failure of ejaculation, impotence, decreased libido, gynaecomastia, hyperprolactinaemia, amenorrhoea

**Dose**  
- Initially 250 mg 2–3 times daily, increased gradually at intervals of at least 2 days, max. 3 g daily; Elderly initially 125 mg twice daily, increased gradually, max. 2 g daily

**Methyldopa (Non-proprietary) Tablets**  
Coated, methyldopa (anhydrous) 125 mg, net price 56-tab pack = £16.29; 250 mg, 56-tab pack = £8.26; 500 mg, 56-tab pack = £11.49. Label: 3, 8

**Aldomet® (Rofok) Tablets**  
All yellow, f/c, methyldopa (anhydrous) 250 mg, net price 60 = £6.15; 500 mg, 30 = £4.55. Label: 3, 8

### MOXONIDINE

**Indications**  
Mild to moderate essential hypertension

**Cautions**  
Avoid abrupt withdrawal (if concomitant treatment with beta-blocker has to be stopped, discontinue beta-blocker first, then moxonidine after a few days); severe coronary artery disease; unstable angina; first-degree AV block; moderate heart failure; interactions: see Appendix 1 (moxonidine)

**Contra-indications**  
Conduction disorders (sick sinus syndrome, sino-atrial block, second- or third-degree AV block); bradycardia; severe heart failure

**Renal impairment**  
Max. single dose 200 micrograms and max. daily dose 400 micrograms if eGFR 30–60 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy**  
Manufacturer advises avoid—no information available

**Breast-feeding**  
Present in milk—manufacturer advises avoid

**Side-effects**  
Dry mouth, diarrhoea, nausea, vomiting, headache, dizziness, euphoria, nocturnal unrest, rash, retention, bradycardia, Raynaud’s phenomenon, interference with laboratory tests; interactions: Appendix 1 (moxonidine)

**Moxonidine (Non-proprietary) Tablets**  
f/c, moxonidine 200 micrograms, net price 28-tab pack = £3.76; 300 micrograms, net price 28-tab pack = £4.82; 400 micrograms, net price 28-tab pack = £5.01. Label: 3

**Physiotens® (Solvay) Tablets**  
f/c, moxonidine 200 micrograms (pink), net price 28-tab pack = £9.72; 300 micrograms (red), 28-tab pack = £11.49; 400 micrograms (red), 28-tab pack = £13.26. Label: 3

### 2.5.3 Adrenergic neurone blocking drugs

Adrenergic neurone blocking drugs prevent the release of noradrenaline from postganglionic adrenergic neurones. These drugs do not control supine blood pressure and may cause postural hypotension. For this reason they have largely fallen from use, but may be necessary with other therapy in resistant hypertension.
2 Cardiovascular system

Guanethidine, which also depletes the nerve endings of noradrenaline, is licensed for rapid control of blood pressure, however alternative treatments are preferred (see section 2.5).

**GUANETHIDINE MONOSULPHATE**

**Indications** hypertensive crisis (but no longer recommended—see section 2.5)

**Cautions** coronary or cerebral arteriosclerosis, asthma, history of peptic ulceration; **interactions:** Appendix 1 (adrenergic neurone blockers)

**Contra-indications** phaeochromocytoma, heart failure

**Renal impairment** reduce dose if eGFR 40–65 mL/minute/1.73 m²; avoid if eGFR less than 40 mL/minute/1.73 m²

**Pregnancy** postural hypotension and reduced utero-placental perfusion; should not be used to treat hypertension in pregnancy

**Side-effects** postural hypotension, failure of ejaculation, fluid retention, nasal congestion, headache, diarrhoea, drowsiness

**Dose**
- By intramuscular injection, 10–20 mg, repeated after 3–6 hours if required
- Ismelin® (Amdipharm) Injection, guanethidine monosulphate 10 mg/mL, net price 1-mL amp = £1.56

**2.5.4 Alpha-adrenoceptor blocking drugs**

Prazosin has post-synaptic alpha-blocking and vasodilator properties and rarely causes tachycardia. It may, however, reduce blood pressure rapidly after the first dose and should be introduced with caution. Doxazosin, indoramin, and terazosin have properties similar to those of prazosin. Alpha-blockers can be used with other antihypertensive drugs in the treatment of resistant hypertension (section 2.5).

**Prostatic hyperplasia** Alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, and terazosin are indicated for benign prostatic hyperplasia (section 7.4.1).

**DOXAZOSIN**

**Indications** hypertension (see notes above); benign prostatic hyperplasia (section 7.4.1)

**Cautions** care with initial dose (postural hypotension); pulmonary oedema due to aortic or mitral stenosis; cataract surgery (risk of intra-operative floppy iris syndrome); heart failure; **interactions:** Appendix 1 (alpha-blockers)

**Driving** May affect performance of skilled tasks e.g. driving

**Contra-indications** history of hypotension; monotherapy in overflow bladder or anuria

**Hepatic impairment** use with caution; manufacturer advises in severe impairment—no information available

**Pregnancy** no evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk

**Breast-feeding** accumulates in milk—manufacturer advises avoid

**Side-effects** see section 7.4.1; also dyspnoea, coughing, fatigue, vertigo, paraesthesia, sleep disturbance, anxiety, influenza-like symptoms; back pain, myalgia; less commonly weight changes, angina, myocardial infarction, hypoaesthesia, tremor, agitation, micturition disturbance, epistaxis, arthralgia, tinnitus, and gout; very rarely cholestasis, hepatitis, jaundice, bradycardia, arrhythmias, bronchospasm, hot flushes, gynaecomastia, abnormal ejaculation, leucopenia, thrombocytopenia, and alopecia

**Dose**
- Hypertension, 1 mg daily, increased after 1–2 weeks to 2 mg once daily, and thereafter to 4 mg once daily, if necessary; max. 16 mg daily

**Doxazosin** (Non-proprietary) 

**Tablets**
- Tablets, doxazosin (as mesilate) 1 mg, net price 28-tab pack = £9.39; 2 mg, 28-tab pack = £9.98; 4 mg, 28-tab pack = £11.39. Counselling, initial dose, driving

**Brands include** Doxadura®

**Cardura®** (Pfizer) 

**Tablets**
- Tablets, doxazosin (as mesilate) 1 mg, net price 28-tab pack = £10.56; 2 mg, 28-tab pack = £14.08. Counselling, initial dose, driving

**Modified-release**

**Doxazosin** (Non-proprietary) 

**Tablets**
- Tablets, m/r, doxazosin (as mesilate) 4 mg, net price 28-tab pack = £6.33. Label: 25, counselling, initial dose, driving

**Dose** hypertension, benign prostatic hyperplasia, 4 mg once daily, increased to 8 mg once daily after 4 weeks if necessary

**Brands include** Doxadura® XL, Rapores® XL, Slocinx® XL

**Cardura®** (Pfizer) 

**Tablets**
- Tablets, m/r, doxazosin (as mesilate) 4 mg, net price 28-tab pack = £5.70; 8 mg, 28-tab pack = £9.98. Label: 25, counselling, driving, initial dose

**Dose** hypertension, benign prostatic hyperplasia, 4 mg once daily, increased to 8 mg once daily after 4 weeks if necessary

**INDORAMIN**

**Indications** hypertension (see notes above); benign prostatic hyperplasia (section 7.4.1)

**Cautions** avoid alcohol (enhances rate and extent of absorption); control incipient heart failure before initiating indoramin; elderly; Parkinson’s disease (extrapyramidal disorders reported); epilepsy (convulsions in animal studies); history of depression, cataract surgery (risk of intra-operative floppy iris syndrome); **interactions:** Appendix 1 (alpha-blockers)

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced

**Contra-indications** established heart failure

**Hepatic impairment** manufacturer advises caution

**Renal impairment** manufacturer advises caution

**Pregnancy** no evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk

**Breast-feeding** no information available

**Side-effects** see section 7.4.1; also sedation; less commonly fatigue, weight gain, failure of ejaculation;
Phaeochromocytoma

Long-term management of phaeochromocytoma involves surgery. However, surgery should not take place until there is adequate blockade of both alpha- and beta-adrenoceptors; the optimal choice of drug therapy remains unclear. Alpha-blockers are used in the short-term management of hypertensive episodes in phaeochromocytoma. Once alpha blockade is established, tachycardia can be controlled by the cautious addition of a beta-blocker (section 2.4); a cardioselective beta-blocker is preferred.

Phenoxybenzamine, a powerful alpha-blocker, is effective in the management of phaeochromocytoma but it has many side-effects. Phentolamine is a short-acting alpha-blocker used mainly during surgery of phaeochromocytoma; its use for the diagnosis of phaeochromocytoma has been superseded by measurement of catecholamines in blood and urine.

Metiozine (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) inhibits the enzyme tyrosine hydroxylase, and hence the synthesis of catecholamines. It is rarely used in the pre-operative management of phaeochromocytoma, and long term in patients unsuitable for surgery; an

Also reported extrapyramidal disorders, urinary frequency, and incontinence

**Dose**

- Hypertension, initially 25 mg twice daily, increased by 25–50 mg daily at intervals of 2 weeks; max. daily dose 200 mg in 2–3 divided doses
- Raynaud’s syndrome (but efficacy not established; see section 2.6.4); benign prostatic hyperplasia (section 7.4.1)
- Congestive heart failure (but see section 2.5.5; see also section 2.6.4); benign prostatic hyperplasia (section 7.4.1)
- Hypertension (see notes above), 500 micrograms 2–3 times daily followed by 1 mg at bedtime (compliance with long-term treatment important)
- Renal impairment initially 500 micrograms daily in moderate to severe impairment; increased with caution
- Pregnancy no evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk
- Breast-feeding no information available

**PRAZOSIN**

**Indications** hypertension (see notes above); congestive heart failure (but see section 2.5.5); Raynaud’s syndrome (see also section 2.6.4); benign prostatic hyperplasia (section 7.4.1)

**Cautions** first dose may cause collapse due to hypotension (therefore should be taken on retiring to bed); elderly; cataract surgery (risk of intra-operative floppy iris syndrome); interactions: Appendix 1 (alpha-blockers)

**Driving** May affect performance of skilled tasks e.g. driving

**Contra-indications** not recommended for congestive heart failure due to mechanical obstruction (e.g. aortic stenosis)

**Hepatic impairment** initially 500 micrograms daily; increased with caution

**Renal impairment** initially 500 micrograms daily in moderate to severe impairment; increased with caution

**Pregnancy** no evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk

**Breast-feeding** amount probably too small to be harmful

**Side-effects** see section 7.4.1; also drowsiness; nervousness; urinary frequency; less commonly insomnia, paraesthesia, sweating, arthritis, eye disorders, tinnitus, and epistaxis; rarely pancreatitis, flushing, vasculitis, bradycardia, hallucinations, worsening of hyperplasia (section 7.4.1)

**Dose**

- Hypertension (see notes above), 500 micrograms 2–3 times daily for 3–7 days, the initial dose on retiring to bed (to avoid collapse, see Cautions); increased to 1 mg 2–3 times daily for a further 3–7 days; further increased if necessary to max. 20 mg daily in divided doses
- Congestive heart failure (but see section 2.5.5), 500 micrograms 2–4 times daily for 3–7 days, the initial dose on retiring to bed (to avoid collapse, see Cautions); increased to 1 mg 2–3 times daily for a further 3–7 days; further increased if necessary to max. 20 mg daily in divided doses
- Raynaud’s syndrome (but efficacy not established, see section 2.6.4), initially 500 micrograms twice daily (initial dose at bedtime, see above) increased, if necessary, after 3–7 days to usual maintenance 1–2 mg twice daily

**Prazosin** (Non-proprietary)

**Pharmaceuticals** Tablets, prazosin (as hydrochloride) 500 micrograms, net price 60-tab pack = £2.51; 1 mg, 60-tab pack = £3.23; 2 mg, 56-tab pack = £4.39; 5 mg, 56-tab pack = £8.75. Counselling, initial dose, driving

**HYPOVASE®** (Pfizer)

**Pharmaceuticals** Tablets, prazosin (as hydrochloride) 500 micrograms, net price 60-tab pack = £2.69; 1 mg, scored, 60-tab pack = £3.46. Counselling, initial dose, driving

**TARAZOSIN**

**Indications** mild to moderate hypertension (see notes above); benign prostatic hyperplasia (section 7.4.1)

**Cautions** first dose may cause collapse due to hypotension (within 30–90 minutes, therefore should be taken on retiring to bed) (may also occur with rapid dose increase); cataract surgery (risk of intra-operative floppy iris syndrome); interactions: Appendix 1 (alpha-blockers)

**Driving** May affect performance of skilled tasks e.g. driving

**Pregnancy** no evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk

**Breast-feeding** no information available

**Side-effects** see section 7.4.1; also reported weight gain, drowsiness, parasthesia, nervousness, decreased libido, thrombocytopenia, back pain, and pain in extremities

**Dose**

- Hypertension, 1 mg at bedtime (compliance with bedtime dose important, see Cautions); dose doubled after 7 days if necessary; usual maintenance dose 2–10 mg once daily; more than 20 mg daily rarely improves efficacy
- Terazosin (Non-proprietary)

**Pharmaceuticals** Tablets, terazosin (as hydrochloride) 2 mg, net price 28-tab pack = £2.16; 5 mg, 28-tab pack = £2.58; 10 mg, 28-tab pack = £7.88. Counselling, initial dose, driving

**Hytrin®** (Amdipharm)

**Pharmaceuticals** Tablets, terazosin (as hydrochloride) 2 mg (yellow), net price 28-tab pack = £2.29; 5 mg (tan), 28-tab pack = £4.29; 10 mg (blue), 28-tab pack = £8.57; starter pack (for hypertension) of 7 × 1-mg tabs with 21 × 2-mg tabs = £13.00. Counselling, initial dose, driving

**Phaeochromocytoma**

Long-term management of phaeochromocytoma involves surgery. However, surgery should not take place until there is adequate blockade of both alpha- and beta-adrenoceptors; the optimal choice of drug therapy remains unclear. Alpha-blockers are used in the short-term management of hypertensive episodes in phaeochromocytoma. Once alpha blockade is established, tachycardia can be controlled by the cautious addition of a beta-blocker (section 2.4); a cardioselective beta-blocker is preferred.

Phenoxybenzamine, a powerful alpha-blocker, is effective in the management of phaeochromocytoma but it has many side-effects. Phentolamine is a short-acting alpha-blocker used mainly during surgery of phaeochromocytoma; its use for the diagnosis of phaeochromocytoma has been superseded by measurement of catecholamines in blood and urine.

Metiozine (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) inhibits the enzyme tyrosine hydroxylase, and hence the synthesis of catecholamines. It is rarely used in the pre-operative management of phaeochromocytoma, and long term in patients unsuitable for surgery; an
alpha-adrenoceptor blocking drug may also be required. Metrosine should not be used to treat essential hypertension.

**PHENOXYBENZAMINE HYDROCHLORIDE**

**Indications** hypertensive episodes in phaeochromocytoma

**Cautions** elderly; congestive heart failure; severe inchaemic heart disease; concurrent use of other alpha-blocking agents; increased risk of hypotension; heart failure; cerebral vascular accident; monitor blood pressure regularly during infusion; carcinogenic in animals; avoid in acute porphyria (section 9.8.2); avoid extravasation (irritant to tissues)

**Contra-indications** history of cerebrovascular accident; during recovery period after myocardial infarction (usually 3–4 weeks); avoid infusion in hypovolaemia

**Renal impairment** use with caution

**Pregnancy** hypotension may occur in newborn

**Breast-feeding** may be present in milk

**Side-effects** postural hypotension with dizziness and marked compensatory tachycardia, lassitude, nasal congestion, miosis, inhibition of ejaculation; rarely gastro-intestinal disturbances; decreased sweating and dry mouth after intravenous infusion; idiosyncratic profound hypotension within few minutes of starting infusion; convulsions following rapid intravenous infusion also reported

**Dose**

- See under preparations

**Phenoxybenzamine (Goldshield)**

- **Injection concentrate**, phenoxybenzamine hydrochloride 50 mg/mL. To be diluted before use, net price 2-mL amp = £57.14 (hosp. only)

- **Dose** by intravenous infusion (preferably through large vein), adjacent in severe shock (but rarely used) and phaeochromocytoma, 1 mg/kg/daily over at least 2 hours; do not repeat within 24 hours (intensive care facilities needed)

- **Caution** Owing to risk of contact sensitisation healthcare professionals should avoid contamination of hands

**Dibenylene® (Alliance)**

- **Capsules**, red/white, phenoxybenzamine hydrochloride 10 mg, net price 30-cap pack = £10.84

- **Dose** phaeochromocytoma, 10 mg daily, increased by 10 mg daily; usual dose 1–2 mg/kg daily in 2 divided doses

**PHENTOLAMINE MESILATE**

**Indications** hypertensive episodes due to phaeochromocytoma e.g. during surgery; diagnosis of phaeochromocytoma (but see notes above)

**Cautions** monitor blood pressure (avoid in hypertension), heart rate; gastritis, peptic ulcer; elderly; interactions: Appendix 1 (alpha-blockers)

**Contra-indications** hypotension; history of myocardial infarction; coronary insufficiency, angina, or other evidence of coronary artery disease

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** use with caution—may cause marked decrease in maternal blood pressure with resulting fetal anoxia

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** postural hypotension, tachycardia, dizziness, flushing; nausea and vomiting, diarrhoea, nasal congestion; also acute or prolonged hypotension, angina, chest pain, arrhythmias

**Dose**

- Hypertensive episodes, by intravenous injection, 2–5 mg repeated if necessary

- Diagnosis of phaeochromocytoma, consult product literature

**Rogitine® (Alliance)**

- **Injection**, phentolamine mesilate 10 mg/mL, net price 1-mL amp = £1.53

- Excipients include sulphites

**2.5.5 Drugs affecting the renin-angiotensin system**

**2.5.5.1 Angiotensin-converting enzyme inhibitors**

**2.5.5.2 Angiotensin-II receptor antagonists**

**2.5.5.3 Renin inhibitors**

**Heart failure**

Drug treatment of heart failure associated with a reduced left ventricular ejection fraction (left ventricular systolic dysfunction) is covered below; optimal management of heart failure with a preserved left ventricular ejection fraction has not been established.

The treatment of chronic heart failure aims to relieve symptoms, improve exercise tolerance, reduce the incidence of acute exacerbations, and reduce mortality. An ACE inhibitor, titrated to a ‘target dose’ (or the maximum tolerated dose if lower), together with a beta-blocker, form the basis of treatment for all patients with heart failure due to left ventricular systolic dysfunction. An ACE inhibitor (section 2.5.5.1) is generally advised for patients with asymptomatic left ventricular systolic dysfunction or symptomatic heart failure. An angiotensin-II receptor antagonist (section 2.5.5.2) may be a useful alternative for patients who, because of side-effects such as cough, cannot tolerate ACE inhibitors; a relatively high dose of the angiotensin-II receptor antagonist may be required to produce benefit. Candesartan, an angiotensin-II receptor antagonist, can also be added to ACE inhibitor and beta-blocker therapy in patients with mild to moderate heart failure who continue to remain symptomatic.

The beta-blockers bisoprolol and carvedilol (section 2.4) are of value in any grade of stable heart failure due to left ventricular systolic dysfunction; nebivolol (section 2.4) is licensed for stable mild to moderate heart failure in patients over 70 years. Beta-blocker treatment should be started by those experienced in the management of heart failure, at a very low dose and titrated very slowly over a period of weeks or months. Symptoms may deteriorate initially, calling for adjustment of concomitant therapy.

The aldosterone antagonist spironolactone (section 2.2.3) can be considered for patients with moderate to severe heart failure who are already taking an ACE inhibitor and a beta-blocker; low doses of spironolactone (usually 25 mg daily) reduce symptoms and mortality in these patients. If spironolactone cannot be
ACE inhibitors are used for the management of heart failure after an acute myocardial infarction with evidence of left ventricular systolic dysfunction. Close monitoring of serum creatinine, eGFR, and potassium is necessary, particularly following any change in treatment or any change in the patient’s clinical condition.

Patients who cannot tolerate an ACE inhibitor or an angiotensin-II receptor antagonist, or in whom they are contraindicated, may be given isosorbide dinitrate (section 2.6.1) with hydralazine (section 2.5.1), but this combination may be poorly tolerated. In patients of African or Caribbean origin, and those with moderate to severe heart failure, the combination of isosorbide dinitrate and hydralazine may be considered in addition to standard therapy with an ACE inhibitor and a beta-blocker, if necessary.

Digoxin (section 2.1.1) improves symptoms of heart failure and exercise tolerance and reduces hospitalisation due to acute exacerbations but it does not reduce mortality. Digoxin is reserved for patients with worsening or severe heart failure due to left ventricular systolic dysfunction who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker in combination with either an aldosterone antagonist, candesartan, or isosorbide dinitrate with hydralazine.

Patients with fluid overload should also receive either a loop or a thiazide diuretic (with salt or fluid restriction where appropriate). A thiazide diuretic (section 2.2.1) may be of benefit in patients with mild heart failure and good renal function; however, thiazide diuretics are ineffective in patients with poor renal function (eGFR less than 30 mL/minute/1.73 m², see Renal Impairment, section 2.2.1) and a loop diuretic (section 2.2.2) is preferred. If diuresis with a single diuretic is insufficient, a combination of a loop diuretic and a thiazide diuretic may be tried; addition of metolazone (section 2.2.1) may also be considered but the resulting diuresis may be profound and care is needed to avoid potentially dangerous electrolyte disturbances.

**2.5.5.1 Angiotensin-converting enzyme inhibitors**

Angiotensin-converting enzyme inhibitors (ACE inhibitors) inhibit the conversion of angiotensin I to angiotensin II. They have many uses and are generally well tolerated. The main indications of ACE inhibitors are shown below.

**Heart failure** ACE inhibitors are used in all grades of heart failure, usually combined with a beta-blocker (section 2.5.5). Potassium supplements and potassium-sparing diuretics should be discontinued before introducing an ACE inhibitor because of the risk of hyperkalaemia. However, a low dose of spironolactone may be beneficial in severe heart failure (section 2.5.5) and can be used with an ACE inhibitor provided serum potassium is monitored carefully. Profound first-dose hypotension may occur when ACE inhibitors are introduced to patients with heart failure who are already taking a high dose of a loop diuretic (e.g. furosemide 80 mg daily or more). Temporary withdrawal of the loop diuretic reduces the risk, but may cause severe rebound pulmonary oedema. Therefore, for patients on high doses of loop diuretics, the ACE inhibitor may need to be initiated under specialist supervision, see below. An ACE inhibitor can be initiated in the community in patients who are receiving a low dose of a diuretic or who are not otherwise at risk of serious hypotension; nevertheless, care is required and a very low dose of the ACE inhibitor is given initially.

**Hypertension** An ACE inhibitor may be the most appropriate initial drug for hypertension in younger Caucasian patients; Afro-Caribbean patients, those aged over 55 years, and those with primary aldosteronism respond less well (see section 2.5). ACE inhibitors are particularly indicated for hypertension in patients with type 1 diabetes with nephropathy (see section 2.5.1). They may reduce blood pressure very rapidly in some patients particularly in those receiving diuretic therapy (see Cautions, below); the first dose should preferably be given at bedtime.

**Diabetic nephropathy** For comment on the role of ACE inhibitors in the management of diabetic nephropathy, see section 6.1.5.

**Prophylaxis of cardiovascular events** ACE inhibitors are used in the early and long-term management of patients who have had a myocardial infarction, see section 2.10.1. ACE inhibitors may also have a role in preventing cardiovascular events.

**Initiation under specialist supervision** ACE inhibitors should be initiated under specialist supervision and with careful clinical monitoring in those with severe heart failure or in those:

- receiving multiple or high-dose diuretic therapy (e.g. more than 80 mg of furosemide daily or its equivalent);
- with hypovolaemia;
- with hyperkalaemia (plasma-sodium concentration below 130 mmol/litre);
- with hypotension (systolic blood pressure below 90 mmHg);
- with unstable heart failure;
- receiving high-dose vasodilator therapy;
- known renovascular disease.

**Renal effects** Renal function and electrolytes should be checked before starting ACE inhibitors (or increasing the dose) and monitored during treatment (more frequently if features mentioned below present); hyperkalaemia and other side-effects of ACE inhibitors are more common in those with impaired renal function and the dose may need to be reduced (see Renal Impairment below and under individual drugs). Although ACE inhibitors now have a specialised role in some forms of renal disease, including chronic kidney disease, they also occasionally cause impairment of renal function which may progress and become severe in other circumstances (at particular risk are the elderly). A specialist should be involved if renal function is significantly reduced as a result of treatment with an ACE inhibitor. Concomitant treatment with NSAIDs increases the risk of renal damage, and potassium-sparing diuretics (or potassium-containing salt substitutes) increase the risk of hyperkalaemia.

In patients with severe bilateral renal artery stenosis (or severe stenosis of the artery supplying a single functioning kidney), ACE inhibitors reduce or abolish glomerular filtration and are likely to cause severe and progressive renal failure. They are therefore not recommended in
patients known to have these forms of critical renovascular disease.

ACE inhibitor treatment is unlikely to have an adverse effect on overall renal function in patients with severe unilateral renal artery stenosis and a normal contralateral kidney, but glomerular filtration is likely to be reduced (or even abolished) in the affected kidney and the long-term consequences are unknown.

ACE inhibitors are therefore best avoided in patients with known or suspected renovascular disease, unless the blood pressure cannot be controlled by other drugs. If ACE inhibitors are used, they should be initiated only under specialist supervision and renal function should be monitored regularly.

ACE inhibitors should also be used with particular caution in patients who may have undiagnosed and clinically silent renovascular disease. This includes patients with peripheral vascular disease or those with severe generalised atherosclerosis.

**Caution**

ACE inhibitors need to be initiated with care in patients receiving diuretics (important: see Concomitant diuretics, below); first doses can cause hypertension especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure (see above). They should also be used with caution in peripheral vascular disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease; for use in pre-existing renovascular disease, see Renal Effects above. The risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended). ACE inhibitors should be used with care in patients with severe or symptomatic aortic stenosis (risk of hypotension) and in hypertrophic cardiomyopathy. They should also be used with care (or avoided) in those with a history of idiopathic or hereditary angioedema. If jaundice or marked elevations of hepatic enzymes occur during treatment then the ACE inhibitor should be discontinued—risk of hepatic necrosis (see also Hepatic impairment, below). **Interactions:** Appendix 1 (ACE inhibitors).

**Anaphylactoid reactions** To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polyacrylonitrile membranes and during low-density lipoprotein apheresis with dextran sulphate; they should also be withheld before desensitisation with wasp or bee venom.

**Concomitant diuretics** ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24 hours beforehand (may not be possible in heart failure—risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor; for at least 2 hours or until the blood pressure has stabilised.

**Contraindications** ACE inhibitors are contra-indicated in patients with hypersensitivity to ACE inhibitors (including angioedema).

**Hepatic impairment** Use of prodrugs such as cilazapril, enalapril, fosinopril, imidapril, moexipril, perindopril, quinapril, ramipril, andtrandolapril requires close monitoring in patients with impaired liver function.

**Renal impairment** ACE inhibitors should be used with caution and the response monitored (see Renal effects above); hyperkalaemia and other side effects more common; the dose may need to be reduced, see individual drugs.

**Pregnancy** ACE inhibitors should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.

**Side-effects** ACE inhibitors can cause profound hypotension (see Caution) and renal impairment (see Renal effects above), and a persistent dry cough. They can also cause angioedema (onset may be delayed; higher incidence reported in Afro-Caribbean patients), rash (which may be associated with pruritus and urticaria), pancreatitis, and upper respiratory-tract symptoms such as sinusitis, rhinitis, and sore throat. Gastro-intestinal effects reported with ACE inhibitors include nausea, vomiting, dyspepsia, diarrhoea, constipation, and abdominal pain. Altered liver function tests, cholestatic jaundice, hepatitis, fulminant hepatic necrosis, and hepatic failure have been reported—discontinue if marked elevation of hepatic enzymes or jaundice. Hyperkalaemia, hypoglycaemia, and blood disorders including thrombocytopenia, leucopenia, neutropenia, and haemolytic anaemia have also been reported. Other reported side effects include headache, dizziness, fatigue, malaise, taste disturbance, paraesthesia, bronchospasm, fever, soroitis, vasculitis, myalgia, arthralgia, positive antinuclear antibody, raised erythrocyte sedimentation rate, eosinophilia, leucocytosis, and photosensitivity.

**Combination products** Products incorporating an ACE inhibitor with a thiazide diuretic or a calcium-channel blocker are available for the management of hypertension. Use of these combination products should be reserved for patients whose blood pressure has not responded adequately to a single antihypertensive drug and who have been stabilised on the individual components of the combination in the same proportions.

**CAPTOPRIL**

**Indications** Mild to moderate essential hypertension alone or with thiazide therapy and severe hypertension resistant to other treatment; congestive heart failure with left ventricular dysfunction (adjunct—see section 2.5.5); following myocardial infarction, see
Co-zidocapt (Non-proprietary)  
Capoten (Non-proprietary)  
Captopril  

Diabetic nephropathy, 75–100 mg daily in divided doses;
Prophylaxis after infarction in clinically stable patients.
Heart failure (adjunct), initially 6.25–12.5 mg 2–3 times daily under close medical supervision (see notes above), increased gradually at intervals of at least 2 weeks up to max. 150 mg daily in divided doses if tolerated.

Prophylaxis after infarction in clinically stable patients with asymptomatic or symptomatic left ventricular dysfunction (radionuclide ventriculography or echocardiography undertaken before initiation), initially 6.25 mg, starting as early as 3 days after infarction, then increased over several weeks to 150 mg daily (if tolerated) in divided doses.

Diabetic nephropathy, 75–100 mg daily in divided doses; if further blood pressure reduction required, other antihypertensives may be used in conjunction with captopril; in severe renal impairment, initially 12.5 mg twice daily (if concomitant diuretic therapy required, loop diuretic rather than thiazide should be chosen).

Captopril (Non-proprietary)  
Tablets, captopril 12.5 mg, net price 56-tab pack = £1.96; 50 mg, 56-tab pack = £1.96
Brands include Ecopace®, Kaplon®

Capoten® (Squibb)  
Tablets, captopril 25 mg, net price 28-tab pack = £5.26; 50 mg (scored), 56-tab pack = £17.96

With diuretic
Note For mild to moderate hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on thiazides, see section 2.2.1

Co-zidocapt (Non-proprietary)  
Tablets, co-zidocapt 12.5/25 (hydrochlorothiazide 12.5 mg, captopril 25 mg), net price 28-tab pack = £14.10
Brands include Capto-co®

Tablets, co-zidocapt 25/50 (hydrochlorothiazide 25 mg, captopril 50 mg), net price 28-tab pack = £14.00
Brands include Capto-co®

Capozide® (Squibb)  
LS tablets, scored, co-zidocapt 12.5/25 (hydrochlorothiazide 12.5 mg, captopril 25 mg), net price 28-tab pack = £10.05
Tablets, scored, co-zidocapt 25/50 (hydrochlorothiazide 25 mg, captopril 50 mg), net price 28-tab pack = £7.02

CILAZAPRIL  
Indications essential hypertension; congestive heart failure (adjunct—see section 2.5.5)
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above; max. dose 500 micrograms daily in liver cirrhosis; manufacturer advises avoid in asics
Renal impairment see notes above; max. initial dose 500 micrograms once daily (do not exceed 2.5 mg once daily) if eGFR 10–40 mL/minute/1.73 m²; avoid if eGFR less than 10 mL/minute/1.73 m²
Pregnancy see notes above
Breast-feeding see notes above

Side-effects see notes above; also less commonly dry mouth, decreased appetite, angina, tachycardia, palpitation, flushing, dyspnoea, impotence, excessive sweating; rarely glossitis, bronchitis, interstitial lung disease, gynaecomastia, peripheral neuropathy, Stevens-Johnson syndrome, toxic epidermal necrolysis

Hypertension, initially 1 mg once daily (reduced to 0.5 mg if eGFR less than 30 mL/minute/1.73 m² of 250 micrograms once daily if used in addition to diuretic (see notes above), or in cardiac decompensation, in severe hypertension, in volume depletion, in the elderly, or in renal impairment), then adjusted according to response; usual maintenance dose 2.5–5 mg once daily; max. 5 mg daily.

Heart failure (adjunct), initially 500 micrograms once daily under close medical supervision (see notes above), or in cardiac decompensation, in severe hypertension, in volume depletion, in the elderly, or in renal impairment), then adjusted according to response; usual maintenance dose 2.5–5 mg once daily; max. 5 mg once daily.

Vascace® (Roche)  
Tablets, f/c, cilazapril 500 micrograms (white), net price 30-tab pack = £3.68; 1 mg (yellow), 30-tab pack = £6.07; 2.5 mg (pink), 28-tab pack = £7.20; 5 mg (brown), 28-tab pack = £12.51

ENALAPRIL MALEATE  
Indications hypertension; symptomatic heart failure (adjunct—see section 2.5.5); prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above; max. initial dose 2.5 mg daily if eGFR less than 30 mL/minute/1.73 m²
Pregnancy see notes above
Breast-feeding see notes above

Side-effects see notes above; also dyspnoea; depression, asthenia; blurred vision; less commonly dry mouth, peptic ulcer, anorexia, ileus; arrhythmias, palpitation, flushing; confusion, nervousness, drowsiness, insomnia, vertigo; impotence; muscle cramps; tinnitus; alopecia, sweating; hyponatraemia; rarely...
stomatitis, glossitis, Raynaud’s syndrome, pulmonary infiltrates, allergic alveolitis, dream abnormalities, gynaecomastia, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pemphigus; very rarely gastro-intestinal angioedema

Dose

- Hypertension, used alone, initially 5 mg once daily; if used in addition to diuretic (see notes above), or in renal impairment, lower initial doses may be required; usual maintenance dose 20 mg once daily; max. 40 mg once daily
- Heart failure (adjunct), asymptomatic left ventricular dysfunction, initially 2.5 mg once daily under close medical supervision (see notes above), increased gradually over 2–4 weeks to 10–20 mg twice daily if tolerated

Enalapril Maleate (Non-proprietary) (Trade)

Tablets, enalapril maleate 2.5 mg, net price 28-tab pack = £1.05; 5 mg, 28-tab pack = £9.60; 10 mg, 28-tab pack = £1.05; 20 mg, 28-tab pack = £1.24

Brands include: Ednyp®

Innovace® (MSD) (Trade)

Tablets, yellow, scored, enalapril maleate 20 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £12.82

Note: Non-proprietary tablets containing enalapril maleate (20 mg) and hydrochlorothiazide (12.5 mg) are available

With diuretic

Note: For mild to moderate hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on thiazides, see section 2.2.1

Innozide® (MSD) (Trade)

Tablets, yellow, scored, enalapril maleate 20 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £12.82

Note: Non-proprietary tablets containing enalapril maleate (20 mg) and hydrochlorothiazide (12.5 mg) are available

FOSINOPRIL SODIUM

Indications: hypertension; congestive heart failure (adjunct—see section 2.5.5)

Cautions: see notes above

Contra-indications: see notes above

Hepatic impairment: see notes above

Renal impairment: see notes above

Pregnancy: see notes above

Breast-feeding: see notes above

Side-effects: see notes above; chest pain; musculoskeletal pain

Dose

- Hypertension, initially 10 mg daily, increased if necessary after 4 weeks; usual dose range 10–40 mg (doses over 40 mg not shown to increase efficacy); if used in addition to diuretic see notes above
- Heart failure (adjunct), initially 10 mg once daily under close medical supervision (see notes above), increased gradually to 40 mg once daily if tolerated

Fosinopril sodium (Non-proprietary) (Trade)

Tablets, fosinopril sodium 10 mg, net price 28-tab pack = £2.18; 20 mg, 28-tab pack = £2.53

IMIDAPRIL HYDROCHLORIDE

Indications: essential hypertension

Cautions: see notes above

Contra-indications: see notes above

Hepatic impairment: see notes above

Renal impairment: see notes above; initial dose 2.5 mg daily if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy: see notes above

Breast-feeding: see notes above

Side-effects: see notes above; dry mouth, glossitis, ileus; bronchitis, dyspnoea; sleep disturbances, depression, confusion, blurred vision, tinnitus, impotence

Dose

- Initially 5 mg daily before food; if used in addition to diuretic (see notes above), in elderly, in patients with heart failure, angina or cerebrovascular disease, or in renal or hepatic impairment, initially 2.5 mg daily; if necessary increase dose at intervals of at least 3 weeks; usual maintenance dose 10 mg once daily; max. 20 mg daily (elderly, 10 mg daily)

Tanatril® (Chiesi) (Trade)

Tablets, scored, imidapril hydrochloride 5 mg, net price 28-tab pack = £6.40; 10 mg, 28-tab pack = £7.22; 20 mg, 28-tab pack = £8.67

Lisinopril

Indications: hypertension (but see notes above); symptomatic heart failure (adjunct—see section 2.5.5); short-term treatment following myocardial infarction in haemodynamically stable patients; renal complications of diabetes mellitus

Cautions: see notes above

Contra-indications: see notes above

Renal impairment: see notes above; max. initial doses 5–10 mg daily if eGFR 30–80 mL/minute/1.73 m² (max. 40 mg daily); 2.5–5 mg daily if eGFR 10–30 mL/minute/1.73 m² (max. 40 mg daily); 2.5 mg daily if eGFR less than 10 mL/minute/1.73 m²

Pregnancy: see notes above

Breast-feeding: see notes above

Side-effects: see notes above; also less commonly tachycardia, palpitation, cerebrovascular accident, myocardial infarction, Raynaud’s syndrome, confusion, mood changes, vertigo, sleep disturbances, asthenia, impotence; rarely dry mouth, gynaecomastia, alopecia, psoriasis; very rarely allergic alveolitis, pulmonary infiltrates, profuse sweating, pemphigus, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Dose

- Hypertension, initially 10 mg once daily; if used in addition to diuretic (see notes above) or in cardiac decompensation or in volume depletion, initially 2.5–5 mg once daily; usual maintenance dose 20 mg once daily; max. 80 mg once daily
- Heart failure (adjunct), initially 2.5 mg once daily under close medical supervision (see notes above); increased in steps no greater than 10 mg at intervals of at least 2 weeks up to max. 35 mg once daily if tolerated
- Prophylaxis after myocardial infarction, systolic blood pressure over 120 mmHg, 5 mg within 24 hours, followed by further 5 mg 24 hours later, then 10 mg after a further 24 hours, and continuing with 10 mg once daily for 6 weeks (or continued if heart failure), sys-
tolic blood pressure 100–120 mmHg, initially 2.5 mg once daily, increased to maintenance dose of 5 mg once daily

**Note** Should not be started after myocardial infarction if systolic blood pressure less than 100 mmHg; temporarily reduce maintenance dose to 5 mg and if necessary 2.5 mg daily if systolic blood pressure 100 mmHg or less during treatment; withdraw if prolonged hypotension occurs (systolic blood pressure less than 90 mmHg for more than 1 hour)

- Renal complications of diabetes mellitus, initially 2.5–5 mg once daily adjusted according to response; usual dose range 10–20 mg once daily

**Lisinopril** (Non-proprietary) Tablets, lisinopril (as dihydrate) 2.5 mg, net price 28-tab pack = £87p; 5 mg, 28-tab pack = £93p; 10 mg, 28-tab pack = £1.01; 20 mg, 28-tab pack = £1.19

**Zestril** (AstraZeneca) Tablets, lisinopril (as dihydrate) 2.5 mg, net price 28-tab pack = £1.19; 5 mg (pink), 28-tab pack = £1.31; 10 mg (pink), 28-tab pack = £2.05; 20 mg (pink), 28-tab pack = £2.17

**With diuretic**

**Note** For mild to moderate hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on thiazides, see section 2.2.1

**Carace Plus** (MSD) Tablets, carace plus tablets, blue, lisinopril 10 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £10.10

**Carace 20 Plus tablets** yellow, scored, lisinopril 20 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £11.43

**Lisicostad** (Genus) Tablets, lisicostad 10/12.5 mg tablets, scored, lisinopril (as dihydrate) 10 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £10.99

**Lisicostad 20/12.5 mg tablets** scored, lisinopril (as dihydrate) 20 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £11.99

**Zestoretic** (AstraZeneca) Tablets, zestoretic tablets, peach, lisinopril (as dihydrate) 10 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £2.27

**Zestoretic 20 tablets** lisinopril (as dihydrate) 20 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £3.84

**MOEXIPRIL HYDROCHLORIDE**

**Indications** essential hypertension

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above; if eGFR less than 40 mL/minute/1.73 m², initial dose 3.75 mg once daily titrated to max. 15 mg once daily

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; arrhythmias, angina, chest pain, syncope, cerebrovascular accident, myocardial infarction; appetite and weight changes; dry mouth, photosensitivity, flushing, nervousness, mood changes, anxiety, drowsiness, sleep disturbance, tin-

**nitus, influenza-like syndrome, sweating and dyspnoea**

**Dose**

- Monotherapy, initially 7.5 mg once daily; if used in addition to diuretic (see notes above), with nifedipine, or in elderly, initially 3.75 mg once daily; usual range 7.5–30 mg once daily; doses above 30 mg daily not shown to increase efficacy

**Perdix** (UCB Pharma) Tablets, f/c, pink, scored, moexipril hydrochloride 7.5 mg, net price 28-tab pack = £6.04; 15 mg, 28-tab pack = £6.96

**PERINDOPRIL ERBUMINE**

**Indications** hypertension (but see notes above); symptomatic heart failure (adjunct—see section 2.5.5); prophylaxis of cardiac events following myocardial infarction or revascularisation in stable coronary artery disease

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above; max. initial dose 2 mg once daily if eGFR 30–60 mL/minute/1.73 m²; 2 mg once daily on alternate days if eGFR 15–30 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also asthenia, mood and sleep disturbances

**Dose**

- Hypertension, initially 4 mg once daily in the morning for 1 month, subsequently adjusted according to response; if used in addition to diuretic (see notes above), in elderly, in renal impairment, in cardiac decompensation, or in volume depletion, initially 2 mg once daily; max. 8 mg daily

- Heart failure (adjunct), initially 2 mg once daily in the morning under close medical supervision (see notes above), increased after at least 2 weeks to max. 4 mg once daily if tolerated

- Following myocardial infarction or revascularisation, initially 4 mg once daily in the morning increased after 2 weeks to 8 mg once daily if tolerated; elderly 2 mg once daily for 1 week, then 4 mg once daily for 1 week, thereafter increased to 8 mg once daily if tolerated

**Perindopril** (Non-proprietary) Tablets, perindopril erbumine (= tert-butylamine) 2 mg, net price 30-tab pack = £1.72; 4 mg, 30-tab pack = £1.81; 8 mg, 30-tab pack = £1.94. Label: 22

**PERINDOPRIL ARGININE**

**Indications** see under Perindopril Erbumine and notes above

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above; max. initial dose 2.5 mg once daily if eGFR 30–60 mL/minute/1.73 m²; 2.5 mg once daily on alternate days if eGFR 15–30 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above
**Side-effects** see under Perindopril Erbumine and notes above

**Dose**
- Hypertension, initially 5 mg once daily in the morning for 1 month, subsequently adjusted according to response; if used in addition to diuretic (see notes above), in elderly, in renal impairment, in cardiac decompensation, or in volume depletion, initially 2.5 mg once daily; max. 10 mg daily
- Heart failure (adjunct), initially 2.5 mg once daily in the morning under close medical supervision (see notes above), increased after 2 weeks to max. 5 mg once daily if tolerated
- Following myocardial infarction or revascularisation, initially 5 mg once daily in the morning increased after 2 weeks to 10 mg once daily if tolerated; elderly, 2.5 mg once daily for 1 week, then 5 mg once daily for 1 week, thereafter increased to 10 mg once daily if tolerated

**Conversyl® Arginine** (Servier)

*Tablets, f/c, perindopril arginine 2.5 mg (white), net price 30-tab pack = £8.27; 5 mg (light green, scored), 30-tab pack = £9.36; 10 mg (green), 30-tab pack = £11.02. Label: 22

**Perindopril arginine with diuretic**

*Note* For hypertension not adequately controlled by perindopril alone. For prescribing information on indapamide, see section 2.2.1

**Conversyl® Arginine Plus** (Servier)

*Tablets, f/c, perindopril arginine 5 mg, indapamide 1.25 mg, net price 30-tab pack = £12.65. Label: 22

**QUINAPRIL**

**Indications** essential hypertension; congestive heart failure (adjunct—see section 2.5.5)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above; max. initial dose 2.5 mg once daily if eGFR less than 40 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; asthenia, chest pain, oedema, flatulence, nervousness, depression, insomnia, blurred vision, impotence, and back pain

**Dose**
- Hypertension, initially 10 mg once daily; with a diuretic (see notes above), in elderly, or in renal impairment initially 2.5 mg daily; usual maintenance dose 20–40 mg daily in single or 2 divided doses; up to 80 mg daily has been given
- Heart failure (adjunct), initial dose 2.5 mg daily under close medical supervision (see notes above), increased gradually at intervals of 1–2 weeks to max. 10 mg daily if tolerated; max. 40 mg daily

**Quinapril (Non-proprietary)**

*Tablets, quinapril (as hydrochloride) 5 mg, net price 28-tab pack = £2.05; 10 mg, net price 28-tab pack = £2.39; 40 mg, 28-tab pack = £8.81

*Brands include: Quinapril®*

**Accupro® (Pfizer)**

*Tablets, f/c, quinapril (as hydrochloride) 5 mg (brown), net price 28-tab pack = £8.60; 10 mg (brown), 28-tab pack = £8.60; 20 mg (brown), 28-tab pack = £10.79; 40 mg (red-brown), 28-tab pack = £9.75

**With diuretic**

*Note* For hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on thiazides, see section 2.2.1

**Accuretic® (Pfizer)**

*Tablets, pink, f/c, scored, quinapril (as hydrochloride) 10 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £11.75

**RAMIPRIL**

**Indications** hypertension; symptomatic heart failure (adjunct—see section 2.5.5); following myocardial infarction in patients with clinical evidence of heart failure; prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease or with diabetes mellitus and at least one additional risk factor for cardiovascular disease; nephropathy (consult product literature)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** max. daily dose 2.5 mg; see also notes above

**Renal impairment** see notes above; max. daily dose 5 mg if eGFR 30–60 mL/minute/1.73 m²; max. initial dose 1.25 mg once daily (do not exceed 5 mg once daily) if eGFR 10–30 mL/minute/1.73 m²; max. initial dose 1.25 mg once daily (do not exceed 2.5 mg once daily) if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; arrhythmias, angina, chest pain, syncope, cerebrovascular accident, myocardial infarction, loss of appetite, stomatitis, dry mouth, skin reactions including erythema multiforme and pemphigoid exanthema; precipitation or exacerbation of Raynaud’s syndrome; conjunctivitis, onycholyisis, confusion, nervousness, depression, anxiety, impotence, decreased libido, alopecia, bronchitis and muscle cramps

**Dose**
- Hypertension, initially 1.25–2.5 mg once daily, increased at intervals of 2–4 weeks to max. 10 mg once daily; if used in addition to diuretic see notes above
- Heart failure (adjunct), initially 1.25 mg once daily under close medical supervision (see notes above), increased gradually at intervals of 1–2 weeks to max. 10 mg daily if tolerated (preferably taken in 2 divided doses)
- Prophylaxis after myocardial infarction (started at least 48 hours after infarction), initially 2.5 mg twice daily, increased after 3 days to 5 mg twice daily

**Note** If initial 2.5 mg dose not tolerated, give 1.25 mg twice daily for 2 days before increasing to 2.5 mg twice daily, then 5 mg twice daily; withdraw if dose cannot be increased to 2.5 mg twice daily

- Prophylaxis of cardiovascular events, initially 2.5 mg once daily, increased after 1–2 weeks to 5 mg once daily; then increased after a further 2–3 weeks to 10 mg once daily
2.5.5 Drugs affecting the renin-angiotensin system

- Nephropathy, initially 1.25 mg once daily, increased after 2 weeks to 2.5 mg once daily, then increased after a further 2 weeks to 5 mg once daily if tolerated

Ramipril (Non-proprietary) (£19.43)

Capsules, ramipril 1.25 mg, net price 28-cap pack = £1.10; 2.5 mg, 28-cap pack = £1.18; 5 mg, 28-cap pack = £1.25; 10 mg, 28-cap pack = £1.41

Tablets, ramipril 1.25 mg, net price 28-tab pack = £1.71; 2.5 mg, 28-tab pack = £1.42; 5 mg, 28-tab pack = £1.66; 10 mg, 28-tab pack = £1.89

Tritace® (Sanofi-Aventis) (£11.07)

Tablets, scored, ramipril 1.25 mg (white), net price 28-tab pack = £5.09; 2.5 mg (yellow), 28-tab pack = £7.22; 5 mg (red), 28-tab pack = £10.05; 10 mg (white), 28-tab pack = £13.68

Tiratric® tablets, 35-day starter pack of ramipril 7 × 2.5 mg with 21 × 5 mg and 7 × 10 mg, net price = £13.00

With calcium-channel blocker

Note For hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on felodipine, see section 2.6.2

Triapin® (Sanofi-Aventis) (£24.55)

Capsules, trandolapril 1.25 mg, net price 28-cap pack = £1.49; 1 mg, 28-cap pack = £7.23; 2 mg, 28-cap pack = £3.75; 4 mg, 28-cap pack = £12.31

Gopten® (Abbott) (£24.55)

Capsules, trandolapril 500 micrograms (red/yellow), net price 14-cap pack = £1.19; 1 mg (red/orange), 28-cap pack = £3.81; 2 mg (red/red), 28-cap pack = £5.81; 4 mg (red/maroon), 28-cap pack = £9.86

With calcium-channel blocker

Note For hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on verapamil, see section 2.6.2

Tarka® (Abbott) (£24.55)

Capsules, pink, trandolapril 2 mg, verapamil hydrochloride 180 mg (m/r), net price 28 cap-pack = £10.29. Label: 25

2.5.5.2 Angiotensin-II receptor antagonists

Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan are angiotensin-II receptor antagonists with many properties similar to those of the ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause the persistent dry cough which can complicate ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough.

An angiotensin-II receptor antagonist may be used as an alternative to an ACE inhibitor in the management of heart failure (section 2.5.5) or diabetic nephropathy (section 6.1.5).

Cautions Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).

Pregnancy Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.

Breast-feeding Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.

Side-effects Side-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion

TRANDOLAPRIL

Indications mild to moderate hypertension; following myocardial infarction in patients with left ventricular dysfunction

Cautions see notes above

Contra-indications see notes above

Renal impairment see notes above; max. 2 mg daily if eGFR less than 10 mL/minute/1.73 m²

Pregnancy see notes above

Breast-feeding see notes above

Dose

- Hypertension, initially 500 micrograms once daily, increased at intervals of 2–4 weeks; usual range 1–2 mg once daily; max. 4 mg daily; if used in addition to diuretics see notes above

- Prophylaxis after myocardial infarction (starting as early as 3 days after infarction), initially 500 micrograms once daily; gradually increased to max. 4 mg once daily

Note If symptomatic hypotension develops during titration, do not increase dose further; if possible, reduce dose of any adjunctive treatment and if this is not effective or feasible, reduce dose of trandolapril

Trandolapril (Non-proprietary) (£24.55)

Capsules, trandolapril 500 micrograms, net price 14-cap pack = £1.49; 1 mg, 28-cap pack = £7.23; 2 mg, 28-cap pack = £3.75; 4 mg, 28-cap pack = £12.31

Gopten® (Abbott) (£24.55)

Capsules, trandolapril 500 micrograms (red/yellow), net price 14-cap pack = £1.19; 1 mg (red/orange), 28-cap pack = £3.81; 2 mg (red/red), 28-cap pack = £5.81; 4 mg (red/maroon), 28-cap pack = £9.86

Angiotensin-II receptor antagonists

Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan are angiotensin-II receptor antagonists with many properties similar to those of the ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause the persistent dry cough which can complicate ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough.

An angiotensin-II receptor antagonist may be used as an alternative to an ACE inhibitor in the management of heart failure (section 2.5.5) or diabetic nephropathy (section 6.1.5).

Cautions Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).

Pregnancy Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.

Breast-feeding Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.

Side-effects Side-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion
2.5.5 Drugs affecting the renin-angiotensin system

EPROSARTAN

Indications hypertension (see also notes above)

Cautions see notes above

Hepatic impairment half dose in severe liver disease

Renal impairment initial dose if eGFR less than 60 mL/minute/1.73 m²

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; also flatulence, hypertriglyceridaemia, arthralgia, rhinitis; rarely headache, asthenia, anaemia, hypersensitivity reactions (including rash, pruritus, urticaria); very rarely anaphylaxis, angioedema

Dose

600 mg once daily (elderly over 75 years, moderate hepatic impairment, renal impairment, initially 300 mg once daily); if necessary increased after 2–3 weeks to 800 mg once daily

Teveten® (Solvay) Tablets, f/c, eprosartan (as mesilate) 300 mg (white), net price 28-tab pack = £7.31; 400 mg (pink), 56-tab pack = £15.77; 600 mg (white), 28-tab pack = £14.31. Label: 21

IRBESARTAN

Indications hypertension; renal disease in hypertensive type 2 diabetes mellitus (see also notes above)

Cautions see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; also nausea, vomiting; fatigue; musculoskeletal pain; less commonly diarrhoea, dyspepsia, flushing, tachycardia, chest pain, cough, and sexual dysfunction; rarely rash, urticaria; very rarely headache, myalgia, arthralgia, tinnitus, taste disturbance, hepatitis, renal dysfunction, and cutaneous vasculitis

Dose

Hypertension, initially 150 mg once daily, increased if necessary to 300 mg once daily (in haemodialysis or in ELDERLY over 75 years, initial dose of 75 mg once daily may be used); CHILD not recommended

Renal disease in hypertensive type 2 diabetes mellitus, initially 150 mg once daily, increased to 300 mg once daily if tolerated (in haemodialysis or in ELDERLY over 75 years, consider initial dose of 75 mg once daily); CHILD not recommended

Aprovel® (Bristol-Myers Squibb, Sanofi-Aventis) Tablets, f/c, irbesartan 75 mg, net price 28-tab pack = £9.69; 150 mg, 28-tab pack = £11.84; 300 mg, 28-tab pack = £15.93

With diuretic

Note For hypertension not adequately controlled with irbesartan alone. For prescribing information on thiazides, see section 2.2.1

CoAprovel® (Bristol-Myers Squibb, Sanofi-Aventis) Tablets, f/c, irbesartan 150 mg, hydrochlorothiazide 12.5 mg (peach), net price 28-tab pack = £11.84; irbesartan 300 mg, hydrochlorothiazide 12.5 mg (peach), 28-tab pack = £15.93; irbesartan 300 mg, hydrochlorothiazide 25 mg (pink), 28-tab pack = £15.93

LOSARTAN POTASSIUM

Indications hypertension (including reduction of stroke risk in hypertension with left ventricular hypertrophy); chronic heart failure when ACE inhibitors are unsuitable or contra-indicated; diabetic nephropathy in type 2 diabetes mellitus (see also notes above)

Cautions see notes above; severe heart failure

Hepatic impairment consider dose reduction in mild to moderate impairment; manufacturer advises avoid in severe impairment—no information available

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; asthenia, fatigue, vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including Henoch-Schönlein purpura)

Dose

Hypertension, diabetic nephropathy in type 2 diabetes mellitus, usually 50 mg once daily (intravenous volume depletion, initially 25 mg once daily); if
chronic heart failure, 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated.

**Losartan Potassium** (Non-proprietary)

**Tablets**, losartan potassium 12.5 mg, net price 28-tab pack = £7.70; 25 mg, 28-tab pack = £2.64; 50 mg, 28-tab pack = £2.58; 100 mg, 28-tab pack = £2.64.

**Cozaar** (MSD)

**Tablets**, f/c, losartan potassium 12.5 mg (blue), net price 28-tab pack = £8.09; 25 mg (white), net price 28-tab pack = £16.18; 50 mg (white, scored), 28-tab pack = £12.80; 100 mg (white), 28-tab pack = £16.18.

**Oral suspension**, losartan potassium 12.5 mg/5 mL when reconstituted with solvent provided, net price 200-mL (berry-citrus flavour) = £53.68.

**With diuretic**

**Note** For hypertension not adequately controlled with losartan alone. For prescribing information on thiazides, see section 2.2.1.

**Cozaar-Comp** (MSD)

**Tablets**, 50/12.5, yellow, f/c, losartan potassium 50 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £12.80.

**Tablets**, 100/12.5, white, f/c, losartan potassium 100 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £16.18.

**Tablets**, 100/25, yellow, f/c, losartan potassium 100 mg, hydrochlorothiazide 25 mg, net price 28-tab pack = £16.18.

**OLMESARTAN MEDOXOMIL**

**Indications** hypertension (see also notes above)

**Cautions** see notes above

**Contra-indications** biliary obstruction

**Hepatic impairment** dose should not exceed 20 mg daily in moderate impairment; manufacturer advises avoid in severe impairment—no information available

**Renal impairment** max. 20 mg daily if eGFR 20–60 mL/minute/1.73 m²; avoid if eGFR less than 20 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also gastrointestinal disturbances; chest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like symptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria, hyperuricaemia; arthritis; musculoskeletal pain; less commonly angina, vertigo, rash; very rarely headache, thrombocytopenia, myalgia, pruritus, urticaria

**Dose**

- Initially 10 mg once daily; if necessary increased to 20 mg once daily; max. 40 mg daily

**Ometec** (Daiichi Sankyo)

**Tablets**, f/c, olmesartan medoxomil 10 mg, net price 28-tab pack = £10.95; 20 mg, 28-tab pack = £12.95; 40 mg, 28-tab pack = £17.50

**With calcium-channel blocker**

**Note** For hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on amlodipine, see section 2.6.2

**Sevikar** (Daiichi Sankyo)

**Tablets** 20/5, white, f/c, olmesartan medoxomil 20 mg, amlodipine (as besilate) 5 mg, net price 28-tab pack = £16.95.

**Tablets** 40/5, ivory, f/c, olmesartan medoxomil 40 mg, amlodipine (as besilate) 5 mg, net price 28-tab pack = £16.95.

**Tablets** 40/10, brownish-red, f/c, olmesartan medoxomil 40 mg, amlodipine (as besilate) 10 mg, net price 28-tab pack = £16.95.

**With diuretic**

**Note** For hypertension not adequately controlled with olmesartan alone. For prescribing information on thiazides, see section 2.2.1.

**Ometec Plus** (Daiichi Sankyo)

**Tablets**, f/c, olmesartan medoxomil 20 mg, hydrochlorothiazide 12.5 mg (red-yellow), net price 28-tab pack = £12.95; olmesartan medoxomil 20 mg, hydrochlorothiazide 25 mg (pink), 28-tab pack = £12.95; olmesartan medoxomil 40 mg, hydrochlorothiazide 12.5 mg (red-yellow), 28-tab pack = £17.50

**TELMSARTAN**

**Indications** hypertension (see also notes above); prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease, or type 2 diabetes mellitus with target-organ damage

**Cautions** see notes above

**Hepatic impairment** 20–40 mg once daily in mild or moderate impairment; avoid in severe impairment or biliary obstruction

**Renal impairment** manufacturer advises initial dose of 20 mg once daily in severe impairment

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also gastrointestinal disturbances; chest pain; influenza-like symptoms including pharyngitis and sinusitis; urinary-tract infection; arthralgia, myalgia, back pain, leg cramps; eczema; less commonly dry mouth, flatulence, anxiety, vertigo, tendinitis-like symptoms, abnormal vision, increased sweating; rarely Bradycardia, tachycardia, dyspnoea, insomnia, depression, blood disorders, increase in uric acid, eosinophilia, rash, and pruritus; syncope and asthenia also reported

**Dose**

- Hypertension, usually 40 mg once daily (but 20 mg may be sufficient), increased if necessary after at least 4 weeks, to max. 80 mg once daily

- Prevention of cardiovascular events, 80 mg once daily

**Micardis** (Boehringer Ingelheim)

**Tablets**, telmisartan 20 mg, net price 28-tab pack = £8.00; 40 mg, 28-tab pack = £12.50; 80 mg, 28-tab pack = £17.00
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs

### Nitrates

**Diovan**
- **Capsules**, valsartan 40 mg (grey), net price 28-caps pack = £13.97; 80 mg (grey/pink), 28-caps pack = £13.97; 160 mg (dark grey/pink), 28-caps pack = £18.41
- **Tablets**, f/c, valsartan 40 mg (yellow, scored), net price 7-tab pack = £3.49; 320 mg (dark grey-violet), 28-tab pack = £20.23

### Calcium-channel blockers

**Co-Diovan**
- **Tablets** 80/12.5, orange, f/c, valsartan 80 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £13.97

**Micardis Plus**
- **Tablets** 40/12.5, red/white, telmisartan 40 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £12.50
- **Tablets** 80/12.5, red/white, telmisartan 80 mg, hydrochlorothiazide 12.5 mg, net price 28-tab pack = £17.00
- **Tablets** 80/25, yellow/white, telmisartan 80 mg, hydrochlorothiazide 25 mg, net price 28-tab pack = £17.00

### Other antianginal drugs

**ALISKIREN**
- **Indications** essential hypertension
- **Cautions** patients taking concomitant diuretics, on a low-sodium diet, or who are dehydrated (first doses may cause hypotension—initiate with care); renal artery stenosis; patients at risk of renal impairment; monitor plasma-potassium concentration and renal function in diabetes mellitus and heart failure; interactions: Appendix 1 (aliskiren)
- **Renal impairment** caution in renal artery stenosis or if eGFR less than 30 mL/minute/1.73 m²—no information available; monitor plasma-potassium concentration
- **Pregnancy** manufacturer advises avoid—no information available; other drugs acting on the renin-angiotensin system have been associated with fetal malformations and neonatal death
- **Breast-feeding** present in milk in animal studies—manufacturer advises avoid
- **Side-effects** diarrhoea; less commonly rash; rarely angioedema; acute renal failure (reversible on discontinuation of treatment), anaemia, and hyperkalaemia also reported
- **Dose**
  - **ADULT** over 18 years, 150 mg once daily, increased if necessary to 300 mg once daily

**Rasilez**
- **Tablets**, f/c, aliskiren (as hemifumarate) 150 mg (pink), net price 28-tab pack = £19.80; 300 mg (red), net price 28-tab pack = £23.80. Label: 21

### Peripheral vasodilators and related drugs

**Nitrites**
- **Diethylnitrite**
- **Isosorbide dinitrate**
- **Isosorbide nitrate**

### With diuretic

**Note** For patients with hypertension not adequately controlled by telmisartan alone. For prescribing information on thiazides, see section 2.2.1

### With diuretic

**Note** For hypertension not adequately controlled by valsartan alone. For prescribing information on thiazides, see section 2.2.1

### Renin inhibitors

Renin inhibitors inhibit renin directly; renin converts angiotensinogen to angiotensin I. **Aliskiren** is licensed for the treatment of hypertension, either alone or in combination with other antihypertensives. The Scottish Medicines Consortium (p. 4) has advised (January 2010) that aliskiren (**Rasilez**) is not recommended for use within NHS Scotland.
left ventricular pressure during systole resulting in improved cardiac output. They can also cause venous dilatation, which results in dilatation of capacitance vessels, increase of venous pooling, and diminution of venous return to the heart (decreasing left ventricular end-diastolic pressure).

For details on the management of stable angina and acute coronary syndromes, see section 2.10.1.

2.6.1 Nitrates

Nitrates have a useful role in angina (for details on the management of stable and unstable angina, see section 2.10.1). Although they are potent coronary vasodilators, their principal benefit follows from a reduction in venous return which reduces left ventricular work. Unwanted effects such as flushing, headache, and postural hypotension may limit therapy, especially when angina is severe or when patients are unusually sensitive to the effects of nitrates.

Sublingual glyceryl trinitrate is one of the most effective drugs for providing rapid symptomatic relief of angina, but its effect lasts only for 20 to 30 minutes; the 300-microgram tablet is often appropriate when glyceryl trinitrate is first used. The aerosol spray provides an alternative method of rapid relief of symptoms for those who find difficulty in dissolving sublingual preparations. Duration of action may be prolonged by modified-release and transdermal preparations (but tolerance may develop, see below).

Isosorbide dinitrate is active sublingually and is a more stable preparation for those who only require nitrates infrequently. It is also effective by mouth for prophylaxis, although the effect is slower in onset, it may persist for several hours. Duration of action of up to 12 hours is claimed for modified-release preparations. The activity of isosorbide dinitrate may depend on the production of active metabolites, the most important of which is isosorbide mononitrate. Isosorbide mononitrate itself is also licensed for angina prophylaxis; modified-release formulations (for once daily administration) are available.

Glyceryl trinitrate or isosorbide dinitrate may be tried by intravenous injection when the sublingual form is ineffective in patients with chest pain due to myocardial infarction or severe ischaemia. Intravenous injections are also useful in the treatment of congestive heart failure.

Tolerance Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 8 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for several consecutive hours in each 24 hours; in these cases of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.

GLYCERYL TRINITRATE

Indications

anal fissure (section 1.7.4); extravasation (section 10.3)

Sublingual prophylaxis and treatment of angina

Buccal: prophylaxis and treatment of angina; adjunct in unstable angina; acute and congestive heart failure

Injection: control of hypertension and myocardial ischaemia during and after cardiac surgery; induction of controlled hypotension during surgery; congestive heart failure; unstable angina

Transferable: see under preparations below

Cautions

hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion abnormalities; susceptibility to angle-closure glaucoma; metal-containing transdermal systems should be removed before magnetic resonance imaging procedures, cardioversion, or diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (see notes above); interactions: Appendix I (nitrates)

Contra-indications

hypersensitivity to nitrates; hypertensive conditions and hypovolaemia; hypertrophic cardiomyopathy; aortic stenosis; cardiac tamponade; constrictive pericarditis; mitral stenosis; toxic pulmonary oedema; head trauma; cerebral haemorrhage; cerebrovascular disease; marked anaemia

Hepatic impairment caution in severe impairment

Renal impairment manufacturers advise use with caution in severe impairment

Pregnancy not known to be harmful

Breast-feeding no information available—manufacturers advise use only if potential benefit outweighs risk

Side-effects

postural hypotension, tachycardia (but paradoxical bradycardia also reported); throbbing headache, dizziness; less commonly nausea, vomiting, heartburn, flushing, syncope, temporary hypoxaemia, rash, application site reactions with transdermal patches; very rarely angle-closure glaucoma

Injection Specific side-effects following injection (particular if given too rapidly) include severe hypotension, diaphoresis, apprehension, restlessness, muscle twitching, retrosternal discomfort, palpitation, abdominal pain, prolonged administration has been associated with methaemoglobinemia

Dose

Sublingually, 0.3–1 mg, repeated as required; see also under preparations

By buccal administration, see under preparation

By intravenous infusion, 10–200 micrograms/minute, adjusted according to response; max. 400 micrograms/minute; consult product literature for recommended starting doses specific to indication

By transdermal application, see under preparations

Short-acting tablets and sprays

Glyceryl Trinitrate (Non-proprietary)

Sublingual tablets, glyceryl trinitrate 300 micrograms, net price 100 = £2.71; 500 micrograms, 100 = £3.27; 600 micrograms, 100 = £12.31. Label: 16

Note Glyceryl trinitrate tablets should be supplied in glass containers of not more than 100 tablets, closed with a foil-lined cap, and containing no cotton wool wadding; they should be discarded after 8 weeks in use

Aerosol spray, glyceryl trinitrate 400 micrograms/ metered dose, net price 200-dose unit = £3.13

Dose treatment or prophylaxis of angina, spray 1–2 doses under tongue and then close mouth
2.6.1 Nitrates

**Coro-Nitro Pump Spray®** (Aytont Saunders)  
**Aerosol spray,** glyceryl trinitrate 400 micrograms/metered dose, net price 200-dose unit = £3.13

**Dose**  
Treatment or prophylaxis of angina, spray 1–2 doses under tongue and then close mouth.

**Glytrin Spray®** (Sanofi-Aventis)  
**Aerosol spray,** glyceryl trinitrate 400 micrograms/metered dose, net price 200-dose unit = £3.29

**Dose**  
Treatment or prophylaxis of angina, spray 1–2 doses under tongue and then close mouth.

**Cautions**  
Flammable.

**GTN 300 mcg** (Martindale)  
**Sublingual tablets,** glyceryl trinitrate 300 micrograms, net price 100 = £2.71. Label: 16

**Nitroglycerin Pumpspray®** (Merck Serono)  
**Aerosol spray,** glyceryl trinitrate 400 micrograms/metered dose, net price 200-dose unit = £3.44

**Dose**  
Treatment or prophylaxis of angina, spray 1–2 doses under tongue and then close mouth.

**Nitromin®** (Egis)  
**Aerosol spray,** glyceryl trinitrate 400 micrograms/metered dose, net price 180-dose unit = £2.63, 200-dose unit = £2.71

**Dose**  
Treatment or prophylaxis of angina, spray 1–2 doses under tongue and then close mouth.

**Cautions**  
Flammable.

**Nitrolingual Pumpspray**  
**Injection**, glyceryl trinitrate 5 mg/mL. To be diluted before use or given undiluted with syringe pump. Net price 50-mL vial = £15.90

**Injection**, glyceryl trinitrate 1 mg/mL. To be diluted before use. Net price 5-mL amp = £6.49; 10-mL amp = £12.98

**Excipients** may include ethanol, propylene glycol (see Excipients, p. 2)

**Nitrospray®** (UCB Pharma)  
**Injection**, glyceryl trinitrate 1 mg/mL. To be diluted before use or given undiluted with syringe pump. Net price 10-mL amp = £5.88; 50-mL bottle = £13.77

**Excipients** include propylene glycol (see Excipients, p. 2)

**Nitronal®** (Merck Serono)  
**Injection**, glyceryl trinitrate 1 mg/mL. To be diluted before use or given undiluted with syringe pump. Net price 5-mL vial = £1.80; 50-mL vial = £14.76

### Transdermal preparations

**Deponit®** (UCB Pharma)  
**Patches,** self-adhesive, transparent, glyceryl trinitrate, '5' patch (releasing approx. 5 mg/24 hours when in contact with skin), net price 28 = £12.77; '10' patch (releasing approx. 10 mg/24 hours), 28 = £14.06

**Dose**  
Prophylaxis of angina, apply one '5' or one '10' patch to lateral chest wall, upper arm, thigh, abdomen, or shoulder. Increase to two '10' patches every 24 hours if necessary; replace every 24 hours, site replacement patch on different area; see also notes above (Tolerance).

**Minitran®** (Meda)  
**Patches,** self-adhesive, transparent, glyceryl trinitrate, '5' patch (releasing approx. 5 mg/24 hours when in contact with skin), net price 30 = £11.62; '10' patch (releasing approx. 10 mg/24 hours), 30 = £12.87; '15' patch (releasing approx. 15 mg/24 hours), 30 = £14.19

**Dose**  
Prophylaxis of angina, apply one '5' patch to chest or upper arm; replace every 24 hours, site replacement patch on different area; adjust dose according to response; see also notes above (Tolerance).

Maintenance of venous patency ('5' patch only), consult product literature.

**Nitro-Dur®** (Schering-Plough)  
**Patches,** self-adhesive, buff, glyceryl trinitrate, '0.2 mg/h' patch (releasing approx. 5 mg/24 hours when in contact with skin), net price 28 = £10.59; '0.4 mg/h' patch (releasing approx. 10 mg/24 hours), 28 = £11.72; '0.6 mg/h' patch (releasing approx. 15 mg/24 hours), 28 = £12.90

**Dose**  
Prophylaxis of angina, apply one '0.2 mg/h' patch to chest or outer upper arm; replace every 24 hours, site replacement patch on different area; adjust dose according to response; max. 15 mg in 24 hours; see also notes above (Tolerance).

**Perculot®** (Aspire)  
**Ointment,** glyceryl trinitrate 2%, net price 60 g = £59.65. Counselling, see administration below

**Excipients** include wool fat

**Dose**  
Prophylaxis of angina, usual dose 1–2 inches of ointment measured on to Appletrides®, and applied (usually to chest, arm, or thigh) without rubbing in and secured with surgical tape, every 3–4 hours as required; to determine dose, ½ inch on first day then increased by ½ inch/day until headache occurs, then reduced by ½ inch

**Note**  
Approx. 800 micrograms/hour absorbed from 1 inch of ointment

### ISOSORBIDE DINITRATE

#### Indications  
Prophylaxis and treatment of angina; left ventricular failure

**Cautions**  
see under Glyceryl Trinitrate

**Contra-indications**  
see under Glyceryl Trinitrate

**Hepatic impairment**  
see under Glyceryl Trinitrate

**Renal impairment**  
see under Glyceryl Trinitrate

**Pregnancy**  
may cross placenta—manufacturers advise avoid unless potential benefit outweighs risk

**Breast-feeding**  
see under Glyceryl Trinitrate
Isosorbide Mononitrate
• Initially 20 mg 2–3 times daily.
• By mouth, daily in divided doses, angina 30–120 mg, left ventricular failure 40–160 mg, up to 240 mg if required.
• By intravenous infusion, 2–10 mg/hour; higher doses up to 20 mg/hour may be required.

Short-acting tablets and sprays
Isosorbide Dinitrate (Non-proprietary)
Tablets, isosorbide dinitrate 10 mg, net price 56-tab pack = £12.24; 20 mg, 56-tab pack = £13.50

Angitak® (LPC)
Aerosol spray, isosorbide dinitrate 1.25 mg/metered dose, net price 200-dose unit = £3.95
Dose: treatment or prophylaxis of angina, spray 1–3 doses under tongue whilst holding breath; allow 30 second interval between each dose.

Modified-release preparations
Isoket Retard® (UCB Pharma)
Retard-20 tablets, m/r, scored, isosorbide dinitrate 20 mg, net price 56-tab pack = £2.58. Label: 25
Retard-40 tablets, m/r, scored, isosorbide dinitrate 40 mg, net price 56-tab pack = £6.36. Label: 25
Dose: prophylaxis of angina, 40 mg daily in 1–2 divided doses, increased if necessary to 60–80 mg daily in 2–3 divided doses.

Parenteral preparations
Isoket® (UCB Pharma) (w)
Injection 0.1%, isosorbide dinitrate 1 mg/mL. To be diluted before use. Net price 10-mL amp = £2.69
Note: Glass or polyethylene infusion apparatus is preferable, loss of potency if PVC used.

Isosorbide Mononitrate
Indications: prophylaxis of angina; adjunct in congestive heart failure
Cautions: see under Glyceryl Trinitrate
Contra-indications: see under Glyceryl Trinitrate
Hepatic impairment: see under Glyceryl Trinitrate
Renal impairment: see under Glyceryl Trinitrate
Pregnancy: manufacturers advise avoid unless potential benefit outweighs risk
Breast-feeding: see under Glyceryl Trinitrate
Side-effects: see under Glyceryl Trinitrate
Dose:
• Initially 20 mg 2–3 times daily or 40 mg twice daily (10 mg twice daily in those who have not previously received nitrates); up to 120 mg daily in divided doses if required.

Isosorbide Mononitrate (Non-proprietary)
Tablets, isosorbide mononitrate 10 mg, net price 56 = £1.05; 20 mg, 56 = £1.08; 40 mg, 56 = £1.40. Label: 25
Brands include: Anginec®

Elantan® (UCB Pharma)
Elantan 10 tablets, scored, isosorbide mononitrate 10 mg, net price 56-tab pack = £1.32; 84-tab pack = £4.97. Label: 25
Elantan 20 tablets, scored, isosorbide mononitrate 20 mg, net price 56-tab pack = £1.73; 84-tab pack = £8.13. Label: 25
Elantan 40 tablets, scored, isosorbide mononitrate 40 mg, net price 56-tab pack = £2.81; 84-tab pack = £10.56. Label: 25

Ismo® (Riemser)
Ismo 10 tablets, isosorbide mononitrate 10 mg, net price 60-tab pack = £3.31. Label: 25
Ismo 20 tablets, scored, isosorbide mononitrate 20 mg, net price 60-tab pack = £4.85. Label: 25

Modified release
Chemydur® 60XL (Sovereign) (w)
Tablets, m/r, scored, isosorbide mononitrate 60 mg, net price 28-tab pack = £3.99. Label: 25
Dose: prophylaxis of angina, 1 tablet in the morning (half a tablet for 2–4 days to minimise possibility of headache), increased if necessary to 2 tablets.

Elantan LA® (UCB Pharma)
Elantan LA 25 capsules, m/r, brown/white, enclosing white micropellets, isosorbide mononitrate 25 mg, net price 28-cap pack = £2.64. Label: 25
Dose: prophylaxis of angina, 1 capsule in the morning, increased if necessary to 2 capsules
Elantan LA 50 capsules, m/r, brown/pink, enclosing white micropellets, isosorbide mononitrate 50 mg, net price 28-cap pack = £3.69. Label: 25
Dose: prophylaxis of angina, 1 capsule daily in the morning, increased if necessary to 2 capsules

Imdur® (AstraZeneca)
Durules® (= tablets m/r), yellow, f/c, scored, isosorbide mononitrate 60 mg, net price 28-cap pack = £10.50. Label: 25
Dose: prophylaxis of angina, 1 tablet in the morning (half a tablet if headache occurs), increased to 2 tablets in the morning if required.

Isib 60XL® (Ranbaxy)
Tablets, m/r, scored, yellow, isosorbide mononitrate 60 mg, net price 28-tab pack = £8.15. Label: 25
Dose: prophylaxis of angina, 1 tablet in the morning (half a tablet for 2–4 days if headache occurs), increased if necessary to 2 tablets
Note: Also available as Cibral 60XL®, Ximox 60XL®

Ismo Retard® (Riemser)
Tablets, m/r, s/c, isosorbide mononitrate 40 mg, net price 30-tab pack = £10.71. Label: 25
Dose: prophylaxis of angina, 1 tablet daily in morning

Isodur® (Galeni)
Isodur 25XL capsules, m/r, brown/white, isosorbide mononitrate 25 mg, net price 28-cap pack = £5.50. Label: 25
Isodur 50XL capsules, m/r, brown/red, isosorbide mononitrate 50 mg, net price 28-cap pack = £6.50. Label: 25
Dose: prophylaxis of angina, 25–50 mg daily in the morning, increased if necessary to 50–100 mg once daily

Isotard® (ProStrakan)
Isotard 25XL tablets, m/r, ivory, isosorbide mononitrate 25 mg, net price 28-tab pack = £5.95. Label: 25
Isotard 40XL tablets, m/r, ivory, isosorbide mononitrate 40 mg, net price 28-tab pack = £6.78. Label: 25
Isotard 50XL tablets, m/r, ivory, isosorbide mononitrate 50 mg, net price 28-tab pack = £6.78. Label: 25
Isotard 60XL tablets, m/r, ivory, isosorbide mononitrate 60 mg, net price 28-tab pack = £5.75. Label: 25
Dose: prophylaxis of angina, 25–60 mg daily in the morning, increased if necessary to 60–120 mg daily

Modisal XL® (Sandoz)
Tablets, m/r, ivory, isosorbide mononitrate 60 mg, net price 28-tab pack = £10.36. Label: 25
Dose: prophylaxis of angina, 1 tablet daily in the morning (half a tablet for first 2–4 days to minimise possibility of headache), increased if necessary to 2 tablets once daily.
2.6.2 Calcium-channel blockers

Calcium-channel blockers (less correctly called ‘calcium-antagonists’) interfere with the inward displacement of calcium ions through the slow channels of active cell membranes. They influence the myocardial cells, the cells within the specialised conducting system of the heart, and the cells of vascular smooth muscle. Thus, myocardial contractility may be reduced, the formation and propagation of electrical impulses within the heart may be depressed, and coronary or systemic vascular tone may be diminished.

Calcium-channel blockers differ in their predilection for the various possible sites of action and, therefore, their therapeutic effects are disparate, with much greater variation than those of beta-blockers. There are important differences between verapamil, diltiazem, and the dihydropyridine calcium-channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine). Verapamil and diltiazem should usually be avoided in heart failure because they may further depress cardiac function and cause clinically significant deterioration.

Verapamil is used for the treatment of angina (section 2.10.1), hypertension (section 2.5), and arrhythmias (section 2.3.2). It is a highly negatively inotropic calcium-channel-blocker and it reduces cardiac output, slows the heart rate, and may impair atrioventricular conduction. It may precipitate heart failure, exacerbate conduction disorders, and cause hypotension at high doses and should not be used with beta-blockers (see p. 153). Constipation is the most common side-effect.

Nifedipine relaxes vascular smooth muscle and dilates coronary and peripheral arteries. It has more influence on vessels and less on the myocardium than does verapamil, and unlike verapamil has no anti-arrhythmic activity. It rarely precipitates heart failure because any negative inotropic effect is offset by a reduction in left ventricular work. Short-acting formulations of nifedipine are not recommended for angina or long-term management of hypertension; their use may be associated with large variations in blood pressure and reflex tachycardia. Nicardipine has similar effects to those of nifedipine and may produce less reduction of myocardial contractility. Amlodipine and felodipine also resemble nifedipine and nicardipine in their effects and do not reduce myocardial contractility and they do not produce clinical deterioration in heart failure. They have a longer duration of action and can be given once daily. Nifedipine, nicardipine, amlodipine, and felodipine are used for the treatment of angina (section 2.10.1) or hypertension. All are valuable in forms of angina associated with coronary vasospasm. Side-effects associated with vasodilatation such as flushing and headache (which become less obtrusive after a few days), and ankle swelling (which may respond only partially to diuretics) are common.

Iratazpine, lacidipine, and lercanidipine have similar effects to those of nicardipine and nifedipine; they are indicated for hypertension only.

Nimodipine is related to nifedipine but the smooth muscle relaxant effect preferentially acts on cerebral arteries. Its use is confined to prevention and treatment of vascular spasm following aneurysmal subarachnoid haemorrhage.

Diltiazem is effective in most forms of angina (section 2.10.1); the longer-acting formulation is also used for hypertension. It may be used in patients for whom beta-blockers are contra-indicated or ineffective. It has a less negative inotropic effect than verapamil and significant myocardial depression occurs rarely. Nevertheless because of the risk of bradycardia it should be used with caution in association with beta-blockers.

Unstable angina

Calcium-channel blockers do not reduce the risk of myocardial infarction in unstable angina. The use of diltiazem or verapamil should be reserved for patients resistant to treatment with beta-blockers.

Withdrawal

There is some evidence that sudden withdrawal of calcium-channel blockers may be associated with an exacerbation of angina.

AMLODIPINE

Indications hypertension, prophylaxis of angina
Cautions acute porphyria (but see section 9.8.2); interactions: Appendix 1 (calcium-channel blockers)
Contra-indications cardiogenic shock, unstable angina, significant aortic stenosis
Hepatic impairment may need dose reduction—half-life prolonged
Pregnancy no information available—manufacturer advises avoid, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension
Breast-feeding manufacturer advises avoid—no information available

Monoxam® SR, capsules, m/r, isosorbide mononitrate 40 mg, net price 28-cap pack = £6.52; 60 mg, 28-cap pack = £8.86. Label: 25
Note Available as Anerge SR®

Monoxam XL tablets, m/r, isosorbide mononitrate 60 mg, net price 28-tab pack = £5.25. Label: 25
Note Prophylaxis of angina, in the morning (half a tablet for first 2–4 days to minimise possibility of headache), increased if necessary to 2 tablets

Monoxim XL® (TEVA UK) Tablets, m/r, isosorbide mononitrate 60 mg, net price 28-tab pack = £3.98. Label: 25
Note Prophylaxis of angina, 1 tablet daily in the morning (half a tablet daily for first 2–4 days to minimise possibility of headache), increased if necessary to 2 tablets once daily

Monosorb XL 60® (Dexcel) Tablets, m/r, f/c, isosorbide mononitrate 60 mg, net price 28-tab pack = £16.66. Label: 25
Note Prophylaxis of angina, 1 tablet daily in the morning (half a tablet for first 2–4 days to minimise possibility of headache), increased if necessary to 2 tablets

Zemon® (Neolab)
Zemon 40XL tablets, m/r, t/c, isosorbide mononitrate 40 mg, net price 28-tab pack = £14.25. Label: 25
Zemon 60XL tablets, scored, m/r, t/c, isosorbide mononitrate 60 mg, net price 28-tab pack = £11.14. Label: 25
Note Prophylaxis of angina, 40–60 mg daily in the morning (half a 60 mg tablet may be given for 2–4 days to minimise possibility of headache), increased if necessary to 80–120 mg once daily
Side-effects abdominal pain, nausea; palpitation, flushing, oedema; headache, dizziness, sleep disturbances, fatigue; less commonly gastro-intestinal disturbances, dry mouth, taste disturbances, hypotension, syncope, chest pain, dyspnoea, rhinitis, mood changes, asthenia, tremor, paraesthesia, urinary disturbances, impotence, gynaecomastia, weight changes, myalgia, muscle cramps, back pain, arthralgia, visual disturbances, tinnitus, pruritus, rashes (including isolated reports of erythema multiforme), sweating, alopecia, purpura, and skin discolouration; very rarely gastritis, pancreatitis, hepatitis, jaundice, cholestasis, gingival hyperplasia, myocardial infarction, arrhythmias, tachycardia, vasculitis, coughing, peripheral neuropathy, hyperglycaemia, thrombocytopenia, angioedema, and urticaria

Dose
- Hypertension or angina, initially 5 mg once daily; max. 10 mg once daily
Note Tablets from various suppliers may contain different salts (e.g. amlodipine besilate, amlodipine maleate, and amlodipine mesilate) but the strength is expressed in terms of amlodipine (e.g. amlodipine besilate, amlodipine maleate, and amlodipine mesilate) but the strength is expressed in terms of amlodipine (base); tablets containing different salts are considered interchangeable.

Amlodipine (Non-proprietary)

Tablets, amlodipine (as maleate or as mesilate) 5 mg, net price 28-tab pack = £1.05; 10 mg, 28-tab pack = £1.20
Brands include Amlodin®

Istin® (Pfizer)
Tablets, amlodipine (as besilate) 5 mg, net price 28-tab pack = £1.10; 10 mg, 28-tab pack = £1.55

With valsartan
Note For hypertension in patients stabilised on the individual components in the same proportions. For prescribing information on valsartan, see section 2.5.5.2

Exforge® (Novartis) ▼

Tablets 5/80, I/c, dark yellow, amlodipine 5 mg, valsartan 80 mg, net price 28-tab pack = £13.97
Tablets 5/160, I/c, dark yellow, amlodipine 5 mg, valsartan 160 mg, net price 28-tab pack = £18.41
Tablets 10/160, I/c, light yellow, amlodipine 10 mg, valsartan 160 mg, net price 28-tab pack = £18.41

DILTIAZEM HYDROCHLORIDE

Indications prophylaxis and treatment of angina; hypertension

Cautions heart failure or significantly impaired left ventricular function, bradycardia (avoid if severe), first degree AV block, or prolonged PR interval; interactions: Appendix 1 (calcium-channel blockers)

Contra-indications severe bradycardia, left ventricular failure with pulmonary congestion, second- or third-degree AV block (unless pacemaker fitted), sick sinus syndrome; acute porphyria (section 9.6.2)

Hepatic impairment reduce-dose

Renal impairment start with smaller dose

Pregnancy avoid

Breast-feeding significant amount present in milk—no evidence of harm but avoid unless no safer alternative

Side-effects bradycardia, sino-atrial block, AV block, palpitation, dizziness, hypotension, malaise, asthenia, headache, hot flushes, gastro-intestinal disturbances, oedema (notably of ankles); rarely rashes (including erythema multiforme and exfoliative dermatitis), photosensitivity; hepatitis, gynaecomastia, gum hyperplasia, extrapyramidal symptoms, depression reported

Dose
- Angina, 60 mg 3 times daily (elderly initially twice daily); increased if necessary to 360 mg daily
- Longer-acting formulations, see under preparations below

Standard formulations
Note These formulations are licensed as generics and there is no requirement for brand name dispensing. Although their means of formulation has called for the strict designation ‘modified-release’ their duration of action corresponds to that of tablets requiring administration 3 times daily

Diltiazem (Non-proprietary) ▼

Tablets, m/r (but see note above), diltiazem hydrochloride 60 mg, net price 84 = £2.93. Label: 25
Brands include Opti®

Tildiem® (Sanofi-Aventis) ▼
Tablets, m/r (but see note above), off-white, diltiazem hydrochloride 60 mg, net price 90-tab pack = £7.96. Label: 25

Longer-acting formulations
Note Different versions of modified-release preparations containing more than 60 mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed

Adizem-SR® (Napp) ▼
Capsules, m/r, diltiazem hydrochloride 90 mg (white), net price 56-cap pack = £8.45; 120 mg (brown/white), 56-cap pack = £9.40; 180 mg (brown/white), 56-cap pack = £14.08. Label: 25
Tablets, m/r, I/c, scored, diltiazem hydrochloride 120 mg, net price 56-tab pack = £14.72. Label: 25
Dose mild to moderate hypertension, usually 120 mg twice daily (dose form not appropriate for initial dose titration)
Angina, initially 90 mg twice daily (elderly, dose form not appropriate for initial dose titration), increased to 180 mg twice daily if required

Adizem-XL® (Napp) ▼
Capsules, m/r, diltiazem hydrochloride 120 mg (pink/blue), net price 28-cap pack = £9.09; 180 mg (dark pink/blue), 28-cap pack = £10.32; 200 mg (brown), 28-cap pack = £6.66; 240 mg (red/blue), 28-cap pack = £11.46; 300 mg (maroon/blue), 28-cap pack = £9.09. Label: 25
Dose angina and mild to moderate hypertension, initially 240 mg once daily, increased if necessary to 300 mg once daily; in elderly and in hepatic or renal impairment, initially 120 mg daily

Angitil SR® (Chiesi) ▼
Capsules, m/r, diltiazem hydrochloride 90 mg (white), net price 56-cap pack = £7.03; 120 mg (brown), 56-cap pack = £6.91; 180 mg (brown), 56-cap pack = £13.27. Label: 25
Dose angina and mild to moderate hypertension, initially 90 mg twice daily; increased if necessary to 120 mg or 180 mg twice daily

Angitil XL® (Chiesi) ▼
Capsules, m/r, diltiazem hydrochloride 240 mg (white), net price 28-cap pack = £7.94; 300 mg (yellow), 28-cap pack = £8.98. Label: 25
Dose angina and mild to moderate hypertension, initially 240 mg once daily (elderly and in hepatic and renal impairment, dose form not appropriate for initial dose titration), increased if necessary to 300 mg once daily
2.6.2 Calcium-channel blockers

CalciCard CR® (IVAX) 
Tablets, m/r, both f/c, diltiazem hydrochloride 90 mg, net price 56-tab pack = £6.33; 120 mg, 56-tab pack = £7.04. Label: 25

Dose mild to moderate hypertension, initially 90 mg or 120 mg twice daily; up to 360 mg daily may be required; ELDERLY and in hepatic and renal impairment, initially 120 mg once daily; up to 240 mg daily may be required

Angina, initially 90 mg or 120 mg twice daily; up to 480 mg daily in divided doses may be required. ELDERLY and in hepatic and renal impairment, dose form not appropriate for initial dose titration; up to 240 mg daily may be required

Dilzem SR® (Generics) 
Capsules, m/r, both f/c, diltiazem hydrochloride 60 mg (pink/white), net price 56-cap pack = £6.03; 90 mg (pink/yellow), 56-cap pack = £10.33; 120 mg (pink/orange), 56-cap pack = £11.49. Label: 25

Dose angina and mild to moderate hypertension, initially 90 mg twice daily; increased if necessary to up to 180 mg twice daily; ELDERLY and in hepatic or renal impairment, initially 60 mg twice daily; max. 90 mg twice daily

Dilzem XL® (Cephalon) 
Tablets, m/r, all beige, diltiazem hydrochloride 60 mg, net price 56-cap pack = £6.03; 90 mg, 56-cap pack = £11.29; 120 mg, 56-cap pack = £12.89. Label: 25

Dose angina and mild to moderate hypertension, initially 90 mg twice daily (elderly 60 mg twice daily); up to 180 mg twice daily may be required

Dilzem SR® (Cephalon) 
Capsules, m/r, both f/c, diltiazem hydrochloride 120 mg, net price 28-cap pack = £7.78; 180 mg, 28-cap pack = £11.55; 240 mg, 28-cap pack = £11.03. Label: 25

Dose angina and mild to moderate hypertension, initially 90 mg once daily; increased if necessary to 120 mg once daily; ELDERLY and in hepatic or renal impairment, initially 60 mg once daily; max. 90 mg twice daily

Dilzem XL® (Cephalon) 
Capsules, m/r, diltiazem hydrochloride 120 mg, net price 28-cap pack = £7.78; 180 mg, 28-cap pack = £11.55; 240 mg, 28-cap pack = £11.03. Label: 25

Dose angina and mild to moderate hypertension, initially 180 mg once daily (elderly and in hepatic and renal impairment, 120 mg once daily); if necessary may be increased to 360 mg once daily

Slozem® (Merck Serono) 
Capsules, m/r, diltiazem hydrochloride 120 mg (pink/clear), net price 28-cap pack = £7.00; 180 mg (pink/clear), 28-cap pack = £7.80; 240 mg (red/clear), 28-cap pack = £8.20; 300 mg (red/white), 28-cap pack = £8.50. Label: 25

Dose angina and mild to moderate hypertension, initially 240 mg once daily (elderly and in hepatic and renal impairment, 120 mg once daily); if necessary may be increased to 360 mg once daily

Tildium LA® (Sanofi-Aventis) 
Capsules, m/r, diltiazem hydrochloride 200 mg (pink/grey, containing white pellets), net price 28-cap pack = £6.27; 300 mg (white/yellow, containing white pellets), 28-cap pack = £7.22. Label: 25

Dose angina and mild to moderate hypertension, initially 200 mg once daily before or with food, increased if necessary to 300–400 mg daily. ELDERLY and in hepatic or renal impairment, initially 200 mg daily, increased if necessary to 300 mg daily

Tildium Retard® (Sanofi-Aventis) 
Tablets, m/r, diltiazem hydrochloride 90 mg, net price 56-tab pack = £7.27; 120 mg, 56-tab pack = £7.15. Label: 25

Counselling Tablet membrane may pass through gastrointestinal tract unchanged, but being porous has no effect on efficacy

Dose mild to moderate hypertension, initially 90 mg or 120 mg twice daily; increased if necessary to 360 mg daily in divided doses; ELDERLY and in hepatic or renal impairment, initially 120 mg once daily, increased if necessary to 240 mg daily twice daily; if necessary may be increased to 480 mg daily in divided doses; ELDERLY and in hepatic or renal impairment, dose form not appropriate for initial titration; up to 120 mg twice daily may be required

Viazem XL® (Generics) 
Capsules, m/r, diltiazem hydrochloride 120 mg (lavender), net price 28-cap pack = £6.60; 180 mg (white/blue-green), 28-cap pack = £7.36; 240 mg (blue-green/lavender), 28-cap pack = £7.74; 300 mg (white/lavender), 28-cap pack = £8.03, 360 mg (blue-green), 28-cap pack = £13.85. Label: 25

Dose angina and mild to moderate hypertension, initially 180 mg once daily, adjusted according to response to 240 mg once daily; max. 360 mg once daily; ELDERLY and in hepatic or renal impairment, initially 120 mg once daily, adjusted according to response

Zemtard® (Astellas) 
Capsules, m/r, brown/orange, diltiazem hydrochloride 120 mg, net price 28-cap pack = £6.10. Label: 25

Zemtard 120XL capsules, m/r, brown/orange, diltiazem hydrochloride 120 mg, net price 28-cap pack = £6.10. Label: 25

Zemtard 180XL capsules, m/r, grey/pink, diltiazem hydrochloride 180 mg, net price 28-cap pack = £6.20. Label: 25

Zemtard 240XL capsules, m/r, blue, diltiazem hydrochloride 240 mg, net price 28-cap pack = £6.30. Label: 25

Zemtard 300XL capsules, m/r, white/blue, diltiazem hydrochloride 300 mg, net price 28-cap pack = £6.70. Label: 25

Dose angina and mild to moderate hypertension, 180–300 mg once daily, increased if necessary to 360 mg once daily in hypertension and to 480 mg once daily in angina. ELDERLY and in hepatic or renal impairment, initially 120 mg once daily

**FELODIPINE**

**Indications** hypertension, prophylaxis of angina

**Cautions** withdraw if ischaemic pain occurs or existing pain worsens shortly after initiating treatment or if cardiogenic shock develops; severe left ventricular dysfunction; avoid grapefruit juice (may affect metabolism); acute porphyria (but see section 9.8.2);

**Interactions:** Appendix 1 (calcium-channel blockers)

**Contra-indications** unstable angina, uncontrolled heart failure; significant aortic stenosis; within 1 month of myocardial infarction

**Hepatic impairment** reduce dose

**Pregnancy** avoid; toxicity in animal studies; may inhibit labour

**Breast-feeding** present in milk

**Side-effects** flushing, headache, palpitation, dizziness, fatigue, gravitational oedema; rarely rash, pruritus, cutaneous vasculitis, gum hyperplasia, urinary frequency, impotence, fever

**Dose**

- Hypertension, initially 5 mg (elderly 2.5 mg) daily in the morning; usual maintenance 5–10 mg once daily; doses above 20 mg daily rarely needed
- Angina, initially 5 mg daily in the morning; increased if necessary to 10 mg once daily

**Felodipine** (Non-proprietary)

**Tablets**

- Felodipine 2.5 mg, net price 28-tab pack = £6.31; 5 mg, 28-tab pack = £4.21; 10 mg, 28-tab pack = £5.66, 30-tab pack = £12.87. Label: 25

**Brands include Cardioplen XL®, Zemtard XL®,** Felogen XL®, Plendil®, Viazem XL®

**Plendil** (AstraZeneca) 
Tablets, m/r, felodipine 2.5 mg (yellow), net price 28-tab pack = £6.31; 5 mg (pink), 28-tab pack = £4.21; 10 mg (brown), 28-tab pack = £5.66. Label: 25
**ISRADIPINE**

**Indications** hypertension

**Cautions** sick sinus syndrome (if pacemaker not fitted); avoid grapefruit juice (may affect metabolism); poor cardiac reserve; **interactions:** Appendix 1 (calcium-channel blockers)

**Contra-indications** cardiogenic shock; symptomatic or tight aortic stenosis; during or within 1 month of myocardial infarction; unstable angina; acute porphyria (section 9.8.2)

**Hepatic impairment** reduce dose

**Renal impairment** reduce dose

**Pregnancy** may inhibit labour; risk to fetus should be balanced against risk of uncontrolled maternal hypertension

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** abdominal discomfort; tachycardia, palpitation, flushing, peripheral oedema; dyspnoea; headache; fatigue, dizziness; polyuria; rash; less commonly hypertension, weight gain; very rarely vomiting, nausea; tumours, pulmonary oedema, anorexia, drowsiness, arrhythmia, bradycardia, heart failure; cough, depression, paraesthesia, anxiety, erectile dysfunction, blood disorders (such as thrombocytopenia, leucopenia, anaemia), arthralgia, visual disturbance, hypersensitivity reactions; hepatitis and gynaecomastia also reported

**Dose**
- 2.5 mg twice daily, increased if necessary after 3–4 weeks to 5 mg twice daily (exceptionally up to 10 mg twice daily); **Elderly** (or in hepatic or renal impairment) 1.25 mg twice daily, increased if necessary after 3–4 weeks according to response, maintenance dose of 2.5 mg or 5 mg once daily may be sufficient

**Presca** (Novartis) **Tablets**
- Yellow, scored, isradipine 2.5 mg, net price 56-tab pack = £16.54

**NICARDIPINE HYDROCHLORIDE**

**Indications** prophylaxis of angina; mild to moderate hypertension

**Cautions** withdraw if ischaemic pain occurs or existing pain worsens within 30 minutes of initiating treatment or increasing dose; congestive heart failure or significantly impaired left ventricular function; elderly; avoid grapefruit juice (may affect metabolism); **interactions:** Appendix 1 (calcium-channel blockers)

**Contra-indications** cardiogenic shock; advanced aortic stenosis; unstable or acute attacks of angina; avoid within 1 month of myocardial infarction; acute porphyria (section 9.8.2)

**Hepatic impairment** half-life prolonged in severe impairment—may need dose reduction

**Renal impairment** start with small dose

**Pregnancy** may inhibit labour; toxicity in animal studies; manufacturer advises avoid, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** dizziness, headache, peripheral oedema, flushing, palpitation, nauscea; also gastro-intestinal disturbances, drowsiness, insomnia, tinnitus, hypotension, rashes, dyspnoea, paraesthesia, frequency of micturition; thrombocytopenia, depression and impotence reported

**Motens®** (Boehringer Ingelheim) **Tablets**, both f/c, lercanidipine 2 mg, net price 28-tab pack = £2.95; 4 mg (scored), 28-tab pack = £3.10

**LERCANIDIPINE HYDROCHLORIDE**

**Indications** mild to moderate hypertension

**Cautions** left ventricular dysfunction; sick sinus syndrome (if pacemaker not fitted); avoid grapefruit juice (may affect metabolism); **interactions:** Appendix 1 (calcium-channel blockers)

**Contra-indications** aortic stenosis; unstable angina, uncontrolled heart failure; within 1 month of myocardial infarction; acute porphyria (section 9.8.2)

**Hepatic impairment** avoid in severe disease

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** avoid if eGFR less than 30 mL/minute/1.73 m²

**Breast-feeding** manufacturer advises avoid

**Side-effects** less commonly flushing, peripheral oedema, palpitation, tachycardia, headache, dizziness; rarely gastro-intestinal disturbances, angina, asthenia, drowsiness, polyuria, myalgia, rash; very rarely gingival hyperplasia, myocardial infarction, hypotension

**Dose**
- Initially 10 mg once daily; increased, if necessary, after at least 2 weeks to 20 mg daily

**Lercanidipine Hydrochloride** (Non-proprietary)

**Tablets**, lercanidipine hydrochloride 10 mg, net price 28-tab pack = £5.52; 20 mg, 28-tab pack = £8.56.

Label: 22

**Zanidip®** (Recordati) **Tablets**, f/c, lercanidipine hydrochloride 10 mg (yellow), net price 28-tab pack = £5.70; 20 mg (pink), 28-tab pack = £10.82.

Label: 22

**LACIDIPINE**

**Indications** hypertension

**Cautions** cardiac conduction abnormalities; poor cardiac reserve; avoid grapefruit juice (may affect metabolism); **interactions:** Appendix 1 (calcium-channel blockers)

**Contra-indications** cardiogenic shock, unstable angina, aortic stenosis; avoid within 1 month of myocardial infarction; acute porphyria (section 9.8.2)

**Hepatic impairment** antihypertensive effect possibly increased

**Pregnancy** manufacturer advises avoid; may inhibit labour

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** flushing, palpitation, oedema; headache, dizziness; rarely gastro-intestinal disturbances, gum hyperplasia, aggravation of angina, mood disturbances, asthenia, polyuria, muscle cramps, skin rash (including pruritus and erythema)

**Dose**
- Initially 2 mg as a single daily dose, preferably in the morning; increased after 3–4 weeks to 4 mg daily; then if necessary to 6 mg daily

Label: 22

BNF 61

2. Cardiovascular system

2.6.2 Calcium-channel blockers 131
Cardiovascular system

Dose

- Initially 20 mg 3 times daily increased, after at least three days, to 30 mg 3 times daily (usual range 60–120 mg daily)

Nicardipine (Non-proprietary) [BNF 61]

- Capsules, nicardipine hydrochloride 20 mg, net price 56-cap pack = £4.02; 30 mg, 56-cap pack = £5.16

Cardene® (Astellas) [BNF 61]

- Capsules, nicardipine hydrochloride 20 mg (blue/white), net price 56-cap pack = £6.00; 30 mg (blue/pale blue), 56-cap pack = £6.96

Modified release

Cardene SR® (Astellas) [BNF 61]

- Capsules, m/r, nicardipine hydrochloride 30 mg, net price 56-cap pack = £7.15; 45 mg (blue), 56-cap pack = £10.40. Label: 25
- Dose mild to moderate hypertension, initially 30 mg twice daily; usual effective dose 45 mg twice daily (range 30–60 mg twice daily)

NIFEDIPINE

Indications

- prophylaxis of angina; hypertension;
- Raynaud’s phenomenon

Caution

- see notes above: also withdraw if ischaemic pain occurs or existing pain worsens shortly after initiating treatment; poor cardiac reserve; heart failure or significantly impaired left ventricular function (heart failure deterioration observed); severe hypotension; elderly; diabetes mellitus; avoid grapefruit juice (may affect metabolism); acute porphyria (but see section 9.8.2);
- interactions: Appendix 1 (calcium-channel blockers)

Contra-indications

- cardiacogenic shock; advanced aortic stenosis; within 1 month of myocardial infarction; unstable or acute attacks of angina

Hepatic impairment

dose reduction may be required in severe liver disease

Pregnancy

- may inhibit labour; manufacturer advises avoid before week 20; risk to fetus should be balanced against risk of uncontrolled maternal hypertension; use only if other treatment options are not indicated or have failed

Breast-feeding

- amount too small to be harmful but manufacturers advise avoid

Side-effects

- gastrointestinal disturbance: hypo-tension, oedema, vasodilatation, palpitation; headache, dizziness, lethargy, asthenia; less commonly tachycardia, syncope, chills, nasal congestion, dyspnoea, anxiety, sleep disturbance, vertigo, migraine, paraesthesia, tremor, polyuria, dysuria, nocturia, erectile dysfunction, epistaxis, myalgia, joint swelling, visual disturbance, sweating, hypersensitivity reactions (including angioedema, jaundice, pruritus, urticaria, and rash); rarely anorexia, gum hyperplasia, mood disturbances, hyperglycaemia, male infertility, purpura, and photosensitivity reactions; also reported dysphagia, intestinal obstruction, intestinal ulcer, bezoar formation (with some modified-release preparations), gynaecomastia, agranulocytosis, and anaphylaxis

Dose

- See preparations below

Nifedipine (Non-proprietary) [BNF 61]

- Capsules, nifedipine 5 mg, net price 84-cap pack = £2.97; 10 mg, 84-cap pack = £4.00
- Dose angina prophylaxis (but not recommended, see notes above) and Raynaud’s phenomenon, initially 5 mg 3 times daily, adjusted according to response to 20 mg 3 times daily
- Hypertension, not recommended therefore no dose stated

Adalat® (Bayer Schering) [BNF 61]

- Capsules, orange, nifedipine 5 mg, net price 90-cap pack = £5.73; 10 mg, 90-cap pack = £7.30
- Dose angina prophylaxis (but not recommended, see notes above) and Raynaud’s phenomenon, initially 5 mg 3 times daily, adjusted according to response to max. 20 mg 3 times daily
- Hypertension, not recommended therefore no dose stated

Adalat® LA (Bayer Schering) [BNF 61]

- LA 20 tablets, m/r, f/c, pink, nifedipine 20 mg, net price 28-tab pack = £4.97. Label: 25
- LA 30 tablets, m/r, f/c, pink, nifedipine 30 mg, net price 28-tab pack = £6.85. Label: 25
- LA 60 tablets, m/r, f/c, pink, nifedipine 60 mg, net price 28-tab pack = £9.03. Label: 25
- Counselling Tablett membrane may pass through gastro-intestinal tract unchanged, but being porous has no effect on efficacy
- Caution dose form not appropriate for use in hepatic impairment or where there is a history of oesophageal or gastro-intestinal obstruction, decreased lumen diameter of the gastro-intestinal tract, or inflammatory bowel disease
- Dose hypertension, 20–30 mg once daily, increased if necessary to max. 90 mg once daily
- Angina prophylaxis, 30 mg once daily, increased if necessary to max. 90 mg once daily

Adalat® Retard (Bayer Schering) [BNF 61]

- Retard 10 tablets, m/r, f/c, grey-pink, nifedipine 10 mg, net price 56-tab pack = £7.34. Label: 25
- Retard 20 tablets, m/r, f/c, grey-pink, nifedipine 20 mg, net price 56-tab pack = £8.81. Label: 25
- Dose hypertension and angina prophylaxis, 10 mg twice daily, adjusted according to response to 40 mg twice daily

Adipine® MR (Chiesi) [BNF 61]

- Tablets, m/r, nifedipine 10 mg (pink), net price 56-tab pack = £3.73; 20 mg (pink), 56-tab pack = £5.21. Label: 25
- Dose hypertension and angina prophylaxis, 10 mg twice daily, adjusted according to response to 40 mg twice daily

Adipine® XL (Chiesi) [BNF 61]

- Tablets, m/r, red, nifedipine 30 mg, net price 28-tab pack = £4.70; 60 mg, 28-tab pack = £7.10. Label: 25
- Dose hypertension and angina prophylaxis, 30 mg once daily, increased if necessary, max. 90 mg once daily

Coracten SR® (UCB Pharma) [BNF 61]

- Capsules, m/r, nifedipine 10 mg (grey/pink, enclosing yellow pellets), net price 60-cap pack = £3.90; 20 mg (pink/brown, enclosing yellow pellets), 60-cap pack = £5.41. Label: 25
- Dose hypertension and angina prophylaxis, 10 mg twice daily, increased if necessary to max. 40 mg twice daily
Coracens XL® (UCB Pharma) Tablets, m/r, nifedipine 30 mg (brown), net price 28-cap pack = £4.89; 60 mg (orange), 28-cap pack = £7.34. Label: 25 Dose hypertension and angina prophylaxis, 30 mg once daily, increased if necessary; max. 90 mg once daily

Fortipine LA 40® (Goldshield) Tablets, m/r, red, nifedipine 40 mg, net price 30-tab pack = £9.60. Label: 21, 25 Dose hypertension and angina prophylaxis, 40 mg once daily, increased if necessary to 80 mg daily in 1-2 divided doses

Hypolar® Retard 20 (Sandoz) Tablets, m/r, red, f/c, nifedipine 20 mg, net price 56-tab pack = £5.75. Label: 25 Dose hypertension and angina prophylaxis, 20 mg twice daily, increased if necessary to 40 mg twice daily

Nifedipress Tablets, m/r, pink, nifedipine 10 mg, net price 56-tab pack = £9.23; 20 mg, 56-tab pack = £10.06. Label: 25 Dose hypertension and angina prophylaxis, initially 10 mg twice daily adjusted according to response to 40 mg twice daily Note Also available as Calchon® MR, Kentipine® MR

Tensipine MR® (Genus) Tablets, m/r, pink-grey, nifedipine 10 mg, net price 56-tab pack = £4.30; 20 mg, 56-tab pack = £5.49. Label: 21, 25 Dose hypertension and angina prophylaxis, initially 10 mg twice daily adjusted according to response to 40 mg twice daily

Valni XL® (Winthrop) Tablets, m/r, red, nifedipine 30 mg, net price 28-tab pack = £7.29; 60 mg, 28-tab pack = £9.13. Label: 25 Cautions dose form not appropriate for use in hepatic impairment, or where there is a history of oesophageal or gastro-intestinal obstruction, decreased lummen diameter of the gastro-intestinal tract, inflammatory bowel disease, or ileostomy after proctocolectomy. Dose severe hypertension and prophylaxis of angina, 30 mg once daily, increased if necessary to max. 90 mg once daily

With atenolol Section 2.4

**NIMODIPINE**

**Indications** prevention and treatment of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage

**Cautions** cerebral oedema or severely raised intracranial pressure; hypotension; avoid concomitant administration of nimodipine tablets and infusion, other calcium-channel blockers, or beta-blockers; concomitant nephrotoxic drugs; avoid grapefruit juice (may affect metabolism); interactions: Appendix 1 (calcium-channel blockers)

**Contra-indications** within 1 month of myocardial infarction; unstable angina; acute porphyria (section 9.8.2)

**Hepatic impairment** elimination reduced in cirrhosis—monitor blood pressure

**Renal impairment** manufacturer advises monitor renal function closely with intravenous administration

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid—present in milk

**Side-effects** hypotension, variation in heart-rate, flushing, headache, gastro-intestinal disorders, nausea, sweating and feeling of warmth; thrombocytopenia and leucopenia reported

---

**VERAPAMIL HYDROCHLORIDE**

**Indications** see under Dose and preparations

**Cautions** first-degree AV block; acute phase of myocardial infarction (avoid if bradycardia, hypotension, left ventricular failure); patients taking beta-blockers (important: see below); avoid grapefruit juice (may affect metabolism); interactions: Appendix 1 (calcium-channel blockers)

**Contra-indications** hypotension, bradycardia, second- and third-degree AV block; sick sinus syndrome, cardiogenic shock, sino-atrial block; history of heart failure or significantly impaired left ventricular function, even if controlled by therapy; atrial flutter or fibrillation associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome); acute porphyria (section 9.8.2)

**Hepatic impairment** oral dose may need to be reduced

**Pregnancy** may reduce uterine blood flow with fetal hypoxia; manufacturer advises avoid in first trimester unless absolutely necessary; may inhibit labour

**Breast-feeding** amount too small to be harmful

**Side-effects** constipation; less commonly nausea, vomiting, flushing, headache, dizziness, fatigue, anorexia oedema; rarely allergic reactions (erythema, pruritus, urticaria, angioedema, Stevens-Johnson syndrome); myalgia, arthralgia, paraesthesia, erythromelalgia; increased prolactin concentration; rarely gynaecomastia and gingival hyperplasia after long-term treatment; after intravenous administration or high doses, hypotension, heart failure, bradycardia, heart block, and asystole

**Dose**

- By mouth, supraventricular arrhythmias (but see also Contra-indications), 40–120 mg 3 times daily
- Angina, 80–120 mg 3 times daily
- Hypertension, 240–480 mg daily in 2–3 divided doses
2.6.3 Other antianginal drugs

Prophylaxis of cluster headache [unlicensed] (under specialist supervision), 240–960 mg daily in 3–4 divided doses

- By slow intravenous injection over 2 minutes (3 minutes in elderly), supraventricular arrhythmias (but see also Contra-indications), 5–10 mg (preferably with ECG monitoring); in paroxysmal tachyarrhythmias a further 5 mg after 5–10 minutes if required

Verapamil (Non-proprietary) (Abbott)
Tablets, coated, verapamil hydrochloride 40 mg, net price 84-tab pack = £1.55; 80 mg, 84-tab pack = £1.91; 120 mg, 28-tab pack = £1.54; 160 mg, 56-tab pack = £2.80
Oral solution, verapamil hydrochloride 40 mg/5 mL, net price 150 mL = £36.90
Brands include Zolvent®

Cordilox® (Dexcel) (Abbott)
Tablets, yellow, f/c, verapamil hydrochloride 40 mg, net price 84-tab pack = £1.50; 80 mg, 84-tab pack = £2.05; 120 mg, 28-tab pack = £1.15; 160 mg, 56-tab pack = £2.80
Injection, verapamil hydrochloride 2.5 mg/mL, net price 2-mL amp = £1.08
Brands include

Securon® (Abbott) (Chiesi)
Tablets, pale green, f/c, scored, verapamil hydrochloride 240 mg, net price 28-tab pack = £5.00. Label: 25
Dose see Securon®

Securon SR® (Abbott) (Chiesi)
Tablets, m/r, pale green, f/c, scored, verapamil hydrochloride 240 mg, net price 28-tab pack = £5.00. Label: 25
Dose hypertension, 240 mg daily (new patients initially 120 mg), increased if necessary to max. 480 mg daily (doses above 240 mg daily as 2 divided doses)
Angina, 240 mg twice daily (may sometimes be reduced to once daily)
Prophylaxis after myocardial infarction where beta-blockers not appropriate (started at least 1 week after infarction), 360 mg daily, max. 480 mg daily
Univer® (Cephalon) (Abbott)
Capsules, m/r, verapamil hydrochloride 120 mg (yellow/dark blue), net price 28-cap pack = £4.86; 180 mg (yellow), 56-cap pack = £11.38; 240 mg (yellow/dark blue), 28-cap pack = £7.87. Label: 25
Dose hypertension, 240 mg daily, max. 480 mg daily (new patients, initial dose 120 mg). Angina, 360 mg daily, max. 480 mg daily
Verapress MR® (Dexcel) (Abbott)
Tablets, m/r, pale green, f/c, verapamil hydrochloride 240 mg, net price 28-tab pack = £6.04. Label: 25
Dose hypertension, 1 tablet daily, increased to twice daily if necessary. angina, 1 tablet twice daily (may be reduced to once daily)
Note Also available as Cordilox®
Vertab® SR 240 (Chiesi) (Abbott)
Tablets, m/r, pale green, f/c, scored, verapamil hydrochloride 240 mg, net price 28-tab pack = £5.45. Label: 25
Dose mild to moderate hypertension, 240 mg daily, increased to twice daily if necessary. angina, 240 mg twice daily (may sometimes be reduced to once daily)

2.6.3 Other antianginal drugs

Nicorandil, a potassium-channel activator with a nitrate component, has both arterial and venous vasodilating properties and is licensed for the prevention and long-term treatment of angina (section 2.10.1). Nicorandil has similar efficacy to other antianginal drugs in controlling symptoms; it may produce additional symptomatic benefit in combination with other antianginal drugs [unlicensed indication].

Ivabradine lowers the heart rate by its action on the sinus node. It is licensed for the treatment of angina in patients in normal sinus rhythm in combination with a beta-blocker, or when beta-blockers are contra-indicated or not tolerated.

Ranolazine is licensed as adjunctive therapy in patients who are inadequately controlled or intolerant of first-line antianginal drugs.

Ivabradine

Indications treatment of angina in patients in normal sinus rhythm (see notes above)
Caution mild heart failure including asymptomatic left ventricular dysfunction; monitor for atrial fibrillation or other arrhythmias (treatment ineffective); hypotension (avoid if severe); retinitis pigmentosa; elderly; interactions Appendix 1 (ivabradine)
Contra-indications severe bradycardia (not to be initiated if heart rate below 60 beats per minute); cardiogenic shock; acute myocadial infarction; immediately after cerebrovascular accident; sick-sinus syndrome; sino-atrial block; moderate to severe heart failure; patients with pacemaker; unstable angina; second- and third-degree heart block; congenital QT syndrome
Hepatic impairment manufacturer advises caution in moderate impairment; avoid in severe impairment
Renal impairment manufacturer advises use with caution if eGFR less than 15 mL/minute/1.73 m²—no information available
Pregnancy manufacturer advises avoid—xicity in animal studies
Breast-feeding present in milk in animal studies—manufacturer advises avoid
Side-effects bradycardia, first-degree heart block, ventricular extrasystoles; headache, dizziness; visual disturbances including phosphenes and blurred vision; less common nausea, constipation, diarrhoea, palpitations, supraventricular extrasystoles, dyspnoea, vertigo, muscle cramps, eosinophilia, hyperuricaemia, and raised plasma-creatinine concentration
Dose
- Initially 5 mg twice daily, increased if necessary after 3–4 weeks to 7.5 mg twice daily (if not tolerated reduce dose to 2.5–5 mg twice daily); ELDERLY initially 2.5 mg twice daily
- Note Ventricular rate at rest should not be allowed to fall below 50 beats per minute

Procoralan® (Servier) (Abbott)
Tablets, pink, f/c, ivabradine (as hydrochloride) 5 mg (scored), net price 56-tab pack = £39.00; 7.5 mg, 56-tab pack = £39.00

ELDERLY
**NICORANDIL**

**Indications**  prophylaxis and treatment of angina

**Cautions** hypovolaemia; low systolic blood pressure; acute pulmonary oedema; acute myocardial infarction with acute left ventricular failure and low filling pressures; **interactions:** Appendix 1 (nicorandil)

**Driving** Patients should be warned not to drive or operate machinery until it is established that their performance is unimpaired.

**Contra-indications** cardiogenic shock; left ventricular failure with low filling pressures; hypotension

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—no information available

**Breast-feeding** no information available—manufacturer advises avoid

**Side-effects** headache (especially on initiation, usually transitory); cutaneous vasodilatation with flushing; nausea, vomiting, dizziness, weakness also reported; rarely oral ulceration, royalgia, and rash; at high dosage, reduction in blood pressure and/or increase in heart rate; angioedema, hepatic dysfunction, and anal ulceration also reported.

**Dose**
- Initially 10 mg twice daily (if susceptible to headache)
- usual dose 10–20 mg twice daily; up to 30 mg twice daily may be used

**Ikorel®** (Sanofi-Aventis)  Tablets, scored, nicorandil 10 mg, net price 60-tab pack = £7.71; 20 mg, 60-tab pack = £14.64

**RANOLAZINE**

**Indications** as adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

**Cautions** moderate to severe congestive heart failure; QT interval prolongation; elderly; body-weight less than 60 kg; **interactions:** Appendix 1 (ranolazine)

**Hepatic impairment** use with caution in mild impairment; avoid in moderate and severe impairment

**Renal impairment** use with caution if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

**Driving** no information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** constipation, nausea, vomiting; dizziness, headache, asthenia; less commonly abdominal pain, weight loss, dry mouth, dyspepsia, flatulence; hot flush, hypotension, syncope, prolonged QT interval, peripheral oedema; dyspnoea, cough, epistaxis; lethargy, hypoesthesia, drowsiness, tremor, anxiety, insomnia, anorexia; dysuria, haematuria, chromaturia; dehydration; pain in extremities, muscle cramp, joint swelling; visual disturbance; tinnitus; pruritus, sweating; rarely pancreatitis, erosive duodenitis; cold extremities; throat tightness; amnesia, loss of consciousness, disorientation; erectile dysfunction; parosmia, impaired hearing; allergic dermatitis, urticaria, rash

**Dose**
- **ADULT** over 18 years, initially 375 mg twice daily, increased after 2–4 weeks to 500 mg twice daily and then adjusted according to response to max. 750 mg twice daily (reduce dose to 375–500 mg twice daily if not tolerated)

**Ranexa®** (Menarini)  Tablets, m/r, ranolazine 375 mg (blue), net price 60-tab pack = £48.98; 500 mg (orange), 60-tab pack = £48.98; 750 mg (green), 60-tab pack = £48.98. Label: 25, patient alert card

**2.6.4 Peripheral vasodilators and related drugs**

Peripheral vascular disease can be either occlusive (e.g. *intermittent claudication*) in which occlusion of the peripheral arteries is caused by atherosclerosis, or vasospastic (e.g. *Raynaud’s syndrome*).

Peripheral arterial occlusive disease is associated with an increased risk of cardiovascular events; this risk is reduced by measures such as smoking cessation (section 4.10.2), effective control of blood pressure (section 2.5), regulating blood lipids (section 2.12), optimising glycaemic control in diabetes (section 6.1), taking aspirin in a dose of 75 mg daily (section 2.9), and possibly weight reduction in obesity (section 4.5). Exercise training, treatment with cilostazol or naftidrofuryl (see below), and possibly statin therapy can improve symptoms of intermittent claudication.

Cilostazol is licensed for use in intermittent claudication to improve walking distance in patients without peripheral tissue necrosis who do not have pain at rest. Patients receiving cilostazol should be assessed for improvement after 3 months. The *Scottish Medicines Consortium* (p. 4) has advised (October 2005) that cilostazol is not recommended for the treatment of intermittent claudication within NHS Scotland.

Naftidrofuryl can alleviate symptoms of intermittent claudication and improve pain-free walking distance in moderate disease. Patients taking naftidrofuryl should be assessed for improvement after 3–6 months. Inositol nicotinate, pentoxifylline, and cinnarizine are not established as being effective for the treatment of intermittent claudication.

Management of *Raynaud’s syndrome* includes avoidance of exposure to cold and stopping smoking. More severe symptoms may require vasodilator treatment, which is most often successful in primary Raynaud’s syndrome. Nifedipine (section 2.6.2) is useful for reducing the frequency and severity of vasospastic attacks. Alternatively, naftidrofuryl may produce symptomatic improvement; inositol nicotinate (a nicotinic acid derivative) may also be considered. Cinnarizine, pentoxifylline, prazosin, and moxisylyte are not established as being effective for the treatment of Raynaud’s syndrome.

Vasodilator therapy is not established as being effective for chilblains (section 13.13).

**CILOSTAZOL**

**Indications** intermittent claudication in patients without rest pain and no peripheral tissue necrosis

**Cautions** atrial or ventricular ectopy, atrial fibrillation, atrial flutter; diabetes mellitus (higher risk of intraocular bleeding); concomitant drugs that increase risk of bleeding; **interactions:** Appendix 1 (cilostazol)

**Contra-indications** predisposition to bleeding (e.g. active peptic ulcer, haemorrhagic stroke in previous 6 months, surgery in previous 3 months, proliferative diabetic retinopathy, poorly controlled hypertension)
136 2.6.4 Peripheral vasodilators and related drugs BNF 61

history of ventricular tachycardia, of ventricular fibrillation and of multifocal ventricular ectopics, prolongation of QT interval, congestive heart failure

**Hepatic impairment** avoid in moderate or severe liver disease

**Renal impairment** avoid if eGFR less than 25 mL/minute/1.73 m²

**Pregnancy** avoid—xicity in animal studies

**Breast-feeding** present in milk in animal studies—manufacturer advises avoid

**Side-effects** gastro-intestinal disturbances; tachycardia, palpitation, angina, arrhythmia, chest pain, oedema; rhinitis; dizziness, headache; asthenia; rash; pruritus, ecchymosis; less commonly gastritis, congestive heart failure, postural hypotension, dyspnoea, pneumonia, cough, insomnia, abnormal dreams, anxiety, hyperglycaemia, diabetes mellitus, anaemia, haemorrhage, myalgia, hypersensitivity reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis in rare cases); rarely anorexia, hypertension, paresis, increased urinary frequency, bleeding disorders, renal impairment, conjunctivitis, tinnitus, and jaundice

**Dose**

- 100 mg twice daily (30 minutes before or 2 hours after food)

**Pletal®** (Otsuka)

- Tablets, cilostazol 50 mg, net price 56-tab pack = £35.31; 100 mg, 56-tab pack = £35.31

**INOSITOL NICOTINATE**

**Indications** peripheral vascular disease; hyperlipidaemia (section 2.12)

**Cautions** cerebrovascular insufficiency, unstable angina

**Contra-indications** recent myocardial infarction, acute phase of a cerebrovascular accident

**Pregnancy** no information available—manufacturer advises avoid

**Side-effects** nausea, vomiting, hypotension, flushing, syncope, oedema, headache, dizziness, paraesthesia, rash

**Dose**

- 3 g daily in 2–3 divided doses; max. 4 g daily

**Hexopal®** (Genus)

- Tablets, scored, inositol nicotinate 500 mg, net price 100 = £30.76
- Tablets forte, scored, inositol nicotinate 750 mg, net price 112-tab pack = £51.03

**MOXISLYTE**

**Indications** primary Raynaud’s syndrome (short-term treatment)

**Cautions** diabetes mellitus

**Contra-indications** active liver disease

**Pregnancy** manufacturer advises avoid

**Side-effects** nausea, diarrhoea, flushing, headache, dizziness; hepatic reactions including cholestatic jaundice and hepatitis reported to CSM

**Dose**

- Initially 40 mg 4 times daily, increased to 80 mg 4 times daily if poor initial response; discontinue after 2 weeks if no response

**Opilon®** (Archimedes)

- Tablets, yellow, Film, moxisylyte 40 mg (as hydrochloride), net price 112-tab pack = £75.18. Label: 21

**NAFTIDROFURYL OXALATE**

**Indications** see under Dose

**Side-effects** nausea, epigastric pain, rash, hepatitis, hepatic failure

**Dose**

- Peripheral vascular disease (see notes above), 100–200 mg 3 times daily
- Cerebral vascular disease, 100 mg 3 times daily

**Nafidrofuryl** (Non-proprietary)

- Capsules, nafidrofuryl oxalate 100 mg, net price 84-cap pack = £4.52. Label: 25, 27

**Praxilene®** (Merck Serono)

- Capsules, pink, nafidrofuryl oxalate 100 mg, net price 84-cap pack = £8.10. Label: 25, 27

**PENTOXIFYLLINE**

**Indications** peripheral vascular disease; venous leg ulcers [unlicensed indication] (Appendix A8.2.5)

**Cautions** hypotension, coronary artery disease; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (pentoxifylline)

**Contra-indications** cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial infarction

**Hepatic impairment** manufacturer advises reduce dose in severe impairment

**Renal impairment** reduce dose by 30–50% if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid—no information available

**Breast-feeding** present in milk—manufacturer advises use only if potential benefit outweighs risk

**Side-effects** gastro-intestinal disturbances, dizziness, agitation, sleep disturbances, headache; rarely flushing, tachycardia, angina, hypotension, thrombocytopenia, intrahepatic cholestasis, hypersensitivity reactions including rash, pruritus and bronchospasm

**Dose**

- 400 mg 2–3 times daily

**Trental®** (Sanofi-Aventis)

- Tablets, m/r, pink, s/c, pentoxifylline 400 mg, net price 90-tab pack = £19.68. Label: 21, 25

**Other preparations used in peripheral vascular disease**

Rutosides (oxerutins, Paroven®) are not vasodilators and are not generally regarded as effective preparations as capillary sealants or for the treatment of cramps; side-effects include headache, flushing, rashes, mild gastro-intestinal disturbances.

**Paroven®** (Novartis Consumer Health)

- Capsules, yellow, oxerutins 250 mg, net price 120-cap pack = £13.05
- Capsules, yellow, oxerutins 250 mg, net price 120-cap pack = £13.05

**Dose** relief of symptoms of oedema associated with chronic venous insufficiency, 500 mg twice daily
2.7 Sympathomimetics

2.7.1 Inotropic sympathomimetics

The cardiac stimulants dobutamine and dopamine act on alpha, receptors in cardiac muscle, and increase contractility with little effect on rate.

Dopexamine acts on beta, receptors in cardiac muscle to produce its positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.

Isoprenaline injection is available from ‘special-order’ manufacturers or specialist importing companies, see p. 988.

Shock. Shock is a medical emergency associated with a high mortality. The underlying causes of shock such as haemorrhage, sepsis, or myocardial insufficiency should be corrected. The profound hypotension of shock must be treated promptly to prevent tissue hypoxia and organ failure. Volume replacement is essential to correct the hypovolaemia associated with haemorrhage and sepsis but may be detrimental in cardiogenic shock. Depending on haemodynamic status, cardiac output may be improved by the use of sympathomimetic inotropes such as adrenaline (epinephrine), dobutamine or dopamine (see notes above). In septic shock, when fluid replacement and inotropic support fail to maintain blood pressure, the vasoconstrictor noradrenaline (nor-epinephrine) (section 2.7.2) may be considered. In cardiogenic shock peripheral resistance is frequently high and to raise it further may worsen myocardial performance and exacerbate tissue ischaemia.

The use of sympathomimetic inotropes and vasoconstrictors should preferably be confined to the intensive care setting and undertaken with invasive haemodynamic monitoring.

For advice on the management of anaphylactic shock, see section 3.4.3.

DOBUTAMINE

Indications inotropic support in infarction, cardiac surgery, cardiomyopathies, septic shock, and cardiogenic shock; cardiac stress testing (consult product literature)

Cautions arrhythmias, acute myocardial infarction, acute heart failure, severe hypotension, marked obstruction of cardiac ejection (such as idiopathic hypertrophic subaortic stenosis); correct hypovolaemia before starting treatment; tolerance may develop with continuous infusions longer than 72 hours; hyperthyroidism; interactions: Appendix 1 (sympathomimetics)

Contra-indications phaeochromocytoma

Pregnancy no evidence of harm in animal studies—manufacturers advise use only if potential benefit outweighs risk

Breast-feeding manufacturers advise avoid—no information available

Side-effects nausea; hypotension, hypertension (marked increase in systolic blood pressure indicates overdose), arrhythmias, palpitations, chest pain; dyspnoea, bronchospasm; headache; fever; increased urinary urgency; eosinophilia; rash, phlebitis; very rarely myocardial infarction, hypokalaemia; coronary artery spasm and thrombocytopenia also reported

Dose

• By intravenous infusion, 2.5–10 micrograms/kg/minute, adjusted according to response

Dobutamine (Non-proprietary) injection, dobutamine (as hydrochloride) 5 mg/mL. To be diluted before use or given undiluted with syringe pump. Net price 50-mL vial = £7.50 Excipients may include sulphites

Concentrate for intravenous infusion, dobutamine (as hydrochloride) 12.5 mg/mL. To be diluted before use. Net price 20-mL amp = £5.20 Excipients may include sulphites

DOPAMINE HYDROCHLORIDE

Indications cardiogenic shock in infarction or cardiac surgery

Cautions correct hypovolaemia; low dose in shock due to acute myocardial infarction—see notes above; hyperthyroidism; interactions: Appendix 1 (sympathomimetics)

Contra-indications tachyarrhythmia, phaeochromocytoma

Pregnancy manufacturer advises use only if potential benefit outweighs risk

Side-effects nausea and vomiting, peripheral vasoconstriction, hypotension, hypertension, tachycardia

Dose

• By intravenous infusion, 2–5 micrograms/kg/minute initially (see notes above)

Dopamine (Non-proprietary) injection, dopamine hydrochloride 40 mg/mL, net price 5-mL amp = 90p; 160 mg/mL, 5-mL amp = £3.40. To be diluted before use

Concentrate for intravenous infusion, dopamine hydrochloride 1.6 mg/mL in glucose 5% intravenous infusion, net price 250-mL container (400 mg) = £11.69. Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

DOPEXAMINE HYDROCHLORIDE

Indications inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery

Cautions myocardial infarction, recent angina, hypokalaemia, hyperglycaemia; correct hypovolaemia before starting and during treatment, monitor blood pressure, pulse, plasma potassium, and blood glucose; hyperthyroidism; avoid abrupt withdrawal; interactions: Appendix 1 (sympathomimetics)
2.7.2 Vasoconstrictor sympathomimetics

Vasoconstrictor sympathomimetics raise blood pressure transiently by acting on alpha-adrenergic receptors to constrict peripheral vessels. They are sometimes used as an emergency method of elevating blood pressure where other measures have failed (see also section 2.7.1).

The danger of vasoconstrictors is that although they raise blood pressure they also reduce perfusion of vital organs such as the kidney.

Spinal and epidural anaesthesia may result in sympathethic block with resultant hypotension. Management may include intravenous fluids (which are usually given prophylactically), oxygen (section 3.6), elevation of the legs, and injection of a pressor drug such as ephedrine. As well as constricting peripheral vessels ephedrine also accelerates the heart rate (by acting on beta receptors). Use is made of this dual action of ephedrine to manage associated bradycardia (although intravenous injection of atropine sulphate 400 to 600 micrograms may also be required if bradycardia persists).

### Ephedrine Hydrochloride

**Contra-indications** Left ventricular outlet obstruction such as hypertrophic cardiomyopathy or aortic stenosis; phaeochromocytoma, thrombocytopenia

**Pregnancy** No information available—manufacturer advises avoid

**Side-effects** Nausea, vomiting; tachycardia, bradycardia, arrhythmias, angina, myocardial infarction, tremor, headache; dyspnœa; reversible thrombocytopenia; sweating

**Dose**
- **By intravenous infusion** into central or large peripheral vein, 500 nanograms/kg/minute, may be increased up to 1 microgram/kg/minute and further increased up to 6 micrograms/kg/minute in increments of 0.5–1 microgram/kg/minute at intervals of not less than 15 minutes

**Dopacard** (Cephalon) Concentrate for intravenous infusion, dopexamine hydrochloride 10 mg/mL (1%). To be diluted before use. Net price 5-mL amp = £19.80

**Note** Contact with metal in infusion apparatus should be minimised

**Indications** Acute hypotension (see notes above); priapism (section 7.4.5) [unlicensed indication]

**Cautions** See under Noradrenaline Acid Tartrate; longer duration of action than noradrenaline (norepinephrine), see below; cirrhosis

**Hypertensive response** Metaraminol has a longer duration of action than noradrenaline, and an excessive vasopressor response may cause a prolonged rise in blood pressure

**Contra-indications** See under Noradrenaline Acid Tartrate

**Pregnancy** May reduce placental perfusion—manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** Manufacturer advises caution—no information available

**Side-effects** See under Noradrenaline Acid Tartrate; tachycardia; fatal ventricular arrhythmia reported in Laennec’s cirrhosis

**Dose**
- **By intravenous infusion**, 15–100 mg, adjusted according to response
- **In emergency, by intravenous injection**, 0.5–5 mg then by intravenous infusion, 10–150 mg, adjusted according to response

**Metaraminol** (Non-proprietary) Injection, metaraminol 10 mg (as tartrate)/mL Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

**Indications** See under dose

**Cautions** Coronary, mesenteric, or peripheral vascular thrombosis; following myocardial infarction, Prinzmetal’s variant angina, hyperthyroidism, diabetes mellitus; hypoxia or hypercapnia; uncorrected hypovolaemia; elderly; extravasation at injection site may cause necrosis; interactions: Appendix 1 (sympathomimetics)

**Contra-indications** Hypertension (monitor blood pressure and rate of flow frequently); pregnancy Avoid—may reduce placental perfusion

**Side-effects** Hypertension, headache, bradycardia, arrhythmias, peripheral ischaemia

**Dose**
- **Acute hypotension, by intravenous infusion**, via central venous catheter, of a solution containing noradrenaline acid tartrate 80 micrograms/mL (equivalent to noradrenaline base 40 micrograms/mL) at an initial rate of 0.16–0.33 mL/minute, adjusted according to response
● Cardiac arrest, by rapid intravenous or intracardiac injection, 0.5–0.75 mL of a solution containing noradrenaline acid tartrate 200 micrograms/mL (equivalent to noradrenaline base 100 micrograms/mL)

Noradrenaline/Norepinephrine (Non-proprietary)
Injection, noradrenaline acid tartrate 2 mg/mL (equivalent to noradrenaline base 1 mg/mL). For dilution before use. Net price 2-mL amp. = £2.40, 4-mL amp. = £4.40, 20-mL amp. = £6.35

PHENYLEPHRINE HYDROCHLORIDE

Indications acute hypotension (see notes above); priapism (section 7.4.5) [unlicensed indication]
Cautions see under Noradrenaline Acid Tartrate; longer duration of action than noradrenaline (norepinephrine), see below; coronary disease
Hypertensive response Phenylephrine has a longer duration of action than noradrenaline, and an excessive vasoconstrictor response may cause a prolonged rise in blood pressure
Contra-indications see under Noradrenaline Acid Tartrate; severe hyperthyroidism

Pregnancy avoid if possible; malformations reported following use in first trimester; fetal hypoxia and bradyarrhythmia reported in late pregnancy and labour

Side-effects see under Noradrenaline Acid Tartrate; tachycardia or reflex bradycardia

Dose

● By subcutaneous or intramuscular injection, 2–5 mg, followed if necessary by further doses of 1–10 mg

● By slow intravenous injection of a 1 mg/mL solution, 100–500 micrograms repeated as necessary after at least 15 minutes

● By intravenous infusion, initial rate up to 180 micrograms/minute reduced to 30–60 micrograms/minute according to response

Phenylephrine (Sovereign)
Injection, phenylephrine hydrochloride 10 mg/mL (1%), net price 1-mL amp. = £5.50

2.7.3 Cardiopulmonary resuscitation

The algorithm for cardiopulmonary resuscitation (see inside back cover) reflects the most recent recommendations of the Resuscitation Council (UK). These guidelines are available at www.resus.org.uk.

Cardiac arrest can be associated with ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity (electromechanical dissociation). Adrenaline (epinephrine) 1 in 10 000 (100 micrograms/mL) is recommended in a dose of 1 mg (10 mL) by intravenous injection repeated every 3–5 minutes if necessary. Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest compressions; drugs administered peripherally must be followed by a flush of at least 20 mL. Sodium Chloride 0.9% injection to aid entry into the central circulation. Intravenous injection of amiodarone 300 mg (from a prefilled syringe or diluted in 20 mL). Glucose 5% should be considered after adrenaline to treat ventricular fibrillation or pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation. An additional dose of amiodarone 150 mg can be given by intravenous injection if necessary, followed by an intravenous infusion of amiodarone 900 mg over 24 hours. Lidocaine, in a dose of 1 mg/kg, is an alternative if amiodarone is not available; a total dose of 3 mg/kg lidocaine should not be exceeded during the first hour. Atropine is no longer recommended in the treatment of asystole or pulseless electrical activity.

During cardiopulmonary arrest if intravenous access cannot be obtained, the intravenous route can be used instead. Drug administration via the endotracheal route is no longer recommended.

For the management of acute anaphylaxis see section 3.4.3.

ADRENALINE/EPINEPHRINE

Indications see notes above
Cautions ischaemic heart disease, severe angina, obstructive cardiomyopathy, hypertension, arrhythmias, cerebrovascular disease, occlusive vascular disease, arteriosclerosis, monitor blood pressure and ECG; cor pulmonale; organic brain damage, psychoneurosis; diabetes mellitus, hyperthyroidism, phaeochromocytoma; prostate disorders; hypokalaemia, hypercalcaemia; susceptibility to angle-closure glaucoma; elderly, interactions: Appendix 1 (sympathomimetics)

Renal impairment manufacturers advise use with caution in severe impairment

Pregnancy may reduce placental perfusion and can delay second stage of labour; manufacturers advise use only if benefit outweighs risk

Breast-feeding present in milk but unlikely to be harmful as poor oral bioavailability

Side-effects nausea, vomiting, dry mouth, hypersalivation; arrhythmias, syncope, angina, pallor, palpitation, cold extremities, hypertension (risk of cerebral haemorrhage); dyspnoea, pulmonary oedema (on excessive dosage or extreme sensitivity); anxiety, tremor, restlessness, headache, weakness, dizziness, hallucinations; hyperglycaemia; urinary retention, difficulty in micturition; metabolic acidosis; hypokalaemia; tissue necrosis at injection site and of extremities, liver and kidneys; mydriasis, angle-closure glaucoma, and sweating

Dose

● See notes above

Adrenaline/Epinephrine 1 in 10 000, Dilute (Non-proprietary) Injection, adrenaline (as acid tartrate) 100 micrograms/mL. 10-mL amp.

Brands include Minjet® Adrenaline

2.8 Anticoagulants and protamine

2.8.1 Parenteral anticoagulants

2.8.2 Oral anticoagulants

2.8.3 Protamine sulphate

The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the
anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little fibrin. For the uses of anticoagulants see Parenteral anticoagulants, below and Oral anticoagulants, p. 146

Venous thromboembolism
Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism, and occurs as a result of thrombus formation in a vein.

Prophylaxis of venous thromboembolism
All patients admitted to hospital should undergo a risk assessment for venous thromboembolism on admission. Patients considered to be at high risk include those anticipated to have a substantial reduction in mobility, those with obesity, malignant disease, history of venous thromboembolism, thrombophilic disorder, or patients over 60 years. Patients with risk factors for bleeding (e.g. acute stroke, thrombocytopenia, acquired or untreated inherited bleeding disorders) should only receive pharmacological prophylaxis when the risk of bleeding does not outweigh the risk of venous thromboembolism. A NICE Guideline provides a full list of risk factors, and gives recommendations for prophylaxis. A venous thromboembolism risk assessment checklist is also available from the Department of Health (www.dh.gov.uk).

Patients scheduled for surgery should be offered mechanical prophylaxis (e.g. anti-embolism stockings) on admission if appropriate; prophylaxis should continue until the patient is sufficiently mobile. Choice of mechanical prophylaxis will depend on factors such as the type of surgery, suitability for the patient, and their condition.

Patients undergoing general or orthopaedic surgery, who are considered to be at high risk of venous thromboembolism (see above), should be offered pharmacological prophylaxis. Choice of prophylaxis will depend on the type of surgery, suitability for the patient, and local policy. A low molecular weight heparin is suitable in all types of general and orthopaedic surgery; unfractionated heparin is preferred for patients in renal failure. Fondaparinux is an option for patients undergoing hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures. The oral anticoagulants dabigatran etexilate and rivaroxaban are indicated for thromboprophylaxis following hip or knee replacement surgery, hip fracture surgery, gastrointestinal, bariatric, or day surgery procedures.

Thrombus consists of a fibrin web enmeshed with platelets and red cells.

Medical condition, suitability for the patient, and local policy. Patients should receive either a low molecular weight heparin, unfractionated heparin (if patient in renal failure), or fondaparinux. Prophylaxis should continue until the patient is no longer considered to be at significant risk of venous thromboembolism. Mechanical prophylaxis (e.g. anti-embolism stockings) can be offered to medical patients in whom pharmacological prophylaxis is contra-indicated, and continued until the patient is sufficiently mobile.

Heparin
Heparin initiates anticoagulation rapidly but has a short duration of action. It is often referred to as ‘standard’ or ‘unfractionated heparin’ to distinguish it from the low molecular weight heparins (see p. 141), which have a longer duration of action. Although a low molecular weight heparin is generally preferred for routine use, unfractionated heparin can be used in those at high risk of bleeding because its effect can be terminated rapidly by stopping the infusion.

Treatment For the initial treatment of deep-vein thrombosis and pulmonary embolism a low molecular weight heparin is used; alternatively, unfractionated heparin is given as an intravenous loading dose, followed by continuous intravenous infusion (using an infusion pump) or by intermittent subcutaneous injection. Intermittent intravenous injection of unfractionated heparin is no longer recommended. An oral anticoagulant (usually warfarin, section 2.8.2) is started at the same time as unfractionated or low molecular weight heparin (the heparin needs to be continued for at least 5 days and until the INR has been in the therapeutic range for 2 consecutive days). Laboratory monitoring for unfractionated heparin, preferably on a daily basis, is essential; determination of the activated partial thromboplastin time (APTT) is the most widely used measure (for unfractionated heparin). A low molecular weight heparin or, in some circumstances, unfractionated heparin is also used in regimens for the management of myocardial infarction and unstable angina (section 2.10.1).

Prophylaxis For details on the use of heparins in the prophylaxis of venous thromboembolism see section 2.8.

Pregnancy Heparins are used for the management of venous thromboembolism in pregnancy because they do not cross the placenta. Low molecular weight heparins are preferred because they have a lower risk of osteoporosis and of heparin-induced thrombocytopenia. Low molecular weight heparins are eliminated more rapidly in pregnancy, requiring alteration of the dosage regimen for drugs such as dalteparin, enoxaparin, and tinzaparin; see also under individual drugs. Treatment should be stopped at the onset of labour and advice sought from a specialist on continuing therapy after birth.

Extracorporeal circuits Unfractionated heparin is also used in the maintenance of extracorporeal circuits in cardiopulmonary bypass and haemodialysis.
Haemorrhage  If haemorrhage occurs it is usually sufficient to withdraw unfractionated or low molecular weight heparin, but if rapid reversal of the effects of the heparin is required, protamine sulphate (section 2.8.3) is a specific antidote (but only partially reverses the effects of low molecular weight heparins).

HEPARIN

Indications see under Dose

Cautions see notes above; also elderly; concomitant use of drugs that increase risk of bleeding; interactions: Appendix 1 (heparin).

Heparin-induced thrombocytopenia  Clinically important heparin-induced thrombocytopenia is immune-mediated and does not usually develop until after 5–10 days; it can be complicated by thrombosis. Platelet counts should be measured just before treatment with unfractionated or low molecular weight heparin, and regular monitoring of platelet counts is recommended if given for longer than 4 days. Signs of heparin-induced thrombocytopenia include a 50% reduction of platelet count, thrombosis, or skin allergy. If heparin-induced thrombocytopenia is strongly suspected or confirmed, the heparin should be stopped and an alternative anticoagulant, such as lepirudin or danaparoid, should be given. Ensure platelet counts return to normal range in those who require warfarin.

Hyperkalaemia  Inhibition of aldosterone secretion by unfractionated or low molecular weight heparin can result in hyperkalaemia; patients with diabetes mellitus, chronic renal failure, acidosis, raised plasma potassium or those taking potassium-sparing drugs seem to be more susceptible. The risk appears to increase with duration of therapy, and plasma-potassium concentration should be measured in patients at risk of hyperkalaemia before starting the heparin and monitored regularly thereafter, particularly if treatment is to be continued for longer than 7 days.

Contra-indications  haemophilia and other haemorrhagic disorders, thrombocytopenia (including history of heparin-induced thrombocytopenia), recent cerebral haemorrhage, severe hypertension; peptic ulcer; after major trauma or recent surgery to eye or nervous system; acute bacterial endocarditis; spinal or cerebrovascular arterial occlusion, followed by intravenous injection, loading dose of 5000 units or 75 units/kg (10 000 units in severe pulmonary embolism), followed by continuous intravenous infusion of 18 units/kg/hour or treatment of deep-vein thrombosis, by subcutaneous injection of 15 000 units every 12 hours (laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly); CHLD under 18 years see BNF for Children.

● Prophylaxis in surgery (see also notes above), by subcutaneous injection, 5000 units 2 hours before surgery, then every 8–12 hours (monitoring not needed); during pregnancy (with monitoring), 5000–10 000 units every 12 hours (important; prevention of prosthetic heart-valve thrombosis in pregnancy calls for specialist management).

● Haemodialysis by intravenous injection initially 1000–5000 units, followed by continuous intravenous infusion of 250–1000 units/hour.

● Prevention of clotting in extracorporeal circuits, consult product literature.

Doses above reflect the guidelines of the British Society for Haematology; for doses of the low molecular weight heparins, see below.

Heparin Sodium (Non-proprietary) Heparin calcium Injection, heparin sodium 1000 units/mL, net price 1-mL amp = £0.99, 5-mL amp = £2.50, 5-mL vial = £2.50, 10-mL amp = £4.31, 20-mL amp = £7.09, 5000 units/mL, 1-mL amp = £1.94, 5-mL amp = £5.06, 5-mL vial = £5.64; 25 000 units/mL, 0.2-mL amp = £2.49, 1-mL amp = £5.13, 5-mL vial = £11.11.

Excipients may include benzyl alcohol (avoid in neonates, see Excipients, p. 2).

Heparin Calcium (Non-proprietary) Heparin calcium Injection, heparin calcium 25 000 units/mL, net price 0.2-mL amp = £2.61.

Low molecular weight heparins

Low molecular weight heparins (bemiparin, dalteparin, enoxaparin, and tinzaparin) are usually preferred over unfractionated heparin in the prevention of venous thromboembolism because they are as effective and they have a lower risk of heparin-induced thrombocytopenia; see Prophylaxis of Venous Thromboembolism, p. 140. The standard prophylactic regimen does not require monitoring. The duration of action of low molecular weight heparins is longer than that of unfractionated heparin and once-daily subcutaneous administration is possible for some indications, making them convenient to use.

Low molecular weight heparins are also used in the treatment of deep-vein thrombosis, pulmonary embolism (see also Treatment, above), myocardial infarction (section 2.10.1), unstable coronary artery disease (section 2.10.1) and for the prevention of clotting in extracorporeal circuits.

Dalteparin is also licensed for the extended treatment and prophylaxis of venous thromboembolism in patients with solid tumours; treatment is recommended for a duration of 6 months.

Routine monitoring of anti-Factor Xa activity is not usually required during treatment with low molecular weight heparins, but may be necessary in patients at
increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).

Haemorrhage  See under Heparin.

Pregnancy  See under Heparin.

BEMIPARIN SODIUM

Indications  see notes above and under preparations

Cautions  see under Heparin and notes above

Contra-indications  see under Heparin

Hepatic impairment  manufacturer advises use with caution and avoid in severe impairment

Renal impairment  risk of bleeding may be increased—use with caution; monitoring of anti-Factor Xa may be required; use of unfractionated heparin may be preferable

Pregnancy  manufacturer advises avoid unless essential—no information available; see also Pregnancy, p. 140

Breast-feeding  manufacturer advises avoid—no information available

Side-effects  see under Heparin

Dose

•  See under preparations below

Zibor® (Archimedes) ▼ (BN)
Injection, bemiparin sodium 12 500 units/mL, net price 2500-unit (0.2-mL) prefilled syringe = £1.86; 17 500 units/mL, 3500-unit (0.2-mL) prefilled syringe = £2.75

Dose  prophylaxis of deep-vein thrombosis, by subcutaneous injection, moderate risk, 2500 units 2 hours before or 6 hours after surgery then 2500 units every 24 hours; high risk, 3500 units 2 hours before or 6 hours after surgery then 3500 units every 24 hours

Prevention of clotting in extracorporeal circuits, consult product literature

Injection, bemiparin sodium 25 000 units/mL, net price 0.2-mL (5000-unit) prefilled syringe = £4.22, 0.3-mL (7500-unit) prefilled syringe = £5.34, 0.4-mL (10 000-unit) prefilled syringe = £4.59

Dose  treatment of deep-vein thrombosis (with or without pulmonary embolism), by subcutaneous injection, 115 units/kg every 24 hours until adequate oral anticoagulation established

DALTEPARIN SODIUM

Indications  see notes above and under preparations

Cautions  see under Heparin and notes above

Contra-indications  see under Heparin

Hepatic impairment  dose reduction may be required in severe impairment

Renal impairment  risk of bleeding may be increased—dose reduction, and monitoring of anti-Factor Xa may be required; use of unfractionated heparin may be preferable

Pregnancy  not known to be harmful; multidose vial contains benzyl alcohol—manufacturer advises avoid; see also Pregnancy, p. 140

Breast-feeding  no information available

Side-effects  see under Heparin

Dose

•  See under preparations below

Fragmin® (Pharmacia) ▼ (BN)
Injection (single-dose syringe), dalteparin sodium 12 500 units/mL, net price 2500-unit (0.2-mL) syringe = £1.86; 25 000 units/mL, 5000-unit (0.2-mL) syringe = £2.82, 7500-unit (0.3-mL) syringe = £4.23, 10 000-unit (0.4-mL) syringe = £5.65, 12 500-unit (0.5-mL) syringe = £7.06, 15 000-unit (0.6-mL) syringe = £8.47, 18 000-unit (0.72-mL) syringe = £10.16

Dose  prophylaxis of deep-vein thrombosis, in surgical patients, by subcutaneous injection, moderate risk, 2500 units 1–2 hours before surgery then 2500 units every 24 hours; high risk, 2500 units 1–2 hours before surgery, then 2500 units 8–12 hours later (or 5000 units on the evening before surgery, then 5000 units on the following evening), then 5000 units every 24 hours

Prophylaxis of deep-vein thrombosis in medical patients, by subcutaneous injection, 5000 units every 24 hours

Treatment of deep-vein thrombosis and of pulmonary embolism, by subcutaneous injection, as a single daily dose, ADULT body-weight under 46 kg, 7500 units daily; body-weight 46–56 kg, 10 000 units daily; body-weight 57–68 kg, 12 500 units daily; body-weight 69–82 kg, 15 000 units daily; body-weight 83 kg and over, 18 000 units daily, with oral anticoagulant treatment until adequate oral anticoagulation established; monitoring of anti-Factor Xa not usually required; for patients at increased risk of haemorrhage, see below

Treatment of venous thromboembolism in pregnancy (unlicensed indication), by subcutaneous injection, early pregnancy body-weight under 50 kg, 5000 units twice daily; body-weight 50–70 kg, 6000 units twice daily; body-weight 70–90 kg, 8000 units twice daily; body-weight over 90 kg, 10 000 units twice daily

Extended treatment and prophylaxis of venous thromboembolism in patients with solid tumors, by subcutaneous injection, once daily for 30 days, ADULT body-weight 40–45 kg, 7500 units daily; body-weight 46–56 kg, 10 000 units daily; body-weight 57–68 kg, 12 500 units daily; body-weight 69–82 kg, 15 000 units daily; body-weight 83 kg and over, 18 000 units daily; then once daily for a further 5 months, by subcutaneous injection, ADULT body-weight 40–56 kg, 7500 units daily; body-weight 57–68 kg, 10 000 units daily; body-weight 69–82 kg, 12 500 units daily; body-weight 83–98 kg, 15 000 units daily; body-weight 99 kg and over, 18 000 units daily; interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature

Injection, dalteparin sodium 2500 units/mL (for subcutaneous or intravenous use), net price 4-mL (10 000-unit) amp = £5.12; 10 000-units/mL (for subcutaneous or intravenous use), 1-mL (10 000-unit) amp = £5.12, 25 000 units/mL (for subcutaneous use only), 4-mL (100 000-unit) vial = £48.66

Exipients include benzyl alcohol (to 100 000-unit/4-mL multidose vial) (avoid in neonates, see Excipients, p. 2)

Dose  treatment of deep-vein thrombosis and of pulmonary embolism, by subcutaneous injection, 200 units/kg (max. 10 000 units) as a single daily dose (or 100 units/kg twice daily if increased risk of haemorrhage) until adequate oral anticoagulation established

Note  For monitoring, blood should be taken 3–4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5–1 unit/mL; monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen

Unstable coronary artery disease, by subcutaneous injection, 120 units/kg every 12 hours (max. 10 000 units twice daily) for 5–8 days

Prevention of clotting in extracorporeal circuits, consult product literature

Injection (graduated syringe), dalteparin sodium 10 000 units/mL, net price 1-mL (10 000-unit) syringe = £5.65

Dose  unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction), by subcutaneous injection, 120 units/kg every 12 hours (max. 10 000 units twice daily) for up to 8 days, beyond 8 days (if awaiting angiography or revascularisation) women body-weight less than 80 kg and men less than 70 kg, 5000 units every 12 hours, women body-weight greater than 80 kg and men greater than 70 kg, 7500 units every 12 hours, until day of procedure (max. 45 days)

ENOXAPARIN SODIUM

Indications  see notes above and under preparations

Cautions  see under Heparin and notes above; low body-weight (increased risk of bleeding)

Contra-indications  see under Heparin
Hepatic impairment

manufacturer advises caution—
no information available

Renal impairment

risk of bleeding increased; reduce
dose if eGFR less than 30 mL/minute/1.73 m²—
consult product literature for details; monitoring of
anti-factor Xa may be required; use of unfractionated
heparin may be preferable

Pregnancy

not known to be harmful; see also
Pregnancy, p. 140

Breast-feeding

manufacturer advises avoid—no
information available

Side-effects

see under Heparin

Dose

See under preparation below

Clexane® (Sanofi-Aventis) \(\text{\textregistered}\)

Injection, enoxaparin sodium 100 mg/mL, net price
20 mg (0.2-mL, 2000-units) syringe = £3.03, 40-mg
(0.4-mL, 4000-units) syringe = £4.04, 60-mg (0.6-mL,
6000-units) syringe = £4.57, 80-mg (0.8-mL, 8000-
units) syringe = £8.49, 100-mg (1-mL, 10 000-units)
syringe = £8.04, 300 mg (3-mL, 30 000-units) vial
(Clexane® Multidose) = £21.33; 150 mg/mL
(Clexane® Forte), 120-mg (0.8-mL, 12 000-units)
syringe = £9.77, 150-mg (1-mL, 15 000-units) syringe
= £11.10

Excipients include benzyl alcohol (in 300 mg multidose vials) (avoid in
neonates, see Excipients, p. 2)

Dose

prophylaxis of deep-vein thrombosis especially in surgical
patients, by subcutaneous injection, moderate risk; 20 mg
(200 units) approx. 2 hours before surgery then 20 mg
(200 units) every 24 hours; high risk (e.g. orthopaedic surgery),
40 mg (4000 units) 12 hours before surgery then 40 mg
(4000 units) every 24 hours

Prophylaxis of deep-vein thrombosis in medical patients, by
subcutaneous injection, 40 mg (4000 units) every 24 hours

Treatment of deep-vein thrombosis or pulmonary embolism, by
subcutaneous injection, 1.5 mg/kg (150 units/kg) every 24 hours until
adequate oral anticoagulation established

Treatment of acute ST-segment elevation myocardial infarction,
ADULT under 75 years, by intravenous injection, 30 mg
(3000 units) followed by subcutaneous injection, 1 mg/kg
(100 units/kg), then by subcutaneous injection, 1 mg/kg every 12
hours for up to 8 days (max. 100 mg (10 000 units) for first two
subcutaneous doses only); ELDERLY over 75 years, by subcuta-
neous injection only, 750 micrograms/kg (75 units/kg) every 12
hours (max. 75 mg (7500 units) for first two doses only); patients
undergoing percutaneous coronary intervention, additional dose,
by intravenous injection, 300 micrograms/kg (30 units/kg) at
time of procedure if last subcutaneous dose given more than 8
hours previously

Note

When administered in conjunction with a thrombolytic,
enoxaparin should be given between 15 minutes before and 30
minutes after the start of thrombolytic therapy

Unstable angina and non-ST-segment-elevation myocardial
infarction, by subcutaneous injection, 1 mg/kg (100 units/kg)
every 12 hours usually for 2–8 days (minimum 2 days)

Prevention of clotting in extracorporeal circuits, consult product
literature

Treatment of venous thromboembolism in pregnancy [unlicensed indication], by
subcutaneous injection, early pregnancy body-
weight under 50 kg, 40 mg (4000 units) twice daily; body-weight
50–70 kg, 60 mg (6000 units) twice daily; body-weight 70–90 kg,
80 mg (8000 units) twice daily; body-weight over 90 kg, 100 mg
(10 000 units) twice daily

2.8.1 Parenteral anticoagulants

Factor Xa may be required; use with caution in elderly
and avoid if age over 90 years; unfractionated heparin
can be preferable

Pregnancy

not known to be harmful; vials contain
benzyl alcohol—manufacturer advises avoid; see also
Pregnancy, p. 140

Breast-feeding

manufacturer advises avoid—no
information available

Side-effects

see under Heparin

Dose

See under preparations below

Innohep® (LEO) \(\text{\textregistered}\)

Injection, tinzaparin sodium 10 000 units/mL, net
price 2500-unit (0.25-mL) syringe = £1.98, 3500-unit
(0.35-mL) syringe = £2.77, 4500-unit (0.45-mL)
syringe = £3.56, 20 000-unit (2-mL) vial = £10.56

Excipients include benzyl alcohol (in vial) (avoid in neonates, see Exci-
pients, p. 2)

Dose

prophylaxis of deep-vein thrombosis, by subcutaneous
injection, general surgery, 3500 units 2 hours before surgery, then
3500 units every 24 hours, orthopaedic surgery, 30 units/kg 2
hours before surgery, then 50 units/kg every 24 hours or
4500 units 12 hours before surgery; then 4500 units every 24 hours

Prevention of clotting in extracorporeal circuits, consult product
literature

Injection, tinzaparin sodium 20 000 units/mL, net
price 0.5-mL (10 000-unit) syringe = £8.46, 0.7-mL
(14 000-unit) syringe = £11.85, 0.9-mL (18 000-unit)
syringe = £15.23, 2-mL (40 000-unit) vial = £34.20

Excipients include benzyl alcohol (in vial) (avoid in neonates, see Exci-
pients, p. 2), sulphates (in 20 000 units/mL vial and syringe)

Dose

treatment of deep-vein thrombosis and of pulmonary
embolism, by subcutaneous injection, 175 units/kg once daily
until adequate oral anticoagulation established

Treatment of venous thromboembolism in pregnancy [unlicensed indication], by
subcutaneous injection, 175 units/kg once daily

(based on early pregnancy body-weight)

Note

Treatment regimens do not require anticoagulation mon-
toring

Heparinoids

Danaparoid is a heparinoid used for prophylaxis of
deep-vein thrombosis in patients undergoing general
or orthopaedic surgery. Providing there is no evidence
of cross-reactivity, it also has a role in patients who
develop heparin-induced thrombocytopenia.

DANAPAROID SODIUM

Indications

prevention of deep-vein thrombosis in
general or orthopaedic surgery; thromboembolic dis-
ease in patients with history of heparin-induced
thrombocytopenia

Cautions

recent bleeding or risk of bleeding; concomi-
tant use of drugs that increase risk of bleeding;
antibodies to heparins (risk of antibody-induced
thrombocytopenia); body-weight over 90 kg (monitor
anti factor Xa activity)

Contra-indications

haemophilia and other haemor-
rhagic disorders, thrombocytopenia (unless patient
has heparin-induced thrombocytopenia), recent
cerebral haemorrhage, severe hypertension, active
peptic ulcer (unless this is the reason for operation),
diabetic retinopathy, acute bacterial endocarditis,
spinal or epidural anaesthesia with treatment doses of
danaparoid

Hepatic impairment

caution in moderate impairment
(increased risk of bleeding); avoid in severe impair-
ment unless patient has heparin-induced thrombocy-
topenia and no alternative available
## Cardiovascular system

### 144 2.8.1 Parenteral anticoagulants

**Renal impairment** caution in moderate impairment; increased risk of bleeding (monitor anti-Factor Xa activity); avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available

**Pregnancy** manufacturer advises avoid—limited information available but not known to be harmful

**Breast-feeding** amount probably too small to be harmful but manufacturer advises avoid

**Side-effects** bleeding; hypersensitivity reactions (including rash)

**Dose**
- Prevention of deep-vein thrombosis, by subcutaneous injection, 750 units twice daily for 7–10 days; initiate treatment before operation (with last pre-operative dose 1–4 hours before surgery)
- Thromboembolic disease in patients with history of heparin-induced thrombocytopenia, by intravenous injection, 2500 units (1250 units if body-weight under 55 kg, 3750 units if over 90 kg), followed by intravenous infusion of 400 units/hour for 2 hours, then 300 units/hour for 2 hours, then 200 units/hour for 5 days

**Angiox** (The Medicines Company) ▼  
Injection, danaparoid sodium 1250 units/mL, net price 0.6-mL amp (750 units) = £26.68

### Hirudins

**Lepirudin**, a recombinant hirudin, is licensed for anticoagulation in patients with Type II (immune) heparin-induced thrombocytopenia who require parenteral anti-thrombotic treatment. The dose of lepirudin is adjusted according to activated partial thromboplastin time (APTT). **Bivalirudin**, a hirudin analogue, is a thrombin inhibitor which is licensed for acute coronary syndromes in patients planned for urgent or early intervention, and as an anticoagulant for patients undergoing percutaneous coronary intervention (see also section 2.10.1); bivalirudin should be administered in combination with aspirin and clopidogrel. The **Scottish Medicines Consortium** (p. 4) has advised (November 2008) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland for patients with acute coronary syndromes planned for urgent or early intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone. The **Scottish Medicines Consortium** (p. 4) has advised (August 2010) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland as an anticoagulant in patients undergoing percutaneous coronary intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone.

### Bivalirudin

**Indications** acute coronary syndromes in patients planned for urgent or early intervention; anti-coagulation for patients undergoing percutaneous coronary intervention (PCI)

**Cautions** exposure to lepirudin (theoretical risk from lepirudin antibodies); brachytherapy procedures; concomitant use of drugs that increase risk of bleeding

**Contra-indications** severe hypertension; subacute bacterial endocarditis; active bleeding; bleeding disorders

**Renal impairment** for percutaneous coronary intervention, reduce rate of infusion to 1.4 mg/kg/hour if eGFR 30–60 mL/minute/1.73 m² and monitor blood clotting parameters; for acute coronary syndromes and percutaneous coronary intervention, avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk—no information available

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** bleeding (discontinue), thrombosis, ecchymosis; less commonly nausea, vomiting, tachycardia, bradycardia, hypotension, angina, dyspnoea, allergic reactions (including isolated reports of anaphylaxis), headache, thrombocytopenia, anaemia, back and chest pain, and injection-site reactions

**Dose**
- Acute coronary syndromes (in addition to aspirin and clopidogrel), initially by intravenous injection, 100 micrograms/kg then by intravenous infusion 250 micrograms/kg/hour (for up to 72 hours in medically managed patients); patients proceeding to percutaneous coronary intervention or coronary artery bypass surgery without cardiopulmonary bypass, additional bolus dose by intravenous injection 500 micrograms/kg, then by intravenous infusion 1.75 mg/kg/hour for duration of procedure; following percutaneous coronary intervention, reduce infusion rate to 250 micrograms/kg/hour for 4–12 hours as necessary; patients proceeding to coronary artery bypass surgery with cardiopulmonary bypass, discontinue intravenous infusion 1 hour before procedure and treat with unfractionated heparin
- Anticoagulation in patients undergoing percutaneous coronary intervention (in addition to aspirin and clopidogrel), initially by intravenous injection, 750 micrograms/kg then by intravenous infusion 1.75 mg/kg/hour for up to 4 hours after procedure; a reduced infusion rate of 250 micrograms/kg/hour may be continued for a further 4–12 hours if necessary

**Angiox** (The Medicines Company) ▼ 
Injection, powder for reconstitution, bivalirudin, net price 250-mg vial = £310.00

### Lepirudin

**Indications** thromboembolic disease requiring parenteral anticoagulation in patients with heparin-induced thrombocytopenia type II

**Cautions** recent bleeding or risk of bleeding including recent puncture of large vessels, organ biopsy, recent major surgery, stroke, bleeding disorders, severe hypertension, bacterial endocarditis; concomitant use of drugs that increase risk of bleeding; determine activated partial thromboplastin time 4 hours after start of treatment (or after infusion rate altered) and at least once daily thereafter

**Hepatic impairment** no information—manufacturer advises that cirrhosis may affect renal excretion

**Renal impairment** reduce initial intravenous injection dose to 200 micrograms/kg and reduce subsequent infusion dose by 50–85% if eGFR less than 60 mL/
Flolan® (GSK) Inject, powder for reconstitution, epoprostenol (as sodium salt), net price 500-microgram vial (with diluent) = £62.05; 1.5-mg vial (w) (with diluent) = £125.00

Fondaparinux

Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.

For details on the use of fondaparinux in the prophylaxis of venous thromboembolism, see section 2.8, p. 140.

Heparin flushes

The use of heparin flushes should be kept to a minimum. For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear.

Heparin Sodium (Non-proprietary) Solution, heparin sodium 10 units/mL, net price 5-mL amp = £1.00; 100 units/mL, 2-mL amp = £1.05

Dose to maintain patency of catheters, cannulas, etc. 10–200 units flushed through every 4–8 hours. Not for therapeutic use. Excipients may include benzyl alcohol (avoid in neonates, see Excipients, p. 2).

Epoprostenol

Epoprostenol (prostacyclin) can be given to inhibit platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated. It is also licensed for the treatment of primary pulmonary hypertension resistant to other treatment, usually with oral anti-coagulation. Since its half-life is only about 3 minutes it must be given by continuous intravenous infusion. It is a potent vasodilator and therefore its side-effects include flushing, headache, and hypotension.

2.8.1 Parenteral anticoagulants

Epoprostenol

Indications see notes above

Cautions anticoagulant monitoring required when given with anticoagulants; haemorrhagic diathesis; dose titration for pulmonary hypertension should be in hospital (risk of pulmonary oedema); concomitant use of drugs that increase risk of bleeding

Contra-indications severe left ventricular dysfunction

Pregnancy manufacturer advises caution—no information available

Side-effects see notes above; also bradycardia, tachycardia, pallor, sweating with higher doses; gastro-intestinal disturbances; lassitude, anxiety, agitation; dry mouth, jaw pain, chest pain; also reported, hyperglycaemia and injection-site reactions

Dose

● See product literature

Fondaparinux Sodium

Indications prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness, and patients undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery; treatment of deep-vein thrombosis, superficial-vein thrombosis, and pulmonary embolism; treatment of unstable angina or non-ST-segment elevation myocardial infarction; treatment of ST-segment elevation myocardial infarction

Cautions bleeding disorders, active gastro-intestinal ulcer disease; recent intracranial haemorrhage; brain, spinal, or ophthalmic surgery; spinal or epidural anaesthesia (risk of spinal haematoma—avoid if using treatment doses); risk of catheter thrombus during percutaneous coronary intervention; low body-weight; elderly patients; concomitant use of drugs that increase risk of bleeding

Contra-indications active bleeding; bacterial endocarditis

Hepatic impairment caution in severe impairment (increased risk of bleeding)

Renal impairment increased risk of bleeding; for treatment of acute coronary syndromes avoid if eGFR less than 20 mL/minute/1.73 m²; for treatment of venous thromboembolism use with caution if eGFR 30–50 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²; for prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis reduce dose to 1.5 mg daily if eGFR 20–50 mL/minute/1.73 m²; avoid if eGFR less than 20 mL/minute/1.73 m²

Pregnancy manufacturer advises avoid unless potential benefit outweighs possible risk—no information available

Breast-feeding present in milk in animal studies—manufacturer advises avoid

Side-effects bleeding, purpura, anaemia; less commonly gastro-intestinal disturbances, oedema, hepatic impairment, chest pain, dyspnoea, thrombocytopenia, thrombocythaemia, rash, pruritus; rarely hypo-tension, flushing, cough, vertigo, dizziness, anxiety, drowsiness, confusion, headache, hypokalaemia, hyperbilirubinaemia, injection-site reactions; also reported atrial fibrillation, tachycardia, and pyrexia

Dose

● Prophylaxis of venous thromboembolism after surgery, by subcutaneous injection, 2.5 mg 6 hours after surgery then 2.5 mg once daily; CHILD under 17 years not recommended

Minute/1.73 m², but avoid or stop infusion if eGFR less than 15 mL/minute/1.73 m² (consult product literature)

Pregnancy avoid

Breast-feeding avoid

Side-effects bleeding; reduced haemoglobin concentration without obvious source of bleeding; fever, hypersensitivity reactions (including rash); injection-site reactions

Dose

● Initially by slow intravenous injection (of 5 mg/mL solution), 400 micrograms/kg followed by continuous intravenous infusion of 150 micrograms/kg/hour (max. 16.5 mg/hour), adjusted according to activated partial thromboplastin time, for 2–10 days (longer if necessary)

Refludan® (Celgene) Injection, powder for reconstitution, lepirudin, net price 50-mg vial = £57.00

Heparin flushes

The use of heparin flushes should be kept to a minimum. For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear.

Heparin Sodium (Non-proprietary) Solution, heparin sodium 10 units/mL, net price 5-mL amp = £1.00; 100 units/mL, 2-mL amp = £1.05

Dose to maintain patency of catheters, cannulas, etc. 10–200 units flushed through every 4–8 hours. Not for therapeutic use. Excipients may include benzyl alcohol (avoid in neonates, see Excipients, p. 2).
2.8.2 Oral anticoagulants

- Prophylaxis of venous thromboembolism in medical patients, by subcutaneous injection, 2.5 mg once daily; CHILD under 17 years not recommended
- Treatment of superficial-vein thrombosis, by subcutaneous injection, ADULT body-weight over 50 kg, 2.5 mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications); treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively; CHILD under 17 years not recommended
- Unstable angina and non-ST-segment elevation myocardial infarction, by subcutaneous injection, 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner); treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively; CHILD under 17 years not recommended
- ST-segment elevation myocardial infarction, initially by intravenous injection or infusion, 2.5 mg for first day; thereafter by subcutaneous injection 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner); treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively; CHILD under 17 years not recommended
- Treatment of deep-vein thrombosis and of pulmonary embolism, by subcutaneous injection, ADULT body-weight under 50 kg, 5 mg every 24 hours; body-weight 50–100 kg, 7.5 mg every 24 hours; body-weight over 100 kg, 10 mg every 24 hours; continue until adequate oral anticoagulation established; CHILD under 17 years not recommended
- Arixtra® (GSK) Injection, fondaparinux sodium 5 mg/mL, net price 0.3 mL (1.5-mg) prefilled syringe = £6.28; 0.5 mL (2.5-mg) prefilled syringe = £6.28
- Injection, fondaparinux sodium 12.5 mg/mL, net price 0.4 mL (5-mg) prefilled syringe = £11.66, 0.6 mL (7.5-mg) prefilled syringe = £11.66, 0.8 mL (10-mg) prefilled syringe = £11.66

2.8.2 Oral anticoagulants

**Coumarins and phenindione**

The oral anticoagulants warfarin, acenocoumarol and phenindione, antagonise the effects of vitamin K, and take at least 48 to 72 hours for the anticoagulant effect to develop fully; warfarin is the drug of choice. If an immediate effect is required, unfractionated or low molecular weight heparin must be given concomitantly.

**Uses**

- Indications for these oral anticoagulants include deep-vein thrombosis, pulmonary embolism, atrial fibrillation in those who are at risk of embolisation (see also section 2.3.1), and mechanical prosthetic heart valves (to prevent emboli developing on the valves).
- These oral anticoagulants should not be used in cerebral artery thrombosis or peripheral artery occlusion as first-line therapy; aspirin is more appropriate for reduction of risk in transient ischaemic attack (see p. 151). Unfractionated or a low molecular weight heparin (section 2.8.1) is usually preferred for the prophylaxis of venous thromboembolism in patients undergoing surgery; alternatively, warfarin can be continued in selected patients currently taking long-term warfarin and who are at high risk of thromboembolism (seek expert advice).

**Dose**

The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.

For patients who require rapid anticoagulation the usual adult induction dose of warfarin is 5–10 mg on the first day; subsequent doses depend upon the prothrombin time, reported as INR (international normalised ratio). For patients who do not require rapid anticoagulation, a lower loading dose can be used over 3–4 weeks. The daily maintenance dose of warfarin is usually 3–9 mg (taken at the same time each day). The following indications and target INRs take into account recommendations of the British Society for Haematology:

- INR 2.5 for treatment of deep-vein thrombosis and pulmonary embolism (including those associated with antiphospholipid syndrome or for recurrence in patients no longer receiving warfarin), for atrial fibrillation, cardioversion (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR; anticoagulation should continue for at least 4 weeks following the procedure), dilated cardiomyopathy, mural thrombus, symptomatic inherited thrombophilia, coronary artery thrombosis (if anticoagulated), and paroxysmal nocturnal haemoglobinuria.
- INR 3.5 for recurrent deep-vein thrombosis and pulmonary embolism (in patients currently receiving warfarin with INR above 2).
- For mechanical prosthetic heart valves, the recommended target INR depends on the type and location of the valve. Generally, a target INR of 3 is recommended for mechanical aortic valves, and 3.5 for mechanical mitral valves.

**Monitoring**

It is essential that the INR be determined daily or on alternate days in early days of treatment, then at longer intervals (depending on response) then up to every 12 weeks.

**Haemorrhage**

The main adverse effect of all oral anticoagulants is haemorrhage. Checking the INR and omitting doses when appropriate is essential; if the anticoagulant is stopped but not reversed, the INR should be measured 2–3 days later to ensure that it is falling. The following recommendations are based on the result of the INR and whether there is major or

1. First dose reduced if base-line prothrombin time prolonged, if liver-function tests abnormal, or if patient in cardiac failure, on parenteral feeding, less than average body weight, elderly, or receiving other drugs known to potentiate oral anticoagulants.
2. An INR which is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended.
4. Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. See also interactions, Appendix 1 (warfarin). Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect warfarin control.
minor bleeding; the recommendations apply to patients taking warfarin:

- Major bleeding—stop warfarin; give phytonadione (vitamin K$_1$) 5–10 mg by slow intravenous injection; give dried prothrombin complex (factors II, VII, IX, and X—section 2.11) 30–50 units/kg (if dried prothrombin complex unavailable, fresh frozen plasma 15 mL/kg can be given but is less effective)
- INR > 8.0, no bleeding or minor bleeding—stop warfarin and give phytonadione (vitamin K$_1$) 2.5–5 mg by mouth using the intravenous preparation orally [unlicensed use], or 0.5–1 mg by slow intravenous injection (if complete reversal required 5–10 mg by slow intravenous injection); repeat dose of phytonadione if INR still too high after 24 hours; restart warfarin when INR < 5.0
- INR 5.0–8.0, no bleeding—stop warfarin; minor bleeding—stop warfarin and give phytonadione (vitamin K$_1$) 1–2.5 mg by mouth using the intravenous preparation orally [unlicensed use]; restart warfarin when INR < 5.0
- Unexpected bleeding at therapeutic levels—always investigate possibility of underlying cause e.g. unsuspected renal or gastro-intestinal tract pathology

Hepatic impairment  Warfarin, acenocoumarol, and phenindione should be avoided in severe impairment, especially if prothrombin time is already prolonged.

Renal impairment  Warfarin, acenocoumarol, and phenindione should be used with caution in mild to moderate impairment and avoided in severe impairment.

Pregnancy  Warfarin, acenocoumarol, and phenindione are teratogenic and should not be given in the first trimester of pregnancy. Women of child-bearing age should be warned of this danger since stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality. These oral anticoagulants cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery. Therefore, if at all possible, they should be avoided in pregnancy, especially in the first and third trimesters. Difficult decisions may have to be made, particularly in women with prosthesis heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism.

Breast-feeding  With warfarin, acenocoumarol, and phenindione there is a risk of haemorrhage which is increased by vitamin-K deficiency. Warfarin is not present in milk in significant amounts, and appears safe, but phenindione should be avoided; the manufacturer of acenocoumarol recommends prophylactic vitamin K for the infant (consult product literature).

Treatment booklets  Anticoagulant treatment booklets should be issued to patients, and are available for distribution to local healthcare professionals from Health Authorities and from: Synthrome (Alliance) £1.49; 1 mg (brown), 28-tab pack = £9.50; 5 mg (pink), 28-tab pack = £10.00. Label: 10, anticoagulant card

These booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information. Electronic copies and further advice are also available at www.npsa.nhs.uk/nrls/alerts-directives/alerts/anticoagulant.

WARFARIN SODIUM

Indications  prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation; prophylaxis after insertion of prostatic heart valve; prophylaxis and treatment of venous thrombosis and pulmonary embolism; transient ischaemic attacks

Cautions  see notes above; also recent surgery; recent ischaemic stroke; history of gastro-intestinal bleeding; peptic ulcer; concomitant use of drugs that increase risk of bleeding; bacterial endocarditis (increased risk of bleeding; use only if warfarin otherwise indicated); avoid cranberry juice; interactions: Appendix 1 (coumarins)

Contra-indications  haemorrhagic stroke; significant bleeding; avoid use within 48 hours postpartum

Hepatic impairment  see notes above

Renal impairment  see notes above

Pregnancy  see notes above

Breast-feeding  see notes above

Side-effects  haemorrhage—see notes above; also nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)

Dose  
- See notes above

Warfarin  (Non-proprietary)  Tablets, warfarin sodium 500 micrograms (white), net price 28-tab pack = £1.49; 1 mg (brown), 28-tab pack = £9.50; 3 mg (blue), 28-tab pack = £9.50; 5 mg (pink), 28-tab pack = £10.03. Label: 10, anticoagulant card

BRANDS INCLUDE Morenau®

Oral suspension, warfarin sodium 5 mg/5 mL, net price 150 mL = £90.00. Label: 10, anticoagulant card

ACENOCOUMAROL  (Nicoumalone)

Indications  see under Warfarin Sodium

Cautions  see under Warfarin Sodium

Contra-indications  see under Warfarin Sodium

Hepatic impairment  see notes above

Renal impairment  see notes above

Pregnancy  see notes above

Breast-feeding  see notes above

Side-effects  see under Warfarin Sodium

Dose  
- 4 mg on first day, 4–8 mg on second day; maintenance dose usually 1–8 mg daily adjusted according to response

Synthrome (Alliance) £4.27. Label: 10, anticoagulant card
### PHENINDIONE

**Indications** prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation; prophylaxis after insertion of prosthetic heart valve; prophylaxis and treatment of venous thrombosis and pulmonary embolism

**Cautions** see under Warfarin Sodium; interactions: Appendix 1 (phenindione)

**Contra-indications** see under Warfarin Sodium

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Warfarin Sodium; also hyper-sensitivity reactions including exfoliative dermatitis, exanthesma, fever, leucopenia, agranulocytosis, eosinophilia, and renal damage; micro-adenopathy and urine coloured pink or orange

---

### Dabigatran etexilate

Dabigatran etexilate, a direct thrombin inhibitor, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; see Prophylaxis of Venous Thromboembolism in adults after total hip replacement or total knee replacement surgery.

**NICE guidance** Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008)

Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.

---

### Rivaroxaban

**Indications** see notes above

**Cautions** see notes above; also bleeding disorders; concomitant use of drugs that increase risk of bleeding; severe hypertension; active or recent gastrointestinal ulceration; vascular retinopathy; anaesthesia with postoperative indwelling epidural catheter (risk of paralyis—monitor neurological signs and wait at least 18 hours after rivaroxaban dose before catheter removal); recent surgery; interactions: Appendix 1 (rivaroxaban)

**Contra-indications** active bleeding

**Hepatic impairment** avoid in severe liver disease, especially if prothrombin time already prolonged

---

## Renal impairment

- Reduce initial dose to 75 mg and subsequent doses to 150 mg once daily if eGFR 30–50 mL/minute/1.73 m²; reduce dose to 75 mg once daily if eGFR 30–50 mL/minute/1.73 m² and patient receiving concomitant treatment with verapamil; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid—no information available

**Breast-feeding** manufacturer advises avoid—no commonly hepatobiliary disorders

### Dose

- **200 mg** on day 1; **100 mg** on day 2, then adjusted according to response; maintenance dose usually **50–150 mg** daily

**Phenindione (Non-proprietary)**

**Tablets**, phenindione 10 mg, net price 28-tab pack = £21.10; 25 mg, 28-tab pack = £27.36; 50 mg, 28-tab pack = £52.33.

**Pradaxa®** (Boehringer Ingelheim) Capsules, blue/ivory, dabigatran etexilate (as mesilate) 75 mg, net price 10-cap pack = £21.00, 60-cap pack = £126.00; 110 mg 10-cap pack = £21.00, 60-cap pack = £126.00.

**Label:** 10, anticoagulant card, 14, (urine pink or orange)
Hepatic impairment manufacturer advises caution in cirrhotic patients with moderate hepatic impairment; avoid in liver disease with coagulopathy

Renal impairment use with caution if eGFR 15–29 mL/minute/1.73 m² or if eGFR 30–49 mL/minute/1.73 m² and concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature); avoid if eGFR less than 15 mL/minute/1.73 m²

Pregnancy manufacturer advises avoid—toxicity in animal studies

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects nausea; haemorrhage (see notes above); less commonly constipation, diarrhoea, dyspepsia, dry mouth, vomiting, hypotension, oedema, tachycardia, thrombocytopenia, syncope, dizziness, headache, renal impairment, pain in extremities, pruritus, and rash; jaundice also reported

Dose
- Prophylaxis of venous thromboembolism following knee replacement surgery, ADULT over 18 years, 10 mg once daily for 2 weeks starting 6–10 hours after surgery
- Prophylaxis of venous thromboembolism following hip replacement surgery, ADULT over 18 years, 10 mg once daily for 5 weeks starting 6–10 hours after surgery

Xarelto® (Bayer Schering) ▼ ▼ ▼
Tablets, red, f/c, rivaroxaban 10 mg, net price 10-tab pack = £44.15, 30-tab pack = £132.44, 100-tab pack = £441.45

2.8.3 Protamine sulphate

Protamine sulphate is used to treat overdosage of unfractionated or low molecular weight heparin. The long half-life of low molecular weight heparins should be taken into consideration when determining the dose of protamine sulphate; the effects of low molecular weight heparins can persist for up to 24 hours after administration. Excessive doses of protamine sulphate can have an anticoagulant effect.

PROTAMINE SULPHATE (Protamine Sulfate)

Indications see above

Cautions see above; also monitor activated partial thromboplastin time or other appropriate blood clotting parameters; increased risk of allergic reaction to protamine (including previous treatment with protamine or protamine insulin, allergy to fish, men who are infertile or who have had a vasectomy)

Side-effects nausea, vomiting, lassitude, flushing, hypotension, hypertension, bradycardia, dyspnoea, rebound bleeding, back pain; hypersensitivity reactions (including angioedema, anaphylaxis) and pulmonary oedema reported

Dose
- Overdosage with intravenous injection of unfractionated heparin, by intravenous injection (rate not exceeding 5 mg/minute), 25–50 mg once heparin infusion stopped
- Overdosage with subcutaneous injection of unfractionated heparin, 1 mg neutralises 100 units heparin; give 25–50 mg by intravenous injection (rate not exceeding 5 mg/minute) then any remaining dose given by intravenous infusion over 8–16 hours; max. total dose 50 mg
- Overdosage with subcutaneous injection of low molecular weight heparin, by intermittent intravenous injection (rate not exceeding 5 mg/minute) or by continuous intravenous infusion, 1 mg neutralises approx. 100 units low molecular weight heparin (consult product literature of low molecular weight heparin for details); max. 50 mg

Protamine Sulphate (Non-proprietary) ▼ ▼ ▼
Injection, protamine sulphate 10 mg/mL, net price 5-mL amp = £1.43, 10-mL amp = £4.15

2.9 Antiplatelet drugs

Antiplatelet drugs decrease platelet aggregation and inhibit thrombus formation in the arterial circulation, because in faster-flowing vessels, thrombi are composed mainly of platelets with little fibrin.

Use of aspirin in primary prevention of cardiovascular events, in patients with or without diabetes, is of unproven benefit. Long-term use of aspirin, in a dose of 75 mg daily, is of benefit in established cardiovascular disease (secondary prevention); unduly high blood pressure must be controlled before aspirin is given. If the patient is at a high risk of gastrointestinal bleeding, a proton pump inhibitor (section 1.3.5) can be added.

Aspirin in a dose of 75–300 mg daily is given following coronary bypass surgery. For details on the use of aspirin in atrial fibrillation see section 2.3.1; for intermittent claudication see section 2.6.4; for stable angina and acute coronary syndromes see section 2.10.1; for use following placement of coronary stents see below; for use in stroke see also below.

Clopidogrel is licensed for the prevention of ischaemic events in patients with a history of symptomatic ischaemic disease. Clopidogrel, in combination with low-dose aspirin, is also licensed for acute coronary syndrome without ST-segment elevation (section 2.10.1); in these circumstances the combination is given for up to 12 months (most benefit occurs during the first 3 months; there is no evidence of benefit beyond 12 months). Clopidogrel, in combination with low-dose aspirin, is also licensed for acute myocardial infarction with ST-segment elevation (section 2.10.1); the combination is licensed for at least 4 weeks, but the optimum treatment duration has not been established. In patients undergoing percutaneous coronary intervention, clopidogrel is used as an adjunct with aspirin (see also below). Patients, who are not already taking clopidogrel, should receive a 300 mg loading dose prior to the procedure; alternatively, a 600 mg [unlicensed] loading dose may produce a greater and more rapid inhibition of platelet aggregation. Use of clopidogrel with aspirin increases the risk of bleeding. Clopidogrel monotherapy is an alternative when aspirin is contra-indi-
2 Cardiovascular system

Prasugrel, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (section 2.10.1); the combination is usually given for up to 12 months. The Scottish Medicines Consortium (p. 4) has advised (August 2009) that prasugrel (Efient®), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10 mg dose of prasugrel.

NICE guidance

Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (October 2009)

Prasugrel, in combination with aspirin, is an option for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention, only when:
- immediate primary percutaneous coronary intervention is necessary for ST-segment elevation myocardial infarction, or
- stent thrombosis occurred during treatment with clopidogrel, or
- the patient has diabetes mellitus.

Patients selected for percutaneous coronary intervention, with the placement of a coronary stent, will require dual antiplatelet therapy with aspirin and clopidogrel, or aspirin and prasugrel. Aspirin therapy should continue indefinitely. Clopidogrel is recommended for 1 month following elective percutaneous coronary intervention with placement of a bare-metal stent, and for 12 months if percutaneous coronary intervention with placement of a bare-metal stent was for an acute coronary syndrome; clopidogrel should be given for 12 months following placement of a drug-eluting stent. Clopidogrel should not be discontinued prematurely in patients with a drug-eluting stent—there is an increased risk of stent thrombosis as a result of the eluted drug slowing the re-endothelialisation process. Patients considered to be at high risk of developing late stent thrombosis with a drug-eluting stent may require a longer duration of treatment with clopidogrel. Prasugrel is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see notes above).

Glycoprotein IIb/IIIa inhibitors

Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation by blocking the binding of fibrinogen to receptors on platelets. Abciximab is a monoclonal antibody which binds to glycoprotein IIb/IIIa receptors and to other related sites; it is licensed as an adjunct to unfractionated heparin and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary intervention. Abciximab should be used once only (to avoid additional risk of thrombocytopenia). Eptifibatide and tirofiban also inhibit glycoprotein IIb/IIIa receptors; they are licensed for use with unfractionated heparin and aspirin to prevent early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (section 2.10.1). Abciximab, eptifibatide and tirofiban should be used by specialists only.

For use of epoprostenol, see section 2.8.1.

Management of stroke

Stroke is associated with a significant risk of morbidity and mortality. Patients presenting with acute symptoms should be immediately transferred to hospital for accurate diagnosis of stroke type, and urgent initiation of appropriate treatment; patients should be managed by a specialist multidisciplinary stroke team.

The following notes give an overview of the initial and long-term management of transient ischaemic attack, ischaemic stroke, and intracerebral haemorrhage.

cated, for example in those with aspirin hypersensitivity, or when aspirin is not tolerated despite the addition of a proton pump inhibitor.

For details on the use of clopidogrel in stroke, see below. The Scottish Medicines Consortium (p. 4) has advised (February 2004) that clopidogrel be accepted for restricted use for the treatment of confirmed acute coronary syndrome (without ST-segment elevation), in combination with aspirin. Clopidogrel should be initiated in hospital inpatients only. The Scottish Medicines Consortium has also advised (July 2007) that clopidogrel be accepted for restricted use for patients with ST-segment elevation acute myocardial infarction in combination with aspirin; treatment with clopidogrel is restricted to 4 weeks only.

Dipyridamole is used by mouth as an adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. Modified-release dipyridamole monotherapy is restricted to 4 weeks only.

in combination with aspirin, is recommended as an option to prevent occlusive vascular events in patients who have had:
- an ischaemic stroke, or who have peripheral arterial disease or multivascular disease, or
- a myocardial infarction, only if aspirin is contra-indicated or not tolerated.

Modified-release dipyridamole, in combination with aspirin, is recommended as an option to prevent occlusive vascular events in patients who have had:
- a transient ischaemic attack, or
- an ischaemic stroke, only if clopidogrel is contra-indicated or not tolerated.

Modified-release dipyridamole monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:
- an ischaemic stroke, only if aspirin and clopidogrel are contra-indicated or not tolerated, or
- a transient ischaemic attack, only if aspirin is contra-indicated or not tolerated.
Transient ischaemic attack

Patients suspected of having a transient ischaemic attack should immediately receive aspirin 300 mg once daily (patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel 75 mg once daily [unlicensed use] as an alternative). Following a confirmed diagnosis, patients should receive treatment for secondary prevention (see Long-term Management, under Ischaemic Stroke, below).

Ischaemic stroke

Initial management  Alteplase (section 2.10.2) is recommended in the treatment of acute ischaemic stroke if it can be administered within 3 hours of symptom onset; it should be given by medical staff experienced in the administration of thrombolitics and the treatment of acute stroke, preferably within a specialist stroke centre. Treatment with aspirin 300 mg once daily for 14 days should be initiated 24 hours after thrombolysis (or as soon as possible within 48 hours of symptom onset in patients not receiving thrombolysis); patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel 75 mg once daily [unlicensed use] as an alternative.

Anticoagulants are not recommended as an alternative to antiplatelet drugs in acute ischaemic stroke in patients who are in sinus rhythm. However, parental anticoagulants (section 2.8.1) may be indicated in patients who are symptomatic of, or at high risk of developing, deep vein thrombosis or pulmonary embolism; warfarin should not be commenced in the acute phase of ischaemic stroke.

Anticoagulants (section 2.8.2) should be considered after cardio-embolic ischaemic stroke in patients with atrial fibrillation, however patients presenting with atrial fibrillation following a disabling ischaemic stroke should receive aspirin 300 mg once daily for 14 days, before being considered for warfarin treatment. Patients already receiving anticoagulation for a prosthetic heart valve who experience a disabling ischaemic stroke and are at significant risk of haemorrhagic transformation, should have their anticoagulant treatment stopped for 7 days and substituted with aspirin 300 mg once daily.

Treatment of hypertension in the acute phase of ischaemic stroke can result in reduced cerebral perfusion, and should therefore only be instituted in the event of a hypertensive emergency (see section 2.5). Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.

All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

Long-term management  Patients receive treatment for secondary prevention (see Long-term Management, under Ischaemic Stroke, above, and section 2.3). Anticoagulants are not routinely recommended in the long-term prevention of recurrent stroke, except in patients with atrial fibrillation (section 2.3).

A statin (section 2.12) should be initiated 48 hours after stroke symptom onset, irrespective of the patient’s serum-cholesterol concentration.

Following the acute phase of ischaemic stroke, blood pressure should be measured and treatment initiated to achieve a target blood pressure of <130/80 mmHg (see section 2.5). Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.

All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

Intracerebral haemorrhage

Initial management  Surgical intervention may be required following intracerebral haemorrhage to remove the haematoma and relieve intracranial pressure. Patients taking anticoagulants should have this treatment stopped and reversed (see section 2.8.2); anticoagulant therapy has, however, been used in patients with intracerebral haemorrhage who are symptomatic of deep vein thrombosis or pulmonary embolism; placement of a caval filter is an alternative in this situation.

Long-term management  Aspirin therapy should only be given to patients at a high risk of a cardiac ischaemic event. Blood pressure should be measured and treatment initiated where appropriate (see section 2.5), taking care to avoid hypoperfusion. Statins should be avoided following intracerebral haemorrhage, however they can be used with caution when the risk of a vascular event outweighs the risk of further haemorrhage.

ABCIXIMAB

Indications  prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention; short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (use under specialist supervision)

Cautions  measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit; monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2–4 hours and 24 hours after start of treatment; concomitant use of drugs that increase risk of bleeding; discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed; consult product literature for details of procedures to minimise bleeding; elderly
Contra-indications active internal bleeding; major surgery, intracranial or intraspinal surgery or trauma within last 2 months; stroke within last 2 years; intracranial neoplasm, arteriovenous malformation or aneurysm, severe hypertension, haemorrhagic diathesis, thrombocytopenia, vasculitis, hypertensive retinopathy

Renal impairment avoid in severe liver disease—increased risk of bleeding

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—no information available

Side-effects bleeding manifestations; nausea, vomiting, hypotension, bradycardia, chest pain, back pain, headache, fever, puncture site pain, thrombocytopenia; rarely cardiac tamponade, adult respiratory distress, hypersensitivity reactions

Dose

• ADULT initially by intravenous injection over 1 minute, 250 micrograms/kg, then by intravenous infusion, 125 nanograms/kg/minute (max. 10 micrograms/minute); for prevention of ischaemic complications start 10–60 minutes before percutaneous coronary intervention and continue infusion for 12 hours; for unstable angina start up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention

ReoPro® (Lilly) Injection, abciximab 2 mg/mL, net price 5-mL vial = £250.24

ASPIRIN (antiplatelet)
(Acetylsalicylic Acid)

Indications secondary prevention of thrombotic cerebrovascular or cardiovascular disease, and following by-pass surgery (see also section 2.10.1 and notes above)

Cautions asthma; uncontrolled hypertension; previous peptic ulceration (but manufacturers may advise avoidance of low-dose aspirin in history of peptic ulceration); concomitant use of drugs that increase risk of bleeding; G6PD deficiency (section 9.1.5); interactions: Appendix 1 (aspirin)

Contra-indications use other than as an antiplatelet in children and adolescents under 16 years (Reye’s syndrome, section 4.7.1); active peptic ulceration; haemophilia and other bleeding disorders

Hypersensitivity Aspirin and other NSAIDs are contraindicated in history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria, or rhinitis have been precipitated by aspirin or any other NSAID

Hepatic impairment avoid in severe impairment—increased risk of gastro-intestinal bleeding

Renal impairment use with caution; avoid in severe impairment; sodium and water retention; deterioration in renal function; increased risk of gastro-intestinal bleeding

Pregnancy use with caution during third trimester; impaired platelet function and risk of haemorrhage; delayed onset and increased duration of labour with increased blood loss; avoid analgesic doses if possible in last few weeks (low doses probably not harmful); with high doses, closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of newborn; kernicterus in jaundiced neonates

Breast-feeding avoid—possible risk of Reye’s syndrome; regular use of high doses could impair platelet function and produce hypoprothrombinaemia in infant if neonatal vitamin K stores low

Side-effects bronchospasm; gastro-intestinal irritation, gastro-intestinal haemorrhage (occasionally major), also other haemorrhage (e.g. subconjunctival)

Dose

• See notes above

1 Aspirin (Non-proprietary) (Farr)

Dispersible tablets, aspirin 75 mg, net price 28 = £3.12; 300 mg, see section 4.7.1. Label: 5, 25, 32

Tablets, e/c, aspirin 75 mg, net price 28-tab pack = £1.51, 56-tab pack = £2.52, 100-tab pack = £5.24; 300 mg, see section 4.7.1. Label: 5, 25, 32

Brands include Microprin®

Caprin® (Pinewood) (Fm)

Tablets, e/c, pink, aspirin 75 mg, net price 28-tab pack = £1.51, 56-tab pack = £2.52, 100-tab pack = £5.24; 300 mg, see section 4.7.1. Label: 5, 25, 32

Nu-Seals® Aspirin (Alliance) (Fm)

Tablets, e/c, aspirin 75 mg, net price 56-tab pack = £3.12; 300 mg, see section 4.7.1. Label: 5, 25, 32

Note Tablets may be chewed at diagnosis for rapid absorption

CLOPIDOGREL

Indications prevention of atherosclerotic events in peripheral arterial disease, or within 35 days of myocardial infarction, or within 6 months of ischaemic stroke; prevention of atherosclerotic events in acute coronary syndrome without ST-segment elevation (given with aspirin—see notes above) and in acute myocardial infarction with ST-segment elevation (given with aspirin—see notes above)

Cautions patients at risk of increased bleeding from trauma, surgery or other pathological conditions; concomitant use of drugs that increase risk of bleeding; discontinue 7 days before elective surgery if antiplatelet effect not desirable; interactions: Appendix 1 (clopidogrel)

Contra-indications active bleeding

Hepatic impairment manufacturer advises caution (risk of bleeding); avoid in severe impairment

Renal impairment manufacturer advises caution

Pregnancy manufacturer advises avoid—no information available

Breast-feeding manufacturer advises avoid

Side-effects dyspepsia, abdominal pain, diarrhoea; bleeding disorders (including gastro-intestinal and intracranial); less commonly nausea, vomiting, gastrointestinal, flatulence, constipation, gastric and duodenal ulcers, headache, dizziness, paraesthesia, leucopénia, decreased platelets (very rarely severe thrombocytopenia), eosinophilia, rash, and pruritus; rarely vertigo; very rarely colitis, pancreatitis, hepatitis, acute liver failure, vasculitis, confusion, hallucinations, taste disturbance, stomatitis, bronchospasm, interstitial pneumonitis, blood disorders (including thrombocytopenic

1. Aspirin tablets 75 mg may be sold to the public in packs of up to 100 tablets; for details relating to other strengths see section 4.7.1 and Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)
purpura, agranulocytosis and pancytopenia), and hypersensitivity-like reactions (including fever, glomerulonephritis, arthritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichen planus)

Dose
- Prevention of atherosclerotic events in peripheral arterial disease or after myocardial infarction or ischaemic stroke, 75 mg once daily
- Acute coronary syndrome (without ST-segment elevation), initially 300 mg then 75 mg daily (with aspirin—see notes above)
- Acute myocardial infarction (with ST-segment elevation), initially 300 mg then 75 mg daily (with aspirin—see notes above); initial dose omitted if patient over 75 years

Clopidogrel (Non-proprietary) (Boehringer Ingelheim)

Tablets, clopidogrel (as besilate or hydrochloride) 75 mg, net price 28-tab pack = £3.17, 30-tab pack = £3.40
Brands include: Grepida®

Plavix® (Sanofi-Aventis) (Boehringer Ingelheim)

Tablets, pink, f/c, clopidogrel (as hydrogen sulphate) 75 mg, net price 30-tab pack = £35.64; 300 mg, 30-tab pack = £142.54

Dipyridamole

Indications see notes above and under Dose

Cautions rapidly worsening angina, aortic stenosis, recent myocardial infarction, left ventricular outflow obstruction, heart failure; may exacerbate migraine; hypotension; myasthenia gravis (risk of exacerbation); coagulation disorders; concomitant use of drugs that increase risk of bleeding; interactions: Appendix 1 (dipyridamole)

Pregnancy not known to be harmful

Breast-feeding manufacturers advise use only if essential—small amount present in milk

Side-effects gastro-intestinal effects, dizziness, myalgia, throbbing headache, hypotension, hot flushes and tachycardia; worsening symptoms of coronary heart disease; hypersensitivity reactions such as rash, urticaria, severe bronchospasm and angioedema; increased bleeding during or after surgery; thrombocytopenia reported

Dose
- By mouth, 300–600 mg daily in 3–4 divided doses
- Modified-release preparations, see under preparation below
- By intravenous injection, diagnostic only; consult product literature

Dipyridamole (Non-proprietary) (Boehringer Ingelheim)

Tablets, coated, dipyridamole 25 mg, net price 84 = £13.11; 100 mg, net price 84-tab pack = £8.20. Label: 22

Oral suspension, dipyridamole 50 mg/5 mL, net price 150 mL = £40.63

Persantin® (Boehringer Ingelheim) (GSK)

Tablets, s/c, dipyridamole 25 mg (orange), net price 84-tab pack = £14.99; 100 mg, 84-tab pack = £4.16. Label: 22
Injection, dipyridamole 5 mg/mL, net price 2-mL amp = 12p

2.9 Antiplatelet drugs

Modified release

Persantin® Retard (Boehringer Ingelheim) (GSK)

Capsules, m/r, red/orange containing yellow pellets, dipyridamole 200 mg, net price 60-cap pack = £9.00. Label: 21, 25

Dose secondary prevention of ischaemic stroke and transient ischaemic attacks (used alone or with aspirin), adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves, 200 mg twice daily preferably with food

Note Dispense in original container (pack contains a desiccant) and discard any capsules remaining 6 weeks after opening

With aspirin

For prescribing information on aspirin, see under Aspirin, p. 152

Asasantin® Retard (Boehringer Ingelheim) (GSK)

Capsules, red/ivory, aspirin 25 mg, dipyridamole 200 mg (m/r), net price 60-cap pack = £7.79. Label: 21, 25

Dose secondary prevention of ischaemic stroke and transient ischaemic attacks, 1 capsule twice daily

Note Dispense in original container (pack contains a desiccant) and discard any capsules remaining 6 weeks after opening

EPTIFIBATIDE

Indications prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 24 hours (use under specialist supervision)

Cautions risk of bleeding, concomitant drugs that increase risk of bleeding—discontinue immediately if uncontrolled serious bleeding; measure baseline prothrombin time, activated partial thromboplastin time, platelet count, haemoglobin, haematocrit and serum creatinine; monitor haemoglobin, haematocrit and platelets within 6 hours after start of treatment then at least once daily; discontinue if thrombolytic therapy, intra-aortic balloon pump or emergency cardiac surgery necessary

Contra-indications abnormal bleeding within 30 days, major surgery or severe trauma within 6 weeks, stroke within last 30 days or any history of haemorrhagic stroke, intracranial disease (aneurysm, neoplasm or arteriovenous malformation), severe hypertension, haemorrhagic diathesis, increased prothrombin time or INR, thrombocytopenia

Hepatic impairment avoid in severe liver disease—increased risk of bleeding

Renal impairment reduce infusion to 1 microgram/kg/minute if eGFR 30–50 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—no information available

Side-effects bleeding manifestations; very rarely anaphylaxis and rash

Dose
- Initially by intravenous injection, 180 micrograms/kg, then by intravenous infusion, 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)

Integrilin® (GSK) (Sanofi-Aventis)

Injection, eptifibatide 2 mg/mL, net price 10-mL (20-mg) vial = £13.61
Infusion, eptifibatide 750 micrograms/mL, net price 100-mL (75-mg) vial = £42.79
2.10 Stable angina, acute coronary syndromes, and fibrinolysis

**PRASUGREL**

**Indications** in combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

**Contraindications** abnormal bleeding within 30 days, stroke within 30 days or any history of haemorrhagic stroke, intracranial disease (aneurysm, neoplasm or arteriovenous malformation), severe hypertension, haemorrhagic diathesis, increased prothrombin time or INR, thrombocytopenia, increased risk of bleeding; avoid in severe liver disease—increased risk of bleeding.

**Renal impairment** increased risk of bleeding; monitor carefully if eGFR less than 60 mL/minute/1.73 m²; use half normal dose if eGFR less than 30 mL/minute/1.73 m².

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—no information available.

**Breast-feeding** manufacturer advises avoid—no information available.

**Hepatic impairment** caution in mild to moderate liver disease; avoid in severe liver disease—increased risk of bleeding.

**Side-effects** bleeding manifestations; reversible thrombocytopenia.

**Dose**  
- **ADULT** over 18 years, (with aspirin—see notes above) initially 60 mg as a single dose then body-weight over 60 kg, 10 mg once daily or body-weight under 60 kg or **ELDERLY** over 75 years, 5 mg once daily.

**Eliet® (Lilly)** Tablets, f/c, prasugrel (as hydrochloride) 5 mg (yellow), net price 28-tab pack = £47.56; 10 mg (beige), 28-tab pack = £47.56.

**TIROFIBAN**

**Indications** prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 12 hours (use under specialist supervision).

**Contra-indications** active bleeding; history of stroke or transient ischaemic attack.

**Cautions** patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease); concomitant use of drugs that increase risk of bleeding; discontinue at least 7 days before elective surgery if antplatelet effect not desirable; elderly; body-weight less than 60 kg; **interactions**: Appendix 1 (prasugrel).

**Eliet® (Lilly)** Concentrate for intravenous infusion, tirofiban (as hydrochloride) 250 micrograms/mL, net price 250-mL vial = £160.72.

**Aggrastat® (Chiesi)** Concentrate for intravenous infusion, tirofiban (as hydrochloride) 50 micrograms/mL, net price 50-mL (12.5-mg) vial = £146.11.

2.10 Stable angina, acute coronary syndromes, and fibrinolysis

2.10.1 Management of stable angina and acute coronary syndromes

2.10.2 Fibrinolytic drugs

**Stable angina**

It is important to distinguish stable angina from unstable angina. **Stable angina** usually results from atherosclerotic plaques in the coronary arteries and is often precipitated by exertion and relieved by rest. Treatment involves management of acute anginal pain, and long-term management to prevent angina attacks and to reduce the risk of cardiovascular events.

**Management of stable angina**

Acute attacks of stable angina should be managed with sublingual glyceryl trinitrate (section 2.6.1); sublingual glyceryl trinitrate can also be taken before performing activities that are known to bring on an attack. If attacks occur more than twice a week, regular drug therapy is required and should be introduced in a step-wise manner according to response.
Patients with mild or moderate stable angina should be given a beta-blocker (section 2.4). In those with left-ventricular dysfunction, beta-blocker treatment should be started at a very low dose and titrated very slowly over a period of weeks or months (section 2.5.5).

For those patients in whom beta-blockers are not tolerated or are contra-indicated, a long-acting nitrateg (section 2.6.1) or a rate-limiting calcium-channel blocker (diltiazem or verapamil, section 2.6.2) can be used; in patients with left-ventricular dysfunction, diltiazem and verapamil are contra-indicated because heart failure may be precipitated (important: see p. 128); however, a long-acting dihydropyridine calcium-channel blocker, such as amlopidine or felodipine, is suitable. Nicorandil or ivabradine (section 2.6.3) are alternatives.

When a single drug fails to control symptoms, combination treatment can be used. A calcium-channel blocker can be added to a beta-blocker, although combining verapamil with a beta-blocker should be avoided (see p. 133); combinations including diltiazem and a beta-blocker should be used with caution. Long-acting nitrates can also be used with a beta-blocker or a calcium-channel blocker, if appropriate. Combinations that include nicorandil or ranolazine (section 2.6.3) can also be considered.

Patients should be referred to a specialist if a combination of two drugs fails to control symptoms. Revascularisation procedures may be appropriate; see section 2.9 for the use of antiplatelet drugs in patients undergoing coronary stenting.

For long-term prevention of cardiovascular events, see Prevention of cardiovascular events, p. 156.

Management of unstable angina and non-ST-segment elevation myocardial infarction

These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myocardial infarction (STEMI), see below.

Initial management. Oxygen (section 3.6) should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.

Nitrates (section 2.6.1) are used to relieve ischaemic pain. If sublingual glyceryl trinitrate is not effective, intravenous or buccal glyceryl trinitrate or intravenous isosorbide dinitrate is given. If pain continues, diamorphine or morphine (section 4.7.2) can be given by slow intravenous injection; an antiemetic such as metoclopramide should also be given (section 4.6).

Aspirin (chewed or dispersed in water) is given for its antiplatelet effect in a dose of 300 mg (section 2.9). If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel in a dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous coronary intervention) should also be given (see section 2.9). Prasugrel, in a dose of 60 mg, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance, p. 150). Patients should also receive either unfractionated heparin, a low molecular weight heparin, or fondaparinux (section 2.8.1).

Patients without contra-indications should receive beta-blockers (section 2.4) which should be continued indefinitely. In patients without left ventricular dysfunction and in whom beta-blockers are inappropriate, diltiazem or verapamil can be given (section 2.6.2).

The glycoprotein IIB/IIIa inhibitors eptifibatide and tirofiban (section 2.9) can be used (with aspirin and unfractionated heparin) for unstable angina or for non-ST-segment elevation myocardial infarction in patients at a high risk of either myocardial infarction or death.

In intermediate- and high-risk patients, abciximab, eptifibatide, or tirofiban can also be used with aspirin and unfractionated heparin in patients undergoing percutaneous coronary intervention, to reduce the immediate risk of vascular occlusion. In intermediate- and high-risk patients in whom early intervention is planned, bivalirudin (section 2.8.1) can be considered as an alternative to the combination of a glycoprotein IIB/IIIa inhibitor plus a heparin.

Revascularisation procedures are often appropriate for patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI); see section 2.9 for the use of antiplatelet drugs in patients undergoing coronary stenting.

Long-term management. The need for long-term angina treatment or for coronary angiography should be assessed. Most patients will require standard angina treatment (see management of stable angina, above) to prevent recurrence of symptoms.

Acute coronary syndromes

Acute coronary syndromes encompass a spectrum of conditions which include unstable angina, and myocardial infarction with or without ST-segment elevation. Patients with different acute coronary syndromes may present similarly; definitive diagnosis is made on the basis of clinical presentation, ECG changes, and measurement of biochemical cardiac markers.

Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) are related acute coronary syndromes that fall between the classifications of stable angiia and ST-segment elevation myocardial infarction (STEMI). They usually occur as a result of atheromatous plaque rupture, and are often characterised by stable angina that suddenly worsens, recurring or prolonged angina at rest, or new onset of severe angina. Patients with unstable angina have no evidence of myocardial necrosis, whereas in NSTEMI, myocardial necrosis (less significant than with STEMI) will be evident. There is a risk of progression to STEMI or sudden death, particularly in patients who experience pain at rest.

ST-segment elevation myocardial infarction (STEMI) is an acute coronary syndrome where atheromatous plaque rupture leads to thrombosis and myocardial ischaemia, with irreversible necrosis of the heart muscle, often leading to long-term complications. STEMI can also occasionally occur as a result of coronary spasm or embolism, arthritis, spontaneous thrombosis, or sudden severe elevation in blood pressure.
Prevention of cardiovascular events Patients with stable and unstable angina should be given advice and treatments to reduce their cardiovascular risk. The importance of lifestyle changes, especially stopping smoking, should be emphasised. Patients should take aspirin indefinitely in a dose of 75 mg daily. In patients with non-ST-segment elevation acute coronary syndrome, a combination of aspirin and clopidogrel (section 2.9) is given for up to 12 months; most benefit occurs during the first 3 months. An ACE inhibitor (section 2.5.5.1) and a statin (section 2.12) should also be given.

Management of ST-segment elevation myocardial infarction

These notes give an overview of the initial and long-term management of myocardial infarction with ST-segment elevation. For advice on the management of non-ST-segment elevation myocardial infarction and unstable angina, see above. The aims of management of ST-segment elevation myocardial infarction are to provide supportive care and pain relief, to promote reperfusion and to reduce mortality. Oxygen, nitrates, and diamorphine or morphine can provide initial support and pain relief; aspirin and percutaneous coronary intervention or thrombolysis promote reperfusion; antiplatelet drugs help to reduce re-occlusion and systemic embolisation; long-term use of aspirin, beta-blockers, ACE inhibitors, and statins help to reduce mortality further.

Initial management Oxygen (section 3.6) should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease. The pain (and anxiety) of myocardial infarction is managed with slow intravenous injection of diamorphine or morphine (section 4.7.2); an antiemetic such as metoclopramide (or, if left ventricular function is not compromised, cyclizine) by intravenous injection should also be given (section 4.6).

Aspirin (chewed or dispersed in water) is given for its antiplatelet effect (section 2.9); a dose of 300 mg is suitable. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel, in a dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous coronary intervention), should also be given (section 2.9). Prasugrel, in a dose of 60 mg, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance, p. 150). Patency of the occluded artery can be restored by percutaneous coronary intervention or by giving a thrombolytic drug (section 2.10.2), unless contra-indicated. Percutaneous coronary intervention is the preferred method; a glycoprotein IIb/IIIa inhibitor (section 2.9) can be used to reduce the risk of immediate vascular occlusion in intermediate- and high-risk patients. Patients undergoing percutaneous coronary intervention should also receive either unfractionated heparin or a low molecular weight heparin (e.g. enoxaparin); bivalirudin (section 2.8.1) is an alternative to the combination of a glycoprotein IIb/IIIa inhibitor plus a heparin. In patients who cannot be offered percutaneous coronary intervention within 90 minutes of diagnosis, a thrombolytic drug should be administered along with either unfractionated heparin (for maximum 2 days), a low molecular weight heparin (e.g. enoxaparin), or fondaparinux. See section 2.9 for the use of antiplatelet drugs in patients undergoing coronary stenting. Patients who do not receive reperfusion therapy (with percutaneous coronary intervention or a thrombolytic) should be treated with either fondaparinux, enoxaparin, or unfractionated heparin. Prescribers should consult product literature and local protocols (where they exist) for details of anticoagulant dose and duration.

Nitrates (section 2.6.1) are used to relieve ischaemic pain. If sublingual glyceryl trinitrate is not effective, intravenous glyceryl trinitrate or isosorbide dinitrate is given.

Early administration of some beta-blockers (section 2.4) has been shown to be of benefit and should be given to patients without contra-indications.

ACE inhibitors (section 2.5.5.1), and angiotensin-II receptor antagonists (section 2.5.5.2) if an ACE inhibitor cannot be used, are also of benefit to patients who have no contra-indications; in hypertensive and normotensive patients treatment with an ACE inhibitor, or an angiotensin-II receptor antagonist, can be started within 24 hours of the myocardial infarction and continued for at least 5–6 weeks (see below for long-term treatment). All patients should be closely monitored for hyperglycaemia; those with diabetes or raised blood-glucose concentration should receive insulin.

Long-term management Long-term management following ST-segment elevation myocardial infarction involves the use of several drugs which should ideally be started before the patient is discharged from hospital.

Aspirin (section 2.9) should be given to all patients, unless contra-indicated, at a dose of 75 mg daily. The addition of clopidogrel (section 2.9) has been shown to reduce morbidity and mortality. For those intolerant of both aspirin and clopidogrel, warfarin alone can be used. Warfarin should be continued for those who are already being treated for another indication, such as atrial fibrillation, with the addition of aspirin if there is a low risk of bleeding. The combination of aspirin with clopidogrel or warfarin increases the risk of bleeding. See section 2.9 for details of antiplatelet drug duration following coronary stenting.

Beta-blockers (section 2.4) should be given to all patients in whom they are not contra-indicated. Atebrutolol, metoprolol, propranolol, and timolol are suitable; for patients with left ventricular dysfunction, carve-dilol, bisoprolol, or long-acting metoprolol may be appropriate (section 2.5.5).

Diltiazem [unlicensed] or verapamil (section 2.6.2) can be considered if a beta-blocker cannot be used; however, they are contra-indicated in those with left ventricular dysfunction. Other calcium-channel blockers have no place in routine long-term management after a myocardial infarction.
An ACE inhibitor (section 2.5.5.1) should be considered for all patients, especially those with evidence of left ventricular dysfunction. If an ACE inhibitor cannot be used, an angiotensin-II receptor antagonist may be used for patients with heart failure. A relatively high dose of either the ACE inhibitor or angiotensin-II receptor antagonist may be required to produce benefit.

Nitrates (section 2.6.1) are used for patients with angina.

Eplerenone (section 2.2.3) is licensed for use following a myocardial infarction in those with left ventricular dysfunction and evidence of heart failure.

For the role of statins in preventing recurrent cardiovascular events, see section 2.12.

### 2.10.2 Fibrinolytic drugs

Fibrinolytic drugs act as thrombolytics by activating plasminogen to form plasmin, which degrades fibrin and so breaks up thrombi.

The value of thrombolytic drugs for the treatment of myocardial infarction has been established (section 2.10.1). Streptokinase and alteplase have been shown to reduce mortality. Reteplase and tenecteplase are also licensed for acute myocardial infarction. Thrombolytic drugs are indicated for any patient with acute myocardial infarction for whom the benefit is likely to outweigh the risk of treatment. Trials have shown that the benefit is greatest in those with ECG changes that include ST segment elevation (especially in those with anterior infarction) and in patients with bundle branch block. Patients should not be denied thrombolytic treatment on account of age alone because mortality in the elderly is high and the reduction in mortality is the same as in younger patients.

Alteplase, reteplase and streptokinase need to be given within 12 hours of symptom onset, ideally within 1 hour; use after 12 hours requires specialist advice. Tenecteplase should be given as early as possible and usually within 6 hours of symptom onset.

Alteplase, streptokinase, and urokinase can be used for other thromboembolic disorders such as deep-vein thrombosis and pulmonary embolism. Alteplase is also used for acute ischaemic stroke (see section 2.9).

Urokinase is also licensed to restore the patency of fibrin clots.

### Cautions

Thrombolytic drugs should be used with caution if there is a risk of bleeding including that from venepuncture or invasive procedures. They should also be used with caution in external chest compression, elderly, hypertension, conditions in which thrombolyisis might give rise to embolic complications such as enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolisation), and recent or concurrent use of drugs that increase the risk of bleeding.

### Contra-indications

Thrombolytic drugs are contra-indicated in recent haemorrhage, trauma, or surgery (including dental extraction), coagulation defects, bleeding diathesis, aortic dissection, aneurysm, coma, history of cerebrovascular disease especially recent events or with any residual disability, recent symptoms of possible peptic ulceration, heavy vaginal bleeding, severe hypertension, active pulmonary disease with cavitation, acute pancreatitis, pericarditis, bacterial endocarditis, and oesophageal varices; also in the case of streptokinase, previous allergic reactions to either streptokinase or anistreplase (no longer available).

Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.

### Hepatic impairment

Thrombolytic drugs should be avoided in severe hepatic impairment as there is an increased risk of bleeding.

### Pregnancy

Thrombolytic drugs can possibly lead to premature separation of the placenta in the first 18 weeks of pregnancy. There is also a risk of maternal haemorrhage throughout pregnancy and post-partum, and also a theoretical risk of fetal haemorrhage throughout pregnancy.

### Side-effects

Side-effects of thrombolytics are mainly nausea and vomiting and bleeding. When thrombolytics are used in myocardial infarction, reperfusion arrhythmias and recurrent ischaemia and angina may occur. Reperfusion may also cause cerebral and pulmonary oedema. Hypotension can also occur and can usually be controlled by elevating the patient’s legs, or by reducing the rate of infusion or stopping it temporarily. Back pain, fever, and convulsions have been reported. Bleeding is usually limited to the site of injection, but intracerebral haemorrhage or bleeding from other sites can occur.

Serious bleeding calls for discontinuation of the thrombolytic and may require administration of coagulation factors and antifibrinolytic drugs (e.g. tranexamic acid). Rarely further embolism may occur (either due to clots that break away from the original thrombus or to cholesterol crystal emboli). Thrombolytics can cause allergic reactions (including rash, flushing and uveitis) and anaphylaxis has been reported (for details of management see Allergic Emergencies, section 3.4.3). Guillain-Barré syndrome has been reported rarely after streptokinase treatment.

---

**ALTEPLASE**

(rt-PA, tissue-type plasminogen activator)

### Indications

- acute myocardial infarction (see notes above and section 2.10.1); pulmonary embolism; acute ischaemic stroke (treatment under specialist neurology physician only)

### Cautions

- see notes above; in acute stroke, monitor for intracranial haemorrhage, monitor blood pressure (antihypertensive recommended if systolic above 180 mmHg or diastolic above 105 mmHg)

### Contra-indications

- see notes above; in acute stroke, convulsion accompanying stroke, severe stroke, history of stroke in patients with diabetes, stroke in last 3 months, hypoglycaemia, hyperglycaemia

### Hepatic impairment

- see notes above

### Pregnancy

- see notes above

### Side-effects

- see notes above; also risk of cerebral bleeding increased in acute stroke
Dose
- Myocardial infarction, accelerated regimen (initiated within 6 hours of symptom onset), 15 mg by intravenous injection, followed by intravenous infusion of 50 mg over 30 minutes, then 35 mg over 60 minutes (total dose 100 mg over 90 minutes); in patients less than 65 kg, 15 mg by intravenous injection, followed by intravenous infusion of 0.75 mg/kg over 30 minutes, then 0.5 mg/kg over 60 minutes (max. total dose 100 mg over 90 minutes)
- Myocardial infarction, initiated within 6–12 hours of symptom onset, 10 mg by intravenous injection, followed by intravenous infusion of 50 mg over 60 minutes, then 4 infusions each of 10 mg over 30 minutes (total dose 100 mg over 3 hours; max. 1.5 mg/kg in patients less than 65 kg)
- Pulmonary embolism, 10 mg by intravenous injection over 1–2 minutes, followed by intravenous infusion of 90 mg over 2 hours; max. 1.5 mg/kg in patients less than 65 kg
- Acute stroke (treatment must begin within 3 hours of symptom onset), by intravenous administration over 60 minutes, 900 micrograms/kg (max. 90 mg); initial 10% of dose by intravenous injection, remainder by intravenous infusion; ELDERLY over 80 years not recommended

Actilyse® (Boehringer Ingelheim) Injection, powder for reconstitution, alteplase 10 mg (5.8 million units)/vial, net price per vial (with diluent) = £120.00; 20 mg (11.6 million units)/vial (with diluent and transfer device) = £180.00; 50 mg (29 million units)/vial (with diluent, transfer device, and infusion bag) = £300.00

Retepase
Indications acute myocardial infarction (see notes above and section 2.10.1)
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Pregnancy see notes above
Breast-feeding manufacturer advises avoid breast-feeding for 24 hours after dose (express and discard milk during this time)
Side-effects see notes above
Dose
- By intravenous injection over 10 seconds (initiated within 6 hours of symptom onset), 30–50 mg according to body-weight—consult product literature; max. 50 mg

Tenecteplase
Indications acute myocardial infarction (see notes above and section 2.10.1)
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Pregnancy see notes above
Breast-feeding manufacturer advises avoid breast-feeding for 24 hours after dose (express and discard milk during this time)
Side-effects see notes above
Dose
- By intravenous injection over 10 seconds (initiated within 12 hours of symptom onset), by intravenous infusion, 1.5 million units over 60 minutes
- Deep-vein thrombosis, pulmonary embolism, acute arterial thromboembolism, central retinal venous or arterial thrombosis, by intravenous infusion, 250 000 units over 30 minutes, then 100 000 units every hour for up to 12–72 hours according to condition with monitoring of clotting parameters (consult product literature)

Streptokinase
Indications deep-vein thrombosis, pulmonary embolism, acute arterial thromboembolism, central retinal venous or arterial thrombosis, by intravenous infusion, 250 000 units over 30 minutes, then 100 000 units every hour for up to 12–72 hours according to condition with monitoring of clotting parameters (consult product literature)
Cautions see notes above and section 2.10.1
Contra-indications see notes above
Hepatic impairment see notes above
Pregnancy see notes above
Breast-feeding manufacturer advises avoid breast-feeding for 24 hours after dose (express and discard milk during this time)
Side-effects see notes above
Dose
- By intravenous injection over 10 seconds (initiated within 6 hours of symptom onset), 30–50 mg according to body-weight—consult product literature; max. 50 mg

Urokinase
Indications thromboembolic occlusive vascular disease including deep-vein thrombosis, pulmonary embolism, and peripheral vascular occlusion; occluded intravenous catheters and cannulas blocked by fibrin clots
Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Pregnancy see notes above
Breast-feeding manufacturer advises avoid—no information available
Side-effects see notes above
Dose
- Deep-vein thrombosis, by intravenous infusion, initially 4400 units/kg in 15 mL sodium chloride 0.9% over 10 minutes, followed by 4400 units/kg/hour for 12–24 hours
- Pulmonary embolism, by intravenous infusion, initially 4400 units/kg in 15 mL sodium chloride 0.9% over 10 minutes, followed by 4400 units/kg/hour for 12 hours or by injection into pulmonary artery, initially 15 000 units/kg, subsequent doses adjusted according to response; max. 3 doses in 24 hours
2.11 Antifibrinolytic drugs and haemostatics

Fibrin dissolution can be impaired by the administration of tranexamic acid, which inhibits fibrinolysis. It can be used to prevent bleeding or to treat bleeding associated with excessive fibrinolysis (e.g. in prostatectomy, bladder surgery, in dental extraction in patients with haemophilia, in conisation of the cervix, and in traumatic haemorrhage) and in the management of menorrhagia. Tranexamic acid may also be used in hereditary angioedema, epistaxis, and in thrombotic overdose.

Desmopressin (section 6.5.2) is used in the management of mild to moderate haemophilia and von Willebrand’s disease. It is also used for fibrinolytic response testing.

Etamsylate reduces capillary bleeding in the presence of a normal number of platelets; it does not act by fibrin stabilisation, but probably by correcting abnormal adhesion. Etamsylate is less effective than other treatments in the management of heavy menstrual bleeding and its use is no longer recommended.

ETAMSYLATE

(Ethamsylate)

Indications  blood loss in menorrhagia

Cautions  exclude structural or histological causes of menorrhagia, or fibrinoids causing distortion of the uterine cavity, before initiating treatment

Contra-indications  acute porphyria (see section 9.8.2)

Breast-feeding  present in milk—manufacturer advises avoid

Side-effects  nausea, vomiting, diarrhoea, fever (discontinue treatment), headache, rashes

Dose  ● 500 mg 4 times daily during menstruation

Dicynene® (Sanofi-Aventis)

Tablets, scored, etamsylate 500 mg, net price 100-tab pack = £8.44

Excipients include sulphites

TRANEXAMIC ACID

Indications  see notes above

Cautions  massive haematuria (avoid if risk of ureteric obstruction); not for use in disseminated intravascular coagulation, irregular menstrual bleeding (exclude structural or histological causes of menorrhagia, or fibrinoids causing distortion of the uterine cavity, before initiating treatment); regular liver function tests in long-term treatment of hereditary angioedema

Contra-indications  thromboembolic disease

Renal impairment  reduce dose—consult product literature for details

Pregnancy  no evidence of teratogenicity in animal studies; manufacturer advises use only if potential benefit outweighs risk—crosses the placenta

Breast-feeding  small amount present in milk—antifibrinolytic effect in infant unlikely

Side-effects  nausea, vomiting, diarrhoea (reduce dose); rarely disturbances in colour vision (discontinue), thromboembolic events, convulsions, allergic skin reactions; dizziness and hypotension on rapid intravenous injection

Dose  ● By mouth, local fibrinolysis, 1–1.5 g (or 15–25 mg/kg) 2–3 times daily

Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; max. 4 g daily

Hereditary angioedema, 1–1.5 g 2–3 times daily

Epistaxis, 1 g 3 times daily for 7 days

By slow intravenous injection, local fibrinolysis, 0.5–1 g 3 times daily

By continuous intravenous infusion, local fibrinolysis, following initial treatment by intravenous injection, 25–50 mg/kg over 24 hours

Tranexamic acid (Non-proprietary)

Tablets, tranexamic acid 500 mg, net price 60-tab pack = £5.27

Cyklokapron® (Meda)

Tablets, f/c, scored, tranexamic acid 500 mg, net price 60-tab pack = £14.30

Cyklokapron® (Pfizer)

Injection, tranexamic acid 100 mg/mL, net price 5-mL amp = £1.55

Blood products

DRIED PROTHROMBIN COMPLEX

(Human Prothrombin Complex)

Dried prothrombin complex is prepared from human plasma by a suitable fractionation technique, and contains factor IX, together with variable amounts of factors II, VII, and X

Indications  treatment and peri-operative prophylaxis of haemorrhage in patients with congenital deficiency of factors II, VII, IX, or X or if purified specific coagulation factors not available; treatment and peri-operative prophylaxis of haemorrhage in patients with acquired deficiency of factors II, VII, IX, or X (e.g. during warfarin treatment—see section 2.8.2)

Cautions  risk of thrombosis; disseminated intravascular coagulation; history of myocardial infarction or coronary heart disease; postoperative use

Contra-indications  angina; recent myocardial infarction (except in life-threatening haemorrhage following overdosage of oral anticoagulants, and before induction of fibrinolytic therapy); history of heparin-induced thrombocytopenia
2.11 Antifibrinolytic drugs and haemostatics

**Hepatic impairment** monitor closely (risk of thrombomembolic complications)

**Side-effects** thrombotic events (including disseminated intravascular coagulation); rarely headache; very rarely pyrexia, antibody formation, hypersensitivity reactions (including anaphylaxis); nephrotic syndrome also reported

Available from CSL Behring (Berplex® P/M), Octapharma (Octaplex®)

**DROTRECOGIN ALFA (ACTIVATED)**
Recombinant activated protein C

**Indications** adjunctive treatment of severe sepsis with multiple organ failure—start treatment within 24 hours (and no later than 48 hours) after onset of organ failure

**Cautions** increased risk of bleeding, concomitant use of drugs that increase risk of bleeding; interactions: Appendix 1 (drotrecog alfa)

**Contra-indications** internal bleeding; intracranial neoplasm or cerebral herniation; thrombocytopenia; not recommended for use in children under 18 years or in single organ failure

**Hepatic impairment** avoid in chronic severe liver disease

**Pregnancy** manufacturer advises avoid unless benefit outweighs risk—no information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** bleeding; headache; ecchymosis; pain
Available from Lilly (Xigris®)

**NICE guidance**
Drotrecog alfa (activated) for severe sepsis (September 2004)

Drotrecog alfa (activated) should be considered for adults with severe sepsis that has resulted in the failure of two or more major organs and who are receiving optimum intensive care support. Drotrecog alfa (activated) should be initiated and supervised only by a specialist consultant with intensive care skills and experience in the care of patients with sepsis.

**FACTOR VIII FRACTION, DRIED**
Eptacog alfa (activated)

**Indications** treatment and prophylaxis of haemorrhage in patients with haemophilia A or B with inhibitors to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann’s thrombasthenia

**Cautions** risk of thrombosis or disseminated intravascular coagulation

**Side-effects** very rarely nausea, thrombotic events (including myocardial infarction and cerebrovascular accident), coagulation disorders, fever, pain, and allergic reactions including rash
Available from Novo Nordisk (NovoSeven®)

**FACTOR VIII INHIBITOR BYPASSING FRACTION**
Preparations with factor VIII inhibitor bypassing activity are prepared from human plasma

**Indications** treatment and prophylaxis of haemorrhage in patients with congenital factor VIII deficiency (haemophilia A) and factor VIII inhibitors; treatment of haemorrhage in non-haemophiliac patients with acquired factor VIII inhibitors

**Contra-indications** disseminated intravascular coagulation

**Side-effects** thrombosis, disseminated intravascular coagulation, myocardial infarction; paraesthesia; pyrexia; hypersensitivity reactions including hypotension, flushing, urticaria, rash, and anaphylaxis
Available from Baxter (FEIBA®)

**FACTOR IX FRACTION, DRIED**
Dried factor IX fraction is prepared from human plasma by a suitable fractionation technique; it may also contain clotting factors II, VII, and X

**Indications** treatment and prophylaxis of haemorrhage in congenital factor IX deficiency (haemophilia B)

**Cautions** risk of thrombosis—principally with former low purity products

**Contra-indications** disseminated intravascular coagulation

**Side-effects** gastro-intestinal disturbances; headache, dizziness; allergic reactions, including chills, fever
Available from CSL Behring (Mononine®), BPL (Replene®®, VIF, Dried Factor IX Fraction), Grifols (AlphaNine®)

**Note** Preparation of recombinant coagulation factor IX (non-acog alfa) available from Wyeth (BenefIX®)

**FACTOR XIII FRACTION, DRIED**
(Human Fibrin-stabilising Factor, Dried)

**Indications** congenital factor XIII deficiency

**Side-effects** rarely, allergic reactions and fever
Available from CSL Behring (Fibrogammin® P)
1. Cardiovascular disease risk may be determined from the sclerotic cardiovascular disease; those with a 10-year risk of developing atherosclerotic disease, those with diabetes mellitus (primary prevention) and to prevent recurrence of cardiovascular disease events, irrespective of serum cholesterol concentration, and is the drug of first choice for primary and secondary prevention of cardiovascular disease.

Preventative measures should be taken in individuals with a high risk of developing cardiovascular disease (primary prevention) and to prevent recurrence of events in those with established cardiovascular disease (secondary prevention).

Indications to replace coagulation factors or other plasma proteins where their concentration or functional activity is critically reduced.

Cautions need for compatibility.

Side-effects allergic reactions including chills, fever, bronchospasm; adult respiratory distress syndrome.

Note A preparation of solvent/detergent treated human plasma (frozen) from pooled donors is available from Octapharma (Octaplasm®).

2.12 Lipid-regulating drugs

Preventative measures should be taken in individuals with a high risk of developing cardiovascular disease; those with diabetes mellitus aged over 40 years, and those with familial hypercholesterolaemia. The risk also increases with age; those over 75 years are at particularly high risk, especially if they smoke or have hypertension.

Preventative measures are also required for other individuals who may be at high risk of developing atherosclerotic cardiovascular disease; those with diabetes mellitus aged over 40 years, and those with familial hypercholesterolaemia. The risk also increases with age; those over 75 years are at particularly high risk, especially if they smoke or have hypertension.

Preventative measures are also required for other individuals who may be at high risk of developing atherosclerotic cardiovascular disease; those with diabetes mellitus aged over 40 years, and those with familial hypercholesterolaemia. The risk also increases with age; those over 75 years are at particularly high risk, especially if they smoke or have hypertension.

Patients with hypothyroidism should receive adequate thyroid replacement therapy before assessing the risk in individual patients.

Patients with hypothyroidism should receive adequate thyroid replacement therapy before assessing the risk in individual patients.

1 Cardiovascular disease risk may be determined from the chart issued by the Joint British Societies (Heart 2005; 91 (Suppl V): v1–v52)—see inside back cover. The Joint British Societies’ “Cardiac Risk Assessor” computer programme may also be used to determine cardiovascular disease risk.
risk of Muscle Effects, below. Patients with heterozygous familial hypercholesterolemia who have contra-indica-
tions to, or are intolerant of, statins should receive ezetimibe. The combination of a statin and ezetimibe can be considered if a statin alone fails to provide adequate control (or if intolerance limits dose titration), and when a switch to an alternative statin is being considered. Patients for whom statins and ezetimibe are inappropriate, should be referred to a specialist for the consideration of treatment with a bile acid seque-
trant, nicotinic acid, or a fibrate.

The prescribing of drug therapy in homozygous familial hypercholesterolaemia should be undertaken in a spe-
cialist centre.

**Statins**

The statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis, especially in the liver. Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration but they are less effective than the fibrates in reducing triglyceride concentration. How-
ner, statins reduce cardiovascular disease events and total mortality irrespective of the initial cholesterol concentration. Statins should be considered for all patients, including the elderly, with symptomatic cardiovascular disease such as those with coronary heart disease (including history of angina or acute myocardial infarction), occlu-
sive arterial disease (including peripheral vascular dis-
eease, non-haemorrhagic stroke, or transient ischaemic attacks).

In patients with diabetes mellitus, the risk of developing cardiovascular disease depends on the duration and complications of diabetes, age, and concomitant risk factors. Statin therapy should be considered for all patients over 40 years with diabetes mellitus (type 1 and 2). In younger patients with diabetes, treatment with a statin should be considered if there is target-
organ damage, poor glycaemic control (HbA1c greater than 9%), low HDL-cholesterol and raised triglyceride concentration, hypertension, or a family history of pre-
mature cardiovascular disease.

Statins are also used for the prevention of cardiovascu-
lar disease events in asymptomatic individuals who are at increased risk (see p. 161). Statin treatment should also be considered if the total cholesterol concentration to HDL-cholesterol ratio exceeds 6.

**Cautions**

Hypothyroidism should be managed ade-
quately before starting treatment with a statin (see p. 161). Statins should be used with caution in those with a history of liver disease or with a high alcohol intake—see also Hepatic impairment, below. There is little information available on a rational approach to liver-function monitoring; however, a NICE guideline suggests that liver enzymes should be measured before treatment, and repeated within 3 months and at 12 months of starting treatment, unless indicated at other times by signs or symptoms suggestive of hepatotoxi-
city. Those with serum transaminases that are raised, but less than 3 times the upper limit of the reference range, should be routinely excluded from statin therapy. Those with serum transaminases of more than 3 times the upper limit of the reference range should discontinue statin therapy. Statins should be used with caution in those with risk factors for myo-
pathy or rhabdomyolysis; patients should be advised to report unexplained muscle pain (see Muscle Effects below). Statins should be avoided in acute porphyria (section 9.8.2) but rosuvastatin is thought to be safe.

**Interactions:** Appendix 1 (statins).

**Hepatic impairment** Statins should be used with caution in those with a history of liver disease and avoided in active liver disease or when there are unex-
plained persistent elevations in serum transaminases.

**Pregnancy** Statins should be avoided in pregnancy as congenital anomalies have been reported and the decreased synthesis of cholesterol possibly affects fetal development. Adequate contraception is required during treatment and for 1 month afterwards.

**Breast-feeding** The manufacturers of atorvastatin, fluvastatin, rosuvastatin, and simvastatin advise avoid-
ing use in mothers who are breast-feeding as there is no information available. The manufacturers of pravastatin advise against use in breast-feeding mothers as a small amount of drug is present in breast milk.

**Side-effects** The statins can cause various muscular side-effects, including myositis, which can lead to rhab-
domyolysis. Muscular effects are rare but often signifi-
cant (see Muscle Effects below). Statins can cause gastro-intestinal disturbances, and very rarely pancreat-
itis. They can also cause altered liver function tests, and rarely hepatitis and jaundice; hepatic failure has been reported very rarely. Other side-effects include sleep disturbance, headache, dizziness, depression, paraes-
thesia, asthenia, peripheral neuropathy, amnesia, fati-
gue, sexual dysfunction, thrombocytopenia, arthralgia,
visual disturbance, alopecia, and hypersensitivity reac-
tions (including rash, pruritus, urticaria, and very rarely lupus erythematosus-like reactions). In very rare cases, statins can cause interstitial lung disease; if patients develop symptoms such as dyspnoea, cough, and weight loss, they should seek medical attention.

**Muscle effects** Myalgia, myositis, myopathy and rarely rhab-
domyolysis have been reported with the statins; if myopathy is suspected and creatine kinase is markedly elevated (more than 5 times upper limit of normal), or muscular symptoms are severe, treatment should be discontinued, in patients at increased risk of muscle effects, a statin should not be started if creatine kinase is elevated. Patients at increased risk of myo-
pathy include those with a personal or family history of muscular disorders, previous history of muscular toxicity; those with a high alcohol intake, renal impairment, hypothyroidism, women, and the elderly. There is also an increased incidence of myopathy if a statin is given at a high dose or given with a fibrate, with lipid-lowering doses of nicotinic acid, or with drugs that increase the plasma-statin concentration, such as ciclosporin; close monitoring of liver function and, if symptomatic, of creatine kinase is required in patients receiving these drugs. Rhabdomyolysis with acute renal impairment secondary to myoglobinuria has also been reported.

**Counselling** Advise patient to report promptly unex-
plained muscle pain, tenderness, or weakness.
**ATORVASTATIN**

**Indications** primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia, homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia in patients who have not responded adequately to diet and other appropriate measures; prevention of cardiovascular events in patients with type 2 diabetes and at least one additional risk factor for cardiovascular disease

**Cautions** see notes above; also haemorrhagic stroke

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also chest pain; back pain; less commonly anorexia, malaise, weight gain, hypoglycaemia, hyperglycaemia, tinnitus; rarely cholesterol jaundice, peripheral oedema; very rarely taste disturbances, gynaecomastia, hearing loss, Stevens-Johnson Syndrome, and toxic epidermal necrolysis

**Dose**
- Primary hypercholesterolaemia and combined hyperlipidaemia, usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily; **CHILD 10–17 years** initially 10 mg once daily (limited experience with doses above 20 mg daily)
- Familial hypercholesterolaemia, initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia); **CHILD 10–17 years** initially 10 mg daily; increased if necessary after at least 4 weeks to 20 mg once daily (limited experience with higher doses)
- Prevention of cardiovascular events in type 2 diabetes, 10 mg once daily

**Note** Max. 10 mg daily with concomitant ciclosporin; max. 20 mg once daily (or temporarily discontinue atorvastatin) with concomitant clarithromycin; max. 40 mg daily (or temporarily discontinue atorvastatin) with concomitant immunosuppressive therapy following solid-organ transplantation

**Lipitor** (Pfizer)

- **Tablets**, all f/c, atorvastatin (as calcium trihydrate) 10 mg, net price 28-tab pack = £13.00; 20 mg, 28-tab pack = £24.64; 40 mg 28-tab pack = £24.64; 80 mg 28-tab pack = £28.21. Counselling, muscle effects, see notes above

**FLUVASTATIN**

**Note** The Scottish Medicines Consortium (p. 4) has advised (February 2004) that fluvastatin is accepted for restricted use for the secondary prevention of coronary events after percutaneous coronary angioplasty; if the patient has previously been receiving another statin, then there is no need to change the statin

**Indications** adjunct to diet in primary hypercholesterolaemia or combined (mixed) hyperlipidaemia (types IIa and IIb); adjunct to diet to slow progression of coronary atherosclerosis in primary hypercholesterolaemia and concomitant coronary heart disease; prevention of coronary events after percutaneous coronary intervention

**Cautions** see notes above

**Hepatic impairment** see notes above

**Renal impairment** manufacturer advises doses above 40 mg daily should be initiated with caution if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also very rarely vasculitis

**Dose**
- Hypercholesterolaemia or combined hyperlipidaemia, initially 20–40 mg daily in the evening, adjusted at intervals of at least 4 weeks; up to 80 mg daily may be required; **CHILD under 18 years**, see **BNF for Children**
- Prevention of progression of coronary atherosclerosis, 40 mg daily in the evening
- Following percutaneous coronary intervention, 80 mg daily

Fluvastatin (Non-proprietary)  

- **Capsules**, fluvastatin (as sodium salt) 20 mg, net price 28-cap pack = £5.03; 40 mg, 28-cap pack = £5.36.
- **Counselling**, muscle effects, see notes above

**Lescol** (Novartis)

- **Capsules**, fluvastatin (as sodium salt) 20 mg (brown/yellow), net price 28-cap pack = £15.26; 40 mg (brown/orange), 28-cap pack = £15.26; 56-cap pack = £30.53. Counselling, muscle effects, see notes above

**Modified release**

Lescol® XL (Novartis)

- **Tablets**, m/r, yellow, fluvastatin (as sodium salt) 80 mg, net price 28-tab pack = £19.20. Label: 25, counselling, muscle effects, see notes above

- **Dose** 80 mg once daily (dose form not appropriate for initial dose titration in hypercholesterolaemia or combined hyperlipidaemia)

**PRAVASTATIN SODIUM**

**Indications** adjunct to diet for primary hypercholesterolaemia or combined (mixed) hyperlipidaemias in patients who have not responded adequately to dietary control; adjunct to diet to prevent cardiovascular events in patients with hypercholesterolaemia; prevention of cardiovascular events in patients with previous myocardial infarction or unstable angina; reduction of hyperlipidaemia in patients receiving immunosuppressive therapy following solid-organ transplantation

**Cautions** see notes above

**Hepatic impairment** see notes above

**Renal impairment** manufacturer advises initial dose of 10 mg once daily in moderate to severe impairment

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; less commonly abnormal urination (including dysuria, nocturia and frequency); very rarely fulminant hepatic necrosis

**Dose**
- Hypercholesterolaemia or combined hyperlipidaemias, 10–40 mg once daily at night, adjusted at intervals of at least 4 weeks
- Familial hypercholesterolaemia, **CHILD 8–14 years** 10–20 mg once daily at night, 14–18 years 10–40 mg once daily at night
- Prevention of cardiovascular events, 40 mg once daily at night
- Post-transplantation hyperlipidaemia, initially 20 mg once daily at night, increased if necessary (under close medical supervision) to max. 40 mg once daily at night
2 Cardiovascular system

Pravastatin (Non-proprietary) Tablets, pravastatin sodium 10 mg, net price 28-tab pack = £1.72; 20 mg, 28-tab pack = £2.02; 40 mg, 28-tab pack = £2.78. Counselling, muscle effects, see notes above

Lipostat® Tablets, all yellow, pravastatin sodium 10 mg, net price 28-tab pack = £14.18; 20 mg, 28-tab pack = £26.01; 40 mg, 28-tab pack = £26.01. Counselling, muscle effects, see notes above

## ROSUVASTATIN

### Indications
Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures; prevention of cardiovascular events in patients at high risk of a first cardiovascular event

### Cautions
See notes above; patients of Asian origin (see under Dose); max. dose 20 mg in patients with risk factors for myopathy or rhabdomyolysis (including personal or family history of muscular disorders or toxicity)

### Hepatic impairment
See notes above

### Renal impairment
Initially 5 mg once daily (do not exceed 20 mg daily) if eGFR 30–60 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

### Pregnancy
See notes above

### Breast-feeding
See notes above

### Side-effects
See notes above; also diabetes mellitus; proteinuria; very rarely haematuria

### Dose
- Hypercholesterolaemia, initially 5–10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily only in severe hypercholesterolaemia with high cardiovascular risk and under specialist supervision; ELDERLY initially 5 mg once daily; patients of ASIAN origin, initially 5 mg once daily increased if necessary to max. 20 mg daily
- Prevention of cardiovascular events, 20 mg once daily

### Note
Initially 5 mg once daily with concomitant fibrate increased if necessary to max. 20 mg daily

### With ezetimibe
Note For homozygous familial hypercholesterolaemia, primary hypercholesterolaemia, and mixed hyperlipidaemia in patients stabilised on the individual components in the same proportions, or for patients not adequately controlled by statin alone. For prescribing information on ezetimibe, see Ezetimibe

### Inegy® Tablets, simvastatin 20 mg, ezetimibe 10 mg, net price 28-tab pack = £33.42; simvastatin 40 mg, ezetimibe 10 mg, 28-tab pack = £38.98; simvastatin 80 mg, ezetimibe 10 mg, 28-tab pack = £41.21. Counselling, muscle effects, see notes above

---

## SIMVASTATIN

### Indications
Primary hypercholesterolaemia, homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia in patients who have not responded adequately to diet and other appropriate measures; prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease or diabetes mellitus

### Cautions
See notes above; also 80-mg dose only for those with severe hypercholesterolaemia and at high risk of cardiovascular complications

### Hepatic impairment
See notes above

### Renal impairment
doses above 10 mg daily should be used with caution if eGFR less than 30 mL/minute/1.73 m²

### Pregnancy
See notes above

### Breast-feeding
See notes above

### Side-effects
See notes above; also rarely anaemia

### Dose
- Primary hypercholesterolaemia, combined hyperlipidaemia, 10–20 mg daily at night, adjusted at intervals of at least 4 weeks; usual range 10–80 mg once daily at night
- Homozygous familial hypercholesterolaemia, 40 mg daily at night or 80 mg daily in 3 divided doses (with largest dose at night)
- Prevention of cardiovascular events, initially 20–40 mg once daily at night, adjusted at intervals of at least 4 weeks; max. 80 mg once daily at night

### Note
Max. 10 mg daily with concomitant ciclosporin, danazol, or fibrate (except fenofibrate). Max. 20 mg daily with concomitant amiodarone or verapamil. Max. 40 mg daily with diltiazem or amiodipine

### With ezetimibe
Note For homozygous familial hypercholesterolaemia, primary hypercholesterolaemia, and mixed hyperlipidaemia in patients stabilised on the individual components in the same proportions, or for patients not adequately controlled by statin alone. For prescribing information on ezetimibe, see Ezetimibe

### Inegy® Tablets, simvastatin 20 mg, ezetimibe 10 mg, net price 28-tab pack = £33.42; simvastatin 40 mg, ezetimibe 10 mg, 28-tab pack = £38.98; simvastatin 80 mg, ezetimibe 10 mg, 28-tab pack = £41.21. Counselling, muscle effects, see notes above

---

### Bile acid sequestrants

Colestervelam, colestipol, and colestyramine are bile acid sequestrants used in the management of hypercholesterolaemia. They act by binding bile acids, preventing their reabsorption; this promotes hepatic conversion of cholesterol into bile acids; the resultant increased LDL-receptor activity of liver cells increases the clearance of LDL-cholesterol from the plasma. Bile

---

1. Simvastatin 10 mg tablets can be sold to the public to reduce risk of first coronary event in individuals at moderate risk of coronary heart disease (approx. 10–15% risk of major event in 10 years), max. daily dose 10 mg and pack size of 28 tablets; treatment should form part of a programme to reduce risk of coronary heart disease
acid sequestrants effectively reduce LDL-cholesterol but can aggravate hypertriglyceridaemia.

**Cautions** Bile acid sequestrants interfere with the absorption of fat-soluble vitamins; supplements of vitamins A, D, K, and folic acid may be required when treatment is prolonged. **Interactions:** Appendix 1 (bile acid sequestrants)

**Pregnancy and breast-feeding** Bile acid sequestrants should be used with caution as although the drugs are not absorbed, they may cause fat-soluble vitamin deficiency on prolonged use.

**Side-effects** As bile acid sequestrants are not absorbed, gastro-intestinal side-effects predominate. Constipation is common, but diarrhoea has occurred, as have nausea, vomiting, and gastro-intestinal discomfort. Hypertriglyceridaemia may be aggravated. An increased bleeding tendency has been reported due to hypoprothrombinaemia associated with vitamin K deficiency.

**Counselling** Other drugs should be taken at least 1 hour before (4 hours before colesevelam), or 4–6 hours after bile acid sequestrants to reduce possible interference with absorption. Colesevelam can be taken at the same time as a statin or ezetimibe.

---

**COLESEVELAM HYDROCHLORIDE**

**Indications** primary hypercholesterolaemia as an adjunct to dietary measures, either alone or with a statin; primary and familial hypercholesterolaemia, in combination with ezetimibe, either with or without a statin

**Cautions** see notes above; also gastro-intestinal motility disorders, major gastro-intestinal surgery, inflammatory bowel disease; patients receiving ciclosporin should have their blood-ciclosporin concentration monitored before, during, and after treatment with colesevelam; **interactions:** Appendix 1 (colesevelam)

**Contra-indications** bowel or biliary obstruction

**Hepatic impairment** manufacturer advises caution

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also headache; myalgia

**Dose**

- Lipid reduction, initially 4 g daily increased by 4 g at weekly intervals to 12–24 g daily in 1–4 divided doses, then adjusted as required; max. 36 g daily
- **Pruritus**, see section 1.9.2
- Diarrhoeal disorders, see section 1.9.2

**Note** The contents of each sachet should be mixed with at least 150 mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits with a high moisture content

**Colestyramine (Non-proprietary)**

- **Powder**, sugar-free, colestyramine (anhydrous) 4 g/sachet, net price 50-sachet pack = £18.34. Label: 13, counselling, avoid other drugs at same time (see notes above)
- Excipients may include aspartame (see section 9.4.1)

**Questran®** (Bristol-Myers Squibb)

- **Powder**, colestyramine (anhydrous) 4 g/sachet, net price 50-sachet pack = £10.76. Label: 13, counselling, avoid other drugs at same time (see notes above)
- Excipients include sucrose 3.79 g/sachet

**Questran Light®** (Bristol-Myers Squibb)

- **Powder**, sugar-free, colestyramine (anhydrous) 4 g/sachet, net price 50-sachet pack = £16.15. Label: 13, counselling, avoid other drugs at same time (see notes above)
- Excipients include aspartame (see section 9.4.1)

---

**COLESTIPOL HYDROCHLORIDE**

**Indications** hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures

**Cautions** see notes above; **interactions:** Appendix 1 (colestipol)

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**

- Initially 5 g 1–2 times daily in liquid increased if necessary in 5-g increments at intervals of 1 month to max. 30 g daily (in 1–2 divided doses)

**Note** The contents of each sachet should be mixed with at least 100 mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, yoghurt, and pulpy fruits with a high moisture content

**Colestid®** (Pharmacia)

- **Granules**, yellow, colestipol hydrochloride 5 g/sachet, net price 30 sachets = £15.05. Label: 13, counselling, avoid other drugs at same time (see notes above)

**Colestid Orange**, granules, yellow/orange, colestipol hydrochloride 5 g/sachet, with aspartame, net price 30 sachets = £15.05. Label: 13, counselling, avoid other drugs at same time (see notes above)
### Ezetimibe

Ezetimibe inhibits the intestinal absorption of cholesterol. It is licensed as an adjunct to dietary manipulation in patients with primary hypercholesterolaemia in combination with a statin or alone (if a statin is inappropriate), in patients with homozygous familial hypercholesterolaemia in combination with a statin, and in patients with homozygous familial sitosterolaemia (phytosterolaemia). If ezetimibe is used in combination with a statin, there is an increased risk of rhabdomyolysis (see also Muscle Effects, p. 162).

### BEZAFIBRATE

Indications hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who have not responded adequately to diet and other appropriate measures; also see notes above

Cautions correct hypothyroidism before initiating treatment (see p. 161); interactions: Appendix 1 (fibrates)

Contra-indications hypoalbuminaemia, primary biliary cirrhosis, gall bladder disease, nephrotic syndrome

Hepatic impairment avoid in severe liver disease

Renal impairment reduce dose to 400 mg daily if eGFR 40–60 mL/minute/1.73 m²; reduce dose to 200 mg every 1–2 days if eGFR 15–40 mL/minute/1.73 m²; avoid if eGFR less than 15 mL/minute/1.73 m²; avoid modified-release preparations if eGFR less than 60 mL/minute/1.73 m²

Myotoxicity Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly

Pregnancy manufacturers advise avoid—embryotoxicity in animal studies

Breast-feeding manufacturer advises avoid—no information available

Side-effects gastro-intestinal disturbances; headache, fatigue, myalgia; rarely arthralgia, hypersensitivity reactions (including rash, angioedema, and anaphylaxis); hepatitis; very rarely pancreatitis, cholelithiasis, cholecytitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis

### Fibrates

Fibrates can cause a myositis-like syndrome, especially if renal function is impaired. Also, combination of a fibrate with a statin increases the risk of muscle effects (especially rhabdomyolysis) and should be used with caution (see Muscle Effects, p. 162) and monitoring of liver function and creatine kinase should be considered; gemfibrozil and statins should not be used concomitantly.

### Appendix 1 (ezetimibe)

- **Dose**
  - **Adult** and **Child** over 10 years, 10 mg once daily
  - **Ezetrol** (MSD, Schering-Plough)
    - Tablets, ezetimibe 10 mg, net price 28-tab pack = £26.31
  - **With simvastatin**
    - See under Simvastatin

### Bezafibrate

Bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil act mainly by decreasing serum triglycerides; they have variable effects on LDL-cholesterol. Although a fibrate can reduce the risk of coronary heart disease events in those with low HDL-cholesterol or with raised triglycerides, a fibrate should be used first. Fibrates are first-line therapy only in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin. In type 2 diabetes a fibrate can be added to a statin for those with a serum-triglyceride concentration exceeding 2.3 mmol/litre, despite 6 months of treatment with a statin and optimal glycaemic control.
**CIPROFIBRATE**

**Indications** hyperlipidaemias of types IIa, IIb, III, and IV in patients who have not responded adequately to diet; also see notes above

**Cautions** see under Bezafibrate

**Contra-indications** see under Bezafibrate

**Hepatic impairment** avoid in severe liver disease

**Renal impairment** manufacturer advises reduce dose to 100 mg on alternate days in moderate impairment; avoid in severe impairment; see also Myotoxicity under Bezafibrate

**Pregnancy** manufacturers advise avoid—embryotoxicity in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** see under Bezafibrate

- 100 mg daily

**Ciprofibrate (Non-proprietary) £28.00**

**Dose**

- 100 mg daily

**FENOFIBRATE**

**Indications** hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who have not responded adequately to diet and other appropriate measures; also see notes above

**Cautions** see under Bezafibrate; liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised)

**Contra-indications** gall bladder disease; pancreatitis (unless due to severe hypertriglyceridaemia); photosensitivity to ketoprofen

**Hepatic impairment** avoid in severe liver disease

**Renal impairment** reduce dose to 134 mg daily if eGFR less than 60 mL/minute/1.73 m²; reduce dose to 67 mg daily if eGFR less than 20 mL/minute/1.73 m²; avoid if eGFR less than 15 mL/minute/1.73 m²; see also Myotoxicity under Bezafibrate

**Pregnancy** manufacturer advises avoid—embryotoxicity in animal studies

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** see under Bezafibrate; also very rarely hepatitis, pancreatitis, and interstitial pneumopathies

**Dose**

- See preparations below

**Fenofibrate (Non-proprietary) £28.00**

- **Capsules**, fenofibrate (micronised) 200 mg, net price 28-cap pack = £23.30. Label: 21
- **Dose** 1 capsule daily (dose form not appropriate for children or in renal impairment)

- **Capsules**, fenofibrate (micronised) 267 mg, net price 28-cap pack = £17.95. Label: 21
- **Dose** initially 1 capsule daily (dose form not appropriate for children or in renal impairment)

**Lipantil® 160 (Abbott) £28.00**

- **Tablets**, f/c, fenofibrate (micronised) 160 mg, net price 28-tab pack = £6.69. Label: 21
- **Dose** 160 mg daily (dose form not appropriate for children or in renal impairment)

**GEMFIBROZIL**

**Indications** hyperlipidaemias of types IIa, IIb, III, IV and V in patients who have not responded adequately to diet and other appropriate measures; primary prevention of cardiovascular disease in men with hyperlipidaemias that have not responded to diet and other appropriate measures; also see notes above

**Cautions** lipid profile, blood counts, and liver-function tests before initiating long-term treatment; preferably avoid use with statins (high risk of rhabdomyolysis); correct hypothyroidism before initiating treatment (see p. 161); elderly; **interactions**: Appendix 1 (fibrates)

**Contra-indications** alcoholism, biliary-tract disease including gallbladder, photosensitivity to fibrates

**Hepatic impairment** avoid in liver disease

**Renal impairment** initially 900 mg daily if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²; see also Myotoxicity under Bezafibrate

**Pregnancy** manufacturers advise avoid—embryotoxicity in animal studies

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances; headache, fatigue, vertigo; eczema, rash; less commonly atrial fibrillation; rarely pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase (discontinue if raised significantly), blurred vision, exfoliative dermatitis, alopecia, and photosensitivity

**Dose**

- 1.2 g daily; usually in 2 divided doses; range 0.9–1.2 g daily; **CHILD** not recommended

**Gemfibrozil (Non-proprietary) £28.00**

- **Capsules**, gemfibrozil 300 mg, net price 112-cap pack = £35.57. Label: 22
- **Dose** initially 3 capsules daily in divided doses; usual range 2–4 capsules daily; CHILD 4–15 years 1 capsule/20 kg daily

**Supralip® 160 (Abbott) £28.00**

- **Tablets**, f/c, fenofibrate (micronised) 160 mg, net price 28-tab pack = £6.69. Label: 21
- **Dose** 160 mg daily (dose form not appropriate for children or in renal impairment)
Nicotinic acid group

The value of nicotinic acid is limited by its side-effects, especially vasodilatation. In doses of 1.5 to 3 g daily it lowers both cholesterol and triglyceride concentrations by inhibiting synthesis; it also increases HDL-cholesterol. Nicotinic acid is licensed for use with a statin if the statin alone cannot adequately control dyslipidaemia (raised LDL-cholesterol, triglyceridaemia, and low HDL-cholesterol); it can be used alone if the patient is intolerant of statins (for advice on treatment of dyslipidaemia, including use of combination treatment, see p. 161).

A preparation combining laropiprant with nicotinic acid (Tredaptive®) is available; laropiprant has no lipid-regulating effect, but reduces the symptoms of flushing associated with nicotinic acid. Acipimox seems to have fewer side-effects than nicotinic acid but may be less effective in its lipid-regulating capabilities.

**ACIPIMOX**

- **Indications** hyperlipidaemias of types Iib and IV in patients who have not responded adequately to diet and other appropriate measures
- **Contra-indications** peptic ulcer
- **Renal impairment** reduce dose if eGFR 30–60 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²
- **Pregnancy** manufacturer advises avoid
- **Breast-feeding** manufacturer advises avoid
- **Side-effects** vasodilatation, flushing, itching, rashes, urticaria, erythema; heartburn, epigastric pain, nausea, diarrhoea, headache, malaise, dry eyes; rarely angioedema, bronchospasm, anaphylaxis
- **Dose**
  - Usually 500–750 mg daily in divided doses

**Omaclor®** (Pfizer) 168

- **Dose** '300’ capsules, white/maroon, gemfibrozil 300 mg, net price 112-cap pack = £35.57. Label: 22
- **Dose** '600’ tablets, I/c, gemfibrozil 600 mg, net price 56-tab pack = £35.57. Label: 22

**Lopid®** (Pfizer) 168

- **Dose** Usually 500–750 mg daily in divided doses

**Nicotinic acid**

- **Indications** adjunct to diet in type IIb or III hypertriglyceridaemia; adjunct to diet in type IV hypertriglyceridaemia; adjunct in secondary prevention in those who have had a myocardial infarction in the preceding 3 months
- **Contra-indications** unstable angina, acute myocardial infarction, diabetes mellitus, gout, history of peptic ulceration; interactions: Appendix 1 (nicotinic acid)
- **Contra-indications** arterial bleeding; active peptic ulcer disease
- **Hepatic impairment** manufacturer advises monitor liver function in mild to moderate impairment and avoid in severe impairment; discontinue if severe abnormalities in liver function tests
- **Renal impairment** manufacturer advises use with caution—no information available
- **Pregnancy** no information available—manufacturer advises avoid unless potential benefit outweighs risk

**OMECA-3-ACID ETHYL ESTERS**

- **Indications** adjunc to diet and statin in type IIb or III hypertriglyceridaemia; adjunc to diet in type IV hypertriglyceridaemia; adjunc in secondary prevention in those who have had a myocardial infarction in the preceding 3 months

**OMEGA-3-ACID ETHYL ESTERS**

- **Indications** present in milk—avoid
- **Side-effects** diarrhoea, nausea, vomiting, abdominal pain, dyspepsia; flushing; pruritus, rash; less commonly tachycardia, palpitation, shortness of breath, peripheral oedema, headache, dizziness, increase in uric acid, hypophosphataemia, prolonged prothrombin time, and reduced platelet count; rarely hypotension, syncope, rhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy, myasthenia; very rarely anorexia, rhabdomyolysis, visual disturbance, and jaundice also reported

**Note** Prostaglandin-mediated symptoms (such as flushing) can be reduced by low initial doses taken with meals or, if patient taking aspirin, aspirin dose should be taken 30 minutes before nicotinic acid

**Dose**

- See under preparation

**Modified release**

**Niaspan®** (Abbott) 168

- **Dose** Tablets, m/r, nicotinic acid 500 mg, net price 56-tab pack = £18.98; 750 mg, 56-tab pack = £28.88; 1 g, 56-tab pack = £38.23; 21-day starter pack of 7 × 375-mg tab with 7 × 500-mg tab and 7 × 750-mg tab = £15.40. Label: 21, 25

**Omacor®** (MSD) 168

- **Dose** 375 mg once daily at night (after a low-fat snack) for 1 week, then 500 mg once daily at night for 1 week, then 750 mg once daily at night for 1 week, then 1 g once daily at night for 4 weeks, increased if necessary in steps of 500 mg at intervals of at least 4 weeks to max. 2 g daily; usual maintenance dose 1–2 g once daily at night

- **With laropiprant**

**Tredaptive®** (MSD) 168

- **Dose** Tablets, m/r, nicotinic acid 1 g, laropiprant 20 mg, net price 28-tab pack = £16.73; 56-tab pack = £33.46. Label: 21, 25

- **Omaclor®** (Pfizer) 168

- **Dose** '600’ tablets, m/r, nicotinic acid 600 mg, net price 56-tab pack = £38.23; 21-day starter pack of 7 × 375-mg tab = £15.10. Label: 21, 25

**Lopid®** (Pfizer) 168

- **Dose** '300’ capsules, white/maroon, gemfibrozil 300 mg, net price 112-cap pack = £35.57. Label: 22

**Breast-feeding** present in milk—avoid

**Side-effects** diarrhoea, nausea, vomiting, abdominal pain, dyspepsia; flushing; pruritus, rash; less commonly tachycardia, palpitation, shortness of breath, peripheral oedema, headache, dizziness, increase in uric acid, hypophosphataemia, prolonged prothrombin time, and reduced platelet count; rarely hypotension, syncope, rhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy, myasthenia; very rarely anorexia, rhabdomyolysis, visual disturbance, and jaundice also reported

**Note** Prostaglandin-mediated symptoms (such as flushing) can be reduced by low initial doses taken with meals or, if patient taking aspirin, aspirin dose should be taken 30 minutes before nicotinic acid

**Dose**

- See under preparation

**Modified release**

**Niaspan®** (Abbott) 168

- **Dose** Tablets, m/r, nicotinic acid 500 mg, net price 56-tab pack = £18.98; 750 mg, 56-tab pack = £28.88; 1 g, 56-tab pack = £38.23; 21-day starter pack of 7 × 375-mg tab with 7 × 500-mg tab and 7 × 750-mg tab = £15.40. Label: 21, 25

**Omacor®** (MSD) 168

- **Dose** 375 mg once daily at night (after a low-fat snack) for 1 week, then 500 mg once daily at night for 1 week, then 750 mg once daily at night for 1 week, then 1 g once daily at night for 4 weeks, increased if necessary in steps of 500 mg at intervals of at least 4 weeks to max. 2 g daily; usual maintenance dose 1–2 g once daily at night

- **With laropiprant**

**Tredaptive®** (MSD) 168

- **Dose** Tablets, m/r, nicotinic acid 1 g, laropiprant 20 mg, net price 28-tab pack = £16.73; 56-tab pack = £33.46. Label: 21, 25

- **Omaclor®** (Pfizer) 168

- **Dose** '600’ tablets, m/r, nicotinic acid 600 mg, net price 56-tab pack = £38.23; 21-day starter pack of 7 × 375-mg tab = £15.10. Label: 21, 25
Cautions haemorrhagic disorders, anticoagulant treatment (bleeding time increased)

Hepatic impairment monitor liver function

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—no information available

Side-effects gastro-intestinal disturbances; less commonly taste disturbances, dizziness, and hypersensitivity reactions; rarely hepatic disorders, headache, hyperglycaemia, acne, and rash; very rarely hypotension, nasal dryness, urticaria, and increased white cell count

Dose

See under preparation below

Omacor® (Abbott Healthcare)
Capsules, 1 g of omega-3-acid ethyl esters 90 containing eicosapentaenoic acid 460 mg and docosahexaenoic acid 380 mg, net price 28-cap pack = £14.24, 100-cap pack = £50.84. Label: 21

Dose hypertriglyceridaemia, initially 2 capsules daily with food, increased if necessary to 4 capsules daily
Secondary prevention after myocardial infarction, 1 capsule daily with food

OMEGA-3-MARINE TRIGLYCERIDES

Indications adjunct in the reduction of plasma triglycerides in severe hypertriglyceridaemia

Cautions haemorrhagic disorders, anticoagulant treatment; aspirin-sensitive asthma; type 2 diabetes

Side-effects occasional nausea and belching

Dose

See under preparations below

Maxepra® (Seven Seas)
Capsules, 1 g (approx. 1.1 mL) concentrated fish oils containing eicosapentaenoic acid 170 mg, docosahexaenoic acid 115 mg. Vitamin A content less than 100 units/g, vitamin D content less than 10 units/g. net price 200-cap pack = £29.28. Label: 21

Dose 5 capsules twice daily with food

Liquid, golden-coloured, concentrated fish oils containing eicosapentaenoic acid 170 mg, docosahexaenoic acid 115 mg/g (1.1 mL). Vitamin A content less than 100 units/g, vitamin D content less than 10 units/g, net price 150 mL = £21.59. Label: 21

Dose 5 mL twice daily with food

SODIUM TETRADECYL SULPHATE

Indications sclerotherapy of varicose veins

Cautions see under Ethanolamine Oleate

Contra-indications see under Ethanolamine Oleate

Side-effects see under Ethanolamine Oleate

Fibro-Vein® (STD Pharmaceutical)
Injection, sodium tetradecyl sulphate 0.2%, net price 5-mL amp = £5.51; 0.5%, 2-mL amp = £2.87; 1%, 2-mL amp = £3.31; 3%, 2-mL amp = £4.07, 5-mL vial = £10.25

Dose by slow injection into empty isolated segment of vein, 0.1–1 mL according to site and condition being treated (consult product literature)

2.13 Local sclerosants

Ethanolamine oleate and sodium tetradecyl sulphate are used in sclerotherapy of varicose veins, and phenol is used in haemorrhoids (section 1.7.3).

ETHANOLAMINE OLEATE
(Monoethanolamine Oleate)

Indications sclerotherapy of varicose veins

Cautions extravasation may cause necrosis of tissues

Contra-indications inability to walk, acute phlebitis, oral contraceptive use, obese legs

Side-effects allergic reactions (including anaphylaxis)
3 Respiratory system

3.1 Bronchodilators

3.1.1 Adrenoceptor agonists

3.1.1.1 Selective beta₂ agonists

3.1.1.2 Other adrenoceptor agonists

3.1.2 Antimuscarinic bronchodilators

3.1.3 Theophylline

3.1.4 Compound bronchodilator preparations

3.1.5 Peak flow meters, inhaler devices and nebulisers

3.2 Corticosteroids

3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors

3.3.1 Cromoglicate and related therapy

3.3.2 Leukotriene receptor antagonists

3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation, and allergic emergencies

3.4.1 Antihistamines

3.4.2 Allergen Immunotherapy

3.4.3 Allergic emergencies

3.5 Respiratory stimulants and pulmonary surfactants

3.5.1 Respiratory stimulants

3.5.2 Pulmonary surfactants

3.6 Oxygen

3.7 Mucolytics

3.8 Aromatic inhalations

3.9 Cough preparations

3.9.1 Cough suppressants

3.9.2 Demulcent and expectorant cough preparations

3.10 Systemic nasal decongestants

Asthma

Drugs used in the management of asthma include beta₂ agonists (section 3.1.1), antimuscarinic bronchodilators (section 3.1.2), theophylline (section 3.1.3), corticosteroids (section 3.2), cromoglicate and nedocromil (section 3.3.1), leukotriene receptor antagonists (section 3.3.2), and, in specialist centres, omalizumab (section 3.4.2).

For tables outlining the management of chronic and acute asthma, see p. 172 and p. 173. For advice on the management of medical emergencies in dental practice, see p. 27.

Administration of drugs for asthma

Inhalation This route delivers the drug directly to the airways; the dose required is smaller than when given by mouth and side-effects are reduced. See also Inhaler devices, section 3.1.5.

Solutions for nebulisation are available for use in severe acute asthma. They are administered over 5–10 minutes from a nebuliser, usually driven by oxygen in hospital. See also Nebulisers, section 3.1.5.

Oral The oral route is used when administration by inhalation is not possible. Systemic side-effects occur more frequently when a drug is given orally rather than by inhalation. Drugs given by mouth for the treatment of asthma include beta₂ agonists, corticosteroids, theophylline, and leukotriene receptor antagonists.

Parenteral Drugs such as beta₂, agonists, corticosteroids, and aminophylline can be given by injection in acute severe asthma when administration by nebulisation is inadequate or inappropriate. If the patient is being treated in the community, urgent transfer to hospital should be arranged.

Pregnancy and breast-feeding

It is particularly important that asthma should be well controlled during pregnancy; when this is achieved asthma has no important effects on pregnancy, labour, or on the fetus. Drugs for asthma should preferably be administered by inhalation to minimise exposure of the fetus. Inhaled drugs, theophylline, and prednisolone (see section 6.3.2) can be taken as normal during pregnancy and breast-feeding. Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.

Severe acute exacerbations of asthma can have an adverse effect on pregnancy and should be treated...
Management of severe acute asthma

Severe acute asthma can be fatal and must be treated promptly and energetically. All patients with severe acute asthma should be given high-flow oxygen (if available) and an inhaled short-acting beta 2 agonist plus a corticosteroid with a long-acting antimuscarinic bronchodilator. Inhale technique should be checked and regular treatment should be reviewed in accordance with the Management of Chronic Asthma table, p. 172. Patients should be given a written asthma action plan aimed at preventing relapse, optimising treatment, and preventing delay in seeking assistance in future exacerbations. Follow-up within 48 hours should be arranged with the general practitioner or appropriate primary care health professional. Patients should also be reviewed by a respiratory specialist within one month of the exacerbation.

Chronic obstructive pulmonary disease

Smoking cessation (section 4.10.2) reduces the progressive decline in lung function in chronic obstructive pulmonary disease (COPD, chronic bronchitis, or emphysema). Infection can complicate chronic obstructive pulmonary disease and may be prevented by vaccination (pneumococcal vaccine and influenza vaccine, section 14.4).

A trial of a high-dose inhaled corticosteroid or an oral corticosteroid is recommended for patients with moderate or severe airflow obstruction if the diagnosis is in doubt.

Symptoms of chronic obstructive pulmonary disease may be alleviated by an inhaled short-acting beta, agonist (section 3.1.1.1) or a short-acting antimuscarinic bronchodilator (section 3.1.2) used as required.

When the airways obstruction is more severe, regular inhaled therapy should be used, see also Use of Inhaled Therapies in Chronic Obstructive Pulmonary Disease, p. 174.

If the Forced Expiratory Volume in 1 second (FEV1), is 50% of predicted or more, either a long-acting antimuscarinic bronchodilator (section 3.1.2) or a long-acting beta, agonist (section 3.1.1.1) should be used. Short-acting antimuscarinic bronchodilators should be discontinued when a long-acting antimuscarinic bronchodilator is started. A long-acting beta, agonist with a corticosteroid (section 3.2) in a combination inhaler can be used for patients who remain symptomatic despite regular treatment with a long-acting beta, agonist.

If FEV1 is less than 50% of predicted, either a long-acting antimuscarinic bronchodilator or a long-acting beta, agonist with a corticosteroid in a combination inhaler plus a long-acting antimuscarinic bronchodilator should be used.

In any patient who remains breathless or continues to have exacerbations, triple therapy with a long-acting beta, agonist and a corticosteroid in a combination inhaler plus a long-acting antimuscarinic bronchodilator should be used.

If an inhaled corticosteroid is not appropriate, a long-acting antimuscarinic bronchodilator can be used with a long-acting beta, agonist.

If symptoms persist or if the patient is unable to use an inhaler, oral modified-release aminophylline or theophylline (section 3.1.3) can be used.
Management of chronic asthma

<table>
<thead>
<tr>
<th>Adult and Child over 5 years</th>
<th>Child under 5 years*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1: occasional relief bronchodilator</strong></td>
<td><strong>Step 1: occasional relief bronchodilator</strong></td>
</tr>
<tr>
<td>Inhaled short-acting beta, agonist as required (up to once daily)</td>
<td>Short-acting beta, agonist as required (not more than once daily)</td>
</tr>
<tr>
<td>Note: Move to step 2 if needed more than twice a week, or if night-time symptoms more than once a week, or if exacerbation in the last 2 years</td>
<td>Note: Preferably by inhalation (less effective and more side-effects when given by mouth)</td>
</tr>
<tr>
<td><strong>Step 2: regular inhaled preventer therapy</strong></td>
<td><strong>Step 2: regular preventer therapy</strong></td>
</tr>
<tr>
<td>Inhaled short-acting beta, agonist as required</td>
<td>Inhaled short-acting beta, agonist as required</td>
</tr>
<tr>
<td>Regular standard-dose inhaled corticosteroid (alternatives are considerably less effective)</td>
<td><em>Either regular standard-dose inhaled corticosteroid</em></td>
</tr>
<tr>
<td><strong>Step 3: inhaled corticosteroid + long-acting inhaled beta, agonist</strong></td>
<td><strong>Step 3: add-on therapy</strong></td>
</tr>
<tr>
<td>Inhaled short-acting beta, agonist as required</td>
<td>Child under 2 years:</td>
</tr>
<tr>
<td>Regular standard-dose inhaled corticosteroid</td>
<td>Refer to respiratory paediatrician</td>
</tr>
<tr>
<td>Regular inhaled long-acting beta, agonist (salmeterol or formoterol)</td>
<td>Child 2–5 years:</td>
</tr>
<tr>
<td><em>If asthma not controlled</em></td>
<td>Inhaled short-acting beta, agonist as required</td>
</tr>
<tr>
<td>Increase dose of inhaled corticosteroid to upper end of standard dose range and <em>Either</em> stop long-acting beta, agonist if of no benefit</td>
<td>Regular inhaled corticosteroid in standard dose</td>
</tr>
<tr>
<td>or <em>continue long-acting beta, agonist if of some benefit</em></td>
<td>Leukotriene receptor antagonist</td>
</tr>
<tr>
<td><em>If asthma still not controlled and long-acting beta, agonist stopped, add one of</em></td>
<td><strong>Step 4: persistent poor control</strong></td>
</tr>
<tr>
<td>Leukotriene receptor antagonist</td>
<td>Refer to respiratory paediatrician</td>
</tr>
<tr>
<td>Modified-release oral theophylline</td>
<td><strong>Stepping down</strong></td>
</tr>
<tr>
<td>Modified-release oral beta, agonist; CHILD under 12 years not recommended</td>
<td>Regularly review need for treatment</td>
</tr>
</tbody>
</table>

**Step 4: high-dose inhaled corticosteroid + regular bronchodilators**

Inhaled short-acting beta, agonist as required

- Regular high-dose inhaled corticosteroid
- Inhaled long-acting beta, agonist
- In adults 6-week sequential therapeutic trial of one or more of Leukotriene receptor antagonist
- Modified-release oral theophylline
- Modified-release oral beta, agonist

**Step 5: regular corticosteroids**

Refer to a respiratory specialist

- Inhaled short-acting beta, agonist as required
- Regular high-dose inhaled corticosteroid
- One or more long-acting bronchodilators (see step 4)
- Regular prednisolone tablets (as single daily dose)

Note: In addition to regular prednisolone, continue high-dose inhaled corticosteroid (in exceptional cases may exceed licensed doses); these patients should normally be referred to an asthma clinic

Stepping down

Review treatment every 3 months; if control achieved, stepwise reduction may be possible; reduce dose of inhaled corticosteroid slowly (consider reduction every 3 months, decreasing dose by up to 50% each time)

Advice on the management of chronic asthma is based on the recommendations of the British Thoracic Society and Scottish Intercollegiate Guidelines Network (updated June 2009); updates available at www.brit-thoracic.org.uk

1. Standard-dose inhaled corticosteroids
   - Beclometasone dipropionate or budesonide 100–400 micrograms twice daily; CHILD under 12 years 100–200 micrograms twice daily
   - Fluticasone propionate 50–200 micrograms twice daily; CHILD 4–12 years 50–100 micrograms twice daily
   - Mometasone furoate 200 micrograms twice daily
   - Note: Dose adjustments may be required for some inhaler devices, see under individual preparations, section 3.2

2. Alternatives to inhaled corticosteroid are leukotriene receptor antagonists, theophylline, inhaled cromoglicate, or inhaled nedocromil

3. High-dose inhaled corticosteroids
   - Beclometasone dipropionate or budesonide 0.4–1 mg twice daily; CHILD 5–12 years 200–400 micrograms twice daily
   - Fluticasone propionate 200–500 micrograms twice daily; CHILD 5–12 years 100–200 micrograms twice daily
   - Mometasone furoate 200–400 micrograms twice daily
   - Note: Dose adjustments may be required for some inhaler devices, see under individual preparations, section 3.2

4. Lung-function measurements cannot be used to guide management in those under 5 years
Management of acute asthma

**Important** Patients with severe or life-threatening acute asthma may not be distressed and may not have all of these abnormalities; the presence of any should alert the doctor. Regard each emergency consultation as being for severe acute asthma until shown otherwise.

<table>
<thead>
<tr>
<th>Moderate acute asthma</th>
<th>Severe acute asthma</th>
<th>Life-threatening acute asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Able to talk</td>
<td>Cannot complete sentences in one breath; CHILD too breathless to talk or feed</td>
<td>Silent chest, feeble respiratory effort, cyanosis</td>
</tr>
<tr>
<td>Respiration (breaths/minute) &lt; 25; CHILD 2–5 years ≤ 40, 5–12 years ≤ 30</td>
<td>Respiration (breaths/minute) ≥ 25; CHILD 2–5 years &gt; 40; 5–12 years &gt; 30</td>
<td>Hypotension, bradycardia, arrhythmia, exhaustion, agitation (in children), or reduced level of consciousness</td>
</tr>
<tr>
<td>Pulse (beats/minute) &lt; 110; CHILD 2–6 years ≤ 140, 5–12 years ≤ 125</td>
<td>Pulse (beats/minute) &gt; 110; CHILD 2–5 years &gt; 140; 5–12 years &gt; 125</td>
<td>Arterial oxygen saturation &lt; 92%</td>
</tr>
<tr>
<td>Arterial oxygen saturation ≥ 92%</td>
<td>Arterial oxygen saturation ≥ 92%, CHILD under 12 years &lt; 92%</td>
<td>Peak flow &lt; 33% of predicted or best; CHILD 5–12 years &lt; 33%</td>
</tr>
<tr>
<td>Peak flow &gt; 50% of predicted or best; CHILD 5–12 years ≥ 50%</td>
<td>Peak flow 33–50% of predicted or best; CHILD 5–12 years 33–50%</td>
<td>Start treatment below and send immediately to hospital; consult with senior medical staff and refer to intensive care</td>
</tr>
<tr>
<td>Treat at home or in surgery and assess response to treatment</td>
<td>Start treatment below and send immediately to hospital</td>
<td></td>
</tr>
</tbody>
</table>

**Treatment**

**Moderate acute asthma**
- Inhaled short-acting beta, agonist via a large-volume spacer or oxygen-driven nebuliser (if available); give 2–10 puffs of salbutamol 100 micrograms/metered inhalation each inhaled separately, and repeat at 10–20 minute intervals if necessary or give nebulised salbutamol 5 mg (CHILD under 5 years 2.5 mg, 5–12 years 2.5–5 mg) or terbutaline 10 mg (CHILD under 5 years 5 mg, 5–12 years 5–10 mg), and repeat at 20–30 minute intervals if necessary
- Prednisolone 40–50 mg by mouth for at least 5 days; CHILD 1–2 mg/kg (max. 40 mg) for up to 3 days, or longer if necessary; if the child has been taking an oral corticosteroid for more than a few days, give prednisolone 2 mg/kg (max. 60 mg)

**Severe acute asthma**
- High-flow oxygen (if available)
- Inhaled short-acting beta, agonist via a large-volume spacer or oxygen-driven nebuliser (if available) as for moderate acute asthma
- Prednisolone by mouth as for moderate acute asthma or intravenous hydrocortisone (preferably as sodium succinate) 100 mg every 6 hours until conversion to oral prednisolone is possible; CHILD 4 mg/kg (CHILD under 2 years max. 25 mg, 2–5 years max. 50 mg, 6–12 years max. 100 mg)
- Monitor response for 15–30 minutes
  - If response is poor:
    - Inhaled ipratropium bromide via oxygen-driven nebuliser (if available) 500 micrograms every 4–6 hours (CHILD under 12 years 250 micrograms repeated every 20–30 minutes for the first 2 hours, then every 4–6 hours as necessary)
    - Refer those who fail to respond and require ventilatory support to an intensive care or high-dependency unit
  - Consider intravenous beta, agonists, aminophylline (p. 181) or magnesium sulphate [unlicensed indication] (p. 171) only after consultation with senior medical staff
- Consider intravenous aminophylline (p. 181) or magnesium sulphate [unlicensed indication] (p. 171) only after consultation with senior medical staff
- Consider intravenous aminophylline (p. 181) or magnesium sulphate [unlicensed indication] (p. 171) only after consultation with senior medical staff

**Follow up in all cases**
- Monitor symptoms and peak flow. Set up asthma action plan and check inhaler technique
- Review by general practitioner or appropriate primary care health professional within 48 hours, see also p. 171

Advice on the management of acute asthma is based on the recommendations of the British Thoracic Society and Scottish Intercollegiate Guidelines Network (updated June 2009); updates available at [www.brit-thoracic.org.uk](http://www.brit-thoracic.org.uk).
Indacaterol (section 3.1.1.1) is a long-acting beta2 agonist licensed for the maintenance treatment of chronic obstructive pulmonary disease. In patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations, roflumilast (section 3.3.3) is licensed as an adjunct to existing bronchodilator treatment. A mucolytic drug (section 3.7) may be considered for a patient with a chronic productive cough.

Long-term oxygen therapy (section 3.6) prolongs survival in patients with severe chronic obstructive pulmonary disease and hypoxaemia. During an exacerbation of chronic obstructive pulmonary disease, bronchodilator therapy can be administered through a nebuliser if necessary and oxygen given if appropriate. Aminophylline can be given intravenously if response to nebulised bronchodilators is poor. A short course of oral corticosteroid (section 6.3.2), such as prednisolone 30 mg daily for 7–14 days, should be given if increased breathlessness interferes with daily activities. Antibacterial treatment (Table 1, section 5.1) is required when sputum becomes purulent or if there are other signs of infection.

Patients who have had an episode of hypercapnic respiratory failure should be given a 24% or 28% Venturi mask and an oxygen alert card (see below) endorsed with the oxygen saturations required during previous exacerbations. Patients and their carers should be instructed to show the card to emergency healthcare providers in the event of an exacerbation, see also section 3.6.

### Oxygen alert card

Name: ________________________________

I am at risk of type II respiratory failure with a raised CO₂ level.

Please use my ____% Venturi mask to achieve an oxygen saturation of ____% to ____% during exacerbations.

Use compressed air to drive nebulisers (with nasal oxygen at 2 litres/minute). If compressed air not available, limit oxygen-driven nebulisers to 6 minutes.

Oxygen alert card based on British Thoracic Society guideline for emergency oxygen use in adult patients (October 2008); available at www.brit-thoracic.org.uk

### Croup

Mild croup is largely self-limiting, but treatment with a single dose of a corticosteroid (e.g. dexamethasone 150 micrograms/kg) by mouth may be of benefit.
BNF 61

More severe croup (or mild croup that might cause complications) calls for hospital admission; a single dose of a corticosteroid (e.g. dexamethasone 150 micrograms/kg or prednisolone 1–2 mg/kg by mouth, section 6.3.2) should be administered before transfer to hospital. In hospital, dexamethasone 150 micrograms/kg (by mouth or by injection) or budesonide 2 mg (by nebulisation, section 3.2) will often reduce symptoms; the dose may need to be repeated after 12 hours if necessary.

For severe croup not effectively controlled with corticosteroid treatment, nebulised adrenaline solution 1 in 1000 (1 mg/mL) should be given with close clinical monitoring in a dose of 400 micrograms/kg (max. 5 mg) repeated after 30 minutes if necessary; the effects of nebulised adrenaline last 2–3 hours and the child needs to be monitored carefully for recurrence of the obstruction.

### 3.1.1 Adrenoceptor agonists

#### (Sympathomimetics)

**Selective beta, agonists**

The selective beta, agonists (selective beta, adrenoceptor agonists, selective beta, stimulants) (section 3.1.1.1) such as salbutamol or terbutaline are the safest and most effective short-acting beta, agonists for asthma. Less selective beta, agonists such as ephedrine (section 3.1.1.2) should be avoided whenever possible. Adrenaline (epinephrine) (which has both alpha- and beta-adrenoceptor agonist properties) is used in the emergency management of allergic and anaphylactic reactions (section 3.4.3) and in the management of croup (see above).

#### 3.1.1.1 Selective beta, agonists

Selective beta, agonists produce bronchodilation. A short-acting beta, agonist is used for immediate relief of asthma symptoms while some long-acting beta, agonists are added to an inhaled corticosteroid in patients requiring prophylactic treatment.

#### 3.1.1.2 Other adrenoceptor agonists

Management of Chronic Asthma table, see p. 172 Management of Acute Asthma table, see p. 173

**Indacaterol** is a long-acting beta, agonist recently licensed for chronic obstructive pulmonary disease; it is not indicated for the relief of acute bronchospasm.

### CHM advice

To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta, agonists (formoterol and salmeterol) should:

- be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;
- not be initiated in patients with rapidly deteriorating asthma;
- be introduced at a low dose and the effect properly monitored before considering dose increase;
- be discontinued in the absence of benefit;
- not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;
- be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved. A daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.

Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta, agonist, see Management of Chronic Asthma table, p. 172.

**Inhalation**

Pressurised-metered dose inhalers are an effective and convenient method of drug administration in mild to moderate asthma. A spacer device (section 3.1.5) may improve drug delivery. At recommended inhaled doses the duration of action of salbutamol, terbutaline and fenoterol is about 3 to 5 hours and for salmeterol and formoterol 12 hours. The dose, the frequency, and the maximum number of inhalations in 24 hours of the beta, agonist should be stated explicitly to the patient. The patient should be advised to seek medical advice when the prescribed dose of beta, agonist fails to provide the usual degree of symptomatic relief because this usually indicates a worsening of the asthma and the patient may require a prophylactic drug such as an inhaled corticosteroid (see Management of Chronic Asthma table, p. 172).

**Short-acting beta, agonists**

Mild to moderate symptoms of asthma respond rapidly to the inhalation of a selective short-acting beta, agonist such as salbutamol or terbutaline. If beta, agonist inhalation is needed more often than once daily, prophylactic treatment should be considered, using a stepped approach as outlined in the Management of Chronic Asthma table, p. 172. Regular treatment with an inhaled short-acting beta, agonist is less effective than ‘as required’ inhalation and is not appropriate prophylactic treatment. A short-acting beta, agonist inhaled immediately before exertion reduces exercise-induced asthma; however, frequent exercise-induced asthma probably reflects poor overall control and calls for reassessment of asthma treatment.

**Long-acting beta, agonists** Formoterol (efomefor terol) and salmeterol are longer-acting beta, agonists which are administered by inhalation. They should be used for asthma only in patients who regularly use an inhaled corticosteroid (see CHM advice below). They have a role in the long-term control of chronic asthma (see Management of Chronic Asthma table, p. 172) and they can be useful in nocturnal asthma. Salmeterol should not be used for the relief of an asthma attack; it has a slower onset of action than salbutamol or terbutaline. Formoterol is licensed for short-term symptom relief and for the prevention of exercise-induced bronchospasm; its speed of onset of action is similar to that of salbutamol.

Combination inhalers that contain a long-acting beta, agonist and a corticosteroid (section 3.2) ensure that long-acting beta, agonists are not used without concomitant corticosteroids, but reduce the flexibility to adjust the dose of each component.
Nebuliser (or respirator) solutions of salbutamol and terbutaline are used for the treatment of severe acute asthma in hospital or in general practice. Patients with a severe attack of asthma should preferably have oxygen during nebulisation since beta, agonists can increase arterial hypoxaemia. For the use of nebulisers in chronic obstructive pulmonary disease, see section 3.1.5. The dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution, see also section 3.1.5.

Oral Oral preparations of beta, agonists may be used by patients who cannot manage the inhaled route. They are sometimes used for children and the elderly, but inhaled beta, agonists are more effective and have fewer side-effects. The longer-acting oral preparations, including bambuterol, may be of value in nocturnal asthma but they have a limited role and inhaled long-acting beta, agonists are usually preferred.

Parenteral Salbutamol or terbutaline can be given intravenously for severe or life-threatening acute asthma; patients should be carefully monitored and the dose adjusted according to response and heart rate. The regular use of beta, agonists by the subcutaneous route is not recommended since the evidence of benefit is uncertain and it may be difficult to withdraw such treatment once started. Beta, agonists may also be given by intramuscular injection.

Children Selective beta, agonists are useful even in children under the age of 18 months. They are most effective by the inhaled route; a pressurised metered-dose inhaler should be used with a spacer device in children under 5 years (see NICE guidance, section 3.1.5). A beta, agonist may also be given by mouth but administration by inhalation is preferred; a long-acting inhaled beta, agonist may be used where appropriate (see Management of Chronic Asthma table, p. 172). In severe attacks nebulisation using a selective beta, agonist or iratropium is advisable (see also Management of Chronic Asthma table and Management of Acute Asthma table, p. 172 and p. 173).

Cautions Beta, agonists should be used with caution in hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypokalaemia. Beta, agonists should be used with caution in diabetes—monitor blood glucose (risk of ketoacidosis, especially when beta, agonist given intravenously). Interactions: Appendix 1 (sympathomimetics, beta, ).

Hypokalaemia Potentially serious hypokalaemia may result from beta, agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.

Side-effects Side-effects of the beta, agonists include fine tremor (particularly in the hands), nervous tension, headache, muscle cramps, and palpitation. Other side-effects include tachycardia, arrhythmias, peripheral vasodilatation, myocardial ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm (occasionally severe), urticaria, angioedema, hypotension, and collapse have also been reported. High doses of beta, agonists are associated with hypokalaemia (see Hypokalaemia above).

**BAMBU T EROL HYDROCHLORIDE**

Note: Bambuterol is a pro-drug of terbutaline.

**Indications** asthma and other conditions associated with reversible airways obstruction

**Cautions** see notes above

**Hepatic impairment** avoid in severe impairment

**Renal impairment** reduce initial dose by half if eGFR less than 50 mL/minute/1.73m²

**Pregnancy** manufacturer advises avoid—no information available; see also p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above

**Dose**
- 20 mg once daily at bedtime if patient has previously tolerated beta, agonists: other patients, initially 10 mg once daily at bedtime, increased if necessary after 1–2 weeks to 20 mg once daily; **CHILD** not recommended

**BAMBE C (AstraZeneca)**

**Tablets**, both scored, bambuterol hydrochloride 10 mg, net price 28-tab pack = £12.05; 20 mg, 28-tab pack = £13.14

**FENOTEROL HYDROBROMIDE**

**Indications** reversible airways obstruction

**Cautions** see notes above

**Pregnancy** see p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above

**Compound preparations**

For compound preparation containing fenoterol, see section 3.1.4

**FORMOTEROL FUMARATE**

(Eformoterol fumarate)

**Indications** reversible airways obstruction (including nocturnal asthma and prophylaxis of exercise-induced bronchospasm) in patients requiring long-term regular bronchodilator therapy, see also Management of Chronic Asthma table, p. 172; chronic obstructive pulmonary disease

**Note** For use in asthma only in patients who regularly use an inhaled corticosteroid, see notes above

**Cautions** see notes above

**Pregnancy** see p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above; very rarely QT-interval prolongation; taste disturbances, nausea, dizziness, rash, and pruritus also reported

**Dose**
- See under preparations below

Counselling: Advise patients not to exceed prescribed dose, and to follow manufacturer’s directions; if a previously effective dose of inhaled formoterol fails to provide adequate relief, a doctor’s advice should be obtained as soon as possible

Formoterol (Non-proprietary) **Eformoterol**

**Dry powder for inhalation**, formoterol fumarate 12 micrograms/metered inhalation, net price 120-dose unit = £23.75. Counselling, administration brands include Easyhaler® Formoterol

**Dose** by inhalation of powder, asthma, **ADULT** and **CHILD** over 6 years, 12 micrograms twice daily, increased to 24 micro-
oqrams twice daily in more severe airways obstruction (see also CHM advice below)
Chronic obstructive pulmonary disease, 12 micrograms twice daily

Atimos Modulite® (Chiesi) ▼ (Turbohaler)
Aerosol inhalation, formoterol fumarate 12 micrograms/ metered inhalation, net price 100-dose unit = £30.06. Counselling, administration

Dose by aerosol inhalation, asthma, ADULT and CHILD over 12 years, 12 micrograms twice daily, increased to max. 24 micrograms twice daily in more severe airways obstruction.
Chronic obstructive pulmonary disease, ADULT over 18 years, 12 micrograms twice daily; for symptom relief additional doses may be taken to total max. 48 micrograms daily (max. single dose 24 micrograms)

Foradil® (Novartis) ▼ (Turbohaler)
Dry powder for inhalation, formoterol fumarate 12 micrograms/capsule, net price 60-cap pack (with inhaler device) = £23.38. Counselling, administration

Dose by inhalation of powder, asthma, ADULT and CHILD over 12 years, 12 micrograms twice daily, increased to max. 24 micrograms twice daily in more severe airways obstruction.
CHILD 5–12 years 12 micrograms twice daily
Chronic obstructive pulmonary disease, 12 micrograms twice daily

Oxis® (AstraZeneca) ▼ (Turbohaler)
Turbohaler® (= dry powder inhaler), formoterol fumarate 6 micrograms/metered inhalation, net price 60-dose unit = £24.80; 12 micrograms/metered inhalation, 60-dose unit = £24.80. Counselling, administration

Dose by inhalation of powder, chronic asthma, 6–12 micrograms 1–2 times daily, increased up to 24 micrograms twice daily if necessary; occasionally up to 72 micrograms daily may be needed (max. single dose 36 micrograms); re-assess treatment if additional doses required on more than 2 days a week; CHILD 6–18 years, 6–12 micrograms 1–2 times daily, occasionally up to 48 micrograms daily may be needed (max. single dose 12 micrograms) (see also CHM advice below)
Relief of bronchospasm, ADULT and CHILD over 6 years, 6–12 micrograms
Prophylaxis of exercise-induced bronchospasm, 12 micrograms before exercise; CHILD 6–18 years, 6–12 micrograms before exercise
Chronic obstructive pulmonary disease, 12 micrograms 1–2 times daily; for symptom relief additional doses can be taken to total max. 48 micrograms daily (max. single dose 24 micrograms)

For compound preparations containing formoterol, see section 3.2

INDACATEROL

Indications maintenance treatment of chronic obstructive pulmonary disease
Cautions see notes above; convulsive disorders
Hepatic impairment use with caution in severe impairment—no information available
Pregnancy manufacturer advises use only if potential benefit outweighs risk
Breast-feeding manufacturer advises use only if potential benefit outweighs risks—present in milk in animal studies

Side-effects see notes above; also peripheral oedema, cough, pharyngolaryngeal pain, nasopharyngitis, sinusitis, rhinorrhea; less commonly atrial fibrillation, non-cardiac chest pain, paraesthesia

Dose
By inhalation of powder, ADULT over 18 years, 150 micrograms once daily, increased to max. 300 micrograms once daily

3.1.1 Adrenoceptor agonists

Onbrez Breezhaler® (Novartis) ▼ (Onbrez Breezhaler®)
Inhalation powder, hard capsule (for use with Onbrez Breezhaler® device), indacaterol (as maleate) 150 micrograms, net price 30-cap pack with Onbrez Breezhaler® device = £29.26; 300 micrograms, net price 30-cap pack with Onbrez Breezhaler® device = £29.26. Counselling, administration

Indications asthma and other conditions associated with reversible airways obstruction; premature labour (section 7.1.3)

Cautions see notes above

Pregnancy see p. 170
Breast-feeding see p. 170

Side-effects see notes above; also lactic acidosis with high doses

Dose
By mouth (but use by inhalation preferred), 4 mg (elderly and sensitive patients initially 2 mg) 3–4 times daily; max. single dose 8 mg (but unlikely to provide much extra benefit or to be tolerated); CHILD under 2 years see BNF for Children, 2–6 years 1–2 mg 3–4 times daily; 6–12 years 2 mg 3–4 times daily
By subcutaneous or intramuscular injection, 500 micrograms, repeated every 4 hours if necessary
By slow intravenous injection (but see also Management of Acute Asthma table, p. 173), (dilute to a concentration of 50 micrograms/mL), 250 micrograms, repeated if necessary; CHILD under 18 years see BNF for Children
By intravenous infusion (but see also Management of Acute Asthma table, p. 173), initially 5 micrograms/ minute, adjusted according to response and heart-rate usually in range 3–20 micrograms/minute, or more if necessary; CHILD under 18 years see BNF for Children
By aerosol inhalation (but see also Management of Acute Asthma table, p. 173, or Management of Chronic Asthma table, p. 172), 100–200 micrograms (1–2 puffs); for persistent symptoms up to 4 times daily; CHILD 100 micrograms (1 puff), increased to 200 micrograms (2 puffs) if necessary; for persistent symptoms up to 4 times daily
Prophylaxis of allergen- or exercise-induced bronchospasm, 200 micrograms (2 puffs); CHILD 100 micrograms (1 puff), increased to 200 micrograms (2 puffs) if necessary

By inhalation of powder (but see also Management of Chronic Asthma table, p. 172), 200–400 micrograms; for persistent symptoms up to 4 times daily; CHILD over 5 years 200 micrograms; for persistent symptoms up to 4 times daily (for Asmasal Clickhaler®, Salmulon Novolog®, and Ventolin Accuhaler® doses, see under preparations)

Prophylaxis of allergen- or exercise-induced bronchospasm, 400 micrograms; CHILD 200 micrograms
By inhalation of nebulised solution, ADULT and CHILD over 5 years 2.5–5 mg, repeated up to 4 times daily or more frequently in severe cases; CHILD under 5 years 2.5 mg, repeated up to 4 times daily or more frequently in severe cases; see also Management of Acute Asthma table, p. 173 and Management of Chronic Asthma table, p. 172

SALBUTAMOL (Albuterol)
3 Respiratory system

3.1.1 Adrenoceptor agonists

- **Salmeterol (Non-proprietary)**
  - **Tablets**, salbutamol (as sulphate) 2 mg, net price 28-pack tab = £17.74; 4 mg, 28-tab pack = £16.40
  - **Oral solution**, salbutamol (as sulphate) 2 mg/5 mL, net price 150 mL = £1.55
    - Brands include: Salmep (sugar-free)

- **Ventolin** (Non-proprietary)
  - **Salbutamol** (as sulphate) 178 micrograms/metered inhalation, 100-dose unit = £6.30. Counselling, administration

- **Salmol Easi-Breathe** (IVAX)
  - **Aerosol inhalation**, salbutamol 100 micrograms/metered inhalation, net price 200-dose breath-actuated unit = £6.30. Counselling, administration

- **Salbutin Novolizer** (Meda)
  - **Dry powder for inhalation**, salbutamol (as sulphate) 100 micrograms/metered inhalation, net price refillable 200-dose unit = £4.95; 200-dose refill = £2.75. Counselling, administration

- **Ventolin** (A&H)
  - **Syrup**, sugar-free, salbutamol (as sulphate) 2 mg/5 mL, net price 150 mL = 60p

- **Parenteral**
  - **Ventolin** (A&H)
    - **Injection**, salbutamol (as sulphate) 500 micrograms/mL, net price 1-mL amp = £3.82
    - **Solution for intravenous infusion**, salbutamol (as sulphate) 1 mg/mL. Dilute before use. Net price 5-mL amp = £2.48

- **Inhalation**
  - **Dry powder for inhalation**, salbutamol 100 micrograms/metered inhalation, net price 200-dose unit = £3.19. Counselling, administration
  - **Dry powder inhalation**, salbutamol (as sulphate) 1 mg/mL. Dilute before use. Net price 5-mL amp = £2.48
  - **Dry powder for inhalation**, salbutamol 100 micrograms/metered inhalation, net price 200-dose unit = £3.11; 200 micrograms/metered inhalation, 100-dose unit = £4.85; 200-dose unit = £6.63. Counselling, administration
  - **Nebuliser solution**, salbutamol (as sulphate) 1 mg/mL, net price 20 × 2.5 mL (2.5 mg) = £1.91; 2 mL/mL, 20 × 2.5 mL (5 mg) = £3.82. May be diluted with sterile sodium chloride 0.9%.
  - **Nebuliser solution**, salbutamol (as sulphate) 1 mg/mL, net price 20 × 2.5 mL (2.5 mg) = £1.91; 2 mL/mL, 20 × 2.5 mL (5 mg) = £3.82. May be diluted with sterile sodium chloride 0.9%
  - **Nebuliser solution**, salbutamol (as sulphate) 1 mg/mL, net price 20 × 2.5 mL (2.5 mg) = £1.91; 2 mL/mL, 20 × 2.5 mL (5 mg) = £3.82. May be diluted with sterile sodium chloride 0.9%

- **Compound preparations**
  - For compound preparations containing salbutamol, see section 3.1.4

**Management of Chronic Asthma table**, see p. 172

**Management of Acute Asthma table**, see p. 173
tion; CHILD 5–12 years, 50 micrograms (2 puffs or 1 blister) twice daily
Chronic obstructive pulmonary disease 50 micrograms (2 puffs or 1 blister) twice daily

Counselling Advise patients that salmeterol should not be used for relief of acute attacks, not to exceed prescribed dose, and to follow manufacturer’s directions; if a previously effective dose of inhaled salmeterol fails to provide adequate relief, a doctor’s advice should be obtained as soon as possible.

**Serevent** (A&H) / Turbohaler® (dry powder for inhalation), disk containing 60 blisters of salmeterol (as xinafoate) 50 micrograms/blister with **Accuhaler** device, net price = £29.26. Counselling, administration

**Evoluhaler® aerosol inhalation** ▼, salmeterol (as xinafoate) 25 micrograms/metered inhalation, net price 120-dose unit = £29.26. Counselling, administration

**Diskhaler®** (dry powder for inhalation), disks containing 4 blisters of salmeterol (as xinafoate) 50 micrograms/blister, net price 15 disks with **Diskhaler®** device = £35.79, 15-disk refill = £35.15. Counselling, administration

**Compound preparations**
For compound preparations containing salmeterol, see section 3.2

### TERBUTALINE SULPHATE

**Indications** asthma and other conditions associated with reversible airways obstruction; premature labour (section 7.1.3)

**Cautions** see notes above

**Pregnancy** see p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above

**Dose**
- **By mouth** (but use by inhalation preferred), initially 2.5 mg 3 times daily for 1–2 weeks, then up to 5 mg 3 times daily; CHILD 1 month–7 years 75 micrograms/kg 3 times daily; 7–15 years 2.5 mg 2–3 times daily
- **By subcutaneous or slow intravenous injection**, 250–500 micrograms up to 4 times daily; CHILD 2–15 years 10 micrograms/kg to a max. of 300 micrograms
- **By continuous intravenous infusion** as a solution containing 3–5 micrograms/mL, 90–300 micrograms/hour for 8–10 hours; CHILD 1 month–18 years, initially 2–4 micrograms/kg as a loading dose, then 1–10 micrograms/kg/hour according to response and heart rate (max. 300 micrograms/hour); high doses with close monitoring
- **By inhalation of powder** (Turbohaler®). ADULT and CHILD over 5 years, 500 micrograms (1 inhalation); for persistent symptoms up to 4 times daily (but see Management of Chronic Asthma table, p. 172)
- **By inhalation of nebulised solution** (but see also Management of Acute Asthma table, p. 173), 5–10 mg 2–4 times daily; additional doses may be necessary in severe acute asthma; CHILD under 5 years 5 mg 2–4 times daily, 5–12 years 5–10 mg 2–4 times daily [unlicensed dose]

**Oral and parenteral**

**Bricanyl®** (AstraZeneca) / Turbohaler® (= dry powder inhaler), terbutaline sulphate 500 micrograms/metered inhalation, net price 100-dose unit = £6.92. Counselling, administration

**Respules®** (= single-dose units for nebulisation), terbutaline sulphate 2.5 mg/mL, net price 20 × 2-mL units (5-mg) = £4.04

### 3.1.2 Other adrenoceptor agonists

Ephedrine is less suitable and less safe for use as a bronchodilator than the selective beta, agonists, because it is more likely to cause arrhythmias and other side-effects; it should be avoided whenever possible.

**Adrenaline (epinephrine) injection** (1 in 1000) is used in the emergency treatment of acute allergic and anaphylactic reactions (section 3.4.3), in angioedema (section 3.4.3), and in cardiopulmonary resuscitation (section 2.7.3). Adrenaline solution (1 in 1000) is used by nebulisation in the management of severe croup (section 3.1).

### EPHEDRINE HYDROCHLORIDE

**Indications** reversible airways obstruction, but see notes above

**Cautions** hyperthyroidism; diabetes mellitus; ischaemic heart disease; hypertension; elderly; prostatic hypertrophy (risk of acute retention); interactions: Appendix 1 (sympathomimetics)

**Renal impairment** use with caution

**Pregnancy** manufacturer advises avoid

**Breast-feeding** present in milk; manufacturer advises avoid—irritability and disturbed sleep reported

**Side-effects** tachycardia; anxiety, restlessness, insomnia; tremor, arrhythmias, dry mouth, and cold extremities also reported

**Dose**
- 15–60 mg 3 times daily; CHILD up to 1 year 7.5 mg 3 times daily, 1–5 years 15 mg 3 times daily, 6–12 years 30 mg 3 times daily
- 1 Ephedrine Hydrochloride (Non-proprietary)

**Tablets**, ephedrine hydrochloride 15 mg, net price 28 = £6.62; 30 mg, 28 = £10.01

1. For exemptions see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)

### 3.1.2 Antimuscarinic bronchodilators

Ipratropium can provide short-term relief in chronic asthma, but short-acting beta, agonists act more quickly and are preferred. Ipratropium by nebulisation can be added to other standard treatment in life-threatening asthma or if acute asthma fails to improve with standard
therapy (see Management of Acute Asthma table, p. 175).

The aerosol inhalation of ipratropium can be used for short-term relief in mild chronic obstructive pulmonary disease in patients who are not using a long-acting antimuscarinic drug. Its maximal effect occurs 30–60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day.

**Tiotropium**, a long-acting antimuscarinic bronchodilator, is effective for the management of chronic obstructive pulmonary disease; it is not suitable for the relief of acute bronchospasm.

**Cautions** Antimuscarinic bronchodilators should be used with caution in patients with prostatic hyperplasia, bladder outflow obstruction, and those susceptible to angle-closure glaucoma (see below); **interactions**: Appendix 1 (antimuscarinics).

**Glaucma** Acute angle-closure glaucoma reported with nebulised ipratropium, particularly when given with nebulised salbutamol (and possibly other beta, agonists); care needed to protect patient’s eyes from nebulised drug or from drug powder.

**Side-effects** Dry mouth is the most common side-effect of antimuscarinic bronchodilators; also constipation, cough, paradoxical bronchospasm, headache, dizziness; less commonly nausea, tachycardia, palpitation, atrial fibrillation, urinary retention, angle-closure glaucoma, and blurred vision occur. Raised intra-ocular pressure has occurred rarely.

### IPRATROPIUM BROMIDE

**Indications** reversible airways obstruction, particularly in chronic obstructive pulmonary disease; rhinitis (section 12.2.2)

**Cautions** see notes above

**Pregnancy** see p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above; also vomiting, diarrhoea, local irritation; rarely laryngospasm, eye pain, mydriasis

**Dose**

- **By aerosol inhalation**, 20–40 micrograms, 3–4 times daily; **CHILD** up to 6 years 20 micrograms 3 times daily, 6–12 years 20–40 micrograms 3 times daily

- **By inhalation of powder**, ADULT and **CHILD** over 12 years, 40 micrograms 3–4 times daily (may be doubled in less responsive patients)

- **By inhalation of nebulised solution**, reversible airways obstruction in chronic obstructive pulmonary disease, 250–500 micrograms 3–4 times daily

  **Acute bronchospasm** (but see also Management of Acute Asthma table, p. 173), 500 micrograms repeated as necessary; **CHILD** under 5 years 125–250 micrograms, max. 1 mg daily; 6–12 years 250 micrograms, max. 1 mg daily

**Counselling** Advise patient not to exceed prescribed dose and to follow manufacturer’s directions

**Ipratropium Bromide** (Non-proprietary name) (A&H)

- **Nebuliser solution**, ipratropium bromide 250 micrograms/mL, net price 20 × 1 mL (250-microgram) unit-dose vials = £4.14, 60 × 1 mL vials = £12.44; 20 × 2 mL vials = £4.87, 60 × 2 mL vials = £14.59. If dilution is necessary use only sterile sodium chloride 0.9%

### TIOTROPIUM

**Indications** maintenance treatment of chronic obstructive pulmonary disease

**Cautions** see notes above; also cardiac rhythm disorders (with Spiriva Respimat)

**Renal impairment** plasma-tiotropium concentration raised; use with caution if eGFR less than 50 mL/minute/1.73 m²

**Side-effects** see notes above; less commonly taste disturbance, stomatitis, gastro-oesophageal reflux disease, pharyngitis, dysphonia, dysphagia, dysuria, epistaxis, oropharyngeal candidiasis; rarely intestinal obstruction (including paralytic ileus), laryngitis, insomnia, urinary-tract infection, skin infection, sinusitis, dental caries, gingivitis, glossitis, skin ulcer; also reported dehydration, joint swelling, dry skin

**Dose**

- See under preparations below

**Spiriva** (Boehringer Ingelheim) (A&H)

- **Inhalation powder, hard capsule** (for use with HandiHaler® device, green, tiotropium (as tiotropium bromide monohydrate) 18 micrograms, net price 30-cap pack with HandiHaler® device = £34.87, 30-cap refill = £31.89. Counselling, administration

**Dose** by inhalation of powder, ADULT over 18 years, 18 micrograms once daily

**Respimat** (sul phate for inhalation) (A&H), tiotropium (as tiotropium bromide monohydrate) 2.5 micrograms/ metered inhalation, net price 60-dose unit = £36.27. Counselling, administration

**Dose** by inhalation, ADULT over 18 years, 5 micrograms (2 puffs) once daily

**Note** The Scottish Medicines Consortium has advised (November 2007) that Spiriva Respimat® is restricted for use in chronic obstructive pulmonary disease in patients who have poor manual dexterity and difficulty using the HandiHaler® device.
3.1.3 Theophylline

Theophylline is a xanthine used as a bronchodilator in asthma (see Management of Chronic Asthma table, p. 172) and stable chronic obstructive pulmonary disease, (see p. 171); it is not generally effective in exacerbations of chronic obstructive pulmonary disease. Theophylline may have an additive effect when used in conjunction with small doses of beta, agonists, the combination may increase the risk of side-effects, including hypokalaemia (see p. 176).

Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, viral infections, in the elderly, and by drugs that inhibit its metabolism. The plasma-theophylline concentration is decreased in smokers, by alcohol consumption, and by drugs that induce its metabolism. For interactions: see Appendix 1 (theophylline).

Differences in the half-life of theophylline are important because the toxic dose is close to the therapeutic dose. In most individuals, satisfactory bronchodilation is associated with a plasma-theophylline concentration of 10–20 mg/litre (see Note below), although a lower plasma-theophylline concentration may be effective. Adverse effects can occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.

Theophylline is given by injection as aminophylline, a mixture of theophylline with ethylenediamine, which is 20 times more soluble than theophylline alone. Aminophylline injection is needed rarely for severe acute asthma, see Management of Acute Asthma table, p. 173. It must be given by very slow intravenous injection (over at least 20 minutes); it is too irritant for intramuscular use. Measurement of plasma-theophylline concentration may be helpful, and is essential if aminophylline is to be given to patients who are already taking theophylline, because serious side-effects such as convulsions and arrhythmias can occasionally precede other symptoms of toxicity.

Caffeine is a xanthine derivative used as a respiratory stimulant in neonatal apnoea, see BNF for Children section 3.5.1.

**THEOPHYLLINE**

**Indications** reversible airways obstruction, severe acute asthma; see also Management of Chronic Asthma table p. 172 and Management of Acute Asthma table p. 173

**Cautions** see notes above, also cardiac disease; hypertension; hyperthyroidism; peptic ulcer; epilepsy; elderly; fever; hypokalaemia risk, see p. 176; avoid in acute porphyria (section 9.8.2); monitor plasma-theophylline concentration (see notes above); dose adjustment may be necessary if smoking started or stopped during treatment

**Hepatic impairment** reduce dose

**Pregnancy** neonatal irritability and apnoea have been reported; see also p. 170

**Breast-feeding** present in milk—irritability in infant reported; modified release preparations preparable; see also p. 170

**Side-effects** nausea, vomiting, gastric irritation, diarrhoea; palpitation, tachycardia, arrhythmias, hypotension; anxiety, dizziness, tremor, headache.

**AMINOPHYLLINE**

**Note** Aminophylline is a stable mixture or combination of theophylline and ethylenediamine; the ethylenediamine confers greater solubility in water

**Indications** reversible airways obstruction, severe acute asthma

**Cautions** see under Theophylline

**Hepatic impairment** see under Theophylline

**Pregnancy** see under Theophylline

**Breast-feeding** see under Theophylline

**Side-effects** see under Theophylline; also allergy to ethylenediamine can cause urticaria, erythema, and exfoliative dermatitis; hypotension, arrhythmias, and convulsions especially if given rapidly by intravenous injection

**Dose**

- See under preparations, below

*Note* Plasma-theophylline concentration for optimum response 10–20 mg/litre (55–110 micromol/litre); measure plasma-theophylline concentration 4–6 hours after dose by
mouth and at least 5 days after starting oral treatment; measure plasma-theophylline concentration 4–6 hours after the start of intravenous infusion; narrow margin between therapeutic and toxic dose, see also notes above

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal weight for height

Aminophylline (Non-proprietary)

**Injection**, aminophylline 25 mg/mL, net price 10-mL amp = £0.84

Dose severe acute asthma or acute exacerbation of chronic obstructive pulmonary disease in patients not previously treated with theophylline, by slow intravenous injection over at least 20 minutes (with close monitoring), 250–500 mg (5 mg/kg), then see below; **CHILD** under 12 years 5 mg/kg, then see below.

Severe acute asthma or acute exacerbation of chronic obstructive pulmonary disease by intravenous injection (with close monitoring) 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.

**Elderly** 300 micrograms/kg/hour, adjusted according to plasma-theophylline concentration.

**Note** Patients taking oral theophylline or aminophylline should not normally receive a loading dose of intravenous aminophylline; plasma-theophylline concentration should be measured in all patients receiving intravenous aminophylline (see note above).

**Modified release**

**Note** Advice about modified-release theophylline preparations (see p. 181) also applies to modified-release aminophylline preparations

Phyllocontin Continus® (Napp)

**Tablets**, m/r, yellow, f/c, aminophylline hydrate 225 mg, net price 56-tab pack = £2.39. Label: 25

Dose **ADULT** and **CHILD** body-weight over 40 kg initially 1 tablet twice daily; increased after 1 week to 2 tablets twice daily according to plasma-theophylline concentration.

**Forte tablets**, m/r, yellow, f/c, aminophylline hydrate 350 mg, net price 56-tab pack = £4.22. Label: 25

Dose initially 1 tablet twice daily; increased after 1 week to 2 tablets twice daily if necessary.

**Note** Phyllocontin Continus®. Forte tablets are for smokers and other patients with shorter theophylline half-life (see notes above).

3.1.4 Compound bronchodilator preparations

In general, patients are best treated with single-ingredient preparations, such as a selective beta 2 agonist (section 3.1.1) or ipratropium bromide (section 3.1.2), so that the dose of each drug can be adjusted. The flexibility is lost with compound bronchodilator preparations. However, a combination product may be appropriate for patients stabilised on individual components in the same proportion.

For prescribing information, see under individual drugs.

Ipratropium bromide with salbutamol (Non-proprietary)

**Nebuliser solution**, ipratropium bromide 500 micrograms, salbutamol (as sulphate) 2.5 mg/2.5-mL vial, net price 60 unit-dose vials = £23.75.

**Brands** include Salbutrol, Ipramon

Dose bronchospasm in chronic obstructive pulmonary disease, by inhalation of nebulised solution, **ADULT** and **CHILD** over 12 years, 1 vial (2.5 mL) 3–4 times daily.

**Glaucoma** In addition to other potential side-effects acute angle-closure glaucoma has been reported with nebulised ipratropium—

- **for details**, see p. 180

- **Combivent®** (Boehringer Ingelheim) (BNF) | **Nebuliser solution**, isotonlc, ipratropium bromide 500 micrograms, salbutamol (as sulphate) 2.5 mg/2.5-mL vial, net price 60 unit-dose vials = £24.10

Dose bronchospasm in chronic obstructive pulmonary disease, by inhalation of nebulised solution, **ADULT** and **CHILD** over 12 years, 1 vial (2.5 mL) 3–4 times daily.

**Glaucoma** In addition to other potential side-effects acute angle-closure glaucoma has been reported with nebulised ipratropium—

- **for details**, see p. 180

- **Duvovent®** (Boehringer Ingelheim) (BNF) | **Nebuliser solution**, isotonlc, fenoterol hydrobromide 1.25 mg, ipratropium bromide 500 micrograms/4-mL vial, net price 20 unit-dose vials = £8.00

Dose acute severe asthma or acute exacerbation of chronic asthma, by inhalation of nebulised solution, **ADULT** and **CHILD** over 14 years, 1 vial (4 mL), may be repeated up to max. 4 vials in 24 hours.

**Glaucoma** In addition to other potential side-effects acute angle-closure glaucoma has been reported with nebulised ipratropium—

- **for details**, see p. 180

3.1.5 Peak flow meters, inhaler devices and nebulisers

**Peak flow meters**

Measurement of peak flow is particularly helpful for patients who are ‘poor perceivers’ and hence slow to detect deterioration in their asthma, and for those with moderate or severe asthma.

Standard-range peak flow meters are suitable for both adults and children; low-range peak flow meters are appropriate for severely restricted airflow in adults and children. Patients must be given clear guidelines as to the action they should take if their peak flow falls below a certain level. Patients can be encouraged to adjust some of their own treatment (within specified limits) according to changes in peak flow rate.

**Standard Range Peak Flow Meter**


- **AirZone®**, range 60–720 litres/minute, net price = £4.50, replacement mouthpiece = 38p (Clement Clarke).
- **Medi®**, range 60–800 litres/minute, net price = £4.50 (Medicare).
- **MicroPeak®**, range 60–800 litres/minute, net price = £6.50, replacement mouthpiece = 38p (Micro Medical).
- **Mini-Wright**, range 60–800 litres/minute, net price = £6.86, replacement mouthpiece = 38p (Clement Clarke).
- **Personal Best®**, range 60–800 litres/minute, net price = £6.86, replacement mouthpiece = 25p (Respirisons).
- **Piko-1®**, range 15–999 litres/minute, net price = £9.50, replacement mouthpiece = 38p (nSPIRE Health).
- **Pinnacle®**, range 60–990 litres/minute, net price = £6.50 (Fyne Dynamics).
- **Pocketpeak®**, range 60–800 litres/minute, net price = £6.53, replacement mouthpiece = 38p (nSPIRE Health).
- **Vitalograph®**, range 50–800 litres/minute, net price = £4.75 (children’s coloured version also available), replacement mouthpiece = 40p (Vitalograph).

**Note** Readings from new peak flow meters are often lower than those obtained from old Wright-scale peak flow meters and the correct recording chart should be used.

**Low Range Peak Flow Meter**

Compliant to standard EN 23747:2007 except for scale range.

- **Medi®**, range 40–420 litres/minute, net price = £6.50 (Medicare).
Spacer devices are difficult to use. Patients, particularly the elderly and children, find them pressurised metered-dose inhaler effectively, but some dose inhalers. These include Spacer devices remove the need for pressurised metered-dose inhaler. Many patients can be taught to use a pressurised metered-dose inhaler effectively but some patients, particularly the elderly and children, find them difficult to use. Spacer devices (see below) can help such patients because they remove the need to coordinate actuation with inhalation. Dry powder inhalers may be useful in adults and children over 5 years who are unwilling or unable to use a pressurised metered-dose inhaler. Alternatively, breath-actuated inhalers are suitable for adults and older children provided they can use the device effectively.

On changing from a pressurised metered-dose inhaler to a dry powder inhaler, patients may notice a lack of sensation in the mouth and throat previously associated with each actuation. Coughing may also occur.

The patient should be instructed carefully on the use of the inhaler and it is important to check that the inhaler continues to be used correctly because inadequate inhalation technique may be mistaken for a lack of response to the drug.

NICE guidance

Inhaler devices for children with chronic asthma (children under 5 years, August 2000; children 5–15 years, March 2002)

A child's needs, ability to develop and maintain effective technique, and likelihood of good compliance should govern the choice of inhaler and spacer device; only then should cost be considered. For children aged under 5 years:

- corticosteroid and bronchodilator therapy should be delivered by pressurised metered-dose inhaler and spacer device, with a facemask if necessary;
- if this is not effective, and depending on the child’s condition, nebulised therapy may be considered and, in children over 3 years, a dry powder inhaler may also be considered (but see notes above).

For children aged 5–15 years:

- corticosteroid therapy should be routinely delivered by a pressurised metered-dose inhaler and spacer device;
- children and their carers should be trained in the use of the chosen device; suitability of the device should be reviewed at least annually. Inhaler technique and compliance should be monitored.

Spacers

Spacers

Spacers are used to improve the delivery of inhaled corticosteroids and bronchodilators by reducing the velocity of the aerosol and subsequent impact on the oropharynx and allowing more time for evaporation of the propellant so that a larger proportion of the particles can be inhaled and deposited in the lungs. Spacers are particularly useful for patients with poor inhalation technique, for children, for patients requiring high doses of inhaled corticosteroids (see Management of Chronic Asthma table, p. 172), for nocturnal asthma, and for patients prone to candidiasis with inhaled corticosteroids. The size of the spacer is important, the larger spacers with a one-way valve (Volumatic®) being most effective. It is important to prescribe a spacer device that is compatible with the metered-dose inhaler, see devices below. Spacers devices should not be regarded as interchangeable; patients should be advised not to switch between spacer devices.

Use and care of spacer devices

Patients should inhale from the spacer device as soon as possible after actuation because the drug aerosol is very short-lived; single-dose actuation is recommended. Tidal breathing is as effective as single breaths. The device should be cleaned once a month by washing in mild detergent and then allowed to dry in air without rinsing, the mouth-piece should be wiped clean of detergent before use. Some manufacturers recommend more frequent cleaning, but this should be avoided since any electrostatic charge may affect drug delivery. Spacer devices should be replaced every 6–12 months.

Able Spacer® (Clement Clarke)

Spacer device, small-volume device. For use with all pressurised (aerosol) inhalers, net price standard device = £4.20; with infant, child or adult mask = £6.86

AeroChamber® Plus (GSK)

Spacer device, medium-volume device. For use with all pressurised (aerosol) inhalers, net price standard device = £4.53, with mask (blue) = £7.56, infant device (orange) with mask = £7.56, child device (yellow) with mask = £7.56

Babyhaler® (A&H)®

Spacer device, for paediatric use with Flixotide®, and Ventoline® inhalers, net price = £11.34

Haleraid® (A&H)®

Inhalation aid, device to place over pressurised (aerosol) inhalers to aid when strength in hands is impaired (e.g. in arthritis). For use with Flixotide®, Seretide®, Serevent®, and Ventoline® inhalers. Available as Haleraid®-120 for 120-dose inhalers and Haleraid®-200 for 200-dose inhalers, net price = 80p

Nebuchamber® (AstraZeneca)

Spacer device, for use with Palmicort® aerosol inhalers, net price = £8.56

Optichamber® (Respironic)®

Spacer device, for use with all pressurised (aerosol) inhalers, net price = £4.28; with small, medium or large mask = £7.00

PARI Vortex Spacer® (Pari)

Spacer device, medium-volume device. For use with all pressurised (aerosol) inhalers, net price with mouthpiece = £8.07; with mask for infant or child = £7.91; with adult mask = £9.97

Pocket Chamber® (nSPIRE Health)

Spacer device, small-volume device. For use with all pressurised (aerosol) inhalers, net price = £4.18; with infant, small, medium, or large mask = £9.75

Volumatic® (A&H)®

Spacer inhaler, large-volume device. For use with Clem Modulite®, Flixotide®, Seretide®, Serevent®, and Ventoline® inhalers, net price = £2.81, with paediatric mask = £2.81
Respiratory system

In England and Wales nebulisers and compressors are not available on the NHS (but they are free of VAT); some nebulisers (but not compressors) are available on form GP10A in Scotland (for details consult Scottish Drug Tariff).

A nebuliser converts a solution of a drug into an aerosol for inhalation. It is used to deliver higher doses of drug to the airways than is usual with standard inhalers. The main indications for use of a nebuliser are to deliver:

- a beta, agonist or ipratropium to a patient with an acute exacerbation of asthma or of chronic obstructive pulmonary disease;
- a beta, agonist, corticosteroid, or ipratropium on a regular basis to a patient with severe asthma or reversible airways obstruction when the patient is unable to use other inhalational devices;
- an antibiotic (such as colistin) or a mucolytic to a patient with cystic fibrosis;
- budesonide or adrenaline to a child with severe croup;
- pentamidine for the prophylaxis and treatment of pneumocystis pneumonia.

The use of nebulisers in chronic persistent asthma and chronic obstructive pulmonary disease should be considered only:

- after a review of the diagnosis;
- after review of therapy (see Management of Chronic Asthma, p. 172 and Chronic Obstructive Pulmonary Disease, p. 171) and the patient’s ability to use hand-held devices;
- after increased doses of inhaled therapy from hand-held inhalers (with a spacer if necessary) have been tried for 2 weeks;
- if the patient remains breathless, despite correctly using optimal therapy.

Before prescribing a nebuliser, a home trial should preferably be undertaken to monitor response for up to 2 weeks on standard treatment and up to 2 weeks on nebulised treatment. If prescribed, patients must:

- have clear instructions from a doctor, specialist nurse or pharmacist on the use of the nebuliser (including maintenance and cleaning) and on peak-flow monitoring;
- be instructed not to treat acute attacks at home without also seeking help;
- have regular follow up by a doctor, specialist nurse or physiotherapist after about 1 month and annually thereafter.

The proportion of a nebuliser solution that reaches the lungs depends on the type of nebuliser and although it can be as high as 30%, it is more frequently close to 10% and sometimes below 10%. The remaining solution is left in the nebuliser as residual volume or is deposited in the mouthpiece and tubing. The extent to which the nebulised solution is deposited in the airways or alveoli depends on the droplet size, pattern of breath inhalation, and condition of the lung. Droplets with a mass median diameter of 1–5 microns are deposited in the airways and are therefore appropriate for asthma, whereas a particle size of 1–2 microns is needed for alveolar deposition of pentamidine to combat pneumocystis infection. The type of nebuliser is therefore chosen according to the deposition required and according to the viscosity of the solution (antibiotic solutions usually being more viscous).

Jet nebulisers are more widely used than ultrasonic nebulisers. Most jet nebulisers require an optimum gas flow rate of 6–8 litres/minute and in hospital can be driven by piped air or oxygen; in acute asthma the nebuliser should be driven by oxygen. Domiciliary oxygen cylinders do not provide an adequate flow rate therefore an electrical compressor is required for domiciliary use.

For patients at risk of hypercapnia, such as those with chronic obstructive pulmonary disease, oxygen can be dangerous and the nebuliser should be driven by air (see section 3.1). If oxygen is required, it should be given simultaneously by nasal cannula.

### Tubing

The Department of Health has reminded users of the need to use the correct grade of tubing when connecting a nebuliser to a medical gas supply or compressor.

Ultrasonic nebulisers produce an aerosol by ultrasonic vibration of the drug solution and therefore do not require a gas flow; they are not suitable for the nebulisation of some drugs, such as dornase alfa and nebulised suspensions.

### Nebuliser diluent

Nebulisation may be carried out using an undiluted nebuliser solution or it may require dilution beforehand. The usual diluent is sterile sodium chloride 0.9% (physiological saline).

<table>
<thead>
<tr>
<th>Sodium Chloride (Non-proprietary)</th>
<th>£/5 mL</th>
<th>£/25 mL</th>
<th>£/50 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride (Non-proprietary)</td>
<td>£/5 mL</td>
<td>£/25 mL</td>
<td>£/50 mL</td>
</tr>
</tbody>
</table>

Brands include Saline Steripoule®, Saline Steri-Neb®

### 3.2 Corticosteroids

Corticosteroids are used for the management of reversible and irreversible airways disease. An inhaled corticosteroid used for 3–4 weeks may help to distinguish asthma from chronic obstructive pulmonary disease; clear improvement over 3–4 weeks suggests asthma.

**Asthma** Corticosteroids are effective in asthma; they reduce airway inflammation (and hence reduce oedema and secretion of mucus into the airway).

An inhaled corticosteroid is used regularly for prophylaxis of asthma when patients require a beta, agonist more than twice a week; or if symptoms disturb sleep more than once a week, or if the patient has suffered exacerbations in the last 2 years requiring a systemic corticosteroid or a nebulised bronchodilator (see Management of Chronic Asthma table, p. 172). **Regular use** of inhaled corticosteroids reduces the risk of exacerbation of asthma.

Current and previous smoking reduces the effectiveness of inhaled corticosteroids and higher doses may be necessary.

Corticosteroid inhalers must be used regularly for maximum benefit; alleviation of symptoms usually occurs 3
to 7 days after initiation. Beclometasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate appear to be equally effective. Preparations that combine a corticosteroid with a long-acting beta2 agonist may be helpful for patients stabilised on the individual components in the same proportion.

In adults using an inhaled corticosteroid and a long-acting beta2 agonist, agonist for the prophylaxis of asthma, but who are poorly controlled, (see step 3 of the Management of Chronic Asthma table, p. 172). Symbicort® (budesonide with formoterol) can be used as a reliever (instead of a short-acting beta, agonist), in addition to its regular use for the prophylaxis of asthma. Symbicort® can also be used in this way in adults using an inhaled corticosteroid with a dose greater than beclometasone dipropionate 400 micrograms daily\(^1\), but who are poorly controlled (see step 2 of the Management of Chronic Asthma table, p. 172). When starting this treatment, the total regular daily dose of inhaled corticosteroid should not be reduced. Patients must be carefully instructed on the appropriate dose and management of exacerbations before initiating this therapy, see Symbicort® p. 188. Patients using budesonide with formoterol as a reliever once a day or more should have their treatment reviewed regularly. This management approach is also used by some specialists in children 12–18 years [unlicensed]. It has not been investigated with combination inhalers containing other corticosteroids and long-acting beta, agonists.

High doses of inhaled corticosteroid can be prescribed for patients who respond only partially to standard doses with a long-acting beta2 agonist, agonist or another long-acting bronchodilator (see Management of Chronic Asthma table, p. 172). High doses should be continued only if there is clear benefit over the lower dose. The recommended maximum dose of an inhaled corticosteroid should not generally be exceeded. However, if a higher dose is required, then it should be initiated and supervised by a specialist. The use of high doses of inhaled corticosteroid can minimise the requirement for an oral corticosteroid.

Systemic corticosteroid therapy may be necessary during episodes of stress, such as severe infection, or if the asthma is worsening, when higher doses are needed and access of inhaled drug to small airways may be reduced; patients may need a reserve supply of corticosteroid tablets.

**Chronic obstructive pulmonary disease** In chronic obstructive pulmonary disease inhaled corticosteroid therapy may reduce exacerbations when given in combination with an inhaled long-acting beta, agonist, see section 3.1. p. 171.

**Cautions of inhaled corticosteroids**

**Paradoxical bronchospasm** The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind—mild bronchospasm may be prevented by inhalation of a short-acting beta, agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).

**CFC-free inhalers** Chlorofluorocarbon (CFC) propellants in pressurised aerosol inhalers have been replaced by hydrofluoroalkanes (HFA) propellants.

Doses for corticosteroid CFC-free pressurised metered-dose inhalers may be different from traditional CFC-containing inhalers and may differ between brands, see MHRA/CHM advice below.

For **interactions**: see Appendix 1 (corticosteroids)

<table>
<thead>
<tr>
<th>MHRA/CHM advice (July 2008)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Qvar® and Clenil Modulite®) are interchangeable and should be prescribed by brand name; Qvar® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil Modulite®;</td>
</tr>
<tr>
<td>• Fostair® is a combination beclometasone dipropionate and formoterol fumarate CFC-free pressurised metered-dose inhaler; Fostair® has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.</td>
</tr>
</tbody>
</table>

**Side-effects of inhaled corticosteroids** Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids (section 6.3.2), but adverse effects have been reported.

High doses of inhaled corticosteroids (see Management of Chronic Asthma table, p. 172) used for prolonged periods can induce adrenal suppression. Inhaled corticosteroids have been associated with adrenal crisis and coma in children; excessive doses should be **avoided**. Patients using high doses of inhaled corticosteroids should be given a ‘steroid card’ (section 6.3.2) and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intermittent illness or an operation.

High doses of inhaled corticosteroids have been associated with lower respiratory tract infections, including pneumonia, in older patients with chronic obstructive pulmonary disease.

Bone mineral density may be reduced following long-term inhalation of higher doses of corticosteroids, predisposing patients to osteoporosis (section 6.6). It is therefore sensible to ensure that the dose of an inhaled corticosteroid is no higher than necessary to keep a patient’s asthma under good control.

In children, growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. However, the height of children receiving prolonged treatment of inhaled corticosteroid should be monitored; if growth is slowed, referral to a paediatrician should be considered. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 5 years (see NICE guidance, section 3.1.5); they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.

A small risk of glaucoma with prolonged high doses of inhaled corticosteroids has been reported; cataracts have also been reported with inhaled corticosteroids. Hoarseness and candidiasis of the mouth or throat have been reported, usually only with large doses (see also below). Hypersensitivity reactions (including rash and

---

1. For standard doses of other inhaled corticosteroids, see Management of Chronic Asthma table, p. 172.
Respiratory system

3.2 Corticosteroids

Pregnancy see p. 170
Breast-feeding see p. 170
Side-effects see notes above

Dose

- By aerosol inhalation, see Management of Chronic Asthma, p. 172 (important: for Clenil Modulite® and Qvar®, see under preparations)
- By inhalation of dry powder (important: for Asmabec® and Becodisks®, see under preparations), 200–400 micrograms twice daily; adjusted as necessary up to 800 micrograms twice daily; CHILD over 5 years 100–200 micrograms twice daily, adjusted as necessary

Beclometasone (Non-proprietary) (BNF 61)

Dry powder for inhalation, beclometasone dipropionate 100 micrograms/metered inhalation, net price 100-dose unit = £5.36; 200 micrograms/metered inhalation, 100-dose unit = £9.89, 200-dose unit = £14.93; 400 micrograms/metered inhalation, 100-dose unit = £19.61. Label: 8, counselling, administration; also 10 and steroid card with high doses

Brands include: Pulmicort® Beclometasone Dipropionate, Easyhaler® Beclometasone Dipropionate

Inhalation powder, hard capsule (for use with Cyclohaler® device), beclometasone dipropionate 100 micrograms, net price 120-cap pack = £15.99; 200 micrograms, 120-cap pack = £25.00; 400 micrograms, 120-cap pack = £32.25. Label: 8, counselling, administration; also 10 and steroid card with high doses

Brands include: Beclometasone Cyclohalers®

Asmabec Clickhaler® (UCB Pharma) (BNF 61)

Dry powder for inhalation, beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £6.42; 100 micrograms/metered inhalation, 200-dose unit = £9.43; 250 micrograms/metered inhalation, 100-dose unit = £11.83. Label: 8, counselling, administration; also 10 and steroid card with high doses

Dose by inhalation of powder; prophylaxis of asthma, 100–400 micrograms twice daily, adjusted as necessary; max. 4 mg twice daily; CHILD 6–12 years 50–200 micrograms twice daily, adjusted as necessary

Becodisks® (A&H) (BNF 61)

Dry powder for inhalation, disks containing 8 blisters of beclometasone dipropionate 100 micrograms/bister, net price 15 disks with Diskhaler® device = £11.30, 15-disk refill = £10.76; 200 micrograms/bister, 15 disks with Diskhaler® device = £21.54, 15-disk refill = £20.99; 400 micrograms/bister, 15 disks with Diskhaler® device = £42.52, 15-disk refill = £41.98. Label: 8, counselling, administration; also 10 and steroid card with high doses

Dose by inhalation of powder; prophylaxis of asthma, 400 micrograms twice daily; CHILD 5–12 years 100–200 micrograms twice daily; CHILD 5–12 years 100–200 micrograms twice daily, adjusted as necessary

Clenil Modulite® (Chiesi) (BNF 61)

Aerosol inhalation, beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £3.70; 100 micrograms/metered inhalation = £7.42; 200 micrograms/metered inhalation = £16.17; 250 micrograms/metered inhalation = £16.29.

Angioedema have been reported rarely. Other side-effects that have been reported very rarely include paradoxical bronchospasm, anxiety, depression, sleep disturbances, and behavioural changes including hyperactivity, irritability, and aggression (particularly in children); skin thinning and bruising have also been reported.

Candidiasis The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water (or cleaning a child’s teeth) after inhalation of a dose may also be helpful. Antifungal oral suspension or lozenges (section 12.3.2) can be used to treat oral candidiasis without discontinuing therapy.

Oral An acute attack of asthma should be treated with a short course of an oral corticosteroid starting with a high dose, see Management of Acute Asthma table, p. 173. Patients whose asthma has deteriorated rapidly usually respond quickly to corticosteroids. The dose can usually be stopped abruptly; tapering is not needed provided that the patient receives an inhaled corticosteroid in an adequate dose (apart from those on maintenance oral corticosteroid treatment or where oral corticosteroids are required for 3 or more weeks); see also Withdrawal of Corticosteroids, section 6.3.2. In patients who have needed several courses of oral corticosteroids and in whom the possibility of a period on maintenance corticosteroids is being considered, it may be useful to taper the corticosteroid dose gradually to identify a threshold dose for asthma control. This should only be done after other standard options for controlling asthma have been tried (see the Management of Chronic Asthma table, p. 172).

In chronic asthma, when the response to other drugs has been inadequate, longer term administration of an oral corticosteroid may be necessary; in such cases high doses of an inhaled corticosteroid should be continued to minimise oral corticosteroid requirements, see Management of Chronic Asthma, p. 172. Patients taking long-term oral corticosteroids for asthma can often be transferred to an inhaled corticosteroid but the transfer must be slow, with gradual reduction in the dose of the oral corticosteroid, and at a time when the asthma is well controlled.

During an acute exacerbation of chronic obstructive pulmonary disease, prednisolone 30 mg daily should be given for 7–14 days; treatment can be stopped abruptly. Prolonged treatment with oral prednisolone is of no benefit and maintenance treatment is not normally recommended.

An oral corticosteroid should normally be taken as a single dose in the morning to reduce the disturbance to sleep. An oral corticosteroid should normally be taken as a single dose in the morning to reduce the disturbance to sleep. Regular peak-flow measurements help to optimise the dose.

Parenteral For the use of hydrocortisone injection in the emergency treatment of acute severe asthma, see Management of Acute Asthma table, p. 173.

Beclometasone Dipropionate (Beclometasone Dipropionate)

Indications prophylaxis of asthma (see also Management of Chronic Asthma, p. 172)

Cautions see notes above

Aerosol inhalation, beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £3.70; 100 micrograms/metered inhalation = £7.42; 200 micrograms/metered inhalation = £16.17; 250 micrograms/metered inhalation = £16.29.
Label: 8, counselling, administration; also 10 and steroid card with high doses

**Dose by aerosol inhalation**, 200–400 micrograms twice daily, adjusted as necessary up to 1 mg twice daily; **CHILD** under 12 years 100–200 micrograms twice daily.

**Note** **Clenil Modulite** is not interchangeable with other CFC-free beclometasone dipropionate inhalers; the MHRA has advised (July 2008) that CFC-free beclometasone dipropionate inhalers should be prescribed by brand name, see p. 185

**Dental prescribing on NHS** **Clenil Modulite** 50 micrograms/metered inhalation may be prescribed

**Qvar** (TEVA UK) **BNF 61 3.2 Corticosteroids 187**

**Aerosol inhalation**, beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £8.86; 100 micrograms/metered inhalation, 200-dose unit = £17.71. Label: 8, counselling, administration; also 10 and a steroid card with high doses

**Autohaler** (breath-actuated aerosol inhalation), beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £7.87; 100 micrograms/metered inhalation, 200-dose unit = £17.21. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Easy-Breathe** (breath-actuated aerosol inhalation), beclometasone dipropionate 50 micrograms/metered inhalation, net price 200-dose unit = £7.74; 100 micrograms/metered inhalation, 200-dose unit = £16.95. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Dose by aerosol inhalation**, prophylaxis of asthma, **ADULT** and **CHILD** over 12 years, 50–200 micrograms twice daily, increased if necessary to max. 400 micrograms twice daily

**Important** When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially a 100 microgram metered dose of **Qvar** should be prescribed for:

- 200–250 micrograms of beclometasone dipropionate or budesonide
- 100 micrograms of fluticasone propionate

When switching a patient with poorly controlled asthma from another corticosteroid inhaler, initially a 100-microgram metered dose of **Qvar** should be prescribed for 100 micrograms of beclometasone dipropionate, budesonide, or fluticasone propionate; the dose of **Qvar** should be adjusted according to response.

**Note** **Qvar** is not interchangeable with other CFC-free beclometasone dipropionate inhalers; the MHRA has advised (July 2008) that beclometasone dipropionate CFC-free inhalers should be prescribed by brand name, p. 185

**Compound preparations**

For prescribing information on formoterol fumarate, see section 3.1.1.1

**Fostair** (Chiesi) **BNF 61 3.2 Corticosteroids 187**

**Aerosol inhalation**, beclometasone dipropionate 100 micrograms, formoterol fumarate 6 micrograms/metered inhalation, net price 120-dose unit = £29.32. Label: 8, counselling, administration, 10, steroid card with high doses

**Dose by aerosol inhalation**, asthma, **ADULT** over 18 years, 1–2 puffs twice daily; max. 4 puffs daily

When switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, **Fostair** 100/6 can be prescribed for patients already using beclometasone dipropionate 250 micrograms in another CFC-free inhaler; the dose of **Fostair** should be adjusted according to response.

**Note** The MHRA has advised (July 2008) that beclometasone dipropionate CFC-free inhalers should be prescribed by brand name, see p. 185

**BUDESONIDE**

**Indications** prophylaxis of asthma (see also Management of Chronic Asthma, p. 172); croup

**Cautions** see notes above

**Pregnancy** see p. 170

**Breast-feeding** see p. 170

**Side-effects** see notes above

**Dose**

- See preparations below

**Budesonide** (Non-proprietary) **BNF 61 3.2 Corticosteroids 187**

**Dry powder for inhalation**, budesonide 100 micrograms/metered inhalation, net price 200-dose unit = £8.86; 200 micrograms/metered inhalation, 200-dose unit = £17.71. 400 micrograms/metered inhalation, 100-dose unit = £17.71. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Brands include** Budesonide Cyclohaler®

**Dose by inhalation of powder, ADULT and **CHILD** over 12 years, 100–400 micrograms twice daily, adjusted as necessary; alternatively, in mild to moderate asthma, for patients previously stabilised on a twice daily dose, 200–400 micrograms as a single dose in the evening.

**Inhalation powder, hard capsule** (for use with Cyclohaler® device), budesonide 200 micrograms, net price 100-cap pack = £15.48; 400 micrograms, 50-cap pack = £15.48. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Brands include** Budesonide Novolizer®

**Budelin Novolizer** (Meda) **BNF 61 3.2 Corticosteroids 187**

**Dry powder for inhalation**, budesonide 200 micrograms, net price refillable inhaler device and 100-dose cartridge = £14.86; 100-dose refill cartridge = £9.59. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Dose by inhalation of powder, ADULT and **CHILD** over 12 years, 200–400 micrograms twice daily, adjusted as necessary; alternatively, in mild to moderate asthma, for patients previously stabilised on a twice daily dose, 200–400 micrograms as a single dose in the evening.

**CHILD** 6–12 years 100–400 micrograms twice daily, adjusted as necessary; alternatively, in mild to moderate asthma, for patients previously stabilised on a twice daily dose, 200–400 micrograms as a single dose in the evening.

**Pulmicort** (AstraZeneca) **BNF 61 3.2 Corticosteroids 187**

**Aerosol inhalation**, budesonide 100 micrograms/metered inhalation, net price 120-dose unit = £9.60; 200 micrograms/metered inhalation, 120-dose unit = £13.20. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Dose by aerosol inhalation**, **ADULT** and **CHILD** over 12 years, 100–400 micrograms twice daily, adjusted as necessary; max. 800 micrograms as a single dose in the evening; **CHILD** 6–12 years 200–400 micrograms twice daily, adjusted as necessary; alternatively, in mild to moderate asthma, for patients previously stabilised on a twice daily dose, 200–400 micrograms as a single dose in the evening.

**Turbohaler** (= dry powder inhaler), budesonide 100 micrograms/metered inhalation, net price 200-dose unit = £11.84; 400 micrograms/metered inhalation, 50-dose unit = £13.86. Label: 8, counselling, administration; also 10 and steroid card with high doses

**Dose by inhalation of powder, ADULT and **CHILD** over 12 years, 100–400 micrograms twice daily, adjusted as necessary; alternatively, in mild to moderate asthma, for patients previously stabilised on a twice daily dose, 200–400 micrograms as a single dose in the evening.

**Respules** (= single-dose units for nebulisation), budesonide 250 micrograms/mL, net price 20 × 2-mL
Respiratory system

Side-effects
see notes above

see p. 170

Pregnancy
see notes above

Cautions

Symbicort
188 3.2 Corticosteroids BNF 61

Symbicort 200/6 Turbohaler® (= dry powder inhaler), budesonide 200 micrograms, formoterol fumarate 6 micrograms/metered inhalation, net price 120-dose unit = £33.00. Label: 8, counselling, administration; also 10 and steroid card with high doses

Aerosol inhalation, ciclesonide 80 micrograms/metered inhalation, net price 120-dose unit = £32.83; 160 micrograms/metered inhalation, 60-dose unit = £19.31, 120-dose unit = £38.62. Label: 8, counselling, administration

Indications
prophylaxis of asthma (see also Management of Chronic Asthma table, p. 172)

Cautions
see notes above

Pregnancy
see p. 170

Breast-feeding
see p. 170

Side-effects
see notes above; also very rarely dyspepsia, hyperglycaemia, and arthralgia

Dose

See preparations below

FLUTICASONE PROPIONATE

Accuhaler® (dry powder for inhalation), disk containing 60 blisters of fluticasone propionate 50 micrograms/blister with Accuhaler® device, net price = £6.38; 100 micrograms/blister with Accuhaler® device = £8.93; 250 micrograms/blister with Accuhaler® device = £31.26; 500 micrograms/blister with Accuhaler® device = £36.14. Label: 8, counselling, administration; also label 10 and steroid card with high doses

Note Fluticortide® (A&H) is not indicated for children

Dose
by inhalation of powder, prophylaxis of asthma, ADULT and CHILD over 16 years, 100–500 micrograms twice daily; increased according to severity of asthma; max. 1 mg twice daily (doses above 500 micrograms twice daily initiated by a specialist); CHILD 5–16 years, 50–100 micrograms twice daily adjusted as necessary; max. 200 micrograms twice daily

Evohaler® aerosol inhalation, fluticasone propionate 50 micrograms/metered inhalation, net price 120-dose unit = £5.44; 125 micrograms/metered inhalation, 120-dose unit = £21.28; 250 micrograms/metered inhalation, 120-dose unit = £38.14. Label: 8, counselling, administration; also label 10 and steroid card with high doses

Note Fluticortide® Evohaler is not indicated for children

Dose
by aerosol inhalation, prophylaxis of asthma, ADULT and CHILD over 16 years, 100–500 micrograms twice daily; increased according to severity of asthma; max. 1 mg twice daily (doses above 500 micrograms twice daily initiated by a specialist); CHILD 5–16 years, 50–100 micrograms twice daily adjusted as necessary; max. 200 micrograms twice daily

Nebules® (= single-dose units for nebulisation), fluticasone propionate 250 micrograms/mL, net price 10 × 2-mL (500-microgram) unit = £9.34; 1 mg/mL, 10 × 2-mL (2-mg) unit = £37.35. May be diluted with sterile sodium chloride 0.9%. Label: 8, counselling, administration, 10, steroid card

Dose
by inhalation of nebulised suspension, prophylaxis of asthma, ADULT and CHILD over 16 years, 0.5–2 mg twice daily; CHILD 4–16 years, 1 mg twice daily

Note Not suitable for use in ultrasonic nebulisers

Compound preparations
For prescribing information on formoterol fumarate, see section 3.1.1.1

Symbicort® (AstraZeneca) Symbicort 100/6 Turbohaler® (= dry powder inhaler), budesonide 100 micrograms, formoterol fumarate 6 micrograms/metered inhalation, net price 120-dose unit = £33.00. Label: 8, counselling, administration

Dose
by inhalation of powder, asthma maintenance therapy, 1–2 puffs twice daily increased if necessary to max. 4 puffs twice daily, reduced to 1 puff once daily if control maintained. CHILD 6–12 years, 1–2 puffs twice daily reduced to 1 puff once daily if control maintained. 12–17 years, 1–2 puffs twice daily reduced to 1 puff once daily if control maintained

Asthma, maintenance and reliever therapy, (but see p. 185) 2 puffs daily in 1–2 divided doses; for relief of symptoms, 1 puff as needed up to max. 6 puffs at a time; max. 8 puffs daily; up to 12 puffs daily can be used for a limited time but medical assessment should be considered; CHILD 12–18 years, see BNF for Children

Symbicort 200/6 Turbohaler® (= dry powder inhaler), budesonide 200 micrograms, formoterol fumarate 6 micrograms/metered inhalation, net price 120-dose unit = £38.00. Label: 8, counselling, administration; also 10 and steroid card with high doses

Dose
by inhalation of powder, asthma maintenance therapy, 1–2 puffs twice daily increased if necessary to max. 4 puffs twice daily, reduced to 1 puff once daily if control maintained. CHILD 6–12 years, 1–2 puffs twice daily reduced to 1 puff once daily if control maintained

Asthma, maintenance and reliever therapy, (but see p. 185) 2 puffs daily in 1–2 divided doses, for relief of symptoms, 1 puff as needed up to max. 6 puffs at a time; max. 8 puffs daily; up to 12 puffs daily can be used for a limited time but medical assessment should be considered; CHILD 12–18 years, see BNF for Children

Symbicort 400/12 Turbohaler® (= dry powder inhaler), budesonide 400 micrograms, formoterol fumarate 12 micrograms/metered inhalation, net price 60-dose unit = £38.00. Label: 8, counselling, administration; also 10 and steroid card with high doses

Dose
by inhalation of powder, asthma maintenance therapy, 1 puff twice daily increased if necessary to max. 2 puffs twice daily, reduced to 1 puff once daily if control maintained. CHILD 6–12 years 1 puff twice daily reduced to 1 puff once daily if control maintained

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second <50% of predicted, 1 puff twice daily

Ciclesonide
Indications
prophylaxis of asthma

Cautions
see notes above

Pregnancy
see p. 170

Breast-feeding
see p. 170

Side-effects
see notes above

Dose

By aerosol inhalation, 160 micrograms daily as a single dose reduced to 80 micrograms daily if control maintained; dose may be increased to max. 320 micrograms twice daily if necessary in severe asthma [unlicensed]. CHILD 12–18 years, 160 micrograms daily as a single dose reduced to 80 micrograms daily if control maintained

Alvesco® (Nycomed) Aerosol inhalation, ciclesonide 80 micrograms/metered inhalation, net price 120-dose unit = £32.83; 160 micrograms/metered inhalation, 60-dose unit = £19.31, 120-dose unit = £38.62. Label: 8, counselling, administration

BNF 61

(500-microgram) unit = £20.02; 500 micrograms/mL, 20 × 2-mL (1-mg) unit = £30.30. May be diluted with sterile sodium chloride 0.9%. Label: 8, counselling, administration, 10, steroid card

Dose
prophylaxis of asthma, by inhalation of nebulised suspension, ADULT and CHILD over 12 years, 1–2 mg twice daily, reduced to 0.5–1 mg twice daily; CHILD 3 months–12 years, 0.5–1 mg twice daily, reduced to 250–500 micrograms twice daily

Croup, by inhalation of nebulised suspension, 2 mg as a single dose (or as two 1-mg doses separated by 30 minutes)

Note Not suitable for use in ultrasonic nebulisers

BNF 61

Accuhaler is not indicated for children

Dose
by inhalation of powder, prophylaxis of asthma, ADULT and CHILD over 16 years, 100–500 micrograms twice daily; increased according to severity of asthma; max. 1 mg twice daily (doses above 500 micrograms twice daily initiated by a specialist); CHILD 5–16 years, 50–100 micrograms twice daily adjusted as necessary; max. 200 micrograms twice daily
3.3 Cromoglicate and related therapy 189

3.3.1 Cromoglicate and related therapy

The mode of action of sodium cromoglicate and nedocromil is not completely understood. They may be of value in asthma with an allergic basis, but, in practice, it is difficult to predict who will benefit; they could probably be given for 4 to 6 weeks to assess response. Dose frequency is adjusted according to response but is usually 3 to 4 times a day initially; this may subsequently be reduced. Withdrawal of sodium cromoglicate or nedocromil should be done gradually over a period of one week—symptoms of asthma may recur.

In general, prophylaxis with sodium cromoglicate is less effective than prophylaxis with corticosteroid inhalations (see Management of Chronic Asthma, p. 172). There is evidence of efficacy of nedocromil in children aged 5–12 years. Sodium cromoglicate and nedocromil are of no value in the treatment of acute attacks of asthma.

Sodium cromoglicate can prevent exercise-induced asthma. However, exercise-induced asthma may reflect poor overall control and the patient should be reassessed.

Paradoxical bronchospasm If paradoxical bronchospasm occurs, a short-acting beta, agonist such as salbutamol or terbutaline (section 3.1.1.1) should be used to control symptoms; treatment with sodium cromoglicate or nedocromil should be discontinued.

Side-effects Side-effects associated with inhalation of sodium cromoglicate and nedocromil include throat irritation, cough, bronchospasm (including paradoxical bronchospasm—see above), and headache.

3.3.2 Leukotriene receptor antagonists

MOMETASONE FURFATE

Indications prophylaxis of asthma (see also Management of Chronic Asthma, p. 172)

Cautions see notes above

Pregnancy see p. 170

Breast-feeding see p. 170

Side-effects see notes above; also pharyngitis, headache; less commonly palpitation

Dose

- By inhalation of powder, 200–400 micrograms as a single dose in the evening or in 2 divided doses; dose increased to 400 micrograms twice daily if necessary; CHILD not recommended

Asmanex® (Schering-Plough) ▼ ▼ ▼ ▼

Twisthaler (= dry powder inhaler), mometasone furoate 200 micrograms/metered inhalation, net price 30-dose unit = £15.70, 60-dose unit = £23.54; 400 micrograms/metered inhalation, 30-dose unit = £21.78, 60-dose unit = £36.05. Label: 8, counselling, administration, 10, steroid card

Note The Scottish Medicines Consortium has advised (November 2003) that Asmanex® is restricted for use following failure of first-line inhaled corticosteroids
The leukotriene receptor antagonists, montelukast and zafirlukast, block the effects of cysteinyl leukotrienes in the airways. They are effective in asthma when used alone or with an inhaled corticosteroid (see Management of Chronic Asthma table, p. 172). Montelukast has not been shown to be more effective than a standard dose of inhaled corticosteroid, but the two drugs appear to have an additive effect. The leukotriene receptor antagonists may be of benefit in exercise-induced asthma and in those with concomitant rhinitis, but they are less effective in those with severe asthma who are also receiving high doses of other drugs.

Churg-Strauss syndrome has occurred very rarely in association with the use of leukotriene receptor antagonists; in many of the reported cases the reaction followed the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or peripheral neuropathy.

Pregnancy

There is limited evidence for the safe use of leukotriene receptor antagonists during pregnancy; however, they can be taken as normal in women who have shown a significant improvement in asthma not achievable with other drugs before becoming pregnant, see also p. 170.

**3.3.2 Leukotriene receptor antagonists**

**SODIUM CROMOGLICATE**

(Sodium Cromoglycate)

**Indications**
prophylaxis of asthma (see also Management of Chronic Asthma table, p. 172); food allergy (section 1.5.4); allergic conjunctivitis (section 11.4.2); allergic rhinitis (section 12.2.1)

**Cautions**
see notes above; also discontinue if eosinophilic pneumonia occurs

**Pregnancy**
see p. 170

**Breast-feeding**
see p. 170

**Side-effects**
see notes above; also rhinitis; very rarely eosinophilic pneumonia

**Dose**
- By aerosol inhalation, ADULT over 5 years, 10 mg (2 puffs) 4 times daily, increased if necessary to 6–8 times daily, or additional dose may also be taken before exercise; maintenance, 5 mg (1 puff) 4 times daily

**Intal® CFC-Free Inhaler** (Sanofi-Aventis)

Aerosol inhalation, sodium cromoglicate 5 mg/ metered inhalation, net price 112-dose unit = £14.84. Label: 8, counselling, administration

**NEDOCROMIL SODIUM**

**Indications**
prophylaxis of asthma (see also Management of Chronic Asthma table, p. 172)

**Cautions**
see notes above

**Pregnancy**
see p. 170

**Breast-feeding**
see p. 170

**Side-effects**
see notes above; also nausea, vomiting, dyspepsia, abdominal pain, pharyngitis; rarely taste disturbances

**Dose**
- By aerosol inhalation, ADULT and CHILD over 6 years 4 mg (2 puffs) 4 times daily when control achieved may be possible to reduce to twice daily

**Monoject CFC-Free Inhaler** (Sanofi-Aventis)

Aerosol inhalation, mint-flavoured, nedocromil sodium 2 mg/metered inhalation, net price 112-dose unit = £39.94. Label: 8, counselling, administration

**MONTELUKAST**

**Indications**
prophylaxis of asthma, see notes above and Management of Chronic Asthma table, p. 172; symptomatic relief of seasonal allergic rhinitis in patients with asthma

**Cautions**
interactions: Appendix 1 (leukotriene receptor antagonists)

**Pregnancy**
manufacturer advises avoid unless essential, see also notes above

**Breast-feeding**
manufacturer advises avoid unless essential

**Side-effects**
abdominal pain, thirst; hyperkinesia (in young children), headache; very rarely Churg-Strauss syndrome (see notes above); dry mouth, diarrhoea, dyspepsia, nausea, vomiting, hepatic disorders, palpititation, oedema, increased bleeding, epistaxis, hypersensitivity reactions (including anaphylaxis, angiooedema, and skin reactions), respiratory infections, depression, suicidal thoughts and behaviour, tremor, asthenia, dizziness, hallucinations, parasthesia, hypoaesthesia, sleep disturbances, sleepwalking, abnormal dreams, agitation, anxiety, aggression, seizures, pyrexia, arthralgia, and myalgia, also reported

**Dose**
- Prophylaxis of asthma, ADULT and CHILD over 15 years, 10 mg once daily in the evening; CHILD 6 months–6 years 4 mg once daily in the evening, 6–15 years 5 mg once daily in the evening
- Seasonal allergic rhinitis, ADULT and CHILD over 15 years, 10 mg once daily in the evening

**SINGULAR® (MSD)**

**Chewable tablets**
pink, cherry-flavoured, montelukast (as sodium salt) 4 mg, net price 28-tab pack = £25.69; 5 mg, 28-tab pack = £25.69. Label: 23, 24

**Exipients**
include aspartame equivalent to phenylalanine 674 micrograms/4-mg tablet and 842 micrograms/5-mg tablet (section 9.4.1)

**Granules**
montelukast (as sodium salt) 4 mg, net price 28-sachet pack = £25.69. Counselling, administration

**Counselling**
Granules may be swallowed or mixed with cold food (but not fluid) and taken immediately

**Tablets**
beige, f/c, montelukast (as sodium salt) 10 mg, net price 28-tab pack = £26.97

**Note**
The Scottish Medicines Consortium has advised (June 2007) that Singular® chewable tablets and granules are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2–14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; Singular® chewable tablets and granules should be initiated by a specialist in paediatric asthma.
3.3.3 Phosphodiesterase type-4 inhibitors

Rofumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties; it is licensed as an adjunct to bronchodilators for the maintenance treatment of patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations.

**ROFLUMILAST**

**Indications** see notes above

**Contra-indications** severe immunological disease; severe acute infectious disease; cancer (except basal cell carcinoma); concomitant treatment with immunosuppressive drugs (except short-term systemic corticosteroids)

**Hepatic impairment** caution in mild impairment; avoid in moderate to severe impairment

**Pregnancy** manufacturer advises avoid—presence in milk and antidepressants, headache, insomnia.

**Breast-feeding** manufacturer advises avoid—presence in milk and antidepressants, headache, insomnia.

**Side-effects** gastrointestinal disturbances, respiratory infections, headache, insomnia; rarely bleeding disorders, hypersensitivity reactions including angioedema and skin reactions, arthralgia, myalgia, hepatitis, hyperbilirubinaemia, thrombocytopenia; very rarely Churg-Strauss syndrome (see notes above), agranulocytosis

**Dose**
- **ADULT** over 18 years, 500 micrograms once daily
- **CHILD** over 12 years, 20 mg twice daily

**Accolate** (AstraZeneca) Tablets, f/c, roflumilast 20 mg, net price 56-tab pack = £17.75. Label: 23

**Counselling** Patients should be given a patient card before starting treatment and advised to record body-weight at regular intervals.
antihistamines because they penetrate the blood brain barrier only to a slight extent.

Cautions and contra-indications Sedating antihistamines have significant antimuscarinic activity and they should therefore be used with caution in prostatic hyper trophy, urinary retention, susceptibility to angle-closure glaucoma, and pyloroduodenal obstruction. Caution may be required in epilepsy. Children and the elderly are more susceptible to side-effects. Many antihistamines should be avoided in acute porphyria but some are thought to be safe, see section 9.6.2. Interactions: Appendix 1 (antihistamines).

Hepatic impairment Sedating antihistamines should be avoided in severe liver disease—increased risk of coma.

Pregnancy Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity except for hydroxyzine where toxicity has been reported with high doses in animal studies. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitation, and tremor.

Breast-feeding Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

Side-effects Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines (see also notes above). Side-effects that are more common with the older antihistamines include headache, psychomotor impairment, and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastro-intestinal disturbances. Other rare side-effects of antihistamines include hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasam, angioedema, and anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, and angle-closure glaucoma.

Non-sedating antihistamines

Driving Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. driving); excess alcohol should be avoided.

ACRIVASTINE

Indications symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

Cautions see notes above

Contra-indications see notes above; also hypersensitivity to triprolidine; elderly

Renal impairment avoid in severe impairment

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

• ADULT and CHILD over 12 years, 8 mg 3 times daily

Acrivastine (Non-proprietary)

Capsules, acrivastine 8 mg, net price 12-cap pack = £2.59, 24-cap pack = £4.49. Counselling, driving

Brands include Benadryl® Allergy Relief

CETIRIZINE HYDROCHLORIDE

Indications symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

Cautions see notes above

Contra-indications see notes above

Renal impairment use half normal dose if eGFR 30–50 mL/minute/1.73 m²; use half normal dose and reduce dose frequency to alternate days if eGFR 10–30 mL/minute/1.73 m²; avoid if eGFR less than 10 mL/minute/1.73 m²

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

• ADULT and CHILD over 12 years, 10 mg once daily; CHILD 1–2 years see BNF for Children, 2–6 years 2.5 mg twice daily, 6–12 years 5 mg twice daily

Cetirizine (Non-proprietary)

Tablets, cetirizine hydrochloride 10 mg, net price 30-tab pack = 95p. Counselling, driving

Dental prescribing on NHS Cetirizine 10 mg tablets may be prescribed

Oral solution, cetirizine hydrochloride 5 mg/5 mL, net price 200 mL = £2.03. Counselling, driving

Note Sugar-free versions are available and can be ordered by specifying sugar-free on the prescription

Excipients may include propylene glycol (see Excipients, p. 2)

DESLORATADINE

Note Desloratadine is a metabolite of loratadine

Indications symptomatic relief of allergic rhinitis and urticaria

Cautions see notes above

Contra-indications see notes above; also hypersensitivity to loratadine

Renal impairment use with caution in severe impairment

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; rarely myalgia; very rarely hallucinations

Dose

• 5 mg once daily; CHILD 1–6 years 1.25 mg once daily, 6–12 years 2.5 mg once daily

Neoclaritin® (Schering-Plough) (c)

Tablets, blue, f/c, desloratadine 5 mg, net price 30-tab pack = £6.77. Counselling, driving

Oral solution, desloratadine 2.5 mg/5 mL, net price 100 mL (bubblegum-flavour) = £6.77, 150 mL = £10.15. Counselling, driving

Excipients include propylene glycol (see Excipients, p. 2)

FEXOFENADINE HYDROCHLORIDE

Note Fexofenadine is a metabolite of terfenadine

Indications see under Dose

Cautions see notes above

Contra-indications see notes above
### MIZOLASTINE

**Indications**  
Symptomatic relief of allergy such as hay fever, urticaria

**Cautions**  
See notes above

**Contra-Indications**  
See notes above; also susceptibility to QT-interval prolongation (including cardiac disease and hypokalaemia); elderly

**Hepatic impairment**  
Manufacturer advises avoid—no information available

**Pregnancy**  
See notes above

**Breast-feeding**  
See notes above

**Side-effects**  
See notes above; weight gain; anxiety, asthenia; less commonly arthralgia and myalgia

**Dose**  
- **ADULT** and **CHILD** over 12 years, 10 mg once daily

### RUPATADINE

**Indications**  
Symptomatic relief of allergic rhinitis, chronic idiopathic urticaria

**Cautions**  
See notes above; also susceptibility to QT-interval prolongation (including cardiac disease and hypokalaemia); elderly

**Hepatic impairment**  
Manufacturer advises avoid in significant impairment

**Pregnancy**  
See notes above

**Breast-feeding**  
See notes above

**Side-effects**  
See notes above; also susceptibility to QT-interval prolongation (including cardiac disease and hypokalaemia)

**Dose**  
- **ADULT** and **CHILD** over 12 years, 10 mg once daily

### Sedating antihistamines

**Driving**  
Drowsiness may affect performance of skilled tasks (e.g. driving); sedating effects enhanced by alcohol.

### ALIMEMAZINE TARTRATE

**Indications**  
Urticaria and pruritus, premedication

**Cautions**  
See notes above; see also section 4.2.1

**Contra-Indications**  
See notes above; see also section 4.2.1

**Hepatic impairment**  
See notes above

**Renal impairment**  
Avoid

**Pregnancy**  
See notes above

**Breast-feeding**  
See notes above

**Side-effects**  
See notes above; see also section 4.2.1

**Dose**  
- Urticaria and pruritus, 10 mg 2–3 times daily, in severe cases up to max. 100 mg daily has been used; **ELDERLY** 10 mg 1–2 times daily; **CHILD** under 2 years, see
3.4.1 Antihistamines

**CHLORPHENAMINE MALEATE**
(Chlorpheniramine maleate)

**Indications**  symptomatic relief of allergy such as hay fever, urticaria; emergency treatment of anaphylactic reactions (section 3.4.3)

**Cautions**  see notes above

**Contra-indications**  see notes above

**Pregnancy**  see notes above

**Hepatic impairment**  reduce daily dose by one-third;

**Contra-indications**  see notes above

**Cautions**  see notes above

**Indications**  symptomatic relief of allergy such as hay fever

**Breast-feeding**  see notes above

**Side-effects**  see notes above

**Dose**  
• By mouth, 4 mg every 4–6 hours, max. 24 mg daily (ELDERLY max. 12 mg daily); CHILD under 1 year see **BNF for Children**, 1–2 years 1 mg twice daily; 2–6 years 1 mg every 4–6 hours, max. 6 mg daily; 6–12 years 2 mg every 2–4 hours, max. 12 mg daily.

• By intramuscular injection or by intravenous injection over 1 minute, 10 mg, repeated if required up to max. 4 doses in 24 hours; CHILD under 6 months 250 micrograms/kg (max. 2.5 mg); 6 months–6 years 2.5 mg; 6–12 years 5 mg; these doses may be repeated if required up to max. 4 doses in 24 hours.

**Chlorphenamine**  (Non-proprietary)

**Tablets**, chlorphenamine maleate 4 mg, net price 28-tab pack = £4.28. Label: 2

**Syrup**, alimemazine tartrate 10 mg, net price 100 mL = £6.83; 30 mg/5 mL, 100 mL = £7.55. Label: 2

**CYPROHEPTADINE HYDROCHLORIDE**

**Indications**  symptomatic relief of allergy such as hay fever, urticaria

**Cautions**  see notes above

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Pregnancy**  see notes above

**Renal impairment**  reduce daily dose by half

**Contra-indications**  see notes above

**Cautions**  see notes above

**Indications**  pruritus

**Breast-feeding**  manufacturer advises avoid; see also notes above

**Side-effects**  see notes above

**Dose**  
• Pruritus, initially 25 mg at night increased if necessary to 25 mg 3–4 times daily; CHILD 1–6 years initially 5–15 mg at night increased if necessary to 50 mg daily in 3–4 divided doses; 6–12 years initially 15–25 mg at night increased if necessary to 50–100 mg daily in 2–4 divided doses; CHILD under 1 year see **BNF for Children**.

**Piriton**  (GSK Consumer Healthcare)

**Tablets**, yellow, scored, chlorphenamine maleate 4 mg, net price 25-tab pack = £1.22. Label: 2

**Oral solution**, chlorphenamine maleate 2 mg/5 mL, net price 150 mL = £2.51. Label: 2

1. **Note**  In the United Kingdom, a prescription is required for this medicine.

2. **Label**  2

3. **Price**  2

**Tavegil**  (Novartis Consumer Health)

**Tablets**, scored, clemastine (as hydrogen fumarate) 1 mg. Net price 60-tab pack = £2.35. Label: 2

**HYDROXYZINE HYDROCHLORIDE**

**Indications**  pruritus

**Cautions**  see notes above; also susceptibility to QT-interval prolongation

**Contra-indications**  see notes above

**Hepatic impairment**  reduce daily dose by one-third;

**Renal impairment**  reduce daily dose by half

**Pregnancy**  toxicity in animal studies with high doses; see also notes above

**Breast-feeding**  manufacturer advises avoid; see also notes above

**Side-effects**  see notes above

**Dose**  
• Allergy, usual dose 4 mg 3–4 times daily; usual range 4–20 mg daily, max. 32 mg daily; INFANT under 2 years not recommended, CHILD 2–6 years 2 mg 2–3 times daily, max. 12 mg daily; 7–14 years 4 mg 2–3 times daily, max. 16 mg daily.

**Periactin**  (MSD)

**Tablets**, scored, cyproheptadine hydrochloride 4 mg, net price 30-tab pack = 86p. Label: 2

**Atarax**  (Alliance)

**Tablets**, both f/c, hydroxyzine hydrochloride 10 mg (orange), net price 84-tab pack = £2.18; 25 mg (green), 28-tab pack = £1.17. Label: 2

**Ucerax**  (UCB Pharma)

**Tablets**, both f/c, scored, hydroxyzine hydrochloride 25 mg, net price 25-tab pack = £1.01. Label: 2

**Oral solution**, hydroxyzine hydrochloride 10 mg/5 mL, net price 200-mL pack = £1.78. Label: 2

**CLEMASTINE**

**Indications**  symptomatic relief of allergy such as hay fever, urticaria

**Cautions**  see notes above

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Pregnancy**  see notes above

**Breast-feeding**  see notes above

**Side-effects**  see notes above

**Dose**  
• 1 mg twice daily, increased up to 6 mg daily if required; INFANT under 1 year not recommended, CHILD 1–3 years 250–500 micrograms twice daily; 3–6 years 500 micrograms twice daily; 6–12 years 0.5–1 mg twice daily.
### 3.4.2 Allergen Immunotherapy

**Immunotherapy using allergen vaccines containing house dust mite, animal dander (cat or dog), or extracts of grass and tree pollen can reduce symptoms of asthma and allergic rhinoconjunctivitis. A vaccine containing extracts of wasp and bee venom is used to reduce the risk of severe anaphylaxis and systemic reactions in individuals with hypersensitivity to wasp and bee stings. An oral preparation of grass pollen extract (Grazax®) is also licensed for grass pollen-induced rhinitis and conjunctivitis.** Those requiring immunotherapy must be referred to a hospital specialist for accurate diagnosis, assessment, and treatment.

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- **seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;**
- **hypersensitivity to wasp and bee venom.**

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

### KETOTIFEN

**Indications** allergic rhinitis

**Cautions** see notes above

**Contra-indications**see notes above

**Hepatic impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also excitation, irritability, nervousness; less commonly cystitis; rarely weight gain; very rarely Stevens-Johnson syndrome

**Dose**

- **By mouth**
  - CHILD 0–1 year, 0.25 mg twice daily; 1–5 years, 0.5 mg twice daily; 5–10 years, 1 mg twice daily

- **By slow intravenous injection**
  - CHILD 3 years and over, 1 mg twice daily

- **By deep intramuscular injection**
  - CHILD 2–5 years, 5–10 years 6.25–12.5 mg

- **By subcutaneous injection**
  - CHILD 3 years and over, 50 mg

**Zaditen®** (Swedish Orphan)

- **Tablets,** scored, ketotifen (as hydrogen fumarate) 1 mg, net price 60-tab pack = £7.53. Label: 2, 21
- **Elixir,** ketotifen (as hydrogen fumarate), 1 mg/5 mL, net price 300 mL (strawberry-flavoured) = £8.91. Label: 2, 21

### PROMETHAZINE HYDROCHLORIDE

**Indications** symptomatic relief of allergy such as hay fever and urticaria; emergency treatment of anaphylactic reactions; sedation (section 4.1.1); nausea and vomiting (section 4.6)

**Cautions** see notes above; avoid extravasation with intravenous injection; severe coronary artery disease

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** use with caution

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also restlessness; intramuscular injection may be painful

**Dose**

- **By mouth**
  - CHILD 0–1 year, 0.5–1 mg at night; 1–5 years, 2 mg twice daily; initial treatment in readily sedated patients 0.5–1 mg at night; CHILD 3 years and over, 1 mg twice daily

- **By slow intravenous injection**
  - CHILD 3 years and over, 100 mg;
  - CHILD 2–5 years, 25–50 mg; max.
  - CHILD 5–10 years, 25 mg daily in 1–2 divided doses
  - CHILD 11 years and over, 5–10 mg daily in 1–2 divided doses

- **By deep intramuscular injection**
  - CHILD 5–10 years 6.25–12.5 mg

- **By slow intravenous injection in emergencies**
  - CHILD 5–10 years 25–50 mg as a solution containing 2.5 mg/mL in water for injections; max. 100 mg

**Promethazine** (Non-proprietary)

- **Tablets,** scored, promethazine hydrochloride 25 mg/mL, net price 1-mL amp = 68p, 2-mL amp = £1.20

#### Promethazine Hydrochloride Oral Solution 5 mg/5 mL

- **Tablets,** scored, promethazine hydrochloride 25 mg/mL, net price 56-tab pack = £2.85; 25 mg, 56-tab pack = £4.34. Label: 2

#### Promethazine Hydrochloride Oral Solution 10 mg, net price 56-tab pack = £7.53. Label: 2

**Phenergan®** (Sanofi-Aventis)

- **Tablets,** both blue, f/c, promethazine hydrochloride 10 mg, net price 56-tab pack = £2.85; 25 mg, 56-tab pack = £4.34. Label: 2

**Dental prescribing on NHS** May be prescribed as Promethazine Hydrochloride Tablets 10 mg or 25 mg

- **Elixir,** golden, promethazine hydrochloride 5 mg/5 mL, net price 100 mL = £2.67. Label: 2

**Dental prescribing on NHS** May be prescribed as Promethazine Hydrochloride Oral Solution 5 mg/5 mL

**Injection** (Swedish Orphan), promethazine hydrochloride 25 mg/mL, net price 1-mL amp = £1.20

- **Tablets,** scored, promethazine hydrochloride 25 mg/mL, net price 56-tab pack = £2.85; 25 mg, 56-tab pack = £4.34. Label: 2

- **Elixir,** golden, promethazine hydrochloride 5 mg/5 mL, net price 100 mL = £2.67. Label: 2

**Dental prescribing on NHS** May be prescribed as Promethazine Hydrochloride Oral Solution 5 mg/5 mL

**Injection** (Swedish Orphan), promethazine hydrochloride 25 mg/mL, net price 1-mL amp = £1.20

**Dental prescribing on NHS** May be prescribed as Promethazine Hydrochloride Oral Solution 5 mg/5 mL

**Injection** (Swedish Orphan), promethazine hydrochloride 25 mg/mL, net price 1-mL amp = £1.20

**Patients** undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

### BEE AND WASP ALLERGEN EXTRACTS

**Indications** hypersensitivity to wasp or bee venom (see notes above)

**Cautions** see notes above and consult product literature

**Contra-indications** see notes above and consult product literature

**Pregnancy** avoid

**Side-effects** consult product literature

**Dose**

- **By subcutaneous injection,** consult product literature
Respiratory system

beta2 agonist. Omalizumab should be initiated by high-dose inhaled corticosteroid together with a long-acting beta2 agonist in individuals with proven IgE-mediated sensitivity to inhaled allergens, whose severe persistent allergic asthma cannot be controlled adequately with high-dose inhaled corticosteroids and long-acting beta2 agonists in addition to leukotriene receptor antagonists, theophylline, oral corticosteroids, oral beta2 agonists, and smoking cessation where clinically appropriate. The following conditions apply:

- confirmation of IgE-mediated allergy to a perennial allergen by clinical history and allergy skin testing;
- either 2 or more severe exacerbations of asthma requiring hospital admission within the previous year, or 3 or more severe exacerbations of asthma within the previous year, at least one of which required hospital admission, and a further 2 which required treatment or monitoring in excess of the patient’s usual regimen, in an accident and emergency unit.

Omalizumab should be initiated and monitored by a physician experienced in both allergy and respiratory medicine in a specialist centre, and discontinued at 16 weeks in patients who have not shown an adequate response to therapy.

**GRASS AND TREE POLLEN EXTRACTS**

**Indications** treatment of seasonal allergic hay fever due to grass or tree pollen in patients who have failed to respond to anti-allergy drugs (see notes above)

**Cautions** see notes above and consult product literature

**Contra-indications** see notes above and consult product literature

**Pregnancy** avoid

**Side-effects** see notes above and consult product literature

**Dose**

- See under preparations below

**Pollinex® (Allergy)** (ALK-Abello)

Grasses and rye or tree pollen extract, net price initial treatment set (3 vials) and extension course treatment (1 vial) = £450.00

**Dose** By subcutaneous injection, consult product literature

**Grass pollen extract**

**Grazax® (ALK-Abello)** (ALK-Abello)

Oral lycophilisates (= freeze-dried tablets), grass pollen extract 75 000 units, net price 30-tab pack = £66.56. Counselling, administration

**Dose**

- ADULT over 5 years, 1 tablet daily; start treatment at least 4 months before start of pollen season and continue for up to 3 years

- CHILD over 5 years, 1 tablet daily; start treatment with omalizumab or sometimes more than 24 hours after the first injection.

- For details on the management of anaphylaxis, see section 3.4.3.1

The Scottish Medicines Consortium p. 4 has advised (September 2007 and March 2010) that omalizumab is accepted for restricted use within NHS Scotland as add-on therapy to improve asthma control in children (6 to 12 years), adolescents, and adults with severe persistent allergic asthma. Omalizumab is restricted to patients who are prescribed chronic systemic corticosteroids and in whom all other treatments have failed. The response should be assessed at 16 weeks and omalizumab treatment discontinued in patients who have not shown a marked improvement in overall asthma control.

**OMALIZUMAB**

Omalizumab is a monoclonal antibody that binds to immunoglobulin E (IgE). It is used as additional therapy in individuals with proven IgE-mediated sensitivity to inhaled allergens, whose severe persistent allergic asthma cannot be controlled adequately with high-dose inhaled corticosteroid together with a long-acting beta2 agonist, omalizumab should be initiated by physicians in specialist centres experienced in the treatment of severe persistent asthma.

Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy. Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.

For details on the management of anaphylaxis, see section 3.4.3.

The Scottish Medicines Consortium p. 4 has advised (September 2007 and March 2010) that omalizumab is accepted for restricted use within NHS Scotland as add-on therapy to improve asthma control in children (6 to 12 years), adolescents, and adults with severe persistent allergic asthma. Omalizumab is restricted to patients who are prescribed chronic systemic corticosteroids and in whom all other treatments have failed. The response should be assessed at 16 weeks and omalizumab treatment discontinued in patients who have not shown a marked improvement in overall asthma control.

**NICE guidance**

**Omalizumab for severe persistent allergic asthma (November 2007)**

Omalizumab is recommended as additional therapy for the prophylaxis of severe persistent allergic asthma in adults and children over 12 years, who cannot be controlled adequately with high-dose inhaled corticosteroids and long-acting beta2 agonists in addition to leukotriene receptor antagonists, theophylline, oral corticosteroids, oral beta2 agonists, and smoking cessation where clinically appropriate. The following conditions apply:

- confirmation of IgE-mediated allergy to a perennial allergen by clinical history and allergy skin testing;
- either 2 or more severe exacerbations of asthma requiring hospital admission within the previous year, or 3 or more severe exacerbations of asthma within the previous year, at least one of which required hospital admission, and a further 2 which required treatment or monitoring in excess of the patient’s usual regimen, in an accident and emergency unit.

Omalizumab should be initiated and monitored by a physician experienced in both allergy and respiratory medicine in a specialist centre, and discontinued at 16 weeks in patients who have not shown an adequate response to therapy.

**OMALIZUMAB**

**Indications** prophylaxis of allergic asthma (see notes above)

**Cautions** autoimmune disease; susceptibility to helminth infection—discontinue if infection does not respond to anthelmintic

**Hepatic impairment** manufacturer advises caution—no information available

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises avoid unless essential

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies
### Side-effects
- Headache; injection-site reactions; less commonly, nausea, diarrhoea, dyspepsia, flushing, fatigue, dizziness, drowsiness, paraesthesia, influenza-like symptoms, photosensitivity, hypersensitivity reactions (including hypotension, bronchospasm, laryngoedema, rash, pruritus, serum sickness, and anaphylaxis); Churg-Strauss syndrome (see notes above); thrombocytopenia, arthralgia, myalgia, and alopecia also reported.

### Dose
- By subcutaneous injection, **Adult** and **Child** over 6 years, according to immunoglobulin E concentration and body-weight, consult product literature.

<table>
<thead>
<tr>
<th>Xolair® (Novartis)</th>
<th>(BNF 61)</th>
<th>( \text{Epinephrine} ) (Epinephrine), below.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection, powder for reconstitution, omalizumab, net price 150-mg vial = £256.15 (with solvent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Excipients</strong> include sucrose 108 mg/vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3.4.3 Allergic emergencies

Anaphylaxis

Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by the rapid onset of respiratory and/or circulatory problems and is usually associated with skin and mucosal changes; prompt treatment is required. Patients with pre-existing asthma, especially poorly controlled asthma, are at particular risk of life-threatening reactions. Insect stings are a recognised risk (in particular wasp and bee stings). Latex and certain foods, including eggs, fish, cow’s milk protein, peanuts, sesame, shellfish, soy, and tree nuts may also precipitate anaphylaxis. Medicinal products particularly associated with anaphylaxis include blood products, vaccines, hyposensitising (allergen) preparations, antibacterials, aspirin and other NSAIDs, and neuromuscular blocking drugs. In the case of drugs, anaphylaxis is more likely after parenteral administration; resuscitation facilities must always be available for injections associated with special risk. Anaphylactic reactions may also be associated with *additives and excipients* in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergenic fats or oils.

Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by the rapid onset of respiratory and/or circulatory problems and is usually associated with skin and mucosal changes; prompt treatment is required. Patients with pre-existing asthma, especially poorly controlled asthma, are at particular risk of life-threatening reactions. Insect stings are a recognised risk (in particular wasp and bee stings). Latex and certain foods, including eggs, fish, cow’s milk protein, peanuts, sesame, shellfish, soy, and tree nuts may also precipitate anaphylaxis. Medicinal products particularly associated with anaphylaxis include blood products, vaccines, hyposensitising (allergen) preparations, antibacterials, aspirin and other NSAIDs, and neuromuscular blocking drugs. In the case of drugs, anaphylaxis is more likely after parenteral administration; resuscitation facilities must always be available for injections associated with special risk. Anaphylactic reactions may also be associated with *additives and excipients* in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergenic fats or oils.

### Intramuscular adrenaline (epinephrine)

The *intramuscular route* is the *first choice route* for the administration of adrenaline (epinephrine) in the management of anaphylaxis. Adrenaline is best given as an intramuscular injection into the anterolateral aspect of the middle third of the thigh; it has a rapid onset of action after intramuscular administration and in the shocked patient its absorption from the intramuscular site is faster and more reliable than from the subcutaneous site (the intravenous route should be reserved for extreme emergency when there is doubt about the adequacy of the circulation, see Intravenous Adrenaline (Epinephrine), below).

Patients with severe allergy should be instructed in the self-administration of adrenaline by intramuscular injec-
**Respiratory system**

**3.4.3 Allergic emergencies**

Prompt injection of adrenaline is of paramount importance. The following adrenaline doses are based on the revised recommendations of the Working Group of the Resuscitation Council (UK).

<table>
<thead>
<tr>
<th>Dose of intramuscular injection of adrenaline (epinephrine) for anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
</tr>
<tr>
<td>Child under 6 years</td>
</tr>
<tr>
<td>Child 6–12 years</td>
</tr>
<tr>
<td>Adult and child 12–18 years</td>
</tr>
</tbody>
</table>

These doses may be repeated several times if necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function.

### Intravenous adrenaline (epinephrine)

Intravenous adrenaline should be given only by those experienced in its use, in a setting where patients can be carefully monitored. When the patient is severely ill and there is real doubt about the adequacy of the circulation and absorption after intramuscular injection, adrenaline (epinephrine) can be given by slow intravenous injection in a dose of 50 micrograms (0.5 mL of the dilute 1 in 10 000 adrenaline injection) repeated according to response; if multiple doses are required, adrenaline should be given as a slow intravenous infusion stopping when a response has been obtained. Children may respond as little as 1 microgram/kg (0.01 mL/kg) of the dilute 1 in 10 000 adrenaline injection by slow intravenous injection.

Great vigilance is needed to ensure that the correct strength of adrenaline injection is used; anaphylactic shock kits need to make a very clear distinction between the 1 in 10 000 strength and the 1 in 1000 strength. It is also important that, where intramuscular injection might still succeed, time should not be wasted seeking intravenous access.

For reference to the use of the intravenous route for cardiac resuscitation, see section 2.7.3.

### Self-administration of adrenaline (epinephrine)

Individuals at considerable risk of anaphylaxis need to carry adrenaline (epinephrine) at all times and need to be instructed in advance when and how to inject it; injection technique is device specific. In addition, the packs need to be labelled so that in the case of rapid collapse someone else is able to administer the adrenaline. It is important to ensure that an adequate supply is provided to treat symptoms until medical assistance is available.

Adrenaline for administration by intramuscular injection is available in ‘auto-injectors’ (e.g. Anapen® and EpiPen®), pre-assembly syringes fitted with a needle suitable for very rapid administration (if necessary by a bystander or a healthcare provider if it is the only preparation available).

### Adrenaline/Epinephrine

**Indications** Emergency treatment of acute anaphylaxis; angioedema; cardiorespiratory resuscitation (section 2.7.3); priapism (unlicensed) (section 7.4.5)

**Cautions** For cautions in non-life-threatening situations, see section 2.7.3

**Interactions** Severe anaphylaxis in patients taking beta-blockers may not respond to adrenaline, calling for bronchodilator therapy; see intravenous salbutamol (p. 177); adrenaline can cause severe hypertension and bradycardia in those taking non-cardioselective beta-blockers. Other interactions, see Appendix 1 (sympathomimetics).

**Renal impairment** section 2.7.3

**Pregnancy** section 2.7.3

**Breast-feeding** section 2.7.3

**Side-effects** section 2.7.3

**Dose**

- Acute anaphylaxis, by intramuscular injection (preferably midpoint in anterolateral thigh) of 1 in 1000 (1 mg/mL) solution, see notes and table above
- Acute anaphylaxis when there is doubt as to the adequacy of the circulation, by slow intravenous injection of 1 in 10 000 (100 micrograms/mL) solution (extreme caution—specialist use only), see notes above

**Important** Intravenous route should be used with extreme care by specialists only, see notes above

#### Intramuscular or subcutaneous

1. Adrenaline/Epinephrine 1 in 10 000 (Non-proprietary)

   **Injection**, adrenaline (as acid tartrate) 1 mg/mL, net price 0.5-mL amp = 52p; 1-mL amp = 57p

2. Minijet® Adrenaline 1 in 10 000 (UCB Pharma)

   **Injection**, adrenaline (as hydrochloride) 1 in 1000 (1 mg/mL), net price 1 mL (with 25 gauge × 0.25 inch needle for subcutaneous injection) = £10.79, 1 mL (with 21 gauge × 1.5 inch needle for intramuscular injection) = £6.36 (both disposable syringes)

   **Excipients** include sodium chloride

#### Intravenous

- Extreme caution, see notes above

Adrenaline/Epinephrine 1 in 10 000, Dilute (Non-proprietary)

**Injection**, adrenaline (as acid tartrate) 100 micrograms/mL, 10-mL amp, 1-mL and 10-mL prefilled syringe

Minijet® Adrenaline 1 in 10 000 (UCB Pharma)

**Injection**, adrenaline (as hydrochloride) 1 in 10 000 (100 micrograms/mL), net price 3-mL prefilled syringe = £6.27; 10-mL prefilled syringe = £6.15

**Excipients** include sodium chloride

#### Intramuscular injection for self-administration

Anapen® (Lincoln Medical)

- **Anapen® 500** (delivering a single dose of adrenaline 500 micrograms), adrenaline 1.7 mg/mL, net price 1.05-mL auto-injector device = £30.67

**Excipients** include sulfites

**Note** 0.75 mL of the solution remains in the auto-injector device after use

**Dose** by intramuscular injection, ADULT and CHILD body-weight over 60 kg or those at risk of severe anaphylaxis, 500 micrograms repeated after 10–15 minutes as necessary

---

¹ For reference to the use of the intravenous route for anaphylaxis

² Note: 0.75 mL of the solution remains in the auto-injector device after use

---

1. Non-proprietary restriction does not apply to adrenaline injection 1 mg/mL where administration is for saving life in emergency
Angioedema

Angioedema is dangerous if laryngeal oedema is present. In this circumstance adrenaline (epinephrine) injection and oxygen should be given as described under Anaphylaxis (see p. 197); antihistamines and corticosteroids should also be given. Tracheal intubation may be necessary.

Hereditary angioedema  The administration of C1-esterase inhibitor, an endogenous complement blocker derived from human plasma, (in fresh frozen plasma or in partially purified form) can terminate acute attacks of hereditary angioedema, but is not practical for long-term prophylaxis; it can also be used for short-term prophylaxis before surgery or dental procedures [unlicensed indication]. Icatibant is licensed for the treatment of acute attacks of hereditary angioedema in adults with C1-esterase inhibitor deficiency.

Tranexamic acid (section 2.11) and danazol (section 6.7.2) [unlicensed indication] are used for short-term and long-term prophylaxis of hereditary angioedema. Short-term prophylaxis with tranexamic acid or danazol is started several days before planned procedures (e.g. dental work) and continued for 2–5 days afterwards. Danazol should be avoided in children because of its androgenic effects.

C1-ESTERASE INHIBITOR

Indications acute attacks of hereditary angioedema; prophylaxis prior to surgery or major dental procedures [unlicensed]

Cautions vaccination against hepatitis A, p. 754 and hepatitis B, p. 755 may be required

Pregnancy manufacturer advises avoid unless essential

Breast-feeding manufacturer advises use only if potential benefit outweighs risk—no information available

Side-effects rarely injection-site reactions, hypersensitivity reactions (including anaphylaxis)

Dose

- By slow intravenous injection or intravenous infusion, ADULT and CHILD 20 units/kg

Berinert® (CSL Behring) ▼

Injection, powder for reconstitution C1-esterase inhibitor, net price 500-unit vial = £550.00

Electrolytes Na⁺ 2.1 mmol/10mL vial

ICATIBANT

Indications acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency

Cautions ischaemic heart disease, stroke

Pregnancy manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies

Breast-feeding manufacturer advises avoid for 12 hours after administration

Side-effects dizziness, headache, injection-site reactions, rash, pruritus, erythema

Dose

- By subcutaneous injection, ADULT over 18 years, 30 mg as a single dose, repeated after 6 hours if necessary; a third dose may be given after a further 6 hours (max. 3 doses in 24 hours)

Firazyr® (Shire HGT) ▼

Injection, icatibant (as acetate) 10 mg/mL, net price 3-mL prefilled syringe = £1395.00

3.5 Respiratory stimulants and pulmonary surfactants

3.5.1 Respiratory stimulants

3.5.2 Pulmonary surfactants
Respiratory system

3.5.2 Pulmonary surfactants

Pulmonary surfactants are used in the management of respiratory distress syndrome (hyaline membrane disease) in neonates and preterm neonates. They may also be given prophylactically to those considered at risk of developing the syndrome.

Cautions Continuous monitoring is required to avoid hyperoxaemia caused by rapid improvement in arterial oxygen concentration.

Side-effects Pulmonary haemorrhage and bradycardia have been rarely associated with pulmonary surfactants; obstruction of the endotracheal tube by mucous secretions and intracranial haemorrhage have also been reported.

BERACTANT

Indications treatment of respiratory distress syndrome in preterm neonates over 700 g; prophylaxis of respiratory distress syndrome in preterm neonates less than 32 weeks post-menstrual age

Cautions see notes above and consult product literature

Side-effects see notes above

Dose

- By endotracheal tube, phospholipid 100 mg/kg, equivalent to a volume of 4 mL/kg, preferably within 8 hours of birth (preferably within 15 minutes of birth for prophylaxis); dose may be repeated within 48 hours at intervals of at least 6 hours for up to 4 doses

Survanta® (Abbott) Suspension, beractant (bovine lung extract) providing phospholipid 25 mg/mL, with lipids and proteins, net price 8-mL vial = £306.43

PORACTANT ALFA

Indications treatment of respiratory distress syndrome or hyaline membrane disease in neonates over 700 g; prophylaxis of respiratory distress syndrome in preterm neonates 24–32 weeks post-menstrual age

Cautions see notes above and consult product literature

Side-effects see notes above; also rarely hypotension

Dose

- By endotracheal tube, treatment, 100–200 mg/kg; further doses of 100 mg/kg may be repeated at intervals of 12 hours; max. total dose 300–400 mg/kg; prophylaxis, 100–200 mg/kg soon after birth (preferably within 15 minutes); further doses of 100 mg/kg may be repeated 6–12 hours later and after a further 12 hours if still intubated; max. total dose 300–400 mg/kg

Curosurf® (Chiesi) Suspension, poractant alfa (porcine lung phospholipid fraction) 80 mg/mL, net price 1.5-mL vial = £281.64; 3-mL vial = £547.40

DOXAPRAM HYDROCHLORIDE

Indications see under Dose

Cautions give with oxygen in severe irreversible airways obstruction or severely decreased lung compliance (because of increased work load of breathing); give with beta, agonist in bronchoconstriction; hypertension (avoid if severe), impaired cardiac reserve; phaeochromocytoma; interactions: Appendix 1 (doxapram)

Contra-indications severe hypertension; status asthmaticus; coronary artery disease; hyperthyroidism; epilepsy and other convulsive disorders; physical obstruction of respiratory tract; cerebral oedema, cerebrovascular accident

Hepatic impairment use with caution

Pregnancy no evidence of harm, but manufacturer advises avoid unless benefit outweighs risk

Side-effects nausea, vomiting; hypertension, tachycardia, bradycardia, extrasystoles, arrhythmias, chest pain, flushing; dyspnoea, cough, bronchospasm, laryngospasm; pyrexia, headache, dizziness, hyperactivity, confusion, hallucination, convulsions; urinary retention, incontinence, perineal warmth; muscle spasms

Dose

- Postoperative respiratory depression, by intravenous injection over at least 30 seconds, 1–1.5 mg/kg repeated if necessary after intervals of 1 hour or alternatively by intravenous infusion, 2–3 mg/minute adjusted according to response; CHILD not recommended

- Acute respiratory failure, by intravenous infusion, 1.5–4 mg/minute adjusted according to response (given concurrently with oxygen and whenever possible monitor with frequent measurement of blood gas tensions); CHILD not recommended

- Neonatal apnoea, see BNF for Children

Dopram® (Goldshield) Injection, doxapram hydrochloride 20 mg/mL. Net price 5-mL amp = £3.00

Intravenous infusion, doxapram hydrochloride 2 mg/mL in glucose 5%. Net price 500-mL bottle = £21.33

BNF 61

A reproducibility
Oxygen should be regarded as a drug. It is prescribed for hypoxaemic patients to increase alveolar oxygen tension and decrease the work of breathing. The concentration of oxygen required depends on the condition being treated; the administration of an inappropriate concentration of oxygen can have serious or even fatal consequences.

Oxygen is probably the most common drug used in medical emergencies. It should be prescribed initially to achieve a normal or near-normal oxygen saturation; in most acutely ill patients with a normal or low arterial carbon dioxide ($P_{CO2}$), oxygen saturation should be 94–98% oxygen saturation. However, in some clinical situations such as cardiac arrest and carbon monoxide poisoning (see also Emergency Treatment of Poisoning, p. 40) it is more appropriate to aim for the highest possible oxygen saturation until the patient is stable. A lower target of 88–92% oxygen saturation is indicated for patients at risk of hypercapnic respiratory failure, see below.

**High concentration oxygen therapy** is safe in uncomplicated cases of conditions such as pneumonia, pulmonary thromboembolism, pulmonary fibrosis, shock, severe trauma, sepsis, or anaphylaxis. In such conditions low arterial oxygen ($P_{O2}$) is usually associated with low or normal arterial carbon dioxide ($P_{CO2}$), and therefore there is little risk of hypoventilation and carbon dioxide retention.

In acute severe asthma, the arterial carbon dioxide ($P_{CO2}$) is usually subnormal but as asthma deteriorates it may rise steeply (particularly in children). These patients usually require high concentrations of oxygen and if the arterial carbon dioxide ($P_{CO2}$) remains high despite other treatment, intermittent positive-pressure ventilation needs to be considered urgently.

**Low concentration oxygen therapy** (controlled oxygen therapy) is reserved for patients at risk of hypercapnic respiratory failure, which is more likely in those with:

- chronic obstructive pulmonary disease;
- advanced cystic fibrosis;
- severe non-cystic fibrosis bronchiectasis;
- severe kyphoscoliosis or severe ankylosing spondylitis;
- severe lung scarring caused by tuberculosis;
- musculoskeletal disorders with respiratory weakness, especially if on home ventilation;
- an overdose of opioids, benzodiazepines, or other drugs causing respiratory depression.

Until blood gases can be measured, initial oxygen should be given using a controlled concentration of 28% or less, titrated towards a target oxygen saturation of 88–92%. The aim is to provide the patient with enough oxygen to achieve an acceptable arterial oxygen tension without worsening carbon dioxide retention and respiratory acidosis. Patients may carry an oxygen alert card, see section 3.1.

### Domiciliary oxygen

Oxygen should only be prescribed for use in the home after careful evaluation in hospital by respiratory experts. Patients should be advised of the risks of continuing to smoke when receiving oxygen therapy, including the risk of fire. Smoking cessation therapy (section 4.10.2) should be tried before home oxygen prescription.

**Air travel** Some patients with arterial hypoxaemia require supplementary oxygen for air travel. The patient’s requirement should be discussed with the airline before travel.

### Long-term oxygen therapy

**Long-term** administration of oxygen (usually at least 15 hours daily) prolongs survival in some patients with chronic obstructive pulmonary disease.

Assessment for long-term oxygen therapy requires measurement of arterial blood gas tensions. Measurements should be taken on 2 occasions at least 3 weeks apart to demonstrate clinical stability, and not sooner than 4 weeks after an acute exacerbation of the disease.

Long-term oxygen therapy should be considered for patients with:

- chronic obstructive pulmonary disease with $P_{O2} < 7.3$ kPa when breathing air during a period of clinical stability;
- chronic obstructive pulmonary disease with $P_{O2} 7.3–8$ kPa in the presence of secondary polycythaemia, nocturnal hypoxaemia, peripheral oedema, or evidence of pulmonary hypertension;
- severe chronic asthma with $P_{O2} < 7.3$ kPa or persistent disabling breathlessness;
- interstitial lung disease with $P_{O2} < 8$ kPa and in patients with $P_{O2} > 8$ kPa with disabling dyspnoea;
- cystic fibrosis when $P_{O2} < 7.3$ kPa or if $P_{O2} 7.3–8$ kPa in the presence of secondary polycythaemia, nocturnal hypoxaemia, pulmonary hypertension, or peripheral oedema;
- pulmonary hypertension, without parenchymal lung involvement when $P_{O2} < 8$ kPa;
- neuromuscular or skeletal disorders, after specialist assessment;
- obstructive sleep apnoea despite continuous positive airways pressure therapy, after specialist assessment;
- pulmonary malignancy or other terminal disease with disabling dyspnoea;
- heart failure with daytime $P_{O2} < 7.3$ kPa when breathing air or with nocturnal hypoxaemia;
- paediatric respiratory disease, after specialist assessment.

Increased respiratory depression is seldom a problem in patients with stable respiratory failure treated with low concentrations of oxygen although it may occur during exacerbations; patients and relatives should be warned to call for medical help if drowsiness or confusion occur.

### Short-burst oxygen therapy

Oxygen is occasionally prescribed for short-burst (intermittent) use for episodes of breathlessness not relieved by other treatment in patients with severe chronic obstructive pulmonary disease, interstitial lung disease, heart failure, and in palliative care. It is important, however, that the patient does not rely on oxygen instead of obtaining medical help or taking more specific treatment. Short-burst oxygen therapy can be used...
to improve exercise capacity and recovery; it should only be continued if there is proven improvement in breathlessness or exercise tolerance.

Ambulatory oxygen therapy
Ambulatory oxygen is prescribed for patients on long-term oxygen therapy who need to be away from home on a regular basis. Patients who are not on long-term oxygen therapy can be considered for ambulatory oxygen therapy if there is evidence of exercise-induced oxygen desaturation and of improvement in blood oxygen saturation and exercise capacity with oxygen. Ambulatory oxygen therapy is not recommended for patients with heart failure or those who smoke.

Oxygen therapy equipment
Under the NHS oxygen may be supplied as oxygen cylinders. Oxygen flow can be adjusted as the cylinders are equipped with an oxygen flow meter with ‘medium’ (2 litres/minute) and ‘high’ (4 litres/minute) settings.

Oxygen concentrators are more economical for patients who require oxygen for long periods, and in England and Wales can be ordered on the NHS on a regional tendering basis (see below). A concentrator is recommended for a patient who requires oxygen for more than 8 hours a day (or 21 cylinders per month). Exceptionally, if a higher concentration of oxygen is required the output of 2 oxygen concentrators can be combined using a ‘Y’ connection.

A nasal cannula is usually preferred for long-term oxygen therapy from an oxygen concentrator. It can, however, produce dermatitis and mucosal drying in sensitive individuals.

Giving oxygen by nasal cannula allows the patient to talk, eat, and drink, but the concentration of oxygen is not controlled; this may not be appropriate for acute respiratory failure. When oxygen is given through a nasal cannula at a rate of 1–2 litres/minute the inspiratory oxygen concentration is usually low, but it varies with ventilation and can be high if the patient is under-ventilating.

Arrangements for supplying oxygen
The following oxygen services may be ordered in England and Wales:
- emergency oxygen;
- short-burst (intermittent) oxygen therapy;
- long-term oxygen therapy;
- ambulatory oxygen.

The type of oxygen service (or combination of services) should be ordered on a Home Oxygen Order Form (HOOF); the amount of oxygen required (hours per day) and flow rate should be specified. The supplier will determine the appropriate equipment to be provided. Special needs or preferences should be specified on the HOOF.

The clinician should obtain the patient’s consent to pass on the patient’s details to the supplier and the fire brigade. The supplier will contact the patient to make arrangements for delivery, installation, and maintenance of the equipment. The supplier will also train the patient to use the equipment.

The clinician should send order forms to the supplier by facsimile (see below); a copy of the HOOF should be sent to the Primary Care Trust or Local Health Board. The supplier will continue to provide the service until a revised order is received, or until notified that the patient no longer requires the home oxygen service.

In Scotland refer the patient for assessment by a respiratory consultant. If the need for a concentrator is confirmed the consultant will arrange for the provision of a concentrator through the Common Services Agency. In Northern Ireland oxygen concentrators and cylinders should be prescribed on form HS21; oxygen concentrators are supplied by a local contractor. In Scotland and Northern Ireland prescriptions for oxygen cylinders and accessories can be dispensed by pharmacists contracted to provide domiciliary oxygen services.

3.7 Mucolytics
Mucolytics are prescribed to facilitate expectoration by reducing sputum viscosity. In some patients with chronic obstructive pulmonary disease and a chronic productive cough, mucolytics can reduce exacerbations; mucolytic therapy should be stopped if there is no benefit after a 4-week trial. Steam inhalation with postural drainage is effective in bronchiectasis and in some cases of chronic bronchitis.

Mucolytics should be used with caution in those with a history of peptic ulceration because they may disrupt the gastric mucosal barrier.

For reference to dornase alfa and hypertonic saline, see below.

CARBOCISTEINE

Indications reduction of sputum viscosity, see notes above
Cautions see notes above
Contra-indications active peptic ulceration
Pregnancy manufacturer advises avoid in first trimester
Breast-feeding no information available
### Side-effects
Rarely gastro-intestinal bleeding; hypersensitivity reactions (including rash and anaphylaxis) also reported.

**Dose**
- Initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves; **CHILD** 2–5 years 62.5–125 mg 4 times daily, 5–12 years 250 mg 3 times daily.

### Carbocisteine (Sanofi-Aventis)
**Capsules** carbocisteine 375 mg, net price 120-cap pack = £16.03. **Brands include** Mucodyne®.

**Oral liquid** carbocisteine 125 mg/5 mL, net price 300 mL = £4.39; 250 mg/5 mL, 300 mL = £5.61. **Brands include** Mucodyne® Poedathe 125 mg/5 mL (cherry- and raspberry-flavoured) and Mucodyne® 250 mg/5 mL (cinnamon- and rum-flavoured).

### ERDOSTEINE
**Indications** Symptomatic treatment of acute exacerbations of chronic bronchitis.

**Cautions** See notes above.

**Hepatic impairment** Manufacturer advises max. 300 mg daily in mild to moderate impairment; avoid in severe impairment.

**Renal impairment** Avoid if eGFR less than 25 mL/minute/1.73 m²—no information available.

**Pregnancy** Manufacturer advises avoid—no information available.

**Breast-feeding** Manufacturer advises avoid—no information available.

**Side-effects** Rarely nausea, vomiting, diarrhoea, abdominal pain, taste disturbance, headache, rash, and urticaria.

**Dose**
- **ADULT** over 18 years, 300 mg twice daily for up to 10 days.
- **Erdotin** (Galen) ▼ [Tel]
**Capsules** yellow/green, erdosteine 300 mg, net price 20-cap pack = £5.75.

**Note** The Scottish Medicines Consortium (October 2007) has advised that erdosteine (Erdotin®) is not recommended for the symptomatic treatment of acute exacerbations of chronic bronchitis.

### MECYSTEINE HYDROCHLORIDE
(Methyl Cysteine Hydrochloride)

**Indications** Reduction of sputum viscosity.

**Cautions** See notes above.

**Pregnancy** Manufacturer advises avoid.

**Breast-feeding** Manufacturer advises avoid.

**Dose**
- 200 mg 4 times daily for 2 days, then 200 mg 3 times daily for 6 weeks, then 200 mg twice daily; **CHILD** 5–12 years 100 mg 3 times daily.

**Viscain®** (Ranbaxy)
**Tablets** yellow, s/c, e/c, mecysteine hydrochloride 100 mg, net price 100 = £17.65. Label: 5, 22, 25.

### 3.8 Aromatic inhalations

**Dornase alfa**
Dornase alfa is a genetically engineered version of a naturally occurring human enzyme which cleaves extracellular deoxyribonucleic acid (DNA). It is used in cystic fibrosis and is administered by inhalation using a jet nebuliser (section 3.1.5).

**DORNASE ALFA**
Phosphorylated glycosylated recombinant human deoxyribonuclease 1 (rhDNase)

**Indications** Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted to improve pulmonary function.

**Pregnancy** No evidence of teratogenicity; manufacturer advises use only if potential benefit outweighs risk.

**Breast-feeding** Amount probably too small to be harmful—manufacturer advises caution.

**Side-effects** Rarely dyspepsia, chest pain, dysphonia, dyspnoea, pharyngitis, laryngitis, pyrexia, conjunctivitis, rhinitis, rash, urticaria.

**Dose**
- **ADULT and CHILD** over 5 years, by inhalation of nebulised solution (by jet nebuliser), 2500 units (2.5 mg) once daily (patients over 21 years may benefit from twice daily dosage).

** Pulmozyme® (Roche)** ▼ [Tel]
**Nebuliser solution** dornase alfa 1000 units (1 mg)/mL. Net price 2.5-mL (2500 units) vial = £16.55.

**Note** For use undiluted with jet nebulisers only; ultrasonic nebulisers are unsuitable.

### Hypertonic sodium chloride

Nebulised hypertonic sodium chloride solution (3–7%) is used to mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis). Temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment with hypertonic sodium chloride to reduce the risk of these adverse effects.

**MucoClear®** 6% (Pari)
**Nebuliser solution** sodium chloride 6%, net price 20 × 4 mL = £12.98, 60 × 4 mL = £27.00.

**Dose** By inhalation of nebulised solution, 4 mL twice daily.

**Nebusal®** 7% (Forest)
**Nebuliser solution** sodium chloride 7%, net price 60 × 4 mL = £27.00.

**Dose** By inhalation of nebulised solution, 4 mL up to twice daily.

### 3.8 Aromatic inhalations

Inhalations containing volatile substances such as eucalyptus oil are traditionally used and although the vapour may contain little of the additive it encourages deliberate inspiration of warm moist air which is often comforting in bronchitis; boiling water should not be
used owing to the risk of scalding. Inhalations are also used for the relief of nasal obstruction in acute rhinitis or sinusitis. Menthol and eucalyptus inhalation is used to relieve sinusitis affecting the maxillary antrum (section 12.2.2).

**Children** The use of strong aromatic decongestants (applied as rubs or to pillows) is not advised for infants under the age of 3 months. Carers of young infants in whom nasal obstruction with mucus is a problem can readily be taught appropriate techniques of suction aspiration but sodium chloride 0.9% given as nasal drops is preferred.

Benzoin Tincture, Compound, BP
(Friars’ Balsam)
Tincture, balsamic acids approx. 4.5%. Label: 15
Dose add one teaspoonful to a pint of hot, not boiling, water and inhale the vapour.

**Menthol and Eucalyptus Inhalation, BP 1980**
inhalation, racemethanol or levomethanol 2 g, eucalyptus oil 10 mL, light magnesium carbonate 7 g, water to 100 mL
Dose add one teaspoonful to a pint of hot, not boiling, water and inhale the vapour.

Dental prescribing on the NHS Menthol and Eucalyptus Inhalation BP, 1980 may be prescribed

MHRA/CHM advice (March 2008 and February 2009) Over-the-counter cough and cold medicines for children
Children under 6 years should not be given over-the-counter cough and cold medicines containing the following ingredients:
- brompheniramine, chlorphenamine, diphenhydramine, doxylamine, promethazine, or triprolidine (antihistamines);
- dextromethorphan or pholcodine (cough suppressants);
- guaifenesin or ipecacuana (expectorants);
- phenylephrine, pseudoephedrine, ephedrine, oxymetazoline, or xylometazoline (decongestants).

Over-the-counter cough and cold medicines can be considered for children aged 6–12 years after basic principles of best care have been tried, but treatment should be restricted to 5 days or less. Children should not be given more than 1 cough or cold preparation at a time because different brands may contain the same active ingredient; care should be taken to give the correct dose.

MHRA/CHM advice (October 2010) Over-the-counter codeine-containing liquid medicines for children
Children under 18 years should not use codeine-containing over-the-counter liquid medicines for cough suppression

**3.9 Cough preparations**

**3.9.1 Cough suppressants**

Cough may be a symptom of an underlying disorder, such as asthma (section 3.1.1), gastro-oesophageal reflux disease (section 1.1), or rhinitis (section 12.2.1), which should be addressed before prescribing cough suppressants. Cough may be a side-effect of another drug, such as an ACE inhibitor (section 2.5.5.1), or it can be associated with smoking or environmental pollutants. Cough can also have a significant habit component. When there is no identifiable cause, cough suppressants may be useful, for example if sleep is disturbed. They may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis.

**Codeine** may be effective but it is constipating and can cause dependence; **dextromethorphan** and **pholcodine** have fewer side-effects.

**Sedating antihistamines** are used as the cough suppressant component of many compound cough preparations on sale to the public; all tend to cause drowsiness which may reflect their main mode of action.

**Children** The use of over-the-counter cough suppressants containing codeine should be avoided in children under 18 years. Cough suppressants containing similar opioid analgesics such as dextromethorphan and pholcodine are not generally recommended in children and should be avoided in children under 6 years.

**CODEINE PHOSPHATE**

**Indications** dry or painful cough; diarrhoea (section 1.4.2); pain (section 4.7.2)

**Cautions** see notes above and section 4.7.2

**Contra-indications** section 4.7.2

**Hepatic impairment** section 4.7.2

**Renal impairment** section 4.7.2

**Pregnancy** section 4.7.2

**Breast-feeding** section 4.7.2

**Side-effects** section 4.7.2

**Dose**
- See under preparations below

**Codeine Linctus, BP**

**Linctus** (= oral solution), codeine phosphate 15 mg/5 mL. Net price 100 mL = 35p (diabetic, 39p)

Brands include Galcodine®

Dose 5–10 mL 3–4 times daily. **CHILD** (but not generally recommended, see MHRA advice above) 5–12 years, 2.5–5 mL.

**Note** BP directs that when Diabetic Codeine Linctus is prescribed, Codeine Linctus formulated with a vehicle appropriate for administration to diabetics, whether or not labelled ‘Diabetic Codeine Linctus’, shall be dispensed or supplied.

**Codeine Linctus, Paediatric, BP**

**Linctus** (= oral solution), codeine phosphate 3 mg/5 mL. Net price 100 mL = 18p

Brands include Galcodine® Paediatric (sugar-free)

Dose **CHILD** (but not generally recommended, see MHRA advice above) 2–5 years 5 mL, 3–4 times daily;

**Note** BP directs that Paediatric Codeine Linctus may be prepared extemporaneously by diluting Codeine Linctus with a suitable vehicle in accordance with the manufacturer’s instructions.

**Other preparations**

Tablets, syrup, and injection section 4.7.2
PHOLCODINE

Indications dry cough
Cautions asthma; chronic, persistent, or productive cough; interactions: Appendix 1 (pholcodine)
Contra-indications chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, patients at risk of respiratory failure

Hepatic impairment avoid
Renal impairment use with caution; avoid in severe impairment
Pregnancy manufacturer advises avoid unless potential benefit outweighs risk
Breast-feeding manufacturer advises avoid unless potential benefit outweighs risk—no information available

Side-effects nausea, vomiting, constipation, sputum retention, drowsiness, dizziness, excitation, confusion, rash

Dose
- See under preparations below

Pholcodine Linctus, BP
Linctus (= oral solution), pholcodine 5 mg/5 mL in a suitable flavoured vehicle, containing citric acid monohydrate 1%. Net price 100 mL = 31p
Brands include Favocon-D® (sugar-free), Galenphol® (sugar-free)
Dose 5–10 mL 3–4 times daily. CHILD (but not generally recommended; see notes above) 6–12 years 2.5–5 mL

Pholcodine Linctus, Strong, BP
Linctus (= oral solution), pholcodine 10 mg/5 mL in a suitable flavoured vehicle, containing citric acid monohydrate 2%. Net price 100 mL = 44p
Dose ADULT and CHILD over 12 years, 5 mL 3–4 times daily
Brands include Galenphol®

Galenphol® (Thornton & Ross)
Paediatric linctus (= oral solution), orange, sugar-free, pholcodine 2 mg/5 mL. Net price 90-mL pack = £1.20
Dose CHILD (but not generally recommended, see notes above) 6–12 years 10 mL 3 times daily

Palliative care
Diamorphine and methadone have been used to control distressing cough in terminal lung cancer although morphine is now preferred (see p. 22). In other circumstances they are contra-indicated because they induce sputum retention and ventilatory failure as well as causing opioid dependence. Methadone linctus should be avoided because it has a long duration of action and tends to accumulate.

METHADONE HYDROCHLORIDE

Indications cough in terminal disease
Cautions section 4.7.2
Contra-indications section 4.7.2
Hepatic impairment section 4.7.2
Renal impairment section 4.7.2
Pregnancy section 4.7.2
Breast-feeding section 4.7.2
Side-effects section 4.7.2; longer-acting than morphine therefore effects may be cumulative

Dose
- See below

Methadone Linctus
Linctus (= oral solution), methadone hydrochloride 2 mg/5 mL in a suitable vehicle with a tolu flavour.
Label: 2
Dose 2.5–5 mL every 4–6 hours, reduced to twice daily on prolonged use

MORPHINE HYDROCHLORIDE

Indications cough in terminal disease (see also Prescribing in Palliative Care p. 22)
Cautions section 4.7.2
Contra-indications section 4.7.2
Hepatic impairment section 4.7.2
Renal impairment section 4.7.2
Pregnancy section 4.7.2
Breast-feeding section 4.7.2
Side-effects section 4.7.2

Dose
- Initially 5 mg every 4 hours

Preparations
Section 4.7.2

3.9.2 Demulcent and expectorant cough preparations

Demulcent cough preparations contain soothing substances such as syrup or glycerol and some patients believe that such preparations relieve a dry irritating cough. Preparations such as simple linctus have the advantage of being harmless and inexpensive; paediatric simple linctus is particularly useful in children. Expectorants are claimed to promote expulsion of bronchial secretions, but there is no evidence that any drug can specifically facilitate expectoration.

Compound preparations are on sale to the public for the treatment of cough and colds but should not be used in children under 6 years; the rationale for some is dubious. Care should be taken to give the correct dose and not use more than one preparation at a time, see MHRA/CHM advice, p. 204.

Simple Linctus, BP
Linctus (= oral solution), citric acid monohydrate 2.5% in a suitable vehicle with an anise flavour. Net price 200 mL = 55p
Dose ADULT and CHILD over 12 years 5 mL 3–4 times daily
A sugar-free version is also available

Simple Linctus, Paediatric, BP
Linctus (= oral solution), citric acid monohydrate 0.625% in a suitable vehicle with an anise flavour. Net price 200 mL = 82p
Dose CHILD 1 month–12 years 5–10 mL 3–4 times daily
A sugar-free version is also available

3.10 Systemic nasal decongestants

Nasal decongestants for administration by mouth may not be as effective as preparations for local application (section 12.2.2) but they do not give rise to rebound nasal congestion on withdrawal. Pseudoephedrine is
available over the counter; it has few sympathomimetic effects.

Systemic decongestants should be used with caution in diabetes, hypertension, hyperthyroidism, susceptibility to angle-closure glaucoma, prostatic hypertrophy, ischaemic heart disease, and should be avoided in patients taking monoamine oxidase inhibitors; interactions: Appendix 1 (sympathomimetics).

**PSEUDOEPHEDRINE HYDROCHLORIDE**

**Indications** see notes above
**Cautions** see notes above
**Hepatic impairment** manufacturer advises caution in severe impairment
**Renal impairment** manufacturer advises caution in moderate to severe impairment
**Pregnancy** defective closure of the abdominal wall (gastroschisis) reported very rarely in newborns after first trimester exposure
**Breast-feeding** amount too small to be harmful
**Side-effects** tachycardia, anxiety, restlessness, insomnia; rarely hallucinations, rash; very rarely angle-closure glaucoma; urinary retention also reported

**Dose**
- 60 mg 3–4 times daily; **CHILD** 6–12 years 30 mg 3–4 times daily

1. **Galpseud** (Thornton & Ross)
   - Tablets, pseudoephedrine hydrochloride 60 mg, net price 24-tab pack = £2.00
   - Linctus, orange, sugar-free, pseudoephedrine hydrochloride 30 mg/5 mL, net price 100 mL = 70p

2. **Sudafed** (McNeil)
   - Tablets, red, f/c, pseudoephedrine hydrochloride 60 mg, net price 24 = £2.12
   - Elixir, red, pseudoephedrine hydrochloride 30 mg/5 mL, net price 100 mL = £1.05

---

1. Can be sold to the public provided no more than 720 mg of pseudoephedrine salts are supplied, and ephedrine base (or salts) are not supplied at the same time; for details see *Medicines, Ethics and Practice*, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)
4.1 Hypnotics and anxiolytics

4.1.1 Hypnotics

Most anxiolytics (‘sedatives’) will induce sleep when given at night and most hypnotics will sedate when given during the day. Prescribing of these drugs is widespread but dependence (both physical and psychological) and tolerance occur. This may lead to difficulty in withdrawing the drug after the patient has been taking it regularly for more than a few weeks (see Dependence and Withdrawal, below). Hypnotics and anxiolytics should therefore be reserved for short courses to alleviate acute conditions after causal factors have been established.

Benzodiazepines are the most commonly used anxiolytics and hypnotics; they act at benzodiazepine receptors which are associated with gamma-aminobutyric acid (GABA) receptors. Older drugs such as meprobamate and barbiturates are not recommended—they have more side-effects and interactions than benzodiazepines and are much more dangerous in overdosage.

Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

Driving Hypnotics and anxiolytics may impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day. See also Drugs and Driving under General Guidance, p. 3.

Dependence and withdrawal Withdrawal of a benzodiazepine should be gradual because abrupt withdrawal may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. Abrupt withdrawal of a barbiturate is even more likely to have serious effects.
The benzodiazepine withdrawal syndrome may develop at any time up to 3 weeks after stopping a long-acting benzodiazepine, but may occur within a day in the case of a short-acting one. It is characterised by insomnia, anxiety, loss of appetite and of body-weight, tremor, perspiration, tinnitus, and perceptual disturbances. Some symptoms may be similar to the original complaint and encourage further prescribing; some symptoms may continue for weeks or months after stopping benzodiazepines.

A benzodiazepine can be withdrawn in steps of about one-eighth (range one-tenth to one-quarter) of the daily dose every fortnight. A suggested withdrawal protocol for patients who have difficulty is as follows:

1. Transfer patient to equivalent daily dose of diazepam\(^1\) preferably taken at night
2. Reduce diazepam dose every 2–3 weeks in steps of 2 or 2.5 mg; if withdrawal symptoms occur, maintain this dose until symptoms improve
3. Reduce dose further, if necessary in smaller steps,\(^2\) it is better to reduce too slowly rather than too quickly
4. Stop completely; period needed for withdrawal can vary from about 4 weeks to a year or more

Counselling may help; beta-blockers should only be tried if other measures fail; antidepressants should be used only where depression or panic disorder co-exist or emerge; avoid antipsychotics (which may aggravate withdrawal symptoms).

Important: benzodiazepine indications

1. Benzodiazepines are indicated for the short-term relief (two to four weeks only) of anxiety that is severe, disabling, or causing the patient unacceptable distress, occurring alone or in association with insomnia or short-term psychiatric, organic, or psychotic illness.
2. The use of benzodiazepines to treat short-term ‘mild’ anxiety is inappropriate.
3. Benzodiazepines should be used to treat insomnia only when it is severe, disabling, or causing the patient extreme distress.

**4.1.1 Hypnotics**

Before a hypnotic is prescribed the cause of the insomnia should be established and, where possible, underlying factors should be treated. However, it should be noted that some patients have unrealistic sleep expectations, and others underestimate their alcohol consumption which is often the cause of the insomnia. Short-acting hypnotics are preferable in patients with sleep onset insomnia, when sedation the following day is undesirable; a hypnotic can be useful but should not be given for more than three weeks (preferably only one week). Intermittent use is desirable with omission of some doses. A short-acting drug is usually appropriate.

**Chronic insomnia** is rarely benefited by hypnotics and is sometimes due to mild dependence caused by injudicious prescribing of hypnotics. Psychiatric disorders such as anxiety, depression, and abuse of drugs and alcohol are common causes. Sleep disturbance is very common in depressive illness and early wakening is often a useful pointer. The underlying psychiatric complaint should be treated, adapting the drug regimen to alleviate insomnia. For example, clomipramine or mirtazapine prescribed for depression will also help to promote sleep if taken at night. Other causes of insomnia include daytime cat-napping and physical causes such as pain, pruritus, and dyspnoea.

Hypnotics should not be prescribed indiscriminately and routine prescribing is undesirable. They should be reserved for short courses in the acutely distressed. Tolerance to their effects develops within 3 to 14 days of continuous use and long-term efficacy cannot be assured. A major drawback of long-term use is that withdrawal can cause rebound insomnia and a withdrawal syndrome (section 4.1).

Where prolonged administration is unavoidable hypnotics should be discontinued as soon as feasible and the patient warned that sleep may be disturbed for a few days before normal rhythm is re-established; broken sleep with vivid dreams may persist for several weeks.

**Children** The prescribing of hypnotics to children, except for occasional use such as for night terrors and somnambulism (sleep-walking), is not justified.

**Elderly** Hypnotics should be avoided in the elderly, because the elderly are at greater risk of becoming ataxic and confused, leading to falls and injury.

**Dental procedures** Some anxious patients may benefit from the use of a hypnotic the night before the dental appointment. Hypnotics do not relieve pain, and if pain interferes with sleep an appropriate analgesic should be given. Diazepam (section 4.1.2), nitrazepam or temazepam are used at night for dental patients. Temazepam is preferred when it is important to minimise any residual effect the following day. For information on anxiolytics for dental procedures, see section 15.1.4.1.

**Benzodiazepines**

Benzodiazepines used as hypnotics include nitrazepam and flurazepam which have a prolonged action and may give rise to residual effects on the following day; repeated doses tend to be cumulative. Loprazolam, lormetazepam, and temazepam act for a shorter time and they have little or no hangover effect.
Withdrawal phenomena are more common with the short-acting benzodiazepines. If insomnia is associated with daytime anxiety then the use of a long-acting benzodiazepine anxiolytic such as diazepam given as a single dose at night may effectively treat both symptoms.

For general guidelines on benzodiazepine prescribing see section 4.1.2 and for benzodiazepine withdrawal see section 4.1.

**Hepatic impairment** Benzodiazepines can precipitate coma if used in hepatic impairment. If treatment is necessary, benzodiazepines with shorter half lives are safer, such as temazepam or oxazepam. Start with smaller initial doses or reduce dose; avoid in severe impairment.

**Renal impairment** Patients with renal impairment have increased cerebral sensitivity to benzodiazepines; start with small doses in severe impairment.

**Pregnancy** There is a risk of neonatal withdrawal symptoms when benzodiazepines are used during pregnancy. Avoid regular use and use only if there is a clear indication such as seizure control. High doses administered during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.

**Breast-feeding** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

### Nitrazepam

**Indications** insomnia (short-term use; see p. 208)

**Cautions** respiratory disease, muscle weakness and myasthenia gravis, history of drug or alcohol abuse, marked personality disorder; reduce dose in elderly and debilitated; avoid prolonged use (and abrupt withdrawal thereafter); acute porphyria (section 9.8.2); interactions: Appendix 1 (anxiolytics and hypnotics)

**Driving** Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** respiratory depression; marked neuromuscular respiratory weakness including unstable myasthenia gravis; acute pulmonary insufficiency; sleep apnoea syndrome; not for use alone to treat depression (or anxiety associated with depression) or chronic psychosis.

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** drowsiness and lightheadedness the next day; confusion and ataxia (especially in the elderly); amnesia may occur; dependence; see also under Nitrazepam

**Overdosage:** see Emergency Treatment of Poisoning, p. 37

**Dose**

- 5–10 mg at bedtime; **ELDERLY** (or debilitated) 2.5–5 mg; **CHILD** not recommended

**Labels**

- Tablets, nitrazepam 5 mg, net price 28 = £0.98. Label: 19

**Brands include** Meda

Dental prescribing on NHS Nitrazepam Tablets may be prescribed

### Flurazepam

**Indications** insomnia (short-term use; see p. 208)

**Cautions** see under Nitrazepam

**Contra-indications** see under Nitrazepam

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Nitrazepam

**Dose**

- 15–30 mg at bedtime; **ELDERLY** (or debilitated) 15 mg; **CHILD** not recommended

**Labels**

- Tablets, flurazepam (as hydrochloride), 15 mg (grey/yellow), net price 30-cap pack = £6.73; 30 mg (black/grey), 30-cap pack = £8.63. Label: 19

### Loprazolam

**Indications** insomnia (short-term use; see p. 208)

**Cautions** see under Nitrazepam

**Contra-indications** see under Nitrazepam

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Nitrazepam; shorter acting

**Dose**

- 1 mg at bedtime, increased to 1.5 or 2 mg if required; **ELDERLY** (or debilitated) 0.5 or 1 mg; **CHILD** not recommended

**Labels**

- Tablets, loprazolam 1 mg (as mesilate). Net price 28-tab pack = £18.00. Label: 19

### Lormetazepam

**Indications** insomnia (short-term use; see p. 208)

**Cautions** see under Nitrazepam

**Contra-indications** see under Nitrazepam

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see under Nitrazepam

**Dose**

- 0.5–1.5 mg at bedtime; **ELDERLY** (or debilitated) 500 micrograms; **CHILD** not recommended

**Labels**

- Tablets, lormetazepam 500 micrograms, net price 30-tab pack = £56.25; 1 mg, 30-tab pack = £54.60. Label: 19

### Temezepam

**Indications** insomnia (short-term use; see p. 208); see also section 15.1.4.1 for peri-operative use

**Cautions** see under Nitrazepam

**Contra-indications** see under Nitrazepam

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

Oral suspension, nitrazepam 2.5 mg/5 mL. Net price 150 mL = £5.09. Label: 19

**Brands include** Somnite®

4 Central nervous system
Central nervous system

4

210 4.1.1 Hypnotics

ZOLEPID TARTRATE

Indications  insomnia (short-term use—up to 4 weeks)

Cautions  depression, muscle weakness and myasthenia gravis, history of drug or alcohol abuse; elderly; avoid prolonged use (and abrupt withdrawal thereafter); interactions: Appendix 1 (anxiolytics and hypnotics)

Driving  Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Contra-indications  obstructive sleep apnoea, acute or severe respiratory depression, marked neuromuscular respiratory weakness including unstable myasthenia gravis, psychotic illness

Hepatic impairment  can precipitate coma; reduce dose to 5 mg (avoid if severe impairment)

Renal impairment  use with caution

Pregnancy  avoid regular use (risk of neonatal withdrawal symptoms); high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression

Breast-feeding  small amounts present in milk—avoid

Side-effects  diarrhoea, nausea, vomiting, dizziness, headache, drowsiness, hallucination, agitation, asthenia, amnesia; dependence, memory disturbances, nightmares, depression, confusion, perceptual disturbances or diplopia, tremor, ataxia, falls, skin reactions, changes in libido; paradoxical effects (see p. 207), muscular weakness, and sleep-walking also reported

Dose

• ADULT over 18 years, 10 mg at bedtime; ELDERLY (or debilitated) 5 mg

Zolpidem (Non-proprietary) (Sanofi-Aventis) Tablets, zolpidem tartrate 5 mg, net price 28-tab pack = £1.41; 10 mg, 28-tab pack = £1.46. Label: 19

Stilnoct® (Sanofi-Aventis) Tablets, both f/c, zolpidem tartrate 5 mg, net price 28-tab pack = £2.96; 10 mg, 28-tab pack = £4.31. Label: 19

ZOPICLONE

Indications  insomnia (short-term use—up to 4 weeks)

Cautions  elderly; muscle weakness and myasthenia gravis, history of drug or alcohol abuse, psychiatric illness; avoid prolonged use (risk of tolerance and withdrawal symptoms); interactions: Appendix 1 (anxiolytics and hypnotics)

Driving  Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Contra-indications  marked neuromuscular respiratory weakness including unstable myasthenia gravis, respiratory failure, severe sleep apnoea syndrome

Hepatic impairment  can precipitate coma; reduce dose (avoid if severe impairment)

Renal impairment  start with small doses in severe impairment; increased cerebral sensitivity

Pregnancy  avoid regular use (risk of neonatal withdrawal symptoms); high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression

Breast-feeding  present in milk—avoid

Side-effects  taste disturbance; less commonly nausea, vomiting, dizziness, drowsiness, dry mouth, headache;

ZALEPLON

Indications  insomnia (short-term use—up to 2 weeks)

Cautions  respiratory insufficiency (avoid if severe); muscle weakness and myasthenia gravis, history of drug or alcohol abuse; depression (risk of suicidal ideation); avoid prolonged use (risk of tolerance and withdrawal symptoms); interactions: Appendix 1 (anxiolytics and hypnotics)

Contra-indications  sleep apnoea syndrome, marked neuromuscular respiratory weakness including unstable myasthenia gravis

Hepatic impairment  can precipitate coma; reduce dose to 5 mg (avoid if severe impairment)

Pregnancy  use only if necessary and restrict to occasional short-term use; risk of withdrawal symptoms in neonate if used in late pregnancy

Breast-feeding  present in milk but amount probably too small to be harmful

Side-effects  amnesia, paraesthesia, drowsiness; dysmenorrhea; less commonly nausea, anorexia, asthenia, incoordination, confusion, impaired concentration, depression, depersonalisation, dizziness, hallucinations, disturbances of smell, hearing, speech, and vision; photosensitivity; paradoxical effects (see p. 207) and sleep-walking also reported

Dose

• ADULT over 18 years, 10 mg at bedtime; ELDERLY (or debilitated) 5 mg

Sonata® (Meda) Capsules, zaleplon 5 mg (white/light brown), net price 14-cap pack = £3.12; 10 mg (white), 14-cap pack = £3.76. Label: 2

Zaleplon, zolpidem, and zopiclone

Zaleplon, zolpidem, and zopiclone are non-benzodiazepine hypnotics, but they act at the benzodiazepine receptor. They are not licensed for long-term use; dep-
rarely amnesia, confusion, depression, hallucinations, nightmares; very rarely light headiness, incoordination; paradoxical effects (see p. 207) and sleep-walking also reported

**Dose**
- **ADULT** over 18 years, 7.5 mg at bedtime; **ELDERLY** initially 3.75 mg at bedtime increased if necessary

**Zopiclone (Non-proprietary)**

**Tablets**, zopiclone 3.75 mg, net price 28-tab pack = £1.34; 7.5 mg, 28-tab pack = £1.35. Label: 19

**Zimovane® (Sanofi-Aventis)**

**Tablets**, f/c, zopiclone 3.75 mg (Zimovane® LS), net price 28-tab pack = £2.24; 7.5 mg (scored), 28-tab pack = £3.26. Label: 19

### Chloral and derivatives

Chloral hydrate and derivatives were formerly popular hypnotics for children (but the use of hypnotics in children is not usually justified). There is no convincing evidence that they are particularly useful in the elderly and their role as hypnotics is now very limited.

#### CHLORAL HYDRATE

**Indications** insomnia (short-term use)

**Cautions** reduce dose in elderly and debilitated; avoid prolonged use (and abrupt withdrawal thereafter); avoid contact with skin and mucous membranes; interactions: Appendix 1 (anxiolytics and hypnotics)

**Driving** Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** severe cardiac disease; gastritis; acute porphyria (section 9.8.2)

**Hepatic impairment** can precipitate coma; reduce dose in mild to moderate impairment; avoid in severe impairment

**Renal impairment** avoid in severe impairment

**Pregnancy** avoid

**Breast-feeding** risk of sedation in infant—avoid

**Side-effects** gastric irritation (nausea and vomiting reported), abdominal distention, flatulence, headache, tolerance, dependence, excitement, delirium (especially on abrupt withdrawal), ketonuria, and rash

**Dose**
- See under preparations below

#### Chloral Mixture, BP 2000

(Chloral Oral Solution)

**Mixture**, chloral hydrate 500 mg/5 mL in a suitable vehicle. Label: 19, 27

**Dose** 5–20 mL; **CHILD** 1–12 years 30–50 mg/kg (max. 1 g), taken well diluted with water at bedtime

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

#### Chloral Elixir, Paediatric, BP 2000

(Chloral Oral Solution, Paediatric)

**Elixir**, chloral hydrate 200 mg/5 mL (4%) in a suitable vehicle with a black currant flavour. Label: 1, 27

**Dose** **CHILD** 1 month–1 year 30–50 mg/kg, taken well diluted with water at bedtime

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

---

**Cloral betaine**

**Welldorm® (Alphashow)**

**Tablets**, blue-purple, f/c, cloral betaine 707 mg (≡ chloral hydrate 414 mg), net price 30-tab pack = £12.10. Label: 19, 27

**Dose** **ADULT** and **CHILD** over 12 years, 1–2 tablets with water or milk at bedtime, max. 9 tablets (chloral hydrate 2 g) daily

**Elixir**, red, chloral hydrate 143.3 mg/5 mL, net price 150-mL pack = £8.70. Label: 19, 27

**Dose** 15–45 mL (chloral hydrate 0.4–1.3 g) with water or milk, at bedtime, max. 70 mL (chloral hydrate 2 g) daily; **CHILD** 2–12 years, 1–1.75 mL/kg (chloral hydrate 30–50 mg/kg), max. 35 mL (chloral hydrate 1 g) daily

---

**Clomethiazole**

Clomethiazole may be a useful hypnotic for elderly patients because of its freedom from hangover but, as with all hypnotics, routine administration is undesirable and dependence occurs. It is also licensed for use in acute alcohol withdrawal, but see section 4.10.1.

**CLOMETHIAZOLE**

(Chlormethiazole)

**Indications** see under Dose; alcohol withdrawal (section 4.10.1)

**Cautions** cardiac and respiratory disease (confusional state may indicate hypoxia), chronic pulmonary insufficiency, sleep apnoea syndrome; history of drug abuse; avoid prolonged use (and abrupt withdrawal thereafter); marked personality disorder; elderly; excessive sedation may occur (particularly with higher doses); interactions: Appendix 1 (anxiolytics and hypnotics)

**Driving** Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** acute pulmonary insufficiency; alcohol-dependent patients who continue to drink

**Hepatic impairment** can precipitate coma; reduce dose

**Renal impairment** start with small doses in severe impairment; increased cerebral sensitivity

**Pregnancy** avoid if possible—especially during first and third trimesters

**Breast-feeding** amount too small to be harmful

**Side-effects** nasal congestion and irritation (increased nasopharyngeal and bronchial secretions), conjunctival irritation, headache; rarely gastro-intestinal disturbances, paradoxical excitement, confusion, dependence, rash, urticaria, bulous eruption, anaphylaxis, alterations in liver enzymes

**Dose**
- Severe insomnia in the elderly (short-term use), 1–2 capsules at bedtime; **CHILD** not recommended
- Restlessness and agitation in the elderly, 1 capsule 3 times daily
- Alcohol withdrawal (but see section 4.10.1), initially 2–4 capsules, if necessary repeated after some hours; day 1 (first 24 hours), 9–12 capsules in 3–4 divided doses; day 2, 6–8 capsules in 3–4 divided doses; day 3, 4–6 capsules in 3–4 divided doses; then gradually reduced over days 4–6; total treatment for not more than 9 days

**Heminevrin® (AstraZeneca)**

**Capsules**, grey-brown, clomethiazole base 192 mg in an oily basis. Net price 60-cap pack = £4.78. Label: 19
Central nervous system

4.1.1 Hypnotics

Antihistamines

Some antihistamines (section 3.4.1) such as promethazine are on sale to the public for occasional insomnia; their prolonged duration of action can often cause drowsiness the following day. The sedative effect of antihistamines may diminish after a few days of continued treatment; antihistamines are associated with headache, psychomotor impairment and antimuscarinic effects.

Promethazine is also popular for use in children, but the use of hypnotics in children is not usually justified.

PROMETHAZINE HYDROCHLORIDE

Indications sedation (short-term use); allergy and urticaria (section 3.4.1); nausea and vomiting (section 4.6)

Cautions see Promethazine Hydrochloride, section 3.4.1

Contra-indications see notes in section 3.4.1

Renal impairment see Promethazine Hydrochloride, section 3.4.1

Pregnancy see notes in section 3.4.1

Breast-feeding see notes in section 3.4.1

Side-effects see Promethazine Hydrochloride, section 3.4.1

Dose

- By mouth, 25–50 mg; CHILD 2–5 years 15–20 mg, 5–10 years 20–25 mg
- By deep intramuscular injection, 25–50 mg; CHILD 5–10 years 6.25–12.5 mg

Preparations

Section 3.4.1

Alcohol

Alcohol is a poor hypnotic because the diuretic action interferes with sleep during the latter part of the night. Alcohol also disturbs sleep patterns, and so can worsen sleep disorders; interactions: Appendix 1 (alcohol).

Sodium oxybate

Sodium oxybate is a central nervous system depressant that is licensed for the treatment of narcolepsy with cataplexy.

SODIUM OXYBATE

Indications narcolepsy with cataplexy (under specialist supervision)

Cautions history of drug abuse or depression; epilepsy; elderly; respiratory disorders; heart failure and hypertension (high sodium content); risk of discontinuation effects including rebound cataplexy and withdrawal symptoms; acute porphyria (section 9.8.2); interactions: Appendix 1 (sodium oxybate)

Hepatic impairment halve initial dose

Renal impairment caution—contains 3.96 mmol Na+ /mL

Pregnancy avoid

Breast-feeding no information available

Side-effects nausea, vomiting, diarrhoea, abdominal pain, anorexia; hypertension, peripheral oedema; dyspnoea; sleep disorders, confusion, disorientation, paraesthesia, hypoaesthesia, impaired attention, depression, drowsiness, anxiety, dizziness, headache, tremor, asthma, fatigue; urinary incontinence, nocturnal enuresis; arthralgia, muscle cramps; blurred vision; sweating; less commonly faecal incontinence, myoclonus, psychosis, paranoia, hallucination, agitation, amnesia, and rash; respiratory depression, dependence, seizures, suicidal ideation, and urticaria also reported

Dose

- ADULT over 18 years, initially 2.25 g on retiring and repeated 2.5–4 hours later, increased according to response in steps of 1.5 g daily in 2 divided doses at intervals of 1–2 weeks; max. 9 g daily in two divided doses

Note Dose titration should be repeated if restarting after interval of more than 14 days

Counselling Dilute each dose with 60 mL water; prepare both doses before retiring. Observe the same time interval (2–3 hours) each night between the last meal and the first dose

Xyrem® (UCB Pharma) ▼ Pat

Oral solution, sugar-free, sodium oxybate 500 mg/mL, net price 180 mL (with graduated syringe) = £360.00. Label: 13, 19, counselling, administration

Electrolytes Na+ 3.96 mmol/mL

Melatonin

Melatonin is a pineal hormone; it is licensed for the short-term treatment of insomnia in adults over 55 years. For information on the use of melatonin in children and adolescents, see BNF for Children.

MELATONIN

Indications insomnia (short-term use)

Cautions autoimmune disease (manufacturer advises avoid—no information available); interactions: Appendix 1 (melatonin)

Hepatic impairment clearance reduced—avoid

Renal impairment no information available—use with caution

Pregnancy no information available—avoid

Breast-feeding present in milk—avoid

Side-effects less commonly abdominal pain, dyspepsia, dry mouth, mouth ulceration, weight gain, hypertension, chest pain, malaise, dizziness, restlessness, nervousness, irritability, anxiety, migraine, proteinuria, glycosuria, pruritus, rash, dry skin; rarely thirst, flatulence, hallucosis, salivation, vomiting, gastritis, hypertriglyceridaemia, angina, palpitation, syncope, hot flushes, aggression, impaired memory, restless legs syndrome, paraesthesia, mood changes, priapism, increased libido, prostatitis, polyuria, haematuria, leucopenia, thrombocytopenia, electrolyte disturbances, muscle spasm, arthritis, lacermination, visual disturbances, nail disorder

Dose

- ADULT over 55 years, 2 mg once daily 1–2 hours before bedtime for up to 13 weeks; CHILD 1 month–18 years see BNF for Children

Circadin® (Lundbeck) ▼ Pat

Tablets, m/r, melatonin 2 mg, net price 21-tab pack = £10.77. Label: 2, 21, 25
**4.1.2 Anxiolytics**

Benzodiazepine anxiolytics can be effective in alleviating anxiety states. Although these drugs are sometimes prescribed for stress-related symptoms, unhappiness, or minor physical disease, their use in such conditions is inappropriate. Benzodiazepine anxiolytics should not be used as sole treatment for chronic anxiety, and they are not appropriate for treating depression or chronic psychosis. In bereavement, psychological adjustment may be inhibited by benzodiazepines. In children, anxiolytic treatment should be used only to relieve acute anxiety (and related insomnia) caused by fear (e.g. before surgery).

Anxiolytic benzodiazepine treatment should be limited to the lowest possible dose for the shortest possible time (see p. 208). Dependence is particularly likely in patients with a history of alcohol or drug abuse and in patients with marked personality disorders.

Some antidepressants (section 4.3) are licensed for use in anxiety and related disorders; see section 4.3 for a comment on their role in chronic anxiety. Some antipsychotics, in low doses, are also sometimes used in severe anxiety for their sedative action, but long-term use should be avoided because of the risk of adverse effects (section 4.2.1). The use of antihistamines (e.g. hydroxyzine) for their sedative effect in anxiety is not appropriate.

Beta-blockers (section 2.4) do not affect psychological symptoms of anxiety, such as worry, tension, and fear, but they do reduce autonomic symptoms, such as palpitation and tremor; they do not reduce non-autonomic symptoms, such as muscle tension. Beta-blockers are therefore indicated for patients with predominantly somatic symptoms; this, in turn, may prevent the onset of worry and fear.

### Benzodiazepines

Benzodiazepines are indicated for the short-term relief of severe anxiety; long-term use should be avoided (see p. 208). Diazepam, alprazolam, chlordiazepoxide, and clonazepam have a sustained action. Shorter-acting compounds such as lorazepam and oxazepam may be preferred in patients with hepatic impairment but they carry a greater risk of withdrawal symptoms.

In panic disorders (with or without agoraphobia) resistant to antidepressant therapy (section 4.3), a benzodiazepine (lorazepam 3–5 mg daily or clonazepam 1–2 mg daily (section 4.8.1) [both unlicensed]) may be used; alternatively, a benzodiazepine may be used as short-term adjunctive therapy at the start of antidepressant treatment to prevent the initial worsening of symptoms. Diazepam or lorazepam are very occasionally administered intravenously for the control of panic attacks. This route is the most rapid but the procedure is not without risk (section 4.8.2) and should be used only when alternative measures have failed. The intramuscular route has no advantage over the oral route.

For guidelines on benzodiazepine withdrawal, see p. 207.

### Hepatic impairment

Benzodiazepines can precipitate coma if used in hepatic impairment. If treatment is necessary, benzodiazepines with shorter half lives are safer, such as temazepam or oxazepam. Start with smaller initial doses or reduce dose; avoid in severe impairment.

#### Renal impairment

Patients with renal impairment have increased cerebral sensitivity to benzodiazepines; start with small doses in severe impairment.

#### Pregnancy

There is a risk of neonatal withdrawal symptoms when benzodiazepines are used during pregnancy. Avoid regular use and use only if there is a clear indication such as seizure control. High doses administered during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.

**Breast-feeding** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.
5 mg/minute), for severe acute anxiety, control of acute panic attacks, and acute alcohol withdrawal, 10 mg, repeated if necessary after not less than 4 hours.

**Note** Only use intramuscular route when oral and intravenous routes not possible; emulsion formulation preferred for intravenous injection. Special precautions for intravenous injection section 4.8.2.

- By rectum as rectal solution, acute anxiety and agitation, 500 micrograms/kg repeated after 12 hours as required; ELDERLY: 250 micrograms/kg. CHILD not recommended.

As suppositories, anxiety when oral route not appropriate, 10–30 mg (higher dose divided); dose form not appropriate for less than 10 mg.

**Diazepam (Non-proprietary)**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand(s)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets</td>
<td>Rimapam (®)</td>
<td>Label: 2 or 19</td>
</tr>
<tr>
<td>5 mg, 28-tab pack = 89p; 10 mg, 28-tab pack = 92p. Label: 2 or 19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsules</td>
<td>Dialor (®)</td>
<td>Label: 2 or 19</td>
</tr>
<tr>
<td>5 mg, 100-cap pack = £13.13. Label: 2 or 19</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dental prescribing on NHS**

- Diazepam Tablets may be prescribed for intramuscular injection section 4.8.2.
- Diazepam Rectubes are available for intramuscular injection section 4.8.2.
- Diazemuls is available for rectal injection.

**Injection** (emulsion), diazepam 5 mg/mL, net price 2-mL amp = 45p.

- Excipients may include benzyl alcohol (avoid in neonates, see Excipients, p. 2), ethanol, propylene glycol.

**Note** Do not dilute (except for intravenous infusion, see Appendix 6).

**Injection** (solution), diazepam 2 mg/mL, net price 100-mL pack = £6.08. Label: 2 or 19.

- Brands include Dialor (®) and Diastat (®).

**Oral solution** (emulsion), diazepam 5 mg/mL, net price 2-mL amp = 45p.

**Strong oral solution** (emulsion), diazepam 5 mg/mL, net price 100-mL pack = £5.38. Label: 2 or 19.

- Brands include Diastat (®).

**Suppositories**

<table>
<thead>
<tr>
<th>Brand(s)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam 10 mg, net price 6 = £10.20. Label: 2 or 19</td>
<td></td>
</tr>
</tbody>
</table>

**Chlordiazepoxide (Non-proprietary)**

- Capsules, chlordiazepoxide hydrochloride 5 mg, net price 100-cap pack = £6.21; 10 mg, 100-cap pack = £13.13. Label: 2.

- Brands include Librium (®).

**Chlordiazepoxide Hydrochloride (Non-proprietary)**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Brand(s)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets</td>
<td>Lorazepam (®)</td>
<td>Label: 2</td>
</tr>
<tr>
<td>5 mg, 100-cap pack = £4.24; 10 mg, 100 = £11.34. Label: 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Lorazepam (Non-proprietary)**

- Tablets, lorazepam 1 mg, net price 28-tab pack = £5.42; 2.5 mg, 28-tab pack = £7.11. Label: 2 or 19.

**Injection**, lorazepam 4 mg/mL, net price 1-mL amp = 35p.

- Excipients include benzyl alcohol, propylene glycol (see Excipients, p. 2).

- Brands include Ativan (®).

**Note** For intramuscular injection it should be diluted with an equal volume of water for injections or physiological saline (but only use when oral and intravenous routes not possible).
**Meprobamate**

*Indications* short-term use in anxiety, but see notes above

*Cautions* respiratory disease, muscle weakness, epilepsy (may induce seizures), history of drug or alcohol abuse, marked personality disorder; elderly and debilitated; avoid prolonged use, abrupt withdrawal (may precipitate convulsions); *interactions*: Appendix 1 (anxiolytics and hypnotics)

*Driving* Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

*Contra-indications* acute pulmonary insufficiency; respiratory depression; acute porphyria (section 9.8.2)

*Hepatic impairment* can precipitate coma

*Renal impairment* start with small doses in severe impairment; increased cerebral sensitivity

*Pregnancy* avoid if possible

*Breast-feeding* avoid; concentration in milk may exceed maternal plasma concentrations fourfold and may cause drowsiness in infant

*Side-effects* see under Diazepam

*Dosage*
- 400 mg 3–4 times daily; **ELDERLY** half adult dose or less; **CHILD** not recommended
- **Note** Meprobamate treatment should not be initiated in new patients, see notes above

*Meprobamate (Non-proprietary)*

- **Tablets**, scored, meprobamate 400 mg, net price 84-tab pack = £19.95. Label: 2

---

**Central nervous system**

**4.1.3 Barbiturates**

**BNF 61**

**Oxazepam**

*Indications* anxiety (short-term use; see p. 208)

*Cautions* see under Diazepam; short acting

*Contra-indications* see under Diazepam

*Hepatic impairment* see notes above

*Renal impairment* see notes above

*Pregnancy* see notes above

*Breast-feeding* see notes above

*Side-effects* see under Diazepam

*Dosage*
- Anxiety, 15–30 mg (elderly or debilitated 10–20 mg) 3–4 times daily; **CHILD** not recommended
- Insomnia associated with anxiety, 15–25 mg (max. 50 mg) at bedtime; **CHILD** not recommended

*Oxazepam (Non-proprietary)*

- **Tablets**, oxazepam 10 mg, net price 28-tab pack = £4.85; 15 mg, 28-tab pack = £5.16. Label: 2

**Buspirone**

Buspirone is thought to act at specific serotonin (5HT1A) receptors. Response to treatment may take up to 2 weeks. It does not alleviate the symptoms of benzodiazepine withdrawal. Therefore a patient taking a benzodiazepine still needs to have the benzodiazepine withdrawn gradually; it is advisable to do this before starting buspirone. The dependence and abuse potential of buspirone is low; it is, however, licensed for short-term use only (but specialists occasionally use it for several months).

**BUSPIRONE HYDROCHLORIDE**

*Indications* anxiety (short-term use)

*Cautions* does not alleviate benzodiazepine withdrawal (see notes above); *interactions*: Appendix 1 (anxiolytics and hypnotics)

*Driving* May affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced

*Contra-indications* epilepsy; acute porphyria (section 9.8.2)

*Hepatic impairment* reduce dose in mild to moderate disease; avoid in severe disease

*Renal impairment* reduce dose; avoid if eGFR less than 20 mL/minute/1.73 m²

*Pregnancy* avoid

*Breast-feeding* avoid

*Side-effects* nausea; dizziness, headache, nervousness; excitement; rarely dry mouth, tachycardia, palpitation, chest pain, drowsiness, confusion, seizures, fatigue, and sweating

*Dosage*
- **ADULT** over 18 years, 5 mg 2–3 times daily, increased as necessary every 2–3 days; usual range 15–30 mg daily in divided doses; max. 45 mg daily

*Buspirone Hydrochloride (Non-proprietary)*

- **Tablets**, buspirone hydrochloride 5 mg, net price 30-tab pack = £13.01; 10 mg, 30-tab pack = £15.34.

*Counselling, driving*

**Meprobamate**

Meprobamate is less effective than the benzodiazepines, more hazardous in overdosage, and can also induce dependence. It is not recommended.

**Important:** MHRA/CHM have advised that treatment with meprobamate should not be initiated.

---

**4.2 Drugs used in psychoses and related disorders**

**4.2.1 Antipsychotic drugs**

**4.2.2 Antipsychotic depot injections**

**4.2.3 Antimanic drugs**

Advice of Royal College of Psychiatrists on doses of antipsychotic drugs above BNF upper limit. Unless otherwise stated, doses in the BNF are licensed doses—
Antipsychotic drugs

Antipsychotic drugs are also known as ‘neuroleptics’ and (misleadingly) as ‘major tranquillisers’. Antipsychotic drugs generally tranquilise without impairing consciousness and without causing paradoxical excitement but they should not be regarded merely as tranquillisers. For conditions such as schizophrenia the tranquilising effect is of secondary importance.

In the short term they are used to calm disturbed patients whatever the underlying psychopathology, which may be schizophrenia, brain damage, mania, toxic delirium, or agitated depression. Antipsychotic drugs are used to alleviate severe anxiety but this too should be a short-term measure.

Schizophrenia Antipsychotic drugs relieve psychotic symptoms such as thought disorder, hallucinations, and delusions, and prevent relapse. Although they are usually less effective in apathetic withdrawn patients, they sometimes appear to have an activating influence. Patients with acute schizophrenia generally respond better than those with chronic symptoms. Patients should receive antipsychotic drugs for 4–6 weeks before the drug is deemed ineffective.

Long-term treatment of a patient with a definite diagnosis of schizophrenia may be necessary even after the first episode of illness in order to prevent the illness from becoming chronic. Withdrawal of drug treatment requires careful surveillance because the patient who appears well on medication may suffer a disastrous relapse if treatment is withdrawn inappropriately. In addition the need for continuation of treatment may not become immediately evident because relapse is often delayed for several weeks after cessation of treatment.

Antipsychotic drugs are considered to act by interfering with dopaminergic transmission in the brain by blocking dopamine D2 receptors, which may give rise to the extrapyramidal effects described below, and also to hyperprolactinaemia. Antipsychotic drugs may also affect cholinergic, alpha-adrenergic, histaminergic, and serotonergic receptors.

Caution Antipsychotic drugs should be used with caution in patients with cardiovascular disease; an ECG may be required (see individual drug monographs), particularly if physical examination identifies cardiovascular risk factors, if there is a personal history of cardiovascular disease, or if the patient is being admitted as an inpatient. Antipsychotic drugs should also be used with caution in Parkinson’s disease (may be exacerbated by antipsychotics), epilepsy (and conditions predisposing to epilepsy), depression, myasthenia gravis, prostatic hypertrophy, or a susceptibility to angle-closure glaucoma. Caution is also required in severe respiratory disease and in patients with a history of jaundice or who have blood dyscrasias (perform blood counts if unexplained infection or fever develops). As photosensitisation may occur with higher dosages, patients should avoid direct sunlight. Patients with schizophrenia should have physical health monitoring (including cardiovascular disease risk assessment) at least once per year. Interaction: Appendix 1 (antipsychotics).

Contra-indications Antipsychotic drugs may be contra-indicated in comatose states, CNS depression, and phaeochromocytoma.

Prescribing for the elderly

The balance of risks and benefit should be considered before prescribing antipsychotic drugs for elderly patients. In elderly patients with dementia, antipsychotic drugs are associated with a small increased risk of mortality and an increased risk of stroke or transient ischaemic attack. Furthermore, elderly patients are particularly susceptible to postural hypotension and to hyper- and hypothermia in hot or cold weather. It is recommended that:

- Antipsychotic drugs should not be used in elderly patients to treat mild to moderate psychotic symptoms.
- Initial doses of antipsychotic drugs in elderly patients should be reduced (to half the adult dose or less), taking into account factors such as the patient’s weight, co-morbidity, and concomitant medication.
- Treatment should be reviewed regularly.

Driving Drowsiness may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment; effects of alcohol are enhanced.

Withdrawal There is a high risk of relapse if medication is stopped after 1–2 years. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse. Patients should be monitored for 2 years after withdrawal of antipsychotic medication for signs and symptoms of relapse.
Hepatic impairment All antipsychotics can precipitate coma if used in hepatic impairment; phenothiazines are hepatotoxic. The manufacturer of zuclopenthixol (Clopitol®) advises that the dose should be halved in hepatic impairment, and serum-level monitoring should be considered.

Renal impairment Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity. Pericyazine should be avoided in renal impairment. The dose of zuclopenthixol should be halved in patients with renal failure.

Pregnancy Extrapyramidal effects have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.

Breast-feeding There is limited information available on the short- and long-term effects of antipsychotics on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotics whilst breast-feeding should be avoided unless absolutely necessary.

Side-effects Extrapyramidal symptoms are the most troublesome. They occur most frequently with the piperazine phenothiazines (fluphenazine, perphenazine, prochlorperazine, and trifluoperazine), the butyrophenones (benperidol and haloperidol), and the depot preparations. They are easy to recognise but cannot be predicted accurately because they depend on the dose, the type of drug, and on individual susceptibility. Extrapyramidal symptoms consist of:

- **parkinsonian symptoms** (including tremor), which may occur more commonly in adults or the elderly and may appear gradually;
- **dystonia** (abnormal face and body movements) and **dyskinesia**, which occur more commonly in children or young adults and appear after only a few doses;
- **akathisia** (restlessness), which characteristically occurs after large initial doses and may resemble an exacerbation of the condition being treated; and
- **tardive dyskinesia** (rhythmic, involuntary movements of tongue, face, and jaw), which usually develops on long-term therapy or with high dosage, but it may develop on short-term treatment with low doses—short-lived tardive dyskinesia may occur after withdrawal of the drug.

**Parkinsonian symptoms** remit if the drug is withdrawn and may be suppressed by the administration of antimuscarinic drugs (section 4.9.2). However, routine administration of such drugs is not justified because not all patients are affected and because they may unmask or worsen tardive dyskinesia.

**Tardive dyskinesia** is of particular concern because it may be irreversible on withdrawing therapy and treatment is usually ineffective. However, some manufacturers suggest that drug withdrawal at the earliest signs of tardive dyskinesia (fine vermicular movements of the tongue) may halt its full development. Tardive dyskinesia occurs fairly frequently, especially in the elderly, and treatment must be carefully and regularly reviewed.

**Hypotension and interference with temperature regulation** are dose-related side-effects and are liable to cause dangerous falls and hypoactivity or hyperthermia in the elderly.

**Neuroleptic malignant syndrome** (hyperthermia, fluctuating level of consciousness, muscle rigidity, and autonomic dysfunction with pallor, tachycardia, labile blood pressure, sweating, and urinary incontinence) is a rare but potentially fatal side-effect of some drugs. Discontinuation of the antipsychotic is essential because there is no proven effective treatment, but cooling, bromocriptine, and dantrolene have been used. The syndrome, which usually lasts for 5–7 days after drug discontinuation, may be unduly prolonged if depot preparations have been used.

**Other side-effects** include: drowsiness; apathy; agitation, excitement and insomnia; convulsions; dizziness; headache; confusion; gastro-intestinal disturbances; nasal congestion; antimuscarinic symptoms (such as dry mouth, constipation, difficulty with micturition, and blurred vision; very rarely, precipitation of angle-closure glaucoma); cardiovascular symptoms (such as hypotension, tachycardia, and arrhythmias); ECG changes (cases of sudden death have occurred); venous thromboembolism; endocrine effects such as menstrual disturbances, galactorrhoea, gynaecomastia, impotence, and weight gain; blood dyscrasias (such as agranulocytosis and leucopenia), photosensitisation, contact sensitisation and rashes, and jaundice (including cholestatic); corneal and lens opacities, and purplish pigmentation of the skin, cornea, conjunctiva, and retina.

**Overdose** for poisoning with phenothiazines and related compounds, see Emergency Treatment of Poisoning, p. 38.

**Classification of antipsychotics** The phenothiazine derivatives can be divided into 3 main groups.

- **Group 1**: chlorpromazine, levoamphetamine, and promazine, generally characterised by pronounced sedative effects and moderate antimuscarinic and extrapyramidal side-effects.
- **Group 2**: pericyazine and pipotiazine, generally characterised by moderate sedative effects, marked antimuscarinic effects, but fewer extrapyramidal side-effects than groups 1 or 3.
- **Group 3**: fluphenazine, perphenazine, prochlorperazine, and trifluoperazine, generally characterised by fewer sedative effects, fewer antimuscarinic effects, but more pronounced extrapyramidal side-effects than groups 1 and 2.

Drugs of other chemical groups resemble the phenothiazines of group 3 in their clinical properties. They include the **butyrophenones** (benperidol and haloperidol), **diphenylbutylipeperidines** (pimozide); **thioxanthenes** (flupentixol and zuclopenthixol); and the **substituted benzamides** (sulpiride).

For details of the newer antipsychotic drugs amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, and risperidone see under Atypical Antipsychotic Drugs, p. 222.

**Choice** As indicated above, the various drugs differ somewhat in predominant actions and side-effects. Selection is influenced by the degree of sedation required and the patient’s susceptibility to extrapyramidal side-effects. However, the differences between antipsychotic drugs are less important than the great variability in patient response; moreover, tolerance to secondary effects such as sedation usually develops. The atypical antipsychotics may be appropriate if extrapyramidal side-effects are a particular concern (see
under Atypical Antipsychotic Drugs, below). Clozapine is used for schizophrenia when other antipsychotics are ineffective or not tolerated.

Prescribing of more than one antipsychotic drug at the same time is not recommended; it may constitute a hazard and there is no significant evidence that side-effects are minimised.

Chlorpromazine is still widely used despite the wide range of adverse effects associated with it. It has a marked sedating effect and is useful for treating violent patients without causing stupor. Agitated states in the elderly can be controlled without confusion, a dose of 10 to 25 mg once or twice daily usually being adequate.

Flupentixol and pimozide (see ECG monitoring, p. 220) are less sedating than chlorpromazine.

Sulpiride in high doses controls florid positive symptoms, but in lower doses it can have an alerting effect on apathetic withdrawn schizophrenics. Fluphenazine, haloperidol, and trifluoperazine are also of value but their use is limited by the high incidence of extrapyramidal symptoms. Haloperidol may be preferred for the rapid control of hyperactive psychotic states; it causes less hypotension than chlorpromazine and is therefore also popular for agitation and restlessness in the elderly, despite the high incidence of extrapyramidal side-effects.

Promazine is not sufficiently active by mouth to be used as an antipsychotic drug; it has been used to treat psychomotor agitation should be investigated for an underlying cause; it can be managed with low doses of chlorpromazine or haloperidol used for short periods. Antipsychotic drugs can be used with caution for the short-term treatment of severe agitation and restlessness in the elderly (see Other uses, below).

Other uses Nausea and vomiting (section 4.6), choreas, motor tics (section 4.9.3), and intractable hiccup (see under Chlorpromazine Hydrochloride and under Haloperidol). Benperidol is used in deviant antisocial sexual behaviour but its value is not established; see also section 6.4.2 for the role of cyproterone acetate.

Psychomotor agitation should be investigated for an underlying cause; it can be managed with low doses of chlorpromazine or haloperidol used for short periods. Antipsychotic drugs can be used with caution for the short-term treatment of severe agitation and restlessness in the elderly (but see p. 216).

**Equivalent doses of oral antipsychotics**

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication.

<table>
<thead>
<tr>
<th>Antipsychotic drug</th>
<th>Daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpromazine</td>
<td>100 mg</td>
</tr>
<tr>
<td>Clozapine</td>
<td>50 mg</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>2 – 3 mg</td>
</tr>
<tr>
<td>Pimozide</td>
<td>2 mg</td>
</tr>
<tr>
<td>Risperidone</td>
<td>0.5 – 1 mg</td>
</tr>
<tr>
<td>Sulpiride</td>
<td>200 mg</td>
</tr>
<tr>
<td>Trifluoperazine</td>
<td>5 mg</td>
</tr>
</tbody>
</table>

Important These equivalences must not be extrapolated beyond the maximum dose for the drug. Higher doses require careful titration in specialist units and the equivalences shown here may not be appropriate.

### Dosage

**After an initial period of stabilisation, in most patients, the total daily oral dose can be given as a single dose.** For the advice of The Royal College of Psychiatrists on doses above the BNF upper limit, see p. 215.

### Benperidol

**Indications** control of deviant antisocial sexual behaviour (but see notes above)

**Cautions** see notes above; also manufacturer advises regular blood counts and liver function tests during long-term treatment; risk factors for stroke

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**

- 0.25–1.5 mg daily in divided doses, adjusted according to response; ELDERLY (or debilitated) initially half adult dose; CHILD not recommended

**Anquilt** (Archimedes) Tablets, scored, benperidol 250 micrograms, net price 112-tab pack = £97.76. Label: 2

**Note** The proprietary name Benquilt has been used for benperidol tablets

### Chlorpromazine Hydrochloride

**Warning** Owing to the risk of contact sensitisation, pharmacists, nurses, and other health workers should avoid direct contact with chlorpromazine; tablets should not be crushed and solutions should be handled with care

**Indications** see under Dose; antiemetic in palliative care (section 4.6)

**Cautions** see notes above; also diabetes; patients should remain supine, with blood pressure monitoring for 30 minutes after intramuscular injection; dose adjustment may be necessary if smoking started or stopped during treatment

**Contra-indications** see notes above; hypothyroidism

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also hyperglycaemia

**Dose**

- **By mouth**, schizophrenia and other psychoses, mania, short-term adjunctive management of severe anxiety, psychomotor agitation, excitement, and violent or dangerously impulsive behaviour, initially 25 mg 3 times daily (or 75 mg at night), adjusted according to response, to usual maintenance dose of 75–300 mg daily (but up to 1 g daily may be required in psychoses); ELDERLY (or debilitated) third to half adult dose; CHILD (childhood schizophrenia and autism) 1–6 years 500 micrograms/kg every 4–6 hours (max. 40 mg daily); 6–12 years 10 mg 3 times daily (max. 75 mg daily)

Intractable hiccup, 25–50 mg 3–4 times daily

**Important** These equivalences must not be extrapolated beyond the maximum dose for the drug. Higher doses require careful titration in specialist units and the equivalences shown here may not be appropriate.
4.2.1 Antipsychotic drugs

- **Fluanxol**
- **Depixol**

**Indications**
- Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity; depression (section 4.3.4)
- Cautions
  - see notes above
  - diabetes; avoid in acute porphyria (section 9.8.2)
- Contra-indications
  - see notes above
  - Pregnancy
  - see notes above
  - Breast-feeding
  - see notes above

- **Chlorpromazine**
  - (Non-proprietary)
  - Tablets, coated, chlorpromazine hydrochloride 25 mg, net price 28-tab pack = £1.77; net price 100 = £6.86. Label: 2, 11
  - Oral solution, chlorpromazine hydrochloride 25 mg/5 mL, net price 150 mL = £1.79, 100 mg/5 mL, 150 mL = £4.28. Label: 2, 11
  - Injection, chlorpromazine hydrochloride 25 mg/mL, net price 1-mL amp = 60p; 2-mL amp = 63p
  - Suppositories, chlorpromazine 25 mg and 100 mg.
  - Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988
  - **Largactil** (Sanofi-Aventis)
    - Injection, chlorpromazine hydrochloride 25 mg/mL, net price 2-mL amp = 60p

**FLUPENTIXOL** (Flupentixol)

- **Indications**
  - schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity; depression (section 4.3.4)
  - Cautions
  - see notes above
  - diabetes; avoid in acute porphyria (section 9.8.2)
- Contra-indications
  - see notes above
  - Renal impairment
  - see notes above
  - Pregnancy
  - see notes above
- Hepatic impairment
  - see notes above
  - Breast-feeding
  - see notes above
- Side-effects
  - see notes above; less sedating but with extrapyramidal symptoms frequent; hyperglycaemia

**Dose**
- Psychosis, initially 3–9 mg twice daily adjusted according to the response; max. 18 mg daily; ELDENRY (or debilitated) initially half adult dose
- CHILD, not recommended

**Depixol** (Lundbeck)

- Tablets, yellow, s/c, flupentixol 3 mg (as dihydrochloride), net price 100 = £6.23. Label: 2
- **Fluanxol** (Lundbeck)
  - Section 4.3.4 (depression)
  - Depot preparation
  - Section 4.2.2

**HALOPERIDOL**

- **Indications**
  - see under Dose; motor tics (section 4.9.3)
  - Cautions
  - see notes above; also subarachnoid haemorrhage; metabolic disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia; thyrotoxicosis; arteriosclerosis; dose adjustment may be necessary if smoking started or stopped during treatment
- **Contra-indications**
  - see notes above; QT-interval prolongation (avoid concomitant administration of drugs that prolong QT interval); bradycardia
- **Hepatic impairment**
  - see notes above
  - Pregnancy
  - see notes above
  - Renal impairment
  - see notes above
- **Breast-feeding**
  - see notes above
- **Side-effects**
  - see notes above, but less sedating and fewer antimuscarinic or hypotensive symptoms; pigmentation and photosensitivity reactions rare; depression; weight loss; less commonly dyspnoea, oedema; rarely bronchospasm, hypoglycaemia, and inappropriate antidiuretic hormone secretion; hypertension, sweating, Stevens-Johnson syndrome, and toxic epidermal necrolysis also reported

**Dose**
- Schizophrenia and other psychoses, mania, short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour, ADULT and CHILD over 12 years, by mouth, initially 0.5–3 mg 2–3 times daily or 3–5 mg 2–3 times daily in severely affected or resistant patients; in resistant schizophrenia up to 30 mg daily may be needed; adjusted according to response to lowest effective maintenance dose (as low as 5–10 mg daily); ELDENRY (or debilitated) initially half adult dose
  - By intramuscular or by intravenous injection, ADULT over 18 years, initially 2–10 mg, then every 4–8 hours according to response to total max. 18 mg daily; severely disturbed patients may require initial dose of up to 18 mg; ELDENRY (or debilitated) initially half adult dose
- Agitation and restlessness in the elderly, by mouth, initially 0.5–1.5 mg once or twice daily
- Short-term adjunctive management of severe anxiety, by mouth, ADULT over 18 years, 500 micrograms twice daily
- Motor tics, adjunctive treatment in choreas and Tourette syndrome, by mouth, 0.5–1.5 mg 3 times daily adjusted according to response; 10 mg daily or more may occasionally be necessary in Tourette syndrome; CHILD 5–12 years, Tourette syndrome, 12.5–25 microgram/kg twice daily, adjusted according to response up to max. 10 mg daily
- Intractable hiccup, by mouth, ADULT over 18 years, 1.5 mg 3 times daily adjusted according to response
- Nausea and vomiting, see Prescribing in Palliative Care, p. 22
  - By intramuscular or intravenous injection, 1–2 mg

**Haloperidol** (Non-proprietary)

- Tablets, haloperidol 500 micrograms, net price 28-tab pack = 91p; 1.5 mg, 28-tab pack = £1.39; 5 mg, 28-tab pack = £2.15; 10 mg, 28-tab pack = £5.53; 20 mg, 28-tab pack = £14.07. Label: 2
- **Injection**, haloperidol 5 mg/mL, net price 1-mL amp = 37p

**Dozic** (Rosemont)

- Oral liquid, sugar-free, haloperidol 1 mg/mL, net price 100-mL pack = £6.86. Label: 2

**Haldol** (Janssen-Cilag)

- Tablets, both scored, haloperidol 5 mg (blue), net price 100 = £7.21; 10 mg (yellow), 100 = £14.08. Label: 2
4.2.1 Antipsychotic drugs

**Oral liquid**, sugar-free, haloperidol 2 mg/mL, net price 100-mL pack (with pipette) = £4.45. Label: 2

**Injection**, haloperidol 5 mg/mL, net price 1-mL amp = 37p

**Serentan**

**Capsules**, green, haloperidol 500 micrograms, net price 30-cap pack = 98p. Label: 2

**Tablets**, haloperidol 1.5 mg, net price 30-tab pack = £1.74; 5 mg (pink), 30-tab pack = £3.95; 10 mg (pale pink), 30-tab pack = £6.76. Label: 2

**Oral liquid**, sugar-free, haloperidol 2 mg/mL, net price 500-mL pack = £34.48. Label: 2

- **Depot preparation**
  - **Section 4.2.2**

**LEVOMEPROMAZINE**

(Methotrimeprazine)

- **Indications** see under Dose
- **Cautions** see notes above; diabetes; patients receiving large initial doses should remain supine
- **Elderly** Risk of postural hypotension, not recommended for ambulant patients over 50 years unless risk of hypotensive reaction assessed
- **Contra-indications** see notes above
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above
- **Pregnancy** see notes above
- **Breast-feeding** see notes above
- **Side-effects** see notes above; occasionally raised erythrocyte sedimentation rate occurs; hyperglycaemia also reported

**Dose**

- Schizophrenia, by mouth initially 25–50 mg daily in divided doses increased as necessary; bedpatients initially 100–200 mg daily usually in 3 divided doses, increased if necessary to 1 g daily; ELDERLY, see Cautions
- Pain in palliative care, see p. 21
- Restlessness and confusion in palliative care, see p. 23; CHILD 1–18 years, see **BNF for Children**
- Nausea and vomiting in palliative care, by mouth, see p. 22, or by subcutaneous infusion, see p. 23; CHILD 1 month–18 years, see **BNF for Children**

**Nozinar**

(Sanoﬁ-Aventis) [35]

**Tablets**, scored, levomepromazine maleate 25 mg, net price 84-tab pack = £9.23; 10 mg, 84-tab pack = £24.95. Label: 2

**Syrup**, brown, levomepromazine 10 mg/5 mL, net price 100-mL pack = £12.08. Label: 2

**PERICYZANE**

(Pericyazine)

- **Indications** see under Dose
- **Cautions** see notes above; hypothyroidism
- **Contra-indications** see notes above; also agitation and restlessness in the elderly
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above
- **Pregnancy** see notes above
- **Breast-feeding** see notes above
- **Side-effects** see notes above; less sedating; extrapyramidal symptoms, especially dystonia, more frequent, particularly at high dosage; rarely systemic lupus erythematosus

**Dose**

- Schizophrenia and other psychoses, mania, short-term adjunctive management of anxiety, severe psychomotor agitation, excitement, and violent or dangerously impulsive behaviour, initially 15–30 mg (elderly 5–10 mg) daily divided into 2 doses, taking the larger dose at bedtime, adjusted according to response; CHILD not recommended

**Fentazin**

(Goldshield) [35]

**Tablets**, s/c, perphenazine 2 mg, net price 100 = £22.38; 4 mg, 100 = £26.34. Label: 2

**PERPHENAZINE**

- **Indications** see under Dose
- **Cautions** see notes above
- **Contra-indications** see notes above; also prolonged QT interval

**BNF 61**

**PIMOZIDE**

- **Indications** see under Dose
- **Cautions** see notes above; ECG monitoring
- **Contra-indications** see notes above; also prolonged QT interval
- **Hepatic impairment** see notes above
- **Renal impairment** see notes above
- **Pregnancy** see notes above
- **Breast-feeding** see notes above

steps of 25 mg according to response; usual max. 300 mg daily (elderly initially 15–30 mg daily); CHILD and INFANT over 1 year (schizophrenia or behavioural disorders only), initially, 500 micrograms daily for 10-kg child, increased by 1 mg for each additional 5 kg body-weight to max. total daily dose of 10 mg; dose may be gradually increased according to response but maintenance should not exceed twice initial dose

- Short-term adjunctive management of severe anxiety, psychomotor agitation, and violent or dangerously impulsive behaviour, initially 15–30 mg (elderly 5–10 mg) daily divided into 2 doses, taking the larger dose at bedtime, adjusted according to response; CHILD not recommended

**label:** 2
**Side-effects** see notes above; less sedating; serious arrhythmias reported; glycosuria and, rarely, hypotraemia reported

**Dose**
- Schizophrenia, **ADULT** and **CHILD** over 12 years, initially 2–4 mg daily, increased according to response in steps of 2–4 mg at intervals of not less than 1 week; usual dose range 2–20 mg daily; **ELDERLY** half usual starting dose
- Monosymptomatic hypochondriacal psychosis, paranoia psychosis, **ADULT** and **CHILD** over 12 years, initially 4 mg daily, increased according to response in steps of 2–4 mg at intervals of not less than 1 week; max. 16 mg daily; **ELDERLY** half usual starting dose
- **Orap** (Janssen-Cilag) (Non-proprietary) Tablets, scored, green, pimozide 4 mg, net price 100 = £26.87. Label: 2

### PROCHLORPERAZINE

**Indications** see under Dose; antiemetic (section 4.6)

**Cautions** see notes above; also hypotension more likely after intramuscular injection

**Contra-indications** see notes above; children, but see section 4.6 for use as antiemetic

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; less sedating; extrapyramidal symptoms, particularly dystonias, more frequent; respiratory depression may occur in susceptible patients

**Dose**
- By mouth, schizophrenia and other psychoses, mania, prochlorperazine maleate or mesilate, 12.5 mg twice daily for 7 days adjusted at intervals of 4–7 days to usual dose of 75–100 mg daily according to response; **CHILD** not recommended
- Short-term adjunctive management of severe anxiety, 15–20 mg daily in divided doses; max. 40 mg daily; **CHILD** not recommended
- By deep intramuscular injection, psychoses, mania, prochlorperazine mesilate 12.5–25 mg 2–3 times daily; **CHILD** not recommended

### PROMAZINE HYDROCHLORIDE

**Indications** see under Dose

**Cautions** see notes above; also cerebral arteriosclerosis

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also haemolytic anaemia

**Dose**
- Short-term adjunctive management of psychomotor agitation, 100–200 mg 4 times daily; **CHILD** not recommended
- Agitation and restlessness in elderly, 25–50 mg 4 times daily

### SULPIRIDE

**Indications** schizophrenia

**Cautions** see notes above; also excited, agitated, or aggressive patients (even low doses may aggravate symptoms)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also hepatitis

**Dose**
- **ADULT** and **CHILD** over 14 years, 200–400 mg twice daily; max. 800 mg daily in predominantly negative symptoms, and 2.4 g daily in mainly positive symptoms; **ELDERLY** lower initial dose, increased gradually according to response

**Sulpiride** (Non-proprietary) Tablets, sulphiride 200 mg, net price 30-tab pack = £8.09, 56-tab pack = £6.46; 400 mg, 30-tab pack = £18.57. Label: 2

**Dolmatil** (Sanofi-Aventis) Tablets, both scored, sulphiride 200 mg, net price 100-tab pack = £13.31; 400 mg (f/c), 100-tab pack = £34.87. Label: 2

**Sulpor** (Rosemont) Oral solution, sugar-free, lemon- and aniseed-flavoured, sulphiride 200 mg/5 mL, net price 150 mL = £25.38. Label: 2

### TRIFLUOPERAZINE

**Indications** see under Dose; antiemetic (section 4.6)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; extrapyramidal symptoms more frequent, especially at doses exceeding 6 mg daily; anorexia; muscle weakness

**Dose**
- Schizophrenia and other psychoses, short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour, **ADULT** and **CHILD** over 12 years, initially 5 mg twice daily, increased by 5 mg daily after 1 week, then at intervals of 3 days, according to the response; **ELDERLY** reduce initial dose by at least half
- Short-term adjunctive management of severe anxiety, **ADULT** and **CHILD** over 12 years, 2–4 mg daily in divided doses, increased if necessary to 6 mg daily; **CHILD** 3–5 years up to 1 mg daily, 6–12 years up to 4 mg daily; **ELDERLY** reduce initial dose by at least half

**Trifluoperazine** (Non-proprietary) Tablets, coated, trifluoperazine (as hydrochloride) 1 mg, net price 112-tab pack = £6.57; 5 mg, 112-tab pack = £4.89. Label: 2
222 4.2.1 Antipsychotic drugs

Oral solution, trifluoperazine (as hydrochloride) 5 mg/mL, net price 150 mL = £10.84. Label: 2

Stelazine® (Goldshield) [fs]
TABLETS, both blue, f/c, trifluoperazine (as hydrochloride) 1 mg, net price 112 = £3.43; 5 mg, 112 = £4.89. Label: 2

Syrup, sugar-free, yellow, trifluoperazine (as hydrochloride) 1 mg/5 mL, net price 200-mL pack = £2.95. Label: 2

**ZUCLOPENTHIXOL ACETATE**

**Indications** short-term management of acute psychosis, mania, or exacerbations of chronic psychosis

**Cautions** see notes above; avoid in acute porphyria (section 9.8.2)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**
- By deep intramuscular injection into the gluteal muscle or lateral thigh, 50–150 mg (ELDERLY 50–100 mg), if necessary repeated after 2–3 days (1 additional dose may be needed 1–2 days after the first injection); max. cumulative dose 400 mg per course and max. 4 injections; max. duration of treatment 2 weeks—if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate; **CHILD** not recommended

**Clopixol Acuphase® (Lundbeck) [fs]
Injection (oily), zuclopenthixol acetate 50 mg/mL, net price 1–mL amp. = £2.17; 2–mL amp. = £2.94

**Depot preparation** Section 4.2.2

**ZUCLOPENTHIXOL**

**Indications** schizophrenia and other psychoses

**Cautions** see notes above; avoid in acute porphyria (section 9.8.2)

**Contra-indications** see notes above; apathetic or withdrawn states

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; urinary frequency or incontinence; weight loss (less common than weight gain)

**Dose**
- By mouth, initially 20–30 mg daily in divided doses, increasing to a max. of 150 mg daily if necessary; usual maintenance dose 20–50 mg daily; max. single dose 40 mg; ELDERLY (or debilitated) initially quarter to half adult dose; **CHILD** not recommended

**Clopixol® (Lundbeck) [fs]
Tablets, f/c, zuclopenthixol (as dihydrochloride) 2 mg (red), net price 100 = £3.14; 10 mg (light red-brown), 100 = £5.64; 25 mg (red-brown), 100 = £7.22. Label: 2

**Depot preparation** Section 4.2.2

**Atypical antipsychotic drugs**

The ‘atypical’ antipsychotic drugs amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, and risperidone may be better tolerated than other antipsychotic drugs; extrapyramidal symptoms may be less frequent than with older antipsychotic drugs.

Aripiprazole, clozapine, olanzapine, and quetiapine cause little or no elevation of prolactin concentration; when changing from other antipsychotic drugs, a reduction in prolactin may increase fertility.

Clozapine is licensed for the treatment of schizophrenia only in patients unresponsive to, or intolerant of, conventional antipsychotic drugs. It can cause agranulocytosis and its use is restricted to patients registered with a clozapine patient monitoring service (see under Clozapine).

The Scottish Medicines Consortium (p. 4) has advised (April 2009) that quetiapine (Seroquel®) is not recommended for use within NHS Scotland for the treatment of major depressive episodes associated with bipolar disorder.

**NICE guidance Atypical antipsychotics for schizophrenia (June 2002) and schizophrenia (March 2009)**

NICE has recommended that:
- the atypical antipsychotics (amisulpride, olanzapine, quetiapine, risperidone, and zotepine) should be considered when choosing first-line treatment of newly diagnosed schizophrenia;
- an atypical antipsychotic is considered the treatment option of choice for managing an acute schizophrenic episode when discussion with the individual is not possible;
- an atypical antipsychotic should be considered for an individual who is suffering unacceptable side-effects from a conventional antipsychotic;
- an atypical antipsychotic should be considered for an individual in relapse whose symptoms were previously inadequately controlled;
- changing to an atypical antipsychotic is not necessary if a conventional antipsychotic controls symptoms adequately and the individual does not suffer unacceptable side-effects;
- clozapine should be introduced if schizophrenia is inadequately controlled despite the sequential use of two or more antipsychotics (one of which should be an atypical antipsychotic) each for at least 6–8 weeks.
- If symptoms do not respond adequately to an optimised dose of clozapine, measure clozapine plasma levels before adding a second antipsychotic to augment clozapine. If a second antipsychotic is added, there should be 8–10 weeks treatment duration to assess for response.

**Cautions and contra-indications** While atypical antipsychotic drugs have not generally been associated with clinically significant prolongation of the QT interval, they should be used with care if prescribed with other drugs that increase the QT interval. Atypical antipsychotic drugs should be used with caution in patients with cardiovascular disease, or a history of epilepsy; they should be used with great caution in the elderly (see p. 216); **Interactions**: Appendix 1 (antipsychotics).
Driving  Atypical antipsychotic drugs may affect performance of skilled tasks (e.g. driving); effects of alcohol are enhanced.

Withdrawal  Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.

Side-effects  Side-effects of the atypical antipsychotic drugs include weight gain, dizziness, postural hypotension (especially during initial dose titration) which may be associated with syncope or reflex tachycardia in some patients, extrapyramidal symptoms (usually mild and transient and which respond to dose reduction or to an antimuscarinic drug), and occasionally tardive dyskinesia on long-term administration (discontinue drug on appearance of early signs); venous thromboembolism has been reported. Hyperglycaemia and sometimes diabetes can occur, particularly with clozapine, olanzapine, and risperidone; monitoring weight and plasma-glucose concentration may identify the development of hyperglycaemia. Neuroleptic malignant syndrome has been reported rarely. Hyposalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication] (p. 256), provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.

AMISULPRIDE

Indications  schizophrenia

Cautions  see notes above; also Parkinson’s disease

Contra-indications  see notes above; also phaeochromocytoma, prolactin-dependent tumours

Renal impairment  halve dose if eGFR 30–60 mL/minute/1.73 m²; use one-third dose if eGFR 10–30 mL/minute/1.73 m²; no information available if eGFR less than 10 mL/minute/1.73 m²

Pregnancy  avoid

Breast-feeding  avoid—no information available

Side-effects  see notes above; gastro-intestinal disturbances; tachycardia; fatigue, insomnia, akathisia, drowsiness, restlessness, tremor, headache, asthenia; blurred vision; less commonly depression; very rarely anorexia, dysphagia, oropharyngeal spasm, laryngospasm, hepatitis, jaundice, hyperprolactinaemia; occasionally bradycardia; rarely seizures

Dose  ● Acute psychotic episode, 400–800 mg daily in 2 divided doses, adjusted according to response; max. 1.2 g daily; CHILD under 15 years not recommended
  ● Predominantly negative symptoms, 50–300 mg daily; CHILD under 15 years not recommended

Amisulpride  (Non-proprietary)  Tablets, amisulpride 50 mg, net price 60-tab pack = £7.18; 100 mg, 60-tab pack = £31.74; 200 mg, 60-tab pack = £16.47; 400 mg, 60-tab pack = £105.68.

Label: 2

Solan®  (Sanofi-Aventis)  Tablets, scored, amisulpride 50 mg, net price 60-tab pack = £22.76; 100 mg, 60-tab pack = £35.29; 200 mg, 60-tab pack = £58.99; 400 mg, 60-tab pack = £117.97.

Label: 2

Solution, 100 mg/mL, net price 60 mL (caramel flavour) = £33.76. Label: 2

ARIPIPRAZOLE

Indications  see under Dose

Cautions  see notes above; cerebrovascular disease; elderly (reduce initial dose)

Contra-indications  see notes above

Hepatic impairment  use with caution in severe impairment

Pregnancy  use only if potential benefit outweighs risk—no information available

Breast-feeding  avoid—present in milk in animal studies

Side-effects  see notes above; gastrointestinal disturbances; tachycardia; fatigue, insomnia, akathisia, drowsiness, restlessness, tremor, headache, asthenia; blurred vision; less commonly depression; very rarely anorexia, dysphagia, oropharyngeal spasm, laryngospasm, hepatitis, jaundice, hyperprolactinaemia; occasionally bradycardia, hypertension, chest pain, agitation, anxiety, speech disorder, suicidal ideation, seizures, hyponatraemia, stiffness, myalgia, rhabdomyolysis, priapism, urinary retention and incontinence, blood disorders, sweating, alopecia, photosensitivity reactions, rash, weight loss, and impaired temperature regulation; with injection, dry mouth

Dose  ● Schizophrenia, by mouth, ADULT over 18 years 10–15 mg once daily, usual maintenance 15 mg once daily; max. 30 mg once daily; CHILD 15–18 years, initially 2 mg once daily for 2 days, then 5 mg once daily for 2 days, then 10 mg daily; thereafter increased if necessary in steps of 5 mg to max. 30 mg daily
  ● Treatment and prevention of mania, by mouth, ADULT over 18 years, 15 mg once daily; increased if necessary; max. 30 mg once daily
  ● Control of agitation and disturbed behaviour in schizophrenia, by intramuscular injection, ADULT over 18 years, initially 5.25–15 mg (usual dose 9.75 mg) as a single dose followed by 5.25–15 mg after 2 hours if necessary; max. 3 injections daily; max. daily combined oral and parental dose 30 mg

Abilify®  (Bristol-Myers Squibb)  Tablets, aripiprazole 5 mg (blue), net price 28-tab pack = £95.74; 10 mg (pink), 28-tab pack = £95.74; 15 mg (yellow), 28-tab pack = £95.74, 28-tab pack = £191.47. Label: 2

Orodispersible tablets, aripiprazole 10 mg (pink), net price 28-tab pack = £95.74; 15 mg (yellow), 28-tab pack = £95.74. Label: 2, counselling, administration

Excipients include aspartame (section 9.4.1)

Counselling  Tablets should be placed on the tongue and allowed to dissolve, or be dispersed in water and swallowed

Oral solution, aripiprazole 1 mg/mL, net price 150 mL with measuring cup = £102.57. Label: 2

Injection, aripiprazole 7.5 mg/mL, net price 1.3-mL (9.75-mg) vial = £3.42

CLOZAPINE

Indications  schizophrenia (including psychosis in Parkinson’s disease) in patients unresponsive to, or intolerant of, conventional antipsychotic drugs

Cautions  see notes above; elderly; monitor leucocyte and differential blood counts (see Agranulocytosis, below); prostatic hypertrophy, susceptibility to angle-closure glaucoma; taper off other antipsychotics
before starting; close medical supervision during initiation (risk of collapse because of hypotension); dose adjustment may be necessary if smoking started or stopped during treatment

Withdrawal

On planned withdrawal reduce dose over 1–2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.

Agranulocytosis

Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation), if leucocyte count below 3000/mm³ or if absolute neutrophil count below 1500/mm³ discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucocytes; patients should report immediately symptoms of infection, especially influenza-like illness

Myocarditis and cardiomyopathy

Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.

- Perform physical examination and take full medical history before starting
- Specialist examination required if cardiac abnormalities or history of heart disease found—clozapine initiated only in absence of severe heart disease and if benefit outweighs risk
- Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy
- If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist
- Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy

Gastro-intestinal obstruction

Reactions resembling gastro-intestinal obstruction reported. Clozapine should be used cautiously with drugs which cause constipation (e.g. antimuscarinic drugs) or in history of colonic disease or bowel surgery. Monitor for constipation and prescribe laxative if required.

Contra-indications

severe cardiac disorders (e.g. myocarditis; see Cautions); history of neutropenia or agranulocytosis (see Cautions); bone-marrow disorders; paralytic ileus (see Cautions); alcoholic and toxic psychoses; history of circulatory collapse; drug intoxication; coma or severe CNS depression; uncontrolled epilepsy

Hepatic impairment

monitor hepatic function regularly; avoid in symptomatic or progressive liver disease or hepatic failure

Renal impairment

avoid in severe impairment

Pregnancy

use with caution

Breast-feeding

avoid

Side-effects

see notes above; also constipation (see Cautions); hypersalivation, dry mouth, nausea, vomiting, anorexia; tachycardia, ECG changes, hypertensive; drowsiness, dizziness, headache, tremor, seizures, fatigue, impaired temperature regulation; urinary incontinence and retention; leukopenia, eosinophilia, leucocytosis; blurred vision, sweating; less commonly agranulocytosis (important: see Cautions); rarely dysphagia, hepatitis, cholestatic jaundice, pancreatitis, circulatory collapse, arrhythmia, myocarditis (important: see Cautions); peri-carditis, thromboembolism, agitation, confusion, delirium, anaemia; very rarely parotid gland enlargement, intestinal obstruction (see Cautions), cardiomyopathy, myocardial infarction, respiratory depression, priapism, intermittent nephritis, thrombocytopenia, thrombocytopenia, hyperglycaemia, hypercholesterolaemia, hyperlipidaemia, angle-closure glaucoma, fulminant hepatic necrosis, and skin reactions

Dose

- Schizophrenia, ADULT over 16 years, 12.5 mg once or twice (ELDERLY 12.5 mg once) on first day then 25–50 mg (ELDERLY 25–37.5 mg) on second day then increased gradually (if well tolerated) in steps of 25–50 mg daily (ELDERLY max. increment 25 mg daily) over 14–21 days up to 300 mg daily in divided doses (larger dose at night, up to 200 mg daily may be taken as a single dose at bedtime); if necessary may be further increased in steps of 50–100 mg once (preferably) or twice weekly, usual dose 200–450 mg daily (max. 900 mg daily)

Note Restoring after interval of more than 2 days, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)—extreme caution if previous respiratory or cardiac arrest with initial dosing

- Psychosis in Parkinson’s disease, ADULT over 16 years, 12.5 mg at bedtime then increased according to response in steps of 12.5 mg up to twice weekly; usual dose range 25–37.5 mg at bedtime, usual max. 50 mg daily; exceptionally, dose may be increased further in steps of 12.5 mg weekly to max. 100 mg daily in 1–2 divided doses

Clozaril® (Novartis) (NW)

Tablets, yellow, clozapine 25 mg (scored), net price 28-tab pack = £5.40, 84-tab pack (hosp. only) = £16.18, 100-tab pack (hosp. only) = £19.26; 100 mg, 28-tab pack = £21.56, 84-tab pack (hosp. only) = £64.68, 100-tab pack (hosp. only) = £77.00. Label: 2, 10, patient information leaflet

Note Patient, prescriber, and supplying pharmacist must be registered with the Clozaril Patient Monitoring Service—takes several days to do this

Denzapine® (Merz) (NW)

Tablets, yellow, scored, clozapine 25 mg, net price 28-tab pack = £6.17, 84-tab pack = £16.64, 100-tab pack = £19.80; 50 mg, 50-tab pack = £19.80; 100 mg, 28-tab pack = £24.64, 84-tab pack = £66.53, 100-tab pack = £79.20; 200 mg, 50-tab pack = £79.20. Label: 2, 10, patient information leaflet

Suspension, clozapine 50 mg/mL, net price 100 mL = £59.60. Label: 2, 10, patient information leaflet, counselling, administration

Counselling

Shake well for 90 seconds when dispensing or if visibly settled; otherwise shake well for 10 seconds before use

Note May be diluted with water

Note Patient, prescriber, and supplying pharmacist must be registered with the Denzapine Patient Monitoring Service—takes several days to do this

Zaponex® (TEVA UK) (NW)

Tablets, yellow, scored, clozapine 25 mg, net price 84-tab pack = £8.28; 100 mg, 84-tab pack = £33.88. Label: 2, 10, patient information leaflet

Note Patient, prescriber, and supplying pharmacist must be registered with the Zaponex Treatment Access System—takes several days to do this
marrow depression, hypereosinophilic disorders, myeloproliferative disease, Parkinson’s disease; dose adjustment may be necessary if smoking started or stopped during treatment

**CNS and respiratory depression** Blood pressure, pulse and respiratory rate should be monitored for at least 4 hours after intramuscular injection, particularly in those also receiving another antipsychotic or benzodiazepine

**Contra-indications for injection**, acute myocardial infarction, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery

**Hepatic impairment** consider initial dose of 5 mg daily

**Renal impairment** consider initial dose of 5 mg daily

**Pregnancy** use only if potential benefit outweighs risk—present in milk

**Breast-feeding** avoid—present in milk

**Side-effects** see notes above; also dry mouth, constipation, dyspepsia; tachycardia, hypertension, electrolyte abnormalities; rarely seizures, leucopenia, and rash; very rarely hepatitis, pancreatitis, thromboembolism, hypercholesterolaemia, hypothyroidism, urinary retention, priapism, thrombocytopenia, neutropenia, rhabdomyolysis, and alopecia; with injection, sinus pause and hypovolaemia

**Dose**

- Schizophrenia, combination therapy for mania, preventing recurrence in bipolar disorder, by mouth, **ADULT** over 18 years, 10 mg daily adjusted to usual range of 5–20 mg daily; doses greater than 10 mg daily only after reassessment; max. 20 mg daily; **CHILD** 12–18 years, see BNF for Children
- Monotherapy for mania, by mouth, **ADULT** over 18 years, 15 mg daily adjusted to usual range of 5–20 mg daily; doses greater than 15 mg daily only after reassessment; max. 20 mg daily; **CHILD** 12–18 years, see BNF for Children
- Control of agitation and disturbed behaviour in schizophrenia or mania, by intramuscular injection, **ADULT** over 18 years, initially 5–10 mg (usual dose 10 mg) as a single dose followed by 5–10 mg after 2 hours if necessary; **ELDERLY** initially 2.5–5 mg as a single dose followed by 2.5–5 mg after 2 hours if necessary; max. 3 injections daily for 3 days; max. daily combined oral and parenteral dose 20 mg

**Note** When one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase

**Contraindications**

- Pregnancy
- Renal impairment
- Hepatic impairment
- Breast-feeding

**Drug interactions**

- Contra-indications
- Cautions
- Indications
- Dose
- Side-effects
- Contraindications
- Cautions
- Indications
- Dose
- Side-effects

**Depot preparation**

**Note** Paliperidone is a metabolite of risperidone

**Indications** schizophrenia

**Cautions** see notes above; predisposition to gastrointestinal obstruction; elderly patients with dementia and risk factors for stroke; Parkinson’s disease

**Hepatic impairment** caution in severe impairment—no information available

**Renal impairment** initially 3 mg once daily if eGFR 50–80 mL/minute/1.73 m² (max. 6 mg once daily); initially 1.5 mg once daily if eGFR 10–50 mL/minute/1.73 m² (max. 3 mg once daily); avoid if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** use only if potential benefit outweighs risk—toxicity in animal studies; if discontinuation during pregnancy is necessary, withdraw gradually

**Breast-feeding** avoid—present in milk

**Side-effects** see notes above; also abdominal pain, dry mouth, hypersalivation, vomiting; tachycardia, bradycardia, first-degree AV block, bundle branch block, drowsiness, agitation, headache, asthenia; less commonly palpitation, arrhythmias, ischaemia, oedema, seizures, nightmare, syncope, menstrual disturbances, erectile dysfunction, galactorrhoea, gynaecomastia, and rash; cerebrovascular accident also reported

**Dose**

- **ADULT** over 18 years, 6 mg once daily in the morning, adjusted if necessary in increments of 3 mg over at least 5 days; usual range 3–12 mg daily
- **Counselling** Always take with breakfast or always take on an empty stomach

**Invega** (Janssen-Cilag)

**Tablets**, m/c, paliperidone 3 mg (white), net price 28-tab pack = £97.28; 6 mg (beige), 28-tab pack = £97.28; 9 mg (pink), 28-tab pack = £145.92. Label: 2, 25, counselling, administration

**QUETIAPINE**

**Indications** schizophrenia; mania, either alone or with mood stabilisers; depression in bipolar disorder; adjunctive treatment in major depressive disorder

**Cautions** see notes above; also cerebrovascular disease; patients at risk of aspiration pneumonia; treatment of depression in patients under 25 years (increased risk of suicide)

**Hepatic impairment** for immediate-release tablets, initially 25 mg daily, increased daily in steps of 25–50 mg; for modified-release tablets, initially 50 mg daily, increased daily in steps of 50 mg

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** avoid—no information available

**Side-effects** see notes above; also dry mouth, constipation, dyspepsia; tachycardia, hypertension, elevated plasma-triglyceride and -cholesterol concentrations, peripheral oedema; drowsiness, headache,
irritability, dysarthria, asthenia; hyperprolactinaemia; leucopenia, neutropenia; blurred vision; rhinitis; less commonly dysphagia, seizures, restless legs syndrome, and eosinophilia; rarely jaundice and priapism; very rarely hepatitis, angioedema, and Stevens-Johnson syndrome; suicidal behaviour (particularly on initiation) also reported.

**Dose**

- **Schizophrenia.** ADULT over 18 years, 25 mg twice daily on day 1, 50 mg twice daily on day 2. 100 mg twice daily on day 3, 150 mg twice daily on day 4, then adjusted according to response, usual range 300–450 mg daily in 2 divided doses; max. 750 mg daily; ELDERLY initially 25 mg daily as a single dose, increased in steps of 25–50 mg daily in 2 divided doses;

- **Treatment of mania in bipolar disorder.** ADULT over 18 years, 50 mg twice daily on day 1, 100 mg twice daily on day 2, 150 mg twice daily on day 3, 200 mg twice daily on day 4, then adjusted according to response in steps of up to 200 mg daily to max. 800 mg daily; usual range 400–800 mg daily in 2 divided doses; ELDERLY initially 25 mg daily as a single dose, increased in steps of 25–50 mg daily in 2 divided doses;

- **Treatment of depression in bipolar disorder.** ADULT over 18 years, 50 mg once daily (at bedtime) on day 1, 100 mg once daily on day 2, 200 mg once daily on day 3, 300 mg once daily on day 4; adjust according to response, usual dose 300 mg once daily, max. 600 mg daily;

- **Prevention of mania and depression in bipolar disorder.** ADULT over 18 years, continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual range 300–800 mg in 2 divided doses.

**Seroquel® (AstraZeneca)**

- **Tablets.** f/c, quetiapine (as fumarate) 25 mg (peach), net price 60-tab pack = £33.83; 100 mg (yellow), 60-tab pack = £113.10; 150 mg (pale yellow), 60-tab pack = £113.10; 200 mg (white), 60-tab pack = £113.10; 300 mg (white), 60-tab pack = £170.00. Label: 2

**Risperidone**

**Indications**

- **Early and chronic psychoses, mania; short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological interventions and when there is a risk of harm to self or others; short-term treatment (up to 6 weeks) of persistent aggression in conduct disorder (under specialist supervision)**

**Cautions**

- see notes above; Parkinson’s disease; dementia with Lewy bodies; dehydration; avoid in acute porphyria (section 9.8.2)

**Hepatic impairment**

- initial and subsequent oral doses should be halved

**Renal impairment**

- initial and subsequent oral doses should be halved

**Pregnancy**

- use only if potential benefit outweighs risk; extrapyramidal effects reported in neonates when taken in third trimester

**Breast-feeding**

- use only if potential benefit outweighs risk—small amount present in milk

**Side-effects**

- see notes above; also gastro-intestinal disturbances (including diarrhoea, constipation, nausea and vomiting, dyspepsia, abdominal pain), dry mouth; dysphoria; drowsiness, asthenia, tremor, sleep disturbances, agitation, anxiety, headache; urinary incontinence; arthralgia, myalgia; abnormal vision; epistaxis; rash; less commonly anorexia, ECG changes, hypoesthesia, impaired concentration, hyperprolactinaemia (with galactorrhoea, menstrual disturbances, gynaecomastia), sexual dysfunction, blood disorders, tinnitus, angioedema; rarely intestinal obstruction, pancreatitis, jaundice, seizures, hyponatraemia, abnormal temperature regulation; oedema and priapism also reported

**Dose**

- **Psychoses.** 2 mg in 1–2 divided doses on first day then 4 mg in 1–2 divided doses on second day (slower titration appropriate in some patients); usual dose range 4–6 mg daily; doses above 10 mg daily only if benefit considered to outweigh risk (max. 16 mg daily); ELDERLY initially 500 micrograms twice daily increased in steps of 500 micrograms twice daily to 1–2 mg twice daily; CHILD 12–18 years see BNF for Children

- **Mania.** initially 2 mg once daily, increased if necessary in steps of 1 mg daily; usual dose range 1–6 mg daily; ELDERLY initially 500 micrograms twice daily increased in steps of 500 micrograms twice daily to 1–2 mg twice daily

- **Persistent aggression in Alzheimer’s dementia,** initially 250 micrograms twice daily, increased according to response in steps of 250 micrograms twice daily on alternate days; usual dose 500 micrograms twice daily (up to 1 mg twice daily has been reported)

- **Persistent aggression in conduct disorder.** CHILD over 5 years, body-weight under 50 kg, initially 250 micrograms once daily, increased according to response in steps of 250 micrograms on alternate days; usual dose 500 micrograms once daily (up to 750 micrograms once daily has been reported); CHILD over 5 years, body-
weight over 50 kg, initially 500 micrograms once daily, increased according to response in steps of 500 micrograms on alternate days; usual dose 1 mg daily (up to 1.5 mg once daily has been required).

**Risperidone** (Non-proprietary) ▼ [Tab]

Tablets, risperidone 500 micrograms, net price 20-tab pack = £97.9p; 1 mg, 20-tab pack = £1.18, 60-tab pack = £1.70; 2 mg, 60-tab pack = £2.13; 3 mg, 60-tab pack = £2.71; 4 mg, 60-tab pack = £3.52; 6 mg, 28-tab pack = £4.12. Label: 2.

**Orodispersible tablets**, risperidone 0.5 mg, net price 28-tab pack = £16.68; 1 mg, 28-tab pack = £20.51; 2 mg, 28-tab pack = £37.72; 3 mg, 28-tab pack = £41.39; 4 mg, 28-tab pack = £15.20. Label: 2, counselling, administration.

**Counselling** Tablets should be placed on the tongue, allowed to dissolve and swallowed.

**Liquid**, risperidone 1 mg/mL, net price 100-mL pack = £57.40. Label: 2, counselling, use of dose syringe.

**Note** Liquid may be diluted with any non-alcoholic drink, except tea.

**Risperdal®** (Janssen-Cilag) ▼ [Tab]

Tablets, f/c, scored, risperidone 500 micrograms (brown-red), net price 20-tab pack = £5.08; 1 mg (white), 20-tab pack = £8.36, 60-tab pack = £25.08; 2 mg (orange), 60-tab pack = £49.46; 3 mg (yellow), 60-tab pack = £72.73; 4 mg (green), 60-tab pack = £96.00; 6 mg (yellow), 28-tab pack = £157.88. Label: 2.

**Orodispersible tablets** (Quicklet®), pink, risperidone 500 micrograms, net price 28-tab pack = £8.23; 1 mg, 28-tab pack = £17.32; 2 mg, 28-tab pack = £32.65; 3 mg, 28-tab pack = £56.24; 4 mg, 28-tab pack = £66.68. Label: 2, counselling, administration.

**Excipients** include aspartame (section 9.4.1)

**Counselling** Tablets should be placed on the tongue, allowed to dissolve and swallowed.

**Liquid**, risperidone 1 mg/mL, net price 100 mL pack = £52.87. Label: 2, counselling, use of dose syringe.

**Note** Liquid may be diluted with any non-alcoholic drink, except tea.

**Depot preparation**

Section 4.2.2

### 4.2.2 Antipsychotic depot injections

Long-acting depot injections are used for maintenance therapy especially when compliance with oral treatment is unreliable. However, depot injections of conventional antipsychotics may give rise to a higher incidence of extrapyramidal reactions than oral preparations; extrapyramidal reactions occur less frequently with atypical antipsychotic depot preparations, such as risperidone and olanzapine embonate.

**Administration** Depot antipsychotics are administered by deep intramuscular injection at intervals of 1 to 4 weeks. When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged. In general not more than 2–3 mL of oily injection should be administered at any one site; correct injection technique (including the use of z-track technique) and rotation of injection sites are essential. If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

### Dosage

Individual responses to neuroleptic drugs are very variable and to achieve optimum effect, dosage and dosage interval must be titrated according to the patient’s response. For the advice of The Royal College of Psychiatrists on doses above the BNF upper limit, see p. 215.

### Equivalent doses of depot antipsychotics

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication.

<table>
<thead>
<tr>
<th>Antipsychotic drug</th>
<th>Dose (mg)</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flupentixol decanoate</td>
<td>40</td>
<td>2 weeks</td>
</tr>
<tr>
<td>Fluphenazine decanoate</td>
<td>25</td>
<td>2 weeks</td>
</tr>
<tr>
<td>Haloperidol (as decanoate)</td>
<td>100</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Pipotiazine palmitate</td>
<td>50</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate</td>
<td>200</td>
<td>2 weeks</td>
</tr>
</tbody>
</table>

**Important** These equivalences must not be extrapolated beyond the maximum dose for the drug.

### Choice

There is no clear-cut division in the use of the conventional antipsychotics, but zuclopenthixol may be suitable for the treatment of agitated or aggressive patients whereas flupentixol can cause over-excitation in such patients. The incidence of extrapyramidal reactions is similar for the conventional antipsychotics.

### Cautions

See section 4.2.1. Treatment requires careful monitoring for optimum effect. When transferring from oral to depot therapy, the dose by mouth should be reduced gradually.

### Contra-indications

See section 4.2.1. Do not use in children.

### Side-effects

See section 4.2.1. Pain may occur at injection site and occasionally erythema, swelling, and nodules. For side-effects of specific antipsychotics see under the relevant drug.

### FLUPENTIXOL DECANOATE

(Fupentixol Decanoate)

**Indications** maintenance in schizophrenia and other psychoses.

**Cautions** see Flupentixol (section 4.2.1) and notes above; an alternative antipsychotic may be necessary if symptoms such as aggression or agitation appear.

**Contra-indications** see Flupentixol (section 4.2.1) and notes above.

**Hepatic impairment** see section 4.2.1.

**Renal impairment** see section 4.2.1.

**Pregnancy** see section 4.2.1.

**Breast-feeding** see section 4.2.1.

**Side-effects** see Flupentixol (section 4.2.1) and notes above, but may have a mood elevating effect.
228 4.2.2 Antipsychotic depot injections

Dose
- By deep intramuscular injection into the upper outer buttck or lateral thigh, test dose 20 mg, then after at least 7 days 20–40 mg repeated at intervals of 2–4 weeks, adjusted according to response; max. 400 mg weekly; usual maintenance dose 50 mg every 4 weeks to 300 mg every 2 weeks; ELDERLY initially quarter to half adult dose; CHILD not recommended

Depixol® (Lundbeck) injection (oily), fluphenazine decanoate 20 mg/mL, net price 1-mL amp = £1.28; 2-mL amp = £2.49
Depixol Conc.® (Lundbeck) injection (oily), fluphenazine decanoate 100 mg/mL, net price 0.5-mL amp = £1.53; 1-mL amp = £1.84
Depixol Low Volume® (Lundbeck) injection (oily), fluphenazine decanoate 200 mg/mL, net price 1-mL amp = £3.01

FLUPHENAZINE DECANOATE

Indications maintenance in schizophrenia and other psychoses
Cautions see section 4.2.1 and notes above; less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent; systemic lupus erythematosus, inappropriate antidiuretic hormone secretion, and oedema also reported; extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed
Hepatic impairment see section 4.2.1; avoid in hepatic failure
Renal impairment see section 4.2.1; manufacturer advises caution, avoid in renal failure
Pregnancy see section 4.2.1
Breast-feeding see section 4.2.1
Side-effects see section 4.2.1 and notes above; also marked cerebral atherosclerosis

Dose
- By deep intramuscular injection into the gluteal muscle, test dose 12.5 mg (6.25 mg in elderly), then after 4–7 days 12.5–100 mg repeated at intervals of 2–4 weeks; QT-interval prolongation (avoid concomitant drugs that prolong QT interval) not recommended

Note if 2-weekly administration preferred, doses should be halved

Haldol Decanoate® (Janssen-Cilag) injection (oily), haloperidol (as decanoate) 50 mg/mL, net price 1-mL amp = £3.82; 100 mg/mL, 1-mL amp = £5.06
Excipients include sesame oil

HALOPERIDOL

Indications maintenance in schizophrenia and other psychoses
Cautions see Haloperidol (section 4.2.1) and notes above
Contra-indications see Haloperidol (section 4.2.1) and notes above
Hepatic impairment see section 4.2.1
Renal impairment see section 4.2.1
Pregnancy see section 4.2.1
Breast-feeding see section 4.2.1
Side-effects see Haloperidol (section 4.2.1) and notes above

Dose
- By deep intramuscular injection into the gluteal muscle, initially 50 mg every 4 weeks, if necessary increasing by 50-mg increments to 300 mg every 4 weeks; higher doses may be needed in some patients; ELDERLY, initially 12.5–25 mg every 4 weeks; CHILD not recommended

Note if 2-weekly administration preferred, doses should be halved

Haldol Decanoate® (Janssen-Cilag) injection (oily), haloperidol (as decanoate) 50 mg/mL, net price 1-mL amp = £3.82; 100 mg/mL, 1-mL amp = £5.06
Excipients include sesame oil

OLANZAPINE EMBONATE

(olanzapine Pamoate)

Indications maintenance in schizophrenia in patients tolerant to olanzapine by mouth
Cautions see under Olanzapine (section 4.2.1) and notes above; observe patient for at least 3 hours after injection
Contra-indications see under Olanzapine (section 4.2.1) and notes above
Hepatic impairment initially 150 mg every 4 weeks; increase with caution in moderate impairment
Renal impairment initially 150 mg every 4 weeks
Pregnancy see under Olanzapine (section 4.2.1)
Breast-feeding see under Olanzapine (section 4.2.1)
Side-effects see under Olanzapine (section 4.2.1) and notes above; post-injection reactions have been reported leading to signs and symptoms of overdose

Dose
- By deep intramuscular injection into the gluteal muscle, ADULT 18–75 years, patients taking oral olanzapine 10 mg daily, initially 210 mg every 2 weeks or 405 mg every 4 weeks, then maintenance dose after 2 months treatment, 150 mg every 2 weeks or 300 mg every 4 weeks; patients taking oral olanzapine 15 mg daily, initially 300 mg every 2 weeks, then maintenance dose after 2 months treatment, 210 mg every 2 weeks or 405 mg every 4 weeks; patients taking oral olanzapine 20 mg daily, initially 300 mg every 2 weeks, then maintenance dose after 2 months treatment 300 mg every 2 weeks; dose adjusted according to response; max. 300 mg every 2 weeks

Note If supplementation with oral olanzapine required, consult product literature
ZypAdhera® (Lilly) ▼ (BNF)
Injection, powder for reconstitution, olanzapine embonate 210-mg vial, net price = £142.76, 300-mg vial = £222.64, 405-mg vial = £285.52 (all with diluent)

PIPOTIAZINE PALMITATE
(Pipotiazine Palmitate)

**Indications** maintenance in schizophrenia and other psychoses
**Cautions** see Risperidone (section 4.2.1) and notes above; also thyrotoxicosis; hypothyroidism
**Contra-indications** see section 4.2.1 and notes above
**Hepatic impairment** see section 4.2.1
**Renal impairment** see section 4.2.1
**Pregnancy** see section 4.2.1
**Breast-feeding** avoid unless essential
**Side-effects** see section 4.2.1 and notes above; respiratory depression also reported

**Dose**
- By deep intramuscular injection into the gluteal muscle, test dose 25 mg, then a further 25–50 mg after 4–7 days, then adjusted according to response at intervals of 4 weeks; usual maintenance range 50–100 mg (max. 200 mg) every 4 weeks; ELDERLY initially 5–10 mg; CHILD not recommended

Pipotril Depot® (Sanofi-Aventis) ▼ (BNF)
Injection (oily), pipotiazine palmitate 50 mg/mL, net price 1-mL amp = £16.29; 2-mL amp = £26.65

**RISPERIDONE**

**Indications** schizophrenia and other psychoses in patients tolerant to risperidone by mouth
**Cautions** see Risperidone (section 4.2.1) and notes above
**Hepatic impairment** if an oral dose of at least 2 mg daily tolerated, 25 mg as a depot injection can be given every 2 weeks
**Renal impairment** see Risperidone (section 4.2.1)
**Pregnancy** see Risperidone (section 4.2.1)
**Breast-feeding** see Risperidone (section 4.2.1)
**Side-effects** see Risperidone (section 4.2.1); also hypertension; depression, paraesthesia; less commonly apathy, weight loss, injection-site reactions, and pruritus
**Dose**
- By deep intramuscular injection into the deltoid or gluteal muscle, patients taking oral risperidone up to 4 mg daily, initially 25 mg every 2 weeks; patients taking oral risperidone over 4 mg daily, initially 37.5 mg every 2 weeks; dose adjusted at intervals of at least 4 weeks in steps of 12.5 mg to max. 50 mg every 2 weeks; CHILD under 18 years not recommended

Note During initiation risperidone by mouth may need to be continued for 4–6 weeks; risperidone by mouth may also be used during dose adjustment of depot injection

Risperdal Consta® (Janssen-Cilag) ▼ (BNF)
Injection, powder for reconstitution, risperidone 25-mg vial, net price = £79.69; 37.5-mg vial = £111.32; 50-mg vial = £142.76 (all with diluent)

4.2.3 Antimanic drugs

**ZUCLOPENTHIXOL DECANOATE**

**Indications** maintenance in schizophrenia and paranoid psychoses
**Cautions** see section 4.2.1 and notes above; QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval); avoid in acute porphyria (section 9.8.2)
**Contra-indications** see section 4.2.1 and notes above
**Hepatic impairment** see section 4.2.1
**Renal impairment** see section 4.2.1
**Pregnancy** see section 4.2.1
**Breast-feeding** see section 4.2.1
**Side-effects** see section 4.2.1 and notes above

**Dose**
- By deep intramuscular injection into the upper outer buttock or lateral thigh, test dose 100 mg, followed after at least 7 days by 200–500 mg or more, repeated at intervals of 1–4 weeks, adjusted according to response; max. 600 mg weekly; ELDERLY quarter to half usual starting dose; CHILD not recommended

Clopixol® (Lundbeck) ▼ (BNF)
Injection (oily), zuclopenthixol decanoate 200 mg/mL, net price 1-mL amp = £1.99

Clopixol Conc.® (Lundbeck) ▼ (BNF)
Injection (oily), zuclopenthixol decanoate 500 mg/mL, net price 1-mL amp = £3.65

4.2.3 Antimanic drugs

Antimanic drugs are used to control acute attacks and to prevent recurrence of episodes of mania or hypomania. Long-term treatment of bipolar disorder should continue for at least two years from the last manic episode and up to five years if the patient has risk factors for relapse.

An antidepressant drug (section 4.3) may also be required for the treatment of co-existing depression, but should be avoided in patients with rapid-cycling bipolar disorder, a recent history of hypomania, or with rapid mood fluctuations.

Benzodiazepines

Use of benzodiazepines (such as lorazepam) (section 4.1) may be helpful in the initial stages of treatment for behavioural disturbance or agitation; they should not be used for long periods because of the risk of dependence.

Antipsychotic drugs

Antipsychotic drugs (normally olanzapine, quetiapine, or risperidone) (section 4.2.1) are useful in acute episodes of mania and hypomania; if the response to antipsychotic drugs is inadequate, lithium or valproate may be added. An antipsychotic drug may be used concurrently with lithium or valproate in the initial treatment of severe acute mania.

Olanzapine can be used for the long-term management of bipolar disorder [unlicensed use] either as monotherapy, or in combination with lithium or valproate if the patient has frequent relapses or continuing functional impairment.
When discontinuing antipsychotics, the dose should be reduced gradually over at least 4 weeks if the patient is continuing with other antipsychotic drugs; if the patient is not continuing with other antipsychotic drugs or if there is a history of manic relapse, a withdrawal period of up to 3 months should be considered.

High doses of haloperidol or flupentixol may be hazardous when used with lithium; irreversible toxic encephalopathy has been reported.

**Carbamazepine**

Carbamazepine (section 4.8.1) may be used under specialist supervision for the prophylaxis of bipolar disorder (manic-depressive disorder) in patients unresponsive to a combination of other prophylactic drugs; it is used in patients with rapid-cycling manic-depressive illness (4 or more affective episodes per year). The dose of carbamazepine should not normally be increased if an acute episode of mania occurs.

When stopping treatment with carbamazepine, reduce the dose gradually over a period of at least 4 weeks.

**Valproate**

Valproic acid (as the semismsodium salt) is licensed for the treatment of manic episodes associated with bipolar disorder. Sodium valproate (section 4.8.1) is unlicensed for the treatment of bipolar disorder.

Valproate is also used for the prophylaxis of bipolar disorder [unlicensed use]; however, it should not normally be prescribed for women of child-bearing potential. In patients with frequent relapse or continuing functional impairment, consider switching therapy to lithium or olanzapine, or adding lithium or olanzapine to valproate. If a patient taking valproate experiences an acute episode of mania that is not ameliorated by increasing the valproate dose, consider concomitant therapy with olanzapine, quetiapine, or risperidone.

If treatment with valproate is stopped, reduce the dose gradually over at least 4 weeks.

**Lithium**

Lithium salts are used in the prophylaxis and treatment of mania, in the prophylaxis of bipolar disorder (manic-depressive disorder), as concomitant therapy with anti-depressant medication in patients who have had an incomplete response to treatment for acute depression in bipolar disorder, and in the prophylaxis of recurrent depression (unipolar illness or unipolar depression). Lithium is also used as an augmenting agent in patients with treatment-resistant depression (section 4.3).

In acute mania, lithium should only be used in patients who have responded to lithium before and whose symptoms are not severe.

The decision to give prophylactic lithium usually requires specialist advice, and must be based on careful consideration of the likelihood of recurrence in the individual patient, and the benefit of treatment weighed against the risks. The full prophylactic effect of lithium may not occur for six to twelve months after the initiation of therapy. Olanzapine or valproate (given alone or as adjunctive therapy with lithium) are alternative prophylactic treatments in patients who experience frequent relapses or continued functional impairment.

Long-term use of lithium has been associated with thyroid disorders and mild cognitive and memory impairment. Long-term treatment should therefore be undertaken only with careful assessment of risk and benefit, and with monitoring of thyroid function every 6 months [more often if there is evidence of deterioration]. Renal function should be monitored at baseline and every 6 months thereafter [more often if there is evidence of deterioration or if the patient has other risk factors, such as starting ACE inhibitors, NSAIDs, or diuretics]. The need for continued therapy should be assessed regularly and patients should be maintained on lithium after 3–5 years only if benefit persists.

**Serum concentrations**

Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available. Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4–1 mmol/litre (lower end of the range for maintenance therapy and elderly patients). A target serum-lithium concentration of 0.8–1 mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms. It is important to determine the optimum range for each individual patient. Routine serum-lithium monitoring should be performed weekly after initiation and after each dose change until levels are stable, then every 3 months thereafter. Additional serum-lithium measurements should be made if a patient develops significant intercurrent disease or if there is a significant change in a patient’s sodium or fluid intake.

Overdosage, usually with serum-lithium concentration of over 1.5 mmol/litre, may be fatal and toxic effects...
include tremor, ataxia, dysarthria, nystagmus, renal impairment, and convulsions. If these potentially hazardous signs occur, treatment should be stopped, serum-lithium concentrations redetermined, and steps taken to reverse lithium toxicity. In mild cases withdrawal of lithium and administration of sodium salts and fluid will reverse the toxicity. A serum-lithium concentration in excess of 2 mmol/litre requires urgent treatment as described under Emergency Treatment of Poisoning, p. 38.

**Interactions** Lithium toxicity is made worse by sodium depletion, therefore concurrent use of diuretics (particularly thiazides) is hazardous and should be avoided. For other interactions with lithium, see Appendix 1 (lithium).

**Withdrawal** While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be stopped or is to be discontinued abruptly, consider withdrawal or rebound psychosis, abrupt discontinuation of therapy to an atypical antipsychotic or valproate.

While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be stopped or is to be discontinued abruptly, consider

**Pregnancy** Avoid if possible in the first trimester (risk of teratogenicity, including cardiac abnormalities); close monitoring of serum-lithium concentration advised (risk of toxicity in neonate)

**Breast-feeding** Present in milk and risk of toxicity in infant—avoid

**Side-effects** Gastro-intestinal disturbances, fine tremor, renal impairment (particularly impaired urinary concentration and polyuria), polydipsia, leucocytosis; also weight gain and oedema (may respond to dose reduction); hyperparathyroidism, hyperthyroidism, hyperglycaemia, hypermagnesaemia, and hypercalcaemia reported; signs of intoxication are blurred vision, increasing gastro-intestinal disturbances (anorexia, vomiting, diarrhoea), muscle weakness, increased CNS disturbances (mild drowsiness and slurred speech increasing to giddiness with ataxia, coarse tremor, lack of co-ordination, dysarthria), and require withdrawal of treatment; with severe overdose (serum-lithium concentration above 2 mmol/litre) hyperreflexia and hyperextension of limbs, convulsions, toxic psychoses, syncope, renal failure, circulatory failure, coma, and occasionally, death; goitre, raised antidiuretic hormone concentration, hypothyroidism, hypokalaemia, ECG changes, and kidney changes may also occur; see also Emergency Treatment of Poisoning, p. 38

**Dose**

- See under preparations below, adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter; doses are initially divided throughout the day; but once daily administration is preferred when serum-lithium concentration stabilised

**Note** Preparations vary widely in bioavailability, changing the preparation requires the same precautions as initiation of treatment

- Camcolit® (Norgine)
  - **Camcolit 250® tablets**; f/c, scored, lithium carbonate 250 mg (Li⁺ 6.8 mmol), net price 100-tab pack = £3.09. Label: 10, lithium card, counselling, see above
  - **Camcolit 400® tablets**; m/r, f/c, scored, lithium carbonate 400 mg (Li⁺ 10.8 mmol), net price 100-tab pack = £4.13. Label: 10, lithium card, 25, counselling, see above

- **Dose** (see Dose above for advice on bioavailability and serum monitoring)
  - **ADULT** and **CHILD** over 12 years, treatment, initially 1–1.5 g daily; prophylaxis, initially 300–400 mg daily
  - **Note** Camcolit 400® also available as Lithoson® (TEVA UK)

- **Liskonum®** (GSK)
  - **Tablets**; m/r, f/c, scored, lithium carbonate 450 mg (Li⁺ 12.2 mmol), net price 60-tab pack = £2.88. Label: 10, lithium card, 25, counselling, see above
  - **Dose** (see Dose above for advice on bioavailability and serum monitoring)

- **Priadel®** (Sanofi-Aventis)
  - **Tablets**; m/r, both scored, lithium carbonate 200 mg (Li⁺ 5.4 mmol), net price 100-tab pack= £2.30; 400 mg (Li⁺ 10.8 mmol), 100-tab pack = £3.35. Label: 10, lithium card, 25, counselling, see above
  - **Dose** (see Dose above for advice on bioavailability and serum monitoring)

- **Liquid**; see under Lithium Carbonate below

**Lithium treatment packs**

A lithium treatment pack may be given to patients on initiation of treatment with lithium. The pack consists of a patient information booklet, lithium alert card, and a record book for tracking serum-lithium concentration. Packs may be purchased from 3M.

Tel: 0845 610 1112
nhsforms@spsl.uk.com

**4.2.3 Antimanic drugs 231**

Central nervous system
Central nervous system

4.3 Antidepressant drugs

232

**LITHIUM CITRATE**

**Indications** see under Lithium Carbonate and notes above

**Cautions** see under Lithium Carbonate and notes above

**Counselling** Patients should maintain an adequate fluid intake and should avoid dietary changes which might reduce or increase sodium intake; lithium treatment cards are available from pharmacies (see above).

**Renal impairment** see Lithium Carbonate

**Pregnancy** see Lithium Carbonate

**Breast-feeding** see Lithium Carbonate

**Side-effects** see under Lithium Carbonate and notes above

**Dose**

- See under preparations below, adjusted to achieve serum-lithium concentration of 0.4–1 mmol/litre as described under Lithium Carbonate

**Note** Preparations vary widely in bioavailability, changing the preparation requires the same precautions as initiation of treatment

**Li-Liquid® (Rosemont)**

**Oral solution**. Lithium citrate 509 mg/5 mL (Li⁺ 5.4 mmol/5 mL), yellow, net price 150-mL pack = £5.79; 1.018 g/5 mL (Li⁺ 10.8 mmol/5 mL), orange, 150-mL pack = £11.58. Label: 10, lithium card, counselling, see above

**Dose** (see Dose above for advice on bioavailability and serum monitoring):

- Treatment and prophylaxis, initially 1.018–3.054 g daily in 2 divided doses (elderly or patients less than 50 kg, initially 509 mg twice daily). CHILD: not recommended

**Note** 5-mL dose of 509 mg/5 mL oral solution is equivalent to 200 mg lithium carbonate

**Pridad® (Sanofi-Aventis)**

**Tablets**, see under Lithium Carbonate

**Liquid**, sugar-free, lithium citrate 520 mg/5 mL (approx. Li⁺ 5.4 mmol/5 mL), net price 150-mL pack = £5.61. Label: 10, lithium card, counselling, see above

**Dose** (see Dose above for advice on bioavailability and serum monitoring):

- Treatment and prophylaxis, initially 1.04–3.12 g daily in 2 divided doses (elderly or patients less than 50 kg, 520 mg twice daily). CHILD: not recommended

**Note** 5-mL dose is equivalent to 204 mg lithium carbonate

**Choice** The major classes of antidepressant drugs include the tricyclic and related antidepressants (section 4.3.1), the selective serotonin re-uptake inhibitors (SSRIs) (section 4.3.3), and the monoamine oxidase inhibitors (MAOIs) (section 4.3.2). A number of antidepressant drugs cannot be accommodated easily into this classification; these are included in section 4.3.4.

There is little to choose between the different classes of antidepressant drugs in terms of efficacy, so choice should be based on the individual patient's requirements, including the presence of concomitant disease, existing therapy, suicide risk, and previous response to antidepressant therapy. Since there may be an interval of 2 weeks before the antidepressant action takes place, electroconvulsive treatment may be required in severe depression when delay is hazardous or intolerable. During the first few weeks of treatment, there is an increased potential for agitation, anxiety, and suicidal ideation (see p. 233).

SSRIs are better tolerated and are safer in overdose than other classes of antidepressants and should be considered first-line for treating depression. In patients with unstable angina or who have had a recent myocardial infarction, sertraline has been shown to be safe.

Tricyclic antidepressants have similar efficacy to SSRIs but are more likely to be discontinued because of side-effects; toxicity in overdosage is also a problem. See section 4.3.1 for more details.

MAOIs have dangerous interactions with some foods and drugs, and should be reserved for use by specialists. Although anxiety is often present in depressive illness (and may be the presenting symptom), the use of an antipsychotic or an anxiolytic may mask the true diagnosis. Anxiolytics (section 4.1.2) or antipsychotic drugs (section 4.2.1) should therefore be used with caution in depression but they are useful adjuncts in agitated patients. Augmenting antidepressants with antipsychotics under specialist supervision may also be necessary in patients who have depression with psychotic symptoms.

See section 4.2.3 for notes on the management of bipolar disorder.

St John's wort (Hypericum perforatum) is a popular herbal remedy on sale to the public for treating mild depression. It should not be prescribed or recommended for depression because St John's wort can induce drug metabolising enzymes and a number of important interactions with conventional drugs, including conventional antidepressants, have been identified (see Appendix 1, St John's wort). Furthermore, the amount of active ingredient varies between different preparations of St John's wort and switching from one to another can change the degree of enzyme induction. If a patient stops taking St John's wort, concentrations of interacting drugs may increase, leading to toxicity.
Electroconvulsive therapy may be initiated in severe depression with special experience of these combinations. Such adjunctive treatment should be initiated only by prescribers with appropriate experience in the use of these agents. Aripiprazole [unlicensed], olanzapine [unlicensed], quetiapine, and other antidepressants of a different class, or use of other tricyclic antidepressants should be considered in all patients who develop drowsiness, confusion, or convulsions while taking an antidepressant.

Suicidal behaviour and antidepressant therapy

The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.

Management

Patients should be reviewed every 1–2 weeks at the start of antidepressant treatment. Treatment should be continued for at least 4 weeks (6 weeks in the elderly) before considering whether to switch antidepressant due to lack of efficacy. In cases of partial response, continue for a further 2–4 weeks (elderly patients may take longer to respond).

Following remission, antidepressant treatment should be continued at the same dose for at least 6 months (about 12 months in the elderly). Patients with a history of recurrent depression should receive maintenance treatment for at least 2 years.

Failure to respond

Failure to respond to initial treatment with an SSRI may require an increase in the dose, or switching to a different SSRI or mirtazapine. Other second-line choices include nefazodone, moclobemide, and reboxetine. Other tricyclic antidepressants and venlafaxine should be considered for more severe forms of depression; irreversible MAOIs should only be prescribed by specialists. Failure to respond to a second antidepressant may require the addition of another antidepressant of a different class, or use of an augmenting agent (such as lithium (section 4.2.3), aripiprazole [unlicensed], olanzapine [unlicensed], quetiapine, or risperidone [unlicensed] (section 4.2.1)), but such adjunctive treatment should be initiated only by doctors with special experience of these combinations. Electroconvulsive therapy may be initiated in severe refractory depression.

Withdrawal

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. Drugs with a shorter half-life, such as paroxetine (p. 241) and venlafaxine (p. 244), are associated with a higher risk of withdrawal symptoms. The risk of withdrawal symptoms is also increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). See also section 4.3.1, section 4.3.2, and section 4.3.3.

Anxiety disorders and obsessive-compulsive disorder

Management of acute anxiety generally involves the use of a benzodiazepine or buspirone (section 4.1.2). For chronic anxiety (of longer than 4 weeks’ duration) it may be appropriate to use an antidepressant. Combined therapy with a benzodiazepine may be required until the antidepressant takes effect. Generalised anxiety disorder, a form of chronic anxiety, is treated with an SSRI such as escitalopram or paroxetine; pregabalin and venlafaxine are also licensed for the treatment of generalised anxiety disorder.

Panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and phobic states such as social anxiety disorder are treated with SSRIs. Clomipramine or imipramine can be used second-line in panic disorder [unlicensed]; clomipramine can also be used second-line for obsessive-compulsive disorder. Moclobemide is licensed for the treatment of social anxiety disorder.

Cautions

Tricyclic and related antidepressant drugs should be used with caution in patients with cardiovascular disease (see also Contra-indications, below); because of the risk of arrhythmias, patients with comorbid conditions such as hyperthyroidism and phaeochromocytoma should be treated with care. Care is also needed in patients with epilepsy and diabetes.

Tricyclic antidepressant drugs have antimuscarinic activity, and therefore caution is needed in patients with prostatic hypertrophy, chronic constipation, increased intra-ocular pressure, urinary retention, or those with a susceptibility to angle-closure glaucoma. Tricyclic and related antidepressant drugs should be used with caution in patients with a significant risk of suicide, or a history of psychosis or bipolar disorder, because antidepressant therapy may aggravate these conditions; treatment should be stopped if the patient enters a manic phase.

Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

Overdosage

Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose. In particular, overdosage with dosulepin and amitriptyline is associated with a relatively high rate of fatality. Lofepramine is associated with the lowest risk of fatality in overdose, in comparison with other tricyclic antidepressant drugs. For advice on overdose see Emergency Treatment of Poisoning, p. 37.
**Withdrawing** Amitriptyline and imipramine are the tricyclic antidepressants most commonly associated with withdrawal symptoms. These symptoms include influenza-like symptoms (chills, myalgia, sweating, headache, nausea), insomnia, vivid dreams, and may occasionally include movement disorders, mania, and cardiac arrhythmia. If possible tricyclic and related antidepressants should be withdrawn slowly (see also section 4.3).

**Interactions** A tricyclic or related antidepressant (or an SSRI or related antidepressant) should not be started until 2 weeks after stopping an MAOI (3 weeks if starting clomipramine or imipramine). Conversely, an MAOI should not be started until at least 7–14 days after a tricyclic or related antidepressant (3 weeks in the case of clomipramine or imipramine) has been stopped. For guidance relating to the reversible monoamine oxidase inhibitor, moclobemide, see p. 239. For other tricyclic antidepressant interactions, see Appendix 1 (antidepressants, tricyclic and related antidepressants, tricyclic (related)).

**Driving** Drowsiness may affect the performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

**Contra-indications** Tricyclic and related antidepressants are contra-indicated in the immediate recovery period after myocardial infarction, in arrhythmias (particularly heart block), and in the manic phase of bipolar disorder. Avoid treatment with tricyclic antidepressant drugs in acute porphyria (section 9.8.2).

**Hepatic impairment** Tricyclic antidepressants are preferable to MAOIs in hepatic impairment but sedative effects are increased. They should be avoided in severe liver disease.

**Breast-feeding** The amount of tricyclic antidepressants (including related drugs such as mianserin and trazodone) secreted into breast milk is too small to be harmful (but see Doxepin, p. 236).

**Side-effects** Arrhythmias and heart block occasionally follow the use of tricyclic antidepressants, particularly amitriptyline, and may be a factor in the sudden death of patients with cardiac disease; other cardiovascular side-effects include postural hypotension, tachycardia, and ECG changes. The tricyclic-related antidepressant drugs may be associated with a lower risk of cardiotoxicity in overdose.

Central nervous system side-effects are common, particularly in the elderly, and include anxiety, dizziness, agitation, confusion, sleep disturbances, irritability, and paraesthesia; drowsiness is associated with some of the tricyclic antidepressants (see under Choice, below). Convulsions, hallucinations, delusions, mania, and hypomania may occur (see also under Cautions, above), and, rarely, extrapyramidal symptoms including tremor and dysarthria. Antimuscarinic side-effects include dry mouth, blurred vision (very rarely precipitation of angle-closure glaucoma), constipation (rarely) leading to paralytic ileus, particularly in the elderly, and urinary retention. Tricyclic-related antidepressant drugs have a lower incidence of antimuscarinic side-effects than older tricyclics.

Endocrine effects include breast enlargement, galactorrhoea, and gynaecomastia. Sexual dysfunction may occur. Changes in blood sugar, increased appetite, and weight gain can accompany treatment with tricyclic antidepressant drugs, but anorexia and weight loss are also seen. Hepatic and haematological reactions may occur and have been particularly associated with mianserin. Another side-effect to which the elderly are particularly susceptible is hyponatraemia (see Hyponatraemia and Antidepressant Therapy, p. 233). Other class side-effects include nausea, vomiting, taste disturbance, tinnitus, rash, urticaria, pruritus, photosensitivity, alopecia, and sweating.

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Neuroleptic malignant syndrome (section 4.2.1) may, very rarely, occur in the course of antidepressant drug treatment.

Suicidal behaviour has been linked with antidepressants (see p. 233).

**Dosage** About 10 to 20% of patients fail to respond to tricyclic and related antidepressant drugs and inadequate dosage may account for some of these failures. It is important to use doses that are sufficiently high for effective treatment but not so high as to cause toxic effects. Low doses should be used for initial treatment in the elderly (see under Side-effects, below).

In most patients the long half-life of tricyclic antidepressant drugs allows once-daily administration, usually at night; the use of modified-release preparations is therefore unnecessary.

**Choice** Tricyclic and related antidepressants block the re-uptake of both serotonin and noradrenaline, although to different extents. For example, clomipramine is more selective for serotoninergic transmission, and imipramine is more selective for noradrenergic transmission. Tricyclic and related antidepressant drugs can be roughly divided into those with additional sedative properties and those that are less sedating. Agitated and anxious patients tend to respond best to the sedative compounds, whereas withdrawn and apathetic patients will often obtain most benefit from the less sedating ones. Those with sedative properties include amitriptyline, clomipramine, doxepin, doxepin, mianserin, trazodone, and trimipramine. Those with less sedative properties include imipramine, lofepramine, and nor-triptyline.

Tricyclic and related antidepressants also have varying degrees of antimuscarinic side-effects and cardiotoxicity in overdose, which may be important in individual patients. Lofepramine has a lower incidence of side-effects and is less dangerous in overdose but is infrequently associated with hepatic toxicity. Imipramine is also well established, but has more marked antimuscarinic side-effects than other tricyclic and related antidepressants.

* Amitriptyline and doxepin are effective but they are particularly dangerous in overdose (see Overdose, above) and are not recommended for the treatment of depression; doxepin should only be prescribed by specialists.

**Children and adolescents** Studies have shown that tricyclic antidepressants are not effective for treating depression in children; see also Depressive Illness in Children and Adolescents, p. 239.
Tricyclic antidepressants

Amitriptyline Hydrochloride

**Indications** depressive illness (but not recommended, see notes above); nocturnal enuresis in children (section 7.4.2); neuropathic pain (unlicensed) (section 4.7.3); migraine prophylaxis (unlicensed) (section 7.4.2)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** see notes above

**Side-effects** see notes above; also abdominal pain, diarrhoea, hypertension, flushing, restlessness, fatigue, mydriasis, and increased intra-ocular pressure; high rate of fatality in overdose—see notes above

**Dose**

- **Depression** (but not recommended, see notes above), ADULT and CHILD over 14 years, initially 75 mg (elderly and adolescents 30–75 mg) daily in divided doses or as a single dose at bedtime increased gradually as necessary to 150–200 mg
- **Nocturnal enuresis**, CHILD 7–11 years 10–20 mg at night, 11–16 years 25–50 mg at night; max. period of treatment (including gradual withdrawal) 3 months—full physical examination, including ECG, before further course
- **Neuropathic pain** (unlicensed indication), initially 10 mg daily at night, gradually increased if necessary to 75 mg daily; higher doses under specialist supervision
- **Migraine prophylaxis** (unlicensed indication), initially 10 mg at night, increased if necessary to maintenance of 50–75 mg at night; max. 150 mg at night

**Amitriptyline** *(Non-proprietary)*

**Tablets**, coated, amitriptyline hydrochloride 10 mg, net price 28-tab pack = £0.90; 25 mg, 28-tab pack = £0.99; 50 mg, 28-tab pack = £1.00. Label: 2

**Oral solution**, amitriptyline hydrochloride 25 mg/5 mL, net price 150 mL = £15.47; 50 mg/5 mL, 150 mL = £16.82. Label: 2

**Compound preparations**

**Triptafen** *(Goldshield)*

**Tablets**, pink, s/c, amitriptyline hydrochloride 25 mg, perphenazine 2 mg, net price 100-tab pack = £25.49. Label: 2

Dose depression with anxiety, ADULT and CHILD over 14 years, 1 tablet 3 times daily; an additional tablet may be taken at bedtime when required

Clopipramine Hydrochloride

**Indications** depressive illness, phobic and obsessional states; adjunctive treatment of cataplexy associated with narcolepsy

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Pregnancy** neonatal withdrawal symptoms reported if used during third trimester

**Breast-feeding** see notes above

**Side-effects** see notes above; also abdominal pain, diarrhoea, hypertension, flushing, restlessness, fatigue, aggression, impaired memory, muscle weakness, muscle hypertonia, myoclonus, mydriasis, and yawning; very rarely allergic alveolitis

**Dose**

- **Depressive illness**, ADULT over 18 years, initially 10 mg daily, increased gradually as necessary to 30–150 mg daily in divided doses or as a single dose at bedtime; max. 250 mg daily; ELDERLY initially 10 mg daily increased carefully over approx. 10 days to 30–75 mg daily
- **Phobic and obsessional states**, ADULT over 18 years, initially 25 mg daily (ELDERLY 10 mg daily) increased over 2 weeks to 100–150 mg daily; max. 250 mg daily
- **Adjunctive treatment of cataplexy associated with narcolepsy**, ADULT over 18 years, initially 10 mg daily, gradually increased until satisfactory response (range 10–75 mg daily)

**Clomipramine** *(Non-proprietary)*

**Capsules**, clomipramine hydrochloride 10 mg, net price 28-cap pack = £1.71; 25 mg, 28-cap pack = £2.01; 50 mg, 28-cap pack = £2.75. Label: 2

**Anafanril** *(Novartis)*

**Capsules**, clomipramine hydrochloride 10 mg (yellow/caramel), net price 84-cap pack = £8.35; 50 mg (grey/caramel), 56-cap pack = £8.06. Label: 2

**Modified release**

**Anafanril SR** *(Novartis)*

**Tablets**, m/r, grey-red, f/c, clomipramine hydrochloride 75 mg, net price 28-tab pack = £8.83. Label: 2, 25

**Dose** see above; to be taken once daily

**Dosulepin Hydrochloride** *(Dothiepin hydrochloride)*

**Indications** depressive illness, particularly where sedation is required

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** see notes above

**Side-effects** see notes above; also increased intra-ocular pressure; high rate of fatality in overdose—see notes above

**Dose**

- Initially 75 mg (ELDERLY 50–75 mg) daily in divided doses or as a single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient); up to 225 mg daily in some circumstances (e.g. hospital use); CHILD not recommended

**Dosulepin** *(Non-proprietary)*

**Capsules**, dosulepin hydrochloride 25 mg, net price 28-cap pack = £1.11. Label: 2

**Tablets**, dosulepin hydrochloride 75 mg, net price 28-tab pack = £1.34. Label: 2

**Prothiaden** *(Teofarma)*

**Capsules**, red/red-brown, dosulepin hydrochloride 25 mg, net price 28-cap pack = £1.70. Label: 2

**Tablets**, red, s/c, dosulepin hydrochloride 75 mg, net price 28-tab pack = £2.97. Label: 2
4 Central nervous system

**DOXEPIN**

**Indications** depressive illness, particularly where sedation is required; pruritus in eczema (section 13.3)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** use with caution

**Pregnancy** neonatal withdrawal symptoms and respiratory depression reported if used during third trimester

**Breast-feeding** see notes above

**Side-effects** see notes above; accumulation of metabolite may cause sedation and respiratory depression in neonate

**Dose**
- **ADULT** and **CHILD** over 12 years, initially 75 mg daily in divided doses or as a single dose at bedtime, adjusted according to response; usual maintenance 30–300 mg daily (doses above 100 mg given in 3 divided doses); **ELDERLY** initially 10–50 mg daily adjusted according to response (usual maintenance 50–50 mg daily)

**Sinapin** (Marlborough) (TM)

**Capsules**, doxepin (as hydrochloride) 25 mg, net price 28-cap pack = £3.77; 50 mg, 28-cap pack = £5.71. Label: 2

**LOFEPRAMINE**

**Indications** depressive illness

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** see notes above

**Side-effects** see notes above; also oedema and hepatic disorders reported

**Dose**
- 140–210 mg daily in divided doses; **ELDERLY** may respond to lower doses; **CHILD** under 18 years not recommended

**Lofepramine** (Non-proprietary) (TM)

**Tablets**, lofepramine 70 mg (as hydrochloride), net price 56-tab pack = £5.69. Label: 2

**Brands include** Feprapax®

**Oral suspension**, lofepramine 70 mg/5 mL (as hydrochloride), net price 150 mL = £22.22. Label: 2

**Brands include** Lomont® (sugar-free)

**NORTRIPTYLINE**

**Indications** depressive illness; nocturnal enuresis in children (section 7.4.2); neuropathic pain [unlicensed] (section 4.7.3)

**Cautions** see notes above; manufacturer advises plasma-nortriptyline concentration monitoring if dose above 100 mg daily, but evidence of practical value uncertain

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** see notes above

**Side-effects** see notes above; also abdominal pain, stomatitis, diarrhoea, flushing, and oedema

**Dose**
- Depression, low dose initially increased as necessary to 75–100 mg daily in divided doses or as a single dose at bedtime (max. 150 mg daily); **ADOLESCENT** and **ELDERLY** 30–50 mg daily in divided doses; **CHILD** not recommended for depression
- Nocturnal enuresis, **CHILD** 7 years 10 mg, 8–11 years 10–20 mg, over 11 years 25–35 mg, 30 minutes before bedtime; max. period of treatment (including gradual withdrawal) 3 months—full physical examination and ECG before further course
- Neuropathic pain [unlicensed], initially 10 mg daily at night, gradually increased if necessary to 75 mg daily; higher doses under specialist supervision

**Allegron** (King) (TM)

**Tablets**, nortriptyline (as hydrochloride) 10 mg, net price 100-tab pack = £12.06; 25 mg (orange, scored), 100-tab pack = £24.02. Label: 2

**IMIPRAMINE HYDROCHLORIDE**

**Indications** depressive illness; nocturnal enuresis in children (section 7.4.2)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** use with caution in severe impairment

**Pregnancy** use with caution in severe impairment

**Breast-feeding** see notes above

**Side-effects** see notes above; also abdominal pain, stomatitis, diarrhoea, hypertension, oedema, flushing, restlessness, fatigue, and mydriasis

**Dose**
- Depression, initial dose (max. 150 mg daily); **ADOLESCENT** and **ELDERLY** 30–50 mg daily in divided doses; **CHILD** not recommended for depression
- Nocturnal enuresis, **CHILD** 7 years 10 mg, 8–11 years 10–20 mg, over 11 years 25–35 mg, 30 minutes before bedtime; max. period of treatment (including gradual withdrawal) 3 months—full physical examination and ECG before further course
- Neuropathic pain [unlicensed], initially 10 mg daily at night, gradually increased if necessary to 75 mg daily; higher doses under specialist supervision

**Imipramine** (Non-proprietary) (TM)

**Tablets**, coated, imipramine hydrochloride 10 mg, net price 28-tab pack = £1.30; 25 mg, 28-tab pack = £1.24. Label: 2

**Oral solution**, imipramine hydrochloride 25 mg/5 mL, net price 150-mL = £20.00. Label: 2

**TRIMIPRAMINE**

**Indications** depressive illness, particularly where sedation required

**Cautions** see notes above
Monamine-oxidase inhibitors (MAOIs)

Monoamine-oxidase inhibitors are used much less frequently than tricyclic and related antidepressants, or SSRIs and related antidepressants because of the dangers of dietary and drug interactions and the fact that it is easier to prescribe MAOIs when tricyclic antidepressants have been unsuccessful than vice versa. Transylcypromine is the most hazardous of the MAOIs because of its stimulant action. The drugs of choice are phenelzine or isocarboxazid which are less stimulant and therefore safer.

Phobic patients and depressed patients with atypical, hypochondriacal, or hysterical features are said to respond best to MAOIs. However, MAOIs should be tried in any patients who are refractory to treatment with other antidepressants as there is occasionally a dramatic response. Response to treatment may be delayed for 3 weeks or more and may take an additional 1 or 2 weeks to become maximal.

Withdrawal MAOIs are associated with withdrawal symptoms on cessation of therapy. Symptoms include agitation, irritability, ataxia, movement disorders, insomnia, drowsiness, vivid dreams, cognitive impairment, and slowed speech. Withdrawal symptoms occasionally experienced when discontinuing MAOIs include hallucinations and paranoid delusions. If possible MAOIs should be withdrawn slowly (see also section 4.3).

Hepatic impairment MAOIs may cause idiosyncratic hepatotoxicity if used in patients with hepatic impairment. See also individual monographs.

Pregnancy There is an increased risk of neonatal malformations when phenelzine, isocarboxazid, or tranylcypromine is used during pregnancy. The safety of moclobemide in pregnancy has not been established. Manufacturers advise avoid use unless there are compelling reasons.
4.3.2 Monoamine-oxidase inhibitors

**Interactions** MAOIs inhibit monoamine oxidase, thereby causing an accumulation of amine neurotransmitters. The metabolism of some amine drugs such as indirect-acting sympathomimetics (present in many cough and decongestant preparations, section 3.10) is also inhibited and their pressor action may be potentiated; the pressor effect of tyramine (in some foods, such as mature cheese, pickled herring, broad bean pods, and Bovril, Oxo®, Marmite® or any similar meat or yeast extract or fermented soya bean extract) may also be dangerously potentiated. These interactions may cause a dangerous rise in blood pressure. An early warning symptom may be a throbbing headache. Patients should be advised to eat only fresh foods and avoid food that is suspected of being stale or ‘going off’. This is especially important with meat, fish, poultry or offal; game should be avoided. The danger of interaction persists for up to 2 weeks after treatment with MAOIs is discontinued. Patients should also avoid alcoholic drinks or de-alcoholised (low alcohol) drinks.

**Other antidepressants** should not be started for 2 weeks after treatment with MAOIs has been stopped (3 weeks if starting clomipramine or imipramine). Some psychiatrists use selective tricyclics in conjunction with MAOIs but this is hazardous, indeed potentially lethal, except in experienced hands and there is no evidence that the combination is more effective than when either constituent is used alone. The combination of tranylcypromine with clomipramine is particularly dangerous.

Conversely, an MAOI should not be started until at least 7–14 days after a tricyclic or related antidepressant (3 weeks in the case of clomipramine or imipramine) has been stopped.

In addition, an MAOI should not be started for at least 2 weeks after a previous MAOI has been stopped (then started at a reduced dose).

For other interactions with MAOIs including those with opioid analgesics (notably pethidine), see Appendix 1 (MAOIs). For guidance on interactions relating to the reversible monoamine oxidase inhibitor, moclobemide, see p. 239; for guidance on interactions relating to SSRIs, see p. 240.

**PHENELZINE**

**Indications** depressive illness

**Cautions** diabetes mellitus, cardiovascular disease, epilepsy, blood disorders, concurrent electroconvulsive therapy, elderly (great caution); monitor blood pressure (risk of postural hypotension and hypertensive responses—discontinue if palpitations or frequent headaches); if possible avoid abrupt withdrawal; severe hypertensive reactions to certain drugs and foods; avoid in agitated patients; acute porphyria (section 9.8.2); surgery (section 15.1); interactions: Appendix 1 (MAOIs).

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving).

**Contra-indications** cerebrovascular disease, phaeochromocytoma; not indicated in manic phase

**Hepatic impairment** avoid in hepatic impairment; see also notes above

**Renal impairment** use with caution

**Pregnancy** see notes above

**Breast-feeding** avoid

**Side-effects** commonly postural hypotension (especially in elderly) and dizziness; less common side-effects include drowsiness, insomnia, headache, weakness and fatigue, dry mouth, constipation and other gastro-intestinal disturbances, oedema, myoclonic movement, hyperreflexia, elevated liver enzymes; agitation and tremors, nervousness, euphoria, arrhythmias, blurred vision, nystagmus, difficulty in micturition, sweating, convulsions, rashes, purpura, leucopenia, sexual disturbances, and weight gain with inappropriate appetite may also occur; psychotic episodes with hypomanic behaviour, confusion, and hallucinations may be induced in susceptible persons; suicidal behaviour (see p. 233); jaundice has been reported and, on rare occasions, fatal progressive hepatocellular necrosis; paraesthesia, peripheral neuritis, peripheral neuropathy may be due to pyridoxine deficiency; hypotension (see Hypotension and Antidepressant Therapy, p. 233)

**Dose**

- Initially 30 mg daily in single or divided doses until improvement occurs (increased after 4 weeks if necessary to max. 60 mg daily for 4–6 weeks under close supervision), then reduced to usual maintenance dose 10–20 mg daily (but up to 40 mg daily may be required); Elderly 5–10 mg daily; Child not recommended

**Isocarboxazid** (Non-proprietary)

Tablets, pink, scored, isocarboxazid 10 mg, net price 100-tab pack = £18.75. Label: 3, 10, patient information leaflet

**TRANYLCYROMINE**

**Indications** depressive illness

**Cautions** see under Phenelzine

**Contra-indications** see under Phenelzine

**Hepatic impairment** avoid in hepatic impairment; see also notes above

**Dose**

- Initially 15 mg 3 times daily, increased if necessary to 4 times daily after 2 weeks (hospital patients, max. 30 mg 3 times daily), then reduced gradually to lowest possible maintenance dose (15 mg on alternate days may be adequate); Child not recommended

**Breast-feeding** present in milk in animal studies

**Side-effects** see under Phenelzine; insomnia; hypertensive crises with throbbing headache requiring discontinuation of treatment more frequent than with other MAOIs; liver damage less frequent than with phenelzine; blood dyscrasias also reported
4.3.3 Selective serotonin re-uptake inhibitors

**Moclobemide**

**Indications**
- Depressive illness; social anxiety disorder

**Cautions**
- Avoid in agitation or excited patients (or give with sedative for up to 2–3 weeks), thyrotoxicosis, or for at least 4 weeks after an MAOI has been stopped.

**Contra-indications**
- Acute confusional states, phaeochromocytoma

**Hepatic impairment**
- Reduce dose in severe disease

**Breast-feeding**
- Amount too small to be harmful, but patient information leaflet advises against

**Side-effects**
- Sleep disturbances, dizziness, gastrointestinal disorders, headache, restlessness, agitation; paraesthesia, dry mouth, visual disturbances; oedema, skin reactions, confusional states reported; rarely raised liver enzymes, galactorrhoea, hyperprolactinaemia (see Hypotenaemia and Antidepressant Therapy, p. 233)

**Dose**
- Depression, usually 300 mg daily divided doses after food, adjusted according to response; usual range 150–600 mg daily; **CHILD not recommended**
- Social anxiety disorder, initially 300 mg daily increased on fourth day to 600 mg daily in 2 divided doses, continued for 8–12 weeks to assess efficacy; **CHILD not recommended**

- **Moclobemide (Non-proprietary)**
  - Tablets, moclobemide 150 mg, net price 30-tab pack = £3.76; 300 mg, 30-tab pack = £5.86. Label: 10, patient information leaflet, 21

**Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline**

- Are termed selective serotonin re-uptake inhibitors (SSRIs). For a general comment on the management of depression and on the comparison between tricyclic and related antidepressants and the SSRIs and related antidepressants, see section 4.3.

**Depressive illness in children and adolescents**

- The balance of risks and benefits for the treatment of depressive illness in children under 18 years is considered unfavourable for the SSRIs citalopram, escitalopram, paroxetine, and sertraline, and for mirtazapine and venlafaxine. Clinical trials have failed to show efficacy and have shown an increase in harmful outcomes. However, it is recognised that specialists may sometimes decide to use these drugs in response to individual clinical need; children and adolescents should be monitored carefully for suicidal behaviour, self-harm or hostility, particularly at the beginning of treatment.
- Only fluoxetine has been shown in clinical trials to be effective for treating depressive illness in children and adolescents. However, it is possible that, in common with the other SSRIs, it is associated with a small risk of self-harm and suicidal thoughts. Overall, the balance of risks and benefits for fluoxetine in the treatment of depressive illness in individuals under 18 years is considered favourable, but children and adolescents must be carefully monitored as above.

**Cautions**
- SSRIs should be used with caution in patients with epilepsy (avoid if poorly controlled, discontinue if convulsions develop), cardiac disease, diabetes mellitus, susceptibility to angle-closure glaucoma, a history of mania or bleeding disorders (especially gastro-intestinal bleeding), and if used with other drugs that increase the risk of bleeding. They should also be used with caution in those receiving concurrent electroconvulsive therapy (prolonged seizures reported with fluoxetine). SSRIs may also impair performance of skilled tasks (e.g. driving).

**Withdrawal**
- The risk of withdrawal reactions is higher with paroxetine (see also Withdrawal, section 4.3). Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in the head, neck, and spine, tinnitus, sleep disturbances, fatigue, influenza-like symptoms, and sweating are the most com-
mon features of abrupt withdrawal of an SSRI or marked reduction of the dose; palpititation and visual disturbances can occur less commonly. The dose should be tapered over a few weeks to avoid these effects. For some patients, it may be necessary to withdraw treatment over a longer period; consider obtaining specialist advice if symptoms persist.

**Interactions** An SSRI or related antidepressant should not be started until 2 weeks after stopping an MAOI. Conversely, an MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case of sertraline, at least 5 weeks in the case of fluoxetine). For guidance relating to the reversible monoamine oxidase inhibitor, moclobemide, see above. For other SSRI antidepressant interactions, see Appendix 1 (antidepressants, SSRI).

**Contra-indications** SSRIs should not be used if the patient enters a manic phase.

**Pregnancy** Manufacturers advise that SSRIs should not be used if the patient enters a manic phase.

**Breast-feeding** present in milk—avoid

**Pregnancy** no information available for eGFR

**Renal impairment** indicated over a longer period; consider obtaining specialist advice if symptoms persist.

**Hepatic impairment** tapered over a few weeks to avoid these effects. For guidance relating to the reversible monoamine oxidase inhibitor, moclobemide, see above. For other SSRI antidepressant interactions, see Appendix 1 (antidepressants, SSRI).

**Contra-indications** SSRIs should not be used if the patient enters a manic phase.

**Cautions** see notes above

**Indications** see notes above; also hepatitis, palpititation, tachycardia, oedema, bradycardia, postural hypotension, coughing, yawning, confusion, impaired concentration, aggression, malaise, amnesia, migraine, paraesthesia, abnormal dreams, mydriasis, taste disturbance, increased salivation, rhinitis, tinnitus, polynya, micturition disorders, euphoria, pruritus; paradoxical increased anxiety during initial treatment of panic disorder (reduce dose)

**Dose**
- **By mouth as tablets**, depressive illness, 20 mg once daily increased if necessary in steps of 20 mg daily at intervals of 3–4 weeks; max. 60 mg daily **ELDERLY over 65 years, max. 40 mg daily**; CHILd under 18 years see **BNF for Children and Depressive Illness in Children and Adolescents**, p. 239
- **Panic disorder, ADULT over 18 years, initially 10 mg daily increased gradually if necessary in steps of 10 mg daily, usual dose 20–30 mg daily; max. 60 mg daily (ELDERLY over 65 years, max. 40 mg daily)
- **By mouth as oral drops**, depressive illness, 16 mg daily as a single dose increased if necessary in steps of 16 mg daily at intervals of 3–4 weeks; max. 48 mg daily **ELDERLY over 65 years, max. 32 mg daily**; CHILd under 18 years see **BNF for Children and Depressive Illness in Children and Adolescents**, p. 239
- **Panic disorder, ADULT over 18 years, initially 8 mg daily as a single dose increased gradually if necessary in steps of 8 mg, usual dose 16–24 mg daily; max. 48 mg daily (ELDERLY over 65 years, max. 32 mg daily)

**Citalopram (Non-proprietary) (BNF 61)**

**Tablets**, citalopram (as hydrobromide) 10 mg, net price 28-tab pack = £1.03; 20 mg, 28-tab pack = £1.30; 40 mg, 28-tab pack = £1.37. Counselling, driving

**Oral drops**, citalopram (as hydrochloride) 40 mg/mL, net price 15 mL = £17.92. Counselling, driving, administration

**Note 4 drops (8 mg) is equivalent in therapeutic effect to 10-mg tablet**

Mix with water, orange juice, or apple juice before taking

**Cipramil** (Lundbeck) (BNF 61)

**Tablets**, f/c, citalopram (as hydrobromide) 10 mg, net price 28-tab pack = £5.38; 20 mg (scored), 28-tab pack = £8.95; 40 mg, 28-tab pack = £15.12. Counselling, driving

**Oral drops**, sugar-free, citalopram (as hydrochloride) 40 mg/mL, net price 15 mL = £10.08. Counselling, driving, administration

**Expiants include alcohol.**

**Note 4 drops (8 mg) is equivalent in therapeutic effect to 10-mg tablet**

Mix with water, orange juice, or apple juice before taking

**ESCITALOPRAM**

Note: Escitalopram is the active enantiomer of citalopram

**Indications** see under Dose

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** initial dose 5 mg daily for 2 weeks, thereafter increased to 10 mg daily according to response; particular caution in severe impairment

**Renal impairment** caution if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** present in milk; avoid

**Side-effects** see notes above; also hepatitis, palpititation, tachycardia, oedema, bradycardia, postural hypotension, coughing, yawning, confusion, impaired concentration, aggression, malaise, amnesia, migraine, paraesthesia, abnormal dreams, mydriasis, taste disturbance, increased salivation, rhinitis, tinnitus, polynya, micturition disorders, euphoria, pruritus; paradoxical increased anxiety during initial treatment of panic disorder (reduce dose)

240 4.3.3 Selective serotonin re-uptake inhibitors

**CITALOPRAM**

**Indications** depressive illness, panic disorder

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** use doses at lower end of range

**Renal impairment** no information available for eGFR less than 20 mL/minute/1.73 m²

**Pregnancy** see notes above

**Breast-feeding** present in milk—avoid
4.3.3 Selective serotonin re-uptake inhibitors

**Side-effects** see notes above; also sinusitis, yawning, fatigue, restlessness, abnormal dreams, paraesthesia; pyrexia; less commonly taste disturbance, bruxism, syncope, tachycardia, oedema, confusion, menstrual disturbances, epistaxis, mydriasis, tinnitus, pruritus, and alopecia; rarely Bradycardia, aggression, and depersonalisation; hepatitis, postural hypotension, QT interval prolongation, and thrombocytopenia also reported; paradoxical increased anxiety during initial treatment of panic disorder (reduce dose)

**Dose**
- **ADULT** over 18 years, depressive illness, generalised anxiety disorder, and obsessive-compulsive disorder, 10 mg once daily if necessary to max. 20 mg daily; **ELDERLY** initially half adult dose, lower maintenance dose may be sufficient; **CHILD** not recommended (see Depressive Illness in Children and Adolescents, p. 239)
- **ADULT** over 18 years, panic disorder, initially 5 mg once daily increased to 10 mg daily after 7 days; max. 20 mg daily; **ELDERLY** initially half adult dose, lower maintenance dose may be sufficient
- **ADULT** over 18 years, social anxiety disorder, initially 10 mg once daily adjusted after 2–4 weeks; usual dose 5–20 mg daily

**Cipralex** (Lundbeck) Tablets, f/c, escitalopram (as oxalate) 5 mg, net price 28-tab pack = £14.91; 20 mg (scored), 28-tab pack = £25.20. Counselling, driving

**Oral drops**—sugar-free, escitalopram (as oxalate) 10 mg/mL, net price 28 mL = £18.82; 20 mg/mL, 15 mL = £20.16. Counselling, driving, administration

**Note** Can be mixed with water, orange juice, or apple juice before taking

---

### FLUOXETINE MALEATE

**Indications** depressive illness, obsessive-compulsive disorder

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** reduce dose or increase dose interval

**Pregnancy** see notes above

**Breast-feeding** present in milk—avoid

**Side-effects** see notes above; also vasodilatation, postural hypotension, pharyngitis, dyspnoea, chills, taste disturbance, sleep disturbances, euphoria, confusion, yawning, impaired concentration, changes in blood sugar, alopecia, urinary frequency; rarely pulmonary inflammation and fibrosis; very rarely hepatotoxic, toxic epidermal necrolysis, and neuroleptic malignant syndrome-like event

**Dose**
- Depression, **ADULT** over 18 years, initially 50–100 mg daily in the evening, increased gradually if necessary to max. 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily
- Obsessive-compulsive disorder, initially 50 mg in the evening increased gradually if necessary after some weeks to max. 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100–300 mg daily; **CHILD** over 8 years initially 25 mg daily increased if necessary in steps of 25 mg every 4–7 days to max. 200 mg daily (over 50 mg in 2 divided doses)

**Note** If no improvement in obsessive-compulsive disorder within 10 weeks, treatment should be reconsidered

**Fluvoxamine** (Non-proprietary) Tablets, fluvoxamine maleate 50 mg, net price 30-tab pack = £10.81; 100 mg, 30-tab pack = £11.67. Counselling, driving

**Faverin** (Abbott Healthcare) Tablets, f/c, scored, fluvoxamine maleate 50 mg, net price 60-tab pack = £10.81; 100 mg, 30-tab pack = £11.67. Counselling, driving

---

### PAROXETINE

**Indications** major depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder; generalised anxiety disorder

**Cautions** see notes above; also achlorhydria or high gastric pH (reduced absorption of oral suspension)

**Contra-indications** see notes above

**Hepatic impairment** reduce dose
242  4.3.4 Other antidepressant drugs

Renal impairment  reduce dose if eGFR less than 30 mL/minute/1.73 m²

Pregnancy  increased risk of congenital malformations, especially if used in the first trimester; see also notes above

Breast-feeding  present in milk but amount too small to be harmful

Side-effects  see notes above; also yawning; abnormal dreams; raised cholesterol; less commonly arrhythmias, confusion, urinary incontinence; rarely panic attacks and paradoxical increased anxiety during initial treatment of panic disorder (reduce dose), depersonalisation, and neuropsychiatric malignant syndrome-like event; rarely restless legs syndrome; very rarely peripheral oedema, acute glaucoma, hepatic disorders (e.g. hepatitis), and priapism; also reported tinnitus, extrapyramidal reactions (including orofacial dystonias) and withdrawal reactions (see notes above)

Dose
- Major depression, social anxiety disorder, post-traumatic stress disorder, generalised anxiety disorder, ADULT over 18 years, recommended dose 20 mg each morning (no evidence of greater efficacy at higher doses); max. 50 mg daily (ELDERLY 40 mg daily); CHILD under 18 years not recommended (see Depressive Illness In Children and Adolescents, p. 239)
- Obsessive-compulsive disorder, ADULT over 18 years, initially 20 mg each morning, increased gradually in steps of 10 mg to recommended dose of 40 mg daily (no evidence of greater efficacy at higher doses); max. 60 mg daily (ELDERLY 40 mg daily)
- Panic disorder, ADULT over 18 years, initially 10 mg each morning, increased gradually in steps of 10 mg to recommended dose of 40 mg daily (no evidence of greater efficacy at higher doses); max. 60 mg daily (ELDERLY 40 mg daily)

Paroxetine  (Non-proprietary)  (A)
- Tablets, paroxetine (as hydrochloride) 20 mg, net price 30-tab pack = £2.29; 30 mg, 30-tab pack = £3.17. Label: 21, counselling, driving

Sertraline  (Non-proprietary)  (BNF 61)
- Tablets, paroxetine (as hydrochloride) 10 mg, net price 28-tab pack = £1.15; 100 mg, 30-tab pack = £1.53. Counselling, driving
- Tablets, f/c, scored, paroxetine (as hydrochloride) 20 mg, net price 28-tab pack = £1.15; 100 mg, 28-tab pack = £1.53. Counselling, driving
- Oral suspension, orange, sugar-free, paroxetine (as hydrochloride) 10 mg/5 mL, net price 150 mL pack = £9.12. Label: 5, 21, counselling, driving

SERTRALINE

Indications  see under Dose

Cautions  see notes above

Contra-indications  see notes above

Hepatic impairment  reduce dose or increase dose interval in mild or moderate impairment; avoid in severe impairment

Renal impairment  use with caution

Pregnancy  see notes above

Breast-feeding  not known to be harmful but consider discontinuing breast-feeding

Side-effects  see notes above; pancreatitis, hepatitis, jaundice, liver failure, stomatitis, palpitation, hyperpyrexia, hyperglycaemia, tachycardia, postural hypotension, bronchospasm, amnesia, paraesthesia, aggression, hypoglycaemia, hypothyroidism, hyperprolactinaemia, urinary incontinence, menstrual irregularities, leucopenia, and tinnitus also reported

Dose
- Depressive illness, initially 50 mg daily, increased if necessary by increments of 50 mg at intervals of at least 1 week to max. 200 mg daily; usual maintenance dose 50 mg daily; CHILD under 18 years, see BNF for Children and Depressive Illness in Children and Adolescents, p. 239
- Obsessive-compulsive disorder, ADULT and CHILD over 12 years initially 50 mg daily, increased if necessary in steps of 50 mg at intervals of at least 1 week; max. 200 mg daily; CHILD 6–12 years initially 25 mg daily, increased to 50 mg daily after 1 week, further increased if necessary in steps of 50 mg at intervals of at least 1 week; max. 200 mg daily
- Panic disorder, post-traumatic stress disorder, or social anxiety disorder, ADULT over 18 years, initially 25 mg daily, increased after 1 week to 50 mg daily; if response is partial and if drug tolerated, dose increased in steps of 50 mg at intervals of at least 1 week to max. 200 mg daily

Sertraline  (Non-proprietary)  (A)
- Tablets, sertraline (as hydrochloride) 50 mg, net price 28-tab pack = £1.15; 100 mg, 28-tab pack = £1.53. Counselling, driving
- Lustral® (Pfizer)  (BNF 61)
- Tablets, f/c, sertraline (as hydrochloride) 50 mg (scored), net price 28-tab pack = £17.82; 100 mg, 28-tab pack = £29.16. Counselling, driving

4.3.4 Other antidepressant drugs

Agomelatine  is a melatonin receptor agonist and a selective serotonin-receptor antagonist; it does not affect the uptake of serotonin, noradrenaline, or dopamine.

Duloxetine  inhibits the re-uptake of both serotonin and noradrenaline and is licensed to treat major depressive disorder.

The thioxanthenes flupentixol  (Fluanxol®)  has antidepressant properties when given by mouth in low doses. Flupentixol is also used for the treatment of psychoses (section 4.2.1 and section 4.2.2)

Mirtazapine  is a presynaptic alpha-, adrenoreceptor antagonist, increases central noradrenergic and serotonergic neurotransmission. It has few antimuscarinic effects, but causes sedation during initial treatment.

Reboxetine  is a selective inhibitor of noradrenaline re-uptake, has been introduced for the treatment of depressive illness.

Tryptophan  is licensed as adjunctive therapy for depression resistant to standard antidepressants; it has been associated with eosinophilia-myalgia syndrome. Tryptophan should be initiated under specialist supervision.

Venlafaxine  is a serotonin and noradrenaline re-uptake inhibitor; it lacks the sedative and antimuscarinic effects of the tricyclic antidepressants. Treatment with venlafaxine is associated with a higher risk of withdrawal effects compared with other antidepressants.
AGOMELATINE

Indications major depression

Cautions elderly; mania or hypomania; concomitant use of drugs associated with hepatic injury; excessive alcohol consumption; monitor liver function before treatment and after 6, 12 and 24 weeks of treatment, then as appropriate (discontinue if serum transaminases exceed 3 times the upper limit of reference range); interactions: Appendix 1 (agomelatine)

Contra-indications dementia

Renal impairment caution in moderate to severe impairment

Pregnancy caution

Breast-feeding avoid—present in milk in animal studies

Side-effects nausea, diarrhoea, constipation, abdominal pain, increased serum transaminases (see Cautions); headache, dizziness, drowsiness, insomnia, fatigue, anxiety; back pain; sweating; less commonly paraesthesia, blurred vision, and eczema; rarely hepatitis and rash; suicidal behaviour (see Suicidal Behaviour and Antidepressant Therapy; p. 235) also reported

Dose

• ADULT over 18 years, 25 mg at bedtime, increased if necessary after 2 weeks to 50 mg at bedtime

Valdoxan® (Servier) Tablets, orange-yellow, 1/c, agomelatine 25 mg, net price 28-tab pack = £43.77

DULOXETINE

Indications major depressive disorder; generalised anxiety disorder; diabetic neuropathy (section 6.1.5); stress urinary incontinence (section 7.4.2)

Cautions section 7.4.2

Contra-indications section 7.4.2

Hepatic impairment section 7.4.2

Renal impairment section 7.4.2

Pregnancy toxicity in animal studies—use only if potential benefit outweighs risk; risk of neonatal withdrawal symptoms if used near term

Breast-feeding section 7.4.2

Side-effects section 7.4.2

Dose

• Major depressive disorder, ADULT over 18 years, 60 mg once daily

• Generalised anxiety disorder, ADULT over 18 years, initially 30 mg daily, increased if necessary to 60 mg once daily; max. 120 mg daily

• Diabetic neuropathy, ADULT over 18 years, 60 mg once daily; max. 120 mg daily in divided doses

Note In diabetic neuropathy, discontinue if inadequate response after 2 months; review treatment at least every 3 months

Cymbalta® (Lilly) Capsules, duloxetine (as hydrochloride) 30 mg (white/blue), net price 28-cap pack = £22.40; 60 mg (green/blue), 28-cap pack = £27.72. Label: 2

Note The Scottish Medicines Consortium has advised (September 2006) that duloxetine (Cymbalta®) should be restricted for use by specialists when other treatments for diabetic peripheral neuropathic pain are unsuitable or inadequate

Yentreve® (Lilly) Section 7.4.2 (stress urinary incontinence)

FLUPENTIXOL (Flupentixol)

Indications depressive illness; psychoses (section 4.2.1)

Cautions cardiovascular disease (including cardiac disorders and cerebral arteriosclerosis), QT-interval prolongation (avoid concomitant administration of drugs that prolong QT interval); diabetes; senile confusional states, parkinsonism; elderly; acute porphyria (section 9.8.2); see also section 4.2.1; interactions: Appendix 1 (antipsychotics)

Contra-indications excitable and overactive patients; impaired consciousness; cardiovascular collapse; coma

Hepatic impairment can precipitate coma; consider serum-flupentixol concentration monitoring

Renal impairment increased cerebral sensitivity in severe impairment; manufacturer advises caution in renal failure

Pregnancy avoid unless potential benefit outweighs risk

Breast-feeding present in milk—avoid

Side-effects section 4.2.1; also hypersalivation, dysphagia, asthenia, hyperglycaemia, myalgia; torsade de pointes and sudden death also reported

Dose

• ADULT over 18 years, initially 1 mg (ELDERLY 500 micrograms) in the morning, increased after 1 week to 2 mg (ELDERLY 1 mg) if necessary; max. 3 mg (ELDERLY 1.5 mg) daily, doses above 2 mg (ELDERLY 1 mg) in divided doses, last dose before 4 pm; discontinue if no response after 1 week at max. dosage

Counselling Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening

Fluanxol® (Lundbeck) Tablets, yellow, s/c, flupentixol (as dihydrochloride) 500 micrograms, net price 60-tab pack = £2.63; 1 mg, 60-tab pack = £2.72. Label: 2, counselling, administration

Depixol® (Lundbeck) Section 4.2.1 (psychoses)

MIRTAZAPINE

Indications major depression

Cautions elderly, cardiac disorders, hypotension, history of urinary retention, susceptibility to angle-closure glaucoma, diabetes mellitus, psychoses (may aggravate psychotic symptoms), history of seizures or bipolar depression; interactions: Appendix 1 (mirtazapine)

Blood disorders Patients should be advised to report any fever, sore throat, stomatitis or other signs of infection during treatment. Blood count should be performed and the drug stopped immediately if blood dyscrasia suspected

Withdrawal Nausea, vomiting, dizziness, agitation, anxiety, and headache are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks

Hepatic impairment use with caution

Renal impairment clearance reduced by 30% if eGFR less than 40 mL/minute/1.73 m2; clearance reduced by 50% if eGFR less than 10 mL/minute/1.73 m2

Pregnancy use with caution—limited experience; monitor neonate for withdrawal effects

Breast-feeding present in milk; use only if potential benefit outweighs risk

Side-effects increased appetite, weight gain, dry mouth; postural hypotension, peripheral oedema;
4 Central nervous system

4.3.4 Other antidepressant drugs

drowsiness, fatigue, tremor, dizziness, abnormal dreams, confusion, anxiety, insomnia; arthritis, myalgia; less commonly syncope, hypotension, mania, hallucinations, movement disorders; rarely myoclonus; very rarely blood disorders (see Cautions), convulsions, hyponatraemia (see Hyponatraemia and Antidepressants Therapy, p. 233), suicidal behaviour (see p. 233), and angle-closure glaucoma.

Dose

• Initially 15–30 mg daily at bedtime increased within 2–4 weeks according to response; max. 45 mg daily as a single dose at bedtime or in 2 divided doses; CHILD under 18 years not recommended (see Depressive Illness in Children and Adolescents, p. 239)

Mirtazapine (Non-proprietary)

Tablets, mirtzapine 15 mg, net price 28-tab pack = £3.36; 30 mg, 28-tab pack = £2.04; 45 mg, 28-tab pack = £3.71. Label: 2, 25

Orodispensible tablets, mirtzapine 15 mg, net price 30-tab pack = £2.59; 30 mg, 30-tab pack = £2.94; 45 mg, 30-tab pack = £2.98. Label: 2, counselling, administration

Oral solution, mirtzapine 15 mg/mL, net price 66 mL = £47.00. Label: 2

Zispin SolTab® (Organon)

Orodispensible tablets, mirtzapine 15 mg, net price 6-tab pack = £3.84, 30-tab pack = £15.06; 30 mg, 30-tab pack = £15.06; 45 mg, 30-tab pack = £15.06. Label: 2, counselling, administration

Excipients include aspartame (section 9.4.1) counselling Zispin SolTab® should be placed on the tongue, allowed to disperse and swallowed

Edronax® (Pharmacia) Tablets, scored, reboxetine (as mesilate) 4 mg, net price 60-tab pack = £18.91. Counselling, driving

TRYPTOPHAN

(-L-Tryptophan)

Indications see notes above

Cautions eosinophilia-myalgia syndrome has been reported (withdraw treatment if increased eosinophil count, myalgia, arthralgia, fever, dyspnoea, neuropathy, oedema or skin lesions develop until possibility of eosinophilia-myalgia syndrome excluded); interactions: Appendix 1 (tryptophan)

Contra-indications history of eosinophilia-myalgia syndrome following use of tryptophan

Pregnancy no information available

Breast-feeding no information available

Side-effects drowsiness, nausea, headache, light-headedness, suicidal behaviour (see p. 233); eosinophilia-myalgia syndrome, see Cautions

Dose

• 1 g 3 times daily; max. 6 g daily; ELDERLY lower dose may be appropriate especially in renal or hepatic impairment; CHILD not recommended

Optinax® (Merck Serono) Tablets, scored, tryptophan 500 mg, net price 84-tab pack = £23.47. Label: 3

VENLAFAXINE

Indications major depression, generalised anxiety disorder

Cautions heart disease (monitor blood pressure); diabetes; history of epilepsy; history or family history of mania; susceptibility to angle-closure glaucoma; concomitant use of drugs that increase risk of bleeding, history of bleeding disorders; interactions: Appendix 1 (venlafaxine)

Driving May affect performance of skilled tasks (e.g. driving)

Withdrawal Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, tremor, sleep disturbances, and sweating are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks

Contra-indications conditions associated with high risk of cardiac arrhythmia, uncontrolled hypertension

Hepatic impairment consider reducing dose by 50% in mild or moderate impairment; use with caution and reduce dose by at least 50% in severe impairment

Renal impairment use with caution; use half normal dose (immediate-release tablets may be given once daily) if eGFR less than 30 mL/minute/1.73 m²

Pregnancy avoid unless potential benefit outweighs risk—toxicity in animal studies; risk of withdrawal effects in neonate

Breast-feeding present in milk—avoid

Side-effects constipation, nausea, anorexia, weight changes, vomiting; hypertension; palpitation, vasodilation, changes in serum cholesterol; chilli, yawning; dizziness, dry mouth, insomnia, nervousness, drowsiness, asthenia, headache, abnormal dreams, anxiety, confusion, hypertonia, sensory disturbances, tremor; difficulty with micturition, sexual dysfunction, menstrual disturbances; visual disturbances, mydriasis (very rarely angle-closure glaucoma); sweating; less commonly—bruxism, diarrhoea, taste disturbance, postural hypotenstion, arhythmias, agitation, apathy, incoordination, hallucinations, myoclonus, urinary
Central nervous system stimulants include the amphetamines (notably dexamfetamine) and related drugs (e.g. methylphenidate). They have very few indications and in particular, should not be used to treat depression, obesity, senility, delirium, or for relief of fatigue.

CMS stimulants should be prescribed for children with severe and persistent symptoms of attention deficit hyperactivity disorder (ADHD), when the diagnosis has been confirmed by a specialist; children with moderate symptoms of ADHD can be treated with CNS stimulants when psychological interventions have been unsuccessful or are unavailable. Prescribing of CNS stimulants may be continued by general practitioners, under a shared-care arrangement. Treatment of ADHD often needs to be continued into adolescence, and may need to be continued into adulthood. Initiating treatment in adulthood is unlicensed.

Drug treatment of ADHD should be part of a comprehensive treatment programme. The choice of medication should take into consideration co-morbid conditions (such as tic disorders, Tourette syndrome, and epilepsy), the adverse effect profile, potential for drug misuse, and preferences of the patient and carers. Methylphenidate and atomoxetine are used for the management of ADHD; dexamfetamine is an alternative in children who do not respond to these drugs. Before initiation of drug therapy, and every 6 months thereafter, pulse, blood pressure, weight, and height should be measured.

The need to continue drug treatment for ADHD should be reviewed at least annually. This may involve suspending treatment.

Modafinil is used for the treatment of daytime sleepiness associated with narcolepsy or obstructive sleep apnoea syndrome; dependence with long-term use cannot be excluded and it should therefore be used with caution.

Dexamfetamine and methylphenidate [unlicensed indication] are also used to treat narcolepsy.

**ATOMOXETINE**

**Indications** attention deficit hyperactivity disorder (initiated by a specialist physician experienced in managing the condition)

**Cautions** see notes above; also cardiovascular disease including hypertension and tachycardia; structural cardiac abnormalities; QT-interval prolongation (avoid concomitant administration of drugs that prolong QT interval); psychosis or mania; history of seizures; aggressive behaviour, hostility, or emotional lability; susceptibility to angle-closure glaucoma; interactions: Appendix 1 (atomoxetine) 

**Hepatic disorders** Following rare reports of hepatic disorders, patients and carers should be advised of the risk and be told how to recognise symptoms; prompt medical attention should be sought in case of abdominal pain, unexplained nausea, malaise, darkening of the urine, or jaundice

**Suicidal ideation** Following reports of suicidal thoughts and behaviour, patients and their carers should be informed about the risk and told to report clinical worsening, suicidal thoughts or behaviour, irritability, agitation, or depression
Hepatic impairment  halve dose in moderate impairment; quarter dose in severe impairment; see also Hepatic Disorders above

Pregnancy  no information available; avoid unless potential benefit outweighs risk

Breast-feeding  avoid—present in milk in animal studies

Side-effects  anorexia, dry mouth, nausea, vomiting, abdominal pain, constipation, dyspepsia, flatulence; palpitation, tachycardia, increased blood pressure, postural hypotension, hot flushes; sleep disturbance, dizziness, headache, fatigue, lethargy, depression, psychotic or manic symptoms, aggression, hostility, emotional lability, drowsiness, anxiety, irritability, tremor, rigors; urinary retention, enuresis, prostatitis, sexual dysfunction, menstrual disturbances; mydriasis, conjunctivitis; dermatitis, pruritus, rash, sweating, tremor, rigors; urinary retention, enuresis, prostatitis, emotional lability, drowsiness; susceptibility to angle-closure glaucoma, and Raynaud's phenomenon

Dose
- ADULT over 18 years, body-weight over 70 kg, initially 40 mg daily for 7 days, increased according to response; usual maintenance 80–100 mg daily, but may be increased to max. 120 mg daily [unlicensed] under the direction of a specialist; CHILD 6–18 years, body-weight over 70 kg, initially 40 mg daily for 7 days, increased according to response; usual maintenance 80 mg daily, but may be increased to max. 120 mg daily [unlicensed] under the direction of a specialist; ADULT and CHILD over 6 years, body-weight under 70 kg, initially 500 micrograms/kg daily for 7 days, increased according to response; usual maintenance 1.2 mg/kg daily, but may be increased to max. 1.8 mg/kg daily [max. 120 mg daily] [unlicensed] under the direction of a specialist

Note  Total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening

Strattera® (Lilly) (see also Cautions); seizures, angle-closure glaucoma, and Raynaud's phenomenon

Capsules, atomoxetine (as hydrochloride) 10 mg (white), net price 7-cap pack = £15.62, 28-cap pack = £62.46; 18 mg (gold/white), 7-cap pack = £83.28. Label: 3

Dose
- Narcolepsy, initially 10 mg [ELDERLY] 5 mg daily in divided doses increased at weekly intervals by 10 mg [ELDERLY] 5 mg daily to a max. of 60 mg daily
- Refractory attention deficit hyperactivity disorder, ADULT over 18 years [unlicensed use], initially 5 mg twice daily, increased at weekly intervals according to response; max. 60 mg daily; CHILD 6–18 years, initially 5–10 mg daily, increased if necessary at weekly intervals by 5 mg daily, usual max. 1 mg/kg (up to 20 mg) daily (40 mg daily has been required in some children)

Note  Maintenance dose given in 2–4 divided doses

Dexamfetamine (Non-proprietary) (see also under Cautions); dry mouth, sweating, intestinal symptoms, growth restriction in children

Indications  attention deficit hyperactivity disorder (under specialist supervision); narcolepsy [unlicensed indication]

Cautions  see notes above; also anorexia; mild hypertension (contra-indicated if moderate or severe); psychosis or bipolar disorder; monitor for aggressive behaviour or hostility during initial treatment; history of epilepsy (discontinue if convulsions occur); tics and Tourette syndrome (use with caution)—discontinue if tics occur; monitor growth in children (see also below); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal; data on safety and efficacy of long-term use not complete; acute porphyria (section 9.8.2); interactions: Appendix 1 (sympathomimetics)

Methylphenidate hydrochloride

Indications  attention deficit hyperactivity disorder (under specialist supervision); narcolepsy [unlicensed indication]

Cautions  see notes above; also monitor for psychiatric disorders; anxiety or agitation; tics or a family history of Tourette syndrome; epilepsy (discontinue if increased seizure frequency); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal; interactions: Appendix 1 (sympathomimetics)

Contra-indications  severe depression, suicidal ideation; anorexia nervosa; drug or alcohol dependence; psychosis; uncontrolled bipolar disorder; hyperthyroidism; cardiovascular disease (including heart failure);
Ritalin
Methylphenidate Hydrochloride.
Narcolepsy [unlicensed indication], 10–60 mg (usually
Attention deficit hyperactivity disorder,
Side-effects abdominal pain, nausea, vomiting, diarr-
hoea, dyspepsia, dry mouth, anorexia, reduced weight
gain; tachycardia, palpitation, arrhythmias, changes in
blood pressure; cough, nasopharyngitis; tics (very
rarely Tourette syndrome), insomnia, nervousness,
asthenia, depression, irritability, aggression, head-
ache, drowsiness, dizziness, movement disorders;
fever; arthralgia; rash, pruritus, alopecia; growth
restriction; less commonly constipation, dyspnoea,
abnormal dreams, confusion, suicidal ideation,
urinary frequency, haematuria, muscle cramps, epis-
taxis; rarely angina, sweating, and visual disturbances;
very rarely hepatic dysfunction, myocardial infarction,
cerebral arteritis, psychosis, neuroleptic malignant
sindrome, tolerance and dependence, blood disor-
ders including leucopenia and thrombocytopenia,
angle-closure glaucoma, exfoliative dermatitis, and
erythema multiforme; supraventricular tachycardia,
bradycardia, and convulsions also reported

Dose
- Attention deficit hyperactivity disorder, ADULT over 18
years [unlicensed use], 5 mg 2–3 times daily increased
if necessary at weekly intervals according to response,
max. 100 mg daily in 2–3 divided doses; CHILD 6–18
years, initially 5 mg 1–2 times daily; increased if
necessary at weekly intervals by 5–10 mg daily; usual
max. 60 mg daily in 2–3 divided doses but may be
increased to 2.1 mg/kg daily in 2–3 divided doses
(max. 90 mg daily) under the direction of a specialist;
discontinue if no response after 1 month; CHILD 4–6
years see BNF for Children
Evening dose if effect wears off in evening (with rebound
hyperactivity) a dose at bedtime may be appropriate
(establish need with trial bedtime dose)
Note Treatment may be started using a modified-release
preparation
- Narcolepsy [unlicensed indication], 10–60 mg (usually
20–30 mg) daily in divided doses before meals

Methylphenidate Hydrochloride (Non-proprietary)
Tablets, methylphenidate hydrochloride 5 mg, net
price 30-tab pack = £2.67; 10 mg, 30-tab pack = £6.74;
20 mg, 30-tab pack = £9.59
Brands include Medikinet®
Ritalin® (Novartis)
Tablets, scored, methylphenidate hydrochloride
10 mg, net price 30-tab pack = £5.57

MODAFINIL
Concerta® XL (Janssen-Cilag)
Tablets, m/r, methylphenidate hydrochloride 18 mg
(yellow), net price 30-tab pack = £31.19; 27 mg (grey),
30-tab pack = £36.81; 36 mg (white), 30-tab pack = £42.45. Label: 25
Note Concerta® XL tablets consist of an immediate-release
component (22% of the dose) and a modified-release component
(78% of the dose)
Counselling Tablet membrane may pass through gastro-intestinal
tract unchanged
Cautions dose form not appropriate for use in dysphagia or if
gastro-intestinal lumen restricted
Dose attention deficit hyperactivity disorder, ADULT over 18
years [unlicensed use], initially 18 mg once daily in the morning,
adjusted at weekly intervals according to response, max. 108 mg
daily; CHILD 6–18 years, initially 18 mg once daily (in the morn-
ing), increased if necessary at weekly intervals by 18 mg according
to response, usual max. 54 mg once daily but may be increased to
2.1 mg/kg daily (max. 108 mg daily) [unlicensed] under the
direction of a specialist; discontinue if no response after 1 month
Note Total daily dose of 15 mg of standard-release formulation is
equivalent to Concerta® XL 18 mg once daily

Equasym XL® (Shire)
Capsules, m/r, methylphenidate hydrochloride 10 mg
(white/green), net price 30-cap pack = £25.20; 20 mg
(white/blue), 30-cap pack = £30.00; 30 mg (white/
brown), 30-cap pack = £35.00. Label: 25
Note Equasym XL® capsules consist of an immediate-release component (30% of the dose) and a modified-release component (70% of the dose)
Dose attention deficit hyperactivity disorder, ADULT over 18
years [unlicensed use], initially 10 mg once daily in the morning
before breakfast, increased gradually at weekly intervals if
necessary, max. 100 mg daily; CHILD 6–18 years, initially 10 mg
once daily in the morning before breakfast, increased gradually at weekly
intervals if necessary, usual max. 60 mg daily but may be
increased to 2.1 mg/kg daily (max. 90 mg daily) [unlicensed]
under the direction of a specialist; discontinue if no response after 1 month
Note Contents of capsule can be sprinkled on a tablespoon of
apple sauce (then swallowed immediately without chewing)

Medikinet XL® (Flynn)
Capsules, m/r, methylphenidate hydrochloride 10 mg
(filac/white), net price 28-cap pack = £20.18; 20 mg
(lilac), 28-cap pack = £26.91; 30 mg (purple/light
grey), 28-cap pack = £31.39; 40 mg (purple/grey), 28-
cap pack = £34.20. Label: 25
Note Medikinet XL® capsules consist of an immediate-release component (50% of the dose) and a modified-release component (50% of the dose)
Dose attention deficit hyperactivity disorder, ADULT over 18
years [unlicensed use], initially 10 mg once daily in the morning
with breakfast, adjusted at weekly intervals according to response,
max. 100 mg daily; CHILD 6–18 years, initially 10 mg once daily in
the morning with breakfast, adjusted at weekly intervals according to response,
usual max. 60 mg daily but may be increased to
2.1 mg/kg daily (max. 90 mg daily) [unlicensed] under the
direction of a specialist; discontinue if no response after 1 month
Note Contents of capsule can be sprinkled on a tablespoon of
apple sauce (then swallowed immediately without chewing)

Indications daytime sleepiness associated with
narcolepsy, obstructive sleep apnoea syndrome, and
chronic shift work
Cautions monitor blood pressure and heart rate in
hypertensive patients (but see Contra-indications);
history of psychosis, depression, mania, alcohol or
drug abuse; discontinue treatment if psychiatric
symptoms develop; possibility of dependence; dis-
continue treatment if rash develops; interactions:
Appendix 1 (modafinil)
Contra-indications moderate to severe uncontrolled
hypertension, arhythmia; history of left ventricular
hypertrophy, cor pulmonale, or of clinically significant
signs of CNS stimulant-induced mitral valve prolapse
(including ischaemic ECG changes, chest pain and
arrhythmias)
Hepatic impairment halve dose in severe impairment
Renal impairment halve dose in severe impairment
Pregnancy avoid
Breast-feeding avoid—present in milk in animal
studies
Side-effects dry mouth, appetite changes, gastro-
intestinal disturbances (including nausea, diarrhoea,
constipation, and dyspepsia), abdominal pain; tachy-
cardia, vasodilatation, chest pain, palpitation, head-
4.5 Drugs used in the treatment of obesity

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract

Orlistat: a lipase inhibitor, reduces the absorption of dietary fat. It is used in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m² or more in individuals with a BMI of 28 kg/m² in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia.

Orlistat should be used in conjunction with other lifestyle measures to manage obesity (section 4.5); treatment should only be continued beyond 12 months after discussing potential benefits and risks with the patient. On stopping orlistat, there may be a gradual reversal of weight loss. Some of the weight loss in those taking orlistat probably results from individuals reducing their fat intake to avoid severe gastro-intestinal effects including steatorrhoea. Vitamin supplementation (especially of vitamin D) may be considered if there is concern about deficiency of fat-soluble vitamins.

Methylcellulose is claimed to reduce food intake by producing a feeling of satiety, but there is little evidence to support its use in the management of obesity.

4.5.2 Centrally acting appetite suppressants

Orlistat is claimed to reduce food intake by producing a feeling of satiety, but there is little evidence to support its use in the management of obesity.

Orlistat: a lipase inhibitor, reduces the absorption of dietary fat. It is used in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m² or more in individuals with a BMI of 28 kg/m² in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia.

Orlistat should be used in conjunction with other lifestyle measures to manage obesity (section 4.5); treatment should only be continued beyond 12 months after discussing potential benefits and risks with the patient. On stopping orlistat, there may be a gradual reversal of weight loss. Some of the weight loss in those taking orlistat probably results from individuals reducing their fat intake to avoid severe gastro-intestinal effects including steatorrhoea. Vitamin supplementation (especially of vitamin D) may be considered if there is concern about deficiency of fat-soluble vitamins.

Methylcellulose is claimed to reduce food intake by producing a feeling of satiety, but there is little evidence to support its use in the management of obesity.
Phenothiazines, especially in children. Some antihistamines, and cytotoxics. Prochlorperazine emesis caused by drugs such as opioids, general anaesthesia, diffuse neoplastic disease, radiation sickness, and the treatment of nausea and vomiting associated with centrally by blocking the chemoreceptor trigger zone. The adverse effects (drowsiness and antimuscarinic effects) another but their duration of action and incidence of no evidence that any one antihistamine is superior to ting resulting from many underlying conditions. There is are effective against nausea and vomiting is known because otherwise they may delay Antiemetics should be prescribed only when the cause does not outweigh the risk of serious adverse effects.

Dose
- ADULT over 18 years, 120 mg taken immediately before, during, or up to 1 hour after each main meal (up to max. 360 mg daily); continue treatment beyond 12 weeks only if weight loss since start of treatment exceeds 5% (target for initial weight loss may be lower in patients with type 2 diabetes); CHILD over 12 years, initiated by specialist only [unlicensed use] Note: If a meal is missed or contains no fat, the dose of orlistat should be omitted

4.5.2 Centrally acting appetite suppressants

Phentermine and diethylpropion are central stimulants; they are not recommended for the treatment of obesity. Phentermine has been associated with a risk of pulmonary hypertension. Sibutramine, dexfenfluramine, and fenfluramine have been withdrawn from the market because the benefit of treatment does not outweigh the risk of serious adverse effects.

Antiemetics should be prescribed only when the cause of vomiting is known because otherwise they may delay diagnosis, particularly in children. Antiemetics are unnecessary and sometimes harmful when the cause can be treated, such as in diabetic ketoacidosis, or in digoxin or antiepileptic overdose.

If antiemetic drug treatment is indicated, the drug is chosen according to the aetiology of vomiting.

Antihistamines are effective against nausea and vomiting resulting from many underlying conditions. There is no evidence that any one antihistamine is superior to another but their duration of action and incidence of adverse effects (drowsiness and antimuscarinic effects) differ.

The phenothiazines are dopamine antagonists and act centrally by blocking the chemoreceptor trigger zone. They are of considerable value for the prophylaxis and treatment of nausea and vomiting associated with diffuse neoplastic disease, radiation sickness, and the emesis caused by drugs such as opioids, general anaesthetics, and cytotoxics. Prochlorperazine, perphenazine, and trifluoperazine are less sedating than chlorpromazine; severe dystonic reactions sometimes occur with phenothiazines, especially in children. Some phenothiazines are available as rectal suppositories, which can be useful in patients with persistent vomiting or with severe nausea; prochlorperazine can also be administered as a buccal tablet which is placed between the upper lip and the gum.

Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone. Other antipsychotic drugs including haloperidol and levomepromazine are used for the relief of nausea and vomiting in terminal illness (see Palliative Care, p. 22).

Metoclopramide is an effective antiemetic and its activity closely resembles that of the phenothiazines. Metoclopramide also acts directly on the gastro-intestinal tract and it may be superior to the phenothiazines for emesis associated with gastroduodenal, hepatic, and biliary disease. In postoperative nausea and vomiting, metoclopramide in a dose of 10 mg has limited efficacy. High-dose metoclopramide injection is now less commonly used for cytotoxic-induced nausea and vomiting. As with the phenothiazines, metoclopramide can induce acute dystonic reactions involving facial and skeletal muscle spasms and oculogyric crises. These dystonic effects are more common in the young (especially girls and young women) and the very old; they usually occur shortly after starting treatment with metoclopramide and subside within 24 hours of stopping it. Injection of an antiparkinsonian drug such as procyclidine (section 4.9.2) will abort dystonic attacks.

Donomeridone acts at the chemoreceptor trigger zone; it is used for the relief of nausea and vomiting, especially when associated with cytotoxic therapy. It has the advantage over metoclopramide and the phenothiazines of being less likely to cause central effects such as sedation and dystonic reactions because it does not readily cross the blood-brain barrier. In Parkinson’s disease, it is used to prevent nausea and vomiting during treatment with apomorphine and also to treat nausea caused by other dopaminergic drugs (section 4.9.1). Domperidone is also used to treat vomiting due to emergency hormonal contraception (section 7.3.5).

Granisetron, ondansetron, and palonosetron are specific 5HT3-receptor antagonists which block 5HT3 receptors in the gastro-intestinal tract and in the CNS. Granisetron and ondansetron are of value in the management of nausea and vomiting in patients receiving cytotoxics and in postoperative nausea and vomiting. Palonosetron is licensed for prevention of nausea and vomiting associated with moderately or highly emetogenic cytotoxic chemotherapy.

Dexamethasone (section 6.3.2) has antiemetic effects and it is used in vomiting associated with cancer chemotherapy. It can be used alone or with metoclopramide, prochlorperazine, lorazepam, or a 5HT3 antagonist (section 8.1).

Aprepitant and fosaprepitant are neurokinin 1 receptor antagonists licensed for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based cytotoxic chemotherapy; they are given with dexamethasone and a 5HT3 antagonist.

Nabumetone is a synthetic cannabinoid with antiemetic properties. It may be used for nausea and vomiting caused by cytotoxic chemotherapy that is unresponsive to conventional antiemetics. Side-effects such as drowsiness and dizziness occur frequently with standard doses.
4.6 Drugs used in nausea and vertigo

Vomiting during pregnancy

Nausea in the first trimester of pregnancy is generally mild and does not require drug therapy. On rare occasions if vomiting is severe, short-term treatment with an antihistamine, such as promethazine, may be required. Prochlorperazine or metoclopramide may be considered as second-line treatments. If symptoms do not settle in 24 to 48 hours then specialist opinion should be sought. Hyperemesis gravidarum is a more serious condition, which requires intravenous fluid and electrolyte replacement and sometimes nutritional support. Supplementation with thiamine must be considered in order to reduce the risk of Wernicke’s encephalopathy.

Postoperative nausea and vomiting

The incidence of postoperative nausea and vomiting depends on many factors including the anaesthetic used, and the type and duration of surgery. Other risk factors include female sex, a history of postoperative nausea and vomiting or motion sickness, and intraoperative and postoperative use of opioids. Therapy to prevent postoperative nausea and vomiting should be based on the assessed risk of postoperative nausea and vomiting in each patient. Drugs used include 5HT
d receptor antagonists, droperidol, dexamethasone (section 6.3.2), some phenothiazines (e.g. prochlorperazine), and antihistamines (e.g. cyclizine). A combination of two or more antiemetic drugs that have different mechanisms of action is often indicated in those at high risk of postoperative nausea and vomiting or where postoperative vomiting presents a particular danger (e.g. in some types of surgery). When a prophylactic antiemetic drug has failed, postoperative nausea and vomiting should be treated with one or more drugs from a different class.

Motion sickness

Antiemetics should be given to prevent motion sickness rather than after nausea or vomiting develops. The most effective drug for the prevention of motion sickness is hyoscine. A transdermal hyoscine patch provides prolonged activity but it needs to be applied several hours before travelling. The sedating antihistamines are slightly less effective against motion sickness, but are generally better tolerated than hyoscine. If a sedative effect is desired promethazine is useful, but generally a slightly less sedating antihistamine such as cyclizine or cinnarizine is preferred. The 5HT
d antagonists, domperidone, metoclopramide, and the phenothiazines (except the antihistamine phenothiazine promethazine) are ineffective in motion sickness.

Other vestibular disorders

Management of vestibular diseases is aimed at treating the underlying cause as well as treating symptoms of the balance disturbance and associated nausea and vomiting. Vertigo and nausea associated with Ménière’s disease and middle-ear surgery can be difficult to treat. Betahistine is an analogue of histamine and is claimed to reduce endolympathic pressure by improving the microcirculation. Betahistine is licensed for vertigo, tinnitus, and hearing loss associated with Ménière’s disease.

Cytotoxic chemotherapy

For the management of nausea and vomiting induced by cytotoxic chemotherapy, see section 8.1.

Palliative care

For the management of nausea and vomiting in palliative care, see p. 22 and p. 23.

Migraine

For the management of nausea and vomiting associated with migraine, see p. 277.

Antihistamines

CINNARIZINE

Indications vestibular disorders, such as vertigo, tinnitus, nausea, and vomiting in Ménière’s disease; motion sickness

Cautions section 3.4.1; also Parkinson’s disease

Contra-indications section 3.4.1

Hepatic impairment section 3.4.1

Renal impairment use with caution—no information available

Pregnancy section 3.4.1

Breast-feeding section 3.4.1

Side-effects section 3.4.1; also rarely weight gain, sweating, lichen planus, and lupus-like skin reactions

Dose

● Vestibular disorders, 30 mg 3 times daily; CHILD 5–12 years 15 mg 3 times daily

● Motion sickness, 30 mg 2 hours before travel then 15 mg every 8 hours during journey if necessary; CHILD 5–12 years, 15 mg 2 hours before travel then 7.5 mg every 8 hours during journey if necessary

Cinnarizine (Non-proprietary)

Tablets, cinnarizine 15 mg, net price 84-tab pack = £8.84. Label: 2

Stugeron® (Janssen-Cilag)

Tablets, scored, cinnarizine 15 mg, net price 15-tab pack = £4.18. Label: 2

With dimenhydrinate

Arlevert® (Hampton)

Tablets, cinnarizine 20 mg, dimenhydrinate 40 mg, net price 100-tab pack = £24.00. Label: 2

Dose ADULT over 18 years, 1 tablet 3 times daily
4.6 Drugs used in nausea and vertigo

**CYCLIZINE**

**Indications** nausea, vomiting, vertigo, motion sickness, labyrinthine disorders

**Cautions** section 3.4.1; severe heart failure; may counteract haemodynamic benefits of opioids; **Interactions**: Appendix 1 (antihistamines)

**Contra-indications** see notes in section 3.4.1

**Hepatic impairment** section 3.4.1

**Pregnancy** section 3.4.1

**Breast-feeding** no information available

**Side-effects** section 3.4.1; also hypertension, paraesthesia, and twitching

**Dose**
- By mouth, cyclizine hydrochloride 50 mg up to 3 times daily; CHILD 6–12 years 25 mg up to 3 times daily
- By intramuscular or intravenous injection, cyclizine lactate 50 mg 3 times daily

**Valoid** (Amdipharm)

- Tablets, scored, cyclizine hydrochloride 50 mg, net price 100-tab pack = £7.41. Label: 2
- Injection (Amdipharm), cyclizine lactate 50 mg/mL, net price 1-ML amp = 51p

**Phenothiazines and related drugs**

**CHLORPROMAZINE HYDROCHLORIDE**

**Indications** nausea and vomiting of terminal illness (where other drugs have failed or are not available); other indications (section 4.2.1)

**Cautions** see Chlorpromazine Hydrochloride, section 4.2.1

**Contra-indications** see notes in section 4.2.1

**Hepatic impairment** see notes in section 4.2.1

**Renal impairment** see Promethazine Hydrochloride, section 3.4.1

**Pregnancy** see notes in section 4.2.1

**Breast-feeding** see notes in section 4.2.1

**Side-effects** see Chlorpromazine Hydrochloride, section 4.2.1

**Dose**
- By mouth, 10–25 mg every 4–6 hours; CHILD 500 micrograms/kg every 4–6 hours (1–5 years max. 40 mg daily, 6–12 years max. 75 mg daily)
- By deep intramuscular injection initially 25 mg then 25–50 mg every 3–4 hours until vomiting stops; CHILD 500 micrograms/kg every 6–8 hours (1–5 years max. 40 mg daily, 6–12 years max. 75 mg daily)
- By rectum in suppositories, chlorpromazine 100 mg every 6–8 hours [unlicensed]

**Preparations**

Section 4.2.1

**PROMETHAZINE HYDROCHLORIDE**

**Indications** nausea, vomiting, vertigo, labyrinthine disorders, motion sickness, allergy and urticaria (section 3.4.1); sedation (section 4.1.1)

**Cautions** see Promethazine Hydrochloride, section 3.4.1

**Contra-indications** see notes in section 3.4.1

**Hepatic impairment** see notes in section 3.4.1

**Renal impairment** see Promethazine Hydrochloride, section 3.4.1

**Pregnancy** see notes in section 3.4.1

**Breast-feeding** see notes in section 3.4.1

**Side-effects** see Promethazine Hydrochloride, section 3.4.1

**Dose**
- By mouth, 20–25 mg at bedtime on night before travel, repeat following morning if necessary; CHILD 2–5 years 5 mg at night, and following morning if necessary, 5–10 years 10 mg at night, and following morning if necessary

**Preparations**

Section 3.4.1

**PROMETHAZINE TEOCLATE**

**Indications** nausea, vertigo, labyrinthine disorders, motion sickness (acts longer than the hydrochloride)

**Cautions** section 3.4.1; severe coronary artery disease, asthma, bronchitis, bronchiectasis; Reye’s syndrome

**Contra-indications** section 3.4.1

**Hepatic impairment** section 3.4.1

**Renal impairment** use with caution

**Pregnancy** section 3.4.1

**Breast-feeding** section 3.4.1

**Side-effects** section 3.4.1

**DROPERIDOL**

**Indications** prevention and treatment of postoperative nausea and vomiting

**Cautions** section 4.2.1; also chronic obstructive pulmonary disease or respiratory failure; electrolyte disturbances; history of alcohol abuse; continuous pulse oximetry required if risk of ventricular arrhythmia—continue for 30 minutes following administration; **Interactions**: Appendix 1 (droperidol)

**Contra-indications** section 4.2.1; QT-interval prolongation (avoid concomitant administration of drugs
4.6 Drugs used in nausea and vertigo

that prolong QT interval); hypokalaemia; hypomagnesaemia; bradycardia

Hepatic impairment in postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required; for nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose

Renal impairment in postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required; for nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose

Renal impairment in postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required; for nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose

Pregnancy section 4.2.1

Breast-feeding see notes in section 4.2.1

Side-effects see Prochlorperazine, section 4.2.1

Contra-indications

Indications severe nausea, vomiting (see notes above); other indications (see section 4.2.1)

Cautions see notes in section 4.2.1

Hepatic impairment see notes in section 4.2.1

Renal impairment see notes in section 4.2.1

Pregnancy see notes in section 4.2.1

Breast-feeding see notes in section 4.2.1

Side-effects see Prochlorperazine, section 4.2.1

Dose

Note Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate = 1 mg prochlorperazine mesilate

By mouth, nausea and vomiting, acute attack, 20 mg initially then 10 mg after 2 hours; prevention 5–10 mg 2–3 times daily; CHILD (over 10 kg only) 250 micrograms/kg 2–3 times daily

Labyrinthine disorders, 5 mg 3 times daily, gradually increased if necessary to 30 mg daily in divided doses, then reduced after several weeks to 5–10 mg daily; CHILD not recommended

By deep intramuscular injection, nausea and vomiting, 12.5 mg when required followed if necessary after 6 hours by an oral dose, as above; CHILD and ADOLESCENT under 18 years, see BNF for Children

Prochlorperazine (Non-proprietary) (UK)

Tablets, prochlorperazine maleate 5 mg, net price 28-tab pack = £1.25, 84-tab pack = £2.28. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Stemetil® (Sanofi-Aventis) (UK)

Tablets, prochlorperazine maleate 5 mg (off-white), net price 28-tab pack = £1.98, 84-tab pack = £5.94. Label: 2

Injection, prochlorperazine mesilate 5 mg/5 mL, net price 100-mL pack = £3.34. Label: 2

Syrup, straw-coloured, prochlorperazine mesilate 5 mg/5 mL, net price 100-mL pack = £3.34. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Buccal preparation

Buccastem® (Alliance) (UK)

Tablets (buccal), pale yellow, prochlorperazine maleate 3 mg, net price 5 × 10-tab pack = £5.89. Label: 2, counselling, administration, see under Dose below

Dose ADULT and CHILD over 12 years, 1–2 tablets twice daily, tablets are placed high between upper lip and gum and left to dissolve

1. Prochlorperazine maleate can be sold to the public for adults over 18 years (provided packs do not contain more than 24 mg) for the treatment of nausea and vomiting in previously diagnosed migraine only (max. daily dose 12 mg)

PERPHENAZINE

Indications severe nausea, vomiting (see notes above); other indications (see section 4.2.1)

Cautions see notes in section 4.2.1

Hepatic impairment see notes in section 4.2.1

Renal impairment see notes in section 4.2.1

Pregnancy see notes in section 4.2.1

Breast-feeding see notes in section 4.2.1

Side-effects see Perphenazine, section 4.2.1

Dose

• Prevention and treatment of postoperative nausea and vomiting, ADULT over 18 years, by intravenous injection, 0.625–1.25 mg (ELDERLY 625 micrograms) 30 minutes before end of surgery, repeated every 6 hours as required; CHILD over 2 years (second-line use only) 20–50 micrograms/kg (max. 1.25 mg)

• Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia (PCA), ADULT over 18 years, by intravenous injection, 15–50 micrograms of droperidol for every 1 mg of morphine in PCA (max. 5 mg droperidol daily); ELDERLY reduce dose

Perphenazine (Non-proprietary) (UK)

Injection, droperidol 2.5 mg/mL, net price 1–mL amp = £3.94

PROCHLORPERAZINE

Indications severe nausea, vomiting, vertigo, labyrinthine disorders (see notes above); other indications section 4.2.1

Cautions see Prochlorperazine, section 4.2.1; oral route only for children (avoid if under 10 kg); elderly (see notes above)

Contra-indications see Prochlorperazine, section 4.2.1

Hepatic impairment see notes in section 4.2.1

Renal impairment see notes in section 4.2.1

Pregnancy see notes in section 4.2.1

Breast-feeding see notes in section 4.2.1

Side-effects see Prochlorperazine, section 4.2.1

Dose

Note Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate = 1 mg prochlorperazine mesilate

By mouth, nausea and vomiting, acute attack, 20 mg initially then 10 mg after 2 hours; prevention 5–10 mg 2–3 times daily; CHILD (over 10 kg only) 250 micrograms/kg 2–3 times daily

Labyrinthine disorders, 5 mg 3 times daily, gradually increased if necessary to 30 mg daily in divided doses, then reduced after several weeks to 5–10 mg daily; CHILD not recommended

By deep intramuscular injection, nausea and vomiting, 12.5 mg when required followed if necessary after 6 hours by an oral dose, as above; CHILD and ADOLESCENT under 18 years, see BNF for Children

Prochlorperazine (Non-proprietary) (UK)

Tablets, prochlorperazine maleate 5 mg, net price 28-tab pack = £1.25, 84-tab pack = £2.28. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Stemetil® (Sanofi-Aventis) (UK)

Tablets, prochlorperazine maleate 5 mg (off-white), net price 28-tab pack = £1.98, 84-tab pack = £5.94. Label: 2

Injection, prochlorperazine mesilate 5 mg/5 mL, net price 100-mL pack = £3.34. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Buccal preparation

Buccastem® (Alliance) (UK)

Tablets (buccal), pale yellow, prochlorperazine maleate 3 mg, net price 5 × 10-tab pack = £5.89. Label: 2, counselling, administration, see under Dose below

Dose ADULT and CHILD over 12 years, 1–2 tablets twice daily, tablets are placed high between upper lip and gum and left to dissolve

1. Prochlorperazine maleate can be sold to the public for adults over 18 years (provided packs do not contain more than 24 mg) for the treatment of nausea and vomiting in previously diagnosed migraine only (max. daily dose 12 mg)

TRIFLUOPERAZINE

Indications severe nausea and vomiting (see notes above); other indications (see section 4.2.1)

Cautions see notes in section 4.2.1

Contra-indications see notes in section 4.2.1

Hepatic impairment see notes in section 4.2.1

Renal impairment see notes in section 4.2.1

Pregnancy see notes in section 4.2.1

Breast-feeding see notes in section 4.2.1

Side-effects see Trifluoperazine, section 4.2.1

Dose

Note Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate = 1 mg prochlorperazine mesilate

By mouth, nausea and vomiting, acute attack, 20 mg initially then 10 mg after 2 hours; prevention 5–10 mg 2–3 times daily; CHILD (over 10 kg only) 250 micrograms/kg 2–3 times daily

Labyrinthine disorders, 5 mg 3 times daily, gradually increased if necessary to 30 mg daily in divided doses, then reduced after several weeks to 5–10 mg daily; CHILD not recommended

By deep intramuscular injection, nausea and vomiting, 12.5 mg when required followed if necessary after 6 hours by an oral dose, as above; CHILD and ADOLESCENT under 18 years, see BNF for Children

Prochlorperazine (Non-proprietary) (UK)

Tablets, prochlorperazine maleate 5 mg, net price 28-tab pack = £1.25, 84-tab pack = £2.28. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Stemetil® (Sanofi-Aventis) (UK)

Tablets, prochlorperazine maleate 5 mg (off-white), net price 28-tab pack = £1.98, 84-tab pack = £5.94. Label: 2

Injection, prochlorperazine mesilate 5 mg/5 mL, net price 100-mL pack = £3.34. Label: 2

Injection, prochlorperazine mesilate 12.5 mg/mL, net price 1-mL amp = 52p

Buccal preparation

Buccastem® (Alliance) (UK)

Tablets (buccal), pale yellow, prochlorperazine maleate 3 mg, net price 5 × 10-tab pack = £5.89. Label: 2, counselling, administration, see under Dose below

Dose ADULT and CHILD over 12 years, 1–2 tablets twice daily, tablets are placed high between upper lip and gum and left to dissolve

1. Prochlorperazine maleate can be sold to the public for adults over 18 years (provided packs do not contain more than 24 mg) for the treatment of nausea and vomiting in previously diagnosed migraine only (max. daily dose 12 mg)
Domperidone and metoclopramide

DOMPERIDONE

**Indications**
nausea and vomiting, dyspepsia, gastrointestinal reflux

**Cautions**
children; interactions: Appendix 1 (domperidone)

**Contra-indications**
prolactinoma; if increased gastrointestinal motility harmful

**Hepatic impairment**
avoid

**Renal impairment**
reduce dose

**Pregnancy**
use only if potential benefit outweighs risk

**Breast-feeding**
amount too small to be harmful

**Side-effects**
rarely gastro-intestinal disturbances (including cramps) and hyperprolactinaemia; very rarely ventricular arrhythmias, agitation, drowsiness, nervousness, seizures, extrapyramidal effects, headache, and rashes; also reported QT-interval prolongation

**Dose**

- **By mouth**
  - **ADULT** and **CHILD**
    - body-weight over 35 kg, 10–20 mg 3–4 times daily; max. 80 mg daily; **CHILD** body-weight up to 35 kg (nausea and vomiting only), 250–500 micrograms/kg 3–4 times daily; max. 2.4 mg/kg daily
  - **By rectum**
    - **ADULT** and **CHILD**
      - body-weight over 35 kg, 60 mg twice daily; **CHILD** 15–35 kg (nausea and vomiting only), 30 mg twice daily; **CHILD** body-weight under 15 kg, not recommended

**Domperidone**

- **Non-proprietary**
  - Tablets, 10 mg (as maleate), net price 30-tab pack = £1.12; 100-tab pack = £1.90
  - Suspension, domperidone 5 mg/5 mL, net price 200-mL pack = £12.00

**Mettolium**

- (Sanofi-Aventis)
  - Tablets, f/c, domperidone 10 mg (as maleate), net price 30-tab pack = £2.71; 100-tab pack = £9.04
  - Suppositories domperidone 30 mg, net price 10 = £3.06

METOCLOPRAMIDE

**Indications**
adults, nausea and vomiting, particularly in gastro-intestinal disorders (section 1.2) and treatment with cytotoxics or radiotherapy; migraine (section 4.7.4.1)

**Patients under 20 years**
Use restricted to severe intractable vomiting of known cause, vomiting of radiotherapy and cytotoxics, to aid gastro-intestinal intubation, premedication; dose should be determined on the basis of body-weight

**Cautions**
elderly, young adults (15–19 years old), and children; atopic allergy (including asthma); may mask underlying disorders such as cerebral irritation; acute porphyria (section 9.8.2); epilepsy; interactions: Appendix 1 (metoclopramide)

**Contra-indications**
gastro-intestinal obstruction, perforation or haemorrhage; 3–4 days after gastro-intestinal surgery; phaeochromocytoma

**Hepatic impairment**
reduce dose

**Renal impairment**
avoid or use small dose in severe impairment; increased risk of extrapyramidal reactions

**Pregnancy**
not known to be harmful

**Breast-feeding**
small amount present in milk; avoid

**Side-effects**
extrapyramidal effects (especially in children and young adults (15–19 years old)—see p. 249), hyperprolactinaemia, occasionally tardive dyskinesia on prolonged administration; also reported, anxiety, confusion, drowsiness, restlessness, diarrhoea, depression, neuroleptic malignant syndrome, rashes, pruritus, oedema; cardiac conduction abnormalities reported following intravenous administration; rarely methaemoglobinemia (more severe in G6PD deficiency)

**Dose**

- **By mouth**
  - or by intramuscular injection or by intravenous injection over 1–2 minutes, nausea and vomiting, 10 mg (5 mg in young adults 15–19 years, body-weight under 60 kg) 3 times daily; **CHILD** up to 1 year (body-weight up to 10 kg) 100 micrograms/kg (max. 1 mg) twice daily, 1–3 years (body-weight 10–14 kg) 1 mg 2–3 times daily, 3–5 years (body-weight 15–19 kg) 2 mg 2–3 times daily, 5–9 years (body-weight 20–29 kg) 2.5 mg 3 times daily, 9–15 years (body-weight 30 kg and over) 5 mg 3 times daily
  - **Note** Daily dose of metoclopramide should not normally exceed 500 micrograms/kg, particularly for children and young adults (restricted use, see above)
  - For diagnostic procedures, as a single dose 5–10 minutes before examination, 10–20 mg (10 mg in young adults 15–19 years); **CHILD** under 3 years 1 mg, 5–9 years 2 mg, 5–9 years 2.5 mg, 9–14 years 5 mg

**Metoclopramide**

- **Non-proprietary**
  - Tablets, metoclopramide hydrochloride 10 mg, net price 28-tab pack = £1.01
  - **Oral solution**, metoclopramide hydrochloride 5 mg/5 mL, net price 150-mL pack = £6.51
  - Counselling, use of pipette
  - **Injection**, metoclopramide hydrochloride 5 mg/mL, net price 2-mL amp = 26p

**Maxolon**

- **(Amdipharm)**
  - Tablets, scored, metoclopramide hydrochloride 10 mg, net price 94-tab pack = £5.24
  - **Injection**, metoclopramide hydrochloride 5 mg/mL, net price 2-mL amp = 27p

**High-dose (with cytotoxic chemotherapy only)**

**Maxolon High Dose**

- **(Amdipharm)**
  - **Injection**, metoclopramide hydrochloride 5 mg/mL, net price 20-mL amp = £2.67
  - For dilution and use as an intravenous infusion in nausea and vomiting associated with cytotoxic chemotherapy only
  - **Dose** by continuous intravenous infusion (preferred method), initially (before starting chemotherapy), 2–4 mg/kg over 15–20 minutes, then 3–5 mg/kg over 8–12 hours; max. in 24 hours, 10 mg/kg
  - By intermittent intravenous infusion, up to 2 mg/kg over at least 15 minutes then up to 2 mg/kg over at least 15 minutes every 2 hours; max. in 24 hours, 10 mg/kg
4 Central nervous system

4.6 Drugs used in nausea and vertigo

GRANISETRON

Indications see under Dose

Cautions QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval)

Pregnancy use only when compelling reasons—no information available

Breast-feeding avoid—no information available

Side-effects constipation, headache, flushing, injection site-reactions; less commonly hiccups, hypotension, bradycardia, chest pain, arthralgia, movement disorders, seizures; on intravenous administration, rarely dizziness, transient visual disturbances (very rarely transient blindness); suppositories may cause rectal irritation

Dose

● Moderately emetogenic chemotherapy or radiotherapy, ADULT over 18 years, by mouth, 8 mg 1–2 hours before treatment or by rectum, 16 mg 1–2 hours before treatment or by intramuscular injection or slow intravenous injection, 8 mg immediately before treatment then by mouth, 8 mg every 12 hours for up to 5 days or by rectum, 16 mg daily for up to 5 days

● Severely emetogenic chemotherapy, ADULT over 18 years, by intramuscular injection or slow intravenous injection, 8 mg immediately before treatment, where necessary followed by 2 further doses of 8 mg at intervals of 2–4 hours (or followed by 1 mg/hour by continuous intravenous infusion for up to 24 hours) then by mouth, 8 mg every 12 hours for up to 5 days or by rectum, 16 mg daily for up to 5 days; alternatively, by intravenous infusion over at least 15 minutes, 32 mg immediately before treatment or by rectum, 16 mg 1–2 hours before treatment then by mouth, 8 mg every 12 hours for up to 5 days or by rectum, 16 mg daily for up to 5 days

● Chemotherapy-induced nausea and vomiting, CHILD 6 months–18 years, by intravenous infusion over at least 15 minutes, 5 mg/m² (max. 8 mg) immediately before chemotherapy, then for body-surface area less than 0.6 m² 2 mg by mouth every 12 hours for up to 5 days; for body-surface area 0.6 m² or greater 4 mg by mouth every 12 hours for up to 5 days; max. total daily dose 32 mg; alternatively, by intravenous infusion over at least 15 minutes, 150 micrograms/kg (max. 8 mg) immediately before chemotherapy repeated at intervals of 4 hours for 2 further doses, then for body-weight 10 kg or less 2 mg by mouth every 12 hours for up to 5 days; for body-weight over 10 kg 4 mg by mouth every 12 hours for up to 5 days; max. total daily dose 32 mg

● Prevention of postoperative nausea and vomiting, by mouth, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for 2 further doses alternatively, by intramuscular or slow intravenous injection, 4 mg at induction of anaesthesia; CHILD 1 month–18 years, by slow intravenous injection over at least 30 seconds, 100 micrograms/kg (max. 4 mg) before, during, or after induction of anaesthesia

● Treatment of postoperative nausea and vomiting, by intramuscular or slow intravenous injection, 4 mg,
**Neurokinin receptor antagonists**

### APREPITANT

**Indications** adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy

**Cautions** interactions: Appendix 1 (aprepitant)

**Hepatic impairment** caution in moderate to severe impairment

**Pregnancy** avoid unless potential benefit outweighs risk—no information available

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** hiccup, dyspepsia, diarrhoea, constipation, anorexia, nausea, headache, dizziness; *less commonly* weight changes, dry mouth, colitis, flatulence, stomatitis, abdominal pain, duodenal ulcer, taste disturbance, oedema, Bradycardia, palpitations, cough, euphoria, anxiety, confusion, drowsiness, thirst, abnormal dreams, chills, hyperglycaemia, polyuria, anaemia, dysuria, haematuria, hypernatraemia, neutropenia, myalgia, conjunctivitis, pharyngitis, sneezing, tinnitus, sweating, pruritus, rash, acne, photosensitivity, and flushing; dyspnoea, insomnia, visual disturbances, dysarthria, urticaria, and Stevens-Johnson syndrome also reported

**Dose**

- **ADULT** over 18 years 125 mg 1 hour before chemotherapy, then 80 mg daily as a single dose for the next 2 days; consult product literature for dose of concomitant corticosteroid and 5HT3 antagonist

**Emend® (MSD)**

- **Capsules** aprepitant 80 mg (white), net price 2-cap pack = £31.61; 125 mg (white/pink), 5-cap pack = £79.03; 3-day pack of one 125-mg capsule and two 80-mg capsules = £47.42

### FOSAPREPITANT

**Note** Fosaprepitant is a prodrug of aprepitant

**Indications** adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy

**Cautions** interactions: Appendix 1 (aprepitant)

**Pregnancy** see Aprepitant

**Breast-feeding** see Aprepitant

**Side-effects** see Aprepitant

**Dose**

- **By intravenous infusion**, over 15 minutes, **ADULT** over 18 years, 115 mg 30 minutes before chemotherapy on day 1 of cycle (followed by aprepitant on days 2 and 3 of cycle); consult product literature for dose of concomitant corticosteroid and 5HT3 antagonist

**Ivemend® (MSD)**

- **Injection**, powder for reconstitution, fosaprepitant (as dimeglumine), net price 115-mg vial = £20.55

The Scottish Medicines Consortium (p. 4) has advised (September 2008) that fosaprepitant (Ivemend®) is accepted for restricted use for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.
Cannabidiol

**NABILONE**

**Indications** nausea and vomiting caused by cytotoxic chemotherapy, unresponsive to conventional antiemetics (under close observation, preferably in hospital setting)

**Cautions** history of psychiatric disorder; elderly; hypertension; heart disease; adverse effects on mental state can persist for 48–72 hours after stopping; **interactions:** Appendix 1 (nabilone)

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Hepatic impairment** avoid in severe impairment

**Contra-indications**

- motion sickness; hypersalivation associated with clozapine therapy (unlicensed indication), by mouth, 300 micrograms up to 3 times daily; max. 900 micrograms daily; **CHILD** under 18 years, see *BNF for Children*

**Joy Rides®** (GSK Consumer Healthcare)

- Tablets, chewable, raspberry-flavoured, hyoscine hydrobromide 150 micrograms, net price 12-tab pack = £1.49. Label: 2, 24

**Kwells®** (Bayer Consumer Care)

- Tablets, chewable, scored, hyoscine hydrobromide 150 micrograms (Kwells® Kids) (white), net price 12-tab pack = £1.67; 300 micrograms (pink), 12-tab pack = £1.67. Label: 2

**Patches**

**Scopoderm TTS®** (Novartis Consumer Health)

- Patch, self-adhesive, pink, releasing hyoscine approx. 1 mg/72 hours when in contact with skin, net price 2 = £4.30. Label: 19, counselling, see below

**Dose** motion sickness prevention, apply 1 patch to hairless area of skin behind ear 5–6 hours before journey; replace if necessary after 72 hours, stting replacement patch behind other ear; **CHILD** under 10 years not recommended

**Counselling** Explain accompanying instructions to patient and in particular emphasise advice to wash hands after handling and to wash application site after removing, and to use one patch at a time

**Parenteral preparations**

Section 15.1.3

Other drugs for Ménière’s disease

Betahistine has been promoted as a specific treatment for Ménière’s disease.

**BETAHISTINE DIHYDROCHLORIDE**

**Indications** vertigo, tinnitus and hearing loss associated with Ménière’s disease

**Cautions** asthma, history of peptic ulcer; **interactions:** Appendix 1 (betahistine)

**Contra-indications** phaeochromocytoma

**Pregnancy** avoid unless clearly necessary—no information available

**Breast-feeding** use only if potential benefit outweighs risk—no information available

**Side-effects** gastro-intestinal disturbances; headache, rashes and pruritus reported

**Dose**

- Initially 16 mg 3 times daily, preferably with food; maintenance 24–48 mg daily; **CHILD** not recommended

Betahistine Dihydrochloride (Non-proprietary)

- Tablets, beta histine dihydrochloride 8 mg, net price 84-tab pack = £2.15 120-tab pack = £1.76; 16 mg, 84-tab pack = £2.24. Label: 21

**Serc®** (Solvay)

- Tablets, beta histine dihydrochloride 8 mg (Serc®-8), net price 120-tab pack = £9.04; 16 mg (Serc®-16) (scored), 84-tab pack = £12.65. Label: 21
analgesics

4.7.1 Non-opioid analgesics and compound analgesic preparations

The non-opioid drugs (section 4.7.1), paracetamol and aspirin (and other NSAIDs), are particularly suitable for pain in musculoskeletal conditions, whereas the opioid analgesics (section 4.7.2) are more suitable for moderate to severe pain, particularly of visceral origin.

Pain in palliative care For advice on pain relief in palliative care, see p. 20.

Pain in sickle-cell disease The pain of mild sickle-cell crises is managed with paracetamol, a NSAID (section 10.1.1), codeine, or dihydrocodeine. Severe crises may require the use of morphine or diamorphine; concomitant use of a NSAID may potentiate analgesia and allow lower doses of the opioid to be used. Pethidine should be avoided if possible because accumulation of a neurotoxic metabolite can precipitate seizures; the relatively short half-life of pethidine necessitates frequent injections.

Dental and orofacial pain Analgesics should be used judiciously in dental care as a temporary measure until the cause of the pain has been dealt with. Dental pain of inflammatory origin, such as that associated with pulpitis, apical infection, localised osteitis (dry socket) or pericoronitis is usually best managed by treating the infection, providing drainage, restorative procedures, and other local measures. Analgesics provide temporary relief of pain (usually for about 1 to 7 days) until the causative factors have been brought under control. In the case of pulpitis, intra-ossseous injections of an analgesic for dental purposes should be avoided if possible because accumulation of a neurotoxic metabolite can precipitate seizures; the relatively short half-life of pethidine necessitates frequent injections.

Similarly the pain and discomfort associated with acute problems of the oral mucosa (e.g. acute herpetic gingivostomatitis, erythema multiforme) may be relieved by benzoyldine mouthwash or spray (p. 694) until the cause of the mucosal disorder has been dealt with. However, where a patient is febrile, the antipyretic action of paracetamol (p. 259) or ibuprofen (p. 636) is often helpful.

The choice of an analgesic for dental purposes should be based on its suitability for the patient. Most dental pain is relieved effectively by non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs that are used for dental pain include ibuprofen, diclofenac, and aspirin; for further details see section 4.7.1 and section 10.1.1. Paracetamol has analgesic and antipyretic effects but no anti-inflammatory effect.

Opioid analgesics (section 4.7.2) such as dihydrocodeine act on the central nervous system and are traditionally used for moderate to severe pain. However, opioid analgesics are relatively ineffective in dental pain and their side-effects can be unpleasant. Paracetamol, ibuprofen, or aspirin are adequate for most cases of dental pain and an opioid is rarely required.

Combining a non-opioid with an opioid analgesic can provide greater relief of pain than either analgesic given alone. However, this applies only when an adequate dose of each analgesic is used. Most combination analgesic preparations have not been shown to provide greater relief of pain than an adequate dose of the non-opioid component given alone. Moreover, combination preparations have the disadvantage of an increased number of side-effects.

Any analgesic given before a dental procedure should have a low risk of increasing postoperative bleeding. In the case of pain after the dental procedure, taking an analgesic before the effect of the local anaesthetic has worn off can improve control. Postoperative analgesia with ibuprofen or aspirin is usually continued for about 24 to 72 hours.

Temporomandibular dysfunction can be related to anxiety in some patients who may clench or grind their teeth (bruxism) during the day or night. The muscle spasm (which appears to be the main source of pain) may be treated empirically with an overlay appliance which provides a free sliding occlusion and may also interfere with grinding. In addition, diazepam (section 4.1.2), which has muscle relaxant as well as anxiolytic properties, may be helpful but it should only be prescribed on a short-term basis during the acute phase. Analgesics such as aspirin (section 4.7.1) or ibuprofen (section 10.1.1) may also be required.

For the management of neuropathic pain, persistent idiopathic facial pain, and trigeminal neuralgia, see section 4.7.3.

Dysmenorrhoea Use of an oral contraceptive prevents the pain of dysmenorrhoea which is generally associated with ovulatory cycles. If treatment is necessary paracetamol or a NSAID (section 10.1.1) will generally provide adequate relief of pain. The vomiting and severe pain associated with dysmenorrhoea in women with endometriosis may call for an antiemetic (in addition to an analgesic). Antispasmodics (such as alverine citrate, section 1.2) have been advocated for dysmenorrhoea but the antispasmodic action does not generally provide significant relief.

Aspirin is indicated for headache, transient musculoskeletal pain, dysmenorrhoea and pyrexia. In inflammatory conditions, most physicians prefer anti-inflammatory treatment with another NSAID which may be better tolerated and more convenient for the patient. Aspirin is used increasingly for its antplatelet properties (section 2.9). Aspirin tablets or dispersible aspirin tablets are adequate for most purposes as they act rapidly. Gastric irritation may be a problem; it is minimised by taking the dose after food. Enteric-coated preparations are available, but have a slow onset of action and are therefore unsuitable for single-dose analgesic use (though their prolonged action may be useful for night pain).

Aspirin interacts significantly with a number of other drugs and its interaction with warfarin is a special hazard, see interactions: Appendix 1 (aspirin).

Paracetamol is similar in efficacy to aspirin, but has no demonstrable anti-inflammatory activity; it is less irri- tant to the stomach and for that reason is now generally preferred to aspirin, particularly in the elderly. Over-
4.7.1 Non-opioid analgesics and compound analgesic preparations

**dosage** with paracetamol is particularly dangerous as it may cause hepatic damage which is sometimes not apparent for 4 to 6 days (see Emergency Treatment of Poisoning, p. 34).

**Nefopam** may have a place in the relief of persistent pain unresponsive to other non-opioid analgesics. It causes little or no respiratory depression, but sympathomimetic and antimuscarinic side-effects may be troublesome.

**Non-steroidal anti-inflammatory analgesics** (NSAIDs, section 10.1.1) are particularly useful for the treatment of patients with chronic disease accompanied by pain and inflammation. Some of them are also used in the short-term treatment of mild to moderate pain including transient musculoskeletal pain but paracetamol is now often preferred, particularly in the elderly (see also p. 25). They are also suitable for the relief of pain in *dysmenorrhoea* and to treat pain caused by *secondary bone tumours*, many of which produce lysis of bone and release prostaglandins (see Prescribing in Palliative Care, p. 20). Selective inhibitors of cyclo-oxygenase-2 may be used in preference to non-selective NSAIDs for patients at high risk of developing serious gastro-intestinal side-effects. NSAIDs including ketorolac are also used for peri-operative analgesia (section 15.1.4.2).

A non-opioid analgesic administered by intrathecal infusion (*ziconotide* (Prialt™), available from Eisai) is licensed for the treatment of chronic severe pain; ziconotide can be used by a hospital specialist as an adjunct to opioid analgesics.

**Dental and orofacial pain** Most dental pain is relieved effectively by NSAIDs (section 10.1.1). **Aspirin** (below) is effective against mild to moderate dental pain; dispersible tablets provide a rapidly absorbed form of aspirin suitable for most purposes.

The analgesic effect of paracetamol in mild to moderate dental pain is probably less than that of aspirin, but it does not affect bleeding time or interact significantly with warfarin. Moreover, it is less irritant to the stomach. Paracetamol is a suitable analgesic for children; sugar-free versions can be requested by specifying 'sugar-free' on the prescription.

For further information on the management of dental and orofacial pain, see p. 257.

**Compound analgesic preparations**

Compound analgesic preparations that contain a simple analgesic (such as aspirin or paracetamol) with an opioid component reduce the scope for effective titration of the individual components in the management of pain of varying intensity.

Compound analgesic preparations containing paracetamol or aspirin with a **low dose** of an opioid analgesic (e.g. 8 mg of codeine phosphate per compound tablet) are commonly used, but the advantages have not been substantiated. The low dose of the opioid may be enough to cause opioid side-effects (in particular, constipation) and can complicate the treatment of **over-dosage** (see p. 36) yet may not provide significant additional relief of pain.

A **full dose** of the opioid component (e.g. 60 mg codeine phosphate) in compound analgesic preparations effectively augments the analgesic activity but is associated with the full range of opioid side-effects (including nausea, vomiting, severe constipation, drowsiness, respiratory depression, and risk of dependence on long-term administration). For details of the **side-effects** of opioid analgesics, see p. 262 (**important**: the elderly are particularly susceptible to opioid side-effects and should receive lower doses).

In general, when assessing pain, it is necessary to weigh up carefully whether there is a need for a non-opioid and an opioid analgesic to be taken simultaneously.

For information on the use of combination analgesic preparations in dental and orofacial pain, see p. 257.

**Caffeine** is a weak stimulant that is often included, in small doses, in analgesic preparations. It is claimed that the addition of caffeine may enhance the analgesic effect, but the alerting effect, mild habit-forming effect and possible provocation of headache may not always be desirable. Moreover, in excessive dosage or on withdrawal caffeine may itself induce headache.

**Co-proxamol** tablets (dextropropoxyphene in combination with paracetamol) are no longer licensed because of safety concerns, particularly toxicity in overdose. Co-proxamol tablets [unlicensed] may still be prescribed for patients who find it difficult to change, because alternatives are not effective or suitable.

**ASPIRIN** (Acetylsalicylic Acid)

**Indications** mild to moderate pain, pyrexia; anti-platelet (section 2.9)

**Cautions** asthma, allergic disease, dehydration; preferably avoid during fever or viral infection in children (risk of Reye’s syndrome, see below); elderly, G6PD-deficiency (section 9.1.5); concomitant use of drugs that increase risk of bleeding; **interactions**: Appendix 1 (aspirin)

**Contra-indications** children under 16 years (Reye’s syndrome, see below); previous or active peptic ulceration, haemophilia; not for treatment of gout

**Hypersensitivity** Aspirin and other NSAIDs are contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angio-oedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID

**Reye’s syndrome** Owing to an association with Reye’s syndrome, aspirin-containing preparations should not be given to children under 16 years, unless specifically indicated, e.g. for Kawasaki syndrome

**Hepatic impairment** avoid in severe impairment—increased risk of gastro-intestinal bleeding

**Renal impairment** use with caution; avoid in severe impairment; sodium and water retention; deterioration in renal function; increased risk of gastro-intestinal bleeding

**Pregnancy** impaired platelet function with risk of haemorrhage, and delayed onset and increased duration of labour with increased blood loss, can occur if used during delivery; avoid analgesic doses if possible in last few weeks (low doses probably not harmful); with high doses, closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of newborn; kernicterus in jaundiced neonates

**Breast-feeding** avoid—possible risk of Reye’s syndrome; regular use of high doses could impair platelet function and produce hypoprothrombinaemia in infant if neonatal vitamin K stores low

**Side-effects** generally mild and infrequent but high incidence of gastro-intestinal irritation with slight asymptomatic blood loss, increased bleeding time,
bronchospasm and skin reactions in hypersensitive patients. Prolonged administration, see section 10.1.1.

**Overdose:** see Emergency Treatment of Poisoning, p. 34

### Dose
- **By mouth,** 300–900 mg every 4–6 hours when necessary; max. 4 g daily; **CHILD** under 16 years not recommended (see Raye’s Syndrome, above).
- **By rectum,** 450–900 mg every 4 hours (max. 3.6 g daily); **CHILD** under 16 years not recommended (see Raye’s Syndrome, above).

#### Aspirin (Non-proprietary)
- **Tablets** (R), aspirin 300 mg, net price 32-tab pack = 31p. Label: 21, 32
- **Tablets** (R), e/c, aspirin 300 mg, net price 100-tab pack = £5.29; 75 mg, see section 2.9. Label: 25, 25, 32
- **Dispersible tablets** (R), aspirin 300 mg, net price 100-tab pack = £2.88; 75 mg, see section 2.9.
- Label: 13, 21, 32

#### Nu-Seals® (Aspirin) (Alliance)
- **Tablets** (R), e/c, aspirin 300 mg, net price 100-tab pack = £4.15; 75 mg, see section 2.9. Label: 5, 25, 32

#### With codeine phosphate 8 mg

- **Co-codaprin (Non-proprietary)**
  - **Dispersible tablets,** co-codaprin 8/400 (codeine phosphate 8 mg, aspirin 400 mg), net price 100-tab pack = £35.22. Label: 21, 25, 32
  - **Dose** 1–2 tablets in water every 4–6 hours; max. 8 tablets daily
  - When co-codaprin tablets or dispersible tablets are prescribed and no strength is stated, tablets or dispersible tablets, respectively, containing codeine phosphate 8 mg and aspirin 400 mg should be dispensed

#### With metoclopramide

For prescribing information on metoclopramide, see section 4.6

#### MigraMax® (Cephalon) (R)
- **Oral powder,** aspirin (as lysine acetylsalicylate) 900 mg, metoclopramide hydrochloride 10 mg/sachet, net price 6-sachet pack = £6.60, 20-sachet pack = £21.99. Label: 21, 25, 32
- **Dose** acute migraine, **ADULT** over 20 years 1 sachet in water at onset of attack, repeated after 2 hours if necessary (max. 3 sachets in 24 hours); **YOUNG ADULT** (under 20 years) and **CHILD** not recommended

**Important** Metoclopramide can cause severe extrapyramidal effects, particularly in children and young adults (for further details, see p. 249)

**Excipients** include aspartame (section 9.4.1)

---

1. Can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances; for details see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)

2. Can be sold to the public in certain circumstances; for exemptions see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)
### Co-codamol 15/500
When co-codamol tablets, dispersible (or effervescent) tablets, or capsules are prescribed and no strength is stated, tablets, dispersible (or effervescent) tablets, or capsules, respectively, containing codeine phosphate 8 mg and paracetamol 500 mg should be dispensed (see preparations above).

See warnings and notes on p. 258 (important: special care in elderly—reduce dose).

### Co-codamol 30/500
When co-codamol tablets, dispersible (or effervescent) tablets, or capsules are prescribed and no strength is stated, tablets, dispersible (or effervescent) tablets, or capsules, respectively, containing codeine phosphate 8 mg and paracetamol 500 mg should be dispensed (see preparations above).

See warnings and notes on p. 258 (important: special care in elderly—reduce dose).

---

#### Paediatric soluble tablets
(= Paediatric dispersible tablets), paracetamol 120 mg, net price 16-tab pack = 89p; Label: 13, 30

**Brands include** Diapro® Soluble Paracetamol (AU)

**Oral suspension** 120 mg/5 mL (= Paediatric Mixtures), paracetamol 120 mg/5 mL, net price 100 mL = 72p, 150 mL = 84p, 200 mL = £1.05, 500 mL = £1.94.

**Label:** 30

**Note** BP directs that when Paediatric Paracetamol Oral Suspension or Paediatric Paracetamol Mixtue is prescribed Paracetamol Oral Suspension 120 mg/5 mL should be dispensed; sugar-free versions can be ordered by specifying ‘sugar-free’ on the prescription.

**Brands include** Calpol® Paediatric, Calpol® Paediatric sugar-free, Diapro® Paediatric, Medinol® Paediatric sugar-free, Parano® sugar-free

**Oral suspension** 250 mg/5 mL (= Mixture), paracetamol 250 mg/5 mL, net price 100 mL = 82p, 200 mL = £1.10, 500 mL = £3.28. Label: 30

**Brands include** Calpol® Plus (AU), Medinol® Over 6 (AU)

**Note** Other strengths available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

#### Panadol OA® (GSK) (AU)
Tablets, f/c, paracetamol 1 g, net price 100-tab pack = £3.80. Label: 30

**Dose**

- **ADULT** and **CHILD** over 12 years, 1 tablet up to 4 times daily, not more often than every 4 hours

**Perfalgan® (Bristol-Myers Squibb) (AU)**

**Intravenous infusion** paracetamol 10 mg/mL, net price 50-mL vial = £1.39, 100-mL vial = £1.52

#### Co-codamol 8/500
When co-codamol tablets, dispersible (or effervescent) tablets, or capsules are prescribed and no strength is stated, tablets, dispersible (or effervescent) tablets, or capsules, respectively, containing codeine phosphate 8 mg and paracetamol 500 mg should be dispensed.

**Co-codamol 8/500 (Non-proprietary) (AU)**

**Tablets**, co-codamol 8/500 (codeine phosphate 8 mg, paracetamol 500 mg), net price 10-tab pack = £1.15, 20-tab pack = £3.55. Label: 29, 30

**Dose**

- 1–2 tablets every 4–6 hours; max. 8 tablets daily
- CHILD 6–12 years ½–1 tablet, max. 4 tablets daily

**Effervescent or dispersible tablets**, co-codamol 8/500 (codeine phosphate 8 mg, paracetamol 500 mg), net price 32-tab pack = £1.50, 100-tab pack = £4.32. Label: 13, 29, 30

**Brands include** Paracodene®

**Note** The Drug Tariff allows tablets of co-codamol labelled ‘dispersible’ to be dispensed against an order for ‘effervescent’ and vice versa

**Dose**

- 1–2 tablets in water every 4–6 hours, max. 8 tablets daily; CHILD 6–12 years ½–1 tablet, max. 4 tablets daily

**Capsules**, co-codamol 8/500 (codeine phosphate 8 mg, paracetamol 500 mg), net price 10-cap pack = £1.10, 20-cap pack = £1.71. Label: 29, 30

**Brands include** Paracodene®

**Dose**

- 1–2 capsules every 4 hours; max. 8 capsules daily

---

1. Can be sold to the public in certain circumstances; for exemptions see Medicines, Ethics and Practice, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions as available)
BNF 61

4.7.1 Non-opioid analgesics and compound analgesic preparations 261

Solpadol® (Sanofi-Aventis) *(CM)*

Caplets (= tablets), co-codamol 30/500 (codeine phosphate 30 mg, paracetamol 500 mg), net price 100-tab pack = £6.74. Label: 2, 29, 30

Dose 2 tablets every 4 hours; max. 8 tablets daily; CHILD under 12 years not recommended

Capsules, grey/purple, co-codamol 30/500 (codeine phosphate 30 mg, paracetamol 500 mg), net price 100-cap pack = £6.74. Label: 2, 29, 30

Dose 2 capsules every 4 hours; max. 8 capsules daily; CHILD under 12 years not recommended

Effervescent tablets, co-codamol 30/500 (codeine phosphate 30 mg, paracetamol 500 mg), net price 32-tab pack = £2.59, 100-tab pack = £8.09. Label: 2, 13, 29, 30

Electrolytes Na⁺ 16.9 mmol/tablet

Dose 2 tablets in every 4 hours; max. 8 tablets daily. CHILD under 12 years not recommended

Tylex® (UCB Pharma) *(CM)*

Capsules, co-codamol 30/500 (codeine phosphate 30 mg, paracetamol 500 mg), net price 100-cap pack = £7.70. Label: 2, 29, 30

Dose 1–2 capsules every 4 hours; max. 8 capsules daily; CHILD under 12 years not recommended

Effervescent tablets, co-codamol 30/500 (codeine phosphate 30 mg, paracetamol 500 mg), net price 100-tab pack = £8.80. Label: 2, 13, 29, 30

Electrolytes Na⁺ 14.2 mmol/tablet

Dose 1–2 tablets in water every 4 hours; max. 8 tablets daily; CHILD under 12 years not recommended

With methionine (co-methiamol)

A mixture of methionine and paracetamol; methionine has no analgesic activity but may prevent paracetamol-induced liver toxicity if overdose taken

Paradote® (Pernot)

Tablets, f/c, co-methiamol 100/500 (ox-methionine 100 mg, paracetamol 500 mg), net price 24-tab pack = £1.05, 96-tab pack = £2.77. Label: 29, 30

Dose 2 tablets every 4 hours; max. 8 tablets daily; CHILD under 12 years not recommended

With dihydrocodeine tartrate 10 mg

See notes on p. 258

When co-dydramol tablets are prescribed and no strength is stated, tablets containing dihydrocodeine tartrate 10 mg and paracetamol 500 mg should be dispensed

Co-dydramol (Non-proprietary) *(CM)*

Tablets, scored, co-dydramol 10/500 (dihydrocodeine tartrate 10 mg and paracetamol 500 mg) should be dispensed

Dose 1–2 tablets every 4–6 hours; max. 8 tablets daily; CHILD under 12 years not recommended

With dihydrocodeine tartrate 20 or 30 mg

See warnings and notes on p. 258 (important: special care in elderly—reduce dose)

When co-dydramol tablets are prescribed and no strength is stated, tablets containing dihydrocodeine tartrate 10 mg and paracetamol 500 mg should be dispensed

Remedeine® (Napp) *(CM)*

Tablets, paracetamol 500 mg, dihydrocodeine tartrate 20 mg, net price 112-tab pack = £10.57. Label: 2, 29, 30

Dose 1–2 tablets every 4–6 hours; max. 8 tablets daily; CHILD under 12 years not recommended

Forté tablets, paracetamol 500 mg, dihydrocodeine tartrate 30 mg, net price 56-tab pack = £6.53. Label: 2, 29, 30

Dose 1–2 tablets every 4–6 hours; max. 8 tablets daily; CHILD under 12 years not recommended

With isometheptene mucate

Isometheptene mucate (in combination with paracetamol) is licensed for the treatment of acute attacks of migraine; other more effective treatments are available.

Midrid® (Mann) *(CM)*

Tablets, red, isometheptene mucate 65 mg, paracetamol 325 mg, net price 30-cap pack = £5.50. Label: 30, counselling, dosage

Dose 1 migraine, 2 capsules at onset of attack, followed by 1 capsule every hour if necessary. max. 5 capsules in 12 hours; CHILD not recommended

1. A pack containing 15 capsules may be sold to the public

With tramadol

For prescribing information on tramadol, see section 4.7.2

Tramacet® (Grunenthal) *(CM)*

Tablets, f/c, yellow, tramadol hydrochloride 37.5 mg, paracetamol 325 mg, net price 60-tab pack = £9.68. Label: 2, 25, 29, 30

Dose 2 tablets not more often than every 6 hours; max. 8 tablets daily. CHILD under 12 years not recommended

Effervescent tablets, pink, tramadol hydrochloride 37.5 mg, paracetamol 325 mg, net price 60-tab pack = £9.68. Label: 2, 13, 29, 30

Electrolytes Na⁺ 7.8 mmol/tablet

Dose 2 tablets not more often than every 6 hours; max. 8 tablets daily; CHILD under 12 years not recommended

With antiemetics

Migraleve® (McNeil)

Tablets, f/c, pink tablets, buclizine hydrochloride 6.25 mg, paracetamol 500 mg, codeine phosphate 8 mg; yellow tablets, paracetamol 500 mg, codeine phosphate 8 mg, net price 48-tab pack Migraleve (32 pink + 16 yellow) = £4.81; 48 pink (Migraleve Pink) = £5.24; 48 yellow (Migraleve Yellow) = £4.70. Label: 2, (Migraleve Pink), 17, 30

Dose acute migraine, 2 pink tablets at onset of attack, followed by 2 yellow tablets every 4 hours if necessary. max. 2 pink and 6 yellow in 24 hours; CHILD under 10 years, only under close medical supervision; 10–14 years, half adult dose

Paramax® (Sanofi-Aventis) *(CM)*

Tablets, scored, paracetamol 500 mg, metoclopramide hydrochloride 5 mg, net price 42-tab pack = £9.64. Label: 17, 30

Sachets, effervescent powder, sugar-free, the contents of 1 sachet = 1 tablet; to be dissolved in ¼ tumblerful of liquid before administration, net price 42-sachet pack = £12.52. Label: 13, 17, 30

Dose acute migraine, (tablets or sachets): 2 at onset of attack then every 4 hours when necessary to max. of 6 in 24 hours; YOUNG ADULT 12–19 years, 1 at onset of attack then 1 every 4 hours when necessary to max. of 3 in 24 hours (max. dose of metoclopramide 500 micrograms/kg daily)

Important Metoclopramide can cause severe extrapyramidal effects, particularly in children and young adults (for further details, see p. 249)

**NEFOPAM HYDROCHLORIDE**

**Indications** moderate pain

**Cautions** elderly, urinary retention; **interactions:** Appendix 1 (nefopam)

**Contra-indications** convulsive disorders; not indicated for myocardial infarction

**Hepatic impairment** caution

**Renal impairment** caution

**Pregnancy** no information available—avoid unless no safer treatment
4 Central nervous system

The effects of opioid analgesia are

Renal impairment

Hepatic impairment

Opioid analgesics should be

In the control of pain in terminal illness, the

Palliative care

Opioids should be used with caution in

Cautions

Patient should be assessed at regular intervals.

Treatment should be supervised by a specialist and the

For certain cases of chronic non-malignant pain; treat-

Acupan (Meda) Tablets, f/c, nefopam hydrochloride 30 mg, net price

90-tab pack = £10.53. Label: 2, 14

4.7.7 Opioid analgesics

Opioid analgesics are usually used to relieve moderate
to severe pain particularly of visceral origin. Repeated
administration may cause dependence and tolerance,
but this is no deterrent in the control of pain in terminal
illness, for guidelines see Prescribing in Palliative Care,
p. 20. Regular use of a potent opioid may be appropriate for
certain cases of chronic non-malignant pain; treat-
ment should be supervised by a specialist and the
patient should be assessed at regular intervals.

Cautions

Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypo-
throidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical depend-
ence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the
dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).

Palliative care In the control of pain in terminal illness, the

cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.

Contra-indications

Opioid analgesics should be avoided in patients with acute respiratory depression and when there is a risk of paralytic ileus. They are also contra-indicated in conditions associated with raised intracranial pressure and in head injury (opioid analgesics interfere with papillary responses vital for neu-
rological assessment). Comatose patients should not be treated with opioid analgesics.

Hepatic impairment

Opioid analgesics may precipi-
tate coma in patients with hepatic impairment; avoid
use or reduce dose.

Renal impairment

The effects of opioid analgesia are increased and prolonged and there is increased cerebral

sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.

Pregnancy

Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour.

Side-effects

Opioid analgesics share many side-
effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizzi-

ness, confusion, drowsiness, sleep disturbances, head-
ache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual distur-
bances, sweating, flushing, rash, urticaria, and pruritus.

Overdose: see Emergency Treatment of Poisoning, p. 36.

Long-term use of opioid analgesics can cause hypo-

gonadism and adrenal insufficiency in both men and women. This can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-
term use of opioid analgesics has been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually qualitatively dis-
tinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.

Driving

Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced. Driving at the start of therapy with opioid analgesics, and following dose changes, should be avoided.

Strong opioids

Morphine remains the most valuable opioid analgesic for severe pain although it frequently causes nausea and vomiting. It is the standard against which other opioid analgesics are compared. In addition to relief of pain, morphine also confers a state of euphoria and mental detachment.

Morphine is the opioid of choice for the oral treatment of severe pain in palliative care. It is given regularly every 4 hours (or every 12 or 24 hours as modified-
release preparations). For guidelines on dosage adjust-
ment in palliative care, see p. 20.

A modified-release epidural preparation of morphine is available from Flynn Pharma Ltd (Depodur®).

Buprenorphine has both opioid agonist and antagonist properties and may precipitate withdrawal symptoms, including pain, in patients dependent on other opioids. It has abuse potential and may itself cause dependence. It has a much longer duration of action than morphine and sublingually is an effective analgesic for 6 to 8 hours. Unlike most opioid analgesics, the effects of bupren-

orphine are only partially reversed by naloxone.
Dipipanone used alone is less sedating than morphine but the only preparation available contains an anti-emetic and is therefore not suitable for regular regimens in palliative care.

Diamorphine (heroin) is a powerful opioid analgesic. It may cause less nausea and hypotension than morphine. In palliative care the greater solubility of diamorphine allows effective doses to be injected in smaller volumes and this is important in the emaciated patient.

Alfentanil, fentanyl and remifentanil are used by injection for intra-operative analgesia (section 15.1.4.3); fentanyl is available in a transdermal drug delivery system as a self-adhesive patch which is changed every 72 hours.

Methadone is less sedating than morphine and acts for longer periods. In prolonged use, methadone should not be administered more often than twice daily to avoid the risk of accumulation and opioid overdose. Methadone may be used instead of morphine in the occasional patient who experiences excitation (or exacerbation of pain) with morphine.

Oxycodone has an efficacy and side-effect profile similar to that of morphine. It is used primarily for control of pain in palliative care.

Papaveretum is rarely used; morphine is easier to prescribe and less prone to error with regard to the strength and dose.

Pentazocine has both agonist and antagonist properties and precipitates withdrawal symptoms, including pain in patients dependent on other opioids. By injection it is more potent than dihydrocodeine or codeine, but hallucinations and thought disturbances may occur. It is not recommended and, in particular, should be avoided after myocardial infarction as it may increase pulmonary and aortic blood pressure as well as cardiac work.

Pethidine produces prompt but short-lasting analgesia; it is less constipating than morphine, but even in high doses is a less potent analgesic. It is not suitable for severe continuing pain. It is used for analgesia in labour; however, other opioids, such as morphine or diamorphine, are often preferred for obstetric pain.

Pentazocine produces prompt but short-lasting analgesia; it is less constipating than morphine, but even in high doses is a less potent analgesic. It is not suitable for severe continuing pain. It is used for analgesia in labour; however, other opioids, such as morphine or diamorphine, are often preferred for obstetric pain.

Tramadol produces analgesia by two mechanisms: an opioid effect and an enhancement of serotonergic and adrenergic pathways. It has fewer of the typical opioid side-effects (notably, less respiratory depression, less constipation and less addiction potential); psychiatric reactions have been reported.

Weak opioids Codeine is used for the relief of mild to moderate pain but is too constipating for long-term use.

Dihydrocodeine has an analgesic efficacy similar to that of codeine. The dose of dihydrocodeine by mouth is usually 30 mg every 4 hours; doubling the dose to 60 mg may provide some additional pain relief but this may be at the cost of more nausea and vomiting. A 40-mg tablet is also available.

Meptazinol is claimed to have a low incidence of respiratory depression. It has a reported length of action of 2 to 7 hours with onset within 15 minutes.

Dose The dose of opioids in the BNF may need to be adjusted individually according to the degree of analgesia and side-effects; patients’ response to opioids varies widely.

Postoperative analgesia A combination of opioid and non-opioid analgesics (section 4.7.1 and section 15.1.4.2) is used to treat postoperative pain. The use of intra-operative opioids affects the prescribing of post-operative analgesics. A postoperative opioid analgesic should be given with care since it may potentiate any residual respiratory depression (for the treatment of opioid-induced respiratory depression, see section 15.1.7).

Morphine is used most widely. Tramadol is not as effective in severe pain as other opioid analgesics. Buprenorphine may antagonise the analgesic effect of previously administered opioids and is generally not recommended. Pethidine is generally not recommended for postoperative pain because it is metabolised to norpethidine which may accumulate, particularly in renal impairment; norpethidine stimulates the central nervous system and may cause convulsions.

Opioids are also given epidurally [unlicensed route] in the postoperative period but are associated with side-effects such as pruritus, urinary retention, nausea and vomiting; respiratory depression can be delayed, particularly with morphine.

For details of patient-controlled analgesia (PCA) to relieve postoperative pain, consult hospital protocols. Formulations specifically designed for PCA are available (Pharma-Ject® Morphine Sulphate).

Dental and orofacial pain Opioid analgesics are relatively ineffective in dental pain. Like other opioids, dihydrocodeine often causes nausea and vomiting which limits its value in dental pain; if taken for more than a few doses it is also liable to cause constipation. Dihydrocodeine is not very effective in postoperative dental pain.

For the management of dental and orofacial pain, see p. 257.

Pain management and opioid dependence Although caution is necessary, patients who are dependent on opioids or have a history of drug dependence may be treated with opioid analgesics when there is a clinical need. Treatment with opioid analgesics in this patient group should normally be carried out with the advice of specialists. However, doctors do not require a special license to prescribe opioid analgesics to patients with opioid dependence for relief of pain due to organic disease or injury.

**BUPRENORPHINE**

**Indications** see under Dose and under Patches; opioid dependence (section 4.10.3)

**Caution** see notes above; also impaired consciousness; effects only partially reversed by naloxone

**Fever or external heat** Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat (may also increase absorption)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above and section 4.10.3

**Breast-feeding** avoid unless essential—may inhibit lactation; see also section 4.10.3

**Side-effects** see notes above; can induce mild withdrawal symptoms in patients dependent on opioids; also diarrhoea, abdominal pain, anorexia, dyspepsia; vasodilatation; dyspnoea; paraesthesia, asthenia, fatigue, agitation, anxiety; less commonly flatulence, taste disturbance, angina, hypertension, syncope,
hypoxia, wheezing, cough, restlessness, depersonalisation, dysarthria, impaired memory, hypoaesthesia, tremor, influenza-like symptoms, pyrexia, rhinitis, rigors, muscle cramp, myalgia, tinnitus, dry skin, and dry skin; rarely paralytic ileus, dysphagia, impaired concentration, and psychosis; very rarely retching, hyperventilation, hiccup, and muscle fasciculation.

**Dose**

- Moderate to severe pain, by sublingual administration:
  - 200–400 micrograms every 6–8 hours; **CHILD** over 6 years, 16–25 kg, 100 micrograms every 6–8 hours; 25–37.5 kg, 100–200 micrograms every 6–8 hours; 37.5–50 kg, 200–300 micrograms every 6–8 hours

**By intramuscular or slow intravenous injection, 300–600 micrograms every 6–8 hours; **CHILD** over 6 months 3–6 micrograms/kg every 6–8 hours (max. 9 micrograms/kg).

- Premedication, by sublingual administration, 400 micrograms

**By intramuscular injection, 300 micrograms

- Intra-operative analgesia, by slow intravenous injection, 300–450 micrograms

**Temgesic** (Reckitt Benckiser) 

**Tablets** (sublingual), buprenorphine (as hydrochloride), 200 micrograms, net price 50-tab pack = £5.13; 400 micrograms, 50-tab pack = £10.26. Label: 2, 26

**Injection**, buprenorphine (as hydrochloride) 300 micrograms/mL, net price 1-mL amp = 48p

**Patches**

**BuTrans** (Napp) 

- **Patches**, self-adhesive, beige, buprenorphine, ‘5’ patch (releasing 5 micrograms/hour for 7 days), net price 4 = £17.60; ‘10’ patch (releasing 10 micrograms/hour for 7 days), 4 = £31.18; ‘20’ patch (releasing 20 micrograms/hour for 7 days), 4 = £57.16. Label: 2

**Dose moderate, moderate-malignant pain unresponsive to non-opioid analgesics, ADULT over 18 years, apply to dry, non-irritated, non-hairy skin on upper torso, removing after 7 days and siting replacement patch on a different area (avoid same area for at least 3 weeks)

**Dose adjustment** When starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Max. 2 patches can be used at any one time. For breakthrough pain, consider 200–400 micrograms buprenorphine sublingually.

**Important:** it may take approx. 30 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**Long duration of action** in view of the long duration of action, patients who have severe side-effects should be monitored for up to 30 hours after removing patch.

### CODEINE PHOSPHATE

**Indications** mild to moderate pain; diarrhoea (section 1.4.2); cough suppression (section 3.9.1)

**Cautions** see notes above; also cardiac arrhythmias; acute abdomen; gallstones

**Variation in metabolism** The capacity to metabolise codeine can vary considerably and lead to either reduced therapeutic effect or marked increase in side-effects

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** amount usually too small to be harmful; however mothers vary considerably in their capacity to metabolise codeine—risk of morphine overdose in infant

**Side-effects** see notes above; also abdominal pain, anorexia, seizures, malaise, hypothermia, and muscle fasciculation; pancreatitis also reported

**Dose**

- By mouth, 30–60 mg every 4 hours when necessary, to a max. of 240 mg daily; **CHILD** 1–12 years, 3 mg/kg daily in divided doses

- By intramuscular injection, 30–60 mg every 4 hours when necessary

**Codeine Phosphate** (Non-proprietary) 

**Tablets** (Napp), codeine phosphate 15 mg, net price 28-tab pack = £1.14; 30 mg, 28-tab pack = £1.22; 60 mg, 28-tab pack = £1.84. Label: 2

**Syrup** (Napp), codeine phosphate 25 mg/5 mL, net price 100 mL = 93p. Label: 2

**Injection** (Napp), codeine phosphate 60 mg/mL, net price 1-mL amp = £2.44

**Linctus**

Section 3.9.1

### DIAMORPHINE HYDROCHLORIDE

(Heroin Hydrochloride)

**Indications** see under Dose

**Cautions** see notes above; also severe diarrhoea; toxic psychosis, CNS depression; severe cor pulmonale

**Contra-indications** see notes above; also delayed gastric emptying; phaeochromocytoma

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** therapeutic doses unlikely to affect infant; withdrawal symptoms in infants of dependent mothers; breast-feeding not best method of treating dependence in offspring.
Side-effects see notes above; also anorexia, taste disturbance; syncope; ashenia, raised intracranial pressure; myocardial infarction also reported.

Dose
- Acute pain, by subcutaneous or intramuscular injection, 5 mg repeated every 4 hours if necessary (up to 10 mg for heavier well-muscled patients); by slow intravenous injection, quarter to half corresponding intramuscular dose.
- Myocardial infarction, by slow intravenous injection (1–2 mg/minute), 5 mg followed by a further 2.5–5 mg if necessary; elderly or frail patients, reduce dose by half.
- Acute pulmonary oedema, by slow intravenous injection (1 mg/minute) 2.5–5 mg.
- Chronic pain, by mouth or by subcutaneous or intramuscular injection, 5–10 mg regularly every 4 hours; dose may be increased according to needs; intramuscular dose should be approx. half corresponding oral dose, and approx. one third corresponding oral morphine dose—see also Prescribing in Palliative Care, p. 20; by subcutaneous infusion (using syringe driver), see Prescribing in Palliative Care, p. 23.

Diamorphine (Non-proprietary) (a)
- Tablets, diamorphine hydrochloride 10 mg, net price 100-tab pack = £16.62. Label: 2.
- Injection, powder for reconstitution, diamorphine hydrochloride, net price 5-mg amp = £2.57, 10-mg amp = £3.59, 30-mg amp = £3.82, 100-mg amp = £9.34, 500-mg amp = £42.07.

Dihydrocodeine Tartrate

Indications moderate to severe pain.

Cautions see notes above; also pancreatitis; severe cor pulmonale.

Contra-indications see notes above.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding use only if potential benefit outweighs risk.

Side-effects see notes above; also paralytic ileus, abdominal pain, and parasthesia.

Dose
- By mouth, 30 mg every 4–6 hours when necessary (see also notes above); CHILD over 4 years 0.5–1 mg/kg every 4–6 hours.
- By deep subcutaneous or intramuscular injection, up to 50 mg repeated every 4–6 hours if necessary; CHILD over 4 years 0.5–1 mg/kg every 4–6 hours.

Dihydrocodeine (Non-proprietary)
- Dental prescribing on NHS Dihydrocodeine Tablets 30 mg may be prescribed.
- Oral solution, dihydrocodeine tartrate 10 mg/5 mL, net price 150 mL = £3.50. Label: 2.
- Injection, dihydrocodeine tartrate 50 mg/mL, net price 1-mL amp = £3.17.

DF118 Forte (Martindale) (a)
- Tablets, dihydrocodeine tartrate 40 mg, net price 100-tab pack = £11.51. Label: 2.
- Dose ADULT and CHILD over 12 years, severe pain, 40–80 mg 3 times daily; max. 240 mg daily.

Modified release

DHC Continus® (Napp) (a)
- Tablets, m/r, dihydrocodeine tartrate 60 mg, net price 56-tab pack = £5.18; 90 mg, 56-tab pack = £8.66; 120 mg, 56-tab pack = £10.89. Label: 2, 25.
- Dose ADULT and CHILD over 12 years, chronic severe pain, 60–120 mg every 12 hours.

Dipipanone Hydrochloride

Indications moderate to severe pain.

Cautions see notes above; also diabetes mellitus; phaeochromocytoma.

Contra-indications see notes above.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding no information available.

Side-effects see notes above; also psychosis, restlessness, raised intracranial pressure.

Dose
- See preparation below.

Diconal® (Amdipharm) (a)
- Tablets, pink, scored, dipipanone hydrochloride 10 mg, cyclizine hydrochloride 30 mg, net price 50-tab pack = £9.57. Label: 2.
- Dose acute pain, 1 tablet gradually increased to 3 tablets every 6 hours; CHILD not recommended.

Caution Not recommended in palliative care, see Nausea and Vomiting, p. 22.

Fentanyl

Indications severe chronic pain, breakthrough pain; parenteral indications (section 15.1.4.3).

Cautions see notes above; also diabetes mellitus, impaired consciousness, cerebral tumour; see also Transdermal Fentanyl, p. 267.

Contra-indications see notes above.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding monitor infant for opioid-induced side-effects.

Side-effects see notes above; also abdominal pain, anorexia, dyspepsia, dysphagia, mouth ulceration, taste disturbance, stomatitis, dry mouth; vasodilatation; anopia; anxiety; myoclonus; less commonly flatulence, diarrhoea, laryngospasm, dyspnoea, hypoventilation, depersonalisation, dysarthria, amnesia, incoordination, paraesthesia, malaise, agitation, tremor, thirst and muscle weakness; rarely hiccups and arrhythmia; very rarely paralytic ileus, haemoptysis, psychosis, and seizures; shock, astyole, pyrexia, ataxia, and muscle fasciculation also reported; with nasal spray throat irritation, epistaxis, nasal ulcer, rhinorrhoea.

Dose
- Chronic intractable pain, by transdermal route, apply to dry, non-irritated, non-irradiated, non-hairy skin on torso or upper arm, removing after 72 hours and siting replacement patch on a different area (avoid using the...
same area for several days). ADULT over 16 years not currently treated with a strong opioid analgesic (but see Transdermal Fentanyl, p. 267), initial dose, one ‘12’ or ‘25 micrograms/hour’ patch replaced after 72 hours; ADULT and CHILD over 2 years currently treated with a strong opioid analgesic, initial dose based on previous 24-hour opioid requirement (consult product literature).

**Dose adjustment** When starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)—previous analgesic therapy should be phased out gradually from time of first patch application; if necessary dose should be adjusted at 48–72-hour intervals in steps of 12–25 micrograms/hour. More than one patch may be used at a time for doses greater than 100 micrograms/hour (but applied at the same time to avoid confusion)—consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it may take up to 25 hours for the plasma-fentanyl concentration to decrease by 50%—replacement opioid therapy should be initiated at a low dose and increased gradually).

**Long duration of action** In view of the long duration of action, patients who have had severe side-effects should be monitored for up to 24 hours after patch removal.

- **Breakthrough pain, see under oral preparations**
- **Conversion** (from oral morphine to transdermal fentanyl) see.

266 4.7.2 Opioid analgesics BNF 61

**£49.99, 30-tab pack = £149.70; 400 micrograms, 10-tab pack = £49.99, 30-tab pack = £139.72; 200 micrograms, 30-tab pack = £149.70; 600 micrograms, 30-tab pack = £149.70; 800 micrograms, 30-tab pack = £149.70; 1.2 mg, 3 = £17.52, 30 = £175.16; 1.6 mg, 3 = £17.52, 30 = £175.16. Label: 2.

**Dose** breakthrough pain in patients receiving opioid therapy for chronic cancer pain, initially 200 micrograms (over 15 minutes) repeated if necessary 15 minutes after first dose (no more than 2 dose units for each pain episode); adjust dose according to response; max. 4 dose units daily.

**Note** If more than 4 episodes of breakthrough pain each day, adjust background analgesia.

### Lozenges

**Actiq®** (Fylnon) (C)

Lozenge (buccal), with oromucosal applicator, fentanyl (as citrate) 200 micrograms, net price 3 = £17.52, 30 = £175.16; 400 micrograms, 3 = £17.52, 30 = £175.16; 600 micrograms, 3 = £17.52, 30 = £175.16; 1.2 mg, 3 = £17.52, 30 = £175.16; 1.6 mg, 3 = £17.52, 30 = £175.16. Label: 2.

**Dose** breakthrough pain in patients receiving opioid therapy for chronic cancer pain, initially 200 micrograms (over 15 minutes) repeated if necessary 15 minutes after first dose (no more than 2 dose units for each pain episode); adjust dose according to response; max. 4 dose units daily.

**Note** If more than 4 episodes of breakthrough pain each day, adjust background analgesia.

### Nasal spray

**Instanyl®** (Nycosrned) (E)

Nasal spray, fentanyl (as citrate) 50 micrograms/metered spray, net price 10-dose pack = £59.50, 20-dose pack = £119.00; 100 micrograms/metered spray, 10-dose pack = £59.50, 20-dose pack = £119.00; 200 micrograms/metered spray, 10-dose pack = £59.50, 20-dose pack = £119.00. Label: 2, counselling, administration.

**Dose** breakthrough pain in patients receiving opioid therapy for chronic cancer pain, ADULT over 18 years, initially 50 micrograms into one nostril, repeated once if necessary after 10 minutes; adjust dose according to response; max. 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode.

**Note** If more than 4 breakthrough pain episodes daily, adjust background analgesia.

**Counselling** Patient should sit or stand during administration. Avoid concomitant use of other nasal preparations.

The Scottish Medicines Consortium (p. 4) has advised that Instanyl® nasal spray should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

**ScrFent®** (Archimecnes) (E)

Nasal spray, fentanyl (as citrate) 100 micrograms/metered spray. net price 8-dose pack = £30.40, 32-dose pack = £121.60; 400 micrograms/metered spray, 8-dose pack = £50.30, 32-dose pack = £212.60. Label: 2, counselling, administration.

**Dose** breakthrough pain in patients receiving opioid therapy for chronic cancer pain, ADULT over 18 years, initially 100 micrograms into one nostril, adjust dose according to response; max. 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode.

**Note** If more than 4 breakthrough pain episodes daily, adjust background analgesia.

**Counselling** Avoid concomitant use of other nasal preparations.

### Patches

**Prescriptions** Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write ‘Fentanyl 25 patches’ to preSCRIBE patches that release fentanyl 25 micrograms per hour. The dosage should be expressed in terms of the interval between applying a patch and replacing it with a new one, e.g. ‘one patch to be applied every 72 hours’. The total quantity of patches to be supplied should be written in words and figures.

The Scottish Medicines Consortium (p. 4) has advised that Effentora® buccal tablets should be restricted for the manage-
Transdermal fentanyl
Fever or external heat Monitor patients using patches for increased side-effects if fever present (increased absorption possible). Avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption).

Respiratory depression Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patients.

Counselling Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdose. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.

Fentanyl (Non-proprietary)

Patches self-adhesive, fentanyl. ‘12’ patch (releasing approx. 12 micrograms/hour for 72 hours), net price 5 = £17.76; ‘25’ patch (releasing approx. 25 micrograms/hour for 72 hours), 5 = £25.38; ‘50’ patch (releasing approx. 50 micrograms/hour for 72 hours), 5 = £47.40; ‘75’ patch (releasing approx. 75 micrograms/hour for 72 hours), 5 = £66.08; ‘100’ patch (releasing approx. 100 micrograms/hour for 72 hours), 5 = £81.45. Label: 2, counselling, administration.

Brands include Fentanyl®, Matriven®, Mezolan®, Oramani®, Tilby®, Victrela®.

Durogesic DiTrans® (Janssen-Cilag) Patches self-adhesive, transparent, fentanyl. ‘12’ patch (releasing approx. 12 micrograms/hour for 72 hours), net price 5 = £17.76; ‘25’ patch (releasing approx. 25 micrograms/hour for 72 hours), 5 = £25.38; ‘50’ patch (releasing approx. 50 micrograms/hour for 72 hours), 5 = £47.40; ‘75’ patch (releasing approx. 75 micrograms/hour for 72 hours), 5 = £66.08; ‘100’ patch (releasing approx. 100 micrograms/hour for 72 hours), 5 = £81.45. Label: 2, counselling, administration.

HYDROMORPHONE HYDROCHLORIDE

Indications severe pain in cancer.

Cautions see notes above; also pancreatitis; toxic psychosis.

Contra-indications see notes above; also acute abdomen.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding avoid — no information available.

Side-effects see notes above; also paralytic ileus, peripheral oedema, seizures, asthma, dyskinesia, agitation, and tremor.

Dose see under preparations below.

Palladone® (Napp)

Capsules, hydromorphone hydrochloride 1.3 mg (orange/clear), net price 56-cap pack = £8.82; 2.6 mg (red/clear), 56-cap pack = £17.64. Label: 2, counselling. see below.

Dose 1.3 mg every 4 hours, increased if necessary according to severity of pain. CHILD under 12 years not recommended.

Counselling Swallow whole or open capsule and sprinkle contents on soft food.

Modiﬁed release

Palladone® SR (Napp)

Capsules, m/r, hydromorphone hydrochloride 2 mg (yellow/clear), net price 56-cap pack = £20.98; 4 mg (pale blue/clear), 56-cap pack = £28.75; 8 mg (pink/clear), 56-cap pack = £56.08; 16 mg (brown/clear), 56-cap pack = £106.53; 24 mg (dark blue/clear), 56-cap pack = £159.82. Label: 2, counselling, see below.

Dose 4 mg every 12 hours, increased if necessary according to severity of pain. CHILD under 12 years not recommended.

Counselling Swallow whole or open capsule and sprinkle contents on soft food.

MEPTAZINOL

Indications moderate to severe pain, including post-operative and obstetric pain and renal colic; peri-operative analgesia, section 15.1.4.3.

Cautions see notes above; effects only partially reversed by naloxone.

Contra-indications see notes above; also myocardial infarction; phaeochromocytoma.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding use only if potential benefit outweighs risk.

Side-effects see notes above; can induce withdrawal symptoms in patients dependent on opioids; also diarrhoea, abdominal pain, dyspepsia, and hypothermia.

Dose see below.

Meptid® (Almirall): Tablets, orange, 1/2, meptazinol 200 mg, net price 112-tab pack = £22.11. Label: 2.

Injection, meptazinol 100 mg (as hydrochloride)/mL, net price 1-mL amp = £1.92.

METHADONE HYDROCHLORIDE

Indications severe pain, see notes above; cough in terminal disease (section 3.9.1); adjunct in treatment of opioid dependence (section 4.10.3).

Cautions see notes above; also history of cardiac conduction abnormalities, family history of sudden death (ECG monitoring recommended; see also QT Interval Prolongation, below).

QT interval prolongation Patients with the following risk factors for QT interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100 mg daily should also be monitored.

Contra-indications see notes above; also phaeochromocytoma.

Hepatic impairment see notes above.

Renal impairment see notes above.

Pregnancy see notes above.

Breast-feeding withdrawal symptoms in infant; breast-feeding permissible during maintenance but dose should be as low as possible and infant monitored to avoid sedation.
4 Central nervous system

268 4.7.2 Opioid analgesics

**Side-effects** see notes above; also QT interval prolongation, tordase de pointes, hypothermia, restlessness, raised intracranial pressure, dysmenorrhoea, dry eyes, and hyperprolactinaemia

**Dose**

- **By mouth or by subcutaneous or intramuscular injection**, 5–10 mg every 6–8 hours, adjusted according to response; on prolonged use not to be given more frequently than every 12 hours; **CHILD** not recommended

**Methadone** (Non-proprietary)

**Tablets**, methadone hydrochloride 5 mg, net price 50 = £2.84. Label: 2

**Brands include:** Physeptone®

**Injection**, methadone hydrochloride, 10 mg/mL, net price 1-mL amp = £1.00, 2-mL amp = £1.67, 3.5-mL amp = £2.11, 5-mL amp = £2.28

**Brands include:** Physeptone®, Synastone®

**Notes**

- Premedication, **by subcutaneous or intramuscular injection**, up to 10 mg 60–90 minutes before operation; **CHILD**, by intramuscular injection, 150 micrograms/kg
- **Patient controlled analgesia** (PCA), consult hospital protocols
- **Myocardial infarction**, by slow intravenous injection (1–2 mg/minute), 5–10 mg followed by a further 5–10 mg if necessary; **ELDERLY** or frail patients, reduce dose by half
- **Acute pulmonary oedema**, by slow intravenous injection (2 mg/minute) 5–10 mg; **ELDERLY** or frail patients, reduce dose by half
- **Chronic pain**, by mouth or by subcutaneous injection (not suitable for oedematous patients) or by intramuscular injection, initially 5–10 mg every 4 hours, adjusted according to response; see also Prescribing in Palliative Care, p. 20
- **By rectum**, initially 15–30 mg every 4 hours, adjusted according to response

**Note**

- The doses stated above refer equally to morphine hydrochloride and sulphate

**MORPHINE SALTS**

**Indications** see notes above and under Dose; acute diarrhoea (section 1.4.2); cough in terminal care (section 3.9.1)

**Cautions** see notes above; also pancreatitis, cardiac arrhythmias, severe cor pulmonale

**Contra-indications** see notes above; also delayed gastric emptying, acute abdomen; heart failure secondary to chronic lung disease; phaeochromocytoma

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** therapeutic doses unlikely to affect infant; withdrawal symptoms in infants of dependent mothers; breast-feeding not best method of treating dependence in offspring

**Side-effects** see notes above; also paralytic ileus, dry mouth, dysmenorrhoea, dry eyes, and hyperprolactinaemia

**Dose**

- **Acute pain**, **by subcutaneous injection** (not suitable for oedematous patients) or **by intramuscular injection**, initially 10 mg (**ELDERLY** or frail) 5 mg every 4 hours (or more frequently during titration), adjusted according to response; **NEONATE** initially 100 micrograms/kg every 6 hours, adjusted according to response; **CHILD** 1–6 months initially 100 micrograms/kg every 6 hours, adjusted according to response; **CHILD** 6 months–2 years initially 100–200 micrograms/kg every 4 hours, adjusted according to response; **CHILD** 2–18 years initially 2.5–10 mg every 4 hours, adjusted according to response

- **By slow intravenous injection**, initially 5 mg (reduce dose in **ELDERLY** or frail) every 4 hours (or more frequently during titration), adjusted according to response; **NEONATE** initially 50 micrograms/kg every 6 hours, adjusted according to response; **CHILD** 1–6 months initially 100 micrograms/kg every 6 hours, adjusted according to response; **CHILD** 6 months–12 years initially 100 micrograms/kg every 4 hours, adjusted according to response

- **Premedication**, **by subcutaneous or intramuscular injection**, up to 10 mg 60–90 minutes before operation; **CHILD**, by intramuscular injection, 150 micrograms/kg
- **Patient controlled analgesia** (PCA), consult hospital protocols
- **Myocardial infarction**, by slow intravenous injection (1–2 mg/minute), 5–10 mg followed by a further 5–10 mg if necessary; **ELDERLY** or frail patients, reduce dose by half
- **Acute pulmonary oedema**, by slow intravenous injection (2 mg/minute) 5–10 mg; **ELDERLY** or frail patients, reduce dose by half
- **Chronic pain**, by mouth or by subcutaneous injection (not suitable for oedematous patients) or by intramuscular injection, initially 5–10 mg every 4 hours, adjusted according to response; see also Prescribing in Palliative Care, p. 20
- **By rectum**, initially 15–30 mg every 4 hours, adjusted according to response

**Note**

- The doses stated above refer equally to morphine hydrochloride and sulphate

**Oral solutions**

**Note** For advice on transfer from oral solutions of morphine to modified-release preparations of morphine, see Prescribing in Palliative Care, p. 20

**Morphine Oral Solutions**

**Tablets**

**Tablets**, f/c, scored, morphine sulphate 10 mg (blue), net price 50-mL pack = £4.95; 300-mL pack = £4.98; 500-mL pack = £7.47. Label: 2

**Oramorph** (Boehringer Ingelheim)

**Oramorph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oramorph** (Boehringer Ingelheim)

**Oramorph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oramorph** (Boehringer Ingelheim)

**Oramorph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2

**Oormalph** (Boehringer Ingelheim)

**Oormalph** oral solution (oral), morphine sulphate 10 mg/5 mL, net price 100-mL pack = £1.78; 300-mL pack = £4.95; 500-mL pack = £7.47. Label: 2
4.7.2 Opioid analgesics

Morphine Sulphate (Non-proprietary) (9)

Injection, morphine sulphate 10, 15, 20, and 30 mg/mL, net price 1- and 2-mL amp (all) = £72–£1.40

Intravenous infusion, morphine sulphate 1 mg/mL, net price 50-mL vial = £5.00; 2 mg/mL, 50-mL vial = £5.89

Minijet® Morphine Sulphate (UCB Pharma) (9)

Injection, morphine sulphate 1 mg/mL, net price 10-mL disposable syringe = £15.00

Injection with antiemetic

For prescribing information on cyclizine, see section 4.6

Caution In myocardial infarction cyclizine may aggravate severe heart failure and counteract the haemodynamic benefits of opioids, section 4.6. Not recommended in cardiovascular disease, see Naunyn and Vormling, p. 22

Cyclimorph® (Andipharm) (9)

Cyclimorph-10® Injection, morphine tartrate 10 mg, cyclazoline tartrate 50 mg/mL, net price 1-mL amp = £1.75

Dose ADULT and CHILD over 12 years, moderate to severe pain (short-term use only) by subcutaneous, intramuscular, or intravenous injection, 1 mL, repeated not more often than every 4 hours; max. 3 doses in any 24-hour period

Cyclimorph-15® Injection, morphine tartrate 15 mg, cyclazoline tartrate 50 mg/mL, net price 1-mL amp = £1.82

Dose ADULT and CHILD over 12 years, moderate to severe pain (short-term use only) by subcutaneous, intramuscular, or intravenous injection, 1 mL, repeated not more often than every 4 hours; max. 3 doses in any 24-hour period

Oxycodeone Hydrochloride

Indications moderate to severe pain in patients with cancer; postoperative pain; severe pain

Cautions see notes above; also toxic psychosis; pancreatitis

Contra-indications see notes above; also acute abdomen; delayed gastric emptying; chronic constipation; cor pulmonale; acute porphyria (section 9.8.2)

Hepatic impairment avoid in moderate to severe impairment; see also notes above

Renal impairment avoid if eGFR less than 10 mL/minute/1.73m²; see also notes above

Pregnancy see notes above

Breast-feeding present in milk—avoid

Side-effects see notes above; also diarrhoea, abdominal pain, anorexia, dyspnoea; bronchospasm, dyspnoea, impaired cough reflex; asthenia, anxiety; chills; muscle fasciculation; less commonly paralytic ileus, cholestasis, gastritis, flatulence, dysphagia, taste disturbance, belching, hiccups, vasodilatation, supraventricular tachycardia, syncope, amnesia, hypoesthesia, restlessness, seizures, pyrexia, amniorrhoea, hypotonia, paraesthesia, disorientation, malaise, agitation, speech disorder, tremor, thirst, and dry skin

Dose

• By mouth, initially 5 mg every 4–6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses; CHILD under 18 years, see BNF for Children

• By slow intravenous injection, 1–10 mg every 4 hours when necessary; CHILD under 18 years, not recommended
270 4.7.2 Opioid analgesics

- By intravenous infusion, initially 2 mg/hour, adjusted according to response; CHILD under 18 years not recommended
- By subcutaneous injection, initially 5 mg every 4 hours when necessary; CHILD under 18 years, not recommended
- By subcutaneous infusion, initially 7.5 mg/24 hours adjusted according to response; CHILD under 18 years, not recommended
- Patient controlled analgesia (PCA), consult hospital protocols

**Note** 2 mg oral oxycodone is approximately equivalent to 1 mg parenteral oxycodone

**Oxycodone** (Non-proprietary) (B)

**Injection**, oxycodone hydrochloride 10 mg/mL, net price 1-mL amp = £1.60, 2-mL amp = £3.20

**OxyNorm** (Napp) (B)

**Capsules**, oxycodone hydrochloride 5 mg (orange/beige), net price 56-cap pack = £11.36; 10 mg (white/beige), 56-cap pack = £22.73; 20 mg (pink/beige), 56-cap pack = £45.47. Label: 2

**Liquid** (= oral solution), sugar-free, oxycodone hydrochloride 5 mg/5 mL, net price 250 mL = £9.66. Label: 2

**Concentrate** (= concentrated oral solution), sugar-free, oxycodone hydrochloride 10 mg/mL, net price 120 mL = £66.39. Label: 2

**Injection**, oxycodone hydrochloride 10 mg/mL, net price 1-mL amp = £1.60, 2-mL amp = £3.20; 50 mg/mL, 1-mL amp = £14.02

**Note** The Scottish Medicines Consortium (p. 4) has advised (October 2004 and November 2010) that OxyNorm® injection is restricted for use within NHS Scotland for patients with cancer who have difficulty in tolerating morphine or diamorphine

**Modified release**

**OxyContin** (Napp) (B)

**Tablets**, f/c, m/r, oxycodone hydrochloride 5 mg (blue), price 28-tab pack = £12.46; 10 mg (white), 56-tab pack = £24.91; 20 mg (pink), 56-tab pack = £49.82; 40 mg (yellow), 56-tab pack = £99.66; 80 mg (green), 56-tab pack = £199.33. Label: 2, 25

**Dose** initially, 10 mg every 12 hours, increased if necessary according to severity of pain, usual max. 200 mg every 12 hours, but some patients may require higher doses—CHILD under 18 years see BNF for Children

**With naloxone**

**Targinact** (Napp) ▼ (B)

**Tablets** 5 mg/2.5 mg, f/c, m/r, oxycodone hydrochloride 5 mg, naloxone hydrochloride 2.5 mg (blue), net price 28-tab pack = £17.56. Label: 2, 25

**Tablets** 10 mg/5 mg, f/c, m/r, oxycodone hydrochloride 10 mg, naloxone hydrochloride 5 mg (white), net price 56-tab pack = £35.11. Label: 2, 25

**Tablets** 20 mg/10 mg, f/c, m/r, oxycodone hydrochloride 20 mg, naloxone hydrochloride 10 mg (pink), net price 56-tab pack = £70.22. Label: 2, 25

**Tablets** 40 mg/20 mg, f/c, m/r, oxycodone hydrochloride 40 mg, naloxone hydrochloride 20 mg (yellow), net price 56-tab pack = £140.44. Label: 2, 25

**Dose** severe pain responsive only to opioid analgesics. ADULT over 18 years not currently treated with opioid analgesics, initially 10 mg/5 mg every 12 hours, increased according to response; patients already receiving opioid analgesics can start with a higher

**dose of Targinact®; max. Targinact® 40 mg/20 mg every 12 hours**

**Note** Supplemental modified-release oxycodone (without naloxone) can be prescribed for patients who need higher doses—consult product literature

---

**PAPAVERETUM (Non-proprietary)** (B)

**Injection**, papaveretum 15.4 mg/mL (providing the equivalent of 5 mg of anhydrous morphine/mL), net price 1-mL amp = £1.64

**Note** The name Omnopon® was formerly used for papaveretum preparations

**With hyoscine**

For prescribing information on hyoscine, see section 4.6

**Papaveretum and Hyoscine Injection** (Non-proprietary) (B)

**Injection**, papaveretum 15.4 mg/mL (providing the equivalent of 10 mg of anhydrous morphine/mL), hyoscine hydrobromide 400 micrograms/mL, net price 1-mL amp = £3.57

**Dose** premedication, by subcutaneous or intramuscular injection, 0.5–1 mL

**Indications** moderate to severe pain, but see notes above

**Cautions** see notes above; also pancreatitis, arterial or pulmonary hypertension, cardiac arrhythmias, myocardial infarction, phaeochromocytoma; effects only partially reversed by naloxone

**Contra-indications** see notes above; patients dependent on opioids (can precipitate withdrawal); heart

**PENTAZOCINE (Non-proprietary)** (B)

**Injection**, pentazocine 40 mg/mL (providing the equivalent of 10 mg of anhydrous morphine/mL), net price 1-mL amp = £3.57

**Dose** pentazocine 10 mg/mL (providing the equivalent of 5 mg of anhydrous morphine/mL), hyoscine hydrobromide 400 micrograms/mL, net price 1-mL amp = £3.57

**Indications** moderate to severe pain, but see notes above

**Cautions** see notes above; also treated with opioid analgesics, initially 10 mg/5 mg every 12 hours, increased according to response; patients already receiving opioid analgesics can start with a higher

**PENTAZOCINE (Non-proprietary)** (B)

**Injection**, pentazocine 40 mg/mL (providing the equivalent of 10 mg of anhydrous morphine/mL), hyoscine hydrobromide 400 micrograms/mL, net price 1-mL amp = £3.57

**Dose** premedication, by subcutaneous or intramuscular injection, 0.5–1 mL

**Indications** moderate to severe pain, but see notes above

**Cautions** see notes above; also pancreatitis, arterial or pulmonary hypertension, cardiac arrhythmias, myocardial infarction, phaeochromocytoma; effects only partially reversed by naloxone

**Contra-indications** see notes above; patients dependent on opioids (can precipitate withdrawal); heart
failure secondary to chronic lung disease; acute porphyria (section 9.8.2)

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** small amount present in milk—caution

**Side-effects** see notes above; also abdominal pain, hypertension, syncope, sero, paraesthesia, tremor, raised intracranial pressure, disorientation, hypothermia, chills, blood disorders, myalgia, and toxic epidermal necrolysis

**Dose**
- By mouth, pentazocine hydrochloride 50 mg every 3–4 hours preferably after food (range 25–100 mg); max. 600 mg daily; **CHILD** 6–12 years 25 mg
- By subcutaneous, intramuscular, or intravenous injection, moderate pain, pentazocine 30 mg, severe pain 45–60 mg every 3–4 hours when necessary; max. 360 mg daily; **CHILD** over 1 year, by subcutaneous or intramuscular injection, up to 1 mg/kg, by intravenous injection up to 500 micrograms/kg

**Pentazocine (Non-proprietary)**

Capsules, pentazocine hydrochloride 50 mg, net price 28-cap pack = £16.55. Label: 2, 21

Tablets, pentazocine hydrochloride 25 mg, net price 28-tab pack = £23.09. Label: 2, 21

Injection, pentazocine 30 mg, (as lactate)/mL, net price 1-mL amp = £1.67; 2-mL amp = £3.21

**Dose**
- By mouth, **by mouth**, pentazocine hydrochloride 50 mg every 3–4 hours preferably after food (range 25–100 mg); max. 600 mg daily; **CHILD** 6–12 years 25 mg
- By subcutaneous, intramuscular, or intravenous injection, moderate pain, pentazocine 30 mg, severe pain 45–60 mg every 3–4 hours when necessary; max. 360 mg daily; **CHILD** over 1 year, by subcutaneous or intramuscular injection, up to 1 mg/kg, by intravenous injection up to 500 micrograms/kg

**Pentazocine (Non-proprietary)**

Capsules, pentazocine hydrochloride 50 mg, net price 28-cap pack = £16.55. Label: 2, 21

Tablets, pentazocine hydrochloride 25 mg, net price 28-tab pack = £23.09. Label: 2, 21

Injection, pentazocine 30 mg (as lactate)/mL, net price 1-mL amp = £1.67; 2-mL amp = £3.21

**PETHIDINE HYDROCHLORIDE**

**Indications** moderate to severe pain, obstetric analgesia; peri-operative analgesia

**Cautions** see notes above; not suitable for severe continuing pain; accumulation of metabolites may result in neurotoxicity; cardiac arrhythmias, severe cor pulmonale

**Contra-indications** see notes above; phaeochromocytoma

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** present in milk but not known to be harmful

**Side-effects** see notes above; also restlessness, tremor, and hypothermia; convulsions reported in overdosage

**Dose**
- **Acute pain**, by mouth, 50–150 mg every 4 hours; **CHILD** 0.5–2 mg/kg
- By subcutaneous or intramuscular injection, 25–100 mg (**ELDERLY** or debilitated, initially 25 mg), repeated after 4 hours; **CHILD**, by intramuscular injection, 0.5–2 mg/kg
- By slow intravenous injection, 25–50 mg (**ELDERLY** or debilitated, initially 25 mg), repeated after 4 hours
- Obstetric analgesia, by subcutaneous or intramuscular injection, 50–100 mg, repeated 1–3 hours later if necessary; max. 400 mg in 24 hours
- Premedication, by intramuscular injection, 25–100 mg 1 hour before operation (**ELDERLY** or debilitated, 25 mg); **CHILD** 0.5–2 mg/kg

**Pethidine (Non-proprietary)**

**Injection**, pethidine hydrochloride 50 mg, net price 1-mL amp = 48p, 2-mL amp = 51p; 10 mg/mL, 5-mL amp = £3.17, 10-mL amp = £2.18

**With promethazine** For prescribing information on promethazine hydrochloride, see section 3.4.1.

**Pamergan P100®** (Martindale)

**Injection**, pethidine hydrochloride 50 mg, promethazine hydrochloride 25 mg/mL, net price 2-mL amp = £1.44

**Dose** by intramuscular injection, p Comcast, 2 mL 60–90 minutes before operation, **CHILD** 8–12 years 0.75 mL, 13–16 years 1 mL, Obstetric analgesia, 1–2 mL every 4 hours if necessary

**Severe pain**, 1–2 mL every 4–6 hours if necessary

**Note** Although usually given intramuscularly, may be given intravenously after dilution to at least 10 mL with water for injections

**TRAMADOL HYDROCHLORIDE**

**Indications** moderate to severe pain

**Cautions** see notes above; impaired consciousness; excessive bronchial secretions; not suitable as a substitute in opioid-dependent patients

**General anaesthesia** Not recommended for analgesia during potentially light planes of general anaesthesia (possibly increased intra-operative recall reported)

**Contra-indications** see notes above; uncontrolled epilepsy

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** embryotoxic in animal studies—manufacturers advise avoid; see also notes above

**Breast-feeding** amount probably too small to be harmful, but manufacturer advises avoid

**Side-effects** see notes above; also diarrhoea; fatigue; rarely anorexia, syncope, hypertension, bronchospasm, dyspnoea, wheezing, seizures, paraesthesia, and muscle weakness; blood disorders also reported

**Dose**
- **ADULT** and **CHILD** over 12 years, by mouth, 50–100 mg not more than every 4 hours; total of more than 400 mg daily not usually required
- **ADULT** and **CHILD** over 12 years, by intramuscular injection or by intravenous injection (over 2–3 minutes) or by intravenous infusion, 50–100 mg every 4–6 hours

Postoperative pain, 100 mg initially then 50 mg every 10–20 minutes if necessary during first hour to total max. 250 mg (including initial dose) in first hour, then 50–100 mg every 4–6 hours; max. 600 mg daily

**Tramadol Hydrochloride (Non-proprietary)**

Capsules, tramadol hydrochloride 50 mg, net price 30-cap pack = £1.22, 100-cap pack = £2.07. Label: 2

**Brands include Tramaks®**
Central nervous system

4.7.3 Neuropathic pain

Injection, tramadol hydrochloride 50 mg/mL, net price 2-mL amp = 95p

Zamadol® (Meda) (£)
Capsules, tramadol hydrochloride 50 mg, net price 100-cap pack = £8.00. Label: 2
Orodispersible tablets (Zamadol Meit®), tramadol hydrochloride 50 mg, net price 60-tab pack = £7.12. Label: 2, counselling, administration
Excipients include aspartame (section 9.4.1)

Tramquil® (Chiesi) (£)
Capsules, m/r, tramadol hydrochloride 10 mg (white), net price 60-cap pack = £12.14; 150 mg (yellow), 60-cap pack = £18.26; 150 mg, 30-tab pack = £36.52. Label: 2, 25
Dose ADULT and CHILD over 12 years, 50–100 mg twice daily increased if necessary; usual max. 200 mg once daily

Maxitram SR® (Chiesi) (£)
Capsules, m/r, tramadol hydrochloride 50 mg (white), net price 60-cap pack = £4.55; 100 mg (yellow), 60-cap pack = £12.14; 150 mg (yellow), 60-cap pack = £18.26; 200 mg (yellow), 60-cap pack = £24.28. Label: 2, 25
Dose ADULT and CHILD over 12 years, 100–200 mg twice daily, total of more than 400 mg daily not usually required

Zamadol® (Meda) (£)
Capsules, m/r, tramadol hydrochloride 50 mg (green), net price 60-cap pack = £7.20; 100 mg, 60-cap pack = £14.39; 150 mg (dark green), 60-cap pack = £21.59; 200 mg (yellow), 60-cap pack = £28.78. Label: 2, counselling, administration
Dose ADULT and CHILD over 12 years, 50–100 mg twice daily increased if necessary to 150–200 mg twice daily; total of more than 400 mg daily not usually required
Counselling Swallow whole or open capsule and swallow contents immediately without chewing

Zydol SR® (Grunenthal) (£)
Tablets, m/r, tramadol hydrochloride 100 mg, net price 60-tab pack = £18.21; 200 mg (yellow), 60-tab pack = £24.28. Label: 2, 25
Dose ADULT and CHILD over 12 years, 100 mg twice daily increased if necessary to 150–200 mg twice daily; usual max. 400 mg daily

Zydol SR® (Grunenthal) (£)
Tablets, m/r, tramadol hydrochloride 100 mg, net price 60-tab pack = £18.21; 200 mg (yellow), 60-tab pack = £24.28. Label: 2, 25
Dose ADULT and CHILD over 12 years, 100 mg twice daily increased if necessary to 150–200 mg twice daily; total of more than 400 mg daily not usually required

With paracetamol

Section 4.7.1

4.7.3 Neuropathic pain

Neuropathic pain, which occurs as a result of damage to neural tissue, includes phantom limb pain, compression neuropathies, peripheral neuropathies (e.g. due to diabetes (section 6.1.5), alcoholism, HIV infection, chemotherapy, idiopathic neuropathy), trauma, central pain (e.g. pain following stroke, spinal cord injury, and syringomyelia), and postherpetic neuralgia (peripheral nerve damage following acute herpes zoster infection (shingles)). The pain occurs in an area of sensory deficit and may be described as burning, shooting or scalding and is sometimes accompanied by pain that is evoked by a non-noxious stimulus (allodynia).

Trigeminal neuralgia is also caused by dysfunction of neural tissue, but its management (see below) is distinct from other forms of neuropathic pain.

Neuropathic pain is generally managed with a tricyclic antidepressant or with certain antiepileptic drugs. Amin-
4.7.4 Antimigraine drugs

4.7.4.1 Treatment of acute migraine

Treatment of a migraine attack should be guided by response to previous treatment and the severity of the attacks. A simple analgesic such as aspirin, paracetamol (preferably in a soluble or dispersible form) or a NSAID is often effective; concomitant antiemetic treatment may be required. If treatment with an analgesic is inadequate, an attack may be treated with a specific antimigraine compound such as a 5HT1-receptor agonist (‘triptan’). Ergot alkaloids are rarely required now; oral and rectal preparations are associated with many side-effects and they should be avoided in cerebrovascular or cardiovascular disease.

Excessive use of acute treatments for migraine (opoid and non-opioid analgesics, 5HT1 receptor agonists, and ergotamine) is associated with medication-overuse headache (analgesic-induced headache); therefore, increasing consumption of these medicines needs careful management.

Analgesics

Most migraine headaches respond to analgesics such as aspirin (p. 258) or paracetamol (p. 259) but because peristalsis is often reduced during migraine attacks the medication may not be sufficiently well absorbed to be effective; dispersible or effervescent preparations are therefore preferred. Compound preparations containing analgesics and antiemetics are available (section 4.7.1). The NSAID tolfenamic acid is licensed specifically for the treatment of an acute attack of migraine; diclofenac potassium, flurbiprofen, ibuprofen, and naproxen sodium (section 10.1.1) are also licensed for use in migraine.

**TOLFENAMIC ACID**

**Indications** treatment of acute migraine

**Cautions** see NSAIDs, section 10.1.1

**Contra-indications** see NSAIDs, section 10.1.1

**Hepatic impairment** section 10.1.1

**Renal impairment** section 10.1.1

**Pregnancy** section 10.1.1

**Breast-feeding** amount too small to be harmful

**Side-effects** see NSAIDs, section 10.1.1; also dysuria (most commonly in men), confusion, malaise, hallucination, paraesthesia, tremor, euphoria, fatigue, and visual disturbances reported

**Trigeminal neuralgia**

Surgery may be the treatment of choice in many patients; a neurological assessment will identify those who stand to benefit. Carbamazepine (p. 281) taken during the acute stages of trigeminal neuralgia, reduces the frequency and severity of attacks. It is very effective for the severe pain associated with trigeminal neuralgia and (less commonly) glossopharyngeal neuralgia. Blood counts and electrolytes should be monitored when high doses are given. Small doses should be used initially to reduce the incidence of side-effects e.g. dizziness. Some cases respond to phenytoin (p. 288); the drug may be given by intravenous infusion (possibly as fosphenytoin) in a crisis (specialist use only).

**Chronic facial pain**

Chronic oral and facial pain including persistent idiopathic facial pain (also termed ‘atypical facial pain’) and temporomandibular dysfunction (previously termed temporomandibular joint dysfunction syndrome) may call for prolonged use of analgesics or for other drugs. Tricyclic antidepressants (section 4.3.1) may be useful for facial pain [unlicensed indication], but are not on the Dental Practitioners’ List. Disorders of this type require specialist referral and psychological support to accompany drug treatment. Patients on long-term therapy need to be monitored both for progress and for side-effects.

**Gabapentin** (p. 284) is also effective for the treatment of neuropathic pain.

Neuropathic pain may respond to opioid analgesics. There is evidence of efficacy for tramadol (p. 271), morphine (p. 268), and oxycodone (p. 269); however, treatment with morphine or oxycodone should be initiated only under specialist supervision. Tramadol can be prescribed when other treatments have been unsuccessful, while the patient is waiting for assessment by a specialist.

Patients with localised pain who are unable to take oral medicines may benefit from topical local anaesthetic preparations, such as lidocaine medicated plasters (section 15.2), while awaiting specialist review.

Capsaicin (p. 664) is licensed for neuropathic pain (but the intense burning sensation during initial treatment may limit use). Capsaicin 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia. A self-adhesive patch containing capsaicin 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients.

A corticosteroid may help to relieve pressure in compression neuropathy and thereby reduce pain. Neuromodulation by spinal cord stimulation may be of benefit in some patients. Many patients with chronic neuropathic pain require multidisciplinary management, including physiotherapy and psychological support.

The management of trigeminal neuralgia and chronic facial pain are outlined below; for the management of neuropathic pain in palliative care, see p. 21; for the management of diabetic neuropathy, see section 6.1.5.

**Trigeminal neuralgia**

Surgery may be the treatment of choice in many patients; a neurological assessment will identify those who stand to benefit. Carbamazepine (p. 281) taken during the acute stages of trigeminal neuralgia, reduces the frequency and severity of attacks. It is very effective for the severe pain associated with trigeminal neuralgia and (less commonly) glossopharyngeal neuralgia. Blood counts and electrolytes should be monitored when high doses are given. Small doses should be used initially to reduce the incidence of side-effects e.g. dizziness. Some cases respond to phenytoin (p. 288); the drug may be given by intravenous infusion (possibly as fosphenytoin) in a crisis (specialist use only).
Dose

- **ADULT** over 18 years, 200 mg at onset repeated once after 1–2 hours if necessary

Clotam Rapid® (Galen) (Galen)

Tablets, tolfenamic acid 200 mg, net price 10-tab pack = £15.00. Label: 21

5HT1-receptor agonists

A 5HT1-receptor agonist is of considerable value in the treatment of an acute migraine attack. The 5HT1-receptor agonists (‘triptans’) act on the 5HT (serotonin) 1B/1D receptors and are therefore sometimes referred to as 5HT1B/1D-receptor agonists. A 5HT1-receptor agonist may be used during the established headache phase of an attack and is the preferred treatment in those who fail to respond to conventional analgesics. 5HT1-receptor agonists are not indicated for the treatment of hemiplegic, basilar, or ophthalmoplegic migraine.

The 5HT1-receptor agonists available for treating migraine are almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. If a patient does not respond to one 5HT1-receptor agonist, an alternative 5HT1-receptor agonist should be tried. For patients who have prolonged attacks that frequently recur despite treatment with a 5HT1-receptor agonist, combination therapy with a NSAID such as naproxen should be considered. Sumatriptan or zolmitriptan are also used to treat(cluster headache (section 4.7.4.3).

Cautions

- 5HT1-receptor agonists should be used with caution in the elderly [unlicensed], and in conditions which predispose to coronary artery disease (pre-existing cardiac disease, see Contra-indications below); interactions: Appendix 1 (5HT1 agonists).

Contra-indications

- 5HT1-receptor agonists are contra-indicated in ischaemic heart disease, previous myocardial infarction, coronary vasospasm (including Prinzmetal’s angina), and uncontrolled or severe hypertension.

Breast-feeding

- present in milk—avoid breast-feeding

Pregnancy

- There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

Side-effects

- Side-effects of the 5HT1-receptor agonists include sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body (including throat and chest—discontinue if intense, may be due to coronary vasospastic reaction or to anaphylaxis), flushing, dizziness, feeling of weakness; fatigue; nausea and vomiting also reported.

ALMOTRIPTAN

Indications

- treatment of acute migraine

Cautions

- see under 5HT1-receptor agonists above; sensitivity to sulfonamides; interactions: Appendix 1 (5HT1 agonists)

Contra-indications

- see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; peripheral vascular disease

Hepatic impairment

- caution in mild to moderate impairment; avoid in severe impairment

Dose

- **ADULT** over 18 years, 40 mg repeated after 2 hours if migraine recurs (patient not responding to initial dose should not take second dose for same attack); max. 80 mg in 24 hours; **CHILD** and **adolescent** under 18 years not recommended

Almogran® (Almirall) (Almirall)

Tablets, f/c, almotriptan (as hydrogen malate) 12.5 mg, net price 3-tab pack = £0.97, 6-tab pack = £18.14; 9-tab pack = £27.20. Label: 3

ELETRIPTAN

Indications

- treatment of acute migraine

Cautions

- see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT1 agonists)

Contra-indications

- see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; arrhythmias; heart failure; peripheral vascular disease

Hepatic impairment

- avoid in severe impairment

Breast-feeding

- present in milk—avoid breast-feeding for 24 hours

Side-effects

- see under 5HT1-receptor agonists above; also abdominal pain, dry mouth, dyspepsia; tachycardia, palpitation; drowsiness, headache; pharyngitis, rhinitis, chills; myasthenia, myalgia; sweating; less commonly diarrhea, dyspepsia, thirst, anorexia, taste disturbance; dyspnoea, yawning, oedema, agitation, confusion, euphoria, depression, insomnia, depersonalisation, tremor, dysarthria, stupor, movement disorders, hyperventilation, urinary frequency, arthralgia, photophobia, visual disturbances, tinnitus, rash, and pruritus; rarely constipation, oesophagitis, bradycardia, asthma, syncope, lymphadenopathy, and menorrhagia; ischaemic colitis and hypertension also reported

Dose

- **ADULT** over 18 years, 40 mg repeated after 2 hours if migraine recurs (patient not responding to initial dose should not take second dose for same attack); increase to 80 mg for subsequent attacks if 40-mg dose inadequate; max. 80 mg in 24 hours

Relpax® (Pfizer) (Pfizer)

Tablets, f/c, orange, eletriptan (as hydrobromide) 20 mg, net price 6-tab pack = £22.50; 40 mg, 6-tab pack = £45.00. Label: 3

Renal impairment

- max. 12.5 mg in 24 hours if eGFR less than 30 mL/minute/1.73 m²

Pregnancy

- see notes above

Breast-feeding

- present in milk in animal studies— withhold breast-feeding for 24 hours

Side-effects

- see under 5HT1-receptor agonists above; also transient increase in blood pressure, drowsiness; less commonly diarrhea, dyspepsia, dry mouth, chest pain, palpitation, paraesthesia, headache, myalgia, bone pain, tinnitus; very rarely myocardial infarction, and tachycardia

Dose

- 12.5 mg as soon as possible after onset repeated after 2 hours if migraine recurs (patient not responding should not take second dose for same attack); max. 25 mg in 24 hours; **CHILD** and **adolescent** under 18 years not recommended

BNF 61

Central nervous system

274 4.7.4 Antimigraine drugs

Clotam Rapid® (Galen) (Galen)

Tablets, tolfenamic acid 200 mg, net price 10-tab pack = £15.00. Label: 21

Almogran® (Almirall) (Almirall)

Tablets, f/c, almotriptan (as hydrogen malate) 12.5 mg, net price 3-tab pack = £0.97, 6-tab pack = £18.14; 9-tab pack = £27.20. Label: 3

ELETRIPTAN

Indications

- treatment of acute migraine

Cautions

- see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT1 agonists)

Contra-indications

- see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; arrhythmias; heart failure; peripheral vascular disease

Hepatic impairment

- avoid in severe impairment

Breast-feeding

- present in milk—avoid breast-feeding for 24 hours

Side-effects

- see under 5HT1-receptor agonists above; also abdominal pain, dry mouth, dyspepsia; tachycardia, palpitation; drowsiness, headache; pharyngitis, rhinitis, chills; myasthenia, myalgia; sweating; less commonly diarrhea, dyspepsia, thirst, anorexia, taste disturbance; dyspnoea, yawning, oedema, agitation, confusion, euphoria, depression, insomnia, depersonalisation, tremor, dysarthria, stupor, movement disorders, hyperventilation, urinary frequency, arthralgia, photophobia, visual disturbances, tinnitus, rash, and pruritus; rarely constipation, oesophagitis, bradycardia, asthma, syncope, lymphadenopathy, and menorrhagia; ischaemic colitis and hypertension also reported

Dose

- **ADULT** over 18 years, 40 mg repeated after 2 hours if migraine recurs (patient not responding to initial dose should not take second dose for same attack); increase to 80 mg for subsequent attacks if 40-mg dose inadequate; max. 80 mg in 24 hours

Relpax® (Pfizer) (Pfizer)

Tablets, f/c, orange, eletriptan (as hydrobromide) 20 mg, net price 6-tab pack = £22.50; 40 mg, 6-tab pack = £45.00. Label: 3

Renal impairment

- max. 12.5 mg in 24 hours if eGFR less than 30 mL/minute/1.73 m²

Pregnancy

- see notes above

Breast-feeding

- present in milk in animal studies— withhold breast-feeding for 24 hours

Side-effects

- see under 5HT1-receptor agonists above; also transient increase in blood pressure, drowsiness; less commonly diarrhea, dyspepsia, dry mouth, chest pain, palpitation, paraesthesia, headache, myalgia, bone pain, tinnitus; very rarely myocardial infarction, and tachycardia

Dose

- 12.5 mg as soon as possible after onset repeated after 2 hours if migraine recurs (patient not responding should not take second dose for same attack); max. 25 mg in 24 hours; **CHILD** and **adolescent** under 18 years not recommended

Almogran® (Almirall) (Almirall)

Tablets, f/c, almotriptan (as hydrogen malate) 12.5 mg, net price 3-tab pack = £0.97, 6-tab pack = £18.14; 9-tab pack = £27.20. Label: 3
FROVATRIPTAN

Indications  treatment of acute migraine
Cautions  see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT, agonists)
Contra-indications  see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; peripheral vascular disease
Hepatic impairment  avoid in severe impairment
Pregnancy  see notes above
Breast-feeding  present in milk in animal studies— withhold breast-feeding for 24 hours

Side-effects  see under 5HT1-receptor agonists above; also acute radiation sickness

Dose  2.5 mg as soon as possible after onset repeated after 2 hours if migraine recurs (patient not responding should not take second dose for same attack); max. 5 mg in 24 hours; CHILD and ADOLESCENT under 18 years not recommended

Migard® (Menarini) Tablets, f/c, frovatriptan (as succinate) 2.5 mg, net price 6-tab pack = £16.67. Label: 3

NARATRIPTAN

Indications  treatment of acute migraine
Cautions  see under 5HT1-receptor agonists above; sensitivity to sulfonamides; interactions: Appendix 1 (5HT, agonists)
Driving  Drowsiness may affect performance of skilled tasks (e.g. driving)
Contra-indications  see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; peripheral vascular disease
Hepatic impairment  avoid in severe impairment
Renal impairment  reduce dose to 5 mg in mild to moderate impairment; avoid in severe impairment
Pregnancy  see notes above
Breast-feeding  present in milk in animal studies— withhold breast-feeding for 24 hours

Side-effects  see under 5HT1-receptor agonists above; also dry mouth, dyspepsia, abdominal pain, paraesthesia, drowsiness, headache, visual disturbances, sweating, less commonly diarrhoea, dysphagia, flatulence, tachycardia, palpitation, hypertension, rhinitis, pharyngitis, sinusitis, laryngitis, tremor, anxiety, asthenia, insomnia, confusion, nervousness, impaired concentration, agitation, depression, depersonalisation, taste disturbances, micturition disorders, thirst, dehydration, arthralgia, muscle stiffness, tinnitus, vertigo, pruritus; rarely constipation, gastro-oesophageal reflux, irritable bowel syndrome, hiccup, peptic ulcer, stomatitis, bradycardia, hyperventilation, amnesia, abnormal dreams, hypertension, hypotonia, breast tenderness, hypocalcaemia, hypoglycaemia, bilirubinaemia, epistaxis, urticaria, pyrexia, and purpura

Dose  10 mg as soon as possible after onset repeated after 2 hours if migraine recurs (patient not responding should not take second dose for same attack); max. 20 mg in 24 hours; CHILD and ADOLESCENT under 18 years not recommended

Maxalt® (MSD) Tablets, pink, rizatriptan (as benzoate) 5 mg, net price 6-tab pack = £26.74, 10 mg, 3-tab pack = £13.37, 6-tab pack = £26.74. Label: 3

Oral lyophilisates (Maxalt® Melt Wafers), rizatriptan (as benzoate) 10 mg, net price 3-wafer pack = £13.37, 6-wafer pack = £26.74. Label: 3, counselling, administration

Counselling Maxalt® Melt wafers should be placed on the tongue and allowed to dissolve
Excipients include aspartame equivalent to phenylalanine 2.1 mg (section 9.4.1)

SUMATRIPTAN

Indications  treatment of acute migraine; cluster headache (subcutaneous injection only)
Cautions  see under 5HT1-receptor agonists above; history of seizures; sensitivity to sulfonamides; interactions: Appendix 1 (5HT, agonists)
Driving  Drowsiness may affect performance of skilled tasks (e.g. driving)
Contra-indications  see under 5HT1-receptor agonists above; previous cerebrovascular accident or transient ischaemic attack; peripheral vascular disease; moderate and severe hypertension
Hepatic impairment  reduce oral dose to 25–50 mg; avoid in severe impairment
Renal impairment  use with caution
Pregnancy  see notes above
Central nervous system

Breast-feeding present in milk but amount probably too small to be harmful; withhold breast-feeding for 12 hours

Side-effects see under 5HT₁-receptor agonists above; also dyspnoea, drowsiness, transient increase in blood pressure, myalgia; also reported diarrhoea, ischaemic colitis, hypotension, bradycardia or tachycardia, palpitation, arrhythmias, myocardial infarction, Raynaud’s syndrome, anxiety, seizures, tremor, dystonia, nystagmus, arthralgia, visual disturbances, and sweating; epistaxis with nasal spray

Dose
- By mouth, 50 mg (some patients may require 100 mg); dose may be repeated after at least 2 hours if migraine recurs; max. 300 mg in 24 hours; CHILD under 18 years, see BNF for Children
- By subcutaneous injection using auto-injector, 6 mg; dose may be repeated once after at least 1 hour if headache recurs; max. 12 mg in 24 hours; CHILD 10–18 years see BNF for Children

Important Not for intravenous injection which may cause coronary vasospasm and angina
- Intranasally, 10–20 mg into one nostril; dose may be repeated once after at least 2 hours if migraine recurs; max. 40 mg in 24 hours; CHILD 12–18 years [unlicensed dose], 10–20 mg into one nostril; dose may be repeated once after at least 2 hours if migraine recurs; max. 40 mg in 24 hours

Note Patient not responding to initial dose should not take second dose for same attack

^

Zolmitriptan (Non-proprietary) [H]

Tablets, sumatriptan (as succinate) 50 mg, net price 6-tab pack = £1.71, 12-tab pack = £2.49; 100 mg, 6-tab pack = £2.43. Label: 3, 10, patient information leaflet

1. Sumatriptan 50 mg tablets can be sold to the public to treat acute migraine, cluster headache [unlicensed] or migraine, ADULT over 18 years, 2.5 mg repeated after not less than 2 hours if migraine persists or recurs (increase to 5 mg for subsequent attacks in patients not achieving satisfactory relief with 2.5-mg dose); max. 10 mg in 24 hours; CHILD 12–18 years see BNF for Children

Intranasally, 10–20 mg into one nostril; dose may be repeated once after at least 2 hours if migraine recurs; max. 40 mg in 24 hours; CHILD 12–18 years [unlicensed dose], 10–20 mg into one nostril; dose may be repeated once after at least 2 hours if migraine recurs; max. 40 mg in 24 hours

Note Patient not responding to initial dose should not take second dose for same attack

^

Imigran® (GSK) [H]

Tablets, sumatriptan (as succinate) 50 mg, net price 6-tab pack = £28.54; 100 mg, 6-tab pack = £42.90. Label: 3, 10, patient information leaflet

Injection, sumatriptan (as succinate) 12 mg/mL (= 6 mg/0.5-mL syringe), net price, treatment pack (2 x 0.5-mL prefilled syringes and auto-injector) = £42.47; refill pack 2 x 0.5-mL prefilled cartridges = £40.41. Label: 3, 10, patient information leaflet

Nasal spray, sumatriptan 10 mg/0.1-mL actuation, net price 2 unit-dose spray device = £11.80; 20 mg/0.1-mL actuation, 2 unit-dose spray device = £11.80, 6 unit-dose spray device = £35.39. Label: 3, 10, patient information leaflet

Imigran® Radis (GSK) [H]

Tablets, f/c, sumatriptan (as succinate) 50 mg (pink), net price 6-tab pack = £23.90; 100 mg (white), 6-tab pack = £42.90. Label: 3, 10, patient information leaflet

Ergot alkaloids

The value of ergotamine for migraine is limited by difficulties in absorption and by its side-effects, particularly nausea, vomiting, abdominal pain, and muscular cramps; it is best avoided. The recommended doses of ergotamine preparations should not be exceeded and treatment should not be repeated at intervals of less than 4 days. To avoid habituation the frequency of administration of ergotamine should be limited to no more than twice a month. It should never be prescribed prophylactically but in the management of cluster headache a low dose (e.g. ergotamine 1 mg at night for 6 nights in 7) is occasionally given for 1 to 2 weeks [unlicensed indication].

Ergot alkaloids

Indications treatment of acute migraine and migraine variants unresponsive to analgesics

Cautions risk of peripheral vasospasm (see below); elderly; dependence (see Ergot Alkaloids above); cardiac disease; anaemia; interactions: Appendix 1 (ergot alkaloids)

Peripheral vasospasm Warn patient to stop treatment immediately if numbness or tingling of extremities develops and to contact doctor

^
Contra-indications peripheral vascular disease, coronary heart disease, obliteratorive vascular disease and Raynaud’s syndrome, temporal arteritis, sepsis, severe or inadequately controlled hypertension, hyperthyroidism, acute porphyria (section 9.8.2)

Hepatic impairment avoid in severe impairment—risk of toxicity increased

Renal impairment avoid; risk of renal vasoconstriction

Pregnancy avoid; oxytocic effect on the uterus

Breast-feeding avoid; ergotism may occur in infant; repeated doses may inhibit lactation

Side-effects abdominal pain, nausea, vomiting; dizziness; less commonly diarrhoea, pain and weakness in extremities, cyanosis, peripheral vasoconstriction, paraesthesia, and hypoaesthesia; rarely intestinal ischaemia, arrhythmias, increased blood pressure, bradycardia, tachycardia, dyspnoea, ergotism (including absence of pulse and numbness in extremities), myalgia, rash, and urticaria; very rarely myocardial ischaemia, myocardial infection, heart-valve fibrosis, and gangrene; constipation, dry mouth, cerebral ischaemia, thrombosis, drowsiness, sleep disturbances, tremor, seizures, extrapyramidal effects, anxiety, depression, confusion, hallucinations, renal artery spasm, urinary retention, blood disorders, blurred vision, and arthralgia also reported; with suppositories rectal and anal ulcers on prolonged use

Dose

• See under preparations below

Caffergot® (Alliance) Tablets, s/c, ergotamine tartrate 1 mg, caffeine 100 mg, net price 30-tab pack = £5.02. Label: 18, counselling, dosage

Dose ADULT and CHILD over 12 years, 1–2 tablets at onset; max. 4 tablets in 24 hours; not to be repeated at intervals of less than 4 days; max. 8 tablets in one week (but see also notes above)

Suppositories, ergotamine tartrate 2 mg, caffeine 100 mg, net price 30 = £10.13. Label: 18, counselling, dosage

Dose ADULT and CHILD over 12 years, 1 suppository at onset; max. 2 in 24 hours; max. 4 suppositories in one week (but see also notes above)

Migril® (Wockhardt) Tablets, scored, ergotamine tartrate 2 mg, cyclazine hydrochloride 50 mg, caffeine hydrate 100 mg, net price 100 = £51.00. Label: 2, 18, counselling, dosage

Dose 1 tablet at onset, followed after 30 minutes by ½–1 tablet, repeated every 30 minutes if necessary; max. 3 tablets in 24 hours, 4 tablets per attack, 6 tablets in one week (but see also notes above); CHILD not recommended

Antiemetics

Antiemetics (section 4.6), such as metoclopramide or domperidone, or phenothiazine and antihistamine antiemetics, relieve the nausea associated with migraine attacks. Antiemetics may be given by intramuscular injection or rectally if vomiting is a problem. Metoclopramide and domperidone have the added advantage of promoting gastric emptying and normal peristalsis; a single dose should be given at the onset of symptoms. Oral analgesic preparations containing metoclopramide are a convenient alternative (important: for warnings relating to extrapyramidal effects of metoclopramide particularly in children and young adults, see p. 249).

4.7.4.2 Prophylaxis of migraine

Where migraine attacks are frequent, possible provoking factors such as stress, irregular life-style (e.g. lack of sleep), or chemical triggers (e.g. alcohol and nitrates) should be sought; combined oral contraceptives may also provoke migraine, see section 7.3.1 for advice.

Preventive treatment for migraine should be considered for patients who:

• suffer at least two attacks a month;
• suffer an increasing frequency of headaches;
• suffer significant disability despite suitable treatment for migraine attacks;
• cannot take suitable treatment for migraine attacks.

Prophylaxis is also necessary in some rare migraine subtypes and those at risk of migrainous infarction.

The beta-blockers propranolol, atenolol, metoprolol, nadolol, and timolol (section 2.4) are all effective. Propranolol is the most commonly used. Tricyclic antidepressants (section 4.3.1) [unlicensed indication], topiramate (section 4.8.1), sodium valproate (section 4.8.1) [unlicensed indication], valproic acid (section 4.2.3) [unlicensed indication], and gabapentin (section 4.8.1) [unlicensed indication] are also effective for preventing migraine.

Pizotifen is an antihistamine and a serotonin-receptor antagonist, structurally related to the tricyclic antidepressants. It is of limited value and may cause weight gain.

Botulinum toxin type A is licensed for the prophylaxis of headaches in adults with chronic migraine, defined as headache on at least 15 days per month, of which at least 8 of those days are with migraine.

Clonidine (Dixarit®) is not recommended; it can aggravate depression and cause insomnia. Methylsergide, a semi-synthetic ergot alkaloid, has dangerous side-effects (retroperitoneal fibrosis and fibrosis of the heart valves and pleura); important: it should only be administered under hospital supervision.

Pizotifen

Indications prevention of vascular headache including classical migraine, common migraine, and cluster headache

Cautions urinary retention; susceptibility to angle-closure glaucoma; history of epilepsy; interactions: Appendix 1 (pizotifen)

Driving Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Renal impairment use with caution

Pregnancy avoid unless potential benefit outweighs risk

Breast-feeding amount probably too small to be harmful, but manufacturer advises avoid

Side-effects dry mouth, nausea; dizziness, drowsiness, increased appetite, weight gain; less commonly constipation; rarely anxiety, aggression, insomnia, paraesthesia, hallucination, depression, arthralgia, myalgia; very rarely seizures

Dose

• Initially 500 micrograms at night increased gradually to usual dose of 1.5 mg at night or in 3 divided doses; may be further increased up to max. daily dose 4.5 mg (but rarely necessary), max. single dose 3 mg. CHILD
278 4.7.4 Antimigraine drugs

over 5 years, up to 1.5 mg daily in divided doses; max. single dose at night 1 mg

Pizotifen (Non-proprietary) [NH]
Tablets, pizotifen (as hydrogen malate), 500 micrograms, net price 28-tab pack = £1.28; 1.5 mg, 28-tab pack = £2.17. Label: 2

Sanomigran® (Novartis) [NH]
Tablets, both ivory-yellow, s/c, pizotifen (as hydrogen malate), 500 micrograms, net price 60-tab pack = £2.06; 1.5 mg, 28-tab pack = £3.42. Label: 2

Elxi®; pizotifen (as hydrogen malate) 250 micrograms/5 mL, net price 300 mL = £3.61. Label: 2

CLONIDINE HYDROCHLORIDE

Indications prevention of recurrent migraine (but see notes above), vascular headache, menopausal flushing; hypertension (section 2.5.2)

Cautions depressive illness; heart failure; Raynaud’s syndrome; concurrent antihypertensive therapy; cerebrovascular disease; polynuropathy; constipation; interactions: Appendix 1 (clonidine)

Contra-indications severe bradyarrhythmia

Renal impairment use with caution in severe impairment—reduce initial dose and increase gradually

Pregnancy avoid unless potential benefit outweighs risk

Breast-feeding avoid

Side-effects constipation, dry mouth, nausea, vomiting; postural hypotension; depression, sleep disorder, dizziness, headache, drowsiness; erectile dysfunction; less commonly Raynaud’s syndrome, paraesthesia, hallucination, rash, and pruritus; rarely AV block, gynaecomastia, and alopecia

Dose
- Initially 1 mg at bedtime, increased gradually over about 2 weeks to 2–3 mg 3 times daily with food (see notes above); CHILD not recommended
- Diarrhoea associated with carcinoid syndrome, usual range, 12–20 mg daily (hospital supervision); CHILD not recommended

Deseril® (Alliance) [NH]
Tablets, s/c, methysergide (as maleate) 1 mg, net price 60-tab pack = £12.94. Label: 2, 21

Hepatic impairment avoid

Renal impairment avoid

Pregnancy avoid

Breast-feeding avoid

Side-effects nausea, vomiting, heartburn, abdominal discomfort, drowsiness, and dizziness occur frequently in initial treatment; mental and behavioural disturbances, insomnia, oedema, weight gain, rashes, loss of scalp hair, cramps, arterial spasm (including coronary artery spasm with angina and possible myocardial infarction), paraesthesias of extremities, postural hypotension, and tachycardia also occur; retroperitoneal and other abnormal fibrotic reactions may occur on prolonged administration, requiring immediate withdrawal of treatment

Dose

- Initially 1 mg at bedtime, increased gradually over about 2 weeks to 2–3 mg 3 times daily with food (see notes above); CHILD not recommended
- Diarrhoea associated with carcinoid syndrome, usual range, 12–20 mg daily (hospital supervision); CHILD not recommended

Cluster headache and the trigeminal autonomic cephalalgias

Cluster headache rarely responds to standard analgesics. Sumatriptan (p. 275) given by subcutaneous injection is the drug of choice for the treatment of cluster headache. If an injection is unsuitable, sumatriptan nasal spray or zolmitriptan nasal spray [both unlicensed use] may be used. Alternatively, 100% oxygen at a rate of 10–15 litres/minute for 10–20 minutes is useful in aborting an attack.

Prophylaxis of cluster headache is considered if the attacks are frequent, last over 3 weeks, or if they cannot be treated effectively. Verapamil (p. 133) or lithium [both unlicensed use] are used for prophylaxis.

Prednisolone (section 6.3.2) can be used for short-term prophylaxis of episodic cluster headache [unlicensed use] either as monotherapy, or in combination with verapamil during verapamil titration. The dose of prednisolone for monotherapy or adjunctive therapy is 60–100 mg once daily for 2–5 days followed by a dose reduction of 10 mg every 2–3 days until prednisolone is discontinued.

Ergotamine, used on an intermittent basis is an alternative for patients with short bouts, but it should not be used for prolonged periods. Methysergide is effective but must be used with extreme caution (section 4.7.4.2) and only if other drugs cannot be used or if they are not effective.

The other trigeminal autonomic cephalalgias, paroxysmal hemicrania (sensitive to indometacin), and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, are seen rarely and are best managed by a specialist.
Interactions

Interactions between antiepileptics are complex and may increase toxicity without a corresponding increase in antiepileptic effect. Interactions are usually caused by hepatic enzyme induction or hepatic enzyme inhibition; displacement from protein binding sites is not usually a problem. These interactions are highly variable and unpredictable.

For interactions of antiepileptic drugs, see Appendix 1; for advice on hormonal contraception and enzyme-inducing drugs, see section 7.3.1 and section 7.3.2.

Significant interactions that occur between antiepileptics and that may affect dosing requirements are as follows:

- **Carbamazepine**
  - Often lowers plasma concentration of clonazepam, clonazepam, lamotrigine, phenytoin (but may also raise phenytoin concentration), tiagabine, topiramate, valproate, zonisamide, and an active metabolite of oxcarbazepine
  - Sometimes lowers plasma concentration of eslicarbazepine, ethosuximide, primidone (but tendency for corresponding increase in phenobarbital level), and rufinamide

- **Eslicarbazepine**
  - Often raises plasma concentration of phenytoin
  - Sometimes lowers plasma concentration of carbamazepine

- **Ethosuximide**
  - Sometimes raises plasma concentration of an active metabolite of carbamazepine

- **Lamotrigine**
  - Sometimes raises plasma concentration of an active metabolite of carbamazepine

- **Oxcarbazepine**
  - Sometimes lowers plasma concentration of carbamazepine (but may raise concentration of an active metabolite of carbamazepine)
  - Sometimes raises plasma concentration of phenytoin

- **Phenytoin**
  - Often lowers plasma concentration of clonazepam, carbamazepine, eslicarbazepine, lamotrigine, tiagabine, topiramate, valproate, zonisamide, and an active metabolite of oxcarbazepine
  - Often raises plasma concentration of phenobarbital

- **Phenobarbital or primidone**
  - Often lowers plasma concentration of carbamazepine, clonazepam, lamotrigine, phenytoin (but may also raise phenytoin concentration), tiagabine, valproate, and zonisamide

- **Rufinamide**
  - Sometimes lowers plasma concentration of ethosuximide and rufinamide

- **Phenobarbital**
  - Sometimes lowers plasma concentration of ethosuximide, primidone (by increasing conversion to phenobarbital), and rufinamide

- **Topiramate**
  - Sometimes raises plasma concentration of phenytoin

- **Valproate**
  - Sometimes lowers plasma concentration of an active metabolite of oxcarbazepine
  - Often raises plasma concentration of lamotrigine, primidone, phenobarbital, phenytoin (but may also lower), and an active metabolite of carbamazepine

- **Vigabatrin**
  - Often lowers plasma concentration of phenytoin

- **Valproate**
  - Sometimes lowers plasma concentration of an active metabolite of carbamazepine

Note: Check under each drug for possible interactions when two or more antiepileptic drugs are used.
Withdrawal Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal, particularly of barbiturates and benzodiazepines, because this may precipitate severe rebound seizures. Reduction in dosage should be gradual and, in the case of barbiturates, withdrawal of the drug may take months.

The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal.

In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.

Driving Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.

Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards (see also Drugs and Driving under General Guidance, p. 3).

Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.

Pregnancy Women of child-bearing potential should discuss the impact of both epilepsy and the treatment of epilepsy on the outcome of pregnancy with a specialist. There is an increased risk of teratogenicity associated with the use of antiepileptic drugs (especially if used during the first trimester and if the patient takes two or more antiepileptic drugs). Valproate is associated with the highest risk of major and minor congenital malformations, and with developmental delay. Valproate should not be prescribed unless there is no safer alternative and only after a careful discussion of the risks; doses greater than 1 g daily are associated with an increased risk of teratogenicity. There is also an increased risk of teratogenicity with phenytoin, primidone, lamotrigine, and carbamazepine. There is not enough evidence to establish the risk of teratogenicity with other antiepileptic drugs.

Women of child-bearing potential who take antiepileptic drugs should be given contraceptive advice. Some antiepileptic drugs, in particular benzodiazepines and antiepileptic drugs, in particular benzodiazepines and phenobarbitals, increase the risk of harm to the fetus.

Once an unplanned pregnancy is discovered it is usually too late for changes to be made to the treatment regimen; the risk of harm to the mother and fetus from convulsive seizures outweighs the risk of continued therapy. The likelihood of a woman who is taking antiepileptic drugs having a baby with no malformations is at least 90%, and it is important that women do not stop taking essential treatment because of concern over harm to the fetus.

To reduce the risk of neural tube defects, folate supplementation (section 9.1.2) is advised before conception and throughout the first trimester.

The concentration of antiepileptic drugs in the plasma can change during pregnancy, particularly in the later stages. Doses of phenytoin (see p. 288), carbamazepine, and lamotrigine should be adjusted on the basis of plasma-drug concentration monitoring; the dose of other antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis. Plasma-drug concentration monitoring during pregnancy is also useful to check compliance. Additionally, in patients taking topiramate or levetiracetam, it is recommended that fetal growth should be monitored.

Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol, see section 4.8.2.

Routine injection of vitamin K (section 9.6.6) at birth minimises the risk of neonatal haemorrhage associated with antiepileptics.

Withdrawal effects in the newborn may occur with some antiepileptic drugs, in particular benzodiazepines and phenobarbital.

Epilepsy and Pregnancy Register All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

Breast-feeding Breast-feeding is acceptable with all antiepileptic drugs taken in normal doses, with the possible exception of the barbiturates and some of the newer antiepileptics (see under individual drugs).

Focal seizures with or without secondary generalisation Carbamazepine, lamotrigine, oxcarbazepine, and sodium valproate are the drugs of choice for focal seizures; second-line drugs include clobazam, gabapentin, levetiracetam, pregabalin, tiagabine, topiramate, and zonisamide.

Generalised seizures Tonic-clonic seizures The drugs of choice for tonic-clonic seizures are carbamazepine, lamotrigine, and sodium valproate. Clobazam, levetiracetam, oxcarbazepine, and topiramate are second-line drugs.
Absence seizures Ethosuximide and sodium valproate are the drugs of choice in typical absence seizures; alternatives include clonazepam and lamotrigine. Sodium valproate is also highly effective in treating the generalised tonic-clonic seizures which can co-exist with absence seizures in idiopathic primary generalised epilepsy.

Myoclonic seizures Myoclonic seizures (myoclonic jerks) occur in a variety of syndromes, and response to treatment varies considerably. Sodium valproate is the drug of choice; clonazepam and levetiracetam can also be used. Alternatives include lamotrigine and topiramate, but lamotrigine may occasionally exacerbate myoclonic seizures. For reference to the adjunctive use of piracetam, see section 4.9.3. Sodium valproate and levetiracetam are effective in treating the generalised tonic-clonic seizures that co-exist with myoclonic seizures in idiopathic generalised epilepsy.

Atypical absence, atonic, and tonic seizures Atypical absence, atonic, and tonic seizures are usually seen in childhood, in specific epilepsy syndromes, or associated with cerebral damage or mental retardation. They may respond poorly to the traditional drugs. Sodium valproate, lamotrigine, and clonazepam can be tried. Second-line drugs that are occasionally helpful include clonazepam, ethosuximide, levetiracetam, and topiramate.

Epilepsy syndromes Some drugs are licensed for use in particular epilepsy syndromes, such as lamotrigine and rufinamide in Lennox-Gastaut syndrome. The epilepsy syndromes are specific types of epilepsy that are characterised according to a number of features including seizure type, age of onset, and EEG characteristics.

For more information on epilepsy syndromes in children, see BNF for Children, section 4.8.1. Prescribing information for stiripentol (Diacomit) in severe myoclonic epilepsy of infancy (Draevet syndrome) can also be found in BNF for Children.

Carbamazepine and related antiepileptics

Carbamazepine is a drug of choice for simple and complex focal seizures and for tonic-clonic seizures secondary to a focal discharge. It is essential to initiate carbamazepine therapy at a low dose and build this up slowly with increments of 100–200 mg every two weeks. Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. They may be reduced by altering the timing of medication; use of modified-release tablets also significantly lessens the incidence of dose-related side-effects.

Oxcarbazepine is licensed as monotherapy or adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures.

Eslicarbazepine is licensed for adjunctive treatment in adults with focal seizures with or without secondary generalisation.

Myoclonic seizures Myoclonic seizures (myoclonic jerks) occur in a variety of syndromes, and response to treatment varies considerably. Sodium valproate is the drug of choice; clonazepam and levetiracetam can also be used. Alternatives include lamotrigine and topiramate, but lamotrigine may occasionally exacerbate myoclonic seizures. For reference to the adjunctive use of piracetam, see section 4.9.3. Sodium valproate and levetiracetam are effective in treating the generalised tonic-clonic seizures that co-exist with myoclonic seizures in idiopathic generalised epilepsy.

Atypical absence, atonic, and tonic seizures Atypical absence, atonic, and tonic seizures are usually seen in childhood, in specific epilepsy syndromes, or associated with cerebral damage or mental retardation. They may respond poorly to the traditional drugs. Sodium valproate, lamotrigine, and clonazepam can be tried. Second-line drugs that are occasionally helpful include clonazepam, ethosuximide, levetiracetam, and topiramate.

Epilepsy syndromes Some drugs are licensed for use in particular epilepsy syndromes, such as lamotrigine and rufinamide in Lennox-Gastaut syndrome. The epilepsy syndromes are specific types of epilepsy that are characterised according to a number of features including seizure type, age of onset, and EEG characteristics.

For more information on epilepsy syndromes in children, see BNF for Children, section 4.8.1. Prescribing information for stiripentol (Diacomit) in severe myoclonic epilepsy of infancy (Draevet syndrome) can also be found in BNF for Children.

Carbamazepine and related antiepileptics

Carbamazepine is a drug of choice for simple and complex focal seizures and for tonic-clonic seizures secondary to a focal discharge. It is essential to initiate carbamazepine therapy at a low dose and build this up slowly with increments of 100–200 mg every two weeks. Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. They may be reduced by altering the timing of medication; use of modified-release tablets also significantly lessens the incidence of dose-related side-effects.

Oxcarbazepine is licensed as monotherapy or adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures.

Eslicarbazepine is licensed for adjunctive treatment in adults with focal seizures with or without secondary generalisation.

The Scottish Medicines Consortium (p. 4) has advised (October 2010) that eslicarbazepine (Zebinix®) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with focal seizures with or without secondary generalisation. It is restricted for use in refractory epilepsy.

**CARBAMAZEPINE**

**Indications** focal and secondary generalised tonic-clonic seizures, primary generalised tonic-clonic seizures; trigeminal neuralgia; prophylaxis of bipolar disorder unresponsive to lithium; adjunct in acute alcohol withdrawal [unlicensed] (section 4.10.1); diabetic neuropathy [unlicensed] (section 6.1.5)

**Cautions** cardiac disease (see also Contra-indications); skin reactions (see also Blood, Hepatic, or Skin Disorders, below and under Side-effects); test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele); history of haematological reactions to other drugs; manufacturer recommends blood counts and hepatic and renal function tests (but evidence of practical value uncertain); may exacerbate absence and myoclonic seizures; consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium; susceptibility to angle-closure glaucoma, cross-sensitivity reported with oxcarbazepine and with phentoin; avoid abrupt withdrawal; interactions: see p. 279 and Appendix 1 (carbamazepine)

**Blood, hepatic, or skin disorders** Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Carbamazepine should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).

**Contra-indications** AV conduction abnormalities (unless paced); history of bone marrow depression, acute porphyria (section 9.8.2); hypersensitivity to tricyclic antidepressants

**Hepatic impairment** metabolism impaired in advanced liver disease; see also Blood, Hepatic, or Skin Disorders, above

**Renal impairment** use with caution

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** amount probably too small to be harmful but monitor infant for possible adverse reactions; see also Breast-feeding, p. 280

**Side-effects** see notes above; dry mouth, nausea, vomiting; oedema; ataxia, dizziness, drowsiness, fatigue, headache; hyponatraemia (leading in rare cases to water intoxication); blood disorders (including eosinophilia, leucopenia, thrombocytopenia, haemolytic anaemia, and aplastic anaemia); dermatitis, and urticaria; less commonly diarrhoea, constipation, involuntary movements (including myastigmas), visual disturbances; rarely abdominal pain, anorexia, hepatitis, jaundice, vanishing bile duct syndrome, cardiac conduction disorders, hypertension, hypotension, peripheral neuropathy, dysarthria, aggression, agitation, confusion, depression, hallucinations, restlessness, paraesthesia, lymph node enlargement, muscle weakness, systemic lupus erythematosus, and delayed multi-organ hypersensitivity disorder; very
rarely pancreatitis, stomatitis, hepatic failure, taste disturbance, exacerbation of coronary artery disease, AV block with syncope, circulatory collapse, hypercholesterolaemia, thrombophlebitis, thromboembolism, pulmonary hypersensitivity (with dyspnoea, pneumonia, or pneumonia), psychosis, neuroleptic malignant syndrome, osteomalacia (see Caution), osteoporosis, galactorrhoea, gynaecomastia, impaired male fertility, interstitial nephritis, renal failure, sexual dysfunction, urinary frequency, urinary retention, arthralgia, muscle pain, muscle spasm, conjunctivitis, angle-closure glaucoma, hearing disorders, acne, alterations in skin pigmentation, alopecia, hirsutism, sweating, photosensitivity, purpura, Stevens-Johnson syndrome, toxic epidermal necrolysis, and aseptic meningitis; suicidal ideation.

**Dose**

**Note**

Different preparations may vary in bioavailability; to avoid reduced effect or excessive side-effects, it may be prudent to avoid changing the formulation.

- **By mouth**, epilepsy, initially, 100–200 mg 1–2 times daily; increased slowly (see above) to usual dose of 0.8–1.2 g daily in divided doses; in some cases 1.6–2 g daily in divided doses may be needed; **Elderly** reduce initial dose; **Child** daily in divided doses, up to 1 year 100–200 mg, 1–5 years 200–400 mg, 5–10 years 400–600 mg, 10–15 years 0.6–1 g.

- **Trigeminal neuralgia**, initially 100 mg 1–2 times daily (but some patients may require higher initial dose), increased gradually according to response; usual dose 200 mg 3–4 times daily, up to 1.6 g daily in some patients.

Diabetic neuropathy [unlicensed indication], initially 100 mg 1–2 times daily, increased gradually according to response; usual dose 200 mg 3–4 times daily, up to 1.6 g daily in some patients.

Prophylaxis of bipolar disorder unresponsive to lithium (see also section 4.2.3), initially 400 mg daily in divided doses increased until symptoms controlled; usual range 400–600 mg daily; max. 1.6 g daily.

Treatment of alcohol withdrawal [unlicensed indication], initially 800 mg daily in divided doses, reduced gradually over 5 to 20 days to usual treatment duration 7–10 days.

- **By rectum**, epilepsy, for short-term use (max. 7 days); when oral therapy temporarily not possible; 125 mg suppository approx. equivalent to 100-mg tablet, but final adjustment should always depend on clinical response (plasma concentration monitoring recommended); max. 1 g daily in 4 divided doses.

**Note**

Plasma concentration for optimum response 4–12 mg/litre (20–50 micromol/litre).

**Carbamazepine Tablets** (Non-proprietary)

<table>
<thead>
<tr>
<th>Brand</th>
<th>Description</th>
<th>Net price</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>scored, carbamazepine 100 mg, net price 84-tab pack = £2.07; 200 mg, 84-tab pack = £3.83; 400 mg, 56-tab pack = £5.02. Label: 3, 8, counselling, blood, hepatic or skin disorder symptoms (see above), driving (see notes above)</td>
<td>£10.24. Label: 3, 8, counselling, blood, hepatic or skin disorder symptoms (see above), driving (see notes above)</td>
</tr>
<tr>
<td>B</td>
<td>scored, carbamazepine 100 mg, net price 56-tab pack = £5.20; 400 mg, 56-tab pack = £10.24. Label: 3, 8, 25, counselling, blood, hepatic or skin disorder symptoms (see above), driving (see notes above)</td>
<td>£2.07; 200 mg, 84-tab pack = £3.83; 400 mg, 56-tab pack = £5.02. Label: 3, 8, counselling, blood, hepatic or skin disorder symptoms (see above), driving (see notes above)</td>
</tr>
</tbody>
</table>

**ESLICARBAZEPINE ACETATE**

**Indications**

see notes above.

**Cautions**

avoid abrupt withdrawal; hyponatraemia (monitor plasma-sodium concentration in patients at risk and discontinue treatment if hyponatraemia occurs); PR-interval prolongation (avoid concomitant administration of drugs that prolong PR interval); elderly: interactions: see p. 279 and Appendix 1 (eslicarbazine);

**Contra-indications**

second- or third-degree AV block

**Hepatic impairment**

avoid in severe impairment—no information available.

**Renal impairment**

reduce initial dose to 400 mg every other day for 2 weeks then 400 mg once daily if eGFR 30–60 mL/minute/1.73 m²; adjusted according to response; avoid if eGFR less than 30 mL/minute/1.73 m².

**Pregnancy**

see Pregnancy, p. 280

**Breast-feeding**

manufacturer advises avoid—present in milk in animal studies; see also Breast-feeding, p. 280

**Side-effects**

gastro-intestinal disturbances; dizziness, drowsiness, headache, impaired coordination, tremor, visual disturbances, fatigue; rash; less commonly dry mouth, dehydration, gingival hyperplasia, stomatitis; palpititation, bradycardia, hypertension, hypotenension, epistaxis, appetite changes, weight changes, agitation, hyperactivity, confusion, mood changes, psychosis, impaired memory, insomnia, dysaesthesia, dystonia, parosmia, movement disorders, convulsions, peripheral neuropathy, nyctagmus, dysarthria, taste disturbance, liver disorders, hypothroidism, anaemia, hyponatraemia (see Caution), electrolyte imbalance, tinnitus, alopecia, sweating, nail disorder, myalgia, nocturia, menstruation changes, malaise, chills, per...
Oxcarbazepine

**Indications**  see notes above

**Cautions** hypersensitivity to carbamazepine; avoid abrupt withdrawal; hypotenaraemia (monitor plasma-sodium concentration in patients at risk); heat failure (monitor body-weight), cardiac conduction disorders; avoid in acute porphyria (section 9.8.2); **interactions:** see p. 279 and Appendix 1 (oxcarbazepine)

**Blood, hepatic, or skin disorders** Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as lethargy, confusion, muscular twitching, fever, sore throat, rash, blistering, mouth ulcers, bruising, or bleeding develop

**Hepatic impairment** caution in severe impairment—no information available

**Renal impairment** halve initial dose if eGFR less than 30 mL/minute/1.73 m²; increase according to response at intervals of at least 1 week

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** present in milk—manufacturer advises avoid; see also Breast-feeding, p. 280

**Side-effects** nausea, vomiting, constipation, diarrhoea, abdominal pain; dizziness, headache, drowsiness, agitation, amnesia, anaesthesia, ataxia, confusion, impaired concentration, depression, tremor; hypotenaraemia; acne, alopecia, rash, nyctagmus, visual disorders including diplopia; less commonly urticaria, leucopenia; very rarely hepatitis, pancreatitis, arthralgias, blood disorders, systemic lupus erythematosus, Stevens-Johnson syndrome, and toxic epidermal necrolysis; hypertension and hypothyroidism also reported; suicidal ideation

**Dose**

- **ADULT** over 18 years, initially 400 mg once daily, increased after 1–2 weeks to 800 mg once daily; max. 1.2 g

- **CHILD**
  - 1 month–6 years, initially 10 mg/kg (max. 250 mg) daily in 2 divided doses, increased gradually over 2–3 weeks to usual dose of 20–40 mg/kg (max. 1 g) daily in 2 divided doses; total daily dose may be given in 3 divided doses
  - 6–9 years, initially 500 mg daily in 2 divided doses; total daily dose may be given in 3 divided doses
  - 9–12 years initially 1 g) daily in 2 divided doses; total daily dose may be given in 3 divided doses
  - over 12 years, initially 1 g daily in 2 divided doses; total daily dose may be given in 3 divided doses

**Note** In adjunctive therapy, the dose of concomitant antiepileptics may need to be reduced when using high doses of oxcarbazepine

**Oxcarbazepine (Non-proprietary)**

**Tablets**, oxcarbazepine 150 mg, net price 50-tab pack = £11.02; 300 mg, 50-tab pack = £22.38; 600 mg, 50-tab pack = £44.72. Label: 3, 8, counselling, blood disorders (see above), driving (see notes above)

**Trileptal® (Novartis)**

**Tablets**, f/c, scored, oxcarbazepine 150 mg (green), net price 50-tab pack = £8.50; 300 mg (yellow), 50-tab pack = £17.00; 600 mg (pink), 50-tab pack = £34.00. Label: 3, 8, counselling, blood, hepatic or skin disorders (see above), driving (see notes above)

**Oral suspension**, sugar-free, oxcarbazepine 300 mg/5 mL, net price 250 mL (with oral syringe) = £34.00. Label: 3, 8, counselling, blood, hepatic or skin disorders (see above), driving (see notes above)

Ethosuximide

**Indications**  see notes above

**Cautions** avoid abrupt withdrawal avoid in acute porphyria (section 9.8.2); **interactions:** see p. 279 and Appendix 1 (ethosuximide)

**Blood disorders** Patients or their carers should be told how to recognise signs of blood disorders, and advised to seek immediate medical attention if symptoms such as fever, sore throat, mouth ulcers, bruising, or bleeding develop

**Hepatic impairment** use with caution

**Renal impairment** use with caution

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** present in milk; hyperexcitability and sedation reported; see also Breast-feeding, p. 280

**Side-effects** gastro-intestinal disturbances (including nausea, vomiting, diarrhea, abdominal pain, anorexia, weight loss); less frequently headache, fatigue, drowsiness, dizziness, hiccup, ataxia, euphoria, irritability, aggresssion, impaired concentration; rarely tongue swelling, sleep disturbances, night terrors, depression, psychosis, photophobia, dyskinesia, increased libido, vaginal bleeding, myopia, gingival hypertrophy, and rash; also reported hyperactivity, increase in seizure frequency, blood disorders such as leucopenia, agranulocytosis, pancytopenia, and aplastic anaemia (blood counts required if features of infection), systemic lupus erythematosus, and Stevens-Johnson syndrome; suicidal ideation

**Dose**

- **ADULT** and **CHILD** over 6 years, initially 500 mg daily in 2 divided doses, increased by 250 mg every 4–7 days to usual dose of 1–1.5 g daily in 2 divided doses; occasionally up to 2 g daily may be needed;
- **CHILD** 1 month–6 years, initially 10 mg/kg (max. 250 mg) daily in 2 divided doses, increased gradually over 2–3 weeks to usual dose of 20–40 mg/kg (max. 1 g) daily in 2 divided doses; total daily dose may be given in 3 divided doses

**Ethosuximide (Non-proprietary)**

**Capsules**, ethosuximide 250 mg, net price 56-cap pack = £38.23. Label: 8, counselling, blood disorders (see above), driving (see notes above)

**Emeside® (Chemidex)**

**Syrup**, black currant, ethosuximide 250 mg/5 mL, net price 200-mL pack = £6.60. Label: 8, counselling, blood disorders (see above), driving (see notes above)

**Zarontin® (Pfizer)**

**Syrup**, yellow, ethosuximide 250 mg/5 mL, net price 200-mL pack = £4.22. Label: 8, counselling, blood disorders (see above), driving (see notes above)
Gabapentin and pregabalin

Gabapentin and pregabalin are used for the treatment of focal seizures with or without secondary generalisation. They are also licensed for the treatment of neuropathic pain (p. 272). Pregabalin is licensed for the treatment of generalised anxiety disorder (p. 233). Gabapentin is an effective treatment for migraine prophylaxis [unlicensed] (p. 277).

The Scottish Medicines Consortium (p. 4) has advised (July 2007) that pregabalin (Lyrica®) is not recommended for the treatment of central neuropathic pain. The Scottish Medicines Consortium (p. 4) has advised (April 2009) that pregabalin (Lyrica®) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain in adults who have not achieved adequate pain relief with, or have not tolerated, first- or second-line treatments; discontinue if patient has not achieved adequate pain relief with, or have not tolerated, first- or second-line treatments; discontinue if patient.

Indications

Gabapentin monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation; peripheral neuropathic pain (section 4.7.3); migraine prophylaxis (section 4.7.4.2)

Caution

Avoid abrupt withdrawal (may cause anxiety, insomnia, nausea, pain, and sweating—taper off over at least 1 week); elderly; diabetes mellitus; false positive readings with some urinary protein tests; history of psychiatric illness; interactions: Appendix 1 (gabapentin)

Renal impairment

Reduce dose to 600–1800 mg daily in 3 divided doses if eGFR 50–80 mL/minute/1.73 m²; reduce dose to 300–900 mg daily in 3 divided doses if eGFR 30–50 mL/minute/1.73 m²; reduce dose to 300 mg on alternate days (up to max. 600 mg daily) in 3 divided doses if eGFR 15–30 mL/minute/1.73 m²; reduce dose to 300 mg on alternate days (up to max. 300 mg daily) in 3 divided doses if eGFR less than 15 mL/minute/1.73 m²—consult product literature.

Pregnancy

See Pregnancy, p. 280

Breast-feeding

Present in milk—manufacturer advises use only if potential benefit outweighs risk; see also Breast-feeding, p. 280

Side-effects

Diarrhoea, dry mouth, dyspepsia, nausea, vomiting, constipation, abdominal pain, flatulence, appetite changes, gingivitis, weight gain, hypertension, vasodilation, oedema, dysphonia, cough, rhiinitis; confusion, depression, hostility, sleep disturbances, headache, dizziness, anxiety, amnesia, ataxia, dysarthria, nystagmus, tremor, asthenia, paraesthesia, hyperkinesia; influenza-like symptoms; impotence, urinary incontinence; leucopenia; myalgia, arthralgia; diplopia, amblyopia; rash, purpura, pruritus, acne; rarely pancreatitis, hepatitis, jaundice, palpitation, hallucinations, movement disorders, thrombocytopenia, blood-glucose fluctuations in patients with diabetes, tinnitus, acute renal failure, Stevens-Johnson syndrome, and alopecia; suicidal ideation; psychosis also reported

Dose

• Epilepsy, 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times daily on day 3 or initially 300 mg 3 times daily on day 1; then increased according to response in steps of 300 mg (in 3 divided doses) every 2–3 days; usual dose 0.9–3.6 g daily in 3 divided doses; CHILD 6–12 years (adjunctive therapy only) initially 10–15 mg/kg (max. 300 mg) once daily, then increased according to response over 3 days to usual dose 25–35 mg/kg daily in 3 divided doses; max. 50 mg/kg daily in 3 divided doses; CHILD 2–6 years see BNF for Children

• Neuropathic pain, ADULT over 18 years, 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times daily on day 3 or initially 300 mg 3 times daily on day 1, then increased according to response in steps of 300 mg (in 3 divided doses) every 2–3 days up to max. 3.6 g daily

• Migraine prophylaxis [unlicensed], initially 300 mg daily, increased according to response up to 2.4 g daily in divided doses

Gabapentin (non-proprietary) (BNF)

Capsules, gabapentin 100 mg, net price 100-cap pack = £3.57; 300 mg, 100-cap pack = £8.83; 400 mg, 100-cap pack = £5.53. Label: 3, 5, 8, counselling, driving (see notes above)

Tablets, gabapentin 600 mg, net price 100-tab pack = £24.85; 800 mg, 100-tab pack = £36.42. Label: 3, 5, 8, counselling, driving (see notes above)

Neurontin® (Pfizer) (BNF)

Capsules, gabapentin 100 mg (white), net price 100-cap pack = £18.29; 300 mg (yellow), 100-cap pack = £42.40; 400 mg (orange), 100-cap pack = £49.06. Label: 3, 5, 8, counselling, driving (see notes above)

Tablets, 5/c, gabapentin 600 mg, net price 100-tab pack = £84.80; 800 mg, 100-tab pack = £98.13. Label: 3, 5, 8, counselling, driving (see notes above)

Pregabalin

Indications

Peripheral and central neuropathic pain (section 4.7.3); adjunctive therapy for focal seizures with or without secondary generalisation; generalised anxiety disorder (section 4.3)

Caution

Avoid abrupt withdrawal (taper over at least 1 week); severe congestive heart failure; conditions that may precipitate encephalopathy

Renal impairment

Initially 75 mg daily and max. 300 mg daily if eGFR 30–60 mL/minute/1.73 m²; initially 25–50 mg daily and max. 150 mg daily in 1–2 divided doses if eGFR 15–30 mL/minute/1.73 m²; initially 25 mg once daily and max. 75 mg once daily if eGFR less than 15 mL/minute/1.73 m²

Pregnancy

See Pregnancy, p. 280

Breast-feeding

Present in milk in animal studies—manufacturer advises avoid; see also Breast-feeding, p. 280

Side-effects

Dry mouth, constipation, vomiting, flatulence, oedema, dizziness, drowsiness, irritability, impaired attention, disturbances in muscle control and movement, speech disorder, impaired memory, paraesthesia, euphoria, confusion, malaise, appetite changes, insomnia, weight gain, sexual dysfunction, visual disturbances (including blurred vision, diplopia, visual field defects); less commonly: abdominal distension, hypersalivation, gastro-oesophageal reflux disease, thirst, taste disturbance, flushing, hypotension, hypertension, tachycardia, syncope, first-degree AV block, dyspnoea, nasal dryness, stupor, depersonalisation, depression, abnormal dreams, hallucinations, agitation, cognitive impairment, panic
attacks, chills, hypoglycaemia, thrombocytopenia, urinary incontinence, dysuria, myalgia, arthralgia, dry eye, lacrimation, hyperacusis, nasopharyngitis, sweating, rash; rarely ascites, dysphagia, pancreatitis, weight loss, cold extremities, arthralgia, bradycardia, cough, epistaxis, rhinitis, parosmia, hyperglycaemia, renal failure, oligaemia, menstrual disturbances, breast pain, breast discharge, breast hypertrophy, neuropenia, hypokalaemia, leucopenia, rhabdomyolysis, urticaria; also reported diarrhoea, nausea, congestive heart failure, QT-interval prolongation, aggression, headache, convulsions, encephalopathy, urinary retention, keraotis. Stevens-Johnson syndrome, pruritus; suicidal ideation

**Dose**
- Neuropathic pain, **ADULT** over 18 years, initially 150 mg daily in 2–3 divided doses, increased if necessary after 3–7 days to 300 mg daily in 2–3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2–3 divided doses
- Epilepsy, **ADULT** over 18 years, initially 25 mg twice daily, increased at 7-day intervals in steps of 50 mg daily to 300 mg daily in 2–3 divided doses, increased further if necessary after 7 days to max 600 mg daily in 2–3 divided doses
- Generalised anxiety disorder, **ADULT** over 18 years, initially 150 mg daily in 2–3 divided doses, increased if necessary at 7-day intervals in steps of 150 mg daily; max. 600 mg daily in 2–3 divided doses

**Note** Pregabalin doses in BNF may differ from those in product literature

**Lyrica®** (Pfizer)  
Capsules, pregabalin 25 mg (white), net price 56-cap pack = £64.40; 48-cap pack = £96.60; 50 mg (white), 84-cap pack = £96.60; 75 mg (white/orange), 56-cap pack = £64.40; 100 mg (orang), 84-cap pack = £96.60; 150 mg (white), 56-cap pack = £64.40; 200 mg (orange), 84-cap pack = £96.60; 225 mg (white/orange), 56-cap pack = £64.40; 300 mg (white/orange), 56-cap pack = £64.40. Label: 3, 8, counselling, driving (see notes above)

**Lacosamide**

Lacosamide is licensed for adjunctive treatment of focal seizures with or without secondary generalisation. The *Scottish Medicines Consortium* (p. 4) has advised (January 2009) that lacosamide *(Vimpat®)* is accepted for restricted use within NHS Scotland as adjunctive treatment for focal seizures with or without secondary generalisation in patients from 16 years. It is restricted for specialist use in refractory epilepsy.

**LACOSAMIDE**

**Indications** see notes above

**Cautions** risk of PR-interval prolongation (including conduction problems, severe cardiac disease, and concomitant use of drugs that prolong PR interval), elderly; **interactions:** Appendix 1 (lacosamide)

**Contra-indications** second- or third-degree AV block

**Hepatic impairment** caution in severe impairment—no information available

**Renal impairment** titrate dose with caution; max. 250 mg daily if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies; see also Breast-feeding, p. 280

**Side-effects** nausea, vomiting, constipation, flatulence, dizziness, headache, impaired coordination, cognitive disorder, drowsiness, tremor, depression, fatigue, abnormal gait, blurred vision, nystagmus, pruritus; also reported dysuria, dry mouth, first-degree AV block, bradycardia, PR-interval prolongation, confusion, hypothesia, dysarthria, irritability, muscle spasm, tinnitus, rash; suicidal ideation

**Dose**
- By intravenous infusion over 15–60 minutes (for up to 5 days) or by mouth, **ADULT** and **CHILD** over 16 years, initially 50 mg twice daily, increased weekly by 50 mg twice daily; max. 200 mg twice daily

**Vimpat®** (UCB Pharma)  
Tablets, f/c, lacosamide 50 mg (pink), net price 14-tab pack = £10.81; 100 mg (yellow), 14-tab pack = £21.62, 56-tab pack = £56.50; 150 mg (pink), 14-tab pack = £32.44, 56-tab pack = £129.74; 200 mg (blue), 56-tab pack = £144.16. Label: 8, counselling, driving (see notes above)

**Syrup**, lacosamide 15 mg/mL, net price 200 mL = £38.61. Label: 8, counselling, driving (see notes above)

**Electrolytes** Na⁺ 0.4 mmol/5 mL

**Excipients** include aspartame (section 9.4.1)

**Intravenous infusion**, lacosamide 10 mg/mL, net price 200-mg vial = £29.70

**Electrolytes** Na⁺ 2.6 mmol/vial

**4.8.1 Control of the epilepsies**

**Breast-feeding**

**Lamotrigine**

Lamotrigine is an antiepileptic for focal seizures and primary and secondary generalised tonic-clonic seizures. It is also licensed for typical absence seizures in children (but efficacy may not be maintained in all children). Lamotrigine may cause serious rashes especially in children; dose recommendations should be adhered to closely.

Lamotrigine is used either as sole treatment or as an adjunct to treatment with other antiepileptic drugs. Valproate increases plasma-lamotrigine concentration, whereas the enzyme-inducing antiepileptics reduce it; care is therefore required in choosing the appropriate initial dose and subsequent titration. When the potential for interaction is not known, treatment should be initiated with lower doses, such as those used with valproate.

**LAMOTRIGINE**

**Indications** monotherapy and adjunctive treatment of focal seizures and generalised seizures including tonic-clonic seizures; seizures associated with Lennox-Gastaut syndrome; monotherapy of typical absence seizures in children; prevention of depressive episodes associated with bipolar disorder

**Cautions** closely monitor and consider withdrawal if rash, fever, or other signs of hypersensitivity syndrome develop; avoid abrupt withdrawal (taper off over 2 weeks or longer) unless serious skin reaction occurs; myoclonic seizures (may be exacerbated); Parkinson’s disease (may be exacerbated); **interactions:** see p. 279 and Appendix 1 (lamotrigine)

**Blood disorders** be alert for symptoms and signs suggestive of bone-marrow failure such as anaemia, bruising, or
infection. Aplastic anemia, bone-marrow depression and pancytopenia have been associated rarely with lamotrigine

Hepatic impairment halve dose in moderate impairment, quarter dose in severe impairment

Renal impairment caution in renal failure; metabolite may accumulate; consider reducing maintenance dose in significant impairment

Pregnancy see Pregnancy, p. 280

Breast-feeding present in milk but limited data suggest no harmful effects on infants; see also Breast-feeding, p. 280

Side-effects nausea, vomiting, diarrhoea, dry mouth, aggression, agitation, headache, drowsiness, dizziness, tremor, insomnia, ataxia, back pain, arthralgia, nystagmus, diplopia, blurred vision, rash (see Skin Reactions, below); rarely conjunctivitis, very rarely hepatic failure, aseptic meningitis, movement disorders, unsteadiness, increase in seizure frequency, exacerbation of Parkinson’s disease, confusion, hallucination, blood disorders (including anaemia, leucopenia, thrombocytopenia, pancytopenia—see Blood Disorders, above), hypersensitivity syndrome (possibly including rash, fever, facial oedema, lymphadenopathy, hepatic dysfunction, blood disorders, disseminated intravascular coagulation, and multi-organ dysfunction), lupus erythematosus-like reactions; also reported suicidal ideation

Skin reactions Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed especially in children; most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome (see Side-effects, above) and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.

Counselling Warn patients to see their doctor immediately if rash or signs or symptoms of hypersensitivity syndrome develop

Dose Important Do not confuse the different combinations or indications; see also notes above

Note Dose titration should be repeated if restarting after an interval of more than 5 days

• Monotherapy of seizures, ADULT and CHILD over 12 years, initially 25 mg once daily for 14 days, increased to 50 mg once daily for further 14 days, then increased by max. 100 mg every 7–14 days; usual maintenance 100–200 mg daily in 1–2 divided doses (up to 500 mg daily has been required)

• Monotherapy of typical absence seizures, CHILD 2–12 years see BNF for Children

• Adjunctive therapy of seizures with valproate, ADULT and CHILD over 12 years, initially 25 mg on alternate days for 14 days then 25 mg once daily for further 14 days, thereafter increased by max. 50 mg every 7–14 days; usual maintenance, 100–200 mg daily in 1–2 divided doses; CHILD 2–12 years initially 150 micrograms/kg once daily for 14 days (those under 13 kg may receive 2 mg on alternate days for first 14 days) then 300 micrograms/kg once daily for further 14 days, thereafter increased by max. 300 micrograms/kg every 7–14 days; usual maintenance 1–5 mg/kg daily in 1–2 divided doses (max. single dose 100 mg)

• Adjunctive therapy of seizures (with enzyme inducing drugs) without valproate, ADULT and CHILD over 12 years, initially 50 mg once daily for 14 days then 50 mg twice daily for further 14 days, thereafter increased by max. 100 mg every 7–14 days; usual maintenance 200–400 mg daily in 2 divided doses (up to 700 mg daily has been required); CHILD 2–12 years initially 600 micrograms/kg daily in 2 divided doses for 14 days then 1.2 mg/kg daily in 2 divided doses for further 14 days, thereafter increased by max. 1.2 mg/kg every 7–14 days; usual maintenance 5–15 mg/kg daily in 2 divided doses (max. single dose 200 mg)

• Adjunctive therapy of seizures (without enzyme inducing drugs) without valproate, ADULT and CHILD over 12 years, initially 25 mg once daily for 14 days, increased to 50 mg once daily for further 14 days, then increased by max. 100 mg every 7–14 days; usual maintenance 100–200 mg daily in 1–2 divided doses; CHILD 2–12 years initially 300 micrograms/kg daily in 1–2 divided doses for 14 days then 600 micrograms/kg daily in 1–2 divided doses for further 14 days, thereafter increased by max. 600 micrograms/kg every 7–14 days; usual maintenance 1–10 mg/kg daily in 1–2 divided doses; max. 200 mg daily

• Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate, ADULT over 18 years, initially 25 mg once daily for 14 days, then 50 mg daily in 1–2 divided doses for further 14 days, then 100 mg daily in 1–2 divided doses for further 7 days; usual maintenance 200 mg daily in 1–2 divided doses; max. 400 mg daily

• Adjunctive therapy of bipolar disorder with valproate, ADULT over 18 years, initially 25 mg on alternate days for 14 days, then 25 mg once daily for further 14 days, then 50 mg daily in 1–2 divided doses for further 7 days; usual maintenance 100 mg daily in 1–2 divided doses; max. 200 mg daily

• Adjunctive therapy of bipolar disorder (with enzyme inducing drugs) without valproate, ADULT over 18 years, initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then 100 mg twice daily for further 7 days, then 150 mg twice daily for further 7 days; usual maintenance 200 mg twice daily

Note Patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature

Lamotrigine (Non-proprietary) ▼ (Tab)

Tablets, lamotrigine 25 mg, net price 56-tab pack = £2.25; 50 mg, 56-tab pack = £3.07; 100 mg, 56-tab pack = £4.53; 200 mg, 30-tab pack = £27.53, 56-tab pack = £7.51. Label: 8, counselling, driving (see notes above), skin reactions (see above)

Dispersible tablets, lamotrigine 5 mg, net price 28-tab pack = £2.27; 25 mg, 56-tab pack = £2.91; 100 mg, 56-tab pack = £5.86. Label: 8, 13, counselling, driving (see notes above), skin reactions (see above)

Lamictal® (GSK) ▼ (Tab)

Tablets, yellow, lamotrigine 25 mg, net price 56-tab pack = £19.61; 50 mg, 56-tab pack = £33.35; 100 mg, 56-tab pack = £57.53; 200 mg, 56-tab pack = £97.79. Label: 8, counselling, driving (see notes above), skin reactions (above)

Dispersible tablets, chewable, lamotrigine 2 mg, net price 30-tab pack = £10.45; 5 mg, 28-tab pack = £7.82; 25 mg, 56-tab pack = £19.61; 100 mg, 56-tab pack = £57.53. Label: 8, 13, counselling, driving (see notes above), skin reactions (above)
**LEVETIRACETAM**

**Indications** see notes above

**Cautions** avoid abrupt withdrawal; interactions:
- Appendix 1 (levetiracetam)
- Hepatic impairment halve dose in severe hepatic impairment if eGFR less than 60 mL/minute/1.73 m²
- Renal impairment max. 2 g daily if eGFR 50–80 mL/minute/1.73 m²; max. 1.5 g daily if eGFR 30–50 mL/minute/1.73 m²; max. 1 g daily if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** present in milk—manufacturer advises avoid; see also Breast-feeding, p. 280

**Side-effects** anorexia, weight changes, abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, cough, drowsiness, amnesia, ataxia, confusion, dizziness, headache, tremor, hyperkinesia, malaise, impaired attention, aggression, agitation, depression, insomnia, anxiety, irritability, personality disorder, thrombocytopenia, myalgia, diplopia, blurred vision, rash; also reported pancreatitis, hepatic failure, paraesthesia, confusion, psychosis, suicidal ideation, leucopenia, neutropenia, pancytopenia, alopecia, toxic epidermal necrolysis, Stevens-Johnson syndrome

**Dose**

- Monotherapy of focal seizures with or without secondary generalisation, by mouth or by intravenous infusion, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD over 6 months, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 50 mg/kg twice daily; CHILD 1–6 months, initially 7 mg/kg once daily, adjusted in steps not exceeding 7 mg/kg twice daily every 2 weeks; max. 21 mg/kg twice daily

- Adjuvant therapy of focal seizures with or without secondary generalisation, by mouth, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD over 4 years, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 30 mg/kg twice daily

- By intravenous infusion, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD over 4 years, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 50 mg/kg twice daily

- Adjuvant therapy of myoclonic seizures and tonic-clonic seizures, by mouth or by intravenous infusion, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD 12–18 years, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 30 mg/kg twice daily

- If switching from oral to intravenous therapy (because oral route temporarily unavailable), by intravenous infusion, same as established oral dose

**Note** Lefetiracetam doses in BNF may differ from those in product literature

**Keppra®** (UCB Pharma) Tablets, 1/c, levetiracetam 250 mg (blue), net price 60-tab pack = £29.70; 500 mg (yellow), 60-tab pack = £52.30; 750 mg (orange) 60-tab pack = £89.10; 1 g (white), 60-tab pack = £103.10. Label: 8

Oral solution, sugar-free, levetiracetam 100 mg/mL, net price 150 mL (with 1 mL or 3 mL syringe) = £42.60, 300 mL = £71.00. Label: 8

Concentrate for intravenous infusion, levetiracetam 100 mg/mL, net price 5-mL vial = £13.50

**Electrolytes** Na⁺ 0.83 mmol/vial

**Note** For dilution before use

---

**Phenobarbital and other barbiturates**

Phenobarbital is effective for tonic-clonic and focal seizures but may be sedative in adults and cause behavioural disturbances and hyperkinesia in children. It may be tried for atypical absence, atonic, and tonic seizures. Rebound seizures may be a problem on withdrawal. For therapeutic purposes phenobarbital and phenobarbital sodium should be considered equivalent in effect. Plasma-phenobarbital concentration for optimum response is 15–40 mg/litre (60–180 micromol/litre); however, monitoring the plasma concentration is less useful than with other drugs because tolerance occurs.

Primidone is largely converted to phenobarbital and this is probably responsible for its antiepileptic action. A low initial dose of primidone is essential, and the drug should be introduced over several weeks.

---

**PHENOBARBITAL** (Phenobarbitone)

**Indications** all forms of epilepsy except typical absence seizures; status epilepticus (section 4.8.2)

**Cautions** see notes above; elderly; debilitated; children; respiratory depression (avoid if severe); avoid abrupt withdrawal (dependence with prolonged use); history of drug or alcohol abuse; consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium; avoid in acute porphyria (section 9.8.2); interactions: see p. 279 and Appendix 1 (barbiturates)

**Hepatic impairment** may precipitate coma; avoid in severe impairment

**Renal impairment** use with caution

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** avoid if possible; drowsiness may occur; see also Breast-feeding, p. 280

**Side-effects** hepatitis, cholestasis; hypotension; respiratory depression; behavioural disturbances, nystagmus, irritability, drowsiness, lethargy, depression, ataxia, paradoxical excitement, hallucinations, impaired memory and cognition, hyperactivity particularly in the elderly and in children; osteomalacia (see Cautions); megaloblastic anaemia (may be treated with folic acid); agranulocytosis, thrombocytopenia; allergic skin reactions; very rarely Stevens-John-
Central nervous system

Phenobarbital

Phenytoin is effective for tonic-clonic and focal seizures. It has a narrow therapeutic index and the relationship between dose and plasma concentration is nonlinear; small dosage increases in some patients may produce large increases in plasma concentration with acute toxic side-effects. Similarly, a few missed doses or a small change in drug absorption may result in a marked change in plasma concentration. Monitoring of plasma concentration improves dosage adjustment. Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.

Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients. When only parenteral administration is possible, fosphenytoin (section 4.8.2), a pro-drug of phenytoin, may be convenient to give. Whereas phenytoin can be given intravenously only, fosphenytoin may also be given by intramuscular injection.

Phenytoin

Indications all forms of epilepsy except absence seizures; status epilepticus (section 4.8.2); trigeminal neuralgia if carbamazepine inappropriate (see also section 4.7.3)

Cautions cross-sensitivity reported with carbamazepine; avoid abrupt withdrawal; HLA-B*1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome); manufacturer recommends blood counts (but evidence of practical value uncertain); consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium; enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary); avoid in acute porphyria (section 9.8.2); interactions: see p. 279 and Appendix 1 (phenytoin)

Blood or skin disorders Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative)

Hepatic impairment reduce dose to avoid toxicity

Pregnancy changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction; see also Pregnancy, p. 280

Breast-feeding small amount present in milk, but not known to be harmful; see also Breast-feeding, p. 280

Side-effects nausea, vomiting, constipation, drowsiness, insomnia, transient nervousness, tremor, paraesthesia, dizziness, headache, anorexia; rarely psychosis, lupus erythematosus, arthralgia; also reported Dupuytren's contracture

Dose

• Epilepsy. ADULT and CHILD over 9 years, initially 125 mg daily at bedtime, increased by 125 mg every 3 days to 500 mg daily in 2 divided doses, then increased according to response by 250 mg every 3 days to usual maintenance 0.75–1.5 g daily in 2 divided doses; CHILD under 9 years, initially 125 mg daily at bedtime, increased by 125 mg every 3 days according to response; usual maintenance. CHILD under 2 years, 250–500 mg daily in 2 divided doses; 2–5 years, 500–750 mg daily in 2 divided doses; 5–9 years 0.75–1 g daily in 2 divided doses

• Essential tremor, initially 50 mg daily increased gradually over 2–3 weeks according to response; max. 750 mg daily

Note Monitor plasma concentrations of derived phenobarbital; optimum range as for phenobarbital.

Mysoline® (Acorus) Tablets, scored, primidone 50 mg, net price 100–tab pack = £12.60; 250 mg, 100-tab pack = £12.60. Label: 2, 8, counselling, driving (see notes above)

Phenobarbital (Non-proprietary)

By mouth, 5–8 mg/kg daily

Tablets, phenobarbital 15 mg, net price 28-tab pack = 95p; 30 mg, 28-tab pack = 96p; 60 mg, 28-tab pack = 71p. Label: 2, 8, counselling, driving (see notes above)

Note Some hospitals supply alcohol-free formulations of varying phenobarbital strengths

Injection

Section 4.8.2

PHENYTOIN

Indications all forms of epilepsy except absence seizures; status epilepticus (section 4.8.2); trigeminal neuralgia if carbamazepine inappropriate (see also section 4.7.3)

Cautions cross-sensitivity reported with carbamazepine; avoid abrupt withdrawal; HLA-B*1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome); manufacturer recommends blood counts (but evidence of practical value uncertain); consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium; enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary); avoid in acute porphyria (section 9.8.2); interactions: see p. 279 and Appendix 1 (phenytoin)

Blood or skin disorders Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative)

Hepatic impairment reduce dose to avoid toxicity

Pregnancy changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction; see also Pregnancy, p. 280

Breast-feeding small amount present in milk, but not known to be harmful; see also Breast-feeding, p. 280

Side-effects nausea, vomiting, constipation, drowsiness, insomnia, transient nervousness, tremor, paraesthesia, dizziness, headache, anorexia; rarely psychosis, lupus erythematosus, arthralgia; also reported Dupuytren's contracture

Dose

• By mouth, initially 3–4 mg/kg daily or 150–300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary (with plasma-phenytoin concentration monitoring); usual dose 200–500 mg daily (exceptionally, higher doses may be used); CHILD initially 5 mg/kg daily in 2 divided doses, usual dose range 4–8 mg/kg daily (max. 300 mg daily)

Note Plasma concentration for optimum response 10–20 mg/litre (40–80 micromol/litre)

Counselling Take preferably with or after food
Phenytoin (Non-proprietary) 

Tablets, coated, phenytoin sodium 100 mg, net price 28-tab pack = £30.00. Label: 8, counselling, administration, blood or skin disorder symptoms (see above), driving (see notes above)  

Note On the basis of single dose tests there are no clinically relevant differences in bioavailability between available phenytoin sodium tablets and capsules but there may be a pharmacokinetic basis for maintaining the same brand of phenytoin in some patients  

Epanutin® (Pfizer) 

Capsules, phenytoin sodium 25 mg (white/purple), net price 28-cap pack = 66p; 50 mg (white/pink), 28-cap pack = 67p; 100 mg (white/orange), 84-cap pack = £2.83; 300 mg (white/green), 28-cap pack = £2.83. Label: 8, counselling, administration, blood or skin disorder symptoms (see above), driving (see notes above)  

Chewable tablets (Infatabs®), yellow, scored, phenytoin 50 mg, net price 112 = £7.38. Label: 8, 24, counselling, blood or skin disorder symptoms (see above), driving (see notes above)  

Note Contain phenytoin 50 mg (as against phenytoin sodium) therefore care is needed on changing to capsules or tablets containing phenytoin sodium  

Suspension, red, phenytoin 30 mg/5 mL, net price 500 mL = £4.27. Label: 8, counselling, administration, blood or skin disorder symptoms (see above), driving (see notes above)  

Note Suspension of phenytoin 90 mg in 15 mL may be considered to be approximately equivalent in therapeutic effect to capsules or tablets containing phenytoin sodium 100 mg, but nevertheless care is needed in making changes

4.8.1 Control of the epilepsies

Rufinamide

Rufinamide is licensed for the adjunctive treatment of seizures in Lennox-Gastaut syndrome. The Scottish Medicines Consortium (p. 4) has advised (October 2008) that rufinamide (Inovelon®) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years and above. It is restricted for use when alternative traditional antiepileptic drugs are unsatisfactory.

Indications see notes above  

Cautions closely monitor and consider withdrawal if rash, fever, or other signs of hypersensitivity syndrome develop; avoid abrupt withdrawal; interactions: see p. 279 and Appendix 1 (rufinamide)  

Hepatic impairment caution and careful dose titration in mild to moderate impairment; avoid in severe impairment  

Pregnancy see Pregnancy, p. 280  

Breast-feeding manufacturer advises avoid—no information available; see also Breast-feeding, p. 280  

Side-effects nausea, vomiting, constipation, diarrhoea, dyspepsia, abdominal pain, weight loss, anaemia, rhabdomyolysis, dizziness, headache, drowsiness, insomnia, anxiety, fatigue, increase in seizure frequency, impaired coordination, hyperactivity, tremor, gait disturbances; influenza-like symptoms; oligomenorrhea; back pain; myalgia, diaphorosis, blurred vision; rash and acne; hypersensitivity syndrome (possibly including rash, fever, lymphade-nopathy, hepatic dysfunction, haematuria, and multi-organ dysfunction) also reported

Hypersensitivity syndrome Serious hypersensitivity syndrome (see Side-effects) has developed, especially in children and upon initiation of therapy; consider withdrawal if rash or signs of hypersensitivity syndrome develop  

Counselling Warn patients to seek immediate medical attention if signs or symptoms of hypersensitivity develop

Dose

- ADULT and CHILD over 4 years body-weight over 30 kg, initially 200 mg twice daily increased according to response in steps of 200 mg twice daily at intervals of not less than 2 days; body-weight 30–50 kg max. 900 mg twice daily; body-weight 50–70 kg max. 1.2 g twice daily; body-weight over 70 kg max. 1.6 g twice daily; CHILD over 4 years body-weight less than 30 kg, initially 100 mg twice daily increased according to response in steps of 100 mg twice daily at intervals of not less than 2 days; max. 500 mg twice daily (max. 300 mg twice daily if adjunctive therapy with valproate)  

Inovelon® (Eisai) Tablets, pink, f/c, scored, rufinamide 100 mg, net price10-tab pack = £5.15; 200 mg, 60-tab pack = £61.77; 400 mg, 60-tab pack = £102.96. Label: 21, counselling, driving (see notes above), hypersensitivity syndrome (see above)

Tiagabine

Tiagabine is used as adjunctive treatment for focal seizures with or without secondary generalisation that are not satisfactorily controlled by other antiepileptics.

Indications see notes above  

Cautions avoid in acute porphyria (section 9.8.2); avoid abrupt withdrawal; interactions: Appendix 1 (tiagabine)  

Driving May impair performance of skilled tasks (e.g. driving)  

Hepatic impairment maintenance dose 5–10 mg 1–2 times daily initially in mild to moderate impairment; avoid in severe impairment  

Pregnancy see Pregnancy, p. 280  

Breast-feeding manufacturer advises use only if potential benefit outweighs risk; see also Breast-feeding, p. 280  

Side-effects diarrhoea; dizziness, tiredness, nervousness, tremor, impeded concentration, emotional lability, speech impairment; rarely confusion, depression, drowsiness, psychosis, non-convulsive status epilepticus, bruising, and visual disturbances; suicidal ideation; leucopenia also reported

Dose

- Adjunctive therapy, ADULT and CHILD over 12 years, with enzyme-inducing drugs, 5 mg twice daily for 1 week, then increased at weekly intervals in steps of 5–10 mg daily; usual maintenance dose 30–45 mg daily (doses above 30 mg given in 5 divided doses); in patients receiving non-enzyme-inducing drugs, initial maintenance dose 15–30 mg daily
Topiramate
Topiramate can be given alone or as adjunctive treatment in generalised tonic-clonic seizures or focal seizures with or without secondary generalisation. It can be used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome. Topiramate is also licensed for prophylaxis of migraine (section 4.7.4.2).

**Indications** see notes above

**Cautions** avoid abrupt withdrawal; risk of metabolic acidosis; risk of nephrolithiasis—ensure adequate hydration (especially in strenuous activity or warm environment); avoid in acute porphyria (section 9.8.2);

**interactions:** see p. 279 and Appendix 1 (topiramate)

**Important** Topiramate has been associated with acute myopia with secondary angle-closure glaucoma, typically occurring within 1 month of starting treatment. Choroidal effusions resulting in anterior displacement of the lens and iris have also been reported. If raised intra-ocular pressure occurs:

- seek specialist ophthalmological advice;
- use appropriate measures to reduce intra-ocular pressure;
- stop topiramate as rapidly as feasible

**Hepatic impairment** use with caution in moderate to severe impairment—clearance may be reduced

**Renal impairment** use with caution if eGFR less than 60 mL/minute/1.73 m²—reduced clearance and longer time to steady-state plasma concentration

**Pregnancy** see Pregnancy, p. 280

**Breastfeeding** manufacturer advises avoid—present in milk; see also Breast-feeding, p. 280

**Side-effects** nausea, diarrhoea, vomiting, constipation, myopia, abdominal pain, dry mouth, taste disturbance, gastritis, appetite changes, dry eye, photophobia, blepharospasm, increased lacrimation, mydriasis, hearing loss, reduced sweating, skin discoloration; rarely Raynaud’s syndrome, periorbital oedema, unilateral blindness, Stevens-Johnson syndrome, abnormal skin odour, calcinosis; very rarely angle-closure glaucoma; also reported maculopathy, toxic epidermal necrolysis

**Dose**

- Monotherapy, initially 25 mg at night for 1 week then increased in steps of 25–50 mg taken in 2 divided doses at intervals of 1–2 weeks; usual dose 100–200 mg daily in 2 divided doses, adjusted according to response; max. 500 mg daily (doses of 1 g daily have been used in refractory epilepsy); CHILD 6–18 years, initially 0.5–1 mg/kg (max. 25 mg) at night for 1 week then increased in steps of 0.5–1 mg/kg taken in 2 divided doses at intervals of 1–2 weeks; initial target dose 100 mg daily in 2 divided doses; max. 15 mg/kg (max. 500 mg) daily

- Adjunctive therapy, initially 25–50 mg at night for 1 week then increased in steps of 25–50 mg taken in 2 divided doses at intervals of 1–2 weeks; usual dose 200–400 mg daily in 2 divided doses; max. 400 mg daily; CHILD 2–18 years, initially 1–3 mg/kg (max. 25 mg) at night for 1 week then increased in steps of 1–3 mg/kg (max. 50 mg) taken in 2 divided doses at intervals of 1–2 weeks; usual dose 5–9 mg/kg daily in 2 divided doses; max. 15 mg/kg (max. 400 mg) daily

- Migraine prophylaxis, ADULT, initially 25 mg daily at night for 1 week then increased in steps of 25 mg at intervals of 1 week; usual dose 50–100 mg daily in 2 divided doses; max. 200 mg daily

**Topiramate (Non-proprietary)**

**Tablets**, topiramate 25 mg, net price 60-tab pack = £6.17; 50 mg, 60-tab pack = £10.74; 100 mg, 60-tab pack = £12.52; 200 mg, 60-tab pack = £17.21. Label: 3, 8, counselling, driving (see notes above)

**Capsules**, topiramate 15 mg, net price 60-cap pack = £16.61; 25 mg, 60-cap pack = £24.91; 50 mg, 60-cap pack = £40.93. Label: 3, 8, counselling, driving (see notes above)

**Topamax® (Janssen-Cilag)**

**Tablets**, f/c, topiramate 25 mg, net price 60-tab pack = £19.29; 50 mg (light yellow), 60-tab pack = £31.69; 100 mg (yellow), 60-tab pack = £56.76; 200 mg (salmon), 60-tab pack = £110.23. Label: 3, 8, counselling, driving (see notes above)

**Capsules** (Sprinkle®), topiramate 15 mg, net price 60-cap pack = £14.79; 25 mg, 60-cap pack = £22.18; 50 mg, 60-cap pack = £36.45. Label: 3, 8, counselling, administration, driving (see notes above)

**Counselling** Swallow whole or sprinkle contents of capsule on soft food and swallow immediately without chewing

**Valproate**

Sodium valproate is effective in controlling tonic-clonic seizures, particularly in primary generalised epilepsy. It is a drug of choice in primary generalised epilepsy, generalised absences and myoclonic seizures, and can be tried in atypical absence, tonic, and tonic seizures. Sodium valproate has widespread metabolic effects and monitoring is essential (see Cautions below).

**Valproic acid** (as semisodium valproate) (section 4.2.3) is licensed for acute mania associated with bipolar disorder.
SODIUM VALPROATE

**Indications**  all forms of epilepsy; migraine prophylaxis [unlicensed] (section 4.7.4.2).

**Cautions**  monitor liver function before therapy and during first 6 months especially in patients most at risk (see also below); measure full blood count and ensure no undue potential for bleeding before starting and before surgery; systemic lupus erythematosus; false-positive urine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium; interactions: see p. 279 and Appendix 1 (valproate).

**Liver toxicity**  Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities).

**Blood or hepatic disorders**  Patients or their carers should be told how to recognise signs and symptoms of blood or liver disorders and advised to seek immediate medical attention if symptoms develop.

**Pancreatitis**  Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek immediate medical attention if symptoms such as abdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed.

**Contra-indications**  family history of severe hepatic dysfunction; acute porphyria (section 9.8.2).

**Hepatic impairment**  avoid if possible—haptototoxicity and hepatic failure may occasionally occur (usually in first 6 months); avoid in active liver disease; see also under Cautions.

**Renal impairment**  reduce dose; adjust dosage according to free serum-valproic acid concentration.

**Pregnancy**  see Pregnancy, p. 280; neonatal bleeding (related to hyophosphinemia) and neonatal hepatotoxicity also reported.

**Breast-feeding**  amount too small to be harmful; see also Breast-feeding, p. 280.

**Side-effects**  nausea, gastric irritation, diarrhoea; weight gain; hyperammonaemia, thyrocytopenia; transient hair loss (regrowth may be curly); less frequently increased alertness, aggression, hyperactivity, behavioural disturbances, ataxia, tremor, and vasculitis; rarely hepatic dysfunction (see under Cautions); withdrawal treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control), lethargy, drowsiness, confusion, stupor, hallucinations, blood disorders (including anaemia, leucopenia, pancytopenia), hearing loss, and rash; very rarely pancreatitis (see under Cautions); peripheral oedema, increase in bleeding time, extrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia, Fanconi's syndrome, hirsutism, acne, enuresis, hypoprolactinaemia, toxic epidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation; reduced bone mineral density (see Cautions); also reported menstrual disturbances.

**Dose**

- **Epilepsy, by mouth**  initially 600 mg daily in 1–2 divided doses, increased by 200 mg daily every 3 days; usual maintenance dose 1–2 g daily (20–30 mg/kg daily), max. 2.5 g daily; **CHILD** body-weight up to 20 kg, initially 20 mg/kg daily in 1–2 divided doses, increased according to response (dose above 40 mg/kg daily monitor clinical chemistry and haematological parameters); **CHILD** under 12 years body-weight over 20 kg, initially 400 mg daily in 1–2 divided doses increased according to response; usual maintenance dose 20–30 mg/kg daily, max. 35 mg/kg daily.

- **Initiation of valproate treatment, by intravenous injection**  (over 3–5 minutes), up to 10 mg/kg (usually 400–800 mg) followed by **intravenous infusion** up to max. 2.5 g daily; **CHILD** under 12 years, usually 20–30 mg/kg daily, increased according to response (dose above 40 mg/kg daily monitor clinical chemistry and haematological parameters).

Continuation of valproate treatment by **intravenous injection**  (over 3–5 minutes) in 2 divided doses or by **intravenous infusion**, same as established oral dose.

- **Migraine prophylaxis** [unlicensed], by mouth, initially 200 mg twice daily, increased if necessary to 1.2–1.5 g daily in divided doses.

### Oral

**Sodium Valproate**  (Non-proprietary)

- **Tablets** (crushable, scored, sodium valproate 100 mg, net price 100-tab pack = £5.60. Label: 8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

- **Tablets**, e/c, sodium valproate 200 mg, net price 100-tab pack = £4.85, 500 mg, 100-tab pack = £10.09. Label: 5, 8, 25, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

**Brands include**  Orilix®

- **Oral solution**, sodium valproate 200 mg/5 mL, net price 300 mL = £5.42. Label: 8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

**Brands include**  Orilix®  (sugar-free).

**Epilim**  (Sanofi-Aventis)

- **Tablets** (crushable, scored, sodium valproate 100 mg, net price 100 = £5.60. Label: 8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

- **Tablets**, e/c, iliac, sodium valproate 200 mg, net price 100 = £7.70, 500 mg, 100 = £19.25. Label: 5, 8, 25, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

**Liquid**, red, sugar-free, sodium valproate 200 mg/5 mL, net price 300 mL = £5.42. Label: 8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

**Epilim**, red, sodium valproate 200 mg/5 mL, net price 300-mL pack = £9.33. Label: 8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above).

**Note**  May be diluted, preferably in Syrup BP, use within 14 days.

**Modified release**

**Epilim Chrono**  (Sanofi-Aventis)

- **Tablets**, m/t, iliac, sodium valproate 200 mg (as sodium valproate and valproic acid), net price 100-tab pack = £11.65, 300 mg, 100-tab pack = £17.47, 500 mg, 100-tab pack = £29.10. Label: 8, 21, 25,
counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above)

**Dose**

**ADULT** and **CHILD** over 20 kg, as above, total daily dose given in 1–2 divided doses

### Epilim Chronosphere® (Sanofi-Aventis) (Beacon)

**Granules**, m/r, sodium valproate 50 mg (as sodium valproate and valproic acid), net price 30-sachet pack = £30.00; 100 mg, 30-sachet pack = £30.00; 250 mg, 30-sachet pack = £30.00; 500 mg, 30-sachet pack = £30.00; 750 mg, 30-sachet pack = £30.00; 1000 mg, 30-sachet pack = £30.00. Label: 8, 21, 25, counselling, administration, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above)

**Dose**

**ADULT** and **CHILD** as above to the nearest whole 50-mg sachet; total daily dose given in 1–2 divided doses

**Counselling**

Granules may be mixed with soft food or drink that is cold or at room temperature, and swallowed immediately without chewing

### Convulex® (Pharmacia) (Sanofi-Aventis)

**Capsules**, e/c, valproic acid 150 mg, net price 100-cap pack = £3.68; 300 mg, 100-cap pack = £7.35; 500 mg, 100-cap pack = £12.25. Label: 8, 21, 25, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above)

**Dose**

**ADULT** and **CHILD** over 12 years, initially 600 mg daily in 2–4 divided doses; increased by 300 mg every 3 days to max. 2.5 g daily; usual maintenance dose 1–2 g daily (30–60 mg/kg daily)

**CHILD** body-weight up to 20 kg, initially 20 mg/kg daily in 2–4 divided doses, increased according to response (dose above 60 mg/kg daily monitor clinical chemistry and haematological parameters). **CHILD** body-weight over 20 kg, initially 300 mg daily in 2–4 divided doses increased according to response

**Equivalence to sodium valproate**

Convulex® has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching

### DepoKote® (Sanofi-Aventis) (Beacon)

Section 4.2.3 (bipolar disorder)

---

**Vigabatrin**

Vigabatrin can be prescribed in combination with other antiepileptic treatment for focal epilepsy with or without secondary generalisation. It should not be prescribed unless all other appropriate drug combinations are ineffective or have not been tolerated, and it should be initiated and supervised by an appropriate specialist.

Vigabatrin can be prescribed as monotherapy in the management of infantile spasms in West’s syndrome.

About one-third of patients treated with vigabatrin have suffered visual field defects; counselling and careful monitoring for this side-effect are required (see also Visual Field Defects under Cautions below). Vigabatrin has prominent behavioural side-effects in some patients.

---

**Indications**

see notes above

**Cautions**

elderly; closely monitor neurological function; avoid sudden withdrawal (taper off over 2–4 weeks); history of psychosis, depression or behavioural problems; absence seizures (may be exacerbated); interactions: see p. 279 and Appendix 1 (vigabatrin)

**Visual field defects** Vigabatrin is associated with visual field defects. The onset of symptoms varies from 1 month to several years after starting. In most cases, visual field defects have persisted despite discontinuation, and further deterioration after discontinuation cannot be excluded. Product literature advises visual field testing before treatment and at 6-month intervals. Patients should be warned to report any new visual symptoms that develop and those with symptoms should be referred for an urgent ophthalmological opinion. Gradual withdrawal of vigabatrin should be considered.

**Contra-indications**

visual field defects

Renal impairment consider reduced dose or increased dose interval if eGFR less than 60 mL/minute/1.73 m²

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** present in milk—manufacturer advises avoid; see also Breast-feeding, p. 280

**Side-effects**

nausea, abdominal pain; oedema; drowsiness (rarely encephalopathic symptoms including marked sedation, stupor, and confusion with non-specific slow wave EEG—reduce dose or withdraw), fatigue, excitement (in children), agitation, dizziness, headache, nervousness, depression, aggression, irritability, paranoia, impaired concentration, impaired memory, tremor, paraesthesia, speech disorder, weight gain; visual field defects (see under Cautions), blurred vision, nystagmus, diplopia; less commonly ataxia, psychosis, mania, and rash; occasional increase in seizure frequency (especially if myoclonic); rarely suicidal ideation and retinal disorders (including peripheral retinal neuropathy); very rarely hepatitis, optic neuritis, and optic atrophy, also reported movement disorders in infantile spasms

**Dose**

- With current antiepileptic therapy, initially 1 g daily in single or 2 divided doses then increased according to response in steps of 500 mg at weekly intervals; usual range 2–3 g daily (max. 3 g daily); **CHILD** initially 40 mg/kg daily in single or 2 divided doses then adjusted according to body-weight 10–15 kg, 0.5–1 g daily; body-weight 15–30 kg, 1–1.5 g daily; body-weight 30–50 kg, 1.5–3 g daily; body-weight over 50 kg, 2–3 g daily
Zonisamide

Zonisamide can be used as adjunctive treatment for refractory focal seizures with or without secondary generalisation.

**ZONISAMIDE**

**Indications** see notes above

**Cautions** elderly; ensure adequate hydration (especially if predisposition to nephrolithiasis or in strenuous activity or warm environment); concomitant use of drugs that increase risk of hyperthermia or nephrolithiasis; metabolic acidosis (consider dose reduction or discontinuation); avoid abrupt withdrawal; **interactions:** see p. 279 and Appendix 1 (zonisamide)

**Contra-indications** hypersensitivity to sulfonamides

**Hepatic impairment** initially increase dose at 2-week intervals if mild or moderate impairment; avoid in severe impairment

**Renal impairment** initially increase dose at 2-week intervals; discontinue if renal function deteriorates

**Pregnancy** see Pregnancy, p. 280

**Breast-feeding** manufacturer advises avoid for 4 weeks after administration; see also Breast-feeding, p. 280

**Side-effects** nausea, diarrhoea, abdominal pain, constipation, dyspepsia, anorexia, weight loss; drowsiness, dizziness, confusion, agitation, irritability, depression, psychosis, ataxia, speech disorder, impaired memory and attention, fatigue, myasthenia, paraesthesia, tremor, pyrexia, insomnia; diplopia; ecchymosis; rash (consider withdrawal); less commonly vomiting, cholelithiasis, cholecystitis, agression, suicidal ideation, seizures, pneumonia, urinary tract infection, urinary calculus, and hypokalaemia; very rarely hepatitis, pancreatitis, aspiration, dyspnoea, hallucinations, amnesia, coma, myasthenic syndrome, neuromuscular malignant syndrome, heat stroke, hyponatraemia, renal failure, metabolic acidosis, renal tubular acidosis, blood disorders, rhabdomyolysis, impaired sweating, pruritus, Stevens-Johnson syndrome, and toxic epidermal necrolysis

**Dose**

- **ADULT** over 18 years, initially 50 mg daily in 2 divided doses, increased after 7 days to 100 mg daily in 2 divided doses; then increase if necessary by 100 mg every 7 days; usual maintenance 300–500 mg daily in 1–2 divided doses

4.8.1 Control of the epilepsies

**Zonegran** (Eisai) ▼ (TM)

Capsules, zonisamide 25 mg (white), net price 14-cap pack = £8.82; 50 mg (white/grey), 56-cap pack = £47.04; 100 mg (white/red), 56-cap pack = £62.72. Label: 3

**Benzodiazepines**

Clobazam may be used as adjunctive therapy in the treatment of epilepsy. **Clonazepam** is occasionally used in tonic-clonic or focal seizures, but its sedative side-effects may be prominent.

The effectiveness of clobazam and clonazepam may decrease significantly after weeks or months of continuous therapy.

**CLOBAZAM**

**Indications** adjunct in epilepsy; anxiety (short-term use)

**Cautions** see Diazepam, section 4.1.2

**Contra-indications** see Diazepam, section 4.1.2

**Hepatic impairment** see Benzodiazepines, section 4.1.2

**Renal impairment** see Benzodiazepines, section 4.1.2

**Pregnancy** see Benzodiazepines, section 4.1.2

**Breast-feeding** see Benzodiazepines, section 4.1.2

**Side-effects** see Diazepam, section 4.1.2

**Dose**

- Epilepsy, 20–30 mg daily; max. 60 mg daily; **CHILD** over 3 years, not more than half adult dose
- Anxiety, 20–30 mg daily in divided doses or as a single dose at bedtime, increased in severe anxiety (in hospital patients) to a max. of 60 mg daily in divided doses; **ELDERLY** (or debilitated) 10–20 mg daily

1. Clobazam (Non-proprietary) ▼ (TM)

**Tablets**, clobazam 10 mg. Net price 30-tab pack = £4.68. Label: 2 or 19, 8, counselling, driving (see notes above)

Brands include: **Frisium** ▼ (TM)

1. ▼ except for epilepsy and endorsed ‘SLS’

**CLONAZEPAM**

**Indications** all forms of epilepsy; myoclonus; status epilepticus (section 4.8.2)

**Cautions** see notes above; elderly and debilitated, respiratory disease, spinal or cerebellar ataxia; history of alcohol or drug abuse, depression or suicidal ideation; avoid sudden withdrawal; myasthenia gravis (avoid if unstable); acute porphyria (section 9.8.2); **interactions:** Appendix 1 (anxiolytics and hypnotics)

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** respiratory depression; acute pulmonary insufficiency; sleep apnoea syndrome; marked neuromuscular respiratory weakness including unstable myasthenia gravis

**Hepatic impairment** see Benzodiazepines, section 4.1.2

**Renal impairment** see Benzodiazepines, section 4.1.2

**Pregnancy** see Benzodiazepines, section 4.1.2

**Breast-feeding** see Benzodiazepines, section 4.1.2
Central nervous system

4.8.2 Drugs used in status epilepticus

**Side-effects** drowsiness, fatigue, dizziness, muscle hypotonia, co-ordination disturbances; also poor concentration, restlessness, confusion, amnesia, dependence, and withdrawal; salivary or bronchial hypersecretion in infants and small children; rarely gastro-intestinal symptoms, respiratory depression, headache, paradoxical effects including aggression and anxiety, sexual dysfunction, urinary incontinence, urticaria, pruritus, reversible hair loss, skin pigmentation changes; dysartha, and visual disturbances on long-term treatment; blood disorders reported; suicidal ideation; **overdose** see Emergency Treatment of Poisoning, p. 37

**Dose**
- 1 mg (Elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2–4 weeks to usual maintenance dose of 4–8 mg usually at night (may be given in 3–4 divided doses if necessary);
- Child up to 1 year, initially 250 micrograms increased as above to usual maintenance dose of 0.5–1 mg; 1–5 years, initially 250 micrograms increased as above to 1–3 mg; 5–12 years, initially 500 micrograms increased as above to 3–6 mg

**Note** Clonazepam doses in BNF may differ from those in product literature

**Rivotril** (Roche) 2 mg

**Tablets**, both scored, clonazepam 500 micrograms (beige), net price 100-tab pack = £3.69; 2 mg (white), 100-tab pack = £4.93. Label: 2, 8, counselling, driving (see notes above)

**Injection**, section 4.8.2

**Other drugs**

**Acetazolamide** (section 11.6), a carbonic anhydrase inhibitor, has a specific role in treating epilepsy associated with menstruation. It can also be used with other antiepileptics for refractory tonic-clonic, absence, and focal seizures. It is occasionally helpful in atypical absence, atomic, and tonic seizures.

**Piracetam** (section 4.9.3) is used as adjunctive treatment for cortical myoclonus.

4.8.2 Drugs used in status epilepticus

**Convulsive status epilepticus** Immediate measures to manage status epilepticus include positioning the patient to avoid injury, supporting respiration including the provision of oxygen, maintaining blood pressure, and the correction of any hypoglycaemia. Parenteral thiamine should be considered if alcohol abuse is suspected. **Pyridoxine** (section 9.6.2) should be given if the status epilepticus is caused by pyridoxine deficiency.

Convulsive status epilepticus should be treated urgently with intravenous clonazepam, repeated once after 10 minutes if seizures recur or fail to respond. Intravenous diazepam is effective but it carries a high risk of thrombophlebitis (reduced by using an emulsion formulation). Absorption of diazepam from intramuscular injection or from suppositories is too slow for treatment of status epilepticus. Clonazepam can also be used as an alternative.

Where facilities for resuscitation are not immediately available, **diazepam** can be administered as a rectal solution or **midazolam** [unlicensed use] can be given into the buccal cavity.

**Important**

If, after initial treatment with benzodiazepines, seizures recur or fail to respond 20 minutes after onset, phenytoin sodium, fosphenytoin, or phenobarbital sodium should be used; contact intensive care unit if seizures continue at 30 minutes after onset. If these measures fail to control seizures 40 minutes after onset, anaesthesia with thiopental (section 15.1.1), midazolam (section 15.1.4), or in adults, a non-barbiturate anaesthetic such as propofol [unlicensed indication] (section 15.1.1), should be instituted with full intensive care support.

Phenytoin sodium may be given by slow intravenous injection, followed by the maintenance dosage if appropriate; monitor ECG and blood pressure and reduce rate of administration if bradycardia or hypotension occurs. Intramuscular use of phenytoin is not recommended (absorption is slow and erratic).

Alternatively, fosphenytoin, a pro-drug of phenytoin, can be given more rapidly and when given intravenously causes fewer injection-site reactions than phenytoin. Intravenous administration requires ECG monitoring. Although it can also be given intramuscularly, absorption is too slow by this route for treatment of status epilepticus. Doses of fosphenytoin should be expressed in terms of phenytoin sodium.

**Paraldehyde** also remains a valuable drug. Given rectally it causes little respiratory depression and is therefore useful where facilities for resuscitation are poor.

For advice on the management of epileptic seizures in dental practice, see p. 27.

**Non-convulsive status epilepticus** The urgency to treat non-convulsive status epilepticus depends upon the severity of the patient’s condition. If there is incomplete loss of awareness, usual oral antiepileptic therapy should be continued or restarted. Patients who fail to respond to oral antiepileptic therapy or have complete lack of awareness can be treated in the same way as for convulsive status epilepticus, although anaesthesia is rarely needed.

**CLONAZEPAM**

**Indications** status epilepticus; other forms of epilepsy, and myoclonus (section 4.8.1)

**Cautions** see Clonazepam, section 4.8.1; facilities for reversing respiratory depression with mechanical ventilation must be at hand (but see also notes above)

**Intravenous infusion** Intravenous infusion of clonazepam is potentially hazardous (especially if prolonged), calling for close and constant observation and best carried out in specialist centres with intensive care facilities. Prolonged infusion may lead to accumulation and delay recovery

**Contra-indications** see Clonazepam, section 4.8.1; avoid injections containing benzyl alcohol in neonates (see under preparations below)

**Hepatic impairment** see Benzodiazepines, section 4.1.2

**Renal impairment** see Benzodiazepines, section 4.1.2
4.8.2 Drugs used in status epilepticus

Pregnancy see Benzodiazepines, section 4.1.2, and Pregnancy, p. 280
Breast-feeding see Benzodiazepines, section 4.1.2
Side-effects see Clonazepam, section 4.8.1; hypotension and apnoea

Dose
- By intravenous injection into a large vein (over at least 2 minutes) or by intravenous infusion, 1 mg, repeated if necessary; CHILD all ages, 500 micrograms

Rivotril® (Roche) \( \text{Injection, clonazepam 1 mg/mL in solvent, for dilution with 1 mL water for injections immediately before injection or as described in Appendix 6. Net price 1-mL amp (with 1 mL water for injections) = 60p. Excipients include benzyl alcohol (avoid in neonates unless there is no safer alternative available; see Excipients, p. 2), ethanol, propylene glycol} \)

Oral preparations
Section 4.8.1

DIAZEPAM

Indications status epilepticus; febrile convulsions (section 4.8.3); convulsions due to poisoning (see p. 33); other indications (section 4.1.2, section 10.2.2, and section 15.1.4.1)

Cautions see Diazepam, section 4.1.2; when given intravenously facilities for reversing respiratory depression with mechanical ventilation must be at hand (but see also notes above)

Contra-indications see Diazepam, section 4.1.2

Hepatic impairment see Benzodiazepines, section 4.1.2

Renal impairment see Benzodiazepines, section 4.1.2, and Pregnancy, p. 280

Breast-feeding see Benzodiazepines, section 4.1.2

Side-effects see Diazepam, section 4.1.2; hypotension and apnoea

Dose
- Status epilepticus (but see notes above), febrile convulsions, status epilepticus; febrile convulsions (but see notes above), see Diazepam, section 4.1.2; hypotension and apnoea

Rivotril® (Roche) \( \text{Injection, clonazepam 1 mg/mL in solvent, for dilution with 1 mL water for injections immediately before injection or as described in Appendix 6. Net price 1-mL amp (with 1 mL water for injections) = 60p. Excipients include benzyl alcohol (avoid in neonates unless there is no safer alternative available; see Excipients, p. 2), ethanol, propylene glycol} \)

Oral preparations
Section 4.8.1

DIAZEPAM

Indications status epilepticus; febrile convulsions (section 4.8.3); convulsions due to poisoning (see p. 33); other indications (section 4.1.2, section 10.2.2, and section 15.1.4.1)

Cautions see Diazepam, section 4.1.2; when given intravenously facilities for reversing respiratory depression with mechanical ventilation must be at hand (but see also notes above)

Contra-indications see Diazepam, section 4.1.2

Hepatic impairment see Benzodiazepines, section 4.1.2

Renal impairment see Benzodiazepines, section 4.1.2, and Pregnancy, p. 280

Breast-feeding see Benzodiazepines, section 4.1.2

Side-effects see Diazepam, section 4.1.2; hypotension and apnoea

Dose
- Status epilepticus, febrile convulsions, status epilepticus; febrile convulsions (but see notes above), see Diazepam, section 4.1.2; hypotension and apnoea

Rivotril® (Roche) \( \text{Injection, clonazepam 1 mg/mL in solvent, for dilution with 1 mL water for injections immediately before injection or as described in Appendix 6. Net price 1-mL amp (with 1 mL water for injections) = 60p. Excipients include benzyl alcohol (avoid in neonates unless there is no safer alternative available; see Excipients, p. 2), ethanol, propylene glycol} \)

Oral preparations
Section 4.8.1

DIAZEPAM

Indications status epilepticus; febrile convulsions (section 4.8.3); convulsions due to poisoning (see p. 33); other indications (section 4.1.2, section 10.2.2, and section 15.1.4.1)

Cautions see Diazepam, section 4.1.2; when given intravenously facilities for reversing respiratory depression with mechanical ventilation must be at hand (but see also notes above)

Contra-indications see Diazepam, section 4.1.2

Hepatic impairment see Benzodiazepines, section 4.1.2

Renal impairment see Benzodiazepines, section 4.1.2, and Pregnancy, p. 280

Breast-feeding see Benzodiazepines, section 4.1.2

Side-effects see Diazepam, section 4.1.2; hypotension and apnoea

Dose
- Status epilepticus, febrile convulsions, status epilepticus; febrile convulsions (but see notes above), see Diazepam, section 4.1.2; hypotension and apnoea

Rivotril® (Roche) \( \text{Injection, clonazepam 1 mg/mL in solvent, for dilution with 1 mL water for injections immediately before injection or as described in Appendix 6. Net price 1-mL amp (with 1 mL water for injections) = 60p. Excipients include benzyl alcohol (avoid in neonates unless there is no safer alternative available; see Excipients, p. 2), ethanol, propylene glycol} \)
4.8.2 Drugs used in status epilepticus

Midazolam (Non-proprietary) (C)
Buccal liquid, midazolam 10 mg/mL.
Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

Injections
Section 15.1.4

Paraldehyde (Non-proprietary) (C)
Enema, 8–50%, available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

Phenobarbital Sodiu
m
(Phenobarbitalone sodiu
m)

Indications status epilepticus; other forms of epilepsy except absence seizures (section 4.8.1)

Cautions see Phenobarbital, section 4.8.1; interactions: see p. 279 and Appendix 1 (phenobarbital)

Hepatic impairment see Phenobarbital, section 4.8.1

Renal impairment see Phenobarbital, section 4.8.1

Pregnancy see Phenobarbital, section 4.8.1

Breast-feeding see Phenobarbital, section 4.8.1

Side-effects see Phenobarbital, section 4.8.1

Dose

● Status epilepticus, by intravenous injection (dilute injection 1 in 10 with water for injections), 10 mg/kg at a rate of not more than 100 mg/minute; max. 1 g

Note For therapeutic purposes phenobarbital and phenobarbital sodium may be considered equivalent in effect

Phenobarbital (Non-proprietary) (C)
Injection, phenobarbital sodium 200 mg/mL, net price 1-mL amp = £2.00

Excipients include propylene glycol 90% (see Excipients, p. 2)

Note Must be diluted before intravenous administration (see under Dose)

Oral preparations
Section 4.8.1

Note

Pro-Epanutin

Fosphenytoin sodium doses in BNF may differ from those in product literature

Note

ELDERLY consider 10–25% reduction in dose or infusion rate

Note

Fosphenytoin sodium doses in BNF may differ from those in product literature

Note
4.8.3 Febrile convulsions

Brief febrile convulsions need no specific treatment; antipyretic medication, e.g. paracetamol (section 4.7.1) is commonly used to reduce fever and prevent further convulsions but evidence to support this practice is lacking. Prolonged febrile convulsions (those lasting 5 minutes or longer), recurrent convulsions, or those occurring in a child at known risk must be treated more actively, as there is the possibility of resulting brain damage. Diazepam is the drug of choice given either by slow intravenous injection or preferably rectally in solution (section 4.8.2). The rectal route is preferred as satisfactory absorption is achieved within minutes and administration is much easier. Suppositories are not suitable because absorption is too slow. Intermittent prophylaxis (i.e. the anticonvulsant administered at the onset of fever) is possible in only a small proportion of children. Again, diazepam is the treatment of choice, orally or rectally.

Long-term anticonvulsant prophylaxis for febrile convulsions is rarely indicated. Anticonvulsant treatment needs to be considered only for children at risk from prolonged or complex febrile convulsions, including those whose first seizure occurred at under 14 months or who have neurological abnormalities or who have had previous prolonged or focal convulsions.
Elderly Antiparkinsonian drugs can cause confusion in the elderly. It is particularly important to initiate treatment with low doses and to increase the dose gradually.

4.9.1 Dopaminergic drugs used in Parkinson’s disease

**Dopamine-receptor agonists**

The dopamine-receptor agonists, bromocriptine, cabergoline, pergolide, pramipexole, ropinirole, and rotigotine have a direct action on dopamine receptors. Initial treatment of Parkinson’s disease is often with dopamine-receptor agonists. They are also used with levodopa in more advanced disease. If a dopamine-receptor agonist is added to levodopa therapy, the dose of levodopa needs to be reduced (see individual monographs).

When used alone, dopamine-receptor agonists cause fewer motor complications in long-term treatment compared with levodopa treatment but the overall motor performance improves slightly less. The dopamine-receptor agonists are associated with more psychiatric side-effects than levodopa. The ergot-derived dopamine-receptor agonists bromocriptine, cabergoline, and pergolide, are associated with fibrotic reactions (see notes below). Patients should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped recurring.

Apo morphine is a potent dopamine-receptor agonist that is sometimes helpful in advanced disease for patients experiencing unpredictable ‘off’ periods with levodopa treatment. Apomorphine should be initiated in a specialist clinic with at least two days pretreatment with domperidone (p. 253) for nausea and vomiting. After an overnight withdrawal of oral antiparkinsonian medication to induce an ‘off’ episode, the threshold dose of apomorphine is determined. Oral antiparkinsonian medication is then restarted. The patient must be taught to self-administer apomorphine by subcutaneous injection into the lower abdomen or outer thigh at the first sign of an ‘off’ episode. Once treatment has been established it may be possible to gradually reduce other antiparkinsonian medications and reduce or withdraw domperidone therapy. Treatment with apomorphine should remain under specialist supervision.

Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

**Fibrotic reactions**

Ergot-derived dopamine-receptor agonists, bromocriptine, cabergoline, and pergolide, have been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson’s disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline or pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).

**Driving**

**Sudden onset of sleep** Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and dopamine-receptor agonists.

- Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped recurring.
- Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication that can disturb sleep. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**APOMORPHINE HYDROCHLORIDE**

**Indications** refractory motor fluctuations in Parkinson’s disease (‘off’ episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (for capable and motivated patients under specialist supervision)

**Cautions** see notes above; pulmonary disease, cardiovascular disease, history of postural hypotension (special care on initiation); susceptibility to QT-interval prolongation; neuropsychiatric conditions; monitor hepatic, haemopoietic, renal, and cardiovascular function; with concomitant levodopa test initially and every 6 months for haemolytic anaemia and thrombocytopenia (development calls for specialist haematological care with dose reduction and possible discontinuation); **interactions:** Appendix 1 (apomorphine)

**Contra-indications** respiratory depression, dementia, hypersensitivity to opioids, psychosis; avoid if ‘on’
response to levodopa marred by severe dyskinesia or dystonia

**Hepatic impairment** avoid

**Renal impairment** use with caution

**Pregnancy** avoid unless clearly necessary

**Breast-feeding** no information available; may suppress lactation

**Side-effects** see notes above; also nausea, vomiting (see notes above); yawning; drowsiness (including sudden onset of sleep); confusion, hallucinations, less commonly postural hypotension, dyspnoea, dyskinesia during ‘off’ periods (may require discontinuation), haemolytic anaemia and thrombocytopenia with levodopa (see Cautions), and rash; rarely eosinophilia; peripheral oedema, compulsive behaviour, and dizziness also reported

**Dose**

- **By subcutaneous injection, ADULT** over 18 years, to determine threshold dose (see also notes above), initially 1 mg at the first sign of ‘off’ episode; if inadequate or no response after 30 minutes, then a further 2 mg should be given; thereafter increase dose at minimum 40-minute intervals until satisfactory response obtained; usual range 3–30 mg daily in divided doses; subcutaneous infusion may be preferable in those requiring division of injections into more than 10 doses daily; max. single dose 10 mg

- **By continuous subcutaneous infusion, ADULT** over 18 years, (those requiring division into more than 10 injections daily) initially 1 mg/hour increased according to response (not more often than every 4 hours) in max. steps of 500 micrograms/hour, to usual rate of 1–4 mg/hour (15–60 micrograms/kg/hour); change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is a 4-hour treatment-free period at night—24-hour infusions not recommended unless severe night-time symptoms); intermittent bolus boosts may be needed

  **Note** Total daily dose by either route (or combined routes) max. 100 mg

**Apomorphine (Non-proprietary)**

**Injection** apomorphine hydrochloride 10 mg/mL, net price 2-mL amp = £7.21, 5-mL amp = £13.89. Label: 10, counselling, driving, see notes above

**APO-go® (Genus)**

**Injection** apomorphine hydrochloride 10 mg/mL, net price 2-mL amp = £7.59, 5-mL amp = £14.62. Label: 10, counselling, driving, see notes above

**Excipients** include sulphites

**Injection (APO-go® Pen)**, apomorphine hydrochloride 10 mg/mL, net price 3-mL pen injector = £24.78. Label: 10, counselling, driving, see notes above

**Excipients** include sulphites

**Injection (APO-go® PFS)**, apomorphine hydrochloride 5 mg/mL, net price 10-mL prefilled syringe = £14.62. Label: 10, counselling, driving, see notes above

**Excipients** include sulphites

**BROMOCRIPTINE**

**Indications** Parkinson’s disease; endocrine disorders (Section 6.7.1)

**Cautions** see Bromocriptine in section 6.7.1 and notes above

**Contra-indications** see Bromocriptine, section 6.7.1

**Hepatic impairment** see Bromocriptine, section 6.7.1

**Pregnancy** see Bromocriptine, section 6.7.1

**Breast-feeding** see Bromocriptine, section 6.7.1

**Side-effects** see notes above and Bromocriptine, section 6.7.1

**Dose**

- First week 1–1.25 mg at night, second week 2–2.5 mg at night, third week 2.5 mg twice daily, fourth week 2.5 mg 3 times daily then increasing by 2.5 mg every 3–4 days according to response to a usual range of 10–30 mg daily; taken with food

**Preparations**

Section 6.7.1

**CABERGOLINE**

**Indications** alone or as adjunct to co-beneldopa or co-careldopa in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate; endocrine disorders (section 6.7.1)

**Cautions** see Cabergoline in section 6.7.1 and notes above

**Contra-indications** see Cabergoline, section 6.7.1

**Hepatic impairment** see Cabergoline, section 6.7.1

**Pregnancy** see Cabergoline, section 6.7.1

**Breast-feeding** see Cabergoline, section 6.7.1

**Side-effects** see notes above and Cabergoline, section 6.7.1

**Dose**

- Initially 1 mg daily, increased by increments of 0.5–1 mg at 7 or 14 day intervals; max. 3 mg daily

**Note** Concurrent dose of levodopa may be decreased gradually while dose of cabergoline is increased

**Cabergoline (Non-proprietary)**

**Tablets** scored, cabergoline 1 mg, net price 20-tab pack = £59.08; 2 mg, 20-tab pack = £71.13. Label: 10, 21, counselling, driving, see notes above

**Note** Dispense in original container (contains desiccant)

**Cabaser® (Pharmacia)**

**Tablets** scored, cabergoline 1 mg, net price 20-tab pack = £83.00; 2 mg, 20-tab pack = £83.00. Label: 10, 21, counselling, driving, see notes above

**Note** Dispense in original container (contains desiccant)

**PERGOLIDE**

**Indications** alone or as adjunct to co-beneldopa or co-careldopa in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate

**Cautions** see notes above; arrhythmias or underlying cardiac disease; history of confusion, psychosis, or hallucinations, dyskinesia (may exacerbate); acute porphyria (section 9.8.2); interactions: Appendix 1 (pergolide)

**Contra-indications** history of fibrotic disorders; cardiac valvulopathy (exclude before treatment, see Fibrotic Reactions, p. 298)

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** may suppress lactation

**Side-effects** see notes above; also nausea, vomiting, dyspepsia, abdominal pain; dyspnoea, rhinitis; hallucinations, dyskinesia, drowsiness (including sudden onset of sleep); diplopia, also reported constipation,
diarrhoea, hiccupps, tachycardia, atrial premature contractions, palpitation, hypotension, syncope, Raynaud’s phenomenon, compulsive behaviour, insomnia, confusion, dizziness, fever, erythromelalgia, and rash

**Dose**

- **Monotherapy**, 50 micrograms at night on day 1, then 50 micrograms twice daily on days 2–4, then increased by 100–250 micrograms daily every 3–4 days to 1.5 mg daily in 3 divided doses at day 28; after day 30, further increases every 3–4 days of up to 250 micrograms daily; usual maintenance dose 2.1–2.5 mg daily; max. 3 mg daily

- **Adjunctive therapy with levodopa**, 50 micrograms daily for 2 days, increased gradually by 100–150 micrograms every 3 days over next 12 days, usually given in 3 divided doses; further increases of 250 micrograms every 3 days; max. 3 mg daily; during pergolide titration levodopa dose may be reduced cautiously

**Pergolide (Non-proprietary) (p)

**Tablets**, pergolide (as mesilate) 50 micrograms, net price 100-tab pack = £17.42; 250 micrograms, 100-tab pack = £14.68; 1 mg, 100-tab pack = £41.95. Label: 10, counselling, driving, see notes above

**Celance® (Lilly) (p)

**Tablets**, scored, pergolide (as mesilate) 50 micrograms (ivory), net price 100-tab pack = £20.70; 250 micrograms (green), 100-tab pack = £21.12; 1 mg (pink), 100-tab pack = £43.44. Label: 10, counselling, driving, see notes above

**Note** Caution if splitting tablets—may cause eye irritation, nasal irritation, and headache

**Pramipexole**

**Indications** Parkinson’s disease, used alone or as an adjunct to co-beneldopa or co-careldopa; moderate to severe restless legs syndrome

**Cautions** see notes above; psychotic disorders; ophthalmological testing recommended (risk of visual disturbance); severe cardiovascular disease; risk of postural hypotension (especially on initiation)—monitor blood pressure; **interactions**: Appendix 1 (pramipexole)

**Renal impairment**

- for **immediate-release** in Parkinson’s disease, initially 88 micrograms twice daily (max. 1.57 mg daily in 2 divided doses) if eGFR 20–50 mL/minute/1.73m²; initially 88 micrograms once daily (max. 1.1 mg once daily) if eGFR less than 20 mL/minute/1.73 m²; if renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR

- for **immediate-release** in restless legs syndrome, reduce dose if eGFR less than 20 mL/minute/1.73 m²

- for **modified-release** tablets, initially 260 micrograms on alternate days if eGFR 30–50 mL/minute/1.73m², increased to 260 micrograms once daily after 1 week, further increased if necessary by 260 micrograms daily at weekly intervals to max. 1.57 mg daily; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** use only if potential benefit outweighs risk—no information available

**Breast-feeding** may suppress lactation; avoid—present in milk in animal studies

**Side-effects** see notes above; also nausea, constipation, vomiting, weight changes, hypotension (including postural hypotension), peripheral oedema, dizziness, dyskinesia, drowsiness (including sudden onset of sleep), amnesia, headache, sleep disturbances, confusion, hallucinations, restlessness, visual disturbances; less commonly syncope, pneumonia, dysphoria, compulsive behaviour, delusion, paranoia, pruritus, rash; also reported paradoxical worsening of restless legs syndrome

**Dose**

**Important** Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows:

- 88 micrograms base = 125 micrograms salt
- 180 micrograms base = 250 micrograms salt
- 350 micrograms base = 500 micrograms salt
- 700 micrograms base = 1 mg salt

- Parkinson’s disease, ADULT over 18 years, initially 88 micrograms 3 times daily, dose doubled every 5–7 days if tolerated to 350 micrograms 3 times daily; further increased if necessary by 180 micrograms 3 times daily at weekly intervals; max. 3.3 mg daily in 3 divided doses

**Note** During dose titration and maintenance, levodopa dose may be reduced

- Restless legs syndrome, ADULT over 18 years, initially 88 micrograms once daily 2–3 hours before bedtime, dose doubled every 4–7 days if necessary; max. 540 micrograms daily

**Note** Repeat dose titration if restarting treatment after an interval of more than a few days

**Mirapexin® (Boehringer Ingelheim) (p)

**Tablets**, pramipexole 88 micrograms, net price 30-tab pack = £9.55; 180 micrograms (scored), 30-tab pack = £19.10; 100-tab pack = £63.67; 350 micrograms (scored), 30-tab pack = £38.20; 100-tab pack = £127.34; 700 micrograms (scored), 30-tab pack = £76.40; 100-tab pack = £254.69. Label: 10, counselling, driving, see notes above

**Modified release**

**Mirapexin® Prolonged Release** (Boehringer Ingelheim) (p)

**Tablets**, m/r, pramipexole 260 micrograms, net price 30-tab pack = £28.65; 520 micrograms, 30-tab pack = £57.30; 1.05 mg, 30-tab pack = £114.60; 1.57 mg, 30-tab pack = £171.90; 2.1 mg, 30-tab pack = £229.20; 2.62 mg, 30-tab pack = £286.50; 3.15 mg, 30-tab pack = £343.80. Label: 10, 25, counselling, driving, see notes above

**Important** Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows:

- 260 micrograms base = 375 micrograms salt
- 520 micrograms base = 750 micrograms salt
- 1.05 mg base = 1.5 mg salt
- 1.57 mg base = 2.25 mg salt
- 2.1 mg base = 3 mg salt
- 2.62 mg base = 3.75 mg salt
- 3.15 mg base = 4.5 mg salt

**Dose** Parkinson’s disease (with or without co-beneldopa or co-careldopa), ADULT over 18 years, initially 260 micrograms once daily, dose doubled every 5–7 days to 1.05 mg once daily; further increased if necessary by 520 micrograms daily at weekly intervals; max. 3.15 mg once daily

**Note** During dose titration and maintenance, levodopa dose may be reduced
ROPINROLE

**Indications** Parkinson’s disease, either used alone or as adjunct to co-beneldopa or co-careldopa; moderate to severe restless legs syndrome

**Cautions** see notes above; severe cardiovascular disease, major psychiatric disorders; dose adjustment may be necessary if smoking started or stopped during treatment; interactions: Appendix 1 (ropinirole)

**Hepatic impairment** caution in moderate impairment; avoid in severe impairment

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** avoid unless potential benefit outweighs risk—tOXICITY in animal studies

**Breast-feeding** may suppress lactation—avoid

**Side-effects** see notes above; also nausea, vomiting, abdominal pain, dyspepsia, constipation; hypotension; syncope, peripheral oedema; drowsiness (including sudden onset of sleep, see p. 298); dizziness, nervousness, fatigue, dyskinesia, hallucinations, confusion; less commonly psychosis, compulsive behaviour; very rarely hepatic disorders; also reported paradoxical worsening of restless legs syndrome

**Dose**
- Parkinson’s disease, initially 750 micrograms daily in 3 divided doses, increased by increments of 750 micrograms at weekly intervals to 3 mg daily; further increased by increments of up to 3 mg at weekly intervals according to response; usual range 9–16 mg daily (but higher doses may be required if used with levodopa); max. 24 mg daily
- Restless legs syndrome, **ADULT** over 18 years initially 250 micrograms at night for 2 days, increased if tolerated to 500 micrograms at night for 5 days and then to 1 mg at night for 7 days; further increased at weekly intervals in steps of 500 micrograms daily according to response; usual dose 2 mg at night; max. 4 mg daily

**Note** Repeat dose titration if restarting after interval of more than a few days

**Ropinirole (Non-proprietary)**

Tablets, ropinirole (as hydrochloride) 250 micrograms, net price 12-tab pack = £2.79; 500 micrograms, 28-tab pack = £7.72; 1 mg, 84-tab pack = £27.65; 2 mg, 84-tab pack = £54.43; 5 mg, 84-tab pack = £107.55. Label: 10, 21, counselling, driving, see notes above

**Adartrel®** (GSK)

Tablets, f/c, ropinirole (as hydrochloride) 250 micrograms (white), net price 12-tab pack = £3.94; 500 micrograms (yellow), 28-tab pack = £15.75, 84-tab pack = £47.26; 2 mg (pink), 28-tab pack = £31.51, 84-tab pack = £94.53. Label: 10, 21, counselling, driving, see notes above

**Requip®** (GSK)

Tablets, f/c, ropinirole (as hydrochloride) 1 mg (green), net price 84-tab pack = £47.26; 2 mg (pink), 84-tab pack = £94.53; 5 mg (blue), 84-tab pack = £163.27; 28-day starter pack of 42 × 500-microgram (white) tablets, 42 × 500-microgram (yellow) tablets, and 21 × 1-mg (green) tablets = £40.10; 28-day follow-on pack of 42 × 500-microgram (yellow) tablets, 42 × 1-mg (green) tablets, and 63 × 2-mg (pink) tablets = £74.40. Label: 10, 21, counselling, driving, see notes above

**Modified release**

Requip® XL (GSK)

Tablets, m/r, f/c, ropinirole (as hydrochloride) 2 mg (pink), net price 28-tab pack = £31.36; 4 mg (brown), 28-tab pack = £62.72; 8 mg (red), 28-tab pack = £105.28. Label: 10, 25, counselling, driving, see notes above

Dose stable Parkinson’s disease in patients transferring from ropinirole immediate-release tablets, initially Requip® XL once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, in patients receiving less than 8 mg once daily, increase in steps of 2 mg at intervals of at least 1 week to 8 mg once daily according to response; in patients receiving 8 mg once daily or more, increase in steps of 2 mg at intervals of at least 2 weeks according to response: max. 24 mg once daily

**Note** When administered as adjunct to levodopa, concurrent dose of levodopa may be reduced

ROTIGOTINE

**Indications** Parkinson’s disease, either used alone or as adjunct to co-beneldopa or co-careldopa; moderate to severe restless legs syndrome

**Cautions** see notes above; ophthalmic testing recommended; avoid exposure of patch to heat; withdraw gradually; interactions: Appendix 1 (rotigotine)

**Hepatic impairment** caution in severe impairment—no information available

**Pregnancy** avoid—no information available

**Breast-feeding** may suppress lactation; avoid—present in milk in animal studies

**Side-effects** see notes above; also constipation, dry mouth, dyspepsia, nausea, vomiting, weight changes; hypertension, postural hypotension, palpitation, peripheral oedema; hiccup; asthma, dizziness, drowsiness (including sudden onset of sleep), sleep disturbances, dyskinesia, hallucinations, headache, syncope, sweating, rash, pruritus; less commonly abdominal pain, atrial fibrillation, hypotension, confusion, paranoia, compulsive behaviour, erectile dysfunction, and visual disturbances; rarely tachycardia, seizures, irritability, obsessive compulsive disorder, and psychotic disorder

**Dose**
- Monotherapy in Parkinson’s disease, initially apply ‘2 mg/24 hours’ patch, increased in steps of 2 mg/24 hours at weekly intervals if required; max. 8 mg/24 hours
- Adjunctive therapy with levodopa in Parkinson’s disease, initially apply ‘4 mg/24 hours’ patch, increased in steps of 2 mg/24 hours at weekly intervals if required; max. 16 mg/24 hours
- Restless legs syndrome, initially apply ‘1 mg/24 hours’ patch, increased in steps of 1 mg/24 hours at weekly intervals if required: max. 3 mg/24 hours

**Note** Apply patch to dry, non-irritated skin on torso, thigh, or upper arm, removing after 24 hours and siting replacement patch on a different area (avoid using the same area for 14 days)

**Neuproc®** (UCB Pharma)

Patches, self-adhesive, beige, rotigotine 1 mg/24 hours, net price 28 = £77.24; 2 mg/24 hours, 28 = £97.48; 4 mg/24 hours,
Levodopa

Levodopa, the amino-acid precursor of dopamine, acts by replenishing depleted striatal dopamine. It is given with an extracerebral dopa-decarboxylase inhibitor that reduces the peripheral conversion of levodopa to dopamine, thereby limiting side-effects such as nausea, vomiting and cardiovascular effects. Additionally, effective brain-dopamine concentrations can be achieved with lower doses of levodopa. The extracerebral dopa-decarboxylase inhibitors used with levodopa are benserazide (in co-beneldopa) and carbidopa (in co-careldopa).

Levodopa, in combination with a dopa-decarboxylase inhibitor, is useful in the elderly or frail, in patients with other significant illnesses, and in those with more severe symptoms. It is effective and well tolerated in the majority of patients.

Levodopa therapy should be initiated at a low dose and increased in small steps; the final dose should be as low as possible. Intervals between doses should be chosen to suit the needs of the individual patient.

Note When co-careldopa is used, the total daily dose of carbidopa should be at least 70 mg. A lower dose may not achieve full inhibition of extracerebral dopa-decarboxylase, with a resultant increase in side-effects.

Nausea and vomiting with co-beneldopa or co-careldopa are rarely dose-limiting but domperidone (section 4.6) may be useful in controlling these effects. Levodopa treatment is associated with potentially troublesome motor complications including response fluctuations and dyskinesias. Response fluctuations are characterised by large variations in motor performance, with normal function during the ‘on’ period, and weakness and restricted mobility during the ‘off’ period. ‘End-of-dose’ deterioration with progressively shorter duration of benefit also occurs. Modified-release preparations may help with ‘end-of-dose’ deterioration or nocturnal immobility and rigidity. Motor complications are particularly problematic in young patients treated with levodopa.

Cautions Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing’s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving, p. 298).

Interactions

Pregnancy Levodopa should be used with caution in pregnancy—toxicity has occurred in animal studies.

Breast-feeding Levodopa may suppress lactation. It is present in milk—avoid.

Side-effects Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving, p. 298), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideas), anxiety, dizziness, dystonia, dyskinesia, and chorea.

Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastrointestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dysphoria, agitation, parasthesia, bruxism, trismus, hiccup, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Homer’s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Schönlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour and false positive tests for urinary ketones have also been reported.

A mixture of benserazide hydrochloride and levodopa in mass proportions corresponding to 1 part of benserazide and 4 parts of levodopa

Indications Parkinson’s disease, see notes above

Cautions see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

● See preparations

Madopar® (Roche) (Table 4.9.1.4.2.1 Dopaminergic drugs used in Parkinson’s disease)

Capsules (Madopar®-62.5 mg), blue/grey, co-beneldopa 12.5/50 (benserazide 12.5 mg (as hydrochloride), levodopa 50 mg), net price 100-cap pack = £4.96. Label: 10, 14, counselling, driving, see notes above

Capsules (Madopar®-125 mg), blue/pink, co-beneldopa 25/100 (benserazide 25 mg (as hydrochloride), levodopa 100 mg), net price 100-cap pack = £8.91. Label: 10, 14, counselling, driving, see notes above

CO-BENELDOPA

A mixture of benserazide hydrochloride and levodopa in mass proportions corresponding to 1 part of benserazide and 4 parts of levodopa

Indications Parkinson’s disease, see notes above

Cautions see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

● See preparations

Madopar® (Roche) (Table 4.9.1.4.2.1 Dopaminergic drugs used in Parkinson’s disease)

Capsules (Madopar®-62.5 mg), blue/grey, co-beneldopa 12.5/50 (benserazide 12.5 mg (as hydrochloride), levodopa 50 mg), net price 100-cap pack = £4.96. Label: 10, 14, counselling, driving, see notes above

Capsules (Madopar®-125 mg), blue/pink, co-beneldopa 25/100 (benserazide 25 mg (as hydrochloride), levodopa 100 mg), net price 100-cap pack = £8.91. Label: 10, 14, counselling, driving, see notes above

Note Remove patch (aluminium-containing) before magnetic resonance imaging or cardioversion.

The Scottish Medicines Consortium (p. 4) has advised that Neupro® is accepted as monotherapy for the treatment of early-stage idiopathic Parkinson’s disease (June 2007) and for restricted use for the treatment of advanced Parkinson’s disease in combination with levodopa where the transdermal route would facilitate treatment (July 2007).

Note The Scottish Medicines Consortium (p. 4) has advised (April 2009) that rotigotine (Neupro®) is accepted for restricted use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults with a baseline score of 15 points or more on the International Restless Legs Scale.
Capsules (Madopar® 250 mg, blue/caramel, co-beneldopa 50/200 (benzerazide 50 mg (as hydrochloride), levodopa 200 mg), net price 100-cap pack = £11.78. Label: 10, 14, counselling, driving, see notes above

Dispersible tablets, scored, co-beneldopa 12.5/50 (benzerazide 12.5 mg (as hydrochloride), levodopa 50 mg), net price 100-tab pack = £5.90. Label: 10, 14, counselling, administration, see below, driving, see notes above

Dispersible tablets, scored, co-beneldopa 25/100 (benzerazide 25 mg (as hydrochloride), levodopa 100 mg), net price 100-tab pack = £10.45. Label: 10, 14, counselling, administration, see below, driving, see notes above

Counselling: The dispensible tablets can be dispersed in water or orange squash (not orange juice) or swallored whole

Dose: expressed as levodopa, initially 50 mg 3–4 times daily (100 mg 3 times daily in advanced disease), increased by 100 mg daily once or twice weekly according to response; usual maintenance dose 400–600 mg daily in divided doses. ELDERLY initially 50 mg once or twice daily, increased by 50 mg daily every 3–4 days according to response.

Note: When transferring patients from another levodopa/dopamine-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before (although interval can be shorter).

Modified release

Madopar® CR (Roche) 5M
Capsules, m/r, dark green/light blue, co-beneldopa 25/100 (benzerazide 25 mg (as hydrochloride), levodopa 100 mg), net price 100-cap pack = £12.77. Label: 5, 10, 14, 25, counselling, driving, see notes above

Dose: patients not taking levodopa/dopa-decarboxylase inhibitor therapy, initially 1 capsule 3 times daily (max. initial dose 6 capsules daily).

Patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations, initially 1 capsule substituted for every 100 mg of levodopa and given at same dosage frequency, increased every 2–3 days according to response; average increase of 50% needed over previous levodopa dose and titration may take up to 4 weeks

Supplementary dose of immediate-release Madopar® may be needed with first morning dose; if response still poor to total daily dose of Madopar® CR plus Madopar® corresponding to 1 g levodopa, consider alternative therapy

CO-CARELDOPA

A mixture of carbidopa and levodopa, the proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively

Indications: Parkinson’s disease, see notes above

Cautions: see notes above

Pregnancy: see notes above

Breast-feeding: see notes above

Side-effects: see notes above

Dose:

- Expressed as levodopa, initially 100 mg (with carbidopa 25 mg) 3 times daily, increased by 50–100 mg (with carbidopa 12.5–25 mg) daily or on alternate days according to response, up to 800 mg (with carbidopa 200 mg) daily in divided doses.

- Alternatively, initially 50–100 mg (with carbidopa 10–12.5 mg) 3–4 times daily, increased by 50–100 mg daily or on alternate days according to response, up to 800 mg (with carbidopa 80–100 mg) daily in divided doses.

- Alternatively, initially 125 mg (with carbidopa 12.5 mg, as ½ tablet of co-careldopa 25/250) 1–2 times daily, increased by 125 mg (with carbidopa 12.5 mg) daily or on alternate days according to response.

Note: At least 70 mg carbidopa daily is necessary to achieve full inhibition of peripheral dopa-decarboxylase. When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before.

Co-careldopa (Non-proprietary) 5M

Tablets, co-careldopa 10/100 (carbidopa 10 mg (anhydrous), levodopa 100 mg), net price 100-tab pack = £7.30. Label: 10, 14, counselling, driving, see notes above.

Tablets, co-careldopa 25/100 (carbidopa 25 mg (anhydrous), levodopa 100 mg), net price 100-tab pack = £24.45. Label: 10, 14, counselling, driving, see notes above.

Tablets, co-careldopa 25/250 (carbidopa 25 mg (anhydrous), levodopa 250 mg), net price 100-tab pack = £34.58. Label: 10, 14, counselling, driving, see notes above.

Sinemet® (MSD) 5M

Tablets (Sinemet®-62.5), yellow, scored, co-careldopa 12.5/50 (carbidopa 12.5 mg (anhydrous), levodopa 50 mg), net price 90-tab pack = £6.28. Label: 10, 14, counselling, driving, see notes above.

Note: 2 tablets Sinemet®-62.5 = 1 tablet Sinemet Plus®.

Tablets (Sinemet®-110), blue, scored, co-careldopa 10/100 (carbidopa 10 mg (anhydrous), levodopa 100 mg), net price 90-tab pack = £6.57. Label: 10, 14, counselling, driving, see notes above.

Tablets (Sinemet®-Plus), yellow, scored, co-careldopa 25/100 (carbidopa 25 mg (anhydrous), levodopa 100 mg), net price 90-tab pack = £9.66. Label: 10, 14, counselling, driving, see notes above.

Note: Co-careldopa 25/100 provides an adequate dose of carbidopa when low doses of levodopa are needed.

Tablets (Sinemet®-275), blue, scored, co-careldopa 25/250 (carbidopa 25 mg (anhydrous), levodopa 250 mg), net price 90-tab pack = £13.72. Label: 10, 14, counselling, driving, see notes above.

For use with enteral tube

Duodopa® (Abbott Healthcare) 5M

Intestinal gel, co-careldopa 5/20 (carbidopa 5 mg as monohydrate, levodopa 20 mg)/mL, net price 100 mL cassette (for use with Duodopa® portable pump) = £77.00. Label: 10, 14, counselling, driving, see notes above.

Dose: severe Parkinson’s disease inadequately controlled by other preparations, consult product literature.

Modified release

Caramet® CR (TEVA UK) 5M

Tablets, m/r, orange-brown, co-careldopa 25/100 (carbidopa 25 mg (as monohydrate), levodopa 100 mg), net price 60-tab pack = £11.47; co-careldopa 50/200 (carbidopa 50 mg (as monohydrate), levodopa 200 mg), 60-tab pack = £11.47. Label: 10, 14, 25, counselling, driving, see notes above.

Dose: patients not receiving levodopa/dopa-decarboxylase inhibitor preparations, expressed as levodopa, initially 100–200 mg twice daily (at least 6 hours between doses); dose adjusted according to response at intervals of at least 2 days.

Patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations, discontinue previous preparation at least 12 hours before first dose of Caramet® CR; substitute Caramet® CR to provide a similar amount of levodopa daily and extend dosing interval by 30–50%, dose then adjusted according to response at intervals of at least 2 days.

Central nervous system

BNF 61

4.9.1 Dopaminergic drugs used in Parkinson’s disease

303
Central nervous system

4.9.1 Dopaminergic drugs used in Parkinson’s disease

**Half Sinemet® CR (MSD)**

- **Tablets**, m/r, pink, co-careldopa 25/100 (carbidopa 25 mg, levodopa 100 mg), net price 60-tab pack = £11.60. Label: 10, 14, 25, counselling, driving, see notes above
- **Dose** for fine adjustment of Sinemet® CR dose (see below)

**Sinemet® CR (MSD)**

- **Tablets**, m/r, peach, scored, co-careldopa 50/200 (carbidopa 50 mg, levodopa 200 mg), net price 60-tab pack = £11.60. Label: 10, 14, 25, counselling, driving, see notes above
- **Dose** patients not receiving levodopa/dopa-decarboxylase inhibitor therapy, initially, 1 Sinemet® CR tablet twice daily; both dose and interval then adjusted according to response at intervals of not less than 3 days
- Patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations, 1 Sinemet® CR tablet twice daily can be substituted for a daily dose of levodopa 300–400 mg in immediate-release Sinemet® tablets (substitute Sinemet® CR to provide approx. 10% more levodopa per day and extend dosing interval by 30–50%); dose and interval then adjusted according to response at intervals of not less than 3 days

### With entacapone

For Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

**Stalevo**® (Orion)

- **Tablets**, f/c, brown, levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg, net price 30-tab pack = £20.79, 100-tab pack = £69.31. Label: 10, 14 (urine reddish-brown), 25, counselling, driving, see notes above
- **Dose** only 1 tablet to be taken for each dose; max. 7 tablets daily

- **Tablets**, f/c, brown, levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg, net price 30-tab pack = £20.79, 100-tab pack = £69.31. Label: 10, 14 (urine reddish-brown), 25, counselling, driving, see notes above
- **Dose** only 1 tablet to be taken for each dose; max. 10 tablets daily

- **Tablets**, f/c, brown, levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg, net price 30-tab pack = £20.79, 100-tab pack = £69.31. Label: 10, 14 (urine reddish-brown), 25, counselling, driving, see notes above
- **Dose** only 1 tablet to be taken for each dose; max. 10 tablets daily

- **Tablets**, f/c, brown, levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg, net price 30-tab pack = £20.79, 100-tab pack = £69.31. Label: 10, 14 (urine reddish-brown), 25, counselling, driving, see notes above
- **Dose** only 1 tablet to be taken for each dose; max. 10 tablets daily

**RASAGILINE**

**Indications** Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa

**Cautions** avoid abrupt withdrawal; **interactions:** Appendix 1 (rasagiline)

**Hepatic impairment** use with caution in mild impairment; avoid in moderate to severe impairment

**Pregnancy** use with caution

**Breast-feeding** use with caution—may suppress lactation

**Side-effects** dry mouth, dyspepsia, constipation, flatulence; angina; headache, depression, anorexia, weight loss, abnormal dreams, vertigo, hallucinations; influenza-like symptoms; urinary urgency; leukopenia; arthralgia; conjunctivitis; rhinitis; rash, skin carcinoma; less commonly myocardial infarction, and cerebrovascular accident

**Dose**

- 1 mg daily

**Azilect®** (Teva)

- **Tablets**, rasagiline (as mesilate) 1 mg, net price 28-tab pack = £70.72

**SELEGILINE HYDROCHLORIDE**

**Indications** Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa

**Cautions** avoid abrupt withdrawal; gastric and duodenal ulceration (avoid in active ulceration), uncontrolled hypertension, arrhythmias, angina, psychosis, side-effects of levodopa may be increased, concurrent levodopa dosage can be reduced by 10–30%; avoid in acute porphyria (section 9.8.2); **interactions:** Appendix 1 (selegiline)

**Hepatic impairment** use with caution in severe impairment

**Renal impairment** use with caution in severe impairment
Pregnancy avoid—no information available
Breast-feeding avoid—no information available

**Side-effects**
- Nausea, constipation, diarrhoea, dry mouth; postural hypotension; dyskinesia, vertigo, sleeping disorders, confusion, hallucinations; arthralgia, myalgia; mouth ulcers with oral lypophilisate; rarely arrhythmias, agitation, headache, micturition difficulties, skin reactions; very rarely hypersexuality; also reported chest pain

**Dose**
- *Eldepryl*® (Orion)® Tablets, scored, selegiline hydrochloride 5 mg, net price 60-tab pack = £9.91; 10 mg, 30-tab pack = £6.67

**Selegiline Hydrochloride** (Non-proprietary)

Tablets, selegiline hydrochloride 5 mg, net price 60-tab pack = £5.59; 10 mg, 30-tab pack = £6.87

**Eldepryl® (Orion)® Tablets**, scored, selegiline hydrochloride 5 mg, net price 60-tab pack = £9.91; 10 mg, 30-tab pack = £6.67

**Selegiline Hydrochloride** (Non-proprietary)

Oral liquid, selegiline hydrochloride 10 mg/5 mL, net price 200 mL = £17.93

**Oral lypophilisate**

**Zelapar**® (Cephalon)®

Oral lypophilisates (freeze-dried tablets), yellow, selegiline hydrochloride 1.25 mg, net price 30-tab pack = £43.16. Counselling, administration: Excipients include aspartame (section 9.4.1)

**Dose** 1.25 mg daily before breakfast

**Counselling** Tablets should be placed on the tongue and allowed to dissolve. Advise patient not to drink, rinse, or wash mouth out for 5 minutes after taking the tablet

**Note** Patients receiving 10 mg conventional selegiline hydrochloride tablets can be switched to Zelapar® 1.25 mg

**Catechol-O-methyltransferase inhibitors**

Entacapone and tolcapone prevent the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain. They are licensed for use as an adjunct to co-beneldopa or co-careldopa for patients with Parkinson’s disease who experience ‘end-of-dose’ deterioration and cannot be stabilised on these combinations. Due to the risk of hepatotoxicity, tolcapone should be prescribed under specialist supervision only, when other catechol-O-methyltransferase inhibitors combined with co-beneldopa or co-careldopa are ineffective.

**ENTACAPONE**

**Indications**
- Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease and ‘end-of-dose’ motor fluctuations

**Cautions**
- Ischaemic heart disease; avoid abrupt withdrawal; concurrent levodopa dose may need to be reduced by about 10–30%; interactions: Appendix 1 (entacapone)

**Contra-indications**
- Phaeochromocytoma; history of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis

**BNF 61 4.9.1 Dopaminergic drugs used in Parkinson’s disease 305**

**Hepatic impairment**

**Pregnancy** avoid—no information available

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects**
- Nausea, vomiting, abdominal pain, constipation, diarrhoea, urine may be coloured reddish-brown, dry mouth; ischaemic heart disease; confusion, dizziness, abnormal dreams, fatigue, insomnia, dystonia, dyskinesia, hallucinations; sweating, less commonly myocardial infarction; rarely rash; very rarely anorexia, weight loss, agitation, and urticaria; also reported hepatitis, colitis, neuroleptic malignant syndrome, rhabdomyolysis, and skin, hair, and nail discoloration

**Dose**
- 200 mg with each dose of levodopa with decarboxylase inhibitor; max. 2 g daily

**Comtess® (Orion)® Tablets**, f/c, brown/orange, entacapone 200 mg, net price 30-tab pack = £17.24, 100-tab pack = £57.45. Label: 14, (urine reddish-brown), counselling, driving, see notes above, avoid iron-containing products at the same time of day

**TOLCAPONE**

**Indications**
- Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease and ‘end-of-dose’ motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under specialist supervision)

**Cautions**
- Avoid abrupt withdrawal; most patients receiving more than 600 mg levodopa daily require reduction of levodopa dose by about 30%; interactions: Appendix 1 (tolcapone)

**Hepatotoxicity**

**Potentially life-threatening hepatotoxicity** including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased); discontinue if abnormal liver function tests or symptoms of liver disorder (counselling, see below); do not re-introduce tolcapone once discontinued

**Counselling** Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop

**Contra-indications**
- Severe dyskinesia, phaeochromocytoma, previous history of neuroleptic malignant syndrome, rhabdomyolysis, or hyperthermia

**Hepatic impairment** avoid; see also under Cautions

**Renal impairment**
- Caution if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy**
- Toxicity in animal studies—use only if potential benefit outweighs risk

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects**
- Diarrhoea, constipation, dyspepsia, abdominal pain, nausea, vomiting, anorexia, xerostomia, hepatotoxicity (see above); chest pain; confusion, dystonia, dyskinesia, drowsiness, headache, dizziness, sleep disturbances, excessive dreaming, hallucinations; syncope; urinary discoloration; sweating; neuroleptic malignant syndrome and rhabdomyolysis reported on dose reduction or withdrawal
4.9.2 Antimuscarinic drugs used in parkinsonism

Antimuscarinic drugs exert their antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency. Antimuscarinic drugs can be useful in drug-induced parkinsonism, but they are generally not used in idiopathic Parkinson’s disease because they are less effective than dopaminergic drugs and they are associated with cognitive impairment.

The antimuscarinic drugs orphenadrine, procyclidine, and trihexyphenidyl reduce the symptoms of parkinsonism induced by antipsychotic drugs, but there is no justification for giving them routinely in the absence of parkinsonian side-effects. Tardive dyskinesia is not improved by antimuscarinic drugs and may be made worse.

In idiopathic Parkinson’s disease, antimuscarinic drugs reduce tremor and rigidity but they have little effect on bradykinesia. They may be useful in reducing salivation.

No important differences exist between the antimuscarinic drugs, but some patients tolerate one better than another. Procyclidine can be given parenterally and is effective emergency treatment for acute drug-induced dystonic reactions.

Cautions Antimuscarinics should be used with caution in cardiovascular disease, hypertension, psychotic disorders, prostatic hypertrophy, pyrexia, in those susceptible to angle-closure glaucoma, and in the elderly. Antimuscarinics should not be withdrawn abruptly in patients receiving long-term treatment. Antimuscarinics are liable to abuse. Interactions: Appendix 1 (Antimuscarinics)

Driving May affect performance of skilled tasks (e.g. driving)

Contra-indications Antimuscarinics should be avoided in gastro-intestinal obstruction and myasthenia gravis.

Hepatic and renal impairment Orphenadrine, procyclidine, and trihexyphenidyl should be used with caution in patients with hepatic or renal impairment.

Side-effects Side-effects of antimuscarinics include constipation, dry mouth, nausea, vomiting, tachycardia, dizziness, confusion, euphoria, hallucinations, impaired memory, anxiety, restlessness, urinary retention, blurred vision, and rash. Angle-closure glaucoma may occur very rarely.

4.9.2 Antimuscarinic drugs used in parkinsonism

Antimuscarinic drugs exert their antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency. Antimuscarinic drugs can be useful in drug-induced parkinsonism, but they are generally not used in idiopathic Parkinson’s disease because they are less effective than dopaminergic drugs and they are associated with cognitive impairment.

The antimuscarinic drugs orphenadrine, procyclidine, and trihexyphenidyl reduce the symptoms of parkinsonism induced by antipsychotic drugs, but there is no justification for giving them routinely in the absence of parkinsonian side-effects. Tardive dyskinesia is not improved by antimuscarinic drugs and may be made worse.

In idiopathic Parkinson’s disease, antimuscarinic drugs reduce tremor and rigidity but they have little effect on bradykinesia. They may be useful in reducing salivation.

No important differences exist between the antimuscarinic drugs, but some patients tolerate one better than another. Procyclidine can be given parenterally and is effective emergency treatment for acute drug-induced dystonic reactions.

Cautions Antimuscarinics should be used with caution in cardiovascular disease, hypertension, psychotic disorders, prostatic hypertrophy, pyrexia, in those susceptible to angle-closure glaucoma, and in the elderly. Antimuscarinics should not be withdrawn abruptly in patients receiving long-term treatment. Antimuscarinics are liable to abuse. Interactions: Appendix 1 (Antimuscarinics)

Driving May affect performance of skilled tasks (e.g. driving)

Contra-indications Antimuscarinics should be avoided in gastro-intestinal obstruction and myasthenia gravis.

Hepatic and renal impairment Orphenadrine, procyclidine, and trihexyphenidyl should be used with caution in patients with hepatic or renal impairment.

Side-effects Side-effects of antimuscarinics include constipation, dry mouth, nausea, vomiting, tachycardia, dizziness, confusion, euphoria, hallucinations, impaired memory, anxiety, restlessness, urinary retention, blurred vision, and rash. Angle-closure glaucoma may occur very rarely.

4.9.2 Antimuscarinic drugs used in parkinsonism

Antimuscarinic drugs exert their antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency. Antimuscarinic drugs can be useful in drug-induced parkinsonism, but they are generally not used in idiopathic Parkinson’s disease because they are less effective than dopaminergic drugs and they are associated with cognitive impairment.

The antimuscarinic drugs orphenadrine, procyclidine, and trihexyphenidyl reduce the symptoms of parkinsonism induced by antipsychotic drugs, but there is no justification for giving them routinely in the absence of parkinsonian side-effects. Tardive dyskinesia is not improved by antimuscarinic drugs and may be made worse.

In idiopathic Parkinson’s disease, antimuscarinic drugs reduce tremor and rigidity but they have little effect on bradykinesia. They may be useful in reducing salivation.

No important differences exist between the antimuscarinic drugs, but some patients tolerate one better than another. Procyclidine can be given parenterally and is effective emergency treatment for acute drug-induced dystonic reactions.

Cautions Antimuscarinics should be used with caution in cardiovascular disease, hypertension, psychotic disorders, prostatic hypertrophy, pyrexia, in those susceptible to angle-closure glaucoma, and in the elderly. Antimuscarinics should not be withdrawn abruptly in patients receiving long-term treatment. Antimuscarinics are liable to abuse. Interactions: Appendix 1 (Antimuscarinics)

Driving May affect performance of skilled tasks (e.g. driving)

Contra-indications Antimuscarinics should be avoided in gastro-intestinal obstruction and myasthenia gravis.

Hepatic and renal impairment Orphenadrine, procyclidine, and trihexyphenidyl should be used with caution in patients with hepatic or renal impairment.

Side-effects Side-effects of antimuscarinics include constipation, dry mouth, nausea, vomiting, tachycardia, dizziness, confusion, euphoria, hallucinations, impaired memory, anxiety, restlessness, urinary retention, blurred vision, and rash. Angle-closure glaucoma may occur very rarely.
Kemadrin® (Auden Mckenzie) (Non-proprietary)
Injection, procyclidine hydrochloride 5 mg/mL, net price 2-mL amp = £1.49

TRIHEXYPHENIDYL HYDROCHLORIDE
(Benzhexol hydrochloride)

Indications parkinsonism; drug-induced extrapyramidal symptoms (but not tardive dyskinesia, see notes above)

Cautions see notes above

Contra-indications see notes above

Hepatic impairment see notes above

Pregnancy use only if potential benefit outweighs risk

Breast-feeding avoid

Side-effects see notes above

Dose

- 1 mg daily, increased gradually; usual maintenance dose 5–15 mg daily in 3–4 divided doses (max. 20 mg daily); ELDERLY preferably lower end of range; CHILD under 18 years see BNF for Children

Trihexyphenidyl (Non-proprietary)
Tablets, trihexyphenidyl hydrochloride 2 mg, net price 84-tab pack = £19.60; 5 mg, 84-tab pack = £18.59. 100-tab pack = £15.60. Counselling, with or after food, driving, see notes above

Broflex® (Alliance) (Non-proprietary)
Tablets, trihexyphenidyl hydrochloride 2 mg, net price 42-tab pack = £7.54. Counselling, driving, see notes above

Kemadrin® (Aspen) (Non-proprietary)
Tablets, scored, procyclidine hydrochloride 5 mg, net price 100-tab pack = £4.72. Counselling, driving, see notes above

PROCYCLIDINE HYDROCHLORIDE

Indications parkinsonism; drug-induced extrapyramidal symptoms (but not tardive dyskinesia, see notes above)

Cautions see notes above

Contra-indications see notes above

Hepatic impairment see notes above

Pregnancy use only if potential benefit outweighs risk

Breast-feeding no information available

Side-effects see notes above, but causes sedation rather than stimulation; also gingivitis

Dose

- By mouth, 2.5 mg 3 times daily, increased gradually in steps of 2.5–5 mg daily every 2–3 days if necessary; usual max. 30 mg daily in 2–4 divided doses (60 mg daily in exceptional circumstances); ELDERLY preferably lower end of range

- By intramuscular or intravenous injection, acute dystonia, 5–10 mg (occasionally more than 10 mg), usually effective in 5–10 minutes but may need 30 minutes for relief; ELDERLY preferably lower end of range

Procyclidine (Non-proprietary)
Tablets, procyclidine hydrochloride 5 mg, net price 28-tab pack = £2.77. Counselling, driving, see notes above

Arpicolin® (Rosemont) (Non-proprietary)
Tablets, sugar-free, procyclidine hydrochloride 2.5 mg/5 mL, net price 150 mL = £4.22. 5 mg/5 mL, 150 mL pack = £7.54. Counselling, driving, see notes above

Kemadrin® (Asten)(Rosemont) (Non-proprietary)
Tablets, scored, procyclidine hydrochloride 5 mg, net price 100-tab pack = £4.72. Counselling, driving, see notes above

4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders

Tetrazenazine is mainly used to control movement disorders in Huntington's chorea and related disorders. Tetrabenazine can also be prescribed for the treatment of tardive dyskinesia if switching or withdrawing the causative antipsychotic drug is not effective. It may act by depleting nerve endings of dopamine. It is effective in only a proportion of patients and its use may be limited by the development of depression.

Haloperidol (p. 219) can improve motor tics and symptoms of Tourette syndrome and related choras. Other treatments for Tourette syndrome include pimozide (p. 220) [unlicensed indication] important: ECG monitoring required, clonidine (p. 278) [unlicensed indication], and sulpiride (p. 221) [unlicensed indication].

Trihexyphenidyl (above) in high dosage can also improve some movement disorders; it is sometimes necessary to build the dose up over many weeks, to 20 to 30 mg daily or higher. Chlorpromazine (p. 218) and haloperidol (p. 219) are used to relieve intractable hiccup.

Propranolol or another beta-adrenergic blocking drug (section 2.4) may be useful in treating essential tremor or tremors associated with anxiety or thyrotoxicosis.
4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders BNF 61

Primidone (p. 288) in some cases provides relief from benign essential tremor; the dose is increased slowly to reduce side-effects. Piracetam is used as an adjunctive treatment for myoclonus of cortical origin. Riluzole is used to extend life in patients with motor neurone disease who have amyotrophic lateral sclerosis.

---

**PIRACETAM**

**Indications**
adjunctive treatment of cortical myoclonus

**Cautions**
avoid abrupt withdrawal; elderly; haemostasis, major surgery, or severe haemorrhage

**Contra-indications**
cerebral haemorrhage; Huntington’s chorea

**Hepatic impairment**
avoid

**Renal impairment**
use two-thirds of normal dose if eGFR 50–80 mL/minute/1.73 m²; use one-third of normal dose in 2 divided doses if eGFR 30–50 mL/minute/1.73 m²; use one-sixth normal dose as a single dose if eGFR 20–30 mL/minute/1.73 m²; avoid if eGFR less than 20 mL/minute/1.73 m²

**Pregnancy**
avoid

**Breast-feeding**
avoid

**Side-effects**
weight gain, nervousness, hypokinesia; less commonly drowsiness, depression, asthenia; also reported abdominal pain, nausea, vomiting, diarrhoea, headache, anxiety, confusion, hallucination, vertigo, ataxia, insomnia, and rash

**Dose**
- Initially 7.2 g daily in 2–3 divided doses, increased according to response by 4.8 g daily every 3–4 days to max. 20 g daily (subsequently, attempts should be made to reduce dose of concurrent therapy); CHILD under 16 years not recommended
- Oral solution Follow the oral solution with a glass of water (or soft drink) to reduce bitter taste.

Nootropil® (UCB Pharma) ³
Tablets, f/c, scored, piracetam 800 mg, net price 90-tab pack = £11.75; 1.2 g, 60-tab pack = £10.97. Label: 3

Oral solution, piracetam, 333.3 mg/mL, net price 300-mL pack = £16.31. Label: 3

---

**RILUZOLE**

**Indications**
to extend life in patients with amyotrophic lateral sclerosis, initiated by specialists experienced in the management of motor neurone disease

**Cautions**
history of abnormal hepatic function (consult product literature for details)

**Blood disorders**
Patients or their carers should be told how to recognise signs of neutropenia and advised to seek immediate medical attention if symptoms such as fever occur; white blood cell counts should be determined in febrile illness; neutropenia requires discontinuation of riluzole

**Interstitial lung disease**
Perform chest radiography if symptoms such as dry cough or dyspnoea develop; discontinue if interstitial lung disease is diagnosed

**Driving**
Dizziness or vertigo may affect performance of skilled tasks (e.g. driving)

**Hepatic impairment**
avoid; see also under Cautions

**Renal impairment**
avoid—no information available

**Pregnancy**
avoid—no information available

**Breast-feeding**
avoid—no information available

**Side-effects**
nausea, vomiting, diarrhoea, abdominal pain; tachycardia; asthenia, headache, dizziness, drowsiness, oral paraesthesia; less commonly interstitial lung disease, pancreatitis, angioedema, and anaemia; rarely neutropenia; very rarely hepatitis

**Dose**
- 50 mg twice daily; CHILD not recommended

Rilutek® (Sanofi-Aventis) ³
Tablets, f/c, riluzole 50 mg. Net price 56-tab pack = £278.55. Counselling, blood disorders, driving, see Cautions

---

**TETRABENAZINE**

**Indications**
see Dose

**Cautions**
interactions: Appendix 1 (tetrabenazine)

**Driving**
May affect performance of skilled tasks (e.g. driving)

**Pregnancy**
inadequate information but no evidence of harm

**Breast-feeding**
avoid

**Side-effects**
drowsiness, gastrointestinal disturbances, depression, extrapyramidal dysfunction, hypotension; rarely parkinsonism; neuroleptic malignant syndrome reported

**Dose**
- Movement disorders due to Huntington’s chorea, hemiballismus, senile chorea, and related neurological conditions, initially 12.5 mg twice daily (elderly 25 mg daily) gradually increased to 12.5–25 mg 3 times daily, max. 200 mg daily
- Moderate to severe tardive dyskinesia, initially 12.5 mg daily, gradually increased according to response

Xenazine® 25 (Alliance) ³
Tablets, yellow, scored, tetrabenazine 25 mg. Net price 112-tab pack = £100.00. Label: 2

---

**Torsion dystonias and other involuntary movements**

Botulinum toxin type A should be used under specialist supervision.

Botox® and Dysport® are licensed for the treatment of focal spasticity (including arm symptoms in conjunction with physiotherapy, dynamic equinus foot deformity caused by spasticity in ambulant paediatric cerebral palsy patients over 2 years, and hand and wrist disability associated with stroke), blepharospasm, hemifacial spasm, and spasmodic torticolis. Botox® is also licensed for severe hyperhidrosis of the axillae, and for the prophylaxis of headaches in adults with chronic migraine (section 4.7.4.2).

Azulfidine®, Bocouture®, and Vistabe® are licensed for the temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years.
Xeomin® is licensed for the treatment of blepharospasm, spasmodic torticollis, and post-stroke spasticity of the upper limb.

**BOTULINUM TOXIN TYPE A**

**Indications** see notes above; preparations are not interchangeable and should be used under specialist supervision

**Cautions** history of dysphagia or aspiration; chronic respiratory disorder; neurological disorders (can lead to increased sensitivity and exaggerated muscle weakness)

**Specific cautions for blepharospasm or hemifacial spasm** Caution if risk of angle-closure glaucoma; reduced blinking can lead to corneal exposure, persistent epithelial defect and corneal ulceration (especially in those with VIIth nerve disorders)—careful testing of corneal sensation in previously operated eyes, avoidance of injection in lower lid area to avoid ectropion, and vigorous treatment of epithelial defect needed

**Contra-indications** generalised disorders of muscle activity (e.g. myasthenia gravis); injection at injection site

**Pregnancy** low risk of systemic absorption but avoid unless essential

**Breast-feeding** low risk of systemic absorption but avoid unless essential

**Side-effects** increased electrophysiologic jitter in some distant muscles; misplaced injections may paralyse nearby muscle groups and excessive doses may paralyse distant muscles; influenza-like symptoms; rarely arrhythmias, myocardial infarction, seizures, and antibody formation (substantial deterioration in response); very rarely exaggerated muscle weakness, dysphagia, and aspiration (seek medical attention if swallowing, speech, or respiratory disorders)

**Specific side-effects for blepharospasm or hemifacial spasm** ptosis, keratitis, lagophthalmos, dry eye, irritation, photophobia, lacrimation, facial oedema, less commonly dry mouth, facial weakness (including drooping), dizziness, paraesthesia, headache, tiredness, entropion, dry mouth, dyspepsia, worsening torticollis, neck pain, myasthenia, voice changes, taste disturbances; very rarely eyelid bruising and swelling (minimized by applying gentle pressure at injection site immediately after injection); very rarely angle-closure glaucoma, corneal ulceration

**Specific side-effects in paediatric cerebral palsy** drowsiness, paraesthesia, urinary incontinence, myalgia

**Specific side-effects for temporary improvement of moderate to severe wrinkles between the eyebrows** facial oedema, headache, ptosis, less commonly nausea, dry mouth, dizziness, asthenia, paraesthesia, muscle cramp, visual disturbances, tinnitus, blepharitis, photo-sensitivity reactions, and dry skin

**Specific side-effects in spasmodic torticollis** dysphagia and pooling of saliva (occurs most frequently after injection into sternomastoid muscle), nausea, dry mouth, rhinitis, drowsiness, headache, dizziness, malaise, numbness, stiffness, hyperemia; back pain, weakness; less commonly diarrhoea, vomiting, colitis, dyspepsia, voice alteration, tremor, skeletal pain, myalgia, diplopia, eye pain, ptosis, and sweating

**Specific side-effects in axillary hyperhidrosis** non-axillary sweating, hot flushes; less commonly myalgia and joint pain

**Specific side-effects in focal upper-limb spasticity associated with stroke** dysphagia, hypertension, purpura, less commonly nausea, dry mouth, cough, haematoxia, peripheral oedema, depression, insomnia, vertigo, arm weakness, malaise, paraesthesia, dysaesthesia, headache, pain in extremities, arthralgia, and bucrisis

**Dose**

- Consult product literature (important: specific to each individual preparation and not interchangeable)

---

**BOTULINUM TOXIN TYPE B**

**Indications** spasmodic torticollis (cervical dystonia)—specialist use only

**Cautions** history of dysphagia or aspiration; inadvertent injection into a blood vessel; tolerance may occur

**Contra-indications** neuromuscular or neuromuscular junctional disorders

**Pregnancy** low risk of systemic absorption but avoid unless essential

**Breast-feeding** low risk of systemic absorption but avoid unless essential

**Side-effects** increased electrophysiologic jitter in some distant muscles; dry mouth, dyspepsia, worsening torticollis, neck pain, myasthenia, voice changes, taste disturbances; very rarely exaggerated muscle weakness, dysphagia, and aspiration (seek medical attention if swallowing, speech, or respiratory disorders)

**Dose**

- By intramuscular injection, initially 5000–10 000 units divided between 2–4 most affected muscles; adjust dose and frequency according to response; important: not interchangeable with other botulinum toxin preparations

**NeuroBloc** *(Eisai)*

**Injection** botulinum toxin type B 5000 units/mL, net price 0.5-mL vial = £111.20; 1-mL vial = £148.27; 2-mL vial = £197.69

**Note** May be diluted with sodium chloride 0.9%

---

**4.10 Drugs used in substance dependence**

This section includes drugs used in alcohol dependence, cigarette smoking, and opioid dependence.

4 Central nervous system

4.10.1 Alcohol dependence

Excessive drinking of alcoholic beverages over a prolonged period of time can result in an alcohol withdrawal syndrome on abrupt cessation of, or marked reduction in, drinking; for some patients the withdrawal syndrome can be severe and even fatal.

Acute alcohol withdrawal. Long-acting benzodiazepines, usually chlordiazepoxide (p. 214), are used to attenuate alcohol withdrawal symptoms. In primary care, fixed-dose reducing regimens are usually used, whilst a symptom-triggered flexible regimen is used in hospital or other settings where continued assessment and monitoring is carried out for 24–48 hours, usually followed by a fixed 5-day reducing dose schedule. Patients with decompensated liver disease should be treated under specialist supervision.

Carbamazepine [unlicensed indication] (p. 281) is sometimes used as an alternative treatment in acute alcohol withdrawal when benzodiazepines are contra-indicated or not tolerated. Clomethiazole (p. 211) is licensed for use in acute alcohol withdrawal, but benzodiazepines are preferred. It should only be used in an inpatient setting and should not be prescribed if the patient is liable to continue drinking alcohol.

Patients with marked agitation or hallucinations and those at risk of delirium tremens (characterised by delirium, hallucinations, course tremor, and disorientation) may be prescribed antipsychotic drugs, such as haloperidol (p. 219) or olanzapine (p. 224) [unlicensed indication], as adjunctive therapy to benzodiazepines; antipsychotics should not be used alone because they do not treat alcohol withdrawal and may lower the seizure threshold. Delirium tremens is a medical emergency that requires specialist inpatient care.

If a patient taking a benzodiazepine as part of a withdrawal regimen develops alcohol withdrawal seizures, a fast-acting benzodiazepine (such as intravenous lorazepam [unlicensed indication] (p. 296) or rectal diazepam (p. 295)) should be prescribed; thereafter an increase in the dose of oral benzodiazepine should be considered to prevent further seizures from occurring.

Alcohol dependence. Acamprosate and disulfiram are effective treatments for relapse prevention in patients with alcohol dependence (see below).

Patients with alcohol dependence are at risk of developing Wernicke’s encephalopathy; patients at high-risk are those who are malnourished, at risk of malnutrition, or have decompensated liver disease. Parenteral thiamine (as Pabrinex®, section 9.6.2) should be prescribed for treatment of suspected or confirmed Wernicke’s encephalopathy, and for prophylaxis in alcohol-dependent patients attending hospital for acute treatment (including treatment unrelated to alcohol dependence); parenteral prophylaxis may also be considered for high-risk patients being treated in primary care. High-dose oral thiamine (p. 616) should be prescribed following parenteral treatment until cognitive function is maximised. In primary care, prophylactic high-dose oral thiamine should be prescribed during acute withdrawal of alcohol, before planned withdrawal, and for patients not undergoing withdrawal but who are at high-risk of developing Wernicke’s encephalopathy.

Patients with chronic alcohol-related pancreatitis who have symptoms of steatorrhoea or who have poor nutritional status due to exocrine pancreatic insufficiency should be prescribed pancreatic enzyme supplements (section 1.9.4); supplements are not indicated when pain is the only symptom.

Corticosteroids (section 6.3.2) are used in patients with severe acute alcohol-related hepatitis.

Acamprosate

Acamprosate, in combination with counselling, may be helpful for maintaining abstinence in alcohol-dependent patients. It is useful for patients who are concerned that strong cravings will result in relapse. It should be initiated as soon as possible after abstinence has been achieved and continued for 1 year; treatment should be maintained if the patient has a temporary relapse. Acamprosate is not effective in all patients, so efficacy should be regularly assessed.

Disulfiram

Disulfiram is used as an adjunct in the treatment of alcohol dependence (under specialist supervision). It gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol because it causes accumulation of acetaldehyde in the body; it is only effective if taken daily. Symptoms can occur within 10 minutes of ingesting alcohol and include flushing of the face, throbbing headache, palpitation, tachycardia, nausea, vomiting, and, with large doses of alcohol, arrhythmias, hypotension, and collapse; these reactions can last several hours. Small amounts of alcohol such as those included in many oral medicines may be sufficient to precipitate a reaction—even toiletries and mouthwashes that contain alcohol should be avoided. Alcohol should be avoided for at least 1 week after stopping treatment.

Before initiating disulfiram, prescribers should evaluate the patient’s suitability for treatment, because some patient factors, for example memory impairment or social circumstances, make compliance to treatment or abstinence from alcohol difficult.
4.10.2 Nicotine dependence

Smoking cessation interventions are a cost-effective way of reducing ill health and prolonging life. Smokers should be advised to stop and offered help with follow-up when appropriate. If possible, smokers should have access to smoking cessation services for behavioural support.

Therapy to aid smoking cessation is chosen according to the smoker's likely compliance, availability of counselling and support, previous experience of smoking-cessation aids, contra-indications and adverse effects of the products, and the smoker's preferences. Nicotine replacement therapy, bupropion, and varenicline are effective aids to smoking cessation. The use of nicotine replacement preparations in an individual who is already accustomed to nicotine introduces few new risks and it is widely accepted that there are no circumstances in which it is safer to smoke than to use nicotine replacement therapy.

Some patients benefit from having more than one type of nicotine replacement therapy prescribed, such as a combination of transdermal and oral preparations. The combination of nicotine replacement therapy with varenicline or bupropion is not recommended.

Concomitant medication Cigarette smoking increases the metabolism of some medicines by stimulating the hepatic enzyme CYP1A2. When smoking is discontinued, the dose of these drugs, in particular theophylline (p. 181), cinacalcet (p. 610), ropinirole (p. 301), and some antipsychotics (including clozapine (p. 223), olanzapine (p. 224), chlorpromazine (p. 218), and haloperidol (p. 219)), may need to be reduced. Regular monitoring for adverse effects is advised.

**Bupropion**

Bupropion has been used as an antidepressant but its mode of action in smoking cessation is not clear and may involve an effect on noradrenaline and dopamine neurotransmission.

**BUPROPION HYDROCHLORIDE**

(Bupropion; Amfebutamone hydrochloride)

**Indications** see notes above

**Cautions** elderly; predisposition to seizures (prescribe only if benefit clearly outweighs risk) including concomitant use of drugs that lower seizure threshold, alcohol abuse, history of head trauma, and diabetes; measure blood pressure before and during treatment; avoid in severe hepatic cirrhosis; CNS tumour; history of seizures, eating disorders, or bipolar disorder

**Hepatic impairment** reduce dose to 150 mg daily; avoid in severe hepatic cirrhosis

**Renal impairment** reduce dose to 150 mg daily

**Pregnancy** avoid—no information available

**Breast-feeding** present in milk—avoid

**Side-effects** dry mouth, gastro-intestinal disturbances, taste disturbance; agitation, anxiety, dizziness, depression, headache, impaired concentration, insomnia (reduced by avoiding dose at bedtime), tremor; fever; pruritus, rash; sweating; loss commonly chest pain, flushing, hypertension, tachycardia, anorexia, asthenia, confusion, tinnitus, and visual disturbances; rarely hepatitis, jaundice, palpitation, postural hypotension, vasodilatation, abnormal dreams, ataxia, dystonia, depersonalisation, hallucinations, hostility, incoordination, irritability, impaired memory, parasthesia, seizures, twitching, blood-glucose changes, urinary frequency, urinary retention, exacerbation of psoriasis, and Stevens-Johnson syndrome; very rarely aggression, delusions, paranoid ideation, and restlessness; also reported suicidal ideation

**Dose**

- **ADULT** over 18 years, start 1–2 weeks before target stop date, initially 150 mg daily for 6 days then 150 mg twice daily (max. single dose 150 mg, max. daily dose 300 mg; minimum 8 hours between doses); period of treatment 7–9 weeks; discontinue if abstinence not achieved at 7 weeks; consider max. 150 mg daily in patients with risk factors for seizures; **ELDERLY** max. 150 mg daily

**Zyban®** (GSK) Tablets, m/r, f/c, bupropion hydrochloride 150 mg, net price 60-tab pack = £47.82. Label: 25, counselling, driving, see Cautions

**Nicotine replacement therapy**

Nicotine replacement therapy can be used in place of cigarettes after abrupt cessation of smoking, or alternatively to reduce the amount of cigarettes used in...
advancing of making a quit attempt. Nicotine replacement therapy can also be used to minimise passive smoking, and to treat cravings and reduce compensatory smoking after enforced abstinence in smoke-free environments. Smokers who find it difficult to achieve abstinence should consult a healthcare professional for advice.

**Choice** Nicotine patches are a prolonged-release formulation and are applied for 16 hours (with the patch removed overnight) or for 24 hours. If patients experience strong cravings for cigarettes on waking, a 24-hour patch may be more suitable. Immediate-release nicotine preparations (gum, lozenges, sublingual tablets, inhalator, nasal spray) are used whenever the urge to smoke occurs.

The choice of nicotine replacement preparation depends largely on patient preference, and should take into account what preparations, if any, have been tried before. Patients with a high level of nicotine dependence, or who have failed with nicotine replacement therapy previously, may benefit from using a combination of immediate-release preparation and patches to achieve abstinence.

All preparations are licensed for adults and children over 12 years (with the exception of Nicotinell® lozenges which are licensed for children under 18 years only when recommended by a doctor).

**Cautions** Most warnings for nicotine replacement therapy also apply to continued cigarette smoking, but the risk of continued smoking outweighs any risks of using nicotine preparations. Nicotine replacement therapy should be used with caution in haemodynamically unstable patients hospitalised with severe arrhythmias, myocardial infarction, or cerebrovascular accident, and in patients with phaeochromocytoma or uncontrolled hyperthyroidism. Care is also needed in patients with diabetes mellitus—blood-glucose concentration should be monitored closely when initiating treatment.

Specific cautions for individual preparations are usually related to the local effect of nicotine. Oral preparations should be used with caution in patients with oesophagitis, gastritis, or peptic ulcers because swallowed nicotine can aggravate these conditions. The gum may also stick to and damage dentures. Acidic beverages, such as coffee or fruit juice, may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral nicotine replacement therapy. Care should be taken with the inhalation cartridges in patients with obstructive lung disease, chronic throat disease, or bronchospastic disease. The nasal spray can cause worsening of bronchial asthma. Patches should not be placed on broken skin and should be used with caution in patients with skin disorders.

**Hepatic impairment** Nicotine replacement therapy should be used with caution in moderate to severe hepatic impairment.

**Renal impairment** Nicotine replacement therapy should be used with caution in severe renal impairment.

**Pregnancy** The use of nicotine replacement therapy in pregnancy is preferable to the continuation of smoking, but should be used only if smoking cessation without nicotine replacement fails. Intermittent therapy is preferable over patches but avoid liquorice-flavoured nicotine products. Patches are useful, however, if the patient is experiencing pregnancy-related nausea and vomiting. If patches are used, they should be removed before bed.

**Breast-feeding** Nicotine is present in milk; however, the amount to which the infant is exposed is small and less hazardous than second-hand smoke. Intermittent therapy is preferred.

**Side-effects** Some systemic effects occur on initiation of therapy, particularly if the patient is using high-strength preparations; however, the patient may confuse side-effects of the nicotine-replacement preparation with nicotine withdrawal symptoms. Common symptoms of nicotine withdrawal include malaise, headache, dizziness, sleep disturbance, coughing, influenza-like symptoms, depression, irritability, increased appetite, weight gain, restlessness, anxiety, drowsiness, aphthous ulcers, decreased heart rate, and impaired concentration.

Mild topical reactions at the beginning of treatment are common because of the irritant effect of nicotine. _Oral preparations and inhalation cartridges can cause irritation of the throat, gum and lozenges can cause increased salivation, and patches can cause minor skin irritation._ The _nasal spray_ commonly causes coughing, nasal irritation, epistaxis, sneezing, and watery eyes.

Gastro-intestinal disturbances are common and may be caused by swallowed nicotine. Nausea, vomiting, dyspepsia, and hiccup occur most frequently. Ulcerative stomatitis has also been reported. Dry mouth is a common side-effect of lozenges, patches and sublingual tablets. _Lozenges_ cause diarrhoea, constipation, dysphagia, oesophagitis, gastritis, mouth ulcers, bloating, flatulence, and less commonly, taste disturbance, thirst, gingival bleeding, and halitosis. Palpitations may occur with nicotine replacement therapy and rarely patches can cause arrhythmia. _Patches_ and _lozenges_ can cause chest pain.

Abnormal dreams can occur with patches; removal of the patch before bed may help. _Lozenges_ may cause hot flushes; sweating, arthralgia, and myalgia can occur with _patches_.

**Nicotine medicated chewing gum** Individuals who smoke fewer than 20 cigarettes each day should use one piece of 2-mg strength gum when the urge to smoke occurs; individuals who smoke more than 20 cigarettes each day or who require more than 15 pieces of 2-mg strength gum each day should use the 4-mg strength. Patients should not exceed 15 pieces of 4-mg strength gum daily. If attempting _smoking_ cessation, treatment should continue for 3 months before reducing the dose.

**Administration** Chew the gum until the taste becomes strong, then rest it between the cheek and gum; when the taste starts to fade, repeat this process. One piece of gum lasts for approximately 30 minutes.

**Nicotine inhalation cartridge** The cartridges can be used when the urge to smoke occurs or to prevent cravings, up to a maximum of 12 cartridges daily.

**Administration** Insert the cartridge into the device and draw in air through the mouthpiece. The amount of nicotine from 1 puff of the cartridge is less than that from a cigarette, therefore it is necessary to inhale more often than when smoking a cigarette. A single cartridge lasts for approximately 20 minutes of intense use.

**Nicotine lozenge** One lozenge should be used every 1–2 hours when the urge to smoke occurs. Individuals
who smoke less than 20 cigarettes each day should usually use the lower-strength lozenges; individuals who smoke more than 20 cigarettes each day and those who fail to stop smoking with the low-strength lozenges should use the higher-strength lozenges. Patients should not exceed 15 lozenges daily. If attempting smoking cessation, treatment should continue for 6–12 weeks before attempting a reduction in dose.

**Administration** Slowly allow each lozenge to dissolve in the mouth; periodically move the lozenge from one side of the mouth to the other. Lozenges last for 10–30 minutes, depending on their size.

**Nicotine transdermal patches** As a general guide for smoking cessation, individuals who smoke more than 10 cigarettes daily should apply a high-strength patch daily for 6–8 weeks, followed by the medium-strength patch for 2 weeks, and then the low-strength patch for the final 2 weeks; individuals who smoke fewer than 10 cigarettes daily can usually start with the medium-strength patch for 6–8 weeks, followed by the low-strength patch for 2–4 weeks. A slower titration schedule can be used in patients who are not ready to quit but want to reduce cigarette consumption before a quit attempt.

If abstinence isn’t achieved, or if withdrawal symptoms are experienced, the strength of the patch used should be maintained or increased until the patient is stabilised. Patients using the high-strength patch who experience excessive side-effects, that do not resolve within a few days, should change to a medium-strength patch for the remainder of the initial period and then use the low-strength patch for 2–4 weeks.

**Administration** Patches should be applied on waking to help smoking cessation, treatment should continue for up to 3 months before reducing the dose.

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**

- See notes above

**Nicorette**<sup>®</sup> (McNeil)<br>Tablets (sublingual) (Nicorette Microtab<sup>®</sup>), nicotine (as a cyclodextrin complex) 2 mg, net price starter pack of 2 × 15-tablet discs with dispenser = £4.46; pack of 100 = £12.12. Label: 26

**Note** Also available in lemon flavour, also available as NicAssist<sup>®</sup>

**Excipients** lemon flavour includes aspartame (section 9.4.1)

**Chewing gum**, sugar-free, nicotine (as resin) 2 mg, net price pack of 30 = £3.41, pack of 105 = £9.37, pack of 210 = £14.82; 4 mg, pack of 30 = £3.99, pack of 105 = £11.48, pack of 210 = £18.24

**Note** Also available in mint, freshfruit, freshmint, and icy white flavours. Also available as NicAssist<sup>®</sup>

**Note** Nicorette<sup>®</sup>Combifit patch + gum (containing Invisi patches 15 mg and Icy White gum 2 mg) also available

**Patches**, self-adhesive, beige, nicotine, ‘5 mg’ patch (releasing approx. 5 mg/16 hours), net price 7 = £9.07; ‘10 mg’ patch (releasing approx. 10 mg/16 hours), net price 7 = £9.07; ‘15 mg’ patch (releasing approx. 15 mg/16 hours), 2 = £2.85, 7 = £9.07

**Note** Also available as NicAssist<sup>®</sup>

**Invisi** patches, self-adhesive, beige, nicotine, ‘10 mg’ patch (releasing approx. 10 mg/16 hours), net price 7 = £9.97; ‘15 mg’ patch (releasing approx. 15 mg/16 hours), 7 = £9.97; ‘25 mg’ patch (releasing approx. 25 mg/16 hours), 7 = £9.97

**Note** Nicorette<sup>®</sup>Combifit patch + gum (containing Invisi patches 15 mg and Icy White gum 2 mg) also available

**Nasal spray**, nicotine 500 microgram/metered spray, net price 200-spray unit = £13.40

**Note** Also available as NicAssist<sup>®</sup>

**Inhalator** (nicotine-impregnated plug for use in inhalator mouthpiece), nicotine 10 mg/cartridge, net price 6-cartridge (starter) pack = £4.46, 42-cartridge (refill) pack = £14.01. Counselling, administration, see notes above

**Note** Also available as NicAssist<sup>®</sup>

**Nicotinell**<sup>®</sup> (Novartis Consumer Health)

**Chewing gum**, sugar-free, nicotine (as polacrilin complex) 2 mg, net price pack of 12 = £1.71, pack of 24 = £3.01, pack of 96 = £8.26, pack of 204 = £14.23; 4 mg, pack of 12 = £1.70, pack of 24 = £3.30, pack of 96 = £10.26

**Note** Also available in fruit, licorice and mint flavours

**Mint lozenge**, sugar-free, nicotine (as bitartrate) 1 mg, net price pack of 12 = £1.71, pack of 36 = £4.27, pack of 96 = £9.12; 2 mg, net price pack of 12 = £1.99, pack of 36 = £4.95, pack of 96 = £10.60. Label: 24

**Excipients** include aspartame (section 9.4.1)

**TTS Patches**, self-adhesive, all yellowish-ochre, nicotine, ‘10 mg’ patch (releasing approx. 7 mg/24 hours), net price 7 = £9.12; ‘20 mg’ patch (releasing approx. 14 mg/24 hours), net price 2 = £2.57, 7 = £9.40; ‘30 mg’ patch (releasing approx. 21 mg/24 hours), net price 2 = £2.85, 7 = £9.97, 21 = £24.51

**NiQuitin**<sup>®</sup> (GSK Consumer Healthcare)<br>Chewing gum, sugar-free, mint-flavour, nicotine 2 mg (white), net price pack of 12 = £1.71, pack of 24 = £3.65, pack of 96 = £8.55; 4 mg (yellow), net price pack of 12 = £1.71, pack of 24 = £3.65, pack of 96 = £8.55

**Lozenges**, sugar-free, nicotine (as resinate) 1.5 mg (cherry- and mint-flavoured), net price pack of 20 = £...
### 4.10.3 Opioid dependence

The management of opioid dependence requires medical, social, and psychological treatment; access to a multidisciplinary team is recommended. Treatment for opioid dependence should be initiated under the supervision of an appropriately qualified prescriber.

Untreated heroin dependence shows early withdrawal symptoms within 8 hours, with peak symptoms at 36–72 hours; symptoms subside substantially after 5 days. Methadone or buprenorphine withdrawal occurs later, with longer-lasting symptoms.

#### Varenicline

Varenicline is a selective nicotine-receptor partial agonist used as an aid for smoking cessation.

**Indications** see notes above

**Cautions** risk of relapse, irritability, depression, and insomnia on discontinuation (consider dose tapering on completion of 12-week course); history of psychiatric illness (may exacerbate underlying illness including depression)

**MHRA/CHM advice**

**Suicidal behaviour and varenicline**

Patients should be advised to discontinue treatment and seek prompt medical advice if they develop agitation, depressed mood, or suicidal thoughts. Patients with a history of psychiatric illness should be monitored closely while taking varenicline.

**Renal impairment** if eGFR less than 30 mL/minute/1.73 m², initial dose 500 micrograms once daily, increased after 3 days to 1 mg once daily

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** present in milk in animal studies

**Side-effects** gastro-intestinal disturbances, appetite changes, dry mouth, taste disturbance; headache, drowsiness, dizziness, sleep disorders, abnormal dreams; less commonly thirst, weight gain, anphotheatosis, gingival pain, chest pain, hypertension, tachycardia, atrial fibrillation, palpitation, panic attack, mood swings, dysarthria, asthma, tremor, incoordination, hyperesthesia, restlessness, hypoesthesia, impaired temperature regulation, menorrhagia, vaginal discharge, sexual dysfunction, dysuria, arthralgia, muscle spasm, visual disturbances, eye pain, lacrimation, tinnitus, acne, sweating, rash, and pruritus; myocardial infarction, anxiety, depression, aggression, irrational behaviour, psychosis, suicidal ideation (see MHRA/CHM advice above), and Stevens-Johnson syndrome also reported

**Dose**

- **ADULT** over 18 years, start 1–2 weeks before target stop date, initially 500 micrograms once daily for 3 days, increased to 500 micrograms twice daily for 4 days, then 1 mg twice daily for 11 weeks (reduce to 500 micrograms twice daily if not tolerated); 12-week course can be repeated in abstinent individuals to reduce risk of relapse

**Champix® (Pfizer)**

 Tablets, f/c, varenicline (as tartrate) 500 micrograms (white), net price 56-tab pack = £54.60; 1 mg (blue)

28-tab pack = £27.30, 56-tab pack = £54.60; starter pack of 11 × 500-microgram tabs with 14 × 1-mg tabs = £27.30. Label: 3

---

**Missed doses**

Patients who miss 3 days or more of their regular prescribed dose of opioid maintenance therapy are at risk of overdose because of loss of tolerance. Consider reducing the dose in these patients.

If the patient misses 5 or more days of treatment, an assessment of illicit drug use is also recommended before restarting substitution therapy; this is particularly important for patients taking buprenorphine, because of the risk of precipitated withdrawal.
Buprenorphine Buprenorphine is an opioid-receptor partial agonist (it has opioid agonist and antagonist properties). Buprenorphine is preferred by some patients because it is less sedating than methadone; for this reason it may be more suitable for employed patients or those undertaking other skilled tasks such as driving. Buprenorphine is safer than methadone when used in conjunction with other sedating drugs, and has fewer drug interactions. Dose reductions may be easier than with methadone because the withdrawal symptoms are milder, and patients generally require fewer adjunctive medications; there is also a lower risk of overdose. Buprenorphine can be given on alternate days in higher doses and it requires a shorter drug-free period than methadone before induction with naltrexone for prevention of relapse (p. 317).

Patients dependent on high doses of opioids may be at increased risk of precipitated withdrawal. Precipitated withdrawal may occur in any patient if buprenorphine is administered when other opioid agonist drugs are in circulation. Precipitated opioid withdrawal, if it occurs, starts within 1–3 hours of the first buprenorphine dose and peaks at around 6 hours. Non-opioid adjunctive therapy, such as lofexidine (p. 317), may be required if symptoms are severe.

The first dose of buprenorphine should be given when the patient is exhibiting signs of withdrawal, or 6–12 hours after the last use of heroin (or other short-acting opioid), or 24–48 hours after the last dose of methadone. It is possible to titrate the dose of buprenorphine within one week—more rapidly than with methadone therapy—but care is still needed to avoid toxicity or precipitated withdrawal, dividing the dose on the first day may be useful.

In patients taking methadone who want to switch to buprenorphine, the dose of methadone should be reduced to a maximum of 30 mg daily before starting buprenorphine treatment. If the dose of methadone is over 10 mg daily, buprenorphine can be started at a dose of 4 mg daily and titrated according to requirements; if the methadone dose is below 10 mg daily, buprenorphine can be started at a dose of 2 mg daily.

Buprenorphine should not normally be used in patients with liver dysfunction. Baseline liver function tests and documentation of viral hepatitis status is recommended prior to commencing therapy, and regular liver function tests should be performed throughout treatment.

A combination preparation containing buprenorphine with naloxone (Suboxone®, p. 316) can be prescribed for patients when there is a risk of dose diversion for parenteral administration; the naloxone component precipitates withdrawal if the preparation is injected, but it has little effect when the preparation is taken sublingually.

**Methadone** Methadone, a long-acting opioid agonist, is usually administered in a single daily dose as methadone oral solution 1 mg/mL. Patients with a long history of opioid misuse, those who typically abuse a mixture of sedative drugs and alcohol, and those who experience increased anxiety during withdrawal of opioids may prefer methadone to buprenorphine because it has a more pronounced sedative effect.

Methadone is initiated at least 8 hours after the last heroin dose, provided that there is objective evidence of withdrawal symptoms. A supplementary dose on the first day may be considered if there is evidence of persistent opioid withdrawal symptoms. Because of the long half-life, blood levels progressively rise during initial treatment even if the patient remains on the same daily dose (it takes 3–10 days for plasma levels to reach steady-state in patients on a stable dose); a dose tolerated on the first day of treatment may become a toxic dose on the third day as cumulative toxicity develops. Thus, titration to the optimal dose in methadone maintenance treatment may take several weeks.

**Pregnancy** Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone or buprenorphine should be undertaken gradually during the second trimester; for example, the dose of methadone may be reduced by 2–3 mg every 3–5 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.

Further withdrawal of methadone or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.

The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute. Signs of neonatal withdrawal from opioids usually develop 24–72 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe but rare, symptoms include hypertonicity and convulsions.
Breast-feeding  The dose of methadone should be kept as low as possible in breast-feeding mothers and the infant should be monitored for sedation (high doses of methadone carry an increased risk of sedation and respiratory depression in the neonate). Buprenorphine is excreted in low levels in breast milk and has low oral bioavailability; however, neonates should be monitored for drowsiness, adequate weight gain, and developmental milestones.

Increased sleepiness, breathing difficulties, or limpness should be monitored for drowsiness, adequate weight gain, and has low oral bioavailability; however, neonates should be monitored for drowsiness, adequate weight gain, and developmental milestones.

Buprenorphine is excreted in low levels in breast milk (with naloxone) and is for drug dependent persons (see also p. 8).

METHADONE HYDROCHLORIDE

Indications  adjunct in treatment of opioid dependence; premedication, peri-operative analgesia, analgesia in other situations (section 4.7.2).

Cautions  see Methadone, section 4.7.2.

Contra-indications  see Methadone, section 4.7.2.

Hepatic impairment  see notes in section 4.7.2.

Renal impairment  see notes in section 4.7.2.

Pregnancy  see notes above.

Breast-feeding  see notes above.

Side-effects  see Methadone, section 4.7.2; overdose: see Emergency Treatment of Poisoning, p. 36.

Important  Methadone, even in low doses is a special hazard for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.

Incompatibility  Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.

Dose  Initially 10–40 mg daily, increased by up to 10 mg daily (max. weekly increase 150 mg) until no signs of withdrawal or intoxication; usual dose range 60–120 mg daily; CHILD not recommended (see also important note above).

Note  Methadone hydrochloride doses in the BNF may differ from those in the product literature.

Methadone (Non-proprietary)

Oral solution 1 mg/mL, methadone hydrochloride 1 mg/mL, net price 20 mL = £0.89, 30 mL = £2.42, 40 mL = £7.20, 50 mL = £10.00, 80 mL = £17.00, 100 mL = £22.76, 200 mL = £45.00, 500 mL = £113.34. Label: 2

Brands include Methadone® (sugar-free), Physeptone (sugar-free).

Important  Methadone oral solution 1 mg/mL is 2½ times the strength of Methadone Linctus (section 3.9.1). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.

Injection, methadone hydrochloride 25 mg/mL, net price 2-mL amp = £2.05; 50 mg/mL, 1-mL amp = £2.05.

Brands include Synastone®.

Methadose® (Rosemont)

Oral concentrate, methadone hydrochloride 10 mg/mL (blue), net price 150 mL = £12.01, 20 mg/mL (brown), 150 mL = £24.02. Label: 2

Note  The final strength of the methadone mixture to be dispensed to the patient must be specified on the prescription.

Important  Care is required in prescribing and dispensing the correct strength since any confusion could lead to an overdose; this preparation should be dispensed only after dilution as appropriate with Methadose® Diluent (life of diluted solution 3 months) and is for drug dependent persons (see also p. 8).

Adjunctive therapy and symptomatic treatment

Adjunctive therapy may be required for the management of opioid withdrawal symptoms. Loperamide (p. 58) may be used for the control of diarrhoea; mebeverine (p. 48) for controlling stomach cramps; paracetamol (p. 259) and non-steroidal anti-inflammatory drugs (p. 630) for muscular pains and headaches; metoclopramide (p. 253) or prochlorperazine (p. 252) may be useful for nausea or vomiting. Topical rubefacients (p. 664) can be helpful for relieving muscle pain associated with methadone withdrawal. If a patient is suffering from insomnia, benzodiazepines (section 4.1) or zopiclone (p. 210) may be prescribed, but because of
the potential for abuse, prescriptions should be limited to a short course of a few days only. If anxiety or agitation is severe, specialist advice should be sought.

**Lofexidine** Lofexidine is an alpha-2-adrenergic agonist. It may alleviate some of the physical symptoms of opioid withdrawal by attenuating the increase in adrenergic neurotransmission that occurs during opioid withdrawal. Lofexidine can be prescribed as an adjuvant to opioid substitution therapy, initiated either at the same time as the opioid substitute, or during withdrawal of the opioid substitute. Alternatively, lofexidine may be prescribed instead of an opioid substitute in patients who have mild or uncertain dependence (including young people), and those with a short history of illicit drug use. The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal. Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation; treatment should be discontinued gradually over 2–4 days to reduce the risk of rebound hypertension.

**LOFEXIDINE HYDROCHLORIDE**

**Indications** management of symptoms of opioid withdrawal

**Cautions** severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, bradycardia, hypotension (monitor pulse rate and blood pressure); history of QT prolongation, concomitant administration of drugs that prolong QT interval, metabolic disturbances; withdraw gradually over 2–4 days (or longer) to minimise risk of rebound hypertension and associated symptoms; depression; interaction: Appendix 1 (lofexidine)

**Renal impairment** caution in chronic impairment

**Pregnancy** use only if benefit outweighs risk—no information available

**Breast-feeding** use only if benefit outweighs risk—no information available

**Side-effects** dry mucous membranes; hypotension, bradycardia; dizziness, drowsiness; QT-interval prolongation also reported

**Dose**

- Initially, 800 micrograms daily in divided doses, increased as necessary in steps of 400–800 micrograms daily to max. 2.4 mg daily in divided doses; max. single dose 800 micrograms; recommended duration of treatment 7–10 days if no opioid use (but longer may be required)

**BritLofex** (Genus) Tablets, peach, f/c, lofexidine hydrochloride 200 micrograms, net price 60-tab pack = £61.79. Label: 2

**Opioid-receptor antagonists**

Naloxone is an opioid-receptor antagonist used to reverse opioid overdose. Patients dependant on opioids can be given a supply of naloxone to be used in case of accidental overdose; see Emergency Treatment of Poisoning, p. 36.

Naltrexone is an opioid-receptor antagonist that precipitates withdrawal symptoms in opioid-dependent subjects. Because the effects of opioid-receptor agonists are blocked by naltrexone, it is prescribed as an aid to prevent relapse in formerly opioid-dependent patients.

**NICE guidance**

**Naltrexone for the management of opioid dependence (January 2007)**

Naltrexone is recommended for the prevention of relapse in formerly opioid-dependent patients who are motivated to remain in a supportive care abstinence programme. Naltrexone should be administered under supervision and its effectiveness in preventing opioid misuse reviewed regularly.

**NALTREXONE HYDROCHLORIDE**

**Indications** adjunct to prevent relapse in formerly opioid-dependent patients (who have remained opioid-free for at least 7–10 days)

**Cautions** liver function tests needed before and during treatment; test for opioid dependence with naltrexone before treatment; avoid concomitant use of opioids but increased dose of opioid analgesic may be required for pain (monitor for opioid intoxication)

**Note** Patients should be warned that an attempt to overcome the blockade of opioid receptors by overdosing could result in acute opioid intoxication

**Contra-indications** patients currently dependent on opioids

- **Hepatic impairment** avoid in acute hepatitis, hepatic failure, or severe impairment

- **Renal impairment** avoid in severe impairment

- **Pregnancy** use only if benefit outweighs risk

- **Breast-feeding** avoid—present in milk in animal studies

**Side-effects** nausea, vomiting, abdominal pain, diarrhoea, constipation, reduced appetite, increased thirst; chest pain; anxiety, sleep disorders, headache, depression; reduced energy, increased energy, irritability, emotional lability, dizziness; chills; urinary retention; delayed ejaculation, decreased potency; arthralgia, myalgia; increased laceration; rash; and increased sweating; rarely hepatic dysfunction, suicidal ideation, and speech disorders; very rarely hallucinations, tremor, and idiopathic thrombocytopenia

**Dose**

- **ADULT** over 18 years (initiate in specialist clinics only), 25 mg initially then 50 mg daily; total weekly dose (350 mg) may be divided and given on 3 days of the week for improved compliance (e.g. 100 mg on Monday and Wednesday, and 150 mg on Friday)

**Naloxone** (Bristol-Myers Squibb) Tablets, yellow, f/c, scored, naltrexone hydrochloride 50 mg, net price 28-tab pack = £23.00

**Opizone** (Genus) Tablets, beige, f/c, scored, naltrexone hydrochloride 50 mg, net price 28-tab pack = £22.34

**Opizone** (Genus) Tablets, beige, f/c, scored, naltrexone hydrochloride 50 mg, net price 28-tab pack = £23.00

**Opizone** (Genus) Tablets, beige, f/c, scored, naltrexone hydrochloride 50 mg, net price 28-tab pack = £23.00

**4.11 Drugs for dementia**

Acetylcholinesterase inhibiting drugs are used in the treatment of Alzheimer’s disease, specifically for mild to moderate disease. Rivastigmine is also licensed for
4.11 Drugs for dementia

DONEPEZIL HYDROCHLORIDE

**Indications**  mild to moderate dementia in Alzheimer’s disease

**Cautions** sick sinus syndrome or other supraventricular conduction abnormalities; susceptibility to peptic ulcers; asthma, chronic obstructive pulmonary disease; interactions: Appendix 1 (parasympathomimetics)

**Hepatic impairment** caution in mild to moderate impairment, no information available for severe impairment

**Side-effects** nausea, vomiting, anorexia, diarrhoea; fatigue, insomnia, headache, dizziness, syncope, hallucinations, agitation, aggression; muscle cramps; urinary incontinence; rash, pruritus; less commonly gastric and duodenal ulcers, gastro-intestinal haemorrhage, bradycardia, seizures; rarely sino-atrial block, AV block, hepatitis, extrapyramidal symptoms; potential for bladder outflow obstruction

**Dose**
- Initially 5 mg once daily at bedtime, increased if necessary after one month to max. 10 mg daily

**Aricept®** (Eisai)®

- **Tablets,** f/c, donepezil hydrochloride 5 mg (white), net price 28-tab pack = £59.85; 10 mg (yellow), 28-tab pack = £83.89.

**Aricept Evess®** (Eisai)®

- **Orodispersible tablets,** donepezil hydrochloride 5 mg (white), net price 28-tab pack = £59.85; 10 mg (yellow), 28-tab pack = £83.89. Counselling, administration

**Counselling**  Aricept Evess® should be placed on the tongue, allowed to disperse, and swallowed

---

**NICE guidance**

**Donepezil, galantamine, rivastigmin, and memantine for Alzheimer’s disease (August 2009)**

Donepezil, galantamine, and rivastigmine can be used for the treatment of moderate Alzheimer’s disease in patients whose mini mental-state examination (MMSE) score is 10–20 points under the following conditions:
- Alzheimer’s disease must be diagnosed in a specialist clinic; cognitive, global, and behavioural functioning, activities of daily living, and the likelihood of compliance with treatment must be assessed;
- treatment should be initiated by specialists but can be continued by general practitioners under a shared-care protocol;
- the carers’ views of the condition should be sought before and during treatment;
- the patient should be assessed every 6 months and drug treatment should continue only if the MMSE score remains at or above 10 points and if treatment is considered to have a worthwhile effect on the global, functional, and behavioural condition.

Healthcare professionals should not rely solely on the MMSE score to assess the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties. NICE does not recommend initiation of memantine for Alzheimer’s disease except as part of clinical studies.

---

**GALANTAMINE**

**Indications**  mild to moderate dementia in Alzheimer’s disease

**Cautions** cardiac disease (including sick sinus syndrome or other supraventricular conduction abnormalities, unstable angina, congestive heart failure); electrolyte disturbances; susceptibility to peptic ulcers; asthma, chronic obstructive pulmonary disease, pulmonary infection; avoid in urinary retention, gastro-intestinal obstruction, and while recovering from bladder or gastro-intestinal surgery; interactions: Appendix 1 (parasympathomimetics)

**Hepatic impairment**
- for immediate-release preparations in moderate impairment, initially 4 mg once daily (preferably in the morning) for at least 7 days, then 4 mg twice daily for at least 4 weeks; max. 8 mg twice daily; avoid in severe impairment
- for modified-release preparations in moderate impairment, initially 8 mg on alternate days (preferably in the morning) for 7 days, then 8 mg once daily for 4 weeks; max. 16 mg daily; avoid in severe impairment

**Renal impairment**  avoid if eGFR less than 9 mL/minute/1.73m²

**Side-effects** vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, anorexia, weight loss, bradycardia, hypertension, syncope, hallucination, depression, dizziness, tremor, headache, drowsiness, malaise, muscle spasm, sweating; less commonly taste disturbance, palpitation, arrhythmias, first-degree AV block,
hypotension, flushing, paraesthesia, dehydration, muscular weakness, blurred vision, tinnitus; rarely hepatitis, exacerbation of Parkinson’s disease, seizures

**Dose**
- Initially 4 mg twice daily for 4 weeks increased to 8 mg twice daily for 4 weeks; maintenance 8–12 mg twice daily

**Reminyl®** *(Shire)*
- **Tablets**, f/c, galantamine (as hydrobromide) 8 mg (pink), net price 56-tab pack = £68.32; 12 mg (orange-brown), 56-tab pack = £64.00. Label: 3, 21, 25
- **Oral solution**, galantamine (as hydrobromide) 4 mg/mL, net price 100 mL with pipette = £120.00. Label: 3, 21

**Cautions**
- moderate to severe dementia in Alzheimer’s disease
- monitor body-weight; sick sinus syndrome, anorexia, weight loss, increased salivation, abdominal pain, bradycardia, dizziness, headache, drowsiness, malaise, agitation, anxiety, restlessness, confusion, insomnia, extrapyramidal symptoms (and worsening of Parkinson’s disease), dehydration, sweating; less commonly atrial fibrillation, AV block, depression, syncope; rarely gastric and duodenal ulceration, angina, seizures, rash; very rarely gastro-intestinal haemorrhage, pancreatitis, tachycardia, hypertension, hallucinations

**Note** Transdermal administration less likely to cause gastrointestinal disturbance

**Dose**
- See under preparations

---

**MEMANTINE HYDROCHLORIDE**

**Indications** moderate to severe dementia in Alzheimer’s disease

**Cautions** history of convulsions; interactions: Appendix 1 (memantine)

**Hepatic impairment** avoid in severe impairment—no information available

**Renal impairment** reduce dose to 10 mg daily if eGFR 30–49 mL/minute/1.73 m², if well tolerated after at least 7 days dose can be increased in steps to 20 mg daily; reduce dose to 10 mg daily if eGFR 5–29 mL/minute/1.73 m²; avoid if eGFR less than 5 mL/minute/1.73 m²

**Side-effects** constipation; hypertension; dyspnoea; headache, dizziness, drowsiness; less commonly vomiting, thrombosis, heart failure, confusion, fatigue, hallucinations, and abnormal gait; very rarely seizures; pancreatitis, psychosis, depression, and suicidal ideation also reported

**Dose**
- Initially 5 mg once daily, increased in steps of 5 mg at weekly intervals; max. 20 mg daily

**Ebixa®** *(Lundbeck)*
- **Tablets**, f/c, scored, memantine hydrochloride 10 mg, net price 28-tab pack = £34.50, 56-tab pack = £69.01, 112-tab pack = £138.01; 20 mg, 28-tab pack = £69.01; treatment initiation pack, 7 × 5 mg, 7 × 10 mg, 7 × 15 mg, and 7 × 20 mg = £43.13
- **Oral solution**, memantine hydrochloride 5 mg/actuation (10 mg/mL), net price 50-g pump pack = £61.61, 100-g pump pack = £123.23
- **Counselling** Solution should be dosed onto a spoon or into a glass of water

**RIVASTIGMINE**

**Indications** mild to moderate dementia in Alzheimer’s disease or in Parkinson’s disease

**Cautions** gastric or duodenal ulcers (or susceptibility to ulcers); monitor body-weight; sick sinus syndrome, conduction abnormalities; history of asthma or chronic obstructive pulmonary disease; history of seizures; bladder outflow obstruction; interactions: Appendix 1 (parasympathomimetics)

**Hepatic impairment** use with caution; avoid in severe impairment

**Renal impairment** use with caution

**Side-effects** nausea, vomiting, diarrhoea, dyspepsia, anorexia, weight loss, increased salivation, abdominal pain, bradycardia, dizziness, headache, drowsiness, malaise, agitation, anxiety, restlessness, confusion, insomnia, extrapyramidal symptoms (and worsening of Parkinson’s disease), dehydration, sweating; less commonly atrial fibrillation, AV block, depression, syncope; rarely gastric and duodenal ulceration, angina, seizures, rash; very rarely gastro-intestinal haemorrhage, pancreatitis, tachycardia, hypertension, hallucinations

**Cautions** use with caution; avoid in severe impairment

**Renal impairment** use with caution

**Side-effects** nausea, vomiting, diarrhoea, dyspepsia, anorexia, weight loss, increased salivation, abdominal pain, bradycardia, dizziness, headache, drowsiness, malaise, agitation, anxiety, restlessness, confusion, insomnia, extrapyramidal symptoms (and worsening of Parkinson’s disease), dehydration, sweating; less commonly atrial fibrillation, AV block, depression, syncope; rarely gastric and duodenal ulceration, angina, seizures, rash; very rarely gastro-intestinal haemorrhage, pancreatitis, tachycardia, hypertension, hallucinations

**Note** Transdermal administration less likely to cause gastrointestinal disturbance

**Dose**
- See under preparations

**Exelon** *(Novartis)*
- **Capsules**, rivastigmine (as hydrogen tartrate) 1.5 mg (yellow), net price 28-cap pack = £33.25, 56-cap pack = £66.51; 3 mg (orange), 28-cap pack = £33.25, 56-cap pack = £66.51; 4.5 mg (red), 28-cap pack = £33.25, 56-cap pack = £66.51; 6 mg (red/orange), 28-cap pack = £33.25, 56-cap pack = £66.51. Label: 21, 25
- **Oral solution**, rivastigmine (as hydrogen tartrate) 2 mg/mL, net price 120 mL (oral syringe) = £99.14. Label: 21
- **Dose** initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily at intervals of at least 2 weeks according to response and tolerance; usual range 3–6 mg twice daily; max. 6 mg twice daily; if treatment interrupted for more than several days, treatment should be retarded from 1.5 mg twice daily

**Patches**, self-adhesive, beige, rivastigmine 4.6 mg/24 hours, net price 30 = £77.97; 9.5 mg/24 hours, 30 = £77.97
- **Dose** initially apply 4.6 mg/24 hours patch to clean, dry, non-hairy, non-irritated skin on back, upper arm, or chest, removing after 24 hours and using a replacement patch on a different area (avoid using the same area for 14 days); if well tolerated increase to 9.5 mg/24 hours patch daily after at least 4 weeks; if treatment interrupted for more than several days, treatment should be retarded from 4.6 mg/24 hours patch

**Note** When switching from oral to transdermal therapy, patients taking 3–6 mg by mouth daily should initially switch to 4.6 mg/24 hours patch (then titrate as above); patients taking 9–12 mg by mouth daily should initially switch to 9.5 mg/24 hours patch daily after at least 4 weeks; if treatment interrupted for more than several days, treatment should be retarded from 4.6 mg/24 hours patch

**Note** When switching from oral to transdermal therapy, patients taking 3–6 mg by mouth daily should initially switch to 4.6 mg/24 hours patch (then titrate as above); patients taking 9–12 mg by mouth daily should switch to 9.5 mg/24 hours patch daily after at least 4 weeks; if treatment interrupted for more than several days, treatment should be retarded from 4.6 mg/24 hours patch

**Note** The Scottish Medicines Consortium (p. 4) has advised (October 2007) that Exelon® patches should be restricted for use in patients with moderately severe Alzheimer’s disease under the conditions of the NICE guidance (September 2007) and when a transdermal patch is an appropriate choice of formulation
5 Infections

5.1 Antibacterial drugs

5.1.1 Penicillins

5.1.1.1 Benzylpenicillin and phenoxy-methylpenicillin

5.1.1.2 Penicillinase-resistant penicillins

5.1.1.3 Broad-spectrum penicillins

5.1.1.4 Antipseudomonal penicillins

5.1.1.5 Mecillinams

5.1.2 Cephalosporins, carbapenems, and other beta-lactams

5.1.2.1 Cephalosporins

5.1.2.2 Carbapenems

5.1.2.3 Other beta-lactam antibiotics

5.1.3 Tetracyclines

5.1.4 Aminoglycosides

5.1.5 Macrolides

5.1.6 Clindamycin

5.1.7 Some other antibacterials

5.1.8 Sulfonamides and trimethoprim

5.1.9 Antituberculosis drugs

5.1.10 Antileprotic drugs

5.1.11 Metronidazole and tinidazole

5.1.12 Quinolones

5.1.13 Urinary-tract infections

5.2 Antifungal drugs

5.2.1 Triazole antifungals

5.2.2 Imidazole antifungals

5.2.3 Polyene antifungals

5.2.4 Echinocandin antifungals

5.2.5 Other antifungals

5.3 Antiviral drugs

5.3.1 HIV infection

5.3.2 Herpesvirus infections

5.3.2.1 Herpes simplex and varicella–zoster infection

5.3.2.2 Cytomegalovirus infection

5.3.3 Viral hepatitis

5.3.4 Influenza

5.3.5 Respiratory syncytial virus

5.4 Antiprotozoal drugs

5.4.1 Antimalarials

5.4.2 Amoebicides

5.4.3 Trichomonacides

5.4.4 Antigiardial drugs

5.4.5 Leishmaniacides

5.4.6 Trypanocides

5.4.7 Drugs for toxoplasmosis

5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

5.5.1 Drugs for threadworms

5.5.2 Ascaricides

5.5.3 Drugs for tapeworm infections

5.5.4 Drugs for hookworms

5.5.5 Schistosomicides

5.5.6 Filaricides

5.5.7 Drugs for cutaneous larva migrans

5.5.8 Drugs for strongylodiasis

This chapter also includes advice on the drug management of the following:
- anthrax, p. 368
- Clostridium difficile infection, p. 322
- bacterial infections: table 1, summary of antibacterial treatment, p. 322
- bacterial infections: table 2, summary of antibacterial prophylaxis, p. 330
- Lyme disease, p. 336
- MRSA infections, p. 334
- oral infections, p. 321, p. 328, p. 373

Notifiable diseases

Doctors must notify the Proper Officer of the local authority (usually the consultant in communicable disease control) when attending a patient suspected of suffering from any of the diseases listed below; a form is available from the Proper Officer.

- Anthrax
- Botulism
- Brucellosis
- Cholera
- Diarrhoea (infectious bloody)
- Diphtheria
- Encephalitis, acute
- Food poisoning
- Haemolytic uraemic syndrome
- Haemorrhagic fever (viral)
- Hepatitis, viral
- Legionnaires’ disease
- Leprosy
- Malaria
- Measles
- Meningitis
- Meningococcal septicaemia
- Paratyphoid fever
- Plague
- Poliomyelitis, acute
- Rabies
- Rubella
- SARS
- Scarlet fever
- Smallpox
- Streptococcal disease (Group A, invasive)
- Tuberculosis
- Typhoid fever
- Typhus
- Whooping cough
- Yellow fever

Note: It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.
5.1 Antibacterial drugs

Choice of a suitable drug  Before selecting an antibacterial the clinician must first consider two factors—the patient and the known or likely causative organism. Factors related to the patient which must be considered include history of allergy, renal and hepatic function, susceptibility to infection (i.e., whether immunocompromised), ability to tolerate drugs by mouth, severity of illness, ethnic origin, age, whether taking other medication and, if female, whether pregnant, breast-feeding or taking an oral contraceptive.

The known or likely organism and its antibacterial sensitivity, in association with the above factors, will suggest one or more antibacterials, the final choice depending on the microbiological, pharmacological, and toxicological properties.

An example of a rational approach to the selection of an antibacterial is treatment of a urinary-tract infection in a patient complaining of nausea and symptoms of a urinary-tract infection in early pregnancy. The organism is reported as being resistant to ampicillin but sensitive to nitrofurantoin (can cause nausea), gentamicin (can be given only by injection and best avoided in pregnancy), tetracycline (causes dental discoloration) and trimethoprim (folate antagonist therefore theoretical teratogenic risk), and cefalexin. The safest antibiotics in pregnancy are the penicillins and cephalosporins; therefore, cefalexin would be indicated for this patient.

The principles involved in selection of an antibacterial must allow for a number of variables including changing renal and hepatic function, increasing bacterial resistance, and new information on side-effects. Duration of therapy depends on the microbiological, pharmacological, and toxicological properties.

Before starting therapy  The following precepts need to be considered before starting:

- Viral infections should not be treated with antibacterials. However, antibacterials may be used to treat secondary bacterial infection (e.g., bacterial pneumonia secondary to influenza);
- Samples should be taken for culture and sensitivity testing; ‘blind’ antibacterial prescribing for unexplained pyrexia usually leads to further difficulty in establishing the diagnosis;
- Knowledge of prevalent organisms and their current sensitivity is of great help in choosing an antibacterial before bacteriological confirmation is available. Generally, narrow-spectrum antibacterials are preferred to broad-spectrum antibacterials unless there is a clear clinical indication (e.g., life-threatening sepsis);
- The dose of an antibacterial varies according to a number of factors including age, weight, hepatic function, renal function, and severity of infection. The prescribing of the so-called ‘standard’ dose in serious infections may result in failure of treatment or even death of the patient; therefore it is important to prescribe a dose appropriate to the condition. An inadequate dose may also increase the likelihood of antibacterial resistance. On the other hand, for an antibacterial with a narrow margin between the toxic and therapeutic dose (e.g., an aminoglycoside) it is also important to avoid an excessive dose and the concentration of the drug in the plasma may need to be monitored;
- The route of administration of an antibacterial often depends on the severity of the infection. Life-threatening infections require intravenous therapy. Antibacterials that are well absorbed may be given by mouth even for some serious infections. Parenteral administration is also appropriate when the oral route cannot be used (e.g., because of vomiting) or if absorption is inadequate. Whenever possible, painful intramuscular injections should be avoided in children;
- Duration of therapy depends on the nature of the infection and the response to treatment. Courses should not be unduly prolonged because they encourage resistance, they may lead to side-effects and they are costly. However, in certain infections such as tuberculosis or osteomyelitis it may be necessary to treat for prolonged periods. Conversely a single dose of an antibacterial may cure uncomplicated urinary-tract infections.

Oral bacterial infections  Antibacterial drugs should only be prescribed for the treatment of oral infections on the basis of defined need. They may be used in conjunction with (but not as an alternative to) other appropriate measures, such as providing drainage or extracting a tooth.

The ‘blind’ prescribing of an antibacterial for unexplained pyrexia, cervical lymphadenopathy, or facial swelling can lead to difficulty in establishing the diagnosis. In severe oral infections, a sample should always be taken for bacteriology.

Oral infections which may require antibacterial treatment include acute periapical or periodontal abscess, cellulitis, acutely created oral-antral communication (and acute sinusitis), severe pericoronitis, localised osteitis, acute necrotising ulcerative gingivitis, and destructive forms of chronic periodontal disease. Most of these infections are readily resolved by the early establishment of drainage and removal of the cause (typically an infected necrotic pulp). Antibacterials may be required if treatment has to be delayed, in immunocompromised patients, or in those with conditions such as diabetes or Paget’s disease. Certain rarer infections including bacterial sialadenitis, osteomyelitis, actinomycosis, and infections involving fascial spaces such as Ludwig’s angina, require antibiotics and specialist hospital care.

Antibacterial drugs may also be useful after dental surgery in some cases of spread of infection. Infection may spread to involve local lymph nodes, to fascial spaces (where it can cause airway obstruction), or into the bloodstream (where it can lead to cavernous sinus thrombosis and other serious complications). Extension of an infection can also lead to maxillary sinusitis; osteomyelitis is a complication, which usually arises when host resistance is reduced.

If the oral infection fails to respond to antibacterial treatment within 48 hours the antibacterial should be changed, preferably on the basis of bacteriological...
investigation. Failure to respond may also suggest an incorrect diagnosis, lack of essential additional measures (such as drainage), poor host resistance, or poor patient compliance.

Combination of a penicillin (or erythromycin) with metronidazole may sometimes be helpful for the treatment of severe oral infections or oral infections that have not responded to initial antibacterial treatment.

See also Penicillins (section 5.1.1), Cephalosporins (section 5.1.2), Tetracyclines (section 5.1.3), Macrolides (section 5.1.5), Clindamycin (section 5.1.6), Metronidazole (section 5.1.11), Fusidic acid (section 13.10.1.2).

Superinfection In general, broad-spectrum antibacterial drugs such as the cephalosporins are more likely to be associated with adverse reactions related to the selection of resistant organisms e.g. fungal infections or antibiotic-associated colitis (pseudomembranous colitis); other problems associated with superinfection include vaginitis and pruritus ani.

**Therapy** Suggested treatment is shown in table 1. When the pathogen has been isolated treatment may be changed to a more appropriate antibacterial if necessary. If no bacterium is cultured the antibacterial can be continued or stopped on clinical grounds. Infections for which prophylaxis is useful are listed in table 2.

---

**Table 1. Summary of antibacterial therapy**

If treating a patient suspected of suffering from a notifiable disease, the consultant in communicable disease control should be informed (see p. 320)

### Gastro-intestinal system

**Gastro-enteritis**

Frequently self-limiting and may not be bacterial.

Antibacterial not usually indicated

**Campylobacter enteritis**

Frequently self-limiting; treat if immunocompromised or if severe infection.

- Clarithromycin
  - Alternative, ciprofloxacin

**Salmonella (non-typhoid)**

Treat invasive or severe infection. Do not treat less severe infection unless there is a risk of developing invasive infection (e.g. immunocompromised patients, those with haemoglobinopathy, the elderly, or children under 6 months of age).

- Ciprofloxacin or ceftaxime

**Shigellosis**

Antibacterial not indicated for mild cases.

- Ciprofloxacin or azithromycin
  - Alternatives if micro-organism sensitive, amoxicillin or trimethoprim

**Typhoid fever**

Infections from Middle-East, South Asia, and South-East Asia may be multiple-antibacterial-resistant and sensitivity should be tested.

- Cefotaxime
  - Azithromycin may be an alternative in mild or moderate disease caused by multiple-antibacterial-resistant organisms.
  - Alternative, ciprofloxacin

- Strains with decreased sensitivity to ciprofloxacin being isolated

**Clostridium difficile infection**

- Oral metronidazole
  - Suggested duration of treatment 10–14 days

  For third or subsequent episode of infection, for severe infection, for infection not responding to metronidazole, or in patients intolerant of metronidazole, oral vancomycin

  - Suggested duration of treatment 10–14 days

  For infection not responding to vancomycin, or for life-threatening infection, or in patients with ileus, oral vancomycin + i/v metronidazole

  - Suggested duration of treatment 10–14 days

**Biliary-tract infection**

- Ciprofloxacin or gentamicin or a cephalosporin

---

1. Where clarithromycin is suggested azithromycin or erythromycin may be used
2. Where cefotaxime is suggested ceftriaxone may be used
Peritonitis
A cephalosporin + metronidazole or gentamicin + metronidazole or gentamicin + clindamycin or piperacillin with tazobactam alone

Peritonitis: peritoneal dialysis-associated
Vancomycin1 + ceftazidime added to dialysis fluid or vancomycin added to dialysis fluid + ciprofloxacin by mouth
Suggested duration of treatment 14 days or longer

Cardiovascular system

Endocarditis: initial 'blind' therapy
Flucloxacillin (or benzylpenicillin if symptoms less severe) + gentamicin
If cardiac prostheses present, or if penicillin-allergic, or if meticillin-resistant Staphylococcus aureus suspected, vancomycin + rifampicin + gentamicin

Endocarditis caused by staphylococci
Flucloxacillin
Add rifampicin for at least 2 weeks in prosthetic valve endocarditis.
Suggested duration of treatment at least 4 weeks (at least 6 weeks for prosthetic valve endocarditis)
If penicillin-allergic or if meticillin-resistant Staphylococcus aureus, vancomycin + rifampicin
Suggested duration of treatment at least 4 weeks (at least 6 weeks for prosthetic valve endocarditis)

Native-valve endocarditis caused by fully-sensitive streptococci (e.g. viridans streptococci)
Benzylpenicillin
Suggested duration of treatment 4 weeks
Alternatively if a large vegetation, intracardial abscess, or infected emboli are absent, benzylpenicillin + gentamicin
Suggested duration of treatment 2 weeks
If penicillin-allergic, vancomycin
Suggested duration of treatment 4 weeks

Native-valve endocarditis caused by less-sensitive streptococci
Benzylpenicillin + gentamicin
Suggested duration of treatment 4–6 weeks (stop gentamicin after 2 weeks for micro-organisms moderately sensitive to penicillin)
If aminoglycoside cannot be used and if streptococci moderately sensitive to penicillin, benzylpenicillin
Suggested duration of treatment 4 weeks
If penicillin-allergic or highly penicillin-resistant, vancomycin1 + gentamicin
Suggested duration of treatment 4–6 weeks (stop gentamicin after 2 weeks for micro-organisms moderately sensitive to penicillin)

Prosthetic valve endocarditis caused by streptococci
Benzylpenicillin + gentamicin
Suggested duration of treatment at least 6 weeks (stop gentamicin after 2 weeks if micro-organisms fully sensitive to penicillin)
If penicillin-allergic or highly penicillin-resistant, vancomycin1 + gentamicin
Suggested duration of treatment at least 6 weeks (stop gentamicin after 2 weeks if micro-organisms fully sensitive to penicillin)

Endocarditis caused by enterococci (e.g. Enterococcus faecalis)
Amoxicillin2 + gentamicin
If gentamicin-resistant, substitute gentamicin with streptomycin.
Suggested duration of treatment at least 4 weeks (at least 6 weeks for prosthetic valve endocarditis)
If penicillin-allergic or penicillin-resistant, vancomycin1 + gentamicin
If gentamicin-resistant, substitute gentamicin with streptomycin.
Suggested duration of treatment at least 4 weeks (at least 6 weeks for prosthetic valve endocarditis)

Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK' micro-organisms)
Amoxicillin2 + low-dose gentamicin
Suggested duration of treatment 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin after 2 weeks
If amoxicillin-resistant, ceftriaxone + low-dose gentamicin
Suggested duration of treatment 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin after 2 weeks

1. Where vancomycin is suggested teicoplanin may be used
2. Where amoxicillin is suggested ampicillin may be used

Infections
Respiratory system

Haemophilus influenzae epiglottitis
Cefotaxime

If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol

Chronic bronchitis: acute exacerbations
Treat if increase in sputum purulence accompanied by an increase in sputum volume or increase in dyspnoea.

Amoxicillin or tetracycline
Some pneumococci and *Haemophilus influenzae* strains tetracycline-resistant; approx. 20% *H. influenzae* strains amoxicillin-resistant.

**Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients**

Alternative, clarithromycin

**Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients**

Pneumonia: low-severity community-acquired
Amoxicillin

Pneumococci with decreased penicillin sensitivity being isolated, but not yet common in UK.
If atypical pathogens suspected, add clarithromycin.

**Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients**

Alternatives, doxycycline or clarithromycin

**Suggested duration of treatment 5 days (14–21 days for infections caused by staphylococci)**

Pneumonia: moderate-severity community-acquired
Amoxicillin + clarithromycin or doxycycline alone

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

**Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)**

Pneumonia: high-severity community-acquired
Co-amoxiclav + clarithromycin

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

**Suggested duration of treatment 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)**

Alternative, cefuroxime + clarithromycin or cefotaxime + clarithromycin

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

**Suggested duration of treatment 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)**

Pneumonia possibly caused by atypical pathogens
Clarithromycin

If high-severity Legionella infection, add rifampicin for the first few days.

**Suggested duration of treatment 14 days (usually 7–10 days for Legionella)**

Alternative if Legionella infection suspected, a quinolone
If high-severity Legionella infection, add clarithromycin or rifampicin for the first few days.

**Suggested duration of treatment usually 7–10 days**

Alternative for chlamydial or mycoplasma infections, doxycycline

**Suggested duration of treatment 14 days**

Pneumonia: hospital-acquired

*Early-onset infection* (less than 5 days after admission to hospital), co-amoxiclav or cefuroxime

If life-threatening infection, or if history of antibacterial treatment in the last 3 months, or if resistant microorganisms suspected, treat as for late-onset hospital-acquired pneumonia.

**Suggested duration of treatment 7 days**

*Late-onset infection* (more than 5 days after admission to hospital), an antipseudomonal penicillin (e.g. piperacillin with tazobactam) or a broad-spectrum cephalosporin (e.g. ceftazidime) or another antipseudomonal beta-lactam or a quinolone (e.g. ciprofloxacin)

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

For severe illness caused by *Pseudomonas aeruginosa*, consider adding an aminoglycoside.

**Suggested duration of treatment 7 days (longer if *Pseudomonas aeruginosa* confirmed)**

---

1. Where cefotaxime is suggested ceftriaxone may be used
2. Where amoxicillin is suggested ampicillin may be used
3. Where clarithromycin is suggested azithromycin or erythromycin may be used
4. Where vancomycin is suggested teicoplanin may be used
Central nervous system

Meningitis: initial empirical therapy

- Transfer patient to hospital urgently
- If meningococcal disease (meningitis with non-blanching rash or meningococcal septicaemia) suspected, benzylpenicillin (see p. 334 for dose) can be given before transfer to hospital, so long as this does not delay the transfer. If a patient with suspected bacterial meningitis without non-blanching rash cannot be transferred to hospital urgently, benzylpenicillin (see p. 334 for dose) can be given before the transfer. Cefotaxime (section 5.1.2) may be an alternative in penicillin allergy; chloramphenicol (section 5.1.7) may be used if history of immediate hypersensitivity reaction to penicillin or to cephalosporins.

- In hospital, consider adjunctive treatment with dexamethasone (particularly if pneumococcal meningitis suspected in adults; section 6.3.2), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial; avoid dexamethasone in septic shock, meningococcal septicaemia, or if immunocompromised, or in meningitis following surgery.

- In hospital, if aetiology unknown:
  - Adult and child 3 months–50 years, cefotaxime
    Consider adding vancomycin if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
    Suggested duration of treatment at least 10 days
  - Adult over 50 years, cefotaxime + amoxicillin
    Consider adding vancomycin if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
    Suggested duration of treatment at least 10 days

Meningitis caused by meningococci

Benzylenpicillin or cefotaxime

Suggested duration of treatment 7 days.

To eliminate nasopharyngeal carriage give rifampicin for 2 days (see Table 2, section 5.1)

If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol

Suggested duration of treatment 7 days.

To eliminate nasopharyngeal carriage give rifampicin for 2 days (see Table 2, section 5.1)

Meningitis caused by pneumococci

Cefotaxime

Consider adjunctive treatment with dexamethasone (section 6.3.2), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial (may reduce penetration of vancomycin into cerebrospinal fluid).

If micro-organism penicillin-sensitive, replace cefotaxime with benzylpenicillin.

If micro-organism highly penicillin- and cephalosporin-resistant, add vancomycin and if necessary rifampicin.

Suggested duration of antibacterial treatment 14 days

Meningitis caused by Haemophilus influenzae

Cefotaxime

Consider adjunctive treatment with dexamethasone (section 6.3.2), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.

Suggested duration of antibacterial treatment 10 days.

For H. influenzae type b give rifampicin for 4 days before hospital discharge (see Table 2, section 5.1)

If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, or if micro-organism resistant to cefotaxime, chloramphenicol

Consider adjunctive treatment with dexamethasone (section 6.3.2), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.

Suggested duration of antibacterial treatment 10 days.

For H. influenzae type b give rifampicin for 4 days before hospital discharge (see Table 2, section 5.1)

Meningitis caused by Listeria

Amoxicillin + gentamicin

Suggested duration of treatment 21 days.

Consider stopping gentamicin after 7 days

If history of immediate hypersensitivity reaction to penicillin, co-trimoxazole

Suggested duration of treatment 21 days

1. Where cefotaxime is suggested ceftriaxone may be used
2. Where amoxicillin is suggested ampicillin may be used
Urinary tract

Pyelonephritis: acute
A broad-spectrum cephalosporin or a quinolone
Suggested duration of treatment 10–14 days (longer treatment may be necessary in complicated pyelonephritis)

Prostatitis: acute
Ciprofloxacin or ofloxacin
Suggested duration of treatment 28 days
Alternative, trimethoprim
Suggested duration of treatment 28 days

Urinary-tract infection: ‘lower’
Trimethoprim or nitrofurantoin
Suggested duration of treatment 7 days, but a short course (e.g. 3 days) is usually adequate for uncomplicated urinary-tract infections in women. See also section 5.1.13
Alternative, amoxicillin\(^1\) or oral cephalosporin
Suggested duration of treatment 7 days, but a short course (e.g. 3 days) is usually adequate for uncomplicated urinary-tract infections in women. See also section 5.1.13

Genital system

Early syphilis (infection of less than 2 years)
Contact tracing recommended.
Benzathine benzylpenicillin [unlicensed]
Suggested duration of treatment single-dose (repeat dose after 7 days for women in the third trimester of pregnancy)
Alternative, doxycycline or erythromycin
Suggested duration of treatment 14 days

Late latent syphilis (asymptomatic infection of more than 2 years)
Contact tracing recommended.
Benzathine benzylpenicillin [unlicensed]
Suggested duration of treatment once weekly for 2 weeks
Alternative, doxycycline
Suggested duration of treatment 28 days

Asymptomatic contacts of patients with infectious syphilis
Doxycycline
Suggested duration of treatment 14 days

Gonorrhoea: uncomplicated
Contact tracing recommended. Remember chlamydia. Choice of antibacterial depends on locality where infection acquired.
Cefixime
Suggested duration of treatment single-dose
Alternative if micro-organism sensitive, ciprofloxacin
Suggested duration of treatment single-dose
Pharyngeal infection, ceftriaxone
Suggested duration of treatment single-dose

Uncomplicated genital chlamydial infection, non-gonococcal urethritis and non-specific genital infection
Contact tracing recommended.
Azithromycin or doxycycline
Suggested duration of treatment azithromycin as a single dose or doxycycline for 7 days
Alternative, erythromycin
Suggested duration of treatment 14 days

Pelvic inflammatory disease
Contact tracing recommended.
Doxycycline + metronidazole + i/m ceftriaxone or ofloxacin + metronidazole
Suggested duration of treatment 14 days (use i/m ceftriaxone as a single dose).
In severely ill patients initial treatment with doxycycline + i/v ceftriaxone (as a single dose) + i/v metronidazole, then switch to oral treatment with doxycycline + metronidazole to complete 14 days’ treatment

---
\(^1\) Where amoxicillin is suggested ampicillin may be used
**Bacterial vaginosis**

Oral metronidazole

*Suggested duration of treatment* 5–7 days (or high-dose metronidazole as a single dose)

Alternatively, topical metronidazole or topical clindamycin

*Suggested duration of treatment* 5 days with metronidazole or 7 days with clindamycin

**Septicaemia: community-acquired**

A broad-spectrum antipseudomonal penicillin (e.g. piperacillin with tazobactam, ticarcillin with clavulanic acid) or a broad-spectrum cephalosporin (e.g. cefuroxime)

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

If anaerobic infection suspected, add metronidazole to broad-spectrum cephalosporin.

If other resistant micro-organisms suspected, use a more broad-spectrum beta-lactam antibacterial (e.g. meropenem)

**Septicaemia: hospital-acquired**

A broad-spectrum antipseudomonal beta-lactam antibacterial (e.g. piperacillin with tazobactam, ticarcillin with clavulanic acid, cefuroxime, imipenem with cilastatin, or meropenem)

If meticillin-resistant *Staphylococcus aureus* suspected, add vancomycin.

If anaerobic infection suspected, add metronidazole to broad-spectrum cephalosporin

**Septicaemia related to vascular catheter**

Vancomycin

If Gram-negative sepsis suspected, especially in the immunocompromised, add a broad-spectrum antipseudomonal beta-lactam.

Consider removing vascular catheter, particularly if infection caused by *Staphylococcus aureus*, pseudomonas, or *Candida* species

**Meningococcal septicaemia**

If meningococcal disease suspected, a single dose of benzylpenicillin (see p. 334 for dose) can be given before urgent transfer to hospital, so long as this does not delay the transfer; cefotaxime (section 5.1.2) may be an alternative in penicillin allergy; chloramphenicol may be used if history of immediate hypersensitivity reaction to penicillin or to cephalosporins.

Benzylpenicillin or cefotaxime

To eliminate nasopharyngeal carriage give rifampicin for 2 days (see Table 2, section 5.1)

If *history of immediate hypersensitivity reaction to penicillin or to cephalosporins*, chloramphenicol

To eliminate nasopharyngeal carriage give rifampicin for 2 days (see Table 2, section 5.1)

**Musculoskeletal system**

**Osteomyelitis**

Seek specialist advice if chronic infection or prostheses present.

Flucloxacillin

Consider adding fusidic acid or rifampicin for initial 2 weeks.

*Suggested duration of treatment* 6 weeks for acute infection

If *penicillin-allergic*, clindamycin

Consider adding fusidic acid or rifampicin for initial 2 weeks.

*Suggested duration of treatment* 6 weeks for acute infection

If meticillin-resistant *Staphylococcus aureus* suspected, vancomycin

Consider adding fusidic acid or rifampicin for initial 2 weeks.

*Suggested duration of treatment* 6 weeks for acute infection

**Septic arthritis**

Seek specialist advice if prostheses present.

Flucloxacillin

*Suggested duration of treatment* 4–6 weeks (longer if infection complicated)

If *penicillin-allergic*, clindamycin

*Suggested duration of treatment* 4–6 weeks (longer if infection complicated)

If meticillin-resistant *Staphylococcus aureus* suspected, vancomycin

*Suggested duration of treatment* 4–6 weeks (longer if infection complicated)

If *gonococcal arthritis or Gram-negative infection suspected*, cefotaxime

*Suggested duration of treatment* 4–6 weeks (longer if infection complicated; treat gonococcal infection for 2 weeks)

---

1. Where vancomycin is suggested teicoplanin may be used
2. Where cefotaxime is suggested ceftriaxone may be used
5.1 Antibacterial drugs

**Eye**

**Purulent conjunctivitis**
Chloramphenicol eye-drops
See also section 11.3.1

**Ear, nose, and oropharynx**

**Pericoronitis**
Antibacterial required only in presence of systemic features of infection, or of trismus, or persistent swelling despite local treatment.
- Metronidazole
  - *Suggested duration of treatment* 3 days or until symptoms resolve
- *Alternative*, amoxicillin
  - *Suggested duration of treatment* 3 days or until symptoms resolve

**Gingivitis: acute necrotising ulcerative**
Antibacterial required only if systemic features of infection.
- Metronidazole
  - *Suggested duration of treatment* 3 days or until symptoms resolve
- *Alternative*, amoxicillin
  - *Suggested duration of treatment* 3 days or until symptoms resolve

**Periapical or periodontal abscess**
Antibacterial required only in severe disease with cellulitis or if systemic features of infection.
- Amoxicillin
  - *Suggested duration of treatment* 5 days
- *Alternative*, metronidazole
  - *Suggested duration of treatment* 5 days

**Periodontitis**
Antibacterial used as an adjunct to debridement in severe disease or disease unresponsive to local treatment alone.
- Metronidazole
- *Alternative*, doxycycline

**Throat infections**

Most throat infections are caused by viruses and many do not require antibacterial therapy. Consider antibacterial, if history of valvular heart disease, if marked systemic upset, if peritonsillar cellulitis or abscess, or if at increased risk from acute infection (e.g. in immunosuppression, cystic fibrosis); prescribe antibacterial for beta-haemolytic streptococcal pharyngitis.

- Phenoxymethylpenicillin
  - In severe infection, initial parenteral therapy with benzylpenicillin, then oral therapy with phenoxymethylpenicillin or amoxicillin¹. Avoid amoxicillin if possibility of glandular fever, see section 5.1.1.3.
  - *Suggested duration of treatment* 10 days
- *If penicillin-allergic*, clarithromycin²
  - *Suggested duration of treatment* 10 days

**Sinusitis**

Antibacterial should usually be used only for persistent symptoms and purulent discharge lasting at least 7 days or if severe symptoms. Also, consider antibacterial for those at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis).

- Amoxicillin¹ or doxycycline or clarithromycin²
  - *Suggested duration of treatment* 7 days.
  - Consider oral co-amoxiclav if no improvement after 48 hours.
  - In severe infection, initial parenteral therapy with co-amoxiclav or cefuroxime may be required

**Otitis externa**

Consider systemic antibacterial if spreading cellulitis or patient systemically unwell.
For topical preparations see section 12.1.1.

- Flucloxacinilin
  - *If penicillin-allergic*, clarithromycin²
  - *If pseudomonas suspected*, ciprofloxacin (or an aminoglycoside)

---

¹ Where amoxicillin is suggested ampicillin may be used
² Where clarithromycin is suggested azithromycin or erythromycin may be used
Otitis media
Many infections caused by viruses. Most uncomplicated cases resolve without antibacterial treatment. In children without systemic features, antibacterial treatment may be started after 72 hours if no improvement. Consider earlier treatment if deterioration, if systemically unwell, if at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis), if mastoiditis present, or in children under 2 years of age with bilateral otitis media.

Amoxicillin¹
Consider co-amoxiclav if no improvement after 48 hours.

If penicillin-allergic, clarithromycin²

Suggested duration of treatment 5 days (longer if severely ill)

Skin
Impetigo: small areas of skin infected
Seek local microbiology advice before using topical treatment in hospital.

Topical fusidic acid

Suggested duration of treatment 7 days is usually adequate (max. 10 days)

Alternative if meticillin-resistant Staphylococcus aureus, topical mupirocin

Suggested duration of treatment 7 days is usually adequate (max. 10 days)

Impetigo: widespread infection

Oral flucloxacillin

If streptococci suspected in severe infection, add phenoxymethylpenicillin.

Suggested duration of treatment 7 days

If penicillin-allergic, oral clarithromycin²

Suggested duration of treatment 7 days

Erysipelas

Phenoxymethylpenicillin or benzylpenicillin

If staphylococci suspected, replace phenoxymethylpenicillin or benzylpenicillin with flucloxacillin.

Suggested duration of treatment at least 7 days

If penicillin-allergic, clindamycin or clarithromycin²

Suggested duration of treatment at least 7 days

Cellulitis: mild or moderate

Flucloxacillin

If streptococcal infection confirmed, replace flucloxacillin with phenoxymethylpenicillin or benzylpeni-
cillin.

If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibacterials

If penicillin-allergic, clindamycin or clarithromycin²

If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibacterials

Cellulitis: severe

Benzylpenicillin + flucloxacillin

If oral treatment required, replace benzylpenicillin with phenoxymethylpenicillin.

If streptococcal infection confirmed, discontinue flucloxacillin.

If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibacterials

If penicillin-allergic, clindamycin or clarithromycin²

If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibacterials

Animal and human bites
Cleanse wound thoroughly. For tetanus-prone wound, give human tetanus immunoglobulin (with a tetanus-containing vaccine if necessary, according to immunisation history and risk of infection), see under Tetanus Vaccines, section 14.4. Consider rabies prophylaxis (section 14.4) for bites from animals in endemic countries; assess risk of blood-borne viruses.

Co-amoxiclav

If penicillin-allergic, doxycycline + metronidazole

Acne
See section 13.6

¹ Where amoxicillin is suggested ampicillin may be used
² Where clarithromycin is suggested azithromycin or erythromycin may be used
Table 2. Summary of antibacterial prophylaxis

Prevention of recurrence of rheumatic fever
Phenoxymethylpenicillin 250 mg twice daily or sulfadiazine 1 g daily (500 mg daily for patients under 30 kg)

Prevention of secondary case of invasive group A streptococcal infection
Phenoxymethylpenicillin 250–500 mg every 6 hours for 10 days; CHILD under 1 year 62.5 mg every 6 hours, 1–5 years 125 mg every 6 hours, 6–12 years 250 mg every 6 hours
Patients who are penicillin allergic,
either erythromycin Adult and CHILD over 8 years, 250–500 mg every 6 hours for 10 days; CHILD under 2 years 125 mg every 6 hours, 2–8 years 250 mg every 6 hours
or azithromycin [unlicensed indication] 500 mg once daily for 5 days; CHILD over 6 months, 12 mg/kg (max. 500 mg) once daily

Prevention of secondary case of meningococcal meningitis
Rifampicin 600 mg every 12 hours for 2 days; CHILD 10 mg/kg (under 1 year, 5 mg/kg) every 12 hours for 2 days
or ciprofloxacin 500 mg as a single dose; CHILD [unlicensed] 2–5 years 125 mg; 5–12 years 250 mg
or i/v ceftriaxone [unlicensed indication] 250 mg as a single dose; CHILD under 12 years 125 mg

Prevention of secondary case of Haemophilus influenzae type b disease
Rifampicin 600 mg once daily for 4 days (regimen of choice for adults); CHILD 1–3 months 10 mg/kg once daily for 4 days, over 3 months 20 mg/kg once daily for 4 days (max. 600 mg daily)

Prevention of secondary case of diphtheria in non-immune patient
Erythromycin ⁵ 500 mg every 6 hours for 7 days; CHILD up to 2 years 125 mg every 6 hours, 2–8 years 250 mg every 6 hours
Treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment. For immunisation against diphtheria see section 14.4

Prevention of secondary case of pertussis in non-immune patient or partially immune patient
Erythromycin ³ Adult and CHILD over 8 years, 250–500 mg every 6 hours for 7 days; CHILD under 2 years 125 mg every 6 hours, 2–8 years 250 mg every 6 hours

Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease
Phenoxymethylpenicillin 500 mg every 12 hours; CHILD under 5 years 125 mg every 12 hours, 6–12 years 250 mg every 12 hours—if cover also needed for *H. influenzae* in CHILD give amoxicillin instead (under 5 years 125 mg every 12 hours, over 5 years 250 mg every 12 hours)
Note Antibiotic prophylaxis is not fully reliable; for vaccines in asplenia see p. 749

Prevention of gas-gangrene in high lower-limb amputations
Benzylenicillin 300–600 mg every 6 hours for 5 days or if penicillin-allergic metronidazole 400–500 mg every 8 hours

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive
Isoniazid 300 mg daily for 6 months; CHILD 5 mg/kg daily (max. 300 mg daily)
or isoniazid 300 mg daily + rifampicin 600 mg daily (450 mg if less than 50 kg) for 3 months; CHILD isoniazid 5 mg/kg daily (max. 300 mg daily) + rifampicin 10 mg/kg daily (max. 450 mg daily if body-weight less than 50 kg; max. 600 mg daily if body-weight over 50 kg)
or (if isoniazid-resistant tuberculosis in patients under 35 years) rifampicin 600 mg daily (450 mg if less than 50 kg) for 6 months; CHILD 10 mg/kg daily (max. 450 mg daily if body-weight less than 50 kg; max. 600 mg daily if body-weight over 50 kg)

Prevention of infection in gastro-intestinal procedures
Operations on stomach or oesophagus
Single dose of i/v gentamicin or i/v cefuroxime or i/v co-amoxiclav
Add i/v teicoplanin if high risk of meticillin-resistant *Staphylococcus aureus*

1. For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Health Protection Agency Laboratory). Unless there has been direct exposure of the mouth or nose to infectious droplets from a patient with meningococcal disease who has received less than 24 hours of antibacterial treatment, healthcare workers do not generally require chemoprophylaxis.
2. For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Health Protection Agency Laboratory).
3. Where erythromycin is suggested another macrolide (e.g. azithromycin or clarithromycin) may be used
4. For details of those who should receive chemoprophylaxis contact the lead clinician for local tuberculosis services (or a consultant in communicable disease control). See also section 5.1.9, for advice on immunocompromised patients and on prevention of tuberculosis.
5. Intravenous antibiotic prophylaxis should be given up to 30 minutes before the procedure.
6. Additional intra-operative or postoperative doses of antibacterial may be given for prolonged procedures or if there is major blood loss.
7. Where teicoplanin is suggested vancomycin may be used.
Open biliary surgery

Single dose of i/v cefuroxime + i/v metronidazole or i/v gentamicin + i/v metronidazole or i/v co-amoxiclav alone

Add i/v teicoplanin if high risk of meticillin-resistant Staphylococcus aureus

Resections of colon and rectum for carcinoma, and resections in inflammatory bowel disease, and appendicectomy

Single dose of i/v gentamicin + i/v metronidazole or i/v cefuroxime + i/v metronidazole or i/v co-amoxiclav alone

Add i/v teicoplanin if high risk of meticillin-resistant Staphylococcus aureus

Endoscopic retrograde cholangiopancreatography

Single dose of i/v gentamicin or oral or i/v ciprofloxacin

Prophylaxis recommended if pancreatic pseudocyst, immunocompromised, history of liver transplantation, or risk of incomplete biliary drainage. For biliary complications following liver transplantation, add i/v amoxicillin or i/v vancomycin

Percutaneous endoscopic gastrostomy or jejunostomy

Single dose of i/v co-amoxiclav or i/v cefuroxime

Use single dose of i/v teicoplanin if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant Staphylococcus aureus

Prevention of infection in orthopaedic surgery

Joint replacement including hip and knee

Single dose of i/v cefuroxime alone or i/v flucloxacillin + i/v gentamicin

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant Staphylococcus aureus, use single dose of i/v teicoplanin + i/v gentamicin

Closed fractures

Single dose of i/v cefuroxime or i/v flucloxacillin

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant Staphylococcus aureus, use single dose of i/v teicoplanin

Open fractures

i/v co-amoxiclav alone or i/v cefuroxime + i/v metronidazole (or i/v clindamycin alone if history of allergy to penicillins or to cephalosporins)

Add i/v teicoplanin if high risk of meticillin-resistant Staphylococcus aureus. Start prophylaxis within 3 hours of injury and continue until soft tissue closure (max. 72 hours); at first debridement also use a single dose of i/v cefuroxime + i/v metronidazole + i/v gentamicin or i/v co-amoxiclav + i/v gentamicin (or i/v clindamycin + i/v gentamicin if history of allergy to penicillins or to cephalosporins). At time of skeletal stabilisation and definitive soft tissue closure use a single dose of i/v gentamicin + i/v teicoplanin.

Prevention of infection in urological procedures

Transrectal prostate biopsy

Single dose of oral ciprofloxacin + oral metronidazole or i/v gentamicin + i/v metronidazole

Use single dose of i/v gentamicin + i/v metronidazole if high risk of meticillin-resistant Staphylococcus aureus

Transurethral resection of prostate

Single dose of oral ciprofloxacin or i/v gentamicin or i/v cefuroxime

Use single dose of i/v gentamicin if high risk of meticillin-resistant Staphylococcus aureus

Prevention of infection in obstetric and gynaecological surgery

Caesarean section

Single dose of i/v cefuroxime

Administer immediately after umbilical cord is clamped. Substitute i/v clindamycin if history of allergy to penicillins or cephalosporins. Add i/v teicoplanin if high risk of meticillin-resistant Staphylococcus aureus

Hysterectomy

Single dose of i/v cefuroxime + i/v metronidazole or i/v gentamicin + i/v metronidazole or i/v co-amoxiclav alone

Use single dose of i/v gentamicin + i/v metronidazole or add i/v teicoplanin to other regimens if high risk of meticillin-resistant Staphylococcus aureus

Termination of pregnancy

Single dose of oral metronidazole

If genital chlamydial infection cannot be ruled out, give doxycycline (section 5.1.3) postoperatively

Prevention of infection in cardiology procedures

Cardiac pacemaker insertion

Single dose of i/v cefuroxime alone or i/v flucloxacillin + i/v gentamicin or i/v teicoplanin + i/v gentamicin

Use single dose of i/v teicoplanin if high risk of meticillin-resistant Staphylococcus aureus

Prevention of infection in vascular surgery

Reconstructive arterial surgery of abdomen, pelvis or legs

Single dose of i/v cefuroxime alone or i/v flucloxacillin + i/v gentamicin

Add i/v metronidazole for patients at risk from anaerobic infections including those with diabetes, gangrene, or undergoing amputation. Use single dose of i/v teicoplanin if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant Staphylococcus aureus.
Prevention of endocarditis

NICE guidance
Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (March 2008)

Antibacterial prophylaxis and chlorhexidine mouthwash are not recommended for the prevention of endocarditis in patients undergoing dental procedures.

Antibacterial prophylaxis is not recommended for the prevention of endocarditis in patients undergoing procedures of the:
- upper and lower respiratory tract (including ear, nose, and throat procedures and bronchoscopy);
- genito-urinary tract (including urological, gynaecological, and obstetric procedures);
- upper and lower gastro-intestinal tract.

Whilst these procedures can cause bacteraemia, there is no clear association with the development of infective endocarditis. Prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

Any infection in patients at risk of endocarditis should be investigated promptly and treated appropriately to reduce the risk of endocarditis.

If patients at risk of endocarditis are undergoing a gastro-intestinal or genito-urinary tract procedure at a site where infection is suspected, they should receive appropriate antibacterial therapy that is followed by infection in patients with indwelling intraperitoneal catheters.

Patients at risk of endocarditis should be:
- advised to maintain good oral hygiene;
- told how to recognise signs of infective endocarditis, and advised when to seek expert advice.

Dermatological procedures
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who undergo dermatological procedures do not require antibacterial prophylaxis against endocarditis.

Joint prostheses and dental treatment

Joint prostheses and dental treatment
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intercurrent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive.

The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.

Immunosuppression and indwelling intraperitoneal catheters
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis.

The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

Dermatological procedures
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who undergo dermatological procedures do not require antibacterial prophylaxis against endocarditis.

Joint prostheses and dental treatment
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intercurrent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive.

The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.

Immunosuppression and indwelling intraperitoneal catheters
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis.

The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

5.1.1 Penicillins

5.1.1.1 Benzylpenicillin and phenoxymethylpenicillin
5.1.1.2 Penicillinase-resistant penicillins
5.1.1.3 Broad-spectrum penicillins
5.1.1.4 Antipseudomonal penicillins
5.1.1.5 Mecillinams

The penicillins are bactericidal and act by interfering with bacterial cell wall synthesis. They diffuse well into body tissues and fluids, but penetration into the cerebrospinal fluid is poor except when the meninges are inflamed. They are excreted in the urine in therapeutic concentrations.

Hypersensitivity reactions
The most important side-effect of the penicillins is hypersensitivity which causes rashes and anaphylaxis and can be fatal. Allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients. Patients with a history of atopic allergy (e.g. asthma, eczema, hay fever) are at a higher risk of anaphylactic reactions to penicillins. Indi-
Individuals with a history of a minor rash (i.e. non-confluent, non-pruritic rash restricted to a small area of the body) or a rash that occurs more than 72 hours after penicillin administration are probably not allergic to penicillin and in these individuals a penicillin should not be withheld unnecessarily for serious infections; the possibility of an allergic reaction should, however, be borne in mind. Other beta-lactam antibiotics (including cephalosporins) can be used in these patients.

**Other side-effects** A rare but serious toxic effect of the penicillins is encephalopathy due to cerebral irritation. This may result from excessively high doses or in patients with severe renal failure. The penicillins should not be given by intrathecal injection because they can cause encephalopathy which may be fatal.

Another problem relating to high doses of penicillin, or normal doses given to patients with renal failure, is the accumulation of electrolyte since most injectable penicillins contain either sodium or potassium. Diarrhoea frequently occurs during oral penicillin therapy. It is most common with broad-spectrum penicillins, which can also cause antibiotic-associated colitis.

**Benzylpenicillin and phenoxymethylpenicillin**

Benzylpenicillin sodium (Penicillin G) remains an important and useful antibiotic but is inactivated by bacterial beta-lactamases. It is effective for many streptococcal (including pneumococcal), gonococcal, and meningococcal infections and also for anthrax (section 5.1.12), diphtheria, gas-gangrene, leptospirosis, and treatment of Lyme disease (section 5.1.1.3). Pneumococci, meningococci, and gonococci which have decreased sensitivity to penicillin have been isolated; benzylpenicillin is no longer the drug of first choice for pneumococcal meningitis. Although benzylpenicillin is effective in the treatment of tetanus, metronidazole (section 5.1.11) is preferred. Benzylpenicillin is inactivated by gastric acid and absorption from the gut is low; therefore it is best given by injection.

Benzathine benzylpenicillin (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is used for the treatment of early syphilis and late latent syphilis; it is given by intramuscular injection.

Phenoxymethylpenicillin (Penicillin V) has a similar antibacterial spectrum to benzylpenicillin, but is less active. It is gastric acid-stable, so is suitable for oral administration. It should not be used for serious infections because absorption can be unpredictable and plasma concentrations variable. It is indicated principally for respiratory-tract infections in children, for streptococcal tonsillitis, and for continuing treatment after one or more injections of benzylpenicillin when clinical response has begun. It should not be used for meningococcal or gonococcal infections. Phenoxymethylpenicillin is used for prophylaxis against streptococcal infections following rheumatic fever and against pneumococcal infections following splenectomy or in sickle-cell disease.

**Oral infections** Phenoxymethylpenicillin is effective for dentoalveolar abscess.

---

**BENZYLPCENILLIN SODIUM**

(Penicillin G)

**Indications** throat infections, otitis media, endocarditis, meningococcal disease, pneumonia, cellulitis (Table 1, section 5.1); anthrax; intrapartum prophylaxis against group B streptococcal infection; prophylaxis in limb amputation (Table 2, section 5.1); see also notes above

**Cautions** history of allergy; false-positive urinary glucose (if tested for reducing substances); interactions: Appendix 1 (penicillins)

**Contra-indications** penicillin hypersensitivity

**Renal impairment** reduce dose—consult product literature; high doses may cause cerebral irritation, convulsions, or coma

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction; rarely CNS toxicity including convulsions (especially with high doses or in severe renal impairment), interstitial nephritis, haemolytic anaemia, leucopenia, thrombocytopenia, and coagulation disorders; also reported diarrhoea (including antibiotic-associated colitis)

**Dose**

- By intramuscular or by slow intravenous injection or by infusion, 0.6–1.2 g every 6 hours, increased if necessary in more serious infections (single doses over 1.2 g intravenous route only; see also below); NEONATE under 7 days, 25 mg/kg every 12 hours, dose doubled in severe infection; NEONATE 7–28 days, 25 mg/kg every 8 hours, dose doubled in severe infection; CHILD 1 month–18 years, 25 mg/kg every 6 hours (increased in severe infection to 50 mg/kg every 4–6 hours (max. 2.4 g every 4 hours); intravenous route recommended in neonates and infants
- Endocarditis (in combination with another antibiotic if necessary, see Table 1, section 5.1.1), by slow intravenous injection or by infusion, 1.2 g every 4 hours, increased if necessary (e.g. in enterococcal endocarditis or if benzylpenicillin used alone) to 2.4 g every 4 hours; CHILD 1 month–18 years see BNF for Children
- Anthrax (in combination with other antibiotics, see also section 5.1.12), by slow intravenous injection or by infusion, 2.4 g every 4 hours; CHILD 37.5 mg/kg every 6 hours
5.1.1 Penicillins

- Intrapartum prophylaxis against group B streptococcal infection, by slow intravenous injection or by infusion, initially 3 g then 1.5 g every 4 hours until delivery
- Meningitis, meningococcal disease, by slow intravenous injection or by infusion, 2.4 g every 4 hours;
- **NEONATE**, 75 mg/kg every 8 hours;  **CHILD** 1 month–18 years, 50 mg/kg every 4–6 hours (max. 2.4 g every 4 hours)

**Important.** If meningococcal disease (meningitis with non-blanching rash or meningococcal septicaemia) is suspected, a single dose of benzylpenicillin can be given before transferring the patient to hospital urgently, so long as this does not delay the transfer. If a patient with suspected bacterial meningitis without non-blanching rash cannot be transferred to hospital urgently, a single dose of benzylpenicillin can be given before the transfer. Suitable doses of benzylpenicillin by intravenous injection (or by intramuscular injection) are:
- **ADULT** 1.2 g, **INFANT** under 1 year 300 mg;  **CHILD** 1–9 years 600 mg, 10 years and over as for adults.
- In **penicillin allergy**, cefotaxime (section 5.1.2) may be an alternative; chloramphenicol (section 5.1.7) may be used if there is a history of anaphylaxis to penicillin

**By intrathecal injection, not recommended**

**Note** Benzylpenicillin doses in BNF may differ from those in product literature

**Crystapen** (Genus) \[\text{TM}\]

**Injection**, powder for reconstitution, benzylpenicillin sodium (unbuffered), net price 600-mg vial = £9.5p, 2-vial ‘GP pack’ = £2.64; 1.2-g vial = £1.89

**Electrolytes** Na\(^+\) 1.68 mmol/600-mg vial; 3.36 mmol/1.2-g vial

**PHENOXYMETHYLPENICILLIN** (Penicillin V)

**Indications**
oral infections (see notes above); tonsillitis, otitis media, erysipelas, cellulitis; group A streptococcal infection, rheumatic fever and pneumococcal infection prophylaxis (Table 2, section 5.1)

**Caution** see under Benzylpenicillin; **Interactions:** Appendix 1 (penicillins)

**Contra-indications** see under Benzylpenicillin

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** see under Benzylpenicillin

**Dose**
- 500 mg every 6 hours increased up to 1 g every 6 hours in severe infections; **CHILD** up to 1 year 62.5 mg every 6 hours, increased up to 12.5 mg/kg every 6 hours in severe infections; 1–6 years, 125 mg every 6 hours, increased up to 12.5 mg/kg every 6 hours in severe infections; 6–12 years, 250 mg every 6 hours, increased up to 12.5 mg/kg every 6 hours in severe infections

**Note** Phenoxymercaptilcin doses in the BNF may differ from those in product literature

**Phenoxymercaptilcin** (Non-proprietary) \[\text{TM}\]

**Tablets**, phenoxymercaptilcin (as potassium salt) 250 mg, net price 28-tab pack = £1.27. Label: 9, 23

**Dental prescribing on NHS** Phenoxymercaptilcin Tablets may be prescribed

**Oral solution**, phenoxymercaptilcin (as potassium salt) for reconstitution with water, net price 125 mg/5 mL, 100 mL = £1.90; 250 mg/5 mL, 100 mL = £2.59. Label: 9, 23

**Note** Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription

**Dental prescribing on NHS** Phenoxymercaptilcin Oral Solution may be prescribed

---

5.1.1.2 Penicillinase-resistant penicillins

Most staphylococci are now resistant to benzylpenicillin because they produce penicillinas. **Fluclaxillin**, however, is not inactivated by these enzymes and is thus effective in infections caused by penicillin-resistant staphylococci, which is the sole indication for its use. Fluclaxillin is acid-stable and can, therefore, be given by mouth as well as by injection.

Fluclaxillin is well absorbed from the gut. For a warning on hepatic disorders see under Fluclaxillin.

**Temocillin** is active against Gram-negative bacteria and is stable against a wide range of beta-lactamas. It should be reserved for the treatment of infections caused by beta-lactamase-producing strains of Gram-negative bacteria, including those resistant to third-generation cephalosporins. Temocillin is not active against **Pseudomonas aeruginosa** or **Acinetobacter spp**.

**MRSA** Infection from **Staphylococcus aureus** strains resistant to meticillin [now discontinued] (meticillin-resistant **Staph. aureus**, MRSA) and to fluclaxillin can be difficult to manage. Treatment is guided by the sensitivity of the infecting strain.

**Rifampicin** (section 5.1.9) or **sodium fusidate** (section 5.1.7) should not be used alone because resistance may develop rapidly. A **tetracycline** alone or a combination of rifampicin and sodium fusidate can be used for skin and soft-tissue infections caused by MRSA; **clindamycin** alone is an alternative. A **glycopeptide** (e.g. vancomycin, section 5.1.7) can be used for severe skin and soft-tissue infections associated with MRSA, if a glycopeptide is unsuitable, **linezolid** (section 5.1.7) can be used on expert advice. As linezolid is not active against Gram-negative organisms, it can be used for mixed skin and soft-tissue infections only when other treatments are not available; linezolid must be given with other antibacterials if the infection also involves Gram-negative organisms. A combination of a glycopeptide and sodium fusidate or a glycopeptide and rifampicin can be considered for skin and soft-tissue infections that have failed to respond to a single antibacterial.

**Tigecycline** (section 5.1.3) and **daptomycin** (section 5.1.7) are licensed for the treatment of complicated skin and soft-tissue infections involving MRSA.

A **tetracycline** or **clindamycin** can be used for **bronchectasis** caused by MRSA. A **glycopeptide** can be used for **pneumonia** associated with MRSA; if a glycopeptide is unsuitable, **linezolid** can be used on expert advice. Linezolid must be given with other antibacterials if the infection also involves Gram-negative organisms.

A **tetracycline** can be used for urinary-tract infections caused by MRSA; **trimethoprim** or **nitrofurantoin** are alternatives. A **glycopeptide** can be used for urinary-tract infections that are severe or resistant to other antibacterials.

A **glycopeptide** can be used for **septicaemia** associated with MRSA.

For the management of **endocarditis, osteomyelitis, or septic arthritis** associated with MRSA, see Table 1, section 5.1.

Prophylaxis with vancomycin or teicoplanin (alone or in combination with another antibacterial active against
other pathogens) is appropriate for patients undergoing surgery if:
- there is a history of MRSA colonisation or infection without documented eradication;
- there is a risk that the patient’s MRSA carriage has recurred;
- the patient comes from an area with a high prevalence of MRSA.

For eradication of nasal carriage of MRSA, see section 12.2.3.

**FLUCLOXACILLIN**

**Indications** infections due to beta-lactamase-producing staphylococci including otitis externa; adjunct in pneumonia, impetigo, cellulitis, osteomyelitis and in staphylococcal endocarditis (Table 1, section 5.1)

**Cautions** see under Benzylpenicillin (section 5.1.1.1); risk of kermicterus in jaundiced neonates when high doses given parenterally; interactions: Appendix 1 (penicillins)

**Hepatic disorders** Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Healthcare professionals are reminded that:
- flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin;
- flucloxacillin should be used with caution in patients with hepatic impairment;
- careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials.

**Contra-indications** see under Benzylpenicillin (section 5.1.1.1)

**Hepatic impairment** see Cautions and Hepatic Disorders above

**Renal impairment** reduce dose if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** see under Benzylpenicillin (section 5.1.1.1); also gastro-intestinal disturbances; very rarely hepatitis and cholestatic jaundice (see also Hepatic disorders above)

**Dose**
- **By mouth**, 250–500 mg every 6 hours, at least 30 minutes before food; **NEONATE** see BNF for Children; **CHILD** 1 month–2 years, 62.5–125 mg every 6 hours, at least 30 minutes before food; 2–10 years, 125–250 mg every 6 hours, at least 30 minutes before food
- **By intramuscular injection**, 250–500 mg every 6 hours; **CHILD** 1 month–18 years see BNF for Children
- **By slow intravenous injection or by intravenous infusion**, 0.25–2 g every 6 hours; **CHILD** under 18 years see BNF for Children

Endocarditis (in combination with another antibiotic, see Table 1, section 5.1), body-weight under 85 kg, 8 g daily in 4 divided doses; body-weight over 85 kg, 12 g daily in 6 divided doses; **CHILD** 1 month–18 years see BNF for Children

Osteomyelitis (see Table 1, section 5.1), up to 8 g daily in 3–4 divided doses; **CHILD** under 18 years see BNF for Children

Surgical prophylaxis, by slow intravenous injection or by intravenous infusion, 1–2 g up to 30 minutes before the procedure; up to 4 further doses of 500 mg may be given every 6 hours by mouth, or by intramuscular injection, or by slow intravenous injection or by intravenous infusion for high risk procedures

**Note** Flucloxacillin doses in BNF may differ from those in product literature

**Flucloxacillin** (Non-proprietary) \*FN\*

**Capsules**, flucloxacillin (as sodium salt) 250 mg, net price 28 = £2.07; 500 mg, 28 = £3.21. Label: 9, 23

**Brands** include Floxapen\*c, Floxomic\*c, Lodrophen\*c

**Oral solution** (= elixir or syrup), flucloxacillin (as sodium salt) for reconstitution with water, 125 mg/5 mL, net price 100 mL = £4.41; 250 mg/5 mL, 100 mL = £31.28. Label: 9, 23

**Brands** include Lodrophen\*c

Note Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription

**Injection**, powder for reconstitution, flucloxacillin (as sodium salt), net price 250-mg vial = £1.23; 500-mg vial = £2.45; 1-g vial = £4.90

**TEMOCILLIN**

**Indications** septicaemia, urinary-tract infections, lower respiratory-tract infections caused by susceptible Gram-negative bacteria

**Cautions** see under Benzylpenicillin (section 5.1.1.1); interactions: Appendix 1 (penicillins)

**Contra-indications** see under Benzylpenicillin (section 5.1.1.1)

**Renal impairment** 1 g every 12 hours if eGFR 20–60 mL/minute/1.73 m²; 1 g every 24 hours if eGFR 10–30 mL/minute/1.73 m²; 1 g every 48 hours or 500 mg every 24 hours if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** see under Benzylpenicillin (section 5.1.1.1)

**Dose**
- **ADULT** over 18 years, by intramuscular injection or by intravenous injection over 3–4 minutes, or by intravenous infusion, 1–2 g every 12 hours

**Negabam** (Eumedica) \*FN\*

**Injection**, powder for reconstitution, temocillin (as sodium salt), net price 1-g vial = £25.45

**Electrolytes** Na⁺ 5 mmol/L

**5.1.1.3 Broad-spectrum penicillins**

Ampicillin is active against certain Gram-positive and Gram-negative organisms but is inactivated by penicillinases including those produced by *Staphylococcus aureus* and by common Gram-negative bacilli such as *Escherichia coli*. Almost all staphylococci, approx. 60% of *E. coli* strains and approx. 20% of *Haemophilus influenzae* strains are now resistant. The likelihood of resistance should therefore be considered before using ampicillin for the ‘blind’ treatment of infections; in particular, it should not be used for hospital patients without checking sensitivity.

Ampicillin is well excreted in the bile and urine. It is principally indicated for the treatment of exacerbations of chronic bronchitis and middle ear infections, both of which may be due to *Streptococcus pneumoniae* and *H. influenzae*, and for urinary-tract infections (section 5.1.13).
Ampicillin can be given by mouth but less than half the dose is absorbed, and absorption is further decreased by the presence of food in the gut. Maculopapular rashes commonly occur with ampicillin (and amoxicillin) but are not usually related to true penicillin allergy. They almost always occur in patients with glandular fever; broad-spectrum penicillins should not therefore be used for 'blind' treatment of a sore throat. The risk of rash is also increased in patients with acute or chronic lymphocytic leukaemia or in cytomegalovirus infection.

Amoxicillin is a derivative of ampicillin and has a similar antibacterial spectrum. It is better absorbed than ampicillin when given by mouth, producing higher plasma and tissue concentrations; unlike ampicillin, absorption is not affected by the presence of food in the stomach. Amoxicillin may also be used for the treatment of Lyme disease [not licensed], see below.

Co-amoxiclav consists of amoxicillin with the beta-lactamase inhibitor clavulanic acid. Clavulanic acid itself has no significant antibacterial activity but, by inactivating beta-lactamases, it makes the combination active against beta-lactamase-producing bacteria that are resistant to amoxicillin. These include resistant strains of Staph. aureus, E. coli, and H. influenzae, as well as many Bacteroides and Klebsiella spp. Co-amoxiclav should be reserved for infections likely, or known, to be caused by amoxicillin-resistant beta-lactamase-producing strains.

A combination of amoxicillin with fluclouxacin (as co-fluampicil) is available to treat infections involving either streptococci or staphylococci (e.g. cellulitis). Fluampicil) is available to treat infections involving staphylococci (e.g. cellulitis).

**Indications** see under Ampicillin; also oral infections, Lyme disease (see notes above); endocarditis treatment (Table 1, section 5.1); anthrax (section 5.1.12); adjunct in laterial meningitis (Table 1, section 5.1); Helicobacter pylori eradication (section 1.3).

**Cautions** see under Ampicillin; maintain adequate hydration with high doses (particularly during parenteral therapy); interactions: Appendix 1 (penicillins).

**Contra-indications** see under Ampicillin

**Renal impairment** risk of crystalluria with high doses (particularly during parenteral therapy). Reduce dose in severe impairment; rashes more common

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** see under Ampicillin

**Dose**

- **By mouth, ADULT** and **CHILD** over 5 years, 250 mg every 8 hours, dose doubled in severe infection; **CHILD**, 1 month–1 year, 62.5 mg every 8 hours, dose doubled in severe infection; 1–5 years, 125 mg every 8 hours, dose doubled in severe infection

- **Otitis media, 500 mg every 8 hours; CHILD 40 mg/kg daily** in 3 divided doses (max. 1.5 g daily)

- **Pneumonia, ADULT** over 18 years, 0.5–1 g every 8 hours

- **Lyme disease** (see also notes above), **ADULT** and **CHILD** over 5 years, 500 mg every 8 hours for 14–21 days [for 28 days in Lyme arthritis] (unlicensed indication).

- **CHILD** 1 month–5 years see BNF for Children

- **Anthrax** (treatment and post-exposure prophylaxis—see also section 5.1.12), 500 mg every 8 hours; **CHILD body-weight under 20 kg, 80 mg/kg daily** in 3 divided doses, body-weight over 20 kg, adult dose

- **Short-course oral therapy**

  - **Dental abscess, ADULT** over 18 years, 3 g repeated after 8 hours

  - **Urinary-tract infections, ADULT** over 18 years, 3 g repeated after 10–12 hours

  - **By intramuscular injection, ADULT** over 18 years, 500 mg every 8 hours

  - **By intravenous injection, ADULT** over 18 years, 500 mg every 8 hours increased to 1 g every 6 hours in severe infection

  - **CHILD** 1 month–18 years, 20–30 mg/kg (max. 500 mg) every 8 hours; dose doubled in severe infection (max. 4 g daily)

- **Listerial meningitis** (in combination with another antibiotic, see Table 1, section 5.1), **by intravenous infusion, ADULT** over 18 years, 2 g every 4 hours for 10–14 days; **CHILD** under 18 years see BNF for Children

- **Endocarditis** (in combination with another antibiotic if necessary, see Table 1, section 5.1), **by intravenous infusion, ADULT** over 18 years, 2 g every 6 hours, increased to 2 g every 4 hours e.g. in enterococcal endocarditis or if amoxicillin used alone; **CHILD** under 18 years see BNF for Children

**Note** Amoxicillin doses in BNF may differ from those in product literature.

**Amoxicillin (Non-proprietary)†**

**Capsules** amoxicillin (as trihydrate) 250 mg, net price 21 = £1.07; 500 mg, 21 = £1.31. Label: 9

**Brands** include Amix®, Amoram®, Amoxident®, Galenamox®, Rimoxallin®

**Dental prescribing on NHS** Amoxicillin Capsules may be prescribed

**Oral suspension** amoxicillin (as trihydrate) for reconstitution with water, 125 mg/5 mL, net price 100 mL = £1.22; 250 mg/5 mL, 100 mL = £1.39.

**Label:** 9

**Note** Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription

**Brands** include Amoram®, Galenamox®, Rimoxallin®

**Dental prescribing on NHS** Amoxicillin Oral Suspension may be prescribed.
**Sachets**, sugar-free, amoxicillin (as trihydrate) 3 g/sachet, net price 2-sachet pack = £8.34, 14-sachet pack = £31.94. Label: 9, 13

**Dental prescribing on NHS** Amoxicillin Sachets may be prescribed as Amoxicillin Oral Powder

**Injection** powder for reconstitution, amoxicillin (as sodium salt), net price 250-mg vial = 52p; 500-mg vial = 66p; 1-g vial = £1.16

**Amoxil** (GSK)  \( \text{Capsules, both maroon/gold, amoxicillin (as trihydrate), 250 mg, net price 21-cap pack = £3.45; 500 mg, 21-cap pack = £6.91. Label: 9} \)

**Paediatric suspension**, amoxicillin 125 mg (as trihydrate)/1.25 mL when reconstituted with water, net price 20 mL (peach- strawberry- and lemon-flavoured) = £2.25. Label: 9, counselling, use of pipette

**Sachets 5F** powder, sugar-free, amoxicillin (as trihydrate) 3 g/sachet, 2-sachet pack (peach- strawberry- and lemon-flavoured) = £2.99. Label: 9, 13

**Injection** powder for reconstitution, amoxicillin (as sodium salt), net price 500-mg vial = 56p; 1-g vial = £1.12

**Electrolytes** Na+ 3.3 mmol/L

---

**AMPICILLIN**

**Indications** urinary-tract infections, otitis media, sinusitis, oral infections (see notes above), bronchitis, low or moderate-severity community-acquired pneumonia (Table 1, section 5.1), invasive salmonellosis; listerial meningitis (Table 1, section 5.1)

**Cautions** history of allergy; erythematous rashes common in glandular fever (see notes above); increased risk of erythematous rashes in cytomegalovirus infection, and acute or chronic lymphocytic leukaemia (see notes above); **interactions**: Appendix 1 (penicillins)

**Contra-indications** penicillin hypersensitivity

**Renal impairment** reduce dose if eGFR less than 10 mL/minute/1.73 m²; rashes more common

**Pregnancy** not known to be harmful

**Breast-feeding** trace amounts in milk

**Side-effects** nausea, vomiting, diarrhoea; rashes (discontinue treatment); rarely, antibiotic-associated colitis; see also under Benzylpenicillin (section 5.1.1.1)

**Dose**

- By mouth, 0.25–1 g every 6 hours, **CHILD** 1 month–1 year, 62.5 mg every 6 hours, dose doubled in severe infection; 1–5 years, 125 mg every 6 hours, dose doubled in severe infection; 5–12 years, 250 mg every 6 hours, dose doubled in severe infection
- Urinary-tract infections, **ADULT** and **CHILD** over 10 years, 500 mg every 8 hours; **CHILD** under 10 years, half adult dose
- By intramuscular injection or intravenous injection or infusion, 500 mg every 4–6 hours; **CHILD** under 18 years see BNF for Children
- Endocarditis (in combination with another antibiotic if necessary, see Table 1, section 5.1), by intravenous infusion, **ADULT** over 18 years, 2 g every 6 hours, increased to 2 g every 4 hours e.g. in enterococcal endocarditis or if ampicillin used alone; **CHILD** under 18 years see BNF for Children
- Listerial meningitis (in combination with another antibiotic, see Table 1, section 5.1), by intravenous infusion, **ADULT** over 18 years, 2 g every 4 hours for 10–14 days; **CHILD** under 18 years see BNF for Children

**Note** Amoxicillin doses in BNF may differ from those in product literature

**Ampicillin (Non-proprietary)**

**Capsules**, amoxicillin 250 mg, net price 28-cap pack = £7.18; 500 mg, 28-cap pack = £32.93. Label: 9, 23

**Brands include Rimaciclav**

**Dental prescribing on NHS** Ampicillin Capsules may be prescribed

**Oral suspension**, amoxicillin 125 mg/5 mL when reconstituted with water, net price 100 mL = £9.23; 250 mg/5 mL, 100 mL = £14.17. Label: 9, 23

**Brands include Rimaciclav**

**Dental prescribing on NHS** Ampicillin Oral Suspension may be prescribed

**Injection**, powder for reconstitution, amoxicillin (as sodium salt), net price 500-mg vial = £7.83

**Penbritin** (Chemidex)

**Capsules**, grey/red, amoxicillin (as trihydrate) 250 mg, net price 28-cap pack = £2.10; 500 mg, 28-cap pack = £5.28. Label: 9, 23

**Syrup**, apricot- caramel- and peppermint-flavoured, amoxicillin (as trihydrate) for reconstitution with water, 125 mg/5 mL, net price 100 mL = £3.78; 250 mg/5 mL, 100 mL = £7.39. Label: 9, 23

**Excipients** include sucrose 3.6 g/5 mL

**With fluoxacillin** See Co-fluampicil

---

**CO-AMOXICLAV**

A mixture of amoxicillin (as the trihydrate or as the sodium salt) and clavulanic acid (as potassium clavulanate); the proportions are expressed in the form \( x/y \) where \( x \) and \( y \) are the strengths in milligrams of amoxicillin and clavulanic acid respectively

**Indications** infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate) including respiratory-tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis, animal bites, severe dental infection with spreading cellulitis or dental infection not responding to first-line antibacterial

**Cautions** see under Ampicillin and notes above; maintain adequate hydration with high doses (particularly during parenteral therapy); **interactions**: Appendix 1 (penicillins)

**Cholestatic jaundice** Cholestatic jaundice can occur either during or shortly after the use of co-amoxiclav. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days

**Contra-indications** penicillin hypersensitivity, history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction

**Hepatic impairment** monitor liver function in liver disease; see also Cholestatic Jaundice above

**Renal impairment** risk of crystalluria with high doses (particularly during parenteral therapy).

**Co-amoxiclav 250/125 tablets or 500/125 tablets**: if eGFR 10–30 mL/minute/1.73 m², one 250/125 strength tablet every 12 hours or one 500/125 strength tablet every 12 hours; if eGFR less than
Infections (Non-proprietary)  

By mouth. Dose see under Ampicillin; hepatitis, cholestatic jaundice (see above); Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, vasculitis reported; rarely prolongation of bleeding time, dizziness, headache, convulsions (particularly with high doses or in renal impairment); superficial staining of teeth with suspension, phlebitis at injection site.

Dose  
- By mouth, expressed as co-amoxiclav, one 250/125 strength tablet every 8 hours, increased in severe infections to one 500/125 strength tablet every 8 hours; NEONATE 0.25 mL/kg of 125/31 suspension every 8 hours; CHILD 1 month–1 year, 0.25 mL/kg of 125/31 suspension every 8 hours, dose doubled in severe infection; 1–6 years, 5 mL of 125/31 suspension every 8 hours or 0.25 mL/kg of 125/31 suspension every 8 hours, dose doubled in severe infection; 6–12 years, 5 mL of 250/62 suspension every 8 hours or 0.15 mL/kg of 250/62 suspension every 8 hours, dose doubled in severe infection. Severe dental infections (but not generally first-line, see notes above), expressed as co-amoxiclav, ADULT and CHILD over 12 years, one 250/125 strength tablet every 8 hours for 5 days.
- By intravenous injection over 3–4 minutes or by intravenous infusion, expressed as co-amoxiclav, 1.2 g every 8 hours; INFANTS up to 3 months 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); CHILD 3 months–18 years, 30 mg/kg (max. 1.2 g) every 8 hours. Surgical prophylaxis, expressed as co-amoxiclav, 1.2 g up to 30 minutes before the procedure; for high risk procedures up to 2–3 further doses of 1.2 g may be given every 8 hours.

Co-amoxiclav (Non-proprietary)  
Tablets, co-amoxiclav 250/125 (amoxicillin 250 mg as trihydrate, clavulanic acid 125 mg as potassium salt), net price 21-tab pack = £2.63. Label: 9
Dental prescribing on NHS Co-amoxiclav 250/125 Tablets may be prescribed
Tablets, co-amoxiclav 500/125 (amoxicillin 500 mg as trihydrate, clavulanic acid 125 mg as potassium salt), net price 21-tab pack = £4.38. Label: 9
Oral suspension, co-amoxiclav 125/31 (amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL when reconstituted with water, net price 100 mL = £6.29. Label: 9
Note Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription
Dental prescribing on NHS Co-amoxiclav 125/31 Suspension may be prescribed
Oral suspension, co-amoxiclav 250/62 (amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL when reconstituted with water, net price 100 mL = £6.29. Label: 9
Note Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription
Dental prescribing on NHS Co-amoxiclav 250/62 Suspension may be prescribed

CO-FLUAMPCIL  
A mixture of equal parts by mass of flucloxacillin and ampicillin.

Indications mixed infections involving beta-lactamase-producing staphylococci.

Cautions see under Ampicillin and Flucloxacillin; interactions: Appendix 1 (penicillins).

Contra-indications see under Ampicillin and Flucloxacillin.

Hepatic impairment see under Flucloxacillin.

Twice daily oral preparations  
Co-amoxiclav (Non-proprietary)  
Suspension 400/57, co-amoxiclav 400/57 (amoxicillin 400 mg as trihydrate, clavulanic acid 57 mg as potassium salt)/5 mL when reconstituted with water, net price 35 mL = £4.13, 70 mL = £5.79. Label: 9
Excipients may be aspartame (section 9.4.1)
Note Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription
Brands include Augmentin-Duo.
Dose CHILD 2 months–2 years 0.15 mL/kg twice daily, 2–6 years (13–21 kg) 2.5 mL twice daily, 7–12 years (22–40 kg) 5 mL twice daily, dosage in severe infections.

Infections

Co-amoxiclav injection (expressed as co-amoxiclav): if eGFR 10–30 mL/minute/1.73 m², 1.2 g initially, then 600 mg every 12 hours; if eGFR less than 10 mL/minute/1.73 m², 1.2 g initially, then 600 mg every 24 hours.
Pregnancy not known to be harmful.

Breast-feeding trace amounts in milk.

Side-effects see under Ampicillin; hepatitis, cholestatic jaundice (see above); Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, vasculitis reported; rarely prolongation of bleeding time, dizziness, headache, convulsions (particularly with high doses or in renal impairment); superficial staining of teeth with suspension, phlebitis at injection site.

Electrolytes Na⁺ 1.35 mmol/L, K⁺ 0.5 mmol/L/400 mg vial
Injection 1.2 g, powder for reconstitution, co-amoxiclav 1000/200 (amoxicillin 1 g as sodium salt, clavulanic acid 200 mg as potassium salt), net price per vial = £2.61
Electrolytes Na⁺ 2.7 mmol/L, K⁺ 1 mmol/L/1.2 g vial

Injection 500/100, powder for reconstitution, co-amoxiclav 500/100 (amoxicillin 500 mg as sodium salt, clavulanic acid 100 mg as potassium salt), net price per vial = £1.21

Injection 1000/200, powder for reconstitution, co-amoxiclav 1000/200 (amoxicillin 1 g as sodium salt, clavulanic acid 200 mg as potassium salt), net price per vial = £2.63

Augmentin® (GSK)  
Tablets 375 mg, f/c, co-amoxiclav 250/125 (amoxicillin 250 mg as trihydrate, clavulanic acid 125 mg as potassium salt), net price 21-tab pack = £4.19. Label: 9
Tablets 625 mg, f/c, co-amoxiclav 500/125 (amoxicillin 500 mg as trihydrate, clavulanic acid 125 mg as potassium salt), net price 21-tab pack = £8.00. Label: 9
Suspension ‘125/31 SF’, sugar-free, co-amoxiclav 125/31 (amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL when reconstituted with water, net price 100 mL (raspberry-and orange-flavoured) = £4.08. Label: 9
Excipients include aspartame 12.5 mg/5 mL (section 9.4.1)
Suspension ‘250/62 SF’, sugar-free, co-amoxiclav 250/62 (amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL when reconstituted with water, net price 100 mL (raspberry-and orange-flavoured) = £5.74. Label: 9
Excipients include aspartame 12.5 mg/5 mL (section 9.4.1)

Co-amoxiclav 250/62 Suspension may be prescribed

Dose CHILD 2 months–2 years 0.15 mL/kg twice daily, 2–6 years (13–21 kg) 2.5 mL twice daily, 7–12 years (22–40 kg) 5 mL twice daily, dosage in severe infections.

BNF 61
Renal impairment see under Ampicillin and Flucloxacillin

Pregnancy not known to be harmful

Breast-feeding trace amounts in milk

Side-effects see under Ampicillin and Flucloxacillin

Dose
- **By mouth**, co-fluamicil, 250/250 every 6 hours, dose doubled in severe infections; **CHILD** under 10 years half adult dose, dose doubled in severe infections
- **By intramuscular or slow intravenous injection** or by **intravenous infusion**, co-fluamicil 250/250 every 6 hours, dose doubled in severe infections; **CHILD** under 2 years quarter adult dose, 2–10 years half adult dose, dose doubled in severe infections

Co-fluamicil (Non-proprietary) (Non-proprietary)

Capsules, co-fluamicil 250/250 (flucloxacillin 250 mg as sodium salt, ampicillin 250 mg as trihydrate), net price 28-cap pack = £14.73. Label: 9, 22
Brands include Flu-Amp®

Syrup, co-fluamicil 125/125 (flucloxacillin 125 mg as magnesium salt, ampicillin 125 mg as trihydrate)/5 mL when reconstituted with water, net price 100 mL = £6.99. Label: 9, 22

Magnapen® (Wockhardt) (Non-proprietary)

Injection 500 mg, powder for reconstitution, co-fluamicil 250/250 (flucloxacillin 250 mg as sodium salt, ampicillin 250 mg as sodium salt), net price per vial = £1.33
Electrolytes Na⁺ 1.3 mmol/vial

5.1.1.4 Antipseudomonal penicillins

Piperacillin, a ureidopenicillin, is only available in combination with the beta-lactamase inhibitor tazobactam.

Ticarcillin, a carboxypenicillin, is only available in combination with the beta-lactamase inhibitor clavulanic acid (section 5.1.1.3). Both preparations have a broad spectrum of activity against a range of Gram-positive and Gram-negative bacteria, and anaerobes. Piperacillin with tazobactam has activity against a wider range of Gram-negative organisms than ticarcillin with clavulanic acid and it is more active against *Pseudomonas aeruginosa*. These antibacterials are not active against MRSA. They are used in the treatment of septicaemia, peritonitis, hospital-acquired pneumonia, complicated urinary-tract infections, and skin and soft-tissue infections.

For severe pseudomonas infections (especially in neutropenia or endocarditis) these antipseudomonal penicillins can be given with an aminoglycoside (e.g. gentamicin section 5.1.1.4) since they have a synergistic effect. Owing to the sodium content of many of these antimicrobials, it is important to reduce dose to 20 mL/minute/1.73 m² in patients with mild renal impairment.

**TICARCELLIN WITH CLAVULANIC ACID**

**Indications** infections due to *Pseudomonas* and *Proteus* spp, see notes above

**Cautions** see under Benzylpenicillin (section 5.1.1.1); interactions: Appendix 1 (penicillins)

**Chelexis jaundice** For a warning on chelexis jaundice possibly associated with clavulanic acid, see under Co-amoxyclav, p. 337

**Contra-indications** see under Benzylpenicillin (section 5.1.1.1)

**Hepatic impairment** manufacturer advises caution in severe impairment; also chelexis jaundice, see under Co-amoxyclav, p. 337

**Renal impairment** reduce dose to 3.2 g every eight hours if eGFR 30–60 mL/minute/1.73 m²; 1.6 g every eight hours if eGFR 10–30 mL/minute/1.73 m²; 1.6 g every twelve hours if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** not known to be harmful
5.1.2 Cephalosporins, carbapenems, and other beta-lactams

Antibiotics in this section include the cephalosporins, such as cefotaxime, cefazidime, cefuroxime, ceferidine, and cefadroxil, the monobactam, aztreonam, and the carbapenems, imipenem (a thienamycin derivative), meropenem, doripenem, and ertapenem.

The cephalosporins are broad-spectrum antibiotics which are used for the treatment of septicaemia, pneumonia, meningitis, biliary-tract infections, peritonitis, and urinary-tract infections. The pharmacology of the cephalosporins is similar to that of the penicillins, excepting being principally renal. Cephalosporins penetrate the cerebrospinal fluid poorly unless the meninges are inflamed; cefotaxime is a suitable cephalosporin for infections of the CNS (e.g. meningitis).

The principal side-effect of the cephalosporins is hypersensitivity and about 0.5–6.5% of penicillin-sensitive patients will also be allergic to the cephalosporins. Patients with a history of immediate hypersensitivity to penicillin should not receive a cephalosporin. If a cephalosporin is essential in these patients because a suitable alternative antibacterial is not available, then cefixime, cefotaxime, ceftazidime, ceftriaxone, or cefuroxime can be used with caution; cefaclor, cefadroxil, ceftaxime, and cefradine should be avoided. Antibiotic-associated colitis may occur with the use of broad-spectrum cephalosporins, particularly second- and third-generation cephalosporins.

Cefuroxime is a ‘second generation’ cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamasases. It is, therefore, active against certain bacteria which are resistant to the other drugs and has greater activity against Haemophilus influenzae.

Cefotaxime, ceftazidime, and ceftriaxone are ‘third generation’ cephalosporins with greater activity than the ‘second generation’ cephalosporins against certain Gram-negative bacteria. However, they are less active than cefuroxime against Gram-positive bacteria, most notably Staphylococcus aureus. Their broad antibacterial spectrum may encourage superinfection with resistant bacteria or fungi.

Cefadroxil has good activity against pseudomonas. It is also active against other Gram-negative bacteria. Ceftriaxone has a longer half-life and therefore needs to be given only once daily. Indications include serious infections such as septicaemia, pneumonia, and meningitis. The calcium salt of ceftriaxone forms a precipitate in the gall bladder which may rarely cause symptoms but these usually resolve when the antibiotic is stopped.

Orally active cephalosporins The orally active ‘first generation’ cephalosporins, cefalexin, ceftaroline, and cefadroxil, and the ‘second generation’ cephalosporin, cefaclor, have a similar antimicrobial spectrum. They are useful for urinary-tract infections which do not respond to other drugs or which occur in pregnancy,
respiratory-tract infections, otitis media, sinovitis, and skin and soft-tissue infections. Cefaclor has good activity against *H. influenzae*, but it is associated with protracted skin reactions especially in children. Cefadroxil has a long duration of action and can be given twice daily; it has poor activity against *H. influenzae*. Cefuroxime axetil, an ester of the 'second generation' cephalosporin cefuroxime, has the same antibacterial spectrum as the parent compound: it is poorly absorbed.

Cefixime and cefpodoxime proxetil are orally active 'third generation' cephalosporins. Cefixime has a longer duration of action than the other cephalosporins that are active by mouth. It is only licensed for acute infections. Cefpodoxime proxetil is more active than the other oral cephalosporins against respiratory bacterial pathogens and it is licensed for upper and lower respiratory-tract infections.

For treatment of Lyme disease, see section 5.1.1.3.

**Oral infections** The cephalosporins offer little advantage over the penicillins in dental infections, often being less active against anaerobes. Infections due to oral streptococci (often termed viridans streptococci) which become resistant to penicillin are usually also resistant to cephalosporins. This is of importance in the case of patients who have had rheumatic fever and are on long-term penicillin therapy. Cefalexin and cefradine have been used in the treatment of oral infections.

### CEFACLOR

**Indications** infections due to sensitive Gram-positive and Gram-negative bacteria, but see notes above

**Cautions** sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction; see also notes above and p. 322); false positive urinary glucose (if tested for reducing substances) and false positive Coombs' test; **interactions:** Appendix 1 (cephalosporins)

**Contra-indications** cephalosporin hypersensitivity

**Renal impairment** no dose adjustment required—manufacturer advises caution

**Pregnancy** not known to be harmful

**Breast-feeding** present in milk in low concentration, but appropriate to use

**Side-effects** diarrhoea (rarely antibiotic-associated colitis), nausea and vomiting, abdominal discomfort, headache; allergic reactions including rashes, pruritus, urticaria, serum sickness-like reactions with rashes, fever and arthralgia, and anaphylaxis; Stevens-Johnson syndrome, toxic epidermal necrolysis reported; disturbances in liver enzymes, transient hepatitis and cholestatic jaundice; other side-effects reported include eosinophilia and blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia); reversible interstitial nephritis, hyperactivity, nervousness, sleep disturbances, hallucinations, confusion, hyperventilation, and dizziness

**Dose**

- 250 mg every 8 hours, doubled for severe infections; max. 4 g daily; **CHILD** over 1 month, 20 mg/kg daily in 3 divided doses, doubled for severe infections, max. 1 g daily; or 1 month–1 year, 62.5 mg every 8 hours; 1–5 years, 125 mg; over 5 years, 250 mg; doses doubled for severe infections

### CEFADROXIL

**Indications** see under Cefaclor; see also notes above

**Cautions** see under Cefaclor; **interactions:** Appendix 1 (cephalosporins)

**Contra-indications** see under Cefaclor

**Renal impairment** 1 g initially, then 500 mg every 12 hours if eGFR 26–50 mL/minute/1.73 m²; 1 g initially, then 500 mg every 24 hours if eGFR 11–26 mL/minute/1.73 m²; 1 g initially, then 500 mg every 36 hours if eGFR less than 11 mL/minute/1.73 m²

**Pregnancy** see under Cefaclor

**Breast-feeding** see under Cefaclor

**Side-effects** see under Cefaclor

**Dose**

- 0.5–1 g twice daily; skin, soft-tissue, and uncomplicated urinary-tract infections, 1 g daily; **CHILD** 6–18 years, body-weight under 40 kg, 500 mg twice daily; body-weight over 40 kg, adult dose

**Cefadroxil** (Non-proprietary) Capsules, cefadroxil (as monohydrate) 500 mg, net price 20-cap pack = £4.82. Label: 9

### CEFALEXIN

(Cephalexin)

**Indications** see under Cefaclor

**Cautions** see under Cefaclor; **interactions:** Appendix 1 (cephalosporins)

**Contra-indications** see under Cefaclor

**Renal impairment** max. 3 g daily if eGFR 40–50 mL/minute/1.73 m²; max. 1.5 g daily if eGFR 10–40 mL/minute/1.73 m²; max. 750 mg daily if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** see under Cefaclor

**Breast-feeding** see under Cefaclor

**Side-effects** see under Cefaclor

**Dose**

- 250 mg every 6 hours or 500 mg every 8–12 hours increased to 1–1.5 g every 6–8 hours for severe
Infections; CHILD 25 mg/kg daily in divided doses, doubled for severe infections, max. 100 mg/kg daily; or under 1 year 125 mg every 12 hours, 1–5 years 125 mg every 8 hours, 5–12 years 250 mg every 8 hours

- Prophylaxis of recurrent urinary-tract infection, ADULT 125 mg at night

**Cefalexin** (Non-proprietary) (Sanofi-Aventis)

Capsules, cefalexin 250 mg, net price 28-cap pack = £1.66; 500 mg, 21-cap pack = £2.09. Label: 9

**Dental prescribing on NHS** Cefalexin Capsules may be prescribed

Tablets, cefalexin 250 mg, net price 28-cap pack = £1.94; 500 mg, 21-cap pack = £2.39. Label: 9

**Dental prescribing on NHS** Cefalexin Tablets may be prescribed

**Oral suspension**, cefalexin for reconstitution with water, 125 mg/5 mL, net price 100 mL = £1.75; 250 mg/5 mL, 100 mL = £2.15. Label: 9

**Dental prescribing on NHS** Cefalexin Oral Suspension may be prescribed

**Ceporex** (Co-Pharma) (Sanofi-Aventis)

Capsules, both caramel/grey, cefalexin 250 mg, net price 28-cap pack = £4.02; 500 mg, 28-cap pack = £7.85. Label: 9

Tablets, all pink, f/c, cefalexin 250 mg, net price 28-tab pack = £4.02; 500 mg, 28-tab pack = £7.85. Label: 9

**Syrup**, all orange, cefalexin for reconstitution with water, 125 mg/5 mL, net price 100 mL = £1.43; 250 mg/5 mL, 100 mL = £2.87; 500 mg/5 mL, 100 mL = £5.57. Label: 9

**Kellex** (Flynn) (Sanofi-Aventis)

Capsules, cefalexin 250 mg (green/white), net price 28-cap pack = £1.46; 500 mg (pale green/dark green), 21-cap pack = £1.98. Label: 9

Tablets, both peach, cefalexin 250 mg, net price 28-tab pack = £1.60; 500 mg (scored), 21-tab pack = £2.08. Label: 9

**Suspension**, cefalexin for reconstitution with water, 125 mg/5 mL, net price 100 mL = £1.40; 250 mg/5 mL, 100 mL = £2.87; 500 mg/5 mL, 100 mL = £5.57. Label: 9

**CEFOTAXIME**

**Indications** see under Cefaclor; gonorrhoea; surgical prophylaxis; Haemophilus epiglottitis and meningitis (Table 1, section 5.1); see also notes above

**Cautions** see under Cefaclor; interactions: Appendix 1 (cephalosporins)

**Contra-indications** see under Cefaclor

**Renal impairment** if eGFR less than 5 mL/minute/1.73 m², initial dose of 1 g then use half normal dose

**Pregnancy** see under Cefaclor

**Breast-feeding** see under Cefaclor

**Side-effects** see under Cefaclor; rarely arrhythmias following rapid injection reported

**Dose**

- By intramuscular or intravenous injection or by intravenous infusion, 1 g every 12 hours increased in severe infections (e.g. meningitis) to 8 g daily in 4 divided doses; higher doses (up to 12 g daily in 3–4 divided doses) may be required; NEOANTE 50 mg/kg daily in 2–4 divided doses increased to 150–200 mg/kg daily in severe infections, CHILD 100–150 mg/kg daily in 2–4 divided doses increased up to 200 mg/kg daily in very severe infections

Uncomplicated gonorrhoea, 500 mg as a single dose

**Important** If meningococcal disease (meningitis with non-blanching rash or meningococcal septicaemia) is suspected, and the patient cannot be given benzylpenicillin (e.g. because of an allergy), a single dose of cefotaxime can be given (if available) before urgent transfer to hospital, so long as this does not delay the transfer. If a patient with suspected bacterial meningitis without non-blanching rash cannot be transferred to hospital urgently and cannot be given benzylpenicillin, a single dose of cefotaxime can be given before transfer. Suitable doses of cefotaxime by intravenous injection (or by intramuscular injection) are ADULT and CHILD over 12 years 1 g; CHILD under 12 years 50 mg/kg; chloramphenicol (section 5.1.7) may be used if there is a history of anaphylaxis to penicillins or cephalosporins

**Cefotaxime** (Non-proprietary)

**Injection**, powder for reconstitution, cefotaxime (as sodium salt), net price 500-mg vial = £2.14; 1-g vial = £4.31; 2-g vial = £8.57

**CEFPODOXIME**

**Indications** see under Dose

**Cautions** see under Cefaclor; interactions: Appendix 1 (cephalosporins)

**Contra-indications** see under Cefaclor

**Renal impairment** increase dose interval to every 24 hours if eGFR 10–40 mL/minute/1.73 m²; increase dose interval to every 48 hours if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** see under Cefaclor

**Breast-feeding** see under Cefaclor

**Side-effects** see under Cefaclor

**Dose**

- Upper respiratory-tract infections (but in pharyngitis and tonsillitis reserved for infections which are recurrent, chronic, or resistant to other antibacterials), 100 mg twice daily (200 mg twice daily in sinusitis); CHILD 15 days–6 months 4 mg/kg every 12 hours, 6
months—2 years 40 mg every 12 hours, 3–8 years 80 mg every 12 hours, over 9 years 100 mg every 12 hours

- Lower respiratory tract infections (including bronchitis and pneumonia), 100–200 mg twice daily; CHILD 15 days–6 months 4 mg/kg every 12 hours, 6 months–2 years 40 mg every 12 hours, 3–8 years 80 mg every 12 hours, over 9 years 100 mg every 12 hours

- Skin and soft-tissue infections, 200 mg twice daily; CHILD 15 days–6 months 4 mg/kg every 12 hours, 6 months–2 years 40 mg every 12 hours, 3–8 years 80 mg every 12 hours, over 9 years 100 mg every 12 hours

- Uncomplicated urinary-tract infections, 100 mg twice daily (200 mg twice daily in uncomplicated upper urinary-tract infections); CHILD 15 days–6 months 4 mg/kg every 12 hours, 6 months–2 years 40 mg every 12 hours, 3–8 years 80 mg every 12 hours, over 9 years 100 mg every 12 hours

- Breast-feeding see under Cefaclor

- Pregnancy see under Cefaclor; see also notes above

- Hepatic impairment reduce dose and monitor plasma concentration if both hepatic and severe renal impairment

- Renal impairment reduce dose if eGFR less than 50 mL/minute/1.73 m²—consult product literature

- Pregnancy see under Cefaclor

- Breast-feeding see under Cefaclor

- Dose

  - By deep intramuscular injection or intravenous injection or infusion, 1 g every 8 hours or 2 g every 12 hours; 2 g every 6–12 hours or 3 g every 12 hours in severe infections; single doses over 1 g intravenous

route only; ELDERLY usual max. 3 g daily; CHILD, up to 2 months 25–60 mg/kg daily in 2 divided doses, over 2 months 30–100 mg/kg daily in 2–3 divided doses; up to 150 mg/kg daily (max. 6 g daily) in 3 divided doses if immunocompromised or meningitis; intravenous route recommended for children

Urinary-tract and less serious infections, 0.5–1 g every 12 hours

Pseudomonal lung infection in cystic fibrosis, ADULT 100–150 mg/kg daily in 3 divided doses; CHILD up to 150 mg/kg daily (max. 6 g daily) in 3 divided doses; intravenous route recommended for children

Surgical prophylaxis, prostatic surgery, 1 g up to 30 minutes before the procedure, repeated if necessary when catheter removed

Ceftazidime (Non-proprietary) \(^\text{A} \)

Injection, powder for reconstitution, ceftazidime (as pentahydrate), with sodium carbonate, net price 1-g vial = £8.50; 2-g vial = £17.90

Fortum\(^\text{®} \) (GSK) \(^\text{A} \)

Injection, powder for reconstitution, ceftazidime (as pentahydrate), with sodium carbonate, net price 250-mg vial = £2.20, 500-mg vial = £4.40, 1-g vial = £8.79, 2-g vial = £17.59, 3-g vial = £25.76, Monovial, 2 g vial (with transfer needle) = £17.59

Electrolytes Na⁺ 2.3 mmol/g

Kefadim\(^\text{®} \) (Flynn) \(^\text{A} \)

Injection, powder for reconstitution, ceftazidime (as pentahydrate), with sodium carbonate, net price 1-g vial = £7.92; 2-g vial = £15.84

Electrolytes Na⁺ 2.3 mmol/g

CEFTRIAXONE

Indications see under Cefaclor and notes above; surgical prophylaxis; prophylaxis of meningococcal meningitis [unlicensed indication] (Table 2, section 5.1)

Cautions see under Cefaclor, may displace bilirubin from serum albumin, administer over 60 minutes in neonates (see also Contra-indications); treatment longer than 14 days, renal failure, dehydration—risk of ceftriaxone precipitation in gall bladder; interactions: Appendix 1 (cephalosporins)

Contra-indications see under Cefaclor; neonates less than 41 weeks postmenstrual age; neonates over 41 weeks postmenstrual age with jaundice, hypoalbuminaemia, or acidosis; concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks postmenstrual age—risk of precipitation in urine and lungs

Hepatic impairment reduce dose and monitor plasma concentration if both hepatic and severe renal impairment

Renal impairment reduce dose if eGFR less than 10 mL/minute/1.73 m² (max. 2 g daily); monitor plasma concentration if both hepatic and severe renal impairment

Pregnancy see under Cefaclor

Breast-feeding see under Cefaclor

Side-effects see under Cefaclor; calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised) or in gall bladder—consider discontinuation if symptomatic; rarely prolongation of prothrombin time, pancreatitis
5.1.2 Cephalosporins, carbapenems, and other beta-lactams

**Dose**
- By deep intramuscular injection, or by intravenous injection over at least 2–4 minutes, or by intravenous infusion, 1 g daily; 2–4 g daily in severe infections; intramuscular doses over 1 g divided between more than one site; single intravenous doses above 1 g by intravenous infusion only
- **NEONATE**, by intravenous infusion over 60 minutes, 20–50 mg/kg daily (max. 50 mg/kg daily); **INFANT** and **CHILD** under 50 kg, by deep intramuscular injection, or by intravenous injection over 2–4 minutes, or by intravenous infusion, 20–50 mg/kg daily; up to 80 mg/kg daily in severe infections; doses of 50 mg/kg and over by intravenous infusion only; 50 kg and over, adult dose
- Endocarditis caused byhaemophilus, actinobacillus, cardio-bacterium, eikenella, and kingella species (‘HACEK organisms’) (in combination with another antibacterial, see Table 1, section 5.1; [unlicensed indication]), by intravenous infusion, 2–4 g daily
- Early syphilis [unlicensed indication], by deep intramuscular injection, 500 mg daily for 10 days
- Uncomplicated gonorrhoea, pelvic inflammatory disease (see also Table 1, section 5.1) by deep intramuscular injection, 250 mg as a single dose
- Surgical prophylaxis, by deep intramuscular injection or by intravenous injection over at least 2–4 minutes, 1 g up to 30 minutes before the procedure; colorectal surgery, by deep intramuscular injection or by intravenous infusion, 2 g up to 30 minutes before the procedure; intramuscular doses over 1 g divided between more than one site

**Ceftriaxone (Non-proprietary)**
- **Injection**, powder for reconstitution, ceftriaxone (as sodium salt), net price 1-g vial = £10.17; 2-g vial = £20.36

**Rocephin® (Roche)**
- **Injection**, powder for reconstitution, ceftriaxone (as sodium salt), net price 250-mg vial = £4.56; 1.5-g vial = £5.05

**Cefuroxime (Non-proprietary)**
- **Tablets**, cefuroxime (as axetil) 250 mg, net price 14-tab pack = £10.39. Label: 9, 21, 25
- **Injection**, powder for reconstitution, cefuroxime (as sodium salt), net price 750-mg vial = £2.52; 1.5-g vial = £5.05

**Zinacef® (GSK)**
- **Injection**, powder for reconstitution, cefuroxime (as sodium salt), net price 250-mg vial = 94p; 750-mg vial = £2.34; 1.5-g vial = £4.70
- **Electrolytes** Na⁺ 1.8 mmol/750-mg vial

**Zinnat® (GSK)**
- **Tablets**, both f/c, cefuroxime (as axetil) 125 mg, net price 14-tab pack = £4.56; 250 mg, 14-tab pack = £9.11. Label: 9, 21, 25
- **Suspension**, cefuroxime (as axetil) 125 mg/5 mL when reconstituted with water, net price 70 mL (tutti-frutti-flavoured) = £5.20. Label: 9, 21
- **Exipients** include aspartame (section 9.4.1), sucrose 3.1 g/5 mL

**CEFUROXIME**

**Indications** see under Cefaclor; surgical prophylaxis; more active against *Haemophilus influenzae*, Lyme disease

**Cautions** see under Cefaclor; **interactions**: Appendix 1 (cephalosporins)

**Contra-indications** see under Cefaclor

**Renal impairment** use parenteral dose of 750 mg twice daily if eGFR 10–20 mL/minute/1.73 m²; use parenteral dose of 750 mg once daily if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** see under Cefaclor

**Breast-feeding** see under Cefaclor

**Side-effects** see under Cefaclor

**Dose**
- By mouth (as cefuroxime axetil), 250 mg twice daily in most infections including mild to moderate lower respiratory-tract infections (e.g. bronchitis); doubled for more severe lower respiratory-tract infections or if pneumonia suspected
- Urinary-tract infection, 125 mg twice daily, doubled in pyelonephritis
- **CHILD** over 3 months, 125 mg twice daily, if necessary doubled in child over 2 years with otitis media

**Lyme disease** (see also section 5.1.1.3), **ADULT** and **CHILD** over 12 years, 500 mg twice daily for 14–21 days (for 28 days in Lyme arthritis) [unlicensed duration]
- By intramuscular injection or intravenous injection or infusion, 750 mg every 6–8 hours; 1.5 g every 6–8 hours in severe infections; single doses over 750 mg intravenous route only
- **CHILD** usual dose 60 mg/kg daily (range 30–100 mg/kg daily) in 3–4 divided doses (2–3 divided doses in neonates)
- Surgical prophylaxis, 1.5 g by intravenous injection up to 30 minutes before the procedure; up to 3 further doses of 750 mg may be given by intravenous or intramuscular injection every 8 hours for high-risk procedures

**Cefuroxime (Non-proprietary)**
- **Tablets**, cefuroxime (as axetil) 250 mg, net price 14-tab pack = £10.39. Label: 9, 21, 25
- **Injection**, powder for reconstitution, cefuroxime (as sodium salt), net price 750-mg vial = £2.52; 1.5-g vial = £5.05
- **Zinacef® (GSK)**
- **Injection**, powder for reconstitution, cefuroxime (as sodium salt), net price 250-mg vial = 94p; 750-mg vial = £2.34; 1.5-g vial = £4.70
- **Electrolytes** Na⁺ 1.8 mmol/750-mg vial

**Zinnat® (GSK)**
- **Tablets**, both f/c, cefuroxime (as axetil) 125 mg, net price 14-tab pack = £4.56; 250 mg, 14-tab pack = £9.11. Label: 9, 21, 25
- **Suspension**, cefuroxime (as axetil) 125 mg/5 mL when reconstituted with water, net price 70 mL (tutti-frutti-flavoured) = £5.20. Label: 9, 21
- **Exipients** include aspartame (section 9.4.1), sucrose 3.1 g/5 mL

5.1.2.2 Carbapenems

The carbapenems are beta-lactam antibacterials with a broad-spectrum of activity which includes many Gram-positive and Gram-negative bacteria, and anaerobes; imipenem, meropenem, and doripenem have good activity against *Pseudomonas aeruginosa*. The carbapenems are not active against meticillin-resistant *Staphylococcus aureus* and *Enterococcus faecium*.

Imipenem and meropenem are used for the treatment of severe hospital-acquired infections and polymicrobial infections including sepsicaemia, hospital-acquired pneumonia, intra-abdominal infections, skin and soft-tissue infections, and complicated urinary-tract infections. Doripenem is an alternative for hospital-acquired pneumonia, complicated intra-abdominal infections, and complicated urinary-tract infections.

**Ertapenem** is licensed for treating abdominal and gynaecological infections and for community-acquired pneumonia, but it is not active against atypical respiratory pathogens and it has limited activity against penicillin-resistant pneumococci. It is also licensed for treating foot infections of the skin and soft tissue in patients with diabetes. Unlike the other carbapenems, ertapenem is not active against *Pseudomonas* or against *Acinetobacter* spp.

Imipenem is partially inactivated in the kidney by enzymatic activity and is therefore administered in combination with cilastatin, a specific enzyme inhibitor, which blocks its renal metabolism. Meropenem, doripenem,
and ertapenem are stable to the renal enzyme which inactivates imipenem and therefore can be given without cilastatin.

Side-effects of imipenem with cilastatin are similar to those of other beta-lactam antibiotics; neurotoxicity has been observed at very high dosage, in renal failure, or in patients with CNS disease. Ertapenem has been associated with seizures uncommonly. Meropenem has less seizure-inducing potential and can be used to treat central nervous system infection.

**DORIPENEM**

**Indications** hospital-acquired pneumonia; complicated intra-abdominal infections; complicated urinary-tract infections

**Cautions** sensitivity to beta-lactam antibiotics (avoid if history of immediate hypersensitivity reaction, see also p. 332); interactions: Appendix 1 (doripenem)

**Renal impairment** 250 mg every 8 hours if eGFR 30–50 mL/minute/1.73 m²; 250 mg every 12 hours if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies

**Side-effects** nausea, diarrhoea; headache; phlebitis, pruritus, rash; less commonly antibiotic-associated colitis, thrombocytopenia, neutropenia; also reported, toxic epidermal necrolysis, and Stevens-Johnson syndrome

**Dose**

- By intravenous infusion, **ADULT** over 18 years, 500 mg every 8 hours; max. duration of treatment 14 days
- **Doribax** (Janssen-Cilag) By intravenous infusion, powder for reconstitution, doripenem (as monohydrate), net price 500-mg vial = £14.52

**IMIPENEM WITH CILASTATIN**

**Indications** aerobic and anaerobic Gram-positive and Gram-negative infections; surgical prophylaxis; hospital-acquired septicemia (Table 1, section 5.1); not indicated for CNS infections

**Cautions** sensitivity to beta-lactam antibiotics (avoid if history of immediate hypersensitivity reaction, see also p. 332); CNS disorders (e.g. epilepsy); interactions: Appendix 1 (imipenem with cilastatin)

**Renal impairment** risk of CNS side-effects; reduce dose if eGFR less than 70 mL/minute/1.73 m²—consult product literature

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies)

**Breast-feeding** present in milk but unlikely to be absorbed (however, manufacturer advises avoid)

**Side-effects** nausea, vomiting, diarrhoea (antibiotic-associated colitis reported), taste disturbances, tooth or tongue discoloration, hearing loss; blood disorders, positive Coombs’ test; allergic reactions (with rash, pruritus, urticaria, Stevens-Johnson syndrome, fever, anaphylactic reactions, rarely toxic epidermal necrolysis, exfoliative dermatitis); myoclonic activity, convulsions, confusion and mental disturbances reported; slight increases in liver enzymes and bilirubin reported, rarely hepatitis; increases in serum creatinine and blood urea; red coloration of urine in children reported; local reactions: erythema, pain and induration, and thrombophlebitis

**Dose**

- By intravenous infusion, **ADULT** and **ADOLESCENT** over 13 years, 1 g once daily; **CHILD** 3 months–13 years, 15 mg/kg every 12 hours (max. 1 g daily)
- Surgical prophylaxis, colorectal surgery, **ADULT** over 18 years, 1 g completed within 1 hour before surgery

**Invanz® (MSD) Intravenous infusion**, powder for reconstitution, ertapenem (as sodium salt), net price 1-g vial = £31.65 Electrolytes *N* +6 mmol/1-g vial

---

**BNF 61**

**5.1.2 Cephalosporins, carbapenems, and other beta-lactams**

---
### MEROPENEM

**Indications**
- aerobics and anaerobics Gram-positive and Gram-negative infections (see notes above); hospital-acquired septicaemia (Table 1, section 5.1)

**Cautions**
- sensitivity to beta-lactam antibiotics (avoid if history of immediate hypersensitivity reaction, see also p. 332); interactions: Appendix 1 (meropenem)

**Hepatic impairment**
- monitor liver function

**Renal impairment**
- use normal dose every 12 hours if eGFR 26–50 mL/minute/1.73 m²; use half normal dose every 12 hours if eGFR 10–25 mL/minute/1.73 m²; use half normal dose every 24 hours if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy**
- manufacturer advises use only if potential benefit outweighs risk—no information available

**Breast-feeding**
- unlikely to be absorbed (however, manufacturer advises avoid unless potential benefit justifies potential risk)

**Side-effects**
- nausea, vomiting, diarrhoea (antibiotic-associated colitis reported), abdominal pain, disturbances in liver function tests, headache, thrombocytopenia, rash, pruritus; less commonly paraesthesia, eosinophilia, thrombocytopenia, leucopenia; rarely convulsions; also reported haemolytic anaemia, positive Coombs’ test, Stevens-Johnson syndrome, toxic epidermal necrolysis

**Dose**
- **By intravenous injection** over 5 minutes or by intravenous infusion, 0.5–1 g every 8 hours; **CHILD 3 months–12 years** 10–20 mg/kg every 8 hours, body-weight over 50 kg, adult dose
- **Exacerbations of chronic lower respiratory-tract infection in cystic fibrosis, meningitis, by intravenous infusion**, 2 g every 8 hours; **CHILD 3 months–12 years** 40 mg/kg every 8 hours, body-weight over 50 kg, adult dose

**Meropenem® (AstraZeneca)**

- **Injection**, powder for reconstitution, meropenem (as trihydrate), net price 500-mg vial = £8.60; 1-g vial = £17.19
- **Electrolytes Na+ 3.9 mmol/g**

### 5.1.3 Tetracyclines

**BNF 61**

**Cautions**
- hypersensitivity to beta-lactam antibiotics; interactions: Appendix 1 (aztreonam)

**Specific cautions for inhaled treatment**
- Other inhaled drugs should be administered before aztreonam; a bronchodilator should be administered before each dose

**Contra-indications**
- aztreonam hypersensitivity

**Hepatic impairment**
- use injection with caution and monitor liver function

**Renal impairment**
- if eGFR 10–30 mL/minute/1.73 m², usual initial dose of injection, then half normal dose; if eGFR less than 10 mL/minute/1.73 m², usual initial dose of injection, then one-quarter normal dose

**Pregnancy**
- no information available; manufacturer of injection advises avoid; manufacturer of powder for nebuliser solution advises avoid unless essential

**Breast-feeding**
- amount in milk probably too small to be harmful

**Side-effects**
- **Specific side-effects for parenteral treatment**
  - Nausea, vomiting, diarrhoea, abdominal cramps, mouth ulcers, altered taste, jaundice and hepatitis, flushing; hypersensitivity reactions; blood disorders (including thrombocytopenia and neutropenia); rashes, injection-site reactions; rarely hypotension, seizures, asthma, confusion, dizziness, headache, halitosis, and breast tenderness; very rarely antibiotic-associated colitis, gastro-intestinal bleeding, and toxic epidermal necrolysis

- **Specific side-effects for inhaled treatment**
  - Wheezing, bronchospasm, cough; pyrexia; rash; rhinorrhoea, pharyngolaryngeal pain

**Dose**
- **By deep intramuscular injection or by intravenous injection** over 3–5 minutes or by intravenous infusion, 1 g every 8 hours or 2 g every 12 hours; 2 g every 6–8 hours for severe infections (including systemic *Pseudomonas aeruginosa* and lung infections in cystic fibrosis); single doses over 1 g intravenous route only
- **Urinary-tract infections**, 0.5–1 g every 8–12 hours
- **CHILD over 1 week, by intravenous injection or infusion**, 30 mg/kg every 6–8 hours increased in severe infections for child of 2 years or older to 50 mg/kg every 6–8 hours; max. 8 g daily
- **Gonorrhoea, cystitis, by intramuscular injection**, 1 g as a single dose
- **Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis**, by inhalation of nebulised solution, ADULT over 18 years, 75 mg 3 times daily (at least 4 hours apart) for 28 days; if additional courses required, a minimum of 28 days after aztreonam nebuliser solution recommended between courses

#### Parenteral

**Azactam® (Squibb)**

- **Injection**, powder for reconstitution, azactam, net price 1-g vial = £9.40; 2-g vial = £18.82

#### Inhalation

**Cayston® (Gilead)**

- **Powder for nebuliser solution**, aztreonam (as lysine), net price 84 × 75 mg vials (with solvent and nebuliser handset) = £2566.50

### 5.1.3 Tetracyclines

The tetracyclines are broad-spectrum antibiotics whose value has decreased owing to increasing bacterial resistance. They remain, however, the treatment of choice...
for infections caused by chlamydia (trachoma, psittacosis, salpingitis, urethritis, and lymphogranuloma venereum), rickettsia (including Q-fever), brucella (doxycycline with either streptomycin or rifampicin), and the spirochaete, Borrelia burgdorferi (Lyme disease—see section 5.1.1.3). They are also used in respiratory and genital mycoplasma infections; in acne, in destructive (refractory) periodontal disease, in exacerbations of chronic bronchitis (because of their activity against Haemophilus influenzae), and for leptospirosis in penicillin hypersensitivity (as an alternative to erythromycin).

For the role of tetracyclines in the management of meticillin-resistant Staphylococcus aureus (MRSA) infection, see p. 334. Microbiologically, there is little to choose between the various tetracyclines, the only exception being minocycline which has a broader spectrum; it is active against Neisseria meningitidis and has been used for meningococcal prophylaxis but is no longer recommended because of side-effects including dizziness and vertigo (see section 5.1, table 2 for current recommendations). Compared to other tetracyclines, minocycline is associated with a greater risk of lupus-erythematosus-like syndrome. Minocycline sometimes causes irreversible pigmentation.

**Oral infections** In adults, tetracyclines can be effective against oral anaerobes but the development of resistance (especially by oral streptococci) has reduced their usefulness for the treatment of acute oral infections; they may still have a role in the treatment of destructive (refractory) forms of periodontal disease. Doxycycline has a longer duration of action than tetracycline or oxytetracycline and need only be given once daily; it is reported to be more active against anaerobes than some other tetracyclines.

For the use of doxycycline in the treatment of recurrent aphthous ulceration, oral herpes, or as an adjunct to gingival scaling and root planing for periodontitis, see section 12.3.1 and section 12.3.2.

**Cautions** Tetracyclines may increase muscle weakness in patients with myasthenia gravis, and exacerbate systemic lupus erythematosus. Antacids, and aluminium, calcium, iron, magnesium and zinc salts decrease the absorption of tetracyclines; milk also reduces the absorption of demeclocycline, oxytetracycline, and tetracycline. Other interactions: Appendix 1 (tetracyclines).

**Contra-indications** Deposition of tetracyclines in teeth may cause discoloration and occasionally dental hypoplasia, and they should not be given to children under 12 years, or to pregnant or breast-feeding women. However, doxycycline may be used in children for treatment and post-exposure prophylaxis of anthrax when an alternative antibacterial cannot be given [unlicensed indication]. Tetracyclines should not be given to patients with acne in the infant is probably usually prevented by chelation with calcium in milk).

**Side-effects** Side-effects of the tetracyclines include nausea, vomiting, diarrhea (antibiotic-associated colitis reported occasionally), dysphagia, and oesophageal irritation. Other rare side-effects include hepatotoxicity, pancreatitis, blood disorders, photosensitivity (particularly with demeclocycline), and hypersensitivity reactions (including rash, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria, angiodema, anaphylaxis, pericarditis). Headache and visual disturbances may indicate benign intracranial hypertension (discontinue treatment); bulging fontanelles have been reported in infants.

### TETRACYCLINE

**Indications** see notes above; acne vulgaris, rosacea (section 13.6)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above; max. 1 g daily in divided doses

**Renal impairment** see notes above

**Pregnancy** Tetracyclines should not be given to pregnant women. Effects on skeletal development have been documented when tetracyclines have been used in the first trimester of pregnancy in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parenteral doses.

**Breast-feeding** Tetracyclines should not be given to women who are breast-feeding (although absorption and therefore discoloration of teeth in the infant is probably usually prevented by chelation with calcium in milk).

**Dose**

- 250 mg every 6 hours, increased in severe infections to 500 mg every 6–8 hours
- Acne, see section 13.6.2
- Non-gonococcal urethritis, 500 mg every 6 hours for 7–14 days (21 days if failure or relapse after first course)

**Counselling** Tablets should be swallowed whole with plenty of fluid while sitting or standing

### DEMECLOCYCLINE HYDROCHLORIDE

**Indications** see notes above; also inappropriate secretion of antidiuretic hormone, section 6.5.2

**Cautions** see notes above, but photosensitivity more common (avoid exposure to sunlight or sun lamps)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Dental prescribing on NHS** Tetracycline Tablets may be prescribed

**Renal impairment** see notes above
DOXYCYCLINE

**Indications**  see notes above; chronic prostatitis; sinusitis, syphilis, pelvic inflammatory disease (Table 1, section 5.1); treatment and prophylaxis of anthrax [unlicensed indication]; malaria treatment and prophylaxis (section 5.4.1); recurrent aphthous ulceration, adjunct to gingival scaling and root planing for periodontitis (section 12.3.1); oral herpes simplex (section 12.3.2); rosacea, acne vulgaris (section 13.6)

**Cautions**  see notes above; alcohol dependence; photosensitivity reported (avoid exposure to sunlight or sun lamps)

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  use with caution (avoid excessive doses)

**Pregnancy**  see notes above

**Breast-feeding**  see notes above

**Side-effects**  see notes above; also anorexia, dry mouth, flushing, anxiety, and tinnitus

**Dose**
- 200 mg on first day, then 100 mg daily; severe infections (including refractory urinary-tract infections), 200 mg daily
- Early syphilis, 100 mg twice daily for 14 days; late latent syphilis, 100 mg twice daily for 28 days; neurosyphilis, 200 mg twice daily for 28 days
- Uncomplicated genital chlamydia, non-gonococcal urethritis, 100 mg twice daily for 7 days (14 days in pelvic inflammatory disease, see also Table 1, section 5.1)
- Lyme disease (see also section 5.1.1.3), 100 mg twice daily for 10–14 days (28 days in Lyme arthritis)
- Anthrax (treatment or post-exposure prophylaxis; see also section 5.1.12), 100 mg twice daily; CHILD (only if alternative antibacterial cannot be given) [unlicensed dose] 5 mg/kg daily in 2 divided doses (max. 200 mg daily)

**Counselling** Capsules should be swallowed whole with plenty of fluid during meals while sitting or standing

**Note** Doxycycline doses in BNF may differ from those in product literature

**Doxycycline** (Non-proprietary)

**Capsules**, doxycycline (as hyclate) 50 mg, net price 28-cap pack = £1.16. Label: 6, 9, 11, 23

**Dental prescribing on NHS** Doxycycline Capsules 100 mg may be prescribed

**Vibramycin-D®** (Pfizer)

**Dispersible tablets**, yellow, scored, doxycycline 100 mg, net price 8-tab pack = £4.91. Label: 6, 9, 11, 13

**Dental prescribing on NHS** May be prescribed as Dispersible Doxycycline Tablets

**Modified-release**

**Efacec®** (Galderma) Capsules, m/r, beige, doxycycline (as monohydrate) 40 mg, net price 56-cap pack = £29.78. Label: 6, 11, 27, counselling, posture

**Dose** papulosquamous, facial rosacea (without ocular involvement), 40 mg daily in the morning for 16 weeks; consider discontinuing treatment if no response after 6 weeks

**LYMECTYLNE**

**Indications**  see notes above

**Cautions**  see notes above

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  see notes above

**Pregnancy**  see notes above

**Breast-feeding**  see notes above

**Side-effects**  see notes above

**Dose**
- 408 mg every 12 hours, increased to 1.224–1.632 g daily in severe infections
- Acne, 408 mg daily for at least 8 weeks

**Tetralysal 300®** (Galderma) Capsules, red/yellow, lymecycline 408 mg (= tetracycline 300 mg), net price 28-cap pack = £7.77, 56-cap pack = £14.97. Label: 6, 9

**MINOCYCLINE**

**Indications**  see notes above; meningococcal carrier state; acne vulgaris (section 13.6.2)

**Cautions**  see notes above; if treatment continued for longer than 6 months, monitor every 3 months for hepatotoxicity, pigmentation and for systemic lupus erythematosus—discontinue if these develop or if pre-existing systemic lupus erythematosus worsens

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  use with caution (avoid excessive doses)

**Pregnancy**  see notes above

**Breast-feeding**  see notes above

**Side-effects**  see notes above; also dizziness and vertigo (more common in women); rarely anorexia, tinnitus, impaired hearing, hyperaesthesia, paraesthesia, acute renal failure, pigmentation (sometimes irreversible), and alopecia; very rarely systemic lupus erythematosus, discoloration of conjunctiva, tears, and sweat

**Dose**
- 100 mg twice daily
- Acne, see section 13.6.2 and under preparations, below
- Prophylaxis of asymptomatic meningococcal carrier state (but no longer recommended, see notes above), 100 mg twice daily for 5 days usually followed by rifampicin

**Counselling** Tablets or capsules should be swallowed whole with plenty of fluid while sitting or standing

**Minocycline** (Non-proprietary)

**Capsules**, minocycline (as hydrochloride) 50 mg, net price 56-cap pack = £15.27. 100 mg, 28-cap pack = £13.09. Label: 6, 9, counselling, posture

**Brands include** Akneum®
Tigecycline

Tigecycline is a glycyclcline antibacterial structurally related to the tetracyclines; side-effects similar to those of the tetracyclines can potentially occur. Tigecycline is active against Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms, and some anaerobes. It is also active against meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, but *Pseudomonas aeruginosa* and many strains of *Proteus* spp are resistant to tigecycline. Tigecycline should be reserved for the treatment of complicated skin and soft-tissue infections and complicated abdominal infections caused by multiple-antibacterial resistant organisms; however, it is not recommended for the treatment of foot infections in patients with diabetes.

**TIGECYCLINE**

**Indications** complicated intra-abdominal infections; complicated skin and soft-tissue infections, but not diabetic foot infections

**Cautions** cholestasis; interactions: Appendix 1 (tigecycline)

**Contra-indications** hypersensitivity to tetracyclines

** Hepatic impairment** initially 100 mg then 25 mg every 12 hours in severe impairment

** Pregnancy** see under Tetracyclines, p. 347

** Breast-feeding** manufacturer advises caution—present in milk in animal studies

** Side-effects** see notes above; also nausea, vomiting, abdominal pain, dyspepsia, diarrhoea, anorexia, bilirubinaemia, dizziness, headache, prolonged prothrombin time, prolonged activated partial thromboplastin time, rash, pruritus, and injection-site reactions; less commonly pancreatitis, cholestatic jaundice, and hypoproteinaemia; also reported, anti-biotic-associated colitis, hepatic failure, and thrombocytopenia

**Dose**

- **By intravenous infusion, Adult**: over 18 years, initially 100 mg, then 50 mg every 12 hours for 5–14 days

**Tygacil®** (Wyeth) v/t

*Intravenous infusion,* powder for reconstitution, tigecycline, net price 50-mg vial = £32.31

5.1.4 Aminoglycosides

These include amikacin, gentamicin, neomycin, streptomycin, and tobramycin. All are bactericidal and active against some Gram-positive and many Gram-negative organisms. Amikacin, gentamicin, and tobramycin are also active against *Pseudomonas aeruginosa*, streptomycin is active against *Mycobacterium tuberculosis* and is now almost entirely reserved for tuberculosis (section 5.1.9).

The aminoglycosides are not absorbed from the gut (although there is a risk of absorption in inflammatory bowel disease and liver failure) and must therefore be given by injection for systemic infections.

Most side-effects of this group of antibiotics are dose-related therefore care must be taken with dosage and whenever possible treatment should not exceed 7 days. The important side-effects are ototoxicity, and nephrotoxicity; they occur most commonly in the elderly and in patients with renal failure.

Aminoglycosides may impair neuromuscular transmission and should not be given to patients with myasthenia gravis; large doses given during surgery have been responsible for a transient myasthenic syndrome and should not be given to patients with myasthenia gravis; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function.

Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable.

**Renal impairment** Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment. Ototoxicity and nephrotoxicity occur commonly in patients with renal failure. If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well. Serum-aminoglycoside concentrations must be monitored in patients with renal impairment, see Serum Concentrations below; renal, auditory, and vestibular function should also be monitored. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20 mL/minute.

**Once daily dosage** *Once daily administration* of aminoglycosides is more convenient, provides adequate serum concentrations, and in many cases has largely superseded *multiple daily dose regimens* (given in 2–3 divided doses during the 24 hours). Local guidelines on dosage and serum concentrations should be consulted.

A once-daily, high-dose regimen of an aminoglycoside
should be avoided in patients with endocarditis, burns of more than 20% of the total body surface area, or creatinine clearance less than 20 ml/minute.

**Serum concentrations** Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy. In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen; patients with renal impairment may require earlier and more frequent measurement of aminoglycoside concentration.

For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (‘peak’ concentration) and also just before the next dose (‘trough’ concentration). If the pre-dose (‘trough’) concentration is high, the dose must be decreased. For once daily dose regimens, consult local guidelines on serum concentration monitoring.

Serum-aminoglycoside concentrations should be measured in all patients and must be determined in infants, in the elderly, in obesity, and in cystic fibrosis, or if high doses are being given, or if there is renal impairment.

**Endocarditis** Gentamicin is used in combination with other antibiotics for the treatment of bacterial endocarditis (Table 1, section 5.1). Serum-gentamicin concentration should be determined twice each week (more often in renal impairment). Streptomycin may be used as an alternative in gentamicin-resistant enterococcal endocarditis.

Gentamicin is the aminoglycoside of choice in the UK and is used widely for the treatment of serious infections. It has a broad spectrum but is inactive against anaerobes and has poor activity against haemolytic streptococci and pneumococci. When used for the ‘blind’ therapy of undiagnosed serious infections it is usually given in conjunction with a penicillin or metronidazole (or both). Gentamicin is used together with another antibiotic for the treatment of endocarditis (see above and Table 1, section 5.1).

Loading and maintenance doses of gentamicin may be calculated on the basis of the patient’s weight and renal function (e.g. using a nomogram); adjustments are then made according to serum-gentamicin concentrations. High doses are occasionally indicated for serious infections, especially in the neonate, in the patient with cystic fibrosis, or in the immunocompromised patient. Whenever possible treatment should not exceed 7 days.

Amikacin is more stable than gentamicin to enzymatic inactivation. Amikacin is used in the treatment of serious infections caused by gentamicin-resistant Gram-negative bacilli.

Tobramycin has similar activity to gentamicin. It is slightly more active against *Ps. aeruginosa* but shows less activity against certain other Gram-negative bacteria. Tobramycin may be administered by nebuliser on a cyclical basis (28 days of tobramycin followed by a 28-day tobramycin-free interval) for the treatment of chronic pulmonary *Ps. aeruginosa* infection in cystic fibrosis; however, resistance may develop and some patients do not respond to treatment.

Neomycin is too toxic for parenteral administration and can only be used for infections of the skin or mucous membranes or to reduce the bacterial population of the colon prior to bowel surgery or in hepatic failure. Oral administration may lead to malabsorption. Small amounts of neomycin may be absorbed from the gut in patients with hepatic failure and, as these patients may also be uraemic, cumulation may occur with resultant ototoxicity.

**Pregnancy** There is a risk of auditory or vestibular nerve damage when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (section 5.1.9). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential).

### GENTAMICIN

**Indications** septicaemia and neonatal sepsis; meningitis and other CNS infections; biliary-tract infection, acute pyelonephritis or prostatitis, endocarditis (see notes above); pneumonia in hospital patients, adjunct in listerial meningitis (Table 1, section 5.1); eye (section 11.3.1); ear (section 12.1.1)

**Cautions** neonates, infants and elderly (adjust dose and monitor renal, auditory and vestibular function together with serum gentamicin concentrations); avoid prolonged use; conditions characterised by muscular weakness; see also notes above; interactions: Appendix 1 (aminoglycosides)

**Contra-indications** myasthenia gravis

**Renal impairment** see notes above

**Pregnancy** see notes above

**Side-effects** vestibular and auditory damage, nephrotoxicity; rarely, hypomagnesaemia on prolonged therapy, antibiotic-associated colitis, stomatitis; also reported, nausea, vomiting, rash, blood disorders; see also notes above

**Dose**

To avoid excessive dosage in obese patients, use ideal weight for height to calculate dose and monitor serum-gentamicin concentration closely.

- Multiple daily dose regimen, by intramuscular or by slow intravenous injection over at least 3 minutes or by intravenous infusion, 3–5 mg/kg daily (in divided doses every 8 hours), see also notes above; **CHILD under 18 years see BNF for Children**

Endocarditis (in combination with other antibiotics, see Table 1, section 5.1), **ADULT 1 mg/kg every 8 hours; CHILD under 18 years see BNF for Children**

- Once daily dose regimen (see notes above and also consult local guidelines), by intravenous infusion, initially 5–7 mg/kg, then adjust according to serum-gentamicin concentration; **CHILD under 18 years see BNF for Children**

- **By intrathecal injection.** seek specialist advice. 1 mg daily (increased if necessary to 5 mg daily); only preservative-free, intrathecal preparation should be used; **CHILD under 18 years see BNF for Children**

**Note** For multiple daily dose regimen, one-hour (‘peak’) serum concentration should be 5–10 mg/litre (3–5 mg/litre for endocarditis); pre-dose (‘trough’) concentration should be less than 2 mg/litre (less than 1 mg/litre for endocarditis). For once-daily dose regimen, consult local guidelines on monitoring serum-gentamicin concentration.
### Gentamicin (Non-proprietary) (Ampicillin)

**Injection**, gentamicin (as sulphate), net price 40 mg/mL, 1-mL amp = £1.40, 2-mL amp = £1.54, 2-mL vial = £1.48

**Paediatric injection**, gentamicin (as sulphate) 10 mg/mL, net price 2-mL vial = £1.80

**Intravenous injection**, gentamicin (as sulphate) 5 mg/mL, net price 1-mL amp = 74p

**Intravenous infusion**, gentamicin (as sulphate) 1 mg/mL, net price 80-mL (80 mg) bottle = £1.95; 3 mg/mL, 80-mL (240 mg) bottle = £5.95, 120-mL (360 mg) bottle = £8.45

**Cidomycin**<sup>®</sup> (Sanofi-Aventis) (Ampicillin)

**Injection**, gentamicin (as sulphate) 40 mg/mL. Net price 2-mL amp or vial = £1.48

**Gentamicin**<sup>®</sup> (Amdipharm)

**Injection**, gentamicin (as sulphate) 40 mg/mL. Net price 2-mL amp = £1.40

**Isotonic Gentamicin Injection**<sup>®</sup> (Baxter)

**Intravenous infusion**, gentamicin (as sulphate) 800 micrograms/mL in sodium chloride intravenous infusion 0.9%. Net price 100-mL (80-mg) Viaflex<sup>®</sup> bag = £1.61

**Electrolytes**

- Sodium: Na⁺ 15 mmol/100-mL bag
- Chloride: Cl⁻ 14 mmol/100-mL bag
- Bicarbonate: HCO₃⁻ 3 mmol/100-mL bag
- Potassium: K⁺ 4 mmol/100-mL bag
- Calcium: Ca²⁺ 1 mmol/100-mL bag
- Magnesium: Mg²⁺ 0.5 mmol/100-mL bag

### AMIKACIN

**Indications** serious Gram-negative infections resistant to gentamicin

**Cautions** see under Gentamicin; interactions: Appendix 1 (aminoglycosides)

**Contra-indications** see under Gentamicin and notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Side-effects** see under Gentamicin

**Dose** To avoid excessive dosage in obese patients, use ideal weight for height to calculate dose and monitor serum-amikacin concentration closely

**By intramuscular or by slow intravenous injection** or by infusion, 15 mg/kg daily in 2 divided doses, increased to 22.5 mg/kg daily in 3 divided doses in severe infections; max. 1.5 g daily for up to 10 days (max. cumulative dose 15 g); **CHILD** under 18 years see **BNF for Children**

**Note**: One-hour (‘peak’) serum concentration should not exceed 30 mg/litre; pre-dose (‘trough’) concentration should be less than 10 mg/litre

**Amikacin** (Non-proprietary)

**Injection**, amikacin (as sulphate) 250 mg/mL. Net price 2-mL vial = £10.14

**Electrolytes** Na⁺ 0.56 mmol/300-mg vial

**Amikin**<sup>®</sup> (Bristol-Myers Squibb)

**Injection**, amikacin (as sulphate) 50 mg/mL. Net price 2-mL vial = £2.07

**Electrolytes** Na⁺ < 0.5 mmol/vial

### NEOMYCIN SULPHATE

**Indications** bowel sterilisation before surgery, see also notes above

**Cautions** see under Gentamicin but too toxic for systemic use, see notes above; interactions: Appendix 1 (aminoglycosides)

**Contra-indications** see under Gentamicin; intestinal obstruction

**Hepatic impairment** absorbed from gastro-intestinal tract in liver disease—increased risk of ototoxicity

**Renal impairment** avoid; ototoxic; nephrotoxic

**Pregnancy** see notes above

**Side-effects** see under Gentamicin but poorly absorbed on oral administration; increased salivation, stomatitis, impaired intestinal absorption with steatorrhoea and diarrhoea

**Dose**

- **By mouth**, pre-operative bowel sterilisation, 1 g every hour for 4 hours, then 1 g every 4 hours for 2–3 days
- **Hepatic coma**, up to 4 g daily in divided doses usually for 5–7 days

**Neomycin** (Non-proprietary)

**Tablets**, neomycin sulphate 500 mg. Net price 100 = £20.65

**Brands** include Neivemycin<sup>®</sup>

### TOBRAMYCIN

**Indications** see under Gentamicin and notes above

**Cautions** see under Gentamicin; interactions: Appendix 1 (aminoglycosides)

**Specific cautions for inhaled treatment** Other inhaled drugs should be administered before tobramycin, monitor for bronchospasm with initial dose, measure peak flow before and after nebulisation—if bronchospasm occurs, repeat test using bronchodilator; monitor renal function before treatment and then annually, severe haemoptysis

**Contra-indications** see under Gentamicin

**Renal impairment** see notes above

**Pregnancy** see notes above

**Side-effects** see under Gentamicin; **on inhalation**, mouth ulcers, taste disturbances, voice alteration, cough, bronchospasm (see Cautions)

**Dose**

- **By intramuscular injection** or by slow intravenous injection or by intravenous infusion, 3 mg/kg daily in divided doses every 8 hours, see also notes above; in severe infections up to 5 mg/kg daily in divided doses every 6–8 hours (reduced to 3 mg/kg as soon as clinically indicated); **CHILD** under 18 years see **BNF for Children**
- **Urinary-tract infection**, by intramuscular injection, 2–3 mg/kg daily as a single dose
- **Note**: One-hour (‘peak’) serum concentration should not exceed 10 mg/litre; pre-dose (‘trough’) concentration should be less than 2 mg/litre
- **Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis**, by inhalation of nebulised solution, **ADULT** and **CHILD** over 6 years, 300 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution

**Parenteral**

**Tobramycin** (Non-proprietary)

**Injection**, tobramycin (as sulphate) 40 mg/mL. Net price 1-mL (40-mg) vial = £4.00, 2-mL (80-mg) vial = £4.16, 6-mL (240-mg) vial = £19.20

**Inhalation**

**Bramitob**<sup>®</sup> (Chiesi)

**Nebuliser solution**, tobramycin 75 mg/mL, net price 56 × 4-mL (300-mg) unit = £1187.00

**Price**

- 2-mL vial = £1.40
- 3 mg/mL, 80-mL (240 mg) bottle = £5.95
- 120-mL (360 mg) bottle = £8.45
- 80-mL (80 mg) bottle = £1.95
- 1-mL (40-mg) vial = £4.00
- 2-mL (80-mg) vial = £4.16
- 6-mL (240-mg) vial = £19.20

**BNF 61 5.1.4 Aminoglycosides 351**
### 5.1.5 Macrolides

**Erythromycin** has an antibacterial spectrum that is similar but not identical to that of penicillin; it is thus an alternative in penicillin-allergic patients.

Indications for erythromycin include respiratory infections, whooping cough, legionnaires’ disease, and campylobacter enteritis. It is active against many penicillin-resistant staphylococci but some are now also resistant to erythromycin; it has poor activity against *Haemophilus influenzae*. Erythromycin is also active against chlamydia and mycoplasmas.

Erythromycin causes nausea, vomiting, and diarrhoea in some patients; in mild to moderate infections this can be avoided by giving a lower dose (250 mg 4 times daily) but if a more serious infection, such as Legionella pneumonia, is suspected higher doses are needed.

**Azithromycin** is a macrolide with slightly less activity than erythromycin against Gram-positive bacteria but enhanced activity against some Gram-negative organisms including *H. influenzae*. Plasma concentrations are very low but tissue concentrations are much higher. It has a long tissue half-life and once daily dosage is recommended. Azithromycin is also used in the treatment of trachoma [unlicensed indication] (section 11.3.1).

**Clarithromycin** is an erythromycin derivative with slightly greater activity than the parent compound. Tissue concentrations are higher than with erythromycin. It is given twice daily.

For the role of erythromycin, azithromycin, and clarithromycin in the treatment of Lyme disease, see section 5.1.1.3

**Spiramycin** is also a macrolide (section 5.4.7).

#### Oral infections

Clarithromycin or erythromycin is an alternative for oral infections in penicillin-allergic patients or in the presence of a beta-lactamase producing organism. However, many organisms are now resistant to macrolides or rapidly develop resistance; their use should therefore be limited to short courses. Metronidazole (section 5.1.11) may be preferred as an alternative to a penicillin.

**Cautions**

Macrolides should be used with caution in patients with a predisposition to QT interval prolongation (including electrolyte disturbances and concomitant use of drugs that prolong the QT interval).

**Side-effects**

Nausea, vomiting, abdominal discomfort, and diarrhoea are the most common side-effects of the macrolides, but they are mild and less frequent with azithromycin and clarithromycin than with erythromycin. Hepatotoxicity (including cholestasis jaundice) and rash occur less frequently. Other side-effects reported rarely or very rarely include pancreatitis, antibiotic-associated colitis, QT interval prolongation, arrhythmias, generally reversible hearing loss (sometimes with tinnitus) after large doses, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Intravenous infusion may cause local tenderness and phlebitis.

---

### AZITHROMYCIN

**Indications**

- Respiratory-tract infections; otitis media; skin and soft-tissue infections; uncomplicated genital chlamydial infections and non-gonococcal urethritis (Table 1, section 5.1);
- Mild or moderate typhoid due to multiple-antibacterial-resistant organisms [unlicensed indication]; Lyme disease (see also section 5.1.1.3 [unlicensed indication]); prophylaxis of group A streptococcal infection (Table 2, section 5.1)

**Cautions**

- See notes above; interactions: Appendix 1 (macrolides)

**Hepatic impairment**

Manufacturers advise avoiding in severe liver disease—no information available

**Renal impairment**

- Use with caution if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy**

- Manufacturers advise use only if adequate alternatives not available

**Breast-feeding**

- Present in milk; use only if no suitable alternatives

**Side-effects**

- See notes above; also anorexia, dyspepsia, flatulence, dizziness, headache, drowsiness, convulsions, arthralgia, and disturbances in taste and smell; rarely constipation, syncope, insomnia, agitation, anxiety, asthenia, paraesthesia, hyperactivity, thrombocytopenia, haemolytic anaemia, interstitial nephritis, acute renal failure, photosensitivity, tooth and tongue discoloration

**Dose**

- 500 mg once daily for 3 days or 500 mg on first day then 250 mg once daily for 4 days; **CHILD** over 6 months 10 mg/kg once daily for 3 days; or body-weight 15–25 kg, 200 mg once daily for 3 days; body-weight 26–55 kg, 300 mg once daily for 3 days; body-weight 36–45 kg, 400 mg once daily for 3 days

- Uncomplicated genital chlamydial infections and non-gonococcal urethritis, 1 g as a single dose

- Lyme disease (see also section 5.1.1.3), typhoid [unlicensed indications], 500 mg once daily for 7–10 days (7 days in typhoid)

**Azithromycin (Non-proprietary)**

- **Capsules**, azithromycin (as dihydrate) 250 mg, net price 4-cap pack = £9.82, 6-cap pack = £14.73. Label: 5, 9, 23
- **Tablets**, azithromycin (as monohydrate hemi-etanolate) 250 mg, net price 4-tab pack = £9.83; 500 mg, 3-tab pack = £6.75. Label: 5, 9
- **Note** Azithromycin tablets can be sold to the public for the treatment of confirmed, asymptomatic *Chlamydia trachomatis* genital infection in those over 18 years of age, and for the epidemiological treatment of their sexual partners, subject to max. single dose of 1 g, max. daily dose 1 g, and a pack size of 1 g

**Oral suspension**, azithromycin (as monohydrate) 200 mg/5 mL when reconstituted with water, net price 15-mL pack = £5.86, 30-mL pack = £11.04. Label: 5, 9

**Dental prescribing on NHS**

May be prescribed as Azithromycin Oral Suspension 200 mg/5 mL

**Zithromax® (Pfizer)**

- **Capsules**, azithromycin (as dihydrate) 250 mg, net price 4-cap pack = £7.16, 6-cap pack = £10.74. Label: 5, 9, 23
- **Oral suspension**, cherry/banana-flavoured, azithromycin (as dihydrate) 200 mg/5 mL when reconstituted with water. Net price 15-mL pack = £4.06, 22.5-mL pack = £6.10, 30-mL pack = £11.04. Label: 5, 9
**CLARITHROMYCIN**

**Indications**  respiratory-tract infections, mild to moderate skin and soft-tissue infections, otitis media; Lyme disease (see also section 5.1.1.3); Helicobacter pylori eradication (section 1.3)

**Cautions** see notes above; Interactions: Appendix 1 (macrolides)

**Hepatic impairment** hepatic dysfunction including jaundice reported

**Renal impairment** use half normal dose if eGFR less than 30 mL/minute/1.73 m²; avoid Klaricid XL® if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid unless potential benefit outweighs risk—present in milk

**Side-effects** see notes above; also tooth and tongue discoloration, smell and taste disturbances, stomatitis, glossitis, and headache; very rarely dizziness, insomnia, nightmares, anxiety, confusion, psychosis, paraesthesia, convulsions, hypoglycaemia, renal failure, interstitial nephritis, leucopenia, and thrombocytopenia

**Dose**

- **By mouth,** ADULT and CHILD over 12 years, 250 mg every 12 hours for 7 days, increased in pneumonia or severe infections to 500 mg every 12 hours for up to 14 days (see also Table 1, section 5.1); CHILD body-weight under 8 kg, 7.5 mg/kg twice daily; 8–11 kg, 12.5 mg/kg twice daily; 12–19 kg, 125 mg twice daily; 20–29 kg, 187.5 mg twice daily; 30–40 kg, 250 mg twice daily

- **By intravenous infusion** into larger proximal vein, ADULT and CHILD over 12 years, 500 mg every 12 hours for 14–21 days [unlicensed duration]; CHILD 1 month–12 years see BNF for Children

- **By intravenous infusion** into larger proximal vein, ADULT and CHILD over 12 years, 500 mg twice daily; CHILD 1 month–12 years see BNF for Children

**Clarithromycin (Non-proprietary)**

- **Tablets,** clarithromycin 250 mg, net price 14-tab pack = £3.17; 500 mg, 14-tab pack = £4.10. Label: 9
- **Dental prescribing on NHS** Clarithromycin Tablets may be prescribed

- **Oral suspension,** clarithromycin for reconstitution with water 125 mg/5 mL, net price 70 mL = £6.16; 250 mg/5 mL, 70 mL = £12.36. Label: 9

- **Dental prescribing on NHS** Clarithromycin Oral Suspension may be prescribed

- **Intravenous infusion,** powder for reconstitution, clarithromycin, net price 500-mg vial = £10.31

**Klaricid® (Abbott)**

- **Tablets,** both yellow, f/c, clarithromycin 250 mg, net price 14-tab pack = £6.30; 500 mg, 14-tab pack = £10.17; 20-tab pack = £14.54. Label: 9

- **Paediatric suspension,** clarithromycin for reconstitution with water 125 mg/5 mL, net price 70 mL = £4.73; 100 mL = £8.14; 250 mg/5 mL, 70 mL = £9.46. Label: 9

- **Granules,** clarithromycin 250 mg/sachet, net price 14-sachet pack = £11.68. Label: 9, 13

- **Intravenous infusion,** powder for reconstitution, clarithromycin. Net price 500-mg vial = £9.45

Electrolytes Na⁺ < 0.5 mmol/500-mg vial

---

**ERYTHROMYCIN**

**Indications** susceptible infections in patients with penicillin hypersensitivity; oral infections (see notes above); campylobacter enteritis, syphilis, non-gonococcal urethritis, respiratory-tract infections (including Legionella infection), skin infections (Table 1, section 5.1); chronic prostatitis; prophylaxis of diphtheria, group A streptococcal infection, and whooping cough (Table 2, section 5.1); acne vulgaris and rosacea (section 13.6)

**Cautions** see notes above; neonate under 2 weeks (risk of hypertrophic pyloric stenosis); avoid in acute porphyria (section 9.8.2); Interactions: Appendix 1 (macrolides)

**Hepatic impairment** may cause idiosyncratic hepatotoxicity

**Renal impairment** max. 1.5 g daily in severe renal impairment (ototoxicity)

**Pregnancy** not known to be harmful

**Breast-feeding** only small amounts in milk—not known to be harmful

**Side-effects** see notes above; also myasthenia-like syndrome

**Dose**

- **By mouth,** ADULT and CHILD over 8 years, 250–500 mg every 6 hours or 0.5–1 g every 12 hours (see notes above) up to 4 g daily in divided doses in severe infections; NEONATE 12.5 mg/kg every 6 hours; CHILD 1 month–2 years 125 mg every 6 hours, 2–8 years 250 mg every 6 hours, doses doubled for severe infections

- **Early synphils,** 500 mg 4 times daily for 14 days

- **Uncomplicated genital chlamydia,** non-gonococcal urethritis, 500 mg twice daily for 14 days

- **Lyme disease** (see also section 5.1.1.3), 500 mg 4 times daily for 14–21 days

- **By intravenous infusion,** ADULT and CHILD severe infections, 12.5 mg/kg every 6 hours; mild infections (when oral treatment not possible), 6.25 mg/kg every 6 hours; NEONATE see BNF for Children

**Erythromycin (Non-proprietary)**

- **Capsules,** enclosing e/c microgranules, erythromycin 250 mg, net price 28–cap pack = £15.00. Label: 5, 9, 25

- **Brands include** Tilor®

- **Tablets,** e/c, erythromycin 250 mg, net price 28 = £1.54. Label: 5, 9, 25

- **Dental prescribing on NHS** Erythromycin Tablets e/c may be prescribed

**Erythromycin Ethyl Succinate (Non-proprietary)**

- **Oral suspension,** erythromycin (as ethyl succinate) for reconstitution with water 125 mg/5 mL, net price 100 mL = £1.99; 250 mg/5 mL, 100 mL = £2.64; 500 mg/5 mL, 100 mL = £4.31. Label: 9

- **Note** Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription

- **Brands include** Primacin®

- **Dental prescribing on NHS** Erythromycin Ethyl Succinate Oral Suspension may be prescribed
Erythromycin Lactobionate (Non-proprietary)  

**Intravenous infusion** powder for reconstitution, erythromycin (as lactobionate), net price 1-g vial = £9.98

**Erymax** (Cephalon)  
**Capsules** opaque orange/clear orange, enclosing orange and white e/c pellets, erythromycin 250 mg, net price 28-cap pack = £5.61, 112-cap pack = £22.44. Label: 5, 9, 25

Dose 1 capsule every 6 hours or 2 capsules every 12 hours; acne, 1 capsule twice daily for 1 month then 1 capsule daily

**Erythrocin** (Amidipharm)  
**Tablets** both f/c, erythromycin (as stearate), 250 mg, net price 100 = £18.20; 500 mg, 100 = £36.40. Label: 9

**Dental prescribing on NHS** May be prescribed as Erythromycin Stearate Tablets

**Erythroped A** (Amidipharm)  
**Suspension SF** sugar-free, banana-flavoured, erythromycin (as ethyl succinate) for reconstitution with water, 125 mg/5 mL (Suspension PI SF), net price 140 mL = £3.06; 250 mg/5 mL, 140 mL = £5.95; 500 mg/5 mL (Suspension SF Forte), 140 mL = £10.56. Label: 9

**Erythroped A** (Amidipharm)  
**Tablets**, yellow, f/c, erythromycin 500 mg (as ethyl succinate), Net price 28-tab pack = £10.78. Label: 9

**Dental prescribing on NHS** May be prescribed as Erythromycin Ethyl Succinate Tablets

**Telithromycin**

The ketolide telithromycin is a derivative of erythromycin. The antibacterial spectrum of telithromycin is similar to that of macrolides and it is also active against penicillin- and erythromycin-resistant *Streptococcus pneumoniae*. Telithromycin should only be used to treat beta-haemolytic streptococcal pharyngitis and tonsillitis, sinusitis, community-acquired pneumonia, and exacerbations of chronic bronchitis if caused by organisms resistant to beta-lactam antibacterials and other macrolides, or if conventional treatment is contra-indicated.

**TELITHROMYCIN**

**Indications** see notes above

**Cautions** coronary heart disease, ventricular arrhythmias, bradycardia, hypokalaemia, hypomagnesaemia—risk of QT interval prolongation; concomitant administration of drugs that prolong QT-interval; avoid in acute porphyria (section 9.8.2); **interactions**: Appendix 1 (telithromycin)

**Hepatic disorders** Patients should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, abdominal pain, jaundice, or dark urine develop

**Driving** Visual disturbances or transient loss of consciousness may occur after the first dose. Administration at bedtime may reduce these side-effects. Patients should be advised not to drive or operate machinery if affected

**Contra-indications** myasthenia gravis; history of telithromycin-associated hepatitis or jaundice; prolongation of QT interval; congenital or family history of QT interval prolongation (if not excluded by ECG)

**Hepatic impairment** manufacturer advises caution; see also Hepatic Disorders above

**Renal impairment** manufacturer advises avoid if possible if eGFR less than 30 mL/minute/1.73 m²—if no alternative, use alternating daily doses of 800 mg and 400 mg, starting with 800 mg dose

**Pregnancy** toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** diarrhoea, nausea, vomiting, flatulence, abdominal pain, taste disturbances; dizziness, headache; less commonly constipation, stomatitis, anorexia, hepatitis, flushing, palpitations, drowsiness, insomnia, nervousness, eosinophilia, blurred vision, rash, urticaria, and pruritus; rarely choletic jaundice, arthrythmias, hypotension, transient loss of consciousness, paraesthesia, and diplopia; very rarely antibiotic-associated colitis, altered sense of smell, muscle cramp, erythema multiforme; also reported pancreatitis, confusion, hallucinations and arthralgia

**Dose**

- 800 mg once daily for 5 days for sinusitis or exacerbation of chronic bronchitis or for 7–10 days in community-acquired pneumonia; **CHILD** under 18 years safety and efficacy not established
- Tonsillitis or pharyngitis caused by *Streptococcus pyogenes*, **ADULT** and **CHILD** over 12 years, 800 mg once daily for 5 days

**Ketek** (Sanofi-Aventis)  
**Tablets**, orange, f/c, telithromycin 400 mg, net price 10-tab pack = £18.56. Label: 9, counselling, driving, hepatic disorders

### 5.1.6 Clindamycin

Clindamycin is active against Gram-positive cocci, including streptococci and penicillin-resistant staphylococci, and also against many anaerobes, especially *Bacteroides fragilis*. It is well concentrated in bone and excreted in bile and urine.

Clindamycin is recommended for staphylococcal joint and bone infections such as osteomyelitis, and intra-abdominal sepsis; it is an alternative to macrolides for erysipelas or cellulitis in penicillin-allergic patients. Clindamycin can also be used for infections associated with meticillin-resistant *Staphylococcus aureus* (MRSA) in bronchiectasis, bone and joint infections, and skin and soft-tissue infections.

Clindamycin has been associated with antibiotic-associated colitis (section 1.5), which may be fatal; it is most common in middle-aged and elderly women, especially following an operation. Although antibiotic-associated colitis can occur with most antibacterials, it occurs more frequently with clindamycin. Patients should therefore discontinue treatment immediately if diarrhoea develops.

**Oral infections** Clindamycin should not be used routinely for the treatment of oral infections because it may be no more effective than penicillins against anaerobes and there may be cross-resistance with erythromycin-resistant bacteria. Clindamycin can be used for the treatment of dentoalveolar abscess that has not responded to penicillin or to metronidazole.

### Renal impairment

Manufacturer advises avoid if possible if eGFR less than 30 mL/minute/1.73 m²—if no alternative, use alternating daily doses of 800 mg and 400 mg, starting with 800 mg dose

### Pregnancy

Toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk

### Breast-feeding

Manufacturer advises avoid—present in milk in animal studies

### Side-effects

Diarrhoea, nausea, vomiting, flatulence, abdominal pain, taste disturbances; dizziness, headache; less commonly constipation, stomatitis, anorexia, hepatitis, flushing, palpitations, drowsiness, insomnia, nervousness, eosinophilia, blurred vision, rash, urticaria, and pruritus; rarely choletic jaundice, arrhythmias, hypotension, transient loss of consciousness, paraesthesia, and diplopia; very rarely antibiotic-associated colitis, altered sense of smell, muscle cramp, erythema multiforme; also reported pancreatitis, confusion, hallucinations and arthralgia

### Dose

- 800 mg once daily for 5 days for sinusitis or exacerbation of chronic bronchitis or for 7–10 days in community-acquired pneumonia; **CHILD** under 18 years safety and efficacy not established
- Tonsillitis or pharyngitis caused by *Streptococcus pyogenes*, **ADULT** and **CHILD** over 12 years, 800 mg once daily for 5 days

### Ketek

Tablets, orange, f/c, telithromycin 400 mg, net price 10-tab pack = £18.56. Label: 9, counselling, driving, hepatic disorders

**BNF 61**
**CLINDAMYCIN**

**Indications** see notes above; staphylococcal bone and joint infections, peritonitis; *falciparum* malaria (section 5.4.1)

**Cautions** discontinue immediately if diarrhoea or colitis develops; monitor liver and renal function if treatment exceeds 10 days, and in neonates and infants; avoid rapid intravenous administration; avoid in acute porphyria (section 9.8.2); **interactions:** Appendix 1 (clindamycin)

**Contra-indications** diarrhoeal states; avoid injections containing benzyl alcohol in neonates (see under preparations below)

**Pregnancy** not known to be harmful

**Breast-feeding** amount probably too small to be harmful but bloody diarrhoea reported in 1 infant

**Side-effects** diarrhoea (discontinue treatment), abdominal discomfort, oesophagitis, oesophageal ulcers, taste disturbances, nausea, vomiting, antibiotic-associated colitis; jaundice; leucopenia, eosinophilia, and thrombocytopenia reported; polyarthritis reported; rash, pruritus, urticaria, anaphylactoid reactions; Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative and vesiculobullous dermatitis reported; pain, induration, and abscess after intramuscular injection; thrombophlebitis after intravenous injection

**Dose**
- **By mouth**, 150–300 mg every 6 hours; up to 450 mg every 6 hours in severe infections; **CHILD**, 3–6 mg/kg every 6 hours
- **Counselling** Patients should discontinue immediately and contact doctor if diarrhoea develops; capsules should be swallowed with a glass of water
- **By deep intramuscular injection** or by intravenous infusion, 0.6–2.7 g daily (in 2–4 divided doses); life-threatening infection, up to 4.8 g daily; single doses above 600 mg by intravenous infusion only; single doses by intravenous infusion not to exceed 1.2 g; **CHILD** over 1 month, 15–40 mg/kg daily in 3–4 divided doses; severe infections, at least 300 mg daily regardless of weight

**Clindamycin** (Non-proprietary) (Pharmacia)

**Capsules**, clindamycin (as hydrochloride) 150 mg, net price 24-cap pack = £11.75. Label: 9, 27, counselling, see above (diarrhoea)

**Dental prescribing on NHS** Clindamycin Capsules may be prescribed

**Dalacin C** (Pharmacia) (Non-proprietary)

**Capsules**, clindamycin (as hydrochloride) 75 mg (green/white), net price 24-cap pack = £7.45. 150 mg, (white), 24-cap pack = £13.72. Label: 9, 27, counselling, see above (diarrhoea)

**Dental prescribing on NHS** May be prescribed as Clinda- mycin Capsules

**Injection**, clindamycin (as phosphate) 150 mg/mL, net price 2-ml amp = £5.20; 4-ml amp = £12.35

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients, p 2)

5.1.7 Some other antibacterials

Antibacterials discussed in this section include chloramphenicol, fusidic acid, glycopeptide antibiotics (vancomycin and teicoplanin), linezolid, and the poly- mycin, colistin.

**Chloramphenicol**

Chloramphenicol is a potent broad-spectrum antibiotic; however, it is associated with serious haematological side-effects when given systemically and should therefore be reserved for the treatment of life-threatening infections, particularly those caused by *Haemophilus influenzae*, and also for typhoid fever.

Chloramphenicol eye drops (section 11.3.1) and chloramphenicol ear drops (section 12.1.1) are also available.

**CHLORAMPHENICOL**

**Indications** see notes above

**Cautions** avoid repeated courses and prolonged treatment; blood counts required before and periodically during treatment; monitor plasma-chloramphenicol concentration in neonates (see below); **interactions:** Appendix 1 (chloramphenicol)

**Contra-indications** acute porphyria (section 9.8.2)

**Hepatic impairment** avoid if possible—increased risk of bone-marrow depression; reduce dose and monitor plasma-chloramphenicol concentration

**Renal impairment** avoid in severe renal impairment unless no alternative; dose-related depression of haematopoiesis

**Pregnancy** manufacturer advises avoid; neonatal ‘grey syndrome’ if used in third trimester

**Breast-feeding** manufacturer advises avoid; use another antibiotic; may cause bone-marrow toxicity in infant; concentration in milk usually insufficient to cause ‘grey syndrome’

**Side-effects** blood disorders including reversible and irreversible aplastic anaemia (with reports of resulting leukaemia), peripheral neuritis, optic neuritis, headache, depression, urticaria, erythema multiforme, nausea, vomiting, diarrhoea, stomatitis, glossitis, dry mouth; nocturnal haemoglobinuria reported; grey syndrome (abdominal distension, pallid cyanosis, circulatory collapse) may follow excessive doses in neonates with immature hepatic metabolism

**Dose**
- **By mouth** or by intravenous injection or infusion, 12.5 mg/kg every 6 hours (exceptionally, can be doubled for severe infections such as septicaemia and meningitis, providing high doses reduced as soon as clinically indicated); **CHILD** over 1 month, 12.5 mg/kg twice daily; 2 weeks–1 month, 12.5 mg/kg 2–4 times daily

**Note** Plasma concentration monitoring required in neonates and preferred in those under 4 years of age, in the elderly, and in hepatic impairment; recommended peak plasma concentration (approx. 2 hours after administration by mouth, intravenous injection or infusion) 10–25 mg/litre; pre-dose (‘trough’) concentration should not exceed 15 mg/litre

**Chloramphenicol** (Non-proprietary) (Pharmacia)

**Capsules**, chloramphenicol 250 mg. Net price 60 = £377.00

**Kemicetine** (Pharmacia) (Non-proprietary)

**Injection**, powder for reconstitution, chloramphenicol (as sodium succinate). Net price 1-g vial = £1.59

**Electrolytes** Na⁺ 134 mmol/l
Fusidic acid

Fusidic acid and its salts are narrow-spectrum antibiotics. The only indication for their use is in infections caused by penicillin-resistant staphylococci, especially osteomyelitis, as they are well concentrated in bone; they are also used for staphylococcal endocarditis. A second antistaphylococcal antibiotic is usually required to prevent emergence of resistance.

**SO D I U M F U S I D A T E**

**Indications** penicillin-resistant staphylococcal infection including osteomyelitis; staphylococcal endocarditis in combination with other antibacterials (Table 1, section 5.1)

**Cautions** monitor liver function with high doses or on prolonged therapy; elimination may be reduced in biliary disease or biliary obstruction; **interactions:** Appendix 1 (fusidic acid)

**Hepatic impairment** impaired biliary excretion; possibly increased risk of hepatotoxicity; avoid or reduce dose; monitor liver function

**Pregnancy** not known to be harmful; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** present in milk—manufacturer advises caution

**Side-effects** nausea, vomiting, reversible jaundice, especially after high dosage or rapid infusion (withdraw therapy if persistent); rarely hypersensitivity reactions, acute renal failure (usually with jaundice), blood disorders

**Dose**
- See under Preparations, below

**Sodium fusidate** (LEO)

**Intravenous infusion**, powder for reconstitution, sodium fusidate 500 mg (= fusidic acid 480 mg), with buffer, net price per vial (with diluent) = £70.04

**Dose** as sodium fusidate, by intravenous infusion, ADULT over 50 kg, 500 mg 3 times daily, ADULT under 50 kg and CHILD, 6–7 mg/kg 3 times daily

**Fucidin** (LEO)

**Tablets**, f/c, sodium fusidate 250 mg, net price 10-tab pack = £6.02. Label: 9

**Dose** as sodium fusidate, 500 mg every 8 hours, doubled for severe infections

**Skin infection**, as sodium fusidate, 250 mg every 12 hours for 5–10 days

**Suspension**, off-white, banana- and orange-flavoured, fusidic acid 250 mg/5 mL, net price 50 mL = £6.73. Label: 9, 21

**Dose** as fusidic acid, ADULT 750 mg every 8 hours; CHILD up to 1 year 50 mg/kg/daily (in 3 divided doses), 1–5 years 250 mg every 8 hours, 5–12 years 500 mg every 8 hours

**Note** Fusidic acid is incompletely absorbed and doses recommended for suspension are proportionately higher than those for sodium fusidate tablets

**Vancomycin and teicoplanin**

The glycopeptide antibiotics vancomycin and teicoplanin have bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci.

Vancomycin is used by the intravenous route in the treatment of endocarditis and other serious infections caused by Gram-positive cocci. It has a long duration of action and can therefore be given every 12 hours. Vancomycin (added to dialysis fluid) is also used in the treatment of peritonitis associated with peritoneal dialysis [unlicensed route] (Table 1 section 5.1).

Vancomycin given by mouth for 10–14 days is effective in the treatment of *Clostridium difficile* infection (see also section 1.5); low doses are considered adequate (higher dose may be considered if the infection fails to respond or if it is life threatening). Vancomycin should not be given by mouth for systemic infections since it is not significantly absorbed.

Teicoplanin is similar to vancomycin but has a significantly longer duration of action allowing once-daily administration. Unlike vancomycin, teicoplanin can be given by intramuscular as well as by intravenous injection; it is not given by mouth.

**Vancomycin**

**Indications** see notes above

**Cautions** avoid rapid infusion (risk of anaphylactoid reactions, see Side-effects); rotate infusion sites; elderly, avoid if history of deafness; all patients require plasma-vancomycin measurement (after 3 or 4 doses if renal function normal, earlier if renal impairment), blood counts, urinalysis, and renal function tests; monitor auditory function in elderly or if renal impairment; teicoplanin sensitivity; systemic absorption may follow oral administration especially in inflammatory bowel disorders or following multiple doses; **interactions:** Appendix 1 (vancomycin)

**Renal impairment** reduce dose—monitor plasma-vancomycin concentration and renal function regularly; see also Cautions above

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—plasma-vancomycin concentration monitoring essential to reduce risk of fetal toxicity

**Breast-feeding** present in milk—significant absorption following oral administration unlikely

**Side-effects** after parenteral administration: nephrotoxicity including renal failure and interstitial nephritis; ototoxicity (discontinue if tinnitus occurs); blood disorders including neutropenia (usually after 1 week or cumulative dose of 2.5 g), rarely agranulocytosis and thrombocytopenia; nausea; chills, fever; eosinophilia, anaphylaxis, rashes (including exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and vasculitis); phlebitis (irritant to tissue); on rapid infusion, severe hypotension (including shock and cardiac arrest), wheezing, dyspnoea, urticaria, pruritus, flushing of the upper body (‘red man’ syndrome), pain and muscle spasm of back and chest

**Dose**
- **By mouth**, *Clostridium difficile* infection, (see also notes above), **ADULT** and **CHILD** over 12 years, 125 mg every 6 hours for 10–14 days (increased up to 500 mg every 6 hours if infection fails to respond or is life-threatening); **CHILD 1 month–5 years, 5 mg/kg every 6 hours for 10–14 days (increased up to 10 mg/kg every 6 hours if infection fails to respond or is life-threatening); 5–12 years, half adult dose
By intravenous infusion, 1–1.5 g every 12 hours; ELDERLY over 65 years, 500 mg every 12 hours or 1 g once daily; CHILD over 1 month, 15 mg/kg every 8 hours (max. 2 g daily)

Note Plasma concentration monitoring required (see Cautions above); pre-dose (‘trough’) concentration should be 10–15 mg/litre (15–20 mg/litre for less sensitive strains of meticillin-resistant Staphylococcus aureus)

● Surgical prophylaxis, by intravenous infusion, ADULT over 18 years, 1 g

Note Vancomycin doses in BNF may differ from those in product literature

Vancomycin (Non-proprietary)

Capsules, vancomycin (as hydrochloride) 125 mg, net price 28-cap pack = £132.47; 250 mg, 28-cap pack = £132.47. Label: 9

Injection, powder for reconstitution, vancomycin (as hydrochloride), for use as an infusion, net price 500-mg vial = £7.25; 1-g vial = £14.50

Note Can be used to prepare solution for oral administration

Vanocin® (Flynn)

Matrigel capsules, vancomycin (as hydrochloride) 125 mg, net price 28-cap pack = £88.31. Label: 9

Injection, powder for reconstitution, vancomycin (as hydrochloride), for use as an infusion, net price 500-mg vial = £8.05; 1-g vial = £16.11

Note Can be used to prepare solution for oral administration

5.1.7 Some other antibacterials

Daptomycin

Daptomycin is a lipopeptide antibacterial with a spectrum of activity similar to vancomycin but its efficacy against enterococci has not been established. Daptomycin should be reserved for complicated skin and soft-tissue infections caused by resistant Gram-positive bacteria including meticillin-resistant Staphylococcus aureus (MRSA). It needs to be given with other antibiotics for mixed infections involving Gram-negative bacteria and some anaerobes.

The Scottish Medicines Consortium (p. 4) has advised (February 2008) that daptomycin (Cubicin®) is accepted for restricted use within NHS Scotland for the treatment of MRSA bacteraemia associated with right-sided endocarditis or with complicated skin and soft-tissue infections.

DAPTOMYCIN

Indications see under Dose

Cautions interference with assay for prothrombin time and INR—take blood sample immediately before daptomycin dose; interactions: Appendix 1 (daptomycin)

Muscle effects Myalgia, muscle weakness, and myositis may occur uncommonly; rhabdomyolysis is very rare. Monitor creatine kinase before treatment and then weekly during treatment (more frequently if creatine kinase elevated more than 5 times upper limit of normal before treatment, or if receiving another drug known to cause myopathy (preferably avoid concomitant use), or if eGFR less than 30 mL/

BNF 61

Note Plasma-teicoplanin concentration is not measured routinely because a relationship between plasma concentration and toxicity has not been established. However, the plasma-teicoplanin concentration can be used to optimise treatment in some patients (see Cautions). Pre-dose (‘trough’) concentrations should be greater than 10 mg/litre (greater than 15–20 mg/litre in endocarditis; greater than 20 mg/litre in deep-seated infection such as bone and joint infection), but less than 60 mg/litre. Teicoplanin doses in BNF may differ from those in product literature

Targocid® (Sanofi-Aventis)

Injection, powder for reconstitution, teicoplanin, net price 200-mg vial (with diluent) = £3.57; 400-mg vial (with diluent) = £6.10

Electrolytes Na+<sub>+</sub> 0.5 mmol/200- and 400-mg vial

Daptomycin dose

By intravenous injection or infusion, ADULT body-weight under 70 kg, initially 400 mg every 12 hours for 3 doses, subsequently 400 mg once daily (subsequent doses can alternatively be given by intramuscular injection); body-weight over 70 kg, initially 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg daily; higher doses may be required in severe infection (including burns, sepsicaemia, septic arthritis, and osteomyelitis), consult product literature
Infections

5 Infections

5.1.7 Some other antibacterials

minute/1.73 m²). If unexplained muscle pain, tenderness, weakness, or cramps develop during treatment, measure creatine kinase every 2 days; discontinue if unexplained muscular symptoms and creatine kinase elevated markedly.

Hepatic impairment manufacturer advises caution in severe hepatic impairment—no information available

Renal impairment see Muscle Effects above; also monitor renal function if eGFR less than 80 mL/minute/1.73 m²; use normal dose every 48 hours if eGFR less than 30 mL/minute/1.73 m²

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid

Side-effects nausea, vomiting, abdominal pain, flatulence, diarrhea (antibiotic-associated colitis reported), constipation, hypertension, hypotension, headache, anxiety, insomnia, dizziness, asthenia, anaemia, arthralgia, rash, pruritus, injection-site reactions; less commonly dyspepsia, anorexia, taste disturbance, glossitis, flushing, arthralgias, tremor, paresthesia, hyperglycaemia, renal failure, eosinophilia, thrombocytopenia, electrolyte disturbances, muscle effects (see Cautions); rarely jaundice; also reported syncope, wheezing, pulmonary eosinophilia, peripheral neuropathy

Dose

By slow intravenous injection over 2 minutes or by intravenous infusion, complicated skin and soft-tissue infections caused by Gram-positive bacteria, ADULT over 18 years, 4 mg/kg once daily; increased to 6 mg/kg once daily if associated with Staphylococcus aureus bacteremia

Right-sided endocarditis caused by Staphylococcus aureus, ADULT over 18 years, 6 mg/kg once daily

Cubicin® (Novartis) ▼ [Hal]

Intravenous infusion, powder for reconstitution, daptomycin, net price 350-mg vial = £26.00; 500-mg vial = £88.57

**Linezolid**

Linezolid, an oxazolidinone antibacterial, is active against Gram-positive bacteria including metillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant enterococci. Resistance to linezolid can develop with prolonged treatment or if the dose is less than that recommended. Linezolid is an option if a glycopeptide, such as vancomycin, cannot be used to treat pneumonia or severe skin and soft-tissue infections caused by MRSA. Linezolid is not active against Gram-negative organisms and must be given with other antibacterials if the infection also involves Gram-negative organisms (the combination should be used for mixed skin and soft tissue infections only when other treatments are not available). A higher incidence of blood disorders and optic neuropathy have been reported in patients receiving linezolid for more than 28 days. The CHM advice (optic neuropathy) Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days. The CHM recommends that:

- patients should be warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately.
- patients experiencing new visual symptoms (regardless of treatment duration) should be evaluated promptly, and referred to an ophthalmologist if necessary.
- visual function should be monitored regularly if treatment is required for longer than 28 days.

Monoamine oxidase inhibition Linezolid is a reversible, non-selective monoamine oxidase inhibitor (MAOI). Patients should avoid consuming large amounts of tyramine-rich foods (such as mature cheese, yeast extracts, undistilled alcoholic beverages, and fermented soya bean products). In addition, linezolid should not be given with another MAOI or within 2 weeks of stopping another MAOI. Unless close observation and blood-pressure monitoring is possible, avoid in those receiving SSRIs. SHT, agonists (‘triptans’), tricyclic antidepressants, sympathomimetics, dopaminergics, buspirone, pethidine and possibly other opioid analgetics. For other interactions see Appendix 1 (MAOIs)

Contra-indications see Monoamine Oxidase Inhibition above

Hepatic impairment in severe hepatic impairment manufacturer advises use only if potential benefit outweighs risk

Renal impairment manufacturer advises metabolites may accumulate if eGFR less than 30 mL/minute/1.73 m²; see also Blood Disorders, above

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—present in milk in animal studies

**SIDE-EFFECTS** diarrhea (antibiotic-associated colitis reported), nausea, vomiting, taste disturbances, headache; less commonly thirst, dry mouth, glossitis, stomatitis, tongue discolouration, abdominal pain, dyspepsia, gastritis, constipation, pancreatitis, hypertension, fever, fatigue, dizziness, insomnia, hypoaesthesia, paraesthesia, tinnitus, polyuria, leucopenia, thrombocytopenia, eosinophilia, electrolyte disturbances, blurred vision, rash, pruritus, diarrhoea, injection-site reactions; rarely tachycardia, transient ischaemic attacks, renal failure; also reported tooth discoloration, convulsions, lactic acidosis, pancytopenia, anaemia, Stevens-Johnson syndrome,

Blood disorders Haematopoietic disorders (including thrombocytopenia, anaemia, leucopenia, and pancytopenia) have been reported in patients receiving linezolid. It is recommended that full blood counts are monitored weekly. Close monitoring is recommended in patients who:

- receive treatment for more than 10–14 days.
- have pre-existing myelosuppression.
- are receiving drugs that may have adverse effects on haemoglobin, blood counts, or platelet function.
- have severe renal impairment.

If significant myelosuppression occurs, treatment should be stopped unless it is considered essential, in which case intensive monitoring of blood counts and appropriate management should be implemented.

**CHM advice (optic neuropathy)** Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days. The CHM recommends that:

- patients should be warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately.
- patients experiencing new visual symptoms (regardless of treatment duration) should be evaluated promptly, and referred to an ophthalmologist if necessary.
- visual function should be monitored regularly if treatment is required for longer than 28 days.

**LINEZOLID**

**Indications** pneumonia, complicated skin and soft-tissue infections caused by Gram-positive bacteria (initiated under expert supervision)

**Cautions** monitor full blood count (including platelet count) weekly (see also Blood disorders below); history of seizures; unless close observation and blood-pressure monitoring possible, avoid in uncontrolled hypertension, phaeochromocytoma, carcinoid tumour, thyrotoxicosis, bipolar depression, schizophrenia, or acute confusional states; interactions: Appendix 1 (MAOIs)

**Dose**

- For intravenous infusion, see above
- For oral use, see above

**Breast-feeding** manufacturer advises avoid

**Side-effects** nausea, vomiting, abdominal pain, flatulence, diarrhea (antibiotic-associated colitis reported), constipation, hypertension, hypotension, headache, anxiety, insomnia, dizziness, asthenia, anaemia, arthralgia, rash, pruritus, injection-site reactions; less commonly dyspepsia, anorexia, taste disturbance, glossitis, flushing, arthralgias, tremor, paresthesia, hyperglycaemia, renal failure, eosinophilia, thrombocytopenia, electrolyte disturbances, muscle effects (see Cautions); rarely jaundice; also reported syncope, wheezing, pulmonary eosinophilia, peripheral neuropathy

**Dose**

- By slow intravenous injection over 2 minutes or by intravenous infusion, complicated skin and soft-tissue infections caused by Gram-positive bacteria, ADULT over 18 years, 4 mg/kg once daily; increased to 6 mg/kg once daily if associated with *Staphylococcus aureus* bacteremia

- Right-sided endocarditis caused by *Staphylococcus aureus*, ADULT over 18 years, 6 mg/kg once daily

**Cubicin® (Novartis) ▼ [Hal]**

- Intravenous infusion, powder for reconstitution, daptomycin, net price 350-mg vial = £26.00; 500-mg vial = £88.57

**Linezolid**

Linezolid, an oxazolidinone antibacterial, is active against Gram-positive bacteria including metillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant enterococci. Resistance to linezolid can develop with prolonged treatment or if the dose is less than that recommended. Linezolid is an option if a glycopeptide, such as vancomycin, cannot be used to treat pneumonia or severe skin and soft-tissue infections caused by MRSA. Linezolid is not active against Gram-negative organisms and must be given with other antibacterials if the infection also involves Gram-negative organisms (the combination should be used for mixed skin and soft tissue infections only when other treatments are not available). A higher incidence of blood disorders and optic neuropathy have been reported in patients receiving linezolid for more than 28 days. The CHM advice (optic neuropathy) Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days. The CHM recommends that:

- patients should be warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately.
- patients experiencing new visual symptoms (regardless of treatment duration) should be evaluated promptly, and referred to an ophthalmologist if necessary.
- visual function should be monitored regularly if treatment is required for longer than 28 days.

Monoamine oxidase inhibition Linezolid is a reversible, non-selective monoamine oxidase inhibitor (MAOI). Patients should avoid consuming large amounts of tyramine-rich foods (such as mature cheese, yeast extracts, undistilled alcoholic beverages, and fermented soya bean products). In addition, linezolid should not be given with another MAOI or within 2 weeks of stopping another MAOI. Unless close observation and blood-pressure monitoring is possible, avoid in those receiving SSRIs. SHT, agonists (‘triptans’), tricyclic antidepressants, sympathomimetics, dopaminergics, buspirone, pethidine and possibly other opioid analgetics. For other interactions see Appendix 1 (MAOIs)

Contra-indications see Monoamine Oxidase Inhibition above

Hepatic impairment in severe hepatic impairment manufacturer advises use only if potential benefit outweighs risk

Renal impairment manufacturer advises metabolites may accumulate if eGFR less than 30 mL/minute/1.73 m²; see also Blood Disorders, above

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects diarrhea (antibiotic-associated colitis reported), nausea, vomiting, taste disturbances, headache; less commonly thirst, dry mouth, glossitis, stomatitis, tongue discolouration, abdominal pain, dyspepsia, gastritis, constipation, pancreatitis, hypertension, fever, fatigue, dizziness, insomnia, hypoaesthesia, paraesthesia, tinnitus, polyuria, leucopenia, thrombocytopenia, eosinophilia, electrolyte disturbances, blurred vision, rash, pruritus, diarrhoea, injection-site reactions; rarely tachycardia, transient ischaemic attacks, renal failure; also reported tooth discoloration, convulsions, lactic acidosis, pancytopenia, anaemia, Stevens-Johnson syndrome,
5.1.8 Sulfonamides and trimethoprim

The importance of the sulfonamides has decreased as a result of increasing bacterial resistance and their replacement by antibacterials which are generally more active and less toxic.

Sulfamethoxazole and trimethoprim are used in combination (as co-trimoxazole) because of their synergistic activity. However, co-trimoxazole is associated with rare but serious side-effects (e.g. Stevens-Johnson syndrome and blood dyscrasias, notably bone marrow depression and agranulocytosis) especially in the elderly (see Restrictions on the use of co-trimoxazole below).

Trimethoprim can be used alone for urinary- and respiratory-tract infections and for prostatitis, shigellosis,
and invasive salmonella infections. Trimethoprim has side-effects similar to co-trimoxazole but they are less severe and occur less frequently. For topical preparations of sulfonamides used in the treatment of burns see section 13.10.1.1.

### CO-TRIMOXAZOLE

A mixture of trimethoprim and sulfamethoxazole (sulphamethoxazole) in the proportions of 1 part to 5 parts

#### Indications

- see restrictions above

#### Cautions

- maintain adequate fluid intake; avoid in blood disorders (unless under specialist supervision); monitor blood counts on prolonged treatment; discontinue immediately if blood disorders or rash develop; predisposition to folate deficiency or hyperkalaemia; elderly (see Restrictions on the use of Co-trimoxazole above); asthma; G6PD deficiency (section 9.1.5); avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia); interactions: Appendix 1 (trimethoprim, sulfamethoxazole)

#### Hepatic impairment

- manufacturer advises avoid in acute porphyria (section 9.8.2)

#### Renal impairment

- use half normal dose if eGFR 15–30 mL/minute/1.73 m²; avoid if eGFR less than 15 mL/minute/1.73 m² and if plasma-sulfamethoxazole concentration cannot be monitored

#### Pregnancy

- teratogenic risk in first trimester (trimethoprim a folate antagonist). Neonatal haemolysis and methaemoglobinaemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded

#### Breast-feeding

- small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants (due to sulfamethoxazole)

#### Side-effects

- nausea, diarrhoea; headache; hyperkalaemia; rash (very rarely including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity)—discontinue immediately; less commonly: vomiting; very rarely: glossitis, stomatitis, anorexia, liver damage (including jaundice and hepatic necrosis), pancreatitis, antibiotic-associated colitis, myocardiitis, cough and shortness of breath, pulmonary infiltrates, aspetic meningitis, depression, convulsions, peripheral neuropathy, ataxia, tinnitus, vertigo, hallucinations, hypoglycaemia, blood disorders (including leucopenia, thrombocytopenia, megaloblastic anaemia, eosinophilia), hyponatraemia, renal disorders including interstitial nephritis, arthralgia, myalgia, vasculitis, systemic lupus erythematosus and uveitis; rhabdomyolysis reported in HIV-infected patients

#### Dose

- **By mouth**
  - trimethoprim 16 mg/kg daily in 2–4 divided doses for 14–21 days
  - prophylaxis of *Pneumocystis jirovecii* (*Pneumocystis carinii*) infections, by mouth, 960 mg once daily (may be reduced to 480 mg once daily to improve tolerance) or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week)
  - CHILD 6 weeks–5 months, 120 mg twice daily on 3 consecutive or alternate days per week or on 7 days per week; 6 months–5 years, 240 mg, 6–12 years, 480 mg

- **Note** 480 mg of co-trimoxazole consists of sulfamethoxazole 400 mg and trimethoprim 80 mg

#### Co-trimoxazole (Non-proprietary)

- **Tablets**, co-trimoxazole 480 mg, net price 28-tab pack = £18.99, 960 mg, 100 = £23.46. Label: 9
- **Brands include**: Fectrim®, Fectrin®, Forte

- **Paediatric oral suspension**, co-trimoxazole 240 mg/5 mL, net price 100 mL = £1.12. Label: 9
- **Oral suspension**, co-trimoxazole 485 mg/5 mL. Net price 100 mL = £4.41. Label: 9

- **Seprin®** (Aspen)
- **Tablets**, co-trimoxazole 480 mg, net price 100-tab pack = £15.52. Label: 9
- **Forte tablets**, scored, co-trimoxazole 960 mg, net price 100-tab pack = £23.46. Label: 9
- **Adult suspension**, co-trimoxazole 480 mg/5 mL, net price 100 mL (vanilla-flavoured) = £4.41. Label: 9
- **Paediatric suspension**, sugar-free, co-trimoxazole 240 mg/5 mL, net price 100 mL (banana- and vanilla-flavoured) = £2.45. Label: 9
- **Intravenous infusion**, co-trimoxazole 96 mg/mL. To be diluted before use. Net price 5-mL amp = £1.78
- **Electrolytes** Na⁺ 1.7 mmol/5 mL
- **Excipients** include alcohol 13.2%, propylene glycol, sulphates

### SULFADIAZINE

(Sulphadiazine)

#### Indications

- prevention of rheumatic fever recurrence, toxoplasmosis [unlicensed]—see section 5.4.7

#### Cautions

- see under Co-trimoxazole; interactions: Appendix 1 (sulfonamides)

#### Contra-indications

- see under Co-trimoxazole

#### Hepatic impairment

- use with caution in mild to moderate impairment; avoid in severe impairment

#### Renal impairment

- use with caution in mild to moderate impairment; avoid in severe impairment; high risk of crystalluria

#### Pregnancy

- neonatal haemolysis and methaemoglobinaemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded

#### Breast-feeding

- small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants

#### Side-effects

- see under Co-trimoxazole; also hypothyroidism, benign intracranial hypertension, optic neuropathy

#### Dose

- **Prevention of rheumatic fever, by mouth**, 1 g daily (500 mg daily for patients less than 30 kg)

#### Sulfadiazine (Non-proprietary)

- **Tablets**, sulfadiazine 500 mg, net price 56-tab pack = £37.50. Label: 9, 27

### TRIMETHOPRIM

#### Indications

- urinary-tract infections, acute and chronic bronchitis; pneumocystis pneumonia (section 5.4.8)

#### Cautions

- predisposition to folate deficiency; elderly; manufacturer recommends blood counts on long-
term therapy (but evidence of practical value unsatisfactory); neonates (specialist supervision required); acute porphyria (section 9.8.2); interactions: Appendix 1 (trimethoprim).

**Blood disorders** On long-term treatment, patients and their carers should be told how to recognise signs of blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop.

**Contra-indications** blood dyscrasias.

**Renal impairment** use half normal dose after 3 days if eGFR 15–30 mL/minute/1.73 m²; use half normal dose if eGFR less than 15 mL/minute/1.73 m² (monitor plasma-trimethoprim concentration if eGFR less than 10 mL/minute/1.73 m²).

**Pregnancy** teratogenic risk in first trimester (folate antagonists); manufacturers advise avoid.

**Breast-feeding** present in milk—short-term use not known to be harmful.

**Side-effects** gastro-intestinal disturbances including nausea, vomiting, diarrhoea, dyspepsia, depression of haematopoiesis; rarely erythema multiforme, toxic epidermal necrolysis, photosensitivity and other allergic reactions including angioedema and anaphylaxis; aseptic meningitis and uveitis reported.

**Dose**
- Acute infections, 200 mg every 12 hours; **CHILD** 1 month–12 years, 4 mg/kg (max. 200 mg) every 12 hours; or 6 weeks–6 months 25 mg every 12 hours, 6 months–6 years 50 mg every 12 hours, 6–12 years 100 mg every 12 hours.
- Prophylaxis, 100 mg at night; **CHILD** under 12 years, 2 mg/kg (max.100 mg) at night.

**Trimethoprim** (Non-proprietary) (non)
- Tablets, trimethoprim 100 mg, net price 28 = 94p; 200 mg, 14-tab pack = 91p. Label: 9. Brands includeTrimopan.
- Suspension, trimethoprim 50 mg/5 mL, net price 100 mL = £2.37. Label: 9.

## 5.1.9 Antituberculosis drugs

Tuberculosis is treated in two phases—an initial phase using 4 drugs and a continuation phase using 2 drugs in fully sensitive cases. Treatment requires specialised knowledge, particularly where the disease involves resistant organisms or non-respiratory organs.

The regimens given below are recommended for the treatment of tuberculosis in the UK; variations occur in other countries. Either the unsupervised regimen or the supervised regimen described below should be used; the two regimens should not be used concurrently.

### Initial phase

The concurrent use of 4 drugs during the initial phase is designed to reduce the bacterial population as rapidly as possible and to prevent the emergence of drug-resistant bacteria. The drugs are best given as combination preparations unless one of the components cannot be given because of resistance or intolerance.

The treatment of choice for the initial phase is the daily use of isoniazid, rifampicin, pyrazinamide and ethambutol. Treatment should be started without waiting for culture results if clinical features or histology results are consistent with tuberculosis; treatment should be continued even if initial culture results are negative. The initial phase drugs should be continued for 2 months. Where a positive culture for *M. tuberculosis* has been obtained, but susceptibility results are not available after 2 months, treatment with rifampicin, isoniazid, pyrazinamide and ethambutol should be continued until full susceptibility is confirmed, even if this is for longer than 2 months.

**Streptomycin** is rarely used in the UK but it may be used in the initial phase of treatment if resistance to isoniazid has been established before therapy is commenced.

### Continuation phase

After the initial phase, treatment is continued for a further 4 months with isoniazid and rifampicin (preferably given as a combination preparation). Longer treatment is necessary for meningitis, direct spinal cord involvement, and for resistant organisms which may also require modification of the regimen.

**Unsupervised treatment** The following regimen should be used for patients who are likely to take antituberculous drugs reliably without supervision. Patients who are unlikely to comply with daily administration of antituberculous drugs should be treated with the regimen described under Supervised Treatment.

**Recommended dosage for standard unsupervised 6-month treatment**

**Rifater** [rifampicin, isoniazid, and pyrazinamide] (for 2-month initial phase only)
- **ADULT** body-weight under 40 kg 3 tablets daily, body-weight 40–49 kg 4 tablets daily, body-weight 50–64 kg 5 tablets daily; body-weight over 65 kg 6 tablets daily.
- **Ethambutol** (for 2-month initial phase only)
- **ADULT AND CHILD** 15 mg/kg daily.

**Rifinah** [rifampicin and isoniazid] (for 4-month continuation phase following initial treatment with Rifater®)
- **ADULT** body-weight under 50 kg 3 tablets daily of Rifinah® 150/100, body-weight 50 kg and over, 2 tablets daily of Rifinah® 300/150.
- **or** (if combination preparations not appropriate): **Isoniazid** (for 2-month initial and 4-month continuation phases)
- **ADULT** 300 mg daily; **CHILD** 10 mg/kg (max. 300 mg) daily.
- **Rifampicin** (for 2-month initial and 4-month continuation phases)
- **ADULT** body-weight under 50 kg 450 mg daily; body-weight 50 kg and over, 600 mg daily; **CHILD** 10 mg/kg daily (max. 450 mg daily if body-weight under 50 kg; max. 600 mg daily if body-weight 50 kg and over).

**Pyrazinamide** (for 2-month initial phase only)
- **ADULT** body-weight under 50 kg 1.5 g daily, body-weight 50 kg and over, 2 g daily; **CHILD** 35 mg/kg daily (max. 1.5 g daily if body-weight under 50 kg; max. 2 g daily if body-weight 50 kg and over).
- **Ethambutol** (for 2-month initial phase only)
- **ADULT AND CHILD** 15 mg/kg daily.

**Pregnancy** The standard regimen (above) may be used during pregnancy. Streptomycin should not be given in pregnancy.

**Breast-feeding** The standard regimen (above) may be used during breast-feeding.

**Children** Children are given isoniazid, rifampicin, pyrazinamide, and ethambutol for the first 2 months followed by isoniazid and rifampicin during the next 4 months. However, care is needed in young children receiving ethambutol because of the difficulty in testing eye-sight and in obtaining reports of visual symptoms (see below).
Supervised treatment Drug administration needs to be fully supervised (directly observed therapy, DOT) in patients who cannot comply reliably with the treatment regimen. These patients are given isoniazid, rifampicin, pyrazinamide and ethambutol (or streptomycin) 3 times a week under supervision for the first 2 months followed by isoniazid and rifampicin 3 times a week for a further 4 months.

Recommended dosage for intermittent supervised 6-month treatment

Isoniazid (for 2-month initial and 4-month continuation phases)
- **ADULT AND CHILD** 15 mg/kg (max. 900 mg) 3 times a week

Rifampicin (for 2-month initial and 4-month continuation phases)
- **ADULT** 600–900 mg 3 times a week; **CHILD** 15 mg/kg (max. 900 mg) 3 times a week

Pyrazinamide (for 2-month initial phase only)
- **ADULT** body-weight under 50 kg 2 g 3 times a week; body-weight 50 kg and over; 2.5 g 3 times a week; **CHILD** 50 mg/kg 3 times a week (max. 2 g 3 times a week if body-weight under 50 kg; max. 2.5 g 3 times a week if body-weight 50 kg and over)

Ethambutol (for 2-month initial phase only)
- **ADULT AND CHILD** 30 mg/kg 3 times a week

Immunocompromised patients Multi-resistant *Mycobacterium tuberculosis* may be present in immunocompromised patients. The organism should always be cultured to confirm its type and drug sensitivity. Confirmed *M. tuberculosis* infection sensitive to first-line drugs should be treated with a standard 6-month regimen; after completing treatment, patients should be closely monitored. The regimen may need to be modified if infection is caused by resistant organisms, and specialist advice is needed.

Specialist advice should be sought about tuberculosis treatment or chemoprophylaxis in an HIV-positive individual; care is required in choosing the regimen and in avoiding potentially serious interactions. Starting antiretroviral treatment in the first 2 months of antituberculosis treatment increases the risk of immune reconstitution syndrome.

Infection may also be caused by other mycobacteria e.g. *M. avium* complex in which case specialist advice on management is needed.

Corticosteroids In meningeal or pericardial tuberculosis, a corticosteroid should be started at the same time as antituberculosis therapy.

Prevention of tuberculosis Some individuals may develop tuberculosis owing to reactivation of previously latent disease. Chemoprophylaxis may be required in those who have evidence of latent tuberculosis and are receiving treatment with immunosuppressants (including cytotoxics and possibly long-term treatment with systemic corticosteroids). In these cases, chemoprophylaxis involves use of either isoniazid alone for 6 months or of isoniazid and rifampicin for 3 months, see Table 2, section 5.1. For advice on immunisation against tuberculosis, see section 14.4

Monitoring Since isoniazid, rifampicin and pyrazinamide are associated with liver toxicity, hepatic function should be checked before treatment with these drugs. Those with pre-existing liver disease or alcohol dependence should have frequent checks particularly in the first 2 months. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. In view of the need to comply fully with antituberculosis treatment on the one hand and to guard against serious liver damage on the other, patients and their carers should be informed carefully how to recognise signs of liver disorders and advised to discontinue treatment and seek immediate medical attention should symptoms of liver disease occur.

Renal function should be checked before treatment with antituberculous drugs and appropriate dosage adjustments made. Streptomycin or ethambutol should preferably be avoided in patients with renal impairment, but if used, the dose should be reduced and the plasma drug concentration monitored.

Visual acuity should be tested before ethambutol is used (see below).

Isoniazid is cheap and highly effective. Like rifampicin it should always be included in any antituberculous regimen unless there is a specific contra-indication. Its only common side-effect is peripheral neuropathy which is more likely to occur where there are pre-existing risk factors such as diabetes, alcohol dependence, chronic renal failure, malnutrition and HIV infection. In these circumstances pyridoxine 10 mg daily (or 20 mg daily if suitable product not available) (section 9.6.2) should be given prophylactically from the start of treatment. Other side-effects such as hepatitis (important: see Monitoring above) and psychosis are rare.

Rifampicin, a rifamycin, is a key component of any antituberculous regimen. Like isoniazid it should always be included unless there is a specific contra-indication.

During the first two months (‘initial phase’) of rifampicin administration transient disturbance of liver function with elevated serum transaminases is common but generally does not require interruption of treatment. Occasionally more serious liver toxicity requires a change of treatment particularly in those with pre-existing liver disease (important: see Monitoring above). On intermittent treatment six toxicity syndromes have been recognised—fever, malaise, abdominal, respiratory symptoms, sepsis, renal failure, and thrombocytopenic purpura—and can occur in 20 to 30% of patients. Rifampicin induces hepatic enzymes which accelerate the metabolism of several drugs including oestrogens, corticosteroids, phenytoin, sulfonylureas, and anticoagulants; **interactions:** Appendix 1 (rifamycins). **Important:** the effectiveness of hormonal contraceptives is
Capreomycin

**Indications** in combination with other drugs, tuberculosis resistant to first-line drugs

**Cautions** monitor haematological, renal, and hepatic function; **interactions**: Appendix 1 (cycloserine)

**Contra-indications** epilepsy, depression, severe anxiety, psychotic states, alcohol dependence, acute porphyria (section 9.8.2)

**Renal impairment** reduce dose and monitor blood-cycloserine concentration; avoid in severe impairment

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—teratogenic in animal studies

**Breast-feeding** amount too small to be harmful

**Side-effects** mainly neurological, including headache, dizziness, vertigo, drowsiness, tremor, convulsions, confusion, psychosis, depression (discontinue or reduce dose if symptoms of CNS toxicity); rashes, allergic dermatitis (discontinue or reduce dose); megaloblastic anaemia; changes in liver function tests; heart failure at high doses reported

**Dose**
- Initially 250 mg every 12 hours for 2 weeks increased according to blood concentration and response to max. 500 mg every 12 hours; **CHILD 2–18 years** see BNF for Children

**Note** Blood concentration monitoring required especially in renal impairment or if dose exceeds 500 mg daily or if signs of toxicity; blood concentration should not exceed 30 mg/litre

**Cycloserine** (King) 58

**Capsules** red/grey cycloserine 250 mg, net price 100-cap pack = £33.80. Label: 2, 8

**ETHAMBUTOL HYDROCHLORIDE**

**Indications** tuberculosis, in combination with other drugs

**Cautions** elderly; test visual acuity before treatment and warn patients to report visual changes—see Monitoring in notes above; young children (see notes above)—routine ophthalmological monitoring recommended
Contra-indications optic neuritis, poor vision

Renal impairment reduce dose; if creatinine clearance less than 30 mL/minute, monitor plasma-ethambutol concentration; optic nerve damage

Pregnancy not known to be harmful; see also p. 361

Breast-feeding amount too small to be harmful; see also p. 361

Side-effects optic neuritis, red/green colour blindness, peripheral neuritis, rarely rash, pruritus, urticaria, thrombocytopenia

Dose

- See notes above

Note 'Peak' concentration (2–2.5 hours after dose) should be 2–6 mg/litre (7–22 micromol/litre); 'trough' (pre-dose) concentration should be less than 1 mg/litre (4 micromol/litre). See Cautions above, for advice on laboratory assay of ethambutol contact the Poisons Unit at New Cross Hospital (Tel (020) 7771 5360)

Ethambutol (Non-proprietary)

Tablets, ethambutol hydrochloride 100 mg, net price 56-tab pack = £12.00; 400 mg, 56-tab pack = £44.18. Label: 8

ISONIAZID

Indications tuberculosis, in combination with other drugs; prophylaxis—Table 2, section 5.1

Cautions see Monitoring in notes above; also slow acetylator status (increased risk of side-effects); epilepsy; history of psychosis; alcohol dependence, malnutrition, diabetes mellitus, HIV infection (risk of peripheral neuritis); acute porphyria (section 9.8.2); interactions: Appendix 1 (isoniazid)

Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop

Contra-indications drug-induced liver disease

Hepatic impairment use with caution; monitor liver function regularly and particularly frequently in first 2 months; see also Hepatic Disorders above

Renal impairment max. 200 mg daily if eGFR less than 10 mL/minute/1.73 m²; peripheral neuropathy

Pregnancy not known to be harmful; see also p. 361

Breast-feeding monitor infant for possible toxicity; theoretical risk of convulsions and neuropathy; prophylactic pyridoxine advisable in mother and infant; see also p. 361

Side-effects nausea, vomiting, constipation, dry mouth; peripheral neuritis with high doses (pyridoxine prophylaxis, see notes above), optic neuritis, convulsions, psychotic episodes, vertigo; hypersensitivity reactions including fever, Stevens-Johnson syndrome, purpura; blood disorders including agranulocytosis, haemolytic anaemia, aplastic anaemia; hepatitis (especially over age of 35 years); pancreatitis; interstitial pneumonia; systemic lupus erythematosus-like syndrome, pellagra, hyperreflexia, difficulty with micturition, hyperglycaemia, and gynaecomastia reported; hearing loss and tinnitus (in patients with end-stage renal impairment); when used with tyramine or histamine rich foods, tachycardia, palpitation, hypotension, flushing, headache, dizziness, and sweating also reported

Dose

- By mouth or by intramuscular or intravenous injec-

ion, see notes above

Isoniazid (Non-proprietary)

Tablets, isoniazid 50 mg, net price 56-tab pack = £11.10; 100 mg, 28-tab pack = £11.30. Label: 8, 22

Elixir (BPC), isoniazid 50 mg, citric acid monohydrate 12.5 mg, sodium citrate 60 mg, concentrated anise water 0.05 mL, compound tartrazine solution 0.05 mL, glycerol 1 mL, double-strength chloroform water 2 mL, water to 5 mL. Label: 8, 22

Available from 'special-order' manufacturers or specialist importing companies, see p. 988

Injection, isoniazid 25 mg/mL, net price 2-mL amp = £11.04

PYRAZINAMIDE

Indications tuberculosis in combination with other drugs (unlicensed)

Cautions see Monitoring in notes above; also diabetes; gout (avoid in acute attack); interactions: Appendix 1 (pyrazinamide)

Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop

Contra-indications acute porphyria (section 9.8.2)

Hepatic impairment monitor hepatic function—idiosyncratic hepatotoxicity more common; avoid in severe hepatic impairment; see also Hepatic Disorders above

Pregnancy manufacturer advises use only if potential benefit outweighs risk; see also p. 361

Breast-feeding amount too small to be harmful; see also p. 361

Side-effects hepatotoxicity including fever, anorexia, hepatomegaly, splenomegaly, jaundice, liver failure; nausea, vomiting, flushing, dysuria, arthralgia, sideroblastic anaemia, thrombocytopenia, rash and occasionally photosensitivity

Dose

- See notes above

Pyrazinamide (Non-proprietary)

Tablets, scored, pyrazinamide 500 mg. Label: 8 Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

RIFABUTIN

Indications see under Dose

Cautions see under Rifampicin; acute porphyria (section 9.8.2)

Hepatic impairment reduce dose in severe impair-

ment

Renal impairment use half normal dose if eGFR less than 30 mL/minute/1.73 m²

Pregnancy manufacturer advises avoid—no information available

Breast-feeding manufacturer advises avoid—no information available

Side-effects nausea, vomiting; leucopenia, thrombocytopenia, anaemia, rarely haemolytic; raised liver enzymes, jaundice, rarely hepatitis; uraemia following high doses or administration with drugs which raise plasma concentration—see also interactions: Appendix 1 (rifampicins); arthralgia, myalgia, influenza-like syndrome, dyspnoea; also hypersensitivity reactions including fever, rash, eosinophilia, bron-
5.1.9 Antituberculosis drugs

**Dosage**

- **Prophylaxis of Mycobacterium avium complex infections** in immunosuppressed patients with low CD4 count (see product literature), 300 mg daily as a single dose.

- **Treatment of non-tuberculous mycobacterial disease**, in combination with other drugs, 450–600 mg daily as a single dose for up to 6 months after cultures negative.

- **Treatment of pulmonary tuberculosis**, in combination with other drugs, 150–450 mg daily as a single dose for at least 6 months.

**Cautions**

- **Side-effects**
  - amount too small to be harmful; see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged therapy (see also below); acute porphyria (section 9.8.2); important: advise patients on hormonal contraceptives to use additional means (see also section 7.3.1); disclours soft contact lenses; see also notes above; interactions: Appendix 1 (rifamycins).

- **Note**: If treatment interrupted re-introduce with low dosage and increase gradually; discontinue permanently if serious side-effects develop.

- **Hepatic disorders**: Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

- **Contra-indications**: jaundice.

- **Hepatic impairment**: impaired elimination; monitor liver function; avoid or do not exceed 8 mg/kg daily; see also Cautions above.

- **Renal impairment**: use with caution if dose above 600 mg daily.

- **Pregnancy**: manufacturers advise very high doses teratogenic in animal studies in first trimester; risk of neonatal bleeding may be increased in third trimester; see also p. 361.

- **Breast-feeding**: amount too small to be harmful; see also p. 361.

- **Side-effects**: gastro-intestinal symptoms including anorexia, nausea, vomiting, diarrhoea (antibiotic-associated colitis reported); headache, drowsiness; those occurring mainly on intermittent therapy include influenza-like symptoms (with chills, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure; alterations of liver function, jaundice; flushing, urticaria, and rashes; other side-effects reported include oedema, psychoses, adrenal insufficiency, muscular weakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pempigoid reactions, leucopenia, eosinophilia, menstrual disturbances; urine, saliva, and other body secretions coloured orange-red; thrombophlebitis reported if infusion used for prolonged period.

**Dose**

- **Brucellosis, legionnaires’ disease, endocarditis and serious staphylococcal infections**, in combination with other drugs, **by mouth or by intravenous infusion**, 0.6–1.2 g daily (in 2–4 divided doses).

- **Tuberculosis**, in combination with other drugs, see notes above.

- **Leprosy, section 5.1.10**.

- **Prophylaxis of meningococcal menigitis and Haemophilus influenzae (type b) infection, section 5.1, table 2.**

**Rifampicin**

**Indications**: see under Dose

**Cautions**: see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged therapy, see also below; acute porphyria (section 9.8.2).

**Note**: If treatment interrupted re-introduce with low dosage and increase gradually; discontinue permanently if serious side-effects develop.

**Hepatic disorders**: Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

**Contra-indications**: jaundice.

**Hepatic impairment**: impaired elimination; monitor liver function; avoid or do not exceed 8 mg/kg daily; see also Cautions above.

**Renal impairment**: use with caution if dose above 600 mg daily.

**Pregnancy**: manufacturers advise very high doses teratogenic in animal studies in first trimester; risk of neonatal bleeding may be increased in third trimester; see also p. 361.

**Breast-feeding**: amount too small to be harmful; see also p. 361.

**Side-effects**: gastro-intestinal symptoms including anorexia, nausea, vomiting, diarrhoea (antibiotic-associated colitis reported); headache, drowsiness; those occurring mainly on intermittent therapy include influenza-like symptoms (with chills, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure; alterations of liver function, jaundice; flushing, urticaria, and rashes; other side-effects reported include oedema, psychoses, adrenal insufficiency, muscular weakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pempigoid reactions, leucopenia, eosinophilia, menstrual disturbances; urine, saliva, and other body secretions coloured orange-red; thrombophlebitis reported if infusion used for prolonged period.

**Dose**

- **Brucellosis, legionnaires’ disease, endocarditis and serious staphylococcal infections**, in combination with other drugs, **by mouth or by intravenous infusion**, 0.6–1.2 g daily (in 2–4 divided doses).

- **Tuberculosis**, in combination with other drugs, see notes above.

- **Leprosy, section 5.1.10**.

- **Prophylaxis of meningococcal menigitis and Haemophilus influenzae (type b) infection, section 5.1, table 2.**

**Rifampicin**

**Indications**: see under Dose

**Cautions**: see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged therapy, see also below; acute porphyria (section 9.8.2).

**Note**: If treatment interrupted re-introduce with low dosage and increase gradually; discontinue permanently if serious side-effects develop.

**Hepatic disorders**: Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

**Contra-indications**: jaundice.

**Hepatic impairment**: impaired elimination; monitor liver function; avoid or do not exceed 8 mg/kg daily; see also Cautions above.

**Renal impairment**: use with caution if dose above 600 mg daily.

**Pregnancy**: manufacturers advise very high doses teratogenic in animal studies in first trimester; risk of neonatal bleeding may be increased in third trimester; see also p. 361.

**Breast-feeding**: amount too small to be harmful; see also p. 361.

**Side-effects**: gastro-intestinal symptoms including anorexia, nausea, vomiting, diarrhoea (antibiotic-associated colitis reported); headache, drowsiness; those occurring mainly on intermittent therapy include influenza-like symptoms (with chills, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure; alterations of liver function, jaundice; flushing, urticaria, and rashes; other side-effects reported include oedema, psychoses, adrenal insufficiency, muscular weakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pempigoid reactions, leucopenia, eosinophilia, menstrual disturbances; urine, saliva, and other body secretions coloured orange-red; thrombophlebitis reported if infusion used for prolonged period.

**Dose**

- **Brucellosis, legionnaires’ disease, endocarditis and serious staphylococcal infections**, in combination with other drugs, **by mouth or by intravenous infusion**, 0.6–1.2 g daily (in 2–4 divided doses).

- **Tuberculosis**, in combination with other drugs, see notes above.

- **Leprosy, section 5.1.10**.

- **Prophylaxis of meningococcal menigitis and Haemophilus influenzae (type b) infection, section 5.1, table 2.**
Renal impairment see under Aminoglycosides, section 5.1.4
Pregnancy see under Aminoglycosides, section 5.1.4
Side-effects see under Aminoglycosides, section 5.1.4; also hypersensitivity reactions, paraesthesia of mouth

Dose

- By deep intramuscular injection, tuberculosis [unlicensed], see notes above; brucellosis, expert advice essential

Note One-hour (‘peak’) concentration should be 15–40 mg/litre; pre-dose (‘trough’) concentration should be less than 5 mg/litre (less than 1 mg/litre in renal impairment or in those over 50 years)

Streptomycin Sulphate (Non-proprietary) [full]
Injection, powder for reconstitution, streptomycin (as sulphate), net price 1-g vial = £8.25
Available as an unlicensed preparation from UCB Pharma

366 5.1.10 Antileprotic drugs

Advice from a member of the Panel of Leprosy Opinion is essential for the treatment of leprosy (Hansen’s disease). Details of the Panel can be obtained from the Department of Health telephone (020) 7972 4480.

The World Health Organization has made recommendations to overcome the problem of dapsone resistance and to prevent the emergence of resistance to other antileprotic drugs. Drugs recommended are dapsone, rifampicin (section 5.1.9), and clofazimine. Other drugs with significant activity against Mycobacterium leprae include ofloxacin, minocycline and clarithromycin, but none of these are as active as rifampicin; at present they should be reserved as second-line drugs for leprosy.

A three-drug regimen is recommended for multibacillary leprosy (lepromatous, borderline-lepromatous, and borderline leprosy) and a two-drug regimen for paucibacillary leprosy (borderline-tuberculoid, tuberculoid, and paucibacillary). The following regimens are widely used throughout the world (with minor local variations):

Multibacillary leprosy (3-drug regimen)

- Rifampicin 600 mg once-monthly, supervised (450 mg for adults weighing less than 35 kg)
- Dapsone 100 mg daily, self-administered (50 mg daily or 1–2 mg/kg daily for adults weighing less than 35 kg)
- Clofazimine 300 mg once-monthly, supervised, and 50 mg daily (or 100 mg on alternate days), self-administered

Multibacillary leprosy should be treated for at least 2 years. Treatment should be continued unchanged during both type I (reversal) or type II (erythema nodosum leprosum) reactions. During reversal reactions neuritic pain or weakness can herald the rapid onset of permanent nerve damage. Treatment with prednisolone (initially 40–60 mg daily) should be instituted at once. Mild type II reactions may respond to aspirin. Severe type II reactions may require corticosteroids; thalidomide (unlicensed) is also useful in men and post-menopausal women who have become corticosteroid dependent, but it should be used under specialist supervision and it should never be used in women of child-bearing potential (significant teratogenic risk—for CSM guidance on prescribing, see Current Problems in Pharmacovigilance 1994; 20, 8). Increased doses of clofazimine 100 mg 3 times daily for the first month with subsequent reductions, are also useful but may take 4–6 weeks to attain full effect.

Paucibacillary leprosy (2-drug regimen)

- Rifampicin 600 mg once-monthly, supervised (450 mg for those weighing less than 35 kg)
- Dapsone 100 mg daily, self-administered (50 mg daily or 1–2 mg/kg daily for adults weighing less than 35 kg)

Paucibacillary leprosy should be treated for 6 months. If treatment is interrupted the regimen should be recommenced where it was left off to complete the full course.

Neither the multibacillary nor the paucibacillary anti-leprosy regimen is sufficient to treat tuberculosis.

DAPSONE

Indications leprosy, dermatitis herpetiformis; Pneumocystis jirovecii (Pneumocystis carinii) pneumonia (section 5.4.8)

Cautions cardiac or pulmonary disease; anaemia (treat severe anaemia before starting); susceptibility to haemolysis including G6PD deficiency (section 9.1.5); avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (dapsone)

Blood disorders On long-term treatment, patients and their carers should be told how to recognise signs of blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop

Pregnancy folic acid 5 mg daily should be given to mother throughout pregnancy; neonatal haemolysis and methaemoglobinemia reported in third trimester

Breast-feeding haemolytic anaemia; although significant amount in milk, risk to infant very small unless infant is G6PD deficient

Side-effects (dose-related and uncommon at doses used for leprosy), haemolytic anaemia, methaemoglobinemia, neutropathy, allergic dermatitis (rarely including toxic epidermal necrolysis and Stevens-Johnson syndrome), anorexia, nausea, vomiting, tachycardia, headache, insomnia, psychosis, hepatitis, agranulocytosis; dapsone syndrome (rash with fever and eosinophilia)—discontinue immediately (may progress to exfoliative dermatitis, hepatitis, hypoaalbuminaemia, psychosis and death)

Dose

- Leprosy. 1–2 mg/kg daily, see notes above
- Dermatitis herpetiformis, see specialist literature

Dapsone (Non-proprietary) [full]
Tablets, dapsone 50 mg, net price 28-tab pack = £32.53; 100 mg, 28-tab pack = £47.44 Label: 8

CLOFAZIMINE

Indications leprosy

Cautions may discolor soft contact lenses; avoid if persistent abdominal pain and diarrhoea

Hepatic impairment use with caution

Renal impairment use with caution
BNF 61

5.1.11 Metronidazole and tinidazole

Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa; indications include trichomonal vaginitis (section 5.4.3), bacterial vaginosis (notably Gardnerella vaginalis infections), and Entamoeba histolytica infections (section 13.6). It is also used for surgical and gynaecological sepsis in which its activity against colonic anaerobes, especially Bacteroides fragilis, is important. Metronidazole by rectal route is an effective alternative to the intravenous route when oral administration is not possible. Intravenous metronidazole is used for the treatment of established cases of tetanus; diazepam (section 10.2.2) and tetanus immunoglobulin (section 13.5.2) are also used.

Metronidazole by mouth is effective for the treatment of Clostridium difficile infection, see also section 1.5; it can be given by intravenous infusion if oral treatment is inappropriate.

Topical metronidazole (section 13.10.1.2) reduces the odour produced by anaerobic bacteria in fungating tumours; it is also used in the management of rosacea (section 13.6).

Tinidazole is similar to metronidazole but has a longer duration of action.

Oral infections Metronidazole is an alternative to a penicillin for the treatment of many oral infections where the patient is allergic to penicillin or the infection is due to beta-lactamase-producing anaerobes (Table 1, section 5.1). It is the drug of first choice for the treatment of acute necrotising ulcerative gingivitis (Vincent’s infection) and periodontitis; suitable alternatives are amoxicillin (section 5.1.1.3) and erythromycin (section 5.1.5).

For these purposes metronidazole in a dose of 200 mg 3 times daily for 3 days is sufficient, but the duration of treatment may need to be longer in periconditis. Tinidazole is licensed for the treatment of acute ulcerative gingivitis.

Indications anaerobic infections (including dental), see under Dose below; protozoal infections (section 5.4.2); Helicobacter pylori eradication (section 1.3); skin (section 13.10.1.2)

Cautions disulfiram-like reaction with alcohol; avoid in acute porphyria (section 9.8.2); clinical and laboratory monitoring advised if treatment exceeds 10 days; interactions: Appendix 1 (metronidazole)

Hepatic impairment in severe liver disease reduce total daily dose to one-third, and give once daily; use with caution in hepatic encephalopathy

Pregnancy manufacturer advises avoidance of high-dose regimens

Breast-feeding significant amount in milk; manufacturer advises avoid large single doses

Side-effects gastro-intestinal disturbances (including nausea and vomiting), taste disturbances, furred tongue, oral mucositis, anorexia; very rarely hepatitis, jaundice, pancreatitis, drowsiness, dizziness, headache, ataxia, psychotic disorders, darkening of urine, thrombocytopenia, pancytopenia, myalgia, arthralgia, visual disturbances, rash, pruritus, and erythema multiforme; on prolonged or intensive therapy peripheral neuropathy, transient epileptiform seizures, and leucopenia

Dose

• Anaerobic infections (usually treated for 7 days and for 10–14 days in Clostridium difficile infection), by mouth, either 400 mg every 8 hours or 500 mg every 8 hours, CHILD 1 month–12 years 7.5 mg/kg (max. 400 mg) every 8 hours; by rectum, 1 g every 8 hours for 3 days, then 1 g every 12 hours, CHILD every 8 hours for 3 days, then every 12 hours, 1 month–1 year 125 mg, 1–5 years 250 mg, 5–10 years 500 mg, over 10 years, adult dose; by intravenous infusion over 20 minutes, 500 mg every 8 hours; CHILD 7.5 mg/kg (max. 500 mg) every 8 hours

• Leg ulcers and pressure sores, by mouth, 400 mg every 8 hours for 7 days

• Bacterial vaginosis, by mouth, 400–500 mg twice daily for 5–7 days or 2 g as a single dose

• Pelvic inflammatory disease (see also Table 1, section 5.1), by mouth, 400 mg twice daily for 14 days

• Acute ulcerative gingivitis, by mouth, 200–250 mg every 8 hours for 3 days; CHILD 1–3 years 50 mg every 8 hours for 3 days; 3–7 years 100 mg every 12 hours; 7–10 years 100 mg every 8 hours

• Acute oral infections, by mouth, 200 mg every 8 hours for 3–7 days (see also notes above); CHILD 1–3 years 50 mg every 8 hours for 3–7 days; 3–7 years 100 mg every 12 hours; 7–10 years 100 mg every 8 hours

• Surgical prophylaxis, by mouth, 400–500 mg 2 hours before surgery; up to 3 further doses of 400–500 mg may be given every 8 hours for high-risk procedures; CHILD 1 month–12 years 7.5 mg/kg (max. 400 mg) 2 hours before surgery; up to 3 further doses of 7.5 mg/kg may be given every 8 hours for high-risk procedures

By rectum, 1 g 2 hours before surgery; up to 3 further doses of 1 g may be given every 8 hours for high-risk procedures; CHILD 5–10 years 500 mg 2 hours before surgery; up to 3 further doses of 500 mg may be given every 8 hours for high-risk procedures

By intravenous infusion (if rectal administration inappropriate), 500 mg up to 30 minutes before the
Infections

**Bacterial vaginosis and acute ulcerative gingivitis**, a.

Fasigyn.

Anaerobic infections, 2 g initially, followed by 1 g daily

**Dose**

**Side-effects**

Breast-feeding

present in milk—manufacturer advises avoid in first trimester.

**Cautions** see under Metronidazole; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (tinidazole).

**Pregnancy** manufacturer advises avoid in first trimester.

**Breast-feeding** present in milk—manufacturer advises avoid breast-feeding during and for 3 days after stopping treatment

**Side-effects** see under Metronidazole

### Dose

- Anaerobic infections, 2 g initially, followed by 1 g daily or 500 mg twice daily; usually for 5–6 days
- Bacterial vaginosis and acute ulcerative gingivitis, a single 2-g dose
- Abdominal surgery prophylaxis, a single 2-g dose approximately 12 hours before surgery

Fasigyn® (Pfizer)®

Tablets, f/c, tinidazole 500 mg. Net price 16-tab pack = £11.04. Label: 4, 9, 21, 25

**Note** Metronidazole doses in BNF may differ from those in product literature

### Metronidazole

**Non-proprietary**

Tablets, metronidazole 200 mg, net price 21-tab pack = £1.36; 400 mg, 21-tab pack = £1.35. Label: 4, 9, 21, 25

**Brands** include Vagopy®

**Dental prescribing on NHS** Metronidazole Tablets may be prescribed

Tablets, metronidazole 500 mg, net price 21-tab pack = £29.84. Label: 4, 9, 21, 25

**Dental prescribing on NHS** Metronidazole Tablets may be prescribed

Suspension, metronidazole (as benzoate) 200 mg/5 mL. Net price 100 mL = £11.43. Label: 4, 9

**Brands** include Noraz®

**Dental prescribing on NHS** Metronidazole Oral Suspension may be prescribed

**Intravenous infusion**, metronidazole 5 mg/mL. Net price 20-mL amp = £1.56, 100-mL container = £3.41

Flagyl® (Winthrop)®

Tablets, both f/c, ivory, metronidazole 200 mg, net price 21-tab pack = £4.49; 400 mg, 14-tab pack = £6.34. Label: 4, 9, 21, 25

Suppositories, metronidazole 500 mg, net price 10 = £15.18; 1 g, 10 = £23.06. Label: 4, 9

Flagyl® S® (Winthrop)®

Suspension, orange- and lemon-flavoured, metronidazole (as benzoate) 200 mg/5 mL. Net price 100 mL = £11.18. Label: 4, 9

Metrolyl® (Sandoz)®

Intravenous infusion, metronidazole 5 mg/mL, net price 100-mL Steriflex® bag = £1.22

Electrolytes Na+ 14.53 mmol/100-mL bag

Suppositories, metronidazole 500 mg, net price 10 = £12.34; 1 g, 10 = £18.34. Label: 4, 9

**TINIDAZOLE**

**Indications** anaerobic infections, see under Dose below; protozoal infections (section 5.4.2); Helicobacter pylori eradication (section 1.3)

**Cautions** see under Metronidazole; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (tinidazole).

**Pregnancy** manufacturer advises avoid in first trimester.

**Breast-feeding** present in milk—manufacturer advises avoid breast-feeding during and for 3 days after stopping treatment

**Side-effects** see under Metronidazole

- Anaerobic infections, 2 g initially, followed by 1 g daily or 500 mg twice daily; usually for 5–6 days
- Bacterial vaginosis and acute ulcerative gingivitis, a single 2-g dose
- Abdominal surgery prophylaxis, a single 2-g dose approximately 12 hours before surgery

Fasigyn® (Pfizer)®

Tablets, f/c, tinidazole 500 mg. Net price 16-tab pack = £11.04. Label: 4, 9, 21, 25

**Nalidixic acid and norfloxacin** are effective in uncomplicated urinary-tract infections.

**Ciprofloxacin** is active against both Gram-positive and Gram-negative bacteria. It is particularly active against Gram-negative bacteria, including salmonella, shigella, campylobacter, neisseria, and pseudomonas. Ciprofloxacin has only moderate activity against Gram-positive bacteria such as Streptococcus pneumoniae and Enterococcus faecalis; it should not be used for pneumococcal pneumonia. It is active against chlamydia and some mycobacteria. Most anaerobic organisms are not susceptible. Ciprofloxacin can be used for respiratory tract infections (but not for pneumococcal pneumonia), urinary-tract infections, infections of the gastro-intestinal system (including typhoid fever), bone and joint infections, gonorrhoea and septicemia caused by sensitive organisms.

**Floxacin** is used for urinary-tract infections, lower respiratory-tract infections, gonorrhoea, and non-gonococcal urethritis and cervicitis.

**Levofloxacin** is active against Gram-positive and Gram-negative organisms. It has greater activity against pneumococci than ciprofloxacin. Levofloxacin is licensed for community-acquired pneumonia but it is considered to be second-line treatment for this indication. Although ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin are licensed for skin and soft-tissue infections, many staphylococci are resistant to the quinolones and their use should be avoided in MRSA infections.

**Moxifloxacin** should be reserved for the treatment of sinusitis, community-acquired pneumonia, exacerbations of chronic bronchitis, or complicated skin and soft-tissue infections which have failed to respond to other antibacterials or for patients who cannot be treated with other antibacterials. It has been associated with life-threatening hepatotoxicity. Moxifloxacin is active against Gram-positive and Gram-negative organisms. It has greater activity against Gram-positive organisms, including pneumococci, than ciprofloxacin. Moxifloxacin is not active against Pseudomonas aeruginosa or meticillin-resistant Staphylococcus aureus (MRSA).

**Anthrax** Inhaling or gastro-intestinal anthrax should be treated initially with either ciprofloxacin [not licensed for gastro-intestinal anthrax] or doxycycline [unlicensed indication] (section 5.1.3) combined with one or two other antibacterials [such as amoxicillin, benzylpenicillin, chloramphenicol, clarithromycin, clindamycin, imipenem with cilastatin, rifampicin [unlicensed indication], and vancomycin]. When the condition improves and the sensitivity of the Bacillus anthracis strain is known, treatment may be switched to a single antibacterial. Treatment should continue for 60 days because germination may be delayed.

**Cutaneous anthrax** should be treated with either ciprofloxacin [unlicensed indication] or doxycycline [unlicensed indication] (section 5.1.3) for 7 days. Treatment may be switched to amoxicillin (section 5.1.1.3) if the infecting strain is susceptible. Treatment may need to be extended to 60 days if exposure is due to aerosol. A combination of antibacterials for 14 days is recommended for cutaneous anthrax with systemic features, extensive oedema, or lesions of the head or neck.

Ciprofloxacin or doxycycline may be given for post-exposure prophylaxis. If exposure is confirmed, anti-
bacterial prophylaxis should continue for 60 days. Antibi-

teractive: Appendix 1 (quinolones).

Cautions Quinolones should be used with caution in patients with a history of epilepsy or conditions that predispose to seizures, in G6PD deficiency (section 9.1.5), myasthenia gravis (risk of exacerbation), and in children or adolescents (arthropathy has developed in predispose to seizures, in G6PD deficiency (section 9.1.5), myasthenia gravis (risk of exacerbation), and in children or adolescents (arthropathy has developed in young animals—see below). Exposure to excessive sunlight should be avoided (dis-

Tendon damage Tendon damage (including rupture) has been reported rarely in patients receiving quinolones. Tendon rupture may occur within 48 hours of start-

ting treatment; cases have also been reported several months after stopping a quinolone. Healthcare pro-

Ciprofloxacin (Non-proprietary) Tablets, ciprofloxacin (as hydrochloride) 100 mg, net price 6-tab pack = £1.42; 250 mg, 10-tab pack = £0.96, 20-

Ciprofloxacin® (Bayer Schering) Tablets, all f/c, ciprofloxacin (as hydrochloride) 250 mg (scored), 10-tab pack = £8.59; 500 mg (scored), 10-tab pack = £12.49; 750 mg, 10-tab pack = £17.78. Label: 7, 9, 25, counselling, driving

Suspension, strawberry-flavoured, ciprofloxacin for reconstitution with diluent provided, 250 mg/5 mL,
Levofoxacin

**Indications**

see under Dose

**Cautions**

see notes above; predisposition to QT interval prolongation (including cardiac disease, congenital long QT syndrome, electrolyte disturbances, concomitant use with other drugs known to prolong QT interval); history of psychiatric illness; **interactions**: Appendix 1 (quinolones)

**Driving**

May impair performance of skilled tasks (e.g. driving)

**Contra-indications**

see notes above

**Renal impairment**

usual initial dose then use half normal dose if eGFR 20–50 mL/minute/1.73 m²; consult product literature if eGFR less than 20 mL/minute/1.73 m²

**Pregnancy**

see notes above

**Breast-feeding**

manufacturer advises avoidance

**Side-effects**

see notes above; also reported toxic hepatitis, peripheral neuropathy, and hypoglycaemia; also reported, rhabdomyolysis and potentially life-threatening hepatic failure; local reactions and transient hypotension reported with infusion

**Dose**

- **By mouth**, acute sinusitis, 500 mg daily for 10–14 days

  Exacerbation of chronic bronchitis, 250–500 mg daily for 7–10 days

  Community-acquired pneumonia, 500 mg once or twice daily for 7–14 days

  Urinary-tract infections, 250 mg daily for 7–10 days

  (for 3 days in uncomplicated infection)

  Chronic prostatitis, 500 mg once daily for 28 days

  Skin and soft tissue infections, 250 mg daily or 500 mg once or twice daily for 7–14 days

- **By intravenous infusion** (over at least 60 minutes for 500 mg), community-acquired pneumonia, 500 mg once or twice daily for 7–14 days

  Complicated urinary-tract infections, 250 mg daily, increased in severe infections

  Skin and soft tissue infections, 500 mg twice daily

**Tavanic**® (Sanofi-Aventis) (BNF for Children)

Tablets, yellow-red, 1/2, scored, levofloxacin 250 mg, net price 5-tab pack = £16.83. Label: 1, 2, 15, counselling

**Intravenous infusion**, levofloxacin 5 mg/mL, net price 100-mL bottle = £26.40

Electrolytes Na⁺ 15.4 mmol/100-mL bottle

**Contra-indications**

see notes above; history of QT-interval prolongation, bradycardia, history of symptomatic arrhythmias, heart failure with reduced left ventricular ejection fraction, electrolyte disturbances, concomitant use with other drugs known to prolong QT-interval

**Hepatic impairment**

manufacturer advises avoid in severe impairment

**Pregnancy**

see notes above

**Breast-feeding**

manufacturer advises avoid—present in milk in animal studies

**Side-effects**

see notes above; also gastritis, flatulence, constipation, arrhythmias, palpitation, angina, vasodilatation, hyperlipidaemia, and sweating; rarely oedema, hypertension, syncope, dysphagia, abnormal dreams, incoordination, amnesia, hyperglycaemia, hyperuricaemia, and stomatitis; very rarely rhabdomyolysis and potentially life-threatening hepatic failure; on intravenous infusion, pain and phlebitis at injection site

**Dose**

- **By mouth**, 400 mg once daily

- **By intravenous infusion** over 60 minutes, community-acquired pneumonia, complicated skin and soft-tissue infections, 400 mg once daily

**Note**

Recommended duration of treatment is 7–14 days for community-acquired pneumonia, 5–10 days in exacerbations of chronic bronchitis, 7 days in sinusitis, 7–21 days for complicated skin and soft-tissue infections

**Avelox**® (Bayer Schering) (BNF 61)

Tablets, red, 1/2, c. moxifloxacin (as hydrochloride) 400 mg, net price 5-tab pack = £12.45. Label: 6, 9, 25, counselling, driving

**Intravenous infusion**, moxifloxacin (as hydrochloride) 1.6 mg/mL, net price 250-mL bottle (400 mg) = £39.95

Electrolytes Na⁺ 34 mmol/250-mL bottle

**Nalidixic Acid**

**Indications**

urinary-tract infections

**Cautions**

see notes above; avoid in acute porphyria (section 9.2.2); false positive urinary glucose (if tested for reducing substances); monitor blood counts, renal and liver function if treatment exceeds 2 weeks; **interactions**: Appendix 1 (quinolones)

**Contra-indications**

see notes above

**Hepatic impairment**

manufacturer advises caution in liver disease

**Renal impairment**

use with caution; avoid if eGFR less than 20 mL/minute/1.73 m²

**Pregnancy**

see notes above

**Breast-feeding**

risk to infant very small but one case of haemolytic anaemia reported

**Side-effects**

see notes above; also reported toxic psychosis, increased intracranial pressure, cranial nerve palsy, peripheral neuropathy, and metabolic acidosis

**Dose**

- 900 mg every 6 hours for 7 days, reduced in chronic infections to 600 mg every 6 hours; **CHILD** 3 months–18 years see **BNF for Children**

Nalidixic Acid (Roemmet) (BNF 61)

Suspension, pink, nalidixic acid 300 mg/5 mL, net price 150 mL (raspberry- and strawberry-flavoured) = £12.50. Label: 9, 11

Excipients include sorcrose 450 mg/5 mL
NORFLOXACIN

Indications  see under Dose
Cautions  see notes above; Interactions: Appendix 1 (quinolones)

Driving  May impair performance of skilled tasks (e.g. driving)

Contra-indications  see notes above

Renal impairment  use 400 mg once daily if eGFR less than 30 mL/minute/1.73 m²

Breast-feeding  see notes above

Side-effects  see notes above; also tinnitus, epiphora; rarely pancreatitis; very rarely arrhythmias; also reported, polyneuropathy and exfoliative dermatitis

Dose  • ‘Lower’ urinary-tract infections, 400 mg twice daily for 7–10 days (for 3 days for uncomplicated infections in women)
  • Chronic relapsing ‘lower’ urinary-tract infections, 400 mg twice daily for up to 12 weeks; may be reduced to 400 mg once daily if adequate suppression within first 4 weeks
  • Chronic prostatitis, 400 mg twice daily for 28 days

Norfloxacin  (Non-proprietary) [A]

Tablets  norfloxacin 400 mg, net price 6-tab pack = £2.30, 14-tab pack = £6.20. Label: 7, 9, 23, counselling, driving

Utinor®  (MSD) [A]

Tablets  scored, norfloxacin 400 mg. Net price 7-tab pack = £2.56, 14-tab pack = £5.11. Label: 7, 9, 23, counselling, driving

OFLOXACIN

Indications  see under Dose
Cautions  see notes above; history of psychiatric illness; Interactions: Appendix 1 (quinolones)

Driving  May affect performance of skilled tasks (e.g. driving); effects enhanced by alcohol

Contra-indications  see notes above

Hepatic impairment  use with caution; elimination may be reduced in severe impairment

Renal impairment  usual initial dose, then use half normal dose if eGFR 20–50 mL/minute/1.73 m²; 100 mg every 24 hours if eGFR less than 20 mL/minute/1.73 m²

Pregnancy  see notes above

Breast-feeding  amount probably too small to be harmful but manufacturer advises avoid

Side-effects  see notes above; also eye irritation; rarely arrhythmias, abnormal dreams, hot flushes, hyperhidrosis; very rarely neuropathy, extrapyramidal symptoms; also reported pneumonitis, changes in blood sugar, myopathy, rhabdomyolysis; on intravenous infusion, hypotension and local reactions (including thrombophlebitis)

Dose  • By mouth, urinary-tract infections, 200–400 mg daily preferably in the morning, increased if necessary in upper urinary-tract infections to 400 mg twice daily
  • Acute or chronic prostatitis, 200 mg twice daily for 28 days

Skin and soft-tissue infections, 400 mg twice daily

Pelvic inflammatory disease (see also section 5.1, table 1), 400 mg twice daily for 14 days

By intravenous infusion (over at least 30 minutes for each 200 mg), complicated urinary-tract infection, 200 mg daily

Lower respiratory-tract infection, 200 mg twice daily

Skin and soft-tissue infections, 400 mg twice daily

Severe or complicated infections, dose may be increased to 400 mg twice daily

Ofloxacin  (Non-proprietary) [A]

Tablets  ofloxacin 200 mg, net price 10-tab pack = £8.29; 400 mg, 5-tab pack = £5.71, 10-tab pack = £5.52. Label: 6, 9, 11, counselling, driving

Tarivid®  (Sanofi-Aventis) [A]

Tablets, f/c, scored, ofloxacin 200 mg, net price 10-tab pack = £7.53, 20-tab pack = £15.05; 400 mg (yellow), 5-tab pack = £7.52, 10-tab pack = £14.99. Label: 6, 9, 11, counselling, driving

Intravenous infusion, ofloxacin (as hydrochloride) 2 mg/mL, net price 100-mL bottle = £16.16 (hosp. only)

5.1.13 Urinary-tract infections

Urinary-tract infection is more common in women than in men; when it occurs in men there is frequently an underlying abnormality of the renal tract. Recurrent episodes of infection are an indication for radiological investigation especially in children in whom untreated pyelonephritis may lead to permanent kidney damage. Escherichia coli is the most common cause of urinary-tract infection; Staphylococcus saprophyticus is also common in sexually active young women. Less common causes include Proteus and Klebsiella spp. Pseudomonas aeruginosa infections usually occur in the hospital setting and may be associated with functional or anatomical abnormalities of the renal tract. Staphylococcus epidermidis and Enterococcus faecalis infection may complicate catheterisation or instrumentation.

A specimen of urine should be collected for culture and sensitivity testing before starting antibacterial therapy:
  • in men;
  • in pregnant women;
  • in children under 3 years of age;
  • in patients with suspected upper urinary-tract infection, complicated infection, or recurrent infection;
  • if resistant organisms are suspected;
  • if urine dipstick testing gives a single positive result for leucocyte esterase or nitrite;
  • if clinical symptoms are not consistent with results of dipstick testing.

Treatment should not be delayed while waiting for results. The antibacterial chosen should reflect current local bacterial sensitivity to antibacterials.

Uncomplicated gonorrhoea, 400 mg as a single dose

Uncomplicated genital chlamydial infection, non-gonococcal urethritis, 400 mg daily in single or divided doses for 7 days

Pelvic inflammatory disease (see also section 5.1, table 1), 400 mg twice daily for 14 days

Uncomplicated lower urinary-tract infections often respond to trimethoprim, nitrofurantoin, amoxicillin, or nalidixic acid given for 7 days (3 days may be
5 Infections

During pregnancy; trimethoprim should also preferably be used but it should be avoided at term. Sulfonamides, quinolones, and tetracyclines should be avoided; nitrofurantoin should be avoided altogether. Acute pyelonephritis may lead to sepsis and is treated initially by injection of a broad-spectrum antibacterial such as ceftriaxone or a quinolone if the patient is severely ill; gentamicin can also be used. Prostatitis can be difficult to cure and requires treatment for several weeks with an antibacterial which penetrates prostatic tissue such as trimethoprim, or some quinolones. Where infection is localised and associated with an indwelling catheter a bladder instillation is often effective (section 7.4.4).

Pregnancy

Urinary-tract infection in pregnancy may be asymptomatic and requires prompt treatment to prevent progression to acute pyelonephritis. Penicillins and cephalosporins are suitable for treating urinary-tract infection during pregnancy. Nitrofurantoin may also be used but it should be avoided at term. Sulfonamides, quinolones, and tetracyclines should be avoided during pregnancy; trimethoprim should also preferably be avoided particularly in the first trimester.

Renal impairment

In renal failure antibacterials nor- mally excreted by the kidney accumulate with resultant toxicity unless the dose is reduced. This applies especially to the aminoglycosides which should be used with great caution; tetracyclines, methenamine, and nitrofurantoin should be avoided altogether.

Children

Urinary-tract infections in children require prompt antibacterial treatment to minimise the risk of renal scarring. Uncomplicated ‘lower’ urinary-tract infections in children over 3 months of age can be treated with trimethoprim, nitrofurantoin, a first generation cephalosporin (e.g. cefalexin), or amoxicillin for 3 days; children should be reassessed if they continue to be unwell 24–48 hours after the initial assessment. Amoxicillin should only be used if the organism causing the infection is sensitive to it. Acute pyelonephritis in children over 3 months of age can be treated with a first generation cephalosporin or co-amoxiclav for 7–10 days. If the patient is severely ill, then the infection is best treated initially by injection of a broad-spectrum antibacterial such as cefotaxime or co-amoxiclav; gentamicin is an alternative.

Children under 3 months of age should be transferred to hospital and treated initially with intravenous anti-bacterial drugs such as ampicillin with gentamicin, or cefotaxime alone, until the infection responds; full doses of oral antibacterials are then given for a further period. Recurrent episodes of infection are an indication for imaging tests. Antibacterial prophylaxis with low doses of trimethoprim or nitrofurantoin may be considered for children with recurrent infection, significant urinary-tract anomalies, or significant kidney damage.

### NITROFURANTOIN

**Indications** urinary-tract infections

**Cautions** anaemia; diabetes mellitus; electrolyte imbalance; vitamin B and folate deficiency; pulmonary disease; on long-term therapy, monitor liver function and monitor for pulmonary symptoms, especially in the elderly (discontinue if deterioration in lung function); susceptibility to peripheral neuropathy; false positive urinary glucose (if tested for reducing substances); urine may be coloured yellow or brown; interactions: Appendix 1 (nitrofurantoin)

**Contra-indications** infants less than 3 months old, G6PD deficiency (section 9.1.5); acute porphyria (section 9.8.2)

**Hepatic impairment** use with caution; cholestatic jaundice and chronic active hepatitis reported

**Renal impairment** avoid if eGFR less than 60 mL/minute/1.73 m²; risk of peripheral neuropathy; ineffective because of inadequate urine concentrations

**Pregnancy** avoid at term—may produce neonatal haemolysis

**Breast-feeding** avoid; only small amounts in milk but could be enough to produce haemolysis in G6PD-deficient infants (section 9.1.5)

**Side-effects** anorexia, nausea, vomiting, and diarrhoea; acute and chronic pulmonary reactions (pulmonary fibrosis reported; possible association with lupus erythematosus-like syndrome); peripheral neuropathy; also reported, hypersensitivity reactions (including angioedema, anaphylaxis, sialadenitis, urticaria, rash and pruritus); rarely, cholestatic jaundice, hepatitis, exfoliative dermatitis, erythema multiforme, pancreatitis, arthralgia, blood disorders (including agranulocytosis, thrombocytopenia, and aplastic anaemia), benign intracranial hypertension, and transient alopecia

**Dose**

- Acute uncomplicated infection, 50 mg every 6 hours with food for 7 days (3 days usually adequate in women); CHILD over 3 months, 3 mg/kg daily in 4 divided doses
- Severe chronic recurrent infection, 100 mg every 6 hours with food for 7 days (dose reduced or discontinued if severe nausea)
- Prophylaxis (but see Cautions), 50–100 mg at night; CHILD over 3 months, 1 mg/kg at night

**Nitrofurantoin (Non-proprietary)**

**Tablets** nitrofurantoin 50 mg, net price 28-tab pack = £1.84; 100 mg, 28-tab pack = £4.43. Label: 9, 14, 21

**Oral suspension** nitrofurantoin 25 mg/5 mL, net price 300 mL = £99.05. Label: 9, 14, 21

**Note** Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription.
Aspergillosis

Aspergillosis most commonly affects section 13.10.2 (skin), section 12.1.1 (ear), section 12.3.2 (oropharynx), and (genital), section 7.4.4 (bladder), section 11.3.2 (eye), local treatment of fungal infections, see section 7.2.2 forms of systemic or disseminated fungal infections. For outlined below; specialist treatment is required in most

The systemic treatment of common fungal infections is

Treatment of fungal infections

The systemic treatment of common fungal infections is outlined below; specialist treatment is required in most forms of systemic or disseminated fungal infections. For local treatment of fungal infections, see section 7.2.2 (genital), section 7.4.4 (bladder), section 11.3.2 (eye), section 12.1.1 (ear), section 12.3.2 (oropharynx), and section 13.10.2 (skin).

Aspergillosis

Aspergillosis most commonly affects the respiratory tract but in severely immunocompromised patients, invasive forms can affect the heart, brain, and skin. Voriconazole (section 5.2.1) is the treatment of choice for aspergillosis; liposomal amphotericin (section 5.2.3) is an alternative first-line treatment when voriconazole cannot be used. Caspo-

5.2 Antifungal drugs

Furadantin® (Goldshield) Tablets, all yellow, scored, nitrofurantoin 50 mg, net price 100-tab pack = £9.79; 100 mg, 100-tab pack = £18.11. Label: 9, 14, 21

Macrobid® (Goldshield) Capsules, yellow/white, nitrofurantoin 100 mg (as macrocrystals), yellow/white, 30-cap pack = £4.81. Label: 9, 14, 21

Modified release

Macrobid® (Goldshield) Capsules, m/r, blue/yellow, nitrofurantoin 100 mg (as nitrofurantoin macrocrystals and nitrofurantoin monohydrate), net price 14-cap pack = £4.89. Label: 9, 14, 21, 25

Dose uncomplicated urinary-tract infection, 1 capsule twice daily with food

Genito-urinary surgical prophylaxis, 1 capsule twice on day of procedure and for 3 days after

METHENAMINE HIPPURATE (Hexamine hippurate)

Indications prophylaxis and long-term treatment of chronic or recurrent lower urinary-tract infections

Cautions avoid concurrent administration with sulfonamides (risk of crystalluria) or urinary alkalinising agents; interactions: Appendix 1 (methenamine)

Contra-indications severe dehydration, gout, metabolic acidosis

Hepatic impairment avoid

Renal impairment avoid if eGFR less than 10 mL/minute/1.73 m²—risk of hippurate crystalluria

Pregnancy use with caution

Breast-feeding amount too small to be harmful

Side-effects gastro-intestinal disturbances, bladder irritation, rash

Dose

• 1 g every 12 hours (may be increased in patients with catheters to 1 g every 8 hours); CHILD 6–12 years 500 mg every 12 hours

Hiprox® (Meda) Tablets, scored, methenamine hippurate 1 g, net price 60-tab pack = £6.58. Label: 9

5.2 Antifungal drugs

Candidiasis

Many superficial candidal infections including infections of the skin (section 13.10.2) are treated locally; widespread or intractable infection requires systemic antifungal treatment. Vaginal candidiasis (section 7.2.2) may be treated with locally acting antifungals or with fluconazole (section 5.2.1) given by mouth; for resistant organisms, itraconazole (section 5.2.1) can be given by mouth.

Oropharyngeal candidiasis generally responds to topical therapy (section 12.3.2); fluconazole is given by mouth for unresponsive infections; it is effective and is reliably absorbed. Itraconazole may be used for fluconazole-resistant infections. Topical therapy may not be adequate in immunocompromised patients and an oral triazole antifungal is preferred.

For invasive or disseminated candidiasis, an echinocandin (section 5.2.4) can be used. Fluconazole (section 5.2.1) is an alternative for Candida albicans infection in clinically stable patients who have not received an azole antifungal recently. Amphotericin (section 5.2.3) is an alternative when an echinocandin or fluconazole cannot be used, however, amphotericin should be considered for the initial treatment of CNS candidiasis. Voriconazole (section 5.2.1) can be used for infections caused by fluconazole-resistant Candida spp. when oral therapy is required, or in patients intolerant of amphotericin or an echinocandin. In refractory cases, flucytosine (section 5.2.5) can be used with intravenous amphotericin.

Cryptococcosis

Cryptococcosis is uncommon but infection in the immunocompromised, especially in HIV-positive patients, can be life-threatening; cryptococcal meningitis is the most common form of fungal meningitis. The treatment of choice in cryptococcal meningitis is amphotericin (section 5.2.3) by intravenous infusion and flucytosine (section 5.2.5) by intravenous infusion for 2 weeks, followed by fluconazole (section 5.2.1) by mouth for 8 weeks or until cultures are negative. In cryptococcosis, fluconazole is sometimes given alone as an alternative in HIV-positive patients with mild, localised infections or in those who cannot tolerate amphotericin. Following successful treatment, fluconazole can be used for prophylaxis against relapse until immunity recovers.

Histoplasmosis

Histoplasmosis is rare in temperate climates; it can be life-threatening, particularly in HIV-infected persons. Itraconazole (section 5.2.1) can be used for the treatment of immunocompetent patients with indolent non-meningeal infection, including chronic pulmonary histoplasmosis. Amphotericin (section 5.2.3) by intravenous infusion is preferred in patients with fulminant or severe infections. Following successful treatment, itraconazole can be used for prophylaxis against relapse until immunity recovers.

Skin and nail infections Mild localised fungal infections of the skin (including tinea corporis, tinea cruris, and tinea pedis) respond to topical therapy (section
13.10.2). Systemic therapy is appropriate if topical ther-apy fails, if many areas are affected, or if the site of infection is difficult to treat such as in infections of the nails (onychomycosis) and of the scalp (tinea capitis). Oral imidazole or triazole antifungals (particularly itraconazole) and terbinafine are more used frequently than griseofulvin as they have a broader spectrum of activity and require a shorter duration of treatment. 

Tinea capitis is treated systemically; additional topical application of an antifungal (section 13.10.2) may reduce transmission. Griseofulvin (section 5.2.5) is used for tinea capitis in adults and children; it is effective against infections caused by Trichophyton tonsurans and Microsporum spp. Terbinafine (section 5.2.5) is used for tinea capitis caused by T. tonsurans [unli-censed indication]. The role of terbinafine in the manage-ment of Microsporum infections is uncertain. 

Pityriasis versicolor (section 13.10.2) may be treated with itraconazole (section 5.2.1) by mouth if topical therapy is ineffective; fluconazole (section 5.2.1) by mouth is an alternative. Oral terbinafine is not effective for pityriasis versicolor. Antifungal treatment may not be necessary in asympto-matic patients with tinea infection of the nails. If treat-ment is necessary, a systemic antifungal is more effec-tive than topical therapy. Terbinafine (section 5.2.5) and itraconazole (section 5.2.1) have largely replaced griseofulvin for the systemic treatment of onycho-myocysis, particularly of the toenail; terbinafine is con-sidered to be the drug of choice. Itraconazole can be administered as intermittent ‘pulse’ therapy. For the role of topical antifungals in the treatment of onycho-myocysis, see section 13.10.2. 

Immunocompromised patients Immunocompromised patients are at particular risk of fungal infections and may receive antifungal drugs prophylactically; oral triazole antifungals are the drugs of choice for prophylaxis. Fluconazole (section 5.2.1) is more reliably absorbed than itraconazole (section 5.2.1), but flucona-zole is not effective against Aspergillus spp. Itracon-azole is preferred in patients at risk of invasive asper-gillosis. Posaconazole (section 5.2.1) can be used for prophylaxis in patients who are undergoing haemato-poietic stem cell transplantation or receiving chemo-therapy for acute myeloid leukaemia and myelodysplas-tic syndrome, if they are intolerant of fluconazole or itraconazole. Micafungin (section 5.2.4) can be used for prophylaxis of candidiasis in patients undergoing haemato-poietic stem cell transplantation when fluconazole, itraconazole or posaconazole cannot be used. 

Amphotericin (section 5.2.3) by intravenous infusion or caspofungin (section 5.2.4) is used for the empirical treatment of serious fungal infections; caspofungin is not effective against fungal infections of the CNS. 

5.2.1 Triazole antifungals 

For the role of triazole antifungal drugs in the prevention and systemic treatment of fungal infections, see p. 373. Fluconazole is very well absorbed after oral administra-tion. It also achieves good penetration into the cere-brosplinal fluid to treat fungal meningitis. Fluconazole is excreted largely unchanged in the urine and can be used to treat candiduria. 

Itraconazole is active against a wide range of derma-tophytes. Itraconazole capsules require an acid environ-ment in the stomach for optimal absorption. Itraconazole has been associated with liver damage and should be avoided or used with caution in patients with liver disease; fluconazole is less frequently associated with hepatotoxicity. Posaconazole is licensed for the treatment of invasive fungal infections unresponsive to conventional treat-ment. Voriconazole is a broad-spectrum antifungal drug which is licensed for use in life-threatening infections.
infections (including meningitis), by mouth or intravenous infusion, 400 mg on first day then 200–400 mg daily; max. 800 mg daily in severe infections [unlicensed dose]; treatment continued according to response (at least 8 weeks for cryptococcal meningitis). CHILD 6–12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2–4 weeks old); max. 800 mg daily [unlicensed dose].

- Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy, by mouth or by intravenous infusion, 200 mg daily.

- Prevention of fungal infections in immunocompromised patients, by mouth or by intravenous infusion, 50–400 mg daily adjusted according to risk; 400 mg daily if high risk of systemic infections e.g. following bone-marrow transplantation; commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range. CHILD according to extent and duration of neutropenia, 3–12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2–4 weeks old); max. 400 mg daily.

**Fluconazole** (Non-proprietary) (Non-proprietary)

Capsules, fluconazole 50 mg, net price 7-cap pack = £1.14; 150 mg, single-capsule pack = 98p; 200 mg, 7-cap pack = £5.04. Label: 9. (50 and 200 mg)

Dental prescribing on NHS Fluconazole Capsules 50 mg may be prescribed.

Intravenous infusion, fluconazole 2 mg/mL, net price 25 mL bottle = £7.31; 100 mL bottle = £29.27; 100 mL infusion bag = £27.82.

**Diflucan® (Pfizer)** (Pfizer)

Capsules, fluconazole 50 mg (blue/white), net price 7-cap pack = £1.16; 150 mg (blue), single-capsule pack = £7.12; 200 mg (purple/white), 7-cap pack = £66.42. Label: 9. (50 and 200 mg)

Oral suspension, orange-flavoured, fluconazole for reconstitution with water, 50 mg/5 mL, net price 35 mL = £16.61; 200 mg/5 mL, 35 mL = £66.42. Label: 9

Dental prescribing on NHS May be prescribed as Fluconazole Oral Suspension 50 mg/5 mL.

Intravenous infusion, fluconazole 2 mg/mL in sodium chloride intravenous infusion 0.9%, net price 25 mL bottle = £7.32; 100 mL bottle = £29.28.

**Electrolytes** Na+ 15 mmol/100 mL bottle.

---

**5.2.1 Triazole antifungals 375**

**Heart failure**

Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure. Those at risk include:

- patients receiving high doses and longer treatment courses;
- older patients and those with cardiac disease;
- patients receiving treatment with negative inotropic drugs, e.g. calcium channel blockers.

Itraconazole should be avoided in patients with ventricular dysfunction or a history of heart failure unless the infection is serious.

**Contra-indications**

Acute porphyria (section 9.8.2)

**Hepatic impairment**

Use only if potential benefit outweighs risk of hepatotoxicity (see Hepatotoxicity above); dose reduction may be necessary.

**Renal impairment**

Risk of congestive heart failure; bioavailability of oral formulations possibly reduced; use intravenous infusion with caution if eGFR > 80 mL/minute/1.73 m²; avoid intravenous infusion if eGFR less than 30 mL/minute/1.73 m².

**Pregnancy**

Manufacturer advises use only in life-threatening situations (toxicity at high doses in animal studies); ensure effective contraception during treatment and until the next menstrual period following end of treatment.

**Breast-feeding**

Small amounts present in milk—may accumulate; manufacturer advises avoid.

**Side-effects**

Nausea, abdominal pain, rash; less commonly vomiting, dyspepsia, taste disturbances, flatulence, diarrhoea, constipation, oedema, headache, dizziness, paraesthesia (discontinue treatment if neuropathy), menstrual disorder, and alopecia; rarely pancreatitis, hypoaesthesia, urinary frequency, leucopenia, visual disturbances, and tinnitus; also reported, heart failure (see Cautions above), hypertriglyceridaemia, hepatitis (see Hepatotoxicity above), erectile dysfunction, thrombocytopenia, hyponatraemia, myalgia, arthralgia, phototoxicity, toxic epidermal necrolysis, and Stevens–Johnson syndrome; with intravenous injection hypertension and hyperglycaemia.

**Dose**

- **By mouth**, oropharyngeal candidiasis, see under *Sporanox®* oral liquid below.

Vulvovaginal candidiasis, see also Recurrent Vulvovaginal Candidiasis, section 7.2.2) 200 mg twice daily for 1 day.

Pityriasis versicolor, 200 mg once daily for 7 days.

Tinea corporis and tinea cruris, either 100 mg once daily for 15 days or 200 mg once daily for 7 days.

Tinea pedis and tinea manuum, either 100 mg once daily for 30 days or 200 mg twice daily for 7 days.

Onychomycosis, either 200 mg once daily for 3 months or course (pulse) of 200 mg twice daily for 7 days, subsequent courses repeated after 21-day interval; fingernails 2 courses, toenails 3 courses.

Histoplasmosis, 200 mg 3 times daily for 3 days, then 200 mg once or twice daily.

Systemic aspergillosis, candidiasis and cryptococcosis including cryptococcal meningitis where other antifungal drugs inappropriate or ineffective, 200 mg once daily (candidiasis 100–200 mg once daily) increased in invasive or disseminated disease and in cryptococcal meningitis to 200 mg twice daily.
Maintenance in HIV-infected patients to prevent relapse of underlying fungal infection and prophylaxis in neutropaenia when standard therapy inappropriate, 200 mg once daily, increased to 200 mg twice daily if low plasma-itraconazole concentration (see Cautions) Prophylaxis in patients with haematological malignancy or undergoing bone-marrow transplant, see under Sporanox® oral liquid below

- **By intravenous infusion**, systemic aspergillosis, candidiasis and cryptocoCCOSIS including cryptocoCCAL meningitis where other antifungal drugs inappropriate or ineffective, histoplasmosis, 200 mg every 12 hours for 2 days, then 200 mg once daily for max. 12 days
- **CHILD** under 18 years see BNF for Children

**Note** Itraconazole doses in BNF may differ from those in product literature

**Itraconazole** (Non-proprietary)

**Capsules**, 100 mg, net price 15-cap pack = £7.21. Label: 5, 9, 21, 25, counselling, hepatotoxicity

**Sporanox®** (Janssen-Cilag)

**Capsules**, blue/pink, 100 mg, net price 4-cap pack = £5.67; 15-cap pack = £13.77; 28-cap pack (Sporanox®-Pulse) = £25.72; 60-cap pack = £55.10. Label: 5, 9, 21, 25, counselling, hepatotoxicity

**Oral liquid**, sugar-free, cherry-flavoured, 10 mg/mL, net price 150 mL (2 measuring cups) daily in 1–2 divided doses for 1 week (continue for another week if no responses)

- Fluconazole-resistant oral or oesophageal candidiasis in HIV-positive or other immunocompromised patients, 20 mL (2 measuring cups) daily in 1–2 divided doses for 1 week (continue for another week if no responses)

- Prophylaxis of deep fungal infections (when standard therapy is inappropriate) in patients with haematological malignancy or undergoing bone-marrow transplant. 200 mg 3 times daily in 2 divided doses; stopping before transplantation or before chemotherapy (taking care to avoid interaction with cytotoxic drugs) and continued until neutrophil count recovers; CHILD and ELDERLY safety and efficacy not established

**Counselling** Do not take with food; swish around mouth and swallow, do not rinse afterwards

**Concentrate for intravenous infusion**, 10 mg/mL. For dilution before use. Net price 25-mL amp (with infusion bag and filter) = £62.58

**POSACONAゾLE**

**Indications** invasive aspergillosis; serious infections caused by Scedosporium spp., Fusarium spp., or invasive fluconazole-resistant Candida spp. (including C. krusei)

**Cautions** electrolyte disturbances, cardiomyopathy, bradycardia, symptomatic arrhythmias, history of QT interval prolongation, concomitant use with other drugs known to cause QT-interval prolongation; monitor electrolytes (including potassium, magnesium, and calcium) before and during therapy, monitor liver function; **interactions**: Appendix 1 (antifungals, triazole)

**Contra-indications** acute porphyria (section 9.8.2)

**Hepatic impairment** monitor liver function; manufacturer advises caution

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk and recommends effective contraception during treatment; toxicity in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** gastro-intestinal disturbances (including nausea, vomiting, abdominal pain, diarrhoea, dyspepsia, and flatulence); dizziness, headache, paraesthesia, drowsiness, fatigue, fever, anorexia; blood disorders (including anaemia, neutropenia, and thrombocytopenia), electrolyte disturbances; dry mouth; rash; less commonly pancreatitis, hepatic disorders, arrhythmias, palpitation, changes in blood pressure, oedema, convulsions, neuropathy, tremor, hyperglycaemia, menstrual disorders, renal failure, musculoskeletal pain, visual disturbances, mouth ulcers, and alopecia; rarely ileus, cardiac failure, myocardial infarction, stroke, thrombosis, syncope, pneumonitis, psychosis, depression, encephalopathy, adrenal insufficiency, breast pain, hearing impairment, and Stevens-Johnson syndrome

**Dose**

- 400 mg twice daily with food or if food not tolerated, 200 mg 4 times daily

- Oropharyngeal candidiasis (severe infection or in immunocompromised patients only), 200 mg with food on first day, then 100 mg once daily for 13 days

- Prophylaxis of invasive fungal infections in patients undergoing bone-marrow transplantation or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic syndrome who are expected to become neutropenic, and who are intolerant of fluconazole or itraconazole, 200 mg 3 times daily with food, starting before transplantation or before chemotherapy and continued until neutrophil count recovers

- **CHILD** under 18 years not recommended

**Noxafil®** (Schering-Plough)

**Suspension**, posaconazole 200 mg/5 mL, net price 105 mL (cherry-flavoured) = £491.20. Label: 3, 9, 21

**VORICONAゾLE**

**Indications** invasive aspergillosis; serious infections caused by Scedosporium spp., Fusarium spp., or invasive fluconazole-resistant Candida spp. (including C. krusei)

**Cautions** electrolyte disturbances, cardiomyopathy, bradycardia, symptomatic arrhythmias, history of QT interval prolongation, concomitant use with other drugs that prolong QT interval; avoid exposure to sunlight; patients at risk of pancreatitis; monitor liver function before treatment and during treatment; haematological malignancy (increased risk of hepatic reactions); monitor renal function; **interactions**: Appendix 1 (antifungals, triazole)

**Contra-indications** acute porphyria (section 9.8.2)

**Hepatic impairment** in mild to moderate hepatic cirrhosis use usual initial dose then halve subsequent
doses; no information available for severe hepatic cirrhosis—manufacturer advises use only if potential benefit outweighs risk

**Renal impairment** intravenous vehicle may accumulate if eGFR less than 50 mL/minute/1.73 m²—use intravenous infusion only if potential benefit outweighs risk, and monitor renal function; alternatively, use tablets or oral suspension (no dose adjustment required)

**Pregnancy** toxicity in animal studies—manufacturer advises avoid unless potential benefit outweighs risk; effective contraception required during treatment

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** nausea, vomiting, abdominal pain, diarrhoea, jaundice, oedema, hypotension, chest pain, respiratory distress syndrome, sinusitis, headache, dizziness, asthma, anxiety, depression, confusion, agitation, hallucinations, paraesthesia, tremor, influenza-like symptoms, hypoglycaemia, haematuria, blood disorders (including anaemia, thrombocytopenia, leucopenia, pancytopenia), acute renal failure, hypokalaemia, visual disturbances (including altered perception, blurred vision, and photophobia), rash, pruritus, photosensitivity, alopecia, cheilitis, injection-site reactions; less commonly, dyspepsia, duodenitis, cholecystitis, pancreatitis, hepatitis, constipation, arhythmias (including QT interval prolongation), syncope, raised serum cholesterol, hypersensitivity reactions (including flushing), ataxia, nyctagmus, hypoaesthesia, adrenocortical insufficiency, arthritis, blepharitis, optic neuritis, scieritis, glossitis, gingivitis, psoriasis, Stevens-Johnson syndrome; rarely, pseudomembranous colitis, taste disturbances (more common with oral suspension), convulsions, insomnia, tinnitus, hearing disturbances, extrapyramidal effects, hypertonia, hypothyroidism, hyperthyroidism, lipoysis, pseudoporphyria, retinal haemorrhage, optic atrophy; also reported squamous cell carcinoma of skin (particularly in presence of phototoxicity or in the immunosuppressed)

**Dose**
- By mouth, ADULT and CHILD over 12 years, body-weight over 40 kg, 400 mg every 12 hours for 2 doses then 200 mg every 12 hours, increased if necessary to 300 mg every 12 hours; body-weight under 40 kg, 200 mg every 12 hours for 2 doses then 100 mg every 12 hours, increased if necessary to 150 mg every 12 hours; CHILD 2–12 years, (oral suspension recommended) 200 mg every 12 hours
- By intravenous infusion, 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours (reduced to 3 mg/kg every 12 hours if not tolerated) for max. 6 months; CHILD 2–18 years see BNF for Children

**KETOCONAZOLE**

**Indications** dermatophytoses and *Malassezia* folliculitis either resistant to fluconazole, terbinafine, or itraconazole or in patients intolerant of these antifungals; chronic mucocutaneous, cutaneous, and oropharyngeal candidiasis either resistant to fluconazole or itraconazole or in patients intolerant of these antifungals

**Cautions** predisposition to adrenocortical insufficiency; interactions: Appendix 1 (antifungals, imidazole)

**Hepatotoxicity** Potentially life-threatening hepatotoxicity reported very rarely; risk of hepatotoxicity greater if given for longer than 10 days. Monitor liver function before treatment, then on weeks 2 and 4 of treatment, then every month. Avoid or use with caution if abnormal liver function test results (avoid in active liver disease) or if history of hepatotoxicity with other drugs

**Counselling** Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, jaundice, or dark urine develop

**Contra-indications** acute porphyria (section 9.8.2)

**Hepatic impairment** avoid; see also Hepatotoxicity above

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk (teratogenicity in animal studies)

**Breast-feeding** manufacturer advises avoid

**Side-effects** nausea, vomiting, abdominal pain; pruritus; less commonly, diarrhoea, headache, dizziness, drowsiness, and rash; also reported fatal liver damage (see Hepatotoxicity above), dyspepsia, raised intracranial pressure, paraesthesia, adrenocortical insufficiency, erectile dysfunction, menstrual disorders, azoospermia (with high doses), gynaecomastia, thrombocytopenia, photophobia, photosensitivity, and alopecia

**Dose**
- 200 mg once daily, increased if response inadequate to 400 mg once daily; continued until symptoms have cleared and cultures negative, but see Cautions (max. duration of treatment 4 weeks for *Malassezia* infection); **CHILD** body-weight 15–30 kg, 100 mg once daily; body-weight over 30 kg, adult dose

**Vfend®** (Pfizer)
- **Tablets**, f/c, voriconazole 50 mg, net price 28-tablet pack = £275.68; 200 mg, 28-tab pack = £1102.74. Label: 9, 11, 23
- **Oral suspension**, voriconazole 200 mg/5 mL when reconstituted with water; net price 75 mL (orange-flavoured) = £551.37. Label: 9, 11, 23
- **Intravenous infusion**, powder for reconstitution, voriconazole, net price 200 mg vial = £77.14

**Excipients** include sulphobutylether beta cyclodextrin sodium (risk of accumulation in renal impairment)

**Electrolytes** Na⁺ 9.47 mmol/vial

**BNF for Children**

**5.2.2 Imidazole antifungals**

The imidazole antifungals include clotrimazole, econazole, ketoconazole, and toconazole. They are used for the local treatment of vaginal candidiasis (section 7.2.2) and for dermatophyte infections (section 13.10.2).

**Ketoconazole** is better absorbed by mouth than other imidazoles. However, its use is restricted because it is associated with fatal hepatotoxicity (see below).

**Miconazole** (section 12.3.2) can be used locally for oral infections; it is also effective in intestinal infections. Systemic absorption may follow use of miconazole oral gel and may result in significant drug interactions.
5.2.3 Polyene antifungals

The polyene antifungals include amphotericin and nystatin; neither drug is absorbed when given by mouth. Amphotericin is used for oral, oropharyngeal, and perirectal infections by local application in the mouth (section 13.10.2). Nystatin is also used for Candida albicans infection of the skin (section 13.10.2).

Amphotericin by intravenous infusion is used for the treatment of systemic fungal infections and is active against most fungi and yeasts. It is highly protein bound and penetrates poorly into body fluids and tissues. When given parenterally amphotericin is toxic and side-effects are common. Lipid formulations of amphotericin (Abelcet® and AmBisome®) are significantly less toxic and are recommended when the conventional formulation of amphotericin is contra-indicated because of toxicity, especially nephrotoxicity or when response to conventional amphotericin is inadequate; lipid formulations are more expensive. For the role of amphotericin in the systemic treatment of fungal infections, see p. 572.

**AMPHOTERICIN**

**(Amphotericin B)**

**Indications** See under Dose

**Cautions** when given parenterally, toxicity common (close supervision necessary and test dose required; see Anaphylaxis below); hepatic and renal function tests, blood counts, and plasma electrolyte (including plasma-potassium and magnesium concentration) monitoring required; corticosteroids (avoid except to control reactions); avoid rapid infusion (risk of arrhythmias); interactions: Appendix 1 (amphotericin)

Anaphylaxis Anaphylaxis occurs rarely with any intravenous amphotericin product and a test dose is advisable before the first infusion; the patient should be carefully observed for at least 30 minutes after the test dose. Prophylactic antipyretics or hydrocortisone should only be used in patients who have previously experienced acute adverse reactions (in whom continued treatment with amphotericin is essential)

Renal impairment use only if no alternative; nephrotoxicity may be reduced with use of lipid formulation

Pregnancy not known to be harmful but manufacturers advise avoid unless potential benefit outweighs risk

Breast-feeding no information available

**Side-effects** when given parenterally, anorexia, nausea and vomiting, diarrhoea, epigastric pain; febrile reactions, headache, muscle and joint pain; anaemia; disturbances in renal function (including hypokalaemia and hypomagnesaemia) and renal toxicity; also cardiovascular toxicity (including arrhythmias, blood pressure changes), blood disorders, neurological disorders (including hearing loss, diplopia, convulsions, peripheral neuropathy, encephalopathy), abnormal liver function (discontinue treatment), rash, anaphylactoid reactions (see Anaphylaxis, above); pain and thrombophlebitis at injection site

**Dose**

- By intravenous infusion, see preparations

*Note* Different preparations of intravenous amphotericin vary in their pharmacodynamics, pharmacokinetics, dosage, and administration; these preparations should not be considered interchangeable. To avoid confusion, prescribers should specify the brand to be dispensed.

**Lipid formulations**

Abelcet® (Cephalon) (ω)

**Intravenous infusion**, amphotericin 5 mg/mL as lipid complex with 1-α-dimyristoylphosphatidylcholine and 1-α-dimyristoylphosphatidylglycerol, net price 20-mL vial = £77.43 (hosp. only)

**Electrolytes** Na⁺ 3.12 mmol/vial

**Dose** by intravenous infusion, severe invasive candidiasis; severe systemic fungal infections in patients not responding to conventional amphotericin or to other antifungal drugs or where toxicity or renal impairment precludes conventional amphotericin, including invasive aspergillosis, cryptococcal meningitis and disseminated cryptococcosis in HIV patients; initial test dose 1 mg over 10 minutes then 5 mg/kg once daily for at least 14 days.

CHILD under 18 years see BNF for Children

AmBisome® (Gilead) (ω)

**Intravenous infusion**, powder for reconstitution, amphotericin 50 mg encapsulated in liposomes, net price 50-mg vial = £96.69

**Electrolytes** Na⁺ < 0.5 mmol/vial

**Excipients** include sucrose 900 mg/vial

**Dose** by intravenous infusion, severe systemic or deep mycoses where toxicity (particularly nephrotoxicity) precludes use of conventional amphotericin, aspergillosis, initial test dose 1 mg over 10 minutes then 3 mg/kg once daily; max. 5 mg/kg once daily (unlicensed dose). CHILD under 18 years see BNF for Children

Suspected or proven infection in febrile neutropenic patients unresponsive to broad-spectrum antibiotics, initial test dose 1 mg over 10 minutes then 3 mg/kg once daily until afebrile for 3 consecutive days; max. period of treatment 42 days; max. 5 mg/kg once daily (unlicensed dose). CHILD under 18 years see BNF for Children

Visceral leishmaniasis, see section 5.4.5 and product literature

5.2.4 Echinocandin antifungals

The echinocandin antifungals include anidulafungin, caspofungin and micafungin. They are only active against Aspergillus spp. and Candida spp.; however, anidulafungin and micafungin are not used for the treatment of aspergillosis. Echinocandins are not effective against fungal infections of the CNS. For the role of echinocandin antifungals in the prevention and systemic treatment of fungal infections, see p. 572.

**ANIDULAFUNGIN**

**Indications** invasive candidiasis (see notes above)

**Pregnancy** manufacturer advises avoid—no information available

**Breast-feeding** manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies

**Side-effects** diarrhoea, nausea, vomiting, flushing, convulsion, headache, coagulopathy, hypokalaemia, raised serum creatinine, rash, pruritus, loose, commonly abdominal pain, cholestatic, hypertension, hyper-
glycaemia, urticaria, injection-site pain; also reported, hypotension, dyspnoea, bronchospasm, hepatitis

**Dose**
- **By intravenous infusion,** ADULT over 18 years, 200 mg on first day then 100 mg once daily

**Ecalta** *(Pfizer) ▼ ▼
Intravenous infusion, powder for reconstitution, anidulafungin, net-price 100-mg vial = £299.99

---

**CASPOFUNGIN**

**Indications** invasive aspergillosis (see notes above); invasive candidiasis (see notes above); empirical treatment of systemic fungal infections in patients with neutropenia

**Cautions** interactions: Appendix 1 (caspofungin)

**Hepatic impairment** 70 mg on first day then 35 mg once daily in moderate impairment; no information available for severe impairment

**Pregnancy** manufacturer advises avoid unless essential—toxicity in animal studies

**Breast-feeding** present in milk in animal studies—manufacturer advises avoid

**Side-effects** nausea, vomiting, diarrhea, abdominal pain; headache; fever; hypokalaemia; hypomagnesaemia; hypocalcaemia; leucopenia, anaemia; rash; phlebitis; less commonly dyspepsia, constipation, hepatomegaly, hepatitis and cholestasis (see also Hepatotoxicity above), taste disturbances, anorexia, tachycardia, palpitation, bradycardia, blood pressure changes, flushing, dyspnoea, sleep disturbances, anxiety, confusion, dizziness, tremor, pancytopenia, thrombocytopenia, eosinophilia, hyponatraemia, hypophosphataemia, hyperkalaemia, hyperhidrosis, and pruritus; rarely haemolytic anaemia; also reported renal failure (more frequent in children)

**Dose**
- **By intravenous infusion,** invasive candidiasis, ADULT body-weight over 40 kg, 100 mg once daily (increased to 200 mg daily if inadequate response) for at least 14 days; body-weight under 40 kg, 2 mg/kg once daily (increased to 4 mg/kg daily if inadequate response) for at least 14 days; **CHILD** under 18 years see BNF for Children

Oesophageal candidiasis, **ADULT** body-weight over 40 kg, 150 mg once daily; body-weight under 40 kg, 3 mg/kg once daily; **CHILD** 18–18 years see BNF for Children

Prophylaxis of candidiasis in patients undergoing bone-marrow transplantation or who are expected to become neutropenic for over 10 days, **ADULT** body-weight over 40 kg, 50 mg once daily; body-weight under 40 kg, 1 mg/kg once daily; continue for at least 7 days after neutrophil count in desirable range; **CHILD** under 18 years see BNF for Children

**Mycamine** *(Astellas) ▼ ▼
Intravenous infusion, powder for reconstitution, micafungin (as sodium), net price 50-mg vial = £196.08; 100-mg vial = £341.00

**Flucytosine** is used with amphotericin in a synergistic combination. Bone marrow depression can occur which limits its use, particularly in AIDS patients; weekly blood counts are necessary during prolonged therapy. Resistance to flucytosine can develop during therapy and sensitivity testing is essential before and during treatment. For the role of flucytosine in the treatment of systemic candidiasis and cryptococcal meningitis, see p. 373. Griseofulvin is effective for widespread or intractable dermatophyte infections but has been superseded by newer antifungals, particularly for nail infections. It is the drug of choice for trichophyton infections in children. Duration of therapy is dependent on the site of the infection and may extend to a number of months. For the role of griseofulvin in the treatment of tinea capitis, see p. 373. Terbinfine is the drug of choice for fungal nail infections and is also used for ringworm infections where oral treatment is considered appropriate (see p. 373).
**FLUCYTOSINE**

**Indications** systemic yeast and fungal infections; adjunct to amphotericin in cryptococcal meningitis (see Cryptococcosis, p. 373), adjunct to amphotericin in severe systemic candidiasis and in other severe or long-standing infections

**Cautions** elderly; blood disorders; liver- and kidney-function tests and blood counts required (weekly in blood disorders); **interactions:** Appendix 1 (flucytosine)

**Renal impairment** liver- and kidney-function tests and blood counts required weekly; use 50 mg/kg every 12 hours if creatinine clearance 20–40 mL/minute; use 50 mg/kg every 24 hours if creatinine clearance 10–20 mL/minute; use initial dose of 50 mg/kg if creatinine clearance less than 10 mL/minute and then adjust dose according to plasma-flucytosine concentration

**Pregnancy** teratogenic in animal studies; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid

**Side-effects** nausea, vomiting, diarrhoea, rashes; less frequently cardiotoxicity, confusion, hallucinations, convulsions, headache, sedation, vertigo, alterations in liver function tests (hepatitis and hepatic necrosis reported), and toxic epidermal necrolysis; blood disorders including thrombocytopenia, leucopenia, and aplastic anaemia reported

**Dose**
- By intravenous infusion over 20–40 minutes, 200 mg/kg daily in 4 divided doses usually for not more than 7 days; extremely sensitive organisms, 100–150 mg/kg daily may be sufficient; **CHILD** under 18 years see **BNF for Children**
- Cryptococcal meningitis (adjunct to amphotericin, see Cryptococcosis, p. 373) 100 mg/kg daily in 4 divided doses for 2 weeks [unlicensed duration]; **CHILD** under 18 years see **BNF for Children**

**Note** For plasma concentration monitoring, blood should be taken shortly before starting the next infusion; plasma concentration for optimum response 25–50 mg/litre (200–400 micromol/litre)—should not be allowed to exceed 80 mg/litre (620 micromol/litre)

**Ancotil** (Meda) **Intravenous infusion**, flucytosine 10 mg/mL, net price 250 mL infusion bottle = £30.33 (hosp. only)

**ELECTROLYTES Na+ 34.5 mmol/250-mL bottle**

**Note** Flucytosine tablets [unlicensed] may be available from ‘special-order’ manufacturers or specialist-importing companies, see p. 988

---

**GRISEOFULVIN**

**Indications** dermatophyte infections of the skin, scalp, hair and nails where topical therapy has failed or is inappropriate

**Cautions** interactions: Appendix 1 (griseofulvin)

**Driving** May impair performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** severe liver disease; systemic lupus erythematosus (risk of exacerbation); acute porphyria (section 9.8.2)

**Hepatic impairment** avoid in severe liver disease

**Pregnancy** avoid (fetotoxicity and teratogenicity in animals); effective contraception required during and for at least 1 month after administration to women (important: effectiveness of oral contraceptives may be reduced, additional contraceptive precautions e.g. barrier method, required); also men should avoid fathering a child during and for at least 6 months after administration

**Breast-feeding** avoid—no information available

**Side-effects** nausea, vomiting, diarrhoea; headache; also reported, abdominal pain, dyspepsia, hepatotoxicity, glossitis, taste disturbances, sleep disturbances, dizziness, fatigue, confusion, agitation, depression, impaired coordination and hearing, peripheral neuropathy, menstrual disturbances, renal failure, leucopenia, systemic lupus erythematosus, rash (including rarely erythema multiforme, toxic epidermal necrolysis), and photosensitivity

**Dose**
- Dermatophyte infections, 500 mg once daily or in divided doses; in severe infection may be doubled, reducing when response occurs; **CHILD** under 50 kg, 10 mg/kg once daily or in divided doses
- Tinea capitis caused by Trichophyton tonsurans, 1 g once daily or in divided doses; **CHILD** under 50 kg, 15–20 mg/kg once daily or in divided doses

**Note** Griseofulvin doses in **BNF** may differ from those in product literature

**Griseofulvin** (Non-proprietary) **Tablets**, griseofulvin 125 mg, net price 100 = £34.86; 500 mg, 100 = £90.34. Label: 9, 21, counselling, driving

**Fulsovin** (Kappin) **Oral suspension**, griseofulvin 125 mg/5 mL, net price 100 mL (peppermint-flavoured) = £59.90. Label: 9, 21, counselling, driving

---

**TERBINAFINE**

**Indications** dermatophyte infections of the nails, ringworm infections (including tinea pedis, cruris, and corporis) where oral therapy appropriate (due to site, severity or extent)

**Cautions** psoriasis (risk of exacerbation); autoimmune disease (risk of lupus-erythematosus-like effect); **interactions:** Appendix 1 (terbinafine)

**Hepatic impairment** manufacturer advises avoid—elimination reduced

**Renal impairment** use half normal dose if eGFR less than 50 mL/minute/1.73 m2 and no suitable alternative available

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk—no information available

**Breast-feeding** avoid—present in milk

**Side-effects** abdominal discomfort, anorexia, nausea, diarrhoea; headache; rash and urticaria occasionally with arthralgia or myalgia; less commonly taste disturbance; rarely liver toxicity (including jaundice, cholestasis and hepatitis)—discontinue treatment, angioedema, dizziness, malaise, paraesthesia, hypoaesthesia, photosensitivity, serious skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)—discontinue treatment if progressive skin rash; very rarely psychiatric disturbances, blood disorders (including leucopenia and thrombocytopenia), lupus erythematosus-like effect, and exacerbation of psoriasis

**Dose**
- **By mouth**. 250 mg daily usually for 2–6 weeks in tinea pedis, 2–4 weeks in tinea cruris, 4 weeks in tinea corporis, 6 weeks–3 months in nail infections (occas-
sionally longer in toenail infections); CHILD [unlicensed] usually for 4 weeks, tinea capitis, over 1 year, body-weight 10–20 kg, 62.5 mg once daily; body-weight 20–40 kg, 125 mg once daily; body-weight over 40 kg, 250 mg once daily

**Terbinafine** (Non-proprietary) Tablets, terbinafine (as hydrochloride) 250 mg, net price 14-tab pack = £2.33, 28-tab pack = £3.02. Label: 9

**Lamisil** (Novartis) Tablets, off-white, scored, terbinafine (as hydrochloride) 250 mg, net price 14-tab pack = £21.30, 28-tab pack = £41.09. Label: 9

### 5.3 Antiviral drugs

#### 5.3.1 HIV infection

There is no cure for infection caused by the human immunodeficiency virus (HIV) but a number of drugs slow or halt disease progression. Drugs for HIV infection (antiretrovirals) may be associated with serious side-effects. Although antiretrovirals increase life expectancy considerably and decrease the risk of complications associated with premature ageing, mortality and morbidity remain slightly higher than in uninfected individuals. Treatment should be undertaken only by those experienced in their use.

**Principles of treatment** Treatment is aimed at reducing the plasma viral load as much as possible and for as long as possible; it should be started before the immune system is irreversibly damaged. The need for early drug treatment should, however, be balanced against the risk of toxicity. Commitment to treatment and strict adherence over many years are required; the regimen chosen should take into account convenience and patient tolerance. The development of drug resistance is reduced by using a combination of drugs; such combinations should have synergistic or additive activity while ensuring that their toxicity is not additive. It is recommended that viral sensitivity to antiretroviral drugs is established before starting treatment or before switching drugs if the infection is not responding.

**Initiation of treatment** The optimum time for initiating antiretroviral treatment depends primarily on the CD4 cell count; the plasma viral load and clinical symptoms may also help. The timing and choice of treatment should also take account of the possible effects of antiretroviral drugs on factors such as the risk of cardiovascular events. Treatment includes a combination of drugs known as ‘highly active antiretroviral therapy’. Treatment is initiated with 2 nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor; the regimen of choice contain either tenofovir, emtricitabine, and efavirenz or abacavir, lamivudine, and efavirenz. Regimens containing 2 nucleoside reverse transcriptase inhibitors and a boosted protease inhibitor are reserved for patients with resistance to first-line regimens, women wishing to become pregnant, or patients with psychiatric illness. Patients who require treatment for both HIV and chronic hepatitis B should be treated with antivirals active against both diseases (section 5.3.3).

**Switching therapy** Deterioration of the condition (including clinical and virological changes) may require a change in therapy. The choice of an alternative regimen depends on factors such as the response to previous treatment, tolerance and the possibility of cross-resistance.

**Pregnancy** Treatment of HIV infection in pregnancy aims to reduce the risk of toxicity to the fetus (although the teratogenic potential of most antiretroviral drugs is unknown), to minimise the viral load and disease progression in the mother, and to prevent transmission of infection to the neonate. **All treatment options require careful assessment by a specialist.** Tenofovir/emtricitabine/efavirenz/ranuvir (tenofovir, emtricitabine, efavirenz and abacavir) is the recommended regimen for pregnant women and breastfeeding mothers. Women who are planning pregnancy should be switched to this regimen if they are on a different regimen.

**Breast-feeding** Breast-feeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided.

**Children** HIV disease in children has a different natural course from that in adults. Children infected with HIV should be managed within a formal paediatric HIV clinical network by specialists with access to guidelines and information on antiretroviral drugs for children.

**Post-exposure prophylaxis** Prophylaxis with antiretroviral drugs [unlicensed indication] may be appropriate following exposure to HIV-contaminated material. Immediate expert advice should be sought in such cases; national guidelines on post-exposure prophylaxis for healthcare workers have been developed (by the Chief Medical Officer’s Expert Advisory Group on AIDS, www.dh.gov.uk) and local ones may also be available. Antiretrovirals for prophylaxis are chosen on the basis of efficacy and potential for toxicity. Prompt prophylaxis with antiretroviral drugs [unlicensed indication] is also appropriate following potential sexual exposure to HIV; recommendations have been developed by the British Association for Sexual Health and HIV, www.bashh.org

**Drugs for HIV infection** Zidovudine, a nucleoside reverse transcriptase inhibitor (or ‘nucleoside analogue’), was the first anti-HIV drug to be introduced.
Other nucleoside reverse transcriptase inhibitors include abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir.

The protease inhibitors include atazanavir, darunavir, fosamprenavir (a pro-drug of amprenavir), indinavir, lopinavir, nefinavir, ritonavir, saquinavir, and tipranavir. Ritonavir in low doses boosts the activity of the subtype HIV-1 but not HIV-2, a subtype that is rare in the UK. These drugs may interact with a number of drugs metabolised in the liver. Nevirapine is associated with a high incidence of rash (including Stevens-Johnson syndrome) and occasionally fatal hepatitis. Rash is also associated with efavirenz and etravirine but it is usually milder. Psychiatric or CNS disturbances are common with efavirenz. CNS disturbances are often self-limiting and can be reduced by taking the dose at bedtime (especially in the first 2–4 weeks of treatment). Efavirenz has also been associated with an increased plasma cholesterol concentration. Etravirine is used in regimens containing a boosted protease inhibitor for HIV infection resistant to other non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Enfuvirtide, which inhibits the fusion of HIV to the host cell, is licensed for managing infection that has failed to respond to a regimen of other antiretroviral drugs; enfuvirtide should be combined with other potentially active antiretroviral drugs.

Maraviroc is an antagonist of the CCR5 chemokine receptor. It is licensed for patients exclusively infected with CCR5-tropic HIV. The Scottish Medicines Consortium (p. 4) has advised (March 2008) that maraviroic (Celsentri®) is not recommended for use within NHS Scotland.

Raltegravir is an inhibitor of HIV integrase. It is licensed for the treatment of HIV infection in combination with other antiretroviral drugs. The Scottish Medicines Consortium (p. 4) has advised (April 2010) that raltegravir (Santrest®) is accepted for restricted use within NHS Scotland for the treatment of HIV infection when non-nucleoside reverse transcriptase inhibitors or protease inhibitors cannot be used because of intolerance, drug interactions, or resistance.

**Immune reconstitution syndrome** Improvement in immune function as a result of antiretroviral treatment may provoke a marked inflammatory reaction against residual opportunistic organisms.

**Lipodystrophy syndrome** Metabolic effects associated with antiretroviral treatment include fat redistribution, insulin resistance, and dyslipidaemia; collectively these have been termed lipodystrophy syndrome. The usual risk factors for cardiovascular disease should be taken into account before starting antiretroviral therapy and patients should be advised about lifestyle changes to reduce their cardiovascular risk. Plasma lipids and blood glucose should be measured before starting antiretroviral therapy, after 3–6 months of treatment, and then annually.

Fat redistribution (with loss of subcutaneous fat, increased abdominal fat, ‘buffalo hump’ and breast enlargement) is associated with regimens containing protease inhibitors and nucleoside reverse transcriptase inhibitors. Stavudine (especially in combination with didanosine), and to a lesser extent zidovudine, are associated with a higher risk of lipoatrophy and should be used only if alternative regimens are not suitable. Dyslipidaemia is associated with antiretroviral treatment, particularly with protease inhibitors. Protease inhibitors and some nucleoside reverse transcriptase inhibitors are associated with insulin resistance and hyperglycaemia. Of the protease inhibitors, atazanavir and darunavir may be less likely to cause dyslipidaemia, while saquinavir and atazanavir may be less likely to impair glucose tolerance.

**Osteonecrosis** Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy.

### Nucleoside reverse transcriptase inhibitors

#### Cautions

**Lactic acidosis** Life-threatening lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with nucleoside reverse transcriptase inhibitors. They should be used with caution in patients (particularly obese women) with hepatomegaly, hepatitis (especially hepatitis C treated with interferon α and ribavirin), liver-enzyme abnormalities and with other risk factors for liver disease and hepatic steatosis (including alcohol abuse). Treatment with the nucleoside reverse transcriptase inhibitor should be discontinued in case of symptomatic hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function. Stavudine, especially in combination with didanosine, is associated with a higher risk of lactic acidosis and should be used only if alternative regimens are not suitable.

**Hepatic impairment** Nucleoside reverse transcriptase inhibitors should be used with caution in patients with chronic hepatitis B or C (greater risk of hepatic side-effects); see also Lactic acidosis above.

**Pregnancy** see p. 381

**Breast-feeding** see p. 381

#### Side-effects

Side-effects of the nucleoside reverse transcriptase inhibitors include gastro-intestinal disturbances (such as nausea, vomiting, abdominal pain, flatulence and diarrhoea), anorexia, pancreatitis, liver damage (see also Lactic Acidosis, above), dyspnoea, cough, headache, insomnia, dizziness, fatigue, blood disorders (including anaemia, neutropenia, and thrombocytopenia), myalgia, arthralgia, rash, urticaria, and fever. See notes above for metabolic effects and lipodystrophy (Lipodystrophy Syndrome), and Osteonecrosis.
**ABACAVIR**

**Indications**  HIV infection in combination with other antiretroviral drugs

**Cautions**  see notes above; also test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known—increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele; HIV load greater than 100,000 copies/mL; patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%); interactions:  Appendix 1 (abacavir)

**Hypersensitivity reactions**  Life-threatening hypersensitivity reactions reported—characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis, laboratory abnormalities may include raised liver function tests (see Lactic Acidosis p. 382) and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time; monitor for symptoms every 2 weeks for 2 months; discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible—if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available, care needed with concomitant use of drugs which cause skin toxicity

**Counselling**  Patients should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation); how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment; patients should be advised to keep Alert Card with them at all times

**Hepatic impairment**  see notes above; also avoid in moderate impairment unless essential; avoid in severe impairment

**Renal impairment**  manufacturer advises avoid in end-stage renal disease; avoid Kivexa® or Trizivir® if eGFR less than 50 mL/minute/1.73 m² (consult product literature)

**Pregnancy**  manufacturer advises avoid (toxicity in animal studies); see also p. 381

**Breast-feeding**  see p. 381

**Side-effects**  see notes above; also hypersensitivity reactions (see above); very rarely Stevens-Johnson syndrome and toxic epidermal necrolysis; rash and gastrointestinal disturbances more common in children

**Dose**

- 600 mg daily in 1–2 divided doses; **CHILD** 3 months–12 years, 8 mg/kg every 12 hours (max. 600 mg daily) or body-weight 14–21 kg, 150 mg every 12 hours; body-weight 21–30 kg, 150 mg in the morning and 300 mg in the evening; body-weight over 30 kg, 300 mg every 12 hours

**Ziagen® (ViiV) (c)**

- Tablets, yellow, f/c, scored, abacavir (as sulphate) 300 mg, net price 60-tab pack = £208.95. Counselling, hypersensitivity reactions

**With lamivudine**

For **cautions, contra-indications and side-effects** see under individual drugs

**Kivexa® (ViiV) (c)**

- Tablets, orange, f/c, abacavir (as sulphate) 600 mg, lamivudine 300 mg, net price 30-tab pack = £352.25. Counselling, hypersensitivity reactions

**Dose**  **ADULT** and **CHILD** over 12 years, body-weight over 40 kg; 1 tablet daily

**With lamivudine and zidovudine**

**Note**  For patients stabilised (for 6–8 weeks) on the individual components in the same proportions. For **cautions, contra-indications and side-effects** see under individual drugs

**Trizivir® (ViiV) (c)**

- Tablets, blue-green, f/c, abacavir (as sulphate) 300 mg, lamivudine 150 mg, zidovudine 300 mg, net price 60-tab pack = £509.06. Counselling, hypersensitivity reactions

**Dose**  **ADULT** over 18 years, 1 tablet twice daily

**DIDANOSINE**

(ddi, DDI)

**Indications**  HIV infection in combination with other antiretroviral drugs

**Cautions**  see notes above; also history of pancreatitis (preferably avoid, otherwise extreme caution, see also below); peripheral neuropathy or hyperuricaemia (see under Side-effects); ophthalmological examination (including visual acuity, colour vision, and dilated fundus examination) recommended annually or if visual changes occur; interactions:  Appendix 1 (didanosine)

**Pancreatitis**  Suspend treatment if serum lipase raised (even if asymptomatic) or if symptoms of pancreatitis develop; discontinue if pancreatitis confirmed. Whenever possible avoid concomitant treatment with other drugs known to cause pancreatic toxicity (e.g. intravenous pentamidine isethionate); monitor closely if concomitant therapy unavoidable. Since significant elevations of triglycerides cause pancreatitis monitor closely if elevated

**Hepatic impairment**  see notes above; also insufficient information but monitor for toxicity

**Renal impairment**  reduce dose if eGFR less than 60 mL/minute/1.73 m²; consult product literature

**Pregnancy**  manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding**  see p. 381

**Side-effects**  see notes above; also pancreatitis (see also under Cautions), liver failure, anaphylactic reactions, peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops), diabetes mellitus, hypo- or hyperglycaemia, acute renal failure, rhabdomyolysis, dry eyes, retinal and optic nerve changes, dry mouth, parotid gland enlargement, salalodenitis, alopecia, hyperuricaemia (suspend if raised significantly)

**Dose**

- **ADULT** under 60 kg 250 mg daily in 1–2 divided doses, 60 kg and over 400 mg daily in 1–2 divided doses; **CHILD** over 3 months (under 6 years Videx® tablets only), 240 mg/m² daily (180 mg/m² daily in combination with zidovudine) in 1–2 divided doses

---

**BNF 61**

5.3.1 HIV infection 383
**EMTRICITABINE (FTC)**

**Indications** HIV infection in combination with other antiretroviral drugs

**Cautions** see notes above; also on discontinuation, monitor patients with hepatitis B (risk of exacerbation of hepatitis); **interactions**: Appendix 1 (emtricitabine)

**Hepatic impairment** see notes above and Cautions above

**Renal impairment** reduce dose if eGFR less than 50 mL/minute/1.73 m²; consult product literature

**Pregnancy** no information available—manufacturer advises use only if essential

**Breast-feeding** can be used with caution in women infected with chronic hepatitis B alone, providing adequate measures are taken to prevent hepatitis B infection in infants; for women infected with HIV, see p. 381

**Side-effects** see notes above; also peripheral neuropathy, muscle disorders including rhabdomyolysis, nasal symptoms, alopecia

**Dose**
- See preparations below

**Epivir® (ViiV)**

- Tablets, every 12 hours
  - Formalin (3TC) capsules, 150 mg, net price 60-tab pack = £143.32; 300 mg (grey), 30-tab pack = £157.51
  - Oral solution, banana- and strawberry-flavoured, lamivudine 50 mg/5 mL, net price 240-mL pack = £39.01
- **Excipients** include sucrose 1 g/5 mL

- **Dose** HIV infection in combination with other antiretroviral drugs, 150 mg every 12 hours or 300 mg once daily; **CHILD** 3 months–12 years, 4 mg/kg (max. 150 mg) every 12 hours or body-weight 14–21 kg, 75 mg twice daily; body-weight 21–30 kg, 75 mg in the morning and 150 mg in the evening; body-weight over 30 kg, 150 mg twice daily

**Zeffix® (ViiV)**

- Tablets, brown, 150 mg, net price 28-tab pack = £78.09
- **Excipients** include sucrose 1 g/5 mL

- **Dose** chronic hepatitis B infection either with compensated liver disease (with evidence of viral replication and histology of active liver inflammation or fibrosis) or with decompensated liver disease, 150 mg every 12 hours, or body-weight 14–21 kg, 75 mg twice daily; body-weight 21–30 kg, 75 mg in the morning and 150 mg in the evening; body-weight over 30 kg, 150 mg twice daily

**Note** Patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection

- **With abacavir**
  - See under Abacavir
- **With zidovudine**
  - See under Zidovudine
- **With efavirenz and tenofovir**
  - See under Tenofovir

**LAMIVUDINE (3TC)**

**Indications** see preparations below

**Cautions** see notes above; **interactions**: Appendix 1 (lamivudine)

**Chronic Hepatitis B** Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lami-

**Dose**
- **ADULT** oral solution
  - 240 mg oral solution = 200 mg capsule; where appropriate the capsule may be used instead of the oral solution

- **With tenofovir**
  - See under Tenofovir

- **With efavirenz and tenofovir**
  - See under Tenofovir

**STAVUDINE (d4T)**

**Indications** HIV infection in combination with other antiretroviral drugs

**Cautions** see notes above; also history of peripheral neuropathy (see under Side-effects); history of pan-
creatitis or concomitant use with other drugs associated with pancreatitis; interactions: Appendix 1 (stavudine)

**Hepatic impairment** see notes above

**Renal impairment** use half normal dose every 12 hours if eGFR 25–50 mL/minute/1.73 m²; use half normal dose every 24 hours if eGFR less than 25 mL/minute/1.73 m²

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** see notes above; also peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops), abnormal dreams, cognitive dysfunction, drowsiness, depression, pruritus; less commonly anxiety, gynaecomastia

**Dose**

- **ADULT** under 60 kg, 30 mg every 12 hours preferably at least 1 hour before food; 60 kg and over, 40 mg every 12 hours; **NEONATE** under 2 weeks, 50 micrograms/kg every 12 hours; **CHILD** over 2 weeks, body-weight under 30 kg, 1 mg/kg every 12 hours; body-weight 30 kg and over, adult dose

**Atripla** (Gilead)

- Tablets, f/c, efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil (as fumarate) 245 mg, net price 30-tab pack = £255.00. Label: 21, counselling, administration

Counselling Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste)

**Dose** HIV infection in combination with other antiretroviral drugs, **ADULT** over 18 years, 1 tablet once daily

**With emtricitabine**

For cautions, contra-indications, and side-effects see under individual drugs

**Truvada** (Gilead)

- Tablets, blue, f/c, tenofovir disoproxil (as fumarate) 245 mg, emtricitabine 200 mg, net price 30-tab pack = £418.50. Label: 21, counselling, administration

Counselling Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste)

**Dose** HIV infection in combination with other antiretroviral drugs, **ADULT** over 18 years, 1 tablet once daily

**With efavirenz and emtricitabine**

For cautions, contra-indications, and side-effects see under individual drugs

**Tenofovir Disoproxil**

- **Indications** HIV infection in combination with other antiretroviral drugs; chronic hepatitis B infection with either compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) or decompensated liver disease

- **Cautions** see notes above; also test renal function and serum phosphate before treatment, then every 4 weeks (more frequently if at increased risk of renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate decreases; concomitant or recent use of nephrotoxic drugs; on discontinuation, monitor patients with hepatitis B (risk of exacerbation of hepatitis); interactions: Appendix 1 (tenofovir)

**Hepatic impairment** see notes above and Cautions above

**Renal impairment** monitor renal function—interrupt treatment if further deterioration; 245 mg every 2 days if eGFR 30–50 mL/minute/1.73 m²; 245 mg every 3–4 days if eGFR 10–30 mL/minute/1.73 m²; avoid **Atripla** if eGFR less than 50 mL/minute/1.73 m²; use normal dose of **Truvada** every 2 days if eGFR 30–50 mL/minute/1.73 m²; avoid **Truvada** if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** no information available—manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** see notes above; hypophosphataemia; rarely renal failure, proximal renal tubulopathy, nephrogenic diabetes insipidus; also reported reduced bone density

**Dose**

- **ADULT over 18 years, 245 mg once daily**

**Viread** (Gilead) ▼ (TA)

- Tablets, f/c, blue, tenofovir disoproxil (as fumarate) 245 mg, net price 30-tab pack = £255.00. Label: 21, counselling, administration

Counselling Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste)

**Dose** HIV infection in combination with other antiretroviral drugs, **ADULT** over 18 years, 1 tablet once daily

**Zidovudine** (Azidothymidine, AZT)

- **Note** The abbreviation AZT which is sometimes used for zidovudine has also been used for another drug

- **Indications** HIV infection in combination with other antiretroviral drugs; prevention of maternal-fetal HIV transmission (see notes above under Pregnancy and Breast-feeding)

- **Cautions** see notes above; also haematological toxicity particularly with high dose and advanced disease—monitor full blood count after 4 weeks of treatment, then every 3 months; vitamin B₁₂ deficiency (increased risk of neutropenia); if anaemia or myelosuppression occur, reduce dose or interrupt treatment according to product literature, or consider other treatment; elderly; interactions: Appendix 1 (zidovudine)

- **Contra-indications** abnormally low neutrophil counts or haemoglobin concentration (consult product literature); neonates with hyperbilirubinaemia requiring treatment other than phototherapy, or with raised transaminase (consult product literature); acute porphyria (section 9.8.2)

**Hepatic impairment** see notes above; also accumulation may occur

**Renal impairment** reduce oral dose to 300–400 mg daily in divided doses or intravenous dose to 1 mg/kg 3–4 times daily if eGFR is less than 10 mL/minute/1.73 m²; avoid **Combivir** if eGFR less than 50 mL/minute/1.73 m² (consult product literature)

**Pregnancy** limited information available; manufacturer advises use only if clearly indicated; see also p. 381
Breast-feeding see p. 381

Side-effects see notes above; also anaemia (may require transfusion), taste disturbance, chest pain, influenza-like symptoms, paraesthesia, neuropathy, convulsions, dizziness, drowsiness, anxiety, depression, loss of mental acuity, myopathy, gynaecomastia, urinary frequency, sweating, pruritus, pigmentation of nails, skin and oral mucosa.

Dose

- By mouth, ADULT body-weight over 30 kg, 250–300 mg twice daily; CHILD body-weight 4–9 kg, 12 mg/kg twice daily; body-weight 9–30 kg, 9 mg/kg twice daily or body-weight 8–14 kg, 100 mg twice daily; body-weight 14–21 kg, 100 mg in the morning and 200 mg in the evening; body-weight 21–28 kg, 200 mg twice daily; body-weight 28–30 kg, 200–250 mg twice daily.
- Prevention of maternal-fetal HIV transmission, seek specialist advice (combination therapy preferred).
- Patients temporarily unable to take zidovudine by mouth, by intravenous infusion over 1 hour, 0.8–1 mg/kg every 4 hours (approximating to 1.2–1.5 mg/kg every 4 hours by mouth) usually for not more than 2 weeks; CHILD 3 months; 60–80 mg/m² every 6 hours (approximating to 9–12 mg/kg twice daily by mouth).

Zidovudine (Non-proprietary) Capsules, zidovudine 100 mg, net price 60-cap pack = £50.17; 250 mg, 60-cap pack = £125.44.

Retrovir® (ViiV) Capsules, zidovudine 100 mg (white/blue band), net price 100-cap pack = £104.54; 250 mg (blue/white/ dark blue band), 40-cap pack = £104.54.

Oral solution, sugar-free, strawberry-flavoured, zidovudine 50 mg/5 mL, net price 200-mL pack with 10-mL oral syringe = £20.91.

Injection, zidovudine 10 mg/mL. For dilution and use as an intravenous infusion. Net price 20-mL vial = £10.50.

Avoid with lamivudine

For cautions, contra-indications, and side-effects see under individual drugs.

Combivir® (ViiV) Tablets, f/c, scored, zidovudine 300 mg, lamivudine 150 mg, net price 60-tab pack = £30.12.

Dose ADULT and CHILD body-weight 8–14 kg, 1 tablet twice daily; CHILD body-weight 14–21 kg, half a tablet twice daily; body-weight 21–30 kg, half a tablet in the morning and one tablet in the evening.

Note Tablets may be crushed and mixed with semi-solid food or liquid just before administration.

Avoid with abacavir and lamivudine

See under Abacavir and Lamivudine.

Protease inhibitors

Cautions Protease inhibitors are associated with hyperglycaemia and should be used with caution in diabetes (see Lipodystrophy Syndrome, p. 382). Caution is also needed in patients with haemophilia who may be at increased risk of bleeding.

Contra-indications Protease inhibitors should not be given to patients with acute porphyria (but see section 9.8.2).

Hepatic impairment Protease inhibitors should be used with caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects).

Pregnancy See p. 381

Breast-feeding See p. 381

Side-effects Side-effects of the protease inhibitors include gastro-intestinal disturbances (including diarrhoea, nausea, vomiting, abdominal pain, flatulence), anorexia, hepatic dysfunction, pancreatitis; blood disorders including anaemia, neutropenia, and thrombocytopenia; sleep disturbances, fatigue, headache, dizziness, paraesthesia, myalgia, myositis, rhabdomyolysis; taste disturbances; rash, pruritus, Stevens-Johnson syndrome, hypersensitivity reactions including anaphylaxis; see also notes above for lipodystrophy and metabolic effects (Lipodystrophy Syndrome), and Osteonecrosis.

ATAZANAVIR

Indications HIV infection in combination with other antiretroviral drugs

Cautions see notes above; also concomitant use with drugs that prolong PR interval; cardiac conduction disorders; predisposition to QT interval prolongation (including electrolyte disturbances, concomitant use of drugs that prolong QT interval); interactions: Appendix 1 (atazanavir).

Contra-indications see notes above.

Hepatic impairment see notes above; also manufacturer advises caution in mild impairment; avoid in moderate to severe impairment.

Pregnancy manufacturer advises use only if potential benefit outweighs risk; theoretical risk of hyperbilirubinemia in neonate if used at term.

Breast-feeding see p. 381

Side-effects see notes above; also AV block (in children); less commonly mouth ulcers, dry mouth, hypertension, syncope, chest pain, dyspnoea, peripheral neuropathy, abnormal dreams, amnesia, disorientation, depression, anxiety, weight changes, increased appetite, gynaecomastia, nephrolithiasis, urinary frequency, haematuria, proteinuria, arthralgia, and alopecia; rarely hepatosplenomegaly, oedema, palpitation, and abnormal gait; also reported, cholelithiasis, cholecystitis, and torsade de pointes.

Dose

- With low-dose ritonavir, 300 mg once daily; CHILD over 6 years, body-weight 15–20 kg, 150 mg once daily; body-weight 20–40 kg, 200 mg once daily; body-weight over 40 kg, adult dose.

Reyataz® (Bristol-Myers Squibb) Capsules, atazanavir (as sulphate) 150 mg (dark blue/light blue), net price 60-cap pack = £303.38; 200 mg (dark blue), 60-cap pack = £303.38; 300 mg (red/blue), 30-cap pack = £303.38. Label: 5, 21.

DARUNAVIR

Indications HIV infection in combination with other antiretroviral drugs

Cautions see notes above; also sulfonamide sensitivity; monitor liver function before and during treatment; interactions: Appendix 1 (darunavir).

Rash Mild to moderate rash occurs commonly, usually within the first 4 weeks of therapy and resolves without...
stopping treatment. Severe skin rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis) occurs less frequently and may be accompanied by fever, malaise, arthralgia, myalgia, oral lesions, conjunctivitis, hepatitis, or eosinophilia; treatment should be stopped if severe rash develops.

**Contra-indications** see notes above

**Hepatic impairment** see notes above; also manufacturer advises caution in mild to moderate impairment; avoid in severe impairment — no information available

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk — no information available

**Breast-feeding** see p. 381

**Side-effects** see notes above; also haematemesis, myocardial infarction, angina, QT interval prolongation, syncope, bradycardia, tachycardia, palpitation, hypertension, flushing, peripheral oedema, dyspnoea, cough, peripheral neuropathy, anxiety, confusion, memory impairment, depression, abnormal dreams, convulsions, increased appetite, weight changes, pyrexia, hypothyroidism, osteoporosis, gynaecomastia, erectile dysfunction, reduced libido, dysuria, polyuria, nephrolithiasis, renal failure, arthralgia, visual disturbances, dry eyes, conjunctival hyperaemia, rhinorrhea, throat irritation, dry mouth, stomatitis, nail discoloration, acne, seborrhoeic dermatitis, eczema, increased sweating, alopecia.

**Dose**

- With low-dose ritonavir, **ADULT** and **CHILD** over 6 years, body-weight over 40 kg, previously treated with antiretroviral therapy, 600 mg twice daily; **CHILD** over 6 years, previously treated with antiretroviral therapy, body-weight 20–30 kg, 375 mg twice daily; body-weight 30–40 kg, 450 mg twice daily.
- With low-dose ritonavir, **ADULT** over 18 years not previously treated with antiretroviral therapy, 800 mg once daily.
- **Missed dose** if a dose is more than 6 hours late on the twice daily regimen (or more than 12 hours late on the once daily regimen), the missed dose should not be taken and the next dose should be taken at the normal time.

**Prezista®** (Janssen-Cilag)

- **Tablets**, f/c, darunavir (as ethanolate) 75 mg (white), net price 480-tab pack = £446.70; 150 mg (white), 240-tab pack = £446.70; 400 mg (light orange), 60-tab pack = £297.80; 600 mg (orange), 60-tab pack = £446.70. Label: 21.

**FOSAMPRENAVIR**

- **Note** Fosamprenavir is a pro-drug of amprenavir

**Indications** HIV infection in combination with other antiretroviral drugs

**Cautions** see notes above; **interactions**: Appendix 1 (fosamprenavir)

- **Rash** Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption — usually resolves within 2 weeks and may respond to antihistamines.

- **Contra-indications** see notes above

- **Hepatic impairment** see notes above; also manufacturer advises caution in mild impairment; reduce dose to 450 mg twice daily in moderate impairment; reduce dose to 300 mg twice daily in severe impairment.

- **Pregnancy** toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risk.

- **Breast-feeding** see p. 381

**Side-effects** see notes above; also reported, rash including rarely Stevens-Johnson syndrome (see also Rash above)

**Dose**

- With low-dose ritonavir, **ADULT** and **CHILD** over 6 years, body-weight over 39 kg, 700 mg twice daily; **CHILD** over 6 years, body-weight 25–39 kg, 18 mg/kg twice daily.

**Note** 700 mg fosamprenavir is equivalent to approx. 600 mg amprenavir

**Telzir®** (ViiV)

- **Tablets**, f/c, pink, fosamprenavir (as calcium) 700 mg, net price 60-tab pack = £258.97.

- **Oral suspension**, fosamprenavir (as calcium) 50 mg/mL, net price 225-mL pack (grape-bubblegum-and peppermint-flavoured) (with 10-mL oral syringe) = £299.06.

**Counselling** In adults, oral suspension should be taken on an empty stomach; in children under 18 years, oral suspension should be taken with food.

**INDINAVIR**

**Indications** HIV infection in combination with nucleoside reverse transcriptase inhibitors

- **Cautions** see notes above; also ensure adequate hydration (risk of nephrolithiasis especially in children); patients at risk of nephrolithiasis (monitor for nephrolithiasis); patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%); **interactions**: Appendix 1 (indinavir)

- **Contra-indications** see notes above

- **Hepatic impairment** see notes above; also increased risk of nephrolithiasis; reduce dose in mild to moderate impairment; not studied in severe impairment.

- **Renal impairment** use with caution; monitor for nephrolithiasis

- **Pregnancy** toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risk; theoretical risk of hyperbilirubinaemia and renal stones in neonate if used at term

- **Breast-feeding** see p. 381

- **Side-effects** see notes above; also reported, dry mouth, hypoesthesia, dry skin, hyperpigmentation, alopecia, paronychia, interstitial nephritis (with medullary calcification and cortical atrophy in asymptomatic severe leucocyturia), nephrolithiasis (may require interruption or discontinuation; more frequent in children), dysuria, haematuria, crystalluria, proteinuria, pyuria (in children), pylonephritis; haemolytic anaemia.

**Dose**

- **ADULT** over 18 years, seek specialist advice

**Crixivan®** (MSD)

- **Capsules**, indinavir (as sulphate), 200 mg, net price 360-cap pack = £226.28; 400 mg, 180-cap pack = £226.28. Label: 27.

**Counselling** Administer 1 hour before or 2 hours after a meal; may be administered with a low-fat light meal; in combination with didanosine tablets, allow 1 hour between each drug (antacids in didanosine tablets reduce absorption of indinavir); in combination with low-dose ritonavir, give with food.

**Note** Dispense in original container (contains desiccant)

**LOPINAVIR WITH RITONAVIR**

**Indications** HIV infection in combination with other antiretroviral drugs

- **Dose**

  - With low-dose ritonavir, **ADULT** over 6 years, body-weight over 39 kg, 700 mg twice daily; **CHILD** over 6 years, body-weight 25–39 kg, 18 mg/kg twice daily.

  **Note** 700 mg fosamprenavir is equivalent to approx. 600 mg amprenavir
5.3.1 HIV infection

**Hepatic impairment** see notes above; also manufacturer advises caution

**Renal impairment** manufacturer advises caution

**Pregnancy** no information available—manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** see notes above; also reported, fever

**Dose**
- 1.25 g twice daily or 750 mg 3 times daily; **CHILD** 3–13 years, initially 50–55 mg/kg twice daily (max. 1.25 g twice daily) or 25–50 mg/kg 3 times daily (max. 750 mg 3 times daily)

**Viracept** (Roche) Tablets, blue, f/c, nelfinavir (as mesilate) 250 mg, net price 300-tab pack = £257.32. Label: 21

### NELFINAVIR

**Indications** HIV infection in combination with other antiretroviral drugs

**Cautions** see notes above; interactions: Appendix 1 (nelfinavir, ritonavir)

**Contra-indications** see notes above

**Hepatic impairment** see notes above; also manufacturer advises caution

**Renal impairment** manufacturer advises caution

**Pregnancy** no information available—manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** see notes above; also reported, fever

**Dose**
- Initially 300 mg every 12 hours for 3 days, increased in steps of 100 mg every 12 hours over not longer than 14 days to 600 mg every 12 hours; **CHILD** over 2 years initially 250 mg/m² every 12 hours, increased by 50 mg/m² at intervals of 2–3 days to 350 mg/m² every 12 hours (max. 600 mg every 12 hours)
- Low-dose booster to increase effect of other protease inhibitors, 100–200 mg once or twice daily

**Norvir** (Abbott) Tablets, f/c, ritonavir 100 mg, net price 30-tab pack = £33.70. Label: 21, 25

**Oral solution** sugar-free, ritonavir 400 mg/5 mL, net price 5 × 90-mL packs (with measuring cup) = £403.20. Label: 21, counselling, administration

Counselling Oral solution contains 4% alcohol; bitter taste can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry

With nelfinavir See under Lopinavir with Ritonavir

### RITONAVIR

**Indications** HIV infection in combination with other antiretroviral drugs; low doses used to increase effect of some protease inhibitors

**Cautions** see notes above; concomitant use with drugs that prolong PR interval; cardiac conduction disorders, structural heart disease; pancreatitis (see below); interactions: Appendix 1 (ritonavir)

**Contra-indications** see notes above

**Hepatic impairment** see notes above; avoid oral solution due to propylene glycol content; manufacturer advises use only if potential benefit outweighs risk

**Pregnancy** avoid oral solution due to propylene glycol content; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** see notes above; also reported, fever

**Dose**
- Initially 300 mg every 12 hours for 3 days, increased in steps of 100 mg every 12 hours over not longer than 14 days to 600 mg every 12 hours; **CHILD** over 2 years initially 250 mg/m² every 12 hours, increased by 50 mg/m² at intervals of 2–3 days to 350 mg/m² every 12 hours (max. 600 mg every 12 hours)
- Low-dose booster to increase effect of other protease inhibitors, 100–200 mg once or twice daily

**Norvir** (Abbott) Tablets, f/c, ritonavir 100 mg, net price 30-tab pack = £33.70. Label: 21, 25

**Oral solution** sugar-free, ritonavir 400 mg/5 mL, net price 5 × 90-mL packs (with measuring cup) = £403.20. Label: 21, counselling, administration

Counselling Oral solution contains 4% alcohol; bitter taste can be masked by mixing with chocolate milk; do not mix with water, measuring cup must be dry

With nelfinavir See under Lopinavir with Ritonavir

### 5 Infections

**Cautions** see notes above; concomitant use with drugs that prolong QT or PR interval; cardiac conduction disorders, structural heart disease; patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%); pancreatitis (see below); interactions: Appendix 1 (lopinavir, ritonavir)

**Pancreatitis** Signs and symptoms suggestive of pancreatitis (including raised serum lipase) should be evaluated—discontinue if pancreatitis diagnosed

**Contra-indications** see notes above

**Hepatic impairment** see notes above; also avoid oral solution due to propylene glycol content; manufacturer advises use capsules and tablets in severe impairment

**Renal impairment** avoid oral solution due to propylene glycol content; use tablets with caution in severe impairment

**Pregnancy** avoid oral solution due to high propylene glycol content; manufacturer advises use capsules and tablets only if potential benefit outweighs risk (toxicity in animal studies)

**Breast-feeding** see p. 381

**Side-effects** see notes above; also electrolyte disturbances in children; *less commonly* haemorrhagic colitis, weight changes, chest pain, oedema, anxiety, depression, abnormal dreams, peripheral neuropathy, pyrexia, Cushing’s syndrome, sexual dysfunction, dehydration, arthralgia, tinnitus, dry mouth, acne, alopecia, and sweating; rarely cholecytitis, gastric ulcer, rectal bleeding, myocardial infarction, myocardial infarction, hyperension, palpitation, AV block, deep vein thrombosis, thrombomoblitopites, vasculitis, dyspnoea, cough, appetite changes, agitation, confusion, amnesia, ataxia, hyperpnea, extrapyramidal effects, influenza-like symptoms, hypothyroidism, amenorrhoea, menorrhagia, gynaecomastia, nephrolithiasis, nephritis, albuminuria, haematuria, hypercalciuria, hypophosphataemia, lactic acidosis, hyperuricaemia, visual disturbances, otitis media, dysphagia, mouth ulceration, stomatitis, periodontitis, sialadenitis, eczema, skin discoloration, and nail disorders

**Dose**
- See preparations below

**Kaletra** (Abbott) Tablets, pale yellow, f/c, lopinavir 100 mg, ritonavir 25 mg, net price 60-tab pack = £76.85. Label: 25

**CHILD** over 2 years with body weight under 40 kg and body surface area 0.5–0.9 m², 2 tablets twice daily; body surface area 0.9–1.4 m², 3 tablets twice daily

**Tablets**, yellow, f/c, lopinavir 200 mg, ritonavir 50 mg, net price 120-tab pack = £307.39. Label: 25

**Dose** ADULT and CHILD with body surface area greater than 1.4 m² or body weight 40 kg and over, 2 tablets twice daily

**Note** Alternatively, in adults with a HIV strain that has less than 3 mutations to protease inhibitors, 4 tablets may be taken once daily

**Oral solution**, lopinavir 400 mg, ritonavir 100 mg/5 mL, net price 5 × 60-mL packs = £307.39. Label: 21

**Excipients** include propylene glycol 153 mg/mL (see Excipients, p. 2), alcohol 42%

**Dose** 5 mL twice daily with food; **CHILD** 2–12 years 2.9 mL/m² twice daily with food, max. 5 mL twice daily
SAQUINAVIR

Indications  HIV infection in combination with other antiretroviral drugs

Cautions  see notes above; monitor ECG before starting treatment and then on day 3 or 4 of treatment—discontinue if QT interval over 480 milliseconds, if QT interval more than 20 milliseconds above baseline, or if prolongation of PR interval; concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration); interactions: Appendix 1 (saquinavir)

Counselling  Patients should be told how to recognise signs of arthrythma and advised to seek medical attention if symptoms such as palpitation or syncope develop

Contra-indications  see notes above; predisposition to cardiac arrhythmias (including congenital QT prolongation, bradycardia, history of symptomatic arrhythmias, heart failure with reduced left ventricular ejection fraction, electrolyte disturbances, concomitant use of drugs that prolong QT or PR interval); concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available)

Hepatic impairment  see notes above; also manufacturer advises caution in moderate impairment; avoid in decompensated liver disease

Renal impairment  see notes above; also monitor ECG before starting treatment and then on day 3 or 4 of treatment—discontinue if QT interval over 480 milliseconds, if QT interval more than 20 milliseconds above baseline, or if prolongation of PR interval; concomitant use of garlic (avoid garlic capsules—reduces plasma-saquinavir concentration); interactions: Appendix 1 (saquinavir)

Breast-feeding  see p. 381

Side-effects  see notes above; also dyspnoea, anaesthesia, peripheral neuropathy, influenza-like symptoms, renal impairment and photosensitivity; rarely dehydration

Dose  • See preparations

Aptivus® (Boehringer Ingelheim)▼

Capsules, pink, tipranavir 250 mg, net price 120–cap pack = £441.00. Label: 5, 21

Dose  with low-dose ritonavir, ADULT and ADOLESCENT over 16 years previously treated with antiretroviral therapy, 500 mg every 12 hours

Invinase® (Roche) ▼

Capsules, brown/green, saquinavir (as mesilate) 200 mg, net price 270-cap pack = £226.14. Label: 21, counselling, arrhythmias

Tablets, orange, F/C, saquinavir (as mesilate) 500 mg, net price 120-tab pack = £251.26. Label: 21, counselling, arrhythmias

Non-nucleoside reverse transcriptase inhibitors

EFAVIRENZ

Indications  HIV infection in combination with other antiretroviral drugs

Cautions  elderly; history of mental illness or seizures; monitor liver function if receiving other hepatotoxic drugs; interactions: Appendix 1 (efavirenz)

Rash  Rash, usually in the first 2 weeks, is the most common side-effect; discontinue if severe rash with blistering, desquamation, mucosal involvement or fever; if rash mild or moderate, may continue without interruption—usually resolves within 1 month

Psychiatric disorders  Patients or their carers should be advised to seek immediate medical attention if symptoms such as severe depression, psychosis or suicidal ideation occur

Contra-indications  acute porphyria (but see section 9.8.2)

Hepatic impairment  in mild liver disease, monitor for dose related side-effects (e.g. CNS effects) and monitor liver function; avoid in moderate to severe impairment; greater risk of hepatic side-effects in chronic hepatitis B or C

Renal impairment  manufacturer advises caution in severe renal failure—no information available

Pregnancy  manufacturer advises avoid (effective contraception required during treatment and for 12 weeks after treatment); use efavirenz only if no alternative available

Breast-feeding  see p. 381
Side-effects rash including Stevens-Johnson syndrome (see Rash above); abdominal pain, diarrhoea, nausea, vomiting; anxiety, depression, sleep disturbances, abnormal dreams, dizziness, headache, fatigue, impaired concentration (administration at bedtime especially in first 2–4 weeks reduces CNS effects); pruritus; less commonly pancreatitis, hepatitis, flushing, psychosis, mania, suicidal ideation, amnesia, ataxia, tremor, convulsions, gynaecomastia, blurred vision, tinnitus; rarely hepatic failure, photosensitivity; also reported raised serum cholesterol (see Lipodystrophy Syndrome, p. 382); see also Osteonecrosis, p. 382

Dose

> See preparations below

**Sustiva** (Bristol-Myers Squibb)

Capsules, efavirenz 50 mg (yellow/white), net price 30-cap pack = £16.73; 100 mg (white), 30-cap pack = £33.41; 200 mg (yellow), 90-cap pack = £200.27.

Label: 23

Dose ADULT and CHILD over 3 years, body-weight 13–15 kg, 200 mg once daily; body-weight 15–20 kg, 250 mg once daily; body-weight 20–25 kg, 300 mg once daily; body-weight 25–32.5 kg, 350 mg once daily; body-weight 32.5–40 kg, 400 mg once daily; body-weight 40 kg and over, 600 mg once daily

Tablets, f/c, yellow, efavirenz 600 mg, net price 30-tab pack = £200.27. Label: 23

Dose ADULT and CHILD, body-weight over 40 kg, 600 mg once daily

**Oral solution**, sugar-free, strawberry and mint flavour; efavirenz 30 mg/mL, net price 180-mL pack = £38.88.

Dose ADULT and CHILD over 5 years, body-weight 13–15 kg, 270 mg once daily; body-weight 15–20 kg, 300 mg once daily; body-weight 20–25 kg, 360 mg once daily; body-weight 25–32.5 kg, 400 mg once daily; body-weight 32.5–40 kg, 510 mg once daily; body-weight 40 kg and over, 720 mg once daily; CHILD 3–5 years, body-weight 13–15 kg, 360 mg once daily; body-weight 15–20 kg, 390 mg once daily; body-weight 20–25 kg, 450 mg once daily; body-weight 25–32.5 kg, 510 mg once daily

**Note** The bioavailability of Sustiva® oral solution is lower than that of the capsules and tablets; the oral solution is not interchangeable with either capsules or tablets on a milligram-for-milligram basis

*With emtricitabine and tenofovir* See under Tenofovir

**ETRAVIRINE**

**Indications** in combination with other antiretroviral drugs

**Cautions** chronic hepatitis B or C, high CD4 cell count, and women (all at greater risk of hepatic side-effects—if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250 cells/mm³ or in men with CD4 cell count greater than 400 cells/mm³ unless potential benefit outweighs risk); **interactions:** Appendix 1 (nevirapine)

**Hepatic disease** Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; close monitoring required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly, discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction—discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction

**Rash** Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased after 14 days; monitor closely for skin reactions during first 18 weeks; discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, and hepatitis. Discontinue permanently if hypersensitivity reaction or severe rash develop. If rash mild or moderate (without signs of hypersensitivity reaction), may continue without interruption—usually resolves within 2 weeks

**Counselling** Patients should be told how to recognise hypersensitivity reactions and advised to seek immediate medical attention if hypersensitivity reaction or severe rash develop

**Contra-indications** acute porphyria (but see section 9.8.2)

**BHF IMPAIRMENT** manufacturer advises caution in moderate impairment; avoid in severe impairment—no information available; greater risk of hepatic side-effects in chronic hepatitis B or C

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** see p. 381

**Side-effects** rash (including Stevens-Johnson syndrome rarely and toxic epidermal necrolysis very rarely; see also Hypersensitivity Reactions above); gastro-oesophageal reflux, nausea, abdominal pain, flatulence, gastritis, myocardial infarction, hypertension; peripheral neuropathy, diabetes, hyperlipidaemia (see also Lipodystrophy Syndrome, p. 382); renal failure; anaemia; less commonly pancreatitis, haemorrhagic stroke and hypersensitivity reactions; see also Osteonecrosis, p. 382

**Dose**

> ADULT over 18 years, 200 mg twice daily after food

**Missed dose** If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time

**Intolerance** (Janssen-Cilag)

Tablets, etravirine 100 mg, net price 120-tab pack = £301.27. Label: 21, counselling, rash and hypersensitivity reactions

**Note** Dispense in original container (contains desiccant). Patients with swallowing difficulties may disperse tablets in a glass of water just before administration

**NEVIRAPINE**

**Indications** HIV infection in combination with other antiretroviral drugs

**Cautions** chronic hepatitis B or C, high CD4 cell count, and women (all at greater risk of hepatic side-effects—if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250 cells/mm³ or in men with CD4 cell count greater than 400 cells/mm³ unless potential benefit outweighs risk); **interactions:** Appendix 1 (nevirapine)

**Hepatic disease** Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; close monitoring required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly, discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction—discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction

**Rash** Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased after 14 days; monitor closely for skin reactions during first 18 weeks; discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, and hepatitis. Discontinue permanently if hypersensitivity reaction or severe rash develop. If rash mild or moderate (without signs of hypersensitivity reaction), may continue without interruption—usually resolves within 2 weeks

**Counselling** Patients should be told how to recognise hypersensitivity reactions and advised to seek immediate medical attention if hypersensitivity reaction or severe rash develop

**Contra-indications** acute porphyria (but see section 9.8.2)
Contra-indications acute porphyria (but see section 9.8.2); post-exposure prophylaxis

Hepatic impairment manufacturer advises caution in moderate impairment; avoid in severe impairment; see also Hepatic Disease, above

Pregnancy although manufacturer advises caution, may be appropriate to use if clearly indicated; see also p. 381

Breast-feeding see p. 381

Side-effects rash including Stevens-Johnson syndrome and rarely, toxic epidermal necrolysis (see also Cautions above); nausea, hepatitis (see also Hepatic Disease above), headache; less commonly vomiting, abdominal pain, fatigue, fever, and myalgia; rarely diarrhoea, angioedema, anaphylaxis, hypersensitivity reactions (may involve hepatic reactions and rash, see Hepatic Disease above), arthralgia, anaemia, and granulocytopenia (more frequent in children); see also Osteonecrosis, p. 382

Dose

ADULT and CHILD over 16 years, 200 mg once daily for first 14 days then (if no rash present) 200 mg twice daily; NEONATE and CHILD under 8 years, 150 mg/m² (max. 200 mg) once daily for first 14 days, then (if no rash present) 150 mg/m² (max. 200 mg) twice daily or 4 mg/kg (max. 200 mg) once daily for first 14 days then (if no rash present) 7 mg/kg (max. 200 mg) twice daily; CHILD 8–16 years, 150 mg/m² (max. 200 mg) once daily for first 14 days then (if no rash present) 150 mg/m² (max. 200 mg) twice daily or 4 mg/kg (max. 200 mg) once daily for first 14 days then (if no rash present) 4 mg/kg (max. 200 mg) twice daily

Note Duration of once daily dose regimen should not exceed 28 days; if rash not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose for the first 14 days as for new treatment

Viramune® (Boehringer Ingelheim) [TH]

Tablets, nevirapine 200 mg, net price 14-tab pack = £39.67, 60-tab pack = £170.00. Counselling, hypersensitivity reactions

Suspension, nevirapine 50 mg/5 mL, net price 240-mL pack = £59.40. Counselling, hypersensitivity reactions

Other antiretrovirals

ENFUVIRTIDE

Indications HIV infection in combination with other antiretroviral drugs for resistant infection or for patients intolerant to other antiretroviral regimens

Cautions

Hypersensitivity reactions Hypersensitivity reactions including rash, fever, nausea, vomiting, chills, rigors, low blood pressure, respiratory distress, glomerulonephritis, and raised liver enzymes reported; discontinue immediately if any signs or symptoms of systemic hypersensitivity develop and do not rechallenge

Counselling Patients should be told how to recognise signs of hypersensitivity, and advised to discontinue treatment and seek immediate medical attention if symptoms develop

Hepatic impairment manufacturer advises caution—no information available; chronic hepatitis B or C (possibly greater risk of hepatic side-effects)

Pregnancy manufacturer advises use only if potential benefit outweighs risk

Breast-feeding see p. 381

Side-effects injection-site reactions; pancreatitis, gastro-oesophageal reflux disease, anorexia, weight loss; hypertriglyceridaemia; peripheral neuropathy, asthenia, tremor, anxiety, nightmares, irritability, impaired concentration, vertigo; pneumonia, sinusitis, influenza-like illness; diabetes mellitus; haematuria; renal calculi, lymphadenopathy; myalgia; conjunctivitis; dry skin, acrrosis, skin palmaris; less commonly hypersensitivity reactions (see Cautions); see also Osteonecrosis, p. 382

Dose

BY subcutaneous injection, ADULT and ADOLESCENT over 16 years, 90 mg twice daily; CHILD 6–15 years, 2 mg/kg twice daily (max. 90 mg twice daily)

Fuzen® (Roche) [TH]

Injection, powder for reconstitution, enfuvirtide 108 mg (= enfuvirtide 90 mg/mL when reconstituted with 1.1 mL Water for Injections), net price 108-mg vial = £18.03 (with solvent, syringe, and alcohol swabs). Counselling, hypersensitivity reactions

MARAVIROC

Indications CCR5-tropic HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretrovirals

Cautions cardiovascular disease; chronic hepatitis B or C; interactions: Appendix 1 (maraviroc)

Hepatic impairment manufacturer advises caution

Renal impairment if eGFR less than 80 mL/minute/1.73 m², consult product literature

Pregnancy manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies

Breast-feeding see p. 381

Side-effects nausea, vomiting, abdominal pain, dyspepsia, constipation, diarrhoea; cough; dizziness, paraesthesia, asthenia, sleep disturbances, headache, weight loss; muscle spasms, back pain; taste disturbances; rash, pruritus; less commonly pancreatitis, hepatic cirrhosis, rectal bleeding, myocardial infarction, myocardial ischaemia, bronchospasm, seizures, hallucinations, loss of consciousness, polynuropathy, pancytopenia, neutropenia, lymphadenopathy, renal failure, polyuria, and myositis; see also Osteonecrosis, p. 382

Dose

ADULT over 18 years, 300 mg twice daily

Celsentri® (ViiV) [TH]

Tablets, blue, f/c, maraviroc, 150 mg, net-price 60-tab pack = £519.14; 300 mg, 60-tab pack = £519.14

RALTEGRAVIR

Indications HIV infection in combination with other antiretroviral drugs

Cautions risk factors for myopathy or rhabdomyolysis; chronic hepatitis B or C (greater risk of hepatic side-effects); interactions: Appendix 1 (raltegravir)

Hepatic impairment manufacturer advises caution in severe impairment—no information available

Pregnancy manufacturer advises avoid—toxicity in animal studies

Breast-feeding see p. 381

Side-effects diarrhoea, nausea, vomiting, abdominal pain, flatulence, hypertriglyceridaemia, dizziness,
headache, insomnia, abnormal dreams, asthenia, rash (Stevens-Johnson syndrome reported); less commonly gastritis, hepatitis, pancreatitis, dry mouth, gastro-oesophageal reflux, taste disturbances, pain on swallowing, peptic ulcer, constipation, rectal bleeding, lipodystrophy (see Lipodystrophy Syndrome, p. 382), palpitation, ventricular extrasystoles, bradycardia, hypertension, flushing, chest pain, oedema, dysphonia, epistaxis, nasal congestion, drowsiness, anxiety, appetite changes, confusion, impaired memory and attention, depression, pyrexia, chills, carpal tunnel syndrome, tremor, peripheral neuropathy, erectile dysfunction, gynaecomastia, menopausal symptoms, osteopenia, renal failure, nocturia, polydipsia, anaemia, thrombocytopenia, neutropenia, arthralgia, myalgia, rhombomylitis, visual disturbances, tinnitus, gingivitis, glossitis, acne, pruritus, hyperhidrosis, dry skin, skin papilloma, and alopecia; also reported suicidal ideation; see also Osteonecrosis, p. 382.

Choice

Aciclovir is active against herpesviruses but does not eradicate them. Uses of aciclovir include systemic treatment of varicella–zoster and the systemic and topical treatment of herpes simplex infections of the skin (section 13.10.3) and mucous membranes (including genital herpes); it is also licensed for preventing cytomegalovirus disease following renal transplantation. Foscarnet or valaciclovir are suitable alternatives to aciclovir for oral lesions associated with herpes zoster. Valaciclovir once daily may reduce the risk of transmitting genital herpes to heterosexual partners—specialist advice should be sought.

Idoxuridine (section 13.10.3) has been used topically for treating herpes simplex infections of the skin and external genitalia with variable results. Its value in the treatment of shingles is unclear.

Foscarnet (section 5.3.2.2) is used for mucocutaneous herpes simplex virus infection unresponsive to aciclovir in immunocompromised patients; it is toxic and can cause renal impairment.

Inosine pranobex has been used by mouth for herpes simplex infections; its effectiveness remains unproven.
ACICLOVIR (Acyclovir)

**Indications** herpes simplex and varicella–zoster (see also under Dose)

**Cautions** maintain adequate hydration (especially with infusion or high doses, or during renal impairment); elderly (risk of neurological reactions); **interactions:** Appendix 1 (aciclovir)

**Renal impairment** see Cautions above; also risk of neurological reactions increased; use normal intravenous dose every 12 hours if eGFR 25–50 mL/minute/1.73 m² (every 24 hours if eGFR 10–25 mL/minute/1.73 m²); consult product literature for intravenous dose if eGFR less than 10 mL/minute/1.73 m²; for herpes zoster, use normal oral dose every 8 hours if eGFR 10–25 mL/minute/1.73 m² (every 12 hours if eGFR less than 10 mL/minute/1.73 m²); for herpes simplex, use normal oral dose every 12 hours if eGFR less than 10 mL/minute/1.73 m².

**Breast-feeding** significant amount in milk after systemic administration—not known to be harmful—manufacturers advise use only when potential benefit outweighs risk.

**Pregnancy** not known to be harmful—manufacturers advise use only when potential benefit outweighs risk.

**Side-effects** nausea, vomiting, abdominal pain, diarrhoea, headache, fatigue, rash, urticaria, pruritus, photosensitivity; very rarely hepatitis, jaundice, dyspnoea, neurological reactions (including dizziness, confusion, hallucinations, convulsions, ataxia, dysarthria, and drowsiness), acute renal failure, anaemia, thrombocytopenia and leucopenia; on intravenous administration—not known to be harmful but manufacturers advises caution.

**Interactions**

- **Drug interactions**
  - Thiazide diuretics: increased risk of renal impairment.
  - Other nephrotoxic agents: increased risk of renal impairment.
  - Neomycin: increased risk of renal impairment.
  - Cimetidine (H₂ receptor antagonist): increased plasma concentration.

- **Food interactions**
  - None known.

**Effects on laboratory tests**

- **Blood** renal impairment, increased creatinine.
- **Respiratory** respiratory depression.
- **Cardiovascular** hypotension, tachycardia.
- **Nervous system** ataxia, dizziness.
- **Liver** increased liver enzymes.
- **Electrolytes** increased serum calcium levels.

**Dose**

- **By mouth**
  - **NEONATE**
    - 5 months–6 months: 200 mg/day; 6 months–1 year: 300 mg/day; 1 year–2 years: 400 mg/day; 2 years–4 years: 600 mg/day.
  - **CHILD**
    - 2–6 years: 800 mg/day (20 mg/kg/day); 6–12 years: 1200 mg/day (20 mg/kg/day).
  - **ADULT**
    - 200 mg/day (20 mg/kg/day).

- **By intravenous infusion**
  - **NEONATE**
    - 5 months–6 months: 6 mg/kg/day; 6 months–1 year: 12 mg/kg/day; 1 year–2 years: 18 mg/kg/day; 2 years–4 years: 24 mg/kg/day.
  - **CHILD**
    - 2–6 years: 30 mg/kg/day; 6–12 years: 40 mg/kg/day.
  - **ADULT**
    - 10–15 mg/kg/day.

**Renal impairment** see Cautions above; also risk of neurological reactions increased; use normal intravenous dose every 12 hours if eGFR 25–50 mL/minute/1.73 m² (every 24 hours if eGFR 10–25 mL/minute/1.73 m²); consult product literature for intravenous dose if eGFR less than 10 mL/minute/1.73 m²; for herpes zoster, use normal oral dose every 8 hours if eGFR 10–25 mL/minute/1.73 m² (every 12 hours if eGFR less than 10 mL/minute/1.73 m²); for herpes simplex, use normal oral dose every 12 hours if eGFR less than 10 mL/minute/1.73 m².

**By topical application**

- **ADULT**
  - 1% cream: 20 mg/day.
  - 5% cream: 100 mg/day.
  - 1% gel: 20 mg/day.

**By subcutaneous administration**

- **ADULT**
  - 5 mg/kg/day.

**By intramuscular administration**

- **ADULT**
  - 10 mg/kg/day.

**By rectal administration**

- **ADULT**
  - 20 mg/kg/day.

**By intranasal administration**

- **ADULT**
  - 2 mg/kg/day.

**By intrathecal administration**

- **ADULT**
  - 1 mg/kg.

**By intraventricular administration**

- **ADULT**
  - 1 mg/kg.

**Note** Aciclovir doses in BNF may differ from those in product literature.

**Using gel**

- **ADULT**
  - 5% gel: 120 mg/day.

**Infections**

**Herpesvirus infections**

- **Herpes simplex**
  - Genital herpes simplex, treatment of recurrences—consider restarting after two or more recurrences.
  - Non-genital herpes simplex, treatment, 200 mg 5 times daily for 5 days, 3 times daily for 2 days, 2–6 years 400 mg 4 times daily for 5 days; 6–12 years 800 mg 4 times daily for 5 days.

- **Varicella and herpes zoster**
  - Varicella–zoster [unlicensed use] 10–25 mg/kg every 8 hours for 5 days, doubled to 10 mg/kg every 8 hours in varicella–zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis, possibly for 14–21 days); prophylaxis of herpes simplex in the immunocompromised, 5 mg/kg every 8 hours.

- **Note** To avoid excessive dosage in obese patients, parental dose should be calculated on the basis of ideal weight for height.

- **Herpes simplex encephalitis** usually given for at least 10 days in encephalitis, possibly for 14–21 days.

- **By topical application**
  - see section 13.10.3 (skin) and section 11.3.3 (eye).

**Aciclovir** (Non-proprietary)

- **Tablets**
  - aciclovir 200 mg, net price 25-tab pack = £4.45; 400 mg, 56-tab pack = £8.10; 800 mg, 35-tab pack = £10.21.

- **Brands include**
  - Virox®

**Dental prescribing on NHS**

- **Aciclovir Tablets** 200 mg or 800 mg may be prescribed.

**Dispersible tablets**

- aciclovir 200 mg, net price 25-tab pack = £2.05; 400 mg, 56-tab pack = £7.24; 800 mg, 35-tab pack = £7.02.

- **Suspension**
  - aciclovir 200 mg/5 mL, net price 125 mL = £38.22; 400 mg/5 mL, 100 mL = £41.55.

- **Note**
  - Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription.

**Intravenous infusion**

- Powder for reconstitution, aciclovir (as sodium salt), net price 250-mg vial = £9.13; 500-mg vial = £20.22.

**Electrolytes**

- Na⁺ 1.1 mmol/250-mg vial
  - 20-mL (500-mg) vial = £19.21; 40-mL (1-g) vial = £40.44.

**Zovirax® (GSK)**

- **Tablets**
  - all dispersible, 1 tab, aciclovir 200 mg, net price 25-tab pack = £17.71; 800 mg (scored, Shingles Treatment Pack), 35-tab pack = £55.80.

- **Suspension**
  - both off-white, sugar-free, aciclovir 200 mg/5 mL (banana-flavoured), net price 125 mL = £29.53; 400 mg/5 mL (Double Strength Suspension, orange-flavoured) 100 mL = £33.01.

- **Intravenous infusion**
  - powder for reconstitution, aciclovir (as sodium salt), net price 250-mg vial = £9.96; 500-mg vial = £17.72.

**Note** Aciclovir tablets in BNF may differ from those in product literature.

**Attenuation of chickenpox** (if varicella–zoster immunoglobulin not indicated) [unlicensed use].

- **ADULT** and **CHILD** 40 mg/kg daily in 4 divided doses for 7 days starting 1 week after exposure.

- **By intravenous infusion**, treatment of herpes simplex in the immunocompromised, severe initial genital herpes, and varicella–zoster, 5 mg/kg every 8 hours usually for 5 days, doubled to 10 mg/kg every 8 hours in varicella–zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis, possibly for 14–21 days); prophylaxis of herpes simplex in the immunocompromised, 5 mg/kg every 8 hours.

**NEONATE and INFANT** up to 3 months, herpes simplex, 20 mg/kg every 8 hours for 14 days (21 days if CNS involvement); varicella–zoster [unlicensed use] 10–20 mg/kg every 8 hours for at least 7 days; **CHILD** 3 months–12 years, herpes simplex or varicella–zoster, 250 mg/m² every 8 hours usually for 5 days, doubled to 500 mg/m² every 8 hours for varicella–zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis, possibly for 14–21 days).

- **By topical application**, see section 13.10.3 (skin) and section 11.3.3 (eye).

**Note** Aciclovir doses in BNF may differ from those in product literature.
## FAMCICLOVIR

**Note** Famciclovir is a pro-drug of penciclovir

### Indications
See under Dose

### Cautions
Interactions: Appendix 1 (famciclovir)

### Hepatic impairment
Usual dose in well compensated liver disease (information not available on decompensated)

### Renal impairment
Reduce dose; consult product literature

### Pregnancy
Manufacturer advises avoid unless potential benefit outweighs risk

### Breast-feeding
No information available—present in milk in animal studies

### Side-effects
Nausea, vomiting, abdominal pain, diarrhoea; headache, fatigue, sweating; rare confusion; very rarely jaundice, dizziness, drowsiness, hallucinations, thrombocytopenia, rash (including Stevens-Johnson syndrome); also reported, constipation and fever

### Dose
- Herpes zoster treatment, 500 mg 3 times daily for 7 days or 750 mg 1–2 times daily for 7 days (in immunocompromised, 500 mg 3 times daily for 10 days)
- Genital herpes, treatment of first episode, 250 mg 3 times daily for 5 days, longer if new lesions appear during treatment or if healing incomplete (500 mg twice daily for 5–10 days in immunocompromised or HIV-positive patients); treatment of recurrent infection, 125 mg twice daily for 5 days or 1 g twice daily for 1 day (500 mg twice daily for 5–10 days in immunocompromised or HIV-positive patients)
- Genital herpes, suppression, 250 mg twice daily (500 mg twice daily in immunocompromised or HIV-positive patients); therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences
- Non-genital herpes simplex, treatment in the immunocompromised, 500 mg twice daily for 7 days
- **Child** not recommended

**Note** Famciclovir doses in BNF may differ from those in product literature

**Famciclovir (Non-proprietary)**

<table>
<thead>
<tr>
<th>Tablets</th>
<th>famciclovir 125 mg</th>
<th>net price</th>
<th>10-tab pack = £34.98; 250 mg, 15-tab pack = £109.49, 21-tab pack = £152.34, 56-tab pack = £408.74; 500 mg, 14-tab pack = £199.57, 30-tab pack = £433.69, 56-tab pack = £831.46; 750 mg, 7-tab pack = £143.05. Label: 9</th>
</tr>
</thead>
</table>

**Famvir® (Novartis)**

| Tablets | famciclovir 125 mg, net price 10-tab pack = £37.12; 250 mg, 15-tab pack = £111.35, 21-tab pack = £155.87; 56-tab pack = £415.67; 500 mg, 14-tab pack = £207.86, 30-tab pack = £445.28, 56-tab pack = £831.46, 750 mg, 7-tab pack = £148.79. Label: 9 |

## VALACICLOVIR

**Note** Valaciclovir is a pro-drug of aciclovir

### Indications
Treatment of herpes zoster; treatment of initial and suppression of recurrent herpes simplex infections of skin and mucous membranes including initial and recurrent genital herpes; reduction of transmission of genital herpes; prevention of cytomegalovirus disease following solid organ transplantation when valganciclovir or ganciclovir cannot be used

### Cautions
See under Aciclovir

### Hepatic impairment
Manufacturer advises caution with high doses used for herpes labialis and prevention of cytomegalovirus disease—no information available

### Renal impairment
Maintain adequate hydration; for herpes zoster, 1 g every 12 hours if eGFR 30–50 mL/minute/1.73 m²; 1 g every 24 hours if eGFR 10–30 mL/minute/1.73 m²; 500 mg every 24 hours if eGFR less than 10 mL/minute/1.73 m²; for treatment of herpes simplex, 500 mg (1 g in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30 mL/minute/1.73 m²; for treatment of herpes labialis, if eGFR 30–50 mL/minute/1.73 m², initially 1 g, then 1 g 12 hours after initial dose (if eGFR 10–30 mL/minute/1.73 m², initially 500 mg, then 500 mg 12 hours after initial dose; if eGFR less than 10 mL/minute/1.73 m², 500 mg as a single dose); for suppression of herpes simplex, 250 mg (500 mg in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30 mL/minute/1.73 m²; for reduction of genital herpes transmission, 250 mg every 24 hours if eGFR less than 15 mL/minute/1.73 m²; reduce dose according to eGFR for cytomegalovirus prophylaxis following solid organ transplantation (consult product literature)

### Pregnancy
See under Aciclovir

### Breast-feeding
See under Aciclovir

### Side-effects
See under Aciclovir but neurological reactions more frequent with high doses

### Dose
- Herpes zoster, 1 g 3 times daily for 7 days; **Child** 12–18 years see BNF for Children
- Herpes simplex, treatment of first episode, 500 mg twice daily for 5 days, longer if new lesions appear during treatment or if healing incomplete (1 g twice daily for 10 days in immunocompromised or HIV-

---

**INOSINE PRANOBEK**

(Inosine acedoben dimepranol)

### Indications
See under Dose

### Cautions
History of gout or hyperuricaemia

### Renal impairment
Manufacturer advises caution; metabolised to uric acid

### Pregnancy
Manufacturer advises avoid

### Side-effects
Reversible increase in serum and urinary uric acid; less commonly nausea, vomiting, epigastric discomfort, headache, vertigo, fatigue, arthralgia, rashes and itching; rarely diarrhoea, constipation, anxiety, sleep disturbances, and polyuria

### Dose
- Muco-cutaneous herpes simplex, 1 g 4 times daily for 7–14 days
- Adjunctive treatment of genital warts, 1 g 3 times daily for 14–28 days
- Subacute sclerosing panencephalitis, 50–100 mg/kg daily in 6 divided doses

**Imunovir® (Newport)**

<table>
<thead>
<tr>
<th>Tablets</th>
<th>scored, inosine pranobex 500 mg, net price</th>
<th>100-tab pack = £39.50. Label: 9</th>
</tr>
</thead>
</table>

---

**BNF 61**

5.3.2 Herpesvirus infections
positive patients); treatment of recurrent infection, 500 mg twice daily for 3–5 days (1 g twice daily for 5–10 days in immunocompromised or HIV-positive patients); CHILD 12–18 years see BNF for Children

- Herpes labialis, treatment, ADULT and CHILD over 12 years, initially 2 g, then 2 g 12 hours after initial dose
- Herpes simplex, suppression, 500 mg daily in 1–2 divided doses (in immunocompromised or HIV positive patients, 500 mg twice daily); therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences; CHILD 12–18 years see BNF for Children
- Reduction of transmission of genital herpes, seek specialist advice, 500 mg once daily to be taken by the infected partner
- Prevention of cytomegalovirus disease following solid organ transplantation (preferably starting within 72 hours of transplantation), 2 g 4 times daily usually for 90 days; CHILD 12–18 years see BNF for Children

Valaciclovir (Non-proprietary) (GSK)

Tablets, valaciclovir 500 mg, net price 10-tab pack = £19.48, 42 tab-pack = £81.64. Label: 9

Valtrex® (GSK) (A)

Tablets, f/c, valaciclovir (as hydrochloride) 250 mg, net price 60-tab pack = £123.28; 500 mg, 10-tab pack = £20.59, 42-tab pack = £86.30. Label: 9

5.3.2 Cytomegalovirus infection

Recommendations for the optimum maintenance therapy of cytomegalovirus (CMV) infections and the duration of treatment are subject to rapid change.

Ganciclovir is related to aciclovir but it is more active against cytomegalovirus; it is also much more toxic than aciclovir and should therefore be prescribed only when the potential benefit outweighs the risks. Ganciclovir is administered by intravenous infusion for the initial treatment of CMV infection. Ganciclovir causes profound myelosuppression when given with zidovudine; the two should not normally be given together particularly during initial ganciclovir therapy. The likelihood of ganciclovir resistance increases in patients with a high viral load or in those who receive the drug over a long duration; cross-resistance to cidofovir is common.

Valaciclovir (see p. 394) is licensed for prevention of cytomegalovirus disease following renal transplantation.

Valganciclovir is an ester of ganciclovir which is licensed for the initial treatment and maintenance treatment of CMV retinitis in AIDS patients. Valganciclovir is also licensed for preventing CMV disease following solid organ transplantation from a cytomegalovirus-positive donor.

Foscarnet is also active against cytomegalovirus; it is toxic and can cause renal impairment.

Cidofovir is given in combination with probenecid for CMV retinitis in AIDS patients when ganciclovir and foscarnet are contra-indicated. Cidofovir is nephrotoxic.

For local treatment of CMV retinitis, see section 11.3.3.

CIDOFOVIR

Indications cytomegalovirus retinitis in AIDS patients for whom other drugs are inappropriate

Cautions monitor renal function (serum creatinine and urinary protein) and neutrophil count within 24 hours before each dose; co-treatment with probenecid and prior hydration with intravenous fluids necessary to minimise potential nephrotoxicity (see below); diabetes mellitus (increased risk of ocular hypotony); interactions: Appendix 1 (cidofovir)

Nephrotoxicity Do not initiate treatment in renal impairment (assess creatinine clearance and proteinuria—consult product literature); discontinue treatment and give intravenous fluids if renal function deteriorates—consult product literature

Ocular disorders Regular ophthalmological examinations recommended; iritis and uveitis have been reported which may respond to a topical corticosteroid with or without a cycloplegic drug—discontinue cidofovir if no response to topical corticosteroid or if condition worsens, or if iritis or uveitis recurs after successful treatment

Contra-indications concomitant administration of potentially nephrotoxic drugs (discontinue potentially nephrotoxic drugs at least 7 days before starting cidofovir)

Renal impairment avoid if creatinine clearance less than 55 mL/minute; nephrotoxic

Pregnancy avoid (toxicity in animal studies); effective contraception required during and for 1 month after treatment; also men should avoid fathering a child during and for 3 months after treatment

Breast-feeding manufacturer advises avoid

Side-effects nephrotoxicity (see Cautions above); nausea, vomiting, diarrhoea; dyspnoea; headache, fever, asthenia; neutropenia; decreased intra-ocular pressure, iritis, uveitis (see Cautions above); alopecia, rash, less commonly Fanconi syndrome; also reported, hearing impairment and pancreatitis

Dose

- Initial (induction) treatment, ADULT over 18 years, by intravenous infusion over 1 hour, 5 mg/kg once weekly for 2 weeks (give probenecid and intravenous fluids with each dose, see below)
- Maintenance treatment, beginning 2 weeks after completion of induction, ADULT over 18 years, by intravenous infusion over 1 hour, 5 mg/kg once every 2 weeks (give probenecid and intravenous fluids with each dose, see below)

Probenecid co-treatment By mouth (preferably after food), probenecid 2 g 3 hours before cidofovir infusion followed by probenecid 1 g at 2 hours and 1 g at 8 hours after the end of cidofovir infusion (total probenecid 4 g); for cautions, contra-indications and side-effects of probenecid see section 10.1.4

Prior hydration Sodium chloride 0.9%, by intravenous infusion, 1 litre over 1 hour immediately before cidofovir infusion (if tolerated an additional 1 litre may be given over 1–3 hours, starting at the same time as the cidofovir infusion or immediately afterwards)

Vistide® (Gilead) (C)

Intravenous infusion, cidofovir 75 mg/mL, net price 5-mL vial = £653.22

Caution in handling Cidofovir is toxic and personnel should be adequately protected during handling and administration; if solution comes into contact with skin or mucosa, wash off immediately with water
**GANCICLOVIR**

**Indications**  life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients only; prevention of cytomegalovirus disease during immunosuppressive therapy following organ transplantation; local treatment of CMV retinitis (section 11.3.3)

**Cautions** close monitoring of full blood count (severe deterioration may require correction and possibly treatment interruption); history of cytopenia; potential carcinogen and teratogen; radiotherapy; ensure adequate hydration during intravenous administration; venous—infuse into vein with adequate flow preferably using plastic cannula; children (possible risk of long-term carcinogenic or reproductive toxicity); interactions: Appendix 1 (ganciclovir).

**Contra-indications** hypersensitivity to valganciclovir, ganciclovir, aciclovir, or valaciclovir; abnormally low haemoglobin, neutrophil, or platelet counts (consult product literature)

**Renal impairment** reduce dose if eGFR less than 70 mL/minute/1.73 m²; consult product literature

**Pregnancy** avoid—teratogenic risk; ensure effective contraception during treatment and barrier contraception for men during and for at least 90 days after treatment

**Breast-feeding** avoid—present in milk in unquantified quantities

**Side-effects** diarrhoea, nausea, vomiting, dyspepsia, abdominal pain, constipation, flatulence, dysphagia, taste disturbance, hepatic dysfunction; dysphoria, chest pain, cough; headache, insomnia, convulsions, dizziness, peripheral neuropathy, depression, anxiety, confusion, abnormal thinking, fatigue, weight loss, anorexia; infection, pyrexia, night sweats; anaemia, leucopenia, thrombocytopenia, pancytopenia, renal impairment; myalgia, arthralgia; macular oedema, retinal detachment, vitreous floaters, eye pain; ear pain; dermatitis, pruritus; injection-site reactions; less commonly mouth ulcers, pancreatitis, arrhythmias, hypotension, anaphylactic reactions, psychosis, tremor, male infertility, haematuria, disturbances in hearing and vision, and alopecia

**Dose**

- By intravenous infusion, initially (induction) 5 mg/kg every 12 hours for 14–21 days for treatment or for 7–14 days for prevention; maintenance (for patients at risk of relapse of retinitis) 6 mg/kg daily on 5 days per week or 5 mg/kg daily until adequate recovery of immunity; if retinitis progresses initial induction treatment may be repeated; CHILD under 18 years, see **BNF for Children**

**Cymevene** (Roche).

**Intravenous infusion**, powder for reconstitution, ganciclovir (as sodium salt). Net price 500-mg vial = £29.77

**Electrolytes** Na+ 2 mmol/500-mg vial

**Caution in handling** Ganciclovir is toxic and personnel should be adequately protected during handling and administration; if solution comes into contact with skin or mucosa, wash off immediately with soap and water

**VALGANCICLOVIR**

**Note** Valganciclovir is a pro-drug of ganciclovir

**Indications** induction and maintenance treatment of cytomegalovirus retinitis in AIDS patients; prevention of cytomegalovirus disease following solid organ transplantation from a cytomegalovirus-positive donor.

**Cautions** see under Ganciclovir

**Contra-indications** see under Ganciclovir

**Renal impairment** reduce dose; consult product literature

**Pregnancy** see under Ganciclovir

**Breast-feeding** see under Ganciclovir

**Side-effects** see under Ganciclovir

**Dose**

- CMV retinitis, induction, ADULT over 18 years, 900 mg twice daily for 21 days then 900 mg once daily; induction regimen may be repeated if retinitis progresses

- Prevention of cytomegalovirus disease following solid organ transplantation (starting within 10 days of...

**FOSCARNET SODIUM**

**Indications** cytomegalovirus disease [licensed for cytomegalovirus retinitis in AIDS patients only]; mucocutaneous herpes simplex virus infections unresponsive to aciclovir in immunocompromised patients

**Cautions** monitor electrolytes, particularly calcium and magnesium; monitor serum creatinine every second day during induction and every week during maintenance; ensure adequate hydration; avoid rapid infusion; interactions: Appendix 1 (foscarnet)

**Renal impairment** reduce dose; consult product literature

**Pregnancy** manufacturer advises avoid

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** nausea, vomiting, diarrhoea (occasionally constipation and dyspepsia), abdominal pain, anorexia; changes in blood pressure and ECG; headache, fatigue, mood disturbances (including psychosis), anaemia, paraesthesia, convulsions, tremor, dizziness, and other neurological disorders; rash; impairment of renal function including acute renal failure; hypocalcaemia (sometimes symptomatic) and other electrolyte disturbances; abnormal liver function tests; decreased haemoglobin concentration, leucopenia, granulocytopenia, thrombocytopenia; thrombophlebitis if given undiluted by peripheral vein; genital irritation and ulceration (due to high concentrations excreted in urine); isolated reports of pancreatitis

**Dose**

- CMV disease [licensed for CMV retinitis only], by intravenous infusion, initially (induction) 60 mg/kg every 8 hours or 90 mg/kg every 12 hours, for 2–3 weeks; maintenance 60 mg/kg daily, increased to 90–120 mg/kg if tolerated; if disease progresses on maintenance dose, repeat induction regimen

- Mucocutaneous herpes simplex infection, by intravenous infusion, 40 mg/kg every 8 hours for 2–3 weeks or until lesions heal

**Note** Foscarnet doses in BNF may differ from those in product literature

**Foscavir** (Clinigen).

**Intravenous infusion**, foscarnet sodium hexahydrate 24 mg/mL, net price 250-mL bottle = £34.49
transplantation), **ADULT** over 18 years, 900 mg once daily for 100 days (for 100–200 days following kidney transplantation)

**Note** Oral valganciclovir 900 mg twice daily is equivalent to intravenous ganciclovir 5 mg/kg twice daily

**Valcyte** (Roche) tablets, pink, 5/c, valganciclovir (as hydrochloride) 450 mg, net price 60-tab pack = £1081.46. Label: 21

**Oral solution**, tutti-frutti flavoured, valganciclovir (as hydrochloride) 250 mg/5 mL when reconstituted with water, net price 100 mL = £239.32. Label: 21

**Caution in handling** Valganciclovir is a potential teratogen and carcinogen and caution is advised when handling the powder, reconstituted solution, or broken tablets; if these come into contact with skin or mucosa, wash off immediately with water; avoid inhalation of powder

### 5.3.3 Viral hepatitis

Treatment for viral hepatitis should be initiated by a specialist. The management of uncomplicated acute viral hepatitis is largely symptomatic. Early treatment of acute hepatitis C with interferon alfa [unlicensed indication] may reduce the risk of chronic infection. Hepatitis B and hepatitis C viruses are major causes of chronic hepatitis. For details on immunisation against hepatitis A and B infections, see section 14.4 (active immunisation), section 14.5.1 (passive immunisation against hepatitis A), and section 14.5.2 (passive immunisation against hepatitis B).

**Chronic Hepatitis B** Peginterferon alfa (section 8.2.4) is an option for the initial treatment of chronic hepatitis B and may be preferable to **interferon alfa**. The use of peginterferon alfa and interferon alfa is limited by a response rate of 30–40% and relapse is frequent. Treatment should be discontinued if no improvement occurs after 4 months. The manufacturers of peginterferon alfa-2a and interferon alfa contraindicate use in decompensated liver disease, but low doses can be used with great caution in these patients. Although interferon alfa is contra-indicated in patients receiving immunosuppressant treatment (or who have received it recently), caution use of peginterferon alfa-2a may be justified in some cases.

**Entecavir** or **tenofovir disoproxil** (see p. 385) are options for the initial treatment of chronic hepatitis B. If the response is inadequate after 6–9 months of treatment, a change in treatment should be considered. Other drugs that are licensed for the treatment of chronic hepatitis B include **adefovir dipivoxil**, lamivudine (see p. 384), or telbivudine (but see NICE guidance below).

Entecavir alone, tenofovir disoproxil alone, or a combination of lamivudine with either adefovir dipivoxil or tenofovir disoproxil can be used in patients with decompensated liver disease; entecavir is not licensed for these patients.

If drug-resistant hepatitis B virus emerges during treatment, another antiviral drug with a different resistance profile should be added. Hepatitis B viruses with reduced susceptibility to lamivudine have emerged following extended therapy. Adefovir or tenofovir can be given with lamivudine in lamivudine-resistant chronic hepatitis B; telbivudine or entecavir should not be used because cross-resistance can occur.

If there is no toxicity or loss in efficacy, treatment with adefovir, entecavir, lamivudine, telbivudine, or tenofovir is usually continued until 6 months after adequate seroconversion has occurred. Treatment is usually continued long-term in patients with decompensated liver disease.

Tenofovir, or a combination of tenofovir with either emtricitabine or lamivudine may be used with other antiretrovirals, as part of ‘highly active antiretroviral therapy’ (section 5.3.1) in patients who require treatment for both HIV and chronic hepatitis B. If patients infected with both HIV and chronic hepatitis B only require treatment for chronic hepatitis B, they should receive antivirals that are not active against HIV, such as peginterferon alfa or adefovir. Treatment may be continued long-term, even if adequate seroconversion occurs. Management of these patients should be co-ordinated between HIV and hepatology specialists.

**NICE guidance**

**Entecavir and telbivudine for chronic hepatitis B (August 2008)**

Entecavir is an option for the treatment of chronic hepatitis B.

Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop.

**NICE guidance**

**Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009)**

Tenofovir is an option for the treatment of chronic hepatitis B.

**Chronic Hepatitis C** Before starting treatment, the genotype of the infecting hepatitis C virus should be determined and the viral load measured as this may affect the choice and duration of treatment. A combination of **ribavirin** (see p. 400) and **peginterferon alfa** (section 8.2.4) is used for the treatment of chronic hepatitis C (see NICE guidance, below). The combination of ribavirin and interferon alfa is less effective than the combination of peginterferon alfa and ribavirin. Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Ribavirin monotherapy is ineffective.

**NICE guidance**

**Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)**

The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (‘watchful waiting’). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated.
NICE guidance

Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)

The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:

- not previously treated with interferon alfa or peginterferon alfa;
- treated previously with interferon alfa alone or in combination with ribavirin;
- whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;
- co-infected with HIV.

Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.

Full guidance available at www.nice.org.uk/TA075.

ADEFOVIR DIPIVOXIL

Indications chronic hepatitis B infection with either compensated liver disease, with evidence of viral replication, and histologically documented active liver inflammation and fibrosis or decompensated liver disease

Cautions monitor liver function tests every 3 months, and viral and serological markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation); monitor renal function before treatment then every 3 months, more frequently in renal impairment or in patients receiving nephrotoxic drugs; elderly; discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis

Renal impairment 10 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m²; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m²; consult product literature

Pregnancy toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk; effective contraception required during treatment

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects nausea, vomiting, dyspepsia, diarrhoea, raised serum amylase and lipase, headache, fatigue, dizziness, sleep disturbances; less commonly thrombocytopaenia, rash, alopecia

Dose

- ADULT over 18 years, not previously treated with nucleoside analogues, 500 micrograms once daily
- ADULT over 18 years with lamivudine-resistant chronic hepatitis B (but see notes above), 1 mg once daily; consider other treatment if inadequate response after 6 months

Counselling To be taken at least 2 hours before or 2 hours after food

Baraclude® (Bristol-Myers Squibb) Tablets, f/c, entecavir (as monohydrate) 500 micrograms (white), net price 30-tab pack = £363.26; 1 mg (pink), 30-tab pack = £363.26. Counselling, administration

Oral solution, entecavir (as monohydrate) 50 micrograms/mL, net price 210-mL pack (orange-flavoured) = £423.80. Counselling, administration

Tельбивудин

Indications chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis

Cautions monitor liver function tests every 3 months, and viral and serological markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation); lamivudine-resistant chronic hepatitis B—risk of telbivudine resistance; discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis

Renal impairment 600 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m²; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m²

Pregnancy manufacturer advises use only if potential benefit outweighs risk

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Dose

- ADULT over 18 years, 10 mg once daily

Hepsera® (Gilead) Tablets, adefovir dipivoxil 10 mg, net price 30-tab pack = £296.73

ENTECAVIR

Indications chronic hepatitis B infection with compensated liver disease, evidence of viral replication,
### 5.3.4 Influenza

**Side-effects** nausea, diarrhoea, abdominal pain, raised serum amylase and lipase; cough; dizziness, headache, fatigue; rash; less commonly; taste disturbance, arthralgia, myalgia, myopathy (discontinue treatment), and peripheral neuropathy; also reported, lactic acidosis and rhabdomyolysis.

**Dose**
- **ADULT** and **CHILD over 16 years, 600 mg once daily**

**Sebivo** (Novartis) 

Tablets, f/c, telbivudine 600 mg, net price 28-tab pack = £290.33. Counselling, muscle effects, peripheral neuropathy

**Oseltamivir**

**Oseltamivir in children under 1 year of age**

Data on the use of oseltamivir in children under 1 year of age is limited. Furthermore oseltamivir may be ineffective in neonates because they may not be able to metabolise oseltamivir to its active form. In exceptional circumstances, oseltamivir can be used (under specialist supervision) for the treatment or post-exposure prophylaxis of influenza in children under 1 year of age. The Department of Health has advised (May 2009) that during a pandemic, treatment with oseltamivir can be overseen by healthcare professionals experienced in assessing children.

**Pregnancy and breast-feeding**

Although safety data are limited, either oseltamivir or zanamivir can be used in women who are pregnant or breast-feeding when the potential benefit outweighs the risk (e.g. during a pandemic). Zanamivir is preferred during pregnancy; however, oseltamivir is recommended during severe infection or when zanamivir cannot be used.

Oseltamivir is the preferred drug in women who are breast-feeding.

**AMANTADINE HYDROCHLORIDE**

**Indications** see under Dose; parkinsonism (section 4.9.1)

**Cautions** section 4.9.1

**Contra-indications** section 4.9.1

---

1. National surveillance schemes, including those run by the Health Protection Agency, should be used to indicate when influenza is circulating in the community.
2. The Department of Health in England has advised (November 2010) that ‘at risk patients’ also includes women who are pregnant.
Renal impairment section 4.9.1

Pregnancy section 4.9.1

Breast-feeding section 4.9.1

Side-effects section 4.9.1

Dose

- Influenza (see also notes above), ADULT and CHILD over 10 years, treatment, 100 mg daily for 4–5 days; prophylaxis, 100 mg daily usually for 6 weeks or with influenza vaccination for 2–3 weeks after vaccination

Lysovir (Alliance)...

Capsules, red-brown, amantadine hydrochloride 100 mg, net price 5-cap pack = £2.40, 14-cap pack = £3.76. Counselling, driving

Symmetrel (Alliance)...

Section 4.9.1

OSELTMIVIR

Indications see notes above

Renal impairment for treatment, use 75 mg once daily or 30 mg twice daily if eGFR 10–30 mL/minute/1.73 m²; for prevention, use 75 mg every 48 hours or 30 mg once daily if eGFR 10–30 mL/minute/1.73 m²; avoid for treatment and prevention if eGFR less than 10 mL/minute/1.73 m²

Pregnancy use only if potential benefit outweighs risk (e.g. during a pandemic); see also p. 399

Breast-feeding amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic); see also p. 399

Side-effects nausea, vomiting, abdominal pain, diarrhoea; headache; conjunctivitis; less commonly eczema; also reported hepatitis, gastro-intestinal bleeding, arrhythmias, neuropsychiatric disorders (more frequent in children and adolescents), visual disturbances, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Dose

- Prevention of influenza, ADULT and CHILD over 13 years, 75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic; CHILD under 1 month (see notes above), 2 mg/kg once daily for 10 days for post-exposure prophylaxis; 1–3 months (see notes above), 2.5 mg/kg once daily for 10 days for post–exposure prophylaxis; 3 months–1 year (see notes above), 3 mg/kg once daily for 10 days for post-exposure prophylaxis; 1–13 years, body-weight under 15 kg, 30 mg once daily for 10 days for post-exposure prophylaxis (for up to 6 weeks during an epidemic); body-weight 15–23 kg, 45 mg once daily for 10 days for post-exposure prophylaxis (for up to 6 weeks during an epidemic); body-weight 23–40 kg, 60 mg once daily for 10 days for post-exposure prophylaxis (for up to 6 weeks during an epidemic); body-weight over 40 kg, adult dose

- Treatment of influenza, ADULT and CHILD over 13 years, 75 mg every 12 hours for 5 days; CHILD under 1 month (see notes above), 2 mg/kg every 12 hours for 5 days; 1–3 months (see notes above), 2.5 mg/kg every 12 hours for 5 days; 3 months–1 year (see notes above), 3 mg/kg every 12 hours for 5 days; 1–13 years, body-weight under 15 kg, 30 mg every 12 hours for 5 days, body-weight 15–23 kg, 45 mg every 12 hours for 5 days, body-weight 23–40 kg, 60 mg every 12 hours for 5 days, body-weight over 40 kg, adult dose

Note Not licensed for use in children under 1 year of age unless there is a pandemic

5.3.5 Respiratory syncytial virus

Ribavirin inhibits a wide range of DNA and RNA viruses. It is licensed for administration by inhalation for the treatment of severe bronchiolitis caused by the respiratory syncytial virus (RSV) in infants, especially when they have other serious diseases. However, there is no evidence that ribavirin produces clinically relevant benefit in RSV bronchiolitis. Ribavirin is given by mouth with peginterferon alfa or interferon alfa for the treatment of chronic hepatitis C infection (see Viral Hepatitis, p. 397). Ribavirin is also effective in Lassa fever (unlicensed indication).
Palivizumab is a monoclonal antibody licensed for preventing serious lower respiratory-tract disease caused by respiratory syncytial virus in children at high risk of the disease; it should be prescribed under specialist supervision and on the basis of the likelihood of hospitalisation.

Palivizumab is recommended for:

- children under 9 months of age with chronic lung disease (defined as requiring oxygen for at least 28 days from birth) and who were born preterm;
- children under 6 months of age with haemodynamically significant, acyanotic congenital heart disease who were born preterm.

Palivizumab should be considered for:

- children under 2 years of age with severe combined immunodeficiency syndrome;
- children under 1 year of age who require long-term ventilation;
- children 1–2 years of age who require long-term ventilation and have an additional co-morbidity (including cardiac disease or pulmonary hypertension).

**PALIVIZUMAB**

**Indications** see notes above

**Cautions** moderate to severe acute infection or febrile illness; thrombocytopenia; serum-palivizumab concentration may be reduced after cardiac surgery

**Contra-indications** hypersensitivity to humanised monoclonal antibodies

**Side-effects** fever, injection-site reactions, nervousness; less commonly diarrhoea, vomiting, constipation, haemorrhage, rhinitis, cough, wheeze, pain, drowsiness, asthenia, hypokinesia, leucopenia, and rash; also reported, apnoea, hypersensitivity reactions (including anaphylaxis), convulsions and thrombocytopenia

**Dose**

- By intramuscular injection (preferably in anterolateral thigh), 15 mg/kg once a month during season of RSV risk (child undergoing cardiac bypass surgery, 15 mg/kg as soon as stable after surgery, then once a month during season of risk); injection volume over 1 mL should be divided between more than one site

**Synagis®** (Abbott) ▼ [Ribavi]

**Injection** powder for reconstitution, palivizumab, net price 50-mg vial = £360.40; 100-mg vial = £663.11

**5.3.5 Respiratory syncytial virus 401**

**treatment and for 4 months after treatment in women and for 7 months after treatment in men; routine monthly pregnancy tests recommended; condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen); cardiac disease (assessment including ECG recommended before and during treatment—discontinue if deterioration); goitre, determine full blood count, platelets, electrolytes, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically—should discontinue if abnormalities or laboratory abnormalities develop (consult product literature); eye examination recommended before treatment; eye examination also recommended during treatment if pre-existing ophthalmological disorder or if decrease in vision reported—discontinue treatment if ophthalmological disorder deteriorates or if new ophthalmological disorder develops; test thyroid function before starting and then every 3 months in children; risk of growth retardation in children, the reversibility of which is uncertain—if possible, consider starting treatment after pubertal growth spurt

**Interactions:** Appendix 1 (ribavirin)

**Contra-indications** Specific contra-indications for oral treatment: Severe cardiac disease, including unstable or uncontrolled cardiac disease in previous 6 months; haemoglobinopathies; severe debilitating medical conditions; autoimmune disease (including autoimmune hepatitis); uncontrolled severe psychiatric history; history of severe psychiatric condition in children

**Hepatic impairment** no dosage adjustment required; use oral ribavirin with caution in severe hepatic dysfunction or decompensated cirrhosis

**Renal impairment** plasma-ribavirin concentration increased; avoid oral ribavirin unless essential if eGFR less than 50 mL/minute/1.73 m²—monitor haemoglobin concentration closely

**Pregnancy** avoid; teratogenicity in animal studies; see also Cautions above

**Breast-feeding** avoid—no information available

**Side-effects**

Specific side-effects for inhaled treatment

- Worsening respiration, bacterial pneumonia, and pneumothorax
- Haemolytic anaemia (anaemia may be improved by epoetin); also (in combination with peginterferon alfa or interferon alfa) nausea, vomiting, dyspepsia, abdominal pain, flatulence, constipation, diarrhoea, colitis, chest pain, palpitation, tachycardia, peripheral oedema, changes in blood pressure, syncope, flushing, cough, dyspnoea, headache, dizziness, anaemia, impaired concentration and memory, sleep disturbances, abnormal dreams, anxiety, depression, suicidal ideation (more frequent in children), psychoses, dysphagia, weight loss, dysphonia, paraesthesia, hypo/hyperthermia, rashes, sweating, psoriasis, photosensitivity, and acne; hyperglycaemia, menstrual disturbances, breast pain, arthralgia, sexual dysfunction, micturition disorders, leucopenia, thrombocytopenia, lymphadenopathy, dehydration, hypocalcaemia, myalgia, arthralgia, hyperuricaemia, visual disturbances, eye pain, dry eyes, hearing impairment, tinnitus, earache, dry mouth, taste disturbances, mouth ulcers, stomatitis, glositis, tooth disorders, gingivitis, alopecia, pruritus, dry skin, rash (including very rarely Stevens-Johnson syndrome and toxic epidermal necrolysis), increased sweating, psoriasis, photosensitivity, and acne; less commonly pancreatitis, gastro-intestinal bleeding, and hypertriglyceridaemia, rarely peptic ulcer, arthralgia, cardiomyopathy, myocardial infarction, pericarditis, stroke, interstitial pneumonitis, pulmonary embolism, seizures, renal failure, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, optic neuropathy, and retinal haemorrhage; very rarely aplastic anaemia and peripheral ischaemia, in children also growth retardation (including decrease in height and weight), palor, tachypnoea, hyperkinesia, vini- lism, and skin discoloration

**Dose**

- See preparations below

---

1. For details of the preterm age groups included in the recommendations, see *Immunisation against Infectious Disease* (2006), available at www.dh.gov.uk/immunisation
5.4 Antiprotozoal drugs

Copegus® (Roche) Tablets, f/c, ribavirin 200 mg (pink), net price 42-tab pack = £78.50, 112-tab pack = £236.65, 168-tab pack = £369.98; 400 mg (red-brown), 56-tab pack = £246.65. Label: 21

**Dose** chronic hepatitis C (in combination with interferon alfa or peginterferon alfa), ADULT over 18 years, body-weight under 75 kg, 400 mg in the morning and 600 mg in the evening; body-weight 75 kg and over, 600 mg twice daily

Note: Patients with chronic hepatitis C genotype 2 or 3 (not previously treated), or patients infected with HIV and hepatitis C require a lower dose of Copegus® (in combination with peginterferon alfa), usual dose 400 mg twice daily

Rebetol® (Schering-Plough) Capsules, ribavirin 200 mg, net price 94-cap pack = £160.69, 140-cap pack = £267.81, 168-cap pack = £321.38. Label: 21

**Oral solution**, ribavirin 200 mg/5 mL, net price 100 mL (bubble-gum-flavoured) = £67.08. Label: 21

**Dose** chronic hepatitis C (in combination with interferon alfa or peginterferon alfa), ADULT over 18 years, body-weight under 65 kg, 400 mg twice daily; body-weight 65–81 kg, 600 mg twice daily; body-weight 81–105 kg, 600 mg twice daily; body-weight over 105 kg, 600 mg in the morning and 600 mg in the evening; body-weight 75 kg and over, 600 mg twice daily

**Inhalation**, ribavirin 6 g for reconstitution with 300 mL water for injections. Net price 3 × 6-g vials = £349.00

**Dose** bronchiolitis, by aerosol inhalation or nebulisation (via small particle aerosol generator) of solution containing 20 mg/mL for 12–18 hours for at least 3 days; max. 7 days

Virazole® (Meda) Inhalation, ribavirin 6 g for reconstitution with 300 mL water for injections. Net price 3 × 6-g vials = £349.00

**Dose** bronchiolitis, by aerosol inhalation or nebulisation (via small particle aerosol generator) of solution containing 20 mg/mL for 12–18 hours for at least 3 days; max. 7 days

5.4.1 Antimalarials

5.4.2 Amoebicides

5.4.3 Trichomonacides

5.4.4 Antigiardial drugs

5.4.5 Leishmaniacides

5.4.6 Trypanocides

5.4.7 Drugs for toxoplasmosis

5.4.8 Drugs for pneumocystis pneumonia

Advice on specific problems available from:

**Advice for healthcare professionals**

HPA (Health Protection Agency) Malaria (020) 7637 0248 Reference Laboratory (fax) (prophylaxis only)

www.hpa.org.uk/infections/topics_az/malaria

National Travel Health Network and Centre 0845 602 6712

Travel Medicine Team, Health Protection Scotland (registered users of Travax only) 0141 300 1100 (weekdays 2–4 p.m. only)

www.travax.nhs.uk (for registered users of the NHS Travax website only)

Birmingham (0121) 424 0357

Liverpool (0151) 705 3100

London 0845 155 5000 (treatment)

Oxford (01865) 225 430

5.4.1 Antimalarials

Malarone

Alternatively, Malarone® or Riamet® may be given instead of quinine. It is not necessary to give

1. Valid for quinine hydrochloride, dihydrochloride, and sulphate; not valid for quinine bisulphate which contains a correspondingly smaller amount of quinine.
doxycycline, clindamycin or pyrimethamine with sulfadoxine after Malarone® or Riamet® treatment.

The adult dose of Malarone® by mouth is:
- 4 ('standard') tablets once daily for 3 days.

The dose of Riamet® by mouth for adult with body-weight over 35 kg is:
- 4 tablets initially, followed by 5 further doses of 4 tablets each given at 8, 24, 36, 48, and 60 hours (total 24 tablets over 60 hours).

**Parenteral.** If the patient is seriously ill or unable to take tablets, quinine should be given by intravenous infusion [unlicensed]. The adult dosage regimen for quinine by infusion is:
- Loading dose of 20 mg/kg (up to maximum 1.4 g) of quinine salt infused over 4 hours then 8 hours after the start of the loading dose, maintenance dose of 10 mg/kg (up to maximum 700 mg) of quinine salt infused over 4 hours every 4 hours (until patient can swallow tablets to complete the 7-day course together with or followed by either doxycycline or clindamycin as above).

Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ‘named-patient’ use.

**Children**

**Oral.** Quinine is well tolerated by children although the salts are bitter. The dosage regimen for quinine by mouth for children is:
- 10 mg/kg (of quinine salt3; max. 600 mg) every 8 hours for 7 days together with or followed by Clindamycin 7–15 mg/kg (max. 450 mg) every 8 hours for 7 days [unlicensed indication] or in children over 12 years, doxycycline 200 mg once daily for 7 days or if the parasite is likely to be sensitive, pyrimethamine with sulfadoxine as a single dose [unlicensed; up to 4 years and body-weight over 5 kg, pyrimethamine 12.5 mg with sulfadoxine 250 mg; 5–6 years, pyrimethamine 25 mg with sulfadoxine 500 mg; 7–9 years, pyrimethamine 37.5 mg with sulfadoxine 750 mg; 10–14 years, pyrimethamine 50 mg with sulfadoxine 1 g; 14–18 years, pyrimethamine 75 mg with sulfadoxine 1.5 g

Alternatively, Malarone® or Riamet® may be given instead of quinine; it is not necessary to give clindamycin, doxycycline, or pyrimethamine with sulfadoxine after Malarone® or Riamet® treatment. The dose regimen for Malarone® by mouth for children over 40 kg is the same as for adults (see above); the dose regimen for Malarone® for smaller children is reduced as follows:
- body-weight 5–8 kg, 2 ‘paediatric’ tablets once daily for 3 days; body-weight 9–10 kg, 3 ‘paediatric’ tablets once daily for 3 days; body-weight 11–20 kg, 1 ‘standard’ tablet once daily for 3 days; body-weight 21–30 kg, 2 ‘standard’ tablets once daily for 3 days; body-weight 31–40 kg, 3 ‘standard’ tablets once daily for 3 days.

The dose regimen of Riamet® by mouth for children over 12 years and body-weight over 35 kg is the same as for adults (see above). The dose regimen for Riamet® for children under 12 years is as follows:
- body-weight 5–15 kg 1 tablet initially, followed by 5 further doses of 1 tablet each given at 8, 24, 36, 48, and 60 hours (total 6 tablets over 60 hours); body-weight 15–25 kg 2 tablets initially, followed by 5 further doses of 2 tablets each given at 8, 24, 36, 48, and 60 hours (total 12 tablets over 60 hours); body-weight 25–35 kg 3 tablets initially, followed by 5 further doses of 3 tablets each given at 8, 24, 36, 48, and 60 hours (total 18 tablets over 60 hours)

**Parenteral.** The dose regimen for quinine by intravenous infusion for children is calculated on a mg/kg basis as for adults (see above).

**Pregnancy**

Falciparum malaria is particularly dangerous in pregnancy, especially in the last trimester. The adult treatment doses of oral and intravenous quinine given above (including the loading dose) can safely be given to pregnant women. Clindamycin 450 mg every 8 hours for 7 days [unlicensed indication] should be given with or after quinine. Doxycycline should be avoided in pregnancy (affects teeth and skeletal development); pyrimethamine with sulfadoxine, Malarone®, and Riamet® are also best avoided until more information is available. Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ‘named-patient’ use.

**Benign malarials (treatment)**

Benign malaria is usually caused by Plasmodium vivax and less commonly by P. ovale and P. malariae. Chloroquine® is the drug of choice for the treatment of benign malarials (but chloroquine-resistant P. vivax infection has been reported from Indonesia, New Guinea and some adjacent islands).

The adult dosage regimen for chloroquine by mouth is:
- initial dose of 620 mg of base then
- a single dose of 310 mg of base after 6 to 8 hours

Chloroquine alone is adequate for P. malariae infections but in the case of P. vivax and P. ovale, a radical approach is required for radical cure.

---

1. In intensive care units the loading dose can alternatively be given as quinine salt® 7 mg/kg infused over 30 minutes followed immediately by 10 mg/kg over 4 hours then (after 8 hours) maintenance dose as described.
2. Important: the loading dose of 20 mg/kg should not be used if the patient has received quinine or mefloquine during the previous 12 hours.
3. Valid for quinine hydrochloride, dihydrochloride, and sulphate; not valid for quinine bisulphate which contains a correspondingly smaller amount of quinine.
4. Maintenance dose should be reduced to 5–7 mg/kg of quinine salt® in patients with severe renal impairment, severe hepatic impairment, or if parentral treatment is required for more than 48 hours.
5. For the treatment of chloroquine-resistant benign malaria, Malarone® [unlicensed indication], quinine, or Riamet® [unlicensed indication] can be used; as with chloroquine, primaquine should be given for radical cure.
cure (to destroy parasites in the liver and thus prevent relapses) is required. This is achieved with primaquine\textsuperscript{1} [unlicensed] given after chloroquine; in P. vivax infection primaquine is given in an adult dosage of 30 mg daily for 14 days and for P. ovale infection it is given in an adult dosage of 15 mg daily for 14 days.

**Children** The dosage regimen of chloroquine for benign malaria in children is:
- initial dose of 10 mg/kg of base (max. 620 mg) then
  - a single dose of 5 mg/kg of base (max. 310 mg) after 6–8 hours
  - a single dose of 5 mg/kg of base (max. 310 mg) daily for 2 days

For a *radical cure*, primaquine\textsuperscript{1} [unlicensed] is then given to children over 6 months of age; specialist advice should be sought for children under 6 months of age. In *P. vivax* infection primaquine is given in a dose of 500 micrograms/kg (max. 30 mg) daily for 14 days, and for *P. ovale* infection it is given in a dose of 250 micrograms/kg (max. 15 mg) daily for 14 days.

**Parenteral** If the patient is unable to take oral therapy, quinine can be given by *intravenous infusion* [unlicensed]. The dose (for adults and children) is 10 mg/kg (max. 700 mg) of quinine salt\textsuperscript{2} infused over 4 hours every 8 hours, changed to oral chloroquine as soon as the patient’s condition permits.

**Pregnancy** The adult treatment doses of chloroquine can be given for benign malaria. In the case of *P. vivax* or *P. ovale*, however, the radical cure with primaquine should be **postponed** until the pregnancy is over; instead chloroquine should be continued at a dose of 310 mg each week during the pregnancy.

### Prophylaxis against malaria

The recommendations on prophylaxis reflect guidelines agreed by UK malaria specialists; the advice is aimed at residents of the UK who travel to endemic areas. The recommendations on prophylaxis reflect guidelines agreed by UK malaria specialists and may differ from advice in product literature. Weight is a better guide than age. If in doubt telephone centres listed on p. 402.

#### Risk of exposure to malaria
- **Risk factors:** age, pregnancy, renal or hepatic impairment, compliance with prophylactic regimen).

### Protection against bites

**Prophylaxis is not absolute,** and breakthrough infection can occur with any of the drugs recommended. Personal protection against being bitten is very important. Mosquito nets impregnated with permethrin provide the most effective barrier protection against insects; mats and vapourised insecticides are also useful. Diethyltoluamide (DEET) 20–50% in lotions, sprays, or roll-on formulations is safe and effective when applied to the skin of adults and children over 2 months of age. It can also be used during pregnancy and breast-feeding. The duration of protection varies according to the concentration of DEET and is longest for DEET 50%. Long sleeves and trousers worn after dusk also provide protection.

### Length of prophylaxis

In order to determine tolerance and to establish habit, prophylaxis should generally be started one week (preferably 2–3 weeks in the case of mefloquine) before travel into an endemic area (or if not possible at earliest opportunity up to 1 or 2 days before travel); *Malarone*\textsuperscript{c} or doxycycline prophylaxis should be started 1–2 days before travel. Prophylaxis should be continued for **4 weeks after leaving** (except for *Malarone*\textsuperscript{c} prophylaxis which should be stopped 1 week after leaving).

In those requiring long-term prophylaxis, chloroquine and proguanil may be used for periods of over 5 years. Mefloquine is licensed for up to 1 year (although it has been used for up to 3 years without undue problems). Doxycycline can be used for up to 2 years. *Malarone*\textsuperscript{c} is licensed for use for up to 28 days but can be used for up to 1 year (and possibly longer) with caution. Specialist advice should be sought for long-term prophylaxis.

### Return from malarial region

It is important to be aware that any illness that occurs within 1 year and especially within 3 months of return might be malaria even if all recommended precautions against malaria were taken. Travellers should be warned of this and told that if they develop any illness **particularly within 3 months** of their return they should go immediately to a doctor and specifically mention their exposure to malaria.

**Children** Prophylactic doses are based on guidelines agreed by UK malaria experts and may differ from advice in product literature. Weight is a better guide than age. If in doubt telephone centres listed on p. 402.

### Epilepsy

Both chloroquine and mefloquine are unsuitable for malaria prophylaxis in individuals with a history of epilepsy. In areas **without chloroquine resistance** proguanil 200 mg daily alone is recommended; in areas with chloroquine resistance, doxycycline or *Malarone*\textsuperscript{c} may be considered; the metabolism of doxycycline may be influenced by antiepileptics (see interactions: Appendix 1 [tetracyclines]).

### Asplenia

Asplenic individuals (or those with severe splenic dysfunction) are at particular risk of severe malaria. If travel to malarious areas is unavoidable, rigorous precautions are required against contracting the disease.

### Renal impairment

**Avoidance (or dosage reduction)** of proguanil is recommended since it is excreted by the kidneys. *Malarone*\textsuperscript{c} should not be used for prophylaxis in patients with estimated glomerular filtration rate less than 30 mL/minute/1.73 m\textsuperscript{2}. Chloroquine is only partially excreted by the kidneys and reduction of the dose for prophylaxis is not required except in severe impairment. Mefloquine is considered to be appropriate.
to use in renal impairment and does not require dosage reduction. Doxycycline is also considered to be appropriate.

**Pregnancy**  Travel to malarious areas should be avoided during pregnancy; if travel is unavoidable, effective prophylaxis must be used. Chloroquine and proguanil can be given in the usual doses during pregnancy, but these drugs are not appropriate for most areas because their effectiveness has declined, particularly in Sub-Saharan Africa; in the case of proguanil, folic acid 5 mg daily should be given. The centres listed on p. 402 should be consulted for advice on prophylaxis in chloroquine-resistant areas. Although the manufacturer advises that mefloquine should not be used during pregnancy, particularly in the first trimester, unless the potential benefit outweighs the risk, studies of mefloquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas. Doxycycline is contra-indicated during pregnancy. Malaria® should be avoided during pregnancy unless there is no suitable alternative.

**Breast-feeding**  Prophylaxis is required in breast-fed infants, although antimalarials are present in milk, the amounts are too variable to give reliable protection.

**Anticoagulants**  Travellers taking warfarin should begin chemoprophylaxis at least 1 week (2–3 weeks for mefloquine) before departure. The INR should be measured before starting chemoprophylaxis, 7 days after starting, and after completing the course. For prolonged stays, the INR should be checked at regular intervals.

### Specific recommendations

Where a journey requires two regimens, the regimen for the higher risk area should be used for the whole journey. Those travelling to remote or little-visited areas may require expert advice.

**Risk may vary in different parts of a country—check under all risk levels**

**Important**  Settled immigrants (or long-term visitors) to the UK may be unaware that they will have lost some of their immunity and also that the areas where they previously lived may now be malarious

### North Africa, the Middle East, and Central Asia

**Very low risk**  Risk very low in Algeria, Egypt (but low risk in El Faiyum, see below), Georgia (south-east, July–October), Kyrgyzstan (but low risk in south-west, see below), Libya, most tourist areas of Turkey (but low risk in Adana and border with Syria, see below), Uzbekistan (extreme south-east only):

chemoprophylaxis not recommended but avoid mosquito bites and consider malaria if fever presents

**Low risk**  Risk low in Armenia (June–October), Azerbaijan (southern border areas, June–September), Egypt (El Faiyum only, June–October), Iran (northern border with Azerbaijan, May–October; variable risk in rural south-east provinces; see below), rural north Iraq (May–November), Kyrgyzstan (south-west, May–October), north border of Syria (May–October), Turkey (plain around Adana and east of there, border with Syria, March–November):

preferably

chloroquine or (if chloroquine not appropriate) proguanil hydrochloride

**Variable risk**  Risk variable and chloroquine resistance present in Afghanistan (below 2000 m, May–November), Iran (rural south-east provinces, March–November, see also Low Risk above), Oman (remote rural areas only), Saudi Arabia (south-west and rural areas of western region; no risk in Mecca, Medina, Jeddah, or high-altitude areas of Asir Province), Tajikistan (June–October), Yemen (no risk in Sana’a):

chloroquine + proguanil hydrochloride or (if chloroquine + proguanil not appropriate) doxycycline

**Sub-Saharan Africa**

No chemoprophylaxis recommended for Cape Verde (some risk on São Tiago) and Mauritius (but avoid mosquito bites and consider malaria if fever presents)

**Very high risk**  Risk very high (or locally very high) and chloroquine resistance very widespread in Angola, Benin, Botswana (northern half, November–June), Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Comoros, Congo, Democratic Republic of the Congo (formerly Zaïre), Djibouti, Equatorial Guinea, Eritrea, Ethiopia (below 2000 m; no risk in Addis Ababa), Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania (all year in south; July–October in north), Mozambique, Namibia (all year along Kavango and Kunene rivers; November–June in northern third), Niger, Nigeria, Principe, Rwanda, São Tomé, Senegal, Sierra Leone, Somalia, South Africa (low-altitude areas of Mpumalanga and Limpopo Provinces, Kruger National Park, and north-east KwaZulu-Natal as far south as Jozini), Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia, Zimbabwe (all year in Zambezi valley; November–June in other areas below 1200 m; risk negligible in Harare and Bulawayo):

mefloquine or doxycycline or Malarone®

**Note**  In Zimbabwe and neighbouring countries, pyrimethamine with dapsone (also known as Deltaprim®) prophylaxis is used by local residents (sometimes with chloroquine)—this regimen is not recommended
### South Asia

**Low risk** Risk low in Bangladesh (but high risk in Chittagong Hill Tracts, see below), India (Kerala [southem states], Tamil Nadu, Karnataka, Southern Andhra Pradesh [including Hyderabad], Mumbai, Rajasthan [including Jaipur], Uttar Pradesh [including Agra], Har- yana, Uttaranchal, Himachal Pradesh, Jammu, Kashmir, Punjab, Delhi; variable risk in other areas, see below; high risk in Assam), Sri Lanka (but variable risk north of Vavuniya, see below):

- chloroquine + proguanil hydrochloride or (if chloroquine + proguanil not appropriate) mefloquine or doxycycline or Malarone®

**Variable risk** Risk variable and chloroquine resistance usually moderate in southern districts of Bhutan, India (low risk in some areas, see above; high risk in Assam, see below), Nepal below 1500 m, especially Terai di- tricts; no risk in Kathmandu), Pakistan (below 2000 m), Sri Lanka (north of Vavuniya; low risk in other areas, see above):

- chloroquine + proguanil hydrochloride or (if chloroquine + proguanil not appropriate) mefloquine or doxycycline or Malarone®

**High risk** Risk high and chloroquine resistance high in Bangladesh (only in Chittagong Hill Tracts; low risk in other areas, see above), India (Assam only; see also Low Risk and Variable Risk above):

- mefloquine or doxycycline or Malarone® or (if mefloquine, doxycycline, or Malarone® not appropriate) chloroquine + proguanil hydrochloride

### South-East Asia

**Very low risk** Risk very low in Bali, Brunei, Cambodia (Angkor Wat and Siem Reap, but no risk in Phnom Penh; substantial risk in other areas, see below; great risk in western provinces, see below), main tourist areas of China (but substantial risk in Yunnan and Hainan, see below; chloroquine prophylaxis appropriate for other remote areas), Hong Kong, Korea (both North and South), Malaysia (both East and West including Camer- on Highlands, but substantial risk in Sabah [except Kota Kinabalu], and variable risk in deep forests, see below), Singapore, Thailand (important: regional risk exists, see under Great Risk, below), Vietnam (cities, coast between Ho Chi Minh and Hanoi, and Mekong River until close to Cambodian border; substantial risk in other areas, see below):

- chloroquine + proguanil hydrochloride or (if chloroquine + proguanil not appropriate) mefloquine or doxycycline or Malarone®

### Oceania

**Risk** Risk high and chloroquine resistance high in Papua New Guinea (below 1800 m), Solomon Islands, Vanuatu:

- doxycycline or mefloquine or Malarone®

### Central and South America and the Caribbean

**Very low risk** Risk very low in Jamaica:

- chemoprophylaxis not recommended but avoid mosquito bites and consider malaria if fever present

### Variable to low risk** Risk variable to low in Argentina (rural areas along northern borders only), rural Belize (except Belize district), Costa Rica (Limon Province except Puerto Limon and northern canton of Pococci), Dominican Republic, El Salvador (Santa Ana province in west), Guatemala (below 1500 m), Haiti, Honduras, Mexico (states of Oaxaca and Chiapas), Nicaragua,
5.4.1 Antimalarials

**Artemether with lumefantrine**

Artemether with lumefantrine is licensed for the treatment of acute uncomplicated falciparum malaria.

**ARTEMETHER WITH LUMEFANTRINE**

**Indications**
treatment of acute uncomplicated falciparum malaria; treatment of benign malaria [unlicensed indication]

**Cautions**
- Electrolyte disturbances, concomitant use with other drugs known to cause QT-interval prolongation; monitor patients unable to take food (greater risk of recrudescence); interactions: Appendix 1 (artemether with lumefantrine)
- Driving
  - Dizziness may affect performance of skilled tasks (e.g. driving)

**Contra-indications**
- History of arrhythmias, of clinically relevant bradycardia, and of congestive heart failure accompanied by reduced left ventricular ejection fraction; family history of sudden death or of congenital QT interval prolongation

**Hepatic impairment**
- Manufacturer advises caution in severe impairment—monitor ECG and plasma-potassium concentration

**Renal impairment**
- Manufacturer advises caution in severe impairment—monitor ECG and plasma-potassium concentration

**Pregnancy**
- Toxicity in animal studies with artemether; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding**
- Manufacturer advises avoid breast-feeding for at least 1 week after last dose; present in milk in animal studies

**Side-effects**
- Abdominal pain, anorexia, diarrhoea, vomiting, nausea; palpitation, prolonged QT interval; cough, headache, dizziness, sleep disturbances, asthenia, paraesthesia; atrial fibrillation, myalgia, pruritus, rash; less commonly ataxia, hypoesthesia, and clonus

**Dose**
- Treatment of malaria, see p. 402

**Riamet® (Novartis)**
- Tablets, yellow, artemether 20 mg, lumefantrine 120 mg, net price 24-tab pack = £22.50. Label: 21, counselling, driving

**Note**
- Tablets may be crushed just before administration

---

**Chloroquine**

Chloroquine is used for the prophylaxis of malaria in areas of the world where the risk of chloroquine-resistant falciparum malaria is still low. It is also used with proguanil when chloroquine-resistant falciparum malaria is present but this regimen may not give optimal protection (see specific recommendations by country, p. 405).

Chloroquine is no longer recommended for the treatment of falciparum malaria owing to widespread resistance, nor is it recommended if the infective species is not known or if the infection is mixed; in these cases treatment should be with quinine, Malarone®, or Riamet® (for details, see p. 402). It is still recommended for the treatment of benign malarial parasitaemias (for details, see p. 403).

---

**Standby treatment**

Travellers visiting remote, malarious areas for prolonged periods should carry standby treatment if they are likely to be more than 24 hours away from medical care. Self-medication should be avoided if medical help is accessible.

In order to avoid excessive self-medication, the traveller should be provided with written instructions that urgent medical attention should be sought if fever (38°C or more) develops 7 days (or more) after arriving in a malarious area and that self-treatment is indicated if medical help is not available within 24 hours of fever onset.

In view of the continuing emergence of resistant strains and of the different regimens required for different areas expert advice should be sought on the best treatment course for an individual traveller. A drug used for chemoprophylaxis should not be considered for standby treatment for the same traveller.

**Variable to high risk**
- Risk variable to high and chloroquine resistance present in rural areas of Bolivia (below 2500 m), Ecuador (below 1500 m; no malaria in Galapagos Islands and Guayaquil; see below for Esmeraldas Province), Panama (east of Panama Canal, Peru (rural areas east of the Andes and west of the Amazon basin area), Venezuela (northern coastal region), Brazil (throughout ‘Legal Amazon’ area, high risk south of and including Orinoco river and Amazon basin area, see below; Caracas free of malaria):

**High risk**
- Risk high and marked chloroquine resistance in Bolivia (Amazon basin area; see also variable to high risk above), Brazil (throughout ‘Legal Amazon’ area which includes the Amazon basin area, Mato Grosso and Maranhao only; elsewhere very low risk—no chemoprophylaxis), Colombia (most areas below 800 m), Ecuador (Esmeraldas Province; variable to high risk in other areas, see above), French Guiana, all interior regions of Guyana, Peru (Amazon basin area), Suriname (except Paramaribo and coast), Venezuela (Amazon basin area, areas south of and including Orinoco river):

---

**Chloroquine or if chloroquine not appropriate** proguanil hydrochloride

---

**chloroquine + proguanil hydrochloride or if chloroquine + proguanil not appropriate** mefloquine or doxycycline or Malarone®

---

**High risk**
- Risk high and marked chloroquine resistance in Bolivia (below 2500 m), Ecuador (below 1500 m; no malaria in Galapagos Islands and Guayaquil; see below for Esmeraldas Province), Panama (east of Panama Canal, Peru (rural areas east of the Andes and west of the Amazon basin area), Venezuela (north of Orinoco river; high risk south of and including Orinoco river and Amazon basin area, see below; Caracas free of malaria):

---

**Variable to high risk**
- Risk variable to high and chloroquine resistance present in rural areas of Bolivia (below 2500 m), Ecuador (below 1500 m; no malaria in Galapagos Islands and Guayaquil; see below for Esmeraldas Province), Panama (east of Panama Canal, Peru (rural areas east of the Andes and west of the Amazon basin area), Venezuela (north of Orinoco river; high risk south of and including Orinoco river and Amazon basin area, see below; Caracas free of malaria):

---

**chloroquine or if chloroquine not appropriate** proguanil hydrochloride

---

**Variable to high risk**
- Risk variable to high and chloroquine resistance present in rural areas of Bolivia (below 2500 m), Ecuador (below 1500 m; no malaria in Galapagos Islands and Guayaquil; see below for Esmeraldas Province), Panama (east of Panama Canal, Peru (rural areas east of the Andes and west of the Amazon basin area), Venezuela (north of Orinoco river; high risk south of and including Orinoco river and Amazon basin area, see below; Caracas free of malaria):

---

**chloroquine + proguanil hydrochloride or if chloroquine + proguanil not appropriate** mefloquine or doxycycline or Malarone®

---

**Standby treatment**
- Travellers visiting remote, malarious areas for prolonged periods should carry standby treatment if they are likely to be more than 24 hours away from medical care. Self-medication should be avoided if medical help is accessible.

In order to avoid excessive self-medication, the traveller should be provided with written instructions that urgent medical attention should be sought if fever (38°C or more) develops 7 days (or more) after arriving in a malarious area and that self-treatment is indicated if medical help is not available within 24 hours of fever onset.

In view of the continuing emergence of resistant strains and of the different regimens required for different areas expert advice should be sought on the best treatment course for an individual traveller. A drug used for chemoprophylaxis should not be considered for standby treatment for the same traveller.

---

**Chloroquine**
- Chloroquine is used for the prophylaxis of malaria in areas of the world where the risk of chloroquine-resistant falciparum malaria is still low. It is also used with proguanil when chloroquine-resistant falciparum malaria is present but this regimen may not give optimal protection (see specific recommendations by country, p. 405).

Chloroquine is no longer recommended for the treatment of falciparum malaria owing to widespread resistance, nor is it recommended if the infective species is not known or if the infection is mixed; in these cases treatment should be with quinine, Malarone®, or Riamet® (for details, see p. 402). It is still recommended for the treatment of benign malarial parasitaemias (for details, see p. 403).
CHLOROQUINE

**Indications**  chemoprophylaxis and treatment of malaria; rheumatoid arthritis and lupus erythematosus (section 10.1.3)

**Cautions**  may exacerbate psoriasis; neurological disorders (avoid for prophylaxis if history of epilepsy; see notes above); may aggravate myasthenia gravis; severe gastro-intestinal disorders; G6PD deficiency (see section 9.1.5); ophthalmic examination and long-term therapy, see under Chloroquine, section 10.1.3; avoid concurrent therapy with hepatotoxic drugs—other interactions: Appendix 1 (chloroquine and hydroxychloroquine)

**Hepatic impairment**  use with caution in moderate to severe impairment

**Renal impairment**  manufacturers advise caution; see also Prophylaxis Against Malaria, p. 404

**Pregnancy**  benefit of prophylaxis and treatment in malaria outweighs risk; see also Benign Malaria (treatment), p. 404 and Prophylaxis Against Malaria, p. 405

**Breast-feeding**  amount in milk probably too small to be harmful; see also Prophylaxis Against Malaria, p. 405

**Side-effects**  gastro-intestinal disturbances, headache; also hypotension, convulsions, visual disturbances, depigmentation or loss of hair, skin reactions (rashes, pruritus); rarely, bone-marrow suppression, hypersensitivity reactions such as urticaria and angioedema; other side-effects (not usually associated with malaria prophylaxis or treatment), see under Chloroquine, section 10.1.3; very toxic in overdose—immediate advice from poisons centres essential (see also p. 37)

**Dose**

- **Note**  Doses expressed as chloroquine base
- **Prophylaxis of malaria, preferably started 1 week before entering endemic area and continued for 4 weeks after leaving (see notes above), 310 mg once weekly:** INFANT up to 12 weeks body-weight under 6 kg, 37.5 mg once weekly; 12 weeks–1 year body-weight 6–10 kg, 75 mg once weekly; CHILD 1–4 years body-weight 10–16 kg, 112.5 mg once weekly; 4–8 years body-weight 16–25 kg, 150 mg once weekly (or 155 mg once weekly if tablets used); 8–13 years body-weight 25–45 kg, 225 mg once weekly (or 232.5 mg once weekly if tablets used); over 13 years body-weight over 45 kg, adult dose
- **Treatment of benign malaria, see p. 403**

**Counselling**  Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if illness within 1 year and especially within 3 months of return. For details, see notes above

- **Note**  Chloroquine doses in BNF may differ from those in product literature

1. Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria. Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials are prescribed

2. Malaron® (Wallace Mfg)

- **Syrup**, chloroquine phosphate 80 mg/5 mL (≡ chloroquine base 50 mg/5 mL), net price 75 mL = £8.75. Label: 5, counselling, prophylaxis, see above

3. Nivaquine® (Sanofi-Aventis)

- **Syrup**, golden, chloroquine sulphate 68 mg/5 mL (≡ chloroquine base 50 mg/5 mL), net price 100 mL = £4.60. Label: 5, counselling, prophylaxis, see above

**Mefloquine**

Mefloquine is used for the prophylaxis of malaria in areas of the world where there is a high risk of chloroquine-resistant falciparum malaria (for details, see specific recommendations by country, p. 405).

Mefloquine is now rarely used for the treatment of falciparum malaria because of increased resistance. It is rarely used for the treatment of benign malaria because better tolerated alternatives are available. Mefloquine should not be used for treatment if it has been used for prophylaxis.

**MEFLOQUEINE**

**Indications**  chemoprophylaxis of malaria, treatment of malaria, see notes above

**Cautions**  cardiac conduction disorders; epilepsy (avoid for prophylaxis); not recommended in infants under 3 months (5 kg); interactions: Appendix 1 (mefloquine)

- **Driving**  Dizziness or a disturbed sense of balance may affect performance of skilled tasks (e.g. driving); effects may persist for up to 3 weeks

**Contra-indications**  hypersensitivity to quinine; avoid for prophylaxis if history of psychiatric disorders (including depression) or convulsions

**Hepatic impairment**  avoid for prophylaxis in severe liver disease

**Pregnancy**  manufacturer advises adequate contraception during prophylaxis and for 3 months after stopping (teratogenicity in animal studies), but see also p. 405

**Breast-feeding**  present in milk but risk to infant minimal; see also p. 405

**Side-effects**  nausea, vomiting, dyspepsia, abdominal pain, diarrhoea; headache, dizziness, sleep disturbances; less frequently: anorexia, Bradycardia, fatigue, abnormal dreams, fever, tinnitus, and neuropsychiatric reactions (including sensory and motor neuropathies, tremor, ataxia, anxiety, depression, panic attacks, agitation, hallucinations, psychosis, convulsions); rarely suicidal ideation; very rarely pneumonitis; also reported, circulatory disorders (including hypotension and hypertension), chest pain, tachycardia, palpitation, cardiac conduction disorders, oedema, dyspnoea, encephalopathy, leucopenia,
leucocytosis, thrombocytopenia, muscle weakness, myalgia, arthralgia, visual disturbances, vestibular disorders, rash (including Stevens-Johnson syndrome), pruritus, and alopecia

**Dose**
- Prophylaxis of malaria, preferably started **2½ weeks** before entering endemic area and continued for **4 weeks** after leaving (see notes above). ADULT and CHILD body-weight over 45 kg, 250 mg once weekly; body-weight 6–16 kg, 62.5 mg once weekly; body-weight 16–25 kg, 125 mg once weekly; body-weight 25–45 kg, 187.5 mg once weekly
- Treatment of malaria, see notes above

**Counselling** Inform travellers about adverse reactions of mefloquine and, if they occur, to seek medical advice on antimalarials before the next dose is due. Also warn travellers about the importance of avoiding mosquito bites, of taking prophylaxis regularly, and of immediate visit to doctor if ill within 1 year and especially within 3 months of return. For details, see notes above.

**Note** Mefloquine doses in BNF may differ from those in product literature

**PRIMAQUINE**

**Indications** adjunct in the treatment of *Plasmodium vivax* and *P. ovale* malaria (eradication of liver stages)

**Cautions** G6PD deficiency (test blood, see under Benign Malaria - treatment). Systemic diseases associated with glucocorticoid-induced acne (e.g. rheumatoid arthritis, lupus erythematosus);

**Interactions:** Appendix 2 (primaquine)

**Pregnancy** risk of neonatal haemolysis and mehaemoglobinemia in third trimester; see also notes above

**Breast-feeding** no information available; theoretical risk of haemolysis in G6PD-deficient infants

**Side-effects** nausea, vomiting, anorexia, abdominal pain; less commonly methaemoglobinaemia, haemolytic anaemia especially in G6PD deficiency, leucopenia

**Dose**
- Treatment of benign malaria, see p. 403

**Proguanil**

**Dose**
- Proguanil used alone is not suitable for the treatment of malaria; however, Malarone® (a combination of atovaquone with proguanil) is licensed for the treatment of acute uncomplicated falciparum malaria. Malarone® is also used for the prophylaxis of falciparum malaria in areas of widespread mefloquine or chloroquine resistance. Malarone® is also used as an alternative to mefloquine or doxycycline. Malarone® is particularly suitable for short trips to highly chloroquine-resistant areas because it needs to be taken only for 7 days after leaving an endemic area.

**PROGUANIL HYDROCHLORIDE**

**Indications** chemoprophylaxis of malaria

**Cautions** interactions: Appendix 1 (proguanil)

**Renal impairment** 100 mg once daily if eGFR 20–60 mL/minute/1.73 m²; 50 mg on alternate days if eGFR 10–20 mL/minute/1.73 m²; 50 mg once weekly if eGFR less than 10 mL/minute/1.73 m² (increased risk of haematological toxicity)

**Pregnancy** benefit of prophylaxis in malaria outweighs risk; adequate folate supplements should be given to mother; see also p. 405

**Breast-feeding** amount in milk probably too small to be harmful when used for malaria prophylaxis; see also p. 405

**Side-effects** mild gastric intolerance, diarrhoea, and constipation; occasionally mouth ulcers and stomatitis; very rarely cholestasis, vasculitis, skin reactions, and hair loss

**Dose**
- Prophylaxis of malaria, preferably started **1 week** before entering endemic area and continued for **4 weeks** after leaving (see notes above), **250 mg** once daily; **125 mg** once daily; **62.5 mg** once daily; **50 mg** once daily; **25 mg** once daily; **12 weeks–1 year** body-weight **6–16 kg**; **10 kg**; **16–25 kg**; **25 mg** once daily; **body-weight over 45 kg**, adult dose

**Counselling** Inform travellers about the importance of avoiding mosquito bites, of taking prophylaxis regularly, and of immediate visit to doctor if ill within 1 year and especially within 3 months of return. For details, see notes above.

**Note** Proguanil doses in BNF may differ from those in product literature

**ATOVQUONE**

**Indications** treatment of acute uncomplicated falciparum malaria and prophylaxis of falciparum malaria, particularly where resistance to other antimalarials is prescribed

1. Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed

2. Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria. Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials are prescribed

---

**BNF 61**

**5.4.1 Antimalarials**

---

**BNF 61 Antimalarials**

---

**Primaquine**

Primaquine is used to eliminate the liver stages of *P. vivax* or *P. ovale* following chloroquine treatment (for details, see p. 405).

**Indications**

**Cautions**

**Interactions**: Appendix 1 (primaquine)

**Pregnancy** risk of neonatal haemolysis and mehaemoglobinemia in third trimester; see also notes above

**Breast-feeding** no information available; theoretical risk of haemolysis in G6PD-deficient infants

**Side-effects** nausea, vomiting, anorexia, abdominal pain; less commonly methaemoglobinaemia, haemolytic anaemia especially in G6PD deficiency, leucopenia

**Dose**
- Treatment of benign malaria, see p. 403

**Primaquine** (Non-proprietary)

Tablets, primaquine (as phosphate) 7.5 mg or 15 mg
Available from ‘special-order’ manufacturers or specialist-importing companies, see p. 988

**Proguanil**

Proguanil is used (usually with chloroquine, but occasionally alone) for the prophylaxis of malaria. (For details, see specific recommendations by country; p. 405).
drugs suspected; treatment of benign malaria [unlicensed indication]

**Cautions** diarrhoea or vomiting (reduced ability of atovaquone); efficacy not embedded in cerebral or complicated malaria (including hyperparasitaemia, pulmonary oedema or renal failure); **interractions:** see Appendix 1 (proguanil, atovaquone)

**Renal impairment** avoid for malaria prophylaxis (and following) if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid unless essential

**Breast-feeding** use only if no suitable alternative available; see also p. 405

**Side-effects** abdominal pain, nausea, vomiting, diarrhoea; cough; headache, dizziness, insomnia, abnormal dreams, depression, anorexia, fever, rash, pruritus; less frequently stomatitis, palpitation, anxiety, blood disorders, hyponatraemia, and hair loss; also reported, hepatisis, cholestasis, tachycardia, hallucinations, seizures, vasculitis, mouth ulcers, and Stevens-Johnson syndrome

**Dose**

- **See preparations**
  - **Counselling** Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 3 months of return. For details, see notes above

### Malarone® (GSK)

<table>
<thead>
<tr>
<th><strong>Tablets</strong> <em>(standard)</em>, pink, f/c, proguanil hydrochloride 100 mg, atovaquone 250 mg. Net price 12-tab pack = £25.21. Label: 21, counselling, prophylaxis, see above</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong> prophylaxis of malaria, started 1–2 days before entering endemic area and continued for 1 week after leaving, ADULT and CHILD over 40 kg, 1 tablet daily</td>
</tr>
<tr>
<td><strong>Treatment of malaria,</strong> ADULT and CHILD body-weight over 40 kg, 4 tablets once daily for 3 days; CHILD body-weight 11–21 kg 1 tablet daily for 3 days, body-weight 21–31 kg 2 tablets once daily for 3 days; body-weight 31–40 kg 3 tablets once daily for 3 days</td>
</tr>
</tbody>
</table>

### Malarone Paediatric (GSK)

<table>
<thead>
<tr>
<th><strong>Tablets</strong> <em>(standard)</em>, pink, f/c proguanil hydrochloride 25 mg, atovaquone 62.5 mg, net price 12-tab pack = £6.26. Label: 21, counselling, prophylaxis, see above</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong> prophylaxis of malaria, started 1–2 days before entering endemic area and continued for 1 week after leaving, ADULT and CHILD body-weight 11–21 kg, 1 tablet once daily; body-weight 21–31 kg, 2 tablets once daily; body-weight 31–40 kg, 3 tablets once daily; body-weight over 40 kg use Malarone® <em>(standard)</em> tablets</td>
</tr>
<tr>
<td><strong>Treatment of malaria,</strong> CHILD body-weight 5–9 kg, 2 tablets once daily for 3 days; body-weight 9–11 kg, 3 tablets once daily for 3 days; body-weight 11 kg and over use Malarone® <em>(standard)</em> tablets</td>
</tr>
</tbody>
</table>
| **Note** Tablets may be crushed and mixed with food or milky drink just before administration

---

**Pyrimethamine**

Pyrimethamine should not be used alone, but is used with sulfadoxine.

Pyrimethamine with sulfadoxine is not recommended for the prophylaxis of malaria, but it can be used in the treatment of falciparum malaria with (or following) quinine.

---

1 Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed

### Pyrimethamine

**Indications** malaria (but used only in combined preparations incorporating sulfadoxine); toxoplasmosis—section 5.4.7

**Cautions** blood counts required with prolonged treatment; history of seizures—avoid large loading doses; **interractions:** Appendix 1 (pyrimethamine)

**Hepatic impairment** manufacturer advises caution

**Pregnancy** theoretical teratogenic risk in **first trimester** (folate antagonist); adequate folate supplements should be given to mother

**Breast-feeding** significant amount in milk—avoid administration of other folate antagonists to infant; avoid breast-feeding during toxoplasmosis treatment

**Side-effects** depression of haematopoiesis with high doses, rashes, insomnia

**Dose**

- Malaria, no dose stated because not recommended alone, see Pyrimethamine with Sulfadoxine below
- Toxoplasmosis, section 5.4.7

**Daraprim® (GSK)**

| **Tablets,** scored, pyrimethamine 25 mg. Net price 30-tab pack = £2.60 |

---

**Pyrimethamine with Sulfadoxine**

**Indications** adjunct to quinine in treatment of *Plasmodium falciparum* malaria; **not** recommended for prophylaxis

**Cautions** see under Pyrimethamine and under *Co-trimoxazole* (section 5.1.8); not recommended for prophylaxis (severe side-effects on long-term use); **interractions:** Appendix 1 (pyrimethamine, sulfonamides)

**Contra-indications** see under Pyrimethamine and under *Co-trimoxazole* (section 5.1.8); sulfonamide allergy

**Pregnancy** possible teratogenic risk in **first trimester** (pyrimethamine a folate antagonist); in **third trimester**—risk of neonatal haemolysis and methaemoglobinemia; fear of increased risk of kernicterus in neonates appears to be unfounded; see also p. 403

**Breast-feeding** small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants (due to sulfadoxine)

**Side-effects** see under Pyrimethamine and under *Co-trimoxazole* (section 5.1.8); pulmonary infiltrates (e.g. eosinophilic or allergic alveolitis) reported—discontinue if cough or shortness of breath

**Dose**

- Treatment of falciparum malaria, see p. 402
- Prophylaxis, not recommended by UK malaria experts

**Pyrimethamine with sulfadoxine** *(Non-proprietary)*

| **Tablets,** scored, pyrimethamine 25 mg, sulfadoxine 500 mg, net price 3-tab pack = 74p |

**Note** Also known as Fansidar®

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988
Quinine

Quinine is not suitable for the prophylaxis of malaria. Quinine is used for the treatment of falciparum malaria or if the infective species is not known or if the infection is mixed (for details see p. 402).

Doxycycline (section 5.1.3) is used for the treatment of falciparum malaria (for details see p. 402).

DOXYCYCLINE

Indications prophylaxis of malaria; adjunct to quinine in treatment of Plasmodium falciparum malaria; see also section 5.1.3

Cautions section 5.1.3

Contra-indications section 5.1.3

Hepatic impairment section 5.1.3

Renal impairment section 5.1.3

Pregnancy section 5.1.3

Breast-feeding section 5.1.3

Side-effects section 5.1.3

Dose

- Prophylaxis of malaria, started 1–2 days before entering endemic area and continued for 4 weeks after leaving (see notes above), ADULT and child over 12 years, 100 mg once daily
- Treatment of falciparum malaria, see p. 402

Preparations

Section 5.1.3

5.4.2 Amoebicides

Metronidazole is the drug of choice for acute invasive amoebic dysentery since it is very effective against vegetative forms of Entamoeba histolytica in ulcers; it is given in an adult dose of 800 mg three times daily for 5 days. Tinidazole is also effective. Metronidazole and tinidazole are relatively ineffective against amoebae which may have migrated to the liver. Treatment with metronidazole (or tinidazole) is followed by a 10-day course of diloxanide furoate.

Diloxanide furoate is the drug of choice for asymptomatic patients with E. histolytica cysts in the faeces; metronidazole and tinidazole are relatively ineffective. Diloxanide furoate is relatively free from toxic effects and the usual course is of 10 days, given alone for chronic infections or following metronidazole or tinidazole treatment.

For amoebic abscesses of the liver metronidazole is effective; tinidazole is an alternative. Aspiration of the abscess is indicated where it is suspected that it may rupture or where there is no improvement after 72 hours of metronidazole; the aspiration may need to be repeated. Aspiration aids penetration of metronidazole and, for abscesses with more than 100 mL of pus, if carried out in conjunction with drug therapy, may reduce the period of disability.

Diloxanide furoate is not effective against hepatic amoebiasis, but in malaria benefit of treatment outweighs risk; see also section 5.1.3

Preparations

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

Note Intravenous injection of quinine is so hazardous that it has been superseded by infusion.

Tetracyclines

Doxycycline (section 5.1.3) is used for the prophylaxis of malaria in areas of widespread mefloquine or chloroquine resistance. Doxycycline is also used as an alternate to mefloquine or Malarone® (for details, see specific recommendations by country, p. 405).
412 5.4.3 Trichomonacides

**Pregnancy** manufacturer advises avoid—no information available

**Breast-feeding** manufacturer advises avoid

**Side-effects** flatulence, vomiting, urticaria, pruritus

**Dose**
- 500 mg every 8 hours for 10 days; **CHILD** body-weight over 25 kg, 20 mg/kg daily in 3 divided doses for 10 days; body-weight under 25 kg, see **BNF for Children**

See also notes above

Diloxanide (Sovereign)
- Tablets, diloxanide furoate 500 mg, net price 30-tab pack = £93.50. Label: 9

### METRONIDAZOLE

**Indications** see under Dose below; anaerobic infections, section 5.1.11  
**Cautions** section 5.1.11  
**Hepatic impairment** section 5.1.11  
**Pregnancy** section 5.1.11  
**Breast-feeding** section 5.1.11  
**Side-effects** section 5.1.11  

**Dose**
- **By mouth**, invasive intestinal amoebiasis, extra-intestinal amoebiasis (including liver abscess), 800 mg every 8 hours for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection); **CHILD** 1–3 years 200 mg every 8 hours; 3–7 years 200 mg every 6 hours; 7–10 years 400 mg every 8 hours

Urogenital trichomoniasis, 200 mg every 8 hours for 7 days or 400–500 mg every 12 hours for 5–7 days, or 2 g as a single dose; **CHILD** 1–3 years 30 mg every 8 hours for 7 days; 3–7 years 100 mg every 12 hours; 7–10 years 100 mg every 8 hours

Giardiasis, 2 g daily for 3 days or 400 mg 3 times daily for 5 days or 500 mg twice daily for 7–10 days; **CHILD** 1–3 years 500 mg daily for 3 days; 3–7 years 600–800 mg daily; 7–10 years 1 g daily

### MEPACRINE HYDROCHLORIDE

**Indications** giardiasis; discoid lupus erythematosus (Antimalarials, section 10.1.3)

**Cautions** hepatic impairment, elderly, history of psychosis; avoid in psoriasis; **interactions**: Appendix 1 (mepacrine)

**Side-effects** gastro-intestinal disturbances; dizziness, headache; with large doses nausea, vomiting and occasionally transient acute toxic psychosis and CNS stimulation; on prolonged treatment yellow discoloration of skin and urine, chronic dermatoses (including severe exfoliative dermatitis), hepatitis, aplastic anaemia; also reported blue/black discoloration of palate and nails and corneal deposits with visual disturbances

**Dose**
- Giardiasis (unlicensed), 100 mg every 8 hours for 5–7 days

**Mepacrine Hydrochloride**
- Tablets, mepacrine hydrochloride 100 mg. Label: 4, 9, 14, 21

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

### TINIDAZOLE

**Indications** see under Dose below; anaerobic infections, section 5.1.11

**Cautions** section 5.1.11

**Pregnancy** section 5.1.11

**Breast-feeding** section 5.1.11

**Side-effects** section 5.1.11

**Dose**
- Intestinal amoebiasis, 2 g daily for 2–3 days; **CHILD** 50–60 mg/kg daily for 3 days

- Amoebic involvement of liver, 1.5–2 g daily for 3–6 days; **CHILD** 50–60 mg/kg daily for 5 days

- Urogenital trichomoniasis and giardiasis, single 2 g dose; **CHILD** single dose of 50–75 mg/kg (repeated once if necessary)

### Preparations
- Section 5.1.11

### 5.4.5 Leishmaniacides

Cutaneous leishmaniasis frequently heals spontaneously but if skin lesions are extensive or unsightly, treatment is indicated, as it is in visceral leishmaniasis (kala-azar). Leishmaniasis should be treated under specialist supervision.

**Sodium stibogluconate**, an organic pentavalent antimony compound, is used for visceral leishmaniasis. The dose is 20 mg/kg daily (max. 850 mg) by intramuscular or intravenous injection for 28 days in visceral leishmaniasis and for 20 days in cutaneous infection; the dosage varies with different geographical regions and expert advice should be obtained. Some early non-inflamed lesions of cutaneous leishmaniasis can be treated with intraleisional injections of sodium stibogluconate under specialist supervision.

**Amphoterin** is used with or after an antimony compound for visceral leishmaniasis unresponsive to the antimonial alone; side-effects may be reduced by using liposomal amphoterin (Ambisome™—section 5.2) at a dose of 1–3 mg/kg daily for 10–21 days to a cumulative dose of 21–30 mg/kg or at a dose of 3 mg/kg for 5 consecutive days followed by a single dose of...
SODIUM STIBOGLUCONATE

Indications leishmaniasis

Cautions intravenous injections must be given slowly over 5 minutes (to reduce risk of local thrombosis) and stopped if coughing or substernal pain; mucocutaneous disease (see below); monitor ECG before and during treatment; heart disease (withdraw if conjugation disturbances occur); treat intercurrent infection (e.g. pneumonia)

Mucocutaneous disease Successful treatment of mucocutaneous leishmaniasis may induce severe inflammation around the lesions (may be life-threatening if pharyngeal or tracheal involvement)—may require corticosteroid

Hepatic impairment use with caution

Renal impairment avoid in significant impairment

Pregnancy manufacturer advises use only if potential benefit outweighs risk

Breast-feeding amount probably too small to be harmful

Side-effects anorexia, nausea, vomiting, abdominal pain, diarrhoea; ECG changes; coughing (see Cautions); headache, lethargy; arthralgia, myalgia; rarely jaundice, flushing, bleeding from nose or gum, substernal pain (see Cautions), vertigo, fever, sweating, and rash; also reported pancreatitis and anaphylaxis; pain and thrombosis on intravenous administration, intramuscular injection also painful

Dose

- See notes above

Pentostam® (GSK)

Injection, sodium stibogluconate equivalent to pentavalent antimony 100 mg/mL. Net price 100-mL bottle = £66.43

Note Injection should be filtered immediately before administration using a filter of 5 microns or less

5.4.6 Trypanocides

The prophylaxis and treatment of trypanosomiasis is difficult and differs according to the strain of organism. Expert advice should therefore be obtained.

5.4.7 Drugs for toxoplasmosis

Most infections caused by Toxoplasma gondii are self-limiting, and treatment is not necessary. Exceptions are patients with eye involvement (toxoplasma chorioido-retinitis), and those who are immunosuppressed. Toxoplasmal encephalitis is a common complication of AIDS. The treatment of choice is a combination of pyrimethamine and sulfadiazine, given for several weeks (expert advice essential). Pyrimethamine is a folate antagonist, and adverse reactions to this combination are relatively common (folinic acid supplements and weekly blood counts needed). Alternative regimens use combinations of pyrimethamine with clindamycin or clarithromycin or azithromycin. Long-term secondary prophylaxis is required after treatment of toxoplasmosis in immunocompromised patients; prophylaxis should continue until immunity recovers.

If toxoplasmosis is acquired in pregnancy, transplacental infection may lead to severe disease in the fetus. Spiramycin (unlicensed) (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) may reduce the risk of transmission of maternal infection to the fetus.

5.4.8 Drugs for pneumocystis pneumonia

Pneumonia caused by Pneumocystis jirovecii (Pneumocystis carinii) occurs in immunosuppressed patients; it is a common cause of pneumonia in AIDS. Pneumocystis pneumonia should generally be treated by those experienced in its management. Blood gas measurement is used to assess disease severity.

Treatment

Mild to moderate disease Co-trimoxazole (section 5.1.8) in high dosage is the drug of choice for the treatment of mild to moderate pneumocystis pneumonia.

Atovaquone is licensed for the treatment of mild to moderate pneumocystis infection in patients who cannot tolerate co-trimoxazole. A combination of dapsone 100 mg daily (section 5.1.10) with trimethoprim 5 mg/kg every 6–8 hours (section 5.1.8) is given by mouth for the treatment of mild to moderate disease [unlicensed indication].

A combination of clindamycin 600 mg by mouth every 8 hours (section 5.1.6) and primaquine 30 mg daily by mouth (section 5.4.1) is used in the treatment of mild to moderate disease [unlicensed indication]; this combination is associated with considerable toxicity.

Severe disease Co-trimoxazole (section 5.1.8) in high dosage, given by mouth or by intravenous infusion, is the drug of choice for the treatment of severe pneumocystis pneumonia. Pentamidine isethionate given by intravenous infusion is an alternative for patients who cannot tolerate co-trimoxazole, or who have not responded to it. Pentamidine isethionate is a potentially toxic drug that can cause severe hypotension during or immediately after infusion. Corticosteroid treatment can be lifesaving in those with severe pneumocystis pneumonia (see Adjunctive Therapy below).

Adjunctive therapy In moderate to severe infections associated with HIV infection, prednisolone 50–80 mg daily is given by mouth for 5 days (alternatively, hydrocortisone may be given parenterally); the dose is then reduced to complete 21 days of treatment. Corticosteroid treatment should ideally be started at the same time as the anti-pneumocystis therapy and certainly no later than 24–72 hours afterwards. The corticosteroid should be withdrawn before anti-pneumocystis treatment is complete.
Prophylaxis

Prophylaxis against pneumocystis pneumonia should be given to all patients with a history of the infection. Prophylaxis against pneumocystis pneumonia should also be considered for severely immunocompromised patients. Prophylaxis should continue until immunity recovers sufficiently. It should not be discontinued if the patient has oral candidiasis, continues to lose weight, or is receiving cytotoxic therapy or long-term immunosuppressant therapy.

Co-trimoxazole by mouth is the drug of choice for prophylaxis against pneumocystis pneumonia. It is given in a dose of 960 mg daily or 960 mg on alternate days (3 times a week); the dose may be reduced to co-trimoxazole 480 mg daily to improve tolerance.

Inhaled pentamidine isetionate is better tolerated than parenteral pentamidine. Intermittent inhalation of pentamidine isetionate is used for prophylaxis against pneumocystis pneumonia in patients unable to tolerate co-trimoxazole. It is effective but patients may be prone to extrapulmonary infection. Alternatively, dapsone 100 mg daily (section 5.1.10) can be used. Atovaquone 750 mg twice daily has also been used for prophylaxis [unlicensed indication].

ATOVAQUONE

Indications treatment of mild to moderate Pneumocystis jirovecii (Pneumocystis carinii) pneumonia in patients intolerant of co-trimoxazole

Cautions initial diarrhoea and difficulty in taking with food may reduce absorption (and require alternative therapy); other causes of pulmonary disease should be sought and treated; elderly; interactions: Appendix 1 (atovaquone)

Hepatic impairment manufacturer advises caution—monitor more closely

Renal impairment manufacturer advises caution—monitor more closely

Pregnancy manufacturer advises avoid unless potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid unless essential

Side-effects nausea, diarrhoea, vomiting; headache, insomnia; fever; anaemia, neutropenia, hypotension; rash, pruritus; also reported, Stevens-Johnson syndrome

Dose

- 750 mg twice daily with food (particularly high fat) for 21 days; CHILD not recommended

Wellvone® (GSK) Suspension, sugar-free, atovaquone 750 mg/5 mL, net price 226 mL (tutti-frutti-flavoured) = £405.31. Label: 21

With progurani hydrochloride See section 5.4.1

PENTAMIDINE ISETIONATE

Indications see under Dose (should only be given by specialists)

Cautions risk of severe hypotension following administration (monitor blood pressure before starting treatment, during administration, and at regular intervals, until treatment concluded; patient should be lying down when receiving drug parenterally); hypokalaemia, hypomagnesaemia, coronary heart disease, bradycardia, history of ventricular arrhythmias, concomitant use with other drugs which prolong QT-interval, hypertension or hypotension; hyperglycaemia or hypoglycaemia; leucopenia, thrombocytopenia, or anaemia; carry out laboratory monitoring according to product literature; care required to protect personnel during handling and administration; interactions: Appendix 1 (pentamidine isetionate)

Hepatic impairment manufacturer advises caution—monitor more closely

Renal impairment reduce intravenous dose for pneumocystis pneumonia if creatinine clearance less than 10 mL/minute: in life-threatening infection, use 4 mg/kg once daily for 7–10 days, then 4 mg/kg on alternate days to complete course of at least 14 doses; in less severe infection, use 4 mg/kg on alternate days for at least 14 doses

Pregnancy manufacturer advises avoid unless essential

Breast-feeding manufacturer advises avoid unless essential—no information available

Side-effects severe reactions, sometimes fatal, due to hypotension, hypoglycaemia, pancreatitis, and arrhythmias; also leucopenia, thrombocytopenia, acute renal failure, hypocalcaemia; also reported: azotaemia, abnormal liver-function tests, anaemia, hyperkalaemia, nausea and vomiting, dizziness, syncope, flushing, hyperglycaemia, rash, and taste disturbances; Stevens-Johnson syndrome reported; on inhalation, bronchoconstriction (may be prevented by prior use of bronchodilators), cough, and shortness of breath, discomfort, pain, induration, abscess formation, and muscle necrosis at injection site

Dose

- Treatment of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia, by intravenous infusion, 4 mg/kg once daily for at least 14 days

Prophylaxis of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia, by inhalation of nebulised solution (using suitable equipment—consult product literature), 300 mg every 4 weeks or 150 mg every 2 weeks [unlicensed for primary prevention]

- Visceral leishmaniasis (kala-azar, section 5.4.5), by deep intramuscular injection, 3–4 mg/kg on alternate days to max. total of 10 injections; course may be repeated if necessary

- Cutaneous leishmaniasis, by deep intramuscular injection, 3–4 mg/kg once or twice weekly until condition resolves (but see also section 5.4.5)

- Trypanosomiasis, by deep intramuscular injection or intravenous infusion, 4 mg/kg daily or on alternate days to total of 7–10 injections

Note Direct intravenous injection should be avoided whenever possible and never given rapidly; intramuscular injections should be deep and preferably given into the buttock

Pentacarinat® (Sanofi-Aventis) Injection, powder for reconstitution, pentamidine isetionate, net price 300-mg vial = £30.45

Nebuliser solution, pentamidine isetionate, net price 300-mg bottle = £32.15

Caution in handling Pentamidine isetionate is toxic and personnel should be adequately protected during handling and administration—consult product literature
5.5 Anthelmintics

5.5.1 Drugs for threadworms (pinworms, Enterobius vermicularis)

Anthelmintics are effective in threadworm infections, but their use needs to be combined with hygienic measures to break the cycle of auto-infection. All members of the family require treatment.

Adult threadworms do not live for longer than 6 weeks and for development of fresh worms, ova must be swallowed and exposed to the action of digestive juices in the upper intestinal tract. Direct multiplication of worms does not take place in the large bowel. Adult female worms lay ova on the perianal skin which causes pruritus; scratching the area then leads to ova being transmitted on fingers to the mouth, often via food eaten with unwashed hands. Washing hands and scrubbing nails before each meal and after each visit to the toilet is essential. A bath taken immediately after rising will remove ova laid during the night.

Mebendazole is the drug of choice for treating threadworm infection in patients of all ages over 2 years. It is the drug of choice for treating threadworm, roundworm, whipworm, and non-filarial hookworm infections. It is available in combination with sennosides in a single-dose preparation.

Note: The package insert in the Vermox® pack includes the statement that it is not suitable for women known to be pregnant or children under 2 years.

5.5.2 Ascaricides

5.5.3 Drugs for tapeworm infections

5.5.4 Drugs for hookworms

5.5.5 Schistosomicides

5.5.6 Filariicides

5.5.7 Drugs for cutaneous larva migrans

5.5.8 Drugs for strongyloidiasis

Advice on prophylaxis and treatment of helminth infections is available from:

- Birmingham (0121) 424 0357
- Scottish Centre for Infection and Environmental Health (registered users of Travax only) (0141) 300 1100 (weekdays 2–4 p.m. only)
- Liverpool (0151) 708 9393
- London 0845 155 5000 (treatment)

5.5.1 Drugs for threadworms

Indications threadworm and roundworm infections

Cautions
- epilepsy; packs on sale to the general public carry a warning to avoid in epilepsy, or in liver or kidney disease, and to seek medical advice in pregnancy
- Hepatic impairment manufacturer advises avoid
- Renal impairment use with caution; avoid in severe renal impairment; risk of neurotoxicity
- Pregnancy not known to be harmful but manufacturer advises avoid in first trimester
- Breast-feeding present in milk—manufacturer advises avoid breast-feeding for 8 hours after dose (express and discard milk during this time)
- Side-effects nausea, vomiting, colic, diarrhoea, allergic reactions including urticaria, bronchospasm, and rare reports of arthralgia, fever, Stevens-Johnson syndrome and angioedema; rarely dizziness, muscular incoordination (‘worm wobble’); drowsiness, nystagmus, vertigo, blurred vision, confusion and chronic contractions in patients with neurological or renal abnormalities

Dose
- See under Preparation, below

With sennosides

For cautions, contra-indications, side-effects of senna see section 1.6.2

5.5.1 Drugs for threadworms

1. Mebendazole (Non-proprietary) (Vermox®)

Tablets, chewable, mebendazole 100 mg

2. Piperazine (Non-proprietary) (Pipersen®)

Tablets, orange, scored, chewable, mebendazole 100 mg. Net price 6-tab pack = £1.36

Oral suspension, mebendazole 100 mg/5 mL (banana-flavoured). Net price 30 mL = £1.59
5.5.2 Ascaricides
(common roundworm infections)

Mebendazole (section 5.5.1) is effective against *Ascaris lumbricoides* and is generally considered to be the drug of choice; the usual dose is 100 mg twice daily for 3 days or 500 mg as a single dose [unlicensed single dose].

Levamisole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is an alternative when mebendazole cannot be used. It is very well tolerated; mild nausea or vomiting has been reported in about 1% of treated patients; it is given as a single dose of 120–150 mg in adults.

Piperazine may be given in a single adult dose, see Piperazine, above.

5.5.3 Drugs for tapeworm infections

Taenicides

Niclosamide [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is the most widely used drug for tapeworm infections and side-effects are limited to occasional gastro-intestinal upset, lightheadedness, and pruritus; it is not effective against larval worms. Fears of developing cysticercosis in *Taenia solium* infections have proved unfounded. All the same, an antiemetic can be given before treatment and a laxative can be given 2 hours after niclosamide.

Praziquantel [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is as effective as niclosamide and is given as a single dose of 5–10 mg/kg after a light breakfast (a single dose of 25 mg/kg for *Hymenolepis nana*).

Hydatid disease

Cysts caused by *Echinococcus granulosus* grow slowly and asymptomatic patients do not always require treatment. Surgical treatment remains the method of choice in many situations. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is used in conjunction with surgery to reduce the risk of recurrence or as primary treatment in inoperable cases. Alveolar echinococcosis due to *E. multilocularis* is usually fatal if untreated.

Surgical removal with albendazole cover is the treatment of choice, but where effective surgery is impossible, repeated cycles of albendazole (for a year or more) may help. Careful monitoring of liver function is particularly important during drug treatment.

5.5.4 Drugs for hookworms
(ancylostomiasis, necatoriasis)

Hookworms live in the upper small intestine and draw blood from the point of their attachment to their host. An iron-deficiency anaemia may occur and, if present, effective treatment of the infection requires not only expulsion of the worms but treatment of the anaemia.

Mebendazole (section 5.5.1) has a useful broad-spectrum activity and is effective against hookworms; the usual dose is 100 mg twice daily for 3 days. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) given as a single dose of 400 mg, is an alternative.

5.5.5 Schistosomicides
(bilharziasis)

Adult *Schistosoma haematobium* worms live in the genito-urinary veins and adult *S. mansoni* in those of the colon and mesentery. *S. japonicum* is more widely distributed in veins of the alimentary tract and portal system.

Praziquantel [unlicensed] is available from Merck Serono (Cysticide®) and is effective against all human schistosomes. The dose is 20 mg/kg followed after 4–6 hours by one further dose of 20 mg/kg (20 mg/kg given 3 times on one day for *S. japonicum* infections). No serious adverse effects have been reported. Of all the available schistosomicides, it has the most attractive combination of effectiveness, broad-spectrum activity, and low toxicity.

Hycanthone, lucanthone, niridazole, oxamniquine, and sodium stibogluconate have now been superseded.

5.5.6 Filaricides

Diethylcarbamazine [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is effective against microfilariae and adults of *Loa loa*, *Wuchereria bancrofti*, and *Brugia malayi*. To minimise reactions treatment is commenced with a dose of diethylcarbamazine citrate 1 mg/kg on the first day and increased gradually over 3 days to 6 mg/kg daily in divided doses for *Loa loa*; this dosage is maintained for a further period. Close medical supervision is necessary particularly in the early phase of treatment.

In heavy infections there may be a febrile reaction, and in heavy *Loa loa* infection there is a small risk of encephalopathy. In such cases specialist advice should be sought, and treatment must be given under careful in-patient supervision and stopped at the first sign of cerebral involvement.

Ivermectin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is very effective in onchocerciasis and it is now the drug of choice. A single dose of 150 micrograms/kg by mouth produces a prolonged reduction in microfilarial levels. Retreatment at intervals of 6 to 12 months depending on symptoms must be given until the adult worms die out. Reactions are usually slight and most commonly take the form of temporary aggravation of itching and rash. Diethylcarbamazine or suramin should no longer be used for onchocerciasis because of their toxicity.
5.5.7 Drugs for cutaneous larva migrans
(creeping eruption)

Dog and cat hookworm larvae may enter human skin where they produce slowly extending itching tracks usually on the foot. Single tracks can be treated with topical thiabendazole (no commercial preparation available). Multiple infections respond to ivermectin, albendazole or thiabendazole (thiabendazole) by mouth [all unlicensed] and available from ‘special-order’ manufacturers or specialist importing companies, see p. 988).

5.5.8 Drugs for strongyloidiasis

Adult Strongyloides stercoralis live in the gut and produce larvae which penetrate the gut wall and invade the tissues, setting up a cycle of auto-infection. Ivermectin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) in a dose of 200 micrograms/kg daily for 2 days is the treatment of choice for chronic Strongyloides infection. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is an alternative given in a dose of 400 mg twice daily for 3 days, repeated after 3 weeks if necessary.
Diabetes mellitus occurs because of a lack of insulin or resistance to its action. It is diagnosed by measuring fasting or random blood-glucose concentration (and occasionally by oral glucose tolerance test). Although there are many subtypes, the two principal classes of diabetes are type 1 diabetes and type 2 diabetes.

**Type 1 diabetes**, (formerly referred to as insulin-dependent diabetes mellitus (IDDM)), occurs as a result of a deficiency of insulin following autoimmune destruction of pancreatic beta cells. Patients with type 1 diabetes require administration of insulin.

**Type 2 diabetes**, (formerly referred to as non-insulin-dependent diabetes (NIDDM)), is due to reduced secretion of insulin or to peripheral resistance to the action of insulin or to a combination of both. Although patients may be controlled on diet alone, many also require oral antidiabetic drugs or insulin (or both) to maintain satisfactory control. In overweight individuals, type 2 diabetes may be prevented by losing weight and increasing physical activity; use of the anti-obesity drug orlistat (section 4.5.1) may be considered in obese patients.

### Treatment of diabetes
Treatment of all forms of diabetes should be aimed at alleviating symptoms and minimising the risk of long-term complications (see below); tight control of diabetes is essential.

Diabetes is a strong risk factor for cardiovascular disease (section 2.12). Other risk factors for cardiovascular disease such as smoking (section 4.10.2), hypertension (section 2.5), obesity (section 4.5), and hyperlipidaemia...
(section 2.12) should be addressed. Cardiovascular risk in patients with diabetes can be further reduced by the use of an ACE inhibitor (section 2.5.5.1), low-dose aspirin (section 2.9) and a lipid-regulating drug (section 2.12).

**Prevention of diabetic complications** Optimal glycaemic control in both type 1 diabetes and type 2 diabetes reduces, in the long term, the risk of microvascular complications including retinopathy, development of proteinuria and to some extent neuropathy. However, a temporary deterioration in established diabetic retinopathy may occur when normalising blood-glucose concentration. For reference to the use of an ACE inhibitor or an angiotensin-II receptor antagonist in the management of diabetic nephropathy, see section 6.1.5.

A measure of the total glycosylated (or glycated) haemoglobin (HbA$_1c$) or a specific fraction (HbA$_1$) provides a good indication of glycaemic control over the previous 2–3 months. Overall it is ideal to aim for an HbA$_1c$ of 48–59 mmol/mol (6.5–7.5%) or less (reference range 20–42 mmol/mol or 4–6%) but this cannot always be achieved and for those using insulin there is a significantly increased risk of disabling hypoglycaemia; in those at risk of arterial disease, the aim should be to maintain the HbA$_1c$ concentration at 48 mmol/mol (6.5%) or less. HbA$_1c$ should be measured every 3–6 months.

---

**Measurement of HbA$_1c$**

HbA$_1c$ values currently expressed as a percentage, are aligned to the assay used in the Diabetes Control and Complications Trial (DCCT). A new standard, specific for HbA$_1c$, has been created by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which expresses HbA$_1c$ values in mmol of glycosylated haemoglobin per mol of haemoglobin. UK laboratories now express results in both IFCC-standardised units (mmol/mol) and DCCT-aligned units (%). From 1 June 2011, results will only be reported in IFCC-standardised units.

**Equivalent values**

<table>
<thead>
<tr>
<th>IFCC-HbA$_1c$ (mmol/mol)</th>
<th>DCCT-HbA$_1c$ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>6.0</td>
</tr>
<tr>
<td>48</td>
<td>6.5</td>
</tr>
<tr>
<td>53</td>
<td>7.0</td>
</tr>
<tr>
<td>59</td>
<td>7.5</td>
</tr>
<tr>
<td>64</td>
<td>8.0</td>
</tr>
<tr>
<td>75</td>
<td>9.0</td>
</tr>
</tbody>
</table>

Laboratory measurement of serum-fructosamine concentration is technically simpler and cheaper than the measurement of HbA$_1c$, and can be used to assess control over short periods of time, particularly when HbA$_1c$ monitoring is invalid (e.g. disturbed erythrocyte turnover or abnormal haemoglobin type).

Tight control of blood pressure in hypertensive patients with type 2 diabetes reduces mortality and protects visual acuity (by reducing considerably the risks of maculopathy and retinal photocoagulation) (see also section 2.5).

**Driving** Drivers with diabetes are required to notify the Driver and Vehicle Licensing Agency (DVLA) of their condition if they are treated with insulin or if they are treated with oral antidiabetic drugs and also have complications. Detailed guidance on eligibility to drive is available from the DVLA (www.dvla.gov.uk/medical.aspx). Driving is not permitted when hypoglycaemic awareness is impaired or frequent hypoglycaemic episodes occur.

Drivers need to be particularly careful to avoid hypoglycaemia (see also above) and should be warned of the problems. Drivers treated with insulin should normally check their blood-glucose concentration before driving and, on long journeys, at 2-hour intervals; these precautions may also be necessary for drivers taking oral antidiabetic drugs who are at particular risk of hypoglycaemia. Drivers treated with insulin should ensure that a supply of sugar is always available in the vehicle and they should avoid driving if their meal is delayed. If hypoglycaemia occurs, or warning signs develop, the driver should:

- stop the vehicle in a safe place;
- switch off the ignition;
- eat or drink a suitable source of sugar;
- wait until recovery is complete before continuing journey; recovery may take 15 minutes or longer and should preferably be confirmed by checking blood-glucose concentration.

---

**Endocrine system**

**6.1.1 Insulins**

**6.1.1.1 Short-acting insulins**

**6.1.1.2 Intermediate- and long-acting insulins**

**6.1.1.3 Hypodermic equipment**

Insulin plays a key role in the regulation of carbohydrate, fat, and protein metabolism. It is a polypeptide hormone of complex structure. There are differences in the amino-acid sequence of animal insulins, human insulins and the human insulin analogues. Insulin may be extracted from pork pancreas and purified by crystallisation; it may also be extracted from beef pancreas, but beef insulins are now rarely used. Human sequence insulin may be produced semi-synthetically by enzymatic modification of porcine insulin (emp) or biosynthetically by recombinant DNA technology using bacteria (crb, prb) or yeast (pyr).

All insulin preparations are to a greater or lesser extent immunogenic in man but immunological resistance to insulin action is uncommon. Preparations of human sequence insulin should theoretically be less immunogenic, but no real advantage has been shown in trials. Insulin is inactivated by gastro-intestinal enzymes, and must therefore be given by injection; the subcutaneous route is ideal in most circumstances. Insulin is usually injected into the upper arms, thighs, buttocks, or abdomen; absorption from a limb site may be increased if the limb is used in strenuous exercise after the injection. Generally subcutaneous insulin injections cause few problems; lipodystrophy may occur but can be minimised by using different injection sites in rotation. Local allergic reactions are rare.
Insulin is needed by all patients with ketoacidosis, and it is likely to be needed by most patients with:

- rapid onset of symptoms;
- substantial loss of weight;
- weakness;
- ketonuria;
- a first-degree relative who has type 1 diabetes.

Insulin is required by almost all children with diabetes. It is also needed for type 2 diabetes when other methods have failed to achieve good control, and temporarily in the presence of intercurrent illness or peri-operatively. Pregnant women with type 2 diabetes may be treated with insulin when diet alone fails. For advice on use of oral antidiabetic drugs in the management of diabetes in pregnancy, see section 6.1.2.

Management of diabetes with insulin

The aim of treatment is to achieve the best possible control of blood-glucose concentration without making the patient obsolescent and to avoid disabling hypoglycaemia; close co-operation is needed between the patient and the medical team because good control reduces the risk of complications.

Insulin preparations can be divided into 3 types:

- those of short duration which have a relatively rapid onset of action, namely soluble insulin and the rapid-acting insulin analogues, insulin aspart, insulin glulisine, and insulin lispro (section 6.1.1.1);
- those with an intermediate action, e.g. isophane insulin (section 6.1.1.2); and
- those whose action is slower in onset and lasts for long periods, e.g. protamine zinc insulin, insulin detemir, and insulin glargine (section 6.1.1.2).

The duration of action of a particular type of insulin varies considerably from one patient to another, and needs to be assessed individually.

Mixtures of insulin preparations may be required and appropriate combinations have to be determined for the individual patient. Treatment should be started with a short-acting insulin (e.g. soluble insulin) or a rapid-acting insulin analogue (e.g. insulin aspart) given before meals with intermediate-acting or long-acting insulin once or twice daily. Alternatively, for those who have difficulty with, or prefer not to use, multiple injection regimens, a mixture of premixed short-acting insulin or rapid acting insulin analogue with an intermediate-acting or long-acting insulin (most commonly in a proportion of 30% soluble insulin and 70% isophane insulin) can be given once or twice daily. The dose of short-acting or rapid-acting insulin (or the proportion of the short-acting soluble insulin component in premixed insulin) can be increased in those with excessive post-prandial hyperglycaemia. The dose of insulin is increased gradually according to the patient’s individual requirements, taking care to avoid troublesome hypoglycaemic reactions.

Insulin requirements may be increased by infection, stress, accidental or surgical trauma, and during puberty. Requirements may be decreased in those with certain endocrine disorders (e.g. Addison’s disease, hypopituitarism), or in coeliac disease.

Examples of recommended insulin regimens

- Multiple injection regimen: short-acting insulin or rapid-acting insulin analogue, before meals
- With intermediate-acting or long-acting insulin, once or twice daily;
- Short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting or long-acting insulin, once or twice daily (before meals);
- Intermediate-acting or long-acting insulin, once or twice daily
- With or without short-acting insulin or rapid-acting insulin before meals;
- Continuous subcutaneous insulin infusion (see below).

Hepatic impairment

Insulin requirements may be decreased in patients with hepatic impairment.

Renal impairment

Insulin requirements may fall in patients with renal impairment and therefore dose reduction may be necessary. The compensatory response to hypoglycaemia is impaired in renal impairment.

Pregnancy and breast-feeding

During pregnancy and breast-feeding, insulin requirements may alter and doses should be assessed frequently by an experienced diabetes physician. The dose of insulin generally needs to be increased in the second and third trimesters of pregnancy. The short-acting insulin analogues, insulin aspart and insulin lispro, are not known to be harmful, and may be used during pregnancy and lactation. The safety of long-acting insulin analogues in pregnancy has not been established, therefore isophane insulin is recommended where longer-acting insulins are needed.

Insulin administration

Insulin is generally given by subcutaneous injection; the injection site should be rotated to prevent lipodystrophy. Injection devices ('pens') (section 6.1.1.3), which hold the insulin in a cartridge and meter the required dose, are convenient to use. Insulin syringes (for use with needles) are required for insulins not available in cartridge form.

For intensive insulin regimens multiple subcutaneous injections (3 or more times daily) are usually recommended.

Short-acting injectable insulins (soluble insulin, insulin aspart, insulin glulisine, and insulin lispro) can also be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens (see also NICE guidance, below). Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.
Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or
- whose glycaemic control remains inadequate (HbA1c over 8.5%) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.

Soluble insulin by the intravenous route is reserved for urgent treatment, e.g. in diabetic ketoacidosis, and for fine control in serious illness and in the peri-operative period (see under Diabetes and Surgery, below).

**Units**

The word ‘unit’ should not be abbreviated.

**Monitoring**

Many patients now monitor their own blood-glucose concentrations (section 6.1.6). Since blood-glucose concentration varies substantially throughout the day, ‘normoglycaemia’ cannot always be achieved throughout a 24-hour period without causing damaging hypoglycaemia. It is therefore best to recommend that patients should maintain a blood-glucose concentration of between 4 and 9 mmol/litre for most of the time (4–7 mmol/litre before meals and less than 9 mmol/litre after meals), while accepting that on occasions, for brief periods, it will be above these values; strenuous efforts should be made to prevent the blood-glucose concentration from falling below 4 mmol/litre. Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen. The intake of energy and of simple and complex carbohydrates should be adequate to allow normal growth and development but obesity must be avoided.

**Hypoglycaemia**

Hypoglycaemia is a potential problem with insulin therapy. All patients must be carefully instructed on how to avoid it.

Loss of warning of hypoglycaemia among insulin-treated patients can be a serious hazard, especially for drivers and those in dangerous occupations. Very tight control of diabetes lowers the blood-glucose concentration needed to trigger hypoglycaemic symptoms; an increase in the frequency of hypoglycaemic episodes may reduce the warning symptoms experienced by the patient. Beta-blockers can also blunt hypoglycaemic awareness (and also delay recovery).

To restore the warning signs, episodes of hypoglycaemia must be minimised; this involves appropriate adjustment of insulin type, dose and frequency together with suitable timing and quantity of meals and snacks.

Some patients have reported loss of hypoglycaemia warning after transfer to human insulin. Clinical studies do not confirm that human insulin decreases hypoglycaemia awareness. If a patient believes that human insulin is responsible for the loss of warning it is reasonable to revert to animal insulin and essential to educate the patient about avoiding hypoglycaemia. Great care should be taken to specify whether a human or an animal preparation is required.

Few patients are now treated with beef insulins; when undertaking conversion from beef to human insulin, the total dose should be reduced by about 10% with careful monitoring for the first few days. When changing between pork and human-sequence insulins, a dose change is not usually needed, but careful monitoring is still advised.

**Diabetes and surgery**

Perioperative control of blood-glucose concentrations in patients with type 1 diabetes is achieved via an adjustable, continuous, intravenous infusion of insulin. Detailed local protocols should be available to all healthcare professionals involved in the treatment of these patients; in general, the following steps should be followed:

- Give an injection of the patient’s usual insulin on the night before the operation;
- Early on the day of the operation, start an intravenous infusion of glucose containing potassium chloride (provided that the patient is not hyperka-laemic) and infuse at a constant rate appropriate to the patient’s fluid requirements (usually 125 mL per hour); make up a solution of soluble insulin in sodium chloride 0.9% and infuse intravenously using a syringe pump piggy-backed to the intravenous infusion. Glucose and potassium infusions, and insulin infusions should be made up according to locally agreed protocols;
- The rate of the insulin infusion should be adjusted according to blood-glucose concentration (frequent monitoring necessary) in line with locally agreed protocols. Other factors affecting the rate of infusion include the patient’s volume depletion, cardiac function, and age.

Protocols should include specific instructions on how to manage resistant cases (such as patients who are in shock or severely ill or those receiving corticosteroids or sympathomimetica) and those with hyperglycaemia.

If a syringe pump is not available, soluble insulin should be added to the intravenous infusion of glucose and potassium chloride (provided the patient is not hyperka-laemic), and the infusion run at the rate appropriate to the patient’s fluid requirements (usually 125 mL per hour) with the insulin dose adjusted according to blood-glucose concentration in line with locally agreed protocols.

Once the patient starts to eat and drink, give subcutaneous insulin before breakfast and stop intravenous insulin 30 minutes later; the dose may need to be 10–20% more than usual if the patient is still in bed or unwell. If the patient was not previously receiving insulin, an appropriate initial dose is 30–40 units daily in four divided doses using soluble insulin before meals and intermediate-acting insulin at bedtime and the dose adjusted from day to day. Patients with hyperglycaemia...
often relapse after conversion back to subcutaneous insulin calling for one of the following approaches:
- additional doses of soluble insulin at any of the four injection times (before meals or bedtime) or
- temporary addition of intravenous insulin infusion (while continuing the subcutaneous regimen) until blood-glucose concentration is satisfactory or
- complete reversion to the intravenous regimen (especially if the patient is unwell).

### 6.1.1.1 Short-acting insulins

**Soluble insulin** is a short-acting form of insulin. For maintenance regimens it is usual to inject it 15 to 30 minutes before meals.

Soluble insulin is the most appropriate form of insulin for use in diabetic emergencies e.g. diabetic ketoacidosis (section 6.1.3) and at the time of surgery. It can be given intravenously and intramuscularly, as well as subcutaneously.

When injected subcutaneously, soluble insulin has a rapid onset of action (30 to 60 minutes), a peak action between 2 and 4 hours, and a duration of action of up to 8 hours.

When injected intravenously, soluble insulin has a very short half-life of only about 5 minutes and its effect disappears within 30 minutes.

The rapid-acting human insulin analogues, **insulin aspart**, **insulin glulisine**, and **insulin lispro** have a faster onset and shorter duration of action than soluble insulin; as a result, compared to soluble insulin, fasting and preprandial blood-glucose concentrations are a little higher, postprandial blood-glucose concentration is a little lower, and hypoglycaemia occurs slightly less frequently. Subcutaneous injection of insulin analogues may be convenient for those who wish to inject shortly before or, when necessary, shortly after a meal. They can also help those susceptible to hypoglycaemia before lunch and those who eat late in the evening and are prone to nocturnal hypoglycaemia. They can also be administered intravenously and can be used as alternatives to soluble insulin for diabetic emergencies and at the time of surgery.

### Dose

- **By subcutaneous, intramuscular or intravenous injection or intravenous infusion**, according to requirements

### Highly purified animal

#### Counselling

Show container to patient and confirm that patient is expecting the version dispensed

- **Hypurin® Bovine Neutral (Wockhardt)**
  - **Injection**, soluble insulin (bovine, highly purified)
  - 100 units/mL. Net price 10-mL vial = £18.48; cartridges (for Autoopen® Classic) 5 × 3 mL = £27.72

- **Hypurin® Porcine Neutral (Wockhardt)**
  - **Injection**, soluble insulin (porcine, highly purified)
  - 100 units/mL. Net price 10-mL vial = £16.80; cartridges (for Autoopen® Classic) 5 × 3 mL = £25.20

### Human sequence

#### Counselling

Show container to patient and confirm that patient is expecting the version dispensed

- **Actrapid® (Novo Nordisk)**
  - **Injection**, soluble insulin (human, pyr) 100 units/mL. Net price 10-mL vial = £17.48
  - Note: Not recommended for use in subcutaneous insulin infusion pumps—may precipitate in catheter or needle

- **Humulin S® (Lilly)**
  - **Injection**, soluble insulin (human, prb) 100 units/mL. Net price 10-mL vial = £15.68; 5 × 3-mL cartridge (for most Autoopen® Classic or HumanPen®) = £19.08

- **Insuman® Rapid (Sanofi-Aventis)**
  - **Injection**, soluble insulin (human, crb) 100 units/mL. Net price 5 × 3-mL cartridge (for ClikSTAR® and OptiPen® Pro 1) = £17.50; 5 × 3-mL Insuman® Rapid OptiSet® pre-filled disposable injection devices (range 2–40 units, allowing 2-unit dosage adjustment) = £17.50
  - Note: Not recommended for use in subcutaneous insulin infusion pumps

### Mixed preparations

See Biphasic Isophane Insulin (section 6.1.1.2)

### INSULIN ASPART

(Recombinant human insulin analogue)

#### Indications

diabetes mellitus

#### Cautions

section 6.1.1; interactions: Appendix 1 (antidiabetics)

#### Hepatic impairment

section 6.1.1

#### Renal impairment

section 6.1.1

#### Pregnancy

section 6.1.1

#### Breast-feeding

section 6.1.1

#### Side-effects

see under Insulin

#### Dose

- **By subcutaneous injection, ADULT and CHILD over 2 years, immediately before meals or when necessary shortly after meals, according to requirements**
- **By subcutaneous infusion, intravenous injection or intravenous infusion, ADULT and CHILD over 2 years, according to requirements**

- **NovoRapid® (Novo Nordisk)**
  - **Injection**, insulin aspart (recombinant human insulin analogue) 100 units/mL. Net price 10-mL vial = £16.28; Penfil® cartridge (for NovoPen® devices) 5 × 3 mL = £28.84; 5 × 3 mL FlexPen® pre-filled
disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £32.00
Counselling Show container to patient and confirm that patient is expecting the version dispensed

**INSULIN GLULISINE**
(Recombinant human insulin analogue)

**Indications** diabetes mellitus

**Cautions** section 6.1.1; interactions: Appendix 1 (antidiabetics)

**Hepatic impairment** section 6.1.1

**Renal impairment** section 6.1.1

**Pregnancy** section 6.1.1

**Breast-feeding** section 6.1.1

**Side-effects** see under Insulin

**Dose**
- By subcutaneous injection, ADULT and CHILD over 6 years, immediately before meals or when necessary shortly after meals, according to requirements
- By subcutaneous infusion, or intravenous infusion
ADULT and CHILD over 6 years, according to requirements

**Apidra** (Sanofi-Aventis)

**Injection**, insulin glulisine (recombinant human insulin analogue) 100 units/mL net price 10-mL vial = £16.60; 5 x 3-mL cartridge (for ClikSTAR®, OptiPen® Pro 1, and Autopen® 24) = £28.30; 5 x 3-mL OptiClick® cartridge (for OptiClick® Pen) = £30.27; 5 x 3-mL Apidra® Optise® prefilled disposable injection devices (range 2–40 units, allowing 2-unit dosage adjustment) = £28.31; 5 x 3-mL Apidra® SoloStar® prefilled disposable injection devices (range 1–80 units, allowing 1-unit dosage adjustment) = £25.00
Counselling Show container to patient and confirm that patient is expecting the version dispensed

**INSULIN LISPRO**
(Recombinant human insulin analogue)

**Indications** diabetes mellitus

**Cautions** section 6.1.1; children (use only if benefit likely compared to soluble insulin); interactions: Appendix 1 (antidiabetics)

**Hepatic impairment** section 6.1.1

**Renal impairment** section 6.1.1

**Pregnancy** section 6.1.1

**Breast-feeding** section 6.1.1

**Side-effects** see under Insulin

**Dose**
- By subcutaneous injection shortly before meals or when necessary shortly after meals, according to requirements
- By subcutaneous infusion, or intravenous infusion

**Humalog** (Lilly)

**Injection**, insulin lispro (recombinant human insulin analogue) 100 units/mL net price 10-mL vial = £16.61; 5 x 3-mL cartridge (for Autopen® Classic or HumaPen®) = £28.31; 5 x 3-mL Humalog®-Pen prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £29.46;

5 x 3-mL Humalog® KwikPen prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £29.46
Counselling Show container to patient and confirm that patient is expecting the version dispensed

**6.1.1.2 Intermediate- and long-acting insulins**

When given by subcutaneous injection, intermediate- and long-acting insulins have an onset of action of approximately 1–2 hours, a maximal effect at 4–12 hours, and a duration of 16–35 hours. Some are given twice daily in conjunction with short-acting (soluble) insulin, and others are given once daily, particularly in elderly patients. Soluble insulin can be mixed with intermediate and long-acting insulins (except insulin detemir and insulin glargine) in the syringe, essentially retaining the properties of the two components, although there may be some blunting of the initial effect of the soluble insulin component (especially on mixing with protamine zinc insulin, see below).

**Isophane insulin** is a suspension of insulin with protamine; it is of particular value for initiation of twice-daily insulin regimens. Patients usually mix isophane with soluble insulin but ready-mixed preparations may be appropriate (biphasic isophane insulin, biphasic insulin aspart, or biphasic insulin lispro).

**Insulin zinc suspension** (30% amorphous, 70% crystalline) has a more prolonged duration of action.

**Protamine zinc insulin** is usually given once daily with short-acting (soluble) insulin. It has the drawback of binding with the soluble insulin when mixed in the same syringe and is now rarely used.

**Insulin glargine** and insulin detemir are both long-acting human insulin analogues with a prolonged duration of action; insulin glargine is given once daily and insulin detemir is given once or twice daily. NICE (December 2002) has recommended that insulin glargine should be available as an option for patients with type 1 diabetes.

NICE (May 2009) has recommended that, if insulin is required in patients with type 2 diabetes, insulin detemir or insulin glargine may be considered for those:
- who require assistance with injecting insulin or whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemia or who would otherwise need twice-daily basal insulin injections in combination with oral antidiabetic drugs or who cannot use the device needed to inject isophane insulin.

**INSULIN DETEMIR**
(Recombinant human insulin analogue—long acting)

**Indications** diabetes mellitus

**Cautions** section 6.1.1.1; interactions: Appendix 1 (antidiabetics)

**Hepatic impairment** section 6.1.1

**Renal impairment** section 6.1.1

**Pregnancy** section 6.1.1
Endocrine system

6 Endocrine system

6.1 Insulins

Breast-feeding section 6.1.1

Side-effects see under Insulin (section 6.1.1.1)

Dose

- By subcutaneous injection, ADULT and CHILD over 6 years, according to requirements

Levemir® (Novo Nordisk) [FW]

Injection, insulin detemir (recombinant human insulin analogue) 100 units/mL, net price 5 × 3-mL cartridge (for NovoPen® devices) = £42.00; 5 × 3-mL FlexPen® prefilled disposable injection device (range 1–60 units, allowing 1-unit dosage adjustment) = £42.00; 5 × 3-mL Levemir InnoLet® prefilled disposable injection devices (range 1–50 units, allowing 1-unit dosage adjustment) = £44.85

Counselling Show container to patient and confirm that patient is expecting the version dispensed

INSULIN GLARGINE

(Recombinant human insulin analogue—long acting)

Indications diabetes mellitus

Cautions section 6.1.1.1; interactions: Appendix 1 (antidiabetics)

Hepatic impairment section 6.1.1

Renal impairment section 6.1.1

Pregnancy section 6.1.1

Breast-feeding section 6.1.1

Side-effects see under Insulin (section 6.1.1.1)

Dose

- By subcutaneous injection, ADULT and CHILD over 6 years, according to requirements

Lantus® (Sanofi-Aventis) [FW]

Injection, insulin glargine (recombinant human insulin analogue) 100 units/mL, net price 10-mL vial = £26.00; 5 × 3-mL cartridge (for ClickSTAR®, OptiPen® Pro 1, and Autopen® 2®) = £39.00; 5 × 3-mL OptiClick® cartridge (for OptiClick® Pen) = £40.36; 5 × 3-mL Lantus® OptiSet® prefilled disposable injection devices (range 2–40 units, allowing 2-unit dosage adjustment) = £39.00; 5 × 3-mL Lantus® SoloStar® prefilled disposable injection devices (range 1–80 units, allowing 1-unit dosage adjustment) = £40.36

Note The Scottish Medicines Consortium (p. 4) has advised (October 2002) that insulin glargine is accepted for restricted use within NHS Scotland for the treatment of type 1 diabetes:

- in those who are at risk of or experience unacceptable frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with other insulins
- as a once daily insulin therapy for patients who require a carer to administer their insulin

It is not recommended for routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections.

Counselling Show container to patient and confirm that patient is expecting the version dispensed

INSULIN ZINC SUSPENSION

(Insulin Zinc Suspension (Mixed)—long acting)

A sterile neutral suspension of bovine and/or porcine insulin or of human insulin in the form of a complex obtained by the addition of a suitable zinc salt; consists of rhombohedral crystals (10–40 microns) and of particles of no uniform shape (not exceeding 2 microns).

Indications diabetes mellitus

Cautions section 6.1.1.1; interactions: Appendix 1 (antidiabetics)

Hepatic impairment section 6.1.1

Renal impairment section 6.1.1

Pregnancy section 6.1.1

Breast-feeding section 6.1.1

Side-effects see under Insulin (section 6.1.1.1)

Dose

- By subcutaneous injection, according to requirements

Highly purified animal

Hypurin® Bovine Lente (Wockhardt) [FW]

Injection, insulin zinc suspension (bovine, highly purified) 100 units/mL. Net price 10-mL vial = £27.72

Counselling Show container to patient and confirm that patient is expecting the version dispensed

ISOPHANE INSULIN

(Isophane Insulin Injection; Isophane Protamine Insulin Injection; Isophane Insulin (NPH)—intermediate acting)

A sterile suspension of bovine or porcine insulin or of human insulin in the form of a complex obtained by the addition of protamine sulphate or another suitable protamine

Indications diabetes mellitus

Cautions section 6.1.1.1; interactions: Appendix 1 (antidiabetics)

Hepatic impairment section 6.1.1

Renal impairment section 6.1.1

Pregnancy section 6.1.1

Breast-feeding section 6.1.1

Side-effects see under Insulin (section 6.1.1.1); protamine may cause allergic reactions

Dose

- By subcutaneous injection, according to requirements

Highly purified animal

Counselling Show container to patient and confirm that patient is expecting the version dispensed

Hypurin® Bovine Isophane (Wockhardt) [FW]

Injection, isophane insulin (bovine, highly purified) 100 units/mL. Net price 10-mL vial = £27.72; cartridges (for Autopen® Classic) 5 × 3 mL = £41.58

Hypurin® Porcine Isophane (Wockhardt) [FW]

Injection, isophane insulin (porcine, highly purified) 100 units/mL. Net price 10-mL vial = £25.20; cartridges (for Autopen® Classic) 5 × 3 mL = £37.80

Human sequence

Counselling Show container to patient and confirm that patient is expecting the version dispensed

Insulatard® (Novo Nordisk) [FW]

Injection, isophane insulin (human, pyr) 100 units/mL. Net price 10-mL vial = £7.48; Insulatard Penfill® cartridge (for Novopen® devices) 5 × 3 mL = £22.90; 5 × 3-mL Insulatard InnoLet® prefilled disposable injection devices (range 1–50 units, allowing 1-unit dosage adjustment) = £20.40

Humuline® (Lilly) [FW]

Injection, isophane insulin (human, prb) 100 units/mL. Net price 10-mL vial = £15.68; 5 × 3-mL cartridge (for Autopen® Classic or Humapen®) = £19.08; 5 × 3-mL Humuline I-Pen® prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £28.44; 5 × 3-mL Humuline I KwikPen® prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £21.70
**6.1.1 Insulins**

**PROTAMINE ZINC INSULIN**

(Protamine Zinc Insulin Injection—long acting)

A sterile suspension of insulin in the form of a complex obtained by the addition of a suitable protamine and zinc chloride; this preparation was included in BP 1980 but is not included in BP 1988

**Indications**
diabetes mellitus

**Cautions**
see section 6.1.1.1; see also notes above; interactions: Appendix 1 (antidiabetics)

**Hepatic impairment**
section 6.1.1

**Renal impairment**
section 6.1.1

**Pregnancy**
section 6.1.1

**Breast-feeding**
section 6.1.1

**Side-effects**
see under Insulin (section 6.1.1.1); protamine may cause allergic reactions

**Dose**
- By subcutaneous injection, according to requirements

**Hypurin® Bovine Protamine Zinc**

(Wockhardt)

Injection, protamine zinc insulin (bovine, highly purified) 100 units/mL. Net price 10-mL vial = £27.72

**Counselling**
Show container to patient and confirm that patient is expecting the version dispensed

**BIPHASIC INSULIN ASPART**

(Intermediate-acting insulin)

**Indications**
diabetes mellitus

**Cautions**
see section 6.1.1.1; interactions: Appendix 1 (antidiabetics)

**Hepatic impairment**
section 6.1.1

**Renal impairment**
section 6.1.1

**Pregnancy**
section 6.1.1

**Breast-feeding**
section 6.1.1

**Side-effects**
see under Insulin (section 6.1.1.1); protamine may cause allergic reactions

**Dose**
- By subcutaneous injection, up to 15 minutes before or soon after a meal, according to requirements

**NovoMix® 30**

(Novo Nordisk)

Injection, biphasic insulin aspart (recombinant human insulin analogue), 30% insulin aspart, 70% insulin aspart protamine, 100 units/mL, net price 5 × 3-mL Penfill® cartridges (for NovoPen® devices) = £28.84; 5 × 3-mL FlexPen® prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £32.00

**Counselling**
Show container to patient and confirm that patient is expecting the version dispensed; the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries)

**BIPHASIC ISOPHANE INSULIN**

(Biphasic Isophane Insulin Injection—intermediate-acting)

A sterile buffered suspension of either porcine or human insulin complexed with protamine sulphate (or another suitable protamine) in a solution of insulin of the same species

**Indications**
diabetes mellitus

**Cautions**
see section 6.1.1.1 and Insulin Lispro; interactions: Appendix 1 (antidiabetics)

**Hepatic impairment**
section 6.1.1

**Renal impairment**
section 6.1.1

**Pregnancy**
section 6.1.1

**Breast-feeding**
section 6.1.1

**Side-effects**
see under Insulin (section 6.1.1.1); protamine may cause allergic reactions

**Dose**
- By subcutaneous injection, according to requirements

**Humalog® Mix50**

(Lilly)

Injection, biphasic insulin lispro (recombinant human insulin analogue), 50% insulin lispro, 50% insulin lispro protamine, 100 units/mL, net price 10-mL vial = £16.61; 5 × 3-mL cartridge (for AutoPen® Classic or HumaPen®) = £29.46; 5 × 3-mL prefilled disposable injection devices (range 1–60 units, allowing 1-unit dosage adjustment) = £30.98

**Counselling**
Show container to patient and confirm that patient is expecting the version dispensed; the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries)
6.1 Insulins

- Highly purified animal
  **Counselling** Show container to patient and confirm that patient is expecting the version dispensed; the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

- **Humulin M3** (Lilly) (BNF 61)
  **Injection** biphasic isophane insulin (human, prb), 30% soluble, 70% isophane, 100 units/mL. Net price 10-mL vial = £15.68; cartridges (for **Autopen Classic**) 5 × 3 mL = £25.20

- **Insuman** **Comb 15** (Sanofi-Aventis) (BNF 61)
  **Injection** biphasic isophane insulin (human, crb), 15% soluble, 85% isophane, 100 units/mL, net price 5 × 3 mL **Insuman Comb 15 OptiSet** prefilled disposable injection devices (range 2–40 units, allowing 1-unit dosage adjustment) = £17.50

- **Insuman** **Comb 25** (Sanofi-Aventis) (BNF 61)
  **Injection** biphasic isophane insulin (human, crb), 25% soluble, 75% isophane, 100 units/mL, net price 5–10 mL vial = £5.61; 5 × 3-mL cartridge (for **Comb 25 OptiSet** and **Comb 50 OptiSet**) = £17.50; 5 × 3 mL **Insuman Comb 25 OptiSet** prefilled disposable injection devices (range 2–40 units, allowing 2-unit dosage adjustment) = £17.50

- **Insuman** **Comb 50** (Sanofi-Aventis) (BNF 61)
  **Injection** biphasic isophane insulin (human, crb), 50% soluble, 50% isophane, 100 units/mL, net price 5 × 3-mL cartridge (for **Comb 50 OptiSet** and **OptiPen Pro I**) = £17.50; 5 × 3 mL **Insuman Comb 50 OptiSet** prefilled disposable injection devices (range 1–80 units, allowing 1-unit dosage adjustment) = £19.00

- **Hypurin** Porcine 30/70 Mix (Wockhardt) (BNF 61)
  **Injection** biphasic isophane insulin (porcine, highly purified), 30% soluble, 70% isophane, 100 units/mL. Net price 10-mL vial = £16.80; cartridges (for **Autopen Classic** 5 × 3 mL = £25.20

- **Injection devices**
  **Autopen** (Owen Mumford)
  **Injection device**. **Autopen** 24 (for use with Sanofi-Aventis 3-mL insulin cartridges), allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version), net price (both) = £15.73. **Autopen Classic** (for use with Lilly and Wockhardt 3-mL insulin cartridges), allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version), net price (all) = £15.97

- **ClikSTAR** (Sanofi-Aventis)
  **Injection device** for use with **Lantus**, **Apidra**, and **Insuman** 3-mL insulin cartridges; allowing 1-unit dose adjustment, max. 80 units, net price = £25.00

- **HumanaPen Luxura** (Lilly)
  **Injection device** for use with **Humulin** and **Humalog** 3-mL cartridges; allowing 0.5-unit dosage adjustment, max. 30 units, net price = £26.36

- **HumanaPen Luxura HD** (Lilly)
  **Injection device** for use with **Humulin** and **Humalog** 3-mL cartridges; allowing 0.5-unit dosage adjustment, max. 30 units, net price = £26.36

- **NovoPen** (Novo Nordisk)
  **Injection device** for use with **Penfill** insulin cartridges. **NovoPen Junior** (for 3-mL cartridges), allowing 0.5-unit dosage adjustment, max. 35 units, net price = £24.79. **NovoPen 3 Demi** (for 3-mL cartridges), allowing 0.5-unit dosage adjustment, max. 35 units, net price = £25.21; **NovoPen 4** (for 3-mL cartridges), allowing 1-unit dosage adjustment, max. 60 units, net price = £26.56

- **OptiClik** (Sanofi-Aventis)
  **Injection device** for use with **Lantus OptiClik** or **Apidra Opticlik** insulin cartridges, allowing 1-unit dosage adjustment, max. 80 units, net price = £20.13

- **OptiPen Pro 1** (Sanofi-Aventis)
  **Injection device** for use with **Insuman** insulin cartridges; allowing 1-unit dosage adjustment, max. 60 units, net price = £22.00

- **Lancets**
  **Lancets—sterile, single use** (Drug Tariff)

<table>
<thead>
<tr>
<th>Brand</th>
<th>Price (0.5 mL)</th>
<th>Price (1.0 mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascensia Microlite</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>BD MicroFine</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>CareSense</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>ComforTouch</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>One Touch UltraSoft</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>Softclix</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
<tr>
<td>Softclix XL</td>
<td>£0.37</td>
<td>£0.74</td>
</tr>
</tbody>
</table>

- **Compatible finger-pricking devices** (unless indicated otherwise, see footnotes), all **Softclix**, **BD Optimus**, **Glucotest**, **Moneyject**, **Penlet IV**, **Soft Touch**

1. **Autolet** and **Autolet Impression** are also compatible finger-pricking devices
2. **Softclix** finger-pricking device

6.1.3 Hypodermic equipment

Patients should be advised on the safe disposal of lancets, single-use syringes, and needles. Suitable arrangements for the safe disposal of contaminated waste must be made before these products are prescribed for patients who are carriers of infectious diseases.
6.1.2 Antidiabetic drugs

6.1.2.1 Sulfonylureas

The sulfonylureas act mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extra-pancreatic action. All may cause hypoglycaemia but this is uncommon and usually indicates excessive dosage. Sulfonylurea-induced hypoglycaemia may persist for many hours and must always be treated in hospital.

Sulfonylureas are considered for patients who are not overweight, or in whom metformin is contra-indicated or not tolerated. Several sulfonylureas are available and choice is determined by side-effects and the duration of action as well as the patient’s age and renal function. Glibenclamide, a long-acting sulfonylurea, is associated with a greater risk of hypoglycaemia; for this reason it should be avoided in the elderly, and shorter-acting alternatives, such as gliclazide or tolbutamide, should be used instead.

When the combination of strict diet and sulfonylurea treatment fails, other options include:

- combining with metformin (section 6.1.2.2) (reports of increased hazard with this combination remain unconfirmed);
- combining with pioglitazone, but see section 6.1.2.3;
- combining with saxagliptin, sitagliptin, or vildagliptin (section 6.1.2.3);
- combining with exenatide or liraglutide (section 6.1.2.3);
- combining with acarbose (section 6.1.2.3), which may have a small beneficial effect, but flatulence can be a problem;
- combining with bedtime isophane insulin (section 6.1.1) but weight gain and hypoglycaemia can occur.

The risk of hypoglycaemia associated with sulfonylureas (see notes above) should be discussed with the patient, especially when concomitant glucose-lowering drugs are prescribed.

Insulin therapy should be instituted temporarily during intercurrent illness (such as myocardial infarction, coma, infection, and trauma). Sulfonylureas should be...
Endocrine system

6 Endocrine system

Diabetic drugs

Sulfonylureas

Sulfonylurea therapy is generally started with one of the short-acting drugs, e.g. tolbutamide, because of the theoretical possibility of hypoglycaemia in the infant. Jaundice may occur.

Pregnancy

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2.

Breast-feeding

The use of sulfonylureas (except glibenclamide [unlicensed use], see section 6.1.2) in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.

Side-effects

Side-effects of sulfonylureas are generally mild and infrequent and include gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and constipation. Hypoglycaemia has been reported with glibenclamide and glipizide.

Sulfonylureas can occasionally cause a disturbance in liver function, which may rarely lead to cholestatic jaundice, hepatitis, and hepatocellular necrosis. Hypersensitivity reactions can occur, usually in the first 6–8 weeks of therapy. They consist mainly of allergic skin reactions which progress rarely to erythema multiforme and exfoliative dermatitis, fever, and jaundice; photosensitivity has rarely been reported with glipizide. Blood disorders are also rare but may include leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia.

Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic impairment, because there is an increased risk of hypoglycaemia. Jaundice may occur.

Sulfonylureas should be avoided in those with mild to moderate renal impairment, because of the risk of hypoglycaemia; they should be avoided where possible in severe renal impairment. Glipizide should also be avoided if the patient has both renal and hepatic impairment. If necessary, the short-acting drug tolbutamide can be used in renal impairment, as can gliclazide which is principally metabolised in the liver, but careful monitoring of blood-glucose concentration is essential; care is required to use the lowest dose that adequately controls blood glucose.

Hepatic impairment

Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic impairment, because there is an increased risk of hypoglycaemia. Jaundice may occur.

Renal impairment

Sulfonylureas should be used with care in those with mild to moderate renal impairment, because of the hazard of hypoglycaemia; they should be avoided where possible in severe renal impairment. Glipizide should also be avoided if the patient has both renal and hepatic impairment. If necessary, the short-acting drug tolbutamide can be used in renal impairment, as can gliclazide which is principally metabolised in the liver, but careful monitoring of blood-glucose concentration is essential; care is required to use the lowest dose that adequately controls blood glucose.

Sulfonylureas should be avoided in those with mild to moderate renal impairment, because there is an increased risk of hypoglycaemia; they should be avoided where possible in severe renal impairment. Glipizide should also be avoided if the patient has both renal and hepatic impairment. If necessary, the short-acting drug tolbutamide can be used in renal impairment, as can gliclazide which is principally metabolised in the liver, but careful monitoring of blood-glucose concentration is essential; care is required to use the lowest dose that adequately controls blood glucose.

Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic impairment, because there is an increased risk of hypoglycaemia. Jaundice may occur.

Pregnancy

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2.

Breast-feeding

The use of sulfonylureas (except glibenclamide [unlicensed use], see section 6.1.2) in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.

Side-effects

Side-effects of sulfonylureas are generally mild and infrequent and include gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and constipation. Hypoglycaemia has been reported with glibenclamide and glipizide.

Sulfonylureas can occasionally cause a disturbance in liver function, which may rarely lead to cholestatic jaundice, hepatitis, and hepatocellular necrosis. Hypersensitivity reactions can occur, usually in the first 6–8 weeks of therapy. They consist mainly of allergic skin reactions which progress rarely to erythema multiforme and exfoliative dermatitis, fever, and jaundice; photosensitivity has rarely been reported with glipizide. Blood disorders are also rare but may include leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia.

Glibenclamide

Indications

type 2 diabetes mellitus

Cautions

see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications

see notes above

Hepatic impairment

see notes above

Glibenclamide (Non-proprietary) Tablets, glibenclamide 2.5 mg, net price 28-tab pack = 95p; 5 mg, 28-tab pack = £1.07

Glimepiride

Indications

type 2 diabetes mellitus

Cautions

see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications

see notes above

Hepatic impairment

see notes above

Renal impairment

see notes above

Pregnancy

see notes above

Breast-feeding

see notes above

Side-effects

see notes above

Dose

• Initially 1 mg daily, adjusted according to response (ELDERLY avoid, see notes above); max. 15 mg daily

Glimepiride should also be avoided if the patient has both renal and hepatic impairment. If necessary, the short-acting drug tolbutamide can be used in renal impairment, as can gliclazide which is principally metabolised in the liver, but careful monitoring of blood-glucose concentration is essential; care is required to use the lowest dose that adequately controls blood glucose.

Pregnancy

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2.

Breast-feeding

The use of sulfonylureas (except glibenclamide [unlicensed use], see section 6.1.2) in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.

Side-effects

Side-effects of sulfonylureas are generally mild and infrequent and include gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and constipation. Hypoglycaemia has been reported with glibenclamide and glipizide.

Sulfonylureas can occasionally cause a disturbance in liver function, which may rarely lead to cholestatic jaundice, hepatitis, and hepatocellular necrosis. Hypersensitivity reactions can occur, usually in the first 6–8 weeks of therapy. They consist mainly of allergic skin reactions which progress rarely to erythema multiforme and exfoliative dermatitis, fever, and jaundice; photosensitivity has rarely been reported with glipizide. Blood disorders are also rare but may include leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia.

Appendix 1

GLICLAZIDE

Indications

type 2 diabetes mellitus

Cautions

see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications

see notes above

Hepatic impairment

see notes above

Renal impairment

see notes above

Pregnancy

see notes above

Breast-feeding

see notes above

Side-effects

see notes above

Dose

• Initially, 40–80 mg daily, adjusted according to response; up to 160 mg as a single dose, with breakfast; higher doses divided; max. 120 mg daily

Gliclazide (Non-proprietary) Tablets, scored, gliclazide 80 mg, net price 28-tab pack = £1.10, 60-tab pack = £1.52

Brands include DUAGLYK™

Diamicron® (Servier) Tablets, scored, gliclazide 80 mg, net price 60-tab pack = £4.38

Modiﬁed release

Diamicron® MR (Servier) Tablets, m/r, gliclazide 30 mg, net price 28-tab pack = £2.81, 56-tab pack = £5.62. Label: 25

Dose

• Initially 30 mg daily with breakfast, adjusted according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); max. 120 mg daily

Note Diamicron® MR 30 mg may be considered to be approximately equivalent in therapeutic effect to standard formulation Diamicron® 80 mg

GLIMEPIRIDE

Indications

type 2 diabetes mellitus

Cautions

see notes above; manufacturer recommends regular hepatic and haematological monitoring but limited evidence of clinical value; interactions: Appendix 1 (antidiabetics)

Contra-indications

see notes above

Hepatic impairment

see notes above

Renal impairment

see notes above

Pregnancy

see notes above

Breast-feeding

see notes above

Side-effects

see notes above

Dose

• Initially 1 mg daily, adjusted according to response in 1-mg steps at 1–2 week intervals; usual max. 4 mg daily (exceptionally, up to 6 mg daily may be used); taken shortly before or with first main meal

Appendix 1

GLIBENCLAMIDE

Indications

type 2 diabetes mellitus

Cautions

see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications

see notes above

Hepatic impairment

see notes above

Renal impairment

see notes above

Pregnancy

see notes above

Breast-feeding

see notes above

Side-effects

see notes above

Dose

• Initially 5 mg daily with or immediately after breakfast, dose adjusted according to response (ELDERLY avoid, see notes above); max. 15 mg daily

Glibenclamide (Non-proprietary) Tablets, glibenclamide 2.5 mg, net price 28-tab pack = 95p; 5 mg, 28-tab pack = £1.07
6.1.2 Antidiabetic drugs

Glimepiride (Non-proprietary) (Non-proprietary)

Tablets, glimepiride 1 mg, net price 30-tab pack = £1.40; 2 mg, 30-tab pack = £1.38; 3 mg, 30-tab pack = £4.57; 4 mg, 30-tab pack = £1.75

Amaryl® (Sanofi-Aventis) (Sanofi-Aventis)

Tablets, all scored, glimepiride 1 mg (pink), net price 30-tab pack = £4.33; 2 mg (green), 30-tab pack = £7.13; 3 mg (yellow), 30-tab pack = £10.75; 4 mg (blue), 30-tab pack = £14.24

GLIPIZIDE

Indications type 2 diabetes mellitus

Cautions see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications see notes above

Hepatic impairment see notes above

Renal impairment see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; also dizziness, drowsiness

Dose

- Initially 2.5–5 mg daily shortly before breakfast or lunch, adjusted according to response; max. 20 mg daily; up to 15 mg may be given as a single dose; higher doses divided

Glipizide (Non-proprietary) (Pharmacia)

Tablets, glipizide 5 mg, net price 56-tab pack = £4.23

Minodiab® (Pharmacia) (Pharmacia)

Tablets, scored, glipizide 5 mg, net price 28-tab pack = £1.26

TOLBUTAMIDE

Indications type 2 diabetes mellitus

Cautions see notes above; interactions: Appendix 1 (antidiabetics)

Contra-indications see notes above

Hepatic impairment see notes above

Renal impairment see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above; also headache, tinnitus

Dose

- 0.5–1.5 g (max. 2 g) daily in divided doses with or immediately after meals or as a single dose with or immediately after breakfast

Tolbutamide (Non-proprietary) (Pharmacia)

Tablets, tolbutamide 500 mg, net price 28-tab pack = £1.74

6.1.2.2 Biguanides

Metformin, the only available biguanide, has a different mode of action from the sulfonylureas, and is not interchangeable with them. It exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.

Metformin is the drug of first choice in overweight patients in whom strict dieting has failed to control diabetes, if appropriate it may also be considered as an option in patients who are not overweight. It is also used when diabetes is inadequately controlled with sulfonylurea treatment. When the combination of strict diet and metformin treatment fails, other options include:

- combining with a sulfonylurea (section 6.1.2.1) (reports of increased hazard with this combination remain unconfirmed);
- combining with pioglitazone (section 6.1.2.3);
- combining with repaglinide or nateglinide (section 6.1.2.3);
- combining with saxagliptin, sitagliptin, or vildagliptin (section 6.1.2.3);
- combining with exenatide or liraglutide (section 6.1.2.3);
- combining with acarbose (section 6.1.2.3), which may have a small beneficial effect, but flatulence can be a problem;
- combining with insulin (section 6.1.1) but weight gain and hypoglycaemia can be problems (weight gain minimised if insulin given at night).

Insulin treatment is almost always required in medical and surgical emergencies; insulin should also be substituted before elective surgery (omit metformin on the morning of surgery and give insulin if required).

Hypoglycaemia does not usually occur with metformin; other advantages are the lower incidence of weight gain and lower plasma-insulin concentration. It does not exert a hypoglycaemic action in non-diabetic subjects unless given in overdose.

Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses such as 3 g daily are given. Very rarely, metformin can provoke lactic acidosis. It is most likely to occur in patients with renal impairment, see Lactic Acidosis below.

Metformin is used for the symptomatic management of polycystic ovary syndrome [unlicensed indication]; however, treatment should be initiated by a specialist. Metformin improves insulin sensitivity, may aid weight reduction, helps to normalise menstrual cycle (increasing the rate of spontaneous ovulation), and may improve hirsutism.

METFORMIN HYDROCHLORIDE

Indications diabetes mellitus (see notes above); polycystic ovary syndrome [unlicensed indication]

Cautions see notes above; determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected); interactions: Appendix 1 (antidiabetics)

Lactic acidosis Use with caution in renal impairment—increased risk of lactic acidosis; avoid in significant renal impairment. NICE recommends that the dose should be reviewed if eGFR less than 45 mL/minute/1.73 m² and to 1. NICE clinical guideline 87 (May 2009): Type 2 diabetes. The management of type 2 diabetes.
6.1.2 Antidiabetic drugs

avoid if eGFR less than 30 mL/minute/1.73 m². Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.

Contra-indications ketoadosis, see also Lactic Acidosis above; use of general anaesthesia (suspended metformin on the morning of surgery and restart when renal function returns to baseline). Iodine-containing X-ray contrast media Intravascular administration of iodinated contrast agents can cause renal failure. Suspend metformin prior to the test; restart at least 48 hours after the test if renal function has returned to baseline.

Hepatic impairment withdraw if tissue hypoxia likely.

Renal impairment see under Cautions.

Pregnancy used in pregnancy for both pre-existing and gestational diabetes—see also p. 427.

Breast-feeding may be used during breast-feeding—see p. 427.

Side-effects anorexia, nausea, vomiting, diarrhoea (usually transient), abdominal pain, taste disturbance, rarely lactic acidosis (withdraw treatment), decreased vitamin-B₁₂ absorption, erythema, pruritus and urticaria; hepatitis also reported.

Dose

- Diabetes mellitus, ADULT and CHILD over 10 years initially 500 mg with breakfast for at least 1 week then 500 mg with breakfast and evening meal for at least 1 week then 500 mg with breakfast, lunch and evening meal; usual max. 2 g daily in divided doses.
- Polycystic ovary syndrome [unlicensed], initially 500 mg with breakfast for 1 week, then 500 mg with breakfast and evening meal for 1 week, then 1.5–1.7 g daily in 2–3 divided doses.

Note Metformin doses in the BNF may differ from those in the product literature.

Metformin (Non-proprietary) Tablets, coated, metformin hydrochloride 500 mg, net price 28-tab pack = £1.07, 84-tab pack = £1.57; 850 mg, 56-tab pack = £1.67. Label: 21.

Oral solution, sugar-free, metformin hydrochloride 500 mg/5 mL, net price 100 mL = £62.48. Label: 21. Brands include Metformin SR, Bolamyn SR.

Glucophage® (Merck Serono) Tablets, f/c, metformin hydrochloride 500 mg, net price 84-tab pack = £2.88; 850 mg, 56-tab pack = £3.20. Label: 21.

Oral powder, sugar-free, metformin hydrochloride 500 mg/sachet, net price 30-sachet pack = £3.29, 60-sachet pack = £6.58; 1 g/sachet, 30-sachet pack = £6.58; 60-sachet pack = £13.16. Label: 13, 21, counselling, administration. Excipients include aspartame (section 9.4.1) and fucose concentration. Pioglitazone can be used alone or in combination with metformin or with a sulfonylurea (if metformin inappropriate), or with both; the combination of pioglitazone plus metformin is preferred to pioglitazone plus sulfonylurea, particularly for obese patients. Inadequate response to a combination of metformin and sulfonylurea may indicate failing insulin release; the introduction of pioglitazone has a limited role in these circumstances and the initiation of insulin is often more appropriate. Pioglitazone is also licensed in combination with insulin.
with insulin, in patients who have not achieved ade-
quate glycaemic control with insulin alone, when met-
formin is inappropriate. Blood-glucose control may
deteriorate temporarily when pioglitazone is substitut-
ed for an oral antidiabetic drug that is being used in
combination with another. Long-term benefits of piogi-
tazone have not yet been demonstrated. NICE (May
2009) has recommended that, when glycaemic control
is inadequate with existing treatment, pioglitazone can
be added to:
• a sulfonylurea, if metformin is contra-indicated or
not tolerated;
• metformin, if risks of hypoglycaemia with sulfony-
lurea are unacceptable or a sulfonylurea is contra-
indicated or not tolerated;
• a combination of metformin and a sulfonylurea, if
insulin is unacceptable because of lifestyle or other
personal issues, or because the patient is obese.

NICE has recommended that treatment with piogli-
tazone is continued only if HbA1c concentration is reduced
by at least 0.5% within 6 months of starting treatment.
The Scottish Medicines Consortium (p. 4) accepts use of
pioglitazone (February 2007) with metformin and a
sulfonylurea, for patients (especially if overweight)
whose glycaemic control is inadequate despite the use
of 2 oral hypoglycaemic drugs and who are unable or
unwilling to take insulin; treatment should be initiated
and monitored by an experienced diabetes physician.

MHRA/CHM advice
Pioglitazone cardiovascular safety
(December 2007 and January 2011)
Incidence of heart failure is increased when piogi-
tazone is combined with insulin especially in
patients with predisposing factors e.g. previous myo-
cardial infarction. Patients who take pioglitazone
should be closely monitored for signs of heart fail-
ure; treatment should be discontinued if any dete-
rioration in cardiac status occurs.
Pioglitazone should not be used in patients with
heart failure or a history of heart failure.

Rosiglitazone
The marketing authorisation for rosiglitazone
(Avandia®, Avandamet®) has been suspended
(September 2010) following a review by the
European Medicines Agency. The European Medi-
cines Agency concluded that the benefits of
rosiglitazone treatment do not outweigh the cardio-
avascular risks. Prescribers should not issue new or
repeat prescriptions for rosiglitazone. Treatment of
patients who are taking rosiglitazone should be re-
viewed.

Saxagliptin, sitagliptin, and vildagliptin inhibit dipep-
tidylpeptidase-4 to increase insulin secretion and lower
glucagon secretion. They are licensed for use in type 2
diabetes in combination with metformin or a sulfonylur-
ea (if metformin inappropriate) or pioglitazone, when
treatment with either metformin or a sulfonylurea or
pioglitazone fails to achieve adequate glycaemic con-
trol. Sitagliptin is also licensed for use as monotherapy
(if metformin inappropriate), or in combination with
both metformin and a sulfonylurea, or both metformin
and pioglitazone when dual therapy with these drugs
fails to achieve adequate glycaemic control. The com-
bination of sitagliptin and insulin (with or without met-
formin) is also licensed for use when a stable dose of
insulin has not provided adequate glycaemic control.

NICE (May 2009) has recommended that, when glycae-
ic control is inadequate with existing treatment:
• sitagliptin or vildagliptin (instead of a sulfonylurea)
can be added to metformin, if there is a significant
risk of hypoglycaemia or if a sulfonylurea is contra-
indicated or not tolerated;
• sitagliptin or vildagliptin can be added to a sulfo-
ylurea, if metformin is contra-indicated or not tolerance;
• sitagliptin can be added to both metformin and a
sulfonylurea, if insulin is unacceptable because of
lifestyle or other personal issues, or because the
patient is obese.

NICE has recommended that treatment with sitagliptin
or vildagliptin is continued only if HbA1c concentration is reduced by at least 0.5% within 6 months of starting
treatment.
The Scottish Medicines Consortium (p. 4) has advised
that vildagliptin (Galvus®) is accepted for restricted use
within NHS Scotland for the treatment of type 2 dia-
betes mellitus in combination with metformin when
addition of a sulfonylurea is inappropriate (March 2008),
and also in combination with a sulfonylurea if metformin is
inappropriate (September 2009).

Exenatide and liraglutide both bind to, and activate,
the GLP-1 (glucagon-like peptide-1) receptor to increase
insulin secretion, suppress glucagon secretion, and slow
gastric emptying. Treatment with exenatide and liraglu-
tide is associated with the prevention of weight gain and
possible promotion of weight loss which can be bene-
ferial in overweight patients. They are both given by
subcutaneous injection for the treatment of type 2 dia-
betes mellitus.

Exenatide is licensed in combination with metformin or
a sulfonylurea, or both, or with pioglitazone, or with
both metformin and pioglitazone, in patients who have
not achieved adequate glycaemic control with these
drugs alone or in combination.

NICE (May 2009) has recommended that, when glycae-
ic control is inadequate with metformin and sulfony-
lurea treatment, the addition of exenatide may be con-
sidered if the patient has:
• a body mass index of 35 kg/m² or over and is of
European descent (with appropriate adjustment for
other ethnic groups) and weight-related psycholo-
gical or medical problems or
• a body mass index less than 35 kg/m², and insulin
would be unacceptable for occupational reasons or
weight loss would benefit other significant obesity-
related comorbidities.

NICE has recommended that treatment with exenatide
is continued only if HbA1c concentration is reduced by
at least 1% and a weight loss of at least 3% is achieved
within 6 months of starting treatment.
The Scottish Medicines Consortium (p. 4) has advised
(June 2007) that exenatide (Byetta®) is accepted for
restricted use within NHS Scotland for the treatment of
type 2 diabetes in combination with metformin or
sulfonylurea (or both), as an alternative to treatment
with insulin in patients where treatment with metformin
or sulfonylurea (or both) at maximally tolerated doses
has been inadequate, and treatment with insulin would be the next option.

Liraglutide is licensed for the treatment of type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination. Liraglutide is also licensed for use in combination with both metformin and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control.

### NICE guidance

**Liraglutide for the treatment of type 2 diabetes mellitus (October 2010)**

Liraglutide in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione) is recommended for the treatment of type 2 diabetes, only when glycaemic control is inadequate, and the patient has:
- a body mass index of 35 kg/m² or over and is of European descent (with appropriate adjustment for other ethnic groups) and weight-related psychological or medical problems, or
- a body mass index of less than 35 kg/m², and insulin would be unacceptable for occupational reasons or weight loss would benefit other significant obesity-related comorbidities.

Treatment with liraglutide in a triple therapy regimen should be continued only if HbA₁c concentration is reduced by at least 1% and a weight loss of at least 3% is achieved within 6 months of starting treatment.

Liraglutide in dual therapy regimens (in combination with metformin or a sulfonylurea) is recommended only if:
- treatment with metformin or a sulfonylurea is contra-indicated or not tolerated, and
- treatment with thiazolidinediones and dipeptidylpeptidase-4 inhibitors is contra-indicated or not tolerated.

Liraglutide in combination with metformin or a sulfonylurea should be continued only if HbA₁c concentration is reduced by at least 1% within 6 months of starting treatment.

Liraglutide 1.8 mg daily is not recommended.

### ACARBOSE

**Indications** diabetes mellitus inadequately controlled by diet or by diet with oral antidiabetic drugs

**Cautions** monitor liver function; may enhance hypoglycaemic effects of insulin and sulfonylureas (hypoglycaemic episodes may be treated with oral glucose but not with sucrose); interactions: Appendix 1 (antidiabetics)

**Contra-indications** inflammatory bowel disease, predisposition to partial intestinal obstruction; hernia, previous abdominal surgery

**Hepatic impairment** avoid

**Renal impairment** avoid if eGFR less than 25 mL/minute/1.73 m²

**Pregnancy** avoid

**Breast-feeding** avoid

**Side-effects** flatulence, soft stools, diarrhoea (may need to reduce dose or withdraw), abdominal dis-...

### EXENATIDE

**Indications** see notes above

**Cautions** elderly; pancreatitis (see below); interactions: Appendix 1 (antidiabetics)

**Pancreatitis** Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely. Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop; discontinue permanently if pancreatitis is diagnosed

**Contra-indications** ketoacidosis; severe gastro-intestinal disease

**Renal impairment** use with caution if eGFR 30–50 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** avoid—no information available

**Side-effects** gastro-intestinal disturbances including nausea, vomiting, diarrhoea, dyspepsia, abdominal pain and distention, gastro-oesophageal reflux disease, decreased appetite; headache, dizziness, agitation, asthma; hypoglycaemia; increased sweating, injection-site reactions; antibody formation; less commonly pancreatitis (see Cautions above); very rarely anaphylactic reactions; also reported constipation, flatulence, urticaria, and angioedema

**Dose**
- by subcutaneous injection, ADULT over 18 years, initially 5 micrograms twice daily within 1 hour before 2 main meals (at least 6 hours apart), increased if necessary after at least 1 month to max. 10 micrograms twice daily
- Counselling if a dose is missed, continue with the next scheduled dose—do not administer after a meal. Some oral medications should be taken at least 1 hour before or 4 hours after exenatide injection—consult product literature for details

**Byetta®** (Lilly)

**Injection**, exenatide 250 micrograms/mL, net price 5 micrograms/dose prefilled pen (60 doses) = £68.24, 10 micrograms/dose prefilled pen (80 doses) = £68.24.

**Counselling, administration**
**LIRAGLUTIDE**

**Indications** see notes above

**Cautions** discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain); **interactions:** Appendix 1 (antidiabetics)

**Contra-indications** ketoacidosis; inflammatory bowel disease; diabetic gastroparesis

**Hepatic impairment** avoid—limited experience

**Renal impairment** avoid if eGFR less than 60 mL/minute/1.73 m²—limited experience

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** avoid—no information available

**Side-effects** gastro-intestinal disturbances including nausea, vomiting, constipation, diarrhoea, dyspepsia, abdominal pain and distension, flatulence, gastritis, gastro-oesophageal reflux disease, decreased appetite, headache, dizziness, fatigue, fever, bronchitis, nasopharyngitis; hypoglycaemia; injection site reactions; also reported; subcutaneous injection, ADULT over 18 years, initially 0.6 mg once daily, increased after at least 1 week to 1.2 mg once daily, further increased if necessary after an interval of at least 1 week to max. 1.8 mg once daily

**Note** Dose of concomitant sulfonylurea may need to be reduced

**Victoza®** (Novo Nordisk)

- **Injection**, liraglutide 6 mg/mL, net price 2 × 3-mL prefilled pens = £78.48, 3 × 3-mL prefilled pens = £117.72. Counselling, administration

**NATEGLINIDE**

**Indications** type 2 diabetes mellitus in combination with metformin (section 6.1.2.2) when metformin alone inadequate

**Cautions** substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and trauma) and during surgery (omit nateglinide on morning of surgery and recommence when eating and drinking normally); elderly, debilitated and malnourished patients; **interactions:** Appendix 1 (antidiabetics)

**Contra-indications** ketoacidosis

**Hepatic impairment** caution in moderate hepatic impairment; avoid in severe impairment—no information available

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** hypoglycaemia; hypersensitivity reactions including pruritus, rashes and urticaria

**Dose**

- **ADULT** over 18 years, initially 60 mg 3 times daily within 30 minutes before main meals, adjusted according to response up to max. 180 mg 3 times daily

**Starlix®** (Novartis)

- **Tablets**, f/c, nateglinide 60 mg (pink), net price 84-tab pack = £22.71; 120 mg (yellow), 84-tab pack = £25.88; 180 mg (red), 84-tab pack = £25.88

**PIOGLITAZONE**

**Indications** type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin—see also notes above)

**Cautions** monitor liver function (see below); cardiovascular disease or in combination with insulin (risk of heart failure—see MHRA/CHM advice p. 431); substitute insulin during peri-operative period (omit pioglitazone on morning of surgery and recommence when eating and drinking normally); increased risk of bone fractures, particularly in women; avoid in acute porphyria (but see section 9.8.2); **interactions:** Appendix 1 (antidiabetics)

**Liver toxicity** Rare reports of liver dysfunction; monitor liver function before treatment, and periodically thereafter; advise patients to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop; discontinue if jaundice occurs

**Contra-indications** history of heart failure

**Hepatic impairment** avoid; see also Cautions above

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** gastro-intestinal disturbances, weight gain, oedema, anaemia, headache, visual disturbances, dizziness, arthralgia, hypoaesthesia, haematuria, impotence; less commonly hypoglycaemia, fatigue, insomnia, vertigo, sweating, altered blood lipids, proteinuria; see also Liver Toxicity above

**Dose**

- **ADULT** over 18 years, initially 15–30 mg once daily increased to 45 mg once daily according to response

**Actos®** (Takeda)

- **Tablets**, pioglitazone (as hydrochloride) 15 mg, net price 28-tab pack = £25.83; 30 mg, 28-tab pack = £35.89; 45 mg, 28-tab pack = £39.55

**With metformin**

For prescribing information on metformin, see section 6.1.2.2

**Competact®** (Takeda)

- **Tablets**, f/c, pioglitazone (as hydrochloride) 15 mg, metformin hydrochloride 850 mg, net price 56-tab pack = £35.89; Label: 21

**Dose**

- **ADULT** over 18 years, type 2 diabetes not controlled by metformin alone, 1 tablet twice daily

**Note** Titration with the individual components (pioglitazone and metformin) desirable before initiating Competact®

**REPAGLINDIDE**

**Indications** type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate)

**Cautions** substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and trauma) and during surgery (omit repaglinide on morning of surgery and recommence when eating and drinking normally); debilitated and malnourished patients; **interactions:** Appendix 1 (antidiabetics)

**Contra-indications** ketoacidosis

**Hepatic impairment** avoid in severe liver disease

**Renal impairment** use with caution

**Pregnancy** avoid
**SAXAGLIPTIN**

**Indications** see notes above

**Cautions** elderly; **interactions:** Appendix 1 (anti-diabetics)

**Hepatic impairment** use with caution in moderate impairment; avoid in severe impairment

**Renal impairment** avoid if eGFR less than 50 mL/minute/1.73m²

**Pregnancy** avoid—present in milk in animal studies

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** vomiting, dyspepsia, gastritis; peripheral oedema; headache, diziness, fatigue; upper respiratory tract infection, urinary tract infection, gastro-enteritis, sinusitis, nasopharyngitis; hypoglycaemia, myalgia; less commonly dyslipidaemia, hypertriglyceridaemia, erectile dysfunction, arthralgia; also reported rash

**Dose**

- **ADULT** over 18 years, 5 mg once daily

**Note** Dose of concomitant sulfonylurea may need to be reduced

Onglyza® (Bristol-Myers Squibb) Tablets, pink, f/c, saxagliptin (as hydrochloride) 5 mg, net price 28-tab pack = £31.60

**VILDAGLIPTIN**

**Indications** type 2 diabetes mellitus (in combination with metformin or with a sulfonylurea or with pioglitazone—see also notes above)

**Cautions** elderly; monitor liver function (see below); heart failure (avoid if moderate or severe); **interactions:** Appendix 1 (anti-diabetics)

Liver toxicity Rare reports of liver dysfunction; monitor liver function before treatment and every 3 months for first year and periodically thereafter; advise patients to seek prompt medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop; discontinue if jaundice or other signs of liver dysfunction occur

**Contra-indications** ketoacidosis

**Hepatic impairment** avoid; see also Cautions above

**Renal impairment** avoid if eGFR less than 50 mL/minute/1.73 m²

**Pregnancy** avoid—toxicity in animal studies

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** nausea, peripheral oedema, headache, tremor, asthenia, dizziness; less commonly constipation, hypoglycaemia, arthralgia; rarely hepatic dysfunction (see also Liver Toxicity above); very rarely nasopharyngitis, upper respiratory tract infection; pancreatitis also reported

**Dose**

- **ADULT** over 18 years, in combination with metformin or pioglitazone, 50 mg twice daily; in combination with a sulfonylurea, 50 mg daily in the morning

Galvus® (Novartis) Tablets, pale yellow, vildagliptin 50 mg, net price 56-tab pack = £31.76

**Dose of concomitant sulfonylurea or insulin may need to be reduced**

Januvia® (MSD) Tablets, beige, f/c, sitagliptin (as phosphate) 100 mg, net price 28-tab pack = £33.26

The Scottish Medicines Consortium (p. 4) has advised (July 2008) that Januvia® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus when the addition of a sulfonylurea to metformin is not appropriate; it is also accepted for use in NHS Scotland in combination with a sulfonylurea in patients inadequately controlled on maximum tolerated doses of metformin and a sulfonylurea.

**With metformin**

For prescribing information on metformin, see section 6.1.2.2
With metformin

For prescribing information on metformin, see section 6.1.2.2

Eucreas® (Novartis) ▼ (p. 366)

Eucreas® 50 mg/850 mg tablets, f/c, yellow, vildaglitin 50 mg, metformin hydrochloride 850 mg, net price 60-tab pack = £31.76. Label: 21

Eucreas® 50 mg/1 g tablets, f/c, dark yellow, vildaglitin 50 mg, metformin hydrochloride 1 g, net price 60-tab pack = £31.76. Label: 21

Dose: type 2 diabetes mellitus not controlled by metformin alone, ADULT over 18 years, 1 Eucreas® tablet twice daily (based on patient’s current metformin dose)

The Scottish Medicines Consortium (p. 4) has advised (June 2008) that Eucreas® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in patients unable to achieve adequate glycaemic control with metformin alone or those already treated with vildaglitin and metformin as separate tablets

6.1.3 Diabetic ketoacidosis

The management of diabetic ketoacidosis involves the replacement of fluid and electrolytes and the administration of insulin. Guidelines for the Management of Diabetic Ketoacidosis in Adults, published by the Joint British Diabetes Societies Inpatient Care Group1, should be followed.

- To restore circulating volume if systolic blood pressure is below 90 mmHg (adjusted for age, sex, and medication as appropriate), give 500 mL sodium chloride 0.9% by intravenous infusion over 10–15 minutes; repeat if blood pressure remains below 90 mmHg and seek senior medical advice.

- When blood pressure is over 90 mmHg, sodium chloride 0.9% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance; see guideline for suggested regimen.

- Include potassium chloride in the fluids unless anuria is suspected; adjust according to plasma-potassium concentration (measure at 60 minutes, 2 hours, and 2 hourly thereafter; measure hourly if outside the normal range).

- Start an intravenous insulin infusion: soluble insulin should be diluted (and mixed thoroughly) with sodium chloride 0.9% intravenous infusion to a concentration of 1 unit/mL; infuse at a fixed rate of 0.1 units/kg/hour.

- Established subcutaneous therapy with long-acting insulin analogues (insulin detemir or insulin glargine) should be continued during treatment of diabetic ketoacidosis.

- Monitor blood-ketone and blood-glucose concentrations hourly and adjust the insulin infusion rate accordingly. Blood-ketone concentration should fall by at least 0.1 units/mL/hour and blood-glucose concentration should fall by at least 3 mmol/L/hour.

- Once blood-glucose concentration falls below 14 mmol/Litre, glucose 10% should be given by intravenous infusion (into a large vein through a large-gauge needle) at a rate of 125 mL/hour, in addition to the sodium chloride 0.9% infusion.

- Continue insulin infusion until blood-ketone concentration is below 0.3 mmol/Litre, blood pH is above 7.3 and the patient is able to eat and drink; ideally give subcutaneous fast-acting insulin and a meal, and stop the insulin infusion 1 hour later.

For the management of diabetic ketoacidosis in children under 18 years, see BNF for Children.

The management of hyperosmolar hyperglycaemic state or hyperosmolar hyperglycaemic nonketotic coma is similar to that of diabetic ketoacidosis, although lower rates of insulin infusion are usually necessary and slower rehydration may be required.

6.1.4 Treatment of hypoglycaemia

Initially glucose 10–20 g is given by mouth either in liquid form or as granulated sugar or sugar lumps. Approximately 10 g of glucose is available from nondiet versions of Lucozade® Energy Original 55 mL, Coca-Cola® 100 mL, Ribena® Blackcurrant 18 mL (to be diluted), 2 teaspoons of sugar, and also from 3 sugar lumps. If necessary this may be repeated in 10–15 minutes. After initial treatment, a snack providing sustained availability of carbohydrate (e.g. a sandwich, fruit, milk, or biscuits) or the next meal, if it is due, can prevent blood-glucose concentration from falling again.

Hypoglycaemia which causes unconsciousness is an emergency. Glucagon, a polypeptide hormone produced by the alpha cells of the islets of Langerhans, increases plasma-glucose concentration by mobilising glycogen stored in the liver. In hypoglycaemia, if sugar cannot be given by mouth, glucagon can be given by injection. Carbohydrates should be given as soon as possible to restore liver glycogen; glucagon is not appropriate for chronic hypoglycaemia. Glucagon may be required. Patients whose hypoglycaemia is caused by insulin or sulfonylureas should be given an emergency prescription for the patient to keep to hand in case of hypoglycaemia.

1. Available at www.diabetes.nhs.uk

2. Proprietary products of quick-acting carbohydrate (e.g. GlucoGel®, Dextrogel®, Hypo-Fit®) are available on prescription for the patient to keep to hand in case of hypoglycaemia.
6.1.5 Treatment of diabetic nephropathy and neuropathy

**GLUCAGON**

**Indications**
see notes above and under Dose

**Cautions**
see notes above, insulinoma, glucagonoma;
ineffective in chronic hypoglycaemia, starvation, and adrenal insufficiency

**Contra-indications**
phaeochromocytoma

**Side-effects**
nausea, vomiting, abdominal pain,
hypokalaemia, hypotension, rarely hypersensitivity

**Dose**
- Insulin-induced hypoglycaemia, by subcutaneous,
  intramuscular, or intravenous injection, ADULT and
  CHILD over 8 years (or body-weight over 25 kg), 1 mg;
  CHILD under 8 years (or body-weight under 25 kg),
  500 micrograms; if no response within 10 minutes
  intravenous glucose must be given
- Diagnostic aid, consult product literature
- Beta-blocker poisoning, see p. 37

**Note**
1 unit of glucagon = 1 mg of glucagon

1. GlucaGen® HypoKit (Novo Nordisk) 

   **Injection**, powder for reconstitution, glucagon (rys) as
   hydrochloride with lactose, net price 1-mg vial with
   prefilled syringe containing water for injection = £11.52

2. (UK) restriction does not apply where administration is for
   saving life in emergency

**DIAZOXIDE**

**Indications**
chronic intractable hypoglycaemia;
hypertensive emergency—but no longer recom-
med, see section 2.5

**Cautions**
ischaemic heart disease; monitor blood
pressure; during prolonged use monitor white cell and
platelet count, and in children, regularly assess
growth, bone, and psychological development; inter-
actions: Appendix 1 (diazoxide)

**Renal impairment**
dose reduction may be required

**Pregnancy**
prolonged use in second or third trimesters
may produce alopecia and impaired glucose tolerance
in neonate; inhibits uterine activity during labour

**Side-effects**
anasxia, nausea, vomiting, hyperuric-
aemia, hypotension, oedema, tachycardia, arrhyth-
mias, extrapyramidal effects; hypertrichosis on pro-
longed treatment

**Dose**
- By mouth, ADULT and CHILD, initially 5 mg/kg daily in
  2–3 divided doses

**Eudemine®** (UCB Pharma) 

- **Tablets**, diazoxide 50 mg. Net price 100 = £44.64
- **Injection**, see section 2.5.1

---

**Diabetic nephropathy**

Regular review of diabetic patients should include an
annual test for urinary protein (using *Albuslitix®*)
and serum creatinine measurement. If the urinary protein
test is negative, the urine should be tested for
microalbuminuria (the earliest sign of nephropathy). If
reagent strip tests (*Micro-Test 17th* or Micro-
muntest®) are used and prove positive, the result
should be confirmed by laboratory analysis of a urine
sample. Provided there are no contra-indications, all
diabetic patients with nephropathy causing proteinuria
or with established microalbuminuria (at least 3 positive
tests) should be treated with an ACE inhibitor (section
2.5.5.1) or an angiotensin-II receptor antagonist (section
2.5.5.2) even if the blood pressure is normal; in any case,
to minimise the risk of renal deterioration, blood
pressure should be carefully controlled (section 2.5).

ACE inhibitors can potentiate the hypoglycaemic effect
of insulin and oral antidiabetic drugs; this effect is more
likely during the first weeks of combined treatment and
in patients with renal impairment.

For the treatment of hypertension in diabetes, see sec-
tion 2.5.

**Diabetic neuropathy**

Optimal diabetic control is beneficial for the manage-
ment of painful neuropathy in patients with type 1
 diabetes (see also section 4.7.3). *Paracetamol* (p. 259)
or a non-steroidal anti-inflammatory drug such as ibu-
profen (p. 636) may relieve *mild to moderate pain*.

**Duloxetine** (p. 243) is effective for the treatment of
painful diabetic neuropathy; *amitriptyline* (p. 235)
[unlicensed use] can be used if duloxetine is ineffective
or unsuitable. *Nortriptyline* (p. 236) [unlicensed] may
be better tolerated than amitriptyline. If treatment with
amitriptyline or duloxetine is inadequate, treatment with
pregabalin (p. 284) should be tried. Combination ther-
apy of duloxetine or amitriptyline with pregabalin can be
used if monotherapy at the maximum tolerated dose
does not control symptoms.

Neuropathic pain may respond to opioid analgesics.
There is evidence of efficacy for *tramadol* (p. 271),
*morphine* (p. 268), and *oxycodeone* (p. 269); however,
treatment with morphine or oxycodone should be
initiated only under specialist supervision. *Tramadol*
can be prescribed while the patient is waiting for assess-
ment by a specialist if other treatments have been
unsuccessful.

**Gabapentin** (p. 284) and *carbamazepine* (p. 281) are
sometimes used for the treatment of neuropathic pain.
*Capsaicin* cream 0.075% (p. 664) is licensed for painful
diabetic neuropathy and may have some effect, but it
produces an intense burning sensation during the initial
treatment period.

In *autonomic neuropathy* diabetic diarrhoea can often
be managed by 2 or 3 doses of *tetracycline* 250 mg
[unlicensed use] (p. 347). Otherwise *codeine* (p. 58) is
the best drug, but other antidiarrhoeal preparations can be tried. An antidiarrhoeal which promotes gastric transit, such as metoclopramide (p. 253) or domperidone (p. 253), is helpful for gastroparesis. In rare cases when an antidiarrhoeal does not help, erythromycin (especially when given intravenously) may be beneficial but this needs confirmation.

In neuropathic postural hypotension increased salt intake and the use of the mineralocorticoid fludrocortisone 100–400 micrograms daily [unlicensed use] (p. 442) may help by increasing plasma volume, but uncomfortable oedema is a common side-effect. Fludrocortisone can also be combined with flurbiprofen (p. 636) and ephedrine hydrochloride (p. 179) [both unlicensed]. Midodrine [unlicensed], an alpha agonist, may also be useful in postural hypotension.

Gustatory sweating can be treated with an antimuscarinic such as propantheline bromide (p. 48); side-effects are common. For the management of hyperhidrosis, see section 13.12.

In some patients with neuropathic oedema, ephedrine hydrochloride [unlicensed use] 30–60 mg 3 times daily offers effective relief.

For the management of erectile dysfunction, see section 7.4.5.

If the patient is unwell and diabetic ketoacidosis is suspected, blood ketones should be measured according to local guidelines (section 6.1.3). Patients and their carers should be trained in the use of blood ketone monitoring systems and to take appropriate action on the results obtained, including when to seek medical attention.

### Urinalysis

Tests for glucose range from reagent strips specific to glucose to reagent tablets which detect all reducing sugars. Few patients still use Clinistix®, Clinistix® is suitable for screening purposes only. Tests for ketones by patients are rarely required unless they become unwell—see also Blood Monitoring, above.

Microalbuminuria can be detected with Microlit-Test II but this should be followed by confirmation in the laboratory, since false positive results are common.

#### Glucose

- **Clinitest®** (Bayer Diabetes Care) Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £3.27
- **Clinistix®** (Bayer Diabetes Care) Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £2.87
- **Diabur-Test 5000®** (Roche Diagnostics) Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £2.78
- **Medi-Test® Glucose** (BHR) Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £2.33

#### Ketones

- **Ketostix®** (Bayer Diabetes Care) Reagent strips, for detection of ketones in urine. Net price 50-strip pack = £2.95
- **Ketodiastix** (Bayer Diabetes Care) Reagent strips, for detection of ketones in urine. Net price 50-strip pack = £2.76
- **Ketur Test®** (Roche Diagnostics) Reagent strips, for detection of ketones in urine. Net price 50-strip pack = £2.76
- **Ketostix®** (Bayer Diabetes Care) Reagent strips, for detection of ketones in urine. Net price 50-strip pack = £2.76
- **Albustix®** (Siemens) Reagent strips, for detection of protein in urine. Net price 50-strip pack = £4.10
- **Medi-Test® Protein 2** (BHR) Reagent strips, for detection of protein in urine. Net price 50-strip pack = £3.27

#### Other reagent strips available for urinalysis include:

- **Combur-3 Test®** (glucose and protein—Roche Diagnostics), **Clinitek Microalbumin®** (albumin and creatinine—Siemens), **Ketodiastix®** (glucose and ketones—Bayer Diagnostics), **Medi-Test Combi 2®** (glucose and protein—BHR), **Microalbumin®** (albumin—Roche Diagnostics), **Microalbumin®** (albumin and creatinine—Siemens), **Uristix®** (glucose and protein—Siemens)
## Meters and test strips

<table>
<thead>
<tr>
<th>Meter (all)</th>
<th>Type of monitoring</th>
<th>Meter retail price</th>
<th>Compatible test strips</th>
<th>Test strip net price</th>
<th>Sensitivity range (mmol/litre)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accu-Chek™ Active&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Active&lt;sup&gt;a&lt;/sup&gt;</td>
<td>50-strip pack = £15.16</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accu-Chek™ Advantage&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Advantage Plus&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £15.17</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accu-Chek™ Aviva</td>
<td>Blood glucose</td>
<td>Aviva&lt;sup&gt;a&lt;/sup&gt;</td>
<td>50-strip pack = £16.89</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accu-Chek™ Compact&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Compact&lt;sup&gt;®&lt;/sup&gt;</td>
<td>3 × 17-strip pack = £15.29</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accu-Chek™ Compact Plus</td>
<td>Blood glucose</td>
<td>Compact&lt;sup&gt;®&lt;/sup&gt;</td>
<td>3 × 17-strip pack = £15.29</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accu-Chek™ Mobile</td>
<td>Blood glucose</td>
<td>Mobile&lt;sup&gt;®&lt;/sup&gt;</td>
<td>100 tests = £30.12</td>
<td>0.3–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Accutrend&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>BM-Accutest&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.31</td>
<td>1.1–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Ascensia Breeze&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Ascensia&lt;sup&gt;®&lt;/sup&gt; Autodisc</td>
<td>5 × 10-disc pack = £14.62</td>
<td>0.6–33.3</td>
<td>Bayer Diabetes Care</td>
<td></td>
</tr>
<tr>
<td>Ascensia Esprit&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Ascensia&lt;sup&gt;®&lt;/sup&gt; Autodisc</td>
<td>5 × 10-disc pack = £14.62</td>
<td>0.6–33.3</td>
<td>Bayer Diabetes Care</td>
<td></td>
</tr>
<tr>
<td>Breeze 2&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Breeze 2&lt;sup&gt;®&lt;/sup&gt;</td>
<td>5 × 10-disc pack = £14.34</td>
<td>0.6–33.3</td>
<td>Bayer Diabetes Care</td>
<td></td>
</tr>
<tr>
<td>CareSens N&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>CareSens N&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £12.75</td>
<td>1.1–33.3</td>
<td>Spirit Healthcare</td>
<td></td>
</tr>
<tr>
<td>Contour&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Contour&lt;sup&gt;®&lt;/sup&gt; Formerly Ascensia&lt;sup&gt;®&lt;/sup&gt; Microfill</td>
<td>50-strip pack = £14.74</td>
<td>0.6–33.3</td>
<td>Bayer Diabetes Care</td>
<td></td>
</tr>
<tr>
<td>FreeStyle&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>FreeStyle&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.90</td>
<td>1.1–27.8</td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Freedom&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>FreeStyle&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.90</td>
<td>1.1–27.8</td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Freedom Lite&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>FreeStyle Lite&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.90</td>
<td>1.1–27.8</td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Lite&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>FreeStyle Lite&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.90</td>
<td>1.1–27.8</td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>FreeStyle Mini&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>FreeStyle&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.90</td>
<td>1.1–27.8</td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; Glyc&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £13.67</td>
<td>1.1–33.3</td>
<td>Menarini Diagnostics</td>
<td></td>
</tr>
<tr>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; GM</td>
<td>Blood glucose</td>
<td>GlucoMen GM&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.67</td>
<td>0.6–33.3</td>
<td>Menarini Diagnostics</td>
<td></td>
</tr>
<tr>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; LX</td>
<td>Blood glucose</td>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; LX</td>
<td>50-strip pack = £14.65</td>
<td>1.1–33.3</td>
<td>Menarini Diagnostics</td>
<td></td>
</tr>
<tr>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; PC&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £13.67</td>
<td>1.1–33.3</td>
<td>Menarini Diagnostics</td>
<td></td>
</tr>
<tr>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; Visio</td>
<td>Blood glucose</td>
<td>GlucoMen&lt;sup&gt;®&lt;/sup&gt; Visio Sensor</td>
<td>50-strip pack = £14.53</td>
<td>1.1–33.3</td>
<td>Menarini Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Glucotrend&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>Active&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.76</td>
<td>0.6–33.3</td>
<td>Roche Diagnostics</td>
<td></td>
</tr>
<tr>
<td>One Touch&lt;sup&gt;®&lt;/sup&gt; II&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>One Touch&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.59</td>
<td>1.1–33.3</td>
<td>LifeScan</td>
<td></td>
</tr>
<tr>
<td>One Touch&lt;sup&gt;®&lt;/sup&gt; Basic&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Blood glucose</td>
<td>One Touch&lt;sup&gt;®&lt;/sup&gt;</td>
<td>50-strip pack = £14.59</td>
<td>1.1–33.3</td>
<td>LifeScan</td>
<td></td>
</tr>
</tbody>
</table>

---

1. Meter no longer available
2. Free of charge from diabetes healthcare professionals
Oral glucose tolerance test

The oral glucose tolerance test is used mainly for diagnosis of impaired glucose tolerance; it is not recommended or necessary for routine diagnostic use when severe symptoms of hyperglycaemia are present. In patients who have less severe symptoms and blood glucose levels that do not establish or exclude diabetes (e.g. impaired fasting glycaemia), an oral glucose tolerance test may be required. It is also used to establish the presence of gestational diabetes. The oral glucose tolerance test generally involves giving anhydrous glucose 75 g (equivalent to Glucose BP 82.5 g) by mouth to the fasting patient, and measuring blood-glucose concentrations at intervals.

The appropriate amount of glucose should be given with 200–300 mL fluid. Anhydrous glucose 75 g may alternatively be given as 113 mL Polycal® (Nutricia Clinical) with extra fluid to administer a total volume of 200–300 mL.

### 6.2 Thyroid and antithyroid drugs

#### 6.2.1 Thyroid hormones

Thyroid hormones are used in hypothyroidism (myxoedema), and also in diffuse non-toxic goitre, Hashimoto's thyroiditis (lymphadenoid goitre), and thyroid carcinoma. Neonatal hypothyroidism requires prompt treatment for normal development. **Levothyroxine sodium** (thyroxine sodium) is the treatment of choice for maintenance therapy.

In infants and children with congenital hypothyroidism and juvenile myxoedema, the dose of levothyroxine should be titrated according to clinical response, growth assessment, and measurements of plasma thyroxine and thyroid-stimulating hormone. See *BNF for Children* (section 6.2.1) for suitable dosage regimens.
6.2.2 Antithyroid drugs

Levotyroxine sodium has a similar action to levothyroxine but is more rapidly metabolised and has a more rapid effect; 20 micrograms is equivalent to 100 micrograms of levothyroxine. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment. It may be used in severe hypothyroid states when a rapid response is desired.

Levotyroxine by intravenous injection is the treatment of choice in hypothyroid coma. Adjunctive therapy includes intravenous fluids, hydrocortisone, and treatment of infection; assisted ventilation is often required.

**LIOTHYRONINE SODIUM**
(†-Tri-iodothyronine sodium)

**Indications**
Hypothyroidism; see also notes above

**Cautions**
Panhypopituitarism or predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting levotyroxine), elderly, cardiovascular disorders (including hypertension, myocardial insufficiency or myocardial infarction, see Initial Dosage below), long-standing hypothyroidism, diabetes insipidus, diabetes mellitus (dose of antidiabetic drugs including insulin may need to be increased); interactions: Appendix 1 (hormone therapy)

**Initial dosage**
Baseline ECG is valuable because changes induced by hypothyroidism can be confused with ischaemia. If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1–2 days and start again at a lower dose

**Contra-indications**
Thyrotoxicosis

**Pregnancy**
Monitor maternal serum-thyrotrophin concentration—levothyroxine may cross the placenta and excessive maternal concentration can be detrimental to fetus

**Breast-feeding**
Amount too small to affect tests for neonatal hypothyroidism

**Side-effects**
Usually at excessive dosage (see Initial Dosage above) include diarrhoea, vomiting, anginal pain, arrhythmias, palpitation, tachycardia, tremor, restlessness, excitability, insomnia; headache, flushing, sweating, fever, heat intolerance, weight-loss, muscle cramp, and muscular weakness; transient hair loss in children; hypersensitivity reactions including rash, pruritus and oedema also reported

**Dose**
- **Adult** over 18 years, initially 50–100 micrograms once daily; preferably before breakfast, adjusted in steps of 25–50 micrograms every 3–4 weeks according to response (usual maintenance dose 100–200 micrograms once daily); in cardiac disease, severe hypothyroidism, and patients over 50 years, initially 25 micrograms once daily, adjusted in steps of 25 micrograms every 4 weeks according to response; usual maintenance dose 50–200 micrograms once daily; **Child** under 18 years see BNF for Children (section 6.2.1)
- Congenital hypothyroidism and juvenile myxoedema, see BNF for Children (section 6.2.1)

**Levothyroxine (Non-proprietary)**

- **Tablets**, levotyroxine sodium 25 micrograms, net price 28-tab pack = £2.22; 50 micrograms, 28-tab pack = £1.09; 100 micrograms, 28-tab pack = £1.09
  - Brands include Evotrox® (sugar-free)
- **Oral solution**, levotyroxine sodium 25 micrograms/5 mL, net price 100 mL = £42.75; 50 micrograms/5 mL, 100 mL = £52.75

**Note**
All strengths of levothyroxine oral solution by Almus and branded as Evotrox®, have been reformulated (August 2010) leading to an increase in potency of approximately 10%; the manufacturer advises that the recommended dose has not changed, but recommends increased monitoring of patients on these preparations as dose adjustments may be necessary

**LIOTHYRONINE SODIUM**
(†-Tri-iodothyronine sodium)

**Indications**
See notes above

**Cautions**
See under Levothyroxine Sodium; interactions: Appendix 1 (thyroid hormones)

**Contra-indications**
See under Levothyroxine Sodium

**Pregnancy**
Does not cross the placenta in significant amounts; monitor maternal thyroid function tests—dosage adjustment may be necessary

**Breast-feeding**
Amount too small to affect tests for neonatal hypothyroidism

**Side-effects**
See under Levothyroxine Sodium

**Dose**
- **By mouth**, initially 10–20 micrograms daily gradually increased to 60 micrograms daily in 2–3 divided doses; **Elderly** smaller initial doses; **Child**, adult dose reduced in proportion to body-weight
- **By slow intravenous injection**, hypothyroid coma, 5–20 micrograms repeated every 12 hours or as often as every 4 hours if necessary; **alternatively** initially 50 micrograms then 25 micrograms every 8 hours reducing to 25 micrograms twice daily

**Liothyronine sodium** (Goldshield) *(†)*

- Tablets, scored, liothyronine sodium 20 micrograms, net price 28-tab pack = £26.15
- Triiodothyronine (Goldshield) *(†)*
  - Injection, powder for reconstitution, liothyronine sodium with dextran. Net price 20-microgram amp = £37.92

6.2.2 Antithyroid drugs

Antithyroid drugs are used for hypothyroidism either to prepare patients for thyroidectomy or for long-term management. In the UK carbimazole is the most commonly used drug. Propylthiouracil should be reserved for patients who are intolerant of carbimazole or for those who suffer sensitivity reactions to carbimazole, because sensitivity is not necessarily displayed to both drugs. Both drugs act primarily by interfering with the synthesis of thyroid hormones.

**Neutropenia and agranulocytosis**
Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
1. Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.
2. A white blood cell count should be performed if there is any clinical evidence of infection.
3. Carbimazole should be stopped promptly if there is any clinical or laboratory evidence of neutropenia.
Carbimazole is given in a dose of 15 to 40 mg daily; higher doses should be prescribed under specialist supervision only. This dose is continued until the patient becomes euthyroid, usually after 4 to 8 weeks and the dose is then gradually reduced to a maintenance dose of 5 to 15 mg. Therapy is usually given for 12 to 18 months. Children may be given carbimazole in an initial dose of 250 micrograms/kg three times daily, adjusted according to response; treatment in children should be undertaken by a specialist. Rash and pruritus are common but they can be treated with antihistamines without discontinuing therapy; alternatively propylthiouracil can be substituted. All patients should be advised to report any sore throat immediately because of the rare complication of agranulocytosis (see Neutropenia and Agranulocytosis, above).

Propylthiouracil is given in a dose of 200 to 400 mg daily in divided doses in adults and this dose is maintained until the patient becomes euthyroid; the dose may then be gradually reduced to a maintenance dose of 50 to 150 mg daily in divided doses. Over-treatment with antithyroid drugs can result in the rapid development of hypothyroidism and should be avoided particularly during pregnancy because it can cause fetal goitre. A combination of carbimazole, 40 to 60 mg daily with levothyroxine, 50 to 150 micrograms daily, may be used in a blocking-replacement regimen; therapy is usually given for 18 months. The blocking-replacement regimen is not suitable during pregnancy.

Iodine has been used as an adjunct to antithyroid drugs for 10 to 14 days before partial thyroidectomy; however, there is little evidence of a beneficial effect. Iodine should not be used for long-term treatment because its antithyroid action tends to diminish.

Radioactive sodium iodide ($^{131}$I) solution is used increasingly for the treatment of thyrotoxicosis at all ages, particularly where medical therapy or compliance is a problem, in patients with cardiac disease, and in patients who relapse after thyroideectomy.

Propranolol is useful for rapid relief of thyrotoxic symptoms and may be used in conjunction with antithyroid drugs or as an adjunct to radioactive iodine. Beta-blockers are also useful in neonatal thyrotoxicosis and in supraventricular arrhythmias due to hyperthyroidism. Propranolol has been used in conjunction with iodine to prepare mildly thyrotoxic patients for surgery but it is preferable to make the patient euthyroid with carbimazole. Laboratory tests of thyroid function are not altered by beta-blockers. Most experience in treating thyrotoxicosis has been gained with propranolol but nadolol is also used. For doses and preparations of beta-blockers see section 2.4.

Thyrotoxic crisis (‘thyroid storm’) requires emergency treatment with intravenous administration of fluids, propranolol (5 mg) and hydrocortisone (100 mg every 6 hours, as sodium succinate), as well as oral iodine solution and carbimazole or propylthiouracil which may need to be administered by nasogastric tube.

Pregnancy and breast-feeding Radioactive iodine therapy is contra-indicated during pregnancy. Propylthiouracil and carbimazole can be given but the blocking-replacement regimen (see above) is not suitable. Rarely, carbimazole has been associated with congenital defects, including aplasia cutis of the neonate—use carbimazole in pregnancy only if propylthiouracil is not suitable. Both propylthiouracil and carbimazole cross the placenta and in high doses may cause fetal goitre and hypothyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

Carbimazole and propylthiouracil appear in breast milk but this does not preclude breast-feeding as long as neonatal development is closely monitored and the lowest effective dose is used.

### CARBIMAZOLE

**Indications**

hyperthyroidism

**Contra-indications**

severe blood disorders

**Hepatic impairment**

use with caution in mild to moderate impairment; avoid in severe impairment

**Pregnancy**

neonatal goitre and hypothyroidism; has been associated with congenital defects including aplasia cutis of the neonate; see also notes above

**Breast-feeding**

amount in milk may be sufficient to affect neonatal thyroid function therefore lowest effective dose should be used; see also notes above

**Side-effects**

nausea, mild gastro-intestinal disturbances, taste disturbance, headache; fever, malaise; rash, pruritus, arthralgia; rarely myopathy, alopecia, bone marrow suppression (including pancytopenia and agranulocytosis, see Neutropenia and Agranulocytosis above), and jaundice

**Counselling**

Warn patient to tell doctor immediately if sore throat, mouth ulcers, bruising, fever, malaise, or non-specific illness develops

**Dose**

- See notes above

Carbimazole (Non-proprietary) tablets

Tablets, carbimazole 5 mg, net price 100-tab pack = £4.53; 20 mg, 100-tab pack = £16.83. Counselling, blood disorder symptoms

Neo-Mercazole® tablets, both pink, carbimazole 5 mg, net price 100-tab pack = £3.85; 20 mg, 100-tab pack = £11.44. Counselling, blood disorder symptoms

### IODINE AND IODIDE

**Indications**

thyrotoxicosis (pre-operative)

**Cautions**

children; not for long-term treatment

**Pregnancy**

neonatal goitre and hypothyroidism; see also notes above

**Breast-feeding**

stop breast-feeding; danger of neonatal hypothyroidism or goitre; appears to be concentrated in milk; see also notes above

**Side-effects**

hypersensitivity reactions including cornea-like symptoms, headache, lacrimation, conjunctivitis, pain in salivary glands, laryngitis, bronchitis, rashes; on prolonged treatment depression, insomnia, impotence; goitre in infants of mothers taking iodides

**Dose**

- See under preparation

**Aqueous Iodine Oral Solution**

**Oral solution**, iodine 5%, potassium iodide 10% in purified water, freshly boiled and cooled, total iodine 130 mg/mL, net price 500 mL = £6.24. Label: 27

Dose 0.1-0.3 mL 3 times daily well diluted with milk or water
**PROPYLTHIOURACIL**

**Indications** hyperthyroidism

**Caution** monitor for hepatotoxicity

**Hepatotoxicity** Severe hepatic reactions have been reported, including fatal cases and cases requiring liver transplant—discontinue if significant liver-enzyme abnormalities develop.

**Counselling** Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, jaundice, dark urine, or pruritus develop.

**Hepatic impairment** reduce dose (see also Hepatotoxicity above).

**Renal impairment** use three-quarters normal dose if eGFR 10–50 mL/minute/1.73 m²; use half normal dose if eGFR less than 10 mL/minute/1.73 m².

**Pregnancy** neonatal goitre and hypothyroidism; see also notes above.

**Breast-feeding** monitor infant’s thyroid status but amount in milk probably too small to affect infant; high doses may affect neonatal thyroid function; see also notes above.

**Side-effects** see under Carbimazole; leucopenia; rarely cutaneous vasculitis, thrombocytopenia, aplastic anaemia, hyperprothrombinaemia, hepatic disorders (including hepatitis, hepatic failure, encephalopathy, hepatic necrosis; see also Hepatotoxicity above), nephritis, lupus erythematosus-like syndromes.

**Dose**

- See notes above.

**Propylthiouracil** (Non-proprietary)

Tablets, propylthiouracil 50 mg. Net price 56-tab pack = £47.11, 100-tab pack = £67.38

---

**6.3 Corticosteroids**

**6.3.1 Replacement therapy**

The adrenal cortex normally secretes hydrocortisone (cortisol) which has glucocorticoid activity and weak mineralocorticoid activity. It also secretes the mineralocorticoid aldosterone.

In deficiency states, physiological replacement is best achieved with a combination of hydrocortisone and the mineralocorticoid fludrocortisone; hydrocortisone alone does not usually provide sufficient mineralocorticoid activity for complete replacement.

In *Addison’s disease* or following adrenalectomy, hydrocortisone 20 to 30 mg daily by mouth is usually required. This is given in 2 doses, the larger in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion. The optimum daily dose is determined on the basis of clinical response. Glucocorticoid therapy is supplemented by fludrocortisone 50 to 300 micrograms daily.

In *acute adrenocortical insufficiency*, hydrocortisone is given intravenously (preferably as sodium succinate) in doses of 100 mg every 6 to 8 hours in sodium chloride intravenous infusion 0.9%.

**Fludrocortisone Acetate**

**Indications** mineralocorticoid replacement in adrenocortical insufficiency

**Caution** section 6.3.2; interactions: Appendix 1 (corticosteroids).

**Contra-indications** section 6.3.2.

**Hepatic impairment** section 6.3.2.

**Renal impairment** section 6.3.2.

**Pregnancy** section 6.3.2.

**Breast-feeding** section 6.3.2.

**Side-effects** section 6.3.2.

**Dose**

- 50–300 micrograms daily; *CHILD* 5 micrograms/kg daily.

**Florinef®** (Squibb) (TR)

Tablets, scored, fludrocortisone acetate 100 micrograms. Net price 100-tab pack = £5.05. Label: 10, steroid card.

**6.3.2 Glucocorticoid therapy**

In comparing the relative potencies of corticosteroids in terms of their anti-inflammatory (glucocorticoid) effects it should be borne in mind that high glucocorticoid activity in itself is of no advantage unless it is accompanied by relatively low mineralocorticoid activity (see Disadvantages of Corticosteroids below). The mineralocorticoid activity of fludrocortisone (section 6.3.1) is so high that its anti-inflammatory activity is of no clinical relevance. The table below shows equivalent anti-inflammatory doses.

**Equivalent anti-inflammatory doses of corticosteroids**

This table takes no account of mineralocorticoid effects; nor does it take account of variations in duration of action.

<table>
<thead>
<tr>
<th>Corticosteroids</th>
<th>Equivalent dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone 5 mg</td>
<td>Betamethasone 750 micrograms</td>
</tr>
<tr>
<td>Cortisone acetate 25 mg</td>
<td>Dexamethasone 750 micrograms</td>
</tr>
<tr>
<td>Deflazacort 6 mg</td>
<td>Hydrocortisone 20 mg</td>
</tr>
<tr>
<td>Methylprednisolone 4 mg</td>
<td>Triamcinolone 4 mg</td>
</tr>
</tbody>
</table>

The relatively high mineralocorticoid activity of cortisone and hydrocortisone, and the resulting fluid retention, make them unsuitable for disease suppression on a long-term basis. However, they can be used for adrenal replacement therapy (section 6.3.1); hydrocortisone is preferred because cortisone requires conversion in the
liver to hydrocortisone. Hydrocortisone is used on a short-term basis by intravenous injection for the emergency management of some conditions. The relatively moderate anti-inflammatory potency of hydrocortisone also makes it a useful topical corticosteroid for the management of inflammatory skin conditions because side-effects (both topical and systemic) are less marked (section 13.4); cortisone is not active topically.

Prednisolone and prednisone have predominantly glucocorticoid activity. Prednisolone is the corticosteroid most commonly used by mouth for long-term disease suppression.

Betamethasone and dexamethasone have very high glucocorticoid activity in conjunction with insignificant mineralocorticoid activity. This makes them particularly suitable for high-dose therapy in conditions where fluid retention would be a disadvantage.

Betamethasone and dexamethasone also have a long duration of action and this, coupled with their lack of mineralocorticoid action makes them particularly suitable for conditions which require suppression of corticotropin (corticotrophin) secretion (e.g. congenital adrenal hyperplasia). Some esters of betamethasone and of beclometasone (beclomethasone) exert a considerably more marked topical effect (e.g. on the skin or the lungs) than when given by mouth; use is made of this to obtain topical effects whilst minimising systemic side-effects (e.g. for skin applications and asthma inhalations).

Deflazacort has a high glucocorticoid activity; it is derived from prednisolone.

Use of corticosteroids

Dosages of corticosteroids vary widely in different diseases and in different patients. If the use of a corticosteroid can save or prolong life, as in exfoliative dermatitis, pemphigus, acute leukaemia or acute transplant rejection, high doses may need to be given, because the complications of therapy are likely to be less serious than the effects of the disease itself.

When long-term corticosteroid therapy is used in some chronic diseases, the adverse effects of treatment may become greater than the disabilities caused by the disease. To minimise side-effects the maintenance dose should be kept as low as possible.

When potentially less harmful measures are ineffective corticosteroids are used topically for the treatment of inflammatory conditions of the skin (section 13.4). Corticosteroids should be avoided or used only under specialist supervision in psoriasis (section 13.5).

Corticosteroids are used both topically (by rectum) and systemically (by mouth or intravenously) in the management of ulcerative colitis and Crohn’s disease (section 1.5). They are also included in locally applied creams for haemorrhoids (section 1.7.2).

Use can be made of the mineralocorticoid activity of fludrocortisone to treat postural hypotension in autonomic neuropathy (section 6.1.5).

High-dose corticosteroids should be avoided for the management of septic shock. However, there is evidence that administration of lower doses of hydrocortisone (50 mg intravenously every 6 hours) and fludrocortisone (50 micrograms daily by mouth) is of benefit in adrenocortical insufficiency resulting from septic shock.

Dexamethasone and betamethasone have little if any mineralocorticoid action and their long duration of action makes them particularly suitable for suppressing corticotropin secretion in congenital adrenal hyperplasia where the dose should be tailored to clinical response and by measurement of adrenal androgens and 17-hydroxyprogesterone. In common with all glucocorticoids their suppressive action on the hypothalamic-pituitary-adrenal axis is greatest and most prolonged when they are given at night. In most individuals a single dose of 1 mg of dexamethasone at night, is sufficient to inhibit corticotropin secretion for 24 hours. This is the basis of the ‘overnight dexamethasone suppression test’ for diagnosing Cushing’s syndrome.

Betamethasone and dexamethasone are also appropriate for conditions where water retention would be a disadvantage.

A corticosteroid may be used in the management of raised intracranial pressure or cerebral oedema that occurs as a result of malignancy (see also p. 22); high doses of betamethasone or dexamethasone are generally used. However, a corticosteroid should not be used for the management of head injury or stroke because it is unlikely to be of benefit and may even be harmful.

In acute hypersensitivity reactions such as angioedema of the upper respiratory tract and anaphylaxis, corticosteroids are indicated as an adjunct to emergency treatment with adrenaline (epinephrine) (section 3.4.3). In such cases hydrocortisone (as sodium succinate) by intravenous injection in a dose of 100 to 300 mg may be required.

Corticosteroids are preferably used by inhalation in the management of asthma (section 3.2) but systemic therapy in association with bronchodilators is required for the emergency treatment of severe acute asthma (section 3.1.1).

Corticosteroids may also be useful in conditions such as autoimmune hepatitis, rheumatoid arthritis and sarcoidosis; they may also lead to remissions of acquired haemolytic anaemia (section 9.1.3), and some cases of the nephrotic syndrome (particularly in children) and thrombocytopenic purpura (section 9.1.4).

Corticosteroids can improve the prognosis of serious conditions such as systemic lupus erythematosus, temporal arteritis, and polyarteritis nodosa; the effects of the disease process may be suppressed and symptoms relieved, but the underlying condition is not cured, although it may ultimately remit. It is usual to begin therapy in these conditions at fairly high dose, such as 40 to 60 mg prednisolone daily, and then to reduce the dose to the lowest commensurate with disease control.

For other references to the use of corticosteroids see Prescribing in Palliative Care, section 8.2.2 (immunosuppression), section 10.1.2 (rheumatic diseases), section 11.4 (eye), section 12.1.1 (otitis externa), section 12.2.1 (allergic rhinitis), and section 12.3.1 (aphthous ulcers).

Administration

Whenever possible local treatment with creams, intraarticular injections, inhalations, eye-drops, or enemas should be used in preference to systemic treatment. The suppressive action of a corticosteroid on cortisol secretion is least when it is given as a single dose in the morning. In an attempt to reduce pituitary-adrenal suppression further, the total dose for two days can...
sometimes be taken as a single dose on alternate days; alternate-day administration has not been very successful in the management of asthma (section 3.2). Pituitary-adrenal suppression can also be reduced by means of intermittent therapy with short courses. In some conditions it may be possible to reduce the dose of corticosteroid by adding a small dose of an immunosuppressive drug (section 8.2.1).

Cautions and contra-indications of corticosteroids

Adrenal suppression

During prolonged therapy with corticosteroids, adrenal atrophy develops and can persist for years after stopping. Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency, hypotension or death (see Withdrawal of Corticosteroids, below). Withdrawal can also be associated with fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and weight loss.

To compensate for a diminished adrenocortical response caused by prolonged corticosteroid treatment, any significant intercurrent illness, trauma, or surgical procedure requires a temporary increase in corticosteroid dose, or if already stopped, a temporary reintroduction of corticosteroid treatment. To avoid a precipitous fall in blood pressure during anaesthesia or in the immediate postoperative period, anaesthetists must know whether a patient is taking or has been taking a corticosteroid. A suitable regimen for corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of surgery, is:

- **Minor surgery under general anaesthesia**—usual oral corticosteroid dose on the morning of surgery or hydrocortisone 25–50 mg (usually the sodium succinate) intravenously at induction; the usual oral corticosteroid dose is recommenced after surgery.

- **Moderate or major surgery**—usual oral corticosteroid dose on the morning of surgery and hydrocortisone 25–50 mg intravenously at induction, followed by hydrocortisone 25–50 mg 3 times a day by intravenous injection for 24 hours after moderate surgery or for 48–72 hours after major surgery; the usual pre-operative oral corticosteroid dose is recommenced on stopping hydrocortisone injections.

Patients on long-term corticosteroid treatment should carry a Steroid Treatment Card (see p. 445) which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment.

Infections

Prolonged courses of corticosteroids increase susceptibility to infections and severity of infections; clinical presentation of infections may also be atypical. Serious infections e.g. *septicaemia* and *tuberculosis* may reach an advanced stage before being recognised, and *amoebiasis* or *strongyloidiasis* may be activated or exacerbated (exclude before initiating a corticosteroid in those at risk or with suggestive symptoms). Fungal or viral *ocular infections* may also be exacerbated (see also section 11.4.1).

**Chickenpox** Unless they have had chickenpox, patients receiving oral or parenteral corticosteroids for purposes other than replacement should be regarded as being at risk of severe chickenpox (see Steroid Treatment Card). Manifestations of fulminant illness include pneumonia, hepatitis and disseminated intravascular coagulation; rash is not necessarily a prominent feature. Passive immunisation with variella–zoster immunoglobulin (section 14.5.2) is needed for exposed non-immune patients receiving systemic corticosteroids or for those who have used them within the previous 3 months. Confirmed chickenpox warrants specialist care and urgent treatment (section 5.3.2.1). Corticosteroids should not be stopped and dosage may need to be increased.

Topical, inhaled or rectal corticosteroids are less likely to be associated with an increased risk of severe chickenpox.

**Measles** Patients taking corticosteroids should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin (section 14.5.1) may be needed.

Withdrawal of corticosteroids

The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case-by-case basis, taking into consideration the underlying condition that is being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:

- received more than 40 mg prednisolone (or equivalent) daily for more than 1 week;
- been given repeat doses in the evening;
- received more than 3 weeks’ treatment;
- recently received repeated courses (particularly if taken for longer than 3 weeks);
- taken a short course within 1 year of stopping long-term therapy;
- other possible causes of adrenal suppression.

Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who have received treatment for 3 weeks or less and who are not included in the patient groups described above.

During corticosteroid withdrawal the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.

**Psychiatric reactions**

Systemic corticosteroids, particularly in high doses, are linked to psychiatric reactions including euphoria, nightmares, insomnia, irritability, mood lability, suicidal thoughts, psychotic reactions, and behavioural disturbances. A serious paranoid state or depression with risk of suicide can be induced, particularly in patients with a history of mental disorder. These reactions frequently subside on reducing the dose or discontinuing the corticosteroid but they may also require specific management. Patients should be advised to seek medical advice if psychiatric symptoms (especially depression and suicidal thoughts) occur and they should also be...
alert to the rare possibility of such reactions during withdrawal of corticosteroid treatment.

Systemic corticosteroids should be prescribed with care in those predisposed to psychiatric reactions, including those who have previously suffered corticosteroid-induced psychosis, or who have a personal or family history of psychiatric disorders.

Advice to patients
A patient information leaflet should be supplied to every patient when a systemic corticosteroid is prescribed. Patients should especially be advised of the following (for details, see Infections, Adrenal Suppression, Psychiatric Reactions, and Withdrawal of Corticosteroids above):

- **Immunosuppression** Prolonged courses of corticosteroids can increase susceptibility to infection and serious infections can go unrecognised. Unless already immune, patients are at risk of severe chickenpox and should avoid close contact with people who have chickenpox or shingles. Similarly, precautions should also be taken against contracting measles;

- **Adrenal suppression** If the corticosteroid is given for longer than 3 weeks, treatment must not be stopped abruptly. Adrenal suppression can last for a year or more after stopping treatment and the patient must mention the course of corticosteroid when receiving treatment for any illness or injury;

- **Mood and behaviour changes** Corticosteroid treatment, especially with high doses, can alter mood and behaviour early in treatment—the patient can become confused, irritable and suffer from delusion and suicidal thoughts. These effects can also occur when corticosteroid treatment is being withdrawn. Medical advice should be sought if worrying psychological changes occur;

- **Other serious effects** Serious gastro-intestinal, musculoskeletal, and ophthalmic effects which require medical help can also occur; for details see Side-effects of Corticosteroids, p. 446.

Steroid treatment cards (see below) should be issued where appropriate. Doctors and pharmacists can obtain supplies of the card from:

**England and Wales**
3M Security Printing and Systems Limited
Gorse Street, Chadderton
Oldham, OL9 9QH
Tel: (0161) 683 2189
Fax: (0161) 683 2188
nhsforms@spsl.uk.com

**Scotland**
R.R. Donnelley Global Document Solutions
20–22 South Gyle Crescent
Edinburgh, EH12 9EB
Tel: (0131) 334 1229
Fax: (0131) 334 5946
ian.fruish@rrd.com

**Northern Ireland**
Pharmaceutical Directorate
Business Services Organisation
2 Franklin Street
Belfast, BT2 8DQ
Tel: (028) 9053 5652

Steroid treatment cards

**STEROID TREATMENT CARD**

I am a patient on STEROID treatment which must not be stopped suddenly

- If you have been taking this medicine for more than three weeks, the dose should be reduced gradually when you stop taking steroids unless your doctor says otherwise.

- Read the patient information leaflet given with the medicine.

- Always carry this card with you and show it to anyone who treats you (for example a doctor, nurse, pharmacist or dentist). For one year after you stop the treatment, you must mention that you have taken steroids.

- If you become ill, or if you come into contact with anyone who has an infectious disease, consult your doctor promptly. If you have never had chickenpox, you should avoid close contact with people who have chickenpox or shingles. If you do come into contact with chickenpox, see your doctor urgently.

- Make sure that the information on the card is kept up to date.

**Other cautions and contra-indications**

Other cautions include: children and adolescents (growth restriction possibly irreversible), elderly (close supervision required particularly on long-term treatment); frequent monitoring required if history of tuberculosis (or X-ray changes), hypertension, recent myocardial infarction (rupture reported), congestive heart failure, diabetes mellitus including family history, osteoporosis (post-menopausal women at special risk), glaucoma (including family history), ocular herpes simplex—risk of corneal perforation, severe affective disorders (particularly if history of steroid-induced psychosis—see also Psychiatric Reactions, p. 444), epilepsy, peptic ulcer, hypothyroidism, history of steroid myopathy, ulcerative colitis, diverticulitis, recent intestinal anastomoses, thromboembolic disorders; myasthenia gravis; **interactions**: Appendix 1 (corticosteroids).

Other contra-indications include: systemic infection (unless specific therapy given); avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished).
446 6.3.2 Glucocorticoid therapy

**Hepatic impairment**

When corticosteroids are administered orally or parenterally, the plasma-drug concentration may be increased in patients with hepatic impairment. Corticosteroids should be used with caution in hepatic impairment and the patient should be monitored closely.

**Renal impairment**

Oral and parenteral preparations of corticosteroids should be used with caution in patients with renal impairment.

**Pregnancy and breast-feeding**

The benefit of treatment with corticosteroids during pregnancy and breast-feeding outweighs the risk; pregnant women with fluid retention should be monitored closely. Corticosteroid cover is required during labour. Following a review of the data on the safety of systemic corticosteroids used in pregnancy and breast-feeding the CSM (May 1998) has concluded:

- corticosteroids vary in their ability to cross the placenta; betamethasone and dexamethasone cross the placenta readily while 88% of prednisolone is inactivated as it crosses the placenta;
- there is no convincing evidence that systemic corticosteroids increase the incidence of congenital abnormalities such as cleft palate or lip;
- when administration is prolonged or repeated during pregnancy, systemic corticosteroids increase the risk of intra-uterine growth restriction; there is no evidence of intra-uterine growth restriction following short-term treatment (e.g. prophylactic treatment for neonatal respiratory distress syndrome);
- any adrenal suppression in the neonate following prenatal exposure usually resolves spontaneously after birth and is rarely clinically important;
- prednisolone appears in small amounts in breast milk but maternal doses of up to 40 mg daily are unlikely to cause systemic effects in the infant; infants should be monitored for adrenal suppression if the mothers are taking a higher dose.

**Side-effects of corticosteroids**

Overdosage or prolonged use can exaggerate some of the normal physiological actions of corticosteroids leading to mineralocorticoid and glucocorticoid side-effects.

**Mineralocorticoid** side-effects include hypertension, sodium and water retention, and potassium and calcium loss. They are most marked with fludrocortisone, but are significant with cortisol, hydrocortisone, corticosterone, and tetrahydrocortisone (tetracortisone). Mineralocorticoid actions are negligible with the high potency glucocorticoids, betamethasone and dexamethasone, and occur only slightly with methylprednisolone, prednisolone, and triamcinolone.

**Glucocorticoid** side-effects include diabetes and osteoporosis (section 6.6), which is a danger, particularly in the elderly, as it can result in osteoporotic fractures for example of the hip or vertebrae; in addition high doses are associated with avascular necrosis of the femoral head. Muscle wasting (proximal myopathy) can also occur. Corticosteroid therapy is also weakly linked with peptic ulceration and perforation (the potential advantage of soluble or enteric-coated preparations to reduce the risk is speculative only). See also Psychiatric Reactions, p. 444.

High doses of corticosteroids can cause Cushing’s syndrome, with moon face, striae, and acne; it is usually reversible on withdrawal of treatment, but this must always be gradually tapered to avoid symptoms of acute adrenal insufficiency (important: see also Adrenal Suppression, p. 444). In children, administration of corticosteroids may result in suppression of growth. For the effect of corticosteroids given in pregnancy, see Pregnancy and Breast-feeding, above.

Side-effects can be minimised by using lowest effective dose for minimum period possible. Other side-effects include: gastro-intestinal effects: dyspepsia, abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis; musculoskeletal effects: muscle weakness, vertebral and long bone fractures, tendon rupture; endocrine effects: menstrual irregularities and amenorrhoea, hirsutism, weight gain, hypercholesterolaemia, hyperlipidaemia, negative nitrogen and calcium balance, increased appetite; increased susceptibility to and severity of infection, reactivation of dormant tuberculosis; neuropsychiatric effects: psychological dependence, insomnia, increased intracranial pressure with papilloedema in children (usually after withdrawal), aggravation of schizophrenia, aggravation of epilepsy; ophthalmic effects: glaucoma, papilloedema, posterior subcapsular cataracts, corneal or scleral thinning and exacerbation of ophthalmic viral or fungal disease, increased intra-ocular pressure, exophthalmos; also impaired healing, petechiae, ecchymoses, facial erythema, suppression of skin test reactions, urticaria, hyperhidrosis, skin atrophy, bruising, telangiectasia, myocardial rupture following recent myocardial infarction, congestive heart failure, leucocytosis, hyperglycaemia, thromboembolism, nausea, malaise, hiccups, headache, vertigo.

For other references to the side-effects of corticosteroids see section 3.2 (asthma), section 11.4 (eye) and section 13.4 (skin).

**BETAMETHASONE**

**Indications** suppression of inflammatory and allergic disorders; congenital adrenal hyperplasia; see also notes above; ear (section 12.1.1); eye (section 11.4.1); nose (section 12.2.1); oral ulceration (section 12.3.1)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above; transient effect on fetal movements and heart rate

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**

- **By mouth**, usual range 0.5–5 mg daily; see also Administration (above)
- **By intramuscular injection or slow intravenous injection or infusion**, 4–20 mg, repeated up to 4 times in 24 hours; **CHILD**, by slow intravenous injection, up to 1 year 1 mg, 1–5 years 2 mg, 6–12 years 4 mg, repeated up to 4 times in 24 hours according to response
**CORTISONE ACETATE**

**Indications** see under Dose but now superseded, see also notes above

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above; hepatic conversion to active metabolite hydrocortisone may be affected

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**
- For replacement therapy, 25–37.5 mg daily in divided doses

**Cortisone (Non-proprietary)**

**Indications** suppression of inflammatory and allergic disorders

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above

**Dose**
- Usual maintenance 3–18 mg daily (acute disorders, initially up to 120 mg daily); see also Administration (above)
- CHILD 0.25–1.5 mg/kg daily (or on alternate days); see also Administration (above)

**Betnelan** (UCB Pharma) [®]

**Tablets** scored, betamethasone 500 micrograms. Net price 100-tab pack = £4.22. Label: 10, steroid card, 21

**Betnesol** (UCB Pharma) [®]

**Soluble tablets** pink, scored, betamethasone 500 micrograms (as sodium phosphate). Net price 100-tab pack = £4.97. Label: 10, steroid card, 13, 21

**Injection** betamethasone 4 mg (as sodium phosphate) /mL. Net price 1-mL amp = £1.17. Label: 10, steroid card

**DEXAMETHASONE**

**Injection**, dexamethasone (as sodium phosphate) 4 mg/mL, net price 1-mL amp = 83p. Label: 10, steroid card

**Dose**
- By intramuscular injection or slow intravenous injection or infusion, 0.4–20 mg. CHILD 200–400 micrograms/kg daily
- Cerebral oedema, by intravenous injection 8–16 mg initially, then 5 mg by intramuscular injection or intravenous injection every 6 hours as required for 2–4 days then gradually reduced and stopped over 5–7 days
- Adjuvant treatment of bacterial meningitis, (starting before or with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3 mg every 6 hours for 4 days; CHILD 125 micrograms/kg every 6 hours for 4 days
- Injection, dexamethasone (as sodium phosphate) 3.3 mg/mL, net price 1-mL amp = £1.00, 2-mL vial = £1.98. Label: 10, steroid card

**Dexamethasone (Non-proprietary)**

**Tablets**, dexamethasone 500 micrograms, net price 28-tab pack = £38.00; 2 mg, 50-tab pack = £7.46, 100-tab pack = £13.85. Label: 10, steroid card, 21

**Oral solution**, sugar-free, dexamethasone (as sodium phosphate) 2 mg/5 mL, net price 150-mL = £42.30. Label: 10, steroid card, 21

**Brands include Dexno®**

**Injection**, dexamethasone (as sodium phosphate) 4 mg/mL, net price 1-mL amp = 83p. Label: 10, steroid card

**Dose**
- By intramuscular injection or slow intravenous injection or infusion, 0.4–20 mg. CHILD 200–400 micrograms/kg daily
- Cerebral oedema, by intravenous injection 8–16 mg initially, then 5 mg by intramuscular injection or intravenous injection every 6 hours as required for 2–4 days then gradually reduced and stopped over 5–7 days
- Adjuvant treatment of bacterial meningitis, (starting before or with first dose of antibacterial treatment), [unlicensed indication], by intravenous injection 8.3 mg every 6 hours for 4 days; CHILD 125 micrograms/kg every 6 hours for 4 days
- Injection, dexamethasone (as sodium phosphate) 3.3 mg/mL, net price 1-mL amp = £1.00, 2-mL vial = £1.98. Label: 10, steroid card

**HYDROCORTISONE**

**Indications** adrenocortical insufficiency (section 6.3.1); shock; see also notes above; hypersensitivity reactions e.g. anaphylaxis and angioedema (section 3.4.3); asthma [section 3.1]; severe inflammatory bowel disease (section 1.5); haemorrhoids (section 1.7.2); rheumatic disease (section 10.1.2); eye (section 11.4.1); skin (section 13.4)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also perineal irritation

**Dose**
- By mouth, replacement therapy, 20–30 mg daily in divided doses—see section 6.3.1; CHILD 10–30 mg
- By intramuscular injection or slow intravenous injection or infusion, 100–500 mg, 3–4 times in 24 hours or
6.3.2 Glucocorticoid therapy

as required, CHILD by slow intravenous injection up to 1 year 25 mg, 1–5 years 50 mg, 6–12 years 100 mg

Hydrocortisone (Non-proprietary)  F
Tablets, scored, hydrocortisone 10 mg, net price 30-tab pack = £44.25; 20 mg, 30-tab pack = £47.17. Label: 10, steroid card, 21

Ectofosse® (Sovereign)  F
Injection, hydrocortisone 100 mg (as sodium phosphate)/mL, net price 1-mL amp = £1.08, 5-mL amp = £4.89. Label: 10, steroid card

Note: Paraesthesia and pain (particularly in the perineal region) may follow intravenous injection of the phosphate ester

1. This restriction does not apply where administration is for saving life in emergency

METHYLPREDNISOLONE

Indications suppression of inflammatory and allergic disorders; severe inflammatory bowel disease (section 1.5); cerebral oedema associated with malignancy; see also notes above; rheumatic disease (section 10.1.2); skin (section 13.4)

Cautions see notes above; also rapid intravenous administration of large doses associated with cardiovascular collapse

Contra-indications see notes above

Hepatic impairment see notes above

Renal impairment see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

• By mouth, usually 2–40 mg daily; see also Administration (above)

• By intramuscular injection or slow intravenous injection or infusion, initially 10–500 mg; graft rejection, up to 1 g daily by intravenous infusion for up to 3 days

Prednisolone (Non-proprietary)  F
Tablets, prednisolone 1 mg, net price 28-tab pack = 93p; 5 mg, 28-tab pack = £1.03; 25 mg, 56-tab pack = £30.00. Label: 10, steroid card, 21

Tablets, e/c, prednisolone 2.5 mg (brown), net price 30-tab pack = £4.65, 100-tab pack = £30.79; 5 mg (red), 28-tab pack = £8.69, 100-tab pack = £31.04. Label: 5, 10, steroid card, 25

Brands include Deltacortril

Soluble tablets, prednisolone 5 mg (as sodium phosphate), net price 30-tab pack = £8.85. Label: 10, steroid card, 13, 21

Injection, see section 10.1.2.2

PREDNISONE

Indications moderate to severe rheumatoid arthritis (section 10.1.2.1)

Cautions see notes above

Contra-indications see notes above

Hepatic impairment see notes above

Renal impairment see notes above

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above

Dose

• ADULT over 18 years, initially 10–20 mg at bedtime, adjusted according to response

Lodotra® (Napp)  F
Tablets, m/r, yellow, prednisone 1 mg, net price 30-tab pack = £26.70; 2 mg, 30-tab pack = £26.70, 100-tab pack = £89.00; 5 mg, 30-tab pack = £26.70, 100-tab pack = £89.00. Label: 10, steroid card, 13, 21
TRIAMCINOLONE

Indications  suppression of inflammatory and allergic disorders; see also notes above; rheumatic disease (section 10.1.2); skin (section 13.4)
Cautions  see notes above

Side-effects
• By deep intramuscular injection, into gluteal muscle, 40 mg of acetonide for depot effect, repeated at intervals according to the patient’s response; max. single dose 100 mg

Kenalog® Intra-articular/Intramuscular (Squibb) injection (aqueous suspension), triamcinolone acetonide 40 mg/mL, net price 1- mL vial = £1.49.

Label: 10, steroid card

6.4 Sex hormones

6.4.1 Female sex hormones

6.4.1.1 Oestrogens and HRT

6.4.1.2 Progestogens

6.4.3 Anabolic steroids

6.4.2 Male sex hormones and antagonists

6.4.3.1 Male sex hormones

6.4.3.2 Hormonal antagonists

6.4.3.3 Estrogens and HRT

6.4.3.3.1 Oestrogens and HRT

6.4.3.3.3 Progestogens

6.4.3.3.4 Estrogen receptors

6.4.3.3.5 Progestogen receptors

6.4.3.3.6 Contraceptive effects

Risk of breast cancer  It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment, see HRT Risk table, p. 450 for details. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.

Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use; tibolone has only a limited effect on mammographic density.

Risk of endometrial cancer  The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT, see HRT Risk table, p. 450 for details.

In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

Oestrogens are necessary for the development of female secondary sexual characteristics; they also stimulate myometrial hypertrophy with endometrial hyperplasia.

In terms of oestrogenic activity natural oestrogens (estradiol (oestradiol), estrone (oestrone), and estriol (oestriol)) have a more appropriate profile for hormone replacement therapy (HRT) than synthetic oestrogens (ethinylestradiol (ethinyloestradiol) and mestranol). Tibolone has oestrogenic, progestogenic and weak androgenic activity.

Oestrogen therapy is given cyclically or continuously for a number of gynaecological conditions. If long-term therapy is required in women with a uterus, a progestogen should normally be added to reduce the risk of cystic hyperplasia of the endometrium (or of endometriotic foci in women who have had a hysterectomy) and possible transformation to cancer.

Oestrogens are no longer used to suppress lactation because of their association with thromboembolism.

Hormone replacement therapy

Hormone replacement therapy (HRT) with small doses of an oestrogen (together with a progestogen in women with a uterus) is appropriate for alleviating menopausal symptoms such as vaginal atrophy or vasomotor instability. Oestrogen given systemically in the perimenopausal and postmenopausal period or tibolone given in the postmenopausal period also diminish postmenopausal osteoporosis (section 6.6.1) but other drugs (section 6.6) are preferred. Menopausal atrophic vaginitis may respond to a short course of a topical vaginal oestrogen preparation (section 7.2.1) used for a few weeks and repeated if necessary.

Systemic therapy with an oestrogen or drugs with oestrogenic properties alleviates the symptoms of oestrogen deficiency such as vasomotor symptoms. Tibolone combines oestrogenic and progestogenic activity with weak androgenic activity; it is given continuously, without cyclical progestogen.

HRT may be used in women with early natural or surgical menopause (before age 45 years), since they are at high risk of osteoporosis. For early menopause, HRT can be given until the approximate age of natural menopause (i.e. until age 50 years). Alternatives to HRT should be considered if osteoporosis is the main concern (section 6.6).

Clonidine (section 2.5.2 and section 4.7.4.2) may be used to reduce vasomotor symptoms in women who cannot take an oestrogen, but clonidine may cause unacceptable side-effects.

HRT increases the risk of venous thromboembolism, stroke, endometrial cancer (reduced by a progestogen), breast cancer, and ovarian cancer; there is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. For details of these risks see HRT Risk table, p. 450. The minimum effective dose of HRT should be used for the shortest duration. Treatment should be reviewed at least annually and for osteoporosis alternative treatments considered (section 6.6). HRT does not prevent coronary heart disease or protect against a decline in cognitive function and it should not be prescribed for these purposes. Experience of treating women over 65 years with HRT is limited.

For the treatment of menopausal symptoms the benefits of short-term HRT outweigh the risks in the majority of women, especially in those aged under 60 years.

Risk of endometrial cancer  The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT, see HRT Risk table, p. 450 for details.

In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

Risk of breast cancer  It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment, see HRT Risk table, p. 450 for details. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.

Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use; tibolone has only a limited effect on mammographic density.

6.6 Endocrine system
Risk of ovarian cancer
Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer, see HRT Risk table, below for details; this excess risk disappears within a few years of stopping.

Risk of venous thromboembolism
Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use, see HRT Risk table, below for details.

In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. See below for advice on surgery.

Travel involving prolonged immobility further increases the risk of deep vein thrombosis, see under Travel in section 7.3.1.

Risk of stroke
Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment, see HRT Risk table, below for details.

Risk of coronary heart disease
HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause, see HRT Risk table, below for details. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

Choice
The choice of HRT for an individual depends on an overall balance of indication, risk, and convenience. A woman with a uterus normally requires oestrogen with cyclical progestogen for the last 12 to 14 days of the cycle or a preparation which involves continuous administration of an oestrogen and a progestogen (or one which provides both oestrogenic and progestogenic effects).

HRT Risk

<table>
<thead>
<tr>
<th>Risk</th>
<th>Age range (years)</th>
<th>Background incidence per 1000 women in Europe not using HRT</th>
<th>Additional cases per 1000 women using oestrogen only HRT (estimated)</th>
<th>Additional cases per 1000 women using combined (oestrogen-progestogen) HRT (estimated)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Over 5 years</td>
<td>Over 10 years</td>
<td>For 5 years’ use</td>
<td>For 10 years’ use</td>
</tr>
<tr>
<td>Breast cancer²</td>
<td>50–59</td>
<td>10</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>60–69</td>
<td>15</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>Endometrial cancer² ³</td>
<td>50–59</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>60–69</td>
<td>3</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>50–59</td>
<td>2</td>
<td>&lt;1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>60–69</td>
<td>3</td>
<td>6</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Venous thromboembolism⁴ ⁵</td>
<td>50–59</td>
<td>5</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>60–69</td>
<td>8</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Stroke⁶</td>
<td>50–59</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>60–69</td>
<td>9</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Coronary heart disease⁷ ⁸</td>
<td>70–79</td>
<td>29–44</td>
<td>NS</td>
<td>15</td>
</tr>
</tbody>
</table>

Note
Where background incidence or additional cases have not been included in the table, this indicates a lack of available data. NS indicates a non-significant difference.

Taken from MHRA/CHM (Drug Safety Update 2007; 1 (2): 2–6) available at www.mhra.gov.uk/drugsafetyupdate

1. Tibolone increases the risk of breast cancer but to a lesser extent than with combined HRT.
2. Evidence suggests an increased risk of endometrial cancer with tibolone. After 2.7 years of use (in women of average age 68 years), 1 extra case of endometrial hyperplasia and 4 extra cases of endometrial cancer were diagnosed compared with placebo users.
3. The risk of endometrial cancer cannot be reliably estimated in those using combined HRT because the addition of progestogen for at least 10 days per 28-day cycle greatly reduces the additional risk, and addition of a daily progestogen eliminates the additional risk. The risk of endometrial cancer in women who have not used HRT increases with body mass index (BMI); the increased risk of endometrial cancer in users of oestrogen-only HRT or tibolone is more apparent in women who are not overweight.
4. Limited data does not suggest an increased risk of thromboembolism with tibolone compared with combined HRT or women not taking HRT.
5. Although the level of risk of thromboembolism associated with non-oral routes of administration of HRT has not been established, it may be lower for the transdermal route.
6. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment; risk of stroke is age-dependent and therefore the absolute risk of stroke with tibolone increases with age.
7. Increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause.
8. There is insufficient data to draw a conclusion on the risk of coronary heart disease with tibolone.
activity in a single preparation). Continuous combined preparations or bironale are not suitable for use in the perimenopause or within 12 months of the last menstrual period; women who use such preparations may bleed irregularly in the early stages of treatment—if bleeding continues endometrial abnormality should be ruled out and consideration given to changing to cyclical HRT.

An oestrogen alone is suitable for continuous use in women without a uterus. However, in endometriosis, endometrial foci may remain despite hysterectomy and the addition of a progestogen should be considered in these circumstances.

An oestrogen may be given by mouth or it may be given by subcutaneous or transdermal administration, which avoids first-pass metabolism. In the case of subcutaneous implants, recurrence of vasomotor symptoms at supraphysiological plasma concentrations may occur; moreover, there is evidence of prolonged endometrial stimulation after discontinuation (calling for continued cyclical progestogen). For the use of topical HRT preparations see section 7.2.1.

**Contraception**

HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill (section 7.3.1) to provide both relief of menstrual symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary.

Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone necessarily preclude the possibility of becoming pregnant.

**Surgery**

Major surgery under general anaesthesia, including orthopaedic and vascular leg surgery, is a contraindication; factors predisposing to thromboembolism may be exacerbated; history of endometriosis may be exacerbated; history of endometrial hyperplasia; factors predisposing to thromboembolism (see notes above); presence of antiphospholipid antibodies (increased risk of thrombotic events); increased risk of gall-bladder disease reported; hypophysal tumours; acute porphyria (see section 9.8.2). Interactions: Appendix 1 (oestrogens)

Other conditions

The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present, see above). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**Contra-indications**

Oestrogen-dependent cancer, history of breast cancer, active thrombophlebitis, active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction), venous thromboembolism, or history of recurrent venous thromboembolism (unless already on anticoagulant treatment), liver disease (where liver function tests have failed to return to normal), Dubin-Johnson andRotor syndromes (or monitor closely), untreated endometrial hyperplasia, undiagnosed vaginal bleeding.

**Hepatic impairment**

See Combined Hormonal Contraceptives, section 7.3.1

**Renal impairment**

See Other Conditions, above

**Pregnancy**

See Combined Hormonal Contraceptives, section 7.3.1

**Breast-feeding**

See Combined Hormonal Contraceptives, section 7.3.1

**Side-effects**

See notes above for risks of long-term use; nausea and vomiting, abdominal cramps and bloating, weight changes, breast enlargement and tenderness, premenstrual-like syndrome, sodium and fluid retention, cholestatic jaundice, glucose intolerance, altered blood lipids—may lead to pancreatitis, rashes and chloasma, changes in libido, depression, mood changes, headache, migraine, dizziness, leg cramps (rule out venous thrombosis), vaginal candidiasis, contact lenses may irritate; transdermal delivery systems may cause contact sensitisation (possible severe hypersensitivity reaction on continued exposure), and headache has been reported on vigorous exercise.

**Withdrawal bleeding**

Cyclical HRT (where a progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

**Dose**

- See under preparations

**Counselling on patches**

Patch should be removed after 3–4 days (or once a week in case of 7-day patch) and replaced with fresh patch on slightly different site, recommended sites: clean, dry, unbroken areas of skin on trunk below waistline; not to be applied on or near breasts or under waistband. If patch falls off in bath allow skin to cool before applying new patch.
Conjugated oestrogens with progestogen

For prescribing information on progestogens, see section 6.4.1.2

Premique® (Wyeth) [BNF]

Premique® Low Dose tablets, m/r, ivory, s/c, conjugated oestrogen (equine) 300 micrograms and medroxyprogesterone acetate 1.5 mg, net price 3 × 28-tab pack = £6.52

Dose  menopausal symptoms in women with a uterus, 1 tablet daily continuously

Premique® tablets, s/c, blue, conjugated oestrogen (equine) 625 micrograms and medroxyprogesterone acetate 5 mg, net price 3 × 28-tab pack = £10.61

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 tablet daily continuously

Prempak-C® (Wyeth) [BNF]

Prempak C® 0.625 Calendar pack, s/c, 28 maroon tablets, conjugated oestrogens (equine) 625 micrograms; 12 light brown tablets, noregestrel 150 micrograms (equiv levonorgestrel 75 micrograms), net price 3 × 40-tab pack = £6.25

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 tablet daily continuously, starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), and 1 brown tablet daily on days 17–28 of each 28-day treatment cycle; subsequent courses are repeated without interval

Prempak C® 1.25 Calendar pack, s/c, 28 yellow tablets, conjugated oestrogens (equine) 1.25 mg; 12 light brown tablets, noregestrel 150 micrograms (equiv levonorgestrel 75 micrograms), net price 3 × 40-tab pack = £7.40

Dose  see under 0.625 Calendar pack, but taking 1 yellow tablet daily continuously (instead of 1 maroon tablet) if symptoms not fully controlled with lower strength

Estradiol with progestogen

For prescribing information on progestogens, see section 6.4.1.2

Angeliq® (Bayer Schering) [BNF]

Tablets, f/c, red, estradiol 1 mg, drospirenone 2 mg, net price 3 × 28-tab pack = £24.32

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously; 1 tablet daily continuously (if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase)

Cautions  use with care if an increased concentration of potassium might be hazardous

Renal impairment  avoid if eGFR less than 30 mL/minute/1.73m²

Climagest® (Novartis) [BNF]

Climagest® 1-mg tablets, 16 grey-blue, estradiol valerate 1 mg; 12 white, estradiol valerate 1 mg and norethisterone 1 mg, net price 28-tab pack = £4.59; 3 × 28-tab pack = £13.35

Dose  menopausal symptoms, 1 grey-blue tablet daily for 16 days, starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) then 1 white tablet daily for 12 days; subsequent courses are repeated without interval

Climagest® 2-mg tablets, 16 blue, estradiol valerate 2 mg; 12 yellow, estradiol valerate 2 mg and norethisterone 1 mg, net price 28-tab pack = £4.59; 3 × 28-tab pack = £13.35

Dose  see Climagest® 1-mg, but starting with 1 blue tablet daily (instead of 1 grey-blue tablet) if symptoms not controlled with lower strength

Climesse® (Novartis) [BNF]

Tablets, pink, estradiol valerate 2 mg, norethisterone 700 micrograms, net price 1 × 28-tab pack = £8.27; 3 × 28-tab pack = £24.82

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously; 1 tablet daily continuously

Clinorette® (ReSource Medical) [BNF]

Tablets, f/c, 16 white, estradiol 2 mg; 12 pink, estradiol 2 mg and norethisterone 1 mg, net price 3 × 28-tab pack = £9.23

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 white tablet daily for 16 days starting on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 pink tablet daily for 12 days; subsequent courses repeated without interval

Cyclo-Progynova® (Meda) [BNF]

Cyclo-Progynova® 2-mg tablets, s/c, 11 white, estradiol valerate 2 mg; 10 brown, estradiol valerate 2 mg and norgestrel 500 micrograms (equiv levonorgestrel 250 micrograms), net price per pack = £3.11

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus, 1 tablet daily for 11 days, starting on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 brown tablet daily for 10 days, followed by a 7-day tablet-free interval

Elleste-Duet® (Meda) [BNF]

Elleste-Duet® 1-mg tablets, 16 white, estradiol 1 mg; 12 green, estradiol 1 mg and norethisterone acetate 1 mg, net price 3 × 28-tab pack = £9.16

Dose  menopausal symptoms, 1 white tablet daily for 16 days starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) then 1 green tablet daily for 12 days; subsequent courses are repeated without interval

Elleste-Duet® 2-mg tablets, 16 orange, estradiol 2 mg; 12 grey, estradiol 2 mg, norethisterone acetate 1 mg, net price 3 × 28-tab pack = £9.72

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), 1 orange tablet daily for 16 days, starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent) then 1 grey tablet daily for 12 days; subsequent courses are repeated without interval

Elleste-Duet Conti® tablets, f/c, grey, estradiol 2 mg, norethisterone acetate 1 mg, net price 3 × 28-tab pack = £16.93

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously; 1 tablet daily on a continuous basis (if changing from cyclical HRT begin treatment at the end of scheduled bleed)

Evorel® (Janssen-Cilag) [BNF]

Evorel® Conti patches, self-adhesive, (releasing estradiol approx. 50 micrograms/24 hours and norethisterone acetate approx. 170 micrograms/24 hours), net price 8-patch pack = £13.00, 24-patch pack = £57.22. Counselling, administration

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 patch to be applied twice weekly continuously

Evorel® Sequi combination pack, 4 self-adhesive patches of Evorel® 50 (releasing estradiol approx. 50 micrograms/24 hours) and 4 self-adhesive patches of Evorel® Conti (releasing estradiol approx. 50 micrograms/24 hours and norethisterone acetate approx. 170 micrograms/24 hours), net price 8-patch pack = £11.09. Counselling, administration

Dose  menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 Evorel® 50 patch to be applied twice weekly for 2 weeks, starting within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), followed by 1 Evorel® Conti patch twice weekly for 2 weeks; subsequent courses are repeated without interval
**Femapak® (Abbott Healthcare)**  
*Femapak® 40 combination pack of 8 self-adhesive patches of Fematrix® 40 (releasing estradiol approx. 40 micrograms/24 hours) and 14 tablets of dydrogesterone 10 mg, net price per pack = £7.61. Counselling, administration  
*Dose see under Femapak® 80  
*Femapak® 80 combination pack of 8 self-adhesive patches of Fematrix® 80 (releasing estradiol approx. 80 micrograms/24 hours) and 14 tablets of dydrogesterone 10 mg, net price per pack = £8.06. Counselling, administration  
*Dose* menopausal symptoms and (osteoporous prophylaxis (see section 6.6) in case of Femapak® 80 only), in women with a uterus, starting within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), apply 1 patch twice weekly continuously and take 1 tablet daily on days 15–28 of each 28-day treatment cycle. Therapy should be initiated with Femapak® 40 in those with menopausal symptoms, prolonged oestrogen deficiency or anticipated intolerance to higher strengths, subsequently adjusted to lowest effective dose.

**Femoston® (Abbott Healthcare)**  
*Femoston® 1/10 tablets, f/c, 14 white, estradiol 1 mg; 14 grey, estradiol 1 mg, dydrogesterone 10 mg, net price 3 x 28-tab pack = £13.47  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 white tablet daily for 14 days, starting within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent) then 1 grey tablet daily for 14 days; subsequent courses repeated without interval if cycles have ceased or are infrequent). Then 1 tablet daily in sequence (without interruption) starting within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent). Then 1 tablet daily in sequence (without interruption) if cycles have ceased or are infrequent. Then 1 tablet daily in sequence (without interruption) if cycles have ceased or are infrequent. Then 1 tablet daily in sequence (without interruption) if cycles have ceased or are infrequent. Then 1 tablet daily in sequence (without interruption) if cycles have ceased or are infrequent. Then 1 tablet daily in sequence (without interruption) if cycles have ceased or are infrequent.

**Femoston® 2/10 tablets, f/c, 14 red, estradiol 2 mg; 14 yellow, estradiol 2 mg, dydrogesterone 10 mg, net price 3 x 28-tab pack = £13.47  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 red tablet daily for 14 days, starting within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent) then 1 yellow tablet daily for 14 days; subsequent courses repeated without interval; where therapy required for menopausal symptoms alone, Femoston® 1/10 given initially and Femoston® 2/10 substituted if symptoms not controlled.

**Femoston®-conti tablets, f/c, salmon, estradiol 1 mg, dydrogesterone 5 mg, net price 3 x 28-tab pack = £22.44  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 red tablet daily for 14 days, starting within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent) then 1 yellow tablet daily for 14 days; subsequent courses repeated without interval; where therapy required for menopausal symptoms alone, Femoston® 1/10 given initially and Femoston® 2/10 substituted if symptoms not controlled.

**FemSeven® Conti (Merck Serono)**  
*Patches, self-adhesive (releasing estradiol approx. 50 micrograms/24 hours) and levonorgestrel approx. 7 micrograms/24 hours), net price 4-patch pack = £15.46, 12-patch pack = £44.12. Counselling, administration  
*Dose* menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously. 1 tablet daily continuously (if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase).

**FemSeven® Sequi (Merck Serono)**  
*Combination pack, self-adhesive patches of FemSeven® Sequi Phase 1 (releasing estradiol approx. 50 micrograms/24 hours) and of FemSeven® Sequi Phase 2 (releasing estradiol approx. 50 micrograms/24 hours and levonorgestrel approx. 10 micrograms/24 hours); net price 1-month pack (2 of each) = £13.16, 3-month pack (6 of each) = £37.54. Counselling, administration  
*Dose* menopausal symptoms in women with a uterus, 1 Phase 1 patch applied once a week for 2 weeks followed by 1 Phase 2 patch once a week for 2 weeks; subsequent courses are repeated without interval.

**Indivina® (Orion)**  
*Indivina® 1 mg/2.5 mg tablets, estradiol valerate 1 mg, medroxyprogesterone acetate 2.5 mg, net price 3 x 28-tab pack = £20.58.  
Indivina® 1 mg/5 mg tablets, estradiol valerate 1 mg, medroxyprogesterone acetate 5 mg, net price 3 x 28-tab pack = £20.58.

**Indivina® 2 mg/5 mg tablets, estradiol valerate 2 mg, medroxyprogesterone acetate 5 mg, net price 3 x 28-tab pack = £20.58.**

*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 3 years previously, 1 tablet daily continuously; initiate therapy with Indivina® 1 mg/2.5 mg tablets and adjust according to response, start at end of scheduled bleed if changing from cyclical HRT.

**Kliofem® (Novo Nordisk)**  
*Tablets, f/c, yellow, estradiol 2 mg, norethisterone acetate 1 mg, net price 3 x 28-tab pack = £11.43.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously, 1 tablet daily continuously; start at end of scheduled bleed if changing from cyclical HRT.

**Kliovance® (Novo Nordisk)**  
*Tablets, f/c, estradiol 1 mg, norethisterone acetate 500 micrograms, net price 3 x 28-tab pack = £13.20.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously, 1 tablet daily continuously; start at end of scheduled bleed if changing from cyclical HRT.

**Novofem® (Novo Nordisk)**  
*Tablets, f/c, pink, estradiol 2 mg, norethisterone acetate 1 mg, net price 3 x 28-tab pack = £15.89.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously, 1 tablet daily continuously; if changing from cyclical HRT, start treatment the day after finishing oestrogen plus progestogen phase.

**Nuvelle® Continuous (Bayer Schering)**  
*Tablets, f/c, pink, estradiol 2 mg, norethisterone acetate 1 mg, net price 3 x 28-tab pack = £15.89.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6) in women with a uterus whose last menstrual period occurred over 12 months previously, 1 tablet daily continuously; if changing from cyclical HRT, start treatment the day after finishing oestrogen plus progestogen phase.

**Tridestra® (Orion)**  
*Tablets, 70 white, estradiol valerate 2 mg; 14 blue, estradiol valerate 2 mg and medroxyprogesterone acetate 20 mg; 7 yellow, inactive, net price 91-tab pack = £20.49.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 white tablet daily for 70 days, then 1 blue tablet daily for 14 days, then 1 yellow tablet daily for 7 days; subsequent courses are repeated without interval.

**Trisequens® (Novo Nordisk)**  
*Tablets, 12 blue, estradiol 2 mg; 10 white, estradiol 2 mg, norethisterone acetate 1 mg; 6 red, estradiol 1 mg, net price 3 x 28-tab pack = £11.10.  
*Dose* menopausal symptoms and osteoporosis prophylaxis (see section 6.6), in women with a uterus, 1 blue tablet daily, starting on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily in sequence (without interruption).
### Conjugated oestrogens only

**Premarin® (Wyeth)**

- Tablets, all s/c, conjugated oestrogens (equine)
  - 300 micrograms (green): net price 3 × 28-tab pack = £6.07; 625 micrograms (maroon), 3 × 28-tab pack = £4.02; 1.25 mg (yellow), 3 × 28-tab pack = £3.38
- **Dose**: menopausal symptoms, 0.3–1.25 mg daily continuously; osteoporosis prophylaxis (see section 6.6), 0.625–1.25 mg daily continuously; with cyclical progestogen for 12–14 days of each cycle in women with a uterus.

**Estradiol only**

**Estradiol Implants** (Organon)

- **Implant**: estradiol 25 mg, net price each = £12.47; 50 mg, each = £20.29
- **Dose**: by implantation, oestrogen replacement, and osteoporosis prophylaxis (see section 6.6) (with cyclical progestogen for 12–14 days of each cycle in women with a uterus, see notes above), 25–100 mg as required (usually every 4–6 months) according to oestrogen levels—check before each implant
- **Note**: On cessation of treatment if or if implants are removed from those with a uterus, cyclical progestogen should be continued until withdrawal bleed stops

**Bedol® (ReSource Medical)**

- **Tablets**: t/c, estradiol 2 mg, net price 3 × 28-tab pack = £5.07
- **Dose**: menopausal symptoms and osteoporosis prophylaxis (see section 6.6), with cyclical progestogen for 12–14 days of each cycle in women with a uterus; for cycles have ceased or are infrequent, with cyclical progestogen for at least 12 days of each cycle in women with a uterus; subsequently adjust according to response

**Climaval® (Novartis)**

- **Tablets**: estradiol valerate 1 mg (grey-blue), net price 1 × 28-tab pack = £2.45, 3 × 28-tab pack = £7.35; 2 mg (blue), 1 × 28-tab pack = £2.45, 3 × 28-tab pack = £7.35
- **Dose**: menopausal symptoms (if patient has had a hysterectomy), 1–2 mg daily

**Elleste-Solo® (Meda)**

- **Elleste-Solo® 1-mg tablets**: estradiol 1 mg, net price 3 × 28-tab pack = £5.03
- **Dose**: menopausal symptoms with cyclical progestogen for 12–14 days of each cycle in women with a uterus; 1 mg daily starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent)

**Elleste-Solo® 2-mg tablets**: orange, estradiol 2 mg, net price 3 × 28-tab pack = £5.34
- **Dose**: menopausal symptoms not controlled with lower strength and osteoporosis prophylaxis (see section 6.6), with cyclical progestogen for 12–14 days of each cycle in women with a uterus, 2 mg daily starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent)

**Elleste Solo® MX (Meda)**

- **Patches**: self-adhesive, estradiol, MX 40 patch (releasing approx. 40 micrograms/24 hours), net price 8-patch pack = £5.19; MX 80 patch (releasing approx. 80 micrograms/24 hours), 8-patch pack = £5.99
- **Dose**: menopausal symptoms and osteoporosis prophylaxis (see section 6.6), 1 patch to be applied twice weekly continuously starting within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent); with cyclical progestogen for at least 12 days of each cycle in women with a uterus; subsequently adjust according to response

**Estradot® (Novartis)**

- **Patches**: self-adhesive, estradiol, 25 patch (releasing approx. 25 micrograms/24 hours), net price 8-patch pack = £4.16; ’37.5’ patch (releasing approx. 37.5 micrograms/24 hours), 8-patch pack = £4.17; ’50’ patch (releasing approx. 50 micrograms/24 hours), 8-patch pack = £4.18; ’75’ patch (releasing approx. 75 micrograms/24 hours), 8-patch pack = £4.86; ’100’ patch (releasing approx. 100 micrograms/24 hours), 8-patch pack = £5.05
- **Dose**: menopausal symptoms and osteoporosis prophylaxis (see section 6.6), 1 patch to be applied twice weekly continuously after 100 mg as required (usually every 4–6 months) according to oestrogen levels—check before each implant

**Evorel® (Janssen-Cilag)**

- **Patches**: self-adhesive, estradiol, 25 patch (releasing approx. 25 micrograms/24 hours), net price 8-patch pack = £3.42; ’50’ patch (releasing approx. 50 micrograms/24 hours), 8-patch pack = £3.88
- **Dose**: menopausal symptoms and osteoporosis prophylaxis (see section 6.6), 1 patch to be applied twice weekly continuously starting within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent); with cyclical progestogen for at least 12 days of each cycle in women with a uterus; subsequently adjust according to response

**Femstatix® (Abbott Healthcare)**

- **Patches**: self-adhesive, estradiol, 40 patch (releasing approx. 40 micrograms/24 hours), net price 8-patch pack = £4.95; ’80’ patch (releasing approx. 80 micrograms/24 hours), 8-patch pack = £5.40
- **Dose**: menopausal symptoms and osteoporosis prophylaxis (see section 6.6), 1 patch to be applied twice weekly continuously starting within 5 days of onset of menstruation (or at any time if...
Oestrogel® (Ferring) (GBP)

Gel, estradiol 0.06%, net price 64-dose pump pack = £4.80. Counselling, administration

Dose
menopausal symptoms and osteoporosis prophylaxis (see section 6.6). 1 patch to be applied once a week continuously, with cyclical progestogen for at least 12 days of each cycle in women with a uterus; for menopausal symptoms may continue with this strength for osteoporosis prophylaxis in women at risk of fractures (second-line)

Cautions
see Hormone Replacement Therapy, p. 449 and under Oestrogens for HRT; vaginal bleeding (investigate for endometrial cancer if bleeding continues beyond 6 months or after stopping treatment); history of liver disease, epilepsy, migraine, diabetes mellitus, hypercholesterolaemia; withdraw if signs of thromboembolic disease, abnormal liver function tests or cholestatic jaundice; see also Note below; interactions: Appendix 1 (tibolone)

Contra-indications see notes above and under Oestrogens for HRT; hormone-dependent tumours, history of cardiovascular or cerebrovascular disease (e.g. thrombophlebitis, thromboembolism), uninvestigated vaginal bleeding

Hepatic impairment avoid in severe impairment

Renal impairment risk of fluid retention—patients with renal impairment should be closely monitored

Pregnancy avoid, toxicity in animal studies

Breast-feeding avoid

Side-effects see notes above; also abdominal pain, weight changes, vaginal bleeding, leucorrhoea, facial hair, and rarely amenorrhea; gastro-intestinal disturbances, oedema, dizziness, headache, migraine, depression, breast cancer (see notes above and section 6.4.1.1), arthralgia, myalgia, visual disturbances, seborrhoeic dermatitis, rash and pruritus also reported

Dose
0.1 mg daily

Note Unsuitable for use in the premenopause (unless being treated with gonadotrophin-releasing hormone analogue) and as (or with) an oral contraceptive; also unsuitable for use within 12 months of last menstrual period (may cause irregular bleeding); induce withdrawal bleed with progestogen if transferring from another form of HRT

Livial® (Organon) (GBP)

Tablets, tibolone 2.5 mg, net price 28-tab pack = £10.36; 3 x 28-tab pack = £31.08
Ethinylestradiol

Ethinylestradiol (ethinylestradiol) is licensed for short-term treatment of symptoms of oestrogen deficiency, for osteoporosis prophylaxis if other drugs (section 6.6) cannot be used and for the treatment of female hypogonadism and menstrual disorders.

Ethinylestradiol is occasionally used under specialist supervision for the management of hereditary haemorrhagic telangiectasia (but evidence of benefit is limited). Side-effects include nausea, fluid retention, and thrombosis. Impotence and gynaecomastia have been reported in men.

For use in prostate cancer, see section 8.3.1.

**ETHINYLESTRADIOL**

**Indications** see notes above

**Cautions** cardiovascular disease (sodium retention with oedema, thromboembolism); see also under Combined Hormonal Contraceptives (section 7.3.1) and under Oestrogens for HRT (p. 451)

**Contra-indications** see under Combined Hormonal Contraceptives (section 7.3.1) and under Oestrogens for HRT (p. 451)

**Hepatic impairment** avoid; see also Combined Hormonal Contraceptives, section 7.3.1

**Pregnancy** see Combined Hormonal Contraceptives, section 7.3.1

**Breast-feeding** see Combined Hormonal Contraceptives, section 7.3.1

**Side-effects** feminising effects in men; see also under Combined Hormonal Contraceptives (section 7.3.1) and under Oestrogens for HRT (p. 451)

**Dose**

- Menopausal symptoms and osteoporosis prophylaxis, (with progestogen for 12–14 days per cycle in women with intact uterus), 10–50 micrograms daily for 21 days, repeated after 7-day tablet-free period
- Female hypogonadism, 10–50 micrograms daily, usually on cyclical basis; initial oestrogen therapy should be followed by combined oestrogen and progestogen therapy
- Menstrual disorders, 20–50 micrograms daily from day 5 to 25 of each cycle, with progestogen added either throughout the cycle or from day 15 to 25

**Ethinylestradiol**

Tablets, ethinylestradiol 10 micrograms, net price 21-tab pack = £29.95; 50 micrograms, 21-tab pack = £38.20; 1 mg, 28-tab pack = £49.50

**Raloxifene**

**Indications** treatment and prevention of postmenopausal osteoporosis

**Cautions** risk factors for venous thromboembolism (discontinue if prolonged immobilisation); risk factors for stroke; breast cancer (see notes above); history of oestrogen-induced hypertriglyceridaemia (monitor serum triglycerides); **interactions**: Appendix 1 (raloxifene)

**Contra-indications** history of venous thromboembolism, undiagnosed uterine bleeding, endometrial cancer, cholestasis

**Hepatic impairment** avoid

**Renal impairment** caution in mild to moderate impairment; avoid in severe impairment

**Side-effects** hot flushes, leg cramps, peripheral oedema, influenza-like symptoms; less commonly venous thromboembolism, thrombophlebitis; rarely rashes, gastrointestinal disturbances, hypertension, arterial thromboembolism, headache (including migraine), breast discomfort, thrombocytopenia

**Dose**

- 60 mg once daily

Evista® (Daiichi Sankyo) Tablets, f/c, raloxifene hydrochloride 60 mg, net price 28-tab pack = £17.06; 84-tab pack = £59.59

**Progestogens**

There are two main groups of progestogen, progesterone and its analogues (dydrogesterone and medroxy-progesterone) and testosterone analogues (noretosterone and norgestrel). The newer progestogens (desogestrel, norgestimate, and gestodene) are all derivatives of norgestrel; levonorgestrel is the active isomer of norgestrel and has twice its potency. Progesterone and its analogues are less androgenic than the testosterone derivatives and neither progesterone nor dydrogesterone causes virilisation.

Where endometriosis requires drug treatment, it may respond to a progestogen, e.g. norethisterone, administered on a continuous basis. Danazol and gonadorelin analogues are also available (section 6.7.2).

Although oral progestogens have been used widely for menorrhagia they are relatively ineffective compared with tranexamic acid (section 2.11) or, particularly where dysmenorrhoea is also a factor, mefenamic acid (section 10.1.1); the levonorgestrel-releasing intrauterine system (section 7.3.2.3) may be particularly useful for women also requiring contraception. Oral progestogens have also been used for severe dysmenorrhoea, but where contraception is also required in younger women the best choice is a combined oral contraceptive (section 7.3.1).

Progestogens have also been advocated for the alleviation of premenstrual symptoms, but no convincing physiological basis for such treatment has been shown. Progestogens have been used for the prevention of spontaneous abortion in women with a history of recurrent miscarriage (habitual abortion) but there is no evidence of benefit and they are not recommended for this purpose. In pregnant women with antiphospholipid antibody syndrome who have suffered recurrent miscarriage, administration of low-dose
apart from aspirin (section 2.9) and a prophylactic dose of a low molecular weight heparin (section 2.8.1) may decrease the risk of fetal loss (use under specialist supervision only).

**Hormone replacement therapy** In women with a uterus a progestogen needs to be added to long-term oestrogen therapy for hormone replacement, to prevent cystic hyperplasia of the endometrium and possible transformation to cancer; it can be added on a cyclical or a continuous basis (see section 6.4.1.1). Combined packs incorporating suitable progestogen tablets are available, see p. 452.

**Oral contraception** Desogestrel, etynodiol (ethynodiol), gestodene, levonorgestrel, norethisterone, and norgestimate are used in combined oral contraceptives (section 7.3.2).

**Diabetes** should be monitored closely. For gens can decrease glucose tolerance and patients with epilepsy, hypertension, migraine, asthma, or cardiac dysfunctions (including urticaria, pruritus, rash, and acne), weight change, nausea, headache, dizziness, insomnia, drowsiness, depression, change in libido; also skin reactions (including bloating, fluid retention, breast tenderness), menstrual disturbances, premenstrual-like syndrome, hirsutism and alopecia. Jaundice and anaphylactoid reactions have also been reported.

**MEDROXYPROGESTERONE ACETATE**

**Indications** see under Dose; contraception (section 7.3.2.2); malignant disease (section 8.3.2)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** section 8.3.2

**Renal impairment** use with caution

**Pregnancy** section 8.3.2

**Breast-feeding** section 8.3.2

**Side-effects** see notes above; indigestion

**Dose**

- By mouth, 2.5–10 mg daily for 5–10 days beginning on day 16 to 21 of cycle, repeated for 2 cycles in dysfunctional uterine bleeding and 3 cycles in secondary amenorrhoea
- Mild to moderate endometriosis, 10 mg 3 times daily for 90 consecutive days, beginning on day 1 of cycle
- Progestogenic opposition of oestrogen HRT, 10 mg daily for the last 14 days of each 28-day oestrogen HRT cycle

**Provera® (Pharmacia)**

- Tablets, all scored, medroxyprogesterone acetate 2.5 mg (orange), net price 30-tab pack = £1.84; 5 mg (blue), 10-tab pack = £1.23; 10 mg (white), 10-tab pack = £2.47, 90-tab pack = £22.16

**Climanor® (Resourke Medical)**

- Tablets, f/c, medroxyprogesterone acetate 5 mg, net price 28-tab pack = £3.27

**Combined preparations**

- See Appendix 1 (progestogens).

**Contra-indications** Progestogens should be avoided in patients with a history of liver tumours. They are also contra-indicated in those with genital or breast cancer (unless progestogens are being used in the management of these conditions), severe arterial disease, undiagnosed vaginal bleeding and acute porphyria (section 9.8.2). Progestogens should not be used if there is a history during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis.

**Side-effects** Side-effects of progestogens include menstrual disturbances, premenstrual-like syndrome (including bloating, fluid retention, breast tenderness), weight change, nausea, headache, dizziness, insomnia, drowsiness, depression, change in libido; also skin reactions (including urticaria, pruritus, rash, and acne), hirsutism and alopecia. Jaundice and anaphylactoid reactions have also been reported.

**NORETHISTERONE**

**Indications** see under Dose; HRT (section 6.4.1.1); contraception (section 7.3.1 and section 7.3.2); malignant disease (section 8.3.2)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** section 8.3.2

**Renal impairment** use with caution

**Pregnancy** section 8.3.2

**Breast-feeding** section 8.3.2

**Side-effects** see notes above

**Dose**

- Endometriosis, by mouth, 10–15 mg daily for 4–6 months or longer, starting on day 5 of cycle (if spotting occurs increase dose to 20–25 mg daily; reduced once bleeding has stopped)
- Dysfunctional uterine bleeding, menorrhagia (but see notes above), by mouth, 5 mg 3 times daily for 10 days to arrest bleeding; to prevent bleeding 5 mg twice daily from day 19 to 26
- Dysmenorrhoea (but see notes above), by mouth, 5 mg 3 times daily from day 5 to 24 for 3–4 cycles
- Premenstrual syndrome (but not recommended, see notes above), by mouth, 5 mg 2–3 times daily from day 19 to 26 for several cycles
- Postponement of menstruation, by mouth, 5 mg 3 times daily starting 3 days before expected onset (menstruation occurs 2–3 days after stopping)
6.4.2 Male sex hormones and antagonists

**PROGESTERONE**

**Indications** see under preparations

**Cautions** see notes above

**Contra-indications** see notes above; missed or incomplete abortion

**Hepatic impairment** avoid; see also Combined Hormonal Contraceptives, section 7.3.1

**Renal impairment** use with caution

**Pregnancy** not known to be harmful

**Breast-feeding** avoid—present in milk

**Side-effects** see notes above; injection-site reactions; pain, diarrhoea and flatulence can occur with rectal administration

**Dose**

- See under preparations

**Crinone** (Merck Serono)

- **Vaginal gel**, progesterone 90 mg/application (8%), 15 = £30.83

- **Dose** by vagina, infertility due to inadequate luteal phase, insert 1 applicatorful daily starting either after documented ovulation or on day 18–21 of cycle. *In vitro* fertilisation, daily application continued for 30 days after laboratory evidence of pregnancy

**Cyclogest** (Actavis)

- **Pessaries**, progesterone 200 mg, net price 15 = £7.03; 400 mg, 15 = £10.18

- **Dose** by vagina or rectum, premenstrual syndrome and postnatal depression, 200 mg daily to 400 mg twice daily; for premenstrual syndrome start on day 12–14 and continue until onset of menstruation (but not recommended, see notes above); rectally if barrier methods of contraception are used, in patients who have recently given birth or in those who suffer from vaginal infection or recurrent cystitis

**Gestone** (Nordic)

- **Injection**, progesterone 50 mg/mL, net price 1 mL amp = £4.50, 2 mL amp = £4.50

- **Dose** by deep intramuscular injection into buttock: dysfunction uterine bleeding, 5–10 mg daily for 5–10 days until 2 days before expected onset of menstruation

- Recurrent miscarriage due to inadequate luteal phase (but not recommended, see notes above) or following *in vitro* fertilisation or gamete intra-fallopian transfer, 25–100 mg 2–7 times a week from day 15, or day of embryo or gamete transfer, until 8–16 weeks of pregnancy; max. 200 mg daily

**Utrogestan** (Perring)

- **Capsules**, progesterone (micronised) 100 mg, net price 30-cap pack = £5.13; 200 mg 15-cap pack = £5.13. Counselling, administration

- **Excipients** include arachis (peanut) oil

- **Dose** progesterone opposition of oestrogen HRT 200 mg once daily on days 15–26, or 100 mg once daily on days 1–25, of each 28-day oestrogen HRT cycle

---

**TESTOSTERONE AND ESTERS**

**Indications** see under preparations

**Cautions** cardiac impairment, elderly, ischaemic heart disease, hypertension, epilepsy, migraine, diabetes mellitus, skeletal metastases (risk of hypercalcaemia), undertake regular examination of the prostate and breast during treatment; monitor full blood count, lipid profile and liver function; pre-pubertal boys (see notes above and under Side-effects); interactions: Appendix 1 (testosterone)

**Contra-indications** breast cancer in men, prostate cancer, history of primary liver tumours, hypercalcaemia, nephrotic syndrome

**Hepatic impairment** avoid if possible—fluid retention and dose-related toxicity

**Renal impairment** caution—potential for fluid retention

Androgens cause masculinisation; they may be used as replacement therapy in castrated adults and in those who are hypogonadal due to either pituitary or testicular disease. In the normal male they inhibit pituitary gonadotrophin secretion and depress spermatogenesis. Androgens also have an anabolic action which led to the development of anabolic steroids (section 6.4.3).

Androgens are useless as a treatment of impotence and impaired spermatogenesis unless there is associated hypogonadism; they should not be given until the hypogonadism has been properly investigated. Treatment should be under expert supervision.

When given to patients with hypopituitarism they can lead to normal sexual development and potency but not to fertility. If fertility is desired, the usual treatment is with gonadotrophins or pulsatile gonadotrophin-releasing hormone (section 6.5.1) which will stimulate spermatogenesis as well as androgen production.

Caution should be used when androgens or chorionic gonadotrophin are used in treating boys with delayed puberty since the fusion of epiphyses is hastened and may result in short stature; skeletal maturation should be monitored.

Intramuscular depot preparations of testosterone esters are preferred for replacement therapy. Testosterone enantate, propionate or undecanoate, or alternatively *Sustanon®,* which consists of a mixture of testosterone esters and has a longer duration of action, may be used. Satisfactory replacement therapy can sometimes be obtained with 1 mL of *Sustanon 250®,* given by intramuscular injection once a month, although more frequent dose intervals are often necessary. Impacts of testosterone can be used for hypogonadism; the implants are replaced every 4 to 5 months.

Testosterone implants can be used in postmenopausal women as an adjunct to hormone replacement therapy. A testosterone patch is also licensed to improve libido in surgically induced menopausal women (receiving concomitant oestrogen therapy).
Pregnancy  avoid; causes masculinisation of female fetus  
Breast-feeding  avoid; may cause masculinisation in the female infant or precocious development in the male infant; high doses suppress lactation  
Side-effects  prostate abnormalities and prostate cancer, headache, depression, gastro-intestinal bleeding, nausea, vomiting, cholestatic jaundice, changes in libido, gynaecomastia, polycystic ovaries, anxiety, irritability, nervousness, anemia, parasympathetic, hypertension, electrolyte disturbances including sodium retention with oedema and hypercalcaemia, weight gain; increased bone growth, muscle cramps, arthralgia; androgenic effects such as hirsutism, male-pattern baldness, seborrhoea, acne, pruritus, excessive frequency and duration of penile erection, precocious sexual development and premature closure of epiphyses in pre-pubertal males, suppression of spermatogenesis in men and virilism in women; rarely liver tumours; sleep apnoea also reported; with patches, buccal tablets, and gel, local irritation and allergic reactions (including burn-like lesions with patches), and taste disturbances  

Dose  
- See under preparations  

Oral  
Restandol® Testocaps (Organon) caps, orange, testosterone undecanoate 40 mg in oily solution, net price 30-cap pack = £8.55; 60-cap pack = £17.10. Label: 21, 25  
Dose androgen deficiency, 120–160 mg daily for 2–3 weeks; maintenance 40–120 mg daily  

Buccal  
Striant® SR (The Urology Co.) mucoadhesive buccal tablets, m/t, testosterone 30 mg, net price 60-tab pack = £45.84. Counselling, see under Dose below  
Dose hypoandrogenism, 30 mg every 12 hours; CHILD and ADOLESCENT under 18 years not recommended. Counselling Place rounded side of tablet on gum above front teeth and hold lip firmly over the gum for 30 seconds. If tablet detaches within 4 hours of next dose, replace with new tablet which is considered the second dose for the day.  

Intramuscular  
Testosterone Enantate (Non-proprietary) Injection (oily), testosterone enantate 250 mg/mL, net price 1-mL amp = £13.33  
Dose by slow intramuscular injection, hypogonadism, initially 250 mg every 2–3 weeks; maintenance 250 mg every 3–6 weeks Breast cancer, 250 mg every 2–3 weeks  

Nebido® (Bayer Schering) Injection (oily), testosterone undecanoate 250 mg/mL, net price 4-mL amp = £76.70  
Dose by deep intramuscular injection, hypogonadism in men over 18 years, 1 g every 14–10 weeks; if necessary, second dose may be given after 6 weeks to achieve rapid steady state plasma testosterone levels and then every 10–14 weeks  

Sustanon 250® (Organon) Injection (oily), testosterone propionate 30 mg, testosterone phenylpropionate 60 mg, testosterone isocaproate 60 mg, and testosterone decanoate 100 mg/mL, net price 1-mL amp = £2.45  
Excipients include arachis (peanut) oil, benzyl alcohol (see Excipients p. 2)  
Dose by deep intramuscular injection, androgen deficiency. 1 mL usually every 3 weeks  

Viorormone® (Nordic) Injection, testosterone propionate 50 mg/mL, net price 2-mL amp = £4.50  
Dose by intramuscular injection, androgen deficiency. 50 mg 2–3 times weekly  
Delayed puberty, 50 mg weekly  
Breast cancer in women, 100 mg 2–3 times weekly  

Implant  
Testosterone (Organon) Implant, testosterone 100 mg, net price = £7.40; 200 mg = £13.79.  
Dose by implantation, male hypogonadism, 100–600 mg; 600 mg usually maintains plasma-testosterone concentration within the normal range for 4–5 months  
Postmenopausal women, 50–100 mg every 4–8 months, as an adjunct to oestrogen replacement therapy  

Transdermal preparations  
Intrinsa® (Warner Chilcott) Patches, self-adhesive, releasing testosterone approx. 300 micrograms/24 hours, net price 8-patch pack = £26.91. Counselling, administration  
Dose hyposexual sexual desire disorder associated with surgically induced menopause (in women receiving concomitant oestrogen therapy (section 6.4.1.1)), apply 1 patch twice weekly continuously to clean, dry, unbroken skin on lower abdomen below waistline; site replacement patch on a different area (avoid using same area for 7 days); assess treatment after 3–6 months, discontinue if no benefit  
Note Not recommended for women naturally menopausal or those taking conjugated oestrogens: Safety and efficacy of use beyond 1 year not established  
Testim® (Ferring) Gel, testosterone 50 mg/5 g tube, net price 30-tube pack = £32.00. Counselling, administration  
Excipients include propylene glycol (see section 13.1.3)  
Dose hypogonadism due to testosterone deficiency in men (over 18 years), 50 mg testosterone (5 g gel) applied once daily; subsequent application adjusted according to response; max. 100 mg (10 g gel) daily  
Counselling Squeeze entire content of tube onto one palm and apply as a thin layer on clean, dry, healthy skin of shoulder or upper arm, preferably in the morning after washing or bathing (if 2 tubes required use 1 per shoulder or upper arm), rub in and allow to dry before putting on clothing to cover site; wash hands with soap after application; avoid washing application site for at least 6 hours  
Avoid skin contact with application sites to prevent testosterone transfer to other people, especially pregnant women and children—consult product literature  
Testogel® (Bayer Schering) Gel, testosterone 50 mg/5 g sachet, net price 30-sachet pack = £31.11. Counselling, administration  
Dose hypogonadism due to androgen deficiency in men (over 18 years), 50 mg testosterone (5 g gel) to be applied once daily; subsequent application adjusted according to response in 25-mg (2.5 g gel) increments to max. 100 mg (10 g gel) daily  
Counselling Apply thin layer of gel on clean, dry, healthy skin such as shoulders, arms or abdomen. Immediately after sachet is opened. Not to be applied on genital area as high alcohol content may cause local irritation. Allow to dry for 3–5 minutes before dressing. Wash hands with soap and water after applying gel, avoid shower or bath for at least 6 hours  
Avoid skin contact with gel application sites to prevent testosterone transfer to other people, especially pregnant women and children—consult product literature  
Tostran® (ProStrakan) Gel, testosterone 2% (10 mg metered application), net price 60-g multidose dispenser = £26.67. Counselling, administration  
Excipients include butylhydroxytoluene, propylene glycol (see section 13.1.3)  
Dose hypogonadism due to testosterone deficiency in men (over 18 years), initially 60 mg testosterone (3 g gel) applied
once daily; subsequent applications adjusted according to response; max. 80 mg (4 g gel) daily

Counselling Apply gel on clean, dry, intact skin of abdomen or both inner thighs, preferably in the morning. Gently rub in with a finger until dry before dressing. Wash hands with soap and water after applying gel; avoid washing application site for at least 2 hours. Not to be applied on genital area.

Avoid skin contact with gel application sites to prevent testosterone transfer to other people, especially pregnant women and children—consult product literature

MESTEROLONE

Indications see under Dose

Cautions see under Testosterone and Esters

Contra-indications see under Testosterone and Esters

Hepatic impairment see under Testosterone and Esters

Renal impairment see under Testosterone and Esters

Pregnancy see under Testosterone and Esters

Breast-feeding see under Testosterone and Esters

Side-effects see under Testosterone and Esters but spermatogenesis unimpaired

Dose

• Androgen deficiency and male infertility associated with hypogonadism, 25 mg 3–4 times daily for several months, reduced to 50–75 mg daily in divided doses for maintenance; CHILD not recommended

Pro-Viron® (Bayer Schering)

Tablets, scored, mesterolone 25 mg. Net price 30-tab pack = £4.19

Anti-androgens

Cyproterone acetate

Cyproterone acetate is an anti-androgen used in the treatment of severe hypersexuality and sexual deviation in the male. It inhibits spermatogenesis and produces reversible infertility (but is not a male contraceptive); abnormal sperm forms are produced. Fully informed consent is recommended and an initial spermatogram. As hepatic tumours have been produced in animal studies, careful consideration should be given to the risk/benefit ratio before treatment. Cyproterone acetate is also used as an adjunct in prostatic cancer (section 8.3.4.2) and in the treatment of acne and hirsutism in women (section 13.6.2).

CYPROTERONE ACETATE

Indications see notes above; prostate cancer (section 8.3.4.2)

Cautions ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known); blood counts initially and throughout treatment; monitor hepatic function regularly (liver function tests should be performed before treatment, see also under Side-effects below); monitor adrenocortical function regularly; diabetes mellitus (see also Contra-indications)

Driving Fatigue and lassitude may impair performance of skilled tasks (e.g. driving)

Contra-indications (do not apply in prostate cancer), severe diabetes (with vascular changes), sickle-cell anaemia, liver-disease including Dubin-Johnson and Rotor syndromes, previous or existing liver tumours, malignant or wasting diseases, meningioma or history of meningioma, severe depression, history of thromboembolic disorders; youths under 18 years (may arrest bone maturation and testicular development)

Hepatic impairment dose-related toxicity; see also side-effects, p. 573

Side-effects fatigue and lassitude, breathlessness, weight changes, reduced sebum production (may clear acne), changes in hair pattern, gynaecomastia (rarely leading to galactorrhoea and benign breast nodules); rarely hypersensitivity reactions, rash and oedema; inhibition of spermatogenesis (see notes above); hepatotoxicity reported (including jaundice, hepatitis and hepatic failure usually in men given 200–300 mg daily for prostate cancer, see section 8.3.4.2 for details and warnings)

Dose

• ADULT over 18 years, male hypersexuality, 50 mg twice daily after food

Cyproterone Acetate (Non-proprietary)

Tablets, cyproterone acetate 50 mg, net price 56-tab pack = £31.54. Label: 21 counselling, driving

Androcure® (Bayer Schering)

Tablets, scored, cyproterone acetate 50 mg, net price 56-tab pack = £24.41. Label: 21 counselling, driving

Dutasteride and finasteride

Dutasteride and finasteride are specific inhibitors of the enzyme 5α-reductase, which metabolises testosterone into the more potent androgen, dihydrotestosterone. This inhibition of testosterone metabolism leads to reduction in prostate size, with improvement in urinary flow rate and in obstructive symptoms. Dutasteride and finasteride are alternatives to alpha-blockers (section 7.4.1) particularly in men with a significantly enlarged prostate. Finasteride is also licensed for use with doxazosin in the management of benign prostatic hyperplasia.

A low strength of finasteride is licensed for treating male-pattern baldness in men (section 13.9).

Cautions Dutasteride and finasteride decrease serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment. Both dutasteride and finasteride are excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant. Women of childbearing potential should avoid handling crushed or broken tablets of finasteride and leaking capsules of dutasteride.

Side-effects The side-effects of dutasteride and finasteride include impotence, decreased libido, ejaculation disorders, and breast tenderness and enlargement.

DUTASTERIDE

Indications benign prostatic hyperplasia

Cautions see notes above; interactions: Appendix 1 (dutasteride)

Hepatic impairment avoid in severe impairment—no information available

Side-effects see notes above

Dose

• 500 micrograms daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained)

Avodart® (GSK)

Capsules, yellow, dutasteride 500 micrograms, net price 30-cap pack = £19.80. Label: 25

With tamsulosin Section 7.4.1
FINASTERIDE

**Indications** benign prostatic hyperplasia; male-pattern baldness in men (section 13.9)

**Cautions** see notes above; also obstructive uropathy

**Male breast cancer** Cases of male breast cancer have been reported. Patients or their carers should be told to promptly report to their doctor any changes in breast tissue such as lumps, pain, or nipple discharge

**Side-effects** see notes above; also testicular pain, hypersensitivity reactions (including lip and face swelling, pruritus and rash); male breast cancer also reported (see Cautions above)

**Dose** 5 mg daily, review treatment at 3–6 months and then every 6–12 months (may require several months’ treatment before benefit is obtained)

Finasteride (Non-proprietary)

Tablets, finasteride 5 mg, net price 28-tab pack = £2.19

Proscar® (MSD)

Tablets, blue, f/c, finasteride 5 mg, net price 28-tab pack = £13.94

6.4.3 Anabolic steroids

Anabolic steroids have some androgenic activity but they cause less virilisation than androgens in women. They are used in the treatment of some aplastic anaemias (section 9.1.3). Anabolic steroids have been given for osteoporosis in women but they are no longer advocated for this purpose.

The protein-building properties of anabolic steroids have not proved beneficial in the clinical setting. Their use as body builders or tonics is unjustified; some athletes abuse them.

NANDROLONE

**Indications** osteoporosis in postmenopausal women (but not recommended, see notes above); aplastic anaemia (section 9.1.3)

**Cautions** cardiac impairment, hypertension, diabetes mellitus, epilepsy, migraine; monitor skeletal maturation in young patients; skeletal metastases (risk of hypercalcaemia); **interactions:** Appendix 1 (anabolic steroids)

**Contra-indications** prostate cancer, male breast cancer, acute porphyria (section 9.8.2)

**Hepatic impairment** use in severe hepatic impairment only if benefit outweighs risk

**Renal impairment** use with caution—may cause sodium and water retention

**Side-effects** acne, sodium retention with oedema, virilisation with high doses including voice changes (sometimes irreversible), amenorrhoea, inhibition of spermatogenesis, premature epiphyseal closure; abnormal liver-function tests reported with high doses; liver tumours reported occasionally on prolonged treatment with anabolic steroids

**Dose** see below

Use of preparations in these sections requires detailed prior investigation of the patient and should be reserved for specialist centres.

Deca-Durabolin® (Organon)

Injection (oily), nandrolone decanoate 50 mg/mL, net price 1-mL amp = £3.17

**Excipients** include arachis (peanut) oil, benzyl alcohol (see **Excipients**, p. 2)

**Dose** by deep intramuscular injection, 50 mg every 3 weeks

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens

6.5.2 Posterior pituitary hormones and antagonists

Anti-oestrogens

The anti-oestrogens clomifene (clomiphene) and tamoxifen (section 8.3.4.1) are used in the treatment of female infertility due to oligomenorrhoea or secondary amenorrhoea (e.g. associated with polycystic ovarian disease). They induce gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used as an adjunct.

Patients should be warned that there is a risk of multiple pregnancy (rarely more than twins).

CLOMIFENE CITRATE

(Clophiphene Citrate)

**Indications** anovulatory infertility—see notes above

**Cautions** see notes above; polycystic ovary syndrome (cysts may enlarge during treatment, also risk of exaggerated response to usual doses), ovarian hyperstimulation syndrome, uterine fibroids, ectopic pregnancy, incidence of multiple births increased (consider ultrasound monitoring), visual symptoms (discontinue and initiate ophthalmological examination)

**CSM Advice** The CSM has recommended that clomifene should not normally be used for longer than 6 cycles (possibly increased risk of ovarian cancer)

**Contra-indications** ovarian cysts, hormone-dependent tumours or abnormal uterine bleeding of undetermined cause

**Hepatic impairment** avoid in severe liver disease
6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens BNF 61

**Pregnancy** exclude pregnancy before treatment; possible effects on fetal development

**Breast-feeding** may inhibit lactation

**Side-effects** visual disturbances (withdraw), ovarian hyperstimulation (withdraw), hot flushes, abdominal discomfort, occasionally nausea, vomiting, depression, insomnia, breast tenderness, headache, intestinal spotting, menorrhagia, endometriosis, convulsions, weight gain, rashes, dizziness, hair loss

**Dose**
- 50 mg daily for 5 days, starting within about 5 days of onset of menstruation (preferably on 2nd day) or at any time (normally preceded by a progestogen-induced withdrawal bleed) if cycles have ceased; second course of 100 mg daily for 5 days may be given in absence of ovulation; most patients who are going to respond will do so to first course; 3 courses should constitute adequate therapeutic trial; long-term cyclical therapy not recommended—see CSM advice, above

**Clomifene** (Non-proprietary) Tablets, clomifene citrate 50 mg, net price 30-tab pack = £15.94

**Clomid** (Sanofi-Aventis) Tablets, yellow, scored, clomifene citrate 50 mg. Net price 30-tab pack = £8.46

---

### Anterior pituitary hormones

#### Corticotrophins

**Tetracosactide** (tetracosactrin), an analogue of corticotropin (ACTH), is used to test adrenocortical function; failure of the plasma cortisol concentration to rise after administration of tetracosactrin indicates adrenocortical insufficiency.

Both corticotropin and tetracosactrin were formerly used as alternatives to corticosteroids in conditions such as Crohn’s disease or rheumatoid arthritis; their use in primary gonadal failure.

- **Dose**
  - 50 mg daily for 5 days
  - Second course of 100 mg daily for 5 days may be given in absence of ovulation; most patients who are going to respond will do so to first course; 3 courses should constitute adequate therapeutic trial; long-term cyclical therapy not recommended—see CSM advice, above

**Synacthen** (Alliance) **Injection**, tetracosactride 250 micrograms (as acetate)/mL. Net price 1-mL amp = £2.70

**Dose**
- Diagnostic (30-minute test), by intramuscular or intravenous injection, 250 micrograms as a single dose

**Synacthen Depot** (Alliance) **Injection** (aqueous suspension), tetracosactride acetate 1 mg/mL, with zinc phosphate complex. Net price 1-mL amp = £3.87

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients p.3)

**Dose**
- Diagnostic (5-hour test), by intramuscular injection, 1 mg as a single dose

**Note** Formerly used therapeutically by intramuscular injection, in an initial dose of 1 mg daily (or every 12 hours in acute cases); reduced to 1 mg every 2–3 days, then 1 mg weekly (or 500 micrograms every 2–3 days) but value was limited (see notes above)

#### Gonadotrophins

Follicle-stimulating hormone (FSH) and luteinising hormone (LH) together (as in human menopausal gonadotrophin), follicle-stimulating hormone alone (as in follitropin), or chorionic gonadotrophin, are used in the treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene, or in superovulation treatment for assisted conception (such as *in vitro* fertilisation).

The gonadotrophins are also occasionally used in the treatment of hypogonadotrophic hypogonadism and associated oligosperma. There is no justification for their use in primary gonadal failure.

Chorionic gonadotrophin has also been used in delayed puberty in the male to stimulate endogenous testosterone production, but has little advantage over testosterone (section 6.4.2).

**CHORIONIC GONADOTROPHIN**

(A Human Chorionic Gonadotrophin; HCG)

A preparation of a glycoprotein fraction secreted by the placenta and obtained from the urine of pregnant women having the action of the pituitary luteinising hormone

**Indications** see notes above

**Cautions** cardiac impairment, asthma, epilepsy, migraine; prepubertal boys (risk of premature epiphyseal closure or precocious puberty); acute porphyria (section 9.8.2)

**Contra-indications** androgen-dependent tumours

**Renal impairment** use with caution

**Side-effects** oedema (particularly in males—reduce dose), headache, tiredness, mood changes, gynaecomastia, local reactions; may aggravate ovarian hyperstimulation, multiple pregnancy

**Dose**
- By subcutaneous or intramuscular injection, according to patient’s response

**Choragon** (Ferring) **Injection**, powder for reconstitution, chorionic gonadotrophin. Net price 5000-unit amp (with solvent) = £3.26

**Pregnyl** (Organon) **Injection**, powder for reconstitution, chorionic gonadotrophin. Net price 1500-unit amp = £2.12; 5000-unit amp = £3.15 (both with solvent). For subcutaneous or intramuscular injection
CHORIOGONADOTROPIN ALFA
(Human choric gonadotropin)

Indications see notes above

Contra-indications ovarian enlargement or cyst (unless caused by polycystic ovarian disease); ectopic pregnancy in previous 3 months; active thromboembolic disorders; hypothalamus, pituitary, ovarian, uterine or mammary malignancy

Side-effects nausea, vomiting, abdominal pain; headache, tiredness; injection-site reactions; ovarian hyperstimulation syndrome; rarely diarrhoea, depression, irritability, breast pain; ectopic pregnancy and ovarian torsion reported

Dose
- By subcutaneous injection, according to patient's response

OVITRELLE® (Merck Serono)  
Injection, choriogonadotropin alfa, net price 6500-unit/0.5 mL (250-micrograms/0.5 mL) prefilled syringe = £31.38

CORIFOLLITROPIN ALFA

Indications controlled ovarian stimulation in combination with a gonadotrophin-releasing hormone antagonist

Contra-indications risk factors for thromboembolism; risk of ovarian hyperstimulation syndrome; acute porphyria (section 9.8.2)

Contra-indications ovarian enlargement or cyst; polycystic ovarian syndrome; tumours of hypothalamus, pituitary, ovaries, uterus, or breast; vaginal bleeding of unknown cause; history of ovarian hyperstimulation syndrome

Renal impairment avoid

Breast-feeding avoid

Side-effects nausea, headache, fatigue; ovarian hyperstimulation, pelvic pain, breast pain; less commonly vomiting, abdominal distension and pain, diarrhoea, constipation, dizziness, ovarian torsion; also reported ectopic pregnancy, miscarriage, and multiple pregnancies

Dose
- By subcutaneous injection, body-weight under 60 kg, 100 micrograms; body-weight over 60 kg, 150 micrograms

ELOVRA® (Organon)  
Injection, prefilled syringe, corifollitropin alfa, net price 100 micrograms/0.5 mL = £638.00; 150 micrograms/0.5 mL = £638.00

FOLLITROPIN ALFA and BETA
(Recombinant human follicle stimulating hormone)

Indications see notes above

Contra-indications acute porphyria (section 9.8.2)

Pregnancy avoid

Breast-feeding avoid

Side-effects see under Human Menopausal Gonadotrophins

Dose
- By subcutaneous injection, according to patient’s response

FOLLITROPIN ALFA

Gonal-F® (Merck Serono)

Injection, powder for reconstitution, follitropin alfa. Net price 75-unit amp = £21.02; 450 units/0.75 mL, multidose vial = £126.10; 1050 units/1.75 mL, multidose vial = £294.22 (all with solvent). For subcutaneous injection

Injection, prefilled pen, follitropin alfa 600 units/mL, net price 0.5 mL (300 units) = £94.00, 0.75 mL (450 units) = £141.00, 1.5 mL (900 units) = £282.00. For subcutaneous injection

FOLLITROPIN ALFA with lutropin alfa

PERGOVERIS® (Merck Serono)

Injection, powder for reconstitution, follitropin alfa 150 units (11 micrograms), lutropin alfa 75 units (3 micrograms), net price per vial (with solvent) = £60.29. For subcutaneous injection

Injection, follitropin beta 100 units/mL, net price 0.5 mL (50-unit) vial = £18.03; 200 units/mL, 0.5 mL (100-unit) vial = £36.06; 300 units/mL, 0.5 mL (150-unit) vial = £50.62; 400 units/mL, 0.5 mL (200-unit) vial = £67.49; 0.36 mL (300-unit) cartridge = £97.41, 0.72 mL (600-unit) cartridge = £194.82, 1.08 mL (900-unit) cartridge = £292.23, (cartridges for use with Pergoveris® pen). For subcutaneous (cartridges and vials) or intramuscular injection (vials)

Excipients may include neomycin and streptomycin

HUMAN MENOPAUSAL GONADOTROPHINS

Indications see notes above

Contra-indications acute porphyria (section 9.8.2)

Pregnancy avoid

Breast-feeding avoid

Side-effects ovarian hyperstimulation, increased risk of multiple pregnancy and miscarriage, hypersensitivity reactions, gastro-intestinal disturbances, headache, joint pain, fever, injection site reactions, very rarely thromboembolism; gynaecomastia, acne, and weight gain reported in men

Dose
- By deep intramuscular or subcutaneous injection, according to patient’s response

Menotrophin

Purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH) and luteinising hormone (LH) in a ratio of 1:1

Merional® (Pharmasure)

Injection, powder for reconstitution, menotrophin as follicle-stimulating hormone 75 units and luteinising hormone 75 units, net price per vial (with solvent) = £13.95; follicle-stimulating hormone 150 units, luteinising hormone 150 units, net price per vial (with solvent) = £27.90. For intramuscular injection
Menopur® (Feringa)
Injection, powder for reconstitution, menotrophin as follicle-stimulating hormone 75 units and luteinising hormone 75 units, net price per vial (with solvent) = £13.38. For intramuscular or subcutaneous injection.

Urofollitropin
Purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH).

Fostimon® (Pharmasure)
Injection, powder for reconstitution, urofollitropin as follicle-stimulating hormone 75 units, net price per vial (with solvent) = £27.90; follicle-stimulating hormone 150 units, net price per vial (with solvent) = £55.80. For intramuscular or subcutaneous injection.

LUTROPIN ALFA (Recombinant human luteinising hormone)
Indications see notes above.

Cautions acute porphyria (section 9.8.2).

Contra-indications ovarian enlargement or cyst (unless caused by polycystic ovarian disease); undiagnosed vaginal bleeding; tumours of hypothalamus and pituitary; ovarian, uterine or mammary carcinoma.

Side-effects nausea, vomiting, abdominal and pelvic pain; headache, somnolence; injection-site reactions; ovarian hyperstimulation syndrome, ovarian cyst, breast pain, ectopic pregnancy; thromboembolism, adnexal torsion, and haemoperitoneum.

Dose
By subcutaneous injection, in conjunction with follicle-stimulating hormone, according to response.

Luveris® (Merck Serono)
Injection, powder for reconstitution, lutropin alfa, net price 75-unit vial = £31.38 (with solvent).

Growth hormone
Growth hormone is used to treat deficiency of the hormone in children and in adults (see NICE guidance below). In children it is used in Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency; short children considered small for gestational age at birth, and short stature homeobox-containing gene (SHOX) deficiency.

Growth hormone of human origin (HGH; somatotropin) has been replaced by a growth hormone of human sequence, somatropin, produced using recombinant DNA technology.

NICE guidance

Somatropin is recommended for children with growth failure who:

- have growth-hormone deficiency;
- have Turner syndrome;
- have Prader-Willi syndrome;
- have chronic renal insufficiency;
- are born small for gestational age with subsequent growth failure at 4 years of age or later;
- have short stature homeobox-containing gene (SHOX) deficiency.

Treatment should be discontinued if growth velocity increases by less than 50% from baseline in the first year of treatment.

NICE guidance
Somatropin for adults with growth hormone deficiency (August 2003).

Somatropin is recommended in adults only if the following criteria are fulfilled:

- Severe growth hormone deficiency, established by an appropriate method.
- Impaired quality of life, measured by means of a specific questionnaire.
- Already receiving treatment for another pituitary hormone deficiency.

Somatropin treatment should be discontinued if the quality of life has not improved sufficiently by 9 months.

Severe growth hormone deficiency developing after linear growth is complete but before the age of 25 years should be treated with growth hormone; treatment should continue until adult peak bone mass has been achieved. Treatment for adult-onset growth hormone deficiency should be stopped only when the patient and the patient’s physician consider it appropriate.

Treatment with somatropin should be initiated and managed by a physician with expertise in growth hormone disorders; maintenance treatment can be prescribed in the community under a shared-care protocol.

Mecasermin, a human insulin-like growth factor-1 (rhIGF-I), is licensed to treat growth failure in children and adolescents with severe insulin-like growth factor-I deficiency (section 6.7.4).

SOMATROPIN (Recombinant Human Growth Hormone)
Indications see under Dose.

Cautions diabetes mellitus (adjustment of antidiabetic therapy may be necessary), papilloedema (see under Side-effects), relative deficiencies of other pituitary hormones (notably hypothyroidism—manufacturers recommend periodic thyroid function tests but limited evidence of clinical value), history of malignant disease, disorders of the epiphysis of the hip (monitor for limping), resolved intracranial hypertension (monitor closely), initiation of treatment close to puberty not recommended in child born small for gestational age; Silver-Russell syndrome; rotate subcutaneous injection sites to prevent lipoatrophy; interactions: Appendix 1 (somatropin).

Contra-indications evidence of tumour activity (complete antitumour therapy and ensure intracranial lesions inactive before starting); not to be used after renal transplantation or for growth promotion in children with closed epiphyses (or near closure in Prader-Willi syndrome); severe obesity or severe respiratory impairment in Prader-Willi syndrome.

Pregnancy discontinue if pregnancy occurs—no information available.

Breast-feeding no information available.

Side-effects headache, funduscropy for papilloedema recommended if severe or recurrent headache, visual problems, nausea and vomiting occur—if papilloedema confirmed consider benign intracranial hypertension (rare cases reported); fluid retention (peripheral oedema), arthralgia, myalgia, carpal tunnel syndrome, paraesthesia, antibody formation, hypothyroidism, insulin resistance, hyperglycaemia, hypo-
glycaemia, reactions at injection site; leukaemia in children with growth hormone deficiency also reported.

**Dose**

- Gonadal dysgenesis (Turner syndrome), by subcutaneous injection, 45–50 micrograms/kg daily or 1.4 mg/m² daily.
- Deficiency of growth hormone in children, by subcutaneous or intramuscular injection, 23–39 micrograms/kg daily or 0.7–1.5 mg/m² daily.
- Growth disturbance in short children born small for gestational age whose growth has not caught up by 4 years or later, by subcutaneous injection, 35 micrograms/kg daily or 1 mg/m² daily.
- Prader-Willi syndrome, by subcutaneous injection in children with growth velocity greater than 1 cm/year, in combination with energy-restricted diet, 35 micrograms/kg daily or 1 mg/m² daily; max. 2.7 mg daily.
- Chronic renal insufficiency in children (renal function decreased to less than 50%), by subcutaneous injection, 45–50 micrograms/kg daily or 1.4 mg/m² daily (higher doses may be needed) adjusted if necessary after 6 months.
- Adult growth hormone deficiency, by subcutaneous injection, initially 150–300 micrograms daily, gradually increased if required to max. 1 mg daily, use minimum effective dose (requirements may decrease with age).
- SHOX deficiency in children, by subcutaneous injection, 45–50 micrograms/kg daily.

**Note**

Dose formerly expressed in units; somatropin 1 mg = 3 units.

**Genotropin** (Pharmacia) [pms]

- Injection, two-compartment cartridge containing powder for reconstitution, somatropin (rbe) and diluent, net price 5.3-mg (16-unit) cartridge = £122.87, 12-mg (36-unit) cartridge = £278.20. For use with Genotropin® Pen (Ferring) device (available free of charge from clinics). For subcutaneous injection.

**GoQuick** injection, two-compartment, multi-dose disposable, prefilled pen containing powder for reconstitution, somatropin (rbe) and diluent, net price 5.3-mg (16-unit) prefilled pen = £122.87; 12-mg (36-unit) prefilled pen = £278.20. For subcutaneous injection.

**MiniQuick** injection, two-compartment single-dose syringe containing powder for reconstitution, somatropin (rbe) and diluent, net price 5.3-mg (16-unit) prefilled pen = £122.87; 12-mg (36-unit) prefilled pen = £278.20. For subcutaneous injection.

**Humatrope** (Lilly) [pms]

- Injection, powder for reconstitution, somatropin (rbe), net price 6-mg (18-unit) cartridge = £108.02; 12-mg (36-unit) cartridge = £216.00; 24-mg (72-unit) cartridge = £432.00; all supplied with diluent. For subcutaneous or intramuscular injection; cartridges for subcutaneous injection.

**Norditropin** (Novo Nordisk) [pms]

- SimpleXx injection, somatropin (epir) 3.3 mg (10 units)/mL, net price 1.5-mL (5-unit) cartridge = £106.35; 6.7 mg (20 units)/mL, 1.5-mL (10-mg, 30-unit) cartridge = £212.70; 10 mg (30 units)/mL, 1.5-mL (15-mg, 45-unit) cartridge = £319.05. For use with appropriate NordiPen® device (available free of charge from clinics). For subcutaneous injection.

**Nutropin** ( Ipsen) [pms]

- Injection, somatropin (rbe), net price 10 mg (30 units) 2-ml cartridge = £203.00. For use with Nutropin® Pen device (available free of charge from clinics). For subcutaneous injection.

**Omnitrope** (Sandoz) [pms]

- Injection, somatropin (rbe) 3.3 mg (10 units)/mL, net price 1.5 mL (5-mg, 15-unit) cartridge = £86.77; 6.7 mg (20 units)/mL, 1.5 mL (10-mg, 30-unit) cartridge = £175.50. For use with Omnitrope Pen 5® and Omnitrope Pen 10® devices respectively (available free of charge from clinics). For subcutaneous injection.

**Saizen** (Merck Serono) [pms]

- Injection, powder for reconstitution, somatropin (rmc), net price 1.33-mg (4-unit) vial (with diluent) = £29.28; 3.33-mg (10-unit) vial (with diluent) = £73.20. For subcutaneous or intramuscular injection.

**Click.easy** powder, for reconstitution, somatropin (rbc), net price 8-mg (24-unit) vial (in Click.easy® device with diluent) = £185.44. For use with One.click® and Cool.Click® needle-free device (both available free of charge from clinics). For subcutaneous injection.

**Exipients** include benzyl alcohol (in 5-mg cartridge) (avoid in neonates, see Excipients, p. 2).

**Note**

Biosimilar medicine, see p. 1.

**Saizen** 3.33 mg vial may be reconstituted with sodium chloride intravenous infusion or water for injections for immediate use when administering to children under 3 years of age.

**Zomacton** (Ferring) [pms]

- Injection, powder for reconstitution, somatropin (rbe), net price 4-mg (12-unit) vial (with diluent) = £79.69, for use with ZomaJet 2nd Vision needle-free device (available free of charge from clinics) or with needles and syringes; 10 mg (30-unit) vial (with diluent) = £199.23, for use with ZomaJet Vision X needle-free device (available free of charge from clinics) or with needles and syringes. For subcutaneous injection.

**Exipients** include benzyl alcohol (in 4-mg vial) (avoid in neonates, see Excipients, p. 2).

**Growth hormone receptor antagonists**

Pegvisomant is a genetically modified analogue of human growth hormone and is a highly selective growth hormone receptor antagonist. Pegvisomant is licensed for the treatment of acromegaly in patients with inadequate response to surgery, radiation, or both, and to treatment with somatostatin analogues. Pegvisomant should be initiated only by physicians experienced in the treatment of acromegaly.

**PEGVISOMANT**

**Indications** see notes above.

**Cautions**

Liver disease (monitor liver enzymes every 4–6 weeks or if symptoms of hepatitis develop); diabetes mellitus (adjustment of antidiabetic therapy may be necessary); possible increase in female fertility.
6.5.2 Posterior pituitary hormones and antagonists

**Pregnancy** avoid

**Breast-feeding** avoid

**Side-effects** diarrhea, constipation, nausea, vomiting, abdominal distension, dyspepsia, flatulence, elevated liver enzymes; hypertension; headache, asthenia, dizziness, drowsiness, tremor, sleep disturbances; influenza-like syndrome, weight gain, hyperglycaemia, hypoglycaemia; arthralgia, myalgia; injection-site reactions, sweating, pruritus, rash; fatigue; hypercholesterolaemia; less commonly thrombocytopenia, leucopenia, leucocytosis, bleeding tendency

**Dose**
- By subcutaneous injection, initially 80 mg, then 10 mg daily, increased in steps of 5 mg daily according to response; max. 30 mg daily; CHILD not recommended

**Somavert** (Pfizer) \( \text{HRT} \)

**Injection**, powder for reconstitution, pegvisomant, net price 10-mg vial = £50.00; 15-mg vial = £75.00; 20-mg vial = £100.00 (all with solvent)

**Thyrotrophin**

Thyrotropin alfa is a recombinant form of thyrotrophin (thyroid stimulating hormone). It is licensed for use with or without radioiodine imaging, together with serum thyroglobulin testing, for the detection of thyroid remnants and thyroid cancer in post-thyroidectomy patients. It is also licensed to increase radio-iodine uptake for the ablation of thyroid remnant tissue in suitable post-thyroidectomy patients.

**Indications** see notes above and product literature

**Cautions** presence of thyroglobulin autoantibodies may give false negative results

**Contra-indications** hypersensitivity to bovine or human thyrotrophin

**Pregnancy** avoid

**Breast-feeding** avoid

**Side-effects** nausea, vomiting; headache, dizziness, fatigue; less commonly asthenia, paraesthesia, back pain, influenza-like symptoms, rash, urticaria; rarely diarrhoea; very rarely palpitation, flushing, dyspnoea, pain at site of metastases, tremor, arthralgia, myalgia, hyperhidrosis, and injection-site reactions including pain, pruritus, and rash

**Dose**
- By intramuscular injection into the gluteal muscle, 900 micrograms every 24 hours for 2 doses, consult product literature

**Thyrogen** (Genzyme) \( \text{HRT} \)

**Injection**, powder for reconstitution, thyrotropin alfa 900 micrograms/vial, net price = £291.52

**Hypothalamic hormones**

Gonadorelin when injected intravenously in normal subjects leads to a rapid rise in plasma concentrations of both luteinising hormone (LH) and follicle-stimulating hormone (FSH). It has not proved to be very helpful, however, in distinguishing hypothalamic from pituitary lesions. Gonadorelin analogues are indicated in endometriosis and infertility (section 6.7.2) and in breast and prostate cancer (section 6.3.4).

**GONADORELIN** (Gonadotrophin-releasing hormone; GnRH; LH–RH)

**Indications** see preparations below

**Cautions** pituitary adenoma

**Pregnancy** avoid

**Breast-feeding** avoid

**Side-effects** rarely, nausea, headache, abdominal pain, increased menstrual bleeding; rarely, hypersensitivity reaction on repeated administration of large doses; irritation at injection site

**Dose**
- See under preparations

**HRF** (Intrapharm) \( \text{HRT} \)

**Injection**, powder for reconstitution, gonadorelin. Net price 100-microgram vial (with diluent) = £13.72 (hosp. only)

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients p. 2)

**Dose** for assessment of pituitary function (adults), by subcutaneous or intravenous injection, 100 micrograms

6.5.2 Posterior pituitary hormones and antagonists

**Posterior pituitary hormones**

**Diabetes insipidus** Vasopressin (antidiuretic hormone, ADH) is used in the treatment of pituitary (‘cranial’) diabetes insipidus as is its analogue desmopressin. Dosage is tailored to produce a slight diuresis every 24 hours to avoid water intoxication. Treatment may be required for a limited period only in diabetes insipidus following trauma or pituitary surgery.

Desmopressin is more potent and has a longer duration of action than vasopressin; unlike vasopressin it has no vasoconstrictor effect. It is given by mouth or intranasally for maintenance therapy, and by injection in the postoperative period or in unconscious patients. Desmopressin is also used in the differential diagnosis of diabetes insipidus. Following a dose of 2 micrograms intramuscularly or 20 micrograms intranasally, restoration of the ability to concentrate urine after water deprivation confirms a diagnosis of cranial diabetes insipidus. Failure to respond occurs in nephrogenic diabetes insipidus.

In nephrogenic and partial pituitary diabetes insipidus benefit may be gained from the paradoxical antidiuretic effect of thiazides (section 2.2.1) e.g. chlorothalidone 100 mg twice daily reduced to maintenance dose of 50 mg daily.

Carbamazepine (section 4.8.1) is sometimes useful in partial pituitary diabetes insipidus (in a dose of 200 mg once or twice daily) [unlicensed]; it may act by sensitising the renal tubules to the action of remaining endogenous vasopressin.

**Other uses** Desmopressin is also used to boost factor VIII concentration in mild to moderate haemophilia and in von Willebrand’s disease; it is also used to test fibrinolytic response. For a comment on use of desmopressin in nocturnal enuresis see section 7.4.2.
Vasopressin infusion is used to control variceal bleeding in portal hypertension, prior to more definitive treatment and with variable results. Terlipressin, a derivative of vasopressin, is used similarly.

Oxytocin, another posterior pituitary hormone, is indicated in obstetrics (section 7.1.1).

**DESMOPRESSIN**

**Indications** see under Dose

**Cautions** see under Vasopressin; less pressor activity, less reduction of glomerular filtration rate

**Contra-indications** cardiac insufficiency and other conditions treated with diuretics; psychogenic polydipsia and polyuria in alcohol dependence

**Renal impairment** use with caution; antidiuretic effect may be reduced

**Pregnancy** small oxytocic effect in third trimester; increased risk of pre-eclampsia

**Breast-feeding** not known to be harmful

**Side-effects** fluid retention, and hyponatraemia (in young children, and in those over 65 years); also considerable caution in cystic fibrosis; in nocturia and nocturnal enuresis limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards; in nocturia periodic blood pressure and weight checks needed to monitor for fluid overload; interactions: Appendix 1 (desmopressin)

**Hyponatraemic convulsions** Patients being treated for primary nocturnal enuresis should be warned to avoid fluid overload (including during swimming) and to stop taking desmopressin during an episode of vomiting or diarrhoea (until fluid balance normal). The risk of hyponatraemic convulsions can also be minimised by keeping to the recommended starting doses and by avoiding concomitant use of drugs which increase secretion of vasopressin (e.g. tricyclic antidepressants)

**Contra-indications** cardiac insufficiency and other conditions treated with diuretics; psychogenic polydipsia and polyuria in alcohol dependence

**Renal impairment** use with caution; antidiuretic effect may be reduced

**Pregnancy** small oxytocic effect in third trimester; increased risk of pre-eclampsia

**Breast-feeding** not known to be harmful

**Side-effects** fluid retention, and hyponatraemia (in more serious cases with convulsions) on administration without restricting fluid intake; stomach pain, headache, nausea, vomiting, allergic reactions, and emotional disturbance in children also reported; epistaxis, nasal congestion, rhinitis with nasal spray

**Dose**

- By mouth (as desmopressin acetate)
  - Diabetes insipidus, treatment, ADULT and CHILD initially 300 micrograms daily (in 3 divided doses); maintenance, 300–600 micrograms daily in 3 divided doses; range 0.2–1.2 mg daily
  - Primary nocturnal enuresis, ADULT (under 65 years) and CHILD over 5 years (preferably over 7 years) 200 micrograms at bedtime, only increased to 400 micrograms if lower dose not effective (important: see also Cautions); withdraw for at least 1 week for reassessment after 3 months
  - Postoperative polyuria or polydipsia, adjust dose according to urine osmolality

- Sublingually (as desmopressin base)
  - Diabetes insipidus, treatment, ADULT and CHILD initially 180 micrograms daily in 3 divided doses; range 120–720 micrograms daily
  - Primary nocturnal enuresis, ADULT (under 65 years) and CHILD over 5 years (preferably over 7 years) 120 micrograms at bedtime, only increased to 240 micrograms if lower dose not effective (important: see also Cautions); withdraw for at least 1 week for reassessment after 3 months
  - Polyuria or polydipsia after hypophysectomy, adjust dose according to urine osmolality

- Intranasally (as desmopressin acetate)
  - Diabetes insipidus, diagnosis, ADULT and CHILD 20 micrograms (limit fluid intake to 500 mL from 1 hour before to 8 hours after administration)
  - Diabetes insipidus, treatment, ADULT 10–40 micrograms daily (in 1–2 divided doses); CHILD 5–20 micrograms daily; infants may require lower doses
  - Nocturia associated with multiple sclerosis (when other treatments have failed), ADULT (under 65 years) 10–20 micrograms at bedtime (important: see also Cautions), dose not to be repeated within 24 hours
  - Renal function testing (empty bladder at time of administration and limit fluid intake to 500 mL from 1 hour before until 8 hours after administration), ADULT 40 micrograms; INFANT under 1 year 10 micrograms (restrict fluid intake to 50% at next 2 feeds to avoid fluid overload), CHILD 1–15 years 20 micrograms
  - Mild to moderate haemophilia and von Willebrand’s disease, ADULT 300 micrograms (one 150-microgram spray into each nostril) 30 minutes before surgery or when bleeding; may be repeated at intervals of 12 hours (or at intervals of at least 3 days if self-administered)
  - Fibrinolytic response testing, ADULT 300 micrograms (one 150-microgram spray into each nostril); blood sampled after 1 hour for fibrinolytic activity

- By injection (as desmopressin acetate)
  - Diabetes insipidus, diagnosis (subcutaneous or intramuscular), ADULT and CHILD 2 micrograms (limit fluid intake to 500 mL from 1 hour before to 8 hours after administration)
  - Fibrinolytic response testing, (as desmopressin acetate)
  - Mild to moderate haemophilia and von Willebrand’s disease, (subcutaneous or intravenous), ADULT 1–4 micrograms daily; INFANT and CHILD 400 nanograms
  - Renal function testing (empty bladder at time of administration and limit fluid intake to 500 mL from 1 hour before until 8 hours after administration) (subcutaneous or intramuscular), ADULT and CHILD 2 micrograms; INFANT 400 nanograms (restrict fluid intake to 50% at next 2 feeds)
  - Mild to moderate haemophilia and von Willebrand’s disease, (subcutaneous or intravenous), ADULT and CHILD over 1 month 300 nanograms/kg as a single dose immediately before surgery or after trauma; may be repeated at intervals of 12 hours
  - Fibrinolytic response testing, (subcutaneous or intravenous), ADULT and CHILD 300 nanograms/kg; blood sampled after 20 minutes for fibrinolytic activity

**Lumbar-puncture-associated headache**

**Diabetes insipidus, diagnosis**

- **Diabetes insipidus, treatment**
  - Infants may require lower doses
  - Mild to moderate haemophilia and von Willebrand’s disease
  - Mild to moderate haemophilia and von Willebrand’s disease

**Brands include**

- Presven (Ferring)
- Presven (Schering-Plough)
- DDAVP® (Ferring)

**Fibrinolytic response testing**

**Diabetes insipidus, diagnosis**

- **Diabetes insipidus, treatment**
  - Infants may require lower doses
  - Mild to moderate haemophilia and von Willebrand’s disease
  - Mild to moderate haemophilia and von Willebrand’s disease

**Brands include**

- Presven (Ferring)
- Presven (Schering-Plough)
- DDAVP® (Ferring)
£50.53; 120 micrograms, 100-tab pack = £101.07; 240 micrograms, 100-tab pack = £202.14. Label: 26, counselling, fluid intake, see above

**Intranasal solution**, desmopressin acetate 100 micrograms/mL. Net price 2.5-mL dropper bottle and catheter = £9.72. Counselling, fluid intake, see above

**Injection**, desmopressin acetate 4 micrograms/mL. Net price 1-mL amp = £1.10

**Desmobil®** (Ferring) ▼
Tablets, scored, desmopressin acetate 200 micrograms, net price 30-tab pack = £29.43. Counselling, fluid intake, see above

**DesmoMelt®** (Ferring) ▼
Oral lyophilisates, desmopressin (as acetate) 120 micrograms, net price 30-tab pack = £30.34; 240 micrograms, 30-tab pack = £60.68. Label: 26, counselling, fluid intake, see above

**Desmospray®** (Ferring) ▼
Nasal spray, desmopressin acetate 10 micrograms/metered spray. Net price 6-mL unit (60 metered sprays) = £25.02. Counselling, fluid intake, see above

Note Children requiring dose of less than 10 micrograms should be given DDAVP® intranasal solution

**Octim®** (Ferring) ▼
Nasal spray, desmopressin acetate 150 micrograms/metered spray, net price 2.5-mL unit (25 metered sprays) = £576.60. Counselling, fluid intake, see above

**Injection**, desmopressin acetate 15 micrograms/mL, net price 1-mL amp = £19.22

**VASOPRESSIN**

**Indications** pituitary diabetes insipidus; bleeding from oesophageal varices

**Cautions** heart failure, hypertension, asthma, epilepsy, migraine or other conditions which might be aggravated by water retention; avoid fluid overload

**Contra-indications** vascular disease (especially disease of coronary arteries) unless extreme caution, chronic nephritis (until reasonable blood nitrogen concentrations attained)

**Renal impairment** see Contra-indications

**Pregnancy** oxytocic effect in third trimester

**Breast-feeding** not known to be harmful

**Side-effects** fluid retention, pallor, tremor, sweating, vertigo, headache, nausea, vomiting, belching, abdominal cramps, desire to defaecate, hypersensitivity reactions (including anaphylaxis), constriction of coronary arteries (may cause anginal attacks and myocardial ischaemia), peripheral ischaemia and rarely gangrene

**Dose**
- By subcutaneous or intramuscular injection, diabetes insipidus, 5–20 units every four hours
- By intravenous infusion, initial control of variceal bleeding, 20 units over 15 minutes

**Synthetic vasopressin**

**Pitressin®** (Goldshield) ▼
Injection, argipressin (synthetic vasopressin) 20 units/mL. Net price 1-mL amp = £17.14 (hosp. only)

**Antidiuretic hormone antagonists**

**Demeclocycline** (section 5.1.3) can be used in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Demeclocycline is thought to act by directly blocking the renal tubular effect of antidiuretic hormone. Initially 0.9–1.2 g is given daily in divided doses, reduced to 600–900 mg daily for maintenance.

**Tolvaptan**

Tolvaptan is a vasopressin V2-receptor antagonist licensed for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion; treatment duration with tolvaptan is determined by the underlying disease and its treatment.

**Side-effects** nausea, constipation, dry mouth; postural hypotension; thirst, decreased appetite, fever, asthenia, hyperglycaemia, urinary frequency,
Osteoporosis

Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids (glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack of physical activity, family history of osteoporosis, and early menopause.

Those at risk of osteoporosis should maintain an adequate intake of calcium and vitamin D and any deficiency should be corrected by increasing dietary intake or taking supplements.

Elderly patients, especially those who are housebound or live in residential or nursing homes, are at increased risk of calcium and vitamin D deficiency and may benefit from supplements (section 9.5.1.1 and section 9.6.4). Reversible secondary causes of osteoporosis such as hyperthyroidism, hyperparathyroidism, osteomalacia or hypogonadism should be excluded, in both men and women, before treatment for osteoporosis is initiated.

Postmenopausal osteoporosis The bisphosphonates (alendronic acid, disodium etidronate, and risedronate, section 6.6.2) are effective for preventing postmenopausal osteoporosis. Hormone replacement therapy (HRT section 6.4.1.1) is an option where other therapies are contra-indicated, cannot be tolerated, or if there is a lack of response. The CSM has advised that HRT should not be considered first-line therapy for long-term prevention of osteoporosis in women over 50 years of age. HRT is of most benefit for the prophylaxis of postmenopausal osteoporosis if started early in menopause and continued for up to 5 years, but bone loss resumes (possibly at an accelerated rate) on stopping HRT. Calcitonin (section 6.6.1) may be considered for those at high risk of osteoporosis for whom a bisphosphonate is unsuitable. Women of Afro-Caribbean origin appear to be less susceptible to osteoporosis than those who are white or of Asian origin.

Postmenopausal osteoporosis may be treated with a bisphosphonate (section 6.6.2). The bisphosphonates (such as alendronate, etidronate, and risedronate) decrease the risk of vertebral fracture; alendronate and risedronate have also been shown to reduce non-vertebral fractures. If bisphosphonates are unsuitable calcitriol (section 9.6.4), calcitonin or strontium ranelate (section 6.6.2) may be considered. Calcitonin [unlicensed indication] may also be useful for pain relief for up to 3 months after a vertebral fracture if other analgesics are ineffective. Parathyroid hormone, and teriparatide (section 6.6.1) have been introduced for the treatment of postmenopausal osteoporosis.

Raloxifene (section 6.4.1.1) is licensed for the prophylaxis and treatment of vertebral fractures in postmenopausal women.

NICE guidance

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)

Alendronate is recommended as a treatment option for the primary prevention of osteoporotic fractures in the following susceptible postmenopausal women:

- Women over 70 years who have an independent risk factor for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis) or an indicator of low bone mineral density (body mass index under 22 kg/m², ankylosing spondylitis, Crohn’s disease, prolonged immobility, untreated premature menopause, or rheumatoid arthritis) and confirmed osteoporosis
- Women aged 65–69 years who have an independent risk factor for fracture and confirmed osteoporosis
- Women under 65 years who have an independent risk factor for fracture and at least one additional indicator of low bone mineral density and confirmed osteoporosis

Risedronate or etidronate are recommended as alternatives for women:

- in whom alendronate is contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance

Strontium ranelate is recommended as an alternative for women:

- in whom alendronate and either risedronate or etidronate are contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance

Raloxifene is not recommended as a treatment option in postmenopausal women for primary prevention of osteoporotic fractures.

1. Available at www.nice.org.uk/TA160
Corticosteroid-induced osteoporosis. To reduce the risk of osteoporosis doses of oral corticosteroids should be as low as possible and courses of treatment as short as possible. The risk of osteoporosis may be related to cumulative dose of corticosteroids; even intermittent courses can therefore increase the risk. The greatest rate of bone loss occurs during the first 6–12 months of corticosteroid use and so early steps to prevent the development of osteoporosis are important. Long-term use of high-dose inhaled corticosteroids may also contribute to corticosteroid-induced osteoporosis (section 3.2). Patients taking (or who are likely to take) an oral corticosteroid for 3 months or longer should be assessed and where necessary given prophylactic treatment; those aged over 65 years are at greater risk. Patients taking oral corticosteroids who have sustained a low-trauma fracture should receive treatment for osteoporosis. The therapeutic options for prophylaxis and treatment of corticosteroid-induced osteoporosis are the same:
- A bisphosphonate (section 6.6.2);
- Calcitriol [unlicensed indication] (section 9.6.4);
- Hormone replacement (HRT in women (section 6.4.1), testosterone in men [unlicensed indication] (section 6.4.2)).

### 6.6.1 Calcitonin and parathyroid hormone

Calcitonin is involved with parathyroid hormone in the regulation of bone turnover and hence in the maintenance of calcium balance and homoeostasis. Calcitonin (salmon) (salcatonin, synthetic or recombinant salmon calcitonin) is used to lower the plasma-calcium concentration in some patients with hypercalcaemia (notably when associated with malignant disease). Calcitonin is licensed for treatment of Paget’s disease of bone. It can also be used in the prevention and treatment of postmenopausal osteoporosis (see section 6.6).

Recombinant parathyroid hormone is used for the treatment of postmenopausal osteoporosis. Teriparatide (a recombinant fragment of parathyroid hormone) is used for the treatment of postmenopausal osteoporosis, osteoporosis in men at increased risk of fracture, and corticosteroid-induced osteoporosis. The Scottish Medicines Consortium, p. 4 has advised (February 2007) that parathyroid hormone (Preotact®) should be initiated by specialists experienced in the treatment of osteoporosis; also that the use of teriparatide (Forstero®) (December 2003) in postmenopausal women should be restricted to the treatment of established (severe) osteoporosis and should be initiated by specialists experienced in the treatment of osteoporosis.

Cinacalcet (section 9.5.1.2) is licensed for the treatment of hypercalcaemia in parathyroid carcinoma.

### NICE guidance

**Alendronate, etidronate, risendronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)**

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

**Alendronate** is recommended as a treatment option for the secondary prevention of osteoporotic fractures in susceptible postmenopausal women.

**Risedronate** or **etidronate** are recommended as alternatives for women:

- in whom alendronate is contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance).

**Strontium ranelate** or **raloxifene** are recommended as alternatives for women:

- in whom alendronate and either risedronate or etidronate are contra-indicated or not tolerated and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.

**Teriparatide** is recommended as an alternative for women:

- in whom alendronate and either risedronate or etidronate, or strontium ranelate are contra-indicated or not tolerated, or where treatment with alendronate, risedronate or etidronate has been unsatisfactory (indicated by another fragility fracture and a decline in bone mineral density despite treatment for 1 year) and
- who comply with particular combinations of bone mineral density measurement, age, and number of fractures, as indicated in the full NICE guidance.

---

1. Available at [www.nice.org.uk/TA161](http://www.nice.org.uk/TA161)
BNF 61

6.6.2 Bisphosphonates and other drugs affecting bone metabolism

**Dose**
- Hypercalcaemia of malignancy (see also section 9.5.1.2). ADULT over 18 years, by subcutaneous or intramuscular injection, 100 units every 6–8 hours adjusted according to response; max. 400 units every 6–8 hours; in severe or emergency cases, by intravenous infusion, up to 10 units/kg over at least 6 hours
- Paget’s disease of bone, ADULT over 18 years, by subcutaneous or intramuscular injection, 50 units 3 times weekly to 100 units daily adjusted according to response
- Postmenopausal osteoporosis to reduce risk of vertebral fractures, intranasally, 200 units (1 spray) into one nostril daily, with dietary calcium and vitamin D supplements (section 9.5.1.1 and section 9.6.4)
- Prevention of acute bone loss due to sudden immobility, ADULT over 18 years, by subcutaneous or intramuscular injection, 100 units daily in 1–2 divided doses for 2–4 weeks, reduced to 50 units daily at start of mobilisation and continued until fully mobile

**Side-effects**
- Gastro-intestinal disorders (including nausea, vomiting, dyspepsia, constipation, diarrhoea; palpitation; headache, dizziness, fatigue, asthenia; transient hypercalcaemia, hypercalciuria; muscle cramp, pain in extremities, back pain; injection-site reactions; less commonly abdominal pain, altered sense of smell, taste disturbance, anorexia, influenza, hyperuricaemia
- By subcutaneous injection, 100 micrograms daily, max. duration of treatment 24 months

**Preotact®** (Nycomed) **Injection**, dual-chamber cartridge containing powder for reconstitution, parathyroid hormone (rdna) and diluent, net price 1.61-mg (14-dose) cartridge = £156.24. For use with Preotact® pen device.

**TERIPARATIDE**

**Indications**
- Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; treatment of corticosteroid-induced osteoporosis; see also notes above

**Contra-indications**
- Pre-existing hypercalcaemia, skeletal malignancies or bone metastases, metabolic bone diseases, including Paget’s disease and hyperparathyroidism, unexplained raised alkaline phosphatase, previous radiation therapy to the skeleton

**Renal impairment**
- Caution in moderate impairment; avoid if severe

**Pregnancy**
- Avoid

**Breast-feeding**
- Avoid

**Side-effects**
- Gastro-intestinal disorders (including nausea, reflux and haemorrhoids); palpitation; dyspnoea; headache, fatigue, asthenia, depression, dizziness, vertigo; anaemia, increased sweating, muscle cramps, sciatica, myalgia, arthralgia; less commonly urinary disorders, hypercalcaemia; injection-site reactions; rarely hypersensitivity reactions

**Dose**
- By subcutaneous injection, 20 micrograms daily, max. duration of treatment 18 months (course not to be repeated)

**Forsteo®** (Lilly) **Injection**, teriparatide 250 micrograms/mL, net price 2.4-mL prefilled pen = £271.88, 3-mL prefilled pen = £271.88

**Note**
- 3-mL prefilled pen intended for 28 doses

**PARATHYROID HORMONE**

(Human recombinant parathyroid hormone)

**Indications**
- Treatment of osteoporosis in postmenopausal women at high risk of fractures (to reduce the risk of vertebral fractures) (see also notes above)

**Cautions**
- Monitor serum or urinary calcium concentration at 1, 3 and 6 months after initiation of treatment (consult product literature for guidance if serum-calcium concentration raised); active or previous urolithiasis; concomitant cardiac glycosides

**Contra-indications**
- Previous radiation therapy to skeleton, pre-existing hypercalcaemia, metabolic bone disease (including hyperparathyroidism and Paget’s disease), unexplained raised levels of alkaline phosphatase

**Hepatic impairment**
- Avoid

**Renal impairment**
- Avoid if eGFR less than 30 mL/minute/1.73m²

**Pregnancy**
- Avoid

**Breast-feeding**
- Avoid

**Side-effects**
- Nausea, vomiting, dyspepsia, constipation, diarrhoea; palpitation; headache, dizziness, fatigue, asthenia; transient hypercalcaemia, hypercalciuria; muscle cramp, pain in extremities, back pain; injection-site reactions; less commonly abdominal pain, altered sense of smell, taste disturbance, anorexia, influenza, hyperuricaemia

**Dose**
- By subcutaneous injection, 100 micrograms daily, max. duration of treatment 24 months

**Bisphosphonates**

Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover. Bisphosphonates have an important role in the prophylaxis and treatment of osteoporosis and corticosteroid-induced osteoporosis; alendronic acid or risedronate sodium are considered the drugs of choice for these conditions, but disodium etidronate may be considered if these drugs are unsuitable or not tolerated (see also section 6.8).

Bisphosphonates are also used in the treatment of Paget’s disease, hypercalcaemia of malignancy (section 9.5.1.2), and in bone metastases in breast cancer (section 8.3.4.1). Disodium etidronate can impair bone mobilisation and continued until fully mobile.
mineralisation when used continuously or in high doses (such as in the treatment of Paget’s disease).

MHRA/CHM advice

**Bisphosphonates: osteonecrosis of the jaw**

(October 2007 and November 2009)

The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease.

Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of dental disease. All patients receiving bisphosphonates for cancer should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment. However, urgent bisphosphonate treatment should not be delayed, and a dental check-up should be carried out as soon as possible in these patients. All other patients who are prescribed bisphosphonates should have a dental examination only if they have poor dental health.

During bisphosphonate treatment patients should maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms.

**ALENDRONIC ACID**

**Indications** see under Dose

**Cautions** upper gastro-intestinal disorders (dysphagia, symptomatic oesophageal disease, gastritis, duodenitis, or ulcers—see also under Contra-indications and Side-effects); history (within 1 year) of ulcers, active gastro-intestinal bleeding, or surgery of the upper gastro-intestinal tract; correct disturbances of calcium and mineral metabolism (e.g. vitamin-D deficiency, hypocalcaemia) before starting and monitor serum-calcium concentration during treatment; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, above); exclude other causes of osteoporosis; atypical stress fractures reported (discontinue unless benefits of continued treatment clearly outweigh risks); inter-actions: Appendix 1 (bisphosphonates)

**Contra-indications** abnormalities of oesophagus and other factors which delay emptying (e.g. stricture or oesophageal motility disorders); hypocalcaemia

**Renal impairment** avoid if eGFR less than 35 mL/minute/1.73 m²

**Pregnancy** avoid

**Breast-feeding** no information available

**Side-effects** oesophageal reactions (see below), abdominal pain and distension, dyspepsia, regurgitation, nausea, diarrhoea or constipation, flatulence, musculoskeletal pain, headache; rarely rash, pruritus, erythema, photosensitivity, urticaria, scleritis, transient decrease in serum calcium and phosphate; vomiting, gastritis, peptic ulceration, hypersensitivity reactions (including urticaria and angioedema), and atypical stress fractures with long-term use also reported; myalgia, malaise, and fever at initiation of treatment; very rarely severe skin reactions (including Stevens-Johnson syndrome), osteonecrosis of the jaw (see MHRA/CHM advice, above)

**Oesophageal reactions** Severe oesophageal reactions (oesophagitis, oesophageal ulcers, oesophageal stricture and oesophageal erosions) have been reported, patients should be advised to stop taking the tablets and to seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, new or worsening heartburn, pain on swallowing or retrosternal pain

**Dose**

- Treatment of postmenopausal osteoporosis, 10 mg daily or 70 mg once weekly
- Treatment of osteoporosis in men, 10 mg daily
- Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy, 10 mg daily

Counselling Tablets should be swallowed whole with plenty of water while sitting or standing, to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet

**Alendronic acid (Non-proprietary)**

Tablets, alendronic acid (as sodium alendronate) 10 mg, net price 28-tab pack = £1.65. Counselling, administration

**Fosamax® (MSD)**

Tablets, alendronic acid (as sodium alendronate) 10 mg, 28-tab pack = £23.12. Counselling, administration

**Alendronic Acid Once-Weekly (Non-proprietary)**

Tablets, alendronic acid (as sodium alendronate) 70 mg, net price 4-tab pack = £1.05. Counselling, administration

**Fosamax® Once Weekly** (MSD)

Tablets, alendronic acid (as sodium alendronate) 70 mg, net price 4-tab pack = £22.80. Counselling, administration

With colecaciferol

For prescribing information on colecaciferol, see section 9.6.4

**Fosavance® (MSD)**

Tablets, alendronic acid (as sodium alendronate) 70 mg, colecaciferol 70 micrograms (2 800 units), net price 4-tab pack = £22.80. Counselling, administration

**Dose** treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency, 1 tablet once weekly

Counselling Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet

**DISODIUM ETIDRONATE**

**Indications** see under Dose

**Cautions** consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, above); inter-actions: Appendix 1 (bisphosphonates)

**Contra-indications** not indicated for osteoporosis in presence of hypercalcaemia or hypercalciuria or for osteomalacia

**Renal impairment** reduce dose in mild impairment; avoid in moderate to severe renal impairment
BNF 61 6.6.2 Bisphosphonates and other drugs affecting bone metabolism 473

Pregnancy avoid
Breast-feeding no information available

Side-effects nausea, diarrhoea or constipation, abdominal pain; increased bone pain in Paget’s disease, also increased risk of fractures with high doses in Paget’s disease (discontinue if fractures occur); rarely exacerbation of asthma, skin reactions (including angioedema, rash, urticaria and pruritus), transient hyperphosphataemia, headache, paraesthesia, peripheral neuropathy reported; blood disorders (including leucopenia, agranulocytosis and pancreatic) also reported; very rarely osteonecrosis of the jaw (see MHRA/CHM advice, p. 472)

Dose

- Paget’s disease of bone, by mouth, 5 mg/kg as a single daily dose for up to 6 months; doses above 10 mg/kg daily for up to 3 months may be used with caution but doses above 20 mg/kg daily are not recommended; after interval of not less than 3 months may be repeated where evidence of reactivation—including biochemical indices (avoid premature retreatment)

- Osteoporosis, see under Didronel PMO®

Counselling Avoid food for at least 2 hours before and after oral treatment, particularly calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids

Didronel® (Warner Chilcott) Tablets, disodium etidronate 200 mg. Net price 60-tab pack = £19.48. Counselling, food and calcium (see above)

- With calcium carbonate
  For prescribing information on calcium carbonate see section 9.5.1.1

Didronel PMO® (Warner Chilcott) Tablets, 14 white, disodium etidronate 400 mg: 76 pink, effervescent, calcium carbonate 1.25 g (Cacit®). Net price per pack = £19.89. Label: 10, patient information leaflet, counselling, food and calcium (see above)

Dose treatment of osteoporosis, prevention of bone loss in postmenopausal women (particularly if hormone replacement therapy inappropriate), and prevention and treatment of corticosteroid-induced osteoporosis, given in 90-day cycles. 1 Didronel® tablet daily for 14 days, then 1 Cacit® tablet daily for 76 days

Hepatic impairment caution in severe hepatic impairment—no information available
Renal impairment max. infusion rate 20 mg/hour; avoid if eGFR less than 30 mL/minute/1.73 m², except in life-threatening hypercalcaemia if benefit outweighs risk; if renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value
Pregnancy avoid
Breast-feeding avoid

Side-effects hypophosphataemia, fever and influenza-like symptoms (sometimes accompanied by malaise, rigors, fatigue and flushes); nausea, vomiting, anorexia, abdominal pain, diarrhoea, constipation; symptomatic hypercalcaemia (paraesthesia, tetany), hypomagnesaemia, headache, insomnia, drowsiness; hypertension; anaemia, thrombocytopenia, lymphocytopenia; rash; arthralgia, myalgia, bone pain; rarely muscle cramps, dyspepsia, agitation, confusion, dizziness, lethargy; leucopenia, hypotension, pruritus, hyperkalaemia or hypokalaemia, and hyperparathyroidism; osteonecrosis of the jaw (see also MHRA/CHM advice, p. 472), isolated cases of seizures, hallucinations, haematuria, acute renal failure, deterioration of renal disease, conjunctivitis and other ocular symptoms; atrial fibrillation, and reactivation of herpes simplex and zoster also reported; also injection-site reactions

Dose

- By slow intravenous infusion (via cannula in a relatively large vein), see also Appendix 6

Hypercalcaemia of malignancy, according to serum calcium concentration 15–60 mg in single infusion or in divided doses over 2–4 days; max. 90 mg per treatment course

Osteolytic lesions and bone pain in bone metastases associated with breast cancer or multiple myeloma, 90 mg every 4 weeks (or every 3 weeks to coincide with chemotherapy in breast cancer)

Paget’s disease of bone, 30 mg once a week for 6 weeks (total dose 180 mg) or 30 mg in first week then 60 mg every other week (total dose 210 mg); max. total 360 mg (in divided doses of 60 mg) per treatment course; may be repeated every 6 months

- CHL0 not recommended
Calcium and vitamin D supplements Oral supplements are advised to minimise potential risk of hypocalcaemia for those with mainly lytic bone metastases or multiple myeloma at risk of calcium or vitamin D deficiency (e.g. through malabsorption or lack of exposure to sunlight) and in those with Paget’s disease

Disodium pamidronate (Non-proprietary) Concentrate for intravenous infusion, disodium pamidronate 3 mg/mL, net price 5-mL vial = £27.50, 10-mL vial = £55.00; 6 mg/mL, 10-mL vial = £95.00; 9 mg/mL, 10-mL vial = £165.00; 15 mg/mL, 1-mL vial = £29.83, 2-mL vial = £59.66, 4-mL vial = £119.32, 6-mL vial = £170.46
Aredia Dry Powder® (Novartis) Injection, powder for reconstitution, disodium pamidronate, for use as an infusion. Net price 15-mg vial = £29.83; 30-mg vial = £59.66; 90-mg vial = £170.45 (all with diluents)

DISODIUM PAMIDRONATE
Disodium pamidronate was formerly called aminohydroxypropylidendiphosphonate disodium (APD)

Indications see under Dose

Cautions assess renal function before each dose; ensure adequate hydration; cardiac disease (especially in elderly); previous thyroid surgery (risk of hypercalcaemia); monitor serum electrolytes, calcium and phosphate—possibility of convulsions due to electrolyte changes; avoid concurrent use with other bisphosphonates; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); interactions: Appendix 1 (bisphosphonates)

Driving Patients should be warned against driving or operating machinery immediately after treatment (somnolence or dizziness can occur)
IBANDRONIC ACID

**Indications**  see under Dose

**Cautions**  consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); monitor renal function and serum calcium, phosphate and magnesium; cardiac disease (avoid fluid overload); interactions: Appendix 1 (bisphosphonates)

**Contra-indications**  hypocalcaemia; oral route abnormalities of the oesophagus and other factors which delay emptying (e.g. stricture or achalasia)

**Renal impairment**  for treatment of osteoporosis, avoid if eGFR less than 30 mL/minute/1.73 m²; for reduction of bone damage in bone metastases, if eGFR 30–50 mL/minute/1.73 m² reduce intravenous dose to 4 mg and infuse over 1 hour, reduce oral dose to 50 mg on alternative days, if eGFR less than 30 mL/minute/1.73 m² reduce intravenous dose to 2 mg and infuse over 1 hour, reduce oral dose to 50 mg once weekly

**Pregnancy**  avoid

**Breast-feeding**  avoid—present in milk in animal studies

**Side-effects**  hypocalcaemia, oral route abnormalities of the oesophagus and other factors which delay emptying (e.g. stricture or achalasia), diarrhea, nausea, vomiting, gastritis, abdominal pain, dyspepsia, pharyngitis; headache, asthenia, rash; rarely anaemia, hypersensitivity reactions (pruritus, bronchospasm and angioedema reported); urticaria; injection-site reactions; very rarely osteonecrosis of the jaw (see MHRA/CHM advice, p. 472); oesophageal reactions Severe oesophageal reactions (pruritus, bronchospasam and angioedema reported); urticaria; injection-site reactions; very rarely osteonecrosis of the jaw (see MHRA/CHM advice, p. 472); oesophageal reactions Patients should be advised to stop tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn

**Dose**

- Reduction of bone damage in bone metastases in breast cancer, **by mouth**, 50 mg daily, or **by intravenous infusion**, 6 mg every 3–4 weeks
- Hypercalcaemia of malignancy **by intravenous infusion**, according to serum calcium concentration, 2–4 mg in single infusion
- Treatment of postmenopausal osteoporosis, **by mouth**, 150 mg once a month or **by intravenous injection** over 15–30 seconds, 3 mg every 3 months
- **CHILD** not recommended

**Counselling**  Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach 30 minutes (IBandron® tablets, 50 mg) or 1 hour (Bonviva® tablets, 150 mg) before first food or drink (other than water) of the day, or another oral medicine; patient should stand or sit upright for at least 1 hour after taking tablet

**Bondronat** (Roche)  Tablets, f/c, ibandronic acid 50 mg, net price 28-tab pack = £183.69. Counselling, administration

**Concentrate for intravenous infusion**, ibandronic acid 1 mg/mL, net price 2-mL amp = £89.36, 6-mL vial = £183.69

**Bonviva** (Roche)  Tablets, f/c, ibandronic acid 150 mg, net price 1-tab pack = £18.40, 3-tab pack = £55.21. Counselling, administration

**Injection**, ibandronic acid 1 mg/mL, net price 3-mL prefilled syringe = £68.64

RISEDRONATE SODIUM

**Indications**  see under Dose

**Cautions**  oesophageal abnormalities and other factors which delay transit or emptying (e.g. stricture or achalasia)—see also under Side-effects); correct hypocalcaemia before starting, correct other disturbances of bone and mineral metabolism (e.g. vitamin-D deficiency) at onset of treatment; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); interactions: Appendix 1 (bisphosphonates)

**Contra-indications**  hypocalcaemia (see Cautions above)

**Renal impairment**  avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy**  avoid

**Breast-feeding**  avoid

**Side-effects**  abdominal pain, dyspepsia, nausea, diarrhea, constipation, headache, musculoskeletal pain; less commonly oesophagitis, oesophageal ulcer, dysphagia, gastritis, duodenitis, uveitis; rarely glossitis, oesophageal stricture; also reported gastro-duodenal ulceration, hepatic disorders, Stevens-Johnson syndrome, toxic epidermal necrolysis, hair loss; osteonecrosis of the jaw (see MHRA/CHM advice, p. 472)

**Oesophageal reactions**  Patients should be advised to stop taking the tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn

**Dose**

- Paget’s disease of bone, 30 mg daily for 2 months; may be repeated if necessary after at least 2 months
- Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures, 5 mg daily or 35 mg once weekly
- Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women, 5 mg daily
- Treatment of osteoporosis in men at high risk of fractures, 35 mg once weekly
- **CHILD** see BNF for Children

**Counselling**  Swallow tablets whole with full glass of water; on rising, take on an empty stomach at least 30 minutes before first food or drink of the day or, if taking at any other time of the day, avoid food and drink for at least 2 hours before or after risedronate (particularly avoid calcium-containing products e.g. milk, also avoid iron and mineral supplements and antacids); stand or sit upright for at least 30 minutes; do not take tablets at bedtime or before rising

**Actonel®** (Warner Chilcott)  Tablets, f/c, risedronate sodium 5 mg (yellow), net price 28-tab pack = £17.99; 30 mg (white), 28-tab pack = £143.95. Counselling, administration, food and calcium (see above)

**Actonel Once a Week®** (Warner Chilcott)  Tablets, f/c, orange, risedronate sodium 35 mg, net price 4-tab pack = £19.12. Counselling, administration, food and calcium (see above)

**With calcium carbonate and coecalciferol**

For cautions, contra-indications, and side-effects of calcium carbonate, see section 9.5.1.1 and of coecalciferol, see section 9.6.4

**Actonel® Combi** (Warner Chilcott)  Tablets, f/c, orange, risedronate sodium 35 mg (Actonel Once a Week®):
**SODIUM CLODRONATE**

**Indications** see under Dose

**Cautions** monitor renal and hepatic function and white cell count; also monitor serum calcium and phosphate periodically; renal dysfunction reported in patients receiving concomitant NSAIDs; maintain adequate fluid intake during treatment; consider dental check-up before initiating bisphosphate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); interactions: Appendix 1 (bisphosphonates)

**Contra-indications** acute gastro-intestinal inflammatory conditions

**Renal impairment** use half normal dose if eGFR 10–20 mL/minute/1.73 m²; avoid if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** avoid

**Breast-feeding** no information available

**Side-effects** nausea, diarrhoea; skin reactions; bronchospasm; very rarely osteonecrosis of the jaw (see MHRA/CHM advice, p. 472);

**Dose**
- Osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma, by mouth, 1.6 g daily in single or 2 divided doses increased if necessary to a max. of 3.2 g daily
- Osteonecrosis of the jaw

**Counselling**
- Avoid food for 1 hour before and after treatment, particularly calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids; maintain adequate fluid intake
- Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet. Granules should be stirred into a glass of water and after dissolution complete taken immediately

**Bonefos®** (Bayer Schering)
- **Capsules**, yellow, sodium clodronate 400 mg, net price 120-cap pack = £139.83. Counselling, food and calcium
- **Tablets**, f/c, scored, sodium clodronate 800 mg, net price 60-tab pack = £146.43. Counselling, food and calcium

**Clasteon®** (Beacon)
- **Capsules**, blue/white, sodium clodronate 400 mg, net price 30-cap pack = £34.96, 120-cap pack = £139.83. Counselling, food and calcium

**Loron 520®** (Roche)
- **Tablets**, f/c, scored, sodium clodronate 520 mg, net price 60-tab pack = £152.59. Label: 10, patient information leaflet, counselling, food and calcium
- **Dose** 2 tablets daily in single or two divided doses. may be increased to max. 4 tablets daily

**TILDURONIC ACID**

**Indications** Paget's disease of bone

**Cautions** correct disturbances of calcium metabolism (e.g. vitamin D deficiency, hypocalcaemia) before starting; avoid concomitant use of indomethacin, consider dental check-up before initiating bisphosphate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); interactions: Appendix 1 (bisphosphonates)

**Contra-indications** juvenile Paget's disease

**Renal impairment** use with caution and monitor renal function regularly if eGFR 30–90 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** avoid

**Breast-feeding** avoid—no information available

**Side-effects** stomach pain, nausea, diarrhoea; very rarely asthenia, dizziness, headache and skin reactions; very rarely osteonecrosis of the jaw (see MHRA/CHM advice, p. 472)

**Dose**
- 400 mg daily as a single dose for 12 weeks; may be repeated if necessary after 6 months
- **Counselling** Avoid food for 2 hours before and after treatment, particularly calcium-containing products e.g. milk; also avoid antacids

**Skeld®** (Sanofi-Aventis)
- **Tablets**, tiludronic acid (as tiludronate disodium) 200 mg. Net price 28-tab pack = £95.14. Counselling, food and calcium

**ZOLEDRONIC ACID**

**Indications** see under preparations

**Cautions** correct disturbances of calcium metabolism (e.g. vitamin D deficiency, hypocalcaemia) before starting; monitor serum electrolytes, calcium, phosphate and magnesium; cardiac disease (avoid fluid overload); consider dental check-up before initiating bisphosphate (risk of osteonecrosis of the jaw, see MHRA/CHM advice, p. 472); interactions: Appendix 1 (bisphosphonates)

**Renal function** Renal impairment and renal failure have been reported. Before each dose ensure patient is hydrated and assess renal function. Continue to monitor renal function in patients at risk, such as those with pre-existing renal impairment, those of advanced age, those taking concomitant nephrotoxic drugs or diuretics, or those who are dehydrated. Use with caution with concomitant medicines that affect renal function

**Contra-indications** women of child-bearing potential

**Hepatic impairment** caution in severe hepatic impairment—limited information available

**Renal impairment** avoid if serum creatinine above 400 micromol/litre in tumour-induced hypercalcaemia; in advanced malignancies involving bone, if eGFR 50–60 mL/minute/1.73 m² reduce dose to 3.5 mg every 3–4 weeks, if eGFR 40–50 mL/minute/1.73 m² reduce dose to 3.3 mg every 3–4 weeks, if eGFR 30–40 mL/minute/1.73 m² reduce dose to 3 mg every 3–4 weeks, if eGFR less than 30 mL/minute/1.73 m² (or if serum creatinine greater than 265 micromol/litre); if renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value; avoid in Paget’s disease, treatment of postmenopausal osteoporosis and osteoporosis in men if
Denosumab

Denosumab is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption. It is licensed for the treatment of postmenopausal osteoporosis in women at increased risk of fractures and for the treatment of bone loss associated with hormone ablation in men with prostate cancer.

NICE guidance

Denosumab for the prevention of osteoporotic fractures in postmenopausal women (October 2010)

Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures:

- who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contra-indication to, those treatments and
- who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance (available at www.nice.org.uk/TA204).

Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contra-indication to, those treatments.

DENOSUMAB

Indications see notes above

Cautions correct hypocalcaemia and vitamin D deficiency before starting (monitor plasma-calcium concentration during therapy); consider dental check-up and carry out invasive procedures before initiating treatment (risk of osteonecrosis of the jaw)

Renal impairment increased risk of hypocalcaemia if eGFR less than 30 mL/minute/1.73 m²—monitor plasma-calcium concentration

Pregnancy avoid

Breast-feeding avoid

Side-effects constipation, urinary tract infection, upper respiratory tract infection; pain in extremity, sciatia; cataracts, rash; less commonly diverticulitis, cellulitis (seek prompt medical attention), ear infection, eczema; rarely osteonecrosis of the jaw; very rarely uveitis

Dose

- By subcutaneous injection, 60 mg every 6 months

Note Supplement with calcium and vitamin D

Prolia® (Amgen) ▼ (BNF)

Injection, denosumab 60 mg/mL, net price 1-mL prefilled syringe = £183.00

Strontium ranelate

Strontium ranelate stimulates bone formation and reduces bone resorption. It is licensed for the treatment of postmenopausal osteoporosis. The Scottish Medicines Consortium (p. 4) has advised (July 2005) that treatment with strontium ranelate should be restricted to those patients in whom bisphosphonates are contraindicated or not tolerated, and then only in women aged over 75 years with a previous fracture and low bone mineral density or in other women at equivalent risk.
similar side-effects to bromocriptine, however patients intolerant of bromocriptine may be able to tolerate cabergoline (and vice versa).

Quinagolide is a non-ergot dopamine D1 agonist; it has actions and uses similar to those of ergot-derived dopamine agonists, but its side-effects differ slightly.

Cautions see notes below, also bromocriptine and cabergoline should be used with caution in patients with a history of peptic ulcer, particularly in acromegalic patients. Treatment should be withdrawn if gastro-intestinal bleeding occurs. In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment). Bromocriptine and cabergoline should be used with caution in patients with Raynaud's syndrome and cardiovascular disease (see also Contra-indications under Bromocriptine, below). Monitor for fibrotic disease (see Fibrotic Reactions, below). Caution is also advised in patients with a history of serious mental disorders (especially psychotic disorders) and in those with acute porphyria (see section 9.8.2). Tolerance may be reduced by alcohol.

Contra-indications Bromocriptine and cabergoline should not be used in patients with hypersensitivity to ergot alkaloids. They are contra-indicated in those with cardiac valvulopathy (exclude before treatment, see Fibrotic Reactions, below). They should also be avoided in pre-eclampsia (see also Contra-indications under Bromocriptine, below).

Side-effects Nausea, constipation, and headache are common side-effects of bromocriptine and cabergoline. Parasthesia has been reported rarely. Other reported side-effects include hypotension (see also Hypotensive Reactions, below), dyskinesia, pathological gambling, increased libido, hypersexuality, leg cramps, allergic skin reactions, alopecia, and peripheral oedema. Bromocriptine and cabergoline have been associated with pleuritis, pleural effusion, cardiac valvulopathy, pericardial effusion, constrictive pericarditis, and retroperitoneal, pleural, and pulmonary fibrosis (see Fibrotic Reactions).

Fibrotic reactions Ergot-derived dopamine-receptor agonists, bromocriptine, cabergoline, lisuride [discontinued], and pergolide have been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for chronic endocrine disorders (excludes suppression of lactation) or Parkinson's disease; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline or pergolide should be regularly monitored for cardiac fibrosis, by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).
**Driving**

Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with dopaminergic drugs.

Patients starting treatment with these drugs should be warned of the possibility of these effects and of the need to exercise caution when driving or operating machinery.

Patients who have suffered excessive sedation or sudden onset of sleep should refrain from driving or operating machines until those effects have stopped recurring.

**Hypotensive reactions** Hypotensive reactions can be disturbing in some patients during the first few days of treatment with bromocriptine, cabergoline, or quinagolide—monitor blood pressure for a few days after starting treatment and following dosage increases; particular care should be exercised when driving or operating machinery.

**Suppression of lactation** Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engagement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred. Quinagolide is not licensed for the suppression of lactation.

**BROMOCRIPTINE**

**Indications** see notes above and under Dose; Parkinson’s disease (section 4.9.1)

**Cautions** see notes above; also specialist evaluation—monitor for pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss in macroadenoma; contraceptive advice if appropriate (oral contraceptives may increase prolactin concentration); **interactions:** Appendix 1 (bromocriptine)

**Contra-indications** see notes above; also hypertension in postpartum women or in puerperium (see also below)

**Postpartum or puerperium** Should not be used postpartum or in puerperum in women with high blood pressure, coronary artery disease, or symptoms (or history) of serious mental disorder; monitor blood pressure carefully (especially during first few days) in postpartum women. Very rarely hypertension, myocardial infarction, seizures or stroke (both sometimes preceded by severe headache or visual disturbances), and mental disorders have been reported in postpartum women given bromocriptine for lactation suppression—caution with antihypertensive therapy and avoid other ergot alkaloids. Discontinue immediately if hypertension, unremitting headache, or signs of CNS toxicity develop

**Hepatic impairment** dose reduction may be necessary

**Pregnancy** see Cautions above

**Breast-feeding** suppresses lactation; avoid breast feeding for about 5 days if lactation prevention fails

**Side-effects** see notes above; also drowsiness (see also Driving, above), nasal congestion; less commonly vomiting, postural hypotension, fatigue, dizziness, dry mouth; also, particularly with high doses, confusion, psychomotor excitation, hallucinations; rarely diarrhoea, gastro-intestinal bleeding, gastric ulcer, abdominal pain, tachycardia, bradycardia, arrhythmia, insomnia, psychosis, visual disturbances, tinnitus; very rarely vasospasm of fingers and toes particularly in patients with Raynaud’s syndrome, and effects like neuroleptic malignant syndrome on withdrawal; urinary incontinence, leucopenia, thrombocytopoenia, hyponatraemia, reversible hearing loss, increased libido, and hypersexuality also reported

**Dose**

- Prevention or suppression of lactation (but see notes above and under Cautions), 2.5 mg on day 1 (prevention) or daily for 2–3 days (suppression); then 2.5 mg twice daily for 14 days
- Hypogonadism, galactorrhoea, infertility, initially 1–1.25 mg at bedtime, increased gradually; usual dose 7.5 mg daily in divided doses, increased if necessary to max. 30 mg daily, usual dose in infertility without hyperprolactinaemia, 2.5 mg twice daily
- Acromegaly, initially 1–1.25 mg at bedtime; increased gradually to 5 mg every 6 hours
- Prolactinoma, initially 1–1.25 mg at bedtime; increased gradually to 5 mg every 6 hours (occasional patients may require up to 30 mg daily)
- CHILD under 15 years, not recommended

**Bromocriptine (Non-proprietary)**

- **Tablets**, bromocriptine (as mesilate) 2.5 mg, net price 30-tab pack = £22.92. Label: 10, 21, counselling, driving, see notes above
- **Parlodel** (Meda)

- **Tablets**, both scored, bromocriptine (as mesilate) 1 mg, net price 100-tab pack = £9.90; 2.5 mg, 30-tab pack = £5.78. Label: 10, 21, counselling, driving; see notes above

- **Capsules**, bromocriptine (as mesilate) 5 mg (blue/white), net price 100-cap pack = £37.57; 10 mg (white), 100-cap pack = £69.50. Label: 10, 21, counselling, driving, see notes above

**CABERGOLINE**

**Indications** see notes above and under Dose

**Cautions** see notes above; also monthly pregnancy tests during the amenorrhoeic period; advise non-hormonal contraception if pregnancy not desired (see also Pregnancy, below); **interactions:** Appendix 1 (cabergoline)

**Contra-indications** see notes above; history of puerperal psychosis; history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see Fibrotic Reactions in notes above); cardiac valvulopathy

**Hepatic impairment** reduce dose in severe hepatic impairment

**Pregnancy** no evidence of harm; exclude pregnancy before starting and discontinue 1 month before intended conception (ovulatory cycles persist for 6 months)—discontinue if pregnancy occurs during treatment (specialist advice needed)

**Breast-feeding** suppresses lactation; avoid breast-feeding if lactation prevention fails

**Side-effects** see notes above; also cardiac valvulopathy, drowsiness (see also Driving, above), dyspepsia, gastritis, epigastric and abdominal pain, angina, syncope, depression, confusion, hallucinations, breast pain; rarely vomiting, palpitation, epistaxis, digital vasospasm, hot flushes, transient hemianopia, muscle weakness; also reported erythromelalgia
Dose

- Prevention of lactation (but see notes above and under Contra-indications), during first day postpartum, 1 mg as a single dose; suppression of established lactation (but see notes above) 250 micrograms every 12 hours for 2 days; CHILD under 16 years, not recommended
- Hyperprolactinaemic disorders, 500 micrograms weekly (as a single dose or as 2 divided doses on separate days) increased at monthly intervals in steps of 500 micrograms until optimal therapeutic response (usually 1 mg weekly, range 0.25–2 mg weekly) with monthly monitoring of serum prolactin levels; reduce initial dose and increase more gradually if patient intolerant; over 1 mg weekly give as divided doses; up to 4.5 mg weekly has been used in hyperprolactinaemic patients; CHILD under 16 years, not recommended
- Parkinson’s disease, section 4.9.1

Cabergoline (Non-proprietary)

Tablet, scored, cabergoline 500 micrograms, net price 8-tab pack = £34.03. Label: 10, 21, counselling, driving, see notes above

Note
Dispense in original container (contains desiccant)

Dostinex® (Pharmacia)

Tablets, scored, cabergoline 500 micrograms. Net price 8-tab pack = £30.04. Label: 10, 21, counselling, driving, see notes above

Note
Dispense in original container (contains desiccant)

QUINAGOLIDE

Indications see notes above and under Dose

Cautions see notes above; history of psychotic illness; advise non-hormonal contraception if pregnancy not desired; interactions: Appendix 1 (quinagolide)

Contra-indications hypersensitivity to quinagolide (but not ergot alkaloids)

Hepatic impairment avoid—no information available

Renal impairment avoid—no information available

Pregnancy discontinue when pregnancy confirmed unless medical reason for continuing (specialist advice needed)

Breast-feeding suppresses lactation

Side-effects nausea, vomiting, anorexia, abdominal pain, constipation or diarrhoea; syncope, hypotension (see also notes above), oedema, flushing; nasal congestion, headache, dizziness, fatigue, insomnia; rarely sudden onset of sleep (see notes above); very rarely psychosis

Dose

- Hyperprolactinaemia, 25 micrograms at bedtime for 3 days; increased at intervals of 3 days in steps of 25 micrograms to usual maintenance dose of 75–150 micrograms daily; for doses higher than 300 micrograms daily increase in steps of 75–150 micrograms at intervals of not less than 4 weeks; CHILD not recommended

Norprolac® (Ferring)

Tablets, quinagolide (as hydrochloride) 75 micrograms (white), net price 30-tab pack = £27.00; starter pack of 3 x 25-microgram tabs (pink) with 3 x 50-microgram tabs (blue) = £4.50. Label: 10, 21, counselling, driving, see notes above

Danazol inhibits pituitary gonadotrophins; it combines androgenic activity with antioestrogenic and antiprogestogenic activity. It is licensed for the treatment of endometriosis and for the relief of severe pain and tenderness in benign fibrocystic breast disease where other measures have proved unsatisfactory. It may also be effective in the long-term management of hereditary angioedema [unlicensed indication].

Cetrorelix and ganirelix are luteinising hormone releasing hormone antagonists, which inhibit the release of gonadotrophins (luteinising hormone and follicle-stimulating hormone). They are used in the treatment of infertility by assisted reproductive techniques.

CETRORELIX

Indications adjunct in the treatment of female infertility (under specialist supervision)

Hepatic impairment avoid in moderate or severe liver impairment

Renal impairment avoid in moderate or severe renal impairment

Pregnancy avoid in confirmed pregnancy

Breast-feeding avoid

Side-effects nausea, headache, injection site reactions; rarely hypersensitivity reactions

Dose

- By subcutaneous injection into the lower abdominal wall, either 250 micrograms in the morning, starting on day 5 or 6 of ovarian stimulation with gonadotrophins (or each evening starting on day 5 of ovarian stimulation); continue throughout administration of gonadotrophin including day of ovulation induction (or evening before ovulation induction) or 3 mg on day 7 of ovarian stimulation with gonadotrophins; if ovulation induction not possible on day 5 after 3-mg dose, additional 250 micrograms once daily until day of ovulation induction

Cetrotide® (Merck Serono)

Injection, powder for reconstitution, cetrorelix (as acetate), net price 250-micrograms vial = £22.61; 3-mg vial = £158.26 (both with solvent)

DANAZOL

Indications see notes above and under Dose

Cautions cardiac impairment (avoid if severe), elderly, polycythaeemia, epilepsy, diabetes mellitus, hypertension, migraine, lipoprotein disorder; history of thrombosis or thromboembolic disease; withdrawal if virilisation (may be irreversible on continued use); non-hormonal contraceptive methods should be used, if appropriate; interactions: Appendix 1 (danazol)

Contra-indications ensure that patients with amenorrhoea are not pregnant; thromboembolic disease; undiagnosed genital bleeding; androgen-dependent tumours; acute porphyria (section 9.8.2)

Hepatic impairment caution in hepatic impairment (avoid if severe)

Renal impairment caution in renal impairment (avoid if severe)
Pregnancy avoid; has weak androgenic effects and virilisation of female fetus reported

Breast-feeding no data available but avoid because of possible androgenic effects in infant

Side-effects nausea, dizziness, skin reactions including rashes, photosensitivity and exfoliative dermatitis, fever, backache, nervousness, mood changes, anxiety, changes in libido, vertigo, fatigue, epigastric and pleuritic pain, headache, weight gain; menstrual disturbances, vaginal dryness and irritation, flushing and reduction in breast size; musculo-skeletal spasm, joint pain and swelling, hair loss; androgenic effects including acne, oily skin, oedema, hirsutism, voice changes and rarely clitoral hypertrophy (see also Cautions); temporary alteration in lipoproteins and other metabolic changes, insulin resistance; thrombotic events; leucopenia, thrombocytopenia, eosinophilia, reversible erythrocytosis or polycythaemia reported; headache and visual disturbances may indicate benign intracranial hypertension; rarely cholestatic jaundice, pancreatitis, peliosis hepatitis and benign hepatic adenomata

Dose Note. In women of child-bearing potential, treatment should start during menstruation, preferably on day 1. Doses of 300 mg daily in divided doses usually for 3–6 months

Hereditary angioedema [unlicensed indication], between 300 mg daily in divided doses, adjusted to achieve amenorrhoea, usually for 3–6 months

In women of child-bearing potential, treatment should be given during menstruation or shortly afterwards. Contra-indicated for use longer than 6 months in the treatment of endometriosis (do not repeat) and when there is unexplained vaginal bleeding.

Gonadorelin analogues Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

Gonadorelin analogues are used in the treatment of endometriosis, precocious puberty, infertiltiy, anaemia due to uterine fibroids (together with iron supplementation), breast cancer (section 8.3.4.1), prostate cancer (section 8.3.4.2) and before intra-uterine surgery. Use of leuprorelin and triptorelin for 3 to 4 months before surgery reduces the uterine volume, fibroid size and associated bleeding. For women undergoing hysterectomy or myomectomy, a vaginal procedure is made more feasible following the use of a gonadorelin analogue.

Cautions Non-hormonal, barrier methods of contraception should be used during entire treatment period with gonadorelin analogues; also use with caution in patients with metabolic bone disease because decrease in bone mineral density can occur.

Contra-indications Gonadorelin analogues are contra-indicated for use longer than 6 months in the treatment of endometriosis (do not repeat) and when there is unexplained vaginal bleeding.

Pregnancy The use of gonadorelin analogues in pregnancy is contra-indicated. Pregnancy should be excluded before treatment; the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

Breast-feeding Gonadorelin analogues are contra-indicated in breast-feeding.

Side-effects Side-effects of the gonadorelin analogues related to the inhibition of oestrogen production include menopausal-like symptoms (e.g. hot flushes, increased sweating, vaginal dryness, dyspareunia and loss of libido) and a decrease in trabecular bone density; these effects can be reduced by hormone replacement (e.g. with an oestrogen and a progestogen or with tibolone). Side-effects of gonadorelin analogues also include headache (rarely migraine) and hypersensitivity reactions including urticaria, pruritus, rash, asthma and anaphylaxis; when treating uterine fibroids, bleeding associated with fibroid degeneration can occur; spray formulations can cause irritation of the nasal mucosa including nose bleeds; local reactions at injection site can occur; other side-effects also reported with some gonadorelin analogues include palpitation, hypertension, ovarian cysts (may require withdrawal), changes in breast size, musculoskeletal pain or weakness, visual disturbances, paraesthesia, changes in scalp and body hair, oedema of the face and extremities, weight changes, and mood changes including depression.

Danazol (Non-proprietary) [704]

Capsules, danazol 100 mg, net price 28-cap pack = £18.40, 60-cap pack = £17.04; 200 mg, 56-cap pack = £66.20

Danof® (Sanofi-Aventis) [704]

Capsules, danazol 100 mg (grey/white), net price 60-cap pack = £16.38; 200 mg (pink/white), 60-cap pack = £32.43

GANIRELIX

Indications adjunct in the treatment of female infertility (under specialist supervision)

Hepatic impairment avoid in moderate or severe hepatic impairment

Renal impairment avoid in moderate to severe renal impairment

Pregnancy avoid in confirmed pregnancy—toxicity in animal studies

Breast-feeding avoid—no information available

Side-effects nausea, headache, malaise, injection-site reactions; very rarely hypersensitivity reactions including rash, facial oedema, and dyspnoea also reported

Dose By subcutaneous injection preferably into the upper leg (rotate injection sites to prevent lipoatrophy). 250 micrograms in the morning (or each afternoon) starting on day 5 or day 6 of ovarian stimulation with gonadotrophins; continue throughout administration of gonadotrophins including day of ovulation induction (if administering in afternoon, give last dose in afternoon before ovulation induction)

Orgalan® (Organon) [704]

Injection, ganirelix, 500 micrograms/mL, net price 0.5-mL prefilled syringe = £21.48

Gonadorelin analogues

Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

Gonadorelin analogues are used in the treatment of endometriosis, precocious puberty, infertility, anaemia due to uterine fibroids (together with iron supplementation), breast cancer (section 8.3.4.1), prostate cancer (section 8.3.4.2) and before intra-uterine surgery. Use of leuprorelin and triptorelin for 3 to 4 months before surgery reduces the uterine volume, fibroid size and associated bleeding. For women undergoing hysterectomy or myomectomy, a vaginal procedure is made more feasible following the use of a gonadorelin analogue.

Cautions Non-hormonal, barrier methods of contraception should be used during entire treatment period with gonadorelin analogues; also use with caution in patients with metabolic bone disease because decrease in bone mineral density can occur.

Contra-indications Gonadorelin analogues are contra-indicated for use longer than 6 months in the treatment of endometriosis (do not repeat) and when there is unexplained vaginal bleeding.

Pregnancy The use of gonadorelin analogues in pregnancy is contra-indicated. Pregnancy should be excluded before treatment; the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

Breast-feeding Gonadorelin analogues are contra-indicated in breast-feeding.

Side-effects Side-effects of the gonadorelin analogues related to the inhibition of oestrogen production include menopausal-like symptoms (e.g. hot flushes, increased sweating, vaginal dryness, dyspareunia and loss of libido) and a decrease in trabecular bone density; these effects can be reduced by hormone replacement (e.g. with an oestrogen and a progestogen or with tibolone). Side-effects of gonadorelin analogues also include headache (rarely migraine) and hypersensitivity reactions including urticaria, pruritus, rash, asthma and anaphylaxis; when treating uterine fibroids, bleeding associated with fibroid degeneration can occur; spray formulations can cause irritation of the nasal mucosa including nose bleeds; local reactions at injection site can occur; other side-effects also reported with some gonadorelin analogues include palpitation, hypertension, ovarian cysts (may require withdrawal), changes in breast size, musculoskeletal pain or weakness, visual disturbances, paraesthesia, changes in scalp and body hair, oedema of the face and extremities, weight changes, and mood changes including depression.
BUSERELIN

Indications see under Dose; prostate cancer (section 8.3.4.2).

Cautions see notes above; polycystic ovarian disease, depression, hypertension, diabetes.

Contra-indications see notes above; hormone-dependent tumours.

Pregnancy see notes above.

Breast-feeding see notes above.

Side-effects see notes above; initially withdrawal bleeding and subsequently breakthrough bleeding, leucorrhoea; nausea, vomiting, constipation, diarrhoea; anxiety, memory and concentration disturbances, sleep disturbances, nervousness, dizziness, drowsiness; breast tenderness, lactation; abdominal pain; fatigue; increased thirst, changes in appetite; acne, dry skin, splitting nails, dry eyes; altered blood lipids, leucopenia, thrombocytopenia; hearing disturbances; reduced glucose tolerance.

Dose
- Endometriosis, intranasally, 300 micrograms (one 150-microgram spray in each nostril) 3 times daily (starting on days 1 or 2 of menstruation); max. duration of treatment 6 months (do not repeat).
- Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (under specialist supervision), by subcutaneous injection, 200–500 micrograms daily given as a single injection (occasionally up to 500 micrograms twice daily may be needed) starting in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually about 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choric gonadotrophin at appropriate stage of follicular development).

Preparation Section 8.3.4.2.

LEUPRORELIN ACETATE

Indications see under Dose; prostate cancer (section 8.3.4.2).

Cautions see notes above; monitor liver function; family history of osteoporosis; chronic use of other drugs which reduce bone density including alcohol and tobacco; diabetes.

Contra-indications see notes above.

Pregnancy teratogenic in animal studies; see also notes above.

Breast-feeding see notes above.

Side-effects see notes above; breast tenderness; nausea, vomiting, diarrhoea, anorexia; fever, chills; sleep disturbances, dizziness, fatigue, leucopenia, thrombocytopenia, altered blood lipids, pulmonary embolism; spinal fracture, paralysis, hypotension and worsening of depression also reported.

Dose
- By subcutaneous or intramuscular injection (as Prostap® SR)
  - Endometriosis, 3.75 mg as a single dose in first 5 days of menstrual cycle then every month for max. 6 months (course not to be repeated).
  - Endometrial thinning before intra-uterine surgery, 3.75 mg as a single dose (given between days 3 and 5 of menstrual cycle) 5–6 weeks before surgery.
  - Reduction of size of uterine fibroids and of associated bleeding before surgery, 3.75 mg as a single dose every month for 3–4 months (max. 6 months).
- By intramuscular injection (as Prostap®).
  - Endometriosis, 11.25 mg as a single dose in first 5 days of menstrual cycle then every 3 months for max. 6 months (course not to be repeated).

Preparations Section 8.3.4.2.
6.7.3 Metrapone and trilostane

**NAFARELIN**

**Indications** see under Dose

**Cautions** see notes above

**Contra-indications** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; acne

**Dose**

- Endometriosis, women over 18 years, 200 micrograms twice daily as one spray in each nostril in the morning and one spray in the other nostril in the evening (starting on days 2–4 of menstruation), max. duration of treatment 6 months (do not repeat)

- Pituitary desensitisation before induction of ovulation for *in vitro* fertilisation (under specialist supervision), 400 micrograms (one spray in each nostril) twice daily starting in early follicular phase (day 2) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually within 4 weeks) then maintained (usually for 8–12 days) during gonadotrophin administration (stopping gonadotrophin and nafarelin on administration of chorionic gonadotrophin at follicular maturity); discontinue if down-regulation not achieved within 12 weeks

**Counselling** Avoid use of nasal decongestants before and for at least 30 minutes after treatment; repeat dose if sneezing occurs during or immediately after administration

**Synarel®** (Pharmacia) (PN)

Nasal spray, nafarelin (as acetate) 200 micrograms/ metered spray. Net price 30-dose unit = £30.41; 60-dose unit = £52.43. Label: 10, patient information leaflet, counselling, see above

**TRIPTORELIN**

**Indications** endometriosis, precocious puberty, reduction in size of uterine fibroids; advanced prostate cancer (section 8.3.4.2)

**Cautions** see notes above

**Contra-indications** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also gastro-intestinal disturbances; in precocious puberty, withdrawal bleeding may occur in the first month of treatment; asthenia

**Dose**

- See under preparations below

**Decapetyn® SR** (Ipsen) (PN)

Injection, (powder for suspension), m/r, triptorelin (as acetate), net price 3-mg vial (with diluent) = £69.00

**Dose** by intramuscular injection, endometriosis and reduction in size of uterine fibroids, 3 mg every 4 weeks starting during first 5 days of menstrual cycle for uterine fibroids continue treatment for at least 3 months; max. duration of treatment 6 months (not to be repeated)

**Note** Each vial includes an overage to allow accurate administration of 3-mg dose

**Injection**, (powder for suspension), m/r, triptorelin (as acetate), net price 11.25-mg vial (with diluent) = £207.00

**Dose** by intramuscular injection, endometriosis, 11.25 mg every 3 months starting during first 5 days of menstrual cycle; max. duration of treatment 6 months (not to be repeated)

**Gonapeptin Depot®** (Ferring) (PN)

**Injection**, (powder for suspension), triptorelin (as acetate), net price 3.75-mg prefilled syringe (with prefilled syringe of vehicle) = £81.69

**Dose** by subcutaneous or deep intramuscular injection, endometriosis and reduction in size of uterine fibroids, 3.75 mg every 4 weeks starting during first 5 days of menstrual cycle; max. duration of treatment 6 months (not to be repeated)

Precocious puberty, body-weight over 30 kg, initially 3.75 mg every 2 weeks for 3 doses; then every 3–4 weeks; body-weight 20–30 kg, initially 2.5 mg every 2 weeks for 3 doses; then every 3–4 weeks; body-weight under 20 kg, initially 1.875 mg every 2 weeks for 3 doses; then every 3–4 weeks; discontinue when bone maturation consistent with age over 12 years in girls or over 13 years in boys

**Breast pain (mastalgia)**

Once any serious underlying cause for breast pain has been ruled out, most women will respond to reassurance and reduction in dietary fat; withdrawal of an oral contraceptive or of hormone replacement therapy may help to resolve the pain.

Mild, non-cyclical breast pain is treated with simple analgesics (section 4.7.1); moderate to severe pain, cyclical pain or symptoms that persist for longer than 6 months may require specific drug treatment.

**Danazol** (section 6.7.2) is licensed for the relief of severe pain and tenderness in benign fibrocystic breast disease which has not responded to other treatment.

**Tamoxifen** (section 8.3.4.1) may be a useful adjunct in the treatment of mastalgia [unlicensed indication] especially when symptoms can definitely be related to cyclic oestrogen production; it may be given on the days of the cycle when symptoms are predicted.

Treatment for breast pain should be reviewed after 6 months and continued if necessary. Symptoms recur in about 50% of women within 2 years of withdrawal of therapy but may be less severe.

**6.7.3 Metrapone and trilostane**

**Metrapone** is a competitive inhibitor of 11β-hydroxylase in the adrenal cortex; the resulting inhibition of cortisol (and to a lesser extent aldosterone) production leads to an increase in ACTH production which, in turn, leads to increased synthesis and release of cortisol precursors. It may be used as a test of anterior pituitary function.

Although most types of Cushing's syndrome are treated surgically, that which occasionally accompanies carcinoma of the bronchus is not usually amenable to surgery. Metrapone has been found helpful in controlling the symptoms of the disease; it is also used in other forms of Cushing's syndrome to prepare the patient for surgery. The dosages used are either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed.

**Trilostane** reversibly inhibits the enzyme system essential for the production of mineralocorticoids and gluco-
corticoids in the adrenal cortex, and may be useful in Cushing’s syndrome and primary hyperaldosteronism. Trilostane appears to be less effective than metyrapone for Cushing’s syndrome (where it is tailored to corticosteroid production). It also has a minor role in postmenopausal breast cancer that has relapsed following initial oestrogen antagonist therapy (corticosteroid replacement therapy is also required). Ketoconazole (section 5.2.2) is also used by specialists for the management of Cushing’s syndrome [unlicensed indication].

### METRAPONE

**Indications** see notes above and under Dose (specialist supervision in hospital)

**Cautions** gross hypopituitarism (risk of precipitating acute adrenal failure); hypertension on long-term administration; hypothyroidism (delayed response); many drugs interfere with diagnostic estimation of steroids; avoid in acute porphyria (section 9.8.2) Driving Drowsiness may affect the performance of skilled tasks (e.g. driving)

**Contra-indications** adrenocortical insufficiency (see Cautions)

**Hepatic impairment** use with caution in hepatic impairment (delayed response)

**Pregnancy** avoid (may impair biosynthesis of fetal-placental steroids)

**Breast-feeding** avoid—no information available

**Side-effects** occasional nausea, vomiting, dizziness, headache, hypotension, sedation; rarely abdominal pain, allergic skin reactions, hypoadrenalism, hirsutism

**Dose**

- Differential diagnosis of ACTH-dependent Cushing’s syndrome, 750 mg every 4 hours for 6 doses; CHILD 15 mg/kg (minimum 250 mg) every 4 hours for 6 doses
- Management of Cushing’s syndrome, range 0.25–6 g daily; tailored to cortisol production; see notes above
- Resistant oedema due to increased aldosterone secretion in cirrhosis, nephrotic syndrome, and congestive heart failure (with glucocorticoid replacement therapy) 3 g daily in divided doses

**Metopirone** (Alliance) SH

Capsules, ivory, metyrapone 250 mg, net price 100-tab pack = £38.88. Label: 21, counselling, driving

### TRILOSTANE

**Indications** see notes above and under Dose (specialist supervision)

**Cautions** breast cancer (concurrent corticosteroid replacement therapy needed, see under Dose); adrenal cortical hyperfunction (tailored to cortisol and electrolytes, concurrent corticosteroid therapy may be needed, see under Dose); **interactions**: Appendix 1 (trilostane)

**Contra-indications** children

**Hepatic impairment** use with caution

**Renal impairment** use with caution

**Pregnancy** avoid; interferes with placental sex hormone production; use non-hormonal method of contraception

**Breast-feeding** avoid

---

**Side-effects** flushing, tingling and swelling of mouth, rhinorrhoea, nausea, vomiting, diarrhoea, and rashes reported; rarely granulocytopenia

**Dose**

- Adrenal cortical hyperfunction, 240 mg daily in divided doses for at least 3 days then tailored according to response with regular monitoring of plasma electrolytes and circulating corticosteroids (both mineralocorticoid and glucocorticoid replacement therapy may be needed); usual dose: 120–480 mg daily (may be increased to 960 mg)
- Postmenopausal breast cancer (with glucocorticoid replacement therapy) following relapse to initial oestrogen receptor antagonist therapy, initially 240 mg daily increased every 3 days in steps of 240 mg to a maintenance dose of 960 mg daily (720 mg daily if not tolerated)

**Modrenal** (Bioenvision) NH

Capsules, trilostane 60 mg (pink/black), net price 100-cap pack = £49.50; 120 mg (pink/yellow), 100-cap pack = £98.50. Label: 21

---

### 6.7.4 Somatomedins

Somatomedins are a group of polypeptide hormones structurally related to insulin and commonly known as insulin-like growth factors (IGFs). **Mecasermin**, a human insulin-like growth factor-I (rhIGF-I), is the principal mediator of the somatotropic effects of human growth hormone and is used to treat growth failure in children and adolescents with severe primary insulin-like growth factor-I deficiency.

#### MECASERMIN

(Recombinant human insulin-like growth factor-I; rhIGF-I)

**Indications** see notes above

**Cautions** correct hypothyroidism before initiating treatment; diabetes mellitus (adjustment of antidiabetic therapy may be necessary), monitor ECG before and on termination of treatment (and during treatment if ECG abnormal), papilloedema (see under Side-effects), monitor for disorders of the epiphysis of the hip (monitor for limping), monitor for signs of tonsillar hypertrophy (snoring, sleep apnoea, and chronic middle ear effusions)

**Contra-indications** evidence of tumour activity (discontinue treatment)

**Pregnancy** avoid unless essential; contraception advised in women of child-bearing potential

**Breast-feeding** avoid

**Side-effects** headache, funduscopy for papilloedema recommended if severe or recurrent headache, visual problems, nausea and vomiting occur—if papilloedema confirmed consider benign intracranial hypertension (rare cases reported); cardiomegaly, ventricular hypertrophy, tachycardia; convulsions, sleep apnoea, night terrors, dizziness, nervousness; tonsillar hypertrophy (see Cautions above); hypoglycaemia (especially in first month, and in younger children), hyperglycaemia, gynaecomastia; arthralgia, myalgia; visual disturbance, impaired hearing; antibody formation; injection-site reactions (rotate site)

---

**BNF 61 6.7.4 Somatomedins 483**
Dose

By subcutaneous injection, ADOLESCENT and CHILD over 2 years, initially 40 micrograms/kg twice daily for 1 week, if tolerated increase dose in steps of 40 micrograms/kg to max. 120 micrograms/kg twice daily; discontinue if no response within 1 year.

Counselling: Dose should be administered just before or after food; do not increase dose if a dose is missed.

Note: Reduce dose if hypoglycaemia occurs despite adequate food intake; withhold injection if patient unable to eat.

Increlex® (Ipsen) ▼
Injection, mecasermin 10 mg/mL, net price 4-mL vial = £605.00. Counselling, administration
Excipients include benzyl alcohol (avoid in neonates; see Excipients, p. 2).
7 Obstetrics, gynaecology, and urinary-tract disorders

7.1 Drugs used in obstetrics

7.1.1 Prostaglandins and oxytocics

7.1.1.1 Drugs affecting the ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal and vulval conditions

7.2.1 Preparations for vaginal and vulval changes

7.2.2 Vaginal and vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.3 Spermicidal contraceptives

7.3.4 Contraceptive devices

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary frequency, enuresis, and incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations and urological surgery

7.4.5 Drugs for erectile dysfunction

For hormonal therapy of gynaecological disorders see section 6.4.1 (including HRT), section 6.5.1 and section 6.7.2.

7.1 Drugs used in obstetrics

7.1.1 Prostaglandins and oxytocics

Prostaglandins and oxytocics are used to induce abortion or induce or augment labour and to minimise blood loss from the placental site. They include oxytocin, carbetocin, ergometrine, and the prostaglandins. All induce uterine contractions with varying degrees of pain according to the strength of contractions induced.

Induction of abortion Gemeprost, a prostaglandin administered vaginally as pessaries, is suitable for the medical induction of late therapeutic abortion; gemeprost is also used to ripen the cervix before surgical abortion, particularly in primigravidas. The prostaglandin misoprostol (section 7.1.2) is given by mouth or by vaginal administration to induce medical abortion [unlicensed indication]; intravaginal use ripens the cervix before surgical abortion [unlicensed indication]. Extravesical dinoprostone is rarely used nowadays.

Pre-treatment with mifepristone (section 7.1.2) can facilitate the process of medical abortion. It sensitises the uterus to subsequent administration of a prostaglandin and, therefore, abortion occurs in a shorter time and with a lower dose of prostaglandin.

Induction and augmentation of labour Dinoprostone is available as vaginal tablets, pessaries and
vaginal gels for the induction of labour. The intravenous solution is rarely used; it is associated with more side-effects.

**Oxytocin** (Syntocinon®) is administered by slow intravenous infusion, using an infusion pump, to induce or augment labour, usually in conjunction with amniotomy. Uterine activity must be monitored carefully and hypertension avoided. Large doses of oxytocin may result in excessive fluid retention.

**Misoprostol** is given orally or vaginally for the induction of labour [unlicensed indication].

**Prevention and treatment of haemorrhage**

Bleeding due to incomplete abortion can be controlled with ergometrine and oxytocin (Syntometrine®) given intramuscularly. The dose is adjusted according to the patient's condition and blood loss. This is commonly used before surgical evacuation of the uterus, particularly when surgery is delayed. Oxytocin and ergometrine combined are more effective in early pregnancy than either drug alone.

Active management of the third stage of labour reduces the risk of postpartum haemorrhage; oxytocin is given by intramuscular injection [unlicensed] on delivery of the anterior shoulder or, at the latest, immediately after the baby is delivered. Alternatively, ergometrine 500 micrograms with oxytocin 5 units (Syntometrine® 1 mL) can be given by intramuscular injection in the absence of hypertension; oxytocin alone causes less nausea, vomiting, and hypertension than when given with ergometrine.

In excessive uterine bleeding, any placental products remaining in the uterus should be removed. Oxytocic drugs are used to treat postpartum haemorrhage caused by uterine atony; treatment options are as follows:

- oxytocin 5 units by slow intravenous injection (dose may be repeated), followed in severe cases by intravenous infusion of oxytocin 40 units in 500 mL infusion fluid (prolonged administration—see Appendix 6) at a rate that controls uterine atony or
- ergometrine 250–500 micrograms by intramuscular injection or
- ergometrine 250–500 micrograms by slow intravenous injection (use with caution—risk of hypotension) or
- ergometrine 500 micrograms with oxytocin 5 units (Syntometrine® 1 mL) by intramuscular injection

**Carboprost** has an important role in severe postpartum haemorrhage unresponsive to ergometrine and oxytocin.

**Misoprostol** [unlicensed] can be used in postpartum haemorrhage when oxytocin, ergometrine, and carboprost are not available or are inappropriate.

---

**CARBETOCIN**

**Indications** prevention of uterine atony after caesarean section

**Cautions** hyponatraemia; cardiovascular disease (avoid if severe); migraine; asthma

**Contra-indications** pre-eclampsia and eclampsia; epilepsy

**Hepatic impairment** manufacturer advises avoid

**Renal impairment** manufacturer advises avoid

**Side-effects** nausea, vomiting, abdominal pain, metallic taste; flushing, hypotension, chest pain; dyspnoea; headache, tremor, dizziness; anaemia; back pain; pruritus; feeling of warmth, chills; tachycardia and sweating also reported

**Dose**

- By slow intravenous injection over 1 minute, a single dose of 100 micrograms, as soon as possible after delivery, preferably before removal of placenta

**Pabalin®** (Ferring) £18.20 (hosp. only)

**Injection** carboprost 100 micrograms/mL, net price 1-mL amp = £17.64

---

**CARBOPROST**

**Indications** postpartum haemorrhage due to uterine atony in patients unresponsive to ergometine and oxytocin

**Cautions** history of glaucoma or raised intra-ocular pressure, asthma, hypertension, hypotension, anaemia, jaundice, diabetes, epilepsy; uterine scars; excessive dosage may cause uterine rupture; **interactions**: Appendix 1 (prostaglandins)

**Contra-indications** untreated pelvic infection; cardiac or pulmonary disease

**Hepatic impairment** manufacturer advises avoid

**Renal impairment** manufacturer advises avoid

**Side-effects** nausea, vomiting and diarrhoea, hypertension and flushing, bronchospasm; less frequent effects include raised blood pressure, dyspnoea, and pulmonary oedema; chills, headache, diaphoresis, dizziness; cardiovascular collapse also reported; erythema and pain at injection site reported

**Dose**

- By deep intramuscular injection, 250 micrograms repeated if necessary at intervals of not less than 15 minutes; total dose should not exceed 2 mg (8 doses)

**Hemabate®** (Pharmacia) £18.20 (hosp. only)

**Injection** carbetocin as trometamol salt (tromethamine salt) 250 micrograms/mL, net price 1-mL amp = £18.20 (hosp. only)

---

**DINOPROSTONE**

**Indications** see notes above and under preparations below

**Cautions** history of asthma, glaucoma and raised intra-ocular pressure; hypertension; history of epilepsy; uterine scarring; monitor uterine activity and fetal status (particular care if history of uterine hypertony); uterine rupture; see also notes above; monitor for disseminated intravascular coagulation after partrumion; risk factors for disseminated intravascular coagulation; effect of oxytocin enhanced (care needed in monitoring uterine activity when used in sequence); **interactions**: Appendix 1 (prostaglandins)

**Contra-indications** active cardiac, or pulmonary disease; placenta praevia or unexplained vaginal bleeding during pregnancy, ruptured membranes, major cephalopelvic disproportion or fetal malpresentation, history of caesarean section or major uterine surgery,
untreated pelvic infection, fetal distress, grand multiparas and multiple pregnancy, history of difficult or traumatic delivery; avoid extra-amniotic route in cervicitis or vaginitis

**Hepatic impairment** manufacturers advise avoid

**Renal impairment** manufacturers advise avoid

**Side-effects** nausea, vomiting, diarrhoea; other side-effects include uterine hypertonus, severe uterine contractions, pulmonary or amniotic fluid embolism, abruptio placenta, fetal distress, maternal hypertension, bronchospasm, rapid cervical dilation, fever, backache; uterine hypercontractility with or without fetal bradycardia, low Apgar scores; cardiac arrest, uterine rupture, stillbirth or neonatal death also reported; vaginal symptoms (warmth, irritation, pain); after intravenous administration—flushing, shivering, headache, dizziness, temporary pyrexia and raised white blood cell count; disseminated intravascular coagulation reported; also local tissue reaction and erythema after intrauterine administration and possibility of infection after extra-amniotic administration

**Dose**

- See under preparations, below

**Important** Do not confuse dose of Prostin E2® vaginal gel with that of Prostin E2® vaginal tablets—not bioequivalent.

**Propess** (Ferring)®

**Pessaries** (within retrieval device), releasing dinoprostone approx. 10 mg over 24 hours; net price 1-pessary pack = £30.00

**Dose** by vagina, cervical ripening and induction of labour at term, 1 pessary (in retrieval device) inserted high into posterior fornix and removed when cervical ripening adequate; if oxytocin necessary, remove 30 minutes before oxytocin infusion; remove if cervical ripening inadequate after 24 hours (dose not to be repeated)

Prostin E2® (Pharmacia)®

**Intravenous solution** for dilution and use as an infusion, dinoprostone 1 mg/mL, net price 0.75-mL amp = £8.52; 10 mg/mL, 0.5-mL amp = £18.40 (both hosp. only; rarely used, consult product literature for dose and indications)

**Extra-amniotic solution** dinoprostone 10 mg/mL, net price 0.5-mL amp (with diluent) = £18.40 (hosp. only; less commonly used nowadays, consult product literature for dose and indications)

**Vaginal gel**, dinoprostone 400 micrograms/mL, net price 2.5 mL (1 mg) = £13.28; 800 micrograms/mL, 2.5 mL (2 mg) = £13.28

**Dose** by vagina, induction of labour, inserted high into posterior fornix (avoid administration into cervical canal), 1 mg (unfavourable primigravida 2 mg), followed after 6 hours by 1–2 mg if required; max. [gel] 3 mg (unfavourable primigravida 4 mg)

**Vaginal tablets**, dinoprostone 3 mg, net price 8-vaginal tab pack = £106.23

**Dose** by vagina, induction of labour, inserted high into posterior fornix, 3 mg, followed after 6–8 hours by 3 mg if labour is not established; max. 6 mg [vaginal tablets]

**Note** Prostin E2 Vaginal Gel and Vaginal Tablets are not bioequivalent

**GEMEPROST**

**Indications** see under Dose

**Cautions** obstructive airways disease, cardiovascular insufficiency, raised intra-ocular pressure, cervicitis or vaginitis; **interactions**: Appendix 1 (prostaglandins)

**Important** For warnings relating to use of gemeprost in a patient undergoing induction of abortion with mifepristone, see under Mifepristone and Note below

**Contra-indications** unexplained vaginal bleeding, uterine scarring, placenta praevia

**Renal impairment** manufacturer advises avoid

**Side-effects** vaginal bleeding and uterine pain; nausea, vomiting, or diarrhoea; headache, muscle weakness, dizziness, flushing, chills, backache, dyspnoea, chest pain, palpitation and mild pyrexia; uterine rupture reported (most commonly in multiparas or if history of uterine surgery or if given with intravenous oxytocics); also reported severe hypertension, coronary artery spasm and myocardial infarction

**Dose**

- **By vagina**, cervical ripening prior to first trimester surgical abortion, 1 mg inserted into posterior fornix 3 hours before surgery
- **Second trimester abortion**, 1 mg inserted into posterior fornix every 3 hours for max. of 5 administrations; second course may begin 24 hours after start of treatment (if treatment fails pregnancy should be terminated by another method)
- **Second trimester intra-uterine death**, 1 mg inserted into posterior fornix every 3 hours for max. of 5 administrations only; monitor for coagulopathy

**Note** If used in combination with mifepristone, carefully monitor blood pressure and pulse for 3 hours

**Gemeprost** (Sanofi-Aventis)®

**Pessaries**, gemeprost 1 mg, net price 5-pessary pack = £215.00

**7.1.1 Prostaglandins and oxytocics**

**Hepatic impairment** manufacturer advises caution in mild or moderate impairment and avoid in severe impairment

**Renal impairment** manufacturer advises caution in mild or moderate impairment and avoid in severe impairment

**Side-effects** nausea, vomiting, abdominal pain; chest pain, arrhythmias (including bradycardia), palpitation, hypertension, vasocostriction; dyspnoea, pulmonary oedema; headache, dizziness; tinnitus; rash; very rarely myocardial infarction

**Dose**

- See notes above

**Ergometrine** (Non-proprietary)®

**Injection**, ergometrine maleate 500 micrograms/mL, net price 1-mL amp = 60p

**With oxytocin**

**Syntometrine®** (Alliance)®

**Injection**, ergometrine maleate 500 micrograms, oxytocin 5 units/mL, net price 1-mL amp = £1.35

**Dose** by intramuscular injection, 1 mL by intravenous injection, no longer recommended
7.1.2 Mifepristone

**OXYTOCIN**

**Indications** see under Dose and notes above

**Cautions** induction or enhancement of labour—pressure of borderline cephalopelvic disproportion (avoid if significant); secondary uterine inertia; moderate pregnancy-induced hypertension or cardiac disease, women over 35 years or with history of lower-uterine segment caesarean section (see also under Contra-indications below); risk factors for disseminated intravascular coagulation; monitor for disseminated intravascular coagulation after parturition; avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication—see also Appendix 6); effects enhanced by concomitant prostaglandins (very careful monitoring of uterine activity); caudal block anaesthesia (may enhance hypertensive effects of sympathomimetic vasopressors); see also interactions: Appendix 1 (oxytocin)

**Contra-indications** hypertonic uterine contractions, fetal distress; any condition where spontaneous labour or vaginal delivery inadvisable; avoid prolonged administration in oxytocin-resistant uterine inertia, severe pre-eclamptic toxemia, or severe cardiovascular disease

**Side-effects** nausea; vomiting; arhythmia; headache; rarely disseminated intravascular coagulation, rash, and anaphylactoid reactions (with dyspnoea, hypotension, or shock); uterine spasm (may occur at low doses), uterine hyperstimulation (usually with excessiv doses—may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture); water intoxication and hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid (see also under Dose below); placental abruption and amniotic fluid embolism also reported on overdose

**Dose**

- Induction of labour for medical reasons or stimulation of labour in hypotonic uterine inertia, by intravenous infusion (not to be started for at least 6 hours after administration of vaginal prostaglandin), initially 0.001–0.004 units/minute, increased at intervals of at least 10 minutes until a maximum of 3–4 contractions occur every 10 minutes (0.01 units/minute is often adequate) up to max. 0.02 units/minute; if regular contractions not established after total of 5 units stop induction attempt (may be repeated next day starting again at 0.001–0.004 units/minute)

  **Important** Careful monitoring of fetal heart rate and uterine motility essential for dose titration (avoid intravenous injection during labour), discontinue immediately in uterine hyperactivity or fetal distress

- Caesarean section, by slow intravenous injection immediately after delivery, 5 units
- Prevention of postpartum haemorrhage, after delivery of placenta, by slow intravenous injection, 5 units (if infusion used for induction or enhancement of labour, increase rate during third stage and for next few hours)

  **Important** Avoid rapid intravenous injection (may transiently reduce blood pressure)

  **Note** Can be given in a dose of 10 units by intramuscular injection (unlicensed route) instead of oxytocin with ergometrine (Syntometrine®), see notes above

- Treatment of postpartum haemorrhage, by slow intravenous injection, 5 units (dose may be repeated), followed in severe cases by intravenous infusion of 40 units in 500 mL infusion fluid at a rate sufficient to control uterine atony

  **Important** Avoid rapid intravenous injection (may transiently reduce blood pressure); prolonged administration, see warning below

- Incomplete, inevitable, or missed abortion, by slow intravenous injection, 5 units followed if necessary by intravenous infusion, 0.02–0.04 units/minute or faster

  **Important** Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed abortion or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing infusate (i.e., not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.

  **Note** Oxytocin doses in the BNF may differ from those in the product literature

**Syntocinon® (Alliance)**

- **Injection**, oxytocin, net price 5 units/mL, 1-mL amp = 76p; 10 units/mL, 1-mL amp = 86p

  **With ergometrine**

  See Syntometrine®, p. 487

**7.1.1 Drugs affecting the ductus arteriosus**

This section is not included in the BNF. For the management of ductus arteriosus, see BNF for Children section 2.14.

**7.1.2 Mifepristone**

Mifepristone, an antiprogestogenic steroid, sensitises the myometrium to prostaglandin-induced contractions and ripens the cervix. For termination of pregnancy, a single dose of mifepristone is followed by administration of a prostaglandin (gemeprost or misoprostol [unlicensed]). Guidelines of the Royal College of Obstetricians and Gynaecologists (September 2004) include the following [unlicensed] regimen for inducing medical abortion:

- For gestation up to 9 weeks, mifepristone 200 mg by mouth followed 1–3 days later by misoprostol 800 micrograms vaginally in women at more than 7 weeks gestation (49–63 days), if the abortion has not occurred 4 hours after misoprostol, a further dose of misoprostol 400 micrograms may be given vaginally or by mouth

- For gestation between 9 and 13 weeks, mifepristone 200 mg by mouth followed 36–48 hours later by misoprostol 800 micrograms vaginally followed if necessary by a maximum of 4 further doses at 3-hourly intervals of misoprostol 400 micrograms vaginally or by mouth

- For gestation between 13 and 24 weeks, mifepristone 200 mg by mouth followed 36–48 hours later by misoprostol 800 micrograms vaginally then a maximum of 4 further doses at 3-hourly intervals of misoprostol 400 micrograms by mouth

**MIFEPRISTONE**

**Indications** see under dose

**Cautions** asthma (avoid if severe and uncontrolled); haemorrhagic disorders and anticoagulant therapy; prosthetic heart valve or history of endocarditis (see

**BNF 61**
section 5.1 table 2); risk factors for or existing cardio-vascular disease; adrenal suppression (may require corticosteroids); interactions: Appendix 1 (mifepristone).

**Important** For warnings relating to use of gemeprost in a patient undergoing induction of abortion with mifepristone, see under Gemeprost.

**Contra-indications** uncontrolled severe asthma; suspected ectopic pregnancy (use other specific means of termination); chronic adrenal failure; acute porphyria (section 9.8.2).

**Hepatic impairment** manufacturer advises avoid

**Renal impairment** manufacturer advises avoid

**Side-effects** gastro-intestinal cramps; uterine contractions, vaginal bleeding (sometimes severe) may occur between administration of mifepristone and surgery (and rarely abortion may occur before surgery); less commonly hypersensitivity reactions including rash and urticaria; rarely hypotension, malaise, headache, fever, hot flushes, dizziness, and chills; infections (including toxic shock syndrome) also reported

**Dose**
- Medical termination of intra-uterine pregnancy of up to 49 days gestation, by mouth, mifepristone 600 mg as a single dose under medical supervision followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina or misoprostol 400 micrograms by mouth [unlicensed]; alternative regimen, mifepristone 200 mg by mouth as a single dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding
- Medical termination of intra-uterine pregnancy of 50–63 days gestation, by mouth, mifepristone 600 mg (200 mg also effective) as a single dose under medical supervision, followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding
- Cervical ripening before mechanical cervical dilatation for termination of pregnancy of up to 84 days gestation, by mouth, mifepristone 200 mg as a single dose under medical supervision 36–48 hours before procedure
- Termination of pregnancy of 13–24 weeks gestation (in combination with a prostaglandin), by mouth, mifepristone 600 mg (200 mg may be effective) as a single dose under medical supervision followed 36–48 hours later by gemeprost 1 mg by vagina every 3 hours up to max. 5 mg or misoprostol (see above [unlicensed]); if abortion does not occur, 24 hours after start of treatment repeat course of gemeprost 1 mg by vagina up to max. 5 mg; follow-up visit after appropriate interval to assess vaginal bleeding recommended

**Note** Careful monitoring of blood pressure and pulse essential for 3 hours after administration of gemeprost (pessary risk of profound hypotension)
- Labour induction in fetal death in utero where prostaglandin or oxytocin inappropriate, by mouth, mifepristone 600 mg daily as a single dose for 2 days under medical supervision; if labour not started within 72 hours of first dose, another method should be used

### 7.1.3 Myometrial relaxants

**Mifepriste**® (Nordic) Tablets, yellow, mifepristone 200 mg, net price 3-tab pack = £52.66 (supplied to NHS hospitals and premises approved under Abortion Act 1967). Label: 10, patient information leaflet

**ATOSIBAN**

**Indications** uncomplicated premature labour (see notes above)

**Cautions** monitor blood loss after delivery; intra-uterine growth restriction; abnormal placental site

**Contra-indications** eclampsia and severe pre-eclampsia, intra-uterine infection, intra-uterine fetal death, antepartum haemorrhage (requiring immediate delivery), placenta praevia, abruptio placenta, intra-uterine growth restriction with abnormal fetal heart rate, premature rupture of membranes after 30 weeks' gestation

**Hepatic impairment** no information available

**Renal impairment** no information available

**Side-effects** nausea, vomiting, tachycardia, hypertension, headache, dizziness, hot flushes, hyperglycaemia, injection-site reaction; less commonly pruritus, rash, fever, insomnia
7 Obstructive, gynaecology, and urinary-tract disorders

7.1.3 Myometrial relaxants

**Dose**
- By intravenous injection, initially 6.75 mg over 1 minute, then by intravenous infusion 18 mg/hour for 3 hours, then 6 mg/hour for up to 45 hours; max. duration of treatment 48 hours

**Tractocile** (Ferring)
Injection, atosiban (as acetate) 7.5 mg/mL, net price 0.9-mL (6.75-mg) vial = £18.41
Concentrate for intravenous infusion, atosiban (as acetate) 7.5 mg/mL, net price 5-mL vial = £52.82

**Beta2 agonists**

**Cautions**
Beta2 agonists should be used with caution in patients with suspected cardiovascular disease (such patients should be assessed by a cardiologist before initiating therapy—see also Contra-indications, below), hypertensin, mild to moderate pre-eclampsia, hyperthyroidism, and hypokalaemia (particular risk with potassium-depleting diuretics—see also Hypokalaemia, p. 176). It is important to monitor pulse rate (should not exceed 140 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), and the patient’s fluid and electrolyte status (avoid over-hydration—discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs). Beta2 agonists should also be used with caution in diabetes—monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially with intravenous beta, agonists).

**Contra-indications**
Beta2 agonists are contra-indicated in cardiac disease and in patients with significant risk factors for myocardial ischaemia; they should also be avoided in antepartum haemorrhage, intra-uterine infection, intra-uterine fetal death, placenta praevia, abruptio placentae, threatened miscarriage, cord compression, and eclampsia or severe pre-eclampsia.

**Side-effects**
Side-effects of the beta2 agonists include tachycardia, arrhythmias, myocardial ischaemia, peripheral vasodilation, headache, tremor, hyperglycaemia, hypokalaemia, muscle cramps and tension, and hypersensitivity reactions (including angioedema, urticaria, rash, bronchospasm, hypotension, and collapse).

**RITODRINE HYDROCHLORIDE**

**Indications**
uncomplicated premature labour (see notes above)

**Cautions**
see notes above; also reported sleep disturbances and behavioural disturbances

**Contra-indications**
see notes above

**Dose**
- By intravenous infusion (important: minimum fluid volume, see below), initially 50 micrograms/minute, increased gradually according to response by 50 micrograms/minute every 10 minutes until contractions stop or maternal heart rate reaches 140 beats per minute; continue for 12–48 hours after contractions cease (usual rate 150–350 micrograms/minute); max. rate 350 micrograms/minute; or by intramuscular injection, 10 mg every 3–8 hours continued for 12–48 hours after contractions have ceased; then by mouth (but see notes above), 10 mg 30 minutes before termination of intravenous infusion, repeated every 2 hours for 24 hours, followed by 10–20 mg every 4–6 hours, max. oral dose 120 mg daily

**Important**
Manufacturer states that although fatal pulmonary oedema associated with ritodrine infusion is almost certainly multifactorial in origin, evidence suggests that fluid overload may be the most important single factor. The volume of infusion should therefore be kept to a minimum; for further guidance see Appendix 6. For specific guidance on infusion rates, consult product literature

**Yutopar** (Dubin)
Injection, ritodrine hydrochloride 10 mg, net price 90-tab pack = £30.40

**Contra-indications**
see notes above

**Side-effects**
see notes above

**Dose**
- By intravenous infusion, initially 10 micrograms/minute, rate increased gradually according to response at 10-minute intervals until contractions diminish then increase rate slowly until contractions cease (max. rate 45 micrograms/minute); maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours; then by mouth (but see notes above), 4 mg every 6–8 hours

**Preparations**
Section 3.1.1.1

**TERBUTALINE SULPHATE**

**Indications**
uncomplicated premature labour (see notes above); asthma (section 3.1.1)
7.2 Treatment of vaginal and vulval conditions

7.2.1 Preparations for vaginal and vulval changes

Topical HRT for vaginal atrophy

A cream containing an oestrogen may be applied on a short-term basis to improve the vaginal epithelium in menopausal atrophic vaginitis. It is important to bear in mind that topical oestrogens should be used in the smallest effective amount to minimise systemic effects. Modified-release vaginal tablets and an impregnated vaginal ring are now also available.

The risk of endometrial hyperplasia is increased when systemic oestrogens are administered alone for prolonged periods (section 6.4.1.1). The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

Topical oestrogens are used in postmenopausal women before vaginal surgery for prolapse when there is epithelial atrophy.

For a general comment on hormone replacement therapy, including the role of topical oestrogens, see section 6.4.1.1.

OESTROGENS, TOPICAL

Indications see notes above

Cautions see notes above; see also Oestrogens for HRT (section 6.4.1.1); interrupt treatment periodically to assess need for continued treatment

Contra-indications see notes above; see also Oestrogens for HRT (section 6.4.1.1)

7.2.2 Vaginal and vulval infections

Symptoms are often restricted to the vulva, but infections almost invariably involve the vagina which should also be treated. Applications to the vulva alone are likely to give only symptomatic relief without cure.

Aqueous medicated douches may disturb normal vaginal acidity and bacterial flora.

Topical anaesthetic agents give only symptomatic relief and may cause sensitivity reactions. They are indicated only in cases of pruritus where specific local causes have been excluded.

Systemic drugs are required in the treatment of infections such as gonorrhoea and syphilis (section 5.1).

Hepatic impairment see Combined Hormonal Contraceptives, section 7.3.1

Pregnancy see Combined Hormonal Contraceptives, section 7.3.1

Breast-feeding avoid; adverse effects on lactation; see also Combined Hormonal Contraceptives, section 7.3.1

Side-effects see notes above; see also Oestrogens for HRT (section 6.4.1.1); local irritation

Gynest® (Marlborough) (R) *Intravaginal cream, estril 0.01%, net price 80 g with applicator = £4.67 *Excipients include arachis (peanut) oil *Condoms may damage latex condoms and diaphragms *Dose insert 1 applicatorful daily, preferably in the evening until improvement occurs, reduced to 1 applicatorful twice a week; attempts to discontinue should be made at 3–6 month intervals with re-examination

Ortho-Gynest® (Janssen-Cilag) (R) *Pessaries, estril 500 micrograms, net price 15 pessaries = £4.73 *Excipients include butylated hydroxytoluene *Condoms damages latex condoms and diaphragms *Dose insert 1 pessary daily, preferably in the evening, until improvement occurs; maintenance 1 pessary twice a week; attempts to reduce or discontinue should be made at 3–6 month intervals with re-examination

Ovestin® (Organon) (R) *Intravaginal cream, estril 0.1%, net price 15 g with applicator = £4.45 *Excipients include cetyl alcohol, polysorbates, stearyl alcohol *Condoms effect on latex condoms and diaphragms not yet known *Dose insert 1 applicator–dose daily for 2–3 weeks, then reduce to twice a week (discontinue every 2–3 months for 4 weeks to assess need for further treatment); vaginal surgery, 1 applicator–dose daily for 2 weeks before surgery, resuming 2 weeks after surgery

Vagifem® (Novo Nordisk) (R) *Vaginal tablets, f /c, estradiol 10 micrograms in disposable applicators, net price 24-applicator pack = £16.72; estradiol 25 micrograms in disposable applicators, 15-applicator pack = £9.50 *Excipients none as listed in section 13.1.3 *Condoms no evidence of damage to latex condoms and diaphragms *Dose insert 1 vaginal tablet daily for 2 weeks then reduce to 1 tablet twice weekly; initiate therapy with 10 microgram vaginal tablets, increased after 3 months to 25 microgram vaginal tablet if response inadequate

Vaginal ring

Estring® (Pharmera) (R) *Vaginal ring, releasing estradiol approx. 7.5 micrograms/24 hours, net price 1-ring pack = £31.42. *Label: 10, patient information leaflet *Dose for postmenopausal urogenital conditions (not suitable for vasomotor symptoms or osteoporosis prophylaxis), to be inserted into upper third of vagina and worn continuously; replace after 3 months; max. duration of continuous treatment 2 years

Non-hormonal preparations for vaginal atrophy

Replens MD® and Syik® are acidic, non-hormonal vaginal moisturisers; Replens MD® provides a high moisture content for up to 3 days.
7 Obstetrics, gynaecology, and urinary-tract disorders

7.2.2 Vaginal and vulval infections

Effective specific treatments are available for the common vaginal infections.

Fungal infections

*Candidal vulvitis* can be treated locally with cream, but is almost invariably associated with vaginal infection which should also be treated. *Vaginal candidiasis* is treated primarily with antifungal pessaries or cream inserted high into the vagina (including during menstruation). Single-dose preparations offer an advantage when compliance is a problem. Local irritation may occur on application of vaginal antifungal products.

**Imidazole** drugs (clotrimazole, econazole, fenticonazole, and miconazole) are effective against candida in short courses of 1 to 14 days according to the preparation used; treatment can be repeated if initial course fails to control symptoms or if symptoms recur. Vaginal applications may be supplemented with antifungal cream for vulvitis and to treat other superficial sites of infection.

Oral treatment of vaginal infection with *fluconazole* or *itraconazole* (section 5.2.1) is also effective; oral ketoconazole has been associated with fatal hepatotoxicity (see section 5.2.2).

**Vulvovaginal candidiasis in pregnancy** Vulvovaginal candidiasis is common during pregnancy and can be treated with vaginal application of an imidazole (such as clotrimazole), and a topical imidazole cream for vulvitis. Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection. Oral antifungal treatment should be avoided during pregnancy.

**Recurrent vulvovaginal candidiasis** Recurrence of vulvovaginal candidiasis is particularly likely if there are predisposing factors such as antibiotic therapy, pregnancy, diabetes mellitus and possibly oral contraceptive use. Reservoirs of infection may also lead to recontamination and should be treated; these include other skin sites such as the digits, nail beds, and umbilicus as well as the gastro-intestinal tract and the bladder. The partner may also be the source of re-infection and, if symptomatic, should be treated with cream at the same time.

Treatment against candida may need to be extended for 6 months in recurrent vulvovaginal candidiasis. Some recommended regimens [all unlicensed] include:

- initially, *fluconazole* (section 5.2.1) by mouth 150 mg every 72 hours for 3 doses, then 150 mg once every week for 6 months;
- initially, vaginal application of a topical imidazole for 10–14 days, then clotrimazole vaginally 500-mg pessary once every week for 6 months;
- initially, vaginal application of a topical imidazole for 10–14 days, then clotrimazole (section 5.2.1) by mouth 50–100 mg daily for 6 months.

## PREPARATIONS FOR VAGINAL AND VULVAL CANDIDIASIS

**Indications** see notes above

**Pregnancy** see notes above

**Side-effects** occasional local irritation

**Dose**

- See under preparations below

### Clotrimazole (Non-proprietary)

- **Cream** (topical), clotrimazole 1%, net price 20 g = £1.52, 50 g = £4.12
- **Condoms** check with manufacturer of cream for effect on latex condoms and diaphragms
- **Dose** apply to anogenital area 2–3 times daily
- **Pessary**, clotrimazole 500 mg, net price 1 pessary with applicator = £3.13
- **Dose** insert 1 pessary at night as a single dose; can be repeated once if necessary

### Canesten® (Bayer Consumer Care)

- **Cream** (topical), clotrimazole 1%, net price 20 g = £2.14, 50 g = £3.50
- **Exipients** include benzy alcohol, cetostearyl alcohol, poloxamers
- **Condoms** damages latex condoms and diaphragms
- **Dose** apply to anogenital area 2–3 times daily
- **Thrush Cream** (topical), clotrimazole 2%, net price 20 g = £3.99
- **Exipients** include benzy alcohol, cetostearyl alcohol, poloxamers
- **Condoms** damages latex condoms and diaphragms
- **Dose** insert 5 g at night as a single dose; can be repeated once if necessary
- **Note** Brands for sale to the public include *Canesten* Internal Cream

### Cream Combi, clotrimazole 10% vaginal cream and 2% topical cream, net price 5-g vaginal cream (with applicator) and 10-g topical cream = £6.81

- **Condoms** damages latex condoms and diaphragms
- **Dose** see under individual components

### Pessaries, clotrimazole 100 mg, net price 6 pessaries with applicator = £3.63; 200 mg, 3 pessaries with applicator = £3.63

- **Exipients** include benzyl alcohol, cetostearyl alcohol, poloxamers
- **Condoms** damages latex condoms and diaphragms
- **Dose** insert 200 mg for 3 nights or 100 mg for 6 nights; course can be repeated once if necessary
- **Pessary**, clotrimazole 500 mg, net price 1 pessary with applicator = £2.00

- **Exipients** none as listed in section 13.1.3
- **Condoms** damages latex condoms and diaphragms
- **Dose** insert 1 pessary at night as a single dose; can be repeated once if necessary

### Combi, clotrimazole 500-mg pessary and cream (topical) 2%, net price 1 pessary and 10-g cream = £5.21

- **Condoms** damages latex condoms and diaphragms
- **Dose** see under individual components

### Gyno-Daktarin® (Janssen-Cilag)

- **Intravaginal cream**, miconazole nitrate 2%, net price 78 g with applicator = £4.33

- **Exipients** include butylated hydroxyanisole
- **Condoms** damages latex condoms and diaphragms
- **Dose** insert 5-g applicatorful once daily for 10–14 days or twice daily for 7 days; course can be repeated once if necessary; topical, apply to anogenital area twice daily
7.3 Contraceptives

The antiviral drugs aciclovir, famiclovir, and valaciclovir can be used in the treatment of genital infection due to herpes simplex virus, the HSV type 2 being a major cause of genital ulceration; they have a beneficial effect on virus shedding and healing, generally giving relief from pain and other symptoms. See section 5.3.2.1 for systemic preparations, and section 13.10.3 for topical preparations.

PREPARATIONS FOR OTHER VAGINAL INFECTIONS

Dalacin® (Pharmacia) 
Cream, clindamycin 2% (as phosphate), net price 40-g pack with 7 applicators = £10.86
Excipients include benzyl alcohol, cetoconazol alcohol, polysorbates, propylene glycol
Condoms damages latex condoms and diaphragms
Side-effects irritation, cervicitis, and vaginitis; poorly absorbed into the blood—low risk of systemic effects, see section 5.1.6
Dose bacterial vaginosis, insert 5-g applicatorful at night for 3–7 nights

Zidoval® (Meda)
Vaginal gel, metronidazole 0.75%, net price 40-g pack with 5 applicators = £4.31
Excipients include disodium edetate, hydroxybenzoates (parabens), propylene glycol
Cautions not recommended during menstruation; some absorption may occur, see section 5.1.11 for systemic effects
Side-effects local effects including irritation, candidiasis, abnormal discharge, pelvic discomfort
Dose bacterial vaginosis, insert 5-g applicatorful at night for 5 nights

Relactagel® (KoRa)
Vaginal gel, lactic acid 4.5%, glycolgen 0.1%, net price 7 × 5 mL-tube = £5.25
Excipients include propylene glycol
Cautions not recommended if trying to conceive
Side-effects mild irritation
Dose prevention of bacterial vaginosis, ADULT over 18 years insert contents of 1 tube at right for 2–3 nights after menstruation

Other infections

Trichomonal infections commonly involve the lower urinary tract as well as the genital system and need systemic treatment with metronidazole or tinidazole (section 5.1.11).

Bacterial infections with Gram-negative organisms are particularly common in association with gynaecological operations and trauma. Metronidazole is effective against certain Gram-negative organisms, especially Bacteroides spp. and can be used prophylactically in gynaecological surgery.

Clindamycin cream and metronidazole gel are indicated for bacterial vaginosis.

Vaginal preparations intended to restore normal acidity may prevent recurrence of vaginal infections and permit the re-establishment of the normal vaginal flora.

BNF 61

7.3 Contraceptives

The Fraser Guidelines1 should be followed when prescribing contraception for women under 16 years. The UK Medical Eligibility Criteria for Contraceptive Use (available at www.fsrh.org) is published by the Faculty of Sexual and Reproductive Healthcare; it categorises the risks of using contraceptive methods with pre-existing medical conditions.

Hormonal contraception is the most effective method of fertility control, but can have major and minor side-effects, especially for certain groups of women.

Intra-uterine devices are a highly effective method of contraception but may produce undesirable local side-effects. They may be used in women of all ages irre-
7.3.1 Combined hormonal contraceptives

Oral contraceptives containing an oestrogen and a progestogen (‘combined oral contraceptives’) are effective preparations for general use. Advantages of combined oral contraceptives include:

- reliable and reversible;
- reduced dysmenorrhea and menorrhagia;
- reduced incidence of premenstrual tension;
- less symptomatic fibroids and functional ovarian cysts;
- less benign breast disease;
- reduced risk of ovarian and endometrial cancer;
- reduced risk of pelvic inflammatory disease.

Combined oral contraceptives containing a fixed amount of an oestrogen and a progestogen in each active tablet are termed ‘monophasic’, those with varying amounts of the two hormones are termed ‘phasic’. A transdermal patch and a vaginal ring, both containing an oestrogen with a progestogen, are also available.

Choice. The majority of combined oral contraceptives contain ethinylestradiol as the oestrogen component; mestranol and estradiol valerate are also used. The ethinylestradiol content of combined oral contraceptives ranges from 20 to 40 micrograms. Generally a preparation with the lowest oestrogen and progestogen content which gives good cycle control and minimal side-effects in the individual woman is chosen.

- Low strength preparations (containing ethinylestradiol 20 micrograms) are particularly appropriate for women with risk factors for circulatory disease, provided a combined oral contraceptive is otherwise suitable. It is recommended that the combined oral contraceptive is not continued beyond 50 years of age since more suitable alternatives exist.
- Standard strength preparations (containing ethinylestradiol 30 or 35 micrograms or in 30–40 microgram phased preparations) are appropriate for standard use—but see Risk of Venous Thromboembolism below. Phased preparations are generally reserved for women who either do not have withdrawal bleeding or who have breakthrough bleeding with monophasic products.

The progestogens desogestrel, drospirenone, and gestodene (in combination with ethinylestradiol) may be considered for women who have side-effects (such as acne, headache, depression, weight gain, breast symptoms, and breakthrough bleeding) with other progestogens. However, women should be advised that desogestrel and gestodene have also been associated with an increased risk of venous thromboembolism. Drospirenone, a derivative of spironolactone, has antiandrogenic and anti-mineralocorticoid activity; it should be used with care if an increased plasma-potassium concentration might be hazardous.

The progestogen norelgestromin is combined with ethinylestradiol in a transdermal patch (Evra®). The vaginal contraceptive ring contains the progestogen etonogestrel combined with ethinylestradiol (NuvaRing®).

Risk of venous thromboembolism. There is an increased risk of venous thromboembolic disease (particularly during the first year) in users of oral contraceptives, but this risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100 000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors for venous thromboembolism, such as obesity.

The incidence of venous thromboembolism in healthy, non-pregnant women who are not taking an oral contraceptive is about 5–10 cases per 100 000 women per year. For those using combined oral contraceptives containing second-generation progestogens, such as levonorgestrel, this incidence is about 15 per 100 000 women per year of use. The risk of venous thromboembolism with transdermal patches may be slightly increased compared with combined oral contraceptives that contain levonorgestrel. Some studies have reported a greater risk of venous thromboembolism in women using combined oral contraceptives containing the third-generation progestogens desogestrel and gestodene; the incidence in these women is about 25 per 100 000 women per year of use. The absolute risk of venous thromboembolism in women using combined oral contraceptives containing these third-generation progestogens is very small and well below the risk associated with pregnancy. The risk of venous thromboembolism in women using a combined oral contraceptive containing drospirenone may be between that associated with combined oral contraceptives containing second-generation progestogens and those containing third-generation progestogens. The risk of venous thromboembolism associated with vaginal ring use compared to the risk with other combined hormonal contraceptives is unknown.

Provided that women are informed of the relative risks of venous thromboembolism and accept them, the choice of oral contraceptive is for the woman together with the prescriber jointly to make in light of her individual medical history and any contra-indications.

Travel. Women taking oral contraceptives or using the patch or vaginal ring are at an increased risk of deep-vein thrombosis during travel involving long periods of immobility (over 5 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.

Missed pill. The critical time for loss of contraceptive protection is when a pill is omitted at the beginning or end of a cycle (which lengthens the pill-free interval).

If a woman forgets to take a pill, it should be taken as soon as she remembers, and the next one taken at the normal time (even if this means taking 2 pills together). A missed pill is one that is 24 or more hours late; for women taking Qlaira®, see below. If a woman misses only one pill, she should take an active pill as soon as
she remembers and then resume normal pill-taking. No additional precautions are necessary.

If a woman misses 2 or more pills (especially from the first 7 in a packet), she may not be protected. She should take an active pill as soon as she remembers and then resume normal pill-taking. In addition, she must either abstain from sex or use an additional method of contraception such as a condom for the next 7 days. If these 7 days run beyond the end of the packet, the next packet should be started at once, omitting the pill-free interval (or, in the case of everyday (ED) pills, omitting the 7 inactive tablets).

A missed pill for a woman taking Qlaira® is one that is 12 hours or more late; for information on how to manage missed pills in women taking 12 hours or more late; for information on how to manage missed pills in women taking Qlaira®, refer to product literature.

Emergency contraception (section 7.3.5) is recommended if 2 or more combined oral contraceptive tablets are missed from the first 7 tablets in a packet and unprotected intercourse has occurred since finishing the last packet. Note: The Faculty of Sexual and Reproductive Healthcare offers 2 different types of missed pill advice depending on the ethinylestradiol content of the contraceptive pill. The missed pill information above offers the same advice regardless of the ethinylestradiol content of the contraceptive pill, it is a simplified, more cautious version of advice issued by the Faculty of Sexual and Reproductive Healthcare.

Delayed application or detached patch If a patch is partly detached for less than 24 hours, reapply to the same site or replace with a new patch immediately; no additional contraception is needed and the next patch should be applied on the usual ‘change day’. If a patch remains detached for more than 24 hours or if the user is not aware when the patch became detached, then stop the current contraceptive cycle and start a new cycle by applying a new patch, giving a new ‘Day 1’; an additional non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle.

If application of a new patch at the start of a new cycle is delayed, contraceptive protection is lost. A new patch should be applied as soon as remembered giving a new ‘Day 1’; additional non-hormonal methods of contraception should be used for the first 7 days of the new cycle. If intercourse has occurred during this extended patch-free interval, a possibility of fertilisation should be considered. If application of a patch in the middle of the cycle is delayed (i.e. the patch is not changed on day 8 or day 15):

- for up to 48 hours, apply a new patch immediately; next patch ‘change day’ remains the same and no additional contraception is required;
- for more than 48 hours, contraceptive protection may have been lost. Stop the current cycle and start a new 4-week cycle immediately by applying a new patch giving a new ‘Day 1’; additional non-hormonal contraception should be used for the first 7 days of the new cycle.

If the patch is not removed at the end of the cycle (day 22), remove it as soon as possible and start the next cycle on the usual ‘change day’, the day after day 28; no additional contraception is required.

Expulsion, delayed insertion or removal, or broken vaginal ring If the vaginal ring is expelled for less than 3 hours, rinse the ring with cool water and reinsert immediately; no additional contraception is needed.

If the ring remains outside the vagina for more than 3 hours or if the user does not know when the ring was expelled, contraceptive protection may be reduced:

- If ring expelled during week 1 or 2 of cycle, rinse ring with cool water and reinsert; use additional precautions (barrier methods) for next 7 days;
- If ring expelled during week 3 of cycle, either insert a new ring to start a new cycle or allow a withdrawal bleed and insert a new ring no later than 7 days after ring was expelled; latter option only available if ring was used continuously for at least 7 days before expulsion.

If insertion of a new ring at the start of a new cycle is delayed, contraceptive protection is lost. A new ring should be inserted as soon as possible; additional precautions (barrier methods) should be used for the first 7 days of the new cycle. If intercourse occurred during the extended ring-free interval, pregnancy should be considered.

No additional contraception is required if removal of the ring is delayed by up to 1 week (4 weeks of continuous use). The 7-day ring-free interval should be observed and subsequently a new ring should be inserted. Contraceptive protection may be reduced with continuous use of the ring for more than 4 weeks—pregnancy should be ruled out before inserting a new ring.

If the ring breaks during use, remove it and insert a new ring immediately; additional precautions (barrier methods) should be used for the first 7 days of the new cycle.

Diarrhoea and vomiting Vomiting and persistent, severe diarrhoea can interfere with the absorption of combined oral contraceptives. If vomiting occurs within 2 hours of taking a combined oral contraceptive another pill should be taken as soon as possible. In cases of persistent vomiting or severe diarrhoea lasting more than 24 hours, additional precautions should be used during and for 7 days (9 days for Qlaira®) after recovery (see also under Missed pill, above). If the vomiting and diarrhoea occurs during the last 7 tablets, the next pill-free interval should be omitted (in the case of ED tablets the inactive ones should be omitted).

Interactions The effectiveness of combined oral contraceptives, progestogen-only oral contraceptives (section 7.3.2.1), contraceptive patches, and vaginal rings can be considerably reduced by interaction with drugs that induce hepatic enzyme activity (e.g. carbamazepine, eslicarbazepine, modafinil, nelfinavir, nevirapine, oxicarbazepine, phenytoin, phenobarbital, primidone, ritonavir, St John’s Wort, topiramate, and, above all, rifabutin and rifampicin). A condom together with a long-acting method, such as an injectable contraceptive, may be more suitable for patients with HIV infection or at risk of HIV infection; advice on the possibility of interaction with antiretroviral drugs should be sought from HIV specialists.

For a short course of an enzyme-inducing drug, the dose of combined oral contraceptives should be adjusted to provide ethinylestradiol 50 micrograms or more daily (unlicensed use); furthermore, additional contraceptive precautions should be taken whilst taking the enzyme-inducing drug and for 4 weeks after stopping it. Additional contraceptive precautions are also required for women using contraceptive patches and vaginal rings whilst taking the enzyme-inducing drug and for 4 weeks after stopping. If concomitant administration runs
beyond the 3 weeks of patch or vaginal ring use, a new treatment cycle should be started immediately without a patch-free or ring-free break.

Women requiring a long-term course of an enzyme-inducing drug should be encouraged to consider a contraceptive method that is unaffected by the interacting drug. In women unable to use an alternative method of contraception (for rifampicin and rifabutin see also below), a regimen of combined oral contraceptives should be taken which provides a daily intake of ethinyloestradiol 50 micrograms or more [unlicensed use]; ‘tricycling’ (i.e. taking 3 or 4 packets of monophasic tablets without a break followed by a short tablet-free interval of 4 days) may be recommended. Rifampicin and rifabutin are such potent enzyme-inducing drugs that an alternative method of contraception (such as an IUD) is always recommended. Since enzyme activity does not return to normal for several weeks after stopping an enzyme-inducing drug, appropriate contraceptive measures are required for 4 to 8 weeks after stopping. Contraceptive patches and vaginal rings are not recommended for women taking enzyme-inducing drugs over a long period.

In the past there have been concerns that some antibacterials that do not induce liver enzymes (e.g. ampicillin, doxycycline) reduce the efficacy of combined oral contraceptives by impairing the bacterial flora responsible for recycling ethinylestradiol from the large bowel. However, there is a lack of evidence to support this interaction. Current recommendations are that no additional contraceptive precautions are required when combined oral contraceptives are used with antibacterials that do not induce liver enzymes.

Surgery Oestrogen-containing contraceptives should preferably be discontinued (and adequate alternative contraceptive arrangements made) 4 weeks before major elective surgery and all surgery to the legs or surgery which involves prolonged immobilisation of a lower limb should preferably be discontinued at the first menses occurring at least 2 weeks after full mobilisation. A progesteron-only contraceptive may be offered as an alternative and the oestrogen-containing contraceptive restarted after mobilisation, as above. When discontinuation of an oestrogen-containing contraceptive is not possible, e.g. after trauma or if a patient admitted for an elective procedure is still on an oestrogen-containing contraceptive, thromboprophylaxis (with unfractionated or low molecular weight heparin and graduated compression hosiery) is advised. These recommendations do not apply to minor surgery with short duration of anaesthesia, e.g. laparoscopic sterilisation or tooth extraction, or to women using oestrogen-free hormonal contraceptives.

Reason to stop immediately Combined hormonal contraceptives or hormone replacement therapy (HRT) should be stopped (pending investigation and treatment) if, of any of the following occur:
- sudden severe chest pain (even if not radiating to left arm);
- sudden breathlessness (or cough with blood-stained sputum);
- unexplained swelling or severe pain in calf of one leg;
- severe stomach pain;
- serious neurological effects including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body;
- hepatitis, jaundice, liver enlargement;
- blood pressure above systolic 160 mmHg or diastolic 95 mmHg;
- prolonged immobility after surgery or leg injury;
- detection of a risk factor which contra-indicates treatment (see Cautions and Contra-indications under Combined Hormonal Contraceptives below or under Oestrogens for HRT (section 6.4.1.1)).

COMBINED HORMONAL CONTRACEPTIVES

Indications contraception; menstrual symptoms (section 6.4.1.2)

Cautions see notes above; risk factors for venous thromboembolism (see below and also notes above), arterial disease and migraine, see below; personal or family history of hypertriglyceridaemia (increased risk of pancreatitis); hyperprolactinaemia (seek specialist advice); history of severe depression especially if induced by hormonal contraceptive; undiagnosed breast mass; gene mutations associated with breast cancer (e.g. BRCA 1); sickle-cell disease; inflammatory bowel disease including Crohn’s disease; reduced efficacy of contraceptive patch in women with body-weight > 90 kg; active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice; interactions: see above and Appendix 1 (oestrogens, progestogens)

Risk factors for venous thromboembolism See also notes above. Use with caution if any of the following factors present but avoid if two or more factors present:
- family history of venous thromboembolism in first-degree relative aged under 45 years (avoid contraceptive containing desogestrel or gestodene, or avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));
- obesity—body mass index > 30 kg/m² (avoid if body mass index > 35 kg/m² unless no suitable alternative);
- long-term immobilisation e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);
- history of superficial thrombophlebitis;
- age over 35 years (avoid if over 50 years);
- smoking.

Risk factors for arterial disease Use with caution if any of the following factors present but avoid if two or more factors present:
- family history of arterial disease in first degree relative aged under 45 years (avoid if atherogenic lipid profile);
- diabetes mellitus (avoid if diabetes complications present);
- hypertension—blood pressure above systolic 140 mmHg or diastolic 90 mmHg (avoid if blood pressure above systolic 160 mmHg or diastolic 95 mmHg);
- smoking (avoid if smoking 40 or more cigarettes daily);
- age over 35 years (avoid if over 50 years);
- obesity (avoid if body mass index ≥ 35 kg/m² unless no suitable alternative).
By mouth

Side-effects avoid until weaning or for 6 months Breast-feeding not known to be harmful Pregnancy Hepatic impairment avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours

Contra-indications see notes above; personal history of venous or arterial thrombosis, severe or multiple risk factors for arterial disease or for venous thromboembolism (see above), heart disease associated with pulmonary hypertension or risk of embolus; sclerosing treatment for varicose veins; migraine with aura (see also above); transient cerebral ischaemic attacks without headaches; systemic lupus erythematosus with (or unknown) antiphospholipid antibodies; acute porphyria (section 9.8.2); gallstones; history of haemolytic uraemic syndrome or history during pregnancy of pruritus, cholestatic jaundice, chorea, pemphigoid gestationis; history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable; undiagnosed vaginal bleeding

Migraine Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour—see also Reason To Stop Immediately in notes above)

Contra-indications see notes above; personal history of venous or arterial thrombosis, severe or multiple risk factors for arterial disease or for venous thromboembolism (see above), heart disease associated with pulmonary hypertension or risk of embolus; sclerosing treatment for varicose veins; migraine with aura (see also above); transient cerebral ischaemic attacks without headaches; systemic lupus erythematosus with (or unknown) antiphospholipid antibodies; acute porphyria (section 9.8.2); gallstones; history of haemolytic uraemic syndrome or history during pregnancy of pruritus, cholestatic jaundice, chorea, pemphigoid gestationis; history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable; undiagnosed vaginal bleeding

Hepatic impairment avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours

Pregnancy not known to be harmful

Breast-feeding avoid until weaning or for 6 months after birth (adverse effects on lactation)

Side-effects see notes above; also nausea, vomiting, abdominal cramps, changes in body-weight, liver impairment, hepatic tumours; fluid retention, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB; see also notes above), hypertension, changes in lipid metabolism; headache, depression, chorea, nervousness, irritability; changes in libido, breast tenderness, changes in lipid metabolism (e.g. Dubin-Johnson or Rotor syndromes); seizures; leg cramps; skin reactions; risk of varicose veins; migraine treated with ergot derivatives)
traceptive used correctly and pregnancy unlikely, can switch to ring on any day of cycle. 

Changing from progestogen-only method From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed, from an injection, insert ring when next injection due, from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.

After first trimester abortion Start immediately.

After childbirth (not breast-feeding) or second trimester abortion Start 4 weeks after birth or abortion; if started later than 4 weeks after birth or abortion, additional precautions (barrier methods) should be used for first 7 days.

Oral (low and standard strength)
For information on these preparations, see Combined Oral Contraceptives table, below.

---

**Combined Oral Contraceptives**

See Risk of Venous Thromboembolism in notes above before prescribing.

**Ethinylestradiol with Norelgestromin**

See Risk of Venous Thromboembolism in notes above before prescribing.

**Evra** (Janssen-Cilag) Patches, self-adhesive (releasing ethinylestradiol approx. 33.9 micrograms/24 hours and norelgestromin approx. 203 micrograms/24 hours); net price 9-patch pack = £16.70. Counselling, administration Dose 1 patch to be applied once weekly for three weeks, followed by a 7-day patch-free interval; subsequent courses repeated after 7-day patch-free interval (during which withdrawal bleeding occurs); for starting routines see under Dose above. Note Adhesives or bandages should not be used to hold patch in place. If patch no longer sticky do not reapply but use a new patch.

**Evra** patches should be restricted for use in women who are likely to comply poorly with combined oral contraceptives.

---

**Transdermal (standard strength)**

<table>
<thead>
<tr>
<th>Type of preparation</th>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Tablets per cycle</th>
<th>Brand</th>
<th>Price, 3-cycle pack (unless stated)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Monophasic low strength (21-day preparations)</td>
<td>Ethinylestradiol 20 micrograms</td>
<td>Desogestrel 150 micrograms</td>
<td>21</td>
<td>Gedarel® 20/150</td>
<td>£5.98</td>
<td>Consilient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mercilon®</td>
<td>£7.97</td>
<td>Organon</td>
</tr>
<tr>
<td></td>
<td>Gestodene 75 micrograms</td>
<td>21</td>
<td>Femodette®</td>
<td>£8.85</td>
<td>Bayer Schering</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Millinette® 20/75</td>
<td>£6.37</td>
<td>Consilient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sunya 20/75®</td>
<td>£6.62</td>
<td>Stragen</td>
</tr>
<tr>
<td></td>
<td>Norethisterone acetate 1 mg</td>
<td>21</td>
<td>Loestrin 20®</td>
<td>£2.75</td>
<td>Galen</td>
<td></td>
</tr>
<tr>
<td>1 Monophasic standard strength (21-day preparations)</td>
<td>Ethinylestradiol 30 micrograms</td>
<td>Desogestrel 150 micrograms</td>
<td>21</td>
<td>Gedarel® 30/150</td>
<td>£4.93</td>
<td>Consilient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Marvelon®</td>
<td>£6.45</td>
<td>Organon</td>
</tr>
<tr>
<td></td>
<td>Drosiprenone 3 mg</td>
<td>21</td>
<td>2 Yasmin®</td>
<td>£1.70</td>
<td>Bayer Schering</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gestodene 75 micrograms</td>
<td>21</td>
<td>Femodene®</td>
<td>£6.73</td>
<td>Bayer Schering</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Katya 30/75®</td>
<td>£5.03</td>
<td>Stragen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Millinette® 30/75</td>
<td>£4.85</td>
<td>Consilient</td>
</tr>
<tr>
<td></td>
<td>Levonorgestrel 150 micrograms</td>
<td>21</td>
<td>Levest®</td>
<td>£2.55</td>
<td>Monensides</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Microgynon 30®</td>
<td>£2.82</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ovranette®</td>
<td>£2.20</td>
<td>Wyeth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rigeviron®</td>
<td>£1.89</td>
<td>Consilient</td>
</tr>
<tr>
<td></td>
<td>Norethisterone acetate 1.5 mg</td>
<td>21</td>
<td>Loestrin 30®</td>
<td>£3.95</td>
<td>Galen</td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td>Norgestimate 250 micrograms</td>
<td>21</td>
<td>Cilest®</td>
<td>3-cycle pack = £2.87; 6-cycle pack = £5.74</td>
<td>Janssen-Cilag</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norethisterone 500 micrograms</td>
<td>21</td>
<td>Brevinor®</td>
<td>£1.99</td>
<td>Pharmacia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ovysmen®</td>
<td>£1.49</td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td></td>
<td>Norethisterone 1 mg</td>
<td>21</td>
<td>Norinyl®</td>
<td>£2.28</td>
<td>Pharmacia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mestranol 50 micrograms</td>
<td>Norethisterone 1 mg</td>
<td>21</td>
<td>Norinyl®-1®</td>
<td>£2.19</td>
<td>Pharmacia</td>
</tr>
</tbody>
</table>

1. Dose 1 tablet daily for 21 days starting on day 1 of cycle; subsequent courses repeated after 7-day tablet-free interval (during which withdrawal bleeding occurs); for starting routines see under Dose above.
2. Caution with care if increased plasma-potassium concentration might be hazardous; renal impairment avoid if eGFR less than 30 mL/minute/1.73 m².
### Combined Oral Contraceptives (continued)

See Risk of Venous Thromboembolism in notes above before prescribing.

<table>
<thead>
<tr>
<th>Type of preparation</th>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Tablets per cycle</th>
<th>Brand</th>
<th>Price, 3-cycle pack (unless stated)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 Monophasic standard strength (28-day ‘Every day’ preparations)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td></td>
<td></td>
<td>21 active</td>
<td>Femodene® ED</td>
<td>£6.73</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Gestodene 75 micrograms</td>
<td>7 inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td></td>
<td></td>
<td>21 active</td>
<td>Microgynon 30 ED®</td>
<td>£2.54</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Levonorgestrel 150 micrograms</td>
<td>7 inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2 Phasic standard strength (21-day preparations)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td></td>
<td></td>
<td>6</td>
<td>Triadene®</td>
<td>£8.99</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Gestodene 50 micrograms</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestodene 70 micrograms</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 40 micrograms</td>
<td></td>
<td></td>
<td>6</td>
<td>Logynon®</td>
<td>£3.96</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Gestodene 50 micrograms</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestodene 75 micrograms</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td></td>
<td></td>
<td>6</td>
<td>TriRegol®</td>
<td>£2.87</td>
<td>Consilient</td>
</tr>
<tr>
<td>Levonorgestrel 50 micrograms</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel 75 micrograms</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td></td>
<td></td>
<td>7</td>
<td>BINovum®</td>
<td>£1.96</td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td>Norethisterone 500 micrograms</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone 1 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td></td>
<td></td>
<td>7</td>
<td>Synphase®</td>
<td>1-cycle pack = £1.20</td>
<td>Pharmaclia</td>
</tr>
<tr>
<td>Norethisterone 500 micrograms</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone 1 mg</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td></td>
<td></td>
<td>7</td>
<td>Trinovum®</td>
<td>£2.72</td>
<td>Janssen-Cilag</td>
</tr>
<tr>
<td>Norethisterone 500 micrograms</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone 750 micrograms</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 Phasic standard strength (28-day ‘Every day’ preparation)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td></td>
<td></td>
<td>6 active</td>
<td>Logynon ED®</td>
<td>£3.82</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Ethinylestradiol 40 micrograms</td>
<td>5 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td>10 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td>7 inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td></td>
<td></td>
<td>2 active</td>
<td>Qlaira® ▼</td>
<td>£25.18</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Levonorgestrel 50 micrograms</td>
<td>5 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel 75 micrograms</td>
<td>17 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel 125 micrograms</td>
<td>2 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 Phasic (28-day ‘Every day’ preparation)</strong></td>
<td>Estradiol valerate 3 mg</td>
<td></td>
<td>2 active</td>
<td>Qlaira® ▼</td>
<td>£25.18</td>
<td>Bayer Schering</td>
</tr>
<tr>
<td>Estradiol valerate 2 mg</td>
<td>5 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate 2 mg</td>
<td>17 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate 1 mg</td>
<td>2 active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Dose: 1 tablet daily for 28 days, starting on day 1 of cycle with first active tablet (withdrawal bleeding occurs when inactive tablets being taken); subsequent courses repeated without interval; for starting routines see under Dose above.

2. Dose: 1 tablet daily for 21 days starting on day 1 of cycle; subsequent courses repeated after 7-day tablet-free interval (during which withdrawal bleeding occurs); for starting routines see under Dose above.
7 Obstetrics, gynaecology, and urinary-tract disorders

Vaginal (low strength)

*Ethinylestradiol with Etonogestrel*

See Risk of Venous Thromboembolism in notes above before prescribing

**Nuvaring® (Organon)**

**Vaginal ring**, releasing ethinylestradiol approx. 15 micrograms/24 hours and etonogestrel approx. 120 micrograms/24 hours, net price 3-ring pack = £27.00.

**Counselling, administration**

**Dose** 1 ring to be inserted into the vagina, removed on day 22; subsequent courses repeated after 7-day ring-free interval (during which withdrawal bleeding occurs); for starting routines see under Dose above.

**Counselling** The presence of the ring should be checked regularly. In case of expulsion see Expulsion, Delayed Insertion or Removal, or Broken Vaginal Ring, p. 495

### 7.3.2 Progestogen-only contraceptives

#### 7.3.2.1 Oral progestogen-only contraceptives

Oral progestogen-only preparations may offer a suitable alternative when oestrogens are contra-indicated (including those patients with venous thrombosis or a past history or predisposition to venous thrombosis), but may have a higher failure rate than combined preparations. They are suitable for older women, for heavy smokers, and for those with hypertension, valvular heart disease, diabetes mellitus, and migraine. Menstrual irregularities (oligomenorrhoea, menorrhagia) are more common but tend to resolve on long-term treatment.

**Interactions** Effectiveness of oral progestogen-only preparations is not affected by antibacterials that do not induce liver enzymes. The efficacy of oral progestogen-only preparations is, however, reduced by enzyme-inducing drugs and an additional or alternative contraceptive method is recommended during treatment with an enzyme-inducing drug and for at least 4 weeks afterwards—see p. 495 and Appendix 1 (progestogens).

**Surgery** All progestogen-only contraceptives (including those given by injection) are suitable for use as an alternative to combined oral contraceptives before major elective surgery, before all surgery to the legs, or before surgery which involves prolonged immobilisation of a lower limb.

**Starting routine** One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours (12 hours for Cerazette®) overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days.)

The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception (see p. 505) if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours (12 hours for Cerazette®) late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.

**Diarrhoea and vomiting** Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours (12 hours for Cerazette®) of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery (see also under Missed pill above).

#### 7.3.2.2 Parenteral progestogen-only contraceptives

#### 7.3.2.3 Intra-uterine progestogen-only device

**ORAL PROGESTOGEN-ONLY CONTRACEPTIVES**

**(Progestogen-only pill, ‘POP’)**

**Indications** contraception

**Cautions** arterial disease; sex-steroid dependent cancer; past ectopic pregnancy; malabsorption syndromes; active thrombophilic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice; systemic lupus erythematosus with positive (or unknown) anti-phospholipid antibodies; functional ovarian cysts; past ectopic pregnancy; malabsorption syndrome

**Other conditions** The product literature advises caution in patients with history of venous thromboembolism, hypertension, diabetes mellitus and migraine, evidence for caution in these conditions is unsatisfactory

**Contra-indications** undiagnosed vaginal bleeding; severe arterial disease; acute porphyria (section 9.8.2); history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable

**Hepatic impairment** caution in severe liver disease and recurrent cholestatic jaundice; avoid in liver tumour

**Pregnancy** not known to be harmful

**Breast-feeding** progestogen-only contraceptives do not affect lactation; see also After Childbirth above

**Side-effects** menstrual irregularities (see also notes above); nausea, vomiting, headache, dizziness, breast discomfort, depression, skin disorders, disturbance of appetite, weight changes, changes in libido

**Breast cancer** There is a small increase in the risk of having breast cancer diagnosed in women using, or who have
recently used, a progestogen-only contraceptive pill, this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

**Dose**
- 1 tablet daily at same time each day, starting on day 1 of cycle then continuously; if administration delayed for 3 hours (12 hours for Cerazette®) or more it should be regarded as a ‘missed pill’, see notes above

Cerazette® (Organon) (©)
- Tablets, P/c, desogestrel 75 micrograms, net price 3 × 28-tab pack = £8.68
- The Scottish Medicines Consortium has advised (September 2003) that Cerazette® should be restricted for use in women who cannot tolerate oestrogen-containing contraceptives or in whom such preparations are contra-indicated

Femulen® (Pharmacia) (©)
- Tablets, etynodiol diacetate 500 micrograms, net price 3 × 28-tab pack = £3.31

Micronor® (Janssen-Cilag) (©)
- Tablets, norethisterone 350 micrograms, net price 3 × 28-tab pack = £1.96

Norgeston® (Bayer Schering) (©)
- Tablets, s/c, levonorgestrel 30 micrograms, net price 35-tab pack = £2.92

Noriday® (Pharmacia) (©)
- Tablets, norethisterone 350 micrograms, net price 3 × 28-tab pack = £2.10

**7.3.2.2 Parenteral progestogen-only contraceptives**

**Medroxyprogesterone acetate (Depo-Provera®)** is a long-acting progestogen given by intramuscular injection; it is as effective as the combined oral preparations but because of its prolonged action it should never be used without full counselling backed by the patient information leaflet. It may be used as a short-term or long-term contraceptive for women who have been counselled about the likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility. Heavy bleeding has been reported in patients given medroxyprogesterone acetate in the immediate puerperium; delaying the first injection until 6 weeks after birth may minimise bleeding problems. If the woman is not breast-feeding, the first injection may be given within 5 days postpartum (she should be warned that the risk of heavy or prolonged bleeding may be increased). The manufacturer advises that in heavier women, blood medroxyprogesterone concentrations are lower and therefore the implant may not provide effective contraception during the third year; they advise that earlier replacement may be considered in such patients—however, evidence to support this recommendation is lacking. Local reactions such as bruising and itching can occur at the insertion site. The contraceptive effect of etonogestrel is rapidly reversed on removal of the implant. The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.

**Implanon®,** also an etonogestrel-releasing implant, has been discontinued (October 2010), but some women may have the implant in place until 2013. The cautions, contra-indications, and side-effects of oral progestogen-only contraceptives apply to parenteral progestogen-only contraceptives, except that parenteral preparations reliably inhibit ovulation and therefore protect against ectopic pregnancy and functional ovarian cysts.

**Interactions** Effectiveness of parenteral progestogen-only contraceptives is not affected by antibacterials that do not induce liver enzymes. However, effectiveness of norethisterone and etonogestrel (but not depot medroxyprogesterone acetate) may be reduced by enzyme-inducing drugs; additional contraceptive precautions should be taken whilst taking the enzyme-inducing drug and for 4 weeks after stopping it or an alternative contraceptive method should be considered if long-term use of the enzyme-inducing drug is contemplated.

**Indications** contraception, see also notes above and under preparations (roles vary according to preparation)

**Cautions** see notes above and under preparations; possible risk of breast cancer, see oral progestogen-only contraceptives (section 7.3.2.1); history during pregnancy of pruritus or of deterioration of oto-
sclerosis, disturbances of lipid metabolism; interactions: see notes above and Appendix 1 (progestogens)

Counselling Full counselling backed by patient information leaflet required before administration

Contra-indications see notes above; history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable

Hepatic impairment see Oral Progestogen-only Contraceptives, section 7.3.2.1

Pregnancy not known to be harmful; for Implanon® or Nexplanon® if pregnancy occurs remove implant

Breast-feeding progestogen-only contraceptives do not affect lactation; see also notes above and under preparations

Side-effects see notes above; injection-site reactions

Cervical cancer Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives, see p. 496. The risk of cervical cancer with other progestogen-only contraceptives is not yet known.

Dose

See under preparations

Injectable preparations

Depo-Provera® (Pfizer) Injection (aqueous suspension), medroxyprogesterone acetate 150 mg/mL, net price 1-mL prefilled syringe = £6.01, 1-mL vial = £5.01. Counselling, see patient information leaflet

Dose by deep intramuscular injection, 150 mg within first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding), for long-term contraception, repeated every 12 weeks (if interval greater than 12 weeks and 5 days, rule out pregnancy before next injection and advise patient to use additional contraceptive measures (e.g. barrier) for 14 days after the injection)

Noristerat® (Bayer Schering) Injection (oily), norethisterone enantate 200 mg/mL, net price 1-mL amp = £3.38. Counselling, see patient information leaflet

Dose by deep intramuscular injection given very slowly into gluteal muscle, short-term contraception, 200 mg within first 5 days of cycle or immediately after parturition (duration 8 weeks); may be repeated once after 8 weeks (withhold breast-feeding for neonates with severe or persistent jaundice requiring medical treatment)

Implants

Nexplanon® (Organon) Implant, containing etonorgestrel 68 mg in radiopaque flexible rod, net price = £79.46. Counselling, see patient information leaflet

Dose by subdermal implantation, no hormonal contraceptive use in previous month, 1 implant inserted during first 5 days of cycle; postpartum, 1 implant inserted 21–28 days after delivery, in breast-feeding mothers, 1 implant inserted after 28 days postpartum; abortion or miscarriage in the second trimester, 1 implant inserted 21–28 days after abortion or miscarriage; abortion or miscarriage in first trimester, 1 implant inserted within 5 days; changing from other hormonal contraceptive, consult product literature; remove implant within 3 years of insertion

replacement therapy. This may therefore be a contraceptive method of choice for women who have excessively heavy menses.

The effects of the progestogen-only intra-uterine system are mainly local and hormonal including prevention of endometrial proliferation, thickening of cervical mucus, and suppression of ovulation in some women (in some cycles). In addition to the progestogenic activity, the intra-uterine system itself may contribute slightly to the contraceptive effect. Return of fertility after removal is rapid and appears to be complete.

Advantages of the progestogen-only intra-uterine system over copper intra-uterine devices are that there may be an improvement in any dysmenorrhoea and a reduction in blood loss; there is also evidence that the frequency of pelvic inflammatory disease may be reduced (particularly in the youngest age groups who are most at risk).

In primary menorrhagia, menstrual bleeding is reduced significantly within 3–6 months of inserting the progestogen-only intra-uterine system, probably because it prevents endometrial proliferation. Another treatment should be considered if menorrhagia does not improve within this time (section 6.4.1.2).

Cautions and contra-indications Generally the cautions and contra-indications for the progestogen-only intra-uterine system are as for standard intra-uterine devices (section 7.3.4), but the risk of ectopic pregnancy is considerably smaller. Although the progestogen-only intra-uterine system produces little systemic progestogenic activity, it is usually avoided for 5 years after any evidence of breast cancer. However, the system can be considered for a woman in long-term remission from breast cancer who has menorrhagia and requires effective contraception. Since levonorgestrel is released close to the site of the main contraceptive action (on cervical mucus and endometrium) progestogenic side-effects and interactions are less likely; in particular, enzyme-inducing drugs are unlikely to significantly reduce the contraceptive effect of the progestogen-only intra-uterine system and additional contraceptive precautions are not required.

Side-effects Initially, changes in the pattern and duration of menstrual bleeding (spotting or prolonged bleeding) are common; endometrial disorders should be ruled out before insertion and the patient should be fully counselled (and provided with a patient information leaflet). Improvement in progestogenic side-effects, such as mastalgia and in the bleeding pattern usually occurs a few months after insertion and bleeding may often become very light or absent. Functional ovarian cysts (usually asymptomatic) can occur and usually resolve spontaneously (ultrasound monitoring recommended).

INTRA-UTERINE PROGESTOGEN-ONLY SYSTEM

Indications see under preparation

Cautions see notes above; history of depression; advanced uterine atrophy; systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies; not suitable for emergency contraception; interactions: see notes above and Appendix 1 (progestogens)

7.3.2.3 Intra-uterine progestogen-only device

The progestogen-only intra-uterine system, Mirena®, releases levonorgestrel directly into the uterine cavity. It is licensed for use as a contraceptive, for the treatment of primary menorrhagia and for the prevention of endometrial hyperplasia during oestrogen replacement therapy. This may therefore be a contraceptive method of choice for women who have excessively heavy menses.
Spermicidal contraceptives

Spermicidal contraceptives are useful additional safeguards but do not give adequate protection if used alone unless fertility is already significantly diminished (section 6.4.1.1). They have two components: a spermicide and a vehicle which itself may have some inhibiting effect on sperm activity. They are suitable for use with barrier methods, such as diaphragms made from latex rubber, and may render them less effective as a barrier method of contraception and as a protection from sexually transmitted infections (including HIV).

Products such as petroleum jelly (Vaseline®), baby oil and oil-based vaginal and rectal preparations are likely to damage condoms and contraceptive diaphragms made from latex rubber, and may render them less effective as a barrier method of contraception and as a protection from sexually transmitted infections (including HIV).

Gygel® (Marlborough)

Dose
- See under preparation

Mirena® (Bayer Schering) (NW)

Intra-uterine system, T-shaped plastic frame (impregnated with barium sulphate and with threads attached to base) with polydimethylsiloxane reservoir releasing levonorgestrel 20 micrograms/24 hours, net price = £85.66. Counselling, see patient information leaflet

Dose contraception and menorrhagia, insert into uterine cavity within 7 days of onset of menstruation or any time if replacement, or any time if reasonably certain woman is not pregnant and there is no risk of conception (additional precautions (e.g. barrier methods) necessary for next 7 days), or immediately after first-trimester termination by curettage; postpartum insertions should be delayed until at least 4 weeks after delivery; effective for 5 years.

Prevention of endometrial hyperplasia during oestrogen replacement therapy, insert during last days of menstruation or withdrawal bleeding or any time if amenorrhoeic; effective for 4 years.

Note When system is removed (and not immediately replaced), if pregnancy is not desired, remove during the first few days of the onset of menstruation, otherwise additional contraceptive measures should be used for at least 7 days before removal.

7.3.3 Spermicidal contraceptives

Intra-uterine devices

The intra-uterine device (IUD) is a suitable contraceptive for women of all ages irrespective of parity; however, it is less appropriate for those with an increased risk of pelvic inflammatory disease (see below). The most effective intra-uterine devices have at least 380 mm² of copper and have banded copper on the arms.

Smaller devices have been introduced to minimise side-effects; these consist of a plastic carrier wound with copper wire or fitted with copper bands; some also have a central core of silver to prevent fragmentation of the copper. Fertility declines with age and therefore a copper intra-uterine device which is fitted in a woman over the age of 40, may remain in the uterus until menopause.

A frameless, copper-bearing intra-uterine device (GyneFix®) is also available. It consists of a knotted, polypropylene thread with 6 copper sleeves; the device is anchored in the uterus by inserting the knot into the uterine fundus. The intra-uterine devices Multiload® Cu250 and Multiload® Cu250 Short (Organon) have been discontinued, but some women may have the devices in place until 2011.

The timing and technique of fitting an intra-uterine device are critical for its subsequent performance. The healthcare professional inserting (or removing) the device should be fully trained in the technique and should provide full counselling backed, where available, by the patient information leaflet. Devices should not be fitted during the heavy days of the period; they are best fitted after the end of menstruation and before the calculated time of implantation. The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:
- they are under 25 years old
- they are over 25 years old and
  - have a new partner or
  - have had more than one partner in the past year or
  - their regular partner has other partners.

In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, Neisseria gonorrhoeae) should be performed. If results are unavailable at the time of fitting an intra-uterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend as an emergency if she experiences sustained pain during the next 20 days.

An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for...
the previous 7 days. If removal is essential post-coital contraception should be considered.

If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible.

**INTRA-UTERINE CONTRACEPTIVE DEVICES**

**Indications** see notes above

**Cautions** see notes above; also anaemia, menorrhagia (progestogen intra-uterine system might be preferable, section 7.2.3), endometriosis, severe primary dysmenorrhoea, history of pelvic inflammatory disease, diabetes, fertility problems, nulliparity and young age, severely scarred uterus (including after endometrial resection) or severe cervical stenosis; drug- or disease-induced immunosuppression (risk of infection—avoid if marked immunosuppression); epilepsy (risk of seizure at time of insertion); increased risk of expulsion if inserted before uterine involution; gynaecological examination before insertion, 6–8 weeks after then annually but counsel women to see doctor promptly in case of significant symptoms, especially pain; anticoagulant therapy (avoid if possible).

**Intra-implants** severe anaemia, recent sexually transmitted infection (if not fully investigated and treated), unexplained uterine bleeding, distorted or small uterine cavity, genital malignancy, active trophoblastic disease (until return to normal of urine and plasma-gonadotrophin concentration), pelvic inflammatory disease, established or marked immunosuppression, copper devices: copper allergy, Wilson’s disease, medical diarrhoea

**Pregnancy** remove device; if pregnancy occurs, increased likelihood that it may be ectopic

**Breast-feeding** not known to be harmful

**Side-effects** uterine or cervical perforation, displacement, expulsion; pelvic infection may be exacerbated, menorrhagia, dysmenorrhoea, allergy; on insertion: pain (allayed by NSAID such as ibuprofen 30 minutes before insertion) and bleeding, occasionally epileptic seizure and vasovagal attack

**Cu-Safe** T300 (Williams) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 300 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £9.11

For uterine length over 5 cm, replacement every 5 years (see notes above)

**Flexi-T** 300 (Durbin) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 300 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £9.47

For uterine length over 5 cm, replacement every 5 years (see notes above)

**Flexi-T** + 380 (Durbin) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier with copper sleeve on each arm, total surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £10.06

For uterine length over 6 cm, replacement every 5 years (see notes above)

**GyneFix** (Williams) 
*Intra-uterine device*, 6 copper sleeves with surface area of 330 mm² on polypropylene thread, net price = £26.64

Suitable for all uterine sizes; replacement every 5 years

**Load** 375 (Durbin) 
*Intra-uterine device*, copper wire, wound on vertical stem of U-shaped plastic carrier, surface area approx. 375 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £8.52

For uterine length over 7 cm, replacement every 5 years (see notes above)

**Mini TT 380® Slimline** (Durbin) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier with copper sleeves fitted flush on to distal portion of each horizontal arm, total surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; easy-loading system, no capsule, net price = £12.46

For minimum uterine length 5 cm, replacement every 5 years (see notes above)

**Multiload® Cu375** (Organon) 
*Intra-uterine device*, as Load 375, with copper surface area approx. 375 mm² and vertical stem length 3.5 cm, net price = £9.24

For uterine length 6-9 cm, replacement every 5 years (see notes above)

**Multi-Safe® 375** (Williams) 
*Intra-uterine device*, copper wire, wound on vertical stem of U-shaped plastic carrier, surface area approx. 375 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £8.80

For uterine length over 6-9 cm, replacement every 5 years (see notes above)

**Multi-Safe® 375 Short Stem** (Williams) 
*Intra-uterine device*, copper wire, wound on vertical stem of U-shaped plastic carrier, surface area approx. 375 mm², impregnated with barium sulphate for radio-opacity, monofilament thread attached to base of vertical stem; preloaded in inserter, net price = £8.80

For uterine length 5-7 cm, replacement every 5 years (see notes above)

**Neo-Safe® T380** (Williams) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, threads attached to base of vertical stem, net price = £13.80

For uterine length 6.5-9 cm, replacement every 5 years (see notes above)

**Nova-T® 380** (Bayer Schering) 
*Intra-uterine device*, copper wire with silver core, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, threads attached to base of vertical stem, net price = £11.97

For uterine length 6.5-9 cm, replacement every 5 years (see notes above)

**T-Safe® 380A QuickLoad** (Williams) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier with copper collar on the distal portion of each arm, total surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, threads attached to base of vertical stem, quick-loading system, net price = £10.29, also available with a capsule loading device (T-Safe® 380A Capped JM), net price = £10.29

For uterine length 6.5-9 cm, replacement every 10 years (see notes above)

**TT 380® Slimline** (Durbin) 
*Intra-uterine device*, copper wire, wound on vertical stem of T-shaped plastic carrier, with copper sleeves fitted flush on to distal portion of each horizontal arm, total surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; easy-loading system, no capsule, net price = £12.46

For uterine length 6-9 cm, replacement every 5 years (see notes above)
radio-opacity, thread attached to base of vertical stem; easy-loading system, no capsule, net price = £12.46
For uterine length 6.5–9 cm; replacement every 10 years (see also notes above)

UT 380 Short® (Durbin)
Intra-uterine device, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; net price = £11.22
For uterine length 5–7 cm; replacement every 5 years (see also notes above)

UT 380 Standard® (Durbin)
Intra-uterine device, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; net price = £11.22
For uterine length 6.5–9 cm; replacement every 5 years (see also notes above)

Other contraceptive devices

Rubber contraceptive caps
Type A Contraceptive Pessary
Opaque rubber, sizes 1 (50 mm), 2 (55 mm), 3 (60 mm), 4 (65 mm), 5 (75 mm), net price = £6.85

Type B Contraceptive Pessary
Opaque rubber, sizes 22 to 31 mm (rising in steps of 3 mm), net price = £8.46

Type C Contraceptive Pessary
Opaque rubber, sizes 1 to 3 (42, 48, and 54 mm), net price = £7.26

Silicone contraceptive caps
Silicone Contraceptive Pessary
Silicone, sizes 22, 26, and 30 mm, net price = £15.00
Brands include FemCap®

Rubber contraceptive diaphragms
Type A Diaphragm with Flat Metal Spring
Transparent rubber with flat metal spring, sizes 55–95 mm (rising in steps of 5 mm), net price = £5.78
Brands include Reflexicon®

Type B Diaphragm with Coiled Metal Spring
Opaque rubber with coiled metal spring, sizes 60–100 mm (rising in steps of 5 mm), net price = £8.79

Type C Arcing Spring Diaphragm
Opaque rubber with arcing spring, sizes 60–95 mm (rising in steps of 5 mm), net price = £7.72

Silicone contraceptive diaphragms
Type B Diaphragm with Coiled Metal Spring
Silicone with coiled metal spring, sizes 60–90 mm (rising in steps of 5 mm), net price = £8.35
Brands include Milex Omunix®

Type C Arcing Spring Diaphragm
Silicone with arcing spring, sizes 60–90 mm (rising in steps of 5 mm), net price = £8.35
Brands include Miles Arcing Style®, Ortho All-flex®

7.3.5 Emergency contraception

Hormonal methods
Hormonal emergency contraceptives include levonorgestrel and ulipristal; either drug should be taken as soon as possible after unprotected intercourse to increase efficacy.

Levonorgestrel is effective if taken within 72 hours (3 days) of unprotected intercourse and may also be used between 72 and 120 hours after unprotected intercourse [unlicensed use], but efficacy decreases with time. Ulipristal, a progesterone receptor modulator, is effective if taken within 120 hours (5 days) of unprotected intercourse.

Levonorgestrel is less effective than insertion of an intra-uterine device (see below). Ulipristal is as effective as levonorgestrel, but its efficacy compared to an intra-uterine device is not yet known.

If vomiting occurs within 2 hours of taking levonorgestrel or within 3 hours of taking ulipristal, a replacement dose should be given. If an antiemetic is required domperidone is preferred.

When prescribing hormonal emergency contraception the doctor should explain:
- that the next period may be early or late;
- that a barrier method of contraception needs to be used until the next period;
- the need to return promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy (and also in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned).

Interactions
The effectiveness of levonorgestrel, and possibly ulipristal, is reduced in women taking enzyme-inducing drugs (and possibly for 4 weeks after stopping); a copper intra-uterine device can be offered instead or the dose of levonorgestrel should be increased to a total of 3 mg taken as a single dose [unlicensed dose—advise women accordingly]. There is no need to increase the dose for emergency contraception if the patient is taking antibiotics that are not enzyme inducers.

LEVONORGESTREL

Indications emergency contraception

Cautions
see notes above; past ectopic pregnancy; severe malabsorption syndromes; active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice; interactions: see notes above and Appendix 1 (progestogens)

Contra-indications
acute porphyria (section 9.8.2)
Pregnancy not known to be harmful
Breast-feeding progestogen-only contraceptives do not affect lactation

Side-effects menstrual irregularities (see also notes above), nausea, low abdominal pain, fatigue, headache, dizziness, breast tenderness, vomiting

Dose
- 1.5 mg as a single dose as soon as possible after coitus (preferably within 12 hours but no later than after 72 hours)

1. Levonelle® One Step (Bayer Schering)
Tablets, levonorgestrel 1.5 mg, net price 1-tab pack = £13.83

1. Can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society of Great Britain

Levonelle® 1500 (Bayer Schering) Tablets, levonorgestrel 1.5 mg, net price 1-tab pack = £5.20

---

radio-opacity, thread attached to base of vertical stem; easy-loading system, no capsule, net price = £12.46
For uterine length 6.5–9 cm; replacement every 10 years (see also notes above)

UT 380 Short® (Durbin)
Intra-uterine device, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; net price = £11.22
For uterine length 5–7 cm; replacement every 5 years (see also notes above)

UT 380 Standard® (Durbin)
Intra-uterine device, copper wire, wound on vertical stem of T-shaped plastic carrier, surface area approx. 380 mm², impregnated with barium sulphate for radio-opacity, thread attached to base of vertical stem; net price = £11.22
For uterine length 6.5–9 cm; replacement every 5 years (see also notes above)

Other contraceptive devices

Rubber contraceptive caps
Type A Contraceptive Pessary
Opaque rubber, sizes 1 (50 mm), 2 (55 mm), 3 (60 mm), 4 (65 mm), 5 (75 mm), net price = £6.85

Type B Contraceptive Pessary
Opaque rubber, sizes 22 to 31 mm (rising in steps of 3 mm), net price = £8.46

Type C Contraceptive Pessary
Opaque rubber, sizes 1 to 3 (42, 48, and 54 mm), net price = £7.26

Silicone contraceptive caps
Silicone Contraceptive Pessary
Silicone, sizes 22, 26, and 30 mm, net price = £15.00
Brands include FemCap®

Rubber contraceptive diaphragms
Type A Diaphragm with Flat Metal Spring
Transparent rubber with flat metal spring, sizes 55–95 mm (rising in steps of 5 mm), net price = £5.78
Brands include Reflexicon®

Type B Diaphragm with Coiled Metal Spring
Opaque rubber with coiled metal spring, sizes 60–100 mm (rising in steps of 5 mm), net price = £8.79

Type C Arcing Spring Diaphragm
Opaque rubber with arcing spring, sizes 60–95 mm (rising in steps of 5 mm), net price = £7.72

Silicone contraceptive diaphragms
Type B Diaphragm with Coiled Metal Spring
Silicone with coiled metal spring, sizes 60–90 mm (rising in steps of 5 mm), net price = £8.35
Brands include Milex Omunix®

Type C Arcing Spring Diaphragm
Silicone with arcing spring, sizes 60–90 mm (rising in steps of 5 mm), net price = £8.35
Brands include Miles Arcing Style®, Ortho All-flex®

Hormonal methods
Hormonal emergency contraceptives include levonorgestrel and ulipristal; either drug should be taken as soon as possible after unprotected intercourse to increase efficacy.

Levonorgestrel is effective if taken within 72 hours (3 days) of unprotected intercourse and may also be used between 72 and 120 hours after unprotected intercourse [unlicensed use], but efficacy decreases with time. Ulipristal, a progesterone receptor modulator, is effective if taken within 120 hours (5 days) of unprotected intercourse.

Levonorgestrel is less effective than insertion of an intra-uterine device (see below). Ulipristal is as effective as levonorgestrel, but its efficacy compared to an intra-uterine device is not yet known.

If vomiting occurs within 2 hours of taking levonorgestrel or within 3 hours of taking ulipristal, a replacement dose should be given. If an antiemetic is required domperidone is preferred.

When prescribing hormonal emergency contraception the doctor should explain:
- that the next period may be early or late;
- that a barrier method of contraception needs to be used until the next period;
- the need to return promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy (and also in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned).

Interactions
The effectiveness of levonorgestrel, and possibly ulipristal, is reduced in women taking enzyme-inducing drugs (and possibly for 4 weeks after stopping); a copper intra-uterine device can be offered instead or the dose of levonorgestrel should be increased to a total of 3 mg taken as a single dose [unlicensed dose—advise women accordingly]. There is no need to increase the dose for emergency contraception if the patient is taking antibiotics that are not enzyme inducers.

LEVONORGESTREL

Indications emergency contraception

Cautions
see notes above; past ectopic pregnancy; severe malabsorption syndromes; active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice; interactions: see notes above and Appendix 1 (progestogens)

Contra-indications
acute porphyria (section 9.8.2)
Pregnancy not known to be harmful
Breast-feeding progestogen-only contraceptives do not affect lactation

Side-effects menstrual irregularities (see also notes above), nausea, low abdominal pain, fatigue, headache, dizziness, breast tenderness, vomiting

Dose
- 1.5 mg as a single dose as soon as possible after coitus (preferably within 12 hours but no later than after 72 hours)

1. Levonelle® One Step (Bayer Schering)
Tablets, levonorgestrel 1.5 mg, net price 1-tab pack = £13.83

1. Can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society of Great Britain

Levonelle® 1500 (Bayer Schering) Tablets, levonorgestrel 1.5 mg, net price 1-tab pack = £5.20
7 Obstetrics, gynaecology, and urinary-tract disorders

7.1.13. For drugs used in the treatment of urinary-tract infections see section 5.1.13.

Drug for genito-urinary disorders

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

**ULIPRISTAL ACETATE**

**Indications** emergency contraception

**Cautions** see notes above; uncontrolled severe asthma; effectiveness of combined hormonal and progestogen-only contraceptives may be reduced—additional precautions (barrier methods) required; repeated use within a menstrual cycle; **interactions:** see notes above and Appendix 1 (ulipristal)

**Hepatic impairment** manufacturer advises avoid in severe impairment—no information available

**Pregnancy** limited information available

**Breast-feeding** manufacturer advises avoid for at least 36 hours—no information available

**Side-effects** gastro-intestinal disturbances (including nausea, vomiting, diarrhoea, and abdominal pain); dizziness, fatigue, headache; menstrual irregularities (see notes above); back pain, muscle spasms; less commonly tremor, hot flushes, uterine spasm, breast tenderness, dry mouth, blurred vision, pruritus, and rash

**Dose**

- 30 mg as a single dose as soon as possible after coitus, but no later than after 120 hours

** ellaOne® (HRA Pharma)**

- Tablets, ulipristal acetate 30 mg, net price 1-tab pack £16.95

**Intra-uterine device**

Insertion of an intra-uterine device is more effective than oral levonorgestrel for emergency contraception. A copper intra-uterine contraceptive device (section 7.3.4) can be inserted up to 120 hours (5 days) after unprotected intercourse; sexually transmitted infections should be tested for and insertion of the device should usually be covered by antibacterial prophylaxis (e.g. azithromycin 1 g as a single dose). If intercourse has occurred more than 5 days previously, the device can still be inserted up to 5 days after the earliest likely calculated ovulation (i.e. within the minimum period before implantation), regardless of the number of episodes of unprotected intercourse earlier in the cycle.

**Alpha-blockers**

The alpha1-selective alpha blockers, alfuzosin, doxazosin, indoramin, prazosin, tamsulosin and terazosin relax smooth muscle in benign prostatic hyperplasia producing an increase in urinary flow-rate and an improvement in obstructive symptoms.

**Cautions** Since alpha1-selective alpha blockers reduce blood pressure, patients receiving antihypertensive treatment may require reduced dosage and specialist supervision. Caution is required in the elderly and in patients undergoing cataract surgery (risk of intra-operative floppy iris syndrome). For **interactions**, see Appendix 1 (alpha-blockers).

**Contra-indications** Alpha-blockers should be avoided in patients with a history of postural hypotension and micturition syncope.

**Side-effects** Side-effects of alpha1-selective alpha blockers include drowsiness, hypotension (notably postural hypotension), syncope, asthenia, dizziness, depression, headache, dry mouth, gastro-intestinal disturbances, oedema, blurred vision, intra-operative floppy iris syndrome (most strongly associated with tamsulosin), rhinitis, erectile disorders (including priapism), tachycardia, and palpitations. Hypersensitivity reactions including rash, pruritus and angioedema have also been reported.

**ALFUZOSIN HYDROCHLORIDE**

**Indications** benign prostatic hyperplasia

**Cautions** see notes above; discontinue if angina worsens

**Driving** May affect performance of skilled tasks e.g. driving

**Contra-indications** see notes above

**Hepatic impairment** initial dose 2.5 mg once daily, adjusted according to response to 2.5 mg twice daily in mild to moderate impairment—avoid if severe; avoid modified-release preparations

**Renal impairment** initial dose 2.5 mg twice daily and adjust according to response; manufacturers advise use modified-release preparations with caution in severe impairment as limited experience

**Side-effects** see notes above; also less commonly flushes and chest pain; also reported liver damage and cholestasis
**DOXAZOSIN**

**Indications**  
benign prostatic hyperplasia; hypertension (section 2.5.4)

**Cautions**  
see notes above and section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 1 mg daily; dose may be doubled at intervals of 1–2 weeks according to response, up to max. 8 mg daily; usual maintenance 2–4 mg daily

**Preparations**  
Section 2.5.4

---

**INDORAMIN**

**Indications**  
benign prostatic hyperplasia; hypertension (section 2.5.4)

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above and section 2.5.4

**Hepatic impairment**  
section 2.5.4

**Renal impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 1 mg daily; dose may be doubled at intervals of 1–2 weeks according to response, up to max. 8 mg daily; usual maintenance 2–4 mg daily

**Preparations**  
Section 2.5.4

---

**TAMSULOSIN HYDROCHLORIDE**

**Indications**  
benign prostatic hyperplasia

**Cautions**  
see notes above

**Driving**  
May affect performance of skilled tasks e.g. driving

**Contra-indications**  
see notes above

**Hepatic impairment**  
avoid in severe impairment

**Renal impairment**  
use with caution if eGFR less than 30 mL/minute/1.73 m²

**Side-effects**  
see notes above

**Dose**  
- Initially 1 mg daily; dose may be increased if necessary by 1 mg every 2 weeks (max. 8 mg daily)

**Preparations**  
Section 2.5.4

---

For prescribing information on dutasteride, see section 6.4.2

**With dutasteride**

For prescribing information on dutasteride, see section 6.4.2

**Flomaxtra® XL** (Astellas)

**Indications**  
benign prostatic hyperplasia; hypertension, congestive heart failure and Raynaud’s syndrome (section 2.5.4)

**Cautions**  
see notes above

**Contra-indications**  
see notes above

**Hepatic impairment**  
section 2.5.4

**Renal impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 500 micrograms twice daily for 3–7 days, subsequently adjusted according to response; usual maintenance (and max.) 2 mg twice daily; ELDERLY initiate with lowest possible dose

**Preparations**  
Section 2.5.4

---

**DOXAZOSIN**

**Indications**  
benign prostatic hyperplasia; hypertension (section 2.5.4)

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above

**Hepatic impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 1 mg daily; dose may be doubled at intervals of 1–2 weeks according to response, up to max. 8 mg daily; usual maintenance 2–4 mg daily

**Preparations**  
Section 2.5.4

---

**INDORAMIN**

**Indications**  
benign prostatic hyperplasia; hypertension (section 2.5.4)

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above and section 2.5.4

**Hepatic impairment**  
section 2.5.4

**Renal impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

---

**Dose**  
- 20 mg twice daily; increased if necessary by 20 mg every 2 weeks to max. 100 mg daily in divided doses; ELDERLY; 20 mg at night may be adequate

**Doralese®** (Chemidex)

**Indications**  
benign prostatic hyperplasia

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above and section 2.5.4

**Hepatic impairment**  
section 2.5.4

**Renal impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 500 micrograms twice daily for 3–7 days, subsequently adjusted according to response; usual maintenance (and max.) 2 mg twice daily; ELDERLY initiate with lowest possible dose

**Preparations**  
Section 2.5.4

---

**TAMSULOSIN HYDROCHLORIDE**

**Indications**  
benign prostatic hyperplasia

**Driving**  
May affect performance of skilled tasks e.g. driving

**Contra-indications**  
see notes above

**Hepatic impairment**  
avoid in severe impairment

**Renal impairment**  
use with caution if eGFR less than 30 mL/minute/1.73 m²

**Side-effects**  
see notes above

**Dose**  
- 400 micrograms daily

**FLOMAX® XL** (Winthrop)

**Indications**  
benign prostatic hyperplasia

**Cautions**  
see notes above

**Driving**  
May affect performance of skilled tasks e.g. driving

**Contra-indications**  
see notes above

**Hepatic impairment**  
avoid in severe impairment

**Renal impairment**  
use with caution if eGFR less than 30 mL/minute/1.73 m²

**Side-effects**  
see notes above

**Dose**  
- 20 mg twice daily; increased if necessary by 20 mg every 2 weeks to max. 100 mg daily in divided doses; ELDERLY; 20 mg at night may be adequate

**Doralese®** (Chemidex)

**Indications**  
benign prostatic hyperplasia

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above and section 2.5.4

**Hepatic impairment**  
section 2.5.4

**Renal impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 500 micrograms twice daily for 3–7 days, subsequently adjusted according to response; usual maintenance (and max.) 2 mg twice daily; ELDERLY initiate with lowest possible dose

**Preparations**  
Section 2.5.4

---

**DOXAZOSIN**

**Indications**  
benign prostatic hyperplasia; hypertension (section 2.5.4)

**Cautions**  
see notes above and section 2.5.4

**Contra-indications**  
see notes above

**Hepatic impairment**  
section 2.5.4

**Side-effects**  
see notes above and section 2.5.4

**Dose**  
- Initially 1 mg daily; dose may be doubled at intervals of 1–2 weeks according to response, up to max. 8 mg daily; usual maintenance 2–4 mg daily

**Preparations**  
Section 2.5.4
7.4.2 Drugs for urinary frequency, enuresis, and incontinence

**TeraZosin**

- **Indications**: benign prostatic hyperplasia; hypertension (section 2.5.4)
- **Cautions**: see notes above and section 2.5.4
- **Driving**: May affect performance of skilled tasks e.g. driving
- **Contra-indications**: see notes above
- **Side-effects**: see notes above and section 2.5.4
- **Dose**: Initially 1 mg at bedtime; if necessary dose may be doubled at intervals of 1–2 weeks according to response, up to max. 10 mg once daily; usual maintenance 5–10 mg daily
- **First dose effect**: First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patient should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely

- **Terazosin** (Non-proprietary)
  - **Tablets**: terazosin (as hydrochloride) 2 mg, net price 28-tab pack = £2.16; 5 mg, 28-tab pack = £2.58; 10 mg, 28-tab pack = £7.88. Counselling, initial dose, driving advice available

**Distigmine Bromide**

- **Indications**: postoperative urinary retention (see notes above), neurogenic bladder; myasthenia gravis (section 10.2.1)
- **Cautions**: peptic ulcer; conditions where increased motility of the urinary or gastro-intestinal tract could be harmful; oesophagitis; cardiovascular disease; bronchospasm; epilepsy; parkinsonism; **interactions**: Appendix 1 (parasympathomimetics)
- **Contra-indications**: intestinal or urinary obstruction; severe circulatory insufficiency; asthma
- **Pregnancy**: manufacturer advises avoid (may stimulate uterine contractions)
- **Breast-feeding**: manufacturer advises avoid—no information available
- **Side-effects**: abdominal pain, diarrhoea, increased salivation; bradycardia, AV block, hypotension; dyspnoea; muscle twitching; increased lacrimation, miosis; increased sweating
- **Dose**: Urinary retention, 5 mg daily, half an hour before breakfast
- **Neurogenic bladder, 5 mg daily, half an hour before breakfast
- **Driving**: May affect performance of skilled tasks e.g. driving

**Parasympathomimetics**

The parasympathomimetic **bethanechol** increases detrusor muscle contraction. However, it has only a limited role in the relief of urinary retention; its use has been superseded by catheterisation.

**Distigmine** inhibits the breakdown of acetylcholine. It may help patients with an upper motor neurone neurogenic bladder.

**Bethanechol Chloride**

- **Indications**: urinary retention, but see notes above
- **Cautions**: autonomic neuropathy (use lower initial dose); **interactions**: Appendix 1 (parasympathomimetics)
- **Contra-indications**: peptic ulcer; intestinal or urinary obstruction; conditions where increased motility of the urinary or gastro-intestinal tract could be harmful; cardiovascular disorders (including recent myocardial infarction, bradycardia, and heart block); hypotension; obstructive airways disease; epilepsy; parkinsonism; hyperhydrosis
- **Pregnancy**: manufacturer advises avoid—no information available
- **Breast-feeding**: manufacturer advises avoid; gastro-intestinal disturbances in infant reported
- **Side-effects**: nausea, vomiting, diarrhoea, abdominal pain, increased salivation, eructation; flushing, hypotension, bradycardia; bronchoconstriction, rhinorrhea; headache; increased lacrimation; increased sweating
- **Dose**: 10–25 mg 3–4 times daily half an hour before food

**Myotonine** (Glenwood)

- **Tablets**: scored, bethanechol chloride 10 mg, net price 100-tab pack = £5.07; 25 mg, 100-tab pack = £6.48. Label: 22

**Duloxetine**

- **Tablets**: scored, terazosin (as hydrochloride) 2 mg (yellow) and 2 mg (blue), 28-tab pack = £8.57; starter pack = £7.88. Counselling, initial dose, driving advice available

**Urinary incontinence**

Incontinence in adults which arises from detrusor instability is managed by combining drug therapy with conservative methods for managing urge incontinence such as pelvic floor exercises and bladder training; stress incontinence is generally managed by non-drug methods. Duloxetine, an inhibitor of serotonin and noradrenaline re-uptake can be added and is licensed for the treatment of moderate to severe stress incontinence in women; it may be more effective when used as an adjunct to pelvic floor exercises.

Antimuscarinic drugs reduce symptoms of urgency and urge incontinence and increase bladder capacity. Oxybutynin also has a direct relaxant effect on urinary smooth muscle. Side-effects limit the use of oxybutynin, but they may be reduced by starting at a lower dose. A modified-release preparation of oxybutynin is effective and has fewer side-effects; a transdermal patch is also available. The efficacy and side-effects of tolterodine are comparable to those of modified-release oxybutynin. Flavoxate has less marked side-effects but it is also less effective. Darifenacin, fesoterodine, propiverine,
The Scottish Medicines Consortium (p. 4) has advised that solifenacin (Toviaz®) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome. Propantheline and tricyclic antidepressants were used for severe urge incontinence but they are little used now because of their side-effects. The use of imipramine is limited by its potential to cause cardiac side-effects. Purified bovine collagen implant (Contigen®, Bard) is indicated for urinary incontinence caused by intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism). The implant should be inserted only by surgeons or physicians trained in the technique for injection of the implant.

Cautions Antimuscarinic drugs should be used with caution in the elderly (especially if frail), in those with autonomic neuropathy, and in those susceptible to angle-closure glaucoma. They should also be used with caution in hiatus hernia with reflux oesophagitis. Antimuscarinics can worsen hyperthyroidism, coronary artery disease, congestive heart failure, hypertension, prostatic hyperplasia, arrhythmias, and tachycardia. For interactions, see Appendix 1 (antimuscarinics).

Contra-indications Antimuscarinic drugs should be avoided in patients with myasthenia gravis, significant bladder outlet obstruction or urinary retention, severe ulcerative colitis, toxic megacolon, and in gastro-intestinal obstruction or intestinal atony.

Side-effects Antimuscarinics can cause constipation, flatulence, decrease appetite, dry mouth, palpitation, and skin reactions (including dry skin, rash, and photosensitivity); also headache, diarrhoea, angioedema, arthralgias, and tachycardia. Central nervous system stimulation, such as restlessness, disorientation, hallucination, and convulsion may occur; children are at higher risk of these effects. Antimuscarinic drugs can reduce sweating, leading to heat sensations and fainting in hot environments or in patients with fever; very rarely may precipitate angle-closure glaucoma.

**DULOXETINE**

Indications moderate to severe stress urinary incontinence in women; major depressive disorder (section 4.3.4); diabetic neuropathy (section 4.3.4); generalised anxiety disorder (section 4.3.4)

Cautions elderly; cardiac disease; hypertension (avoid if uncontrolled); history of mania; history of seizures; raised intra-ocular pressure; susceptibility to angle-closure glaucoma; bleeding disorders or concomitant use of drugs that increase risk of bleeding; interactions; Appendix 1 (duloxetine)

Withdrawal Nausea, vomiting, headache, anxiety, dizziness, paraesthesia, sleep disturbances, and tremor are the most common features of abrupt withdrawal or marked reduction of the dose; dose should be reduced over at least 1–2 weeks

Hepatic impairment manufacturer advises avoid

Renal impairment avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy toxicity in animal studies—avoid in patients with stress urinary incontinence; risk of neonatal withdrawal symptoms if used near term

Breast-feeding present in milk—manufacturer advises avoid

Side-effects nausea, vomiting, dyspepsia, constipation, diarrhoea, abdominal pain, weight changes, decreased appetite, flatulence, dry mouth, palpitation, hot flush; insomnia, abnormal dreams, paraesthesia, drowsiness, anxiety, headache, dizziness, fatigue, weakness, tremor, nervousness, anorexia; sexual dysfunction; visual disturbances; sweating, pruritus; less commonly gastritis, hallucosis, hepatitis, bruxism, tachycardia, hypertension, postural hypotension; syncope, raised cholesterol, vertigo, taste disturbance, cold extremities, impaired temperature regulation, impaired attention, movement disorders, muscle twitching, musculoskeletal pain, thirst, stomatitis, hypothyroidism, urinary disorders, and photosensitivity; rarely mania; very rarely angle-closure glaucoma; also reported suprapontine arthrythmia, chest pain, hallucinations, suicidal behaviour (see Suicidal Behaviour and Antidepressant Therapy, p. 233), seizures, hypersensitivity reactions including urticaria, angioedema, rash (including Stevens-Johnson syndrome) and anaphylaxis, hyponatraemia (see Hyponatraemia and Antidepressant Therapy, p. 233)

Dose

ADULT over 18 years, 40 mg twice daily, assess for benefit and tolerability after 2–4 weeks

Note Initial dose of 20 mg twice daily for 2 weeks can minimise side-effects

**DARIFENACIN**

Indications urinary frequency, urgency, and incontinence

Cautions see notes above

Contra-indications see notes above

Hepatic impairment max. 7.5 mg daily in moderate impairment; avoid in severe impairment

Pregnancy manufacturer advises avoid— toxicity in animal studies

Breast-feeding present in milk in animal studies—manufacturer advises caution

Side-effects see notes above; also less commonly ulcerative stomatitis, oedema, hypertension, dyspnoea, cough, rhinitis, weakness, insomnia, impotence, and vaginitis

Dose

ADULT over 18 years, 7.5 mg once daily, increased if necessary after 2 weeks to 15 mg once daily

**Emselex** (Novartis) Tablets, m/r, darifenacin (as hydrobromide) 7.5 mg (white), net price 28-tab pack = £20.90; 15 mg (peach), 28-tab pack = £20.90. Label: 3, 25

**DULOXETINE**

Indications moderate to severe stress urinary incontinence in women; major depressive disorder (section 4.3.4); diabetic neuropathy (section 4.3.4); generalised anxiety disorder (section 4.3.4)

Cautions elderly; cardiac disease; hypertension (avoid if uncontrolled); history of mania; history of seizures; raised intra-ocular pressure; susceptibility to angle-closure glaucoma; bleeding disorders or concomitant use of drugs that increase risk of bleeding; interactions; Appendix 1 (duloxetine)

Withdrawal Nausea, vomiting, headache, anxiety, dizziness, paraesthesia, sleep disturbances, and tremor are the most common features of abrupt withdrawal or marked reduction of the dose; dose should be reduced over at least 1–2 weeks

Hepatic impairment manufacturer advises avoid

Renal impairment avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy toxicity in animal studies—avoid in patients with stress urinary incontinence; risk of neonatal withdrawal symptoms if used near term

Breast-feeding present in milk—manufacturer advises avoid

Side-effects nausea, vomiting, dyspepsia, constipation, diarrhoea, abdominal pain, weight changes, decreased appetite, flatulence, dry mouth, palpitation, hot flush; insomnia, abnormal dreams, paraesthesia, drowsiness, anxiety, headache, dizziness, fatigue, weakness, tremor, nervousness, anorexia; sexual dysfunction; visual disturbances; sweating, pruritus; less commonly gastritis, hallucosis, hepatitis, bruxism, tachycardia, hypertension, postural hypotension; syncope, raised cholesterol, vertigo, taste disturbance, cold extremities, impaired temperature regulation, impaired attention, movement disorders, muscle twitching, musculoskeletal pain, thirst, stomatitis, hypothyroidism, urinary disorders, and photosensitivity; rarely mania; very rarely angle-closure glaucoma; also reported suprapontine arthrythmia, chest pain, hallucinations, suicidal behaviour (see Suicidal Behaviour and Antidepressant Therapy, p. 233), seizures, hypersensitivity reactions including urticaria, angioedema, rash (including Stevens-Johnson syndrome) and anaphylaxis, hyponatraemia (see Hyponatraemia and Antidepressant Therapy, p. 233)

Dose

ADULT over 18 years, 40 mg twice daily, assess for benefit and tolerability after 2–4 weeks

Note Initial dose of 20 mg twice daily for 2 weeks can minimise side-effects

**DARIFENACIN**

Indications urinary frequency, urgency, and incontinence

Cautions see notes above

Contra-indications see notes above

Hepatic impairment max. 7.5 mg daily in moderate impairment; avoid in severe impairment

Pregnancy manufacturer advises avoid— toxicity in animal studies

Breast-feeding present in milk in animal studies—manufacturer advises caution

Side-effects see notes above; also less commonly ulcerative stomatitis, oedema, hypertension, dyspnoea, cough, rhinitis, weakness, insomnia, impotence, and vaginitis

Dose

ADULT over 18 years, 7.5 mg once daily, increased if necessary after 2 weeks to 15 mg once daily

**Emselex** (Novartis) Tablets, m/r, darifenacin (as hydrobromide) 7.5 mg (white), net price 28-tab pack = £20.90; 15 mg (peach), 28-tab pack = £20.90. Label: 3, 25
### 7.4.2 Drugs for urinary frequency, enuresis, and incontinence

<table>
<thead>
<tr>
<th><strong>Cymbalta</strong> (Lilly)</th>
<th><strong>Toviaz</strong> (Pfizer)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Urinary frequency, urgency, and urge incontinence</td>
<td>Urinary frequency, urgency, and urge incontinence; dysuria, urgency; bladder spasms due to catheterisation, cystocele, or surgery</td>
</tr>
<tr>
<td><strong>Cautions</strong></td>
<td><strong>Cautions</strong></td>
</tr>
<tr>
<td>Refer to the nearest equivalent daily dose of oxybutynin approx. 3.9 mg/24 hours</td>
<td>Refer to the nearest equivalent daily dose of oxybutynin approx. 3.9 mg/24 hours</td>
</tr>
<tr>
<td><strong>Contra-indications</strong></td>
<td><strong>Contra-indications</strong></td>
</tr>
<tr>
<td>See notes above</td>
<td>See notes above; gastro-oesophageal reflux disease</td>
</tr>
<tr>
<td><strong>Hepatic impairment</strong></td>
<td><strong>Hepatic impairment</strong></td>
</tr>
<tr>
<td>Manufacturer advises caution - no data available</td>
<td>None</td>
</tr>
<tr>
<td><strong>Renal impairment</strong></td>
<td><strong>Renal impairment</strong></td>
</tr>
<tr>
<td>Manufacturer advises caution</td>
<td>Manufacturer advises caution</td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td><strong>Pregnancy</strong></td>
</tr>
<tr>
<td>Manufacturer advises avoid unless safer alternative</td>
<td></td>
</tr>
</tbody>
</table>
PROPANTHELINE BROMIDE

**Indications**  
adult enuresis

**Cautions**  
see notes above; ulcerative colitis

**Contra-indications**  
see notes above

**Hepatic impairment**  
manufacturer advises caution

**Renal impairment**  
manufacturer advises caution

**Pregnancy**  
manufacturer advises avoid—no information available

**Breast-feeding**  
may suppress lactation

**Side-effects**  
see notes above; also facial flushing

**Dose**
- Initially 15 mg 3 times daily at least one hour before food and 30 mg at bedtime, subsequently adjusted according to response (max. 120 mg daily)

**Preparations**
Section 1.2

**TOLTERODINE TARTRATE**

**Indications**  
see under Dose

**Cautions**  
see notes above; history of QT-interval prolongation; concomitant use with other drugs known to prolong QT interval

**Contra-indications**  
see notes above

**Hepatic impairment**  
reduce dose to 1 mg twice daily; avoid Detrusitol® XL

**Renal impairment**  
reduce dose to 1 mg twice daily if eGFR less than 30 mL/minute/1.73 m²; avoid Detrusitol® XL if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy**  
manufacturer advises avoid—toxicity in animal studies

**Breast-feeding**  
manufacturer advises avoid—no information available

**Side-effects**  
see notes above; also chest pain, peripheral oedema; sinusitis, bronchitis; paraesthesia, fatigue, vertigo, weight gain; flushing also reported

**Dose**
- Urinary frequency, urgency, and incontinence, ADULT over 18 years, 2 mg twice daily; reduce to 1 mg twice daily if necessary to minimise side-effects; CHILD 2–18 years, see BNF for Children
- Nocturnal enuresis associated with overactive bladder, CHILD 7–18 years, see BNF for Children

**Detrusitol®** (Pharmacia)  
Tablets, f/c, tolterodine tartrate 1 mg, net price 56-tab pack = £29.03; 2 mg, net price 56-tab pack = £30.56. Label: 3

**Modified release**

**Detrusitol® XL** (Pharmacia)  
Capsules, blue, m/r, tolterodine tartrate 4 mg, net price 28-cap pack = £25.78. Label: 3, 25

**SOLIFENACIN SUCCINATE**

**Indications**  
urinary frequency, urgency and urge incontinence

**Cautions**  
see notes above; neurogenic bladder disorder

**Contra-indications**  
see notes above

**Hepatic impairment**  
max. 5 mg daily in moderate impairment; avoid in moderate impairment in those already taking itraconazole, ketoconazole, nelfinavir, or ritonavir; avoid in severe impairment

**Renal impairment**  
max. 5 mg daily if eGFR less than 30 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m² in those already taking itraconazole, ketoconazole, nelfinavir, or ritonavir

**Pregnancy**  
manufacturer advises caution—no information available

**Breast-feeding**  
manufacturer advises avoid—present in milk in animal studies

**Side-effects**  
see notes above; also gastro-oesophageal reflux, oedema

**Dose**
- ADULT over 18 years, 5 mg daily, increased if necessary to 10 mg once daily
- Child 2–18 years, see BNF for Children

**Kentera** (Amdipharm)  
Tablets, f/c, solifenacin succinate 5 mg (yellow), net price 30-tab pack = £27.62; 10 mg (pink), 30-tab pack = £35.91. Label: 3

**Modified release**

**Kentera® XL** (Amdipharm)  
Tablets, blue, m/r, solifenacin succinate 5 mg (yellow), net price 56-tab pack = £35.91. Label: 3

**TROSPUIM CHLORIDE**

**Indications**  
urinary frequency, urgency and incontinence

**Cautions**  
see notes above

**Contra-indications**  
see notes above
7 Obstetrics, gynaecology, and urinary-tract disorders

7.4.3 Drugs used in urological pain

**Hepatic impairment** manufacturer advises caution in mild to moderate impairment; avoid in severe impairment

**Renal impairment** use with caution; reduce dose to 20 mg once daily or 20 mg on alternate days if eGFR 10–30 mL/minute/1.73 m²; avoid Regurin® XL

**Pregnancy** manufacturer advises caution

**Breast-feeding** see notes above; rarely chest pain, dyspnoea, and asthenia; very rarely myalgia and arthralgia

**Dose**
- **ADULT** and **CHILD** over 12 years, 20 mg twice daily before food
- **Trospium chloride** (Non-proprietary) [®]
  - Tablets, 1/10 c, trospium chloride 20 mg, net price 60-tab pack = £18.20. Label: 23
  - Brands include Flotros®
- **Regurin**® (Speciality European) [®]
  - Tablets, brown-yellow, f/c, trospium chloride 20 mg, net price 60-tab pack = £26.00. Label: 23
- **Modified release**
  - **Regurin**® XL (Speciality European) [®]
    - Capsules, orange/white, m/r, trospium chloride 60 mg, net price 28-cap pack = £23.05. Label: 23, 25
  - **Dose** ADULT over 18 years, 60 mg once daily

**Nocturnal enuresis**

Nocturnal enuresis is common in young children, but persists in as many as 5% by 10 years of age. Treatment is not appropriate in children under 5 years and it is usually not needed in those aged under 7 years and in cases where the child and parents are not anxious about the bedwetting; however, children over 10 years usually require prompt treatment. An enuresis alarm should be first-line treatment for well-motivated, well-supported children aged over 7 years because alarms have a lower relapse rate than drug treatment when discontinued. Use of an alarm can be combined with drug therapy if either method alone is unsuccessful.

Drug therapy is not usually appropriate for children under 7 years of age; it can be used when alternative measures have failed, preferably on a short-term basis, for example to cover periods away from home, or if the child and family are anxious about the condition.

Desmopressin (section 6.5.2), an analogue of vasopressin, is used for nocturnal enuresis; it is given by oral or by sublingual administration. Particular care is needed to avoid fluid overload. Treatment should not be continued for longer than 3 months without interrupting treatment for 1 week for full re-assessment. Desmopressin should not be given intranasally for nocturnal enuresis due to an increased incidence of side-effects.

Tricyclic antidepressants (section 4.3.1) such as imipramine, and rarely amitriptyline and nortriptyline, are used but behavioural disturbances can occur and relapse is common after withdrawal. Treatment should not normally exceed 3 months unless a full physical examination is made and the child is fully re-assessed; toxicity following overdosage with tricyclics is of particular concern.

Nocturnal enuresis associated with daytime symptoms (overactive bladder) can be managed by antimuscarinic drugs (see Urinary incontinence, p. 508), with the addition of desmopressin if necessary.

**POTASSIUM CITRATE**

**Indications** relief of discomfort in mild urinary-tract infections; alkalinisation of urine

**Cautions** cardiac disease; elderly; interactions: Appendix 1 (potassium salts)

**Renal impairment** close monitoring required—high risk of hyperkalaemia; avoid in severe impairment

**Side-effects** hyperkalaemia on prolonged high dosage, mild diuresis

**Dose**
- See under preparation

**Potassium Citrate Mixture BP** (Potassium Citrate Oral Solution)

- **Oral solution**, potassium citrate 30%, citric acid monohydrate 5% in a suitable vehicle with a lemon flavour. Extemporaneous preparations should be recently prepared according to the following formula: potassium citrate 3 g, citric acid monohydrate 500 mg, syrup 2.5 mL, quillaja tincture 0.1 mL, lemon spirit 0.05 mL, double-strength chloroform water 3 mL, water to 10 mL. Contains about 28 mmol K⁺/10 mL. Label: 27
- **Dose** 10 mL 3 times daily well diluted with water

Proprietary brands of potassium citrate are on sale to the public for the relief of discomfort in mild urinary-tract infections

**SODIUM BICARBONATE**

**Indications** relief of discomfort in mild urinary-tract infections; alkalinisation of urine

**Cautions** cardiac disease; patients on sodium-restricted diet; elderly; avoid prolonged use; interactions: Appendix 1 (antacids)

**Hepatic impairment** section 1.1.1

**Renal impairment** avoid; specialised role in some forms of renal disease, see section 9.2.1.3

**Pregnancy** use with caution
Side-effects  eructation, alkalosis on prolonged use

Dose  • 3 g in water every 2 hours until urinary pH exceeds 7; maintenance of alkaline urine 5–10 g daily

Preparations  Section 9.2.1.3

SODIUM CITRATE

Indications  relief of discomfort in mild urinary-tract infections

Cautions  cardiac disease; hypertension; patients on a sodium-restricted diet; elderly; interactions: Appendix 1 (sodium citrate)

Renal impairment  section 1.1.1

Pregnancy  use with caution

Side-effects  mild diuresis

Note  Proprietary brands of sodium citrate are on sale to the public for the relief of discomfort in mild urinary-tract infections

Other preparations for urinary disorders

A terpene mixture (Rowatinex®) is claimed to be of benefit in urolithiasis for the expulsion of calculi.

Rowatinex® (Rowa)  
Capsules, yellow, e/c, anethol 4 mg, borneol 10 mg, camphene 15 mg, cineole 3 mg, fenchone 4 mg, pinene 31 mg, net price 50 = £7.35. Label: 25

Dose  1–2 capsules 3–4 times daily before food; CHILD not recommended

7.4.4 Bladder instillations and urological surgery

Bladder infection  Various solutions are available as irrigations or washouts.

Aqueous chlorhexidine (section 13.11.2) can be used in the management of common infections of the bladder but it is ineffective against most Pseudomonas spp. Solutions containing chlorhexidine 1 in 5000 (0.02%) are used but they may irritate the mucosa and cause burning and haematuria (in which case they should be discontinued); sterile sodium chloride solution 0.9% (physiological saline) is usually adequate and is preferred as a mechanical irrigant.

Continuous bladder irrigation with amphotericin 50 micrograms/mL (section 5.2.3) may be of value in mycotic infections.

Dissolution of blood clots  Clot retention is usually treated by irrigation with sterile sodium chloride solution 0.9% but sterile sodium citrate solution for bladder irrigation 3% may also be helpful.

Bladder cancer  Bladder instillations of doxorubicin (section 8.1.2), mitomycin (section 8.1.2), and thiopeta (section 8.1.1) are used for recurrent superficial bladder tumours. Such instillations reduce systemic side-effects; adverse effects on the bladder (e.g. micturition disorders and reduction in bladder capacity) may occur.

Instillation of epirubicin (section 8.1.2) is used for treatment and prophylaxis of certain forms of superficial bladder cancer; instillation of doxorubicin (section 8.1.2) is also used for some papillary tumours.

Instillation of BCG (Bacillus Calmette-Guérin), a live attenuated strain derived from Mycobacterium bovis (section 8.2.4), is licensed for the treatment of primary or recurrent bladder carcinoma in-situ and for the prevention of recurrence following transurethral resection.

Interstitial cystitis  Dimethyl sulfoxide may be used for symptomatic relief in patients with interstitial cystitis (Hunner’s ulcer). 50 mL of a 50% solution (Rimso-50®—available from ‘special-order’ manufacturers or specialist importing companies, p. 988) is instilled into the bladder, retained for 15 minutes, and voided by the patient. Treatment is repeated at intervals of 2 weeks. Bladder spasm and hypersensitivity reactions may occur and long-term use requires ophthalmic, renal, and hepatic assessment at intervals of 6 months. Interactions: see Appendix 1 (dimethyl sulfoxide).

SODIUM CITRATE

Indications  bladder washouts, see notes above

Sterile Sodium Citrate Solution for Bladder Irrigation  sodium citrate 3%, dilute hydrochloric acid 0.2%, in purified water, freshly boiled and cooled, and sterilised

Urological surgery

There is a high risk of fluid absorption from the irrigant used in endoscopic surgery within the urinary tract; if this occurs in excess, hypervolaemia, haemolysis, and renal failure may result. Glycine irrigation solution 1.5% is the irrigant of choice for transurethral resection of the prostate gland and bladder tumours; sterile sodium chloride solution 0.9% (physiological saline) is used for percutaneous renal surgery.

GLYCINE

Indications  bladder irrigation during urological surgery; see notes above

Cautions  see notes above

Side-effects  see notes above

Glycine Irrigation Solution (Non-proprietary)

Irrigation solution, glycine 1.5% in water for injections

Maintenance of indwelling urinary catheters

The deposition which occurs in catheterised patients is usually chiefly composed of phosphate and to minimise this the catheter (if latex) should be changed at least as often as every 6 weeks. If the catheter is to be left for longer periods a silicone catheter should be used together with the appropriate use of catheter maintenance solutions. Repeated blockage usually indicates that the catheter needs to be changed.
514 7.4.5 Drugs for erectile dysfunction

CATHETER PATENCY SOLUTIONS

Chlorhexidine 0.02%
Brands include Uro-Tainer Chlorhexidine®, 100-mL sachet = £2.60

Sodium chloride 0.9%
Brands include OptiFlo S®, 50- and 100-mL sachets = £3.20; Uriflex S®, 100-mL sachet = £2.40; Uriflex S™, with integral drug additive port, 100-mL sachet = £2.40; Uro-Tainer Sodium Chloride®, 50- and 100-mL sachets = £3.25; Uro-Tainer M®, with integral drug additive port, 50- and 100-mL sachets = £2.90

Solution G
Citic acid 3.23%, magnesium oxide 0.38%, sodium bicarbonate 0.7%, disodium edetate 0.01%. Brands include Optiflo G®, 50- and 100-mL sachets = £3.40; Uriflex G®, 100-mL sachet = £2.40; Uro-Tainer® Twin Suby G, 2 x 30-mL = £4.46

Solution R
Citic acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%. Brands include Optiflo R®, 50- and 100-mL sachets = £3.40; Uriflex R®, 100-mL sachet = £2.40; Uro-Tainer® Twin Soluto R, 2 x 30-mL = £4.46

7.4.5 Drugs for erectile dysfunction

Reasons for failure to produce a satisfactory erection include psychogenic, vascular, neurogenic, and endocrine abnormalities; impotence can also be drug-induced. Intracavernosal injection or urethral application of vasoactive drugs under careful medical supervision is used for both diagnostic and therapeutic purposes. Erectile disorders may also be treated with drugs given by mouth which increase the blood flow to the penis. Drugs should be used with caution if the penis is deformed (e.g. in angulation, cavernosal fibrosis, and Peyronie’s disease).

Priapism
If priapism occurs with alprostadil, treatment should not be delayed more than 6 hours and is as follows:

Initial therapy by penile aspiration—using aseptic technique a 19–21 gauge butterfly needle inserted into the corpus cavernosum and 20–50 mL of blood aspirated; if necessary the procedure may be repeated on the opposite side. If initial aspiration is unsuccessful a second 19–21 gauge butterfly needle inserted into the opposite corpus cavernosum and sterile physiological saline introduced through the first needle and drained through the second.

If aspiration and lavage of corpora are unsuccessful, cautious intracavernosal injection of a sympathomimetic (section 2.7.2) with action on alpha-adrenergic receptors, continuously monitoring blood pressure and pulse (extreme caution: coronary heart disease, hypertension, cerebral ischaemia or if taking antidepressant) as follows:

- intracavernosal injections of phenylephrine 100–200 micrograms (0.5–1 mL of a 200 microgram/mL solution) every 5–10 minutes; max. total dose 1 mg [unlicensed indication] [important: if suitable strength of phenylephrine injection not available may be specially prepared by diluting 0.1 mL of the phenylephrine 1% (10 mg/mL) injection (section 2.7.2) to 5 mL with sodium chloride 0.9%]; alternatively
- intracavernosal injections of adrenaline 10–20 micrograms (0.5–1 mL of a 20 microgram/mL solution) every 5–10 minutes; max. total dose 100 micrograms [unlicensed indication] [important: if suitable strength of adrenaline not available may be specially prepared by diluting 0.1 mL of the adrenaline 1 in 1000 (1 mg/mL, section 3.4.3) injection to 5 mL with sodium chloride 0.9%]; alternatively
- intracavernosal injection of metaraminol (caution: has been associated with fatal hypertensive crises); metaraminol 1 mg (0.1 mL of 10 mg/mL metaraminol injection, section 2.7.2) is diluted to 50 mL with sodium chloride injection 0.9% and given carefully by slow injection into the corpora in 5–10 mL injections every 15 minutes [unlicensed indication].

If necessary the sympathomimetic injections can be followed by further aspiration of blood through the same butterfly needle. If sympathomimetics unsuccessful, urgent surgical referral for management (possibly including shunt procedure).

Prescribing on the NHS Drug treatments for erectile dysfunction may only be prescribed on the NHS under certain circumstances (see individual preparations). The Department of Health (England) has recommended that treatment should also be available from specialist services (commissioned by Health Authorities and Primary Care Groups, and operating under local agreement) when the condition is causing severe distress; specialist centres should use form FP10(HP) or form HBP in Scotland or form WP10HP in Wales and endorse them ‘SLS’ if the treatment is to be dispensed in the community. The following criteria should be considered when assessing distress:

- significant disruption to normal social and occupational activities;
- a marked effect on mood, behaviour, social and environmental awareness;
- a marked effect on interpersonal relationships.

Alprostadil
Alprostadil (prostaglandin E₁) is given by intracavernosal injection or intrarethral application for the management of erectile dysfunction (after exclusion of treatable medical causes); it is also used as a diagnostic test.

ALPROSTADIL

Indications erectile dysfunction (including aid to diagnosis)

Cautions priapism—patients should be instructed to report any erection lasting 4 hours or longer—for management, see section 7.4.5; anatomical deformations of penis (painful erection more likely)—follow up
regularly to detect signs of penile fibrosis (consider discontinuation if angulation, cavernosal fibrosis or Peyronie’s disease develop); interactions: Appendix 1 (prostaglandins)

Contra-indications predisposition to prolonged erection (as in sickle cell anaemia, multiple myeloma or leukaemia; not for use with other agents for erectile dysfunction, in patients with penile implants or when sexual activity medically inadvisable; urethral application also contra-indicated in urethral stricture, severe hypospadia, severe curvature, balanitis, urethritis

Side-effects hypotension, hypertension; dizziness, headache; penile pain, other localised pain (buttocks, leg, testicular, abdominal); influenza-like syndrome; urethral burning, urethral bleeding; injection site reactions including penile fibrosis, penile oedema, penile rash, haematoma, haemosiderin deposits; less commonly nausea, dry mouth, vasodilatation, syncope, supraventricular extrasystole, rapid pulse, asthenia, leg cramps, pelvic pain, scrotal or testicular oedema, scrotal erythema, testicular thickening, mic- turation difficulties, haematuria, mydriasis, and sweating; local reactions including penile warmth, pruritus, irritation, penile numbness or sensitivity, balanitis, phimosis, priapism (see section 7.4.5 and under Cautions), abnormal ejaculation; rarely vertigo, urinary-tract infection, and hypersensitivity reactions (including rash, erythema, urticaria, and anaphylaxis)

Dose

- See under preparations below

![Intracavernosal injection

1Caverject (Pharmacia). 2MUSE, 3Viridal

Injection, powder for reconstitution, alprostadil, net price 5-microgram vial = £7.73; 10-microgram vial = £9.24; 20-microgram vial = £11.94; 40-microgram vial = £21.58 (all with diluent-filled syringe, needles and swabs)

Caverject Dual Chamber, double-chamber cartridges (containing alprostadil and diluent), net price 10-microgram cartridge (for doses 2.5–10 micrograms) = £7.35; 20-microgram cartridge (for doses 5–20 micrograms) = £9.50 (both with needles)

Dose by direct intracavernosal injection, ADULT over 18 years, erectile dysfunction, first dose 2.5 micrograms, second dose 5 micrograms (if some response to first dose) or 7.5 micrograms (if no response to first dose), increasing in steps of 5–10 micrograms to obtain dose suitable for producing erection lasting not more than 1 hour; usual range 10–20 micrograms; max. frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

Note The first dose must be given by medically trained personnel; self-administration may only be undertaken after proper training

1MUSE (Meda). 2Viridal

Urethral application

Counselling If partner pregnant barrier contraception should be used

![Phosphodiesterase type-5 inhibitors

Sildenafil, tadalafil, and vardenafil are phosphodiesterase type-5 inhibitors licensed for the treatment of erectile dysfunction; they are not recommended for use with other treatments for erectile dysfunction. The patient should be assessed appropriately before prescribing sildenafil, tadalafil or vardenafil. Since these drugs are given by mouth there is a potential for drug interactions.

Cautions Sildenafil, tadalafil, and vardenafil should be used with caution in cardiovascular disease, left ventricular outflow obstruction, anatomical deformations of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease), and in those with a predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia). Concomitant treatment with a phosphodiesterase type-5 inhibitor and an alpha-blocker (section 2.5.4 and section 7.4.1) can increase the risk of postural hypotension—initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the
patient is stable on the alpha-blocker; see also interactions: Appendix 1 (sildenafil, tadalafil, vardenafil).

Contra-indications Sildenafil, tadalafil, and vardenafil are contra-indicated in patients receiving nitrates, in patients in whom vasodilatation or sexual activity are inadvisable, or in patients with a previous history of non-arteritic anterior ischaemic optic neuropathy. In the absence of information, manufacturers contra-indicate these drugs in hypotension (avoid if systolic blood pressure below 90 mmHg), recent stroke, unstable angina, and myocardial infarction.

Side-effects The side-effects of sildenafil, tadalafil, and vardenafil include dyspepsia, nausea, vomiting, headache (including migraine), flushing, dizziness, myalgia, back pain, visual disturbances (non-arteritic anterior ischaemic optic neuropathy has been reported—stop drug if sudden visual impairment occurs), and nasal congestion. Less common side-effects include painful red eyes, palpitation, tachycardia, hypotension, hypertension, epistaxis. Other side-effects reported rarely include syncope, hypersensitivity reactions (including rash, facial oedema, and Stevens-Johnson syndrome), seizures, sudden hearing loss (discontinue drug and seek medical advice), and retinal vascular occlusion have also been reported.

SILDENAFIL

Indications erectile dysfunction; pulmonary hypertension (section 2.5.1)

Cautions see notes above; also bleeding disorders or active peptic ulceration; interactions: Appendix 1 (sildenafil)

Contra-indications see notes above; also hereditary degenerative retinal disorders

Hepatic impairment initial dose 25 mg; manufacturer advises avoid in severe impairment

Renal impairment initial dose 25 mg if eGFR less than 30 mL/minute/1.73 m²

Side-effects see notes above; also less commonly chest pain, drowsiness, hypoesthesia, vertigo, tinnitus, dry mouth, fatigue; rarely cerebrovascular accident and atrial fibrillation

Dose

• ADULT over 18 years initially 10 mg at least 30 minutes before sexual activity, subsequent doses adjusted according to response, up to 20 mg as a single dose; max. 1 dose in 24 hours (but daily dose of 10–20 mg not recommended); for patients who anticipate sexual activity at least twice weekly, 5 mg once daily can be taken, reduced to 2.5 mg once daily according to response

Note Effect of intermittent dosing may persist for longer than 24 hours

1Viagra® (Pfizer) Tablets, all blue, f/c, sildenafil (as citrate), 25 mg, net price 4-tab pack = £16.59, 8-tab pack = £33.19; 50 mg, 4-tab pack = £19.34, 8-tab pack = £38.67; 100 mg, 4-tab pack = £23.50, 8-tab pack = £46.99

Revatio® (Pfizer) Tablets
Section 2.5.1 (pulmonary hypertension)

TADALAFIL

Indications erectile dysfunction; pulmonary hypertension (section 2.5.1)

Cautions see notes above; interactions: Appendix 1 (tadalafil)

Contra-indications see notes above; also moderate or severe hepatic impairment

Hepatic impairment max. dose 10 mg; manufacturer advises monitor patient in severe impairment

Renal impairment max. dose 10 mg if eGFR less than 30 mL/minute/1.73 m² (avoid regular once-daily dosing)

Side-effects see notes above; also increased sweating, abdominal pain, and transient amnesia reported

Dose

• ADULT over 18 years initially 10 mg at least 30 minutes before sexual activity, subsequent doses adjusted according to response, up to 20 mg as a single dose; max. 1 dose in 24 hours (but daily dose of 10–20 mg not recommended); for patients who anticipate sexual activity at least twice weekly, 5 mg once daily can be taken, reduced to 2.5 mg once daily according to response

Note Effect of intermittent dosing may persist for longer than 24 hours

1Cialis® (Lilly) Tablets, f/c, tadalafil 2.5 mg (orange), net price 28-tab pack = £54.99; 5 mg (light yellow), 28-tab pack = £54.99; 10 mg (light yellow), 4-tab pack = £26.99; 20 mg (yellow), 4-tab pack = £26.99; 8-tab pack = £53.98

VARDENAFIL

Indications erectile dysfunction

Cautions see notes above; also elderly; bleeding disorders or active peptic ulceration; susceptibility to prolongation of QT interval (including concomitant use of drugs which prolong QT interval); interactions: Appendix 1 (vardenafil)

Contra-indications see notes above; also hereditary degenerative retinal disorders

Hepatic impairment initial dose 5 mg in mild to moderate impairment, increased subsequently according to response (max. 10 mg in moderate impairment); manufacturer advises avoid in severe impairment

Renal impairment initial dose 5 mg if eGFR less than 30 mL/minute/1.73 m²

Side-effects see notes above; also less commonly drowsiness, dyspepsia, increased lacrimation, photosensitivity; rarely anxiety, transient amnesia, hypotonia, and raised intra-ocular pressure
Dose
- **ADULT** over 18 years, initially 10 mg (patients on alpha-blocker therapy 5 mg) approx. 25–60 minutes before sexual activity, subsequent doses adjusted according to response up to max. 20 mg as a single dose; max. 1 dose in 24 hours
  - **Note** Onset of effect may be delayed if taken with high-fat meal

1**Levitra**® (Bayer Schering)
Tablets, all orange, f/c, vardenafil (as hydrochloride trihydrate) 5 mg, net price 4-tab pack = £7.56, 8-tab pack = £15.12; 10 mg, 4-tab pack = £14.08, 8-tab pack = £28.16; 20 mg, 4-tab pack = £23.48, 8-tab pack = £46.96

Papaverine and phentolamine
Although not licensed the smooth muscle relaxant papaverine has also been given by intracavernosal injection for erectile dysfunction. Patients with neurological or psychogenic impotence are more sensitive to the effect of papaverine than those with vascular abnormalities. Phentolamine is added if the response is inadequate [unlicensed indication].

Persistence of the erection for longer than 4 hours is an emergency, see advice in section 7.4.5.

1 except to treat erectile dysfunction in men who:
- have diabetes, multiple sclerosis, Parkinson’s disease, poliomyelitis, prostate cancer, severe pelvic injury, single gene neurological disease, spina bifida, or spinal cord injury;
- are receiving dialysis for renal failure;
- have had radical pelvic surgery, prostatectomy (including transurethral resection of the prostate), or kidney transplant;
- were receiving Caverject®, Erecnos®, MUSE®, Viagra®, or Viridal® for erectile dysfunction, at the expense of the NHS, on 14 September 1998;
- are suffering severe distress as a result of impotence (prescribed in specialist centres only; see notes above).

The prescription must be endorsed ‘SLS’.
The chemotherapy of cancer is complex and should be confined to specialists in oncology. Cytotoxic drugs have both anti-cancer activity and the potential to damage normal tissue; most cytotoxic drugs are teratogenic. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. In an increasing number of cases chemotherapy may be combined with radiotherapy or surgery or both as either neoadjuvant treatment (initial chemotherapy aimed at shrinking the primary tumour, thereby rendering local therapy less destructive or more effective) or as adjuvant treatment (which follows definitive treatment of the primary disease, when the risk of subclinical metastatic disease is known to be high). All cytotoxic drugs cause side-effects and a balance has to be struck between likely benefit and acceptable toxicity.

Guidelines for handling cytotoxic drugs

- Trained personnel should reconstitute cytotoxics;
- Reconstitution should be carried out in designated pharmacy areas;
- Protective clothing (including gloves, gowns, and masks) should be worn;
- The eyes should be protected and means of first aid should be specified;
- Pregnant staff should avoid exposure to cytotoxic drugs (all females of child-bearing age should be informed of the reproductive hazard);
- Use local procedures for dealing with spillages and safe disposal of waste material, including syringes, containers, and absorbent material;
- Staff exposure to cytotoxic drugs should be monitored.

Combinations of cytotoxic drugs, as continuous or pulsed cycles of treatment, are frequently more toxic than single drugs but have the advantage in certain tumours of enhanced response, reduced development of drug resistance and increased survival. However for some tumours, single-agent chemotherapy remains the treatment of choice.

Cytotoxic drugs fall into a number of classes, each with characteristic antitumour activity, sites of action, and
toxicity. A knowledge of sites of metabolism and excretion is important because impaired drug handling as a result of disease is not uncommon and may result in enhanced toxicity.

### Intrathecal chemotherapy

A Health Service Circular (HSC 2008/001) provides guidance on the introduction of safe practice in NHS Trusts where intrathecal chemotherapy is administered; written local guidance covering all aspects of national guidance should be available. Support for training programmes is also available. Copies, and further information may be obtained from:

- Department of Health
- PO Box 777
- London SE1 6XH
- Fax: 01623 724524
- It is also available from the Department of Health website (www.dh.gov.uk)

### Safe systems for cytotoxic medicines

NHS cancer networks have been established across the UK to bring together all stakeholders in all sectors of care, to work collaboratively to plan and deliver high quality cancer services for a given population. NHS cancer networks have websites containing information on local chemotherapy services and treatment (see www.cancer.nhs.uk/networks.htm).

Safe system requirements:

- cytotoxic drugs for the treatment of cancer should be given as part of a wider pathway of care coordinated by a multidisciplinary team;
- cytotoxic drugs should be prescribed, dispensed, and administered only in the context of a written protocol or treatment plan;
- injectable cytotoxic drugs should only be dispensed if they are prepared for administration;
- oral cytotoxic medicines should be dispensed with clear directions for use.

### Risks of incorrect dosing of oral anti-cancer medicines

The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:

- non-specialists who prescribe or administer ongoing oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;
- staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.

### Intravenous chemotherapy

Doses of cytotoxic drugs are determined using a variety of different methods including body-surface area or body-weight. Alternatively, doses may be fixed. Doses may be further adjusted following consideration of a patient’s neutrophil count, renal and hepatic function, and history of previous adverse effects to the cytotoxic drug. Doses may also differ depending on whether a drug is used alone or in combination.

Because of the complexity of dosage regimens in the treatment of malignant disease, dose statements have been omitted from some of the drug entries in this chapter. However, even where dose statements have been provided, detailed specialist literature, individual hospital chemotherapy protocols, or local cancer networks (www.cancer.nhs.uk/networks.htm) should be consulted prior to prescribing, dispensing, or administering cytotoxic drugs.

Prescriptions should not be repeated except on the instructions of a specialist.

### Side-effects of cytotoxic drugs

Side-effects common to most cytotoxic drugs are discussed below whilst side-effects characteristic of a particular drug or class of drugs (e.g. neurotoxicity with vinca alkaloids) are mentioned in the appropriate sections. Manufacturers’ product literature, hospital-trust protocols, and cancer-network protocols should be consulted for full details of side-effects associated with individual drugs and specific chemotherapy regimes.

Many side-effects of cytotoxic drugs often do not occur at the time of administration, but days or weeks later. It is therefore important that patients and healthcare professionals can identify symptoms that cause concern and can contact an expert for advice. Toxicities should be accurately recorded using a recognised scoring system such as the Common Toxicity Criteria for Adverse Events (CTCAE) developed by the National Cancer Institute.

### Extravasation of intravenous drugs

A number of cytotoxic drugs will cause severe local tissue necrosis if leakage into the extravascular compartment occurs. To reduce the risk of extravasation injury it is recommended that cytotoxic drugs are administered by appropriately trained staff. For information on the prevention and management of extravasation injury, see section 10.3.

### Oral mucositis

A sore mouth is a common complication of cancer chemotherapy; it is most often associated with fluorouracil, methotrexate, and the anthracyclines. It is best to prevent the complication. Good oral hygiene (rinsing the mouth frequently and effective brushing of the teeth with a soft brush 2–3 times daily) is probably beneficial. For fluorouracil, sucking ice chips during short infusions of the drug is also helpful. Once a sore mouth has developed, treatment is much less effective. Saline mouthwashes should be used but there is no good evidence to support the use of anti-septic or anti-inflammatory mouthwashes. In general, mucositis is self-limiting but with poor oral hygiene it can be a focus for blood-borne infection.
Hyperuricaemia
Hyperuricaemia, which may be present in high-grade lymphoma and leukaemia, can be markedly worsened by chemotherapy and is associated with acute renal failure. Allopurinol (section 10.1.4) should be started 24 hours before treating such tumours and patients should be adequately hydrated. The dose of allopurinol or azathioprine should be reduced if allopurinol needs to be given concomitantly (see Appendix 1). Rasburicase (section 10.1.4), a recombinant urate oxidase, is licensed for hyperuricaemia in patients with haematological malignancy, for details, see p. 657. It rapidly reduces plasma uric acid and may be of particular value in preventing complications following treatment of leukemias or bulky lymphomas.

Nausea and vomiting
Nausea and vomiting cause considerable distress to many patients who receive chemotherapy and to a lesser extent abdominal radiotherapy, and may lead to refusal of further treatment; prophylaxis of nausea and vomiting is therefore extremely important. Symptoms may be acute (occurring within 24 hours of treatment), delayed (first occurring more than 24 hours after treatment), or anticipatory (occurring prior to subsequent doses). Delayed and anticipatory symptoms are more difficult to control than acute symptoms and require different management.

Patients vary in their susceptibility to drug-induced nausea and vomiting; those affected more often include women, patients under 50 years of age, anxious patients, and those who experience motion sickness. Susceptibility also increases with repeated exposure to the cytotoxic drug.

Drugs may be divided according to their emetogenic potential and some examples are given below, but the symptoms vary according to the dose, to other drugs administered and to individual susceptibility.

Mildly emetogenic treatment—fluorouracil, etopoide, methotrexate (less than 100 mg/m²), the vinca alkaloids, and abdominal radiotherapy.

Moderately emetogenic treatment—the taxanes, doxorubicin, intermediate and low doses of cyclophosphamide, mitoxantrone, and high doses of methotrexate (0.1–1.2 g/m²).

Highly emetogenic treatment—cisplatin, dacarbazine, and high doses of cyclophosphamide.

Prevention of acute symptoms. For patients at low risk of emesis, pretreatment with domperidone or with metoclopramide, continued for up to 24 hours after chemotherapy, is often effective (section 4.6). If metoclopramide or domperidone are not sufficiently effective, additional drugs such as dexamethasone (6–10 mg by mouth) or lorazepam (1–2 mg by mouth) may be used.

For patients at high risk of emesis or when other treatment is inadequate, a specific (5HT,) serotonin antagonist (section 4.6), usually given by mouth, is often highly effective, particularly when used with dexamethasone; adding the neurokinin receptor antagonist, aprepitant (section 4.6) can improve control of cisplatin-related nausea and vomiting.

Prevention of delayed symptoms. Dexamethasone, given by mouth, is the drug of choice for preventing delayed symptoms; it is used alone or with metoclopramide or prochlorperazine. The 5HT, antagonists may be less effective for delayed symptoms.

Prevention of anticipatory symptoms. Good symptom control is the best way to prevent anticipatory symptoms. Lorazepam can be helpful for its amnesic, sedative, and anxiolytic effects.

Bone-marrow suppression
All cytotoxic drugs except vincristine and bleomycin cause bone-marrow depression. This commonly occurs 7 to 10 days after administration, but is delayed for certain drugs, such as carbamustine, lomustine, and melphalan. Peripheral blood counts must be checked before each treatment, and doses should be reduced or therapy delayed if bone marrow has not recovered.

Fever in a neutropenic patient (neutrophil count less than 1.0 × 10⁹/litre) requires immediate broad-spectrum antibacterial therapy. Appropriate bacteriological investigations should be conducted as soon as possible. All patients should initially be investigated and treated under the supervision of the appropriate oncology or haematology specialist.

In selected patients, the duration and the severity of neutropenia can be reduced by the use of amifostine, p. 522 or recombinant human granulocyte-colony stimulating factors, section 9.1.6.

Symptomatic anaemia is usually treated with red blood cell transfusions. For guidance on the use of erythropoietins in patients with cancer, see MHRA/CHM advice (p. 582) and NICE guidance (p. 583).

For advice on the use of live vaccines in individuals with impaired immune response, see section 14.1.

Alopecia
Reversible hair loss is a common complication, although it varies in degree between drugs and individual patients. No pharmacological methods of preventing this are available.

Reproductive function
Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

Contraceptive advice should be offered where appropriate before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended). Regimens that do not contain an alkylating drug may have less effect on fertility, but those with an alkylating drug carry the risk of causing permanent...
male sterility (there is no effect on potency). Pre-treatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion-rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.

Thromboembolism  Venous thromboembolism can be a complication of cancer itself, but chemotherapy increases the risk.

### Treatment for cytotoxic-induced side-effects

#### Anthracycline side-effects

**Anthracycline-induced cardiotoxicity**  The anthracycline cytotoxic drugs are associated with dose-related, cumulative, and potentially life-threatening cardiotoxic side-effects.

**Dexrazoxane**  an iron chelator, is licensed for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin treatment in advanced or metastatic cancer patients who have previously received anthracycline therapy. Patients receiving dexrazoxane should still be monitored for cardiac toxicity. The myelosuppressive effects of dexrazoxane may be additive to those of chemotherapy.

**Anthracycline extravasation**  Dexrazoxane is licensed for the treatment of anthracycline extravasation. The first dose should be given as soon as possible and within six hours after the injury. For further information on the prevention and management of extravasation injury, see section 10.3.

Local guidelines for the management of extravasation should be followed or specialist advice sought.

### DEXRAZOXANE

**Indications**  see notes above and under preparations  
**Cautions**  see notes above; monitor full blood count  
**Hepatic impairment**  monitor liver function  
**Renal impairment**  use with caution—risk of accumulation; manufacturer of Cardioxane® advises reduce dose by 50% if creatinine clearance less than 40 mL/minute  
**Pregnancy**  avoid unless essential (toxicity in animal studies); ensure effective contraception during and for at least 3 months after treatment in men and women  
**Breast-feeding**  discontinue breast-feeding  
**Side-effects**  nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, stomatitis, dry mouth, anorexia; dyspnœa; dizziness, syncope, asthenia, paraesthesia, tremor, fatigue, drowsiness; pyrexia; vaginal haemorrhage; myalgia; blood disorders (including anaemia, leucopenia, neutropenia, and thrombocytopenia); alopecia, pruritus; peripheral oedema, injection-site reactions including phlebitis

**Dose**  see under preparations

---

#### Cardioxane** (Novartis)  
**Intravenous infusion**, powder for reconstitution, dexrazoxane (as hydrochloride), net price 500-mg vial = £156.57

**Dose**  prevention of anthracycline-induced cardiotoxicity.  
**ADULT**  over 18 years, by intravenous infusion (30 minutes prior to anthracycline administration), 20 times the doxorubicin-equivalent dose or 10 times the epirubicin-equivalent dose

#### Savene® (SpePharm)  
**Intravenous infusion**, powder for reconstitution, dexrazoxane (as hydrochloride), net price 10 x 500-mg vials (with diluent) = £6750.00

**Dose**  anthracycline extravasation.  
**ADULT**  over 18 years, by intravenous infusion, 1 g/m² (max. 2 g) daily for 2 days, then 500 mg/m² for 1 day  
**Note**  Local coolants such as ice packs should be removed at least 15 minutes before administration

---

### Chemotherapy-induced mucositis and myelosuppression

Folinic acid (given as calcium folinate) is used to counteract the folate-antagonist action of methotrexate and thus speed recovery from methotrexate-induced mucositis or myelosuppression (‘folinic acid rescue’).

Folinic acid is also used in the management of methotrexate overdose, together with other measures to maintain fluid and electrolyte balance, and to manage possible renal failure.

Folinic acid does not counteract the antibacterial activity of folate antagonists such as trimethoprim. When folinic acid and fluorouracil are used together in metastatic colorectal cancer the response-rate improves compared to that with fluorouracil alone.

The calcium salt of levofolinic acid, a single isomer of folinic acid, is also used for rescue therapy following methotrexate administration, for cases of methotrexate overdose, and for use with fluorouracil for colorectal cancer. The dose of calcium levofolinate is generally half that of calcium folinate.

The disodium salts of folinic acid and levofolinic acid are also used for rescue therapy following methotrexate therapy, and for use with fluorouracil for colorectal cancer.

Palifermin, a human keratinocyte growth factor, is licensed for the management of oral mucositis in patients with haematological malignancies receiving myeloablative radiochemotherapy with autologous haematopoietic stem-cell support.

---

### FOLINIC ACID

**Indications**  see notes above  
**Cautions**  avoid simultaneous administration of methotrexate; not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B₁₂ deficiency;  
**Interactions**  Appendix 1 (folates)  
**Contra-indications**  intrathecal injection  
**Pregnancy**  not known to be harmful; benefit outweighs risk  
**Breast-feeding**  presence in milk unknown but benefit outweighs risk

**Side-effects**  rarely pyrexia after parenteral use; insomnia, agitation, and depression after high doses
**Calcium folinate** (Calcium leucovorin)

**Calcium Folinate (Non-proprietary)**

**Tablets**, scored, folic acid (as calcium salt) 15 mg, net price 10-tab pack = £39.20, 30-tab pack = £85.74

*Brands include Refolinon*®

**Note** Not all strengths and pack sizes are available from all manufacturers

**Injection**, folic acid (as calcium salt) 3 mg/mL, net price 1-mL amp = £4.00, 10-mL amp = £4.62; 7.5 mg/mL, net price 2-mL amp = £7.80; 10 mg/mL, net price 5-mL vial = £19.41, 10-mL vial = £35.09, 30-mL vial = £94.63, 35-mL vial = £90.98

*Brands include Refolinon*®

**Note** Not all strengths and pack sizes are available from all manufacturers

**Injection**, powder for reconstitution, folic acid (as calcium salt), net price 15-mg vial = £4.46; 30-mg vial = £8.36

**Dose**

*Note* Doses expressed as folic acid

Prevention of methotrexate-induced adverse effects, usually started 12–24 hours after start of methotrexate infusion, by intramuscular injection, or by intravenous injection, or by intravenous infusion, 13 mg, repeated every 6 hours for 24 hours (may be continued by mouth); consult local treatment protocol for further information

Suspected methotrexate overdose, by intravenous injection or by intravenous infusion (at a max. rate of 160 mg/minute), initial dose equal to or exceeding dose of methotrexate; consult poisons information service (p. 32) for advice on continuing management

Adjunct to fluorouracil in colorectal cancer, consult product literature

**Disodium levofolate**

**Levofolinic Acid (Non-proprietary)**

**Injection**, levofolinic acid (as disodium salt) 50 mg/mL, net price 1-mL vial = £24.70, 4-mL vial = £80.40

**Dose** as an antidote to methotrexate, by intravenous injection or infusion, consult product literature

Adjunct to fluorouracil in colorectal cancer, consult product literature

**Calcium levofolinate**

**Calcium Levofolate (Non-proprietary)**

**Injection**, levofolinic acid (as calcium salt) 10 mg/mL, net price 17.5-mL vial = £94.63

**Isosorine**® (Wyeth)

**Injection**, levofolinic acid (as calcium salt) 10 mg/mL, net price 2.5-mL vial = £11.62, 17.5-mL vial = £81.33

**Dose**

*Note* Doses expressed as levofolinic acid

Prevention of methotrexate-induced adverse effects, usually started 12–24 hours after beginning of methotrexate infusion, by intramuscular injection, or by intravenous injection or by intravenous infusion, usually 7.5 mg every 6 hours for 10 doses

Suspected methotrexate overdose, by intravenous injection or by intravenous infusion (at a max. rate of 160 mg/minute), initial dose at least 50% of the dose of methotrexate, consult poisons information service (p. 32) for advice on continuing management

Adjunct to fluorouracil in colorectal cancer, consult product literature

**Chemotherapy-induced neutropenic infection and nephrotoxicity**

Amifostine is licensed for the reduction of risk of infection associated with cisplatin- and cyclophosphamide-induced neutropenia in advanced ovarian carcinoma, and for the reduction of nephrotoxicity caused by cisplatin use in advanced solid tumours of non-germ-cell origin. Amifostine is also licensed for protection against xerostomia during radiotherapy for head and neck cancer.

Other drugs for the reduction of risk of infection associated with neutropenia include granulocyte-colony stimulating factors (section 9.1.6).

**AMIFOSTINE**

**Indications** see under Dose

**Cautions** ensure adequate hydration before treatment; infuse with patient supine and monitor arterial blood pressure (interrupt infusion if blood pressure decreases significantly, consult product literature); during chemotherapy interrupt antihypertensive therapy 24 hours before treatment with amifostine and monitor closely; during radiotherapy monitor closely if concomitant antihypertensive therapy; monitor serum-calcium concentration in patients at risk of hypocalcaemia; patients at risk of renal impairment; caution in handling—risk of cutaneous reactions

**Hepatic impairment** avoid—no information available

**Renal impairment** avoid—no information available

**Pregnancy** toxicity in animal studies; avoid

**Breast-feeding** avoid—no information available

**Side-effects** nausea, vomiting, hiccups; hypotension (managed by infusion of sodium chloride 0.9% and
postural management), hypertension, flushing, arrhythmias (including rarely atrial fibrillation, supraventricular tachycardia); sneezing; drowsiness, dizziness, syncope; hypocalcaemia; rarely chest pain, apnoea, seizures, serious skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and very rarely exfoliative and bullous dermatitis, toxicodermia), and renal failure; very rarely myocardial infarction, laryngeal oedema, and respiratory arrest.

**Dose**
- Reduction of neutropenia-related risk of infection due to cyclophosphamide and cisplatin treatment in patients with advanced ovarian carcinoma, by intravenous infusion over 15 minutes, ADULT under 70 years, 910 mg/m² started within 30 minutes before chemotherapy (reduced to 740 mg/m² for subsequent cycles if full dose could not be given first time due to hypotension lasting more than 5 minutes after interruption, consult product literature)
- Reduction of nephrotoxicity associated with cisplatin in patients with advanced solid tumours of non-gemcitabine origin, consult product literature
- Prevention of xerostomia during radiotherapy for head and neck cancer, consult product literature

**Ethylol® (Genopharm)**

**Intravenous infusion**, powder for reconstitution, amifostine, net price 500-mg vial = £225.00

**Urothelial toxicity**

Haemorrhagic cystitis is a common manifestation of urothelial toxicity which occurs with the oxazaphosphorines, cyclophosphamide and ifosfamide; it is caused by the metabolite acrolein. **Mesna** reacts specifically with this metabolite in the urinary tract, preventing toxicity. Mesna is used routinely (preferably by mouth) in patients receiving ifosfamide, and in patients receiving cyclophosphamide by the intravenous route at a high dose (e.g. more than 2 g) or in those who experienced urothelial toxicity when given cyclophosphamide previously.

**Mesna (Baxter)**

**Tablets**, f/c, mesna 400 mg, net price 10-tab pack = £42.90; 600 mg, 10-tab pack = £61.10

**Injection**, mesna 100 mg/mL, net price 4-mL amp = £3.95; 10-mL amp = £9.77

**Note** For oral administration contents of ampoule are taken in a flavoured drink such as orange juice or cola which may be stored in a refrigerator for up to 24 hours in a sealed container.

**8.1.1 Alkylating drugs**

Extensive experience is available with these drugs, which are among the most widely used in cancer chemotherapy. They act by damaging DNA, thus interfering with cell replication. In addition to the side-effects common to many cytotoxic drugs (section 8.1), there are two problems associated with prolonged usage. Firstly, gametogenesis is often severely affected (section 8.1). Secondly, prolonged use of these drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**Cyclophosphamide** is used mainly in combination with other agents for treating a wide range of malignancies, including some leukemias, lymphomas, and solid tumours. It is given by mouth or intravenously; it is inactive until metabolised by the liver. A urinary metabolite of cyclophosphamide, acrolein, can cause haemorrhagic cystitis; this is a rare but serious complication; increased fluid intake for 24–48 hours after intravenous injection, can prevent this complication.

When high-dose therapy (e.g. more than 2 g intravenously) is used or when the patient is considered to be at high risk of cystitis (e.g. because of pelvic irradiation) mesna (given initially intravenously then by mouth) can also help prevent cystitis—see under Urothelial Toxicity (section 8.1).

**Ifosfamide** is related to cyclophosphamide and is given intravenously; mesna (section 8.1) is routinely given with it to reduce urothelial toxicity.

**Chlorambucil** is used either alone or in combination therapy for some lymphomas and chronic leukemias. It is given by mouth. Side-effects, apart from bone-marrow suppression, are uncommon. However, patients occasionally develop severe widespread rashes which can progress to Stevens-Johnson syndrome or to toxic epidermal necrolysis. If a rash occurs further chlorambucil is contra-indicated and cyclophosphamide is substituted.

**Melphalan** is licensed for the treatment of multiple myeloma, polycythemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities. Intestinal pneumonitis and life-threatening pulmonary fibrosis are rarely associated with melphalan.

**Busulfan** is given by mouth to treat chronic myeloid leukaemia. Busulfan given by mouth or intravenously, followed by cyclophosphamide, is also licensed as conditioning treatment before haematopoietic stem-cell transplantation in adults and children. Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia. Rarely, progressive pulmonary fibrosis is associated
with busulfan. Skin hyperpigmentation is a common side-effect of oral therapy.

**Lomustine** is a lipid-soluble nitrosourea and is given by mouth. It is used mainly to treat Hodgkin’s disease resistant to conventional therapy, malignant melanoma and certain solid tumours. Bone-marrow toxicity is delayed, and the drug is therefore given at intervals of 4 to 6 weeks. Permanent bone-marrow damage can occur with prolonged use. Nausea and vomiting are common and moderately severe.

**Bendamustine** given intravenously is licensed for the treatment of chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma, and for the treatment of multiple myeloma.

**Carmustine** given intravenously has similar activity to lomustine; it is given to patients with multiple myeloma, non-Hodgkin’s lymphomas, and brain tumours. Cumulative renal damage and delayed pulmonary fibrosis may occur with intravenous use. Carmustine implants are licensed for intralesional use in adults for the treatment of recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also licensed for high-grade malignant glioma as adjunctive treatment to surgery and radiotherapy.

---

**NICE guidance** (carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma)

See p. 540

**BENDAMUSTINE HYDROCHLORIDE**

**Indications** see notes above

**Cautions** see section 8.1; monitor cardiac function; monitor serum potassium and ECG; avoid in acute porphyria (but see section 9.8.2); **interactions:** Appendix 1 (busulfan)

**Hepatic impairment** manufacturer advises monitor liver function—no information available

**Pregnancy** avoid (teratogenic in animals); manufacturers advise effective contraception during and for 6 months after treatment in men or women; see also Reproductive function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1; also anorexia, diarrhoea, constipation, haemorrhage, hypotension, hypertension, palpitation, angina, arrhythmias, respiratory dysfunction, insomnia, pain, chills, malaise, infection, pyrexia, amenorrhoea, dehydration, electrolyte disturbances (including hypokalaemia); less commonly pericardial effusion; rarely acute circulatory failure, drowsiness, voice changes, sweating; very rarely taste disturbance, tachycardia, myocardial infarction, cardiac failure, pulmonary fibrosis, paraesthesia, peripheral neuropathy, neurological disorders, ataxia, anticholinergic syndrome, encephalitis, phlebitis, multiple organ failure, haemolysis; also reported secondary tumours, Stevens-Johnson syndrome, toxic epidermal necrolysis

**Levact** (Napp) £5.20

Injection, powder for reconstitution, bendamustine hydrochloride, net price 25-mg vial = £69.45; 100-mg vial = £275.81

---

**BUSULFAN** (Busulphan)

**Indications** see notes above

**Cautions** see section 8.1 and notes above; monitor cardiac function; previous radiation therapy; avoid in acute porphyria (but see section 9.8.2); **interactions:** Appendix 1 (busulfan)

**Hepatic impairment** manufacturer advises monitor liver function—no information available

**Pregnancy** avoid (teratogenic in animals); manufacturers advise effective contraception during and for 6 months after treatment in men or women; see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above; also hematotoxicity (including hepatic veno-occlusive disease, hyperbilirubinaemia, jaundice and fibrosis); cardiac tamponade in thalassaemia; pneumonia; skin hyperpigmentation

**Dose**
- Chronic myeloid leukaemia, induction of remission, by mouth, 60 micrograms/kg daily (max. 4 mg); maintenance, usually 0.5–2 mg daily
- Conditioning treatment before haematopoietic stem-cell transplantation, by mouth or by intravenous infusion, consult product literature

**Myleran** (GSK) £5.20

Tablets, f/c, busulfan 2 mg, net price 25-tab pack = £5.20

**Busilvex** (Fabre) £5.20

Concentrate for intravenous infusion, busulfan 6 mg/mL, net price 10-mL vial = £201.25

---

**CARMUSTINE**

**Indications** see notes above

**Cautions** see section 8.1 and notes above; avoid in acute porphyria (but see section 9.8.2); **interactions:** Appendix 1 (carmustine)

**Pregnancy** avoid (teratogenic and embryotoxic in animals); manufacturer advises effective contra-
Contraindications: See section 8.1; congestive heart failure; pregnancy.
Indications: Cyclophosphamide (Non-proprietary) - see section 8.1 and notes above; irritant to tissues.

Gliadel® (Archimedes) Implant, carmustine 7.7 mg, net price = £585.34

CHLORAMBUCIL
Indications: see notes above
Cautions: see section 8.1 and notes above; history of epilepsy and children with nephrotic syndrome (increased risk of seizures); avoid in acute porphyria (but see section 9.8.2). Hepatic impairment: manufacturer advises consider dose reduction in severe impairment—limited information available.

Pregnancy: avoid; manufacturer advises effective contraception during treatment in men or women; see also Reproductive Function, p. 520.
Breast-feeding: discontinue breast-feeding.
Side-effects: see section 8.1 and notes above.

Leukeran® (GSK) Tablets, f/c, brown, chlorambucil 2 mg, net price 25-tab pack = £8.36

CYCLOPHOSPHAMIDE
Indications: see notes above; rheumatoid arthritis (section 10.1.3)
Cautions: see section 8.1 and notes above; previous or concurrent mediastinal irradiation—risk of cardiotoxicity; diabetes mellitus; avoid in acute porphyria (but see section 9.8.2). Hepatic impairment: reduce dose—consult local treatment protocol for details.

Renal impairment: reduce dose—consult local treatment protocol for details.

Pregnancy: avoid (manufacturer advises effective contraception during and for at least 3 months after treatment in men or women); see also Reproductive Function, p. 520.
Breast-feeding: discontinue breast-feeding.

Side-effects: see section 8.1 and notes above.

Cyclophosphamide (Non-proprietary) Tablets, s/c, cyclophosphamide (anhydrous) 50 mg, net price 100 = £20.20. Label: 25, 27
Injection, powder for reconstitution, cyclophosphamide, net price 500-mg vial = £5.66; 1-g vial = £10.66

Estracyt® (Pharmacia) Capsules, estramustine phosphate 140 mg (as disodium salt), net price 100-cap pack = £171.28. Label: 23, counselling, see above

IFOSFAMIDE
Indications: see notes above
Cautions: see section 8.1 and notes above; ensure satisfactory electrolyte balance and renal function before each course (risk of tubular dysfunction, Fanconi’s syndrome or diabetes insipidus if renal toxicity not treated promptly); diabetes mellitus; avoid in acute porphyria (but see section 9.8.2). Interactions: Appendix 1 (ifosfamide)

Contra-indications: urinary-tract obstruction; acute infection (including urinary-tract infection); urothelial damage.

Hepatic impairment: avoid
Renal impairment: avoid if serum creatinine concentration greater than 120 micromol/litre.

Pregnancy: avoid (teratogenic and carcinogenic in animals); manufacturer advises adequate contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520.
Breast-feeding: discontinue breast-feeding.

Side-effects: see section 8.1 and notes above; also: drowsiness, confusion, disorientation, restlessness, psychosis; urothelial toxicity; renal toxicity (see Cautions above); less commonly severe encephalopathy; rarely diarrhoea, constipation, convulsions, anorexia, very rarely jaundice, thrombophlebitis, syndrome of inappropriate antidiuretic hormone secretion; acute pancreatitis, arrhythmias, and heart failure also reported.

Ifosfamide (Non-proprietary) Injection, powder for reconstitution, ifosfamide, net price 1-g vial = £43.53; 2-g vial = £88.62 (hosp. only)

LOMUSTINE
Indications: see notes above
Cautions: see section 8.1 and notes above; avoid in acute porphyria (but see section 9.8.2). Interactions: Appendix 1 (lomustine).

Contra-indications: coeliac disease.

Renal impairment: avoid in severe impairment.
8 Malignant disease and immunosuppression

Pregnancy avoid (manufacturer advises effective contraception during and for at least 6 months after treatment in men or women); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above
Dose
- Used alone, 120–130 mg/m² body-surface every 6–8 weeks

Lomustine (Medac) Capsules, blue/clear, lomustine 40 mg, net price 20-cap pack = £455.62
Note The brand name CCNU® has been used for lomustine capsules.

**MELPHALAN**

Indications see notes above
Cautions see section 8.1 and notes above; avoid in acute porphyria (but see section 9.8.2); interactions: Appendix 1 (melphalan)
Renal impairment reduce dose initially (consult product literature)
Pregnancy avoid (manufacturer advises adequate contraception during treatment in men and women); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above
Dose
- By mouth, multiple myeloma, dose may vary according to regimen; typical dose 150 micrograms/kg daily for 4 days, repeated every 6 weeks
- Polychaetemia vera, initially, 6–10 mg daily reduced after 5–7 days to 2–4 mg daily until satisfactory response then further reduce to 2–6 mg per week
- By intravenous injection or infusion and regional arterial perfusion, consult product literature

Alkeran® (GSK) Tablets, melphalan 2 mg, net price 25 = £13.75
Injection, powder for reconstitution, melphalan 50 mg (as hydrochloride), net price 50-mg vial (with solvent-diluent) = £33.13

**THIOTEPA**

Indications see notes above and section 7.4.4
Cautions see section 8.1; avoid in acute porphyria (but see section 9.8.2); interactions: Appendix 1 (thiotepa)
Pregnancy avoid (teratogenic and embryotoxic in animals); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1
Thiotepa (Goldshield) Injection, powder for reconstitution, thiotepa, net price 15-mg vial = £5.20
Tepadina® (Intrapharm) Injection, powder for reconstitution, thiotepa, net price 15-mg vial = £123.00; 100-mg vial = £736.00

**TREOSULFAN**

Indications see notes above
Cautions see section 8.1; avoid in acute porphyria (but see section 9.8.2)

Pregnancy avoid; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above
Dose
- Consult product literature

Treasulfan (Medac) Capsules, treosulfan 250 mg, net price 100-cap pack = £435.03 Label: 25
Injection, powder for reconstitution, treosulfan, net price 1 g = £39.44; 5 g = £152.41 (both in infusion bottle with transfer needle)

**8.1.2 Anthracyclines and other cytotoxic antibiotics**

Drugs in this group are widely used. Many cytotoxic antibiotics act as radiomimetics and simultaneous use of radiotherapy should be avoided as it may result in markedly enhanced toxicity.

Daunorubicin, doxorubicin, epirubicin and idarubicin are anthracycline antibiotics. Mitoxantrone is an anthracycline derivative.

Doxorubicin is used to treat the acute leukaemias, Hodgkin’s and non-Hodgkin’s lymphomas, paediatric malignancies, and some solid tumours including breast cancer. It is given by injection into a fast-running infusion, commonly at 21-day intervals. Extravasation can cause severe tissue necrosis. Doxorubicin is largely excreted in the bile and an elevated bilirubin concentration is an indication for reducing the dose. Diarrhoea, dehydration, and red coloration of the urine can commonly occur, and renal damage has been reported. Supraventricular tachycardia related to drug administration is an uncommon complication. Higher cumulative doses are associated with cardiomyopathy and it is usual to limit total cumulative doses to 450 mg/m² because symptomatic and potentially fatal heart failure is common above this dose. Patients should be assessed before treatment by echocardiography; the elderly, and those with cardiac disease, hypertension, or who have received myocardial irradiation, should be treated cautiously. Cardiac monitoring may assist in determining safe dosage. Some evidence suggests that weekly low-dose administration may be less cardiotoxic. Doxorubicin is also given by bladder instillation for the treatment of transitional cell carcinoma, papillary bladder tumours and carcinoma in-situ.

Liposomal formulations of doxorubicin for intravenous use are also available. They may reduce the incidence of cardiotoxicity and lower the potential for local necrosis, but infusion reactions, sometimes severe, may occur. Hand-foot syndrome (painful, macular reddening skin eruptions) occurs commonly with liposomal doxorubicin and may be dose limiting. It can occur after 2–3 treatment cycles and may be prevented by cooling hands and feet and avoiding socks, gloves, or tight-fitting footwear for 4–7 days after treatment.

NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer) See p. 542
Epirubicin is structurally related to doxorubicin and clinical trials suggest that it is as effective in the treatment of breast cancer. A maximum cumulative dose of 0.9–1 g/m² is recommended to help avoid cardiotoxicity. Like doxorubicin it is given intravenously and by bladder instillation. Hyperpigmentation of skin, nails, and oral mucosa, and red coloration of the urine, may occur.

Idarubicin has general properties similar to those of doxorubicin; it is mostly used in the treatment of haematological malignancies. Diarrhoea, abdominal pain, haemorrhage, cardiac disorders, rash, and red pigmentation of the urine are commonly reported. Skin and nail hyperpigmentation have been reported less frequently. Idarubicin is given intravenously and it may also be given by mouth.

Daunorubicin also has general properties similar to those of doxorubicin. It should be given by intravenous infusion and is indicated for acute leukaemias. A liposomal formulation for intravenous use is licensed for infusion and is indicated for acute leukaemias. A liposomal formulation for intravenous use is licensed for AIDS-related Kaposis sarcoma.

Mitoxantrone is structurally related to doxorubicin; it is used for metastatic breast cancer. Mitoxantrone is also licensed for treatment of non-Hodgkin’s lymphoma, adult acute non-lymphocytic leukaemia, and non-resectable primary hepatocellular carcinoma. It is given intravenously and is well tolerated, but myelosuppression and dose-related cardiotoxicity occur; cardiac examinations are recommended after a cumulative dose of 160 mg/m².

Bleomycin is given intravenously or intramuscularly to treat metastatic germ cell cancer and, in some regimens, non-Hodgkin’s lymphoma. It causes little bone-marrow suppression but dermatological toxicity is common and increased pigmention particularly affecting the flexures and subcutaneous sclerotic plaques may occur. Mucositis is also relatively common and an association with Raynaud’s phenomenon is reported. Hypersensitivity reactions manifest by chills and fevers commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously. The principal problem associated with the use of bleomycin is progressive pulmonary fibrosis. This is dose-related, occurring more commonly at cumulative doses greater than 300 000 units (see Bleomycin, below) and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug. Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000 units—see Bleomycin below) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.

Daunorubicin is principally used to treat paediatric cancers; it is given intravenously. Its side-effects are similar to those of doxorubicin, except that cardiac toxicity is not a problem.

Mitomycin is given intravenously to treat upper gastrointestinal and breast cancers and by bladder instillation for superficial bladder tumours. It causes delayed bone-marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.

**BLEOMYCIN**

**Indications** squamous cell carcinoma; see also notes above

**Cautions** see section 8.1 and notes above; caution in handling—irritant to tissues; **Interactions**: Appendix 1 (bleomycin)

**Renal impairment** reduce dose by half if serum-creatinine 177–354 micromol/litre; reduce dose further if serum-creatinine greater than 354 micromol/litre

**Pregnancy** avoid (teratogenic and carcinogenic in *animal* studies); see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

**Bleomycin (Non-proprietary)***

Injection, powder for reconstitution, bleomycin (as sulphate), net price 15 000-unit vial = £15.56

**Note** To conform to the European Pharmacopoeia vials previously labelled as containing ‘15 units’ of bleomycin are now labelled as containing 15 000 units. The amount of bleomycin in the vial has not changed.

**Brands** include *Bleo-Kyowa*®

**DACTINOMYCIN**

(Actinomycin D)

**Indications** see notes above

**Cautions** see section 8.1 and notes above; caution in handling—irritant to tissues

**Pregnancy** avoid (teratogenic in *animal* studies); see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

**Cosmegen Lyovac® (Ovation)***

Injection, powder for reconstitution, dactinomycin, net price 500-microgram vial = £8.75

**DAUNORUBICIN**

**Indications** see notes above

**Cautions** see section 8.1 and notes above; caution in handling—irritant to tissues

**Hepatic impairment** reduce dose according to serum bilirubin concentration—consult local protocol for details

**Renal impairment** reduce dose by 25% if serum creatinine 105–265 micromol/litre and by 50% if serum creatinine greater than 265 micromol/litre

**Pregnancy** avoid (teratogenic and carcinogenic in *animal* studies); see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

**Daunorubicin (Non-proprietary)***

Injection, powder for reconstitution, daunorubicin (as hydrochloride), net price 20-mg vial = £55.00

**Note** The brand name *Corubid®* was formerly used.
8 Malignant disease and immunosuppression

Hepatic impairment

Cautions

see section 8.1 and notes above; caution in

Indications

Myocet

Doxorubicin

(Non-proprietary)

see section 8.1 and notes above

Side-effects

discontinue breast-feeding

Breast-feeding

Pregnancy

Hepatic impairment

reduce dose according to bili-

Contra-indications

see notes above; ; severe myo-

Cautions

see section 8.1 and notes above; caution in

see notes above and section 7.4.4

Indications

see notes above and section 7.4.4

Cautions

see section 8.1 and notes above; caution in

see notes above and section 7.4.4

Indications

acute leukaemias (see notes above);

advanced breast cancer after failure of first-line

chemotherapy (not including anthracyclines)

Cautions

see section 8.1 and notes above; caution in handling—irritant to tissues; interactions: Appendix 1 (idarubicin)

Contra-indications

severe myocardial insufficiency; recent myocardial infarction; severe arrhythmias

Hepatic impairment

reduce dose according to serum-

Renal impairment

reduce dose; avoid in severe impairment

Pregnancy

avoid (teratogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above

Doxorubicin (Non-proprietary)

Injection, powder for reconstitution, doxorubicin hydrochloride, net price 10-mg vial = £18.86

Note

The brand name Adriamycin® was formerly used

Injection, doxorubicin hydrochloride 2 mg/mL, net price 5-mL vial = £20.60, 25-mL vial = £103.00, 100-

Malignant disease and immunosuppression

528 8.1.2 Anthracyclines and other cytotoxic antibiotics

BNF 61

DOXORUBICIN HYDROCHLORIDE

Indications

see notes above and section 7.4.4

Cautions

see section 8.1 and notes above; caution in handling—irritant to tissues; interactions: Appendix 1 (doxorubicin)

Contra-indications

see notes above; ; severe myocar-

dial insufficiency, recent myocardial infarction,

Hepatic impairment

reduce dose according to bilirubin concentration; avoid in severe impairment

Pregnancy

avoid (teratogenic and toxic in animal studies); manufacturer of liposomal product advises effective contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above

Doxorubicin

(Schering-Plough)

Concentrate for intravenous infusion, pegylated doxorubicin hydrochloride 2 mg/mL encapsulated in liposomes. For dilution before use, net price 50-mg vial = £137.67

For advanced AIDS-related Kaposi’s sarcoma

Side-effects

discontinue breast-feeding

Breast-feeding

Pregnancy

Hepatic impairment

reduce dose according to serum-

Contra-indications

see notes above; ; severe myo-

Cautions

see section 8.1 and notes above; caution in

see notes above and section 7.4.4

Indications

see notes above and section 7.4.4

Cautions

see section 8.1 and notes above; caution in handling—irritant to tissues

Hepatic impairment

reduce dose according to bilirubin concentration

Pregnancy

avoid (carcinogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above

Epirubicin

(Non-proprietary)

Injection, epirubicin hydrochloride 2 mg/mL, net price 5-mL vial = £18.31, 25-mL vial = £92.13, 50-mL vial = £95.54, 100-mL vial = £306.20

Pharmorubicin® Solution for Injection

(Pharmacia)

Injection, epirubicin hydrochloride 2 mg/mL, net price 5-mL vial = £19.31, 25-mL vial = £96.54, 100-mL vial = £386.16

IDAURUBICIN HYDROCHLORIDE

Indications

acute leukaemias (see notes above);

advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines)

Cautions

see section 8.1 and notes above; caution in handling—irritant to tissues; interactions: Appendix 1 (idarubicin)

Contra-indications

severe myocardial insufficiency; recent myocardial infarction; severe arrhythmias

Hepatic impairment

reduce dose according to serum-

Renal impairment

reduce dose; avoid in severe impairment

Pregnancy

avoid (teratogenic and toxic in animal studies); see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above

Dose

• By mouth, acute non-lymphocytic leukemia, monotherapy, 30 mg/m² daily for 3 days or in combination therapy, 15–30 mg/m² daily for 3 days

Advanced breast cancer, monotherapy, 45 mg/m² as a single dose or 15 mg/m² daily for 3 consecutive days; repeat every 3–4 weeks

Note

Max. cumulative dose by mouth (for all indications) 400 mg/m²

• By intravenous administration, consult product liter-ature

Zavedos®

(Pharmacia)

Capsules, idarubicin hydrochloride, 5 mg (red), net price 1-cap pack = £41.47, 10 mg (red/white), 1-cap pack = £69.12. Label: 25

Injection, powder for reconstitution, idarubicin hydrochloride, net price 5-mg vial = £87.36; 10-mg vial = £174.72

MALIGNANT DISEASE AND IMMUNOSUPPRESSION

MITOMYCIN

Indications

see notes above and section 7.4.4

Cautions

see section 8.1 and notes above; caution in handling—irritant to tissues

Pregnancy

avoid (teratogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above

Mitomycin C

Kyowa®

(Kyowa Hakko)

Injection, powder for reconstitution, mitomycin, net price 2-mg vial = £5.89; 10-mg vial = £19.57; 20-mg vial = £36.94; 40-mg vial = £73.88 (hosp. only)
Malignant disease and immunosuppression

8.1.3 Antimetabolites

Antimetabolites are incorporated into new nuclear material or combine irreversibly with cellular enzymes, preventing normal cellular division.

Methotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines. It is given by mouth, intravenously, intramuscularly, or intrathecally.

Methotrexate is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, non-Hodgkin’s lymphoma, and a number of solid tumours. Intrathecal methotrexate is used in the CNS prophylaxis of childhood acute lymphoblastic leukaemia, and as a therapy for established meningeal cancer or lymphoma.

Methotrexate causes myelosuppression, mucositis, and rarely pneumonitis. It is contraindicated in significant renal impairment because it is excreted primarily by the kidney. It is also contra-indicated in patients with severe hepatic impairment. It should also be avoided in the presence of significant pleural effusion or ascites because it can accumulate in these fluids, and its subsequent return to the circulation may cause myelosuppression. Systemic toxicity may follow intrathecal administration and blood counts should be carefully monitored.

Folinic acid (section 8.1) following methotrexate administration helps to prevent methotrexate-induced mucositis or myelosuppression.

Capecitabine, which is metabolised to fluorouracil, is given by mouth. It is licensed as monotherapy or combination therapy for adjuvant treatment of advanced colon cancer following surgery, for monotherapy or combination therapy of metastatic colorectal cancer, and for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine is also licensed for second-line treatment of locally advanced or metastatic breast cancer either in combination with docetaxel (where previous therapy included an anthracycline) or alone (after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated). For the role of capecitabine in the treatment of breast cancer, see section 8.3.4.1.

**NICE guidance**

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer

(April 2006)

Capecitabine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes’ C) colon cancer.

**NICE guidance**

Capecitabine and tegafur with uracil for metastatic colorectal cancer

(May 2003)

Capecitabine or tegafur with uracil (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.

Cytarabine acts by interfering with pyrimidine synthesis. It is given subcutaneously, intravenously, or intrathecally. Its predominant use is in the induction of remission of acute myeloblastic leukaemia. It is a potent myelosuppressant and requires careful haematological monitoring. A liposomal formulation of cytarabine for intrathecal use is licensed for lymphomatous meningitis.

Fludarabine is licensed for the initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first-line treatment in patients with sufficient bone-marrow reserves; it is usually given by mouth, but can be given by intravenous injection or infusion. Fludarabine is well tolerated but it does cause myelosuppression, which may be cumulative. Immunosuppression is also common (see panel on cladribine and fludarabine below), and co-trimoxazole is used to prevent pneumocystis infection. Immune-mediated haemolytic anaemia, thrombocytopenia, and neutropenia are less common side-effects.

The Scottish Medicines Consortium (p. 4) has advised (October 2006) that fludarabine is accepted for restricted use for the treatment of B-cell chronic lymphocytic leukaemia (CLL) or after first-line treatment in patients with sufficient bone-marrow reserves. First-line treatment should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease-related symptoms or evidence of progressive disease.

**NICE guidance**

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

(February 2007)

Fludarabine monotherapy, is not recommended for the first-line treatment of chronic lymphocytic leukaemia.
Cladribine is given by intravenous infusion for the treatment of hairy cell leukaemia. It is also given for chronic lymphocytic leukaemia in patients who have failed to respond to standard regimens containing an alkylating agent. Cladribine produces severe myelosuppression, with neutropenia, anaemia, and thrombocytopenia; haemolytic anaemia has also been reported. High doses of cladribine have been associated with acute renal failure and severe neurotoxicity.

Nelarabine (Atriance®) is accepted for restricted use within NHS Scotland in combination (January 2010) that pemetrexed (Alimta®) in combination with cisplatin is accepted for restricted use within NHS Scotland for previously untreated patients with stage III/IV unresectable malignant pleural mesothelioma.

Fluorouracil is usually given intravenously because absorption following oral administration is unpredictable. It is used to treat a number of solid tumours, including gastro-intestinal tract cancers and breast cancer. It is commonly used with folic acid in advanced colorectal cancer. It may also be used topically for certain malignant and pre-malignant skin lesions. Toxicity is unusual, but may include myelosuppression, mucositis, and rarely a cerebellar syndrome. On prolonged infusion, a desquamative hand–foot syndrome may occur.

Gemcitabine for the treatment of metastatic breast cancer (January 2007)

Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 (Karnofsky score is a measure of the ability to perform ordinary tasks). Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.
Pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland as monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer without predominantly squamous cell histology; it is restricted for use in patients with good performance status who would otherwise be eligible for docetaxel treatment.

**NICE guidance**

**Pemetrexed for the malignant pleural mesothelioma (January 2008)**

Pemetrexed is an option for the treatment of malignant pleural mesothelioma in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.

**Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009)**

Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.

**Pemetrexed for the treatment of non-small cell lung cancer (August 2007)**

Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.

**Pemetrexed for the treatment of non-small cell lung cancer (June 2010)**

Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.

Raltitrexed, a thymidylate synthase inhibitor, is given intravenously for palliation of advanced colorectal cancer when fluorouracil and folinic acid cannot be used. It is probably of similar efficacy to fluorouracil. Raltitrexed is generally well tolerated, but can cause marked myelosuppression and gastrointestinal side-effects.

**NICE guidance (irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer)**

See p. 542

Mercaptopurine is used as maintenance therapy for the acute leukaemias and in the management of ulcerative colitis and Crohn’s disease (section 1.5.3). Azathioprine, which is metabolised to mercaptopurine, is generally used as an immunosuppressant (section 8.2.1 and section 10.1.3). The dose of both drugs should be reduced if the patient is receiving allopurinol since it interferes with their metabolism.

**Tegafur** (in combination with uracil) is given by mouth, together with calcium folinate, in the management of metastatic colorectal cancer. Tegafur is a prodrug of fluorouracil; uracil inhibits the degradation of fluorouracil. Tegafur (with uracil) has been shown to be of similar efficacy as a combination of fluorouracil and folinic acid for metastatic colorectal cancer. For NICE guidance on capecitabine and tegafur with uracil for metastatic colorectal cancer, see above.

**Tioguanine** is given by mouth for the treatment of acute leukaemias and chronic myeloid leukaemia. It can be given at various stages of treatment in short-term cycles. Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine. Long-term therapy is no longer recommended because of the high risk of liver toxicity; treatment with tioguanine should be discontinued if liver toxicity develops.

Azacitidine is a pyrimidine analogue that is given by subcutaneous injection. It is used in the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, in adults who are not eligible for haemopoietic stem cell transplantation.
CAPECITABINE

Indications  see notes above

Cautions  see section 8.1; history of significant cardiovascular disease, arrhythmias; monitor plasma-calciu m concentration; diabetes mellitus; interactions: Appendix 1 (fluorouracil)

Hepatic impairment  manufacturer advises avoid in severe impairment

Renal impairment  reduce starting dose of 1.25 g/m² to 75% if creatinine clearance 30–50 mL/minute; avoid if creatinine clearance less than 30 mL/minute

Pregnancy  avoid (teratogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; hand–foot (desquamative) syndrome; diarrhoea

Dose

- Stage III colon cancer, adjuvant following surgery, monotherapy, ADULT over 18 years 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval; recommended duration of treatment 6 months
- Stage III colon cancer, adjuvant following surgery, in combination therapy, ADULT over 18 years 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7–day interval; recommended duration of treatment 6 months
- Metastatic colorectal cancer, monotherapy, ADULT over 18 years 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval
- Metastatic colorectal cancer, in combination therapy, ADULT over 18 years 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval
- Advanced gastric cancer, in combination with a platinum-based regimen, ADULT over 18 years 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval or 625 mg/m² twice daily given continuously
- Locally advanced or metastatic breast cancer, monotherapy or in combination with docetaxel, ADULT over 18 years 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval

Note  Adjust dose according to tolerability—consult product literature

Xeloda® (Roche)

Tablets  f/c, peach, capecitabine 150 mg, net price 60-tab pack = £40.02; 500 mg, 120-tab pack = £265.55. Label: 21

CLOFARABINE

Indications  see notes above

Cautions  see section 8.1 and notes above; cardiac disease

Hepatic impairment  manufacturer advises caution in mild to moderate impairment; avoid in severe impairment

Renal impairment  manufacturer advises caution in mild to moderate impairment; avoid in severe impairment

Pregnancy  manufacturer advises avoid (teratogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; also diarrhoea, abdominal pain, flatulence; oedema, tachycardia; cough, dyspnoea; dizziness, insomnia, anxiety, headache; chills, asthenia, malaise; myalgia, arthralgia; sweating, rash, pruritus, and purpura

Leustat® (Janssen-Cilag) [BNF]

Concentrate for intravenous infusion, cladribine 1 mg/mL. For dilution and use as an infusion, net price 10-mL vial = £159.70

For hairy cell leukaemia and for B-cell chronic lymphocytic leukaemia in patients who have failed to respond to standard regimens containing an alkylating agent

Litak® (Lipomed) [BNF]

Injection (for subcutaneous use only—no dilution required), cladribine 2 mg/mL, net price 5-mL vial = £165.00

For hairy cell leukaemia

CYTARABINE

Indications  see notes above

Cautions  see section 8.1 and notes above; interactions: Appendix 1 (cytarabine)

Hepatic impairment  reduce dose

Pregnancy  avoid (teratogenic in animal studies); see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1 and notes above

Cytarabine (Non-proprietary) [BNF]

Injection (for intravenous, subcutaneous, or intrathecal use), cytarabine 20 mg/mL, net price 5-mL vial = £4.00

Injection (for intravenous or subcutaneous use), cytarabine 20 mg/mL, net price 5-mL vial = £3.90, 25-mL vial = £19.50; 100 mg/mL, 1-mL vial = £4.00, 5-mL vial = £20.00, 10-mL vial = £39.00, 20-mL vial = £77.50

Electrolytes  Na⁺ 3.08 mmol/vial
**Lipid formulation for intrathecal use**

*DepoCyte®* (Napp) (FLUDARABINE PHOSPHATE)

**Indications** see notes above

**Cautions** see section 8.1 and notes above; monitor for signs of haemolysis; monitor for neurological toxicity; worsening of existing and increased susceptibility to skin cancer; interactions: Appendix 1 (fludarabine)

**Contra-indications** haemolytic anaemia

**Renal impairment** reduce dose by up to 50% if creatinine clearance 30–70 mL/minute; avoid if creatinine clearance less than 30 mL/minute

**Pregnancy** avoid (embryotoxic and teratogenic in animal studies); manufacturer advises effective contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above; also diarrhoea, anorexia; oedema; pneumonia; cough; peripheral neuropathy; visual disturbances; chills, fever, malaise, weakness; rash

**Dose**
- By mouth, ADULT 40 mg/m² for 5 days every 28 days usually for 6 cycles
- By intravenous injection or infusion, consult product literature

*Fludarabine (Non-proprietary)* (GENZYME)

**Injection**, powder for reconstitution, fludarabine phosphate, net price 50-mg vial = £140.40

*Fludara®* (Genzyme)

**Tablets**, f/c, pink, fludarabine phosphate 10 mg, net price 15-tab pack = £268.12, 20-tab pack = £350.70

**Injection**, powder for reconstitution, fludarabine phosphate, net price 50-mg vial = £147.07

**FLUOROURACIL**

**Indications** see notes above; pre-malignant and malignant skin lesions (section 13.8.1)

**Cautions** see section 8.1 and notes above; caution in handling—irritant to tissues; interactions: Appendix 1 (fluorouracil)

**Hepatic impairment** manufacturer advises caution

**Pregnancy** avoid (teratogenic); see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above; also local irritation with topical preparation

**Dose**
- By mouth, maintenance 15 mg/kg weekly; max. in one day 1 g
- By intravenous injection or infusion or by intra-arterial infusion, consult product literature

*Fluorouracil (Non-proprietary)* (GSK)

**Capsules**, fluorouracil 250 mg, available from ‘special-order’ manufacturers or specialist importing companies, p. 988

**Injection**, fluorouracil (as sodium salt) 25 mg/mL, net price 10-mL vial = £3.20, 20-mL vial = £6.40, 100-mL vial = £32.00; 50 mg/mL, 10-mL vial = £6.40; 20-mL vial = £12.80; 50-mL vial = £32.00; 100-mL vial = £64.00

**GEMCITABINE**

**Indications** see notes above

**Cautions** see section 8.1 and notes above; interactions: Appendix 1 (gemcitabine)

**Hepatic impairment** manufacturer advises caution

**Renal impairment** manufacturer advises caution

**Pregnancy** avoid (teratogenic in animal studies); manufacturer advises effective contraception during treatment; men must avoid fathering a child during and for 6 months after treatment; see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

*Gemcitabine (Non-proprietary)* (Lilly)

**Injection**, powder for reconstitution, gemcitabine (as hydrochloride), net price 200-mg vial = £32.00, 1-g vial = £162.00, 1.5-g vial = £213.93, 2-g vial = £324.00

**Gemzar®** (Lilly)

**Injection**, powder for reconstitution, gemcitabine (as hydrochloride), net price 200-mg vial = £32.55; 1-g vial = £162.76

**MERCAPTOPURINE** (6-Mercaptopurine)

**Indications** acute leukaemias and chronic myeloid leukaemia; inflammatory bowel disease [unlicensed indication] (section 1.5.3)

**Cautions** see section 8.1 and notes above; monitor liver function; interactions: Appendix 1 (mercaptopurine)

**Hepatic impairment** may need dose reduction

**Renal impairment** reduce dose

**Pregnancy** avoid (teratogenic); see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above; also gastrointestinal ulceration, pancreatitis; very rarely lymphoma

**Dose**
- Initially 2.5 mg/kg daily

*Puri-Nethol®* (GSK)

**Tablets**, yellow, scored, mercaptopurine 50 mg, net price 25-tab pack = £22.54

**METHOTREXATE**

**Indications** see notes above and under Dose: Crohn’s disease [unlicensed indication] (section 1.5.3); rheumatoid arthritis (section 10.1.3); psoriasis (section 13.5.3)

**Cautions** see section 8.1, notes above and section 10.1.3; interactions: Appendix 1 (methotrexate)

**Hepatic impairment** avoid in severe impairment
Renal impairment  reduce dose; risk of nephrotoxicity at high doses; avoid in severe impairment

Pregnancy avoid (teratogenic; fertility may be reduced during therapy but this may be reversible); manufacturer advises effective contraception during and for at least 3 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding—present in milk.

Side-effects see section 8.1, notes above and section 10.1.3

Dose  

- By mouth, leukaemia in children (maintenance), 15 mg/m² weekly in combination with other drugs

Important  

Note that the above dose is a weekly dose.

- By intravenous injection or infusion, or by intra-arterial infusion, or by intramuscular injection, or intrathecal administration, consult product literature

Methotrexate (Non-proprietary)  

Injection, methotrexate (as sodium salt) 2.5 mg/mL, net price 2-mL vial = £1.68, 25 mg/mL, 2-mL vial = £3.00, 20-mL vial = £30.00

Injection, methotrexate 100 mg/mL (not for intrathecal use), net price 10-mL vial = £78.33, 50-mL vial = £380.07

Oral preparations  

Section 10.1.3

NELARABINE  

Indications see notes above
Cautions see section 8.1 and notes above; previous or concurrent intrathecal chemotherapy or craniospinal irradiation (increased risk of neurotoxicity)

Driving May affect performance of skilled tasks (e.g. driving)

Pregnancy avoid (toxicity in animal studies); manufacturer advises effective contraception during and for at least 3 months after treatment in men and women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1, also gastrointestinal disturbances; oedema; neuropathy; dehydration; conjunctivitis; increased lacrimation; skin disorders; less commonly colitis, arrhythmias, and interstitial pneumonitis; rarely hepatitis; peripheral ischaemia and acute renal failure also reported

Alimta® (Lilly)  

Injection, powder for reconstitution, pemetrexed (as disodium), net price 100-mg vial = £160.00, 500-mg vial = £800.00

Electrolytes Na⁺ < 0.5 mmol/vial

RALTITREXED  

Indications see notes above
Cautions see section 8.1 and notes above; interactions: Appendix 1 (raltitrexed)

Hepatic impairment caution in mild to moderate impairment; avoid if severe

Renal impairment reduce dose and increase dosing interval if creatinine clearance less than 65 mL/minute (consult product literature); avoid if creatinine clearance less than 25 mL/minute

Pregnancy pregnancy must be excluded before treatment; ensure effective contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1 and notes above

Tomudex® (Hospira)  

Injection, powder for reconstitution, raltitrexed, net price 2-mg vial = £152.33

TEGAFUR WITH URACIL  

Indications see notes above
Cautions see section 8.1; cardiac disease; interactions: Appendix 1 (fluorouracil)

Hepatic impairment manufacturer advises monitor liver function in mild to moderate impairment and avoid in severe impairment

Renal impairment use with caution

Pregnancy avoid; manufacturer advises effective contraception during and for 3 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1 and notes above

Dose  

- ADULT, tegafur 300 mg/m² (with uracil 672 mg/m²) daily in 3 divided doses for 28 days; subsequent courses repeated after 7-day interval; for dose adjustment due to toxicity, consult product literature

PEMETREXED  

Indications see notes above
Cautions see section 8.1 and notes above; history of cardiovascular disease; diabetes; prophyllactic folic acid and vitamin B₁₂ supplementation required (consult product literature); concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature); interactions: Appendix 1 (pemetrexed)

Renal impairment manufacturer advises avoid if creatinine clearance less than 45 mL/minute—no information available

Pregnancy avoid (toxicity in animal studies); manufacturer advises effective contraception during treatment; men must avoid fathering a child during and for 6 months after treatment; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1, also gastro-intestinal disturbances; oedema; neuropathy; dehydration; conjunctivitis; increased lacrimation; skin disorders; less commonly colitis, arrhythmias, and interstitial pneumonitis; rarely hepatitis; peripheral ischaemia and acute renal failure also reported

Alimta® (GSK)  

Injection, methotrexate (as sodium salt) 2.5 mg/mL, net price 2-mL vial = £1.68, 25 mg/mL, 2-mL vial = £3.00, 20-mL vial = £30.00

Injection, methotrexate 100 mg/mL (not for intrathecal use), net price 10-mL vial = £78.33, 50-mL vial = £380.07

Oral preparations  

Section 10.1.3

BENEFIXED

Tomudex® (Hospira)  

Injection, powder for reconstitution, raltitrexed, net price 2-mg vial = £152.33

TEGAFUR WITH URACIL  

Indications see notes above
Cautions see section 8.1; cardiac disease; interactions: Appendix 1 (fluorouracil)

Hepatic impairment manufacturer advises monitor liver function in mild to moderate impairment and avoid in severe impairment

Renal impairment use with caution

Pregnancy avoid; manufacturer advises effective contraception during and for 3 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1 and notes above

Dose  

- ADULT, tegafur 300 mg/m² (with uracil 672 mg/m²) daily in 3 divided doses for 28 days; subsequent courses repeated after 7-day interval; for dose adjustment due to toxicity, consult product literature

PEMETREXED  

Indications see notes above
Cautions see section 8.1 and notes above; history of cardiovascular disease; diabetes; prophyllactic folic acid and vitamin B₁₂ supplementation required (consult product literature); concomitant nephrotoxic drugs including non-steroidal anti-inflammatory drugs (consult product literature); interactions: Appendix 1 (pemetrexed)

Renal impairment manufacturer advises avoid if creatinine clearance less than 45 mL/minute—no information available

Pregnancy avoid (toxicity in animal studies); manufacturer advises effective contraception during treatment; men must avoid fathering a child during and for 6 months after treatment; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1, also gastro-intestinal disturbances; oedema; neuropathy; dehydration; conjunctivitis; increased lacrimation; skin disorders; less commonly colitis, arrhythmias, and interstitial pneumonitis; rarely hepatitis; peripheral ischaemia and acute renal failure also reported

Alimta® (GSK)  

Injection, methotrexate (as sodium salt) 2.5 mg/mL, net price 2-mL vial = £1.68, 25 mg/mL, 2-mL vial = £3.00, 20-mL vial = £30.00

Injection, methotrexate 100 mg/mL (not for intrathecal use), net price 10-mL vial = £78.33, 50-mL vial = £380.07

Oral preparations  

Section 10.1.3

BENEFIXED

Tomudex® (Hospira)  

Injection, powder for reconstitution, raltitrexed, net price 2-mg vial = £152.33

TEGAFUR WITH URACIL  

Indications see notes above
Cautions see section 8.1; cardiac disease; interactions: Appendix 1 (fluorouracil)

Hepatic impairment manufacturer advises monitor liver function in mild to moderate impairment and avoid in severe impairment

Renal impairment use with caution

Pregnancy avoid; manufacturer advises effective contraception during and for 3 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1 and notes above

Dose  

- ADULT, tegafur 300 mg/m² (with uracil 672 mg/m²) daily in 3 divided doses for 28 days; subsequent courses repeated after 7-day interval; for dose adjustment due to toxicity, consult product literature
8.1.4 Vinca alkaloids and etoposide

The vinca alkaloids, vinblastine, vincristine, vindesine, vinorelbine, and vinflunine cause severe local irritation and care must be taken to avoid extravasation. Severe bronchospasm has been reported following administration of the vinca alkaloids (more commonly when used in combination with mitomycin-C).

Important
Vinblastine, vincristine, vindesine, vinorelbine, and vinflunine injections are for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

Etoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3–5 days and courses should not be repeated more frequently than at intervals of 21 days. It has particularly useful activity in small cell carcinoma of the bronchus, the lymphomas, and testicular cancer.

8.1.4 Vinca alkaloids and etoposide

The vinca alkaloids, vinblastine, vincristine, vindesine, and vinorelbine, are used to treat a variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer). Vinorelbine is a semi-synthetic vinca alkaloid. It is given intravenously or orally for the treatment of advanced breast cancer and for advanced non-small cell lung cancer. For the role of vinorelbine in the treatment of breast cancer, see section 8.3.4.1.

Vincristine is licensed as monotherapy for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen.

Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vincristine; it occurs less often with vindesine, vinblastine, vinorelbine, and vinflunine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; otoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur, and increasing motor weakness calls for dose reduction or discontinuation of these drugs. Recovery from neurotoxic effects is usually slow but complete.

Myelosuppression is a dose-limiting side-effect of vinblastine, vindesine, vinorelbine, and vinflunine; vincristine causes negligible myelosuppression. The vinca alkaloids cause severe local irritation and care must be taken to avoid extravasation. Severe bronchospasm has been reported following administration of the vinca alkaloids (more commonly when used in combination with mitomycin-C).
8.1.4 Vinca alkaloids and etoposide

**Vinblastine** (Non-proprietary) *(Genus)*

Injection, vinblastine sulphate 1 mg/mL, net price 1-mL vial = £13.09

Cautions

see section 8.1 and notes above; neuro-muscular disease; caution in handling; interactions: Appendix 1 (vinblastine)

Contra-indications

see section 8.1 and notes above; muscular disease; caution in handling; interactions: Appendix 1 (vincristine)

Hepatic impairment

dose reduction may be necessary

Renal impairment

reduce dose if creatinine clearance less than 60 mL/minute—consult product literature

Pregnancy

avoid unless essential—teratogenicity and embryotoxicity in animal studies; manufacturer advises effective contraception during and for up to 3 months after treatment; see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above; also anorexia, diarrhoea, dyspepsia, tachycardia, hypertension, hypotension, thrombosis; oedema; insomnia; fatigue; dehydration; cutaneous reactions, sweating; less commonly increased weight, myocardial infarction, renal failure; also reported QT-interval prolongation, inappropriate anti-diuretic hormone secretion, blurred vision

Javlor® (Fabre) *(Genus)*

Concentrate for intravenous infusion, vinflunine (as ditartrate) 25 mg/mL, net price 2-mL vial = £212.50, 10-mL vial = £1062.50

**Vinflunine** (Non-proprietary) *(Genus)*

Concentrate for intravenous infusion, vinflunine (as tartrate) 20 mg (brown), net price 2-mL vial = £212.50, 10-mL vial = £1062.50

Cautions

see section 8.1 and notes above; ischaemic heart disease; caution in handling; interactions: Appendix 1 (vinorelbine)

Contra-indications

see section 8.1 and notes above; with capsules previous significant surgical resection of stomach or small bowel, long-term oxygen therapy, concurrent radiotherapy if treating the liver

Hepatic impairment

reduce oral dose in moderate impairment, avoid oral use in severe impairment; reduce intravenous dose in severe impairment; consult product literature

Pregnancy

avoid unless essential (teratogenicity, and fetal loss in animal studies); manufacturer advises effective contraception during and for 3 months after treatment; men must avoid fathering a child during and for 3 months after treatment; see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above; also rarely pancreatitis; inappropriate secretion of anti-diuretic hormone also reported; irritant to tissues

Dose

- By mouth, 60 mg/m² once weekly for 3 weeks, increased if tolerated to 80 mg/m² once weekly; max. 160 mg once weekly
- By intravenous injection or infusion, consult product literature

**Vinorelbine** (Non-proprietary) *(Genus)*

Concentrate for intravenous infusion, vinorelbine (as tartrate) 10 mg/mL, net price 1-mL vial = £29.00, 5-mL vial = £139.00

Cautions

see section 8.1 and notes above; cardiovascular disease; QT-interval prolongation (avoid hypokalaemia or concomitant use of drugs that prolong QT-interval); interactions: Appendix 1 (vinorelbine)

Contra-indications

see section 8.1 and notes above; with capsules previous significant surgical resection of stomach or small bowel, long-term oxygen therapy, concurrent radiotherapy if treating the liver

Hepatic impairment

reduce dose—consult product literature

Renal impairment

reduce dose if creatinine clearance less than 60 mL/minute—consult product literature

Pregnancy

avoid unless essential—teratogenicity and embryotoxicity in animal studies; manufacturer advises effective contraception during and for up to 3 months after treatment; see also Reproductive Function, p. 520

Breast-feeding

discontinue breast-feeding

Side-effects

see section 8.1 and notes above; also anorexia, diarrhoea, dyspepsia, tachycardia, hypertension, hypotension, thrombosis; oedema; insomnia; fatigue; dehydration; cutaneous reactions, sweating; less commonly increased weight, myocardial infarction, renal failure; also reported QT-interval prolongation, inappropriate anti-diuretic hormone secretion, blurred vision

Navelbine® (Fabre) *(Genus)*

Concentrate for intravenous infusion, vinorelbine (as tartrate) 10 mg/mL, net price 1-mL vial = £29.75; 5-mL vial = £139.98

Capsules, vinorelbine (as tartrate) 20 mg (brown), net price 1-cap pack = £43.98; 30 mg (pink), 1-cap pack = £85.98; 80 mg (yellow), 1-cap pack = £175.92

Label: 21, 25
Amsacrine

Amsacrine has an action and toxic effects similar to those of doxorubicin (section 8.1.2) and is given intra-venously. It is occasionally used in acute myeloid leukaemia. Side-effects include myelosuppression and mucositis; electrolytes should be monitored as fatal arrhythmias have occurred in association with hypokalaemia.

AMSACRINE

Indications see notes above
Cautions see section 8.1 and notes above; also caution in handling—irritant to skin and tissues
Hepatic impairment manufacturer advises reduce initial dose by 20–30%
Renal impairment manufacturer advises reduce initial dose by 20–30%
Pregnancy avoid (teratogenic and toxic in animal studies); may reduce fertility; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above
Amsidine® (Goldshield) Concentrate for intravenous infusion, amsacrine 5 mg (as lactate)/mL, when reconstituted by mixing two solutions, net price 1.5-mL (75-mg) amp with 13.5-mL diluent vial = £54.08 (hosp. only)

Arsenic trioxide

Arsenic trioxide is licensed for acute promyelocytic leukaemia in patients who have relapsed or failed to respond to previous treatment with a retinoid and chemotherapy.

ARSENIC TRIOXIDE

Indications see notes above
Cautions see section 8.1; correct electrolyte abnormalities before treatment; ECG required before and during treatment—consult product literature; avoid concomitant administration with drugs causing QT interval prolongation, hypokalaemia, and hypomagnesaemia; previous treatment with anthracyclines (increased risk of QT interval prolongation); interactions: Appendix 1 (arsenic trioxide)
Hepatic impairment manufacturer advises caution—limited information available
Renal impairment manufacturer advises caution—limited information available
Pregnancy avoid (teratogenic and embryotoxic in animal studies); manufacturer advises effective contraception during treatment in men and women; see also Reproductive function, p. 520
Breast-feeding discontinue breast-feeding

Bevacizumab

Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor. It is licensed for the treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy (but see NICE guidance below). It is also licensed for first-line treatment of metastatic breast cancer in combination with paclitaxel, or docetaxel, and also for advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a (but see NICE Guidance, p. 545).

Bevacizumab, in combination with platinum-based chemotherapy, is licensed for first-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab is given by intravenous infusion.

MHRA/CHM advice

Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)
Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw. Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk. Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib. If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

NICE guidance

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)
- Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer;
- Cetuximab in combination with irinotecan is not recommended for the second-line or subsequent treatment of metastatic colorectal cancer after the failure of an irinotecan-containing chemotherapy regimen.
**Bexarotene**

Bexarotene is an agonist at the retinoid X receptor, which is involved in the regulation of cell differentiation and proliferation. It is associated with little myelosuppression or immunosuppression. Bexarotene can cause regression of cutaneous T-cell lymphoma. The main adverse effects are hyperlipidaemia, hypothyroidism, leucopenia, headache, rash, and pruritus.

The Scottish Medicines Consortium (p. 4) has advised (November 2002) that bexarotene is recommended for restricted use as a second-line treatment for patients with advanced cutaneous T-cell lymphoma.

**Indications**

skin manifestations of cutaneous T-cell lymphoma refractory to previous systemic treatment

**Cautions**

see section 8.1 and notes above; hyperlipidaemia (avoid if uncontrolled), hypothyroidism (avoid if uncontrolled), hypersensitivity to retinoids; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (bexarotene)

**Contra-indications**

see section 8.1 and notes above; history of pancreatitis, hypervitaminosis A

**Hepatic impairment**

avoid

**Pregnancy**

avoid—toxicity in animal studies; effective contraception required during and for at least 6 months after treatment in women; see also Reproductive Function, p. 520

**Breast-feeding**

manufacturer advises avoid breast-feeding during and for at least 6 months after treatment

**Side-effects**

see section 8.1 and notes above

**Dose**

- Initially 300 mg/m² daily as a single dose with a meal; adjust dose according to response

**Targretin®** (Cephalon) ▼

Capsules, bexarotene 75 mg in a liquid suspension, net price 100-cap pack = £937.50

**NICE guidance**

Bortezomb monotherapy for relapsed multiple myeloma (October 2007)

Bortezomb monotherapy is an option for the treatment of progressive multiple myeloma in patients who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone-marrow transplantation, under the following circumstances:

- the response to bortezomib is measured using serum M protein after a maximum of four cycles of treatment, and treatment is continued only in patients who have a reduction in serum M protein of 50% or more (where serum M protein is not measurable, an appropriate alternative biochemical measure of response should be used) and
- the manufacturer rebates the full cost of bortezomib if there is an inadequate response (as defined above) after four cycles of treatment.

**Bortezomib**

Bortezomib, a proteasome inhibitor, is licensed as monotherapy for the treatment of multiple myeloma that has progressed despite the use of at least one therapy, and where the patient has already had, or is unable to have, bone-marrow transplantation. It is also licensed for use in combination with melphalan and prednisolone for the treatment of previously untreated multiple myeloma in patients who are not eligible for high-dose chemotherapy with bone marrow transplantation. Bortezomib is given by intravenous injection.

**Indications**

see notes above

**Cautions**

see section 8.1; cardiovascular disease; pulmonary disease (chest x-ray recommended before treatment—discontinue if interstitial lung disease develops); consider antiviral prophylaxis for herpes

**Hepatic impairment**

avoid

**Pregnancy**

avoid—manufacturer advises effective contraception during and for at least 1 month after treatment in men or women; see also Reproductive Function, p. 520

**Breast-feeding**

discontinue breast-feeding

**Side-effects**

see section 8.1 and notes above

**Dose**

- Initially 300 mg/m² daily as a single dose with a meal; adjust dose according to response

**Targretin®** (Cephalon) ▼

Capsules, bexarotene 75 mg in a liquid suspension, net price 100-cap pack = £937.50

**NICE guidance**

Bortezomb monotherapy for relapsed multiple myeloma (October 2007)

Bortezomb monotherapy is an option for the treatment of progressive multiple myeloma in patients who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone-marrow transplantation, under the following circumstances:

- the response to bortezomib is measured using serum M protein after a maximum of four cycles of treatment, and treatment is continued only in patients who have a reduction in serum M protein of 50% or more (where serum M protein is not measurable, an appropriate alternative biochemical measure of response should be used) and
- the manufacturer rebates the full cost of bortezomib if there is an inadequate response (as defined above) after four cycles of treatment.
zoster infection; history of seizures; amyloidosis; risk of neuropathy—consult product literature; monitor blood-glucose concentration in patients on oral anti-diabetics; interactions: Appendix 1 (bortezomib)

Contra-indications acute diffuse infiltrative pulmonary disease; pericardial disease

Hepatic impairment manufacturer advises caution in mild to moderate impairment—consider dose reduction; avoid in severe impairment

Renal impairment no information available for creatinine clearance less than 20 mL/minute/1.73 m²

Pregnancy manufacturer advises effective contraception during and for 3 months after treatment in men or women—toxicity in animal studies; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1; also gastrointestinal disturbances including constipation (cases of ileus reported), taste disturbance, dry mouth, decreased appetite; postural hypotension, hypertension, haematoma, phlebitis, chest pain, oedema; dyspnoea, cough; confusion, depression, insomnia, anxiety, peripheral neuropathy, paraesthesia, headache, dizziness, tremor, asthenia, fatigue; reactivation of herpes zoster infection, influenza-like symptoms; renal impairment, dysuria; dehydration, hypokalaemia, hyperglycaemia; muscle cramps, arthralgia, bone pain; blurred vision, eye pain; episaxis; urticaria, pruritus, erythema, dry skin, eczema, rash, increased sweating; less commonly syncope, seizures; reversible posterior leucoencephalopathy syndrome (discontinue treatment), toxic epidermal necrolysis, Sweet’s syndrome, and vasculitic rash also reported

Velcade® (Janssen-Cilag) ▼ the
Injection, powder for reconstitution, bortezomib (as mannitol boronic ester), net price 3.5-mg vial = £762.38

Cetuximab

Cetuximab is licensed for the treatment of metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated (but see NICE guidance below, and under Bevacizumab on p. 537). Cetuximab is also licensed, in combination with radiotherapy, for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008). Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.

NICE guidance
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008)
Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.

NICE guidance
Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009)
Cetuximab in combination with platinum-based chemotherapy is not recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.

NICE guidance
Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:

- the primary tumour has been resected or is potentially operable;
- the metastatic disease is confined to the liver and is resectable;
- the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.

In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.

In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.

Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.

CETUXIMAB

Indications see notes above and product literature

Cautions cardiovascular disease, cardiopulmonary disease, pulmonary disease—discontinue if interstitial lung disease

Contra-indications KRAS mutated colorectal tumours (avoid if KRAS tumour status unknown)

Pregnancy use only if potential benefit outweighs risk—no information available; see also Reproductive Function, p. 520

Breast-feeding avoid breast-feeding during and for 2 months after treatment—no information available

Side-effects infusion-related reactions including dyspnoea, dizziness, chills, fever, and hypersensitivity reactions (possibly delayed onset) such as rash, urti-
540 8.1.5 Other antineoplastic drugs

Malignant disease and immunosuppression

Crisantaspase
Crisantaspase is the enzyme asparaginase produced by Erwinia chrysanthemi. It is given intramuscularly, intravenously, or subcutaneously almost exclusively in acute lymphoblastic leukaemia. Facilities for the management of anaphylaxis should be available.

DACARBAZINE
Indications see notes above
Cautions see section 8.1; caution in handling; interactions: Appendix 1 (dacarbazine)
Hepatic impairment dose reduction may be required in combined renal and hepatic impairment; avoid in severe impairment
Renal impairment dose reduction may be required in combined renal and hepatic impairment; avoid in severe impairment
Pregnancy avoid (carcinogenic and teratogenic in animal studies); ensure effective contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above; rarely liver necrosis due to hepatic vein thrombosis; irritant to skin and tissues

DACARBAZINE
Appendix 1 (dacarbazine)
Injection, powder for reconstitution, dacarbazine, as citrate), net price 100-mg vial = £5.05; 200-mg vial = £7.16; 500-mg vial = £16.50; 600-mg vial = £22.50; 1-g vial = £31.80

TEMZOLOMIDE
Indications see notes above
Cautions see section 8.1; interactions: Appendix 1 (temozolomide)
Hepatic impairment use with caution in severe impairment—no information available
Renal impairment manufacturer advises caution—no information available
Pregnancy avoid (teratogenic and embryotoxic in animal studies); manufacturer advises adequate contraception during treatment; men should avoid fathering a child during and for at least 6 months after treatment; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1
Dose
• Consult product literature; CHILD under 3 years not recommended

NICE guidance
Temozolomide for the treatment of recurrent malignant glioma (brain cancer) (April 2001)
Temozolomide may be considered for the treatment of recurrent malignant glioma, which has not responded to first-line chemotherapy.

NICE guidance
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (June 2007)
Temozolomide is an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a WHO performance status of 0 or 1. Carmustine implants are an option for the treatment of newly diagnosed high-grade (Grade 3 or 4) glioma only for patients in whom at least 90% of the tumour has been resected. Carmustine implants should only be used within specialist centres.

540 8.1.5 Other antineoplastic drugs

Malignant disease and immunosuppression
Hydroxyurea

Hydroxyurea is an orally active drug used mainly in the treatment of chronic myeloid leukaemia. It is also licensed for the treatment of cancer of the cervix in conjunction with radiotherapy. It is occasionally used for polycythaemia (the usual treatment is venesection). Myelosuppression, nausea, and skin reactions are the most common toxic effects.

**HYDROXYCARBAMIDE**

(Hydroxyurea)

**Indications** see notes above; sickle-cell disease (section 9.1.3)

**Cautions** see section 8.1 and notes above; interactions: Appendix 1 (hydroxyurea)

**Hepatic impairment** use with caution

**Renal impairment** use with caution

**Pregnancy** avoid (teratogenic in animal studies)

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

**Dose**

- 20–30 mg/kg daily or 80 mg/kg every third day

**Hydroxyurea**

(Non-proprietary)

**Capsules**, hydroxyurea 500 mg, net price 100-cap pack = £10.47

**Hydrea**

(Squibb)

**Capsules**, pink/green, hydroxyurea 500 mg, net price 100-cap pack = £10.47

**Mitotane**

Mitotane is licensed for the symptomatic treatment of advanced or inoperable adrenocortical carcinoma. It selectively inhibits the activity of the adrenal cortex, necessitating corticosteroid replacement therapy (section 6.3.1); the dose of glucocorticoid should be increased in case of shock, trauma, or infection.

Gastro-intestinal side-effects such as anorexia, nausea, and vomiting, and endocrine side-effects, such as hypogonadism and thyroid disorders, are very common with mitotane; neurotoxicity occurs in many patients.

**MITOTANE**

**Indications** see notes above

**Cautions** see section 8.1 and notes above; risk of accumulation in overweight patients; monitor plasma-mitotane concentration—consult product literature; interactions: Appendix 1 (mitotane)

**Driving** CNS effects may affect performance of skilled tasks (e.g. driving)

**Counselling** Warn patient to contact doctor immediately if injury, infection, or illness occurs (because of risk of acute adrenal insufficiency)

**Hepatic impairment** manufacturer advises caution in mild to moderate impairment—monitoring of plasma-mitotane concentration recommended; avoid in severe impairment

**Renal impairment** manufacturer advises caution in mild to moderate impairment—monitoring of plasma-mitotane concentration recommended; avoid in severe impairment

**Pregnancy** manufacturer advises avoid—women of childbearing age should use effective contraception during and after treatment; see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above; also gastro-intestinal disturbances (including nausea, vomiting, diarrhoea, epigastric discomfort), anorexia, liver disorders; hypercholesterolaemia, hyperglycæmia, ataxia, confusion, asthenia, myasthenia, paraesthesia, drowsiness, neuropathy, cognitive impairment, movement disorder, dizziness, headache; gynaecomastia; prolonged bleeding time, leucopenia, thrombocytopenia, anaemia; rash; rarely hypersalivation, hypertension, postural hypotension, flushing, pyrexia, haematuria, proteinuria, haemorrhagic cystitis, hypouricaemia, visual disturbances, and ocular disorders

**Dose**

- **ADULT** over 18 years, initially 2–3 g daily, (up to 6 g daily in severe illness) in 2–3 divided doses, adjusted according to plasma-mitotane concentration; reduce dose or interrupt treatment if signs of toxicity; discontinue if inadequate response after 3 months

**Note** Plasma-mitotane concentration for optimum response 14–20 mg/litre

**Lysodren**

(HRA Pharma)

**Tablets**, scored, mitotane 500 mg, net price 100-tab pack = £590.97. Label: 2, 10, 21, counselling, driving, adrenal suppression

**Panitumumab**

Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It is indicated as monotherapy for the treatment of EGFR expressing metastatic colorectal cancer with non-mutated *KRAS* gene after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab is given by intravenous infusion.

**PANITUMUMAB**

**Indications** see notes above

**Cautions** monitor for dermatological reactions (may require temporary or permanent discontinuation—consult product literature); pulmonary disease—discontinue if pneumonitis or lung infiltrates occur; monitor for hypomagnesaemia and hypocalcaemia

**Contra-indications** intestinal pulmonary disease

**Pregnancy** avoid (toxicity in animal studies); manufacturer advises effective contraception

**Breast-feeding** manufacturer advises avoid—breastfeeding during and for 3 months after treatment

**Side-effects** see section 8.1; also infusion-related reactions including hypertension, hypotension, tachycardia, and severe hypersensitivity reactions (possibly delayed onset); diarrhoea, abdominal pain, constipation, dry mouth and nose, dyspnoea, cough,
embolism; fatigue, dizziness, headache; hypomagnesaemia, hypocalcaemia, hypokalaemia, dehydration; ocular disorders (including conjunctivitis, increased lacrimation, dry eyes, ocular hyperaemia); skin reactions (including rash, erythema, pruri tus, dry skin, acne, hand-foot syndrome and exfoliation), mucosal inflammation, hypertrichosis, and nail disorders.

**Vectorix**® (Amgen) ▼ 1/58
Concentrate for intravenous infusion, panitumumab
20 mg/mL, net price 5-mL vial = £379.29, 20-mL vial = £1517.16
Electrolytes Na⁺ 0.75 mmol/vial

**Pentostatin**

Pentostatin is active in hairy cell leukaemia. It is given intravenously on alternate weeks and can induced prolonged complete remission. It can cause myelosuppression, immunosuppression, and a number of other side-effects that may be severe. Treatment should be withheld in patients who develop a severe rash, and withheld or discontinued in patients showing signs of neurotoxicity. Its use should be confined to specialist centres.

**Indications** see notes above

**Cautions** see section 8.1 and notes above; interactions: Appendix 1 (pentostatin)

**Hepatic impairment** manufacturer advises caution—limited information available

**Renal impairment** avoid if creatinine clearance less than 60 mL/minute

**Pregnancy** avoid if teratogenic in animal studies; manufacturer advises that men should not father children during and for 6 months after treatment; see also Reproductive Function, p. 520

**Breast-feeding** discontinue breast-feeding

**Side-effects** see section 8.1 and notes above

**Nipent**® (Hospira) ▼ 1/56
Injection, powder for reconstitution, pentostatin, net price 10-mg vial = £863.78

**Platinum compounds**

Carboplatin is widely used in the treatment of advanced ovarian cancer and lung cancer (particularly the small cell type). It is given intravenously. The dose of carboplatin is determined according to renal function rather than body surface area. Carboplatin can be given on an outpatient basis and is better tolerated than cisplatin; nausea and vomiting are reduced in severity and nephrotoxicity, neurotoxicity, and ototoxicity are much less of a problem than with cisplatin. It is, however, more myelosuppressive than cisplatin.

Cisplatin is used alone or in combination for the treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (but carboplatin is preferred for ovarian cancer). It is given intravenously. Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting. Cisplatin is toxic, causing nephrotoxicity (monitoring of renal function is essential), ototoxicity, peripheral neuropathy, hypomagnesaemia and myelosuppression. It is, however, increasingly given in a day-care setting.

Oxaliplatin is licensed in combination with fluorouracil and folinic acid, for the treatment of metastatic colorectal cancer and as adjuvant treatment of colon cancer after resection of the primary tumour; it is given by intravenous infusion. Neurotoxic side-effects (including sensory peripheral neuropathy) are dose limiting. Other side-effects include gastro-intestinal disturbances, ototoxicity, and myelosuppression. If unexplained respiratory symptoms occur, oxaliplatin should be discontinued until investigations exclude interstitial lung disease and pulmonary fibrosis.
8.1.5 Other antineoplastic drugs

Porfimer sodium and temoporfin

Porfimer sodium and temoporfin are used in the photodynamic treatment of various tumours. The drugs accumulate in malignant tissue and are activated by laser light to produce a cytotoxic effect.

Porfimer sodium is licensed for photodynamic therapy of non-small cell lung cancer and obstructing oesophageal cancer. Temoporfin is licensed for photodynamic therapy of advanced head and neck cancer.

CARBOPLATIN

Indications see notes above
Cautions see section 8.1 and notes above; interactions: Appendix 1 (platinum compounds)
Renal impairment reduce dose and monitor haematological parameters and renal function; avoid if creatinine clearance less than 30 mL/minute
Pregnancy avoid (teratogenic and embryotoxic in animal studies); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above

CISPLATIN

Indications see notes above
Cautions see section 8.1 and notes above; interactions: Appendix 1 (platinum compounds)
Renal impairment avoid if possible; nephrotoxic
Pregnancy avoid (teratogenic and toxic in animal studies); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above

OXALIPLATIN

Indications metastatic colorectal cancer in combination with fluorouracil and folic acid; colon cancer—see notes above
Cautions see section 8.1 and notes above; interactions: Appendix 1 (platinum compounds)
Contra-indications see section 8.1; peripheral neuropathy with functional impairment
Renal impairment manufacturer advises avoid if creatinine clearance less than 30 mL/minute
Pregnancy manufacturer advises avoid—toxicity in animal studies; effective contraception required during and for 4 months after treatment in women and 6 months after treatment in men; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding
Side-effects see section 8.1 and notes above

Oxaliplatin (Non-proprietary) (M)
Injection, oxaliplatin 10 mg/mL, net price 5-mL vial = £22.04, 15-mL vial = £56.92, 45-mL vial = £168.85, 60-mL vial = £260.00

TEMOPORFIN

Indications advanced head and neck squamous cell carcinoma refractory to, or unsuitable for, other treatments
Cautions see section 8.1; avoid exposure of skin and eyes to direct sunlight or bright indoor light for at least 30 days
Contra-indications see section 8.1; tracheo-oesophageal or broncho-oesophageal fistula; acute porphyria (section 9.8.2)
Hepatic impairment avoid in severe impairment
Pregnancy manufacturer advises avoid unless essential
Breast-feeding no information available—manufacturer advises avoid
Side-effects see section 8.1; photosensitivity (see Cautions above—sunscreens offer no protection), constipation

Photofrin® (Axcan) (M)
Injection, powder for reconstitution, porfimer sodium, net price 15-mg vial = £154.00; 75-mg vial = £770.00

Foscan® (BioIntec) ▼ (M)
Injection, temoporfin 1 mg/mL, net price 1-mL vial = £900.00, 3-mL vial = £1800.00, 6-mL vial = £3400.00

BNF 61

Malignant disease and immunosuppression
8 Malignant disease and immunosuppression

The Scottish Medicines Consortium (p. 4) has advised (April 2007) that the use of dasatinib (Sprycel®) in NHS Scotland is restricted to patients in the chronic phase of chronic myeloid leukaemia.

**Procarbazine**

Procarbazine is most often used in Hodgkin’s disease. It is given by mouth. Toxic effects include nausea, myelosuppression, and a hypersensitivity rash. Preventing further use of this drug requires dietary restriction, which is rarely considered necessary. Alcohol ingestion may cause a disulfiram-like reaction.

**Procarbazine**

**Indications**

- see notes above

**Cautions**

- see section 8.1 and notes above; cardiovascular or cerebrovascular disease; phaeochromocytoma; epilepsy; interactions: Appendix 1 (procarbazine)

**Hepatic impairment**

- caution in mild to moderate impairment; avoid in severe impairment

**Renal impairment**

- caution in mild to moderate impairment; avoid in severe impairment

**Pregnancy**

- avoid (teratogenic in animal studies and isolated reports in humans); see also Reproductive Function, p. 520

**Breast-feeding**

- discontinue breast-feeding

**Side-effects**

- see section 8.1 and notes above; also loss of appetite; jaundice also reported

Procarbazine (Non-proprietary) 50 mg

Capsules, procarbazine (as hydrochloride) 50 mg, net price 50-cap pack = £199.60. Label: 4

**Protein kinase inhibitors**

Dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapa-tinib, nilotinib, pazopanib, sorafenib, sunitinib, and temsirolimus are protein kinase inhibitors.

**Dasatinib**, a tyrosine kinase inhibitor, is licensed for the treatment of chronic myeloid leukaemia in those who have resistance to or intolerance of previous therapy, including imatinib. It is also licensed for acute lymphoblastic leukaemia (Philadelphia chromosome positive) in those who have resistance to or intolerance of previous therapy.

The Scottish Medicines Consortium (p. 4) has advised (April 2007) that the use of dasatinib (Sprycel®) in NHS Scotland is restricted to patients in the chronic phase of chronic myeloid leukaemia.

**Erlotinib**, a tyrosine kinase inhibitor, is licensed in combination with gemcitabine for the treatment of metastatic pancreatic cancer. It is also licensed for the treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy and as monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy.

**Protein kinase inhibitors**

The Scottish Medicines Consortium (p. 4) has advised (May 2006) that erlotinib (Tarceva®) is accepted for restricted use within NHS Scotland for the treatment of locally advanced or metastatic non-small cell lung cancer, after failure of at least one chemotherapy regimen. Erlotinib is restricted to use in patients who would otherwise be eligible for treatment with docetaxel monotherapy.

**Protein kinase inhibitors**

The Scottish Medicines Consortium (p. 4) has advised (October 2003) that imatinib (Glivec®) should be used for chronic myeloid leukaemia only under specialist supervision in accordance with British Society of Haematology guidelines (November 2001).

**NICE guidance**

- **Erlotinib for non-small-cell lung cancer** (November 2008)

Erlotinib is recommended, as an alternative to docetaxel, as second-line treatment for locally advanced or metastatic non-small-cell lung cancer after failure of previous chemotherapy, on the basis that it is provided by the manufacturer at an overall treatment cost equal to that of docetaxel. Erlotinib is not recommended in patients for whom docetaxel is unsuitable or as third-line treatment after docetaxel.

**Everolimus**, a protein kinase inhibitor, is licensed for the treatment of advanced renal cell carcinoma when the disease has progressed despite treatment with vascular endothelial growth factor-targeted therapy.

**Gefitinib**, a tyrosine kinase inhibitor, is licensed for the treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor.

**Imatinib**, a tyrosine kinase inhibitor, is licensed for the treatment of newly diagnosed chronic myeloid leukaemia where bone marrow transplantation is not considered first-line treatment, and for chronic myeloid leukaemia in chronic phase after failure of interferon alfa, or in accelerated phase, or in blast crisis (see NICE guidance below). It is also licensed for the treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST), and as adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse. Imatinib is licensed for the treatment of newly diagnosed acute lymphoblastic leukaemia in combination with other chemotherapy, and as monotherapy for relapsed or refractory acute lymphoblastic leukaemia. Imatinib is also licensed for the treatment of unresectable dermatofibrosarcoma protuberos and for patients with recurrent or metastatic dermatofibrosarcoma protuberos who cannot have surgery. Imatinib is also licensed for the treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement and for the treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia.

The Scottish Medicines Consortium (p. 4) has advised (March 2002) that imatinib (Glivec®) should be used for chronic myeloid leukaemia only under specialist supervision in accordance with British Society of Haematology guidelines (November 2001).

**NICE guidance**

- **Imatinib for chronic myeloid leukaemia** (October 2003)

Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously. Where imatinib has failed to stop disease progression from chronic phase to accelerated phase or to blast crisis, continued use is recommended only as part of further clinical study.
Lapatinib, a tyrosine kinase inhibitor, is licensed for the treatment of advanced or metastatic breast cancer in patients with tumors that overexpress human epidermal growth factor receptor-2 (HER2). It is indicated, in combination with capecitabine, for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab, or for postmenopausal women in combination with an aromatase inhibitor section 8.3.4.1.

Nilotinib, a tyrosine kinase inhibitor, is licensed for the treatment of chronic myeloid leukaemia in those who have resistance to or intolerance of previous therapy, including imatinib.

The Scottish Medicines Consortium (p. 4) has advised (February 2008) that nilotinib (Tasigna®) is accepted for restricted use within NHS Scotland for the treatment of chronic-phase chronic myeloid leukaemia in adults resistant to or intolerant of at least one previous therapy, including imatinib.

Pazopanib, a tyrosine kinase inhibitor, is licensed for the treatment of advanced renal cell carcinoma, as first-line treatment and for the treatment of patients who have had previous treatment with cytokine therapy for advanced disease.

Sorafenib, an inhibitor of multiple kinases, is licensed for the treatment of advanced renal cell carcinoma when treatment with interferon alfa or interleukin-2 has failed or is contra-indicated (but see NICE Guidance below). It is also licensed for the treatment of hepatocellular carcinoma.

Temsirolimus is a protein kinase inhibitor licensed for the first-line treatment of advanced renal cell carcinoma (see NICE Guidance above), and for the treatment of relapsed or refractory mantle cell lymphoma. Hyper-sensitivity reactions, including some life-threatening and rare fatal reactions, are associated with temsirolimus therapy, usually during administration of the first dose. Symptoms include flushing, chest pain, dyspnoea, apnoea, hypotension, loss of consciousness, and anaphylaxis. Where possible, patients should receive an intravenous dose of antihistamine 30 minutes before starting the temsirolimus infusion. The infusion may have to be stopped temporarily for the treatment of infusion-related effects—consult product literature for appropriate management. If adverse reactions are not managed with dose delays, a dose reduction should be considered—consult product literature.
DASATINIB

Indications  see notes above

Cautions  see section 8.1; susceptibility to QT-interval prolongation (correct hypokalaemia or hypomagnesaemia before starting treatment); interactions: Appendix 1 (dasatinib)

Hepatic impairment  manufacturer advises caution in hepatic impairment

Pregnancy  manufacturer advises avoid—no information available

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; also diarrhoea, anorexia, weight changes, abdominal pain, taste disturbance, constipation, dyspepsia, colitis, gastritis; arrhythmias, congestive heart failure, hypertension, chest pain, flushing, haemorrhage (including gastro-intestinal and CNS haemorrhage), palpitation; dyspnoea, pulmonary hypertension, cough, oedema (more common in patients over 65 years old), pleural effusion; dyspepsia, diarrhea, headache, insomnia, nervousness, vertigo; influenza-like symptoms; musculoskeletal pain; visual disturbances; tinnitus; acne, dry skin, sweating, pruritus, dermatitis, urticaria; disturbances; tinnitus; acne, dry skin, sweating, pruritus, dermatitis, urticaria; less commonly, hypertenison, transient ischaemic attack; thrombophlebitis, syncope, asthma, seizures, amnesia, tremor, drowsiness, gynaecomastia, irregular menstruation, urinary frequency, proteinuria, hypocalcaemia, rhabdomyolysis, hypersensitivity reactions (including erythema nodosum), photosensitivity, and pigmentation and nail disorders; rarely cor pulmonale; thrombosis and interstitial lung disease also reported

Dose  ● Chronic phase chronic myeloid leukaemia, ADULT over 18 years 100 mg once daily; increased if necessary to max. 140 mg once daily
  ● Accelerated and blast phase chronic myeloid leukaemia, acute lymphoblastic leukaemia, ADULT over 18 years 140 mg once daily, increased if necessary to max. 180 mg once daily

Sprycel® (Bristol-Myers Squibb) Tablets, f/c, dasatinib (as monohydrate) 20 mg, net price 60-tab pack = £1252.48; 50 mg, 60-tab pack = £2504.96; 70 mg, 60-tab pack = £2504.96; 100 mg, 30-tab pack = £2504.96. Label: 25

ERLOTINIB

Indications  see notes above

Cautions  see section 8.1; pre-existing liver disease or concomitant use with hepatotoxic drugs—monitor liver function; dose adjustment may be necessary if smoking started or stopped during treatment; interactions: Appendix 1 (erlotinib)

Hepatic impairment  manufacturer advises caution in mild to moderate impairment; avoid in severe impairment

Renal impairment  manufacturer advises avoid in severe impairment

Pregnancy  manufacturer advises avoid—toxicity in animal studies; effective contraception required during treatment; see also Reproductive Function, p. 520

Breast-feeding  manufacturer advises avoid—no information available

Side-effects  see section 8.1 and notes above; also diarrhoea, abdominal pain, dyspepsia, flatulence; anorexia, depression, neuropathy, headache; fatigue, rigor; conjunctivitis; pruritus, dry skin; less commonly gastro-intestinal perforation, interstitial lung disease—discontinue if unexplained symptoms such as dyspnoea, cough or fever occur; eyelash changes; rarely hepatic failure; very rarely corneal perforation or ulceration, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Dose  ● Non-small cell lung cancer, 150 mg once daily
  ● Pancreatic cancer, 100 mg once daily in combination with gemcitabine

Tarceva® (Roche) Tablets, f/c, white-yellow, erlotinib (as hydrochloride) 25 mg, net price 30-tab pack = £378.33; 100 mg, 30-tab pack = £1524.14; 150 mg, 30-tab pack = £1631.53. Label: 23

EVEROLIMUS

Indications  see notes above

Cautions  see section 8.1; monitor blood-glucose concentration before treatment and periodically thereafter; reduce dose or discontinue if severe side-effects occur—consult product literature; interactions: Appendix 1 (everolimus)

Pneumonitis  Non-infectious pneumonitis reported. Patients should be advised to seek urgent medical advice if new or worsening respiratory symptoms occur

Hepatic impairment  reduce dose to 5 mg daily in moderate impairment; avoid in severe impairment—no information available

Pregnancy  manufacturer advises avoid (toxicity in animal studies); effective contraception must be used; see also Reproductive Function, p. 520

Breast-feeding  manufacturer advises avoid

Side-effects  see section 8.1; also diarrhoea, dry mouth, abdominal pain, dysphagia, anorexia, taste disturbance; chest pain, hypertension, hyperlipidaemia, hypercholesterolaemia, peripheral oedema; pneumonitis (including interstitial lung disease); asthenia, fatigue, headache, insomnia; increased susceptibility to infections (including pneumonia, aspergillosis, and candidiasis); hyperglycaemia, dehydration; eyelid oedema; epistaxis; skin and nail disorders (including hand-foot syndrome); less commonly congestive heart failure and impaired wound healing; hepatitis B reactivation and haemorrhage also reported

Dose  ● ADULT over 18 years, 10 mg once daily

Afinitor® (Novartis) Tablets, white-yellow, everolimus, 5 mg, net price 30-tab pack = £2250.00; 10 mg, 30-tab pack = £2970.00. Label: 25, counselling, pneumonitis

GEFITINIB

Indications  see notes above

Cautions  monitor liver function—consider discontinuing if severe changes in liver function occur; monitor for worsening of dyspnoea, cough and fever—discontinue if interstitial lung disease confirmed; patients should seek immediate medical advice if they experience any ocular symptoms; interactions: Appendix 1 (gefitinib)
Hepatic impairment  manufacturer advises caution in moderate to severe impairment due to cirrhosis
Renal impairment  manufacturer advises caution if creatinine clearance less than 20 mL/minute
Pregnancy  manufacturer advises avoid unless essential—toxicity in animal studies; see also Reproductive Function, p. 520
Breast-feeding  discontinue breast-feeding
Side-effects  see section 8.1; also anorexia, diarrhoea, constipation, mouth; epistaxis, interstitial lung disease; continue if confirmed; asthenia; pyrexia; haematuria, proteinuria; dry eye, conjunctivitis, blepharitis; nail disorder, skin reactions (including dry skin, rash, acne, and pruritus); less commonly pancreatitis, corneal erosion; rarely hepatic, toxic epidermal necrolysis
Dose
• ADULT over 18 years, 250 mg once daily

Iressa® (AstraZeneca) ▼Tablets, f/c, brown, geftinib 250 mg, net price 30-tab pack = £2167.71

IMATINIB

Indications  see notes above
Cautions  see section 8.1; cardiac disease; monitor for fluid retention; monitor liver function; interactions: Appendix (imatinib)
Hepatic impairment  max. 400 mg daily; reduce dose further if not tolerated
Renal impairment  max. starting dose 400 mg daily if creatinine clearance less than 60 mL/minute; reduce dose further if not tolerated
Pregnancy  manufacturer advises avoid unless potential benefit outweighs risk; effective contraception required during treatment; see also Reproductive Function, p. 520
Breast-feeding  discontinue breast-feeding
Side-effects  see section 8.1; also abdominal pain, appetite changes, constipation, diarrhoea, flatulence, gastro-oesophageal reflux, taste disturbance, weight changes, dry mouth, oedema (including pulmonary oedema, pleural effusion, and ascites), flushing, haemorrhage: cough, dyspnoea; dizziness, headache, insomnia, hypoaesthesia, paraesthesia, fatigue; influenza-like symptoms; cramps, arthralgia; visual disturbances, increased lacrimation, conjunctivitis, dry eyes; epistaxis; dry skin, sweating, rash, pruritus, photosensitivity; less commonly gastric ulceration, pancreatitis, hepatic dysfunction (rarely hepatic failure, hepatic necrosis), dysphagia, heart failure, tachycardia, palpitation, syncope, hypertension, hypotension, cold extremities, cough, acute respiratory failure, depression, drowsiness, anxiety, peripheral neuropathy, tremor, migraine, impaired memory, vertigo, gynaecomastia, menorrhagia, irregular menstruation, sexual dysfunction, electrolyte disturbances, renal failure, urinary frequency, gout, tinnitus, hearing loss; skin hyperpigmentation; rarely intestinal obstruction, gastro-intestinal perforation, inflammatory bowel disease, arthralgia, atrial fibrillation, myocardial infarction, angina, pulmonary fibrosis, pulmonary hypertension, increased intracranial pressure, convulsions, confusion, haemolytic anaemia, rhombomyllosis, myopathy, aseptic necrosis of bone, cataract, glaucoma, angioedema, exfoliative dermatitis, and Stevens-Johnson syndrome
Dose
• Chronic phase chronic myeloid leukaemia, ADULT 400 mg once daily, increased if necessary to max. 800 mg daily (in 2 divided doses); CHILD (chronic and advanced phase) 2–18 years 340 mg/m2 (max. 800 mg) daily (in 1–2 divided doses), increased to 570 mg/m2 (max. 800 mg) daily if necessary (consult product literature)
• Accelerated phase and blast crisis chronic myeloid leukaemia, ADULT 600 mg once daily, increased if necessary to max. 800 mg daily (in 2 divided doses)
• Acute lymphoblastic leukaemia, ADULT 600 mg once daily
• Gastro-intestinal stromal tumours, ADULT 400 mg once daily
• Myelodysplastic/myeloproliferative diseases, ADULT 400 mg once daily
• Advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia, ADULT 100–400 mg once daily

Glivec® (Novartis) ▼Tablets, f/c, imatinib (as mesilate) 100 mg (yellow-brown, scored), net price 60-tab pack = £802.04; 400 mg (yellow), 30-tab pack = £1604.08. Label: 21, 27 Counselling Tablets may be dispersed in water or apple juice

LAPATINIB

Indications  see notes above
Cautions  see section 8.1; low gastric pH (reduced absorption); susceptibility to QT-interval prolongation (including concomitant use of drugs that prolong QT-interval and electrolyte disturbances); monitor left ventricular function; monitor for pulmonary toxicity; monitor liver function before treatment and at monthly intervals; interactions: Appendix (lapatinib)
Hepatic impairment  caution in moderate to severe impairment—metabolism reduced
Renal impairment  caution in severe impairment—no information available
Pregnancy  avoid unless potential benefit outweighs risk—toxicity in animal studies; see also Reproductive Function, p. 520
Breast-feeding  discontinue breast-feeding
Side-effects  see section 8.1; anorexia, diarrhoea (treat promptly), decreased left ventricular ejection fraction, cardiac failure (fatal cases reported), malaise, rash, nail disorders, hyperbilirubinaemia, hepatotoxicity (discontinue permanently if severe); less commonly interstitial lung disease; respiratory failure (including fatal cases) also reported
Dose
• In combination with capecitabine, ADULT over 18 years, 1.25 g once daily
• In combination with an aromatase inhibitor, ADULT over 18 years, 1.5 g once daily Counselling Always take at the same time in relation to food: either one hour before or one hour after food. Patients should report unexpected changes in bowel habit

Tyverb® (GSK) ▼Tablets, yellow, f/c, lapatinib 250 mg, net price 70-tab pack = £804.30, 84 tab-pack = £965.16. Counselling, administration
NILOTINIB

Indications  see notes above

Cautions  see section 8.1; history of pancreatitis; susceptibility to QT-interval prolongation (including electrolyte disturbances, concomitant use of drugs that prolong QT interval); Interactions: Appendix 1 (nilotinib)

Hepatic impairment  manufacturer advises caution

Pregnancy  manufacturer advises avoid unless potential benefit outweighs risk— toxicity in animal studies; effective contraception advised during treatment; see also Reproductive Function, p. 520

Breast-feeding  manufacturer advises avoid—present in milk in animal studies

Side-effects  see section 8.1; also abdominal pain, constipation, diarhoea, dyspepsia, flatulence, anorexia, weight changes; palpitation, QT-interval prolongation, hypertension, oedema, flushing; dyspnoea, cough, dysphonia; headache, fatigue, asthenia, dizziness, paraesthesia, insomnia, vertigo; hypomagnesemia, hyperkalaemia, blood glucose changes; bone pain, arthralgia, muscle spasm; urticaria, erythema, hyperhidrosis, dry skin, rash, pruritus; less commonly muscular weakness, back pain, leg pain, myalgia, tinnitus, rash, pruritus; less commonly hyperglycaemia, ketonuria, hyperuricemia, acne, pleural effusion, interstitial lung disease, migraine, hypoesthesia, hyperaesthesia, depression, anxiety, tremor, influenza-like symptoms, hyperthyroidism, breast pain, gynaecomastia, erectile dysfunction, dysuria, urinary frequency, hypokalaemia, hyponatraemia, hypocalcaemia, hyponatraemia, hyperphosphatasaemia, dehydration, decreased visual acuity, conjunctivitis, dry eyes, epistaxis, and ecchymosis

Dose  Adult  over 18 years, 400 mg twice daily

Tasigna® (Novartis)  ▼  [21]

Capsules, yellow, nilotinib (as hydrochloride monohydrate) 200 mg, net price 112-cap pack = £2432.85. Label: 23, 25, 27

PAZOPANIB

Indications  see notes above

Cautions  see section 8.1; monitor liver function before treatment and at least monthly for the first 4 months—consult product literature; control blood pressure before initiating and monitor blood pressure throughout treatment (consider dose reduction or interruption if hypertension uncontrolled despite antihypertensive therapy); susceptibility to QT-interval prolongation (including electrolyte disturbances, concomitant use of drugs that prolong QT interval); patients at risk of myocardial infarction, ischaemic stroke or transient ischaemic attack, cardiac disease; increased risk of haemorrhage; increased risk of gastrointestinal perforation or fistulas; discontinue treatment 7 days before elective surgery and restart only if adequate wound healing; monitor thyroid function; monitor for proteinuria; Interactions: Appendix 1 (pazopanib)

Contra-indications  cerebral or clinically significant gastrointestinal haemorrhage or haemoptysis in the past 6 months

Contra-indications  see section 8.1; monitor liver function before

Cautions  see notes above

Indications  see notes above

Breast-feeding  manufacturer advises caution in major surgical procedures; cardiac ischaemia; interactions: Appendix 1 (sorafenib)

Hepatic impairment  manufacturer advises caution in severe impairment—no information available

Pregnancy  manufacturer advises avoid unless essential— toxicity in animal studies; see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; also diarrhoea, constipation, dyspepsia, dysphagia, anorexia, hypertension, haemorrhage, flushing, hoarseness, fatigue, asthenia, depression, peripheral neuropathy, fever, erectile dysfunction, renal failure, hypophosphataemia, arthralgia, myalgia, tinnitus, rash, pruritus, erythema, dry skin, desquamation, acne, hand-foot skin reaction; less commonly gastro-intestinal perforations, myocardial infarction, congestive heart failure, hypertensive crisis, reversible posterior leucoencephalopathy, thyroid dysfunction, and Stevens-Johnson syndrome

Dose  Adult  over 18 years, 400 mg twice daily

SORAFENIB

Indications  see notes above

Cautions  major surgical procedures; cardiac ischaemia; interactions: Appendix 1 (sorafenib)

Hepatic impairment  manufacturer advises caution in severe impairment—no information available

Pregnancy  manufacturer advises avoid unless essential— toxicity in animal studies; see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; also diarrhoea, constipation, dyspepsia, dysphagia, anorexia, hypertension, haemorrhage, flushing, hoarseness, fatigue, asthenia, depression, peripheral neuropathy, fever, erectile dysfunction, renal failure, hypophosphataemia, arthralgia, myalgia, tinnitus, rash, pruritus, erythema, dry skin, desquamation, acne, hand-foot skin reaction; less commonly gastro-intestinal perforations, myocardial infarction, congestive heart failure, hypertensive crisis, reversible posterior leucoencephalopathy, thyroid dysfunction, and Stevens-Johnson syndrome

Dose  Adult  over 18 years, 400 mg twice daily

Nexavar® (Bayer Schering)  ▼  [24]

Tablets, f/c, red, sorafenib (as tosylate) 200 mg, net price 112-tab pack = £2980.47 Label: 23

BNF 61

Hepatic impairment  use with caution in mild impairment; reduce dose to 200 mg once daily in moderate impairment; avoid in severe impairment

Renal impairment  use with caution if creatinine clearance less than 30 mL/minute—no information available

Pregnancy  avoid unless potential benefit outweighs risk— toxicity in animal studies; effective contraception advised during treatment; see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1; also abdominal pain, dyspepsia, diarrhoea, weight loss, anorexia, taste disturbance, flatulence, hepatic dysfunction, hyperbilirubinaemia, hypertension, flushing, chest pain, oedema, epistaxis, voice changes, headache, dizziness, malaise, paraesthesia, hypothyroidism, proteinuria (discontinue if grade 4), blood disorders (including thrombocytopenia), muscle spasm, myalgia, sweating, skin reactions, dry skin, hair and skin discoloration; less commonly hepatic failure, gastrointestinal perforation, peritonitis, pancreatitis, fistula, cardiac dysfunction, transient ischaemic attack, stroke, myocardial infarction, myocardial ischaemia, bradycardia, haemorrhage, hypertensive crisis, QT-interval prolongation, pulmonary embolism, peripheral neuropathy, menstrual disturbances

Dose  Adult  over 18 years, 800 mg once daily; adjust dose in steps of 200 mg according to tolerability (max. 800 mg daily)

Votrient® (GSK)  ▼  [30]

Tablets, f/c, pazopanib (as hydrochloride) 200 mg (pink), net price 30-tab pack = £560.50; 400 mg (white), 30-tab pack = £1121.00. Label: 23, 25
BNF 61

8.1.5 Other antineoplastic drugs

SUNITINIB

Indications: see notes above

Cautions: see section 8.1; cardiovascular disease—discontinue if congestive heart failure develops; susceptibility to QT-interval prolongation; hypertension; increased risk of bleeding; monitor for thyroid dysfunction; consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw); see MHRA/CHM advice, p. 537; Interactions: Appendix 1 (sunitinib)

Pregnancy: manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies; effective contraception required during treatment; see also Reproductive Function, p. 520

Breast-feeding: discontinue breast-feeding

Side-effects: see section 8.1; abdominal pain, nausea, vomiting, constipation, altered taste, altered sense of smell, cough, fatigue, dizziness, headache, insomnia, peripheral neuropathy, arthralgia, myalgia, increased lactic acidemia, epistaxis, skin, hair, and urine discoloration, hand-foot syndrome, dry skin, and rash; gastro-intestinal perforation; fistula formation; interupt treatment if occurs; pancreatitis, osteonecrosis of the jaw; see MHRA/CHM advice, p. 537; hepatic failure, proteinuria (rarely nephrotic syndrome) and seizures reported

Dose: 50 mg daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle; adjust dose in steps of 12.5 mg according to tolerability; dose range 25–75 mg daily

SU
cent® (Pfizer) Capsules, sunitinib (as malate) 12.5 mg (orange), net price 28-cap pack = £784.70; 25 mg (caramel/orange), 28-cap pack = £1569.40; 50 mg (caramel), 28-cap pack = £3138.80. Label: 14

TEMSIROLIMUS

Indications: see notes above

Cautions: see notes above; monitor respiratory function; monitor blood lipids; Interactions: Appendix 1 (temsirolimus)

Hepatic impairment: use with caution; in renal cell carcinoma, reduce dose in severe impairment (consult product literature); in mantle cell lymphoma, avoid in moderate or severe impairment

Renal impairment: manufacturer advises caution in severe impairment—no information available

Pregnancy: manufacturer advises avoid (toxicity in animal studies); ensure effective contraception during treatment in men and women; see also Reproductive Function, p. 520

Breast-feeding: manufacturer advises discontinue breast-feeding

Side-effects: see section 8.1; abdominal pain, diarrhea, anorexia, taste disturbance, gastrointestinal haemorrhage, bowel perforation, dysphagia, hypertension, oedema, thrombosis, thrombophlebitis; cough, dyspnoea, chest pain, interstitial lung disease; hypersensitivity reactions (see notes above); insomnia, anxiety, depression, drowsiness, paraesthesia, dizziness, asthenia; increased susceptibility to infection (including urinary-tract infection and pneumonia), pyrexia; hyperglycaemia; renal failure; hypophosphataemia, hypokalaemia, hypercholesterolaemia, hyperlipidaemia; myalgia, arthralgia; eye disorders; rhinitis, epistaxis; skin disorders (including rash and acne); folliculitis, impaired wound healing; less commonly intracerebral bleeding

Torisel® (Wyeth) Infusion, temsirolimus 25 mg/mL, net price 1.2-mL amp (with diluent) = £620.00

Excipients: include propylene glycol and ethanol

Taxanes

Paclitaxel is a member of the taxane group of drugs. It is given by intravenous infusion. Paclitaxel given with carboplatin or cisplatin is used for the treatment of ovarian cancer (see NICE guidance p. 542); the combination is also considered appropriate for women whose ovarian cancer is initially considered inoperable. Paclitaxel is also licensed for the secondary treatment of metastatic breast cancer. There is limited evidence to support its use in non-small cell lung cancer. Routine premedication with a corticosteroid, an antihistamine and a histamine H₂-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication, although more commonly only bradycardia or asymptomatic hypotension occur.

Other side-effects of paclitaxel include myelosuppression, peripheral neuropathy, and cardiac conduction defects with arrhythmias (which are nearly always asymptomatic). It also causes alopecia and muscle pain; nausea and vomiting is mild to moderate.

Docetaxel is licensed for use in locally advanced or metastatic breast cancer and non-small cell lung cancer resistant to other cytotoxic drugs or for initial chemotherapy in combination with other cytotoxic drugs. It is also licensed for hormone-resistant prostate cancer; for use with other cytotoxic drugs for gastric adenocarcinoma and head and neck cancer, and for adjuvant treatment of operable node-negative and operable node-positive breast cancer. Its side-effects are similar to those of paclitaxel but persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment; hypersensitivity reactions also occur. Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions.

For the role of taxanes in the treatment of breast cancer, see section 8.3.4.1.

The Scottish Medicines Consortium (p. 4) has advised that docetaxel (Taxotere®) in combination with cisplatin and 5-fluorouracil is accepted for restricted use within NHS Scotland for the induction treatment of patients with unresectable (May 2007) and resectable (June 2008) locally advanced squamous cell carcinoma of the head and neck.

NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer) See p. 542
8 Malignant disease and immunosuppression

DOCETAXEL

Indications  adjuvant treatment of operable node-positive and operable node-negative breast cancer, in combination with doxorubicin and cyclophosphamide; with doxorubicin for initial chemotherapy of locally advanced or metastatic breast cancer; mono-therapy for locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed; with capcitabine for locally advanced or metastatic breast cancer where first-line chemotherapy has failed; with cisplatin for unresectable, locally advanced or metastatic non-small cell lung cancer; with prednisolone for hormone-refractory metastatic prostate cancer; with capecitabine for locally advanced squamous cell carcinoma of the head and neck

Cautions  see section 8.1 and notes above; avoid in severe impairment

Hepatic impairment  monitor liver function—reduce dose according to liver enzymes; avoid in severe impairment

Pregnancy  avoid (toxicity and reduced fertility in animal studies); manufacturer advises effective contraception during and for at least 3 months after treatment; see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1 and notes above

Docetaxel (Non-proprietary)  In infusion, docetaxel 10 mg/mL, net price 2-mL vial = £162.75, 8-mL vial = £534.75, 16-mL vial = £1069.50

Taxotere® (Sanofi-Aventis)  In infusion, docetaxel 20 mg/mL, net price 1-mL vial = £162.75, 4-mL vial = £534.75, 8-mL vial = £1069.50 (hosp. only)

Note  Contains ethanol

PACLITAXEL

Indications  ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin; metastatic ovarian cancer where platinum-containing therapy has failed; locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate); adjuvant treatment of node-positive breast cancer following treatment with anthra-cycline and cyclophosphamide; non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate; advanced AIDS-related Kaposi’s sarcoma where liposomal anthracycline therapy has failed

Cautions  see section 8.1 and notes above; avoid in acute porphyria (but see section 9.8.2); interactions: Appendix 1 (paclitaxel)

Contra-indications  see section 8.1 and notes above

Hepatic impairment  avoid in severe impairment

Pregnancy  avoid (toxicity in animal studies); ensure effective contraception during and for at least 6 months after treatment in men or women; see also Reproductive Function, p. 520

Breast-feeding  discontinue breast-feeding

Side-effects  see section 8.1 and notes above

Paclitaxel (Non-proprietary)  In infusion, paclitaxel 6 mg/mL, net price 5-mL vial = £66.85, 16.7-mL vial = £200.35, 25-mL vial = £300.52, 50-mL vial = £601.03

Excipients include polysorbate 80 (risk of anaphylaxis, see Excipients, p. 2)

Abraxane® (Abraxis)  Intravenous infusion, powder for reconstitution, paclitaxel, net price 100-mg vial = £246.00

Electrolytes  Contains approx. 18.5 mmol Na+/dose

Topotecan  (Bristol-Myers Squibb)  In infusion, paclitaxel 6 mg/mL, net price 5-mL vial = £116.05, 16.7-mL vial = £347.82, 25-mL vial = £521.73, 50-mL vial = £1043.46 (hosp. only)

Excipients include polysorbate 80 (risk of anaphylaxis, see Excipients, p. 2)

Topoisomerase 1 inhibitors

Irinotecan and topotecan inhibit topoisomerase 1, an enzyme involved in DNA replication.

Irinotecan  is licensed for metastatic colorectal cancer in combination with fluorouracil and folic acid or as monotherapy when treatment containing fluorouracil has failed. It is also licensed in combination with cetuximab for the treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan. Irinotecan is also licensed in combination with bevacizumab for the first-line treatment of metastatic carcinoma of the colon or rectum. Irinotecan is also licensed in combination with capcitabine with or without bevacizumab for the first-line treatment of metastatic colorectal carcinoma. Irinotecan is given by intravenous infusion.

NICE guidance (irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer)  See p. 542

Topotecan  is given by intravenous infusion or orally in relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate. Topotecan injection is also licensed for metastatic ovarian cancer when first-line or subsequent treatment has failed. Topotecan injection is licensed in combination with cisplatin for treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease.

In addition to dose-limiting myelosuppression, side-effects of irinotecan and topotecan include gastro-intes-
tinal effects (delayed diarrhoea requiring prompt treatment) may follow irinotecan treatment, anemia, alopecia, and anorexia.

The Scottish Medicines Consortium (p. 4) has advised (November 2007) that topotecan (Hycamtin®) is accepted for restricted use in combination with cisplatin for treatment of recurrent carcinoma of the cervix after radiotherapy and for stage IVB disease; it is restricted to patients who have not previously received cisplatin treatment.

The Scottish Medicines Consortium (p. 4) has advised (March 2009) that use of topotecan capsules within NHS Scotland is restricted to patients in whom standard intravenous chemotherapy is inappropriate and who would otherwise receive best supportive care.

NICE guidance
Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.

NICE guidance
Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if re-treatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.

NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer)
See p. 542

IRINOTECAN HYDROCHLORIDE

Indications see notes above
Cautions see section 8.1 and notes above; raised plasma-bilirubin concentration (see under Hepatic impairment); monitor respiratory function; interactions: Appendix 1 (irinotecan)
Contra-indications see section 8.1 and notes above; also chronic inflammatory bowel disease, bowel obstruction
Hepatic impairment monitor closely for neutropenia if plasma-bilirubin concentration 1.5–3 times upper limit of normal range (consult product literature); avoid if plasma-bilirubin concentration greater than 3 times upper limit of normal range
Renal impairment manufacturer advises avoid—no information available
Pregnancy avoid (teratogenicity and toxic in animal studies); manufacturer advises effective contraception during and for at least 3 months after treatment; see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding

8.1.5 Other antineoplastic drugs

Side-effects see section 8.1 and notes above; also acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature); less commonly interstitial pulmonary disease

Irinotecan (Non-proprietary) Infusion, irinotecan hydrochloride 20 mg/mL, net price 2-mL vial = £49.03, 5-mL vial = £120.25, 15-mL vial = £370.50, 25-mL vial = £601.25
Campto® (Pfizer) Infusion, irinotecan hydrochloride 20 mg/mL, net price 2-mL vial = £53.00; 5-mL vial = £130.00; 15-mL vial = £390.00

TOPOTECAN

Indications see notes above
Cautions see section 8.1 and notes above
Contra-indications see section 8.1 and notes above
Hepatic impairment avoid in severe impairment
Renal impairment reduce dose; avoid infusion if creatinine clearance less than 20 mL/minute; avoid oral route if creatinine clearance less than 60 mL/minute

Pregnancy avoid (teratogenicity and fetal loss in animal studies); see also Reproductive Function, p. 520
Breast-feeding discontinue breast-feeding

Side-effects see section 8.1 and notes above

Hycamtin® (GSK)

Capsules, topotecan (as hydrochloride) 250 micrograms (white), net price 10-cap pack = £75.00; 1 mg (pink), 10-cap pack = £300.00. Label: 25

Intravenous infusion, powder for reconstitution, topotecan (as hydrochloride), net price 1-mg vial = £97.65; 4-mg vial = £290.62

Trabectedin

Trabectedin is licensed for the treatment of advanced soft tissue sarcoma when treatment with anthracyclines and ifosfamide has failed or is contra-indicated and in combination with pegylated liposomal doxorubicin for the treatment of relapsed platinum-sensitive ovarian cancer.

Trabectedin is given by intravenous infusion. A corticosteroid, such as dexamethasone by intravenous infusion, should be given 30 minutes before therapy for its anti-emetic and hepatoprotective effects.

NICE guidance
Trabectedin for the treatment of advanced soft tissue sarcoma (February 2010)
Trabectedin is an option for advanced soft tissue sarcoma when treatment with anthracyclines and ifosfamide has failed, is inappropriate or is not tolerated. The cost of trabectedin for treatment after the fifth cycle is met by the manufacturer.

NICE guidance
Trabectedin for the treatment of advanced soft tissue sarcoma (February 2010)
Trabectedin is an option for advanced soft tissue sarcoma when treatment with anthracyclines and ifosfamide has failed, is inappropriate or is not tolerated. The cost of trabectedin for treatment after the fifth cycle is met by the manufacturer.

TRABECTEDIN

Indications see notes above
Cautions see section 8.1 and notes above; measure creatine phosphokinase, renal function and hepatic function before starting (consult product literature);
monitor haematological and hepatic parameters weekly during first 2 cycles and at least once between treatments in subsequent cycles; concomitant use with hepatotoxic drugs (avoid alcohol)

**Hepatic impairment** manufacturer advises caution in impairment—consider dose reduction; avoid in patients with raised bilirubin

**Renal impairment** avoid monotherapy if creatinine clearance less than 30 mL/minute; avoid combination regimens if creatinine clearance less than 60 mL/minute

**Pregnancy** effective contraception recommended during and for at least 3 months after treatment in women and at least 5 months after treatment in men; see also Reproductive Function, p. 520

**Breast-feeding** manufacturer advises avoid breast-feeding during and for 3 months after treatment

**Side-effects** see section 8.1; also abdominal pain, constipation, diarrhoea, dyspepsia, taste disturbance, hepatobiliary disorders; hypotension, oedema, flushing; dyspnoea, cough; headache, insomnia, peripheral neuropathy, paraesthesia, dizziness, anorexia, asthenia, fatigue; pyrexia; hypokalaemia, dehydration, increased blood creatine phosphokinase; myalgia, arthralgia, back pain

**Yondelis** (Pharma Mar) \(\updownarrow\) [NW]

*Injection*, powder for reconstitution, trabectedin, net price 250-microgram vial = £363.00; 1-mg vial = £1366.00

**Trastuzumab**

Trastuzumab is licensed for the treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2).

Trastuzumab is also licensed, in combination with paclitaxel or docetaxel, for metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate.

Trastuzumab is also licensed, in combination with an aromatase inhibitor, for metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab.

Trastuzumab is also licensed as monotherapy for metastatic breast cancer in patients with tumours that overexpress HER2 who have received at least 2 chemotherapies regimens in which, appropriate, an anthracycline and a taxane; women with oestrogen-receptor-positive breast cancer should also have received hormonal therapy.

Trastuzumab is also licensed, in combination with capecitabine or fluorouracil and cisplatin, for metastatic gastric cancer in patients with HER2-positive tumours who have not received treatment for metastatic gastric cancer.

Trastuzumab is given by intravenous infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist. See section 8.3.4.1 for the role of trastuzumab in the treatment of breast cancer.

**Use with anthracyclines** Concomitant use of trastuzumab with anthracyclines (section 8.1.2) is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If an anthracycline needs to be used, cardiac function should be monitored closely.

**NICE guidance**

**Trastuzumab for the treatment of HER2-positive metastatic gastric cancer** (November 2010)

Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who:

- have not received treatment for metastatic disease and
- have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3.

**Trastuzumab**

**Indications** see notes above and product literature

**Cautions** see section 8.1 and notes above; symptomatic heart failure, history of hypertension, coronary artery disease, uncontrolled arrhythmias

**Cardiotoxicity** Monitor cardiac function before and during treatment—for details of monitoring and managing cardiotoxicity, consult product literature

**Contra-indications** see section 8.1 and notes above; severe dyspnoea at rest

**Pregnancy** avoid unless potential benefit outweighs risk; oligohydramnios and anhydramnios reported

**Breast-feeding** avoid breast-feeding during treatment and for six months afterwards

**Side-effects** see section 8.1; also infusion-related side-effects including chills, fever, hypersensitivity reactions such as anaphylaxis, urticaria, and angioedema; gastro-intestinal symptoms; cardiotoxicity (see also above), chest pain, hypotension; pulmonary events (possibly delayed onset); headache, taste disturbance, anxiety, malaise, depression, insomnia, drowsiness, dizziness, paraesthesia, tremor, asthenia, peripheral neuropathy, hypotonia; mastitis, urinary tract infection; ecchymosis, oedema, weight loss; arthralgia, myalgia, arthritis, bone pain, leg cramps; rash, pruritus, sweating, dry skin, alopecia, acne, nail disorders

**Herceptin** (Roche) \(\updownarrow\) [NW]

*Intravenous infusion*, powder for reconstitution, trastuzumab, net price 150-mg vial = £407.40

**Tretinoin**

**Indications** see notes above; acne (section 13.6.1); photodamage (section 13.8.1)

**Caution** exclude pregnancy before starting treatment; monitor haematological and coagulation profile, liver function, serum calcium and plasma lipids

**Note** Tretinoin is the acid form of vitamin A
before and during treatment; increased risk of thromboembolism during first month of treatment; interactions: Appendix 1 (retinoids)

**Hepatic impairment** reduce dose to 25 mg/m²

**Renal impairment** reduce dose to 25 mg/m²

**Pregnancy** teratogenic; effective contraception must be used for at least 1 month before oral treatment, during treatment and for at least 1 month after stopping (oral progestogen-only contraceptives not considered effective)

**Breast-feeding** avoid

**Side-effects** retinoic acid syndrome (fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural effusion, hyperleukocytosis, hypotension, oedema, weight gain, hepatic, renal and multi-organ failure) requires immediate treatment—consult product literature; gastro-intestinal disturbances, pancreatitis; arthralgia; flushing, oedema; headache; benign intracranial hypertension (mainly in children—consider dose reduction if intractable headache in children), shivering, dizziness, confusion, anxiety, depression, insomnia, paraesthesia, visual and hearing disturbances; raised liver enzymes, serum creatinine and lipids; bone and chest pain, alopecia, erythema, rash, pruritus, sweating, dry skin and mucous membranes, chelitis; thromboembolism, hypercalcaemia, and genitai ulceration reported

**Dose**

- **ADULT** and **CHILD** 45 mg/m² daily in 2 divided doses, max. duration of treatment 90 days (consult product literature for details of concomitant chemotherapy)

**Vesanoid** (Roche)

Capsules, yellow/brown, tretinoin 10 mg, net price 100-cap pack = £160.63. Label: 21, 25

---

### 8.2 Drugs affecting the immune response

#### 8.2.1 Antiproliferative immunosuppressants

**Azathioprine** is widely used for transplant recipients and is also used to treat a number of auto-immune conditions, usually when corticosteroid therapy alone provides inadequate control. It is metabolised to mercaptopurine, and doses should be reduced when allopurinol is given concurrently.

Blood tests and monitoring for signs of myelosuppression are essential in long-term treatment with azathioprine. The enzyme thiopurine methyltransferase (TPMT) metabolises azathioprine; the risk of myelosuppression is increased in those with reduced activity of the enzyme, particularly in the few individuals who are deficient for TPMT activity. Consider measuring TPMT activity before starting azathioprine therapy. Patients with deficient TPMT activity should not receive azathioprine; those with reduced TPMT activity may be treated under specialist supervision.

**Mycophenolate mofetil** is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal, hepatic or cardiac transplantation when used in combination with cyclosporin and corticosteroids. There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher. Cases of pure red cell aplasia have been reported with mycophenolate mofetil; dose reduction or discontinuation of mycophenolate mofetil should be considered under specialist supervision.

**Cyclophosphamide** (section 8.1.1) is less commonly prescribed as an immunosuppressant.
AZATHIOPRINE

Indications see notes above; inflammatory bowel disease [unlicensed indication] (section 1.5.3); rheumatoid arthritis (section 10.1.3); severe refractory eczema [unlicensed indication] (section 13.5.3)

Cautions see notes above; monitor for toxicity throughout treatment; monitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months; reduce dose in elderly; interactions: Appendix 1 (azathioprine)

Bone marrow suppression Patients should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection

Contra-indications see notes above; hypersensitivity to mercaptopurine

Hepatic impairment reduce dose; monitor liver function; see also Cautions

Renal impairment reduce dose; see also Cautions

Pregnancy treatment should not generally be initiated during pregnancy; see also p. 553

Breast-feeding present in milk in low concentration; no evidence of harm in small studies—use if potential benefit outweighs risk

Side-effects hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis—calling for immediate withdrawal); dose-related bone marrow suppression (see also Cautions); liver impairment, cholestatic jaundice, hair loss and increased susceptibility to infections and colitis in patients also receiving corticosteroids; nausea, rarely pancreatitis, pneumonitis, hepatic veno-occlusive disease, lymphoma

Dose
● By mouth, or (if oral administration not possible—intravenous solution very irritant, see below) by intravenous injection over at least 1 minute (followed by 50 mL sodium chloride intravenous infusion), or by intravenous infusion

Autoimmune conditions, 1–3 mg/kg daily, adjusted according to response (consider withdrawal if no improvement within 3 months)

Suppression of transplant rejection, 1–2.5 mg/kg daily according to response

Note Azathioprine doses in BNF may differ from those in product literature

Note Intravenous injection is alkaline and very irritant, intravenous route should therefore be used only if oral route not feasible, see also Appendix 6

Azathioprine (Non-proprietary) \(\text{\textregistered}\)

Tablets, azathioprine 25 mg, net price 28-tab pack = £8.67; 50 mg, 60-tab pack = £15.56. Label: 21

Brands include: Azamune \(\text{\textregistered}\)

IMURAN \(\text{\textregistered}\) (Aspen)

Tablets, both f/c, azathioprine 25 mg (orange), net price 100-tab pack = £10.99; 50 mg (yellow), 100-tab pack = £7.99. Label: 21

Injection, powder for reconstitution, azathioprine (as sodium salt), net price 50-mg vial = £15.38

MYCOPHENOLATE MOFETIL

Indications prophylaxis of acute renal, cardiac, or hepatic transplant rejection (in combination with ciclosporin and corticosteroids) under specialist supervision

Cautions full blood counts every week for 4 weeks then twice a month for 2 months then every month in the first year (consider interrupting treatment if neutropenia develops); exclude pregnancy before starting treatment; elderly (increased risk of infection, gastrointestinal haemorrhage and pulmonary oedema); children (higher incidence of side-effects may call for temporary reduction of dose or interruption); active serious gastro-intestinal disease (risk of haemorrhage, ulceration and perforation); delayed graft function; increased susceptibility to skin cancer (avoid exposure to strong sunlight); interactions: Appendix 1 (mycophenolate)

Bone marrow suppression Patients should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. infection or inexplicable bruising or bleeding

Renal impairment no data available in cardiac or hepatic transplant patients with renal impairment

Pregnancy avoid—congenital malformations reported, effective contraception required before treatment, during treatment, and for 6 weeks after discontinuation of treatment

Breast-feeding avoid—present in milk in animal studies

Side-effects taste disturbance, gingival hyperplasia, nausea, constipation, flatulence, anorexia, weight loss, vomiting, abdominal pain, gastro-intestinal inflammation, ulceration, and bleeding, hepatitis, jaundice, pancreatitis, stomatitis, oedema, tachycardia, hypertension, hypotension, vasodilatation, cough, dyspnoea, insomnia, agitation, confusion, depression, anxiety, convulsions, paraesthesia, myasthenic syndrome, tremor, dizziness, headache, influenza-like syndrome, infections, hyperglycaemia, renal impairment, malignancy (particularly of the skin), blood disorders (including leucopenia, anaemia, thrombocytopenia, pancytopenia, and red cell aplasia—see notes above), disturbances of electrolytes and blood lipids, arthralgia, alopecia, acne, skin hypertrophy, and rash; also reported intestinal villous atrophy, progressive multifocal leucoencephalopathy, intestinal lung disease, pulmonary fibrosis

Dose
● Renal transplantation, by mouth, 1 g twice daily starting within 72 hours of transplantation or by intravenous infusion, 1 g twice daily starting within 24 hours of transplantation for max. 14 days (then transfer to oral therapy); CHILD and ADOLESCENT 2–18 years, by mouth 600 mg/m² twice daily (max. 2 g daily)

Note Tablets and capsules not appropriate for dose titration in children with body surface area less than 1.25 m²

● Cardiac transplantation, by mouth, ADULT over 18 years, 1.5 g twice daily starting within 5 days of transplantation

● Hepatic transplantation, by intravenous infusion, ADULT over 18 years, 1 g twice daily starting within 24 hours of transplantation for 4 days (up to max. 14 days), then by mouth, 1.5 g twice daily as soon as is tolerated
8.2.2 Corticosteroids and other immunosuppressants

Prednisolone (section 6.3.2) is widely used in oncology. It has a marked antitumour effect in acute lymphoblastic leukaemia, Hodgkin’s disease, and the non-Hodgkin lymphomas. It has a role in the palliation of symptomatic end-stage malignant disease when it may enhance appetite and produce a sense of well-being (see also Prescribing in Palliative Care, p. 21).

The corticosteroids are also powerful immunosuppressants. They are used to prevent organ transplant rejection, and in high dose to treat rejection episodes.

Ciclosporin is a calcineurin inhibitor, and a potent immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic. It has an important role in organ and tissue transplantation, for prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart, lung, and heart-lung transplantation, and for prophylaxis and treatment of graft-versus-host disease.

Tacrolimus is also a calcineurin inhibitor. Although not chemically related to ciclosporin it has a similar mode of action and side-effects, but the incidence of neurotoxicity appears to be greater; cardiomyopathy has also been reported. Disturbance of glucose metabolism also appears to be significant.

Sirolimus is a non-calcineurin inhibiting immunosuppressant licensed for renal transplantation.

Basiliximab is a monoclonal antibody that prevents T-lymphocyte proliferation; it is used for prophylaxis of acute rejection in allogeneic renal transplantation. It is given with ciclosporin and corticosteroid immunosuppression regimens; its use should be confined to specialist centres.

Antithymocyte immunoglobulin (rabbit) is licensed for the prophylaxis of organ rejection in renal and heart allograft recipients and for the treatment of corticosteroid-resistant allograft rejection in renal transplantation. Tolerability is increased by pretreatment with an intravenous corticosteroid and antihistamine; an antipyretic drug such as paracetamol may also be beneficial.

### NICE guidance

**Immunosuppressive therapy for renal transplantation in adults (September 2004)**

Immunosuppressive therapy for renal transplantation in children and adolescents (April 2006)

For induction therapy in the prophylaxis of organ rejection, either basiliximab or daclizumab (discontinued) are options for combining with a calcineurin inhibitor. For each individual, ciclosporin or tacrolimus is chosen as the calcineurin inhibitor on the basis of side-effects.

Mycophenolate mofetil [mycophenolic acid also available but not licensed for use in children, see above] is recommended as part of an immunosuppressive regimen only if:

- the calcineurin inhibitor is not tolerated, particularly if nephrotoxicity endangers the transplanted kidney; or
- there is very high risk of nephrotoxicity from the calcineurin inhibitor, requiring a reduction in the dose of the calcineurin inhibitor or its avoidance.

Sirolimus is recommended as a component of immunosuppressive regimen only if intolerance necessitates the withdrawal of a calcineurin inhibitor.

These recommendations may not be consistent with the marketing authorisation of some of the products.
Renal transplantation, by intravenous infusion over at least 6 hours, 1–1.5 mg/kg daily for 3–9 days

- Corticosteroid-resistant renal graft rejection, by intravenous infusion over at least 6 hours, 1.5 mg/kg daily for 7–14 days

Note To avoid excessive dosage in obese patients, calculate dose on the basis of ideal body weight

Thymoglobuline® (Genzyme) ▼ ▼

Intravenous infusion, powder for reconstitution, rabbit anti-human thymocyte immunoglobulin, net price 25-mg vial = £158.77

BASILIXIMAB

Indications see notes above

Pregnancy avoid—no information available; adequate contraception must be used during treatment and for 16 weeks after last dose

Breast-feeding avoid—no information available

Side-effects severe hypersensitivity reactions and cytokine release syndrome have been reported

Dose

- By intravenous injection or by intravenous infusion, 20 mg within 2 hours before transplant surgery and 20 mg 4 days after surgery; withhold second dose if severe hypersensitivity or graft loss occurs; CHILD and ADOLESCENT 1–17 years, body-weight under 35 kg, 10 mg within 2 hours before transplant surgery and 10 mg 4 days after surgery; body-weight over 35 kg, adult dose

Simulect® (Novartis) ▼

Injection, powder for reconstitution, basiliximab, net price 10-mg vial = £758.69, 20-mg vial = £842.38 (both with water for injections). For intravenous infusion

CICLOSPORIN (Cyclosporin)

Indications see notes above, and under Dose; severe acute ulcerative colitis [unlicensed indication] (section 1.5.3); rheumatoid arthritis (section 10.1.3); atopic dermatitis and psoriasis (section 13.5.3)

Cautions monitor kidney function—dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients; monitor liver function (see Hepatic Impairment below); monitor blood pressure—discontinue if hypertension develops that cannot be controlled by anti-hypertensives; hyperuricaemia; monitor serum magnesium; measure blood lipids before treatment and thereafter as important changes in blood-ciclosporin concentration. Important changes on long-term administration, see also under Cautions), hyperuricaemia, hyperkalaemia, hyperlipidaemia, hypercholesterolaemia, muscle cramps, myalgia, hypertrichosis; less commonly oedema, weight gain, signs of encephalopathy, anaemia, thrombocytopenia; rarely pancreatitis, motor polyneuropathy, menstrual disturbances, gynaecomastia, microangiopathic haemolytic anaemia, haemolytic uraemic syndrome, hyperglycaemia, muscle weakness, myopathy, visual disturbances secondary to benign intracranial hypertension (discontinue); also reported with infusion anaphylaxis

Dose

- Organ transplantation, used alone, ADULT and CHILD over 3 months 10–15 mg/kg by mouth 4–12 hours before transplantation followed by 10–15 mg/kg daily for 1–2 weeks postoperatively then reduced gradually to 2–6 mg/kg daily for maintenance (dose should be adjusted according to blood-ciclosporin concentration and renal function); dose lower if given concomitantly with other immunosuppressant therapy (e.g. corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2–6 hours

- Bone-marrow transplantation, prevention and treatment of graft-versus-host disease, ADULT and CHILD over 3 months 3–5 mg/kg daily by intravenous infusion over 2–6 hours from day before transplantation to 2 weeks postoperatively (or 12.5–15 mg/kg daily by mouth) then 12.5 mg/kg daily by mouth for 3–6 months then tailed off (may take up to a year after transplantation)

- Nephrotic syndrome, by mouth, 5 mg/kg daily in 2 divided doses; CHILD 6 mg/kg daily in 2 divided doses; maintenance treatment reduce to lowest effective dose according to proteinuria and serum creatine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis)

Hepatic impairment dosage adjustment based on bilirubin and liver enzymes may be needed

Renal impairment dose as in normal renal function but see Cautions above; in nephrotic syndrome reduce dose by 25–50% if serum creatinine more than 30% above baseline on more than one measurement; in patients with nephrotic syndrome and renal impairment initially 2.5 mg/kg daily

Pregnancy crosses placenta; see Immunosuppressant Therapy, p. 553

Breast-feeding present in milk—manufacturer advises avoid

Side-effects anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia, hepatic dysfunction, hypertension, tremor, headache, paraesthesia, fatigue, renal dysfunction (renal structural changes on long-term administration, see also under Cautions), hyperuricaemia, hyperkalaemia, hyperlipidaemia, hypercholesterolaemia, muscle cramps, myalgia, hypertrichosis; less commonly oedema, weight gain, signs of encephalopathy, anaemia, thrombocytopenia; rarely pancreatitis, motor polyneuropathy, menstrual disturbances, gynaecomastia, microangiopathic haemolytic anaemia, haemolytic uraemic syndrome, hyperglycaemia, muscle weakness, myopathy, visual disturbances secondary to benign intracranial hypertension (discontinue); also reported with infusion anaphylaxis

Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration. Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function.
SIROLIMUS

Indications  prophyllaxis of organ rejection in kidney allograft recipients (initially in combination with ciclosporin and corticosteroid, then with corticosteroid only); see also under Dose

Cautions  monitor kidney function when given with ciclosporin; monitor whole blood-sirolimus trough concentration (Afro-Caribbean patients may require higher doses); hyperlipidaemia (monitor lipids); monitor urine proteins; increased susceptibility to infection (especially urinary tract infection); increased susceptibility to lymphoma and other malignancies, particularly of the skin (limit exposure to UV light); interactions: Appendix 1 (sirolimus)

Hepatic impairment  monitor whole blood-sirolimus level closely and consult local treatment protocol; clearance reduced in mild to moderate impairment; in severe impairment decrease dose by 50% and monitor whole blood-sirolimus trough concentration every 5–7 days until 3 consecutive measurements have shown stable blood-sirolimus concentration

Pregnancy  avoid unless essential—(toxicity in animal studies); effective contraception must be used during treatment and for 12 weeks after stopping

Breast-feeding  discontinue breast-feeding

Side-effects  abdominal pain, constipation, nausea, diarrhoea, ascites, stomatitis; oedema, tachycardia, hypertension, hypercholesterolaemia, hypertriglyceridaemia, venous thromboembolism; pleural effusion, pneumonitis; headache; pyrexia; proteinuria, haemolytic uraemic syndrome; anaemia, thrombocytopenia, thrombotic thrombocytopenic purpura, leucopenia, neutropenia, hypokalaemia, hypophosphataemia, hyperglycaemia, lymphocele; arthralgia, osteonecrosis; epistaxis; acne, rash, impaired healing; less commonly pancreatitis, pulmonary embolism, pulmonary haemorrhage, pericardial effusion, nephrotic syndrome, pancytopenia; rarely interstitial lung disease, alveolar proteinosis, hepatic necrosis, lymphoedema, and hypersensitivity reactions including anaphylactic reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis; focal segmental glomerulosclerosis and reversible impairment of male fertility also reported

Dose

- Initially 6 mg, after surgery (once wound has healed), then 2 mg once daily (dose adjusted according to whole blood-sirolimus trough concentration) in combination with ciclosporin and corticosteroid for 2–3 months (sirolimus given 4 hours after ciclosporin); ciclosporin should then be withdrawn over 4–8 weeks (if not possible, sirolimus should be discontinued and an alternate immunosuppressive regimen used)

Note  Manufacturer advises pre-dose (‘trough’) whole blood-sirolimus concentration (using chromatographic assay) when used with ciclosporin should be 4–12 micrograms/litre (local treatment protocols may differ), after withdrawal of ciclosporin pre-dose whole blood-sirolimus concentration should be 12–20 micrograms/litre (local treatment protocols may differ), close monitoring of whole blood-sirolimus concentration required if concomitant treatment with potent inducers or inhibitors of metabolism and after discontinuing them, or if ciclosporin dose reduced significantly or stopped, see also Hepatic Impairment above

When changing between oral solution and tablets, measurement of whole blood ‘trough’ sirolimus concentration after 1–2 weeks is recommended

Therapeutic drug monitoring assays  Sirolimus whole-blood concentration is measured using either high performance liquid chromatography (HPLC) or immunoassay. Switching between different immunoassays or between an immunoassay and HPLC can lead to clinically significant differences in results and therefore incorrect dose adjustments. Adjustment to the target therapeutic dose range should be made with knowledge of the assay used and corresponding reference range

Rapamune® (Wyeth) Tablets, coated, sirolimus 0.5 mg (tan), net price 30-tab pack = £69.00; 1 mg (white), 30-tab pack = £86.49; 2 mg (yellow), 30-tab pack = £172.98. Counselling, administration

Important  The 0.5-mg tablet is not bioequivalent to the 1-mg, 2-mg, and 5-mg tablets. Multiples of 0.5-mg tablets should not be used as a substitute for other tablet strengths

Oral solution, sirolimus 1 mg/mL, net price 60 mL = £162.41. Counselling, administration

Counselling  Food may affect absorption (take at the same time with respect to food). Mix solution with at least 60 mL water or orange juice in a glass or plastic container immediately before taking; refill container with at least 120 mL of water or orange juice and drink immediately (to ensure total dose). Do not mix with any other liquids

BNF 61

8.2.2 Corticosteroids and other immunosuppressants
**TACROLIMUS**

**Indications** prophylaxis of organ rejection in liver, kidney, and heart allograft recipients and allograft rejection resistant to conventional immunosuppressive regimens; see also notes above; moderate to severe atopic eczema (section 13.5.3)

**Cautions** monitor blood pressure, ECG (important: see Cardiomyopathy below), fasting blood-glucose concentration, haematological and neurological (including visual) parameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration especially during episodes of diarrhoea—consult local treatment protocol for details; QT-interval prolongation; neurotoxicity; increased risk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; pregnancy (exclude before starting); interactions: Appendix 1 (tacrolimus);

**Driving** May affect performance of skilled tasks (e.g. driving)

**Contra-indications** hypersensitivity to macrolides; avoid concurrent administration with ciclosporin (care if patient has previously received ciclosporin); hepatic impairment dose reduction may be necessary in severe impairment

**Pregnancy** avoid unless potential benefit outweighs risk—risk of premature delivery, intra-uterine growth restriction, and hyperkalaemia; toxicity in animal studies

**Breast-feeding** avoid—present in milk

**Side-effects** nausea, vomiting, diarrhoea, constipa-
tion, dyspepsia, flatulence, bloating, weight changes, anorexia, gastrointestinal inflammation, ulceration, and perforation, hepatic dysfunction, jaundice, cholestasis, ascites, bile-duct abnormalities, oedema, tachycardia, hypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea, pleural effusion, parenchymal lung disorders, sleep disturb-
tances, tremor, headache, peripheral neuropathy, mood changes, depression, confusion, anxiety, para-
chois, seizures, paraesthesia, dizziness, renal impair-
ment, renal failure, renal tubular necrosis, urinary abnormalities, hyperglycaemia, electrolyte distur-
bances (including hyperkalaemia, hypokalaemia, and hyperuricaemia), blood disorders (including anaemia, leucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle cramp, visual disturbances, photopho-
bia, tinnitus, impaired hearing, alopecia, sweating, acne; less commonly paralytic ileus, gastro-intestinal reflux disease, peritonitis, pancreatitis, heart failure, arrhythmia, cardiac arrest, cerebrovascular accident, cardiomyopathy (important: see Cardiomyopathy below), palpitation, respiratory failure, coma, speech disorder, amnesia, paralysis, influenza-like symptoms, encephalopathy, coagulation disorders, photosensitiv-
ity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia, dermatitis; rarely pericardial effusion, respiratory distress syndrome, posterior reversible encephalopathy syndrome, dehydration, thrombotic thrombocytopenic purpura, blindness, toxic epider-
mal necrolysis, hirsutism; very rarely myasthenia, haemorrhagic cystitis, Stevens-Johnson syndrome

**Cardiomyopathy** Cardiomyopathy has been reported in children. Patients should be monitored by echocardiography for hypertrophic changes—consider dose reduction or discontinuation if these occur

**Dose**

- See under preparations

### Important

**Adopta**®, **Prograf**®, **Modigraf**®, and **Advagraf** (tacrolimus): serious medication errors

- It is important to note the correct use of these medicines:
  - **Adopta**® is an immediate-release formulation that is taken twice daily, once in the morning and once in the evening;
  - **Prograf**® is an immediate-release formulation that is taken twice daily, once in the morning and once in the evening;
  - **Modigraf** granules are used to prepare an immediate-release suspension which is taken twice daily, once in the morning and once in the evening;
  - **Advagraf** is a prolonged-release formulation that is taken once daily in the morning.

Switching between **Adopta**®, **Prograf**®, **Modigraf**®, and **Advagraf** requires careful therapeutic monitoring. Substitution should be made only under the close supervision of a transplant specialist.

#### Adopta® (Sandoz) ▼

- **Capsules**, tacrolimus (as monohydrate) 500 micro-

- Orams (white/yellow), net price 50-cap pack = £50.50; 1 mg (white/brown), 50-cap pack = £65.52, 100-cap pack = £131.02; 5 mg (white/orange), 50-cap pack = £242.05. Label: 23, counselling, driving

**Note** Tacrolimus is incompatible with PVC

Dose

- Liver transplantation, starting 12 hours after transplanta-

- Tion, by mouth, 100–200 micrograms/kg daily in 2 divided doses, **CHILD** 300 micrograms/kg daily in 2 divided doses

Renal transplantation, starting within 24 hours of transplantation, by mouth, 300–400 micrograms/kg daily in 2 divided doses

Heart transplantation with antibody induction, starting within 5 days of transplantation, by mouth, 75 micrograms/kg daily in 2 divided doses, **CHILD** without antibody induction, 300 micro-

- Orams/kg daily in 2 divided doses as soon as clinically possible (8–12 hours after discontinuing intravenous infusion); following antibody induction, 100–300 micrograms/kg daily in 2 divided doses

Maintenance treatment, dose adjusted according to response

Rejection therapy, seek specialist advice

**Modigraf®** (Astellas) ▼

- **Granules**, tacrolimus (as monohydrate), 200 micro-

- Orams, net price 50-sachet pack = £71.30; 1 mg, 50- 

- Sachet pack = £356.65. Label: 13, 23, counselling, driving

**Note** Tacrolimus is incompatible with PVC

Dose

- Liver transplantation, starting 12 hours after transplanta-

- Tion, by mouth, 200–300 micrograms/kg daily in 2 divided doses, **CHILD** 300 micrograms/kg daily in 2 divided doses

Renal transplantation, starting within 24 hours of transplantation, by mouth, 250–300 micrograms/kg daily in 2 divided doses

Heart transplantation with antibody induction, starting within 5 days of transplantation, by mouth, 75 micrograms/kg daily in 2 divided doses, **CHILD** without antibody induction, 300 micro-

- Orams/kg daily in 2 divided doses as soon as clinically possible (8–12 hours after discontinuing intravenous infusion); following antibody induction, 100–300 micrograms/kg daily in 2 divided doses

Maintenance treatment, dose adjusted according to response

Rejection therapy, seek specialist advice

**Prograf®** (Astellas) ▼

- **Capsules**, tacrolimus (as monohydrate) 500 micro-

- Orams (yellow), net price 50-cap pack = £61.88; 1 mg (white), 50-cap pack = £80.28, 100-cap pack = £160.54; 5 mg (greyish-red), 50-cap pack = £296.58. Label: 23, counselling, driving

**Note** Tacrolimus is incompatible with PVC
Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.

Infusion-related side-effects (including cytokine release syndrome) are reported commonly with anti-lymphotoxin monoclonal antibodies and occur predominantly during the first infusion; they include fever and chills, nausea and vomiting, allergic reactions (such as rash, pruritus, angioedema, bronchospasm and dyspnoea), flushing and tumour pain. Patients should be given paracetamol and an antihistamine before each dose of anti-lymphotoxin monoclonal antibodies to reduce these effects. Premedication with a corticosteroid should also be considered. The infusion may have to be stopped temporarily and the infusion-related effects treated—consult product literature for appropriate management. Evidence of pulmonary infiltration and features of tumour lysis syndrome should be sought if infusion-related effects occur.

Fatalities following severe cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphotoxin monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored very closely (and a slower rate of infusion considered).

8.2.3 Anti-lymphotoxin monoclonal antibodies

Rituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin’s lymphoma and, in combination with other chemotherapy, for previously untreated stage III–IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin’s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.

BNF 61

8.2.3 Anti-lymphotoxin monoclonal antibodies

Concentrate for intravenous infusion, tacrolimus

5 mg/mL. To be diluted before use. Net price 1-mL amp = £58.46

Note: Tacrolimus is incompatible with PVC

Dose: intravenous infusion over 24 hours, 30–50 micrograms/kg daily for up to 7 days (then transfer to oral therapy); CHILD by mouth, 300 micrograms/kg daily in 2 divided doses or by intravenous infusion over 24 hours, 50–100 micrograms/kg daily for up to 7 days (then transfer to oral therapy)

Renal transplantation, starting within 24 hours of transplantation, by mouth, 200–300 micrograms/kg daily in 2 divided doses or by intravenous infusion over 24 hours, 50–100 micrograms/kg daily for up to 7 days (then transfer to oral therapy); CHILD by mouth, 300 micrograms/kg daily in 2 divided doses or by intravenous infusion over 24 hours, 75–100 micrograms/kg daily for up to 7 days (then transfer to oral therapy)

Heart transplantation with antibody induction, starting within 5 days of transplantation, by mouth, 75 micrograms/kg daily in 2 divided doses or by intravenous infusion over 24 hours, 10–20 micrograms/kg daily for up to 7 days (then transfer to oral therapy); CHILD, without antibody induction, initially by intravenous infusion over 24 hours, 30–50 micrograms/kg daily; then by mouth, 300 micrograms/kg daily in 2 divided doses as soon as clinically possible (8–12 hours after discontinuing intravenous infusion); following antibody induction, by mouth, 100–300 micrograms/kg daily in 2 divided doses

Maintenance treatment, dose adjusted according to response

Rejection therapy: seek specialist advice

8.2.3 Anti-lymphotoxin monoclonal antibodies

Rituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin’s lymphoma and, in combination with other chemotherapy, for previously untreated stage III–IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin’s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.
8 Malignant disease and immunosuppression

**NICE guidance**

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)

Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.

Rituximab for aggressive non-Hodgkin’s lymphoma (September 2003)

Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV. The use of rituximab for localised (stage I) disease should be limited to clinical trials.

Ofatumumab causes lysis of B and C lymphocytes and is licensed for use in patients with chronic lymphocytic leukaemia for whom fludarabine treatment is not appropriate. In common with rituximab, it causes infusion-related side-effects including cytokine release syndrome (see above); premedication with an analgesic, an anti-histamine, and a corticosteroid is recommended.

Alemtuzumab causes lysis of B and C lymphocytes and is licensed for use in patients with chronic lymphocytic leukaemia for whom fludarabine treatment is not appropriate. In common with rituximab, it causes infusion-related side-effects including cytokine release syndrome (see above); premedication with an analgesic, an anti-histamine, and a corticosteroid is recommended.

The Scottish Medicines Consortium (p. 4) has advised (August 2008) that alemtuzumab is accepted for restricted use within NHS Scotland for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL) when fludarabine combination chemotherapy is not appropriate. Alemtuzumab is restricted to use in patients with previously untreated B-CLL, with the cytogenetic abnormality 17p-deletion.

Ofatumumab causes lysis of B lymphocytes. It is licensed for treatment of chronic lymphocytic leukaemia in patients refractory to fludarabine and alemtuzumab. Infusion-related side-effects (including cytokine release syndrome—see above) have been reported with ofatumumab; premedication with an analgesic, an anti-histamine, and a corticosteroid is recommended.

**ALEMTUZUMAB**

**Indications** see notes above

**Cautions** see notes above—for full details consult product literature

**Contra-indications** for full details consult product literature

**Pregnancy** avoid unless potential benefit outweighs risk; use effective contraception during and for 12 months after treatment

**Breast-feeding** discontinue breast-feeding during and for 12 months after treatment—no information available

**Side-effects** see notes above—for full details (including monitoring and management of side-effects) consult product literature

MabThera® (Roche) Concentrate for intravenous infusion, rituximab 100 mg/5 mL, net price £182.00

**RITUXIMAB**

**Indications** see notes above; severe active rheumatoid arthritis (section 10.1.3)

**Cautions** see notes above—for full details consult product literature

**Pregnancy** avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus—effective contraception required during and for 12 months after treatment

**Breast-feeding** avoid breast-feeding during and for 12 months after treatment

**Side-effects** see notes above—but for full details (including monitoring and management of side-effects) consult product literature

MabThera® (Roche) Concentrate for intravenous infusion, rituximab 100 mg/5 mL, net price £182.00

**Interferon alfa**

Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours. Interferon alfa preparations are also used in the treatment of chronic hepatitis B, and chronic hepatitis C ideally in combination with ribavirin (section 5.3.3). Side-effects are dose-related, but commonly include anorexia, nausea, diarrhoea, influenza-like symptoms, and lethargy. Ocular side-effects and depression (including suicidal behaviour) have also been reported. Myelosuppression may occur, particularly affecting granulocyte counts. Cardiovascular problems (hypotension, hypertension, palpitation, and arrhythmias), nephrotoxicity and hepatotoxicity have been reported. Hypertriglyceridaemia, sometimes severe, has been observed; monitoring of lipid concentration is recommended. Other side-effects include hypersensitivity reactions, thyroid abnormalities, hyperglycaemia, alopecia, psoriasisiform rash,

**OFATUMUMAB**

**Indications** see notes above

**Cautions** see notes above—for full details consult product literature

**Contra-indications** consult product literature

**Renal impairment** no information available for creatinine clearance less than 30 mL/minute

**Pregnancy** avoid unless potential benefit outweighs risk; use effective contraception during and for 12 months after treatment

**Breast-feeding** discontinue breast-feeding during and for 12 months after treatment—no information available

**Side-effects** see notes above—for full details (including monitoring and management of side-effects) consult product literature

Arzerra® (GSK) Concentrate for intravenous infusion, ofatumumab 100 mg/5 mL, net price £182.00

Electrolytes

Na+ 9.3 mmol/g

**MabCampath® (Genzyme)** Concentrate for intravenous infusion, alemtuzumab 30 mg/mL, net price 1-mL vial = £264.11

Electrolytes

Na+ 9.3 mmol/g

8.2.4 Other immunomodulating drugs

**Interferon alfa**

Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours. Interferon alfa preparations are also used in the treatment of chronic hepatitis B, and chronic hepatitis C ideally in combination with ribavirin (section 5.3.3). Side-effects are dose-related, but commonly include anorexia, nausea, diarrhoea, influenza-like symptoms, and lethargy. Ocular side-effects and depression (including suicidal behaviour) have also been reported. Myelosuppression may occur, particularly affecting granulocyte counts. Cardiovascular problems (hypotension, hypertension, palpitation, and arrhythmias), nephrotoxicity and hepatotoxicity have been reported. Hypertriglyceridaemia, sometimes severe, has been observed; monitoring of lipid concentration is recommended. Other side-effects include hypersensitivity reactions, thyroid abnormalities, hyperglycaemia, alopecia, psoriasisiform rash,

Concentrate for intravenous infusion, rituximab 100 mg/5 mL, net price £182.00

Electrolytes

Na+ 9.3 mmol/g

**MabCampath® (Genzyme)** Concentrate for intravenous infusion, alemtuzumab 30 mg/mL, net price 1-mL vial = £264.11

Electrolytes

Na+ 9.3 mmol/g

8.2.4 Other immunomodulating drugs

**Interferon alfa**

Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours. Interferon alfa preparations are also used in the treatment of chronic hepatitis B, and chronic hepatitis C ideally in combination with ribavirin (section 5.3.3). Side-effects are dose-related, but commonly include anorexia, nausea, diarrhoea, influenza-like symptoms, and lethargy. Ocular side-effects and depression (including suicidal behaviour) have also been reported. Myelosuppression may occur, particularly affecting granulocyte counts. Cardiovascular problems (hypotension, hypertension, palpitation, and arrhythmias), nephrotoxicity and hepatotoxicity have been reported. Hypertriglyceridaemia, sometimes severe, has been observed; monitoring of lipid concentration is recommended. Other side-effects include hypersensitivity reactions, thyroid abnormalities, hyperglycaemia, alopecia, psoriasisiform rash,

Concentrate for intravenous infusion, rituximab 100 mg/5 mL, net price £182.00

Electrolytes

Na+ 9.3 mmol/g

**MabCampath® (Genzyme)** Concentrate for intravenous infusion, alemtuzumab 30 mg/mL, net price 1-mL vial = £264.11

Electrolytes

Na+ 9.3 mmol/g

8.2.4 Other immunomodulating drugs

**Interferon alfa**

Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours. Interferon alfa preparations are also used in the treatment of chronic hepatitis B, and chronic hepatitis C ideally in combination with ribavirin (section 5.3.3). Side-effects are dose-related, but commonly include anorexia, nausea, diarrhoea, influenza-like symptoms, and lethargy. Ocular side-effects and depression (including suicidal behaviour) have also been reported. Myelosuppression may occur, particularly affecting granulocyte counts. Cardiovascular problems (hypotension, hypertension, palpitation, and arrhythmias), nephrotoxicity and hepatotoxicity have been reported. Hypertriglyceridaemia, sometimes severe, has been observed; monitoring of lipid concentration is recommended. Other side-effects include hypersensitivity reactions, thyroid abnormalities, hyperglycaemia, alopecia, psoriasisiform rash,

Concentrate for intravenous infusion, rituximab 100 mg/5 mL, net price £182.00

Electrolytes

Na+ 9.3 mmol/g

**MabCampath® (Genzyme)** Concentrate for intravenous infusion, alemtuzumab 30 mg/mL, net price 1-mL vial = £264.11

Electrolytes

Na+ 9.3 mmol/g
fusión, coma y convulsiones (usualmente con altas dosis en el adulto).

Polietileno de glicol-conjugado (‘pegilado’) derivados de interferón alfa (peginterferon alfa-2a y peginterferon alfa-2b) están disponibles; pegilación aumenta la persistencia del interferón en la sangre. Los peginterferones están indicados para el tratamiento de hepatitis crónica C, idealmente en combinación con ribavirina (véase sección 5.3.3). Peginterferon alfa-2a también está indicado para el tratamiento de hepatitis crónica B.

**Dosis**

Véase notas anteriores y consulte el producto.

**Efectos secundarios**

Es poco probable que sean perjudiciales; se deben evitar a menos que el beneficio potencial supere el riesgo (toxicidad en animales).

**Renal insuficiencia**

**Hepatopatía**

Close monitoring in mild to moderate impairment; avoid if severe.

**Contraindicaciones**

Consulte el producto literatura; evite si tiene severa.

**Cautelar**

Consulte el producto literatura; véase apartado preparaciones.

**Indicaciones**

Tratamiento de hepatitis crónica B. 5.3.3). Peginterferon alfa-2a también está licenciado para el tratamiento de hepatitis crónica B.

**Introducción**

**Indicaciones**

Véase preparaciones anteriores.

**Cautelar**

Consulte el producto literatura; interacciones: Appendix 1 (interferones)

**Contraindicaciones**

Consulte el producto literatura.

**Hipertensión**

Evite a menos que el beneficio potencial supere el riesgo (toxicidad en animales);

**Enfermedad del hígado**

Close monitoring required—reduce dose in moderate to severe impairment; consult product literature.

**Embarazo**

Los fabricantes recomiendan evitar a menos que el beneficio potencial supere el riesgo (toxicidad en animales).

**Lactancia materna**

Los fabricantes advierten evitar—no información disponible.

**Efectos secundarios**

Véase notas anteriores y consulte la producto literatura.

**Dosis**

Consulte producto literatura

**Peginterferon alfa**

**Indicaciones**

Véase preparaciones anteriores.

**Cautelar**

Consulte producto literatura; interacciones: Appendix 1 (interferones)

**Contraindicaciones**

Consulte producto literatura.

**Hepatitis**

Avoid in severe impairment.

**Enfermedad del riñón**

Close monitoring required—reduce dose in moderate to severe impairment; consult product literature.

**Embarazo**

Los fabricantes recomiendan evitar a menos que el beneficio potencial supere el riesgo (toxicidad en animales).

**Enfermedad del hígado**

Close monitoring required—consultar producto literatura.

**Lactancia materna**

Los fabricantes advierten evitar—no información disponible.

**Efectos secundarios**

Véase notas anteriores y consulte producto literatura.

**Dosis**

Consulte producto literatura.

**Pegasys**


**Ejemplos**

Véase p. 397

**Preparaciones**

*PEGINTERFERON ALFA*

**Inyecciones**

**Indicaciones**

Véase preparaciones anteriores.

**Cautelar**

Consulte preparaciones anteriores; interacciones: Appendix 1 (interferones)

**Contraindicaciones**

Consulte producto literatura.

**Hipertensión**

Véase preparaciones anteriores.

**Enfermedad del hígado**

Close monitoring required—reduce dose in moderate to severe impairment; consult product literature.

**Embarazo**

Los fabricantes recomiendan evitar a menos que el beneficio potencial supere el riesgo (toxicidad en animales).

**Lactancia materna**

Los fabricantes advierten evitar—no información disponible.

**Efectos secundarios**

Véase notas anteriores y consulte producto literatura.

**Dosis**

Consulte producto literatura.

**ViraferonPeg**

*Inyección*, prefilado pen, polvo para reconstitución, peginterferon alfa-2b (rbe), net price 50-microgramica pen = £66.46, 80-microgramica pen = £106.34, 100-microgramica pen = £159.51, 150-microgramica pen = £199.38 (todos con jeringas y swabs). Para inyección subcutánea—consultar producto literatura.

**Ejemplos**

Véase p. 397

**Preparaciones**

**Interferon beta**

**Interferon beta** está licenciado para uso en pacientes con múltiple esclerosis remitiendo/recaída (caracterizado por al menos dos episodios de desenfocamiento neurológico persistente en el período previo 2 o 3 años, seguido de un proceso completo o incompleto de recuperación) que son capaces de caminar. No todos los pacientes responden a la mejora en la longitud de los brotes que se ha observado en el pasado. También se ha utilizado para pacientes con secundario progresivo múltiple esclerosis, pero su rol en este condición no ha sido establecido.

**Cautelar**

Se advierte a aquellos con enfermedad hepática o renal, o que han padecido en el pasado enfermedad cardíaca, trastornos depresivos (evitar a menos que se presente una depresión intensa).
**Malignant disease and immunosuppression**

reported rarely with interferon beta-1b. alopecia, hepatitis, and thyroid dysfunction have been changes, suicide attempts, confusion and convulsions; disorders, menstrual disorders, mood and personality reactions (including anaphylaxis and urticaria), blood decrease over time; nausea and vomiting occur occasionally. Other side-effects include hypersensitivity reactions (including anaphylaxis and urticaria), blood disorders, menstrual disorders, mood and personality changes, suicide attempts, confusion and convulsions; alopecia, hepatitis, and thyroid dysfunction have been reported rarely with interferon beta-1b.

**Contra-indications** Avoid treatment with interferon beta in patients with severe depressive illness or those with decompensated liver disease.

**Side-effects** Side-effects reported most frequently include irritation at injection site (including inflammation, hypersensitivity, necrosis) and influenza-like symptoms (fever, chills, myalgia, or malaise) but these decrease over time; nausea and vomiting occur occasionally. Other side-effects include hypersensitivity reactions (including anaphylaxis and urticaria), blood disorders, menstrual disorders, mood and personality changes, suicide attempts, confusion and convulsions; alopecia, hepatitis, and thyroid dysfunction have been reported rarely with interferon beta-1b.


Patients who are currently receiving interferon beta or glatiramer acetate for multiple sclerosis, whether as routine therapy or as part of a clinical trial, should have the option to continue treatment until they and their consultant consider it appropriate to stop, having regard to the established criteria for withdrawal from treatment.

**Provision of disease-modifying therapies for multiple sclerosis**

The Department of Health, the National Assembly for Wales, the Scottish Executive, the Northern Ireland Department of Health, Social Services & Public Safety, and the manufacturers have reached agreement on a risk-sharing scheme for the NHS supply of interferon beta and glatiramer acetate for multiple sclerosis. Health Service Circular (HSC 2002/004) explains how patients can participate in the scheme. It is available on the Department of Health website (www.dh.gov.uk)

**INTERFERON BETA**

**Indications** see notes above and under preparations

**Cautions** see notes above and consult product literature

**Contra-indications** see notes above and consult product literature

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Pregnancy** avoid unless potential benefit outweighs risk (toxicity in animal studies); effective contraception required during treatment; consult product literature

**Breast-feeding** avoid—no information available

**Side-effects** see notes above and consult product literature

---

**Interferon beta-1a**

*Avonex*® (Biogen) 

Injection, interferon beta-1a 60 micrograms (12 million-units)/mL, net price 0.5-mL (30-microgram, 6 million-unit) prefilled syringe = £163.50

*Note* For intramuscular injection

Injection, powder for reconstitution, interferon beta-1a, net price 30-microgram (6 million-unit) vial with diluent = £163.50

*Note* For intramuscular injection

**Injection** for relapsing, remitting multiple sclerosis or for a single demyelinating event with an active inflammatory process (if it is severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis), consult product literature

**Rebif®** (Merck Serono) 

Injection, interferon beta-1a, net price 22-microgram (6 million-unit) prefilled syringe = £52.06; 44-microgram (12 million-unit) prefilled syringe = £57.77; starter pack of 6 × 8.8-microgram (2.4 million-unit) prefilled syringes with 6 × 22-microgram (6 million-unit) prefilled syringes = £552.19

*Note* For subcutaneous injection

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients, p. 2)

Injection, interferon beta-1a, 44 micrograms (12 million-units/mL), net price 1.5 mL (66-microgram, 18 million-unit) cartridge = £144.48; 88-micrograms (24 million-units/mL), 1.5 mL (132-microgram, 36 million-unit) cartridge = £171.97; starter pack of 2 × 1.5 mL (132-microgram, 36 million-unit) cartridge = £343.93

**Note** Cartridges for use with RebiSmart® auto-injector device. For subcutaneous injection

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients, p. 2)

**Injection** (RebiDose®), interferon beta-1a, net price 22-microgram (6 million-unit) prefilled pen = £52.06; 44-microgram (12 million-unit) prefilled pen = £57.77; starter pack of 6 × 8.8-microgram (2.4 million-unit) prefilled pens with 6 × 22-microgram (6 million-unit) prefilled pens = £552.19

*Note* For subcutaneous injection

**Excipients** include benzyl alcohol (avoid in neonates, see Excipients, p. 2)

**Injection** for relapsing, remitting multiple sclerosis, consult product literature

**Interferon beta-1b**

*Betaferon*® (Bayer Schering) 

Injection, powder for reconstitution, interferon beta-1b, net price 300-microgram (9.6 million-unit) vial with diluent = £39.78

*Note* For subcutaneous injection

**Injection** An autoinjector device (Betaject® Light) is available from Bayer Schering

**Dose** for relapsing, remitting multiple sclerosis, for secondary progressive multiple sclerosis with active disease, or for a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis), consult product literature

**Extavia®** (Novartis) 

Injection, powder for reconstitution, interferon beta-1b. Net price 300-microgram (9.6 million-unit) vial with diluent = £39.78

*Note* for subcutaneous injection

**Dose** for relapsing, remitting multiple sclerosis, for secondary progressive multiple sclerosis with active disease, or for a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis), consult product literature
Interferon gamma

Interferon gamma-1b is licensed to reduce the frequency of serious infection in chronic granulomatous disease and in severe malignant osteopetrosis.

INTERFERON GAMMA-1b (immune interferon)

Indications see notes above

Cautions seizure disorders (including seizures associated with fever); cardiac disease (including ischaemia, congestive heart failure, and arrhythmias); monitor before and during treatment: haematological tests (including full blood count, differential white cell count, and platelet count); blood chemistry tests (including renal and liver function tests) and urinalysis; avoid simultaneous administration of foreign proteins including immunological products (risk of exaggerated immune response); interactions: Appendix 1 (interferons)

Driving May impair ability to drive or operate machinery; effects may be enhanced by alcohol

Hepatic impairment manufacturer advises caution in severe impairment—risk of accumulation

Renal impairment manufacturer advises caution in severe impairment—risk of accumulation

Pregnancy manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies); effective contraception required during treatment—consult product literature

Breast-feeding patients advised to discontinue breast-feeding

Dose

• See under preparation

Immukin® (Boehringer Ingelheim) Injection, recombinant human interferon gamma-1b 200 micrograms/mL, net price 0.5-ml vial = £66.67

Dose By subcutaneous injection, 50 micrograms/m² 3 times a week; patients with body surface area of 0.5 m² or less, 1.5 micrograms/kg 3 times a week; not yet recommended for children under 6 months with chronic granulomatous disease

Aldesleukin

Aldesleukin (recombinant interleukin-2) is licensed for metastatic renal cell carcinoma excluding patients in whom all three of the following prognostic factors are present: performance status of Eastern Cooperative Oncology Group of 1 or greater, more than one organ present: performance status of Eastern Co-operative Oncology Group of 1 or greater, more than one organ present; and a period of less than 24 months between initial diagnosis of primary tumour and date of evaluation of treatment. It is usually given by subcutaneous injection. It is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension. Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival. Bone-marrow, hepatic, renal, thyroid, and CNS toxicity is common. It is for use in specialist units only.

ALDESLEUKIN

Indications see notes above

Cautions consult product literature; interactions: Appendix 1 (aldesleukin)

Contra-indications consult product literature

Pregnancy use only if potential benefit outweighs risk (toxicity in animal studies); ensure effective contraception during treatment in men and women; see also Reproductive Function, p. 520

Breast-feeding discontinue breast-feeding

Side-effects see section 8.1, notes above, and consult product literature

Dose

• Consult product literature

Proleukin® (Novartis) Injection, powder for reconstitution, aldesleukin. Net price 18-milligram unit vial = £112.00. For subcutaneous injection or intravenous infusion (but see notes above)

BCG bladder instillation

BCG (Bacillus Calmette-Guérin) is a live attenuated strain derived from Mycobacterium bovis. It is licensed as a bladder instillation for the treatment of primary or recurrent bladder carcinoma and for the prevention of recurrence following transurethral resection.

BACILLUS CALMETTE-GUÉRIN

Indications see notes above; BCG immunisation (section 14.4)

Cautions screen for active tuberculosis (contra-indicated if tuberculosis confirmed); traumatic catheterisation or urethral or bladder injury (delay administration until mucosal damage healed)

Contra-indications impaired immune response. HIV infection, urinary-tract infection, severe haematuria, tuberculosis, fever of unknown origin

Pregnancy avoid

Breast-feeding avoid

Side-effects cystitis, dysuria, urinary frequency, haematuria, malaise, fever, influenza-like syndrome; also systemic BCG infection (with fatalities)—consult product literature

Dose

• Consult product literature

ImmuCyst® (Alliance) Bladder instillation, freeze-dried powder containing attenuated Mycobacterium bovis prepared from the Connaught strain of bacillus of Calmette and Guérin, net price 81-milligram vial = £79.23

OncoTICE® (Organon) Bladder instillation, freeze-dried powder containing attenuated Mycobacterium bovis prepared from the TICE strain of bacillus of Calmette and Guérin, net price 12.5-milligram vial = £71.61

8.2.4 Other immunomodulating drugs 563

Malignant disease and immunosuppression
Canakinumab

Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding. It is licensed for the treatment of cryopyrin-associated periodic syndrome, including severe forms of familial cold auto-inflamatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological, cutaneous, articular syndrome), which are rare inherited auto-inflammatory disorders.

Glatteramer acetate

Glatteramer acetate is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding. It is licensed for the treatment of cryopyrin-associated periodic syndrome, including severe forms of familial cold auto-inflamatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological, cutaneous, articular syndrome), which are rare inherited auto-inflammatory disorders.

HISTAMINE DIHYDROCHLORIDE

Histamine

Histamine is licensed for maintenance therapy, in combination with aldesleukin, in patients with acute myeloid leukaemia in first remission.

GLATIRAMER ACETATE

Provision of disease-modifying therapies for multiple sclerosis

See p. 562

NICE guidance (interferon beta and glatiramer for multiple sclerosis)

See p. 562

Indications see notes above

Cautions cardiac disorders

Renal impairment no information available—manufacturer advises caution

Pregnancy manufacturer advises avoid—no information available

Breast-feeding manufacturer advises caution—no information available

Side-effects hypersensitivity reactions; flushing, chest pain, palpitation, tachycardia, and dyspnoea may occur within minutes of injection; nausea, constipation, dyspepsia; syncope, anxiety, asthenia, depression, headache, tremor, sweating; oedema, lymphadenopathy; hypotension, back pain, arthralgia, influenza-like symptoms; injection-site reactions, rash; rarely seizures

Dose

• By subcutaneous injection, ADULT over 18 years, 20 mg daily

Copaxone® (Teva)

Injection, glatiramer acetate 20 mg/mL, net price 1-mL prefilled syringe = £18.73

Histamine

Histamine is licensed for maintenance therapy, in combination with aldesleukin, in patients with acute myeloid leukaemia in first remission.

HISTAMINE DIHYDROCHLORIDE

Indications see notes above

Cautions consult product literature; interactions:

Appendix 1 (histamine)

Contra-indications consult product literature

Hepatic impairment increased risk of tachycardia and hypotension in moderate to severe impairment

Renal impairment increased risk of hypotension in severe impairment

Pregnancy manufacturer advises avoid—no information available; ensure effective contraception during treatment in men and women

Breast-feeding manufacturer advises avoid—no information available

Side-effects consult product literature

Cepelone® (Meda)

Injection, histamine dihydrochloride 1 mg/mL, net price 0.5-mL vial = £84.38

Canakinumab

Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding. It is licensed for the treatment of cryopyrin-associated periodic syndrome, including severe forms of familial cold auto-inflamatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological, cutaneous, articular syndrome), which are rare inherited auto-inflammatory disorders.

Glatteramer acetate

Glatteramer acetate is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding. It is licensed for the treatment of cryopyrin-associated periodic syndrome, including severe forms of familial cold auto-inflamatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological, cutaneous, articular syndrome), which are rare inherited auto-inflammatory disorders.
Lenalidomide and thalidomide

Lenalidomide is an immunomodulating drug with anti-neoplastic, anti-angiogenic, and pro-erythropoietic properties. It is licensed, in combination with dexamethasone, for the treatment of multiple myeloma in patients who have received at least one previous therapy. The most serious side-effects of lenalidomide are venous thromboembolism and severe neutropenia. Lenalidomide is structurally related to thalidomide and there is a risk of teratogenesis.

The Scottish Medicines Consortium (p. 4) has advised (April 2010) that lenalidomide, in combination with dexamethasone, is accepted for restricted use within NHS Scotland for patients with multiple myeloma who have received at least two prior therapies.

NICE guidance

Lenalidomide for the treatment of multiple myeloma (June 2009)

Lenalidomide in combination with dexamethasone is an option for the treatment of multiple myeloma in patients who have received two or more prior therapies. The drug cost of lenalidomide will be met by the manufacturer for patients who remain on treatment for more than 26 cycles.

Thalidomide is used in combination with melphalan and prednisolone as first-line treatment for untreated multiple myeloma, in patients aged 65 years and over, or for those not eligible for high-dose chemotherapy (for example, patients with significant co-morbidity such as cardiac risk factors). It has immunomodulatory and anti-inflammatory activity. Thalidomide can cause drowsiness, constipation, and on prolonged use peripheral neuropathy.

Pregnancy

For women of child-bearing potential, pregnancy must be excluded before starting treatment (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment (oral combined hormonal contraceptives and copper-releasing intrauterine devices not recommended) and men should use condoms during treatment and for at least 1 week after stopping if their partner is pregnant or is of child-bearing potential and not using effective contraception. Women must comply with a pregnancy prevention programme.

Lenalidomide

Indications see notes above

Cautions see notes above; monitor full blood count (including differential white cell count and platelet count) before treatment and every week for the first 8 weeks then every 4 weeks (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develops—consult product literature); concomitant drugs that increase the risk of thromboembolism; high tumour burden—risk of tumour lysis syndrome, see p. 520; monitor thyroid function; risk factors for myocardial infarction; interactions: Appendix 1 (lenalidomide)

Thromboembolism Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb

Neutropenia and thrombocytopenia Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.

Renal impairment starting dose 10 mg once daily if creatinine clearance 30–50 mL/minute; starting dose 15 mg on alternate days if creatinine clearance less than 30 mL/minute

Pregnancy important: teratogenic risk; see also notes above

Breast-feeding discontinue breast-feeding—no information available

Side-effects myocardial infarction, hypotension, deep vein thrombosis; pneumonia, dyspnoea; tremor; hypoaesthesia, fatigue, asthenia; neutropenia, thrombocytopenia, anaemia, lymphopenia, leucopenia; muscle cramp; pruritus, rash; rarely Stevens-Johnson syndrome and toxic epidermal necrolysis; interstitial pneumonitis and pancreatitis also reported

Dose

- ADULT over 18 years, 25 mg once daily for 21 consecutive days of a 28-day cycle; for doses of dexamethasone, consult product literature

Revlimid® (Celgene) ▼ (TA)

Capsules, lenalidomide, 5 mg (white), net price 21-cap pack = £3570.00; 10 mg (blue/yellow), 21-cap pack = £3780.00; 15 mg (blue/white), 21-cap pack = £3969.00; 25 mg (white), 21-cap pack = £4368.00.

Label: 25, counselling, symptoms of thromboembolism, neutropenia, or thrombocytopenia, patient information leaflet

Note Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form, which must be sent to Celgene.

Thalidomide

Indications see notes above

Cautions see notes above; high tumour burden—risk of tumour lysis syndrome, see p. 520; concomitant use of drugs which increase risk of peripheral neuropathy or thromboembolism

Thromboembolism Thromboprophylaxis is recommended for at least the first 5 months of treatment, especially in patients with additional thrombotic risk factors. Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb

Peripheral neuropathy Monitor patients for signs and symptoms of peripheral neuropathy; patients and their carers should be advised to seek medical advice if symptoms such as paraesthesia, abnormal coordination, or weakness develop. Dose reduction, dose interruption, or treatment discontinuation may be necessary—consult product literature. Patients with pre-existing peripheral neuropathy should not be treated with thalidomide unless the potential clinical benefits outweigh the risk

Hepatic impairment caution in severe impairment—no information available

Renal impairment caution in severe impairment—no information available

Pregnancy important teratogenic risk; see also notes above

Breast-feeding avoid—present in milk in animal studies

Side-effects vomiting, dry mouth, dyspepsia, constipation; bradycardia, cardiac failure, deep vein
thrombosis; dyspnoea, interstitial lung disease, pulmonary embolism, peripheral oedema; asthenia, confusion, depression, dizziness, drowsiness, peripheral neuropathy, dysaesthesia, paraesthesia, syncope, tremor; pyrexia, pneumonia, anaemia, leucopenia, neutropenia, lymphopenia, thrombocytopenia; skin reactions including Stevens-Johnson syndrome; also reported toxic epidermal necrolysis, intestinal obstruction, gastrointestinal perforation, hypothyroidism, and sexual dysfunction.

**Dose**
- **ADULT** over 18 years, 200 mg once daily at bedtime for 6-week cycle; max. 12 cycles

**Capsules**
- Mifamurtide, thalidomide 50 mg, net price 28-cap pack = £298.48. Label: 2, counselling, symptoms of peripheral neuropathy and thromboembolism (see above)

**Note**
- Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form.

**Mifamurtide**

**Indications** see notes above

**Cautions**
- asthma and chronic obstructive pulmonary disease—consider prophylactic bronchodilator therapy; history of autoimmune, inflammatory, or collagen disease; monitor renal function, hepatic function and clotting parameters; monitor patients with history of venous thrombosis, vasculitis, or unstable cardiovascular disorders for persistent or worsening symptoms during administration—consult product literature; interactions: Appendix 1 (mifamurtide)

**Hepatic impairment** use with caution—no information available

**Renal impairment** use with caution—no information available

**Pregnancy** avoid; effective contraception required

**Breast-feeding** avoid—no information available

**Side-effects**
- gastro-intestinal disturbances (including anorexia, nausea, vomiting, diarrhoea, constipation, abdominal pain, dyspepsia); tachycardia, hypertension, palpitations, hypotension, phlebitis, flushing; oedema, respiratory disorders (including dyspnoea, epistaxis, cough, tachypnoea, haemoptysis, pleural effusion); confusion, depression, insomnia, headache, dizziness, paraesthesia, hypoesthesia, tremor, drowsiness, anxiety; hypokalaemia, anaemia, leucopenia, thrombocytopenia, granulocytopenia; haematuria, dysuria, pollakiuria; musculoskeletal pain; blurred vision; vertigo, tinnitus, hearing loss; sweating, alopecia, rash, dry skin

**Mepact®** (Takeda)▼

**Infusion** intravenous infusion, powder for reconstitution, mifamurtide encapsulated in liposomes, net price 4-mg vial = £2375.00

**Natalizumab**

**Natalizumab**

**Indications**
- rems in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

**NICE guidance**

Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007)

Natalizumab is a monoclonal antibody that inhibits the migration of leukocytes into the central nervous system, hence reducing inflammation and demyelination. It is licensed for use in patients with highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta or those with rapidly evolving severe relapsing-remitting multiple sclerosis. Treatment with natalizumab should be initiated and supervised by a specialist.

Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leukoencephalopathy (PML). The risk of developing PML increases after 2 years of therapy; the risk beyond 3 years treatment is not known. A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab, and annually thereafter. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML. Treatment should be suspended until PML has been excluded. If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.

Infusion-related side-effects include nausea, vomiting, flushing, headache, dizziness, fatigue, rigors, pyrexia, arthralgia, urticaria, and pruritus. Patients should be observed for hypersensitivity reactions, including anaphylaxis, during the infusion and for 1 hour after completion of the infusion. Natalizumab should be discontinued permanently if hypersensitivity reaction occurs.

The Scottish Medicines Consortium (p. 4) has advised (August 2007) that natalizumab is accepted for restricted use as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

**Liver toxicity** Liver dysfunction reported; advise patients to monitor liver function (see below)

**Progressive multifocal leukoencephalopathy (PML)** Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years,
they should be given an alert card which includes information about the symptoms of PML (see also notes above). Hypersensitivity reactions Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation)

**Contra-indications** progressive multifocal leucoencephalopathy; active infection (see notes above); concurrent use of interferon beta or glatiramer acetate; immunosuppression; active malignancies (except cutaneous basal cell carcinoma)

**Pregnancy** avoid unless essential—toxicity in animal studies

**Breast-feeding** present in milk—no adverse effects

**Side-effects** see notes above; also urinary-tract infection, nasopharyngitis, autoantibodies, and arthralgia; less commonly hypersensitivity reactions (see above); liver toxicity also reported

**Dose**
- By intravenous infusion, ADULT over 18 years, 300 mg once every 4 weeks; discontinue if no response after 6 months

**Tysabri** (Biogen) Concentrate for intravenous infusion
- **Adults** 20 mg/mL, net price 15-mL vial = £1130.00. Counselling, liver toxicity, progressive multifocal leucoencephalopathy, and hypersensitivity, patient alert card

---

**8.3 Sex hormones and hormone antagonists in malignant disease**

**8.3.1 Oestrogens**

**Diethylstilbestrol** (Stilboestrol) is sometimes used to treat prostate cancer, but it is not usually used first-line because of its side-effects. It is occasionally used in postmenopausal women with breast cancer. Toxicity is common and dose-related side-effects include nausea, fluid retention, and venous and arterial thrombosis. Impotence and gynaecomastia always occur in men, and withdrawal bleeding may be a problem in women. Hypercalcaemia and bone pain may also occur in breast cancer.

**Ethinylestradiol** is the most potent oestrogen available; unlike other oestrogens it is only slowly metabolised in the liver. Ethinylestradiol is licensed for the palliative treatment of prostate cancer.

**Hypersensitivity reactions** Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation)

**Contra-indications** progressive multifocal leucoencephalopathy; active infection (see notes above); concurrent use of interferon beta or glatiramer acetate; immunosuppression; active malignancies (except cutaneous basal cell carcinoma)

**Pregnancy** avoid unless essential—toxicity in animal studies

**Breast-feeding** present in milk—no adverse effects

**Side-effects** see notes above; also urinary-tract infection, nasopharyngitis, autoantibodies, and arthralgia; less commonly hypersensitivity reactions (see above); liver toxicity also reported

**Dose**
- Breast cancer, 10–20 mg daily
- Prostate cancer, 1–3 mg daily

**Diethylstilbestrol** (Non-proprietary)
- **Tablets**, diethylstilbestrol 1 mg, net price 28 = £53.34; 5 mg, 28 = £180.05

**8.3.2 Progestogens**

Progestogens have a role in the treatment of endometrial cancer; their use in breast cancer and renal cell cancer has declined. Progestogens are now rarely used to treat prostate cancer. **Medroxyprogesterone** or **megestrol** are usually chosen and can be given orally; high-dose or parenteral treatment cannot be recommended. Side-effects are mild but may include nausea, fluid retention, and weight gain.

---

**8.3.3 Androgens**

**Androsta-1,4-diene-3,17-dione** is also available for use in hormone replacement therapy and for the treatment of palliative conditions. Side-effects reported are similar to those of testosterone (see section 6.4.1.4).

**Androgens**

**Androsta-1,4-diene-3,17-dione** is also available for use in hormone replacement therapy and for the treatment of palliative conditions. Side-effects reported are similar to those of testosterone (see section 6.4.1.4).

**Cautions** see section 6.4.1.1; interactions: Appendix 1 (oestrogens)

**Contra-indications** see section 6.4.1.1

**Hepatic impairment** avoid; see also Combined Hormonal Contraceptives (section 7.3.1)

**Side-effects** see section 6.4.1.1

**Dose**
- Prostate cancer (palliative), 0.15–1.5 mg daily

---

**8.3.4 Hormone antagonists**

**Bisphenol A** is a commonly used industrial chemical. It is not metabolised in the body but is excreted in the urine. It has a weak oestrogenic effect and is thought to be carcinogenic.

**Other hormone antagonists** include **Tamoxifen**, **Fulvestrant**, and **Megestrol acetate**. These treatments are not curative, but may provide excellent palliation of symptoms in selected patients, sometimes for a period of years. Tumour response, and treatment toxicity should be carefully monitored and treatment changed if progression occurs or side-effects exceed benefit.
Malignant disease and immunosuppression

Dose
- See preparations below

Provera® (Pharmacia) Tablets
Medroxyprogesterone acetate 100 mg (scored), net price 60-tab pack = £29.98, 100-tab pack = £49.94; 200 mg (scored), 30-tab pack = £58.67
- Dose endometrial and renal cell cancer, 200–400 mg daily
- Breast cancer, 400–800 mg daily

MEGESTROL ACETATE
Indications
- Breast cancer, 160 mg once daily

NORETHISTERONE
Indications
- Breast cancer, 40 mg daily, increased to 60 mg daily if required

Preparations
- Section 6.4.1.2

8.3.3 Androgens

Testosterone esters (section 6.4.2) have largely been superseded by other drugs for breast cancer.

8.3.4 Hormone antagonists

8.3.4.1 Breast cancer

The management of patients with breast cancer involves surgery, radiotherapy, drug therapy, or a combination of these.

For operable breast cancer, treatment before surgery (neoadjuvant therapy) reduces the size of the tumour and facilitates breast-conserving surgery; hormone antagonist therapy (e.g. letrozole) is chosen for steroid hormone-receptor-positive breast cancer and chemotherapy for steroid hormone-receptor-negative tumours or for younger women.

Early breast cancer
- All women should be considered for adjuvant therapy following surgical removal of the tumour. Adjuvant therapy is used to eradicate the micrometastases that cause relapses. Choice of adjuvant treatment is determined by the risk of recurrence, steroid hormone-receptor status of the primary tumour, and menopausal status.

Adjuvant therapy comprises cytotoxic chemotherapy and hormone-antagonist therapy. Women with steroid hormone-receptor-positive breast cancer are considered for hormone-antagonist therapy (preceded by cytotoxic chemotherapy if necessary) whilst women with steroid hormone-receptor-negative breast cancer should be considered for cytotoxic chemotherapy.

Aromatase inhibitors act predominantly by blocking the conversion of androgens to oestrogens in the peripheral tissues. They do not inhibit ovarian oestrogen synthesis and should not be used in premenopausal women.

Anastrozole and letrozole are non-steroidal aromatase inhibitors; exemestane is a steroidal aromatase inhibitor. Aromatase inhibitors are usually prescribed as initial adjuvant therapy in postmenopausal women with oestrogen-receptor-positive tumours; tamoxifen, an oestrogen-receptor antagonist, is used if an aromatase inhibitor is not appropriate. Adjuvant hormone antagonist therapy should generally be continued for 5 years following removal of the tumour. In postmenopausal women considered for extended adjuvant therapy, 5 years of tamoxifen is followed by letrozole for a further 2–3 years.

Trastuzumab (section 8.1.5) is licensed for use in early breast cancer which overexpresses human epidermal growth factor-2 (HER2) in women who have received surgery, chemotherapy and radiotherapy (as appropriate).

Premenopausal women with oestrogen-receptor-positive breast cancer who decline chemotherapy may benefit from treatment with goserelin (section 8.3.4.2) or ovarian ablation.

Advanced breast cancer
- Treatment of advanced breast cancer depends on the patient’s drug history and an assessment of disease severity. Aromatase inhibitors, such as anastrozole or letrozole, are the preferred...
treatment in postmenopausal women with oestrogen-receptor-positive advanced breast cancer, a long disease-free interval following treatment for early breast cancer, and disease limited to bone or soft tissues; tamoxifen can be used if aromatase inhibitors are not suitable. Progestogens, such as medroxyprogesterone acetate (section 8.3.2), may be used after aromatase inhibitors and tamoxifen in postmenopausal women.

Tamoxifen should be considered for pre- and perimenopausal women with oestrogen-receptor-positive breast cancer not previously treated with tamoxifen. Ovarian suppression is used in pre- and perimenopausal women who have had disease progression despite treatment with tamoxifen. The gonadorelin analogue goserelin (section 8.3.4.2) is licensed for advanced breast cancer in pre- and perimenopausal women for hormone manipulation.

Cytotoxic chemotherapy is indicated for advanced steroid hormone-receptor-negative tumours and for aggressive disease, particularly when metastases involve visceral sites (e.g. the liver) or if the disease-free interval following treatment for early breast cancer is short.

**Cytotoxic drugs used in breast cancer** An anthracycline combined with fluorouracil (section 8.1.3) and cyclophosphamide (section 8.1.1), and sometimes also with methotrexate (section 8.1.3) is effective. Cyclophosphamide, methotrexate, and fluorouracil can be useful if an anthracycline is inappropriate (e.g. in cardiac disease).

**Metastatic disease** The choice of chemotherapy regimen will be influenced by whether the patient has previously received adjuvant treatment and the presence of any co-morbidity.

For women who have not previously received chemotherapy, an anthracycline (such as doxorubicin or epirubicin) alone or in combination with another cytotoxic drug is the standard initial therapy for metastatic breast disease.

Patients with anthracycline-refractory or resistant disease should be considered for treatment with a taxane (section 8.1.5) either alone or in combination with trastuzumab if they have tumours that overexpress HER2. Other cytotoxic drugs with activity against breast cancer include capcitabine (section 8.1.3), mitoxantrone, mitomycin (both section 8.1.2), and vinorelbine (section 8.1.4). Trastuzumab alone (section 8.1.5) is an option for chemotherapy-resistant cancers that overexpress HER2.

**Other drugs used in breast cancer** Trilastone (section 8.7.3) is licensed for postmenopausal breast cancer. It is quite well tolerated but abdominal discomfort may be a problem. Trilastone causes adrenal hypofunction and corticosteroid replacement therapy is needed.

The use of bisphosphonates (section 6.6.2) in patients with metastatic breast cancer may reduce pain and prevent skeletal complications of bone metastases.

**ANASTROZOLE**

**Indications** adjuvant treatment of oestrogen-receptor-positive early invasive breast cancer in postmenopausal women; adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmeno-

8.3.4 Hormone antagonists

**ANASTROZOLE**

Indications adjuvant treatment of oestrogen-receptor-positive early invasive breast cancer in postmenopausal women; adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women following 2–3 years of tamoxifen therapy; advanced breast cancer in postmenopausal women which is oestrogen-receptor-positive or responsive to tamoxifen.

Cautions laboratory test for menopause if doubt; susceptibility to osteoporosis (assess bone mineral density before treatment and at regular intervals).

Contra-indications not for premenopausal women.

Hepatic impairment avoid in moderate to severe impairment.

Renal impairment avoid if creatinine clearance less than 20 mL/minute.

Pregnancy avoid.

Breast-feeding avoid.

Side-effects hot flushes, vaginal dryness, vaginal bleeding, hair thinning, anorexia, nausea, vomiting, diarrhea, headache, arthralgia, bone fractures, rash (including Stevens-Johnson syndrome); asthenia and drowsiness—may initially affect ability to drive or operate machinery; slight increases in total cholesterol levels reported; very rarely allergic reactions including angioedema and anaphylaxis.

Dose

- 1 mg daily.

**Arimidex® (AstraZeneca)**

Tablets, f/c, anastrozole 1 mg. Net price 28-tab pack = £88.56.

The Scottish Medicines Consortium (p. 4) has advised (August 2005 and October 2006) that anastrozole (Arimidex®) is accepted for restricted use within NHS Scotland, within the licensed indications, for early breast cancer and early invasive breast cancer.

**EXEMESTANE**

**Indications** adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women following 2–3 years of tamoxifen therapy; advanced breast cancer in postmenopausal women in whom anti-oestrogen therapy has failed.

Cautions interactions: Appendix 1 ( exemestane).

Contra-indications not indicated for premenopausal women.

Hepatic impairment manufacturer advises caution.

Renal impairment manufacturer advises caution.

Pregnancy avoid.

Breast-feeding avoid.

Side-effects nausea, vomiting, abdominal pain, dyspepsia, constipation, anorexia; dizziness, fatigue, headache, depression, insomnia; hot flushes, sweating; alopecia, rash; less commonly drowsiness, asthenia, and peripheral oedema; rarely thrombocytopenia, leucopenia.

Dose

- 25 mg daily.

**Aromasin® (Pharmacia)**

Tablets, s/c, exemestane 25 mg, net price 30-tab pack = £88.80, 90-tab pack = £266.40. Label: 21.

The Scottish Medicines Consortium (p. 4) has advised (October 2005) that exemestane (Aromasin®) is accepted for restricted use within NHS Scotland as an adjuvant treatment in postmenopausal women with oestrogen-receptor-positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.
Fulvestrant

**Indications** treatment of oestrogen-receptor-positive metastatic or locally advanced breast cancer in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy

**Hepatic impairment** manufacturer advises caution in mild to moderate impairment; avoid in severe impairment

**Renal impairment** manufacturer advises caution if creatinine clearance less than 30 mL/minute—no information available

**Breast-feeding** manufacturer advises avoid—increased incidence of fetal abnormalities and death in animal studies

**Pregnancy** manufacturer advises avoid—in present milk in animal studies

**Side-effects** nausea, vomiting, diarrhoea; venous thromboembolism; anorexia, headache, asthenia; urinary-tract infections; hot flushes; back pain; rash, injection-site reactions, hypersensitivity reactions; less commonly vaginal haemorrhage, vaginal candidiasis, and leucorrhoea

**Dose** by deep intramuscular injection into buttock, 500 mg every 2 weeks for the first 3 doses, then 500 mg every month

**Note** 500 mg dose should be administered as one 250-mg injection (slowly over 1–2 minutes) into each buttock

**Faslodex** (AstraZeneca) (BNF 61)

**Injection** (oily), fulvestrant 50 mg/mL, net price 1 × 5-mL (250-mg) prefilled syringe = £348.27, 2 × 5-mL (250-mg) prefilled syringe = £522.41

**Letrozole**

**Indications** adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women; advanced breast cancer in postmenopausal women (including those in whom other anti-oestrogen therapy has failed); early invasive breast cancer in postmenopausal women after standard adjuvant tamoxifen therapy; pre-operative treatment in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy; early invasive breast cancer in women (including those in whom other anti-oestrogens have failed); early invasive breast cancer in women; advanced breast cancer in postmenopausal women (including those in whom other anti-oestrogen therapy has failed); early invasive breast cancer in postmenopausal women who have received tamoxifen. Patients should be informed of the risk of endometrial cancer and told to report relevant symptoms promptly

**Contra-indications** treatment of infertility contra-indicated if personal or family history of idiopathic venous thromboembolism or genetic predisposition to thromboembolism

**Pregnancy** avoid—possible effects on fetal development; effective contraception must be used during treatment and for 2 months after stopping

**Breast-feeding** suppress lactation; avoid unless potential benefit outweighs risk

**Side-effects** hot flushes, vaginal bleeding and vaginal discharge (important: see also Endometrial Changes under Cautions), suppression of menstruation in some premenopausal women, pruritus vulvae, gastrointestinal disturbances, headache, light-headedness, tumour flare, decreased platelet counts; occasionally oedema, rarely hypercalcaemia if bony metastases, alopecia, rashes, uterine fibroids; also visual disturbances (including corneal changes, cataracts, retinopathy); leucopenia (sometimes with anaemia and thrombocytopenia), rarely neutropenia; hypertriglyceridaemia reported rarely (sometimes with pancreatitis); thromboembolic events reported (see below); liver enzyme changes (rarely fatty liver, cholestasis, hepatitis); rarely interstitial pneumonitis, hypersensitivity reactions including angioedema, Stevens-Johnson syndrome, bullous pemphigoid; see also notes above

**Risk of thromboembolism** Tamoxifen can increase the risk of thromboembolism particularly during and immediately after major surgery or periods of immobility (consider interrupting treatment to initiate anticoagulant measures). Patients should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness and any pain in the calf of one leg

**Dose**

- Breast cancer; 20 mg daily
- Anovulatory infertility; 20 mg daily on days 2, 3, 4 and 5 of cycle; if necessary the daily dose may be

---

**TAMOXIFEN**

**Indications** see under Dose and notes above; mastalgia [unlicensed indication] (section 6.7.2)

**Cautions** occasional cystic ovarian swellings in premenopausal women; increased risk of thromboembolic events, especially when used with cytoxotics (see also below); endometrial changes (important: see below); porphyria, interactions: Appendix 1 (tamoxifen)

**Endometrial changes** Increased endometrial changes, including hyperplasia, polyps, cancer, and uterine sarcoma reported, prompt investigation required if abnormal vaginal bleeding including menstrual irregularities, vaginal discharge, and pelvic pain or pressure in those receiving (or who have received) tamoxifen. Patients should be informed of the risk of endometrial cancer and told to report relevant symptoms promptly

**Contra-indications** treatment of infertility contra-indicated if personal or family history of idiopathic venous thromboembolism or genetic predisposition to thromboembolism

**Pregnancy** avoid—possible effects on fetal development; effective contraception must be used during treatment and for 2 months after stopping

**Breast-feeding** suppress lactation; avoid unless potential benefit outweighs risk

**Side-effects** hot flushes, vaginal bleeding and vaginal discharge (important: see also Endometrial Changes under Cautions), suppression of menstruation in some premenopausal women, pruritus vulvae, gastrointestinal disturbances, headache, light-headedness, tumour flare, decreased platelet counts; occasionally oedema, rarely hypercalcaemia if bony metastases, alopecia, rashes, uterine fibroids; also visual disturbances (including corneal changes, cataracts, retinopathy); leucopenia (sometimes with anaemia and thrombocytopenia), rarely neutropenia; hypertriglyceridaemia reported rarely (sometimes with pancreatitis); thromboembolic events reported (see below); liver enzyme changes (rarely fatty liver, cholestasis, hepatitis); rarely interstitial pneumonitis, hypersensitivity reactions including angioedema, Stevens-Johnson syndrome, bullous pemphigoid; see also notes above

**Risk of thromboembolism** Tamoxifen can increase the risk of thromboembolism particularly during and immediately after major surgery or periods of immobility (consider interrupting treatment to initiate anticoagulant measures). Patients should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness and any pain in the calf of one leg

**Dose**

- Breast cancer: 20 mg daily
- Anovulatory infertility: 20 mg daily on days 2, 3, 4 and 5 of cycle; if necessary the daily dose may be
increased to 40 mg then 80 mg for subsequent courses; if cycles irregular, start initial course on any day, with subsequent course starting 45 days later or on day 2 of cycle if menstruation occurs.

Tamoxifen (Non-proprietary) 

Tablets, tamoxifen (as citrate) 10 mg, net price 30-tab pack = £3.08; 20 mg, 30-tab pack = £2.09; 40 mg, 30-tab pack = £1.12.

Oral solution, tamoxifen (as citrate) 10 mg/5 mL, net price 150 mL = £29.61.

Brands include: Sofihorm®

Toremifene

Indications hormone-dependent metastatic breast cancer in postmenopausal women.

Cautions hypercalcaemia may occur (especially if bone metastases and usually at beginning of treatment); avoid in acute porphyria (but see section 9.8.2); history of severe thromboembolic disease; interac-
tions: Appendix 1 (toremifene).

Endometrial changes Increased endometrial changes, including hyperplasia, polyps and cancer reported. Abnormal vaginal bleeding including menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.

Contra-indications endometrial hyperplasia, QT prolongation (avoid concomitant administration of drugs that prolong QT interval), electrolyte disturbances (particularly uncorrected hypokalaemia), bradycardia, heart failure with reduced left-ventricular ejection fraction, history of arrhythmias.

Hepatic impairment elimination decreased in hepatic impairment—avoid if severe.

Pregnancy avoid.

Breast-feeding avoid.

Side-effects nausea, vomiting; oedema; depression, dizziness, fatigue; sweating, hot flushes, vaginal bleeding or discharge (important: see Cautions); rash; less common anorexia, constipation, increased weight, thromboembolic events, dyspnoea, insomnia, headache, endometrial hypertrophy; very rarely jaundice, transient corneal opacity, and alopecia.

Dose

• 60 mg daily.

Fareston® (Orion) 

Tablets, toremifene (as citrate) 60 mg. Net price 30-tab pack = £29.08.

8.3.4 Hormone antagonists 571

Gonadorelin analogues

Gonadorelin analogues are as effective as orchidectomy or diethylstibestrol (section 8.3.1) but are expensive and require parenteral administration, at least initially. They cause initial stimulation then depression of luteinising hormone release by the pituitary. During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain. When such problems are anticipated, alternative treatments (e.g. orchidectomy) or concomitant use of an anti-androgen such as cyproterone acetate or flutamide (see below) are recommended; anti-androgen treatment should be started before the gonadorelin analogue. Gonadorelin analogues are also used in women for breast cancer (section 8.3.4.1) and other indications (section 6.7.2).

The Scottish Medicines Consortium (p. 4) has advised (June 2009) that histrelin (Vantas®) is accepted for restricted use within NHS Scotland for the palliative treatment of advanced prostate cancer in patients with an anticipated life expectancy of at least one year in whom annual administration will offer advantages.

Cautions Men at risk of tumour ‘flare’ (see above) should be monitored closely during the first month of therapy. Caution is required in patients with metabolic bone disease because reduced bone mineral density can occur. The injection site should be rotated.

Side-effects The gonadorelin analogues cause side-effects similar to the menopause in women and orchidectomy in men and include hot flushes and sweating, sexual dysfunction, vaginal dryness or bleeding, and gynaecomastia or changes in breast size. Signs and symptoms of prostate or breast cancer may worsen initially (managed in prostate cancer with anti-androgen(s), see above). Other side-effects include hypersensitivity reactions (rashes, pruritus, asthma, and rarely anaphylaxis), injection site reactions (see Cautions), headache (rarely migraine), visual disturbances, dizzi-
ness, arthralgia and possibly myalgia, hair loss, periph-
eral oedema, gastro-intestinal disturbances, weight changes, sleep disorders, and mood changes.

Buserelin

Indications advanced prostate cancer; other indica-
tions (section 6.7.2).

Cautions diabetes, hypertension, depression; see also notes above.

Side-effects see notes above; worsening hyper-
tension, palpitation, glucose intolerance, altered blood lipids, thrombocytopenia, leucopenia, nervousness, fatigue, memory and concentration disturbances, anxiety, increased thirst, hearing disorders, quinacrine-
skull pain; nasal irritation, nose bleeds and altered sense of taste and smell (spray formulation only).

Dose

• By subcutaneous injection. 500 micrograms every 8 hours for 7 days, then intranasally, 1 spray into each nostril 6 times daily (see also notes above).

Counselling Avoid use of nasal decongestants before and for at least 30 minutes after treatment.

Suprefact® (Sanofi-Aventis) 

Injection buserelin (as acetate) 1 mg/mL. Net price 2 × 5.5-mL vial = £23.69.
Hormone antagonists

**GOSERELIN**

**Indications** locally advanced prostate cancer as an alternative to surgical castration; adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer; neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer; metastatic prostate cancer; advanced breast cancer; oestrogen-receptor-positive early breast cancer (section 8.3.4.1); endometriosis, endometrial thinning, uterine fibroids, assisted reproduction (section 6.7.2)

**Cautions** see notes above; diabetes; risk of ureteric obstruction and spinal cord compression in men

**Contra-indications** undiagnosed vaginal bleeding

**Pregnancy** see Goserelin, section 6.7.2

**Breast-feeding** see Goserelin, section 6.7.2

**Side-effects** see notes above; also transient changes in blood pressure; paraesthesia; rarely hypercalcaemia (in patients with metastatic breast cancer)

**Dose**
- See under preparations below

**Novogs® (Genus)**

**Implant** goserelin (as acetate) 3.6 mg in prefilled syringe, net price = £58.50

**Dose** advanced prostate cancer by subcutaneous injection into anterior abdominal wall, 3.6 mg every 28 days

**Zoladex® (AstraZeneca)**

**Implant** goserelin (as acetate) 3.6 mg in SafeSystem® syringe applicator, net price each = £65.00

**Dose** breast cancer and prostate cancer (see indications above) by subcutaneous injection into anterior abdominal wall, 3.6 mg every 28 days

**Zoladex® LA (AstraZeneca)**

**Implant** goserelin (as acetate) 10.8 mg in SafeSystem® syringe applicator, net price each = £235.00

**Dose** prostate cancer (see indications above), by subcutaneous injection into anterior abdominal wall, 10.8 mg every 12 weeks

**HISTRELIN**

**Indications** advanced prostate cancer

**Cautions** see notes above; risk of ureteric obstruction and spinal cord compression

**Side-effects** see notes above; also hepatic disorder, dyspnoea, depression, asthma, elevated blood glucose-concentration, increased urinary frequency, hypertrichosis; less commonly hypercholesterolaemia, palpitation, ventricular extrasystole, haemato ma, tremor, anaemia, renal failure, nephrolithiasis, hypercalcaemia

**Dose**
- By subcutaneous implantation into upper arm, 1 implant (50 mg) every 12 months; remove after 12 months of treatment

**Counselling** Avoid wetting arm containing implant for 24 hours and avoid lifting heavy objects or strenuous physical activity for 7 days after implantation

**LEUPRORELIN ACETATE**

**Indications** locally advanced prostate cancer as an alternative to surgical castration; adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer; metastatic prostate cancer; endometriosis, endometrial thinning, uterine fibroids (section 6.7.2)

**Cautions** see notes above and section 6.7.2; risk of ureteric obstruction and spinal cord compression in men

**Side-effects** see notes above and section 6.7.2; also fatigue, muscle weakness, paraesthesia, hypertension, palpitation, alteration of glucose tolerance and of blood lipids; hypotension, jaundice, thrombocytopenia and leucopenia reported

**Dose**
- See under preparations below

**Prostap® SR (Takeda)**

**Injection** (microsphere powder for reconstitution), leuprorelin acetate, net price 3.75-mg vial with 1-mL vehicle-filled syringe = £75.24

**Dose** prostate cancer (see indications), by subcutaneous or by intramuscular injection, 3.75 mg every 4 weeks

**Prostap® 3 (Takeda)**

**Injection** (microsphere powder for reconstitution), leuprorelin acetate, net price 11.25-mg vial with 2-mL vehicle-filled syringe = £225.72

**Dose** prostate cancer (see indications), by subcutaneous injection, 11.25 mg every 3 months

**TRIPTORELIN**

**Indications** prostate cancer; endometriosis, precocious puberty, reduction in size of uterine fibroids (section 6.7.2)

**Cautions** see notes above; risk of ureteric obstruction and spinal cord compression in men

**Side-effects** see notes above; also dry mouth, transient hypertension, paraesthesia, and increased dysuria

**Dose**
- See under preparations below

**Decapeptyl® SR (Ipsen)**

**Injection** (powder for suspension), m/r, triptorelin (as acetate), net price 3-mg vial (with diluent) = £69.00

**Dose** locally advanced non-metastatic prostate cancer as an alternative to surgical castration, metastatic prostate cancer, by intramuscular injection, 3 mg every 4 weeks

**Note** Each vial includes an overage to allow accurate administration of a 3-mg dose

**Injection** (powder for suspension), m/r, triptorelin (as acetate), net price 11.25-mg vial (with diluent) = £207.00

**Dose** locally advanced non-metastatic prostate cancer as an alternative to surgical castration, metastatic prostate cancer, by intramuscular injection, 11.25 mg every 3 months (see also notes above)

**Note** Each vial includes an overage to allow accurate administration of an 11.25-mg dose
to the clinical circumstances. either alone or as an adjunct to other therapy. Bicalutamide is used for prostate cancer which may occur after commencing gonadorelin analogue administration. Cyproterone acetate and flutamide are also licensed for use alone in patients with metastatic prostate cancer refractory to gonadorelin analogue therapy. Bicalutamide is used for prostate cancer either alone or as an adjunct to other therapy, according to the clinical circumstances.

### BICALUTAMIDE

**Indications** locally advanced prostate cancer at high risk of disease progression, either alone or as adjuvant treatment to prostatectomy or radiotherapy; locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate; advanced prostate cancer in combination with gonadorelin analogue or surgical castration.

**Cautions** consider periodic liver function tests; interactions: Appendix 1 (bicalutamide)

**Hepatic impairment** increased accumulation possible in moderate to severe impairment.

**Side-effects** nausea, diarrhoea, cholestasis, jaundice; asthenia, weight gain; gynaecomastia, breast tenderness; hot flushes, impotence, decreased libido; anaemia; alopecia, dry skin, hirsutism, pruritus; less commonly vomiting, abdominal pain, dyspepsia, interstitial lung disease, pulmonary fibrosis, depression, haematuria, thrombocytopenia, hypersensitivity reactions including angioneurotic oedema and urticaria; rarely cardiovascular disorders (including angina, heart failure, and arrhythmias), and hepatic failure.

**Dose**
- Locally advanced prostate cancer at high risk of disease progression, 150 mg once daily
- Locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate, 150 mg once daily
- Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration, 50 mg once daily (started at the same time as surgical castration or at least 3 days before gonadorelin therapy, see also notes above)

**Bicalutamide** (Non-proprietary)

- Tablets, bicalutamide 50 mg, net price 28-tab pack = £8.62; 150 mg, 28-tab pack = £12.21
- Casodex® (AstraZeneca)

- Tablets, 1/2, bicalutamide 50 mg, net price 28-tab pack = £128.00; 150 mg, 28-tab pack = £240.00

### CYPROTERONE ACETATE

**Indications** prostate cancer, see under Dose and also notes above; other indications, see section 6.4.2

**Cautions** in prostate cancer, blood counts initially and throughout treatment; monitor hepatic function (liver function tests should be performed before treatment, see also under Side-effects below); monitor adrenocortical function regularly; risk of recurrence of thromboembolic disease; diabetes mellitus, sickle-cell anaemia, severe depression (in other indications some of these are contra-indicated, see section 6.4.2)

**Driving** Fatigue and lassitude may impair performance of skilled tasks (e.g. driving)

**Contra-indications** patients with meningioma or history of meningioma; for contra-indications relating to other indications see section 6.4.2

**Hepatic impairment** dose-related toxicity; see also under cautions (above) and side-effects (below)

**Side-effects** see section 6.4.2

**Hepatotoxicity** Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (usually after several months) in patients treated with cyproterone acetate 200–300 mg daily. Liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur—if confirmed cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk)

**Dose**
- Prevention of flare with initial gonadorelin analogue therapy. 200 mg daily in 2–3 divided doses for 5–7 days before initiation of gonadorelin analogue, followed by 200 mg daily in 2–3 divided doses for 3–4 weeks after initiation of gonadorelin analogue; max. 300 mg daily
- Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where oral therapy preferred, 200–300 mg daily in 2–3 divided doses
- Hot flushes with gonadorelin analogue therapy or after orchidectomy, initially 50 mg daily, adjusted according to response to 50–150 mg daily in 1–3 divided doses

**Cyproterone Acetate** (Non-proprietary)

- Tablets, cyproterone acetate 50 mg, net price 56-tab pack = £31.54; 100 mg, 84-tab pack = £85.72.
- Label: 21, counselling, driving

**Cyprostat®** (Bayer Schering)

- Tablets, scored, cyproterone acetate 50 mg, net price 168-tab pack = £73.23; 100 mg, 84-tab pack = £73.23.
- Label: 21, counselling, driving

### FLUTAMIDE

**Indications** advanced prostate cancer, see also notes above

**Cautions** cardiac disease (oedema reported); also liver function tests, monthly for first 4 months, periodically thereafter and at the first sign or symptom of liver disorder (e.g. pruritus, dark urine, persistent anorexia, jaundice, abdominal pain, unexplained influenza-like symptoms); avoid excessive alcohol consumption; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (flutamide)

**Hepatic impairment** use with caution (hepatotoxic)

**Side-effects** gynaecomastia (sometimes with galactorrhoea); nausea, vomiting, diarrhoea, increased appetite, insomnia, tiredness; other side-effects reported include decreased libido, reduced sperm count, gastric and chest pain, hypertension, headache, dizziness, oedema, blurred vision, thirst,
rash, pruritus, haemolytic anaemia, systemic lupus erythematosus-like syndrome, and lymphohaedema; hepatic injury (with transaminase abnormalities, cholestatic jaundice, hepatic necrosis, hepatic encephalopathy and occasional fatalality) reported

**Dose**
- 250 mg 3 times daily (see also notes above)

**Flutamide** (Non-proprietary) [\textregistered]

**Tablets**, flutamide 250 mg. Net price 84-tab pack = £22.24

---

**8.3.4 Hormone antagonists**

**Gonadotrophin-releasing hormone antagonists**

**Degarelix** is a gonadotrophin-releasing hormone antagonist used to treat advanced hormone-dependent prostate cancer. It does not induce a testosterone surge or tumour ‘flare’, therefore anti-androgen therapy is not required.

**DEGARELIX**

**Indications** see notes above

**Cautions** susceptibility to QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval); monitor bone density; diabetes

**Hepatic impairment** manufacturer advises caution in severe impairment—no information available

**Renal impairment** manufacturer advises caution in severe impairment—no information available

**Side-effects** nausea; dizziness, headache, drowsiness, insomnia, ashenia; influenza-like symptoms; hot flushes, sweating (including night sweats), weight gain; injection-site reactions; less commonly diarrhoea, vomiting, abdominal discomfort, dry mouth, constipation, anorexia; atrio-ventricular block, QT-interval prolongation, fainting, hypertension, hypersensitivity reactions, depression, anxiety, oedema, gynaecomastia, micturition urgency, renal impairment, sexual dysfunction, pelvic pain, prostatitis, testicular pain, anaemia, musculoskeletal pain, tinnitus, urticaria, alopecia, and rash

**Dose**
- By subcutaneous injection into the abdominal region, **ADULT** over 18 years, initially 240 mg (administered as 2 injections of 120 mg), then 80 mg every 28 days

**Firmagon** [\textregistered] (Ferring) [\textregistered]

**Injection**, powder for reconstitution, degarelix (as acetate), net price 80-mg vial (with diluent) = £129.37; 2 × 120-mg vials (with diluent) = £260.00

---

**8.3.4.3 Somatostatin analogues**

**Lanreotide** and **octreotide** are analogues of the hypothalamic release-inhibiting hormone somatostatin. They are indicated for the relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours and acromegaly. Additionally, lanreotide is licensed for the treatment of thyroid tumours and octreotide is also licensed for the prevention of complications following pancreatic surgery; octreotide may also be valuable in reducing vomiting in palliative care (see p. 23) and in stopping variceal bleeding [unlicensed indication]—see also vasopressin and terlipressin (section 6.5.2).

**Cautions** Growth hormone-secreting pituitary tumours can expand causing serious complications; during treatment with somatostatin analogues patients should be monitored for signs of tumour expansion (e.g. visual field defects). Ultrasound examination of the gallbladder is recommended before treatment and at intervals of 6–12 months during treatment (avoid abrupt withdrawal of short-acting octreotide—see Side-effects below). In insulinoma an increase in the depth and duration of hypoglycaemia may occur (observe patients when initiating treatment and changing doses); in diabetes mellitus, insulin or oral antidiabetic requirements may be reduced.

**Side-effects** Gastro-intestinal disturbances including anorexia, nausea, vomiting, abdominal pain and bloating, flatulence, diarrhoea, and steatorrhoea may occur (administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects). Postprandial glucose tolerance may be impaired and rarely persistent hyperglycaemia occurs with chronic administration; hypoglycaemia has also been reported. Gallstones have been reported after long-term treatment (abrupt withdrawal of subcutaneous octreotide is associated with biliary colic and pancreatitis). Pain and irritation may occur at the injection site and sites should be rotated. Rarely, pancreatitis has been reported shortly after administration.

**Lanreotide**

**Indications** see notes above

**Cautions** see notes above; **interactions**: Appendix 1 (lanreotide)

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid unless potential benefit outweighs risk—no information available

**Side-effects** see notes above; also reported asthenia, fatigue, raised bilirubin; less commonly skin nodule, hot flushes, leg pain, malaise, headache, tenesmus, decreased libido, drowsiness, pruritus, increased sweating; rarely hypothyroidism (monitor as necessary)

**Dose**
- See under preparations

**Somatuline** [\textregistered] **LA** (**Ipsen**) [\textregistered]

**Injection** (copolymer microparticles for aqueous suspension), lanreotide (as acetate) 30-mg vial (with vehicle) = £323.00

**Dose** by intramuscular injection, acromegaly and neuroendocrine (particularly carcinoid) tumours, initially 30 mg every 14 days, frequency increased to every 7–10 days according to response

Thyroid tumours, 30 mg every 14 days, frequency increased to every 10 days according to response

**Somatuline Autogel** (**Ipsen**) [\textregistered]

**Injection**, prefilled syringe, lanreotide (as acetate) 60 mg = £551.00; 90 mg = £736.00; 120 mg = £937.00

**Dose** by deep subcutaneous injection into the gluteal region, acromegaly (if somatostatin analogue not given previously), initially 60 mg every 28 days, adjusted according to response, for patients treated previously with somatostatin analogue, consult product literature for initial dose

Neuroendocrine (particularly carcinoid) tumours, initially 60–120 mg every 28 days, adjusted according to response
OCTREOTIDE

Indications  
see under Dose

Cautions  
see notes above; monitor thyroid function on long-term therapy; interactions: Appendix 1 (octreotide)

Hepatic impairment  
adjustment of maintenance dose of non-depot preparations may be necessary in patients with liver cirrhosis

Pregnancy  
possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk and effective contraception required during treatment

Breast-feeding  
manufacturer advises avoid unless essential—present in milk in animal studies

Side-effects  
see notes above; also bradycardia, dyspnoea, headache, dizziness, alopecia, rash; hepatitis also reported

Dose  
- Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas, by subcutaneous injection, initially 50 micrograms once or twice daily, gradually increased according to response to 200 micrograms 3 times daily (higher doses required exceptionally); maintenance doses variable; in carcinoid tumours discontinue after 1 week if no effect; if rapid response required, initial dose by intravenous injection (with ECG monitoring and after dilution to a concentration of 10–50% with sodium chloride 0.9% injection)
- Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective by subcutaneous injection, 100–200 micrograms 3 times daily; discontinue if no improvement within 3 months
- Prevention of complications following pancreatic surgery, consult product literature

Octreotide (Non-proprietary)  
Injection, octreotide (as acetate) 50 micrograms/mL, net price 1-mL amp = £3.72; 100 micrograms/mL, 1-mL amp = £6.53; 200 micrograms/mL, 5-mL vial = £69.66; 500 micrograms/mL, 1-mL amp = £33.87

Sandostatin  
Injection, octreotide (as acetate) 50 micrograms/mL, net price 1-mL amp = £2.98; 100 micrograms/mL, 1-mL amp = £5.60; 200 micrograms/mL, 5-mL vial = £69.66; 500 micrograms/mL, 1-mL amp = £27.10

Depot preparation  
Sandostatin Lar  
Injection (microsphere powder for aqueous suspension), octreotide (as acetate) 10-mg vial = £637.50; 20-mg vial = £850.00; 30-mg vial = £1062.50 (all supplied with 2.5-mL diluent-filled syringe)

Dose  
acromegaly (test dose by subcutaneous injection 50–100 micrograms if subcutaneous octreotide not previously given), neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide, by deep intramuscular injection into gluteal muscle, initially 20 mg every 4 weeks for 3 months then adjusted according to response; max. 30 mg every 4 weeks

For acromegaly, start depot octreotide 1 day after the last dose of subcutaneous octreotide (for pituitary surgery give last dose of depot octreotide at least 3 weeks before surgery), for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide
9 Nutrition and blood

9.1 Anaemias and some other blood disorders

9.1.1 Iron-deficiency anaemias

9.1.1.1 Oral iron

9.1.1.2 Parenteral iron

9.1.2 Drugs used in megaloblastic anaemias

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

9.1.4 Drugs used in platelet disorders

9.1.5 G6PD deficiency

9.1.6 Drugs used in neutropenia

9.1.7 Drugs used to mobilise stem cells

9.2 Fluids and electrolytes

9.2.1 Oral preparations for fluid and electrolyte imbalance

9.2.1.1 Oral potassium

9.2.1.2 Oral sodium and water

9.2.1.3 Oral bicarbonate

9.2.2 Parenteral preparations for fluid and electrolyte imbalance

9.2.2.1 Electrolytes and water

9.2.2.2 Plasma and plasma substitutes

9.3 Intravenous nutrition

9.4 Oral nutrition

9.4.1 Foods for special diets

9.4.2 Enteral nutrition

9.5 Minerals

9.5.1 Calcium and magnesium

9.5.1.1 Calcium supplements

9.5.1.2 Hypercalcaemia and hypercalciuria

9.5.1.3 Magnesium

9.5.2 Phosphorus

9.5.2.1 Phosphate supplements

9.5.2.2 Phosphate-binding agents

9.5.3 Fluoride

9.5.4 Zinc

9.5.5 Selenium

9.6 Vitamins

9.6.1 Vitamin A

9.6.2 Vitamin B group

9.6.3 Vitamin C

9.6.4 Vitamin D

9.6.5 Vitamin E

9.6.6 Vitamin K

9.6.7 Multivitamin preparations

9.7 Bitters and tonics

9.8 Metabolic disorders

9.8.1 Drugs used in metabolic disorders

9.8.2 Acute porphyrias

Before initiating treatment for anaemia it is essential to determine which type is present. Iron salts may be harmful and result in iron overload if given alone to patients with anaemias other than those due to iron deficiency.

9.1.1.1 Oral iron

Iron salts should be given by mouth unless there are good reasons for using another route. Ferrous salts show only marginal differences between one another in efficiency of absorption of iron. Haemoglobin regeneration rate is little affected by the type of salt used provided sufficient iron is given, and in most patients the speed of response is not critical. Choice of
preparation is thus usually decided by the incidence of side-effects and cost.

The oral dose of elemental iron for iron-deficiency anaemia should be 100 to 200 mg daily. It is customary to give this as dried ferrous sulphate, 200 mg (≈ 65 mg elemental iron) three times daily; for prophylaxis of iron-deficiency anaemia, a dose of ferrous sulphate 200 mg once or twice daily may be effective. For treatment of iron-deficiency anaemia in children and for prophylaxis of iron-deficiency anaemia in babies of low birth weight, see BNF for Children.

Therapeutic response The haemoglobin concentration should rise by about 100–200 mg/100 mL (1–2 g/litre) per day or 2 g/100 mL (20 g/litre) over 3–4 weeks. When the haemoglobin is in the reference range, treatment should be continued for a further 3 months to replenish the iron stores. Epithelial tissue changes such as atrophic glossitis and koilonychia are usually improved, but the response is often slow.

Side-effects Gastro-intestinal irritation can occur with iron salts. Nausea and epigastric pain are dose-related, but the relationship between dose and altered bowel habit (constipation or diarrhoea) is less clear. Oral iron, particularly modified-release preparations, can exacerbate diarrhoea in patients with inflammatory bowel disease; care is also needed in patients with intestinal strictures and diverticular disease. Iron preparations taken orally can be constipating, particularly in older patients and occasionally lead to faecal impaction.

If side-effects occur, the dose may be reduced; alternatively, another iron salt may be used, but an improvement in tolerance may simply be a result of a lower content of elemental iron. The incidence of side-effects due to ferrous sulphate is no greater than with other iron salts when compared on the basis of equivalent amounts of elemental iron. Iron preparations taken orally can be constipating, particularly in older patients and occasionally lead to faecal impaction.

Iron preparations are a common cause of accidental overdose in children. For the treatment of iron overdose, see Emergency Treatment of Poisoning, p. 38.

Counselling Although iron preparations are best absorbed on an empty stomach they can be taken after food to reduce gastro-intestinal side-effects; they may discolour stools.

Compound preparations Preparations containing iron and folic acid are used during pregnancy in women who are at high risk of developing iron and folic acid deficiency; they should be distinguished from those used for the prevention of neural tube defects in women planning a pregnancy (see p. 580).

It is important to note that the small doses of folic acid contained in these preparations are inadequate for the treatment of megaloblastic anaemias.

Some oral preparations contain ascorbic acid to aid absorption of the iron but the therapeutic advantage of such preparations is minimal and cost may be increased.

There is no justification for the inclusion of other ingredients, such as the B group of vitamins (except folic acid for pregnant women, see notes above and on p. 580).

Modified-release preparations Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. These preparations are formulated to release iron gradually; the low incidence of side-effects may reflect the small amounts of iron available for absorption as the iron is carried past the first part of the duodenum into an area of the gut where absorption may be poor.

**Iron content of different iron salts**

<table>
<thead>
<tr>
<th>Iron salt</th>
<th>Amount</th>
<th>Content of ferrous iron</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous fumarate</td>
<td>200 mg</td>
<td>65 mg</td>
</tr>
<tr>
<td>Ferrous gluconate</td>
<td>300 mg</td>
<td>35 mg</td>
</tr>
<tr>
<td>Ferrous sulphate</td>
<td>300 mg</td>
<td>60 mg</td>
</tr>
<tr>
<td>Ferrous sulphate, dried</td>
<td>200 mg</td>
<td>65 mg</td>
</tr>
</tbody>
</table>

**FERROUS SULPHATE**

**Indications** iron-deficiency anaemia

**Cautions interactions:** Appendix 1 (iron)

**Side-effects** see notes above

**Dose**

- See under preparations below and notes above

**Ferrous Sulphate (Non-proprietary)**

- **Tablets**, coated, dried ferrous sulphate 200 mg (65 mg iron), net price 28-tab pack = £1.15
- **Dose** prophylactic, 1 tablet daily; therapeutic, 1 tablet 2–3 times daily; **CHILD**, see BNF for Children

**Ironorm** Drops (Wallace Mfg)

- **Oral drops**, ferrous sulphate 125 mg (25 mg iron)/mL, net price 15-mL = £4.95
- **Dose** ADULT and **CHILD** over 6 years, prophylactic, 0.6 mL daily; **CHILD** under 6 years, see BNF for Children

**Modified-release preparations**

- **Feospan** (Intrapharm)
- **Spansule** (= capsules m/r), clear/red, enclosing green and brown pellets, dried ferrous sulphate 150 mg (47 mg iron), net price 30-cap pack = £2.11. Label: 25
- **Dose** 1–2 capsules daily; **CHILD** over 1 year, 1 capsule daily; can be opened and sprinkled on food

- **Ferrograd** (Teofarma)
- **Tablets**, f/c, m/r, red, dried ferrous sulphate 325 mg (105 mg iron), net price 30-tab pack = £1.84. Label: 25
- **Dose** ADULT and **CHILD** over 12 years, prophylactic and therapeutic, 1 tablet daily before food

**With folic acid**

For prescribing information on folic acid, see section 9.1.2

**Fefol** (Intrapharm)

- **Spansule** (= capsules m/r), clear/green, enclosing brown, yellow, and white pellets, dried ferrous sulphate 150 mg (47 mg iron), folic acid 500 micrograms, net price 30-cap pack = £1.69. Label: 25
- **Dose** 1 capsule daily
9.1.1 Iron-deficiency anaemias

Ferrograd Folic® (Teofarma)
Tablets, f/c, red/yellow, dried ferrous sulphate 325 mg (105 mg iron) for sustained release, folic acid 350 micrograms, net price 30-tab pack = £1.89.
Label: 25
Dose ADULT and CHILD over 12 years, 1 tablet daily before food.

With ascorbic acid
For prescribing information on ascorbic acid, see section 9.6.3

Ferrograd C® (Teofarma)
Tablets, f/c, red, dried ferrous sulphate 325 mg (105 mg iron) for sustained release, ascorbic acid 500 mg (as sodium salt), net price 30-tab pack = £1.85.
Label: 25
Dose ADULT and CHILD over 12 years, 1 tablet daily before food.

FERROUS FUMARATE
Indications iron-deficiency anaemia
Cautions interactions: Appendix 1 (iron)
Side-effects see notes above
Dose
See under preparations below and notes above

Fersaday® (Goldshield)
Tablets, brown, f/c, ferrous fumarate 322 mg (100 mg iron), net price 28-tab pack = 79p
Dose prophylactic, 1 tablet daily; therapeutic, 1 tablet twice daily

Fersanal® (Goldshield)
Tablets, brown, ferrous fumarate 210 mg (68 mg iron), net price 100 = £1.44
Dose prophylactic, 1 tablet 1–2 times daily; therapeutic, 1 tablet 2–3 times daily

Syrup, brown, ferrous fumarate approx. 140 mg (45 mg iron)/5 mL, net price 200 = £3.11
Dose prophylactic, 5 mL twice daily; therapeutic, 10 mL twice daily; CHILD see BNF for Children

Galfer® (Thorton & Ross)
Capsules, red/green, ferrous fumarate 305 mg (100 mg iron), net price 100 = £2.00
Dose ADULT and CHILD over 12 years, prophylactic, 1 capsule daily; therapeutic, 1 capsule twice daily

Syrop, brown, sugar-free ferrous fumarate 140 mg (45 mg iron)/5 mL, net price 200 = £3.11
Dose prophylactic, 5 mL twice daily; therapeutic, 10 mL twice daily; CHILD see BNF for Children

Galfer FA® (Thorton & Ross)
Capsules, red/yellow, ferrous fumarate 305 mg (100 mg iron), folic acid 350 micrograms, net price 100 = £2.17
Dose 1 capsule daily before food

Pregaday® (UCB Pharma)
Tablets, brown, f/c, ferrous fumarate equivalent to 100 mg iron, folic acid 350 micrograms, net price 28-tab pack = £1.20
Dose 1 tablet daily

FERROUS GLUCONATE
Indications iron-deficiency anaemia
Cautions interactions: Appendix 1 (iron)
Side-effects see notes above
Dose
See under preparation below and notes above

Ferrous Glucenate (Non-proprietary)
Tablets, red, coated, ferrous glucenate 300 mg (35 mg iron), net price 28 = £2.95
Dose prophylactic, 2 tablets daily before food; therapeutic, 4–6 tablets daily in divided doses before food; CHILD 6–12 years, prophylactic and therapeutic, 1–3 tablets daily

POLYSACCHARIDE–IRON COMPLEX
Indications iron-deficiency anaemia
Cautions interactions: Appendix 1 (iron)
Side-effects see notes above
Dose
See under preparation below and notes above

Niferex® (Tillomed)
Elixir, brown, sugar-free, polysaccharide–iron complex equivalent to 100 mg of iron/5 mL, net price 240-mL pack = £6.06; 30-mL dropper bottle for paediatric use = £2.16. Counselling, use of dropper
Dose prophylactic, 2.5 mL daily; therapeutic, 5 mL 1–2 times daily (once daily if required during second and third trimester of pregnancy); PRETERM NEONATE, NEONATE, and INFANT (from dropper bottle) 1 drop (approx. 500 micrograms iron) per 450 g body-weight 3 times daily; CHILD 2–6 years 2.5 mL daily, 6–12 years 5 mL daily

SODIUM FEREDATE
(Sodium ironedetate)
Indications iron-deficiency anaemia
Cautions interactions: Appendix 1 (iron)
Side-effects see notes above
Dose
See under preparation below and notes above

Sytron® (Archimedes)
Elixir, sugar-free, sodium feredetate 190 mg equivalent to 27.5 mg of iron/5 mL, net price 100 mL = £1.07
Dose therapeutic, 5 mL increasing gradually to 10 mL 3 times daily; CHILD under 1 year, see BNF for Children; CHILD 1–5 years, therapeutic, 2.5 mL 3 times daily, 6–12 years, therapeutic, 5 mL 3 times daily

9.1.1.2 Parenteral iron
Iron can be administered parenterally as iron dextran, iron sucrose, ferric carboxymaltose or iron isomaltoside 1000. Parenteral iron is generally reserved for use when oral therapy is unsuccessful because the patient cannot tolerate oral iron, or does not take it reliably, or if there is continuing blood loss, or in malabsorption. Parenteral iron may also have a role in the management of chemotherapy-induced anaemia, when given with erythropoietins, in specific patient groups (see NICE guidance, p. 583).
Many patients with chronic renal failure who are receiving haemodialysis (and some who are receiving peritoneal dialysis) also require iron by the intravenous route on a regular basis (see also Erythropoietins, section 9.1.3).

With the exception of patients with severe renal failure receiving haemodialysis, parenteral iron does not produce a faster haemoglobin response than oral iron provided that the oral iron preparation is taken reliably and is absorbed adequately.

Anaphylactic reactions can occur with parenteral administration of iron complexes. Depending on the preparation, patients may be required to have a small test dose initially, see preparations for details; facilities for cardiopulmonary resuscitation must be available.

**FERRIC CARBOXYMALTOSE**
A ferric carboxymaltose complex containing 5% (50 mg/mL) of iron

**Indications** iron-deficiency anaemia, see notes above

**Cautions** hypersensitivity can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available; oral iron should not be given concomitantly; allergic disorders including asthma and eczema; infection (discontinue if ongoing bacteremia); interactions: Appendix 1 (iron)

**Hepatic impairment** use with caution; avoid in conditions where iron overload increases risk of impairment

**Pregnancy** avoid in first trimester; crosses the placenta in animal studies; may influence skeletal development

**Side-effects** gastro-intestinal disturbances; headache, dizziness; rash; injection-site reactions; hepatitis can occur with parenteral iron infusion (see Anaphylaxis above), numbness, cramps, blurred vision, pruritus, and rash; rarely diarrhoea, chest pain, hypotension, angioedema, arthralgias, tachycardia, dizziness, restlessness, fatigue, seizures, tremor, impaired consciousness, myalgia, arthralgia, sweating, and injection-site reactions; very rarely hypertension, palpitation, headache, paraesthesia, haemolysis, and transient deafness

**Dose**
- By slow intravenous injection into the gluteal muscle or by slow intravenous injection or by intravenous infusion, calculated according to body-weight and iron deficit, consult product literature

**Cosmofer® (Vitaline)**

**Injection**, iron (as iron dextran) 50 mg/mL, net price 2-mL amp = £7.97, 10-mL amp = £39.85

**IRON ISOMALTOSIDE 1000**
A complex of ferric iron and isomaltosides containing 10% (100 mg/mL) of iron

**Indications** iron deficiency anaemia, see notes above

**Cautions** hypersensitivity can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available—risk of allergic reactions increased in immune or inflammatory conditions; oral iron therapy should not be given until 5 days after last injection; infection (discontinue if ongoing bacteremia)

**Contra-indications** history of allergic disorders including asthma, and eczema; active rheumatoid arthritis

**Hepatic impairment** avoid in severe impairment

**Renal impairment** avoid in acute renal failure

**Pregnancy** avoid in first trimester

**Side-effects** less commonly nausea, vomiting, abdominal pain, flushing, dyspnoea, anaphylactic reactions (see Anaphylaxis above), numbness, cramps, blurred vision, pruritus, and rash; rarely diarrhoea, chest pain, hypotension, angioedema, arthralgias, tachycardia, dizziness, restlessness, fatigue, seizures, tremor, impaired consciousness, myalgia, arthralgia, sweating, and injection-site reactions; very rarely hypertension, palpitation, headache, paraesthesia, haemolysis, and transient deafness

**Dose**
- By deep intramuscular injection into the gluteal muscle or by slow intravenous injection or by intravenous infusion, calculated according to body-weight and iron deficit, consult product literature

**Monofer® (Vitaline)**

**Injection**, iron (as iron isomaltoside 1000) 100 mg/mL, net price 1-mL vial = £16.95, 5-mL vial = £84.75, 10-mL vial = £169.50

**IRON DEXTRAN**
A complex of ferric hydroxide with dextran containing 5% (50 mg/mL) of iron

**Indications** iron-deficiency anaemia, see notes above

**Cautions** oral iron not to be given until 5 days after last injection; interactions: Appendix 1 (iron)

Anaphylaxis Anaphylactic reactions can occur with parenteral iron and a test dose is recommended before each dose; the patient should be carefully observed for 60 minutes after the first test dose and for 15 minutes after subsequent test doses (subsequent test doses not necessary for intramuscular administration). Facilities for cardiopulmonary resuscitation must be available; risk of allergic reactions increased in immune or inflammatory conditions
In megaloblastic anemias, most result from a lack of either vitamin B12 or folate, and it is essential to establish the underlying cause. In emergencies, when delay might be dangerous, it is sometimes necessary to administer both substances after the bone marrow test while results are available. Normally, however, appropriate treatment should not be instituted until the results of tests are available.

One cause of megaloblastic anemia in the UK is pernicious anemia in which lack of gastric intrinsic factor resulting from an autoimmune gastritis causes malabsorption of vitamin B12. Vitamin B12 is also needed in the treatment of megaloblastic caused by prolonged nitrous oxide anesthesia, which inactivates the vitamin, and in the rare syndrome of congenital transcobalamin II deficiency.

Vitamin B12 should be given prophylactically after total gastrectomy or total ileal resection (or after partial gastrectomy if a vitamin B12 absorption test shows vitamin B12 malabsorption). Apart from dietary deficiency, all other causes of vitamin B12 deficiency are attributable to malabsorption. There is little place for the use of low-dose vitamin B12 orally and none for vitamin B12 intrinsic factor complexes given by mouth. Vitamin B12 in larger oral doses of 1–2 mg daily [unlicensed] may be effective.

Hydroxocobalamin has completely replaced cyanocobalamin as the form of vitamin B12 of choice for therapy; it is retained in the body longer than cyanocobalamin and thus for maintenance therapy can be given at intervals of up to 3 months. Treatment is generally initiated with frequent administration of intramuscular injections to replenish the depleted body stores. Thereafter, maintenance treatment, which is usually for life, can be instituted. There is no evidence that doses larger than those recommended provide any additional benefit in vitamin B12 neuropathy.

Folic acid has few indications for long-term therapy since most causes of folate deficiency are self-limiting or will yield to a short course of treatment. It should not be used in undiagnosed megaloblastic anemia unless vitamin B12 is administered concurrently otherwise neuropathy may be precipitated (see above).

In folate-deficient megaloblastic anemia (e.g. because of poor nutrition, pregnancy, or antiepileptic drugs), daily folic acid supplementation for 4 months brings about haematological remission and replenishes body stores.

For prophylaxis in chronic haemolytic states, malabsorption, or in renal dialysis, folic acid is given daily or sometimes weekly, depending on the diet and the rate of haemolysis.

For prophylaxis in pregnancy, see Prevention of Neural Tube Defects below.

Folic acid is also used for the prevention of methotrexate-induced side-effects in severe Crohn’s disease (see section 1.5.3, p. 65), rheumatic disease (see section 10.1.3, p. 645), and severe psoriasis (see section 13.5.3, p. 721).

Folic acid is also effective in the treatment of folate-deficient megaloblastic anemia but it is generally used in association with cytotoxic drugs (see section 8.1); it is given as calcium folinate.

Prevention of neural tube defects Folic acid supplements taken before and during pregnancy can reduce the occurrence of neural tube defects. The risk of a neural tube defect occurring in a child should be assessed and folic acid given as follows:

- Women at a low risk of conceiving a child with a neural tube defect should be advised to take folic acid as a medicinal or food supplement at a dose of 400 micrograms daily before conception and until week 12 of pregnancy. Women who have not been taking folic acid and who suspect they are pregnant should start at once and continue until week 12 of pregnancy.
- Couples are at a high risk of conceiving a child with a neural tube defect if either partner has a neural tube defect (or either partner has a family history of neural tube defects), if they have had a previous pregnancy affected by a neural tube defect, or if they...
woman has coeliac disease (or other malabsorption state), diabetes mellitus, sickle-cell anaemia, or is taking antiepileptic medicines (see also section 4.8.1).

Women in the high-risk group who wish to become pregnant (or who are at risk of becoming pregnant) should be advised to take folic acid 5 mg daily and continue until week 12 of pregnancy (women with sickle-cell disease should continue taking their normal dose of folic acid 5 mg daily (or to increase the dose to 5 mg daily) and continue this throughout pregnancy).

There is no justification for prescribing multiple-ingredient vitamin preparations containing vitamin B₁₂ or folic acid.

HYDROXOCOBALAMIN

Indications see under dose below; cyanide poisoning (see Emergency Treatment of Poisoning, p. 39)

Cautions should not be given before diagnosis fully established but see also notes above; interactions: Appendix 1 (hydroxocobalamin)

Breast-feeding present in milk but not known to be harmful

Side-effects nausea, headache, dizziness; fever, hypersensitivity reactions (including rash and pruritus); injection-site reactions; hypokalaemia and thrombocytosis during initial treatment; chromaturia

Dose

- By intramuscular injection, pernicious anaemia and other macrocytic anaemias without neurological involvement, initially 1 mg 3 times a week for 2 weeks then 1 mg every 3 months
- Pernicious anaemia and other macrocytic anaemias with neurological involvement, initially 1 mg on alternate days until no further improvement, then 1 mg every 2 months
- Prophylaxis of macrocytic anaemias associated with vitamin B₁₂ deficiency, 1 mg every 2–3 months
- Tobacco amblyopia and Leber's optic atrophy, initially 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, thereafter 1 mg every 1–3 months

CHILD see BNF for Children

Hydroxocobalamin (Non-proprietary)

Injection, hydroxocobalamin 1 mg/mL. Net price 1 mL amp = £1.67

Note The BP directs that when vitamin B₁₂ injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied

Brands include Cobalamin-I², Neo-Cytamen®

FOLIC ACID

Indications see notes above and under dose

Cautions should never be given alone for pernicious anaemia and other vitamin B₁₂ deficiency states (may precipitate subacute combined degeneration of the spinal cord); interactions: Appendix 1 (folates)

Side-effects rarely gastro-intestinal disturbances

Dose

- Folate-deficient megaloblastic anaemia, by mouth, ADULT over 1 year, 5 mg daily for 4 months (until term in pregnant women); up to 15 mg daily may be required in malabsorption states; CHILD under 1 year, 500 micrograms/kg daily (max. 5 mg) for up to 4 months; up to 10 mg daily may be required in malabsorption states
- Prevention of neural tube defects, by mouth, see notes above
- Prevention of methotrexate-induced side-effects in severe Crohn's disease [unlicensed], by mouth, see section 1.5.3
- Prevention of methotrexate-induced side-effects in rheumatic disease [unlicensed], by mouth, ADULT over 18 years 5 mg once weekly; CHILD 2–18 years see BNF for Children
- Prevention of methotrexate-induced side-effects in severe psoriasis [unlicensed], by mouth, see section 13.5.3
- Prophylaxis in chronic haemolytic states, by mouth, ADULT 5 mg every 1–7 days depending on underlying disease
- Prophylaxis of folate deficiency in dialysis, by mouth, ADULT 5 mg every 1–7 days; CHILD 1–12 years 250 micrograms/kg (max. 10 mg) once daily, CHILD 12–18 years 5–10 mg once daily

1 Folic Acid (Non-proprietary)

Tablets, folic acid 400 micrograms, net price 90-tab pack = £2.37; 5 mg, 28-tab pack = £1.00

Injection, folic acid 15 mg, net price 1-mL amp = £1.34

Available from 'special-order' manufacturers or specialist importing companies, see p. 988

2. Can be sold to the public provided daily doses do not exceed 500 micrograms
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

Anabolic steroids (section 6.4.3), pyridoxine, antilymphocyte immunoglobulin, and various corticosteroids are used in hypoplastic and haemolytic anaemias.

Antilymphocyte immunoglobulin given intravenously through a central line over 12–18 hours each day for 5 days produces a response in about 50% of cases of acquired aplastic anaemia; the response rate may be increased when ciclosporin is given as well. Severe reactions are common in the first 2 days and profound immunosuppression may occur; antilymphocyte immunoglobulin should be given under specialist supervision with appropriate resuscitation facilities. Alternatively, oxymetholone tablets (available from ‘special order’ manufacturers or specialist importing companies, see p. 988) can be used in aplastic anaemia at a dose of 1–5 mg/kg daily for 3 to 6 months. It is unlikely that dietary deprivation of pyridoxine (section 9.6.2) produces clinically relevant haematological effects. However, certain forms of sideroblastic anaemia respond to pharmacological doses, possibly reflecting its role as a co-enzyme during haemoglobin synthesis. Pyridoxine is indicated in both idiopathic acquired and hereditary sideroblastic anaemias. Although complete cures have not been reported, some increase in haemoglobin can occur; the dose required is usually high, up to 400 mg daily. Reversible sideroblastic anaemias respond to treatment of the underlying cause but in pregnancy, haemolytic anaemias, and alcohol dependence, or during isoniazid treatment, pyridoxine is also indicated.

Corticosteroids (see section 6.3) have an important place in the management of a wide variety of haematological disorders. They include conditions with an immune basis such as autoimmune haemolytic anaemia, immune thrombocytopenias and neutropenias, and major transfusion reactions. They are also used in chemotherapy schedules for many types of lymphoma, lymphoid leukaemias, and paraproteinaemias, including multiple myeloma.

Erythropoietins

Epoetins (recombinant human erythropoietins) are used to treat symptomatic anaemia associated with erythropoietin deficiency in chronic renal failure, to increase the yield of autologous blood in normal individuals and to shorten the period of symptomatic anaemia in patients receiving cytotoxic chemotherapy. Epoetin beta is also used for the prevention of anaemia in preterm neonates of low birth-weight; only unpreserved formulations should be used in neonates because other preparations may contain benzyl alcohol (see Excipients, p. 2).

Darbeopoin is a hyperglycosylated derivative of epoetin; it has a longer half-life and can be administered less frequently than epoetin.

Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic anaemia associated with chronic kidney disease. It has a longer duration of action than epoetin.

Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients. Aluminium toxicity, concurrent infection, or other inflammatory disease can impair the response to erythropoietin.

MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration

Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:

- patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy unless symptoms of anaemia are present;
- the haemoglobin concentration should be maintained within the range 10–12 g/100 mL;
- haemoglobin concentrations higher than 12 g/100 mL should be avoided;
- the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range).

See also MHRA/CHM advice below.

MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer

Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):

- erythropoietins licensed for the treatment of symptomatic anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy;
- the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis.

See also MHRA/CHM advice above.

Pure red cell aplasia

There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should not be switched to another form of erythropoietin.
NICE guidance
Epoetin alfa, beta and darbepoetin alfa for cancer treatment-induced anaemia (May 2008)

Erythropoietin analogues are not recommended for routine use in the management of cancer treatment-induced anaemia, but may be considered, in combination with intravenous iron, for:

- women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin concentration of 8 g/100 mL or lower (the use of erythropoietin analogues does not preclude the use of existing approaches to the management of anaemia, including blood transfusion when necessary);
- patients who cannot be given blood transfusions and who have profound cancer treatment-related anaemia that is likely to have an impact on survival.

Patients currently treated with erythropoietin analogues for the management of cancer treatment-related anaemia who do not fulfil the criteria outlined above can continue therapy until they and their specialists consider it appropriate to stop.

DARBEPOETIN ALFA

Indications see under Dose below
Cautions see Epoetin
Contra-indications see Epoetin

Hepatic impairment manufacturer advises caution
Pregnancy no evidence of harm in animal studies—manufacturer advises caution
Breast-feeding manufacturer advises avoid—no information available
Side-effects see Epoetin; also, oedema, injection-site pain; isolated reports of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure (discontinue therapy)—see also notes above

Dose

- Symptomatic anaemia associated with chronic renal failure in patients on dialysis (see also MHRA/CHM advice, p. 582), ADULT and CHILD over 11 years, by subcutaneous or intravenous injection, initially 450 nanograms/kg once weekly, adjusted according to response by approx. 25% at intervals of at least 4 weeks; maintenance dose, given once weekly or once every 2 weeks
- Symptomatic anaemia associated with chronic renal failure in patients not on dialysis (see also MHRA/CHM advice, p. 582), ADULT and CHILD over 11 years, by subcutaneous or intravenous injection, initially 450 nanograms/kg once weekly or by subcutaneous injection, initially 750 nanograms/kg once every 2 weeks; adjusted according to response by approx. 25% at intervals of at least 4 weeks; maintenance dose, given subcutaneously or intravenously once weekly or subcutaneously once every 2 weeks or subcutaneously once every month

Note Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. When changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements. Adjust doses not more frequently than every 2 weeks during maintenance treatment.

- Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy (see also MHRA/CHM advice, p. 582), by subcutaneous injection, initially 6.75 micrograms/kg once every 3 weeks or 2.25 micrograms/kg once weekly (if response inadequate after 9 weeks further treatment may not be effective); if adequate response obtained, reduce dose by 25–50%

Note Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

Aranesp® (Amgen) (Recombinant human erythropoietins)

Injection, prefilled syringe, darbepoetin alfa, 25 micrograms/mL, net price 0.4 mL (10 micrograms) = £14.68; 40 micrograms/mL, 0.375 mL (15 micrograms) = £22.03, 0.5 mL (20 micrograms) = £29.37; 100 micrograms/mL, 0.3 mL (30 micrograms) = £44.05, 0.4 mL (40 micrograms) = £58.73, 0.5 mL (50 micrograms) = £73.41; 200 micrograms/mL, 0.3 mL (60 micrograms) = £88.09, 0.4 mL (80 micrograms) = £117.45, 0.5 mL (100 micrograms) = £146.81, 0.65 mL (130 micrograms) = £190.66; 500 micrograms/mL, 0.3 mL (150 micrograms) = £220.22, 0.6 mL (300 micrograms) = £440.43, 1 mL (500 micrograms) = £734.05

Injection (Aranesp® SureClick), prefilled disposable injection device, darbepoetin alfa, 40 micrograms/mL, net price 0.5 mL (20 micrograms) = £29.36; 100 micrograms/mL, 0.4 mL (40 micrograms) = £58.72; 200 micrograms/mL, 0.3 mL (60 micrograms) = £88.09, 0.4 mL (80 micrograms) = £117.45, 0.5 mL (100 micrograms) = £146.81; 500 micrograms/mL, 0.3 mL (150 micrograms) = £220.22, 0.6 mL (300 micrograms) = £440.43, 1 mL (500 micrograms) = £734.05

EPOETIN ALFA, BETA, THETA, and ZETA

(Recombinant human erythropoietins)

Note The prescriber must specify which epoetin is required, see also Biosimilar medicines, p. 1

Indications see under preparations, below
Cautions see notes above; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain is warning of a hypertensive crisis; sickle-cell disease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased...
when used for anaemia before orthopaedic surgery— 
avoid in cardiovascular disease including recent 
myocardial infarction or cerebrovascular accident

Contra-indications pure red cell aplasia following 
erythropoietin therapy (see also notes above); 
uncontrolled hypertension; patients unable to receive 
thromboprophylaxis; avoid injections containing 
benzyl alcohol in neonates (see under preparations, below)

Hepatic impairment manufacturers advise caution in 
chronic hepatic failure

Pregnancy no evidence of harm; benefits probably 
outweigh risk of anaemia and of transfusion in 
pregnancy

Breast-feeding unlikely to be present in milk; minimal 
effect on infant

Side-effects diarrhoea, nausea, vomiting; dose- 
dependent increase in blood pressure or aggravation 
of hypertension; in isolated patients with normal or 
low blood pressure, hypertensive crisis with 
cephalopathy-like symptoms and generalised tonic- 
clonic seizures requiring immediate medical attention;

headache; dose-dependent increase in platelet count 
(but thrombocytopenia rare) regressing during treat- 
ment; influenza-like symptoms (may be reduced if 
intrafuse injection given over 5 minutes); cardio- 
vascular events; shunt thrombosis especially if ten- 
dency to hypotension or arteriovenous shunt com- 
plications; very rarely sudden loss of efficacy because of 
pure red cell aplasia, particularly following subcu- 
taneous administration in patients with chronic renal failure 
(discontinue erythropoietin therapy)—see also notes above, hyperkalaemia, hypertension; in isolated patients with 
haemoglobin concentration decreases and then restart at a dose 
continues to rise, despite dose reduction, suspend treatment until 
haemoglobin concentration decreases and then restart at a dose 
approximately 25% lower than the previous dose.

Symptomatic anaemia in adults receiving cancer chemotherapy 
(see also MHRA/CHM advice, p. 582), by subcutaneous injection 
(max. 1 mL per injection site), initially 150 units/kg 3 times weekly 
(or 450 units/kg once weekly), increased if appropriate rise in 
haemoglobin (or reticulocyte count) not achieved after 4 weeks to 
300 units/kg 3 times weekly; discontinue if inadequate response 
after 4 weeks at higher dose.

Reduce dose by approximately 25–50% if rise in haemoglobin 
concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin 
concentration increases 12 g/100 mL, if haemoglobin concentration 
continues to rise, despite dose reduction, suspend treatment until 
haemoglobin concentration decreases and then restart at a dose 
approximately 25% lower than the previous dose.

Symptomatic anaemia in adults receiving major surgery, 
by intravenous injection over 1–5 minutes, 600 units/kg twice weekly for 3 weeks before surgery; consult product literature for details and advice on 
ensuring high iron stores

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) 
before elective orthopaedic surgery in adults with expected 
moderate blood loss to reduce exposure to allogeneic blood 
transfusion or if autologous transfusion unavailable, by subcuta- 
neous injection (max. 1 mL per injection site), 600 units/kg every 
week for 3 weeks before surgery and on day of surgery or 
300 units/kg daily for 15 days before starting 10 days before surgery; 
consult product literature for details

Eperep (Janssen-Cilag) 
Injection, prefilled syringe, epoetin alfa, net price 
1000 units = £5.53; 2000 units = £11.07; 3000 units = 
£16.60; 4000 units = £22.13; 5000 units = £27.66; 
6000 units = £33.19; 8000 units = £44.25; 10 000 units = 
£55.31; 20 000 units = £110.62; 30 000 units = 
£199.11; 40 000 units = £265.48. An auto-injector 
device is available for use with prefilled syringes

Dose symptomatic anaemia associated with chronic renal failure in 
patients on haemodialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes 
or by subcutaneous injection (max. 1 mL per injection site), initially 50 units/ 
kg 3 times weekly adjusted according to response in steps of 
25 units/kg 3 times weekly at intervals of at least 4 weeks; maintenance dose, usually a total of 75–300 units/kg weekly (as a 
single dose or in divided doses). CHILD by intravenous injection 
initially as for adults; maintenance dose, body-weight under 10 kg 
usually 75–150 units/kg 3 times weekly, body-weight 10–30 kg 
usually 60–150 units/kg 3 times weekly, body-weight over 30 kg 
usually 30–100 units/kg 3 times weekly

Symptomatic anaemia associated with chronic renal failure in 
adults on peritoneal dialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes or by subcu- 
taneous injection (max. 1 mL, per injection site), initially 50 units/ 
kg twice weekly; maintenance dose 25–50 units/kg twice weekly

Severe symptomatic anaemia of renal origin in adults with renal 
insufficiency not yet on dialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes or by subcu- 
taneous injection (max. 1 mL, per injection site), initially 50 units/ 
kg 3 times weekly increased according to response in steps of 
25 units/kg 3 times weekly at intervals of at least 4 weeks; maintenance dose, usually 17–33 units/kg 3 times weekly; max. 
200 units/kg 3 times weekly

Note Intravenous route preferred; reduce dose by approximately 
25% if rise in haemoglobin concentration exceeds 2 g/100 mL, over 4 weeks or if haemoglobin concentration increases 12 g/100 mL, if haemoglobin concentration continues to rise, despite dose reduc- 
tion, suspend treatment until haemoglobin concentration decreases and 
then restart at a dose approximately 25% lower than the previous dose.

Symptomatic anaemia in adults receiving cancer chemotherapy 
(see also MHRA/CHM advice, p. 582), by subcutaneous injection 
(max. 1 mL, per injection site), initially 150 units/kg 3 times weekly 
(or 450 units/kg once weekly), increased if appropriate rise in 
haemoglobin (or reticulocyte count) not achieved after 4 weeks to 
300 units/kg 3 times weekly; discontinue if inadequate response 
after 4 weeks at higher dose.

Note Reduce dose by approximately 25–50% if rise in haemoglobin 
concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentratio
mg/dL after 4 weeks, increased according to response at intervals of 4 weeks in steps of 25% of the previous dose; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 12 weeks; total weekly maintenance dose may be given as a single dose or in 3–7 divided doses; maximum 7200 units/kg weekly.

Note Discontinue route of administration should be used

Dosage

- **Subcutaneous route** preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/dL. Maintenance dose, increased according to response at intervals of 4 weeks in steps of 25% of the previous dose; maximum 7200 units/kg weekly.

- **Note Discontinue treatment if haemoglobin concentration does not increase by at least 1 g/dL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/dL in 4 weeks, increased according to response at intervals of 4 weeks in steps of 25% of the previous dose; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1–2 weeks; total weekly maintenance dose may be given as a single dose or in 3–7 divided doses; maximum 7200 units/kg weekly.

- **Note Discontinue route of administration should be used**

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.

**Note**

If epoetin theta is substituted for another epoetin the same route of administration should be used.
Note
Avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose
Symptomatic anaemia in adults receiving cancer chemotherapy (see also MHRA/CHM advice, p. 582), by subcutaneous injection, initially 20,000 units once weekly, increased if necessary after 4 weeks (if a rise in haemoglobin of at least 1 g/100 mL not achieved) to 40,000 units once weekly, with further increase if needed after 4 weeks to max. 60,000 units once weekly
Note
Discontinue treatment if haemoglobin concentration does not increase by at least 1 g/100 mL after 12 weeks of therapy (response unlikely). Reduce dose by 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

Epoetin zeta
Retacrit® (Hospira) ▼ (Full)
Injection, prefilled syringe, epoetin zeta, net price 1000 units = £5.66; 2000 units = £11.31; 3000 units = £16.97; 4000 units = £22.63; 5000 units = £28.28; 6000 units = £33.94; 8000 units = £45.25; 10,000 units = £56.57; 20,000 units = £103.64; 30,000 units = £150.74; 40,000 units = £179.47
Excipients include phenylalanine up to 500 micrograms/syringe (section 4.1.4)
Note
Biological medicine, p. 1
Dose
Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes or by subcutaneous injection (max. 1 mL per injection site), initially 50 units/kg or 3 times weekly adjusted according to response in steps of 25 units/kg 3 times weekly at intervals of at least 4 weeks; maintenance dose, usually 25–100 units/kg 3 times weekly. CHILD by intravenous injection initially as for adults; maintenance dose, body-weight under 10 kg usually 75–150 units/kg 3 times weekly, body-weight 10–30 kg usually 30–150 units/kg 3 times weekly, body-weight over 30 kg usually 30–180 units/kg 3 times weekly. Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes or by subcutaneous injection (max. 1 mL per injection site), initially 50 units/kg 2 times weekly; maintenance dose 25–50 units/kg 2 times weekly. Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis (see also MHRA/CHM advice, p. 582), by intravenous injection over 1–5 minutes or by subcutaneous injection (max. 1 mL per injection site), initially 50 units/kg 3 times weekly increased according to response in steps of 25 units/kg 3 times weekly at intervals of at least 4 weeks; maintenance dose 17–33 units/kg 3 times weekly; max. 200 units/kg 3 times weekly
Note
Avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks
Symptomatic anaemia in adults receiving cancer chemotherapy (see also MHRA/CHM advice, p. 582), by subcutaneous injection (max. 1 mL per injection site), initially 150 units/kg 3 times weekly (or 450 units/kg once weekly), increased if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks to 300 units/kg 3 times weekly, discontinue if inadequate response after 4 weeks at higher dose
Note
Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose
Discontinue approximately 4 weeks after ending chemotherapy
To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia (max. 1 mL per injection site), initially 150 units/kg 3 times weekly (or 450 units/kg once weekly), increased if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks to 300 units/kg 3 times weekly, discontinue if inadequate response after 4 weeks at higher dose
Sickle-cell disease
Sickle-cell disease is caused by a structural abnormality of haemoglobin resulting in deformed, less flexible red blood cells. Acute complications in the more severe forms include sickle-cell crisis, where infarction of the microvasculature and blood supply to organs results in severe pain. Sickle-cell crisis requires hospitalisation,
intravenous fluids, analgesia (section 4.7), and treatment of any concurrent infection. Chronic complications include skin ulceration, renal failure, and increased susceptibility to infection. Pneumococcal vaccine (section 14.4), haemophilus influenzae type b vaccine (section 14.4), an annual influenza vaccine (section 14.4) and prophylactic penicillin (Table 2, section 5.1) reduce the risk of infection. Hepatitis B vaccine (section 14.4) should be considered if the patient is not immune.

In most forms of sickle-cell disease, varying degrees of haemolytic anaemia are present accompanied by increased erythropoiesis; this may increase folate requirements and folate supplementation may be necessary (section 9.1.2).

**Hydroxyurea** can reduce the frequency of crises and the need for blood transfusions in sickle-cell disease; it should be considered in consultation with a specialist centre. The beneficial effects of hydroxyurea may not become evident for several months. Myelosuppression and skin reactions are the most common side-effects.

### Hydroxyurea (Hydroxycarbamide)

**Indications** sickle-cell disease (see notes above); chronic myeloid leukaemia, cancer of the cervix (section 8.1.5).

**Cautions** see section 8.1 and notes above; also monitor renal and hepatic function before and during treatment; monitor full blood count before treatment, then every 2 weeks for the first 2 months and then every 2 months thereafter (or every 2 weeks if on max. dose); leg ulcers (review treatment if cutaneous vasculitic ulcerations develop); **interactions:** Appendices 1 (hydroxyurea).

**Hepatic impairment** manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.

**Renal impairment** reduce initial dose by 50% if eGFR less than 60 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m².

**Pregnancy** section 8.1.5

**Breast-feeding** section 8.1.5

**Side-effects** see section 8.1 and notes above; also headache, less commonly dizziness and rash; rarely reduced sperm count and activity; fever, ameorohea, skin cancers (in elderly patients); bleeding and hypomagnesaemia also reported.

**Dose**
- By mouth, initially 15 mg/kg daily, increased every 12 weeks in steps of 5 mg/kg daily according to response; usual dose 15–30 mg/kg daily (max. 35 mg/kg daily); **CHILD** under 18 years, see BNf for Children

**Siklos** (Nordic) Tablets, scored, f/c, hydroxyurea 1 g, net price 30-tab pack = £500.00

**Iron overload**

Severe tissue iron overload can occur in aplastic and other refractory anaemias, mainly as the result of repeated blood transfusions. It is a particular problem in refractory anaemias with hyperplastic bone marrow, especially *thalassaemia major*, where excessive iron absorption from the gut and inappropriate iron therapy can add to the tissue siderosis. Iron overload associated with haemochromatosis can be treated with repeated venesection. Venesection may also be used for patients who have received multiple transfusions and whose bone marrow has recovered. Where venesection is contra-indicated, the long-term administration of the iron chelating compound [desferrioxamine mesilate](#) is useful. Subcutaneous infusions of desferrioxamine are given over 8–12 hours, 3–7 times a week. The dose should reflect the degree of iron overload. For children starting therapy (and who have low iron overload) the dose should not exceed 30 mg/kg. For established overload the dose is usually between 20 and 50 mg/kg daily. Desferrioxamine (up to 2 g per unit of blood) may also be given at the time of blood transfusion, provided that the desferrioxamine is not added to the blood and is not given through the same line as the blood (but the two may be given through the same cannula).

Iron excretion induced by desferrioxamine is enhanced by administration of ascorbic acid (vitamin C, section 9.6.3) 200 mg daily by mouth (100 mg in infants); it should be given separately from food since it also enhances iron absorption. Ascorbic acid should not be given to patients with cardiac dysfunction; in patients with normal cardiac function ascorbic acid should be introduced 1 month after starting desferrioxamine.

Desferrioxamine infusion can be used to treat aluminium overload in dialysis patients; theoretically 100 mg of desferrioxamine binds with 4.1 mg of aluminium.

**Deferasirox**, an oral iron chelator, is licensed for the treatment of chronic iron overload in adults and children over 6 years with thalassaemia major who receive frequent blood transfusions (more than 7 mL/kg/month of packed red blood cells). It is also licensed for chronic iron overload when desferrioxamine is contra-indicated or inadequate in patients with thalassaemia major who receive infrequent blood transfusions (less than 7 mL/kg/month of packed red blood cells), in patients with other anaemias, and in children aged 2 to 5 years.

The Scottish Medicines Consortium (p. 4) has advised that deferasirox is accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes.

**Deferiprone**, an oral iron chelator, is licensed for the treatment of iron overload in patients with thalassaemia major in whom desferrioxamine is contra-indicated or is inadequate. Blood dyscrasias, particularly agranulocytosis, have been reported with deferiprone.
interruption if unexplained cytopenia occurs; not recommended in conditions which may reduce life expectancy (e.g. high-risk myelodysplastic syndromes); history of liver cirrhosis; test liver function before treatment, then every 2 weeks during the first month, and then monthly; measure baseline serum creatinine and monitor renal function weekly during the first month of treatment and monthly thereafter; test for proteinuria monthly; interactions: Appendix 1 (deferisirox)

**Hepatic impairment** manufacturer advises caution—no information available; avoid in severe impairment

**Renal impairment** reduce dose by 10 mg/kg if eGFR 60–90 mL/minute/1.73 m² and if serum creatinine increased by more than 35% of baseline measurement on 2 consecutive occasions—interrupt treatment if deterioration in renal function persists after dose reduction; avoid if eGFR less than 60 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid unless essential—toxicity in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** gastro-intestinal disturbances (including ulceration and fatal haemorrhage); headache; proteinuria; pruritus, rash; less commonly hepatitis, cholelithiasis, oedema, fatigue, anxiety, sleep disorder, dizziness, pyrexia, pharyngitis, glucosuria, renal tubulopathy, disturbances of hearing and vision (including lens opacity and maculopathy), and skin pigmentation; hepatic failure, acute renal failure, blood disorders (including agranulocytosis, neutropenia, pancytopenia, and thrombocytopenia); hyper-sensitivity reactions (including anaphylaxis and angioedema), alopecia also reported

**Dose**

- **ADULT** and **CHILD** over 6 years initially 10–30 mg/kg once daily according to serum-ferritin concentration and amount of transfused blood (consult product literature); maintenance, adjust dose every 3–6 months in steps of 5–10 mg/kg according to serum-ferritin concentration; usual max. 30 mg/kg daily, but may be increased to max. 40 mg/kg daily and reduced in steps of 5–10 mg/kg once control achieved

**Exjade** (Novartis) ▼ (SW)

**Dispensable tablets**, deferasirox 125 mg, net price 28-tab pack = £117.60; 250 mg, 28-tab pack = £235.20; 500 mg, 28-tab pack = £470.40. Label: 13, 22, counselling, administration

**Counselling** Tablets should be dispersed in water, orange juice, or apple juice, if necessary, resuspend residue

**DEFERIPRONE**

**Indications** see notes above

**Cautions** monitor neutrophil count weekly and discontinue treatment if neutrophenia develops; monitor plasma-zinc concentration

**Blood disorders** Patients or their carers should be told how to recognise signs of neutropenia and advised to seek immediate medical attention if symptoms such as fever or sore throat develop

**Contra-indications** history of agranulocytosis or recurrent neutropenia

**Hepatic impairment** manufacturer advises monitor liver function—interrupt treatment if persistent elevation in serum alanine aminotransferase

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises avoid before intended conception and during pregnancy—teratogenic and embryotoxic in animal studies; contraception advised in women of child-bearing potential

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances (reducing dose and increasing gradually may improve tolerance), increased appetite; headache; red-brown urine discoloration; neutropenia, agranulocytosis; zinc deficiency; arthropathy

**Dose**

- **ADULT** and **CHILD** over 6 years 25 mg/kg 3 times daily (max. 100 mg/kg daily)

**Ferriprox** (Swedish Orphan) ▼ (SW)

**Tablets**, f/c, scored, deferiprone 500 mg, net price 100-tab pack = £152.39. Label: 14, counselling, blood disorders

**Oral solution**, red, deferiprone 100 mg/mL, net price 500 mL = £152.39. Label: 14, counselling, blood disorders

**DESFERRIOXAMINE MESILATE**

(Deferoxamine Mesilate)

**Indications** see notes above; iron poisoning, see Emergency Treatment of Poisoning, p. 38

**Cautions** eye and ear examinations before treatment and at 3-month intervals during treatment; monitor body-weight and height in children at 3-month intervals—risk of growth retardation with excessive doses; aluminium-related encephalopathy (may exacerbate neurological dysfunction); interactions: Appendix 1 (deferoxamine)

**Renal impairment** use with caution

**Pregnancy** teratogenic in animal studies; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises use only if potential benefit outweighs risk

**Side-effects** nausea, vomiting, abdominal pain; headache; pyrexia; growth retardation and bone disorders (see Cautions); arthralgia, myalgia; hearing disturbances; injection-site reactions; rarely diarrhoea, hepatic impairment, hypotension (especially when given too rapidly by intravenous injection), anaphylaxis, Yersinia and mucormycosis infections, blood dyscrasias (including thrombocytopenia and leucopenia), leg cramps, bone pain, visual disturbances (including lens opacity and retinopathy), rash; very rarely acute respiratory distress, neurological disturbances (including dizziness, neuropathy, convulsions, and paraesthesia), renal impairment; muscle spasms also reported

**Dose**

- **See notes above**; iron poisoning, see Emergency Treatment of Poisoning, p. 38

**Note** For full details and warnings relating to administration, consult product literature

**Desferrioxamine mesilate** (Non-proprietary) ▼ (SW)

**Injection**, powder for reconstitution, desferrioxamine mesilate, net price 500-mg vial = £4.26; 2-g vial = £17.05

**DEFERIPRONE**

**Indications** see notes above

**Cautions** monitor neutrophil count weekly and discontinue treatment if neutrophenia develops; monitor plasma-zinc concentration

**Blood disorders** Patients or their carers should be told how to recognise signs of neutropenia and advised to seek immediate medical attention if symptoms such as fever or sore throat develop

**Contra-indications** history of agranulocytosis or recurrent neutropenia

**Hepatic impairment** manufacturer advises monitor liver function—interrupt treatment if persistent elevation in serum alanine aminotransferase

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises avoid before intended conception and during pregnancy—teratogenic and embryotoxic in animal studies; contraception advised in women of child-bearing potential

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances (reducing dose and increasing gradually may improve tolerance), increased appetite; headache; red-brown urine discoloration; neutropenia, agranulocytosis; zinc deficiency; arthropathy

**Dose**

- **ADULT** and **CHILD** over 6 years 25 mg/kg 3 times daily (max. 100 mg/kg daily)

**Ferriprox** (Swedish Orphan) ▼ (SW)

**Tablets**, f/c, scored, deferiprone 500 mg, net price 100-tab pack = £152.39. Label: 14, counselling, blood disorders

**Oral solution**, red, deferiprone 100 mg/mL, net price 500 mL = £152.39. Label: 14, counselling, blood disorders

**DESFERRIOXAMINE MESILATE**

(Deferoxamine Mesilate)

**Indications** see notes above; iron poisoning, see Emergency Treatment of Poisoning, p. 38

**Cautions** eye and ear examinations before treatment and at 3-month intervals during treatment; monitor body-weight and height in children at 3-month intervals—risk of growth retardation with excessive doses; aluminium-related encephalopathy (may exacerbate neurological dysfunction); interactions: Appendix 1 (deferoxamine)

**Renal impairment** use with caution

**Pregnancy** teratogenic in animal studies; manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises use only if potential benefit outweighs risk

**Side-effects** nausea, vomiting, abdominal pain; headache; pyrexia; growth retardation and bone disorders (see Cautions); arthralgia, myalgia; hearing disturbances; injection-site reactions; rarely diarrhoea, hepatic impairment, hypotension (especially when given too rapidly by intravenous injection), anaphylaxis, Yersinia and mucormycosis infections, blood dyscrasias (including thrombocytopenia and leucopenia), leg cramps, bone pain, visual disturbances (including lens opacity and retinopathy), rash; very rarely acute respiratory distress, neurological disturbances (including dizziness, neuropathy, convulsions, and paraesthesia), renal impairment; muscle spasms also reported

**Dose**

- **See notes above**; iron poisoning, see Emergency Treatment of Poisoning, p. 38

**Note** For full details and warnings relating to administration, consult product literature

**Desferrioxamine mesilate** (Non-proprietary) ▼ (SW)

**Injection**, powder for reconstitution, desferrioxamine mesilate, net price 500-mg vial = £4.26; 2-g vial = £17.05
Paroxysmal nocturnal haemoglobinuria

Eculizumab, a recombinant monoclonal antibody, inhibits terminal complement activation at the C5 protein and thereby reduces haemolysis. It is used to reduce haemolysis in paroxysmal nocturnal haemoglobinuria, a severe and disabling form of haemolytic anaemia.

Eculizumab

**Indications** paroxysmal nocturnal haemoglobinuria, in those with a history of blood transfusions (specialist use only)

**Cautions** active systemic infection; monitor for intravascular haemolysis (including serum-lactate dehydrogenase concentration) for at least 8 weeks after discontinuation

**Meningococcal infection** Vaccinate against *Neisseria meningitidis* at least 2 weeks before treatment (tetravalent vaccine against serotypes A, C, W135 and Y recommended); revaccinate according to current medical guidelines. Advise patient to report promptly any signs of meningococcal infection. Other immunisations should also be up to date (section 14.1)

**Contra-indications** unresolved *Neisseria meningitidis* infection; patients unvaccinated against *Neisseria meningitidis* (see Cautions above); known or suspected hereditary complement deficiencies

**Pregnancy** no information available—use only if potential benefit outweighs risk; human IgG antibodies known to cross placenta; manufacturer advises effective contraception during and for 5 months after treatment

**Breast-feeding** no information available—manufacturer advises avoid breast-feeding during and for 5 months after treatment

**Side-effects** gastro-intestinal disturbances; oedema; cough, nasopharyngitis; headache, dizziness, fatigue, dysgeusia, paraesthesia; infection (including meningococcal infection); spontaneous erection, dysuria, arthralgia, myalgia; blood disorders (including thrombocytopenia); alopecia, pruritus, rash; influenza-like symptoms; infusion-related reactions; less commonly anorexia, gingival pain, jaundice, palpitation, haematoma, hypotension, chest pain, syncope, hot flushing, epistaxis, anxiety, depression, mood changes, sleep disturbances, Graves’ disease, menstrual disorders, renal impairment, malignant melanoma, muscle spasms, myelodysplastic syndrome, visual disturbances, tinnitus, hyperhidrosis, petechiae, and skin depigmentation

**Dose**

- By intravenous infusion, **ADULT** over 18 years, initially 600 mg once a week for 4 weeks, then 900 mg on week 5; maintenance, 900 mg once every 12–16 days

**Soliris** (Alexion) (Novartis) 

**Injection**, powder for reconstitution, desferrioxamine mesilate, net price 500-mg vial = £4.67, 2-g vial = £18.66

**ECULIZUMAB**

**Electrolytes** Na+ 5 mmol/vial

**Concentrate for intravenous infusion**, eculizumab 10 mg/mL, net price 30-mL vial = £3150.00. Counselling, meningococcal infection, patient information card

**Early warning signs** pyrexia, hypotension, rash, dyspnoea, and confusion

**Adverse reactions**

Adverse reactions can be severe and include:

- Gastro-intestinal disturbances: nausea, vomiting, abdominal pain, anorexia, constipation, diarrhoea

- Cardio-vascular disturbances: peripheral oedema, dyspnoea, tachycardia, hypotension

- Haematological disturbances: anaemia, leucopenia, thrombocytopenia

- Neurological disturbances: headache, seizures, convulsions, psychiatric disturbances

- Renal disturbances: proteinuria, haematuria, pyuria, dysuria

- Urogenital disturbances: dysuria, pyuria, and oliguria

- Endocrine disturbances: diabetes mellitus, hyperglycaemia

- Haemorrhage

**Precautions** acute, severe haemorrhage associated with severe anaemia or thrombocytopenia is an absolute contraindication to therapy. Consideration should be given to the use of corticosteroids or other immunosuppressants in cases of severe anaemia, e.g. prednisolone 1 mg/kg daily, gradually reducing the dose over several weeks. Plasmapheresis is considered if a satisfactory platelet count is not achieved or if there is a relapse on reducing the dose of corticosteroid or withdrawing it.

**Idiopathic thrombocytopenic purpura**

Acute idiopathic thrombocytopenic purpura is usually self-limiting in children. In adults, idiopathic thrombocytopenic purpura can be treated with a corticosteroid, e.g. prednisolone 1 mg/kg daily, gradually reducing the dose over several weeks. Splenectomy is considered if a satisfactory platelet count is not achieved or if there is a relapse on reducing the dose of corticosteroid or withdrawing it.

**Immunoglobulin** preparations (section 14.5.1), are also used in idiopathic thrombocytopenic purpura or where a temporary rapid rise in platelets is needed, as in pregnancy or pre-operatively; they are also used for children often in preference to a corticosteroid.

**Anti-D (Rh0) immunoglobulin** (section 14.5.3) is effective in raising the platelet count in about 80% of unsplenectomised rhesus-positive individuals; its effects may last longer than normal immunoglobulin for intravenous use, but further doses are usually required.

Other therapy that has been tried in refractory idiopathic thrombocytopenic purpura includes azathioprine (section 8.2.1), cyclophosphamide (section 8.1.1), vincristine (section 8.1.4), ciclosporin (section 8.2.2), and danazol (section 6.7.2). Rituximab (section 8.2.3) may also be effective and in some cases induces prolonged remission. For patients with chronic severe thrombocytopenia refractory to other therapy, tranexamic acid (section 2.11) may be given to reduce the severity of haemorrhage.

**Eltrombopag** and romiplostim are thrombopoietin receptor agonists licensed for the treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments, such as corticosteroids or immunoglobulins, or as a second-line treatment in non-splenectomised patients when surgery is contra-indicated (see also NICE guidance below). Eltrombopag is an oral preparation and romiplostim is an injection which is made biosynthetically by recombinant DNA technology; they should both be used under the supervision of a specialist.

The **Scottish Medicines Consortium** (p. 4) has advised (July 2010) that **eltrombopag (Revolade®)** is accepted for restricted use within NHS Scotland for the treatment of both splenectomised and non-splenectomised patients with severe symptomatic immune (idiopathic) thrombocytopenic purpura or a high risk of bleeding.

**NICE guidance**

Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (October 2010)

Eltrombopag is not recommended for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in splenectomised adults refractory to other treatments, such as corticosteroids or immunoglobulins, or as a second-line treatment in non-splenectomised adults when surgery is contra-indicated.

The **Scottish Medicines Consortium** (p. 4) has advised (September 2009) that romiplostim (Nplate®) is
accepted for restricted use within NHS Scotland for patients with severe symptomatic idiopathic thrombocytopoietic purpura or those at high risk of bleeding.

**ELTROMBOPEG**

**Indications** see notes above

**Cautions** patients of East Asian origin (see under Dose); risk factors for thromboembolism; monitor full blood count including platelet count and peripheral blood smears every week during treatment until a stable platelet count is reached (50 \times 10^9/litre or more for at least 4 weeks), then monthly thereafter; monitor liver function before and during treatment, every two weeks when adjusting the dose, and monthly thereafter; regular ophthalmological examinations for cataract formation recommended; **interactions:** Appendix 1 (eltrombopag)

**Hepatic impairment** use with caution; avoid in moderate to severe impairment unless potential benefit outweighs risk; reduce initial dose to 25 mg once daily

**Renal impairment** use with caution

**Pregnancy** avoid—toxicity in animal studies; ensure effective contraception during treatment

**Breast-feeding** manufacturer advises avoid

**Side-effects** gastro-intestinal disturbances including nausea, diarrhoea, abdominal pain, and constipation; peripheral oedema; headache, insomnia, paraesthesia, fatigue; arthralgia, bone pain, myalgia; cataract, dry eye; pruritus, rash, alopecia; less commonly dry mouth, gingival bleeding, haemorrhoids, taste disturbances, cholestasis, hepatitis, anorexia, changes in appetite, weight gain, flushing, palpitation, QT-interval prolongation, hypertension, tachycardia, thromboembolic events (including deep vein thrombosis, pulmonary embolism, and acute myocardial infarction); cough, sleep disorders, mood changes, depression, anxiety, dizziness, migraine, hemiparesis, tremor, peripheral neuropathy, respiratory and urinary tract infections, renal failure, nocturia, rectosigmoid cancer, blood disorders (including anaemia, and thrombocytopenia), gout, eye disorders, vertigo, epistaxis, skin reactions including ecchymosis, and sweating

**Dose**

- **ADULT** over 18 years, initially 50 mg once daily (patients of EAST ASIAN origin such as Chinese, Japanese, Taiwanese, or Korean, initially 25 mg once daily), adjusted to achieve a platelet count of 50 \times 10^9/litre or more (consult product literature for dose adjustments); max. 75 mg once daily; discontinue if inadequate response after 4 weeks at maximum dose

**Counselling** Each dose should be taken at least 4 hours before or after any dairy products (or foods containing calcium), indigestion remedies, or medicines containing aluminium, calcium, iron, magnesium, zinc, or selenium to reduce possible interference with absorption

**Revolade** (GSK) Tablets, f/c. eltrombopag (as olamine) 25 mg (white), net price 28-tab pack = £770.00; 50 mg (brown), 28-tab pack = £1540.00. Counselling, see above

**ANAGRELIDE**

**Indications** see notes above

**Cautions** cardiovascular disease—assess cardiac function before and during treatment; concomitant aspirin in patients at risk of haemorrhage; monitor full blood count (monitor platelet count every 2 days for 1 week, then weekly until maintenance dose established), liver function, serum creatinine and urea; **interactions:** Appendix 1 (anagrelide)

**Driving** Dizziness may affect performance of skilled tasks (e.g. driving)

**Hepatic impairment** manufacturer advises caution—no information available

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises use only if essential—toxicity in animal studies

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances; flushing, oedema; dizziness, migraine, insomnia, fatigue, asthenia, paraesthesia; influenza-like symptoms; arthralgia, myalgia, bone pain, muscle spasm; increased bone marrow reticulin; ecchymosis, rash; injection-site reactions

**Dose**

- By subcutaneous injection. **ADULT** over 18 years, initially 1 microgram/kg once weekly, adjusted in steps of 1 microgram/kg at weekly intervals until a stable platelet count of 50 \times 10^9/litre or more is reached (consult product literature for dose adjustments); max. 10 micrograms/kg once weekly; discontinue if inadequate response after 4 weeks at maximum dose

**Nplate** (Amgen) \( \downarrow \) Injection, powder for reconstitution, romiplostim, net price 250-microgram vial (available with or without solvent) = £462.00

---

**ROMIPLOSTIM**

**Indications** see notes above

**Cautions** monitor full blood count and peripheral blood smears for morphological abnormalities before and during treatment; monitor platelet count weekly until 50 \times 10^9/litre or more for at least 4 weeks without dose adjustment, then monthly thereafter

**Driving** Dizziness may affect performance of skilled tasks (e.g. driving)

**Hepatic impairment** manufacturer advises caution—no information available

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises avoid (toxicity in animal studies)

**Breast-feeding** manufacturer advises avoid—no information available
Side-effects  gastro-intestinal disturbances; palpitation, tachycardia, fluid retention; headache, dizziness, fatigue; anaemia; rash; *less commonly* pancreatitis, gastro-intestinal haemorrhage, congestive heart failure, hypertension, arrhythmias, syncope, chest pain, dyspnoea, sleep disturbances, paraesthesia, hypoaesthesia, should be considered, confusion, amnesia, fever, weight changes, impotence, blood disorders, myalgia, arthralgia, epistaxis, dry mouth, alopecia, skin discoloration, and pruritus; *rarely* gastroenteritis, colitis, postural hypotension, angina, myocardial infarction, vasodilatation, pulmonary hypotension, pulmonary infiltrates, migraine, drowsiness, impaired coordination, dysarthria, asthma, tinnitus, renal failure, nocturia, visual disturbances, and gingival bleeding; allergic alveolitis and hepatitis also reported

Dose

- Initially 500 micrograms twice daily adjusted according to response in steps of 500 micrograms at weekly intervals to max. 10 mg daily (max. single dose 2.5 mg); usual dose range 1–3 mg daily in divided doses

Xagrid® (Shire) ▼ [TA]
Capsules, anagrelide (as hydrochloride), 500 micrograms, net price 100-cap pack = £337.14. Counselling, driving, see above

9.1.5 G6PD deficiency

Glucose 6-phosphate dehydrogenase (G6PD) deficiency is highly prevalent in individuals originating from most parts of Africa, from most parts of Asia, from Oceania, and from Southern Europe; it can also occur, rarely, in any other individuals. G6PD deficiency is more common in males than it is in females.

Individuals with G6PD deficiency are susceptible to developing acute haemolytic anaemia when they eat fava beans (*Vicia faba*); this is termed *favism* and can be more severe in children or when the fresh fava beans are eaten raw.

When prescribing drugs for patients with G6PD deficiency, the following three points should be kept in mind:

- G6PD deficiency is genetically heterogeneous; susceptibility to the haemolytic risk from drugs varies; thus, a drug found to be safe in some G6PD-deficient individuals may not be equally safe in others;
- manufacturers do not routinely test drugs for their effects in G6FD-deficient individuals;
- the risk and severity of haemolysis is almost always dose-related.

The lists below should be read with these points in mind. Ideally, information about G6FD deficiency should be available before prescribing a drug listed below. However, in the absence of this information, the possibility of haemolysis should be considered, especially if the patient belongs to a group in which G6FD deficiency is common.

A very few G6FD-deficient individuals with chronic non-spherocytic haemolytic anaemia have haemolysis even in the absence of an exogenous trigger. These patients must be regarded as being at high risk of severe exacerbation of haemolysis following administration of any of the drugs listed below.

### Drugs with definite risk of haemolysis in most G6PD-deficient individuals

- Dapsone and other sulfones (higher doses for dermatitis herpetiformis more likely to cause problems)
- Methyleneblue (higher doses for dermatitis herpetiformis more likely to cause problems)

### Drugs with possible risk of haemolysis in some G6PD-deficient individuals

- Quinine (acceptable in acute malaria and malarias not currently on the market)
- Chloroquine (acceptable in acute malaria)
- Hydroxychloroquine (acceptable in acute malaria)
- Primaquine (30 mg weekly for 8 weeks has been found to be without undue harmful effects in African and Asian people, see section 5.4.1)
- Quinolones (including ciprofloxacin, moxifloxacin, nalidixic acid, norfloxacin, and ofloxacin)
- Rasburicase
- Sulfonamides (including co-trimoxazole; some sulfonamides, e.g. sulfadiazine, have been tested and found not to be haemolytic in many G6FD-deficient individuals)

Note: Methyleneblue in mothballs also causes haemolysis in individuals with G6PD deficiency

### Drugs used in neutropenia

Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropenia and thereby reduce the incidence of associated sepsis; there is as yet no evidence that it improves overall survival. Filgrastim (unglycosylated rhG-CSF) and lenograstim (glycosylated rhG-CSF) have similar effects; both have been used in a variety of clinical settings, but they do not have any clear-cut routine indications. In congenital neutropenia filgrastim usually increases the neutrophil count with an appropriate clinical response. Prolonged use may be associated with an increased risk of myeloid malignancy. Pegfilgrastim is a polyethylene glycol-conjugated (‘pegylated’) derivative of filgrastim; pegylation increases the duration of filgrastim activity. Granulocyte-colony stimulating factors should only be prescribed by those experienced in their use.
Cautions  Granulocyte-colony stimulating factors should be used with caution in patients with pre-malignant or malignant myeloid conditions. Full blood counts including differential white cell and platelet counts should be monitored. Treatment should be withdrawn in patients who develop signs of pulmonary infiltration. There have been reports of pulmonary infiltrates leading to acute respiratory distress syndrome—patients with a history of pulmonary infiltrates or pneumonia may be at higher risk. Granulocyte-colony stimulating factors should be used with caution in patients with sickle-cell disease. Spleen size should be monitored during treatment because there is a risk of splenomegaly and rupture.

Pregnancy  There have been reports of toxicity in animal studies and manufacturers advise not to use granulocyte-colony stimulating factors during pregnancy unless the potential benefit outweighs the risk.

Breast-feeding  There is no evidence for the use of granulocyte-colony stimulating factors during breast-feeding and manufacturers advise avoiding their use.

Side-effects  Side-effects of granulocyte-colony stimulating factors include gastro-intestinal disturbances, anorexia, headache, asthenia, fever, musculoskeletal pain, bone pain, rash, alopecia, injection-site reactions, thrombocytopenia, and leucocytosis. Less commonly, chest pain can occur. Pulmonary side-effects, particularly interstitial pneumonia (see Cautions above), cutaneous vasculitis and acute febrile neutrophilic dermatosis have rarely been reported.

Dose  
- Cytotoxic-induced neutropenia, preferably by subcutaneous injection or by intravenous infusion over 30 minutes, ADULT and CHILD, 500 000 units/kg daily started at least 24 hours after cytotoxic chemotherapy, continued until neutrophil count in normal range, usually for up to 14 days (up to 38 days in acute myeloid leukaemia)
- Myeloablative therapy followed by bone-marrow transplantation, by intravenous infusion over 24 hours, or by subcutaneous infusion over 24 hours, 1 million units/kg daily, started at least 24 hours following cytotoxic chemotherapy (and within 24 hours of bone-marrow infusion), then adjusted according to neutrophil count (consult product literature)
- Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone, by subcutaneous injection or by subcutaneous infusion over 24 hours, 1 million units/kg daily for 5–7 days; used following adjunctive myelosuppressive chemotherapy (to improve yield), by subcutaneous injection, 500 000 units/kg daily, started the day after completing chemotherapy and continued until neutrophil count in normal range; for timing of leucopheresis consult product literature
- Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion, by subcutaneous injection, ADULT under 60 years and CHILD over 16 years, 1 million units/kg daily for 4–5 days; for timing of leucopheresis consult product literature
- Severe chronic neutropenia, by subcutaneous injection, ADULT and CHILD, in severe congenital neutropenia, initially 1.2 million units/kg daily in single or divided doses (initially 500 000 units/kg daily in idiopathic or cyclic neutropenia), adjusted according to response (consult product literature)
- Persistent neutropenia in HIV infection, by subcutaneous injection, initially 500 000 units/kg daily, increased as necessary until neutrophil count in normal range (usual max. 400 000 units/kg daily), then adjusted to maintain neutrophil count in normal range (consult product literature)

FILGRASTIM  (Recombinant human granulocyte-colony stimulating factor, G-CSF)

Indications  (specialist use only) reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes); reduction in duration of neutropenia (and associated sequelae) in myeloblastic therapy followed by bone-marrow transplantation; mobilisation of peripheral blood progenitor cells for harvesting and subsequent autologous or allogeneic infusion; severe congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders, consult product literature); persistent neutropenia in advanced HIV infection

Cautions  see notes above; also regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia); secondary acute myeloid leukaemia; osteoporotic bone disease (monitor bone density if given for more than 6 months); Interactions: Appendix 1 (filgrastim)

Contra-indications  severe congenital neutropenia (Kostmann’s syndrome) with abnormal cytogenetics

Pregnancy  see notes above

Breast-feeding  see notes above

Side-effects  see notes above; also mucositis, splenic enlargement, hepatomegaly, transient hypotension, epistaxis, urinary abnormalities (including dysuria, proteinuria, and haematuria), osteoporosis, exacerbation of rheumatoid arthritis, anaemia, transient decrease in blood glucose, pseudogout, and raised uric acid; very rarely splenic rupture

Appendix 1 (filgrastim)
LENOGRASTIM
(Recombinant human granulocyte-colony stimulating factor, HuG-CSF)

**Indications** (specialist use only) reduction in the duration of neutropenia and associated complications following peripheral stem cells or bone-marrow transplantation for non-myeloid malignancy, or following treatment with cytotoxic chemotherapy associated with a significant incidence of febrile neutropenia; mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion

**Cautions** see notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also very rarely splenic rupture

**Dose**

- Following bone-marrow transplantation, by intravenous infusion or subcutaneous injection, ADULT and CHILD over 2 years 19.2 million units/m² daily started the day after transplantation, continued until neutrophil count stable in acceptable range (max. 28 days)

- Following peripheral stem cells transplantation, by intravenous infusion or subcutaneous injection, ADULT 19.2 million units/m² daily started the day after transplantation, continued until neutrophil count stable in acceptable range (max. 28 days); CHILD see BNF for Children

- Cytotoxic-induced neutropenia, by subcutaneous injection, ADULT 19.2 million units/m² daily started the day after completion of chemotherapy, continued until neutrophil count stable in acceptable range (max. 28 days); CHILD see BNF for Children

- Mobilisation of peripheral blood progenitor cells, used alone, by subcutaneous injection, ADULT 1.28 million units/kg daily for 4–6 days (5–6 days in healthy donors); used following adjunctive myelosuppressive chemotherapy (to improve yield), by subcutaneous injection, 19.2 million units/m² daily, started 1–5 days after completion of chemotherapy and continued until neutrophil count in acceptable range; for timing of leucapheresis consult product literature; CHILD see BNF for Children

**Granocyte®** (Chugai) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, powder for reconstitution, leugranostim, net price 13.4 million-unit (105-microgram) vial = £40.11; 33.6 million-unit (263-microgram) vial = £62.54 (both with 1-mL prefilled syringe water for injections)

**Ratiograstim®** (Ratiopharm UK) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, prefilled syringe, filgrastim, net price 30 million-units (300 micrograms)/0.5 mL = £62.26; 48 million-units (480 micrograms)/0.8 mL = £99.29

**Note** Biosimilar medicine, p. 1

**Tevaragristim®** (TEVA UK) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, prefilled syringe, filgrastim, net price 30 million-units (300 micrograms)/0.5 mL = £59.00; 48 million-units (480 micrograms)/0.5 mL = £94.00

**Note** Biosimilar medicine, p. 1

**Zarzio®** (Sandoz) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, prefilled syringe, filgrastim, net price 30 million-units (300 micrograms)/0.5 mL = £59.00; 48 million-units (480 micrograms)/0.5 mL = £94.00

**Note** Biosimilar medicine, p. 1

**PEGFILGRASTIM**
(Pegylated recombinant methionyl human granulocyte-colony stimulating factor)

**Indications** (specialist use only) reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes)

**Cautions** see notes above; also acute leukaemia and myelosuppressive chemotherapy; **interactions:** Appendix 1 (filgrastim)

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see notes above; also acute leukaemia and myelosuppressive chemotherapy

**Dose**

- By subcutaneous injection, ADULT over 18 years, 6 mg (0.6 mL) for each chemotherapy cycle, starting 24 hours after chemotherapy

**Neulasta®** (Amgen) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, pegfilgrastim (expressed as filgrastim) 10 mg/mL, net price 0.6-mL (6-mg) prefilled syringe = £686.38

**9.1.7 Drugs used to mobilise stem cells**

Plerixafor is a chemokine receptor antagonist licensed to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or multiple myeloma. Plerixafor should be given under specialist supervision following 4 days treatment with a granulocyte-colony stimulating factor (section 9.1.6)

**PLERIXAFOR**

**Indications** see notes above

**Cautions** monitor platelet and white blood cell count

**Renal impairment** reduce dose to 160 micrograms/kg daily if creatinine clearance 20–50 mL/minute; no information available if creatinine clearance less than 20 mL/minute

**Pregnancy** manufacturer advises avoid unless essential and use effective contraception during treatment—teratogenic in animal studies

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** gastro-intestinal disturbances, dry mouth, oral hypoesthesia; dizziness, headache, insomnia, fatigue; arthralgia, musculoskeletal pain; erythema, sweating; injection-site reactions; less commonly hypersensitivity reactions including dyspnoea and periorbital swelling

**Dose**

- By subcutaneous injection, ADULT over 18 years, 240 micrograms/kg daily 6–11 hours before initiation of apheresis; usual duration 2–4 days (max. 7 days)

**Mozobil®** (Genzyme) (BNF 61 9.1.7 Drugs used to mobilise stem cells)

**Injection**, plerixafor 20 mg/mL, net price 1.2 mL-vial = £4882.77

**Electrolytes Na+ < 0.5 mmol/mL**
in this section. Oral preparations for removing excess potassium and preparations for oral rehydration therapy are also included here. Oral bicarbonate, for metabolic acidosis, is also described in this section. For reference to calcium, magnesium, and phosphate, see section 9.5.

**Compensation for potassium loss** is especially necessary:
- in those taking digoxin or anti-arrhythmic drugs, where potassium depletion may induce arrhythmias;
- in patients in whom secondary hyperaldosteronism occurs, e.g. renal artery stenosis, cirrhosis of the liver, the nephrotic syndrome, and severe heart failure;
- in patients with excessive losses of potassium in the faeces, e.g. chronic diarrhoea associated with intestinal malabsorption or laxative abuse.

Measures to compensate for potassium loss may also be required in the elderly since they frequently take inadequate amounts of potassium in the diet (but see below for warning on renal insufficiency). Measures may also be required during long-term administration of drugs known to induce potassium loss (e.g. corticosteroids). Potassium supplements are *seldom required* with the small doses of diuretics given to treat hypertension; *potassium-sparing diuretics* (rather than potassium supplements) are recommended for prevention of hypokalaemia due to diuretics such as furosemide or the thiazides when these are given to eliminate oedema.

**Dosage** If potassium salts are used for the prevention of hypokalaemia, then doses of potassium chloride 2 to 4 g (approx. 25 to 50 mmol) daily (in divided doses) by mouth are suitable in patients taking a normal diet. *Smaller doses must be used if there is renal insufficiency* (common in the elderly) to reduce the risk of hyperkalaemia. Potassium salts cause nausea and vomiting and poor compliance is a major limitation to their effectiveness; when appropriate, potassium-sparing diuretics are preferable (see also above). Regular monitoring of plasma-potassium concentration is essential in those taking potassium supplements. When there is *established potassium depletion* larger doses may be necessary, the quantity depending on the severity of any continuing potassium loss (monitoring of plasma-potassium concentration and specialist advice would be required). Potassium depletion is frequently associated with chloride depletion and with metabolic alkalosis, and these disorders require correction.

**Administration** Potassium salts are preferably given as a liquid (or effervescent) preparation, rather than modified-release tablets; they should be given as the chloride (the use of effervescent potassium tablets BPC 1968 should be restricted to hyperchloraemic states, section 9.2.1.3). Silt substitutes A number of salt substitutes which contain significant amounts of potassium chloride are readily available as health food products (e.g. LoSalt® and Ruthmol®). These should not be used by patients with renal failure as potassium intoxication may result.
Acute severe hyperkalaemia (plasma-potassium concentration above 6.5 mmol/L or in the presence of ECG changes) calls for urgent treatment with 10–20 mL of calcium gluconate 10% by slow intravenous injection, titrated and adjusted to ECG improvement, to temporarily protect against myocardial excitability. An intravenous injection of soluble insulin (5–10 units) with 50 mL glucose 50% given over 5–15 minutes, reduces serum-potassium concentration; it is repeated if necessary or a continuous infusion instituted. Salbutamol [unlicensed indication], by nebulisation or slow intravenous injection may also reduce plasma-potassium concentration; it should be used with caution in patients with cardiovascular disease. The correction of causal or compounding acidosis with sodium bicarbonate infusion (section 9.2.2) should be considered (important: preparations of sodium bicarbonate and calcium salts should not be administered in the same line—risk of precipitation). Drugs exacerbating hyperkalaemia should be reviewed and stopped as appropriate; occasionally haemodialysis is needed.

Management of hyperkalaemia

Ion-exchange resins may be used to remove excess potassium in mild hyperkalaemia or in moderate hyperkalaemia when there are no ECG changes.

POTASSIUM CHLORIDE

**Indications** potassium depletion (see notes above)

**Cautions** see notes above; cardiac disease; elderly; with modified-release preparations, intestinal stricture, history of peptic ulcer, hiatus hernia; interactions: Appendix 1 (potassium salts)

**Contra-indications** plasma-potassium concentration above 5 mmol/litre

**Renal impairment** close monitoring required—risk of hyperkalaemia; avoid in severe impairment

**Side-effects** nausea, vomiting, abdominal pain, diarrhoea, flatulence; with modified-release preparations, gastrointestinal obstruction, ulceration and bleeding also reported

**Dose**

- See notes above

**Note** Do not confuse Effervescent Potassium Tablets BPC 1968 (section 9.2.1) with effervescent potassium chloride tablets. Effervescent Potassium Tablets BPC 1968 do not contain chloride ions and their use should be restricted to hyperchloraemic states (section 9.2.1.3).

**Kay-Cee-L** (Geistlich)

**Syrup**, sugar-free, red, potassium chloride 7.5% (1 mmol/mL each of K⁺ and Cl⁻), net price 500 mL = £4.07. Label: 21

**Sando-K** (HK Pharma)

**Tablets**, effervescent, potassium bicarbonate and chloride equivalent to potassium 470 mg (12 mmol of K⁺) and chloride 285 mg (8 mmol of Cl⁻). Net price 20 = £1.53. Label: 13, 21

**Modified-release preparations**

Avoid unless effervescent tablets or liquid preparations inappropriate

**Slow-K** (Alliance)

**Tablets**, m/t, orange, s/c, potassium chloride 600 mg (8 mmol each of K⁺ and Cl⁻), net price 100 = £2.14. Label: 25, 27, counselling, swallow whole with fluid during meals while sitting or standing

**POLYSTYRENE SULPHONATE RESINS**

**Indications** hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients

**Cautions** children (impaction of resin with excessive dosage or inadequate dilution); monitor for electrolyte disturbances (stop if plasma-potassium concentration below 5 mmol/litre); sodium-containing resin in congestive heart failure, hypertension, and oedema; interactions: Appendix 1 (polystyrene sulphonate resins)

**Contra-indications** obstructive bowel disease; neoplasms with reduced gut motility; calcium-containing resin in hyperparathyroidism, multiple myeloma, sarcoidosis, or metastatic carcinoma

**Renal impairment** use sodium-containing resin with caution

**Pregnancy** manufacturers advise use only if potential benefit outweighs risk—no information available

**Breast-feeding** manufacturers advise use only if potential benefit outweighs risk—no information available

**Side-effects** faecal impaction following rectal administration, gastro-intestinal concretions following oral administration, intestinal necrosis reported with concomitant use of sorbitol, gastric irritation, anorexia, nausea, vomiting, constipation (discontinue treatment—avoid magnesium-containing laxatives), diarrhoea, hypomagnesaemia; gastro-intestinal obstruction, ulceration, necrosis, and ischaemic colitis also reported; with calcium-containing resin, hyperkalaemia (including in dialysed patients and occasionally in those with renal impairment); with sodium-containing resin, sodium retention, hypocaulaemia

**Dose**

- **By mouth**, 15 g 3–4 times daily in water (not fruit squash which has a high potassium content) or as a paste; **CHILD** 0.5–1 g/kg daily in divided doses

- **By rectum**, as an enema, 30 g in methylcellulose solution, retained for 9 hours followed by irrigation to remove resin from colon; **NEONATE** and **CHILD**, 0.5–1 g/kg daily

**Calcium Resonium®** (Sanofi-Aventis)

**Powder**, buff, calcium polystyrene sulphonate. Net price 300 g = £68.47. Label: 13

**Resonium A** (Sanofi-Aventis)

**Powder**, buff, sodium polystyrene sulphonate. Net price 454 g = £67.50. Label: 13

**9.2.1.2 Oral sodium and water**

Sodium chloride is indicated in states of sodium depletion and usually needs to be given intravenously (section 9.2.2). In chronic conditions associated with mild or moderate degrees of sodium depletion, e.g. in salt-losing bowel or renal disease, oral supplements of sodium chloride or sodium bicarbonate (section 9.2.1.3), according to the acid-base status of the patient, may be sufficient.
SODIUM CHLORIDE

Indications  sodium depletion—see also 9.2.2.1; nebuliser diluent (section 3.1.5); eye (section 11.8.1); oral hygiene (section 13.11.1)

Slow Sodium® (HK Pharma)
Tablets, m/tablet, sodium chloride 600 mg (approx. 10 mmol each of Na\(^+\) and Cl\(^-\)). Net price 100-tab pack = £0.05. Label: 25

Dose  prophylaxis of sodium chloride deficiency 4–8 tablets daily with water (in severe depletion up to max. 20 tablets daily)

Oral rehydration solutions used in the UK are lower in sodium, potassium, and glucose or another carbohydrate such as starch.

Oral rehydration solutions should:
- enhance the absorption of water and electrolytes;
- replace the electrolyte deficit adequately and safely;
- contain an alkalinising agent to counter acidosis;
- be slightly hypo-osmolar (about 250 mmol/litre) to prevent the possible induction of osmotic diarrhoea;
- be simple to use in hospital and at home;
- be palatable and acceptable, especially to children;  
- be readily available.

It is the policy of the World Health Organization (WHO) to promote a single oral rehydration solution but to use it flexibly (e.g. by giving extra water between drinks of oral rehydration solution to moderately dehydrated infants).

Oral rehydration solutions used in the UK are lower in sodium (50–60 mmol/litre) than the WHO formulation since, in general, patients suffer less severe sodium loss. Rehydration should be rapid over 3 to 4 hours (except in hypernatraemic dehydration in which case rehydration should occur more slowly over 12 hours). The patient should be reassessed after initial rehydration and if still dehydrated rapid fluid replacement should continue.

Once rehydration is complete further dehydration is prevented by encouraging the patient to drink normal volumes of an appropriate fluid and by replacing continuing losses with an oral rehydration solution; in infants, breast-feeding or formula feeds should be offered between oral rehydration drinks.

For intravenous rehydration see section 9.2.2.

ORAL REHYDRATION SALTS (ORS)

Indications  fluid and electrolyte loss in diarrhoea, see notes above

Dose  According to fluid loss, usually 200–400 mL solution after every loose motion; INFANT 1–1½ times usual feed volume; CHILD 200 mL after every loose motion

UK formulations  After reconstitution any unused solution should be discarded no later than 1 hour after preparation unless stored in a refrigerator when it may be kept for up to 24 hours

Dioralyte® (Sanofi-Aventis)

Oral powder, sodium chloride 470 mg, potassium chloride 300 mg, disodium hydrogen citrate 550 mg, glucose 3.56 g sachet, net price 6-sachet pack = £2.25, 20-sachet pack (black currant- or citrus-flavoured or natural) = £6.72
Note  Reconstitute 1 sachet with 200 mL of water (frequently boiled and cooled for infants). 5 sachets reconstituted with 1 litre of water provide Na\(^+\) 60 mmol, K\(^+\) 20 mmol, Cl\(^-\) 60 mmol, citrate 10 mmol, and glucose 90 mmol

Dioralyte® Relief (Sanofi-Aventis)

Oral powder, sodium chloride 350 mg, potassium chloride 300 mg, sodium citrate 580 mg, cooked rice powder 6 g/sachet, net price 6-sachet pack (apricot-, black currant- or raspberry-flavoured) = £2.50, 20-sachet pack (apricot-flavoured) = £7.13
Note  Reconstitute 1 sachet with 200 mL of water (frequently boiled and cooled for infants). 5 sachets reconstituted with 1 litre of water provide Na\(^+\) 60 mmol, K\(^+\) 20 mmol, Cl\(^-\) 60 mmol and citrate 10 mmol, contains aspartame (section 9.4.1)

Electrolade® (Actavis)

Oral powder, sodium chloride 236 mg, potassium chloride 300 mg, sodium bicarbonate 500 mg, anhydrous glucose 4 g/sachet (banana-, black currant-, lemon and lime-, or orange-flavoured). Net price 6-sachet pack (plain or multiflavoured) pack = £1.33, 20-sachet pack (single- or multiflavoured) pack = £4.99
Note  Reconstitute 1 sachet with 200 mL of water (frequently boiled and cooled for infants). 5 sachets reconstituted with 1 litre of water provide Na\(^+\) 90 mmol, K\(^+\) 20 mmol, Cl\(^-\) 40 mmol, HCO\(_3\)\(^-\) 30 mmol, and glucose 111 mmol

WHO formulation  Oral Rehydration Salts (Non-proprietary)

Oral powder, sodium chloride 2.6 g, potassium chloride 1.5 g, sodium citrate 2.9 g, anhydrous glucose 13.5 g. To be dissolved in sufficient water to produce 1 litre (providing Na\(^+\) 75 mmol, K\(^+\) 20 mmol, Cl\(^-\) 65 mmol, citrate 10 mmol, glucose 75 mmol/litre)
Note  Recommended by the WHO and the United Nations Children’s Fund but not commonly used in the UK

9.2.1.3 Oral bicarbonate

Sodium bicarbonate is given by mouth for chronic acidicotic states such as ureamic acidosis of renal tubular acidosis. The dose for correction of metabolic acidosis is not predictable and the response must be assessed; sodium bicarbonate 4.8 g daily (57 mmol each of Na\(^+\) and HCO\(_3\)\(^-\)) or more may be required. For severe metabolic acidosis, sodium bicarbonate can be given intravenously (section 9.2.2).

Sodium bicarbonate may also be used to increase the pH of the urine (see section 7.4.3); for use in dyspepsia see section 1.1.1.

Sodium supplements may increase blood pressure or cause fluid retention and pulmonary oedema in those at risk; hypokalaemia may be exacerbated.

Where hyperchloraemic acidosis is associated with potassium deficiency, as in some renal tubular and gastro-intestinal disorders it may be appropriate to give oral potassium bicarbonate, although acute or severe deficiency should be managed by intravenous therapy.
**SODIUM BICARBONATE**

**Indications**  
see notes above

**Cautions**  
see notes above; avoid in respiratory acidosis; interactions: Appendix 1 (antacids)

**Hepatic Impairment**  
section 1.1.1

**Dose**

- See notes above

**Sodium Bicarbonate** (Non-proprietary)

**Capsules**, sodium bicarbonate 500 mg (approx. 6 mmol each of Na⁺ and HCO₃⁻), net price 56-cap pack = £5.16

**Tablets**, sodium bicarbonate 600 mg, net price 100 = £2.48

**Important** Oral solutions of sodium bicarbonate are required occasionally; these are available from 'special-order' manufacturers or specialist importing companies, see p. 988; the strength of sodium bicarbonate should be stated on the prescription

**POTASSIUM BICARBONATE**

**Indications**  
see notes above

**Cautions**  
elderly; cardiac disease; interactions: Appendix 1 (potassium salts)

**Contra-indications**  
hypochloraemia; plasma-potassium concentration above 5 mmol/litre

**Renal impairment**  
close monitoring required—high risk of hyperkalaemia; avoid in severe impairment

**Side-effects**  
nausea, vomiting, abdominal pain, diarrhoea, and flatulence

**Dose**

- See notes above

**Potassium Tablets, Effervescent** (Non-proprietary)

**Effervescent tablets**, potassium bicarbonate 500 mg, potassium acid tartrate 300 mg, each tablet providing 6.5 mmol of K⁺. To be dissolved in water before administration. Net price 56-cap pack = £33.38. Label: 13, 21

*Note* These tablets do not contain chloride; for effervescent tablets containing potassium and chloride, see under Potassium Chloride, section 9.2.1.1

9.2.2 Parenteral preparations for fluid and electrolyte imbalance

9.2.2.1 Electrolytes and water

9.2.2.2 Plasma and plasma substitutes

**9.2.2.1 Electrolytes and water**

Solutions of electrolytes are given intravenously to meet normal fluid and electrolyte requirements or to replenish substantial deficits or continuing losses, when the patient is nauseated or vomiting and is unable to take adequate amounts by mouth. When intravenous administration is not possible, fluid (as sodium chloride 0.9% or glucose 5%) can also be given by subcutaneous infusion (hypodermoclysis).

The nature and severity of the electrolyte imbalance must be assessed from the history and clinical and biochemical investigations. Sodium, potassium, chloride, magnesium, phosphate, and water depletion can occur singly and in combination with or without disturbances of acid-base balance; for reference to the use of magnesium and phosphates, see section 9.5.

Isotonic solutions may be infused safely into a peripheral vein. Solutions more concentrated than plasma, e.g. 20% glucose, are best given through an indwelling catheter positioned in a large vein.

**Intravenous sodium**

Sodium chloride in isotonic solution provides the most important extracellular ions in near physiological concentrations and is indicated in sodium depletion, which can arise from such conditions as gastro-enteritis, diabetic ketoacidosis, ileus, and ascites. In a severe deficit of 4 to 8 litres, 2 to 3 litres of isotonic sodium chloride may be given over 2 to 3 hours; thereafter the infusion can usually be at a slower rate. Excessive administration should be avoided; the jugular venous pressure should be assessed; the bases of the lungs should be examined for crepitations, and in elderly or seriously ill patients it is often helpful to monitor the right atrial (central) venous pressure.

Chronic hyponatraemia arising from inappropriate secretion of antidiuretic hormone should ideally be corrected by fluid restriction. However, if sodium chloride is required for acute or chronic hyponatraemia, regardless of the cause, the deficit should be corrected slowly to avoid the risk of osmotic demyelination syndrome and the rise in plasma-sodium concentration should not exceed 10 mmol/litre in 24 hours. In severe hyponatraemia, sodium chloride 1.8% may be used cautiously.

Compound sodium lactate (Hartmann’s solution) can be used instead of isotonic sodium chloride solution during or after surgery, or in the initial management of the injured or wounded; it may reduce the risk of hyperchloraemic acidosis.

Sodium chloride and glucose solutions are indicated when there is combined water and sodium depletion. A 1:1 mixture of isotonic sodium chloride and 5% glucose allows some of the water (free of sodium) to enter body cells which suffer most from dehydration while the sodium salt with a volume of water determined by the normal plasma Na⁺ remains extracellular. Maintenance fluid should accurately reflect daily requirements and close monitoring is required to avoid fluid and electrolyte imbalance. Illness or injury increase the secretion of antidiuretic hormone should ideally be secreted; it may reduce the risk of osmotic demyelination syndrome arising from inappropriate secretion of antidiuretic hormone and therefore the ability to excrete excess water may be impaired. Injudicious use of hypotonic solutions such as sodium chloride 0.18% and glucose 4% may also cause dilutional hyponatraemia especially in children and the elderly; if necessary, guidance should be sought from a clinician experienced in the management of fluid and electrolytes.

Combined sodium, potassium, chloride, and water depletion may occur, for example, with severe diarrhoea or persistent vomiting; replacement is carried out with sodium chloride intravenous infusion 0.9% and glucose intravenous infusion 5% with potassium as appropriate.

**SODIUM CHLORIDE**

**Indications**  
electrolyte imbalance—see also section 9.2.1.2; nebuliser diluent (section 3.1.5); eye (section 11.8.1); oral hygiene (section 12.3.4); wound irrigation (section 13.11.1)
Cautions restrict intake in impaired renal function, cardiac failure, hypertension, peripheral and pulmonary oedema, toxemia of pregnancy

Side-effects administration of large doses may give rise to sodium accumulation, oedema, and hyperchloraeic acidosis

Dose

- See notes above

Sodium Chloride Intravenous Infusion (Non-proprietary)$$$\text{Intravenous infusion, usual strength sodium chloride 0.9\% (9 g, 150 mmol Na}^+\text{ and Cl}^–\text{/litre), this strength being supplied when normal saline for injection is requested. Net price 2-mL amp = £3.26; 5-mL amp = £3.86; 10-mL amp = £5.26; 20-mL amp = £8.26.}

In hospitals, 500- and 1000-mL packs, and sometimes other sizes, are available

Note: The term ‘normal saline’ should not be used to describe sodium chloride intravenous infusion 0.9%; the term ‘physiological saline’ is acceptable but it is preferable to give the composition (i.e. sodium chloride intravenous infusion 0.9%).

With other ingredients

Sodium Chloride and Glucose Intravenous Infusion (Non-proprietary)$$$\text{Intravenous infusion, sodium chloride 0.18\% (Na}^+\text{ and Cl}^–\text{each 30 mmol/litre), glucose 4\%. In hospitals, usually 500-mL packs and sometimes other sizes are available.}

Intravenous infusion, sodium chloride 0.45\% (Na}^+\text{ and Cl}^–\text{each 75 mmol/litre), glucose 2.5\%. In hospitals, usually 500-mL packs and sometimes other sizes are available.}

Intravenous infusion, sodium chloride 0.45\% (Na}^+\text{ and Cl}^–\text{each 75 mmol/litre), glucose 5\%. In hospitals, usually 500-mL packs and sometimes other sizes are available.}

Intravenous infusion, sodium chloride 0.9\% (Na}^+\text{ and Cl}^–\text{each 150 mmol/litre), glucose 5\%. In hospitals, usually 500-mL packs and sometimes other sizes are available.}

Note: See above for warning on hyponatraemia especially in children and elderly

Ringer’s Solution for Injection $$$\text{Calcium chloride (dihydrate) 322 micrograms, potassium chloride 30 micrograms, sodium chloride 8.6 mg/mL, providing the following ions (in mmol/litre), Ca}^{2+}\text{ 2.2, K}^+\text{ 4, Na}^+\text{ 147, Cl}^–\text{ 156. In hospitals, 500- and 1000-mL packs, and sometimes other sizes, are available.}

Sodium Lactate Intravenous Infusion, Compound (Non-proprietary) $$$\text{(Hartmann’s Solution for Injection; Ringer-Lactate Solution for Injection) Intravenous infusion, sodium chloride 0.6\%, sodium lactate 0.32\%, potassium chloride 0.04\%, calcium chloride 0.027\% (containing Na}^+\text{ 131 mmol, K}^+\text{ 5 mmol, Ca}^{2+}\text{ 2 mmol, HCO}_3^–\text{ (as lactate) 29 mmol, Cl}^–\text{ 111 mmol/litre). In hospitals, 500- and 1000-mL packs, and sometimes other sizes, are available.}

Intravenous glucose

Glucose solutions (5\%) are used mainly to replace water deficit and should not be given alone except when there is no significant loss of electrolytes; prolonged administration of glucose solutions without electrolytes can lead to hyponatraemia and other electrolyte disturbances. Average water requirements in a healthy adult are 1.5 to 2.5 litres daily and this is needed to balance unavoidable losses of water through the skin and lungs and to provide sufficient for urinary excretion. Water depletion (dehydration) tends to occur when these losses are not matched by a comparable intake, as may occur in coma or dysphagia or in the elderly or apathetic who may not drink enough water on their own initiative.

Excessive loss of water without loss of electrolytes is uncommon, occurring in fevers, hyperthyroidism, and in uncommon water-losing renal states such as diabetes insipidus or hypercalcaemia. The volume of glucose solution needed to replace deficits varies with the severity of the disorder, but usually lies within the range of 2 to 6 litres.

Glucose solutions are also used to correct and prevent hypoglycaemia and to provide a source of energy in those too ill to be fed adequately by mouth; glucose solutions are a key component of parenteral nutrition (section 9.3).

Glucose solutions are given in regimens with calcium and insulin for the emergency management of hyperkalaemia (see p. 595). They are also given, after correction of hyperglycaemia, during treatment of diabetic ketoacidosis, when they must be accompanied by continuing insulin infusion.

GLUCOSE (Dextrose Monohydrate)

Note: Glucose BP is the monohydrate but Glucose Intravenous Infusion BP is a sterile solution of anhydrous glucose or glucose monohydrate, potency being expressed in terms of anhydrous glucose

Indications fluid replacement (see notes above), provision of energy (section 9.3); hypoglycaemia (section 6.1.4)

Side-effects glucose injections especially if hypertonic may have a low pH and may cause venous irritation and thrombophlebitis

Dose

- Water replacement, see notes above; energy source, 1–3 litres daily of 20–50\% solution

Glucose Intravenous Infusion (Non-proprietary) $$$\text{Intravenous infusion, glucose or anhydrous glucose (potency expressed in terms of anhydrous glucose), usual strength 5\% (50 mg/mL), 10\% (100 mg/mL), and 20\% (200 mg/mL); 20\% solution, net price 20-mL amp = £2.04; 50\% solution, 20-mL amp = £9.50; 50-mL vial = £2.13. In hospitals, 500- and 1000-mL packs, and sometimes other sizes and strengths, are available; also available as Minipor\textsuperscript{®} Glucose, 50\% in 50-mL disposable syringes.}

1. \text{restriction does not apply where administration is for saving life in emergency}

Intravenous potassium

Potassium chloride and sodium chloride intravenous infusion is the initial treatment for the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth. Ready-mixed infusion solutions should be used when possible; alternatively, potassium chloride concentrate, as ampoules containing 1.5 g
Potassium Chloride Concentrate, Sterile (Non-proprietary) 
Sterile concentrate, potassium chloride 15% (150 mg, approximately 2 mmol each of K⁺ and Cl⁻ /mL). Net price 10-mL amp = 48p
Important Must be diluted with not less than 50 times its volume of sodium chloride intravenous infusion 0.9% or other suitable diluent and mixed well
Solutions containing 10 and 20% of potassium chloride are also available in both 5- and 10-mL ampoules

Bicarbonate and lactate

Sodium bicarbonate is used to control severe metabolic acidosis (pH < 7.1) particularly that caused by loss of bicarbonate (as in renal tubular acidosis or from excessive gastro-intestinal losses). Mild metabolic acidosis associated with volume depletion should first be managed by appropriate fluid replacement because acidosis usually resolves as tissue and renal perfusion are restored. In more severe metabolic acidosis or when the acidosis remains unresponsive to correction of anoxia or hypovolaemia, sodium bicarbonate (1.26%) can be infused over 3–4 hours with plasma-pH and electrolyte monitoring. In severe shock (section 2.7.1), for example in cardiac arrest, metabolic acidosis can develop without sodium or volume depletion; in these circumstances sodium bicarbonate is best given as a small volume of hypertonic solution, such as 50 mL of 8.4% solution intravenously; plasma-pH and electrolytes should be monitored.

Sodium lactate intravenous infusion is no longer used in metabolic acidosis because of the risk of producing lactic acidosis, particularly in seriously ill patients with poor tissue perfusion or impaired hepatic function. For chronic acidotic states, sodium bicarbonate can be given by mouth (section 9.2.1.3).
Water

Water for Injections

Net price 1-mL amp = £0.18; 2-mL amp = £0.20; 5-mL amp = £0.38; 10-mL amp = £0.78; 50-mL amp = £1.19; 100-mL vial = £2.01

9.2.2.2 Plasma and plasma substitutes

Plasma and plasma substitutes (‘colloids’) contain large molecules that do not readily leave the intravascular space where they exert osmotic pressure to maintain circulatory volume. Compared to fluids containing electrolytes such as sodium chloride and glucose (‘crystalloids’), a smaller volume of colloid is required to produce the same expansion of blood volume, thereby shifting salt and water from the extravascular space. If resuscitation requires a volume of fluid that exceeds the maximum dose of the colloid then crystalloids can be given; packed red cells may also be required.

Albumin solutions, prepared from whole blood, contain soluble proteins and electrolytes but no clotting factors, blood group antibodies, or plasma coagulation factors; they may be given without regard to the recipient’s blood group.

Albumin is usually used after the acute phase of illness, to correct a plasma-volume deficit; hypoalbuminaemia itself is not an appropriate indication. The use of albumin solutions in acute plasma or blood loss may be wasteful; plasma substitutes are more appropriate. Concentrated albumin solutions (20%) can be used under specialist supervision in patients with an intravascular fluid deficit and oedema because of interstitial fluid overload, to restore intravascular plasma volume with less exacerbation of the salt and water overload than isotonic solutions. Concentrated albumin solutions may also be used to obtain a diuresis in hypoalbuminaemic patients (e.g. in hepatic cirrhosis).

Recent evidence does not support the previous view that the use of albumin increases mortality.

Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

ALBUMIN SOLUTION

(Human Albumin Solution)

A solution containing protein derived from plasma, serum, or normal placentas; at least 95% of the protein is albumin. The solution may be isotonic (containing 3.5–5% protein) or concentrated (containing 15–25% protein).

Indications see under preparations, and also notes above

Cautions history of cardiac or circulatory disease (administer slowly to avoid rapid rise in blood pressure and cardiac failure, and monitor cardiovascular and respiratory function); increased capillary permeability; correct dehydration when administering concentrated solution

Contra-indications cardiac failure; severe anaemia

Side-effects hypersensitivity reactions (including anaphylaxis) with nausea, vomiting, increased salivation, fever, tachycardia, hypotension and chills reported

Isotonic solutions

Indications: acute or sub-acute loss of plasma volume e.g. in burns, pancreatitis, trauma, and complications of surgery; plasma exchange

Available as: Human Albumin Solution 4.5% (50-, 100-, 250- and 400-mL bottles—Baxter); Human Albumin Solution 5% (250- and 500-mL bottles—Baxter); Albunorm® 5% (100-, 250-, and 500-mL bottles—Octapharm); Octalbin® 5% (100- and 250-mL bottles—Octapharm); Zenalb® 4.5% (50-, 100-, 250-, and 500-mL bottles—BPL)

Concentrated solutions (20%)

Indications: severe hypoalbuminaemia associated with low plasma volume and generalised oedema where salt and water restriction with plasma volume expansion are required; adjunct in the treatment of hyperbilirubinaemia by exchange transfusion in the newborn; paracentesis of large volume ascites associated with portal hypertension

Available as: Human Albumin Solution 20% (50- and 100-mL vials—Baxter); Albunorm® 20% (50- and 100-mL bottles—Octapharm); Flexalbin® 20% (50- and 100-mL bags—Baxter); Octalbin® 20% (50- and 100-mL bottles—Octapharm); Zenalb® 20% (50- and 100-mL bottles—BPL)

Plasma substitutes

Dextran, gelatin, and the etherified starches (hetastarch, pentastarch, and tetrastarch) are macromolecular substances which are metabolised slowly; they may be used at the outset to expand and maintain blood volume in shock arising from conditions such as burns or septicemia. Plasma substitutes may be used as an immediate short-term measure to treat haemorrhage until blood is available. They are rarely needed when shock is due to sodium and water depletion because, in these circumstances, the shock responds to water and electrolyte repletion; see also section 2.7.1 for the management of shock.

Plasma substitutes should not be used to maintain plasma volume in conditions such as burns or peritonitis where there is loss of plasma protein, water, and electrolytes over periods of several days or weeks. In these situations, plasma or plasma protein fractions containing large amounts of albumin should be given.

Large volumes of some plasma substitutes can increase the risk of bleeding through depletion of coagulation factors.

Dextran 70 by intravenous infusion is used for volume expansion. Dextran may interfere with blood group cross-matching or biochemical measurements, and these should be carried out before infusion is begun.

Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

Cautions Plasma substitutes should be used with caution in patients with cardiac disease, liver disease, or renal impairment; urine output should be monitored. Care should be taken to avoid haematocrit concentra-
tion from falling below 25–30% and the patient should be monitored for hypersensitivity reactions.

**Side-effects**  Hypersensitivity reactions may occur including, rarely, severe anaphylactic reactions. Transient increase in bleeding time may occur.

### DEXTRAN 70
Dextran of weight average molecular weight about “70 000”

**Indications** short-term blood volume expansion

**Cautions** see notes above; can interfere with some laboratory tests (see also above); where possible, monitor central venous pressure

**Pregnancy** avoid—reports of anaphylaxis in mother causing fetal anoxia, neurological damage and death

**Side-effects** see notes above

**Dose**
- See under preparations below

### Hypertonic solution
**RescueFlow** (Vitaline)\(^{(Y)}\)

**Intravenous infusion**, dextran 70 intravenous infusion 6% in sodium chloride intravenous infusion 7.5%. Net price 250-mL bag = £28.50

**Cautions** see notes above; severe hyperglycaemia and hyperosmolality

**Dose** initial treatment of hypovolaemia with hypotension induced by traumatic injury, *by intravenous infusion* over 2–5 minutes, 250 mL, followed immediately by administration of isotonic fluids

### GELATIN
**Note** The gelatin is partially degraded

**Indications** low blood volume (but see notes above)

**Cautions** see notes above

**Pregnancy** manufacturer of Geloplasma\(^{(Y)}\) advises avoid at the end of pregnancy

**Side-effects** see notes above

**Dose**
- *By intravenous infusion*, initially 500–1000 mL of a 3.5–4% solution (see notes above)

**Gelofusine** (Braun)\(^{(Y)}\)

**Intravenous infusion**, succinylated gelatin (modified fluid gelatin, average molecular weight 30 000) 40 g (4%), Na\(^+\) 154 mmol, Cl\(^-\) 125 mmol/litre, net price 500-mL bag = £4.70, 1-litre bag = £9.09

**Isoplex** (Beacon)\(^{(Y)}\)

**Intravenous infusion**, succinylated gelatin (modified fluid gelatin, average molecular weight 30 000) 40 g (4%), Na\(^+\) 154 mmol, Cl\(^-\) 125 mmol/litre, net price 500-mL bag = £4.70, 1-litre bag = £9.09

**Volplex** (Beacon)\(^{(Y)}\)

**Intravenous infusion**, succinylated gelatin (modified fluid gelatin, average molecular weight 30 000) 40 g (4%), Na\(^+\) 154 mmol, Cl\(^-\) 125 mmol/litre, net price 500-mL bag = £4.70, 1-litre bag = £9.09

### Etherified Starch
A starch composed of more than 90% of amylopectin that has been etherified with hydroxyethyl groups; the terms tetrasacth, pentastarch, and hetastarch reflect the degree of etherification

**Indications** low blood volume

**Cautions** see notes above; children

**Renal impairment** use with caution in mild to moderate impairment; avoid in severe impairment

**Side-effects** see notes above; also pruritus, raised serum amyrase

**Dose**
- *See under preparations below*

### Hetastarch
**Hetastarch** (Non-proprietary)\(^{(Y)}\)

**Intravenous infusion**, hetastarch (weight average molecular weight 450 000) 6% in sodium chloride intravenous infusion 0.9%, net price 500-mL bag = £8.00

**Dose** *by intravenous infusion*, 500–1000 mL; usual daily max. 1500 mL (see notes above)

### Pentastarch
**Pentastarch** (Non-proprietary)\(^{(Y)}\)

**Intravenous infusion**, pentastarch (weight average molecular weight 200 000) 10% in sodium chloride intravenous infusion 0.9%, net price 500 mL = £16.50

**Dose** *by intravenous infusion*, up to 1500 mL daily (see notes above)

### HAES-steril
**HAES-steril** (Fresenius Kabi)\(^{(Y)}\)

**Intravenous infusion**, pentastarch (weight average molecular weight 200 000) 10% in sodium chloride intravenous infusion 0.9%, net price 500 mL = £16.50

**Dose** *by intravenous infusion*, up to 1500 mL daily (see notes above)

### Hemohes
**Hemohes** (Braun)\(^{(Y)}\)

**Intravenous infusion**, pentastarch (weight average molecular weight 200 000), net price (both in sodium chloride intravenous infusion 0.9%) 6%, 500 mL = £12.50; 10%, 500 mL = £16.50

**Cautions** see notes above

**Dose** *by intravenous infusion*, pentastarch 6%, up to 2500 mL daily; pentastarch 10 %, up to 1500 mL daily (see notes above)

### Tetrasacth
**Tetrasacth** (Braun)\(^{(B)}\)

**Intravenous infusion**, hydroxyethyl starch (weight average molecular weight 130 000) 6% in sodium chloride 0.625%, containing Na\(^+\) 140 mmol, K\(^+\) 1 mmol, Mg\(^2\+) 1 mmol, Cl\(^-\) 118 mmol, Ca\(^2\+) 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre, net price 500–1000 mL = £13.50

**Dose** *by intravenous infusion*, up to 50 mL/kg daily (see notes above)

### Intravenous infusion, hydroxyethyl starch (weight average molecular weight 130 000) 10% in sodium chloride 0.625%, containing Na\(^+\) 140 mmol, K\(^+\) 4 mmol, Mg\(^2\+) 1 mmol, Cl\(^-\) 118 mmol, Ca\(^2\+) 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre, net price 500–1000 mL = £17.50

**Dose** *by intravenous infusion*, up to 30 mL/kg daily (see notes above)

### Venofundin
**Venofundin** (Braun)\(^{(Y)}\)

**Intravenous infusion**, hydroxyethyl starch (weight average molecular weight 130 000) 6% in sodium chloride 0.625%, containing Na\(^+\) 140 mmol, K\(^+\) 4 mmol, Mg\(^2\+) 1 mmol, Cl\(^-\) 118 mmol, Ca\(^2\+) 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre, net price 500–1000 mL = £17.50

**Dose** *by intravenous infusion*, up to 30 mL/kg daily (see notes above)
9 Nutrition and blood

The use of soft polyurethane paediatric cannulas and use of feeds of low osmolality and neutral pH. Only nutritional fluids should be given by the dedicated intravenous line.

Before starting, the patient should be well oxygenated with a near normal circulating blood volume and attention should be given to renal function and acid-base status. Appropriate biochemical tests should have been carried out beforehand and serious deficits corrected. Nutritional and electrolyte status must be monitored throughout treatment.

Complications of long-term parenteral nutrition include gall bladder sludging, gall stones, cholestasis and abnormal liver function tests. For details of the prevention and management of parenteral nutrition complications, specialist literature should be consulted.

Protein is given as mixtures of essential and non-essential synthetic L-amino acids. Ideally, all essential amino acids should be included with a wide variety of non-essential ones to provide sufficient nitrogen together with electrolytes (see also section 9.2.2). Solutions vary in their composition of amino acids; they often contain an energy source (usually glucose) and electrolytes. Energy is provided in a ratio of 0.6 to 1.1 megajoules (150–250 kcal) per gram of protein nitrogen. Energy requirements must be met if amino acids are to be utilised for tissue maintenance. A mixture of carbohydrate and fat energy sources (usually 20–50% as fat) gives better utilisation of amino acids than glucose alone.

Glucose is the preferred source of carbohydrate, but if more than 180 g is given per day frequent monitoring of blood glucose is required, and insulin may be necessary. Glucose in various strengths from 10 to 50% must be infused through a central venous catheter to avoid thrombosis.

In parenteral nutrition regimens, it is necessary to provide adequate phosphate in order to allow phosphenation of glucose and to prevent hypophosphataemia; between 20 and 30 mmol of phosphate is required daily.

Fructose and sorbitol have been used in an attempt to avoid the problem of hyperosmolar hyperglycaemic non-ketotic acidosis but other metabolic problems may occur, as with xylitol and ethanol which are now rarely used.

Fat emulsions have the advantages of a high energy to fluid volume ratio, neutral pH, and iso-osmolality with plasma, and provide essential fatty acids. Several days of adaptation may be required to attain maximal utilisation. Reactions include occasional febrile episodes (usually only with 20% emulsions) and rare anaphylactic responses. Interference with biochemical measurements such as those for blood gases and calcium may occur if samples are taken before fat has been cleared. Daily checks are necessary to ensure complete clearance from the plasma in conditions where fat metabolism may be disturbed. Additives should not be mixed with fat emulsions unless compatibility is known.

Administration

Because of the complex requirements relating to parenteral nutrition full details relating to administration have been omitted. In all cases product literature and other specialist literature should be consulted.

---

9.3 Intravenous nutrition

When adequate feeding through the alimentary tract is not possible, nutrients may be given by intravenous infusion. This may be in addition to ordinary oral or tube feeding—supplemental parenteral nutrition, or may be the sole source of nutrition—total parenteral nutrition (TPN). Indications for this method include preparation of undereemboured patients for surgery, chemotherapy, or radiation therapy; severe or prolonged disorders of the gastro-intestinal tract; major surgery, trauma, or burns; prolonged coma or refusal to eat; and some patients with renal or hepatic failure.

The composition of proprietary preparations available is given in the table Proprietary Infusion Fluids for Parenteral Feeding, p. 603.

Parenteral nutrition requires the use of a solution containing amino acids, glucose, fat, electrolytes, trace elements, and vitamins. This is now commonly provided by the pharmacy in the form of a 3-litre bag. A single dose of vitamin B₁₂, as hydroxocobalamin, is given by intramuscular injection; regular vitamin B₁₂ injections are not usually required unless total parenteral nutrition continues for many months. Folic acid is given in a dose of 15 mg once or twice each week, usually in the nutrition solution. Other vitamins are usually given daily; they are generally introduced in the parenteral nutrition solution. Alternatively, if the patient is able to take small amounts by mouth, vitamins may be given orally.

The nutrition solution is infused through a central venous catheter inserted under full surgical precautions. Alternatively, infusion through a peripheral vein may be used for supplementary as well as total parenteral nutrition for periods of up to a month, depending on the availability of peripheral veins; factors prolonging cannula life and preventing thrombophlebitis include
### Proprietary Infusion Fluids for Parenteral Feeding

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aminoplasmal 5% E (Braun)</strong></td>
<td>8</td>
<td>25</td>
<td>2.6</td>
<td>43</td>
</tr>
<tr>
<td><strong>Aminoplasmal 10% (Braun)</strong></td>
<td>16</td>
<td>57</td>
<td>25.7</td>
<td></td>
</tr>
<tr>
<td><strong>Aminoven 25 (Fresenius Kabi)</strong></td>
<td>8 25 2.6 43 59 29</td>
<td>dihydrogen phosphate 9 mmol, malic acid 1.01 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinimix N9G20E (Baxter)</strong></td>
<td>4.6</td>
<td>1680</td>
<td>30</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>Clinimix N14G30E (Baxter)</strong></td>
<td>7</td>
<td>2520</td>
<td>30</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>ClinOleic 20% (Baxter)</strong></td>
<td>8360</td>
<td>purified olive and soya oil 200 g, glycerol 22.5 g, egg phosphatides 12 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glamin (Fresenius Kabi)</strong></td>
<td>22.4</td>
<td>62</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hyperamine 30 (Braun)</strong></td>
<td>30</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intralipid 10% (Fresenius Kabi)</strong></td>
<td>4600</td>
<td>soya oil 100 g, glycerol 22 g, purified egg phospholipids 12 g, phosphate 15 mmol</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intralipid 20% (Fresenius Kabi)</strong></td>
<td>8400</td>
<td>soya oil 200 g, glycerol 22 g, purified egg phospholipids 12 g, phosphate 15 mmol</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intralipid 30% (Fresenius Kabi)</strong></td>
<td>12600</td>
<td>soya oil 300 g, glycerol 16.7 g, purified egg phospholipids 12 g, phosphate 15 mmol</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Kabiven (Fresenius Kabi)</strong></td>
<td>5.3</td>
<td>3275</td>
<td>23</td>
<td>4</td>
</tr>
<tr>
<td><strong>Kabiven Peripheral (Fresenius Kabi)</strong></td>
<td>3.75</td>
<td>2625</td>
<td>17</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Lipidem (Braun)</strong></td>
<td>7900</td>
<td>omega-3-acid triglycerides 20 g, soya oil 80 g, medium-chain triglycerides 100 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lipofundin MCT/LCT 10% (Braun)</strong></td>
<td>4430</td>
<td>soya oil 50 g, medium-chain triglycerides 50 g</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Note: 1000 kcal = 4200 kJ; 1000 kJ = 238 kcal. All entries are net.
2. Excludes protein- or amino acid-derived energy.
### Preparation Nitrogen g/litre  
**Electrolytes mmol/litre**  
**Other components/litre**

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>Energy kl/litre</th>
<th>K(^+)</th>
<th>Mg(^{2+})</th>
<th>Na(^+)</th>
<th>Acet/CO(^2-)</th>
<th>Cl(^-)</th>
<th>soya oil 100 g, medium-chain triglycerides 100 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipofundin MCT/LCT 20% (Braun)</td>
<td>8000</td>
<td>8000</td>
<td>4.6</td>
<td>3.6 mmol, acid phosphate 12.8 mmol, anhydrous glucose 125 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutriflex basal (Braun)</td>
<td>4.6</td>
<td>2095</td>
<td>30</td>
<td>5.7</td>
<td>49.9</td>
<td>35</td>
<td>50</td>
<td>Ca(^{2+}) 2.5 mmol, acid phosphate 5.7 mmol, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>Nutriflex plus (Braun)</td>
<td>6.8</td>
<td>2510</td>
<td>25</td>
<td>5.7</td>
<td>37.2</td>
<td>22.9</td>
<td>35.5</td>
<td>Ca(^{2+}) 3.6 mmol, acid phosphate 20 mmol, anhydrous glucose 150 g</td>
</tr>
<tr>
<td>Nutriflex special (Braun)</td>
<td>10</td>
<td>4020</td>
<td>25.7</td>
<td>5</td>
<td>40.5</td>
<td>22</td>
<td>49.5</td>
<td>Ca(^{2+}) 4.1 mmol, acid phosphate 14.7 mmol, anhydrous glucose 240 g</td>
</tr>
<tr>
<td>NuTRIflex Lipid peri (Braun)</td>
<td>4.56</td>
<td>2664</td>
<td>24</td>
<td>2.4</td>
<td>40</td>
<td>32</td>
<td>38.4</td>
<td>Ca(^{2+}) 2.4 mmol, Zn(^{2+}) 24 micromol, phosphate 6 mmol, anhydrous glucose 64 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTRIflex Lipid plus (Braun)</td>
<td>5.44</td>
<td>3600</td>
<td>28</td>
<td>3.2</td>
<td>40</td>
<td>36</td>
<td>36</td>
<td>Ca(^{2+}) 3.2 mmol, Zn(^{2+}) 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTRIflex Lipid plus without Electrolytes (Braun)</td>
<td>5.44</td>
<td>3600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTRIflex Lipid special (Braun)</td>
<td>8</td>
<td>4004</td>
<td>37.6</td>
<td>4.24</td>
<td>53.6</td>
<td>48</td>
<td>48</td>
<td>Ca(^{2+}) 4.24 mmol, Zn(^{2+}) 32 micromol, phosphate 16 mmol, anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>NuTRIflex Lipid special without Electrolytes (Braun)</td>
<td>8</td>
<td>4004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
</tbody>
</table>

1. Note: 1000 kcal = 4200 kJ. 1000 kJ = 238.8 kcal. All entries are rounded.
2. Excludes protein- or amino acid-derived energy.
### Preparation Nitrogen g/litre Energy 1 kcal/litre Electrolytes mmol/litre Other components/litre

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen</th>
<th>Energy</th>
<th>Electrolytes</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>NuTRIflex Omega plus (Braun)</td>
<td>5.4</td>
<td>3600</td>
<td>28 3.2</td>
<td>Ca²⁺ 3.2 mmol, Zn²⁺ 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>NuTRIflex Omega special (Braun)</td>
<td>8</td>
<td>4004</td>
<td>37.6 4.24</td>
<td>Ca²⁺ 4.24 mmol, Zn²⁺ 30 micromol, phosphate 16 mmol, anhydrous glucose 144 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>OliClinomel N4-550E (Baxter)</td>
<td>3.6</td>
<td>2184</td>
<td>16 2.2</td>
<td>Ca²⁺ 2 mmol, phosphate 8.5 mmol, refined olive and soya oil 20 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N4-720E (Baxter)</td>
<td>3.64</td>
<td>3024</td>
<td>24 2</td>
<td>Ca²⁺ 1.8 mmol, phosphate 8 mmol, refined olive and soya oil 40 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N5-800E (Baxter)</td>
<td>4.6</td>
<td>3360</td>
<td>24 2.2</td>
<td>Ca²⁺ 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>OliClinomel N6-900E (Baxter)</td>
<td>5.6</td>
<td>3696</td>
<td>24 2.2</td>
<td>Ca²⁺ 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 120 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000 (Baxter)</td>
<td>6.6</td>
<td>4368</td>
<td>37 16</td>
<td>phosphate 3 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000E (Baxter)</td>
<td>6.6</td>
<td>4368</td>
<td>24 2.2</td>
<td>Ca²⁺ 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N8-800 (Baxter)</td>
<td>8.25</td>
<td>3360</td>
<td>42.5 20</td>
<td>phosphate 2.25 mmol, refined olive and soya oil 30 g, anhydrous glucose 125 g</td>
</tr>
<tr>
<td>Omevagen (Fresenius Kabi)</td>
<td></td>
<td></td>
<td></td>
<td>highly refined fish oil 100 g, glycerol 25 g, egg phosphatide 12 g</td>
</tr>
<tr>
<td>Plasma-Lyte 148 (water) (Baxter)</td>
<td></td>
<td></td>
<td></td>
<td>gluconate 23 mmol</td>
</tr>
<tr>
<td>Plasma-Lyte 148 (dextrose 5%) (Baxter)</td>
<td></td>
<td></td>
<td></td>
<td>gluconate 23 mmol, anhydrous glucose 50 g</td>
</tr>
</tbody>
</table>

1. Note: 1000 kcal = 4200 kJ; 1000 kJ = 238 kcal. All entries are BNF
2. Excludes protein- or amino acid-derived energy
### 9.3 Intravenous nutrition

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1-2 Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Lyte M (dextrose 5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Baxter) Net price 1000 mL =</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>£1.33</td>
<td>840</td>
<td>16.5</td>
<td>40</td>
<td>12</td>
</tr>
<tr>
<td>³Primene 10% (Baxter) Net</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>price 100 mL = £5.78, 250 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>= £7.92</td>
<td>15</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMOFilipid (Fresenius Kabi)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net price 500 mL = £20.50</td>
<td>8400</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>StructoKabiven Electrolyte</td>
<td>8</td>
<td>3685</td>
<td>74.5</td>
<td></td>
</tr>
<tr>
<td>Free (Fresenius Kabi) Net</td>
<td>8200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>price (triple compartment bag</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of amino acids 500 mL, 750 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>or 1000 mL, glucose 42% 298 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>446 mL or 395 mL, lipid emulsion 188 mL, 281 mL or 375 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>986 mL = £66.50, 1477 mL =</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>£89.00, 1970 mL = £74.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 9 (Baxter) Net</td>
<td>9.1</td>
<td>60.5</td>
<td>70</td>
<td>100</td>
</tr>
<tr>
<td>price 500 mL = £6.66, 1000 mL</td>
<td>12.34</td>
<td>70</td>
<td>70</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Synthamin 9 EF (electrolyte-</td>
<td>9.1</td>
<td>44.2</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>free) (Baxter) Net price 500</td>
<td>12.34</td>
<td>22</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>mL = £6.66, 1000 mL = £12.34</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 14 (Baxter) Net</td>
<td>14</td>
<td>60.5</td>
<td>70</td>
<td>140</td>
</tr>
<tr>
<td>price 500 mL = £8.64, 1000 mL</td>
<td>17.51</td>
<td>70</td>
<td>140</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>= £17.13, 3000 mL = £48.98</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 14 EF (electrolyte-</td>
<td>14</td>
<td>68</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>free) (Baxter) Net price 500</td>
<td>17.51</td>
<td>34</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>mL = £9.87, 1000 mL = £17.51</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 17 (Baxter) Net</td>
<td>16.5</td>
<td>60.5</td>
<td>70</td>
<td>150</td>
</tr>
<tr>
<td>price 500 mL = £12.66, 1000 mL = £23.00</td>
<td>16.5</td>
<td>70</td>
<td>150</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Synthamin 17 EF (electrolyte-</td>
<td>16.5</td>
<td>82</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>free) (Baxter) Net price 500</td>
<td>23.00</td>
<td>40</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>mL = £12.66, 1000 mL = £23.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamin 9 Glucose (Fresenius Kabi)</td>
<td>9.4</td>
<td>1700</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Net price 100 mL = £3.80, 500 mL = £7.70, 1000 mL = £13.40</td>
<td>1.5</td>
<td>50</td>
<td>50</td>
<td>calcium 2.5 mmol, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>Vamin 14 (Fresenius Kabi)</td>
<td>13.5</td>
<td>50</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>Net price 500 mL = £10.80, 1000 mL = £14.67</td>
<td>13.5</td>
<td>100</td>
<td>100</td>
<td>calcium 5 mmol, SO₄²⁻ 8 mmol</td>
</tr>
<tr>
<td>Vamin 14 (Electrolyte-Free)</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>(Fresenius Kabi) Net price 500 mL = £13.70, 1000 mL = £26.70</td>
<td>13.5</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vaminolact (Fresenius Kabi)</td>
<td>9.3</td>
<td>9</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Net price 100 mL = £4.35, 500 mL = £10.00</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

1. Note. 1000 kcal = 4200 kJ, 1000 kJ = 238.8 kcal. All entries are rounded.
2. Excludes protein- or amino acid-derived energy.
3. For use in neonates and children only.
9.4 Oral nutrition

9.4.1 Foods for special diets

These are preparations that have been modified to eliminate a particular constituent from a food or that are nutrient mixtures formulated as food substitutes for patients who either cannot tolerate or cannot metabolise certain common constituents of food. In certain clinical conditions, some food preparations are regarded as drugs and can be prescribed within the NHS if they have been approved by the Advisory Committee on Borderline Substances (ACBS)—see Appendix 7.

Phenylketonuria
Phenylketonuria (hyperphenylalaninaemia, PKU), which results from the inability to metabolise phenylalanine, is managed by restricting dietary intake of phenylalanine to a small amount sufficient for tissue building and repair.

Sapropterin, a synthetic form of tetrahydrobiopterin, is licensed as an adjunct to dietary restriction of phenylalanine in the management of patients with phenylketonuria and tetrahydrobiopterin deficiency.

Aspartame (used as a sweetener in some foods and medicines) contributes to the phenylalanine intake and may affect control of phenylketonuria. Where the presence of aspartame is specified in the product literature this is indicated in the BNF against the preparation; the patient should be informed of this.

Coeliac disease
Intolerance to gluten in coeliac disease is managed by completely eliminating gluten from the diet. A range of gluten-free products is available for prescription—see Appendix 7, p. 925.

Sapropterin dihydrochloride
Note: Sapropterin is a synthetic form of tetrahydrobiopterin

Indications see under Dose below

Cautions monitor blood-phenylalanine concentration before and after first week of treatment—if this is indicated in the BNF against the preparation; the patient should be informed of this.
unsatisfactory response increase dose at weekly intervals to max. dose and monitor blood-phenylalanine concentration weekly; discontinue treatment if unsatisfactory response after 1 month; monitor blood-phenylalanine and tyrosine concentrations 1–2 weeks after dose adjustment and during treatment; history of convulsions

**Hepatic impairment** manufacturer advises caution—no information available

**Renal impairment** manufacturer advises caution—no information available

**Pregnancy** manufacturer advises caution—consider only if strict dietary management inadequate

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** diarrhoea, vomiting, abdominal pain; nasal congestion, cough, pharyngolaryngeal pain; headache

**Dose**
- Phenylketonuria (specialist use only), by mouth, **ADULT** and **CHILD** over 4 years, initially 10 mg/kg once daily, preferably in the morning, adjusted according to response; usual dose 5–20 mg/kg daily
- Tetrahydrobiopterin deficiency (specialist use only), by mouth, **ADULT** and **CHILD** initially 2–5 mg/kg once daily, preferably in the morning, adjusted according to response; max. 20 mg/kg daily; total daily dose may alternatively be given in 2–3 divided doses

**Kuvan®** (Merck Serono)▼ ▼ ▼ ▼

**Dispersible tablets**, sapropterin dihydrochloride 100 mg, net price 30-tab pack = £597.22, 120-tab pack = £3388.88. Label: 13, 21

**Counselling** Tablets should be dissolved in water and taken within 20 minutes

### 9.4.2 Enteral nutrition

The body’s reserves of protein rapidly become exhausted in severely ill patients, especially during chronic illness or in those with severe burns, extensive trauma, pancreatitis, or intestinal fistula. Much can be achieved by frequent meals and by persuading the patient to take supplementary snacks of ordinary food between the meals.

However, extra calories, protein, other nutrients, and vitamins are often best given by supplementing ordinary meals with enteral sip or tube feeds (preparations, see Appendix 7).

When patients cannot feed normally, for example, patients with severe facial injury, oesophageal obstruction, or coma, a nutritionally complete diet of enteral feeds must be given. The advice of a dietitian should be sought to determine the protein and total energy requirement of the patient and the form and relative contribution of carbohydrate and fat to the energy requirements.

Most enteral feeds contain protein derived from cows’ milk or soya. Elemental feeds containing protein hydrolysates or free amino acids can be used for patients who have diminished ability to break down protein, for example in inflammatory bowel disease or pancreatic insufficiency.

Even when nutritionally complete feeds are given, water and electrolyte balance should be monitored. Haematological and biochemical parameters should also be monitored, particularly in clinically unstable patients. Extra minerals (e.g. magnesium and zinc) may be needed in patients where gastro-intestinal secretions are being lost. Additional vitamins may also be needed. Feeds containing vitamin K may affect the INR in patients receiving warfarin—see interactions: Appendix 1 (vitamins).

**Children** Children have special requirements and in most situations liquid feeds prepared for adults are totally unsuitable—the advice of a paediatric dietitian should be sought; see also BNF for Children, section 9.4.2

**Preparations**

See Borderline Substances, Appendix 7.

### 9.5 Minerals

- **Calcium and magnesium**
  - **Calcium supplements**
  - **Hypercalcaemia and hypercalciuria**
  - **Magnesium**

Calcium supplements are usually only required where dietary calcium intake is deficient. This dietary requirement varies with age and is relatively greater in childhood, pregnancy, and lactation, due to an increased demand, and in old age, due to impaired absorption. In osteoporosis, a calcium intake which is double the recommended amount reduces the rate of bone loss. If the actual dietary intake is less than the recommended amount, a supplement of as much as 40 mmol is appropriate, see also Osteoporosis, p. 469 and Vitamin D, p. 617.

In severe acute hypercalcaemia or hypocalcaemic tetany, an initial slow intravenous injection of 10–20 mL of calcium gluconate injection 10% (providing approximately 2.25–4.5 mmol of calcium) should be given, with plasma-calcium and ECG monitoring (risk of arrhythmias if given too rapidly), and either repeated as required or, if only temporary improvement, followed by a continuous intravenous infusion to prevent recurrence. For infusion, dilute 100 mL of calcium gluconate 10% in 1 litre of glucose 5% or sodium chloride 0.9% and give at an initial rate of 50 mL/hour adjusted according to response. Calcium chloride injection is also available, but is more irritant; care should be taken to prevent extravasation. Oral supplements of calcium and vitamin D may also be required in persistent hypocalcaemia (see also section 9.6.4). Concurrent

BNF 61

9.4.2 Enteral nutrition
hypomagnesaemia should be corrected with magnesium sulphate (section 9.5.1.3).

For the role of calcium gluconate in temporarily reducing the toxic effects of hyperkalaemia, see p. 595.

**CALCIUM SALTS**

**Indications** see notes above; calcium deficiency

**Cautions** sarcoidosis; history of nephrolithiasis; avoid calcium chloride in respiratory acidosis or respiratory failure; **interactions:** Appendix 1 (antacids, calcium salts)

**Contra-indications** conditions associated with hypercalcaemia and hypercalciuria (e.g. some forms of malignant disease)

**Renal impairment** use with caution (but see also Calcium Gluconate injection, below)

**Side-effects** gastro-intestinal disturbances; bradycardia, arrhythmias; with injection, peripheral vasodilatation, fall in blood pressure, injection-site reactions, severe tissue damage with extravasation

**Dose**
- **By mouth,** daily in divided doses, see notes above
- **By slow intravenous injection,** acute hypocalcaemia, calcium gluconate 1–2 g (Ca\(^2\)+ 2.25–4.5 mmol); **CHILD** see BNF for Children
- **By continuous intravenous infusion,** acute hypocalcaemia, see notes above

**Oral preparations**

**Calcium Gluconate** *(Non-proprietary)*

- **Effervescent tablets,** calcium gluconate 1 g (calcium 89 mg or Ca\(^2\)+ 2.23 mmol), net price 28-tab pack = £14.83. **Note** Each tablet usually contains 4.46 mmol Na\(^+\)

**Calcium Lactate** *(Non-proprietary)*

- **Tablets,** calcium lactate 300 mg (calcium 39 mg or Ca\(^2\)+ 1 mmol), net price 84 = £2.92

**Adcal\(^\text{®}\)** *(ProStrakan)*

- **Chewable tablets,** fruit flavour, calcium carbonate 1.5 g (calcium 600 mg or Ca\(^2\)+ 15 mmol), net price 100-tab pack = £7.25. **Label:** 24

**Cacit** *(Warner Chilcott)*

- **Tablets,** effervescent, pink, calcium carbonate 1.25 g, providing calcium citrate when dispersed in water (calcium 500 mg or Ca\(^2\)+ 12.5 mmol), net price 76-tab pack = £11.81. **Label:** 13

**Calcichew\(^\text{®}\)** *(Shire)*

- **Tablets** (chewable), orange flavour, calcium carbonate 1.25 g (calcium 500 mg or Ca\(^2\)+ 12.5 mmol), net price 100-tab pack = £9.33. **Label:** 24

- **Forte tablets** (chewable), orange flavour, scored, calcium carbonate 2.5 g (calcium 1 g or Ca\(^2\)+ 25 mmol), net price 60-tab pack = £13.16. **Label:** 24

**Calcium-500** *(Martindale)*

- **Tablets,** pink, f/c, calcium carbonate 1.25 g (calcium 500 mg or Ca\(^2\)+ 12.5 mmol), net price 100-tab pack = £9.46. **Label:** 25

**Calcium-Sandoz\(^\text{®}\)** *(Alliance)*

- **Syrup,** orange flavour, calcium gluconate 1.09 g, calcium lactobionate 727 mg (calcium 108.3 mg or Ca\(^2\)+ 2.7 mmol)/5 mL, net price 300 mL = £4.07

**Parenteral preparations**

**Calcium Gluconate** *(Non-proprietary)* *(Full)*

**Injection,** calcium gluconate 10% (calcium 8.4 mg or Ca\(^2\)+ 226 micromol/mL), net price 10-mL amp = 60p

**Note** The MHRA has advised that repeated or prolonged administration of calcium gluconate injection packaged in 10 mL glass containers is contra-indicated in children under 18 years and in patients with renal impairment owing to the risk of aluminium accumulation; in these patients the use of calcium gluconate injection packaged in plastic containers is recommended

**Calcium Chloride** *(Non-proprietary)* *(Full)*

**Injection,** calcium chloride dihydrate 10% (calcium 27.3 mg or Ca\(^2\)+ 680 micromol/mL), net price 10-mL disposable syringe = £5.10

**Brands include Minigel® Calcium Chloride 10%**

**Injection,** calcium chloride dihydrate 13.4% (calcium 36 mg or Ca\(^2\)+ 910 micromol/mL), net price 10-mL amp = £14.94

**With vitamin D**

Section 9.6.4

**With disodium etidronate**

Section 6.6.2

**With risedronate sodium and colecalciferol**

Section 6.6.2

**9.5.1.2 Hypercalcaemia and hypercalciuria**

**Severe hypercalcaemia** Severe hypercalcaemia calls for urgent treatment before detailed investigation of the cause. Dehydration should be corrected first with intravenous infusion of sodium chloride 0.9%. Drugs (such as thiazides and vitamin D compounds) which promote hypercalcaemia, should be discontinued and dietary calcium should be restricted.

If severe hypercalcaemia persists drugs which inhibit mobilisation of calcium from the skeleton may be required. The bisphosphonates are useful and disodium pamidronate (section 6.6.2) is probably the most effective.

**Corticosteroids** (section 6.3) are widely given, but may only be useful where hypercalcaemia is due to sarcoidosis or vitamin D intoxication; they often take several days to achieve the desired effect.

**Calcitonin** (section 6.6.1) is relatively non-toxic but its effect can wear off after a few days despite continued use; it is rarely effective where bisphosphonates have failed to reduce serum calcium adequately.

After treatment of severe hypercalcaemia the underlying cause must be established. Further treatment is
Nutrition and blood

9

Governed by the same principles as for initial therapy. Salt and water depletion and drugs promoting hypercalcemia should be avoided; oral administration of a bisphosphonate may be useful.

Hyperparathyroidism Cinacalcet is licensed for the treatment of secondary hyperparathyroidism in dialysis patients with end-stage renal disease (but see NICE guidance below), for primary hyperparathyroidism in patients where parathyroidectomy is inappropriate, and for the treatment of hypercalcemia in parathyroid carcinoma. Cinacalcet reduces parathyroid hormone which leads to a decrease in serum calcium concentrations.

Paricalcitol (section 9.6.4) is also licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Parathyroidectomy may be indicated for hyperparathyroidism.

NICE guidance

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (January 2007)

Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.

Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis) only in those:

- who have ‘very uncontrolled’ plasma concentration of intact parathyroid hormone (defined as greater than 85 picomol/litre) refractory to standard therapy, and a normal or high adjusted serum calcium concentration, and

- in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery outweigh the benefits.

Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma concentration of intact parathyroid hormone of 30% or greater is seen within 4 months of treatment.

Hypercalciuria

Hypercalciuria should be investigated for an underlying cause, which should be treated. Where a cause is not identified (idiopathic hypercalciuria), the condition is managed by increasing fluid intake and giving bendroflumethiazide in a dose of 2.5 mg daily (a higher dose is not usually necessary). Reducing dietary calcium intake may be beneficial but severe restriction of calcium intake has not proved beneficial and may even be harmful.

CINACALCET

Indications see under Dose and notes above

Cautions measure serum-calcium concentration before initiation of treatment and within 1 week after starting treatment or adjusting dose, then monthly for secondary hyperparathyroidism and every 2–3 months for primary hyperparathyroidism and parathyroid carcinoma; treatment should not be initiated in patients with hypocalcaemia; in secondary hyperparathyroidism measure parathyroid hormone concentration 1–4 weeks after starting treatment or adjusting dose, then every 1–3 months; dose adjustment may be necessary if smoking started or stopped during treatment; interactions: Appendix 1 (cinacalcet)

Hepatic impairment manufacturer advises caution in moderate to severe impairment—monitor closely especially when increasing dose

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects nausea, vomiting, anorexia; dizziness, paraesthesia, arthria; reduced testosterone concentrations; myalgia; rash; less commonly dyspepsia, diarrhoea, and seizures; hypotension, heart failure, and allergic reactions (including angioedema) also reported

Dose

- Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis (but see notes above), ADULT over 18 years, initially 30 mg once daily, adjusted every 2–4 weeks to max. 180 mg daily
- Hyperparathyroidism or parathyroid carcinoma, ADULT over 18 years, initially 30 mg twice daily, adjusted every 2–4 weeks according to response up to max. 90 mg 4 times daily

Mimpara® (Amgen) 30 mg, green, f/c, cinacalcet (as hydrochloride) tablets, green, f/c, cinacalcet (as hydrochloride) 30 mg, net price 28-tab pack = £121.36; 60 mg, 28-tab pack = £223.87; 90 mg, 28-tab pack = £335.81.

Label: 21

9.5.1.3 Magnesium

Magnesium is an essential constituent of many enzyme systems, particularly those involved in energy generation; the largest stores are in the skeleton. Magnesium salts are not well absorbed from the gastrointestinal systems, particularly those involved in energy generation. Magnesium is excreted mainly by the kidneys and is therefore retained in renal failure, but significant hypomagnesaemia (causing muscle weakness and arrhythmias) is rare.

Hypomagnesaemia Since magnesium is secreted in large amounts in the gastro-intestinal fluid, excessive losses in diarrhoea, stoma or fistula are the most common causes of hypomagnesaemia; deficiency may also occur in alcoholism or as a result of treatment with certain drugs. Hypomagnesaemia often causes secondary hypocalcaemia, and also hypokalaemia and hyponatraemia. Symptomatic hypomagnesaemia is associated with a deficit of 0.5–1 mmol/kg; up to 160 mmol Mg²⁺ over up to 5 days may be required to replace the deficit (allowing for urinary losses). Magnesium is given initially by intravenous infusion or by intramuscular injection of magnesium sulphate; the intramuscular injection is painful. Plasma magnesium concentration should be measured to determine the rate and duration of infusion.
and the dose should be reduced in renal impairment. To prevent recurrence of the deficit, magnesium may be given by mouth in a dose of 24 mmol Mg²⁺ daily in divided doses; suitable preparations are magnesium glycerophosphate tablets or liquid [unlicensed], available from ‘special-order’ manufacturers or specialist importing companies, see p. 988. For maintenance (e.g. in intravenous nutrition), parenteral doses of magnesium are of the order of 10–20 mmol Mg²⁺ daily (often about 12 mmol Mg²⁺ daily).

Arrhythmias Magnesium sulphate has also been recommended for the emergency treatment of serious arrhythmias, especially in the presence of hypokalaemia (when hypomagnesaemia may also be present) and when salvos of rapid ventricular tachycardia show the characteristic twisting wave front known as torsade de pointes (see also section 2.3.1). The usual dose of magnesium sulphate by intravenous injection is 2 g (8 mmol Mg²⁺) over 10–15 minutes (repeated once if necessary).

Myocardial infarction Limited evidence that magnesium sulphate prevents arrhythmias and reperfusion injury in patients with suspected myocardial infarction has not been confirmed by large studies. Routine use of magnesium sulphate for this purpose is not recommended. For the management of myocardial infarction, see section 2.10.1.

Eclampsia and pre-eclampsia Magnesium sulphate is the drug of choice for the treatment of seizures and the prevention of recurrent seizures in women with eclampsia. Regimens may vary between hospitals. Calcium gluconate injection is used for the management of magnesium toxicity.

Mycardial infarction Magnesium sulphate also of benefit in women with pre-eclampsia in whom there is concern about developing eclampsia. The patient should be monitored carefully (see under Magnesium Sulphate).

Magnesium Sulphate

**Indications**
- Hypomagnesaemia, see notes above
- Arrhythmias, see notes above
- Prevention of seizures in pre-eclampsia [unlicensed indication], initially by intravenous injection over 5–15 minutes, 4 g followed by intravenous infusion, 1 g/hour for 24 hours; if seizure occurs, additional dose by intravenous injection, 2 g
- Treatment of seizures and prevention of seizure recurrence in eclampsia, initially by intravenous injection over 5–15 minutes, 4 g, followed by intravenous infusion, 1 g/hour for 24 hours after seizure or delivery, whichever is later; if seizure recurs, increase the infusion rate to 1.5–2 g/hour or give an additional dose by intravenous injection, 2 g
- Intrapartum administration For intravenous injection concentration of magnesium sulphate should not exceed 20% (dilute 1 part of magnesium sulphate injection 50% with at least 1.5 parts of water for injection)

**Note** Magnesium sulphate (as heptahydrate) 1 g equivalent to Mg²⁺ approx. 4 mmol

**Magnesium Sulphate (Non-proprietary)**
- **Injection**, magnesium sulphate (as heptahydrate) 20% (Mg²⁺ approx. 0.8 mmol/mL), net price 20-mL (4-g) amp = £2.75; 50% (Mg²⁺ approx. 2 mmol/mL), 2-mL (1-g) amp = £2.39, 4-mL (2-g) prefilled syringe = £7.39, 5-mL (2.5-g) amp = £3.00, 10-mL (5-g) amp = 69p, 10-mL (5-g) prefilled syringe = £4.95

**Brands include**
- **Minigel® Magnesium Sulphate 50%**

**Phosphorus**

**Phosphate supplements**

**Phosphate-binding agents**

**Oral phosphate supplements** may be required in addition to vitamin D in a small minority of patients with hypophosphataemic vitamin D-resistant rickets. Diarrhoea is a common side-effect and should prompt a reduction in dosage.

Phosphate infusion is occasionally needed in alcohol dependence or in phosphate deficiency arising from use of parenteral nutrition deficient in phosphate supplements; phosphate depletion also occurs in severe diabetic ketoacidosis. For established hypophosphataemia, monobasic potassium phosphate may be infused at a rate of 9 mmol every 12 hours. In critically ill patients, the dose of phosphate can be increased up to 500 micromol/kg (approx. 30 mmol in adults, max. 50 mmol), infused over 6–12 hours, according to severity. Excessive doses of phosphates may cause hypocalcaemia and metastatic calcification; it is essential to monitor closely plasma concentrations of calcium, phosphate, potassium, and other electrolytes.

For phosphate requirements in total parenteral nutrition regimens, see section 9.3.

**Phosphates**

**Intravenous infusion**, phosphates (providing PO₄³⁻ 100 mmol, K⁺ 19 mmol, and Na⁺ 162 mmol/litre), net price 500 mL (Polyfuor®) = £3.75.

For the treatment of moderate to severe hypophosphataemia
Phosphate-Sandoz® (HK Pharma)

**Tablets**, effervescent, anhydrous sodium acid phosphate 1.936 g, sodium bicarbonate 350 mg, potassium bicarbonate 315 mg, equivalent to phosphorus 500 mg (phosphate 16.1 mmol), sodium 468.8 mg (Na⁺ 20.4 mmol), potassium 123 mg (K⁺ 3.1 mmol). Net price 20 = £3.29. Label: 13

**Dose** vitamin D-resistant hypophosphataemic osteomalacia, 4–6 tablets daily. *CHILD* under 5 years 2–3 tablets daily

### 9.5.2.2 Phosphate-binding agents

Calcium-containing preparations are used as phosphate-binding agents in the management of hyperphosphataemia complicating renal failure. Aluminium-containing preparations are rarely used as phosphate-binding agents and can cause aluminium accumulation.

**Sevelamer hydrochloride** and sevelamer carbonate are both licensed for the treatment of hyperphosphataemia in patients on haemodialysis or peritoneal dialysis. Sevelamer carbonate is also licensed for the treatment of patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/L or more.

**Lanthanum** is licensed for the control of hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), and in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/L or more.

**Lanthanum** is licensed for the control of hyperphosphataemia in patients with chronic renal failure on haemodialysis or peritoneal dialysis, as a second-line agent, where a non-aluminium, non-calcium phosphate binder is required.

### Phosphate-binding agents

#### ALUMINIUM HYDROXIDE

**Indications** hyperphosphataemia; dyspepsia (section 1.1)

**Cautions** see notes above; **interactions**: Appendix 1 (antacids)

**Side-effects** constipation; hyperaluminaemia

**Alu-Cap®** (Meda)

**Capsules**, green/red, dried aluminium hydroxide 475 mg (low Na⁺), net price 120-cap pack = £3.75

**Dose** phosphate-binding agent in renal failure, 4–20 capsules daily in divided doses with meals

#### CALCIUM SALTS

**Indications** hyperphosphataemia

**Cautions** interactions: Appendix 1 (antacids, calcium salts)

**Contra-indications** hypercalcaemia, hypercalciuria

**Side-effects** hypercalcaemia

**Adcal**® section 9.5.1.1

**Calcichew**® section 9.5.1.1

**Calcium-500** section 9.5.1.1

**Phosex**® (Vitaline)

**Tablets**, yellow, scored, calcium acetate 1 g (calcium 250 mg or Ca²⁺ 6.2 mmol), net price 180-tab pack = £19.79. Counselling, do not chew, with meals

**Dose** initially 1 tablet 3 times daily with meals, adjusted according to serum-phosphate concentration (usual dose 1–4 tablets daily (1 or 2 tablets with each meal)); max. 12 tablets daily

**PhosLo**® (Fresenius Medical Care)

**Capsules**, calcium acetate (anhydrous) 667 mg (calcium 169 mg or Ca²⁺ 4.2 mmol), net price 200-cap pack = £14.40. Counselling, with meals

**Excipients** include propylene glycol (see Excipients, p. 2)

**Dose** initially 2 capsules with each meal, adjusted according to serum-phosphate concentration (usual dose 3 or 4 capsules with each meal)

#### With magnesium carbonate

**Osvaren**® (Fresenius Medical Care)

**Tablets**, f/c, scored, calcium acetate 435 mg (calcium 110 mg or Ca²⁺ 2.7 mmol), heavy magnesium carbonate 235 mg (magnesium 60 mg), net price 180-tab pack = £24.00. Counselling, do not crush or chew, with meals, avoid other drugs at same time (see below)

**Contra-indications** hypercalcaemia, hypermagnesaemia; third-degree AV block; myasthenia gravis

**Dose** **ADULT** over 18 years, initially 1 tablet 3 times daily with meals, adjusted according to serum-phosphate concentration (usual dose 3–10 tablets daily); max. 12 tablets daily

**Counselling** Manufacturers advise that other drugs should be taken at least 2 hours before or 3 hours after *Osvaren*® to reduce possible interference with absorption of other drugs

#### LANTHANUM

**Indications** see notes above

**Cautions** acute peptic ulcer; ulcerative colitis; Crohn’s disease; bowel obstruction; monitor liver function; **interactions**: Appendix 1 (lanthanum)

**Hepatic impairment** use with caution

**Pregnancy** manufacturer advises avoid—toxicity in animal studies

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** gastro-intestinal disturbances; hypocalcaemia; less commonly anorexia, increased appetite, taste disturbances, dry mouth, thirst, stomatitis, chest pain, peripheral oedema, headache, dizziness, vertigo, asthenia, fatigue, malaise, hyperglycaemia, hyperparathyroidism, hypercalcaemia, hypophosphataemia, eosinophilia, arthralgia, myalgia, osteoporosis, sweating, alopecia, pruritus, and erythematous rash; accumulation of lanthanum in bone, and transient changes in QT interval also reported

**Dose**

- **ADULT** over 18 years, initially 750 mg daily in divided doses chewed with or immediately after meals, adjusted according to serum-phosphate concentration every 2–3 weeks (usual dose range 1.5–3 g daily in divided doses)

**Fosrenol**® (Shire)

**Tablets** (chewable), lanthanum (as carbonate hydrate) 500 mg, net price 90-tab pack = £114.13; 750 mg, 90-tab pack = £152.17; 1 g, 90-tab pack = £161.33. Label: 21, counselling, to be chewed
SEVELAMER HYDROCHLORIDE

Indications hyperphosphataemia in patients on haemodialysis or peritoneal dialysis
Cautions gastrointestinal disorders; interactions: Appendix 1 (sevelamer)
Contra-indications bowel obstruction
Pregnancy manufacturer advises use only if potential benefit outweighs risk
Breast-feeding manufacturer advises use only if potential benefit outweighs risk
Side-effects nausea, vomiting, abdominal pain, constipation, diarrhoea, dyspepsia, flatulence; very rarely intestinal obstruction; also reported intestinal perforation, ileus, diverticulitis, pruritus, rash
Dose
• ADULT over 18 years, initially 2.4–4.8 g daily in 3 divided doses with meals, adjusted according to serum-phosphate concentration (usual dose range 2.4–12 g daily in 3 divided doses)

Renagel® (Genzyme) tablets, f/c, sevelamer hydrochloride 800 mg, net price 180-tab pack = £117.97. Label: 25, counselling, with meals
Excipients include propylene glycol (see Excipients, p. 2)

SEVELAMER CARBONATE

Indications hyperphosphataemia in patients on haemodialysis or peritoneal dialysis, and patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/L or more
Cautions gastrointestinal disorders; interactions: Appendix 1 (sevelamer)
Contra-indications bowel obstruction
Pregnancy manufacturer advises use only if potential benefit outweighs risk
Breast-feeding unlikely to be present in milk (however, manufacturer advises avoid)
Side-effects nausea, vomiting, abdominal pain, constipation, diarrhoea, dyspepsia, flatulence; also reported intestinal obstruction and perforation, ileus, pruritus, rash
Dose
• ADULT over 18 years, initially 2.4–4.8 g daily in 3 divided doses with meals, adjusted according to serum-phosphate concentration every 2–4 weeks (usual dose range 6 g daily in 3 divided doses)

Renvela® (Genzyme) tablets, f/c, sevelamer carbonate 800 mg, net price 180-tab pack = £117.97. Label: 25, counselling, with meals
Excipients include propylene glycol (see Excipients, p. 2)

Pregnancy

Breast-feeding

Side-effects

Dose

Contra-indications

Cautions

Interactions

Appendix 1 (sevelamer)

FLUORIDES

Note Sodium fluoride 2.2 mg provides approx. 1 mg fluoride ion

Indications prophylaxis of dental caries—see notes above
Contra-indications not for areas where drinking water is fluoridated
Side-effects occasional white flecks on teeth with recommended doses; rarely yellowish-brown discoloration if recommended doses are exceeded

Dose

Note Dose expressed as fluoride ion (\(\text{F}^-\))

• Water content less than \(\text{F}^-\) 300 micrograms/litre (0.3 parts per million), CHILD up to 6 months none; 6 months–3 years F\(^-\) 250 micrograms daily, 3–6 years F\(^-\) 500 micrograms daily, over 6 years F\(^-\) 1 mg daily

• Water content between F\(^-\) 300 and 700 micrograms/litre (0.3–0.7 parts per million), CHILD up to 3 years none, 3–6 years F\(^-\) 250 micrograms daily, over 6 years F\(^-\) 500 micrograms daily

• Water content above F\(^-\) 700 micrograms/litre (0.7 parts per million), supplements not advised

Note These doses reflect the recommendations of the British Dental Association, the British Society of Paediatric Dentistry and the British Association for the Study of Community Dentistry (Br Dent J 1997; 182: 6–7)

When the fluoride content of drinking water is less than 700 micrograms per litre (0.7 parts per million), daily administration of fluoride tablets or drops provides suitable supplementation. Systemic fluoride supplements should not be prescribed without reference to the fluoride content of the local water supply. Infants need not receive fluoride supplements until the age of 6 months.

Dentifrices which incorporate sodium fluoride or monofluorophosphate are also a convenient source of fluoride. Individuals who are either particularly caries prone or medically compromised may be given additional protection by use of fluoride rinses or by application of fluoride gels. Rinses may be used daily or weekly; daily use of a less concentrated rinse is more effective than weekly use of a more concentrated one. High-strength gels must be applied regularly under professional supervision; extreme caution is necessary to prevent children from swallowing any excess. Less concentrated gels are available for home use. Varnishes are also available and are particularly valuable for young or disabled children since they adhere to the teeth and set in the presence of moisture.

Fluoride mouthwash, oral drops, tablets and toothpaste are prescribable on form FP10D (GP14 in Scotland, WP10D in Wales; for details see preparations, p. 614). There are also arrangements for health authorities to supply fluoride tablets in the course of pre-school dental schemes, and they may also be supplied in school dental schemes.

Fluoride gels are not prescribable on form FP10D (GP14 in Scotland, WP10D in Wales).

Availability of adequate fluoride confers significant resistance to dental caries. It is now considered that the topical action of fluoride on enamel and plaque is more important than the systemic effect.
Fluoride supplements not considered necessary below 6 months of age (see notes above)

Fluoride Tablets

- **En-De-Kay** (Manx)
  - **Flutabs 3–6 years**, orange-flavoured, scored, sodium fluoride 1.1 mg (F⁻ 500 micrograms), net price 200-tab pack = £2.38
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets
  - **Flutabs 6+ years**, orange-flavoured, scored, sodium fluoride 2.2 mg (F⁻ 1 mg), net price 200-tab pack = £2.38
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets

- **Fluor-a-day** (Dental Health)
  - **Tablets**, buff, sodium fluoride 1.1 mg (F⁻ 500 micrograms), net price 200-tab pack = £2.54
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets

- **FluorGard** (Colgate-Palmolive)
  - **Tablets 0.5**, purple, grape-flavoured, scored, sodium fluoride 1.1 mg (F⁻ 500 micrograms), net price 200-tab pack = £1.91
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets
  - **Tablets 1.0**, orange, orange-flavoured, scored, sodium fluoride 2.2 mg (F⁻ 1 mg), net price 200-tab pack = £1.91
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets

**Oral drops**

- Note Fluoride supplements not considered necessary below 6 months of age (see notes above)

**En-De-Kay** (Manx)

- **Fluorodrops** (≡ paediatric drops), sugar-free, sodium fluoride 550 micrograms (F⁻ 250 micrograms)/0.15 mL. Net price 60 mL = £2.38
- **Dental prescribing on NHS** Corresponds to Sodium Fluoride Oral Drops DPF 0.37% equivalent to sodium fluoride 80 micrograms (F⁻ 36 micrograms)/drop

**Mouthwashes**

- Rinse mouth for 1 minute and spit out
- **Counselling** Avoid eating, drinking, or rinsing mouth for at least 30 minutes after use

**Duraphat** (Colgate-Palmolive)

- **Weekly dental rinse** (≡ mouthwash), blue, sodium fluoride 0.2%. Net price 150 mL = £2.13. Counselling, see above
- **Dose** CHILD 6 years and over, for weekly use, rinse with 10 mL
- **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Mouthwash 0.2%

**En-De-Kay** (Manx)

- **Daily fluoride mouthrinse** (≡ mouthwash), blue, sodium fluoride 0.05%. Net price 250 mL = £1.51
- **Dose** CHILD 6 years and over, for daily use, rinse with 10 mL
- **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Mouthwash 0.05%

**Fluorinse** (≡ mouthwash), red, sodium fluoride 2%. Net price 100 mL = £4.97. Counselling, see above
- **Dose** CHILD 8 years and over, for daily use, dilute 5 drops to 10 mL of water; for weekly use, dilute 20 drops to 10 mL
- **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Mouthwash 2%

---

**Fluoride tablets**

- **Fluoride Oral Drops** (Colgate-Palmolive)
  - **Dose** CHILD 6 years and over, for daily use, rinse with 10 mL
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Mouthwash 0.05%

- **Fluoride Mouthwash 2%** (Duraphat, = mouthwash), blue, sodium fluoride 0.05%. Net price 500 mL = £2.61. Counselling, see above

- **Fluoride Tablets**
  - **Fluor-a-day** (Dental Health)
    - **Tablets**, buff, sodium fluoride 1.1 mg (F⁻ 500 micrograms), net price 200-tab pack = £2.54
    - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets
  - **FluorGard** (Colgate-Palmolive)
    - **Tablets 0.5**, purple, grape-flavoured, scored, sodium fluoride 1.1 mg (F⁻ 500 micrograms), net price 200-tab pack = £1.91
    - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets
    - **Tablets 1.0**, orange, orange-flavoured, scored, sodium fluoride 2.2 mg (F⁻ 1 mg), net price 200-tab pack = £1.91
    - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Tablets

---

9.5.4 Zinc

Zinc supplements should not be given unless there is good evidence of deficiency (hypoprothrominaemia spuriously lowers plasma-zinc concentration) or in zinc-losing conditions. Zinc deficiency can occur as a result of inadequate diet or malabsorption; excessive loss of zinc can occur in trauma, burns, and protein-losing conditions. A zinc supplement is given until clinical improvement occurs, but it may need to be continued in severe malabsorption, metabolic disease (section 9.8.1), or in zinc-losing states.

Parenteral nutrition regimens usually include trace amounts of zinc (section 9.3). If necessary, further zinc can be added to intravenous feeding regimens. A suggested dose for intravenous nutrition is elemental zinc 6.5 mg (Zn⁺² 100 micromol) daily.

**FluoriGard** (Colgate-Palmolive)

- **Daily dental rinse** (= mouthwash), blue, sodium fluoride 0.05%. Net price 500 mL = £2.61. Counselling, see above
- **Dose** CHILD 6 years and over, for daily use, rinse with 10 mL
- **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Mouthwash 0.05%

**Gels**

- **FluoriGard** (Colgate-Palmolive)
  - **Gel-Kam** (= gel), stannous fluoride 0.4% in glycerol basis. Net price 100 mL = £2.63. Counselling, see below
  - **Dose** ADULT and CHILD 3 years and over, for daily use, using a toothbrush, apply onto all tooth surfaces
  - **Counselling** Swish between teeth for 1 minute before spitting out
  - **Avoid** eating, drinking, or rinsing mouth for at least 30 minutes after use

**Toothpastes**

- **Duraphat** (Colgate-Palmolive) (≡ mouthwash), blue, sodium fluoride 0.619%. Net price 75 mL = £3.26, dual pack (2 × 75 mL) = £5.54. Counselling, see below
  - **Dose** ADULT and CHILD over 10 years, apply 1 cm twice daily using a toothbrush
  - **Counselling** Brush teeth for 1 minute before spitting out
  - **Avoid** drinking or rinsing mouth for 30 minutes after use
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Toothpaste 0.619%
  - **Duraphat** *5000 ppm* toothpaste, sodium fluoride 1.1%. Net price 51 g = £6.50. Counselling, see below
  - **Dose** ADULT and ADOLESCENT over 16 years, apply 2 cm 3 times daily after meals using a toothbrush
  - **Counselling** Brush teeth for 3 minutes before spitting out
  - **Dental prescribing on NHS** May be prescribed as Sodium Fluoride Toothpaste 1.1%

---

9.5.4 Zinc

**Indications** zinc deficiency or supplementation in zinc-losing conditions

**Cautions** interactions: Appendix 1 (zinc)

**Renal impairment** accumulation may occur in acute renal failure

**Pregnancy** crosses placenta; risk theoretically minimal, but no information available

**Breast-feeding** present in milk; risk theoretically minimal, but no information available
Side-effects  abdominal pain, dyspepsia, nausea, vomiting, diarrhoea, gastric irritation; irritability, headache, lethargy

Dose  ● See preparation below and notes above

Zinc Sulphate  (Non-proprietary)
Injection, zinc sulphate 14.6 mg/mL (zinc 50 micro-mol/mL), net price 10 mL vial = £2.50

Solvazinc® (Galen)
Effervescent tablets, zinc sulphate monohydrate 125 mg (45 mg zinc), net price 30 = £4.32. Label: 13, 21
Dose  ADULT and CHILD over 30 kg, 1 tablet in water 1–3 times daily after food; CHILD under 10 kg, ½ tablet daily; 10–30 kg, ½ tablet 1–3 times daily

9.5.5 Selenium

Selenium deficiency can occur as a result of inadequate diet or prolonged parenteral nutrition. A selenium supplement should not be given unless there is good evidence of deficiency.

SELENIUM

Indications selenium deficiency
Cautions interactions: Appendix 1 (selenium)
Dose  ● By mouth or by intramuscular injection or by intravenous injection, 100–500 micrograms daily

Selenase® (Oxford Nutrition)
Oral solution, selenium (as sodium selenite pentahydrate) 50 micrograms/mL, net price 2-mL amp = £1.03, 10-mL bottle = £4.05
Injection, selenium (as sodium selenite pentahydrate) 50 micrograms/mL, net price 2-mL amp = £1.50, 10-mL vial = £4.25

9.6 Vitamins

9.6.1 Vitamin A

Deficiency of vitamin A (retinol) is associated with ocular defects (particularly xerophthalmia) and an increased susceptibility to infections, but deficiency is rare in the UK (even in disorders of fat absorption). Massive overdose can cause rough skin, dry hair, an enlarged liver, and a raised erythrocyte sedimentation rate and raised serum calcium and serum alkaline phosphatase concentrations.

Pregnancy  In view of evidence suggesting that high levels of vitamin A may cause birth defects, women who are (or may become) pregnant are advised not to take vitamin A supplements (including tablets and fish-liver oil drops), except on the advice of a doctor or an antenatal clinic; nor should they eat liver or products such as liver paté or liver sausage.

VITAMIN A  (Retinol)

Indications see notes above
Cautions see notes above; interactions: Appendix 1 (vitamins)
Pregnancy  excessive doses may be teratogenic; see also notes above
Breast-feeding  theoretical risk of toxicity in infants of mothers taking large doses
Side-effects see notes above
Dose  ● See notes above and under preparations

>Vitamins A and D

Halibut-liver Oil  (Non-proprietary)
Capsules, vitamin A 4000 units [also contains vitamin D], net price 100-cap pack = £1.05

Vitamins A and D  (Non-proprietary)
Capsules, vitamin A 4000 units, vitamin D 400 units, net price 84-cap pack = £3.44
Note  May be difficult to obtain

>Vitamins A, C and D

Healthy Start Children’s Vitamin Drops  (Non-proprietary)
Oral drops, vitamin A 5000 units, vitamin D 2000 units, ascorbic acid 150 mg/mL
Available free of charge to children under 4 years in families on the Healthy Start Scheme, or alternatively may be available direct to

Dietary reference values for vitamins are available in the Department of Health publication:

Dental patients  It is unjustifiable to treat stomatitis or glossitis with mixtures of vitamin preparations; this delays diagnosis and correct treatment. Most patients who develop a nutritional deficiency despite an adequate intake of vitamins have malabsorption and if this is suspected the patient should be referred to a medical practitioner.
9 Nutrition and blood

9.6.2 Vitamin B group

Deficiency of the B vitamins, other than vitamin B12 (section 9.1.2), is rare in the UK and is usually treated by preparations containing thiamine (B1), riboflavin (B2), and nicotinamide, which is used in preference to nicotinic acid, as it does not cause vasodilatation. Other members (or substances traditionally classified as members) of the vitamin B complex such as aminobenzoic acid, biotin, choline, inositol, and pantothenic acid or pyridoxine may be included in vitamin B preparations but there is no evidence of their value.

The severe deficiency states Wernicke’s encephalopathy and Korsakoff’s psychosis, especially as seen in chronic alcoholism (section 4.10.1), are best treated initially by parenteral administration of vitamin B (see MHRA/CHM advice, below). Followed by oral administration of thiamine in the longer term. Anaphylaxis has been reported with thiamine followed by oral administration of alcoholism (section 4.10.1), are best treated initially by

Note Healthy Start Vitamins for women (containing ascorbic acid, vitamin D, and folic acid) are also available free of charge to women on the Healthy Start Scheme during pregnancy and until their baby is one year old, or alternatively may be available direct to the public—further information on where to obtain supplies.

Breast-feeding severely thiamine-deficient mothers should avoid breast-feeding as toxic methyl-glyoxal present in milk

Indications

see notes above

Cautions

anaphylaxis may occasionally follow injection (see MHRA/CHM advice below)

MHRA/CHM advice (September 2007)

Although potentially serious allergic adverse reactions may rarely occur during, or shortly after, parenteral administration, the CHM has recommended that:

1. This should not preclude the use of parenteral thiamine in patients where this route of administration is required, particularly in patients at risk of Wernicke-Korsakoff syndrome where treatment with thiamine is essential;

2. Intravenous administration should be by infusion over 30 minutes;

3. Facilities for treating anaphylaxis (including resuscitation facilities) should be available when parenteral thiamine is administered.

RIBOFLAVIN

(Riboflavin, vitamin B2)

Indications

see notes above

Preparations

Injections of vitamins B and C, see under Thiamine

Oral vitamin B complex preparations

See p. 617

Oral vitamin B complex preparations

See p. 617

Note

Pabrinex® doses in BNF may differ from those in product literature
PYRIDOXINE HYDROCHLORIDE
(Vitamin B₆)

**Indications**  see under Dose

**Cautions**  interactions: Appendix 1 (vitamins)

**Side-effects**  sensory neuropathy reported with high doses given for extended periods

**Dose**
- Deficiency states, 20–50 mg up to 3 times daily
- Isoniazid-induced neuropathy, prophylaxis 10 mg daily (or 20 mg daily if suitable product not available); treatment, 50 mg three times daily; CHILD under 18 years see BNF for Children
- Idiopathic sideroblastic anaemia, 100–400 mg daily in divided doses
- Penicillamine-induced neuropathy, prophylaxis in Wilson’s disease [unlicensed use] (see also notes above), 20 mg daily; CHILD under 18 years see BNF for Children
- Premenstrual syndrome [unlicensed use], 50–100 mg daily (see notes above)

Prolonged use of pyridoxine in a dose of 10 mg daily is considered safe but the long-term use of pyridoxine in a dose of 200 mg or more daily has been associated with neuropathy. The safety of long-term pyridoxine supplementation with doses above 10 mg daily has not been established.

**Pyridoxine (Non-proprietary)**
- Tablets, pyridoxine hydrochloride 10 mg, net price 500 = £8.53; 20 mg, 500 = £8.53; 50 mg, 28 = £1.52

**Injections of vitamins B and C**
See under Thiamine

NICOTINAMIDE

**Indications**  see notes above; acne vulgaris, see section 13.6.1

**Injections of vitamins B and C**
See under Thiamine

Oral vitamin B complex preparations

Note  Other multivitamin preparations are in section 9.6.7.

**Vitamin B Tablets, Compound**
- Tablets, nicotinamide 15 mg, riboflavin 1 mg, thiamine hydrochloride 1 mg, net price 28 = £1.00
- Dose  prophylactic, 1–2 tablets daily

**Vitamin B Tablets, Compound, Strong**
- Tablets, brown, f/c or s/c, nicotinamide 20 mg, pyridoxine hydrochloride 2 mg, riboflavin 2 mg, thiamine hydrochloride 5 mg. Net price 28 tablets pack = £2.30
- Dose  treatment of vitamin-B deficiency, 1–2 tablets 3 times daily

**Vigranon B** (Wallace Mfg)
- Syrup, thiamine hydrochloride 5 mg, riboflavin 2 mg, nicotinamide 20 mg, pyridoxine hydrochloride 2 mg, panthenol 3 mg/5 mL. Net price 150 mL = £2.41

Other compounds

Potassium aminobenzoate has been used in the treatment of various disorders associated with excessive fibrosis such as scleroderma but its therapeutic value is doubtful.

**Potaba®** (Glenwood)
- Capsules, potassium aminobenzoate 500 mg, net price 240 = £35.80. Label: 21
- Envules® (= powder in sachets), potassium aminobenzoate 3 g, net price 40 sachets = £27.45. Label: 13, 21
- Dose  Peyronie’s disease, scleroderma, 12 g daily in divided doses after food

9.6.3 Vitamin C  
(Ascorbic acid)

Vitamin C therapy is essential in scurvy, but less florid manifestations of vitamin C deficiency are commonly found, especially in the elderly. It is rarely necessary to prescribe more than 100 mg daily except early in the treatment of scurvy.

Severe scurvy causes gingival swelling and bleeding margins as well as petechiae on the skin. This is, however, exceedingly rare and a patient with these signs is more likely to have leukaemia. Investigation should not be delayed by a trial period of vitamin treatment.

Claims that vitamin C ameliorates colds or promotes wound healing have not been proved.

**Ascorbic Acid**

**Indications**  prevention and treatment of scurvy

**Cautions**  interactions: Appendix 1 (vitamins)

**Dose**
- Prophylactic, 25–75 mg daily; therapeutic, not less than 250 mg daily in divided doses

**Ascorbic Acid (Non-proprietary)**
- Tablets, ascorbic acid 50 mg, net price 28 = £1.79; 100 mg, 28 = £1.42; 200 mg, 28 = £1.42; 500 mg (label: 24), 28 = £2.34
- Brands include Redoxon®
- Injection, ascorbic acid 100 mg/mL. Net price 5-mL amp = £4.39

Available from UCB Pharma

9.6.4 Vitamin D

**Note**  The term Vitamin D is used for a range of compounds which possess the property of preventing or curing rickets. They include ergocalciferol (calciferol, vitamin D₂), colecalciferol (vitamin D₃), dihydrotachysterol, alfalcidol (1α-hydroxycholecalciferol), and calcitriol (1,25-dihydroxycholecalciferol).

Simple vitamin D deficiency can be prevented by taking an oral supplement of only 10 micrograms (400 units) of ergocalciferol (calciferol, vitamin D₂) or colecalciferol (vitamin D₃) daily. Vitamin D deficiency can occur in people whose exposure to sunlight is limited and in those whose diet is deficient in vitamin D. In these
individuals, ergocalciferol or colecalciferol in a dose of 20 micrograms (800 units) daily by mouth may be given to treat vitamin D deficiency; higher doses may be necessary for severe deficiency. Patients who do not respond should be referred to a specialist.

Preparations containing calcium with colecalfilerol are available for the management of combined calcium and vitamin D deficiency, or for those at high risk of deficiency (see also Osteoporosis, p. 469 and Calcium Supplements, p. 608).

Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease usually requires vitamin D in pharmacological doses, such as ergocalciferol tablets up to 1 mg (40 000 units) daily; the hypocalcaemia of hypoparathyroidism often requires doses of up to 2.5 mg (100 000 units) daily in order to achieve normocalcaemia.

Vitamin D requires hydroxylation by the kidney to its active form, therefore the hydroxylated derivatives alfacalcidol or calcitriol should be prescribed if patients with severe renal impairment require vitamin D therapy. Calcitriol is also licensed for the management of post-menopausal osteoporosis.

Paricalcitol, a synthetic vitamin D analogue, is licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure (section 9.5.1.2).

Important. All patients receiving pharmacological doses of vitamin D should have their plasma-calcium concentration checked at intervals (initially once or twice weekly) and whenever nausea or vomiting occur.

### Ergocalciferol

(Calciferol, Vitamin D₂)

**Indications** see notes above

**Cautions** take care to ensure correct dose in infants; monitor plasma-calcium concentration in patients receiving high doses and in renal impairment (see notes above); interactions: Appendix 1 (vitamins)

**Contra-indications** hyperparathyroidism; metastatic calcification

**Pregnancy** high systemic doses teratogenic in animals but therapeutic doses unlikely to be harmful

**Breast-feeding** caution with high systemic doses; may cause hyperparathyroidism in infant—monitor serum-calcium concentration

**Side-effects** symptoms of overdosage include anorexia, listlessness, nausea and vomiting, diarrhoea, constipation, weight loss, polyuria, sweating, headache, thirst, vertigo, and raised concentrations of calcium and phosphate in plasma and urine

**Dose**

- See notes above

**Daily supplements**

Note There is no plain vitamin D tablet available for treating simple deficiency (see notes above). Alternatives include vitamin capsules (section 9.6.7), preparations of vitamins A and D (section 9.6.8), and calcium and ergocalciferol tablets (see below).

For prescribing information on calcium, see section 9.5.1.1

### Calcium and Ergocalciferol

(Non-proprietary)

**Calcium and Vitamin D**

**Tablets**, calcium lactate 300 mg, calcium phosphate 150 mg (calcium 97 mg or Ca²⁺ 2.4 mmol), ergocalciferol 10 micrograms (400 units). Net price 28-tab pack = £7.10. Counselling, crush before administration or may be chewed

#### Pharmacological strengths

Note The BP directs that when calciferol is prescribed or demanded, colecalfilerol or ergocalciferol should be dispensed or supplied

### Ergocalciferol (Non-proprietary)

**Tablets**, ergocalciferol 250 micrograms (10 000 units), net price 100 = £21.99; 1.25 mg (50 000 units), 100 = £30.34

Note May be difficult to obtain

Important When the strength of the tablets ordered or prescribed is not clear, the intention of the prescriber with respect to the strength (expressed in micrograms or milligrams per tablet) should be ascertained

**Injection**, for intramuscular use only, ergocalciferol, 7.5 mg (300 000 units)/mL in oil, net price 1-mL amp = £8.50, 2-mL amp = £9.85

### Alfacalcidol (1α-Hydroxycholecalciferol)

**Indications** see notes above

**Cautions** see under Ergocalciferol; also nephrolithiasis

**Contra-indications** see under Ergocalciferol

**Pregnancy** see under Ergocalciferol

**Breast-feeding** see under Ergocalciferol

**Side-effects** see under Ergocalciferol; also rarely nephrocalcinosis, pruritus, rash, and urticaria

**Dose**

- By mouth or by intravenous injection over 30 seconds, ADULT and CHILD over 20 kg, initially 1 microgram daily (elderly 500 nanograms), adjusted to avoid hypercalcaemia; maintenance, usually 0.25–1 microgram daily; NEONATE and PRETERM NEONATE initially 50–100 nanograms/kg daily, CHILD under 20 kg initially 50 nanograms/kg daily

**Alfacalcidol (Non-proprietary)**

**Capsules**, alfacalcidol 250 nanograms, net price 30-cap pack = £5.94; 500 nanograms 30-cap pack = £11.64; 1 microgram 30-cap pack = £15.91

**One-Alpha® (LEO)**

**Capsules**, alfacalcidol 250 nanograms (white), net price 30-cap pack = £3.37; 500 nanograms (red), 30-cap pack = £6.27; 1 microgram (brown), 30-cap pack = £8.75

**Excipients** include sesame oil

**Oral drops**, sugar-free, alfacalcidol 2 micrograms/mL (1 drop contains approx. 100 nanograms), net price 10 mL = £22.49

**Excipients** include alcohol

Note The concentration of alfacalcidol in One-Alpha® drops is 10 times greater than that of the former preparation One-Alpha® solution

**Injection**, alfacalcidol 2 micrograms/mL, net price 0.5-mL amp = £2.16, 1-mL amp = £4.11

**Excipients** include alcohol, propylene glycol (caution in neonates, see Excipients, p. 2)

**Note** Shake ampoule for at least 5 seconds before use

### Calcitriol (1,25-Dihydroxycholecalciferol)

**Indications** see notes above

**Cautions** see under Ergocalciferol; monitor plasma calcium, phosphate, and creatinine during dosage titration
BNF 61

6.6.4 Vitamin D 619

**Contra-indications** see under Ergocalciferol

**Pregnancy** see under Ergocalciferol

**Breast-feeding** see under Ergocalciferol

**Side-effects** see under Ergocalciferol

**Dose**
- **By mouth**, renal osteodystrophy, initially 250 nanograms daily, or on alternate days (in patients with normal or only slightly reduced plasma-calcium concentration), increased if necessary in steps of 250 nanograms at intervals of 2–4 weeks; usual dose 0.5–1 microgram daily; **CHILD** not established
- Established postmenopausal osteoporosis, 250 nanograms twice daily (monitor plasma-calcium concentration and creatinine, consult product literature)

- **By intravenous injection** (or injection through catheter after haemodialysis), hypocalcaemia in dialysis patients with chronic renal failure, initially 500 nanograms (approx. 10 nanograms/kg) 3 times a week; increased if necessary in steps of 250–500 nanograms at intervals of 2–4 weeks; usual dose 0.5–3 micrograms 3 times a week; **CHILD** see **BNF for Children**

Moderate to severe secondary hyperparathyroidism in dialysis patients, initially 0.5–4 micrograms 3 times a week, increased if necessary in steps of 250–500 nanograms at intervals of 2–4 weeks; max. 8 micrograms 3 times a week

**Calcitriol** (Non-proprietary)

**Capsules**, calcitriol 250 nanograms, net price 30-cap pack = £18.04, 100-cap pack = £19.15; 500 nanograms, 30-cap pack = £32.25, 100-cap pack = £56.76

**Roocaltrol** (Roche)

**Capsules**, calcitriol 250 nanograms (red/white), net price 100 = £18.04; 500 nanograms (red), 100 = £32.25

**Calcijex** (Abbott)

**Injection**, calcitriol 1 microgram/mL, net price 1-mL amp = £5.14; 2 micrograms/mL, 1-mL amp = £10.28

**Colecalciferol** (Cholecalciferol, vitamin D₃)

**Indications** see notes above

**Cautions** see under Ergocalciferol

**Contra-indications** see under Ergocalciferol

**Pregnancy** see under Ergocalciferol

**Breast-feeding** see under Ergocalciferol

**Side-effects** see under Ergocalciferol

**Dose**
- **See notes above**

**Colecalciferol** (Non-proprietary)

**Capsules**, colecalciferol 20 000 units

Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

**With calcium**

For prescribing information on calcium, see section 9.5.1.1

**Adcal-D₃** (ProStrakan)

**Tablets** (chewable) (lemon or tutti-frutti flavour), calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units), net price 56-tab pack = £3.89, 112-tab pack = £7.78. **Label**: 24

**Dissolve** (effervescent tablets), lemon flavour, calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units), net price 56-tab pack = £4.99. **Label**: 13

**Cacit** D₃ (Warner Chilcott)

**Granules**, effervescent, lemon flavour, calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 11 micrograms (440 units)/sachet, net price 30-sachet pack = £4.06. **Label**: 13

**Calceos** (Galen)

**Tablets** (chewable), lemon flavour, calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units), net price 60-tab pack = £3.62. **Label**: 24

**Calchew-D₃** (Shire)

**Calchew-D₃ Tablets** (chewable), orange flavour, calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units), net price 100-tab pack = £7.68. **Exipients include** aspartame (section 9.4.1)

**Calchew-D₃ Forte Tablets** (chewable), orange flavour, calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units), net price 60-tab pack = £4.32, 100-tab pack = £7.21. **Label**: 24

**Exipients include** aspartame, see **Exipients**, p. 2

**Calfovit D₃** (Menarini)

**Powder**, lemon flavour, calcium carbonate 3.1 g (calcium 1.2 g or Ca²⁺ 30 mmol), colecalciferol 20 micrograms (800 units), net price 30-sachet pack = £4.32. **Label**: 13, 21

**Natecal D₃** (Chiesi)

**Tablets** (chewable), (aniseed, peppermint, and molasses flavour), calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units), net price 60-tab pack = £3.63. **Label**: 24

**Exipients include** aspartame (section 9.4.1)

**Sandocal®+D** (Novartis Consumer Health)

**Sandocal®+D 600 tablets**, effervescent, orange flavour, calcium lactate gluconate 1.36 g, calcium carbonate 1.05 g, providing calcium 600 mg (Ca²⁺ 15 mmol), colecalciferol concentrate 4 mg, providing colecalciferol 10 micrograms (400 units), net price 60-tab pack = £5.35, 100-tab pack = £8.75. **Label**: 13

**Exipients include** aspartame (section 9.4.1)

**Sandocal®+D 1200 tablets**, effervescent, orange flavour, calcium lactate gluconate 2.72 g, calcium carbonate 2.1 g, providing calcium 1200 mg (Ca²⁺ 30 mmol), colecalciferol concentrate 8 mg, providing colecalciferol 20 micrograms (800 units), net price 30-tab pack = £4.32. **Label**: 13

**Exipients include** aspartame (section 9.4.1)

**With alendronic acid**

Section 6.6.2

**With risedronate sodium and calcium**

Section 6.6.2
**DIHYDROTACHYSTEROL**

**Indications** see notes above

**Cautions** see under Ergocalciferol

**Contra-indications** see under Ergocalciferol

**Pregnancy** see under Ergocalciferol

**Breast-feeding** see under Ergocalciferol

**Side-effects** see under Ergocalciferol

**AT 10® (intraharm) Oral solution**, dihydrotachysterol 250 micrograms/mL. Net price 15-mL dropper bottle = £22.87

Excipients include arachis (peanut) oil

**Dose** acute, chronic, and latent forms of hypocalcaemic tetany due to hypoparathyroidism, consult product literature

**PARICALCITOL**

**Indications** see under preparations below

**Cautions** monitor plasma calcium and phosphate during dose titration and at least monthly when stabilised; monitor parathyroid hormone concentration; interactions: Appendix 1 (vitamins)

**Contra-indications** see under Ergocalciferol

**Pregnancy** toxicity in animal studies—manufacturer advises avoid unless potential benefit outweighs risk; see also under Ergocalciferol

**Breast-feeding** manufacturer advises caution—no information available; see also under Ergocalciferol

**Side-effects** see under Ergocalciferol; also dyspepsia, taste disturbance, breast tenderness, acne, pruritus, and rash

**Dose** consult product literature

Zemplar® (Abbott) [Non-proprietary]

**Capsules**, paricalcitol 1 microgram (grey), net price 28-cap pack = £89.44; 2 micrograms (orange-brown), 28-cap pack = £138.88; 4 micrograms (gold), 28-cap pack = £277.76

For prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure

**Injection**, paricalcitol 5 micrograms/mL, net price 1-mL amp = £12.40, 2-mL amp = £24.80. For injection via haemodialysis access

Excipients include propylene glycol, see Excipients, p. 2

For prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in patients on haemodialysis

**ALPHA TOCOPHERYL ACETATE**

**Indications** see notes above

**Cautions** predisposition to thrombosis; increased risk of necrotising enterocolitis in neonate weighing less than 1.5 kg; interactions: Appendix 1 (vitamins)

**Pregnancy** no evidence of safety of high doses

**Breast-feeding** excreted in milk; minimal risk, although caution with large doses

**Side-effects** diarrhoea and abdominal pain with doses more than 1 g daily

Vitamin E Suspension (Non-proprietary) Suspension, alpha tocopheryl acetate 500 mg/5 mL.

Net price 100 mL = £30.55

**Dose** malabsorption in cystic fibrosis, 100–200 mg daily; CHILD 1 month–1 year 50 mg daily; 1–12 years, 100 mg daily

Malabsorption in abetalipoproteinaemia, ADULT and CHILD 50–100 mg/kg daily

Malabsorption in chronic cholestasis and severe liver disease, CHILD see BNF for Children

Note Tablets containing tocopheryl acetate are available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

**ALPHA TOCOPHEROL**

**Indications** vitamin E deficiency because of malabsorption in congenital or hereditary chronic cholestasis

**Cautions** predisposition to thrombosis; interactions: Appendix 1 (Vitamin E)

**Contra-indications** preterm neonates

**Hepatic impairment** manufacturer advises caution and monitor closely—no information available

**Renal impairment** manufacturer advises caution and monitor closely; risk of renal toxicity due to polyethylene glycol content

**Pregnancy** manufacturer advises caution, no evidence of harm in animal studies

**Breast-feeding** manufacturer advises use only if potential benefit outweighs risk—no information available

**Side-effects** diarrhoea; less commonly asthenia, headache, disturbances in serum-potassium and serum-sodium concentrations, alopecia, pruritus, and rash

Vedrop® (Orphan Europe) [Non-proprietary]

**Oral solution**, yellow, n-alpha tocopherol (as tocopherol) 30 mg/mL, net price 20 mL = £54.55, 60 mL = £163.65 (all with oral syringe)

Note Tocodrol is a water-soluble form of n-alpha tocopherol

Dose CHILD under 18 years, 17 mg/kg daily, adjusted as necessary

**9.6.5 Vitamin E (Tocopherols)**

The daily requirement of vitamin E has not been well defined but is probably about 3 to 15 mg daily. There is little evidence that oral supplements of vitamin E are essential in adults, even where there is fat malabsorption secondary to cholestasis. In young children with congenital cholestasis, abnormally low vitamin E concentrations may be found in association with neuromuscular abnormalities, which usually respond only to the parenteral administration of vitamin E.

Vitamin E has been tried for various other conditions but there is little scientific evidence of its value.

**9.6.6 Vitamin K**

Vitamin K is necessary for the production of blood clotting factors and proteins necessary for the normal calcification of bone.

Because vitamin K is fat soluble, patients with fat malabsorption, especially in biliary obstruction or hepatic disease, may become deficient. Menadiol sodium phosphate is a water-soluble synthetic vitamin K derivative that can be given orally to prevent vitamin K deficiency in malabsorption syndromes.
Oral coumarin anticoagulants act by interfering with vitamin K metabolism in the hepatic cells and their effects can be antagonised by giving vitamin K; for advice on the use of vitamin K in haemorrhage, see section 2.8.2.

**Vitamin K deficiency bleeding** Neonates are relatively deficient in vitamin K and those who do not receive supplements of vitamin K are at risk of serious bleeding including intracranial bleeding. The Chief Medical Officer and the Chief Nursing Officer have recommended that all newborn babies should receive vitamin K to prevent vitamin K deficiency bleeding (previously termed haemorrhagic disease of the newborn). An appropriate regimen should be selected after discussion with parents in the antenatal period.

Vitamin K (as phytomenadione) 1 mg may be given by a single intramuscular injection at birth; this prevents vitamin K deficiency bleeding in virtually all babies. For preterm neonates, see *BNF for Children*.

Alternatively, in healthy babies who are not at particular risk of bleeding disorders, vitamin K may be given by mouth, and arrangements must be in place to ensure the appropriate regimen is followed. Two doses of a colloidal (mixed micelle) preparation of phytomenadione 2 mg should be given by mouth in the first week; the first dose being given at birth and the second dose at 4–7 days. For exclusively breast-fed babies, a third dose of colloidal phytomenadione 2 mg is given by mouth at 1 month of age; the third dose is omitted in formula-fed babies because formula feeds contain adequate vitamin K. An alternative regimen is to give one dose of phytomenadione 1 mg by mouth at birth (using the contents of a phytomenadione capsule, see preparation below) to protect from the risk of vitamin K deficiency bleeding in the first week; for exclusively breast-fed babies, further doses of phytomenadione 1 mg are given by mouth (using the contents of a phytomenadione capsule) at weekly intervals for 12 weeks.

### Menadiol Sodium Phosphate

**Indications** see notes above

**Cautions** G6PD deficiency (section 9.1.5) and vitamin E deficiency (risk of haemolysis); *interactions*: Appendix 1 (vitamins)

**Contra-indications** neonates and infants

**Pregnancy** avoidance in late pregnancy and labour unless benefit outweighs risk of neonatal haemolytic anaemia, hyperbilirubinaemia, and kernicterus in neonate

**Dose**

- 10–40 mg daily, adjusted as necessary; **CHILD** 1–12 years, 5–10 mg daily, adjusted as necessary, 12–18 years, 10–20 mg daily, adjusted as necessary

**Menadil Phosphate** (Non-proprietary)

**Tablets** menadil sodium phosphate equivalent to 10 mg of menadil phosphate, net price 100-tab pack = £58.39

### Phytomenadione

**Vitamin K**

**Indications** see notes above

**Cautions** intravenous injections should be given very slowly (see also below); *interactions*: Appendix 1 (vitamins)

**Pregnancy** use if potential benefit outweighs risk

**Breast-feeding** present in milk, but see notes above

**Dose**

- See notes above and section 2.8.2

**Neokay** (Neoceuticals)  

**Capsules**, brown, phytomenadione 1 mg in an oily basis, net price 12-cap pack = £3.95; 100-cap pack = £34.00

**Note** The contents of one capsule should be administered by cutting the narrow tubular tip off and squeezing the liquid contents into the mouth; if the baby spits out the dose or is sick within three hours of administration a replacement dose should be given

### Colloidal formulation

**Konakion** MM (Roche)  

**Injection**, phytomenadione 10 mg/mL in a mixed micelles vehicle, net price 1-mL amp = 38p

**Excipients** include glycocholic acid 54.6 mg/amp, lecithin

**Cautions** reduce dose in elderly, liver impairment (glycocholic acid may displace bilirubin); reports of anaphylactoid reactions

**Note** Konakion® MM may be administered by slow intravenous injection or by intravenous infusion in glucose 5% (see Appendix 6); not for intramuscular injection

**Konakion** MM Paediatric (Roche)  

**Injection**, phytomenadione 10 mg/mL in a mixed micelles vehicle, net price 0.2-mL amp = 95p

**Excipients** include glycocholic acid 10.9 mg/amp, lecithin

**Cautions** parenteral administration in neonate of less than 2.5 kg (increased risk of kernicterus)

**Note** Konakion® MM Paediatric may be administered by mouth or by intramuscular injection or by intravenous injection

### 9.6.7 Multivitamin preparations

**Vitamins**

**Capsules**, ascorbic acid 15 mg, nicotinamide 7.5 mg, riboflavin 500 micrograms, thiamine hydrochloride 1 mg, vitamin A 2500 units, vitamin D 300 units, net price 28-cap pack = £1.50

**Abidec** (Chefaro UK)

**Drops**, vitamins A, B group, C, and D, net price 25 mL (with dropper) = £2.20

**Excipients** include arachis (peanut) oil

**Note** Contains 1333 units of vitamin A (as palmitate) per 0.6-mL dose

**Dalivit** (LPC)  

**Oral drops**, vitamins A, B group, C, and D, net price 25 mL = £2.98, 50 mL = £4.85

**Note** Contains 5000 units of vitamin A (as palmitate) per 0.6-mL dose

**Vitamin and mineral supplements and adjuncts to synthetic diets**

**Forceval** (Alliance)  

**Capsules**, brown/red, vitamins (ascorbic acid 60 mg, biotin 100 micrograms, cyanocobalamin 3 micrograms, folic acid 400 micrograms, nicotinamide 18 mg, pantothenic acid 4 mg, pyridoxine 2 mg, riboflavin 1.6 mg, thiamine 1.2 mg, vitamin A 2500 units, vitamin D, 400 units, vitamin E 10 mg, minerals and trace elements (calcium 100 mg, chromium 200 micrograms, copper 2 mg, iodine 140 micrograms, iron 12 mg, magnesium 30 mg, manganese
3 mg, molybdenum 250 micrograms, phosphorus 77 micrograms, potassium 4 mg, selenium 50 micrograms, zinc 15 mg), net price 15-cap pack = £2.83, 30-cap pack = £5.19, 90-cap pack = £12.53. Label: 25

**Dose** vitamin and mineral deficiency and as adjunct in synthetic diets. ADULT 1 capsule daily one hour after a meal.

**Junior capsules**, brown, vitamins (ascorbic acid 25 mg, biotin 50 micrograms, cyanocobalamin 2 micrograms, folic acid 100 micrograms, nicotinamide 7.5 mg, pantothenic acid 2 mg, pyridoxine 1 mg, riboflavin 1 mg, thiamine 1.5 mg, vitamin A 1250 units, vitamin D3 200 units, vitamin E 5 mg, vitamin K1 25 micrograms), minerals and trace elements (chromium 50 micrograms, copper 1 mg, iodine 75 micrograms, iron 5 mg, magnesium 1 mg, manganese 1.25 mg, molybdenum 50 micrograms, selenium 25 micrograms, zinc 5 mg), net price 30-cap pack = £5.32, 60-cap pack = £6.69

**Dose** vitamin and mineral deficiency and as adjunct in synthetic diets. CHILD over 5 years, 2 junior capsules daily

**Ketovite** (Paines & Byrne)

- **Tablets** (Paine, yellow, ascorbic acid 16.6 mg, riboflavin 1 mg, thiamine hydrochloride 1 mg, pyridoxine hydrochloride 330 micrograms, nicotinamide 3.3 mg, calcium pantothenate 1.16 mg, alpha tocopheryl acetate 5 mg, inositol 50 mg, biotin 170 micrograms, folic acid 25 micrograms, acetylsalicylic acid 500 micrograms, net price 100-tab pack = £4.17

**Dose** prevention of vitamin deficiency in disorders of carbohydrate or amino-acid metabolism and adjunct in restricted, specialised, or synthetic diets, 1 tablet 3 times daily; use with Ketovite® Liquid for complete vitamin supplementation

- **Liquid**, pink, sugar-free, vitamin A 2500 units, ergocalciferol 400 units, choline chloride 150 mg, cyano-cobalamin 12.5 micrograms/5 mL, net price 150-mL pack = £2.70

**Dose** prevention of vitamin deficiency in disorders of carbohydrate or amino-acid metabolism and adjunct in restricted, specialised, or synthetic diets, 5 mL daily; use with Ketovite® Tablets for complete vitamin supplementation

---

### 9.7 Bitters and tonics

Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use.

### 9.8 Metabolic disorders

#### 9.8.1 Drugs used in metabolic disorders

**Acute porphyrias**

**Indications** Wilson’s disease in patients intolerant of penicillamine; it is not an alternative to penicillamine for rheumatoid arthritis or cystinuria. Penicillamine-induced systemic lupus erythematosus may not resolve on transfer to trientine.

**Zinc** prevents the absorption of copper in Wilson’s disease. Symptomatic patients should be treated initially with a chelating agent because zinc has a slow onset of action. When transferring from chelating treatment to zinc maintenance therapy, chelating treatment should be co-administered for 2–3 weeks until zinc produces its maximal effect.

**Wilson’s disease**

Penicillamine (see also section 10.1.3) is used in Wilson’s disease (hepatolenticular degeneration) to aid the elimination of copper ions. See below for other indications.

**Trientine** is used for the treatment of Wilson’s disease only in patients intolerant of penicillamine; it is not an alternative to penicillamine for rheumatoid arthritis or cystinuria. Penicillamine-induced systemic lupus erythematosus may not resolve on transfer to trientine.

**Penicillamine**

**Indications** see under Dose below

**Cautions** section 10.1.3; also neurological involvement in Wilson’s disease

**Contra-indications** section 10.1.3

**Renal impairment** section 10.1.3

**Pregnancy** section 10.1.3

**Breast-feeding** section 10.1.3

**Side-effects** section 10.1.3; also neuropathy (especially if previous neurological involvement in Wilson’s disease—prophylactic pyridoxine recommended, see section 9.6.2)

**Dose**

- Wilson’s disease, 1.5–2 g daily in divided doses before food; max. 2 g daily for 1 year; maintenance 0.75–1 g daily; **ELDERLY** 20 mg/kg daily in divided doses, adjusted according to response; **CHILD** under 12 years see **BNF for Children**

- Autoimmune hepatitis (used rarely; after disease controlled with corticosteroids), initially 500 mg daily in divided doses increased slowly over 3 months; usual maintenance dose 1.25 g daily; **ELDERLY** not recommended

- Cystinuria, therapeutic, 1–3 g daily in divided doses before food, adjusted to maintain urinary cystine below 200 mg/litre; prophylactic (maintain urinary cystine below 300 mg/litre) 0.5–1 g at bedtime; maintain adequate fluid intake (at least 3 litres daily); **CHILD** and **ELDERLY** minimum dose to maintain urinary cystine below 200 mg/litre

- Severe active rheumatoid arthritis, section 10.1.3

**Preparations**

Section 10.1.3

**Trientine dihydrochloride**

**Indications** Wilson’s disease in patients intolerant of penicillamine

**Cautions** see notes above; **Interactions**: Appendix 1 (trientine)

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk; monitor maternal and neonatal serum-copper concentration; teratogenic in animal studies

**Side-effects** nausea, rash; very rarely anaemia; duodenitis and colitis also reported
Carnitine deficiency
Carnitine is available for the management of primary carnitine deficiency due to inborn errors of metabolism or of secondary deficiency in haemodialysis patients.

CARNITINE

Indications primary and secondary carnitine deficiency
Cautions diabetes mellitus; monitoring of free and acyl carnitine in blood and urine recommended.
Renal impairment accumulation of metabolites may occur with chronic oral administration in severe impairment
Pregnancy appropriate to use; no evidence of teratogenicity in animal studies
Side-effects nausea, vomiting, abdominal pain, diarrhoea, body odour; side-effects may be dose-related—monitor tolerance during first week and after any dose increase
Dose
- Primary deficiency, by mouth, up to 200 mg/kg daily in 2–4 divided doses; higher doses of up to 400 mg/kg daily occasionally required; usual max. 3 g daily.

AGALSIDASE ALFA and BETA

Indications Fabry’s disease (specialist use only)
Cautions interactions: Appendix 1 (agalsidase alfa and beta)
Infusion-related reactions infusion-related reactions very common; manage by slowing the infusion rate or interrupting the infusion, or minimise by pre-treatment with an anti-histamine, antipyretic, or corticosteroid—consult product literature
Pregnancy use with caution
Breast-feeding use with caution—no information available
Side-effects gastro-intestinal disturbances, taste disturbances; tachycardia, bradycardia, palpitation, hypertension, hypotension, chest pain, oedema, flushing, dyspnoea, cough, rhinorrhoea; headache, fatigue, dizziness, asthenia, paraesthesia, syncope, neuropathic pain, tremor, sleep disturbances; influenza-like symptoms, nasopharyngitis; muscle spasms, myalgia, arthralgia; eye irritation; tinnitus; hypersensitivity reactions, angioedema, pruritus, urticaria, rash, acne, less commonly cold extremities, parosmia, ear pain and swelling, skin discoloration, and injection-site reactions
Fabrazyme® (Genzyme) intravenous injection over 2–3 minutes, up to 100 mg/kg daily in 3–4 divided doses
- Secondary deficiency, by intravenous injection over 2–3 minutes, 20 mg/kg after each dialysis session (dosage adjusted according to plasma-carnitine concentration); maintenance (if benefit gained from first intravenous course), by mouth, 1 g daily
Agalsidase beta, net price 5-mg vial = £315.08; 35-mg vial = £1068.64
Dose By intravenous infusion, ADULT and CHILD over 8 years 1 mg/kg every 2 weeks
Replagal® (Shire HGT) Concentrate for intravenous infusion, agalsidase alfa 1 mg/mL, net price 1-mL vial = £356.85; 3.5-mL vial = £1068.64
Dose By intravenous infusion, ADULT and CHILD over 7 years 200 micrograms/kg every 2 weeks

9.8.1 Drugs used in metabolic disorders

ZINC ACETATE

Indications Wilson’s disease (initiated under specialist supervision)
Cautions portal hypertension (risk of hepatic decompensation when switching from chelating agent); monitor full blood count and serum cholesterol;
interactions: Appendix 1 (zinc)
Pregnancy reduce dose to 25 mg 3 times daily adjusted according to plasma-copper concentration and urinary copper excretion
Breast-feeding manufacturer advises avoid; present in milk—may cause zinc-induced copper deficiency in infant
Side-effects gastric irritation (usually transient; may be reduced if first dose taken mid-morning or with a little protein); less commonly sideroblastic anaemia and leucopenia
Dose
Note Dose expressed as elemental zinc
- Wilson’s disease, 50 mg 3 times daily (max. 50 mg 5 times daily), adjusted according to response; CHILD 1–6 years, 25 mg twice daily; 6–18 years, body-weight under 57 kg, 25 mg 3 times daily; body-weight over 57 kg, 50 mg 3 times daily; ADOLESCENT 16–18 years, 50 mg 3 times daily
Wilzin® (Orphan Europe) Capsules, zinc (as acetate) 25 mg (blue), net price 250-cap pack = £132.00; 50 mg (orange), 250-cap pack = £242.00. Label: 23

Carnitine Dihydrochloride (Univar) Capsules, trientine dihydrochloride 300 mg. Label: 6, 22

Dose
- ADULT and CHILD over 12 years, 1.2–2.4 g daily in 2–4 divided doses before food; CHILD 2–12 years, initially 0.6–1.5 g daily in 2–4 divided doses before food, adjusted according to response

Trientine Dihydrochloride (Univar) Dose
Side-effects nausea, vomiting, abdominal pain, diarrhoea, body odour; side-effects may be dose-related—monitor tolerance during first week and after any dose increase
Dose
- Primary deficiency, by mouth, up to 200 mg/kg daily in 2–4 divided doses; higher doses of up to 400 mg/kg daily occasionally required; usual max. 3 g daily; by intravenous injection over 2–3 minutes, up to 100 mg/kg daily in 3–4 divided doses
- Secondary deficiency, by intravenous injection over 2–3 minutes, 20 mg/kg after each dialysis session (dosage adjusted according to plasma-carnitine concentration); maintenance (if benefit gained from first intravenous course), by mouth, 1 g daily
Carnitor® (Sigma-Tau) Capsules, trientine dihydrochloride 300 mg. Label: 6, 22

Dose
- ADULT and CHILD over 12 years, 250-cap pack = £132.00; 50 mg (orange), 250-cap pack = £242.00. Label: 23
**Gaucher’s disease**

Imiglucerase, an enzyme produced by recombinant DNA technology, is administered as enzyme replacement therapy for non-neurological manifestations of type I or type III Gaucher’s disease, a familial disorder affecting principally the liver, spleen, bone marrow, and lymph nodes.

Velaglucerase alfa, an enzyme produced by recombinant DNA technology, is administered as enzyme replacement therapy for the treatment of type 1 Gaucher’s disease.

Miglulstat, an inhibitor of glucosylceramide synthase, is licensed for the treatment of mild to moderate type 1 Gaucher’s disease in patients for whom enzyme replacement therapy is unsuitable; it is given by mouth; see p. 627.

**IMIGLUCERASE**

**Indications** (specialist use only) non-neurological manifestations of type I or type III Gaucher’s disease

**Cautions** monitor for imiglucerase antibodies; when stabilised, monitor all parameters and response to treatment at intervals of 6–12 months

**Pregnancy** manufacturer advises use with caution

**Breast-feeding** no information available

**Side-effects** hypersensitivity reactions (including urticaria, angioedema, cyanosis, hypotension, flushing, tachycardia, paraesthesia, backache); less commonly nausea, vomiting, diarrhoea, abdominal cramps, headache, dizziness, fatigue, fever, arthralgia, and injection-site reactions

**Dose**
- By intravenous infusion, initially 60 units/kg once every 2 weeks (doses as low as 15 units/kg once every 2 weeks may improve haematological parameters and organomegaly, but not bone parameters); maintenance, adjust dose according to response

**Cerezyme** (Genzyme)

*Intravenous infusion*, powder for reconstitution, imiglucerase, net price 200-unit vial = £535.65; 400-unit vial = £1071.29

**Electrolytes** Na⁺ 0.62 mmol/200-unit vial, 1.24 mmol/400-unit vial

**VELAGLUCERASE ALFA**

**Indications** (specialist use only) type 1 Gaucher’s disease

**Cautions** monitor immunoglobulin G (IgG) antibody concentration in severe infusion-related reactions or if there is a lack or loss of effect with velaglucerase alfa

**Infusion-related reactions** Infusion-related reactions very common, manage by slowing the infusion rate, or interrupting the infusion, or minimise by pre-treatment with an antihistamine, antipyretic, or corticosteroid—consult product literature

**Pregnancy** manufacturer advises avoid unless essential

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** nausea, abdominal pain, tachycardia, hypertension, hypotension, flushing, headache, dizziness, malaise, pyrexia, arthralgia, bone pain, back pain, hypersensitivity reactions, rash, urticaria

**Dose**
- By intravenous infusion, ADULT and CHILD over 5 years, 1 mg/kg once weekly

Naglazyme® (BioMarin) ▼ ial

Concentrate for intravenous infusion, galsulfase 1 mg/mL, net price 5-mL vial = £982.00

**Mucopolysaccharidosis**

Laronidase, an enzyme produced by recombinant DNA technology, is licensed for long-term replacement therapy in the treatment of non-neurological manifestations of mucopolysaccharidosis I, a lysosomal storage disorder caused by deficiency of alpha-L-iduronidase.

Idursulfase, an enzyme produced by recombinant DNA technology, is licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase.

Galsulfase, a recombinant form of human N-acetylgalactosamine-4-sulfatase, is licensed for long-term replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

**Infusion-related reactions** Infusion-related reactions often occur with administration of laronidase, idursulfase, and galsulfase; they can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid—consult product literature for details.

**GALSULFASE**

**Indications** (specialist use only) mucopolysaccharidosis VI

**Cautions** respiratory disease; acute febrile or respiratory illness (consider delaying treatment)

**Infusion-related reactions** See notes above

**Pregnancy** manufacturer advises avoid unless essential

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** abdominal pain, umbilical hernia, gastrointestinal; chest pain, hypertension; dyspnoea, apnoea, nasal congestion; rigors, malaise, areflexia; pharyngitis; conjunctivitis, corneal opacity, ear pain; facial oedema

**Dose**
- By intravenous infusion, ADULT and CHILD over 5 years, 1 mg/kg once weekly

**IDURSULFASE**

**Indications** (specialist use only) mucopolysaccharidosis II

**Cautions** severe respiratory disease; acute febrile respiratory illness (consider delaying treatment)

**Infusion-related reactions** See notes above
Contra-indications women of child-bearing potential
Pregnancy manufacturer advises avoid
Breast-feeding manufacturer advises avoid—present in milk in animal studies
Side-effects gastro-intestinal disturbances, swollen tongue; arrhythmia, tachycardia, chest pain, cyanosis, peripheral oedema, hypertension, hypotension, flushing; bronchospasm, hypoxia, cough, wheezing, tachypnoea, dyspnoea; headache, dizziness, tremor; pyrexia; arthralgia; facial oedema, urticaria, pruritus, rash, infusion-site swelling, erythema; pulmonary embolism and anaphylaxis also reported
Dose
- By intravenous infusion, ADULT and CHILD over 5 years, 500 micrograms/kg once weekly

Elaprase® (Shire HGT) ▼ TFM
Concentrate for intravenous infusion, idursulfase 2 mg/mL, net price 3-mL vial = £1985.00

LARONIDASE
Indications (specialist use only) non-neurological manifestations of mucopolysaccharidosis I
Cautions monitor immunoglobulin G (IgG) antibody concentration; interactions: Appendix 1 (laronidase)
Infusion-related reactions See notes above
Pregnancy manufacturer advises avoid unless essential—no information available
Breast-feeding manufacturer advises avoid—no information available
Side-effects nausea, vomiting, diarrhoea, abdominal pain; cold extremities, pallor, flushing, tachycardia, blood pressure changes; dyspnoea, cough, angioedema, anaphylaxis; headache, paraesthesia, dizziness, fatigue, restlessness; influenza-like symptoms; musculoskeletal pain and respiratory arrest also reported
Dose
- By intravenous infusion, 100 units/kg once weekly; CHILD see BNF for Children

Aldurazyme® (Genzyme) ▼ TFM
Concentrate for intravenous infusion, laronidase 100 units/mL, net price 5-mL vial = £444.70
Electrolytes Na+ 1.29 mmol/5-mL vial

Pompe disease
Alglucosidase alfa, an enzyme produced by recombinant DNA technology, is licensed for long-term replacement therapy in Pompe disease, a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase.

ALGLUCOSIDASE ALFA
Indications (specialist use only) Pompe disease
Cautions cardiac and respiratory dysfunction—monitor closely; monitor immunoglobulin G (IgG) antibody concentration
Infusion-related reactions Infusion-related reactions very common, calling for use of antihistamine, antipyretic, or corticosteroid, consult product literature for details
Pregnancy toxicity in animal studies, but treatment should not be withheld
Breast-feeding manufacturer advises avoid—no information available
Side-effects nausea, vomiting, diarrhoea; flushing, tachycardia, blood pressure changes, cold extremities, cyanosis, facial oedema, chest discomfort; cough, tachypnoea, bronchospasm; headache, agitation, tremor, irritability, restlessness, paraesthesia, dizziness, fatigue, pyrexia; antibody formation; myalgia, muscle spasm; sweating, rash, pruritus, urticaria, injection-site reactions; hypersensitivity reactions (including anaphylaxis); severe skin reactions (including ulcerative and necrotising skin lesions) also reported
Dose
- By intravenous infusion, ADULT and CHILD 20 mg/kg every 2 weeks

Myozyme® (Genzyme) ▼ TFM
Intravenous infusion, powder for reconstitution, alglucosidase alfa, net price 50-mg vial = £356.06

Nephropathic cystinosis
Mercaptamine is available for the treatment of nephropathic cystinosis.

MERCAPTAMINE (Cysteamine)
Indications (specialist use only) nephropathic cystinosis
Cautions leucocyte-cystine concentration and haematological monitoring required—consult product literature; dose of phosphate supplement may need to be adjusted
Contra-indications hypersensitivity to mercaptamine or penicillamine

Pregnancy avoid—teratogenic and toxic in animal studies
Breast-feeding avoid
Side-effects breath and body odour, nausea, vomiting, diarrhoea, anorexia, lethargy, fever, rash; also reported dehydration, hypertension, abdominal discomfort, gastroenteritis, drowsiness, encephalopathy, headache, nervousness, depression, anemia, leukopenia; rarely gastro-intestinal ulceration and bleeding, seizures, hallucinations, urticaria, interstitial nephritis
Dose
- Initial doses should be one-sixth to one-quarter of the expected maintenance dose, increased gradually over 4–6 weeks
- Maintenance, ADULT and CHILD over 50 kg body-weight, 2 g daily in 4 divided doses
CHILD up to 12 years, 1.3 g/m² (approx. 50 mg/kg) daily in 4 divided doses

Cystagon® (Orphan Europe) ▼ TFM
Capsules, mercaptamine (as bitartrate) 50 mg, net price 100-cap pack = £70.00; 150 mg, 100-cap pack = £190.00
Note CHILD under 6 years at risk of aspiration, capsules can be opened and contents sprinkled on food (at a temperature suitable for eating); avoid adding to acidic drinks (e.g. orange juice)
Tyrosinaemia type 1
Nitisinone is licensed for the treatment of hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

SODIUM PHENYL BUTYRATE
Indications adjunct in long-term treatment of urea cycle disorders (under specialist supervision)
Cautions congestive heart failure; interactions: Appendix 1 (sodium phenylbutyrate)
Hepatic impairment manufacturer advises caution
Renal impairment manufacturer advises caution
Pregnancy avoid—toxicity in animal studies; manufacturer advises adequate contraception during administration
Breast-feeding manufacturer advises avoid—no information available
Side-effects gastro-intestinal disturbances, weight gain, taste disturbance, decreased appetite; syncope, oedema, headache, depression, irritability; renal tubular acidosis, menstrual disorders; blood disorders, metabolic acidosis, alkalosis; rash, body odour; less commonly rectal bleeding, peptic ulcer, pancreatitis, and arrhythmias
Dose • ADULT and CHILD body-weight over 20 kg, 9.9–13 g/m² daily in divided doses with meals (max. 20 g daily); CHILD body-weight less than 20 kg, 450–600 mg/kg daily in divided doses with meals
Ammonaps® (Swedish Orphan)
Tablets, sodium phenylbutyrate 500 mg. Contains Na+ 2.7 mmol/tablet. Net price 250-tab pack = £493.00
Granules, sodium phenylbutyrate 940 mg/g. Contains Na+ 5.4 mmol/g. Net price 266-g pack = £860.00
Note Granules should be mixed with food before taking

Homocystinuria
Betaine is licensed for the adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase, 5,10-methylene-tetrahydrofolate reductase, or cobalamin cofactor metabolism. Betaine should be used in conjunction with dietary restrictions and may be given with supplements of Vitamin B₁₂, pyridoxine, and folate under specialist advice.
The Scottish Medicines Consortium (p. 4) has advised (July 2010) that betaine anhydrous (Cystadane®) is accepted for restricted use within NHS Scotland for the adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase, 5,10-methylene-tetrahydrofolate reductase, or cobalamin cofactor metabolism in patients who are not responsive to pyridoxine treatment.

BETaine
Indications (specialist use only) adjunctive treatment of homocystinuria
Cautions monitor plasma-methionine concentration before and during treatment—interrupt treatment if symptoms of cerebral oedema occur
Pregnancy manufacturer advises avoid unless essential—limited information available
Breast-feeding manufacturer advises caution—no information available
Side-effects less commonly gastro-intestinal disorders, anorexia, reversible cerebral oedema (see Cau-
BNF 61

Disease

Diarrhoea, flatulence, abdominal pain,

Side-effects

manufacturer advises avoid—no

Breast-feeding

Pregnancy

manufacturer advises avoid (toxicity in

Renal impairment

Hepatic impairment

Other metabolic disorders

Miglustat is available for the treatment of progressive neurological manifestations of Niemann-Pick type C disease, a neurodegenerative disorder characterised by impaired intracellular lipid trafficking; it is also licensed for the treatment of mild to moderate type 1 Gaucher’s disease for whom imiglucerase is unsuitable, see also p. 624.

MIGLUSTAT

Indications mild to moderate type I Gaucher’s disease (specialist supervision only); Niemann-Pick type C disease (specialist supervision only)

Cautions monitor cognitive and neurological function; monitor growth and platelet count in Niemann-Pick type C disease

Hepatic impairment no information available—manufacturer advises caution

Renal impairment for Gaucher’s disease initially 100 mg twice daily if eGFR 50–70 mL/minute/1.73 m²; initially 100 mg once daily if eGFR 30–50 mL/minute/1.73 m²; for Niemann-Pick type C disease, initially 200 mg twice daily if eGFR 50–70 mL/minute/1.73 m²; initially 100 mg twice daily if eGFR 30–50 mL/minute/1.73 m²; child under 12 years—consult product literature; avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy manufacturer advises avoid (toxicity in animal studies)—effective contraception must be used during treatment; also men should avoid fathering a child during and for 3 months after treatment

Breast-feeding manufacturer advises avoid—no information available

Side-effects diarrhoea, flatulence, abdominal pain, dyspepsia, constipation, nausea, vomiting, anorexia, weight changes; tremor, dizziness, headache, peripheral neuropathy, ataxia, hypoesthesia, paraesthesia, insomnia, fatigue, asthenia; decreased libido; thrombocytopenia; muscle spasm

Dose

● Gaucher’s disease, ADULT over 18 years, 100 mg 3 times daily; reduced if not tolerated to 100 mg 1–2 times daily

● Niemann-Pick type C disease, ADULT and CHILD over 12 years, 200 mg 3 times daily; CHILD 4–12 years, body surface area less than 0.47 m², 100 mg once daily; body surface area 0.47–0.73 m², 100 mg twice daily;

body surface area 0.73–0.88 m², 100 mg three times daily; body surface area 0.88–1.25 m², 200 mg twice daily; body surface area greater than 1.25 m², adult dose

Zavesca® (Actelion) Capsules, miglustat 100 mg, net price 84-cap pack = £3934.17 (hospital only)

9.8.2 Acute porphyrias

The acute porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolaevulinic acid dehydratase deficiency porphyria) are hereditary disorders of haem biosynthesis; they have a prevalence of about 1 in 10 000 of the population.

Great care must be taken when prescribing for patients with acute porphyria, since certain drugs can induce acute porphyrin crises. Since acute porphyrias are hereditary, relatives of affected individuals should be screened and advised about the potential danger of certain drugs.

Treatment of serious or life-threatening conditions should not be withheld from patients with acute porphyria. When there is no safe alternative, treatment should be started and urinary porphobilinogen excretion should be measured regularly; if it increases or symptoms occur, the drug can be withdrawn and the acute attack treated. If an acute attack of porphoria occurs during pregnancy, contact an expert porphyria service for further advice.

Haem arginate is administered by short intravenous infusion as haem replacement in moderate, severe, or unremitting acute porphyria crises.

Supplies of haem arginate may be obtained in an emergency outside office hours from the on-call pharmacist at:

St Thomas’ Hospital London Tel: (020) 7188 7188

HAEM ARGINATE

(Human hemin)

Indications acute porphyrias (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria)

Pregnancy manufacturer advises avoid unless essential

Breast-feeding manufacturer advises avoid unless essential—no information available

Side-effects rarely hypersensitivity reactions and fever; pain and thrombophlebitis at injection site

Dose

● By intravenous infusion, ADULT and CHILD 3 mg/kg once daily (max. 250 mg daily) for 4 days; if response inadequate, repeat 4-day course with close biochemical monitoring

Normosang® (Orphan Europe) Concentrate for Intravenous infusion, haem arginate 25 mg/mL, net price 10-mL amp = £434.25

9.8.2 Acute porphyrias

The acute porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolaevulinic acid dehydratase deficiency porphyria) are hereditary disorders of haem biosynthesis; they have a prevalence of about 1 in 10 000 of the population.

Great care must be taken when prescribing for patients with acute porphyria, since certain drugs can induce acute porphyrin crises. Since acute porphyrias are hereditary, relatives of affected individuals should be screened and advised about the potential danger of certain drugs.

Treatment of serious or life-threatening conditions should not be withheld from patients with acute porphyria. When there is no safe alternative, treatment should be started and urinary porphobilinogen excretion should be measured regularly; if it increases or symptoms occur, the drug can be withdrawn and the acute attack treated. If an acute attack of porphoria occurs during pregnancy, contact an expert porphyria service for further advice.

Haem arginate is administered by short intravenous infusion as haem replacement in moderate, severe, or unremitting acute porphyria crises.

Supplies of haem arginate may be obtained in an emergency outside office hours from the on-call pharmacist at:

St Thomas’ Hospital London Tel: (020) 7188 7188

HAEM ARGINATE

(Human hemin)

Indications acute porphyrias (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria)

Pregnancy manufacturer advises avoid unless essential

Breast-feeding manufacturer advises avoid unless essential—no information available

Side-effects rarely hypersensitivity reactions and fever; pain and thrombophlebitis at injection site

Dose

● By intravenous infusion, ADULT and CHILD 3 mg/kg once daily (max. 250 mg daily) for 4 days; if response inadequate, repeat 4-day course with close biochemical monitoring

Normosang® (Orphan Europe) Concentrate for Intravenous infusion, haem arginate 25 mg/mL, net price 10-mL amp = £434.25
Drugs unsafe for use in acute porphyrias

The following list contains drugs on the UK market that have been classified as ‘unsafe’ in porphyria because they have been shown to be porphyrinogenic in animals or in vitro, or have been associated with acute attacks in patients. Absence of a drug from the following lists does not necessarily imply that the drug is safe. For many drugs no information about porphyria is available.

An up-to-date list of drugs considered safe in acute porphyria is available at www.wmic.wales.nhs.uk/porphyria_info.php

Unsafe Drug Groups (check first)

- Alkylating drugs
- Amfotermine
- Anabolic steroids
- Antidepressants
- Antihistamines
- Barbiturates

Unsafe Drugs (check groups above first)

- Acetofenac
- Alcohol
- Aminophylline
- Amiodarone
- Bexorotene
- Bosantan
- Bromocriptine
- Cabergoline
- Carbamazepine
- Chloral hydrate
- Chloramphenicol
- Cocaine
- Clindamycin
- Colchicine
- Cycloserine
- Danazol
- Dapsone
- Dexfenfluramine
- Diazepam
- Dilucifenac

Further information may be obtained from: www.porphyria-europe.org

and also from:
Welsh Medicines Information Centre
University Hospital of Wales
Cardiff, CF14 4XW
Tel: (029) 2074 2979/3877

Note: Quite modest changes in chemical structure can lead to changes in porphyrinogenicity but where possible general statements have been made about groups of drugs: these should be checked first.

1. Contact Welsh Medicines Information Centre for further advice.
2. Includes tricyclic (and related) antidepressants and MAOIs; fluoxetine, venlafaxine, and mianserin thought to be safe.
3. Alimemazine, chlorphenamine, desloratadine, fexofenadine, ketotifen, loratadine, and promethazine thought to be safe.
4. Includes primidone and thiopental.
5. Alkylating drugs; calcium channel blockers; non-nucleoside reverse transcriptase inhibitors; progestogens; protease inhibitors; Statins; sulfonamides.
6. Progestogens are more porphyrinogenic than oestrogens; oestrogens may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.
7. Includes ergometrine (oxytocin probably safe) and ergot derivatives.
8. Applies to oral and intravenous use; topical antifungals are thought to be safe due to low systemic exposure.
9. Rosuvastatin is thought to be safe.
10. Incluedes co-trimoxazole and sulfasalazine.
11. Glipizide is thought to be safe.
12. Although evidence of hazard is uncertain, manufacturer advises avoid.
13. Small amounts in medicines probably safe.
14. Status epilepticus has been treated successfully with intravenous diazepam.
15. When used for local anaesthesia, articaine, bupivacaine, lidocaine, prilocaine, and tetracaine are thought to be safe.
16. May be used with caution if safer alternative not available.
17. Buprenorphine, codeine, damorphine, dihydrocodeine, fentanyl, methadone, morphine, pethidine, and tramadol are thought to be safe.
18. Rifamycins have been used in a few patients without evidence of harm—use with caution if safer alternative not available.
10 Musculoskeletal and joint diseases

10.1 Drugs used in rheumatic diseases and gout

10.1.1 Non-steroidal anti-inflammatory drugs
10.1.2 Corticosteroids
10.1.3 Drugs that suppress the rheumatic disease process
10.1.4 Gout and cytotoxic-induced hyperuricaemia
10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

10.2.1 Drugs that enhance neuromuscular transmission
10.2.2 Skeletal muscle relaxants

10.3 Drugs for the relief of soft-tissue inflammation and topical pain relief

10.3.1 Enzymes
10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices

This chapter also includes advice on the drug management of the following:
- dental and orofacial pain, p. 631
- extravasation, p. 663
- gout, p. 654
- myasthenia gravis, p. 657
- osteoarthritis and soft-tissue disorders, below
- rheumatoid arthritis and other inflammatory disorders, below

For treatment of septic arthritis see Table 1, section 5.1.

Rheumatoid arthritis and other inflammatory disorders

A non-steroidal anti-inflammatory drug (NSAID) is indicated for pain and stiffness resulting from inflammatory rheumatic disease; analgesics such as paracetamol or codeine can also be used. For advice on the prophylaxis and treatment of NSAID-associated gastrointestinal ulcers, see p. 50.

Drugs are also used to influence the rheumatic disease process itself (section 10.1.3). For rheumatoid arthritis these disease-modifying antirheumatic drugs (DMARDs) include methotrexate, cytokine modulators, azathioprine, ciclosporin, cyclophosphamide, leflunomide, penicillamine, gold, antimalarials (chloroquine and hydroxychloroquine), and sulfasalazine. Corticosteroids also have a significant role in the management of rheumatoid arthritis (section 10.1.2.1).

Drugs which may affect the disease process in psoriatic arthritis include sulfasalazine, gold salts, azathioprine, methotrexate, and cytokine modulators (section 10.1.3).

For long-term control of gout, uricosuric drugs and allopurinol (section 10.1.4) can be used.

Osteoarthritis and soft-tissue disorders

For pain relief in osteoarthritis and soft-tissue disorders, paracetamol (section 4.7.1) should be used first and may need to be taken regularly. A topical NSAID (section 10.3.2) or topical capsaicin 0.025% (section 10.3.2) should also be considered, particularly in knee or hand osteoarthritis. An oral NSAID (section 10.1.1) can be substituted for, or used in addition to, paracetamol. If further pain relief is required in osteoarthritis, then the addition of an opioid analgesic (section 4.7.2) may be considered, but with a substantial risk of adverse effects; however, an opioid analgesic should be considered.
before a NSAID in patients taking low-dose aspirin. For advice on the prophylaxis and treatment of NSAID-associated gastro-intestinal ulcers, see p. 50.

Intra-articular corticosteroid injections (section 10.1.2.2) may produce temporary benefit in osteoarthritis, especially if associated with soft-tissue inflammation.

Non-drug measures, such as weight reduction and exercise, should also be encouraged.

Glucosamine (section 10.1.5) and rubefacients (section 10.3.2) are not recommended for the treatment of osteoarthritis.

Hyaluronic acid and its derivatives are available for osteoarthritis of the knee, but are not recommended. Sodium hyaluronate (Duraflex®, Euflexxx®, Fematro®), Hyalgan® (Orthovisc®), Ostenil®, Suplasyne®, Synocrom®, Synovia* or bylan G-F 20 (Synvisc®) is injected intra-articularly to supplement natural hyaluronic acid in the synovial fluid. These injections may reduce pain over 1–6 months, but are associated with a short-term increase in knee inflammation.

Differences in anti-inflammatory activity between NSAIDs are small, but there is considerable variation in individual response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose and a full analgesic effect makes them particularly useful for the treatment of continuous or regular pain associated with inflammation. Therefore, although paracetamol often gives adequate pain control in osteoarthritis, NSAIDs are more appropriate than paracetamol or the opioid analgesics in the inflammatory arthritides (e.g. rheumatoid arthritis) and in some cases of advanced osteoarthritis. NSAIDs can also be of benefit in the less well defined conditions of back pain and soft-tissue disorders.

Choice Differences in anti-inflammatory activity between NSAIDs are small, but there is considerable variation in individual response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose and a full analgesic effect should normally be obtained within a week, whereas an anti-inflammatory effect may not be achieved (or may not be clinically assessable) for up to 3 weeks. If appropriate responses are not obtained within these times, another NSAID should be tried.

NSAIDs reduce the production of prostaglandins by inhibiting the enzyme cyclo-oxygenase. They vary in their selectivity for inhibiting different types of cyclo-oxygenase; selective inhibition of cyclo-oxygenase-2 is associated with less gastro-intestinal intolerance. Several other factors also influence susceptibility to gastro-intestinal effects, and a NSAID should be chosen on the basis of the incidence of gastro-intestinal and other side-effects.

Ibuprofen is a propionic acid derivative with anti-inflammatory, analgesic, and antipyretic properties. It has fewer side-effects than other non-selective NSAIDs but its anti-inflammatory properties are weaker. Doses of 1.6 to 2.4 g daily are needed for rheumatoid arthritis and it is unsuitable for conditions where inflammation is prominent, such as acute gout. Dexibuprofen is the active enantiomer of ibuprofen. It has similar properties to ibuprofen and is licensed for the relief of mild to moderate pain and inflammation.

Other propionic acid derivatives:

Naproxen is one of the first choices because it combines good efficacy with a low incidence of side-effects (but more than ibuprofen, see CSM comment below).

Fenbufen is claimed to be associated with less gastro-intestinal bleeding, but there is a high risk of rash (see p. 635).

Fenoprofen is as effective as naproxen, and flurbiprofen may be slightly more effective. Both are associated with slightly more gastro-intestinal side-effects than ibuprofen.

Ketoprofen has anti-inflammatory properties similar to ibuprofen and has more side-effects (see also CSM advice below). Dextropropafen, an isomer of ketoprofen, has been introduced for the short-term relief of mild to moderate pain.

Tiaprofenic acid is as effective as naproxen; it has more side-effects than ibuprofen (important: reports of severe cystitis, see CSM advice on p. 640).

Drugs with properties similar to those of propionic acid derivatives:

Diclofenac and aceclofenac have actions and side-effects similar to those of naproxen.

Etodolac is comparable in efficacy to naproxen; it is licensed for symptomatic relief of osteoarthritis and rheumatoid arthritis.

Indometacin has an action equal to or superior to that of naproxen, but with a high incidence of side-effects including headache, dizziness, and gastro-intestinal disturbances (see also CSM advice below).

Mefenamic acid has minor anti-inflammatory properties. It has occasionally been associated with diarrhoea and haemolytic anaemia which require discontinuation of treatment.

Meloxicam is licensed for the short-term relief of pain in osteoarthritis and for long-term treatment of rheumatoid arthritis and ankylosing spondylitis.

Nabumetone is comparable in effect to naproxen.

Phenytoin is licensed for ankylosing spondylitis, but is not recommended because it is associated with serious side-effects, in particular haematological reactions; it should be used only by a specialist in severe cases where other treatments have been found unsuitable.

Piroxicam is as effective as naproxen and has a long duration of action which permits once-daily administra-
Heart disease. However, it has more gastrointestinal side-effects than most other NSAIDs, and is associated with more frequent serious skin reactions (important: see CHMP advice, p. 639).

Sulindac is similar in tolerance to naproxen.

Tenofovir is similar in activity and tolerance to naproxen. Its long duration of action allows once-daily administration.

Tolenaemic acid is licensed for the treatment of migraine (section 4.7.4.1).

Ketorolac and the selective inhibitor of cyclo-oxygenase-2, parecoxib, are licensed for the short-term management of postoperative pain (section 15.1.4.2). The selective inhibitors of cyclo-oxygenase-2, etoricoxib and celecoxib, are as effective as non-selective NSAIDs such as diclofenac and naproxen. Short-term data indicate that the risk of serious upper gastrointestinal events is lower with selective inhibitors compared to non-selective NSAIDs; this advantage may be lost in patients who require concomitant low-dose aspirin. There are concerns about the cardiovascular safety of cyclo-oxygenase-2 selective inhibitors (see below).

Celecoxib and etoricoxib are licensed for the relief of pain in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; etoricoxib is also licensed for the relief of pain from acute gout.

Dental and orofacial pain Most mild to moderate dental pain and inflammation is effectively relieved by NSAIDs. Those used for dental pain include ibuprofen and diclofenac.

In an appraisal of the relative safety of 7 non-selective NSAIDs, the CSM assessed ibuprofen to have the lowest risk of serious gastrointestinal side-effects (see p. 632). For further information on the management of dental and orofacial pain, see p. 257.

Cautions and contra-indications NSAIDs should be used with caution in the elderly (risk of serious side-effects and fatalities, see also Prescribing for the Elderly p. 25), in allergic disorders (they are contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID), and in coagulation defects. Long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment. Caution is also required in patients with connective-tissue disorders, see Side-effects below.

In patients with cardiac impairment, caution is required since NSAIDs may impair renal function (see also Side-effects, below). All NSAIDs are contra-indicated in severe heart failure. The selective inhibitors of cyclo-oxygenase-2 (celecoxib, etoricoxib, and parecoxib) are contra-indicated in ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, and moderate or severe heart failure. The selective inhibitors of cyclo-oxygenase-2 should be used with caution in patients with a history of cardiac failure, left ventricular dysfunction, hypertension, in patients with oedema for any other reason, and in patients with risk factors for heart disease.

NSAIDs and cardiovascular events Cyclo-oxygenase-2 selective inhibitors are associated with an increased risk of thrombotic events (e.g. myocardial infarction and stroke) and should not be used in preference to non-selective NSAIDs except when specifically indicated (i.e. for patients at a particularly high risk of developing gastrointestinal ulceration or bleeding) and after assessing their cardiovascular risk.

Non-selective NSAIDs are also associated with a small increased risk of thrombotic events even when used short-term in those with no cardiovascular risk factors. Diclofenac (150 mg daily) and ibuprofen (2.4 g daily) are associated with an increased risk of thrombotic events. The increased risk for diclofenac is similar to that of licensed doses of etoricoxib. Naproxen (1 g daily) is associated with a lower thrombotic risk, and low doses of ibuprofen (1.2 g daily or less) have not been associated with an increased risk of myocardial infarction.

The lowest effective dose of NSAID or cyclo-oxygenase-2 selective inhibitor should be prescribed for the shortest period to control symptoms and that the need for long-term treatment should be reviewed periodically.

The CSM has advised that non-selective NSAIDs are contra-indicated in patients with previous or active peptic ulceration and that selective inhibitors of cyclo-oxygenase-2 are contra-indicated in active peptic ulceration (see also CSM advice below). While it is preferable to avoid NSAIDs in patients with active or previous gastrointestinal ulceration or bleeding, and to withdraw them if gastrointestinal lesions develop, nevertheless patients with serious rheumatic diseases (e.g. rheumatoid arthritis) are usually dependent on NSAIDs for effective relief of pain and stiffness. Patients at risk of gastrointestinal ulceration (including the elderly), who need NSAID treatment should receive gastroprotective treatment; for advice on the prophylaxis and treatment of NSAID-associated gastrointestinal ulcers, see section 1.3.

For interactions of NSAIDs, see Appendix 1 (NSAIDs).

Hepatic impairment NSAIDs should be used with caution in patients with hepatic impairment; there is an increased risk of gastrointestinal bleeding and fluid retention. NSAIDs should be avoided in severe liver disease; see also individual drugs.

Renal impairment NSAIDs should be avoided if possible or used with caution in patients with renal impairment; the lowest effective dose should be used for the shortest possible duration, and renal function should be monitored. Sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure; deterioration in renal function has also been reported after topical use; see also individual drugs.

Pregnancy Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of...
labour may be delayed and its duration may be increased.

**Breast-feeding** NSAIDs should be used with caution during breast-feeding; see also individual drugs.

**Side-effects** Gastro-intestinal disturbances including discomfort, nausea, diarrhoea, and occasionally bleeding and ulceration occur (see also CSM advice below and Cautions above). Systemic as well as local effects of NSAIDs contribute to gastro-intestinal damage; taking oral formulations with milk or food, or using enteric-coated formulations, or changing the route of administration may only partially reduce symptoms such as dyspepsia.

**Aceclofenac**

**Indications** pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis

**Cautions** see notes above; avoid in acute porphyria (section 9.8.2)

**Contra-indications** see notes above

**Hepatic impairment** initially 100 mg daily; see also notes above

**Renal impairment** avoid in moderate to severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** manufacturer advises avoid; see also notes above

**Side-effects** see notes above

**Dose**

- 100 mg twice daily; **CHILD** not recommended

**Acemetacin (Glycolic acid ester of indometacin)**

**Indications** pain and inflammation in rheumatic disease and other musculoskeletal disorders; postoperative analgesia

**Cautions** see under Indometacin and notes above

**Driving** Dizziness may affect performance of skilled tasks (e.g. driving)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** see notes above

**Breast-feeding** manufacturer advises avoid; see also notes above

**Side-effects** see under Indometacin and notes above

**Dose**

- 120 mg daily in divided doses with food, increased if necessary to 180 mg daily; **CHILD** not recommended

**Emflex® (Merck Serono)**

**Capsules** yellow/orange, acemetacin 60 mg, net price 90-cap pack = £28.20. Label: 21, counselling, driving

**Celecoxib**

**Indications** see under preparations

**Cautions** see notes above; monitor blood pressure before treatment and during treatment; anastomatic

Hepatic damage, alveolitis, pulmonary eosinophilia, pancreatitis, visual disturbances, Stevens-Johnson syndrome, and toxic epidermal necrolysis are other rare side-effects. Induction of or exacerbation of colitis or Crohn’s disease has been reported. Aseptic meningitis has been reported rarely with NSAIDs—patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible.
ulcer (avoid concomitant administration of anticoagulants or aspirin)

**Contra-indications** see notes above; sulphonamide sensitivity; inflammatory bowel disease

**Hepatic impairment** in pain and inflammation, halve initial dose in moderate impairment; in familial adenomatous polyposis, halve dose in moderate impairment and avoid in severe impairment; see also notes above

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²; see also notes above

**Pregnancy** avoid (teratogenic in animal studies); see also notes above

**Breast-feeding** avoid—present in milk in animal studies; see also notes above

**Side-effects** see notes above; dyspnoea, influenza-like symptoms; less commonly stomatitis, palpitation, dysphonia, cerebral infarction, fatigue, paraesthesia, lipoma, muscle cramps; rarely taste disturbance, alopecia; very rarely seizures; also reported chest pain

### Pain and inflammation

**Celebrex** (Pharmacia)

- **Capsules**
  - celecoxib 100 mg (white/blue), net price 60-cap pack = £21.55; 200 mg (white/gold), 30-cap pack = £21.55
- **Dose**
  - osteoarthritis, 200 mg daily in 1–2 divided doses, increased if necessary to max. 200 mg twice daily; **CHILD** not recommended
  - Rheumatoid arthritis, 100 mg twice daily, increased if necessary to 200 mg twice daily; **CHILD** not recommended

### Familial adenomatous polyposis

**Onsenal** (Pharmacia)

- **Capsules**
  - celecoxib 400 mg, net price 60-cap pack = £86.20; Label: 21
- **Dose**
  - familial adenomatous polyposis, **ADULT** over 18 years, 400 mg twice daily

### DEXIBUPROFEN

**Indications** pain and inflammation associated with osteoarthritis and other musculoskeletal disorders; mild to moderate pain and inflammation including dysmenorrhoea and dental pain

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** reduce initial dose; avoid if eGFR less than 30 mL/minute/1.73 m²: see also notes above

**Pregnancy** see notes above

**Breast-feeding** avoid—present in milk too small to be harmful; see also notes above

**Side-effects** see notes above

**Dose**

- 600–900 mg daily in up to 3 divided doses; increased if necessary to max. 1.2 g daily (900 mg daily for dysmenorrhoea); max. single dose 400 mg (300 mg for dysmenorrhoea); **CHILD** not recommended

**Seractil** (Genus)

- **Tablets**
  - f/c, dexibuprofen 300 mg, net price 60-tab pack = £9.47; 400 mg (scored) 60-tab pack = £9.47. Label: 21

### DEXKETOPROFEN

**Indications** short-term treatment of mild to moderate pain including dysmenorrhoea

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** reduce initial dose to max. 50 mg daily; avoid in moderate to severe impairment; see also notes above

**Renal impairment** reduce initial dose to 50 mg daily; avoid in moderate to severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** manufacturer advises avoid—no information available; see also notes above

**Side-effects** see notes above

**Dose**

- 12.5 mg every 4–6 hours or 25 mg every 8 hours; max. 75 mg daily; **ELDERLY** initially max. 50 mg daily; **CHILD** not recommended

### DICLOFENAC POTASSIUM

**Indications** pain and inflammation in rheumatoid disease and other musculoskeletal disorders; acute gout; postoperative pain; migraine

**Cautions** see notes above; avoid in acute porphyria (section 9.8.2)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** amount in milk too small to be harmful; see also notes above

**Side-effects** see notes above

**Dose**

- Rheumatic disease, musculoskeletal disorders, acute gout, postoperative pain, 75–150 mg daily in 2–3 divided doses; **CHILD** over 14 years, 75–100 mg daily in 2–3 divided doses
- Migraine, 50 mg at onset, repeated after 2 hours if necessary then after 4–6 hours; max. 200 mg in 24 hours; **CHILD** not recommended

**Diclofenac Potassium** (Non-proprietary)

- **Tablets**

**Voltarol** Rapid (Novartis)

- **Tablets**
  - s/c, diclofenac potassium 25 mg (red), net price 30-tab pack = £3.46; 50 mg (brown), 30-tab pack = £6.62. Label: 21

1. 12.5 mg tablets can be sold to the public for the treatment of headache, dental pain, period pain, rheumatic and muscular pain, backache and the symptoms of cold and flu (including fever), in patients aged over 14 years subject to max. single dose of 25 mg, max. daily dose of 75 mg for max. 3 days, and max. pack size of 18 × 12.5 mg
DICLOFENAC SODIUM

**Indications** pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders; acute gout; postoperative pain

**Cautions** see notes above; avoid in acute porphyria (section 9.8.2)

**Contra-indications** see notes above; avoid injections containing benzyl alcohol in neonates (see preparations below)

**Intravenous use** Additional contra-indications include concomitant NSAID or anticoagulant use (including low-dose heparin), history of haemorrhagic diathesis, history of confirmed or suspected cerebrovascular bleeding, operations with high risk of haemorrhage, history of asthma, moderate or severe renal impairment (see also Renal impairment below), hypovolaemia, dehydration.

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment; avoid intravenous use if serum creatinine greater than 160 micromol/litre; see also notes above

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Pseudoephedrine** see notes above

**Side-effects**

- Breast-feeding

**Dose**

- By mouth, 75–150 mg daily in 2–3 divided doses
- By rectum in suppositories, 75–150 mg daily in divided doses
- By intravenous injection, 2 mg/kg (max. 150 mg) daily in divided doses
- By deep intramuscular injection, 75 SR mg 1–2 times daily preferably with food; max. 150 mg in 24 hours for 2 days
- By intramuscular injection into the gluteal muscle, 75 mg then a further 75 mg after 30 minutes if necessary
- By intravenous infusion (in hospital setting), acute postoperative pain, 75 mg repeated if necessary after 4–6 hours; max. 150 mg in 24 hours for 2 days
- By intravenous injection in supervised healthcare settings, acute exacerbations of pain and postoperative pain, 75 mg once daily (twice daily in severe cases) for max. 2 days; CHILD 2–18 years, see BNF for Children
- By intravenous injection, diclofenac sodium 25 mg/mL, net price 3–ML amp = 83p

**Excipients**

- Include benzyl alcohol (avoid in neonates unless there is no safer alternative, see Excipients, p. 2), propylene glycol

**Special precautions**

- Do not exceed dose for 2 days
- Dose by deep intramuscular injection into the gluteal muscle
- See also Renal impairment (section 9.8.2) and Hepatic impairment
- Avoid injections containing benzyl alcohol in neonates
- Avoid injections and suppositories containing benzyl alcohol in neonates (see preparations below)
- Avoid injections in neonates
- Avoid injections in neonates

**Notes**

- Voltarol Dispersible tablets are more suitable for short-term use in acute conditions for which treatment required for no more than 3 months (no information on use beyond 3 months)
- Voltarol, diclofenac sodium 12.5 mg, net price 10 = £5.86; 25 mg, 10 = £1.03; 50 mg, 10 = £1.70; 100 mg, 10 = £3.03

**Modified release**

**Diclomax SR** (Galen) Capsules, m/r, yellow, diclofenac sodium 75 mg, net price 56-cap pack = £11.40. Label: 21, 25

**Dose** 1 capsule 1–2 times daily or 2 capsules once daily, preferably with food; CHILD not recommended

**Diclomax Retard** (Galen) Capsules, m/r, diclofenac sodium 100 mg, net price 28-cap pack = £8.20. Label: 21, 25

**Dose** 1 capsule daily preferably with food, CHILD not recommended

**Motifene** 75 mg (Daichi Sankyo) Capsules, e/c, m/r, diclofenac sodium 75 mg (enclosing e/c pellets containing diclofenac sodium 25 mg and m/r pellets containing diclofenac sodium 50 mg), net price 56-cap pack = £8.00. Label: 25

**Dose** 1 capsule 1–2 times daily; CHILD not recommended

**Voltarol** 75 mg SR (Novartis) Tablets, m/r, f/c, pink, diclofenac sodium 75 mg, net price 28-tab pack = £6.46; 56-tab pack = £12.92. Label: 21, 25

**Dose** 75 mg 1–2 times daily preferably with food; CHILD not recommended

**Note** Other brands of modified-release tablets containing diclofenac sodium 75 mg include Defenac®, SR, Desamox®, 75 SR, Deflex®, 75 SR, Fenactol®, SR, Flexotard®, MR 75, Rheumatac®, Retard 75, Rhumalgan® CR, Slofenac® SR, Volaid® Retard 75

**Voltarol Retard** (Novartis) Tablets, m/r, f/c, red, diclofenac sodium 100 mg. Net price 28-tab pack = £9.47. Label: 21, 25

**Dose** 1 tablet daily preferably with food; CHILD not recommended

**Note** Other brands of modified-release tablets containing diclofenac sodium 100 mg include Defenac® Retard, Desamox® Retard 100, Deflex® Retard, Fenactol® Retard 100 mg, Flamatac®, 100 MR, Flamara® SR, Rhumalgan® CR, Slofenac® SR, Volaid® Retard 100
With misoprostol

For prescribing information on misoprostol, see section 1.3.4

Arthrotec® (Pharmacia).  

Arthrotec® 50 tablets, diclofenac sodium (in e/c core) 50 mg, misoprostol 200 micrograms, net price 60-tab pack = £11.98; Label: 21, 25  

Dose prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis, 1 tablet 2–3 times daily with food. CHILD not recommended

Arthrotec® 75 tablets, diclofenac sodium (in e/c core) 75 mg, misoprostol 200 micrograms, net price 60-tab pack = £15.83; Label: 21, 25  

Dose prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis, 1 tablet twice daily with food. CHILD not recommended

Note The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by Arthrotec® (see section 1.3.4)

Topical preparations  
Section 10.3.2

ETODOLAC

Indications pain and inflammation in rheumatoid arthritis and osteoarthritis  

Cautions see notes above  

Contra-indications see notes above  

Hepatic impairment see notes above  

Renal impairment avoid in severe impairment; see also notes above  

Pregnancy see notes above  

Breast-feeding manufacturer advises avoid; see also notes above  

Side-effects see notes above; also stomatitis, vasculitis, palpitation, fatigue, paraesthesia, tremor, urinary frequency, dysuria, pyrexia, and pruritus  

Dose  

ADULT over 18 years, 600 mg daily in 1–2 divided doses  

Etodolac (Non-proprietary)  

Tablets, m/r, f/c, grey, etodolac 600 mg, net price 30-tab pack = £8.14  

Brands include Eccoxolac®

Modified release  

Etopan XL® (Taro)  

Tablets, m/r, f/c, grey, etoricoxib 600 mg, net price 30-tab pack = £14.60. Label: 25  

Dose 1 tablet daily; CHILD not recommended  

Lodine SR® (Almirall)  

Tablets, m/r, f/c, light-grey, etoricoxib 600 mg, net price 30-tab pack = £15.50. Label: 25  

Dose 1 tablet daily; CHILD not recommended

Osteoarthritis and other musculoskeletal disorders

ETORICOXIB

Indications pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; acute gout  

Cautions see notes above; also dehydration; monitor blood pressure before treatment, 2 weeks after initiation and periodically during treatment  

Contra-indications see notes above; inflammatory bowel disease; uncontrolled hypertension (persistently above 140/90 mmHg)  

Hepatic impairment max. 60 mg daily in mild impairment; max. 60 mg on alternate days or 30 mg once daily in moderate impairment; see also notes above  

Renal impairment avoid if eGFR less than 30 mL/minute/1.73 m²; see also notes above  

Pregnancy manufacturer advises avoid (teratogenic in animal studies); see also notes above  

Breast-feeding manufacturer advises avoid—present in milk in animal studies; see also notes above  

Side-effects see notes above; also palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations  

Dose  

Osteoarthritis, ADULT and CHILD over 16 years, 30 mg once daily, increased if necessary to 60 mg once daily  

Rheumatoid arthritis and ankylosing spondylitis, ADULT and CHILD over 16 years, 90 mg once daily  

Acute gout, ADULT and CHILD over 16 years, 120 mg once daily for max. 8 days  

Arcoxia® (MSD)  

Tablets, f/c, etoricoxib 30 mg (blue-green), net price 28-tab pack = £13.99; 60 mg (dark green), 28-tab pack = £20.11; 90 mg (white), 28-tab pack = £22.96; 120 mg (pale green), 7-tab pack = £6.03, 28-tab pack = £24.11

FENBUFEN

Indications pain and inflammation in rheumatic disease and other musculoskeletal disorders  

Cautions see notes above  

Contra-indications see notes above  

Hepatic impairment see notes above  

Renal impairment see notes above  

Pregnancy see notes above  

Breast-feeding small amount present in milk—manufacturer advises avoid; see also notes above  

Side-effects see notes above, but also high risk of rashes especially in seronegative rheumatoid arthritis, psoriatic arthritis and in women (discontinue immediately); also allergic interstitial lung disorders (may follow rashes)  

Dose  

300 mg in the morning and 600 mg at bed-time or 450 mg twice daily; CHILD under 14 years not recommended  

Fenbufen (Non-proprietary)  

Tablets, fenbufen 300 mg, net price 84-cap pack = £20.71. Label: 21  

Tablets, fenbufen 300 mg, net price 84-tab pack = £6.00; 450 mg, 56-tab pack = £6.49. Label: 21

FENOPROFEN

Indications pain and inflammation in rheumatic disease and other musculoskeletal disorders; mild to moderate pain
10.1.1 Non-steroidal anti-inflammatory drugs

BNF 61

Cautions see notes above
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment see notes above
Pregnancy see notes above
Breast-feeding amount too small to be harmful; see also notes above
Side-effects see notes above; upper respiratory-tract infection, nasopharyngitis, and cystitis also reported

**Dose**
- 300–600 mg 3–4 times daily with food; max. 3 g daily; CHILD not recommended

**Flurbiprofen**

**Indications** pain and inflammation in rheumatic disease and other musculoskeletal disorders; mild to moderate pain including dysmenorrhea; migraine; postoperative analgesia; sore throat (section 12.3.1)

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** amount too small to be harmful but some manufacturers advise avoid (including topical use); see also notes above

**Side-effects** see notes above

**Dose**
- **ADULT** and **CHILD** over 12 years, initially 300–400 mg 3–4 times daily; increased if necessary to max. 2.4 g daily; maintenance dose of 0.6–1.2 g daily may be adequate
- Pain and fever in children, **CHILD** 1–3 months, see **BNF for Children**; **CHILD** 3–6 months (body-weight over 5 kg), 50 mg 3 times daily (max. 30 mg/kg daily in 3–4 divided doses); **CHILD** 6 months–1 year, 50 mg 3–4 times daily (max. 30 mg/kg daily in 3–4 divided doses); **CHILD** 1–4 years, 100 mg 3 times daily (max. 30 mg/kg/day in 3–4 divided doses); **CHILD** 4–7 years, 150 mg 3 times daily (max. 30 mg/kg/day in 3–4 divided doses); **CHILD** 7–10 years, 200 mg 3 times daily (up to 30 mg/kg/day (max. 2.4 g) in 3–4 divided doses); **CHILD** 10–12 years, 300 mg 3 times daily (up to 30 mg/kg/day (max. 2.4 g) in 3–4 divided doses)
- Rheumatic disease in children (including juvenile idiopathic arthritis), **CHILD** 3 months–18 years (body-weight over 5 kg), 30–40 mg/kg (max. 2.4 g) daily in 3–4 divided doses; in systemic juvenile idiopathic arthritis up to 60 mg/kg (max. 2.4 g) daily [unlicensed] in 4–6 divided doses

** Ibuprofen (Non-proprietary) **

**Tablets**, coated, ibuprofen 200 mg, net price 84-tab pack = £1.62; 400 mg, 84-tab pack = £1.72; 600 mg, 84-tab pack = £4.06. Label: 21
Brands include *Arthrofen®, Ebubium®, Ringaine®*
Dental prescribing on NHS *Ibuprofen Tablets may be prescribed*
**Oral suspension**, ibuprofen 100 mg/5 mL, net price 100 mL = £1.48, 150 mL = £2.71, 500 mL = £8.98. Label: 21
Note *Sugar-free versions are available and can be ordered by specifying ‘sugar-free’ on the prescription*
Brands include *Calprofen®, Feveron®, Nurofen® for Children, Orbifene® for Children*
Dental prescribing on NHS *Ibuprofen Oral Suspension Sugar-free may be prescribed*
1. Can be sold to the public in certain circumstances; for exemptions see *Medicines, Ethics and Practice, No. 34*, London, Pharmaceutical Press, 2010 (and subsequent editions as available)

**Brufen Retard® (Abbott)**

**Tablets**, m/r, ibuprofen 800 mg, net price 56-tab pack = £6.48. Label: 25, 27
Dose **ADULT** and **CHILD** over 12 years, 2 tablets daily as a single dose, preferably in the early evening, increased in severe cases to 3 tablets daily in 2 divided doses
**Fenbid®** (Goldshield) = capsule m/r, maroon/pink, enclosing off-white pellets, ibuprofen 300 mg, net price 120-cap pack = £9.64. Label: 25

**Dose** ADULT and CHILD over 12 years, initially 2 capsules twice daily, increased in severe cases to 3 capsules twice daily; then 1–2 capsules twice daily

#### Topical preparations

Section 10.3.2

**INDOMETACIN** (Indomethacin)

**Indications** pain and moderate to severe inflammation in rheumatic disease and other acute musculoskeletal disorders; acute gout; dysmenorrhoea; premature labour (section 7.1.3)

**Cautions** see notes above; also epilepsy, parkinsonism, psychiatric disturbances; during prolonged therapy ophthalmic and blood examinations particularly advisable; avoid rectal administration in proctitis and haemorrhoids

**Driving** Dizziness may affect performance of skilled tasks (e.g. driving)

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** amount probably too small to be harmful but manufacturer advises avoid unless essential; see also notes above

**Side-effects** see notes above; pain may occur at injection site (occasionally tissue damage); suppositories may cause rectal irritation

**Dose**

- **By mouth**, rheumatic disease, 50–200 mg daily in divided doses; **CHILD** see BNF for Children
- Acute gout, 150–200 mg daily in divided doses
- **By rectum** in suppositories, rheumatic disease, 100 mg at bedtime; **CHILD** not recommended
- Combined oral and rectal treatment, max. total daily dose 200 mg
- **By deep intramuscular injection** into the gluteal muscle, 50–100 mg every 4 hours (max. 200 mg in 24 hours) for up to 3 days; **CHILD** not recommended

**Ketoprofen** (Non-proprietary) =

**Capsules**, ketoprofen 50 mg, net price 28-cap pack = £9.32; 100 mg, 56-cap pack = £6.66. Label: 21

**Orudis®** (Sanofi-Aventis) =

**Capsules**, ketoprofen 50 mg (green/purple), net price 112-cap pack = £15.14; 100 mg (pink), 56-cap pack = £15.49. Label: 21

**Suppositories**, ketoprofen 100 mg. Net price 10 = £6.65

**Oruvail®** (Sanofi-Aventis) =

**Injection**, ketoprofen 50 mg /mL. Net price 2-mL amp = £1.07

**Modified release**

**Oruvail®** (Sanofi-Aventis)

**Capsules**, m/r, enclosing white pellets, ketoprofen 100 mg (pink/purple), net price 56-cap pack = £23.93; 150 mg (pink), 28-cap pack = £13.66; 200 mg (pink/white), 28-cap pack = £23.85. Label: 21, 25

**Dose** 100–200 mg once daily with food; **CHILD** not recommended

**Note** Other brands of modified-release capsules containing ketoprofen 100 mg and 200 mg include Ketocid® 200 mg, Ketorol®.

**Tiloket® CR**

**With omeprazole**

For prescribing information on omeprazole, see section 1.3.5

**Axorid®** (Meda)

**Capsules**, m/r, ketoprofen 100 mg, omeprazole 20 mg (yellow/white), net price 30-cap pack = £13.80; ketoprofen 200 mg, omeprazole 20 mg (white), 30-cap pack = £13.80. Label: 21, 25

**Excipients** include propylene glycol (see Excipients, p. 2)

**Note** Capsules enclose microgranules containing modified-release ketoprofen and gastro-resistant omeprazole

**Dose** (expressed as ketoprofen) patients requiring ketoprofen for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, who are at risk of NSAID-associated duodenal or gastric ulcer or gastroduodenal erosions, **ADULT** and **CHILD** over 15 years, 100 mg (with omeprazole 20 mg) once daily increased to 200 mg (with omeprazole 20 mg) once daily depending on severity of symptoms

#### Topical preparations

Section 10.3.2

**KETOPROFEN**

**Indications** pain and mild inflammation in rheumatic disease and other musculoskeletal disorders, and after orthopaedic surgery; acute gout; dysmenorrhoea

**Cautions** see notes above

**Contra-indications** see notes above

**Hepatic impairment** see notes above

**Renal impairment** avoid in severe impairment; see also notes above

**Pregnancy** see notes above

**Breast-feeding** amount probably too small to be harmful but manufacturer advises avoid unless essential; see also notes above

**Side-effects** see notes above; pain may occur at injection site (occasionally tissue damage); suppositories may cause rectal irritation

**Dose**

- **By mouth**, rheumatic disease, 100–200 mg daily in 2–4 divided doses; **CHILD** not recommended
- Pain and dysmenorrhoea, 50 mg up to 3 times daily; **CHILD** not recommended
- **By rectum** in suppositories, rheumatic disease, 100 mg at bedtime; **CHILD** not recommended
- Combined oral and rectal treatment, max. total daily dose 200 mg
- **By deep intramuscular injection** into the gluteal muscle, 50–100 mg every 4 hours (max. 200 mg in 24 hours) for up to 3 days; **CHILD** not recommended

**Topical preparations**

Section 10.3.2
Mefenamic Acid

**Indications**  pain and inflammation in rheumatoid arthritis and osteoarthritis; postoperative pain; mild to moderate pain; dysmenorrhoea and menorrhagia

**Cautions**  see notes above; epilepsy; acute porphyria (section 9.8.2)

**Contra-indications**  see notes above; inflammatory bowel disease

**Hepatic impairment**  see notes above

**Renal impairment**  avoid in severe impairment; see also notes above

**Pregnancy**  see notes above

**Breast-feeding**  amount too small to be harmful but manufacturer advises avoid; see also notes above

**Side-effects**  see notes above; also diarrhoea or rashes (withdrawal treatment), stomatitis; less commonly: hypotension, palpitation, glucose intolerance, thrombocytopenia, haemolytic anaemia (positive Coombs’ test), and aplastic anaemia

**Dose**
- **ADULT** over 18 years, 500 mg 3 times daily
- **CHILD** 12–18 years, acute pain including dysmenorrhoea, menorrhagia, 500 mg 3 times daily

**Mefenamic Acid** (Non-proprietary) (Trade)

**Capsules**, mefenamic acid 250 mg, net price 100-cap pack = £2.83. Label: 21

**Tablets**, mefenamic acid 500 mg, net price 28-tab pack = £2.20. Label: 21

**Suspension**, mefenamic acid 50 mg/5 mL, net price 125 mL = £79.98. Label: 21

**Excipients** include ethanol

**Ponstan**® (Chemidex) (Trade)

**Capsules**, blue/ivory, mefenamic acid 250 mg, net price 100-cap pack = £8.17. Label: 21

**Forte tablets**, yellow, mefenamic acid 500 mg, net price 100-tab pack = £15.72. Label: 21

Meloxicam

**Indications**  pain and inflammation in rheumatic disease, exacerbation of osteoarthritis (short-term); ankylosing spondylitis

**Cautions**  see notes above; avoid rectal administration in proctitis or haemorrhoids

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  avoid if eGFR less than 25 mL/minute/1.73 m²; see also notes above

**Pregnancy**  see notes above

**Breast-feeding**  present in milk in animal studies—manufacturer advises avoid; see also notes above

**Side-effects**  see notes above

**Dose**
- **ADULT** over 16 years, 7.5 mg once daily; increased if necessary to max. 15 mg once daily
- **CHILD** over 16 years, 15 mg once daily; may be reduced to 7.5 mg once daily; **ELDERLY** 7.5 mg daily
- **By rectum**, in suppositories, rheumatoid arthritis, ankylosing spondylitis, **ADULT** and **CHILD** over 16 years, 15 mg once daily; may be reduced to 7.5 mg once daily; **ELDERLY** 7.5 mg once daily [but Mobic® 7.5 mg suppositories discontinued]

**Meloxicam** (Non-proprietary) (Trade)

**Tablets**, meloxicam 7.5 mg, net price 30-tab pack = £1.36; 15 mg, 30-tab pack = £1.62. Label: 21

**Mobic**® (Boehringer Ingelheim) (Trade)

**Tablets**, yellow, scored, meloxicam 7.5 mg, net price 30-tab pack = £9.30; 15 mg, 30-tab pack = £12.93. Label: 21

**Note**  Tablets may be dispersed in water

**Suppositories**, meloxicam 15 mg, net price 12 = £5.58

Nabumetone

**Indications**  pain and inflammation in osteoarthritis and rheumatoid arthritis

**Cautions**  see notes above

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  avoid in severe impairment; see also notes above

**Pregnancy**  see notes above

**Breast-feeding**  manufacturer advises avoid; see also notes above

**Side-effects**  see notes above

**Dose**
- **CHILD** over 12 years, see BNF for Children

**Meloxicam (Non-proprietary)** (Trade)

**Tablets**, meloxicam 7.5 mg, net price 30-tab pack = £1.36; 15 mg, 30-tab pack = £1.62. Label: 21

**Mobic**® (Boehringer Ingelheim) (Trade)

**Tablets**, yellow, scored, meloxicam 7.5 mg, net price 30-tab pack = £9.30; 15 mg, 30-tab pack = £12.93. Label: 21

**Note**  Tablets may be dispersed in water

**Suppositories**, meloxicam 15 mg, net price 12 = £5.58

Naproxen

**Indications**  pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders; dysmenorrhoea; acute gout

**Cautions**  see notes above

**Contra-indications**  see notes above

**Hepatic impairment**  see notes above

**Renal impairment**  avoid if eGFR less than 30 mL/minute/1.73 m²; see also notes above

**Pregnancy**  see notes above

**Breast-feeding**  amount too small to be harmful but manufacturer advises avoid; see also notes above

**Side-effects**  see notes above

**Dose**
- **Rheumatic disease**, 0.5–1 g daily in 1–2 divided doses; **CHILD** 2–18 years, juvenile idiopathic arthritis, see BNF for Children
- **Acute musculoskeletal disorders and dysmenorrhoea**, 500 mg initially, then 250 mg every 6–8 hours as required; max. dose after first day 1.25 g daily; **CHILD** under 18 years, see BNF for Children
- **Acute gout**, 750 mg initially, then 250 mg every 8 hours until attack has passed; **CHILD** under 18 years not recommended

**Note**  Tablets, meloxicam 7.5 mg, net price 30-tab pack = £1.36; 15 mg, 30-tab pack = £1.62. Label: 21

**Mobic**® (Boehringer Ingelheim) (Trade)

**Tablets**, yellow, scored, meloxicam 7.5 mg, net price 30-tab pack = £9.30; 15 mg, 30-tab pack = £12.93. Label: 21

**Note**  Tablets may be dispersed in water

**Suppositories**, meloxicam 15 mg, net price 12 = £5.58
1Naproxen (Non-proprietary) (AstraZeneca) (Roche) (Pharmacia)
Tablets, yellow, scored, naproxen 250 mg, net price 56-tab pack = £4.29; 500 mg, 56-tab pack = £8.56.
Tablets, e/c, naproxen 250 mg, net price 56-tab pack = £6.18; 375 mg, 56-tab pack = £6.72; 500 mg, 56-tab pack = £10.68.
Tablets, f/c, naproxen 500 mg, net price 56-tab pack = £11.17; 1000 mg, 56-tab pack = £27.41.
Tablets, Naprosyn EC (Roche), naproxen 500 mg, net price 56-tab pack = £18.95.
Tablets, Napratec, naproxen 500 mg, net price 56-tab pack = £23.82; 1000 mg, 56-tab pack = £56.24.
Tablets, Naproxen (proprietary), naproxen 500 mg, net price 56-tab pack = £24.33; 1000 mg, 56-tab pack = £56.45.
Tablets, Synflex, naproxen 250 mg, net price 56-tab pack = £4.83; 375 mg, 56-tab pack = £26.82; 500 mg, 56-tab pack = £50.76.
Tablets, Arthroxen, naproxen 250 mg, net price 28-tab pack = £1.35; 500 mg, 28-tab pack = £1.72. Label: 21
Tablets, Naprosyn EC, naproxen 500 mg, net price 56-tab pack = £4.29; 375 mg, 56-tab pack = £6.42; 500 mg, 56-tab pack = £8.56. Label: 5, 25
Tablets, Naprosyn, naproxen 500 mg, net price 60-tab pack = £7.10. Label: 21
Note 275 mg naproxen sodium = 250 mg naproxen
Dose musculoskeletal disorders, postoperative analgesia, 550 mg twice daily when necessary, preferably after food, max. 1 g daily. CHILD under 16 years not recommended
Dysmenorrhea and acute gout, initially 550 mg then 275 mg every 6–8 hours as required; max. of 1.375 g on first day and 1.1 g daily thereafter; CHILD under 16 years not recommended
Migraine, 825 mg at onset, then 275–550 mg at least 30 minutes daily thereafter; every 6–8 hours as required; max. of 1.375 g on first day and 1.1 g daily thereafter; CHILD under 16 years not recommended
Parkinson’s disease, initially 260 mg then 130 mg every 6–8 hours as required; max. of 1.375 g on first day and 1.1 g daily thereafter; CHILD under 16 years not recommended
Dysmenorrhoea in women aged 15–50 years subject to max. 1.375 g on first day and 1.1 g daily thereafter; CHILD under 16 years not recommended
CHILD 6–18 years, juvenile idiopathic arthritis, see BNF for Children
Topical preparations containing piroxicam are not affected by these restrictions

PREGNANCY see notes above
Breast-feeding amount too small to be harmful; see also notes above
Side-effects see notes above

Piroxicam (Non-proprietary) (Pharmacia) (AstraZeneca) (Roche) (Chiesi)
Capsules, piroxicam 10 mg, net price 56-cap pack = £16.62; 20 mg, 28-cap pack = £32.41. Label: 21
Dispersible tablets, piroxicam 10 mg, net price 56-tab pack = £9.96; 20 mg, 28-tab pack = £19.92. Label: 13, 21
Brexidol (Chiesi) (AstraZeneca) (Roche)
Tablets, yellow, scored, piroxicam (as magnesium trihydrate) 20 mg, net price 60-tab pack = £14.95. Label: 22, 25
Note Naproxen component is gastro-resistant
Dose patients requiring naproxen for osteoarthritis, rheumatoid arthritis, or ankyllosing spondylitis, who are at risk of NSAID-associated duodenal or gastric ulcer and when treatment with lower doses of naproxen or other NSAIDs ineffective, ADULT over 18 years, 1 tablet daily
CHILD under 18 years not recommended

PIROXICAM

Indications rheumatoid arthritis, osteoarthritis, and ankyllosing spondylitis (see also CHMP advice below)
Cautions see notes above and CHMP advice below
Contra-indications inflammatory bowel disease; see also notes above
Hepatic impairment see notes above
Renal impairment see notes above

Pregnancy see notes above

CHMP advice
Piroxicam (June 2007) The CHMP has recommended restrictions on the use of piroxicam because of the increased risk of gastrointestinal side effects and serious skin reactions. The CHMP has advised that:
• piroxicam should be initiated only by physicians experienced in treating inflammatory or degenerative rheumatic diseases
• piroxicam should not be used as first-line treatment
• in adults, use of piroxicam should be limited to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankyllosing spondylitis
• piroxicam dose should not exceed 20 mg daily
• piroxicam should no longer be used for the treatment of acute painful and inflammatory conditions
• treatment should be reviewed 2 weeks after initiating piroxicam, and periodically thereafter
• concomitant administration of a gastro-protective agent (section 1.3) should be considered
Note Topical preparations containing piroxicam are not affected by these restrictions

Piroxicam (Non-proprietary) (Pharmacia) (Roche) (AstraZeneca) (Chiesi)
Capsules, piroxicam 10 mg, net price 56-cap pack = £16.62; 20 mg, 28-cap pack = £32.41. Label: 21
Dispersible tablets, piroxicam 10 mg, net price 56-tab pack = £9.96; 20 mg, 28-tab pack = £19.92. Label: 13, 21
Brexidol (Chiesi) (AstraZeneca) (Roche)
Tablets, yellow, scored, piroxicam (as magnesium trihydrate) 20 mg, net price 60-tab pack = £14.95. Label: 22, 25
Note Naproxen component is gastro-resistant
Dose musculoskeletal disorders, postoperative analgesia, 550 mg twice daily when necessary, preferably after food, max. 1 g daily. CHILD under 16 years not recommended
Dysmenorrhea and acute gout, initially 550 mg then 275 mg every 6–8 hours as required; max. of 1.375 g on first day and 1.1 g daily thereafter; CHILD under 16 years not recommended
Migraine, 825 mg at onset, then 275–550 mg at least 30 minutes after initial dose; max. 1.375 g in 24 hours. CHILD under 16 years not recommended

With esomeprazole
For prescribing information on esomeprazole, see section 3.5
Vimovo (AstraZeneca) (Roche) (Chiesi)
Tablets, f/c, m/r, naproxen 500 mg, esomeprazole (as magnesium trihydrate) 20 mg, net price 60-tab pack = £14.95. Label: 22, 25
Note Naproxen component is gastro-resistant
Dose patients requiring naproxen for osteoarthritis, rheumatoid arthritis, or ankyllosing spondylitis, who are at risk of NSAID-associated duodenal or gastric ulcer and when treatment with lower doses of naproxen or other NSAIDs ineffective, ADULT over 18 years, 1 tablet daily
CHILD under 18 years not recommended

With misoprostol
For prescribing information on misoprostol, see section 3.4
Naprapac (Pharmacia) (Pharmacia)
Combination pack, 56 yellow scored tablets, naproxen 500 mg; 56 white scored tablets, misoprostol 200 micrograms. Net price = £23.76. Label: 21
Dose patients requiring naproxen for rheumatoid arthritis, osteoarthritis, or ankyllosing spondylitis, with prophylaxis against NSAID-induced gastroduodenal ulceration, 1 naproxen 500-mg tablet and 1 misoprostol 200-microgram tablet taken together twice daily with food. CHILD not recommended
Note The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by Naprapac® (see section 3.4)

10Musculoskeletal and joint diseases

SULINDAC

Indications pain and inflammation in rheumatic disease and other musculoskeletal disorders; acute gout
Cautions see notes above; also history of renal stones and ensure adequate hydration
Contra-indications see notes above
Hepatic impairment see notes above
Renal impairment avoid in severe impairment; see also notes above
Pregnancy see notes above
**10.1.2 Corticosteroids**

**Aspirin**

Aspirin (section 4.7.1) has been used in high doses to treat rheumatoid arthritis, but other NSAIDs are now preferred.

**10.1.2.1 Systemic corticosteroids**

The general actions, uses, and cautions of corticosteroids are described in section 6.3. Short-term treatment with corticosteroids can help to rapidly improve symptoms of rheumatoid arthritis. Long-term treatment in rheumatoid arthritis should be considered only after evaluating the risks and all other treatment options have been considered. Corticosteroids can induce osteoporosis, and prophylaxis should be considered on long-term treatment (section 6.6).

In severe, possibly life-threatening, situations a high initial dose of corticosteroid is given to induce remission and the dose is then reduced gradually and discontinued altogether. Relapse may occur as the dose of corticosteroid is reduced, particularly if the reduction is too rapid. The tendency is therefore to increase the maintenance dose and consequently the patient becomes dependent on corticosteroids. For this reason pulse doses of corticosteroids (e.g. methylprednisolone up to 1 g intravenously on 3 consecutive days) are used to suppress highly active inflammatory disease while longer-term treatment with a disease-modifying drug is commenced.

**Prednisolone**

7.5 mg daily may reduce the rate of joint destruction in moderate to severe rheumatoid arthritis of less than 2 years' duration. The reduction in joint destruction must be distinguished from mere symptomatic improvement (which lasts only 6 to 12 months at this dose) and care should be taken to avoid increasing the dose above 7.5 mg daily. Evidence supports maintenance of this anti-erosive dose for 2–4 years only after which treatment should be tapered off to reduce long-term adverse effects.

A modified-release preparation of prednisone (section 6.3.2) is also available for the treatment of moderate to severe rheumatoid arthritis.

**Polymyalgia rheumatica** and giant cell (temporal) arteritis are always treated with corticosteroids. The usual initial dose of prednisolone in polymyalgia rheumatica is 10–15 mg daily and in giant cell arteritis 40–60 mg daily (the higher dose being used if visual symp-
Intra-articular/Intradermal

**Local corticosteroid injections**

Corticosteroids are injected locally for an anti-inflammatory effect. In inflammatory conditions of the joints, particularly in rheumatoid arthritis, they are given by *intra-articular injection* to relieve pain, increase mobility, and reduce deformity in one or a few joints. Full aseptic precautions are essential; infected areas should be avoided. Occasionally an acute inflammatory reaction develops after an intra-articular or soft-tissue injection of a corticosteroid. This may be a reaction to the microcrystalline suspension of the corticosteroid used, but must be distinguished from sepsis introduced into the injection site.

Smaller amounts of corticosteroids may also be injected directly into soft tissues for the relief of inflammation in conditions such as tennis or golfer’s elbow or compression neuropathies. In tendinitis, injections should be made into the tendon sheath and not directly into the tendon (due to the absence of a true tendon sheath and a high risk of rupture, the Achilles tendon should not be injected).

Hydrocortisone acetate or one of the synthetic analogues is generally used for local injection. Intra-articular corticosteroid injections can cause flushing and may affect the hyaline cartilage. Each joint should usually be treated no more than 3 times in one year.

Corticosteroid injections are also injected into soft tissues for the treatment of skin lesions (see section 13.4).

**LOCAL CORTICOSTEROID INJECTIONS**

**Indications**  local inflammation of joints and soft tissues (for details, consult product literature)

**Cautions**  see notes above and consult product literature; see also section 6.3.2

**Contra-indications**  see notes above and consult product literature; avoid injections containing benzyl alcohol in neonates (see preparations below)

**Side-effects**  see notes above and consult product literature

**Dose**

- See under preparations

- **Betamethasone**

  Betnesol® (UCB Pharma)  
  Injection, betamethasone (as sodium phosphate) 4 mg/mL, net price 1-mL amp = £1.17.

- **Dexamethasone**

  Dexamethasone (Non-proprietary)  
  Injection, dexamethasone (as sodium phosphate) 4 mg/mL, net price 1-mL amp = £1.27  
  **Dose** by *intra-articular injection* (for details consult product literature), 0.3–3 mg according to size, where appropriate may be repeated at intervals of 3–21 days according to response

  Injection, dexamethasone (as sodium phosphate) 3.3 mg/mL, net price 1-mL amp = £1.00, 2-mL vial = £1.98  
  **Dose** by *intra-articular injection* (for details consult product literature), 0.33–3 mg according to size (*by soft-tissue infiltration* 1.7–5 mg), where appropriate may be repeated at intervals of 3–21 days

- **Hydrocortisone acetate**

  Hydrocortistab® (Sovereign)  
  Injection (aqueous suspension), hydrocortisone acetate 25 mg/mL, net price 1-mL amp = £5.72  
  **Dose** by *intra-articular injection* (for details consult product literature), 5–25 mg according to size; not more than 3 joints should be treated on any one day; *CHILD* 5–30 mg (divided)

- **Methylprednisolone acetate**

  Depo-Medrone® (Pharmacia)  
  Injection (aqueous suspension), methylprednisolone acetate 40 mg/mL, net price 1-mL vial = £2.87, 2-mL vial = £5.15; 3-mL vial = £7.47  
  **Dose** by *intra-articular injection* (for details consult product literature), 4–80 mg, according to size; where appropriate may be repeated at intervals of 7–35 days; also for *intrathecal injection*

  Depo-Medrone® with Lidocaine (Pharmacia)  
  Injection (aqueous suspension), methylprednisolone acetate 40 mg, lidocaine hydrochloride 10 mg/mL, net price 1-mL vial = £3.28; 2-mL vial = £5.88  
  **Dose** by *intra-articular injection* (for details consult product literature), 4–80 mg, according to size; where appropriate may be repeated at intervals of 7–35 days

- **Prednisolone acetate**

  Deltas-tab® (Sovereign)  
  Injection (aqueous suspension), prednisolone acetate 25 mg/mL, net price 1-mL amp = £5.73  
  **Dose** by *intra-articular injection* (for details consult product literature), 5–25 mg according to size; not more than 3 joints should be treated on any one day; where appropriate may be repeated when relapse occurs

  For *intramuscular injection*, see section 6.3.2

- **Triamcinolone acetonide**

  Adcortyl® *Intra-articular/Intradermal* (Squibb)  
  Injection (aqueous suspension), triamcinolone acetonide 10 mg/mL, net price 1-mL amp = 90p; 5-mL vial = £3.63  
  **Excipients** include benzyl alcohol (avoid in neonates, see Excipients, p. 1)

  **Dose** by *intra-articular injection* (for details consult product literature), 2.5–15 mg according to size (for larger doses use...
10.1.3 Drugs that suppress the rheumatic disease process

Certain drugs such as those affecting the immune response can suppress the disease process in rheumatoid arthritis and psoriatic arthritis; gold, penicillamine, hydroxychloroquine, chloroquine, and sulfasalazine can also suppress the disease process in rheumatoid arthritis while sulfasalazine and possibly gold can suppress the disease process in psoriatic arthritis. Unlike NSAIDs, disease-modifying anti-rheumatic drugs (DMARDs) can affect the progression of disease but may require 2–6 months of treatment for a full therapeutic response. Since in the first few months of treatment, the course of rheumatoid arthritis is unpredictable and the diagnosis uncertain, it is usual to start treatment with an NSAID alone. However, disease-modifying anti-rheumatic drugs should be initiated by specialists as soon as diagnosis, progression, and severity of the disease have been confirmed. Response to a disease-modifying anti-rheumatic drug may allow the dose of the NSAID to be reduced.

Disease-modifying anti-rheumatic drugs can improve not only the symptoms of inflammatory joint disease but also extra-articular manifestations such as vasculitis. They reduce the erythrocyte sedimentation rate, C-reactive protein, and sometimes the titre of rheumatoid factor; some also retard erosive damage as judged radiologically.

Choice

The choice of a disease-modifying anti-rheumatic drug should take into account co-morbidity and patient preference. Methotrexate, sulfasalazine, intramuscular gold, and penicillamine are similar in efficacy. However, methotrexate or sulfasalazine may be better tolerated.

A combination of DMARDs (including methotrexate and at least one other DMARD) and a short-term corticosteroid (section 10.1.2), should be given to patients with newly diagnosed active rheumatoid arthritis, ideally within 3 months of the onset of persistent symptoms if the use of particular DMARDs is contra-indicated and combination therapy is not possible. Monotherapy with a suitable DMARD should be given and the dose rapidly increased until clinically effective. In patients with established and stable rheumatoid arthritis, cautiously reduce drug doses to the lowest that are clinically effective. Response to drug treatment often produces a reduction in requirements of both corticosteroids and other drugs.

Gold and penicillamine are effective in palindromic rheumatism. Systemic and discoid lupus erythematosus are sometimes treated with chloroquine or hydroxychloroquine.

If a disease-modifying anti-rheumatic drug does not lead to an objective benefit within 6 months, it should be replaced by a different one.

Juvenile idiopathic arthritis

Many children with juvenile idiopathic arthritis (juvenile chronic arthritis) do not require disease-modifying anti-rheumatic drugs.

Methotrexate is effective [unlicensed indication]; sulfasalazine is an alternative [unlicensed indication] but it should be avoided in systemic-onset juvenile idiopathic arthritis. Gold and penicillamine are no longer used. For the role of cytokine modulators in polyarticular juvenile idiopathic arthritis, see p. 647.

Gold

Gold can be given as sodium aurothiomalate for active progressive rheumatoid arthritis; it must be given by deep intramuscular injection and the area gently massaged. A test dose of 10 mg must be given followed by doses of 50 mg at weekly intervals until there is definite evidence of remission. Benefit is not to be expected until about 300–500 mg has been given; it should be discontinued if there is no remission after 1 g has been given. In patients who do respond, the interval between injections is then gradually increased to 4 weeks and treatment is continued for up to 5 years after complete remission. If relapse occurs the dosage frequency may be immediately increased to 50 mg weekly and only once control has been obtained again should the dosage frequency be decreased; if no response is seen within 2 months, alternative treatment should be sought. It is important to avoid complete relapse since second courses of gold are not usually effective.

Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastro-intestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300 mg/litre. Urine tests and full blood counts (including total and differential white cell and platelet counts) must therefore be performed before starting treatment and before each intramuscular injection. Rashes with pruritus often occur after 2 to 6 months of treatment and may necessitate discontinuation.

SODIUM AUROTHIOMALATE

Indications active progressive rheumatoid arthritis

Cautions see notes above; elderly, history of urticaria, eczema, colitis; monitor for pulmonary fibrosis with annual chest X-ray; interactions: Appendix 1 (sodium aurothiomalate)

Counselling Patients should be advised to seek prompt medical attention if diarrhoea, sore throat, fever, infection, non-specific illness, unexplained bleeding and bruising, purpura, mouth ulcers, metallic taste, rash, breathlessness, or cough develop

Contra-indications history of blood disorders or bone marrow aplasia, exfoliative dermatitis, systemic lupus erythematosus, necrotising enterocolitis, pulmonary fibrosis, acute porphyria (section 9.8.2)

Hepatic impairment caution in mild to moderate impairment, avoid in severe impairment
Penicillamine

Penicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.

Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.

Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase). A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase. Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2 g.

Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased. Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued; mineral supplements are not recommended. Rashes are a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased. Late rashes are more resistant and often necessitate discontinuation of treatment.

Patients who are hypersensitive to penicillin may react rarely to penicillamine.
Antimalarials

The antimalarial hydroxychloroquine is used to treat rheumatoid arthritis of moderate inflammatory activity; chloroquine is also licensed for treating inflammatory disorders but is used much less frequently and is generally reserved for use if other drugs have failed. Chloroquine and hydroxychloroquine are effective for mild systemic lupus erythematosus, particularly involving the skin and joints. These drugs should not be used for psoriatic arthritis.

Chloroquine and hydroxychloroquine are better tolerated than gold or penicillamine. Retinopathy (see below) rarely occurs provided that the recommended doses are not exceeded; in the elderly it is difficult to distinguish drug-induced retinopathy from changes of ageing.

Mepacrine (section 5.4.4) is sometimes used in discoid drug-induced retinopathy from changes of ageing.

Cautions Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory (see advice of the Royal College of Ophthalmologists, below). Chloroquine and hydroxychloroquine should be used with caution in neurological disorders (especially in those with a history of epilepsy), in severe gastro-intestinal disorders, in G6PD deficiency (section 9.1.5), in acute porphyria, and in the elderly (see also above). Chloroquine and hydroxychloroquine may exacerbate psoriasis and aggravate myasthenia gravis. Concurrent use of hepatotoxic drugs should be avoided; other interactions: Appendix 1 (chloroquine and hydroxychloroquine).

Screening for ocular toxicity A review group convened by the Royal College of Ophthalmologists has updated guidelines for screening to prevent ocular toxicity on long-term treatment with chloroquine and hydroxychloroquine (Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening 2009). Chloroquine should be considered (for treating chronic inflammatory conditions) only if other drugs have failed. All patients taking chloroquine should receive ocular examination according to a protocol arranged locally between the prescriber and the ophthalmologist. The following recommendations relate to hydroxychloroquine, which is only rarely associated with toxicity.

Before treatment:

- Assess renal and liver function (adjust dose if impaired)
- Ask patient about visual impairment (not corrected by glasses). If impairment or eye disease present, assessment by an optometrist is advised and any abnormality should be referred to an ophthalmologist
- Record near visual acuity of each eye (with glasses where appropriate) using a standard reading chart
- Initiate hydroxychloroquine treatment if no abnormality detected (at a dose not exceeding hydroxychloroquine sulphate 6.5 mg/kg daily)

During treatment:

- Ask patient about visual symptoms and monitor visual acuity annually using the standard reading chart
- Refer to ophthalmologist if visual acuity changes or vision blurred and warn patient to seek prescribing doctor’s advice about stopping treatment
- A child treated for juvenile idiopathic arthritis should receive slit-lamp examination routinely to check for uveitis
- If long-term treatment is required (more than 5 years), individual arrangement should be agreed with the local ophthalmologist

Hepatic impairment Chloroquine and hydroxychloroquine should be used with caution in moderate to severe hepatic impairment.

Pregnancy It is not necessary to withdraw an antimalarial drug during pregnancy if the rheumatic disease is well controlled; however, the manufacturer of hydroxychloroquine advises avoiding use.

Breast-feeding Chloroquine and hydroxychloroquine are present in breast milk and breast-feeding should be avoided when they are used to treat rheumatic disease.

Side-effects The side-effects of chloroquine and hydroxychloroquine include gastro-intestinal disturbances, headache and skin reactions (rashes, pruritus); those occurring less frequently include ECG changes, convulsions, visual changes, retinal damage (see above), keratopathy, otopotoxicity, hair depigmentation, hair loss, and discoloration of skin, nails, and mucous membranes. Side-effects that occur rarely include blood disorders (including thrombocytopenia, agranulocytosis, and aplastic anaemia), mental changes (including emotional disturbances and psychosis), myopathy (including cardiomyopathy and neuromyopathy), acute generalised exanthematous pustulosis, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity, and hepatic damage; angioedema has also been reported. Important: very toxic in overdosage—immediate advice from poisons centres essential (see also p. 37).

CHLOROQUINE

Indications active rheumatoid arthritis, systemic and discoid lupus erythematosus; malaria (section 5.4.1)

Cautions see notes above

Hepatic impairment see notes above

Renal impairment manufacturer advises caution; reduce dose

Pregnancy see notes above

Breast-feeding see notes above

Side-effects see notes above
Drugs affecting the immune response

Methotrexate is a disease-modifying antirheumatic drug suitable for moderate to severe rheumatoid arthritis. Azathioprine, ciclosporin, cyclophosphamide, leflunomide, and the cytokine modulators are considered more toxic and they are used in cases that have not responded to other disease-modifying drugs.

Methotrexate is usually given in an initial dose of 7.5 mg by mouth once a week, adjusted according to response to a maximum of 15 mg once a week (occasionally 20 mg once a week). Regular full blood counts (including differential white cell count and platelet counts), renal and liver function tests are required. In patients who experience mucosal or gastrointestinal side-effects with methotrexate, folic acid 5 mg every week [unlicensed indication], on a different day from the methotrexate, may help to reduce the frequency of such side-effects.

Azathioprine is usually given in a dose of up to 2.5 mg/kg daily in divided doses. Blood counts are needed to detect possible neutropenia or thrombocytopenia (usually resolved by reducing the dose). Nausea, vomiting, and diarrhoea may occur, usually starting early during the course of treatment, and may necessitate withdrawal of the drug; herpes zoster infection may also occur.

Leflunomide acts on the immune system as a disease-modifying antirheumatic drug. Its therapeutic effect starts after 4–6 weeks and improvement may continue for a further 4–6 months. Leflunomide, which is similar in efficacy to sulphasalazine and methotrexate, may be chosen when these drugs cannot be used. The active metabolite of leflunomide persists for a long period; active procedures to wash the drug out are required in cases of serious adverse effects, or before starting treatment with another disease-modifying antirheumatic drug, or, in men or women, before conception. Side-effects of leflunomide include bone-marrow toxicity; its immunosuppressive effects increase the risk of infection and malignancy.

Ciclosporin is licensed for severe active rheumatoid arthritis when conventional second-line therapy is inappropriate or ineffective. There is some evidence that ciclosporin may retard the rate of erosive progression and improve symptom control in those who respond only partially to methotrexate.

Cyclophosphamide (section 8.1.1) may be used at a dose of 1 to 1.5 mg/kg daily by mouth for rheumatoid arthritis with severe systemic manifestations [unlicensed indication]; it is toxic and regular blood counts (including platelet counts) should be carried out. Cyclophosphamide can also be given intravenously in a dose of 0.5 to 1 g (with prophylactic mesna) for severe systemic rheumatoid arthritis and for other connective tissue diseases (especially with active vasculitis), repeated initially at fortnightly then at monthly intervals (according to clinical response and haematological monitoring).

Drugs that affect the immune response are also used in the management of severe cases of systemic lupus erythematosus and other connective tissue disorders. They are often given in conjunction with corticosteroids for patients with severe or progressive renal disease. They may be used in cases of polymyositis that are resistant to corticosteroids. They are used for their corticosteroid-sparing effect in patients whose corticosteroid requirements are excessive. Azathioprine is usually used.

Azathioprine and methotrexate are used in the treatment of psoriatic arthropathy [unlicensed indication] for severe or progressive cases that are not controlled with anti-inflammatory drugs.

AZATHIOPRINE

Indications see notes above; inflammatory bowel disease [unlicensed indication] (section 1.5.3); autoimmune conditions and prophylaxis of transplantation rejection (section 8.2.1); severe refractory eczema [unlicensed indication] (section 13.5.3)

Cautions section 8.2.1

Contra-indications section 8.2.1

Hepatic impairment section 8.2.1

Renal impairment section 8.2.1

Pregnancy section 8.2.1

Breast-feeding section 8.2.1

Side-effects section 8.2.1
Dose
• By mouth, initially, rarely more than 3 mg/kg daily, reduced according to response; maintenance 1–3 mg/kg daily; consider withdrawal if no improvement within 3 months

Preparations
Section 8.2.2

CICLOSPORIN (Cyclosporin)

Indications severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective; severe active ulcerative colitis [unlicensed indication] (section 1.5.3); graft-versus-host disease (section 8.2.2); atopic dermatitis and psoriasis (section 13.5.3)

Cautions section 8.2.2

Additional cautions in rheumatoid arthritis Contra-indicated in abnormal renal function, uncontrolled hypertension (see also below), uncontrolled infections, and malignancy. Measure serum creatinine at least twice before treatment and monitor every 2 weeks for first 3 months, then every 4 weeks (or more frequently if dose increased or concomitant NSAIDs introduced or increased (see also interactions: Appendix 1 (cyclosporin)), reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement, if above 50% reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month, monitor blood pressure (discontinue if hypertensive disease that cannot be controlled by antihypertensive therapy); monitor hepatic function if concomitant NSAIDs given.

Hepatic impairment section 8.2.2

Renal impairment see Cautions above

Pregnancy see section 8.2.2

Breast-feeding section 8.2.2

Side-effects section 8.2.2

Dose
• By mouth, administered in accordance with expert advice, initially 2.5 mg/kg daily in 2 divided doses, if necessary increased gradually after 6 weeks; max. 4 mg/kg daily (discontinue if response insufficient after 3 months); dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks); CHILD and under 18 years

Important For preparations and counselling and for advice on conversion between the preparations, see section 8.2.2

Preparations
Section 8.2.2

LEFLUNOMIDE

Indications (specialist use only) moderate to severe active rheumatoid arthritis; active psoriatic arthritis

Cautions impaired bone-marrow function including anaemia, leucopenia or thrombocytopenia (avoid if significant and due to causes other than rheumatoid arthritis); recent treatment with other hepatotoxic or myelotoxic disease-modifying antirheumatic drugs; washout procedures recommended for serious adverse effects or before switching to other disease-modifying antirheumatic drugs (consult product literature and see Washout Procedure, below); history of tuberculosis; exclude pregnancy before treatment; effective contraception essential during treatment and for at least 2 years after treatment in women and at least 3 months after treatment in men (plasma concentration monitoring required; waiting time before conception may be reduced with washout procedure—consult product literature and see Washout Procedure, below); monitor full blood count (including differential white cell count and platelet count) before treatment and every 2 weeks for 6 months then every 8 weeks; monitor liver function—see Hepatic toxicity, below; monitor blood pressure; interactions: Appendix 1 (leflunomide)

Hepatotoxicity Potentially life-threatening hepatotoxicity reported usually in the first 6 months; monitor liver function before treatment and every 2 weeks for first 6 months then every 8 weeks. Discontinue treatment (and institute washout procedure—consult product literature and see Washout Procedure below) or reduce dose according to liver-function abnormality; if liver-function abnormality persists after dose reduction, discontinue treatment and institute washout procedure

Washout procedure To aid drug elimination in case of serious adverse effect, or before starting another disease-modifying antirheumatic drug, or before conception (see also Pregnancy below), stop treatment and give either ciclosporin or azathioprine 8 g 3 times daily for 11 days or activated charcoal 50 g 4 times daily for 11 days; the concentration of the active metabolite after washout should be less than 20 micrograms/litre (measured on 2 occasions 14 days apart) in men or women before conception—consult product literature. Procedure may be repeated as necessary

Contra-indications severe immunodeficiency; severe hypoproteinaemia; serious infection

Hepatic impairment avoid—active metabolite may accumulate; see also Cautions above

Renal impairment manufacturer advises avoid in moderate or severe impairment—no information available

Pregnancy avoid—active metabolite teratogenic in animal studies; effective contraception essential during treatment and for at least 2 years after treatment in women and at least 3 months after treatment in men (see also Cautions above)

Breast-feeding present in milk in animal studies—manufacturer advises avoid

Side-effects diarrhoea, nausea, vomiting, anorexia, oral mucosal disorders, abdominal pain; increased blood pressure; headache, dizziness, asthma, paraesthesia; leucopenia; tenosynovitis, alopecia, rash, dry skin, pruritus; less commonly taste disturbance, anxiety, hyperlipidaemia, hypokalaemia, hypophosphataemia, anaemia, thrombocytopenia, and tendon rupture; rarely hepatitis, jaundice (see Hepatotoxicity, above), interstitial lung disease, severe infection, esinophilia, and pancytopenia; very rarely pancreatitis, hepatic failure (see Hepatotoxicity, above), peripheral neuropathy; vasculitis, progressive multifocal leucoencephalopathy, Stevens-Johnson syndrome, and toxic epidermal necrolysis; hypouricaemia, reduced sperm count, and renal failure also reported; important: discontinue treatment and institute washout procedure (see Washout Procedure under Cautions) in case of serious side-effect

Dose
• Rheumatoid arthritis, ADULT over 18 years, initially 100 mg once daily for 3 days, then 10–20 mg once daily

• Psoriatic arthritis, ADULT over 18 years, initially 100 mg once daily for 3 days, then 20 mg once daily
10.1.3 Drugs that suppress the rheumatic disease process

Leflunomide (Non-proprietary) Tablets, leflunomide, 10 mg, net price 30-tab pack = £46.00; 20 mg, 30-tab pack = £46.00. Label: 4

Arava® (Sanofi-Aventis) Tablets, f/c, leflunomide 10 mg (white), net price 30-tab pack = £51.13; 20 mg (yellow), 30-tab pack = £61.36; 100 mg (white), 3-tab pack = £30.67. Label: 4

**METHOTREXATE**

**Indications** moderate to severe active rheumatoid arthritis; Crohn’s disease [unlensed indication] (section 1.5.3); malignant disease (section 8.1.3); psoriasis (section 13.5.3)

**Cautions** section 8.1; see CSM advice below (blood count, liver and pulmonary toxicity); extreme caution in blood disorders (avoid if severe); peptic ulceration, ulcerative colitis, diarrhoea and ulcerative stomatitis (withdraw if stomatitis develops—may be first sign of gastro-intestinal toxicity); risk of accumulation in pleural effusion or ascites—drain before treatment; acute porphyria (section 9.8.2); interactions: see below and Appendix 1 (methotrexate)

**CSM advice**

In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate, the CSM has advised:

- full blood count and renal and liver function tests before starting treatment and repeated weekly until therapy stabilised, thereafter patients should be monitored every 2–3 months
- that patients should be advised to report all symptoms and signs suggestive of infection, especially sore throat
- Treatment with folic acid (as calcium folinate, section 8.1) may be required in acute toxicity

**Blood count** Bone marrow suppression can occur abruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug. A clinically significant drop in white cell count or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapy.

**Liver toxicity** Liver cirrhosis reported. Treatment should not be started or should be discontinued if any abnormality of liver function tests or liver biopsy is present or develops during therapy. Abnormalities can return to normal within 2 weeks after which treatment may be recommenced if judged appropriate

**Pulmonary toxicity** Pulmonary toxicity may be a special problem in rheumatoid arthritis (patient to seek medical attention if dyspnoea, cough or fever); monitor for symptoms at each visit—discontinue if pneumonitis suspected

**Aspirin and other NSAIDs** If aspirin or other NSAIDs are given concurrently the dose of methotrexate should be carefully monitored. Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen

**Contra-indications** see Cautions above; active infection and immunodeficiency syndromes

**Hepatic impairment** avoid—dose-related toxicity; see also Cautions above

**Renal impairment** reduce dose; risk of nephrotoxicity at high doses; avoid in severe impairment

**Pregnancy** avoid (teratogenic; fertility may be reduced during therapy but this may be reversible); effective contraception required during and for at least 3 months after treatment in men or women; see also section 8.1

**Breast-feeding** discontinue breast-feeding; present in milk

**Side-effects** section 8.1; also anorexia, abdominal discomfort, dyspepsia, gastro-intestinal ulceration and bleeding, diarrhoea, toxic megacolon, hepatotoxicity (see Cautions above); hypotension, pericarditis, pericardial tamponade; pulmonary oedema, pleuritic pain, pulmonary fibrosis, interstitial pneumonitis (see also Pulmonary Toxicity above); ana-phylactic reactions, urticaria; dizziness, fatigue, chills, fever, drowsiness, malaise, headache, mood changes, neurotoxicity; confusion, paraesthesia; precipitation of diabetes; menstrual disturbances, vaginitis, cystitis, reduced libido, impotence; blood disorders; haematuria, dysuria, renal failure; osteoporosis, arthralgia, myalgia, vasculitis; conjunctivitis, visual disturbance; rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity; changes in nail and skin pigmentation, telangiectasia, acne, furunculosis, ecchymosis; injection-site reactions

**Dose**

- Moderate to severe active rheumatoid arthritis, by mouth, 7.5 mg once weekly, adjusted according to response; max. weekly dose 20 mg
- Severe active rheumatoid arthritis, by subcutaneous or by intramuscular or by intravenous injection, 7.5 mg once weekly, increased according to response by 2.5 mg weekly; max. weekly dose 25 mg

**Important**

Note that the above dose is a weekly dose. To avoid error with low-dose methotrexate, it is recommended that:

- the patient is carefully advised of the dose and frequency and the reason for taking methotrexate and any other prescribed medicine (e.g. folic acid)
- only one strength of methotrexate tablet (usually 2.5 mg) is prescribed and dispensed;
- the prescription and the dispensing label clearly show the dose and frequency of methotrexate administration;
- the patient is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort, and dark urine), and respiratory effects (e.g. shortness of breath)

**Methotrexate** (Non-proprietary) Tablets, yellow, methotrexate 2.5 mg, net price 28-tab pack = £3.27. Counselling, dose, NSAIDs

Brands include: Meatrox™

**Parenteral preparations** See also section 8.1.3

**Metotrex®** (Medac) Injection, prefilled syringe, methotrexate (as disodium salt) 50 mg/mL, net price 0.15 mL (7.5 mg) = £14.85, 0.2 mL (10 mg) = £15.29, 0.3 mL (15 mg) = £16.57, 0.4 mL (20 mg) = £17.84, 0.5 mL (25 mg) = £18.48, 0.6 mL (30 mg) = £18.95

**Cytokine modulators**

Cytokine modulators should be used under specialist supervision.

Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab inhibit the activity of tumour necrosis factor alpha (TNF-α).

Adalimumab is licensed for moderate to severe active rheumatoid arthritis when response to other disease-
modifying antirheumatic drugs (including methotrexate) has been inadequate (see also NICE guidance October 2007, below and August 2010, p. 649); it can also be used for severe, active, and progressive disease in adults not previously treated with methotrexate. It is also licensed for active polyarticular juvenile idiopathic arthritis in adolescents who have not responded adequately to one or more disease-modifying antirheumatic drugs. In the treatment of rheumatoid arthritis and polyarticular juvenile idiopathic arthritis, adalimumab should be used in combination with methotrexate, but it can be given alone if methotrexate is inappropriate. Adalimumab is also licensed for the treatment of active and progressive psoriatic arthritis (see also NICE guidance, p. 649) and severe active ankylosing spondylitis (see also NICE guidance, p. 649) that have not responded adequately to other disease-modifying anti-rheumatic drugs. For the role of adalimumab in plaque psoriasis, see section 13.5.3.

Certolizumab pegol is licensed for use in patients with moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (see also NICE guidance, below). Certolizumab pegol can be used in combination with methotrexate, or as a monotherapy if methotrexate is not tolerated or is contra-indicated.

**NICE guidance**

**Certolizumab pegol for the treatment of rheumatoid arthritis (February 2010)**

Certolizumab pegol is recommended as an option for the treatment of patients with rheumatoid arthritis only if:

- certolizumab pegol is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitor treatments, (see Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis, below) and the manufacturer provides the first 12 weeks of certolizumab pegol (10 prefilled 200-mg syringes) free of charge to all patients starting treatment.

Etanercept is licensed for the treatment of moderate to severe active rheumatoid arthritis either alone or in combination with methotrexate when the response to other disease-modifying antirheumatic drugs is inadequate and in severe, active and progressive rheumatoid arthritis in patients not previously treated with methotrexate (see also NICE guidance October 2007, below and August 2010, p. 649). It is also licensed for the treatment of active polyarticular juvenile idiopathic arthritis in children who have not responded adequately to or are intolerant of methotrexate (see also NICE guidance, p. 649), active and progressive psoriatic arthritis inadequately responsive to other disease-modifying antirheumatic drugs (see also NICE guidance, p. 649), and for severe ankylosing spondylitis inadequately responsive to conventional therapy (see also NICE guidance, p. 649). For the role of etanercept in plaque psoriasis, see section 13.5.3.

Golimumab is licensed in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate. Golimumab is also licensed for the treatment of active and progressive psoriatic arthritis, as monotherapy or in combination with methotrexate, when response to DMARD therapy has been inadequate; it is also licensed for the treatment of severe active ankylosing spondylitis when there is an inadequate response to conventional treatment.

**Infliximab** is licensed for the treatment of active rheumatoid arthritis in combination with methotrexate when the response to other disease-modifying anti-rheumatic drugs, including methotrexate, is inadequate (see also NICE guidance October 2007, below and August 2010, p. 649); it is also licensed in combination with methotrexate for patients not previously treated with methotrexate or other DMARDs who have severe, active, and progressive rheumatoid arthritis. Infliximab is also licensed for the treatment of ankylosing spondylitis, in patients with severe axial symptoms who have not responded adequately to conventional therapy (but see also NICE guidance, p. 649) and in combination with methotrexate (or alone if methotrexate is not tolerated or is contra-indicated) for the treatment of active and progressive psoriatic arthritis which has not responded adequately to disease-modifying anti-rheumatic drugs (see also NICE guidance, p. 649).

**Rituximab** is licensed in combination with methotrexate for the treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (see also NICE guidance, p. 649). For the role of rituximab in malignant disease, see section 8.2.3.

**NICE guidance**

**Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)**

The tumour necrosis factor alpha (TNF-α) inhibitors adalimumab, etanercept, and infliximab are options for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-α inhibitors should be given in combination with methotrexate; however, when methotrexate cannot be used because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy.

Adalimumab, etanercept, and infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-α inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.

**Use of TNF-α inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.**
BNF 61 10.1.3 Drugs that suppress the rheumatic disease process 649

NICE guidance
Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of severe active rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)

Adalimumab or etanercept are recommended as treatment options for adults with severe active rheumatoid arthritis (including at least one modifying antirheumatic drug). Adalimumab or etanercept should be used in combination with methotrexate, as an option for the treatment of severe active rheumatoid arthritis in adults who have an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.

Adalimumab, etanercept, infliximab, or abatacept, in combination with methotrexate, are options for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least one TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, adalimumab or etanercept can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.

NICE guidance
Etanercept for the treatment of juvenile idiopathic arthritis (May 2002)

Etanercept is recommended in children aged 4–17 years with active polyarticular-course juvenile idiopathic arthritis who have not responded adequately to methotrexate or who are intolerant of it. Etanercept should be used under specialist supervision according to the guidelines of the British Society for Paediatric and Adolescent Rheumatology (previously the British Paediatric Rheumatology Group).

Etanercept should be withdrawn if severe side-effects develop or if there is no response after 6 months or if the initial response is not maintained. There is no evidence to support treatment for longer than 2 years; a decision to continue therapy should be based on disease activity and clinical effectiveness in individual cases.

Prescribers of etanercept should register consenting patients with the Biologics Registry of the British Society for Paediatric and Adolescent Rheumatology.

NICE guidance
Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)

Etanercept, infliximab, or adalimumab are recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).

Etanercept, infliximab, and adalimumab should be discontinued if there is an inadequate response at 12 weeks.

Side-effects
Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and rituximab have been associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation. Other side-effects include nausea, abdominal pain, worsening heart failure, hypersensitivity reactions, fever, headache, depression, antibody formation (including lupus erythematosus-like syndrome), pruritus, injection-site reactions, and blood disorders (including anaemia, leucopenia, thrombocytopenia, pancytopenia, and aplastic anaemia).

Abatacept prevents the full activation of T-lymphocytes. It is licensed for moderate to severe active rheumatoid arthritis in combination with methotrexate, in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor); see also NICE guidance, above. It is also licensed for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (in combination with methotrexate) in children who have not responded adequately to other disease-modifying antirheumatic drugs (including at least one tumour necrosis factor (TNF) inhibitor). Abatacept is not recommended for use in combination with TNF inhibitors.
The Scottish Medicines Consortium (p. 4) has advised (August 2007) that abatacept is not recommended for the treatment of moderate to severe active rheumatoid arthritis within NHS Scotland.

Anakinra inhibits the activity of interleukin-1. Anakinra (in combination with methotrexate) is licensed for the treatment of rheumatoid arthritis which has not responded to methotrexate alone; it is not, however, recommended for routine management of rheumatoid arthritis, see NICE guidance below.

The Scottish Medicines Consortium (p. 4) has advised (July 2002) that anakinra is not recommended for the treatment of rheumatoid arthritis within NHS Scotland.

(continued on next page)
**Pregnancy** avoid; manufacturer advises effective contraception required during treatment and for at least 5 months after last dose

**Breast-feeding** avoid; manufacturer advises avoid for at least 5 months after last dose

**Side-effects** see under Cytokine Modulators (p. 649) and Cautions above; also vomiting, dyspepsia, gastrointestinal haemorrhage; dizziness, hyperlipidaemia, hypertension, oedema, flushing, chest pain, tachycardia; cough, dyspnoea; mood changes, sleep disturbances, anxiety, paraesthesia; haematuria, renal impairment; benign tumours, non-melanoma skin cancers; electrolyte disturbances, hyperuricaemia; musculoskeletal pain; eye disorders; rash, dermatitis, onycholysis, impaired healing; less commonly dysphagia, pancreatitis, cholecithiasis, hepatitis, pancreatitis, cholestasis, asthma, dyspnoea, interstitial lung disease, pneumonitis, tremor, erectile dysfunction, nocturia, malignancy, rhabdomyolysis, hearing loss, tinnitus; rarely vascular occlusion, myocardial infarction, demyelinating disorders, pulmonary embolism, pleural effusion, Stevens-Johnson syndrome, cutaneous vasculitis, new onset or worsening psoriasis, and hepatosplenic T-cell lymphoma also reported

**Injection**

- **Certolizumab pegol**
  - **Indications** see under Cytokine Modulators above
  - **Cautions** predisposition to infection; monitor for infections before, during, and for 5 months after treatment (see also Tuberculosis below), do not initiate until active infections are controlled; discontinue if new serious infection develops until infection controlled; hepatitis B virus—monitor for active infection; mild heart failure (discontinue if symptoms develop or worsen—avoid in moderate to severe heart failure); demyelinating CNS disorders (risk of exacerbation); history or development of malignancy; **interactions**: Appendix 1 (certolizumab pegol)
  - **Tuberculosis** Patients should be evaluated for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment (section 5.1.9) for at least 2 months before starting certolizumab pegol. Patients who have previously received adequate treatment for tuberculosis can start certolizumab pegol but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting certolizumab pegol. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with certolizumab pegol. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop
  - **Blood disorders** Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop
  - **Contra-indications** severe active infection (see also Cautions)
  - **Pregnancy** avoid; manufacturer advises adequate contraception during treatment and for at least 5 months after last dose
  - **Breast-feeding** manufacturer advises use only if potential benefit outweighs risk—no information available

- **Humira® (Abbott)**
  - **Injection** adalimumab, net price 40-mg prefilled pen or prefilled syringe = £357.50. Counselling, tuberculosis

**Anakinra**

**Indications** see under Cytokine Modulators above

**Cautions** predisposition to infections; history of asthma (risk of serious infection); **interactions**: Appendix 1 (anakinra)

**Blood disorders** Neutropenia reported commonly. Monitor neutrophil count before treatment, then every month; then every 3 months—discontinue if neutropenia develops. Patients should be instructed to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat, infection) develop

**Contra-indications** neutropenia

**Renal impairment** caution if eGFR 30–50 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid; effective contraception must be used during treatment

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** injection-site reactions; headache; infections, neutropenia (see also Cautions), and antibody formation; also reported malignancy

**Dose**

- **By subcutaneous injection, ADULT over 18 years, 100 mg once daily**
ETANERCEPT

Indications  see under Cytokine Modulators above

Cautions  predisposition to infection (avoid if predisposition to septicemia); significant exposure to herpes zoster virus—interrupt treatment and consider varicella–zoster immunoglobulin; hepatitis B virus—monitor for active infection; monitor for worsening interstitial lung disease (e.g. during outbreaks of infectious mononucleosis); monitor for demyelinating CNS disorders; diabetes mellitus;

interactions: Appendix 1

Tuberculosis  Patients should be evaluated for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment (section 5.1.9) for at least 2 months before starting etanercept. Patients who have previously received adequate treatment for tuberculosis can start etanercept but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting etanercept. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with etanercept. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.

Blood disorders  Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Contra-indications  active infection; avoid injections containing benzyl alcohol in neonates (see preparations below)

Hepatic impairment  use with caution in moderate to severe alcoholic hepatitis

Pregnancy  manufacturer advises avoid—no information available

Breast-feeding  manufacturer advises avoid—present in milk in animal studies

Side-effects  see under Cytokine Modulators (p. 649); also less commonly interstitial lung disease, non-melanoma skin cancer, rash, psoriasis (including new onset); rarely demyelinating disorders, seizures, Stevens-Johnson syndrome, and cutaneous vasculitis; very rarely toxic epidermal necrolysis; also reported appendicitis, cholecystitis, gastritis, gastro-intestinal haemorrhage, intestinal obstruction, liver damage, oesophagitis, pancreatitis, ulcerative colitis, vomiting, cerebral ischaemia, hypertension, hypotension, myocardial infarction, thrombophlebitis, thrombocytopenia, asthma, dyspnoea, aseptic meningitis, confusion, paresis, paraesthesia, vertigo, lymphadenopathy, diabetes mellitus, haematuria, malignancy, renal calculi, renal impairment, bone fracture, bursitis, polyomysitis, scleritis, and cutaneous ulcer

Dose  By subcutaneous injection, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ADULT over 18 years, 25 mg twice weekly or 50 mg once weekly Active polyarticular juvenile idiopathic arthritis, CHILD 4–17 years, 400 micrograms/kg (max. 25 mg) twice weekly, with an interval of 3–4 days between doses

GOLIMUBAB

Indications  see under Cytokine Modulators above

Cautions  predisposition to infection; monitor for infections before, during, and for 5 months after treatment (see also Tuberculosis below); do not initiate until active infections are controlled; discontinue if new serious infection develops until infection controlled; hepatitis B virus—monitor for active infection; mild heart failure (discontinue if symptoms develop or worsen); demyelinating CNS disorders (risk of exacerbation); history or development of malignancy;

interactions: Appendix 1 (golimumab)

Tuberculosis  Patients should be evaluated for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment (section 5.1.9) for at least 2 months before starting golimumab. Patients who have previously received adequate treatment for tuberculosis can start golimumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting golimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with golimumab. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.

Blood disorders  Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Contra-indications  severe active infection (see also Cautions); moderate or severe heart failure

Hepatic impairment  manufacturer advises caution—no information available

Pregnancy  use only if essential; manufacturer advises adequate contraception during treatment and for at least 6 months after last dose

Breast-feeding  manufacturer advises avoid during and for at least 6 months after treatment—present in milk in animal studies

Side-effects  see under Cytokine Modulators (p. 649) and Under Cautions above; also constipation, dyspepsia, hypertension, insomnia, dizziness, paraesthesia, asthenia, alopecia, dermatitis; less commonly taste disturbance, gastritis, colitis, stomatitis, gastrooesophageal reflux disease, cholelithiasis, hepatic disorders, hyperlipidaemia, arrhythmia, ischaemic coronary artery disorders, Raynaud’s syndrome, heart failure, thrombosis, flushing, bronchospasm, demyelinating disorders, hyperglycaemia, thyroid disorders, menstrual disorders, malignancy, bone fractures.
visual disturbance, eye irritation, new onset or worsening psoriasis; rarely interstitial lung disease, renal impairment

**Dose**
- **By subcutaneous injection, ADULT** over 18 years, 50 mg once a month on the same date each month, review treatment if no response after 3–4 doses; body weight over 100 kg, if inadequate response to 3–4 doses of 50 mg, once a month, dose can be increased to 100 mg once a month, review treatment if inadequate response to this higher dose after 3–4 doses

**Note** If dose administered more than 2 weeks late, subsequent doses should be administered on the new monthly due date

**Side-effects** see under Cytokine Modulators (p. 649) and under Cautions above; also diarrhoea, dyspepsia, hepatic impairment; flushing, chest pain; dyspnoea; dizziness, fatigue; sinusitis; rash, sweating, dry skin; less commonly constipation, gastro-oesophageal reflux, diverticulitis, cholecystitis, palpitation, arrhythmia, hypertension, hypotension, vasospasm, cyanosis, bradycardia, syncope, oedema, thrombo-phlebitis, epistaxis, bronchospasm, pleurisy, confusion, agitation, nervousness, amnesia, sleep disturbances, vaginitis, demelinating disorders, antibody formation, pyelonephritis, myalgia, arthralgia, eye disorders, abnormal skin pigmentation, antibody formation, Stevens-Johnson syndrome, toxic epidermal necrolysis; neuropathy, paraesthesia, and transverse myelitis; interstitial lung disease, new onset or worsening psoriasis also reported

**Dose**
- **By intravenous infusion**, rheumatoid arthritis (in combination with methotrexate), **ADULT** over 18 years, 3 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 8 weeks; if response inadequate after 12 weeks, dose may be increased in steps of 1.5 mg/kg every 8 weeks, up to max. 7.5 mg/kg every 8 weeks; alternatively, 3 mg/kg may be given every 4 weeks; discontinue if no response by 12 weeks of initial infusion or after dose adjustment

**Note** Ankylosing spondylitis, **ADULT** over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 6–8 weeks; discontinue if no response by 6 weeks of initial infusion

Psoriatic arthritis (in combination with methotrexate), **ADULT** over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 8 weeks

**Preparations** Section 8.2.3
10.1.4 Gout and cytotoxic-induced hyperuricaemia

**TOCILIZUMAB**

**Indications** see under Cytokine Modulators above

**Cautions** predisposition to infection or history of recurrent or chronic infection; interrupt treatment if serious infection occurs; history of intestinal ulceration or diverticulitis; monitor hepatic transaminases every 4–8 weeks for first 6 months, then every 12 weeks; monitor neutrophil and platelet counts 4–8 weeks after starting treatment and then as indicated; low platelet or absolute neutrophil count (avoid if absolute neutrophil count less than 0.5 x 10^9/litre or platelet count less than 50 x 10^9/microlitre); monitor lipid profile 4–8 weeks after starting treatment and then as indicated; monitor for demyelinating disorders; **Interactions**: Appendix I (tocilizumab)

**Tuberculosis** Patients should be evaluated for tuberculosis before treatment. Patients with latent tuberculosis should be treated with standard therapy (section 5.1.9) before starting tocilizumab

**Counselling** Patients should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur

**Contra-indications** severe active infection (see also Cautions)

**Hepatic impairment** manufacturer advises caution (see also Dose below)

**Renal impairment** manufacturer advises monitor renal function closely in moderate or severe impairment

**Pregnancy** manufacturer advises avoid unless essential (toxicity in animal studies); effective contraception required during and for 6 months after treatment

**Breast-feeding** manufacturer advises use only if potential benefit outweighs risk — no information available

**Side-effects** abdominal pain, mouth ulceration, gastritis, raised hepatic transaminases; dizziness, peripheral oedema, hypertension, hypercholesterolaemia; headache; infection (including upper respiratory–tract infection); antibody formation, hypersensitivity, leucopenia, neutropenia; rash, pruritus; less commonly gastric ulcer, gastro-intestinal perforation, hypertriglyceridaemia, hypothyroidism, nephrotic syndrome, infusion related reactions, anaphylaxis, and thrombocytopenia also reported

**Dose**

- By intravenous infusion, **ADULT** over 18 years, 8 mg/kg (max. 800 mg) every 4 weeks; for details of dose adjustment in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature

**RoActemra®** (Roche)

Concentrate for intravenous infusion, tocilizumab 20 mg/mL, net price 4 mL (80-mg) vial = £102.40, 10 mL (200-mg) vial = £256.00, 20 mL (400-mg) vial = £512.00. Alert card, counselling, see above

**Sulfasalazine**

Sulfasalazine has a beneficial effect in suppressing the inflammatory activity of rheumatoid arthritis. Side-effects include rashes, gastro-intestinal intolerance and, especially in patients with rheumatoid arthritis, occasional leucopenia, neutropenia, and thrombocytopenia. These haematological abnormalities occur usually in the first 3 to 6 months of treatment and are reversible on cessation of treatment. Close monitoring of full blood counts (including differential white cell count and platelet count) is necessary initially, and at monthly intervals during the first 3 months (liver function tests also being performed at monthly intervals for the first 3 months). Although the manufacturer recommends renal function tests, evidence of practical value is unsatisfactory.

**SULFASALAZINE**

(Sulphasalazine)

**Indications** active rheumatoid arthritis; inflammatory bowel disease, see section 1.5.1 and notes above

**Cautions** see section 1.5.1 and notes above

**Blood disorders** Patients should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise. A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.

**Contra-indications** see section 1.5.1 and notes above

**Hepatic impairment** section 1.5.1

**Renal impairment** section 1.5.1

**Pregnancy** section 1.5.1

**Breast-feeding** section 1.5.1

**Side-effects** see section 1.5.1 and notes above

**Dose**

- **By mouth,** administered on expert advice, as enteric-coated tablets, initially 500 mg daily, increased by 500 mg at intervals of 1 week to a max. of 2–3 g daily in divided doses

Sulfasalazine (Non-proprietary)

Tablets, e/c, sulfasalazine 500 mg, net price 112-tab pack = £14.46 Label: 5, 14, 25, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

Brands include Salazine BC®

Salazopyrin EN-Tabs® (Pharmacia)

Tablets, e/c, yellow, f/c, sulfasalazine 500 mg, net price 112-tab pack = £8.43. Label: 5, 14, 25, counselling, blood disorder symptoms (see recommendation above), contact lenses may be stained

---

10.1.4 Gout and cytotoxic-induced hyperuricaemia

It is important to distinguish drugs used for the treatment of acute attacks of gout from those used in the long-term control of the disease. The latter exacerbate and prolong the acute manifestations if started during an attack.

**Acute attacks of gout**

Acute attacks of gout are usually treated with high doses of NSAIDs such as diclofenac, etoricoxib, indometacin, ketoprofen, naproxen, or sulindac (section 10.1.1). Colchicine is an alternative in patients in whom NSAIDs are contra-indicated. Aspirin is not indicated in gout. Allopurinol, febuxostat, and uricosurics are not effective in treating an acute attack and may prolong it indefinitely if started during the acute episode.
The use of colchicine is limited by the development of toxicity at higher doses, but it is of value in patients with heart failure since, unlike NSAIDs, it does not induce fluid retention; moreover, it can be given to patients receiving anticoagulants.

Oral or parenteral corticosteroids are an effective alternative in those who cannot tolerate NSAIDs or who are resistant to other treatments. Intra-articular injection of a corticosteroid can be used in acute mono-articular gout [unlicensed indication]. A corticosteroid by intramuscular injection can be effective in podagra.

**COLCHICINE**

**Indications** acute gout; short-term prophylaxis during initial therapy with allopurinol and uricosuric drugs; prophylaxis of familial Mediterranean fever (recurrent polyserositis)

**Cautions** see notes above; also elderly; gastro-intestinal disease; cardiac disease; interactions: Appendix 1 (colchicine)

**Contra-indications** blood disorders

**Hepatic impairment** use with caution

**Renal impairment** reduce dose or increase dosage interval if eGFR 10–50 mL/minute/1.73 m²; avoid if eGFR less than 10 mL/minute/1.73 m²

**Pregnancy** avoid—teratogenicity in animal studies

**Breast-feeding** present in milk but no adverse effects reported; manufacturers advise caution

**Side-effects** nausea, vomiting, and abdominal pain; excessive doses may cause profuse diarrhoea, gastrointestinal haemorrhage, rash, renal and hepatic damage; rarely peripheral neuritis, inhibition of spermatogenesis, myopathy, alopecia, and with prolonged treatment blood disorders

**Dose**
- Acute gout, 500 micrograms 2–4 times daily until symptoms relieved, max. 6 mg per course; course not to be repeated within 3 days
- Prevention of gout attacks during initial treatment with allopurinol or uricosuric drugs, 500 micrograms twice daily
- Prophylaxis of familial Mediterranean fever [unlicensed], 0.5–2 mg once daily

**Note** BNF doses may differ from those in the product literature

**Colchicine** 

**Tablets** colchicine 500 micrograms, net price 100 = £31.33

**Long-term control of gout**

Frequent recurrence of acute attacks of gout, the presence of tophi, or signs of chronic gouty arthritis may call for the initiation of long-term (‘interval’) treatment. For long-term control of gout the formation of uric acid from purines may be reduced with the xanthine-oxidase inhibitors allopurinol or febuxostat; alternatively the uricosuric drug sulfinpyrazone may be used to increase the excretion of uric acid in the urine. Treatment should be continued indefinitely to prevent further attacks of gout by correcting the hyperuricaemia. These drugs should never be started during an acute attack; they are usually started 1–2 weeks after the attack has settled. The initiation of treatment may precipitate an acute attack, and therefore an anti-inflammatory analgesic or colchicine should be used as a prophylactic and continued for at least one month after the hyperuricaemia has been corrected. However, if an acute attack develops during treatment, then the treatment should continue at the same dosage and the acute attack treated in its own right.

Allopurinol is widely used and is especially useful in patients with renal impairment or urate stones when uricosuric drugs cannot be used; it is not indicated for the treatment of asymptomatic hyperuricaemia. It can cause rashes.

Febuxostat is licensed for the treatment of chronic hyperuricaemia where urate deposition has already occurred; it is not indicated for patients in whom the rate of urate formation is greatly increased, such as in malignant disease or in Lesch-Nyhan syndrome.

**NICE guidance**

Febuxostat for the management of hyperuricaemia in patients with gout (December 2008)

Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for patients who are intolerant of allopurinol or for whom allopurinol is contra-indicated.

For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant discontinuation, or to prevent full dose escalation for optimal effectiveness.

Sulfinpyrazone can be used instead of allopurinol, or in conjunction with it in cases that are resistant to treatment.

Probenecid (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is a uricosuric drug used to prevent nephrotoxicity associated with cidofovir (section 5.3.2.2).

Benzbromarone (available from ‘special-order’ manufacturers or specialist importing companies, see p. 988) is a uricosuric drug that can be used in patients with mild renal impairment.

Crystallisation of urate in the urine can occur with the uricosuric drugs and it is important to ensure an adequate urine output especially in the first few weeks of treatment. As an additional precaution the urine may be rendered alkaline.

Aspirin and other salicylates antagonise the uricosuric drugs; they do not antagonise allopurinol but are nevertheless not indicated in gout.

**ALLOPURINOL**

**Indications** prophylaxis of gout and of uric acid and calcium oxalate renal stones; prophylaxis of hyperuricaemia associated with cancer chemotherapy

**Cautions** administer prophylactic NSAID (not aspirin or salicylates) or colchicine until at least 1 month after hyperuricaemia corrected (usually for first 3 months) to avoid precipitating an acute attack; ensure adequate fluid intake (2–3 litres/day); hyperuricaemia associated with cancer therapy, allopurinol treatment should be started before cancer therapy; interactions: Appendix 1 (allopurinol)

1. The Scottish Medicines Consortium issued similar advice in August 2010
Contra-indications not a treatment for acute gout but continue if attack develops when already receiving allopurinol, and treat attack separately (see notes above)

Hepatic impairment reduce dose
Renal impairment max. 100 mg daily, increased only if response inadequate; in severe impairment, reduce daily dose below 100 mg, or increase dose interval; if facilities available, adjust dose to maintain plasma-oxipurinol concentration below 10 micromol/litre
Pregnancy toxicity not reported; manufacturer advises use only if no safer alternative and disease carries risk for mother or child
Breast-feeding present in milk—not known to be harmful

Side-effects rashes [withdraw] therapy; if rash mild re-introduce cautiously but discontinue promptly if recurrence—hypo-osmolarity reactions occur rarely and include exfoliation, fever, lymphadenopathy, arthralgia, and eosinophilia resembling Stevens-Johnson syndrome or toxic epidermal necrolysis, vasculitis, hepatitis, renal impairment, and very rarely seizures); gastro-intestinal disorders; rarely malaise, headache, vertigo, drowsiness, visual and taste disturbances, hypertension, alopecia, hepatotoxicity, paraesthesia and neuropathy, gynaecomastia, blood disorders (including leucopenia, thrombocytopenia, haemolytic anaemia and aplastic anaemia)

Dose
- Initially 100 mg daily, preferably after food, then adjusted according to plasma or urinary uric acid concentration; usual maintenance dose in mild conditions 100–200 mg daily, in moderately severe conditions 300–600 mg daily, in severe conditions 700–900 mg daily; doses over 300 mg daily given in divided doses; CHILD under 15 years, (in neoplastic conditions, enzyme disorders) 10–20 mg/kg daily (max. 400 mg daily)

Allopurinol (non-proprietary)

Tablets, allopurinol 100 mg, net price 28-tab pack = £1.18; 300 mg, 28-tab pack = £1.32. Label: 8, 21, 27

Brands include Clophenal®, Cosar®, Rimapurin®

Zyloric® (GSK)

Tablets, allopurinol 100 mg, net price 100-tab pack = £10.19; 300 mg, 28-tab pack = £7.31. Label: 8, 21, 27

FEBUXOSTAT

Indications treatment of chronic hyperuricaemia in gout (but see also NICE guidance above)

Cautions administer prophylactic NSAID (not aspirin or salicylates) or colchicine for at least 6 months after starting febuxostat to avoid precipitating an acute attack; transplant recipients; monitor liver function tests before and periodically during treatment as indicated; thyroid disorders; interactions: Appendix 1 (febuxostat)

Contra-indications not a treatment for acute gout but continue if attack develops when already receiving febuxostat, and treat attack separately (see notes above); ischaemic heart disease; congestive heart failure

Hepatic impairment max. 80 mg daily in mild impairment; no dose information available in moderate or severe impairment
Renal impairment use with caution if eGFR less than 30 mL/minute/1.73 m²—no information available

Pregnancy manufacturer advises caution

Breast-feeding not a treatment for acute gout but treat attack separately (see notes above)

SULFINPYRAZONE (Sulphinpyrazone)

Indications gout prophylaxis, hyperuricaemia

Cautions see under Probenecid; regular blood counts advisable; cardiac disease (may cause salt and water retention); interactions: Appendix 1 (sulfinpyrazone)

Contra-indications see under Probenecid; avoid in hypersensitivity to NSAIDs

Hepatic impairment avoid in severe impairment

Renal impairment reduce dose; avoid in severe impairment

Pregnancy manufacturer advises caution

PROBENECID

Indications prevention of nephrotoxicity associated with cidofovir (section 5.3.2.2)

Cautions ensure adequate fluid intake (about 2–3 litres daily) and render urine alkaline if uric acid overload is high; peptic ulceration; transient false-positive Benedict’s test; G6PD-deficiency (section 9.1.5); interactions: Appendix 1 (probenecid)

Contra-indications history of blood disorders, nephrotoxicity, acute porphyria (section 9.8.2), acute gout attack; avoid aspirin and salicylates

Renal impairment avoid if eGFR less than 30 mL/minute/1.73 m²

Breast-feeding present in milk

Side-effects gastro-intestinal disturbances; less commonly sore gums, flushing, headache, dizziness, urinary frequency, anaemia, alopecia; hepatic necrosis, hypersensitivity reactions (including anaphylaxis, pruritus, urticaria, fever, and Stevens-Johnson syndrome), nephrotic syndrome, haemolytic anaemia, leucopenia, and aplastic anaemia also reported

Dose
- Used with cidofovir, see section 5.3.2.2

Probenecid (non-proprietary)

Tablets, probenecid 500 mg. Label: 12, 21, 27
Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988
Breast-feeding no information available
Side-effects gastro-intestinal disturbances, occasionally allergic skin reactions, salt and water retention; rarely blood disorders, gastro-intestinal ulceration and bleeding, acute renal failure, raised liver enzymes, jaundice and hepatitis
Dose
- Initially 100–200 mg daily with food (or milk) increasing over 2–3 weeks to 600 mg daily (rarely 800 mg daily), continued until serum uric acid concentration normal then reduced for maintenance (maintenance dose may be as low as 200 mg daily)
Sulfinpyrazone (Non-proprietary) Tablets, sulfinpyrazone 100 mg, net price 84-tab pack = £13.09; 200 mg, 84-tab pack = £25.07. Label: 12, 21
Hyperuricaemia associated with cytotoxic drugs
Allopurinol is used to prevent hyperuricaemia associated with cytotoxic drugs—see section 8.1 (Hyperuricaemia) and Allopurinol above.
Rasburicase is licensed for the prophylaxis and treatment of acute hyperuricaemia, before and during initiation of chemotherapy, in patients with haematological malignancy and a high tumour burden at risk of rapid lysis.

RASBURICASE
Indications prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematological malignancy
Cautions monitor closely for hypersensitivity; atopic allergies; may interfere with test for uric acid—consult product literature
Contra-indications G6PD deficiency (section 9.1.5)
Pregnancy manufacturer advises avoid—no information available
Breast-feeding manufacturer advises avoid—no information available
Side-effects fever; less commonly nausea, vomiting, diarrhoea, headache, hypersensitivity reactions (including rash, bronchospasm and anaphylaxis); haemolytic anaemia, methaemoglobinaemia
Dose
- By intravenous infusion, 200 micrograms/kg once daily for up to 7 days according to plasma-uric acid concentration
Fasturtec® (Sanofi-Aventis) Tablets, rasburicase, net price 1.5-mg vial (with solvent) = £57.88; 7.5-mg vial (with solvent) = £241.20
Glucosamine
Glucosamine is a natural substance found in mucopolysaccharides, mucoproteins, and chitin. It is licensed for symptomatic relief of mild to moderate osteoarthritis of the knee, but is not recommended. The mechanism of action is not understood and there is limited evidence to show it is effective.

The Scottish Medicines Consortium (p. 4) has advised (May 2008) that glucosamine (Alateris®) is not recommended for use within NHS Scotland for the symptomatic relief of mild to moderate osteoarthritis of the knee.

GLUCOSAMINE
Indications symptomatic relief of mild to moderate osteoarthritis of the knee
Cautions impaired glucose tolerance (monitor blood-glucose concentration before treatment and periodically thereafter); predisposition to cardiovascular disease (monitor cholesterol); asthma; interactions: Appendix 1 (glucosamine)
Contra-indications shellfish allergy
Pregnancy manufacturer advises avoid—no information available
Breast-feeding manufacturer advises avoid—no information available
Side-effects nausea, abdominal pain, dyspepsia, flatulence, diarrhoea, headache, fatigue; less commonly flushing, rash, pruritus; also reported hypercholesterolaemia, visual disturbances, hair loss
Dose
- See under preparations
Alateris® (Dee) Tablets, glucosamine (as hydrochloride) 625 mg, net price 60-tab pack = £18.40
Dose ADULT over 18 years, 1 25 g once daily; review treatment if no benefit after 2–3 months
Glarusarte® (HFA Healthcare) Oral powder, sugar-free, glucosamine sulphate (as sodium chloride) 1.5 g/sachet, net price 30-sachet pack = £18.40. Label: 13
Electrolytes Na+ 6.6 mmol/sachet
Excipients include aspartame (section 9.4.1)
Dose ADULT over 18 years, 1 sachet (dissolved in at least 250 mL of water) once daily; review treatment if no benefit after 2–3 months

10.2 Drugs used in neuromuscular disorders
10.2.1 Drugs that enhance neuromuscular transmission
10.2.2 Skeletal muscle relaxants
10.2.1 Drugs that enhance neuromuscular transmission
Anticholinesterases are used as first-line treatment in ocular myasthenia gravis and as an adjunct to immunosuppressant therapy for generalized myasthenia gravis.
Corticosteroids are used when anticholinesterases do not control symptoms completely. A second-line immunosuppressant such as azathioprine is frequently used to reduce the dose of corticosteroid.
Anticholinesterases

Anticholinesterase drugs enhance neuromuscular transmission in voluntary and involuntary muscle in myasthenia gravis. They prolong the action of acetylcholine by inhibiting the action of the enzyme acetylcholinesterase. Excessive dosage of these drugs can impair neuromuscular transmission and precipitate cholinergic crises by causing a depolarising block. This may be difficult to distinguish from a worsening myasthenic state.

Muscarinic side-effects of anticholinesterases include increased sweating, increased salivary and gastric secretions, increased gastro-intestinal and uterine motility, and bradycardia. These parasympathomimetic effects are antagonised by atropine.

Edrophonium has a very brief action and it is therefore used mainly for the diagnosis of myasthenia gravis. However, such testing should be performed only by those experienced in its use; other means of establishing the diagnosis are available. A single test-dose usually causes substantial improvement in muscle power (lasting about 5 minutes) in patients with the disease (if respiration already impaired, only in conjunction with someone skilled at intubation).

Edrophonium can also be used to determine whether a patient with myasthenia is receiving inadequate or excessive treatment with cholinergic drugs. If treatment is excessive an injection of edrophonium will either have no effect or will intensify symptoms (if respiration already impaired, give only in conjunction with someone skilled at intubation). Conversely, transient improvement may be seen if the patient is being inadequately treated. The test is best performed just before the next dose of anticholinesterase.

Neostigmine produces a therapeutic effect for up to 4 hours. Its pronounced muscarinic action is a disadvantage, and simultaneous administration of an antimuscarinic drug such as atropine or propantheline may be required to prevent colic, excessive salivation, or diarrhoea. In severe disease neostigmine can be given every 2 hours. The maximum that most patients can tolerate is 180 mg daily.

Pyridostigmine is less powerful and slower in action than neostigmine but it has a longer duration of action. It is preferable to neostigmine because of its smoother action and the need for less frequent dosage. It is particularly preferred in patients whose muscles are weak on waking. It has a comparatively mild gastrointestinal effect but an antimuscarinic drug may still be required. It is inadvisable to exceed a total daily dose of 450 mg in order to avoid acetylcholine receptor down-regulation; patients requiring doses exceeding 450 mg daily will usually require input from a specialised neuromuscular service. Immunosuppressant therapy is usually considered if the dose of pyridostigmine exceeds 360 mg daily.

Distigmine has the longest action but the danger of a cholinergic crisis caused by accumulation of the drug is greater than with shorter-acting drugs; it is rarely used in the management of myasthenia gravis.

Neostigmine and edrophonium are also used to reverse the actions of the non-depolarising neuromuscular blocking drugs (see section 15.1.6).

**Neostigmine**

**Indications** myasthenia gravis; other indications (section 15.1.6)

**Cautions** asthma (extreme caution), bradycardia, arrhythmias, recent myocardial infarction, epilepsy, hypotension, parkinsonism, vagotonia, peptic ulceration, hyperthyroidism; atropine or other antidote to muscarinic effects may be necessary (particularly when neostigmine is given by injection), but not given routinely because it may mask signs of overdosage; interactions: Appendix 1 (parasympathomimetics)

**Contra-Indications** intestinal or urinary obstruction

**Renal impairment** may need dose reduction

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** amount probably too small to be harmful

**Side-effects** nausea, vomiting, increased salivation, diarrhoea, abdominal cramps (more marked with higher doses); signs of overdosage include bronchoconstriction, increased bronchial secretions, lacrimation, excessive sweating, involuntary defaecation and micturition, miosis, nystagmus, bradycardia, heart block, arrhythmias, hypotension, agitation, excessive dreaming, and weakness eventually leading to fasciculation and paralysis

**Dose**

- By mouth, neostigmine bromide 15–30 mg at suitable intervals throughout day, total daily dose 75–300 mg (but see also notes above); NEONATE 1–5 mg every 4 hours, half an hour before feeds; CHILD up to 6 years initially 7.5 mg, 6–12 years initially 15 mg, usual total daily dose 15–90 mg
- By subcutaneous or intramuscular injection, ADULT and CHILD over 12 years, neostigmine metilsulfate 1–2.5 mg at suitable intervals throughout day (usual total daily dose 5–20 mg); NEONATE 150 micrograms/kg every 6–8 hours 30 minutes before feeds, increased to max. 300 micrograms/kg every 4 hours, if necessary [unlicensed]; CHILD 1 month–12 years 200–500 micrograms as required

**Neostigmine**

 Tablets, scored, neostigmine bromide 15 mg, net price 140 = £56.10

**Injection**

Section 15.1.6

**Edrophonium Chloride**

**Indications** see under Dose and notes above; reversal of non-depolarising neuromuscular blockade and diagnosis of dual block (section 15.1.6)

**Cautions** see under Neostigmine; have resuscitation facilities; extreme caution in respiratory distress (see notes above) and in asthma

**Note** Severe cholinergic reactions can be counteracted by injection of atropine sulphate (which should always be available)

**Contra-Indications** see under Neostigmine
In generalised myasthenia gravis, azathioprine (section 8.2.1) is usually started at a high dose. However, ventilated patients may be started on 1.5 mg/kg (max. 100 mg) on alternate days. Smaller doses of corticosteroid are usually required in ocular myasthenia. Once clinical remission has occurred (usually after 2–6 months), the dose of prednisolone should be reduced slowly to the minimum effective dose (usually 10–40 mg on alternate days).

In generalised myasthenia gravis azathioprine (section 8.2.1) is usually started at the same time as the corticosteroid and it allows a lower maintenance dose of the corticosteroid to be used; azathioprine is initiated at a dose of 0.5–1 mg/kg daily, which is increased over 3–4 weeks to 2–2.5 mg/kg daily. Ciclosporin (section 8.2.2), methotrexate (section 8.1.3), or mycophenolate mofetil (section 8.2.1) can be used in patients unresponsive or intolerant to other treatments [unlicensed indications].

10.2.2 Skeletal muscle relaxants

The drugs described below are used for the relief of chronic muscle spasm or spasticity associated with multiple sclerosis or other neurological damage; they are not indicated for spasm associated with minor

Acetylcholine-release enhancers

Amifampridine is licensed for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare disorder of neuromuscular transmission.

AMIFAMPRIDINE

Indications (specialist use only) symptomatic treatment of Lambert-Eaton myasthenic syndrome

Cautions concomitant use of drugs that lower con-

Hepatic impairment use with caution; in mild impairment reduce initial dose to 10 mg daily in
divided doses, increased in steps of 5 mg every 7 days; in moderate or severe impairment reduce initial dose to 5 mg daily in divided doses, increased in steps of 5 mg every 7 days

Renal impairment use with caution; in mild impair-

Dose

ADULT over 18 years, initially 15 mg daily in 3 divided
doses, increased in steps of 5 mg every 4–5 days; to
max. 60 mg daily in 3–4 divided doses; max. single
dose 20 mg

Firdapse® (Bionar) Tablets, scored, amifampridine (as phosphate) 10 mg, net price 100-tab pack = £1815.00. Label: 3, 21
injuries. Baclofen, diazepam, and tizanidine act principally on the central nervous system. Dantrolene, has a peripheral site of action; cannabis extract has both a central and a peripheral action. Skeletal muscle relaxants differ in action from the muscle relaxants used in anaesthesia (section 15.1.5), which block transmission at the neuromuscular junction.

The underlying cause of spasticity should be treated and any aggravating factors (e.g. pressure sores, infection) remedied. Skeletal muscle relaxants are effective in most forms of spasticity except the rare alpha variety. The major disadvantage of treatment with these drugs is that reduction in muscle tone can cause a loss of splitting action of the spastic leg and trunk muscles and sometimes lead to an increase in disability.

**Baclofen** inhibits transmission at spinal level and also depresses the central nervous system. The dose should be increased slowly to avoid the major side-effects of sedation and muscle hypotonia (other adverse events are uncommon).

A *cannabis extract* containing dronabinol (delta-9-tetrahydrocannabinol) and cannabidiol is licensed as an adjunct treatment for moderate to severe spasticity associated with multiple sclerosis in patients who have not responded adequately to other skeletal muscle relaxants. The dose should be titrated over 2 weeks; response to treatment should be reviewed after 4 weeks and treatment stopped if an adequate response is not achieved.

**Dantrolene** acts directly on skeletal muscle and produces fewer central adverse effects making it a drug of choice. The dose should be increased slowly.

**Diazepam** can also be used. Sedation and occasionally extensor hypotonia are disadvantages. Other benzodiazepines also have muscle-relaxant properties. Muscle-relaxant doses of benzodiazepines are similar to anxiolytic doses (section 4.1.2).

**Tizanidine** is an alpha,-adrenoceptor agonist indicated for spasticity associated with multiple sclerosis or spinal cord injury.

### BACLOFEN

**Indications** chronic severe spasticity resulting from disorders such as multiple sclerosis or traumatic partial section of spinal cord

**Cautions** psychiatric illness, Parkinson’s disease, cerebrovascular disease, elderly, respiratory impairment; epilepsy; history of peptic ulcer (avoid oral route in active peptic ulceration); diabetes; hypertensive bladder sphincter; avoid abrupt withdrawal (risk of hyperactive state, may exacerbate spasticity, and precipitate autonomic dysfunction including hypothermia, psychiatric reactions and convulsions, see also under Withdrawal below); **interactions**: Appendix 1 (muscle relaxants)

**Withdrawal** Serious side-effects can occur on abrupt withdrawal; to minimise risk, discontinue by gradual dose reduction over at least 1–2 weeks (longer if symptoms occur) Drivinger Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Hepatic impairment** manufacturer advises use by mouth with caution

**Renal impairment** risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval; if eGFR less than 15 mL/minute/1.73m² manufacturer advises use by mouth only if potential benefit outweighs risk; excreted by kidney

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk (toxicity in animal studies)

**Breast-feeding** present in milk—amount probably too small to be harmful

**Side-effects** gastro-intestinal disturbances, dry mouth; hypotension, respiratory or cardiovascular depression; sedation, drowsiness, confusion, dizziness, ataxia, hallucinations, paresthesiae, hypothermia, insomnia, depression, anxiety, agitation, tremor; seizure; urinary disturbances; myalgia; visual disorders; rash; hyperhidrosis; rarely taste disturbances, abdominal pain, changes in hepatic function, paraesthesia, erectile dysfunction, dysarthria; very rarely hypothermia

**Dose**

- **By mouth**, **ADULT** and **CHILD** over 10 years, initially 5 mg 3 times daily, gradually increased; usual maintenance dose up to 60 mg daily in divided doses (max. 100 mg daily); **CHILD** 1–2 years, initially 300 micrograms/kg daily in 4 divided doses, increased gradually to usual maintenance dose 0.75–2 mg/kg daily in divided doses (or 10–20 mg daily in divided doses); **CHILD** 2–6 years, initially 300 micrograms/kg daily in 4 divided doses, increased gradually to usual maintenance dose of 0.75–2 mg/kg daily in divided doses (or 20–30 mg daily in divided doses); **CHILD** 6–8 years, initially 300 micrograms/kg daily in 4 divided doses, increased gradually to usual maintenance dose of 0.75–2 mg/kg daily in divided doses (or 30–40 mg daily in divided doses); **CHILD** 8–10 years, initially 300 micrograms/kg daily in 4 divided doses, increased gradually to usual maintenance dose of 0.75–2 mg/kg daily in divided doses (or up to 60 mg daily in divided doses)

**Note** Review treatment if no benefit within 6 weeks

- **By intrathecal injection**, see preparation below

**Baclofen** (Non-proprietary) *Tablets*, baclofen 10 mg, net price 84-tab pack = £1.58. Label: 2, 6, 21

**Oral solution**, baclofen 5 mg/5 mL, net price 300 mL = £9.26. Label: 2, 8, 21

**Brands** include Lyfex* (sugar-free)

**Lioresal** (Novartis) *Tablets*, scored, baclofen 10 mg, net price 84-tab pack = £8.67. Label: 2, 8, 21

**Excipients** include gluten

**Liquid**, sugar-free, raspberry-flavoured, baclofen 5 mg/5 mL, net price 300 mL = £7.16. Label: 2, 8, 21

*By intrathecal injection* Lioresal® (Novartis) *Intrathecal injection*, baclofen, 50 micrograms/mL, net price 1-mL amp (for test dose) = £2.19; 500 micrograms/mL, 20-mL amp (for use with implantable pump) = £48.62; 2 mg/mL, 5-mL amp (for use with implantable pump) = £48.62

**Important** Consult product literature for details on test dose and titration—important to monitor patients closely in appropriately equipped and staffed environment during screening and immediately after pump implantation. Resuscitation equipment must be available for immediate use

**Dose** by intrathecal injection, specialist use only, severe chronic spasticity unresponsive to oral antispastic drugs (or where side-effects of oral therapy unacceptable) or as alternative to ablative neurosurgical procedures, initial test dose 25–50 micrograms over at least 1 minute via catheter or lumbar puncture, increased in 25-microgram steps (not more often than every 24 hours) to max. 100 micrograms to determine appropriate dose then dose-titration phase, most often using infusion pump (implanted into chest wall or abdominal wall tissues) to establish maintenance dose (ranging...
from 12 micrograms to 2 mg daily for spasticity of spinal origin or 22 micrograms to 1.4 mg daily for spasticity of cerebral origin) retaining some spasticity to avoid sensation of paralysis; CHILD 4–18 years (spasticity of cerebral origin only), initial test dose 25 micrograms then titrated as for ADULT to maintenance dose (ranging from 24 micrograms to 1.2 mg daily in children under 12 years).

**CANNABIS EXTRACT**

**Indications** adjunct in moderate to severe spasticity in multiple sclerosis (specialist use only)

**Cautions** significant cardiovascular disease; history of epilepsy; monitor oral mucosa—interrupt treatment if lesions or persistent soreness; **interactions**: Appendix 1 (cannabis extract)

**Contra-indications** personal or family history of psychosis; history of other severe psychiatric disorder

**Hepatic impairment** manufacturer advises more frequent monitoring in significant impairment—possible risk of prolonged or enhanced effect

**Renal impairment** manufacturer advises more frequent monitoring in significant impairment—possible risk of prolonged or enhanced effect

**Pregnancy** manufacturer advises use only if potential benefit outweighs risks, and recommends effective contraception during and for 3 months after treatment in men and women

**Breast-feeding** avoid—present in milk

**Side-effects** increased or decreased appetite, taste disturbance, constipation, diarrhoea, nausea, vomiting, dry mouth, mouth ulcers, oral pain, dizziness, vertigo, malaise, depression, disorientation, dissociation, mood disturbance, amnesia, impaired attention, drowsiness, dysarthria, blurred vision; less commonly abdominal pain, oromucosal and tooth discoloration, stomatitis, palpitation, tachycardia, hypertension, pharyngitis, syncope, hallucinations, paranoia, delusions, suicidal thoughts; also reported anxiety, seizures

**Dose**
- Consult product literature

**Sativex** (Bayer Schering)  

**Oromucosal spray, Cannabis sativa extract** (containing dronabinol (delta-9-tetrahydrocannabinol) 27 mg and cannabidiol 25 mg/mL), net price 3 × 10 mL units = £375.00. Counselling, driving see above

**Excipients** include propylene glycol

**DANTROLENE SODIUM**

**Indications** chronic severe spasticity of voluntary muscle; malignant hyperthermia (section 15.1.8)

**Cautions** impaired cardiac and pulmonary function; therapeutic effect may take a few weeks to develop—discontinue if no response within 45 days; **interactions**: Appendix 1 (muscle relaxants).

**Hepatotoxicity** Potentially life-threatening hepatotoxicity reported, usually if doses greater than 400 mg daily used, in females, patients over 30 years, if history of liver disorders, or concomitant use of hepatotoxic drugs; test liver function before and at intervals during therapy—discontinue if abnormal liver function tests or symptoms of liver disorder are reported, usually if doses greater than 400 mg daily used, in females, patients over 30 years, if history of liver disorders, or concomitant use of hepatotoxic drugs; test liver function before and at intervals during therapy—discontinue if abnormal liver function tests or symptoms of liver disorder

1. Home Office assessing Controlled Drug status of preparation—currently in Schedule 1 of the Misuse of Drugs Regulations 2001, but prescriptions should comply with prescribing requirements for Schedule 2 drugs

(Counselling, see below); re-introduce only if complete reversal of hepatotoxicity

**Counselling** Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Contra-indications** acute muscle spasm; avoid when spasticity is useful, for example, locomotion

**Hepatic impairment** avoid—may cause severe liver damage; injection may be used in an emergency for malignant hyperthermia

**Pregnancy** avoid use in chronic spasticity—embryotoxic in animal studies

**Breast-feeding** present in milk—manufacturer advises avoid use in chronic spasticity

**Side-effects** diarrhoea (withdraw if severe, discontinue treatment if recur on re-introduction), nausea, vomiting, anorexia, hepatotoxicity (see above), abdominal pain; pericarditis; pleural effusion, respiratory depression; headache, drowsiness, dizziness, asthenia, fatigue, seizures, fever, chills; speech and visual disturbances; rash; less commonly dysphagia, constipation, exacerbation of cardiac insufficiency, tachycardia, erratic blood pressure, dyspnoea, depression, confusion, nervousness, insomnia, increased urinary frequency, urinary incontinence or retention, haematuria, crystalluria, and increased sweating

**Dose**
- Initially 25 mg daily, may be increased at weekly intervals to max. 100 mg 4 times daily; usual dose 75 mg 3 times daily; **CHILD** 5–18 years see BNf for Children

**Dantrium** (SpePharm)  

**Capsules**. orange/brown, dantrolene sodium 25 mg, net price 100 = £16.87; 100 mg, 100 = £43.07. Label: 2. counselling, driving, hepatotoxicity

**DIAZEPAM**

**Indications** muscle spasm of varied aetiology, including tetanus; other indications (section 4.1.2, section 4.8, section 15.1.4.1)

**Cautions** section 4.1.2; special precautions for intravenous injection (section 4.8.2)

**Contra-indications** section 4.1.2

**Hepatic impairment** section 4.1.2

**Renal impairment** section 4.1.2

**Pregnancy** section 4.1.2

**Breast-feeding** section 4.1.2

**Side-effects** section 4.1.2; also hypotonia

**Dose**
- Muscle spasm, by mouth, 2–15 mg daily in divided doses, increased if necessary in spastic conditions to 60 mg daily according to response
- Cerebral spasticity in selected cases, **CHILD** 2–40 mg daily in divided doses
- By intramuscular or by slow intravenous injection (into a large vein at a rate of not more than 5 mg/minute), in acute muscle spasm, 10 mg repeated if necessary after 4 hours

**Note** Only use intramuscular route when oral and intravenous routes not possible; emulsion formulation preferred for intravenous injection; special precautions for intravenous injection, see section 4.8.2
TIZANIDINE

Indications spasticity associated with multiple sclerosis or spinal cord injury or disease

Cautions elderly; monitor liver function monthly for first 4 months and in those who develop unexplained nausea, anorexia or fatigue; concomitant administration of drugs that prolong QT interval; avoid abrupt withdrawal (risk of rebound hypertension and tachycardia, see under Withdrawal, below); interactions: Appendix 1 (muscle relaxants)

Withdrawal Rebound hypertension and tachycardia can occur on abrupt withdrawal; to minimise risk, discontinue gradually and monitor blood pressure

Driving Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Hepatic Impairment avoid in severe impairment

Renal impairment manufacturer advises caution

Pregnancy manufacturer advises use only if potential benefit outweighs risk—no information available

Breast-feeding present in milk in animal studies—manufacturer advises caution

Side-effects nausea, vomiting, dyspepsia; hypersensitivity reactions (including urticaria, angioedema, anaphylaxis); fever, headache, drowsiness, dizziness, hypotension, Bradycardia, confusion, amnesia, restlessness, anxiety, tremor, seizures; blurred vision, nasal congestion; rash, pruritus; leucopenia, cholestatic jaundice

Dose

● ADULT over 18 years, initially 2 mg daily as a single dose increased according to response at intervals of at least 3–4 days in steps of 2 mg daily (and given in divided doses) usually up to 24 mg daily in 3–4 divided doses; max. 36 mg daily

Tizanidine (Non-proprietary) (UK)

Tablets, tizanidine (as hydrochloride) 2 mg net price 120-tab pack = £6.22; 4 mg, 120-tab pack = £8.64. Label: 2, 8

Zanaflex® (Cephalon) (UK)

Tablets, scored, tizanidine (as hydrochloride) 2 mg, net price 120-tab pack = £63.00; 4 mg, 120-tab pack = £80.00. Label: 2, 8

Other muscle relaxants

The clinical efficacy of methocarbamol and meprobamate (section 4.1.2) as muscle relaxants is not well established, although they have been included in compound analgesic preparations.

METHOCARBAMOL

Indications short-term symptomatic relief of muscle spasm (but see notes above)

Cautions interactions: Appendix 1 (muscle relaxants)

Driving Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Contra-indications coma or pre-coma, brain damage, epilepsy, myasthenia gravis

Hepatic impairment manufacturer advises caution; half-life may be prolonged

Renal impairment manufacturer advises caution

Pregnancy manufacturer advises avoid unless potential benefit outweighs risk

Breast-feeding present in milk in animal studies—manufacturer advises caution

Side-effects nausea, vomiting, dyspepsia; hyper-sensitivity reactions (including urticaria, angioedema, anaphylaxis); fever, headache, drowsiness, dizziness, hypotension, Bradycardia, confusion, amnesia, restlessness, anxiety, tremor, seizures; blurred vision, nasal congestion; rash, pruritus; leucopenia, cholestatic jaundice

Dose

● 1.5 g 4 times daily; may be reduced to 750 mg 3 times daily; ELDERLY up to 750 mg 4 times daily may be sufficient; CHILD not recommended

Robaxin® (Almirall) (UK)

750 Tablets, f/c, scored, methocarbamol 750 mg, net price 100 = £12.65. Label: 2

Nocturnal leg cramps

Quinine salts (section 5.4.1), such as quinine sulphate 200–300 mg at bedtime, are effective in reducing the frequency of nocturnal leg cramps by about 25% in ambulatory patients; however, because of potential toxicity, quinine is not recommended for routine treatment and should not be used unless cramps cause regular disruption to sleep. Quinine should only be considered when cramps are very painful or frequent; when other treatable causes of cramp have been excluded; and when non-pharmacological treatments have not worked (e.g. passive stretching exercises). It may take up to 4 weeks for improvement to become apparent; if there is benefit, quinine treatment can be continued. Patients should be monitored closely during the early stages for adverse effects as well as for benefit. Treatment should be interrupted at intervals of approximately 3 months to assess the need for further quinine treatment. In patients taking quinine long term, a trial discontinuation may be considered. Quinine is toxic in overdosage and accidental fatalities have occurred (see also below).

QUININE

Indications see notes above; malaria (section 5.4.1)

Cautions see section 5.4.1 and notes above

Contra-indications section 5.4.1

Pregnancy section 5.4.1

Breast-feeding section 5.4.1

Side-effects section 5.4.1; important: very toxic in overdosage—immediate advice from poison centres essential (see also p. 37)

Dose

● See notes above

Preparations Section 5.4.1
Extravasation injury follows leakage of drugs or intravenous fluids from the veins or inadvertent administration into the subcutaneous or subdermal tissue. It must be dealt with promptly to prevent tissue necrosis.

Acidic or alkaline preparations and those with an osmolality greater than that of plasma can cause extravasation injury; excipients including alcohol and polyethylene glycol have also been implicated. Cytotoxic drugs commonly cause extravasation injury. In addition, certain patients such as the very young and the elderly are at increased risk. Those receiving anticoagulants are more likely to lose blood into surrounding tissues if extravasation occurs, while those receiving sedatives or analgesics may not notice the early signs or symptoms of extravasation.

Prevention of extravasation Precautions should be taken to avoid extravasation; ideally, drugs likely to cause extravasation injury should be given through a central line and patients receiving repeated doses of hazardous drugs peripherally should have the cannula resited at regular intervals. Attention should be paid to the manufacturers’ recommendations for administration. Placing a glyceryl trinitrate patch (section 2.6.1) distal to the cannula may improve the patency of the vessel in patients with small veins or in those whose veins are prone to collapse.

Patients should be asked to report any pain or burning at the site of injection immediately.

Management of extravasation If extravasation is suspected the infusion should be stopped immediately but the cannula should not be removed until after an attempt has been made to aspirate the area (through the cannula) in order to remove as much of the drug as possible. Aspiration is sometimes possible if the extravasation presents with a raised bleb or blister at the injection site and is surrounded by hardened tissue, but it is often unsuccessful if the tissue is soft or soggy.

Corticosteroids are usually given to treat inflammation, although there is little evidence to support their use in extravasation. Hydrocortisone or dexamethasone (section 6.3.2) can be given either locally by subcutaneous injection or intravenously at a site distant from the injury. Antihistamines (section 3.4.1) and analgesics (section 4.7) may be required for symptom relief. The management of extravasation beyond these measures is not well standardised and calls for specialist advice. Treatment depends on the nature of the offending substance; one approach is to localise and neutralise the substance whereas another is to spread and dilute it. The first method may be appropriate following extravasation of vesicant drugs and involves administration of an antidote (if available) and the application of cold compresses 3–4 times a day (consult specialist literature for details of specific antidotes). Spreading and diluting the offending substance involves infiltrating the area with physiological saline, applying warm compresses, elevating the affected limb, and administering hyaluronidase (section 10.3.1). A saline flush-out technique (involving flushing the subcutaneous tissue with physiological saline) may be effective but requires specialist advice. Hyaluronidase should not be administered following extravasation of vesicant drugs (unless it is either specifically indicated or used in the saline flush-out technique). Dexrazoxane (section 8.1) is licensed for the treatment of anthracycline-induced extravasation.

**HYALURONIDASE**

**Indications** enhance permeation of subcutaneous or intramuscular injections, local anaesthetics and subcutaneous infusions; promote resorption of excess fluids and blood

**Cautions** infants or elderly (control speed and total volume and avoid overhydration especially in renal impairment)

**Contra-indications** do not apply direct to cornea; avoid sites where infection or malignancy; not for anaesthesia in unexplained premature labour; not to be used to reduce swelling of bites or stings; not for intravenous administration

**Side-effects** oedema; rarely local irritation, infection, bleeding, bruising; occasional severe allergy (including anaphylaxis)

**Dose**
- With subcutaneous or intramuscular injection, 1500 units dissolved directly in solution to be injected (ensure compatibility)
- With local anaesthetics, 1500 units mixed with local anaesthetic solution (ophthalmology, 15 units/mL)
- Hypodermoclysis, 1500 units dissolved in 1 mL water for injections or 0.9% sodium chloride injection, administered before start of 500–1000 mL infusion fluid
- Extravasation (see notes above) or haematoma, 1500 units dissolved in 1 mL water for injections or 0.9% sodium chloride injection, infiltrated into affected area (as soon as possible after extravasation)

**Hyalase®** (Workhardt) **5000**

Injection, powder for reconstitution, hyaluronidase (ovine). Net price 1500-unit amp = £7.60
Rubefacients, topical NSAIDs, capsaicin, and poultices

Rubefacients act by counter-irritation. Pain, whether superficial or deep-seated, is relieved by any method that itself produces irritation of the skin. Topical rubefacient preparations may contain nicotinate and salicylate compounds, essential oils, capsicum, and camphor. The evidence available does not support the use of topical rubefacients in acute or chronic musculoskeletal pain.

Topical NSAIDs

The use of a NSAID by mouth is effective for relieving musculoskeletal pain. Topical NSAIDs (e.g. felbinac, ibuprofen, ketoprofen, and piroxicam) may provide some relief of pain in musculoskeletal conditions; they can be considered as an adjunctive treatment in knee or hand osteoarthritis (see section 10.1).

Cautions

Apply with gentle massage only. Avoid contact with eyes, mucous membranes, and inflamed or broken skin; discontinue if rash develops. Hands should be washed immediately after use. Not for use with occlusive dressings. Topical application of large amounts can result in systemic effects (see section 10.1.1), including hypersensitivity and asthma (renal disease has also been reported). Not generally suitable for children. Patient packs carry a warning to avoid during pregnancy or breast-feeding.

Hypersensitivity

For NSAID hypersensitivity and asthma warning, see p. 631 and p. 632.

Photosensitivity

Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity; patients using preparations containing ketoprofen should be advised to avoid exposure to sunlight of the area treated, and for two weeks after stopping treatment.

Non-proprietary preparations

Ibuprofen (Non-proprietary)

Gel, ibuprofen 5%, net price 30 g = £2.10, 50 g = £3.59, 100 g = £5.88

Dose apply up to 3 times daily

Ketoprofen (Non-proprietary)

Gel, ketoprofen 2.5%, net price 30 g = £3.22, 50 g = £2.83, 100 g = £2.63

Dose apply 2–4 times daily for up to 7 days (usual max. 15 g daily)

Piroxicam (Non-proprietary)

Gel, piroxicam 0.5%, net price 60 g = £2.01; 112 g = £2.93

Dose apply 3–4 times daily

Proprietary preparations

Feldene® (Pfizer)

Gel, piroxicam 0.5%, net price 60 g = £6.00; 112 g = £9.41 (also 7.5 g starter pack, hosp. only)

Excipients include benzyl alcohol, propylene glycol

Dose apply 3–4 times daily; therapy should be reviewed after 4 weeks

Fenbid® Forte Gel (Goldshield)

Gel, ibuprofen 10%, net price 100 g = £6.50

Excipients include benzyl alcohol

Dose apply up to 4 times daily; therapy should be reviewed after 14 days

1. Smaller pack sizes available on sale to the public

Ibugel® Forte (Derma)

Forte gel, ibuprofen 10%, net price 100 g = £5.87

Excipients none as listed in section 13.1.3

Dose apply up to 3 times daily

1. Mobigél® (Goldshield)

Spray, diclofenac sodium 4%, net price 25 g = £5.38

Excipients include propylene glycol

Dose apply 4–5 sprays up to 3 times daily; therapy should be reviewed after 7 days

1. Smaller pack sizes available on sale to the public

1. Oruvail® (Sanofi-Aventis)

Gel, ketoprofen 2.5%, net price 50 g = £3.06; 100 g = £5.89

Excipients include fragrance

Dose apply 2–4 times daily for up to 7 days (usual recommended dose 15 g daily)

1. Smaller pack sizes available on sale to the public

Powergel® (Menarini)

Gel, ketoprofen 2.5%, net price 50 g = £3.06; 100 g = £5.89

Excipients include fragrance

Dose apply 2–3 times daily for up to max. 10 days

Traxam® (Goldshield)

Foam, felbinac 3.17%. Net price 100 g = £7.00.

Label: 15

Excipients none as listed in section 13.1.3

Dose apply 2–4 times daily; max. 25 g daily; therapy should be reviewed after 14 days

Note Felbinac is an active metabolite of the NSAID fenbufen

Voltarol Emulgel® (Novartis)

Gel, diclofenac diethylamine salt 1.16% (equivalent to diclofenac sodium 1%), net price 20 g (hosp. only) = £1.55; 100 g = £7.00

Excipients include propylene glycol, fragrance

Dose apply 3–4 times daily; therapy should be reviewed after 14 days (or after 28 days for osteoarthritis)

1. Various pack sizes available on sale to the public

Voltarol Gel Patch® (Novartis)

Gel patch, diclofenac epolamine (equivalent to 140 mg diclofenac sodium per patch), net price 10-patch pack = £14.09

Excipients include hydroxybenzoates (parabens), propylene glycol

Dose ADULT and CHILD over 15 years, ankle sprain, apply 1 patch daily for up to 3 days; epicondylitis, apply 1 patch twice daily for up to 14 days

Capsaicin

A preparation containing capsaicin 0.025% can be considered as an adjunct in hand or knee osteoarthritis (see section 10.1). It may need to be used for 1–2 weeks before pain is relieved.

A capsaicin 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia (section 4.7.3) after lesions have healed, and for the relief of painful diabetic neuropathy (section 4.1.5).

A self-adhesive patch containing capsaicin 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients.
Zacin® (Cephalon) Cream, capsaicin 0.025%, net price 45 g = £17.71.
Excipients include benzyl alcohol, cetyl alcohol
Cautions avoid contact with eyes, inflamed or broken skin; wash hands immediately after use (or wash hands 30 minutes after application if hands treated); not to be used under tight bandages; avoid hot shower or bath just before or after application (burning sensation enhanced); avoid inhalation of vapours
Side-effects transient burning sensation during initial treatment (particularly if too much used or if administered less than 4 times daily); rarely cough, sneezing, eye irritation; dyspnoea and exacerbation of asthma also reported
Dose symptomatic relief in osteoarthritis, apply sparingly 4 times daily (not more often than every 4 hours)

Axsain® (Cephalon) Cream, capsaicin 0.075%, net price 45 g = £14.30.
Excipients include benzyl alcohol, cetyl alcohol
Cautions avoid contact with eyes, inflamed or broken skin; wash hands immediately after use (or wash hands 30 minutes after application if hands treated); not to be used under tight bandages; avoid hot shower or bath just before or after application (burning sensation enhanced); avoid inhalation of vapours
Side-effects transient burning sensation during initial treatment (particularly if too much used or if administered less than 3–4 times daily); rarely cough, sneezing, eye irritation; dyspnoea and exacerbation of asthma also reported
Dose post-herpetic neuralgia (important: after lesions have healed), apply sparingly up to 3–4 times daily (not more often than every 4 hours)
Post-hypertensive neuropathy, under specialist supervision, apply sparingly 3–4 times daily (not more often than every 4 hours) for 8 weeks then review

Qutenza® (Astellas) Patches, self-adhesive, capsaicin 179 mg (8%), net price 1 × 280 cm² patch (with cleansing gel) = £210.00.
Excipients include butylated hydroxyanisole in cleansing gel (see section 13.1.3)
Cautions avoid holding near eyes or mucous membranes; avoid contact with inflamed or broken skin, the face, scalp or in proximity to mucous membranes; monitor blood pressure during treatment procedure; uncontrolled hypertension; recent cardiovascular events
Side-effects application site reactions including transient burning, erythema, pruritus; less commonly nausea, peripheral oedema, first degree AV block, tachycardia, palpitations, hypertension; cough, throat irritation; hypoesthesia, burning sensation, dysgeusia; pain in extremities, muscle spasm, eye irritation, pruritus
Dose peripheral neuropathic pain in non-diabetic patients, applied under supervision of a physician, consult product literature
Note Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection)

Poultices

Kaolin Poultice Poultice, heavy kaolin 52.7%, thymol 0.05%, boric acid 4.5%, peppermint oil 0.05%, methyl salicylate 0.2%, glycerol 42.5%. Net price 200 g = £2.93
Dose warm and apply directly or between layers of muslin; avoid application of overheated poultice

Kaolin Poultice K/L Pack® (K/L) Kaolin poultice Net price 4 × 100-g pouches = £6.40
11.1 Administration of drugs to the eye

Drugs are most commonly administered to the eye by topical application as eye drops or eye ointments. When a higher drug concentration is required within the eye, a local injection may be necessary.

Eye-drop dispenser devices are available to aid the instillation of eye drops from plastic bottles; they are particularly useful for the elderly, visually impaired, arthritic, or otherwise physically limited patients.

Eye drops and eye ointments Eye drops are generally instilled into the pocket formed by gently pulling down the lower eyelid and keeping the eye closed for as long as possible after application; one drop is all that is needed. Instillation of more than one drop should be discouraged because it may increase systemic side-effects. A small amount of eye ointment is applied similarly; the ointment melts rapidly and blinking helps to spread it.

When two different eye-drop preparations are used at the same time of day, dilution and overflow may occur when one immediately follows the other. The patient should therefore leave an interval of at least 5 minutes between the two.

Systemic effects may arise from absorption of drugs into the general circulation from conjunctival vessels or from the nasal mucosa after the excess preparation has drained down through the tear ducts. The extent of systemic absorption following ocular administration is highly variable; nasal drainage of drugs is associated with eye drops much more often than with eye ointments. Pressure on the lacrimal punctum for at least a minute after applying eye drops reduces nasolacrimal drainage and therefore decreases systemic absorption from the nasal mucosa.

Patients should be warned not to drive or perform other skilled tasks until vision is clear after using eye drops or eye ointments.

For warnings relating to eye drops and contact lenses, see section 11.9.

Eye lotions These are solutions for the irrigation of the conjunctival sac. They act mechanically to flush out irritants or foreign bodies as a first-aid treatment. Sterile sodium chloride 0.9% solution (section 11.8.1) is usually used. Clean water will suffice in an emergency.

Other preparations Subconjunctival injection may be used to administer anti-infective drugs, mydriatics, or corticosteroids for conditions not responding to topical therapy. The drug diffuses through the cornea and sclera to the anterior and posterior chambers and vitreous humour. However, because the dose-volume is limited (usually not more than 1 mL), this route is suitable only for drugs which are readily soluble.
11.2 Control of microbial contamination

Preparations for the eye should be sterile when issued. Eye drops in multiple-application containers include a preservative but care should nevertheless be taken to avoid contamination of the contents during use. Eye drops in multiple-application containers for domiciliary use should not be used for more than 4 weeks after first opening (unless otherwise stated).

Eye drops for use in hospital wards are normally discarded 1 week after first opening. Individual containers should be provided for each patient. A separate bottle should be supplied for each eye only if there are special concerns about contamination. Containers used before an eye operation should be discarded at the time of the operation and fresh containers supplied. A fresh supply should also be provided upon discharge from hospital; in specialist ophthalmology units, it may be acceptable to issue eye-drop bottles that have been dispensed to the patient on the day of discharge.

In out-patient departments single-application packs should preferably be used; if multiple-application packs are used, they should be discarded at the end of each day. In clinics for eye diseases and in accident and emergency departments, where the dangers of infection are high, single-application packs should be used; if a multiple-application pack is used, it should be discarded after single use.

Diagnostic dyes (e.g. fluorescein) should be used only from single-application packs. Eye drops in multiple-application containers include a preservative but should not be used for more than 4 weeks after first opening (unless otherwise stated).

Eye drops for use in hospital wards are normally discarded 1 week after first opening. Individual containers should be provided for each patient. A separate bottle should be supplied for each eye only if there are special concerns about contamination. Containers used before an eye operation should be discarded at the time of the operation and fresh containers supplied. A fresh supply should also be provided upon discharge from hospital; in specialist ophthalmology units, it may be acceptable to issue eye-drop bottles that have been dispensed to the patient on the day of discharge.

Diagnostic dyes (e.g. fluorescein) should be used only from single-application packs.

In eye surgery single-application containers should be used if possible; if a multiple-application pack is used, it should be discarded after single use. Preparations used during intra-ocular procedures and others that may penetrate into the anterior chamber must be isotonic and without preservatives and buffered if necessary to a neutral pH. Specially formulated fluids should be used for intra-ocular surgery; intravenous infusion preparations are not suitable for this purpose. For all surgical procedures, a previously unopened container is used for each patient.

11.3 Anti-infective eye preparations

11.3.1 Antibacterials

Eye infections Most acute superficial eye infections can be treated topically. Blepharitis and conjunctivitis are often caused by staphylococci; keratitis and endophthalmitis may be bacterial, viral, or fungal.

Bacterial blepharitis is treated by application of an antibiotic eye ointment to the conjunctival sac or to the lid margins. Systemic treatment may occasionally be required and is usually undertaken after cultivating organisms from the lid margin and determining their antimicrobial sensitivity; antibiotics such as the tetracyclines given for 3 months or longer may be appropriate.

Most cases of acute bacterial conjunctivitis are self-limiting; where treatment is appropriate, antibiotic eye drops or an eye ointment are used. A poor response might indicate viral or allergic conjunctivitis. Gonococcal conjunctivitis is treated with systemic and topical antibacterials.

Corneal ulcer and keratitis require specialist treatment and may call for hospital admission for intensive therapy.

Endophthalmitis is a medical emergency which also calls for specialist management and often requires per-enteral, subconjunctival, or intra-ocular administration of antimicrobials.

11.3.2 Antifungals

11.3.3 Antivirals

Eye infections Most acute superficial eye infections can be treated topically. Blepharitis and conjunctivitis are often caused by staphylococci; keratitis and endophthalmitis may be bacterial, viral, or fungal.

Bacterial blepharitis is treated by application of an antibiotic eye ointment to the conjunctival sac or to the lid margins. Systemic treatment may occasionally be required and is usually undertaken after cultivating organisms from the lid margin and determining their antimicrobial sensitivity; antibiotics such as the tetracyclines given for 3 months or longer may be appropriate.

Most cases of acute bacterial conjunctivitis are self-limiting; where treatment is appropriate, antibiotic eye drops or an eye ointment are used. A poor response might indicate viral or allergic conjunctivitis. Gonococcal conjunctivitis is treated with systemic and topical antibacterials.

Corneal ulcer and keratitis require specialist treatment and may call for hospital admission for intensive therapy.

Endophthalmitis is a medical emergency which also calls for specialist management and often requires per-enteral, subconjunctival, or intra-ocular administration of antimicrobials.

11.3.1 Antibacterials

Bacterial eye infections are generally treated topically with eye drops and eye ointments. Systemic administration is sometimes appropriate in blepharitis.

Chloramphenicol has a broad spectrum of activity and is the drug of choice for superficial eye infections. Chloramphenicol eye drops are well tolerated and the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded.

Other antibacterials with a broad spectrum of activity include the quinolones, ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin; the aminoglycosides, gentamicin, neomycin [unlicensed], and tobramycin are also active against a wide variety of bacteria. Gentamicin, quinolones (except moxifloxacin), and polymyxin B are effective for infections caused by Pseudomonas aeruginosa.

Ciprofloxacin eye drops are licensed for corneal ulcers; intensive application (especially in the first 2 days) is required throughout the day and night.

Trachoma which results from chronic infection with Chlamydia trachomatis can be treated with azithromycin by mouth [unlicensed indication].

Fusidic acid is useful for staphylococcal infections.

Propamidine isetionate is of little value in bacterial infections but is specific for the rare but potentially sight-threatening condition of acanthamoeba keratitis [unlicensed indication] (see also section 11.9).

With corticosteroids Many antibiotic preparations also incorporate a corticosteroid but such mixtures should not be used unless a patient is under close specialist supervision. In particular they should not be prescribed for undiagnosed ‘red eye’ which is sometimes caused by the herpes simplex virus and may be difficult to diagnose (section 11.4).

Administration Frequency of application depends on the severity of the infection and the potential for irreversible ocular damage; antibiotic eye preparations are usually administered as follows:
**11 Eye**

**FUSIDIC ACID**

**Indications** see notes above

**Dose**
- See under preparation below

**Fucithalmic** (LEO)

Eye drops, m/t, fusidic acid 1% in gel basis (liquifies on contact with eye). Net price 5 g = £1.96

Excipients include benzalkonium chloride, disodium edetate

**Dose** apply twice daily

**GENTAMICIN**

**Indications** see notes above

**Dose**
- See Administration in notes above

**Gentamicin** (Amidpharm)

Drops (for ear or eye), gentamicin 0.3% (as sulphate). Net price 10 mL = £2.13

Excipients include benzalkonium chloride

**LEVOFLOXACIN**

**Indications** see notes above

**Cautions** not recommended for children under 1 year

**Pregnancy** manufacturer advises avoid—systemic quinolones have caused arthropathy in animal studies

**Breast-feeding** manufacturer advises avoid

**Side-effects** transient ocular irritation, visual disturbances, lid margin crusting, lid or conjunctival oedema, hyperaemia, conjunctival follicles, photophobia, headache, rhinitis

**Dose**
- See Administration in notes above

**Oftaquix** (Kestrel Ophthalmics)

Eye drops, levofloxacin 0.5%, net price 5 mL = £6.95

Excipients include benzalkonium chloride

**Eye drops** levofloxacin 0.5%, net price 30 x 0.5-mL single use units = £17.95

**MOXIFLOXACIN**

**Indications** see notes above

**Cautions** not recommended for neonates

**Side-effects** taste disturbances, ocular discomfort (including pain, irritation and dryness), hyperaemia; less commonly vomiting, headache, paraesthesia, corneal disorders (including keratitis, erosion, and staining), conjunctival haemorrhage, eyelid erythema, visual disturbances, nasal discomfort, pharyngolaryngeal pain; also reported: nausea, palpitation, dyspnoea, dizziness, raised intra-ocular pressure, photophobia, rash, pruritus

**Dose**
- **ADULT** and **CHILD** over 1 month, apply 3 times daily (continue treatment for 2–3 days after infection clears; review if no improvement within 5 days)

**Moxivig** (Alcon)

Eye drops, moxifloxacin (as hydrochloride) 0.5%. Net price 5 mL = £9.80

**NEOMYCIN SULPHATE**

**Indications** see notes above

**Dose**
- See Administration in notes above

**Redidrops** (eye drops), chloramphenicol 0.5%. Net price 0.5 mL = £9.17

**Net** price 3.5 g = £5.22

**Side-effects** transient stinging; see also notes above

**Excipients** include benzalkonium chloride, disodium edetate

**Redidrops** (eye drops), chloramphenicol 0.5%. Net price 5 mL = £4.70

**Excipients** include benzalkonium chloride, disodium edetate

**Redidrops** (eye drops), chloramphenicol 0.5%. Net price 10 mL = £9.80

**Excipients** include benzalkonium chloride, disodium edetate

**Ophthalmic solution** (eye drops), ciprofloxacin (as hydrochloride) 0.3%. Net price 5 mL = £4.70

**Excipients** include benzalkonium chloride

**Eye ointment**, ciprofloxacin (as hydrochloride) 0.3%. Net price 3.5 g = £5.22

**Chloramphenicol**

**Indications** see notes above

**Side-effects** transient burning and itching; lid margin crusting; hyperaemia; taste disturbances; corneal staining, keratitis, lid oedema, lacrimation, photophobia, corneal infiltrates; nausea and visual disturbances reported

**Dose**
- Superficial bacterial infection, see Administration in notes above
- Corneal ulcer, apply **eye drops** throughout day and night, day 1 apply every 15 minutes for 6 hours then every 30 minutes, day 2 apply every hour, days 3–14 apply every 4 hours (max. duration of treatment 21 days)

Apply **eye ointment** throughout day and night; apply 1.25 cm ointment every 1–2 hours for 2 days then every 4 hours for next 12 days

**Ciloxan** (Alcon)

**Ophthalmic solution** (= eye drops), ciprofloxacin (as hydrochloride) 0.3%. Net price 5 mL = £4.70

**Excipients** include benzalkonium chloride

**Eye ointment**, ciprofloxacin (as hydrochloride) 0.3%. Net price 3.5 g = £5.22

**Excipients** include benzalkonium chloride

**NEOMYCIN SULPHATE**

**Indications** see notes above

**Dose**
- See Administration in notes above

**Redidrops** (eye drops), chloramphenicol 0.5%. Net price 20 x 0.5 mL = £9.17

**Ciprofloxacin**

**Indications** superficial bacterial infections, see notes above; corneal ulcers

**Cautions** not recommended for children under 1 year

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk
**11.3.2 Antifungals**

Fungal infections of the cornea are rare but can occur after agricultural injuries, especially in hot and humid climates. Orbital mycosis is rarer, and when it occurs it is usually because of direct spread of infection from the paranasal sinuses. Increasing age, debility, or immunosuppression can encourage fungal proliferation. The spread of infection through blood occasionally produces metastatic endophthalmitis.

Many different fungi are capable of producing ocular infection; they can be identified by appropriate laboratory procedures.

Antifungal preparations for the eye are not generally available. Treatment will normally be carried out at specialist centres, but requests for information about supplies of preparations not available commercially should be addressed to the Strategic Health Authority (or equivalent), or to the nearest hospital ophthalmology unit, or to Moorfields Eye Hospital, 162 City Road, London EC1V 2PD (tel. (020) 7253 3411 or www.moorfields.nhs.uk).

Antifungal preparations may be inserted surgically to treat immediate sight-threatening CMV retinitis. Local treatments do not protect against systemic infection; they can be identified by appropriate laboratory procedures.

Many different fungi are capable of producing ocular infection; they can be identified by appropriate laboratory procedures.

Antifungal preparations for the eye are not generally available. Treatment will normally be carried out at specialist centres, but requests for information about supplies of preparations not available commercially should be addressed to the Strategic Health Authority (or equivalent), or to the nearest hospital ophthalmology unit, or to Moorfields Eye Hospital, 162 City Road, London EC1V 2PD (tel. (020) 7253 3411 or www.moorfields.nhs.uk).

**OFLOXACIN**

**Indications** see notes above

**Pregnancy** manufacturer advises use only if benefit outweighs risk; systemic quinolones have caused arthropathy in animal studies

**Breast-feeding** manufacturer advises avoid

**Side-effects** local irritation including photophobia; dizziness, numbness, nausea and headache reported

**Dose**
- Apply every 2–4 hours for the first 2 days then reduce frequency to 4 times daily (max. 10 days treatment)

**Exocin**® (Allergan)™

**Ophthalmic solution** (= eye drops), ofloxacin 0.3%.

Net price 5 mL = £2.17

Excipients include benzalkonium chloride

**POLIMYXIN B SULPHATE**

**Indications** see notes above

**Side-effects** local irriation and dermatitis

**Dose**
- See Administration in notes above

**With other antibacterials**

**Polyfax**® (TEVA UK)™

**Eye ointment**, polymyxin B sulphate 10 000 units, bacitracin zinc 500 units/g. Net price 4 g = £3.26

**PROPAMIDINE ISETIONATE**

**Indications** local treatment of infections (but see notes above)

**Dose**
- See preparations

**Brolene**® (Sanofi-Aventis)

**Eye drops**, propamidine isetionate 0.1%. Net price 10 mL = £2.80

Excipients include benzalkonium chloride

**Dose** apply 4 times daily

**Note** Eye drops containing propamidine isetionate 0.1% also available from Typharm (Golden Eye Drops)

**Eye ointment**, dibrompropamidine isetionate 0.15%. Net price 5 g = £2.92

**Dose** apply 1–2 times daily

**Note** Eye ointment containing dibrompropamidine isetionate 0.15% also available from Typharm (Golden Eye Ointment)

**TOBRAMYCIN**

**Indications** see notes above

**Dose**
- **ADULT and CHILD** over 1 year, apply twice daily for 6–8 days; in severe infection, apply 4 times daily on the first day, then twice daily for 5–7 days

**Tobramycin**® (Alcon)™

**Eye drops**, tobramycin 0.3%, net price 5 mL = £4.74

Excipients include benzalkonium chloride

**GANCICLOVIR**

**Indications** local treatment of herpes simplex infections

**Side-effects** burning sensation, tingling, superficial punctate keratitis

**Dose**
- Apply 5 times daily until healing complete, then apply 3 times daily for a further 7 days

**Zovirax**® (GSK)™

**Eye ointment**, aciclovir 3%. Net price 4.5 g = £9.34

**11.3.3 Antivirals**

Herpes simplex infections producing, for example, dendritic corneal ulcers can be treated with **aciclovir** or **ganciclovir**. Aciclovir eye ointment is used in combination with systemic treatment for ophthalmic zoster (section 5.3.2).

Slow-release ocular implants containing ganciclovir (available on a named-patient basis from specialist importing companies, see p. 988) may be inserted surgically to treat immediate sight-threatening CMV retinitis. Local treatments do not protect against systemic infection or infection in the other eye. For systemic treatment of CMV retinitis, see section 5.3.2.2.

**ACICLOVIR**

(Acylovir)

**Indications** local treatment of herpes simplex infections

**Side-effects** local irritation and inflammation, superficial punctate keratopathy; rarely blepharitis; very rarely hypersensitivity reactions including angioedema

**Dose**
- Apply 5 times daily (continue for at least 3 days after complete healing)

**Zovirax**® (GSK)™

**Eye ointment**, aciclovir 3%. Net price 4.5 g = £9.34

**GANCICLOVIR**

**Indications** local treatment of herpes simplex infections

**Side-effects** burning sensation, tingling, superficial punctate keratitis

**Dose**
- Apply 5 times daily until healing complete, then apply 3 times daily for a further 7 days

**Virgan®** (Spectrum Thea)™

**Ophthalmic gel**, ganciclovir 0.15%, net price 5 g = £19.99
### 11.4 Corticosteroids and other anti-inflammatory preparations

#### 11.4.1 Corticosteroids

Corticosteroids administered locally to the eye or given by mouth are effective for treating anterior segment inflammation, including that which results from surgery.

**Topical corticosteroids** are applied frequently for the first 24–48 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:

- A ‘red eye’, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard.
- ‘Steroid glaucoma’ can follow the use of corticosteroid eye preparations in susceptible individuals;
- A ‘steroid cataract’ can follow prolonged use.

Other side-effects of ocular corticosteroids include thinning of the cornea and sclera. Combination products containing a corticosteroid with an anti-infective drug are sometimes used after ocular surgery to reduce inflammation and prevent infection; use of combination products is otherwise rarely justified.

Systemic corticosteroids (section 6.3.2) may be useful for ocular conditions. The risk of producing a ‘steroid cataract’ increases with the dose and duration of corticosteroid use.

#### BETAMETHASONE

**Indications**  local treatment of inflammation (short-term)

**Cautions** see notes above

**Side-effects** see notes above

**Dose**

- Apply eye drops every 30–60 minutes until controlled then reduce frequency to 4–6 times daily

**Maxidex** *(Alcon)*

Eye drops, dexamethasone 0.1%, hypromellose 0.5%.

- Net price 5 mL = £1.42; 10 mL = £2.80

**Excipients** include benzalkonium chloride, disodium edetate, polysorbate 80

**Single use**

**Minims**® Dexamethasone *(Bausch & Lomb)*

Eye drops, dexamethasone sodium phosphate 0.1%.

- Net price 20 × 0.5 mL = £9.38

**Excipients** include disodium edetate

**With antibacterials**

**Maxitrol** *(Alcon)*

Eye drops, dexamethasone 0.1%, neomycin 0.35% (as sulphate), polymyxin B sulphate 6000 units/mL.

- Net price 5 mL = £1.68

**Excipients** include benzalkonium chloride, polysorbate 20

Eye ointment, dexamethasone 0.1%, neomycin 0.35% (as sulphate), polymyxin B sulphate 6000 units/g.

- Net price 3.5 g = £1.44

**Excipients** include hydroxybenzoates (parabens), wool fat

**Dose** apply 3–4 times daily or at night when used with eye drops

**Sofradex** *(Sanofi-Aventis)*

Eye drops, dexamethasone 0.1%, tobramycin 0.3%.

- Net price 5 mL = £5.37

**Excipients** include benzalkonium chloride, disodium edetate

#### FLUOROMETHOLONE

**Indications** local treatment of inflammation (short-term)

**Cautions** see notes above

**Side-effects** see notes above

**Dose**

- Apply every hour for 24–48 hours then reduce frequency to 2–4 times daily

**FML** *(Allergan)*

**Ophthalmic suspension** (= eye drops), fluorometholone 0.1%, polyvinyl alcohol *(Liquifilm)* 1.4%.

- Net price 5 mL = £1.71; 10 mL = £2.95

**Excipients** include benzalkonium chloride, disodium edetate, polysorbate 80

#### HYDROCORTISONE ACETATE

**Indications** local treatment of inflammation (short-term)

**Cautions** see notes above

**Side-effects** see notes above

**Dose**

- Apply every hour for 24–48 hours then reduce frequency to 2–4 times daily

**Hydrocortisone** *(Non-proprietary)*

Eye drops, hydrocortisone acetate 1%. Net price 10 mL = £3.21

Eye ointment, hydrocortisone acetate 0.5%, net price 3 g = £2.86; 1%, 3 g = £6.71
LOTEPREDNOL ETABONATE

Indications  treatment of post-operative inflammation following ocular surgery
Cautions  see notes above
Side-effects  see notes above
Dose  
- Apply 4 times daily starting 24 hours after surgery; max. duration of treatment 14 days

Lotemax® (Bausch & Lomb) ▼
Ophthalmic suspension (eye drops), loteprednol etabonate 0.5%, net price 10 mL = £1.92
Excipients include benzalkonium chloride, disodium edetate

PREDNISOLONE

Indications  local treatment of inflammation (short-term)
Cautions  see notes above
Side-effects  see notes above
Dose  
- Apply every 1–2 hours until controlled then reduce frequency

Predsol® (UCB Pharma) ▼
Drops (for ear or eye), prednisolone sodium phosphate 0.5%. Net price 10 mL = £1.92
Excipients include benzalkonium chloride, disodium edetate

Pred Forte® (Allergan) ▼
Eye drops, prednisolone acetate 1%. Net price 5 mL = £1.52, 10 mL = £3.05
Excipients include benzalkonium chloride, disodium edetate, polysorbate 80

Dose  
- By intravitreal injection, 700 micrograms into the affected eye

Note  Concurrent administration to both eyes not recommended. For further information on administration and repeat dosing, consult product literature

Dexumethasone

Indications  see notes above—specialist use only
Cautions  monitor intra-ocular pressure and for signs of ocular infection; history of ocular herpes simplex; aphasis; retinal vein occlusion with significant retinal ischaemia; concomitant administration of anticoagulant or antiplatelet drugs
Contra-indications  active or suspected ocular or periocular infection; uncontrolled advanced glaucoma
Pregnancy  manufacturer advises avoid unless potential benefit outweighs risk—no information available
Breast-feeding  manufacturer advises avoid unless potential benefit outweighs risk—no information available
Side-effects  raised intra-ocular pressure, vitreous detachment, cataract, visual disturbance; less commonly headache; also reported glaucoma, ocular infection

Dose  
- By intravitreal injection, 700 micrograms into the affected eye

Note  Concurrent administration to both eyes not recommended. For further information on administration and repeat dosing, consult product literature

Ozurdex® (Allergan) ▼
Intravitreal implant, dexamethasone 700 micrograms in disposable applicator; net price = £870.00

11.4.2 Other anti-inflammatory preparations

Other preparations used for the topical treatment of inflammation and allergic conjunctivitis include antihistamines, lodoxamide, and sodium cromoglicate.

Eye drops containing antihistamines, such as antazoline (with xylometazoline as Otrivine-Antistin®), azelastine, epinastine, ketotifen, and olopatadine, can be used for allergic conjunctivitis.

Sodium cromoglicate (sodium cromoglicate) and nedocromil sodium eye drops can be useful for vernal keratoconjunctivitis and other allergic forms of conjunctivitis.

Lodoxamide eye drops are used for allergic conjunctival conditions including seasonal allergic conjunctivitis.

Diclofenac eye drops (section 11.8.2) and emedastine eye drops are also licensed for seasonal allergic conjunctivitis.

ANTAZOLINE SULPHATE

Indications  allergic conjunctivitis

Otrivine-Antistin® (Novartis Consumer Health)
Eye drops, antazoline sulphate 0.5%, xylometazoline hydrochloride 0.05%. Net price 10 mL = £2.35
Excipients include benzalkonium chloride, disodium edetate

Note  Xylometazoline is a sympathomimetic; it should be used with caution in patients susceptible to angle-closure glaucoma; absorption of antazoline and xylometazoline may result in systemic side-effects and the possibility of interaction with other drugs.
### AZELASTINE HYDROCHLORIDE

**Indications** allergic conjunctivitis  
**Side-effects** mild transient irritation; bitter taste reported  
**Dose**  
- Seasonal allergic conjunctivitis, **ADULT** and **CHILD** over 4 years, apply twice daily; increased if necessary to 4 times daily  
- Perennial conjunctivitis, **ADULT** and **CHILD** over 12 years, apply twice daily; increased if necessary to 4 times daily; max. duration of treatment 6 weeks  

**Optilast**® (Meda) *N*  
Eye drops, azelastine hydrochloride 0.05%. Net price 8 mL = £6.40  
**Excipients** include benzalkonium chloride, disodium edetate

### EMEDESTINE

**Indications** seasonal allergic conjunctivitis  
**Side-effects** transient burning or stinging; blurred vision, local oedema, keratitis, irritation, dry eye, lacrimation, corneal infiltrates (discontinue) and staining; photophobia; headache, and rhinitis occasionally reported  
**Dose**  
- **ADULT** and **CHILD** over 3 years, apply twice daily  

**Emadine**® (Alcon) *N*  
Eye drops, emedastine 0.05% (as difumarate), net price 5 mL = £7.31  
**Excipients** include benzalkonium chloride

### EPINASTINE HYDROCHLORIDE

**Indications** seasonal allergic conjunctivitis  
**Side-effects** burning; *less commonly* dry mouth, taste disturbance; nasal irritation, rhinitis; headache, blepharoconjunctivitis, conjunctival oedema and hyperaemia, dry eye, local irritation, photophobia, visual disturbance; pruritus  
**Dose**  
- **ADULT** and **ADOLESCENT** over 12 years, apply twice daily; max. duration of treatment 8 weeks  

**Relestat**® (Allergan) *N*  
Eye drops, epinastine hydrochloride 500 micrograms/mL, net price 5 mL = £9.90  
**Excipients** include benzalkonium chloride, disodium edetate

### KETOTIFEN

**Indications** seasonal allergic conjunctivitis  
**Side-effects** burning or stinging, punctate corneal epithelial erosion; *less commonly* dry eye, subconjunctival haemorrhage, photophobia; headache, dryness, skin reactions, and dry mouth also reported  
**Dose**  
- **ADULT** and **CHILD** over 3 years, apply twice daily  

**Zaditen**® (Novartis) *N*  
Eye drops, ketotifen (as fumarate) 250 micrograms/mL, net price 5 mL = £7.80  
**Excipients** include benzalkonium chloride

### LODOXAMIDE

**Indications** allergic conjunctivitis  
**Side-effects** burning, stinging, itching; blurred vision; tear production disturbance, and ocular discomfort; *less commonly* flushing, nasal dryness, dizziness, dryness, headache, blepharitis and keratitis  
**Dose**  
- **ADULT** and **CHILD** over 4 years, apply 4 times daily; improvement of symptoms may sometimes require treatment for up to 4 weeks  

**Alomide**® (Alcon) *N*  
**Ophthalmic solution** (eye drops), lodoxamide 0.1% (as trometamol). Net price 10 mL = £5.21  
**Excipients** include benzalkonium chloride, disodium edetate  
**Note** Lodoxamide 0.1% eye drops can be sold to the public for treatment of allergic conjunctivitis in adults and children over 4 years

### NEDOCROMIL SODIUM

**Indications** allergic conjunctivitis; seasonal keratoconjunctivitis  
**Side-effects** burning and stinging; distinctive taste reported  
**Dose**  
- Seasonal and perennial conjunctivitis, **ADULT** and **CHILD** over 6 years, apply twice daily increased if necessary to 4 times daily; max. 12 weeks treatment for seasonal allergic conjunctivitis  
- Seasonal keratoconjunctivitis, **ADULT** and **CHILD** over 4 years, apply 4 times daily  

**Rapitil**® (Sanofi-Aventis) *N*  
Eye drops, nedocromil sodium 2%. Net price 5 mL = £4.92  
**Excipients** include benzalkonium chloride, disodium edetate

### OLOPATADINE

**Indications** seasonal allergic conjunctivitis  
**Side-effects** local irritation; *less commonly* keratitis, dry eye, local oedema, photophobia; headache, asthenia, dizziness; dry nose also reported  
**Dose**  
- **ADULT** and **CHILD** over 3 years, apply twice daily; max. duration of treatment 4 months  

**Opatanol**® (Alcon) *N*  
Eye drops, olopatadine (as hydrochloride) 1 mg/mL, net price 5 mL = £3.91  
**Excipients** include benzalkonium chloride

### SODIUM CROMOGlicate

**Indications** allergic conjunctivitis; seasonal keratoconjunctivitis  
**Side-effects** burning and stinging  
**Dose**  
- **ADULT** and **CHILD** apply eye drops 4 times daily  

**Sodium Cromoglicate (Non-proprietary)** *N*  
**Eye drops**, sodium cromoglicate 2%. Net price 13.5 mL = £1.79  
Brands include Hay-Crom® *Aqueous*, Opticrom® *Aqueous*, Vivadren®  
**Note** Sodium cromoglicate 2% eye drops can be sold to the public (in max. pack size of 10 mL) for treatment of acute seasonal and perennial allergic conjunctivitis
Antimuscarinics dilate the pupil and paralyse the ciliary muscle; they vary in potency and duration of action. Short-acting, relatively weak mydriatics, such as tropicamide 0.5% (action lasts for 4–6 hours), facilitate the examination of the fundus of the eye. Cyclopentolate 1% (action up to 24 hours) or atropine (action up to 7 days) are preferable for producing cycloplegia for refraction in young children. Atropine ointment 1% is sometimes preferred for children aged under 5 years because the ointment formulation reduces systemic absorption. Mydriatics and cycloplegics are used in the treatment of anterior uveitis, usually as an adjunct to corticosteroids (section 11.4.1). Atropine is used in anterior uveitis mainly to prevent posterior synechiae and to relieve ciliary spasm, often in combination with phenylephrine eye drops; cyclopentolate or homatropine (action up to 3 days) can also be used and may be preferred because they have a shorter duration of action.

Phenylephrine is used for mydriasis in diagnostic or therapeutic procedures; mydriasis occurs within 60–90 minutes and lasts up to 5–7 hours. Phenylephrine 10% drops are contra-indicated in children and the elderly owing to the risk of systemic effects.

Cautions Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage. Mydriasis can precipitate acute angle-closure glaucoma in a few patients, usually aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber. Phenylephrine may interact with systemically administered monoamine-oxidase inhibitors; other interactions: Appendix 1 (sympathomimetics).

Driving Patients should be warned not to drive until vision is clear after mydriasis.

Side-effects Ocular side-effects of mydriatics and cycloplegics include transient stinging and raised intra-ocular pressure; on prolonged administration, local irritation, hyperaemia, oedema and conjunctivitis can occur. Contact dermatitis can occur with the antimuscarinic mydriatic drugs, especially atropine. Systemic side-effects of atropine and cyclopentolate can occur, particularly in children and the elderly; see section 1.2 for systemic side-effects of antimuscarinic drugs.

Antimuscarinics

ATROPINE SULPHATE

Indications mydriasis; see also notes above
Cautions risk of systemic effects with eye drops in infants under 3 months—eye ointment preferred; see also notes above
Side-effects see notes above

Side-effects

Minims® Atropine Sulphate (Bausch & Lomb) 
Eye drops, atropine sulphate 0.5%. Net price 20 × 0.5 mL = £12.71

Minims® Cyclopentolate Hydrochloride (Bausch & Lomb) 
Eye drops, cyclopentolate hydrochloride 0.5% and 1%. Net price 20 × 0.5 mL (both) = £9.64

Tropicamide

Indications see notes above
Cautions see notes above
Side-effects see notes above

Minims® Tropicamide (Bausch & Lomb) 
Eye drops, tropicamide 0.5%. Net price 5 mL = £1.29; 1%, 5 mL = £1.60

Excipients include benzalkonium chloride, disodium edetate

Phenylephrine Hydrochloride

Indications mydriasis; see also notes above
Cautions children and elderly (avoid 10% strength); cardiovascular disease (avoid or use 2.5% strength only); tachycardia; hyperthyroidism; diabetes; see also notes above
Side-effects eye pain and stinging; blurred vision, photophobia; systemic effects include palpitations, arrhythmias, hypertension, coronary artery spasm; very rarely angle-closure glaucoma

Side-effects

Minims® Phenylephrine Hydrochloride 10%. Net price 10 mL = £4.86
11.6 Treatment of glaucoma

Glaucoma describes a group of disorders characterised by a loss of visual field associated with cupping of the optic disc and optic nerve damage. While glaucoma is generally associated with raised intra-ocular pressure, it can occur when the intra-ocular pressure is within the normal range.

The commonest form of glaucoma is primary open-angle glaucoma (chronic simple glaucoma; wide-angle primary angle-closure glaucoma). The condition is often asymptomatic and the patient may present with significant loss of visual-field. Primary angle-closure glaucoma (acute closed-angle glaucoma, narrow-angle glaucoma) results from blockage of aqueous humour flow into the anterior chamber and is a medical emergency.

Drugs that reduce intra-ocular pressure by different mechanisms are available for managing glaucoma. A topical beta-blocker or a prostaglandin analogue is usually the drug of first choice. It may be necessary to combine these drugs or add others, such as miotics, sympathomimetics, or carbonic anhydrase inhibitors, to control intra-ocular pressure.

For urgent reduction of intra-ocular pressure and before surgery, mannitol 20% (up to 500 mL) is given by slow intravenous infusion until the intra-ocular pressure has been satisfactorily reduced. Acetazolamide by intravenous infusion is required after iridotomy, iridectomy, or a drainage operation in either primary open-angle or primary angle-closure glaucoma.

Beta-blockers

Topical application of a beta-blocker to the eye reduces intra-ocular pressure effectively in primary open-angle glaucoma, probably by reducing the rate of production of aqueous humour. Administration by mouth also reduces intra-ocular pressure but this route is not used since side-effects may be troublesome.

Beta-blockers used as eye drops include betaxolol, carteolol, levobunolol, metipranolol, and timolol.

Cautions, contra-indications, and side-effects

Systemic absorption can follow topical application to the eyes; therefore, eye drops containing a beta-blocker are contra-indicated in patients with bradycardia, heart block, or uncontrolled heart failure. Important: for a warning to avoid in asthma see below. Consider also other cautions, contra-indications, and side-effects of beta-blockers (p. 97). Local side-effects of eye drops include ocular stinging, burning, pain, itching, erythema, dry eyes and allergic reactions including anaphylaxis and blepharoconjunctivitis, occasionally corneal disorders have been reported. Important: Beta-blockers, even those with apparent cardios-lectivity, should not be used in patients with asthma or a history of obstructive airways disease, unless no alternative treatment is available. In such cases the risk of inducing bronchospasm should be appreciated and appropriate precautions taken.

Interactions

Since systemic absorption may follow topical application the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind. See also Appendix 1 (beta-blockers).

BETAXOLOL HYDROCHLORIDE

Indications see notes above

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

• Apply twice daily

Betaxolol (Non-proprietary)

Eye drops, solution, betaxolol (as hydrochloride) 0.5%, net price 5 mL = £1.90

Excipients may include benzalkonium chloride, disodium edetate

Betoptic® (Alcon)

Ophthalmic solution (= eye drops), betaxolol (as hydrochloride) 0.5%, net price 5 mL = £1.90

Excipients include benzalkonium chloride, disodium edetate

Ophthalmic suspension (= eye drops), betaxolol (as hydrochloride) 0.25%, net price 5 mL = £2.66

Excipients include benzalkonium chloride, disodium edetate

Unit dose eye drop suspension, betaxolol (as hydrochloride) 0.25%, net price 50 × 0.25 mL = £13.77

CARTEOLOL HYDROCHLORIDE

Indications see notes above

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

• Apply twice daily

Teoptic® (Spectrum Thea)

Eye drops, carteolol hydrochloride 1%, net price 5 mL = £7.60; 2%, 5 mL = £8.40

Excipients include benzalkonium chloride

LEVUBUNOLOL HYDROCHLORIDE

Indications see notes above

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above; anterior uveitis occasionally reported

Dose

• Apply once or twice daily

Levobunolol (Non-proprietary)

Eye drops, levobunolol hydrochloride 0.5%, net price 5 mL = £3.05

Betagan® (Allergan)

Eye drops, levobunolol hydrochloride 0.5%, polyvinyl alcohol (Liquifilm®) 1.4%. Net price 5-mL = £1.85

Excipients include benzalkonium chloride, disodium edetate, sodium metabisulphite

Unit dose eye drops, levobunolol hydrochloride 0.5%, polyvinyl alcohol (Liquifilm®) 1.4%. Net price 30 × 0.4 mL = £9.96

Excipients include disodium edetate
**METIPRANOLOL**

**Indications** see notes above but in chronic open-angle glaucoma restricted to patients allergic to preservatives or to those wearing soft contact lenses (in whom benzalkonium chloride should be avoided)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above; granulomatous anterior uveitis reported (discontinue treatment)

**Dose**
- Apply twice daily

**Minims** Metipranolol (Bausch & Lomb) 

Eye drops, metipranolol 0.1%, net price 20 × 0.5 mL = £11.77

**TIMOLOL MALEATE**

**Indications** see notes above

**Cautions** see notes above

**Side-effects** see notes above

**Dose**
- Apply twice daily; long-acting preparations, apply once daily

**Timolol** (Non-proprietary)

Eye drops, timolol (as maleate) 0.25%, net price 5 mL = £1.56; 0.5%, net price 5 mL = £1.56

**Timoptol** (MSD)

Eye drops, in Ocumeter metered-dose unit, timolol (as maleate) 0.25%, net price 5 mL = £3.12; 0.5%, 5 mL = £3.12

Excipients include benzalkonium chloride

Unit dose eye drops, timolol (as maleate) 0.25%, net price 30 × 0.2 mL = £8.45; 0.5%, 30 × 0.2 mL = £9.65

**Once-daily preparations**

**Nyogel** (Novartis)

Eye gel (= eye drops), timolol (as maleate) 0.1%, net price 5 g = £2.85

Excipients include benzalkonium chloride

Dose apply once daily

**Timoptol-**LA (MSD)

Ophthalmic gel-forming solution (= eye drops), timolol (as maleate) 0.25%, net price 2.5 mL = £3.12; 0.5%, 2.5 mL = £3.12

Excipients include benzalkonium bromide

Dose apply once daily

- **With bimatoprost**
  - See under Bimatoprost
- **With brimonidine**
  - See under Brimonidine
- **With brinzolamide**
  - See under Brinzolamide
- **With dorzolamide**
  - See under Dorzolamide
- **With latanoprost**
  - See under Latanoprost
- **With travoprost**
  - See under Travoprost

**Prostaglandin analogues and prostamides**

The prostaglandin analogues latanoprost, tafluprost, and travoprost, and the synthetic prostamide, bimatoprost, increase uveoscleral outflow and subsequently reduce intra-ocular pressure. They are used to reduce intra-ocular pressure in ocular hypertension or open-angle glaucoma.

**Cautions** Before initiating treatment, patients should be monitored for possible change in eye colour since an increase in the brown pigment in the iris may occur; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Use with caution in patients with aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses, and in those with known risk factors for cystoid macular oedema, iritis, or uveitis. Care is also needed in patients with brittle or severe asthma. Do not use within 5 minutes of thiomersal-containing preparations. For use in contact lens wearers see Contact Lenses, p. 684.

**Side-effects** Side-effects of prostaglandin analogues and prostamides include brown pigmentation particularly in those with mixed-colour irides, blepharitis, ocular irritation and pain, conjunctival hyperaemia, transient punctate epithelial erosion, skin rash, dry eyes, headache, and photophobia; they may also cause, darkening, thickening and lengthening of eye lashes. Less frequent side-effects include eyelid oedema and rash, keratitis, blurred vision, and conjunctivitis. There have been rare reports of dyspnoea, exacerbation of asthma, dizziness, arthralgia, myalgia, iritis, uveitis, local oedema, darkening of palpebral skin. Very rarely chest pain, palpitations, and exacerbation of angina has also been reported.

**BIMATOPROST**

**Indications** raised intra-ocular pressure in open-angle glaucoma; ocular hypertension

**Cautions** see notes above

**Hepatic impairment** use with caution in moderate to severe impairment—no information available

**Renal impairment** use with caution—no information available

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** see notes above; also nausea, asthenia, hypertension

**Dose**
- Apply once daily, preferably in the evening; CHILD under 18 years, not recommended

**Lumigan** (Allergan)

Eye drops, bimatoprost 0.01% micrograms/mL, net price 3 mL = £12.43, triple pack (3 × 3 mL) = £37.29; 0.03% micrograms/mL, 3 mL = £10.30, triple pack (3 × 3 mL) = £30.90

Excipients include benzalkonium chloride

- **With timolol**
  - For prescribing information on timolol, see section 11.6, Beta-blockers

**Ganfort** (Allergan)

Eye drops, bimatoprost 0.03% micrograms/mL, timolol (as maleate) 5 mg/mL, net price 3 mL = £13.95

Excipients include benzalkonium chloride

- **With latanoprost**
  - See under Latanoprost
- **With travoprost**
  - See under Travoprost

**11.6 Treatment of glaucoma**

- **TIMOLOL MALEATE**
- **BIMATOPROST**
- **Prostaglandin analogues and prostamides**


**Latanoprost**

**Indications** raised intra-ocular pressure in open-angle glaucoma; ocular hypertension

**Cautions** see notes above, also in cataract surgery

**Pregnancy** manufacturer advises avoid

**Breast-feeding** may be present in milk—manufacturer advises avoid

**Side-effects** see notes above

**Dose**

- Apply once daily, preferably in the evening; CHILD under 18 years, not recommended

**Xalatan®** (Pharmacia) [58]

**Eye drops**; latanoprost 50 micrograms/mL, net price 2.5 mL = £12.48

Excipients include benzalkonium chloride

**With timolol**

For prescribing information on timolol, see section 11.6, Beta-blockers

**Xalacom®** (Pharmacia) [58]

**Eye drops**; latanoprost 50 micrograms, timolol (as maleate) 5 mg/mL, net price 2.5 mL = £14.32

Excipients include benzalkonium chloride

**Dose** for raised intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension when beta-blocker alone not adequate; apply once daily

**Tafluprost**

**Indications** raised intra-ocular pressure in open-angle glaucoma; ocular hypertension

**Cautions** see notes above

**Hepatic impairment** use with caution—no information available

**Renal impairment** use with caution—no information available

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies

**Breast-feeding** manufacturer advises avoid—present in milk in animal studies

**Side-effects** see notes above

**Dose**

- Apply once daily, preferably in the evening; CHILD under 18 years, not recommended

**Saflutan®** (MSD) [58]

**Unit dose eye drops**, tafluprost 15 micrograms/mL, net price 30 × 0.3 mL = £17.41

**Travatan®** (Alcon) [58]

**Eye drops**; travoprost 40 micrograms/mL, net price 2.5 mL = £9.98

**With timolol**

For prescribing information on timolol, see section 11.6, Beta-blockers

**DuoTrav®** (Alcon) [58]

**Eye drops**; travoprost 40 micrograms, timolol (as maleate) 5 mg/mL, net price 2.5 mL = £12.54

Excipients include benzalkonium chloride, disodium edetate

**Dose** for raised intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate; apply once daily; CHILD and ADOLESCENT under 18 years, not recommended

**Sympathomimetics**

**Brimonidine**

A selective alpha2-adrenoceptor agonist, is licensed for the reduction of intra-ocular pressure in open-angle glaucoma or ocular hypertension in patients for whom beta-blockers are inappropriate; it may also be used as adjunctive therapy when intra-ocular pressure is inadequately controlled by other antiglaucoma therapy.

Apraclonidine (section 11.8.2) is another alpha2-adrenoceptor agonist. Eye drops containing apraclonidine 0.5% are used for a short term to delay laser treatment or surgery for glaucoma in patients not adequately controlled by another drug; eye drops containing 1% are used for control of intra-ocular pressure after anterior segment laser surgery.

**Brimonidine Tartrate**

**Indications** raised intra-ocular pressure, see notes above

**Cautions** severe cardiovascular disease; cerebral or coronary insufficiency; Raynaud’s syndrome, thromboangiitis obliterans, postural hypotension, depression; children 2–12 years (increased risk of drowsiness); interactions: Appendix 1 (brimonidine)

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving)

**Contra-indications** neonate or child under 2 years

**Hepatic impairment** manufacturer advises use with caution

**Renal impairment** manufacturer advises use with caution

**Pregnancy** manufacturer advises use only if benefit outweighs risk

**Breast-feeding** manufacturer advises avoid

**Side-effects** dry mouth, gastro-intestinal disturbances, taste disturbances, upper respiratory symptoms, headache, drowsiness, dizziness, malaise, ocular disturbances (including hyperaemia, burning, stinging, pruritus, pain and dryness), visual disturbances, eyelid inflammation, photophobia, corneal erosion and staining, conjunctival disturbances (including Blanching, follicles, and infection); less commonly palpitation, arrhythmia, bradycardia, tachycardia, depression, nasal dryness; rarely dyspnoea, very rarely hypertension, hypotension, syncope, insomnia, irritis, miosis

**Dose**

- Apply twice daily
11.6 Treatment of glaucoma 677

Brimonidine Tartrate (Non-proprietary) \(\text{A}\)  
**Eye drops**, brimonidine tartrate 0.2%, net price 5 mL = £6.55  
*Brands* include *Brymol*®  
*Excipients* may include benzalkonium chloride  
**Alphagan®** (Allergan) \(\text{A}\)  
**Eye drops**, brimonidine tartrate 0.2%, net price 5 mL = £6.85  
*Excipients* include benzalkonium chloride  

\[\text{With timolol}\]

For prescribing information on timolol, see section 11.6, Beta-blockers  
**Combigan®** (Allergan) \(\text{A}\)  
**Eye drops**, brimonidine tartrate 0.2%, timolol (as maleate) 0.5%, net price 5 mL = £10.00  
*Excipients* include benzalkonium chloride  

**Dose**  
For raised intra-ocular pressure in open-angle glaucoma and for ocular hypertension when beta-blocker alone not adequate, apply twice daily  

**Carbonic anhydrase inhibitors and systemic drugs**

The carbonic anhydrase inhibitors, acetazolamide, brinzolamide, and dorzolamide, reduce intra-ocular pressure by reducing aqueous humour production. Systemic use also produces weak diuresis.  
**Acetazolamide** is given by mouth or by intravenous injection (intramuscular injections are painful because of the alkaline pH of the solution). It is used as an adjunct to other treatment for reducing intra-ocular pressure. Acetazolamide is a sulphonamide; blood disorders, rashes, and other sulphonamide-related side-effects occur occasionally; patients should be told to report any unusual skin rash. It is not generally recommended for long-term use; electrolyte disturbances and metabolic acidosis that occur can be corrected by administering potassium bicarbonate (as effervescent potassium tablets, section 9.2.1.3).  
**Dorzolamide** and **brinzolamide** are topical carbonic anhydrase inhibitors. They are licensed for use in patients resistant to beta-blockers or those in whom beta-blockers are contra-indicated. They are used alone or as an adjunct to a topical beta-blocker. Systemic absorption can rarely cause sulphonamide-like side-effects and may require discontinuation if severe.  
**The osmotic diuretics**, intravenous hypertonic mannitol (section 2.2.5) or glycerol by mouth are useful short-term ocular hypotensive drugs.  

**ACETAZOLAMIDE**

**Indications**  
reduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma, and peri-operative in angle-closure glaucoma; diuresis (section 2.2.7); epilepsy  
**Cautions**  
not generally recommended for prolonged use but if given monitor blood count and plasma-electrolyte concentration; pulmonary obstruction and impaired alveolar ventilation (risk of acidosis); elderly; diabetes mellitus; renal calculi; avoid extravasation at injection site (risk of necrosis);  
*interactions*: Appendix 1 (diuretics)  
**Contra-indications**  
hypokalaemia, hypotraemia, hyperchloremic acidosis, adenocortical insufficiency; long-term administration in chronic angle-closure glaucoma; sulfonamide hypersensitivity  
**Hepatic impairment** manufacturer advises avoid  

**Renal impairment** avoid—risk of metabolic acidosis  
**Pregnancy** manufacturer advises avoid, especially in first trimester (toxicity in animal studies)  
**Breast-feeding** amount too small to be harmful  
**Side-effects** see notes above; also nausea, vomiting, diarrhoea, taste disturbance, loss of appetite, paraesthesia, flushing, headache, dizziness, fatigue, irritability, excitement, ataxia, depression; thirst, polyuria, reduced libido, less commonly melena, drowsiness, confusion, hearing disturbances, fever, glycosuria, metabolic acidosis and electrolyte disturbances on long-term therapy, haematuria, crystalluria, renal and ureteric colic, renal lesions or calculi, renal failure, blood disorders, bone marrow suppression, rash (including Stevens-Johnson syndrome and toxic epidermal necrosis); rarely fulminant hepatic necrosis, hepatitis, cholestatic jaundice, flaccid paralysis, convulsions, photosensitivity; also reported transient myopia  

**Dose**

- Glaucoma, by mouth or by intravenous injection, 0.25–1 g daily in divided doses  
- Epilepsy, by mouth or by intravenous injection, 0.25–1 g daily in divided doses; *CHILD* 6–30 mg/kg/day, max. 750 mg/day  
*Note* Dose by intramuscular injection, as for intravenous injection but preferably avoided because of alkalinity  

**Diamox®** (Goldshield) \(\text{A}\)  
**Tablets**, acetazolamide 250 mg. Net price 112-tab pack = £12.68. Label: 3  
**Sodium Parenteral (= injection)**, powder for reconstitution, acetazolamide (as sodium salt). Net price 500-mg vial = £14.76  
**Modified release**  
**Diamox® SR** (Goldshield) \(\text{A}\)  
**Capsules**, m/r, orange, enclosing orange f/c pellets, acetazolamide 250 mg. Net price 30-cap pack = £13.88. Label: 3, 25  
*Dose* glaucoma, 1–2 capsules daily  

**BRINZOLAMIDE**

**Indications**  
adjunct to beta-blockers or used alone in raised intra-ocular pressure in ocular hypertension and in open-angle glaucoma if beta-blocker alone inadequate or inappropriate  
**Cautions** systemic absorption follows topical application;  
*interactions*: Appendix 1 (brinzolamide)  
**Contra-indications** hyperchloremic acidosis  
**Hepatic impairment** manufacturer advises avoid  
**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²  
**Pregnancy** manufacturer advises avoid unless essential—toxicity in animal studies  
**Breast-feeding** manufacturer advises avoid  
**Side-effects** local irritation, taste disturbance; less commonly nausea, dyspepsia, dry mouth, chest pain, epistaxis, haemoptysis, dyspnoea, rhinitis, pharyngitis, bronchitis, paraesthesia, depression, dizziness, headache, dermatitis, alopecia, corneal erosion  
**Dose**

- Apply twice daily increased to 3 times daily if necessary  
**Azopt®** (Alcon) \(\text{A}\)  
**Eye drops**, brinzolamide 10 mg/mL, net price 5 mL = £6.56  
*Excipients* include benzalkonium chloride, disodium edetate
DORZOLAMIDE

**Indications** raised intra-ocular pressure in ocular hypertension, open-angle glaucoma, pseudo-exfoliative glaucoma either as adjunct to beta-blocker or used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated

**Caution** systemic absorption follows topical application; history of renal calculi; chronic corneal defects, history of intra-ocular surgery; interactions: Appendix 1 (dorzolamide)

**Contra-indications** hyperchloraemic acidosis

**Hepatic impairment** manufacturer advises caution—no information available

**Renal impairment** avoid if eGFR less than 30 mL/minute/1.73 m²

**Pregnancy** manufacturer advises avoid—risk—limited information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** nausea, bitter taste, dry mouth; headache, asthenia; ocular irritation, blurred vision, lacrimation, conjunctivitis, superficial punctuate keratitis, eye oedema, epistaxis, throat irritation

**Dose**
- Used alone, apply 3 times daily
- With topical beta-blocker, apply twice daily

**Polassium**

**Eye drops** dorzolamide (as hydrochloride) 2%, net price 5 mL = £5.61

**Excipients** may include benzalkonium chloride

**Trusopt** (MSD) (= eye drops), in Ocumeter Plus metered-dose unit, dorzolamide (as hydrochloride) 2%, net price 5 mL = £6.33

**Excipients** include benzalkonium chloride

**Unit dose eye drops** dorzolamide (as hydrochloride) 2%, timolol (as maleate) 0.5%, net price 60 × 0.2 mL = £28.59

Miotics

The small pupil is an unfortunate side-effect of these drugs (except when pilocarpine is used temporarily before an operation for angle-closure glaucoma). They act by opening up the inefficient drainage channels in the trabecular meshwork resulting from contraction or spasm of the ciliary muscle.

**Pilocarpine**, a miotic, is used in the management of raised intra-ocular pressure.

**Cautions** A darkly pigmented iris may require higher concentration of the miotic or more frequent administration and care should be taken to avoid overdosage. Retinal detachment has occurred in susceptible individuals and those with retinal disease; therefore fundus examination is advised before starting treatment with a miotic. Care is also required in conjunctival or corneal damage. Intra-ocular pressure and visual fields should be monitored in those with chronic simple glaucoma and those receiving long-term treatment with a miotic. Miotics should be used with caution in patients with peptic ulceration, gastro-intestinal spasm, cardiac disease, hypertension, hypotension, marked vasomotor instability, asthma, epilepsy, Parkinson’s disease, hyperthyroidism, and urinary-tract obstruction.

**Counselling** Blurred vision may affect performance of skilled tasks (e.g. driving) particularly at night or in reduced lighting conditions

**Contra-indications** Miotics are contra-indicated in conditions where pupillary constriction is undesirable such as acute iritis, anterior uveitis and some forms of secondary glaucoma. They should be avoided in acute inflammatory disease of the anterior segment.

**Pregnancy** avoid unless potential benefit outweighs risk—limited information available

**Breast-feeding** avoid unless potential benefit outweighs risk—no information available

**Side-effects** Ciliary spasm leads to headache and browache which may be more severe in the initial 2–4 weeks of treatment (a particular disadvantage in patients under 40 years of age). Ocular side-effects include burning, itching, smarting, blurred vision, conjunctival vascular congestion, myopia, lens changes with chronic use, vitreous haemorrhage, and pupillary block. Systemic side-effects (see under Parasympathomimetics, section 7.4.1) are rare following application to the eye.

PILOCARPINE

**Indications** see notes above; dry mouth (section 12.3.5)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Dose**
- Apply up to 4 times daily; long-acting preparations, see under preparations below
Pilocarpine Hydrochloride (Non-proprietary)  
**Eye drops**, pilocarpine hydrochloride 1%, net price 10 mL = £3.00; 2%, 10 mL = £2.87; 4%, 10 mL = £3.83  
**Excipients** may include benzalkonium chloride

- **Single use**  
  **Minims® Pilocarpine Nitrate** (Bausch & Lomb)  
  **Eye drops**, pilocarpine nitrate 2%, net price 20 × 0.5 mL = £10.04

- **Long acting**  
  **Pilogel®** (Alcon)  
  **Ophthalmic gel**, pilocarpine hydrochloride 4%, net price 5 g = £6.52  
  **Excipients** include benzalkonium chloride, disodium edetate  
  **Dose** apply 1–1.5 cm gel once daily at bedtime

---

**11.7 Local anaesthetics**

Oxybuprocaine and tetracaine (amethocaine) are widely used topical local anaesthetics. Proxymetacaine causes less initial stinging and is useful for children. Oxybuprocaine or a combined preparation of lidocaine and fluorescein is used for tonometry. Tetracaine produces a more profound anaesthesia and is suitable for use before minor surgical procedures, such as the removal of corneal sutures. It has a temporary disruptive effect on the corneal epithelium. Lidocaine, with or without adrenaline (epinephrine), is injected into the eyelids for minor surgery, while retrobulbar or peribulbar injections are used for surgery of the globe itself. Local anaesthetics should never be used for the management of ocular symptoms. Local anaesthetic eye drops should be avoided in pre-term neonates because of the immaturity of the metabolising enzyme system.

**LIDOCAINE HYDROCHLORIDE**  
**Indications** local anaesthetic  
**Minims® Lidocaine and Fluorescein** (Bausch & Lomb)  
**Eye drops**, lidocaine hydrochloride 4%, fluorescein sodium 0.25%. Net price 20 × 0.5 mL = £10.61

**OXYBUPROCAINE HYDROCHLORIDE**  
**Indications** local anaesthetic  
**Minims® Oxybuprocaine Hydrochloride** (Bausch & Lomb)  
**Eye drops**, oxybuprocaine hydrochloride 0.4%. Net price 20 × 0.5 mL = £8.92

**PROXYMETACAINA HYDROCHLORIDE**  
**Indications** local anaesthetic  
**Minims® Proxymetacaine** (Bausch & Lomb)  
**Eye drops**, proxymetacaine hydrochloride 0.5%. Net price 20 × 0.5 mL = £9.51

- **With fluorescein**  
  **Minims® Proxymetacaine and Fluorescein** (Bausch & Lomb)  
  **Eye drops**, proxymetacaine hydrochloride 0.5%, fluorescein sodium 0.25%. Net price 20 × 0.5 mL = £10.59

**TETRACAINE HYDROCHLORIDE**  
**Indications** local anaesthetic  
**Minims® Tetracaine Hydrochloride** (Bausch & Lomb)  
**Eye drops**, tetracaine hydrochloride 0.5% and 1%. Net price 20 × 0.5 mL (both) = £9.93

---

**11.8 Miscellaneous ophthalmic preparations**

**11.8.1 Tear deficiency, ocular lubricants, and astringents**

Chronic soreness of the eyes associated with reduced or abnormal tear secretion (e.g. in Sjogren’s syndrome) often responds to tear replacement therapy or pilocarpine given by mouth (section 12.3.5). The severity of the condition and patient preference will often guide the choice of preparation.

Hypromellose is the traditional choice of treatment for tear deficiency. It may need to be instilled frequently (e.g. hourly) for adequate relief. Ocular surface mucin is often abnormal in tear deficiency and the combination of hypromellose with a mucolytic such as acetylcysteine can be helpful. The ability of carboxomers to cling to the eye surface may help reduce frequency of application to 4 times daily.

Polyvinyl alcohol increases the persistence of the tear film and is useful when the ocular surface mucin is reduced.

Povidone and sodium hyaluronate eye drops are also used in the management of tear deficiency.

Sodium chloride 0.9% drops are sometimes useful in tear deficiency, and can be used as ‘comfort drops’ by contact lens wearers, and to facilitate lens removal. Special presentations of sodium chloride 0.9% and other irrigation solutions are used routinely for intraocular surgery.

Eye ointments containing a paraffin can be used to lubricate the eye surface, especially in cases of recurrent corneal epithelial erosion. They may cause temporary visual disturbance and are best suited for application...
before sleep. Ointments should not be used during contact lens wear.

**ACETYL-CYSTEINE**

**Indications**  
Tear deficiency, impaired or abnormal mucus production

**Dose**  
- Apply 3–4 times daily

**lube** (Moorfields)  
Eye drops, acetylcysteine 5%, hypromellose 0.35%.  
Net price 10 mL = £4.40  
Excipients include benzalkonium chloride, disodium edetate

**CARBOMERS**  
(Polyacrylic acid)

**Note**  
Synthetic high molecular weight polymers of acrylic acid cross-linked with either allyl ethers of sucrose or allyl ethers of pentaerythritol

**Indications**  
Dry eyes including keratoconjunctivitis sicca, unstable tear film

**Dose**  
- Apply 3–4 times daily or as required

**Clinitas Gel** (Altacon)  
Gel (= eye drops), carbomer 980 (polyacrylic acid) 0.2%, net price 10 g = £2.80  
Excipients include benzalkonium chloride

**Liposic** (Bausch & Lomb)  
Gel (= eye drops), carbomer 980 (polyacrylic acid) 0.2%, net price 10 g = £2.96  
Excipients include cetrimide

**Liquivisc** (Spectrum Thea)  
Gel (= eye drops), carbomer 974P (polyacrylic acid) 0.2%, net price 10 g = £2.96  
Excipients include cetrimide

**Lumecare Long Lasting Tear Gel** (Medicom)  
Gel (= eye drops), carbomer 980 (polyacrylic acid) 0.2%, net price 10 g = £2.10  
Excipients include cetrimide

**Viscotears** (Novartis)  
Liquid gel (= eye drops), carbomer 980 (polyacrylic acid) 0.2%, net price 10 g = £2.94  
Excipients include cetrimide

**Lumecare Long Lasting Tear Gel** (Medicom)  
Gel (= eye drops), carbomer 980 (polyacrylic acid) 0.2%, net price 30 × 0.6-mL single-dose units = £3.42

**CARMELLOSE SODIUM**

**Indications**  
Dry eye conditions

**Dose**  
- Apply as required

**Optive®** (Allergan)  
Eye drops, carmellose sodium 0.5%, glycerol, net price 10 mL = £7.49

**Single use**

**Celluvisc®** (Allergan)  
Eye drops, carmellose sodium 0.5%, net price 30 × 0.4 mL = £5.75; 90 × 0.4 mL = £15.53; 1%, 30 × 0.4 mL = £3.00, 60 × 0.4 mL = £10.99

**HYDROXYETHYLCELLULOSE**

**Indications**  
Tear deficiency

**Minims® Artificial Tears** (Bausch & Lomb)  
Eye drops, hydroxyethylcellulose 0.44%, sodium chloride 0.35%. Net price 20 × 0.5 mL = £8.21

**HYDROXYPROPYL GUAR**

**Indications**  
Dry eye conditions

**Dose**  
- Apply as required

**Systane®** (Alcon)  
Eye drops, hydroxypropyl guar, net price 10 mL = £4.66

**Single use**

**Systane®** (Alcon)  
Eye drops, hydroxypropyl guar, net price 28 × 0.8 mL = £4.66

**HYPROMELLOSE**

**Indications**  
Tear deficiency

**Note**  
The Royal Pharmaceutical Society has stated that where it is not possible to ascertain the strength of hypromellose prescribed, the prescriber should be contacted to clarify the strength intended.

**Hypromellose** (Non-proprietary)  
Eye drops, hypromellose 0.3%, net price 10 mL = £1.61  
Excipients may include benzalkonium chloride  
Brands include Artefac®, Lumecare® Hypermellose

**Isopo Alkaline®** (Alcon)  
Eye drops, hypromellose 1%, net price 10 mL = 94p  
Excipients include benzalkonium chloride

**Isopo Plain®** (Alcon)  
Eye drops, hypromellose 0.5%, net price 10 mL = 81p  
Excipients include benzalkonium chloride

**Tears Naturale®** (Alcon)  
Eye drops, hypromellose 0.3%, dextran ’70’ 0.1%, net price 15 mL = £1.60  
Excipients include benzalkonium chloride, disodium edetate

**Single use**

**Artelac® SDU** (Pharma-Global)  
Eye drops, hypromellose 0.32%, net price 30 × 0.5 mL = £16.95

**Hydromoor®** (Moorfields)  
Eye drops, hypromellose 0.3%, net price 30 × 0.4 mL = £5.75

**Lumecare® Preservative Free Tear Drops** (Medicom)  
Eye drops, hypromellose 0.3%, net price 30 × 0.5 mL = £5.72

**Tears Naturale® Single Dose** (Alcon)  
Eye drops, hypromellose 0.3%, dextran ’70’ 0.1%, net price 28 × 0.4 mL = £13.26

**LIQUID PARAFFIN**

**Indications**  
Dry eye conditions

**Lacril-Lube®** (Allergan)  
Eye ointment, white soft paraffin 57.3%, liquid paraffin 42.5%, wool alcohols 0.2%. Net price 3.5 g = £2.51, 5 g = £3.32
### PARAFFIN, YELLOW, SOFT

**Indications**  
see notes above

**Simple Eye Ointment**  
*Ointment*, liquid paraffin 10%, wool fat 10%, in yellow soft paraffin. Net price 4 g = £3.06

### POLYVINYL ALCOHOL

**Indications**  
tear deficiency

**Liquifilm Tears**  
(Allergan)  
*Ophthalmic solution* (= eye drops), polyvinyl alcohol 1.4%. Net price 15 mL = £1.93  
Excipients include benzalkonium chloride, disodium edetate

**Sno Tears**  
(Bausch & Lomb)  
*Eye drops*, polyvinyl alcohol 1.4%. Net price 10 mL = £1.06  
Excipients include benzalkonium chloride, disodium edetate

### POVIDONE

**Indications**  
dry eye conditions

**Dose**  
• Apply 4 times daily or as required

**Oculotect**  
(Novartis)  
*Eye drops*, povidone 5%. Net price 20 × 0.4 mL = £3.40

### SODIUM CHLORIDE

**Indications**  
irrigation, including first-aid removal of harmful substances

**Sodium Chloride 0.9% Solutions**  
See section 13.11.1

**Balanced Salt Solution**  
*Solution* (sterile), sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.046%, magnesium chloride 0.03%, potassium chloride 0.075%.  
For intra-ocular or topical irrigation during surgical procedures  
Brands include *Iocare*®

**Fluorescein sodium** is used in diagnostic procedures and for locating damaged areas of the cornea due to injury or disease.

**FLUORESCIN SODIUM**

**Indications**  
detection of lesions and foreign bodies

**Minims® Fluorescein Sodium**  
(Bausch & Lomb)  
*Eye drops*, fluorescein sodium 1% or 2%. Net price 20 × 0.5 mL (both) = £7.53  
With local anaesthetic  
Section 11.7

**Ocular diagnostic preparations**

Fluorescein sodium is used in diagnostic procedures and for locating damaged areas of the cornea due to injury or disease.

**Ocular peri-operative drugs**

Drugs used to prepare the eye for surgery, drugs that are injected into the anterior chamber at the time of surgery, and those used after eye surgery, are included here.

Non-steroidal anti-inflammatory eye drops such as diclofenac, flurbiprofen, ketorolac, and nepafenac, are used for the prophylaxis and treatment of inflammation, pain, and other symptoms associated with ocular surgery or laser treatment of the eye. Diclofenac and flurbiprofen are also used to prevent miosis during ocular surgery.

**Apraclonidine**, an alpha-2-adrenoreceptor agonist, reduces intra-ocular pressure possibly by reducing the production of aqueous humour. It is used to control increases in intra-ocular pressure associated with ocular surgery and as short-term treatment to reduce intra-ocular pressure prior to surgery.

**Acetylcholine**, instilled into the anterior chamber of the eye during surgery, rapidly produces miosis which lasts approximately 20 minutes. If prolonged miosis is required, it can be applied again.
Intra-ocular sodium hyaluronate and balanced salt solution (section 11.8.1) are used during surgical procedures on the eye.

**ACETYLCHOLINE CHLORIDE**

**Indications** cataract surgery, penetrating keratoplasty, iridectomy, and other anterior segment surgery requiring rapid complete miosis

**Cautions** gastrointestinal spasm, peptic ulcer; heart failure; asthma; hyperthyroidism; urinary-tract obstruction; parkinsonism

**Pregnancy** avoid unless potential benefit outweighs risk—no information available

**Breast-feeding** avoid unless potential benefit outweighs risk—no information available

**Side-effects** rarely bradycardia, hypotension, breathing difficulty, sweating, flushing

**Mi chol-E® (Novartis) (SD Healthcare)**

**Intra-ocular irrigation** powder for reconstitution, acetylcholine chloride 10 mg/mL (1%) when reconstituted, net price 20-mg vial (with solvent) = £7.28

**Miptel® (SD Healthcare)**

**Intra-ocular irrigation** powder for reconstitution, acetylcholine chloride 10 mg/mL (1%) when reconstituted, net price 20-mg vial (with solvent) = £7.28

**APRACLONIDINE**

**Note** Apraclonidine is a derivative of clonidine

**Indications** control of intra-ocular pressure

**Cautions** history of angina, severe coronary insufficiency, recent myocardial infarction, heart failure, cerebrovascular disease, vasovagal attack, chronic renal failure; depression; monitor intra-ocular pressure and visual fields; loss of effect may occur over time; suspend treatment if reduction in vision occurs in end-stage glaucoma; monitor for excessive reduction in intra-ocular pressure following peri-operative use; **interactions:** Appendix 1 (apraclonidine)

**Driving** Drowsiness may affect performance of skilled tasks

**Contra-indications** history of severe or unstable and uncontrolled cardiovascular disease

**Pregnancy** manufacturer advises caution—no information available

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** dry mouth, taste disturbance; hyperaemia, ocular pruritus, discomfort and lacrimation (withdraw if ocular intolerance including oedema of lids and conjunctiva); headache, asthenia, dry nose; lid retraction, conjunctival blanching and mydriasis reported after peri-operative use; since absorption may follow topical application systemic effects (see Clonidine, section 2.5.2) may occur

**Dose**

- See under preparations below

**Lopidine® (Alcon) (Sun) (SD Healthcare)**

**Ophthalmic solution** (= eye drops), apraclonidine 0.5% (as hydrochloride), net price 5 mL = £10.88

**Excipients** include benzalkonium chloride

**Dose** short-term adjunctive treatment of chronic glaucoma in patients not adequately controlled by another drug (see note below), apply 1 drop 3 times daily usually for max. 1 month. **CHILD** not recommended

**Note** May not provide additional benefit if patient already using two drugs that suppress the production of aqueous humour

**DICLOFENAC SODIUM**

**Indications** inhibition of intra-operative miosis during cataract surgery (but does not possess intrinsic mydriatic properties); postoperative inflammation in cataract surgery, strabismus surgery or argon laser trabeculoplasty; pain in corneal epithelial defects after photorefractive keratectomy, radial keratotomy or accidental trauma; seasonal allergic conjunctivitis (section 11.4.2)

**Voltarol® Ophtha Multidose** (Novartis) (Allergan)

**Eye drops**, diclofenac sodium 0.1%, net price 5 mL = £6.68

**Excipients** include benzalkonium chloride, disodium edetate, propylene glycol

**Single use**

**Voltarol® Ophtha** (Novartis) (Allergan)

**Eye drops**, diclofenac sodium 0.1%, net price pack of 5 single-dose units = £4.00, 40 single-dose units = £32.00

**FLURBIPROFEN SODIUM**

**Indications** inhibition of intra-operative miosis (but does not possess intrinsic mydriatic properties); anterior segment inflammation following postoperative and post-laser trabeculoplasty when corticosteroids contra-indicated

**Ocufen® (Allergan)** (Allergan)

**Ophthalmic solution** (= eye drops), flurbiprofen sodium 0.03%, polyvinyl alcohol (Liquifilm®) 1.4%, net price 40 x 0.4 mL = £37.15

**KETOROLAC TROMETAMOL**

**Indications** prophylaxis and reduction of inflammation and associated symptoms following ocular surgery

**Acular® (Allergan)** (Allergan)

**Eye drops**, ketorolac trometamol 0.5%, net price 5 mL = £3.00

**Excipients** include benzalkonium chloride, disodium edetate

**NEPAFENAC**

**Indications** prophylaxis and treatment of postoperative pain and inflammation associated with cataract surgery

**Cautions** avoid sunlight; discontinue immediately if evidence of corneal epithelial breakdown

**Side-effects** headache; punctuate keratitis, blurred vision, eye pruritus, dry eye, less commonly nausea, dry mouth; iritis; keratitis, corneal deposits, choroidal effusion, allergic conjunctivitis, increased lacrimation, photophobia, conjunctival hyperaemia

**Nevanac® (Alcon) (Sun) (SD Healthcare)**

**Ophthalmic suspension** (= eye drops), nepafenac 1 mg/mL, net price 5 mL = £14.92

**Excipients** include benzalkonium chloride, disodium edetate
Subfoveal choroidal neovascularisation

Pegaptanib and ranibizumab are vascular endothelial growth factor inhibitors licensed for the treatment of neovascular (wet) age-related macular degeneration; they are given by intravitreal injection by specialists experienced in the management of this condition.

NICE guidance
Ranibizumab and pegaptanib for the treatment of wet age-related macular degeneration (August 2008)

Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:

- the best corrected visual acuity is between 6/12 and 6/96;
- there is no permanent structural damage to the central fovea;
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension;
- there is evidence of recent disease progression;

the cost of ranibizumab beyond 14 injections is met by the manufacturer.

Ranibizumab should only be continued in patients who maintain adequate response to therapy. Pegaptanib is not recommended for the treatment of wet age-related macular degeneration; patients currently receiving pegaptanib for any lesion type can continue therapy until they and their specialist consider it appropriate to stop.

Verteporfin is licensed for use in the photodynamic treatment of age-related macular degeneration associated with predominantly classic subfoveal choroidal neovascularisation or with pathological myopia (see NICE guidance below). Following intravenous infusion, verteporfin is activated by local irradiation using non-thermal red light to produce cytotoxic derivatives. Only specialists experienced in the management of these conditions should use it.

NICE guidance
Photodynamic therapy for wet age-related macular degeneration (September 2003)

Photodynamic therapy is recommended for wet age-related macular degeneration with a confirmed diagnosis of classic (no occult) subfoveal choroidal neovascularisation and best-corrected visual acuity of 6/60 or better. Photodynamic therapy is not recommended for wet age-related macular degeneration with predominantly classic but partly occult subfoveal choroidal neovascularisation except in clinical studies.

Side-effects

Rhinorhoea; headache; eye pain, anterior chamber inflammation, raised intra-ocular pressure, punctate keratits, vitreous floats, cataract, conjunctival and retinal haemorrhage, local oedema, conjunctivitis, corneal dystrophy, dry eye, endophthalmitis, eye discharge, eye irritation, macular degeneration, mydriasis, periorbital haematoma, photophobia, flashing lights, vitreous disorders; less commonly vomiting, dyspepsia, palpitation, chest pain, hypertension, aortic aneurysm, influenza-like symptoms, nightmares, depression, back pain, asthenopia, blepharitis, corneal deposits, vitreous haemorrhage, chaliazon, retinal exudates, eyelid ptosis, decreased intra-ocular pressure, injection-site reactions, retinal detachment, occlusion of retinal blood vessels, ectropion, eye movement disorder, pupillary disorder, iritis, optic nerve cupping, nasopharyngitis, deafness, vertigo, eczema, changes in hair colour, rash, pruritus, night sweats

Dose

- By intravitreal injection, 300 micrograms once every 6 weeks into the affected eye

Note: For further information on administration, consult product literature. Review treatment if no benefit after 2 consecutive injections

Macugen® (Pfizer) ©
Solution for intravitreal injection, pegaptanib (as sodium salt), net price 300-microgram vial = £514.00

RANIBIZUMAB

Indications

see notes above—specialist use only

Cautions

monitor intra-ocular pressure and for signs of ocular infection following injection

Contra-indications

ocular or periorcular infection;
severe intra-ocular inflammation

Pregnancy

manufacturer advises avoid unless potential benefit outweighs risk and recommends effective contraception during treatment

Breast-feeding

manufacturer advises avoid—no information available

Side-effects

nausea; headache; nasopharyngitis, cough; anxiety; anaemia; arthralgia; raised intra-ocular pressure, visual disturbance, conjunctival retinal and vitreous disorders, eye inflammation and irritation, eye haemorrhage; allergic skin reactions; less commonly atrial fibrillation, blindness, corneal disorders, iris adhesion, injection site reactions

Dose

- By intravitreal injection, initially 500 micrograms once a month into the affected eye, thereafter monitor visual acuity once a month; if necessary subsequent doses may be given at least 1 month apart

Note: For further information on administration, consult product literature

Antimicrobial eye drops should be administered into the affected eye for 3 days before and 3 days after each injection

Lucentis® (Novartis) © (BNF)
Solution for intravitreal injection, ranibizumab 10 mg/mL, net price 0.23-mL vial = £761.20

PEGAPTANIB SODIUM

Indications

see notes above—specialist use only

Cautions

monitor intra-ocular pressure following injection

Contra-indications

ocular or periorcular infection

Pregnancy

manufacturer advises avoid unless potential benefit outweighs risk

Breast-feeding

manufacturer advises avoid—no information available

VERTEPORFIN

Indications

see notes above—specialist use only

Cautions

photosensitivity—avoid exposure of unprotected skin and eyes to bright light during infusion and for 48 hours afterwards; concomitant use with other
photosensitising drugs; biliary obstruction; avoid extravasation

**Contra-indications**  
- acute porphyria
- Hepatic impairment use with caution in moderate impairment; avoid in severe impairment
- Pregnancy manufacturer advises use only if potential benefit outweighs risk (teratogenic in animal studies)

**Breast-feeding**  
- no information available—manufacturer advises avoid breast-feeding for 48 hours after administration

**Side-effects**  
- nausea, hypercholesterolaemia, malaise, back pain, photosensitivity, visual disturbances (including reduced visual acuity, flashing lights, visual-field defects), less commonly hypertension, hyperaesthesia, pyrexia, retinal detachment, haemorrhage, rarely retinal or choroidal vessel non-perfusion; also reported chest pain, myocardial infarction

**Dose**  
- By intravenous infusion over 10 minutes, 6 mg/m²

**Note**  
- For information on administration and light activation, consult product literature

**Visudyne** (Novartis)®

Injection, powder for reconstitution, verteporfin, net price 15-mg vial = £850.00

**Excipients** include butylated hydroxytoluene

---

**11.9 Contact lenses**

For cosmetic reasons many people prefer to wear contact lenses rather than spectacles; contact lenses are also sometimes required for medical indications. Visual defects are corrected by either rigid (‘hard’ or gas permeable) lenses or soft (hydrogel or silicone hydrogel) lenses; soft lenses are the most popular type, because they are initially the most comfortable, but they may not give the best vision. Lenses should usually be worn for a specified number of hours each day and removed for sleeping. Continuous (extended) wear involves much greater risks to eye health and is not generally recommended except where medically indicated.

Contact lenses require meticulous care. Poor compliance with directions for use, and with daily cleaning and disinfection, can result in complications including ulcerative keratitis or conjunctivitis. One-day disposable lenses, which are worn only once and therefore require no disinfection or cleaning, are becoming increasingly popular.

*Acanthamoeba keratitis*, a painful and sight-threatening condition, is associated with ineffective lens cleaning and disinfection, the use of contaminated lens cases, or tap water coming into contact with the lenses. The condition is especially associated with the use of soft lenses (including frequently replaced lenses) and should be treated by specialists.

**Contact lenses and drug treatment**  
- Special care is required in prescribing eye preparations for contact lens users. Some drugs and preservatives in eye preparations can accumulate in hydrogel lenses and may induce toxic reactions. Therefore, unless medically indicated, the lenses should be removed before drop instillation and not worn during the period of treatment. Alternatively, unpreserved drops can be used. Eye drops may, however, be instilled while patients are wearing rigid corneal contact lenses. Ointment preparations should never be used in conjunction with contact lens wear; oily eye drops should also be avoided.

Many drugs given systemically can also have adverse effects on contact lens wear. These include oral contraceptives (particularly those with a higher oestrogen content), drugs which reduce blink rate (e.g. anxiolytics, hypnotics, antihistamines, and muscle relaxants), drugs which reduce lacrimation (e.g. antihistamines, antimuscarinics, phenothiazines and related drugs, some beta-blockers, diuretics, and tricyclic antidepressants), and drugs which increase lacrimation (including ephedrine and hydralazine). Other drugs that may affect contact lens wear are isotretinoin (can cause conjunctival inflammation), aspirin (saliicylic acid appears in tears and can be absorbed by contact lenses—leading to irritation), and rifampicin and sulfasalazine (can discolor lenses).
12 Ear, nose, and oropharynx

12.1 Drugs acting on the ear 685
12.1.1 Otitis externa 685
12.1.2 Otitis media 687
12.1.3 Removal of ear wax 688
12.2 Drugs acting on the nose 688
12.2.1 Drugs used in nasal allergy 689
12.2.2 Topical nasal decongestants 691
12.2.3 Nasal preparations for infection 692
12.3 Drugs acting on the oropharynx 693
12.3.1 Drugs for oral ulceration and inflammation 693
12.3.2 Oropharyngeal anti-infective drugs 695
12.3.3 Lozenges and sprays 697
12.3.4 Mouthwashes, gargles, and dentifrices 697
12.3.5 Treatment of dry mouth 698

This chapter also includes advice on the drug management of the following:
- allergic rhinitis, p. 689
- nasal polyps, p. 689
- oropharyngeal infections, p. 695
- periodontitis, p. 693

12.1 Drugs acting on the ear

12.1.1 Otitis externa

Otitis externa is an inflammatory reaction of the meatal skin. It is important to exclude an underlying chronic otitis media before treatment is commenced. Many cases recover after thorough cleansing of the external ear canal by suction or dry mopping. A frequent problem in resistant cases is the difficulty in applying lotions and ointments satisfactorily to the relatively inaccessible affected skin. The most effective method is to introduce a ribbon gauze dressing or sponge wick soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution. When this is not practical, the ear should be gently cleansed with a probe covered in cotton wool and the patient encouraged to lie with the affected ear uppermost for ten minutes after the canal has been filled with a liberal quantity of the appropriate solution.

If infection is present, a topical anti-infective which is not used systemically (such as neomycin or clioquinol) may be used, but for only about a week as excessive use may result in fungal infections; these may be difficult to treat and require expert advice. Sensitivity to the anti-infective or solvent may occur and resistance to antibacterials is a possibility with prolonged use. Aluminium acetate ear drops are also effective against bacterial infection and inflammation of the ear. Chloramphenicol may be used but the ear drops contain propylene glycol and cause hypersensitivity reactions in about 10% of patients. Solutions containing an anti-infective and a corticosteroid (such as Locorten-Vioform) are used for treating cases where infection is present with inflammation and eczema.

In view of reports of ototoxicity in patients with a perforated tympanic membrane (eardrum), manufacturers contra-indicate treatment with a topical aminoglycoside antibiotic in those with a tympanic perforation. However, many specialists do use these drops cautiously in the presence of a perforation in patients with otitis media (section 12.1.2) and when other measures have failed for otitis externa.

A solution of acetic acid 2% acts as an antifungal and antibacterial in the external ear canal. It may be used to treat mild otitis externa but in severe cases an anti-inflammatory preparation with or without an anti-infective drug is required. A proprietary preparation containing acetic acid 2% (EarCalm spray) is on sale to the public.

For severe pain associated with otitis externa, a simple analgesic, such as paracetamol (section 4.7.1) or ibu-
prophen (section 10.1.1), can be used. A systemic antibacterial (Table 1, section 5.1) can be used if there is spreading cellulitis or if the patient is systemically unwell. When a resistant staphylococcal infection (a boil) is present in the external auditory meatus, fluocortolone is the drug of choice; ciprofloxacin (or an aminoglycoside) may be needed in pseudomonal infections which may occur if the patient has diabetes or is immunocompromised.

The skin of the pinna adjacent to the ear canal is often affected by eczema. Topical corticosteroid creams and ointments (section 13.4) are then required, but prolonged use should be avoided.

### Astringent preparations

**ALUMINIUM ACETATE**

**Indications** inflammation in otitis externa (see notes above)

**Dose**
- Insert into meatus or apply on a ribbon gauze dressing or sponge wick which should be kept saturated with the ear drops

**Aluminium Acetate (Non-proprietary)**
- **Ear drops** 13%, aluminium sulphate 2.25 g, calcium carbonate 1 g, tartaric acid 450 mg, acetic acid (33%) 2.5 mL, purified water 7.5 mL
- Available from manufacturers of ‘special order’ products
- **Ear drops** 8%, dilute 8 parts aluminium acetate ear drops (13%) with 5 parts purified water. Must be freshly prepared

### Anti-inflammatory preparations

#### Corticosteroids

Topical corticosteroids are used to treat inflammation and eczema in otitis externa. **Cautions** Prolonged use of topical corticosteroid ear preparations should be avoided.

**Contra-indications** Corticosteroid ear preparations should be avoided in the presence of an untreated ear infection. If infection is present, the corticosteroid should be used in combination with a suitable anti-inflammatory (see notes above).

**Side-effects** Local sensitivity reactions may occur.

#### BETAMETHASONE SODIUM PHOSPHATE

**Indications** eczematous inflammation in otitis externa (see notes above)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Betnesol®** (UCB Pharma)
- **Ear drops** (for ear, eye, or nose), betamethasone sodium phosphate 0.1%. Net price 10 mL = £2.23
- **Excipients** include benzalkonium chloride, disodium edetate
- **Dose** ear, apply 2–3 drops every 2–3 hours; reduce frequency when relief obtained; eye, section 11.4.1; nose, section 12.2.1

### With antibacterial

**Betnesol-N®** (UCB Pharma)
- **Ear drops** (for ear, eye, or nose), betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5%. Net price 10 mL = £2.30
- **Excipients** include benzalkonium chloride, disodium edetate
- **Dose** ear, apply 2–3 drops every 3–4 hours; reduce frequency when relief obtained; eye, section 11.4.1; nose, section 12.2.1

### DEXAMETHASONE

**Indications** eczematous inflammation in otitis externa (see notes above)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

### With antibacterial

**Otimize®** (GSK Consumer Healthcare)
- **Ear spray**, dexamethasone 0.1%, neomycin sulphate 3250 units/mL, glacial acetic acid 2%. Net price 5-mL pump-action aerosol unit = £3.71
- **Excipients** include hydroxybenzoates (parabens)
- **Dose** ear, apply 1 metered spray 3 times daily

**Sofradex®** (Sanofi-Aventis)
- **Ear drops** (for ear or eye), dexamethasone (as sodium metabsulphobenzozate) 0.05%, framycetin sulphate 0.5%, gramicidin 0.005%. Net price 10 mL = £6.25
- **Excipients** include polysorbate 80
- **Dose** ear, apply 2–3 drops 3–4 times daily; eye, section 11.4.1

### FLUMETASONE PIVALATE

(Flumethasone Pivalate)

**Indications** eczematous inflammation in otitis externa (see notes above)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

### With antibacterial

**Locorten-Vioform®** (Amdipharm)
- **Ear drops**, flumetasone pivalate 0.02%, clioquinol 1%. Net price 7.5 mL = £1.76
- **Contra-indications** iodine sensitivity
- **Dose** ADULT and CHILD over 2 years apply 2–3 drops into the ear twice daily for 7–10 days
- **Note** Clioquinol stains skin and clothing

### HYDROCORTISONE

**Indications** eczematous inflammation in otitis externa (see notes above)

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above
With antibacterial

Gentisone® HC (Amdipharm) 

Ear drops, hydrocortisone acetate 1%, gentamicin 0.3% (as sulphate). Net price 10 mL = £3.92

Excipients include benzalkonium chloride, disodium edetate

Dose: ear, apply 2–4 drops 3–4 times daily and at night

Otosporin® (GSK)

Ear drops, hydrocortisone 1%, neomycin sulphate 3400 units, polymyxin B sulphate 10 000 units/mL. Net price 5 mL = £2.00; 10 mL = £4.00

Excipients include cetostearyl alcohol, hydroxybenzoates (parabens), polysorbate 20

Dose: ADULT and CHILD over 3 years, ear, apply 3 drops 3–4 times daily

Predsol® (UCB Pharma)

Drops (for ear or eye), prednisolone sodium phosphate 0.5%. Net price 10 mL = £1.92

Excipients include benzenzium chloride, disodium edetate

Dose: ear, apply 2–3 drops every 2–3 hours; reduce frequency when relief obtained; eye, section 11.4.1

Predsol-N® (UCB Pharma)

Drops (for ear or eye), prednisolone sodium phosphate 0.5%, neomycin sulphate 0.5%. Net price 10 mL = £2.27

Excipients include benzalkonium chloride, disodium edetate

Dose: ear, apply 2–3 drops 3–4 times daily; eye, section 11.4.1

Anti-infective preparations

CHLORAMPHENICOL

Indications: bacterial infection in otitis externa (but see notes above)

Cautions: avoid prolonged use (see notes above)

Side-effects: high incidence of sensitivity reactions to vehicle

Chloramphenicol (Non-proprietary) 

Ear drops, chloramphenicol in propylene glycol, net price 5%, 10 mL = £6.22; 10%, 10 mL = £5.62

Dose: ear, apply 2–3 drops 2–3 times daily

CLOQUINOL

Indications: mild bacterial or fungal infections in otitis externa (see notes above)

Cautions: avoid prolonged use (see notes above); manufacturer advises avoid in perforated tympanic membrane (but used by specialists for short periods)

Side-effects: local sensitivity, stains skin and clothing

With corticosteroid

Locoten-Vioform® see Flumetasone, p. 686

CLOTRIMAZOLE

Indications: fungal infection in otitis externa (see notes above)

Side-effects: occasional local irritation or sensitivity

Canesten® (Bayer Consumer Care)

Solution, clotrimazole 1% in polyethylene glycol 400 (macrogol 400). Net price 20 mL = £2.43

Dose: ear, apply 2–3 times daily continuing for at least 14 days after disappearance of infection; skin, section 13.10.2

FRAMYCETIN SULPHATE

Indications: bacterial infection in otitis externa (see notes above)

Cautions: avoid prolonged use (see notes above)

Contra-indications: perforated tympanic membrane (see p. 685)

Side-effects: local sensitivity

GENTAMICIN

Indications: bacterial infection in otitis externa (see notes above)

Cautions: avoid prolonged use (see notes above)

Contra-indications: perforated tympanic membrane (see also p. 685 and section 12.1.2)

Side-effects: local sensitivity

Gentisone® HC see Hydrocortisone, above

GENTAMICIN

Indications: bacterial infection in otitis externa (see notes above)

Cautions: avoid prolonged use (see notes above)

Contra-indications: perforated tympanic membrane

Side-effects: local sensitivity

Gentisone® HC see Hydrocortisone, above

Betnesol-N® see Dexamethasone, p. 686

Otozint® see Dexamethasone, p. 686

Predsol-N® see Prednisolone, above

12.1.2 Otitis media

Acute otitis media

Acute otitis media is the commonest cause of severe aural pain in small children. Many infections, especially those accompanying coryza,
are caused by viruses. Most uncomplicated cases resolve without antibacterial treatment and a simple analgesic, such as paracetamol, may be sufficient. In children without systemic features, a systemic antibacterial (Table 1, section 5.1) may be started after 72 hours if there is no improvement, or earlier if there is deterioration, if the patient is systemically unwell, if the patient is at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis), if mastoiditis is present, or in children under 2 years of age with bilateral otitis media. Perforation of the tympanic membrane in patients with acute otitis media usually heals spontaneously without treatment; if there is no improvement, e.g. pain or discharge persists, a systemic antibacterial (Table 1, section 5.1) can be given. Topical treatment of acute otitis media is ineffective and there is no place for drops containing a local anaesthetic.

Otitis media with effusion Otitis media with effusion (‘glue ear’) occurs in about 10% of children and in 90% of children with cleft palates. Systemic antibacterials are not usually required. If ‘glue ear’ persists for more than a month or two, the child should be referred for assessment and follow up because of the risk of long-term hearing impairment which can delay language development. Untreated or resistant glue ear may be responsible for some types of chronic otitis media.

Chronic otitis media Opportunistic organisms are often present in the debris, keratin, and necrotic bone of the middle ear and mastoid in patients with chronic otitis media. The mainstay of treatment is thorough cleansing with aural microsuction which may completely resolve long-standing infection. Local cleansing of the meatal and middle ear may be followed by treatment with a sponge wick or ribbon gauze dressing soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution; this is particularly beneficial for discharging ears or infections of the mastoid cavity. An antibacterial ear ointment may also be used. Wax can be softened using simple remedies such as olive oil ear drops or almond oil ear drops; sodium bicarbonate ear drops are also effective, but may cause dryness of the ear canal. If the wax is hard and impacted, the drops can be used twice daily for several days and this may reduce the need for mechanical removal of the wax. The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Some proprietary preparations containing organic solvents can irritate the meatal skin, and in most cases the simple remedies indicated above are just as effective and less likely to cause irritation. Docusate sodium or urea–hydrogen peroxide are ingredients in a number of proprietary preparations for softening ear wax.

If necessary, wax may be removed by irrigation with water (warmed to body temperature). Ear irrigation is generally best avoided in young children, in patients unable to co-operate with the procedure, in those with otitis media in the last six weeks, in otitis externa, in patients with cleft palate, a history of ear drum perforation, or previous ear surgery. A person who has hearing in one ear only should not have that ear irrigated because even a very slight risk of damage is unacceptable in this situation.

**Removal of ear wax** Wax is a normal bodily secretion which provides a protective film on the meatal skin and need only be removed if it causes hearing loss or interferes with a proper view of the ear drum.

**Chronic otitis media** Opportunistic organisms are often present in the debris, keratin, and necrotic bone of the middle ear and mastoid in patients with chronic otitis media. The mainstay of treatment is thorough cleansing with aural microsuction which may completely resolve long-standing infection. Local cleansing of the meatal and middle ear may be followed by treatment with a sponge wick or ribbon gauze dressing soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution; this is particularly beneficial for discharging ears or infections of the mastoid cavity. An antibacterial ear ointment may also be used. Acute exacerbations of chronic infection may also require systemic treatment with amoxicillin (or erythromycin if penicillin-allergic); treatment is adjusted according to the results of sensitivity testing. Parenteral antibacterials are required if **Pseudomonas aeruginosa** and **Proteus** sp. are present. Manufacturers contra-indicate topical treatment with ototoxic antibacterials in the presence of a perforation (section 12.1.1). However, many specialists use ear drops containing aminoglycosides (e.g. neomycin) or polynyxins if the otitis media has failed to settle with systemic antibacterials; it is considered that the pus in the middle ear associated with otitis media carries a higher risk of ototoxicity than the drops themselves. Ciprofloxacin or ofloxacin ear drops (both unlicensed; available from ‘special-order’ manufacturers or specialist importing companies, see p. 968) or eye drops used in the ear (unlicensed indication) are an effective alternative to aminoglycoside ear drops for chronic otitis media in patients with perforation of the tympanic membrane.

**Removal of ear wax** Wax is a normal bodily secretion which provides a protective film on the meatal skin and need only be removed if it causes hearing loss or interferes with a proper view of the ear drum.

Wax can be softened using simple remedies such as olive oil ear drops or almond oil ear drops; sodium bicarbonate ear drops are also effective, but may cause dryness of the ear canal. If the wax is hard and impacted, the drops can be used twice daily for several days and this may reduce the need for mechanical removal of the wax. The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Some proprietary preparations containing organic solvents can irritate the meatal skin, and in most cases the simple remedies indicated above are just as effective and less likely to cause irritation. Docusate sodium or urea–hydrogen peroxide are ingredients in a number of proprietary preparations for softening ear wax.

If necessary, wax may be removed by irrigation with water (warmed to body temperature). Ear irrigation is generally best avoided in young children, in patients unable to co-operate with the procedure, in those with otitis media in the last six weeks, in otitis externa, in patients with cleft palate, a history of ear drum perforation, or previous ear surgery. A person who has hearing in one ear only should not have that ear irrigated because even a very slight risk of damage is unacceptable in this situation.

**Removal of ear wax** Wax is a normal bodily secretion which provides a protective film on the meatal skin and need only be removed if it causes hearing loss or interferes with a proper view of the ear drum.
Nasal polyps  Short-term use of corticosteroid nasal drops helps to shrink nasal polyps; to be effective, the drops must be administered with the patient in the ‘head down’ position. A short course of a systemic corticosteroid (section 6.3.2) may be required initially to shrink large polyps. A corticosteroid nasal spray can be used to maintain the reduction in swelling and also for the initial treatment of small polyps.

12.2.1 Drugs used in nasal allergy

Mild allergic rhinitis is controlled by antihistamines (see also section 3.4.1) or topical nasal corticosteroids; systemic nasal decongestants are of doubtful value (section 3.10). Topical nasal decongestants can be used for a short period to relieve congestion and allow penetration of a topical nasal corticosteroid. More persistent symptoms and nasal congestion can be relieved by topical nasal corticosteroids; cromoglicate (cromoglycate) is an alternative, but may be less effective. The topical antihistamine azelastine is useful for controlling breakthrough symptoms in allergic rhinitis. Topical antihistamines are considered less effective than topical corticosteroids but probably more effective than cromoglicate. In seasonal allergic rhinitis (e.g. hay fever), treatment should begin 2 to 3 weeks before the season commences and may have to be continued for several months; continuous treatment may be required for years in perennial rhinitis. Montelukast (section 3.3.2) is less effective than topical nasal corticosteroids; montelukast can be used in patients with seasonal allergic rhinitis and concomitant asthma.

Sometimes allergic rhinitis is accompanied by vaso- motor rhinitis. In this situation, the addition of topical nasal ipratropium bromide (section 6.2.2) can reduce watery rhinorrhea. Very disabling symptoms occasionally justify the use of systemic corticosteroids for short periods (section 6.3), for example, in students taking important examinations. They may also be used at the beginning of a course of treatment with a corticosteroid spray to relieve severe mucosal oedema and allow the spray to penetrate the nasal cavity.

Pregnancy  If a pregnant woman cannot tolerate the symptoms of allergic rhinitis, treatment with nasal beclometasone, budesonide, fluticasone, or sodium cromoglicate may be considered.

Antihistamines

AZELASTINE HYDROCHLORIDE

Indications  allergic rhinitis

Side-effects  irritation of nasal mucosa; bitter taste (if applied incorrectly)

Corticosteroids

Nasal preparations containing corticosteroids (beclometasone, budesonide, flunisolide, fluticasone, mometasone, and triamcinolone) have a useful role in the prophylaxis and treatment of allergic rhinitis (see notes above).

Cautions  Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, and also after nasal surgery (until healing has occurred); they should also be avoided in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids, see section 6.3.2. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.

Side-effects  Local side-effects include dryness, irritation of nose and throat, and epistaxis. Nasal ulceration has been reported, but occurs commonly with nasal preparations containing fluticasone furoate or mometasone furoate. Nasal septal perforation (usually following nasal surgery) occurs very rarely. Raised intra-ocular pressure or glaucoma may occur rarely. Headache, smell and taste disturbances may also occur. Hypersensitivity reactions, including bronchospasm, have been reported.

BECLOMETASONE DIPROPIONATE
(Beclomethasone Dipropionate)

Indications  prophylaxis and treatment of allergic and vaso-motor rhinitis

Cautions  see notes above

Side-effects  see notes above

Dose  • ADULT and CHILD over 6 years, 100 micrograms (2 sprays) into each nostril twice daily; max. total 400 micrograms (8 sprays) daily; when symptoms controlled, dose reduced to 50 micrograms (1 spray) into each nostril twice daily
12.2.1 Drugs used in nasal allergy

**BETAMETHASONE SODIUM PHOSPHATE**

**Indications** non-infected inflammatory conditions of nose

**Cautions** see notes above

**Side-effects** see notes above

**Betnesol** (UCB Pharma) 

**Drops** (for ear, eye, or nose), betamethasone sodium phosphate 0.1%, net price 10 mL = £2.23

**Excipients** include benzalkonium chloride, disodium edetate

**Dose** nose, 2–3 drops into each nostril 2–3 times daily; ear, section 12.1.1; eye, section 11.4.1

**Vistamethasone** (Martindale)

**Drops** (for ear, eye, or nose), betamethasone sodium phosphate 0.1%. Net price 5 mL = £1.02, 10 mL = £1.16

**Excipients** include benzalkonium chloride, disodium edetate

**Dose** nose, 2–3 drops into each nostril twice daily; ear, section 12.1.1; eye, section 11.4.1

**BUDESONIDE**

**Indications** prophylaxis and treatment of allergic rhinitis and perennial rhinitis; nasal polyps

**Cautions** see notes above; **interactions:** Appendix 1 (corticosteroids)

**Side-effects** see notes above

**Dose**

1. See preparations

2. Beudesone (Non-proprietary)

**Nasal spray**, budesonide 100 micrograms/metered spray, net price 100-spray unit = £5.90

**Dose** rhinitis, ADULT and CHILD over 12 years, 200 micrograms (2 sprays) into each nostril once daily in the morning or 100 micrograms (1 spray) into each nostril twice daily; when control achieved reduce to 100 micrograms (1 spray) into each nostril once daily

Nasal polyps, ADULT and CHILD over 12 years, 64 micrograms (1 spray) into each nostril twice daily for up to 3 months

1. Can be sold to the public for nasal administration (other than by aerosol) if supplied for the prevention and treatment of seasonal allergic rhinitis in adults over 18 years subject to max. single dose of 200 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. period of 3 months, and a pack size of 10 mg

**Rhinocort Aqua** (AstraZeneca)

**Nasal spray**, budesonide 64 micrograms/metered spray, net price 120-spray unit = £2.49

**Excipients** include disodium edetate, polysorbate 80, potassium sorbate

**Dose** rhinitis, ADULT and CHILD over 12 years, 128 micrograms (2 sprays) into each nostril once daily in the morning or 64 micrograms (1 spray) into each nostril twice daily; when control achieved reduce to 64 micrograms (1 spray) into each nostril once daily, max. duration of treatment 3 months

Nasal polyps, ADULT and CHILD over 12 years, 64 micrograms (1 spray) into each nostril twice daily for up to 3 months

---

**FLUNISOLIDE**

**Indications** prophylaxis and treatment of allergic rhinitis

**Cautions** see notes above

**Side-effects** see notes above

**Syntaris** (IVAX)

**Aqueous nasal spray**, flunisolide 25 micrograms/metered spray. Net price 240-spray unit with pump and applicator = £5.05

**Excipients** include benzalkonium chloride, butylated hydroxytoluene, disodium edetate, polysorbate 80, propylene glycol

**Dose** ADULT, 50 micrograms (2 sprays) into each nostril twice daily, increased if necessary to max. 3 times daily then reduced for maintenance; CHILD 5–14 years initially 25 micrograms (1 spray) into each nostril up to 3 times daily

**FLUTICASONE PROPIONATE**

**Indications** prophylaxis and treatment of allergic rhinitis and perennial rhinitis; nasal polyps

**Cautions** see notes above; **interactions:** Appendix 1 (corticosteroids)

**Side-effects** see notes above

**Dose**

1. Rhinitis, 100 micrograms (2 sprays) into each nostril once daily, preferably in the morning, increased to max. twice daily if required; when control achieved reduce to 50 micrograms (1 spray) into each nostril once daily; CHILD 4–11 years, 50 micrograms (1 spray) into each nostril once daily, preferably in the morning, increased to max. twice daily if required

2. Nasal polyps, see Flixonase Nasule® below

**Flixonase** (A&H)

**Aqueous nasal spray**, fluticasone propionate 50 micrograms/metered spray. Net price 150-spray unit with applicator = £11.01

**Excipients** include benzalkonium chloride, polysorbate 80

**Note** Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 3 mg

**Flixonase Nasule** (A&H)

**Nasal drops**, fluticasone propionate 400 micrograms/unit dose, net price 28 × 0.4-mL units = £12.99

**Excipients** include polysorbate 20

**Dose** nasal polyps, ADULT and ADOLESCENT over 16 years, 200 micrograms (approx. 6 drops) into each nostril once or twice daily; consider alternative treatment if no improvement after 4–6 weeks

**Nasofan** (IVAX)

**Aqueous nasal spray**, fluticasone propionate 50 micrograms/metered spray. Net price 150-spray unit = £8.41

**Excipients** include benzalkonium chloride, polysorbate 80
Fluticasone furoate

Avamys® (GSK) *(G2)*

**Nasal spray**, fluticasone furoate 27.5 micrograms/metered spray, net price 120-spray unit = £6.44.

**Excipients** include benzalkonium chloride, disodium edetate, polysorbate 80.

**Dose** prophylaxis and treatment of allergic rhinitis, ADULT and CHILD over 12 years, 55 micrograms (2 sprays) into each nostril once daily; when control achieved reduce to minimum effective dose, 27.5 micrograms (1 spray) into each nostril once daily may be sufficient; CHILD 6–12 years, 27.5 micrograms (1 spray) into each nostril once daily, increased if necessary up to 55 micrograms (2 sprays) into each nostril once daily; when control achieved reduce to 27.5 micrograms (1 spray) into each nostril once daily.

Side-effects see notes above.

Cautions prophylaxis and treatment of allergic rhinitis.

Indications see preparations.

Nasonex® (Scherer-Plough) *(G2)*

**Nasal spray**, mometasone furoate 50 micrograms/metered spray. Net price 140-spray unit = £7.68.

**Excipients** include benzalkonium chloride, polysorbate 80.

**Dose** prophylaxis and treatment of allergic rhinitis, ADULT and CHILD over 12 years, 100 micrograms (2 sprays) into each nostril once daily, increased if necessary up to 250 micrograms (4 sprays) into each nostril once daily; when control achieved reduce to 50 micrograms (1 spray) into each nostril once daily; CHILD 6–11 years, 50 micrograms (1 spray) into each nostril once daily.

**Nasal polyps**, ADULT over 18 years, 100 micrograms (2 sprays) into each nostril once daily, increased if necessary after 5–6 weeks to 200 micrograms (2 sprays) into each nostril twice daily (consider alternative treatment if no improvement after further 5–6 weeks); reduce to the lowest effective dose when control achieved.

**Side-effects** see notes above.

**Excipients** include benzalkonium chloride, disodium edetate, polysorbate 80.

**Dose** ADULT and CHILD over 12 years, 110 micrograms (2 sprays) into each nostril once daily; when control achieved, reduce to 55 micrograms (1 spray) into each nostril once daily; CHILD 6–12 years, 55 micrograms (1 spray) into each nostril once daily, increased if necessary to 110 micrograms (2 sprays) into each nostril once daily; when control achieved, reduce to 55 micrograms (1 spray) into each nostril once daily; max. duration of treatment 3 months; CHILD 2–6 years see BNF for Children.

Note Preparations of triamcinolone acetonide can be sold to the public for nasal administration as a non-pressurised nasal spray if supplied for the symptomatic treatment of seasonal allergic rhinitis.

Sodium cromoglicate

**Indications** prophylaxis of allergic rhinitis.

**Side-effects** local irritation; rarely transient bronchospasm.

Sodium cromoglicate

**Indications** prophylaxis of allergic rhinitis.

**Side-effects** local irritation; prophylaxis of allergic rhinitis.

12.2.2 Topical nasal decongestants

Rynacrom® (Sanofi-Aventis)

4% aqueous nasal spray, sodium cromoglicate 4% (5.2 mg/spray). Net price 22 mL (150-spray unit with pump) = £17.07.

**Excipients** include benzalkonium chloride, disodium edetate.

**Dose** ADULT and CHILD, 1 spray into each nostril 2–4 times daily.

Vividrin® (Pharma-Global)

**Nasal spray**, sodium cromoglicate 2%. Net price 15 mL (approx. 110-spray unit) = £11.60.

**Excipients** include benzalkonium chloride, edetic acid, polysorbate 80.

**Dose** ADULT and CHILD, 1 spray into each nostril 4–6 times daily.

12.2.2 Topical nasal decongestants

The nasal mucosa is sensitive to changes in atmospheric temperature and humidity and these alone may cause slight nasal congestion. The nose and nasal sinuses produce a litre of mucus in 24 hours and much of this finds its way silently into the stomach via the nasopharynx. Slight changes in the nasal airway, accompanied by an awareness of mucus passing along the nasopharynx causes some patients to be inaccurately diagnosed as suffering from chronic sinusitis. These symptoms are particularly noticeable in the later stages of the common cold. Sodium chloride 0.9% given as nasal drops or spray may relieve nasal congestion by helping to liquefy mucous secretions.

Inhalation of warm moist air is useful in the treatment of symptoms of acute infective conditions. The addition of volatile substances such as menthol and eucalyptus may encourage the use of warm moist air (section 3.6).

Symptoms of nasal congestion associated with vaso-motor rhinitis and the common cold can be relieved by the short-term use (usually not longer than 7 days) of decongestant nasal drops and sprays. These all contain sympathomimetic drugs which exert their effect by vasoconstriction of the mucosal blood vessels which in turn reduces oedema of the nasal mucosa. They are of limited value because they can give rise to a rebound congestion (rhinitis medicamentosa) on withdrawal, due to a secondary vasodilatation with a subsequent temporary increase in nasal congestion. This in turn tempts the further use of the decongestant, leading to a vicious cycle of events. Ephedrine nasal drops is the safest sympathomimetic preparation and can give relief for several hours. The more potent sympathomimetic drugs oxymetazoline and xylometazoline are more likely to cause a rebound effect. Symptomatemics may cause a hypertensive crisis if used during treatment with a monoamine-oxidase inhibitor including moclobemide.

The CHM/MHRA has stated that non-prescription cough and cold medicines containing ephedrine, oxymetazoline, or xylometazoline can be considered for up to 5 days in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age (section 3.9.1). Non-allergic watery rhinorrhea often responds well to treatment with the antimuscarinic ipratropium bromide.

Systemic nasal decongestants—see section 3.10.

Sinusitis and oral pain Sinusitis affecting the maxillary antrum can cause pain in the upper jaw. Where
this is associated with blockage of the opening from the sinus into the nasal cavity, it may be helpful to relieve the congestion with inhalation of warm moist air (section 3.8) or with epinephrine nasal drops (see above). For antibacterial treatment of sinusitis, see Table 1, section 5.1.

### Sympathomimetics

#### Ephedrine Hydrochloride

**Indications** nasal congestion  
**Cautions** see section 3.1.1.2 and notes above; also avoid excessive or prolonged use; interactions: Appendix 1 (sympathomimetics)  
**Pregnancy** see section 3.1.1.2  
**Breast-feeding** see section 3.1.1.2  
**Side-effects** local irritation, nausea, headache; after excessive use tolerance with diminished effect, rebound congestion; cardiovascular effects also reported  
**Dose**  
- See below

**Ephedrine** (Non-proprietary)  
**Nasal drops**, ephedrine hydrochloride 0.5%, net price 10 mL = £1.39; 1%, 10 mL = £1.63  
**Note** The BF directs that if no strength is specified 0.5% drops should be supplied  
**Dose**  
- **ADULT** and **CHILD** over 12 years, 1–2 drops into each nostril up to 3 or 4 times daily when required, max. duration 7 days; **CHILD** under 12 years see **BNF for Children**  
**Dental prescribing on NHS** Ephedrine nasal drops may be prescribed  
1. Can be sold to the public provided no more than 180 mg of ephedrine base (or salts) are supplied at one time, and pseudoephedrine salts are not supplied at the same time; for conditions that apply to supplies made at the request of a patient, see **Medicines, Ethics and Practice**, No. 34, London, Pharmaceutical Press, 2010 (and subsequent editions)

#### Xylocaine Hydrochloride

**Indications** nasal congestion  
**Cautions** see under Ephedrine Hydrochloride section 3.1.1.2 and notes above; also avoid excessive or prolonged use  
**Pregnancy** manufacturer advises avoid  
**Side-effects** see under Ephedrine Hydrochloride and notes above; in small children, also restlessness, sleep disturbances, and hallucinations (discontinue treatment)  
**Dose**  
- See below

**Xylocaine** (Non-proprietary)  
**Nasal drops**, xylocaine hydrochloride 0.1%, net price 10 mL = £1.91  
**Dose** 2–3 drops into each nostril 2–3 times daily when required; max. duration 7 days; not recommended for children under 12 years  
**Brands include** Otrivine®.  
**Paediatric nasal drops**, xylocaine hydrochloride 0.05%, net price 10 mL = £1.59  
**Dose**  
- **CHILD** 6–12 years 1–2 drops into each nostril 1–2 times daily when required; max. duration 5 days  
**Brands include** Otrivine®, Rinatec®

### Antimuscarinic

#### Ipratropium Bromide

**Indications** rhinorrhea associated with allergic and non-allergic rhinitis  
**Cautions** see section 3.1.2; avoid spraying near eyes  
**Side-effects** epistaxis, nasal dryness, and irritation; less frequently nausea, headache, and pharyngitis; very rarely antimuscarinic effects such as gastrointestinal motility disturbances, palpitations, and urinary retention  
**Dose**  
- **ADULT** and **CHILD** over 12 years, 42 micrograms (2 sprays) into each nostril 2–3 times daily  
**Rinatec®** (Boehringer Ingelheim)  
**Nasal spray 0.03%**, ipratropium bromide 21 micrograms/metered spray. Net price 180-dose unit = £3.99  
**Excipients** include benzalkonium chloride, disodium edetate

### 12.2.3 Nasal preparations for infection

There is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis; for elimination of nasal staphylococci, see below.

Systemic treatment of sinusitis—see Table 1 section 5.1.

#### Betnesol-N®

**Drops** (for ear, eye, or nose), betamethasone sodium phosphate 0.1%, neomycin sulphate 0.5%. Net price 10 mL = £2.30  
**Excipients** include benzalkonium chloride, disodium edetate  
**Dose**  
- **nose** 2–3 drops into each nostril 2–3 times daily; eye, section 11.4.1; ear, section 12.1.1

### Nasal staphylococci

Elimination of organisms such as staphylococci from the nasal vestibule can be achieved by the use of a cream containing chlorhexidine and neomycin (Naseptin®), but re-colonisation frequently occurs. Coagulase-positive staphylococci are present in the noses of 40% of the population. A nasal ointment containing mupirocin is also available; it should probably be held in reserve for resistant cases. In hospital or in care establishments, mupirocin nasal ointment should be reserved for the eradication (in both patients and staff) of nasal carriage of meticillin-resistant Staphylococcus aureus (MRSA). The ointment should be applied 3 times daily for 5 days and a sample taken 2 days after treatment to confirm eradication. The course may be repeated if the sample is positive (and the throat is not colonised). To avoid the development of resistance, the treatment course should not exceed 7 days and the course should not be repeated on more
than one occasion. If the MRSA strain is mupirocin-resistant or does not respond after 2 courses, consider alternative products such as chlorhexidine and neomycin cream.

Bactroban Nasal® (GSK) Nasal ointment, mupirocin 2% (as calcium salt) in white soft paraffin basis. Net price 3 g = £5.80

Dose for eradication of nasal carriage of *Staphylococcus* including meticillin-resistant *Staphylococcus aureus* (MRSA), apply 2–3 times daily to the inner surface of each nostril

Naseptin® (Alliance) Cream, chlorhexidine hydrochloride 0.1%, neomycin sulphate 0.5%, net price 15 g = £1.90

Excipients include arachis (peanut) oil, cetostearyl alcohol

Dose for eradication of nasal carriage of *Staphylococcus* (including MRSA), apply to nostrils twice daily for 10 days; for preventing nasal carriage of *Staphylococcus* (including MRSA), apply to nostrils twice daily

**12.3 Drugs acting on the oropharynx**

**12.3.1 Drugs for oral ulceration and inflammation**

Ulceration of the oral mucosa may be caused by trauma (physical or chemical), recurrent aphthae, infections, carcinoma, dermatological disorders, nutritional deficiencies, gastro-intestinal disease, haematopoietic disorders, and drug therapy (see also Chemotherapy-induced mucositis and myelosuppression, section 8.1). It is important to establish the diagnosis in each case as the majority of these lesions require specific management in addition to local treatment. Local treatment aims to protect the ulcerated area, to relieve pain, to reduce inflammation, or to control secondary infection. Patients with an unexplained mouth ulcer of more than 3 weeks’ duration require urgent referral to hospital to exclude oral cancer.

**Simple mouthwashes** A saline mouthwash (section 12.3.4) may relieve the pain of traumatic ulceration. The mouthwash is made up with warm water and used at frequent intervals until the discomfort and swelling subside.

**Antiseptic mouthwashes** Secondary bacterial infection may be a feature of any mucosal ulceration; it can increase discomfort and delay healing. Use of chlorhexidine mouthwash (section 12.3.4) is often beneficial and may accelerate healing of recurrent aphthae.

**Mechanical protection** Carmellose gelatin paste may relieve some discomfort arising from ulceration by protecting the ulcer site. As the paste adheres to dry mucosa, it is difficult to apply it effectively to the tongue and oropharynx.

**Corticosteroids** Topical corticosteroid therapy may be used for some forms of oral ulceration. In the case of aphthous ulcers it is most effective if applied in the ‘prodromal’ phase.

**Local analgesics** Local analgesics have a limited role in the management of oral ulceration. When applied topically their action is of a relatively short duration so that analgesia cannot be maintained continuously throughout the day. The main indication for a topical local analgesic is to relieve the pain of otherwise intractable oral ulceration particularly when it is due to major aphthae. For this purpose lidocaine 5% ointment or lozenges containing a local anaesthetic are applied to the ulcer. Lidocaine 10% solution as spray (section 15.2) can be applied thinly to the ulcer [unlicensed indication] using a cotton bud. When local anaesthetics are used in the mouth care must be taken not to produce anaesthesia of the pharynx before meals as this might lead to choking.

**Flurbiprofen** lozenges are licensed for the relief of sore throat.

**Choline salicylate** dental gel has some analgesic action and may provide relief for recurrent aphthae, but excessive application or confinement under a denture irritates the mucosa and can itself cause ulceration.

**Other preparations** Doxycycline rinsed in the mouth may be of value for recurrent aphthous ulceration.

**Periodontitis** Low-dose doxycycline (Periostar®) is licensed as an adjunct to scaling and root planing for the treatment of periodontitis; a low dose of doxycycline reduces collagenase activity without inhibiting bacteria associated with periodontitis. For anti-infectives used in the treatment of destructive (refractory) forms of periodontal disease, see section 12.3.2 and Table 1, section 5.1. For mouthwashes used for oral hygiene and plaque inhibition, see section 12.3.4.
12 Ear, nose, and oropharynx

**BENZYMADINE HYDROCHLORIDE**

**Indications** painful inflammatory conditions of oropharynx

**Side-effects** occasional numbness or stinging; rarely hypersensitivity reactions

**Difflam** (3M)

**Oral rinse**, green, benzymadine hydrochloride 0.15%, net price 200 mL (Difflam® Sore Throat Rinse) = £2.50; 300 mL = £4.01

**Dose**
- **ADULT** and **adolescent** over 12 years, rinse or gargle using 15 mL (dilute with an equal volume of water if stinging occurs) every 1½–3 hours as required, usually for not more than 7 days.
- **Dental prescribing on NHS** May be prescribed as Benzymadine Mouthwash 0.15%

**Spray**, benzymadine hydrochloride 0.15%. Net price 30-mL unit = £3.17

**Dose**
- **ADULT** 4–8 sprays onto affected area every 1½–3 hours.
- **CHILD** under 6 years 1 spray per 4 kg body-weight to max. 4 sprays every 1½–3 hours.
- **Dental prescribing on NHS** May be prescribed as Benzymadine Oromucosal Spray 0.15%

**CARMELLOSE SODIUM**

**Indications** mechanical protection of oral and perioral lesions

**Orabase** (Convatec)

**Protective paste** (= oral paste), carmellose sodium 16.7%, pectin 16.7%, gelatin 16.7%, in Plastibase®.

Net price 30 g = £2.02; 100 g = £4.48

**Dose** apply a thin layer when necessary after meals

**Dental prescribing on NHS** May be prescribed as Carmellose Gelatin Paste

**Orabase** (Convatec)

**Powder**, carmellose sodium, pectin, gelatin, equal parts. Net price 25 g = £2.28

**Dose** sprinkle on the affected area

**CORTICOSTEROIDS**

**Indications** oral and perioral lesions

**Contra-indications** untreated oral infection; thrush or other candidal infections

**Side-effects** occasional exacerbation of local infection; thrush or other candidal infections

**Hydrocortisone** (Non-proprietary)

**Micromechanical buccal tablets** (= oromucosal tablets), hydrocortisone 2.5 mg (as sodium succinate).

Net price 20 = £2.03

**Dose**
- **ADULT** and **CHILD** over 12 years, 1 lozenge 4 times daily, allowed to dissolve slowly in the mouth in contact with the ulcer; **CHILD** under 12 years, only on medical advice.
- **Dental prescribing on NHS** May be prescribed as Hydrocortisone Oromucosal Tablets

**Betnesol** (UCB Pharma)

**Soluble tablets**, pink, scored, betamethasone 500 micrograms (as sodium phosphate), net price 100-tab pack = £4.97. Label: 10, steroid card, 13, 21

**Dose** oral ulceration, **[unlicensed indication]** ADULT and **CHILD** over 12 years, 500 micrograms dissolved in 20 mL water and rinsed around the mouth 4 times daily; not to be swallowed

**Dental prescribing on the NHS** May be prescribed as Betamethasone Soluble Tablets 500 micrograms

**DOXYCYCLINE**

**Indications** see preparations; oral herpes (section 12.2.2); other indications (section 5.1.3)

**Cautions** section 5.1.3; monitor for superficial fungal infection, particularly if predisposition to oral candidiasis

**Contra-indications** section 5.1.3

**Hepatic impairment** section 5.1.3

**Renal impairment** section 5.1.3

**Pregnancy** section 5.1.3

**Breast-feeding** section 5.1.3

**Side-effects** section 5.1.3; fungal superinfection

**Dose**
- See preparations

**Note** Doxycycline stains teeth; avoid in children under 12 years of age

**Periostat** (Alliance)

**Tablets**, f/c, doxycycline (as hyclate) 20 mg, net price 56-tab pack = £16.50. Label: 6, 11, 27, counselling, posture

**Dose** periodontitis (as an adjunct to gingival scaling and root planing), 20 mg twice daily for 3 months; **CHILD** under 12 years not recommended

**Counselling Tablets** should be swallowed whole with plenty of fluid (at least 100 mL), while sitting or standing

**Dental prescribing on NHS** May be prescribed as Doxycycline Tablets 20 mg

**LOCAL application**

For recurrent aphthous ulceration, a 100 mg doxycycline dispersible tablet can be stirred into a small amount of water then rinsed around the mouth for 2–3 minutes 4 times daily usually for 3 days; it should preferably not be swallowed **[unlicensed indication]**.

**FLURBIPROFEN**

**Indications** relief of sore throat

**Cautions** section 10.1.1

**Contra-indications** section 10.1.1

**Hepatic impairment** section 10.1.1

**Renal impairment** section 10.1.1

**Pregnancy** section 10.1.1

**Breast-feeding** section 10.1.1

**Side-effects** taste disturbance, mouth ulcers (move lozenge around mouth); see also section 10.1.1

**Strelen** (Reckitt Benckiser)

**Lozenges**, flurbiprofen 8.75 mg, net price 16 = £2.24

**Dose**
- **ADULT** and **CHILD** over 12 years, allow 1 lozenge to dissolve slowly in the mouth every 3–6 hours, max. 5 lozenges in 24 hours, for max. 3 days

**LOCAL ANAESTHETICS**

**Indications** relief of pain in oral lesions

**Cautions** avoid prolonged use; hypersensitivity; avoid anaesthesia of the pharynx before meals—risk of choking

**Hepatic impairment** see Lidocaine section 15.2

**Renal impairment** see Lidocaine section 15.2

**Pregnancy** see Lidocaine section 15.2

**Breast-feeding** see Lidocaine section 15.2

**Lidocaine** (Non-proprietary)

**Ointment**, lidocaine 5% in a water-miscible basis, net price 15 g = 80p

**Dose** rub sparingly and gently on affected areas

**Dental prescribing on NHS** Lidocaine 5% Ointment may be prescribed
Xylocaine® (Astra Zeneca)
Spray (pump spray): lidocaine 10% (100 mg/g) supplying 10 mg lidocaine/spray; 500 spray doses per container. Net price 50-mL bottle = £3.13
Dose apply thinly to the ulcer (unlicensed indication) using a cotton bud
Dental prescribing on NHS May be prescribed as Lidocaine Spray 10%

Preparations on sale to the public
Many mouth ulcer preparations, throat lozenges, and throat sprays on sale to the public contain a local anaesthetic. To identify the active ingredients in such preparations, consult the product literature of the manufacturer.

Note The correct proprietary name should be ascertained—many products have very similar names but different active ingredients

SALICYLATES
Indications mild oral and perioral lesions
Cautions not to be applied to dentures—leave at least 30 minutes before re-insertion of dentures; frequent application, especially in children, may give rise to salicylate poisoning
Contra-indications children under 16 years
Reye's syndrome The CHM has advised that topical oral pain relief products containing salicylate salts should not be used in children under 16 years, as a cautionsary measure due to the theoretical risk of Reye's syndrome

Choline salicylate
Choline Salicylate Dental Gel, BP
Oral gel, choline salicylate 8.7% in a flavoured gel basis, net price 15 g = £1.89
Brands include Bozole® (sugar-free)
Dose ADULT and CHILD over 16 years, apply ½-inch of gel with gentle massage not more often than every 3 hours
Dental prescribing on NHS Choline Salicylate Dental Gel may be prescribed

Salicylic acid
Pyralvex® (Norgine)
Oral paint, brown, rhubarb extract (anthraquinone glycosides 0.5%), salicylic acid 1%. Net price 10 mL with brush = £3.25
Dose ADULT and CHILD over 16 years, apply 3–4 times daily

Oropharyngeal anti-infective drugs

The most common cause of a sore throat is a viral infection which does not benefit from anti-infective treatment. Streptococcal sore throats require systemic penicillin therapy (Table 1, section 5.1). Acute ulcerative gingivitis (Vincent's infection) responds to systemic metronidazole (section 5.1.11).
Preparations administered in the dental surgery for the local treatment of periodontal disease include gels of metronidazole (Elyzol® Colgate-Palmolive) and of minocycline (Dentomycin®, Blackwell).

Oropharyngeal fungal infections

Fungal infections of the mouth are usually caused by Candida spp. (candidiasis or candidosis). Different types of oropharyngeal candidiasis are managed as follows:

Thrush Acute pseudomembranous candidiasis (thrust), is usually an acute infection but it may persist for months in patients receiving inhaled corticosteroids, cytotoxics or broad-spectrum antibacterials. Thrush also occurs in patients with serious systemic disease associated with reduced immunity such as leukaemia, other malignancies, and HIV infection. Any predisposing condition should be managed appropriately. When thrush is associated with corticosteroid inhalers, rinsing the mouth with water (or cleaning a child's teeth) immediately after using the inhaler may avoid the problem. Treatment with nystatin or miconazole may be needed. Fluconazole (section 5.2.1) is effective for unresponsive infections or if a topical antifungal drug cannot be used or if the patient has dry mouth. Topical therapy may not be adequate in immunocompromised patients and an oral triazole antifungal is preferred (section 5.2.1).

Acute erythematous candidiasis Acute erythematous (atrophic) candidiasis is a relatively uncommon condition associated with corticosteroid and broad-spectrum antibacterial use and with HIV disease. It is usually treated with fluconazole (section 5.2.1).

Denture stomatitis Patients with denture stomatitis (chronic atrophic candidiasis), should cleanse their dentures thoroughly and leave them out as often as possible during the treatment period. To prevent recurrence of the problem, dentures should not normally be worn at night. New dentures may be required if these measures fail despite good compliance.

Miconazole oral gel can be applied to the fitting surface of the denture before insertion (for short periods only). Denture stomatitis is not always associated with candidiasis and other factors such as mechanical or chemical irritation, bacterial infection, or rarely allergy to the denture base material, may be the cause.

Chronic hyperplastic candidiasis Chronic hyperplastic candidiasis (candidal leucoplaikia) carries an increased risk of malignancy; biopsy is essential—this type of candidiasis may be associated with varying degrees of dysplasia, with oral cancer present in a high proportion of cases. Chronic hyperplastic candidiasis is treated with a systemic antifungal such as fluconazole (section 5.2.1) to eliminate candidial over-lay. Patients should avoid the use of tobacco.

Angular cheilitis Angular cheilitis (angular stomatitis) is characterised by soreness, erythema and fissuring at the angles of the mouth. It is commonly associated with denture stomatitis but may represent a nutritional deficiency or it may be related to orofacial granulomatosis or HIV infection. Both yeasts (Candida spp.) and bacteria (Staphylococcus aureus and beta-haemolytic streptococci) are commonly involved as interacting, infective factors. A reduction in facial height related to ageing and tooth loss with maceration in the deep occlusive folds that may subsequently arise, predisposes to such infection. While the underlying cause is being identified and treated, it is often helpful to apply micon-
azole cream (see p. 737) or sodium fusidate ointment (see p. 735); if the angular cheilitis is unresponsive to treatment, miconazole and hydrocortisone cream or ointment (see p. 707) can be used.

Immunocompromised patients For advice on prevention of fungal infections in immunocompromised patients see p. 374.

Drugs used in oropharyngeal candidiasis Nystatin is not absorbed from the gastro-intestinal tract and is applied locally (as a suspension) to the mouth for treating local fungal infections. Miconazole is applied locally (as an oral gel) in the mouth but it is absorbed to the extent that potential interactions need to be considered. Miconazole also has some activity against Gram-positive bacteria including streptococci and staphylococci. Fluconazole (section 5.2.1) is given by mouth for infections that do not respond to topical therapy or where topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole (section 5.2.1) can be used for fluconazole-resistant infections. If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anticandidal therapy; the patient’s partner may also require treatment to prevent reinfection.

For the role of antisepic mouthwashes in the prevention of oral candidiasis in immunocompromised patients and treatment of denture stomatitis, see section 12.3.4.

**MICONAZOLE**

**Indications** see preparations

**Caution** avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (antifungals, imidazole)

**Contra-indications** with oral gel, impaired swallowing reflex in infants, first 5–6 months of life of an infant born preterm

**Hepatic impairment** avoid

**Pregnancy** manufacturer advises avoid if possible—toxicity at high doses in animal studies

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** nausea, vomiting; rash; with buccal tablets, abdominal pain, including streptococci and staphylococci. Fluconazole (section 5.2.1) is given by mouth for infections that do not respond to topical therapy or when topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole (section 5.2.1) can be used for fluconazole-resistant infections. If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anticandidal therapy; the patient’s partner may also require treatment to prevent reinfection.

For the role of antisepic mouthwashes in the prevention of oral candidiasis in immunocompromised patients and treatment of denture stomatitis, see section 12.3.4.

**Dose**

- see preparations

Daktarim® (Janssen-Cilag)

**Oral gel** sugar-free, orange-flavoured, miconazole 24 mg/mL (20 mg/g). Net price 15-g tube = £2.85, 80-g tube = £4.38. Label: 9, counselling, hold in mouth, after food

**Dose** prevention and treatment of oral and intestinal fungal infections, 5–10 mL in the mouth after food 4 times daily, retained near oral lesions before swallowing. CHILD 4 months–2 years 2.5 mL twice daily; smeared around the mouth, 2–6 years 5 mL.

azole cream (see p. 737) or sodium fusidate ointment (see p. 735); if the angular cheilitis is unresponsive to treatment, miconazole and hydrocortisone cream or ointment (see p. 707) can be used.

**Immunocompromised patients** For advice on prevention of fungal infections in immunocompromised patients see p. 374.

**Drugs used in oropharyngeal candidiasis** Nystatin is not absorbed from the gastro-intestinal tract and is applied locally (as a suspension) to the mouth for treating local fungal infections. Miconazole is applied locally (as an oral gel) in the mouth but it is absorbed to the extent that potential interactions need to be considered. Miconazole also has some activity against Gram-positive bacteria including streptococci and staphylococci. Fluconazole (section 5.2.1) is given by mouth for infections that do not respond to topical therapy or when topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole (section 5.2.1) can be used for fluconazole-resistant infections. If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anticandidal therapy; the patient’s partner may also require treatment to prevent reinfection.

For the role of antisepic mouthwashes in the prevention of oral candidiasis in immunocompromised patients and treatment of denture stomatitis, see section 12.3.4.

**MICONAZOLE**

**Indications** see preparations

**Caution** avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (antifungals, imidazole)

**Contra-indications** with oral gel, impaired swallowing reflex in infants, first 5–6 months of life of an infant born preterm

**Hepatic impairment** avoid

**Pregnancy** manufacturer advises avoid if possible—toxicity at high doses in animal studies

**Breast-feeding** manufacturer advises caution—no information available

**Side-effects** nausea, vomiting; rash; with buccal tablets, abdominal pain, including streptococci and staphylococci. Fluconazole (section 5.2.1) is given by mouth for infections that do not respond to topical therapy or when topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole (section 5.2.1) can be used for fluconazole-resistant infections. If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anticandidal therapy; the patient’s partner may also require treatment to prevent reinfection.

For the role of antisepic mouthwashes in the prevention of oral candidiasis in immunocompromised patients and treatment of denture stomatitis, see section 12.3.4.

**Dose**

- see preparations

Daktarim® (Janssen-Cilag)

**Oral gel** sugar-free, orange-flavoured, miconazole 24 mg/mL (20 mg/g). Net price 15-g tube = £2.85, 80-g tube = £4.38. Label: 9, counselling, hold in mouth, after food

**Dose** prevention and treatment of oral and intestinal fungal infections, 5–10 mL in the mouth after food 4 times daily, retained near oral lesions before swallowing. CHILD 4 months–2 years 2.5 mL twice daily; smeared around the mouth, 2–6 years 5 mL.
12.3.3 Lozenges and sprays

There is no convincing evidence that antiseptic lozenges and sprays have a beneficial action and they sometimes irritate and cause sore tongue and sore lips. Some of these preparations also contain local anaesthetics which relieve pain but may cause sensitisation.

12.3.4 Mouthwashes, gargles, and dentifrices

Superficial infections of the mouth are often helped by warm mouthwashes which have a mechanical cleansing effect and cause some local hyperaemia. However, to be effective, they must be used frequently and vigorously. A warm saline mouthwash is ideal and can be prepared either by dissolving half a teaspoonful of salt in a glassful of warm water or by diluting compound sodium chlor-ide mouthwash with an equal volume of warm water. Mouthwash solution-tablets are used to remove unpleasant tastes.

Mouthwashes containing an oxidising agent, such as hydrogen peroxide, may be useful in the treatment of acute ulcerative gingivitis (Vincent’s infection) since the organisms involved are anaerobes. It also has a mechanical cleansing effect arising from frothing when in contact with oral debris.

Chlorhexidine is an effective antiseptic which has the advantage of inhibiting plaque formation on the teeth. It does not, however, completely control plaque deposition and is not a substitute for effective toothbrushing. Moreover, chlorhexidine preparations do not penetrate significantly into stagnation areas and are therefore of little value in the control of dental caries or of periodontal disease once pocketing has developed. Chlorhexidine mouthwash is used in the treatment of denture stomatitis. It is also used in the prevention of oral candidiasis in immunocompromised patients. Chlorhexidine mouthwash reduces the incidence of alveolar osteitis following tooth extraction. Chlorhexidine mouthwash should not be used for the prevention of endocarditis in patients undergoing dental procedures.

Chlorhexidine can be used as a mouthwash, spray or gel for secondary infection in mucosal ulceration and for controlling gingivitis, as an adjunct to other oral hygiene measures. These preparations may also be used instead of toothbrushing where there is a painful periodontal condition (e.g. primary herpetic stomatitis) or if the patient has a haemorrhagic disorder, or is disabled. Chlorhexidine preparations are of little value in the control of acute necrotising ulcerative gingivitis.

There is no convincing evidence that gargles are effective.

CHLORHEXIDINE GLUCONATE

Indications see under preparations below

Side-effects mucosal irritation (if desquamation occurs, discontinue treatment or dilute mouthwash with an equal volume of water); taste disturbance; reversible brown staining of teeth, and of silicate or composite restorations; tongue discoloration; parotid gland swelling reported

Note Chlorhexidine gluconate may be incompatible with some ingredients in toothpaste, leave an interval of at least 30 minutes between using mouthwash and toothpaste

Chlorhexidine (Non-proprietary)

Mouthwash, chlorhexidine gluconate 0.2%, net price 300 mL = £2.51

Dose oral hygine and plaque inhibition, oral candidiasis, gingivitis, and management of aphthous ulcers, rinse mouth with 10 mL for about 1 minute twice daily

Denture stomatitis, cleanse and soak dentures in mouthwash solution for 15 minutes twice daily

Dental prescribing on NHS Chlorhexidine Mouthwash may be prescribed

Corsodyl® (GSK Consumer Healthcare)

Dental gel, chlorhexidine gluconate 1%. Net price 50 g = £1.21

Dose oral hygine and plaque inhibition and gingivitis, brush on the teeth once or twice daily

Oral candidiasis and management of aphthous ulcers, apply to affected areas once or twice daily

Dental prescribing on NHS May be prescribed as Chlorhexidine Gluconate Gel

Mouthwash, chlorhexidine gluconate 0.2%. Net price 300 mL (original or mint) = £2.18, 600 mL (mint) = £3.85

Dose oral hygine and plaque inhibition, oral candidiasis, gingivitis, and management of aphthous ulcers, rinse mouth with 10 mL for about 1 minute twice daily

Denture stomatitis, cleanse and soak dentures in mouthwash solution for 15 minutes twice daily

Oral spray, chlorhexidine gluconate 0.2% (mint-flavoured). Net price 60 mL = £4.10

Dose oral hygine and plaque inhibition, oral candidiasis, gingivitis, and management of aphthous ulcers, apply as required to tooth, gingival, or ulcer surfaces using up to 12 actuations (approx 0.14 mL/actuation) twice daily

Dental prescribing on NHS May be prescribed as Chlorhexidine Oral Spray

Periogard® (Colgate-Palmolive)

Oromucosal solution, alcohol-free, chlorhexidine gluconate 0.2%, net price 300 mL = £1.96

Dose short-term treatment of inflammation of gingival and oral mucosa, ADULT and CHILD over 6 years, rinse mouth with 10 mL for about 1 minute twice daily

Dental prescribing on NHS May be prescribed as Chlorhexidine Oromucosal Solution, Alcohol-free, 0.2%

With chlorobutanol

Eludril® (Fabre)

Mouthwash or gargle, chlorhexidine gluconate 0.1%, chlorobutanol 0.5% (mint-flavoured), net price 90 mL = £1.36, 250 mL = £2.83, 500 mL = £5.06

Dose oral hygiene and plaque inhibition, use 10–15 mL (diluted with warm water in measuring cup provided) 2–3 times daily

Denture dissection, soak previously cleansed dentures in mouthwash (diluted with 2 volumes of water) for 60 minutes

HEXETIDINE

Indications oral hygiene

Side-effects local irritation; very rarely taste disturbance and transient anaesthesia

Oraldene® (McNeil)

Mouthwash or gargle, red or blue-green (mint-flavoured), hexetidine 0.1%. Net price 100 mL = £1.31; 200 mL = £2.02

Dose ADULT and CHILD over 6 years, use 15 mL, undiluted 2–3 times daily

HYDROGEN PEROXIDE

Indications oral hygiene, see notes above

Side-effects hypertherpy of papillae of tongue on prolonged use
12.3.5 Treatment of dry mouth

Hydrogen Peroxide Mouthwash, BP

Mouthwash, consists of Hydrogen Peroxide Solution 6% (= approx. 20 volume) BP

Dose rinse the mouth for 2–3 minutes with 15 mL diluted in half a tablespoonful of warm water 2–3 times daily

Dental prescribing on NHS Hydrogen Peroxide Mouthwash may be prescribed

Peroxyl® (Colgate-Palmolive)

Mouthwash, hydrogen peroxide 1.5%, net price 300 mL = £2.54

Dose rinse the mouth with 10 mL for about 1 minute up to 4 times daily (after meals and at bedtime)

SODIUM CHLORIDE

Indications oral hygiene, see notes above

Sodium Chloride Mouthwash, Compound, BP

Mouthwash, sodium bicarbonate 1%, sodium chloride 1.5% in a suitable vehicle with a peppermint flavour.

Dose extemporaneous preparations should be prepared according to the following formula: sodium chloride 1.5 g, sodium bicarbonate 1 g, concentrated peppermint emulsion 2.5 mL, double-strength chloroform water 50 mL, water to 100 mL.

To be diluted with an equal volume of warm water

Dental prescribing on NHS Compound Sodium Chloride Mouthwash may be prescribed

THYMOL

Indications oral hygiene, see notes above

Mouthwash Solution-tablets

Consist of tablets which may contain antimicrobial, colouring, and flavouring agents in a suitable soluble effervescent basis to make a mouthwash suitable for dental purposes. Net price 100-tab pack = £15.09

Dose dissolve 1 tablet in a tablespoonful of warm water

Note Mouthwash solution tablets may contain ingredients such as thymol

Dental prescribing on NHS Mouthwash Solution-tablets may be prescribed

Local treatment

AS Saliva Orthana® (AS Pharma)

Oral spray, gastric mucin (porcine) 3.5%, xylitol 2%, sodium fluoride 4.2 mg/litre, with preservatives and flavouring agents, pH neutral. Net price 50-mL bottle = £4.92; 450-mL refill = £34.27

Dose ACBS: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome, spray 2–3 times onto oral and pharyngeal mucosa, when required

Dental prescribing on NHS AS Saliva Orthana® Oral Spray may be prescribed

Lozenges, mucin 65 mg, xylitol 59 mg, in a sorbitol basis, pH neutral. Net price 30-lozenge pack = £3.50

Dose ACBS: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome

Note AS Saliva Orthana® lozenges do not contain fluoride

Dental prescribing on NHS AS Saliva Orthana® Lozenges may be prescribed

Biotine Oralbalance® (GSK)

Saliva replacement gel, lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis, net price 50-g tube = £4.10, 24 × 12.4-mL tube = £30.40 (for hospital use)

Dose ACBS: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome, apply to gums and tongue as required

Note Avoid use with toothpastes containing detergents (including foam agents)

Dental prescribing on NHS Biotine Oralbalance® Saliva Replacement Gel may be prescribed

BioXtra® (RIS Products)

Gel, lactoperoxidase, lactoferrin, lysozyme, whey colostrum, xylitol and other ingredients, net price 40-mL tube = £3.94, 50-mL spray = £3.94

Dose ACBS: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome, apply to oral mucosa as required

Dental prescribing on NHS BioXtra® Gel may be prescribed

Glandosane® (Fresenius Kabi)

Aerosol spray, carmellose sodium 500 mg, sorbitol 1.5 g, potassium chloride 60 mg, sodium chloride 42.2 mg, magnesium chloride 2.6 mg, calcium chloride 7.3 mg, and dipotassium hydrogen phosphate 17.1 mg/50 g, pH 5.75. Net price 50-mL unit (neutral, lemon or peppermint flavoured) = £4.62

Dose ACBS: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome, spray onto oral and pharyngeal mucosa as required

Dental prescribing on NHS Glandosane® Aerosol Spray may be prescribed

12.3.5 Treatment of dry mouth

Dry mouth (xerostomia) may be caused by drugs with antimuscarinic (anticholinergic) side-effects (e.g. antispasmodics, tricyclic antidepressants, and some anti-psychotics), by diuretics, by irradiation of the head and neck region or by damage to or disease of the salivary glands. Patients with a persistently dry mouth may develop a burning or scalded sensation and have poor oral hygiene, they may develop increased dental caries, periodontal disease, intolerance of dentures, and oral infections (particularly candidiasis). Dry mouth may be relieved in many patients by simple measures such as frequent sips of cool drinks or sucking pieces of ice or sugar-free fruit pastilles. Sugar-free chewing gum stimulates salivation in patients with residual salivary function.

Artificial saliva can provide useful relief of dry mouth. A properly balanced artificial saliva should be of a neutral pH and contain electrolytes (including fluoride) to correspond approximately to the composition of saliva. The acidic pH of some artificial saliva products may be inappropriate. Of the proprietary preparations, Salinum® or Xerolit® can be used for any condition giving rise to a dry mouth. Biotine Oralbalance®, BioXtra®, Glandosane®, Saliva Orthana®, and Salivex®, have ACBS approval for dry mouth associated only with radiotherapy or sicca syndrome. Salivex® pastilles, which act locally as salivary stimulants, are also available and have similar ACBS approval. SST tablets may be prescribed for dry mouth in patients with salivary gland impairment (and patent salivary ducts).

Pilocarpine tablets are licensed for the treatment of xerostomia following irradiation for head and neck cancer and for dry mouth and dry eyes (xerophthalmia) in Sjögren’s syndrome. They are effective only in patients who have some residual salivary gland function, and therefore should be withdrawn if there is no response.
PILOCARPINE HYDROCHLORIDE

**Indications**  xerostomia following irradiation for head and neck cancer (see also notes above); dry mouth and dry eyes in Sjögren’s syndrome

**Cautions**  asthma and chronic obstructive pulmonary disease (avoid if uncontrolled, see Contra-indications), cardiovascular disease (avoid if uncontrolled); cholelithiasis or biliary-tract disease, peptic ulcer, risk of increased urethral smooth muscle tone and renal colic; maintain adequate fluid intake to avoid dehydration associated with excessive sweating; cognitive or psychiatric disturbances; susceptibility to angle-closure glaucoma; **interactions:** Appendix 1 (parasympathomimetics)

**Counselling**  Blurred vision or dizziness may affect performance of skilled tasks (e.g. driving) particularly at night or in reduced lighting

**Contra-indications**  uncontrolled asthma and chronic obstructive pulmonary disease (increased bronchial secretions and increased airways resistance); uncontrolled cardiorenal disease; acute iritis

**Pregnancy**  avoid—smooth muscle stimulant; toxicity in animal studies

**Breast-feeding**  manufacturer advises avoid—present in milk in animal studies

**Side-effects**  dyspepsia, diarrhoea, abdominal pain, nausea, vomiting, constipation; flushing, hypotension, palpitation, headache, dizziness, asthma, influenza-like symptoms, sweating; increased urinary frequency; visual disturbances, lacrimation, ocular pain, conjunctivitis; rhinitis; rash, pruritus; less commonly: flushing, urinary urgency

**Dose**  • Xerostomia following irradiation for head and neck cancer, 5 mg 3 times daily with or immediately after meals (last dose always with evening meal); if tolerated but response insufficient after 4 weeks, may be increased to max. 30 mg daily in divided doses; max. therapeutic effect normally within 4–8 weeks; discontinue if no improvement after 2–3 months; **CHILD** not recommended

• Dry mouth and dry eyes in Sjögren’s syndrome, 5 mg 4 times daily (with meals and at bedtime); if tolerated but response insufficient, may be increased to max. 30 mg daily in divided doses; discontinue if no improvement after 2–3 months; **CHILD** not recommended

**Salagen®**  **(Novartis)**

**Tablets**, f/c, pilocarpine hydrochloride 5 mg. Net price 84-tab pack = £41.14. Label: 21, 27. counselling, driving
13 Skin

13.1 Management of skin conditions

13.1.1 Vehicles 700

13.1.2 Suitable quantities for prescribing 701

13.1.3 Excipients and sensitisation 701

13.2 Emollient and barrier preparations 701

13.2.1 Emollients 701

13.2.1.1 Emollient bath additives and shower preparations 704

13.2.2 Barrier preparations 705

13.3 Topical local anaesthetics and antipruritics 706

13.4 Topical corticosteroids 707

13.5 Preparations for eczema and psoriasis 714

13.5.1 Preparations for eczema 714

13.5.2 Preparations for psoriasis 715

13.5.3 Drugs affecting the immune response 720

13.6 Acne and rosacea 724

13.6.1 Topical preparations for acne 724

13.6.2 Oral preparations for acne 727

13.7 Preparations for warts and calluses 729

13.8 Sunscreens and camouflagers 730

13.8.1 Sunscreen preparations 730

13.8.2 Camouflagers 732

13.9 Shampoos and other preparations for scalp and hair conditions 732

13.10 Anti-infective skin preparations 734

13.10.1 Antimicrobial preparations 734

13.10.1.1 Antimicrobial preparations only used topically 734

13.10.1.2 Antimicrobial preparations also used systemically 735

13.10.2 Antifungal preparations 736

13.10.3 Antiviral preparations 739

13.10.4 Parasiticidal preparations 740

13.10.5 Preparations for minor cuts and abrasions 742

13.11 Skin cleansers, antiseptics, and preparations for promotion of wound healing 742

13.11.1 Alcohols and saline 742

13.11.2 Chlorhexidine salts 743

13.11.3 Cationic surfactants and soaps 744

13.11.4 Iodine 744

13.11.5 Phenolics 744

13.11.6 Oxidisers and dyes 744

13.11.7 Preparations for promotion of wound healing 744

13.12 Antiperspirants 745

13.13 Topical circulatory preparations 745

This chapter also includes advice on the drug management of the following:
- candidiasis, p. 737
- crab lice, p. 740
- dermatophytoses, p. 736
- head lice, p. 740
- hirsutism, p. 733
- nappy rash, p. 705
- photodamage, p. 731
- pityriasis versicolor, p. 736
- scabies, p. 740

For information on wound management products and elastic hosiery see Appendix 8, p. 935.

The British Association of Dermatologists list of preferred unlicensed dermatological preparations (specials) is available at http://www.bad.org.uk/site/495/default.aspx

13.1 Management of skin conditions

13.1.1 Vehicles

Both vehicle and active ingredients are important in the treatment of skin conditions; the vehicle alone may have more than a mere placebo effect. The vehicle affects the degree of hydration of the skin, has a mild anti-inflammatory effect, and aids the penetration of active drug.

Applications are usually viscous solutions, emulsions, or suspensions for application to the skin (including the scalp) or nails.

Collodions are painted on the skin and allowed to dry to leave a flexible film over the site of application.

Creams are emulsions of oil and water and are generally well absorbed into the skin. They may contain an antimicrobial preservative unless the active ingredient or basis is intrinsically bactericidal and fungicidal. Generally, creams are cosmetically more acceptable than ointments because they are less greasy and easier to apply.
Gels consist of active ingredients in suitable hydrophilic or hydrophobic bases; they generally have a high water content. Gels are particularly suitable for application to the face and scalp.

Lotions have a cooling effect and may be preferred to ointments or creams for application over a hairy area. Lotions in alcoholic basis can sting if used on broken skin. 

Ointments are greasy preparations which are normally anhydrous and insoluble in water, and are more occlusive than creams. They are particularly suitable for chronic, dry lesions. The most commonly used ointment bases consist of soft paraffin or a combination of soft, liquid and hard paraffin. Some ointment bases have both hydrophilic and lipophilic properties; they may have occlusive properties on the skin surface, encourage hydration, and also be miscible with water; they often have a mild anti-inflammatory effect. Water-soluble ointments contain macrogols which are freely soluble in water and are therefore readily washed off; they have a limited but useful role where ready removal is desirable.

Pastes are stiff preparations containing a high proportion of finely powdered solids such as zinc oxide and starch suspended in an ointment. They are used for circumscribed lesions such as those which occur in lichen simplex, chronic eczema, or psoriasis. They are less occlusive than ointments and can be used to protect inflamed, lichenified, or excoriated skin.

Dusting powders are used only rarely. They reduce friction between opposing skin surfaces. Dusting powders should not be applied to moist areas because they can cake and abrade the skin. Talc is a lubricant but it does not absorb moisture; it can cause respiratory irritation. Starch is less lubricant but absorbs water.

Dilution
The BP directs that creams and ointments should not normally be diluted but that should dilution be necessary care should be taken, in particular, to prevent microbial contamination. The appropriate diluent should be used and heating should be avoided during mixing; excessive dilution may affect the stability of some creams. Diluted creams should normally be used within 2 weeks of preparation.

### 13.1.2 Suitable quantities for prescribing

<table>
<thead>
<tr>
<th>Area of the Body</th>
<th>Creams and Ointments</th>
<th>Lotions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face</td>
<td>15–30 g</td>
<td>100 mL</td>
</tr>
<tr>
<td>Both hands</td>
<td>25–50 g</td>
<td>200 mL</td>
</tr>
<tr>
<td>Scalp</td>
<td>50–100 g</td>
<td>200 mL</td>
</tr>
<tr>
<td>Both arms or both legs</td>
<td>100–200 g</td>
<td>200 mL</td>
</tr>
<tr>
<td>Trunk</td>
<td>400 g</td>
<td>500 mL</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15–25 g</td>
<td>100 mL</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for twice daily application for 1 week. The recommendations do not apply to corticosteroid preparations—for suitable quantities of corticosteroid preparations see section 13.4.

### 13.1.3 Excipients and sensitisation

Excipients in topical products rarely cause problems. If a patch test indicates allergy to an excipient, products containing the substance should be avoided (see also Anaphylaxis, p. 197). The following excipients in topical preparations are rarely associated with sensitisation; the presence of these excipients is indicated in the entries for topical products. See also Excipients, under General Guidance, p. 2.

- Beeswax
- Benzyl alcohol
- Butylated hydroxyanisole
- Butylated hydroxytoluene
- Cetostearyl alcohol (including cetyl and stearyl alcohol)
- Chlorocresol
- Edetic acid (EDTA)
- Ethylenediamine
- Fragrances
- Hydroxybenzoates (parabens)
- Imidurea
- Isopropyl palmitate
- N-(3-Chloroallyl)hexamethylenimine chloride (quaternium 15)
- Polysorbates
- Propylene glycol
- Sodium metabisulphite
- Sorbic acid
- Wool fat and related substances including lanolin

1. Purified versions of wool fat have reduced the problem

### 13.2 Emollient and barrier preparations

#### 13.2.1 Emollients

Emollients soothe, smooth and hydrate the skin and are indicated for all dry or scaling disorders. Their effects are short-lived and they should be applied frequently even after improvement occurs. They are useful in dry and eczematous disorders, and to a lesser extent in psoriasis (section 13.5.2). The choice of an appropriate emollient will depend on the severity of the condition, patient preference, and the site of application. Emollients should be applied in the direction of hair growth. Ointments may exacerbate acne and folliculitis. Some ingredients rarely cause sensitisation (section 13.1.3) and this should be suspected if an eczematous reaction
13.2.1 Emollients

Occur. The use of aqueous cream as a leave-on emollient may increase the risk of skin reactions, particularly in eczema.

### Fire hazard with paraffin-based emollients

Emulsifying ointment or 50% Liquid Paraffin and 50% White Soft Paraffin Ointment in contact with dressings and clothing is easily ignited by a naked flame. The risk is greater when these preparations are applied to large areas of the body, and clothing or dressings become soaked with the ointment. Patients should be told to keep away from fire or flames, and not to smoke when using these preparations. The risk of fire should be considered when using large quantities of any paraffin-based emollient.

Preparations such as aqueous cream and emulsifying ointment can be used as soap substitutes for hand washing and in the bath; the preparation is rubbed on the skin before rinsing off completely. The addition of a bath oil (section 13.2.1.1) may also be helpful.

Preparations containing an antibacterial (section 13.10) should be avoided unless infection is present or is a frequent complication.

Urea is a hydrating agent used in the treatment of dry, scaling conditions (including ichthyosis) and may be useful in elderly patients. It is occasionally used with other topical agents such as corticosteroids to enhance penetration of the skin.

#### Non-proprietary emollient preparations

**Aqueous Cream, BP**

Cream, emulsifying ointment 30%, phenoxethanol 1% in freshly boiled and cooled purified water, net price 100 g = £1.51, 500 g = £1.86

Excipients include cetostearyl alcohol

1. The BP permits use of alternative antimicrobials provided their identity and concentration are stated on the label.

**Emulsifying Ointment, BP**

Ointment, emulsifying wax 30%, white soft paraffin 50%, liquid paraffin 20%, net price 500 g = £2.22

Excipients include cetostearyl alcohol

**Hydrous Ointment, BP**

Ointment, oily cream, dried magnesium sulphate 0.5%, phenoxethanol 1%, wool alcohols ointment 50%, in freshly boiled and cooled purified water, net price 500 g = £2.92

**Liquid and White Soft Paraffin Ointment, NPF**

Ointment, liquid paraffin 50%, white soft paraffin 50%, net price 500 g = £6.09

**Paraffin, White Soft, BP**

White petroleum jelly, net price 100 g = 51p

**Paraffin, Yellow Soft, BP**

Yellow petroleum jelly, net price 100 g = 49p

#### Proprietary emollient preparations

**Aquamol®** *(Thornton & Ross)*

Cream, containing liquid paraffin, white soft paraffin, net price 50 g = £1.22, 500-g pump pack = £6.40

Excipients include cetostearyl alcohol, chlorocresol

For dry skin conditions

**Aveeno®** *(J&J)*

Cream, colloidal oatmeal in emollient basis, net price 100 mL = £3.78, 300-mL pump pack = £6.80

Excipients include benzyl alcohol, cetyl alcohol, isopropyl palmitate

ACBS: For endogenous and exogenous eczema, xeroderma, ichthyosis, and senile pruritus (pruritus of the elderly) associated with dry skin

**Lotion**, colloidal oatmeal in emollient basis, net price 400 mL = £6.42

Excipients include benzyl alcohol, cetyl alcohol, isopropyl palmitate

ACBS: as for Aveeno® Cream

**Cetraben®** *(Genus)*

Emollient cream, white soft paraffin 13.2%, light liquid paraffin 10.5%, net price 50-g pump pack = £1.40, 150-g pump pack = £3.98, 500-g pump pack = £5.99, 1.05-kg pump pack = £11.62

Excipients include cetostearyl alcohol, hydroxybenzoates (parabens)

For inflamed, damaged, dry or chapped skin including eczema

**Dermamist®** *(Alliance)*

Spray application, white soft paraffin 10% in a basis containing liquid paraffin, fractionated coconut oil, net price 250-mL pressurised aerosol unit = £5.97

Excipients none as listed in section 13.1.3

For dry skin conditions including eczema, ichthyosis, pruritus of the elderly

Note Flammable

**Diprosone®** *(Schering-Plough)*

Cream, cetomacrogol 2.25%, cetostearyl alcohol 7.2%, liquid paraffin 6%, white soft paraffin 15%, water-miscible basis used for Diprosone® cream, net price 50 g = £1.28; 500-g pump pack = £6.32

Excipients include cetostearyl alcohol, chlorocresol

For dry skin conditions

**Ointment**, liquid paraffin 5%, white soft paraffin 95%, basis used for Diprosone® ointment, net price 50 g = £1.28, 500 g = £5.99

Excipients none as listed in section 13.1.3

For dry skin conditions

**Doublebase®** *(Dermal)*

Gel, isopropyl myristate 15%, liquid paraffin 15%, net price 100 g = £2.65, 500 g = £5.82

Excipients none as listed in section 13.1.3

For dry, chapped, or itchy skin conditions

**E45®** *(Reckitt Benckiser)*

Cream, light liquid paraffin 12.6%, white soft paraffin 14.5%, hypoallergenic anhydrous wool fat (hypoallergenic lanolin) 1% in self-emulsifying monostearin, net price 50 g = £1.40, 125 g = £2.55, 350 g = £4.46, 500-g pump pack = £4.89

Excipients include cetri alcohol, hydroxybenzoates (parabens)

For dry skin conditions

**Lotion**, light liquid paraffin 4%, cetomacrogol, white soft paraffin 10%, hypoallergenic anhydrous wool fat (hypoallergenic lanolin) 1% in glyceryl monostearate, net price 200 mL = £2.42, 500-mL pump pack = £4.50

Excipients include isopropyl palmitate, hydroxybenzoates (parabens), benzyl alcohol

ACBS: for symptomatic relief of dry skin conditions, such as those associated with atopic eczema and contact dermatitis

**Emollin®** *(C D Medical)*

Spray, liquid paraffin 50%, white soft paraffin 50% in aerosol basis, net price 150 mL = £3.74, 240 mL = £5.98

Excipients none as listed in section 13.1.3

For dry skin conditions
13.2.1 Emollients

Epaderm® (Mölnlycke)

- **Cream**, yellow soft paraffin 15%, liquid paraffin 10%, emulsifying wax 5%, net price 50-g pump pack = £1.60, 500-g pump pack = £6.55
- **Exipients** include cetostearyl alcohol, chlorocresol
- For use as an emollient or soap substitute

**Ointment**, emulsifying wax 30%, yellow soft paraffin 30%, liquid paraffin 40%, net price 125 g = £3.72, 500 g = £6.30, 1 kg = £11.61
- **Exipients** include cetostearyl alcohol
- For use as an emollient or soap substitute

Hydromol® (Alliance)

- **Cream**, sodium pilolate 2.5%, liquid paraffin 13.8%, net price 50 g = £2.04, 100 g = £3.80, 500 g = £11.09
- **Exipients** include cetostearyl alcohol, hydroxybenzoates (parabens)
- For dry skin conditions

**Ointment**, yellow soft paraffin 30%, emulsifying wax 30%, liquid paraffin 40%, net price 125 g = £2.79, 500 g = £4.74, 1 kg = £8.81
- **Exipients** include cetostearyl alcohol
- For use as an emollient, bath additive, or soap substitute

**Lipobase®** (Astellas)

- **Cream**, fatty cream basis used for Locoid Lipocream®, net price 50 g = £1.46
- **Exipients** include cetostearyl alcohol, hydroxybenzoates (parabens)
- For dry skin conditions, also for use during treatment with topical corticosteroid and as diluent for Locoid Lipocream®

Oilatum® (Stiefel)

- **Cream**, light liquid paraffin 6%, white soft paraffin 15%, net price 40 g = £1.30, 150 g = £2.46, 500-mL pump pack = £4.99, 1.05-litre pump pack = £9.98
- **Exipients** include benzyl alcohol, cetylstearyl alcohol
- For dry skin conditions

**Oilatum® Junior Cream**, light liquid paraffin 6%, white soft paraffin 15%, 150 g = £3.38, 350 mL = £4.65, 500 mL = £4.99, 1.05-litre pump pack = £9.98
- **Exipients** include benzyl alcohol, cetylstearyl alcohol
- For dry skin conditions

**QV®** (Crawford)

- **Cream**, glycerol 10%, light liquid paraffin 10%, white soft paraffin 5%, net price 100 g = £1.95, 500 g = £5.60
- **Exipients** include cetostearyl alcohol, hydroxybenzoates (parabens)
- For dry skin conditions including eczema, psoriasis, ichthyosis, pruritus

**Lotion**, white soft paraffin 5%, net price 250 mL = £3.00
- **Exipients** include cetostearyl alcohol, hydroxybenzoates (parabens)
- For dry skin conditions including eczema, psoriasis, ichthyosis, pruritus

**Ultrabase®** (Bayer Schering)

- **Cream**, water-miscible, containing liquid paraffin and white soft paraffin, net price 50 g = £1.58, 500-g pump pack = £16.23
- **Exipients** include fragrance, hydroxybenzoates (parabens), disodium edetate, stearyl alcohol
- For dry skin conditions

**Unguentum M®** (Almirall)

- **Cream**, containing saturated neutral oil, liquid paraffin, white soft paraffin, net price 50 g = £1.41, 100 g = £2.78, 200-mL pump pack = £5.50, 500 g = £8.48
- **Exipients** include cetostearyl alcohol, polysorbate 40, propylene glycol, sorbic acid
- For dry skin conditions and nappy rash

**Zerobase®** (Thorton & Ross)

- **Cream**, liquid paraffin 11%, net price 50 g = £1.04, 500-g pump pack = £5.26
- **Exipients** include cetostearyl alcohol, chlorocresol
- For dry skin conditions

**Zerocream®** (Thornton & Ross)

- **Cream**, liquid paraffin 12.6%, white soft paraffin 14.5%, net price 50 g = £1.17, 500-g pump pack = £4.08
- **Exipients** include cetostearyl alcohol, hydroxybenzoates (parabens), lanolin anhydrous
- For dry skin conditions

**Zeroguent®** (Thornton & Ross)

- **Cream**, light liquid paraffin 8%, white soft paraffin 4%, refined soya bean oil 5%, net price 100 g = £2.33, 500 g = £7.07
- **Exipients** include cetostearyl alcohol, polysorbate 40, propylene glycol, sorbic acid
- For dry skin conditions

**Preparations containing urea**

**Aquadrate®** (Alliance)

- **Cream**, urea 10%, net price 100 g = £4.37
- **Exipients** none as listed in section 13.1.3
- **Dose** for dry, scaling and itching skin, apply thinly twice daily

**Balneum®** (Almirall)

- **Cream**, urea 5%, ceramide 0.1%, net price 50-g pump pack = £2.80, 500-g pump pack = £9.80
- **Exipients** include cetostearyl alcohol, polysorbates, propylene glycol
- **Dose** for dry skin conditions, apply twice daily

**Balneum® Plus Cream**, urea 5%, laurmacrogols 3%, net price 100 g = £3.29, 175-g pump pack = £8.33, 500-g pump pack = £16.42
- **Exipients** include benzyl alcohol, polysorbates
- **Dose** for dry, scaling and itching skin, apply twice daily

**Calmidur®** (Galuiderma)

- **Cream**, urea 10%, lactic acid 5%, net price 100 g = £5.70, 500-g pump pack = £27.42
- **Exipients** none as listed in section 13.1.3
- **Dose** for dry, scaling and itching skin, apply a thick layer for 3-5 minutes, massage into area, and remove excess, usually twice daily. Use half-strength cream for 1 week if stinging occurs
- **Note** Can be diluted with aqueous cream (life of diluted cream 14 days)

**Dermatonics Heel Balm®** (Dermatonics)

- **Cream**, urea 25%, net price 75 mL = £4.00, 200 mL = £9.50
- **Exipients** include beeswax, lanolin
- **Dose** for dry skin on soles of feet, apply twice daily

**E45® Itch Relief Cream** (Reckitt Benckiser)

- **Cream**, urea 5%, macrogol lauryl ether 3%, net price 50 g = £2.55, 100 g = £3.47, 500-g pump pack = £14.99
- **Exipients** include benzyl alcohol, polysorbates
- **Dose** for dry, scaling, and itching skin, apply twice daily

**Eucerin® Intensive** (Beiersdorf)

- **Cream**, urea 10%, net price 100 mL = £7.59
- **Exipients** include benzyl alcohol, isopropyl palmitate, wool fat
- **Dose** for dry skin conditions including eczema, ichthyosis, xeroderma, hyperkeratosis, apply thinly and rub into area twice daily

**Lotion**, urea 10%, net price 250 mL = £7.93
- **Exipients** include benzyl alcohol, polysorbates
- **Dose** for dry skin conditions including eczema, ichthyosis, xeroderma, hyperkeratosis, apply sparingly and rub into area twice daily

**Hydromol® Intensive** (Alliance)

- **Cream**, urea 10%, net price 30 g = £1.64, 100 g = £4.37
- **Exipients** none as listed in section 13.1.3
- **Dose** for dry, scaling and itching skin, apply thinly twice daily

**Nutraplus®** (Galderma)

- **Cream**, urea 10%, net price 100 g = £4.37
- **Exipients** include hydroxybenzoates (parabens), propylene glycol
- **Dose** for dry, scaling and itching skin, apply 2-3 times daily
13.2.1 Emollients

With antimicrobials

Dermol® (Dermal)

Cream, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, isopropyl myristate 10%, liquid paraffin 10%, net price 100-g tube = £2.86, 500-g pump pack = £6.63

Excipients include cetostearyl alcohol

Dose for dry and pruritic skin conditions including eczema and dermatitis, apply to skin or use as soap substitute

Dermol® 500 Lotion, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin 2.5%, isopropyl myristate 2.5%, net price 500-mL pump pack = £6.03

Excipients include cetostearyl alcohol

Dose for dry and pruritic skin conditions including eczema and dermatitis, apply to skin or use as soap substitute

Eczezl® (Genus)

Cream, chlorhexidine gluconate 1% in emollient basis, net price 250 mL = £3.70

Excipients include cetostearyl alcohol

Dose for dry and pruritic skin conditions including eczema and dermatitis, apply to skin or use as soap substitute

13.2.1.1 Emollient bath additives and shower preparations

Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin and rinsed off. In dry skin conditions soap should be avoided (see section 13.2.1 for soap substitutes). The quantities of bath additives recommended for adults are suitable for an adult-size bath. Proportionately less should be used for a child-size bath or a washtub; recommended bath additive quantities for children reflect this.

These preparations make skin and surfaces slippery—particularly care is needed when bathing

Aveeno® (J&J)

Aveeno® Bath oil, colloidal oatmeal, white oat fraction in emollient basis, net price 250 mL = £4.28

Excipients include beeswax, fragrance

Dose ACBS: for endogenous and exogenous eczema, xeroderma, ichthyosis, and senile pruritus (pruritus of the elderly) associated with dry skin, add 20–40 mL/bath or apply to wet skin and rinse

Aveeno Colloidal® Bath additive, oatmeal, white oat fraction in emollient basis, net price 10 × 50-g sachets = £7.33, Baby Bath Additive, 10 × 15-g sachets = £4.39

Excipients none as listed in section 13.1.3

Dose ACBS: as for Aveeno® Bath oil, add 50 g/bath (INFANT and CHILD under 12 years, 15 g)

Balneum® (Almirall)

Balneum® bath oil, soya oil 84.75%, net price 200 mL = £2.48, 500 mL = £5.38, 1 litre = £10.39

Excipients include butylated hydroxytoluene, propylene glycol, fragrance

Dose for dry skin conditions including those associated with dermatitis and eczema; add 20–60 mL/bath (INFANT 5–15 mL) do not use undiluted

Balneum Plus® bath oil, soya oil 82.95%, mixed lauromacrogols 15%, net price 500 mL = £6.66

Excipients include butylated hydroxytoluene, propylene glycol, fragrance

Dose for dry skin conditions including those associated with dermatitis and eczema where pruritus also experienced; add 20 mL/bath (INFANT 5 mL) or apply to wet skin and rinse

Cetraben® (Genus)

Emollient bath additive, light liquid paraffin 82.8%, net price 500 mL = £5.75

Excipients none as listed in section 13.1.3

Dose for dry skin conditions, including eczema, add 1–2 capfuls/bath (CHILD ½–1 capful) or apply to wet skin and rinse

Dermalo® (Dermal)

Bath emollient, acetylated wool alcohols 5%, liquid paraffin 65%, net price 500 mL = £3.44

Excipients none as listed in section 13.1.3

Dose for dermatitis, dry skin conditions including ichthyosis and pruritus of the elderly; add 15–20 mL/bath (INFANT and CHILD 5–10 mL) or apply to wet skin and rinse

Diprobas® (Schering-Plough)

Bath additive, isopropyl myristate 30%, light liquid paraffin 46%, net price 500 mL = £6.71

Excipients none as listed in section 13.1.3

Dose for dry skin conditions including dermatitis and eczema; add 25–50 mL/bath (INFANT 10 mL); do not use undiluted

Doublebase® (Dermal)

Emollient bath additive, liquid paraffin 65%, net price 500 mL = £5.45

Excipients include cetostearyl alcohol

Dose for dry skin conditions including dermatitis, ichthyosis, and pruritus of the elderly; add 15–20 mL/bath (INFANT and CHILD 5–10 mL)

Emollient shower gel, isopropyl myristate 15%, light liquid paraffin 15%, net price 200 g = £5.21

Excipients none as listed in section 13.1.3

For dry, chapped, or itchy skin conditions

Note: Also available as Doublebase® Emollient Wash Gel

E45® (Reckitt Benckiser)

Emollient bath oil, cetyl dimethicone 5%, liquid paraffin 91%, net price 250 mL = £3.19, 500 mL = £5.11

Excipients none as listed in section 13.1.3

Dose ACBS: for endogenous and exogenous eczema, xeroderma, ichthyosis, and senile pruritus (pruritus of the elderly) associated with dry skin; add 15 mL/bath (CHILD 5–10 mL) or apply to wet skin and rinse

Emollient wash cream, soap substitute, zinc oxide 5% in an emollient basis, net price 250-mL pump pack = £3.19

Excipients none as listed in section 13.1.3

ACBS: for endogenous and exogenous eczema, xeroderma, ichthyosis and senile pruritus (pruritus of the elderly) associated with dry skin

Hydromol® (Alliance)

Bath and shower emollient, isopropyl myristate 13%, light liquid paraffin 37.8%, net price 350 mL = £3.61, 500 mL = £4.11, 1 litre = £8.19

Excipients none as listed in section 13.1.3

Dose ACBS: for endogenous and exogenous eczema, xeroderma, ichthyosis, and senile pruritus (pruritus of the elderly) associated with dry skin

Oiltatum® (Stiefel)

Emollient bath additive (emulsion), light liquid paraffin 63.4%, net price 250 mL = £2.75, 500 mL = £4.57

Excipients include acetylated lanolin alcohols, isopropyl palmitate, fragrance

Dose for dry skin conditions including dermatitis, pruritus of the elderly and ichthyosis; add 1–3 capfuls/bath (INFANT ½–2 capfuls) or apply to wet skin and rinse

Junior bath additive, light liquid paraffin 63.4%, net price 150 mL = £2.82, 250 mL = £3.25, 500 mL = £5.10, 600 mL = £5.89

Excipients include acetylated lanolin alcohols, isopropyl palmitate

Dose for dry skin conditions including dermatitis, pruritus of the elderly and ichthyosis; add 1–3 capfuls/bath (INFANT 0.5–2 capfuls) or apply to wet skin and rinse

Shower emollient (gel), light liquid paraffin 70%, net price (with fragrance or fragrance-free) 150 g = £5.15

For dry skin conditions including dermatitis
13.2.2 Barrier preparations

Barrier preparations often contain water-repellent substances such as dimeticone or other silicones. They are used on the skin around stomas, bedsores, and pressure areas in the elderly where the skin is intact. Where the skin has broken down, barrier preparations have a limited role in protecting adjacent skin. They are no substitute for adequate nursing care and it is doubtful if they are any more effective than zinc ointments.

Nappy rash
Barrier creams and ointments are used for protection against nappy rash which is usually a local dermatitis. The first line of treatment is to ensure that nappies are changed frequently and that tightly fitting water-proof pants are avoided. The rash may clear when left exposed to the air and a barrier preparation can be helpful. If the rash is associated with a fungal infection, an antifungal cream such as clotrimazole cream (section 13.10.2) is useful. A mild corticosteroid such as hydrocortisone 1% is useful in moderate to severe inflammation, but it should be avoided in neonates. The barrier preparation is applied after the corticosteroid preparation, but it should be avoided in neonates. The barrier preparation is usually referred to as an antifungal and antibacterial drug (section 13.4) if there is considerable inflammation, erosion, and infection. Preparations containing hydrocortisone should be applied for no more than a week; the hydrocortisone should be discontinued as soon as the inflammation subsides. The occlusive effect of nappies and water-proof pants may increase absorption for cautions, see p. 708).

Non-proprietary barrier preparations

Zinc Cream, BP
Cream, zinc oxide 32%, arachis (peanut) oil 32%, calcium hydroxide 0.045%, oleic acid 0.5%, wool fat 8%, in freshly boiled and cooled purified water, net price 50 g = 75p

For nappy and urinary rash and eczematous conditions

Zinc Ointment, BP
Ointment, zinc oxide 15%, in Simple Ointment BP 1988 (which contains wool fat 5%, hard paraffin 5%, cetostearyl alcohol 9%, white soft paraffin 85%), net price 25 g = 30p

For nappy and urinary rash and eczematous conditions

Zinc and Castor Oil Ointment, BP
Ointment, zinc oxide 7.5%, castor oil 50%, arachis (peanut) oil 30.5%, white beeswax 10%, cetostearyl alcohol 2%, net price 500 g = £2.93

For nappy and urinary rash
13.3 Topical local anaesthetics and antipruritics

Proprietary barrier preparations

Conotrate® (Astellas)

Cream, benzalkonium chloride 0.1%, dimeticonic ‘350’, 22%, net price 100 g = £8.80, 500 g = £35.51

Excipients include cetostearyl alcohol, fragrance

For nappy and urinary rash and pressure sores

Drapolene® (Chefaro UK)

Cream, benzalkonium chloride 0.01%, cetrimide 0.2% in a basis containing white soft paraffin, cetyl alcohol and wool fat, net price 100 g = £1.54, 200 g = £2.50, 350 g = £3.75

Excipients include cetyl alcohol, chlorocresol, wool fat

For nappy and urinary rash, minor wounds

Medicaid® (PC)

Cream, cetrimide 0.5% in a basis containing liquid liquid paraffin, white soft paraffin, cetostearyl alcohol, glyceryl monostearate, net price 50 g = £1.69

Excipients include cetostearyl alcohol, fragrance, hydroxybenzoates (parabens), zinc oxide, wool fat

For nappy rash, minor burns and abrasions

Metanium® (Thorn & Ross)

Ointment, titanium dioxide 20%, titanium oxide 5%, titanium salicylate 3% in a basis containing dimeticone, liquid paraffin, white soft paraffin, and benzoin tincture, net price 30 g = £2.01

Excipients none as listed in section 13.1.5

For nappy rash

Morolin® (Actavis)

Ointment, cod-liver oil 11.4%, zinc oxide 38%, in a basis containing liquid paraffin and yellow soft paraffin, net price 50 g = £1.91

Excipients include wool fat derivative

For minor wounds, varicose ulcers, pressure sores, eczema and nappy rash

Siopel® (Derma UK)

Barrier cream, dimeticonic ‘1000’ 10%, cetrimide 0.3%, arachis (peanut) oil, net price 50 g = £2.15

Excipients include butylated hydroxytoluene, cetostearyl alcohol, hydroxybenzoates (parabens), calamine

For protection against water-soluble irritants

Sprilon® (Ayrton Saunders)

Spray application, dimeticonic 1.04%, zinc oxide 12.5%, in a basis containing wool alcohols, cetostearyl alcohol, dextran, white soft paraffin, liquid paraffin, propellants, net price 115-g pressurised aerosol unit = £3.54

Excipients include cetostearyl alcohol, hydroxybenzoates (parabens), wool fat

For urinary rash, pressure sores, leg ulcers, moist eczema, fissures, cutaneous and stomatocystic care

Note: Flammable

Sudocrem® (Forest)

Cream, benzyl alcohol 0.39%, benzyl benzoate 1.01%, benzyl cinnamate 0.15%, hydrous wool fat (hypoa- lergenic lanolin) 4%, zinc oxide 15.25%, net price 30 g = £1.13, 60 g = £1.25, 125 g = £1.84, 250 g = £3.09, 400 g = £4.34

Excipients include beeswax (synthetic), propylene glycol, butylated hydroxyanisole, fragrance

For nappy rash and pressure sores

Vasogen® (Forest)

Barrier cream, dimeticonic 20%, calamine 1.5%, zinc oxide 7.5%, net price 100 g = £2.72

Excipients include hydroxybenzoates (parabens), wool fat

For nappy rash, pressure sores, lichen simplex and eczematous care

Pruritus may be caused by systemic disease (such as obstructive jaundice, endocrine disease, chronic renal disease, iron deficiency, and certain malignant diseases), skin disease (e.g. psoriasis, eczema, urticaria, and scabies), drug hypersensitivity, or as a side-effect of opioid analgesics. Where possible the underlying causes should be treated. An emollient (section 13.2.1) may be of value where the pruritus is associated with dry skin. Pruritus that occurs in otherwise healthy elderly people can also be treated with an emollient. Levomethenol cream can be used to relieve pruritus; it exerts a cooling effect on the skin. For advice on the treatment of pruritus in palliative care, see p. 22.

Preparations containing crotamiton are sometimes used but are of uncertain value. Preparations containing calamine are often ineffective.

A topical preparation containing doxepin 5% is licensed for the relief of pruritus in eczema; it can cause drowsi- ness and there may be a risk of sensitisation.

Pruritus is common in biliary obstruction, especially in primary biliary cirrhosis and drug-induced cholestasis. Oral administration of colestyramine is the treatment of choice (section 1.9.2).

Topical antihistamines and local anaesthetics are only marginally effective and occasionally cause sensitisation. For insect stings and insect bites, a short course of a topical corticosteroid is appropriate. Short-term treatment with a sedating antihistamine (section 3.4.1) may help in insect stings and in intractable pruritus where sedation is desirable. Calamine preparations are of little value for the treatment of insect stings or bites.

For preparations used in pruritus ani, see section 1.7.1.

Calamine

Indications

Pruritus

Calamine (Non-proprietary)

Aqueous cream, calamine 4%, zinc oxide 3%, liquid paraffin 20%, self-emulsifying glyceryl monostearate 5%, cetomacrogol emulsifying wax 5%, phenox- yethanol 0.5%, freshly boiled and cooled purified water 62.5%, net price 100 mL = 64p.

Lotion (cutaneous suspension), calamine 15%, zinc oxide 5%, glycerol 5%, bentonite 3%, sodium citrate 0.5%, liquefied petrol 0.5%, in freshly boiled and cooled purified water, net price 200 mL = 63p.

Oily lotion (BP 1980), calamine 5%, arachis (peanut) oil 50%, oleic acid 0.5%, wool fat 1%, in calcium hydroxide solution, net price 200 mL = £1.57

Crotamiton

Indications

Pruritus (including pruritus after scabies—section 13.10.4); see notes above

Cautions

Avoid use near eyes and broken skin; use on doctor’s advice for children under 3 years

Contra-indications

acute exudative dermatoses

Dose

Pruritus, apply 2–3 times daily; CHILD under 3 years, apply once daily
Eurax® (Novartis Consumer Health)

**Cream**, crotamiton 10%, net price 30 g = £2.38, 100 g = £4.15

**Excipients** include beeswax, fragrance, hydroxybenzoates (parabens), stearyl alcohol.

**Lotion**, crotamiton 10%, net price 100 mL = £3.14

**Excipients** include cetyl alcohol, fragrance, propylene glycol, sorbic acid, stearyl alcohol.

### 13.4 Topical corticosteroids

Topical corticosteroids are used for the treatment of inflammatory conditions of the skin (other than those arising from an infection), in particular eczema (section 13.5.1), contact dermatitis, insect stings (p. 42), and eczema of scabies (section 13.10.4). Corticosteroids suppress the inflammatory reaction during use; they are not curative and on discontinuation a rebound exacerbation of the condition may occur. They are generally used to relieve symptoms and suppress signs of the disorder when other measures such as emollients are ineffective.

Topical corticosteroids are of no value in the treatment of urticaria and they are contra-indicated in rosacea; they may worsen ulcerated or secondarily infected lesions. They should not be used indiscriminately in pruritus (where they will only benefit if inflammation is causing the itch) and are not recommended for acne vulgaris.

Systemic or potent topical corticosteroids should be avoided or given only under specialist supervision in psoriasis because, although they may suppress the psoriasis in the short term, relapse or vigorous rebound occurs on withdrawal (sometimes precipitating severe pustular psoriasis). Topical use of potent corticosteroids on widespread psoriasis can lead to systemic as well as to local side-effects. It is reasonable, however, to prescribe a mild to moderate topical corticosteroid for a short period (2–4 weeks) for flexural and facial psoriasis and to use a more potent corticosteroid such as beta-methasone or fluocinonide for psoriasis of the scalp, palms, or soles (see below for cautions in psoriasis).

In general, the most potent topical corticosteroids should be reserved for recalcitrant dermatoses such as chronic discoid lupus erythematosus, lichen simplex chronicus, hypertrophic lichen planus, and palmoplantar pustulosis. Potent corticosteroids should generally be avoided on the face and skin flexures, but specialists occasionally prescribe them for use on these areas in certain circumstances.

When topical treatment has failed, intralesional corticosteroid injections (section 10.1.2.2) may be used. These are more effective than the very potent topical corticosteroid preparations and should be reserved for severe cases where there are localised lesions such as keloid scars, hypertrophic lichen planus, or localised alopecia areata.

### Perioral lesions

Hydrocortisone cream 1% can be used for up to 7 days to treat uninfected inflammatory lesions on the lips. Hydrocortisone and miconazole cream or ointment is useful where infection by susceptible organisms and inflammation co-exist, particularly for initial treatment (up to 7 days) e.g. in angular cheilitis (see also p. 695). Organisms susceptible to miconazole include *Candida* spp. and many Gram-positive bacteria including *streptococci* and *staphylococci*.

**Children** Children, especially infants, are particularly susceptible to side-effects. However, concern about the safety of topical corticosteroids in children should not result in the child being undertreated. The aim is to control the condition as well as possible; inadequate treatment will perpetuate the condition. A mild corticosteroid such as hydrocortisone 1% ointment or cream is useful for treating nappy rash (section 13.2.2) and for

---

**DOXEPIN HYDROCHLORIDE**

**Indications** pruritus in eczema; depressive illness (section 4.3.1)

**Cautions** susceptibility to angle-closure glaucoma, urinary retention, mania, cardiac arrhythmias, severe heart disease; avoid application to large areas; interactions: Appendix 1 (antidepressants, tricyclic)

**Driving** Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

**Hepatic impairment** manufacturer advises caution in severe liver disease

**Pregnancy** manufacturer advises use only if potential benefit outweighs risk

**Breast-feeding** manufacturer advises use only if potential benefit outweighs risk

**Side-effects** drowsiness; local burning, stinging, irritation, tingling and rash; systemic side-effects such as antimuscarinic effects, headache, fever, dizziness, gastro-intestinal disturbances also reported

**Dose**

- **ADULT and CHILD** over 12 years, apply thinly 3–4 times daily; usual max. 3 g per application; usual total max. 12 g daily; coverage should be less than 10% of body surface area

**Xepin® (CHS)**

**Cream, doxepin hydrochloride 5%**, net price 30 g = £11.70; Label: 2, 10, patient information leaflet

**Excipients** include benzyl alcohol

---

**LEVOMENTHOL**

**Indications** pruritus

**Levomenthol Cream, BP** (also in Anti-pers Cream)

**Cream, levomenthol 0.5%**, net price 500 g = £15.30; 1% 100 g = £3.67, 500 g = £15.30; 2% 50-mL pump pack = £3.19, 500 g = £15.30

**Dose** apply 1–2 times daily

---

**TOPICAL LOCAL ANAESTHETICS**

**Indications** relief of local pain, see notes above. See section 15.2 for use in surface anaesthesia

**Cautions** occasionally cause hypersensitivity

**Note** Topical local anaesthetic preparations may be absorbed, especially through mucosal surfaces, therefore excessive application should be avoided and they should preferably not be used for more than about 3 days; not generally suitable for young children

---

**TOPICAL ANTIHISTAMINES**

**Indications** see notes above

**Cautions** may cause hypersensitivity; avoid in eczema; photosensitivity (diphenhydramine); not recommended for longer than 3 days

---

**TOPICAL CORTICOSTEROIDS**

**Indications** see notes above

**Cautions** may cause hypersensitivity; avoid in eczema; photosensitivity (diphenhydramine); not recommended for longer than 3 days

---
atopic eczema in childhood (section 13.5.1). A moderately potent or potent corticosteroid may be appropriate for severe atopic eczema on the limbs, for 1–2 weeks only, switching to a less potent preparation as the condition improves. In an acute flare-up of atopic eczema, it may be appropriate to use more potent formulations of topical corticosteroids for a short period to regain control of the condition. A very potent corticosteroid should be initiated under the supervision of a specialist. Continuous daily application of a mild corticosteroid such as hydrocortisone 1% is equivalent to a potent corticosteroid such as betamethasone 0.1% applied intermittently. Carers of young children should be advised that treatment should not necessarily be reserved to ‘treat only the worst areas’ and they may need to be advised that patient information leaflets may contain inappropriate advice for the patient’s condition.

Choice of formulation Water-miscible corticosteroid creams are suitable for moist or weeping lesions whereas ointments are generally chosen for dry, lichenified or scaly lesions or where a more occlusive effect is required. Lotions may be useful when minimal application to a large or hair-bearing area is required or for the treatment of exudative lesions. Occlusive polythene or hydrocolloid dressings increase absorption, but also increase the risk of side-effects; they are therefore used only under supervision on a short-term basis for areas of very thick skin (such as the palms and soles). The inclusion of urea or salicylic acid also increases the penetration of the corticosteroid.

In the BNF topical corticosteroids for the skin are categorised as ‘mild’, ‘moderately potent’, ‘potent’ or ‘very potent’ (see p. 709); the least potent preparation which is effective should be chosen but dilution should be avoided whenever possible.

Cautions Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; eradication of infantile sebaceous naevi is useful but the duration of treatment may be uncertain, but such combinations may have a place where inflammatory skin conditions are associated with bacterial or fungal infection, such as infected eczema. In these cases the antimicrobial drug should be chosen according to the sensitivity of the infecting organism and used regularly for a short period (typically twice daily for 1 week). Longer use increases the likelihood of resistance and of sensitisation.

The keratolytic effect of salicylic acid facilitates the absorption of topical corticosteroids; however, excessive and prolonged use of topical preparations containing salicylic acid may cause salicylism.

Suitable quantities of corticosteroid preparations to be prescribed for specific areas of the body

<table>
<thead>
<tr>
<th>Area</th>
<th>Creams and Ointments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both hands</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Scalp</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both arms</td>
<td>30 to 60 g</td>
</tr>
<tr>
<td>Both legs</td>
<td>100 g</td>
</tr>
<tr>
<td>Trunk</td>
<td>100 g</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15 to 30 g</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for a single daily application for 2 weeks.

If a patient is using topical corticosteroids of different potencies, the patient should be told when to use each corticosteroid. The potency of each topical corticosteroid (see Topical Corticosteroid Preparation Potencies, below) should be included on the label with the directions for use. The label should be attached to the container (for example, the tube) rather than the outer packaging.

Mixing topical preparations on the skin should be avoided where possible; several minutes should elapse between application of different preparations.

Compound preparations The advantages of including other substances (such as antibacterials or antifungals) with corticosteroids in topical preparations are uncertain, but such combinations may have a place where inflammatory skin conditions are associated with bacterial or fungal infection, such as infected eczema. In these cases the antimicrobial drug should be chosen according to the sensitivity of the infecting organism and used regularly for a short period (typically twice daily for 1 week). Longer use increases the likelihood of resistance and of sensitisation.

In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.
Hydrocortisone

Apply thinly 1–2 times daily.

Dose

Side-effects

see notes above

see notes above

Cautions

see notes above

see notes above

Mild inflammatory skin disorders such as:

Indications

Very potent.

Potent with salicylic acid:

Moderate with urea:

Potent with antimicrobials:

Mild with crotamiton:

Mild with antimicrobials:

Mild with antimicrobials:

Mild with antimicrobials:

Mild with antimicrobials:

Mild with antimicrobials:

Mild with antimicrobials:

Potency: mild

Potency: moderate

Potency: moderate

Potency: moderate

Potency: very mild

Potency: very potent

Very potent

Clarelux, Dermovate, Etrixev, Nersiene Forte

HYDROCORTISONE

Indications mild inflammatory skin disorders such as:

eczemas (but for over-the-counter preparations, see below); nappy rash, see notes above and section 13.2.2

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

● Apply thinly 1–2 times daily

Hydrocortisone (Non-proprietary) Cream, hydrocortisone 0.5%, net price, 15 g = £1.92, 30 g = £5.19; 1%, 15 g = £1.64, 30 g = £1.99, 50 g = £4.06; 2.5%, 15 g = £1.92, 30 g = £2.38; 1%, 50 g = £7.03. Label: 28, counselling, application, see p. 708. Potency: mild

Dental prescribing on NHS

Hydrocortisone Cream 1% 15 g may be prescribed

Ointment, hydrocortisone 0.5%, net price 15 g = £3.05, 30 g = £5.23; 1%, 15 g = £3.34, 30 g = £2.70, 50 g = £6.67; 2.5%, 15 g = £23.78. Label: 28, counselling, application, see p. 708. Potency: mild

When hydrocortisone cream or ointment is prescribed and no strength is stated, the 1% strength should be supplied

Over-the-counter hydrocortisone preparations

Skin creams and ointments containing hydrocortisone (alone or with other ingredients) can be sold to the public for the treatment of allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema, to be applied sparingly over the affected area 1–2 times daily for max. 1 week. Over-the-counter hydrocortisone preparations should not be sold without medical advice for children under 10 years or for pregnant women; they should not be sold for application to the face, anogenital region, broken or infected skin (including cold sores, acne, and athlete’s foot); over-the-counter hydrocortisone preparations containing clotrimazole or miconazole nitrate can be sold to the public for athlete’s foot and candidal intertrigo

Proprietary hydrocortisone preparations

Dioderm® (Dermal) Cream, hydrocortisone 0.1%, net price 30 g = £2.39. Label: 28, counselling, application, see p. 708. Potency: mild

Note Although this contains only 0.1% hydrocortisone, the formulation is designed to provide a clinical activity comparable to that of Hydrocortisone Cream 1% BP

Mildison® (Astellas) Lipocream, hydrocortisone 1%, net price 30 g = £1.71. Label: 28, counselling, application, see p. 708. Potency: mild

Compound preparations

Compound preparations with coal tar see section 13.5.2

Alphaderm® (Alliance) Cream, hydrocortisone 1%, urea 10%, net price 30 g = £2.38; 100 g = £7.03. Label: 28, counselling, application, see p. 708. Potency: moderate

Calmurid HC® (Galderma) Cream, hydrocortisone 1%, urea 10%, lactic acid 5%, net price 30 g = £2.80, 50 g = £4.67. Label: 28, counselling, application, see p. 708. Potency: moderate

Eurax-Hydrocortisone® (Novartis Consumer Health) Cream, hydrocortisone 0.25%, crotamiton 10%, net price 30 g = £8.7. Label: 28, counselling, application, see p. 708. Potency: mild

1. A 15-g tube is on sale to the public for treatment of contact dermatitis and insect bites

With antimicrobials

See notes above for comment on compound preparations

Canesten HC® (Bayer Consumer Care) Cream, hydrocortisone 1%, clotrimazole 1%, net price 30 g = £2.42. Label: 28, counselling, application, see p. 708. Potency: mild

Exipients include benzyl alcohol, cetostearyl alcohol, crotamiton and hydrocortisone

1. A 15-g tube is on sale to the public for the treatment of athlete’s foot and fungal infection of skin folds with associated inflammation

Daktacort® (Janssen-Cilag) Cream, hydrocortisone 1%, miconazole nitrate 2%, net price 30 g = £2.28. Label: 28, counselling, application, see p. 708. Potency: mild

Exipients include butylated hydroxyanisole, disodium edetate

Dental prescribing on NHS May be prescribed as Miconazole and Hydrocortisone Cream for max. 7 days

Note A 15-g tube is on sale to the public for the treatment of athlete’s foot and candidal intertrigo
**HYDROCORTISONE BUTYRATE**

**Indications**

Severe inflammatory skin disorders such as eczema unresponsive to less potent corticosteroids; psoriasis, see notes above; use of more than 100 g per week of 0.1% preparation likely to cause adrenal suppression.

**Dose**

Apply thinly 1–2 times daily.

**Contra-indications**

See notes above.

**Site-effects**

See notes above.

**Notes**

Thin; apply sparingly.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Formulation</th>
<th>Active Ingredients</th>
<th>Instructions</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betnovate-C</td>
<td>Cream</td>
<td>betamethasone (as valerate) 0.1%, net price 100 mL = £4.58.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Diprosalic</td>
<td>Cream</td>
<td>betamethasone (as valerate) 0.025% in a water-miscible basis, net price 100 mL = £4.99.</td>
<td>Label: 15, 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Bettamousse</td>
<td>Cream</td>
<td>betamethasone (as valerate) 0.025% in an anhydrous paraffin basis (1 in 4 dilution of Betnovate cream), net price 100 g = £3.15.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: moderate</td>
</tr>
<tr>
<td>Betnovate-RD</td>
<td>Ointment</td>
<td>betamethasone (as valerate) 0.025% in an anhydrous paraffin basis, net price 30 g = £2.16, 100 g = £6.12.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Clarelux</td>
<td>Cream, Ointment</td>
<td>betamethasone (as valerate) 0.1%, clioquinol 3%, net price 30 g = £1.76.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Fucibet</td>
<td>Cream</td>
<td>betamethasone (as valerate) 0.1%, fusidic acid 2%, net price 30 g = £5.29, 60 g = £10.58.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Lotriderm</td>
<td>Cream</td>
<td>betamethasone dipropionate 0.064% (≈ betamethasone 0.05%), clotrimazole 1%, net price 30 g = £6.34.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
</tr>
<tr>
<td>Ointment</td>
<td>betamethasone (as valerate) 0.1%, neomycin sulphate 0.5%, net price 30 g = £1.76, 100 g = £4.68.</td>
<td>Label: 28, counselling, application, see p. 708.</td>
<td>Potency: potent</td>
<td></td>
</tr>
</tbody>
</table>

**Clobetasol Propionate**

**Indications**

- short-term treatment only of severe resistant inflammatory skin disorders such as recalcitrant eczemas unresponsive to less potent corticosteroids; psoriasis, see notes above

**Cautions**

- see notes above

**Contra-indications**

- see notes above

**Side-effects**

- see notes above

**Dose**

- Apply thinly 1–2 times daily for up to 4 weeks; max. 50 g of 0.05% preparation per week

**Clarelux** (Fabre) (FR)

- Foam (= scalp application), clobetasol propionate 0.05%, net price 100 g = £11.06. | Label: 15, 28, counselling, application, see p. 708. | Potency: very potent |

**Dermovate** (GSK) (FR)

- Cream, clobetasol propionate 0.05%, net price 30 g = £2.69, 100 g = £7.90. | Label: 28, counselling, application, see p. 708. | Potency: very potent |

**Note**

- Stains clothing

- Flammable

- Apply directly to scalp lesions (foam begins to subside immediately on contact with skin)
13.4 Topical corticosteroids

Etivex® (Galderma) 
**Shampoo**
clobetasol propionate 0.05%, net price 125 mL = £15.43. Label: 28, counselling, application, see p. 708. Potency: very potent
*Excipients* none as listed in section 13.1.3

Dose moderate scalp psoriasis, AD/OUT over 18 years, apply thinly once daily, rinse off after 15 minutes; reduce frequency of application after clinical improvement; max. duration of treatment 4 weeks

■ With antimicrobials
See notes above for comment on compound preparations

Dermovate-NN® (Chemidex)

**Cream**
clobetasol propionate 0.05%, neomycin sulphate 0.5%, nystatin 100 000 units/g, net price 30 g = £3.91. Label: 28, counselling, application, see p. 708. Potency: very potent
*Excipients* include arachis (peanut) oil, beeswax or beeswax substitute

Ointment
clobetasol propionate 0.05%, neomycin sulphate 0.5%, nystatin 100 000 units/g, in a paraffin base, net price 30 g = £3.91. Label: 28, counselling, application, see p. 708. Potency: very potent
*Excipients* none as listed in section 13.1.3

Clobetasone butyrate

Indications eczemas and dermatitis of all types; maintenance between courses of more potent corticosteroids

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

■ Apply thinly 1–2 times daily

**Eumovate** (GSK)

**Cream**
clobetasone butyrate 0.05%, net price 30 g = £1.86, 100 g = £5.44. Label: 28, counselling, application, see p. 708. Potency: moderate
*Excipients* include benzyl alcohol, cetostearyl alcohol, chlorocresol

Ointment
clobetasone butyrate 0.05%, net price 30 g = £1.86, 100 g = £5.44. Label: 28, counselling, application, see p. 708. Potency: moderate
*Excipients* none as listed in section 13.1.3

1. Cream can be sold to the public for short-term symptomatic treatment and control of patches of eczema and dermatitis (but not seborrhoeic dermatitis) in adults and children over 12 years provided pack does not contain more than 15 g

■ With antimicrobials
See notes above for comment on compound preparations

Trimovate® (GSK)

**Cream**
clobetasone butyrate 0.05%, oxytetracycline 3% (as calcium salt), nystatin 100 000 units/g, net price 30 g = £3.29. Label: 28, counselling, application, see p. 708. Potency: moderate
*Excipients* include cetostearyl alcohol, chlorocresol, sodium metabsulphate

Note Stains clothing

Diflucortolone valerate

Indications severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids; high strength (0.3%), short-term treatment of severe exacerbations; psoriasis, see notes above

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

■ Apply thinly 1–2 times daily for up to 4 weeks (0.1% preparations) or 2 weeks (0.3% preparations), reduc-
**FLUOCORTOLONE**

**Indications** severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids; psoriasis, see notes above

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Dose**
- Apply thinly 1–2 times daily, reducing strength as condition responds

**Ultranalum Plain** *(Meadow)*

**Cream**, fluocortolone caprate 0.25%, fluocortolone pivate 0.25%, net price 50 g = £2.95. Label: 28, counselling, application, see p. 708. Potency: moderate

**Excipients** include disodium edetate, fragrance, hydroxybenzoates (parabens), stearyl alcohol

**Ointment**, fluocortolone 0.25%, fluocortolone caprate 0.25%, net price 50 g = £2.95. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include wool fat, fragrance

---

**FLUTICASONE PROPIONATE**

**Indications** inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Dose**
- Apply thinly 1–2 times daily

**Cultivate** *(GSK)*

**Cream**, fluticasone propionate 0.05%, net price 15 g = £2.27, 30 g = £4.24. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include cetostearyl alcohol, stearyl alcohol, polysorbates, propylene glycol

**Ointment**, fluticasone propionate 0.005%, net price 15 g = £2.27, 30 g = £4.24. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol

---

**MOMETASONE F UROATE**

**Indications** severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids; psoriasis, see notes above

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Dose**
- Apply thinly once daily (to scalp in case of lotion)

**Elocon** *(Schering-Plough)*

**Cream**, mometasone furoate 0.1%, net price 30 g = £4.36, 100 g = £12.58. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol, stearyl alcohol

**Ointment**, mometasone furoate 0.1%, net price 30 g = £4.32, 100 g = £12.44. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol

**Scalp lotion**, mometasone furoate 0.1% in an aqueous isopropyl alcohol basis, net price 30 mL = £4.36. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol

---

**FLUCINONIDE**

**Indications** severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids; psoriasis, see notes above

**Cautions** see notes above

**Contra-indications** see notes above

**Side-effects** see notes above

**Dose**
- Apply thinly 1–2 times daily

**Metolsyn** *(GP Pharma)*

**FAPG cream**, flucinonide 0.05%, net price 25 g = £3.30, 100 g = £11.12. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol

**Ointment**, flucinonide 0.05%, net price 25 g = £2.92, 100 g = £10.96. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol, wool fat

---

**Gel**, fluocinolone acetonide 0.025%, net price 30 g = £5.56, 60 g = £10.02. For use on scalp and other hairy areas. Label: 28, counselling, application, see p. 708.

**Potency**: potent

**Excipients** include hydrocortisone (parabens), propylene glycol

**Ointment**, fluocinolone acetonide 0.025%, net price 30 g = £3.76, 100 g = £10.68. Label: 28, counselling, application, see p. 708. Potency: potent

**Excipients** include propylene glycol, wool fat

**Synalar 1 in 4 Dilution** *(GP Pharma)*

**Cream**, fluocinolone acetonide 0.00625%, net price 50 g = £4.40. Label: 28, counselling, application, see p. 708. Potency: moderate

**Excipients** include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol

**Ointment**, fluocinolone acetonide 0.00625%, net price 50 g = £4.40. Label: 28, counselling, application, see p. 708. Potency: moderate

**Excipients** include propylene glycol, wool fat

**Synalar 1 in 10 Dilution** *(GP Pharma)*

**Cream**, fluocinolone acetonide 0.0025%, net price 50 g = £4.16. Label: 28, counselling, application, see p. 708. Potency: mild

**Excipients** include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol

---

**With antimicrobials**

See notes above for comment on compound preparations
TRIAMCINOLONE ACETONIDE

Indications severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids; psoriasis, see notes above

Cautions see notes above

Contra-indications see notes above

Side-effects see notes above

Dose

● Apply thinly 1–2 times daily

With antimicrobials

See notes above for comment on compound preparations

Aureocort® (Goldshield) n

Ointment, triamcinolone acetonide 0.1%, chlortetracycline hydrochloride 3%, in an anhydrous greasy basis containing wool fat and white soft paraffin, net price 15 g = £2.70. Label: 28, counselling, application, see p. 708. Potency: potent

Excipients include wool fat

Note: Stains clothing

13.5 Preparations for eczema

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

13.5 Preparations for eczema

Eczema (dermatitis) has several causes, which may influence treatment. The main types of eczema are irritant, allergic contact, atopic, venous and discoid; different types may co-exist. Lichenification, due to scratching and rubbing, may complicate any chronic different types may co-exist. Lichenification, due to influence treatment. The main types of eczema are

Eczema involving widespread or recurrent infection requires the use of a systemic antibacterial that is active against the infecting organism. Products that combine an antiseptic with an emollient application (section 13.2.1) and with a bath emollient (section 13.2.1.1) can also be used; antiseptic shampoos (section 13.9) can be used on the scalp.

Intertriginous eczema commonly involves candida and bacteria; it is best treated with a mild or moderately potent topical corticosteroid and a suitable antimicrobial drug.

Widespread herpes simplex infection may complicate atopic eczema and treatment with a systemic antiviral drug (section 5.3.2.1) is indicated.

The management of seborrhoeic dermatitis is described below.

Management of other features of eczema Lichenification, which results from repeated scratching is treated initially with a potent corticosteroid. Bandages containing ichthammol paste (to reduce pruritus) and other substances such as zinc oxide can be applied over the corticosteroid or emollient. Coal tar (section 13.5.2) and ichthammol can be useful in some cases of chronic eczema.

A non-sedating antihistamine (section 3.4.1) may be of some value in relieving severe itching or urticaria associated with eczema. A sedating antihistamine (section 3.4.1) can be used if itching causes sleep disturbance.

Exudative (‘weeping’) eczema requires a potent corticosteroid initially; infection may also be present and require specific treatment (see above). Potassium permanganate solution (1 in 10 000) can be used in exudating eczema for its antiseptic and astringent effects; treatment should be stopped when exudation stops.

Severe refractory eczema Severe refractory eczema is best managed under specialist supervision; it may require phototherapy or drugs that act on the immune system (section 13.5.3). Alitretinoin (see p. 715) is licensed for the treatment of severe chronic hand eczema refractory to potent topical corticosteroids; patients with hyperkeratotic features are more likely to respond to alitretinoin than those with pompholyx.

Seborrhoeic dermatitis Seborrhoeic dermatitis (seborrhoeic eczema) is associated with species of the yeast Malassezia and affects the scalp, paranasal areas, and eyebrows. Shampoos active against the yeast (including those containing ketoconazole and coal tar, section 13.9) and combinations of mild corticosteroids with suitable antimicrobials (section 13.4) are used.
Topical preparations for eczema

ICHTHAMMOL

Indications chronic lichenified eczema
Side-effects skin irritation
Dose
• Apply 1–3 times daily

Icthammol Ointment, BP 1980
Ointment, ichthammol 10%, yellow soft paraffin 45%, wool fat 45%
Zinc and Icthammol Cream, BP
Cream, ichthammol 5%, cetostearyl alcohol 3%, wool fat 10%, in zinc cream
Zinc Paste and Icthammol Bandage, BP 1993
See Appendix 8 (section A8.8.9)

Oral retinoid for eczema

The retinoid, alitretinoin, is licensed for the treatment of severe chronic hand eczema refractory to potent topical corticosteroids; patients with hyperkeratotic features are more likely to respond to alitretinoin than those with pannophyly.

Alitretinoin should be prescribed only by, or under the supervision of, a consultant dermatologist.

Alitretinoin is teratogenic and must not be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician. See also Pregnancy Prevention under Cautions, below.

NICE guidance
Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009)
Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after 12 weeks, or if an adequate response has not been achieved by 24 weeks.

ALITRETINOIN

Indications severe chronic hand eczema refractory to potent topical corticosteroids
Cautions avoid blood donation during treatment and for at least 1 month after stopping treatment; monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)—discontinue if uncontrolled hyperlipidaemia; history of depression; dry eye syndrome; interactions: Appendix 1 (retinoids)

Pregnancy prevention In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods. Each prescription for alitretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment

Contra-indications uncontrolled hyperlipidaemia; uncontrolled hypothyroidism; hypervitaminosis A

Hepatic impairment manufacturer advises avoid—no information available

Renal impairment manufacturer advises avoid in severe impairment—no information available

Pregnancy avoid—teratogenic; effective contraception must be used—see Pregnancy Prevention above

Breast-feeding manufacturer advises avoid

Side-effects raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9 mmol/litre), flushing; headache; changes in thyroid function tests; anaemia; myalgia, raised creatine kinase, arthralgia; conjunctivitis, dry eyes (may respond to lubricating eye ointment or tear replacement therapy)—sometimes decreased tolerance to contact lenses, eye irritation; dryness of skin and lips, cheilitis, erythema, alopecia; less commonly epistaxis, hyperosmosis, ankylosing spondylitis, blurred vision, cataracts, pruritus, and astecotic eczema; rarely benign intracranial hypertension (discontinue if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur) and vasculitis; also reported keratitis and impaired night vision

Dose
• ADULT over 18 years, 30 mg once daily, reduced to 10 mg once daily if not tolerated; patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease, initially 10 mg once daily, increased if necessary up to max. 30 mg daily

Note Duration of treatment 12–24 weeks; discontinue if no response after 12 weeks. Course may be repeated in those who relapse. See also Pregnancy Prevention, above

Toctino (Basilea) ▼ ▼ ▼ 30-cap pack = £411.43; 30 mg (red-brown), 30-cap pack = £411.43. Label: 10, patient information leaflet, 11, 21

13.5.2 Preparations for psoriasis

Psoriasis is characterised by epidermal thickening and scaling. It commonly affects extensor surfaces and the scalp. For mild psoriasis, reassurance and treatment with an emollient may be all that is necessary.

Occasionally psoriasis is provoked or exacerbated by drugs such as lithium, chloroquine and hydroxychloroquine, beta-blockers, non-steroidal anti-inflammatory drugs, and ACE inhibitors. Psoriasis may not be seen until the drug has been taken for weeks or months.

Emollients (section 13.2.1), in addition to their effects on dryness, scaling and cracking, may have an anti-proliferative effect in psoriasis. They are particularly useful in inflammatory psoriasis and in plaque psoriasis of palms and soles, in which irritant factors can perpe- tuate the condition. Emollients are useful adjuncts to other more specific treatment.
More specific topical treatment for chronic stable plaque psoriasis on extensor surfaces of trunk and limbs involves the use of vitamin D analogues, coal tar, dithranol, and the retinoid tazarotene. However, they can irritate the skin and are not suitable for the more inflammatory forms of psoriasis; their use should be suspended during an inflammatory phase of psoriasis. The efficacy and the irritancy of each substance varies between patients. If a substance irritates significantly, it should be stopped or the concentration reduced; if it is tolerated, its effects should be assessed after 4 to 6 weeks and treatment continued if it is effective.

Widespread unstable psoriasis of erythrodermic or generalised pustular type requires urgent specialist assessment. Initial topical treatment should be limited to using emollients frequently and generously; emollients should be prescribed in quantities of 1 kg or more. More localised acute or subacute inflammatory psoriasis with hot, spreading or itchy lesions, should be treated topically with emollients or with a corticosteroid of moderate potency.

Calcipotriol and tacalcitol are analogues of vitamin D that affect cell division and differentiation. Calcipotriol is an active form of vitamin D. Vitamin D and its analogues are used as first-line treatment for plaque psoriasis; they do not smell or stain and they may be more acceptable than tar or dithranol products. Of the vitamin D analogues, tacalcitol and calcipotriol are less likely to irritate.

Coal tar has anti-inflammatory properties that are useful in chronic plaque psoriasis; it also has antiscalping properties. Crude coal tar (coal tar, BP) is the most effective form, typically in a concentration of 1 to 10% in a soft paraffin base, but few outpatients tolerate the smell and mess. Cleanser extracts of coal tar included in proprietary preparations, are more practicable for home use but they are less effective and improvement takes longer. Contact of coal tar products with normal skin is not normally harmful and they can be used for widespread small lesions; however, irritation, contact allergy, and sterile folliculitis can occur. The milder tar extracts can be used on the face and flexures. Tar baths and tar shampoos are also helpful.

Dithranol is effective for chronic plaque psoriasis. Its major disadvantages are irritation (for which individual susceptibility varies) and staining of skin and of clothing. It should be applied to chronic extensor plaques only, carefully avoiding normal skin. Dithranol is not generally suitable for widespread small lesions nor should it be used in the flexures or on the face. Treatment should be started with a low concentration such as dithranol 0.1%, and the strength increased gradually every few days up to 3%, according to tolerance. Proprietary preparations are more suitable for home use; they are usually washed off after 5 to 60 minutes (‘short contact’). Specialist nurses may apply intensive treatment with dithranol paste which is covered by stockinette dressings and usually retained overnight. Dithranol should be discontinued if even a low concentration causes acute inflammation; continued use can result in the psoriasis becoming unstable. When applying dithranol, hands should be protected by gloves or they should be washed thoroughly afterwards.

Tazarotene, a retinoid, seems to be less effective than calcipotriol with a greater incidence of irritation. Although irritation is common, it is minimised by applying tazarotene sparingly to the plaques and avoiding normal skin. Tazarotene is clean and odourless.

A topical corticosteroid (section 13.4) is not generally suitable as the sole treatment of extensive chronic plaque psoriasis; any early improvement is not usually maintained and there is a risk of the condition deteriorating or of precipitating an unstable form of psoriasis (e.g. erythrodermic psoriasis or generalised pustular psoriasis). However, it may be appropriate to treat psoriasis in specific sites, such as the face and flexures, usually with a mild corticosteroid, and psoriasis of the scalp, palms, and soles with a potent corticosteroid.

Combining the use of a corticosteroid with another specific topical treatment may be beneficial in chronic plaque psoriasis; the drugs may be used separately at different times of the day or used together in a single formulation. Eczema co-existing with psoriasis may be treated with a corticosteroid, or coal tar, or both.

Scalp psoriasis is usually scaly, and the scale may be thick and adherent. This requires softening with an emollient ointment, cream, or oil and usually combined with salicylic acid as a keratolytic.

Some preparations prescribed for psoriasis affecting the scalp combine salicylic acid with coal tar or sulphur. Preparations containing salicylic acid, sulphur, and coal tar are available as proprietary products. The product should be applied generously and an adequate quantity should be prescribed. It should be left on for at least an hour, often more conveniently overnight, before washing it off. If a corticosteroid lotion or gel is required (e.g. for itch), it can be used in the morning.

Phototherapy Phototherapy is available in specialist centres under the supervision of a dermatologist. Ultraviolet B (UVB) radiation is usually effective for chronic stable psoriasis and for guttate psoriasis. It may be considered for patients with moderately severe psoriasis in whom topical treatment has failed, but it may irritate inflammatory psoriasis.

Photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) is available in specialist centres under the supervision of a dermatologist. The psoralen, which enhances the effect of irradiation, is administered either by mouth or topically. PUVA is effective in most forms of psoriasis, including localised palmoplantar pustular psoriasis. Early adverse effects include photoxicity and pruritus. Higher cumulative doses exaggerate skin ageing, increase the risk of dysplastic and neoplastic skin lesions, especially squamous cancer, and pose a theoretical risk of cataracts.

Phototherapy combined with coal tar, dithranol, tazarotene, topical vitamin D or vitamin D analogues, or oral acitretin, allows reduction of the cumulative dose of phototherapy required to treat psoriasis.

Systemic treatment Systemic treatment is required for severe, resistant, unstable or complicated forms of psoriasis, and it should be initiated only under specialist supervision. Systemic drugs for psoriasis include acitretin (see below) and drugs that affect the immune response (such as ciclosporin and methotrexate, section 13.5.3).

Systemic corticosteroids should be used only rarely in psoriasis because rebound deterioration may occur on reducing the dose.

Acitretin, a metabolite of etretinate, is a retinoid (vitamin A derivative); it is prescribed by specialists. The main indication for acitretin is psoriasis, but it is also used in disorders of keratinisation such as severe
Darier’s disease (keratosis follicularis), and some forms of ichthyosis. Although a minority of cases of psoriasis respond well to acitretin alone, it is only moderately effective in many cases and it is combined with other treatments. A therapeutic effect occurs after 2 to 4 weeks and the maximum benefit after 4 to 6 weeks or longer. The manufacturers of acitretin do not recommend continuous treatment for longer than 6 months. However, some patients may benefit from longer treatment, provided that the lowest effective dose is used.

Apart from teratogenicity, which remains a risk for 3 years after stopping, acitretin is the least toxic systemic treatment for psoriasis; in women with a potential for child-bearing, the possibility of pregnancy must be excluded before treatment and effective contraception must be used during treatment and for at least 3 years afterwards (oral progestogen-only contraceptives not considered effective). Common side-effects derive from its widespread but reversible effects on epithelia, such as dry and cracking lips, dry skin and mucosal surfaces, hair thinning, paronychia, and soft and sticky palms and soles.

Topical preparations for psoriasis

Vitamin D and analogues

Calcipotriol, calcitriol, and tacalcitol are used for the management of plaque psoriasis. They should be avoided by those with calcium metabolism disorders, and used with caution in generalised pustular or erythrodermic exfoliative psoriasis (enhanced risk of hypercalcaemia). Local skin reactions (itching, erythema, burning, paraesthesia, dermatitis) are common. Hands should be washed thoroughly after application to avoid inadvertent transfer to other body areas. Aggravation of psoriasis has also been reported.

CALCIPOTRIOL

Indications see under Dose

Cautions see notes above; avoid use on face; avoid excessive exposure to sunlight and sunlamps

Contra-indications see notes above

Pregnancy manufacturers advise avoid unless essential

Breast-feeding no information available

Side-effects see notes above; also photosensitivity, dry skin; rarely facial or perioral dermatitis, skin atrophy

Dose

- Plaque psoriasis, apply cream or ointment once or twice daily; max. 100 g weekly (less with scalp solution, see below); CHILD over 6 years, apply twice daily; 6–12 years max. 50 g weekly; over 12 years max. 75 g weekly.

Note Patient information leaflets for Dovonex® cream and ointment advise liberal application (but note max. recommended weekly dose, above)

- Scalp psoriasis, apply scalp solution twice daily; max. 60 mL weekly (less with cream or ointment, see below); CHILD under 18 years see BNF for Children

Note When preparations used together max. total calcipotriol 5 mg in any one week (e.g. scalp solution 60 mL with cream or ointment 30 g or cream or ointment 60 g with scalp solution 30 mL)

Calcipotriol (Non-proprietary) (Calcipotriol, calcitriol 50 micrograms/g, net price 120 g = £24.04

Note Not licensed for use in children under 18 years

Scalp solution, calcipotriol 50 micrograms/mL, net price 60 mL = £12.53, 120 mL = £26.07

Dovonex® (LEO) (Calcipotriol, calcitriol 50 micrograms/g, net price 120 g = £23.10

Excipients include cetostearyl alcohol, disodium edetate

Ointment, calcipotriol 50 micrograms/g, net price 120 g = £23.10

Excipients include propylene glycol

With betamethasone

For prescribing information and for comment on the limited role of corticosteroids in psoriasis, see section 13.4.

Dovobet® (LEO) (Calcipotriol, calcitriol (as dipropionate) 0.05%, calcitriol (as monohydrate) 50 micrograms/g, net price 60 g = £32.99, 120 g = £61.27. Label: 28

Excipients note as listed in section 13.13

Dose stable plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily, max. 100 g weekly) for 4 weeks; if necessary, subsequent courses repeated on the advice of a specialist. CHILD under 18 years see BNF for Children

Gel, betamethasone (as dipropionate) 0.05%, calcitriol (as monohydrate) 50 micrograms/g, net price 60 g = £36.50, 2 x 60 g = £67.79. Label: 28

Excipients include butylated hydroxytoluene

Dose scalp psoriasis, ADULT over 18 years, apply 1–4 g to scalp once daily, shampoo off after leaving on scalp overnight or during day; usual duration of therapy 4 weeks; if necessary, subsequent courses repeated on the advice of a specialist

Mild to moderate plaque psoriasis, ADULT over 18 years, apply once daily to max. 30% of body surface (max. 15 g daily, max. 100 g weekly) for 8 weeks; if necessary, subsequent courses repeated on the advice of a specialist

Note When different preparations containing calcipotriol used together, max. total calcipotriol 5 mg in any one week

Xamiol® (LEO) (Calcipotriol, calcitriol (as dipropionate) 0.05%, calcitriol (as monohydrate) 50 micrograms/g, net price 60 g = £36.50, 120 g = £67.79. Label: 28

Excipients include butylated hydroxytoluene

Dose scalp psoriasis, ADULT over 18 years, apply 1–4 g to scalp once daily, shampoo off after leaving on scalp overnight or during day; usual duration of therapy 4 weeks; if necessary, subsequent courses repeated on the advice of a specialist

Mild to moderate plaque psoriasis, ADULT over 18 years, apply once daily to max. 30% of body surface (max. 15 g daily, max. 100 g weekly) for 8 weeks; if necessary, subsequent courses repeated on the advice of a specialist

Note When different preparations containing calcipotriol used together, max. total calcipotriol 5 mg in any one week

CALCITRIOL (1,25-Dihydroxycholecalciferol)

Indications mild to moderate plaque psoriasis

Cautions see notes above

Contra-indications see notes above; do not apply under occlusion

Hepatic impairment manufacturer advises avoid—no information available

Renal impairment manufacturer advises avoid—no information available

Pregnancy avoid—use in restricted amounts if clearly necessary (risk of significant systemic absorption; monitor urine- and plasma-calcium concentration)

Breast-feeding manufacturer advises avoid

Side-effects see notes above
TACALCITOL

Indications plaque psoriasis

Cautions see notes above; avoid eyes; monitor plasma calcium if risk of hypercalcaemia; if used in conjunction with UV treatment, UV radiation should be given in the morning and tacalcitol applied at bedtime

Contra-indications see notes above

Renal impairment monitor serum-calcium concentration

Pregnancy manufacturer advises avoid unless no safer alternative—no information available

Breast-feeding manufacturer advises avoid application to breast area; no information available on presence in milk

Side-effects see notes above

Dose

ADULT and CHILD over 12 years, apply once daily preferably at bedtime; max. 10 g ointment or 10 mL lotion daily

Note When lotion and ointment used together, max. total tacalcitol 280 micrograms in any one week (e.g. lotion 30 mL with ointment 40 g)

Curatoderm® (Almiral) 

Lotion, tacalcitol (as monohydrate) 4 micrograms/g, net price 30 mL = £12.73

Excipients include disodium edetate, propylene glycol

Ointment, tacalcitol (as monohydrate) 4 micrograms/g, net price 30 g = £13.40, 60 g = £23.14, 100 g = £30.86

Excipients none as listed in section 13.1.3

Tazarotene

TAZAROTENE

Indications mild to moderate plaque psoriasis affecting up to 10% of skin area

Cautions wash hands immediately after use, avoid excessive exposure to UV light (including sunlight, solariums, PUVA or UVB treatment); do not apply emollients or cosmetics within 1 hour of application

Pregnancy avoid, effective contraception required (oral progestogen-only contraceptives not considered effective)

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects local irritation (more common with higher concentration and may require discontinuation), pruritus, burning, erythema, desquamation, non-specific rash, contact dermatitis, and worsening of psoriasis; rarely stinging and inflamed, dry or painful skin

Dose

Apply once daily in the evening usually for up to 12 weeks; CHILD under 18 years not recommended

Zorac® (Allergan) 

Gel, tazarotene 0.05%, net price 30 g = £14.09; 0.1%, 30 g = £14.80

Excipients include benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, disodium edetate, polysorbate 40

Tars

Indications psoriasis and occasionally chronic atopic eczema

Cautions application to face and skin flexures; use suitable chemical protection gloves for extemporaneous preparation

Contra-indications not for use in sore, acute, or purulent psoriasis or in presence of infection; avoid eyes, mucosa, genital or rectal areas; broken or inflamed skin

Side-effects skin irritation and acne-like eruptions, photosensitivity; stains skin, hair, and fabric

Dose

Apply 1–3 times daily starting with low-strength preparations

Note For shampoo preparations see section 13.9; for use with dressings see Appendix 8 (section A8.8.9)

Non-proprietary preparations

May be difficult to obtain. Patients may find newer proprietary preparations more acceptable

Calamine and Coal Tar Ointment, BP

Ointment, calamine 12.5 g, strong coal tar solution 2.5 g, zinc oxide 12.5 g, hydrous wool fat 25 g, white soft paraffin 47.5 g

Excipients include wool fat

Dose apply 1–2 times daily

Coal Tar and Salicylic Acid Ointment, BP

Ointment, coal tar 2 g, salicylic acid 2 g, emulsifying wax 11.4 g, white soft paraffin 19 g, coconut oil 54 g, polyethylene glycol 600, liquid paraffin 7.8 g

Excipients include cetostearyl alcohol

Dose apply 1–2 times daily

Coal Tar Paste, BP

Paste, strong coal tar solution 7.5%, in compound zinc paste

Dose apply 1–2 times daily

Zinc and Coal Tar Paste, BP

Paste, zinc oxide 6%, coal tar 6%, emulsifying wax 5%, starch 38%, yellow soft paraffin 45%

Excipients include cetostearyl alcohol

Dose apply 1–2 times daily

Proprietary preparations

Carbo-Dome® (Sandoz)

Cream, coal tar solution 10%, in a water-miscible basis, net price 30 g = £4.77, 100 g = £16.38

Excipients include benzyl alcohol, hydroxybenzoates (parabens)

Dose psoriasis, apply to skin 2–3 times daily

Cocos® (UCB Pharma)

Scalp ointment, coal tar solution 12%, salicylic acid 2%, precipitated sulphur 4%, in a coconut oil emulsion basis, net price 40 g (with applicator nozzle) = £5.98, 100 g = £11.23

Excipients include cetostearyl alcohol

Dose scaly scalp disorders including psoriasis, eczema, seborrheic dermatitis and dandruff, apply to scalp once weekly as necessary (if severe use daily for first 3–7 days), shampoo off after 1 hour; CHILD 6–12 years, medical supervision required (not recommended under 6 years)
**Polytar Emollient** *(Stiefel)*

- **Bath additive,** coal tar solution 2.5%, arachis (peanut) oil extract of coal tar 7.5%, paraffin 5%, cera cata 4.5%, liquid paraffin 5%, net price 500 mL = £8.54. **Excipients** include isopropyl palmitate. **Dose** psoriasis, apply to skin or scalp 1–2 times daily. **Scalp liquid**—section 13.9.

**Psoriderm** *(Derma)*

- **Cream,** coal tar 6%, lecithin 0.4%, net price 225 mL = £9.42. **Excipients** include isopropyl palmitate, propylene glycol. **Dose** psoriasis, apply to skin or scalp 1–2 times daily.

**Scalp lotion**—section 13.9.

**Sebco** *(Derma UK)*

- **Scalp ointment,** coal tar solution 12%, salicylic acid 2%, precipitated sulphur 4%, in a coconut oil emollient basis, net price 40 g = £4.54, 100 g = £8.52. **Excipients** include cetostearyl alcohol. **Dose** scalp scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff, apply to scalp as necessary (if severe use daily for first 3–7 days), shampoo off after 1 hour; (CHILD) 6–12 years, medical supervision required (not recommended over 6 years).

**Seborpure** *(Derma)*

- **Cream,** coal tar 6%, coal tar solution 4%, precipitated sulphur 4%, net price 100 mL = £7.95, 200 mL = £15.90. **Excipients** include isopropyl palmitate, propylene glycol. **Dose** psoriasis, apply to skin or scalp 1–2 times daily. **Scalp solution**—section 13.9.

**SALICYLIC ACID**

- **Cream,** coal tar 1%, salicylic acid 2%, precipitated sulphur 4%, in a coconut oil emollient basis, net price 40 g = £4.54, 100 g = £8.52. **Excipients** include cetostearyl alcohol. **Dose** scalp scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff, apply to scalp as necessary (if severe use daily for first 3–7 days), shampoo off after 1 hour; (CHILD) 6–12 years, medical supervision required (not recommended over 6 years).

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp shampoo**—section 13.9.

**Scalp wash**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp shampoo**—section 13.9.

**Scalp wash**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.

**Scalp cream**—section 13.9.

**Scalp lotion**—section 13.9.

**Scalp oil**—section 13.9.

**Scalp emulsion**—section 13.9.

**Scalp gel**—section 13.9.

**Scalp solution**—section 13.9.
conditions (section 13.9); fungal nail infections (section 13.10.2)

Cautions see notes above; avoid broken or inflamed skin

Salicylate toxicity Salicylate toxicity may occur particularly if applied on large areas of skin or neonatal skin

Side-effects sensitivity, excessive drying, irritation, systemic effects after widespread use (see under Cautions)

Dose
- See preparations

Zinc and Salicylic Acid Paste, BP Paste, (Lassar's Paste), zinc oxide 24%, salicylic acid 2%, starch 24%, white soft paraffin 50%, net price 25 g = 17p

Dose apply twice daily

Oral retinoids for psoriasis

ACITRETIN

Note Acitretin is a metabolite of etretinate

Indications severe extensive psoriasis resistant to other forms of therapy; palmoplantar pustular psoriasis; severe congenital ichthyosis; severe Darier's disease (keratosis follicularis)

Cautions exclude pregnancy before starting (test for pregnancy within 2 weeks before treatment and monthly thereafter; start treatment on day 2 or 3 of menstrual cycle)—women (including those with history of infertility) should avoid pregnancy and use effective contraception for at least 1 month before, during, and for at least 3 years after treatment (oral progesteron-only contraceptives not considered effective); patients should avoid concomitant tetracycline or methotrexate, high doses of vitamin A (more than 4000–5000 units daily), and use of keratolytics, and should not donate blood during or for at least 1 year after stopping therapy (teratogenic risk); check liver function at start, then every 2–4 weeks for first 2 months and then every 3 months; monitor serum-triglyceride and serum-cholesterol concentrations every 2–4 weeks for first 2 months, then every 3 months; diabetes (can alter glucose tolerance—initial frequent blood glucose checks); radiographic assessment on long-term treatment; investigate atypical musculoskeletal symptoms; in children use only in exceptional circumstances (pre-mature epiphyseal closure reported); avoid exposure to sunlight and unsupervised use of sunlamps; interactions: Appendix 1 (retinoids)

Contra-indications hyperlipidaemia

Hepatic impairment avoid—risk of further impairment

Renal impairment avoid; increased risk of toxicity

Pregnancy avoid—teratogenic; effective contraception must be used—see Cautions above

Breast-feeding avoid

Side-effects dryness of mucous membranes (sometimes erosion), of skin (sometimes scaling, thinning, erythema especially of face, and pruritus), and of conjunctiva (sometimes conjunctivitis and decreased tolerance of contact lenses); sticky skin, dermatitis; other side-effects reported include palmoplantar exfoliation, epistaxis, epidermal and nail fragility, peripheral oedema, vulvovaginal candidiasis, paronychia, granulomatous lesions, bullous eruptions, reversible hair thinning and alopecia, myalgia and arthralgia, occasional nausea, headache, malaise, drowsiness, rhinitis, sweating, taste disturbance, stomatitis, cheilitis, and gingivitis; benign intracranial hypertension (discontinue if severe headache, vomiting, diarrhoea, abdominal pain, and visual disturbance occur; avoid concomitant tetracyclines); photosensitivity, corneal ulceration, rarely jaundice and hepatitis (avoid concomitant methotrexate); raised serum-triglyceride or serum-cholesterol concentration; decreased night vision reported; skeletal hyperostosis and extra-osseous calcification reported following long-term administration of etretinate (and premature epiphyseal closure in children, see Cautions above)

Dose
- ADULT over 18 years (under expert supervision), initially 25–30 mg daily (Darier's disease 10 mg daily) for 2–4 weeks, then adjusted according to response, usual range 25–50 mg daily; up to 75 mg daily for short periods in psoriasis and ichthyosis (see p. 716); CHILD under 18 years see BNF for Children

Neotigason® (Actavis) Capsules, acitretin 10 mg (brown/white), net price 60-cap pack = £23.80; 25 mg (brown/yellow), 60-cap pack = £55.24. Label: 10, patient information leaflet, 11, 21

13.5.3 Drugs affecting the immune response

Drugs affecting the immune response are used for eczema or psoriasis. Systemic drugs acting on the immune system are used under specialist supervision.

Pimecrolimus by topical application is licensed for mild to moderate atopic eczema. Tacrolimus is licensed for topical use in moderate to severe atopic eczema. Both are drugs whose long-term safety is still being evaluated and they should not usually be considered first-line treatments unless there is a specific reason to avoid or reduce the use of topical corticosteroids. Treatment with topical pimecrolimus or topical tacrolimus should be initiated only by prescribers experienced in treating atopic eczema

NICE guidance Tacrolimus and pimecrolimus for atopic eczema (August 2004)

Topical pimecrolimus and tacrolimus are options for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy).

Topical pimecrolimus is recommended for moderate atopic eczema on the face and neck of children aged 2–16 years and topical tacrolimus is recommended for moderate to severe atopic eczema in adults and children over 2 years. Pimecrolimus and tacrolimus should be used within their licensed indications.

For the role of topical corticosteroids in eczema, see section 13.5.1, and for comment on their limited role in psoriasis, see section 13.4. A short course of a systemic corticosteroid (section 6.3.2) can be given for eczema flares that have not improved despite appropriate topical treatment.
Ciclosporin by mouth can be used for severe psoriasis and for severe eczema. Azathioprine or mycophenolate mofetil (section 8.2.1) are used for severe refractory eczema [unlicensed indication]. Hydroxychloroquine (section 8.2.2) is used by mouth for severe psoriasis [unlicensed indication].

Methotrexate can be used for severe psoriasis, the dose being adjusted according to severity of the condition and haematological and biochemical measurements. Folic acid 5 mg (section 9.1.2) can be given once weekly [unlicensed indication], on a different day from the methotrexate, to reduce the possibility of side-effects associated with methotrexate; alternative regimens of folic acid may be used in some settings.

Etanercept, adalimumab, and infliximab inhibit the activity of tumour necrosis factor (TNF-α). They are used for severe plaque psoriasis either refractory to at least 2 standard systemic treatments and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications; while either etanercept or adalimumab is considered to be the first choice in stable disease, adalimumab or infliximab may be useful when rapid disease control is required. Ustekinumab (a monoclonal antibody that inhibits interleukins 12 and 23) can be used for severe plaque psoriasis that has not responded to etanercept, adalimumab, or infliximab, or when these drugs cannot be used because of intolerance or contra-indications (see also NICE guidance below). Adalimumab, etanercept, and infliximab are also licensed for psoriatic arthritis (section 10.1.3).

NICE guidance
Adalimumab for plaque psoriasis in adults
Adalimumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Adalimumab should be withdrawn if the response is not adequate after 16 weeks.

NICE guidance
Etanercept and efalizumab for plaque psoriasis in adults
Etanercept is recommended for severe psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Etanercept should be withdrawn if the response is not adequate after 12 weeks. Following suspension of the marketing authorisation for efalizumab, NICE has temporarily withdrawn its guidance on the use of efalizumab for plaque psoriasis.

NICE guidance
Infliximab for plaque psoriasis in adults
Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.

NICE guidance
Ustekinumab for plaque psoriasis in adults
Ustekinumab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Ustekinumab should be withdrawn if the response is not adequate after 16 weeks. For patients weighing over 100 kg, the manufacturer should provide the 90-mg dose of ustekinumab at the same price as the 45-mg dose.

AZATHIOPRINE
Indications
severe refractory eczema [unlicensed indication]; inflammatory bowel disease (section 1.5.3); autoimmune conditions and prophylaxis of transplant rejection (section 8.2.1); rheumatoid arthritis (section 10.1.3)
Cautions
section 8.2.1
Contra-indications
section 8.2.1; also very low or deficient thiopurine methyltransferase (TPMT) activity (homozygous phenotype)
Hepatic impairment
section 8.2.1
Renal impairment
section 8.2.1
Pregnancy
section 8.2.1
Breast-feeding
section 8.2.1
Side-effects
section 8.2.1
Dose
Severe refractory eczema [unlicensed indication], by mouth, normal or high TPMT activity, 1–3 mg/kg daily; low TPMT activity (heterozygous phenotype), 0.5–1 mg/kg daily
Preparations
Section 8.2.1

CICLOSPORIN
(Cyclosporin)
Indications
see under Dose; severe acute ulcerative colitis (section 1.5.3); transplantation and graft-versus-host disease (section 8.2.2)
Cautions
section 8.2.2
Additional cautions in atopic dermatitis and psoriasis
Contra-indicated in abnormal renal function, uncontrolled hypertension (see also below), infections not under control, and malignancy (see also below). Dermatological and physiological examination, including blood pressure and renal function measurements required at least twice before starting. During treatment, monitor serum creatinine every 2

2. The Scottish Medicines Consortium issued similar advice (August 2009) on the use of etanercept in adults and children over 8 years of age
weeks for first 3 months then every month; reduce dose by 25–50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month. Discontinue if hypertension develops that cannot be controlled by dose reduction or antihypertensive therapy. Avoid excessive exposure to sunlight and avoid use of UVB or PUVA. In atopic dermatitis, also allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe). Staphylococcus aureus skin infections not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative—see also interactions: Appendix 1 (ciclosporin)); investigate lymphaedenopathy that persists despite improvement in atopic dermatitis. In psoriasis, also exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis) and treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option); discontinue if lymphoproliferative disorder develops.

**Hepatic impairment** section 8.2.2

**Renal impairment** see Cautions above

**Pregnancy** see Immunosuppressant therapy, p. 553

**Breast-feeding** section 8.2.2

**Side-effects** section 8.2.2

**Dose**
- Short-term treatment (usually for max. 8 weeks but can be longer under specialist supervision) of severe atopic dermatitis where conventional therapy ineffective or inappropriate, administered in accordance with expert advice, by mouth, ADULT and CHILD over 16 years, initially 2.5 mg/kg daily in 2 divided doses, if good initial response not achieved within 2 weeks, increase rapidly to max. 5 mg/kg daily; initial dose of 5 mg/kg daily in 2 divided doses if very severe; CHILD under 16 years see BNF for Children
- Severe psoriasis where conventional therapy ineffective or inappropriate, administered in accordance with expert advice, by mouth, ADULT and CHILD over 16 years, initially 2.5 mg/kg daily in 2 divided doses, increased gradually to max. 5 mg/kg daily if no improvement within 1 month (discontinue if response still insufficient after 6 weeks); initial dose of 5 mg/kg daily justified if rapid control required; CHILD under 16 years see BNF for Children

**Important**

For preparations and counselling and for advice on conversion between the preparations, see section 8.2.2

## METHOTREXATE

**Indications** severe psoriasis unresponsive to conventional therapy (specialist use only); Crohn’s disease (section 1.5.3); malignant disease (section 8.1.3); rheumatoid arthritis (section 10.1.3)

**Cautions** section 10.1.3; also photosensitivity—psoriasis lesions aggravated by UV radiation (skin ulceration reported)

**Contra-indications** section 10.1.3

**Hepatic impairment** avoid—dose-related toxicity

**Renal impairment** section 10.1.3

**Pregnancy** section 10.1.3

**Breast-feeding** section 10.1.3

**Side-effects** section 10.1.3

**Dose**
- By mouth or by intramuscular or intravenous or subcutaneous injection, 2.5–10 mg once weekly; increased according to response in steps of 2.5–5 mg at intervals of at least 1 week; usual dose 7.5–15 mg once weekly; max. weekly dose 30 mg; **ELDERLY** consider dose reduction (extreme caution); **CHILD** 2–18 years see BNF for Children

### Important

Note that the above dose is a weekly dose. To avoid error with low dose methotrexate, it is recommended that:
- the patient is carefully advised of the dose and frequency and the reason for taking methotrexate and any other prescribed medicine (e.g. folic acid);
- only one strength of methotrexate tablet (usually 2.5 mg) is prescribed and dispensed;
- the prescription and the dispensing label clearly show the dose and frequency of methotrexate administration;
- the patient is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers); liver toxicity (e.g. nausea, vomiting, except emollients at treatment site; alcohol consumption (risk of facial flushing and skin irritation)

### Contra-indications

contact with eyes and mucous membranes, application under occlusion, infection at treatment site; congenital epidermal barrier defects; generalised erythroderma; immunodeficiency; concomitant use with drugs that cause immunosuppression (may be prescribed in exceptional circumstances by specialists); application to malignant or potentially malignant skin lesions

**Side-effects** burning sensation, pruritus, erythema, skin infections (including folliculitis and less commonly impetigo, herpes simplex and zoster, molluscum contagiosum); rarely papilloma, skin discoloration, local reactions including pain, paraesthesia, peeling, dryness, oedema, and worsening of eczema; skin malignancy reported

**Dose**
- Short-term treatment, apply twice daily until symptoms resolve (stop treatment if eczema worsens or no response after 6 weeks); **CHILD** under 2 years not recommended

**Eldel®** (Novartis) Cream, pimecrolimus 1%, net price 30 g = £19.69, 60 g = £37.41, 100 g = £59.07. Label: 4, 28

**Excipients** include benzyl alcohol, cetyl alcohol, propylene glycol, stearyl alcohol

## PIMECROLIMUS

**Indications** short-term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used; see also notes above

**Cautions** UV light (avoid excessive exposure to sunlight and sunlamps), avoid other topical treatments except emollients at treatment site; alcohol consumption (risk of facial flushing and skin irritation)

**Contra-indications** contact with eyes and mucous membranes, application under occlusion, infection at treatment site; congenital epidermal barrier defects; generalised erythroderma; immunodeficiency; concomitant use with drugs that cause immunosuppression (may be prescribed in exceptional circumstances by specialists); application to malignant or potentially malignant skin lesions

**Side-effects** burning sensation, pruritus, erythema, skin infections (including folliculitis and less commonly impetigo, herpes simplex and zoster, molluscum contagiosum); rarely papilloma, skin discoloration, local reactions including pain, paraesthesia, peeling, dryness, oedema, and worsening of eczema; skin malignancy reported

**Dose**
- Short-term treatment, apply twice daily until symptoms resolve (stop treatment if eczema worsens or no response after 6 weeks); **CHILD** under 2 years not recommended

**Eldel®** (Novartis) Cream, pimecrolimus 1%, net price 30 g = £19.69, 60 g = £37.41, 100 g = £59.07. Label: 4, 28

**Excipients** include benzyl alcohol, cetyl alcohol, propylene glycol, stearyl alcohol

### Preparations

Section 10.1.3

### TACROLIMUS

**Indications** short-term treatment of moderate to severe atopic eczema (including flares) either unresponsive to, or in patients intolerant of conventional therapy; prevention of flares in patients with moderate to severe atopic eczema and 4 or more flares a year who have responded to initial treatment with topical tacrolimus; see also notes above; other indications section 8.2.2

**BNF 61**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**

---

### BNF for Children

**A** A,

**C**

**c**

—

**TACROLIMUS**
Cautions infection at treatment site, UV light (avoid excessive exposure to sunlight and sunlamps); alcohol consumption (risk of facial flushing and skin irritation)

Contra-indications congenital epidermal barrier defects; generalised erythrodema; immunodeficiency; concomitant use with drugs that cause immunosuppression (may be prescribed in exceptional circumstances by specialists); application to malignant or potentially malignant skin lesions; avoid contact with eyes and mucous membranes; avoid under occlusion

Pregnancy manufacturer advises avoid unless essential; toxicity in animal studies following systemic administration

Breast-feeding manufacturer advises avoid—present in milk following systemic administration

Side-effects application-site reactions including rash, irritation, pain and paraesthesia; herpes simplex infection, Kaposi’s varicelliform eruption; application-site infections; less commonly acne; rosacea and skin malignancy also reported

Dose
- Short-term treatment, ADULT and CHILD over 16 years initially apply 0.1% ointment thinly twice daily until lesion clears (consider other treatment if eczema worsens or no improvement after 2 weeks); reduce to once daily or switch to 0.03% ointment if condition allows; CHILD 2–16 years, initially apply 0.03% ointment thinly twice daily for up to 3 weeks (consider other treatment if eczema worsens or if no improvement after 2 weeks) then reduce to once daily until lesion clears
- Prevention of flares, ADULT and CHILD over 16 years, apply 0.1% ointment thinly twice weekly; use short-term treatment regimen during an acute flare; review need for preventative therapy after 1 year; CHILD 2–16 years, apply 0.03% ointment thinly twice weekly; use short-term treatment regimen during an acute flare; interrupt preventative therapy after 1 year to reassess condition

Protopic® (Astellas) Ointment, tacrolimus (as monohydrate) 0.03%, net price 30 g = £19.44, 60 g = £35.46; 0.1%, 30 g = £21.60, 60 g = £39.40. Label: 4, 11, 28

Excipients include beeswax

Cytokine modulators

ADALIMUMAB

Indications see notes above; Crohn’s disease (section 1.5.3); anklyosing spondylitis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis (section 10.1.3)

Cautions section 10.1.3

Contra-indications section 10.1.3

Pregnancy section 10.1.3

Breast-feeding section 10.1.3

Side-effects section 10.1.3

Dose
- By subcutaneous injection, plaque psoriasis, ADULT over 18 years, initially 80 mg, then 40 mg on alternate weeks starting 1 week after initial dose; discontinue treatment if no response within 16 weeks

Preparations
Section 10.1.3

ETANERCEPT

Indications see notes above; anklyosing spondylitis, psoriatic arthritis, polyarticular course juvenile idiopathic arthritis, rheumatoid arthritis (section 10.1.3)

Cautions section 10.1.3

Contra-indications section 10.1.3

Hepatic impairment section 10.1.3

Pregnancy section 10.1.3

Breast-feeding section 10.1.3

Side-effects section 10.1.3

Dose
- By subcutaneous injection, plaque psoriasis, 25 mg twice weekly or 50 mg once weekly; max. treatment duration 24 weeks; discontinue if no response after 12 weeks; CHILD 8–18 years, 800 micrograms/kg (max. 50 mg) once weekly; max. treatment duration 24 weeks; discontinue if no response after 12 weeks

Preparations
Section 10.1.3

INFLIXIMAB

Indications see notes above; inflammatory bowel disease (section 1.5.3); anklyosing spondylitis, psoriatic arthritis, rheumatoid arthritis (section 10.1.3)

Cautions section 10.1.3; monitor for non-melanoma skin cancer before and during treatment

Contra-indications section 10.1.3

Pregnancy section 10.1.3

Breast-feeding section 10.1.3

Side-effects section 10.1.3

Dose
- By intravenous infusion, plaque psoriasis, ADULT over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial infusion, then every 8 weeks; discontinue if no response within 14 weeks of initial infusion

Preparations
Section 10.1.3

USTEKINUMAB

Indications see notes above

Cautions predisposition to infection; history or development of malignancy; elderly; interactions

Tuberculosis Patients should be evaluated for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment (section 5.1.9) for at least 2 months before starting ustekinumab. Patients who have previously received adequate treatment for tuberculosis can start ustekinumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting ustekinumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with ustekinumab. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop

Contra-indications active infection

Pregnancy avoid; manufacturer advises effective contraception during treatment and for 15 weeks after stopping treatment

Breast-feeding manufacturer advises avoid—present in milk in animal studies

Side-effects infections (sometimes severe); diarrhoea, hypersensitivity reactions (possibly delayed onset),
pain in pharynx and larynx; headache, fatigue, dizziness; depression; arthralgia; myalgia; nasal congestion; pruritus; injection-site reactions

**Dose**

- By subcutaneous injection, plaque psoriasis, ADULT over 18 years, body-weight under 100 kg, initially 45 mg, then 45 mg 4 weeks after initial dose, then 45 mg every 12 weeks; body-weight over 100 kg, initially 45–90 mg, then 45–90 mg 4 weeks after initial dose, then 45–90 mg every 12 weeks

**Note** Discontinue if no response within 16 weeks

Stelara® (Janssen-Cilag) ▼ [inhalation]
**Injection**, ustekinumab 90 mg/mL, net price 0.5–mL (45-mg) prefilled syringe = £2147.00. Label: 10, counselling, tuberculosis

### 13.6 Acne and rosacea

#### 13.6.1 Topical preparations for acne

**Benzoyl peroxide**

In mild to moderate acne, comedones and inflamed lesions respond well to benzoyl peroxide (see below) or to a topical retinoid (see p. 725). Alternatively, topical application of an antibiotic such as erythromycin or clindamycin may be effective for inflammatory acne. If topical preparations prove inadequate, oral preparations may be needed (section 13.6.2).

**Benzoyl peroxide and azelaic acid**

**Benzoyl peroxide** is effective in mild to moderate acne. Both comedones and inflamed lesions respond well to benzoyl peroxide. The lower concentrations seem to be as effective as higher concentrations in reducing inflammation. It is usual to start with a lower strength and to increase the concentration of benzoyl peroxide gradually. Adverse effects include local skin irritation, particularly when therapy is initiated, but the scaling and redness often subside with treatment continued at a reduced frequency of application. If the acne does not respond after 2 months then use of a topical antibacterial should be considered.

**Azelaic acid** has antimicrobial and antimcomedonal properties. It may be an alternative to benzoyl peroxide or to a topical retinoid for treating mild to moderate comedonal acne, particularly of the face. Some patients prefer azelaic acid because it is less likely to cause local irritation than benzoyl peroxide.

**Indications** acne vulgaris

**Cautions** avoid contact with eyes, mouth, and mucous membranes; may bleach fabrics and hair; avoid excessive exposure to sunlight

**Side-effects** skin irritation (reduce frequency or suspend use until irritation subsides and re-introduce at reduced frequency)

- **Dose**
  - Apply 1–2 times daily preferably after washing with soap and water, start treatment with lower-strength preparations

**Note** May bleach clothing

**Acnecide®** (Galderma)

- **Gel**, benzoyl peroxide 5% in an aqueous gel basis, net price 60 g = £10.88
  - Excipients include propylene glycol

**Brevoxy®** (Stiefel)

- **Cream**, benzoyl peroxide 4% in an aqueous basis, net price 40 g = £3.30
  - Excipients include cetyl alcohol, fragrance, stearyl alcohol

**PanOxyl®** (Stiefel)

- **Aquageel** (= aqueous gel), benzoyl peroxide 2.5%, net price 40 g = £1.76; 5%, 40 g = £1.92; 10%, 40 g = £2.13
  - Excipients include propylene glycol

- **Cream**, benzoyl peroxide 5% in a non-greasy basis, net price 40 g = £1.89
  - Excipients include isopropyl palmitate, propylene glycol

- **Gel**, benzoyl peroxide 5% in an aqueous alcoholic basis, net price 40 g = £1.51; 10%, 40 g = £1.69
  - Excipients include fragrance

**Wash**, benzoyl peroxide 10% in a detergent basis, net price 150 mL = £4.00
  - Excipients include sodium bicarbonate

**Benzoyl peroxide**

- **Cream**, benzoyl peroxide 5% in a non-greasy basis, net price 40 g = £1.89
  - Excipients include isopropyl palmitate, propylene glycol

**Azelaic acid** has antimicrobial and antimcomedonal properties. It may be an alternative to benzoyl peroxide or to a topical retinoid for treating mild to moderate comedonal acne, particularly of the face. Some patients prefer azelaic acid because it is less likely to cause local irritation than benzoyl peroxide.
Topical antibiotics for acne

For many patients with mild to moderate inflammatory acne, topical antibacterials may be no more effective than topical benzoyl peroxide or tretinoin. Topical antibacterials are probably best reserved for patients who wish to avoid oral antibacterials or who cannot tolerate them. Topical preparations of erythromycin and clindamycin are effective for inflammatory acne. Topical antibacterials can produce mild irritation of the skin, and on rare occasions cause sensitisation. Antibacterial resistance of Propionibacterium acnes is increasing; there is cross-resistance between erythromycin and clindamycin. To avoid development of resistance:

- when possible use non-antibiotic antimicrobials (such as benzoyl peroxide or azelaic acid);
- avoid concomitant treatment with different oral and topical antibacterials;
- if a particular antibacterial is effective, use it for repeat courses if needed (short intervening courses of benzoyl peroxide or azelaic acid may eliminate any resistant propionibacterium);
- do not continue treatment for longer than necessary (however, treatment with a topical preparation should be continued for at least 6 months).

13.6.1 Topical preparations for acne

**ANTIBACTERIALS**

<table>
<thead>
<tr>
<th>Indications</th>
<th>acn vulgaris</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cautions</strong></td>
<td>some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide</td>
</tr>
</tbody>
</table>

**Dalacin T®** (Pharmacia)  
**Indications** clindamycin 1% (as phosphate), in an aqueous alcoholic basis, net price (both with applicator) 30 mL = £4.34, 50 mL = £7.23  
**Cautions** some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide  
**Dose** apply twice daily  

**Lotion, clindamycin 1% (as phosphate)** in an aqueous basis, net price 30 mL = £5.08, 50 mL = £8.47  
**Cautions** some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide  
**Dose** apply twice daily  

**Stieamycin®** (Stiefel)  
**Indications** erythromycin 2% in an alcoholic basis, net price 50 mL = £7.69  
**Cautions** some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide  
**Dose** apply twice daily  

**Zinclacin®** (Crawford)  
**Indications** clindamycin 1% (as phosphate), net price 30 g = £8.66  
**Cautions** some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide  
**Dose** apply once daily  

**Zineryt**  
**Indications** powder for reconstitution, erythromycin 40 mg, zinc acetate 12 mg/mL when reconstituted with solvent containing ethanol, net price per pack of powder and solvent to provide 30 mL = £7.71, 90 mL = £16.68  
**Cautions** some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide  
**Dose** apply twice daily  

**Topical retinoids and related preparations for acne**

Topical tretinoin, its isomer isoretinoin, and adapalene (a retinoid-like drug), are useful for treating comedones and inflammatory lesions in mild to moderate acne. Patients should be warned that some redness and skin peeling can occur initially but settles with time. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. Isoretinoin is given by mouth in severe acne; see section 13.6.2 for warnings relating to use by mouth.

**Cautions** topical retinoids should be avoided in severe acne involving large areas. Contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin should be avoided. These drugs should be used with caution in sensitive areas such as the neck, and accumulation in angles of the nose should be avoided. Exposure to UV light (including sunlight, solariums) should be avoided; if sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used. Use of retinoids with abrasive cleaners, comedogenic or astringent cosmetics should be avoided. Exposure to UV light (including sunlight, solariums) should be avoided; if sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used. Use of retinoids with abrasive cleaners, comedogenic or astringent cosmetics should be avoided.
Pregnancy  Topical retinoids are contra-indicated in pregnancy; women of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).

Side-effects  Local reactions include burning, erythema, stinging, pruritus, dry or peeling skin (discontinue if severe). Increased sensitivity to UVB light or sunlight occurs. Temporary changes of skin pigmentation with severe). Increased sensitivity to UVB light or sunlight has been reported. Eye irritation and oedema, discomfort (oral). Decrease in breast milk production (breast-feeding women). Contra-indications  Personal or familial history of non-melanoma skin cancer; rosacea; perioral dermatitis; pregnancy; women of child-bearing age.

Indications  For treating acne vulgaris (see notes above; oral treatment (see section 8.1.5).

Cautions  See notes above. Breast-feeding  Amount of drug in milk probably too small to be harmful; ensure infant does not come in contact with treated areas.

Dose  ADULT and CHILD over 12 years, apply thinly once daily before retiring to bed; reduce frequency or suspend treatment if irritation occurs.

With antibacterial  Isotrexin® (Stiefel) Gel, isotretinoin 0.05%, erythromycin 2% in ethanolic basis, net price 30 g = £7.47. Label: 11

Excipients  Include butylated hydroxytoluene.

Retin-A® (Janssen-Cilag) Gel, tretinoin 0.01%, net price 60 g = £5.28; 0.025%, 60 g = £5.28. Label: 11

Excipients  Include butylated hydroxytoluene.

Dose  Acne vulgaris, apply thinly 1–2 times daily.

With antibacterial  Aknemycin® Plus (Almirall) Solution, tretinoin 0.025%, erythromycin 4% in an alcoholic basis, net price 25 mL = £7.05. Label: 11

Excipients  None as listed in section 13.1.3

Dose  Acne, apply thinly 1–2 times daily.

Other topical preparations for acne

Salicylic acid  is available in various preparations for sale direct to the public for the treatment of mild acne. Other products are more suitable for acne; salicylic acid is used mainly for its keratolytic effect.

Preparations containing abrasive agents are not considered beneficial in acne.

A topical preparation of nicotinamide is available for inflammatory acne.

Abrasive agents  Note  Isotretinoin is an isomer of tretinoin. Important: For prescribing information on isotretinoin when given by mouth, see p. 728.

Indications  Acne vulgaris (but see notes above).

Cautions  Avoid contact with eyes; discontinue use temporarily if skin becomes irritated.

Contra-indications  Superficial venules, telangiectasia.

Brasivol® (Stiefel) Paste No. 1, aluminium oxide 38.09% in fine particles, in a soap-detergent basis, net price 75 g = £2.21

Excipients  Include fragrance, N-(3-Chloroallyl)hexamminium chloride (quaternium 15)

Dose  Use instead of soap 1–3 times daily.

Nicotinamide  Indications  See under preparation.

Cautions  Avoid contact with eyes and mucous membranes (including nose and mouth); reduce frequency of application if excessive dryness, irritation or peeling.
Hormone treatment for acne

Co-cyprindiol (cyproterone acetate with ethinylestradiol) contains an anti-androgen. It is no more effective than an oral broad-spectrum antibacterial but is useful in women who also wish to receive oral contraception. Improvement of acne with co-cyprindiol probably occurs because of decreased sebum secretion which is under androgen control. Some women with moderately severe hirsutism may also benefit because hair growth is also androgen-dependent. Contra-indications of co-cyprindiol include pregnancy and a predisposition to thrombosis.

Venous thromboembolism occurs more frequently in women taking co-cyprindiol than in those taking a low-dose combined oral contraceptive. Co-cyprindiol is licensed for use in women with severe acne that has not responded to oral antibacterials and for moderately severe hirsutism; it should not be used solely for contraception. It is contra-indicated in those with a personal or close family history of venous thromboembolism. Women with severe acne or hirsutism may have an inherently increased risk of cardiovascular disease.

13.6.2 Oral preparations for acne

Oral antibacterials for acne

Systemic antibacterial treatment is useful for inflammatory acne if topical treatment is not adequately effective or if it is inappropriate. Anticomedonal treatment (e.g. with topical benzoyl peroxide) may also be required.

Either oxytetracycline or tetracycline (section 5.1.3) is usually given for acne in a dose of 500 mg twice daily. If there is no improvement after the first 3 months another oral antibacterial should be used. Maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer.

Doxycycline and lymecycline (section 5.1.3) are alternatives to tetracycline. Doxycycline can be used in a dose of 100 mg daily. Lymecycline is given in a dose of 408 mg daily.

Although minocycline is as effective as other tetracyclines for acne, it is associated with a greater risk of lupus erythematosus-like syndrome. Minocycline sometimes causes irreversible pigmentation; it is given in a dose of 100 mg once daily or 50 mg twice daily.

Erythromycin (section 5.1.5) in a dose of 500 mg twice daily is an alternative for the management of acne but propionibacteria strains resistant to erythromycin are becoming widespread and this may explain poor response.

Trimethoprim (section 5.1.8) in a dose of 300 mg twice daily may be used for acne resistant to other antibacterials [unlicensed indication]. Prolonged treatment with trimethoprim may depress haematopoesis; it should generally be initiated by specialists.

Concomitant use of different topical and systemic antibacterials is undesirable owing to the increased likelihood of the development of bacterial resistance.
Oral retinoid for acne

The retinoid isotretinoin reduces sebum secretion. It is used for the systemic treatment of nodulo-cystic and conglobate acne, severe acne, scarring, acne which has not responded to an adequate course of a systemic antibacterial, or acne which is associated with psychological problems. It is also useful in women who develop acne in the third or fourth decades of life, since late onset acne is frequently unresponsive to antibacterials.

Isotretinoin is a toxic drug that should be prescribed only by, or under the supervision of, a consultant dermatologist. It is given for at least 16 weeks; repeat courses are not normally required.

Side-effects of isotretinoin include severe dryness of the skin, nose bleeds, and joint pains. The drug is teratogenic and must not be given to women of child-bearing age unless they practise effective contraception (oral progesterone-only contraceptives not considered effective) and then only after detailed assessment and explanation by the physician. Women must also be registered with a pregnancy prevention programme (see under Cautions below).

Although a causal link between isotretinoin use and psychiatric changes (including suicidal ideation) has not been established, the possibility should be considered before initiating treatment; if psychiatric changes occur during treatment, isotretinoin should be stopped, the prescriber informed, and specialist psychiatric advice should be sought.

Note Isotretinoin is an isomer of tretinoin

**Indications** see notes above

**Cautions** see notes above; also avoid blood donation during treatment and for at least 1 month after treatment; history of depression; monitor all patients for depression; measure hepatic function and serum lipids before treatment, 1 month after starting and then every 3 months (reduce dose or discontinue if transaminase or serum lipids persistently raised); discontinue if uncontrolled hypertriglyceridaemia or pancreatitis; diabetes; dry eye syndrome (associated with risk of keratitis); avoid keratoconjunctivitis; **Interactions:** Appendix 1 (retinoids)

**Pregnancy prevention** In women of child-bearing potential, exclude pregnancy up to 3 days before treatment (start treatment on day 2 or 3 of menstrual cycle), every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle. Women must practice effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progesterone-only contraceptives are not considered effective. Barrier methods should not be used alone, but can be used in conjunction with other contraceptive methods. Each prescription for isotretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.

**Counselling** Warn patient to avoid wax epilation (risk of epidermal stripping), dermabrasion, and laser skin treatments (risk of scarring) during treatment and for at least 6 months after stopping; patient should avoid exposure to UV light (including sunlight) and use sunscreen and emollient (including lip balm) preparations from the start of treatment.
13.7 Preparations for warts and calluses

Warts (verrucas) are caused by a human papillomavirus, which most frequently affects the hands, feet (plantar warts), and the anogenital region (see below); treatment usually relies on local tissue destruction. Warts may regress on their own and treatment is required only if the warts are painful, unsightly, persistent, or cause distress.

Preparations of salicylic acid, formaldehyde, glutaraldehyde or silver nitrate are available for purchase by the public; they are suitable for the removal of warts on hands and feet. Salicylic acid is a useful keratolytic which may be considered first; it is also suitable for the removal of corns and calluses. Preparations of salicylic acid in a collodion basis are available but some patients may develop an allergy to colophony in the formulation. An ointment combining salicylic acid with podophyllum resin (Posalfilin®) is available for treating plantar warts; severe systemic toxicity including gastrointestinal, renal haematological, and CNS effects may occur with excessive application of preparations containing podophyllum. Cryotherapy causes pain, swelling, and blistering and may be no more effective than topical salicylic acid in the treatment of warts.

**SALICYLIC ACID**

**Indications** see under preparations; psoriasis (section 13.9.2); acne (section 13.6.1); fungal nail infections (section 13.10.2)

**Cautions** significant peripheral neuropathy, patients with diabetes at risk of neuropathic ulcers; protect surrounding skin and avoid broken skin; not suitable for application to face, anogenital region, or large areas

**Side-effects** skin irritation, see notes above

**Dose** • See under preparations; advise patient to apply carefully to wart and to protect surrounding skin (e.g. with soft paraffin or specially designed plaster); rub wart surface gently with file or pumice stone once weekly; treatment may need to be continued for up to 3 months

**Cuplex®** (Crawford)

**Gel**, salicylic acid 11%, lactic acid 4%, in a collodion basis, net price 5 g = £2.23. Label: 15

**Dose** for plantar and mosaic warts, apply twice daily

**Note** Contains colophony (see notes above)

**Duofilm®** (Stiefel)

**Paint**, salicylic acid 16.7%, lactic acid 16.7%, in flexible collodion, net price 15 mL (with applicator) = £2.25. Label: 15

**Dose** for plantar and mosaic warts, apply daily

**Occlusal®** (Alliance)

**Cutaneous solution**, salicylic acid 26% in polyacrylic solution, net price 10 mL (with applicator) = £3.56.

**Label**: 15

**Dose** for common and plantar warts, apply daily

**Salactol®** (Dermal)

**Paint**, salicylic acid 16.7%, lactic acid 16.7%, in flexible collodion, net price 10 mL (with applicator) = £1.71. Label: 15

**Dose** for warts, particularly plantar warts, verrucas, corns, and calluses, apply daily

**Note** Contains colophony (see notes above)

**Salatac®** (Dermal)

**Gel**, salicylic acid 12%, lactic acid 4% in a collodion basis, net price 8 g (with applicator) = £2.98. Label: 15

**Dose** for warts, verrucas, corns, and calluses, apply daily

**Verrugon®** (Ransom)

**Ointment**, salicylic acid 50% in a paraffin basis, net price 6 g = £3.12

**Dose** for plantar warts, apply daily

- With podophyllum

**Posalfilin®** (Norgine)

**Ointment**, podophyllum resin 20%, salicylic acid 25%, net price 10 g = £3.37

**Pregnancy** avoid—neonatal death and teratogenesis have been reported with podophyllum

**Breast-feeding** avoid

**Dose** for plantar warts apply daily

**Note** Owing to the salicylic acid content, not suitable for anogenital warts; owing to the podophyllum content, also contra-indicated in pregnancy and breast-feeding

**FORMALDEHYDE**

**Indications** see under preparations

**Cautions** see under Salicylic Acid

**Side-effects** see under Salicylic Acid

**Veracur®** (Typharm)

**Gel**, formaldehyde 0.75% in a water-miscible gel basis, net price 15 g = £2.41.

**Dose** for warts, particularly plantar warts, apply twice daily

**GLUTARALDEHYDE**

**Indications** warts, particularly plantar warts

**Cautions** protect surrounding skin; not for application to face, mucosa, or anogenital areas

**Side-effects** rashes, skin irritation (discontinue if severe); stains skin brown

**Dose** • Apply twice daily (see also under Salicylic acid)

**Glutarol®** (Dermal)

**Solution** (= application), glutaraldehyde 10%, net price 10 mL (with applicator) = £2.07

**SILVER NITRATE**

**Indications** warts, verrucas, umbilical granulomas, over-granulating tissue, cauterisation

**Cautions** protect surrounding skin and avoid broken skin; not suitable for application to face, ano-genital region, or large areas

**Side-effects** chemical burns on surrounding skin; stains skin and fabric

**Dose** • Common warts and verrucas, apply moistened caustic pencil tip for 1–2 minutes; repeat after 24 hours up to max. 3 applications for warts or max. 6 applications for verrucas

**Note** Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application

- Umbilical granulomas, apply moistened caustic pencil tip (usually containing silver nitrate 40%) for 1–2 minutes while protecting surrounding skin with soft paraffin

**Silver nitrate** (Non-proprietary)

**Caustic pencil**, tip containing silver nitrate 40%, potassium nitrate 60%, net price = 93p
Skin

13.8 Sunscreens and camouflagers

AVOCA® (Bray)

Caustic pencil, tip containing silver nitrate 95%, potassium nitrate 5%, net price, treatment pack (including emery file, 6 adhesive dressings and protector pads) = £1.94.

Anogenital warts

The treatment of anogenital warts (condylomata acuminata) should be accompanied by screening for other sexually transmitted infections. **Podophyllotoxin** (the major active ingredient of podophyllum) may be used for soft, non-keratinised external anogenital warts. Patients with a limited number of external warts or keratinised lesions may be better treated with cryotherapy or other forms of physical ablation.

**Imiquimod** cream is licensed for the treatment of external anogenital warts; it may be used for both keratinised and non-keratinised lesions. It is also licensed for the treatment of superficial basal cell carcinoma and actinic keratosis (section 13.8.1). Iminosine pranobex (section 5.3.2.1) is licensed for adjunc-tive treatment of genital warts but it has been superseded by more effective drugs.

**IMIQUIMOD**

**Indications** see under Dose

**Cautions** avoid normal or broken skin, and open wounds; not suitable for internal genital warts; uncircumcised males (risk of phimosis or stricture of foreskin), autoimmune disease; immunosuppressed patients

**Pregnancy** no evidence of teratogenicity or toxicity in animal studies; manufacturer advises caution

**Breast-feeding** no information available

**Side-effects** local reactions (including itching, burning sensation, erythema, erosion, oedema, excoriation, and scabbing); headache; influenza-like symptoms; myalgia; less commonly local ulceration and alopecia, rarely Stevens-Johnson syndrome and cutaneous lupus erythematosus-like effect; very rarely dysuria in women; permanent hypopigmentation or hyperpigmentation reported

**Dose**

- Warts (external genital and perianal), apply thinly 3 times a week at night until lesions resolve (max. 16 weeks)
- Superficial basal cell carcinoma, apply to lesion (and 1 cm beyond it) on 5 days each week for 6 weeks; assess response 12 weeks after completing treatment
- Actinic keratosis, apply to lesion 3 times a week for 4 weeks; assess response after a 4 week treatment-free interval; repeat 4-week course if lesions persist; max. 2 courses
- **CHILD under 18 years see BNF for Children**

**Important** Should be rubbed in and allowed to stay on the treated area for 6–10 hours for warts or for 8 hours for basal cell carcinoma and actinic keratosis, then washed off with mild soap and water (uncircumcised males treating warts under foreskin should wash the area daily). The cream should be washed off before sexual contact

**Aldara®** (Meda) (Stiefel)

Cream, imiquimod 5%, net price 12-sachet pack = £48.34. Label: 10, patient information leaflet

**Excipients** include benzyl alcohol, cetyl alcohol, hydroxybenzoates (parabens), polysorbate 60, stearyl alcohol

**Contra-indications** may damage latex condoms and diaphragms

13.8 Sunscreens and camouflagers

**13.8.1 Sunscreen preparations**

**13.8.2 Camouflagers**

Podophyllotoxin

**Indications** see under preparations

**Cautions** avoid normal skin and open wounds; keep away from face; very irritant to eyes

**Pregnancy** avoid

**Breast-feeding** avoid

**Side-effects** local irritation

**Condyline®** (Nycomed)

**Solution**, podophyllotoxin 0.5% in alcoholic basis, net price 3.5 mL (with applicators) = £14.49. Label: 15

**Dose** condylomata acuminata affecting the penis or the female external genitalia, apply twice daily for 3 consecutive days; treatment may be repeated at weekly intervals if necessary for a total of five 3-day treatment courses, direct medical supervision for lesions in the female and for lesions greater than 4 cm² in the male. max. 50 single applications (‘loops’) per session (consult product literature). **CHILD 2–18 years see BNF for Children**

**Warticon®** (Stiefel)

**Cream**, podophyllotoxin 0.15%, net price 5 g (with mirror) = £14.86

**Excipients** include butylated hydroxyanisole, cetyl alcohol, hydroxybenzoates (parabens), sorbic acid, stearyl alcohol

**Dose** condylomata acuminata affecting the penis or the female external genitalia, apply twice daily for 3 consecutive days; treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses; direct medical supervision for lesions greater than 4 cm²; **CHILD 2–18 years see BNF for Children**

**Solution**, blue, podophyllotoxin 0.5% in alcoholic basis, net price 3 mL (with applicators) = £12.38. Label: 15

**Dose** condylomata acuminata affecting the penis or the female external genitalia, apply twice daily for 3 consecutive days; treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses; direct medical supervision for lesions greater than 4 cm²; max. 50 single applications (‘loops’) per session (consult product literature). **CHILD 2–18 years see BNF for Children**

13.8 Sunscreens and camouflagers

**13.8.1 Sunscreen preparations**

**13.8.2 Camouflagers**

Sunscreens and camouflagers

**13.8.1 Sunscreen preparations**

**Sunscreens**

Sunscreens are absorbed by the skin to protect it from ultraviolet radiation. They are more effective if used in combination with protective clothing and shade. They are not effective if worn under clothing or if not applied correctly. They may also reduce the effectiveness of condoms and diaphragms.

**Sunscreens**

Solar ultraviolet radiation can be harmful to the skin. It is responsible for disorders such as **polymorphic light eruption**, **solar urticaria**, and it provokes the various **cutaneous porphyrias**. It also provokes (or at least aggravates) skin lesions of **lupus erythematosus** and may aggravate **rosacea** and some other **dermatoses**. Certain drugs, such as demeclocycline, phenothiazines, or amiodarone, can cause photosensitivity. All these conditions (as well as **sunburn**) may occur after relatively short periods of exposure to the sun. Solar ultraviolet irradiation may provoke attacks of recurrent herpes labialis (but it is not known whether the effect of sunlight exposure is local or systemic).

The effects of exposure over longer periods include **aging changes** and more importantly the initiation of **skin cancer**.

Solar ultraviolet radiation is approximately 200–400 nm in wavelength. The medium wavelengths (290–320 nm, known as UVB) cause sunburn. The long wavelengths (320–400 nm, known as UVA) are responsible for many
photosensitivity reactions and photodermatoses. Both UVA and UVB contribute to long-term photodamage and to the changes responsible for skin cancer and ageing.

Sunscreen preparations contain substances that protect the skin against UVA and UVB radiation, but they are no substitute for covering the skin and avoiding sunlight. The sun protection factor (SPF, usually indicated in the preparation title) provides guidance on the degree of protection offered against UVB; it indicates the multiples of protection provided against burning, compared with unprotected skin; for example, an SPF of 8 should enable a person to remain 8 times longer in the sun without burning. However, in practice, users do not apply sufficient sunscreen product and the protection is lower than that found in experimental studies.

Some manufacturers use a star rating system to indicate the protection against UVA relative to protection against UVB for sunscreen products. However, the usefulness of the star rating system remains controversial. The EU Commission (September 2006) has recommended that the UVA protection factor for a sunscreen should be at least one-third of the sun protection factor (SPF); products that achieve this requirement will be labelled with a UVA logo alongside the SPF classification. Preparations that also contain reflective substances, such as titanium dioxide, provide the most effective protection against UVA.

Sunscreen preparations may rarely cause allergic reactions.

For optimum photoprotection, sunscreen preparations should be applied thickly and frequently (approximately 2 hourly). In photodermatoses, they should be used from spring to autumn. As maximum protection from sunlight is desirable, preparations with the highest SPF should be prescribed.

## Ingredient nomenclature in sunscreen preparations

<table>
<thead>
<tr>
<th>rINN</th>
<th>INCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>amiloxate</td>
<td>isoamyl p-methoxyxanillate</td>
</tr>
<tr>
<td>avobenzone</td>
<td>butyl methoxydibenzoylmethane</td>
</tr>
<tr>
<td>bemotrizinol</td>
<td>bis-ethylhexylxylxoyphenyl methoxysphenyl triazine</td>
</tr>
<tr>
<td>bisoctrizole</td>
<td>methylene bis-benzotriazolyl tetramethyl-butylybenzene</td>
</tr>
<tr>
<td>ensulizole</td>
<td>phenylbenzimidazole sulfonic acid</td>
</tr>
<tr>
<td>enzacamene</td>
<td>4-methylbenzylidene camphor</td>
</tr>
<tr>
<td>octinoxate</td>
<td>octyl (or ethyl)hexyl methoxycinnamamate</td>
</tr>
<tr>
<td>octocrylene</td>
<td>octocrylene</td>
</tr>
<tr>
<td>oxybenzone</td>
<td>benzophenone-3</td>
</tr>
</tbody>
</table>

The European Commission Cosmetic Products Regulation (EC) 1223/2009 requires the use of INCI (International Nomenclature of Cosmetic Ingredients) for cosmetics and sunscreens. This table includes the rINN and the INCI synonym for the active ingredients of sunscreen preparations in the BNF

## Borderline substances

The preparations marked 'ACBS' are regarded as drugs when prescribed for skin protection against ultraviolet radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis. Preparations with SPF less than 30 should not normally be prescribed. See also Appendix 7.

### Delphin® (Fenton)

**Lotion**, (UVA and UVB protection; UVB-SPF 30), oxybenzone 4.8%, oxybenzone 1.5%, titanium dioxide 2%, net price 200 mL = £3.57. ACBS

**Excipients** include cetostearyl alcohol, fragrance, hydroxystearates (parabens), niacinamide.

**Note** For INCI synonyms, see table above

### Sunsense® Ultra (Crawford)

**Lotion** (UVA and UVB protection; UVB-SPF 50+), octinoxate 6%, enzacamene 4%, avobenzone 2%, oxybenzone 2%, ensulizole 2%, titanium dioxide 3%, net price 50-mL bottle with roll-on applicator = £4.11, 125 mL = £6.86, 500 mL = £15.54. ACBS

**Excipients** include butylated hydroxytoluene, cetyl alcohol, fragrance, hydroxystearates (parabens), propylene glycol.

**Note** For INCI synonyms, see table above

### Uvistat® (LPC)

**Cream** (UVA and UVB protection; UVB-SPF 30), avobenzone 5%, bisoctrizole 1.5%, octinoxate 7.5%, octocrylene 4%, titanium dioxide 5.2%, net price 125 mL = £7.45. ACBS

**Excipients** include disodium edetate, hydroxybenzoates (parabens), propylene glycol.

**Note** For INCI synonyms, see table above

**Cream** (UVA and UVB protection; UVB-SPF 50), amiloxate 2%, avobenzone 5%, bisoctrizole 6%, octinoxate 10%, octocrylene 4%, titanium dioxide 4.8%, net price 125 mL = £8.45. ACBS

**Excipients** include disodium edetate, polyisobutyl 60, propylene glycol.

**Note** For INCI synonyms, see table above

**Cream** (UVA and UVB protection; UVB-SPF 50), avobenzone 5%, bemotrizinol 3%, octinoxate 10%, octocrylene 4%, titanium dioxide 3%, net price 5 g = £2.99. ACBS

**Excipients** include butylated hydroxytoluene, hydroxystearates (parabens).

**Note** For INCI synonyms, see table above

### Photodamage

Patients should be advised to use a high-SPF sunscreen and to minimise exposure of the skin to direct sunlight or sun lamps.

Topical treatments are used for non-hypertrophic actinic keratosis. An emollient may be sufficient for mild lesions. **Diclofenac** gel is suitable for the treatment of superficial lesions in mild disease. **Fluorouracil** cream is effective against most types of non-hypertrophic actinic keratosis. **Imiquimod** (section 13.7) is used for lesions on the face and scalp when cryotherapy or other topical treatments cannot be used. Fluorouracil and imiquimod produce a more marked inflammatory reaction than diclofenac but lesions resolve faster. **Photodynamic therapy** in combination with methyl-5-aminolevulinate cream (**Metvix**, available from Galderma) is used in specialist centres for treating superficial and confluent, non-hypertrophic actinic keratoses when other treatments are inadequate or unsuitable; it is particularly suitable for multiple lesions, for peri-orbital lesions, or for lesions located at sites of poor healing.

Imiquimod or topical fluorouracil is used for treating superficial basal cell carcinomas. Photodynamic therapy in combination with methyl-5-aminolevulinate cream is used in specialist centres for treating superficial, nodular basal cell carcinomas when other treatments are unsuitable.

### DICLOFENAC SODIUM

#### Indications

**Actinic keratosis**

**Cautions** as for topical NSAIDs, see section 10.3.2
Contra-indications as for topical NSAIDs, see section 10.3.2
Side-effects as for topical NSAIDs, see section 10.3.2; also paraesthesia; application of large amounts may result in systemic effects, see section 10.1

Dose
- Apply thinly twice daily for 60–90 days; max. 8 g daily

Solaraze® (Almirall) (HF)
Gel, diclofenac sodium 3% in a sodium hyaluronate basis, net price 50 g = £38.30, 100 g = £76.60
Exipients include benzyl alcohol

FLUOROURACIL

Indications superficial malignant and pre-malignant skin lesions; other malignant disease (section 8.1.3)
Cautions avoid contact with mucous membranes; caution in handling—irritant to tissues
Pregnancy manufacturer advises avoid (teratogenic)
Breast-feeding manufacturer advises avoid
Side-effects local irritation (use a topical corticosteroid for severe discomfort associated with inflammatory reactions), photosensitivity, erythema multiforme

Dose
- Apply thinly to the affected area once or twice daily; max. area of skin treated at one time, 500 cm² (e.g. 23 cm × 23 cm); usual duration of initial therapy, 3–4 weeks
Note Alternative regimens may be in use in some settings

Efudix® (Meda) (HF)

Cream, fluorouracil 5%, net price 40 g = £32.73
Exipients include hydroxybenzoates (parabens), polyethylene glycol, stearyl alcohol

13.8.2 Camouflagers

Disfigurement of the skin can be very distressing to patients and may have a marked psychological effect. In skilled hands, or with experience, camouflage cosmetics can be very effective in concealing scars and birthmarks. The depigmented patches in vitiligo are also very disfiguring and camouflage creams are of great cosmetic value.

Borderline substances The preparations marked ACBS are regarded as drugs when prescribed for postoperative scars and other deformities and as an adjunctive therapy in the relief of emotional disturbances due to disfiguring skin disease, such as vitiligo. See also Appendix 7.

Covermark® (Skin Camouflage Co.)

Classic foundation, net price 15 mL (10 shades) = £11.32, ACBS
Exipients include beeswax, hydroxybenzoates (parabens), fragrance
Finishing powder, net price 25 g = £11.32, ACBS
Exipients include beeswax, hydroxybenzoates (parabens), fragrance

Dermacolor® (Fox)

Camouflage cream, (100 shades), net price 25 mL = £9.96
ACBS
Exipients include beeswax, butylhydroxytoluene, fragrance, propylene glycol, stearyl alcohol, wool fat
Fixing powder, (7 shades), net price 60 g = £8.45. ACBS
Exipients include fragrance

Keromask® (Lornamade)

Masking cream, (9 shades), net price 15 mL = £5.68. ACBS
Exipients include butylated hydroxyanisole, hydroxybenzoates (parabens), wool fat, propylene glycol

13.9 Shampoos and other preparations for scalp and hair conditions

Dandruff is considered to be a mild form of seborrhoeic dermatitis (see also section 13.5.1). Shampoos containing antimicrobial agents such as pyrithione zinc (which are widely available) and selenium sulphide may have beneficial effects. Shampoos containing tar extracts may be useful and they are also used in psoriasis.

Ketocanazole shampoo should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Cortico-steroid gels and lotions (section 13.4) can also be used.

Shampoos containing coal tar and salicylic acid may also be useful. A cream or an ointment containing coal tar and salicylic acid is very helpful in psoriasis that affects the scalp (section 13.5.2). Patients who do not respond to these treatments may need to be referred to exclude the possibility of other skin conditions.

Crade cap in infants may be treated with coconut oil or olive oil applications followed by shampooing.

See below for male-pattern baldness and also section 13.5 (psoriasis and eczema), section 13.10.4 (lice), and section 13.10.2 (ringworm).

Shampoos

Ketocanazole (Non-proprietary) (HF)

Cream—section 13.10.2
Shampoo, ketocanazole 2%, net price 120 mL = £3.53
Exipients include imidurea
Brands include Dandrazol® 2% Shampoo, Nitrazol®
Dose treatment of seborrhoeic dermatitis and dandruff apply twice weekly for 2–4 weeks (prophylaxis apply once every 1–2 weeks); treatment of pityriasis versicolor apply once daily for max. 5 days (prophylaxis apply once daily for up to 3 days before sun exposure); leave preparation on for 3–5 minutes before rinsing
1. Can be sold to the public for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp as a shampoo formulation containing ketocanazole max. 2%, in a pack containing max. 120 mL and labelled to show a maximum frequency of application of once every 3 days

Alphosyl 2 in 1® (GSK Consumer Healthcare)

Shampoo, alcoholic coal tar extract 5%, net price 125 mL = £1.81, 250 mL = £3.43
Exipients include hydroxybenzoates (parabens), fragrance
Dose dandruff, use once or twice weekly as necessary; psoriasis, seborrhoeic dermatitis, scaling and itching, use every 2–3 days

Capasal® (Dermal)

Shampoo, coal tar 1%, coconut oil 1%, salicylic acid 0.5%, net price 250 mL = £4.69
Exipients none as listed in section 13.13
Dose scalp scaly disorders including psoriasis, seborrhoeic dermatitis, dandruff, and cradle cap, apply daily as necessary

Veil® (Thomas Blake)

Cover cream, (40 shades), net price 19 g = £20.63, 44 g = £30.68, 70 g = £38.74. ACBS
Exipients include hydroxybenzoates (parabens), wool fat derivative

Finishing powder, translucent, net price 35 g = £22.62. ACBS
Exipients include butylated hydroxyanisole, hydroxybenzoates (parabens)
Hirsutism

Hirsutism may result from hormonal disorders or as a side-effect of drugs such as minoxidil, corticosteroids, anabolic steroids, androgens, danazol, and progestogens.

Weight loss can reduce hirsutism in obese women. Women should be advised about local methods of hair removal, and in the mildest cases this may be all that is required.

Efllornithine, an antiprotozoal drug, inhibits the enzyme ornithine decarboxylase in hair follicles. Topical efllornithine can be used as an adjunct to laser therapy for facial hirsutism in women. Efllornithine should be discontinued in the absence of improvement after treatment for 4 months.

Cyprindiol (section 13.6.2) may be effective for moderately severe hirsutism. Metformin (section 6.1.2.2) is an alternative in women with polycystic ovary syndrome (unlicensed indication). Systemic treatment is required for 6–12 months before benefit is seen.

### Other scalp preparations

#### Cocos®

Section 13.5.2

#### Etrivex®

Section 13.4

#### Polytar® (Stiefel)

**Liquid**, arachis (peanut) oil extract of coal tar 0.3%, cade oil 0.3%, coal tar solution 0.1%, oleyl alcohol 1%, tar 0.3%, net price 250 mL = £2.23

- **Excipients** include fragrance, immurea, polyethylene 80
- **Dose** scalp disorders including psoriasis, seborrhoea, eczema, pruritus, and dandruff, apply 2–3 times weekly

#### Polytar Plus® (Stiefel)

**Liquid**, ingredients as Polytar® liquid with hydrolysed animal protein 5%, net price 500 mL = £3.91

- **Excipients** include fragrance, immurea, polyethylene 80
- **Dose** scalp disorders including psoriasis, seborrhoea, eczema, pruritus, and dandruff, apply 1–2 times weekly

### Androgenetic alopecia

Finasteride is licensed for the treatment of androgenetic alopecia in men. Continuous use for 3–6 months is required before benefit is seen, and effects are reversed 6–12 months after treatment is discontinued.

Topical application of minoxidil may stimulate limited hair growth in a small proportion of adults but only for as long as it is used.

### Efllornithine

#### Indications

- see notes above

#### Pregnancy

- toxicity in animal studies—manufacturer advises avoid

#### Breast-feeding

- manufacturer advises avoid—no information available

#### Side-effects

- acne, application site reactions including burning and stinging sensation, rash; less commonly abnormal hair texture and growth

#### Dose

- Apply thinly twice daily; **CHILD** under 12 years not recommended

- **Note** Preparation must be rubbed in thoroughly; cosmetics may be applied over treated area 5 minutes after efllornithine; do not wash treated area for 4 hours after application

#### Vaniqa® (Almirall)

**Cream**, efllornithine (as hydrochloride) 11.5%, net price 60 g = £52.08

- **Excipients** include cetostearyl alcohol, hydroxybenzoates, stearyl alcohol

- **Note** The Scottish Medicines Consortium has advised (September 2005) that efllornithine for facial hirsutism be restricted for use in women in whom alternative drug treatment cannot be used

### Androgenetic alopecia

Finasteride is licensed for the treatment of androgenetic alopecia in men. Continuous use for 3–6 months is required before benefit is seen, and effects are reversed 6–12 months after treatment is discontinued.

Topical application of minoxidil may stimulate limited hair growth in a small proportion of adults but only for as long as it is used.

### Finasteride

#### Indications

- androgenetic alopecia in men; benign prostatic hyperplasia (section 6.4.2)

#### Cautions

- section 6.4.2

#### Side-effects

- section 6.4.2

#### Dose

- **By mouth** 1 mg daily

#### Proppecia® (MSD)

- **Tablets**, f/c, beige, finasteride 1 mg, net price 28-tab pack = £26.99, 84-tab pack = £81.55
Cellulitis, a rapidly spreading deeply seated inflammation of the skin and subcutaneous tissue, requires systemic antibacterial treatment (see Table 1, section 5.1). Lower leg infections or infections spreading around wounds are almost always cellulitis. *Erysipelothrix*, a superficial infection with clearly defined edges (and often affecting the face), is also treated with a systemic antibacterial (see Table 1, section 5.1).

In the community, acute impetigo on small areas of the skin may be treated by short-term topical application of fusidic acid; mupirocin should be used only to treat meticillin-resistant *Staphylococcus aureus*. If the impetigo is extensive or longstanding, an oral antibacterial such as *flucoxacinil* (or *clarithromycin* in penicillin-allergy) (Table 1, section 5.1) should be used. Mild antiseptics (section 13.11) can be used to soften crusts.

Although many antibacterial drugs are available in topical preparations, some are potentially hazardous and frequently their use is not necessary if adequate hygienic measures can be taken. Moreover, not all skin conditions that are oozing, crusted, or characterised by pustules are actually infected. Topical antibacterials should be avoided on leg ulcers unless used in short courses for defined infections; treatment of bacterial colonisation is generally inappropriate.

To minimise the development of resistant organisms it is advisable to limit the choice of antibacterials applied topically to those not used systemically. Unfortunately some of these, for example neomycin, may cause sensitisation, and there is cross-sensitivity with other aminoglycoside antibiotics, such as gentamicin. *If large areas of skin are being treated*, ototoxicity may also be a hazard with aminoglycoside antibiotics (and also with polymyxins), particularly in children, in the elderly, and in those with renal impairment. *Resistant organisms* are more common in hospitals, and whenever possible swabs should be taken for bacteriological examination before beginning treatment.

*Mupirocin* is not related to any other antibacterial in use; it is effective for skin infections, particularly those due to Gram-positive organisms but it is not indicated for pseudomonal infection. Although *Staphylococcus aureus* strains with low-level resistance to mupirocin are emerging, it is generally useful in infections resistant to other antibacterials. To avoid the development of resistance, mupirocin or fusidic acid should not be used for longer than 10 days and local microbiology advice should be sought before using it in hospital. In the presence of mupirocin-resistant MRSA infection, a topical antiseptic such as povidone-iodine, chlorhexidine, or alcohol can be used; their use should be discussed with the local microbiologist.

*Retapamulin* can be used for impetigo and other superficial bacterial skin infections caused by *Staphylococcus aureus* and *Streptococcus pyogenes* that are resistant to first-line topical antibacterials. However, it is not effective against MRSA. The Scottish Medicines Consortium (p. 4) has advised (March 2008) that retapamulin (*Altargan*) is not recommended for use within NHS Scotland for the treatment of superficial skin infections. *Silver sulfadiazine* is used in the treatment of infected burns.
13.10.1 Antibacterial preparations

Altargo® (GSK) ▼ (TA)

Ointment, retapamulin 1%, net price 5 g = £7.89.
Label: 28
Excipients include butylated hydroxytoluene

Silver sulfadiazine (Silver sulphadiazine)

Indications prophylaxis and treatment of infection in burn wounds; as an adjunct to short-term treatment of infection in leg ulcers and pressure sores; as an adjunct to prophylaxis of infection in skin graft donor sites and extensive abrasions; for conservative management of finger-tip injuries

Cautions G6PD deficiency; may inactivate enzymatic debriding agents—concomitant use may be inappropriate; for large amounts see also interactions: Appendix 1 (sulfonamides)

Large areas Plasma-sulfadiazine concentrations may approach therapeutic levels with side-effects and interactions as for sulfonamides (see section 5.1.8) if large areas of skin are treated. Owing to the association of sulfonamides with severe blood and skin disorders, treatment should be stopped immediately if blood disorders or rashes develop—but leucopenia developing 2–3 days after starting treatment of burns patients is reported usually to be self-limiting and silver sulfadiazine need not usually be discontinued provided blood counts are monitored carefully to ensure return to normality within a few days. Argyria may also occur if large areas of skin are treated (or if application is prolonged).

Contra-indications sensitivity to sulfonamides; not recommended for neonates

Hepatic impairment manufacturer advises caution if significant impairment; see also Large Areas, above

Renal impairment manufacturer advises caution if significant impairment; see also Large Areas, above

Pregnancy risk of neonatal haemolysis and methaemoglobinemia in third trimester

Breast-feeding small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants

Side-effects allergic reactions including burning, itching and rashes; argyria reported following prolonged use; leucopenia reported (monitor blood levels)

Flamazine® (S&N Hlth.) (TA)

Cream, silver sulfadiazine 1%, net price 20 g = £2.91, 50 g = £3.85, 250 g = £10.32, 500 g = £18.27
Excipients include cetyl alcohol, polysorbates, propylene glycol
Dose burns, apply daily or more frequently if very exudative; leg ulcers or pressure sores, apply daily or on alternate days (not recommended if ulcer very exudative); finger-tip injuries, apply every 2–3 days, consult product literature for details
Note Apply with sterile applicator

13.10.1.2 Antibacterial preparations also used systemically

Sodium fusidate is a narrow-spectrum antibacterial used for staphylococcal infections. For the role of sodium fusidate in the treatment of impetigo see p. 794.

Metronidazole is used topically for rosacea and to reduce the odour associated with anaerobic infections; oral metronidazole (section 5.1.11) is used to treat wounds infected with anaerobic bacteria.

Angular chelitis An ointment containing sodium fusidate is used in the fissures of angular chelitis when associated with staphylococcal infection. For further information on angular chelitis, see section 13.2.3.
**13.10.2 Antifungal preparations**

**FUSIDIC ACID**

**Indications**  staphylococcal skin infections; penicillin-resistant staphylococcal infections (section 5.1.7); staphylococcal eye infections (section 11.3.1)

**Cautions**  see notes above; avoid contact with eyes

**Side-effects**  rarely hypersensitivity reactions

**Dose**  
- Apply 3–4 times daily

**Fucidin** (LEO)  
- Cream, fusidic acid 2%, net price 15 g = £1.92, 30 g = £3.64
  - Excipients include butylated hydroxyanisole, cetyl alcohol
- Ointment, sodium fusidate 2%, net price 15 g = £2.23, 30 g = £3.79
  - Excipients include cetyl alcohol, wool fat

**Dental prescribing on NHS**  May be prescribed as Sodium Fusidate ointment

**METRONIDAZOLE**

**Indications**  see preparations; rosacea (see also section 13.6); *Helicobacter pylori* eradication (section 1.3); anaerobic infections (section 5.1.11 and section 7.2.2); protozoal infections (section 5.4.2)

**Cautions**  avoid exposure to strong sunlight or UV light

**Side-effects**  skin irritation

**Dose**  
- See preparations

**Acea** (Ferndale)  
- Gel, metronidazole 0.75%, net price 40 g = £9.95
  - Excipients include disodium edetate, hydroxybenzoates (parabens)
- Cream, metronidazole 0.75%, net price 30 g = £12.00
  - Excipients include benzyl alcohol, disodium edetate, hydroxybenzoates (parabens), propylene glycol

**Anabact** (CHS)  
- Gel, metronidazole 0.75%, net price 15 g = £4.47, 30 g = £7.89
  - Excipients include hydroxybenzoates (parabens), propylene glycol
- Cream, metronidazole 0.75%, net price 40 g = £6.86
  - Excipients include hydroxybenzoates (parabens), propylene glycol

**Dose**  
- Acute inflammatory exacerbation of rosacea, apply thinly twice daily for 8 weeks
- Malodorous fungating tumours, apply to clean wound 1–2 times daily and cover with non-adenherent dressing

**Metrogel** (Galderma)  
- Gel, metronidazole 0.75%, net price 40 g = £6.86
  - Excipients include hydroxybenzoates (parabens), propylene glycol
- Gel, metronidazole 0.8%, net price 15 g = £4.59
  - Excipients none as listed in section 13.1.3

**Dose**  
- Acute inflammatory exacerbation of rosacea, apply thinly twice daily for up to 8 weeks
- Malodorous fungating tumours, apply to clean wound 1–2 times daily and cover with non-adenherent dressing

**Metrosa** (Linderma)  
- Gel, metronidazole 0.75%, net price 40 g = £19.90
  - Excipients include propylene glycol
- Gel, metronidazole 0.8%, net price 15 g = £3.64
  - Excipients include disodium edetate, hydroxybenzoates (parabens)

**Dose**  
- Acute inflammatory papules, pustules and erythema of rosacea, apply twice daily for 3–4 months

**Metrotop** (Malynlycke)  
- Gel, metronidazole 0.8%, net price 15 g = £4.59
  - Excipients none as listed in section 13.1.3
- Cream, metronidazole 0.75%, net price 30 g = £7.50
  - Excipients include propylene glycol

**Dose**  
- Acne inflammatory papules and pustules of rosacea, apply twice daily for 8–9 weeks

**Rosiced** (Fabre)  
- Cream, metronidazole 0.75%, net price 40 g = £6.86
  - Excipients include benzyl alcohol, isopropyl palmitate

**Zyomet** (Goldshield)  
- Gel, metronidazole 0.75%, net price 30 g = £12.00
  - Excipients include benzyl alcohol, disodium edetate, propylene glycol

**Dose**  
- Acute inflammatory exacerbation of rosacea, apply thinly twice daily for 8–9 weeks

**13.10.2 Antifungal preparations**

Most localised fungal infections are treated with topical preparations. To prevent relapse, local antifungal treatment should be continued for 1–2 weeks after the disappearance of all signs of infection. Systemic therapy (section 5.2) is necessary for nail or scalp infection or if the skin infection is widespread, disseminated, or intractable. Skin scrapings should be examined if systemic therapy is being considered or where there is doubt about the diagnosis.

**Dermatophytoposes**  Ringworm infection can affect the scalp (tinea capitis), body (tinea corporis), groin (tinea cruris), hand (tinea manuum), foot (tinea pedis, athlete’s foot), or nail (tinea unguium). Scalp infection requires systemic treatment (section 5.2); additional application of a topical antifungal, during the early stages of treatment, may reduce the risk of transmission. A topical antifungal can also be used to treat asymptomatic carriers of scalp ringworm. Most other local ringworm infections can be treated adequately with topical antifungal preparations (including shampoos, section 13.9). The imidazole antifungals clotrimazole, econazole, ketoconazole, and miconazole are all effective. Terbinaine cream is also effective but it is more expensive. Other topical antifungals include griseofulvin and the undercoenoates. Compound benzoic acid ointment (Whitfield’s ointment) has been used for ringworm infections but it is cosmetically less acceptable than proprietary preparations. Topical preparations for athlete’s foot containing tolnaftate are on sale to the public.

Antifungal dusting powders are of little therapeutic value in the treatment of fungal skin infections and may cause skin irritation; they may have some role in preventing re-infection.

Antifungal treatment may not be necessary in asymptomatic patients with tinea infection of the nails. If treatment is necessary, a systemic antifungal (section 5.2) is more effective than topical therapy. However, topical application of amorolfine or toconazole may be useful for treating early onychomycosis when involvement is limited to mild distal disease in up to 2 nails, or for superficial white onychomycosis, or where there are contra-indications to systemic therapy.

**Pityriasis versicolor**  Pityriasis (tinea) versicolor can be treated with ketoconazole shampoo (section 13.9). Alternatively, selenium sulphide shampoo [unlicensed indication] (section 13.9) can be used as a lotion (diluting with water can reduce irritation) and left on the affected area for 10 minutes before rinsing off; it should be applied once daily for 7 days, and the course repeated if necessary.
Topical imidazole antifungals clotrimazole, econazole, ketoconazole, and miconazole, and topical terbinafine are alternatives, but large quantities may be required. If topical therapy fails, or if the infection is widespread, pityriasis versicolor is treated systemically with a triazole antifungal (section 5.2). Relapse is common, especially in the immunocompromised.

**Candidiasis** Candidal skin infections can be treated with a topical imidazole antifungal, such as clotrimazole, econazole, ketoconazole, or miconazole; topical terbinafine is an alternative. Topical application of nystatin is also effective for candidiasis but it is ineffective against dermatophytes. Refractory candidiasis requires systemic treatment (section 5.2) generally with a triazole such as fluconazole; systemic treatment with terbinafine is not appropriate for refractory candidiasis.

**Angular cheilitis** Miconazole cream is used in the fissures of angular cheilitis when associated with *Candida*. For further information on angular cheilitis, see p. 695.

**Compound topical preparations** Combination of an imidazole and a mild corticosteroid (such as hydrocortisone 1%) (section 13.4) may be of value in the treatment of intertrigo of a mild corticosteroid with either an imidazole or an econazole antifungal, such as clotrimazole, econazole, ketoconazole, or miconazole; topical terbinafine is an alternative. But these preparations are not appropriate for refractory candidiasis.

**Side-effects** Occasional local irritation and hyper-sensitivity reactions include mild burning sensation, erythema, and itching. Treatment should be discontinued if these are severe.

---

**AMOROLFINE**

**Indications** fungal nail infections

**Cautions** see notes above; also avoid contact with ears

**Pregnancy** systemic absorption very low, but manufacturer advises avoid—no information available

**Breast-feeding** manufacturer advises avoid—no information available

**Side-effects** see notes above

**Dose**

- Apply to infected nails 1–2 times weekly after filing and cleaning; allow to dry (approx. 3 minutes); treat finger nails for 6 months, toe nails for 9–12 months (review at intervals of 3 months); avoid nail varnish or artificial nails during treatment

**Loceryl®** (Galderma) [SH]

- Nail lacquer, amorolfin (as hydrochloride) 5%, net price 5-mL pack (with nail files, spatulas, and cleansing swabs) = £18.17. Label: 10, patient information leaflet

**Excipients** none as listed in section 13.1.3

---

**BENZOIC ACID**

**Indications** ringworm (tinea), but see notes above

**Benzoic Acid Ointment, Compound, BP** *(Whitfield’s ointment)*

**Ointment**, benzoic acid 6%, salicylic acid 3%, in emulsifying ointment

**Excipients** include ceteostearly alcohol

**Dose** apply twice daily

---

**CLOTrimazole**

**Indications** fungal skin infections; vaginal candidiasis (section 7.2.2); otitis externa (section 12.1.1)

**Cautions** see notes above

**Pregnancy** minimal absorption from skin; not known to be harmful

**Side-effects** see notes above

**Dose**

- Apply 2–3 times daily

**Clotrimazole** (Non-proprietary)

- **Cream**, clotrimazole 1%, net price 20 g = £1.52

**Canesten®** *(Bayer Consumer Care)*

- **Cream**, clotrimazole 1%, net price 20 g = £2.14, 50 g = £3.50

**Excipients** include benzyl alcohol, ceteostearly alcohol, polysorbate 60

**Solution**, clotrimazole 1% in macrogol 400 (polyethylene glycol 400), net price 20 mL = £2.43. For hairy areas

**Excipients** none as listed in section 13.1.3

**Spray**, clotrimazole 1%, in 30% isopropyl alcohol, net price 40-mL atomiser = £4.99. Label: 15. For large or hairy areas

**Excipients** include propylene glycol

---

**ECONAZOLE NITRATE**

**Indications** fungal skin infections; vaginal candidiasis (section 7.2.2)

**Cautions** see notes above

**Pregnancy** minimal absorption from skin; not known to be harmful

**Side-effects** see notes above

**Dose**

- Skin infections apply twice daily; nail infections, apply once daily under occlusive dressing

**Pevaryl®** *(Janssen-Cilag)*

**Cream**, econazole nitrate 1%, net price 30 g = £2.65

**Excipients** include butylated hydroxyanisole, fragrance

---

**GRISEOFULVIN**

**Indications** tinea pedis; resistant fungal infections (section 5.2.5)

**Cautions** see notes above

**Pregnancy** manufacturer advises avoid unless potential benefit outweighs risk

**Breast-feeding** manufacturer advises avoid unless potential benefit outweighs risk

**Side-effects** see notes above

**Dose**

- Apply 400 micrograms (1 spray) to an area approx. 13 cm² once daily, increased to 1.2 mg (3 sprays, allowing each spray to dry between applications) once daily if necessary; max. treatment duration 4 weeks

---

**Note** Amorolfin nail lacquer can be sold to the public if supplied for the treatment of mild cases of distal and lateral subungual onychomycoses caused by dermatophytes, yeasts and moulds; subject to treatment of max. 2 nails, max. strength of nail lacquer amorolfin 5% and a pack size of 3 mL.
SALICYLIC ACID

**Indications**
- Fungal nail infections, particularly tinea; hyperkeratotic skin disorders (section 13.5.2); acne vulgaris (section 13.6.1); warts and calluses (section 13.7)

**Cautions**
- Avoid broken or inflamed skin
- Salicylate toxicity: Salicylate toxicity can occur particularly if applied on large areas of skin

**Pregnancy**
- Avoid

**Side-effects**
- See notes above

**Dose**
- **ADULT** and **CHILD** over 5 years, apply twice daily and after washing

**Phytox** *(Wynil)* Painter
- Salicylic acid 1.46% (total combined), tannic acid 4.89% and boric acid 3.12% (as borotannic complex), in a vehicle containing alcohol and ethyl acetate, net price 25 mL (with brush) = £2.81
- Excipients: none as listed in section 13.1.3
- **Note**: Flammable

TERBINAFINE

**Indications**
- Fungal skin infections

**Cautions**
- Avoid contact with eyes

**Pregnancy**
- Manufacturer advises use only if potential benefit outweighs risk—animal studies suggest no adverse effects

**Breast-feeding**
- Manufacturer advises avoid—present in milk, but less than 5% of the dose is absorbed after topical application of terbinafine; avoid application to mother's chest

**Side-effects**
- See notes above

**Dose**
- **ADULT** and **CHILD** over 1–2 weeks in tinea pedis, 1–2 weeks in tinea corporis and tinea cruris, 2 weeks in cutaneous candidiasis and pityriasis versicolor; review after 2 weeks; **CHILD** see BNF for Children

**Terbinafine** *(Non-proprietary)* *(BNF)*
- **Cream**, terbinafine hydrochloride 1%, net price 15 g = £5.10, 30 g = £2.69

1. Preparations of terbinafine hydrochloride (max. 1%) can be sold to the public for external use for the treatment of tinea pedis as a cream in a pack containing max. 15 g, or for the treatment of tinea pedis and cruris as a cream in a pack containing max. 15 g, or for the treatment of tinea pedis, cruris, and corporis as a spray in a pack containing max. 30 mL spray or as a gel in a pack containing max. 30 g gel

**Lamisil** *(Novartis Consumer Health)* *(BNF)*
- **Cream**, terbinafine hydrochloride 1%, net price 15 g = £4.86, 30 g = £8.76
- **Excipients** include benzyl alcohol, cetaryl alcohol, polysorbate 60, stearyl alcohol
- **Tablets**—section 5.2.5

TIOCONAZOLE

**Indications**
- Fungal nail infections

**Cautions**
- See notes above

**Pregnancy**
- Manufacturer advises avoid

**Side-effects**
- See notes above; also local oedema, dry skin, nail discoloration, periungual inflammation, nail pain, rash, exfoliation
13.10.3 Antiviral preparations

**Aciclovir**

Aciclovir cream is licensed for the treatment of initial and recurrent labial and genital herpes simplex infections; treatment should begin as early as possible. Systemic treatment is necessary for buccal or vaginal infections and for herpes zoster (shingles) (for details of systemic use see section 5.3.2.1).

**Dose**

- Apply to nails and surrounding skin twice daily usually for up to 6 months (may be extended to 12 months)

**Trosyl** (Pfizer)

**Cutaneous solution**, tioconazole 28%, net price 12 mL (with applicator brush) = £27.38

**Excipients** none as listed in section 13.1.3

**Mycolta** (Thornton & Ross)

**Cream**, zinc undecenoate 20%, undecenoic acid 5%, net price 25 g = £1.64

**Excipients** include fragrance

**Dose**

- Treatment of athlete’s foot, apply twice daily continuing for 7 days after lesions have healed
- Prevention of athlete’s foot, apply once daily

**Powder**, zinc undecenoate 20%, undecenoic acid 2%, net price 70 g = £2.22

**Excipients** include fragrance

**Dose**

- Treatment of athlete’s foot, apply twice daily continuing for 7 days after lesions have healed
- Prevention of athlete’s foot, apply once daily

**Spray application**, undecenoic acid 3.9%, dichlorophen 0.4% (pressurised aerosol pack), net price 100 mL = £2.46

**Excipients** include fragrance

**Dose**

- Treatment of athlete’s foot, apply twice daily continuing for 7 days after lesions have healed
- Prevention of athlete’s foot, apply once daily

**UNDECENOATES**

**Indications** see under preparations below

**Side-effects** see notes above

**Dose**

- See under preparations below

**Mycolta**

**Cream**, zinc undecenoate 20%, undecenoic acid 5%, net price 25 g = £1.64

**Excipients** include fragrance

**Dose**

- Treatment of athlete’s foot, apply twice daily continuing for 7 days after lesions have healed
- Prevention of athlete’s foot, apply once daily

**PENCICLOVIR**

**Indications** see notes above

**Cautions** avoid contact with eyes and mucous membranes

**Side-effects** transient stinging, burning, numbness; hypersensitivity reactions also reported

**Vectavir** (Novartis Consumer Health)

**Cream**, penciclovir 1%, net price 2 g = £4.20

**Excipients** include cetostearyl alcohol, propylene glycol

**Dose**

- Herpes labialis, apply to lesions every 2 hours during waking hours for 4 days, starting at first sign of attack
- Children under 12 years, not recommended

**Dental prescribing on NHS** Aciclovir Cream may be prescribed

1. A 2 g tube and a pump pack are on sale to the public for the treatment of cold sores

**Zovirax** (GSK)

**Cream**, aciclovir 5%, net price 2 g = £4.63, 10 g = £12.96

**Excipients** include cetostearyl alcohol, propylene glycol

**Eye ointment**—section 11.3.3

**Tablets**—section 5.3.2.1

**ACICLOVIR** (Acyclovir)

**Indications** see notes above; herpes simplex and varicella–zoster infections (section 5.3.2.1); eye infections (section 11.3.3)

**Cautions** avoid contact with eyes and mucous membranes

**PREGNANCY** not known to be harmful—manufacturers advise use only when potential benefit outweighs risk; limited absorption from topical aciclovir preparations

**SIDE-EFFECTS** transient stinging or burning; occasionally erythema, itching or drying of the skin

**Dose**

- Apply to lesions every 4 hours (5 times daily) for 5–10 days, starting at first sign of attack

**IDOXURIDINE IN DIMETHYL SULFOXIDE**

**Indications** herpes simplex and herpes zoster infection but of little value

**Cautions** avoid contact with the eyes, mucous membranes, and textiles; **interactions:** Appendix 1 (dimethyl sulfoxide)

**Contra-indications** not to be used in mouth

**PREGNANCY** teratogenic in animal studies—manufacturer advises avoid

**Breast-feeding** may make milk taste unpleasant

**Side-effects** stinging on application, changes in taste; overuse may cause maceration

**Herpid** (Astellas)

**Application**, idoxuridine 5% in dimethyl sulfoxide, net price 5 mL (with applicator) = £6.33

**Dose**

- Apply to lesions 4 times daily for 4 days, starting at first sign of attack
- Children under 12 years, not recommended
13.10.4 Parasiticidal preparations

**Suitable quantities of parasiticidal preparations**

<table>
<thead>
<tr>
<th>Skin creams</th>
<th>Lotions</th>
<th>Cream rinses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp (head lice)</td>
<td>—</td>
<td>50–100 mL</td>
</tr>
<tr>
<td>Body (scabies)</td>
<td>30–60 g</td>
<td>100 mL —</td>
</tr>
<tr>
<td>Body (crab lice)</td>
<td>30–60 g</td>
<td>100 mL —</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for single application.

**Scabies**

Permethrin is used for the treatment of scabies (*Sarcoptes scabiei*); malathion can be used if permethrin is inappropriate.

Benzyl benzoate is an irritant and should be avoided in children; it is less effective than malathion and permethrin.

Ivermectin (available on a named patient basis from ‘special-order’ manufacturers or specialist importing companies, see p. 988) in a single dose of 200 micrograms/kg by mouth has been used, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone.

**Application** Although acaricides have traditionally been applied after a hot bath, this is not necessary and there is evidence that a hot bath may increase absorption into the blood, removing them from their site of action on the skin.

All members of the affected household should be treated simultaneously. Treatment should be applied to the whole body including the scalp, neck, face, and ears. Particular attention should be paid to the webs of the fingers and toes and lotion brushed under the ends of nails. It is now recommended that malathion and permethrin should be applied twice, one week apart; in the case of benzyl benzoate up to 3 applications on consecutive days may be needed. It is important to warn users to reapply treatment to the hands if they are washed. Patients with hyperkeratotic scabies may require 2 or 3 applications of acaricide on consecutive days to ensure that enough penetrates the skin crusts to kill all the mites.

**Itching** The itch and eczema of scabies persists for some weeks after the infestation has been eliminated and treatment for pruritus and eczema (section 13.5.1) may be required. Application of crotamiton can be used to control itching after treatment with more effective acaricides. A topical corticosteroid may help to reduce itch and inflammation after scabies has been treated successfully; however, persistent symptoms suggest that scabies eradication was not successful. Oral administration of a sedating antihistamine (section 3.4.1) at night may also be useful.

**Head lice**

Dimeticone is effective against head lice (*Pediculus humanus capitis*) and acts on the surface of the organism. Malathion, an organophosphorus insecticide, is an alternative, but resistance has been reported. Benzyl benzoate is licensed for the treatment of head lice but it is less effective than other drugs.

Head lice infestation (pediculosis) should be treated using lotion or liquid formulations only if live lice are present. Shampoos are diluted too much in use to be effective. A contact time of 8–12 hours or overnight treatment is recommended for lotions and liquids; a 2-hour treatment is not sufficient to kill eggs.

In general, a course of treatment for head lice should be 2 applications of product 7 days apart to kill lice emerging from any eggs that survive the first application. All affected household members should be treated simultaneously.

**Wet combing methods** Head lice can be mechanically removed by combing wet hair meticulously with a plastic detection comb (probably for at least 30 minutes each time) over the whole scalp at 4-day intervals for a minimum of 2 weeks, and continued until no lice are found on 3 consecutive sessions; hair conditioner or vegetable oil can be used to facilitate the process. Combing devices and topical solutions to aid the removal of head lice are available; some of these products are prescribable on the NHS, including Bug Buster kit, Full Marks solution, Lyclear SprayAway, Nitcomb-M2, Nitcomb-S1, Nitlotion, and Nitty Gritty Nifree.

**Crab lice**

Permethrin and malathion are used to eliminate crab lice (*Pthirus pubis*). An aqueous preparation should be applied, allowed to dry naturally and washed off after 12 hours; a second treatment is needed after 7 days to kill lice emerging from surviving eggs. All surfaces of the body should be treated, including the scalp, neck, and face (paying particular attention to the eyebrows and other facial hair). A different insecticide should be used if a course of treatment fails.

**Benzyl benzoate**

Benzyl benzoate is effective for scabies but is not a first-choice for scabies (see notes above).

**BENZYL BENZOATE**

**Indications** scabies (but see notes above)

**Cautions** children (not recommended, see also under Dose, below); avoid contact with eyes and mucous membranes; do not use on broken or secondarily infected skin

**Breast-feeding** suspend feeding until product has been washed off

**Side-effects** skin irritation, burning sensation especially on genitalia and excoriations, occasionally rashes
13.10.4 Parasiticidal preparations

- Scabies, apply 0.5% preparation over whole body, and wash off after 24 hours; if hands are washed with soap within 24 hours, they should be retreated; see also notes above; repeat application after 7 days

**Note** For scabies, manufacturer recommends application to the body but not necessarily to the head and neck. However, application should be extended to the scalp, neck, face, and ears

**Derbac-M® (SSL)**

**Liquid**, malathion 0.5% in an aqueous basis, net price 50 mL = £2.37, 200 mL = £5.93

**Excipients** include cetostearyl alcohol, fragrance, hydroxybenzoates (parabens)

For crab lice, head lice, and scabies

---

**BNF 61**

**Dose**

- Apply over the whole body; repeat without bathing on the following day and wash off 24 hours later; a third application may be required in some cases

**Note** Not recommended for children—dilution to reduce irritant effect also reduces efficacy. Some manufacturers recommend application to the body but to exclude the head and neck. However, application should be extended to the scalp, neck, face, and ears

**Malathion**

Malathion is recommended for scabies, head lice and crab lice (for details see notes above).

The risk of systemic effects associated with 1–2 applications of malathion is considered to be very low; however, applications of malathion liquid repeated at intervals of less than 1 week or application for more than 3 consecutive weeks should be avoided since the likelihood of eradication of lice is not increased.

**DIMETICONE**

**Indications** head lice

**Cautions** avoid contact with eyes; children under 6 months, medical supervision required

**Side-effects** skin irritation

**Dose**

- Rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight); repeat application after 7 days

**Hedrin® (Thornton & Ross)**

**Lotion**, dimeticone 4%, net price 50 mL = £2.98, 120 mL spray pack = £7.13, 150 mL = £6.92

**Note** Patients should be told to keep hair away from fire and flames during treatment

**MALATHION**

**Indications** see notes above and under preparations

**Cautions** avoid contact with eyes; do not use on broken or secondarily infected skin; children under 6 months, medical supervision required

**Side-effects** skin irritation and hypersensitivity reactions; chemical burns also reported

**Dose**

- Head lice, rub 0.5% preparation into dry hair and scalp, allow to dry naturally, remove by washing after 12 hours (see also notes above); repeat application after 7 days

- Crab lice, apply 0.5% aqueous preparation over whole body, allow to dry naturally, wash off after 12 hours or overnight; repeat application after 7 days

**Lyclear® Creme Rinse (Chefaro UK)**

**Cream rinse**, permethrin 1% in basis containing isopropyl alcohol 20%, net price 59 mL = £2.38, 2 x 59mL pack = £4.32

**Excipients** include cetyl alcohol

**Dose** head lice, not recommended, therefore no dose stated (insufficient contact time)

**Lyclear® Dermal Cream (Chefaro UK)**

**Dermal cream**, permethrin 5%, net price 30 g = £5.71

**Label**: 10, patient information leaflet

**Excipients** include butylated hydroxytoluene, wool fat derivative
13.10.5 Preparations for minor cuts and abrasions

Some of the preparations listed are used in minor burns, and abrasions. They are applied as necessary but should not be used on large wounds or for prolonged periods because of the possibility of hypersensitivity. The effervescence of hydrogen peroxide (section 13.11.6) is used to clean minor cuts and abrasions. Preparations containing camphor and sulphonamides should be avoided. Preparations such as magnesium sulphate paste are also listed but are now rarely used to treat carbuncles and boils as these are best treated with antibiotics (section 5.1.1.2).

Cetrimide Cream, BP
Cream, cetrimide 0.5% in a suitable water-miscible basis such as cetostearyl alcohol 5%, liquid paraffin 50% in freshly boiled and cooled purified water, net price 50 g = £1.11

Proflavine Cream, BPC
Cream, proflavine hemisulphate 0.1%, yellow beeswax 2.5%, chlorocresol 0.1%, liquid paraffin 67.3%, freshly boiled and cooled purified water 25%, wool fat 5%, net price 100 mL = £1.59

Excipients include beeswax, wool fat
Note Stains clothing

Preparations for boils
Magnesium Sulphate Paste, BP
Paste, dried magnesium sulphate 45 g, glycerol 55 g, phenol 500 mg, net price 25 g = 75p, 50 g = 87p
Note Should be stirred before use
Dose apply under dressing

Collodion
Flexible collodion may be used to seal minor cuts and wounds that have partially healed.

Collodion, Flexible, BP
Collodion, castor oil 2.5%, colophony 2.5% in a collodion basis, prepared by dissolving pyroxylin (10%) in a mixture of 3 volumes of ether and 1 volume of alcohol (90%), net price 10 mL = 38p. Label: 15

Contra-indications allergy to colophony in elastic adhesive plasters and tape

Skin tissue adhesive
Tissue adhesives are used for closure of minor skin wounds and for additional suture support. They should be applied by an appropriately trained healthcare professional. Skin tissue adhesives may cause skin sensitisation.

Dermabond ProPen® (Ethicon)
Topical Skin Adhesive, sterile, octyl 2-cyanoacrylate, net price 0.5 mL = £18.38

Epiglu® (Schuco)
Tissue adhesive, sterile, ethyl-2-cyanoacrylate 95.4 mg/g, polymethylmethacrylate, net price 4 × 3-g vials = £149.50 (with dispensing pipettes and pallette)

Histoacryl® (Braun)
Tissue adhesive, sterile, enubcrulate, net price 5 × 200-mg unit (blue) = £22.00, 10 × 200-mg unit (blue) = £67.20, 5 × 500-mg unit (clear or blue) = £34.65, 10 × 500-mg unit (blue) = £69.30

LiquiBand® (MedLogic)
Tissue adhesive, sterile, enubcrulate, net price 0.5-g amp = £5.50

13.11 Skin cleansers, antiseptics, and preparations for promotion of wound healing

13.11.1 Alcohols and saline

Alcohols and saline

Soap or detergent is used with water to cleanse intact skin; emollient preparations such as aqueous cream or emulsifying ointment (section 13.2.1) that do not irritate the skin are best used in place of soap or detergent for cleansing dry skin.

An antiseptic is used for skin that is infected or that is susceptible to recurrent infection. Detergent preparations containing chlorhexidine or povidone-iodine, which should be thoroughly rinsed off, are used. Emollients may also contain antiseptics (section 13.2.1).

Antiseptics such as chlorhexidine or povidone-iodine are used on intact skin before surgical procedures; their antiseptic effect is enhanced by an alcoholic solvent. Antiseptic solutions containing cetrimide can be used if a detergent effect is also required.

For irrigating ulcers or wounds, lukewarm sterile sodium chloride 0.9% solution is used, but tap water is often appropriate.

Potassium permanganate solution 1 in 10 000, a mild antiseptic with astringent properties, can be used for exudative eczematous areas; treatment should be stopped when the skin becomes dry. It can stain skin and nails especially with prolonged use.

13.11.1 Alcohols and saline

Alcohol

Indications skin preparation before injection

Cautions flammable; avoid broken skin; patients have suffered severe burns when diathermy has been preceded by application of alcoholic skin disinfectants

Industrial Methylated Spirit, BP
Solution, 19 volumes of ethanol and 1 volume approved wood naphtha, net price ‘66 OP’ (containing 95% by volume alcohol) 100 mL = 40p, ‘74 OP’ (containing 99% by volume alcohol) 100 mL = 39p. Label: 15
13.11.2 Chlorhexidine salts

**Chlorhexidine**

*Indications*  
See under preparations; bladder irrigation and catheter patency solutions (see section 7.4.4).  
*Cautions*  
Avoid contact with eyes, brain, meninges and catheter (see section 11.8.1); eye (section 12.3.4).  
*Side-effects*  
For skin disinfection before invasive procedures, CHILD under 2 months, not recommended.  

**Note**  
Flammable

**CX Antiseptic Dusting Powder®** (Ecolab)  
*Dusting powder*, sterile, chlorhexidine acetate 1%, net price 15 g = £3.40  
For skin disinfection

**Hibiscrub®** (Mölnlycke)  
*Cleansing solution*, red, chlorhexidine gluconate 4%, perfumed, in a surfactant solution, net price 250 mL = £4.25, 500 mL = £5.25, 1 litre = £9.75  
*Excipients* include fragrance

Use instead of soap for pre-operative hand and skin preparation and for general hand and skin disinfection

**Hibi® Liquid Hand Rub+®** (Mölnlycke)  
*Solution*, chlorhexidine gluconate 0.5%, in isopropyl alcohol 70%, net price 500 mL = £5.25  
To be used undiluted for hand and skin disinfection

**Hibitane Obstetric®** (Derma UK)  
*Cream*, chlorhexidine gluconate solution 5% (≈ 1% chlorhexidine gluconate), in a pourable water-miscible basis, net price 250 mL = £4.44  
For use in obstetrics and gynaecology as an antiseptic and lubricant (for application to skin around vulva and perineum and to hands of midwife or doctor)

**Hydrex®** (Ecolab)  
*Solution*, chlorhexidine gluconate solution 2.5% (= chlorhexidine gluconate 0.5%), in an alcoholic solution, net price 600 mL (clear) = £2.72, 600 mL (pink) = £2.72, 200-mL spray = £1.77, 500-mL spray = £3.01; 600 mL (blue) = £2.26  
For pre-operative skin disinfection  
*Note* Flammable

**Surgical scrub**, chlorhexidine gluconate 4% in a surfactant solution, net price 250 mL = £2.44, 500 mL = £2.58  
For pre-operative hand and skin preparation and for general hand disinfection

**Unisept®** (Medlock)  
*Solution* (sterile), pink, chlorhexidine gluconate 0.05%, net price 25 × 25-mL sachet = £5.40; 10 × 100-mL sachet = £6.67  
For cleansing and disinfecting wounds and burns and swabbing in obstetrics  
*With cetrimide*  
**Tisept®** (Medlock)  
*Solution* (sterile), yellow, chlorhexidine gluconate 0.015%, cetrimide 0.15%, net price 25 × 25-mL sachet = £5.20; 10 × 100-mL sachet = £6.68  
To be used undiluted for general skin disinfection and wound cleansing

**Travasept 100®** (Baxter)  
*Solution* (sterile), yellow, chlorhexidine acetate 0.015%, cetrimide 0.15%, net price 500 mL = £7.20, 1 litre = £77p  
To be used undiluted in skin disinfection such as wound cleansing and obstetrics

---

**SODIUM CHLORIDE**

*Indications*  
See notes above; nebuliser diluent (section 3.1.5); sodium depletion (section 9.2.1.2); electrolyte imbalance (section 9.2.2.1); eye (section 11.8.1); oral hygiene (section 12.3.4).

**Sodium Chloride (Non-proprietary)**  
*Solution* (sterile), sodium chloride 0.9%, net price 25 × 20-mL sachet = £5.50, 200-mL can = £2.65, 1 litre = £9.75

**FlowFusor®** (Fresenius Kabi)  
*Solution* (sterile), sodium chloride 0.9%, net price 120-mL Bellows Pack = £1.53

**Irriclen®** (Convatec)  
*Solution* in aerosol can (sterile), sodium chloride 0.9%, net price 25 × 20-mL sachet = £5.50

**Irripod®** (C D Medical)  
*Solution* (sterile), sodium chloride 0.9%, net price 25 × 20-mL sachet = £5.50

**Miniversol®** (Aguettant)  
*Solution* (sterile), sodium chloride 0.9%, net price 30 × 45-mL unit = £13.20; 30 × 100-mL unit = £19.50

**Normasol®** (Mölnlycke)  
*Solution* (sterile), sodium chloride 0.9%, net price 25 × 25-mL sachet = £6.14, 10 × 100-mL sachet = £7.47

**Stericlens®** (C D Medical)  
*Solution* in aerosol can (sterile), sodium chloride 0.9%, net price 100-mL can = £1.94, 240-mL can = £2.95

**Steripod® Sodium Chloride** (Medlock)  
*Solution* (sterile), sodium chloride 0.9%, net price 25 × 20-mL sachet = £7.57

---

**BNF 61**

**Surgical Spirit, BP**  
*Spirit*, methyl salicylate 0.5 mL, diethyl phthalate 2%, castor oil 2.5%, in industrial methylated spirit, net price 100 mL = 20p. Label: 15

**ChloroPrep®** (Enturia)  
*Cutaneous solution*, sterile, chlorhexidine gluconate 2% in isopropyl alcohol 70%, net price (single applicator) 0.67 mL = 30p, 1.5 mL = 65p, 3 mL = 85p, 10.5 mL = £2.92, 26 mL = £6.50; (single applicator, with tint) 3 mL = 80p, 10.5 mL = £3.07, 26 mL = £6.83

For skin disinfection before invasive procedures, CHILD under 2 months, not recommended

**Note** Flammable

The table lists marketed preparations of chlorhexidine as of September 2017. Prices include excipients.

**Steripod**  
Per 240 mL: £2.72, 200-mL spray = £1.77, 500-mL spray = £3.01; 600 mL (blue) = £2.26

**Sodium Chloride**  
Per 240 mL: £2.72, 200-mL spray = £1.77, 500-mL spray = £3.01; 600 mL (blue) = £2.26

**Travasept 100**  
Per 1 litre: £2.48, 500 mL = £1.54, 100 mL = 97p

---
13.11.3 Cationic surfactants and soaps

CETRIMIDE

Indications skin disinfection

Cautions avoid contact with eyes; avoid use in body cavities

Side-effects skin irritation and occasionally sensitisation

Preparations Ingredient of Tisept® and Travasept® 100, see above

13.11.4 Iodine

POVIDONE–IODINE

Indications skin disinfection

Cautions broken skin (see below)

Large open wounds The application of povidone–iodine to large wounds or severe burns may produce systemic adverse effects such as metabolic acidosis, hypernatraemia and impairment of renal function.

Contra-indications preterm neonate gestational age under 32 weeks; avoid regular use in patients with thyroid disorders or those receiving lithium therapy

Renal impairment avoid regular application to inflamed or broken mucosa

Pregnancy sufficient iodine may be absorbed to affect the fetal thyroid in the second and third trimester

Breast-feeding avoid

Side-effects rarely sensitivity; may interfere with thyroid function tests

Betadine® (Mölnlycke) Dry powder spray, povidone–iodine 2.5% in a pressurised aerosol unit, net price 150-g unit = £2.63

For skin disinfection, particularly cleansing and deodorising wounds and ulcers

Note Not for use in serous cavities

Savlon® Dry (Novartis Consumer Health) Powder spray, povidone–iodine 1.14% in a pressurised aerosol unit, net price 50-mL unit = £2.39

For minor wounds

Videne® (Ecolab) Alcoholic tincture, povidone–iodine 10%, net price 500 mL = £3.46

To be applied undiluted in pre-operative skin disinfection

Antiseptic solution, povidone–iodine 10% in aqueous solution, net price 500 mL = £3.46

To be applied undiluted in pre-operative skin disinfection and general antiseptic

Surgical scrub, povidone–iodine 7.5% in aqueous solution, net price 500 mL = £3.46

To be used as a pre-operative scrub for hand and skin disinfection

13.11.5 Phenolics

Triclosan has been used for disinfection of the hands and wounds, and for disinfection of the skin before surgery.

13.11.6 Oxidisers and dyes

HYDROGEN PEROXIDE

Indications see under preparations below

Cautions large or deep wounds; avoid on healthy skin and eyes; bleaches fabric; incompatible with products containing iodine or potassium permanganate

Hydrogen Peroxide Solution, BP

Solution 6% (20 vols), net price 200 mL = 45p

Solution 3% (10 vols), net price 200 mL = 44p

For skin disinfection, particularly cleansing and deodorising wounds and ulcers

Note The BP directs that when hydrogen peroxide is prescribed, hydrogen peroxide solution 6% (20 vols) should be dispensed.

Important Strong solutions of hydrogen peroxide which contain 27% (90 vols) and 30% (100 vols) are only for the preparation of weaker solutions

Crystacide® (GP Pharma) Cream, hydrogen peroxide 1%, net price 10 g = £4.82, 25 g = £8.07, 40 g = £11.62

Dose superficial bacterial skin infection, apply 2–3 times daily for up to 3 weeks

Excipients include edetic acid (EDTA), propylene glycol

POTASSIUM PERMANGANATE

Indications cleansing and deodorising suppurating eczematous reactions and wounds

Cautions irritant to mucous membranes

Dose

- Wet dressings or baths, approx. 0.01% solution

Note Stains skin and clothing

Potassium Permanganate Solution

Solution, potassium permanganate 0.1% (1 in 1000) in water

Dose to be diluted 1 in 10 to provide a 0.01% (1 in 10 000) solution

Permitabs® (Alliance) Solution tablets, for preparation of topical solution, potassium permanganate 400 mg, net price 30-tab pack = £9.85

Note 1 tablet dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution

13.11.7 Preparations for promotion of wound healing

Desloughing agents

Alginate, hydrogel and hydrocolloid dressings (Appendix 8) are effective at wound debridement. Sterile larvae (maggots) (LarvEx®, Zoobiotic) are also used for managing sloughing wounds and are prescribable on the NHS.

Desloughing solutions and creams are of little clinical value. Substances applied to an open area are easily absorbed and perilesional skin is easily sensitised; gravitational dermatitis may be complicated by superim-
posed contact sensitivity to substances such as neomyacin or lanolin.

For further information on wound management products see Appendix 8, p. 935.

**Growth factor**

A topical preparation of becaplermin (recombinant human platelet-derived growth factor) is licensed as an adjunct treatment of full-thickness, neuropathic, diabetic ulcers. It enhances the formation of granulation tissue, thereby promoting wound healing.

**BECAPLERMIN**

(Recombinant human platelet-derived growth factor)  

**Indications** see notes above  

**Cautions** avoid sites with infection, or peripheral arteriopathy  

**Contra-indications** malignant disease  

**Side-effects** pain; infections including cellulitis and osteomyelitis; local reactions including erythema; rarely bullous eruption, oedema, and hypertrophic granulation  

**Dose**  
- Full-thickness, neuropathic, diabetic ulcers (no larger than 5 cm²), apply thin layer daily and cover with gauze dressing moistened with physiological saline; max. duration of treatment 20 weeks (reassess if no healing after first 10 weeks); **CHILD** under 18 years see BNF for Children  
- Regranex® (Janssen-Cilag) Gel, becaplermin (recombinant human platelet-derived growth factor) 0.01%, net price 15 g = £240.92  
  Excipients include hydroxybenzenes (parabens)  

**13.12 Antiperspirants**

Aluminium chloride is a potent antiperspirant used in the treatment of hyperhidrosis. Aluminium salts are also incorporated in preparations used for minor fungal skin infections associated with hyperhidrosis.

In more severe cases specialists use glycopyrronium bromide as a 0.05% solution in the iontophoretic treatment of hyperhidrosis of plantar and palmar areas. Botox® contains botulinum toxin type A complex and is licensed for use intradermally for severe hyperhidrosis of the axillae unresponsive to topical antiperspirant or other antihidrotic treatment (section 4.9.3).

**ALUMINIUM SALTS**

**Indications** see under Dose below  

**Cautions** avoid contact with eyes or mucous membranes; avoid use on broken or irritated skin; do not shave axillae or use depilatories within 12 hours of application; avoid contact with clothing  

**Side-effects** skin irritation  

**Dose**  
- Hyperhidrosis affecting axillae, hands or feet, apply liquid formulation at night to dry skin, wash off the following morning, initially daily then reduce frequency as condition improves—do not bathe immediately before use  
- Hyperhidrosis, bromidrosis, intertrigo, and prevention of tinea pedis and related conditions, apply powder to dry skin  

**Anhydrol® Forte (Dermal)**  

**Solution** (= application), aluminium chloride hexahydrate 20% in an alcoholic basis, net price 60-mL bottle with roll-on applicator = £2.51. Label: 15  

Excipients none as listed in section 13.1.3  

**Driclor® (Stiefel)**  

**Application**, aluminium chloride hexahydrate 20% in an alcoholic basis, net price 75-mL bottle with roll-on applicator = £3.01. Label: 15  

Excipients none as listed in section 13.1.3  

1. A 30-mL pack is on sale to the public  

**ZeaSORB®** (Stiefel)  

**Dusting powder**, aldioxa 0.22%, chloroxylenol 0.5%, net price 50 g = £2.61  

Excipients include fragrance  

**13.13 Topical circulatory preparations**

These preparations are used to improve circulation in conditions such as bruising, superficial thrombophlebitis, chilblains and varicose veins but are of little value. Chilblains are best managed by avoidance of exposure to cold; neither systemic nor topical vasodilator therapy is established as being effective. Sclerotherapy of varicose veins is described in section 2.13.

Rubefacients are described in section 10.3.2.

**Hirudoid® (Genus)**  

**Cream**, heparinoid 0.3% in a vanishing-cream basis, net price 50 g = £3.99  

Excipients include cetostearyl alcohol, hydroxybenzenes (parabens)  

**Gel**, heparinoid 0.3%, net price 50 g = £3.99  

Excipients include propylene glycol, fragrance  

**Dose** apply up to 4 times daily in superficial soft-tissue injuries and superficial thrombophlebitis
Active immunity can be acquired by natural disease or by vaccination. Vaccines stimulate production of antibodies and other components of the immune mechanism; they consist of either:

1. a live attenuated form of a virus (e.g. measles, mumps and rubella vaccine) or bacteria (e.g. BCG vaccine), or
2. inactivated preparations of the virus (e.g. influenza vaccine) or bacteria, or
3. detoxified exotoxins produced by a micro-organism (e.g. tetanus vaccine), or
4. extracts of a micro-organism, which may be derived from the organism (e.g. pneumococcal vaccine) or produced by recombinant DNA technology (e.g. hepatitis B vaccine).

Live attenuated vaccines usually produce a durable immunity, but not always as long-lasting as that resulting from natural infection.

Inactivated vaccines may require a primary series of injections of vaccine to produce an adequate antibody response, and in most cases booster (reinforcing) injections are required; the duration of immunity varies from months to many years. Some inactivated vaccines are adsorbed onto an adjuvant (such as aluminium hydroxide) to enhance the antibody response.

Advice in this chapter reflects that in the handbook Immunisation against Infectious Disease (2006), which in turn reflects the guidance of the Joint Committee on Vaccination and Immunisation (JCVI).

Cautions Most individuals can safely receive the majority of vaccines. Vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. See also Predisposition to Neurological Problems, below. For individuals with bleeding disorders, see Route of administration, below. If alcohol or disinfectant is used for cleansing the skin it should be allowed to evaporate before vaccination to prevent possible inactivation of live vaccines.

When 2 or more vaccines are required (and are not available as a combined preparation), they should be given simultaneously at different sites, preferably in a different limb; if more than one injection is to be given in the same limb, they should be administered at least 2.5 cm apart (but see also BCG Vaccines, p. 750). When 2 live vaccines cannot be given at the same time, they should be separated by an interval of at least 4 weeks. For interactions see Appendix 1 (vaccines).

See also Cautions under individual vaccines

Contra-indications Vaccines are contra-indicated in those who have a confirmed anaphylactic reaction to a preceding dose of a vaccine containing the same antigens or vaccine component (such as antibacterials in viral vaccines). The presence of the following excipients in vaccines and immunological products has been noted under the relevant entries:

- Gelatin
- Gentamicin
- Neomycin
- Kanamycin
- Polymyxin B
- Streptomycin
- Thiomersal

Hypersensitivity to egg with evidence of previous anaphylactic reaction, contra-indicates influenza vaccine (prepared in hens’ eggs), tick-borne encephalitis vaccine, and yellow fever vaccine. See also Cautions under MMR vaccine.

See also Vaccines and HIV infection, below.

Live vaccines may be contra-indicated temporarily in individuals who are:

- immunosuppressed (see Impaired immune response, below);
- pregnant (see Pregnancy and breast-feeding, below).

See also Contra-indications under individual vaccines.

Impaired immune response Immune response to vaccines may be reduced in immunosuppressed patients and there is also a risk of generalised infection with live vaccines. Severely immunosuppressed patients should not be given live vaccines (including those with severe primary immunodeficiency). Specialist advice should be sought for those being treated with high doses of corticosteroids (dose equivalents of prednisolone: adults, at
least 40 mg daily for more than 1 week; children, 2 mg/ kg daily for at least 1 week or 1 mg/kg daily for 1 month), or other immunosuppressive drugs, and those being treated for malignant conditions with chemotherapy or generalised radiotherapy. For special reference to HIV infection, see below.


**Pregnancy** Live vaccines should not be administered routinely to pregnant women because of the theoretical risk of fetal infection but where there is a significant risk of exposure to disease (e.g. to yellow fever), the need for vaccination usually outweighs any possible risk to the fetus. Termination of pregnancy following inadvertent immunisation is not recommended. There is no evidence of risk from vaccinating pregnant women with inactivated viral or bacterial vaccines or toxoids. For use of specific vaccines during pregnancy, see under individual vaccines.

**Breast-feeding** Although there is a theoretical risk of live vaccine being present in breast milk, vaccination is not contra-indicated for women who are breast-feeding when there is significant risk of exposure to disease. There is no evidence of risk from vaccinating women who are breast-feeding, with inactivated viral or bacterial vaccines or toxoids. For use of specific vaccines during breast-feeding, see under individual vaccines.

**Side-effects** Injection of a vaccine may be followed by local reactions such as pain, inflammation, redness, and lymphangitis. An induration or sterile abscess may develop at the injection site. Gastro-intestinal disturbances, fever, headache, irritability, loss of appetite, fatigue, myalgia, and malaise are among the most commonly reported side-effects. Other side-effects include influenza-like symptoms, dizziness, paraesthesia, asthenia, drowsiness, arthralgia, rash, and lymphadenopathy. Hypersensitive reactions, such as bronchospasm, angioedema, urticaria, and anaphylaxis, are very rare but can be fatal (see section 3.4.3 for management of allergic emergencies).

**Oral** vaccines such as cholera, live poliomyelitis, rotavirus, and live typhoid can also cause gastro-intestinal disturbances such as nausea, vomiting, abdominal pain and cramps, and diarrhoea.

See also *Predisposition to neurological problems, below.*

Some vaccines (e.g. poliomyelitis) produce very few reactions, while others (e.g. measles, mumps and rubella) may cause a very mild form of the disease. Occasionally more serious adverse reactions can occur—these should always be reported to the CHM (see *Adverse Reactions to Drugs, p. 12*). See also Preterm Birth, p. 748.

---

### Post-immunisation pyrexia in infants

The parent should be advised that if pyrexia develops after childhood immunisation, and the infant seems distressed, a dose of paracetamol can be given and, if necessary, a second dose can be given 6 hours later; ibuprofen may be used if paracetamol is unsuitable. The parent should be warned to seek medical advice if the pyrexia persists.

For post-immunisation pyrexia in an infant aged 2–3 months, the dose of paracetamol is 60 mg; the dose of ibuprofen is 50 mg (on a doctor’s advice). An oral syringe can be obtained from any pharmacy to give the small volume required.

### Predisposition to neurological problems

When there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contraindication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended; advice on the management of fever (see Post-immunisation pyrexia in infants, above) should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended.

Children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and perinatal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule.

When there is a still evolving neurological problem, including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable.

Further information on adverse effects associated with specific vaccines can be found under individual vaccines.

**Vaccines and HIV infection**

HIV-positive individuals with or without symptoms can receive the following live vaccines:

- MMR (but avoid if immunity significantly impaired), varicella–zoster (but avoid if immunity significantly impaired—consult product literature), and the following inactivated vaccines:
  - anthrax, cholera (oral), diphtheria, haemophilus influenzae type b, hepatitis A, hepatitis B, human papilloma virus, influenza, meningococcal, pertussis, pneumococcal, poliomyelitis, rabies, tetanus, tick-borne encephalitis, typhoid (injection).

HIV-positive individuals should not receive:

- BCG, typhoid (oral), yellow fever

Note The above advice differs from that for other immunocompromised patients. *Immunisation Guidelines for HIV-infected Adults* issued by British HIV Association (BHIVA) are available at www.bhiva.org.uk and, *Immunisation of HIV-infected Children* issued by Children’s HIV Association (CHIVA) are available at www.chiva.org.uk

---

1. Live vaccines should be postponed until at least 3 months after stopping high-dose systemic corticosteroids and at least 6 months after stopping other immunosuppressive drugs or generalised radiotherapy (at least 12 months after discontinuing immunosuppressants following bone-marrow transplantation).

2. Use of normal immunoglobulin should be considered after exposure to measles (see p 769) and varicella–zoster immunoglobulin considered after exposure to chickenpox or herpes zoster (see p. 772).

3. The Royal College of Paediatrics and Child Health recommends that MMR is not given to a child with HIV infection whilst severely immunosuppressed.

4. If yellow fever risk is unavoidable, specialist advice should be sought.
Immunisation schedule
Vaccines for the childhood immunisation schedule should be obtained from local health organisations or direct from Movianto—not to be prescribed on FP10 (HS21 in Northern Ireland; GP10 in Scotland; WP10 in Wales).

Preterm birth
Babies born preterm should receive all routine immunisations based on their actual date of birth. The risk of apnoea following vaccination is increased in preterm babies, particularly in those born at or before 28 weeks postmenstrual age. If babies at risk of apnoea are in hospital at the time of their first immunisation, they should be monitored for 48 hours after immunisation. If a baby develops apnoea, bradycardia, or desaturation after the first immunisation, the second immunisation should also be given in hospital with similar monitoring. Seroconversion may be unreliable in babies born earlier than 28 weeks’ gestation or in babies treated with corticosteroids for chronic lung disease; consideration should be given to testing for antibodies against *Haemophilus influenzae* (type b), meningococcal C, and hepatitis B after primary immunisation.

When to immunise (for pre-mature infants—see note above)

<table>
<thead>
<tr>
<th>Vaccine given and dose schedule (for details of dose, see under individual vaccines)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neonates at risk only</strong></td>
</tr>
<tr>
<td>- <strong>BCG Vaccine</strong> See section 14.4, BCG Vaccines</td>
</tr>
<tr>
<td>- <strong>Hepatitis B Vaccine</strong> See section 14.4, Hepatitis B Vaccine</td>
</tr>
<tr>
<td><strong>2 months</strong></td>
</tr>
<tr>
<td>- <strong>Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis (Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)</strong> First dose</td>
</tr>
<tr>
<td>- <strong>Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)</strong> First dose</td>
</tr>
<tr>
<td><strong>3 months</strong></td>
</tr>
<tr>
<td>- <strong>Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis (Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)</strong> Second dose</td>
</tr>
<tr>
<td>- <strong>Meningococcal Group C Conjugate Vaccine</strong> First dose</td>
</tr>
<tr>
<td><strong>4 months</strong></td>
</tr>
<tr>
<td>- <strong>Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis (Inactivated), and Haemophilus Type b Conjugate Vaccine (Adsorbed)</strong> Third dose</td>
</tr>
<tr>
<td>- <strong>Meningococcal Group C Conjugate Vaccine</strong> Second dose</td>
</tr>
<tr>
<td>- <strong>Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)</strong> Second dose</td>
</tr>
<tr>
<td><strong>12–13 months</strong></td>
</tr>
<tr>
<td>- <strong>Measles, Mumps and Rubella Vaccine, Live (MMR)</strong> First dose</td>
</tr>
<tr>
<td>- <strong>Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)</strong> Single booster dose</td>
</tr>
<tr>
<td>- <strong>Haemophilus Type b Conjugate Vaccine and Meningococcal Group C Conjugate Vaccine</strong> Single booster dose</td>
</tr>
<tr>
<td><strong>Between 3 years and 4 months, and 5 years</strong></td>
</tr>
<tr>
<td>- <strong>Adsorbed Diphtheria</strong> (low dose), Tetanus, Pertussis (Acellular, Component) and Poliomyelitis (Inactivated) Vaccine** or <strong>Adsorbed Diphtheria, Tetanus, Pertussis (Acellular, Component) and Poliomyelitis (Inactivated) Vaccine</strong> Single booster dose</td>
</tr>
<tr>
<td><strong>Note</strong>: Preferably allow interval of at least 3 years after completing primary course</td>
</tr>
<tr>
<td>- <strong>Measles, Mumps and Rubella Vaccine, Live (MMR)</strong> Second dose</td>
</tr>
<tr>
<td><strong>12–13 years (females only)</strong></td>
</tr>
<tr>
<td>- <strong>Human Papilloma Virus Vaccine</strong> 3 doses; second dose 1–2 months after first dose¹</td>
</tr>
<tr>
<td><strong>13–18 years</strong></td>
</tr>
<tr>
<td>- <strong>Adsorbed Diphtheria</strong> (low dose), Tetanus, and Poliomyelitis (Inactivated) Vaccine** Single booster dose</td>
</tr>
<tr>
<td><strong>During adult life, women of child-bearing age susceptible to rubella</strong></td>
</tr>
<tr>
<td>- <strong>Measles, Mumps and Rubella Vaccine, Live (MMR)</strong> Women of child-bearing age who have not received 2 doses of a rubella-containing vaccine or who do not have a positive antibody test for rubella should be offered rubella immunisation (using the MMR vaccine)—exclude pregnancy before immunisation, but see also section 14.4, Measles, Mumps and Rubella Vaccine</td>
</tr>
<tr>
<td><strong>During adult life, if not previously immunised</strong></td>
</tr>
<tr>
<td>- <strong>Adsorbed Diphtheria</strong> (low dose), Tetanus, and Poliomyelitis (Inactivated) Vaccine** 3 doses at intervals of 1 month Booster dose at least 1 year after primary course and again 5–10 years later</td>
</tr>
</tbody>
</table>

¹. The two human papilloma virus vaccines are not interchangeable and one vaccine product should be used for the entire course; however for individuals with previous incomplete vaccination with Gardasil® who are eligible for HPV vaccination under the national programme, Cervarix® can be used to complete the vaccination course if necessary; the individual must be informed that Cervarix® does not protect against genital warts.
Vaccines and asplenia  The following vaccines are recommended for asplenic patients or those with splenic dysfunction:
  haemophilus influenzae type b; influenza; meningococcal A, C, W135, and Y conjugate; pneumococcal.

For antibiotic prophylaxis in asplenia see p. 330.

Route of administration  Vaccines should not be given intravenously. Most vaccines are given by the intramuscular route; some vaccines are given by others routes—the intradermal route for BCG vaccine, deep subcutaneous route for Japanese encephalitis, and varicella vaccine, and the oral route for cholera, live poliovirus, rotavirus, and live typhoid vaccines. The intramuscular route should not be used in patients with bleeding disorders such as haemophilia or thrombocytopenia. Vaccines usually given by the intramuscular route should be given by deep subcutaneous injection instead.

Note  The Department of Health has advised against the use of jet guns for vaccination owing to the risk of transmitting bloodborne infections, such as HIV.

High-risk groups  For information on high-risk groups, see section 14.4 under individual vaccines

BCG Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccine
Influenza Vaccine
Pneumococcal Vaccines
Tetanus Vaccines

14.2 Passive immunity

Immunity with immediate protection against certain infective organisms can be obtained by injecting preparations made from the plasma of immune individuals with adequate levels of antibody to the disease for which protection is sought (see under Immunoglobulins, section 14.5). The duration of this passive immunity varies according to the dose and the type of immunoglobulin. Passive immunity may last only a few weeks; when necessary, passive immunisation can be repeated.

Antibodies of human origin are usually termed immunoglobulins. The term antiserum is applied to material prepared in animals. Because of serum sickness and other allergic-type reactions that may follow injections of antiserum, this therapy has been replaced wherever possible by the use of immunoglobulins. Reactions are theoretically possible after injection of human immunoglobulins but reports of such reactions are very rare.

14.3 Storage and use

Care must be taken to store all vaccines and other immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many vaccines and immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Vaccines and immunoglobulins should be protected from light. Reconstituted vaccines and opened multi-dose vials must be used within the period recommended in the product literature. Unused vaccines should be disposed of by incineration at a registered disposal contractor.

Particular attention must be paid to instructions on the use of diluents. Vaccines which are liquid suspensions or are reconstituted before use should be appropriately mixed to ensure uniformity of the material to be injected.

14.4 Vaccines and antisera

Availability  Anthrax and yellow fever vaccines, botulism antitoxin, diphtheria antitoxin, and snake and spider venom antitoxins are available from local designated holding centres.

For antivenom, see Emergency Treatment of Poisoning, p. 41.

Enquiries for vaccines not available commercially can also be made to:

Immunisation Policy, Monitoring and Surveillance
Department of Health
Wellington House
133–155 Waterloo Road
London, SE1 8UG
vaccine.supply@dh.gsi.gov.uk

In Scotland information about availability of vaccines can be obtained from a Specialist in Pharmaceutical Public Health. In Wales enquiries for vaccines not available commercially should be directed to:

Welsh Medicines Information Centre
University Hospital of Wales
Cardiff, CF14 4XW
Tel: (029) 2074 2979

and in Northern Ireland:

Pharmacy and Medicines Management Centre
Beech House
Antrim Hospital Site
Northern Health and Social Care Trust
Bush Road
Antrim, BT41 2RL
rphps.admin@northerntrust.hscni.net

For further details of availability, see under individual vaccines.

Anthrax vaccine

Anthrax vaccine is made from antigens from B. anthracis. Anthrax immunisation is indicated for individuals who handle infected animals, for those exposed to imported infected animal products, and for laboratory staff who work with Bacillus anthracis. A 4-dose regimen is used for primary immunisation; booster doses should be given annually to workers at continued risk of exposure to anthrax.

In the event of possible contact with B. anthracis, post-exposure immunisation may be indicated, in addition to antimicrobial prophylaxis (section 5.1.12). Advice on the use of anthrax vaccine for post-exposure prophylaxis must be obtained from the Centre for Infections, Health Protection Agency (tel. 020 8200 4400).
BCG vaccines

BCG (Bacillus Calmette-Guérin) is a live attenuated strain derived from Mycobacterium bovis which stimulates the development of hypersensitivity to M. tuberculosis. BCG vaccine should be given intradermally by operators skilled in the technique (see below).

The expected reaction to successful BCG vaccination is induration at the site of injection followed by a local lesion which starts as a papule 2 or more weeks after vaccination; the lesion may ulcerate then subside over several weeks or months, leaving a small, flat scar. A dry dressing may be used if the ulcer discharges, but air should not be excluded. Apart from children under 6 years, any person being considered for BCG immunisation must first be given a skin test for hypersensitivity to tuberculoprotein (see section 14.1; for the treatment of infection following vaccination, seek expert advice.

BCG is recommended for the following groups if BCG immunisation has not previously been carried out:

- all neonates and infants (0–12 months) born in areas where the incidence of tuberculosis is greater than 40 per 100,000;
- neonates, infants, and children under 16 years with a parent or grandparent born in a country with an incidence of tuberculosis greater than 40 per 100,000;
- new immigrants aged under 16 years who were born in, or lived for more than 3 months in a country with an incidence of tuberculosis greater than 40 per 100,000;
- contacts aged under 36 years of those with active respiratory tuberculosis (for healthcare or laboratory workers who have had contact with clinical materials or patients with tuberculosis, age limit does not apply);
- healthcare workers and laboratory staff (irrespective of age) who are likely to have contact with patients, clinical materials, or derived isolates; other individuals under 35 years at occupational risk including veterinary and other staff who handle animal species susceptible to tuberculosis, and staff working directly with prisoners, in care homes for the elderly, or in hostels or facilities for the homeless or refugees;
- individuals under 16 years intending to live with local people for more than 3 months in a country with an incidence of tuberculosis greater than 40 per 100,000 (section 14.6).

BCG vaccine can be given simultaneously with another live vaccine (see also section 14.1), but if they are not given at the same time an interval of 4 weeks should normally be allowed. When BCG is given to infants, there is no need to delay routine primary immunisations. No further vaccination should be given in the arm used for BCG vaccination for at least 3 months because of the risk of regional lymphadenitis.

For advice on chemoprophylaxis against tuberculosis, see section 5.1.9; for the treatment of infection following vaccination, seek expert advice.

1. List of countries or primary care trusts where the incidence of tuberculosis is greater than 48 cases per 100,000 is available at www.hpa.org.uk

2. There is inadequate evidence of protection by BCG vaccine in adults aged over 35 years; however, vaccination is recommended for healthcare workers irrespective of age because of the increased risk to them or their patients.
showing tips of hair follicles is sign of correct injection; 7 mm bleb = 0.1 mL injection, 3 mm bleb = 0.05 mL injection; if considerable resistance not felt, needle too deep and should be removed and reinserted before giving more vaccine.

To be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be avoided.

### Intradermal

**Bacillus Calmette-Guérin Vaccine**

**Injection (powder for suspension)**, freeze-dried preparation of live bacteria of a strain derived from the bacillus of Calmette and Guérin. Available from health organisations or direct from Movianto (SSI brand, multidose vial with diluent).

### Diagnostic agents

The Mantoux test is recommended for tuberculin skin testing, but no licensed preparation is currently available. Guidance for healthcare professionals is available at [www.dh.gov.uk/imunisation](http://www.dh.gov.uk/imunisation).

In the Mantoux test, the diagnostic dose is administered by intradermal injection of Tuberculin Purified Protein Derivative (PPD). The Heaf test (involving the use of multiple-puncture apparatus) is no longer available.

**Note** Response to tuberculin may be suppressed by live viral vaccines, viral infection, sarcoidosis, corticosteroid therapy, or immunosuppression due to disease or treatment. Tuberculin testing should not be carried out within 4 weeks of receiving a live viral vaccine.

Two interferon gamma release assay (IGRA) tests are also available as an aid in the diagnosis of tuberculosis infection: QuanitFERON® Gold and T-SPO® T.B. Both tests measure T-cell mediated immune response to synthetic antigens. For further information on the use of interferon gamma release assay tests for tuberculosis, see [www.hpa.org.uk](http://www.hpa.org.uk).

### Tuberculin Purified Protein Derivative

**Injection**, heat-treated products of growth and lysis of appropriate *Mycobacterium* spp. 20 units/mL (2 units/0.1-mL dose) (for routine use), 1.5-mL vial; 100 units/mL (10 units/0.1-mL dose), 1.5-mL vial from intradermal injection, for Mantoux test, 2 units (0.1 mL of 20 units/mL strength) for routine Mantoux test; if first test is negative and a further test is considered appropriate 10 units (0.1 mL of 100 units/mL strength) from intradermal injection.

Available from Movianto (SSI brand)

**Note** The strength of tuberculin PPD in this product may be different to the strengths of products used previously for the Mantoux test; care is required to select the correct strength.

### Botulinum Antitoxin

A polyvalent botulinum antitoxin is available for the post-exposure prophylaxis of botulism and for the treatment of persons thought to be suffering from botulism. It specifically neutralises the toxins produced by *Clostridium botulinum* types A, B, and E. It is not effective against infantile botulism as the toxin (type A) is seldom, if ever, found in the blood in this type of infection. Hypersensitivity reactions are a problem. It is essential to read the contra-indications, warnings, and details of sensitivity tests on the package insert. Prior to treatment checks should be made regarding previous administration of any antitoxin and history of any allergic condition, e.g. asthma, hay fever, etc. All patients should be tested for sensitivity (diluting the antitoxin if history of allergy).

### Botulinum Antitoxin

A preparation containing the specific antitoxic globulins that have the power of neutralising the toxins formed by types A, B, and E of *Clostridium botulinum*.

**Note** The BP title Botulinum Antitoxin is not used because the preparation currently in use may have a different specification.

**Dose** prophylaxis, consult product literature. Available from local designated centres, for details see TOXBASE (requires registration) [www.toxbase.org](http://www.toxbase.org). For supplies outside working hours apply to other designated centres or to the duty doctor at the Health Protection Agency (Tel (020) 8200-8808). For major incidents, obtain supplies from the local blood bank.

### Cholera vaccine

**Cholera vaccine** (oral) contains inactivated Inaba (including El-Tor biotype) and Ogawa strains of *Vibrio cholerae*, serotype O1 together with recombinant B-subunit of the cholera toxin produced in Inaba strains of *V. cholerae*, serotype O1.

Oral cholera vaccine is licensed for travellers to endemic or epidemic areas on the basis of current recommendations (see also section 14.6). Immunisation should be completed at least 1 week before potential exposure. However, there is no requirement for cholera vaccination for international travel.

Immunisation with cholera vaccine does not provide complete protection and all travellers to a country where cholera exists should be warned that scrupulous attention to food, water, and personal hygiene is essential. **Injectable cholera vaccine** provides unreliable protection and is no longer available in the UK.

### Inflammatory diseases and vaccines

**CHOLERA VACCINE**

**Indications** see notes above

**Cautions** see section 14.1 and notes above

**Contra-indications** see section 14.1; also acute gastro-intestinal illness

**Pregnancy** see p. 747

**Breast-feeding** see p. 747

**Side-effects** see section 14.1; also rarely respiratory symptoms such as rhinitis and cough; very rarely sore throat, insomnia

**Dose**

- **ADULT** and **CHILD** over 6 years 2 doses separated by an interval of 1–6 weeks; **CHILD** 2–6 years 3 doses each separated by an interval of 1–6 weeks

**Note** If more than 6 weeks have elapsed between doses, the primary course should be restarted

- A single booster dose can be given 2 years after primary course for adults and children over 6 years, and 6 months after primary course for children 2–6 years. If more than 2 years have elapsed since the last vaccination, the primary course should be repeated

Conselliong: Dissolve 0.5 g of the crystalline powder in the recommended saline solution (approximately 15 mL). The solution should be injected into the deltoid muscle. After administration, parents and children should be advised to drink at least 2 hours of water, food, drink, and other oral medicines should be avoided for 1 hour before and after vaccination
14 Immunological products and vaccines

14.4 Vaccines and antisera

Dukoral® (Crucess) (BHMS)
Oral suspension, for dilution with solution of effervescent sodium bicarbonate granules, heat- and formaldehyde-inactivated Inaba (including El-Tor biotype) and Ogawa strains of Vibrio cholerae bacteria and recombinant cholera toxin B-subunit produced in V. cholerae, net price 2-dose pack = £23.42. Counselling, administration

Diphtheria vaccines

Diphtheria vaccines are prepared from the toxin of Corynebacterium diphtheriae and adsorption on aluminium hydroxide or aluminium phosphate improves antigenicity. The vaccine stimulates the production of the protective antitoxin. The quantity of diphtheria toxoid in a preparation determines whether the vaccine is defined as ‘high dose’ or ‘low dose’. Vaccines containing the higher dose of diphtheria toxoid are used for primary immunisation of children under 10 years of age. Vaccines containing the lower dose of diphtheria toxoid are used for primary immunisation in adults and children over 10 years. Single-antigen diphtheria vaccine is not available and adsorbed diphtheria vaccine is given as a combination product containing other vaccines.

For primary immunisation of children aged between 2 months and 10 years vaccination is recommended usually in the form of 3 doses (separated by 1-month intervals) of diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) (see Immunisation schedule, section 14.1). In unimmunised individuals aged over 10 years the primary course comprises of 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine.

A booster dose should be given 3 years after the primary course (this interval can be reduced to a minimum of 5 years if the primary course was delayed). Children under 10 years should receive either adsorbed diphtheria, tetanus, pertussis (acellular, component, poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) (see Immunisation schedule, section 14.1). In unimmunised individuals aged over 10 years the primary course comprises of 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine. A second booster dose, of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine, should be given 10 years after the previous booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed).

Travel Those intending to travel to areas with a risk of diphtheria infection should be fully immunised according to the UK schedule (see also section 14.6). If more than 10 years have lapsed since completion of the UK schedule, a dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine should be administered.

Contacts Staff in contact with diphtheria patients or with potentially pathogenic clinical specimens or working directly with C. diphtheriae or C. ulcerans should receive a booster dose if fully immunised (with 5 doses of diphtheria-containing vaccine given at appropriate intervals); further doses should be given at 10-year intervals if risk persists. Individuals at risk who are not fully immunised should complete the primary course; a booster dose should be given after 5 years and then at 10-year intervals. Adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine is used for this purpose; immunity should be checked by antibody testing at least 3 months after completion of immunisation.

Advice on the management of cases, carriers, contacts and outbreaks must be sought from health protection units. The immunisation history of infected individuals and their contacts should be determined; those who have been incompletely immunised should complete their immunisation and fully immunised individuals should receive a reinforcing dose. For advice on antibacterial treatment to prevent a secondary case of diphtheria in a non-immune individual, see Table 2, section 5.1.

DIPHTHERIA-CONTAINING VACCINES

Indications see notes above
Cautions see section 14.1 and see also individual components of vaccines
Contra-indications see section 14.1 and see also individual components of vaccines
Pregnancy see p. 747
Breast-feeding see p. 747
Side-effects see section 14.1; also restlessness, sleep disturbances, and unusual crying in infants
Dose
• See under preparations

Diphtheria-containing vaccines for children under 10 years

Important Not recommended for persons aged 10 years or over (see Diphtheria-containing Vaccines for Children over 10 years and Adults, p. 753)

Diphtheria, Tetanus, Pertussis (Acellular, Component), Poliomyelitis (Inactivated) and Haemophilus Type b Conjugate Vaccine (Adsorbed) (BMS)
Injection, suspension of diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b (conjugated to tetanus protein), net price 0.5-mL vial = £19.94 Excipients may include neomycin, polymyxin B and streptomycin Dose by intramuscular injection, CHILD 2 months–10 years, primary immunisation, 3 doses each of 0.5 mL separated by intervals of 1 month; see also notes on booster doses, above Brands include Pedipur®, available as part of childhood immunisation schedule, from health organisations or Movianto

Adsorbed Diphtheria, Tetanus, Pertussis (Acellular, Component) and Poliomyelitis (Inactivated) Vaccine (BMS)
Injection, suspension of diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine components adsorbed on a mineral carrier, net price 0.5-mL prefilled syringe = £17.56 Excipients may include neomycin and polymyxin B Dose by intramuscular injection, CHILD 3–10 years, first booster dose 3 years after primary immunisation, 0.5 mL, see also notes on booster doses, above Brands include Infanrix-IPV®, available as part of childhood immunisation schedule, from health organisations or Movianto
Adsorbed Diphtheria [low dose], Tetanus, Pertussis (Acellular, Component) and Poliomyelitis (Inactivated) Vaccine (Pm)

Injection, suspension of diphtheria toxoid [low dose], tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine components adsorbed on a mineral carrier, net price 0.5 mL prefilled syringe = £11.98

Excipients may include neomycin, polymyxin B and streptomycin

Dose by intramuscular injection, CHILD 3–10 years, first booster dose 3 years after primary immunisation, 0.5 mL, see also notes on booster doses, above

Brands include Repevax®, available as part of childhood immunisation schedule, from health organisations or Movianto

Diphtheria-containing vaccines for children over 10 years and adults

A low dose of diphtheria toxoid is sufficient to recall immunity in individuals previously immunised against diphtheria but whose immunity may have diminished with time; it is insufficient to cause serious reactions in an individual who is already immune. Preparations containing low dose diphtheria should be used for adults and children over 10 years, for both primary immunisation and booster doses.

Adsorbed Diphtheria [low dose], Tetanus and Poliomyelitis (Inactivated) Vaccine (Pm)

Injection, suspension of diphtheria toxoid [low dose], tetanus toxoid and inactivated poliomyelitis vaccine components adsorbed on a mineral carrier, net price 0.5 mL prefilled syringe = £6.35

Excipients may include neomycin, polymyxin B and streptomycin

Dose by intramuscular injection, ADULT and CHILD over 10 years, primary immunisation, 3 doses each of 0.5 mL, separated by intervals of 1 month, second booster dose, 0.5 mL given 10 years after first booster dose (may also be used as first booster dose in those over 10 years who have received only 3 previous doses of a diphtheria-containing vaccine); see also notes on booster doses and contacts, above

Brands include Repevax®, available as part of immunisation schedule, from health organisations or Movianto

Diphtheria antitoxin

Diphtheria antitoxin is used for passive immunisation in suspected cases of diphtheria only (without waiting for bacteriological confirmation); tests for hypersensitivity should be first carried out. It is derived from horse serum, and reactions are common after administration; resuscitation facilities should be available immediately.

It is no longer used for prophylaxis because of the risk of hypersensitivity; unimmunised contacts should be promptly investigated and given antibacterial prophylaxis (section 5.1, table 2) and vaccine (see Contacts above).

Diphtheria Antitoxin (Pm)

Dip/Ser

Dose prophylaxis, not recommended therefore no dose stated (see notes above)

Treatment, consult product literature

Available from Centre for Infections (Tel (020) 8200 6868) or in Northern Ireland from Public Health Laboratory, Belfast City Hospital (Tel (028) 9032 9241)

Haemophilus type B conjugate vaccine

Haemophilus influenzae type b (Hib) vaccine is made from capsular polysaccharide; it is conjugated with a protein such as tetanus toxoid to increase immunogenicity, especially in young children. Haemophilus influenzae type b vaccine immunisation is given in combina-

tion with diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine, as a component of the primary course of childhood immunisation (see Immunisation schedule, section 14.1) (see under Diphtheria-containing Vaccines). For infants under 1 year, the course consists of 3 doses of a vaccine containing haemophilus influenzae type b component with an interval of 1 month between doses. A booster dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) should be given at 12–13 months of age.

Children 1–10 years who have not been immunised against *Haemophilus influenzae* type b need to receive only 1 dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine). However, if a primary course of immunisation has not been completed, these children should be given 3 doses of diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed). The risk of infection falls sharply in older children and the vaccine is not normally required for children over 10 years.

Haemophilus influenzae type b vaccine may be given to those over 10 years who are considered to be at increased risk of invasive *H. influenzae* type b disease (such as those with sickle-cell disease or complement deficiency, or those receiving treatment for malignancy).

For use of Rifampicin in the prevention of secondary cases of *Haemophilus influenzae* type b disease, see Table 2, section 5.1.

Asplenia or splenic dysfunction

Haemophilus influenzae type b vaccine is recommended for patients with asplenia or splenic dysfunction. Immunised adults and children over 1 year, who develop splenic dysfunction, should be given 1 additional dose of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine). For elective splenectomy, the vaccine should ideally be given at least 2 weeks before surgery. Adults and children over 1 year, who are not immunised against haemophilus influenzae type b, should be given 2 doses of haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) with an interval of 2 months between doses. However, children under 10 years, who are not immunised against diphtheria, tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b should be given 3 doses (with an interval of 1 month between doses) of combined diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine.

Complement deficiency

Individuals who have been fully immunised with haemophilus influenzae type b vaccine, and who subsequently become complement deficient, may require further doses of haemophilus influenzae type b vaccine if they have insufficient antibody levels.

**HAEMOPHILUS TYPE B CONJUGATE VACCINE**

**Indications** see notes above

**Cautions** see section 14.1

**Contra-indications** see section 14.1

**Pregnancy** see p. 747
Breast-feeding see p. 747
Side-effects see section 14.1; also atopic dermatitis and hypotonia
Dose
- Primary immunisation, see under Diphtheria
- Booster dose, see notes above and under preparation below

Menitrix® (GSK) 
Injection, powder for reconstitution, capular polysaccharide of Haemophilus influenzae type b and capular polysaccharide of Neisseria meningitidis group C (both conjugated to tetanus protein), net price single-dose vial (with syringe containing 0.5 mL diluent) = £29.87
Dose by intramuscular injection, CHILD 1–10 years, 0.5 mL ADULT and CHILD over 1 year, with asplenia or splenic dysfunction (see notes above), 0.5 mL. Available as part of the childhood immunisation schedule from Movano

Combined vaccines
See also under Diphtheria-containing Vaccines

Hepatitis A vaccine

Hepatitis A vaccine is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells.

Immunisation is recommended for:
- laboratory staff who work directly with the virus;
- staff and residents of homes for those with severe learning difficulties;
- workers at risk of exposure to untreated sewage;
- individuals who work with primates;
- patients with haemophilia or other conditions treated with plasma-derived clotting factors;
- patients with severe liver disease;
- travellers to high-risk areas (see p. 774);
- laboratory staff who work directly with the virus;
- individuals who are at risk due to their sexual behaviour;
- parenteral drug abusers.

Immunisation should be considered for:
- patients with chronic liver disease including chronic hepatitis B or chronic hepatitis C;
- prevention of secondary cases in close contacts of confirmed cases of hepatitis A, within 14 days of exposure to the primary case (within 8 weeks of exposure to the primary case where there is more than 1 contact in the household).

A booster dose is usually given 6–12 months after the initial dose. A second booster dose can be given 20 years after the previous booster dose to those who continue to be at risk. Specialist advice should be sought on re-immunisation of immunocompromised individuals.

For rapid protection against hepatitis A after exposure or during an outbreak, in adults a single dose of a monovalent vaccine is recommended; for children under 16 years, a single dose of the combined vaccine Ambirix® can also be used.

Intramuscular normal immunoglobulin (section 14.5.1) is recommended for use in addition to Hepatitis A vaccine for close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age.

HEPATITIS A VACCINE

Indications immunisation against hepatitis A infection
Cautions see section 14.1
Contra-indications see section 14.1
Pregnancy see p. 747
Breast-feeding see p. 747
Side-effects see section 14.1: for combination vaccines, see also Typhoid vaccine, p. 767
Dose
- See under preparations

Single component

Avaxim® (Sanofi Pasteur) 
Injection, suspension of formaldehyde-inactivated hepatitis A virus (GBM grown in human diploid cells) 320 antigen units/mL adsorbed onto aluminium hydroxide, net price 0.5-mL prefilled syringe = £18.10
Excipients include neomycin
Dose by intramuscular injection (see note below), ADULT and CHILD over 16 years, 0.5 mL as a single dose; booster dose 0.5 mL 6–12 months after initial dose
Note Booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose with Avaxim®. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders; not to be injected into the buttock (vaccine efficacy reduced)

Epaxal® (Crucell) 
Injection, suspension of formaldehyde-inactivated hepatitis A virus (RG-SB grown in human diploid cells) at least 48 units/mL, net price 0.5 mL prefilled syringe = £23.81
Dose by intramuscular injection (see note below), ADULT and CHILD over 1 year, 0.5 mL as a single dose; booster dose 0.5 mL, 6–12 months after initial dose (1–6 months if splenicomised)
Note Booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

Havrix Monodose® (GSK) 
Injection, suspension of formaldehyde-inactivated hepatitis A virus (HM 175 grown in human diploid cells) 1440 ELISA units/mL adsorbed onto aluminium hydroxide, net price 1-mL prefilled syringe = £22.14, 0.5-mL (720 ELISA units) prefilled syringe (Havrix Junior Monodose®) = £16.77
Excipients include neomycin
Dose by intramuscular injection (see note below), ADULT and CHILD over 16 years, 1 mL as a single dose; booster dose, 1 mL 6–12 months after initial dose; CHILD 1–15 years 0.5 mL, booster dose, 0.5 mL, 6–12 months after initial dose
Note Booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose with Havrix Monodose®. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

Vaqta® Paediatric (Sanofi Pasteur) 
Injection, suspension of formaldehyde-inactivated hepatitis A virus (grown in human diploid cells) 50 antigen units/mL adsorbed onto aluminium hydroxide, net price 0.5 mL prefilled syringe = £28.35
Dose by intramuscular injection (see note below), ADULT and CHILD over 1 year, 0.5 mL as a single dose; booster dose, 0.5 mL 6–12 months after initial dose
Note Booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose with Havrix Monodose®. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders

A vaccine for close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age.
hydroxyphosphate sulphate, net price 0.5-mL prefilled syringe = £14.74
*Excipients* include neomycin

**Dose** by intramuscular injection (see note below).

**CHILD** 1–17 years, 0.5 mL as a single dose; booster dose 0.5 mL, 6–18 months after initial dose; under 1 year, not recommended

**Note** The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders (but immune response may be reduced)

▲ **With hepatitis B vaccine**

**Ambirix** (GSK) ▼ \( \text{ViATIM} \) (Sanofi Pasteur) \( \text{ViATIM} \)

**Injection**, suspension of inactivated hepatitis A virus (grown in human diploid cells) 720 ELISA units/mL adsorbed onto aluminium hydroxide, and recombinant (DNA) hepatitis B surface antigen (grown in yeast cells) 20 micrograms/mL adsorbed onto aluminium phosphate, net price 1-mL prefilled syringe = £31.18

*Excipients* include neomycin

**Dose** CHILD 1–15 years, by intramuscular injection (see note below); primary course, 2 doses of 1 mL, the second 6–12 months after initial dose

**Note** Primary course should be completed with Ambirix*<sup>®</sup> (single component vaccines given at appropriate intervals may be used for booster dose), the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced); subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**Important** Ambirix™ is not recommended for post-exposure prophylaxis following percutaneous (needle-stick), ocular, or mucous membrane exposure to hepatitis B virus

**Twinrix** (GSK) \( \text{ViATIM} \) (Sanofi Pasteur)

**Injection**, inactivated hepatitis A virus (grown in human diploid cells) 720 ELISA units/mL adsorbed onto aluminium hydroxide and recombinant (DNA) hepatitis B surface antigen (grown in yeast cells) 20 micrograms/mL adsorbed onto aluminium phosphate, net price 1-mL prefilled syringe (Twinrix<sup>®</sup> Adult) = £27.76, 0.5-mL prefilled syringe (Twinrix<sup>®</sup> Paediatric) = £20.79

*Excipients* include neomycin

**Dose** by intramuscular injection (see note below). ADULT and CHILD over 16 years, primary course of 3 doses of 1 mL (Twinrix<sup>®</sup> Adult), the second 1 month and the third 6 months after the first dose; CHILD 1–15 years, 3 doses of 0.5 mL (Twinrix<sup>®</sup> Paediatric) Accelerated schedule (e.g. for travellers departing within 1 month) ADULT, second dose 7 days after first dose, third dose after further 14 days and a fourth dose 12 months after the first dose

**Note** Primary course should be completed with Twinrix™ (single component vaccines given at appropriate intervals may be used for booster dose), the deltoid region is the preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced); subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**Important** Twinrix™ not recommended for post-exposure prophylaxis following percutaneous (needle-stick), ocular or mucous membrane exposure to hepatitis B virus

▲ **With typhoid vaccine**

**Hepatix** (GSK) \( \text{ViATIM} \) (Sanofi Pasteur)

**Injection**, suspension of inactivated hepatitis A virus (grown in human diploid cells) 1440 ELISA units/mL adsorbed onto aluminium hydroxide, combined with typhoid vaccine containing 25 micrograms/mL virulence polysaccharide antigen of *Salmonella typhi*, net price 1-mL prefilled syringe = £32.08

*Excipients* include neomycin

**Dose** by intramuscular injection (see note below). ADULT and CHILD over 15 years, 1 mL as a single dose; booster doses, see under single component hepatitis A vaccine (above) and under polysaccharide typhoid vaccine, p. 767

**Note** The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders; not to be injected into the buttock (vaccine efficacy reduced)

**Hepatitis B vaccine**

Hepatitis B vaccine contains inactivated hepatitis B virus surface antigen (HBsAg) adsorbed onto aluminium hydroxide adjuvant. It is made biosynthetically using recombinant DNA technology. The vaccine is used in individuals at high risk of contracting hepatitis B.

In the UK, groups at high-risk of hepatitis B include:

- parental drug misusers, their sexual partners, and household contacts; other drug misusers who are likely to ‘progress’ to injecting;
- individuals who change sexual partners frequently;
- close family contacts of a case or individual with chronic hepatitis B infection;
- babies whose mothers have had acute hepatitis B during pregnancy or are positive for hepatitis B surface antigen (regardless of e-antigen markers);
- hepatitis B vaccination started immediately on delivery and hepatitis B immunoglobulin (see p. 771) given at the same time (but preferably at a different site). Babies whose mothers are positive for hepatitis B surface antigen and for e-antigen antibody should receive the vaccine only (but babies weighing 1.5 kg or less should also receive the immunoglobulin regardless of the mother’s e-antigen antibody status);
- individuals with haemophilia, those receiving regular blood transfusions or blood products; and other drug misusers who are likely to ‘progress’ to injecting;
- patients with chronic renal failure including those on haemodialysis. Haemodialysis patients should be monitored for antibodies annually and re-immunised if necessary. Home carers (of dialysis patients) should be vaccinated;
- individuals with chronic liver disease;
- healthcare personnel (including trainees) who have direct contact with blood or blood-stained body fluids or with patients’ tissues;
- laboratory staff who handle material that may contain the virus;
- other occupational risk groups such as morticians and embalmers;
- staff and patients of day-care or residential accommodation for those with severe learning difficulties; staff and inmates of custodial institutions;
- those travelling to areas of high or intermediate prevalence who are at increased risk or who plan to remain there for lengthy periods (see p. 774);
families adopting children from countries with a high or intermediate prevalence of hepatitis B;
- foster carers and their families.

Different immunisation schedules for hepatitis B vaccine are recommended for specific circumstances (see under individual preparations). Generally, three or four doses are required for primary immunisation; an ‘accelerated schedule’ is recommended for pre-exposure prophylaxis in high-risk groups where rapid protection is required, and for post-exposure prophylaxis (see below).

Immunisation may take up to 6 months to confer adequate protection; the duration of immunity is not known precisely, but a single booster 5 years after the primary course may be sufficient to maintain immunity for those who continue to be at risk.

Immunisation does not eliminate the need for common-sense precautions for avoiding the risk of infection from known carriers by the routes of infection which have been clearly established, consult Guidance for Clinical Health Care Workers: Protection against Infection with Blood-borne Viruses (available at www.dh.gov.uk). Accidental inoculation of hepatitis B virus-infected blood into a wound, incision, needle-prick, or abrasion may lead to infection, whereas it is unlikely that indirect exposure to a carrier will do so.

Following significant exposure to hepatitis B, an accelerated schedule, with the second dose given 1 month, and the third dose 2 months after the first dose, is recommended. For those at continued risk, a fourth dose should be given 12 months after the first dose. More detailed guidance is given in the handbook Immunisation Against Infectious Disease see p. 746.

Specific hepatitis B immunoglobulin (HBIG) is available for use with the vaccine in those accidentally inoculated and in neonates at special risk of infection (section 14.5.2).

A combined hepatitis A and hepatitis B vaccine is also available.

HEPATITIS B VACCINE

Indications immunisation against hepatitis B infection

Cautions see section 14.1

Contra-indications see section 14.1

Pregnancy see p. 747

Breast-feeding see p. 747

Side-effects see section 14.1

Dose
- See under preparations

Single component

Engerix® B® (GSK) \(\uparrow\)

Injection, suspension of hepatitis B surface antigen (prepared from yeast cells by recombinant DNA technique) 20 micrograms/mL adsorbed onto aluminium hydroxide, net price 0.5-mL (paediatric) prefilled syringe = £9.67, 1-mL vial = £12.34, 1-mL prefilled syringe = £12.99

Dose by intramuscular injection (see note below), ADULT and CHILD over 16 years, 3 doses of 20 micrograms, the second 1 month and the third 6 months after the first dose; NEONATE (except if born to hepatitis B surface antigen positive mother, see below) and CHILD 1 month–16 years, 3 doses of 10 micrograms

Accelerated schedule (all ages), second dose 1 month after first dose, third dose 2 months after first dose and fourth dose 12 months after first dose

Within 1 month, ADULT over 18 years, second dose 7 days after first dose, third dose 21 days after first dose, and fourth dose 12 months after first dose

Alternative schedule for CHILD 11–15 years, 2 doses of 20 micrograms, the second dose 6 months after the first dose (this schedule not suitable if high risk of infection between doses or if compliance with second dose uncertain)

NEONATE born to hepatitis B surface antigen-positive mother (see also notes above), 4 doses of 10 micrograms, first dose at birth with hepatitis B immunoglobulin injection (separate site) the second 1 month, the third 2 months and the fourth 12 months after the first dose

Renal insufficiency (including haemodialysis patients), by intramuscular injection (see note below), ADULT and CHILD over 16 years, 4 doses of 40 micrograms, the second 1 month, the third 2 months and the fourth 6 months after the first dose; immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, NEONATE (except if born to hepatitis B surface antigen positive mother, see above) and CHILD 1 month–16 years 3 doses of 10 micrograms, second dose 1 month and third dose 6 months after first dose or accelerated schedule, 4 doses of 10 micrograms, second dose 1 month, third dose 2 months and fourth dose 12 months after first dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration

Note Deltoit muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in neonates, infants and young children, not to be injected into the buttock (vaccine efficacy reduced)

Fendrix® (GSK) \(\uparrow\)

Injection, suspension of hepatitis B surface antigen (prepared from yeast cells by recombinant DNA technique) 40 micrograms/mL adsorbed onto aluminium phosphate, net price 0.5-mL prefilled syringe = £38.10

Excipients include traces of thiomersal

Dose ADULT and CHILD over 15 years with renal insufficiency (including pre-haemodialysis and haemodialysis patients), by intramuscular injection (see note below) 4 doses of 20 micrograms, the second 1 month, the third 2 months and the fourth 6 months after the first dose; immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration

Note Deltoit muscle is preferred site of injection, not to be injected into the buttock (vaccine efficacy reduced)

HBVaxPRO® (Sanofi Pasteur) \(\uparrow\)

Injection, suspension of hepatitis B surface antigen (prepared from yeast cells by recombinant DNA technique) 10 micrograms/mL adsorbed onto aluminium hydroxyphosphate sulphate, net price 0.5-mL (5-microgram) prefilled syringe = £8.95, 1-mL (10-microgram) prefilled syringe = £12.20; 40 micrograms/mL, 1-mL (40-microgram) vial = £27.60

Dose by intramuscular injection (see note below), ADULT and CHILD over 16 years, 3 doses of 10 micrograms, the second 1 month and the third 6 months after the first dose; CHILD under 16 years, 3 doses of 5 micrograms

Accelerated schedule (all ages), second dose 1 month after first dose, third dose 2 months after first dose with fourth dose at 12 months

Booster doses may be required in immunocompromised patients with low antibody concentration

NEONATE born to hepatitis B surface antigen-positive mother (see also notes above), 5 micrograms, first dose at birth with hepatitis B immunoglobulin injection (separate site), the second 1 month, the third 2 months and the fourth 12 months after the first dose

Chronic haemodialysis patients, by intramuscular injection (see note below) 3 doses of 40 micrograms, the second 1 month and the third 6 months after the first dose; booster doses may be required in those with low antibody concentration

Note Deltoit muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in neonates and infants, not to be injected into the buttock (vaccine efficacy reduced)

With hepatitis A vaccine

See Hepatitis A Vaccine
Human papilloma virus vaccines

Human papilloma virus vaccine is available as a bivalent vaccine (Cervarix®) or a quadrivalent vaccine (Gardasil®). Cervarix® is licensed for use in females for the prevention of cervical cancer and other pre-cancerous lesions caused by human papilloma virus types 16 and 18. Gardasil® is licensed for use in females for the prevention of cervical cancer, genital warts and pre-cancerous lesions caused by human papilloma virus types 6, 11, 16, and 18. The two vaccines are not interchangeable and one vaccine product should be used for an entire course. However, the Department of Health (November 2008) states that for individuals with previous incomplete vaccination with Gardasil®, who are eligible for HPV vaccination under the national programme, Cervarix® can be used to complete the vaccination course if necessary; the individual must be informed that Cervarix® does not protect against genital warts.

Human papilloma virus vaccine will be most effective if given before sexual activity starts. The first dose is given to females aged 12 to 13 years, the second and third doses are given 1–2 and 6 months after the first dose (see Immunisation schedule, section 14.1); all 3 doses should be given within a 12-month period. If the course is interrupted, it should be resumed but not repeated, allowing the appropriate interval between the remaining doses. Where there are significant challenges in scheduling vaccinations, another high likelihood that the third dose will not be given, the third dose of Cervarix® can be given 3 months after the second dose. Under the national programme in England, females remain eligible to receive the vaccine up to the age of 18 years if they did not receive the vaccine when scheduled. Where appropriate, immunisation with human papilloma virus vaccine should be offered to females coming into the UK as they may not have been offered protection in their country of origin. The duration of protection has not been established, but current studies suggest that protection is maintained for at least 6 years after completion of the primary course.

As the vaccines do not protect against all strains of human papilloma virus, routine cervical screening should continue.

**Influenza vaccines**

While most viruses are antigenically stable, the influenza viruses A and B (especially A) are constantly altering their antigenic structure as indicated by changes in the haemagglutinins (H) and neuraminidases (N) on the surface of the viruses. It is essential that influenza vaccines in use contain the H and N components of the prevalent strain or strains as recommended each year by the World Health Organization.

**Seasonal influenza vaccines**

Seasonal influenza vaccines will not control epidemics—immunisation is recommended only for persons at high risk. Annual immunisation is strongly recommended for individuals aged over 6 months with the following conditions:

- chronic respiratory disease (includes asthma treated with continuous or repeated use of inhaled or systemic corticosteroids or asthma with previous exacerbations requiring hospital admission);
- chronic heart disease;
- chronic liver disease;
- chronic renal disease;
- chronic neurological disease;
- diabetes mellitus;
- immunosuppression because of disease (including asplenia or splenic dysfunction) or treatment (including chemotherapy and prolonged corticosteroid treatment);
- HIV infection (regardless of immune status).

Seasonal influenza vaccine is also recommended for all pregnant women, for all persons aged over 65 years, for residents of nursing or residential homes for the elderly and other long-stay facilities, and for carers of persons whose welfare may be at risk if the carer falls ill. Influenza immunisation should also be considered for household contacts of immunocompromised individuals.

**Human papilloma virus vaccines**

**Indications** see notes above and under preparations

**Cautions** see section 14.1

**Contra-indications** see section 14.1

**Pregnancy** not known to be harmful, but vaccination should be postponed until completion of pregnancy

**Breast-feeding** see p. 747

**Side-effects** see section 14.1

**Dose**

- See notes above and under preparations

**Note** To avoid confusion, prescribers should specify the brand to be dispensed

Cervarix® (GSK)

**Injection, suspension of virus-like particles of human papilloma virus type 16 (40 micrograms/mL), type 18 (40 micrograms/mL) capsid protein (prepared by recombinant DNA technique using a Baculovirus expression system) in monophosphoryl lipid A adjuvant adsorbed onto aluminium hydroxide, net price 0.5-mL prefilled syringe = £80.50

**Dose** prevention of pre-malignant genital lesions, cervical cancer and genital warts, by intramuscular injection preferably into deltoid region, ADULT and CHILD 10–25 years, 3 doses of 0.5 mL, the second 1 month and the third 6 months after the first dose

Alternative schedule for ADULT and CHILD 10–25 years, 3 doses of 0.5 mL, the second 1–2 months, and the third 5–12 months after the first dose

Gardasil® (Sanofi Pasteur)

**Injection, suspension of virus-like particles of human papilloma virus type 6 (40 micrograms/mL), type 11 (80 micrograms/mL), type 16 (80 micrograms/mL), type 18 (40 micrograms/mL) capsid protein (prepared from yeast cells by recombinant DNA technique) adsorbed onto aluminium hydroxyphosphate sulphate, net price 0.5-mL prefilled syringe = £86.50

**Dose** prevention of pre-malignant genital lesions, cervical cancer and genital warts, by intramuscular injection preferably into deltoid region or higher anterolateral thigh, ADULT and CHILD 9–26 years, 3 doses of 0.5 mL, the second 2 months and the third 6 months after the first dose

Alternative schedule for ADULT and CHILD 9–26 years, 3 doses of 0.5 mL, the second at least 1 month, and the third at least 4 months after the first dose, schedule should be completed within 12 months

**HUMAN PAPILLOMA VIRUS VACCINES**

**Injections**
As part of winter planning, NHS employers should offer vaccination to healthcare workers who are directly involved in patient care. Employers of social care workers should consider similar action.

For people who work in close contact with poultry on a regular basis, influenza immunisation is recommended as a precautionary public health measure. Seasonal human influenza vaccine does not protect against avian influenza, but it reduces the risk of poultry workers contracting both human and avian influenza simultaneously, and therefore also reduces the risk of a new influenza virus emerging.

A single dose of Pandemrix® can be used instead of the seasonal influenza vaccine if supplies of seasonal influenza vaccine are exhausted and cannot be replenished rapidly.

Monovalent influenza A(H1N1)v vaccines

Pandemrix® and Celvapan® are monovalent vaccines licensed against the influenza A(H1N1)v (swine flu) strain.

Pandemrix® is recommended for children aged 6 months–5 years who have not received the monovalent vaccine previously and who are in the risk groups prioritised for seasonal influenza vaccine. Pandemrix® is also recommended for all immunocompromised patients over 6 months of age who have not received the monovalent vaccine previously. Seasonal influenza vaccine should continue to be offered as normal. Pandemrix® can be given at the same time as the first dose of seasonal influenza vaccine; however, Pandemrix® should be given 4 weeks before the seasonal influenza vaccine to immunocompromised patients who only require one dose of seasonal influenza vaccine.

Further information on pandemic influenza, avian influenza and swine influenza may be found at www.dh.gov.uk/pandemicflu and at www.hpa.org.uk.

### INFLUENZA VACCINES

**Indications**

Annual immunisation against seasonal influenza; immunisation against influenza during a pandemic

**Cautions**

See section 14.1; interactions: Appendix 1 (vaccines)

**Contra-indications**

See section 14.1; avoid Enzira® or preparations marketed by Pfizer, Wyeth or CSL. Biotherapies in child under 5 years—increased risk of febrile convulsions

**Pregnancy**

Not known to be harmful

**Breast-feeding**

Not known to be harmful

**Side-effects**

See section 14.1; also reported febrile convulsions and transient thrombocytopenia

**Dose**

- Seasonal influenza, by intramuscular injection, ADULT and CHILD over 13 years, 0.5 mL as a single dose; CHILD 6 months–3 years, 0.25–0.5 mL; 3–13 years 0.5 mL; for children 6 months to 13 years who have not received seasonal influenza vaccine previously, repeat after 4–6 weeks
- By intradermal injection, see under Intanza® below
- Influenza A(H1N1)v, see under Celvapan® and Pandemrix® below

---

### Seasonal influenza vaccines for intramuscular use

**Inactivated Influenza Vaccine (Split Virion)**

**Flu**

**Injection**, suspension of formaldehyde-inactivated influenza virus (split virion grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £6.29; 0.5-mL prefilled syringe = £6.29

**Exipients** may include neomycin and polymyxin B, and traces of thiomersal

Available from Sanofi Pasteur

**Contra-indications**

Avoid preparations marketed by Pfizer, Wyeth, or CSL. Biotherapies in child under 5 years—increased risk of febrile convulsions

**Inactivated Influenza Vaccine (Surface Antigen)**

**Flu or Flu(adj)**

**Injection**, suspension of propiolactone-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £4.15

**Exipients** may include neomycin and polymyxin B, and traces of thiomersal

Available from Novartis Vaccines

**Note**

Not licensed for children under 4 years

**Agrippal®** (Novartis Vaccines)

**Injection**, suspension of formaldehyde-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £5.85

**Exipients** include polymyxin B

**Begrivic®** (Novartis Vaccines)

**Injection**, suspension of formaldehyde-inactivated influenza virus (split virion, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £5.85

**Exipients** include polymyxin B

**Enzira®** (Pfizer)

**Injection**, suspension of inactivated influenza virus (split virion, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £6.33

**Exipients** include neomycin and polymyxin B

**Contra-indications**

Child under 5 years—increased risk of febrile convulsions

**Fluarix®** (GSK)

**Injection**, suspension of formaldehyde-inactivated influenza virus (split virion, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £6.33

**Exipients** include gentamicin

**Fluvirin®** (Novartis Vaccines)

**Injection**, suspension of formaldehyde-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £5.39

**Exipients** include gentamicin

**Imuvac®** (Abbott)

**Injection**, suspension of formaldehyde-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £6.59

**Exipients** include gentamicin

**Influvac Sub-unit®** (Abbott)

**Injection**, suspension of formaldehyde-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £5.55

**Exipients** include gentamicin

**Mastalvu®** (MASTA)

**Injection**, suspension of formaldehyde-inactivated influenza virus (surface antigen, grown in fertilised hens’ eggs), net price 0.5-mL prefilled syringe = £6.50

**Exipients** include gentamicin
Virolflu® (Cruccell) Injection, suspension of inactivated influenza virus (surface antigen, virosome, grown in fertilised hens’ eggs), net price 0.5 mL prefilled syringe = £6.33 Excipients include neomycin and polysorbate 8

Seasonal influenza vaccine for intradermal use

Intanza® (Sanofi Pasteur) Injection, suspension of formaldehyde-inactivated influenza virus (split virion, grown in fertilised hens’ eggs), net price, prefilled syringe, 9 micrograms (0.1 mL) = £9.05; prefilled syringe, 15 micrograms (0.1 mL) = £9.05 Excipients include neomycin

Dose by intradermal injection into deltoid region

Monovalent influenza A(H1N1)fluenza vaccine

Celvapan® (Baxter) Injection, suspension of formaldehyde-inactivated influenza A(H1N1) virus (whole virion, grown in vero cells), 15 micrograms/mL, 5-mL multidose vial contains 10 doses of 0.5 mL

Dose prevention of influenza A(H1N1) by intramuscular injection, ADULT over 18 years, 9 micrograms as a single dose, ADULT over 60 years, 15 micrograms as a single dose

Note Celvapan® is not interchangeable with Pandemrix®

Pandemrix® (GSK) Injection, suspension of inactivated influenza A(H1N1) virus (split virion, grown in fertilised hens’ eggs) 7.5 micrograms/mL when mixed with emulsion of adjuvant, 5 mL of mixed multidose vial contains 10 doses of 0.5 mL

Excipients include gentamicin and thiomersal

Dose prevention of influenza A(H1N1) by intramuscular injection, ADULT and CHILD over 6 months, 2 doses each of 0.5 mL separated by an interval of at least 3 weeks

Note Pandemrix® is not interchangeable with Celvapan®

Japanese encephalitis vaccine

Japanese encephalitis vaccine is indicated for travellers to areas in Asia and the Far East where infection is endemic and for laboratory staff at risk of exposure to the virus. The primary immunisation course of 2 doses should be completed at least one week before potential exposure to Japanese encephalitis virus.

Up-to-date information on the risk of Japanese encephalitis in specific countries can be obtained from the National Travel Health Network and Centre (www.nathnac.org)

Measles vaccine

Measles vaccine has been replaced by a combined live measles, mumps, and rubella vaccine (MMR vaccine). MMR vaccine may be used in the control of outbreaks of measles (see under MMR Vaccine).

Single antigen vaccine

No longer available in the UK

Combined vaccines

See MMR vaccine

Measles, Mumps and Rubella (MMR) vaccine

A combined live measles, mumps, and rubella vaccine (MMR vaccine) aims to eliminate measles, mumps, and rubella (and congenital rubella syndrome). Every child should receive two doses of MMR vaccine by entry to primary school, unless there is a valid contra-indication (see under MMR Vaccine).

When protection against measles is required urgently (e.g. during a measles outbreak), the second dose of MMR vaccine can be given 1 month after the first dose; if the second dose is given before 18 months of age, children should still receive the routine dose before starting school at 3–5 years of age.

Children presenting for pre-school booster who have not received the first dose of MMR vaccine should be given a dose of MMR vaccine followed 3 months later by a second dose. At school-leaving age or at entry into further education, MMR immunisation should be offered to individuals of both sexes who have not received 2 doses during childhood. In a young adult who has received only a single dose of MMR in childhood, a second dose is recommended to achieve full protection. If 2 doses of MMR vaccine are required, the second dose should be given one month after initial dose.

Note Japanese encephalitis vaccine not prescribable on the NHS; health authorities may investigate circumstances under which vaccine prescribed
MMR vaccine should be used to protect against rubella in **seronegative women of child-bearing age** (see Immunisation Schedule, section 14.1); unimmunised healthcare workers who might put pregnant women and other vulnerable groups at risk of rubella or measles should be vaccinated. MMR vaccine may also be offered to previously **unimmunised and seronegative post-purum women**—vaccination a few days after delivery is important because about 60% of congenital abnormalities from rubella infection occur in babies of women who have borne more than one child. Immigrants arriving after the age of school immunisation are particularly likely to require immunisation.

**Contacts**  MMR vaccine may also be used in the control of outbreaks of measles and should be offered to susceptible children aged over 6 months who are contacts of a case, within 3 days of exposure to infection; these children should still receive routine MMR vaccinations at the recommended ages. Children aged under 9 months for whom avoidance of measles infection is particularly important (such as they who have a history of recent severe illness) can be given normal immunoglobulin (section 14.5.1) after exposure to measles; routine MMR immunisation should then be given after at least 3 months at the appropriate age.

MMR vaccine is **not suitable** for prophylaxis following exposure to mumps or rubella since the antibody response to the mumps and rubella components is too slow for effective prophylaxis.

Children and adults with impaired immune response should not receive live vaccines (for advice on HIV see section 14.1). If they have been exposed to measles infection they should be given normal immunoglobulin (section 14.5.1).

**Travel** Unimmunised travellers, including children over 6 months, to areas where measles is endemic or epidemic should receive MMR vaccine. Children immunised before 12 months of age should still receive two doses of MMR at the recommended ages. If one dose of MMR has already been given to a child, then the second dose should be brought forward to at least one month after the first, to ensure complete protection. If the child is under 18 months of age and the second dose is given within 3 months of the first, then the routine dose before starting school at 3–5 years should still be given.

**Side-effects** See section 14.1; also malaise, fever, or a rash can occur after the first dose of MMR vaccine, most commonly about a week after vaccination and lasting about 2 to 3 days. Leaflets are available for parents on advice for reducing fever (including the use of paracetamol). Febrile seizures occur rarely 6 to 11 days after MMR vaccination; the incidence of febrile seizures is lower than that following measles infection. Parotid swelling occurs occasionally, usually in the third week, and rarely, arthropyathy 2 to 3 weeks after immunisation. Adverse reactions are considerably less frequent after the second dose of MMR vaccine than after the first dose.

Hypersensitivity to egg—there is increasing evidence that MMR vaccine can be given safely even when the child has had an anaphylactic reaction to food containing egg (dislike of egg or refusal to eat eggs is not a contra-indication). For children with a confirmed anaphylactic reaction to egg-containing food, MMR vaccine should be administered in a hospital setting.

Idiopathic thrombocytopenic purpura has occurred rarely following MMR vaccination, usually within 6 weeks of the first dose. The risk of idiopathic thrombocytopenic purpura after MMR vaccine is much less than the risk after infection with wild measles or rubella virus. Children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR should undergo serological testing before the second dose is due; if the results suggest incomplete immunity against measles, mumps or rubella then a second dose of MMR is recommended. The Specialist and Reference Microbiology Division, Health Protection Agency offers free serological testing for children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR.

Post-vaccination aseptic meningitis was reported (rarely and with complete recovery) following vaccination with MMR vaccine containing Urabe mumps vaccine, which has now been discontinued; no cases have been confirmed in association with the currently used Jeryl Lynn mumps vaccine. Children with post-vaccination symptoms are not infectious.

**Reviews undertaken on behalf of the CSM, the Medical Research Council, and the Cochrane Collaboration, have not found any evidence of a link between MMR vaccination and bowel disease or autism.** The Chief Medical Officers have advised that the MMR vaccine is the safest and best way to protect children against measles, mumps, and rubella. Information (including fact sheets and a list of references) may be obtained from: [www.dh.gov.uk/immunisation](http://www.dh.gov.uk/immunisation)

---

**MEASLES, MUMPS AND RUBELLA VACCINE, LIVE**

**Indications** immunisation against measles, mumps, and rubella

**Cautions** see section 14.1; also, after immunoglobulin administration or blood transfusion, leave an interval of at least 3 months before MMR immunisation as antibody response to measles component may be reduced—see also p. 772; **Interactions:** Appendix 1 (vaccines)

**Hypersensitivity to egg** There is increasing evidence that MMR vaccine can be given safely even when the child has had an anaphylactic reaction to food containing egg (dislike of egg or refusal to eat egg is not a contra-indication). For children with a confirmed anaphylactic reaction to egg-containing food, MMR vaccine may be administered in hospital setting

**Contra-indications** see section 14.1

**Pregnancy** avoid pregnancy for at least 1 month after vaccination; see also, p. 747

**Breast-feeding** see p. 747

**Side-effects** see section 14.1 and notes above; also **less commonly** sleep disturbances, unusual crying in infants; also reported peripheral and optic neuritis

**Dose**

- By intramuscular or deep subcutaneous injection, **ADULT** and **CHILD** over 9 months (but see also notes above), primary immunisation, 2 doses each of 0.5 mL, see Immunisation Schedule, section 14.1, p. 748; see also notes above for use in outbreaks, for contacts of cases, and for travel
Meningococcal vaccines

Almost all childhood meningococcal disease in the UK is caused by *Neisseria meningitidis* serogroups B and C. Meningococcal group C conjugate vaccine protects only against infection by serogroup C. The risk of meningococcal disease declines with age—in immunisation is not generally recommended after the age of 25 years.

Tetravalent meningococcal vaccines that cover serotypes A, C, W135, and Y are available. Although the duration of protection has not been established, the meningococcal A, C, W135, and Y conjugate vaccine is likely to provide longer-lasting protection than the unconjugated meningococcal polysaccharide vaccine. The antibody response to serotype C in unconjugated meningococcal polysaccharide vaccines in young children may be suboptimal.

**Childhood immunisation** Meningococcal group C conjugate vaccine provides long-term protection against infection by serogroup C of *Neisseria meningitidis*. Immunisation consists of 2 doses given at 3 months and 4 months of age; a booster should be given at 12–13 months of age, usually combined with haemophilus influenzae type b vaccine (see Immunisation Schedule, section 14.1, p. 748).

It is recommended that meningococcal group C conjugate vaccine be given to anyone aged under 25 years who has not been vaccinated previously with this vaccine; those over 1 year receive a single dose. A single dose of meningococcal group C conjugate vaccine is also recommended for unimmunised individuals attending university, irrespective of age.

Patients under 25 years of age with confirmed serogroup C disease, who have previously been immunised with meningococcal group C vaccine, should be offered meningococcal group C conjugate vaccine before discharge from hospital.

Asplenia or splenic dysfunction Children under 1 year should be vaccinated according to the Immunisation Schedule (section 14.1), but should receive 2 doses of meningococcal A, C, W135, and Y conjugate vaccine at 3 months and 4 months of age instead of the meningococcal group C conjugate vaccine; these children should also receive one dose of meningococcal group C conjugate vaccine (combined with haemophilus influenzae type b vaccine) at 12 months of age, followed 2 months later by one dose of meningococcal A, C, W135, and Y conjugate vaccine. Unimmunised adults and children over 1 year should be given 1 dose of meningococcal group C conjugate vaccine (preferably combined with haemophilus influenzae type b vaccine) followed 2 months later by one dose of meningococcal A, C, W135, and Y conjugate vaccine. Immunised adults and children who develop splenic dysfunction should be given 1 additional dose of meningococcal group C conjugate vaccine (preferably combined with haemophilus influenzae type b vaccine) followed 2 months later by a single dose of meningococcal A, C, W135, and Y conjugate vaccine.

**Complement deficiency** Unimmunised adults and children over 1 year of age with complement deficiency should be given 1 dose of meningococcal group C conjugate vaccine (preferably combined with haemophilus influenzae type b vaccine) followed 2 months later by 1 dose of meningococcal A, C, W135 and Y conjugate vaccine. Immunised adults and children, who subsequently become complement deficient, should be given 1 dose of meningococcal A, C, W135 and Y conjugate vaccine at least 2 months after the last dose of meningococcal group C conjugate vaccine.

**Travel** Individuals travelling to countries of risk (see below) should be immunised with meningococcal A, C, W135, and Y conjugate vaccine, even if they have previously received meningitis C conjugate vaccine. If an individual has recently received meningococcal group C conjugate vaccine, an interval of at least 4 weeks should be allowed before administration of the tetravalent (A, C, W135, and Y) vaccine. Vaccination is particularly important for those living or working with local people or visiting an area of risk during outbreaks.

Immunisation recommendations and requirements for visa entry for individual countries should be checked before travelling, particularly to countries in Sub-Saharan Africa, Asia, and the Indian sub-continent where epidemics of meningococcal outbreaks and infection are reported. Country-by-country information is available from the National Travel Health Network and Centre (www.nathnac.org).

Proof of vaccination with the tetravalent (A, C, W135, and Y) meningococcal vaccine is required for those travelling to Saudi Arabia during the Haj and Umrah pilgrimages (where outbreaks of the W135 strain have occurred).

**Contacts** For advice on the immunisation of laboratory workers and close contacts of cases of meningococcal disease in the UK and on the role of the vaccine in the control of local outbreaks, consult Guidance for Public Health Management of Meningococcal Disease in the UK at www.hpa.org.uk. See Table 2, section 5.1 for antibacterial prophylaxis for prevention of secondary cases of meningococcal meningitis.

The need for immunisation of laboratory staff who work directly with *Neisseria meningitidis* should be considered.
Meningococcal Vaccines

**Indications**  
Immunisation against *Neisseria meningitidis*

**Cautions**  
see section 14.1

**Contra-indications**  
see section 14.1

**Pregnancy**  
see p. 747

**Breast-feeding**  
see p. 747

**Side-effects**  
se on section 14.1; also see p. 747

**Breast-feeding**  
see section 14.1

**Contra-indications**  
see section 14.1

**Cautions**  
see section 14.1

**Immunisation against**

14.4 Vaccines and antisera BNF 61

- **Meningococcal polysaccharide A, C, W135 and Y vaccine**
  - **ACW Yax** (GSK) \(\textsuperscript{\copyright}\) \(\textsuperscript{\textregistered}\)
  - Injection, powder for reconstitution, capillary polysaccharide antigens of *Neisseria meningitidis* groups A, C, W135, and Y, net price single-dose vial (with syringe containing diluent) = £16.73
  - Dose: by deep subcutaneous injection, ADULT and CHILD over 5 years 0.5 mL as a single dose; booster dose for those at continued risk, 0.5 mL 5 years after initial dose

**Mumps vaccine**

- **Single antigen vaccine**  
No longer available in the UK

- **Combined vaccines**  
See MMR Vaccine

**Pertussis vaccine**

**Pertussis vaccine** is given as a combination preparation containing other vaccines (see *Diphtheria containing Vaccines*). Acellular vaccines are derived from highly purified components of *Bordetella pertussis*. Primary immunisation against pertussis (whooping cough) requires 3 doses of an acellular pertussis-containing vaccine (see Immunisation schedule, section 14.1), given at intervals of 1 month from the age of 2 months. A booster dose of an acellular pertussis-containing vaccine should be given 3 years after the primary course.

All children up to the age of 10 years should receive primary immunisation with diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed). Children aged 1–10 years who have not received a pertussis-containing vaccine as part of their primary immunisation should be offered 1 dose of a suitable pertussis-containing vaccine; after an interval of at least 1 year, a booster dose of a suitable pertussis-containing vaccine should be given. Immunisation against pertussis is not currently recommended in individuals over 10 years of age.

**Cautions**  
Section 14.1

**Contra-indications**  
Section 14.1

**Pregnancy**  
See p. 747

**Breast-feeding**  
See p. 747

**Side-effects**  
See also section 14.1. The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses (see below).
The vaccine should not be withheld from children with a history to a preceding dose of:

- fever, irrespective of severity;
- persistent crying or screaming for more than 3 hours;
- severe local reaction, irrespective of extent.

**Combined vaccines**

Combined vaccines, see under Diphtheria-containing vaccines

### Pneumococcal vaccines

Pneumococcal vaccines protect against infection with *Streptococcus pneumoniae* (pneumococcus); the vaccines contain polysaccharide from capsular pneumococci. Pneumococcal polysaccharide vaccine contains purified polysaccharide from 23 capsular types of pneumococci, whereas pneumococcal polysaccharide conjugate vaccine contains polysaccharide from either 10 capsular types (*Streptococcus pneumoniae*) or 13 capsular types (*Prevenar 13*®) and the polysaccharide is conjugated to protein.

The 13-valent conjugate vaccine (*Prevenar 13*®) is used in the childhood immunisation schedule. The recommended schedule consists of 3 doses, the first at 2 months of age, the second at 4 months, and the third at 12–13 months (see Immunisation Schedule, section 14.1).

Pneumococcal vaccination is recommended for individuals at increased risk of pneumococcal infection as follows:

- age over 65 years;
- asplenia or splenic dysfunction (including homozygous sickle cell disease and coeliac disease which could lead to splenic dysfunction);
- chronic respiratory disease (includes asthma treated with continuous or frequent use of a systemic corticosteroid);
- chronic heart disease;
- chronic renal disease;
- chronic liver disease;
- diabetes mellitus requiring insulin or oral hypoglycaemic drugs;
- immune deficiency because of disease (e.g. HIV infection) or treatment (including prolonged systemic corticosteroid treatment);
- presence of cochlear implant;
- conditions where leakage of cerebrospinal fluid may occur;
- child under 5 years with a history of invasive pneumococcal disease.

Where possible, the vaccine should be given at least 2 weeks before splenectomy, cochlear implant surgery, and chemotherapy; patients should be given advice about increased risk of pneumococcal infection. Prophylactic antibacterial therapy against pneumococcal infection (Table 2, section 5.1) should not be stopped after immunisation. A patient card and information leaflet for patients with asplenia are available from the Department of Health or in Scotland from the Scottish Executive, Public Health Division 1 (Tel (0131) 244 2501).

**Choice of vaccine**

Children under 2 years at increased risk of pneumococcal infection (see list above) should receive the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) at the recommended ages, followed by a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday (see below). Children at increased risk of pneumococcal infection presenting late for vaccination should receive 2 doses (separated by at least 1 month) of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) before the age of 12 months, and a third dose at 12–13 months. Children over 12 months and under 5 years (who have not been vaccinated or not completed the primary course) should receive a single dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) before the age of 12 months, and a third dose at 12–13 months. Children over 12 months and under 5 years (who have not been vaccinated or not completed the primary course) should receive a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday and at least 2 months after the final dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed).

Children over 5 years and adults who are at increased risk of pneumococcal disease should receive a single dose of the 23-valent unconjugated pneumococcal polysaccharide vaccine.

**Revaccination**

In individuals with higher concentrations of antibodies to pneumococcal polysaccharides, revaccination with the 23-valent pneumococcal polysaccharide vaccine more commonly produces adverse reactions. Revaccination is therefore not recommended, except every 5 years in individuals in whom the antibody concentration is likely to decline rapidly (e.g. asplenia, splenic dysfunction and nephrotic syndrome). If there is doubt, the need for revaccination should be discussed with a haematologist, immunologist, or microbiologist.

**PNEUMOCOCCAL VACCINE**

**Indications**

Immunisation against pneumococcal infection

**Cautions**

See section 14.1

**Contra-indications**

See section 14.1

**Pregnancy**

See p. 747

**Breast-feeding**

See p. 747

**Side-effects**

See section 14.1; also Revaccination, above

**Dose**

- See under preparations

**Pneumococcal polysaccharide vaccine**

**Pneumovax® II** (Sanofi Pasteur)⃞

Injection, polysaccharide from each of 23 capsular types of pneumococcus, net price 0.5 mL vial = £8.32

**Dose**

By intramuscular or subcutaneous injection, ADULT and CHILD over 2 years, 0.5 mL, revaccination, see notes above.
14 Immunological products and vaccines

Pneumococcal polysaccharide conjugate vaccine (adsorbed)

Prevenar 13® (Wyeth) ▼ ▼

Injection, polysaccharide from each of 13 capsular types of pneumococcus (conjugated to carrier protein) adsorbed onto aluminium phosphate, net price 0.5-mL prefilled syringe = £49.10

Dose by intramuscular injection, CHILD 2 months–5 years, 0.5 mL (see notes above and Immunisation schedule, section 14.1)

Note Deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants.

The dose in the BNF may differ from that in product literature. Available as part of childhood immunisation schedule from Movano.

Synflorix® (GSK) ▼ ▼

Injection, polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate, net price 0.5-mL prefilled syringe = £27.60

Dose by intramuscular injection, CHILD 6 weeks–2 years, 0.5 mL (see notes above and Immunisation schedule, section 14.1)

Note Deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants.

Polio vaccines

A course of primary immunisation consists of 3 doses of a combined preparation containing inactivated poliomyelitis vaccine, starting at 2 months of age with intervals of 1 month between doses (see Immunisation schedule, section 14.1). A course of 3 doses should also be given to all unimmunised adults; no adult should remain unimmunised against poliomyelitis.

Two booster doses of a preparation containing inactivated poliomyelitis vaccine are recommended, the first before school entry and the second before leaving school (see Immunisation schedule, section 14.1).

Further booster doses are only necessary for adults at special risk, such as travellers to endemic areas, or laboratory staff likely to be exposed to the viruses, or healthcare workers in possible contact with cases; booster doses should be given to such individuals every 10 years.

Preparations containing inactivated poliomyelitis vaccine can be used to complete an immunisation course initiated with the live (oral) poliomyelitis vaccine. Live (oral) poliomyelitis vaccine is available only for use during outbreaks. The live (oral) vaccine poses a very rare risk of vaccine-associated paralytic polio because the attenuated strain of the virus can revert to a virulent form. For this reason the live (oral) vaccine must not be used for immunosuppressed individuals or their household contacts. The use of inactivated poliomyelitis vaccine removes the risk of vaccine-associated paralytic polio altogether.

Travel Unimmunised travellers to areas with a high incidence of poliomyelitis should receive a full 3-dose course of a preparation containing inactivated poliomyelitis vaccine. Those who have not been vaccinated in the last 10 years should receive a booster dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine. Information about countries with a high incidence of poliomyelitis can be obtained from www.travax.nhs.uk or from the National Travel Health Network and Centre (www.nathnac.org).

Rabies vaccine

Rabies vaccine contains inactivated rabies virus cultivated in either human diploid cells or purified chick embryo cells; vaccines are used for pre- and post-exposure prophylaxis.

Pre-exposure prophylaxis Immunisation should be offered to those at high risk of exposure to rabies—laboratory staff who handle the rabies virus, those working in quarantine stations, animal handlers, veterinary surgeons and field workers who are likely to be bitten by infected wild animals, certain port officials, and bat handlers. Transmission of rabies by humans has not been recorded but it is advised that those caring for patients with the disease should be vaccinated.

Immunisation against rabies is also recommended where there is limited access to prompt medical care for those living in areas where rabies is enzootic, for those travelling to such areas for longer than 1 month, and for those on shorter visits who may be exposed to unusual risk.

Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.

Up-to-date country-by-country information on the incidence of rabies can be obtained from the National Travel Health Network and Centre (www.nathnac.org)
Pre-exposure prophylaxis, see section 14.1; also reported paresis

Side-effects see p. 747

Breast-feeding

Pregnancy

Contra-indications see section 14.1

Indications immunisation against rabies

Cautions see also Post-exposure Management in notes above

Pregnancy see p. 747

Breast-feeding see p. 747

Side-effects see section 14.1; also reported paresis

Dose

Post-exposure prophylaxis, by intramuscular injection in deltoid region or anterolateral thigh in infants, 1 mL (see notes above)

Post-exposure prophylaxis, by intramuscular injection in deltoid region or anterolateral thigh in infants, 1 mL (see notes above)

Rabies Vaccine

Indications immunisation against rabies

Cautions see section 14.1; also diarrhoea or vomiting (postpone vaccination); immunosuppressed close contacts (see notes above); interactions: Appendix 1 (vaccines)

Contra-indications see section 14.1; also predisposition to, or history of, intussusception

Side-effects see section 14.1

Dose

- By mouth, CHILD over 6 weeks, 2 doses of 1.5 mL, separated by an interval of at least 4 weeks; course should be completed before 24 weeks of age (preferably before 16 weeks)

Rotarix® (GSK) ▼ (Novartis Vaccines)

Oral suspension, live attenuated rotavirus (RIX4414 strain), net price 1.5 mL prefilled oral syringe = £41.38

Rabies Vaccine

Rhulib® (Novartis Vaccines) ▼

Injection, powder for reconstitution, freeze-dried inactivated Flury LEP rabies virus strain cultivated in chick embryo cells, net price single-dose vial = £28.90

Excipients include neomycin

Rotavirus vaccine

Rotavirus vaccine a live, oral vaccine is licensed for immunisation of infants over 6 weeks of age for protection against gastro-enteritis caused by rotavirus infection. The vaccine is not included in the childhood immunisation schedule.

The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; the vaccine should be used with caution in those with immunosuppressed close contacts. Carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby’s nappies.

14.4 Vaccines and antisera

Rubella vaccine

A combined measles, mumps and rubella vaccine (MMR vaccine) aims to eliminate rubella (German measles) and congenital rubella syndrome. MMR vaccine is used for childhood vaccination as well as for vaccinating adults (including women of child-bearing age) who do

14Immunological products and vaccines

and, in Scotland, from Health Protection Scotland (www.hps.scot.nhs.uk).

Immunisation against rabies requires 3 doses of rabies vaccine, with further booster doses for those who remain at continued risk. To ensure continued protection in persons at high risk (e.g. laboratory workers), the concentration of antirabies antibodies in plasma is used to determine the intervals between doses.

Post-exposure management

Following potential exposure to rabies, the wound or site of exposure (e.g. mucous membrane) should be cleansed under running water and washed for several minutes with soapy water as soon as possible after exposure. Disinfectant and a simple dressing can be applied, but suturing should be delayed because it may increase the risk of introducing rabies virus into the nerves.

Post-exposure prophylaxis against rabies depends on the level of risk in the country, the nature of exposure, and the individual’s immunity. In each case, expert risk assessment and advice on appropriate management should be obtained from the Health Protection Agency Virus Reference Department, Colindale, London (tel. (020) 8200 4400) or the Centre for Infections (tel. (020) 8200 6868), in Scotland from Health Protection Scotland (tel. (0141) 300 1100), in Northern Ireland from the Public Health Laboratory, Belfast City Hospital (tel. (028) 9032 9241).

There are no specific contra-indications to the use of rabies vaccine for post-exposure prophylaxis and its use should be considered whenever a patient has been attacked by an animal in a country where rabies is enzootic, even if there is no direct evidence of rabies in the attacking animal. Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis.

For post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine), 2 doses of cell-derived vaccine, given on day 0 and day 3, are likely to be sufficient. Rabies immunoglobulin is not necessary in such cases.

Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete) comprises 5 doses of rabies vaccine given over 1 month (on days 0, 3, 7, 14, and 30); also, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin (section 14.5.2) is given on day 0. The immunisation course can be discontinued if it is proved that the individual was not at risk.

14.4 Vaccines and antisera

Rubella vaccine

A combined measles, mumps and rubella vaccine (MMR vaccine) aims to eliminate rubella (German measles) and congenital rubella syndrome. MMR vaccine is used for childhood vaccination as well as for vaccinating adults (including women of child-bearing age) who do
Immunological products and vaccines

14 Immunological products and vaccines
www.dh.gov.uk

See also section 14.1. When an individual does not have immunity against rubella (see MMR vaccine, p. 759)

- Single antigen vaccine
  No longer available in the UK; the combined live measles, mumps and rubella vaccine is a suitable alternative

- Combined vaccines
  see MMR vaccine

Smallpox vaccine
Limited supplies of smallpox vaccine are held at the Specialist and Reference Microbiology Division, Health Protection Agency (Tel. (020) 8200 4400) for the exclusive use of workers in laboratories where pox viruses (such as vaccinia) are handled.

If a wider use of the vaccine is being considered, Guidance for smallpox response and management in the post-eradication era should be consulted at www.dh.gov.uk

Tetanus vaccines
Tetanus vaccine contains a cell-free purified toxin of Clostridium tetani adsorbed on aluminium hydroxide or aluminium phosphate to improve antigenicity.

Primary immunisation for children under 10 years consists of 3 doses of a combined preparation containing adsorbed tetanus vaccine (see Diphtheria-containing Vaccines), with an interval of 1 month between doses. Following routine childhood vaccination, 2 booster doses of a preparation containing adsorbed tetanus vaccine are recommended, the first before school entry and the second before leaving school (see Immunisation schedule, section 14.1). The recommended schedule of tetanus vaccination not only gives protection against tetanus in childhood but also gives the basic immunity for subsequent booster doses. In most circumstances, a total of 5 doses of tetanus vaccine is considered sufficient for long term protection.

For primary immunisation of adults and children over 10 years previously unimmunised against tetanus, 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine are given with an interval of 1 month between doses (see Diphtheria-containing Vaccines).

Cautions
See also section 14.1. When an individual presents for a booster dose but has been vaccinated following a tetanus-prone wound, the vaccine preparation administered at the time of injury should be determined. If this is not possible, the booster should still be given to ensure adequate protection against all antigens in the booster vaccine.

Very rarely, tetanus has developed after abdominal surgery; patients awaiting elective surgery should be asked about tetanus immunisation and immunised if necessary.

Parenteral drug abuse is also associated with tetanus; those abusing drugs by injection should be vaccinated if unimmunised—booster doses should be given if there is any doubt about their immunisation status.

All laboratory staff should be offered a primary course if unimmunised.

Travel recommendations see section 14.6.

Contra-indications
See section 14.1.

Pregnancy
See p. 747.

Breast-feeding
See p. 747.

Side effects
See section 14.1.

Wounds
Wounds are considered to be tetanus-prone if they are sustained more than 6 hours before surgical treatment or at any interval after injury and are puncture-type (particularly if contaminated with soil or manure) or show much devitalised tissue or are septic or are compound fractures or contain foreign bodies. All wounds should receive thorough cleansing.

- For clean wounds: fully immunised individuals (those who have received a total of 5 doses of a tetanus-containing vaccine at appropriate intervals) and those whose primary immunisation is complete (with boosters up to date), do not require tetanus vaccine; individuals whose primary immunisation is incomplete or whose boosters are not up to date require a reinforcing dose of a tetanus-containing vaccine (followed by further doses as required to complete the schedule); non-immunised individuals (or those whose immunisation status is not known or who have been fully immunised but are now immunocompromised) should be given a dose of the appropriate tetanus-containing vaccine immediately (followed by completion of the full course of the vaccine if records confirm the need).

- For tetanus-prone wounds: management is as for clean wounds with the addition of a dose of tetanus immunoglobulin (section 14.5.2) given at a different site; in fully immunised individuals and those whose primary immunisation is complete (with boosters up to date) the immunoglobulin is needed only if the risk of infection is especially high (e.g. contamination with manure). Antibacterial prophylaxis (with benzylpenicillin, co-amoxiclav, or metronidazole) may also be required for tetanus-prone wounds.

Combined vaccines
See Diphtheria-containing Vaccines

Tick-borne encephalitis vaccine
Tick-borne encephalitis vaccine contains inactivated tick-borne encephalitis virus cultivated in chick embryo cells. It is recommended for immunisation of those working in, or visiting, high-risk areas (see International Travel, section 14.6). Those working, walking or camping in warm forested areas of Central and Eastern Europe, Scandinavia, Northern and Eastern China, and some parts of Japan, particularly from April to November when ticks are most prevalent, are at greatest risk of tick-borne encephalitis. For full protection, 3 doses of the vaccine are required; booster doses are required every 3–5 years for those still at risk. Ideally, immunisation should be completed at least one month before travel.
**TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED**

**Indications** Immunisation against tick-borne encephalitis

**Cautions** see section 14.1

**Contra-indications** see section 14.1

**Pregnancy** see p. 747

**Breast-feeding** see p. 747

**Side-effects** see section 14.1

**Dose**
- Initial immunisation, by intramuscular injection in deltoid region or anterolateral thigh in infants, ADULT and CHILD over 16 years, 3 doses each of 0.5 mL, second dose after 1–3 months and third dose after further 5–12 months; CHILD 1–16 years 3 doses of 0.25 mL, second dose after 1–3 months and third dose after further 5–12 months; ELDERLY over 60 years and immunocompromised (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.

**Note** To achieve more rapid protection, second dose may be given 14 days after first dose

- Booster doses, give first dose within 3 years after initial course completed, then every 3–5 years

**TicoVac®** (MASTA) (Crucell)

**Injection**, suspension, formaldehyde-inactivated Neudorf tick-borne encephalitis virus strain (cultivated in chick embryo cells) adsorbed onto hydrated aluminium hydroxide, net price 0.25–mL prefilled syringe (TicoVac Junior®) = £28.00, 0.5-mL prefilled syringe = £32.00

**Excipients** include gentamicin and neomycin

**Typhoid vaccines**

Typhoid vaccine is available as Vi capsular polysaccharide vaccine and live attenuated Salmonella typhi for oral use.

Typhoid immunisation is advised for
- travellers to areas where typhoid is endemic, especially if staying with or visiting local people
- travellers to endemic areas where frequent or prolonged exposure to poor sanitation and poor food hygiene is likely
- laboratory personnel who, in the course of their work, may be exposed to Salmonella typhi

Typhoid vaccination is not a substitute for scrupulous personal hygiene (see p. 774).

Capsular polysaccharide typhoid vaccine is usually given by intramuscular injection. Children under 2 years may respond suboptimally to the vaccine, but children aged between 1–2 years should be immunised if the risk of typhoid fever is considered high (immunisation is not recommended for infants under 12 months). Booster doses are needed every 3 years on continued exposure.

Oral typhoid vaccine is a live attenuated vaccine contained in an enteric-coated capsule. One capsule taken on alternate days for a total of 3 doses, provides protection 7–10 days after the last dose. Protection may persist for up to 3 years in those constantly (or repeat-
edly) exposed to Salmonella typhi, but occasional travellers require further courses at intervals of 1 year.

**Interactions** Oral typhoid vaccine is inactivated by concomitant administration of antibacterials or antimalarials:
- Antibacterials should be avoided for 3 days before and after oral typhoid vaccination;
- Mefloquine should be avoided for at least 12 hours before or after oral typhoid; vaccination with oral typhoid should preferably be completed at least 3 days before the first dose of mefloquine;
- For other antimalarials vaccination with oral typhoid vaccine should be completed at least 3 days before the first dose of the antimalarial (except proguanil hydrochloride with atovaquone, which may be given concomitantly).

**TYPHOID VACCINE**

**Indications** Immunisation against typhoid fever

**Cautions** section 14.1; interactions: see above and Appendix 1 (vaccines)

**Contra-indications** section 14.1; also for oral vaccine, acute gastro-intestinal illness

**Pregnancy** see p. 747

**Breast-feeding** see p. 747

**Side-effects** section 14.1

**Dose**
- See under preparations

**Typhoid polysaccharide vaccine for injection**

**Typhexir®** (GSK) (Sanofi Pasteur)

**Injection**, Vi capsular polysaccharide typhoid vaccine, 50 micrograms/mL virulence polysaccharide antigen of Salmonella typhi, net price 0.5-mL prefilled syringe = £9.93

**Dose** by intramuscular injection, 0.5 mL at least 2 weeks before potential exposure to typhoid infection, CHILD under 2 years (see notes above)

**Tychim Vi®** (Sanofi Pasteur) (MVA)

**Injection**, Vi capsular polysaccharide typhoid vaccine, 50 micrograms/mL virulence polysaccharide antigen of formaldehyde-inactivated Salmonella typhi, net price 0.5-mL prefilled syringe = £9.00

**Dose** by intramuscular injection, 0.5 mL at least 2 weeks before potential exposure to typhoid infection CHILD under 2 years (see notes above)

**Polysaccharide vaccine with hepatitis A vaccine**

See Hepatitis A Vaccine

**Typhoid vaccine, live (oral)**

**Vivotif®** (Crucell)

**Capsules, e/c, live attenuated Salmonella typhi** (Ty21a), net price 3-cap pack = £14.77. Label: 23, 25, counselling, administration

**Dose** ADULT and CHILD over 6 years, 1 capsule on days 1, 3, and 5

**Counselling** Swallow as soon as possible after placing in mouth with a cold or lukewarm drink; it is important to store capsules in a refrigerator

**Varicella–zoster vaccine**

Varicella–zoster vaccine (live) is licensed for immunisation against varicella in seronegative individuals. It is not recommended for routine use in children but can be
given to seronegative healthy children over 1 year who come into close contact with individuals at high risk of severe varicella infections. The Department of Health recommends varicella–zoster vaccine for seronegative healthcare workers who come into direct contact with patients. Those with a history of chickenpox or shingles can be considered immune, but healthcare workers with a negative or uncertain history should be tested.

Rarely, the varicella–zoster vaccine virus has been transmitted from the vaccinated individual to close contacts. Therefore, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4–6 weeks of the first or second dose:

- varicella-susceptible pregnant women;
- individuals at high risk of severe varicella, including those with immunodeficiency or those receiving immunosuppressive therapy.

Healthcare workers who develop a generalised papular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted. Those who develop a localised rash after vaccination should cover the lesions and be allowed to continue working unless in contact with patients at high risk of severe varicella.

Varicella–zoster immunoglobulin is used to protect susceptible individuals at increased risk of varicella infection, see p. 772.

### VARICELLA-ZOSTER VACCINE

**Indications** immunisation against varicella infection (see notes above)

**Cautions** see section 14.1; also post-vaccination close-contact with susceptible individuals (see notes above);

**Interactions:** Appendix 1 (vaccines)

**Contra-indications** see section 14.1

**Pregnancy** avoid pregnancy for 3 months after vaccination; see also p. 747

**Breast-feeding** see p. 747

**Side-effects** see section 14.1; also varicella-like rash; rarely thrombocytopenia

**Dose**
- See under preparations

#### Varilrix® (GSK) \( \uparrow \uparrow \)

**Injection**, powder for reconstitution, live attenuated varicella–zoster virus (Oka strain) propagated in human diploid cells, net price 0.5 mL vial (with diluent) = £27.31

**Excipients** include neomycin

**Dose** by subcutaneous injection preferably into deltoid region, ADULT and CHILD over 1 year (see notes above); 2 doses of 0.5 mL, separated by an interval of at least 6 weeks (minimum 4 weeks)

#### Varivax® (Sanofi Pasteur) \( \uparrow \uparrow \)

**Injection** powder for reconstitution, live attenuated varicella-zoster virus (Oka/Merck strain) propagated in human diploid cells, net price 0.5 mL vial (with diluent) = £30.28

**Excipients** include gelatin and neomycin

**Dose** by intramuscular or subcutaneous injection into deltoid region (or higher anterolateral thigh in children); ADULT and CHILD over 13 years (see notes above); 2 doses of 0.5 mL, separated by 4–8 weeks; CHILD 1–13 years (see notes above) 2 doses of 0.5 mL, separated by an interval of at least 4 weeks (two doses separated by 12 weeks in children with asymptomatic HIV infection)

### YELLOW FEVER VACCINE, LIVE

**Indications** immunisation against yellow fever

**Cautions** see section 14.1; also individuals over 60 years—greater risk of vaccine-associated adverse effects, see notes above; **interactions:** Appendix 1 (vaccines)

**Contra-indications** see section 14.1 and notes above; also children under 6 months; history of thymus dysfunction

**Pregnancy** see notes above

**Breast-feeding** see notes above

**Side-effects** see section 14.1; also reported neurotropic disease and viscerotropic disease (see notes above)

**Dose**
- By deep subcutaneous injection, ADULT and CHILD over 9 months, 0.5 mL (see also notes above)

#### Yellow Fever Vaccine, Live \( \downarrow \downarrow \)

**Injection**, powder for reconstitution, live, attenuated 17D-204 strain of yellow fever virus, cultivated in chick embryos; single dose vial with syringe containing 0.5 mL diluent

Available (only to designated Yellow Fever Vaccination centres) as Stamaril®
14.5 Immunoglobulins

14.5.1 Normal immunoglobulin

Human normal immunoglobulin (‘HNIG’) is prepared from pools of at least 1000 donations of human plasma; it contains immunoglobulin G (IgG) and antibodies to hepatitis A, measles, mumps, rubella, varicella, and other viruses that are currently prevalent in the general population.

Normal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).

Uses Normal immunoglobulin (containing 10%–18%) is administered by intramuscular injection for the protection of susceptible contacts against hepatitis A virus (infectious hepatitis), measles and, to a lesser extent, rubella. Injection of immunoglobulin produces immediate protection lasting several weeks.

Normal immunoglobulin (containing 3%–12% protein) for intravenous administration is used as replacement therapy for patients with congenital agammaglobulinemia and hypogammaglobulinemia, and for the short-term treatment of idiopathic thrombocytopenic purpura and Kawasaki disease; it is also used for the prophylaxis of infection following bone-marrow transplantation and in children with symptomatic HIV infection who have recurrent bacterial infections. Normal immunoglobulin for replacement therapy may also be given intramuscularly or subcutaneously, but intravenous formulations are normally preferred. Intravenous immunoglobulin is also used in the treatment of Guillain-Barré syndrome as an alternative to plasma exchange.

For guidance on the use of intravenous normal immunoglobulins and alternative therapies for certain conditions, consult Clinical Guidelines for Immunoglobulin Use (www.dh.gov.uk).

Hepatitis A Hepatitis A vaccine is preferred for individuals at risk of infection (see p. 754) including those visiting areas where the disease is highly endemic (all countries excluding Northern and Western Europe, North America, Japan, Australia, and New Zealand). In unimmunised individuals, transmission of hepatitis A is reduced by good hygiene. Intramuscular normal immunoglobulin is no longer recommended for routine prophylaxis in travellers, but it may be indicated for immunocompromised patients if their antibody response to the vaccine is unlikely to be adequate.

Intramuscular normal immunoglobulin is recommended for prevention of infection in close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age; normal immunoglobulin should be given as soon as possible, preferably within 14 days of exposure to the primary case. However, normal immunoglobulin can still be given to contacts at risk of severe disease up to 28 days after exposure to the primary case. Hepatitis A vaccine can be given at the same time, but it should be given at a separate injection site.

Measles Intravenous or subcutaneous normal immunoglobulin may be given to prevent or attenuate an attack of measles in individuals who do not have adequate immunity. Children and adults with compromised immunity who have come into contact with measles should receive intravenous or subcutaneous normal immunoglobulin as soon as possible after exposure. It is most effective if given within 72 hours but can be effective if given within 6 days.

Subcutaneous or intramuscular normal immunoglobulin should also be considered for the following individuals if they have been in contact with a confirmed case of
measles or with a person associated with a local outbreak:

- non-immune pregnant women;
- infants under 9 months.

Further advice should be sought from the Centre for Infections, Health Protection Agency (tel. (020) 8200 6888).

Individuals with normal immunity who are not in the above categories and who have not been fully immunised against measles, can be given MMR vaccine (section 14.4) for prophylaxis following exposure to measles.

Rubella Intramuscular immunoglobulin after exposure to rubella does not prevent infection in non-immune contacts and is not recommended for protection of pregnant women exposed to rubella. It may, however, reduce the likelihood of a clinical attack which may possibly reduce the risk to the fetus. Risk of intrauterine transmission is greatest in the first 11 weeks of pregnancy, between 16 and 20 weeks there is minimal risk of deafness only, after 20 weeks there is no increased risk. Intramuscular normal immunoglobulin should be used only if termination of pregnancy would be unacceptable to the pregnant woman—it should be given as soon as possible after exposure. Serological follow-up of recipients is essential to determine if the woman has become infected despite receiving immunoglobulin.

For routine prophylaxis against Rubella, see MMR vaccine (p. 759).

### Normal Immunoglobulin

#### Indications
- See notes above

#### Cautions
- Hypo- or agammaglobulinaemia with or without IgA deficiency; interference with live virus vaccines—see p. 769

#### Contra-indications
- Patients with selective IgA deficiency who have known antibody against IgA

#### Renal Impairment
- Monitor for acute renal failure; consider discontinuation if renal function deteriorates.

#### Side-effects
- Nausea, diarrhoea, chills, fever, headache, dizziness, arthralgia, myalgia, muscle spasms, low back pain; rarely hypotension, anaphylaxis, cutaneous reactions, urticaria, pruritus, abdominal pain and distension, blood pressure fluctuations, haemolytic anaemia, thromboembolic events including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis

**Note** Adverse reactions are more likely to occur in patients receiving normal immunoglobulin for the first time, or following a prolonged period between treatments, or when a different brand of normal immunoglobulin is administered.

#### Dose
- See under preparations

**Note** Antibody titres can vary widely between normal immunoglobulin preparations from different manufacturers—formulations are not interchangeable; patients should be maintained on the same formulation throughout long-term treatment to avoid adverse effects.
14.5.2 Disease-specific immunoglobulins

Kiovig® (Baxter)  
Intravenous infusion, human normal immunoglobulin (protein 10%), net price 1 g (10 mL) = £49.00, 2.5 g (25 mL) = £122.50, 5 g (50 mL) = £245.00, 10 g (100 mL) = £490.00, 20 g (200 mL) = £980.00.

Note: Use Glucose 5% intravenous infusion, if dilution prior to administration is required.

Privigen® (CSL Behring)  
Intravenous infusion, human normal immunoglobulin (protein 10%), net price 2.5 g (25 mL) = £135.00, 5 g (50 mL) = £270.00, 10 g (100 mL) = £540.00, 20 g (200 mL) = £1080.00.

Note: Contains L-proline, contra-indicated in patients with hyperprolenaemia.

Vigam® (BPL)  
Intravenous infusion, human normal immunoglobulin (protein 5%), net price 2.5 g (50 mL) = £95.00, 5 g (100 mL) = £190.00, 10 g (200 mL) = £380.00.

Note: Contains sucrose (see Renal impairment, above).

14.5.2 Disease-specific immunoglobulins

Specific immunoglobulins are prepared by pooling the plasma of selected human donors with high levels of the specific antibody required. For further information, see Immunoglobulin Handbook (www.hpa.org.uk).

There are no specific immunoglobulins for hepatitis A, measles, or rubella—normal immunoglobulin, section 14.5.1 is used in certain circumstances. There is no specific immunoglobulin for mumps; neither normal immunoglobulin nor MMR vaccine is effective as post-exposure prophylaxis.

Hepatitis B

Disease-specific hepatitis B immunoglobulin (‘HBIG’) is available for use in association with hepatitis B vaccine for the prevention of infection in laboratory and other personnel who have been accidentally inoculated with hepatitis B virus, and in infants born to mothers who have become infected with this virus in pregnancy or who are high-risk carriers (see Hepatitis B Vaccine, p. 755). Hepatitis B immunoglobulin will not inhibit the antibody response when given at the same time as hepatitis B vaccine but should be given in different sites.

An intravenous and subcutaneous preparation of hepatitis B-specific immunoglobulin is licensed for the prevention of hepatitis B recurrence in HBV-DNA negative patients who have undergone liver transplantation for liver failure caused by the virus.

Hepatitis B Immunoglobulin

Indications  prophylaxis against hepatitis B infection

Cautions  IgA deficiency; interference with live virus vaccines see under Normal Immunoglobulin, p. 769.

Side-effects  injection site reactions; less frequently, buccal ulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis, tremor, dizziness, headache, arthralgia; for side-effects associated with intravenous immunoglobulin, see section 14.5.1.

Dose  ● See under preparations and see also notes above.

For intramuscular use

Hepatitis B Immunoglobulin  
Injection, hepatitis B-specific immunoglobulin, 100 units/mL. Vials containing 200 units or 500 units, available from selected Health Protection Agency and NHS laboratories (except for Transplant Centres, see p. 769), also available from BPL.

Dose: by intramuscular injection (as soon as possible after exposure), ideally within 12–48 hours, but no later than 7 days after exposure.

ADULT and CHILD over 10 years 500 units; CHILD under 5 years 200 units, 5–9 years 300 units, NEONATE 200 units.

Prevention of transmitted infection at birth, NEONATE 200 units as soon as possible after birth; for full details consult Immunisation against Infectious Disease (www.dh.gov.uk).

For intravenous use

Note: Hepatitis B immunoglobulin for intravenous use is available from BPL on a named-patient basis.

Hepatect®CP (Biotest UK)  
Intravenous infusion, hepatitis B-specific immunoglobulin 50 units/mL, net price 500 units (10 mL) = £300.00, 2000 units (40 mL) = £1100.00.

Dose: by intravenous infusion, after exposure to hepatitis B virus-contaminated material—consult product literature.

Prevention of transmitted infection at birth—consult product literature.

Prevention of hepatitis B in haemodialysed patients, prophylaxis against re-infection of transplanted liver—consult product literature.

For subcutaneous use

Zutectra® (Biotest UK)  
Injection, hepatitis B-specific immunoglobulin, 500 units/mL, net price 5 x 1 mL prefilled syringes = £1500.00.

Dose: prevention of hepatitis B re-infection more than 6 months after liver transplantation in stable HBV-DNA negative patients starting 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin, by subcutaneous injection, ADULT body-weight under 75 kg 580 units once weekly, increased if necessary up to 1000 units once weekly; body-weight over 75 kg 1000 units once weekly.

Rabies

Following exposure of an unimmunised individual to an animal in or from a country where the risk of rabies is high the site of the bite should be washed with soapy water and specific rabies immunoglobulin of human origin administered. All of the dose should be injected around the site of the wound; if this is difficult or the wound has completely healed it can be given in the anterolateral thigh (remote from the site used for vaccination).

Rabies vaccine should also be given intramuscularly at a different site (for details see Rabies vaccine p. 764).

Rabies Immunoglobulin

Indications  post-exposure prophylaxis against rabies infection

Cautions  IgA deficiency; interference with live virus vaccines—see p. 769 under Normal Immunoglobulin

Side-effects  injection site swelling and pain; very rarely anaphylaxis; buccal ulceration, glossitis, chest tightness, dyspnoea, tremor, dizziness, arthralgia, and facial oedema also reported.

Dose  ● See under preparation.
### 14.5.3 Anti-D (Rh0) immunoglobulin

**Indications**  
Prophylaxis against Rhesus-negative haemolytic disease of the newborn.

**Cautions**  
IgA deficiency; interference with live virus vaccines—see p. 769

**Side-effects**  
Injection site swelling and pain; rarely anaphylaxis

**Dose**  

- **Neonate**: 10 units/kg given as a single dose when significant feto-maternal haemorrhage occurs in Rhesus-negative neonates.
- **Infant**: 10 units/kg given as a single dose when significant feto-maternal haemorrhage occurs in Rhesus-negative neonates.
- **Child** 1–9 years: 20 units/kg given as a single dose when significant feto-maternal haemorrhage occurs in Rhesus-negative neonates.
- **Child** 10–14 years: 25 units/kg given as a single dose when significant feto-maternal haemorrhage occurs in Rhesus-negative neonates.
- **Child** over 14 years: 50 units/kg given as a single dose when significant feto-maternal haemorrhage occurs in Rhesus-negative neonates.

**Note**  
May be difficult to obtain.
sensitising event early in the same pregnancy. Similarly, postpartum anti-D prophylaxis should be given irrespective of previous routine antenatal anti-D prophylaxis or antenatal anti-D prophylaxis for a sensitising event in the same pregnancy.

**NICE guidance**

Routine antenatal anti-D prophylaxis for rhesus-negative women (August 2008)

Routine antenatal anti-D prophylaxis should be offered to all non-sensitised pregnant women who are rhesus negative.

Note

MMR vaccine may be given in the postpartum period with anti-D (Rh) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.

Anti-D (Rh) immunoglobulin is also given to women of child-bearing potential after the inadvertent transfusion of rhesus-incompatible blood components and is used for the treatment of idiopathic thrombocytopenia purpura.

**ANTI-D (Rh) IMMUNOGLOBULIN**

**Indications** see notes above

**Cautions** immunoglobulin A deficiency; possible interference with live virus vaccines, see below p. 769, but see notes above about administration with MMR vaccine

**Contra-indications** treatment of idiopathic thrombocytopenia purpura in rhesus negative or splenectomised patients

**Side-effects** nausea, vomiting, diarrhoea, abdominal pain, hypotension, hypertension, headache, fever, malaise, asthenia, drowsiness, dizziness, back pain, arthralgia, myalgia; pruritus, rash, sweating, injection site pain; rarely tachycardia, anaphylaxis, dyspnoea, hypotension, and urticaria; (for side-effects associated with intravenous immunoglobulins, see section 14.5.1

**Dose**

● See preparations below

**Anti-D (Rh) Immunoglobulin**

Injection, anti-D (Rh) immunoglobulin, net price 250-unit vial = £19.00, 500-unit vial = £27.00, 1500-unit vial = £58.00, 2500-unit vial = £94.40

Dose by deep intramuscular injection, to rhesus-negative woman for prevention of Rh(D) sensitisation:

Following birth of rhesus-positive infant, 500 units immediately or within 72 hours; for large transplacental blood loss, 50–125 units per mL of fetal red cells

Antenatal prophylaxis, 1000–1500 units given at weeks 28 and 34 of pregnancy. If infant rhesus-positive, further dose is needed immediately or within 72 hours of delivery

Following abortion, ectopic pregnancy or hydatidiform mole up to 12 weeks’ gestation, 600–750 units (after 12 weeks, 1250–1650 units) immediately or within 72 hours

Following amniocentesis or chorionic villous sampling, 1250–1500 units immediately or within 72 hours

Following Rh (D) incompatible blood or red cell transfusion, 1250 units per 10 mL of transfused rhesus-positive red cells immediately or within 72 hours

**Note** Subcutaneous route recommended for patients with bleeding disorders.

**Partobulin SDF®** (Baxter) Injection, anti-D (Rh) immunoglobulin 1250 units/mL (250 micrograms/mL), net price 1-mL prefilled syringe = £35.00

Dose by intramuscular injection, to rhesus-negative woman for prevention of Rh (D) sensitisation:

Following birth of rhesus-positive infant, 1000–1650 units immediately or within 72 hours; for large transplacental blood loss, 50–125 units per mL of fetal red cells

Antenatal prophylaxis, 1000–1500 units given at weeks 28 and 34 of pregnancy. If infant rhesus-positive, further dose is needed immediately or within 72 hours of delivery

Following abortion, ectopic pregnancy or hydatidiform mole up to 12 weeks’ gestation, 600–750 units (after 12 weeks, 1250–1650 units) immediately or within 72 hours

Following amniocentesis or chorionic villous sampling, 1250–1500 units immediately or within 72 hours

Following Rh (D) incompatible blood or red cell transfusion, 1250 units per 10 mL of transfused rhesus-positive red cells immediately or within 72 hours

**Note** Subcutaneous route recommended for patients with bleeding disorders.

1. There is inadequate evidence of protection by BCG vaccine in adults aged over 35 years; however, vaccination is recommended for healthcare workers irrespective of age because of the increased risk to them or their patients.
posing to stay for longer than 3 months (or in close contact with the local population) in countries with an incidence of tuberculosis greater than 40 per 100,000; it should preferably be given 3 months or more before departure.

Monovalent influenza A(H1N1) vaccine (see p. 758) can be offered to travellers visiting countries in the southern hemisphere during their influenza season.

Yellow fever immunisation (see p. 768) is recommended for travel to the endemic zones of Africa and South America. Many countries require an International Certificate of Vaccination from individuals arriving from, or who have been travelling through, endemic areas; other countries require a certificate from all entering travellers (consult the Department of Health handbook, Health Information for Overseas Travel, www.dh.gov.uk). Immunisation against meningococcal meningitis is recommended for a number of areas of the world (for details, see p. 761).

Protection against hepatitis A is recommended for travellers to high-risk areas outside Northern and Western Europe, North America, Japan, Australia and New Zealand. Hepatitis A vaccine (see p. 754) is preferred and it is likely to be effective even if given shortly before departure; normal immunoglobulin is no longer given routinely but may be indicated in the immunocompromised (see p. 769). Special care must also be taken with food hygiene (see below).

Hepatitis B vaccine (see p. 755) is recommended for those travelling to areas of high or intermediate prevalence who intend to seek employment as healthcare workers or who plan to remain there for lengthy periods and who may therefore be at increased risk of acquiring infection as the result of medical or dental procedures carried out in those countries. Short-term tourists or business travellers are not generally at increased risk of infection but may put themselves at risk by their sexual behaviour when abroad.

Prophylactic immunisation against rabies (see p. 764) is recommended for travellers to enzootic areas on long journeys or to areas out of reach of immediate medical attention. Travellers who have not had a tetanus booster in the last 10 years and are visiting areas where medical attention may not be accessible should receive a booster dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine (see p. 752), even if they have received 5 doses of a tetanus-containing vaccine previously.

Typhoid vaccine (see p. 767) is indicated for travellers to countries where typhoid is endemic, but the vaccine is no substitute for personal precautions (see below). There is no requirement for cholera vaccination as a condition for entry into any country, but oral cholera vaccine (see p. 751) should be considered for backpackers and those travelling to situations where the risk is greatest (e.g. refugee camps). Regardless of vaccination, travellers to areas where cholera is endemic should take special care with food hygiene (see below).

Advice on diphtheria (see p. 752), on Japanese encephalitis (see p. 759) and on tick-borne encephalitis (see p. 766) is included in Health Information for Overseas Travel, see below.

Food hygiene In areas where sanitation is poor, good food hygiene is important to help prevent hepatitis A, typhoid, cholera, and other diarrhoeal diseases (including travellers’ diarrhoea). Food should be freshly prepared and hot, and uncooked vegetables (including green salads) should be avoided; only fruits which can be peeled should be eaten. Only suitable bottled water, or tap water that has been boiled or treated with sterilising tablets, should be used for drinking.

Immunisation requirements change from time to time, and information on the current requirements for any particular country may be obtained from the embassy or legation of the appropriate country or from:

- National Travel Health Network and Centre
  UCLH NHS Foundation Trust
  250 Euston Road
  London, NW1 2PG
  Tel: 0845 602 6712
  (9 a.m.–noon, 2–4.30 p.m. weekdays for healthcare professionals only)
  www.nathnac.org

- Travel Medicine Team
  Health Protection Scotland
  Clifton House
  Clifton Place
  Glasgow, G3 7LN
  Tel: (0141) 300 1100
  (2 p.m.–4 p.m. weekdays)
  www.travax.nhs.uk (registration required. Annual fee may be payable for users outside NHS Scotland)

- Welsh Medicines Information Centre
  University Hospital of Wales
  Cardiff, CF14 4XW
  Tel: (029) 2074 2979 (8.30 a.m.–5 p.m. weekdays for health professionals in Wales only)

Department of Health and Social Services
Castle Buildings
Stornont
Belfast, BT4 3FP
Tel: (028) 9052 0000

---

1. List of countries where the incidence of tuberculosis is greater than 40 cases per 100,000 is available at www.hpa.org.uk
2. Japanese encephalitis vaccine not prescribable on the NHS; health authorities may investigate circumstances under which vaccine prescribed
# Anaesthesia

## General anaesthesia

15.1.1 Intravenous anaesthetics
15.1.2 Inhalational anaesthetics
15.1.3 Antimuscarinic drugs
15.1.4 Sedative and analgesic peri-operative drugs
15.1.5 Neuromuscular blocking drugs
15.1.6 Drugs for reversal of neuromuscular blockade
15.1.7 Antagonists for central and respiratory depression
15.1.8 Drugs for malignant hyperthermia

### Important

The drugs in section 15.1 should be used by experienced personnel only and when resuscitation equipment is available.

Several different types of drug are given together during general anaesthesia. Anaesthesia is induced with either a volatile drug given by inhalation (section 15.1.2) or with an intravenously administered drug (section 15.1.1); anaesthesia is maintained with an intravenous or inhalational anaesthetic. Analgesics (section 15.1.4), usually short-acting opioids, are also used. The use of neuromuscular blocking drugs (section 15.1.5) necessitates intermittent positive-pressure ventilation. Following surgery, anticholinesterases (section 15.1.6) can be given to reverse the effects of neuromuscular blocking drugs; specific antagonists (section 15.1.7) can be used to reverse central and respiratory depression caused by some drugs used in surgery. A local topical anaesthetic (section 15.2) can be used to reduce pain at the injection site.

Individual requirements vary considerably and the recommended doses are only a guide. Smaller doses are indicated in ill, shocked, or debilitated patients and in significant hepatic impairment, while robust individuals may require larger doses. The required dose of induction agent may be less if the patient has been premedicated with a sedative agent or if an opioid analgesic has been used.

### Surgery and long-term medication

The risk of losing disease control on stopping long-term medication before surgery is often greater than the risk posed by continuing it during surgery. It is vital that the anaesthetist knows about all drugs that a patient is (or has been) taking.

Patients with adrenal atrophy resulting from long-term corticosteroid use (section 6.3.2) may suffer a precipitous fall in blood pressure unless corticosteroid cover is provided during anaesthesia and in the immediate post-operative period. Anaesthetists must therefore know whether a patient is, or has been, receiving corticosteroids (including high-dose inhaled corticosteroids).
Other drugs that should normally not be stopped before surgery include antiepileptics, antiparkinsonian drugs, antipsychotics, anxiolytics, bronchodilators, cardiovascular drugs (but see potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-II receptor antagonists below), glaucoma drugs, immunosuppressants, drugs of dependence, and thyroid or anti-thyroid drugs. Expert advice is required for patients receiving antivirals for HIV infection. For general advice on surgery in diabetic patients see section 6.1.1, p. 421.

Patients taking antplatelet medication or an oral anticoagulant present an increased risk for surgery. In these circumstances, the anaesthetist and surgeon should assess the relative risks and decide jointly whether the antplatelet or the anticoagulant drug should be stopped or replaced with unfractionated or low molecular weight heparin therapy.

Drugs that should be stopped before surgery include combined oral contraceptives (see Surgery, section 7.3.1 for details); for advice on hormone replacement therapy, see section 6.4.1.1. If antidepressants need to be stopped, they should be withdrawn gradually to avoid withdrawal symptoms. MAOIs can have important interactions with some drugs used during surgery, such as pethidine (for interactions of MAOIs, see Appendix 1, MAOIs). Tricyclic antidepressants need not be stopped, but there may be an increased risk of arrhythmias and hypotension (and dangerous interactions with vasopressor drugs); therefore, the anaesthetist should be informed if they are not stopped. Lithium should be stopped 24 hours before major surgery but the normal dose can be continued for minor surgery (with careful monitoring of fluids and electrolytes). Potassium-sparing diuretics may need to be withheld on the morning of surgery because hyperkalaemia may develop if renal perfusion is impaired or if there is tissue damage. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists can be associated with severe hypotension after induction of anaesthesia; these drugs may need to be discontinued 24 hours before surgery.

**Anaesthesia and driving**

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving afterwards. For intravenous benzodiazepines and for a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

**Prophylaxis of acid aspiration**

Regurgitation and aspiration of gastric contents (Mendelson’s syndrome) can be an important complication of general anaesthesia, particularly in obstetrics and during emergency surgery, and requires prophylaxis against acid aspiration. Prophylaxis is also needed in those with gastrooesophageal reflux disease and in circumstances where gastric emptying may be delayed.

An H₂-receptor antagonist (section 1.3.1) or a proton pump inhibitor (section 1.3.5), such as omeprazole, can be used before surgery to increase the pH and reduce the volume of gastric fluid. They do not affect the pH of fluid already in the stomach and this limits their value in emergency procedures; oral H₂-receptor antagonists can be given 1–2 hours before the procedure, but omeprazole must be given at least 12 hours earlier. Antacids are frequently used to neutralise the acidity of the fluid already in the stomach; ‘clear’ (non-particulate) antacids such as sodium citrate are preferred. Sodium citrate 300 mmol/litre (88.2 mg/mL) oral solution is licensed for use before general anaesthesia for caesarean section (available from Viridian).

**Gas cylinders**

Each gas cylinder bears a label with the name of the gas contained in the cylinder. The name or chemical symbol of the gas appears on the shoulder of the cylinder and is also clearly and indelibly stamped on the cylinder valve. The colours on the valve end of the cylinder extend down to the shoulder; in the case of mixed gases the colours for the individual gases are applied in four segments, two for each colour.

Gas cylinders should be stored in a cool well-ventilated room, free from flammable materials.

**Anaesthesia, sedation, and resuscitation in dental practice**

For details see *A Conscious Decision: A review of the use of general anaesthesia and conscious sedation in primary dental care* report by a group chaired by the Chief Medical Officer and Chief Dental Officer, July 2000 and associated documents. Further details can also be found in *Conscious Sedation in the Provision of Dental Care*, report of an Expert Group on Sedation for Dentistry (commissioned by the Department of Health), 2003. Both documents are available at [www.dh.gov.uk](http://www.dh.gov.uk).

Guidance is also included in *Standards for Dental Professionals*, London, General Dental Council, May 2005 (and as amended subsequently), and *Conscious Sedation in Dentistry: Dental Clinical Guidance*, Scottish Dental Clinical Effectiveness Programme, May 2006.

**15.1 Intravenous anaesthetics**

Intravenous anaesthetics may be used either to induce anaesthesia or for maintenance of anaesthesia throughout surgery. Intravenous anaesthetics nearly all produce their effect in one arm-brain circulation time and can cause apnoea and hypotension, and so adequate resuscitative facilities must be available. They are contra-indicated if the anaesthetist is not confident of being able to maintain the airway (e.g. in the presence of a tumour in the pharynx or larynx). Extreme care is required in surgery of the mouth, pharynx, or larynx and in patients with acute circulatory failure (shock) or fixed cardiac output.

**Gas cylinders**

Each gas cylinder bears a label with the name of the gas contained in the cylinder. The name or chemical symbol of the gas appears on the shoulder of the cylinder and is also clearly and indelibly stamped on the cylinder valve. The colours on the valve end of the cylinder extend down to the shoulder; in the case of mixed gases the colours for the individual gases are applied in four segments, two for each colour.

Gas cylinders should be stored in a cool well-ventilated room, free from flammable materials.

**Anaesthesia, sedation, and resuscitation in dental practice**

For details see *A Conscious Decision: A review of the use of general anaesthesia and conscious sedation in primary dental care* report by a group chaired by the Chief Medical Officer and Chief Dental Officer, July 2000 and associated documents. Further details can also be found in *Conscious Sedation in the Provision of Dental Care*, report of an Expert Group on Sedation for Dentistry (commissioned by the Department of Health), 2003. Both documents are available at [www.dh.gov.uk](http://www.dh.gov.uk).

Guidance is also included in *Standards for Dental Professionals*, London, General Dental Council, May 2005 (and as amended subsequently), and *Conscious Sedation in Dentistry: Dental Clinical Guidance*, Scottish Dental Clinical Effectiveness Programme, May 2006.

**15.1 Intravenous anaesthetics**

The drugs in this section should be used by experienced personnel only and when resuscitation equipment is available.

Intravenous anaesthetics may be used either to induce anaesthesia or for maintenance of anaesthesia throughout surgery. Intravenous anaesthetics nearly all produce their effect in one arm-brain circulation time and can cause apnoea and hypotension, and so adequate resuscitative facilities must be available. They are contra-indicated if the anaesthetist is not confident of being able to maintain the airway (e.g. in the presence of a tumour in the pharynx or larynx). Extreme care is required in surgery of the mouth, pharynx, or larynx and in patients with acute circulatory failure (shock) or fixed cardiac output.
To facilitate tracheal intubation, induction is usually followed by a neuromuscular blocking drug (section 15.1.5) or a short-acting opioid (section 15.1.4.3).

The doses of all intravenous anaesthetic drugs should be titrated to effect (except when using ‘rapid sequence induction’). The doses and rates of administration should be reduced in the elderly, and particularly in those with hypovolaemia or cardiovascular disease; lower doses may also be required in premedicated patients.

**Total intravenous anaesthesia** This is a technique in which major surgery is carried out with all drugs given intravenously. Respiration can be spontaneous, or controlled with oxygen-enriched air. Neuromuscular blocking drugs can be used to provide relaxation and prevent reflex muscle movements. The main problem to be overcome is the assessment of depth of anaesthesia. Target Controlled Infusion (TCI) systems can be used to titrate intravenous anaesthetic infusions to predicted plasma-drug concentrations in ventilated adult patients.

**Anaesthesia and driving** See section 15.1.

---

**Drugs used for intravenous anaesthesia**

**Propofol**, the most widely used intravenous anaesthetic, can be used for induction or maintenance of anaesthesia in adults and children, but it is not commonly used in neonates.

Propofol is associated with rapid recovery and less hangover effect than other intravenous anaesthetics. It causes pain on intravenous injection, which can be reduced by intravenous lidocaine. Significant extraneous muscle movements can occur. Rarely, convulsions, anaphylaxis, and delayed recovery from anaesthesia can occur after propofol administration; the onset of convulsions can be delayed. Propofol is associated with bradycardia, occasionally profound; intravenous administration of an anmiscuscaric drug is used to treat this.

Propofol can be used for sedation during diagnostic procedures. In adults, it can be used for sedation in intensive care, but it is contra-indicated in children under 16 years receiving intensive care because of the risk of propofol infusion syndrome (potentially fatal effects, including metabolic acidosis, cardiac failure, rhabdomyolysis, hyperlipidaemia, and hepatomegaly).

**Thiopental sodium** is a barbiturate that is used for induction of anaesthesia, but has no analgesic properties. Induction is generally smooth and rapid, but dose-related cardiovascular and respiratory depression can occur. Awakening from a moderate dose of thiopental is rapid because the drug redistributes into other tissues, particularly fat. However, metabolism is slow and sedative effects can persist for 24 hours. Repeated doses have a cumulative effect and recovery is much slower.

**Etomidate** is an intravenous agent associated with rapid recovery without a hangover effect. Etomidate causes less hypotension than thiopental and propofol during induction. It produces a high incidence of extraneous muscle movements, which can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction. Pain on injection can be reduced by injecting into a larger vein or by giving an opioid analgesic just before induction. Etomidate suppresses adrenocortical function, particularly during continuous administration, and it should not be used for maintenance of anaesthesia.

**Ketamine** is used rarely. Ketamine causes less hypotension than thiopental and propofol during induction. It is used mainly for paediatric anaesthesia, particularly when repeated administration is required (such as for serial burns dressings); recovery is relatively slow and there is a high incidence of extraneous muscle movements. The main disadvantage of ketamine is the high incidence of hallucinations, nightmares, and other transient psychotic effects; these can be reduced by a benzodiazepine such as diazepam or midazolam.

---

**ETOMIDATE**

**Indications** induction of anaesthesia

**Cautions** see under Intravenous Anaesthetics and notes above; avoid in acute porphyria (section 9.8.2); **interactions**: Appendix 1 (anaesthetics, general)

**Contra-indications** see under Intravenous Anaesthetics and notes above

**Hepatic impairment** reduce dose in liver cirrhosis

**Pregnancy** may depress neonatal respiration if used during delivery

**Breast-feeding** breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Side-effects** see notes above; also nausea, vomiting; hypotension; apnoea, hyperventilation, stridor; rash; less commonly hypersalivation, arrhythmia, hypertension, hiccups, cough, phlebitis; AV block, cardiac arrest, respiratory depression, seizures, shivering, and Stevens-Johnson syndrome also reported

**Dose**

- See under preparations

**Etomidate-Lipuro®** (Braun)

**Injection** (emulsion), etomidate 2 mg/mL, net price 10-mL amp = £1.53

**Dose**

- **ADULT** and **CHILD** over 6 months, by slow intravenous injection, 150–300 micrograms/kg; **CHILD** under 10 years may need up to 400 micrograms/kg, **ELDERLY** 150–200 micrograms/kg

**Hypnomidate®** (Janssen-Cilag)

**Injection**, etomidate 2 mg/mL, net price 10-mL amp = £1.38

**Excipients** include propylene glycol (see Excipients, p. 2)

**Dose**

- **ADULT** and **CHILD**, by slow intravenous injection, 300 micrograms/kg (max. total dose 60 mg); **ELDERLY** 150–200 micrograms/kg (max. total dose 60 mg)

---

**KETAMINE**

**Indications** induction and maintenance of anaesthesia (but rarely used)

**Cautions** see under Intravenous Anaesthetics and notes above; dehydration; hypertension; respiratory tract infection; increased cerebrospinal fluid pressure; predisposition to seizures, hallucinations, or nightmares; psychotid disorders; head injury or intracranial mass lesions; thyroid dysfunction, raised intra-ocular pressure; **interactions**: Appendix 1 (anaesthetics, general)

**Contra-indications** see under Intravenous Anaesthetics; hypertension, pre-eclampsia or eclampsia,
severe cardiac disease, stroke; raised intracranial pressure; head trauma; acute porphyria (section 9.8.2)

Hepatic impairment consider dose reduction

Pregnancy may depress neonatal respiration if used during delivery

Breast-feeding avoid for at least 12 hours after last dose

Side-effects see notes above; also nausea, vomiting; tachycardia, hypertension, arrhythmias, hypotension, bradycardia; hypersalivation, laryngospasm; anxiety, insomnia; diplopia, nystagmus, raised intra-ocular pressure; rash; apnoea and respiratory depression also reported

Dose

- By intramuscular injection, short procedures, initially 6.5–13 mg/kg, adjusted according to response (10 mg/kg usually produces 12–25 minutes of surgical anaesthesia)

Diagnostic manoeuvres and procedures not involving intense pain, initially 4 mg/kg

- By intravenous injection over at least 60 seconds, short procedures, initially 1–4.5 mg/kg, adjusted according to response (2 mg/kg usually produces 5–10 minutes of surgical anaesthesia)

- By intravenous infusion of a solution containing 1 mg/mL, longer procedures, induction, total dose of 0.5–2 mg/kg; maintenance, 10–45 micrograms/kg/minute, rate adjusted according to response

Ketalar® (Pfizer) 

Injection, ketamine (as hydrochloride) 10 mg/mL, net price 20-mL vial = £5.06; 50 mg/mL, 10-mL vial = £8.77; 100 mg/mL, 10-mL vial = £16.10 

Note For intravenous injection, dilute 100 mg/mL strength to a concentration of not more than 50 mg/mL with Glucose 5% or Sodium Chloride 0.9% or Water for Injections

PROPOFOL

Indications see under Dose

Cautions see under Intravenous Anaesthetics and notes above; cardiac impairment; respiratory impairment; elderly; hypovolaemia; epilepsy; hypotension; raised intracranial pressure; monitor blood-lipid concentration if risk of fat overload or if sedation longer than 3 days; Interactions: Appendix 1 (anaesthetics, general)

Contra-indications see notes above

Hepatic impairment use with caution

Renal impairment use with caution

Pregnancy may depress neonatal respiration if used during delivery; max. dose for maintenance of anaesthesia 6 mg/kg/hour

Breast-feeding breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

Side-effects see notes above; also hypotension, tachycardia, flushing; transient apnoea, hyperventilation, coughing, and hiccup during induction; head-ache; less commonly thrombosis, phlebitis; rarely arrhythmia, headache, vertigo, shivering, euphoria; very rarely pancreatitis, pulmonary oedema, sexual disinhibition, and discoloration of urine; serious and sometimes fatal side-effects reported with prolonged infusion of doses exceeding 5 mg/kg/hour, including metabolic acidosis, rhabdomyolysis, hyperkalaemia, and cardiac failure; dystonia and dyskinesia also reported

Dose

- Induction of anaesthesia using 0.5% or 1% injection, by intravenous injection or infusion, ADULT under 55 years and CHILD over 12 years, 1.5–2.5 mg/kg at a rate of 20–40 mg every 10 seconds until response; ADULT over 55 years or debilitating, 1–1.5 mg/kg at a rate of 20 mg every 10 seconds until response; CHILD 1 month–12 years, administer slowly until response (usual dose in child over 8 years 2.5 mg/kg, may need more in younger child e.g. 2.5–4 mg/kg)

- Induction of anaesthesia using 2% injection, by intravenous infusion, ADULT under 55 years and CHILD over 12 years, 1.5–2.5 mg/kg at a rate of 20–40 mg every 10 seconds; ADULT over 55 years or debilitating, 1–1.5 mg/kg at a rate of 20 mg every 10 seconds until response; CHILD 3–12 years, administer slowly until response (usual dose in child over 8 years 2.5 mg/kg, may need more in younger child e.g. 2.5–4 mg/kg)

- Maintenance of anaesthesia using 1% injection, by intravenous infusion, 4–12 mg/kg/hour (3–6 mg/kg/hour in ELDERLY or debilitated) or by intravenous injection, 25–50 mg repeated according to response; CHILD 1 month–12 years, by intravenous infusion, 9–15 mg/kg/hour

- Maintenance of anaesthesia using 2% injection, by intravenous infusion, 4–12 mg/kg/hour (3–6 mg/kg/hour in ELDERLY or debilitated); CHILD 3–12 years, by intravenous infusion, 9–15 mg/kg/hour

- Sedation of ventilated patients in intensive care using 1% or 2% injection, by intravenous infusion, ADULT and CHILD over 16 years, 0.3–4 mg/kg/hour

- Induction of sedation for surgical and diagnostic procedures using 0.5% or 1% injection, ADULT and CHILD over 12 years, initially by intravenous injection over 1–5 minutes, 0.5–1 mg/kg, dose and rate of administration adjusted according to desired level of sedation and response; CHILD 1 month–12 years, 1–2 mg/kg, dose and rate of administration adjusted according to desired level of sedation and response

- Induction of sedation for surgical and diagnostic procedures using 2% injection, ADULT and CHILD over 12 years, initially by intravenous infusion over 1–5 minutes, 0.5–1 mg/kg, dose and rate of administration adjusted to desired level of sedation and response

- Maintenance of sedation for surgical and diagnostic procedures using 0.5% injection, by intravenous infusion, ADULT and CHILD over 12 years, 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response (additionally, if rapid increase in sedation required, by intravenous injection, 10–20 mg); patients over 55 years or debilitated may require lower dose and rate of administration

- Maintenance of sedation for surgical and diagnostic procedures using 1% injection, by intravenous infusion, ADULT and CHILD over 12 years, 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response (additionally, if rapid increase in sedation required, by intravenous injection, 10–20 mg); patients over 55 years or debilitated may require lower dose and rate of administration; CHILD 1 month–12 years, 1.5–9 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response (additionally, if rapid increase in response required, by intravenous injection, max. 1 mg/kg).

778 15.1.1 Intravenous anaesthetics
BNF 61

- Maintenance of sedation for surgical and diagnostic procedures using 2% injection, by intravenous infusion, ADULT and CHILD over 12 years, 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response (additionally, if rapid increase in sedation required, by intravenous injection using 0.5% or 1% injection, 10–20 mg); patients over 55 years or debilitated may require lower dose and rate of administration; CHILD 3–12 years, 1.5–9 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response.

Propofol (Non-proprietary) [Trade] 0.5% injection (emulsion), propofol 5 mg/mL, net price 20-mL amp = £3.46
Brands include Propofol-Lipuro®
1% injection (emulsion), propofol 10 mg/mL, net price 20-mL amp = £4.18, 50-mL bottle = £10.10, 100-mL bottle = £19.40
Brands include Propofol-Lipuro®, Propoven®
2% injection (emulsion), propofol 20 mg/mL, net price 50-mL vial = £21.30
Brands include Propofol-Lipuro®, Propoven®

Diprivan® (AstraZeneca) [Trade] 1% injection (emulsion), propofol 10 mg/mL, net price 20-mL amp = £1.07, 50-mL prefilled syringe (for use with Diprifusor® TCI system) = £4.72
2% injection (emulsion), propofol 20 mg/mL, net price 50-mL prefilled syringe (for use with Diprifusor® TCI system) = £5.27

Note Diprifusor® TCI (target controlled infusion) system is licensed only for induction and maintenance of general anaesthesia in adults.

THIOPENTAL SODIUM
(Thiopentone sodium)

Indications induction of general anaesthesia; anaesthesia of short duration; reduction of raised intracranial pressure if ventilation controlled; status epilepticus (see also section 4.8.2)

Cautions see notes above; cardiovascular disease; reconstituted solution is highly alkaline—extravasation causes tissue necrosis and severe pain; avoid intra-arterial injection; interactions: Appendix 1 (anaesthetics, general)

Contra-indications see notes above; acute porphyria (section 9.8.2); myotonic dystrophy

Hepatic impairment use with caution—reduce dose

Renal impairment caution in severe impairment

Pregnancy may depress neonatal respiration if used during delivery; dose should not exceed 250 mg

Breast-feeding breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

Side-effects hypotension, arrhythmias, myocardial depression, laryngeal spasm, cough, headache, sneezing, hypersensitivity reactions, rash

Dose
- Induction of general anaesthesia, by slow intravenous injection usually as a 2.5% (25 mg/mL) solution, ADULT over 18 years, fit and premedicated, initially 100–150 mg (reduced in elderly or debilitated) over 10–15 seconds (longer in elderly or debilitated), followed by further quantity if necessary according to response after 30–60 seconds; or up to 4 mg/kg (max.

15.1.2 Inhalational anaesthetics

500 mg); CHILD 1 month–18 years, initially up to 4 mg/kg, then 1 mg/kg repeated as necessary (max. total dose 7 mg/kg)
- Raised intracranial pressure, by slow intravenous injection, 1.5–3 mg/kg, repeated as required
- Status epilepticus (only if other measures fail, see section 4.8.2), by slow intravenous injection as a 2.5% (25 mg/mL) solution, ADULT over 18 years, 75–125 mg as a single dose; CHILD 1 month–18 years, initially up to 4 mg/kg by slow intravenous injection, then up to 8 mg/kg/hour by continuous intravenous infusion, adjusted according to response

Thiopental (Archimedes) [Trade] Injection, powder for reconstitution, thiopental sodium, net price 500-mg vial = £3.68

Important The drugs in this section should be used by experienced personnel only and when resuscitation equipment is available.

Inhalational anaesthetics include gases and volatile liquids. Gaseous anaesthetics require suitable equipment for storage and administration. They may be supplied via hospital pipelines or from metal cylinders (section 15.1). Volatile liquid anaesthetics are administered using calibrated vapourisers, using air, oxygen, or nitrous oxide-oxygen mixtures as the carrier gas. To prevent hypoxia, the inspired gas mixture should contain a minimum of 25% oxygen at all times. Higher concentrations of oxygen (greater than 30%) are usually required during inhalational anaesthesia when nitrous oxide is being administered, see Nitrous Oxide, p. 781.

Anaesthesia and driving See section 15.1.

Volatile liquid anaesthetics

Volatile liquid anaesthetics can be used for induction and maintenance of anaesthesia, and following induction with an intravenous anaesthetic (section 15.1.1).

Volatile liquid anaesthetics can trigger malignant hyperthermia (section 15.1.8) and are contra-indicated in those susceptible to malignant hyperthermia. They can increase cerebrospinal pressure and should be used with caution in those with raised intracranial pressure. They can also cause hepatotoxicity in those sensitised to halogenated anaesthetics; halothane has been associated with severe hepatotoxicity (important: see below). In children with neuromuscular disease, inhalational anaesthetics are very rarely associated with hyperkalaemia, resulting in cardiac arrhythmias and death. Cardiorespiratory depression, hypotension, and arrhythmias are common side-effects of volatile liquid anaesthetics.

Isoflurane is a volatile liquid anaesthetic. Heart rhythm is generally stable during isoflurane anaesthesia, but heart-rate can rise, particularly in younger patients. Systemic arterial pressure and cardiac output can fall, owing to a decrease in systemic vascular resistance. Muscle relaxation occurs and the effects of muscle...
**Desflurane** is a rapid acting volatile liquid anaesthetic; it is reported to have about one-fifth the potency of isoflurane. Emergence and recovery from anaesthesia are particularly rapid because of its low solubility. Desflurane is not recommended for induction of anaesthesia as it is irritant to the upper respiratory tract; cough, breath-holding, apnoea, laryngospasm, and increased secretions can occur.

**Sevoflurane** is a rapid acting volatile liquid anaesthetic and is more potent than desflurane. Emergence and recovery are particularly rapid, but slower than desflurane. Sevoflurane is non-irritant and seldom induces coughing or breath-holding.

**Isoflurane** is a rapid acting volatile liquid anaesthetic that has largely been superseded by newer agents, but is occasionally used for inhalational induction of anaesthesia; it has little effect on heart rhythm compared with other volatile liquid anaesthetics. Sevoflurane can interact with carbon dioxide absorbents to form compound A, a potentially nephrotoxic vinyl ether. However, in spite of extensive use, no cases of sevoflurane-induced permanent renal injury have been reported and the carbon dioxide absorbents used in the UK produce very low concentrations of compound A, even in low-flow anaesthetic systems.

**Halothane** is a volatile liquid anaesthetic that has largely been superseded by newer agents, but is occasionally used for inhalation induction of anaesthesia. It occurs more frequently after repeated exposure to halothane and has a high mortality. The risk of severe hepatotoxicity appears to be increased by repeated exposures within a short time interval, but even after a long interval (sometimes of several years), susceptible patients have been reported to develop jaundice. Since there is no reliable way of identifying patients at risk, the following precautions are recommended before the use of halothane:

- a careful anaesthetic history should be taken to determine previous exposure and previous reactions to halothane;
- repeated exposure to halothane within a period of at least 3 months should be avoided unless there are overriding clinical circumstances;
- a history of unexplained jaundice or pyrexia in a patient following exposure to halothane is an absolute contra-indication to its future use in that patient.

**Breast-feeding** breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Side-effects** see notes above

**Dose**

- Induction of anaesthesia (but not recommended), by inhalation through specifically calibrated vaporiser, **ADULT 4–11%**
- Maintenance of anaesthesia, by inhalation through specifically calibrated vaporiser, **ADULT 2–6% in nitrous oxide; 2.5–8.5% in oxygen or oxygen-enriched air; CHILD see BNF for Children**

**Halothane**

**Indications** see notes above

**Cautions** see notes above (important: see Halothane Hepatotoxicity, above); avoid for dental procedures in those under 18 years unless treated in hospital (high risk of arrhythmia); avoid in acute porphyria (section 9.8.2); **interactions:** Appendix 1 (anaesthetics, general)

**Contra-indications** see notes above

**Hepatic impairment** avoid if history of unexplained pyrexia or jaundice following previous exposure to halothane

**Pregnancy** may depress neonatal respiration if used during delivery

**Breast-feeding** breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Side-effects** see notes above

**Dose**

- Induction of anaesthesia, using specifically calibrated vaporiser, in oxygen or nitrous oxide-oxygen, **ADULT and CHILD over 1 month, 0.5–2%**
- Maintenance of anaesthesia, using specifically calibrated vaporiser, in oxygen, oxygen-air, or nitrous oxide-oxygen, **ADULT and CHILD over 1 month, 0.5–2%**

**Isoflurane**

**Indications** see notes above

**Cautions** see notes above; **interactions:** Appendix 1 (anaesthetics, general)

**Contra-indications** see notes above

**Pregnancy** may depress neonatal respiration if used during delivery

**Breast-feeding** breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Side-effects** see notes above

**Dose**

- Induction of anaesthesia, using specifically calibrated vaporiser, in oxygen or nitrous oxide-oxygen, increased gradually from 0.5% to 3%
- Maintenance of anaesthesia, using specifically calibrated vaporiser, 1–2.5% in nitrous oxide-oxygen; an additional 0.5–1% may be required when given with oxygen alone; caesarean section, 0.5–0.75% in nitrous oxide-oxygen

**Sevoflurane**

**Indications** see notes above

**Cautions** see notes above; **interactions:** Appendix 1 (anaesthetics, general)
15.1.3 Antimuscarinic drugs

**Nitrous oxide**

Nitrous oxide is used for maintenance of anaesthesia and, in sub-anaesthetic concentrations, for analgesia. For anaesthesia, nitrous oxide is commonly used in a concentration of 50 to 66% in oxygen as part of a balanced technique in association with other inhalational or intravenous agents. Nitrous oxide is unsatisfactory as a sole anaesthetic owing to lack of potency, but is useful as part of a combination of drugs since it allows a significant reduction in dosage.

For analgesia (without loss of consciousness), a mixture of nitrous oxide and oxygen containing 50% of each gas (Entonox®, Equanox®) is used. Self-administration using a demand valve is popular in obstetric practice, for changing painful dressings, as an aid to postoperative physiotherapy, and in emergency ambulances.

Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in the presence of a pneumothorax, which may enlarge to produce compression respiration, or in the presence of intracranial air after head injury.

Hypoxia can occur immediately following the administration of nitrous oxide; additional oxygen should always be given for several minutes after stopping the flow of nitrous oxide.

Exposure of patients to nitrous oxide for prolonged periods, either by continuous or by intermittent administration, may result in megaloblastic anaemia owing to interference with the action of vitamin $B_12$; neurological toxic effects can occur without preceding overt haematological changes. For the same reason, exposure of theatre staff to nitrous oxide should be minimised.

Assessment of plasma-vitamin $B_12$ concentration should be considered in those at risk of deficiency, including the elderly, those with a poor or vegetarian diet, and those with a history of anaemia. Nitrous oxide should be avoided in those with a history of anaemia. Nitrous oxide should be avoided in those with anaemia. Nitrous oxide should not be given continuously for longer than 24 hours or more frequently than every 4 days without close supervision and haematological monitoring.

**Indications**

- Analgesia, up to 50% in oxygen, according to the patient’s needs
- Maintenance of anaesthesia in conjunction with other anaesthetic agents (using suitable anaesthetic apparatus), 50–66% in oxygen
- Analgesia, up to 50% in oxygen, according to the patient’s needs

**Dose**

- Induction of anaesthesia, using a specifically calibrated vaporiser, in oxygen or nitrous oxide-oxygen, adjusted according to response, ADULT and CHILD over 1 month initially 0.5–1%, then increased gradually up to 8%
- Maintenance of anaesthesia, using a specifically calibrated vaporiser, in oxygen or nitrous oxide-oxygen, adjusted according to response, ADULT and CHILD over 1 month 0.5–3%

**Side-effects**

- See notes above; also urinary retention, leucopenia, agitation in children; dystonia and seizures also reported

**Contra-indications**

- Renal impairment
- Pregnancy: may depress neonatal respiration if used during delivery
- Breast-feeding: breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Pregnancy**

- May depress neonatal respiration if used during delivery
- Breast-feeding: breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia

**Breast-feeding**

- Breast-feeding soon as mother has recovered sufficiently from anaesthesia

**Side-effects**

- See notes above

**Dose**

- Maintenance of anaesthesia in conjunction with other anaesthetic agents (using suitable anaesthetic apparatus), 50–66% in oxygen
- Analgesia, up to 50% in oxygen, according to the patient’s needs

**Indications**

- See notes above

**Cautions**

- Use with caution when used alone.

**Phenothiazines**

- Do not effectively reduce secretions
- Do not reduce secretions in patients with air-containing closed space
- Do not effectively reduce secretions in patients with air-containing closed space

**Hyoscine hydrobromide**

- Reduces secretions and also has an emergency role in the treatment of vagotonic side-effects
- For its role in acute arrhythmias after myocardial infarction, see section 2.3.1.

**Glycopyrronium bromide**

- Reduces secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics
- Reduces secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics

**Atropine sulphate**

- Is now rarely used for premedication
- But still has an emergency role in the treatment of vagotonic side-effects
- For its role in acute arrhythmias after myocardial infarction, see section 2.3.1.

**Phenothiazines**

- Do not effectively reduce secretions
- When used alone

**Important**

- The drugs in this section should be used by experienced personnel only.

**Antimuscarinic drugs**

Antimuscarinic drugs are used (less commonly nowadays) as premedicants to dry bronchial and salivary secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics. They are also used before or with neostigmine (section 15.1.6) to prevent bradycardia, excessive salivation, and other muscarinic actions of neostigmine. They also prevent bradycardia and hypotension associated with drugs such as halothane, propofol, and suxamethonium.

**Atropine sulphate**

- Is now rarely used for premedication
- But still has an emergency role in the treatment of vagotonic side-effects
- For its role in acute arrhythmias after myocardial infarction, see section 2.3.1.

**Hyoscine hydrobromide**

- Reduces secretions and also has an emergency role in the treatment of vagotonic side-effects
- For its role in acute arrhythmias after myocardial infarction, see section 2.3.1.

**Glycopyrronium bromide**

- Reduces salivary secretions.

**Atropine sulphate**

- Is now rarely used for premedication
- But still has an emergency role in the treatment of vagotonic side-effects
- For its role in acute arrhythmias after myocardial infarction, see section 2.3.1.

**Phenothiazines**

- Do not effectively reduce secretions
- When used alone

**Antimuscarinic drugs**

- Are used (less commonly nowadays) as premedicants to dry bronchial and salivary secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics.

**Indications**

- Premedication; intra-operative bradycardia; with anticholinesterases for reversal of non-depolarising neuromuscular blocking drugs (section 15.1.5).

**Phenothiazines**

- Do not effectively reduce secretions when used alone.
15.1.4 Sedative and analgesic peri-operative drugs

Cautions section 1.2

Duration of action Since atropine has a shorter duration of action than neostigmine, late unopposed bradycardia may result; close monitoring of the patient is necessary.

Contra-indications section 1.2

Pregnancy not known to be harmful; use with caution.

Breast-feeding small amount present in milk—use with caution.

Side-effects section 1.2

Dose

Premedication, by intravenous injection, 300–600 micrograms immediately before induction of anaesthesia; CHILD under 12 years see BNF for Children.

By subcutaneous or intramuscular injection, 300–600 micrograms 30–60 minutes before induction of anaesthesia; CHILD under 12 years see BNF for Children.

Intra-operative bradycardia, by intravenous injection, 300–600 micrograms (larger doses in emergencies); CHILD under 12 years see BNF for Children.

Control of muscarinic side-effects of neostigmine in reversal of non-depolarising neuromuscular block, by intravenous injection, 200 micrograms per 1 mg of neostigmine, or 10–15 micrograms/kg; CHILD 1 month–12 years, 10 micrograms/kg (max. 500 micrograms).

Duration of action

Atropine has a shorter duration of action than neostigmine (section 13.12).

Hypersensitivity reaction (section 4.3).

Premedication

Premedication These drugs are given to allay fear and anxiety in the pre-operative period (including the night before an operation), to relieve pain and discomfort when present, and to augment the action of subsequent

1 Atropine (Non-proprietary). Injection, atropine sulphate 600 micrograms/mL, net price 1-mL amp $6.20. 

Note Other strengths also available.

Injection, prefilled disposable syringe, atropine sulphate 100 micrograms/mL, net price 5 mL = £4.58, 10 mL = £9.16, 30 mL = £8.95.

Injection, prefilled disposable syringe, atropine sulphate 200 micrograms/mL, net price 5 mL = £5.91, 10 mL = £5.91; 300 micrograms/mL, 1 mL = £5.91.

1. Restriction does not apply where administration is for saving life in emergency.

1 Minijet® Atropine (UCB Pharma). Injection, atropine sulphate 100 micrograms/mL, net price 5 mL = £0.54, 10 mL = £0.93, 30 mL = £0.85.

1. Restriction does not apply where administration is for saving life in emergency.

15.1.4.1 Anxiolytics

15.1.4.2 Non-opioid analgesics

15.1.4.3 Opioid analgesics

Important

The drugs in this section should be used by experienced personnel only.
anaesthetic agents. A number of the drugs used also provide some degree of pre-operative amnesia. The choice will vary with the individual patient, the nature of the operative procedure, the anaesthetic to be used, and other prevailing circumstances such as outpatients, obstetrics, and recovery facilities. The choice also varies between elective and emergency operations.

**Premedication in children** Oral administration is preferred where possible; the rectal route should only be used in exceptional circumstances. For further details, consult *BNF for Children*.

Application of a local anaesthetic (section 15.2) to the injection site can help to prevent pain.

**Dental procedures** Anxiolytics diminish tension, anxiety and panic, and may benefit anxious patients. However, their use is no substitute for sympathy and reassurance.

Diazepam and temazepam are effective anxiolytics for dental treatment in adults, but they are less suitable for children. Diazepam has a longer duration of action than temazepam. When given at night diazepam is associated with more residual effects the following day; patients should be very carefully warned not to drive (important: for general advice on anaesthesia and driving see p. 776). For further information on hypnotics and anxiolytics, see section 4.1. For further information on hypnotics used for dental procedures, see section 4.1.1.

**Anaesthesia and driving** See section 15.1.

### 15.1.4.1 Anxiolytics

Anxiolytic benzodiazepines are widely used for premedication.

**Benzodiazepines**

Benzodiazepines possess useful properties for premedication including relief of anxiety, sedation, and amnesia; short-acting benzodiazepines taken by mouth are the most common premedicants. They have no analgesic effect so an opioid analgesic may sometimes be required for pain.

Benzodiazepines can alleviate anxiety at doses that do not necessarily cause excessive sedation and they are of particular value during short procedures or during operations under local anaesthesia (including dentistry). Amnesia reduces the likelihood of any unpleasant memories of the procedure (although benzodiazepines, particularly when used for more profound sedation, can sometimes induce sexual fantasies). Benzodiazepines are also used in intensive care units for sedation, particularly when used for more profound sedation, can sometimes induce sexual fantasies. Benzodiazepines may occasionally cause marked respiratory depression and facilities for its treatment are essential; flumazenil (section 15.1.7) is used to antagonise the effects of benzodiazepines. They are best avoided in myasthenia gravis, especially peri-operatively.

Diazepam is used to produce mild sedation with amnesia. It is a long-acting drug with active metabolites and a second period of drowsiness can occur several hours after its administration. Peri-operative use of diazepam in children is not generally recommended; its effect and timing of response are unreliable and paradoxical effects may occur.

Diazepam is relatively insoluble in water and preparations formulated in organic solvents are painful on intravenous injection and give rise to a high incidence of venous thrombosis (which may not be noticed for several days after the injection). Intramuscular injection of diazepam is painful and absorption is erratic. An emulsion formulated for intravenous injection is less irritant and reduces the risk of venous thrombosis; it is not suitable for intramuscular injection. Diazepam is also available as a rectal solution but this preparation is not used for premedication or sedation.

Temazepam is given by mouth and has a shorter duration of action and a more rapid onset than diazepam given by mouth. It has been used as a premedicant in inpatient and day-case surgery; anxiolytic and sedative effects last about 90 minutes although there may be residual drowsiness.

Lorazepam produces more prolonged sedation than temazepam and it has marked amnesic effects. It is used as a premedicant the night before major surgery; a further, smaller dose may be required the following morning if any delay in starting surgery is anticipated. Alternatively the first dose may be given early in the morning on the day of operation.

Midazolam is a water-soluble benzodiazepine that is often used in preference to intravenous diazepam; recovery is faster than from diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing. Midazolam is associated with profound sedation when high doses are given intravenously or when it is used with certain other drugs.

**Overdosage with midazolam**

There have been reports of overdosage when high strength midazolam has been used for conscious sedation. The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be restricted to general anaesthesia, intensive care, palliative care, or other situations where the risk has been assessed. It is advised that flumazenil (section 15.1.7) is available when midazolam is used, to reverse the effects if necessary.
Side-effects see notes above and section 4.1.2

Dose
- By mouth, 5–10 mg 1–2 hours before procedure (up to max. 20 mg for dental procedures carried out in hospital); ELDERLY (or debilitated), half adult dose
- By intravenous injection into a large vein (emulsion preparation preferred), sedative cover for minor surgical and medical procedures, ADULT over 18 years, 10–20 mg over 2–4 minutes, immediately before procedure; premedication 100–200 micrograms/kg, CHILD under 18 years see BNF for Children
- By rectum, CHILD 1–18 years see BNF for Children

Preparations
Section 4.1.2

LORAZEPAM

Indications conscious sedation for procedures; premedication; short-term use in anxiety or insomnia (section 4.1.2); status epilepticus (section 4.8.2)

Cautions see notes above and section 4.1.2; interactions: Appendix 1 (anxiolytics and hypnotics)

Contra-indications see notes above and Diazepam, section 4.1.2

Hepatic impairment see Benzodiazepines, section 4.1.2

Renal impairment see Benzodiazepines, section 4.1.2

Pregnancy see Benzodiazepines, section 4.1.2

Breast-feeding see Benzodiazepines, section 4.1.2

Side-effects see notes above and Diazepam, section 4.1.2

Dose
- By mouth, 2–3 mg the night before operation; 2–4 mg 1–2 hours before operation
- By slow intravenous injection, preferably diluted with an equal volume of sodium chloride intravenous infusion 0.9% or water for injections, 50 micrograms/kg 30–45 minutes before operation
- By intramuscular injection, diluted as above, 50 micrograms/kg 60–90 minutes before operation

Preparations
Section 4.1.2

MIDAZOLAM

Indications conscious sedation for procedures; sedation in intensive care; sedation in anaesthesia; premedication; induction of anaesthesia; status epilepticus (section 4.8.2)

Cautions see notes above; cardiac disease; respiratory disease; myasthenia gravis; neonates; children (particularly if cardiovascular impairment); risk of airways obstruction and hypoventilation in children under 6 months (monitor respiratory rate and oxygen saturation); history of drug or alcohol abuse; reduce dose in elderly and debilitated; risk of severe hypotension in hypovolaemia, vasoconstriction, hypothermia; avoid prolonged use (and abrupt withdrawal thereafter); concentration of midazolam in children under 15 kg not to exceed 1 mg/mL; interactions: Appendix 1 (anxiolytics and hypnotics)

Contra-indications marked neuromuscular respiratory weakness including unstable myasthenia gravis; severe respiratory depression; acute pulmonary insufficiency

Hepatic impairment use with caution; can precipitate coma

Renal impairment start with small doses in severe impairment; increased cerebral sensitivity

Pregnancy avoid regular use (risk of neonatal withdrawal symptoms); use only if clear indication such as seizure control (high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression)

Breast-feeding present in milk—avoid breast-feeding for 24 hours after administration

Side-effects see notes above; gastro-intestinal disturbances, increased appetite, jaundice; hypotension, cardiac arrest, heart rate changes, anaphylaxis, thrombosis; laryngospasm, bronchospasm, respiratory depression and respiratory arrest (particularly with high doses or on rapid injection); drowsiness, confusion, ataxia, amnesia, headache, euphoria, hallucinations, convulsions (more common in neonates), dizziness, vertigo, involuntary movements, paradoxical excitement and aggression (especially in children and elderly), dysarthria; urinary retention, incontinence, changes in libido; blood disorders; muscle weakness; visual disturbances; salivation changes; skin reactions; injection-site reactions

Dose
- Conscious sedation for procedures, by slow intravenous injection (approx. 2 mg/minute) 5–10 minutes before procedure, initially 2–2.5 mg ELDERLY 0.5–1 mg), increased if necessary in steps of 1 mg ELDERLY 0.5–1 mg); usual total dose 3.5–5 mg (max. 7.5 mg), ELDERLY max. 3.5 mg; CHILD 1 month–18 years see BNF for Children
- By rectum, CHILD 6 months–18 years see BNF for Children
- By mouth, CHILD 1 month–18 years see BNF for Children
- By buccal administration, CHILD 6 months–18 years see BNF for Children

Sedative in combined anaesthesia, by intravenous injection, 30–100 micrograms/kg repeated as required or by continuous intravenous infusion, 30–100 micrograms/kg/hour (ELDERLY lower doses needed); CHILD not recommended

Premedication, by deep intramuscular injection, ADULT over 18 years, 70–100 micrograms/kg (ELDERLY or debilitated 25–50 micrograms/kg) 20–60 minutes before induction

By intravenous injection, ADULT over 18 years, 1–2 mg 5–30 minutes before procedure, repeated as required (ELDERLY or debilitated 0.5 mg, repeat dose slowly as required)

By rectum, CHILD 6 months–12 years see BNF for Children

By mouth, CHILD 1 month–18 years see BNF for Children

Induction (but rarely used), by slow intravenous injection, 150–200 micrograms/kg (ELDERLY or debilitated 50–150 micrograms/kg) given in divided doses (max. 5 mg) at intervals of 2 minutes; max. total dose 600 micrograms/kg; CHILD 7–18 years initially 150 micrograms/kg (max. 7.5 mg) given in steps of 50 micrograms/kg (max. 2.5 mg) over 2–5 minutes; wait for 2–5 minutes then give additional doses of 50 micrograms/kg (max. 2.5 mg) every 2 minutes if necessary; max. total dose 500 micrograms/kg (not exceeding 25 mg)
● Sedation of patients receiving intensive care, by slow intravenous injection, initially 30–300 micrograms/kg given in steps of 1–2.5 mg every 2 minutes, then by slow intravenous injection or by continuous intravenous infusion, 30–200 micrograms/kg/hour; reduce dose (or reduce or omit initial dose) in hypoventilation, vasoconstriction, or hypothermia; lower doses may be adequate if opioid analgesic also used; CHILD under 12 years see BNF for Children

Midazolam (Non-proprietary)

Oral liquid, midazolam 2.5 mg/mL, 100 mL. Available from ‘special-order’ manufacturers or specialist importing companies, see p. 988

Injection, midazolam (as hydrochloride) 1 mg/mL, net price 2-mL amp = 50p, 5-mL amp = 60p, 50-mL vial = £7.87; 2 mg/mL, 5-mL amp = 65p; 5 mg/mL, 2-mL amp = 58p, 10-mL amp = £2.50

Hypnovel® (Roche) 6

Injection, midazolam (as hydrochloride) 2 mg/mL, net price 5-mL amp = 85p; 5 mg/mL, 2-mL amp = 72p

TEMAZEPAM

Indications premedication before surgery or investigatory procedures; hypnotic (section 4.1.1)

Cautions see notes above and Diazepam, section 4.1.2; interactions: Appendix 1 (anxiolytics and hypnotics)

Contra-indications see notes above and Diazepam, section 4.1.2

Hepatic impairment see Benzodiazepines, section 4.1.1

Renal impairment see Benzodiazepines, section 4.1.1

Pregnancy see Benzodiazepines, section 4.1.1

Breast-feeding see Benzodiazepines, section 4.1.1

Side-effects see notes above and Diazepam, section 4.1.2

Dose

● By mouth, premedication. ADULT, 10–20 mg (up to 30 mg in exceptional circumstances) 1–2 hours before procedure; ELDERLY 10 mg (up to 20 mg in exceptional circumstances); CHILD 1 mg/kg (max. 30 mg)

Note Temazepam doses in BNF may differ from those in product literature

Preparations

Section 4.1.1

KETOROLAC TROMETAMOL

Indications short-term management of moderate to severe acute postoperative pain only

Cautions section 10.1.1; avoid in acute porphyria (section 9.8.2); interactions: Appendix 1 (NSAIDs)

Contra-indications section 10.1.1; also complete or partial syndrome of nasal polyps; haemorrhagic diatheses (including coagulation disorders) and following operations with high risk of haemorrhage or incomplete haemostasis; confirmed or suspected cerebrovascular bleeding; hypovolaemia or dehydration

Hepatic impairment section 10.1.1

Renal impairment max. 60 mg daily by intramuscular or intravenous injection; avoid if serum creatinine greater than 160 micromol/litre; see also section 10.1.1

Pregnancy section 10.1.1

Breast-feeding amount too small to be harmful

Side-effects section 10.1.1; also gastro-intestinal disturbances, taste disturbances, dry mouth; flushing, bradycardia, palpitation, chest pain, hypertension, pallor; dyspnoea, asthma; malaise, euphoria, psychosis, paraesthesia, convulsions, abnormal dreams, hyperkinesia, confusion, hallucinations; urinary frequency, thirst, sweating; hyponatraemia, hyperkalaemia, myalgia; visual disturbances (including optic neuritis); purpura, pain at injection site

Dose

● ADULT and CHILD over 16 years, by mouth, 10 mg every 4–6 hours (ELDERLY every 6–8 hours) as required; max. 40 mg daily; max. duration of treatment 7 days

● ADULT and CHILD over 16 years, by intramuscular injection or by intravenous injection over at least 15 seconds, initially 10 mg, then 10–30 mg every 4–6 hours as required (up to every 2 hours during initial postoperative period); max. 90 mg daily (ELDERLY and patients weighing less than 50 kg max. 60 mg daily); max. duration of treatment 2 days; CHILD 6 months–16 years see BNF for Children

Note When converting from parenteral to oral administration, total combined dose on the day of converting should not exceed 90 mg (60 mg in the elderly and patients weighing less than 50 kg) of which the oral component should not exceed 40 mg

Ketorolac (Non-proprietary)

Injection, ketorolac trometamol 30 mg/mL, net price 1-mL amp = £1.10

Toradol® (Roche) 6

Tablets, ivory, f/c, ketorolac trometamol 10 mg, net price 20-tab pack = £5.45. Label: 17, 21

Injection, ketorolac trometamol 10 mg/mL, net price 1-mL amp = 89p; 30 mg/mL, 1-mL amp = £1.08

15.1.4 Sedative and analgesic peri-operative drugs

Since non-steroidal anti-inflammatory drugs (NSAIDs) do not depress respiration, do not impair gastro-intestinal motility, and do not cause dependence, they may not depress respiration, do not impair gastrointestinal function, do not cause dependence, they may be effective alternatives to the parenteral use of these drugs.

Acemetacin, diclofenac, flurbiprofen, ibuprofen, ketoprofen, (section 10.1.1), parecoxib, and ketorolac are licensed for use as an analgesic for the relief of postoperative pain. NSAIDs may be inadequate for the relief of severe pain.

Acemetacin, diclofenac, flurbiprofen, ibuprofen, ketoprofen, (section 10.1.1), parecoxib, and ketorolac are licensed for use as an analgesic for the relief of postoperative pain. NSAIDs may be inadequate for the relief of severe pain.
**PARECOXIB**

**Indications** short-term management of acute post-operative pain

**Cautions** section 10.1.1; dehydration; following coronary artery bypass graft surgery; **interactions:** Appendix 1 (NSAIDs)

**Contra-indications** section 10.1.1; also history of allergic drug reactions including sulphonamide hypersensitivity; inflammatory bowel disease

**Hepatic impairment** halve dose in moderate impairment (max. 40 mg daily); see also section 10.1.1

**Renal impairment** section 10.1.1

**Pregnancy** section 10.1.1

**Breast-feeding** avoid—present in milk in animal studies

**Side-effects** section 10.1.1; also flatulence, hypertension, hypoesthesia, altered taste, postoperative nausea and vomiting, convulsions; rarely cyanosis; rarely tachycardia

**Dose**

- By deep intramuscular injection or by intravenous injection, initially 40 mg, then 20–40 mg every 6–12 hours when required for up to 3 days; max. 80 mg daily; **ELDERLY** weighing less than 50 kg, initially 20 mg, then max. 40 mg daily; **CHILD** under 18 years, not recommended

**Dynastat® (Pharmacia)** ▼ 75/300

**Injection** powder for reconstitution, parecoxib (as sodium salt), net price 40-mg vial = £4.96, 40-mg vial (with solvent) = £5.67

---

**15.1.4 Opioid analgesics**

Opioid analgesics are now rarely used as premedicants; they are more likely to be administered at induction. Pre-operative use of opioid analgesics is generally limited to those patients who require control of existing pain. The main side-effects of opioid analgesics are respiratory depression, cardiovascular depression, nausea, and vomiting; for general notes on opioid analgesics and their use in postoperative pain, see section 4.7.2.

For the management of opioid-induced respiratory depression, see section 15.1.7.

**Intra-operative analgesia** Opioid analgesics given in small doses before or with induction reduce the dose requirement of some drugs used during anaesthesia.

Alfentanil, fentanyl, and remifentanil are particularly useful because they act within 1–2 minutes and have short durations of action. The initial doses of alfentanil or fentanyl are followed either by successive intravenous injections or by an intravenous infusion; prolonged infusions increase the duration of effect. Repeated intra-operative doses of alfentanil or fentanyl should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive. Alfentanil, fentanyl, and remifentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

In contrast to other opioids which are metabolised in the liver, remifentanil undergoes rapid metabolism by non-specific blood and tissue esterases; its short duration of action allows prolonged administration at high dosage, without accumulation, and with little risk of residual postoperative respiratory depression. Remifentanil should not be given by intravenous injection intraoperatively, but it is well suited to continuous infusion; a supplemental analgesic is given before stopping the infusion of remifentanil.

---

**ALFENTANIL**

**Indications** analgesia especially during short operative procedure and outpatient surgery; enhancement of anaesthesia; analgesia and suppression of respiratory activity in patients receiving intensive care, with assisted ventilation, for up to 4 days

**Cautions** section 4.7.2 and notes above

**Contra-indications** section 4.7.2

**Hepatic impairment** section 4.7.2

**Renal impairment** section 4.7.2

**Pregnancy** section 4.7.2

**Breast-feeding** present in milk— with breast-feeding for 24 hours

**Side-effects** section 4.7.2 and notes above; also hypertension, myoclonic movements; less commonly arrhythmias, hiccup, laryngospasm; rarely epistaxis; also reported cardiac arrest, cough, convulsions, and pyrexia

**Dose**

- To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight

---

**Alfentanil (Non-proprietary)**

**Injection**, alfentanil (as hydrochloride) 500 micrograms/mL, net price 2-mL amp = 70p, 10-mL amp = £3.20

**Intensive care injection**, alfentanil (as hydrochloride) 5 mg/mL, net price 1-mL amp = £2.50

**Note** To be diluted before use
Fentanyl

**Indications** analgesia during operation, enhancement of anaesthesia; respiratory depressant in assisted respiration; analgesia in other situations (section 4.7.2)

**Cautions** see Fentanyl, section 4.7.2 and notes above

**Contra-indications** see notes in section 4.7.2

**Hepatic impairment** see notes in section 4.7.2

**Renal impairment** see notes in section 4.7.2

**Pregnancy** see notes in section 4.7.2

**Breast-feeding** see notes in section 4.7.2

**Side-effects** see Fentanyl, section 4.7.2 and notes above; also myoclonic movements; less commonly laryngospasm; rarely asystole and insomnia

**Dose** To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight

- By slow intravenous injection, with spontaneous respiration, **ADULT** and **CHILD** over 12 years, initially 50–100 micrograms (max. 200 micrograms on specialist advice), then 25–50 micrograms as required; **CHILD** 1 month–12 years see **BNF for Children**

  With assisted ventilation, **ADULT** and **CHILD** over 12 years, initially 0.3–3.5 mg, then 100–200 micrograms as required; **CHILD** 1 month–12 years see **BNF for Children**

- By intravenous infusion, with spontaneous respiration, **ADULT** 3–4.8 micrograms/kg/hour adjusted according to response

  With assisted ventilation, **ADULT**, initially 10 micrograms/kg over 10 minutes then 6 micrograms/kg/hour adjusted according to response; may require up to 180 micrograms/kg/hour during cardiac surgery; **CHILD** 1 month–18 years see **BNF for Children**

**Fentanyl** (Non-proprietary)

**Injection**, fentanyl (as citrate) 50 micrograms/mL, net price 2-mL amp = £4p; 10-mL amp = £2.90

**Intensive care injection**, fentanyl (as hydrochloride) 5 mg/mL, net price 1-mL amp = £2.32

**Note** To be diluted before use

**REMIFENTANIL**

**Indications** supplementation of general anaesthesia during induction and analgesia during maintenance of anaesthesia (consult product literature for use in patients undergoing cardiac surgery); analgesia and sedation in ventilated, intensive care patients

**Cautions** section 4.7.2 (but no dose adjustment necessary in renal impairment) and notes above

**Contra-indications** section 4.7.2 and notes above; left ventricular dysfunction; analgesia in conscious patients

**Hepatic impairment** section 4.7.2

**Pregnancy** no information available: see also section 4.7.2

**Breast-feeding** avoid breast-feeding for 24 hours after administration—present in milk in animal studies

**Side-effects** section 4.7.2 and notes above; also hypertension; less commonly hypoxia; rarely asystole; AV block and convulsions also reported

**Dose** To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- Induction of anaesthesia, **ADULT** and **CHILD** over 12 years, by **intravenous infusion**, 0.5–1 micrograms/kg/minute, with or without an initial dose by intravenous injection of 0.25–1 microgram/kg over at least 30 seconds

  **Note** If patient to be intubated more than 8 minutes after start of intravenous infusion, initial intravenous injection dose is not necessary

- Maintenance of anaesthesia in ventilated patients, **ADULT** and **CHILD** over 12 years, by **intravenous infusion**, 0.05–2 micrograms/kg/minute (with or without an initial dose by intravenous injection of 0.25–1 micrograms/kg over at least 30 seconds) according to anaesthetic technique and adjusted according to response; in light anaesthesia supplemental doses by intravenous injection every 2–5 minutes; **CHILD** 1–12 years, 0.05–1.3 micrograms/kg/minute (with or without an initial dose by intravenous injection of 0.1–1 microgram/kg over at least 30 seconds) according to anaesthetic technique and adjusted according to response

- Maintenance of anaesthesia with spontaneous respiration, **ADULT** and **CHILD** over 12 years, by **intravenous infusion**, initially 40 nanograms/kg/minute adjusted according to response, usual range 25–100 nanograms/kg/minute

- Analgesia and sedation in ventilated, intensive-care patients for max. 3 days, by **intravenous infusion**, **ADULT** over 18 years, initially 100–150 nanograms/kg/minute adjusted according to response in steps of 25 nanograms/kg/minute (allow at least 5 minutes between dose adjustments); usual range 6–740 nanograms/kg/minute; if an infusion rate of 200 nanograms/kg/minute does not produce adequate sedation add another sedative (consult product literature for details)

- Additional analgesia during stimulating or painful procedures in ventilated, intensive-care patients, by **intravenous infusion**, **ADULT** over 18 years, maintain infusion rate of at least 100 nanograms/kg/minute for at least 5 minutes before procedure and adjust every 2–5 minutes according to requirements, usual range 250–750 nanograms/kg/minute

- Cardiac surgery, consult product literature

**Note** Remifentanil doses in BNF may differ from those in product literature

**Ultiva** (GSK)

**Injection**, powder for reconstitution, remifentanil (as hydrochloride), net price 1-mg vial = £5.12; 2-mg vial = £10.23; 5-mg vial = £25.58
15.1.5 Neuromuscular blocking drugs

Neuromuscular blocking drugs used in anaesthesia are also known as muscle relaxants. By specific blockade of the neuromuscular junction they enable light anaesthesia to be used with adequate relaxation of the muscles of the abdomen and diaphragm. They also relax the vocal cords and allow the passage of a tracheal tube. Their action differs from the muscle relaxants used in musculoskeletal disorders (section 10.2.2) that act on the spinal cord or brain.

Patients who have received a neuromuscular blocking drug should always have their respiration assisted or controlled until the drug has been inactivated or antagonised (section 15.1.6). They should also receive sufficient concomitant inhalational or intravenous anaesthetic or sedative drugs to prevent awareness.

Non-depolarising neuromuscular blocking drugs

Non-depolarising neuromuscular blocking drugs (also known as competitive muscle relaxants) compete with acetylcholine for receptor sites at the neuromuscular junction and their action can be reversed with anti-cholinesterases such as neostigmine (section 15.1.6). Non-depolarising neuromuscular blocking drugs can be divided into the aminosteroid group, comprising pancuronium, rocuronium, and vecuronium, and the benzylisoquinolinium group, comprising atracurium, cisatracurium, and mivacurium.

Non-depolarising neuromuscular blocking drugs have a slower onset of action than succinylcholine. These drugs can be classified by their duration of action as short-acting (15–30 minutes), intermediate-acting (30–40 minutes), and long-acting (60–120 minutes), although duration of action is dose-dependent. Drugs with a shorter or intermediate duration of action, such as atracurium and vecuronium, are more widely used than those with a longer duration of action, such as pancuronium.

Non-depolarising neuromuscular blocking drugs have no sedative or analgesic effects and are not considered to trigger malignant hyperthermia.

For patients receiving intensive care and who require tracheal intubation and mechanical ventilation, a non-depolarising neuromuscular blocking drug is chosen according to its onset of effect, duration of action, and side-effects. Rocuronium, with a rapid onset of effect, may facilitate intubation. Atracurium or cisatracurium may be suitable for long-term neuromuscular blockade since their duration of action is not dependent on elimination by the liver or the kidneys.

Cautions Allergic cross-reactivity between neuromuscular blocking drugs has been reported; caution is advised in cases of hypersensitivity to these drugs. Their activity is prolonged in patients with myasthenia gravis and in hypothermia, and lower doses are required. Non-depolarising neuromuscular blocking drugs should be used with great care in those with other neuromuscular disorders and those with fluid and electrolyte disturbances, as response is unpredictable. Resistance can develop in patients with burns, who may require increased doses; low plasma cholinesterase activity in these patients requires dose titration for mivacurium. The rate of administration of neuromuscular blocking drugs should be reduced in patients with cardiovascular disease. Interactions: Appendix 1 (muscle relaxants).

Pregnancy Non-depolarising neuromuscular blocking drugs are highly ionised at physiological pH and are therefore unlikely to cross the placenta in significant amounts.

Breast-feeding Because they are ionised at physiological pH, non-depolarising neuromuscular blocking drugs are unlikely to be present in milk in significant amounts. Breast-feeding may be resumed once the mother has recovered from neuromuscular block.

Side-effects Benzylisoquinolinium non-depolarising neuromuscular blocking drugs (except cisatracurium) are associated with histamine release, which can cause skin flushing, hypotension, tachycardia, bronchospasm, and very rarely anaphylactoid reactions. Most aminosteroid neuromuscular blocking drugs produce minimal histamine release. Drugs with vagolytic activity can counteract any bradycardia that occurs during surgery. Acute myopathy has also been reported after prolonged use in intensive care.

Atracurium, a mixture of 10 isomers, is a benzylisoquinolinium neuromuscular blocking drug with an intermediate duration of action. It undergoes non-enzymatic metabolism which is independent of liver and kidney function, thus allowing its use in patients with hepatic or renal impairment. Cardiovascular effects are associated with significant histamine release.

Cisatracurium is a single isomer of atracurium. It is more potent and has a slightly longer duration of action than atracurium and provides greater cardiovascular stability because cisatracurium lacks histamine-releasing effects.

Mivacurium, a benzylisoquinolinium neuromuscular blocking drug, has a short duration of action. It is metabolised by plasma cholinesterase and muscle paralysis is prolonged in individuals deficient in this enzyme. It is not associated with vagolytic activity or ganglionic blockade although histamine release can occur, particularly with rapid injection.

Pancuronium, an aminosteroid neuromuscular blocking drug, has a long duration of action and is often used in patients receiving long-term mechanical ventilation in intensive care units. It lacks a histamine-releasing effect, but vagolytic and sympathomimetic effects can cause tachycardia and hypertension.

Rocuronium exerts an effect within 2 minutes and has the most rapid onset of any of the non-depolarising neuromuscular blocking drugs. It is an aminosteroid neuromuscular blocking drug with an intermediate duration of action. It is reported to have minimal cardiovascular effects; high doses produce mild vagolytic activity.

Vecuronium, an aminosteroid neuromuscular blocking drug, has an intermediate duration of action. It does not generally produce histamine release and lacks cardiovascular effects.
15.1.5 Neuromuscular blocking drugs

**ATRACURIUM BESILATE**

**(Atracurium besylate)**

**Indications**  
neuromuscular blockade (short to intermediate duration) for surgery or during intensive care

**Cautions**  
see notes above

**Pregnancy**  
see notes above

**Breast-feeding**  
see notes above

**Side-effects**  
see notes above; seizures also reported

**Dose**  
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- Intubation and surgery, **ADULT** and **CHILD** over 1 month, by **intravenous injection**, initially 300–600 micrograms/kg; then 100–200 micrograms/kg as required or initially by **intravenous injection**, 200–600 micrograms/kg followed by **intravenous infusion**, 300–600 micrograms/kg/hour
- Intensive care, **ADULT** and **CHILD** over 1 month, by **intravenous injection**, initially 300–600 micrograms/kg (optional) then by **intravenous infusion** 270–1770 micrograms/kg/hour (usual dose 650–780 micrograms/kg/hour)

**Atracurium**  
**(Non-proprietary)**

**Injection**, atracurium besilate 10 mg/mL, net price 2.5-mL amp = £1.85; 5-mL amp = £3.37; 25-mL vial = £14.45

**Tracrium®**  
**(GSK)**

**Injection**, atracurium besilate 10 mg/mL, net price 2.5-mL amp = £1.66; 5-mL amp = £3.00; 25-mL vial = £12.91

**CISATRACURIUM**

**Indications**  
neuromuscular blockade (intermediate duration) for surgery or during intensive care

**Cautions**  
see notes above

**Pregnancy**  
see notes above

**Breast-feeding**  
see notes above; also bradycardia

**Dose**  
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- Intubation and surgery, **ADULT** and **CHILD** over 1 month, initially 150 micrograms/kg; then 20–100 micrograms/kg approx. every 20 minutes; **CHILD** 2–12 years, initially 20–60 micrograms/kg approx. every 10 minutes; or maintenance, by **intravenous infusion**, **ADULT** and **CHILD** over 2 years, initially 180 micrograms/kg/hour, then **after stabilisation**, 60–120 micrograms/kg/hour  
**Note**  
Lower doses can be used for children over 2 years when not for intubation

- Intensive care, **ADULT** initially 150 micrograms/kg (optional) by **intravenous injection**, then by **intravenous infusion** 180 micrograms/kg/hour adjusted according to response (usual range 30–600 micrograms/kg/hour)

**Nimbex®**  
**(GSK)**

**Injection**, cisatracurium (as besilate) 2 mg/mL, net price 10-mL amp = £7.55

**Forte injection**, cisatracurium (as besilate) 5 mg/mL, net price 30-mL vial = £31.09

**MIVACURUM**

**Indications**  
neuromuscular blockade (short duration) for surgery

**Cautions**  
see notes above; low plasma cholinesterase activity; elderly

**Hepatic impairment**  
reduce dose in severe impairment

**Renal impairment**  
clinical effect prolonged in renal failure—reduce dose according to response

**Pregnancy**  
see notes above

**Breast-feeding**  
see notes above

**Side-effects**  
see notes above

**Dose**  
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- By **intravenous injection**, 70–250 micrograms/kg; maintenance 100 micrograms/kg every 15 minutes; **CHILD** 2–6 months initially 150 micrograms/kg, 7 months–12 years initially 200 micrograms/kg; maintenance (**CHILD** 2 months–12 years) 100 micrograms/kg every 6–9 minutes

**Note**  
Doses up to 150 micrograms/kg may be given over 5–15 seconds, higher doses should be given over 30 seconds. In patients with asthma, cardiovascular disease or those who are sensitive to falls in arterial blood pressure give over 60 seconds

- By **intravenous infusion** after initial bolus intravenous dose, maintenance of block, 8–10 micrograms/kg/minute, adjusted if necessary every 3 minutes by 1 microgram/kg/minute to usual dose of 6–7 micrograms/kg/minute; **CHILD** 2 months–12 years, usual dose 11–14 micrograms/kg/minute

**Mivacuron®**  
**(GSK)**

**Injection**, mivacurium (as chloride) 2 mg/mL, net price 5-mL amp = £2.79; 10-mL amp = £4.51

**PANCURONIUM BROMIDE**

**Indications**  
neuromuscular blockade (long duration) for surgery or during intensive care

**Cautions**  
see notes above

**Hepatic impairment**  
possibly slower onset, higher dose requirement, and prolonged recovery time

**Renal impairment**  
use with caution; prolonged duration of block

**Pregnancy**  
see notes above

**Breast-feeding**  
see notes above

**Side-effects**  
see notes above

**Dose**  
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- Intubation, by **intravenous injection**, **ADULT** and **CHILD** over 1 month, initially 100 micrograms/kg then 20 micrograms/kg as required, **NEONATE** see **BNF for Children**

**Intensive care, by **intravenous injection**, initially 100 micrograms/kg (optional) then 60 micrograms/kg every 60–90 minutes

**Pancuronium**  
**(Non-proprietary)**

**Injection**, pancuronium bromide 2 mg/mL, net price 2-mL amp = £1.20
### Rocuronium Bromide

**Indications**
neuromuscular blockade (intermediate duration) for surgery or during intensive care

**Cautions**
see notes above

**Hepatic Impairment**
reduce dose

**Renal Impairment**
reduce maintenance dose; prolonged paralysis

**Pregnancy**
see notes above

**Breast-feeding**
see notes above

**Side-effects**
see notes above

**Dose**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- Intubation, **ADULT** and **CHILD** over 1 month, **by intravenous injection**, initially 600 micrograms/kg; maintenance by **intravenous injection**, 150 micrograms/kg (**ELDERLY** 75–100 micrograms/kg) or maintenance by **intravenous infusion**, 300–600 micrograms/kg/hour (**ELDERLY** up to 400 micrograms/kg/hour) adjusted according to response

- Intensive care, **by intravenous injection**, **ADULT** initially 600 micrograms/kg (optional); maintenance by **intravenous infusion**, 300–600 micrograms/kg/hour for first hour, then adjusted according to response

**Rocuronium** (Non-proprietary)

**Injection**, rocuronium bromide 10 mg/mL, net price 5-mL vial = £3.00, 10-mL vial = £6.00

**Esmeron** (Organon)

**Injection**, rocuronium bromide 10 mg/mL, net price 5-mL vial = £2.90, 10-mL vial = £5.79

### Vecuronium Bromide

**Indications**
neuromuscular blockade (intermediate duration) for surgery

**Cautions**
see notes above

**Hepatic Impairment**
use with caution in significant impairment

**Renal Impairment**
use with caution in renal failure

**Pregnancy**
see notes above

**Breast-feeding**
see notes above

**Side-effects**
see notes above

**Dose**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight

- **ADULT** and **CHILD** over 1 month, **by intravenous injection**, 80–100 micrograms/kg; then maintenance, **by intravenous injection either 20–30 micrograms/kg** adjusted according to response (max. 100 micrograms/kg in caesarian section), or **by intravenous infusion**, 0.8–1.4 micrograms/kg/minute, adjusted according to response; **NEONATE** see BNF for Children

**Norcuron** (Organon)

**Injection**, powder for reconstitution, vecuronium bromide, net price 10-mg vial = £3.38 (with water for injections)

### Suxamethonium Chloride

(Succinylcholine chloride)

**Indications**
neuromuscular blockade (short duration)

**Cautions**
see notes above: hypersensitivity to other neuromuscular blocking drugs; patients with cardiac, respiratory, or neuromuscular disease; raised intracocular pressure (avoid in penetrating eye injury); severe sepsis (risk of hyperkalaemia); interactions: Appendix 1 (muscle relaxants)

**Contra-indications**
family history of malignant hyperthermia, hyperkalaemia; major trauma, severe burns, neurological disease involving acute wasting of major muscle, prolonged immobilisation—risk of hyperkalaemia, personal or family history of congenital myotonic disease, Duchenne muscular dystrophy, low plasma-cholinesterase activity (including severe liver disease, see Hepatic Impairment)

**Hepatic Impairment**
prolonged apnoea may occur in severe liver disease because of reduced hepatic synthesis of pseudocholinesterase

**Pregnancy**
mildly prolonged maternal neuromuscular blockade may occur

**Breast-feeding**
unlikely to be present in breast milk in significant amounts (ionised at physiological pH); breast-feeding may be resumed once the mother recovered from neuromuscular block

**Side-effects**
see notes above; also increased gastric pressure; hyperkalaemia; postoperative muscle pain, myoglobinuria, myoglobinemia; increased intraocular pressure; flushing, rash; rarely arrhythmias, cardiac arrest; bronchospasm, apnoea, prolonged

### Depolarising neuromuscular blocking drugs

Suxamethonium has the most rapid onset of action of any of the neuromuscular blocking drugs and is ideal if fast onset and brief duration of action are required, e.g. with tracheal intubation.

Suxamethonium acts by mimicking acetylcholine at the neuromuscular junction but hydrolysis is much slower than for acetylcholine; depolarisation is therefore prolonged, resulting in neuromuscular blockade. Unlike the non-depolarising neuromuscular blocking drugs, its action cannot be reversed and recovery is spontaneous; anticholinesterases such as neostigmine potentiate the neuromuscular block.

Suxamethonium should be given after anaesthetic induction because paralysis is usually preceded by painful muscle fasciculations. While tachycardia occurs with single use, bradycardia may occur with repeated doses in adults and with the first dose in children. Premedication with atropine reduces bradycardia as well as the excessive salivation associated with suxamethonium use.

Prolonged paralysis may occur in dual block, which occurs with high or repeated doses of suxamethonium and is caused by the development of a non-depolarising block following the initial depolarising block; edrophonium (section 15.1.6) may be used to confirm the diagnosis of dual block. Individuals with myasthenia gravis are resistant to suxamethonium but can develop dual block resulting in delayed recovery. Prolonged paralysis may also occur in those with low or atypical plasma cholinesterase. Assisted ventilation should be continued until muscle function is restored.
15.1.6 Drugs for reversal of neuromuscular blockade

Anticholinesterases

Anticholinesterases reverse the effects of the non-depolarising (competitive) neuromuscular blocking drugs such as pancuronium but they prolong the action of the depolarising neuromuscular blocking drug suxamethonium.

Edrophonium has a transient action and may be used in the diagnosis of suspected dual block due to suxamethonium. Atropine (section 15.1.3) is given before or with edrophonium to prevent muscarinic effects when given for reversal of non-depolarising neuromuscular blockade.

Neostigmine has a longer duration of action than edrophonium and is used specifically for reversal of non-depolarising (competitive) blockade. It acts within one minute of intravenous injection and its effects last for 20 to 30 minutes; a second dose may then be necessary. Glycopyrronium or alternatively atropine (section 15.1.3), given before or with neostigmine, prevent bradycardia, excessive salivation, and other muscarinic effects of neostigmine.

EDROPHONIUM CHLORIDE

Indications see under Dose; myasthenia gravis (section 10.2.1)

Cautions section 10.2.1; atropine should also be given

Contra-indications section 10.2.1

Pregnancy section 10.2.1

Breast-feeding section 10.2.1

Side-effects section 10.2.1

Dose

• Brief reversal of non-depolarising neuromuscular block by intravenous injection over several minutes, 500–700 micrograms/kg (after or with atropine)

• Diagnosis of dual block, by intravenous injection, 10 mg

NEOSTIGMINE METILSULFATE

(NEostigmine methylsulphate)

Indications see under Dose

Cautions section 10.2.1 and notes above; glycopyrronium or atropine should also be given

Contra-indications section 10.2.1 and notes above

Pregnancy section 10.2.1

Breast-feeding section 10.2.1

Side-effects section 10.2.1 and notes above

Dose

• Reversal of non-depolarising neuromuscular blockade, by intravenous injection over 1 minute, ADULT over 18 years, 2.5 mg repeated if necessary (max. 5 mg) after or with glycopyrronium or atropine; CHILD under 18 years see BNF for Children

• Myasthenia gravis, see section 10.2.1

Neostigmine (Non-proprietary) Injection, neostigmine metilsulfate 2.5 mg/mL, net price 1-mL amp = 58p

With glycopyrronium bromide

Glycopyrronium–Neostigmine (Non-proprietary) Injection, neostigmine metilsulfate 2.5 mg, glycopyrronium bromide 500 micrograms/mL, net price 1-mL amp = 91p

Dose reversal of non-depolarising neuromuscular blockade, by intravenous injection over 10–30 seconds, 1–2 mL or 0.02 mL/kg, dose may be repeated if required (total max. 2 mL); CHILD 0.02 mL/kg (or 0.2 mL/kg of a 1 in 10 dilution using water for injections or sodium chloride injection 0.9%), dose may be repeated if required (total max. 2 mL)

Other drugs for reversal of neuromuscular blockade

Sugammadex is a modified gamma cyclodextrin used for reversal of neuromuscular blockade induced by rocuronium or vecuronium (section 15.1.5).

SUGAMMADEX

Indications reversal of neuromuscular blockade induced by rocuronium or vecuronium

Cautions recurrence of neuromuscular blockade—monitor respiratory function until fully recovered; recovery may be delayed in cardiovascular disease and elderly; pre-existing coagulation disorders or use of anticoagulants (unrelated to surgery); wait 24 hours before re-administering rocuronium or vecuronium; interactions: Appendix 1 (sugammadex)

Renal impairment avoid if eGFR less than 30 mL/minute/1.73 m²

Pregnancy use with caution—no information available

Side-effects taste disturbances; less commonly allergic reactions; bronchospasm also reported
15.1.7 Antagonists for central and respiratory depression

**Dose**
- Routine reversal of neuromuscular blockade induced by rocuronium or vecuronium, by intravenous injection. **ADULT** over 18 years, 2–4 mg/kg (consult product literature); a further dose of 4 mg/kg may be required if recurrence of neuromuscular blockade occurs.
- Routine reversal of neuromuscular blockade induced by rocuronium, by intravenous injection. **CHILD** 2–18 years, 2 mg/kg (consult product literature).
- Immediate reversal of neuromuscular blockade induced by rocuronium, by intravenous injection. **ADULT** over 18 years, 16 mg/kg (consult product literature).

**Indications**
- Flumazenil (Non-proprietary). Injection, flumazenil 100 micrograms/mL, net price 5-mL amp = £14.49.

**Anexate® (Roche)** Injection, flumazenil 100 micrograms/mL, net price 5-mL amp = £13.66.

**Breast-feeding**
- Avoid unless potential benefit outweighs risk.

**Side-effects**
- Nausea, vomiting, and flushing; if waking too rapid, agitation, anxiety, and fear; transient increase in blood pressure and heart-rate in intensive care patients; very rarely convulsions (particularly in those with epilepsy), hypersensitivity reactions including anaphylaxis.

**Dose**
- Routine reversal of neuromuscular blockade induced by rocuronium or vecuronium, by intravenous injection. **ADULT** over 18 years, 2–4 mg/kg (consult product literature).
- Immediate reversal of neuromuscular blockade induced by rocuronium, by intravenous injection. **ADULT** over 18 years, 16 mg/kg (consult product literature).

**Bridion® (Scherling-Plough)** Injection, sugammadex (as sodium salt) 100 mg/mL, net price 2-mL amp = £59.64, 5-mL amp = £149.10.

**Electrolytes** Na⁺ 0.42 mmol/mL

**Breast-feeding**
- Avoid breast-feeding for 24 hours.

**Pregnancy**
- Use only if potential benefit outweighs risk.

**Side-effects**
- Nausea, vomiting; hypotension, hypertension, tachycardia and fibrillation, cardiovascular arrest; hyperventilation, dyspnoea, pulmonary oedema; headache, dizziness; less commonly diarrhoea, dry mouth, agitation, excitement, paraesthesia, tremor, sweating; very rarely seizures, erythema multiforme, and hypersensitivity reactions including anaphylaxis.

**Dose**
- By intravenous injection, 200 micrograms over 15 seconds, then 100 micrograms at 60-second intervals if required; usual dose range, 300–600 micrograms; max. total dose 1 mg (2 mg in intensive care); question aetiology if no response to repeated doses.
- By intravenous infusion, if drowsiness recurs after injection, 100–400 micrograms/hour, adjusted according to level of arousal.

**Indications**
- Respiratory depression is a major concern with opioid anaesthetics and it may be treated by artificial ventilation or be reversed by naloxone. Naloxone will immediately reverse opioid-induced respiratory depression but the dose may have to be repeated because of the short duration of action of naloxone; however, naloxone will also antagonise the analgesic effect.

**Flumazenil** is a benzodiazepine antagonist for the reversal of the central sedative effects of benzodiazepines after anaesthetic and similar procedures. Flumazenil has a shorter half-life and duration of action than naloxone; however, naloxone will also antagonise the analgesic effect.

**Doxapram** (section 3.5.1) is a central and respiratory stimulant but is of limited value in anaesthesia.
Malignant hyperthermia is a rare but potentially lethal complication of anaesthesia. It is characterised by a rapid rise in temperature, increased muscle rigidity, tachycardia, and acidosis. The most common triggers of malignant hyperthermia are the volatile anaesthetics. Suxamethonium has also been implicated, but malignant hyperthermia is more likely if it is given following a volatile anaesthetic. Volatile anaesthetics and suxamethonium should be avoided during anaesthesia in patients at high risk of malignant hyperthermia. Dantrolene is used in the treatment of malignant hyperthermia. It acts on skeletal muscle cells by interfering with calcium efflux, thereby stopping the contractile process.

**DANTROLENE SODIUM**

**Indications** malignant hyperthermia; chronic severe spasticity of voluntary muscle (section 10.2.2)

**Cautions** avoid extravasation (risk of tissue necrosis);

**Pregnancy** use only if potential benefit outweighs risk

**Breast-feeding** present in milk—use only if potential benefit outweighs risk

**Side-effects** hepatotoxicity, pulmonary oedema, dizziness, weakness, and injection-site reactions including erythema, rash, swelling, and thrombophlebitis

**Dose**

- By rapid intravenous injection, ADULT, initially 2–3 mg/kg, then 1 mg/kg repeated as required to a cumulative max. of 10 mg/kg; CHILD 1 month–18 years see BNF for Children

**Dantrolium Intravenous®** (SpePharm) 

**Injection**, powder for reconstitution, dantrolene sodium, net price 20-mg vial = £5.00 (hosp. only)

---

**Use of local anaesthetics** Local anaesthetic drugs act by causing a reversible block to conduction along nerve fibres. They vary widely in their potency, toxicity, duration of action, stability, solubility in water, and ability to penetrate mucous membranes. These factors determine their application, e.g. topical (surface), infiltration, peripheral nerve block, intravenous regional anaesthesia (Bier’s block), plexus, epidural (extradural), or spinal (intrathecal or subarachnoid) block. Local anaesthetics may also be used for postoperative pain relief, thereby reducing the need for analgesics such as opioids.

**Administration** The dose of local anaesthetic depends on the injection site and the procedure used. In determining the safe dosage, it is important to take account of the rate of absorption and excretion, and of the potency. The patient’s age, weight, physique, and clinical condition, and the vascularity of the administration site and the duration of administration, must also be considered.

Uptake of local anaesthetics into the systemic circulation determines their duration of action and produces toxicity. Great care must be taken to avoid accidental intravascular injection; local anaesthetic injections should be given slowly in order to detect inadvertent intravascular administration. When prolonged analgesia is required, a long-acting local anaesthetic is preferred to minimise the likelihood of cumulative systemic toxicity. Local anaesthesia around the oral cavity may impair swallowing and therefore increases the risk of aspiration. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so **careful surveillance** for toxic effects (see Toxicity and Side-effects, below) is necessary during the first 30 minutes after injection.

Epidural anaesthesia is commonly used during surgery, often combined with general anaesthesia, because of its protective effect against the stress response of surgery. It is often used when good postoperative pain relief is essential (e.g. major thoracic or intra-abdominal surgery).

**Use of vasoconstrictors** Local anaesthetics cause dilatation of blood vessels. The addition of a vasoconstrictor such as adrenaline (epinephrine) to the local anaesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anaesthetic effect. Great care should be taken to avoid inadvertent intravenous administration of a preparation containing adrenaline, and it is not advisable to give adrenaline with a local anaesthetic injection in digits or appendages because of the risk of ischaemic necrosis.

Adrenaline must be used in a low concentration when administered with a local anaesthetic (but see also Dental Anaesthesia, below). The total dose of adrenaline should not exceed 500 micrograms and it is essential not to exceed a concentration of 1 in 200 000 (5 micrograms/mL) if more than 50 mL of the mixture is to be injected. Care must also be taken to calculate a safe maximum dose of local anaesthetic when using combination products. For prescribing information on adrena-
line, see section 2.7.3. For drug interactions of adrenaline, see Appendix 1 (sympathomimetics).

In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline should be used.

**Dental anaesthesia** Lidocaine is widely used in dental procedures; it is most often used in combination with adrenaline (epinephrine). Lidocaine 2% combined with adrenaline 1 in 80 000 (12.5 micrograms/mL) is a safe and effective preparation; there is no justification for using higher concentrations of adrenaline. See also Use of Vasoconstrictors, above.

The local anaesthetics articaine and mepivacaine are also used in dentistry; they are available in cartridges suitable for dental use. Mepivacaine is available with or without adrenaline and articaine is available with adrenaline.

**Cautions of local anaesthetics** Local anaesthetics should be administered with caution in children, elderly or debilitated patients (consider dose reduction), or in patients with impaired cardiac conduction, cardiovascular disease, hypovolaemia, shock, impaired respiratory function, epilepsy, or myasthenia gravis. See also Administration and Use of Vasoconstrictors, above.

**Contra-indications of local anaesthetics** Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. In such circumstances, increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH. See also Use of Vasoconstrictors, above.

**Toxicity and side-effects** A single application of a topical lidocaine preparation does not generally cause systemic side-effects. Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.

The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems. CNS effects include a feeling of inebriation and lightheadedness followed by sedation, numbness of the tongue and perioral region, restlessness, paraesthesia (including sensations of hot and cold), dizziness, blurred vision, nausea and vomiting, muscle twitching, tremors, and convulsions. Transient excitation may also occur, followed by depression with drowsiness, respiratory failure, unconsciousness, and coma. Effects on the cardiovascular system include myocardial depression and peripheral vasodilatation resulting in hypotension and bradycardia; arrhythmias and cardiac arrest can occur. Hypersensitivity reactions occur mainly with the ester-type local anaesthetics such as tetracaine; reactions are less frequent with the amide types such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

**Articaine** Articaine is an amide-type local anaesthetic used for dental anaesthesia (see Dental Anaesthesia, above). It is available in a preparation that also contains adrenaline (see Use of Vasoconstrictors, p. 793).

**ARTICAIN HYDROCHLORIDE WITH ADRENALINE** (Carticaine hydrochloride with adrenaline)

**Indications** infiltration anaesthesia in dentistry

**Cautions** see Cautions of Local Anaesthetics, above and Adrenaline, section 2.7.3

**Contra-indications** see Contra-indications of Local Anaesthetics, above and Adrenaline, section 2.7.3

**Hepatic impairment** use with caution; increased risk of side-effects in severe impairment

**Renal impairment** see Adrenaline, section 2.7.3

**Pregnancy** use only if potential benefit outweighs risk—no information available

**Breast-feeding** avoid breast-feeding for 48 hours after administration

**Side-effects** see Toxicity and Side-effects, above and Adrenaline, section 2.7.3; also methaemoglobinaemia (see Prilocaine (p. 797) for treatment)

**Dose**

- **ADULT and CHILD** over 4 years, consult expert dental sources

**Septanest®** (Septodont)®

**Injection**, articaine hydrochloride 40 mg/mL, adrenaline 1 in 200 000 (5 micrograms/mL), net price 2.2-mL cartridge = 41p

**Injection**, articaine hydrochloride 40 mg/mL, adrenaline 1 in 100 000 (10 micrograms/mL), net price 2.2-mL cartridge = 41p

**Bupivacaine**

Bupivacaine has a longer duration of action than other local anaesthetics. It has a slow onset of action, taking up to 30 minutes for full effect. It is often used in lumbar epidural blockade and is particularly suitable for continuous epidural analgesia in labour, or for postoperative pain relief. It is the principal drug used for spinal anaesthesia. Hyperbaric solutions containing glucose may be used for spinal block.

**BUPIVACAINE HYDROCHLORIDE**

**Indications** see under Dose

**Cautions** see Cautions of Local Anaesthetics, above; myocardial depression may be more severe and more...
resistant to treatment; cardiovascular disease; hypertension; hypoponnia; cerebral atheroma; interactions: Appendix 1 (bupivacaine)

Contra-indications see Contra-indications of Local Anaesthetics, p. 794

Hepatic impairment caution in severe impairment

Renal impairment caution in severe impairment

Pregnancy large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after paracervical or epidural block; use lower doses for intrathecal use during late pregnancy

Breast-feeding amount too small to be harmful

Side-effects see Toxicity and Side-effects, p. 794

Dose

Note Doses should be adjusted according to patient's physical status and nature of procedure—important: see also under Administration, p. 793

- Local infiltration, max. 60 mL, using a 2.5 mg/mL (0.25%) solution
- Peripheral nerve block, max. 60 mL (150 mg), using a 2.5 mg/mL (0.25%) solution; max. 30 mL, using a 5 mg/mL (0.5%) solution
- Epidural block
  - Surgery, lumbar, 10–20 mL (50–100 mg), using a 5 mg/mL (0.5%) solution
  - Surgery, caudal, 15–30 mL (75–150 mg), using a 5 mg/mL (0.5%) solution; CHILD (up to 10 years) using a 2.5 mg/mL (0.25%) solution, upper to lower-thoracic (T10) 0.3–0.4 mL/kg (0.75–1 mg/kg), up to mid-thoracic (T6) 0.4–0.8 mL/kg (1–2 mg/kg)
  - Labour, lumbar, 6–12 mL (15–30 mg) using a 2.5 mg/mL (0.25%) or 6–12 mL (30–60 mg) using a 5 mg/mL (0.5%) solution
- Sympathetic block, 20–50 mL (50–125 mg), using a 2.5 mg/mL (0.25%) solution
- Intrathecal anaesthesia, see under preparations

Important The licensed doses stated above may not be appropriate in some settings and expert advice should be sought

Bupivacaine (Non-proprietary) 

Injection, anhydrous bupivacaine hydrochloride

2.5 mg/mL (0.25%), net price 10 mL = 82p; 5 mg/mL (0.5%), 10 mL = 94p

Infusion, anhydrous bupivacaine hydrochloride

1 mg/mL (0.1%), net price 100 mL = £8.41; 250 mL = £10.59; 1.25 mg/mL (0.125%), 250 mL = £10.80

Note continuous lumbar epidural infusion during labour (once epidural block established), 10–15 mg/hour of 0.1% or 0.125% solution; max. 2 mg/kg over 4 hours and total of 400 mg in 24 hours

Continuous thoracic, upper abdominal, or lower abdominal epidural infusion for postoperative pain (once epidural block established), 4–15 mg/hour of 0.1% solution, or 5–15 mg/hour of 0.125% solution; max. 2 mg/kg over 4 hours and total of 400 mg in 24 hours; not recommended for use in children

Marclain® (AstraZeneca) 

Injection, anhydrous bupivacaine hydrochloride

2.5 mg/mL (Marclain® 0.25%), net price 10 mL; Polyamp® = £1.06; 5 mg/mL (Marclain® 0.5%), 10 mL Polyamp® = £1.21

Levobupivacaine 

Levobupivacaine, an isomer of bupivacaine, has anaesthetic and analgesic properties similar to bupivacaine, but is thought to have fewer adverse effects.

LEVOBUPIVACAINE 

Note Levobupivacaine is an isomer of bupivacaine

Indications see under Dose

Cautions see Cautions of Local Anaesthetics, p. 794; cardiovascular disease; interactions: Appendix 1 (levobupivacaine)

Contra-indications see Contra-indications of Local Anaesthetics, p. 794

Hepatic impairment use with caution

Pregnancy large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block; avoid if possible in the first trimester—toxicity in animal studies; may cause fetal distress syndrome; do not use for paracervical block in obstetrics; do not use 7.5 mg/mL strength in obstetrics

Breast-feeding amount too small to be harmful

Side-effects see Toxicity and Side-effects, p. 794; also sweating, pyrexia, and anaemia

Dose

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight

Note Doses should be adjusted according to patient's physical status and nature of procedure—important: see also under Administration, p. 793

- Surgical anaesthesia
  - Lumbar epidural, 10–20 mL (50–150 mg) of 5 mg/mL or 7.5 mg/mL solution over 5 minutes; caesarean section, 15–30 mL (75–150 mg) of 5 mg/mL solution over 15–20 minutes
  - Intrathecal, 3 mL (15 mg) of 5 mg/mL solution
- Peripheral nerve block, 1–40 mL of 2.5 mg/mL or 5 mg/mL solution (max. 150 mg); ilioinguinal/iliohypogastric block, CHILD under 12 years 0.25–0.5 mL/kg (0.625–2.5 mg/kg) of a 2.5 mg/mL or 5 mg/mL solution
- Peribulbar block, 5–15 mL (37.5–112.5 mg) of 7.5 mg/mL solution
- Local infiltration, 1–60 mL (max. 150 mg) of 2.5 mg/mL solution
15.2 Local anaesthesia

**Lidocaine**

Lidocaine is effectively absorbed from mucous membranes and is a useful surface anaesthetic in concentrations up to 10%. Except for surface anaesthesia and dental anaesthesia, solutions should not usually exceed 1% in strength. The duration of the block (with adrenaline) is about 90 minutes.

**LIDOCAINE HYDROCHLORIDE** (Lignocaine hydrochloride)

**Indications** see under Dose; ventricular arrhythmias (section 2.3.2); eye (section 11.7)

**Cautions** See Cautions of Local Anaesthetics, p. 794 and section 2.3.2; hypertension; topical preparations can damage plastic cuffs of endotracheal tubes

**Contra-indications** see notes above, Contra-indications of Local Anaesthetics, p. 794, and section 2.3.2

**Hepatic impairment** section 2.3.2

**Renal impairment** section 2.3.2

**Pregnancy** large doses can cause fetal bradycardia; large doses during delivery can cause neonatal respiratory hypotonia, hypotonia, or bradycardia after paracervical or epidural block

**Breast-feeding** section 2.3.2

**Side-effects** see Toxicity and Side-effects, p. 794 and section 2.3.2; also methaemoglobinemia (see below Prilocaine (p. 797) for treatment), nystagmus, rash; hypoglycaemia also reported following intrathecal or extradural administration

**Dose**

- **To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight**
- **Infiltration anaesthesia, according to patient’s weight and nature of procedure, max. 200 mg (or 500 mg if given in solutions containing adrenaline)—see also Administration on p. 793 and see also important warning below**

**Important**

The licensed doses stated above may not be appropriate in some settings and expert advice should be sought

**Lidocaine hydrochloride injections**

Lidocaine (Non-proprietary) \(^{(a)}\)

**Injection**, lidocaine hydrochloride 5 mg/mL (0.5%), net price 10-mL amp = £1.62; 5 mg/mL, 10-mL amp = £1.62; 7.5 mg/mL, 10-mL amp = £2.43

**Note** For 1.25 mg/mL concentration dilute standard solutions with sodium chloride 0.9%

**Infusion**, lepovupicaine (as hydrochloride) 625 micrograms/mL, net price 100 mL = £6.63, 200 mL = £10.37, 1.25 mg/mL, net price 100 mL = £7.26, 200 mL = £12.20

**With adrenaline**

For prescribing information on adrenaline see section 2.7.3; see also Use of Vasoconstrictors, p. 793.

**Xylocaine** (AstraZeneca) \(^{(a)}\)

**Injection**, anhydrous lidocaine hydrochloride 10 mg/mL (1%), adrenaline 1 in 200 000 (5 micrograms/mL), net price 20-mL vial = 99p

**Injection**, anhydrous lidocaine hydrochloride 20 mg/mL (2%), adrenaline 1 in 200 000 (5 micrograms/mL), net price 20-mL vial = £1.04

**Lidocaine for surface anaesthesia**

Instillagel\(^{(a)}\) (CliniMed)

**Gel**, lidocaine hydrochloride 2%, chlorhexidine gluconate solution 0.25%, in a sterile lubricant basis in disposable syringe, net price 6-mL syringe = £1.41, 11-mL syringe = £1.58

**Excipients** include hydroxybenzoates (parabens)

**Dose** urethral sounding and catheterisation, 6–11 mL into urethra

Cystoscopy, 11 mL (a further instillation of 6–11 mL may be required)

**Laryngojet** (UCB Pharma) \(^{(a)}\)

**Solution**, lidocaine hydrochloride 40 mg/mL (4%), net price per unit (4-mL vial and disposable sterile cannula with cover and vial injector) = £5.10

**Dose** anaesthesia of oropharynx, trachea, or respiratory tract, 40–200 mg (1–5-mL) as a single dose sprayed, instilled (if a cavity), or applied with a swab (reduce dose according to size, age and condition of patient); usual dose 160 mg (4 mL), CHILD up to 3 mg/kg

**LMX 4** (Femdale)

**Cream** lidocaine 4 %, net price 5-g tube = £2.98; 5 × 5-g tube with 10 occlusive dressings = £16.00

**Excipients** include benzyl alcohol and propylene glycol

**Dose** ADULT and CHILD over 1 month, anaesthesia before venous cannulation or venepuncture, apply thick layer (1–2.5 g); CHILD under 1 year max. 1 g) to small area (2.5 cm × 2.5 cm) of non-irritated skin at least 30 minutes before procedure (max. 60 minutes); remove cream with gauze and perform procedure after approximately 5 minutes

---

**Acute pain**

Lumbar epidural, labour pain, 6–10 mL (15–25 mg) of 2.5 mg/mL solution at intervals of at least 15 minutes or 5–12.5 mg/hour as a continuous epidural infusion; postoperative pain, 12.5–18.75 mg/hour as a continuous epidural infusion; max. 400 mg in 24 hours
**Versatis** (Grunenthal) (SM)

**Plasters**, lidocaine 5% (700 mg/medicated plaster), net price 30 = £72.40

**Excipients** include hydroxybenzoates (parabens), propylene glycol

**Dose** postoperative neuraxial, ADULT over 18 years, apply to intact, dry, non-hairy, non-irritated skin once daily for up to 12 hours, followed by a 12-hour plaster-free period; discontinue if no response after 4 weeks

**Note** Up to 3 plasters may be used to cover large areas; plasters may be cut

**The Scottish Medicines Consortium** (p. 4) has advised (July 2008) that Versatis® is accepted for restricted use within NHS Scotland for the treatment of postoperative neuralgia in patients who are intolerant of first-line systemic therapies or when they have been ineffective

**Xylocaine** (AstraZeneca)

**Spray**, lidocaine 10% (100 mg/g) supplying 10 mg lidocaine/dose; 500 spray doses per container, net price 50-mL bottle = £3.13

**Dose** dental practice, 1–5 doses

Maxillary sinus puncture, 3 doses

During delivery in obstetrics, up to 20 doses

Bronchoscopy, laryngoscopy, oesophagoscopy, endotracheal intubation, up to 20 doses; CHILD up to 3 mg/kg

### With prilocaine

For prescribing information on prilocaine, see below

**EMLA** (AstraZeneca)

**Cream**, lidocaine 2.5%, prilocaine 2.5%, net price 5-g tube = £1.73; 30-g tube (surgical pack) = £10.25; 5-g tube with 12 occlusive dressings (premedication pack) = £9.75

**Dose** ADULT and CHILD over 1 year, anaesthesia before minor skin procedures including venepuncture, apply thick layer under occlusive dressing 1–3 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting); max. 2 doses in 24 hours for CHILD 1–12 years; CHILD under 3 months or body-weight less than 5 kg, apply max. 1 g under occlusive dressing for max. 1 hour before procedure; max. 1 dose in 24 hours. CHILD 3–12 months and body-weight over 5 kg, apply max. 2 g under occlusive dressing for max. 4 hours before procedure; max. 2 doses in 24 hours

**Note** Shorter application time of 15–30 minutes is recommended for children with atopic dermatitis

Anaesthesia on genital skin before injection of local anaesthetics in adult men, apply under occlusive dressing for 15 minutes

Anaesthesia before surgical treatment of lesions on genital mucosa in adults, apply up to 10 g 5–10 minutes before procedure

### With adrenaline

For prescribing information on adrenaline, see section 2.7.3: see also Use of Vasoconstrictors, p. 793.

**Scandonest** 3% Plain (Septodont) (SM)

**Injection**, mepivacaine hydrochloride 30 mg/mL, net price 2.2-mL cartridge = 36p

### Prilocaine

**Prilocaine** is a local anaesthetic of low toxicity which is similar to lidocaine. If used in high doses, methaemoglobinemia may occur which can be treated with an intravenous injection of methylthioninium chloride 1% using a dose of 1–2 mg/kg given over 5 minutes. The dose may be repeated after 30–60 minutes if no response. Infants under 6 months are particularly susceptible to methaemoglobinemia. A hyperbaric solution of prilocaine (containing glucose) may be used for spinal anaesthesia.

**Lidocaine for ear, nose, and oropharyngeal use**

For prescribing information on phenylephrine, see section 2.7.2

**Lidocaine with phenylephrine** (Non-proprietary)

**Topical solution**, lidocaine hydrochloride 5%, phenylephrine hydrochloride 0.5%, net price 2.5 mL (with nasal applicator) = £9.98

**Dose** anaesthesia before nasal surgery, endoscopy, laryngoscopy, or removal of foreign bodies from the nose, ADULT and CHILD over 12 years, up to max. 8 sprays

**Mepivacaine**

Mepivacaine is an amide-type local anaesthetic used for dental anaesthesia (see Dental Anaesthesia, p. 794).
bradycardia after epidural block; avoid paracervical or pudendal block in obstetrics (neonatal methaemoglobinemia reported); use lower doses for intrathecal use during late pregnancy

**Breast-feeding** present in milk but not known to be harmful

**Side-effects** see notes above and Toxicity and Side-effects, p. 794; also hypertension, pyrexia; less commonly syncope, and hypothermia

**Dose**

| **To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight** |

- See under preparations—**important**: see also Administration, p. 793

**Citanest 1%** (AstraZeneca)

- **Injection**, prilocaine hydrochloride 10 mg/mL, net price 50-mL multidose vial = £2.01
- **Dose** infiltration anaesthesia and nerve block, adjusted according to site of administration and response, 100–200 mg/minute, or in incremental doses, to max. total dose 400 mg (dose may need to be reduced in ELDERLY or debilitated patients). **CHILD** over 6 months up to 5 mg/kg

**Prilocetak** (Goldshield)

- **Injection**, prilocaine hydrochloride 20 mg/mL (2%), glucose 60 mg/mL, net price 5-mL amp = £7.80
- **Dose** intrathecal anaesthesia, **ADULT** over 18 years, usually 40–60 mg, max. 80 mg (dose may need to be reduced in ELDERLY or debilitated patients, or in late pregnancy)

**With lidocaine**
See Lidocaine, p. 797

**For dental use**

- Note Consult expert dental sources for specific advice in relation to dose of prilocaine for dental anaesthesia.

**Citanest 4%** (Dentsply)

- **Injection**, prilocaine hydrochloride 40 mg/mL, net price 2.2-mL cartridge = 17p

**Citanest 3% with Octapressin** (Dentsply)

- **Injection**, prilocaine hydrochloride 30 mg/mL, felypressin 0.03 unit/mL, net price 2.2-mL cartridge and self-aspirating cartridge (both) = 47p

**Ropivacaine**

Ropivacaine is an amide-type local anaesthetic agent similar to bupivacaine. It is less cardiotonic than bupivacaine, but also less potent.

**ROPIVACAINE HYDROCHLORIDE**

**Indications** see under Dose

**Cautions** see Cautions of Local Anaesthetics, p. 794; also acute porphyria (section 9.8.2); **interactions**: Appendix 1 (ropivacaine)

**Contra-indications** see Contra-indications of Local Anaesthetics, p. 794

**Hepatic impairment** use with caution in severe impairment

**Renal impairment** caution in severe impairment; increased risk of systemic toxicity in chronic renal failure

**Pregnancy** not known to be harmful; do not use for paracervical block in obstetrics

**Breast-feeding** not known to be harmful

**Side-effects** see Toxicity and Side-effects, p. 794; also hypertension, pyrexia; less commonly syncope, and hypothermia

**Dose**

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight

- **Note** Doses should be adjusted according to patient’s physical status and nature of procedure—**important** see also under Administration, p. 793

- **Surgical anaesthesia**

  **Lumbar epidural**, **ADULT** and **CHILD** over 12 years, 15–20 mL (150–200 mg) of 10 mg/mL solution or 15–25 mL (113–188 mg) of 7.5 mg/mL solution; caesarean section, 15–20 mL (113–150 mg) of 7.5 mg/mL solution in incremental doses

  **Thoracic epidural** (to establish block for postoperative pain), **ADULT** and **CHILD** over 12 years, 5–15 mL (38–113 mg) of 7.5 mg/mL solution

  **Major nerve block** (brachial plexus block), **ADULT** and **CHILD** over 12 years, 30–40 mL (225–300 mg) of 7.5 mg/mL solution

  **Field block**, **ADULT** and **CHILD** over 12 years, 1–30 mL (7.5–225 mg) of 7.5 mg/mL solution

- **Acute pain using 2 mg/mL solution**

  **Lumbar epidural**, **ADULT** and **CHILD** over 12 years, 10–20 mL (20–40 mg) followed by 10–15 mL (20–30 mg) at intervals of at least 30 minutes or 6–10 mL/hour (12–20 mg/hour) as a continuous epidural infusion for labour pain or 6–14 mL/hour (12–28 mg/hour) as a continuous epidural infusion for postoperative pain

  **Thoracic epidural**, **ADULT** and **CHILD** over 12 years, 6–14 mL/hour (12–28 mg/hour) as a continuous infusion

  **Field block**, **ADULT** and **CHILD** over 12 years, 1–100 mL (2–200 mg)

- **Peripheral nerve block**, **ADULT** and **CHILD** over 12 years, 5–10 mL/hour (10–20 mg/hour) as a continuous infusion or by intermittent injection

- **CHILD** under 12 years, consult product literature

**Ropivacaine** (Non-proprietary)

- **Infusion**, ropivacaine hydrochloride 2 mg/mL, net price 200-mL = £14.45

**Naropin** (AstraZeneca)

- **Injection**, ropivacaine hydrochloride 2 mg/mL, net price 10-mL **Polyamp** = £1.78; 7.5 mg/mL, 10-mL **Polyamp** = £2.65; 10 mg/mL, 10-mL **Polyamp** = £3.20

  **Electrolytes** Na⁺ = 0.5 mmol/mL

- **Infusion**, ropivacaine hydrochloride 2 mg/mL, net price 200-mL **Polybag** = £14.45

  **Electrolytes** Na⁺ = 0.5 mmol/mL

**Tetracaine**

Tetracaine is an effective local anaesthetic for topical application; a 4% gel is indicated for anaesthesia before venepuncture or venous cannulation. It is rapidly absorbed from mucous membranes and should never be applied to inflamed, traumatised, or highly vascular surfaces. It should never be used to provide anaesthesia for bronchoscopy or cystoscopy because lidocaine is a safer alternative.
**TETRACAINE**  
(Amethocaine)

**Indications**  see under preparation; eye (section 11.7)  
**Cautions**  see Cautions of Local Anaesthetics, p. 794  
**Contra-indications**  see Contra-indications of Local Anaesthetics, p. 794  
**Breast-feeding**  not known to be harmful  
**Side-effects**  see Toxicity and Side-effects, p. 794  
**Important**  Rapid and extensive absorption may result in systemic side-effects (see also notes above)

**Ametop®** (S&N Hlth.)  
**Gel**, tetracaine 4%, net price 1.5-g tube = £1.08  
**Dose**  ADULT and CHILD over 1 month, apply contents of tube to site of venepuncture or venous cannulation and cover with occlusive dressing; remove gel and dressing after 30 minutes for venepuncture and after 45 minutes for venous cannulation;  
**NEONATE**  see BNF for Children  
**Note**  ADULT and CHILD over 5 years, contents of max. 5 tubes applied at separate sites at a single time; CHILD 1 month–5 years, contents of max. 1 tube applied at separate sites at a single time
Appendix 1: Interactions

Two or more drugs given at the same time may exert their effects independently or may interact. The interaction may be potentiation or antagonism of one drug by another, or occasionally some other effect. Adverse drug interactions should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA), through the Yellow Card Scheme (see Adverse Reactions to Drugs, p. 12), as for other adverse drug reactions.

Drug interactions may be pharmacodynamic or pharmacokinetic.

**Pharmacodynamic interactions**

These are interactions between drugs which have similar or antagonistic pharmacological effects or side-effects. They may be due to competition at receptor sites, or occur between drugs acting on the same physiological system. They are usually predictable from a knowledge of the pharmacology of the interacting drugs; in general, those demonstrated with one drug are likely to occur with related drugs. They occur to a greater or lesser extent in most patients who receive the interacting drugs.

**Pharmacokinetic interactions**

These occur when one drug alters the absorption, distribution, metabolism, or excretion of another, thus increasing or reducing the amount of drug available to produce its pharmacological effects. They are not easily predicted and many of them affect only a small proportion of patients taking the combination of drugs. Pharmacokinetic interactions occurring with one drug cannot be assumed to occur with related drugs unless their pharmacokinetic properties are known to be similar. Pharmacokinetic interactions are of several types:

**Affecting absorption**

The rate of absorption or the total amount absorbed can both be altered by drug interactions. Delayed absorption is rarely of clinical importance unless high peak plasma concentrations are required (e.g. when giving an analgesic). Reduction in the total amount absorbed, however, may result in ineffective therapy.

**Due to changes in protein binding**

To a variable extent most drugs are loosely bound to plasma proteins. Protein-binding sites are non-specific and one drug can displace another thereby increasing its proportion free to diffuse from plasma to its site of action. This only produces a detectable increase in effect if it is an extensively bound drug (more than 90%) that is not widely distributed throughout the body. Even so displacement rarely produces more than transient potentiation because this increased concentration of free drug results in an increased rate of elimination. Displacement from protein binding plays a part in the potentiation of warfarin by sulfonamides and tolbutamide but the importance of these interactions is due mainly to the fact that warfarin metabolism is also inhibited.

**Affecting metabolism**

Many drugs are metabolised in the liver. Induction of the hepatic microsomal enzyme system by one drug can gradually increase the rate of metabolism of another, resulting in lower plasma concentrations and a reduced effect. On withdrawal of the inducer plasma concentrations increase and toxicity may occur. Barbiturates, griseofulvin, many antiepileptics, and rifampicin are the most important enzyme inducers. Drugs affected include warfarin and the oral contraceptives. Conversely when one drug inhibits the metabolism of another higher plasma concentrations are produced, rapidly resulting in an increased effect with risk of toxicity. Some drugs which potentiate warfarin and phenytoin do so by this mechanism.

Isoenzymes of the hepatic cytochrome P450 system interact with a wide range of drugs. Drugs may be substrates, inducers or inhibitors of the different isoenzymes. A great deal of in-vitro information is available on the effect of drugs on the isoenzymes; however, since drugs are eliminated by a number of different metabolic routes as well as renal excretion, the clinical effects of interactions cannot be predicted accurately from laboratory data on the cytochrome P450 isoenzymes. Except where a combination of drugs is specifically contra-indicated, the BNF presents only interactions that have been reported in clinical practice. In all cases the possibility of an interaction must be considered if toxic effects occur or if the activity of a drug diminishes.

**Affecting renal excretion**

Drugs are eliminated through the kidney both by glomerular filtration and by active tubular secretion. Competition occurs between those which share active transport mechanisms in the proximal tubule. For example, salicylates and some other NSAIDs delay the excretion of methotrexate; serious methotrexate toxicity is possible.

**Relative importance of interactions**

Many drug interactions are harmless and many of those which are potentially harmful only occur in a small proportion of patients; moreover, the severity of an interaction varies from one patient to another. Drugs with a small therapeutic ratio (e.g. phenytoin) and those which require careful control of dosage (e.g. anticoagulants, antihypertensives, and antiadibiotics) are most often involved. Patients at increased risk from drug interactions include the elderly and those with impaired renal or liver function.

**Serious interactions**

The symbol • has been placed against interactions that are potentially serious and where combined administration of the drugs involved should be avoided (or only undertaken with caution and appropriate monitoring).

Interactions that have no symbol do not usually have serious consequences.
Appendix 1: Interactions

List of drug interactions

The following is an alphabetical list of drugs and their interactions; to avoid excessive cross-referencing each drug or group is listed twice: in the alphabetical list and also against the drug or group with which it interacts; changes in the interactions lists since BNF No. 60 (September 2010) are underlined.

For explanation of symbol • see above

Abacavir

Analgesics: abacavir possibly reduces plasma concentration of methadone

Antibacterials: plasma concentration of abacavir possibly reduced by rifampicin

Antiepileptics: plasma concentration of abacavir possibly reduced by phenytoin

Anti-infectives: abacavir possibly reduces effects of etabaumol; plasma concentration of abacavir reduced by eiprocarb

Barbiturates: plasma concentration of abacavir possibly reduced by phenobarbital

Abatacept

Adalimumab: increased risk of side-effects when abatacept given with adalimumab

Cetolizumab pegol: avoid concomitant use of abatacept with cetolizumab pegol

Etanercept: avoid concomitant use of abatacept with etanercept

Golimumab: avoid concomitant use of abatacept with golimumab

Infliximab: avoid concomitant use of abatacept with infliximab

Vaccines: avoid concomitant use of abatacept with live vaccines (see p. 746)

Acarbose see Antidiabetics

ACE Inhibitors

Alcohol: enhanced hypotensive effect when ACE inhibitors given with alcohol

Aldesleukin: enhanced hypotensive effect when ACE inhibitors given with aldesleukin

Allopurinol: increased risk of leucopenia and hypersensitivity reactions when ACE inhibitors given with allopurinol especially in renal impairment

Alpha-blockers: enhanced hypotensive effect when ACE inhibitors given with alpha-blockers

Anasthetics: General: enhanced hypotensive effect when ACE inhibitors given with general anaesthetics

Analgesics: increased risk in renal impairment when ACE inhibitors given with NSAIDs, also hypotensive effect antagonised

Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia when ACE inhibitors given with angiotensin-II receptor antagonists

Antacids: absorption of ACE inhibitors possibly reduced by antacids: absorption of captopril, enalapril and fosinopril reduced by antacids

Antibacterials: plasma concentration of active metabolite of imidapril reduced by rifampicin (reduced antihypertensive effect); quinapril tablets reduce absorption of tetracyclines (quinapril tablets contain magnesium carbonate); possible increased risk of hyperkalaemia when ACE inhibitors given with trimethoprim

Anticoagulants: increased risk of hyperkalaemia when ACE inhibitors given with anticoagulants

Antidepressants: hypotensive effect of ACE inhibitors possibly enhanced by MAOIs

Antidiabetics: ACE inhibitors possibly enhance hypo-glycaemic effect of insulin, metformin and sulfonylureas

Antipsychotics: enhanced hypotensive effect when ACE inhibitors given with antipsychotics

Anxiolytics and Hypnotics: enhanced hypotensive effect when ACE inhibitors given with anxiolytics and hypnotics

Azathioprine: increased risk of anaemia or leucopenia when captopril given with azathioprine especially in ACE inhibitors

ACE Inhibitors

Azathioprine (continued) renal impairment; increased risk of anaemia when enalapril given with azathioprine especially in renal impairment

Beta-blockers: enhanced hypotensive effect when ACE inhibitors given with beta-blockers

Calcium-channel blockers: enhanced hypotensive effect when ACE inhibitors given with calcium-channel blockers

Cardiac Glycosides: captopril possibly increases plasma concentration of digoxin

Clonidine: enhanced hypotensive effect when ACE inhibitors given with clonidine

Clonidine: antihypertensive effect of captopril possibly delayed by previous treatment with clonidine

Corticosteroids: hypotensive effect of ACE inhibitors antagonised by corticosteroids

Diazoxide: enhanced hypotensive effect when ACE inhibitors given with diazoxide

Diuretics: enhanced hypotensive effect when ACE inhibitors given with diuretics; increased risk of severe hyperkalaemia when ACE inhibitors given with potassium-sparing diuretics and aldosterone antagonists (monitor potassium concentration with low-dose spironolactone in heart failure)

Dopaminergics: enhanced hypotensive effect when ACE inhibitors given with levodopa

Lithium: ACE inhibitors reduce excretion of lithium (increased plasma concentration)

Methylprednisolone: enhanced hypotensive effect when ACE inhibitors given with methylprednisolone

Moxisylyte: enhanced hypotensive effect when ACE inhibitors given with moxisylyte

Moxonidine: enhanced hypotensive effect when ACE inhibitors given with moxonidine

Muscle Relaxants: enhanced hypotensive effect when ACE inhibitors given with baclofen or tizanidine

Nitrites: enhanced hypotensive effect when ACE inhibitors given with nitrites

Oestrogens: hypotensive effect of ACE inhibitors antagonised by oestrogens

Potassium Salts: increased risk of severe hyperkalaemia when ACE inhibitors given with potassium salts

Probenecid: excretion of captopril reduced by probenecid

Prostaglandins: enhanced hypotensive effect when ACE inhibitors given with prostaglandins

Sodium Aurothiomalate: flushing and hypertension reported when ACE inhibitors given with sodium aurothiomalate

Acetobutolol see Beta-blockers

Acelefontac see NSAIDs

Acemetacin see NSAIDs

Acmoocumaro see Coumarins

Acrizolamide see Diuretics

Aciclovir

Note: Interactions do not apply to topical aciclovir preparations

Note: Valaciclovir interactions as for aciclovir

Ciclosporin: increased risk of nephrotoxicity when aciclovir given with ciclosporin

Mycophenolate: plasma concentration of aciclovir increased by mycophenolate, also plasma concentration of inactive metabolite of mycophenolate increased

Probenecid: excretion of aciclovir reduced by probenecid (increased plasma concentration)

Tacrolimus: possible increased risk of nephrotoxicity when aciclovir given with tacrolimus

Theophylline: aciclovir possibly increases plasma concentration of theophylline
Appendix 1: Interactions

Adrenergic Neurone Blockers (continued)
Methylidopa: enhanced hypnotic effect when adrenergic neurone blockers given with methylidopa
Moxisylyte: enhanced hypnotic effect when adrenergic neurone blockers given with moxisylyte
Moxonidine: enhanced hypnotic effect when adrenergic neurone blockers given with moxonidine
Muscle Relaxants: enhanced hypnotic effect when adrenergic neurone blockers given with baclofen or tizanidine
Nitrites: enhanced hypnotic effect when adrenergic neurone blockers given with nitrates
Oestrogens: hypotensive effect of adrenergic neurone blockers antagonised by oestrogens
Pizotifen: hypotensive effect of adrenergic neurone blockers antagonised by pizotifen
Prostaglandins: increased risk of convulsions when alcohol given with prostaglandins
Vaccines: (see p. 746)
Antivirals: avoidance of adefovir advised by manufacturer of tenofovir
Anticoagulants: see Kaolin
Agalsidase Alfa and Beta
Anti-arrhythmics: effects of agalsidase alfa and beta possibly inhibited by amiodarone (manufacturers of agalsidase alfa and beta advise concomitant use)
Antibacterials: effects of agalsidase alfa and beta possibly inhibited by gentamicin (manufacturers of agalsidase alfa and beta advise concomitant use)
Antimalarials: effects of agalsidase alfa and beta possibly inhibited by chloroquine and hydroxychloroquine (manufacturers of agalsidase alfa and beta advise concomitant use)
Agomelatine
Antibacterials: manufacturer of agomelatine advises avoid concomitant use with ciprofloxacin
Antidepressants: metabolism of agomelatine inhibited by fluvoxamine (increased plasma concentration)
Antimalarials: avoidance of antidepressants advised by manufacturer of artesunate/malarone and some dealcoholised beverages contain tyramine
Alcohol
ACE Inhibitors: enhanced hypnotic effect when alcohol given with ACE inhibitors
Adrenergic Neurone Blockers: enhanced hypnotic effect when alcohol given with adrenergic neurone blockers
Alpha-blockers: increased sedative effect when alcohol given with indoramol; enhanced hypnotic effect when alcohol given with alpha-blockers
Analgesics: enhanced hypnotic and sedative effects when alcohol given with opioid analgesics
Angiotensin-II Receptor Antagonists: enhanced hypnotic effect when alcohol given with angiotensin-II receptor antagonists
Antibacterials: disulfiram-like reaction when alcohol given with metronidazole; possibility of disulfiram-like reaction when alcohol given with tinidazole; increased risk of convulsions when alcohol given with cyclizine
Anticausalant: major changes in consumption of alcohol may affect anticalausal control with some beverages containing alcohol and some dealcoholised beverages contain tyramine which interacts with MAOIs (hypertensive crisis)—if no tyramine, enhanced hypnotic effect; sedative effects possibly increased when alcohol given with calcium-channel Blockers: enhanced hypnotic effect when alcohol given with calcium-channel blocke
Clomipramine: enhanced hypnotic effect when adrenergic neurone blockers given with clomipramine
Corticosteroids: hypotensive effect of adrenergic neurone blockers antagonised by corticosteroids
Diazoxide: enhanced hypnotic effect when adrenergic neurone blockers given with diazoxide
Diuretics: enhanced hypnotic effect when adrenergic neurone blockers given with diuretics
Dopaminergics: enhanced hypnotic effect when adrenergic neurine blockers given with levodopa

Appendix 1: Interactions

Acitretin see Retinoids
Acrivastine see Antihistamines
Adalimumab
Abatacept: increased risk of side-effects when adalimumab given with abatacept
Anakinra: avoid concomitant use of adalimumab with anakinra
Vaccines: avoid concomitant use of adalimumab with live vaccines (see p. 746)
Adefovir
Antivirals: avoidance of adefovir advised by manufacturer of tenofovir
Adenosine
Note: Possibility of interaction with drugs tending to impair myocardial conduction
Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with bupivacaine, levobupivacaine, prilocaine or ropivacaine
Anti-arrhythmics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with anti-arrhythmics that prolong the QT interval
Beta-blockers: increased myocardial depression when anti-arrhythmics given with beta-blockers
Dipyridamole: effect of adenosine enhanced and extended by dipyridamole (important risk of toxicity)
Nicotine: effects of adenosine possibly enhanced by nicotine
Theophylline: anti-arrhythmic effect of adenosine antagonised by theophylline
Adrenaline (epinephrine) see Sympathomimetics

Adrenergic Neurone Blockers
Alcohol: enhanced hypnotic effect when adrenergic neurone blockers given with alcohol
Alpha-blockers: enhanced hypnotic effect when adrenergic neurone blockers given with alpha-blockers
Beta-blockers: increased hypnotic effect when adrenergic neurone blockers given with beta-blockers
Dipyridamole: effect of adenosine enhanced and extended by dipyridamole (important risk of toxicity)
Nicotine: effects of adenosine possibly enhanced by nicotine
Theophylline: anti-arrhythmic effect of adenosine antagonised by theophylline

Sympathomimetics see Antihistamines

802 Appendix 1: Interactions

BNF 61
Appendix 1: Interactions

Alcohol
- Antidepressants (continued)
  - SSRIs; increased sedative effect when alcohol given with mirtazapine, tricyclic-related
  - Antidepressants or tricyclics
  - Antidiabetics: alcohol enhances hypoglycaemic effect of antidiabetics; increased risk of lactic acidosis when alcohol given with metformin
  - Anti-infectives: alcohol possibly increases CNS side-effects of carbamazepine; chronic heavy consumption of alcohol possibly reduces plasma concentration of phenytoin; increased sedative effect when alcohol given with primidone
  - Antifungals: effects of alcohol possibly enhanced by griseofulvin
  - Antihistamines: increased sedative effect when alcohol given with antihistamines (possibly less effect with non-sedating antihistamines)
  - Antimuscarinicss: increased sedative effect when alcohol given with hyoscine
  - Antipsychotics: increased sedative effect when alcohol given with antipsychotics
  - Anxiolytics and Hypnotics: increased sedative effect when alcohol given with anxiolytics and hypnotics
  - Barbitalates: increased sedative effect when alcohol given with barbiturates
  - Beta-blockers: increased hypotensive effect when alcohol given with beta-blockers
  - Calcium-channel Blockers: enhanced hypotensive effect when alcohol given with calcium-channel blockers; plasma concentration of alcohol possibly increased by verapamil
  - Clonidine: enhanced hypotensive effect when alcohol given with clonidine
  - Cytoxics: disulfiram-like reaction when alcohol given with procarbazine
  - Diazoxide: enhanced hypotensive effect when alcohol given with diazoxide
  - Disulfiram: disulfiram reaction when alcohol given with disulfiram (see p. 310)
  - Diuretics: enhanced hypotensive effect when alcohol given with diuretics
  - Dopaminergics: alcohol reduces tolerance to bromocriptine
  - Levamisole: possibility of disulfiram-like reaction when alcohol given with levamisole
  - Lofexidine: increased sedative effect when alcohol given with lofevidine
  - Methyldopa: enhanced hypotensive effect when alcohol given with methyldopa
  - Moxonidine: enhanced hypotensive effect when alcohol given with moxonidine
  - Muscle Relaxants: increased sedative effect when alcohol given with baclofen, methocarbamol or tizanidine
  - Nabilone: increased sedative effect when alcohol given with nabilone
  - Nicorandil: alcohol possibly enhances hypotensive effect of nicorandil
  - Natriotes: enhanced hypotensive effect when alcohol given with nitrates
  - Paraldehyde: increased sedative effect when alcohol given with paraldehyde
  - Retinoids: presence of alcohol causes etretinate to be formed from acitretin (increased risk of teratogenicity in women of child-bearing potential)
  - Sympathomimetics: alcohol possibly enhances effects of methylphenidate
  - Vasodilator Antihypertensives: enhanced hypotensive effect when alcohol given with hydralazine, minoxidil or sodium nitroprusside

Aldesleukin
- ACE Inhibitors: increased risk of hypotensive effect when aldesleukin given with ACE inhibitors
  - Alpha-blockers: enhanced hypotensive effect when aldesleukin given with alpha-blockers

Aldesleukin (continued)
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when aldesleukin given with angiotensin-II receptor antagonists
  - Antivirals: aldesleukin possibly increases plasma concentration of indinavir
  - Beta-blockers: enhanced hypotensive effect when aldesleukin given with beta-blockers
  - Calcium-channel Blockers: enhanced hypotensive effect when aldesleukin given with calcium-channel blockers
  - Clonidine: enhanced hypotensive effect when aldesleukin given with clonidine
  - Corticosteroids: manufacturer of aldesleukin advises avoid concomitant use with corticosteroids
  - Cytoxotics: manufacturer of aldesleukin advises avoid concomitant use with cisplatin, dacarbazine and etoposide
  - Diazoxide: enhanced hypotensive effect when aldesleukin given with diazoxide
  - Diuretics: enhanced hypotensive effect when aldesleukin given with diuretics
  - Methyl-α-dopa: enhanced hypotensive effect when aldesleukin given with methyl-α-dopa
  - Moxonidine: enhanced hypotensive effect when aldesleukin given with moxonidine
  - Natriotes: enhanced hypotensive effect when aldesleukin given with nitrates
  - Vasodilator Antihypertensives: enhanced hypotensive effect when aldesleukin given with hydralazine, minoxidil or sodium nitroprusside

Alendronic Acid see Bisphosphonates
- Alfentanil see Opioid Analgesics
- Alifuozin see Alpha-blockers
- Alimemazine see Antihistamines
- Aliskiren
  - Analgesics: hypotensive effect of aliskiren possibly antagonised by NSAIDs
  - Angiotensin-II Receptor Antagonists: plasma concentration of aliskiren possibly reduced by irbesartan
  - Anticoaugulants: increased risk of hyperkalaemia when aliskiren given with heparins
  - Antifungals: plasma concentration of aliskiren increased by ketoconazole
  - Calcium-channel Blockers: manufacturer of aliskiren advises avoid concomitant use with verapamil
  - Ciclosporin: plasma concentration of aliskiren increased by ciclosporin—avoid concomitant use
  - Diuretics: aliskiren reduces plasma concentration of furosemide; increased risk of hyperkalaemia when aliskiren given with potassium-sparing diuretics and aldosterone antagonists
  - Potassium Salts: increased risk of hyperkalaemia
  - When aliskiren given with potassium salts

Alitretinoin see Retinoids
- Alkylyating Drugs see Bendamustine, Busulfan, Carmustine, Cyclophosphamide, Eastrumustine, Ifosfamide, Lomustine, Melphalan, and Thiopeta
- Allopurinol
  - ACE Inhibitors: increased risk of leucopenia and hypersensitivity reactions when allopurinol given with ACE inhibitors especially in renal impairment
  - Antibacterialitls: increased risk of rash when allopurinol given with amoxicillin or ampicillin
  - Anticoaugulants: allopurinol possibly enhances anti-coagulant effect of coumarins
  - Antivirals: allopurinol increases plasma concentration of didanosine (risk of toxicity)—avoid concomitant use
  - Azathioprine: allopurinol enhances effects and increases toxicity of mercaptopurine (reduce dose of azathioprine to one quarter of usual dose)
  - Ciclosporin: allopurinol possibly increases plasma concentration of ciclosporin (risk of nephrotoxicity)
  - Cytoxotics: allopurinol enhances effects and increases toxicity of mercaptopurine (reduce dose of mercaptopurine to one quarter of usual dose);
### Appendix 1: Interactions

#### Alpha-blockers (continued)

Oestrogens: hypotensive effect of alpha-blockers antagonised by oestrogens

Prostaglandins: enhanced hypotensive effect when alpha-blockers given with alprostadil

Sildenafil: enhanced hypotensive effect when alpha-blockers given with sildenafil (avoid alpha-blockers for 4 hours after sildenafil)—see also p. 515

Sympathomimetics: avoid concomitant use of tolazoline with adrenaline (epinephrine) or dopamine

Tadalafil: enhanced hypotensive effect when alpha-blockers given with tadalafil—manufacturer of tadalafil advises avoid concomitant use

Ulcer-healing Drugs: effects of tolazoline antagonised by cimetidine and ranitidine

Vardenafil: enhanced hypotensive effect when alpha-blockers (excludes tamsulosin) given with vardenafil—separate doses by 6 hours—see also p. 515

### Alloprinol

- Cytotoxics (continued): avoidance of alloprinol advised by manufacturer of 5-acetabamine

#### Diuretics

- increased risk of hypersensitivity when alloprinol given with thiazides and related diuretics especially in renal impairment

#### Theophylline

- alloprinol possibly increases plasma concentration of theophylline

#### Almotriptan see SHT, Agonists

#### Alpha-adrenoceptor Stimulants see Apraclonidine, Brimonidine, Clonidine and Methylene

#### Alpha-blockers

- ACE Inhibitors: enhanced hypotensive effect when alpha-blockers given with ACE inhibitors

#### Adrenergic Neurone Blockers: enhanced hypotensive effect when alpha-blockers given with adrenergic neurone blockers

#### Alcohol: enhanced hypotensive effect when alpha-blockers given with alcohol; increased sedative effect when indomarin given with alcohol

#### Aldesleukin: enhanced hypotensive effect when alpha-blockers given with aldesleukin

#### Alpha-blockers, General: enhanced hypotensive effect when alpha-blockers given with general anaesthetics

#### Analgesics: hypotensive effect of alpha-blockers antagonised by NSAIDs

#### Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when alpha-blockers given with angiotensin-II receptor antagonists

#### Antihypertensives: enhanced hypotensive effect when alpha-blockers given with MAOIs; manufacturer of indomarin advises avoid concomitant use with MAOIs

#### Antifungals: plasma concentration of aluzofosin possibly increased by ketoconazole

#### Antipsychotics: enhanced hypotensive effect when alpha-blockers given with antipsychotics

#### Antidepressants: enhanced hypotensive effect when alpha-blockers given with antidepressants

#### Antiarrhythmics: enhanced hypotensive effect when alpha-blockers given with antiarrhythmics and Hypnotics

#### Beta-blockers: enhanced hypotensive effect when alpha-blockers given with beta-blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin

#### Calcium-channel Blockers: enhanced hypotensive effect when alpha-blockers given with calcium-channel blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin

#### Cardiac Glycerides: prazosin increases plasma concentration of digoxin

#### Clonidine: enhanced hypotensive effect when alpha-blockers given with clonidine

#### Corticosteroids: hypotensive effect of alpha-blockers antagonised by corticosteroids

#### Diazoxide: enhanced hypotensive effect when alpha-blockers given with diazoxide

#### Diuretics: enhanced hypotensive effect when alpha-blockers given with diuretics, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin

#### Dopaminergic: enhanced hypotensive effect when alpha-blockers given with dopamine

#### Methylene: increased risk of extrapyramidal side-effects when alpha-blockers given with methyldopa; antiparkinsonian effect of dopaminergics antagonised by methyldopa

#### Tetrabenazine: increased risk of extrapyramidal side-effects when alpha-blockers given with tetrabenazine

#### Amikacin see Aminoglycosides

#### Almikacin see Aminoglycosides

#### Amiloride see Diuretics

#### Aminoglycosides

- Agalsidase Alfa and Beta: gentamicin possibly inhibits effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)

#### Analgesics: plasma concentration of agalsidase alfa and beta possibly increased by indomethacin

#### Antibacterials: neomycin reduces absorption of phe-noxy-methylpenicillin; increased risk of nephrotoxicity when aminoglycosides given with colistin or polymyxins; increased risk of nephrotoxicity and ototoxicity when aminoglycosides given with capreomycin or vancomycin; possible increased risk of nephrotoxicity when aminoglycosides given with cephalosporins

#### Anticoagulants: experience in anticoagulant clinics suggests that INR possibly altered when neomycin (given for local action on gut) is given with coumarins or phenindione

#### Anaesthetic: neomycin possibly enhances hypoglycaemic effect of acarbose, also severity of gastrointestinal effects increased

#### Antihypertensives: increased risk of nephrotoxicity when aminoglycosides given with amphotericin

#### Anti-infectives: experience in anticoagulant clinics suggests that INR possibly altered when neomycin (given for local action on gut) is given with coumarins or phenindione

#### Anticoagulants: increased risk of hypocalcaemia when aminoglycosides given with bisphosphonates

#### Cardiac Glycerides: neomycin reduces absorption of digoxin; gentamicin possibly increases plasma concentration of digoxin
Antivirals:  
· Ciclosporin: increased risk of nephrotoxicity when aminoglycosides given with ciclosporin  
· Co-trimoxazole: increased risk of ventricular arrhythmias; increased risk of ventricular arrhythmias when amiodarone given with rifampicin

Antimalarials:  
· Artesunate: increased risk of nephrotoxicity when aminoglycosides given with mefloquine—avoid concomitant use

Antiepileptics:  
· Lamotrigine: increased risk of nephrotoxicity when aminoglycosides are given with valproic acid

Antidepressants:  
· Duloxetine: increased risk of ventricular arrhythmias when amiodarone given with duloxetine

Anti-arrhythmics:  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with verapamil

Parasympathomimetics:  
· Muscarinic cholinergic antagonists: increased risk of toxicity when aminoglycosides given with loop diuretics

Muscle Relaxants:  
· Aminoglycosides: increased risk of toxicity when aminoglycosides given with non-depolarising muscle relaxants and etidronate disodium

Diuretics:  
· Furosemide: increased risk of ventricular arrhythmias when amiodarone given with diuretics

Aminoglycosides: (continued)  
· Cilastatin: increased risk of toxicity when aminoglycosides given with cilastatin

Cardiac Glycosides:  
· Digoxin: increased risk of ventricular arrhythmias when amiodarone given with digoxin

Antipsychotics:  
· Chlorpromazine: increased risk of ventricular arrhythmias when amiodarone given with chlorpromazine

Anticoagulants:  
· Warfarin: increased risk of bleeding when amiodarone given with warfarin

Antihistamines:  
· Desloratadine: increased risk of bleeding when amiodarone given with desloratadine

Anti-leukotrienes:  
· Leukotriene antagonists: increased risk of bleeding when amiodarone given with leukotriene antagonists

Calcium-channel Blockers:  
· Diltiazem: increased risk of ventricular arrhythmias when amiodarone given with diltiazem

Beta-blockers:  
· Propranolol: increased risk of ventricular arrhythmias when amiodarone given with propranolol

Loop diuretics:  
· Furosemide: increased risk of ventricular arrhythmias when amiodarone given with furosemide

Thyroid Hormones:  
· Levothyroxine: increased risk of ventricular arrhythmias when amiodarone given with levothyroxine

Antimuscarinics:  
· Pirenzepine: increased risk of ventricular arrhythmias when amiodarone given with pirenzepine

Antihypertensives:  
· Amlodipine: increased risk of ventricular arrhythmias when amiodarone given with amlodipine

Cystotoxics:  
· Cisplatin: increased risk of nephrotoxicity when aminoglycosides are given with cisplatin

Colchicine:  
· Colchicine: increased risk of bleeding when amiodarone given with colchicine

Calcium-sparing Diuretics:  
· Spironolactone: increased risk of bleeding when amiodarone given with spironolactone

Lipid-regulating Drugs:  
· Lovastatin: increased risk of myopathy when amiodarone given with lovastatin

Orlistat:  
· Orlistat: increased risk of bleeding when amiodarone given with orlistat

Amisulpride see Antipsychotics

Amitriptyline see Antidepressants, Tricyclic

Amlodipine see Calcium-channel Blockers

Amobarbital see Barbirurates

Amodarone (continued)  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with boloterodine

Antipsychotics: increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval

Amiodarone (continued)  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with amiodarone increased by cimetidine

Antidepressants: increased risk of ventricular arrhythmias when amiodarone given with antidepressants that concomitantly increase plasma concentration of amiodarone

Anticoagulants: amiodarone inhibits metabolism of warfarin and warfarin antagonists: increased risk of bleeding when amiodarone given with warfarin and warfarin antagonists

Antihistamines: increased risk of bleeding when amiodarone given with antihistamines

Antileukotrienes: increased risk of bleeding when amiodarone given with antileukotrienes

Calcium-channel Blockers: increased risk of bleeding when amiodarone given with calcium-channel blockers

Beta-blockers: increased risk of bleeding when amiodarone given with beta-blockers

Loop diuretics: increased risk of bleeding when amiodarone given with loop diuretics

Thyroid Hormones: increased risk of bleeding when amiodarone given with thyroid hormones

Orlistat: increased risk of bleeding when amiodarone given with orlistat

Amisulpride see Antipsychotics

Amitriptyline see Antidepressants, Tricyclic

Amlodipine see Calcium-channel Blockers

Amobarbital see Barbirurates

Amodarone (continued)  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with boloterodine

Antipsychotics: increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when amiodarone given with antipsychotics that prolong the QT interval

Amiodarone (continued)  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with cimetidine

Antidepressants: increased risk of ventricular arrhythmias when amiodarone given with antidepressants that concomitantly increase plasma concentration of amiodarone

Anticoagulants: amiodarone inhibits metabolism of warfarin and warfarin antagonists: increased risk of bleeding when amiodarone given with warfarin and warfarin antagonists

Antihistamines: increased risk of bleeding when amiodarone given with antihistamines

Antileukotrienes: increased risk of bleeding when amiodarone given with antileukotrienes

Calcium-channel Blockers: increased risk of bleeding when amiodarone given with calcium-channel blockers

Beta-blockers: increased risk of bleeding when amiodarone given with beta-blockers

Loop diuretics: increased risk of bleeding when amiodarone given with loop diuretics

Thyroid Hormones: increased risk of bleeding when amiodarone given with thyroid hormones

Orlistat: increased risk of bleeding when amiodarone given with orlistat

Amisulpride see Antipsychotics

Amitriptyline see Antidepressants, Tricyclic

Amlodipine see Calcium-channel Blockers

Amobarbital see Barbirurates

Amodarone (continued)  
· Amiodarone: increased risk of ventricular arrhythmias when amiodarone given with boloterodine
Amphotericin
Note Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics
Antibacterials: increased risk of nephrotoxicity when amphotericin given with aminoglycosides or polymyxins; possible increased risk of nephrotoxicity when amphotericin given with vancomycin
Antifungals: amphotericin reduces renal excretion and increases cellular uptake of flucytosine (toxicity possibly increased); effects of amphotericin possibly antagonised by imidazoles and triazoles; plasma concentration of amphotericin possibly increased by fluconazol
Cardiac Glycosides: hypokalaemia caused by amphotericin increases cardiac toxicity with cardiac glycosides
Ciclosporin: increased risk of nephrotoxicity when amphotericin given with ciclosporin
Corticosteroids: increased risk of hypokalaemia when amphotericin given with corticosteroids; needed to control reactions
Cytotoxics: increased risk of ventilatory arrhythmias when amphotericin given with ciclosporin—avoid concomitant use unless corticosteroids needed to control reactions
Diuretics: increased risk of hypokalaemia when amphotericin given with loop diuretics or thiazides and related diuretics
Vasodilator Antihypertensives: effects of thiopental possibly enhanced by clonidine
Analgesics, General (intravenous) see Anaesthetics, General (intravenous)

Anamphetamines: enhanced hypotensive effect when general anaesthetics given with methyldopa
Antidepressants: increased risk of arrhythmias when volatile liquid general anaesthetics given with methyldopa
Dopaminergics: increased risk of arrhythmias when volatile liquid general anaesthetics given with levodopa
Diuretics: increased hypotensive effect when general anaesthetics given with diuretics
Vasodilator Antihypertensives: increased hypotensive effect when general anaesthetics given with methyldopa

Anesthesia, General (continued)
Cytotoxics: nitrous oxide increases antifolate effect of etoposide; methotrexate—avoid concomitant use
Methotrexate: increased hypotensive effect when general anaesthetics given with methotrexate
Diuretics: enhanced hypotensive effect when general anaesthetics given with diuretics
Dopaminergics: increased risk of arrhythmias when volatile liquid general anaesthetics given with levodopa
Diuretics: increased hypotensive effect when general anaesthetics given with diuretics

Anesthesia, General (vaporized) see Anaesthesia, General

Anesthetics, General
Note See also Surgery and Long-term Medication, p. 775
ACE Inhibitors: enhanced hypotensive effect when general anaesthetics given with ACE inhibitors
Adrenergic Neurone Blockers: enhanced hypotensive effect when general anaesthetics given with adrenergic neurone blockers
Alpha-blockers: enhanced hypotensive effect when general anaesthetics given with alpha-blockers
Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when general anaesthetics given with angiotensin-II receptor antagonists
Antibacterials: metabolism of etomidate inhibited by fentanyl (consider reducing dose of etomidate); effects of thialpine possibly enhanced by aspirin; effects of intravenous general anaesthetics and volatile liquid general anaesthetics possibly enhanced by opioid analgesics
Beta-blockers: enhanced hypotensive effect when general anaesthetics given with beta-blockers
Blot-solvents: increased risk of arrhythmias and hypotension when general anaesthetics given with tricyclics
Antipsychotics: enhanced hypotensive effect when general anaesthetics given with antipsychotics; effects of thialpine enhanced by droperidol
Anxiolytics and Hypnotics: increased sedative effect when general anaesthetics given with anxiolytics and hypnotics

Analgésics see Analgesics
Cytotoxics:

Angiotensin-II Receptor Antagonists

ACE Inhibitors: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with ACE inhibitors

Adrenergic Neurone Blockers: enhanced hypotensive effect when angiotensin-II receptor antagonists given with adrenergic neurone blockers

Alcohol: enhanced hypotensive effect when angiotensin-II receptor antagonists given with alcohol

Aldesleukin: enhanced hypotensive effect when angiotensin-II receptor antagonists given with aldesleukin

Alikiren: rbesanat possibly reduces plasma concentration of aikoiren

Alpha-blockers: enhanced hypotensive effect when angiotensin-II receptor antagonists given with alpha-blockers

Analgesics, General: enhanced hypotensive effect when angiotensin-II receptor antagonists given with general anaesthetics

Analgesics: increased risk of renal impairment when angiotensin-II receptor antagonists given with NSAIDs, also hypotensive effect antagonised

Antibacterials: plasma concentration of losaratan and its active metabolite reduced by rifampin; possible increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with trimethoprim

Anticoagulants: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with heparins

Antidepressants: hypotensive effect of angiotensin-II receptor antagonists possibly enhanced by MAOIs

Antipsyucotics: enhanced hypotensive effect when angiotensin-II receptor antagonists given with anti-psychotics

Anxiolytics and Hypnotics: enhanced hypotensive effect when angiotensin-II receptor antagonists given with anxiolytics and hypnotics

Beta-blockers: enhanced hypotensive effect when angiotensin-II receptor antagonists given with beta-blockers

Calcium-channel Blockers: enhanced hypotensive effect when angiotensin-II receptor antagonists given with calcium-channel blockers

Ciclosporin: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with ciclosporin

Clonidine: enhanced hypotensive effect when angiotensin-II receptor antagonists given with clonidine

Corticosteroids: hypotensive effect of angiotensin-II receptor antagonists antagonised by corticosteroids

Diazoxide: enhanced hypotensive effect when angiotensin-II receptor antagonists given with diazoxide

Diuretics: enhanced hypotensive effect when angiotensin-II receptor antagonists given with diuretics; increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with potassium-sparing diuretics and aldosterone antagonists

Dopaminergics: enhanced hypotensive effect when angiotensin-II receptor antagonists given with levo-dopa

Lithium: angiotensin-II receptor antagonists reduce excretion of lithium (increased plasma concentration)

Methyldopa: enhanced hypotensive effect when angiotensin-II receptor antagonists given with methyldopa

Moxisylyte: enhanced hypotensive effect when angiotensin-II receptor antagonists given with moxisylyte

Moxonidine: enhanced hypotensive effect when angiotensin-II receptor antagonists given with moxonidine

Muscle Relaxants: enhanced hypotensive effect when angiotensin-II receptor antagonists given with baclofen or tizanidine

Nitrates: enhanced hypotensive effect when angiotensin-II receptor antagonists given with nitrates

Note: Antacids should preferably not be taken at the same time as other drugs since they may impair absorption

ACE Inhibitors: antacids possibly reduce absorption of ACE inhibitors; antacids reduce absorption of captopril, enalapril and fosinopril

Analgesics: alkaline urine due to some antacids increases excretion of aspirin

Antibacterials: antacids reduce absorption of azithromycin, cefaclor, cefpodoxime, ciprofloxacin, ivermectin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, rifampin and tetracyclines; avoid concomitant use of antacids with methenamine; oral magnesium salts (as magnesium trisilicate) reduce absorption of nitrofurantoin

Antiepileptics: antacids reduce absorption of gabapentin and phenytoin

Antifungals: antacids reduce absorption of itraconazole and ketoconazole

Antihistamines: antacids reduce absorption of fexofenadine

Antimalarials: antacids reduce absorption of chloroquine and hydroxychloroquine; oral magnesium salts (as magnesium trisilicate) reduce absorption of proguanil

Antipsyucotics: antacids reduce absorption of phenothiazines and sulphide

Antirheumatics: antacids possibly reduce plasma concentration of azastavir; antacids reduce absorption of tipranavir

Bile Acids: antacids possibly reduce absorption of bile acids

Bisphosphonates: antacids reduce absorption of bisphosphonates

Cardiac Glycosides: antacids possibly reduce absorption of digoxin

Corticosteroids: antacids reduce absorption of defla-siurosart

Cytotoxicss: antacids possibly reduce plasma concentration of erlotinib—give antacids at least 4 hours before or 2 hours after erlotinib

Deferasirox: antacids containing aluminium possibly reduce absorption of deferasirox (manufacturer of deferasirox advises avoid concomitant use)

Dipyridamole: antacids possibly reduce absorption of dipyridamole

Erbetropovap: antacids reduce absorption of eltrobro-pap (give at least 4 hours apart)

Iron: oral magnesium salts (as magnesium trisilicate) reduce absorption of oral iron

Lipid-regulating Drugs: antacids reduce absorption of rosuvastatin

Lithium: sodium bicarbonate increases excretion of lithium (reduced plasma concentration)

Mycophenolate: antacids reduce absorption of mycophenolate

Penicillamine: antacids reduce absorption of penicillamine

Polystyrene Sulphonate Resins: risk of intestinal obstruction when aluminium hydroxide given with polystyrene sulphonate resins; risk of metabolic

Appendix 1: Interactions 807

Appendix 1: Interactions

Angiotensin-II Receptor Antagonists (continued)

Oestrogens: hypotensive effect of angiotensin-II receptor antagonists antagonised by oestrogens

Potassium Salts: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with potassium salts

Prostaglandins: enhanced hypotensive effect when angiotensin-II receptor antagonists given with aspirin

Tacroplmus: increased risk of hyperkalaemia when angiotensin-II receptor antagonists given with tacrolimus

Vasodilator Antihypertensives: enhanced hypotensive effect when angiotensin-II receptor antagonists given with hydralazine, minoxidil or sodium nitroprusside
Antacids
Polyvalent Sulphonate Resins (continued)
-alcoholism when oral magnesium salts given with polysulphonate resins
Thyroid Hormones: antacids possibly reduce absorption of levothyroxine
Ulcer-healing Drugs: antacids possibly reduce absorption of lansoprazole
● Ulipristal: avoidance of antacids advised by manufacturer of ulipristal (plasma concentration of ulipristal possibly reduced)
Antazoline see Antihistamines
Anti-arrhythmics see Adenosine, Amiodarone, Disopyramide, Dronedarone, Flecainide, Lidocaine, and Propafenone
Antibacterials see individual drugs
Anticoagulants see Coumarins, Dabigatran etexilate, Heparins, Phenindione, and Rivaroxaban
Antidepressants see Agomelatine; Antidepressants, SSRI; Antidepressants, Tricyclic; Antidepressants, Venlafaxine
Antidepressants, Noradrenaline Re-uptake Inhibitors see Reboxetine
Antidepressants, SSRI
Alcohol: sedative effects possibly increased when SSRIs given with alcohol
Anaesthetics, Local: fluvoxamine inhibits metabolism of ropivacaine—avoid prolonged administration of ropivacaine
● Analgesics: increased risk of bleeding when SSRIs given with NSAIDs or aspirin; fluoxetine, fluvoxamine, paroxetine and sertraline possibly increase plasma concentration of methadone; increased risk of CNS toxicity when SSRIs given with tramadol
Anti-arrhythmics: fluoxetine increases plasma concentration of flecainide; paroxetine possibly inhibits metabolism of propafenone (increased risk of toxicity)
● Anticoagulants: SSRIs possibly enhance anticoagulant effect of coumarins
● Antidepressants: avoidance of fluoxetine advised by manufacturer of venlafaxine; possible increased serotoninergic effects when SSRIs given with duloxetine; fluoxetine inhibits metabolism of duloxetine; fluvoxamine increases plasma concentration of duloxetine; paroxetine possibly increases plasma concentration of duloxetine; paroxetine inhibits metabolism of duloxetine; fluvoxamine possibly inhibits metabolism of duloxetine
Antidepressants, Tricyclic; Antidepressants, Venlafaxine
Antihistamines: antiparkinsonian effect of SSRIs possibly increased by cyproheptadine
Antipsychotics: avoidance of fluoxetine, fluvoxamine or sertraline advised by manufacturer of droperidol (risk of ventricular arrhythmias); fluoxetine increases plasma concentration of clozapine, haloperidol and risperidone; fluvoxamine possibly increases plasma concentration of haloperidol; paroxetine inhibits metabolism of perphenazine (reduce dose of perphenazine); fluoxetine and paroxetine possibly inhibit metabolism of aripiprazole (reduce dose of aripiprazole); citalopram possibly increases plasma concentration of clozapine (increased risk of toxicity); fluvoxamine, paroxetine and sertraline increase plasma concentration of clozapine; fluvoxamine increases plasma concentration of olanzapine; SSRIs possibly increase plasma concentration of olanzapine
● Antivirals: plasma concentration of paroxetine and sertraline possibly reduced by darunavir; plasma concentration of paroxetine possibly reduced by ritonavir; plasma concentration of SSRIs possibly increased by ritonavir
● Anxiolytics and Hypnotics: fluoxetine increases plasma concentration of alprazolam; fluvoxamine increases plasma concentration of some benzodiazepines; fluvoxamine increases plasma concentration of temazepam; fluvoxamine and paroxetine possibly increase plasma concentration of olanzapine; SSRIs possibly increase plasma concentration of olanzapine
● Antiparkinsonians: avoid concomitant use; fluoxetine and paroxetine increase plasma concentration of dopamine; fluoxetine possibly increases plasma concentration of dopamine

Antidepressants, SSRI (continued)
● Antiepileptics (continued)
   concentration of carbamazepine; plasma concentration of sertraline possibly reduced by phenytoin, also plasma concentration of phenytoin possibly increased; plasma concentration of paroxetine reduced by phenytoin and primidone; fluoxetine and fluvoxamine increase plasma concentration of phenytoin
Antihistamines: antidepressant effect of SSRIs possibly antagonised by cyproheptadine
● Antimalarials: avoidance of antidepressants advised by manufacturer of artether/lumefantrine
Antipsychotics: fluoxetine increases plasma concentration of darifenacin and procyclidine
Antipsychotics: avoidance of fluoxetine, fluvoxamine or sertraline advised by manufacturer of droperidol (risk of ventricular arrhythmias); fluoxetine increases plasma concentration of clozapine, haloperidol and risperidone; fluvoxamine possibly increases plasma concentration of haloperidol; paroxetine inhibits metabolism of perphenazine (reduce dose of perphenazine); fluoxetine and paroxetine possibly inhibit metabolism of aripiprazole (reduce dose of aripiprazole); citalopram possibly increases plasma concentration of clozapine (increased risk of toxicity); fluvoxamine, paroxetine and sertraline increase plasma concentration of clozapine; fluvoxamine increases plasma concentration of olanzapine; SSRIs possibly increase plasma concentration of olanzapine
● Antivirals: plasma concentration of paroxetine and sertraline possibly reduced by darunavir; plasma concentration of paroxetine possibly reduced by ritonavir; plasma concentration of SSRIs possibly increased by ritonavir
● Anxiolytics and Hypnotics: fluoxetine increases plasma concentration of alprazolam; fluvoxamine increases plasma concentration of some benzodiazepines; fluvoxamine increases plasma concentration of temazepam; fluvoxamine and paroxetine possibly increase plasma concentration of olanzapine; SSRIs possibly increase plasma concentration of olanzapine
● Antiparkinsonians: avoid concomitant use; fluoxetine and paroxetine increase plasma concentration of dopamine; fluoxetine possibly increases plasma concentration of dopamine

Appendix 1: Interactions

BNF 61

808 Appendix 1: Interactions
Antidepressants, SSRI
- Dopaminergics (continued)
  2 weeks after stopping selegiline: increased risk of hypertension and CNS excitation when fluvoxamine or sertraline given with selegiline (selegiline should not be started until 1 week after stopping fluvoxamine or sertraline, avoid fluvoxamine or sertraline for 2 weeks after stopping selegiline); increased risk of hypertension and CNS excitation when fluoxetine given with selegiline (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline); avoidance of citalopram and escitalopram advised by manufacturer of selegiline
- Norepinephrine Antagonists: fluoxetine and paroxetine possibly inhibit metabolism of clomipramine to active metabolite (avoid concomitant use)
- SHT, Agonists: fluvoxamine inhibits the metabolism of noradrenaline; increased risk of CNS toxicity when citalopram, escitalopram, fluoxetine, fluvoxamine or paroxetine given with sumatriptan; CNS toxicity reported when sertraline given with sumatriptan; fluvoxamine possibly inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)
- Lithium: Increased risk of CNS effects when SSRIs given with lithium (lithium toxicity reported)
- Muscle Relaxants: fluvoxamine increases plasma concentration of galantamine
- Ranolazine: paroxetine increases plasma concentration of ranolazine
- Rofumilast: fluvoxamine inhibits the metabolism of rofumilast
- Sympathomimetics: metabolism of SSRIs possibly inhibited by methylphenidate
- Theophylline: fluvoxamine increases plasma concentration of theophylline (concomitant use should usually be avoided, but where not possible halve theophylline dose and monitor plasma-theophylline concentration)
- Ulcer-healing Drugs: plasma concentration of citalopram, escitalopram and sertraline increased by omeprazole; plasma concentration of Lansoprazole; plasma concentration of escitalopram increased by omeprazole
- Antidepressants, SSRI (related) see Duloxetine and Venlafaxine
- Antidepressants, Tricyclic
- Adrenergic Neurone Blockers: tricyclics antagonise hypotensive effect of adrenergic neurone blockers
- Alcohol: increased sedative effect when tricyclics given with alcohol
- Alpha2-adrenoceptor Stimulants: avoidance of tricyclics advised by manufacturer of apraclonidine and brimonidine
- Anaesthetics, General: increased risk of arrhythmias and hypotension when tricyclics given with general anaesthetics
- Analgesics: increased risk of CNS toxicity when tricyclics given with tramadol; side-effects possibly increased when tricyclics given with nefopam; sedative effects possibly increased when tricyclics given with opioid analgesics
- Anti-arrhythmics: increased risk of ventricular arrhythmias when tricyclics given with disopyramide or flecainide; avoidance of tricyclics advised by manufacturer of disopyramide (risk of ventricular arrhythmias); increased risk of arrhythmias when tricyclics given with propranolone
- Anti-bacterials: increased risk of ventricular arrhythmias when tricyclics given with moxifloxacin—avoid concomitant use

Antidepressants, Tricyclic (continued)
- Anticoagulants: tricyclics may enhance or reduce anticoagulant effect of coumarins
- Antidepressants: increased risk of serotoninergic effects when amitriptyline or clomipramine given with duloxetine; increased risk of hypertension and CNS excitation when tricyclics given with MAOIs, tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine); after stopping tricyclics do not start moclobemide for at least 1 week; plasma concentration of some tricyclics increased by SSRIs; plasma concentration of amitriptyline reduced by St John’s wort
- Antiepileptics: tricyclics antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered); metabolism of tricyclics accelerated by carbamazepine (reduced plasma concentration and reduced effect); plasma concentration of tricyclics possibly reduced by phenytoin; tricyclics antagonises anticonvulsant effect of primidone (convulsive threshold lowered), also metabolism of tricyclics possibly accelerated (reduced plasma concentration) Antifungals: plasma concentration of tricyclics possibly increased by terbinafine
- Antihistamines: increased antimuscarinic and sedative effects when tricyclics given with antihistamines
- Antimalarials: avoidance of antidepressants advised by manufacturer of arteether/lumefantrine Antimuscarinics: increased risk of antimuscarinic side-effects when tricyclics given with antimuscarinics
- Antipsychotics: plasma concentration of tricyclics increased by antipsychotics—possibly increased risk of ventricular arrhythmias; avoidance of tricyclics advised by manufacturer of clozapine; increased risk of antimuscarinic side-effects when tricyclics given with phenothiazines; increased risk of ventricular arrhythmias when tricyclics given with pimozide—avoid concomitant use
- Antivirals: plasma concentration of tricyclics possibly increased by ritonavir; increased risk of ventricular arrhythmias when tricyclics given with saquinavir—avoid concomitant use Antioxidants and Hypnotics: increased sedative effect when tricyclics given with anxiolytics and hypnotics
- Atomoxetine: increased risk of ventricular arrhythmias when tricyclics given with atomoxetine; possible increased risk of convulsions when antidepressants given with atomoxetine
- Barbiturates: tricyclics antagonises anticonvulsant effect of barbiturates (convulsive threshold lowered), also metabolism of tricyclics possibly accelerated (reduced plasma concentration)
- Beta-blockers: plasma concentration of imipramine given with labetalol and propranolol; increased risk of ventricular arrhythmias when tricyclics given with metoprolol
- Bupropion: plasma concentration of tricyclics possibly increased by bupropion (possible increased risk of convulsions)
- Calcium-channel Blockers: plasma concentration of tricyclics possibly increased by diltiazem and verapamil; plasma concentration of imipramine increased by diltiazem and verapamil
- Cannabis Extract: possible increased risk of hypertension and tachycardia when tricyclics given with cannabis extract
- Clonidine: tricyclics antagonise hypotensive effect of clonidine, also increased risk of hypertension on clonidine withdrawal
- Cytotoxics: increased risk of ventricular arrhythmias when amitriptyline or clomipramine given with arsenic trioxide
- Disopyramide: possible increased risk of ventricular arrhythmias when tricyclics given with disopyramide
Antidepressants, Tricyclic (continued)

Disulfiram: metabolism of tricyclics inhibited by disulfiram (increased plasma concentration); concomitant amitriptyline reported to increase disulfiram reaction with alcohol

Diuretics: increased risk of postural hypotension when tricyclics given with diuretics

Dopaminergics: caution with tricyclics advised by manufacturer of entacapone; increased risk of CNS toxicity when tricyclics given with rasagline; CNS toxicity reported when tricyclics given with selegiline

Histamine: tricyclics theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use

Lithium: risk of toxicity when tricyclics given with lithium

Moxonidine: tricyclics possibly antagonise hypotensive effect of moxonidine (manufacturer of moxonidine advises avoid concomitant use)

Muscle Relaxants: tricyclics enhance muscle relaxant effect of baclofen

Nortriptyline: tricyclics possibly enhance hypotensive effect of nicardipine

Nitrites: tricyclics reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)

Oestrogens: antidepressant effect of tricyclic-related antidepressants possibly increased by oestrogens (but side-effects of tricyclics possibly increased due to increased plasma concentration)

Pentamidine isetionate: increased risk of venricular arrhythmias when tricyclics given with pentamidine isetionate

Sodium Oxybate: increased risk of side-effects when tricyclics given with sodium oxybate

Sympathomimetics: increased risk of hypertension and arrhythmias when tricyclics given with adrenaline (epinephrine) (but local anaesthetics with adrenaline appear to be safe); metabolism of tricyclics possibly inhibited by methylphenidate; increased risk of hypertension and arrhythmias when tricyclics given with noradrenaline (norepinephrine)

Thyroid Hormones: effects of tricyclics possibly enhanced by thyroid hormones; effects of amitriptyline and imipramine enhanced by thyroid hormones

Ulcer-healing Drugs: plasma concentration of tricyclics possibly increased by cimetidine; metabolism of amitriptyline, doxepin, imipramine and nortriptyline inhibited by cimetidine (increased plasma concentration)

Antidepressants, Tricyclic (related)

Alcohol: increased sedative effect when tricyclic-related antidepressants given with alcohol

Alpha₂-adrenoceptor Stimulants: avoidance of tricyclic-related antidepressants advised by manufacturer of apraclonidine and brimonidine

Anticoagulants: trazodone may enhance or reduce anticoagulant effect of warfarin

Antidepressants: tricyclic-related antidepressants should not be started until 2 weeks after stopping tricyclic-related antidepressants; after stopping tricyclic-related antidepressants do not start moclobemide for at least 1 week

Antiepileptics: tricyclic-related antidepressants possibly antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered); metabolism of mianserin accelerated by phenytoin (reduced effect); effects of sulfonylureas rarely enhanced by sulfinpyrazone—manufacturer advises avoid concomitant use

Antidepressants: hypoglycaemic effect of antidiabetics possibly enhanced by MAOIs; hypoglycaemic effect of insulin, metformin and sulfonylureas possibly enhanced by diuretics; hypoglycaemic effect of acarbose possibly increased by topiramate or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption

ACE Inhibitors: hypoglycaemic effect of insulin, metformin and sulfonylureas possibly enhanced by ACE inhibitors

Alcohol: hypoglycaemic effect of antidiabetics enhanced by alcohol; increased risk of lactic acidosis when metformin given with alcohol

Anabolic Steroids: hypoglycaemic effect of anti-diabetics possibly enhanced by anabolic steroids

Analgesics: effects of sulfonylureas possibly enhanced by NSAIDs

Anti-arrhythmics: hypoglycaemic effect of glitazones, insulin and metformin possibly enhanced by diuretics

Antibacterials: hypoglycaemic effect of acarbose possibly increased by neomycin, also severity of gastrointestinal effects increased; effects of repaglinide enhanced by clarithromycin; effects of sulfonylureas possibly enhanced by rifampicin; metabolism of tolbutamide accelerated by rifampicin (reduced effect); effects of sulfonylureas rarely enhanced by sulfonamides and trimethoprim; hypoglycaemic effect of sulfonylureas possibly enhanced by tetracyclines; hypoglycaemic effect of repaglinide possibly enhanced by trimethoprim—manufacturer advises avoid concomitant use

Anticonvulsants: exenatide possibly enhances anticonvulsant effect of warfarin; hypoglycaemic effect of sulfonylureas possibly enhanced by cimtemidine, also possible change to anticonvulsant effect

Antidepressants: hypoglycaemic effect of anti-diabetics possibly enhanced by MAOIs; hypoglycaemic effect of insulin, metformin and sulfonylureas enhanced by MAOIs

Antiepileptics: tolbutamide transiently increases plasma concentration of phenytoin (possibility of toxicity); plasma concentration of glibenclamide possibly reduced by topiramate; plasma concentration of metformin possibly increased by topiramate
Antidiabetics (continued)
- Antifungals: plasma concentration of sulfonylureas increased by fluconazole and miconazole; hypoglycaemic effect of glimepiride and glipizide enhanced by miconazole—avoid concomitant use; hypoglycaemic effect of nateglinide possibly increased by gemfibrozil; plasma concentration of sulfonylureas possibly enhanced by voriconazole

Antihistamines: thrombocyte count depressed when metformin given with ketotifen (manufacturer of ketotifen advises avoid concomitant use)

Antipsychotics: hypoglycaemic effect of sulfonylureas possibly antagonised by phenothiazines

Antivirals: plasma concentration of tolbutamide possibly increased by ritonavir

Aprepitant: plasma concentration of tolbutamide reduced by aprepitant

Beta-blockers: warning signs of hypoglycaemia (such as tremor) with antidiabetics may be masked when given with beta-blockers; hypoglycaemic effect of insulin enhanced by beta-blockers

Bosentan: increased risk of hepatotoxicity when glibenclamide given with bosentan—avoid concomitant use

Calcium-channel Blockers: glucose tolerance occasionally impaired when insulin given with nifedipine

Cardiac Glycosides: acarbose possibly reduces plasma concentration of digoxin; sitagliptin increases plasma concentration of digoxin

Ciclosporin: hypoglycaemic effect of repaglinide possibly enhanced by ciclosporin

Corticosteroids: hypoglycaemic effect of antidiabetics antagonised by corticosteroids

Cytoxotics: avoidance of repaglinide advised by manufacturer of lapatinib

Deferasirox: plasma concentration of repaglinide increased by deferasirox

Diazoxide: hypoglycaemic effect of antidiabetics antagonised by diazoxide

Diuretics: hypoglycaemic effect of antidiabetics antagonised by loop diuretics and thiazides and related diuretics

Hormone Antagonists: requirements for insulin, metformin, repaglinide and sulfonylureas possibly reduced by lanreotide; requirements for insulin, metformin, repaglinide and sulfonylureas possibly reduced by octreotide

Leflunomide: hypoglycaemic effect of tolbutamide possibly enhanced by leflunomide

Lipid-regulating Drugs: absorption of glibenclamide reduced by colesevelam; hypoglycaemic effect of acarbose possibly enhanced by colestyramine; hypoglycaemic effect of nateglinide possibly enhanced by gemfibrozil; increased risk of severe hypoglycaemia when repaglinide given with gemfibrozil—avoid concomitant use; plasma concentration of glibenclamide possibly increased by fluvastatin; may be improved effect when insulin or sulfonylureas given with fibrates

Oestrogens: hypoglycaemic effect of antidiabetics antagonised by oestrogens

Orlistat: avoidance of acarbose advised by manufacturer of orlistat

Pancreatins: hypoglycaemic effect of acarbose antagonised by pancreatin

Progestogens: hypoglycaemic effect of antidiabetics antagonised by progestogens

Sulfinpyrazone: effects of sulfonylureas enhanced by sulfinpyrazone

Testosterone: hypoglycaemic effect of antidiabetics possibly enhanced by testosterone

Ulcer-healing Drugs: excretion of metformin reduced by cimetidine (increased plasma concentration)

Antidiabetics Ulcer-healing Drugs (continued)
- Antihistamines: thrombocyte count depressed when metformin given with ketotifen (manufacturer of ketotifen advises avoid concomitant use)

Antipsychotics: hypoglycaemic effect of sulfonylureas enhanced by fluphenazine and mepitolone

Antivirals: plasma concentration of tolbutamide possibly increased by ritonavir

Aprepitant: plasma concentration of tolbutamide reduced by aprepitant

Beta-blockers: warning signs of hypoglycaemia (such as tremor) with antidiabetics may be masked when given with beta-blockers; hypoglycaemic effect of insulin enhanced by beta-blockers

Bosentan: increased risk of hepatotoxicity when glibenclamide given with bosentan—avoid concomitant use

Calcium-channel Blockers: glucose tolerance occasionally impaired when insulin given with nifedipine

Cardiac Glycosides: acarbose possibly reduces plasma concentration of digoxin; sitagliptin increases plasma concentration of digoxin

Ciclosporin: hypoglycaemic effect of repaglinide possibly enhanced by ciclosporin

Corticosteroids: hypoglycaemic effect of antidiabetics antagonised by corticosteroids

Cytoxotics: avoidance of repaglinide advised by manufacturer of lapatinib

Deferasirox: plasma concentration of repaglinide increased by deferasirox

Diazoxide: hypoglycaemic effect of antidiabetics antagonised by diazoxide

Diuretics: hypoglycaemic effect of antidiabetics antagonised by loop diuretics and thiazides and related diuretics

Hormone Antagonists: requirements for insulin, metformin, repaglinide and sulfonylureas possibly reduced by lanreotide; requirements for insulin, metformin, repaglinide and sulfonylureas possibly reduced by octreotide

Leflunomide: hypoglycaemic effect of tolbutamide possibly enhanced by leflunomide

Lipid-regulating Drugs: absorption of glibenclamide reduced by colesevelam; hypoglycaemic effect of acarbose possibly enhanced by colestyramine; hypoglycaemic effect of nateglinide possibly enhanced by gemfibrozil; increased risk of severe hypoglycaemia when repaglinide given with gemfibrozil—avoid concomitant use; plasma concentration of glibenclamide possibly increased by fluvastatin; may be improved effect when insulin or sulfonylureas given with fibrates

Oestrogens: hypoglycaemic effect of antidiabetics antagonised by oestrogens

Orlistat: avoidance of acarbose advised by manufacturer of orlistat

Pancreatins: hypoglycaemic effect of acarbose antagonised by pancreatin

Progestogens: hypoglycaemic effect of antidiabetics antagonised by progestogens

Sulfinpyrazone: effects of sulfonylureas enhanced by sulfinpyrazone

Testosterone: hypoglycaemic effect of antidiabetics possibly enhanced by testosterone

Ulcer-healing Drugs: excretion of metformin reduced by cimetidine (increased plasma concentration)
Antifungals, Imidazole

- Antipsychotics (continued)
  - risk of ventricular arrhythmias when imidazoles given with pimozide—avoid concomitant use; imidazoles possibly increase plasma concentration of quetiapine (reduce dose of quetiapine)
- Antivirals: plasma concentration of both drugs increased when ketoconazole given with darunavir; plasma concentration of ketoconazole increased by fosamprenavir (also plasma concentration of fosamprenavir possibly increased); ketoconazole increases plasma concentration of enfuvirtide and maraviroc (consider reducing dose of enfuvirtide and maraviroc); plasma concentration of ketoconazole reduced by nefazodone—avoid concomitant use; combination of ketoconazole with ritonavir may increase plasma concentration of either drug (or both); ketoconazole increases plasma concentration of saquinavir; imidazoles possibly increase plasma concentration of saquinavir
- Anxiolytics and Hypnotics: ketoconazole increases plasma concentration of alprazolam; ketoconazole increases plasma concentration of midazolam (risk of prolonged sedation)
- Aprepitant: ketoconazole increases plasma concentration of aprepitant
- Bosentan: ketoconazole increases plasma concentration of bosentan
- Calcium-channel Blockers: ketoconazole inhibits metabolism of verapamil (increased plasma concentration); avoidance of ketoconazole advised by manufacturer of lercanidipine; ketoconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)
- Ciclosporin: ketoconazole inhibits metabolism of ciclosporin (increased plasma concentration); miconazole possibly inhibits metabolism of ciclosporin (increased plasma concentration)
- Cilostazol: ketoconazole increases plasma concentration of cilostazol (consider reducing dose of cilostazol)
- Cinnarizine: ketoconazole inhibits metabolism of cinnarizine (increased plasma concentration)
- Citalopram: ketoconazole increases plasma concentration of citalopram (increased plasma concentration)
- Colchicine: ketoconazole possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Corticosteroids: ketoconazole possibly inhibits metabolism of corticosteroids; ketoconazole increases plasma concentration of inhaled and oral budesonide; ketoconazole increases plasma concentration of active metabolite of budesonide; ketoconazole inhibits the metabolism of methylprednisolone; ketoconazole increases plasma concentration of inhaled mometasone
- Cytoxics: ketoconazole possibly increases plasma concentration of daсatinib; ketoconazole inhibits metabolism of erlotinib and amsacrine (increased plasma concentration); ketoconazole increases plasma concentration of everolimus, lapatinib and nilotinib—avoid concomitant use; ketoconazole increases plasma concentration of bortezomib and imatinib; avoidance of ketoconazole advised by manufacturer of pazopanib; ketoconazole increases plasma concentration of active metabolite of tienilic acid—avoid concomitant use; in vitro studies suggest a competitive interaction between ketoconazole and doxetaxel (consult doxetaxel product literature); ketoconazole reduces plasma concentration of vinorelbine (but concentration of active metabolite of vinorelbine increased)—avoid concomitant use; ketoconazole increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use
- Diuretics: ketoconazole increases plasma concentration of eplerenone—avoid concomitant use
- Antifungals, Imidazole (continued)
  - Domperidone: ketoconazole possibly increases risk of arrhythmias with domperidone
  - Ergot Alkaloids: increased risk of ergotism when imidazoles given with ergotamine and methysergide—avoid concomitant use
  - 5HT, Agonists: ketoconazole increases plasma concentration of almotriptan (increased risk of toxicity); ketoconazole increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use
  - Ivermectin: ketoconazole increases plasma concentration of ivermectin—avoid concomitant use
  - Lanthanum: absorption of ketoconazole possibly reduced by lanthanum (give at least 2 hours apart)
  - Lipid-regulating Drugs: possible increased risk of myopathy when imidazoles given with atorvastatin or simvastatin; increased risk of myopathy when ketoconazole given with atorvastatin (avoid concomitant use); possible increased risk of myopathy when miconazole given with simvastatin—avoid concomitant use
  - Oestrone: anecdotal reports of contraceptive failure when imidazoles given with oestrone
  - Parasympathomimetics: ketoconazole increases plasma concentration of galantamine
  - Ranolazine: ketoconazole increases plasma concentration of ranolazine—avoid concomitant use
  - Retinoids: ketoconazole increases plasma concentration of retinoids—reduce initial dose of sildenafil
  - Sirolimus: ketoconazole increases plasma concentration of sirolimus—avoid concomitant use; miconazole increases plasma concentration of sirolimus
  - Tacrolimus: imidazoles possibly increase plasma concentration of tacrolimus; ketoconazole increases plasma concentration of tacrolimus
  - Tadalafil: ketoconazole increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use
  - Theophylline: ketoconazole possibly increases plasma concentration of theophylline
  - Tolvaptan: ketoconazole increases plasma concentration of tolvaptan
  - Ulcer-healing Drugs: absorption of ketoconazole reduced by histamine H₂-antagonists, proton pump inhibitors and sucralfate
  - Vardenafil: ketoconazole increases plasma concentration of vardenafil—manufacturer of vardenafil advises avoid concomitant use
  - Vitamins: ketoconazole possibly increases plasma concentration of vitamin K

Antifungals, Polyene

Note: In general, fluconazole interactions relate to multiple-dose treatment

- Analgesics: fluconazole increases plasma concentration of celecoxib (halve dose of celecoxib); voriconazole increases plasma concentration of diclofenac and ibuprofen; fluconazole increases plasma concentration of parecoxib (reduce dose of parecoxib); voriconazole increases plasma concentration of alfentanil and methadone—consider reducing dose of alfentanil and methadone; fluconazole inhibits metabolism of alfentanil (risk of prolonged or delayed respiratory depression); irtraconazole possibly inhibits metabolism of alfentanil; triazoles possibly increase plasma concentration of entanyl
- Antacids: absorption of itraconazole reduced by antacids
- Anti-arrhythmics: manufacturer of itraconazole advises avoid concomitant use with disopyramide; avoidance of itraconazole, posaconazole and voriconazole advised by manufacturer of dronedarone
Antifungals, Triazole (continued)

- Antibacterials: plasma concentration of itraconazole increased by clarithromycin; triazoles possibly increase plasma concentration of efavirenz (increased risk of uveitis—reduce rifabutin dose); posaconazole increases plasma concentration of efavirenz (also plasma concentration of posaconazole reduced); voriconazole increases plasma concentration of efavirenz, also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity); fluconazole increases plasma concentration of efavirenz; posaconazole and voriconazole possibly increase plasma concentration of efavirenz.

- Anticoagulants: fluconazole, itraconazole and voriconazole enhance anticoagulant effect of coumarins; avoidance of itraconazole, posaconazole and voriconazole advised by manufacturer of voriconazole and voriconazole (St John’s wort—avoid concomitant use).

- Anti-diabetics: posaconazole possibly enhances hypoglycaemic effect of glipizide; fluconazole possibly enhances hypoglycaemic effect of nateglinide; itraconazole possibly enhances hypoglycaemic effect of repaglinide; fluconazole increases plasma concentration of sulfonylureas; voriconazole possibly increases plasma concentration of sulfonylureas.

- Antiepileptics: fluconazole possibly increases plasma concentration of carbamazepine; plasma concentration of voriconazole possibly reduced by carbamazepine and primidone—avoid concomitant use; plasma concentration of voriconazole and posaconazole possibly reduced by carbamazepine; voriconazole increases plasma concentration of phenytoin (consider reducing dose of phenytoin); voriconazole increases plasma concentration of phenytoin, also phenytoin reduces plasma concentration of voriconazole and also monitor for phenytoin toxicity; plasma concentration of posaconazole possibly reduced by primidone.

Antifungals: triazoles possibly antagonise effects of amphotericin; plasma concentration of itraconazole increased by micafungin (consider reducing dose of itraconazole).

- Anti-histamines: itraconazole inhibits metabolism of mizolastine—avoid concomitant use.

- Antimalarials: avoidance of triazoles advised by manufacturer of quinidine.

- Antithrombinics: avoidance of itraconazole advised by manufacturer of darifenacin and tolterodine; manufacturer of fesoterodine advises dose reduction when itraconazole given with fesoterodine—consult fesoterodine product literature; itraconazole increases plasma concentration of solifenacin.

- Antipsychothics: itraconazole possibly increases plasma concentration of aripiprazole (reduce dose of aripiprazole); increased risk of ventricular arrhythmias when triazoles given with pimozide—avoid concomitant use; fluconazole increases plasma concentration of quetiapine (reduce dose of quetiapine).

- Antivirals: posaconazole increases plasma concentration of efavirenz; plasma concentration of itraconazole and posaconazole reduced by efavirenz; plasma concentration of voriconazole reduced by efavirenz, also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose); plasma concentration of both drugs may increase when itraconazole given with fasmpenavir; itraconazole increases plasma concentration of efavirenz (consider reducing dose of efavirenz); plasma concentration of itraconazole possibly reduced by nevirapine—consider increasing dose of itraconazole; fluconazole increases plasma concentration of efavirenz and voriconazole possibly increase plasma concentration of saquinavir; fluconazole increases plasma concentration of efavirenz (increased risk of toxicity).
Antifungals, Triazole
- Cytotoxic (continued)
  - plasma concentration of vinflunine—manufactur er of vinflunine advises avoid concomitant use
- Diuretics: fluconazole increases plasma concentration of eplerenone (reduce dose of eplerenone); itracon azole increases plasma concentration of eplerenone—avoid concomitant use; plasma concentration of fluconazole increased by hydrochlorothiazide
- Ergot Alkaloids: increased risk of ergotism when triazoles given with ergotamine and methyprylon—avoid concomitant use
- SHT, Agonists: itraconazole increases plasma concentration of dihydroergotamine—risk of toxicity—avoid concomitant use
- Itraconazole: fluconazole increases plasma concentration of itraconazole; fluconazole possibly increases plasma concentration of itraconazole—avoid concomitant use
- Ulcer-healing Drugs:
  - Theophylline:
    - increased risk of myopathy when itraconazole or posaconazole given with atorvastatin or simvastatin; increased risk of myopathy when itraconazole or posaconazole given with atorvastatin (avoid concomitant use)
- Lipid-regulating Drugs:
  - Ranolazine:
    - increased plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
  - Simvastatin:
    - increased risk of myopathy when itraconazole or posaconazole given with atorvastatin or simvastatin; increased risk of myopathy when itraconazole or posaconazole given with atorvastatin (avoid concomitant use)
- Antifungals, Triazole (continued)
  - Voriconazole:
    - increased by oestrogens
    - Progestogens:
      - plasma concentration of voriconazole possibly increased by progestogens
- Alcohol:
  - increased sedative effect when antihistamines given with alcohol (possibly less effect with non-sedating antihistamines)
  - Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)
  - Alcohol: increased sedative effect when antihistamines given with alcohol (possibly less effect with non-sedating antihistamines)
  - Analgesics: sedative effects possibly increased when sedating antihistamines given with opioid analgesics
  - Antacid: absorption of fexofenadine reduced by antacids
Antimuscarinics (continued)

Analgesics: increased risk of antimuscarinic side-effects when antimuscarinics given with nefopam.

Anti-arrhythmics: increased risk of ventricular arrhythmias when tolterodine given with omeprazole, disopyramide or etilefrine; increased risk of antimuscarinic side-effects when antimuscarinics given with disopyramide.

Antibacterials: manufacturer of fesoterodine advises dose reduction when fesoterodine given with clarithromycin and telithromycin—consult fesoterodine product literature; manufacturer of tolterodine advises avoid concomitant use with clarithromycin and erythromycin; plasma concentration of darifenacin possibly increased by erythromycin; plasma concentration of active metabolite of fesoterodine reduced by rifampicin.

Antidepressants: plasma concentration of darifenacin and procyclidine increased by paroxetine; increased risk of antimuscarinic side-effects when antimuscarinics given with MAOIs or tricyclics; possibly increased antimuscarinic side-effects when antimuscarinics given with tricyclic-related antidepressants.

Antifungals: antimuscarinics reduce absorption of itraconazole; manufacturer of fesoterodine advises dose reduction when fesoterodine given with itraconazole and ketoconazole—consult fesoterodine product literature; plasma concentration of darifenacin increased by itraconazole and ketoconazole—avoid concomitant use; plasma concentration of solifenacin increased by itraconazole and ketoconazole; manufacturer of tolterodine advises avoid concomitant use with itraconazole and ketoconazole; manufacturer of darifenacin advises avoid concomitant use with itraconazole.

Antihistamines: increased risk of antimuscarinic side-effects when antimuscarinics given with antihistamines.

Antipsychotics: antimuscarinics possibly reduce plasma concentration of phenothiazines, but risk of antimuscarinic side-effects increased.

Antivirals: manufacturer of fesoterodine advises dose reduction when fesoterodine given with atazanavir, indinavir, nelfinavir, ritonavir and saquinavir; consult fesoterodine product literature; manufacturer of darifenacin advises avoid concomitant use with atazanavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tpranavir; manufacturer of tolterodine advises avoid concomitant use with fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir; plasma concentration of solifenacin increased by nelfinavir and ritonavir.

Beta-blockers: increased risk of ventricular arrhythmias when tolterodine given with betablockers.

Calcium-channel Blockers: manufacturer of darifenacin advises avoid concomitant use with verapamil.

Cardiac Glycosides: darifenacin possibly increases plasma concentration of digoxin.

Ciclosporin: manufacturer of darifenacin advises avoid concomitant use with ciclosporin.

Dopemimetics: antimuscarinics possibly reduce absorption of levodopa.

Memantine: effects of antimuscarinics possibly enhanced by memantine.

Metoclopramide: antimuscarinics enhance effects of metoclopramide on gastrointestinal activity.

Nitrates: antimuscarinics possibly reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth).

Parasympathomimetics: antimuscarinics antagonise effects of parasympathomimetics.

Antipsychotics

Note: Increased risk of toxicity with myelosuppressive drugs.

Note: Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis.

ACE Inhibitors: enhanced hypotensive effect when antipsychotics given with ACE inhibitors.

Adrenergic Neurone Blockers: enhanced hypotensive effect when phenothiazines given with adrenergic neurone blockers; higher doses of clonazepam antagonise hypotensive effect of adrenergic neurone blockers; haloperidol antagonises hypotensive effect of adrenergic neurone blockers.

Adsorbents: absorption of phenothiazines possibly reduced by kaolin.

Alcohol: increased sedative effect when antipsychotics given with alcohol.

Alpha-blockers: enhanced hypotensive effect when antipsychotics given with alpha-blockers.

Anaesthetics, General: droperidol enhances effects of thiopental; enhanced hypotensive effect when antipsychotics given with general anaesthetics.

Analgesics: possible severe drowsiness when haloperidol given with indometacin; increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with methadone; increased risk of ventricular arrhythmias when amisulpride given with methadone—avoid concomitant use; increased risk of convulsions when antipsychotics given with tramadol; enhanced hypotensive and sedative effects when antipsychotics given with opioid analgesics.

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when antipsychotics given with angiotensin-II receptor antagonists.

Antacids: absorption of phenothiazines and sulpiride reduced by antacids.

Anti-arrhythmics: increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias when amisulpride, droperidol, haloperidol, phenothiazines, pimozide or zuclopenthixol given with amiodarone—avoid concomitant use; increased risk of ventricular arrhythmias when benperidol given with amiodarone—manufacturer of benperidol advises avoid concomitant use; increased risk of ventricular arrhythmias when sulpiride given with amiodarone or disopyramide; possible increased risk of ventricular arrhythmias when haloperidol given with disopyramide—avoid concomitant use; increased risk of ventricular arrhythmias when amisulpride, droperidol, pimozide or zuclopenthixol given with disopyramide—avoid concomitant use; increased risk of ventricular arrhythmias when phenothiazines given with disopyramide; avoidance of phenothiazines advised by manufacturer of droperidone (risk of ventricular arrhythmias); increased risk of arrhythmias when clozapine given with fexofenadine.

Antibacterials: increased risk of ventricular arrhythmias when pimozide given with clarithromycin, moxifloxacin or telithromycin—avoid concomitant use; increased risk of ventricular arrhythmias when amisulpride given with erythromycin—avoid concomitant use; plasma concentration of clozapine possibly increased by erythromycin (possible increased risk of convulsions); possible increased risk of ventricular arrhythmias when pimozide given with erythromycin—avoid concomitant use; increased risk of ventricular arrhythmias when sulpiride given with parerental erythromycin; increased risk of ventricular arrhythmias when zuclopenthixol given with parerental erythromycin—avoid concomitant use; plasma concentration of clozapine increased by cipofloxacin; plasma concentration of olanzapine possibly increased by cipofloxacin; increased risk of ventricular arrhythmias when droperidol, halo-
Antiepileptics: Antiepileptics

Antipsychotics: Antipsychotics (continued)

Antimalarials: Antimalarials

Antifungals: Antifungals (continued)

Antipsychotics (continued)

Antipsychotics: Antipsychotics (continued)

Antidepressants: Antidepressants

Antibacterials: Antibacterials (continued)
Antipsychotics (continued)

- Anxiety and Hypnotics: increased sedative effect when antipsychotics given with anxiolytics and hypnotics; serious adverse events reported with concomitant use of clozapine and lorazepam (causality not established); increased risk of hypotension, bradycardia and respiratory depression when intramuscular olanzapine given with paroxetine; plasma concentration of haloperidol increased by buspirone

- Atomoxetine: increased rate of ventricular arrhythmias when antipsychotics that prolong the QT interval given with atomoxetine

- Barbiturates: antipsychotics antagonise anti-convulsant effect of barbiturates (convulsive threshold lowered); metabolism of haloperidol accelerated by phenobarbital (reduced plasma concentration); plasma concentration of both drugs reduced when chlorpromazine given with phenobarbital; plasma concentration of aripiprazole possibly reduced by phenobarbital—increased dose of aripiprazole

- Beta-blockers: enhanced hypotensive effect when phenothiazines given with beta-blockers; plasma concentration of both drugs may increase when chlorpromazine given with propranolol; increased risk of ventricular arrhythmias when amisulpride, phenothiazines, pimozide or sulpiride given with sotalol; increased risk of ventricular arrhythmias when droperidol or zuclopenthixol given with sotalol—avoid concomitant use; possible increased risk of ventricular arrhythmias when haloperidol given with sotalol—avoid concomitant use

- Calcium-channel Blockers: enhanced hypotensive effect when antipsychotics given with calcium-channel blockers

- Clonidine: enhanced hypotensive effect when phenothiazines given with clonidine

- Cytototics: avoid concomitant use of clozapine with cytotoxic effects; risk of agranulocytosis; avoidance of pimozide advised by manufacturer of lapatinib; increased risk of ventricular arrhythmias when amisulpride, phenothiazines, pimozide or sulpiride given with arsenic trioxide; increased risk of ventricular arrhythmias when antipsychotics that prolong the QT interval given with arsenic trioxide

- Desferrioxamine: manufacturer of levomepromazine advises avoid concomitant use with desferrioxamine; avoidance of prochlorperazine advised by manufacturer of desferrioxamine

- Diazoxide: enhanced hypotensive effect when phenothiazines given with diazoxide

- Diuretics: risk of ventricular arrhythmias with amisulpride increased by hypokalaemia caused by diuretics; risk of ventricular arrhythmias with pimozide increased by hypokalaemia caused by diuretics (avoid concomitant use); enhanced hypotensive effect when phenothiazines given with diuretics

- Dopaminergics: increased risk of extrapyramidal side-effects when antipsychotics given with amantadine; antipsychotics antagonise effects of apomorphine, levodopa and pergolide; antipsychotics antagonise hypoprolineaemic and antiparkinsonian effects of bromocriptine and cabergoline; manufacturer of amisulpride advises avoid concomitant use of levodopa (agonist of effect); avoidance of antipsychotics advised by manufacturer of pramipexole, ropinirole and rotigotine (antagonism of effect)

- Histamine: antipsychotically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use

- Hormone Antagonists: manufacturer of droperidol advises avoid concomitant use with tamoxifen (risk of ventricular arrhythmias)

Antipsychotics (continued)

- Ibravadinib: increased risk of ventricular arrhythmias when pimozone given with ibrahadinib

- Lithium: increased risk of extrapyramidal side-effects and possibly neurotoxicity when clozapine, flupenthixol, haloperidol, phenothiazines or zuclopenthixol given with lithium; possible risk of toxicity when olanzapine given with lithium; increased risk of extrapyramidal side-effects when sulpiride given with lithium

- Memantine: effects of antipsychotics possibly reduced by memantine

- Methylphenidate: enhanced hypotensive effect when antipsychotics given with methylphenidate (also increased risk of extrapyramidal effects)

- Metoclopramide: increased risk of extrapyramidal side-effects when antipsychotics given with metoclopramide

- Moxonidine: enhanced hypotensive effect when phenothiazines given with moxonidine

- Muscle Relaxants: promazine possibly enhances effects of suxamethonium

- Nitrates: enhanced hypotensive effect when phenothiazines given with nitrates

- Penicillamine: avoid concomitant use of clozapine with penicillamine (increased risk of agranulocytosis)

- Pentamidine isetionate: increased risk of ventricular arrhythmias when amisulpride or droperidol given with pentamidine isetionate—avoid concomitant use; increased risk of ventricular arrhythmias when phenothiazines given with pentamidine isetionate

- Sodium Benzoate: haloperidol possibly reduces effects of sodium benzoate

- Sodium Oxybate: antipsychotics possibly enhance effects of sodium oxybate

- Sodium Phenylbutyrate: haloperidol possibly reduces effects of sodium phenylbutyrate

- Sympathomimetics: antipsychotics antagonise hypertensive effect of sympathomimetics; antipsychotic effects of chlorpromazine possibly antagonised by dexamphetamine; side-effects of risperidone possibly increased by methylphenidate

- Tacrolimus: manufacturer of droperidol advises avoid concomitant use with tacrolimus (risk of ventricular arrhythmias)

- Tetrabenazine: increased risk of extrapyramidal side-effects when antipsychotics given with tetrabenazine

- Telbivudine, Tenofovir, Tipranavir, Valaciclovir, and Truvada: see Antivirals

- Antivirals see Abacavir, Aciclovir, Adefovir, Atazanavir, Cidofovir, Darunavir,Didanosine, Efavirenz, Emtricitabine, Etravirine, Famiclovir, Fosamprenavir, Fosarnet, Ganciclovir, Indinavir, Lamivudine, Lopinavir, Maraviroc, Nelfinavir, Nevirapine, Raltegravir, Ribavirin, Ritonavir, Saquinavir, Stavudine, Telbivudine, Tenofovir, Tipranavir, Valaciclovir, and Zidovudine

Anxiolytics and Hypnotics

- ACE Inhibitors: enhanced hypotensive effect when anxiolytics and hypnotics given with ACE inhibitors

- Adrenergic Neurome Blockers: enhanced hypotensive effect when anxiolytics and hypnotics given with adrenergic neurome blockers

- Alcohol: increased sedative effect when anxiolytics and hypnotics given with alcohol

- Alpha-blockers: enhanced hypotensive and sedative effects when anxiolytics and hypnotics given with alpha-blockers

- Anaesthetics, General: increased sedative effect when anxiolytics and hypnotics given with general anaesthetics
Anxiolytics and Hypnotics (continued)

Analgesics: metabolism of midazolam possibly inhibited by fentanyl; increased sedative effect when anxiolytics and hypnotics given with opioid analgesics.

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when anxiolytics and hypnotics given with angiotensin-II receptor antagonists
- Antihistamines: metabolism of midazolam inhibited by clarithromycin, erythromycin and telithromycin (increased plasma concentration with increased sedation); plasma concentration of buspirone increased by erythromycin (reduce dose of buspirone); metabolism of zopiclone inhibited by erythromycin; metabolism of benzodiazepines possibly accelerated by rifampicin (reduced plasma concentration); metabolism of diazepam accelerated by rifampicin (reduced plasma concentration); metabolism of zopiclone significantly reduced by rifampicin; metabolism of diazepam inhibited by isoniazid

Anticoagulants: chloral and triclofos may transiently enhance anticoagulant effect of coumarins
- Antidepressants: plasma concentration of alprazolam increased by fluoxetine; plasma concentration of melatonin increased by fluvoxamine—avoid concomitant use; plasma concentration of some benzodiazepines increased by fluvoxamine; sedative effects possibly increased when zolpidem given with sertraline; manufacturer of buspirone advises avoid concomitant use with MAOIs; avoidance of buspirone for 10 days after stopping tranylcypromine advised by manufacturer of tranylcypromine; plasma concentration of oral midazolam possibly reduced by St John’s wort; increased sedative effect when anxiolytics and hypnotics given with mirtazapine, tricyclic-related antidepressants or tricryptics

Antiepileptics: plasma concentration of midazolam reduced by carbamazepine; plasma concentration of clonazepam often reduced by carbamazepine, phenytoin and primidone; benzodiazepines possibly increased or decrease plasma concentration of phenytoin; diazepam increases or decreases plasma concentration of phenytoin; plasma concentration of progabide increased by stiripentol; clobazam possibly increases plasma concentration of valproate; plasma concentration of diazepam and lorazepam possibly increased by valproate; increased risk of side-effects when clonazepam given with valproate
- Antifungals: plasma concentration of alprazolam increased by itraconazole and ketoconazole; plasma concentration of midazolam increased by fluconazole, itraconazole and ketoconazole (risk of prolonged sedation); plasma concentration of buspirone increased by itraconazole (reduce dose of buspirone); plasma concentration of midazolam increased by posaconazole

Antihistamines: increased sedative effect when anxiolytics and hypnotics given with antihistamines
- Antipsychotics: increased sedative effect when anxiolytics and hypnotics given with antipsychotics: buspirone increases plasma concentration of haloperidol; serious adverse events reported with concomitant use of lorazepam and clozapine (causality not established); increased risk of hypotension, bradyarrhythmia and respiratory depression when par- enteral benzodiazepines given with intramuscular orlanzapine
- Anxiolytics and Hypnotics (continued)

Anxiolytics and Hypnotics

Antivirals (continued)

longed sedation—avoid concomitant use of oral midazolam); increased risk of prolonged sedation when alprazolam given with indinavir—avoid concomitant use; plasma concentration of alprazolam, diazepam, flurazepam and zolpidem possibly increased by ritonavir (risk of extreme sedation and respiratory depression—avoid concomitant use); plasma concentration of anxiolytics and hypnotics possibly increased by ritonavir; plasma concentration of buspirone increased by ritonavir (increased risk of toxicity); plasma concentration of midazolam increased by saquinavir (risk of prolonged sedation—avoid concomitant use of oral midazolam)

Aprepitant: plasma concentration of midazolam increased by aprepitant (risk of prolonged sedation)

Barbiturates: plasma concentration of clonazepam often reduced by phenobarbital

Beta-blockers: enhanced hypotensive effect when anxiolytics and hypnotics given with beta-blockers

Calcium-channel Blockers: enhanced hypotensive effect when anxiolytics and hypnotics given with calcium-channel blockers; midazolam increases absorption of lercanidipine; plasma concentration of buspirone increased by diltiazem and verapamil (reduce dose of buspirone); metabolism of midazolam inhibited by diltiazem and verapamil (increased plasma concentration with increased sedation)

Cardiac Glycosides: alprazolam increases plasma concentration of digoxin (increased risk of toxicity)

Clonidine: enhanced hypotensive effect when anxiolytics and hypnotics given with clonidine

Cytotoxics: plasma concentration of midazolam increased by milotinib

Dexefasirox: plasma concentration of midazolam possibly reduced by dexefasirox

Diazoxide: enhanced hypotensive effect when anxiolytics and hypnotics given with diazoxide

Disulfiram: metabolism of benzodiazepines inhibited by disulfiram (increased plasma concentration); excretion of midazolam possibly reduced by disulfiram

Diuretics: enhanced hypotensive effect when anxiolytics and hypnotics given with diuretics; administration of chloral or triclofos with parenteral furosemide may displace thyroid hormone from binding sites

Dopamineergics: benzodiazepines possibly antagonise effects of levodopa

Grapefruit Juice: plasma concentration of buspirone increased by grapefruit juice

Lithium: increased risk of neurotoxicity when clonazepam given with lithium

Lofexidine: increased sedative effect when anxiolytics and hypnotics given with lofexidine

Methyldopa: enhanced hypotensive effect when anxiolytics and hypnotics given with methyldopa

Moxonidine: enhanced hypotensive effect when anxiolytics and hypnotics given with moxonidine

Muscle Relaxants: increased sedative effect when anxiolytics and hypnotics given with baclofen or tizanidine

Nabulone: increased sedative effect when anxiolytics and hypnotics given with nabulone

Nitrates: enhanced hypotensive effect when anxiolytics and hypnotics given with nitrates

Oestrogens: plasma concentration of melatonin increased by oestrogens

Probenecid: excretion of lorazepam reduced by probenecid (increased plasma concentration); excretion of nitrazepam possibly reduced by probenecid (increased plasma concentration)
Antibacterials: Sodium Oxybate: benzodiazepines enhance effects of sodium oxybate (avoid concomitant use).

Theophylline: effects of benzodiazepines possibly reduced by theophylline.

Ulcera-feeding Drugs: plasma concentration of melatonin increased by cimetidine; metabolism of benzodiazepines, clomethiazole and zaleplon inhibited by cimetidine (increased plasma concentration); metabolism of diazepam possibly inhibited by esomeprazole and omeprazole (increased plasma concentration).

Antioxidants and Antihypertensive: enhanced hypoten- sive effect when antioxidant and hypotensive given with hydralazine, minoxidil or sodium nitroprusside.

Arsenic Trioxide: see arsenic trioxide.

Oestrogens: increased risk of ventricular arrhythmias when arsenic trioxide given with haloperidol; avoid concomitant use of cytoxics with clozapine (increased risk of agranulocytosis).

Beta-blockers: increased risk of ventricular arrhythmias when arsenic trioxide given with aripiprazole.

Antidepressants: Apraclonidine, apomorphine.

Sodium Oxybate: benzodiazepines enhance effects of sodium oxybate (avoid concomitant use).

Anxiolytics and Hypnotics: BN Fenix Appendix 1: Interactions 819 increased risk of ventricular arrhythmias when arsenic trioxide given with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when arsenic trioxide given with haloperidol; avoid concomitant use of cytoxics with clozapine (increased risk of agranulocytosis).

Beta-blockers: increased risk of ventricular arrhythmias when arsenic trioxide given with aripiprazole.

Cardiac Glycosides: cytoxics reduce absorption of digoxin tablets.

Diuretics: risk of ventricular arrhythmias with arsenic trioxide increased by hypokalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics.

Lithium: increased risk of ventricular arrhythmias when arsenic trioxide given with lithium.

Artemether with Luminetamine: Anti-arrrhythmic: manufacturer of artemether/lumefantrine advises avoid concomitant use with imatinib or disopyramide or ticlidine (risk of ventricular arrhythmias).

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antifungal: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antihypertensive: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Antihypertensive: manufacturer of artemether/lumefantrine advises avoid concomitant use with imatinib or disopyramide or Ticlidine (risk of ventricular arrhythmias).

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Antibacterial: manufacturer of artemether/lumefantrine advises avoid concomitant use with macrolides and quinolones.

Antimalarial: manufacturer of artemether/lumefantrine advises avoid concomitant use with antipsychotics.

Antiviral: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Beta-blocker: manufacturer of artemether/lumefantrine advises avoid concomitant use with metoprolol and esmolol.

Grapefruit Juice: plasma concentration of artemether/lumefantrine possibly increased by grapefruit juice.

Antimicrobial: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.

Anticoagulant: manufacturer of artemether/lumefantrine advises caution with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.
### Appendix 1: Interactions

**Aspirin (continued)**

- Antiepileptics: aspirin enhances effects of phenytoin and valproate
- Clopidogrel: increased risk of bleeding when aspirin given with clopidogrel
- Corticosteroids: increased risk of gastro-intestinal bleeding and ulceration when aspirin given with corticosteroids, also corticosteroids reduce plasma concentration of salicylate
- Cytotoxics: aspirin reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see p. 647
- Diuretics: aspirin antagonises diuretic effect of spironolactone; increased risk of toxicity when high-dose aspirin given with carbonic anhydrase inhibitors
- Floxprost: increased risk of bleeding when aspirin given with floxprost
- Leukotriene Receptor Antagonists: aspirin increases plasma concentration of zafirlukast
- Metoclopramide: rate of absorption of aspirin increased by metoclopramide (enhanced effect)
- Prolonged: aspirin antagonises effects of probenecid
- Sulfinpyrazine: aspirin antagonises effects of sulfinpyrazine

**Atazanavir**

- Antacids: plasma concentration of atazanavir possibly reduced by antacids
- Anti-arrhythmics: atazanavir possibly increases plasma concentration of amiodarone and lidocaine
- Antibacterials: plasma concentration of both drugs increased when atazanavir given with clarithromycin; atazanavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of atazanavir reduced by rifampicin
- Anti-Coagulants: atazanavir possibly increases plasma concentration of warfarin; avoidance of atazanavir advised by manufacturer of warfarin
- Antidepressants: plasma concentration of atazanavir reduced by St John's wort—avoid concomitant use
- Anti-Fungals: plasma concentration of atazanavir increased by posaconazole
- Antimalarials: caution with atazanavir advised by manufacturer of arteether/lumefantrine; atazanavir possibly increases plasma concentration of quinine (increased risk of toxicity)
- Antimuscarinics: avoidance of atazanavir advised by manufacturer of darifenacin; manufacturer of fesoterodine advises dose reduction when atazanavir given with fesoterodine—consult fesoterodine product literature
- Antipsychotics: atazanavir possibly inhibits metabolism of aripiprazole; atazanavir possibly increases plasma concentration of pimozide—avoid concomitant use
- Antivirals: manufacturer of atazanavir advises avoid concomitant use with efavirenz (plasma concentration of atazanavir reduced); avoid concomitant use of atazanavir with indinavir; atazanavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc); plasma concentration of atazanavir possibly reduced by nevirapine—avoid concomitant use; increased risk of ventricular arrhythmias when atazanavir given with saquinavir—avoid concomitant use; plasma concentration of atazanavir reduced by tenofovir, also plasma concentration of tenofovir possibly increased; atazanavir increases plasma concentration of tipranavir (also plasma concentration of atazanavir reduced)
- Anxiolytics and Hypnotics: atazanavir possibly increases plasma concentration of midazolam—avoid concomitant use of oral midazolam
- Calcium-channel Blockers: atazanavir increases plasma concentration of nitrendipine (reduce dose of nitrendipine)
- CYP3A4/isoform inhibitors: atazanavir possibly increases plasma concentration of efavirenz; atazanavir possibly increases plasma concentration of ritonavir
- CYP3A4/isoform inducers: atazanavir possibly increases plasma concentration of midazolam, possibly increased risk of toxicity when given with rifampicin
- Ergot Alkaloids: atazanavir possibly increases plasma concentration of ergot alkaloids—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when atazanavir given with atorvastatin; possible increased risk of myopathy when atazanavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when atazanavir given with simvastatin (avoid concomitant use)
- Oestrogens: atazanavir increases plasma concentration of ethinylestradiol
- Ranolazine: atazanavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: atazanavir possibly increases plasma concentration of sildenafil
- Siroliimus: atazanavir possibly increases plasma concentration of sirolimus
- Tacrolimus: atazanavir possibly increases plasma concentration of tacrolimus
- Urea-removal Drugs: plasma concentration of atazanavir reduced by lamotrigine

**Atenolol** see Beta-blockers

**Atorvastatin**

- Analgesics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Bupropion** see Antidepressants

**Calcium-channel Blockers (continued)**

- Calcium-channel Blockers: atazanavir possibly increases plasma concentration of verapamil
- Ciclosporin: atazanavir possibly increases plasma concentration of ciclosporin
- Colchicine: atazanavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
- Cytotoxics: atazanavir possibly increases plasma concentration of metronomil—manufacturer of metronomil advises avoid concomitant use; avoidance of atazanavir advised by manufacturer of paclitaxel; atazanavir possibly inhibits metabolism of etinotecan (increased risk of toxicity)
- Ergot Alkaloids: atazanavir possibly increases plasma concentration of ergot alkaloids—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when atazanavir given with atorvastatin; possible increased risk of myopathy when atazanavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when atazanavir given with simvastatin (avoid concomitant use)
- Oestrogens: atazanavir increases plasma concentration of ethinylestradiol
- Ranolazine: atazanavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: atazanavir possibly increases plasma concentration of sildenafil
- Siroliimus: atazanavir possibly increases plasma concentration of sirolimus
- Tacrolimus: atazanavir possibly increases plasma concentration of tacrolimus
- Urea-removal Drugs: plasma concentration of atazanavir reduced by lamotrigine

**Clopidogrel** see Antiaplotics

**Corticosteroids**

- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Diuretics** see Antidiuretics

**Diuretics**

- Anti-inflammatory Drugs: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Diltiazem** see Calcium-channel Blockers

**Efavirenz** see Antivirals

**Ergot Alkaloids**

- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Erythromycin** see Antibacterials

**F_EDR** see Antiepileptics

**Furosemide** see Diuretics

**HMG-CoA Reductase Inhibitors**

- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Hydralazine** see Calcium-channel Blockers

**Lidocaine** see Anti-arrhythmics

**Midazolam** see Anxiety

**Nitrendipine** see Calcium-channel Blockers

**Paracetamol** see Analgesics

**Pentazocine** see Antipsychotics

**Phenytoin** see Antiepileptics

**Protein Kinase C Inhibitors**

- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Rosuvastatin** see Lipid-regulating Drugs

**Sildenafil** see Calcium-channel Blockers

**Simvastatin** see Lipid-regulating Drugs

**Spironolactone** see Antihypertensives

**St John's Wort** see Antidiuretics

**Tacrolimus** see Antimalarials

**Valproate** see Antiepileptics

**Zafirlukast** see Antileukotrienes

**Zidovudine** see Antiretrovirals

---

**Appendix 2: Antidepressants**

- Analgesics: increased risk of ventricular arrhythmias when atorvastatin given with methadone; possible increased risk of convulsions when atorvastatin given with tramadol
- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol

**Appendix 3: Antihypertensives**

- Analgesics: increased risk of ventricular arrhythmias when atorvastatin given with methadone; possible increased risk of convulsions when atorvastatin given with tramadol
- Anti-arrhythmics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
- Anti-inflammatory Drugs: increased risk of convulsions when atorvastatin given with tramadol
- Anti-platelets: increased risk of convulsions when atorvastatin given with tramadol
- Antipsychotics: increased risk of ventricular arrhythmias when atorvastatin given with tramadol
Barbiturates

- Antidepressants (continued)
- Antiepileptics: phenobarbital reduces plasma concentration of carbamazepine, lamotrigine, tiagabine and zonisamide; phenobarbital possibly reduces plasma concentration of ethosuximide; plasma concentration of phenobarbital increased by oxcabazepine, also plasma concentration of an active metabolite of oxcabazepine reduced; plasma concentration of phenobarbital often increased by phenytoin, plasma concentration of phenytoin often reduced but may be increased; increased sedative effect when barbiturates given with primidone; phenobarbital possibly reduces plasma concentration of rufinamide, also plasma concentration of phenobarbital possibly increased; plasma concentration of phenobarbital possibly reduced; plasma concentration of phenobarbital reduced especially in renal impairment; increased risk of anaemia or leucopenia when azathioprine given with enalapril especially in renal impairment; increased risk of anaemia when azathioprine given with enalapril especially in renal impairment; increased risk of haematological toxicity when azathioprine given with trimethoprim (also with co-trimoxazole)
- Anticoagulants: phenobarbital possibly reduces plasma concentration of rufinamide; plasma concentration of both drugs reduced when phenobarbital given with chlorpromazine; phenobarbital possibly reduces plasma concentration of trimiprazole—increase dose of trimiprazole
- Antivirals: phenobarbital possibly reduces plasma concentration of abacavir, darunavir, fosamprenavir and lopinavir; avoidance of phenobarbital advised by manufacturer of etravirine; barbiturates possibly reduce plasma concentration of indinavir, nelfinavir and saquinavir; phenobarbital possibly reduces plasma concentration of indinavir, also plasma concentration of phenobarbital possibly increased
- Beta-blockers: barbiturates reduce plasma concentration of metoprolol and timolol; barbiturates possibly reduce plasma concentration of propranolol
- Calcium-channel Blockers: barbiturates reduce effects of elodipine and isradipine; barbiturates probably reduce effects of edihydropyridines, diltiazem and verapamil
- Ciclosporin: barbiturates accelerate metabolism of ciclosporin (reduced effect)
- Corticosteroids: barbiturates accelerate metabolism of corticosteroids (reduced effect)
- Cytotoxics: avoidance of barbiturates advised by manufacturer of gefitinib; phenobarbital possibly reduces plasma concentration of etoposide; phenobarbital reduces plasma concentration of irinotecan and its active metabolite
- Diuretics: phenobarbital reduces plasma concentration of spironolactone—avoid concomitant use; increased risk of osteomalacia when phenobarbital given with carbonic anhydrase inhibitors
- Folates: plasma concentration of phenobarbital possibly reduced by folates

Hormone Antagonists: barbiturates possibly accelerate metabolism of toremifene (reduced plasma concentration)
## Appendix 1: Interactions

### Barbiturates (continued)

Leukotriene Receptor Antagonists: phenobarbital reduces plasma concentration of montelukast

Lofexidine: increased sedative effect when barbiturates given with lofexidine

Methotrexate: effects of barbiturates possibly reduced by memantine

● Oestrogens: barbiturates accelerate metabolism of oestrogens (reduced contraceptive effect—see p. 495)

● Progestogens: barbiturates accelerate metabolism of progestogens (reduced contraceptive effect—see p. 495)

● Sodium Oxybate: barbiturates enhance effects of sodium oxybate (avoid concomitant use)

Sympathomimetics: plasma concentration of phenobarbital possibly increased by methylphenidate

Ticarcillin: phenobarbital reduces plasma concentration of ticarcillin

Theophylline: barbiturates accelerate metabolism of theophylline (reduced plasma concentration)

Thyroid Hormones: barbiturates accelerate metabolism of thyroid hormones (may increase requirements for thyroid hormones in hypothyroidism)

Tibolone: barbiturates accelerate metabolism of tibolone (reduced plasma concentration)

● Ulipristal: avoidance of phenobarbital advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)

Vitamins: barbiturates possibly increase requirements for vitamin D

**Beclometasone** see Corticosteroids

**Bemiparin** see Heparins

**Bendamustine**

Antiepileptics: cytotoxics possibly reduce absorption of phenytoin

● Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)

Cardiac Glysides: cytotoxics reduce absorption of digoxin tablets

**Bendroflumethiazide** see Diuretics

**Benperidol** see Antipsychotics

**Benzodiazepines** see Antiepileptics and Hypnotics

**Benztropine** see Diuretics

**Benzylenecillin** see Penicillins

### Beta-blockers

#### Note

Since systemic absorption may follow topical application, be cautious of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind

**ACE Inhibitors**: enhanced hypotensive effect when beta-blockers given with ACE inhibitors

Adrenergic Neurone Blockers: enhanced hypotensive effect when beta-blockers given with adrenergic neurone blockers

Alcohol: enhanced hypotensive effect when beta-blockers given with alcohol

Aldesleukin: enhanced hypotensive effect when beta-blockers given with aldesleukin

● Alpha-blockers: enhanced hypotensive effect when beta-blockers given with alpha-blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin

Anaesthetics, General: enhanced hypotensive effect when beta-blockers given with general anaesthetics

Anaesthetics, Local: pranoprolol increases risk of bupivacaine toxicity

Analgesics: hypotensive effect of beta-blockers antagonised by NSAIDs; plasma concentration of esmolol possibly increased by morphine

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when beta-blockers given with angiotensin-II receptor antagonists

Anti-arrhythmics: increased myocardial depression when beta-blockers given with anti-arrhythmics; increased risk of bradycardia, AV block and myocardial depression when beta-blockers given with amiodarone; increased risk of ventricular arrhythmias when sotalol given with metoprolol and propranolol increased by propafenone

Antibacterials: increased risk of ventricular arrhythmias when sotalol given with minocycline—avoid concomitant use; metabolism of biperiden and propranolol accelerated by rifampicin (plasma concentration significantly reduced); plasma concentration of carvedilol, celtrolol and metoprolol reduced by rifampicin

Antidepressants: plasma concentration of metoprolol increased by citalopram and escitalopram; plasma concentration of propranolol increased by fluvoxamine; plasma concentration of metoprolol possibly increased by paroxetine (enhanced effect); labetalol and propranolol increase plasma concentration of imipramine; enhanced hypotensive effect when beta-blockers given with MAOIs; increased risk of ventricular arrhythmias when sotalol given with tricyclics

Antidiabetics: beta-blockers may mask warning signs of hypoglycaemia (such as tremor) with anti-diabetics; beta-blockers enhance hypoglycaemic effect of insulin

Antihistamines: increased risk of ventricular arrhythmias when sotalol given with mizolastine—avoid concomitant use

Antimalarials: avoidance of metoprolol and sotalol advised by manufacturer of artepemether/lumefantrine; increased risk of bradycardia when beta-blockers given with metofloquine

Antimuscarnics: increased risk of ventricular arrhythmias when sotalol given with galantamine

Antipsychotics: increased risk of ventricular arrhythmias when sotalol given with clozapine, chlorpromazine, amisulpride, phenothiazines, eipimozide or sulpiride; enhanced hypotensive effect when beta-blockers given with phenothiazines

Antivirals: increased risk of ventricular arrhythmias when sotalol given with saquinavir—avoid concomitant use; avoidance of metoprolol for heart failure advised by manufacturer of tipranavir

Anti-arrhythmics: increased risk of ventricular arrhythmias when sotalol given with atomoxetine

Barbiturates: plasma concentration of metoprolol and timolol reduced by barbiturates; plasma concentration of propranolol possibly reduced by barbiturates

Calcium-channel Blockers: enhanced hypotensive effect when beta-blockers given with calcium-channel blockers; possible severe hypotension and heart failure when beta-blockers given with nifedipine; increased risk of AV block and bradycardia when beta-blockers given with diltiazem; astyole, severe hypotension and heart failure when beta-blockers given with verapamil (see p. 133)

Cardiac Glycosides: increased risk of AV block and bradycardia when beta-blockers given with cardiac glycosides
Betablockers (continued)

- Ciclosporin: carvedilol increases plasma concentration of ciclosporin
- Clonidine: increased risk of withdrawal hypertension when beta-blockers given with clonidine (withdraw beta-blockers several days before slowly withdrawing clonidine)

Corticosteroids: hypertensive effect of beta-blockers antagonised by corticosteroids

- Cytotoxics: increased risk of ventricular arrhythmias when sotalol given with arsenic trioxide
- Diazoxide: enhanced hypertensive effect when beta-blockers given with diazoxide

Diuretics: enhanced hypertensive effect when beta-blockers given with diuretics; risk of ventricular arrhythmias with sotalol increased by hypokaemia caused by loop diuretics or thiazides and related diuretics
- Dopaminergics: enhanced hypertensive effect when beta-blockers given with levodopa

Ergot Alkaloids: increased peripheral vasoconstriction when beta-blockers given with ergotamine and methysergide

- SHT, Agonists: propranolol increases plasma concentration of ziratintrapeut (manufacturer of ziratritape advises half dose and avoid within 2 hours of propranolol)
- Ibabradine: increased risk of ventricular arrhythmias when sotalol given with ibabradine

Methylprednisolone: enhanced hypertensive effect when beta-blockers given with methyldopa
- Moxisylyte: possible severe postural hypotension when beta-blockers given with moxisylyte
- Moxonidine: enhanced hypertensive effect when beta-blockers given with moxonidine

Muscle Relaxants: propranolol enhances effects of muscle relaxants; enhanced hypertensive effect when beta-blockers given with baclofen; possible enhanced hypertensive effect and bradycardia when beta-blockers given with tizanidine

Nitrates: enhanced hypertensive effect when beta-blockers given with nitrates
- Oestrogens: hypertensive effect of beta-blockers antagonised by oestrogens

Parasympathomimetics: propranolol antagonises effects of neostigmine and pyridostigmine; increased risk of arrhythmias when beta-blockers given with pilocarpine

Prostaglandins: enhanced hypertensive effect when beta-blockers given with alprostadil
- Ranolazine: avoidance of sotalol advised by manufacturer of ranolazine

Sympathomimeticones: increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers given with adrenaline (epinephrine), also reponse to adrenaline (epinephrine) may be reduced; increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers given with dobutamine: possible increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers given with noradrenaline (norepinephrine)

Thyroid Hormones: metabolism of propranolol accelerated by levothyroxine

- Ulcer-healing Drugs: plasma concentration of labetalol, metoprolol and propranolol increased by cimetidine

- Vasodilator Antihypertensives: enhanced hypertensive effect when beta-blockers given with hydralazine, minoxidil or sodium nitroprusside
- Betahistine: Antihistamines: effect of betahistine theoretically antagonised by antihistamines
- Betamethasone see Corticosteroids
- Betaxolol see Beta-blockers
- Bethanechol see Parasympathomimetics

Bexarotene
- Antiepileptics: cytoprotection possibly reduce absorption of phenytoin
- Antipsyhtics: avoid concomitant use of cytotoxics with doxorubicine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Lipid-regulating Drugs: plasma concentration of bexarotene increased by simvastatin—avoid concomitant use

Bezafibrate see Fibrates

Bicalutamide
- Anti-coagulants: bicalutamide possibly enhances anticoagulant effect of coumarins

Bigeunides see Antidiabetics

Bile Acid Sequestrants see Colesevelam, Colestipol, and Colestyramine

Bile Acids see Ursodeoxycholic Acid

Bisoprolol see Beta-blockers

Bisphosphonates
- Analgesics: bioavailability of thulordic acid increased by indomethacin
- Antacids: absorption of bisphosphonates reduced by antacids
- Antibacterials: increased risk of hypokaemia when bisphosphonates given with aminoglycosides
- Calcium Salts: absorption of bisphosphonates reduced by calcium salts
- Cytotoxics: sodium clodronate increases plasma concentration of etrastamustine
- Iron: absorption of bisphosphonates reduced by oral iron

Bleomycin
- Antiepileptics: cytoprotection possibly reduce absorption of phenytoin
- Antipsyhtics: avoid concomitant use of cytotoxics with doxorubicine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Bortezomib
- Antiepileptics: cytoprotection possibly reduce absorption of phenytoin
- Antifungals: plasma concentration of bortezomib increased by ketoconazole
- Antipsyhtics: avoid concomitant use of cytotoxics with doxorubicine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Bosantan
- Antibacterials: plasma concentration of bosantan increased by rifampicin—avoid concomitant use
- Anticoagulants: manufacturer of bosantan recommends monitoring anticoagulant effect of coumarins
- Antidiabetics: increased risk of hepatotoxicity when bosantan given with glibenclamide—avoid concomitant use
- Antifungals: plasma concentration of bosantan increased by ketoconazole; plasma concentration of bosantan possibly increased by itraconazole—avoid concomitant use; plasma concentration of bosantan possibly increased by itraconazole
- Antivirals: plasma concentration of bosantan possibly increased by ritonavir
- Ciclosporin: plasma concentration of bosantan increased by ciclosporin (also plasma concentration of ciclosporin reduced—avoid concomitant use)
- Lipid-regulating Drugs: bosantan reduces plasma concentration of simvastatin
- Oestrogens: bosantan possibly causes contraceptive failure of hormonal contraceptives containing
- Oestrogens (alternative contraception recommended)
- Progestogens: bosantan possibly causes contraceptive failure of hormonal contraceptives containing
- Progestogens (alternative contraception recommended)
Antidepressants: manufacturer of bupropion advises avoid concomitant use with MAOIs, tricyclic-related antidepressants and tricyclics

Bupropion

Antipsychotics: plasma concentration of cabergoline increased by erythromycin (increased risk of toxicity); plasma concentration of cabergoline possibly increased by macrolides (increased risk of toxicity)

Antipsychotics: increased risk of hepatotoxicity when busulfan given with tioguanine

Butorphanol see Barbiturates

Butyrophenones see Antipsychotics

Cabe
geline

Antibacterials: plasma concentration of cabergoline increased by erythromycin (increased risk of toxicity); plasma concentration of cabergoline possibly increased by macrolides (increased risk of toxicity)

Antipsychotics: increased risk of hepatotoxicity when busulfan given with tioguanine

Corticotosteroids: absorption of calcium salts reduced by corticosteroids

Diuretics: increased risk of hypercalcaemia when calcium salts given with thiazides and related diuretics

Calcium channel Blockers

ACE Inhibitors: enhanced hypotensive effect when calcium-channel blockers given with ACE inhibitors

Adrenergic Neurone Blockers: enhanced hypotensive effect when calcium-channel blockers given with adrenergic neurone blockers

Alcohol: enhanced hypotensive effect when calcium-channel blockers given with alcohol; verapamil possibly increases plasma concentration of alcohol

Aldesleukin: enhanced hypotensive effect when calcium-channel blockers given with aldesleukin

Alpha-blockers: enhanced hypotensive effect when calcium-channel blockers given with α-blockers, also increased risk of first-dose hypotension with post-synaptic α-blockers such as prazosin

Anaesthetics, General: enhanced hypotensive effect when calcium-channel blockers given with general anaesthetics or isoflurane; hypotensive effect of verapamil enhanced by general anaesthetics (also AV delay)

Antagonists: hypotensive effect of calcium-channel blockers antagonised by NSAIDs; diltiazem inhibits metabolism of alfentanil (risk of prolonged or delayed respiratory depression)

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when calcium-channel blockers given with angiotensin-II receptor antagonists

Anti-arrhythmics: increased risk of bradycardia, AV block and myocardial depression when diltiazem or
Calcium-channel Blockers (continued)

- Verapamil given with lercanidipine; increased risk of myocardial depression and asystole when verapamil given with disopyramide or dronedarone; nifedipine increases plasma concentration of dronedarone.

- Antiarrhythmics: metabolism of verapamil possibly inhibited by amiodarone and verapamil reduces metabolism of nifedipine possibly inhibited by amiodarone; increased risk of bradyarrhythmias and myocardial depression when diltiazem and verapamil given with theophylline; nifedipine increases plasma concentration of theophylline.

- Antibacterials: metabolism of verapamil possibly inhibited by erythromycin and increased risk of toxicity; metabolism of felodipine possibly inhibited by erythromycin; increased plasma concentration of nifedipine; metabolism of diltiazem, nifedipine, and nimodipine accelerated by ifenprodil; plasma concentration significantly increased; metabolism of amlodipine and nifedipine possibly accelerated by ifenprodil (possible significantly reduced plasma concentration).

- Anticoagulants: verapamil possibly increases plasma concentration of dabigatran etexilate (reduce dose of dabigatran etexilate).

- Antidepressants: metabolism of nifedipine possibly inhibited by fluoxetine (increased plasma concentration); diltiazem and verapamil increase plasma concentration of imipramine; enhanced hypotensive effect when calcium-channel blockers given with MAOIs; plasma concentration of verapamil significantly reduced by St John’s wort; plasma concentration of nifedipine reduced by St John’s wort; plasma concentration of amlodipine possibly reduced by St John’s wort; diltiazem and verapamil possibly increase plasma concentration of tricyclic antidepressants: glucose tolerance occasionally impaired when nifedipine given with insulin.

- Anti-epileptics: effects of dihydropyridines, nifedipine, and nifedipine probably reduced by carbamazepine; diltiazem and verapamil enhance effects of carbamazepine; effects of felodipine and isradipine reduced by carbamazepine; effects of felodipine, isradipine, and verapamil reduced by phenytoin; effects of dihydropyridines, nifedipine, and nifedipine probably reduced by phenytoin; diltiazem increases plasma concentration of phenytoin, also increased risk of bradycardia; nifedipine reduces the effect of phenytoin but also affects diltiazem reduced; effects of felodipine and isradipine reduced by primidone; effects of dihydropyridines, diltiazem, and verapamil probably reduced by phenytoin; effects of dihydropyridines, diltiazem, and verapamil probably reduced by phenytoin.

- Antiinflammaty: metabolism of dihydropyridines possibly inhibited by tacrolimus and cyclosporine (increased plasma concentration); metabolism of felodipine inhibited by tacrolimus and cyclosporine; increased plasma concentration of ciclosporin increased by tacrolimus; effects of ciclosporin possibly inhibited by cyclosporine (increased plasma concentration of ciclosporin); effects of ciclosporin possibly inhibited by cyclosporine (increased plasma concentration of ciclosporin); combination of ciclosporin with ciclosporin may increase plasma concentration of eplerenone (reduce dose of eplerenone).

- Cytostatics: plasma concentration of both drugs may increase when verapamil given with atovaquone; nifedipine possibly inhibits metabolism of vincristine and actinomycin D; diazoxide; enhanced hypotensive effect when calcium-channel blockers given with diazoxide.

- Diazoxide: enhanced hypotensive effect when calcium-channel blockers given with diazoxide; plasma concentration of amlodipine possibly increased by grapefruit juice.

- Dopaminergics: enhanced hypotensive effect when calcium-channel blockers given with levodopa; heparin.

- Antithrombotics: plasma concentration of diltiazem increased by warfarin; plasma concentration of verapamil increased by atazanavir; plasma concentration of diltiazem reduced by efavirenz; plasma concentration of calcium-channel blockers possibly increased by atazanavir; manufacturer of lercanidipine advises avoid concomitant use with atazanavir.

- Antivirals: plasma concentration of diltiazem increased by atazanavir (reduce dose of diltiazem); plasma concentration of verapamil possibly increased by atazanavir; plasma concentration of diltiazem reduced by efavirenz; plasma concentration of calcium-channel blockers possibly increased by atazanavir; manufacturer of lercanidipine advises avoid concomitant use with atazanavir.

- Antipsychotics: enhanced hypotensive effect when calcium-channel blockers given with antipsychotics.

- Barbiturates: effects of dihydropyridines, diltiazem, and verapamil possibly reduced by barbiturates; effects of felodipine and isradipine reduced by barbiturates.

- Beta-blockers: enhanced hypotensive effect when calcium-channel blockers given with beta-blockers; increased risk of AV block and bradycardia; nifedipine possibly increases plasma concentration of atorvastatin (reduce dose of atorvastatin).

- Cilostazol: diltiazem increases plasma concentration of cilostazol (consider reducing dose of cilostazol).

- Clonidine: effects of diltiazem and verapamil possibly increased by clonidine.

- Corticosteroids: enhanced hypotensive effect when calcium-channel blockers given with corticosteroids; diltiazem increases plasma concentration of methylprednisolone.

- Cytokines: plasma concentration of both drugs may increase when verapamil given with etanercept; nifedipine possibly inhibits metabolism of vincristine and actinomycin D; diazoxide; enhanced hypotensive effect when calcium-channel blockers given with diazoxide.

- Diazoxide: enhanced hypotensive effect when calcium-channel blockers given with diazoxide; plasma concentration of amlodipine possibly increased by grapefruit juice.

- Dopaminergics: enhanced hypotensive effect when calcium-channel blockers given with levodopa; heparin.

- Antithrombotics: plasma concentration of diltiazem increased by warfarin; plasma concentration of verapamil increased by atazanavir; plasma concentration of diltiazem reduced by efavirenz; plasma concentration of calcium-channel blockers possibly increased by atazanavir; manufacturer of lercanidipine advises avoid concomitant use with atazanavir.

- Antivirals: plasma concentration of diltiazem increased by atazanavir (reduce dose of diltiazem); plasma concentration of verapamil possibly increased by atazanavir; plasma concentration of diltiazem reduced by efavirenz; plasma concentration of calcium-channel blockers possibly increased by atazanavir; manufacturer of lercanidipine advises avoid concomitant use with atazanavir.
Lipid-regulating Drugs

Antiepileptics:

- Lipid-regulating Drugs (continued)
  - possible increased risk of myopathy when amlo-
    dipine given with simvastatin.
  - Lithium: neurotoxicity may occur when diltiazem or
    verapamil given with lithium without increased
    plasma concentration of lithium.
  - Magnesium (parenteral): profound hypotension
    reported with concomitant use of nifedipine and
    parenteral magnesium in pre-eclampsia.
  - Methylprednisolone: enhanced hypotensive effect when
    calcium-channel blockers given with methylpobra.
  - Moxisylyte: enhanced hypotensive effect when
    calcium-channel blockers given with moxisylyte.
  - Moxonidine: enhanced hypotensive effect when
    calcium-channel blockers given with moxonidine.

Muscle Relaxants: verapamil enhances effects of non-
depolarising muscle relaxants and suxamethonium; enhanced
hypotensive effect when calcium-channel blockers given with
baclofen or tizanidine; hypotension, myocardial depression, and
hyperkalaemia when verapamil given with intravenous dantrolene;
possible increased risk of ventricular arrhythmias when diltiazem
given with intravenous dantrolene—manufacturer of diltiazem advises avoid concomitant
use. calcium-channel blockers possibly enhance effects of non-
depolarising muscle relaxants.

Nitrates: enhanced hypotensive effect when calcium-
channel blockers given with nitrates.

Oestrogens: hypotensive effect of calcium-channel
blockers antagonised by oestrogens.

Prostaglandins: enhanced hypotensive effect when
 calcium-channel blockers given with alprostadil.

Ranolazine: diltiazem and verapamil increase plasma
concentration of ranolazine (consider reducing dose of
ranolazine).

Sildenafil: diltiazem and verapamil increase plasma
concentration of sildenafil (consider reducing dose of
diltiazem and verapamil).

Ulcer-healing Drugs: metabolism of calcium-channel
blockers possibly inhibited by cinemidine (increased
plasma concentration); plasma concentration of
isosapine increased by cinemidine (halve dose of
isosapine).

Vardenafil: enhanced hypotensive effect when nife-
dipine given with vardenafil.

Vasodilator Antihypertensives: enhanced hypoten-
sive effect when calcium-channel blockers given with
hydralazine, minoxidil or sodium nitroprusside.

Calcium-channel Blockers (dihydropyridines) see
Calcium-channel Blockers

Calcium-channel Blockers

- Lipid-regulating Drugs (continued)
  - possible increased risk of myopathy when amlo-
    dipine given with simvastatin.
  - Lithium: neurotoxicity may occur when diltiazem or
    verapamil given with lithium without increased
    plasma concentration of lithium.
  - Magnesium (parenteral): profound hypotension
    reported with concomitant use of nifedipine and
    parenteral magnesium in pre-eclampsia.
  - Methylprednisolone: enhanced hypotensive effect when
    calcium-channel blockers given with methylpobra.
  - Moxisylyte: enhanced hypotensive effect when
    calcium-channel blockers given with moxisylyte.
  - Moxonidine: enhanced hypotensive effect when
    calcium-channel blockers given with moxonidine.

Muscle Relaxants: verapamil enhances effects of non-
depolarising muscle relaxants and suxamethonium; enhanced
hypotensive effect when calcium-channel blockers given with
baclofen or tizanidine; hypotension, myocardial depression, and
hyperkalaemia when verapamil given with intravenous dantrolene;
possible increased risk of ventricular arrhythmias when diltiazem
given with intravenous dantrolene—manufacturer of diltiazem advises avoid concomitant
use. calcium-channel blockers possibly enhance effects of non-
depolarising muscle relaxants.

Nitrates: enhanced hypotensive effect when calcium-
channel blockers given with nitrates.

Oestrogens: hypotensive effect of calcium-channel
blockers antagonised by oestrogens.

Prostaglandins: enhanced hypotensive effect when
 calcium-channel blockers given with alprostadil.

Ranolazine: diltiazem and verapamil increase plasma
concentration of ranolazine (consider reducing dose of
ranolazine).

Sildenafil: diltiazem and verapamil increase plasma
concentration of sildenafil (consider reducing dose of
diltiazem and verapamil).

Ulcer-healing Drugs: metabolism of calcium-channel
blockers possibly inhibited by cinemidine (increased
plasma concentration); plasma concentration of
isosapine increased by cinemidine (halve dose of
isosapine).

Vardenafil: enhanced hypotensive effect when nife-
dipine given with vardenafil.

Vasodilator Antihypertensives: enhanced hypoten-
sive effect when calcium-channel blockers given with
hydralazine, minoxidil or sodium nitroprusside.

Calcium-channel Blockers (dihydropyridines) see
Calcium-channel Blockers

Candesartan see Angiotensins-II Receptor Antagonists

Cannabis Extract

Antidepressants: possible increased risk of hyper-
tension and tachycardia when cannabis extract given with
tricycls.

Captopril see Fluorouracil

Capreomycin (continued)

- Antibacterials: increased risk of nephrotoxicity when
  carbapenem given with colistin or polymyxins; in-
  creased risk of nephrotoxicity and ototoxicity when
  carbapenem given with aminoglycosides or vancocin-
  mycin.

Cytotoxics: increased risk of nephrotoxicity and
  ototoxicity when carbapenem given with platinum
  compounds.

Capreomycin

- Antibacterials: increased risk of nephrotoxicity when
  carbapenem given with colistin or polymyxins; in-
  creased risk of nephrotoxicity and ototoxicity when
  carbapenem given with aminoglycosides or vancocin-
  mycin.

Cytotoxics: increased risk of nephrotoxicity and
  ototoxicity when carbapenem given with platinum
  compounds.

Captopril see ACE Inhibitors

Carbamazepine

- Alcohol: CNS side-effects of carbamazepine possibly
  increased by alcohol.

- Analgesics: effects of carbamazepine enhanced by
dextropropoxyphene; carbamazepine reduces
  plasma concentration of methadone; carbamazepine
  reduces effects of tramadol; carbamazepine possibly
  accelerates metabolism of paracetamol.

- Antiarhythmics: carbamazepine possibly reduces
  plasma concentration of enonavirone—avoid con-
  comitant use.

- Antibacterials: plasma concentration of carbama-
  zepine increased by clotrimazole and
  erythromycin; plasma concentration of carba-
  mazepine reduced by rifabutin; carbamazepine
  accelerates metabolism of doxycline (reduced
  effect); plasma concentration of carbamazepine
  increased by azole (also possibly increased
  ionized hepatotoxicity); carbamazepine reduces
  plasma concentration of etilithromycin (avoid during
  and for 2 weeks after carbamazepine).

- Anticoagulants: carbamazepine accelerates metabolism of coumarins (reduced anticoagulant effect).

- Antidepressants: plasma concentration of carba-
  mazepine increased by fluoxetine and
  fluvoxamine; carbamazepine reduces plasma concentration
  of eminister and mirtazapine; manufacturer of carbamazepine advises avoid for 2 weeks
  after stopping MAOIs, also antagonism of anti-
  convulsant effect; anticonvulsant effect of anti-
  epileptics possibly antagonised by MAOIs and
  tricyclic-related antidepressants (convulsive
  threshold lowered); anticonvulsant effect of anti-
  epileptics antagonised by SSRIs and
  tricyclics (convulsive threshold lowered); avoid concomitant
  use of antiepileptics with St John’s wort; carba-
  mazepine accelerates metabolism of tricyclics
  (reduced plasma concentration and reduced effect).

- Antiplatelets: plasma concentration of both drugs
  reduced when carbamazepine given with eslicarba-
  zepine; carbamazepine possibly reduces plasma
  concentration of ethosuximide; carbamazepine often
  reduces plasma concentration of lamotrigine, also
  plasma concentration of an active metabolite of
  carbamazepine sometimes raised (but evidence is
  conflicting); possible increased risk of carba-
  mazepine toxicity when given with levetracetam; plasma
  concentration of carbamazepine sometimes reduced by
  oxcarbazepine (but concentration of an active
  metabolite of carbamazepine may be increased), also
  plasma concentration of an active metabolite of
  oxcarbazepine often reduced; plasma concentration of
  both drugs often reduced when carbamazepine
  given with phenytoin, also plasma concentration of
  phenytoin; also plasma concentration of phenytoin may be increased; plasma concentration
  of carbamazepine often reduced when given with
  rufinamide; plasma concentration of the active metabolite of
  carbamazepine sometimes reduced (but evidence is
  conflicting), also plasma concentration of an active
  metabolite of carbamazepine may be increased), also
  plasma concentration of an active metabolite of
  oxcarbazepine often reduced; plasma concentration of
  both drugs often reduced when carbamazepine
Carbamazepine

- Antifungals (continued): carbamazepine possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin

- Antimalarials: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antibacterials: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihistamines: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anti-inflammatory agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticonvulsants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antidepressants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antidiabetics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihypertensives: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin reduced by rifampicin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antimyotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antineoplastics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antithrombotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antituberculosis agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antivirals: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antidepressants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihypertensives: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antimyotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antineoplastics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antituberculosis agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antivirals: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihypertensives: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antimyotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antineoplastics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antituberculosis agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antivirals: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihypertensives: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antimyotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antineoplastics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antituberculosis agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antivirals: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antihypertensives: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antimyotics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antineoplastics: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antituberculosis agents: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Antivirals: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)

- Anticoagulants: increased cardiac toxicity with cardiac glycosides possibly increased by gentamicin, telithromycin and trimethoprim; absorption of digoxin reduced by neomycin; plasma concentration of digoxin increased by macrolides (increased risk of toxicity)}
Appendix 1: Interactions

Cardiac Glycosides (continued)

Caspofungin (continued)

Antivirals: plasma concentration of digoxin increased by etravirine; plasma concentration of digoxin possibly increased by ritonavir

Anticonvulsants and Hypnotics: plasma concentration of digoxin increased by alprazolam (increased risk of toxicity)

Beta-blockers: increased risk of AV block and bradycardia when cardiac glycosides given with beta-blockers

Calcium Salts: arrhythmias can be precipitated when cardiac glycosides given with large intravenous doses of calcium salts

- Calcium-channel blockers: plasma concentration of digoxin increased by edidazem, lercanidipine and nicardipine; plasma concentration of digoxin possibly increased by minoxidipine; plasma concentration of digoxin increased by verapamil, also increased risk of AV block and bradycardia

- Ciclosporin: plasma concentration of digoxin increased by ciclosporin (increased risk of toxicity)

- Colchicine: possible increased risk of myopathy when digoxin given with colchicine

- Corticosteroids: increased risk of hypokalaemia when cardiac glycosides given with corticosteroids

- Cytotoxic drugs: absorption of digoxin tablets reduced by cytoxic drugs

- Diuretics: increased cardiac toxicity with cardiac glycosides if hypokalaemia occurs with acetazolamide, loop diuretics or thiazides and related diuretics; plasma concentration of digoxin possibly increased by potassium canrenoate; plasma concentration of digoxin increased by epirronolactone

- Lenalidomide: plasma concentration of digoxin possibly increased by lenalidomide

- Lipid-regulating drugs: absorption of cardiac glycosides possibly reduced by colestipol and colestyramine; plasma concentration of digoxin possibly increased by atorvastatin

- Muscle relaxants: risk of ventricular arrhythmias when cardiac glycosides given with suxamethonium; possible increased risk of bradycardia when cardiac glycosides given with tizanidine

- Penicillamine: plasma concentration of digoxin possibly reduced by penicillamine

- Ranolazine: plasma concentration of digoxin increased by ranolazine

- Sympathomimetics, Beta-2: plasma concentration of digoxin possibly reduced by salbutamol

- Tolvaptan: plasma concentration of digoxin increased by tolvaptan (increased risk of toxicity)

- Uler-healing Drugs: plasma concentration of digoxin possibly slightly increased by proton pump inhibitors; absorption of cardiac glycosides possibly reduced by sucralfate

Carmustine

Antiepileptics: cytoxic possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxic with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytoxic reduce absorption of digoxin tablets

Uler-healing Drugs: myelosuppressive effects of carmustine possibly enhanced by cimetidine

Ceftriaxone see Cefalosporins

Cefuroxime see Cefalosporins

Cefuroxime see Cefalosporins

Ceftaxime see Cefalosporins

Ceftobutane see Cefalosporins

Carbapenems see Beta-blockers

Ciclosporin

Antibacterials: plasma concentration of caspofungin initially increased and then reduced by rifampicin (consider increasing dose of caspofungin)

Antiepileptics: plasma concentration of caspofungin possibly reduced by carbamazepine and phenytoin—consider increasing dose of caspofungin

Antivirals: plasma concentration of caspofungin possibly reduced by efavirenz and nevirapine—consider increasing dose of caspofungin
Chloroquine and Hydroxychloroquine
Agalsidase Alfa and Beta (continued)
Antacid: absorption of chloroquine and hydroxychloroquine reduced by antacids
Anti-arrhythmics: increased risk of ventricular arrhythmias when chloroquine and hydroxychloroquine given with amiodarone—avoid concomitant use
Antibacterials: increased risk of nephrotoxicity when chloroquine given with trimethoprim, also plasma concentration of ciclosporin reduced by intravenous trimethoprim
Antidepressants: plasma concentration of ciclosporin reduced by St John’s wort—avoid concomitant use Antidiabetics: ciclosporin possibly enhances hypoglycaemic effect of repaglinide
Antiepileptics: metabolism of ciclosporin accelerated by carbamazepine and phenytoin (reduced plasma concentration); plasma concentration of ciclosporin possibly reduced by oxcarbazepine; metabolism of ciclosporin accelerated by pramidone (reduced effect)
Antifungals: metabolism of ciclosporin inhibited by fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole (increased plasma concentration); metabolism of ciclosporin possibly inhibited by miconazole (increased plasma concentration); increased risk of nephrotoxicity when ciclosporin given with amphotericin; ciclosporin increases plasma concentration of eucapufin; (manufacturer of caspofungin recommends monitoring liver enzymes); plasma concentration of ciclosporin possibly reduced by guselkulin and terbinafine; plasma concentration of ciclosporin possibly increased by micafungin
Antimalarials: plasma concentration of ciclosporin increased by chloroquine and hydroxychloroquine (increased risk of toxicity)
Antimucosities: avoidance of ciclosporin advised by manufacturer of darifenacin
Antivirals: increased risk of nephrotoxicity when ciclosporin given with aciclovir; plasma concentration of ciclosporin possibly increased by etaxanavir, efavirenz and nelfinavir; plasma concentration of ciclosporin possibly reduced by efavirenz; plasma concentration of ciclosporin increased by fosamprenavir and indinavir; plasma concentration of both drugs increased when ciclosporin given with saquinavir
Barbiturates: metabolism of ciclosporin accelerated by barbiturates (reduced effect)
Beta-blockers: plasma concentration of ciclosporin increased by carvedilol
Bile Acids: absorption of ciclosporin increased by ursodeoxycholic acid
Bone:

Ciclosporin

Antibacterials: reduced plasma concentration of ciclosporin possibly increased by amiodarone and propafenone
Anti-arrhythmics: plasma concentration of ciclosporin possibly increased by amiodarone and propafenone
Antibacterials: metabolism of ciclosporin inhibited by clindamycin, doxycycline and etretinomycin (increased risk of nephrotoxicity when ciclosporin given with amiodarone or propafenone; metabolism of ciclosporin possibly increased by amiodarone and propafenone)
Antiepileptics: metabolism of ciclosporin inhibited by efavirenz; plasma concentration of ciclosporin possibly increased by etaxanavir, efavirenz and nelfinavir; plasma concentration of ciclosporin possibly reduced by efavirenz; plasma concentration of ciclosporin increased by fosamprenavir and indinavir; plasma concentration of both drugs increased when ciclosporin given with saquinavir
Antifungals: metabolism of ciclosporin inhibited by fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole (increased plasma concentration); metabolism of ciclosporin possibly inhibited by miconazole (increased plasma concentration); increased risk of nephrotoxicity when ciclosporin given with amphotericin; ciclosporin increases plasma concentration of eucapufin; (manufacturer of caspofungin recommends monitoring liver enzymes); plasma concentration of ciclosporin possibly reduced by guselkulin and terbinafine; plasma concentration of ciclosporin possibly increased by micafungin
Antimalarials: plasma concentration of ciclosporin increased by chloroquine and hydroxychloroquine (increased risk of toxicity)
Antimucosities: avoidance of ciclosporin advised by manufacturer of darifenacin
Antivirals: increased risk of nephrotoxicity when ciclosporin given with aciclovir; plasma concentration of ciclosporin possibly increased by etaxanavir, efavirenz and nelfinavir; plasma concentration of ciclosporin possibly reduced by efavirenz; plasma concentration of ciclosporin increased by fosamprenavir and indinavir; plasma concentration of both drugs increased when ciclosporin given with saquinavir
Barbiturates: metabolism of ciclosporin accelerated by barbiturates (reduced effect)
Beta-blockers: plasma concentration of ciclosporin increased by carvedilol
Bile Acids: absorption of ciclosporin increased by ursodeoxycholic acid
Bone:...
Appendix 1: Interactions

**Cilazapril**
- Antivirals: increases plasma concentration of acyclovir and foscarnet

**Cidofovir**
- Antivirals: increases plasma concentration of cidofovir

**Tacrolimus**
- Calcium-channel Blockers: plasma concentration of ciclosporin increased by diltiazem (consider reducing dose of ciclosporin)

**Cimetidine**
- Histamine H2-antagonists

**Cinacalcet**
- Antifungals: metabolism of cinacalcet inhibited by ketoconazole (increased risk of nephrotoxicity and possibly hyperkalaemia when ciclosporin given with ketoconazole)
Clonidine (continued)
Calcium-channel Blockers: enhanced hypotensive effect when clonidine given with calcium-channel blockers
Corticosteroids: hypotensive effect of clonidine antagonised by corticosteroids
Diazoxide: enhanced hypotensive effect when clonidine given with diazoxide
Diuretics: enhanced hypotensive effect when clonidine given with diuretics
Dopaminergics: enhanced hypotensive effect when clonidine given with levodopa
Histamine: avoidance of clonidine advised by manufacturer of histamine
Methyldopa: enhanced hypotensive effect when clonidine given with methyldopa
Moxisylyte: enhanced hypotensive effect when clonidine given with moxisylyte
Moxonidine: enhanced hypotensive effect when clonidine given with moxonidine
Muscle Relaxants: enhanced hypotensive effect when clonidine given with baclofen or tizanidine
Nitrates: enhanced hypotensive effect when clonidine given with nitrates
Oestrogens: hypotensive effect of clonidine antagonised by oestrogens
Prostaglandins: enhanced hypotensive effect when clonidine given with alprostadil
Sympathomimetics: possible risk of hypertension when clonidine given with adrenaline (epinephrine) or noradrenaline (norepinephrine); serious adverse events reported with concomitant use of clonidine and methylphenidate (causality not established)
Vasodilator Antihypertensives: enhanced hypotensive effect when clonidine given with hydralazine, minoxidil or sodium nitroprusside
Clopamide see Diuretics
Clonidopril
Analgesics: increased risk of bleeding when clonidopril given with NSAIDs or aspirin
Antibacterials: antipatelet effect of clonidopril possibly reduced by ciprofloxacin and erythromycin
Anticoagulants: manufacturer of clonidopril advises avoidance concomitant use with warfarin; antipatelet action of clonidopril enhances anticoagulant effect of coumarins and phenindione; increased risk of bleeding when clonidopril given with heparins
Antidepressants: antipatelet effect of clonidopril possibly reduced by fluoxetine, fluvoxamine and moclobemide
Antiepileptics: antipatelet effect of clonidopril possibly reduced by carbamazepine and eslicarbazepine
Antifungals: antipatelet effect of clonidopril possibly reduced by raconazole, itraconazole, ketoconazole and voriconazole
Antivirals: antipatelet effect of clonidopril possibly reduced by estravirine
Dipyridamole: increased risk of bleeding when clonidopril given with dipyridamole
Iloprost: increased risk of bleeding when clonidopril given with iloprost
Prasugrel: possible increased risk of bleeding when clonidopril given with prasugrel
Ulcer-healing Drugs: antipatelet effect of clonidopril possibly reduced by omeprazole and rabeprazole; antipatelet effect of clonidopril reduced by esomeprazole and omeprazole
Clotrimazole see Antifungals, Imidazole
Clazapine see Antipsychotics
Clo-amoxiclav see Penicillins
Co-beneldopa see Levodopa
Co-careldopa see Levodopa
Codiene see Opioid Analgesics
Co-flumifucit see Penicillins

Appendix 1: Interactions

Co-flumipicil see Penicillins

Anticoagulants: possible increased risk of colchicine toxicity when given with amiodarone
Antibacterials: possible increased risk of colchicine toxicity when given with clarithromycin, erythromycin and telithromycin—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Antifungals: possible increased risk of colchicine toxicity when given with itraconazole and ketoconazole—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Antivirals: possible increased risk of colchicine toxicity when given with atazanavir, indinavir and efavirenz—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Calcium-channel Blockers: possible increased risk of colchicine toxicity when given with dibetazem and verspani—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Cardiac Glycosides: possible increased risk of myopathy when colchicine given with digoxin
Ciclosporin: possible increased risk of nephrotoxicity and myotoxicity when colchicine given with ciclosporin—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Grapefruit Juice: possible increased risk of colchicine toxicity when given with grapefruit juice
Lipid-regulating Drugs: possible increased risk of myopathy when colchicine given with fibrates or statins
Colestevelam
Note Other drugs should be taken at least 4 hours before or after colestevelam to reduce possible interference with absorption
Antidiabetics: colestevelam reduces absorption of glibenclamide
Antiepileptics: colestevelam possibly reduces absorption of phenytoin
Ciclosporin: colestevelam reduces absorption of ciclosporin
Oestrogens: colestevelam reduces absorption of ethinylestradiol
Thyroid Hormones: colestevelam reduces absorption of levothyroxine
Colestipol
Note Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption
Antibacterials: colestipol possibly reduces absorption of tetracycline
Bile Acids: colestipol possibly reduces absorption of bile acids
Cardiac Glycosides: colestipol possibly reduces absorption of cardiac glycosides
Diuretics: colestipol reduces absorption of thiazides and related diuretics (give at least 2 hours apart)
Thyroid Hormones: colestipol reduces absorption of thyroid hormones
Colestramine
Note Other drugs should be taken at least 1 hour before or 4–6 hours after colestramine to reduce possible interference with absorption
Analgesics: colestramine increases the excretion of meloxicam; colestramine reduces absorption of paracetamol
Antibacterials: colestramine possibly reduces absorption of tetracycline; colestramine antagonises effects of oral vancomycin
Anticoagulants: colestramine may enhance or reduce anticoagulant effect of coumarins and phenindione
Anticoagulants:

Antiepileptics:

Aldesleukin:

Corticosteroids

Antidiabetics:

Antibacterials:

Antifungals:

Antivirals:

Barbiturates:

Beta-blockers:

Calcium-channel Blockers:

Calcium Salts:

Cardiac Glycosides:

Clonidine:

Clotrimazole:

Ciclosporin:

Coenzyme A

Coenzyme A

Contraceptives, oral

 Corticosteroids

Dexamethasone possibly reduces plasma concentration of prednisolone (reduced effect)

Diazoxide:

Diltiazem:

Doxycycline:

Duralone:

Dysphagia:

Diuretics:

Calcium-channel Blockers:

Calcium Salts:

Calcium-channel Blockers:

Calcium Salts:

Corticosteroids

Antidiabetics:

Antihypertensives:

Antihistamines:

Anticoagulants:

Antifungal:

Antiviral:

Bile Acids:

Cardiac Glycosides:

Statins:

Sympathomimetics, Beta 2:

Sympathomimetics:

Mometasone:

Somatropin:

Somatotropin:

Somatropin:

Somatotropin:

Somatotropin:

Somatotropin:
Corticosteroids (continued)
Vasodilator Antihypertensives: corticosteroids antagonise hypotensive effect of hydralazine, minoxidil and sodium nitroprusside

Cortisone see Corticosteroids

Co-trimoxazole see Trimethoprim and Sulfamethoxazole

Coumarins

Note: Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control
• Alcohol: anticoagulant control with coumarins may be affected by major changes in consumption of alcohol
  Allopurinol: anticoagulant effect of coumarins possibly enhanced by allopurinol

• Anabolic Steroids: anticoagulant effect of coumarins enhanced by anabolic steroids

• Analgesics: anticoagulant effect of coumarins possibly enhanced by NSAIDs; increased risk of haemorrhage when anticoagulants given with intravenous diclofenac (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with ketorolac (avoid concomitant use, including low-dose heparins); anticoagulant effect of coumarins enhanced by tramadol; increased risk of bleeding when coumarins given with aspirin (due to antiplatelet effect); anticoagulant effect of coumarins possibly enhanced by prolonged regular use of paracetamol

• Anti-arrhythmics: metabolism of coumarins inhibited by amiodarone (enhanced anticoagulant effect); anticoagulant effect of coumarins enhanced by propafenone

• Antibacterials: experience in anticoagulant clinics suggests that INR possibly altered when coumarins are given with neomycin (given for local action on gut); anticoagulant effect of coumarins possibly enhanced by azithromycin, aztreonam, cephalexin, levofloxacin, erythromycin, tigecycline and trimethoprim; anticoagulant effect of coumarins enhanced by chloramphenicol, ciprofloxacin, clarithromycin, erythromycin, metronidazole, nalidixic acid, oxacillin, ofloxacin and sulphonamides; studies have failed to demonstrate an interaction with coumarins, but common experience in anticoagulant clinics is that INR can be altered by a course of broad-spectrum penicillins such as ampicillin; metabolism of coumarins accelerated by rifampicin (reduced anti-coagulant effect)

• Antidepressants: anticoagulant effect of warfarin possibly enhanced by venlafaxine; anticoagulant effect of warfarin may be enhanced or reduced by trazodone; anticoagulant effect of coumarins possibly enhanced by SSRIs; anticoagulant effect of coumarins reduced by St John’s wort (avoid concomitant use); anticoagulant effect of warfarin enhanced by mirtazapine; anticoagulant effect of coumarins may be enhanced or reduced by eticycloxycarbamine (reduced anti-coagulant effect)

• Anti-diabetics: anticoagulant effect of warfarin possibly enhanced by exenatide; coumarins possibly enhance hypoglycaemic effect of sulfonylureas, also possible changes to anticoagulant effect

• Antiepileptics: metabolism of coumarins accelerated by carbamazepine and primidon (reduced anti-coagulant effect); plasma concentration of warfarin reduced by eslicarbazepine; metabolism of coumarins accelerated by topiramate (possibility of reduced anticoagulant effect, but enhancement also reported); anticoagulant effect of coumarins possibly enhanced by valproate

• Antifungals: anticoagulant effect of coumarins enhanced by fluconazole, itraconazole

Appendix 1: Interactions

Co-trimoxazole and voriconazole; anticoagulant effect of coumarins enhanced by fluconazole (miconazole oral gel and possibly vaginal formulations absorbed); anticoagulant effect of coumarins reduced by griseofulvin

Antimalarials: isolated reports that anticoagulant effect of warfarin may be enhanced by proguanil; plasma concentration of both drugs increased when warfarin given with quinine

Antivirals: anticoagulant effect of warfarin may be enhanced or reduced by atazanavir, efavirenz and ritonavir; plasma concentration of warfarin possibly affected by efavirenz; anticoagulant effect of coumarins may be enhanced or reduced by fosamprenavir; anticoagulant effect of coumarins possibly enhanced by ritonavir; anticoagulant effect of warfarin possibly enhanced by saquinavir

Anxiolytics and Hypnotics: anticoagulant effect of coumarins may transiently be enhanced by chloral and triclofos

Aprepitant: anticoagulant effect of warfarin possibly reduced by aprepitant

Azathioprine: anticoagulant effect of coumarins possibly reduced by azathioprine

Barbiturates: metabolism of coumarins accelerated by barbiturates (reduced anticoagulant effect)

Bosentan: monitoring anticoagulant effect of coumarins recommended by manufacturer of bosentan

Clopidogrel: anticoagulant effect of coumarins enhanced due to antiplatelet action of clopidogrel; avoidance of warfarin advised by manufacturer of clopidogrel

Corticosteroids: anticoagulant effect of coumarins may be enhanced or reduced by corticosteroids (high-dose corticosteroids enhance anticoagulant effect)

Craberry Juice: anticoagulant effect of coumarins possibly enhanced by cranberry juice—avoid concomitant use

Cytotoxics: anticoagulant effect of coumarins possibly enhanced by etoposide, ifosfamide and mitomycin; anticoagulant effect of coumarins enhanced by fluorouracil; anticoagulant effect of warfarin possibly enhanced by efavirenz and gemcitabine; anticoagulant effect of coumarins possibly reduced by mercaptopurine and thioguanine; increased risk of bleeding when coumarins given with erlotinib; replacement of warfarin with a heparin advised by manufacturer of imatinib (possibility of enhanced warfarin effect)

Dipyridamole: anticoagulant effect of coumarins enhanced due to antiplatelet action of dipyridamole

Disulfiram: anticoagulant effect of coumarins enhanced by disulfiram

Dopaminergics: anticoagulant effect of warfarin enhanced by entacapone

Enteral Feeds: anticoagulant effect of coumarins antagonised by vitamin K (present in some enteral feeds)

Glucosamine: anticoagulant effect of warfarin enhanced by glucosamine (avoid concomitant use)

Hormone Antagonists: anticoagulant effect of coumarins possibly enhanced by bicalutamide and stenodimene; metabolism of coumarins inhibited by danazol (enhanced anticoagulant effect); anticoagulant effect of coumarins enhanced by flutamide and tamoxifen

Iloprost: anticoagulant effect of coumarins possibly enhanced by iloprost

Lactulose: anticoagulant effect of coumarins possibly enhanced by lactulose

Lefunomide: anticoagulant effect of warfarin possibly enhanced by leflunomide

Leukotriene Receptor Antagonists: anticoagulant effect of warfarin enhanced by zafirlukast
Appendix 1: Interactions

Coomarins (continued)

- Levamisole: anticoagulant effect of warfarin possibly enhanced by levamisole
- Lipid-regulating Drugs: anticoagulant effect of coomarins may be enhanced or reduced by colesteryramine; anticoagulant effect of warfarin may be transiently reduced by atorvastatin; anticoagulant effect of warfarin enhanced by fibrates, Atorvastatin and simvastatin; anticoagulant effect of coomarins possibly enhanced by ezetimibe and rosuvastatin
- Memantine: anticoagulant effect of warfarin possibly enhanced by memantine
- Oestrogens: anticoagulant effect of coomarins may be enhanced or reduced by oestrogens
- Orlistat: monitoring anticoagulant effect of warfarin recommended by manufacturer of orlistat
- Prasugrel: possible increased risk of bleeding when coomarins given with prasugrel
- Progestogens: anticoagulant effect of warfarin may be enhanced or reduced by progestogens
- Sildenafil: anticoagulant effect of warfarin antagonised by sildenafil
- Retinoids: anticoagulant effect of coomarins possibly reduced by acitretin
- Sildenafil: anticoagulant effect of warfarin enhanced by sildenafil
- Sulfinpyrazone: anticoagulant effect of coomarins enhanced by sulfinpyrazone
- Sympathomimetics: anticoagulant effect of coomarins possibly enhanced by methylphenidate
- Testolactone: anticoagulant effect of coomarins enhanced by testolactone
- Testosterone: anticoagulant effect of coomarins enhanced by testosterone
- Thyroid Hormones: anticoagulant effect of coomarins enhanced by thyroid hormones
- Ubidecarenone: anticoagulant effect of warfarin may be enhanced or reduced by ubidecarenone
- Ulcer-healing Drugs: metabolism of coomarins inhibited by omeprazole (enhanced anticoagulant effect); anticoagulant effect of coomarins possibly enhanced by esomeprazole, omeprazole and pantoprazole; absorption of coomarins possibly reduced by sucralfate (reduced anticoagulant effect)
- Vaccines: anticoagulant effect of warfarin possibly enhanced by influenza vaccine
- Vitamins: anticoagulant effect of coomarins possibly enhanced by vitamin E; anticoagulant effect of coomarins antagonised by vitamin K
- Cranberry Juice
- Anticoagulants: cranberry juice possibly enhances anticoagulant effect of coomarins—avoid concomitant use

Cycloclorizine see Antihistamines

Cyclopenthiazide see Diuretics

Cyclosporin see Ciclosporin

Cyclophosphamide
- Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
- Antifungals: enhanced risk of agranulocytosis
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Cytotoxics: increased toxicity when high-dose cyclophosphamide given with pentostatin—avoid concomitant use
- Muscle Relaxants: cyclophosphamide enhances effects of suxamethonium

Cycloserine
- Alcohol: increased risk of convulsions when cycloserine given with alcohol
- Antibacterials: increased risk of CNS toxicity when cycloserine given with isoniazid
- Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Cyprenalidine see Antihistamines

Cytrabine
- Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
- Antifungals: cytrabine possibly reduces plasma concentration of flucytosine
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Cytotoxics: intracellular concentration of cytrabine increased by fludarabine

Cytoxics see individual drugs

Dabigatran Etepliate
- Analgesics: possible increased risk of bleeding when dabigatran etexilate given with NSAIDs; increased risk of haemorrhage when coomarins given with intravenous diltiazem; avoid concomitant use, including low-dose heparins; increased risk of haemorrhage when coomarins given with ketorolac (avoid concomitant use, including low-dose heparins)
- Anti-arrhythmics: plasma concentration of dabigatran etexilate increased by amiodarone (reduce dose of dabigatran etexilate)
- Calcium-channel Blockers: plasma concentration of dabigatran etexilate possibly increased by verapamil (reduce dose of dabigatran etexilate)

Dacarbazine
- Aldesleukin: avoidance of dacarbazine advised by manufacturer of aldesleukin
- Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Daily Products
- Antibacterials: daily products reduce absorption of ciprofloxacin and norfloxacin; daily products reduce absorption of tetracyclines (except doxycycline and minocycline)
- Eltrombopag: daily products possibly reduce absorption of eltrombopag (give at least 4 hours apart)

Dalteparin see Heparins

Danaazol
- Anticoagulants: danazol inhibits metabolism of coumarins (enhanced anticoagulant effect)
- Antiepileptics: danazol inhibits metabolism of carbamazepine (increased risk of toxicity)
- Ciclosporin: danazol inhibits metabolism of ciclosporin (increased plasma concentration)
- Lipid-regulating Drugs: possible increased risk of myopathy when danazol given with simvastatin
- Tacrolimus: danazol possibly increases plasma concentration of tacrolimus

Dantrolene see Muscle Relaxants

Dapsone
- Antibacterials: plasma concentration of dapsone reduced by rifampicin; plasma concentration of both drugs may increase when dapsone given with trimethoprim
- Antivirals: increased risk of ventricular arrhythmias when dapsone given with saquinavir—avoid concomitant use
- Probencid: excretion of dapsone reduced by probenecid (increased risk of side-effects)
- Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Daptomycin
- Ciclosporin: increased risk of myopathy when daptomycin given with ciclosporin (preferably avoid concomitant use)
- Lipid-regulating Drugs: increased risk of myopathy when daptomycin given with fibrates or statins (preferably avoid concomitant use)
- Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
Darifenacin see Antimuscarinics

Darunavir
Ant-arrhythmics: darunavir possibly increases plasma concentration of lidocaine—avoid concomitant use
Antibacterials: darunavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of darunavir significantly reduced by rifampicin—avoid concomitant use
Anticoagulants: avoidance of darunavir advised by manufacturer of rivaroxaban
Antidepressants: darunavir possibly reduces plasma concentration of paroxetine and sertraline; plasma concentration of darunavir reduced by St John’s wort—avoid concomitant use
Antiepileptics: plasma concentration of darunavir possibly reduced when darunavir given with carbamazepine and phenytoin
Antifungals: plasma concentration of both drugs increased when darunavir given with ketoconazole
Antimalarials: caution with darunavir advised by manufacturer of artemether/lumefantrine; darunavir possibly increases plasma concentration of quinine (increased risk of toxicity)
Antivirals: plasma concentration of darunavir reduced by efavirenz and saquinavir; plasma concentration of both drugs increased when darunavir given with indinavir; plasma concentration of darunavir reduced by lopinavir; also plasma concentration of lopinavir increased (avoid concomitant use); darunavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)
Barbiturates: plasma concentration of darunavir possibly reduced by phenobarbital
Cytotoxics: darunavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use
Lipid-regulating Drugs: darunavir possibly increases plasma concentration of pravastatin; possible increased risk of myopathy when darunavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use
Ranolazine: darunavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
Dasatinib
Antibacterials: metabolism of dasatinib accelerated by rifampicin (reduced plasma concentration—avoid concomitant use)
Antiepileptics: cytoxotics possibly reduce absorption of phenytoin
Antifungals: plasma concentration of dasatinib possibly increased by ketoconazole
Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)
Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets
Lipid-regulating Drugs: dasatinib possibly increases plasma concentration of simvastatin
Ulcer-healing Drugs: plasma concentration of dasatinib possibly reduced by famotidine
Deferasirox
Antacids: absorption of deferasirox possibly reduced by antacids containing aluminium (manufacturer of deferasirox advises avoid concomitant use)
Antibacterials: plasma concentration of deferasirox reduced by rifampicin
Antidiabetics: deferasirox increases plasma concentration of repaglinide
Antipsychotics and Hypnotics: deferasirox possibly reduces plasma concentration of midazolam
Deflazacort see Corticosteroids
Demeclocycline see Tetracyclines
Desferrioxamine
Antipsychotics: avoidance of desferrioxamine advised by manufacturer of levetiracetam; manufacturer of deferoxamine advises avoid concomitant use with prochlorperazine
Desflurane see Anaesthetics, General
Desloratadine see Antihistamines
Desmopressin
Analgesics: effects of desmopressin enhanced by indometacin
Loperamide: plasma concentration of oral desmopressin increased by loperamide
Desogestrel see Progestogens
Dexamethasone see Corticosteroids
Dexamfetamine see Sympathomimetics
Dexibuprofen see NSAIDs
Dexketoprofen see NSAIDs
Dextromethorphan see Opioid Analgesics
Dextropropoxyphene see Opioid Analgesics
Diamorphine see Opioid Analgesics
Diazepam see Anxiolytics and Hypnotics
Diazoxide
ACE Inhibitors: enhanced hypertensive effect when diazoxide given with ACE inhibitors
Adrenergic Neurone Blockers: enhanced hypertensive effect when diazoxide given with adrenergic neurone blockers
Alcohol: enhanced hypertensive effect when diazoxide given with alcohol
Aldesleukin: enhanced hypertensive effect when diazoxide given with aldesleukin
Alpha-blockers: enhanced hypertensive effect when diazoxide given with alpha-blockers
Anaesthetics, General: enhanced hypertensive effect when diazoxide given with general anaesthetics
Analgesics: hypertensive effect of diazoxide antagonised by NSAIDs
Angiotensin-II Receptor Antagonists: enhanced hypertensive effect when diazoxide given with angiotensin-II receptor antagonists
Antidpressants: enhanced hypertensive effect when diazoxide given with MAOIs or tricyclic-related antidepressants
Antidiabetics: diazoxide antagonises hypoglycaemic effect of antidiabetics
Antiepileptics: diazoxide reduces plasma concentration of phenytoin, also effect of diazoxide may be reduced
Antipsychotics: enhanced hypertensive effect when diazoxide given with phenothiazines
Anxiolytics and Hypnotics: enhanced hypertensive effect when diazoxide given with anxiolytics and hypnotics
Beta-blockers: enhanced hypertensive effect when diazoxide given with beta-blockers
Calcium-channel Blockers: enhanced hypertensive effect when diazoxide given with calcium-channel blockers
Clonidine: enhanced hypertensive effect when diazoxide given with clonidine
Corticosteroids: hypertensive effect of diazoxide antagonised by corticosteroids
Diuretics: enhanced hypertensive and hyperglycaemic effects when diazoxide given with diuretics
Dopaminergic: enhanced hypertensive effect when diazoxide given with levodopa
Methyldopa: enhanced hypertensive effect when diazoxide given with methyldopa
Moxisylyte: enhanced hypertensive effect when diazoxide given with moxisylyte
Moxonidine: enhanced hypertensive effect when diazoxide given with moxonidine
Muscle Relaxants: enhanced hypertensive effect when diazoxide given with baclofen or tizanidine
Nitrates: enhanced hypertensive effect when diazoxide given with nitrates
Prostaglandins: enhanced hypertensive effect when diazoxide given with alprostadil
Vasodilator Antihypertensives: enhanced hypertensive effect when diazoxide given with hydralazine, minoxidil or sodium nitroprusside
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Diclofenac see NSAIDs
Didanosine

Note: Antacids in tablet formulation may affect absorption of other drugs.

- Allopurinol: plasma concentration of didanosine increased by allopurinol (risk of toxicity)—avoid concomitant use.

Analgesics: plasma concentration of didanosine possibly reduced by methadone.

- Antiarrhythmics: plasma concentration of didanosine possibly increased by ganclovir; increased risk of side-effects when didanosine given with irinotecan—avoid concomitant use; increased risk of side-effects when didanosine given with stavudine; plasma concentration of didanosine increased by tenofovir (increased risk of toxicity)—avoid concomitant use; plasma concentration of didanosine reduced by efavirenz.

- Cytotoxics: risk of toxicity when didanosine given with etidronate—avoid concomitant use.

Disopyramide see Prostaglandins

Digoxin see Cardiac Glycosides

Dihydrocodeine see Opoid Analgesics

Diltiazem see Calcium-channel Blockers

Dimercaprol

- Iron: avoid concomitant use of dimercaprol with iron.

- Dimethyl sulfoxide

Analgesics: avoid concomitant use of dimethyl sulfoxide with esulindac.

Dinoprost see Prostaglandins

Diphenoxylate see Antiarrhythmics

Dipyridamole

- Anaesthetics: absorption of dipyridamole possibly reduced by antacids.

- Antiarrhythmics: dipyridamole enhances and extends the effects of a-adrenoceptor antagonists (important risk of toxicity).

- Anticoagulants: antplatelet action of dipyridamole enhances anticoagulant effect of coumarins and phenindione; dipyridamole enhances anticoagulant effect of heparins.

- Clopidogrel: increased risk of bleeding when dipyridamole given with clopidogrel.

Cytotoxics: dipyridamole possibly reduces effects of fludarabine.

Disodium Etidrone see Bisphosphonates

Disodium Pamidronate see Bisphosphonates

Disopyramide

Anaesthetics, Local: increased myocardial depression when antiarrhythmics given with bupivacaine, levobupivacaine, prilocaine or ropivacaine.

- Antiarrhythmics: increased myocardial depression when antiarrhythmics given with other antiarrhythmics; increased risk of ventricular arrhythmias when disopyramide given with amiodarone or dronedarone—avoid concomitant use.

- Antibacterials: plasma concentration of disopyramide possibly increased by clindamycin (increased risk of toxicity); plasma concentration of disopyramide increased by erythromycin (increased risk of toxicity); increased risk of ventricular arrhythmias when disopyramide given with moxifloxacin—avoid concomitant use; metabolism of disopyramide accelerated by rifampicin (reduced plasma concentration).

- Antidepressants: increased risk of ventricular arrhythmias when disopyramide given with tricyclics.

- Antidiabetics: disopyramide possibly enhances hypoglycaemic effect of glipizide, insulin and metformin.

- Antileukaemics: plasma concentration of disopyramide reduced by phenytoin; metabolism of disopyramide accelerated by primidone (reduced plasma concentration).

- Antifungals: increased risk of ventricular arrhythmias when disopyramide given with miconazole—avoid concomitant use; avoidance of disopyramide advised by manufacturer of miconazole.

Disopyramide (continued)

- Antihistamines: increased risk of ventricular arrhythmias when disopyramide given with mizolastine—avoid concomitant use.

- Antimalarials: avoidance of disopyramide advised by manufacturer of mefloquine/lumefantrine (risk of ventricular arrhythmias).

- Antiarrhythmics: risk of antimuscarinic side-effects when disopyramide given with antiarrhythmics; increased risk of ventricular arrhythmias when disopyramide given with olsateridine.

- Antipsychotics: increased risk of ventricular arrhythmias when antiarrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias when disopyramide given with amisulpride, droperidol, pimozide or zuclopenthixol—avoid concomitant use; possible increased risk of ventricular arrhythmias when disopyramide given with phenothiazines or sulpiride.

- Antituberculars: plasma concentration of disopyramide possibly increased by rifampicin (increased risk of toxicity); increased risk of ventricular arrhythmias when disopyramide given with rifampicin.

- Barbiturates: metabolism of disopyramide accelerated by barbiturates (reduced plasma concentration).

- Beta-blockers: increased myocardial depression when antiarrhythmics given with beta-blockers; increased risk of ventricular arrhythmias when disopyramide given with sotalol—avoid concomitant use.

- Calcium-channel Blockers: increased risk of myocardiad depression and asystole when disopyramide given with verapamil.

- Cytotoxics: increased risk of ventricular arrhythmias when disopyramide given with cisplatin.

- Diuretics: increased cardiac toxicity with disopyramide if hypokalaemia occurs with acetazolamide, loop diuretics or thiazides and related diuretics.

- Ivermectin: increased risk of ventricular arrhythmias when disopyramide given with ivermectin.

- Nitrate: disopyramide reduces effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth).

- Ranolazine: avoidance of disopyramide advised by manufacturer of ranolazine.

Distigmine see Parasympathomimetics

Disulfiram

Alcohol: disulfiram reaction when disulfiram given with alcohol (see p. 310).

- Antibacterials: psychotic reaction reported when disulfiram given with metronidazole; CNS effects of disulfiram possibly increased by isoniazid.

- Anticoagulants: disulfiram enhances anticoagulant effect of coumarins.

- Antidepressants: increased disulfiram reaction with alcohol reported with concomitant amitriptyline; disulfiram inhibits metabolism of tricyclics (increased plasma concentration).

- Antiepileptics: disulfiram inhibits metabolism of phenytoin (increased risk of toxicity).

- Anxiolytics and Hypnotics: disulfiram increases risk of temazepam toxicity; disulfiram inhibits metabolism of benzodiazepines (increased sedative effects).

- Paraldehyde: risk of toxicity when disulfiram given with paraldehyde.

Theophylline: disulfiram inhibits metabolism of theophylline (increased risk of toxicity).
Diuretics

- Note: Since systemic absorption may follow topical application of bromazepam to the eye, the possibility of interactions should be borne in mind.
- Note: Since systemic absorption may follow topical application of dorzolamide to the eye, the possibility of interactions should be borne in mind.
- ACE Inhibitors: enhanced hypertensive effect when diuretics given with •ACE inhibitors; increased risk of severe hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with •ACE inhibitors (monitor potassium concentration with low-dose spironolactone in heart failure).
- Adrenergic Neuron Blockers: enhanced hypertensive effect when diuretics given with adrenergic neuron blockers.
- Alcohol: enhanced hypertensive effect when diuretics given with alcohol.
- Aliskiren: plasma concentration of furosemide increased by aliskiren; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with aliskiren.
- Allopurinol: increased risk of hypersensitivity when thioureas and related diuretics given with allopurinol especially in renal impairment.
- Alpha-blockers: enhanced hypertensive effect when diuretics given with •alpha-blockers, also increased risk of first-dose hypotension with post-synaptic alpha-blockers such as prazosin.
- Analgesics: General: enhanced hypertensive effect when diuretics given with general analgesics.
- Antibacterials: (continued) hyperkalaemia when eplerenone given with trimethoprim.
- Antibiotics: possible increased risk of hypokalaemia when loop diuretics or thiazides and related diuretics given with reboxetine; enhanced hypertensive effect when diuretics given with MAOIs; plasma concentration of eplerenone reduced by •SR John's wort—avoid concomitant use; increased risk of postural hypotension when diuretics given with tricyclics.
- Anti-diabetics: loop diuretics and thiazides and related diuretics antagonise hypoglycaemic effect of anti-diabetics.
- Antiepileptics: plasma concentration of eplerenone reduced by •carbamazepine and •phenytoin—avoid concomitant use; increased risk of hyperkalaemia when diuretics given with carbamazepine; acetazolamide increases plasma concentration of •carbamazepine; effects of furosemide antagonised by phenytoin; acetazolamide possibly increases plasma concentration of •phenytoin; increased risk of osteomalacia when carbonic anhydrase inhibitors given with phenytoin or primidone; acetazolamide possibly reduces plasma concentration of primidone; hydrochlorothiazide possibly increases plasma concentration of toprimate.
- Antifungals: increased concentration of furosemide; plasma concentration of eplerenone increased by •itraconazole and •ketoconazole—avoid concomitant use; increased risk of hyperkalaemia when loop diuretics or thiazides and related diuretics given with amphoterin; hydrochlorothiazide increases plasma concentration of •fluconazole; plasma concentration of eplerenone increased by fluconazole (reduce dose of eplerenone).
- Antipsychotics: hyperkalaemia caused by diuretics increases risk of ventricular arrhythmias with •amisulpride; enhanced hypertensive effect when diuretics given with phenoxyazines; hyperkalaemia caused by diuretics increases risk of ventricular arrhythmias with •epimizide (avoid concomitant use).
- Antivirals: plasma concentration of eplerenone increased by •nelfinavir and •ritonavir—avoid concomitant use; increased risk of hyperkalaemia when loop diuretics or thiazides and related diuretics given with saquinavir (reduce dose of eplerenone).
- Anaesthetics, General: enhanced hypertensive effect when diuretics given with general anaesthetics.
- Antidiabetics: increased concentration of furosemide; plasma concentration of eplerenone increased by •itraconazole and •ketoconazole—avoid concomitant use; increased risk of hyperkalaemia when loop diuretics or thiazides and related diuretics given with amphoterin; hydrochlorothiazide increases plasma concentration of •fluconazole; plasma concentration of eplerenone increased by fluconazole (reduce dose of eplerenone).
- Antiarrhythmics: plasma concentration of eplerenone increased by amiodarone (reduce dose of eplerenone); hyperkalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics increases cardiac toxicity with amiodarone; hyperkalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics increases cardiac toxicity with •disopyramide; hyperkalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics increases cardiac toxicity with •ticlidin—avoid concomitant use; hyperkalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics antagonise action of •lidocaine.
- Antihistamines: plasma concentration of eplerenone increased by •clarithromycin and •erythromycin—avoid concomitant use; plasma concentration of eplerenone reduced by •erythromycin (reduce dose of eplerenone); plasma concentration of eplerenone reduced by •clarithromycin—avoid concomitant use; avoidance of diuretics advised by manufacturer of lymecycline; increased risk of otoxicity when loop diuretics given with •aminoglycosides.
- Antiinfectives: plasma concentration of eplerenone increased by •clarithromycin and •erythromycin—avoid concomitant use; plasma concentration of eplerenone increased by •ditiazem and •verapamil (reduce dose of eplerenone).
- Antidiabetic: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antidiabetic: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antihypertensive: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antimicrobial: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antifungal: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antimicrobial: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antihypertensive: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antimicrobial: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
- Antihypertensive: plasma concentration of eplerenone increased by •digoxin—potassium sparing diuretics such as metolazone and spironolactone increases plasma concentration of •digoxin.
Diuretics (continued)

- Ciclosporin: increased risk of nephrotoxicity and possibly hypermagnesaemia when thiazides and related diuretics given with ciclosporin; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with ciclosporin; acetazolamide possibly increases plasma concentration of ciclosporin.
- Clopidogrel: enhanced hypotensive effect when diuretics given with clopidogrel.

Corticosteroids: diuretic effect of diuretics antagonised by corticosteroids; increased risk of hyperkalaemia when acetazolamide, loop diuretics or thiazides and related diuretics given with corticosteroids.

- Cytotoxics: alkaline urine due to acetazolamide increases excretion of methotrexate; hyperkalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics increases risk of ventricular arrhythmias with arsenic trioxide; avoidance of spiranoxonoleate advised by manufacturer of mitotane (antagonism of effect); increased risk of nephrotoxicity and ototoxicity when diuretics given with platinum compounds.

Diazoxide: enhanced hypotensive and hyperglycaemic effects when diuretics given with diazoxide.

Diuretics: increased risk of hyperkalaemia when loop diuretics or thiazides and related diuretics given with acetazolamide; profound diuresis possible when metolazone given with furosemide; increased risk of hyperkalaemia when thiazides and related diuretics given with loop diuretics.

Dopaminergics: enhanced hypotensive effect when diuretics given with levodopa.

Hormone Antagonists: increased risk of hypercalcaemia when thiazides and related diuretics given with toremifene; increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with triostane.

Lipid-regulating Drugs: absorption of thiazides and related diuretics reduced by colestipol and colestyramine (give at least 2 hours apart).

- Lithium: loop diuretics and thiazides and related diuretics reduce excretion of lithium (increased plasma concentration and risk of toxicity)—loop diuretics safer than thiazides; potassium-sparing diuretics and aldosterone antagonists reduce excretion of lithium (increased plasma concentration and risk of toxicity); acetazolamide increases the excretion of lithium.

MethylpGameObject: enhanced hypotensive effect when diuretics given with methylpGameObject.

Moxisylyte: enhanced hypotensive effect when diuretics given with moxisylyte.

Moxonidine: enhanced hypotensive effect when diuretics given with moxonidine.

Muscle Relaxants: enhanced hypotensive effect when diuretics given with baclofen or tizanidine.

Nitrates: enhanced hypotensive effect when diuretics given with nitrates.

- Oestrogens: diuretic effect of diuretics antagonised by oestrogens.

Potassium Salts: increased risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with potassium salts.

Progestogens: risk of hyperkalaemia when potassium-sparing diuretics and aldosterone antagonists given with drospirenone (monitor serum potassium during first cycle).

Prostaglandins: enhanced hypotensive effect when diuretics given with alprostadil.

- Sympathomimetics, Beta: increased risk of hyperkalaemia when acetazolamide, loop diuretics or thiazides and related diuretics given with high doses of beta, sympathomimetics—see Hypokalaemia, p. 176.
Droxazosin see Alpha-blockers
Doxepin see Antidepressants, Tricyclic
Doxorubicin
Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
Anti-psychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
Antivirals: doxorubicin possibly inhibits effects of stavudine
Cardiac Glycosides: cytotoxins reduce absorption of digoxin tablets
Ciclosporin: increased risk of neurotoxicity when doxorubicin given with ciclosporin
Cytotoxics: plasma concentration of doxorubicin possibly increased by soralfenib

Doxycline see Tetracyclines

Dronedarone
Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with bupivacaine, levobupivacaine, prilocaine or ropivacaine
Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with other anti-arrhythmics; increased risk of ventricular arrhythmias when dronedarone given with amiodarone
Anti-psychotics—avoid concomitant use
Antibacterials: manufacturers of dronedarone advises avoid concomitant use with erithromycin or telithromycin (risk of ventricular arrhythmias); plasma concentration of dronedarone possibly increased by erythromycin (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of dronedarone reduced by trifluperidol—avoid concomitant use
Antidepressants: plasma concentration of dronedarone possibly reduced by carbamazepine and phenytoin—avoid concomitant use
Anti-fungals: plasma concentration of dronedarone increased by fluconazole—avoid concomitant use; manufacturer of dronedarone advises avoid concomitant use with itraconazole, posaconazole and voriconazole
Anti-psychotics: increased risk of ventricular arrhythmias when dronedarone given with metaflonothiazines (risk of ventricular arrhythmias)
Antivirals: manufacturer of dronedarone advises avoid concomitant use with ritonavir; increased risk of ventricular arrhythmias when dronedarone given with saquinavir—avoid concomitant use
Barbiturates: plasma concentration of dronedarone possibly reduced by phenobarbital—avoid concomitant use
Beta-blockers: increased myocardial depression when anti-arrhythmics given with beta-blockers; dronedarone possibly increases plasma concentration of metoprolol and propranolol; increased risk of ventricular arrhythmias when dronedarone given with nisoldipine—avoid concomitant use
Calcium-channel Blockers: plasma concentration of dronedarone increased by nifedipine; increased risk of bradycardia and myocardial depression when dronedarone given with nisoldipine and verapamil
Cardiac Glycosides: dronedarone increases plasma concentration of digoxin (halve dose of digoxin)
Grapefruit juice: plasma concentration of dronedarone increased by grapefruit juice—avoid concomitant use
Lipid-regulating Drugs: increased risk of myopathy when dronedarone given with simvastatin
Sirolimus: manufacturer of dronedarone advises caution with sirolimus

Dronedarone (continued)
Tacrolimus: manufacturer of dronedarone advises caution with tacrolimus
Droperidol see Antipsychotics
Dropsirenone see Progestogens
Drotrecogin Alfa
Anti-coagulants: manufacturer of drotrecogin alfa advises avoid concomitant use with high doses of heparin—consult product literature

Duloxetine
Analgesics: possible increased serotonergic effects when duloxetine given with pethidine or tramadol
Anti-bacterials: metabolism of duloxetine inhibited by ciprofloxacin—avoid concomitant use
Anti-psychotics: metabolism of duloxetine inhibited by fluvoxamine—avoid concomitant use; posaconazole increased serotonergic effects when duloxetine given with SSRIs, St John’s wort, amitriptyline, clonipramine, moclobemide, tryptophan or venlafaxine; duloxetine should not be started until 2 weeks after stopping MAOIs, also MAOIs should not be started until at least 5 days after stopping duloxetine; after stopping SSRi-related antidepressants do not start moclobemide for at least 1 week
Antimalarials: avoidance of antidepressants advised by manufacturer of artemether/lumefantrine
Atomoxetine: possible increased risk of convulsions when antidepressants given with atomoxetine
SHT, Agonists: possible increased serotonergic effects when duloxetine given with SHT, agonists

Dutasteride
Calcium-channel Blockers: plasma concentration of dutasteride increased by diltiazem and verapamil

Dydrogesterone see Progestogens
Edrophonium see Parasympathomimetics
Efavirenz
Analgesics: efavirenz reduces plasma concentration of methadone
Anti-bacterials: increased risk of rash when efavirenz given with clarithromycin; efavirenz reduces plasma concentration of rifabutin—increased dose of rifabutin; plasma concentration of efavirenz reduced by rifampin—increased dose of efavirenz
Anti-coagulants: efavirenz possibly affects plasma concentration of warfarin
Antidepressants: plasma concentration of efavirenz reduced by St John’s wort—avoid concomitant use
Antiepileptics: plasma concentration of both drugs reduced when efavirenz given with carbamazepine
Antifungals: efavirenz reduces plasma concentration of itraconazole and posaconazole; efavirenz reduces plasma concentration of voriconazole, also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose); efavirenz possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin
Antipsychotics: efavirenz possibly reduces plasma concentration of olanzapine—dose efavirenz concentrations of olanzapine, risperidone, quetiapine, zuclopenthixol, and clozapine—consider increasing dose of olanzapine
Antivirals: avoidance of efavirenz advised by manufacturer of atazanavir (plasma concentration of atazanavir reduced); efavirenz reduces plasma concentration of darunavir, fosamprenavir and indinavir; efavirenz possibly reduces plasma concentration of etravirine—avoid concomitant use; efavirenz reduces plasma concentration of maraviroc—consider increasing dose of maraviroc; plasma concentration of efavirenz reduced by nevirapine; toxicity of efavirenz increased by ritonavir, monitor liver function tests; efavirenz significantly reduces plasma concentration of saquinavir
Appendix 1: Interactions

**Efarinaz (continued)**
- Antiulcer: increases risk of protracted sedation when efarinaz given with selegiline—avoid concomitant use
- Calcium-channel Blockers: efarinaz reduces plasma concentration of diltiazem
- Ciclosporin: efarinaz reduces plasma concentration of ciclosporin
- Ergot Alkaloids: increased risk of ergotism when efarinaz given with ergot alkaloids—avoid concomitant use
- Grapefruit Juice: plasma concentration of efarinaz possibly increased by grapefruit juice
- Lipid-Regulating Drugs: efarinaz reduces plasma concentration of atorvastatin, pravastatin and simvastatin
- Oestrogens: efarinaz reduces contraceptive effect of oestrogens
- Progestogens: efarinaz reduces contraceptive effect of progestogens
- Tacrolimus: efarinaz possibly affects plasma concentration of tacrolimus
- Eptifibatide see SHT, Agonists

**Eltrombopag**
- Antacids: absorption of eltrombopag reduced by antacids (give at least 4 hours apart)
- Antivirals: plasma concentration of eltrombopag possibly reduced by lopinavir
- Calcium Salts: absorption of eltrombopag possibly reduced by calcium salts (give at least 4 hours apart)
- Dairy Products: absorption of eltrombopag possibly reduced by dairy products (give at least 4 hours apart)
- Iron: absorption of eltrombopag possibly reduced by oral iron (give at least 4 hours apart)
- Lipid-Regulating Drugs: eltrombopag increases plasma concentration of rosuvastatin (consider reducing dose of rosuvastatin)
- Selenium: absorption of eltrombopag possibly reduced by selenium (give at least 4 hours apart)
- Zinc: Absorption of eltrombopag possibly reduced by zinc (give at least 4 hours apart)

**Emtricitabine**
- Antivirals: manufacturer of emtricitabine advises avoid concomitant use with lamivudine

**Enalapril** see ACE Inhibitors

**Enoxaparin** see Heparins

**Enoximone** see Phosphodiesterase Inhibitors

**Entacapone**
- Anti-CoA synthase: entacapone enhances anticoagulant effect of warfarin
- Antidepressants: manufacturer of entacapone advises caution with moclobemide, paroxetine, tricyclics and venlafaxine; avoid concomitant use of entacapone with non-selective MAOIs
- Dopaminergics: entacapone possibly enhances effects of amphetamine; entacapone possibly reduces plasma concentration of rasagiline; manufacturer of entacapone advises max. dose of 10 mg selegiline if used concomitantly
- Iron: absorption of entacapone reduced by oral iron
- Memantine: effects of dopaminergics possibly enhanced by memantine

**Methyldopa:** entacapone possibly enhances effects of methyldopa; antiparkinsonian effect of dopaminergics antagonised by methyldopa
- Symptomamimetics: entacapone possibly enhances effects of adrenaline (epinephrine), dobutamine, dopamine and noradrenaline (norepinephrine)

**Enteral Foods**
- Anti-CoA synthase: the presence of vitamin K in some enteral feeds can antagonise the anticoagulant effect of coumarins and phenindione
- Antiepileptics: enteral feeds possibly reduce absorption of phenytoin
- Ephedrine see Sympathomimetics
- Epinephrine (adrenaline) see Sympathomimetics

**Epirubicin**
- Antiepileptics: cytoxotics possibly reduce absorption of phenytoin
- Anti-CoA synthase: avoid concomitant use of cytoxotics with oxapiprazine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets
- Ciclosporin: plasma concentration of epirubicin increased by ciclosporin
- Ulcer-healing Drugs: plasma concentration of epirubicin increased by cimetidine

**Eplerenone** see Diuretics

**Eprosartan** see Angiotensin-II Receptor Antagonists

**Eptifibatide**
- Iloprost: increased risk of bleeding when eptifibatide given with iloprost

**Ergot Alkaloids**
- Anaesthetics, General: effects of ergotamine on the parturient uterus reduced by halothane
- Antibacterials: increased risk of ergotamine and methysergide given with macrolides or etidronate—avoid concomitant use; increased risk of ergotism when ergotamine and methysergide given with tetracyclines
- Antidepressants: possible risk of hypertension when ergotamine and methysergide given with reboxetine
- Antifungals: increased risk of ergotamine and methysergide given with triazoles—avoid concomitant use
- Antivirals: plasma concentration of ergot alkaloids possibly increased by azithromycin—avoid concomitant use; increased risk of ergotism when ergotamine and methysergide given with efavirenz—avoid concomitant use; increased risk of ergotism when ergotamine and methysergide given with felodipine, felodipine, nelfinavir, ritonavir or saquinavir—avoid concomitant use
- Beta-blockers: increased peripheral vasoconstriction when ergotamine and methysergide given with beta-blockers
- SHT, Agonists: increased risk of vasospasm when ergotamine and methysergide given with almotriptan, eletriptan, frovatriptan or naratriptan avoid concomitant use
- Ergot Alkaloids see Ergot Alkaloids

**Erlotinib**
- Analgesics: increased risk of bleeding when erlotinib given with NSAIDs
- Antacids: plasma concentration of erlotinib possibly reduced by antacids—give antacids at least 4 hours before or 2 hours after erlotinib
- Antibacterials: plasma concentration of erlotinib increased by ciprofloxacin; metabolism of erlotinib accelerated by rifampicin (reduced plasma concentration)
- Antiepileptics: increased risk of bleeding when erlotinib given with coumarins
- Symptomamimetics: cytoxotics possibly reduce absorption of phenytoin
- Antifungals: metabolism of erlotinib inhibited by ketoconazole (increased plasma concentration)
Erlotinib (continued)

- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Cytotoxics: plasma concentration of erlotinib possibly increased by capecitabine
- Ulcer-healing Drugs; manufacturer of erlotinib advises avoid concomitant use with cimetidine,esomeprazole, famotidine, lansoprazole, nizatidine, pantoprazole and rabeprazole; plasma concentration of erlotinib reduced by ranitidine—manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine; plasma concentration of erlotinib reduced by omeprazole—manufacturer of erlotinib advises avoid concomitant use

Etapenem

- Antiepileptics: carbapenems reduce plasma concentration of valproate—avoid concomitant use
- Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Erythromycin see Macrolides

Escitalopram see Antidepressants, SSRI

Eticarbazepine

Anticoagulants: eslicarbazepine reduces plasma concentration of warfarin—see p. 767
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (conversive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (conversive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort
- Antiepileptics: plasma concentration of both drugs reduced when eslicarbazepine given with carbamazepine; manufacturer of eslicarbazepine advises avoid concomitant use with oxcarbazepine; plasma concentration of eslicarbazepine reduced by phenytoin, also plasma concentration of phenytoin increased
- Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by fenofibrate
- Oestrogens: eslicarbazepine accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495)
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat
- Progestogens: eslicarbazepine accelerates metabolism of progestogens (reduced contraceptive effect—see p. 495)

Esmolol see Beta-blockers

Esomeprazole see Proton Pump Inhibitors

Estradiol see Oestrogens

Estramustine

Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Bisphosphonates: plasma concentration of estramustine increased by sodium clodronate
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Estriol see Oestrogens

Estrone see Oestrogens

Etanercept

- Abatacept: avoid concomitant use of etanercept with abatacept
- Anakinra: avoid concomitant use of etanercept with anakinra
- Vaccines: avoid concomitant use of etanercept with live vaccines see Oestrogens

Ethinylestradiol see Oestrogens

Ethisuximide (continued)

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (conversive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (conversive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort
- Antiepileptics: plasma concentration of ethosuximide possibly reduced by carbamazepine and primidone; plasma concentration of ethosuximide possibly reduced by phenytoin, also plasma concentration of phenytoin possibly increased, plasma concentration of ethosuximide possibly increased by valproate
- Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by fenofibrate
- Oestrogens (reduced contraceptive effect—see p. 767)

Etoricoxib see NSAIDs

Etoposide

- Anticoagulants: etoposide possibly enhances anticoagulant effect of coumarins
- Antiepileptics: plasma concentration of etoposide possibly reduced by phenytoin; cytotoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Barbiturates: plasma concentration of etoposide possibly reduced by phenobarbital
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Etomoxir see NSAIDs

Etravirine

- Antibacterials: plasma concentration of etravirine increased by clarithromycin, also plasma concentration of clarithromycin reduced; plasma concentration of both drugs reduced when etravirine given with rifabutin; manufacturer of etravirine advises avoid concomitant use with rifampicin
- Antiepileptics: manufacturer of etravirine advises avoid concomitant use with St John’s wort
- Antipsychotics: manufacturer of etravirine advises avoid concomitant use with carbamazepine and phenytoin
- Antivirals: plasma concentration of etravirine possibly reduced by efavirenz and nevirapine—avoid concomitant use; etravirine increases plasma concentration of fosamprenavir (consider reducing dose of fosamprenavir); etravirine possibly reduces plasma concentration of enfuvirtide—avoid concomitant use; plasma concentration of enfuvirtide reduced by tipranavir, also plasma concentration of tipranavir increased (avoid concomitant use)
- Barbiturates: manufacturer of etravirine advises avoid concomitant use with phenobarbital
- Cardiac Glycosides: etravirine increases plasma concentration of digoxin
- Lipid-regulating Drugs: etravirine possibly reduces plasma concentration of atorvastatin

Sildenafil: etravirine reduces plasma concentration of sildenafil

BNF 61 Appendix 1: Interactions 841
Antivirals: see Progestogens

**Etonidazole**

**Everolimus**
- Antiarrhythmics: plasma concentration of everolimus possibly increased by citalopram and escitalopram—manufacturer of everolimus advises avoid concomitant use; plasma concentration of everolimus increased by erythromycin; plasma concentration of everolimus reduced by famotidine and ticlopidine—manufacturer of everolimus advises avoid concomitant use
- Antiarrhythmics: plasma concentration of everolimus increased by ketocana zole—avoid concomitant use; plasma concentration of everolimus possibly increased byitraconazole and posaconazole and voriconazole—manufacturer of everolimus advises avoid concomitant use
- Antipsychotics: avoid concomitant use of cytotoxic with clozapine (increased risk of agranulocytosis)
- Antivirals: plasma concentration of everolimus possibly increased by nelfinavir, ritonavir and saquinavir—manufacturer of everolimus advises avoid concomitant use
- Calcium-channel Blockers: plasma concentration of both drugs may increase when everolimus given with verapamil
- Cardiac Glycosides: cytotoxic reactions absorption of digoxin tablets
- Ciclosporin: plasma concentration of everolimus increased by ciclosporin
- Grapefruit Juice: manufacturer of everolimus advises avoid concomitant use with grapefruit juice
- Exemestane
  - Antibacterials: plasma concentration of exemestane possibly reduced by rifampicin
- Ezetimibe
  - Antiarrhythmics: ciclosporin possibly enhances antiarrhythmic effect of cuminarins
  - Ciclosporin: plasma concentration of both drugs may increase when everolimus given with ciclosporin
- Lipid-regulating Drugs: increased risk of cholelithiasis and gallbladder disease when fibrates given with ezetimibe—discontinue if suspected; increased risk of myopathy when fibrates given with statins; increased risk of myopathy when gemfibrozil given with statins (preferably avoid concomitant use)

**Fibrates (continued)**
- Ciclosporin: increased risk of renal impairment when bezafibrate or fenofibrate given with ciclosporin
- Colchicine: possible increased risk of myopathy when fibrates given with colchicine
- Cyttoxotics: gemfibrozil increases plasma concentration of bevacizumab—avoid concomitant use
- Lipid-regulating Drugs: increased risk of cholelithiasis and gallbladder disease when fibrates given with ezetimibe—discontinue if suspected; increased risk of myopathy when fibrates given with statins
- Lipid-regulating Drugs: increased risk of myopathy when gemfibrozil given with statins (preferably avoid concomitant use)

**Flagstatin**
- Note Pegfluglumastat interactions as for flagstatin
- Cytotoxic reactions: neutropenia possibly exacerbated when Flagstatin given with fluorouracil

**Flavoxate** see Antimuscarinics

**Flecainide**
- Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with bupivacaine, ropivacaine, prilocaine or ropivacaine
- Antiarrhythmics: increased myocardial depression when anti-arrhythmics given with other anti-arrhythmics; plasma concentration of flecainide increased by amiodarone (half dose of flecainide)
- Antidepressants: plasma concentration of flecainide increased by fluoxetine; increased risk of ventricular arrhythmias when flecainide given with tricyclics
- Antiinflammatory: increased risk of ventricular arrhythmias when flecainide given with nitrofurantoin—avoid concomitant use
- Antimalarials: avoidance of flecainide advised by manufacturer of artesunate/lumefantrine (risk of ventricular arrhythmias); plasma concentration of flecainide increased by quinine
- Antimuscarinics: increased risk of ventricular arrhythmias when flecainide given with tolterodine
- Antiarrhythmics: increased risk of ventricular arrhythmias when anti-arrhythmics given with amiodarone that prolong the QT interval with antiarrhythmics that prolong the QT interval; increased risk of arrhythmias when flecainide given with clozapine
- Antiarrhythmics: plasma concentration of flecainide possibly increased by fosamprenavir, indinavir, lopinavir and ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use); increased risk of ventricular arrhythmias when flecainide given with amiodarone—avoid concomitant use
- Beta-blockers: increased risk of myocardial depression and bradycardia when flecainide given with beta-blockers; increased myocardial depression when anti-arrhythmics given with beta-blockers
- Calcium-channel Blockers: increased risk of myocardial depression and asystole when flecainide given with verapamil
- Diuretics: increased cardiac toxicity with flecainide if hyponatraemia occurs with amiodarone, loop diuretics or thiazides and related diuretics
- Ulcer-healing Drugs: metabolism of flecainide inhibited by cilostazol (increased plasma concentration)

**Flucloxacinil** see Penicillins

**Flucloxacillin**
- see Antimuscarinics

**Flucytosine**
- see Antiinfectious, Triazole

**Fludarabine**
- Antiarrhythmics: decreased cell uptake increased by amphotericin (toxicity possibly increased)
- Anticytotoxic: plasma concentration of fludarabine possibly reduced by cytarabine

**Fluticasone**
- Antiinfectious: avoid concomitant use of cytoxotics with dexamethasone (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxic reactions absorption of digoxin tablets
BNF 61

Appendix 1: Interactions 843

Fosamprenavir (continued)

Anticoagulants: fosamprenavir may enhance or reduce anticoagulant effect of coumarins; avoidance of fosamprenavir advised by manufacturer of rivaroxaban

Antidepressants: plasma concentration of fosamprenavir reduced by St John’s wort; avoid concomitant use

Antiepileptics: plasma concentration of fosamprenavir possibly reduced by carbamazepine

Antifungals: fosamprenavir increases plasma concentration of ketoconazole (also plasma concentration of fosamprenavir possibly increased); plasma concentration of both drugs may increase when fosamprenavir given with itraconazole

Antimalarials:


Lipid-regulating Drugs:


Anti-arrhythmics:


Fluorides

Corticosteroids

Folic Acid

Cytotoxics:


Antipsychotics:


Anticoagulants:


Analgesics:


Barbiturates:


Antimuscarinics:


Flubrocaine see Corticosteroids

Flunisolide see Corticosteroids

Fludarabine (continued)

Cytoxics: fludarabine increases intracellular concentration of cytarabine; increased pulmonary toxicity when fludarabine given with pentostatin (unacceptably high incidence of fatalities)

Dipyridamole: effects of fludarabine possibly reduced by dipyridamole

Fludrocortisone see Corticosteroids

Flutamide

Flurazepam

Flupentixol

Fluoxetine

Fluorides

Calcium Salts: absorption of fluorides reduced by calcium salts

Fluorouracil

Note: Capecitabine is a prodrug of fluorouracil

Note: Tegafur is a prodrug of fluorouracil

Allpurinol: manufacturer of capecitabine advises avoid concomitant use with allpurinol

Antibacterials: metabolism of fluorouracil inhibited by metronidazole (increased toxicity)

Anticoagonulants: fluorouracil enhances anticoagulant effect of coumarins

Antiepileptics: fluorouracil possibly inhibits metabolism of phenytoin (increased risk of toxicity); cytoxotics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxotics with olanzapine (increased risk of agranulocytosis) Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Cytoxotics: capecitabine possibly increases plasma concentration of erlotinib

Filgrastim: neutropenia possibly exacerbated when fluorouracil given with filgrastim

Temoporfin: increased skin photosensitivity when topical fluouracil used with temoporfin

Ulcet-healing Drugs: metabolism of fluorouracil inhibited by cimetidine (increased plasma concentration)

Fluoxetine see Antidepressants, SSRI

Fluphenazine see Antipsychotics

Flurazepam see Anxiolytics and Hypnotics

Flurbiprofen see NSAIDs

Flutamide

Anticoagonulants: fluamidine enhances anticoagulant effect of coumarins

Fluticasone see Corticosteroids

Fluvastatin see Statins

Fluvaxamine see Antidepressants, SSRI

Folates

Aminosaliclyates: absorption of folate possibly reduced by sulfasalazine

Antiepileptics: folates possibly reduce plasma concentration of phenytoin and primidone

Barbiturates: folates possibly reduce plasma concentration of phenobarbital

Cytoxotics: avoidance of folates advised by manufacturer of raltitrexed

Folic Acid see Folates

Folic Acid see Folates

Fomoterol see Sympathomimetics, Beta, Fosamprenavir

Note: Fosamprenavir is a prodrug of amprenavir

Analgesics: fosamprenavir reduces plasma concentration of methadone

Anti-arrhythmics: fosamprenavir possibly increases plasma concentration of amiodarone, bepridil and propafenone (increased risk of ventricular arrhythmias—avoid concomitant use); fosamprenavir possibly increases plasma concentration of midodrine—avoid concomitant use

Antibacterials: fosamprenavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of fosamprenavir significantly reduced by rifampicin—avoid concomitant use; avoidance of concomitant fosamprenavir in severe renal and hepatic impairment advised by manufacturer of olodaterol

Foscarnet

Amitriptyline is based on the use of fosfomycin

Methotrexate—manufacturer of capecitabine advises avoid concomitant use; plasma concentration of both drugs may increase when fosamprenavir given with irtraconazole

Anxiolytics and Hypnotics: fosamprenavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of oral midazolam)

Barbiturates: plasma concentration of fosamprenavir possibly reduced by phenobarbital

Ciclosporin: fosamprenavir increases plasma concentration of ciclosporin

Ergot Alkaloids: increased risk of ergotism when fosamprenavir given with ergotamine and methysergide—avoid concomitant use

Lipid-regulating Drugs: possible increased risk of myopathy when fosamprenavir given with atorvastatin; possible increased risk of myopathy when fosamprenavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; possible increased risk of myopathy when fosamprenavir given with simvastatin—avoid concomitant use

Ranolazine: fosamprenavir possibly increases plasma concentration of etravirine—manufacturer of etravirine advises avoid concomitant use

Sildenafil: fosamprenavir possibly increases plasma concentration of sildenafil

Tacrolimus: fosamprenavir increases plasma concentration of tacrolimus

Tadalafil: manufacturer of tadalafil advises avoid concomitant use

Vardenafil: fosamprenavir possibly increases plasma concentration of vardenafil

Fosaprepitant see Aprepitant

Foscarin

Antivirals: avoidance of foscarin advised by manufacturer of lamivudine

Pentamidine isethionate: increased risk of hypocalcaemia when foscarin given with pentamidine isethionate

Fosinopril see ACE Inhibitors

Fosphenytoin see Phenytoin

Framycetin see Aminoglycosides

Frovatriptan see 5HT, Agonists

Furosemide see Diuretics

fosamprenavir increases plasma concentration of etravirine (consider reducing dose of fosamprenavir); plasma concentration of fosamprenavir reduced by lopinavir, effect on lopinavir plasma concentration not predictable—avoid concomitant use; plasma concentration of fosamprenavir possibly reduced by nevirapine

Antivirals: plasma concentration of fosamprenavir reduced by efavirenz and etravirine; plasma concentration of fosamprenavir increased by etravirine (consider reducing dose of fosamprenavir); plasma concentration of fosamprenavir reduced by lopinavir, effect on lopinavir plasma concentration not predictable—avoid concomitant use; plasma concentration of fosamprenavir possibly reduced by nevirapine

Antipsychotics: fosamprenavir possibly inhibits metabolism of amiprazole (reduce dose of amiprazole); fosamprenavir increases plasma concentration of olanzapine (increased risk of toxicity) Antimuscarnicines: avoidance of fosamprenavir advised by manufacturer of darifenacin and tolterodine

Foscarnet

Amitriptyline is based on the use of fosfomycin

Methotrexate—manufacturer of capecitabine advises avoid concomitant use; plasma concentration of both drugs may increase when fosamprenavir given with irtraconazole

Anxiolytics and Hypnotics: fosamprenavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of oral midazolam)

Barbiturates: plasma concentration of fosamprenavir possibly reduced by phenobarbital

Ciclosporin: fosamprenavir increases plasma concentration of ciclosporin

Ergot Alkaloids: increased risk of ergotism when fosamprenavir given with ergotamine and methysergide—avoid concomitant use

Lipid-regulating Drugs: possible increased risk of myopathy when fosamprenavir given with atorvastatin; possible increased risk of myopathy when fosamprenavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; possible increased risk of myopathy when fosamprenavir given with simvastatin—avoid concomitant use

Ranolazine: fosamprenavir possibly increases plasma concentration of etravirine—manufacturer of etravirine advises avoid concomitant use

Sildenafil: fosamprenavir possibly increases plasma concentration of sildenafil

Tacrolimus: fosamprenavir increases plasma concentration of tacrolimus

Tadalafil: manufacturer of tadalafil advises avoid concomitant use

Vardenafil: fosamprenavir possibly increases plasma concentration of vardenafil

Fosaprepitant see Aprepitant

Foscarin

Antivirals: avoidance of foscarin advised by manufacturer of lamivudine

Pentamidine isethionate: increased risk of hypocalcaemia when foscarin given with pentamidine isethionate

Fosinopril see ACE Inhibitors

Fosphenytoin see Phenytoin

Framycetin see Aminoglycosides

Frovatriptan see 5HT, Agonists

Furosemide see Diuretics
Fusidic Acid
- Antivirals: plasma concentration of both drugs increased when fusidic acid given with ritonavir—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when fusidic acid given with atorvastatin—increased risk of myopathy when fusidic acid given with simvastatin
- Sugammadex: fusidic acid possibly reduces response to sugammadex
- Vaccines: antibiotics inactivate oral typhoid vaccine—see p. 767

Gabapentin
- Analgesics: bioavailability of gabapentin increased by morphine
- Antacids: absorption of gabapentin reduced by antacids
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort
- Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by mefloquine
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat

Ganciclovir
- Note: Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature
- Valganciclovir interactions as for ganciclovir
- Antivirals: ganciclovir possibly increases plasma concentration of didanosine; avoidance of intravenous ganciclovir advised by manufacturer of lamivudine; profound myelosuppression when ganciclovir given with zidovudine (if possible avoid concomitant administration, particularly during initial ganciclovir therapy)
- Mycophenolate: plasma concentration of ganciclovir possibly increased by mycophenolate, also plasma concentration of inactive metabolite of mycophenolate possibly increased
- Probenecid: excretion of ganciclovir reduced by probenecid (increased plasma concentration and risk of toxicity)
- Tacrolimus: possible increased risk of nephrotoxicity when ganciclovir given with tacrolimus

Gefitinib
- Antivirals: plasma concentration of gefitinib reduced by zidovudine—avoid concomitant use
- Anticoagulants: gefitinib possibly enhances anticoagulant effect of warfarin
- Antidepressants: manufacturer of gefitinib advises avoid concomitant use with St John’s wort
- Antiepileptics: manufacturer of gefitinib advises avoid concomitant use with carbamazepine and phenytoin; cytotoxics possibly reduce absorption of phenytoin
- Antifungals: plasma concentration of gefitinib increased by itraconazole
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Barbiturates: manufacturer of gefitinib advises avoid concomitant use with barbiturates
- Cardiac Glycosides: cytotoxics reduce absorption of digitoxin tablets
- Ocular-healing Drugs: plasma concentration of gefitinib reduced by manukonidine

Gemcitabine
- Anticoagulants: gemcitabine possibly enhances anticoagulant effect of warfarin
- Antiepileptics: cytotoxics possibly reduce absorption of phenytoin

Gemcitabine (continued)
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digitoxin tablets

Gemevir
- See Prostaglandins

Gemfibrozil
- See Fibrates

Gentamicin
- See Aminoglycosides

Gestodene
- See Progestogens

Glibenclamide
- See Antidiabetics

Glimepiride
- See Antidiabetics

Glipizide
- See Antidiabetics

Glucosamine
- Anticoagulants: glucosamine enhances anticoagulant effect of warfarin (avoid concomitant use)

Glycerol Trinitrate
- See Nitrates

Glycopyronium
- See Antimuscarinics

Gold
- See Sodium Aurothiomalate

Golimumab
- Abatacept: avoid concomitant use of golimumab with abatacept
- Anakinra: avoid concomitant use of golimumab with anakinra
- Vaccines: avoid concomitant use of golimumab with live vaccines (see p. 746)

Grapefruit Juice
- Anti-arrhythmics: grapefruit juice increases plasma concentration of amiodarone; grapefruit juice possibly increases plasma concentration of dronedarone—avoid concomitant use
- Antihistamines: grapefruit juice increases plasma concentration of efavirenz—avoid concomitant use
- Antimalarials: grapefruit juice possibly increases plasma concentration of artemether/lumefantrine
- Antivirals: grapefruit juice possibly increases plasma concentration of efavirenz
- Anxiolytics and Hypnotics: grapefruit juice increases plasma concentration of buspirone
- Calcium-Channel Blockers: grapefruit juice possibly increases plasma concentration of amiodarone; grapefruit juice possibly increases plasma concentration of verapamil
- Ciclosporin: grapefruit juice increases plasma concentration of ciclosporin (increased risk of toxicity)
- Colchicine: grapefruit juice possibly increases risk of colchicine toxicity
- Cytotoxics: avoidance of grapefruit juice advised by manufacturer of everolimus, lapatinib, milotinib and pazopanib; grapefruit juice possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use
- Labetalol: grapefruit juice increases plasma concentration of labetalol
- Lipid-regulating Drugs: grapefruit juice possibly increases plasma concentration of atorvastatin; grapefruit juice possibly increases plasma concentration of simvastatin—avoid concomitant use
- Ranolazine: grapefruit juice possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: grapefruit juice possibly increases plasma concentration of sildenafil
- Sirolimus: grapefruit juice increases plasma concentration of sirolimus—avoid concomitant use
- Tacrolimus: grapefruit juice increases plasma concentration of tacrolimus
- Tadalafil: grapefruit juice possibly increases plasma concentration of tadalafil
- Tolvaptan: grapefruit juice increases plasma concentration of tolvaptan—avoid concomitant use
- Vardenafil: grapefruit juice possibly increases plasma concentration of vardenafil—avoid concomitant use

Grapefruit Juice (continued)
- Anti-arrhythmics: grapefruit juice possibly increases plasma concentration of amiodarone; grapefruit juice possibly increases plasma concentration of dronedarone
- Anticoagulants: grapefruit juice possibly increases antiocoagulant effect of warfarin—avoid concomitant use
- Antihistamines: grapefruit juice increases plasma concentration of efavirenz
- Antimalarials: grapefruit juice possibly increases plasma concentration of artemether/lumefantrine
- Antivirals: grapefruit juice possibly increases plasma concentration of efavirenz
- Anxiolytics and Hypnotics: grapefruit juice increases plasma concentration of buspirone
- Calcium-Channel Blockers: grapefruit juice possibly increases plasma concentration of amiodarone; grapefruit juice possibly increases plasma concentration of verapamil
- Ciclosporin: grapefruit juice increases plasma concentration of ciclosporin (increased risk of toxicity)
- Colchicine: grapefruit juice possibly increases risk of colchicine toxicity
- Cytotoxics: avoidance of grapefruit juice advised by manufacturer of everolimus, lapatinib, milotinib and pazopanib; grapefruit juice possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use
- Labetalol: grapefruit juice increases plasma concentration of labetalol
- Lipid-regulating Drugs: grapefruit juice possibly increases plasma concentration of atorvastatin; grapefruit juice possibly increases plasma concentration of simvastatin—avoid concomitant use
- Ranolazine: grapefruit juice possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: grapefruit juice possibly increases plasma concentration of sildenafil
- Sirolimus: grapefruit juice increases plasma concentration of sirolimus—avoid concomitant use
- Tacrolimus: grapefruit juice increases plasma concentration of tacrolimus
- Tadalafil: grapefruit juice possibly increases plasma concentration of tadalafil
- Tolvaptan: grapefruit juice increases plasma concentration of tolvaptan—avoid concomitant use
- Vardenafil: grapefruit juice possibly increases plasma concentration of vardenafil—avoid concomitant use
Griseofulvin
Alcohol: griseofulvin possibly enhances effects of alcohol

Anti-congestants: griseofulvin reduces anticoagulant effect of coumarins
Anti-epileptics: absorption of griseofulvin reduced by primidone (reduced effect)
Barbiturates: absorption of griseofulvin reduced by phenobarbital (reduced effect)
Ciclosporin: griseofulvin possibly reduces plasma concentration of ciclosporin
Oestrogens: anecdotal reports of contraceptive failure and menstrual irregularities when griseofulvin given with oestrogens
Progestogens: anecdotal reports of contraceptive failure and menstrual irregularities when griseofulvin given with progestogens
Guanethidine: see Adrenergic Neurone Blockers
Haloperidol: see Antipsychotics
Halothane: see Anaesthetics, General
Heparin: see Heparins
Heparins
ACE Inhibitors: increased risk of hyperkalaemia when heparins given with ACE inhibitors
Alikiren: increased risk of hyperkalaemia when heparins given with alikiren
Analgesics: possible increased risk of bleeding when heparins given with NSAIDs; increased risk of haemorrhage when anticoagulants and antiplatelet agents given with intravenous diclofenac (avoid concomitant use, including low-dose heparin); increased risk of haemorrhage when anticoagulants and antiplatelet agents given with ketorolac (avoid concomitant use, including low-dose heparins); anticoagulant effect of heparins enhanced by aspirin
Angiotensin-II Receptor Antagonists: increased risk of hyperkalaemia when heparin given with angiotensin-II receptor antagonists
Clopidogrel: increased risk of bleeding when heparins given with clopidogrel
Dipyridamole: anticoagulant effect of heparins enhanced by dipyridamole
Drotrecogin Alfa: avoidance of concomitant use of high doses of heparins with drotrecogin alfa advised by manufacturer of drotrecogin alfa—consult product literature
Hepprost: anticoagulant effect of heparins possibly enhanced by heparprost
Nitrate: anticoagulant effect of heparins reduced by infusions of glyceryl trinitrate
Histamine
Antidepressants: manufacturer of histamine advises avoid concomitant use with MAOIs; effects of histamine theoretically antagonised by tricyclics—manufacturer of histamine advises avoid concomitant use
Antihistamines: effects of histamine theoretically antagonised by antihistamines—manufacturer of histamine advises avoid concomitant use
Antimalarials: manufacturer of histamine advises avoid concomitant use with antimalarials
Antipsychotics: effects of histamine theoretically antagonised by antipsychotics—manufacturer of histamine advises avoid concomitant use
Atovaquone: manufacturer of histamine advises avoid concomitant use with atovaquone
Clonidine: manufacturer of histamine advises avoid concomitant use with clonidine
Corticosteroids: manufacturer of histamine advises avoid concomitant use with corticosteroids
Ulcer-healing Drugs: effects of histamine theoretically antagonised by histamine H₂-antagonists—manufacturer of histamine H₂-antagonists advises avoid concomitant use
Histamine H₂-antagonists
Alpha-blockers: cimetidine and ranitidine antagonised by tolazoline
Analgesics: cimetidine inhibits metabolism of opioid analgesics (increased plasma concentration)
Histamine H₂-antagonists (continued)
Anti-arrhythmics: cimetidine increases plasma concentration of amiodarone and propafenone; cimetidine inhibits metabolism of flecaïnide (increased plasma concentration); cimetidine increases plasma concentration of lidocaine (increased risk of toxicity)
Antibacterials: histamine H₂-antagonists reduce absorption of cefpodoxime; cimetidine increases plasma concentration of erythromycin (increased risk of toxicity, including deafness); cimetidine inhibits metabolism of metronidazole (increased plasma concentration); metabolism of cimetidine accelerated by rifampicin (reduced plasma concentration)
Anti-coagulants: cimetidine inhibits metabolism of coumarins (enhanced anticoagulant effect)
Antidepressants: cimetidine increases plasma concentration of citalopram, escitalopram, mirtrazapine and sertraline; cimetidine inhibits metabolism of amitriptyline, doxepin, imipramine and nortriptyline (increased plasma concentration); cimetidine increases plasma concentration of moclobemide (halve dose of moclobemide); cimetidine possibly increases plasma concentration of tricyclics
Antidiabetics: cimetidine reduces excretion of metformin (increased plasma concentration); cimetidine enhances hypoglycaemic effect of sulfonylureas
Antiepileptics: cimetidine inhibits metabolism of carbamazepine, ethosuximide and valproate (increased plasma concentration)
Antifungals: histamine H₂-antagonists reduce absorption of itraconazole and ketoconazole; avoidance of histamine H₂-antagonists advised by manufacturer of posaconazole (plasma concentration of posaconazole possibly reduced); cimetidine reduces plasma concentration of posaconazole; cimetidine increases plasma concentration of terbinafine
Antihistamines: manufacturer of loratadine advises cimetidine possibly increases plasma concentration of loratadine
Antimalarials: avoidance of cimetidine advised by manufacturer of artemether/lumefantrine; cimetidine inhibits metabolism of chloroquine and hydroxychloroquine and quinine (increased plasma concentration)
Antipsychotics: cimetidine possibly enhances effects of antipsychotics, chlorpromazine and clozapine
Antivirals: histamine H₂-antagonists reduce plasma concentration of zidovudine; histamine H₂-antagonists possibly increase plasma concentration of raltegravir—manufacturer of raltegravir advises avoid concomitant use; cimetidine possibly increases plasma concentration of saquinavir
Anxiolytics and Hypnotics: cimetidine inhibits metabolism of benzodiazepines, clomethiazole and zaleplon (increased plasma concentration); cimetidine increases plasma concentration of melatonin
Beta-blockers: cimetidine increases plasma concentration of labetalol, metoprolol and propranolol (increased plasma concentration)
Calcium-channel Blockers: cimetidine possibly inhibits metabolism of calcium-channel blockers (increased plasma concentration); cimetidine increases plasma concentration of isradipine (halve dose of isradipine)
Ciclosporin: cimetidine possibly increases plasma concentration of ciclosporin
Clonipride: cimetidine possibly reduces antiplatelet effect of clopidogrel
Cytotoxic: cimetidine possibly enhances myelosuppressive effects of carmustine and lomustine; cimetidine increases plasma concentration of cyclosporin; cimetidine inhibits metabolism of fluorouracil (increased plasma concentration); fomatidine possibly reduces plasma concentration of dasatinib; avoidance of cimetidine, fomatidine and naxitine advised by manufacturer of fomitin; ranitidine
Histamine H₂-antagonists

- Cytotoxics (continued)
  - reduces plasma concentration of erlotinib—manufacturer of erlotinib advises at least 2 hours before or 10 hours after ranitidine; ranitidine reduces plasma concentration of gefitinib; histamine H₂-antagonists possibly reduce absorption of lapatinib
  - Ergot Alkaloids: increased risk of ergotism when cimetidine given with ergotamine and methysergide—avoid concomitant use

Histamine: histamine H₂-antagonists theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use

Hormone Antagonists: absorption of cimetidine possibly delayed by octreotide

5HT, Agonists: cinetidine inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)

Mebendazole: cimetidine possibly inhibits metabolism of mebendazole (increased plasma concentration)

Roflumilast: cimetidine inhibits the metabolism of roflumilast

Sildenafil: cimetidine increases plasma concentration of sildenafil (consider reducing dose of sildenafil)

Theophylline: cimetidine inhibits metabolism of theophylline (increased plasma concentration)

Thyroid Hormones: cimetidine reduces absorption of levothyroxine

Ulipristal: avoidance of histamine H₂-antagonists advised by manufacturer of ulipristal (plasma concentration of ulipristal possibly reduced)

Homatropine see Antimuscarinics

Hormone Antagonists see Bicalutamide, Danazol, Dutasteride, Exemestane, Flutamide, Lacreotide, Octreotide, Tamoxifen, Toremifene, and Trilostane

5HT₂, Agonists

- Anti-bacterials: plasma concentration of eritriton increased by clarithromycin and erythromycin (risk of toxicity)—avoid concomitant use; metabolism of zolmitriptan possibly inhibited by quinolones (reduce dose of zolmitriptan)

- Antidepressants: increased risk of CNS toxicity when sumatriptan given with eptalopram, escitalopram, fluoxetine, fluvoxamine or paroxetine; metabolism of zolmitriptan possibly inhibited by fluvoxamine; metabolism of zolmitriptan possibly inhibited by fluvoxamine (reduce dose of zolmitriptan); CNS toxicity reported when sumatriptan given with sertraline; possible increased serotoninergic effects when SHT, agonists given with duloxetine or venlafaxine; increased risk of CNS toxicity when zolmitriptan given with MAOIs; risk of CNS toxicity when rizatriptan or sumatriptan given with MAOIs (avoid rizatriptan or sumatriptan for 2 weeks after MAOIs); risk of CNS toxicity when rizatriptan or sumatriptan given with moclobemide (avoid rizatriptan or sumatriptan for 2 weeks after moclobemide); risk of CNS toxicity when zolmitriptan given with moclobemide (reduce dose of zolmitriptan); increased serotoninergic effects when SHT, agonists given with St. John's wort—avoid concomitant use

- Antifungals: plasma concentration of eritriton increased by itraconazole and ketoconazole (risk of toxicity)—avoid concomitant use; plasma concentration of almotriptan increased by ketoconazole (increased risk of toxicity—avoid concomitant use; plasma concentration of almotriptan increased by prapantolol (manufacturer of rizatriptan advises halve dose and avoid within 2 hours of prapantolol)

Dopaminergics: avoidance of SHT, agonists advised by manufacturer of selegiline

5HT₂, Agonists (continued)

- Ergot Alkaloids: increased risk of vasospasm when eletriptan, frovatriptan or naratriptan given with ergotamine and methysergide for 24 hours after eletriptan, frovatriptan or naratriptan, avoid eletriptan, frovatriptan or naratriptan for 24 hours after ergotamine and methysergide; increased risk of vasospasm when almotriptan, rizatriptan, sumatriptan or zolmitriptan given with ergotamine and methysergide (avoid ergotamine and methysergide for 6 hours after almotriptan, rizatriptan, sumatriptan or zolmitriptan, avoid almotriptan, rizatriptan, sumatriptan or zolmitriptan for 24 hours after ergotamine and methysergide)

Lithium: possible risk of toxicity when sumatriptan given with lithium

Ulcer-healing Drugs: metabolism of zolmitriptan inhibited by cimetidine (reduce dose of zolmitriptan)

5HT₂, Antagonists

Analgesics: ondansetron possibly antagonises effects of tramadol

Antibacterials: metabolism of ondansetron accelerated by rifampicin (reduced effect)

Antiepileptics: metabolism of ondansetron accelerated by carbamazepine and phenytoin (reduced effect)

Hydralazine see Vasodilator Antihypertensives

Hydrochlorothiazide see Diuretics

Hydrocortisone see Corticosteroids

Hydroflumethiazide see Diuretics

Hydromorphone see Opioid Analgesics

Hydrodolal see Antacids

Hydroxocobalamin

Antibacterials: response to hydroxocobalamin reduced by chloramphenicol

Hydroxybenzamide

Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Antivirals: increased risk of toxicity when hydroxybenzamide given with didanosine and stavudine—avoid concomitant use

Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Hydroxychloroquine see Chloroquine and Hydroxychloroquine

Hydroxyzine see Antihistamines

Hyosine see Antimuscarinics

Ibandronic Acid see Bisphosphonates

Ibufrofen see NSAIDs

Idarubicin

Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Ciclosporin: plasma concentration of idarubicin increased by cyclosporin

Ilosulfamate

Anticoagulants: ilosulfamate possibly enhances anti-coagulant effect of coumarins

Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Cytotoxicities: increased risk of otoxicity when iodosulfamate given with cisplatin

Ilprost

Analgesics: increased risk of bleeding when ilprost given with NSAIDs or aspirin

Anticoagulants: ilprost possibly enhances anti-coagulant effect of coumarins and heparins;
Iloprost
Anticoagulants (continued)
increased risk of bleeding when iloprost given with phenindione
Clodigorel: increased risk of bleeding when iloprost given with clodigorel
Eptifibatide: increased risk of bleeding when iloprost given with eptifibatide
Tirofiban: increased risk of bleeding when iloprost given with tirofiban
Imatinib
Analgesics: manufacturer of imatinib advises caution with paracetamol
Antibacterials: plasma concentration of imatinib reduced by rifampicin—avoid concomitant use
Anticoagulants: manufacturer of imatinib advises replacement of warfarin with a heparin (possibility of enhanced warfarin effect)
Antidepressants: plasma concentration of imatinib reduced by St John's wort—avoid concomitant use
Antiepileptics: plasma concentration of imatinib reduced by carbamazepine, oxcarbazepine and phenytoin—avoid concomitant use; cytoxotics possibly reduce absorption of phenytoin
Antifungals: imatinib possibly reduces plasma concentration of itraconazole
Antipsychotics: increased by ketocazole
Antipsychotics: avoid concomitant use of cytoxotics with clobazapine (increased risk of agranulocytosis)
Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets
Ciclosporin: imatinib possibly increases plasma concentration of ciclosporin
Lipid-regulating Drugs: imatinib possibly reduces plasma concentration of levothryroxine
Imidapril see ACE Inhibitors
Imipenem with Cilastatin
Antibacterials: carbapenems reduce plasma concentration of valproate—avoid concomitant use
Antivirals: increased risk of convulsions when imipenem with cilastatin given with ganciclovir
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 167
Imipramine see Antidepressants, Tricyclic
Immunoglobulins
Note For advice on immunoglobulins and live virus vaccines, see under Normal Immunoglobulin, p. 769
Indacaterol see Sympathomimetics, Beta,
Indapamide see Diuretics
Indinavir
Aldesleukin: plasma concentration of indinavir possibly increased by aldesleukin
Anti-arrhythmics: indinavir possibly increases plasma concentration of amiodarone—avoid concomitant use; indinavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)
Antibacterials: indinavir increases plasma concentration of rifabutin—avoid concomitant use; metabolism of indinavir accelerated by rifampicin (reduced plasma concentration—avoid concomitant use); avoidance of concomitant indinavir in severe renal and hepatic impairment advised by manufacturer of efalimumab
Anticoagulants: avoidance of indinavir advised by manufacturer of rivaroxaban
Antidepressants: plasma concentration of indinavir reduced by St John's wort—avoid concomitant use
Antiepileptics: plasma concentration of indinavir possibly reduced by carbamazepine and phenytoin, also plasma concentration of carbamazepine and phenytoin possibly increased; plasma concentration of indinavir possibly reduced by primidone
Antifungals: plasma concentration of indinavir increased byitraconazole and ketoconazole (consider reducing dose of indinavir)
Antimalarials: caution with indinavir advised by manufacturer of artesunate/lumefantrine; indinavir possibly increases plasma concentration of quinine (increased risk of toxicity)
Antimuscarnicains: avoidance of indinavir advised by manufacturer of darifenacin and tolterodine; manufacturer of fesoterodine advises dose reduction when indinavir given with fesoterodine—consult fesoterodine product literature
Antipsychotics: indinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole); indinavir possibly increases plasma concentration of pinozide (increased risk of ventricular arrhythmias—avoid concomitant use)
Antivirals: avoid concomitant use of indinavir with abacavir; plasma concentration of both drugs increased when indinavir given with darunavir; plasma concentration of indinavir reduced by efavirenz and nevirapine; plasma concentration of indinavir possibly reduced by etravirine—avoid concomitant use; indinavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc); combination of indinavir with nelfinavir may increase plasma concentration of either drug (or both); plasma concentration of indinavir increased by ritonavir; indinavir increases plasma concentration of saquinavir
Anxiolytics and Hypnotics: increased risk of prolonged sedation when indinavir given with alprazolam—avoid concomitant use; indinavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of oral midazolam)
Atovalozone: plasma concentration of indinavir possibly reduced by atovaquone
Barbiturates: plasma concentration of indinavir possibly reduced by barbiturates; plasma concentration of indinavir possibly reduced by phenobarbital, also plasma concentration of phenobarbital possibly increased
Ciclosporin: indinavir increases plasma concentration of ciclosporin
Colchicine: indinavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)
Corticosteroids: plasma concentration of indinavir possibly reduced by dexamethasone
Cytotoxics: indinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use; avoidance of indinavir advised by manufacturer of pazopanib
Ergot Alkaloids: increased risk of ergotism when indinavir given with ergotamine and methysergide—avoid concomitant use
5HT, Agonists: indinavir increases plasma concentration of ketotifen (risk of toxicity)—avoid concomitant use
Lipid-regulating Drugs: possible increased risk of myopathy when indinavir given with atorvastatin; possible increased risk of myopathy when indinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when indinavir given with simvastatin (avoid concomitant use)
Ranolazine: indinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
Sildenafil: indinavir increases plasma concentration of sildenafil—reduce initial dose of sildenafil
Tamafafil: indinavir possibly increases plasma concentration of tadalafil
Vardenafil: indinavir increases plasma concentration of vardenafil—avoid concomitant use
Indometacin see NSAIDs
Indoramin see Alpha-blockers
**Infliximab**
- Abatacept: avoid concomitant use of infliximab with abatacept
- Anakinra: avoid concomitant use of infliximab with anakinra
- Vaccines: avoid concomitant use of infliximab with live vaccines (see p. 746)

**Influenza Vaccine** see Vaccines

**Insulin** see Antidiabetics

**Interferon Alfa** see Interferons

**Interferon Gamma** see Interferons

**Interferons**
- Note: Peginterferon alfa interactions as for interferon alfa
- Antivirals: increased risk of peripheral neuropathy when interferon alfa given with telbivudine
- **Theophylline**: interferon alfa inhibits metabolism of theophylline (consider reducing dose of theophylline)
- Vaccines: manufacturer of interferon gamma advises avoid concomitant use with vaccines

**Ipratropium** see Antimuscarinics

**Ibzeran** see Angiotensin-II Receptor Antagonists

**Irinotecan**
- Anti-depressants: metabolism of irinotecan accelerated by St John's wort (reduced plasma concentration—avoid concomitant use)
- Antiepileptics: plasma concentration of irinotecan and its active metabolite reduced by carbamazepine and phenytoin; cytoxotixs possibly reduce absorption of phenytoin
- Anti-fungals: plasma concentration of irinotecan reduced by ketoconazole (but concentration of irinotecan increased)—avoid concomitant use
- Anti-psychotics: avoid concomitant use of cytoxotixs with clozapine (increased risk of agranulocytosis)
- Antivirals: metabolism of irinotecan possibly inhibited by azathoprine (increased risk of toxicity)
- Barbiturates: plasma concentration of irinotecan and its active metabolite reduced by phenobarbital
- Cardiac Glycosides: cytoxotixs reduce absorption of digoxin tablets
- **Cytotoxix**: plasma concentration of active metabolite of irinotecan increased by lapatinib—consider reducing dose of irinotecan; plasma concentration of irinotecan possibly increased by soralenib

**Iron**
- Antacids: absorption of oral iron reduced by oral magnesium salts (as magnesium trisilicate)
- Antibacterials: oral iron reduces absorption of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin; oral iron reduces absorption of tetracyclines, also absorption of oral iron reduced by tetracyclines
- Bisphosphonates: oral iron reduces absorption of bisphosphonates
- Calcium Salts: absorption of oral iron reduced by calcium salts
- Dimercaprol: avoid concomitant use of iron with dimercaprol
- Dapominicergics: oral iron reduces absorption of entacapone; oral iron possibly reduces absorption of levodopa
- Etroombopag: oral iron possibly reduces absorption of etroombopag (give at least 4 hours apart)
- Methyldopa: oral iron antagonises hypotensive effect of methyldopa
- Mycohenolate: oral iron reduces absorption of mycohenolate
- Penicillin: oral iron reduces absorption of penicillin
- Thyroid Hormones: oral iron reduces absorption of levothyroxine (give at least 2 hours apart)
- Trientine: absorption of oral iron reduced by trientine
- Zinc: oral iron reduces absorption of zinc, also absorption of oral iron reduced by zinc

**Isocarboxazid** see MAOIs

**Isopropylurane** see Anaesthetics, General

**Isometheptene** see Sympathomimetics

**Isoniazid**
- Antacids: absorption of isoniazid reduced by antacids
- Antibacterials: increased risk of CNS toxicity when isoniazid given with cycloserine
- **Antiepileptics**: isoniazid increases plasma concentration of carbamazepine (also possibly increased isoniazid hepatotoxicity); isoniazid inhibits metabolism of ethinyl oestradiol (reduced plasma concentration and risk of toxicity); isoniazid possibly inhibits metabolism of phenytoin (increased risk of toxicity)
- Antifungals: isoniazid possibly reduces plasma concentration of ketoconazole
- Antihistametics and Hypnotics: isoniazid inhibits the metabolism of diazepam
- Corticosteroids: plasma concentration of isoniazid possibly reduced by corticosteroids
- Disulfiram: isoniazid possibly increases CNS effects of disulfiram
- Dopaminergics: isoniazid possibly reduces effects of levodopa
- **Theophylline**: isoniazid possibly increases plasma concentration of theophylline

**Vaccines**: isoniazid possibly reduces effects of oral vaccines—see p. 767

**Isosorbide Dinitrate** see Nitrates

**Isosorbide Mononitrate** see Nitrates

**Istretinoin** see Retinoids

**Ivatadrine**
- Anti-arrhythmics: increased risk of ventricular arrhythmias when ivabradine given with amiodarone or disopyramide
- Antibacterials: plasma concentration of ivabradine possibly increased by barbiturates and telithromycin—avoid concomitant use
- Antidepressants: plasma concentration of ivabradine reduced by St John's wort—avoid concomitant use
- Anti-fungals: plasma concentration of ivabradine increased by ketoconazole—avoid concomitant use; plasma concentration of ivabradine increased by fluconazole—reduce initial dose of ivabradine; plasma concentration of ivabradine possibly increased byitraconazole—avoid concomitant use
- Anti-imalarial: increased risk of ventricular arrhythmias when ivabradine given with mephalone
- Antipsychotics: increased risk of ventricular arrhythmias when ivabradine given with phenothiazines
- Antivirals: plasma concentration of ivabradine possibly increased by nelfiltravir and ritonavir—avoid concomitant use
- Beta-blockers: increased risk of ventricular arrhythmias when ivabradine given with sotalol
- Calcium-channel Blockers: plasma concentration of ivabradine increased by diltiazem and verapamil—avoid concomitant use
- Grapefruit Juice: plasma concentration of ivabradine increased by grapefruit juice
- Pentamidine isethionate: increased risk of ventricular arrhythmias when ivabradine given with pentamidine isethionate

**Iveolin**
- Analgesics: kaolin possibly reduces absorption of aspirin
- Antibacterials: kaolin possibly reduces absorption of tetracyclines
- Anti-imalaria: ivadoline reduces absorption of chloroquine and hydroxychloroquine
- Antipsychotics: kaolin possibly reduces absorption of phenothiazines

**Ketamine** see Anaesthetics, General

**Ketorozole** see Antifungals, Imidazoles

**Ketoprofen** see NSAIDs

**Ketorolac** see NSAIDs
Ketotifen see Antihistamines
Labetalol see Beta-blockers
Lacidipine see Calcium-channel Blockers
Lacosamide
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SIRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort
- Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by neftoquine
- Orlistat: possible increased risk of convulsions when antiepileptics given with erlotistat
Lactulose
- Anticoagulants: lactulose possibly enhances anticoagulant effect of coumarins
Lamivudine
- Antimicrobials: plasma concentration of lamivudine increased by trimethoprim (as co-trimoxazole)—avoid concomitant use of high-dose co-trimoxazole
- Antivirals: avoidance of lamivudine advised by manufacturer of emtricitabine; manufacturer of lamivudine advises avoidance of concomitant use with foscamet; manufacturer of lamivudine advises avoid concomitant use of intravenous ganciclovir
Lamotrigin
- Antimicrobials: plasma concentration of lamotrigin reduced by trimampicin
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SIRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort
- Antiepileptics: plasma concentration of lamotrigin often reduced by carbamazepine, also plasma concentration of an active metabolite of carbamazepine sometimes raised (but evidence is conflicting); plasma concentration of lamotrigin reduced by phenobarbital; plasma concentration of lamotrigin increased by valproate
- Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by neftoquine
- Antivirals: plasma concentration of lamotrigin possibly reduced by ritonavir
Barbiturates: plasma concentration of lamotrigin reduced by phenobarbital
- Oestrogens: plasma concentration of lamotrigin reduced by oestrogens—consider increasing dose of lamotrigin
- Oestrogens: possible increased risk of convulsions when antiepileptics given with erlotistat
Progestagens: plasma concentration of lamotrigin possibly increased by desogestrel
Lanreotide
- Antidepressants: lanreotide possibly reduces requirements for insulin, metformin, repaglinide and sulfonylureas
- Ciclosporin: lanreotide reduces plasma concentration of ciclosporin
Lansoprazole see Proton Pump Inhibitors
Lanthanum
- Antitoxics: lanthanum possibly reduces absorption of quinolones (give at least 2 hours before or 4 hours after lanthanum)
- Antifungals: lanthanum possibly reduces absorption of ketoconazole (give at least 2 hours apart)
- Antimalarials: lanthanum possibly reduces absorption of chloroquine and hydroxychloroquine (give at least 2 hours apart)
- Lanreotide: manufacturer of lanreotide advises avoid concomitant use with rifabutin, rifampicin and telithromycin
- Antidepressants: manufacturer of lanreotide advises avoid concomitant use with St John’s wort
- Antidiabetics: manufacturer of lanreotide advises avoid concomitant use with repaglinide
- Antiepileptics: plasma concentration of lanreotide reduced by carbamazepine—avoid concomitant use; cytotoxics possibly reduce absorption of phenytoin; manufacturer of lanreotide advises avoid concomitant use with phenytoin
- Antifungal: plasma concentration of lanreotide increased by ketoconazole—avoid concomitant use; manufacturer of lanreotide advises avoid concomitant use with itraconazole, posaconazole and voriconazole
- Antipsychotics: avoid concomitant use of cytoxoties with clozapine (increased risk of agranulocytosis); manufacturer of lanreotide advises avoid concomitant use with pimozide
- Antivirals: manufacturer of lanreotide advises avoid concomitant use with itaconazole, posaconazole and voriconazole
Cardiac Glycosides: cytoxoties reduce absorption of digoxin tablets
- Anticoagulants: manufacturer of lanreotide advises avoid concomitant use with grapefruit juice
- Ulcer-healing Drugs: absorption of lanreotide possibly reduced by histamine H2-antagonists and proton pump inhibitors
Laronidase
- Antimalarials: effects of laronidase possibly inhibited by chloroquine and hydroxychloroquine (manufacturer of laronidase advises avoid concomitant use)
Leukotriene Receptor Antagonists (continued)  
Barbiturates: plasma concentration of montelukast reduced by phenobarbital 
Theophylline: zafirlukast possibly increases plasma concentration of theophylline, also plasma concentration of zafirlukast reduced

Levamisole  
Alcohol: possibility of diazepam-like reaction when levamisole given with alcohol 
Anticoagulants: levamisole possibly enhances anticoagulant effect of warfarin 
Antiepileptics: levamisole possibly increases plasma concentration of phenytoin

Levetiracetam  
Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSris and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort 
Antiepileptics: levetiracetam possibly increases risk of carbamazepine toxicity

Antimalarias: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of anti-epileptics antagonised by methotrexate 
Orilast: possible increased risk of convulsions when antiepileptics given with orlistat

Levobunolol see Beta-blockers  
Levobupivacaine  
Anti-arrhythmics: increased myocardial depression when levobupivacaine given with anti-arrhythmics  
Levocetirizine see Antihistamines  
Levodopa  
ACE Inhibitors: enhanced hypotensive effect when levodopa given with ACE inhibitors 
Adrenergic Neurone Blockers: enhanced hypotensive effect when levodopa given with adrenergic neurone blockers 
Alpha-blockers: enhanced hypotensive effect when levodopa given with alpha-blockers 
Antidepressants: risk of hypertensive crisis when levodopa given with isoniazid 
Antimuscarinics: absorption of levodopa possibly reduced by antimuscarinics  
Antipsychotics: effects of levodopa possibly reduced by antipsychotics  
Antivirals: plasma concentration of lido- 
 
Levodopa (continued)  
Dopaminergics: enhanced effects and increased toxicity of levodopa when given with selegiline (reduce dose of levodopa) 
Iron: absorption of levodopa possibly reduced by oral iron 
Memantine: effects of dopaminergics possibly enhanced by memantine 
Methyldopa: enhanced hypotensive effect when levodopa given with methyldopa; antiparkinsonian effect of dopaminergics antagonised by methyldopa 
Moxonidine: enhanced hypotensive effect when levodopa given with moxonidine 
Muscle Relaxants: possible agitation, confusion and hallucinations when levodopa given with baclofen 
Nitrates: enhanced hypotensive effect when levodopa given with nitrates 
Vasodilator Antihypertensives: enhanced hypotensive effect when levodopa given with hydralazine, minoxidil or sodium nitroprusside 
Vitamins: effects of levodopa reduced by pyridoxine when given with dopa-decarboxylase inhibitor 

Levofloxacin see Quinolones  
Levofolic Acid see Folicates  
Levomepromazine see Antipsychotics  
Levonorgestrel see Progestogens  
Levothyroxine see Thyroid Hormones  
Lidocaine Note  
Interactions less likely when lidocaine used topically

Anaesthetics, Local: increased myocardial depression when anti-arrhythmics given with bupivacaine, levobupivacaine, prilocaine or ropivacaine  
Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with other anti-arrhythmics

Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval

Antivirals: plasma concentration of lidocaine possibly increased by atazanavir and lopinavir; plasma concentration of lidocaine possibly increased by darunavir and fosamprenavir—avoid concomitant use; increased risk of ventricular arrhythmias when lidocaine given with saquinavir—avoid concomitant use

Beta-blockers: increased myocardial depression when anti-arrhythmics given with beta-blockers; increased risk of lidocaine toxicity when given with propranolol

Diuretics: action of lidocaine antagonised by hypokalaemia caused by acetazolamide, loop diuretics or thiazides and related diuretics

Muscle Relaxants: neuromuscular blockade enhanced and prolonged when lidocaine given with suxamethonium

Uler-healing Drugs: plasma concentration of lidocaine increased by cimetidine (increased risk of toxicity)

Linezolid Note  
Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs

Antibacterial: plasma concentration of linezolid reduced by rifampicin (possible therapeutic failure of linezolid)

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Liothyronine see Thyroid Hormones  
Lipid-regulating Drugs see Colestipol, Colestymarine, Ezetimibe, Fibrates, Nicotinic Acid, and Statins  
Liraglutide see Antidiabetics  
Lisinopril see ACE Inhibitors  
Lithium  
ACE Inhibitors: excretion of lithium reduced by ACE inhibitors (increased plasma concentration)

Analgesics: excretion of lithium reduced by NSAIDs (increased risk of toxicity); excretion of lithium reduced by non-steroidal anti-inflammatory drugs

Note  
Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs
Appendix 1: Interactions

**Lopinavir**

Note: In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir

- Anti-arrhythmics: lopinavir possibly increases plasma concentration of efavirenz (increased risk of ventricular arrhythmias)—avoid concomitant use; lopinavir possibly increases plasma concentration of lidocaine
- Antibacterials: plasma concentration of lopinavir reduced by rifampicin—avoid concomitant use; avoidance of concomitant lopinavir in severe renal and hepatic impairment advised by manufacturer of etrolithromycin
- Anticoagulants: avoidance of lopinavir advised by manufacturer of rivaroxaban
- Antidepressants: plasma concentration of lopinavir possibly reduced by carbamazepine, phenytoin and primidone
- Angiotensin-II Receptor Antagonists: plasma concentration of lopinavir reduced by St John’s wort—avoid concomitant use
- Antiepileptics: plasma concentration of lopinavir possibly reduced by carbamazepine, phenytoin and primidone
- Antihistamines: lopinavir possibly increases plasma concentration of chlorphenamine
- Antimalarials: caution with lopinavir advised by manufacturer of arteether/lumefantrine
- Antivirals: avoidance of lopinavir advised by manufacturer of darifenacin and tolterodine
- Anxiolytics and Hypnotics: lopinavir possibly inhibits metabolism of alprazolam (reduce dose of alprazolam)
- Calcium-channel Blockers: neurotoxicity may occur when lopinavir given with diltiazem or verapamil without increased plasma concentration of lithium
- Cytotoxics: increased risk of ventricular arrhythmias when lopinavir given with warfarin
- Diuretics: increased risk of toxicity when lopinavir given with olsalazine; increased risk of extrapyramidal side-effects when lopinavir given with sulpiride
- Antipsychotics: increased risk of extrapyramidal side-effects and possibly neurotoxicity when lopinavir given with clozapine, fluoxetine, haloperidol, phenothiazines or zuclopenthixol; possible risk of toxicity when lopinavir given with olanzapine; increased risk of extrapyramidal side-effects when lopinavir given with sulpiride
- Antidepressants, Tricyclic: increased risk of neurotoxicity when lopinavir given with clonazepam
- Calcium-channel Blockers: neurotoxicity may occur when lopinavir given with diltiazem or verapamil without increased plasma concentration of lithium
- Diuretics: increased risk of toxicity when lopinavir given with amiloride; increased risk of toxicity by loop diuretics and thiazides and related diuretics (increased plasma concentration and risk of toxicity)—loop diuretics safer than thiazides; increased risk of lithium reduced by potassium-sparing diuretics and aldosterone antagonists (increased plasma concentration and risk of toxicity)
- ACE inhibitors: possible risk of toxicity when lopinavir given with sumatriptan
- Methyldopa: neurotoxicity may occur when lopinavir given with methyldopa without increased plasma concentration of lithium
- Muscle Relaxants: increased risk of muscle relaxation; hyperkinesia caused by lithium possibly aggravated by baclofen
- Parasympathomimetics: lithium antagonises effects of neostigmine and pyridostigmine
- Theophylline: increased risk of toxicity by lopinavir given with sumatriptan
- Barbiturates: plasma concentration of lopinavir possibly reduced by phenobarbital
- Corticosteroids: plasma concentration of lopinavir possibly reduced by dexamethasone
- Eltrombopag: lopinavir possibly reduces plasma concentration of eltrombopag
- Lipoic acid (reduced risk of myopathy when lopinavir given with atorvastatin; possible increased risk of myopathy when lopinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; possible increased risk of myopathy when lopinavir given with simvastatin—avoid concomitant use)
- Ranolazine: lopinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sirtolimus: lopinavir possibly increases plasma concentration of sirolimus
- Loprazolam see Anxiolytics and Hypnotics
- Loratadine see Antihistamines
- Lorazepam see Anxiolytics and Hypnotics
- Lormetazepam see Anxiolytics and Hypnotics
- Losartan see Angiotensin-II Receptor Antagonists
- Lumeefantrine see Artemether with Lumefantrine
- Lymecycline see Tetracyclines
Macrolides

Note  See also Telithromycin

Note Interactions do not apply to small amounts of erythromycin used topically

Analgesics: erythromycin increases plasma concentration of alfentanil

Antacids: absorption of azithromycin reduced by antacids

- Antiarrhythmics: increased risk of ventricular arrhythmias when parenteral erythromycin given with amiodarone—avoid concomitant use; erythromycin increases plasma concentration of disopyramide (increased risk of toxicity); clarithromycin possibly increases plasma concentration of disopyramide (increased risk of toxicity); erythromycin possibly increases plasma concentration of dronedarone (increased risk of ventricular arrhythmias—avoid concomitant use); avoidance of clarithromycin advised by manufacturer of dronedarone (risk of ventricular arrhythmias)

- Antibacterials: increased risk of ventricular arrhythmias when parenteral erythromycin given with moxifloxacin—avoid concomitant use; macrolides possibly increase plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose); clarithromycin increases plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose); plasma concentration of clarithromycin reduced by rifampin

- Anticoagulants: clarithromycin and erythromycin enhance anticoagulant effect of coumarins; azithromycin possibly enhances anticoagulant effect of coumarins

- Antidepressants: avoidance of macrolides advised by manufacturer of reboxetine

Antidiabetics: clarithromycin enhances effects of repaglinide

- Antiepileptics: clarithromycin and erythromycin increase plasma concentration of carbamazepine; clarithromycin inhibits metabolism of phenytoin (increased plasma concentration); erythromycin possibly inhibits metabolism of valproate (increased plasma concentration)

Antifungals: clarithromycin increases plasma concentration of itraconazole

- Antihistamines: manufacturer of loratadine advises erythromycin possibly increases plasma concentration of loratadine; macrolides possibly inhibit metabolism of eminolastine (avoid concomitant use); erythromycin inhibits metabolism of minolastine—avoid concomitant use; erythromycin increases plasma concentration of rupatadine

- Antimalarials: avoidance of macrolides advised by manufacturer of artether/lumefantrine

Antimuscarinics: erythromycin possibly increases plasma concentration of dantefacin; manufacturer of fosoterodine advises dose reduction when clarithromycin given with fosoterodine—consult fosoterodine product literature; avoidance of clarithromycin and erythromycin advised by manufacturer of tolterodine

- Antipsychotics: avoidance of macrolides advised by manufacturer of droperidol (risk of ventricular arrhythmias); increased risk of ventricular arrhythmias when parenteral erythromycin given with moclubenthrin—avoid concomitant use; increased risk of ventricular arrhythmias when erythromycin given with simrilupride—avoid concomitant use; erythromycin possibly increases plasma concentration of econazole; increased risk of ventricular arrhythmias when erythromycin given with ipimidine—avoid concomitant use; macrolides possibly increase plasma concentration of quetiapine (reduce dose of quetiapine); increased risk of ventricular arrhythmias when parenteral erythromycin given with sulpiride

Macrolides (continued)

- Antivirals: plasma concentration of both drugs increased when clarithromycin given with atazanavir; increased risk of rash when clarithromycin given with efavirenz; clarithromycin increases plasma concentration of etravirine, also plasma concentration of clarithromycin reduced; clarithromycin possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc); plasma concentration of clarithromycin reduced by nevirapine (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased; plasma concentration of clarithromycin increased by ritonavir (reduce dose of clarithromycin in renal impairment); plasma concentration of azithromycin and erythromycin possibly increased by ritonavir; increased risk of ventricular arrhythmias when clarithromycin or erythromycin given with saquinavir—avoid concomitant use; plasma concentration of clarithromycin increased by etravirine (reduce dose of clarithromycin in renal impairment), also clarithromycin increases plasma concentration of tipranavir; clarithromycin tablets reduce absorption of zidovudine (give at least 2 hours apart)

- Antiulcer and Hypnotics: clarithromycin and erythromycin inhibit metabolism of midazolam (increased plasma concentration with increased sedation); erythromycin increases plasma concentration of buspirone (reduce dose of buspirone); erythromycin inhibits the metabolism of zopiclone (increased risk of toxicity); aprepitant: clarithromycin possibly increases plasma concentration of aprepitant

- Antidepressants: increased risk of ventricular arrhythmias when parenteral erythromycin given with atomoxetine

- Calcium-channel Blockers: erythromycin possibly inhibits metabolism of felodipine (increased plasma concentration); avoidance of erythromycin advised by manufacturer of lercanidipine; clarithromycin and erythromycin possibly inhibit metabolism of verapamil (increased risk of toxicity)

- Cardiac Glycosides: macrolides increase plasma concentration of digoxin (increased risk of toxicity)

- Ciclosporin: macrolides possibly inhibit metabolism of ciclosporin (increased plasma concentration); clarithromycin and erythromycin inhibit metabolism of ciclosporin (increased plasma concentration)

- Clopidogrel: erythromycin possibly reduces antiplatelet effect of clopidogrel

- Colchicine: azithromycin, clarithromycin and erythromycin possibly increase risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)

- Corticosteroids: erythromycin possibly inhibits metabolism of corticosteroids; erythromycin inhibits the metabolism of methylprednisolone; clarithromycin possibly increases plasma concentration of methylprednisolone

- Cytoprotection: clarithromycin possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use; erythromycin increases plasma concentration of everolimus; avoidance of clarithromycin advised by manufacturer of nilotinib and pazopanib; in vitro studies suggest a possible interaction between erythromycin and docetaxel (consult docetaxel product literature); increased risk of ventricular arrhythmias when erythromycin given with arsenic trioxide; erythromycin increases toxicity of vinblastine—avoid concomitant use; possible increased risk of neutropenia when clarithromycin given with vinorelbine

- Diuretics: clarithromycin increases plasma concentration of spironolactone—avoid concomitant use;
Appendix 1: Interactions

BNF 61

Macrolides
- Diuretics (continued)
  - erythromycin increases plasma concentration of
  - Dopaaminergics: macrolides possibly increase plasma concentration of bromocriptine and cabergoline (increased risk of toxicity); erythromycin increases plasma concentration of bromocriptine and cabergoline (increased risk of toxicity)
- Ergot Alkaloids: increased risk of ergotism when macrolides given with ergotamine and methysergide—avoid concomitant use
- SHT, Agonists: clarithromycin and erythromycin increase plasma concentration of ketorolac (risk of toxicity)—avoid concomitant use
- Ivabradine: clarithromycin possibly increases plasma concentration of silibradine—avoid concomitant use
- Leukotriene Receptor Antagonists: erythromycin reduces plasma concentration of zafirlukast
- Lipid-regulating Drugs: clarithromycin increases plasma concentration of atorvastatin and pravastatin; possible increased risk of myopathy when erythromycin given with atorvastatin; erythromycin increases plasma concentration of pravastatin; erythromycin reduces plasma concentration of rosuvastatin; increased risk of myopathy when clarithromycin or erythromycin given with pravastatin (avoid concomitant use
- Parasympathomimetics: erythromycin increases plasma concentration of galantamine
- Pentamidine isetionate: increased risk of ventricular arrhythmias when parenteral erythromycin given with pentamidine isetionate
- Ranolazine: clarithromycin possibly increases plasma concentration of ranolazine. Manufacturerm of ranolazine advises avoid concomitant use
- Sildenafil: clarithromycin increases plasma concentration of sildenafil—reduce dose of sildenafil
- Sirolimus: clarithromycin increases plasma concentration of sirolimus—avoid concomitant use
- Tadalafil: increase plasma concentration of tadalafil
- Tadalafil: clarithromycin and erythromycin increase plasma concentration of tacrolimus
- Tadalafil: clarithromycin and erythromycin possibly increase plasma concentration of tadalafil
- Theophylline: azithromycin possibly increases plasma concentration of theophylline; clarithromycin inhibits metabolism of theophylline (increased plasma concentration); erythromycin inhibits metabolism of theophylline (increased plasma concentration), if erythromycin given by mouth, also decreased plasma-erythromycin concentration
- Ulcer-healing Drugs: plasma concentration of erythromycin increased by cimetidine (increased risk of toxicity, including deafness); plasma concentration of both drugs increased when clarithromycin given with omeprazole
- Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
- Vardenafil: erythromycin increases plasma concentration of vardenafil (reduce dose of vardenafil)

Magnesium (parenteral)
- Calcium-channel Blockers: profound hypotension reported with concomitant use of parenteral magnesium and nifedipine in pre-eclampsia
- Muscle Relaxants: parenteral magnesium enhances effects of non-depolarising muscle relaxants and suxamethonium

Magnesium Salts (oral) see Antacids

Mannitol
- Ciclosporin: possible increased risk of nephrotoxicity when mannitol given with ciclosporin

MAOIs
- Note For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor
- ACE Inhibitors: MAOIs possibly enhance hypnotic effect of ACE inhibitors
- Adrenergic Neurone Blockers: enhanced hypnotic effect when MAOIs given with adrenergic neurone blockers
- Alcohol: MAOIs interact with tyramine found in some beverages containing alcohol and some dealcoholised beverages (hypertensive crisis)—if no tyramine, enhanced hypnotic effect
- Alpha-2-Adrenoceptor Stimulants: avoidance of MAOIs advised by manufacturer of apraclonidine and brimonidine
- Alpha-blockers: avoidance of MAOIs advised by manufacturer of; enhanced hypnotic effect when MAOIs are given with alpha-blockers
- Analgesics: CNS excitation or depression (hypertension or hypotension) when MAOIs given with
- clonidine—avoid concomitant use and for 2 weeks after stopping MAOIs; possible increased sedation effects and increased risk of convulsions when MAOIs given with tranylcypromine; some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs; avoidance of MAOIs advised by manufacturer of nefazodone; possible CNS excitation or depression (hypertension or hypotension) when MAOIs given with—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs
- Angiotensin-II Receptor Antagonists: MAOIs possibly enhance hypnotic effect of angiotensin-II receptor antagonists
- Antidepressants: increased risk of hypertension and CNS excitation when MAOIs given with
- Reboxetine (MAOIs should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs); after stopping MAOIs do not start;
- Sertraline; after stopping MAOIs do not start
- Venlafaxine—increased risk of hypertension and CNS excitation when MAOIs given with
- Serotonin reuptake inhibitors (SSRIs (risk of serotonin toxicity); after stopping MAOIs do not start
- Venlafaxine; after stopping MAOIs do not start
- Duloxetine for 2 weeks, also MAOIs should not be started until at least 5 days after stopping duloxetine; enhanced CNS effects and toxicity when MAOIs given with venlafaxine (venlafaxine should not be started until at least 2 weeks after stopping venlafaxine), increased risk of hypertension and CNS excitation when MAOIs given with other MAOIs (avoid for at least 2 weeks after stopping previous MAOIs and then start at a reduced dose), after stopping MAOIs do not start
- Mirtazapine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping mirtazapine; increased CNS effects of an SSRI (risk of serious toxicity); after stopping MAOIs do not start
- Nortriptyline for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping nortriptyline; after stopping MAOIs do not start
- Venlafaxine; after stopping MAOIs do not start
- Tricyclic-related antidepressants for 2 weeks, also MAOIs should not be started until at least 1–2 weeks after stopping tricyclic-related antidepressants; increased risk of hypertension and CNS excitation when MAOIs given with tetracyclines, tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine); CNS excitation and confusion when MAOIs given with tryptophan (reduce dose of tryptophan)
Appendix 1: Interactions

MAOIs (continued)

Antidiabetics: MAOIs possibly enhance hypoglycaemic effect of antidiabetics; MAOIs enhance hypoglycaemic effect of insulin, metformin and sulfonylurées.

- Antiepileptics: MAOIs possibly antagonise antiepileptic (convulsive threshold lowered); avoidance for 2 weeks after stopping MAOIs advised by manufacturer of carbamazepine, also antagonism of anticonvulsant effect.

Antihistamines: increased anantimuraria and sedative effects when MAOIs given with antihistamines.

- Antimalarials: avoidance of antidepressants advised by manufacturer of artemether/lumefantrine.

- Antimuscarinics: increased risk of antimuscarinic side-effects when MAOIs given with antimuscarinics.

- Antipsychotics: CNS effects of MAOIs possibly increased by clozapine.

Antidepressants and Antipsychotics: avoidance of MAOIs advised by manufacturer of buspirone; manufacturer of tranylcypromine advises buspirone for 10 days after stopping tranylcypromine.

- Atomoxetine: avoidance of antidepressants advised by manufacturer of atomoxetine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping atomoxetine; possible increase of convulsions when antidepressants given with atomoxetine.

Barbiturates: MAOIs possibly antagonise anticonvulsant effect of barbiturates (convulsive threshold lowered).

Beta-blockers: enhanced hypotensive effect when MAOIs given with beta-blockers.

- Bupropion: avoidance of bupropion for 2 weeks after stopping MAOIs advised by manufacturer of bupropion.

Calcium-channel Blockers: enhanced hypotensive effect when MAOIs given with calcium-channel blockers.

Clonidine: enhanced hypotensive effect when MAOIs given with clonidine.

Diazoxide: enhanced hypotensive effect when MAOIs given with diazoxide.

Diuretics: enhanced hypotensive effect when MAOIs given with diuretics.

- Dopaminergics: avoid concomitant use of non-selective MAOIs with entacapone; risk of hypertensive crisis when MAOIs given with levodopa, avoid levodopa for at least 2 weeks after stopping MAOIs; risk of hypertensive crisis when MAOIs given with rasagiline, avoid MAOs for at least 2 weeks after stopping rasagiline; enhanced hypotensive effect when MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of MAOIs with tolcapone.

Doxapram: MAOIs enhance effects of doxapram.

Histamine: avoidance of MAOIs advised by manufacturer of histamine.

- H1, Agonists: risk of CNS toxicity when MAOIs given with rizatRIPTAN or sumatriptan (avoid rizatRIPTAN or sumatriptan for 2 weeks after MAOIs); increased risk of CNS toxicity when MAOIs given with zolmitriptan.

- Methylxophip: avoidance of MAOs advised by manufacturer of methylxophip.

Moxonidine: enhanced hypotensive effect when MAOIs given with moxonidine.

Muscle Relaxants: phenelzine enhances effects of saxenethionum.

Nicardipine: enhanced hypotensive effect when MAOIs given with nicardipine.

Nitrates: enhanced hypotensive effect when MAOIs given with nitrates.

Pholcodine: avoidance of pholcodine for 2 weeks after stopping MAOIs advised by manufacturer of pholcodine.

- Sympathomimetis: risk of hypertensive crisis when MAOIs given with sympathomimetis; risk of hypertensive crisis when MAOIs given with methyphendidate, some manufacturers advise avoiding methyphendidate for at least 2 weeks after stopping MAOIs.

- Tetrabenazine: risk of CNS excitation and hypertension when MAOIs given with tetrabenazine.

- Vasodilators: Antihypertensives: enhanced hypotensive effect when MAOIs given with hydralazine, minoxidil or sodium nitroprusside.

MAOIs, reversible: see Moclobemide.

Maraviroc

- Antibacterials: plasma concentration of maraviroc possibly increased by clarithromycin and telithromycin (consider reducing dose of maraviroc).

- Anticonvulsants: plasma concentration of maraviroc possibly increased by rifampicin—consider increasing dose of maraviroc.

- Antidepressants: plasma concentration of maraviroc possibly reduced by St John’s wort—avoid concomitant use.

- Antifungals: plasma concentration of maraviroc increased by ketoconazole (consider reducing dose of maraviroc).

- Antivirals: plasma concentration of maraviroc increased by atazanavir, darunavir, indinavir, lopinavir and saquinavir (consider reducing dose of maraviroc); plasma concentration of maraviroc possibly increased by efavirenz—consider increasing dose of maraviroc; plasma concentration of maraviroc possibly reduced by etravirine; plasma concentration of maraviroc possibly increased by nefinavir (consider reducing dose of maraviroc); plasma concentration of maraviroc increased by ritonavir.

Mebendazole

- Ulcer-healing Drugs: metabolism of mebendazole possibly inhibited by cimetidine (increased plasma concentration).

Mefloquine

- Anti-arrhythmics: increased risk of ventricular arrhythmias when mefloquine given with amiodarone—avoid concomitant use.

- Antifungals: mefloquine antagonises anticonvulsant effect of antiepileptics.

- Antihistamines: increased risk of convulsions when mefloquine given with haloperidol—avoid concomitant use; increased risk of ventricular arrhythmias when mefloquine given with oxazolidinones—avoid concomitant use; increased risk of convulsions when mefloquine given with quinine (but should not prevent the use of intravenous quinine in severe cases).

- Antipsychotics: possible increased risk of ventricular arrhythmias when mefloquine given with haloperidol—avoid concomitant use; increased risk of ventricular arrhythmias when mefloquine given with thioridazine—avoid concomitant use.

- Atorvastatin: increased risk of ventricular arrhythmias when mefloquine given with atorvastatin.

- Beta-blockers: increased risk of bradycardia when mefloquine given with beta-blockers.

- Calcium-channel Blockers: possible increased risk of bradycardia when mefloquine given with calcium-channel blockers.

- Cardiac Glycosides: possible increased risk of bradycardia when mefloquine given with digoxin.
Mefloquine (continued)
Histamine: avoidance of antimalarials advised by manufacturer of histamine
● Ibravadin: increased risk of ventricular arrhythmias when mefloquine given with ibradavin
Vaccines: antimalarials inactivate oral typhoid vaccine—see p. 767
Megestrol see Progestogens
Melatonin see Anxiolytics and Hypnotics
Meloxicam see NSAIDs
Melphalan
Antibacterials: increased risk of melphalan toxicity when given with nalidixic acid
Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
● Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
● Ciclosporin: increased risk of nephrotoxicity when melphalan given with ciclosporin
Memantine
● Anaesthetics, General: increased risk of CNS toxicity when memantine given with ketamine (manufacturer of memantine advises avoid concomitant use)● Analgesics: increased risk of CNS toxicity when memantine given with dexromethorphan (manufacturer of memantine advises avoid concomitant use)Anticoagulants: memantine possibly enhances anti-coagulant effect of warfarin
Antiepileptics: memantine possibly reduces effects of primidone
Antimuscarinics: memantine possibly enhances effects of antimuscarinics
Antipyschotics: memantine possibly reduces effects of antipsychotics
Barbiturates: memantine possibly reduces effects of barbiturates
● Dopaminergics: memantine possibly enhances effects of dopaminergics and selegiline; increased risk of CNS toxicity when memantine given with amantadine (manufacturer of memantine advises avoid concomitant use)Muscle Relaxants: memantine possibly modifies effects of baclofen and dantrolene
Mepacrine
Antimalarials: mepacrine increases plasma concentration of primaquine (increased risk of toxicity)Meprobamate see Anxiolytics and Hypnotics
Mepatolazone see Opioid Analgesics
Mercaptopurine
● Allopurinol: increased risk of leucopenia when mercaptopurine given with aminosalicylates; possible increased risk of leukopenia when mercaptopurine given with aminosalicylates
● Anti-infectives: increased risk of haematological toxicity when mercaptopurine given with trimethoprim (also with co-trimoxazole)Aminosalicylates: possible increased risk of leucopenia when mercaptopurine given with aminosalicylates
● Anti-infectives: increased risk of haematological toxicity when mercaptopurine given with trimethoprim (also with co-trimoxazole)Aminosalicylates: possible increased risk of leucopenia when mercaptopurine given with aminosalicylates
● Anticoagulants: mercaptopurine possibly reduces anticoagulant effect of coumarins
Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
● Fexofenadine: avoidance of mercaptopurine advised by manufacturer of fexofenadine
Meropenem
● Antiepileptics: carbapenems reduce plasma concentration of valproate—avoid concomitant use
Meropenem (continued)
Probencid: excretion of meropenem reduced by probenecid
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
Mesalazine see Aminosalicylates
Mestranol see Oestrogens
Metaraminol see Sympathomimetics
Metformin see Antidiabetics
Methadone see Opioid Analgesics
Methenamine
Antacids: avoid concomitant use of methenamine with antacids
● Antibacterials: increased risk of crystalluria when methenamine given with sulfonamides
● Diuretics: effects of methenamine antagonised by acetazolamide
Potassium Salts: avoid concomitant use of methenamine with potassium citrate
Sodium Citrate: avoid concomitant use of methenamine with sodium citrate
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
Methocarbamol see Muscle Relaxants
Methotrexate
● Anaesthetics, General: antifolate effect of methotrexate increased by nitrous oxide—avoid concomitant use
● Analgesics: excretion of methotrexate probably reduced by NSAIDs (increased risk of toxicity)—but for concomitant use in rheumatic disease see p. 647; excretion of methotrexate reduced by aspirin, diclofenac, ibuprofen, endometacin, ketoprofen, meloxicam and enaproxen (increased risk of toxicity)—but for concomitant use in rheumatic disease see p. 647
● Antibacterials: absorption of methotrexate possibly reduced by neomycin; excretion of methotrexate possibly reduced by ciprofloxacin (increased risk of toxicity); increased risk of haematological toxicity when methotrexate given with sulfamethoxazole (as co-trimoxazole); increased risk of methotrexate toxicity when given with doxycycline, sulfonamides or tetracycline; excretion of methotrexate reduced by penicillins (increased risk of toxicity); increased risk of haematological toxicity when methotrexate given with trimethoprim (also with co-trimoxazole)Antipyschotics: antifolate effect of methotrexate increased by phenytoin; cytotoxics possibly reduce absorption of phenytoin
● Antimalarials: antifolate effect of methotrexate increased by pyrimethamine
● Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
● Ciclosporin: risk of toxicity when methotrexate given with ciclosporin
● Cytotoxics: increased pulmonary toxicity when methotrexate given with cisplatin
Diuretics: excretion of methotrexate increased by alkaline urine due to acetazolamide
Leflunomide: risk of toxicity when methotrexate given with leflunomide
● Probencid: excretion of methotrexate reduced by probenecid (increased risk of toxicity)
● Retinoids: plasma concentration of methotrexate increased by acitretin (also increased risk of hepatotoxicity)—avoid concomitant useTherophyline: methotrexate possibly increases plasma concentration of theophylline
Ulcer-healing Drugs: excretion of methotrexate possibly reduced by omeprazole (increased risk of toxicity)
Methoxamine see Sympathomimetics
Appendix 1: Interactions
BNF 61
Methyldopa
ACE Inhibitors: enhanced hypotensive effect when methyldopa given with ACE inhibitors
Alpha-2 Adrenergic Neurone Blockers: enhanced hypotensive effect when methyldopa given with α2-adrenergic neurone blockers
Alcohol: enhanced hypotensive effect when methyldopa given with alcohol
Aldose 1-kinase: enhanced hypotensive effect when methyldopa given with aldose 1-kinase
Alpha-blockers: enhanced hypotensive effect when methyldopa given with alpha-blockers
Anaesthetics, General: enhanced hypotensive effect when methyldopa given with general anaesthetics
Analgesics: hypotensive effect of methyldopa antagonised by NSAIDs
Angiotensin II Receptor Antagonists: enhanced hypotensive effect when methyldopa given with angiotensin II receptor antagonists
Antidepressants: manufacturer of methyldopa advises avoid concomitant use with MAOIs
Antipsychotics: enhanced hypotensive effect when methyldopa given with antipsychotics (also increased risk of extrapyramidal effects)
Anti-inflammatory agents: enhanced hypotensive effect when methyldopa given with anti-inflammatory agents and hypnotics
Beta-blockers: enhanced hypotensive effect when methyldopa given with beta-blockers
Calcium-channel Blockers: enhanced hypotensive effect when methyldopa given with calcium-channel blockers
Clonidine: enhanced hypotensive effect when methyldopa given with clonidine
Corticosteroids: hypotensive effect of methyldopa antagonised by corticosteroids
Diazoxide: enhanced hypotensive effect when methyldopa given with diazoxide
Diuretics: enhanced hypotensive effect when methyldopa given with diuretics
Dopaminergics: methyldopa antagonises antiparkinsonian effect of dopaminergics; increased risk of extrapyramidal side-effects when methyldopa given with amantadine; effects of methyldopa possibly enhanced by entacapone; enhanced hypotensive effect when methyldopa given with levodopa; iron: hypotensive effect of methyldopa antagonised by oral iron
Lithium: neurotoxicity may occur when methyldopa given with lithium without increased plasma concentration of lithium
Moxisylyte: enhanced hypotensive effect when methyldopa given with moxisylyte
Moxonidine: enhanced hypotensive effect when methyldopa given with moxonidine
Muscle Relaxants: enhanced hypotensive effect when methyldopa given with baclofen or tizanidine
Nitrites: enhanced hypotensive effect when methyldopa given with nitrites
Oestrone: hypotensive effect of methyldopa antagonised by oestrone
Prostaglandins: enhanced hypotensive effect when methyldopa given with alprostadil
Sympathomimetics, β2: acute hypotension reported when methyldopa given with infusion of isobutylamine
Vasoconstrictor Antihypertensives: enhanced hypotensive effect when methyldopa given with hydralazine, minoxidil or sodium nitroprusside
Methylphenidate see Sympathomimetics
Methylprednisolone see Corticosteroids
Methysergide see Ergot Alkaloids
Metipranolol see Beta-blockers
Metoclopramide
Anaesthetics, General: metoclopramide enhances effects of thiopental
Analgesics: metoclopramide increases rate of absorption of aspirin (enhanced effect); effects of

"Appendix 1: Interactions"

Metoclopramide
Analgesics (continued)
metoclopramide on gastro-intestinal activity antagonised by opioid analgesics; metoclopramide increases rate of absorption of paracetamol
Antiinflammatory agents: effects of metoclopramide on gastro-intestinal activity antagonised by antiinflammatory agents
Antipsychotics: increased risk of extrapyramidal side-effects when metoclopramide given with antipsychotics
Atovaquone: metoclopramide reduces plasma concentration of atovaquone
Dopaminergic: metoclopramide increases plasma concentration of clozapine
Dopamine antagonists: metoclopramide antagonises hypoprolactinaemic effects of bromocriptine and cabergoline; metoclopramide antagonises antiparkinsonian effect of pergolide; avoidance of metoclopramide advised by manufacturer of ropinirole and rotigotine (antagonism of effect)
Muscle Relaxants: metoclopramide enhances effects of aminophylline
Tetrabenazine: increased risk of extrapyramidal side-effects when metoclopramide given with tetrabenazine

Methylxantheine see Diuretics
Metoprolol see Beta-blockers
Metronidazole
Note: Interactions do not apply to topical metronidazole preparations
Alcohol: disulfram-like reaction when metronidazole given with alcohol
Anticoagulants: metronidazole enhances anticoagulant effect of coumarins
Antiepileptics: metronidazole inhibits metabolism of phenytoin (increased plasma concentration); metabolism of metronidazole accelerated by primidone (reduced plasma concentration)
Barbiturates: metabolism of metronidazole accelerated by barbiturates (reduced plasma concentration)
Cytotoxics: metronidazole increases plasma concentration of etoposide (increased risk of toxicity); metronidazole inhibits metabolism of fluorouracil (increased toxicity)
Dissulfiram: psychic reaction reported when metronidazole given with disulfiram
Lithium: metronidazole increases risk of lithium toxicity
Mycophenolate: metronidazole possibly reduces bioavailability of mycophenolate
Ulcer-healing Drugs: metabolism of metronidazole inhibited by cimetidine (increased plasma concentration)
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
Mianserin see Antidepressants, Tricyclic (related)
Mifafostin Antifungals: mifafostin possibly increases plasma concentration of amphotericin; mifafostin increases plasma concentration of itraconazole (consider reducing dose of itraconazole)
Cytotoxic (related): mifafostin possibly increases plasma concentration of cyclosporin
Siroliumus: mifafostin increases plasma concentration of sirolimus
Miconazole see Antifungals, Imidazole
Midazolam see Anxietytics and Hypnotics
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazole
Mifepristone see Antifungals, Imidazo
**BNF 61**

**Appendix 1: Interactions**

---

**Mifamurtide (continued)**

Tacrolimus: manufacturer of mifamurtide advises avoid concomitant use with tacrolimus

**Mifepristone**

Corticosteroids: mifepristone may reduce effect of corticosteroids (including inhaled corticosteroids) for 3–4 days

**Mirtazapine**

- Alcohol: increased sedative effect when mirtazapine given with alcohol
- Analgesics: increased serotonergic effects when mirtazapine given with tramadol
- Anticoagulants: decreased anticoagulant effect of warfarin
- Antidepressants: possible increased serotonergic effects when mirtazapine given with fluoxetine, fluvoxamine or venlafaxine; mirtazapine should not be started until at least 2 weeks after stopping MAOIs; also MAOIs should not be started until at least 2 weeks after stopping mirtazapine; after stopping mirtazapine do not start mirtazapine for at least 1 week
- Antiepileptics: plasma concentration of mirtazapine reduced by carbamazepine and phenytoin
- Antifungals: plasma concentration of mirtazapine increased by ketoconazole
- Antimalarials: avoidance of antidepressants advised by manufacturer of arteether/lumefantrine
- Anxiolytics and Hypnotics: increased sedative effect when mirtazapine given with anxiolytics and hypnotics
- Atropine: possible increased risk of convulsions when antidepressants given with atomoxetine
- Ulcer-healing Drugs: plasma concentration of mirtazapine increased by cimetidine

**Mitomycin**

- Antiepileptics: cytotoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Anticoagulants: mitotane possibly reduces anticoagulant effect of warfarin
- Antidepressants: cytotoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets
- Diazoxide: increased risk of CNS toxicity when mirtazapine given with clozapine (increased risk of agranulocytosis)
- Carbamazepine: increased risk of CNS toxicity when mirtazapine given with carbamazepine and phenytoin
- Atropine: possible increased risk of convulsions when antidepressants given with atomoxetine
- Mifepristone: mifepristone may reduce effect of mirtazapine
- Selegiline: possible increased risk of convulsions when antidepressants given with atomoxetine
- Modafinil: modafinil possibly increases plasma concentration of phenoxybenzamine
- Diazoxide: enhanced hypotensive effect when moxisylyte given with moxisylyte given with diazoxide
- Calcium-channel Blockers: enhanced hypotensive effect when moxisylyte given with calcium-channel blockers
- Clonidine: enhanced hypotensive effect when moxisylyte given with clonidine
- Diazoxide: enhanced hypotensive effect when moxisylyte given with diazoxide
- Diuretics: enhanced hypotensive effect when moxisylyte given with diuretics
- Methyldopa: enhanced hypotensive effect when moxisylyte given with methyldopa
- Moxonidine: enhanced hypotensive effect when moxisylyte given with moxonidine
- Nitrites: enhanced hypotensive effect when moxisylyte given with nitrites

---

**Moxisylyte**

- ACE Inhibitors: enhanced hypotensive effect when moxisylyte given with ACE inhibitors
- Adrenergic Neurone Blockers: enhanced hypotensive effect when moxisylyte given with adrenergic neurone blockers
- Alpha-blockers: possible severe postural hypotension when moxisylyte given with alpha-blockers
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when moxisylyte given with angiotensin-II receptor antagonists
- Beta-blockers: possible severe postural hypotension when moxisylyte given with beta-blockers
- Calcium-channel Blockers: enhanced hypotensive effect when moxisylyte given with calcium-channel blockers
- Clonidine: enhanced hypotensive effect when moxisylyte given with clonidine
- Diazoxide: enhanced hypotensive effect when moxisylyte given with diazoxide
- Diuretics: enhanced hypotensive effect when moxisylyte given with diuretics
- Methyldopa: enhanced hypotensive effect when moxisylyte given with methyldopa
- Moxonidine: enhanced hypotensive effect when moxisylyte given with moxonidine
- Nitrites: enhanced hypotensive effect when moxisylyte given with nitrites

---

**Moclobemide**

- Antidepressants (continued)
  - related antidepressants, citalopram, fluvoxamine, mirtazapine, paroxetine, sertraline, tricyclic-related antidepressants or tricyclics: increased risk of CNS toxicity when moclobemide given with citalopram, preferably avoid concomitant use; moclobemide should not be started until 5 weeks after stopping fluoxetine; possible increased serotonergic effects when moclobemide given with duloxetine
  - Antimalarials: avoidance of antidepressants advised by manufacturer of arteether/lumefantrine
  - Antiepileptics: possibly reduce absorption
  - Dopaminergics: caution with moclobemide advised by manufacturer of entacapone; increased risk of side-effects when moclobemide given with levodopa; avoid concomitant use of moclobemide with selegiline
  - 5HT, Agonists: risk of CNS toxicity when moclobemide given with eritritapran or sumatriptan (avoid ritritapran or sumatriptan for 2 weeks after moclobemide); risk of CNS toxicity when moclobemide given with zolmitrpan (reduce dose of zolmitrpan)
  - Sympathomimetics: risk of hypertensive crisis when moclobemide given with sympathominetics
  - Ulcer-healing Drugs: plasma concentration of moclobemide increased by cimetidine (halve dose of moclobemide)

---

**Methyldopa**

- ACE Inhibitors: enhanced hypotensive effect when moxisylyte given with ACE inhibitors
- Adrenergic Neurone Blockers: enhanced hypotensive effect when moxisylyte given with adrenergic neurone blockers
- Alpha-blockers: possible severe postural hypotension when moxisylyte given with alpha-blockers
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when moxisylyte given with angiotensin-II receptor antagonists
- Beta-blockers: possible severe postural hypotension when moxisylyte given with beta-blockers
- Calcium-channel Blockers: enhanced hypotensive effect when moxisylyte given with calcium-channel blockers
- Clonidine: enhanced hypotensive effect when moxisylyte given with clonidine
- Diazoxide: enhanced hypotensive effect when moxisylyte given with diazoxide
- Diuretics: enhanced hypotensive effect when moxisylyte given with diuretics
- Methyldopa: enhanced hypotensive effect when moxisylyte given with methyldopa
- Moxonidine: enhanced hypotensive effect when moxisylyte given with moxonidine
- Nitrites: enhanced hypotensive effect when moxisylyte given with nitrites
Appendix 1: Interactions

**Moxisylyte (continued)**

Vasodilator Antihypertensives; enhanced hypotensive effect when moxisylyte given with hydralazine, minoxidil, or sodium nitroprusside

**Moxonidine**

ACE Inhibitors: enhanced hypotensive effect when moxonidine given with ACE inhibitors

Adrenergic Neurome Blockers: enhanced hypotensive effect when moxonidine given with adrenergic neuromne blockers

Alcohol: enhanced hypotensive effect when moxonidine given with alcohol

Aldesleukin: enhanced hypotensive effect when moxonidine given with aldesleukin

Alpha-blockers: enhanced hypotensive effect when moxonidine given with alpha-blockers

Anesthetics, General: enhanced hypotensive effect when moxonidine given with general anaesthetics

Analgesics: hypotensive effect of moxonidine antagonised by NSAIDs

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when moxonidine given with angiotensin-II receptor antagonists

Antidepressants: enhanced hypotensive effect when moxonidine given with MAOIs; hypotensive effect of moxonidine possibly antagonised by tricyclics (manufacturer of moxonidine advises avoid concomitant use)

Anxiolytics and Hypnotics: enhanced hypotensive effect when moxonidine given with phenothiazines

Anxiolytics and Hypnotics: enhanced hypotensive effect when moxonidine given with anxiolytics and hypnotics; sedative effects possibly increased when moxonidine given with benzodiazepines

Beta-blockers: enhanced hypotensive effect when moxonidine given with beta-blockers

Calcium-channel Blockers: enhanced hypotensive effect when moxonidine given with calcium-channel blockers

Clonidine: enhanced hypotensive effect when moxonidine given with clonidine

Corticosteroids: hypotensive effect of moxonidine antagonised by corticosteroids

Diazoxide: enhanced hypotensive effect when moxonidine given with diazoxide

Diuretics: enhanced hypotensive effect when moxonidine given with diuretics

Dopaminergics: enhanced hypotensive effect when moxonidine given with levodopa

Methylodopa: enhanced hypotensive effect when moxonidine given with methylodopa

Moxisylyte: enhanced hypotensive effect when moxonidine given with moxisylyte

Muscle Relaxants: enhanced hypotensive effect when moxonidine given with muscle relaxants

Nitrates: enhanced hypotensive effect when moxonidine given with nitrates

Oestrogens: hypotensive effect of moxonidine antagonised by oestrogens

Prostaglandins: enhanced hypotensive effect when moxonidine given with prostaglandins

Cardiac Glycosides: possible increased risk of bradycardia when tizanidine given with cardiac glycosides; risk of ventricular arrhythmias when suxamethonium given with cardiac glycosides

Clonidine: enhanced hypotensive effect when baclofen or tizanidine given with clonidine

Corticosteroids: effects of pancuronium and vecuronium possibly antagonised by corticosteroids

Cytotoxics: effects of suxamethonium enhanced by cyclophosphamide and thiopeta

Diazoxide: enhanced hypotensive effect when baclofen or tizanidine given with diazoxide

Diuretics: enhanced hypotensive effect when baclofen or tizanidine given with diuretics

Dopaminergics: possible agitation, confusion and hallucinations when baclofen given with levodopa

**Muscle Relaxants**

- Anaesthetics, General (continued)
  - muscle relaxants and suxamethonium enhanced by volatile liquid general anaesthetics
  - Analgesics: excretion of baclofen possibly reduced by NSAIDs (increased risk of toxicity); excretion of baclofen reduced by ibuprofen (increased risk of toxicity); increased sedative effect when baclofen given with fentanyl or morphine
  - Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when baclofen or tizanidine given with angiotensin-II receptor antagonists
  - Anti-arrhythmics: neuromuscular blockade enhanced and prolonged when suxamethonium given with lidocaine
  - Antibacterials: effects of non-depolarising muscle relaxants and suxamethonium enhanced by piperacillin; plasma concentration of tizanidine increased by ciprofloxacin (increased risk of toxicity)—avoid concomitant use; plasma concentration of tizanidine possibly increased by norfloxacin (increased risk of toxicity); effects of non-depolarising muscle relaxants and suxamethonium enhanced by aminglucosides; effects of non-depolarising muscle relaxants and suxamethonium enhanced by clindamycin; effects of non-depolarising muscle relaxants and suxamethonium enhanced by polymyxins; effects of suxamethonium enhanced by vancomycin
  - Antidepressants: plasma concentration of tizanidine increased by fluvoxamine (increased risk of toxicity)—avoid concomitant use; effects of suxamethonium enhanced by phentolamine; muscle relaxant effect of baclofen enhanced by tricyclics
  - Antiepileptics: muscle relaxant effect of non-depolarising muscle relaxants antagonised by carbamazepine and phentoin (accelerated recovery from neuromuscular blockade)
  - Antimalarials: effects of suxamethonium possibly enhanced by quinine
  - Antipsychotics: effects of suxamethonium possibly enhanced by promazine
  - Anxiolytics and Hypnotics: enhanced hypotensive effect when baclofen or tizanidine given with anxiolytics and hypnotics

Beta-blockers: enhanced hypotensive effect when baclofen given with beta-blockers; possible enhanced hypotensive effect and bradycardia when tizanidine given with beta-blockers; effects of muscle relaxants enhanced by propranolol

Calcium-channel Blockers: enhanced hypotensive effect when baclofen or tizanidine given with calcium-channel blockers

Clonidine: enhanced hypotensive effect when baclofen or tizanidine given with clonidine

Corticosteroids: effects of non-depolarising muscle relaxants possibly enhanced by calcium-channel blockers; possible increased risk of ventricular arrhythmias when intravenous dantrolene given with diltiazem—manufacturer of diltiazem advises avoid concomitant use; effects of non-depolarising muscle relaxants and suxamethonium enhanced by verapamil; hypotension, myocardial depression, and hyperkalaemia when intravenous dantrolene given with verapamil

Cardiac Glycosides: possible increased risk of bradycardia when tizanidine given with cardiac glycosides; risk of ventricular arrhythmias when suxamethonium given with cardiac glycosides

Clonidine: enhanced hypotensive effect when baclofen or tizanidine given with clonidine

Corticosteroids: effects of pancuronium and vecuronium possibly antagonised by corticosteroids

Cytotoxics: effects of suxamethonium enhanced by cyclophosphamide and thiopeta

Diazoxide: enhanced hypotensive effect when baclofen or tizanidine given with diazoxide

Diuretics: enhanced hypotensive effect when baclofen or tizanidine given with diuretics

Dopaminergics: possible agitation, confusion and hallucinations when baclofen given with levodopa

Muscle Relaxants: enhanced hypotensive effect when baclofen or tizanidine given with muscle relaxants; effects of non-depolarising muscle relaxants enhanced by muscle relaxants possibly enhanced by calcium-channel blockers; possible increased risk of ventricular arrhythmias when intravenous dantrolene given with diltiazem—manufacturer of diltiazem advises avoid concomitant use; effects of non-depolarising muscle relaxants and suxamethonium enhanced by verapamil; hypotension, myocardial depression, and hyperkalaemia when intravenous dantrolene given with verapamil

Cardiac Glycosides: possible increased risk of bradycardia when tizanidine given with cardiac glycosides; risk of ventricular arrhythmias when suxamethonium given with cardiac glycosides

Clonidine: enhanced hypotensive effect when baclofen or tizanidine given with clonidine

Corticosteroids: effects of pancuronium and vecuronium possibly antagonised by corticosteroids

Cytotoxics: effects of suxamethonium enhanced by cyclophosphamide and thiopeta

Diazoxide: enhanced hypotensive effect when baclofen or tizanidine given with diazoxide

Diuretics: enhanced hypotensive effect when baclofen or tizanidine given with diuretics

Dopaminergics: possible agitation, confusion and hallucinations when baclofen given with levodopa
Muscle Relaxants (continued)
Lithium: effects of muscle relaxants enhanced by lithium; baclofen possibly aggravates hyperkinesia caused by lithium
Magnesium (parenteral): effects of non-depolarising muscle relaxants and suxamethonium enhanced by parenteral magnesium
Mefitoxoamine: effects of baclofen and dantrolene possibly modified by mefenoxamine
Methyldopa: enhanced hypotensive effect when baclofen or tizanidine given with methyldopa
Metoclopramide: effects of suxamethonium enhanced by metoclopramide
Moxonidine: enhanced hypotensive effect when baclofen or tizanidine given with moxonidine
Natrium: enhanced hypotensive effect when baclofen or tizanidine given with natrium
Oestrogens: plasma concentration of tizanidine possibly increased by oestrogens (increased risk of toxicity)
Parasymptomimetics: effects of non-depolarising muscle relaxants possibly antagonised by donepezil; effects of suxamethonium possibly enhanced by donepezil; effects of non-depolarising muscle relaxants antagonised by edrophonium, neostigmine, pyridostigmine and rivastigmine; effects of suxamethonium enhanced by edrophonium, galantamine, neostigmine, pyridostigmine and rivastigmine
Progestogens: plasma concentration of tizanidine possibly increased by progestogens (increased risk of toxicity)
Sympathomimetics, Beta; effects of suxamethonium enhanced by bamberuter
Vasodilator Antihypertensives: enhanced hypotensive effect when baclofen or tizanidine given with hydralazine; enhanced hypotensive effect when baclofen or tizanidine given with minoxidil; enhanced hypotensive effect when baclofen or tizanidine given with sodium nitroprusside
Muscle Relaxants, depolarising see Muscle Relaxants
Muscle Relaxants, non-depolarising see Muscle Relaxants
Mycophenolate
Antacids: absorption of mycophenolate reduced by antacids
Antibacterials: bioavailability of mycophenolate possibly reduced by metronidazole and norfloxacin; plasma concentration of active metabolite of mycophenolate possibly reduced by rifampicin
Antivirals: mycophenolate increases plasma concentration of aciclovir, also plasma concentration of inactive metabolite of mycophenolate increased; mycophenolate possibly increases plasma concentration of ganciclovir, also plasma concentration of active metabolite of mycophenolate possibly increased
Iron: absorption of mycophenolate reduced by oral iron
Lipid-regulating Drugs: absorption of mycophenolate reduced by colesteotamine
Sevelamer: plasma concentration of mycophenolate possibly reduced by sevelamer
Mycophenolate Mofetil see Mycophenolate
Mycophenolate Sodium see Mycophenolate
Mycophenolic Acid see Mycophenolate
Nabionole Alcohol: increased sedative effect when nabionole given with alcohol
Anxiolytics and Hypnotics: increased sedative effect when nabionole given with anxiolytics and hypnotics
Nabumetone see NSAIDs
Nadolol see Beta-blockers
Nalidixic Acid see Quinolones
Nandrolone see Anabolic Steroids
Naproxen see NSAIDs
Naratiplan see SHT, Agonists
Nateglinide see Antidiabetics
Nebivolol see Beta-blockers
Nefopan
Antidepressants: manufacturer of nefopam advises avoid concomitant use with MAOIs; side-effects possibly increased when nefopam given with tricyclics
Antimuscarincs: increased risk of antimuscarinic side-effects when nefopam given with antimuscarincs
Nelfinavir
Analgesics: nelfinavir reduces plasma concentration of methadone
Anti-arrhythmics: increased risk of ventricular arrhythmias when nelfinavir given with amiodarone—avoid concomitant use
Antibacterials: nelfinavir increases plasma concentration of rifabutin (halve dose of rifabutin); plasma concentration of nelfinavir significantly reduced by ertapenem—avoid concomitant use; avoidance of concomitant nelfinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin
Anticoagulants: avoidance of nelfinavir advised by manufacturer of rivaroxaban
Antidepressants: plasma concentration of nelfinavir reduced by St John’s wort—avoid concomitant use
Antiepileptics: plasma concentration of nelfinavir possibly reduced by carbamazepine and primidone; nelfinavir reduces plasma concentration of phenytoin
Antimalarials: caution with nelfinavir advised by manufacturer of arteether/lumefantrine; nelfinavir possibly increases plasma concentration of quinine (increased risk of toxicity)
Antimuscarincs: avoidance of nelfinavir advised by manufacturer of darifenac and tolterodine; manufacturer of fesoterodine advises dose reduction when nelfinavir given with fesoterodine—consult fesoterodine product literature; nelfinavir increases plasma concentration of solifenacin
Antipsychotics: nelfinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole); nelfinavir possibly increases plasma concentration of ephedrine (increased risk of ventricular arrhythmias—avoid concomitant use)
Antivirals: plasma concentration of nelfinavir possibly increased by stravatine—avoid concomitant use; combination of nelfinavir with indinavir or ritonavir may increase plasma concentration of either drug (or both); nelfinavir reduces plasma concentration of lopinavir; also plasma concentration of active metabolite of nelfinavir increased; nelfinavir possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc); nelfinavir increases plasma concentration of everolimus—manufacturer of saquinavir advises avoid concomitant use
Anxiolytics and Hypnotics: nelfinavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of oral midazolam)
Barbiturates: plasma concentration of nefopam possibly reduced by barbiturates
Ciclosporin: nelfinavir possibly increases plasma concentration of ciclosporin
Corticosteroids: nelfinavir possibly increases plasma concentration of inhaled and intranasal fluticasone
Cytoxotics: nelfinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use; avoidance of nelfinavir advised by manufacturer of pazopanib; nelfinavir increases plasma concentration of paclitaxel
Diuretics: nelfinavir increases plasma concentration of spironolactone—avoid concomitant use
Ergot Alkaloids: increased risk of ergotism when nelfinavir given with ergotamine and methylergometrine—avoid concomitant use
Appendix 1: Interactions
Nelfinavir (continued)
- SHT, Agonists: nelfinavir increases plasma concentration of etrindipine (risk of toxicity)—avoid concomitant use
- Ibradibine: nelfinavir possibly increases plasma concentration of aibradibine—avoid concomitant use
- Lipid-regulating Drugs: possible increased risk of myopathy when nelfinavir given with atorvastatin; possible increased risk of myopathy when nelfinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when nelfinavir given with simvastatin (avoid concomitant use)
- Oestrogens: nelfinavir accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495)
- Progestogens: nelfinavir possibly reduces contraceptive effect of progestogens
- Ranolazine: nelfinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use
- Sildenafil: nelfinavir possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil
- Tacrolimus: nelfinavir possibly increases plasma concentration of tacrolimus
- Ulcer-healing Drugs: plasma concentration of nelfinavir reduced by omeprazole—avoid concomitant use
- Neomycin see Aminoglycosides
- Neostigmine see Parasympathomimetics
Nevirapine
- Analgesics: nevirapine possibly reduces plasma concentration of methadone
- Antibacterials: nevirapine reduces plasma concentration of clarithromycin (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased; nevirapine possibly increases plasma concentration of rifabutin; plasma concentration of nevirapine reduced by rifampicin—avoid concomitant use
- Anticoagulants: nevirapine may enhance or reduce anticoagulant effect of warfarin
- Antidepressants: plasma concentration of nevirapine reduced by St John's wort—avoid concomitant use
- Antiepileptics: plasma concentration of nevirapine reduced by carbamazepine
- Antifungals: nevirapine reduces plasma concentration of ketoconazole—avoid concomitant use; plasma concentration of nevirapine increased by fluconazole; nevirapine possibly reduces plasma concentration of caspofungin and itraconazole—consider increasing dose of caspofungin and itraconazole
- Antipsychotics: nevirapine possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole
- Antivirals: nevirapine possibly reduces plasma concentration of stavudine and efavirenz—avoid concomitant use; nevirapine reduces plasma concentration of efavirenz and indinavir; nevirapine possibly plasma concentration of fosamprenavir; nevirapine possibly reduces plasma concentration of lopinavir—consider increasing dose of lopinavir
- Oestrogens: nevirapine accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495)
- Progestogens: nevirapine accelerates metabolism of progestogens (reduced contraceptive effect—see p. 495)
Nicolipid see Calcium-channel Blockers
Nicorandil
- Alcohol: hypotensive effect of nicorandil possibly enhanced by alcohol
- Antidepressants: enhanced hypotensive effect when nicorandil given with MAOIs; hypotensive effect of nicorandil possibly enhanced by tricyclics
BNF 61

Appendix 1: Interactions 861

Nitrates (continued)
Antipsychotics: enhanced hypotensive effect when nitrates given with phenothiazines

Antiemetics and Hypnotics; enhanced hypotensive effect when nitrates given with antiemetics and hypnotics

Beta-blockers: enhanced hypotensive effect when nitrates given with beta-blockers

Calcium-channel Blockers: enhanced hypotensive effect when nitrates given with calcium-channel blockers

Clonidine: enhanced hypotensive effect when nitrates given with clonidine

Corticosteroids: hypotensive effect of nitrates antagonised by corticosteroids

Diazoxide: enhanced hypotensive effect when nitrates given with diazoxide

Diuretics: enhanced hypotensive effect when nitrates given with diuretics

Dopaminergics: enhanced hypotensive effect when nitrates given with levodopa

Methyldopa: enhanced hypotensive effect when nitrates given with methyldopa

Moxisylyte: enhanced hypotensive effect when nitrates given with moxisylyte

Moxonidine: enhanced hypotensive effect when nitrates given with moxonidine

Muscle Relaxants: enhanced hypotensive effect when nitrates given with baclofen or tizanidine

Oestrogens: hypotensive effect of nitrates antagonised by oestrogens

Prostaglandins: enhanced hypotensive effect when nitrates given with alprostadil

Sildenafil: hypotensive effect of nitrates significantly enhanced by sildenafil (avoid concomitant use)

Tadalafil: hypotensive effect of nitrates significantly enhanced by tadalafil (avoid concomitant use)

Vardenafil: possible increased hypotensive effect when nitrates given with vardenafil—avoid concomitant use

Vasodilator Antihypertensives: enhanced hypotensive effect when nitrates given with hydralazine, minoxidil or sodium nitroprusside

Nitrazepam see Antiemetics and Hypnotics

Nitrofurantoin
Antacids: absorption of nitrofurantoin reduced by oral magnesium salts (as magnesium trisilicate)

Antibacterials: nitrofurantoin possibly antagonises effects of nalidixic acid

Probenecid: excretion of nitrofurantoin reduced by probenecid (increased risk of side-effects)

Sulfinpyrazone: excretion of nitrofurantoin reduced by sulfinpyrazone (increased risk of toxicity)

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Nitroimidazoles see Metronidazole and Tinidazole

Nitrous Oxide see Anaesthetics, General

Nizatidine see Histamine H₂-antagonists

Noradrenaline (norepinephrine) see Sympathomimetics

Norelgestromin see Progestogens

Norepinephrine (noradrenaline) see Sympathomimetics

Nor ethisterone see Progestogens

Norfl oxacin see Quinolones

Nor gestimate see Progestogens

Nor gestrel see Progestogens

Nortriptyline see Antidepressants, Tricyclic

NSAIDs
Note See also Aspirin. Interactions do not generally apply to topical NSAIDs

ACE Inhibitors: increased risk of renal impairment when NSAIDs given with ACE inhibitors, also hypotensive effect antagonised

Adrenergic Neurone Blockers: NSAIDs antagonise hypotensive effect of adrenergic neurone blockers

Aliskiren: NSAIDs possibly antagonise hypotensive effect of aliskiren

NSAI Ds (continued)
Alpha-blockers: NSAIDs antagonise hypotensive effect of alpha-blockers

Analgesics: avoid concomitant use of NSAIDs with • NSAIDs or aspirin (increased side-effects); avoid concomitant use of NSAIDs with ketorolac (increased side-effects and haemorrhage); ibuprofen possibly reduces antiplatelet effect of aspirin

Angiotensin-II Receptor Antagonists: increased risk of renal impairment when NSAIDs given with angiotensin-II receptor antagonists, also hypotensive effect antagonised

Antibacterials: indomethacin possibly increases plasma concentration of amikacin and gentamicin in neonates; plasma concentration of cefuroxime, cilastin and etoricoxib reduced by rifampicin; possible increased risk of convulsions when NSAIDs given with quinolones

Anticoagulants: increased risk of haemorrhage when intravenous diclofenac given with anticoagulants (avoid concomitant use, including low-dose heparin); increased risk of haemorrhage when ketorolac given with anticoagulants (avoid concomitant use, including low-dose heparin); NSAIDs possibly enhance anticoagulant effect of • warfarin and • phenindione; possible increased risk of bleeding when NSAIDs given with dabigatran etexilate or heparin

Antidepressants: increased risk of bleeding when NSAIDs given with • SSRIs or • venlafaxine

Antidiabetics: NSAIDs possibly enhance effects of • sulfonylureas

Antifungals: plasma concentration of paxorobic increased by fluconazole (reduce dose of paxorobic); plasma concentration of cefuroxime increased by fluconazole (halve dose of cefuroxime); plasma concentration of diclofenac and ibuprofen increased by voriconazole

Antipsychotics: possible severe drowsiness when indomethacin given with haloperidol

Antivirals: plasma concentration of piroxicam increased by ritonavir (risk of toxicity)—avoid concomitant use; plasma concentration of NSAI Ds possibly increased by ritonavir; increased risk of haematological toxicity when NSAIDs given with zidovudine

Beta-blockers: NSAIDs antagonise hypotensive effect of beta-blockers

Bisphosphonates: indomethacin increases bioavailability of • tiludronic acid

Calcium-channel Blockers: NSAIDs antagonise hypotensive effect of calcium-channel blockers

Cardiac Glycosides: NSAIDs possibly increase plasma concentration of cardiac glycosides, also possible exacerbation of heart failure and reduction of renal function

Ciclosporin: increased risk of nephrotoxicity when NSAIDs given with • ciclosporin; plasma concentration of diclofenac increased by • ciclosporin (halve dose of diclofenac)

Clonidine: NSAIDs antagonise hypotensive effect of clonidine

Clopidogrel: increased risk of bleeding when NSAIDs given with clopidogrel

Corticosteroids: increased risk of gastro-intestinal bleeding and ulceration when NSAIDs given with corticosteroids

Cytotoxics: NSAIDs probably reduce excretion of • methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see p. 647; diclofenac, ibuprofen, indomethacin, ketoprofen, meloxicam and naproxen reduce excretion of • methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see p. 647; increased risk of bleeding when NSAIDs given with • erlotinib

Desmopressin: indomethacin enhances effects of desmopressin
NSAIDs (continued)

Diazoxide: NSAIDs antagonise hypotensive effect of diazoxide

- Dimethyl sulfoxide: avoid concomitant use of sulindac with dimethyl sulfoxide

- Diuretics: risk of nephrotoxicity of NSAIDs increased by diuretics, also antagonism of diuretic effect; indometacin and ketorolac antagonise effects of diuretics; NSAIDs possibly antagonise diuretic effect of potassium canrenoate; occasional reports of reduced renal function when indometacin given with triamterene—avoid concomitant use; possible increased risk of hyperkalaemia when NSAIDs given with potassium-sparing diuretics and aldosterone antagonists; increased risk of hyperkalaemia when indometacin given with potassium-sparing diuretics and aldosterone antagonists

Iloprost: increased risk of bleeding when NSAIDs given with iloprost

Lipid-regulating Drugs: excretion of meloxicam increased by colestyramine

- Lithium: NSAIDs reduce excretion of lithium (increased risk of toxicity); ketorolac reduces excretion of lithium (increased risk of toxicity)—avoid concomitant use

Methyldopa: NSAIDs antagonise hypotensive effect of methyldopa

Mifamurtide: avoidance of high doses of NSAIDs advised by manufacturer of mifamurtide

Moxonidine: NSAIDs antagonise hypotensive effect of moxonidine

Muscle Relaxants: ibuprofen reduces excretion of baclofen (increased risk of toxicity); NSAIDs possibly reduce excretion of baclofen (increased risk of toxicity)

Nitrates: NSAIDs antagonise hypotensive effect of nitrates

Oestrogens: etoricoxib increases plasma concentration of ethinylestradiol

Penicillamine: possible increased risk of nephrotoxicity when NSAIDs given with penicillamine

- Pentoxyfilline: possible increased risk of bleeding when NSAIDs given with pentoxyfilline; increased risk of bleeding when ketorolac given with pentoxyfilline (avoid concomitant use)

Prasugrel: possible increased risk of bleeding when NSAIDs given with prasugrel

Probenecid: excretion of desketoprofen, indometacin, ketoprofen and naproxen reduced by probenecid (increased plasma concentration); excretion of ketorolac reduced by probenecid (increased plasma concentration)—avoid concomitant use

- Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs given with tacrolimus; increased risk of nephrotoxicity when ibuprofen given with tacrolimus

- Vasodilator Antihypertensives: NSAIDs antagonise hypotensive effect of hydralazine, minoxidil and sodium nitroprusside

Octreotide

Antidiabetics: octreotide possibly reduces requirements for insulin, metformin, repaglinide and sulfonylureas

Ciclosporin: octreotide reduces plasma concentration of ciclosporin

- Dopaminergics: octreotide increases plasma concentration of bromocriptine

Ulcer-healing Drugs: octreotide possibly delays absorption of cimetidine

Oestrogens

- Note: Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings

ACE Inhibitors: oestrogens antagonise hypotensive effect of ACE inhibitors

Adrenergic Neurone Blockers: oestrogens antagonise hypotensive effect of adrenergic neurone blockers

Analgesics: plasma concentration of ethinylestradiol increased by etoricoxib

Angiotensin-II Receptor Antagonists: oestrogens antagonise hypotensive effect of angiotensin-II receptor antagonists

Antibacterials: metabolism of oestrogens accelerated by rifampicin (reduced contraceptive effect—see p. 495)

Anticoagulants: oestrogens may enhance or reduce anticoagulant effect of warfarin; oestrogens antagonise anticoagulant effect of aspirin

Antidepressants: contraceptive effect of oestrogens reduced by St John's wort (avoid concomitant use); oestrogens antagonise antidepressant effect of tricyclics (but side-effects of tricyclics possibly increased due to increased plasma concentration)

Antidiabetics: oestrogens antagonise hypoglycaemic effect of antidiabetics

- Antidepressants: metabolism of oestrogens accelerated by carbamazepine, eslicarbazepine, topiramate, phenytoin, primidone, rufinamide and topiramate (reduced contraceptive effect—see p. 495); oestrogens reduce plasma concentration of lamotrigine—consider increasing dose of lamotrigine; ethinylestradiol possibly reduces plasma concentration of valproate

Antifungals: oestrogens increase plasma concentration of voriconazole; anecdotal reports of contraceptive failure and menstrual irregularities when oestrogens given with griseofulvin; anecdotal reports of contraceptive failure when oestrogens given with niacin; occasional reports of breakthrough bleeding when oestrogens (used for contraception) given with terbinafine

Antivirals: plasma concentration of ethinylestradiol increased by atazanavir; contraceptive effect of oestrogens possibly reduced by efavirenz; metabolism of oestrogens accelerated by efavirenz, nevirapine and ritonavir (reduced contraceptive effect—see p. 495)

Aprotinin and Hynptics: oestrogens increase plasma concentration of melatonin

- Aprepitant: possible contraceptive failure of hormonal contraceptives containing oestrogens when given with aprepitant (alternative contraception recommended)

Barbiturates: metabolism of oestrogens accelerated by barbiturates (reduced contraceptive effect—see p. 495)

- Betaxolol (reduced contraceptive effect—see p. 495)

Beta-blockers: oestrogens antagonise hypotensive effect of beta-blockers

Bile Acids: elimination of cholesterol in bile increased when oestrogens given with bile acids

- Bosentan: possible contraceptive failure of hormonal contraceptives containing oestrogens when given with bosentan (alternative contraception recommended)

Calcium-channel Blockers: oestrogens antagonise hypotensive effect of calcium-channel blockers

Ciclosporin: oestrogens possibly increase plasma concentration of ciclosporin

Clonidine: oestrogens antagonise hypotensive effect of clonidine

- Corticosteroids: oral contraceptives containing oestrogens increase plasma concentration of corticosteroids

Diuretics: oestrogens antagonise diuretic effect of diuretics

Dopaminergics: oestrogens increase plasma concentration of ropinirole; oestrogens increase plasma concentration of selegiline—manufacturer of selegiline advises avoid concomitant use

Lipid-regulating Drugs: absorption of ethinylestradiol reduced by clofibrate; plasma concentration of...
BNF 61

Appendix 1: Interactions

### Oestrogens
- Lipid-regulating Drugs (continued): ethinylestradiol increased by atorvastatin and rosuvastatin.
- Methylxypupa: oestrogens antagonise hypotensive effect of methyldopa.
- Modafinil: metabolism of oestrogens accelerated by modafinil (reduced contraceptive effect—see p. 495).
- Moxonidine: oestrogens antagonise hypotensive effect of moxonidine.
- Muscle Relaxants: oestrogens possibly increase plasma concentration of tizanidine (increased risk of toxicity).
- Nitraties: oestrogens antagonise hypotensive effect of nitrate.
- Sitaxentan: plasma concentration of oestrogens increased by sitaxentan.
- Somatropin: oestrogens (when used as oral replacement therapy) may increase dose requirements of somatropin.
- Sugammadex: plasma concentration of oestrogens possibly reduced by sugammadex.
- Tacrolimus: ethinylestradiol possibly increases plasma concentration of tacrolimus.
- Theophylline: oestrogens reduce excretion of theophylline (increased plasma concentration).
- Thyroid Hormones: oestrogens may increase requirements for thyroid hormones in hypothyroidism.
- Vasodilator Antihypertensives: oestrogens antagonise hypotensive effect of hydralazine, minoxidil and sodium nitroprusside.

### Opioid Analgesics

- **Antidepressants** (continued): excitation or depression (hypertension or hypotension) when opioid analgesics given with nortriptyline—manufacturer of moclobemide advises consider reducing dose of opioid analgesics; possible CNS excitation or depression (hypertension or hypotension) when dextromethorphan or pethidine given with moclobemide—avoid concomitant use; increased risk of CNS toxicity when tramadol given with SSRIs or antidepressants; plasma concentration of methadone possibly reduced by St John’s wort; sedative effects possibly increased when opioid analgesics given with tricyclics.
- **Antiepileptics**: dextropropoxyphene enhances effects of carbamazepine; effect of tramadol reduced by carbamazepine; plasma concentration of methadone reduced by carbamazepine; morphine increases bioavailability of gabapentin; metabolism of methadone accelerated by phenytoin (reduced effect and risk of withdrawal effects); plasma concentration of methadone possibly reduced by primidone.
- **Antifungals**: metabolism of buprenorphine inhibited by ketoconazole (reduce dose of buprenorphine); metabolism of alfentanil inhibited by fluconazole (risk of prolonged or delayed respiratory depression); metabolism of alfentanil possibly inhibited by itraconazole; plasma concentration of alfentanil and methadone increased by voriconazole (consider reducing dose of alfentanil and methadone); plasma concentration of fentanyl possibly increased by triazoles.
- **Antihistamines**: sedative effects possibly increased when opioid analgesics given with sedating antihistamines.
- **Antipsychotics**: enhanced hypotensive and sedative effects when opioid analgesics given with antipsychotics; increased risk of ventricular arrhythmias when methadone given with antipsychotics that prolong the QT interval; increased risk of convulsions when tramadol given with antipsychotics; increased risk of ventricular arrhythmias when methadone given with amisulpride—avoid concomitant use.
- **Antivirals**: plasma concentration of methadone possibly reduced by abacavir and nevirapine; methadone possibly reduces plasma concentration of didanosine; plasma concentration of methadone reduced by efavirenz, fosamprenavir, nelfinavir and ritonavir; plasma concentration of dextropropoxyphene increased by ritonavir (risk of toxicity)—avoid concomitant use; plasma concentration of buprenorphine possibly increased by ritonavir; plasma concentration of alfentanil and fentanyl increased by ritonavir; plasma concentration of pethidine reduced by ritonavir, but plasma concentration of toxic pethidine metabolite increased (avoid concomitant use); plasma concentration of morphine possibly reduced by ritonavir; increased risk of ventricular arrhythmias when methadone given with saquinavir—avoid concomitant use; buprenorphine possibly reduces plasma concentration of tipranavir; methadone possibly increases plasma concentration of zidovudine.
- **Anxiolytics and Hypnotics**: increased sedative effect when opioid analgesics given with anxiolytics and hypnotics; fentanyl possibly inhibits metabolism of midazolam.
- **Atomoxetine**: increased risk of ventricular arrhythmias when methadone given with atomoxetine; possible increased risk of convulsions when tramadol given with atomoxetine.
- **Barbiturates**: CNS effects of opioid analgesics possibly increased by barbiturates; plasma concentration of methadone reduced by phenobarbital.

---

### Antidepressants

- Antidepressants
- Antivirals:
  - Ondansetron
  - Omeprazole
  - Olmesartan
  - Olanzapine
  - Ofloxacin
  - Olmesartan
  - Olanzapine
  - Omeprazole
  - Ondansetron

### Antipsychotics

- Atomoxetine:
  - Barbiturates:
    - CNS effects of opioid analgesics possibly increased by barbiturates; plasma concentration of methadone reduced by phenobarbital.
Opioid Analgesics (continued)
Beta-blockers: morphine possibly increases plasma concentration of *emolol*
Calcium-channel blockers: metabolism of alfentanil inhibited by *ditiazem* (risk of prolonged or delayed respiratory depression)
Dorperidone: opioid analgesics antagonise effects of *dorperidone* on gastro-intestinal activity
- Dopaminergics: avoid concomitant use of dextromethorphan with *erasagine*; risk of CNS toxicity when pethidine given with *rasagine* (avoid pethidine for 2 weeks after rasagine); hyperpyrexia and CNS toxicity reported when pethidine given with *selegiline* (avoid concomitant use); avoidance of opioid analgesics advised by manufacturer of *selegiline*
5HT, Antagonists: effects of tramadol possibly antagonized by *ondanestrone*
- Memantine: increased risk of CNS toxicity when dextromethorphan given with *memantine* (manufacturer of memantine advises avoid concomitant use)
- Metoclopramide: opioid analgesics antagonise effects of *metoclopramide* on gastro-intestinal activity
- Muscle Relaxants: increase sedative effect when fentanyl or morphine given with *bacoferin*
- Sodium Oxybate: opioid analgesics enhance effects of *sodium oxybate* (avoid concomitant use)
- Ulcer-Healing Drugs: metabolism of opioid analgesics inhibited by *cimetidine* (increased plasma concentration)
Orilistat
- Anti-arhythmics: orlistat possibly reduces plasma concentration of *amiodarone*
- Anticoagulants: manufacturer of orlistat recommends monitoring anticoagulant effect of *coumarins*
- Antidepressants: manufacturer of orlistat advises avoid concomitant use with *acarbose*
- Antiepileptics: possible increased risk of convulsions when orlistat given with *antiepileptics*
- Ciclosporin: orlistat possibly reduces absorption of *ciclosporin*
- Thyroid Hormones: possible increased risk of hyperthyroidism when orlistat given with *levothyroxine*
Orphenadrine see Antimuscarinics
Oxaliplatin see Platinum Compounds
Oxandrolone see Anabolic Steroids
Oxazepam see Anxiolytics and Hypnotics
Oxcarbazepine
- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonized by MAOIs and *cyclic*-related antidepresants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by *SSRIs* and *cyclics* (convulsive threshold lowered); avoid concomitant use of antiepileptics with *St John's wort*
- Antiepileptics: oxcarbazepine sometimes reduces plasma concentration of *carbamazepine* (but concentration of an active metabolite of carbamazepine may be increased), also plasma concentration of an active metabolite of oxcarbazepine often reduced; avoidance of oxcarbazepine advised by manufacturer of *eslicarbazepine*; oxcarbazepine increases plasma concentration of phenytoin, also plasma concentration of an active metabolite of oxcarbazepine reduced; plasma concentration of an active metabolite of oxcarbazepine sometimes reduced by *valproate*
- Antiinflammatories: possible increased risk of convulsions when antiepileptics given with *chloroquine* and *hydroxychloroquine*; anticonvulsant effect of antiepileptics antagonised by *metofagaine*
- Antipsychotics: anticonvulsant effect of oxcarbazepine antagonised by *antipsychotics* (convulsive threshold lowered)
Barbiturates: oxcarbazepine increases plasma concentration of *phenobarbital*, also plasma concentra-
Oxcarbazepine
Barbiturates (continued)
tion of an active metabolite of oxcarbazepine reduced
- Ciclosporin: oxcarbazepine possibly reduces plasma concentration of *ciclosporin*
- Clopidogrel: oxcarbazepine possibly reduces anti-platelet effect of *clopidogrel*
- Cytotoxics: oxcarbazepine reduces plasma concentration of *imatinib*—avoid concomitant use
- Oestrogens: oxcarbazepine accelerates metabolism of *oestrogens* (reduced contraceptive effect—see p. 495)
- Orlistat: possible increased risk of convulsions when antiepileptics given with *orlistat*
- Progestogens: oxcarbazepine accelerates metabolism of *progestogens* (reduced contraceptive effect—see p. 495)
Oxprenolol see Beta-blockers
Oxybutynin see Antimuscarinics
Oxycodeone see Opioid Analgesics
Oxymetazoline see Sympathomimetics
Oxytetracyline see Tetracyclines
Oxycotin
Anaesthetics, General: oxytocin effect possibly reduced, also enhanced hypotensive effect and risk of arrhythmias when oxytocin given with volatile liquid general anaesthetics
Prostaglandins: uterotonic effect of oxytocin potentiated by *prostaglandins*
Sympathomimetics: risk of hypertension when oxytocin given with vasconstrictor *sympathomimetics* (due to enhanced vasopressor effect)
Paclitaxel
Antiepileptics: cytoxotics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytoxotics with *clozapine* (increased risk of agranulocytosis)
- Antivirals: plasma concentration of paclitaxel increased by *nelfinavir* and *ritonavir*
Cardiac Glycosides: cytotoxics reduce absorption of *digoxin* tablets
- Cytotoxics: increased risk of neutropenia when paclitaxel given with *lapatinib*
Paliperidone see Antipsychotics
Pancreatin
Antidiabetics: pancreatic antagonises hypoglycaemic effect of *acarbose*
Pancuronium see Muscle Relaxants
Pantoprazole see Proton Pump Inhibitors
Papaveretum see Opioid Analgesics
Paracetamol
Anticoagulants: prolonged regular use of paracetamol possibly enhances anticoagulant effect of *coumarins*
- Antiepileptics: metabolism of paracetamol possibly accelerated by *carbamazepine*
- Cytotoxics: paracetamol possibly inhibits metabolism of intravenous *busulfan* (manufacturer of intravenous busulfan advises caution within 72 hours of paracetamol); caution with paracetamol advised by manufacturer of *imatinib*
Lipid-regulating Drugs: absorption of paracetamol reduced by *colestevamine*
Metoclopramide: rate of absorption of paracetamol increased by *metoclopramide*
Paraldehyde
- Alcohol: increased sedative effect when paraldehyde given with *alcohol*
- Disulfiram: risk of toxicity when paraldehyde given with *disulfiram*
Parasympathomimetics
- Anti-arhythmics: effects of neostigmine and pyrido- stigmine possibly antagonised by *propafenone*
- Antibacterial: plasma concentration of galantamine increased by *erythromycin*; effects of neostigmine and pyridostigmine antagonised by *eaminoglycosides*; effects of neostigmine and
Appendix 1: Interactions

BNF 61

Parasympathomimetics
- Anticholinergics: (continued)
  - Antidopaminergic: (continued)
  - Antimuscarinics: effects of parasympathomimetics antagonised by

Antibacterials: clindamycin; effects of neostigmine and pyridostigmine antagonised by erythromycins

Antidepressants: plasma concentration of galantamine increased by paroxetine

Antifungals: plasma concentration of galantamine increased by ketoconazole

Antimalarials: effects of neostigmine and pyridostigmine may be diminished because of potential for chloroquine and hydroxychloroquine to increase symptoms of myasthenia gravis

Antimuscarinics: effects of parasympathomimetics antagonised by antimuscarinics

Beta-blockers: increased risk of arrhythmias when pilocarpine given with beta-blockers; effects of neostigmine and pyridostigmine antagonised by propranolol

Lithium: effects of neostigmine and pyridostigmine antagonised by lithium

Muscle Relaxants: donepezil possibly enhances effects of auranofin, edrophonium, galantamine, neostigmine, pyridostigmine and rivastigmine enhance effects of auranofin; donepezil possibly antagonises effects of non-depolarising muscle relaxants; edrophonium, neostigmine, pyridostigmine and rivastigmine antagonise effects of non-depolarising muscle relaxants

Paradox see NSAIDs

Paricalcitol see Antiepileptics

Parecoxib see Antimicrobial Agents

Penicillamine (continued)
- Zinc: penicillamine reduces absorption of zinc, also absorption of penicillamine reduced by zinc

Penicillins
- Allopurinol: increased risk of rash when amoxicillin or ampicillin given with allopurinol

Antibacterials: absorption of phenoxymethylpenicillin reduced by neomycin; effects of penicillins possibly antagonised by tetracyclines

Anticoagulants: common experience in anticoagulant clinics is that INR can be altered by a course of broad-spectrum penicillins such as ampicillin, although studies have failed to demonstrate an interaction with coumarins or phenindione

Cytotoxics: penicillins reduce excretion of methotrexate (increased risk of toxicity)

Muscle Relaxants: piperacillin enhances effects of non-depolarising muscle relaxants and auxa-methonium

Probenecid: excretion of penicillins reduced by probenecid (increased plasma concentration)

Sulfispropyrazole: excretion of penicillins reduced by sulfispropyrazole

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Pentamidine Isetionate
- Anti-arrhythmics: increased risk of ventricular arrhythmias when pentamidine isetionate given with amiodarone—avoid concomitant use

Antibacterials: increased risk of ventricular arrhythmias when pentamidine isetionate given with parenteral erythromycin; increased risk of ventricular arrhythmias when pentamidine isetionate given with mexitil—avoid concomitant use

Antidepressants: increased risk of ventricular arrhythmias when pentamidine isetionate given with tricyclics

Antifungals: possible increased risk of nephrotoxicity when pentamidine isetionate given with amphotericin

Antipsychotics: increased risk of ventricular arrhythmias when pentamidine isetionate given with amisulpride or droperidol—avoid concomitant use; increased risk of ventricular arrhythmias when pentamidine isetionate given with mexitil—avoid concomitant use

Antivirals: increased risk of hypocalcaemia when parenteral pentamidine isetionate given with foscarnet; increased risk of ventricular arrhythmias when pentamidine isetionate given with saquinavir—avoid concomitant use

Ivabradine: increased risk of ventricular arrhythmias when pentamidine isetionate given with ivabradine

Pentazocine see Opioid Analgesics

Pentostatin
- Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Cytotoxics: plasma concentration of penazocine increased by lapiatinib

Grapefruit Juice: manufacturer of penazocine advises avoid concomitant use with grapefruit juice

Pegfilgrastim see Filgrastim

Peginterferon Alfa see Interferons

Penetrexed
- Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antimalarials: antifolate effect of pentetrexed increased by pyrithymamine

Antipsychotics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets

Penicillamine
- Analgesics: possible increased risk of nephrotoxicity when penicillamine given with NSAIDs

Antacids: absorption of penicillamine reduced by antacids

Antipsychotics: avoid concomitant use of penicillamine with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: penicillamine possibly reduces plasma concentration of digoxin

Iron: absorption of penicillamine reduced by oral iron; Sodium Aurothiomalate: manufacturer of penicillamine advises avoid concomitant use with sodium aurothiomalate (increased risk of toxicity)
Appendix 1: Interactions

Phenobarbital see Barbiturates
Phenothiazines see Antipsychotics
Phenoxymethylpenicillin see Penicillins
Phentolamine see Alpha-blockers
Phenytoine see Sympathomimetics
Phenytoin

Note: Phenytoin interactions as for phenytoin

Alcohol: plasma concentration of phenytoin possibly reduced by chronic heavy consumption of alcohol

Analgesics: phenytoin accelerates metabolism of methadone (reduced effect and risk of withdrawal effects); effects of phenytoin enhanced by aspirin

Antacids: absorption of phenytoin reduced by antacids

Antidepressants: metabolism of phenytoin inhibited by amitriptyline (increased plasma concentration); phenytoin reduces plasma concentration of disopyramide; phenytoin possibly reduces plasma concentration of dronedarone—avoid concomitant use

Antifungals: metabolism of phenytoin by itraconazole (inhibited plasma concentration); plasma concentration of phenytoin possibly increased or decreased by ketoconazole; phenytoin accelerates metabolism of doxycycline (reduced plasma concentration); plasma concentration of phenytoin increased by clarithromycin (increased risk of toxicity); metabolism of phenytoin possibly inhibited by isoniazid (increased risk of toxicity); metabolism of phenytoin accelerated by rifampicin (reduced plasma concentration); plasma concentration of phenytoin possibly increased by rifampicin—avoid concomitant use

Antihistamines: metabolism of phenytoin enhanced by cetirizine (possible increased plasma concentration of phenytoin due to antiepileptic effect)

Antidiabetics: plasma concentration of phenytoin increased by glimepiride and glibenclamide; plasma concentration of phenytoin possibly increased by zeranol, also plasma concentration of sulfonylureas possibly reduced; anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort; phenytoin possibly reduces plasma concentration of tricyclics

Antidiabetics: plasma concentration of phenytoin transiently increased by tolbutamide (possibility of toxicity)

Antiepileptics: plasma concentration of both drugs often reduced when phenytoin given with carbamazepine, also plasma concentration of phenytoin may be increased; phenytoin reduces plasma concentration of eslicarbazepine, also plasma concentration of phenytoin possibly increased by eslicarbazepine; also plasma concentration of phenytoin possibly increased by lamotrigine, tiagabine and zonisamide; plasma concentration of phenytoin increased by oxcarbazepine, also plasma concentration of an active metabolite of oxcarbazepine reduced; phenytoin possibly reduces plasma concentration of primidone (but concentration of an active metabolite increased), plasma concentration of phenytoin often reduced but may be increased; phenytoin possibly reduces plasma concentration of rufinamide, also plasma concentration of phenytoin possibly increased; plasma concentration of phenytoin increased by stiripentol; plasma concentration of phenytoin increased by topiramate (also plasma concentration of topira-
Phenytoin
- Antiepileptics (continued)
  - Potentiation: phenytoin reduces plasma concentration of valproate, also plasma concentration of valproate reduced; plasma concentration of phenytoin reduced by vigabatrin
  - Antifungals: phenytoin reduces plasma concentration of itraconazole and posaconazole; anticonvulsant effect of phenytoin enhanced by micrornyzone (plasma concentration of phenytoin increased); plasma concentration of phenytoin increased by fluconazole (consider reducing dose of phenytoin); phenytoin reduces plasma concentration of itraconazole—avoid concomitant use; plasma concentration of phenytoin by voriconazole, also phenytoin plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity); phenytoin possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin
  - Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by mefloquine; anticonvulsant effect of phenytoin antagonised by pyrimethamine, also increased antifolate effect
  - Antipsychotics: anticonvulsant effect of phenytoin antagonised by antipsychotics (convulsive threshold lowered); phenytoin reduces plasma concentration of haloperidol; plasma concentration of phenytoin possibly increased or decreased by chlorpromazine; phenytoin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole; phenytoin accelerates metabolism of clozapine and quetiapine (reduced plasma concentration)
  - Antivirals: phenytoin possibly reduces plasma concentration of abacavir, darunavir, lopinavir and saquinavir; avoidance of phenytoin advised by manufacturer of etravirine; phenytoin possibly reduces plasma concentration of indinavir, also plasma concentration of phenytoin possibly increased; plasma concentration of phenytoin reduced by neflinavir; phenytoin possibly reduces plasma concentration of ritonavir, also plasma concentration of phenytoin possibly affected; plasma concentration of phenytoin increased or decreased by zidovudine
  - Anxiolytics and Hypnotics: phenytoin often reduces plasma concentration of clonazepam; plasma concentration of phenytoin increased or decreased by diazepam; plasma concentration of phenytoin possibly increased or decreased by benzodiazepines
  - Aprepitant: phenytoin possibly reduces plasma concentration of aprepitant
  - Barbiturates: phenytoin often increases plasma concentration of phenobarbital, plasma concentration of phenytoin often reduced but may be increased by Bupropion: phenytoin reduces plasma concentration of bupropion
- Calcium-channel Blockers: phenytoin reduces effects of felodipine, isradipine and verapamil; phenytoin probably reduces effects of dipyridamides, nicardipine and nifedipine; plasma concentration of phenytoin increased by diiltiazem but also effect of diiltiazem reduced
- Cardiac Glycosides: phenytoin possibly reduces plasma concentration of digoxin
- Ciclosporin: phenytoin accelerates metabolism of ciclosporin (reduced plasma concentration)
- Corticosteroids: phenytoin accelerates metabolism of corticosteroids (reduced effect)
- Cytoxic: phenytoin possibly reduces plasma concentration of busulfan and etoposide; metabolism of phenytoin possibly inhibited by fluoroouracil (increased risk of toxicity); phenytoin increases antifolate effect of methotrexate, absorption of

Phenytoin
- Cytotoxics (continued)
  - Phenytoin possibly reduced by cytoxotics; avoidance of phenytoin advised by manufacturer of gefitinib and lapatinib; phenytoin reduces plasma concentration of matinib—avoid concomitant use; phenytoin reduces plasma concentration of irinotecan and its active metabolite
- Diazoxide: plasma concentration of phenytoin reduced by diazoxide, also effect of diazoxide may be reduced
- Disulfram: metabolism of phenytoin inhibited by disulfram (increased risk of toxicity)
- Diuretics: plasma concentration of phenytoin possibly increased by ecaflatalmide; phenytoin antagonises effects of folineside; phenytoin reduces plasma concentration of eplerenone—avoid concomitant use; increased risk of osteomalacia when phenytoin given with carbonic anhydride inhibitors
- Dopaminergic: phenytoin possibly reduces effects of levodopa

Enteral Foods: absorption of phenytoin possibly reduced by enteral feeds
- Folates: plasma concentration of phenytoin possibly reduced by folates
- Hormone Antagonists: phenytoin possibly accelerates metabolism of toremifene
- SHT, Antagonists: phenytoin accelerates metabolism of ondansetron (reduced effect)
- Lefunomide: plasma concentration of phenytoin possibly increased by lefunomide
- Levamisole: plasma concentration of phenytoin possibly increased by levamisole
- Lipid-regulating Drugs: absorption of phenytoin possibly reduced by colesevelam; combination of phenytoin with fluvastatin may increase plasma concentration of either drug (or both)
- Lithium: neurotoxicity may occur when phenytoin given with lithium without increased plasma concentration of lithium
- Modafinil: plasma concentration of phenytoin possibly increased by modafinil
- Muscle Relaxants: phenytoin antagonises muscle relaxant effect of non-depolarising muscle relaxants (accelerated recovery from neuromuscular blockade)
- Oestrogens: phenytoin accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495)
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat
- Progestogens: phenytoin accelerates metabolism of progestogens (reduced contraceptive effect—see p. 495)
- Sulfipyrazon: plasma concentration of phenytoin increased by sulfipyrazon
- Sympathomimetics: plasma concentration of phenytoin increased by methylphenidate
- Tacrolimus: phenytoin reduces plasma concentration of tacrolimus, also plasma concentration of phenytoin possibly increased
- Theophylline: plasma concentration of both drugs reduced when phenytoin given with theophylline
- Thyroid Hormones: phenytoin antagonises metabolism of thyroid hormones (may increase requirements in hyperthyroidism), also plasma concentration of phenytoin possibly increased
- Tilibione: phenytoin accelerates metabolism of tilibione
- Ulcer-Healing Drugs: metabolism of phenytoin inhibited by cimetidine (increased plasma concentration); effects of phenytoin enhanced by omeprazole; effects of phenytoin possibly enhanced by omeprazole; absorption of phenytoin reduced by sucralfate
- Ulipristal: avoidance of phenytoin advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)

Appendix 1: Interactions

BNF 61
Appendix 1: Interactions 867
Appendix 1: Interactions

Phenotoin (continued)
Vitamins: effects of phenotoin enhanced by influenza vaccine
Vitamins: phenotoin possibly increases requirements for vitamin D

Pholcodine
Antidepressants: manufacturer of pholcodine advises care for 2 weeks after stopping MAOIs

Phosphodiesterase Type-3 Inhibitors
Anadrenaline: avoidance of enoximone and milrinone

Physostigmine see Parasympathomimetics
Pilocarpine see Parasympathomimetics
Pimozide see Antipsychotics
Pindolol see Beta-blockers
Piglitazone see Antidiabetics
Piperacillin see Penicillins
Pipotiazine see Antipsychotics
Piroxicam see NSAIDs
Pivmecillinam see Penicillins
Pizotifen
Adrenergic Neurone Blockers: pizotifen antagonises hypotensive effect of adrenergic neurone blockers

Platinum Compounds
Aldesleukin: avoidance of cisplatin advised by manufacturer of aldesleukin

Antibacterials: increased risk of nephrotoxicity and possibly of otoxicity when platinum compounds given with amnoglycosides or polymyxins; increased risk of nephrotoxicity and otoxicity when platinum compounds given with capreomycin; increased risk of nephrotoxicity and possibly of otoxicity when cisplatin given with vancomycin

Antipileptic drugs: cytotoxics possibly reduce absorption of phenotoin

Antipsychotics: avoid concomitant use of cytotoxics with olanzapine; increased risk of agranulocytosis

Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Cytotoxics: increased risk of otoxicity when cisplatin given with ifosfamide; increased pulmonary toxicity when cisplatin given with bleomycin and methotrexate

Diuretics: increased risk of nephrotoxicity and otoxicity when platinum compounds given with diuretics

Polymyxin B see Polymyxins
Polymyxins
Antibacterials: increased risk of nephrotoxicity when colistin or polymyxins given with aminoglycosides; increased risk of nephrotoxicity when colistin or polymyxins given with capreomycin; increased risk of nephrotoxicity when polymyxins given with vancomycin; increased risk of nephrotoxicity and otoxicity when colistin given with vancomycin

Antifungals: increased risk of nephrotoxicity when polymyxins given with amphotericin

Ciclosporin: increased risk of nephrotoxicity when polymyxins given with ciclosporin

Cytotoxics: increased risk of nephrotoxicity and possibly of otoxicity when polymyxins given with platinum compounds

Diuretics: increased risk of otoxicity when polymyxins given with loop diuretics

Muscle Relaxants: polymyxins enhance effects of non-depolarising muscle relaxants and suxamethonium

Parasympathomimetics: polymyxins antagonise effects of neostigmine and pyridostigmine

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Polystyrene Sulphonate Resins
Antacids: risk of intestinal obstruction when polystyrene sulphonate resins given with aluminium hydroxide; risk of metabolic alkalosis when polystyrene sulphonate resins given with oral magnesium salts
Antiepileptics: primidone accelerates metabolism of ethanol, avoiding anticonvulsant effect

Antidepressants: primidone possibly reduces plasma concentration of ethosuximide and tiagabine; plasma concentration of primidone reduced by phenytoin (but concentration of an active metabolite increased), also metabolism of tricyclics possibly accelerated (reduced plasma concentration)

Antipsychotics: primidone accelerates metabolism of paroxetine; primidone possibly reduces plasma concentration of an active metabolite of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered), avoidance concomitant use of antiepileptics with St John’s wort; anticonvulsant effect of primidone antagonised by tricyclics (convulsive threshold lowered), also metabolism of tricyclics possibly accelerated (reduced plasma concentration)

Antiepileptics: primidone often reduces plasma concentration of carbamazepine, also plasma concentration of primidone sometimes reduced (but concentration of an active metabolite of primidone often increased); primidone possibly reduces plasma concentration of etosuximide and rufinamide; primidone reduces plasma concentration of lamotrigine and tiagabine; plasma concentration of primidone possibly reduced by phenytoin (but concentration of an active metabolite increased), plasma concentration of phenytoin often reduced but may be increased; plasma concentration of primidone possibly increased by valproate (plasma concentration of active metabolite of primidone increased), also plasma concentration of valproate reduced; plasma concentration of primidone possibly reduced by vigabatrin

Antifungals: primidone possibly reduces plasma concentration of posaconazole; primidone possibly reduces plasma concentration of voriconazole—avoid concomitant use; primidone reduces absorption of griseofulvin (reduced effect)

Antimalarias: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by mefloquine

Antipsychoptics: anticonvulsant effect of primidone antagonised by antipsychotics (convulsive threshold lowered); primidone accelerates metabolism of haloperidol (reduced plasma concentration); primidone possibly reduces plasma concentration of aripiprazole—dose of aripiprazole increased; plasma concentration of primidone possibly reduced by saquinavir

Antivirals: primidone possibly reduces plasma concentration of indinavir, lopinavir, nefilnavir and saquinavir

Anxiolytics and Hypnotics: primidone often reduces plasma concentration of clonazepam

Barbiturates: increased sedative effect when primidone given with barbiturates

Calcium-channel Blockers: primidone reduces effects of nifedipine and verapamil

Ciclosporin: primidone accelerates metabolism of ciclosporin (reduced effect)

Corticosteroids: primidone accelerates metabolism of corticosteroids (reduced effect)

Diuretics: plasma concentration of primidone possibly reduced by acetazolamide; increased risk of osteomalacia when primidone given with carboxic anhydrase inhibitors

Folates: plasma concentration of primidone possibly reduced by folic acid

Hormone Antagonists: primidone accelerates metabolism of toremifene (reduced plasma concentration)

Leukotriene Receptor Antagonists: primidone reduces plasma concentration of montelukast

Memantine: effects of primidone possibly reduced by memantine

Probenecid

ACE Inhibitors: probenecid reduces excretion of captopril

Anasthetics, General: probenecid possibly enhances effects of thiopental

Analgesics: probenecid reduces excretion of ketoprofen, indomethacin, ketorolac and naproxen (increased plasma concentration); probenecid reduces excretion of ketorolac (increased plasma concentration)—avoid concomitant use; effects of probenecid antagonised by aspirin

Antibacterials: probenecid reduces excretion of doripenem (manufacturers of doripenem advise avoid concomitant use); probenecid reduces excretion of meropenem; probenecid reduces excretion of cephalosporins, ciprofloxacin, nalidixic acid, norfloxacin and penicillins (increased plasma concentration); probenecid reduces excretion of dapson and nitrofurantoin (increased risk of side-effects); effects of probenecid antagonised by pyrazinamide

Antivirals: probenecid reduces excretion of aciclovir (increased plasma concentration); probenecid possibly reduces excretion of famiclovir (increased plasma concentration); probenecid reduces excretion of ganciclovir and zidovudine (increased plasma concentration and risk of toxicity)

Antipsychoptics: probenecid reduces excretion of lorazepam (increased plasma concentration); probenecid possibly reduces excretion of nitrazepam (increased plasma concentration)

Cytotoxics: probenecid reduces excretion of methotrexate (increased risk of toxicity)

Sodium Benzoate: probenecid possibly reduces excretion of conjugate formed by sodium benzoate

Sodium Phenylbutyrate: probenecid possibly reduces excretion of conjugate formed by sodium phenylbutyrate

Procarbazine: Alcohol: disulfiram-like reaction when procarbazine given with alcohol

Antiepileptics: cytoxotics possibly reduce absorption of phenytoin

Antipsychoptics: avoid concomitant use of cytoxotics with clozapine (increased risk of agranulocytosis)

Cardiac Glysides: cytoxotics reduce absorption of digoxin tablets

Piroclorperazine see Antipsychoptics

Procyclidine see Antimuscarinics

Progestosterone see Progestogens

Progestogens

Note: Interactions of combined oral contraceptive may also apply to combined contraceptive patches and vaginal rings

Antibacterials: metabolism of progestogens accelerated by rifampicin (reduced contraceptive effect—see p. 495)
Progestogens (continued)

- Anticoagulants: progestogens may enhance or reduce anticoagulant effect of *coumarins*; progestogens antagonise anticoagulant effect of *phenindione*
- Antiadrenergics: contraceptive effect of progestogens reduced by *St John's wort* (avoid concomitant use)
- Antidiabetics: progestogens antagonise hypoglycaemic effect of *antidiabetics*
- Antiepileptics: metabolism of progestogens accelerated by *barbiturates*, *eptilharine*, *eslicarbazepine*, *ocarbazepine*, *phenytoin*, *primidone*, *rifampicin* and *topiramate* (reduced contraceptive effect—see p. 495); desogestrel possibly increases plasma concentration of lamotrigine
- Antifungals: progestogens possibly increase plasma concentration of *voriconazole*; anecdotal reports of contraceptive failure and menstrual irregularities when progestogens given with *griseofulvin*; occasional reports of breakthrough bleeding when progestogens (used for contraception) given with *terbinafine*
- Antivirals: contraceptive effect of progestogens possibly reduced by *efavirenz* and *nevirapin*; metabolism of progestogens accelerated by *nevirapin* (reduced contraceptive effect—see p. 495)
- Aprepitant: possible contraceptive failure of hormonal contraceptives containing progestogens when given with *aprepitant* (alternative contraception recommended)
- Barbiturates: metabolism of progestogens accelerated by *barbiturates* (reduced contraceptive effect—see p. 495)
- Bosentan: possible contraceptive failure of hormonal contraceptives containing progestogens when given with *bosentan* (alternative contraception recommended)
- Ciclosporin: progestogens inhibit metabolism of *ciclosporin* (increased plasma concentration)
- Diuretics: risk of hyperkaemia when drosopirenene given with *potassium-sparing diuretics* and *aldosterone antagonists* (monitor serum potassium during first cycle)
- Dopaminergics: progestogens increase plasma concentration of *selegiline*—manufacturer of *selegiline* advises avoid concomitant use
- Lipid-regulating Drugs: plasma concentration of *nor-ethisterone* increased by *atorvastatin*; plasma concentration of norgestrel increased by *rosuvastatin*
- Muscle Relaxants: progestogens possibly increase plasma concentration of *tiotixane* (increased risk of toxicity)
- Sitaxentan: plasma concentration of progestogens increased by *sitaxentan*
- Sugammadex: plasma concentration of progestogens possibly reduced by *sugammadex*
- Ulipristal: contraceptive effect of progestogens possibly reduced by *ulipristal*

Propafenone (continued)

- Anti-arrhythmics: increased myocardial depression when anti-arrhythmics given with other *anti-arrhythmics*
- Antibacterials: metabolism of propafenone accelerated by *rifampicin* (reduced effect)
- Anticoagulants: propafenone enhances anticoagulant effect of *coumarins*
- Antidepressants: metabolism of propafenone possibly inhibited by *paroxetine* (increased risk of toxicity); increased risk of arrhythmias when propafenone given with *tricyclics*
- Antihtamimines: increased risk of ventricular arrhythmias when propafenone given with *mizolastine*—avoid concomitant use
- Antipsychotics: increased risk of ventricular arrhythmias when anti-arrhythmics that prolong the QT interval given with *antipsychotics* that prolong the QT interval
- Antivirals: plasma concentration of propafenone possibly increased by *osumipravir* (increased risk of ventricular arrhythmias—avoid concomitant use); plasma concentration of propafenone increased by *ritonavir* (increased risk of ventricular arrhythmias—avoid concomitant use); increased risk of ventricular arrhythmias when propafenone given with *saquinavir*—avoid concomitant use
- Beta-blockers: increased myocardial depression when anti-arrhythmics given with *beta-blockers*; propafenone increases plasma concentration of metoprolol and propranolol
- Cardiac Glycosides: propafenone increases plasma concentration of *digoxin* (halve dose of digoxin)
- Ciclosporin: propafenone possibly increases plasma concentration of *ciclosporin*
- Parasympathomimetics: propafenone possibly antagonises effects of *neostigmine* and *pyridostigmine*
- Theophylline: propafenone increases plasma concentration of theophylline
- Ulcer-healing Drugs: plasma concentration of propafenone increased by *ecetamide*

Propantheline see Antimuscarinics
Prompiverine see Antimuscarinics
Propofol see Anaesthetics, General
Propranolol see Beta-blockers

Prostaglandins

ACE inhibitors: enhanced hypotensive effect when alprostadil given with ACE inhibitors
- Adrenergic Neurone Blockers: enhanced hypotensive effect when alprostadil given with adrenergic neurone blockers
- Alpha-blockers: enhanced hypotensive effect when alprostadil given with alpha-blockers
- Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when alprostadil given with angiotensin-II receptor antagonists
- Beta-blockers: enhanced hypotensive effect when alprostadil given with beta-blockers
- Calcium-channel Blockers: enhanced hypotensive effect when alprostadil given with calcium-channel blockers
- Clonidine: enhanced hypotensive effect when alprostadil given with *clonidine*
- Diamoxide: enhanced hypotensive effect when alprostadil given with diamexide
- Diuretics: enhanced hypotensive effect when alprostadil given with *diuretics*
- Methylpapda: enhanced hypotensive effect when alprostadil given with *methylpapda*
- Moxnixone: enhanced hypotensive effect when alprostadil given with moxonixone
- Nitrites: enhanced hypotensive effect when alprostadil given with nitrites
- Oxytocin: prostaglandins potentiate uteronic effect of *oxytocin*
- Vasodilator Antihypertensives: enhanced hypotensive effect when alprostadil given with *hydralazine*, *minoxidil* or *sodium nitroprusside*
Protein Kinase Inhibitors see Darotinib, Erlotinib,
Everolimus, Gefitinib, Imitinib, Lapatinib, Nilotinib,
Pazopanib, Sorafenib, Sunitinib, and Temsirolimus

Proton Pump Inhibitors
Antacids: absorption of lansoprazole possibly reduced by antacids
Antibacterials: plasma concentration of both drugs increased when omeprazole given with clarithromycin

● Anticoagulants: esomeprazole, omeprazole and pantoprazole possibly enhance anticoagulant effect of coumarins

Antidepressants: omeprazole increases plasma concentration of escitalopram; plasma concentration of lansoprazole possibly increased by fluvoxamine; plasma concentration of omeprazole possibly reduced by St John’s wort

Antiepileptics: esomeprazole enhances effects of phenytoin; omeprazole possibly enhances effects of phenytoin

Antifungals: proton pump inhibitors reduce absorption of triacanazole and ketoconazole; avoidance of proton pump inhibitors advised by manufacturer of posaconazole (plasma concentration of posaconazole possibly reduced); plasma concentration of esomeprazole possibly increased by voriconazole; plasma concentration of omeprazole increased by voriconazole (consider reducing dose of omeprazole)

Antipsychotics: omeprazole possibly reduces plasma concentration of clozapine

Antivirals: proton pump inhibitors reduce plasma concentration of atazanavir—avoid or adjust dose of both drugs (consult product literature); omeprazole reduces plasma concentration of saquinavir—avoid concomitant use; proton pump inhibitors possibly increase plasma concentration of raltegravir—manufacturer of raltegravir advises avoid concomitant use; omeprazole increases plasma concentration of raltegravir—avoid concomitant use; esomeprazole, lansoprazole, pantoprazole and rabeprazole possibly increase plasma concentration of esapinavir—manufacturer of saquinavir advises avoid concomitant use; omeprazole increases plasma concentration of esapinavir—manufacturer of saquinavir advises avoid concomitant use; plasma concentration of esomeprazole and omeprazole reduced by esapinavir

Anxiolytics and Hypnotics: esomeprazole and omeprazole possibly inhibit metabolism of zolpidem (increased plasma concentration)

Cardiac Glycosides: proton pump inhibitors possibly slightly increase plasma concentration of digoxin

Ciclosporin: omeprazole possibly affects plasma concentration of ciclosporin

Clomazol: omeprazole increases plasma concentration of clomazol (consider reducing dose of clomazol)

Clopidogrel: esomeprazole and omeprazole reduce antiplatelet effect of clopidogrel; lansoprazole, pantoprazole and rabeprazole possibly reduce antiplatelet effect of clopidogrel

Cytotoxics: omeprazole possibly reduces excretion of methotrexate (increased risk of toxicity); avoidance of esomeprazole, lansoprazole, pantoprazole and rabeprazole advised by manufacturer of erlotinib; omeprazole reduces plasma concentration of erlotinib—manufacturer of erlotinib advises avoid concomitant use; proton pump inhibitors possibly reduce absorption of lapatinib

Tacrolimus: omeprazole possibly increases plasma concentration of tacrolimus

Ulcer Healing Drugs: absorption of lansoprazole possibly reduced by sucralfate

Ulipristal: avoidance of proton pump inhibitors advised by manufacturer of ulipristal (plasma concentration of ulipristal possibly reduced)

Pseudoephedrine see Sympathomimetics

Appendix 1: Interactions

Pyrazinamide
Probenecid: pyrazinamide antagonises effects of probenecid
Sulfipyrazine: pyrazinamide antagonises effects of sulfipyrazine

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Pyridostigmine see Parasympathomimetics

Pyridoxine see Vitamins

Pyrimethamine
● Antibacterials: increased antifolate effect when pyrimethamine given with sulfonamides or trimethoprim

● Antiepileptics: pyrimethamine antagonises anti-convulsant effect of phenytoin, also increased antifolate effect

● Antimalarials: avoidance of antimalarials advised by manufacturer of atemether/lumefantrine, increased antifolate effect when pyrimethamine given with propguanil

Antivirals: increased antifolate effect when pyrimethamine given with didovudine

Cytotoxics: pyrimethamine antagonises antifolate effect of mitotrexate and pemetrexed

Histamine: avoidance of antimalarials advised by manufacturer of histamine

Vaccines: antimalarials inactivate oral typhoid vaccine—see p. 767

Quetiapine see Antipsychotics

Quinagolide
Memantine: effects of dopaminergics possibly enhanced by memantine

Methylpiperidine: antiparkinsonian effect of dopaminergics antagonised by methylpiperidine

Quinapril see ACE Inhibitors

Quinine
● Anti-arrhythmics: increased risk of ventricular arrhythmias when quinine given with amiodarone—avoid concomitant use; quinine increases plasma concentration of efecainide

● Antibacterials: increased risk of ventricular arrhythmias when quinine given with moxifloxacin—avoid concomitant use; plasma concentration of quinine reduced by ritampicin

Anticoagulants: plasma concentration of both drugs increased when quinine given with warfarin

Antimalarials: avoidance of antimalarials advised by manufacturer of atemether/lumefantrine; increased risk of ventricular arrhythmias when quinine given with atemether/lumefantrine; increased risk of convulsions when quinine given with metloquine (but should not prevent the use of intravenous quinine in severe cases)

Antipsychotics: increased risk of ventricular arrhythmias when quinine given with risperidone or pimozide—avoid concomitant use; possible increased risk of ventricular arrhythmias when quinine given with haloperidol—avoid concomitant use

Antivirals: plasma concentration of quinine possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir and tipranavir (increased risk of toxicity); plasma concentration of quinine increased by ritonavir (increased risk of toxicity); increased risk of ventricular arrhythmias when quinine given with saquinavir—avoid concomitant use

Cardiac Glycosides: quinine increases plasma concentration of digoxin

Dopaminergics: quinine possibly increases plasma concentration of amantadine

Histamine: avoidance of antimalarials advised by manufacturer of histamine

Muscle Relaxants: quinine possibly enhances effects of aminophenyl

Ulcer Healing Drugs: metabolism of quinine inhibited by cimetidine (increased plasma concentration)
Appendix 1: Interactions

Quinones (continued)
Vaccines: antimalarials inactivate oral typhoid vaccine—see p. 767

Quinolones
- Antidepressants: ciprofloxacin inhibits metabolism of duloxetine—avoid concomitant use; avoidance of ciprofloxacin advised by manufacturer of agomelatine—increased risk of ventricular arrhythmias when moxifloxacin given with
- Beta-blockers: increased risk of ventricular arrhythmias when moxifloxacin given with
disopyramide—avoid concomitant use
- Antacids: absorption of ciprofloxacin, levofloxacin, norfloxacin and ofloxacin reduced by antacids
- Anti-arrhythmics: increased risk of ventricular arrhythmias when levofloxacin or moxifloxacin given with
discoid cataracts—avoid concomitant use; increased risk of ventricular arrhythmias when moxifloxacin co-administered with
discoid cataracts—avoid concomitant use
- Antibacterials: increased risk of ventricular arrhythmias when moxifloxacin given with
discoid cataracts—avoid concomitant use; effects of nalidixic acid possibly antagonised by produces nausea and vomiting—avoid concomitant use
- Anticoagulants: ciprofloxacin, nalidixic acid, norfloxacin and ofloxacin enhance anticoagulant effect of coumarins; levofloxacin possibly enhances anticoagulant effect of coumarins and phenindione
- Antiarrhythmics: ciprofloxacin inhibits metabolism of duloxetine—avoid concomitant use; avoidance of ciprofloxacin advised by manufacturer of agomelatine—increased risk of ventricular arrhythmias when moxifloxacin given with
discoid cataracts—avoid concomitant use
- Antidepressants: ciprofloxacin inhibits metabolism of duloxetine—avoid concomitant use; avoidance of ciprofloxacin advised by manufacturer of agomelatine—increased risk of ventricular arrhythmias when moxifloxacin given with
discoid cataracts—avoid concomitant use
- Antiarrhythmics: increased risk of ventricular arrhythmias when moxifloxacin given with
discoid cataracts—avoid concomitant use
- Calcium Salts: absorption of ciprofloxacin reduced by
calcium salts
- Clopidogrel: increased risk of nephrotoxicity when quinolones given with
clopidogrel
- Clopidogrel: ciprofloxacin possibly reduces antiplatelet effect of
clopidogrel
- Cytoxotics: nalidixic acid increases risk of mesothelioma toxicity; ciprofloxacin possibly reduces excision of methotrexate (increased risk of toxicity); ciprofloxacin increases plasma concentration of etroltinib; increased risk of ventricular arrhythmias when levofloxacin or moxifloxacin given with
- Daily Products: absorption of ciprofloxacin and norfloxacin reduced by daily products
- Dopamine receptors: ciprofloxacin increases plasma concentration of rasagline; ciprofloxacin inhibits

Quinolones
Dopaminergics (continued)
- Dopaminergics: increased plasma concentration of ropinirole (increased plasma concentration)

S-HT: Agonists: quinolones possibly inhibit metabolism of zolmitriptan (reduce dose of zolmitriptan)
- Iron: absorption of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin reduced by iron
- Lanthanum: absorption of quinolones possibly reduced by lanthanum (give at least 2 hours before or 4 hours after lanthanum)
- Muscle Relaxants: norfloxacin possibly increases plasma concentration of tizanidine (increased risk of toxicity); ciprofloxacin increases plasma concentration of tizanidine (increased risk of toxicity)—avoid concomitant use
- Mycophenolate: norfloxacin possibly reduces bioavailability of mycophenolate
- Pentamidine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Pentamidine isethionate: increased risk of ventricular arrhythmias when moxifloxacin given with
- Probenecid: excretion of ciprofloxacin, nalidixic acid and norfloxacin reduced by probenecid (increased plasma concentration)
- Sevelamer: bioavailability of ciprofloxacin reduced by
- Strontium Ranelate: absorption of quinolones reduced by
- Raltegravir: increased plasma concentration of rifampicin (increased plasma concentration)

Raltegravir
- Raltegravir: increased plasma concentration of rifampicin (increased plasma concentration)
- Uler-Healing Drugs: absorption of ciprofloxacin, levofloxacin, norfloxacin and ofloxacin reduced by
cracetate
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
- Zinc: absorption of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin reduced by zinc
- Rabeprazole see Proton Pump Inhibitors

Ranolazine
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
- Ranolazine: increased risk of ventricular arrhythmias when moxifloxacin given with
Antivirals: plasma concentration of ranolazine increased by paroxetine

- Antifungals: plasma concentration of ranolazine increased by ketoconazole, posaconazole and voriconazole—manufacturer of ranolazine advises avoid concomitant use.

- Antivirals: plasma concentration of ranolazine possibly increased by adefovir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir and tipranavir—manufacturer of ranolazine advises avoid concomitant use.

- Beta-blockers: manufacturer of ranolazine advises avoid concomitant use with esmolol. Calcium-channel Blockers: plasma concentration of ranolazine increased by diltiazem and verapamil (consider reducing dose of ranolazine).

Cardiac Glycosides: ranolazine increases plasma concentration of digoxin.

Ciclosporin: plasma concentration of ranolazine possibly increased by ciclosporin.

- Grapefruit juice: plasma concentration of ranolazine possibly increased by grapefruit juice—manufacturer of ranolazine advises avoid concomitant use.

- Lipid-regulating Drugs: ranolazine increases plasma concentration of simvastatin (consider reducing dose of simvastatin).

Rasagiline

Note: Rasagiline is a MAO-B inhibitor.

- Analgesics: avoid concomitant use of rasagiline with tramadol.

- Antibacterials: plasma concentration of rasagiline increased by ciprofloxacin.

- Antidepressants: after stopping rasagiline do not start fluoxetine for 2 weeks, also rasagiline should not be started until at least 5 weeks after stopping fluoxetine.

- Fluvoxamine for 2 weeks: risk of hypertensive crisis when rasagiline given with MAOIs, avoid MAOIs for at least 2 weeks after stopping rasagiline; increased risk of CNS toxicity when rasagiline given with SSRIIs or tricyclics.

- Dopamineergics: plasma concentration of rasagiline possibly reduced by entacapone.

- Memantine: effects of dopamineergics possibly enhanced by memantine.

- Methyldopa: antiparkinsonian effect of dopamineergics antagonised by methyldopa.

- Sympathomimetics: avoid concomitant use of rasagiline with sympathomimetics.

Reboxetine

- Antibacterials: manufacturer of reboxetine advises avoid concomitant use with macrolides.

- Antidepressants: manufacturer of reboxetine advises avoid concomitant use with fluoxetine, flufenoxamine: increased risk of hypertension and CNS excitation when reboxetine given with MAOIs (MAOIs should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs).

- Antifungals: manufacturer of reboxetine advises avoid concomitant use with azoles and eritrotoxines.

- Antimalarials: avoidance of antidepressants advised by manufacturer of aemetether/lumefantrine.

- Atomoxetine: possible increased risk of convulsions when antidepressants given with atomoxetine.

- Diuretics: possible increased risk of hypokalaemia when reboxetine given with loop diuretics or thiazides and related diuretics.

- Ergot Alkaloids: possible risk of hypertension when reboxetine given with ergotamine and methysergide.

Remifentanil see Opioid Analgesics

Rifampicin see Rifamycins

Rifamycins

ACE Inhibitors: rifampicin reduces plasma concentration of active metabolite of imidapril (reduced antihypertensive effect)

- Analgesics: rifampicin reduces plasma concentration of celecoxib, diclofenac and etoricoxib; rifampicin accelerates metabolism of alfentanil, codeine, fentanyl, methadone and morphine (reduced effect); rifampicin possibly accelerates metabolism of oxycodeone.

- Angiotensin-II Receptor Antagonists: rifampicin reduces plasma concentration of losartan and its active metabolite.

- Antacids: absorption of rifampicin reduced by antacids.

- Anti-arrhythmics: rifamycins accelerate metabolism of disopyramide (reduced plasma concentration); rifampicin reduces plasma concentration of dronedarone—avoid concomitant use; rifampicin accelerates metabolism of propafenone (reduced effect).

- Antibacterials: rifamycins reduce plasma concentration of clarithromycin and dapsone; plasma concentration of rifabutin increased by clarithromycin (increased risk of uveitis—reduce rifabutin dose); rifampicin reduces plasma concentration of doxycycline—consider increasing dose of doxycycline; rifampicin accelerates metabolism of chloramphenicol (reduced plasma concentration); rifampicin reduces plasma concentration of linezolid (possible therapeutic failure of linezolid); plasma concentration of rifabutin possibly increased by macrolides (increased risk of uveitis—reduce rifabutin dose); rifampicin reduces plasma concentration of telithromycin (avoid during and for 2 weeks after rifampicin); rifampicin possibly plasma concentration of trimethoprim.

- Anticoagulants: rifamycins accelerate metabolism of coumarins (reduced anticoagulant effect); rifampicin reduces plasma concentration of rivaroxaban.

- Antidiabetics: rifamycins accelerate metabolism of tolbutamide (reduced effect); rifampicin reduces plasma concentration of nateglinide; rifampicin possibly antagonises hypoglycaemic effect of repaglinide; rifamycins possibly accelerate metabolism of nilotinib (reduced effect).
Appendix 1: Interactions

### Rifamycins (continued)

- **Antiepileptics:** rifabutin reduces plasma concentration of carbamazepine; rifampicin reduces plasma concentration of lamotrigine; rifamycins accelerate metabolism of ethosuximide (reduced plasma concentration).

- **Antifungals:** rifampicin accelerates metabolism of ketoconazole and itraconazole (reduced plasma concentration); rifabutin reduces plasma concentration of itraconazole—avoid concomitant use; plasma concentration of rifabutin increased by posaconazole (also plasma concentration of posaconazole reduced); rifampicin reduces plasma concentration of posaconazole and eritromicina; plasma concentration of rifabutin increased by voriconazole, also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity); rifampicin reduces plasma concentration of voriconazole—avoid concomitant use; rifampicin initially increases and then reduces plasma concentration of caspofungin (consider increasing dose of caspofungin); plasma concentration of rifabutin possibly increased by triazoles (increased risk of uveitis—reduce rifabutin dose).

- **Antihistamines:** rifampicin possibly reduces effects of fexofenadine.

- **Antimalarials:** rifampicin reduces plasma concentration of mefloquine—avoid concomitant use; rifampicin reduces plasma concentration of equinone.

- **Antimicrobials:** rifampicin reduces plasma concentrations of active metabolite of fosfomycin.

- **Antipsychotics:** rifampicin accelerates metabolism of haloperidol (reduced plasma concentration); rifabutin and rifampicin possibly reduce plasma concentration of aripiprazole—increase dose of aripiprazole; rifampicin possibly reduces plasma concentration of clozapine.

- **Antivirals:** rifampicin possibly reduces plasma concentration of aciclovir and ritonavir; rifampicin reduces plasma concentration of atazanavir, lopinavir and saquinavir—avoid concomitant use; plasma concentration of rifampicin increased by atazanavir, darunavir, fosamprenavir and tipranavir (reduce dose of rifabutin); rifampicin significantly reduces plasma concentration of darunavir, fosamprenavir and nelfinavir—avoid concomitant use; plasma concentration of rifabutin reduced by efavirenz—increase dose of rifabutin; rifampicin reduces plasma concentration of efavirenz—increase dose of efavirenz; plasma concentration of both drugs reduced when rifabutin given with etravirine; avoidance of rifampicin advised by manufacturer of etravirine and zidovudine; rifampicin accelerates metabolism of indinavir (reduced plasma concentration—avoid concomitant use); plasma concentration of rifabutin increased by indinavir—avoid concomitant use; rifampicin reduces plasma concentration of maraviroc and raltegravir—consider increasing dose of maraviroc and raltegravir; plasma concentration of rifabutin increased by nelfinavir (halve dose of rifabutin); plasma concentration of rifabutin possibly increased by nevirapine; plasma concentration of rifabutin increased by ritonavir (increased risk of toxicity); rifampicin significantly reduces plasma concentration of saquinavir, also risk of hepatotoxicity—avoid concomitant use; plasma concentration ofrifabutin increased by saquinavir (also plasma concentration of saquinavir reduced); rifampicin possibly reduces plasma concentration of tipranavir—avoid concomitant use.

### Rifamycins (continued)

- **Anxiolytics and Hypnotics:** rifampicin accelerates metabolism of diazepam (reduced plasma concentration); rifampicin possibly accelerates metabolism of benzodiazepines (reduced plasma concentration); rifampicin possibly accelerates metabolism of buspirone and zaleplon; rifampicin accelerates metabolism of zolpidem (reduced plasma concentration and reduced effect); rifampicin significantly reduces plasma concentration of zopiclone.

- **Antituberculosis:** rifampicin reduces plasma concentration of aprepitant.

- **Barbiturates:** plasma concentration of rifampicin possibly reduced by phenobarbital.

- **Beta-blockers:** rifampicin accelerates metabolism of bisoprolol and propranolol (plasma concentration significantly reduced); rifampicin reduces plasma concentration of carvedilol, celiprolol and metoprolol.

- **Beta-blockers:** bosentan: rifampicin reduces plasma concentration of bosentan—avoid concomitant use.

- **Calcium-channel Blockers:** rifampicin possibly accelerates metabolism of isradipine and nifedipine (possibly significantly reduced plasma concentration); rifampicin accelerates metabolism of etilsazem, nifedipine, nimohipidone and everapamol (plasma concentration significantly reduced).

- **Cardiac Glycosides:** rifampicin possibly reduces plasma concentration of digoxin.

- **Ciclosporin:** rifampicin accelerates metabolism of ciclosporin (reduced plasma concentration).

- **Corticosteroids:** rifampicin accelerates metabolism of dexamethasone (reduced plasma concentration; avoid concomitant use); rifampicin accelerates metabolism of erlotinib and sunitinib (reduced plasma concentration); rifampicin reduces plasma concentration of everolimus and sorafenib; rifampicin reduces plasma concentration of gefitinib, imatinib and milotinib—avoid concomitant use; avoidance of ritabutin and rifampicin advised by manufacturer of lapatinib; avoidance of rifampicin advised by manufacturer of pazopanib; rifampicin reduces plasma concentration of active metabolite of temsirolimus—avoid concomitant use; rifampicin possibly reduces plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use.

- **Deferasirox:** rifampicin reduces plasma concentration of deferasirox.

- **Diuretics:** rifampicin reduces plasma concentration of eplerenone—avoid concomitant use.

- **Hormone Antagonists:** rifampicin possibly reduces plasma concentration of exemestane; rifampicin accelerates metabolism of tamoxifen (reduced plasma concentration).

- **HIV, Antagonists:** rifampicin accelerates metabolism of ondasertron (reduced effect).

- **Lefunomide:** rifampicin possibly increases plasma concentration of active metabolite of lefunomide.

- **Lipid-regulating Drugs:** rifampicin possibly reduces plasma concentration of atorvastatin and simvastatin; rifampicin accelerates metabolism of fluvastatin (reduced effect).

- **Mycophenolate:** rifampicin reduces plasma concentration of active metabolite of mycophenolate.

- **Oestrogens:** rifampicin accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495).

- **Progestogens:** rifampicin accelerates metabolism of progestogens (reduced contraceptive effect—see p. 495).
BNF 61

Appendix 1: Interactions 875

Rifamycins (continued)
- Tadalafil: rifampicin reduces plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use.
- Rosuvastatin: rifampicin reduces plasma concentration of rosvastatin—consider increasing dose of rosvu-
- Sirolimus: rifabutin and rifampicin reduce plasma concentration of sirolimus—avoid concomitant use.
- Tacrolimus: rifabutin possibly reduces plasma concentration of tacrolimus; rifampicin reduces plasma concentration of tacrolimus.
- Tadalafil: rifampicin reduces plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use.

Ritonavir
- Antidepressants (continued): plasma concentration of trazodone (increased risk of toxicity); ritonavir possibly increases plasma concentration of SSRIAs and SNRIs—avoid concomitant use.
- Antidiabetics: ritonavir possibly increases plasma concentration of tolbutamide.
- Antiepileptics: ritonavir possibly increases plasma concentration of carbamazepine; ritonavir possibly reduces plasma concentration of lamotrigine; plasma concentration of ritonavir possibly reduced by phenytoin, also plasma concentration of phenytoin possibly affected.
- Antifungals: combination of ritonavir with itraconazole or ketoconazole may increase plasma concentration of either drug (or both); plasma concentration of ritonavir increased by fluconazole; ritonavir reduces plasma concentration of voriconazole—avoid concomitant use.
- Antimalarials: caution with ritonavir advised by manufacturer of arteether/lumefantrine; ritonavir increases plasma concentration of equinone (increased risk of toxicity).
- Antimuscarnics: avoidance of ritonavir advised by manufacturer of darifenacin and tolterodine; manu-
- Antipsychotics: ritonavir possibly increases plasma concentration of antipsychotics; ritonavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole); ritonavir increases plasma concentration of olanzapine (increased risk of toxicity)—avoid concomitant use; ritonavir reduces plasma concentration of olanzapine—consider increasing dose of olanzapine; ritonavir increases plasma concentration of pimozide (increased risk of ventricular arrhyth-
- Antivirals: ritonavir increases toxicity of efavirenz, monitor liver function tests; ritonavir increases plasma concentration of indinavir, maraviroc and saquinavir; combination of ritonavir with nevirapine may increase plasma concentration of either drug (or both).
- Anxiolytics and Hypnotics: ritonavir possibly increases plasma concentration of anxiolytics and hypnotics; ritonavir possibly increases plasma concentration of alprazolam, diazepam, flurazepam and zolpidem (risk of extreme sedation and respiratory depression—avoid concomitant use); ritonavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of oral midazolam); ritonavir increases plasma concentration of buspirone (increased risk of toxicity).
- Antihypertensives: ritonavir possibly increases plasma concentration of aprepiant.
- Bacteriostatic: ritonavir possibly increases plasma concentration of fosfomycin.
- Bupropion: ritonavir reduces plasma concentration of bupropion.
- Calcium-channel Blockers: ritonavir possibly increases plasma concentration of calcium-channel blockers; avoidance of ritonavir advised by manu-
- Cardiac Glycosides: ritonavir possibly increases plasma concentration of digoxin.
- Colchicine: ritonavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).
Ritonavir (continued)

- Corticosteroids: ritonavir possibly increases plasma concentration of corticosteroids, dexamethasone and prednisolone; ritonavir increases plasma concentration of inhaled and intranasal budesonide and fluicasone.
- Cytoxicants: ritonavir possibly increases plasma concentration of etorofurilum and enalaprilat—manufacturer of enalaprilat and vasopressin advises avoid concomitant use; avoidance of ritonavir advised by manufacturer of lopatatinib, sitotatinib and pazopanib; ritonavir possibly plasma concentration of diuretics (increased risk of toxicity); ritonavir increases plasma concentration of paclitaxel; ritonavir possibly increases plasma concentration of vinblamine.
- Diuretics: ritonavir increases plasma concentration of spironolactone—avoid concomitant use.
- Ergot Alkaloids: increased risk of ergotism when ritonavir with ergotamine and methylergometrine—avoid concomitant use.
- SHT, Agonists: ritonavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use.
- Ibraprodine: ritonavir possibly increases plasma concentration of vardenafil—avoid concomitant use.
- Lipid-regulating Drugs: possible increased risk of myopathy when ritonavir with atorvastatin; possible increased risk of myopathy when ritonavir with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when ritonavir with simvastatin (avoid concomitant use).
- Oestrogens: ritonavir accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495).
- Ranolazine: ritonavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use.
- Sildenafil: ritonavir significantly increases plasma concentration of sildenafil—avoid concomitant use.
- Tacrolimus: ritonavir possibly increases plasma concentration of tacrolimus.
- Tadalafil: ritonavir increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use.
- Theophylline: ritonavir accelerates metabolism of theophylline (reduced plasma concentration).
- Ulipristal: avoidance of ritonavir advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced).
- Vardenafil: ritonavir increases plasma concentration of vardenafil—avoid concomitant use.

Rivaroxaban

- Analgesics: increased risk of haemorrhage when anticoagulants given with intravenous diclofenac (avoid concomitant use, including low-dose heparins); increased risk of haemorrhage when anticoagulants given with ketorolac (avoid concomitant use, including low-dose heparins).
- Antibacterials: plasma concentration of rivaroxaban reduced by rifampicin.
- Antifungals: plasma concentration of rivaroxaban increased by ketoconazole (avoid concomitant use; manufacturer of rivaroxaban advises avoid concomitant use with iraconazole, posaconazole and voriconazole).
- Antivirals: manufacturer of ravigoxaban advises avoid concomitant use with atazanavir, darunavir and fosamprenavir, indinavir, lopinavir, nelfinavir, saquinavir and tipranavir; plasma concentration of ravigoxaban increased by ritonavir—manufacturer of ravigoxaban advises avoid concomitant use.

Rivastigmine see Parasympathomimetics

Rizatriptan see SHT, Agonists

Rocuronium see Muscle Relaxants

Roflumilast

- Antibacterials: plasma concentration of roflumilast reduced by rifampicin—consider increasing dose of roflumilast.
- Antidepressants: metabolism of roflumilast inhibited by fluvoxamine.
- Theophylline: manufacturer of roflumilast advises avoid concomitant use with theophylline.
- Ulcer-healing Drugs: metabolism of roflumilast inhibited by cimetidine.

Ropinorole

- Antibacterials: metabolism of ropinorrole inhibited by ciprofloxacin (increased plasma concentration).
- Antipsychotics: manufacturer of ropinorrole advises avoid concomitant use of antipsychotics (antagonism of effect).
- Memantine: effects of dopaminergics possibly enhanced by memantine.
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa.
- Metoclopramide: manufacturer of ropinorrole advises avoid concomitant use of metoclopramide (antagonism of effect).
- Oestrogens: plasma concentration of ropinorrole increased by oestrogens.

Ropivacaine

- Anti-arrhythmics: increased myocardial depression when ropivacaine given with anti-arrhythmics.
- Antipsychotics: metabolism of ropivacaine inhibited by fluvoxamine—avoid prolonged administration of ropivacaine.

Rosuvastatin see Statins

Rotigotine

- Antipsychotics: manufacturer of rotigotine advises avoid concomitant use of antipsychotics (antagonism of effect).
- Memantine: effects of dopaminergics possibly enhanced by memantine.
- Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa.
- Metoclopramide: manufacturer of rotigotine advises avoid concomitant use of metoclopramide (antagonism of effect).

Rufinamide

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St. John’s wort.
- Antiepileptics: plasma concentration of both drugs possibly reduced when rufinamide given with carbamazepine; plasma concentration of rufinamide possibly reduced by phenytoin, also plasma concentration of phenytoin possibly increased; plasma concentration of rufinamide possibly reduced by primidone; plasma concentration of rufinamide possibly increased by valproate (reduce dose of rufinamide).
- Antiarrhythmics: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by mefloquine.

Barbiturates: plasma concentration of rufinamide possibly reduced by phenobarbital, also plasma concentration of phenobarbital possibly increased.
- Oestrogens: rufinamide accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495).
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat.
- Progestogens: rufinamide accelerates metabolism of progestogens (reduced contraceptive effect—see p. 495).

Rupatadine see Antihistamines.
BNF 61

Appendix 1: Interactions 877

St John's Wort
Analgesics: St John's wort possibly reduces plasma concentration of methadone

Anti-arrhythmics: St John's wort possibly reduces plasma concentration of "erodenedaron"—avoid concomitant use

Antibacterials: St John's wort reduces plasma concentration of "elithromycin" (avoid during and for 2 weeks after St John's wort)

Anticoagulants: St John's wort reduces anticoagulant effect of coumarins (avoid concomitant use)

Antidepressants: possible increased serotonergic effects when St John's wort given with "duloxetine" or venlafaxine; St John's wort reduces plasma concentration of amitriptyline; increased serotonergic effects when St John's wort given with "SSRIs"—avoid concomitant use

Antiepileptics: avoid concomitant use of St John's wort with antiepileptics

Antifungals: St John's wort possibly reduces plasma concentration of "aripiprazole"—increase dose of aripiprazole

Antivirals: St John's wort reduces plasma concentration of "azazanavir", "darunavir", "efavirenz", "fosamprenavir", "indinavir", "lopinavir", "nelfinavir", "nevirapine", "ritonavir" and "saquinavir"—avoid concomitant use; St John's wort possibly reduces plasma concentration of "maraviroc" and "etripivar"—avoid concomitant use

Antivirals: plasma concentration of saquinavir increased when saquinavir given with "atovaquone"; increased risk of ventricular arrhythmias when saquinavir given with "claritythromycin","dapsone" or "erythromycin"—avoid concomitant use; saquinavir increases plasma concentration of "rifabutin" (also plasma concentration of saquinavir reduced); plasma concentration of saquinavir significantly reduced by "rifampicin", also risk of hepatotoxicity—avoid concomitant use, avoidance of concomitant saquinavir in severe renal and hepatic impairment advised by manufacturer of "elithromycin"

Anticoagulants: saquinavir possibly enhances anti-coagulant effect of warfarin; avoidance of saquinavir advised by manufacturer of rivaroxaban

Antidepressants: increased risk of ventricular arrhythmias when saquinavir given with "clarithromycin", "dapsone" or "erythromycin"—avoid concomitant use; plasma concentration of saquinavir reduced by St John's wort—avoid concomitant use

Antiepileptics: plasma concentration of saquinavir possibly reduced when carbamazepine, phenytoin and primidone

Antifungals: plasma concentration of saquinavir increased by "ketocanazole"; plasma concentration of saquinavir possibly increased by "imidazoles" and "triazoles"

Antihistamines: increased risk of ventricular arrhythmias when saquinavir given with "mizolactam"—avoid concomitant use

Antimalarial: caution with saquinavir advised by manufacturer of "artemether/lumefantrine"; increased risk of ventricular arrhythmias when saquinavir given with "quinine"—avoid concomitant use

Antimuscarinics: avoidance of saquinavir advised by manufacturer of "dabrafenin" and "tolterodine"; manufacturer of "darifenacin" and "tolterodine"; manufacturer of saquinavir advises avoid concomitant use; saquinavir increases plasma concentration of "pimozide" (increased risk of ventricular arrhythmias—avoid concomitant use)

Antivirals: increased risk of ventricular arrhythmias when saquinavir given with "lozacrine", "lapidinavir", "haloperidol" or "phenothiazines"—avoid concomitant use; saquinavir possibly inhibits metabolism of "aripiprazole"; saquinavir possibly increases plasma concentration of "pimozide" (increased risk of ventricular arrhythmias—avoid concomitant use)

Antivirals: increased risk of ventricular arrhythmias when saquinavir given with "atovaquone"; saquinavir reduces plasma concentration of "darunavir"; plasma concentration of saquinavir significantly reduced by "efavirenz"; plasma concentration of saquinavir increased by "indinavir" and "ritonavir"; saquinavir increases plasma concentration of "maraviroc" (consider reducing dose of maraviroc); plasma concentration of saquinavir increased by "nelfinavir" or manufacturer of saquinavir advises avoid concomitant use; plasma concentration of saquinavir reduced by "etripivar"

Antialcoholics and Hypnotics: saquinavir increases plasma concentration of "midazolam" (risk of pro-
Appendix 1: Interactions

**Sildenafil**
- **Antidepressants**: 
  - **continued**
  - with paroxetine (sildenafil should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping sildenafil); enhanced hypotensive effect when sildenafil given with MAOIs—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of selegiline with moclobemide; CNS toxicity reported when sildenafil given with citalopram and escitalopram
  - Dopaminergics: max. dose of 10 mg selegiline advised by manufacturer of entacapone if used concomitantly; selegiline enhances effects and increases toxicity of levodopa (additive increase of levodopa) 5HT, Agonists: manufacturer of selegiline advises avoid concomitant use with 5HT, agonists
  - Memantine: effects of dopaminergics and selegiline possibly enhanced by memantine
  - Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa
- **Oestrogens**: plasma concentration of selegiline increased by oestrogens—manufacturer of selegiline advises avoid concomitant use
- **Progestogens**: plasma concentration of selegiline increased by progestogens—manufacturer of selegiline advises avoid concomitant use
- **Sympathomimetics**: risk of hypertensive crisis when selegiline given with dopamine

**Selenium**
- Eltrombopag: selenium possibly reduces absorption of eltrombopag (give at least 4 hours apart)
- Vitamins: absorption of selenium possibly reduced by ascorbic acid (give at least 4 hours apart)

**Sertraline** see Antidepressants, SSRI

**Selevanin**
- **Antibacterials**: selevanin reduces bioavailability of ciprofloxacin
  - Ciclosporin: selevanin possibly reduces plasma concentration of ciclosporin
  - Mycophenolate: selevanin possibly reduces plasma concentration of mycophenolate
  - Tacrolimus: selevanin possibly reduces plasma concentration of tacrolimus
- **Thyroid Hormones**: selevanin possibly reduces absorption of levothyroxine

**Sevoflurane** see Anaesthetics, General

**Sildenafil**
- **Alpha-blockers**: enhanced hypotensive effect when sildenafil given with alpha-blockers for 4 hours after sildenafil—see also p. 515
- **Antibacterials**: plasma concentration of sildenafil possibly increased by clarithromycin and telithromycin—reduce initial dose of sildenafil; plasma concentration of sildenafil significantly increased by erythromycin—reduce initial dose of sildenafil
- **Antifungals**: plasma concentration of sildenafil increased by itraconazole and ketoconazole—reduce initial dose of sildenafil
- **Antivirals**: side-effects of sildenafil possibly increased by azithromycin; plasma concentration of sildenafil reduced by etravirine; plasma concentration of sildenafil possibly increased by fosamprenavir; plasma concentration of sildenafil increased by indinavir—reduce initial dose of sildenafil; plasma concentration of sildenafil possibly increased by nelfinavir—reduce initial dose of sildenafil; plasma concentration of sildenafil significantly increased by ritonavir—avoid concomitant use; increased risk of ventricular arrhythmias when sildenafil given with saquinavir—avoid concomitant use

**Bosentan**: plasma concentration of sildenafil reduced by bosentan
- Calcium-channel Blockers: enhanced hypotensive effect when sildenafil given with amlopidine
- Grapefruit Juice: plasma concentration of sildenafil possibly increased by grapefruit juice

---

**Serefrin** see Antidepressants, SSRI

**Selenium**
- Eltrombopag: selenium possibly reduces absorption of eltrombopag (give at least 4 hours apart)
- Vitamins: absorption of selenium possibly reduced by ascorbic acid (give at least 4 hours apart)

**Sildenafil**
- **Antidepressants**: 
  - **continued**
  - with paroxetine (sildenafil should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping sildenafil); enhanced hypotensive effect when sildenafil given with MAOIs—manufacturer of selegiline advises avoid concomitant use; avoid concomitant use of selegiline with moclobemide; CNS toxicity reported when sildenafil given with citalopram and escitalopram
  - Dopaminergics: max. dose of 10 mg selegiline advised by manufacturer of entacapone if used concomitantly; selegiline enhances effects and increases toxicity of levodopa (additive increase of levodopa) 5HT, Agonists: manufacturer of selegiline advises avoid concomitant use with 5HT, agonists
  - Memantine: effects of dopaminergics and selegiline possibly enhanced by memantine
  - Methyldopa: antiparkinsonian effect of dopaminergics antagonised by methyldopa
- **Oestrogens**: plasma concentration of selegiline increased by oestrogens—manufacturer of selegiline advises avoid concomitant use
- **Progestogens**: plasma concentration of selegiline increased by progestogens—manufacturer of selegiline advises avoid concomitant use
- **Sympathomimetics**: risk of hypertensive crisis when selegiline given with dopamine

**Selenium**
- Eltrombopag: selenium possibly reduces absorption of eltrombopag (give at least 4 hours apart)
- Vitamins: absorption of selenium possibly reduced by ascorbic acid (give at least 4 hours apart)

**Sertraline** see Antidepressants, SSRI

**Selevanin**
- **Antibacterials**: selevanin reduces bioavailability of ciprofloxacin
  - Ciclosporin: selevanin possibly reduces plasma concentration of ciclosporin
  - Mycophenolate: selevanin possibly reduces plasma concentration of mycophenolate
  - Tacrolimus: selevanin possibly reduces plasma concentration of tacrolimus
- **Thyroid Hormones**: selevanin possibly reduces absorption of levothyroxine

**Sevoflurane** see Anaesthetics, General

**Sildenafil**
- **Alpha-blockers**: enhanced hypotensive effect when sildenafil given with alpha-blockers for 4 hours after sildenafil—see also p. 515
- **Antibacterials**: plasma concentration of sildenafil possibly increased by clarithromycin and telithromycin—reduce initial dose of sildenafil; plasma concentration of sildenafil significantly increased by erythromycin—reduce initial dose of sildenafil
- **Antifungals**: plasma concentration of sildenafil increased by itraconazole and ketoconazole—reduce initial dose of sildenafil
- **Antivirals**: side-effects of sildenafil possibly increased by azithromycin; plasma concentration of sildenafil reduced by etravirine; plasma concentration of sildenafil possibly increased by fosamprenavir; plasma concentration of sildenafil increased by indinavir—reduce initial dose of sildenafil; plasma concentration of sildenafil possibly increased by nelfinavir—reduce initial dose of sildenafil; plasma concentration of sildenafil significantly increased by ritonavir—avoid concomitant use; increased risk of ventricular arrhythmias when sildenafil given with saquinavir—avoid concomitant use

**Bosentan**: plasma concentration of sildenafil reduced by bosentan
- Calcium-channel Blockers: enhanced hypotensive effect when sildenafil given with amlopidine
- Grapefruit Juice: plasma concentration of sildenafil possibly increased by grapefruit juice

---

**Serefrin** see Antidepressants, SSRI

**Selenium**
- Eltrombopag: selenium possibly reduces absorption of eltrombopag (give at least 4 hours apart)
- Vitamins: absorption of selenium possibly reduced by ascorbic acid (give at least 4 hours apart)
Sildenafil (continued)
- Nicardipine: sildenafil significantly enhances hypotensive effect of nicardipine (avoid concomitant use)
- Nitrates: sildenafil significantly enhances hypotensive effect of nitrates (avoid concomitant use)

Ulcer-healing Drugs: plasma concentration of sildenafil increased by cimetidine (consider reducing dose of sildenafil)

Simvastatin see Statins

Sodium

Anti-arrhythmics: caution with sodium advised by manufacturer of dronedarone

Antibacterials: plasma concentration of sirolimus increased by clarithromycin and telithromycin—avoid concomitant use; plasma concentration of both drugs increased when sirolimus given with erythromycin; plasma concentration of sirolimus reduced by rifabutin and rifampicin—avoid concomitant use

Antifungals: plasma concentration of sirolimus increased by itraconazole, ketoconazole and voriconazole—avoid concomitant use; plasma concentration of sirolimus increased by miconafungin and micafungin; plasma concentration of sirolimus possibly increased by posaconazole

Antivirals: plasma concentration of sirolimus possibly increased by abacavir and dolutegravir

Calcium-channel Blockers: plasma concentration of sirolimus increased by diltiazem; plasma concentration of both drugs increased when sirolimus given with verapamil

Ciclosporin: plasma concentration of sirolimus increased by cyclosporin

Grapefruit Juice: plasma concentration of sirolimus increased by grapefruit juice—avoid concomitant use

Sitagliptin see Antidiabetics

Sitaxentan
- Anticoagulants: sitaxentan enhances anticoagulant effect of warfarin; fluvastatin and atorvastatin increased by telithromycin; atorvastatin and simvastatin possibly reduced by rifampicin
- Anticoagulants: sitaxentan increases plasma concentration of pravastatin reduced by atorvastatin and simvastatin possibly reduced by rifampicin
- Anticoagulants: sitaxentan increases plasma concentration of oestrogens possibly increased by rifampicin
- Anticoagulants: sitaxentan increases plasma concentration of progestogens increased by progesterone
- ACE Inhibitors: flushing and hypotension reported when sodium aurothiomalate given with ACE inhibitors
- Penicillamine: avoidance of sodium aurothiomalate advised by manufacturer of penicillamine (increased risk of toxicity)

Sodium Benzoate
- Antiepileptics: effects of sodium benzoate possibly reduced by valproate
- Antipsychotics: effects of sodium benzoate possibly reduced by haloperidol
- Corticosteroids: effects of sodium benzoate possibly reduced by corticosteroids
- Probenecid: excretion of conjugate formed by sodium benzoate possibly reduced by probenecid

Sodium Bicarbonate see Antacids

Sodium Citrate
- Anticoagulants: avoid concomitant use of sodium citrate with methenamine
- Sodium Citraconate see Bisphosphonates

Sodium Nitroprusside see Vasodilators Anti-hypertensives

Sodium Oxalate
- Analgesics: effects of sodium oxalate enhanced by opioid analgesics (avoid concomitant use)
- Antidepressants: increased risk of side-effects when sodium oxalate given with tricyclics
- Antipsychotics: effects of sodium oxalate possibly enhanced by antipsychotics

Sodium Oxybate (continued)
- Anxiolytics and Hypnotics: effects of sodium oxybate enhanced by benzodiazepines (avoid concomitant use)
- Barbiturates: effects of sodium oxybate enhanced by barbiturates (avoid concomitant use)

Sodium Phenylbutyrate
- Antiepileptics: effects of sodium phenylbutyrate possibly reduced by valproate
- Antipsychotics: effects of sodium phenylbutyrate possibly reduced by haloperidol
- Corticosteroids: effects of sodium phenylbutyrate possibly reduced by corticosteroids
- Probenecid: excretion of conjugate formed by sodium phenylbutyrate possibly reduced by probenecid

Sodium Valproate see Valproate

Solifenacin see Antimuscarinics

Somatropin
- Corticosteroids: growth-promoting effect of somatropin may be inhibited by corticosteroids
- Oestrogens: increased doses of somatropin may be needed when given with oestrogens (when used as oral replacement therapy)

Sorafenib
- Anticoagulants: sorafenib possibly enhanced anticoagulant effect of coumarins
- Antiepileptics: cytoxics possibly reduce absorption of phenytoin
- Antipsychotics: avoid concomitant use of cytoxics with doxaprine (increased risk of agranulocytosis)
- Cardiac Glycosides: cytoxics reduce absorption of digoxin tablets
- Cytotoxics: sorafenib possibly increases plasma concentration of doxorubicin and irinotecan; sorafenib increases plasma concentration of docetaxel

Sotalol see Beta-blockers

Spiropionolactone see Diuretics

Statins
- Antacids: absorption of rosuvastatin reduced by antacids
- Anti-arrhythmics: increased risk of myopathy when simvastatin given with amiodarone or dronedarone
- Anticoagulants: plasma concentration of atorvastatin and pravastatin increased by clarithromycin; increased risk of myopathy when simvastatin given with clarithromycin, erythromycin or telithromycin (avoid concomitant use); plasma concentration of rosuvastatin reduced by erythromycin; possible increased risk of myopathy when atorvastatin given with erythromycin or fusidic acid; plasma concentration of pravastatin increased by erthyromycin; plasma concentration of atorvastatin and simvastatin possibly reduced by rifampicin; metabolism of fluvastatin accelerated by rifampicin (reduced effect); increased risk of myopathy when statins given with daptomycin (preferably avoid concomitant use); increased risk of myopathy when simvastatin given with fusidic acid; possible increased risk of myopathy when pravastatin given with telithromycin; increased risk of myopathy when atorvastatin given with telithromycin (avoid concomitant use)
- Anticoagulants: atorvastatin may transiently reduce anticoagulant effect of warfarin; fluvastatin and simvastatin enhance anticoagulant effect of coumarins; rosuvastatin possibly enhances anticoagulant effect of coumarins and phenindione
- Antidepressants: plasma concentration of simvastatin reduced by St John’s wort
- Antidiabetics: fluvastatin possibly increases plasma concentration of glibenclamide
- Antiepileptics: plasma concentration of simvastatin reduced by carbamazepine—consider increasing dose of simvastatin; combination of fluvastatin with
Appendix 1: Interactions

Statins
- Antiepileptics (continued) phenoxybenzamine may increase plasma concentration of either drug (or both)
- Antifungals: increased risk of myopathy when simvastatin given with ketoconazole, itraconazole, fluconazole, posaconazole (avoid concomitant use); possible increased risk of myopathy when simvastatin given with niacin (avoid concomitant use); plasma concentration of fluvastatin increased by fluconazole; increased risk of myopathy when atorvastatin given with ketoconazole or posaconazole (avoid concomitant use); possible increased risk of myopathy when atorvastatin given with itraconazole or ketoconazole (avoid concomitant use); possible increased risk of myopathy when atorvastatin or simvastatin given with imidazoles; possible increased risk of myopathy when atorvastatin or simvastatin given with triazoles
- Antivirals; possible increased risk of myopathy when atorvastatin given with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, and saquinavir—manufacturer of rosuvastatin advises avoid concomitant use; increased risk of myopathy when simvastatin given with atazanavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir or saquinavir; plasma concentration of pravastatin possibly increased by darunavir; plasma concentration of atorvastatin, pravastatin and simvastatin reduced by efavirenz; plasma concentration of atorvastatin possibly reduced by etravirine; possible increased risk of myopathy when simvastatin given with atazanavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir or saquinavir; plasma concentration of pravastatin possibly increased by darunavir; plasma concentration of atorvastatin, pravastatin and simvastatin reduced by efavirenz; plasma concentration of atorvastatin possibly reduced by etravirine; possible increased risk of myopathy when simvastatin given with fosamprenavir or lopinavir—avoid concomitant use; plasma concentration of atorvastatin possibly increased by pranavir—avoid concomitant use; plasma concentration of atorvastatin possibly increased by pranavir (consider reducing dose of atorvastatin); plasma concentration of rosuvastatin possibly increased by pranavir—manufacturer of rosuvastatin advises avoid concomitant use
- Bosentan: plasma concentration of simvastatin reduced by bosentan
- Calcium-channel Blockers: possible increased risk of myopathy when simvastatin given with amlodipine; plasma concentration of atorvastatin and simvastatin increased by diltiazem—possible increased risk of myopathy; increased risk of myopathy when simvastatin given with verapamil
- Ciclosporin: increased risk of myopathy when statins given with ciclosporin; increased risk of myopathy when rosuvastatin given with ciclosporin (avoid concomitant use)
- Colchicine: possible increased risk of myopathy when statins given with colchicine
- Cytotoxics: plasma concentration of ciclosporin possibly increased by dasatinib; plasma concentration of simvastatin increased by imatinib
- Eltrombopag: plasma concentration of rosuvastatin increased by eltrombopag (consider reducing dose of rosuvastatin)
- Grapefruit juice: plasma concentration of atorvastatin possibly increased by grapefruit juice; plasma concentration of simvastatin increased by grapefruit juice—avoid concomitant use
- Hormone Antagonists: possible increased risk of myopathy when simvastatin given with danazol
- Lipid-regulating Drugs: increased risk of myopathy when statins given with fenofibrate (preferably avoid concomitant use); increased risk of myopathy when statins given with fibrates; increased risk of myopathy when statins given with niacin (applies to lipid regulating doses of nicotinic acid)
- Oestrogens: atorvastatin and rosuvastatin increase plasma concentration of ethinylestradiol

Antifungals
- Anticoagulants: increased risk of toxicity when stavudine given with danazol; possibly increased risk of toxicity when stavudine given with ribavirin; effects of stavudine possibly inhibited by zidovudine (manufacturers advise avoid concomitant use)
- Cytotxics: effects of stavudine possibly inhibited by doxorubicin, increased risk of toxicity when stavudine given with hydroxy carbamide—avoid concomitant use

Stavudine
- Antivirals: increased risk of side-effects when stavudine given with didanosine; increased risk of toxicity when stavudine given with ribavirin; effects of stavudine possibly inhibited by zidovudine (manufacturers advise avoid concomitant use)
- Cytotoxics: effects of stavudine possibly inhibited by doxorubicin, increased risk of toxicity when stavudine given with hydroxy carbamide—avoid concomitant use

Stiripentol
- Antiepileptics: possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); antiepileptic effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s Wort
- Antiepileptics: stiripentol increases plasma concentration of carbamazepine and phenytoin
- Antimalarias: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of anti-epileptics antagonised by mefloquine
- Anticonvulsants: sulthiame possibly reduces plasma concentration of carbamazep
- Barbiturates: stiripentol increases plasma concentration of phenobarbital
- Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat

Streptomycin see Aminoglycosides

Stromyrtium Ranelate
- Antibacterials: stromyrtium ranelate reduces absorption of quinolones and tetracyclines (manufacturer of stromyrtium ranelate advises avoid concomitant use)

Sucralfate
- Antibacterials: sucralfate reduces absorption of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin and tetracyclines
- Anticoagulants: sucralfate possibly reduces absorption of warfarin (manufacturer of warfarin advises avoid concomitant use)

Sulfadiazine see Sulfonamides
Sulfadoxine see Sulfonamides
Sulfamethoxazole see Sulfonamides
Sulphasalazine see Aminosaliclylates
**Anticoagulants:** effects of sulfinpyrazone antagonised by aspirin

**Antibacterials:** sulfinpyrazone reduces excretion of nitrofurantoin (increased risk of toxicity); sulfinpyrazone reduces excretion of penicillins; effects of sulfinpyrazone antagonised by pyrazinamide

**Anti-coagulants:** sulfinpyrazone enhances anticoagulant effect of coumarins

**Antidiabetics:** sulfinpyrazone enhances effects of oral antidiabetics

**Antiepileptics:** sulfinpyrazone increases plasma concentration of phenytoin

**Ciclosporin:** sulfinpyrazone reduces plasma concentration of ciclosporin

**Theophylline:** sulfinpyrazone reduces plasma concentration of theophylline

**Sulfonamides**

Anaesthetics, General: sulphonamides enhance effects of thiopental

Anaesthetics, Local: increased risk of methaemoglobinemia when sulphonamides given with prilocaine

Anti-arrhythmics: increased risk of ventricular arrhythmias when sulfamethoxazole (as co-trimoxazole) given with amiodarone—avoid concomitant use of co-trimoxazole

Antibacterials: increased risk of crystalluria when sulphonamides given with metmetamidine

Anticoagulants: sulphonamides enhance anticoagulant effect of coumarins; sulphonamides possibly inhibit metabolism of phenindione

Antidiabetics: sulphonamides rarely enhance the effects of sulfonylureas

Antiepileptics: sulphonamides possibly increase plasma concentration of phenytoin

Antimalarials: increased antifolate effect when sulphonamides given with pyrimethamine

**Anticoagulants:** avoid concomitant use of cytotoxics possibly reduce absorption of phenytoin

**Alpha-blockers:** avoid concomitant use of adrenaline (epinephrine) or noradrenaline (norepinephrine) given with clonidine; serious adverse events reported with concomitant use of methylphenidate (pharmacokinetics not established)

**Alcohol:** enhanced vasopressor effect

**Anaesthetics:** sympathomimetics given with doxapram

**Antacids:** effects of antidepressants (SSRIs and tricyclics) antagonised by antipsychotics; dexamfetamine possibly antagonises antipsychotic effects of chlorpromazine; methylphenidate possibly increases side-effects of risperidone

**Antivirals:** plasma concentration of dexamfetamine possibly increased by ritalin

**Antihistamines:** effects of sympathomimetics antagonised by antihistamines

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** increased risk of hypertension when methylphenidate given with volatile liquids

**Antidepressants:** sympathomimetics antagonised by antidepressants

**Antidiabetics:** sympathomimetics antagonised by antidiabetics

**Antihistamines:** sympathomimetics antagonised by antihistamines

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives

**Antipsychotics:** sympathomimetics antagonised by antipsychotics

**Anticoagulants:** sympathomimetics antagonised by anticoagulants

**Antihypertensives:** sympathomimetics antagonised by antihypertensives
Antibacterials: metabolism of salmefoterol inactivated by ketoconazole (increased plasma concentration)

Atomoxetine: increased risk of cardiovascular side-effects when paroxetine and salbutamol given with atomoxetine

Cardiac Glycosides: increased risk of hypokalaemia when high doses of beta, sympathomimetics given with corticosteroids—see Hypokalaemia, p. 176

Diuretics: increased risk of hypokalaemia when high doses of beta, sympathomimetics given with acetazolamide, loop diuretics and thiazides and related diuretics—see Hypokalaemia, p. 176

Methyldopa: acute hypotension reported when infusion of salbutamol given with methyldopa

Muscle relaxants: bantualone enhances effects of suxamethonium

Theophylline: increased risk of hypokalaemia when high doses of beta, sympathomimetics given with theophylline—see Hypokalaemia, p. 176

Tacrolimus

Note: Interactions do not generally apply to tacrolimus used topically. topical risk of facial flushing and skin irritation with alcohol consumption (p. 722) does not apply to tacrolimus taken systemically

Analgesics: possible increased risk of nephrotoxicity when tacrolimus given with NSAIDs; increased risk of nephrotoxicity when tacrolimus given with ibuprofen

Angiotensin-II Receptor Antagonists: no increased risk of nephrotoxicity when tacrolimus given with angiotensin-II receptor antagonists

Anti-arrhythmics: caution with tacrolimus advised by manufacturer of dronedarone

Antibacterials: plasma concentration of tacrolimus increased by clarithromycin and erythromycin; plasma concentration of tacrolimus possibly reduced by rifabutin; increased risk of nephrotoxicity when tacrolimus given with aminoglycosides; plasma concentration of tacrolimus possibly increased by chloramphenicol and miltefosin; possible increased risk of nephrotoxicity when tacrolimus given with vancomycin

Antidepressants: plasma concentration of tacrolimus reduced by St John's wort—avoid concomitant use

Antiepileptics: plasma concentration of tacrolimus reduced by phenytoin, also plasma concentration of phenytoin possibly increased

Antifungals: plasma concentration of tacrolimus increased by fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole (consider reducing dose of tacrolimus); increased risk of nephrotoxicity when tacrolimus given with amphotericin; plasma concentration of tacrolimus reduced by espofungin; plasma concentration of tacrolimus possibly increased by midazoles

Antipsychotics: avoidance of tacrolimus advised by manufacturer of droperidol (risk of venicular arrhythmias)

Antivirals: possible increased risk of nephrotoxicity when tacrolimus given with aciclovir or ganciclovir; plasma concentration of tacrolimus possibly increased by azidovir or zidovir; plasma concentration of tacrolimus possibly affected by revir; plasma concentration of tacrolimus increased by fosamprenavir; plasma concentration of tacrolimus increased by saquinavir (consider reducing dose of tacrolimus)

Barbiturates: plasma concentration of tacrolimus reduced by phenobarbitol

Calcium-channel Blockers: plasma concentration of tacrolimus possibly increased by felodipine, nicardipine and verapamil; plasma concentration of tacrolimus increased by alitazem and nifedipine

Tacrolimus

(continued)

Ciclosporin: tacrolimus increases plasma concentration of ciclosporin (increased risk of nephrotoxicity—avoid concomitant use)

Diuretics: increased risk of hyperkalaemia when tacrolimus given with potassium-sparing diuretics and aldosterone antagonists

Grapefruit Juice: plasma concentration of tacrolimus increased by grapefruit juice

Hormone Antagonists: plasma concentration of tacrolimus possibly increased by danazol

Mifamurtide: avoidance of tacrolimus advised by manufacturer of mifamurtide

Oestrogens: plasma concentration of tacrolimus possibly increased by ethinylestradiol

Potassium Salts: increased risk of hyperkalaemia when tacrolimus given with potassium salts

Sevelamer: plasma concentration of tacrolimus possibly reduced by sevelamer

Ulcer Healing Drugs: plasma concentration of tacrolimus possibly increased by omeprazole

Tadalafil

Alpha-blockers: enhanced hypertensive effect when tadalafil given with doxazosin—manufacturer of tadalafil advises avoid concomitant use; enhanced hypertensive effect when tadalafil given with alpha-blockers—see also p. 515

Antibacterials: plasma concentration of tadalafil possibly increased by clarithromycin and erythromycin; plasma concentration of tadalafil reduced by rifampicin—manufacturer of tadalafil advises avoid concomitant use

Antivirals: plasma concentration of tadalafil possibly increased by fosamprenavir and indinavir; plasma concentration of tadalafil increased by ritonavir—manufacturer of tadalafil advises avoid concomitant use; increased risk of venicular arrhythmias when tadalafil given with saquinavir—avoid concomitant use

Bosentan: plasma concentration of tadalafil reduced by bosentan

Grapefruit Juice: plasma concentration of tadalafil possibly increased by grapefruit juice

Nicarandil: tadalafil significantly enhances hypertensive effect of nicarandil (avoid concomitant use)

Nitrates: tadalafil significantly enhances hypertensive effect of nitrates (avoid concomitant use)

Tamoxifen

Antibacterials: metabolism of tamoxifen accelerated by rifampicin (reduced plasma concentration)

Anticoagulants: tamoxifen enhances anticoagulant effect of coumarins

Antidepressants: metabolism of tamoxifen to active metabolite possibly inhibited by fluoxetine and paroxetine (avoid concomitant use)

Antipsychotics: avoidance of tamoxifen advised by manufacturer of droperidol (risk of venicular arrhythmias)

BuPROPion: metabolism of tamoxifen to active metabolite possibly inhibited by BuPROPion (avoid concomitant use)

CINacalcet: metabolism of tamoxifen to active metabolite possibly inhibited by cinacalcet (avoid concomitant use)

Tamulosin see Alpha-blockers

Taxanes see Docetaxel and Paclitaxel

TeGafur with uraci1 see Fluorouracil

TeCoPlaIn: Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Telbivudine

Interferons: increased risk of peripheral neuropathy when telbivudine given with interferon alfa
Telithromycin

Analgesics: telithromycin inhibits the metabolism of oxycodeone.

- Anti-arrhythmics: avoidance of telithromycin advised by manufacturer of dronedarone (risk of ventricular arrhythmias).
- Anti-infective agents: plasma concentration of telithromycin reduced by rifampicin (avoid during and for 2 weeks after rifampicin).
- Antidepressants: plasma concentration of telithromycin reduced by St John’s wort (avoid during and for 2 weeks after St John’s wort).
- Anti-infective agents: plasma concentration of telithromycin reduced by carbamazepine, phenytoin and primidone.
- Anti-infective agents: manufacturer of telithromycin advises concomitant use with azithromycin in severe renal and hepatic impairment.
- Anti-infective agents: manufacturer of fosoterodine advises dose reduction when telithromycin given with fosoterodine—consult fosoterodine product literature.
- Anti-infective agents: increased risk of ventricular arrhythmias when telithromycin given with pimozide—avoid concomitant use.
- Anti-infective agents: manufacturer of telithromycin advises concomitant use with lansoprazole (increased risk of myopathy when telithromycin given with lansoprazole).
- Anti-infective agents: increased plasma concentration of telithromycin possibly increased by furosemide (consider reducing dose of furosemide).
- Anti-infective agents: telithromycin inhibits metabolism of midazolam (increased plasma concentration with increased sedation).
- Anti-infective agents: aprepitant: telithromycin possibly increases plasma concentration of aprepitant.
- Anti-infective agents: barbiturates: plasma concentration of telithromycin reduced by phenobarbital (avoid during and for 2 weeks after phenobarbital).
- Anti-infective agents: cardiac glycosides: telithromycin possibly increases plasma concentration of digoxin.
- Anti-infective agents: ciclosporin: telithromycin possibly increases plasma concentration of ciclosporin.
- Anti-infective agents: colchicine: telithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).
- Anti-infective agents: cytoxotics: telithromycin possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use; avoidance of telithromycin advised by manufacturer of pazopanib and apixaban and pazopanib and apixaban.
- Anti-infective agents: diuretics: telithromycin increases plasma concentration of espererone—avoid concomitant use.
- Anti-infective agents: ergot alkaloids: increased risk of ergotism when telithromycin given with ergotamine and methysergide—avoid concomitant use.
- Anti-infective agents: ibaviridine: telithromycin possibly increases plasma concentration of ibaviridine—avoid concomitant use.
- Anti-infective agents: lipid-regulating Drugs: increased risk of myopathy when telithromycin given with stavudine or simvastatin (avoid concomitant use); possible increased risk of myopathy when telithromycin given with pravastatin.
- Anti-infective agents: ranolazine: telithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use.
- Anti-infective agents: sildenafil: telithromycin possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil.
- Anti-infective agents: sirolimus: telithromycin increases plasma concentration of sirolimus—avoid concomitant use.
- Anti-infective agents: tacrolimus: telithromycin possibly increases plasma concentration of tacrolimus.

Telithromycin (continued)

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767.

Telmisartan see Angiotensin-II Receptor Antagonists.

Temazepam see Anxiolytics and Hypnotics.

Temocilin see Penicillins.

Temoporfin
- Cytotoxics: increased skin photosensitivity when temoporfin given with topical fluourouracil.

Temozolomide
- Antiepileptics: cytoxotics possibly reduced absorption of phenytoin; plasma concentration of temozolomide increased by valproate.
- Anti-infective agents: avoid concomitant use of cytoxotics with oxazepine (increased risk of agranulocytosis).
- Cardiac Glycosides: cytoxotics reduce absorption of digoxin tablets.

Temsirolimus

Note: The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature.
- Anti-infective agents: plasma concentration of active metabolite of temsirolimus reduced by rifampicin—avoid concomitant use.
- Anti-infective agents: cytoxotics possibly reduced absorption of phenytoin.
- Anti-infective agents: plasma concentration of active metabolite of temsirolimus increased by furosemide—avoid concomitant use.
- Anti-infective agents: phenytoin: plasma concentration of temozolomide increased by valproate.
- Anti-infective agents: phenytoin: plasma concentration of temozolomide increased by valproate.

Tenofvir

- Anti-infective agents: manufacturer of tenofovir advises avoid concomitant use with adeovir; tenofovir reduces plasma concentration of atazanavir, also plasma concentration of tenofovir possibly increased; manufacturers advise avoid concomitant use of tenofovir with adeovir; tenofovir increases plasma concentration of didanosine (increased risk of toxicity)—avoid concomitant use; plasma concentration of tenofovir increased by lopinavir.

Tenoxicam see NSAIDs.

Terazosin see Alpha-blockers.

Terbinafine
- Anti-infective agents: plasma concentration of terbinafine reduced by rifampicin.
- Antidepressants: terbinafine possibly increases plasma concentration of tricyclics.
- Ciclosporin: terbinafine possibly reduces plasma concentration of ciclosporin.
- Diuretics: terbinafine possibly increases plasma concentration of metolazone and furosemide—avoid concomitant use.
- Diuretics: terbinafine possibly increases plasma concentration of metolazone and furosemide—avoid concomitant use.
- Lipid-regulating Drugs: increased risk of myopathy when telithromycin given with atorvastatin or simvastatin (avoid concomitant use); possible increased risk of myopathy when telithromycin given with pravastatin.
- Ranolazine: telithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use.
- Sildenafil: telithromycin possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil.
- Sirolimus: telithromycin increases plasma concentration of sirolimus—avoid concomitant use.
- Tacrolimus: telithromycin possibly increases plasma concentration of tacrolimus.
Tetrabenazine (continued) Metoclopramide: increased risk of extrapyramidal side-effects when tetrabenazine given with metoclopramide

Tetracosactide see Corticosteroids

Tetracycline see Tetracyclines

Tetracyclines

ACE Inhibitors: absorption of tetracyclines reduced by quinapril tablets (quinapril tablets contain magnesium carbonate)

Adsorbents: absorption of tetracyclines possibly reduced by kaolin

Antacids: absorption of tetracyclines reduced by antacids

Antibacterials: plasma concentration of doxycycline reduced by rifampicin—consider increasing dose of doxycycline; tetracyclines possibly antagonise effects of penicillins

Anticoagulants: metabolism of doxycycline accelerated by warfarin; metabolism of tetracycline accelerated by phenytoin and primidone (reduced plasma concentration)

Atovaquone: tetracycline reduces plasma concentration of atovaquone

Barbiturates: metabolism of doxycycline accelerated by barbiturates (reduced plasma concentration)

Calcium Salts: absorption of tetracycline reduced by calcium salts

Ciclosporin: doxycycline or tetracycline increase risk of hyperkalaemia when theophylline given with ciclosporin

Dairy Products: absorption of tetracyclines (except doxycycline and minocycline) reduced by dairy products

Diuretics: manufacturer of lymecycline advises avoid concomitant use with diuretics

Ergot Alkaloids: increased risk of ergotism when tetracyclines given with ergotamine and methysergide

Iron: absorption of tetracyclines reduced by oral iron, also absorption of oral iron reduced by tetracyclines

Lipid-regulating Drugs: absorption of tetracycline possibly reduced by colestipol and colestyramine

Retinoids: possible increased risk of benign intracranial hypertension when tetracyclines given with retinoids (avoid concomitant use)

Strontium Ranelate: absorption of tetracyclines reduced by strontium ranelate (manufacturer of strontium ranelate advises avoid concomitant use)

Ulcer-healing Drugs: absorption of tetracyclines reduced by sucralfate and tripotassium dicitratobismuthate

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767

Zinc: absorption of tetracyclines reduced by zinc, also absorption of zinc reduced by tetracyclines

Theophylline

Allopurinol: plasma concentration of theophylline possibly increased by allopurinol

Anaesthetics, General: increased risk of convulsions when theophylline given with ketamine; increased risk of arrhythmias when theophylline given with halothane

Anti-arrhythmics: theophylline antagonises anti-arrhythmic effect of adenosine; plasma concentration of theophylline increased by propafenone

Antibacterials: plasma concentration of theophylline possibly increased by azithromycin and clarithromycin; metabolism of theophylline inhibited by fluvoxamine (concomitant use should usually be avoided, but where not possible halve theophylline dose and monitor plasma-theophylline concentration); plasma concentration of theophylline reduced by St John’s wort—avoid concomitant use

Antiepileptics: metabolism of theophylline accelerated by carbamazepine and primidone (reduced effect); plasma concentration of both drugs reduced when theophylline given with phenytoin

Antifungals: plasma concentration of theophylline possibly increased by fluconazole and ketoconazole

Antivirals: plasma concentration of theophylline possibly increased by aciclovir; metabolism of theophylline accelerated by ritonavir (reduced plasma concentration)

Antithrombotics: theophylline possibly reduced by warfarin

Anticoagulants: metabolism of theophylline reduced by warfarin

Barbiturates: metabolism of theophylline accelerated by barbiturates (reduced effect)

Calcium-channel Blockers: plasma concentration of theophylline possibly increased by verapamil (enhanced effect)

Corticosteroids: increased risk of hypokalaemia when theophylline given with corticosteroids

Cytoxics: plasma concentration of theophylline possibly increased by methotrexate

Disulfiram: metabolism of theophylline inhibited by disulfiram (increased risk of toxicity)

Diuretics: increased risk of hypokalaemia when theophylline given with acetazolamide, loop diuretics or thiazides and related diuretics

Doxapram: increased CNS stimulation when theophylline given with doxapram

Febuxostat: caution with theophylline advised by manufacturer of febuxostat

Interferons: metabolism of theophylline inhibited by interferon alfa (consider reducing dose of theophylline)

Leukotriene Receptor Antagonists: plasma concentration of theophylline possibly increased by zafirlukast, also plasma concentration of zafirlukast reduced

Lithium: theophylline increases excretion of lithium (reduced plasma concentration)

Oestrogens: excretion of theophylline reduced by oestrogens (increased plasma concentration)

Pentoxifylline: plasma concentration of theophylline increased by pentoxifylline

Roflumilast: avoidance of theophylline advised by manufacturer of roflumilast

Sulfapyrazine: plasma concentration of theophylline reduced by sulfapyrazine

Sympathomimetics: manufacturer of theophylline advises avoid concomitant use with ephedrine in children

Sympathomimetics, Beta2: increased risk of hypokalaemia when theophylline given with high doses of beta, sympathomimetics—see Hypokalaemia, p. 176

Ulcer-healing Drugs: metabolism of theophylline inhibited by rimoxidine (increased plasma concentration); absorption of theophylline possibly reduced by sucralfate (give at least 2 hours apart)
Theophylline (continued)

Vaccines: plasma concentration of theophylline possibly increased by influenza vaccine

Thiazolidinediones see Antidiabetics

Thiopental see Anaesthetics, General

Thiotepa

Antineoplastic: cytotoxic possibly reduced absorption of phenytoin

Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytotoxic reduces absorption of digoxin tablets

Muscle Relaxants: thiopenta enhances effects of suxamethonium

Thioxanthenes see Antipsychotics

Thyroid Hormones

Antacids: absorption of levothyroxine possibly reduced by antacids

Anti-arrhythmics: for concomitant use of thyroid hormones and amiodarone see p. 94

Antibacterials: metabolism of levothyroxine accelerated by rifampicin (may increase requirements for levothyroxine in hypothyroidism)

Anticoagulants: thyroid hormones enhance anti-coagulant effect of coumarins and phenindione

Antidepressants: thyroid hormones enhance effects of amitriptyline and imipramine; thyroid hormones possibly enhance effects of tricyclics

Antiepileptics: metabolism of thyroid hormones accelerated by carbamazepine and primidone (may increase requirements for thyroid hormones in hypothyroidism); metabolism of thyroid hormones accelerated by phenytoin (may increase requirements in hypothyroidism), also plasma concentration of phenytoin possibly increased

Barbiturates: metabolism of thyroid hormones accelerated by barbiturates (may increase requirements for thyroid hormones in hypothyroidism)

Beta-blockers: levothyroxine accelerates metabolism of propranolol

Calcium Salts: absorption of levothyroxine reduced by calcium salts

Cytotoxics: plasma concentration of levothyroxine possibly reduced by imatinib

Iron: absorption of levothyroxine reduced by oral iron (give at least 2 hours apart)

Lanthanum: absorption of levothyroxine reduced by lanthanum (give at least 2 hours apart)

Lipid-regulating Drugs: absorption of levothyroxine reduced by colestipol; absorption of thyroid hormones reduced by colestipol and colestyramine

Oestrogens: requirements for thyroid hormones in hypothyroidism may be increased by oestrogens

Orlistat: possible increased risk of hypothyroidism when levothyroxine given with orlistat

Polystyrene Sulphonate Resins: absorption of levothyroxine reduced by polystyrene sulphonate resins

Sevelamer: absorption of levothyroxine possibly reduced by sevelamer

Ulcer-healing Drugs: absorption of levothyroxine reduced by cimetidine and sucralfate

Tiagabine (continued)

Barbiturates: plasma concentration of tiagabine reduced by phenobarbital

Orlistat: possible increased risk of convulsions when anti-epileptics given with orlistat

Tiapronenid see NSAIDs

Tibolone

Antibacterials: metabolism of tibolone accelerated by carbamazepine and primidone (reduced plasma concentration); metabolism of tibolone accelerated by phenytoin

Barbiturates: metabolism of tibolone accelerated by barbiturates (reduced plasma concentration)

Ticarcillin see Penicillins

Tigecycline

Antiepileptics: cytotoxic possibly reduces anti-coagulant effect of coumarins

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 787

Tiludronic Acid see Bisphosphonates

Timolol see Beta-blockers

Tinidazole

Alcohol: possibility of disulfiram-like reaction when tinidazole given with alcohol

Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 787

Tinzaparin see Heparins

Tioguanine

Antiepileptics: cytotoxic possibly reduces absorption of phenytoin

Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytotoxic reduces absorption of digoxin tablets

Cytotoxics: increased risk of hepatotoxicity when tioguanine given with busulfan

Tiotropium see Antimuscarinics

Tipranavir

Analgesics: plasma concentration of tipranavir possibly reduced by buprenorphine

Antacids: absorption of tipranavir reduced by antacids

Antibacterials: tipranavir increases plasma concentration of clarithromycin (reduced dose of clarithromycin in renal impairment), also plasma concentration of tipranavir increased by clarithromycin; tipranavir increases plasma concentration of rifabutin (reduce dose of rifabutin); plasma concentration of tipranavir possibly reduced by rifampicin—avoid concomitant use; avoidance of concomitant tipranavir in severe renal and hepatic impairment advised by manufacturer of tipranavir

Anticoagulants: avoid of tipranavir advised by manufacturer of rivaroxaban

Antidepressants: plasma concentration of tipranavir possibly reduced by St John's wort—avoid concomitant use

Antiepileptics: plasma concentration of tipranavir possibly reduced by carbamazepine

Antifungals: plasma concentration of tipranavir increased by fluconazole

Antimalarials: caution with tipranavir advised by manufacturer of artesunate/lumefantrine; tipranavir possibly increases plasma concentration of quinine (increased risk of toxicity)

Antimuscarinics: avoidance of tipranavir advised by manufacturer of darifenacin

Antivirals: tipranavir reduces plasma concentration of abacavir, didanosine, fosamprenavir, lopinavir, saquinavir and zidovudine; plasma concentration of tipranavir increased by atazanavir (also plasma concentration of atazanavir reduced); tipranavir reduces plasma concentration of etravirine, also plasma concentration of tipranavir increased (avoid concomitant use)
Appendix 1: Interactions

Orlistat:

Oestrogens:

Antiepileptics:

Antidepressants:

Topiramate.

Grapefruit Juice:

Tolfenamic Acid

Tolcapone

Tolbutamide

see

Vaccines:

Tocilizumab

see

Tobramycin

see

Tirofiban

Ulcer-healing Drugs:

Ranolazine:

Beta-blockers:

(continued)

886 Appendix 1: Interactions BNF 61

possible increased risk of convulsions

plasma concentration of topiramate

manufacturer of topiramate advises avoid concomitant use

Topiramate possibly affects plasma concentration of omeprazole

Antidiabetics possibly antagonised by MAOIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John's wort

Antidiabetics: topramate possibly increases plasma concentration of metformin or tiglurmine—avoid concomitant use

Antiepileptics: plasma concentration of topiramate often reduced by carbamazepine; topiramate possibly increases plasma concentration of phenytoin (also plasma concentration of topiramate reduced); CNS toxicity reported when topiramate given with valproate

Antimalarials: possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; anticonvulsant effect of antiepileptics antagonised by nefedipine

Diuretics: plasma concentration of topiramate possibly increased by hydrochlorothiazide

Lithium: topramate possibly affects plasma concentration of lithium

Oestrogens: topramate accelerates metabolism of oestrogens (reduced contraceptive effect—see p. 495)

Orlistat: possible increased risk of convulsions when antiepileptics given with orlistat

Topiramate (continued)

Progesterons: topramate accelerates metabolism of progesterons (reduced contraceptive effect—see p. 495)

Terasemide see Diuretics

Toremifene

Anticoagulants: toremifene possibly enhances anti-coagulant effect of coumarins

Antiepileptics: metabolism of toremifene possibly accelerated by carbamazepine (reduced plasma concentration); metabolism of toremifene possibly accelerated by phenytoin; metabolism of toremifene accelerated by primidone (reduced plasma concentration)

Barbiturates: metabolism of toremifene possibly accelerated by barbiturates (reduced plasma concentration)

Diuretics: increased risk of hypercalcaemia when toremifene given with thiazides and related diuretics

Sugammadex: toremifene possibly reduces response to sugammadex

Trabectedin

Antiepileptics: cytotoxics possibly reduce absorption of phenytoin

Antipsychotics: avoid concomitant use of cytotoxics with clozapine (increased risk of agranulocytosis)

Cardiac Glycosides: cytotoxics reduce absorption of digoxin tablets

Tramadol see Opioid Analgesics

Trandolapril see ACE Inhibitors

Tranylcypromine see MAOIs

Trazodone see Antidepressants, Tricyclic (related)

Tretinoin see Retinoids

Triamcinolone see Corticosteroids

Triamterene see Diuretics

Tricyclols see Anxiolytics and Hypnotics

Trientine

Iron: trientine reduces absorption of oral iron

Zinc: trientine reduces absorption of zinc, also absorption of trientine reduced by zinc

Trifluoperazine see Antipsychotics

Trihexyphenidyl see Antimuscarinics

Triostane: Diuretics: increased risk of hyperkalaemia when triostane given with potassium-sparing diuretics and aldosterone antagonists

Trimesthropin

ACE Inhibitors: possible increased risk of hyperkalaemia when trimesthropin given with ACE inhibitors

Angiotensin-II Receptor Antagonists: possible increased risk of hyperkalaemia when trimesthropin given with angiotensin-II receptor antagonists

Anti-arrhythmics: increased risk of ventricular arrhythmias when trimesthropin (as co-trimoxazole) given with amiodarone—avoid concomitant use of co-trimoxazole

Antibacterials: plasma concentration of trimethoprim possibly reduced by rifampicin; plasma concentration of both drugs may increase when trimesthropin given with dapsoné

Anticoagulants: trimesthropin possibly enhances anti-coagulant effect of coumarins

Antidiabetics: trimesthropin possibly enhances hypoglycaemic effect of repaglinide—manufacturer advises avoid concomitant use; trimesthropin rarely enhances the effects of sulfonylureas

Antiepileptics: trimesthropin increases plasma concentration of phenytoin (also increased anticonvulsant effect)

Antiarrhythmals: increased antifolate effect when trimesthropin given with pyrimethamine

Antivirals: trimesthropin (as co-trimoxazole) increases plasma concentration of lamivudine—avoid concomitant use of high-dose co-trimoxazole

Azathioprine: increased risk of haematological toxicity when trimesthropin (also with co-trimoxazole) given with azathioprine
Trimestoprim (continued)
Cardiac Glycosides: trimethoprim possibly increases plasma concentration of digoxin
- Ciclosporin: increased risk of nephrotoxicity when trimethoprim given with ciclosporin, also plasma concentration of ciclosporin reduced by intravenous trimethoprim
- Cytoxotics: increased risk of haematological toxicity when trimethoprim (also with co-trimazole) given with mercaptopurine or methotrexate
Diuretics: increased risk of hyperkalaemia when trimethoprim given with eplerenone
Vaccines: antibacterials inactivate oral typhoid vaccine—see p. 767
Trimepramine see Antidepressants, Tricyclic
Triptosatium Dicitratobismuthate
Antibacterials: triptosatium dicitratobismuthate reduces absorption of tetracyclines
Tropismide see Antimuscarinics
Trophicum see Antimuscarinics
Trimethoprim
- Antidepressants: CNS toxicity reported when tryptophan given with fluoxetine; possible increased serotonergic effects when tryptophan given with duloxetine; CNS excitation and confusion when tryptophan given with MAOIs (reduce dose of tryptophan); agitation and nausea may occur when tryptophan given with SSRIs
- Antimalarias: avoidance of antidepressants advised by manufacturer of atomoxetine
- Atomsoxetine: possible increased risk of convulsions when antidepressants given with atomoxetine
Typhoon Vaccine (oral) see Vaccines
Typhoon Vaccine (parenteral) see Vaccines
Ube dicarone
Anticoagulants: ubedicarone may enhance or reduce anticoagulant effect of warfarin
Ulcer-healing Drugs see Histamine H2 -antagonists, Proton Pump Inhibitors, Sucralfate, and Tripotassium Dicitratobismuthate
Ulprilstal
- Antacids: manufacturer of ulprilstal advises avoid concomitant use with antacids (plasma concentration of ulprilstal possibly reduced)
- Antibacterials: manufacturer of ulprilstal advises avoid concomitant use with ulprilstal (contraceptive effect of ulprilstal possibly reduced)
- Antidepressants: manufacturer of ulprilstal advises avoid concomitant use with St John’s Wort (contraceptive effect of ulprilstal possibly reduced)
- Antiepileptics: manufacturer of ulprilstal advises concomitant use with carbamazepine and phenytoin (contraceptive effect of ulprilstal possibly reduced)
- Antivirals: manufacturer of ulprilstal advises avoid concomitant use with mitonavir (contraceptive effect of ulprilstal possibly reduced)
- Barbiturates: manufacturer of ulprilstal advises avoid concomitant use with phenobarbital (contraceptive effect of ulprilstal possibly reduced)
- Progestogens: ulprilstal possibly reduces contraceptive effect of progestogens
- Ulcer-healing Drugs: manufacturer of ulprilstal advises avoid concomitant use with histamine H2 -antagonists and proton pump inhibitors (plasma concentration of ulprilstal possibly reduced)
Urso deoxycholic Acid
Antacids: absorption of bile acids possibly reduced by antacids
- Ciclosporin: urso deoxycholic acid increases absorption of ciclosporin
Lipid-regulating Drugs: absorption of bile acids possibly reduced by colestipol and colestyramine
Oestrogens: elimination of cholesterol in bile increased when bile acids given with oestrogens
Ustekinumab
- Vaccines: avoid concomitant use of ustekinumab with live vaccines (see p. 746)
Vaccines
Note: For a general warning on live vaccines and high doses of corticosteroids or other immunosuppressive drugs, see p. 746; for advice on live vaccines and immunoglobulins, see under Normal Immunoglobulin, p. 769
- Abatacept: avoid concomitant use of live vaccines with abatacept (see p. 746)
- Adalimumab: avoid concomitant use of live vaccines with adalimumab (see p. 746)
- Anakinra: avoid concomitant use of live vaccines with anakinra (see p. 746)
- Antibacterials: oral typhoid vaccine inactivated by antibacterials—see p. 767
- Anticoagulants: influenza vaccine possibly enhances anticoagulant effect of warfarin
- Antiepileptics: influenza vaccine enhances effects of phenytoin
- Antimalarias: oral typhoid vaccine inactivated by antimalarias—see p. 767
- Certolizumab pegol: avoid concomitant use of live vaccines with certolizumab pegol (see p. 746)
- Corticosteroids: immune response to vaccines impaired by high doses of corticosteroids, avoid concomitant use with live vaccines (see p. 746)
- Etanercept: avoid concomitant use of live vaccines with etanercept (see p. 746)
- Golimumab: avoid concomitant use of live vaccines with golimumab (see p. 746)
- Influnixinab: avoid concomitant use of live vaccines with infliximab (see p. 746)
- Interferons: avoidance of vaccines advised by manufacturer of interferon gamma
- Lefunomide: avoid concomitant use of live vaccines with lefunomide (see p. 746)
- Theophylline: influenza vaccine possibly increases plasma concentration of theophylline
- Tolizumab: avoid concomitant use of live vaccines with tolixumab (see p. 746)
- Ustekinumab: avoid concomitant use of live vaccines with ustekinumab (see p. 746)
Valaciclovir see Aciclovir
Valganciclovir see Ganciclovir
Valporate
Analgesics: effects of valporate enhanced by aspirin
Antibacterials: metabolism of valporate possibly inhibited by erythromycin (increased plasma concentration); plasma concentration of valporate reduced by carbenepem—avoid concomitant use of anticoagulants; valporate possibly enhances anticoagulant effect of coumarins
Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclines (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s Wort
Antiepileptics: plasma concentration of valporate reduced by carbamazepine, also plasma concentration of active metabolite of carbamazepine increased; valporate possibly increases plasma concentration of ethosuximide; valporate increases plasma concentration of lamotrigine; valporate sometimes reduces plasma concentration of an active metabolite of oxcarbazepine; valporate increases or possibly decreases plasma concentration of phenytoin, also plasma concentration of valporate reduced; valporate possibly increases plasma concentration of primidone (plasma concentration of active metabolite of primidone increased), also plasma concentration of valporate reduced; valporate possibly increases plasma concentration of rufinamide (reduce dose of rufinamide); CNS toxicity reported when valporate given with topiramate
Valproate (continued)

- Antimalarials: possible increased risk of convulsions when antimalarials are given with chloroquine and hydroxychloroquine; anticonvulsant effect of anti-malarial drugs antagonised by mefloquine.
- Antipsychotics: anticonvulsant effect of valproate antagonised by antipsychotics (convulsive threshold lowered); valproate possibly increases or decreases plasma concentration of clozapine; increased risk of side-effects including neutropenia when valproate is given with clozapine; valproate possibly increases plasma concentration of quetiapine.

Antivirals: valproate possibly increases plasma concentration of zidovudine (increased risk of toxicity).

Anxiolytics and Hypnotics: plasma concentration of valproate possibly increased by clozapine; increased risk of side-effects when valproate is given with clonazepam; valproate possibly increases plasma concentration of diazepam and lorazepam.

Barbiturates: valproate increases plasma concentration of phenobarbital (also plasma concentration of valproate reduced).

Bupropion: valproate inhibits the metabolism of bupropion.

Cytotoxic: valproate increases plasma concentration of temozolomide.

Lipid-regulating Drugs: absorption of valproate possibly reduced by colestyramine.

Oestrogens: plasma concentration of valproate possibly reduced by ethinylestradiol.

Orlistat: possible increased risk of convulsions when antiepileptics are given with orlistat.

Sodium Benzoate: valproate possibly reduces effects of sodium benzoate.

Sodium Phenylbutyrate: valproate possibly reduces effects of sodium phenylbutyrate.

Valproate increases metabolism of valproate when valproate is given with valproate.

Valsartan see Angiotensin-II Receptor Antagonists.

Vasodilator Antihypertensives

ACE Inhibitors: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with ACE inhibitors.

Adrenergic Neurone Blockers: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with adrenergic neurone blockers.

Alcohol: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with alcohol.

Aldesleukin: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with aldesleukin.

Alpha-blockers: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with alpha-blockers.

Analgesics: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with general anaesthetics.

Antileukins: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with nSAIDs.

Angiotensin-II Receptor Antagonists: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with angiotensin-II receptor antagonists.

Antidepressants: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with tricyclic-related antidepressants.

Antiipsychotics: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with phenothiazines.

Anxiolytics and Hypnotics: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with anxiolytics and hypnotics.

Beta-blockers: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with beta-blockers.

Calcium-channel Blockers: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with calcium-channel blockers.

Clonidine: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with clonidine.

Corticosteroids: hypotensive effect of hydralazine, minoxidil and sodium nitroprusside antagonised by corticosteroids.

Diazoxide: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with diuretics.

Dopaminergics: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with levodopa.

Doxapram see Anaesthetics, General.

Gamma-aminobutyric acid agonists: enhanced hypotensive effect when hydralazine, minoxidil or sodium nitroprusside are given with GABA agonists.

Grapefruit Juice: plasma concentration of vardenafil possibly increased by grapefruit juice.

Hydralazine: enhanced hypotensive effect when hydralazine is given with antiepileptics, clonidine or adrenaline.

Hypnotics: enhanced hypotensive effect when hydralazine is given with hypnotics.

Lignocaine: enhanced hypotensive effect when hydralazine is given with lignocaine.

Nicorandil: enhanced hypotensive effect when hydralazine is given with nicorandil.

Oral Anticoagulants: enhanced hypotensive effect when hydralazine is given with oral anticoagulants.

Pentamidine: enhanced hypotensive effect when hydralazine is given with pentamidine.

Pentazocine: enhanced hypotensive effect when hydralazine is given with pentazocine.

Potassium-sparing Diuretics: enhanced hypotensive effect when hydralazine is given with potassium-sparing diuretics.

Probenecid: enhanced hypotensive effect when hydralazine is given with probenecid.

Radioisotopes: enhanced hypotensive effect when hydralazine is given with radioisotopes.

Suxamethonium: enhanced hypotensive effect when hydralazine is given with suxamethonium.
Antidepressants:

- Venlafaxine possibly enhances antidepressant effects when venlafaxine given with tramadol.

- Antidepressants: possible increased serotoninergic effects when venlafaxine given with St John’s wort, duloxetine or mirtazapine; enhanced toxicity when venlafaxine given with MAOIs. (venlafaxine should not be started until 2 weeks after stopping MAOIs, avoid MAOIs for 1 week after stopping venlafaxine; after stopping SSRI-related antidepressants do not start moclobemide for at least 1 week.

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: enhanced hypotensive effect when venlafaxine given with lithium, possibly increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: plasma concentration of primidone possibly reduced by vigabatrin.

- Antidepressants: plasma concentration of lithium possibly increased by vigabatrin.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.

Antidepressants:

- Antimalarials: possible increased risk of convulsions when antidepressants given with tramadol.

- Antidepressants: possible increased risk of convulsions when antidepressants given with lithium.
Appendix 1: Interactions

Vitamin K (Phytomenadione) see Vitamins

Vitamins

Antibacterials: absorption of vitamin A possibly reduced by neomycin

- Anticoagulants: vitamin E possibly enhances anticoagulant effect of coumarins; vitamin K antagonises anticoagulant effect of coumarins and phenindione

Antiepileptics: vitamin D requirements possibly increased when given with carbamazepine, phenytoin or primidone

Antifungals: plasma concentration of paricalcitol possibly increased by ketoconazole

Antivirals: increased risk of bleeding when given with tizanidine

Calcium Salts: absorption of zinc reduced by calcium salts

Antibacterials:

- increased antifolate effect when zidovudine increases or decreases methotrexate concentration

Antimalarials: zidovudine increases or decreases antimalarial plasma concentration

Antiepileptics:

- anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort

Antiepileptics: plasma concentration of zonisamide reduced by carbamazepine and phenytoin

Antimalarials:

- possible increased risk of convulsions when antiepileptics given with chloroquine and hydroxychloroquine; angioedema possibly increased by MAOIs and tricyclics

Barbiturates:

- absorption of zinc reduced by tetracyclines

Antibacterials:

- increased antifolate effect when zidovudine increases or decreases methotrexate concentration

Antimalarials: zidovudine increases or decreases antimalarial plasma concentration

Antiepileptics:

- anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort

Antiepileptics: plasma concentration of zonisamide reduced by carbamazepine and phenytoin

- possible increased risk of convulsions when antiepileptics given with orlistat

Zopiclone see Anxiolytics and Hypnotics

Zuclopenthixol see Antipsychotics

Zinc (continued)

Iron: absorption of zinc reduced by oral iron, also absorption of oral iron reduced by zinc

Penicillamine: absorption of zinc reduced by penicillamine, also absorption of penicillamine reduced by zinc

Trientine: absorption of zinc reduced by trientine, also absorption of trientine reduced by zinc

Zoledronic Acid see Bisphosphonates

Zomaritipan see SHT, Agonists

Zolpidem see Anxiolytics and Hypnotics

Zonisamide

- Antidepressants: anticonvulsant effect of antiepileptics possibly antagonised by MAOIs and tricyclic-related antidepressants (convulsive threshold lowered); anticonvulsant effect of antiepileptics antagonised by SSRIs and tricyclics (convulsive threshold lowered); avoid concomitant use of antiepileptics with St John’s wort

Antiepileptics: plasma concentration of zonisamide reduced by carbamazepine and phenytoin

- absorpion of vitamin A possibly increased by orlistat

Zopiclone see Anxiolytics and Hypnotics

Zuclopenthixol see Antipsychotics

Zinc

Antibacterials: zinc reduces absorption of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin; zinc reduces absorption of tetracyclines, also absorption of zinc reduced by tetracyclines

Calcium Salts: absorption of zinc reduced by calcium salts

Eltrombopag: zinc possibly reduces absorption of eltrombopag (give at least 4 hours apart)
Liver disease, renal impairment, pregnancy, and breast-feeding

For general guidance on prescribing for patients with hepatic or renal impairment, or for patients who are pregnant or breast-feeding, see pp. 17–19. Specific information has been moved to the relevant chapters and is included under the individual drug or in the prescribing notes.
Appendix 6: Intravenous additives

Intravenous additives policies

A local policy on the addition of drugs to intravenous fluids should be drawn up by a multi-disciplinary team in each Strategic Health Authority (or equivalent) and issued as a document to the members of staff concerned.

Centralised additive services are provided in a number of hospital pharmacy departments and should be used in preference to making additions on wards.

The information that follows should be read in conjunction with local policy documents.

Guidelines

1. Drugs should only be added to infusion containers when constant plasma concentrations are needed or when the administration of a more concentrated solution would be harmful.
2. In general, only one drug should be added to any infusion container and the components should be compatible. Ready-prepared solutions should be used whenever possible. Drugs should not normally be added to blood products, mannitol, or sodium bicarbonate. Only specially formulated additives should be used with fat emulsions or amino-acid solutions (section 9.3).
3. Solutions should be thoroughly mixed by shaking and checked for absence of particulate matter before use.
4. Strict asepsis should be maintained throughout and in general the giving set should not be used for more than 24 hours (for drug admixtures).
5. The infusion container should be labelled with the patient’s name, the name and quantity of additives, and the date and time of addition (and the new expiry date or time). Such additional labelling should not interfere with information on the manufacturer’s label that is still valid. When possible, containers should be retained for a period after use in case they are needed for investigation.
6. It is good practice to examine intravenous infusions from time to time while they are running. If cloudiness, crystallisation, change of colour, or any other sign of interaction or contamination is observed the infusion should be discontinued.

Problems

Microbial contamination

The accidental entry and subsequent growth of micro-organisms converts the infusion fluid pathway into a potential vehicle for infection with micro-organisms, particularly species of Candida, Enterobacter, and Klebsiella. Ready-prepared infusions containing the additional drugs, or infusions prepared by an additive service (when available) should therefore be used in preference to making extemporaneous additions to infusion containers on wards etc.

Incompatibility

Physical and chemical incompatibilities may occur with loss of potency, increase in toxicity, or other adverse effect. The solutions may become opalescent or precipitation may occur, but in many instances there is no visual indication of incompatibility. Interaction may take place at any point in the infusion fluid pathway, and the potential for incompatibility is increased when more than one substance is added to the infusion fluid.

Common incompatibilities

Precipitation reactions are numerous and varied and may occur as a result of pH, concentration changes, ‘salting-out’ effects, complexation or other chemical changes. Precipitation or other particle formation must be avoided since, apart from lack of control of dosage on administration, it may initiate or exacerbate adverse effects. This is particularly important in the case of drugs which have been implicated in either thrombophlebitis (e.g. dexamethasone) or in skin sloughing or necrosis caused by extravasation (e.g. sodium bicarbonate and certain cytotoxic drugs). It is also especially important to effect solution of colloidal drugs and to prevent their subsequent precipitation in order to avoid a pyrogenic reaction (e.g. amphotericin).

It is considered undesirable to mix beta-lactam antibiotics, such as semi-synthetic penicillins and cephalosporins, with proteinaceous materials on the grounds that immunogenic and allergenic conjugates could be formed.

A number of preparations undergo significant loss of potency when added singly or in combination to large volume infusions. Examples include ampicillin in infusions that contain glucose or lactates. The breakdown products of dacarbazine have been implicated in adverse effects.

Blood

Because of the large number of incompatibilities, drugs should not normally be added to blood and blood products for infusion purposes. Examples of incompatibility with blood include hypertonic mannitol solutions (irreversible crenation of red cells), dextranast (rouleaux formation and interference with cross-matching), glucose (clumping of red cells), and oxytocin (inactivated).

If the giving set is not changed after the administration of blood, but used for other infusion fluids, a fibrin clot may form which, apart from blocking the set, increases the likelihood of microbial growth.

Intravenous fat emulsions

These may break down with coalescence of fat globules and separation of phases when additions such as antibacterials or electrolytes are made, thus increasing the possibility of embo-
lism. Only specially formulated products such as Viti-
pid N® (section 9.3) may be added to appropriate
intravenous fat emulsions.

**Other infusions** Infusions that frequently give rise to
incompatibility include amino acids, mannitol, and sodi-
um bicarbonate.

**Bactericides** Bactericides such as chlororesol 0.1% or
phenylmercuric nitrate 0.001% are present in some
injection solutions. The total volume of such solutions
added to a container for infusion on one occasion
should not exceed 15 mL.

---

**Method**

Ready-prepared infusions should be used whenever
available. **Potassium chloride** is usually available in
concentrations of 20, 27, and 40 mmol/litre in sodium
chloride intravenous infusion (0.9%), glucose intra-
venous infusion (5%) or sodium chloride and glucose
intravenous infusion. **Lidocaine hydrochloride** is
usually available in concentrations of 0.1 or 0.2% in
glucose intravenous infusion (5%).

When addition is required to be made extempora-
neously, any product reconstitution instructions such as
those relating to concentration, vehicle, mixing, and
handling precautions should be strictly followed using
an aseptic technique throughout. Once the product has
been reconstituted, addition to the infusion fluid should
be made immediately in order to minimise microbial
contamination and, with certain products, to prevent
degradation or other formulation change which may
occur; e.g. reconstituted ampicillin injection degrades
rapidly on standing, and also may form polymers which
could cause sensitivity reactions.

It is also important in certain instances that an infusion
fluid of specific pH be used (e.g. **furosemide** injection
requires dilution in infusions of pH greater than 5.5).

When drug additions are made it is important to mix
thoroughly; additions should not be made to an infusion
container that has been connected to a giving set, as
mixing is hampered. If the solutions are not thoroughly
mixed a concentrated layer of the additive may form
owing to differences in density. **Potassium chloride** is
particularly prone to this ‘layering’ effect when added
without adequate mixing to infusions packed in non-
rigid infusion containers; if such a mixture is adminis-
tered it may have a serious effect on the heart.

A time limit between addition and completion of admin-
istration must be imposed for certain admixtures to
guarantee satisfactory drug potency and compatibility.
For admixtures in which degradation occurs without the
formation of toxic substances, an acceptable limit is the
time taken for 10% decomposition of the drug. When
toxic substances are produced stricter limits may be
imposed. Because of the risk of microbial contamination
a maximum time limit of 24 hours may be appropriate
for additions made elsewhere than in hospital pharma-
cies offering central additive service.

Certain injections must be protected from light during
continuous infusion to minimise oxidation, e.g. amphot-
ericin, dacarbazine, and sodium nitroprusside.

Dilution with a small volume of an appropriate vehicle
and administration using a motorised infusion pump is
advocated for preparations such as unfractionated hepa-
tinic acid where strict control over administration is required.
In this case the appropriate dose may be dissolved in a
convenient volume (e.g. 24–48 mL) of sodium chloride
intravenous infusion (0.9%).

---

**Use of table**

The table lists preparations given by three methods:

- continuous infusion;
- intermittent infusion;
- addition via the drip tubing.

Drugs for **continuous infusion** must be diluted in a
large volume infusion. Penicillins and cephalosporins
are not usually given by continuous infusion because
of stability problems and because adequate plasma and
tissue concentrations are best obtained by intermittent
infusion. Where it is necessary to administer them by
continuous infusion, detailed literature should be con-
sulted.

Drugs that are both compatible and clinically suitable
may be given by **intermittent infusion** in a relatively
small volume of infusion over a short period of time, e.g.
100 mL in 30 minutes. The method is used if the product
is incompatible or unstable over the period necessary
for continuous infusion; the limited stability of ampicillin
or amoxicillin in large volume glucose or lactate infu-
sions may be overcome in this way.

Intermittent infusion is also used if adequate plasma and
tissue concentrations are not produced by continuous
infusion as in the case of drugs such as dacarbazine,
gentamicin, and ticarcillin.

An in-line burette may be used for intermittent infusion
techniques in order to achieve strict control over the
time and rate of administration, especially for infants
and children and in intensive care units. Intermittent
infusion may also make use of the ‘piggy-back’ techni-
que provided that no additions are made to the primary
infusion. In this method the drug is added to a small
secondary container connected to a Y-type injection site
on the primary infusion giving set; the secondary solu-
tion is usually infused within 30 minutes.

**Addition via the drip tubing** is indicated for a number
of cytotoxic drugs in order to minimise extravasation.
The preparation is added aseptically via the rubber
septum of the injection site of a fast-running infusion.
In general, drug preparations intended for a bolus effect
should be given directly into a separate vein where
possible. Failing this, administration may be made via
the drip tubing provided that the preparation is compa-
tible with the infusion fluid when given in this manner.

---

**Table of drugs given by intravenous infusion**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Method of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ampicillin</strong></td>
<td>Continuous infusion; intermittent infusion; addition via the drip tubing.</td>
</tr>
<tr>
<td><strong>Furosemide</strong></td>
<td>Continuous infusion; intermittent infusion; addition via the drip tubing.</td>
</tr>
<tr>
<td><strong>Potassium chloride</strong></td>
<td>Continuous infusion; intermittent infusion; addition via the drip tubing.</td>
</tr>
</tbody>
</table>

**Covers addition to** **Glucose intravenous infusion**, **0.9%**, **Sodium chloride intravenous infusion**, **0.9%**, **and Sodium chloride intravenous infusion**, **0.9%**. **Compatibility with glucose 5% and with sodium chloride 0.9% indicates compatibility with Sodium chloride and glucose intravenous infusion. Infusion of a large volume of hypotonic solution should be avoided therefore care should be taken if water for injections is used.** The information in the Table relates to the proprietary preparations indicated; for other preparations suitability should be checked with the manufacturer.
Appendix 6: Intravenous additives

Abatacept (Orencia®)
Intermittent in Sodium chloride 0.9%
Reconstitute each vial with 10 mL water for injections using the silicone-free syringe provided; dilute requisite dose in infusion fluid to 100 mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2 or 1.2 micron).

Abciximab (ReoPro®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute requisite dose in infusion fluid and give via infusion pump; filter upon dilution with infusion fluid through a non-pyrogenic low protein-binding 0.2, 0.22, or 5 micron filter or upon administration through an in-line non-pyrogenic low protein-binding 0.2 or 0.22 micron filter.

Acetylcysteine (Parvolex®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Glucose 5% is preferable—see Emergency Treatment of Poisoning.

Aciclovir (as sodium salt) (Zovirax IV; Aciclovir IV; Hospira; Aciclovir IV, Genus; Aciclovir Sodium, Zurich)
Intermittent in Sodium chloride 0.9% or Sodium chloride and glucose
For Zovirax IV®, Aciclovir IV (Genus) initially reconstitute to 25 mg/mL in water for injections or sodium chloride 0.9% then dilute to not more than 5 mg/mL with the infusion fluid; to be given over 1 hour; alternatively, may be administered in a concentration of 25 mg/mL using a suitable infusion pump and given over 1 hour; for Aciclovir IV (Hospira) dilute to not more than 5 mg/mL with infusion fluid; give over 1 hour.

Aciclovir IV (Genus)
Continuously administered in sodium chloride 0.9% or sodium chloride 0.9% at a concentration of 25 mg/mL in water for injections or sodium chloride 0.9%, to be given over 1 hour.

Agalsidase alfa (Replagal®)
Intermittent in Sodium chloride 0.9%
Dilute requisite dose with 100 mL infusion fluid and give over 40 minutes using an in-line filter; use within 3 hours of dilution.

Agalsidase beta (Fabrazyme®)
Intermittent in Sodium chloride 0.9%
Reconstitute with water for injections (35 mg in 7.2 mL, 5 mg in 1.1 mL) to produce a solution containing 5 mg/mL dilute with infusion fluid (for doses less than 35 mg dilute with at least 50 mL), doses 35–70 mg/dose with at least 100 mL doses 70–100 mg dilute with at least 250 mL; doses greater than 100 mg dilute with 500 mL and give through an in-line low protein-binding 0.2 micron filter at an initial rate of no more than 15 mg/hour; for subsequent infusions, infusion rate may be increased gradually once tolerance has been established.

Allantoin (as hydrochloride) (Rapifen®)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%

Ampicillin sodium
Continuous in Glucose 5% or Sodium chloride 0.9%
Reconstitute each vial with 10 mL water for injections to produce a 5 mg/mL colloidal solution; dilute requisite dose with infusion fluid to a final concentration of 0.5–4 mg/mL, give through a low protein-binding in-line filter (0.2 micron) at an initial rate of 1 mg/kg/hour increased by 2 mg/kg/hour every 30 minutes to max. 7 mg/kg/hour.

Amifostine (Ethylol®)
Intermittent in Sodium chloride 0.9%
Reconstitute 500 mg vial with 9.7 mL sodium chloride 0.9% to produce a 50 mg/mL solution.

Amikacin sulphate (Amikin®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
To be given over 30 minutes.

Aminophylline
Continuous in Glucose 5% or Sodium chloride 0.9%

Amiodarone hydrochloride (Cordarone X®) Continuous or intermittent in Glucose 5%
Suggested initial infusion volume 250 mL given over 20–120 minutes; for repeat infusions up to 1.2 g in max. 500 mL, infusion in extreme emergency see section 2.7.3, should not be diluted to less than 600 micrograms/mL, incompatible with sodium chloride infusion; avoid equipment containing the plasticizer di-2-ethylhexylphthalate (DEHP).

Amoxicillin (as sodium salt) (Amoxi®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes via drip tubing in Glucose 5% or Sodium chloride 0.9%
Continuous infusion not usually recommended.

Amphotericin (lipid complex) (Abelcet®)
Intermittent in Glucose 5%
Allow suspension to reach room temperature, shake gently to ensure no yellow settlement, withdraw requisite dose (using 17–19 gauge needle) into one or more 20– mL syringes; replace needle on syringe with a 5-micron filter needle provided (fresh needle for each syringe) and dilute to a concentration of 1 mg/mL (2 mg/mL can be used in fluid restriction and in children), preferably give via an infusion pump at a rate of 2.5 mg/kg/hour (initial test dose of 1 mg given over 15 minutes), an in-line filter (pore size no less than 15 microns) may be used; do not use sodium chloride or other electrolyte solutions, flush existing intravenous line with glucose 5% or use separate line.

Amphotericin (liposomal) (AmBisome®)
Intermittent in Glucose 5% or 10%
Reconstitute each vial with 12 mL water for injections and shake vigorously to produce a preparation containing 4 mg/mL; withdraw requisite dose from vial and introduce into infusion fluid through the 5-micron filter provided to produce a final concentration of 0.2–2 mg/mL, infuse over 30–60 minutes, or if non-anaphylactic infusion-related reactions occur infuse over 2 hours (initial test dose 1 mg over 10 minutes), an in-line filter (pore size no less than 1 micron) may be used; incompatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or 10%, or use separate line.

Amphotericin (as sodium deoxycholate complex) (Fungizone®)
Intermittent in Glucose 5%
Reconstitute each vial with 10 mL water for injections and shake immediately to produce a 5 mg/mL colloidal solution; dilute further in infusion fluid to a concentration of 100 micrograms/mL; pH of the glaucine must be not below 4.2 (check each container—consult product literature for details of buffer); infuse over 2–4 hours, or longer if not tolerated (initial test dose 1 mg over 20–30 minutes); begin infusion immediately after dilution and protect from light; compatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or use separate line; an in-line filter (pore size no less than 1 micron) may be used.

Anaphylactin (Penbritin®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes via drip tubing in Glucose 5% or Sodium chloride 0.9%
Continuous infusion not usually recommended.
Anidulafungin (Ecalta®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute each 100 mg with 30 mL water for injections, allow up to 5 minutes for reconstitution; dilute dose in infusion fluid to a concentration of 770 micrograms/mL, give at a rate not exceeding 1.1 mg/minute
Note Follow product information if using stock supplied with ethanol solvent

Antithymocyte immunoglobulin (Thymoglobulin®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Reconstitute each vial with 5 mL water for injections to produce a solution of 5 mg/mL; gently rotate to dissolve. Dilute requisite dose with infusion fluid to a total volume of 50–500 mL (usually 50 mL/vial), begin infusion immediately after dilution; give through an in-line filter (pore size 0.22 micron), not to be given with unfractionated heparin and hydrocortisone in glucose infusion as precipitation reported

Atefenol (Tenormin®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Suggested infusion time 20 minutes

Atosiban (Tractocile® concentrate for intravenous infusion)
Continuous in Glucose 5% or Sodium chloride 0.9%
Withdraw 10 mL infusion fluid from 100-mL bag and replace with 10 mL atosiban concentrate (7.5 mg/mL) to produce a final concentration of 750 micrograms/mL.

Atracurium besilate (Tracrium®; Atracurium besilate injection, Hospira; Atracurium injection/infusion, Genus)
Continuous in Glucose 5% or Sodium chloride 0.9%
Stability varies with diluent; dilute requisite dose with infusion fluid to a concentration of 0.5–5 mg/mL.

Azathioprine (as sodium salt) (Imuran®)
Intermittent in Sodium chloride 0.9% or Glucose 5%
Reconstitute 10 mL atosiban concentrate (7.5 mg/mL) to produce a final concentration as precipitation reported

Aztreonam (Azactam)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Suggested volume 100 mL given over 30–60 minutes

Calcitonin (salmon) (Miacalcic®)
Intermittent in Sodium chloride 0.9%
Diluted solution given without delay, dilute in 500 mL and give over at least 6 hours; glass or hard plastic containers should not be used; some loss of potency on dilution and administration

Calcium gluconate
Continuous in Glucose 5% or Sodium chloride 0.9%
Avoid bicarbonates, phosphates, or sulphates

Caspofungin (Cancidas®)
Intermittent in Sodium chloride 0.9%
Allow vial to reach room temperature; initially reconstitute each vial with 10.5 mL water for injections, mixing gently to dissolve, then dilute requisite dose in 250 mL infusion fluid (35–or 50-mg doses may be diluted in 100 mL infusion fluid if necessary); give over 60 minutes; incompatible with glucose solutions

Cefotaxime (as sodium salt)
Intermittent in Glucose 5% or Sodium chloride 0.9% or Water for injections
Suggested volume 40–100 mL given over 20–60 minutes; incompatible with alkaline solutions

Ceftazidime (as pentahydrate) (Fortum®, Kefadim®)
Intermittent or via drip tubing in Glucose 5% and 10% or Sodium chloride 0.9%
Dilute to a concentration of 50 mg in 50 mL with infusion fluid to a concentration of 1 mg/mL.

Ceftriaxone (as sodium salt) (Rocephin®; Ceftrixone Injection, Genus)
Intermittent or via drip tubing in Glucose 5% and 10% or Sodium chloride 0.9%
Reconstitute 2-g vial with 40 mL infusion fluid; give intermittent infusion over at least 20 minutes (60 minutes in neonates); not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites

Cefuroxime (as sodium salt) (Zinacef®)
Intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%
Dilute initially in water for injections (at least 2 mL) then dilute to a concentration of less than 20 mg/mL; to be given over 20–60 minutes

Chloramphenicol (as sodium succinate)
Kemicetine®
Intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%
Dilute initially in water for injections (at least 2 mL) then dilute to a concentration of less than 20 mg/mL; to be given over 20–60 minutes (60 minutes in neonates); not to be used with PVC equipment

Clindamycin (as hydrochloride) (Cleocin®)
Intermittent or continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 30 mg in 20–100 mL; give intermittent infusion over 2–6 hours; not to be used with PVC equipment

Cidofovir (Vistide®)
Intermittent in Sodium chloride 0.9%
Dilute requisite dose with 100 mL infusion fluid; infuse over 1 hour

Cisatracurium (Nimbex®, Nimbex Forte®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Solutions of 2 mg/mL and 5 mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1–2 mg/mL.
Appendix 6: Intravenous additives

**Clarithromycin** *(Klaricid® I.V.)*

- Intermittent in Glucose 5% or Sodium chloride 0.9%
- Dissolve initially in water for injections (500 mg in 10 mL) then dilute to a concentration of 2 mg/mL, give over 60 minutes

**Clindamycin (as phosphate)** *(Dalacin® C Phosphate)*

- Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
- Dilute to not more than 18 mg/mL and give over 10–60 minutes at a rate not exceeding 30 mg/minute (1.5 g over at least 60 minutes; higher doses by continuous infusion)

**Clonazepam** *(Rivotril®)*

- Intermittent in Glucose 5% and 10% or Sodium chloride 0.9%
- Suggested volume 250 mL

**Co-amoxiclav** *(Augmentin®)*

- Intermittent in Sodium chloride 0.9% or Water for injections
- Reconstitute 600 mg initially with 10 mL water for injections, then dilute with 50 mL infusion fluid; reconstitute 1.2 g initially with 20 mL water for injections, then dilute with 100 mL infusion fluid; give over 30–40 minutes

**Co-fluampicil (as sodium salts)** *(Magnapen®)*

- Intermittent in Glucose 5% or Sodium chloride 0.9%
- Reconstituted solutions diluted and given without delay; suggested volume 100 mL, given over 30–60 minutes

**Co-amoxiclav (Augmentin®)*

- Intermittent in Sodium chloride 0.9% or Water for injections
- Reconstitute 500 mg with 25 mL sodium chloride 0.9%; reconstitute 1 g with 50 mL sodium chloride 0.9%; reconstitute 2 g with 100 mL sodium chloride 0.9%

**Colistimethate sodium** *(Colymycin®)*

- Intermittent in Sodium chloride 0.9% or Water for injections
- Dilute with 50 mL infusion fluid and give over 30 minutes

**Co-trimoxazole** *(Septin® for infusion)*

- Intermittent in Glucose 5% and 10% or Sodium chloride 0.9%
- Dilute contents of 1 ampoule (5 mL) to 125 mL, 2 ampoules (10 mL) to 250 mL or 3 ampoules (15 mL) to 500 mL, suggested duration of infusion 60–90 minutes (but may be adjusted according to fluid requirements); if fluid restriction necessary, 1 ampoule (5 mL) may be diluted with 75 mL glucose 5% and infused over more than 60 minutes

**Cyclophosphamide** *(Cyclophosphamide injection, Baxter)*

- via drip tubing in Glucose 5% or Sodium chloride 0.9%
- Reconstitute 500 mg with 25 mL sodium chloride 0.9%; reconstitute 1 g with 50 mL sodium chloride 0.9%

**Danaparoid sodium** *(Orgaran®)*

- Continuous in Glucose 5% or Sodium chloride 0.9%

**Daptomycin** *(Cubicin®)*

- Intermittent in Sodium chloride 0.9%
- Reconstitute with sodium chloride 0.9% (350 mg in 7 mL, 500 mg in 10 mL); gently rotate vial without shaking; allow to stand for at least 10 minutes then rotate gently to dissolve; dilute requisite dose in 50 mL infusion fluid and give over 30 minutes

**Desferrioxamine mesilate** *(Desfera®)*

- Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
- Reconstitute with water for injections to a concentration of 100 mg/mL; dilute with infusion fluid

**Desmopressin** *(DDAVP®, Octin®)*

- Intermittent in Sodium chloride 0.9%
- Dilute with 50 mL and give over 20 minutes

**Dexamethasone sodium phosphate** *(Decadron®, Hospira; Dexamethasone, Organon)*

- Continuous or intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%

**Dexrazoxane** *(Cardioxane®)*

- Intermittent in Compound sodium lactate
- Reconstitute each vial with 25 mL water for injections and dilute each vial with 25–100 mL infusion fluid; give requisite dose over 15 minutes

**Diazepam (solution)** *(Diazepam, Wockhardt)*

- Continuous in Glucose 5% or Sodium chloride 0.9%
- Glucose is preferred as infusion fluid

**Diazepam (emulsion)** *(Diazemuls®)*

- Continuous in Glucose 5 and 10%
- May be diluted to a max. concentration of 200 mg in 500 mL, max. 6 hours between addition and completion of administration; adsorbed to some extent by the plastics of bags and infusion sets

**Diclofenac sodium** *(Voltarol®)*

- Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
- Dilute 75 mg with 100–500 mL infusion fluid (previously buffered with 0.5 mL sodium bicarbonate 8.4% solution or with 1 mL sodium bicarbonate 4.2% solution); for intermittent infusion give 25–50 mg over 15–60 minutes or 75 mg over 30–120 minutes; for continuous infusion give at a rate of 5 mg/hour

**Digoxin** *(Lanoxin®)*

- Intermittent in Glucose 5% or Sodium chloride 0.9%
- Dilute to a concentration of not more than 62.5 micrograms/mL. To be given over at least 2 hours

**Digoxin-specific antibody fragments** *(Digibind®)*

- Intermittent in Sodium chloride 0.9%
- Dissolve initially in water for injections (4 mL/vial) then dilute with the sodium chloride 0.9% and give through a 0.22 micron sterile, disposable filter over 30 minutes

**Dinoprostone** *(Prostin E2®)*

- Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%

**Disodium pamidronate** *(Aredia®, Disodium pamidronate, Britannia, Hospira, Medac)*

- Intermittent in Glucose 5% or Sodium chloride 0.9%
- For Aredia® and Pamidronate disodium (Britannia), reconstitute initially with water for injections (15 mg in 5 mL, 30 mg or 90 mg in 10 mL) for Aredia®. Pamidronate disodium (Britannia), Disodium pamidronate (Hospira), dilute with infusion fluid to a concentration of not more than 60 mg in 250 mL; for Dinoprostone pamidronate (Medac) dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL, give at a rate not exceeding 1 mg/minute, not to be given with infusion fluids containing calcium
Disopyramide (as phosphate) *(Rythmodan®)*
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Max. rate by continuous infusion 20–30 mg/hour (or 400 micrograms/kg/hour)

Dobutamine (as hydrochloride)
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 0.5–1 mg/mL and give via a controlled infusion device; give higher concentration (max. 5 mg/mL) with infusion pump; incompatible with bicarbonate

Dopamine hydrochloride
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to max. concentration of 3.2 mg/mL, incompatible with bicarbonate

Dopexamine hydrochloride *(Dopacard®)*
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 400 or 800 micrograms/mL, max. concentration via large peripheral vein 1 mg/mL, concentrations up to 4 mg/mL may be infused via central vein; give via infusion pump or other device which provides accurate control of rate; contact with metal should be minimised; incompatible with bicarbonate

Ertapenem *(Invanz®)*
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute 500 mg with 10 mL water for injections or sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration of 0.25 mg/mL; maximum concentration 5 mg/mL; continuous infusion not usually recommended

Ertapenem *(Nexium®)*
Intermittent in Sodium chloride 0.9%
Reconstitute 1 g with 10 mL water for injections or sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration not exceeding 20 mg/mL; give over 30 minutes; incompatible with glucose solutions

Erythromycin (as lactobionate)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Dissolve initially in water for injections (1 g in 20 mL) then dilute to a concentration of 1 mg/mL for continuous infusion and 1–5 mg/mL for intermittent infusion; give intermittent infusion over 20–60 minutes

Esomeprazole (as sodium salt) *(Nexium®)*
Continuous or intermittent in Sodium chloride 0.9%
Reconstitute 40–80 mg with up to 100 mL infusion fluid; for intermittent infusion, give requisite dose over 10–30 minutes; stable for 12 hours in sodium chloride 0.9%

Esomeprazole (as sodium salt)
Continuous or intermittent in Sodium chloride 0.9%
Dilute to a concentration of 5–10%

Fentanyl *(Sublimaze®)*
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%

Ferric carboxymaltose *(Ferinject®)*
Intermittent in Sodium chloride 0.9%
Dilute 200–500 mg in up to 100 mL infusion fluid and give over at least 6 minutes; dilute 0.5–1 g in up to 250 mL infusion fluid and give over at least 15 minutes

Flecainide acetae *(Tamibor®)*
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Minimum volume in infusion fluids containing chlorides 500 mL

Fonapidarinux *(Arixtra®)*
Intermittent in Sodium chloride 0.9%
For ST-segment elevation myocardial infarction, add requisite dose to 25–50 mL infusion fluid and give over 1–2 minutes

Fosaprepitant *(Ivenem®)*
Intermittent in Sodium chloride 0.9%
Reconstitute each 115-mg vial with 5 mL sodium chloride 0.9% gently without shaking to avoid foaming, then dilute in 110 mL infusion fluid; give over 15 minutes

Foscarnet sodium *(Foscavir®)*
Intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 1.5–25 mg/L (phenytoin sodium equivalent)/mL

Furosemide (as sodium salt) *(Lasix®)*
Continuous in Sodium chloride 0.9%
Infusion pH must be above 5.5 and rate should not exceed 4 mg/min; glucose solutions are unsuitable

Fusidic acid (as sodium salt)
Continuous in Sodium chloride 0.9%
Reconstitute with the buffer solution provided and dilute to 500 mL; give through central venous line over 2 hours (or over 6 hours if superficial vein used); incompatible in solution of pH less than 7.4

Ethanol
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 5–10%

Fusidic acid (as sodium salt)
Continuous in Sodium chloride 0.9%
Reconstitute in water for injections (1 g in 20 mL) then dilute to a concentration of 5 mg/mL for infusion; give intermittent infusion over 20–60 minutes

Glycine buffer diluent only, for pump or other device which provides accurate control of rate; continuous or intermittent in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration of 0.25 mg/mL; compatible with glucose solutions; use only plastic containers or syringes

Glycolate buffer diluent only, for pump or other device which provides accurate control of rate; continuous or intermittent in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration of 0.5 mg/mL; compatible with glucose solutions; use only plastic containers or syringes

Glucose 5% *(neutralised by bicarbonate)*
Continuous or intermittent infusion, give requisite dose over 1 hour (for severe hospital-acquired pneumonia or hospital-acquired pneumonia caused by less sensitive organisms, may extend infusion time to 4 hours using sodium chloride 0.9% as the infusion fluid)

Glucose 5% *(but see below)*
Continuous or intermittent infusion, give requisite dose over 1 hour (infusion-related reactions occur)

Glucose 5%
Suggested volume 100 mL given over 30–60 minutes via drip tubing in Glucose 5% or Sodium chloride 0.9%
Continuous infusion not usually recommended

Flumazenil *(Anexate®)*
Continuous in Glucose 5% or Sodium chloride 0.9%

Fondaparinux *(Arixtra®)*
Intermittent in Sodium chloride 0.9%
For ST-segment elevation myocardial infarction, add requisite dose to 25–50 mL infusion fluid and give over 1–2 minutes

Fosaprepitant *(Ivenem®)*
Intermittent in Sodium chloride 0.9%
Reconstitute each 115-mg vial with 5 mL sodium chloride 0.9% gently without shaking to avoid foaming, then dilute in 110 mL infusion fluid; give over 15 minutes

Foscarnet sodium *(Foscavir®)*
Intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 1.5–25 mg/L (phenytoin sodium equivalent)/mL
Appendix 6: Intravenous additives

**Galsulfase (Naglazyme™)**
Intermittent in Sodium chloride 0.9%
Dilute requisite dose with infusion fluid to final volume of 250 mL and mix gently; infuse through a 0.2 micron in-line filter; give approx. 2.5% of the total volume over 1 hour; then infuse remaining volume over next 3 hours; if body-weight under 20 kg and at risk of fluid overload, dilute requisite dose in 100 mL infusion fluid and give over at least 4 hours

**Ibandronic acid (Bonolonat™)**
Intermittent in Sodium 5% or Sodium chloride 0.9%
Dilute requisite dose in 500 mL infusion fluid and give over 1–2 hours

**Idursulfase (Elaprase™)**
Intermittent in Sodium chloride 0.9%
Dilute requisite dose in 100 mL infusion fluid and mix gently (do not shake); give over 3 hours (gradually reduced to 1 hour if no infusion-related reactions)

**Imiglucerase (Cerezyme™)**
Intermittent in Sodium chloride 0.9%
Initially reconstitute with water for injections (200 units in 5 mL, 400 units in 10 mL) to give 40 units/mL solution; dilute requisite dose with infusion fluid to the final volume of 100–200 mL and give initial dose at a rate not exceeding 0.5 units/kg/minute; subsequent doses to be given at a rate not exceeding 1 unit/kg/minute; administer within 3 hours after reconstitution

**Imipenem with clastatin (as sodium salt) (Primaxin)**
Intermittent in Sodium chloride 0.9% or Sodium chloride and Glucose
Dilute to a concentration of 5 mg (as imipenem)/mL; infuse 250–500 mg (as imipenem) over 20–30 minutes, 1 g over 60 minutes
Continuous infusion not usually recommended

**Infliximab (Remicade™)**
Intermittent in Sodium chloride 0.9%
Reconstitute each 100-mg vial with 10 mL water for injections using a 21-gauge or smaller needle; gently swirl vial without shaking to dissolve; allow to stand for 5 minutes; dilute requisite dose with infusion fluid to a final volume of 250 mL and give through a low protein-binding filter (1.2 micron or less); over at least 2 hours (patients being treated for rheumatoid arthritis who have tolerated 3 initial 2-hour infusions may be given subsequent infusions of up to 6 mg/kg over at least 1 hour); start infusion within 3 hours of reconstitution

**Insulin (soluble)**
Continuous in Sodium chloride 0.9%
Adsorbed to some extent by plastics of infusion set; see also section 6.1.3; ensure insulin is not injected into ‘dead space’ of injection port of the infusion bag

**Insulin aspart**
Continuous in Sodium chloride 0.9% or Glucose 5%
Dilute to 0.05–1 unit/mL with infusion fluid; adsorbed to some extent by plastics of infusion set

**Insulin glulisine (Apidra™)**
Continuous in Sodium chloride 0.9%
Dilute to 1 unit/mL with infusion fluid; use a co-extruded polyolefin/polyamide plastic infusion bag with a dedicated infusion line

**Insulin lispro**
Continuous in Sodium chloride 0.9% or Glucose 5%
Adsorbed to some extent by plastics of infusion set

**Iron dextran (Cosmofer™)**
Intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute 100–200 mg in 100 mL infusion fluid; give 25 mg over 15 minutes as a test dose initially, then give at a rate not exceeding 6.67 mg/minute; total dose to be administered in 500 mL infusion fluid and given over 4–6 hours (initial test dose 25 mg over 15 minutes)

**Iron isomaltoside 1000 (Monofer™)**
Intermittent in Sodium chloride 0.9%
For details consult product literature

**Iron sucrose (Venofer™)**
Intermittent in Sodium chloride 0.9%
Dilute 100 mg in up to 100 mL infusion fluid; give 25 mg over 15 minutes as a test dose initially, then give at a rate not exceeding 3.33 mg/minute
**Appendix 6: Intravenous additives**

**Isosorbide dinitrate** *(Isoket 0.05%, Isoket 0.1%)*
Continuous in Glucose 5% or Sodium chloride 0.9%
AdSORBED to some extent by polyvinyl chloride infusion containers; preferably use glass or polyethylene containers or give via a syringe pump. *Isoket 0.05%* can alternatively be administered undiluted using a syringe pump with a glass or rigid plastic syringe.

**Itraconazole** *(Sporanox®)*
- Intermittent in Sodium chloride 0.9%
  - Dilute 200 mg in 50 mL infusion fluid and infuse only 60 mL through an in-line filter (0.2 micron) over 60 minutes
- **Ketamine (as hydrochloride)** *(Ketalar®)*
  - Continuous
  - In syringe pump;
  - Infusion rate should be given over at least 5 minutes, high doses over at least 15 minutes

**Labetalol hydrochloride** *(Trandate®)*
- Intermittent in Glucose 5% or Sodium chloride 0.9%
  - Dilute to a concentration of 1 mg/mL; suggested volume 200 mL; adjust rate with in-line burette

**Lacosamide** *(Vimpat®)*
- Intermittent in Glucose 5% or Sodium chloride 0.9%
  - May be administered undiluted

**Laronidase** *(Aladurzyme®)*
- Intermittent in Sodium chloride 0.9%
  - Body-weight under 20 kg, use 100 mL infusion fluid; body-weight over 20 kg use 250 mL infusion fluid; withdraw volume of infusion fluid equivalent to volume of laronidase concentrate being added; give through an in-line filter (0.22 micron) at an initial rate of 2 units/kg/hour then increasing gradually every 15 minutes to max. 43 units/kg/hour

**Lenograstim** *(Granocyte®)*
- Intermittent in Sodium chloride 0.9%
  - Initially reconstitute with 1 mL water for injection provided (do not shake vigorously) then dilute with at least 50 mL infusion fluid; protect infusion from light; give over 60 minutes

**Lepirudin** *(Refludan®)*
- Continuous in Glucose 5% or Sodium chloride 0.9%
  - Reconstitute initially with water for injections or sodium chloride 0.9% then dilute to a concentration of 2 mg/mL with infusion fluid

**Levetiracetam** *(Keppra®)*
- Intermittent in Glucose 5% or Sodium chloride 0.9%
  - Dilute requisite dose with at least 100 mL of infusion fluid; give over 15 minutes

**Magnesium sulphate**
Continuous in Glucose 5% or Sodium chloride 0.9%
Suggested concentration up to 200 mg/mL, max. rate 150 mg/minute

**Mepolizumab** *(Mepem®)*
- Intermittent in Sodium chloride 0.9%
  - Dilute dose in infusion fluid to a final concentration of 1–20 mg/mL; give over 15–30 minutes

**Methyldopa** *(as hydrochloride)** *(Lidoderm®)*
Continuous or intermittent via drip tubing in Glucose 5% or Sodium chloride 0.9%
Suggested volume 500 mL

**Methyldopamine hydrochloride** *(Maxolon High Dose®)*
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Continuous infusion recommended; loading dose, dilute with 50–100 mL and give over 15–20 minutes; maintenance dose, dilute with 500 mL and give over 6–12 hours; for intermittent infusion dilute with at least 50 mL and give over at least 15 minutes

**Mivacurium** *(as chloride)*
Continuous in Glucose 5% or Sodium chloride 0.9%
Continuous infusion 1 mg/mL; microdrip infusion for maintenance of muscle relaxation

**Naloxone** *(Ninjax®, Naloxone Hydrochloride)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Natalizumab** *(Tysabri®)*
- Intermittent in Sodium chloride 0.9%
  - Dilute 300 mg in 100 mL infusion fluid, gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour

**Nimodipine** *(Nimotop®)*
via drip tubing in Glucose 5% or Sodium chloride 0.9%
- Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light

**Nizatidine** *(Axid®)*
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
For continuous infusion, dilute 300 mg in 150 mL and give at a rate of 10 mg/hour; for intermittent infusion, dilute 100 mg in 50 mL and give over 15 minutes

**Noradrenaline acid tartrate/Norepinephrine bitartrate**
Continuous in Glucose 5% or Sodium chloride 0.9%
Give via controlled infusion device; for administration via syringe pump, dilute 4 mg noradrenaline acid tartrate (2 mL solution) with 48 mL, for administration via drip counter dilute 40 mg (20 mL solution) with 480 mL, give through a central venous catheter, incompatible with alkalai.

**Omeprazole** *(as sodium salt)* *(Losec®)*
Intermittent or continuous in Glucose 5% or Sodium chloride 0.9%
Reconstitute each 40 mg vial with infusion fluid and dilute to 100 mL; for intermittent infusion, give 40 mg over 20–30 minutes; stable for 3 hours in glucose 5% or 12 hours in sodium chloride 0.9%

**Metoclopramide hydrochloride** *(CellCept®)*
Continuous in Glucose 5% or Sodium chloride 0.9%
Continuous infusion recommended; loading dose, dilute with 50–100 mL and give over 15–20 minutes; maintenance dose, dilute with 500 mL and give over 6–12 hours; for intermittent infusion dilute with at least 50 mL and give over at least 15 minutes

**Micafungin** *(Mycamine®)*
- Intermittent in Glucose 5% or Sodium chloride 0.9%
  - Reconstitute each vial with 5 mL infusion fluid, gently rotate vial, without shaking, to dissolve, dilute requisite dose with infusion fluid to 100 mL (final concentration 0.5–2 mg/mL); protect infusion from light; give over 60 minutes

**Midazolam** *(Hypnovel®)*
Continuous in Glucose 5% or Sodium chloride 0.9%
For neonates and children under 15 kg dilute to a max. concentration of 1 mg/mL

**Mirtolone** *(Primacor®)*
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a suggested concentration of 200 micrograms/mL

**Mivacurium** *(as chloride)** *(Mivacron®)*
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 500 micrograms/mL, may also be given undiluted

**Mycopelate mofetil** *(as hydrochloride)** *(CellCept®)*
- Intermittent in Glucose 5%
  - Reconstitute each 500-mg vial with 14 mL glucose 5% and dilute the contents of 2 vials in 140 mL infusion fluid, give over 2 hours

**Pentamidine** *(as isethionate)* *(Miniset®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Pentazocine** *(Tylazin®)*
- Intermittent in Sodium chloride 0.9%
  - Dilute 300 mg in 100 mL infusion fluid, gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour

**Pentazocine (as isethionate)** *(Tylazin®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Primidone** *(Mysoline®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Procarbazine** *(CellCept®)*
- Continuous in Sodium chloride 0.9%
  - Dilute 300 mg in 50 mL infusion fluid, gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour

**Prochlorperazine** *(as hydrochloride)* *(Compazine®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Promethazine** *(Phenergan®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Propofol** *(Diprivan®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Promethazine** *(as hydrochloride)* *(Phenergan®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”

**Promethazine** *(as hydrochloride)* *(Phenergan®)*
Continuous in Glucose 5%
- Dilute to a concentration of 200 micrograms/mL and administer via an infusion pump, see “Emergency Treatment of Poisoning with Opioids”
Appendix 6: Intravenous additives

Ondansetron (as hydrochloride) (Zofran®)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
For intermittent infusion, dilute 32 mg in 50–100 mL and give over at least 15 minutes

Oxydode hydrochloride (OxyNorm®)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of 1 mg/mL.

Phytomenadione (in mixed micelles vehicle)

Phenytoin sodium

Phenylephrine hydrochloride

Phenoxybenzamine hydrochloride

Pentamidine isetionate

Pantoprazole (as sodium sesquihydrate) (Protium®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute 40 mg with 10 mL, 4.5 g in 20 mL; give over at least 15 minutes

Potassium chloride
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute in a large-volume infusion, mix thoroughly to avoid ‘layering’, especially in non-rigid infusion containers; use ready-prepared solutions when possible

Propofol (emulsion) (Diprivan®; Abbott; Propofol-Lipuro®, Propofen®, Braun; Hospira; Fresenius Kabi)
0.5%, 1%, or 2% emulsion
via drip tubing in Glucose 5% or Sodium chloride 0.9%
To be administered via a Y-piece close to injection site; microbiological filter not recommended

1% emulsion only
Continuous in Glucose 5% or Sodium chloride 0.9%
for Propofol-Lipuro®, Propofen®, Braun, and Fresenius Kabi brands only)
Dilute to a concentration not less than 2 mg/mL; microbiological filter not recommended; administer using suitable device to control infusion rate; use glass or PVC containers (if PVC bag used it should be full—withdraw volume of infusion fluid equal to that of propofol to be added); give within 6 hours of preparation, propofol may alternatively be infused undiluted using a suitable control infusion pump

Quinine dihydrochloride
Continuous in Glucose 5% or Sodium chloride 0.9%
To be given over 4 hours; see also section 5.4.1

Ranitidine (as hydrochloride) (Zantac®)
Intermittent in Glucose 5% or Sodium chloride 0.9%

Rasburicase (Fasturtex®)
Intermittent in Sodium chloride 0.9%
Reconstitute with solvent provided; gently swirl vial without shaking to dissolve; dilute requisite dose to 50 mL with infusion fluid and give over 30 minutes

Remifentanil (Ultiva®)
Continuous in Glucose 5% or Sodium chloride 0.9%
or Water for injections
Reconstitute with infusion fluid to a concentration of 1 mg/mL
then dilute further to a concentration of 20–250 micrograms/mL
50 micrograms/mL recommended for general anaesthesia, 20–25 micrograms/mL recommended for children 1–12 years, 20–50 micrograms/mL recommended when used with target controlled infusion (TCI) device

Rifampicin (Rifadin®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute with solvent provided then dilute with 500 mL infusion fluid; give over 2–3 hours

Ritodrine hydrochloride (Yutopar®)
Continuous in Glucose 5%
Give via controlled infusion device, preferably a syringe pump; if syringe pump available dilute to a concentration of 3 mg/mL if syringe pump not available dilute to a concentration of 300 micrograms/mL; close attention to patient’s fluid and electrolyte status essential

Rituximab (MabThera®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute to 1–4 mg/mL and gently invert bag to avoid foaming

Rocuronium bromide (Esmeron®)
Continuous or via drip tubing in Glucose 5% or Sodium chloride 0.9%

900 Appendix 6: Intravenous additives
Salbutamol (as sulphate) (Ventolin® For Intravenous Infusion)
Continuous in Glucose 5%
For bronchodilatation dilute to a concentration of 200 micrograms/mL with glucose 5% or sodium chloride 0.9%; for premature labour dilute with glucose 5% to a concentration of 100 micrograms/mL for use in a syringe pump or for other infusion methods (preferably via controlled infusion device), dilute to a concentration of 20 micrograms/mL; close attention to patient’s fluid and electrolyte status essential

Sodium calcium edetate (Ledclair®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute to a concentration of not more than 3%; suggested volume 250–500 mL given over at least 1 hour

Sodium nitroprusside
Continuous in Glucose 5%
Infuse via infusion device to allow precise control; protect infusion from light. For further details consult product literature

Sodium valproate
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute Epilim® with solvent provided then dilute with infusion fluid

Streptokinase (Streptase®)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute with sodium chloride 0.9%, then dilute further with infusion fluid

Tacrolimus (Prograf®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Dilute concentrate in infusion fluid to a final concentration of 4–100 micrograms/mL; give over 24 hours; incompatible with PVC

Telcoplan (Targocid®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute initially with water for injections provided; infuse over 30 minutes
Continuous infusion not usually recommended

Temocillin (Negaban®)
Intermittent in Glucose 5% or 10% or Sodium chloride 0.9%
Reconstitute 1 g with 10 mL water for injections then dilute with 50–150 mL infusion fluid, give over 30–60 minutes

Terbutaline sulphate (Bricanyl®)
Continuous in Glucose 5%
For bronchodilatation dilute 1.5–2.5 mg with 500 mL glucose 5% or sodium chloride 0.9% and give over 6–10 hours; for premature labour dilute in glucose 5% and give via controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100 micrograms/mL; if syringe pump not available dilute to a concentration of 10 micrograms/mL; close attention to patient’s fluid and electrolyte status essential

Ticarcillin sodium with clavulanic acid (Timentin®)
Intermittent in Glucose 5% or Water for injections
Suggested volume (depending on dose) glucose 5% 100–150 mL or water for injections 50–100 mL, given over 30–40 minutes

Tigecycline (Tigecycline)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute each vial with 5.3 mL infusion fluid to produce a 10 mg/mL solution; dilute requisite dose in 100 mL infusion fluid; give over 30–60 minutes

Tirofiban (Aggrastat®)
Continuous in Glucose 5% or Sodium chloride 0.9%
Withdraw 50 mL infusion fluid from 250-mL bag and replace with 50 mL tirofiban concentrate (250 micrograms/mL) to give a final concentration of 58 micrograms/mL

Appendix 6: Intravenous additives

Tobramycin (as sulphate) (Nebcin®)
Intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%
For adult intermittent infusion suggested volume 50–100 mL (children proportionately smaller volume) given over 20–60 minutes

Tocilizumab (RoActemra®)
Intermittent in Sodium chloride 0.9%
Dilute requisite dose to a volume of 100 mL with infusion fluid and give over 1 hour

Tramadol hydrochloride (Zydone®)
Continuous or intermittent in Glucose 5% or Sodium chloride 0.9%

Tranexamic acid (Cyklokapron®)
Continuous in Glucose 5% or Sodium chloride 0.9%

Urokinase (Syner-KINASE®)
Continuous or intermittent in Sodium chloride 0.9%

Vancomycin (as hydrochloride) (Vancocin®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute each 500 mg with 10 mL water for injections and dilute with infusion fluid to a concentration of up to 5 mg/mL (10 mg/mL in fluid restriction but increased risk of infusion-related effects); give over at least 60 minutes (rate not to exceed 10 mg/minute for doses over 500 mg); use continuous infusion only if intermittent not feasible

Vasopressin, synthetic (Pitressin®)
Intermittent in Glucose 5%
Suggested concentration 20 units/100 mL given over 15 minutes

Vecuronium bromide (Norcuron®)
Continuous or via drip tubing in Glucose 5% or Sodium chloride 0.9%
Reconstitute each vial with 5 mL water for injections to give 2 mg/mL solution, alternatively reconstitute with up to 10 mL glucose 5% or sodium chloride 0.9% or water for injections—unsuitable for further dilution if not reconstituted with water for injections. For continuous intravenous infusion, dilute to a concentration up to 40 micrograms/mL

Velaglucerase alfa (VPRIV®)
Intermittent in Sodium chloride 0.9%
Reconstitute each 400–unit vial with 4.3 mL water for injections to produce a 100 units/mL solution; dilute requisite dose in 100 mL infusion fluid, give over 60 minutes through a 0.22 micron filter, start infusion within 24 hours of reconstitution

Verteporfin (Visudyne®)
Intermittent in Glucose 5%
Reconstitute each 15 mg with 7 mL water for injections to produce a 2 mg/mL solution then dilute requisite dose with infusion fluid to a final volume of 30 mL and give over 10 minutes; protect infusion from light and administer within 4 hours of reconstitution. Incompatible with sodium chloride infusion

Vitamins B & C (Pabrinex® 1/IV High potency)
Intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%
Ampluole contents should be mixed, diluted, and administered without delay; give over 30 minutes (see MHRA/CHM advice, section 9.6.2)

Vitamins, multiple
(Cernevit®)
Intermittent in Glucose 5% or Sodium chloride 0.9%
Suggested concentration 20 units/100 mL given over 15 minutes

Appendix 6: Intravenous additives 901
Voriconazole ([Vfend®])
Intermittent in Glucose 5% or Sodium chloride 0.9%
Reconstitute each 200 mg with 19 mL water for injections to produce a 10 mg/mL solution; dilute dose in infusion fluid to concentration of 0.5–5 mg/mL, give at a rate not exceeding 3 mg/kg/hour.

Zidovudine ([Retrovir®])
Intermittent in Glucose 5%
Dilute to a concentration of 2 mg/mL or 4 mg/mL and give over 1 hour.

Zoledronic acid ([Zometa®])
Intermittent in Glucose 5% or Sodium chloride 0.9%
Dilute requisite dose with 100 mL infusion fluid, infuse over at least 15 minutes; administer as a single intravenous solution in a separate infusion line; do not mix with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution.
A7 Borderline substances

A7.1 Enteral feeds (non-disease specific) 904
A7.1.1 Enteral feeds (non-disease specific): less than 5 g protein/100 mL 904
A7.1.2 Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL 906
A7.1.3 Enteral feeds (non-disease specific): Child under 12 years 910
A7.2 Nutritional supplements (non-disease specific) 910
A7.2.1 Nutritional supplements: less than 5 g protein/100 mL 910
A7.2.2 Nutritional supplements: 5 g (or more) protein/100 mL 911
A7.3 Specialised formulas 915
A7.3.1 Specialised formulas: Infant and child 916
A7.3.2 Specialised formulas for specific clinical conditions 916
A7.4 Feed supplements 919
A7.4.1 High-energy supplements 919
A7.4.2 Fibre, vitamin, and mineral supplements 924
A7.5 Feed additives 925
A7.5.1 Special additives for conditions of intolerance 925
A7.5.2 Feed thickeners and pre-thickened drinks 925
A7.5.3 Flavouring preparations 925
A7.6 Foods for special diets 925
A7.6.1 Gluten-free foods 925
A7.6.2 Low-protein foods 928
A7.7 Nutritional supplements for metabolic diseases 929

In certain conditions some foods (and toilet preparations) have characteristics of drugs and the Advisory Committee on Borderline Substances (ACBS) advises as to the circumstances in which such substances may be regarded as drugs. Prescriptions issued in accordance with the Committee’s advice and endorsed ‘ACBS’ will normally not be investigated.

General Practitioners are reminded that the ACBS recommends products on the basis that they may be regarded as drugs for the management of specified conditions. Doctors should satisfy themselves that the products can safely be prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.

Foods which may be prescribed on FP10, GP10 (Scotland), or WP10 (Wales) All the food products listed in this appendix have ACBS approval. The clinical condition for which the product has been approved is included with each entry.

Note Foods included in this appendix may contain cariogenic sugars and patients should be advised to take appropriate oral hygiene measures.

Enteral feeds and supplements For most enteral feeds and nutritional supplements, the main source of carbohydrate is either maltodextrin or glucose syrup; other carbohydrate sources are listed in the relevant table, below. Feeds containing residual lactose (less than 1 g lactose/100 mL formula) are described as ‘clinically lactose-free’ or ‘lactose-free’ by some manufacturers. The presence of lactose (including residual lactose) in feeds is indicated in the relevant table, below. The primary sources of protein or amino acids are included with each product entry. The fat or oil content is derived from a variety of sources such as vegetables, soya bean, corn, palm nuts, and seeds; where the fat content is derived from animal or fish sources, this information is included in the relevant table, below. The presence of medium chain triglycerides (MCT) is also noted where the quantity exceeds 30% of the fat content.

Enteral feeds and nutritional supplements can contain varying amounts of vitamins, minerals, and trace elements—the manufacturer’s product literature should be consulted for more detailed information. For further information on enteral nutrition, see section 9.4.2.

Enteral feeds containing vitamin K may affect the INR in patients receiving warfarin; see interactions: Appendix 1 (vitamins).

The suitability of food products for patients requiring a vegan, kosher, halal, or other compliant diet should be confirmed with individual manufacturers.

For details of enteral feeds, nutritional supplements, and specialised formulas suitable for infants and children under 12 years see BNF for Children (Appendix 2)

Note Feeds containing more than 6 g/100 mL protein or 2 g/100 mL fibre should be avoided in children unless recommended by an appropriate specialist or dietician.

Standard ACBS indications
Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
## Appendix 7: Borderline substances

### A7.1 Enteral feeds (non-disease specific)

#### A7.1.1 Enteral feeds (non-disease specific): less than 5 g protein/100 mL

Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 mL)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® Original (Fresenius Kabi)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13.8 g (sugars 3.5 g³)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin Feed in flexible pack contains fish oil and fish gelatin</td>
<td>Standard, p. 903</td>
<td>Bottle: 200 mL = £1.78 Black currant, chocolate, mocha, nut, peach, vanilla Flexible pack: 500 mL = £3.45 1000 mL = £6.81 1500 mL = £10.23</td>
</tr>
<tr>
<td>Fresubin® Original Fibre (Fresenius Kabi)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13.8 g (sugars 1 g)</td>
<td>3.4 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 903 except bowel fistula. Not suitable for child under 2 years</td>
<td>Flexible pack: 500 mL = £3.90 1000 mL = £7.78 1500 mL = £10.69</td>
</tr>
<tr>
<td>Isosource® Fibre (Nestlé)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>422 kJ (100 kcal)</td>
<td>3.8 g cows' milk soya</td>
<td>13.6 g</td>
<td>3.4 g</td>
<td>1.4 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 Not suitable for child under 2 years</td>
<td>Flexible pack: 500 mL = £3.49 1000 mL = £6.97</td>
</tr>
<tr>
<td>Isosource® Standard (Nestlé)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g cows' milk</td>
<td>13.6 g</td>
<td>3.3 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 500 mL = £3.07 1000 mL = £6.13</td>
</tr>
<tr>
<td>Jevity® (Abbott)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>441 kJ (106 kcal)</td>
<td>4 g caseinates</td>
<td>14.1 g (sugars 470 mg)</td>
<td>3.47 g</td>
<td>1.76 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 except bowel fistula. Not suitable for child under 2 years</td>
<td>Flexible pack: 500 mL = £4.16 1000 mL = £7.81 1500 mL = £11.73</td>
</tr>
<tr>
<td>Novasource® GI Control (Nestlé)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>444 kJ (106 kcal)</td>
<td>4.1 g cows' milk</td>
<td>14.4 g (sugars 500 mg)</td>
<td>3.5 g (MCT 40 %)</td>
<td>2.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 500 mL = £4.78</td>
</tr>
<tr>
<td>Nutrison® (Nutricia Clinical)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g cows' milk</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Bottle: 500 mL = £3.76 Flexible pack: 500 mL = £4.17 1000 mL = £7.32 1500 mL = £10.97</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
<table>
<thead>
<tr>
<th>Nutrison® Multi Fibre (Nutricia Clinical)</th>
<th>Liquid (tube feed) per 100 mL</th>
<th>420 kJ (100 kcal)</th>
<th>4 g cows' milk</th>
<th>12.3 g (sugars 1 g)</th>
<th>3.9 g</th>
<th>1.5 g</th>
<th>Gluten-free Residual lactose</th>
<th>Standard, p. 903 except bowel fistula</th>
<th>Bottle: 500 mL = £4.09 Flexible pack: 500 mL = £4.51 1000 mL = £8.16 1500 mL = £12.25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolite® (Abbott)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>424 kJ (100 kcal)</td>
<td>4 g caseinates soy isolate</td>
<td>13.6 g (sugars 630 mg)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Can: 250 mL = £1.88 Bottle: 500 mL = £3.57 1000 mL = £6.81 1500 mL = £10.22</td>
</tr>
<tr>
<td>Fresubin® Soya Fibre (Fresenius Kabi)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g soya protein</td>
<td>13.3 g (sugars 4.1 g)</td>
<td>3.6 g</td>
<td>2 g</td>
<td>Gluten-free Lactose-free Contains fish oil</td>
<td>Standard, p. 903; also cows' milk protein intolerance, lactose intolerance</td>
<td>Flexible pack: 500 mL = £4.03</td>
</tr>
<tr>
<td>Nutrison® Soya Multi Fibre (Nutricia Clinical)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g soya isolate</td>
<td>12.3 g (sugars 700 mg)</td>
<td>3.9 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose Milk protein-free</td>
<td>Standard, p. 903; also cows' milk protein and lactose intolerance</td>
<td>Bottle: 500 mL = £4.34 Flexible pack: 1000 mL = £8.69</td>
</tr>
<tr>
<td>Peptamen® (Nestlé)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g whey peptides</td>
<td>12.7 g (sugars 480 mg)</td>
<td>3.7 g (MCT 70 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Cup (vanilla flavour): 200 mL = £2.83 Flexible pack: 500 mL = £5.86 1000 mL = £11.00</td>
</tr>
<tr>
<td>Peptisorb® (Nutricia Clinical)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>425 kJ (100 kcal)</td>
<td>4 g whey protein hydrolysate</td>
<td>17.6 g (sugars 1.7 g)</td>
<td>1.7 g (MCT 47 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Bottle: 500 mL = £5.76 Flexible pack: 500 mL = £6.31 1000 mL = £11.41</td>
</tr>
<tr>
<td>Survivmed® OPD (Fresenius Kabi)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4.5 g lactalbumin hydrolysate</td>
<td>15 g (sugars 300 mg)</td>
<td>2.4 g (MCT 54 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Standard, p. 903; also growth failure</td>
<td>Flexible pack: 500 mL = £5.75</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
### Amino acid formula (essential and non-essential amino acids)

**A7.1.1.2 Enteral feeds: Less than 1 kcal/mL and less than 5 g protein/100 mL**

Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elemental 028 Extra (SHS)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>360 kJ (86 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11 g (sugars 4.7 g)</td>
<td>3.5 g (MCT 35%)</td>
<td>Nil</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Carton: 250 mL = £3.19</td>
<td>Grapefruit, orange-pineapple, summer fruits</td>
</tr>
<tr>
<td></td>
<td>Standard dilution (20%) of powder (sip or tube feed) per 100 mL</td>
<td>374 kJ (89 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11.8 g (sugars 1.1 g)</td>
<td>3.5 g (MCT 35%)</td>
<td>Nil</td>
<td></td>
<td>Sachet: 100 g = £6.01</td>
<td>Banana, citrus, orange, unflavoured</td>
</tr>
</tbody>
</table>

Powder provides protein equivalent 12.5 g, carbohydrate 59 g, fat 17.45 g, energy 1871 kJ (443 kcal)/100 g.

1. Nutritional values vary with flavour—consult product literature
2. Flavouring: see Modju® Flavour System, p. 925

### A7.1.2 Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL

**A7.1.2.1 Enteral feeds: 1.5 kcal/mL and 5 g (or more) protein/100 mL**

Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 2250 Complete (Fresenius Kabi)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free Contains fish oil and fish gelatin</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 1500 mL = £12.25</td>
</tr>
<tr>
<td>Fresubin® Energy (Fresenius Kabi)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin</td>
<td>Standard, p. 903</td>
<td>Bottle: 200 mL = £1.78</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
2. Strawberry flavour may contain traces of wheat starch and egg
<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Energy per 100 mL</th>
<th>Protein</th>
<th>Carbohydrates</th>
<th>Fat</th>
<th>Lactose</th>
<th>Gluten-free</th>
<th>Residual lactose</th>
<th>Additional Ingredients</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin Energy Fibre (Fresenius Kabi)</td>
<td>Liquid (sip feed)</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.4 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Contains fish gelatin</td>
<td>Bottle: 200 mL = £1.87 Banana, caramel, cherry, chocolate, strawberry, vanilla</td>
</tr>
<tr>
<td></td>
<td>Liquid (tube feed)</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Contains fish gelatin</td>
<td>Flexible pack: 500 mL = £4.63 1000 mL = £8.82</td>
</tr>
<tr>
<td>Fresubin® HP Energy (Fresenius Kabi)</td>
<td>Liquid (tube feed)</td>
<td>630 kJ (150 kcal)</td>
<td>7.5 g cows’ milk</td>
<td>17 g (sugars 1 g)</td>
<td>5.8 g (MCT 57%)</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Contains fish gelatin</td>
<td>Standard, p. 903; also CAPD and haemodialysis Flexible pack: 500 mL = £4.29 1000 mL = £8.60</td>
</tr>
<tr>
<td>Isosource® Energy Fibre (Nestlé)</td>
<td>Liquid (tube feed)</td>
<td>630 kJ (150 kcal)</td>
<td>4.9 g cows’ milk</td>
<td>20.2 g</td>
<td>5.5 g</td>
<td>1.5 g</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Standard, p. 903 except bowel fistula Flexible pack: 500 mL = £4.08 1000 mL = £8.17</td>
<td></td>
</tr>
<tr>
<td>Jevity® 1.5 kcal (Abbott)</td>
<td>Liquid (tube feed)</td>
<td>640 kJ (152 kcal)</td>
<td>6.38 g caseinates soy isolate</td>
<td>20.1 g (sugars 1.47 g)</td>
<td>4.9 g</td>
<td>2.2 g</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Standard, p. 903 Not suitable for child under 2 years; not recommended for child 2–10 years Flexible pack: 500 mL = £4.92 1000 mL = £9.40 1500 mL = £14.67</td>
<td></td>
</tr>
<tr>
<td>Novasource® GI Forte (Nestlé)</td>
<td>Liquid (tube feed)</td>
<td>631 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.3 g (sugars 1.8 g)</td>
<td>5.9 g</td>
<td>2.2 g</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Standard, p. 903 Flexible pack: 500 mL = £4.75 1000 mL = £9.50</td>
<td></td>
</tr>
<tr>
<td>Nutrison® Energy Multi Fibre (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Standard, p. 903 Bottle: 500 mL = £4.38 Flexible pack: 500 mL = £4.86 1000 mL = £8.81 1500 mL = £13.18</td>
<td></td>
</tr>
</tbody>
</table>

### Notes
1. Sugar content varies with flavour.
### Appendix 7: Borderline substances

#### A7.1.2.1 Enteral feeds: 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 mL)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat (sugars)</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolite® 1.5 kcal (Abbott)</td>
<td>Liquid (tube feed)</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g</td>
<td>20 g</td>
<td>5 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 500 mL = £4.37</td>
</tr>
</tbody>
</table>

| Resource® Energy (Nestlé) | Liquid (sip feed) | 630 kJ (150 kcal)   | 5.6 g  | 21 g         | 5 g less than 500 mg | Gluten-free Residual lactose | Standard, p. 903 | Bottle: 4 x 200 mL = £6.97 |

1. Sugar content varies with flavour.

#### A7.1.2.2 Enteral feeds: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 mL)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat (sugars)</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 1000 Complete (Fresenius Kabi)</td>
<td>Liquid (tube feed)</td>
<td>420 kJ (100 kcal)</td>
<td>5.5 g</td>
<td>12.5 g</td>
<td>3.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 1000 mL = £8.82</td>
</tr>
</tbody>
</table>

| Fresubin® 1200 Complete (Fresenius Kabi) | Liquid (tube feed) | 500 kJ (120 kcal)   | 6 g  | 15 g         | 4.1 g        | 2 g    | Gluten-free Residual lactose Contains fish oil | Standard, p. 903 | Flexible pack: 1000 mL = £11.41 |

| Fresubin® 1800 Complete (Fresenius Kabi) | Liquid (tube feed) | 500 kJ (120 kcal)   | 6 g  | 15 g         | 4.1 g        | 2 g    | Gluten-free Residual lactose Contains fish oil | Standard, p. 903 | Flexible pack: 1500 mL = £11.23 |

| Jevity® Plus (Abbott) | Liquid (tube feed) | 504 kJ (120 kcal)   | 5.5 g caseinates soy isolates | 15.1 g (sugars 890 mg) | 3.93 g | 2.2 g | Gluten-free Residual lactose | Standard, p. 903; also CAPD, haemodialysis Not suitable for child under 2 years; not recommended for child 2–10 years | Flexible pack: 500 mL = £4.48 |

<p>| Jevity® Plus HP (Abbott) | Liquid (tube feed) | 547 kJ (130 kcal)   | 8.13 g cows’ milk soy isolates | 14.2 g (sugars 950 mg) | 4.33 g | 1.5 g | Gluten-free Residual lactose | Standard, p. 903; also CAPD, haemodialysis Not suitable for child under 2 years; not recommended for child 2–10 years | Flexible pack: 500 mL = £4.57 |</p>
<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>KJ/mL</th>
<th>Carbohydrates</th>
<th>Fat</th>
<th>Protein</th>
<th>Gluten Status</th>
<th>Lactose Status</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jevity Promote (Abbott)</td>
<td>Liquid (tube feed)</td>
<td>427 kJ</td>
<td>5.55 g caseinates, soy isolates</td>
<td>12 g</td>
<td>3.32 g</td>
<td>Gluten-free</td>
<td>Residual lactose</td>
<td>Standard, p. 903 Not suitable for child under 2 years; not recommended for child 2–10 years Flexible pack: 1000 mL = £8.95</td>
</tr>
<tr>
<td>Nutrison MCT (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>420 kJ</td>
<td>5 g cows' milk</td>
<td>12.6 g</td>
<td>3.3 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 Flexible pack: 1000 mL = £8.15</td>
</tr>
<tr>
<td>Nutrison Protein Plus (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>525 kJ</td>
<td>6.3 g cows' milk</td>
<td>14.2 g</td>
<td>4.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 Flexible pack: 1000 mL = £8.39</td>
</tr>
<tr>
<td>Nutrison Protein Plus Multi Fibre (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>525 kJ</td>
<td>6.3 g cow's milk</td>
<td>14.1 g</td>
<td>4.9 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease-related malnutrition Flexible pack: 1000 mL = £9.34</td>
</tr>
<tr>
<td>Nutrison 1000 Complete Multi Fibre (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>420 kJ</td>
<td>5.5 g cows' milk</td>
<td>11.3 g</td>
<td>3.7 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease-related malnutrition in patients with low energy and/or low fluid requirements Flexible pack: 1000 mL = £8.85</td>
</tr>
<tr>
<td>Nutrison 1200 Complete Multi Fibre (Nutricia Clinical)</td>
<td>Liquid (tube feed)</td>
<td>505 kJ</td>
<td>5.5 g cows' milk</td>
<td>15 g</td>
<td>4.3 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 except bowel fistula Bottle: 500 mL = £6.80 Flexible pack: 1000 mL = £9.59 1500 mL = £14.41</td>
</tr>
<tr>
<td>Osmolite Plus (Abbott)</td>
<td>Liquid (tube feed)</td>
<td>508 kJ</td>
<td>5.55 g caseinates</td>
<td>15.8 g</td>
<td>3.93 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 Not recommended for child under 10 years Flexible pack: 500 mL = £4.18 1000 mL = £8.06 1500 mL = £12.07</td>
</tr>
<tr>
<td>Peptamen HN (Nestlé)</td>
<td>Liquid (tube feed)</td>
<td>556 kJ</td>
<td>6.6 g whey protein hydrolysates</td>
<td>15.6 g</td>
<td>4.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Hydrolysed with pork trypsin</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula Not suitable for child under 3 years Flexible pack: 500 mL = £6.32</td>
</tr>
<tr>
<td>Perative (Abbott)</td>
<td>Liquid (tube feed)</td>
<td>552 kJ</td>
<td>6.7 g caseinate whey protein hydrolysates</td>
<td>17.7 g</td>
<td>3.7 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903 Not suitable for child under 5 years Flexible pack: 500 mL = £5.82 1000 mL = £11.65</td>
</tr>
</tbody>
</table>
## Appendix 7: Borderline substances

### A7.1.2.3 Enteral feeds: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
Not suitable for use in child under 1 year; not recommended for child 1–6 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Twocal (Abbott)</td>
<td>Liquid (sip or</td>
<td>838 kJ</td>
<td>8.4 g cows' milk</td>
<td>21 g</td>
<td>8.9 g</td>
<td>1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903; also haemodia-</td>
<td>Bottle: 200 mL = £2.14</td>
</tr>
<tr>
<td></td>
<td>tube feed) per</td>
<td>(200 kcal)</td>
<td></td>
<td>(sugars 4.5 g)</td>
<td></td>
<td></td>
<td></td>
<td>lysis, CAPD</td>
<td>Banana, neutral, strawberry, vanilla</td>
</tr>
<tr>
<td></td>
<td>100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isosource® Energy</td>
<td>Liquid (tube feed)</td>
<td>670 kJ</td>
<td>5.7 g cows' milk</td>
<td>20 g</td>
<td>6.2 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Flexible pack: 500 mL = £3.77</td>
</tr>
<tr>
<td>(Nestlé)</td>
<td>per 100 mL</td>
<td>(160 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1000 mL = £7.53</td>
</tr>
</tbody>
</table>

| Ensure® Plus Juice       | Liquid (sip feed) | 638 kJ | 4.8 g whey protein isolate | 32.7 g | Nil | Nil | Gluten-free Residual lactose Non-milk taste | Standard, p. 903 | Bottle: 220 mL = £1.80 |
| (Abbott)                 | per 100 mL        | (150 kcal) |              | (sugars 9.4 g) | | |                          |                 | Apple, fruit punch, lemon-lime, orange, peach, strawberry |

1. Nutritional values vary with flavour—consult product literature

### A7.2 Nutritional supplements (non-disease specific)

#### A7.2.1 Nutritional supplements: less than 5 g protein/100 mL

##### A7.2.1.1 Nutritional supplements: 1 kcal/mL and less than 5 g protein/100 mL
Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Plus Juice</td>
<td>Liquid (sip feed)</td>
<td>638 kJ</td>
<td>4.8 g whey protein isolate</td>
<td>32.7 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Standard, p. 903</td>
<td>Bottle: 220 mL = £1.80</td>
</tr>
<tr>
<td>(Abbott)</td>
<td>per 100 mL</td>
<td>(150 kcal)</td>
<td></td>
<td>(sugars 9.4 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apple, fruit punch, lemon-lime, orange, peach, strawberry</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour

### A7.1.3 Enteral feeds (non-disease specific): Child under 12 years see BNF for Children

### A7.2.2 Nutritional supplements: More than 1 kcal/mL and less than 5 g protein/100 mL
Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Plus Juice</td>
<td>Liquid (sip feed)</td>
<td>638 kJ</td>
<td>4.8 g whey protein isolate</td>
<td>32.7 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Standard, p. 903</td>
<td>Bottle: 220 mL = £1.80</td>
</tr>
<tr>
<td>(Abbott)</td>
<td>per 100 mL</td>
<td>(150 kcal)</td>
<td></td>
<td>(sugars 9.4 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apple, fruit punch, lemon-lime, orange, peach, strawberry</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
### A7.2 Nutritional supplements: 5 g (or more) protein/100 mL

#### A7.2.2.1 Nutritional supplements: 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
<th>Bottle: 200 mL = £1.85</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Plus Fibre</td>
<td>Liquid (sip &amp; tube feed) per 100 mL</td>
<td>642 kJ (153 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 5.5 g)</td>
<td>4.92 g</td>
<td>2.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Banana, chocolate, fruits of the forest, raspberry, strawberry, vanilla</td>
<td></td>
</tr>
<tr>
<td>Resource® Dessert</td>
<td>Semi-solid per 100 g</td>
<td>671 kJ (160 kcal)</td>
<td>4.8 g cows’ milk</td>
<td>21.2 g (sugars 9.9 g)</td>
<td>6.2 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Caramel, chocolate, vanilla</td>
<td></td>
</tr>
<tr>
<td>Resource® Fruit</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>520 kJ (125 kcal)</td>
<td>4 g whey protein hydrolysate</td>
<td>27 g (sugars 9.5 g)</td>
<td>less than 200 mg</td>
<td>less than 200 mg</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years</td>
<td>Bottle: 4 × 200 mL = £7.02</td>
</tr>
</tbody>
</table>

1. Nutritional values vary with flavour—consult product literature.

---

### Fortijuce®
(Nutricia Clinical)

<table>
<thead>
<tr>
<th>Liquid (sip feed) per 100 mL</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Bottle: 200 mL = £1.85</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Fortijuce</em></td>
<td>4 g cows’ milk</td>
<td>33.5 g (sugars 13.1 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Start pack (mixed): 4 × 200 mL = £7.40</th>
</tr>
</thead>
</table>

### Provide®
Xtra Juice Drink
(Fresenius Kabi)

<table>
<thead>
<tr>
<th>Liquid (sip feed) per 100 mL</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Bottle: 200 mL = £1.75</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Provide®</em> Xtra Juice Drink</td>
<td>3.75 g pea and soya protein hydrolysates</td>
<td>27.5 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free Non-milk taste Sweet-flavoured products contain fish gelatin</td>
<td>Standard, p. 903</td>
<td>Bottle: 200 mL = £1.75</td>
<td></td>
</tr>
</tbody>
</table>

| Apple, black currant, carrot-apple, cherry, citrus-cola, lemon-lime, melon, orange-pineapple, tomato |

### Resource®
Dessert Energy
(Nestlé)

<table>
<thead>
<tr>
<th>Semi-solid per 100 g</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Bottle: 200 mL = £1.47</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Resource®</em> Dessert</td>
<td>4.8 g cows’ milk</td>
<td>21.2 g (sugars 9.9 g)</td>
<td>6.2 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Caramel, chocolate, vanilla</td>
<td></td>
</tr>
</tbody>
</table>

### Resource®
Fruit
(Nestlé)

<table>
<thead>
<tr>
<th>Liquid (sip feed) per 100 mL</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Bottle: 200 mL = £7.02</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Resource®</em> Fruit</td>
<td>4 g whey protein hydrolysate</td>
<td>27 g (sugars 9.5 g)</td>
<td>less than 200 mg</td>
<td>less than 200 mg</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years</td>
<td></td>
</tr>
</tbody>
</table>

| Apple, orange, pear-cherry, raspberry-black currant |

---

### A7.2 Nutritional supplements: 5 g (or more) protein/100 mL

#### A7.2.2 Nutritional supplements: 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated.
<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ensure® Plus Milkshake style</strong>*(Abbott)***</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows' milk soya protein isolate</td>
<td>20.2 g (sugars 5.6 g)</td>
<td>4.92 g Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Can: 250 mL = £2.35 (chicken or mushroom) Bottle: 220 mL = £1.85 Banana, black currant, caramel, chocolate, coffee, fruits of the forest, orange, peach, raspberry, strawberry, vanilla, neutral</td>
<td></td>
</tr>
<tr>
<td><strong>Ensure® Plus Yoghurt style</strong>*(Abbott)***</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows' milk</td>
<td>20.7 g (sugars 11.7 g)</td>
<td>4.92 g Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Bottle: 220 mL = £1.85 Orange, peach, pineapple, strawberry</td>
<td></td>
</tr>
<tr>
<td><strong>Ensure® Plus Commence</strong>*(Abbott)***</td>
<td>Starter pack (5–10 day's supply), contains: Ensure® Plus Milkshake Style (various flavours), 1 pack (10 x 220-mL) = £18.52.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fortisip® Bottle</strong> <em>(Nutricia Clinical)</em></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.4 g (sugars 7.0 g)</td>
<td>5.8 g Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years Bottle: 200 mL = £1.85 Banana, chocolate, neutral, orange, strawberry, toffee, tropical fruits, vanilla</td>
<td></td>
</tr>
<tr>
<td><strong>Fortisip® Multi Fibre</strong> <em>(Nutricia Clinical)</em></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.4 g (sugars 7.0 g)</td>
<td>5.8 g 2.3 g</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years Bottle: 200 mL = £1.91 Banana, chocolate, orange, strawberry, vanilla</td>
<td></td>
</tr>
<tr>
<td><strong>Fortisip® Yogurt Style</strong> <em>(Nutricia Clinical)</em></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows' milk</td>
<td>18.7 g (sugars 10.8 g)</td>
<td>5.8 g 200 mg</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years Bottle: 200 mL = £1.85 Peach-orange, raspberry, vanilla-lemon</td>
<td></td>
</tr>
<tr>
<td><strong>Fortisip® Range</strong> <em>(Nutricia Clinical)</em></td>
<td>Starter pack contains 4 × Fortisip® Bottle, 4 × Fortijuce®, 2 × Fortisip® Yogurt Style, 1 pack (10 x 200 mL) = £18.50.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fresubin® Protein Energy Drink</strong> <em>(Fresenius Kabi)</em></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>10 g cows' milk</td>
<td>12.4 g (sugars 6.4 g)</td>
<td>6.7 g 3</td>
<td>Gluten-free Residual lactose Contains fish gelatin</td>
<td>Standard, p. 903; also CAPD, haemodialysis</td>
<td>Bottle: 200 mL = £1.82 Cappuccino, chocolate, strawberry, tropical fruits, vanilla</td>
<td></td>
</tr>
</tbody>
</table>

1. Nutritional values vary with flavour—consult product literature
2. Sugar content varies with flavour
3. Fibre content varies with flavour
<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy Energy</th>
<th>Protein Protein</th>
<th>Carbohydrate Carbohydrate</th>
<th>Fat Fat</th>
<th>Fibre Fibre</th>
<th>Special Characteristics</th>
<th>ACBS ACBS</th>
<th>Indications Indications</th>
<th>Presentation Presentation &amp; Flavour Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® Thicken* (Fresenius Kabi)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>10 g cows' milk</td>
<td>12.2 g (sugars 7.1 g)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>6.7 g</td>
<td>480 mg&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Gluten-free Residual lactose Dysphagia or disease-related malnutrition Not suitable for child under 3 years; use with caution in child 3–4 years</td>
<td>Bottle: 200 mL = £2.10</td>
<td></td>
<td>Syrup (Stage 1) and custard (Stage 2) consistencies Strawberry, vanilla</td>
</tr>
<tr>
<td>ACBS Indications</td>
<td>Standard, p. 903; also CAPD, haemodialysis Not suitable for child under 3 years; use with caution in child 3–4 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bottle: 4 x 125 g = £5.88</td>
<td>Caramel, chocolate, peach, vanilla</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure® Plus Crème (Abbott)</td>
<td>Semi-solid per 100 g</td>
<td>574 kJ (137 kcal)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>5.68 g cows' milk and soya protein isolates</td>
<td>18.4 g (sugars 12.4 g)</td>
<td>4.47 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains soya</td>
<td>Standard, p. 903; also CAPD, haemodialysis Not suitable for child under 3 years</td>
<td>Pot: 125 g = £1.72</td>
<td>Banana, chocolate, neutral, vanilla</td>
</tr>
<tr>
<td>Fortimel® Regular (Abbott)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>10 g cows' milk</td>
<td>10.3 g (sugars 8.1 g)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2.1 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903 Not suitable for child under 3 years</td>
<td>Bottle: 200 mL = £1.57</td>
<td>Chocolate, forest fruits, strawberry, vanilla</td>
</tr>
<tr>
<td>Fortisip® Fruit Dessert (Nutricia Clinical)</td>
<td>Semi-Solid per 100 g</td>
<td>560 kJ (133 kcal)</td>
<td>7 g whey isolate</td>
<td>16.7 g (sugars 11.3 g)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>4 g</td>
<td>2.6 g</td>
<td>Residual lactose Gluten-free</td>
<td>Standard, p. 903 except bowel fistula; also CAPD, haemodialysis Not suitable for child under 3 years</td>
<td>Pot: 3 x 150 g = £6.49</td>
<td>Apple, strawberry</td>
</tr>
<tr>
<td>Oral Impact® (Nestlé)</td>
<td>Standard dilution of powder (74 g in 250 mL water) (sip feed) per 100 mL</td>
<td>425 kJ (101 kcal)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>5.6 g cows' milk</td>
<td>13.4 g (sugars 7.4 g)</td>
<td>2.8 g</td>
<td>1 g</td>
<td>Residual lactose Contains fish oil Preoperative nutritional supplement for malnourished patients or patients at risk of malnutrition Not suitable for child under 3 years</td>
<td>Sachet: 5 x 74 g = £15.41</td>
<td>Citrus, coffee, tropical</td>
<td></td>
</tr>
</tbody>
</table>

1. Sugar content varies with consistency
2. Fibre content varies with consistency
3. Nutritional values vary with flavour—consult product literature
### A7.2.2 Nutritional supplements: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL (product list continued)

Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resource® Protein (Nestlé)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>530 kJ (125 kcal)¹</td>
<td>9.4 g cows’ milk</td>
<td>14 g (sugars 4.5 g)</td>
<td>3.5 g Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903</td>
<td>Not suitable for child under 3 years Bottle: 200 mL £1.45 Apricot, chocolate, forest fruits, strawberry, vanilla</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Notes:**
| 1. Nutritional values vary with flavour—consult product literature |

### A7.2.3 Nutritional supplements: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1–5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complan® Shake (Complan Foods)</td>
<td>Powder per 57 g</td>
<td>1057 kJ (251 kcal)³</td>
<td>8.8 g cows’ milk</td>
<td>35.2 g (sugars 22.7 g)</td>
<td>8.4 g Trace</td>
<td>Gluten-free Contains lactose</td>
<td>Standard, p. 903</td>
<td>Sachet: 4 × 57 g £3.44 Banana, chocolate, original, strawberry, vanilla</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Powder 57 g reconstituted with 200 mL whole milk provides:</strong> protein 15.6 g, carbohydrate 44.5 g, fat 16.4 g, energy 1621 kJ (387 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodlink® Complete (Foodlink)</td>
<td>Powder per 100 g</td>
<td>1838 kJ (437 kcal)²</td>
<td>21.9 g cows’ milk</td>
<td>57.3 g</td>
<td>13.3 g Nil</td>
<td>Contains lactose</td>
<td>Standard, p. 903</td>
<td>Carton: 450 g £3.29 Banana, chocolate, neutral, strawberry</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended serving = 3 heaped tablespoonfuls in 250 mL water provides:</strong> protein 12.1 g, carbohydrate 32.7 g, fat 7.6 g, energy 1048 kJ (249 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodlink® Complete with Fibre (Foodlink)</td>
<td>Powder per 100 g</td>
<td>1804 kJ (428 kcal)²</td>
<td>19.5 g cows’ milk</td>
<td>57.1 g (sugars 36.8 g)</td>
<td>12.3 g 8 g</td>
<td>Contains lactose</td>
<td>Standard, p. 903</td>
<td>Sachet: 10 × 63 g £6.67 Vanilla + fibre</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended serving = 4 heaped tablespoonfuls in 250 mL water provides:</strong> protein 12.3 g, carbohydrate 38 g, fat 7.5 g, fibre 5 g, energy 1137 kJ (270 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forticrem® Complete (Nutricia Clinical)</td>
<td>Semi-solid per 100 g</td>
<td>675 kJ (160 kcal)</td>
<td>9.5 g cows’ milk</td>
<td>19.2 g (sugars 10.6 g)</td>
<td>5 g 100 mg²</td>
<td>Gluten-free Residual lactose</td>
<td>Standard, p. 903; also CAPD, haemodialysis Not suitable for child under 3 years</td>
<td>Pot: 4 × 125 g £7.20 Banana, chocolate, forest fruits, vanilla</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fortisip® Compact (Nutricia Clinical)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1010 kJ (240 kcal)</td>
<td>9.6 g cows’ milk</td>
<td>29.7 g (sugars 15 g)</td>
<td>9.3 g Nil</td>
<td>Residual lactose</td>
<td>Standard, p. 903 Not suitable for child under 3 years Bottle: 125 mL £1.85 Apricot, banana, forest fruits, mocha, strawberry, vanilla</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Notes:**
<p>| 1. Nutritional values vary with flavour—consult product literature |
| 2. Fibre content varies with flavour |</p>
<table>
<thead>
<tr>
<th>Nutritional supplements (non-disease specific)</th>
</tr>
</thead>
</table>

### Fortisip® Extra (Nutricia Clinical)
- Liquid (sip feed)
- **per 100 mL**
- 675 kJ (160 kcal)
- 10 g cows' milk
- 18.1 g (sugars 9 g)
- 5.3 g nil
- Gluten-free
- Contains lactose
- Standard, p. 903
- Not suitable for child under 3 years
- Bottle: 200 mL = £1.85
- Chocolate, forest fruits, mocha, strawberry, vanilla
- Starter pack: 4 x 200 mL = £7.58

### Fresubin® 2 kcal Drink (Fresenius Kabi)
- Liquid (sip feed)
- **per 100 mL**
- 840 kJ (200 kcal)
- 10 g cows' milk
- 22.5 g (sugars 5.8 g)
- 7.8 g nil
- Gluten-free
- Contains lactose
- Standard, p. 903; also CAPD, haemodialysis
- Bottle: 200 mL = £1.73
- Apricot-peach, cappuccino, fruits of the forest, toffee, vanilla

### Fresubin® Extra (Fresenius Kabi)
- Liquid (sip feed)
- **per 100 mL**
- 840 kJ (200 kcal)
- 10 g cows' milk
- 22.5 g (sugars 5.8 g)
- 7.8 g 1.6 g gluten-free
- Contains lactose
- Standard, p. 903; also CAPD, haemodialysis
- Bottle: 200 mL = £1.73
- Cappuccino, chocolate, lemon, vanilla

### Fresubin® Crème (Fresenius Kabi)
- Semi-solid
- **per 100 g**
- 756 kJ (180 kcal)
- 10 g cows' milk
- 19 g (sugars 14.4 g)
- 7.2 g 2 g gluten-free
- Residual lactose
- Standard, p. 903; also CAPD, haemodialysis
- Bottle: 125 mL = £1.85
- Cappuccino, chocolate, praline, strawberry, vanilla

### Renilon® 7.5 (Nutricia Clinical)
- Liquid (sip feed)
- **per 100 mL**
- 840 kJ (200 kcal)
- 7.5 g cows' milk
- 20 g (sugars 4.8 g)
- 10 g nil
- Gluten-free
- Residual lactose
- Standard, p. 903
- Not suitable for child under 3 years
- Carton: 125 mL = £1.85
- Apricot, caramel

### Resource® 2.0 Fibre (Nestlé)
- Liquid (sip feed)
- **per 100 mL**
- 836 kJ (200 kcal)
- 9 g cows' milk
- 21.4 g (sugars 5.5 g)
- 8.7 g 2.5 g gluten-free
- Residual lactose
- Standard, p. 903
- Not suitable for child under 6 years; use with caution in child 6–10 years
- Carton: 200 mL = £1.80
- Apricot, coffee, neutral, strawberry, summer fruits, vanilla

### Resource® Dessert Fruit (Nestlé)
- Semi-solid
- **per 100 g**
- 678 kJ (160 kcal)
- 5 g cows' milk
- 24 g (sugars 16.4 g)
- 5 g 1.4 g gluten-free
- Residual lactose
- Standard, p. 903; also CAPD, haemodialysis
- Cup: 3 x 125 g = £4.41
- Apple, apple-peach, apple-strawberry

### Vegenat®-med Balanced Protein (Vegenat)
- Powder
- **per 110 g serving**
- 1924 kJ (458 kcal)
- 18 g cows' milk
- 62 g
- 15.35 g 5.8 g gluten-free
- Residual lactose
- Standard, p. 903 except bowel fistula
- Not suitable for child under 14 years
- Sachet: 12 x 110 g = £36.26
- Apple, chocolate, honey, orange

### Vegenat®-med High Protein (Vegenat)
- Powder
- **per 110 g serving**
- 1940 kJ (463 kcal)
- 23.3 g cows' milk
- 57.2 g
- 15.6 g 6 g gluten-free
- Residual lactose
- Standard, p. 903 except bowel fistula
- Not suitable for child under 14 years
- Sachet: 12 x 110 g = £50.76
- Chicken, chickpea, fish, fish-vegetable, ham, lentil, veal, vegetable, winter vegetable
- 12 x 110 g = £48.95
- Curry chicken
- 12 x 110 g = £48.22
- Lemon, rice with lemon
- 24 x 55 g = £46.50
- Rice with apple

---

1. Fibre content varies with flavour
2. Nutritional values vary with flavour—consult product literature
3. Flavour not suitable for child under 3 years
### A7.3 Specialised formulas

#### A7.3.1 Specialised formulas: Infant and child

*see BNF for Children*

#### A7.3.2 Specialised formulas for specific clinical conditions

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicalm® (SHS)</td>
<td>Standard dilution (30%) of powder per 100 mL</td>
<td>567 kJ (135 kcal)</td>
<td>4.5 g caseinate (whey)</td>
<td>17.4 g (sugars 3.2 g)</td>
<td>5.3 g</td>
<td>Nil</td>
<td>Residual lactose</td>
<td>Crohn’s disease Not suitable for child under 1 year; use as nutritional supplement only in children 1–6 years.</td>
<td>Powder: 400 g = £18.08 Vanilla</td>
</tr>
<tr>
<td></td>
<td>Powder provides: protein 15 g, carbohydrate 58 g, fat 17.5 g, energy 1889 kJ (450 kcal)/100 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forticare® (Nutricia Clinical)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>675 kJ (160 kcal)</td>
<td>9 g cows’ milk</td>
<td>19.1 g (sugars 13.6 g)</td>
<td>5.3 g</td>
<td>2.1 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Nutritional supplement in patients with lung cancer undergoing chemotherapy, or with pancreatic cancer Not suitable in child under 3 years</td>
<td>Carton: 125 mL = £2.02 Cappuccino, orange-lemon, peach-ginger</td>
</tr>
<tr>
<td>Generaid® (SHS)</td>
<td>Powder per 100 g</td>
<td>1586 kJ (374 kcal)</td>
<td>76 g protein equivalent (whey protein, plus branched chain amino acids)</td>
<td>5 g (sugars 5 g)</td>
<td>5.5 g</td>
<td>Nil</td>
<td>Electrolytes/100 g: Na⁺ 6.1 mmol K⁺ 10.8 mmol Ca²⁺ 6.5 mmol P⁺ 6.45 mmol</td>
<td>Nutritional supplement for use in chronic liver disease and/or porto-hepatic encephalopathy</td>
<td>Tub: 400 g = £51.46 Unflavoured¹</td>
</tr>
<tr>
<td>Generaid® Plus (SHS)</td>
<td>Standard dilution (22%) of powder per 100 mL</td>
<td>428 kJ (102 kcal)</td>
<td>2.4 g protein equivalent (whey protein, branched chain amino acids)</td>
<td>13.6 g (sugars 1.4 g)</td>
<td>4.2 g (MCT 32%)</td>
<td>Nil</td>
<td>Electrolytes/100 mL: Na⁺ 0.7 mmol K⁺ 2.7 mmol Ca²⁺ 1.72 mmol P⁺ 1.67 mmol</td>
<td>Enteral feed or nutritional supplement in children over 1 year with hepatic disorders</td>
<td>Can: 400 g = £18.40 Unflavoured¹ (5-g measuring scoop provided)</td>
</tr>
</tbody>
</table>

1. Flavouring: see *Modju® Flavour System*, p. 925

---

Appendix 7: Borderline substances
<table>
<thead>
<tr>
<th>Product</th>
<th>Type</th>
<th>Standard dilution</th>
<th>Energy/Fat</th>
<th>Carbohydrate</th>
<th>Protein</th>
<th>Electrolytes/100 mL:</th>
<th>Uses</th>
<th>Price/Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Heparon Junior</strong> (SHS)</td>
<td><strong>Per 100 mL</strong></td>
<td>363 kJ (86 kcal)</td>
<td>2 g cows' milk</td>
<td>11.6 g (sugars 2.9 g)</td>
<td>3.6 g Nil</td>
<td>Contains lactose Electrolytes/100 mL: Na⁺ 0.56 mmol K⁺ 1.9 mmol Ca²⁺ 2.3 mmol P⁴⁻ 1.6 mmol</td>
<td>Enteral feed or nutritional supplement for children with acute or chronic liver failure</td>
<td>Can: 400 g = £18.20 (4.5-g measuring scoop provided)</td>
</tr>
<tr>
<td><strong>KetoCal</strong> (SHS)</td>
<td><strong>Per 100 mL</strong></td>
<td>602 kJ (146 kcal)</td>
<td>3.1 g cows' milk with additional amino acids</td>
<td>600 mg (sugars 120 mg)</td>
<td>14.6 g Nil</td>
<td>Electrolytes/100 mL: Na⁺ 4.3 mmol K⁺ 4.1 mmol Ca²⁺ 2.15 mmol P⁴⁻ 2.77 mmol</td>
<td>Enteral feed or nutritional supplement as part of ketogenic diet in management of epilepsy resistant to drug therapy, in children over 1 year, only on the advice of secondary care physician with experience of ketogenic diet</td>
<td>Can: 300 g = £25.62 Vanilla, Unflavoured</td>
</tr>
<tr>
<td><strong>Kindergen</strong> (SHS)</td>
<td><strong>Per 100 mL</strong></td>
<td>421 kJ (101 kcal)</td>
<td>1.5 g whey protein</td>
<td>11.8 mg (sugars 1.2 g)</td>
<td>5.3 g (LCT 93%)</td>
<td>Electrolytes/100 mL: Na⁺ 2 mmol K⁺ 0.6 mmol Ca²⁺ 2.8 mmol P⁴⁻ 3 mmol Low Vitamin A</td>
<td>Enteral feed or nutritional supplement for children with chronic renal failure receiving peritoneal rapid overnight dialysis</td>
<td>Tub: 400 g = £24.44 (5-g measuring scoop provided)</td>
</tr>
<tr>
<td><strong>Modulen IBD</strong> (Nestlé)</td>
<td><strong>Per 100 mL</strong></td>
<td>420 kJ (100 kcal)</td>
<td>3.6 g casein</td>
<td>11 g (sugars 3.98 g)</td>
<td>4.7 g Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Crohn's disease active phase, and in remission if malnourished</td>
<td>Can: 400 g = £14.38 Unflavoured¹ (8.3-g measuring scoop provided)</td>
</tr>
<tr>
<td><strong>Nepro</strong> (Abbott)</td>
<td><strong>Liquid (sip or tube feed)</strong></td>
<td>838 kJ (200 kcal)²</td>
<td>7 g cows' milk</td>
<td>20.6 g (sugars 3.26 g)</td>
<td>9.6 g 1.56 g</td>
<td>Gluten-free Residual lactose Electrolytes/100 mL: Na⁺ 3.67 mmol K⁺ 2.72 mmol Ca²⁺ 3.43 mmol P⁴⁻ 2.23 mmol</td>
<td>Enteral feed or nutritional supplement in patients with chronic renal failure who are on haemodialysis or CAPD, or with cirrhosis, or other conditions requiring a high energy, low fluid, low electrolyte diet. Not suitable for child under 1 year; use with caution in child 1–5 years</td>
<td>Carton: 200 mL = £2.41 Strawberry, vanilla Flexible pack: 500 mL = £5.22 Vanilla</td>
</tr>
</tbody>
</table>

1. Flavouring: see Flavour Mix, p. 925
2. Nutritional values vary with flavour—consult product literature
## A7.3.2 Specialised formulas for specific clinical conditions (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 mL)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProSure&lt;sup&gt;c&lt;/sup&gt; (Abbott)</td>
<td>Liquid (sip or tube feed)</td>
<td>529 kJ (125 kcal)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>6.65 g cows' milk</td>
<td>18.3 g (sugars 2.95 g)</td>
<td>2.56 g</td>
<td>2.07 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Nutritional supplement for patients with pancreatic cancer Not suitable for child under 1 year; use with caution in child 1–4 years</td>
<td>Carton: 240 mL = £2.85 Vanilla</td>
</tr>
<tr>
<td>Renamil&lt;sup&gt;c&lt;/sup&gt; (KoRa)</td>
<td>Powder (sip or tube feed when reconstituted)</td>
<td>2003 kJ (477 kcal)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>4.6 g cows' milk</td>
<td>70.8 g</td>
<td>19.3 g</td>
<td>Nil</td>
<td>Contains lactose Gluten-free Electrolytes/100 g: Na&lt;sup&gt;+&lt;/sup&gt; 1.04 mmol K&lt;sup&gt;+&lt;/sup&gt; 0.13 mmol Ca&lt;sup&gt;2+&lt;/sup&gt; 10.22 mmol P&lt;sup&gt;−&lt;/sup&gt; 1.06 mmol Contains no vitamin A or vitamin D</td>
<td>Enteral feed or nutritional supplement for adults and children over 1 year with chronic renal failure</td>
<td>Sachet: 10 × 100 g = £25.40</td>
</tr>
<tr>
<td>Renapro&lt;sup&gt;c&lt;/sup&gt; (KoRa)</td>
<td>Powder</td>
<td>1580 kJ (372 kcal)</td>
<td>90 g whey protein</td>
<td>800 mg</td>
<td>1 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Electrolytes/100 g: Na&lt;sup&gt;+&lt;/sup&gt; 23 mmol K&lt;sup&gt;+&lt;/sup&gt; 2 mmol Ca&lt;sup&gt;2+&lt;/sup&gt; 4.99 mmol P&lt;sup&gt;−&lt;/sup&gt; 4.84 mmol</td>
<td>Nutritional supplement for biochemically proven hypoproteinaemia and patients undergoing dialysis Not suitable for child under 1 year</td>
<td>Sachet: 30 × 20 g = £69.60</td>
</tr>
<tr>
<td>Renastart&lt;sup&gt;c&lt;/sup&gt; (Vitafo)</td>
<td>Standard dilution (20%) of powder</td>
<td>411 kJ (98 kcal)</td>
<td>1.5 g cows' milk soya</td>
<td>12.6 g (sugars 1.2 g)</td>
<td>4.6 g</td>
<td>Nil</td>
<td>Contains lactose Electrolytes/100 mL: Na&lt;sup&gt;+&lt;/sup&gt; 2.1 mmol K&lt;sup&gt;+&lt;/sup&gt; 0.6 mmol Ca&lt;sup&gt;2+&lt;/sup&gt; 0.58 mmol P&lt;sup&gt;−&lt;/sup&gt; 0.58 mmol</td>
<td>Dietary management of renal failure in child from birth to 10 years</td>
<td>Powder: 10 × 100 g = £56.93 Unflavoured (7-g measuring scoop provided)</td>
</tr>
<tr>
<td>Respifor&lt;sup&gt;c&lt;/sup&gt; (Nutricia Clinical)</td>
<td>Liquid (sip feed)</td>
<td>633 kJ (150 kcal)</td>
<td>7.5 g cows' milk</td>
<td>22.5 g (sugars 6.4 g)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>3.3 g</td>
<td>Nil&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Contains lactose</td>
<td>Nutritional supplement for dietary management of disease-related malnutrition in patients with chronic obstructive pulmonary disease and body-mass index less than 20.</td>
<td>Bottle: 125 mL = £1.85 Chocolate, strawberry, vanilla</td>
</tr>
</tbody>
</table>

1. Nutritional values vary with flavour—consult product literature
2. Sugar content varies with flavour
3. Fibre content varies with flavour
### A7.4 Feed supplements

#### A7.4.1 High-energy supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caloreen® (Nestlé)</td>
<td>Powder</td>
<td>1640 kJ</td>
<td>Nil</td>
<td>96 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Powder: 500 g = £3.52</td>
</tr>
<tr>
<td></td>
<td>per 100 g</td>
<td>(390 kcal)</td>
<td>Maltodextrin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not suitable for child under 3 years</td>
<td>(10-g measuring scoop provided)</td>
</tr>
<tr>
<td>Maxijul® Super Soluble</td>
<td>Powder</td>
<td>1615 kJ</td>
<td>Nil</td>
<td>95 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Sachets: 6 x 132 g = £5.44</td>
</tr>
<tr>
<td>(SHS)</td>
<td>per 100 g</td>
<td>(380 kcal)</td>
<td>Glucose polymer (sugars 8.6 g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Can: 200 g = £2.19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.5 kg = £19.25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25 kg = £130.76</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unflavoured</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
2. Fibre content varies with flavour

### Appendix 7: Borderline substances

**Suplena® (Abbott)**

- **Liquid (sip or tube feed)** per 100 mL
  - 840 kJ (200 kcal)
  - 3 g caseinates
  - 25.5 g (sugars 2.7 g)
  - 9.6 g Nil
- **Gluten-free**
- **Residual lactose**
- **Electrolytes/100 mL:**
  - Na⁺ 3.39 mmol
  - K⁺ 2.87 mmol
  - Ca²⁺ 3.48 mmol
  - P⁺ 2.39 mmol
- **Enteral feed or nutritional supplement in patients with chronic or acute renal failure who are not undergoing dialysis, or with chronic or acute liver disease with fluid restriction; other conditions requiring high energy, low protein, low electrolyte, low volume enteral feed Not suitable for child under 1 year; use with caution in child 1–5 years**
- **Can:** 237 mL = £2.47
- **Vanilla**

**Supportan® (Fresenius Kabi)**

- **Liquid (sip or tube feed)** per 100 mL
  - 630 kJ (150 kcal)
  - 10 g cows' milk
  - 12.4 g (sugars 6.1 g¹)
  - 6.7 g (MCT 34% in tube feed)
  - 1.2 g²
- **Gluten-free**
- **Residual lactose**
- **Contains fish oil**
- **Enteral feed or nutritional supplement in patients with pancreatic cancer or with lung cancer undergoing chemotherapy Not suitable for child under 1 year; use with caution in child 1–4 years**
- **Bottle:** 200 mL = £2.30
- **Cappuccino, tropical fruits**
- **Flexible pack:** 500 mL = £5.97
- **Unflavoured**

¹. Sugar content varies with flavour
². Fibre content varies with flavour
### A7.4.1.1 High-energy supplements: carbohydrate (product list continued)

Flavoured carbohydrate supplements are not suitable for child under 1 year; liquid supplements should be diluted before use in child under 5 years

**ACBS Indications:** disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maxijul</td>
<td>Liquid (SHS) per 100 mL</td>
<td>850 kJ (200 kcal)</td>
<td>Nil</td>
<td>61.9 g Glucose polymer (sugars 12.2 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Carton: 200 mL = £1.37 Orange, unflavoured</td>
</tr>
<tr>
<td>Polycal* (Nutricia Clinical) Powder per 100 g</td>
<td>1630 kJ (384 kcal)</td>
<td>Nil</td>
<td>96 g Maltodextrin (sugars 6 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Can: 400 g = £3.75 Neutral (5-g measuring scoop provided)</td>
<td></td>
</tr>
<tr>
<td>Polycal* (Nutricia Clinical) Liquid per 100 mL</td>
<td>1050 kJ (247 kcal)</td>
<td>Nil</td>
<td>61.9 g Maltodextrin (sugars 12.2 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>See above</td>
<td>Liquid not suitable for child under 3 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.O.S.® (Vitaflor) Powder per 100 g</td>
<td>1590 kJ (380 kcal)</td>
<td>Nil</td>
<td>95 g (sugars 9 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>For use as an emergency regimen in the dietary management of inborn errors of metabolism in adults and children from birth</td>
<td>Sachets: 30 x 21 g (S.O.S. 10) = £6.30; 30 x 31 g (S.O.S. 15) = £9.30; 30 x 42 g (S.O.S. 20) = £12.60; 30 x 52 g (S.O.S. 25) = £15.60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitajoule® (Vitaflor) Powder per 100 g</td>
<td>1610 kJ (380 kcal)</td>
<td>Nil</td>
<td>96 g Dried glucose syrup</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Can: 500 g = £3.66 2.5 kg = £17.83 25 kg = £107.39 (10-g measuring scoop provided)</td>
<td></td>
</tr>
</tbody>
</table>

Contents of each sachet should be reconstituted with water to a total volume of 200 mL.

1. Nutritional values vary with flavour—consult product literature
2. Flavour not suitable for child under 3 years

### A7.4.1.2 High-energy supplements: fat

Liquid supplements should be diluted before use in child under 5 years

**ACBS indications:** disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calogen* (Nutricia Clinical) Liquid (emulsion) per 100 mL</td>
<td>1850 kJ (450 kcal)¹</td>
<td>Nil</td>
<td>100 mg</td>
<td>50 g LCT (100%)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Bottle: 200 mL = £4.00 500 mL = £9.83 Banana², neutral, strawberry²</td>
</tr>
</tbody>
</table>

---

¹ Nutritional values vary with flavour—consult product literature
² Flavour not suitable for child under 3 years
<table>
<thead>
<tr>
<th>Product</th>
<th>Type</th>
<th>Energy per 100 mL</th>
<th>Fat</th>
<th>Carbohydrate</th>
<th>Other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquigen&lt;sup&gt;c&lt;/sup&gt; (SHS)</td>
<td>Liquid (emulsion)</td>
<td><strong>1850 kJ</strong> (450 kcal)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free&lt;br&gt;Steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease, liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in epilepsy, and in type 1 lipoproteinemia&lt;br&gt;Not suitable for child under 1 year</td>
</tr>
<tr>
<td>Medium-chain Triglyceride (MCT) Oil</td>
<td>Liquid</td>
<td><strong>3515 kJ</strong> (855 kcal)</td>
<td>Nil</td>
<td>Nil</td>
<td>MCT 100%&lt;br&gt;Nutritional supplement for steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease and liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in management of epilepsy, type 1 hyperlipoproteinemia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fat and Carbohydrate</th>
<th>Duobar&lt;sup&gt;c&lt;/sup&gt; (SHS)</th>
<th>Bar per 45 g</th>
<th>1211 kJ (292 kcal)</th>
<th>Less than 20 mg</th>
<th>22.5 g (sucrose)</th>
<th>22.5 g</th>
<th>Nil</th>
<th>Contains phenylalanine 180 micrograms/45-g bar Gluten-free&lt;br&gt;See above</th>
<th>Bar: 45 g = £1.65 Neutral, strawberry, toffee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duocal&lt;sup&gt;c&lt;/sup&gt; (SHS)</td>
<td>Liquid</td>
<td><strong>695 kJ</strong> (166 kcal)</td>
<td>Nil</td>
<td>23.7 g (sugars 2.1 g)</td>
<td>7.9 g (MCT 30%)</td>
<td>Nil</td>
<td>Contains vitamin E</td>
<td>See above</td>
<td>Bottle: 250 mL = £3.37</td>
</tr>
<tr>
<td>Duocal&lt;sup&gt;c&lt;/sup&gt; Super Soluble (SHS)</td>
<td>Powder</td>
<td><strong>2061 kJ</strong> (492 kcal)</td>
<td>Nil</td>
<td>72.7 g (sugars 6.5 g)</td>
<td>22.3 g (MCT 35%)</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>See above</td>
<td>Can: 400 g = £15.20 (5-g measuring scoop provided)</td>
</tr>
<tr>
<td>Energivit&lt;sup&gt;c&lt;/sup&gt; (SHS)</td>
<td>Standard dilution (15%) of powder per 100 mL</td>
<td><strong>309 kJ</strong> (74 kcal)</td>
<td>Nil</td>
<td>10 g (sugars 900 mg)</td>
<td>3.75 g</td>
<td>Nil</td>
<td>Lactose-free With vitamins, minerals, and trace elements</td>
<td>For children requiring additional energy, vitamins, minerals, and trace elements following a protein-restricted diet</td>
<td>Can: 400 g = £18.49 (5-g measuring scoop provided)</td>
</tr>
<tr>
<td>MCT Duocal&lt;sup&gt;c&lt;/sup&gt; (SHS)</td>
<td>Powder</td>
<td><strong>2082 kJ</strong> (497 kcal)</td>
<td>Nil</td>
<td>72 g (sugars 10.1 g)</td>
<td>23.2 g (MCT 83%)</td>
<td>Nil</td>
<td>See above</td>
<td>Can: 400 g = £18.07</td>
<td></td>
</tr>
</tbody>
</table>

Powder provides: carbohydrate 66.7 g, fat 25 g, energy 2059 kJ (492 kcal)/100 g.
### A7.4.1.3 High-energy supplements: protein

**ACBS indications:** disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casilan® 90</td>
<td>Powder</td>
<td>1572 kJ</td>
<td>90 g</td>
<td>300 mg</td>
<td>1 g</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Nutritional supplement for use in biochemically proven hypoproteinaemia</td>
<td>Can: 250 g = £6.49</td>
</tr>
<tr>
<td>(Heinz)</td>
<td>per 100 g</td>
<td>(370 kcal)</td>
<td>cows' milk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protifar®</td>
<td>Powder</td>
<td>1580 kJ</td>
<td>88.5 g</td>
<td>less than 1.5 g</td>
<td>1.6 g</td>
<td>Nil</td>
<td>Gluten-free</td>
<td>Nutritional supplement for use in biochemically proven hypoproteinaemia</td>
<td>Can: 225 g = £7.44</td>
</tr>
<tr>
<td>(Nutricia Clinical)</td>
<td>per 100 g</td>
<td>(373 kcal)</td>
<td>cows' milk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unflavoured (2.5-g measuring scoop provided)</td>
</tr>
<tr>
<td></td>
<td>Powder</td>
<td>1506 kJ</td>
<td>75 g</td>
<td>6 g</td>
<td>Nil</td>
<td></td>
<td>Contains lactose</td>
<td>Biochemically proven hypoproteinaemia</td>
<td>Tub: 250 g = £7.47</td>
</tr>
<tr>
<td>Vitapro®</td>
<td>Powder</td>
<td>1530 kJ</td>
<td>10 g</td>
<td>15 g</td>
<td>Nil</td>
<td></td>
<td>Contains vitamin C</td>
<td>Hypoproteinaemia, chronic renal failure, wound fistula leakage with excessiveprotein loss, conditions requiring a controlled nitrogen intake, and haemodialysis Not suitable for child under 6 months</td>
<td>Can: 400 g = £61.74</td>
</tr>
<tr>
<td>(Vitaflo)</td>
<td>per 100 g</td>
<td>(360 kcal)</td>
<td>whey protein isolate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Orange</td>
</tr>
<tr>
<td></td>
<td>Liquid</td>
<td>420 kJ</td>
<td>10 g</td>
<td>15 g</td>
<td>Nil</td>
<td></td>
<td>Gluten-free</td>
<td>Biochemically proven hypoproteinaemia</td>
<td>Sachet: 100 × 30 mL = £83.36</td>
</tr>
<tr>
<td>ProSource®</td>
<td>Liquid</td>
<td>1530 kJ</td>
<td>10 g</td>
<td>15 g</td>
<td>Nil</td>
<td></td>
<td>Lactose-free</td>
<td>Biochemically proven hypoproteinaemia</td>
<td>Sachet: 100 × 30 mL = £83.36</td>
</tr>
<tr>
<td>(Nutrinovo)</td>
<td>per 30 mL</td>
<td>(360 kcal)</td>
<td>whey protein isolate</td>
<td></td>
<td></td>
<td></td>
<td>May contain porcine deri-</td>
<td></td>
<td>Neutral</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>vatives</td>
<td></td>
<td></td>
<td>vatives</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Protein, fat, and carbohydrate

| Product Name | Type | Per 100 mL | Per 87 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Powder per 100 g | Power: 85 g reconstituted with 240 mL whole milk provides: protein 11.7 g, carbohydrate 66.8 g, fat 30.4 g, energy 2457 kJ (588 kcal)

1. Nutritional values vary with flavour—consult product literature
2. Flavour not suitable for child under 3 years
## A7.4.1.3 High-energy supplements: protein

**ACBS indications:** disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 g)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitasavoury®</td>
<td>Powder</td>
<td>2590 kJ (619 kcal)</td>
<td>12.7 g</td>
<td>23.5 g</td>
<td>52.3 g</td>
<td>6.2 g</td>
<td>Contains lactose</td>
<td>See above</td>
<td>Cup (200 kcal): 24 × 33 g = £26.80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>cows' milk</td>
<td>(sugars 1.5 g)</td>
<td></td>
<td></td>
<td></td>
<td>Not suitable for child under 3 years</td>
<td>Sachet (300 kcal) 10 × 50 g = £16.35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chicken, leek and potato, mushroom, vegetable</td>
</tr>
</tbody>
</table>

1. Nutritional values vary with flavour—consult product literature

### A7.4.2 Fibre, vitamin, and mineral supplements

#### High-fibre supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 g)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resource®</td>
<td>Powder</td>
<td>123 kJ (42 kcal)</td>
<td>Nil</td>
<td>19 g</td>
<td>Nil</td>
<td>78 g</td>
<td>Gluten-free</td>
<td>Standard, p. 903 except dysphagia</td>
<td>Sachets 16 x 10 g = £7.72</td>
</tr>
<tr>
<td>Optifibre®</td>
<td>Powder</td>
<td>729 kJ (175 kcal)</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
<td>Lactose-free</td>
<td>Not suitable for child under 5 years</td>
<td>Can: 250 g = £9.51</td>
</tr>
</tbody>
</table>

#### Vitamin and Mineral supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy (per 100 g)</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic Mineral Mixture® (SHS)</td>
<td>Powder</td>
<td>1275 kJ (300 kcal)</td>
<td>Nil</td>
<td>75 g</td>
<td>Nil</td>
<td>Nil</td>
<td>Contains trace elements</td>
<td>Mineral supplement for synthetic diets</td>
<td>Tub: 200 g = £14.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(sugars 6.75 g)</td>
<td></td>
<td></td>
<td>Electrolytes/100 g: Na⁺ 172 mmol K⁺ 212 mmol Ca²⁺ 205 mmol P⁻ 192 mmol</td>
<td>Suitable for infants (but may require further dilution)</td>
<td>Unflavoured² 200 g = £15.30 Pineapple³ (5-g measuring scoop provided)</td>
</tr>
<tr>
<td>Paediatric Seravit® (SHS)</td>
<td>Powder</td>
<td>2590 kJ (619 kcal)</td>
<td>Nil</td>
<td>23.5 g</td>
<td>52.3 g</td>
<td>6.2 g</td>
<td>Contains lactose</td>
<td>Vitamin and mineral supplement in infants and children with restrictive therapeutic diets</td>
<td>Tub: 200 g = £14.37</td>
</tr>
</tbody>
</table>

1. Sugar content varies with flavour
2. Flavouring: see Modju® Flavour System, p. 925
3. Flavour not suitable for child under 6 months
A7.5 Feed additives

A7.5.1 Special additives for conditions of intolerance

Colief® (Forum)
**Liquid**, lactase 50 000 units/g. Net price 7-mL dropper bottle = £8.40
For the relief of symptoms associated with lactose intolerance in infants, provided that lactose intolerance is confirmed by the presence of reducing substances and/or excessive acid in stools, a low concentration of the corresponding disaccharide enzyme on intestinal biopsy or by breath hydrogen test or lactose intolerance test. For dosage and administration details, consult product literature.

Fructose (Laevulose)
For proven glucose/galactose intolerance.

VSL#3® (Ferring)
**Powder**, containing 8 strains of live, freeze-dried, lactic acid bacteria. Contains traces of soya, gluten, and lactose. Net price 30 × 4.4-g sachets = £22.98
Nutritional supplement for use under the supervision of a physician, for the maintenance of remission of ileoanal pouchitis induced by antibacterials in adults. For dosage and administration details, consult product literature.

A7.5.2 Feed thickeners and pre-thickened drinks

For pre-thickened infant feeds see *BNF for Children* (Appendix 2)

Carobel, Instant® (Cow & Gate)
**Powder**, carob seed flour. Net price 135 g = £2.97
For thickening feeds in the treatment of vomiting.

Nutilis® (Nutricia Clinical)
**Powder**, modified maize starch, gluten- and lactose-free, Net price 20 × 9-g sachets = £5.88; 225 g = £4.51
For thickening of foods in dysphagia. Not suitable for children under 3 years.

Resource® Thickened Drink (Nestlé)
**Liquid**, carbohydrate 22 g, energy: orange 382 kJ (90 kcal); apple 375 kJ (90 kcal)/100 mL. Syrup and custard consistencies. Gluten- and lactose-free, net price 12 × 114-mL cups = £7.44
For dysphagia. Not suitable for children under 1 year.

Resource® ThickenUp® (Nestlé)
**Powder**, modified maize starch. Gluten- and lactose-free, net price 227 g = £4.35; 75 × 4.5-g sachet = £16.66
For thickening of foods in dysphagia. Not suitable for children under 1 year.

SLO Drinks® (SLO Drinks)
**Powder**, carbohydrate content varies with flavour and chosen consistency (3 consistencies available), see product literature. Flavours: black currant, lemon, orange; (hot drinks) chocolate, white coffee. Net price 25 × 115 mL = £7.50
Nutritional supplement for patient hydration in the dietary management of dysphagia. Not suitable for children under 3 years.

Thick and Easy® (Fresenius Kabi)
**Powder**, modified maize starch, net price 225-g can = £4.46; 100 × 9-g sachets = £26.35; 4.54 kg = £70.53.

Thickened Juices, liquid, modified food starch. Flavours: apple, orange, net price 118-mL pot = 58p; apple, black currant, cranberry, kiwi-strawberry, and orange, 1.42-litre bottle = £3.61.
For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.

Thixo-D® (Sutherland)
**Powder**, modified maize starch, gluten-free. Net price 375-g tub = £7.15.
For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.

Vitaquick® (Vitafo) **Powder**, modified maize starch. Net price 300 g = £6.66; 2 kg = £33.91; 6 kg = £87.83.
For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.

A7.5.3 Flavouring preparations

Flavour Mix® (Nestlé)

FlavourPac® (Vitafo)
**Powder**, flavours: black currant, lemon, orange, tropical or raspberry, net price 30 × 4-g sachets = £11.54.
For use with Vitafo’s range of unflavoured protein substitutes for metabolic diseases.

Modjul® Flavour System (SHS)
**Powder**, flavours: black currant, orange, pineapple, 100 g = £10.24; cherry-vanilla, grapefruit, lemon-lime, 20 × 5-g sachets = £10.24.
For use with unflavoured SHS products based on peptides or amino acids; not suitable for child under 6 months.

A7.6 Foods for special diets

A7.6.1 Gluten-free foods

ACBS indications: established gluten-sensitive enteropathies including steatorrhoea due to gluten sensitivity, coeliac disease, and dermatitis herpetiformis.

Bread

Loaves
Barkat® (Gluten Free Foods Ltd)
**Gluten-free**. Loaf, multigrain 500 g = £4.83. Loaf, sliced, wholemeal 500 g = £3.36. Loaf, sliced, part-baked, country-style 250 g = £3.69. Loaf, sliced, part-baked, white 550 g = £4.88. Rice bread, brown 500 g = £4.83; white 500 g = £4.83.

Dietary Specials® (Nutrition Point)
**Gluten-free**. Loaf, sliced, multigrain, brown 400 g = £3.01; white 400 g = £3.01.

Ener-G® (General Dietary)
**Gluten-free**. Loaf, sliced Seattle brown 600 g = £5.28. Rice bread, sliced, brown 474 g = £4.59; white 456 g = £4.59. Rice loaf, sliced 612 g = £4.59. Tapioca bread, sliced 480 g = £4.59.
Appendix 7: Borderline substances

Genius Gluten Free® (Genius Foods)

- **Gluten-free**: Loaf, unsliced, brown 400 g = £2.49; white 400 g = £2.49

Glutafin® (Nutrition Point)

- **Gluten-free**: Loaf, sliced, fibre 400 g = £3.41; white 400 g = £3.41

Glutafin® Select (Nutrition Point)

- **Gluten-free**: Loaf, sliced, fresh, brown 400 g = £3.25; white 400 g = £3.25. Loaf, sliced, fibre 400 g = £3.12; white 400 g = £3.12. Loaf, seeded 400 g = £3.39.

Juvela® (Juvela)

- **Gluten-free**: Loaf, sliced, fresh, fibre 400 g = £2.97; white 400 g = £3.23. Loaf, sliced, white 400 g = £3.10, fibre 400 g = £3.10. Loaf, part-baked, fibre 400 g = £3.33; white 400 g = £3.46

Lifestyle® (Ultrapharm)

- **Gluten-free**: Loaf, sliced, brown 400 g = £2.82; high fibre 400 g = £2.82; white 400 g = £2.82. Loaf, brown 400 g = £2.82; high fibre 400 g = £2.82, white 400 g = £2.82

Livwell® (Livwell)

- **Gluten-free**: Loaf, sliced, brown (seeded) 200 g = £2.25; white 200 g = £2.25

Pasticely® (GFF Trade)

- **Gluten-free**: Loaf, sandwich, sliced, white 260 g = £3.29; rustic, sliced, white 260 g = £3.29

Sunnyvale® (Everfresh)

- **Gluten-free**: Loaf, mixed grain, sour dough 400 g = £1.91

Ultra® (Ultrapharm)

- **Gluten-free**: Loaf, part-baked, white 400 g = £2.46; high fibre 500 g = £3.35

Wellfoods® (Wellfoods)

- **Gluten-free**: Loaf, sliced 600 g = £4.95; unsliced 600 g = £4.85

Baguettes, buns and rolls

Barkat® (Gluten Free Foods Ltd)

- **Gluten-free**: Baguette, part-baked 200 g = £3.69. Rolls, part-baked 2 x 100 g = £3.30; 6 x 50 g = £3.69

Ener-G® (General Dietary)

- **Gluten-free**: Rolls, dinner × 6 = £3.11; white, long 4 × 55 g = £2.50; round 4 × 50 g = £2.50

Glutafin® (Nutrition Point)

- **Gluten-free**: Baguette 2 x 175 g = £3.20. Rolls, fibre 4 × 50 g = £3.41; white 4 × 50 g = £3.41

Glutafin® Select (Nutrition Point)

- **Gluten-free**: Rolls, fibre 4 × 65 g = £3.25; white 4 × 65 g = £3.25. Rolls, part-baked, white 4 × 50 g = £3.35; long 2 × 75 g = £2.56

Juevella® (Juvela)

- **Gluten-free**: Rolls, fresh, fibre 5 × 85 g = £4.17; white 5 × 85 g = £4.17. Rolls, fibre 5 × 85 g = £4.18; white 5 × 85 g = £4.18. Rolls, part-baked, fibre 5 × 75 g = £4.33; white 5 × 75 g = £4.33

Lifestyle® (Ultrapharm)

- **Gluten-free**: Rolls, brown 5 × 80 g = £2.82; high fibre 5 × 80 g = £2.82; white 5 × 80 g = £2.82

Livwell® (Livwell)

- **Gluten-free**: Baguette, white 250 g = £2.50. Buns, toasting 4 × 50 g = £2.50. Rolls, white 4 × 2.25. Rolls, part-baked, circle (bagel) 2 × 90 g = £2.50; dinner (square) 2 × 80 g = £2.09

Pasticely® (GFF Trade)

- **Gluten-free**: Baguette, part-baked, white 160 g = £1.99. Rolls, part-baked, white 2 × 80 g = £2.39; rustic, part-baked, white 2 × 105 g = £2.39

Procell® (Procell)

- **Gluten-free**: Baguette, part-baked 2 × 125 g = £3.24. Buns 4 × 50 g = £3.26. Lunch rolls, white 8 × 34 g = £3.26. Rolls, part-baked, white, dinner 4 × 35 g = £2.18; hotdog 3 × 35 g = £2.24; long 3 × 85 g = £2.95

Ultra® (Ultrapharm)

- **Gluten-free**: Baguette, part-baked 2 × 200 g = £2.46. Rolls, part-baked 4 × 70 g = £2.46

Wellfoods® (Wellfoods)

- **Gluten-free**: Burger buns 4 × 75 g = £3.95. Rolls 4 × 70 g = £3.46

Speciality breads

Livwell® (Livwell)

- **Gluten-free**: Flat bread (pitta) 4 = £3.00. Tear-drop shape (naan) 2 × 90 g = £3.00

Procell® (Procell)

- **Gluten-free**: Flat bread (pitta), part-baked 3 × 40 g = £4.36

Cookies and biscuits

Barkat® (Gluten Free Foods Ltd)

- **Gluten-free**: Biscuits, coffee-style 200 g = £2.86; digestive 175 g = £2.20

Ener-G® (General Dietary)

- **Gluten-free**: Cookies, vanilla 435 g = £5.23

Glutafin® (Nutrition Point)

- **Gluten-free**: Biscuits, plain 200 g = £3.77; digestive 150 g = £1.94; savoury 125 g = £1.94; savoury shortbread 150 g = £2.65; shortbread 100 g = £1.60, sweet (without chocolate or sugar) 150 g = £1.94; tea 150 g = £1.94

Juevella® (Juvela)

- **Gluten-free**: Biscuits, digestive 150 g = £2.67; savoury 150 g = £3.35; sweet 150 g = £2.52; tea 150 g = £2.67

Ultra® (Ultrapharm)

- **Gluten-free**: Biscuits, sweet 250 g = £2.93

Crackers, crispbreads, and breadsticks

Barkat® (Gluten Free Foods Ltd)

- **Gluten-free**: Crackers, round (matzo) 200 g = £2.97

Dietary Specials® (Nutrition Point)

- **Gluten-free**: Cracker bread 150 g = £1.94

Glutafin® (Nutrition Point)

- **Gluten-free**: Crackers, high fibre 200 g = £2.64; plain 200 g = £3.16; mini 175 g = £2.70

Juevella® (Juvela)

- **Gluten-free**: Crispbread, plain 200 g = £4.06

Ultra® (Ultrapharm)

- **Gluten-free**: Crackerbread 200 g = £1.77

Flour mixes and xanthan gum

Flour mixes

Barkat® (Gluten Free Foods Ltd)

- **Gluten-free**: Flour mix, bread 500 g = £5.74. Plain 750 g = £5.88

Dietary Specials® (Nutrition Point)

- **Gluten-free**: Flour mix, bread, white 500 g = £5.33. Cake, white 750 g = £5.33. Plain, white 500 g = £5.33
**Pasta**

**Barkat**® (Gluten Free Foods Ltd)

**Gluten-free**. Pasta, animal shapes 500 g = £4.95; macaroni 500 g = £4.95; spaghetti 500 g = £4.95; tagliatelle 500 g = £4.95. Buckwheat, penne 250 g = £2.48; spirals 250 g = £2.48.

**BiAlimenta**® (Drossa)

**Gluten-free**. Pasta, potato-based, gnocchi 500 g = £5.59; perle di gnocchi 500 g = £5.60; Tubetti 500 g = £5.90.

**Dietary Specials**® (Nutrition Point)

**Gluten-free**. Pasta, fusilli 500 g = £3.44; penne 500 g = £3.44; spaghetti 500 g = £3.44.

**Ener-G**® (General Dietary)

**Gluten-free**. Pasta, rice-based, lasagne 545 g = £4.27; macaroni 454 g = £4.27; shells, small 454 g = £4.27; spaghetti 454 g = £4.27; vermicelli 300 g = £4.27.

**Glutafin**® (Nutrition Point)

**Gluten-free**. Pasta, lasagne 250 g = £3.21; macaroni penne 500 g = £6.13; shells 500 g = £6.13; spirals 500 g = £6.13; spaghetti, long 500 g = £6.13; tagliatelle 250 g = £3.21.

**Juvela**® (Juvela)

**Gluten-free**. Pasta, fusilli 500 g = £6.31; lasagne 250 g = £3.22; macaroni 500 g = £6.31; spaghetti 500 g = £6.31; tagliatelle 250 g = £3.04. Fibre, linugine 500 g = £5.79; penne 500 g = £5.79.

**Ogron**® (Community)

**Gluten-free**. Pasta, rice and corn, lasagne 200 g = £3.03; macaroni 250 g = £2.35. Spirals, buckwheat 250 g = £2.35; corn 250 g = £2.35; rice and corn 250 g = £2.35; rice and millet 250 g = £2.35.

**Pastically**® (GFF Trade)

**Gluten-free**. Pasta, macaroni penne 250 g = £2.99; penne 250 g = £2.99; spaghetti 500 g = £2.99.

**Proceli**® (Proceli)

**Gluten-free**. Pasta, macaroni penne 250 g = £2.99; penne 250 g = £2.99; spaghetti 500 g = £2.99.

**Rizopia**® (PGR Health Foods)

**Gluten-free**. Pasta, brown rice, fusilli 500 g = £2.60; lasagne 375 g = £2.60; penne 500 g = £2.60; spaghetti 500 g = £2.60.

**Ultra**® (Ultrainpharm)

**Gluten-free**. Pasta, fusilli 250 g = £2.95; penne 250 g = £2.95; spaghetti 250 g = £2.95.

**Pizza bases**

**Barkat**® (Gluten Free Foods Ltd)

**Gluten-free**. Pizza crust, rice, brown 150 g = £4.21; white 150 g = £4.21.

**Dietary Specials**® (Nutrition Point)

**Gluten-free**. Pizza base 2 × 150 g = £5.27.

**Glutafin**® (Nutrition Point)

**Gluten-free**. Pizza base 2 × 150 g = £5.98.

**Juvela**® (Juvela)

**Gluten-free**. Pizza base 2 × 180 g = £7.70.

**Pastically**® (GFF Trade)

**Gluten-free**. Pizza base 165 g = £2.99.

**Proceli**® (Proceli)

**Gluten-free**. Pizza base 2 × 250 g = £3.90.

**Ultra**® (Ultrainpharm)

**Gluten-free**. Pizza base 2 × 200 g = £2.65.

**Wellfoods**® (Wellfoods)

**Gluten-free**. Pizza base 2 × 300 g = £8.95.

**A7.6.1.1 Gluten- and wheat-free foods**

**ACBS indications**: established gluten-sensitive enteropathies with coexisting established wheat sensitivity only.

**Ener-G**® (General Dietary)

**Gluten-free, wheat-free**. Bread loaf, six flour 576 g = £3.60. Rolls, Seattle brown, round (hamburger) 4 × 119 g = £3.00; long (hot dog) 4 × 119 g = £3.00. Pizza base, 3 × 124 g = £3.75.

**Glutafin**® (Nutrition Point)

**Gluten-free, wheat-free**. Flour mix, bread 500 g = £6.06; fibre 500 g = £6.06. Cake mix 500 g = £6.06. Crispbread 150 g = £3.82.

**Heron Foods**® (Gluten Free Foods Ltd)

**Gluten-free, wheat-free**. Flour mix, organic, bread, fibre 500 g = £8.30. Bread and cake mix 500 g = £8.33.
### Bread

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loprofin</td>
<td>Loaf</td>
<td>White, sliced 400g</td>
<td>£3.12</td>
</tr>
<tr>
<td>Juvela</td>
<td>Loaf</td>
<td>White, sliced, part-baked 4x65g</td>
<td>£3.52</td>
</tr>
<tr>
<td>Ultra PKU</td>
<td>Loaf</td>
<td>White, sliced 550g</td>
<td>£4.40</td>
</tr>
</tbody>
</table>

### Low-protein foods

#### Flour mixes and egg substitutes

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loprofin</td>
<td>All purpose mix</td>
<td>500g</td>
<td>£6.66</td>
</tr>
<tr>
<td>Promin</td>
<td>Cake mix</td>
<td>250g</td>
<td>£7.43</td>
</tr>
<tr>
<td>Ener-G</td>
<td>Mix</td>
<td>500g</td>
<td>£6.82</td>
</tr>
</tbody>
</table>

#### Pasta

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promin</td>
<td>Pasta meal</td>
<td>500g</td>
<td>£7.43</td>
</tr>
</tbody>
</table>

#### Pizza bases

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultra PKU</td>
<td>Pizza base</td>
<td>2x180g</td>
<td>£7.55</td>
</tr>
</tbody>
</table>

#### Savoury meals and mixes

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promin</td>
<td>Snack pot</td>
<td>Curry</td>
<td>£3.94</td>
</tr>
</tbody>
</table>

#### Spreads

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Description</th>
<th>Price (per 100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loprofin</td>
<td>Spread</td>
<td>Hazelnut</td>
<td>£6.80</td>
</tr>
</tbody>
</table>

### ACBS indications: inherited metabolic disorders, renal or liver failure, requiring a low-protein diet
**A7.7 Nutritional supplements for metabolic diseases**

### Glutaric aciduria (type 1)

**GA1 Anamix** (Infant) (SHS)
- Powder, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 13.1 g, carbohydrate 49.5 g, fat 23.5 g, fibre 5.3 g, energy 192.5 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements.
- Standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 0.8 mg, energy 28.7 kJ (69 kcal)/100 mL. Unflavoured, net price £4.52.70 (5-g measuring scoop provided).

Nutritional supplement for the dietary management of proven glutaric aciduria in children from birth to 3 years.

### XLYS, Low TRY, Maxamaid (SHS)
- Powder, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 8.4 g, carbohydrate 8.6 g, fat, trace, energy 286 kJ (68 kcal)/20 g, with vitamins, minerals, and trace elements. Unflavoured (flavours see FlavourPac, p. 925), net price £0.30 x 20 g = £14.90. Nutritional supplement for the dietary management of type 1 glutaric aciduria in children 1–10 years.

### Glycogen storage disease

#### Corn flour and corn starch

For hypoglycaemia associated with glycogen-storage disease.

#### Glucose

**Dextrose monohydrate**
- 1457 g/m², protein 200 mg, with vitamins, minerals, and trace elements.

For glycogen storage disease and sucrose/isomaltose intolerance.

#### Glycosade® (Vitaflo)
- Powder, protein 200 mg, carbohydrate (maize starch) 47.6 g, fat 100 mg, fibre less than 600 mg, energy 803 kJ (192 kcal)/60 g, net price 30 x 60 g = £9.23.03.

Nutritional supplement for use in the dietary management of glycogen storage disease and other metabolic conditions where a constant supply of glucose is essential. Not suitable for children under 2 years.

#### Homocystinuria or hypermethioninaemia

**HCU Anamix** (Infant) (SHS)
- Powder, protein equivalent (essential and non-essential amino acids except methionine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 191.5 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements.

Nutritional supplement for the dietary management of proven homocystinuria or hypermethioninaemia in children from birth to 3 years.

### Amino acid substitutions

### Hyperlysinaemia

**HYPER LYS Anamix** (Infant) (SHS)
- Powder, protein equivalent (essential and non-essential amino acids except lysine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 191.5 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements.

Nutritional supplement for the dietary management of proven hyperlysinaemia in children from birth to 3 years.

---

1. Maxamaid products are generally intended for use in children 1–8 years.
2. Maxamaid products are generally intended for use in children over 8 years and adults.
Appendix 7: Borderline substances

3 XLYS Maxamaid (SHS)
Powder, protein equivalent (essential and non-essential amino acids except lysine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1836 kJ (438 kcal)/100 g, with vitamins, minerals, and trace elements. Unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £82.57
Nutritional supplement for the dietary management of hyperlysinaemia

3 Isovaleric acidaemia
IVA Anamix® Infant (SHS)
Powder, protein equivalent (essential and non-essential amino acids except leucine) 13.1 g, carbohydrate 48.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements, standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £32.70 (5-g measuring scoop provided)
Nutritional supplement for the dietary management of isovaleric acidaemia or other proven disorders of leucine metabolism in children from birth to 3 years

XLEU Falaton (SHS)
Powder, protein equivalent (essential and non-essential amino acids except leucine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g. Unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 200 g = £62.55
Nutritional supplement for the dietary management of isovaleric acidaemia

3 XLEU Maxamaid (SHS)
Powder, protein equivalent (essential and non-essential amino acids except leucine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements. Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £82.57
Nutritional supplement for the dietary management of isovaleric acidaemia

Maple syrup urine disease
Isoleucine Amino Acid Supplement (Vitaflò)
Powder, isoleucine 50 mg, carbohydrate 4 g, fat nil, energy 64 kJ (15 kcal)/4 g, net price 30 × 4-g sachets = £44.48
Nutritional supplement for the dietary management of maple syrup urine disease and related conditions in children and adults where it is necessary to limit the intake of branched chain amino acids

MSUD Aid III® (SHS)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 77 g, carbohydrate 4.5 g, energy 1380 kJ (326 kcal)/100 g, Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £115.42
Nutritional supplement for the dietary management of maple syrup urine disease and related conditions in children and adults where it is necessary to limit the intake of branched chain amino acids

MSUD Anamix® Infant (SHS)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 KJ (457 kcal)/100 g, with vitamins, minerals, and trace elements, standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £32.70 (5-g measuring scoop provided)
Nutritional supplement for the dietary management of proven maple syrup urine disease in children from birth to 3 years

MSUD Anamix® Junior (SHS)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 8.4 g, carbohydrate 11 g, fat 3.9 g, energy 474 kJ (113 kcal)/29-g sachet, with vitamins, minerals, and trace elements. Unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 30 × 29-g sachets = £168.73
Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years

MSUD Anamix® Junior LO (SHS)
Liquid, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free. Orange flavour, net price 125-mL carton = £7.58
Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years

MSUD express® (Vitaflò)
Powder, protein equivalent (essential and non-essential amino acids except leucine, isoleucine, and valine) 15 g, carbohydrate 3.8 g, fat less than 150 mg, energy 315 kJ (75 kcal)/25 g with vitamins, minerals, and trace elements. Unflavoured (flavouring: see FlavourPac® sachets, p. 925), net price 30 × 25-g sachets = £271.88
Nutritional supplement for the dietary management of maple syrup urine disease in children over 8 years and adults

MSUD cooler® (Vitaflò)
Liquid, protein equivalent (essential and non-essential amino acids except leucine, isoleucine, and valine) 15 g, carbohydrate 7 g, fat 500 mg, energy 386 kJ (92 kcal)/130-mL pouch, with vitamins, minerals, and trace elements. Orange or red flavour, net price 30 × 130-mL = £277.20
Nutritional supplement for the dietary management of maple syrup urine disease in children over 3 years and adults

MSUD Gel® (Vitaflò)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 25 g, carbohydrate 8.6 g, fat less than 150 mg, energy 286 kJ (68 kcal)/29 g with vitamins, minerals, and trace elements. Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £82.57
Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years

2 MSUD Maxamaid® (SHS)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements. Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £132.36
Nutritional supplement for the dietary management of maple syrup urine disease

2 MSUD Maxamun® (SHS)
Powder, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 39 g, carbohydrate 34 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements. Orange flavour or unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £132.36
Nutritional supplement for the dietary management of maple syrup urine disease and other inborn errors of amino acid metabolism in children over 1 year and adults

Valine Amino Acid Supplement (Vitaflò)
Powder, valine 50 mg, carbohydrate 4 g, fat nil, energy 64 kJ (15 kcal)/4 g, net price 30 × 4-g sachets = £44.48
Nutritional supplement for the dietary management of maple syrup urine disease and other inborn errors of amino acid metabolism in children over 8 years and adults

1 Maxamaid products are generally intended for use in children 1–8 years

2 Maxamum products are generally intended for use in children over 8 years and adults
Methylmalonic or propionic acididaemia

**MMA/PA Anamix® Infant (SHS)**

Powder, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 13.1 g, carbohydrate 49.5 g, fat 23.6 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £32.70 (5-g measuring scoop provided)

Nutritional supplement for the dietary management of proven methylmalonic acididaemia or propionic acididaemia in children from birth to 3 years

**XMTVI Asadon (SHS)**

Powder, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g. Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 200 g = £82.55

Nutritional supplement for the dietary management of methylmalonic acididaemia or propionic acididaemia in children and adults

**XMTVI Maxamum (SHS)**

Powder, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements. Unflavoured, (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £132.36

Nutritional supplement for the dietary management of methylmalonic acididaemia or propionic acididaemia

**XMTVI Maxamum® (SHS)**

Powder, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 39 g, carbohydrate 34.9 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements. Unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 500 g = £32.20

Nutritional supplement for the dietary management of methylmalonic acididaemia or propionic acididaemia

**Other inborn errors of metabolism**

**Cystine Amino Acid Supplement (Vitaflo)**

Powder, cystine 500 mg, carbohydrate 3.4 g, fat nil, energy 63 kJ (15 kcal)/4 g, net price 30 x 4-g sachets = £44.48

Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children over 1 year

**DocOmega® (Vitafo)**

Powder, proteins (cows’ milk, soya protein) 100 mg, carbohydrate 12.2 g, fat 500 mg (of which docosahexaenoic acid 200 mg), fibre nil, energy 74 kJ (18 kcal)/4 g, with minerals, net price 30 x 4-g sachets = £32.20

Nutritional supplement for the dietary management of inborn errors of metabolism for adults and children from birth

**EAA® Supplement (Vitafo)**

Powder, protein equivalent (essential amino acids) 5 g, carbohydrate 4 g, fat nil, energy 151 kJ (36 kcal)/12.5 g, with vitamins, minerals, and trace elements. Tropical flavour, net price 50 x 12.5-g sachets = £174.48

Nutritional supplement for the dietary management of disorders of protein metabolism including urea cycle disorders. Not suitable for children under 3 years

**KeyOmega® (Vitafo)**

Powder, proteins (cows’ milk, soya) 170 mg, carbohydrate 2.8 g, fat 800 mg (of which arachidonic acid 200 mg, docosahexaenoic acid 100 mg), energy 80 kJ (19 kcal)/4 g, net price 30 x 4-g sachets = £32.92

A nutritional supplement for the dietary management of inborn errors of metabolism

1. Maxamum products are generally intended for use in children 1–8 years
2. Maxamum products are generally intended for use in children over 8 years and adults

**Leucine Amino Acid Supplement (Vitafo)**

Powder, leucine 100 mg, carbohydrate 4 g, fat nil, energy 64 kJ (15 kcal)/4 g, net price 30 x 4-g sachets = £44.48

Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in children over 1 year and adults

**Low protein drink (Milupa )**

Powder, protein (cows’ milk) 4.5 g (phenylalanine 100 mg), carbohydrate 59.5 g, fat 28.9 g, fibre nil, energy 2194 kJ (528 kcal)/100 g, with vitamins, minerals, and trace elements. Contains lactose. Net price 400 g = £7.76 (5-g measuring scoop provided)

Nutritional supplement for the dietary management of inborn errors of amino acid metabolism

**Phenylalanine Amino Acid Supplement (Vitafo)**

Powder, phenylalanine 50 mg, carbohydrate 3.8 g, energy 64 kJ (15 kcal)/4 g, net price 30 x 4-g sachets = £43.18

Nutritional supplement for use in the dietary management of inborn errors of metabolism only

**ProZero® (Vitafo)**

Liquid, carbohydrate 8.1 g (of which sugars 3.5 g), fat 3.8 g, energy 278 kJ (66 kcal)/100 mL. Contains lactose. Net price 18 x 250 mL = £22.50; 6 x 1 litre = £30.00

A protein-free nutritional supplement for the dietary management of inborn errors of metabolism in children over 6 months and adults

**Phenylketonuria**

**Add-Ins® (SHS)**

Powder, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 41 g, fat 5.1 g, energy 359 kJ (86 kcal)/18.2-g sachet, with vitamins, minerals, and trace elements. Unflavoured (flavouring: see Modju® Flavour System, p. 925), net price 60 x 18.2-g sachets = £315.60

Nutritional supplement for the dietary management of proven phenylketonuria. Not suitable for children under 4 years

**Easiphen® (SHS)**

Liquid, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 6.7 g, carbohydrate 5.1 g, fat 2 g, energy 275 kJ (65 kcal)/100 mL, with vitamins, minerals, and trace elements. Forest berries flavour, net price 250-mL carton = £8.11

Nutritional supplement for the dietary management of proven phenylketonuria. Not suitable for children under 8 years

**Lophlex® (SHS)**

Powder, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 2.5 g, fat 60 mg, energy 385 kJ (91 kcal)/27.8-g sachet, with vitamins, minerals, and trace elements. Flavours: berry, orange or unflavoured, net price 30 x 27.8-g sachets = £243.60

Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women

**Loprofin® PKU Drink (SHS)**

Liquid, protein (cows’ milk) 400 mg (phenylalanine 10 mg), lactose 9.4 g, fat 2 g, energy 165 kJ (40 kcal)/100 mL. Net price 200-mL carton = 61p.

Nutritional supplement for the dietary management of phenylketonuria in children over 1 year and adults

**Milupa PKU 2-prima® (Milupa )**

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 60 g, carbohydrate 10 g, fat nil, energy 1190 kJ (280 kcal)/100 g, with vitamins, minerals, and trace elements. Vanilla flavour, net price 500 g = £131.68

Nutritional supplement for the dietary management of phenylketonuria in children 1–8 years

Note

1. Nutritional values vary with flavour—consult product literature
### Appendix 7: Borderline substances

#### Milupa PKU 2-secunda® (Milupa)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 70 g, carbohydrate 4.7 g, fat nil, energy 1270 kJ (299 kcal)/100 g, with vitamins, minerals, and trace elements. Vanilla flavour, net price 500 g = £153.62.
Nutritional supplement for the dietary management of phenylketonuria in children 9–14 years

#### Milupa PKU 3-advanta® (Milupa)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 70 g, carbohydrate 4.7 g, fat nil, energy 1270 kJ (299 kcal)/100 g, with vitamins, minerals, and trace elements. Vanilla flavour, net price 500 g = £153.62.
Nutritional supplement for the dietary management of phenylketonuria in patients 15 years and over

#### Phlexy-Vits® (SHS)
- **Capsules**, protein equivalent (essential and non-essential amino acids except phenylalanine) 833 mg/capsule. Net price 75-tab pack = £23.17
- **Tablets**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.8 g/20-g sachet. Apple-black currant, citrus, or tropical flavour. Net price 30 x 20-g sachets = £107.86
Nutritional supplement for the dietary management of phenylketonuria

#### Phlexy-10® Exchange System (SHS)
- **Capsules**, protein equivalent (essential and non-essential amino acids except phenylalanine) 416.5 mg/capsule. Net price 200-cap pack = £35.77
- **Tablets**, protein equivalent (essential and non-essential amino acids except phenylalanine) 8.4 g, carbohydrate 9.9 g, amino acids except phenylalanine) 79 g, carbohydrate 4.5 g, amino acids except phenylalanine) 20 g, carbohydrate 10.2 g, amino acids except phenylalanine) 2 g, carbohydrate 8.6 g, amino acids except phenylalanine) 15 g, carbohydrate 7.8 g, amino acids except phenylalanine) 416.5 mg/capsule. Net price 75-tab pack = £23.17
**Drink Mix**, powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 8.3 g, carbohydrate 8.6 g/29-g sachet. Apple-black currant, citrus, or tropical flavour. Net price 30 x 20-g sachets = £107.86
Nutritional supplement for the dietary management of phenylketonuria

#### PKU Anamix® Infant (SHS)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 79 g, carbohydrate 4.5 g, fat nil, energy 1420 kJ (334 kcal)/100 g. Unflavoured, (flavouring: see Modjul® Flavour System, p. 925), net price 500 g = £120.24 (5-g measuring scoop provided).
Nutritional supplement for the dietary management of phenylketonuria in infants

#### PKU Anamix® Junior (SHS)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 11.1 g, carbohydrate 48.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements. **Standard dilution** (15%) provides protein equivalent 2 g, carbohydrate 74 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £28.72 (5-g measuring scoop provided)
Nutritional supplement for the dietary management of proven phenylketonuria in children from birth to 3 years

#### PKU Anamix® Junior LQ (SHS)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free. Flavours: berry, orange, or unflavoured, net price 125 mL carton = £4.72
Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years

#### PKU Anamix® Junior QC (SHS)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free. Flavours: berry, orange, or unflavoured, net price 125 mL carton = £4.72
Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years

#### PKU cooler10® (Vitaflo)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 5.1 g, energy 258 kJ (62 kcal)/87-mL pouch, with vitamins, minerals, and trace elements. Unflavoured (white) or flavoured (orange, purple, or red), net price 30 x 87 mL = £112.80.
Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years

#### PKU cooler15® (Vitaflo)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15 g, carbohydrate 7.8 g, energy 386 kJ (92 kcal)/150-mL pouch, with vitamins, minerals, and trace elements. Unflavoured (white) or flavoured (orange, purple, or red), net price 30 x 130 mL = £168.00.
Nutritional supplement for the dietary management of phenylketonuria, not recommended for children under 3 years

#### PKU cooler20® (Vitaflo)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 10.2 g, energy 517 kJ (124 kcal)/174-mL pouch, with vitamins, minerals, and trace elements. Lemon, orange, tropical or unflavoured (flavouring; see Flavour Pac®. p. 925), net price 30 x 25-g sachets = £164.84.
Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 8 years

#### PKU express® (Vitaflo)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.6 g, fat less than 100 mg, energy 286 kJ (68 kcal)/20-g sachet
Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years

#### PKU gel® (Vitaflo)
- **Powder**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.6 g, fat less than 100 mg, energy 286 kJ (68 kcal)/100 mL with vitamins, minerals and trace elements. Orange, raspberry, or unflavoured (flavouring; see Flavour Pac®, p. 925), net price 30 x 20-g sachets = £95.03.
Nutritional supplement for use as part of the low-protein dietary management of phenylketonuria

#### PKU Lophlex® LQ 10 (SHS)
- **Liquid**, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 4.4 g, fibre 170 mg, energy 245 kJ (58 kcal)/62.5 mL, with vitamins, minerals, and trace elements. Flavours: berry, citrus, orange, or tropical, net price 62.5-mL carton = £4.35
Nutritional supplement for dietary management of phenylketonuria in children 4 years and adults including pregnant women

#### PKU Lophlex® LQ 20 (SHS)
- **Liquid**, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.8 g, fibre 340 mg, energy 495 kJ (115 kcal)/125 mL, with vitamins, minerals, and trace elements. Flavours: berry, citrus, orange, or tropical, net price 3 x 125 mL = £26.04
Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women

#### PKU Start® (Vitaflo)
- **Liquid**, protein equivalent (essential and non-essential amino acids except phenylalanine) 2 g, carbohydrate 8.3 g, fat 2.9 g, energy 286 kJ (68 kcal)/100 mL with vitamins, minerals, and trace elements. Contains lactose and fish oil. Net price 500-mL bottle = £5.58
Nutritional supplement for the dietary management of phenylketonuria in children under 1 year
Sno-Pro® (SHS)

Liquid, protein (cows’ milk) 220 mg, phenylalanine 12.5 mg, carbohydrate 8.2 g, fat 3.8 g, energy 273 kJ (65 kcal)/100 mL.

Contains lactose. Net price 200 mL = £1.05p

Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure, and other inborn errors of amino acid metabolism

L-Tyrosine (SHS)

Powder, net price 100 g = £18.41

For use as a supplement in maternal phenylketonurics who have low plasma tyrosine concentrations

Tyroside Amino Acid Supplement (Vitaflo)

Powder, tyrosine 1 g, carbohydrate 2.9 g, energy 62 kJ (15 kcal)/100 g, with vitamins, minerals, and trace elements. Orange or unflavoured (flavoured: see Modjul® Flavour System, p. 925), net price 500 g = £48.85

Nutritional supplement for the dietary management of phenylketonuria and other inborn errors of amino acid metabolism

XP Maxamaid® (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 25 g, carbohydrate 51.8 g, fat less than 500 mg, energy 1511 kJ (368 kcal)/100 g, with vitamins, minerals, and trace elements. Orange or unflavoured (flavoured: see Modjul® Flavour System, p. 925), net price 30 x 50-g sachets = £226.50, 500 g = £75.54

Nutritional supplement for the dietary management of phenylketonuria in children 1-8 years

XP Maximum® (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 39 g, carbohydrate 34.8 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements. Flavours: orange, unflavoured (flavoured: see Modjul® Flavour System, p. 925), net price 30 x 50-g sachets = £226.50, 500 g = £75.54

Nutritional supplement for the dietary management of phenylketonuria in children 1-8 years

Tyrosinaemia

Methionine-free TYR Anamix Infant (SHS)

Powder, protein equivalent (essential and non-essential amino acids except methionine, phenylalanine, and tyrosine) 13.1 g, carbohydrate 49.5 g, fat 23.1 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements. Standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 0.8 g, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £32.70 (5-g measuring spoon provided)

Nutritional supplement for the dietary management of proven tyrosinaemia type 1 in children from birth to 3 years

TYR Anamix® Infant (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine, and tyrosine) 13.1 g, carbohydrate 49.5 g, fat 23.1 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements, standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 0.8 g, energy 287 kJ (69 kcal)/100 mL. Unflavoured, net price 400 g = £32.70 (5-g measuring spoon provided)

Nutritional supplement for the dietary management of proven tyrosinaemia where plasma-methionine concentrations are normal in children from birth to 3 years

TYR Anamix® Junior (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 8.4 g, carbohydrate 11.1 g, fat 3.9 g, energy 475 kJ (113 kcal)/20-g sachet, with vitamins, minerals, and trace elements. Unflavoured, net price 30 x 20-g sachets = £173.32

Nutritional supplement for the dietary management of proven tyrosinaemia in children 1–10 years

1. Maxamaid products are generally intended for use in children 1–8 years
2. Maximum products are generally intended for use in children over 8 years and adults

TYR Anamix® Junior LQ (SHS)

Liquid, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 3.1 g, energy 500 kJ (119 kcal)/125 mL, with vitamins, minerals, and trace elements. Orange flavour, net price 36 x 125-mL bottle = £272.79

Nutritional supplement for the dietary management of tyrosinaemia type 1 (when nitisinone (NTBC) is used, see section 9.8.1), type II, and type III, in children over 1 year

TYR cooler® (Vitaflo)

Liquid, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 7 g, fat 50.6 mg, energy 386 kJ (92 kcal)/110 mL, with vitamins, minerals, and trace elements. Unflavoured (flavoured: see FlavourPac® sachets, p. 925), net price 30 x 25-g sachets = £271.89

Nutritional supplement for the dietary management of tyrosinaemia in children over 8 years and adults

TYR express® (Vitaflo)

Powder, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 3.8 g, fat less than 100 mg, energy 315 kJ (76 kcal)/25 g, with vitamins, minerals, and trace elements. Unflavoured (flavoured: see FlavourPac® sachets, p. 925), net price 30 x 20-g sachets = £151.93

Nutritional supplement for the dietary management of tyrosinaemia. Not recommended for children under 8 years

TYR Gel® (Vitaflo)

Gel, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 8.4 g, carbohydrate 8.6 g, fat less than 100 mg, energy 286 kJ (68 kcal)/20 g, with vitamins, minerals, and trace elements. Unflavoured (flavoured: see FlavourPac® sachets, p. 925), net price 30 x 25-g sachets = £271.89

Nutritional supplement for the dietary management of tyrosinaemia in children 1–10 years

XPEN TYR Maximum® (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 25 g, carbohydrate 51.8 g, fat less than 500 mg, energy 1511 kJ (368 kcal)/100 g, with vitamins, minerals, and trace elements. Flavours: orange, unflavoured (flavoured: see Modjul® Flavour System, p. 925), net price 500 g = £82.57

Nutritional supplement for the dietary management of tyrosinaemia in children 1–8 years

XPEN TYR Tyrosidon® (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g. Unflavoured (flavoured: see Modjul® Flavour System, p. 925). Net price 500 g = £156.42

Nutritional supplement for the dietary management of tyrosinaemia in children and adults where plasma-methionine concentrations are normal

XPTM Tyrosidon® (SHS)

Powder, protein equivalent (essential and non-essential amino acids except phenylalanine, tyrosine, and methionine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g. Unflavoured (flavoured: see Modjul® Flavour System, p. 925). Net price 500 g = £156.42

Nutritional supplement for the dietary management of tyrosinaemia type 1 in children and adults where plasma-methionine concentrations are above normal

1. Urea cycle disorders (other than arginase deficiency)

L-Arginine (SHS)

Powder, net price 100 g = £12.27

Nutritional supplement for the dietary management of urea cycle disorders other than arginase deficiency, such as hyperammonaemia types I and II, citrullinaemia, arginosuccinic aciduria, and deficiency of N-acetyl glutamate synthase
Conditions for which ACBS products can be prescribed

**Birthmarks**  See Disfiguring skin lesions, below

**Dermatitis**  Aveeno® Bath Oil; Aveeno® Cream; Aveeno® Colloidal; Aveeno® Lotion; E45® Emollient Bath Oil; E45® Emollient Wash Cream; E45® Lotion

For details of preparations see section 13.2.1, p. 701

**Dermatitis herpetiformis**  See also Gluten-free foods, p. 925

**Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo)**  Covermark® classic foundation and finishing powder; Dermacolor® Camouflage cream and fixing powder; Keromask® masking cream and finishing powder; Veil® Cover cream and Finishing Powder. (Cleansing Creams, Cleansing Milks, and Cleansing Lotions are excluded)

For details of preparations see section 13.8.2, p. 732

**Disinfectants (antiseptics)**  May be prescribed on an FP10 only when ordered in such quantities and with such directions as are appropriate for the treatment of patients, but not for general hygienic purposes.

**Dry mouth (xerostomia)**  For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.

AS Saliva Orthana®; Biotène Oralbalance®; BioXtra®; Glandosane®; Saliveze®, Salivix®.

For details of preparations see section 12.3.5, p. 698

**Eczema**  See Dermatitis, above

**Photodermatoses (skin protection in)**  Delph® Sun Lotion SPF 30; Sansense® Ultra; Uvistat® Lipscreen SPF 30; Uvistat® Suncream SPF 30 and 50.

For details of preparations see section 13.8.1, p. 730

**Pruritus**  See Dermatitis, above
Wound management

products and elasticated garments

A8.1 Basic wound contact dressings
A8.1.1 Low adherence dressings
A8.1.2 Absorbent dressings
A8.2 Advanced wound dressings
A8.2.1 Hydrogel dressings
A8.2.2 Vapour-permeable films and membranes
A8.2.3 Soft polymer dressings
A8.2.4 Hydrocolloid dressings
A8.2.5 Foam dressings
A8.2.6 Alginate dressings
A8.2.7 Capillary-action dressings
A8.2.8 Odour absorbent dressings
A8.3 Antimicrobial dressings
A8.3.1 Honey
A8.3.2 Iodine
A8.3.3 Silver
A8.3.4 Other antimicrobials
A8.4 Specialised dressings
A8.4.1 Protease-modulating matrix dressings
A8.4.2 Silicone keloid dressings
A8.5 Adjunct dressings and appliances
A8.5.1 Surgical absorbents
A8.5.2 Wound drainage pouches
A8.6 Complex adjunct therapies
A8.6.1 Topical negative pressure therapy
A8.7 Wound care accessories
A8.7.1 Dressing packs
A8.7.2 Woven and fabric swabs
A8.7.3 Surgical adhesive tapes
A8.7.4 Adhesive dressings
A8.7.5 Skin closure dressings
A8.8 Bandages
A8.8.1 Non-extensible bandages
A8.8.2 Light-weight conforming bandages
A8.8.3 Tubular bandages and garments
A8.8.4 Support bandages
A8.8.5 Adhesive bandages
A8.8.6 Cohesive bandages
A8.8.7 Compression bandages
A8.8.8 Multi-layer compression bandaging
A8.8.9 Medicated bandages
A8.9 Compression hosiery and garments
A8.9.1 Graduated compression hosiery
A8.9.2 Lymphoedema garments

Wound dressings

The correct dressing for wound management depends not only on the type of wound but also on the stage of the healing process. The principal stages of healing are:

- cleansing, removal of debris;
- granulation, vascularisation;
- epithelialisation.

The ideal dressing for moist wound healing needs to ensure that the wound remains:

- moist with exudate, but not macerated;
- free of clinical infection and excessive slough;
- free of toxic chemicals, particles or fibres;
- at the optimum temperature for healing;
- undisturbed by the need for frequent changes;
- at the optimum pH value.

Advanced wound dressings (section A8.2) are designed to control the environment for wound healing, for example to donate fluid (hydrogels), maintain hydration (hydrocolloids), or to absorb wound exudate (alginate, foams).
Practices such as the use of irritant cleansers and desloughing agents may be harmful and are largely obsolete; removal of debris and dressing remnants should need minimal irrigation with lukewarm sterile sodium chloride 0.9% solution or water. Hydrogel, hydrocolloid, and medical grade honey dressings can be used to deslough wounds by promoting autolytic debridement; there is insufficient evidence to support any particular method of debridement for difficult-to-heal surgical wounds. Sterile larvae (maggots) are also available for biosurgical removal of wound debris. There have been few clinical trials able to establish a clear advantage for any particular product. The choice between different dressings depends not only on the type and stage of the wound, but also on patient preference or tolerance, site of the wound, and cost. For further information, see Buyers’ Guide: Advanced wound dressings (October 2008), NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing. The table below gives suggestions for choices of primary dressing depending on the type of wound (a secondary dressing may be needed in some cases).

### Wound contact material for different types of wounds

<table>
<thead>
<tr>
<th>Wound PINK (Epithelialising)</th>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence A8.1.1</td>
<td>Soft polymer A8.2.3</td>
<td>Foam, low absorbent A8.2.5</td>
<td></td>
</tr>
<tr>
<td>Vapour-permeable film A8.2.2</td>
<td>Foam A8.2.5</td>
<td>Alginate A8.2.6</td>
<td></td>
</tr>
<tr>
<td>Soft polymer A8.2.3</td>
<td>Alginate A8.2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid A8.2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wound RED (Granulating)</th>
<th>Symptoms or signs of infection, see Wounds with signs of infection</th>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence A8.1.1</td>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td>Foam with extra absorbency A8.2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft polymer A8.2.3</td>
<td>Foam A8.2.5</td>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid A8.2.4</td>
<td>Alginate A8.2.6</td>
<td>Alginate A8.2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foam, low absorbent A8.2.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wound YELLOW (Sloughy)</th>
<th>Symptoms or signs of infection, see Wounds with signs of infection</th>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel A8.2.1</td>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid A8.2.4</td>
<td>Alginate A8.2.6</td>
<td>Alginate A8.2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foam, low absorbent A8.2.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wound BLACK (Necrotic/Eschar)</th>
<th>Consider mechanical debridement alongside autolytic debridement</th>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel A8.2.1</td>
<td>Hydrocolloid A8.2.4</td>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid A8.2.4</td>
<td>Foam A8.2.5</td>
<td>Foam, extra absorbent, with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foam, extra absorbent with silver A8.3.3</td>
<td></td>
<td>Alginate with honey A8.3.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid-fibrous A8.2.4</td>
<td>Alginate with silver A8.3.1</td>
<td>Alginate with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alginate A8.2.6</td>
<td>Capillary-action A8.2.7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wounds with signs of infection</th>
<th>Consider systemic antibacterials if appropriate; also consider odour-absorbent dressings (section A8.2.8)</th>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence with honey A8.3.1</td>
<td>Hydrocolloid-fibrous with silver A8.3.3</td>
<td>Hydrocolloid-fibrous with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low adherence with iodine A8.3.2</td>
<td>Foam with silver A8.3.3</td>
<td>Foam, extra absorbent, with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low adherence with silver A8.3.3</td>
<td>Alginate with silver A8.3.3</td>
<td>Alginate with honey A8.3.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocolloid with silver A8.3.3</td>
<td>Honey—topical A8.3.1</td>
<td>Alginate with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honey—topical A8.3.1</td>
<td>Cadexomer—Iodine A8.3.2</td>
<td>Alginate with silver A8.3.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: In each section of this table the dressings are listed in order of increasing absorbency. Some wound contact (primary) dressings require a secondary dressing.
interfere with absorption; dressings with ‘normal loading’ (such as Jelonet®) have been used for skin graft transfer.

Knitted viscose primary dressing is an alternative to tulle dressings for exuding wounds; it can be used as the initial layer of multi-layer compression bandaging in the treatment of venous leg ulcers.

Knitted Viscose Primary Dressing, BP 1993
Warp knitted fabric manufactured from a bright viscose monofilament.
N-A Dressing*, 9.5 cm × 9.5 cm = 35p, 9.5 cm × 19 cm = 67p (Sytagenex)
N-A Ultra®, silicone-coated, 9.5 cm × 9.5 cm = 33p, 9.5 cm × 19 cm = 63p (Sytagenex)
Profore®, 14 cm × 20 cm = 30p (S&N Hlth.)
Tricotex®, 9.5 cm × 9.5 cm = 32p (S&N Hlth.)

Paraffin Gauze Dressing, BP 1993
(Tulle Gauze). Fabric of leno weave, wool and warf threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin, 10 cm × 10 cm, (light loading) = 25p; (normal loading) = 37p (most suppliers including Synergy Healthcare—Furnace® (light loading); BSN Medical—Cuticel® Classic (normal loading); S&N Hlth.—Jelonet® (normal loading); Neoemed—Neotulle® (normal loading); C D Medical—Paragauze® (normal loading))

Atrauman® (Hartmann)
Non-adherent knitted polyester primary dressing impregnated with neutral triglycerides, 5 cm × 5 cm = 24p, 7.5 cm × 10 cm = 26, 10 cm × 20 cm = 58, 20 cm × 30 cm = £1.58

A8.1.2 Absorbent dressings

Absorbent Perforated Plastic Film Faced Dressings
Low-adherence primary dressing consisting of three layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophilic backing. Where no size specified by the prescriber, the 5 cm size to be supplied.

SkinCare® Pad, 5 cm × 5 cm = 13p, 10 cm × 10 cm = 20p, 10 cm × 20 cm = 40p (Braun)
Cutisorb® LA, 5 cm × 5 cm = 8p, 10 cm × 10 cm = 14p, 10 cm × 20 cm = 29p (BSN Medical)
Interpose®, 5 cm × 5 cm = 9p, 10 cm × 10 cm = 15p, 10 cm × 20 cm = 32p (Frontier)
Melolin®, 5 cm × 5 cm = 16p, 10 cm × 10 cm = 26p, 20 cm × 10 cm = 51p (S&N Hlth.)
Release®, 5 cm × 5 cm = 14p, 10 cm × 10 cm = 23p, 20 cm × 10 cm = 44p (Sytagenex)
Skinint®, 5 cm × 5 cm = 10p, 10 cm × 10 cm = 17p, 20 cm × 10 cm = 34p (Robinson)
Solvanne N®, 5 cm × 5 cm = 9p, 10 cm × 10 cm = 17p, 10 cm × 20 cm = 33p (Activa)
Telfa®, 5 cm × 7.5 cm = 12p, 10 cm × 7.5 cm = 15p, 15 cm × 7.5 cm = 17p, 20 cm × 7.5 cm = 25p (Covidien)

For moderately to heavily exuding wounds

Absorbent Cellulose Dressing with Fluid Repellent Backing

Eclipse®, 15 cm × 15 cm = 97p, 20 cm × 30 cm = £2.14, 60 cm × 40 cm = £8.15, 80 cm × 50 cm = £9.35, 60 cm × 70 cm (boot-shape) = £13.54 (Advancis)
Eux-Dry®, 10 cm × 15 cm = £1.06, 15 cm × 23 cm = £2.17, 23 cm × 38 cm = £5.04 (S&N Hlth.)
Mesorb®, cellulose wound pad with gauze wound contact layer and non-woven repellent backing, 10 cm × 10 cm = 59p, 10 cm × 15 cm = 77p, 20 cm × 20 cm = 95p, 15 cm × 20 cm = £1.36, 20 cm × 25 cm = £2.14, 20 cm × 30 cm = £2.43 (Molnlycke)
Telfa® Max®, 22.8 cm × 38 cm = £4.62, 38 cm × 45.7 cm = £5.61, 38 cm × 60.9 cm = £8.16 (Covidien)
Zetuvit®, E, non-stereile, 10 cm × 10 cm = 6p, 10 cm × 20 cm = 8p, 20 cm × 20 cm = 13p, 20 cm × 40 cm = 26p, sterile, 10 cm × 10 cm = 20p, 10 cm × 20 cm = 23p, 20 cm × 20 cm = 37p, 20 cm × 40 cm = £1.02 (Hartmann)

For heavily exuding wounds

Cutisorb® Ultra (BSN Medical)
Super absorbent cellulose and polymer primary dressing, 10 cm × 10 cm = £1.99, 20 cm × 20 cm = £6.25, 10 cm × 20 cm = £3.33, 20 cm × 30 cm = £9.42
DryMax® Extra (Aspen Medical)
Super absorbent cellulose and polymer primary dressing, 10 cm × 10 cm = £1.99, 20 cm × 20 cm = £6.16, 10 cm × 20 cm = £3.28, 20 cm × 30 cm = £8.86
KerraMax® (Ark Therapeutics)
Super absorbent polyacrylate primary dressing, 10 cm × 10 cm = 90p, 10 cm × 22 cm = £1.19, 20 cm × 22 cm = £2.10, 20 cm × 30 cm = £2.40
Zetuvit® Plus (Hartmann)
Super absorbent cellulose primary dressing, 10 cm × 10 cm = 60p, 10 cm × 20 cm = £3.83, 15 cm × 20 cm = 95p, 20 cm × 25 cm = £1.30, 20 cm × 40 cm = £2.00

Proguide® WCL (S&N Hlth.)
Super absorbent hydrocellular primary dressing, 10 cm × 10 cm = £2.05
A8.2 Advanced wound dressings

Advanced wound dressings can be used for both acute and chronic wounds. Categories for dressings in this section (A8.2) start with the least absorptive, moisture-donating hydrogel dressings, followed by increasingly more absorptive dressings. These dressings are classified according to their primary component; some dressings are comprised of several components.

A8.2.1 Hydrogel dressings

Hydrogel dressings are most commonly supplied as an amorphous, cohesive topical application that can take up the shape of a wound. A secondary, non-absorbent dressing is needed. These dressings are generally used to donate liquid to dry sloughy wounds and facilitate autolytic debridement of necrotic tissue; some also have the ability to absorb very small amounts of exudate. Hydrogel products that do not contain propylene glycol can be used if the wound is to be treated with larval therapy.

Hydrogel sheet dressings are best avoided in the presence of infection, and are unsuitable for heavily exuding wounds.

### Hydrogel sheet dressings

- **ActiFormCool** (Activa)
  - Hydrogel dressing, 5 cm x 5 cm = £1.70
  - Hydrogel dressing, 10 cm x 10 cm = £2.49
  - Hydrogel dressing, 20 cm x 20 cm = £7.51

- **AquaFlo** (Covidien)
  - Hydrogel dressing, 7.5 cm diameter = £2.55

- **Gel FX** (Synergy Healthcare)
  - Hydrogel dressing (without adhesive border) 10 cm x 10 cm = £1.60

- **Geliperm** (Geistlich)
  - Hydrogel sheets, 10 cm x 10 cm = £2.45

- **Hydrosorb** (Hartmann)
  - Absorbent, transparent, hydrogel sheets containing polyurethane polymers coated with a semi-permeable film, 5 cm x 7.5 cm = £1.46
  - Hydrogel dressing, 10 cm x 10 cm = £2.09

- **Intrasite Conformable** (S&N Hlth.)
  - Soft non-woven dressing impregnated with *Intrasite* gel, 10 cm x 10 cm = £1.70

- **Novogel** (Ford)
  - Hydrogel-containing guar gum and propylene glycol, 15 g = £1.39

**A8.2.2 Vapour-permeable films and membranes**

Vapour-permeable films and membranes allow the passage of water vapour and oxygen but are impermeable to water and micro-organisms, and are suitable for lightly exuding wounds. They are highly conformable, provide protection, and a moist healing environment; vapour-permeable films and membranes permit constant observation of the wound. Water vapour loss can occur at a slower rate than exudate is generated, so that fluid accumulates under the dressing, which can lead to tissue maceration and to wrinkling at the adhesive contact site (with risk of bacterial entry). Newer versions of these dressings have increased moisture vapour permeability. Despite these advances, vapour-permeable films and membranes are unsuitable for infected, large heavily exuding wounds, and chronic leg ulcers.

Vapour-permeable films and membranes are suitable for partial-thickness wounds with minimal exudate, or wounds with eschar. Most commonly, they are used as a secondary dressing over alginates or hydrols; film dressings can also be used to protect the fragile skin of patients at risk of developing minor skin damage caused by friction or pressure.

### Vapour-permeable Adhesive Film Dressing (Semi-permeable Adhesive Dressing)

Extensible, waterproof, water-vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

- **ActivHeal Film** (MedLogic)
  - Film dressing, 6 cm x 7 cm = £2.09

- **Askina Derm** (Braun)
  - Film dressing, 6 cm x 7 cm = £2.09

- **Bioclusive** (Systagenix)
  - Film dressing, 10 cm x 12.7 cm = £1.54
<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mepore</td>
<td>Film, absorbent pad</td>
<td>Suitable for use on lightly to moderately exuding wounds.</td>
</tr>
<tr>
<td>Leukomed T</td>
<td>Film, absorbent pad</td>
<td>Suitable for use on moderately to heavily exuding wounds.</td>
</tr>
<tr>
<td>Hydrofilm</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 6.5 cm × 5 cm = 30p, 9 cm × 8.5 cm = 83p</td>
</tr>
<tr>
<td>Alldress</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 10 cm = 91p, 6 cm × 9.5 cm = 80p</td>
</tr>
<tr>
<td>Vacufilm</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 9 cm = 12p, 5 cm × 5 cm = 12p</td>
</tr>
<tr>
<td>ProtectFilm</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 4 cm × 4 cm = 36p, 7 cm × 7 cm = 30p</td>
</tr>
<tr>
<td>Suprasorb</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 7 cm = 31p, 12 cm × 12 cm = 21p</td>
</tr>
<tr>
<td>Polyskin P® II</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 5 cm = 35p, 8 cm × 10 cm = 65p</td>
</tr>
<tr>
<td>Mepore® Film (Mölnlycke)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 9 cm × 9 cm = 12p, 10 cm × 10 cm = 50p</td>
</tr>
<tr>
<td>OpSite® Flexifix</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 8 cm × 8 cm = 10p, 8 cm × 10 cm = 39p</td>
</tr>
<tr>
<td>PolySkin® II (Covidien)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 5 cm = 9p, 8 cm × 10 cm = 16p</td>
</tr>
<tr>
<td>ProtectFilm® (Wallace Cameron)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 7 cm × 7 cm = 30p, 15 cm × 15 cm = 80p</td>
</tr>
<tr>
<td>Suprasorb P® (Activa)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 4 cm × 4 cm = 36p, 7 cm × 7 cm = 30p</td>
</tr>
<tr>
<td>Tegaderm® (3M)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 5 cm × 7 cm = 25p, 9 cm × 10 cm = 62p</td>
</tr>
<tr>
<td>Vapour–permeable, transparent, adhesive film dressing, 5 cm × 6 cm (1-hand)</td>
<td>£1.60, 10 cm × 7 cm (non-winged peripheral catheter)</td>
<td>£2.15, 10 cm × 10 cm (peripheral cannula) = £3.87, 14.2 cm × 15.8 cm = £5.45, rectangular pad, 14.9 cm × 15.2 cm = £8.26, 20 cm × 20.3 cm = £13.26, 16.8 cm × 19 cm (sacral) = £9.89</td>
</tr>
</tbody>
</table>

### For intravenous and subcutaneous catheter sites

- **Central Gard® (Unomedical)**
  - Vapour-permeable transparent film dressing with adhesive foam border, 6 cm × 7 cm (central venous catheter) = £9.49, 16 cm × 8 cm (central venous catheter) = £10.03

- **Easi-LVA® (Convatec)**
  - Vapour-permeable transparent film dressing with adhesive foam border, 7 cm × 7.5 cm (intravenous peripheral cannula) = £3.89

- **IV3000® (S&N Hlth.)**
  - Vapour-permeable, transparent, adhesive film dressing, 5 cm × 6 cm (1-hand) = £40, 6 cm × 7 cm (non-winged peripheral catheter) = £52, 7 cm × 9 cm (ported peripheral catheter) = £69, 9 cm × 12 cm (PICC line) = £31.7, 10 cm × 12 cm (central venous catheter) = £10.32

### Hydrofilm® Plus (Hartmann)

<table>
<thead>
<tr>
<th>Brand</th>
<th>Type</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mepore® F® (Mölnlycke)</td>
<td>Film &amp; Pad, absorbent pad</td>
<td>Film dressing, with absorbent pad, 6 cm × 6 cm = 23p, 9 cm × 7 cm = 24p</td>
</tr>
<tr>
<td>Mepore® Ultra (Mölnlycke)</td>
<td>Film, absorbent pad</td>
<td>Film dressing, with absorbent pad, 6 cm × 7 cm = 28p, 7 cm × 8 cm = 39p</td>
</tr>
</tbody>
</table>

### Wound contact dressings

Dressings with soft polymer, often a soft silicone polymer, in a non-adherent or gently adherent layer are suitable for use on lightly to moderately exuding wounds. For moderately to heavily exuding wounds, an absorbent secondary dressing can be added, or a soft polymer dressing with an absorbent pad can be used.

Wound contact dressings coated with soft silicone have gentle adhesive properties and can be used on fragile skin areas or where it is beneficial to reduce the frequency of primary dressing changes.
Appendix B: Wound management

940 A8.2.4 Hydrocolloid dressings

Hydrocolloid dressings are usually presented as a hydrocolloid layer on a vapour-permeable film or foam pad. Semi-permeable to water vapour and oxygen, these dressings form a gel in the presence of exudate to facilitate rehydration in lightly to moderately exuding wounds and promote autolytic debridement of dry, sloughy, or necrotic wounds; they are also suitable for promoting granulation.

Hydrocolloid-fibrous dressings made from modified carboxymethyl cellulose fibres resemble alginate dressings; hydrocolloid dressings form a gel in the presence of exudate to absorb fluid; hydrocolloid-fibrous dressings are more absorptive and suitable for lightly to moderately exuding wounds.

Without absorbent pad

Soft polymer dressings should not be used on heavily bleeding wounds; blood clots can cause the dressing to adhere to the wound surface.

For silicone keloid dressings see section A8.4.2.

<table>
<thead>
<tr>
<th>Brand</th>
<th>Product Description</th>
<th>Size</th>
<th>Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutimed®</td>
<td>Soft silicone, semi-transparent wound contact dressing, 7 cm x 7 cm = £1.57, 12 cm x 15 cm = £6.34, 20 cm x 30 cm = £16.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mepilex® (Mölnlycke)</td>
<td>Soft silicone, semi-transparent wound contact dressing, 7 cm x 7 cm = £1.57, 8 cm x 10 cm = £3.13, 12 cm x 15 cm = £6.34, 20 cm x 30 cm = £16.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiotulle</td>
<td>Non-adherent soft polyurethane foam wound contact dressing, 10 cm x 10 cm = £2.13, 15 cm x 20 cm = £6.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silflex® (Advacns)</td>
<td>Soft silicone-coated polyester wound contact dressing, 5 cm x 7 cm = £2.55, 12 cm x 15 cm = £5.15, 20 cm x 30 cm = £13.25, 35 cm x 60 cm = £39.54</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorbion® S (H&amp;R)</td>
<td>Non-adherent polyethylene wound contact dressing with absorbent core, 8.5 cm x 8.5 cm = £5.00, 12 cm x 12 cm = £6.78, 12 cm x 22 cm = £12.56, 22 cm x 22 cm = £20.14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tegaderm® Contact (3M)</td>
<td>Non-adherent soft polyurethane wound contact dressing, 5 cm x 5 cm = £1.86, 10 cm x 10 cm = £3.00, 15 cm x 20 cm = £4.89, 20 cm x 20 cm = £6.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urgotul® (Urgo)</td>
<td>Non-adherent polyurethane foam film backing, 5 cm x 5 cm = £1.24, 10 cm x 10 cm = £2.45, 15 cm x 20 cm = £3.94, 20 cm x 20 cm = £6.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allevyn® Gentile Border</td>
<td>Silicone gel wound contact dressing, with polyurethane foam film backing, 7.5 cm x 7.5 cm = £1.44, 10 cm x 10 cm = £2.46, 12.5 cm x 12.5 cm = £3.17, 17.5 cm x 17.5 cm = £6.16, 23 cm x 23 cm (heel) = £9.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutimed® Siltec (BSN Medical)</td>
<td>Soft silicone wound contact dressing, with polyurethane foam film backing, 5 cm x 6 cm = £1.23, 10 cm x 10 cm = £2.30, 10 cm x 20 cm = £3.80, 15 cm x 15 cm = £4.30, 20 cm x 20 cm = £6.52, 16 cm x 24 cm (heel) = £6.77, with adhesive border, 17.5 cm x 17.5 cm (sacrum) = £4.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutimed® Siltec B</td>
<td>With adhesive border, for lightly to moderately exuding wounds, 7.5 cm x 7.5 cm = £1.43, 12.5 cm x 12.5 cm = £3.03, 15 cm x 15 cm = £4.66, 17.5 cm x 17.5 cm = £4.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutimed® Siltec Lite</td>
<td>For lightly to moderately exuding wounds, 5 cm x 6 cm = £0.99, 10 cm x 10 cm = £1.98, 15 cm x 15 cm = £3.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eclypse® Adherent (Advacns)</td>
<td>Soft silicone wound contact layer with absorbent pad and film-backing, 10 cm x 10 cm = £2.99, 10 cm x 20 cm = £3.75, 15 cm x 15 cm = £4.99, 20 cm x 30 cm = £9.99, 17 cm x 19 cm (sacral) = £3.76, 22 cm x 23 cm (sacral) = £6.23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episol® Absorbent (Advacns)</td>
<td>Soft silicone wound contact dressing, with polyurethane foam film backing, 7.5 cm x 7.5 cm = £1.91, 10 cm x 10 cm = £2.16, 10 cm x 20 cm = £2.90, 10 cm x 30 cm = £4.25, 15 cm x 15 cm = £3.15, 15 cm x 20 cm = £4.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filvasorb® (Activa)</td>
<td>Absorbent polymer dressing with non-adherent wound contact layer, 10 cm x 10 cm = £2.12, 20 cm x 20 cm = £6.68, 10 cm x 20 cm = £3.55, 20 cm x 30 cm = £9.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mepilex® (Mölnlycke)</td>
<td>Absorbent soft silicone dressing with polyurethane foam film backing, 10 cm x 11 cm = £2.57, 11 cm x 20 cm = £4.24, 15 cm x 16 cm = £4.66, 20 cm x 21 cm = £7.03, 20 cm x 30 cm = £27.44, 13 cm x 20 cm (heel) = £5.22, 15 cm x 22 cm (heel) = £5.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mepilex® Border</td>
<td>Absorbent soft silicone dressing with polyurethane foam and silicone adhesive, 7 cm x 7.5 cm = £1.33, 10 cm x 12.5 cm = £2.63, 10 cm x 20 cm = £3.56, 10 cm x 30 cm = £5.36, 15 cm x 17.5 cm = £4.53, 17 cm x 20 cm = £5.87, 18 cm x 18 cm (sacrum) = £4.69, 23 cm x 23 cm (sacrum) = £7.84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mepilex® Border Lite</td>
<td>Thins absent soft silicone dressing with polyurethane foam and adhesive border, 4 cm x 5 cm = £1.91, 7.5 cm x 7.5 cm = £1.37, 5 cm x 12.5 cm = £1.98, 10 cm x 10 cm = £2.49, 15 cm x 15 cm = £4.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorbion® Sera (H&amp;R)</td>
<td>Non-adherent polyethylene wound contact dressing with absorbent core, 8.5 cm x 8.5 cm = £5.00, 12 cm x 12 cm = £6.78, 12 cm x 22 cm = £12.56, 22 cm x 22 cm = £20.14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Bio-cellulose dressings
| Sorbion® S (H&R)         | Absorbent polymers in cellulose matrix, hypoallergenic fleece envelope (for moderately to heavily exuding wounds). 7.5 cm x 7.5 cm = £1.75, 10 cm x 10 cm = £2.22, 10 cm x 10 cm (drainage) = £2.64, 20 cm x 20 cm = £6.90, 20 cm x 10 cm = £3.68, 30 cm x 10 cm = £5.28, 30 cm x 20 cm = £9.92, 12 cm x 5 cm = £1.86 |
| Suprasorb® X (Activa)    | Biosynthetic cellulose fibre dressing (for lightly to moderately exuding wounds), 5 cm x 5 cm = £1.10, 10 cm x 10 cm = £3.05, 14 cm x 20 cm = £7.83, 2 cm x 21 cm (rope) = £6.08 |

BNF 61
Hydrocoll
Alione
Tegaderm
Hydrocoll
Granuflex
Flexigran
Comfeel
Askina
BNF 61

A8.2.5 Foam dressings

Hydrocoll® (Coloplast)
Semi-permeable hydrocolloid dressing without adhesive border, 10 cm × 10 cm = £3.01, 12.5 cm × 12.5 cm = £4.14, 12 cm × 20 cm = £5.44, 15 cm × 15 cm = £5.24, 20 cm × 20 cm = £7.82

Askina® Biofilm Transparent (Braun)
Semi-permeable, polyurethane film dressing with hydrocolloid adhesive, 10 cm × 10 cm = £1.02, 15 cm × 15 cm = £2.31, 20 cm × 20 cm = £3.02

Comfeel® Plus (Coloplast)
Hydrocolloid dressings containing carmelllose sodium and calcium alginate, contoured, 6 cm × 8 cm = £2.08, 9 cm × 11 cm = £3.61; ulcer, 4 cm × 6 cm = 90p, 10 cm × 10 cm = £2.29, £4.91, 18 cm × 20 cm (triangular) = £5.35, 20 cm × 20 cm = £7.08; transparent, 5 cm × 7 cm = £3.35, 5 cm × 15 cm = £1.48, 5 cm × 25 cm = £2.41, 9 cm × 14 cm = £2.28, 9 cm × 25 cm = £3.24, 10 cm × 10 cm = £1.20, 15 cm × 15 cm = £3.12, 15 cm × 20 cm = £3.17, 20 cm × 20 cm = £3.19, pressure relieving, 7 cm diameter = £3.24, 10 cm diameter = £4.34, 15 cm diameter = £6.54

DuoDERM® Extra Thin (Convatec)
Semi-permeable hydrocolloid dressing, 5 cm × 10 cm = 71p, 7.5 cm × 7.5 cm = 75p, 10 cm × 10 cm = £1.24, 9 cm × 15 cm = £1.66, 9 cm × 25 cm = £2.66, 9 cm × 35 cm = £3.72, 15 cm × 15 cm = £2.68

DuoDERM® Signal, hydrocolloid dressing with ‘Time to change’ indicator, 10 cm × 10 cm = £1.98, 14 cm × 14 cm = £3.48, 20 cm × 20 cm = £6.91, 11 cm × 19 cm (oval) = £3.01, 18.5 cm × 19.5 cm (heel) = £4.86, 22.5 cm × 20 cm (sacral) = £5.68

Flexigran® (A1 Pharmaceuticals)
Semi-permeable hydrocolloid dressing without adhesive border, 10 cm × 10 cm = £2.19, thin, 10 cm × 10 cm = £1.08

Granuflex® (Convatec)
Hydrocolloid wound contact layer bonded to plastic foam layer, with outer semi-permeable polyurethane film, 10 cm × 10 cm = £2.64, 15 cm × 15 cm = £3.00, 15 cm × 20 cm = £5.42, 20 cm × 20 cm = £7.52

Hydrocoll® Basic (Hartmann)
Hydrocolloid dressing with absorbent wound contact pad, 10 cm × 10 cm = £2.28, thin, 7.5 cm × 7.5 cm = £6.5p, 10 cm × 10 cm = £1.07, 15 cm × 15 cm = £2.42

NU DERM® (Systagenix)
Semi-permeable hydrocolloid dressing, 5 cm × 5 cm = 85p, 10 cm × 10 cm = £1.56, 15 cm × 15 cm = £3.18, 20 cm × 20 cm = £6.36, 8 cm × 12 cm (heel/elbow) = £3.18, 15 cm × 18 cm (sacral) = £4.45, thin, 10 cm × 10 cm = £1.06

Tegaderm® Hydrocolloid (3M)
Hydrocolloid dressing without adhesive border, 10 cm × 10 cm = £2.30, 15 cm × 15 cm = £4.46; thin, semi-permeable, clear film dressing with hydrocolloid, 10 cm × 10 cm = £1.51

Ultrec Pro® (Covidien)
Semi-permeable hydrocolloid dressing, without adhesive border 10 cm × 10 cm = £2.23, 15 cm × 15 cm = £4.36, 20 cm × 20 cm = £6.56

Tegaderm® Hydrocolloid (3M)
Hydrocolloid dressing with adhesive border, 10 cm × 12 cm (oval) = £2.26, 13 cm × 15 cm (oval) = £4.22, 17.1 cm × 16.1 cm (sacral) = £4.71; thin, semi-permeable, clear film dressing with hydrocolloid, 10 cm × 12 cm (oval) = £1.50, 13 cm × 15 cm (oval) = £2.81

Ultec Pro® (Covidien)
Semi-permeable hydrocolloid dressing with adhesive border, 21 cm × 21 cm = £4.58, 15 cm × 18 cm (sacral) = £3.23, 19.5 cm × 23 cm (sacral) = £4.88

Hydrocolloid-fibrous dressings
Aquadex® (Convatec)
Soft non-woven pad containing hydrocolloid-fibres, 4 cm × 10 cm = £1.40, 4 cm × 20 cm = £2.07, 4 cm × 30 cm = £3.11, 5 cm × 5 cm = £1.10, 10 cm × 10 cm = £2.81, 15 cm × 15 cm = £4.91; 2 cm × 45 cm (ribbon) = £2.64

Versiva® XC (Convatec)
Hydrocolloid gelling foam dressing, without adhesive border, 7.5 cm × 7.5 cm = £1.39, 11 cm × 11 cm = £2.31, 15 cm × 15 cm = £4.26, 20 cm × 20 cm = £8.37, with adhesive border, 10 cm × 10 cm = £2.36, 14 cm × 14 cm = £3.19, 19 cm × 19 cm = £5.09, 22 cm × 22 cm = £5.85, 18.5 cm × 20.5 cm (heel) = £5.65, 21 cm × 25 cm (sacral) = £6.06

Polyurethane matrix dressing
Cutinova® Hydro (SNH Ltd.)
Polyurethane matrix with absorbent particles and waterproof polyurethane film, 5 cm × 6 cm = £1.19, 10 cm × 10 cm = £2.40, 15 cm × 20 cm = £5.07

A8.2.5 Foam dressings

Dressings containing hydrophilic polyurethane foam (adhesive or non-adhesive), or without plastic film-backing, are suitable for all types of exuding wounds, but not for dry wounds; some foam dressings have a moisture-sensitive film backing with variable permeability dependant on the level of exudate.

Foam dressings vary in their ability to absorb exudate; some are suitable only for lightly to moderately exuding wounds, others have greater fluid-handling capacity and are suitable for heavily exuding wounds. Saturated foam dressings can cause maceration of healthy skin if left in contact with the wound.

Foam dressings can be used in combination with other primary wound contact dressings. If used under compression bandaging or compression garments, the fluid-handling capacity of the foam dressing may be reduced. Foam dressings can also be used to provide a protective cushion for fragile skin.

For lightly exuding wounds
Polyurethane Foam Film Dressing with Adhesive Border
PolyMem®, 5 cm × 5 cm = 48p (Aspen Medical)

Tielle® Lite, 11 cm × 11 cm = £2.28; 7 cm × 9 cm = £1.21; 8 cm × 15 cm = £2.81; 8 cm × 20 cm = £2.97 (Systagenix)

For lightly to moderately exuding wounds
PolyLite® Foam Dressing, BP 1993
Lyfoam®, 7.5 cm × 7.5 cm = £1.05, 10 cm × 10 cm = £1.20, 10 cm × 17.5 cm = £1.94, 15 cm × 20 cm = £2.61 (Molnlycke)

Suprasorb® M, 10 cm × 10 cm = £1.78, 10 cm × 20 cm = £3.14, 20 cm × 20 cm = £5.23 (Activa)

Polyurethane Foam Film Dressing with Adhesive Border
Suprasorb® P, 7.5 cm × 7.5 cm = £1.20, 10 cm × 10 cm = £1.29, 15 cm × 15 cm = £2.32 (Activa)
Appendix 8: Wound management

**Polyurethane Foam Dressing without Adhesive Border**

**Acticoat FlexiPore**, self-adhesive, 6 cm x 7 cm = £9.45, 10 cm x 10 cm = £11.77, 15 cm x 10 cm = £22.55, 20 cm x 20 cm = £34.51, 30 cm x 30 cm = £63.13 (MediLogic)

**Allevyn**

9 cm diameter = £1.50, 10 cm diameter = £2.29, 12.5 cm diameter = £3.35 (S&N Hlth.)

**Allevyn Thin**

9 cm diameter = £1.00, 10 cm diameter = £2.03, 15 cm diameter = £3.35, 15 cm x 20 cm = £4.06 (S&N Hlth.)

**Suprasorb P**

5 cm x 5 cm = £9.35, 7.5 cm x 7.5 cm = £9.95, 10 cm x 10 cm = £11.15, 15 cm x 15 cm = £13.12 (Activa)

**Transolent**, self-adhesive, 5 cm x 7 cm = £1.01, 10 cm x 10 cm = £1.19, 15 cm x 15 cm = £2.70, 20 cm x 20 cm = £5.59 (Braun)

**UrgoCell TLC**

Self-adherent, 6 cm x 6 cm = £1.74, 10 cm x 10 cm = £2.53, 15 cm x 20 cm = £4.57, 12 cm x 19 cm (heal) = £4.52 (Urko)

For moderately to heavily exuding wounds

**Polyurethane Foam Dressing**

**Copa**

5 cm x 5 cm = £7.00, 7.5 cm x 7.5 cm = £7.82, 10 cm x 10 cm = £11.60, 12.5 cm x 12.5 cm = £16.85, 15 cm x 17.5 cm = £23.25, 20 cm x 20 cm = £44.12 (MediLogic)

**CUTMED**

Cavity, 6 cm x 4 cm = £1.74, 10 cm x 10 cm = £2.89, 15 cm x 2 cm = £6.11, 15 cm x 15 cm = £4.34 (BSN Medical)

**Polyurethane Foam Dressing with Adhesive Border**

**Acticoat Foam Island**, 7.5 cm x 7.5 cm = £1.18, 10 cm x 10 cm = £1.60, 12.5 cm x 12.5 cm = £2.68, 15 cm x 15 cm = £3.12, 20 cm x 20 cm = £5.47 (S&N Hlth.)

**Allevyn Adhesive**

7.5 cm x 7.5 cm = £1.43, 10 cm x 10 cm = £2.10, 12.5 cm x 12.5 cm = £2.57, 17.5 cm x 17.5 cm = £5.07, 17.5 cm x 22.5 cm = £4.80, 22.5 cm x 22.5 cm = £8.38 (sacral) 17 cm x 17 cm = £8.60, 22 cm x 22 cm = £10.77 (S&N Hlth.)

**Allevyn Plus Adhesive**

12.5 cm x 12.5 cm = £3.16, 17.5 cm x 17.5 cm = £6.10, 12.5 cm x 22.5 cm = £5.60, 15 cm x 22.5 cm = £5.27, 17 cm x 17 cm = £4.61, 22 cm x 22 cm = £6.67 (S&N Hlth.)

**Biatain Adhesive**

10 cm x 10 cm = £6.15, 12.5 cm x 12.5 cm = £6.41, 18 cm x 18 cm = £4.86, 18 cm x 28 cm = £7.20, 22 cm x 23 cm (sacral) = £4.16, 19 cm x 20 cm (heel) = £4.85, 17 cm diameter (contour) = £4.67 (Coloplast)

**Biatain Silicone**

7.5 cm x 7.5 cm = £1.41, 10 cm x 10 cm = £2.27, 12.5 cm x 12.5 cm = £2.90, 15 cm x 15 cm = £3.98, 17.5 cm x 17.5 cm = £5.49 (Coloplast)

**Copa Island**

10 cm x 10 cm = £1.51, 15 cm x 15 cm = £2.84, 20 cm x 20 cm = £3.56 (Covidien)

**PermaFoam**

16.5 cm x 18 cm (concave) = £1.76, 18 cm x 18 cm (sacral) = £3.99, 22 cm x 22 cm (sacral) = £5.55, 25 cm x 25 cm (sacral) = £9.65, 30 cm x 30 cm = £18.42 (Activa)

**PermaFoam Comfor**

8 cm x 8 cm = £1.04, 10 cm x 20 cm = £3.13, 11 cm x 11 cm = £1.98, 15 cm x 15 cm = £3.23, 20 cm x 20 cm = £4.69 (Hartmann)

**PolyMem**

5 cm x 7 cm = £1.10, 8.8 cm x 12.7 cm = £1.95, 10 cm x 13 cm = £2.08, 15 cm x 15 cm = £2.80, 16.5 cm x 20.9 cm = £6.62, 18.4 cm x 20 cm (sacral) = £4.32 (Aspen Medical)

**Tegaderm**

24 cm x 12 cm = £2.39, 15 cm x 15 cm = £3.82, 20 cm x 20 cm = £5.01, 30 cm x 30 cm = £7.20, 45 cm x 45 cm = £10.02 (3M)

**Allevyn Plus Borderless**

11 cm x 11 cm = £3.04, 15 cm x 15 cm = £5.51 (Systagenix)

**Allevyn Xtra**

11 cm x 11 cm = £2.24, 15 cm x 15 cm = £3.37, 15 cm x 20 cm = £5.51 (Systagenix)

**Trufoam NA**

5 cm x 5 cm = £1.09, 10 cm x 10 cm = £2.07, 15 cm x 15 cm = £3.81 (Aspen Medical)

**Cavi-Care**

Soft, conforming cavity wound dressing prepared by mixing thoroughly for 15 seconds immediately before use and allowing to expand its volume within the cavity: 29 g = £18.62

---

**Alginite dressings**

Non-woven or fibrous, non-occlusive, alginite dressings: made from calcium alginate, or calcium sodium alginate, derived from brown seaweed, form a soft gel in contact with wound exudate.

Alginite dressings are highly absorbent and suitable for use on exuding wounds, and for the promotion of

---

**Trufoam**

11 cm x 11 cm = £2.18, 15 cm x 15 cm = £3.64, 7 cm x 9 cm = £1.14, 15 cm x 20 cm = £4.57 (Aspen Medical)

**BNF 61**
autolytic debridement of debris in very moist wounds. Alginate dressings also act as a haemostatic, but caution is needed because blood clots can cause the dressing to adhere to the wound surface. Alginate dressings should not be used if bleeding is heavy and extreme caution is needed if used for tumours with friable tissue. Alginate sheets are suitable for use as a wound contact dressing for moderately to heavily exuding wounds and can be layered into deep wounds; alginate rope can be used in sinus and cavity wounds to improve absorption of exudate and prevent maceration. If the dressing does not have an adhesive border or integral adhesive plastic film backing, a secondary dressing will be required.

**ActivHeal®** (MedLogic®)
- **ActivHeal Alginate**, calcium sodium alginate dressing, 5 cm × 5 cm = £5.85, 10 cm × 10 cm = £11.13, 10 cm × 20 cm = £27.78, cavity dressing, 2 cm × 30 cm = £2.09

**Algostier M** (S&N Hlth.)
- Calcium alginate fibre, non-woven, 5 cm × 5 cm = £7.87, 10 cm × 10 cm = £11.80, 15 cm × 20 cm = £48.94, cavity dressing, 2 cm × 30 cm = £3.27

**Algostier P** (S&N Hlth.)
- Calcium alginate dressing, 5 cm × 5 cm = £8.97, 10 cm × 10 cm = £14.83, 10 cm × 20 cm = £24.71, 10 cm × 20 cm = £24.71, 10 cm × 20 cm = £29.43, 15 cm × 25 cm = £5.15, 30 cm × 61 cm = £27.03, cavity dressing, 30 cm × £2.84, 61 cm × £4.98, 91 cm × £5.96

**Curasorb Plus** (Protex)
- Calcium alginate dressing, 10 cm × 10 cm = £0.84

**Curasorb Zn**
- Calcium alginate and zinc dressing, 5 cm × 5 cm = £8.09, 10 cm × 10 cm = £11.68, 10 cm × 20 cm = £32.30

**Kaltostat®** (Convatec)
- Calcium alginate fibre, non-woven, 5 cm × 5 cm = £9.09, 7.5 cm × 12 cm = £1.96, 10 cm × 20 cm = £3.84, 15 cm × 25 cm = £6.61, cavity dressing, 2 g × £3.60

**Melgisorb®** (Mölnlycke)
- Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven, 5 cm × 5 cm = 86p, 10 cm × 10 cm = £1.79, 10 cm × 20 cm = £3.36, cavity dressing, 32 cm × 2.2 cm, (2 g) = £3.39

**SeaSorb® Soft** (Coloplast)
- Alginate and carboxymethylcellulose dressing, highly absorbent, dressing, gelling dressing, 5 cm × 5 cm = £9.09, 10 cm × 10 cm = £12.18, 15 cm × 15 cm = £4.13, gelling filler, 44 cm = £2.57

**Sorbalgan®** (Hartmann)
- Calcium alginate dressing, 5 cm × 5 cm = £7.60, 10 cm × 10 cm = £11.59, Sorbalgon® T, cavity dressing, 2 g, 30 cm = £3.24

**SorbSan® Flat** (Aspen Medical)
- Calcium alginate fibre, highly absorbent, flat non-woven pads, 5 cm × 5 cm = £7.99, 10 cm × 10 cm = £11.66, 10 cm × 20 cm = £3.10

**SorbSan® Plus**
- Alginate dressing bonded to a secondary absorbent viscose pad, 7.5 cm × 10 cm = £1.67, 10 cm × 15 cm = £2.96, 10 cm × 20 cm = £3.73, 15 cm × 20 cm = £5.24

**SorbSan® Plus SA**
- Alginate dressing with adhesive border and absorbent backing, 11.5 cm × 14 cm = £2.92, 14 cm × 19 cm = £4.25, 14 cm × 24 cm = £5.14, 19 cm × 24 cm = £6.65

**SorbSan® Ribbon**
- 40 cm (with probe) = £2.01

**SorbSan® Surgical Packing**
- 30 cm (2 g, with probe) = £3.41

**Suprasorb® A** (Activa)
- Calcium alginate dressing, 5 cm × 5 cm = 58p, 10 cm × 10 cm = £1.14, cavity dressing, 30 cm (2 g) = £2.11

**Tegaderm® Alginate** (3M)
- Calcium alginate dressing, 5 cm × 5 cm = 77p, 10 cm × 10 cm = £1.62, cavity dressing, 2 cm × 30 cm × £2.70

**Urgosorb®** (Utgo)
- Alginate and carboxymethylcellulose dressing without adhesive border, 5 cm × 5 cm = 83p, 10 cm × 10 cm = £1.99, 10 cm × 20 cm = £3.64, cavity dressing, 30 cm = £2.65

---

**A8.2.7 Capillary-action dressings**

Capillary-action dressings consist of an absorbent core of hydrophilic fibres sandwiched between two low-adherent wound-contact layers to ensure no fibres are shed on to the wound surface. Wound exudate is taken up by the dressing and retained within the highly absorbent central layer.

The dressing may be applied intact to relatively superficial areas, but for deeper wounds or cavities it may be cut to shape to ensure good contact with the wound base. Multiple layers may be applied to heavily exuding wounds to further increase the fluid-absorbing capacity of the dressing. A secondary adhesive dressing is necessary.

Capillary-action dressings are suitable for use on all types of exuding wounds, but particularly on sloughy wounds where removal of fluid from the wound aids debridement; capillary-action dressings are contra-indicated for heavily bleeding wounds or arterial bleeding.

**Advadraw®** (Advancis)
- Non-adherent dressing consisting of a soft viscose and polyester absorbent pad with central wicking layer between two perforated permeable wound contact layers. 5 cm × 7.5 cm = 56p, 10 cm × 10 cm = 87p, 10 cm × 15 cm = £1.17, 15 cm × 20 cm = £1.54

**Advadraw Spiral®,** 0.5 cm × 40 cm = 81p

**Cerdak® Basic** (CliniMed)
- Non-adhesive wound contact sachet containing ceramic spheres, 5 cm × 5 cm = 70p, 10 cm × 10 cm = £1.56, 10 cm × 15 cm = £2.08, cavity dressing, 10 cm × 10 cm = £2.10, 10 cm × 15 cm = £2.63

**Cerdak® Aerocloth**, non-adhesive wound contact sachet containing ceramic spheres, with non-woven fabric adhesive backing, 5 cm × 5 cm = £1.37, 5 cm × 10 cm = £1.94

**Cerdak® Aerofilm**, non-adhesive wound contact sachet containing ceramic spheres, with waterproof transparent adhesive film backing, 5 cm × 5 cm = £1.51, 5 cm × 10 cm = £2.07

**Sumar® Lite**, for light to moderately exuding wounds and cavities, 5 cm × 5 cm = 93p, 10 cm × 10 cm = £1.59, 10 cm × 15 cm = £2.12

**Sumar® Max**, for heavily exuding wounds, 5 cm × 5 cm = 95p, 10 cm × 10 cm = £1.61, 10 cm × 15 cm = £2.15

**Sumar® Spiral**, 0.5 cm × 40 cm = £1.57

**Vacutex®** (Protex)
- Low-adherent dressing consisting of two external polyester wound contact layers with central wicking polyester/cotton mix absorbent layer. 5 cm × 5 cm = 94p, 10 cm × 10 cm = £1.66, 10 cm × 15 cm = £2.23, 20 cm × 20 cm = £2.68, 15 cm × 20 cm = £3.14, 20 cm × 20 cm = £4.28
A8.2.8 Odour absorbent dressings

Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debriding of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.

A8.3.1 Honey

Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.

A8.2.8 Odour absorbent dressings

Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debriding of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.

A8.3 Antimicrobial dressings

Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound surface but will not eliminate a spreading infection. Some dressings are designed to release the antimicrobial into the wound, others act upon the bacteria after absorption from the wound. The amount of exudate present and the level of infection should be taken into account when selecting an antimicrobial dressing.

Medical grade honey (section A8.3.1), has antimicrobial and anti-inflammatory properties. Dressings impregnated with iodine (section A8.3.2), can be used to treat clinically infected wounds. Dressings containing silver (section A8.3.3), should be used only when clinical signs or symptoms of infection are present.

Dressings containing other antimicrobials (section A8.3.4) such as polihexanide (polyhexamethylene biguanide) or dialkylcarbamoyl chloride are available for use on infected wounds. Although hypersensitivity is unlikely with chlorhexidine impregnated tulle dressing, the antibacterial efficacy of these dressings has not been established.

A8.3.1 Honey

Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.

---

**A8.2.8 Odour absorbent dressings**

**Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debriding of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.**

**A8.3 Antimicrobial dressings**

**Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound surface but will not eliminate a spreading infection. Some dressings are designed to release the antimicrobial into the wound, others act upon the bacteria after absorption from the wound. The amount of exudate present and the level of infection should be taken into account when selecting an antimicrobial dressing.**

**Medical grade honey (section A8.3.1), has antimicrobial and anti-inflammatory properties. Dressings impregnated with iodine (section A8.3.2), can be used to treat clinically infected wounds. Dressings containing silver (section A8.3.3), should be used only when clinical signs or symptoms of infection are present.**

Dressings containing other antimicrobials (section A8.3.4) such as polihexanide (polyhexamethylene biguanide) or dialkylcarbamoyl chloride are available for use on infected wounds. Although hypersensitivity is unlikely with chlorhexidine impregnated tulle dressing, the antibacterial efficacy of these dressings has not been established.

**A8.3.1 Honey**

**Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.**

---

**A8.2.8 Odour absorbent dressings**

**Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debriding of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.**

**A8.3 Antimicrobial dressings**

**Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound surface but will not eliminate a spreading infection. Some dressings are designed to release the antimicrobial into the wound, others act upon the bacteria after absorption from the wound. The amount of exudate present and the level of infection should be taken into account when selecting an antimicrobial dressing.**

**Medical grade honey (section A8.3.1), has antimicrobial and anti-inflammatory properties. Dressings impregnated with iodine (section A8.3.2), can be used to treat clinically infected wounds. Dressings containing silver (section A8.3.3), should be used only when clinical signs or symptoms of infection are present.**

Dressings containing other antimicrobials (section A8.3.4) such as polihexanide (polyhexamethylene biguanide) or dialkylcarbamoyl chloride are available for use on infected wounds. Although hypersensitivity is unlikely with chlorhexidine impregnated tulle dressing, the antibacterial efficacy of these dressings has not been established.

**A8.3.1 Honey**

**Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.**

---

**A8.2.8 Odour absorbent dressings**

**Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debriding of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.**

**A8.3 Antimicrobial dressings**

**Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound surface but will not eliminate a spreading infection. Some dressings are designed to release the antimicrobial into the wound, others act upon the bacteria after absorption from the wound. The amount of exudate present and the level of infection should be taken into account when selecting an antimicrobial dressing.**

**Medical grade honey (section A8.3.1), has antimicrobial and anti-inflammatory properties. Dressings impregnated with iodine (section A8.3.2), can be used to treat clinically infected wounds. Dressings containing silver (section A8.3.3), should be used only when clinical signs or symptoms of infection are present.**

Dressings containing other antimicrobials (section A8.3.4) such as polihexanide (polyhexamethylene biguanide) or dialkylcarbamoyl chloride are available for use on infected wounds. Although hypersensitivity is unlikely with chlorhexidine impregnated tulle dressing, the antibacterial efficacy of these dressings has not been established.

**A8.3.1 Honey**

**Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.**
**Oxyzyme**

**Iodozyme**

**Iodosorb**

**Iodoflex**

from large wounds or with prolonged use. Systemic absorption of iodine may occur, particularly in wound exudate. of antimicrobial activity but it is rapidly deactivated by oxidase and iodide ions generate a low level of free iodine in the presence of moisture and oxygen. Two-component hydrogel dressings containing glucose oxidase and iodide ions generate a low level of free iodine when exposed to wound exudate. The free iodine acts as an antiseptic on the wound surface, the cadexomer absorbs wound exudate and encourages de-sloughing. Povidone–iodine fabric dressing iodine in the presence of moisture and oxygen. oxidase and iodide ions generate a low level of free iodine. Cadexomer–iodine

*Uses*

Antimicrobial dressings containing silver should be used only when infection is suspected as a result of clinical signs or symptoms (see also p. 944). Silver ions exert an antimicrobial effect in the presence of wound exudate; the volume of wound exudate as well as the presence of infection should be considered when selecting a silver-containing dressing. Silver-impregnated dressings should not be used routinely for the management of uncomplicated ulcers. It is recommended that these dressings should not be used on acute wounds as there is some evidence to suggest they delay wound healing. Dressings impregnated with silver sulfadiazine have broad antimicrobial activity; if silver sulfadiazine is applied to large areas, or used for prolonged periods, there is a risk of blood disorders and skin discoloration (see section 13.10.1.1). The use of silver sulfadiazine-impregnated dressings is contra-indicated in neonates, in pregnancy, and in patients with significant renal or hepatic impairment, sensitivity to sulphonamides, or G6PD deficiency. Large amounts of silver sulfadiazine applied topically may interact with other drugs—see Appendix 1 (sulphonamides).

#### Low adherence dressings

**Acticoat** (S&N Hlth.)

Three-layer antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 3-day wear), 5 cm × 5 cm = £3.30, 10 cm × 10 cm = £8.07, 10 cm × 20 cm = £12.62, 20 cm × 40 cm = £43.19.

**Acticoat** 7 three-layer antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 7-day wear), 5 cm × 5 cm = £5.74, 10 cm × 12.5 cm = £17.11, 15 cm × 15 cm = £30.76.

**Acticoat** Flex 3, conformable antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 3-day wear), 5 cm × 5 cm = £3.28, 10 cm × 10 cm = £8.01, 10 cm × 20 cm = £12.52, 20 cm × 40 cm = £42.85.

**Acticoat** Flex 7, conformable antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 7-day wear), 5 cm × 5 cm = £5.70, 15 cm × 15 cm = £30.53, 10 cm × 12.5 cm = £16.98.

**Atrauman® Ag** (Hartmann)

Non-adherent polyamide fabric impregnated with silver and neutral triglycerides, 5 cm × 5 cm = £4.7p, 10 cm × 10 cm = £1.15, 10 cm × 20 cm = £2.25.

#### With charcoal

**Actisorb® Silver 220** (Sytogenesis)

Knitted fabric of activated charcoal, with one-way stretch, with silver residues, within spun-bonded nylon sleeve. 6.5 cm × 9.5 cm = £1.64, 10.5 cm × 10.5 cm = £2.58, 10.5 cm × 19 cm = £4.70.
Appendix 8: Wound management

### Soft polymer dressings

**Allevyn® Ag Gentle** (S&N Hlth.)
Soft polymer wound contact dressing, with silver sulfadiazine impregnated polyurethane foam layer, with adhesive border, 7.5 cm × 7.5 cm = £3.99, 10 cm × 10 cm = £5.99, 12.5 cm × 12.5 cm = £7.71, 17.5 cm × 17.5 cm = £14.69, without adhesive border, 5 cm × 5 cm = £3.12, 10 cm × 10 cm = £5.82, 10 cm × 20 cm = £9.62, 15 cm × 15 cm = £10.83, 20 cm × 20 cm = £16.04. (see notes above)

**Contra-indications**

See notes above

**Biaplex® Ag** (Mölnlycke)
Soft silicone wound contact dressing with polyurethane foam film backing, with silver, 10 cm × 10 cm = £5.85, 10 cm × 20 cm = £9.64, 15 cm × 15 cm = £10.85, 20 cm × 20 cm = £16.08, 20 cm × 50 cm = £20.17

**Urgotul® Silver** (Urgo)
Non-adherent soft polymer wound contact dressing, with silver, 10 cm × 12 cm = £3.34, 15 cm × 20 cm = £9.09

**Urgotul® Duo Silver** (Urgo)
Non-adherent, soft polymer wound contact dressing, with silver, 5 cm × 7 cm = £1.95, 11 cm × 11 cm = £3.87, 15 cm × 20 cm = £9.35

**Urgotul® SS** (Urgo)
Non-adherent, soft polymer wound contact dressing, with silver sulfadiazine, 11 cm × 11 cm = £2.99, 16 cm × 21 cm = £8.46

**Contra-indications**

See notes above

### Hydrocolloid dressings

**Aquacel® Ag** (Convatec)
Soft non-woven pad containing hydrocolloid fibres, (silver impregnated), 4 cm × 10 cm = £2.70, 4 cm × 20 cm = £5.27, 5 cm × 5 cm = £1.86, 10 cm × 10 cm = £4.44, 15 cm × 15 cm = £8.36, 20 cm × 20 cm = £20.73, 2 cm × 45 cm (ribbon) = £4.46

**Biatain® Ag Hydrocolloid** (Coloplast)
Semi-permeable, antimicrobial barrier dressing with silver (silver sodium thiosulphate), 10 cm × 10 cm = £6.72, 15 cm × 15 cm = £13.44

**Physiostick® Ag** (Coloplast)
Non-adherent polyester fabric with hydrocolloid and silver sulfadiazine, 10 cm × 10 cm = £2.14

**Contra-indications**

See notes above

### Foam dressings

**Acticoat® Moisture Control** (S&N Hlth.)
Three layer polyurethane dressing consisting of a silver coated layer, a foam layer, and a waterproof layer, 5 cm × 5 cm = £5.76, 10 cm × 10 cm = £15.82, 10 cm × 20 cm = £30.82

**Allevyn® Ag** (S&N Hlth.)
Silver sulfadiazine impregnated polyurethane foam film dressing with adhesive border, 7.5 cm × 7.5 cm = £3.24, 10 cm × 10 cm = £3.10, 12.5 cm × 12.5 cm = £6.70, 17.5 cm × 17.5 cm = £12.89, 17 cm × 17 cm (sacral) = £10.06, 22 cm × 22 cm (sacral) = £13.48, without adhesive border, 5 cm × 5 cm = £3.02, 10 cm × 10 cm = £5.69, 15 cm × 15 cm = £10.79, 20 cm × 20 cm = £15.81, 10.5 cm × 13.5 cm (heel) = £9.97

**Contra-indications**

See notes above

**Biatain® Ag** (Coloplast)
Silver impregnated polyurethane foam film dressing with adhesive border, 12.5 cm × 12.5 cm = £8.71, 18 cm × 18 cm = £17.47, 19 cm × 20 cm (heel) = £17.23, 23 cm × 23 cm (sacral) = £18.31, without adhesive border, 10 cm × 10 cm = £7.61, 5 cm × 7 cm = £3.13, 10 cm × 20 cm = £13.99, 15 cm × 15 cm = £15.28, 20 cm × 20 cm = £21.55, 5 cm × 6 cm (cavity) = £3.79

**PolyMem® Silver** (Aspen Medical)
Silver impregnated polyurethane foam film dressing, with adhesive border, 5 cm × 7.6 cm (oval) = £1.27, 12.7 cm × 8.8 cm (oval) = £5.34, without adhesive border, 10.8 cm × 10.8 cm = £8.45, 17.1 cm × 19 cm = £16.93, 8 cm × 8 cm (cavity) = £8.72

**UrgoCell® Silver** (Urgo)
Non-adherent, polyurethane foam film dressing with silver in wound contact layer, 6 cm × 6 cm = £4.11, 10 cm × 10 cm = £5.65, 15 cm × 20 cm = £10.17

### Alginate dressings

**Acticoat® Absorbent** (S&N Hlth.)
Calcium alginate dressing with a silver coated antimicrobial barrier, 5 cm × 5 cm = £5.04, 10 cm × 12.5 cm = £12.11, 2 cm × 30 cm (cavity) = £12.18

**Algiscite® Ag** (S&N Hlth.)
Calcium alginate dressing, with silver, 5 cm × 5 cm = £1.54, 10 cm × 10 cm = £3.85, 10 cm × 20 cm = £7.09, 2 g, 30 cm (cavity) = £5.32

**Melgisorb® Ag** (Mölnlycke)
Alginate and carboxymethylcellulose dressing, with silver, 5 cm × 5 cm = £3.43, 15 cm × 15 cm = £7.25, 3 cm × 44 cm (cavity) = £4.32

**Seasorb® Ag** (Coloplast)
Alginate and carboxymethylcellulose dressing, with silver, 5 cm × 5 cm = £1.53, 10 cm × 10 cm = £3.74, 15 cm × 15 cm = £6.12, 3 cm × 44 cm (cavity) = £4.05

**Silvercel®** (Systagenix)
Alginate and carboxymethylcellulose dressing impregnated with silver, 2.5 cm × 30.5 cm = £4.45, 5 cm × 5 cm = £1.68, 10 cm × 20 cm = £6.78, 11 cm × 11 cm = £4.14

**Silvercel® Non-adherent**
Alginate and carboxymethylcellulose dressing with film wound contact layer, impregnated with silver, 5 cm × 5 cm = £1.80, 11 cm × 11 cm = £4.32, 10 cm × 20 cm = £8.05, 2.5 cm × 30.5 cm (cavity) = £4.37

**Sorbasan® Silver** (Aspen Medical)
Alginate Ag, calcium alginate fibre, highly absorbent, flat non-woven pads, with silver, 5 cm × 5 cm = £1.54, 10 cm × 10 cm = £3.91, 10 cm × 20 cm = £7.13

**Sorbasan® Silver Plus, Calcium alginate dressing with absorbent backing, with silver, 7.5 cm × 10 cm = £3.25, 10 cm × 15 cm = £5.41, 10 cm × 20 cm = £6.58, 15 cm × 20 cm = £8.82

**Sorbasan® Silver Plus SA**, calcium alginate dressing with absorbent backing and adhesive dressing, with silver, 11.5 cm × 14 cm = £5.28, 14 cm × 19 cm = £7.60, 14 cm × 24 cm = £8.36, 19 cm × 24 cm = £9.32

**Sorbasan® Silver Ribbon**, with silver, 40 cm (with probe) = £4.08

**Sorbasan® Silver Surgical Packing**, with silver, 30 cm (2 g, with probe) = £5.55

**Suprasorb® A + Ag** (Activa)
Calcium alginate dressing, with silver, 5 cm × 5 cm = £1.51, 10 cm × 10 cm = £3.80, 10 cm × 20 cm = £7.02, cavity dressing, 30 cm (2 g) = £5.82

**Tegaderm® Alginate Ag** (3M)
Calcium alginate and carboxymethylcellulose dressing, with silver, 5 cm × 5 cm = £1.35, 10 cm × 10 cm = £3.15, cavity dressing 3 cm × 30 cm = £3.60

**Urgosorb® Silver** (Urgo)
Alginate and carboxymethylcellulose dressing, impregnated with silver, 5 cm × 5 cm = £1.44, 10 cm × 10 cm = £3.44, 10 cm × 20 cm = £6.48, cavity dressing, 2.5 cm × 30 cm = £3.46

### Other antimicrobials

**Chlorhexidine Gauze Dressing, BP 1993**
Fabric of leno weave, wheat and warp threads of cotton and/or viscose yarn, impregnated with an antimicrobial containing chlorhexidine acetate, 5 cm × 5 cm = 27p, 10 cm × 10 cm = 57p (S&N Hlth.—Bactigras®)

**Cutimeld® Sorbact** (BSN Medical)
Low adherence acetate tissue impregnated with diallylcarbomoly chloride, (dressing pad) 7 cm × 9 cm = £3.20, 10 cm × 10 cm = £5.00, 10 cm × 20 cm = £7.80, (ovals) 4 cm ×
A8.4 Specialised dressings

A8.4.1 Protease-modulating matrix dressings

Protease-modulating matrix dressings alter the activity of proteolytic enzymes in chronic wounds; the clinical significance of this approach is yet to be demonstrated.

<table>
<thead>
<tr>
<th>Brand</th>
<th>Characteristics</th>
<th>Price (per cm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UrgoCell® Start TLC</td>
<td>Soft adherent polymer matrix containing nano-oligosaccharide factor (NOSF), with polyurethane foam film backing.</td>
<td>£14.00, 10 cm = £16.00, 20 cm = £32.00</td>
</tr>
<tr>
<td>Siligel®</td>
<td>silicone gel and gel sheets are used to reduce or prevent hypertrophic and keloid scarring. They should not be used on open wounds. Application times should be increased gradually. Silicone sheets can be washed and reused.</td>
<td>£14.00, 10 cm = £16.00, 20 cm = £32.00</td>
</tr>
</tbody>
</table>

A8.4.2 Silicone keloid dressings

Silicone gel and gel sheets are used to reduce or prevent hypertrophic and keloid scarring. They should not be used on open wounds. Application times should be increased gradually. Silicone sheets can be washed and reused.

<table>
<thead>
<tr>
<th>Brand</th>
<th>Characteristics</th>
<th>Price (per cm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciltech® (Su-Med)</td>
<td>Self-adhesive silicone gel sheet with polyurethane film backing.</td>
<td>£14.00, 10 cm = £16.00, 20 cm = £32.00</td>
</tr>
<tr>
<td>Mepiform® (Mölnlycke)</td>
<td>Self-adhesive silicone gel sheet (clear- or fabric-backed).</td>
<td>£14.00, 10 cm = £16.00, 20 cm = £32.00</td>
</tr>
<tr>
<td>Siligel® (Nagor)</td>
<td>Silicone gel sheet, 10 cm x 10 cm = £13.50, 15 cm x 15 cm = £27.00, 20 cm x 20 cm = £54.00</td>
<td>£14.00, 10 cm = £16.00, 20 cm = £32.00</td>
</tr>
</tbody>
</table>

Appendix 8: Wound management
Appendix 8: Wound management

Gauze and Cotton Tissue

Gauze and Cotton Tissue, BP 1988
Absorbent Cotton and Viscose Ribbon Gauze, BP 1988
Absorbent Cotton, Hospital Quality
Absorbent Cotton, BP

The gauze can be used post-operatively to pack wound cavities, but adherence to the wound bed will cause bleeding and tissue damage on removal of the dressing—an advanced wound dressing (e.g. hydrocolloid-fibrous (section A8.2.4), foam (section A8.2.5), or algin—ate (section A8.2.6)) layered into the cavity is often more suitable.

Cotton

Absorbent Cotton, BP
Carded cotton fibres of not less than 10 mm average staple length, available in rolls and balls, 25 g = 71p; 100 g = £1.61; 500 g = £5.43 (most suppliers).

Drug Tariff specifies 25-g pack to be supplied when weight not stated

Absorbent Cotton, Hospital Quality
As for absorbent cotton but lower quality materials, shorter staple length etc. 100 g = £1.12; 500 g = £3.54 (most suppliers).

Drug Tariff specifies to be supplied only where specifically ordered

Note Not suitable for wound cleansing

Gauze and Tissue

Absorbent Cotton Gauze, BP 1988
Cotton fabric of plain weave, in rolls and as swabs (see below), usually Type 13 light, sterile, 90 cm (all) × 1 m = £1.06; 3 m = £2.22, 5 m = £3.46, 10 m = £6.62 (most suppliers).

1-m packet supplied when no size stated

Note Drug Tariff also includes unsterilised absorbent cotton gauze, 25 m roll = £14.93

Absorbent Cotton and Viscose Ribbon Gauze, BP 1988
Woven fabric in ribbon form with fast selvedge edges, warp yarns. 25 g = 88p; 100 g = £2.69, 500 g = £11.32 (most suppliers).

Drug Tariff specifies 25-g pack supplied where no quantity stated

Note Not recommended for wound management

Pads

Absorbent Dressing Pads, Sterile
Drizoth®, 10 cm × 20 cm = 17p (Synergy Healthcare)
PremierPad®, 10 cm × 20 cm = 18p, 20 cm × 20 cm = 25p (Shermond)

Xupad®, 10 cm × 20 cm = 17p, 20 cm × 20 cm = 28p, 20 cm × 40 cm = 40p (Richardson)

1 Surgipad® (Systagenix)
Absorbent pad of absorbent cotton and viscose in sleeve of non-woven viscose fabric, pouch 12 cm × 10 cm = 18p, 20 cm × 10 cm = 25p, 20 cm × 20 cm = 30p, 40 cm × 20 cm = 41p, non sterile pack 12 cm × 10 cm = 5p, 20 cm × 10 cm = 10p, 20 cm × 20 cm = 17p, 40 cm × 20 cm = 28p

Note Except in Sterile Dressing Pack with Non-woven Pads

Wound drainage pouches

Wound drainage pouches can be used in the management of wounds and fistulas with significant levels of exudate.

Biotrol® (Braun)
Drainage S Fistula, wound drainage pouch, mini (cut to 20 mm), 150-mL capacity = £2.44, medium (cut to 50 mm), 350-mL capacity = £3.64, large (cut to 88 mm), 500-mL capacity = £4.48

Drainage S Vision, wound drainage pouch, (cut to 50 mm), 150-mL capacity = £9.39, (cut to 88 mm), 250-mL capacity = £9.92, (cut to 100 mm), 300-mL capacity = £11.51

Dermasure® (ADI Medical)
Pouch, small (wound size up to 9 cm × 16 cm) = £15.60, medium (wound size up to 15 cm × 27 cm) = £20.80

Eakin® (Eakin)
Wound pouch, fold and tuck closure, small (wound size up to 45 mm × 30 mm) = £4.50, medium (wound size up to 110 mm × 75 mm) = £6.50, large (wound size up to 175 mm × 110 mm) = £8.50, extra large (horizontal wound up to 245 mm × 160 mm) = £15.00

Wound pouch, bung closure, small (wound size up to 45 mm × 30 mm) = £5.00, medium (wound size up to 110 mm × 75 mm) = £7.00, large (wound size up to 175 mm × 110 mm) = £9.50, extra large (horizontal or vertical wound up to 245 mm × 160 mm) = £17.00, (vertical incision wound up to 290 mm × 130 mm) = £17.00, (horizontal wound up to 245 mm × 160 mm), with access window = £19.00

Access window, for use with Eakin® pouches = £7.00

Oakmed® Option (OakMed)

Wound Manager, extra small (wound size up to 90 mm × 180 mm) = £11.00, small (horizontal wound size up to 245 mm × 160 mm) = £12.23, medium (vertical wound size up to 90 mm × 260 mm) = £12.50, large (wound size up to 160 mm × 260 mm) = £14.90, square (vertical wound up to 160 mm × 200 mm) = £13.05

Wound Manager, with access port, extra small (wound size up to 90 mm × 180 mm) = £12.02, small (horizontal wound size up to 245 mm × 160 mm) = £12.77, medium (vertical wound size up to 90 mm × 260 mm) = £15.93, square (vertical wound size up to 160 mm × 200 mm) = £13.59

Wound Manager, cut-to-fit, small (10–30 mm) = £2.25, medium (10–50 mm) = £2.49, large (10–50 mm) = £2.61
Welland® (CliniMed)
Fistula bag, wound manager, cut-to-fit (wound size up to 40 mm x 70 mm) = £2.54

Wound Drainage Collector (Hollister)
Pouch, drainable, small (wound size up to 76 mm) = £7.45, medium (wound size up to 95 mm) = £8.13, large (wound size up to 100 mm x 200 mm) = £16.10

A8.6 Complex adjunct therapies

Topical negative pressure (or vacuum-assisted) therapy requires specific wound dressings for use with the vacuum-pump equipment.

Other complex adjunct therapies include sterile larvae (maggots), and growth factors such as becalpermin (see section 13.11.7).

A8.6.1 Topical negative pressure therapy

- **Vacuum assisted closure products**
  - Exsu-Fast® (Synergy Healthcare)
    - Dressing kit, Kit 1 (small wound, low exudate) = £28.04; Kit 2 (large wound, heavy exudate) = £35.83; Kit 3 (large wound, medium to low exudate) = £35.83; Kit 4 (small wound, heavy exudate) = £28.04
  - Renasys® F/P (S&N Hlth.)
    - Dressing kit, foam dressing with round drain (plus port, dressings and fixation film), small = £19.15, medium = £22.25, large = £26.39, extra large = £42.28
  - Renasys® G (S&N Hlth.)
    - Dressing kit, non-adherent gauze and transparent film dressing, with flat drain, small = £16.64, medium = £20.86, large = £26.48, round drain, small = £16.64, large = £26.48, channel drain, medium = £20.86
  - V.A.C.® (KCI Medical)
    - GranuFoam® dressing kit, polyurethane foam dressing (with adhesive drapes and pad connector), 10 cm x 7.5 cm x 3.3 cm (small) = £21.73, 18 cm x 12.5 cm x 3.3 cm (medium) = £25.88, 26 cm x 15 cm x 3.3 cm (large) = £30.01; bridge dressing kit (for diabetic foot wound) = £30.10; with solear, small = £31.50, medium = £36.54
    - Simplace® dressing kit, spiral-cut polyurethane foam dressings, vapour-permeable adhesive film dressings (with adhesive drapes and pad connector), small = £24.99, medium = £28.73
  - WhiteFoam®, polyvinyl alcohol foam dressing 10 cm x 7.5 cm (small) = £10.00, 10 cm x 15 cm (large) = £16.01, dressing kit (with adhesive drape and pad connector), 10 cm x 7.5 cm (small) = £24.34, 10 cm x 15 cm (large) = £31.51
  - Venturi® (Talley)
    - Wound sealing kit, flat drain, standard = £15.00, large = £17.50, channel drain = £15.00
  - V1STA® (S&N Hlth.)
    - Dressing kit, flat drain, small = £16.98, medium = £21.27, large = £27.01; round drain, small = £16.98, large = £27.01; channel drain, medium = £21.27
  - WoundASSIST® (Huntleigh)
    - Wound pack, small-medium = £20.81, medium-large = £23.85, extra large = £34.95; channel drain, small-medium = £20.81, medium-large = £23.85

- **Wound drainage collection devices**
  - ActiV.A.C.® (KCI Medical)
    - Canister (with gel), 300 mL = £32.91

A8.7 Wound care accessories

A8.7.1 Dressing packs

The role of dressing packs is very limited. They are used to provide a clean or sterile working surface; some packs shown below include cotton wool balls, which are not recommended for use on wounds.

**Multiple Pack Dressing No. 1**

(Drug Tariff). Contains absorbent cotton, absorbent cotton gauze type 13 light (sterile), open-woven bandages (banded). 1 pack = £4.02

**Non-Drug Tariff Specification Sterile Dressing Pack**

Dressit® contains vitrex gloves, large apron, disposable bag, paper towel, softswabs, absorbent pad, sterile field = 60p (Richardson)

Nurse it® contains powder-free vinyl gloves, sterile laminated paper sheet, large apron, non-oven swabs, paper towel, disposable bag, compartmented tray, plastic forceps = 52p (Medicare)

Polyfield® Nitrile Patient Pack contains powder-free nitrile gloves, laminate sheet, non-oven swabs, towel, polythene disposable bag, apron = 52p (Shermond)

Propax® SDP contains paper towel, disposable bag, gauze swabs, dressing pad, sterile field = 45p (INN Medical)

Woundcare® contains nitrile gloves, sterile field, compartmented tray, large apron, disposable bag, non-oven swabs, drape = 44p (Frontier)

Sterile Dressing Pack

(Drug Tariff specification 10). Contains gauze and cotton tissue pad, gauze swabs, absorbent cotton wool balls, absorbent paper towel, water repellent inner wrapper. 1 pack = 50p (Synergy Healthcare—Vernaid®)
Appendix 8: Wound management

950 A8.7.2 Woven and fabric swabs

Sterile Dressing Pack with Non-woven Pads

A8.7.2 Woven and fabric swabs

Gauze Swab, BP 1988
Consists of absorbent cotton gauze type 13 light or absorbent cotton and viscose gauze type 1 folded into squares or rectangles of 8-ply with no cut edges exposed, sterile, 7.5 cm × 7.5 cm 5-pad packet = 30p; non-sterile, 10 cm × 10 cm, 100-pad packet = £1.34 (most suppliers)

Filmated Gauze Swab, BP 1988
As for Gauze Swab, but with thin layer of Absorbent Cotton enclosed within, non-sterile, 10 cm × 10 cm, 100-pad packet = £3.60 (Synergy Healthcare—Cost®)

Non-woven Fabric Swab
(Drug Tariff specification 28). Consists of non-woven fabric folded 4-ply; alternative to gauze swabs, type 13 light, sterile, 7.5 cm × 7.5 cm, 5-pad packet = 25p; non-sterile, 10 cm × 10 cm, 100-pad packet = 78p (Mołnycke)

Filmated Non-woven Fabric Swab
(Drug Tariff specification 29). Film of viscose fibres enclosed within non-woven viscose fabric folded 8-ply, non-sterile, 10 cm × 10 cm, 100-pad packet = £3.55 (Syntagenix—Regul®)

A8.7.3 Surgical adhesive tapes

Adhesive tapes are useful for retaining dressings on joints or awkward body parts. These tapes, particularly those containing rubber, can cause irritant and allergic reactions in susceptible patients; synthetic adhesives have been developed to overcome this problem, but they, too, may sometimes be associated with reactions. Synthetic adhesive, or silicon adhesive, tapes can be used for patients with skin reactions to plasters and strapping containing rubber, or undergoing prolonged treatment.

Adhesive tapes that are occlusive may cause skin maceration. Care is needed not to apply these tapes under tension, to avoid creating a tourniquet effect. If applied over joints they need to be orientated so that the area of maximum extensibility of the fabric is in the direction of movement of the limb.

Permeable adhesive tapes

Elastic Adhesive Tape, BP 1988
(Elastic Adhesive Plaster). Woven fabric, elastic in warp (crepe-treated viscose threads), weft of cotton and/or viscose threads, spread with adhesive mass containing zinc oxide. 4.5 m stretched × 2.5 cm = £1.88 (S&N—Elastoplast®)
For 5 cm width, see Elastic Adhesive Bandage

Permeable, Apertured Non-woven Synthetic Adhesive Tape, BP 1988
Non-woven fabric with a polyacrylate adhesive.
Hyfapi®, 5 cm × 5 m = £1.34, 10 cm × 5 m = £2.25, 10 m (roll); 2.5 cm × 1 m = £1.56, 5 cm × £2.48, 10 cm × £4.33, 15 cm × £6.42, 20 cm × £8.51, 30 cm × £12.31 (BSN Medical)
Mefix®, 5 m (all): 2.5 cm × 98p, 5 cm × £1.72, 10 cm × £2.76, 15 cm × £3.76, 20 cm × £4.82, 30 cm × £6.91 (Mölnlycke)
Omniﬁx®, 10 m (all): 5 cm × £2.24, 10 cm × £3.77, 15 cm × £5.57 (Hartmann)
Primafix®, 5 cm × 10 m = £1.50, 10 cm × 10 m = £2.20, 15 cm × 10 m = £3.25, 20 cm × 10 m = £4.00 (S&N Hlb.)

Permeable Non-woven Synthetic Adhesive Tape, BP 1988
Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass:
Clinipore®, 5 m (all): 1.25 cm × 35p, 2.5 cm × 50p, 5 cm × 99p, 2.5 cm × 10 m = 73p (Clinisupplies)
Leukofix®, 5 m (all): 1.25 cm × 52p, 2.5 cm × 83p, 5 cm × £1.45 (BSN Medical)
Leukoplast®, 5 m (all): 1.25 cm × 49p, 2.5 cm × 72p, 5 cm × £1.26 (BSN Medical)
Mediplast®, 5 m (all): 1.25 cm × 30p, 2.5 cm × 50p (Neomedic)
Micropore®, 5 m (all): 1.25 cm × 60p, 2.5 cm × 89p, 5 cm × £1.57 (3M)
Scapjon®, 5 m (all): 1.25 cm × 40p, 2.5 cm × 65p, 5 cm × £1.12, 10 cm (all), 1.25 cm × 52p, 2.5 cm × 87p, 5 cm × £1.65, 7.5 cm × £2.42 (BioDiagnostics)
Where no brand stated by prescriber, net price of tape supplied not to exceed 35p (1.25 cm), 59p (2.5 cm), 99p (5 cm)

Permeable Woven Synthetic Adhesive Tape, BP 1988
Non-extensible closely woven fabric, spread with a polymeric adhesive. 5 m (all): 1.25 cm × 78p, 2.5 cm × £1.15, 5 cm × £1.99 (Beiersdorfer—Leukosilk®)

Silicone adhesive tape
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
Insifo®, 2 cm × 3 m = £5.60, 4 cm × 1.5 m = £5.60 (Insight)
Mepitac®, 2 cm × 3 m = £6.56, 4 cm × 1.5 m = £6.56 (Mölnlycke)
Silitape®, 2 cm × 3 m = £5.60, 4 cm × 1.5 m = £5.60 (Advancis)

Zinc Oxide Adhesive Tape, BP 1988
(Zinc Oxide Plaster). Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide. 5 m (all): 1.25 cm × 95p, 2.5 cm = £1.38, 5 cm = £2.33, 7.5 cm = £3.51 (most suppliers)

Zinc Oxide Adhesive Tape
Mediplast®, 5 m (all): 1.25 cm × 82p, 2.5 cm = £1.19, 5 cm = £1.99, 7.5 cm = £2.99 (Neomedic)
Strapp®, 5 m (all): 1.25 cm × 89p, 2.5 cm = £1.29, 5 cm = £2.17, 7.5 cm = £3.27 (BSN Medical)

 occlusive adhesive tapes

Impermeable Plastic Adhesive Tape, BP 1988
Extensible water-impermeable plastic film spread with an adhesive mass. 2.5 cm × 3 m = £1.33, 2.5 cm × 5 m = £1.99, 5 cm × 5 m = £2.53, 7.5 cm × 5 m = £3.67 (BSN Medical—Sleek®)

Impermeable Synthetic Plastic Adhesive Tape, BP 1988
Extensible water-impermeable plastic film spread with a polymeric adhesive mass. 5 m (both): 2.5 cm × £1.72, 5 cm × £3.27 (3M—Blenderm®)

A8.7.4 Adhesive dressings

Adhesive dressings (also termed ‘island dressings’) have a limited role for minor wounds only. The inclusion of an antisepctic is not particularly useful and may cause skin irritation in susceptible subjects.

Vapour permeable adhesive dressings

Vapour-permeable Waterproof Plastic Wound Dressing, BP 1993
(former Drug Tariff title: Semi-permeable Waterproof Plastic Wound Dressing). Consists of absorbent pad, may be dyed and impregnated with suitable antisepctic (see under Elastic Adhesive Dressing), attached to piece of semi-permeable waterproof surgical adhesive tape, to leave suitable adhesive margin, both pad and margin covered with suitable protector (S&N Hlb—Elastoplast Airstrip®)
A8.7.5 Skin closure dressings

Skin closure strips are used as an alternative to sutures for minor cuts and lacerations. Skin tissue adhesive (section 13.10.5) can be used for closure of minor skin wounds and for additional suture support.

**Skin closure strips, sterile**
- Leukosti®: 6.4 mm x 76 mm, 3 strips per envelope. 10 envelopes = £5.95 (S&N Hlth.)
- Omnistrip®: 6 mm x 76 mm, 3 strips per envelope. 50 envelopes = £22.50 (Hartmann)
- Steri-strip®: 6 mm x 75 mm, 3 strips per envelope. 12 envelopes = £8.52 (3M)

Drug Tariff specifies that these are specifically for personal administration by the prescriber.

A8.8 Bandages

According to their structure and performance bandages are used for dressing retention, for support, and for compression.

A8.8.1 Non-extendible bandages

Bandages made from non-extendible, woven fabrics have generally been replaced by more conformable products, therefore their role is now extremely limited. Triangular calico bandage has a role as a sling.

**Open-wove Bandage, Type 1 BP 1988**
- Cotton cloth, plain weave, warp of cotton, weft of cotton, viscose, or combination, one continuous length. 5 m (all):
  - 2.5 m = 31p, 5 cm = 52p, 7.5 cm = 74p, 10 cm = 96p (most suppliers)

**Triangular Calico Bandage, BP 1980**
- Unbleached calico right-angled triangle, 90 cm x 90 cm x 1.27 m = £1.15 (most suppliers)

A8.8.2 Light-weight conforming bandages

Lightweight conforming bandages are used for dressing retention, with the aim of keeping the dressing close to the wound without inhibiting movement or restricting blood flow. The elasticity of conforming-stretch bandages (also termed contour bandages) is greater than that of cotton conforming bandages.

**Conforming Bandage (Synthetic)**
- Fabric, plain weave, warp of polyamide, weft of viscose. 4 m stretched (all):
  - Hospifilm®, 6 cm = 13p, 8 cm = 16p, 10 cm = 18p, 12 cm = 22p (Hartmann)

**Cotton Conforming Bandage, BP 1988**
- Cotton cloth, plain weave, treated to impart some elasticity to warp and weft. 3.5 m (all):
  - Type A, 5 cm = 63p, 7.5 cm = 77p, 10 cm = 96p, 15 cm = £1.10 (BSN Medical—Esafix Crims®)

**Knitted Polyamide and Cellulose Contour Bandage, BP 1988**
- Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length. 4 m stretched (all):
  - Easigrip®, 2.5 cm = 9p, 5 cm = 10p, 7.5 cm = 15p, 10 cm = 17p, 15 cm = 30p (BSN Medical)
  - K-Band®, 5 cm = 19p, 7 cm = 24p, 10 cm = 27p, 15 cm = 47p (Urho)

- PremierBand®, 4 m (all):
  - 5 cm = 12p, 7.5 cm = 17p, 10 cm = 17p, 15 cm = 33p (Steraid)

Polyamide and Cellulose Contour Bandage
- Peha-haft®, cohesive, latex-free, 4 m (all):
  - 2.5 cm = 68p, 4 cm = 44p, 6 cm = 52p, 8 cm = 62p, 10 cm = 71p, 12 cm = 84p (Hartmann)
- PremierBand®, 4 m (all):
  - 5 cm = 12p, 7.5 cm = 14p, 10 cm = 17p, 15 cm = 25p (Shermond)

Polyamide and Cellulose Contour Bandage, BP 1988 (Nylon and Viscose Stretch Bandage)
- Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all):
  - Acti-Wrap®, cohesive, latex-free, 6 cm = 44p, 8 cm = 64p, 10 cm = 76p (Activa)
  - Easifix®, 5 cm = 33p, 7.5 cm = 40p, 10 cm = 47p, 15 cm = 80p (BSN Medical)
  - Kontour®, cohesive, 5 cm = 28p, 7.5 cm = 35p, 10 cm = 40p, 15 cm = 66p (Easigrip)

Polyamide and Cellulose Contour Bandage, BP 1993

- Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all):
  - K-Band®, 5 cm = 10p, 7 cm = 15p, 10 cm = 17p, 15 cm = 30p (CliniMed)
  - Knit Fix®, 5 cm = 12p, 7 cm = 17p, 10 cm = 17p, 15 cm = 33p (Steraid)

**Elasticated Surgical Tubular Stockinette, Foam padded**

- Knit Band®, 5 cm = 10p, 7 cm = 15p, 10 cm = 17p, 15 cm = 30p (CliniMed)
- Knit Fix®, 5 cm = 12p, 7 cm = 17p, 10 cm = 17p, 15 cm = 33p (Steraid)

**Polyamide and Cellulose Contour Bandage**

- Peha-haft®, cohesive, latex-free, 4 m (all):
  - 2.5 cm = 68p, 4 cm = 44p, 6 cm = 52p, 8 cm = 62p, 10 cm = 71p, 12 cm = 84p (Hartmann)
- PremierBand®, 4 m (all):
  - 5 cm = 12p, 7.5 cm = 14p, 10 cm = 17p, 15 cm = 25p (Shermond)

**Polyamide and Cellulose Contour Bandage, BP 1988** (Nylon and Viscose Stretch Bandage)

- Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4 m stretched (all):
  - Acti-Wrap®, cohesive, latex-free, 6 cm = 44p, 8 cm = 64p, 10 cm = 76p (Activa)
  - Easifix®, 5 cm = 33p, 7.5 cm = 40p, 10 cm = 47p, 15 cm = 80p (BSN Medical)
  - Kontour®, cohesive, 5 cm = 28p, 7.5 cm = 35p, 10 cm = 40p, 15 cm = 66p (Easigrip)
  - Moll elast®, latex-free, 4 cm = 28p, 6 cm = 34p (Activa)
  - Sillyn®, 7.5 cm = 57p, 10 cm = 68p, 15 cm = 98p (Molynyeke)
  - Stayform®, 5 cm = 29p, 7.5 cm = 36p, 10 cm = 40p, 15 cm = 68p (Robinsons)

A8.8.3 Tubular bandages and garments

Tubular bandages are available in different forms, according to the function required of them. Some are used under orthopaedic casts and some are suitable for protecting areas to which creams or ointments (other than those containing potent corticosteroids) have been applied. The conformability of the elasticated versions makes them particularly suitable for retaining dressings on difficult parts of the body or for soft tissue injury, but their use as the only means of applying pressure to an oedematous limb or to a varicose ulcer is not appropriate, since the pressure they exert is inadequate.

**Compression hosiery** (section A8.9.1) reduces the recurrence of venous leg ulcers and should be considered for use after wound healing.

**Silk clothing** is available as an alternative to elasticated viscose stockinette garments, for use in the management of severe eczema and allergic skin conditions (see below).

### Elasticated Surgical Tubular Stockinette, Foam padded

*(Drug Tariff specification 25)*

Fabric as for Elasticated Tubular Bandage with polyurethane foam lining. Heel, elbow, knee, small = £2.86, medium = £3.09, large = £3.30, sacral, medium, and large (all) = £14.76 (Medlock—Tubipad®)

Uses relief of pressure and elimination of friction in relevant area; porosity of foam lining allows normal water loss from skin surface

### Elasticated Tubular Bandage, BP 1993

(formerly Elasticated Surgical Tubular Stockinette)

Knitted fabric, elastinated threads of rubber-cored polyamide or polyester with cotton or cotton and viscose yarn. Tubular lengths 50 cm and 1 m, widths 6.25 cm, 6.75 cm, 7.5 cm, 8.75 cm, 10 cm, 12 cm. Synergy—Configrip®, Easigrip—Easigrrip®, Sallis—Estiban®, Medlock—Tubigrrip®. Where no size stated by prescriber the 50 cm length should be supplied and width endorsed.
Appendix 8: Wound management

Elasticated Viscose Stockinette

(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage.

**Acti-Fast**, 3.5 cm red line (small limb), length 1 m = 62p; 5 cm green line (medium limb), length 1 m = 58p, 3 m = £1.62, 5 m = £2.81; 7.5 cm blue line (large limb), length 1 m = £1.02, 5 m = £4.04; 10.75 cm yellow line (child trunk), length 1 m = £1.45, 3 m = £4.10, 5 m = £7.10; 17.5 cm beige line (adult trunk), length 1 m = £2.12, 5 m = £9.45, 6 m = £16.04; 25 cm beige line (adult trunk), length 1 m = £1.83; vest (long-sleeved), adult, small = £12.75, medium = £14.54, large = £16.58; vest (short-sleeved), adult, small = £9.00, medium = £11.88, large = £14.63; tights (pair) large = £16.58, one-size = £14.58; gloves, (small-medium or medium-large adult, extra small or small child) = £5.50 (Mölnlycke).

**Non-elasticated**

**Cotton Stockinette, Bleached, BP 1988**

Knitted fabric, cotton yarn, tubular length, 1 m (all), 2.5 cm = 34p, 5 cm = 75p, 6 cm = 10p = £4.32 (A&J, Medlock).

**Uses**: 1 m lengths, basis (with wadding) for Plaster of Paris bandages etc.; 6 m, length, compression bandage.

**Ribbed Cotton and Viscose Surgical Tubular Stockinette, BP 1988**

Knitted fabric, cotton yarn, tubular length, 1 m (all), 2.5 cm = 34p, 5 cm = 75p, 6 cm = 10p = £4.32 (A&J, Medlock).

** Uses**: protective dressings with tar-based and other non-steroidal ointments.

**Silk Clothing**

Knitted, medical grade silk clothing can be used as an adjunct to normal treatment for severe eczema and allergic skin conditions. When used in combination with medical creams and ointments, care should be taken to ensure that the medication is fully absorbed into the skin before the silk clothing is worn; silk garments are not suitable for use in direct contact with emollients used in ‘wet wrapping techniques’.

**DermaSilk** (Espere)

Knitted silk fabric, hypoallergenic, serum-free, body suit, child 0–3 months (height 62 cm) = £38.18, 3–6 months (height 68 cm) = £35.65, 6–9 months (height 74 cm) = £36.67, 9–12 months (height 74 cm) = £38.25, 12–18 months (height 86 cm) = £36.69, 18–24 months (height 92 cm) = £39.29, 2–3 years (height 98 cm) = £38.71, 3–4 years (height 110 cm) = £39.73, boxer shorts, adult (male), small–XXXL = £39.95, briefs, 3–4 years = £20.95, 5–6 years = £20.95, 7–8 years = £26.47, 9–12 months (height 62 cm) = £25.83, 12–18 months (height 70 cm) = £29.39, facial mask, child (head circumference up to 47 cm) = £15.30, child (head circumference up to 50 cm) = £15.30, teen or adult = £20.19; gloves, adult, small, medium, large, or extra large = £19.33, child (small or medium) = £13.98; leggins, child 0–3 months (height 62 cm) = £25.83, 3–4 months (height 68 cm) = £26.47, 9–12 months (height 74 cm) = £27.90, 12–18 months (height 86 cm) = £27.49, 18–24 months (height 92 cm) = £28.94, 2–3 years (height 98 cm) = £28.51, 3–4 years (height 110 cm) = £28.51, adult, small–XXL = £45.66, adult, small–XXXL = £48.49, 7–8 years = £50.51, 10–12 years = £52.50, undersocks, (heelless), 2 pairs standard or longer.
length = £22.95, undersocks, adult shoe-size 5½–6, 7–8½, 9–10½, 11–13, child shoe-size 3–8, 9–1, 2–5, 2 pairs = £17.45

**Cotton, Polyamide and Elastane Bandage**

**Cotton Crepe Bandage**

Crepe Bandage, BP 1988

Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all).

**Cotton Stretch Bandage, BP 1988**

Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all).

**Hosipricrepe**® 233, 5 cm = 52p; 7.5 cm = 72p; 10 cm = 96p; 15 cm = £1.36 (Steraid)

**PremierBand**®, 5 cm = 45p, 7.5 cm = 63p, 10 cm = 79p; 15 cm = £1.18 (Shermond)

**Cotton Suspensory Bandage**

(Drug Tariff). Type 1: cotton net bag with draw tapes and webbing waistband; small, medium, and large (all) = £1.59, extra large = £1.68. Type 2: cotton net bag with elastic edge and webbing waistband with elastic insertion; small, medium, and large (all) = £1.90, extra large = £1.96. Type 3: supplied to be endorsed

**Knitted Elasticom and Viscose Bandage**

Knitted fabric, viscose and elastomer yarn.

**Type 2 (light support bandage)**

**CliniLite**®, 4.5 m (all), 5 cm = 44p, 7.5 cm = 61p, 10 cm = 89p, 15 cm = £1.16 (Clinisupplies)

**K-Lite**®, 4.5 m stretched, 5 cm = 52p, 7.5 cm = 73p, 10 cm = 95p, 15 cm = £1.36, 5.2 m stretched, 10 cm = £1.69 (Urgo)

**Koil-Firm**®, 4.5 m stretched, 5 cm = 53p, 7.5 cm = 75p, 10 cm = 95p, 15 cm = 96p (Steraid)

**Type 3a (light compression bandage)**

**CliniPlus**®, 8.7 m × 10 cm = £1.80 (Clinisupplies)

**Elset®**, 6 m stretched, 10 cm = £2.46, 15 cm = £2.66; 8 m stretched, 10 cm = £3.14; 12 m stretched, 15 cm = £5.27 (Molnlycke)

**K-Plus®**, 8.7 m stretched, 10 cm = £2.14, long, 10.25 m stretched, 10 cm = £2.47 (Urgo)

**Profore® #3**, 8.7 m stretched, 10 cm = £3.70, latex-free = £4.02 (S&N Hlth.)

L, 8.6 m stretched, 10 cm = £2.07 (S&N Hlth.)

**A8.8.4 Support bandages**

Light support bandages, which include the various forms of crepe bandage, are used in the prevention of oedema; they are also used to provide support for mild sprains and joints but their effectiveness has not been proven for this purpose. Since they have limited extensibility, they are able to provide light support without exerting undue pressure. For a warning against injudicious compression see section A8.6.7.

**Crepe Bandage, BP 1988**

Fabric, plain weave, warp of wool threads and crepe-twisted cotton threads, weft of cotton threads; stretch bandage. 4.5 m stretched (all). 5 cm = 92p; 7.5 cm = £1.16, 15 cm = £1.23 (most suppliers)

**Cotton Crepe Bandage**

Light support bandage, 4.5 m stretched (all). 5 cm = 44p; 7.5 cm = 67p, 10 cm = £1.27 (Steraid—Hosipricrepe® 239)

**Cotton Crepe Bandage, BP 1988**

Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton and/or viscose threads; stretch bandage. 4.5 m stretched (both). 7.5 cm = £2.88; 10 cm = £3.70 (most suppliers)

**Cotton, Polyamide and Elastane Bandage**

Fabric, cotton, polyamide, and elastane; light support bandage (Type 2). 4.5 m stretched (all).

**Hosipliite®**, 5 cm = 34p, 7.5 cm = 47p, 10 cm = 57p, 15 cm = 84p (Hartmann)

**Neosport®**, 5 cm = 54p, 7.5 cm = 73p, 10 cm = 91p, 15 cm = £1.12 (Necomedic)

**Profore® #2**, 10 cm = £1.27, latex-free = £1.35 (S&N Hlth.)

**Setocrepe**, 10 cm = £1.13 (Molnlycke)

**Softcrepe®**, 5 cm = 64p, 7.5 cm = 91p, 10 cm = £1.16, 15 cm = £1.67 (BSN Medical)

**A8.8.5 Adhesive bandages**

Elastic adhesive bandages are used to provide compression in the treatment of varicose veins and for the support of injured joints; they should no longer be used for the support of fractured ribs and clavicles. They have also been used with zinc paste bandage in the treatment of venous ulcers, but they can cause skin reactions in susceptible patients and may not produce sufficient pressures for healing (significantly lower than those provided by other compression bandages).

**Elastic Adhesive Bandage, BP 1993**

Woven fabric, elastic in warp (crepe-twisted cotton threads), weft of cotton and/or viscose threads spread with adhesive mass containing zinc oxide. 4.5 m stretched (all). 5 cm = £3.39; 7.5 cm = £4.90, 10 cm = £6.52 (BSN Medical—Elastoplast® Bandage). Drug Tariff specifies 7.5 cm width supplied when size not stated

**A8.8.6 Cohesive bandages**

Cohesive bandages adhere to themselves, but not to the skin, and are useful for providing support for sports use where ordinary stretch bandages might become displaced and adhesive bandages are inappropriate. Care is needed in their application, however, since the loss of ability for movement between turns of the bandage to equalise local areas of high tension carries the potential for creating a tourniquet effect. Cohesive bandages can be used to support sprained joints and as
an outer layer for multi-layer compression bandaging; they should not be used if arterial disease is suspected.

Cohesive extensible bandages
Coban® (3M)  
Bandage, 6 m (stretched), 10 cm = £2.76

K-Press® (Urgo)  
Bandage, 6.5 m × 10 cm (0, short) = £2.78, 7.5 m, 18–25 cm ankle circumference, 8 cm = £3.06, 10 cm = £3.25, 12 cm = £4.09; 10.5 m, 25–32 cm ankle circumference, 8 cm = £3.33, 10 cm = £3.55, 12 cm = £4.48

Profore® #4 (S&N Hlth.)  
Bandage, 2.5 m (unstretched) = £3.06, latex-free = £3.32

Ultra Fast® (Robinsons)  
Bandage, 6.3 m (stretched), 10 cm = £2.59

A.8.7 Compression bandages

High compression products are used to provide the high compression needed for the management of gross varices, post-thrombotic venous insufficiency, venous leg ulcers, and gross oedema in average-sized limbs. Their use calls for an expert knowledge of the elastic properties of the products and experience in the technique of providing careful graduated compression. Incorrect application can lead to uneven and inadequate pressures or to hazardous levels of pressure. In particular, injudicious use of compression in limbs with arterial disease has been reported to cause severe skin and tissue necrosis (in some instances calling for amputation). Doppler testing is required before treatment with compression. Oral pentoxifylline (section 2.6.4) can be used to reduce swelling associated with lymphoedema, 3 m (stretched), 10 cm (red) = £5.51, 10 cm (yellow) = £6.02, 10 cm (green) = £6.52.

Short stretch compression bandage
Short stretch bandages help to reduce oedema and promote healing of venous leg ulcers. They are also used to reduce swelling associated with lymphoedema. They are applied at full stretch over padding (see Sub-compression Wadding Bandage below) which protects areas of high pressure and sites at high risk of pressure damage.

Actiban® (Activa)  
Bandage, 5 m (all), 8 cm = £3.16, 10 cm = £3.40, 12 cm = £4.14

Actico® (Activa)  
Bandage, cohesive, 6 m (all), 4 cm = £2.25, 6 cm = £2.64, 8 cm = £3.03, 10 cm = £3.15, 12 cm = £4.02

Comprilan® (BSN Medical)  
Bandage, 5 m (all), 6 cm = £2.52, 8 cm = £2.96, 10 cm = £3.18; 12 cm = £3.87

Rosidal K® (Activa)  
Bandage, 5 m (all), 4 cm = £1.76, 6 cm = £2.45, 8 cm = £2.93, 10 cm = £3.20, 12 cm = £3.88, 10 m × 10 cm = £5.57

Silkolan® (Urgo)  
Bandage, 5 m (all), 8 cm = £3.00, 10 cm = £3.39

Sub-compression wadding bandage
Advasoft® (Advancis)  
Padding, 3.5 m unstretched, 10 cm = 37p

Cellona® Undercast Padding (Activa)  
Padding, 2.75 m unstretched (all), 5 cm = 29p, 7.5 cm = 35p, 10 cm = 43p, 15 cm = 55p

Coban® 2 Comfort Layer (3M)  
Padding, 2.7 m unstretched, 10 cm = £5.50

Flexi-Ban® (Activa)  
Padding, 3.5 m unstretched, 10cm = 47p

K-Soft® (Urgo)  
Padding, absorbent, 3.5 m unstretched, 10 cm = 43p, 4.5 m unstretched, 10 cm = 53p

K-Tech® (Urgo)  
Padding, 5 m × 10 cm (0, short) = £3.76, 6 m, 18–25 cm ankle circumference, 8 cm = £4.26, 10 cm = £4.51, 12 cm = £5.69, 7.5 m, 25–32 cm ankle circumference, 8 cm = £4.64, 10 cm = £5.92, 12 cm = £6.21

Ortho-Band Plus® (Steraid)  
Padding, 10 cm × 3.5 cm unstretched = 37p

Profore® #1 (S&N Hlth.)  
Padding, viscose fleece, 3.5 m unstretched, 10 cm = 66p, latex-free = 72p

ProGuide® #1 (S&N Hlth.)  
Padding, polyester and viscose fleece, 4 m unstretched, 10 cm = £1.53

Softex® (Mölnlycke)  
Padding, absorbent, 3.5 m unstretched, 10 cm = 69p

SurePress® (Convatec)  
Padding, absorbent, 3 m unstretched, 10 cm = 56p

Ulato Soft® (Robinsons)  
Padding, absorbent, 3.5 m unstretched, 10 cm = 39p

Velband® (BSN Medical)  
Padding, absorbent, 4.5 m unstretched, 10 cm = 67p

A.8.8 Multi-layer compression bandaging

Multi-layer compression bandaging systems are an alternative to High Compression Bandages (section A.8.7) for the treatment of venous leg ulcers. Compression is achieved by the combined effects of two or three extensible bandages applied over a layer of orthopaedic wadding and a wound contact dressing.

Four layer systems
K-Four® (Urgo)  
K-Four® #1 (K-Soft®—see Sub-compression Wadding Bandage, above); K-Four® #2 (K-Lite®—see Knitted Elastomer and Viscose Bandage, p. 953); K-Four® #3 (K-Plus®—see Knitted Elastomer and Viscose Bandage, p. 953); K-Three®—see High compression bandages, above; K-Four® #4 (K-Flex®); 6 m (stretched), 10 cm = £2.84, 7 m (stretched), 10 cm = £3.25

954 A8.8.7 Compression bandages  BNF 61
Multi-layer compression bandaging kit, four layer system, for ankle circumference up to 18 cm = £6.73, 18–25 cm = £6.64, 25–30 cm = £6.44, above 30 cm = £6.87; reduced compression, 18 cm and above = £4.21

**Profore®** (S&N Hlth.)

Profore® wound contact layer (see Knitted Viscose Primary Dressing, p. 937). Profore® W1 (see Sub-compression Wadding Bandage, p. 954); Profore® W2 (see Cotton, Polyamide and Elastane Bandage, p. 953); Profore® W3 (see Knitted Elastomer and Viscose Bandage, p. 953); Profore® W4 (see Cohesive bandages, p. 954). Profore® Plus 3 m (unstretched), 10 cm = £3.46, latex-free = £3.70

### Multi-layer compression bandaging kit

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 cm</td>
<td>£3.24</td>
</tr>
<tr>
<td>12 cm</td>
<td>£3.47</td>
</tr>
<tr>
<td>15 cm</td>
<td>£3.94</td>
</tr>
<tr>
<td>18 cm</td>
<td>£5.15</td>
</tr>
<tr>
<td>21 cm</td>
<td>£5.64</td>
</tr>
<tr>
<td>25 cm</td>
<td>£6.44</td>
</tr>
<tr>
<td>30 cm</td>
<td>£6.73</td>
</tr>
<tr>
<td>Above 30 cm</td>
<td>£8.75</td>
</tr>
</tbody>
</table>

**Zinc Paste and Ichthammol Bandage, BP 1993**

Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide; requires additional bandaging, 6 m × 7.5 cm = £3.44 (S&N Hlth.—Vincapaste F87™ (10%), excipients: include cetostearyl alcohol, hydroxybenzoates)

### Zinc Paste and Ichthammol Bandage, BP 1993

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 m × 7.5 cm</td>
<td>£3.44</td>
</tr>
</tbody>
</table>

**Zinc Paste Bandage, BP 1993**

Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide and ichthammol; requires additional bandaging, 6 m × 7.5 cm = £3.47 S&N Hlth.—Ichthopaste® (6/2%), excipients: include cetostearyl alcohol

#### Uses

- section 13.5

### Steripaste® (Mölnlycke)

Cotton fabric, selvedge weave impregnated with paste containing zinc oxide (requires additional bandaging), 6 m × 7.5 cm = £3.24

#### Excipients

- polyisobutene 80

### Medicated stocking

**Zipzoc** (S&N Hlth.)

Sterile rayon stocking impregnated with ointment containing zinc oxide 20%. 4-pouch carton = £12.52, 10-pouch carton = £31.30

#### Note

- Can be used under appropriate compression bandages or hosiery in chronic venous insufficiency

### Two layer systems

**Coban® 2 (3M)**

Multi-layer compression bandaging kit, two layer system (latex-free, foam bandage and cohesive compression bandage), one size = £8.08. Coban® 2 Lite (reduced compression), one size = £8.08

#### K-Two® (Lurgo)

**K-Tech®** (see Sub-compression Wadding Bandages, p. 954); **K-Press®** (see Cohesive Bandages, p. 954)

### Multi-layer compression bandaging kit

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.5 cm</td>
<td>£3.47</td>
</tr>
<tr>
<td>10 cm</td>
<td>£3.44</td>
</tr>
<tr>
<td>12 cm</td>
<td>£3.47</td>
</tr>
<tr>
<td>15 cm</td>
<td>£3.94</td>
</tr>
<tr>
<td>18 cm</td>
<td>£5.15</td>
</tr>
<tr>
<td>21 cm</td>
<td>£5.64</td>
</tr>
<tr>
<td>25 cm</td>
<td>£6.44</td>
</tr>
<tr>
<td>30 cm</td>
<td>£6.73</td>
</tr>
<tr>
<td>Above 30 cm</td>
<td>£8.75</td>
</tr>
</tbody>
</table>

### ProGuide® (S&N Hlth.)

ProGuide® wound contact layer (see Absorbent dressings, p. 937). ProGuide® W1 (see Sub-compression Wadding Bandage, p. 954). ProGuide® W2 (see High Compression Bandages, p. 954)

### Multi-layer compression bandaging kit

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–28 cm (yellow)</td>
<td>£10.24</td>
</tr>
</tbody>
</table>

### Compression hosiery and garments

**Compression (elastic) hosiery** is used to treat conditions associated with chronic venous insufficiency, to prevent recurrence of thrombosis, or to reduce the risk of further venous ulceration after treatment with compression bandaging (section A8.8.7). Doppler testing to confirm arterial sufficiency is required before recommending the use of compression hosiery.

Before elastic hosiery can be dispensed, the quantity (single or pair), article (including accessories), and compression class must be specified by the prescriber. There are different compression values for graduated compression hosiery and lymphoedema garments (see table below). All dispensed elastic hosiery articles must state on the packaging that they conform with Drug Tariff technical specification No. 40, for further details see Drug Tariff.

#### Note

- Graduated compression tights are **not**

### Compression values for hosiery and lymphoedema garments

<table>
<thead>
<tr>
<th>Compression class</th>
<th>Compression hosiery (British standard)</th>
<th>Lymphoedema garments (European classification)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class 1</td>
<td>14–17 mmHg</td>
<td>18–21 mmHg</td>
</tr>
<tr>
<td>Class 2</td>
<td>18–24 mmHg</td>
<td>23–32 mmHg</td>
</tr>
<tr>
<td>Class 3</td>
<td>25–35 mmHg</td>
<td>34–46 mmHg</td>
</tr>
<tr>
<td>Class 4</td>
<td>Not available</td>
<td>49–70 mmHg</td>
</tr>
<tr>
<td>Class 4 super</td>
<td>Not available</td>
<td>60–90 mmHg</td>
</tr>
</tbody>
</table>
A8.9.1 Graduated compression hosiery

Class 1 Light Support

Hosiery, compression at ankle 14–17 mmHg, thigh length or below knee with knitted in heel. 1 pair, circular knit (standard), thigh length = £7.61, below knee = £6.95, (made-to-measure), thigh length = £37.79, below knee = £23.64; lightweight elastic net (made-to-measure), thigh length = £20.38, below knee = £15.91

Uses superficial or early varices, varicosis during pregnancy

Class 2 Medium Support

Hosiery, compression at ankle 18–24 mmHg, thigh length or below knee with knitted in heel. 1 pair, circular knit (standard), thigh length = £11.31, below knee = £10.16, (made-to-measure), thigh length = £37.79, below knee = £23.64; net (made-to-measure), thigh length = £20.38, below knee = £15.91; flat bed (made-to-measure, only with closed heel and open toe), thigh length = £37.79, below knee = £23.64

Uses varices of medium severity, ulcer treatment and prophylaxis, mild oedema, varicosis during pregnancy

Class 3 Strong Support

Hosiery, compression at ankle 25–35 mmHg, thigh length or below knee with open or knitted in heel. 1 pair, circular knit (standard), thigh length = £13.40, below knee = £11.52, (made-to-measure), thigh length = £37.79, below knee = £23.64; flat bed (made-to-measure, only with open heel and open toe), thigh length = £37.79, below knee = £23.64

Uses gross varices, post thrombotic venous insufficiency, gross oedema, ulcer treatment and prophylaxis

Accessories

In addition to the product listed below, accessories such as application aids for hosiery are available, see Drug Tariff for details

Suspender

Suspender, for thigh stockings = 66p, belt (specification 13), = £4.99, fitted (additional price) = 62p

Anklets

Class 2 Medium Support

Anklets, compression 18–24 mmHg, circular knit (standard and made-to-measure), 1 pair = £6.66; flat bed (standard and made-to-measure) = £13.84, net (made-to-measure) = £13.09

Class 3 Strong Support

Anklets, compression 25–35 mmHg, circular knit (standard and made-to-measure), 1 pair = £9.09; flat bed (standard) = £9.29, (made-to-measure) = £13.84

Knee caps

Class 2 Medium Support

Knee caps, compression 18–24 mmHg, circular knit (standard and made-to-measure), 1 pair = £6.66; flat bed (standard and made-to-measure) = £13.84, net (made-to-measure) = £10.87

Class 3 Strong Support

Knee caps, compression 25–35 mmHg, circular knit (standard and made-to-measure), 1 pair = £8.88; flat bed (standard) = £8.88, (made-to-measure) = £13.84

A8.9.2 Lymphoedema garments

Lymphoedema compression garments are used to maintain limb shape and prevent additional fluid retention. Either flat-bed or circular knitting methods are used in the manufacture of elasticated compression garments. Seamless, circular-knitted garments (in standard sizes) can be used to prevent swelling if the lymphoedema is well controlled and if the limb is in good shape and without skin folds. Flat-knitted garments (usually made-to-measure) with a seam, provide greater rigidity and stiffness to maintain reduction of lymphoedema following treatment with compression bandages.

A standard range of light, medium, or high compression garments are available, as well as low compression (12–16 mmHg) armsleeves, made-to-measure garments up to compression 90 mmHg, and accessories—see Drug Tariff for details.

Note There are different compression values for lymphoedema garments and graduated compression hosiery, see table, p. 955.
Numbers following the preparation entries in the BNF correspond to the code numbers of the cautionary labels that pharmacists are recommended to add when dispensing. It is also expected that pharmacists will counsel patients when necessary.

Counselling needs to be related to the age, experience, background, and understanding of the individual patient. The pharmacist should ensure that the patient understands how to take or use the medicine and how to follow the correct dosage schedule. Any effects of the medicine on driving or work, any foods or medicines to be avoided, and what to do if a dose is missed should also be explained. Other matters, such as the possibility of staining of the clothes or skin by a medicine should also be mentioned.

For some preparations there is a special need for counselling, such as an unusual method or time of administration or a potential interaction with a common food or domestic remedy, and this is indicated where necessary.

**Original packs** Most preparations are dispensed in unbroken original packs that include further advice for the patient in the form of patient information leaflets. Label 10 may be of value where appropriate. More general leaflets advising on the administration of preparations such as eye drops, eye ointments, inhalers, and suppositories are also available.

**Scope of labels** In general no label recommendations have been made for injections on the assumption that they will be administered by a healthcare professional or a well-instructed patient. The labelling is not extensive and pharmacists are recommended to use their professional discretion in labelling new preparations and those for which no labels are shown.

Individual labelling advice is not given on the administration of the large variety of antacids. In the absence of instructions from the prescriber, and if on enquiry the patient has had no verbal instructions, the directions given under ‘Dose’ should be used on the label.

It is recognised that there may be occasions when pharmacists will use their knowledge and professional discretion and decide to omit one or more of the recommended labels for a particular patient. In this case counselling is of the utmost importance. There may also be an occasion when a prescriber does not wish additional cautionary labels to be used, in which case the prescription should be endorsed ‘NCL’ (no cautionary labels). The exact wording that is required instead should then be specified on the prescription.

Pharmacists label medicines with various wordings in addition to those directions specified on the prescription. Such labels include ‘Shake the bottle’, ‘For external use only’, and ‘Store in a cool place’, as well as ‘Discard’.

... days after opening’ and ‘Do not use after ...’, which apply particularly to antibiotic mixtures, diluted liquid and topical preparations, and to eye-drops. Although not listed in the BNF these labels should continue to be used when appropriate; indeed, ‘For external use only’ is a legal requirement on external liquid preparations, while ‘Keep out of the reach of children’ is a legal requirement on all dispensed medicines. Care should be taken not to obscure other relevant information with adhesive labelling.

It is the usual practice for patients to take standard tablets with water or other liquid and for this reason no separate label has been recommended.

The label wordings recommended by the BNF apply to medicines dispensed against a prescription. Patients should be aware that a dispensed medicine should never be taken by, or shared with, anyone other than for whom the prescriber intended it. Therefore, the BNF does not include warnings against the use of a dispensed medicine by persons other than for whom it was specifically prescribed.

The label or labels for each preparation are recommended after careful consideration of the information available. However, it is recognised that in some cases this information may be either incomplete or open to a different interpretation. The BNF will therefore be grateful to receive any constructive comments on the labelling suggested for any preparation.

### Recommended label wordings

**For BNF 61 (March 2011)** a revised set of advisory and cautionary labels has been introduced. All of the existing labels have been user-tested, and the revised wording selected reflects terminology that is better understood by patients.

Wordings which can be given as separate warnings are labels 1–19, 29–30, and 32. New wordings which can be incorporated in an appropriate position in the directions for dosage or administration are labels 21–28. A label has been omitted for number 20; labels 31 and 33 no longer apply to any medicines in the BNF and have therefore been deleted.

If separate labels are used it is recommended that the wordings be used without modification. If changes are made to suit computer requirements, care should be taken to retain the sense of the original.

1 **Warning:** This medicine may make you sleepy

To be used on preparations for children containing antihistamines, or other preparations given to children where the warnings of label 2 on driving or alcohol would not be appropriate.
Cautionary and advisory labels

2 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol.

To be used on preparations for adults that can cause drowsiness, thereby affecting the ability to drive and operate hazardous machinery; label 1 is more appropriate for children. It is an offence to drive while under the influence of drugs.

Some of these preparations only cause drowsiness in the first few days of treatment and some only cause drowsiness in higher doses.

In such cases the patient should be told that the advice applies until the effects have worn off. However many of these preparations can produce a slowing of reaction time and a loss of mental concentration that can have the same effects as drowsiness. Avoidance of alcoholic drink is recommended because the effects of CNS depressants are enhanced by alcohol. Strict prohibition however could lead to some patients not taking the medicine. Pharmacists should therefore explain the risk and encourage compliance, particularly in patients who may think they already tolerate the effects of alcohol (see also label 3).

Queries from patients with epilepsy regarding fitness to drive should be referred back to the patient’s doctor.

Side-effects unrelated to drowsiness that may affect a patient’s ability to drive or operate machinery safely include blurred vision, dizziness, or nausea. In general, no label has been recommended to cover these cases, but the patient should be suitably counselled.

3 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines.

To be used on preparations containing monoamine oxidase inhibitors; the warning to avoid alcohol and dealcoholised (low alcohol) drink is covered by the patient information leaflet.

Also to be used as for label 2 but where alcohol is not an issue.

4 Warning: Do not drink alcohol while taking this medicine.

To be used on preparations where a reaction such as flushing may occur if alcohol is taken (e.g. metronidazole). Alcohol may also enhance the hypoglycaemia produced by some oral antidiabetic drugs but routine application of a warning label is not considered necessary.

5 Do not take indigestion remedies 2 hours before or after you take this medicine.

To be used with label 25 on preparations coated to resist gastric acid (e.g. enteric-coated tablets). This is to avoid the possibility of premature dissolution of the coating in the presence of an alkaline pH.

Label 5 also applies to drugs such as ketoconazole where the absorption is significantly affected by antacids; the usual period of avoidance recommended is 2 hours.

6 Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine.

To be used on preparations containing aloxacinc and some other quinolones, doxycycline, lymecycline, minocycline, and penicillamine. These drugs chelate calcium, iron, magnesium, and zinc and are less well absorbed when taken with calcium-containing antacids or preparations containing iron or zinc. These incompatible preparations should be taken 2 hours apart.

7 Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine.

To be used on preparations containing ciprofloxacin, norfloxacin or tetracyclines that chelate calcium, iron, magnesium, and zinc and are thus less available for absorption; these incompatible preparations should be taken 2 hours apart. Doxycycline, lymecycline and minocycline are less liable to form chelates and therefore only require label 6 (see above).

8 Warning: Do not stop taking this medicine unless your doctor tells you to stop.

To be used on preparations that contain a drug which is required to be taken over long periods without the patient necessarily perceiving any benefit (e.g. anti-tuberculous drugs).

Also to be used on preparations that contain a drug whose withdrawal is likely to be a particular hazard (e.g. clonidine for hypertension). Label 10 (see below) is more appropriate for corticosteroids.

9 Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop.

To be used on preparations where a course of treatment should be completed to reduce the incidence of relapse or failure of treatment.

The preparations are antimicrobial drugs given by mouth. Very occasionally, some may have severe side-effects (e.g. diarrhoea in patients receiving clindamycin) and in such cases the patient may need to be advised of reasons for stopping treatment quickly and returning to the doctor.

10 Warning: Read the additional information given with this medicine.

To be used particularly on preparations containing anticoagulants, lithium and oral corticosteroids. The appropriate treatment card should be given to the patient and any necessary explanations given.

This label may also be used on other preparations to remind the patient of the instructions that have been given.

11 Protect your skin from sunlight—even on a bright cloudy day. Do not use sunbath.

To be used on preparations that may cause phototoxic or photoallergic reactions if the patient is exposed to ultraviolet radiation. Many drugs other than those listed in Appendix 9 (e.g. phenothiazines and sulphonamides) may, on rare occasions, cause reactions in susceptible patients. Exposure to high intensity ultraviolet radiation from sunlamps and sunbeds is particularly likely to cause reactions.

12 Do not take anything containing aspirin while taking this medicine.

To be used on preparations containing probenecid and sulfinpyrazone whose activity is reduced by aspirin.

Label 12 should not be used for antiocoagulants since label 10 is more appropriate.

13 Dissolve or mix with water before taking.

To be used on preparations that are intended to be dissolved in water (e.g. soluble tablets) or mixed with water (e.g. powders, granules) before use. In a few cases other liquids such as fruit juice or milk may be used.

14 This medicine may colour your urine. This is harmless.

To be used on preparations that may cause the patient’s urine to turn an unusual colour. These include triamterene (blue under some lights), levo-dopa (dark reddish), and rifampicin (red).

15 Caution: flammable. Keep your body away from fire or flames after you have put on the medicine.

To be used on preparations containing sufficient flammable solvent to render them flammable if exposed to a naked flame.

16 Dissolve the tablet under your tongue—do not swallow.

Store the tablets in this bottle with the cap tightly closed. Get a new supply 8 weeks after opening.

To be used on glyceryl trinitrate tablets to remind the patient not to transfer the tablets to plastic or less suitable containers.

17 Do not take more than . . . in 24 hours.

To be used on preparations for the treatment of acute migraine except those containing ergotamine, for which label 18 is used. The dose form should be
specified, e.g. tablets or capsules. It may also be used on preparations for which no dose has been specified by the prescriber.

18 Do not take more than . . . in 24 hours. Also, do not take more than . . . in any one week To be used on preparations containing ergotamine. The dose form should be specified, e.g. tablets or suppositories.

19 Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol To be used on preparations containing hypnotics (or some other drugs with sedative effects) prescribed to be taken at night. On the rare occasions (e.g. nitrazepam in epilepsy) when hypnotics are prescribed for daytime administration this label would clearly not be appropriate. Also to be used as an alternative to the label 2 wording (the choice being at the discretion of the pharmacist) for anxiolytics prescribed to be taken at night.

It is hoped that this wording will convey adequately the problem of residual morning sedation after taking ‘sleeping tablets’.

21 Take with or just after food, or a meal To be used on preparations that are liable to cause gastric irritation, or those that are better absorbed with food.

22 Take 30 to 60 minutes before food To be used on some preparations whose absorption is thereby improved. Most oral antibacterials require label 23 instead (see below).

23 Take this medicine when your stomach is empty. This means an hour before food or 2 hours after food To be used on oral preparations whose absorption may be reduced by the presence of food and acid in the stomach.

24 Suck or chew this medicine To be used on preparations that should be sucked or chewed. The pharmacist should use discretion as to which of these words is appropriate.

25 Swallow this medicine whole. Do not chew or break To be used on preparations that are enteric-coated or designed for modified-release.

26 Dissolve this medicine under your tongue To be used on preparations designed for sublingual use. Patients should be advised to hold under the tongue and avoid swallowing until dissolved. The buccal mucosa between the gum and cheek is occasionally specified by the prescriber.

27 Take with a full glass of water To be used on preparations that should be well diluted (e.g. chloral hydrate), where a high fluid intake is required (e.g. sulphonamides), or where water is required to aid the action (e.g. methylcellulose). The patient should be advised that ‘a full glass’ means at least 150 mL. In most cases fruit juice, tea, or coffee may be used.

28 Spread thinly on the affected skin only To be used on external preparations that should be applied sparingly (e.g. corticosteroids, dithranol).

29 Do not take more than 2 at any one time. Do not take more than 8 in 24 hours To be used on containers of dispensed solid dose preparations containing paracetamol for adults when the instruction on the label indicates that the dose can be taken on an ‘as required’ basis. The dose form should be specified, e.g. tablets or capsules. This label has been introduced because of the serious consequences of overdosage with paracetamol.

30 Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine To be used on all containers of dispensed preparations containing paracetamol.

31 Contains aspirin. Do not take aspirin while taking this medicine To be used on containers of dispensed preparations containing aspirin while taking this medicine.

32 Contains aspirin. Do not take anything else containing aspirin while taking this medicine To be used on containers of dispensed preparations containing aspirin when the name on the label does not include the word ‘aspirin’.

### Products and their labels

Proprietary names are in *italic*. C = counselling advised; see BNF = consult product entry in BNF

Abacavir, C, hypersensitivity reactions, see BNF

Abilify, 2
Abilify orodispersible tabs, 2, C, administration, see BNF

Abstral, 2, 26

Acamprosate, 21, 25
Acarbose, C, administration, see BNF

Accolate

Acceledol, 10, patient information leaflet, 11, 21
Aciclovir susp and tabs, 9
Acetaminophen, 3
Acetaminophen m/r, 3, 25
Acetazolamide, 3
Acetazolamide m/r, 3, 25
Aceldol, 24
Acetyl-D, 24
Acetyl-D, Dissolve, 13
Adipine MR, 25
Adipine XL, 25
Adizem preps, 25
Adoport, 23, C, driving, see BNF

Acitretin, 10

Adalimumab, C, tuberculosis, see BNF

Adalat LA, 25
Adalat Retard, 25
Adalimumab, C, administration, food and calcium, see BNF

Alfuzosin, C, initial dose, driving, see BNF

Aldomet, 3, 8
Aldose-1, C, application, see BNF
Appendix 9: Cautionary and advisory labels for dispensed medicines

Aliskiren, 21
Allitretinoin, 10, patient information leaflet, 11, 21
Allegro, 2
Allopurinol, 8, 21, 27
Almogran, 3
Almotriptan, 3
Alphysol HC, 28
Alphadherm, 28, C, application, see BNF
Alprazolam, 2
Altaro, 28
Alvedon, 30
Alvesco, 8, C, administration
Amantadine, C, driving
Amifampridine, 3, 21
Amantadine, C, driving
Anakinra, C, blood disorder symptoms
Anagrelide, C, driving
Anafranil m/r
Anafranil
Ampicillin, 9, C, use of
Amoxil paed susp
Amoxil dispersible sachets
Amoxil
Amoxicillin, 9
Amoxicillin dispersible sachets, 9, 13
Amoxil, 9
Amoxil dispersible sachets, 9, 13
Amoxil paed susp, 9, C, use of pipette
Ampicillin, 9, 23
Anfroanil, 2
Anfroanil m/r, 2, 25
Anagrelide, C, driving
Anakirina, C, blood disorder symptoms
Androcur, 21
Andropatch, C, administration, see BNF
Angitil XL, 25
Anhylord Forte, 15
Anquil, 2
Antabuse, 2, C, alcohol reaction, see BNF
Antacid, see BNF dose statements
Antepsin, 5
Anticoagulants, oral, 10, anti-coagulant card
Antihistamines, (see individual preparations)
APO-gb, 10, C, driving, see BNF
Apomorphine, 10, C, driving, see BNF
Aptivus caps, 5, 21
Aptivus oral solution, 5, 21, C, crystallisation
Aralon, 4
Aristect Eves, C, administration
Aripiprazole, 2
Aripiprazole orodispersible tabs, 2, C, administration, see BNF
Arlevert, 2
Aromasin, 21
Arpicolin, C, driving
Artemether with lumefantrine, 21, C, driving
Arthrotec, 21, 25
Asacol MR tabs, 5, 25, C, blood disorder symptoms, see BNF
Asacol enema and supps, C, blood disorder symptoms, see BNF
Asasatin Retard, 21, 25
Asparagine acid tabs (500 mg), 24
Asmacbev preps, 8, C, administration; with high doses, 10, steroid card
Asmanex, 8, 10, steroid card, C, administration
Amsosal, C, administration
Amsosal, C, administration
Amsosal, C, administration
Ampiristine, C, muscle effects, see BNF
Atovaquone, 21
Atripila, 23, 25
Atrovent inhalations, C, administration
Augmentin susp and tabs, 9
Augmentin Duo, 9
Aureocort, 28, C, application, see BNF
Avandamet, 21
Avelox, 6, 9, C, driving
Avilacor, 5, C, malaria prophylaxis, see BNF
Avodart, 25
Avomine, 2
Axorid, 21, 25
Azathioprine, 21
Azithromycin caps, 5, 9, 23
Azithromycin susp and tabs, 5, 9
Baclofen, 2, 8, 21
Balsalazide, 21, 25
Baraclude, C, administration
Baraltol, 2
Baxan, 9
Beclometasone inhalations, 8, C, administration; with high doses, 10, steroid card
Becodisks, 8, C, administration; with high doses, 10, steroid card
Benemid, 12, 21, 27
Benperidol, 2
Benzoin tincture, compound, 15
Besavar XL, 21, 25, C, initial dose, driving, see BNF
Beta-Adalat, 8, 25
Betacap, 15, 28, C, application, see BNF
Beta-Cardone, 8
Betahistine, 21
Betamethasone inj, 10, steroid card
Betamethasone solub tab, 10, steroid card, 13, 21, (when used as a mouthwash, Label: 10, 13, C, administration)
Betamethasone tab, 10, steroid card, 21
Betamethasone external preps, 28, C, application, see BNF
Betamethasone plaster, C, application, see BNF
Betamethasone scalp application, 15, 28, C, application, see BNF
Betbesil, C, application, see BNF
Bethechol, 22
Betim, 8
Betnelan, 10, steroid card, 21
Betnesol injection, 10, steroid card
Betnesol tabs, 10, steroid card, 13, 21, (when used as a mouthwash, Label: 10, 13, C, administration)
Betnovate external preps, 28, C, application, see BNF
Betnovate scalp application, 15, 28, C, application, see BNF
Betnovate-RO, 28, C, application, see BNF
Bettamousse, 28, C, application, see BNF
Bezafibrate, 21
Bezafibrate m/r, 21, 25
Bezalip, 21
Bezalip-Mono, 21, 25
Biorphen, C, driving
Bisacodyl tabs, 5, 25
Bisoprolol, 8
Bonderonat tabs, C, administration, see BNF
Bonefos caps and tabs, C, food and calcium, see BNF
Bonviva tabs, C, administration, see BNF
Brexidol, 21
Bricanyl inhalations, C, administration
Briloflex, 2
Broflex, C, driving, see BNF
Bromocriptine, 10, 21, C, driving, see BNF
Brouen, 21
Brufen gran, 13, 21
Brufen Retard, 25, 27
Buccastem, 28, C, administration, see BNF
Budelir Novolizer, 8, C, administration; with high doses, 10, steroid card
Budenofolk, 5, 10, steroid card, 22, 25
BNF 61

Appendix 9: Cautionary and advisory labels for dispensed medicines

Ciproxin susp and tabs, 7, 9, 25,
C, driving
Circadin, 2, 21, 25
Citalopram drops, C, driving,
administration
Citalopram tabs, C, driving
CitraFleet, 10, patient information leaflet, 13, C, administration
Citramag, 10, patient information
leaflet, 13, C, administration
Clarelux, 15, 28, C, application,
see BNF
Clarithromycin, 9
Clarithromycin m/r, 9, 21, 25
Clarithromycin sachets, 9, 13
Clasteon, C, food and calcium,
see BNF
Clemastine, 2
Clenil Modulite, 8, C, administration; with high doses, 10,
steroid card
Clindamycin, 9, 27, C, diarrhoea,
see BNF
Clipper, 25
Clobazam, 2 or 19, 8, C, driving,
see BNF
Clobetasol external preps, 28, C,
application, see BNF
Clobetasol scalp application, 15,
28, C, application, see BNF
Clobetasone butyrate, 28, C,
application, see BNF
Clofazimine, 8, 14, (urine red), 21
Clomethiazole, 19
Clomipramine, 2
Clomipramine m/r, 2, 25
Clonazepam, 2, 8, C, driving, see
BNF
Clonidine, see Catapres
Clopixol, 2
Clotam Rapid, 21
Clotrimazole spray, 15
Clozapine tabs, 2, 10, patient
information leaflet
Clozapine susp, 2, 10, patient
information leaflet, C, administration
Clozaril, 2, 10, patient information leaflet
Coal tar paint, 15
Coal tar solution, 15
Co-amoxiclav, 9
Co-beneldopa, 10, 14, (urine
reddish), C, driving, see BNF
Co-beneldopa dispersible tabs,
10, 14, (urine reddish), C,
administration, driving, see
BNF
Co-beneldopa m/r, 5, 10, 14,
(urine reddish), 25, C, driving,
see BNF
Co-careldopa, 10, 14, (urine reddish), C, driving, see BNF
Co-careldopa intestinal gel, 10,
14, (urine reddish), C, driving,
see BNF

Appendix 9: Cautionary and advisory labels

Carbamazepine chewable, 3, 8,
21, 24, C, blood, hepatic or
skin disorder symptoms, driving, see BNF
Carbamazepine liq, supps and
tabs, 3, 8, C, blood, hepatic or
skin disorder symptoms, driving, see BNF
Carbamazepine m/r, 3, 8, 25, C,
blood, hepatic or skin disorder
symptoms, driving, see BNF
Carbimazole, C, blood disorder
symptoms, see BNF
Cardene SR, 25
Cardura, C, initial dose, driving
Cardura XL, 25, C, initial dose,
driving
Cabaser, 10, 21, C, driving, see
Carglumic acid, 13
BNF
Carvedilol, 8
Cabergoline, 10, 21, C, driving,
Catapres, 3, 8
see BNF
Cefaclor, 9
Cacit, 13
Cefaclor m/r, 9, 21, 25
Cacit D3, 13
Cefadroxil, 9
Cafergot, 18, C, dosage
Cefalexin, 9
Calceos, 24
Cefixime, 9
Calcicard CR, 25
Cefpodoxime, 5, 9, 21
Calcichew-D3 tabs, chewable, 24
Cefradine, 9
Calcichew tabs, chewable, 24
Cefuroxime susp, 9, 21
Calcium-500, 25
Cefuroxime tab, 9, 21, 25
Calcium acetate caps, C, with
Celance, 10, C, driving, see BNF
meals
Celectol, 8, 22
Calcium acetate tabs, C, do not
Celevac (constipation or diarrchew, with meals
hoea), C, administration, see
Calcium carbonate tabs, chewBNF
able, 24
Celiprolol, 8, 22
Calcium carbonate tabs and gran
Ceporex, 9
effervescent, 13
Certolizumab pegol, 10, Alert
Calcium gluconate effervescent
card, C, tuberculosis, blood
tabs, 13
disorders
Calcium phosphate sachets, 13
Cetirizine, C, driving
Calcium Resonium, 13
Champix, 3
Calcium and ergocalciferol tabs,
Chemydur 60XL, 25
C, administration, see BNF
Chloral hydrate, 19, 27
Calcort, 5, 10, steroid card
Chloral paed elixir, 1, 27
Calfovit D3, 13, 21
Chloral mixt, 19, 27
Calmurid HC, 28, C, application,
Chlordiazepoxide, 2
see BNF
Chloroquine, 5, C, malaria
Calpol susp, 30
prophylaxis, see BNF
Camcolit 250 tabs, 10, lithium
Chlorphenamine, 2
card, C, fluid and salt intake,
Chlorpromazine solution, supps
see BNF
and tabs, 2, 11
Camcolit 400 tabs, 10, lithium
Cholera vaccine (oral), C, admincard, 25, C, fluid and salt
istration
intake, see BNF
Cholestagel, 21, C, avoid other
Campral EC, 21, 25
drugs at same time, see BNF
Canesten HC, 28, C, application,
Ciclesonide, 8, C, administration
see BNF
Ciclosporin, C, administration,
Canesten spray, 15
see BNF
Cannabis sativa extract, C, drivCimzia, 10, Alert card, C, tubering, see BNF
culosis, blood disorders
Capecitabine, 21
Cinacalcet, 21
Capimune, C, administration, see
Cinnarizine, 2
BNF
Cipralex drops, C, driving,
Caprin, 5, 25, 32
administration
Caramet CR, 10, 14, 25, C, drivCipralex tabs, C, driving
ing, see BNF
Cipramil drops, C, driving,
Carbaglu, 13
administration
Cipramil tabs, C, driving
Ciprofloxacin, 7, 9, 25, C, driving
Budesonide inhalations, 8, C,
administration; with high
doses, 10, steroid card
Budesonide caps, 5, 10, steroid
card, 22, 25
Budesonide m/r caps, 5, 10,
steroid card, 25
Buprenorphine, 2, 26
Bupropion, 25, C, driving
Buserelin nasal spray, C, nasal
decongestants, see BNF
Buspirone, C, driving
BuTrans, 2
Byetta, C, administration, see
BNF

961


Appendix 9: Cautionary and advisory labels for dispensed medicines

Co-careldopa m/r, 10, 14, (urine reddish), 25, C, driving, see BNF
Co-codamol, see preps
Co-codaprin dispersible tabs, 13, 21, 32
Codaxal, 14, (urine red)
Codantherame, 14, (urine red)
Co-danthrusate, 14, (urine red)
Codipar, 2, 29, 30
Co-dydramol, 29, 30
Co-divalprox, 9, 22
Co-enzimide, 21, 25
Co-enzapine, 14, (urine reddish-brown), C, driving, avoid iron-containing preparations at the same time of day
Coferon, 2, 10, patient information leaflet
Coferiton, 2, 10, patient information leaflet
Cooproxal, 2, 10, patient information leaflet
Co-plaxal, 2, 10, patient information leaflet
Co-prenozide, 8, 25
Co-similast, 25
Co-trimoxazole susp and tabs, 9
Co-triamterzide, 14, (urine blue), C, blood disorder symptoms, see BNF
Co-trimoxazole tabs, 13, 21
Dabigatran, 25
Daktaril, 28, C, application, see BNF
Daktarin cream and oint, 28, C, application, see BNF
Daktarin oral gel, 9, C, hold in mouth, after food
Dalcin C, 9, 27, C, diarrhoea, see BNF
Daltroban, 19
Dantrium, 2, C, driving, hepatotoxicity, see BNF
Dantrolene, 2, C, driving, hepatotoxicity, see BNF
Dapsone, 8
Darifenacin e/c, 5, 25
Dasatinib, 25
Daxas, C, patient card
DDAVP Melt, 26, C, fluid intake, see BNF
DDAVP tablets and intranasal, C, fluid intake, see BNF
Deferasirox, 13, 22
Deferasirox, 13, 22
Deferiprone, 14, C, blood disorders
Deltacortril e/c, 5, 10, steroid card
Deflazacort, 5, 10, steroid card
Deltanid, 2
Didronel, C, use of pipette
Dihydrocodeine, 2
Dihydrocodeine m/r, 2, 25
Digitoxin, 3
Diletal, 21
Deltanid, 2
Diletal, 21
Deltanid, 2
Diletal, 21
Diletal, 21
Diletal, 21
Diletal, 21
Distigmine, 22
Disulfiram, 2, C, alcohol reaction, see BNF
Dithranol preps, 28
Dithrocream preps, 28
Dithranol, 28
Ditopam, 28
Diabase, 25, 27
Dolmatil, 2
Donepezil orodispersible tabs, C, administration
Doralese, 2
Dositol, 10, 21, C, driving, see BNF
Dosulepin, 2
Doxepin topical, 2, 10, patient information leaflet
Doxepin, 2
Doxazosin m/r, 25, C, initial dose, driving
Doxazosin, C, initial dose, see BNF
Doxazosin, C, posture, see BNF
Doxepin orodisks, 2
Doxepin m/r, 10, 14, (urine reddish-brown), C, driving, see BNF
Doxepin, 2
Doxepin topical, 2, 10, patient information leaflet
Doxycycline tabs, 5, 9, 25
Doxycycline caps m/r, 6, 11, 27, C, posture, see BNF
Doxycycline caps, 6, 9, 11, 27, C, posture, see BNF
Doxycycline dispersible tabs, 6, 9, 11, 13
Doxycycline tabs, 6, 11, 27, C, posture, see BNF
Doxicic, 2
Driclor, 15
Dronedarone, 21
Dukoral, C, administration
Duloxetine, 2
Dudopha, 10, 14, (urine reddish), C, driving, see BNF
Dufilim, 15
Duvoent inhalations, C, dose
Duraphat toothpaste, C, administration
Durogesic DTrans, 2, C, administration
Dulastide, 25
Dyzide, 14, (urine blue in some lights), 21
Dytac, 14, (urine blue in some lights), 21
Eculizumab, C, meningococcal infection, patient information card
Edronax, C, driving
Efavirenz caps and tabs, 23
Efavite, 10, steroid card
Efexor XL, 3, 25, C, driving
Effentora, 2, C, administration, see BNF
Eflaxa, 6, 11, 27, C, posture, see BNF
Elantan preps, 25
Eletrthropin tabs, 3
Eldel, 4, 28
Elleste Solo MX patches, C, administration, see BNF
Elocon, 28, C, application, see BNF
Eltrobrocap, C, other drugs, see BNF
Emcor preps, 8
Emeside, 8, C, blood disorder symptoms, driving, see BNF
Emflex, 21, C, driving
Enterox, 3, 25
En-De-Kay mouthwash, C, food and drink, see BNF
Enfuvirtide, C, hypersensitivity reactions, see BNF
Entacapone, 14, (urine reddish-brown), C, driving, avoid iron-containing preparations at the same time of day
Entecavir, C, administration
Entocort CR, 5, 10, steroid card, 25
Epanutin caps, 8, C, administration, blood or skin disorder symptoms, driving, see BNF
Epanutin Infatabs, 8, 24, C, blood or skin disorder symptoms, driving, see BNF
Epanutin susp, 8, C, administration, blood or skin disorder symptoms, driving, see BNF
Epiduo, 11
Epilim Chronosphere, 8, 21, 25, C, administration, blood or hepatic disorder symptoms, driving, see BNF
Epilim, C, blood or hepatic disorder symptoms, driving, see BNF
Epilim e/c tabs, 5, 8, 25, C, blood or hepatic disorder symptoms, driving, see BNF
Epilim, C, blood or skin disorder symptoms, driving, see BNF
Eprosartan, 21
Equasym XL, 25
Ergonovine, 18, C, dosage
Erlotinib, 23
Erythromycin caps, 5, 9, 25
Erythromycin, 9
Estraderm TTS, C, administration, see BNF
Estradot, C, administration, see BNF
Estradiol, 25, C, dairy products, see BNF
Estring, 10, patient information leaflet
Ethinylestradiol, 8
Ethinyl estradiol, 8
Etiprol, 21
Etoprofene, 21
Etoposide caps, 23
Etriex, 21, C, rash and hypersensitivity reactions
Etrix, 28, C, application, see BNF
Eurax, 25, C, application, see BNF
Eurax-Hydrocortisone, 28, C, application, see BNF
Everolimus, 25, C, pneumonitis, see BNF
Evorel preps, C, administration, see BNF
Eucardic, 8
Eucreas, 21
Eumovate external preps, 28, C, application, see BNF
Famciclovir, 9
Famvir, 9
Fasigyn, 4, 9, 21, 25
Fenoprofen, 21
Feldene caps, 21
Feldene Melto, 10, patient information leaflet, 21
Fenoldipine m/r, 25
Fenoprofen, 21
Fenoprofen, 21
Fentany buccal tablets, 2, C, administration, see BNF
Fentany lozenges, 2
Fentanyl nasal spray, 2, C, administration, see BNF
Fentanyl patches, 2, C, administration
Emcor preps, 8
Emflex, 21, C, driving
Enterox, 3, 25
En-De-Kay mouthwash, C, food and drink, see BNF
Enfuvirtide, C, hypersensitivity reactions, see BNF
Entacapone, 14, (urine reddish-brown), C, driving, avoid iron-containing preparations at the same time of day
Entecavir, C, administration
Entocort CR, 5, 10, steroid card, 25
Epanutin caps, 8, C, administration, blood or skin disorder symptoms, driving, see BNF
Epanutin Infatabs, 8, 24, C, blood or skin disorder symptoms, driving, see BNF
Epanutin susp, 8, C, administration, blood or skin disorder symptoms, driving, see BNF
Epiduo, 11
Epilim Chronosphere, 8, 21, 25, C, administration, blood or hepatic disorder symptoms, driving, see BNF
Epilim, C, blood or hepatic disorder symptoms, driving, see BNF
Epilim e/c tabs, 5, 8, 25, C, blood or hepatic disorder symptoms, driving, see BNF
Epilim, C, blood or skin disorder symptoms, driving, see BNF
Eprosartan, 21
Equasym XL, 25
Ergonovine, 18, C, dosage
Erlotinib, 23
Erythromycin caps, 5, 9, 25
Erythromycin, 9
Estraderm TTS, C, administration, see BNF
Estradot, C, administration, see BNF
Estradiol, 25, C, dairy products, see BNF
Estring, 10, patient information leaflet
Ethambutol, 8
Ethibide XL, 25
Ethosuximide, 8, C, blood disorder symptoms, driving, see BNF
Etidronate, C, food and calcium, see BNF
Etodolac m/r, 25
Etofonest implant, C, see patient information leaflet
Etoposide caps, 23
Etriex, 21, C, rash and hypersensitivity reactions
Etrix, 28, C, application, see BNF
Eurax-Hydrocortisone, 28, C, application, see BNF
Everolimus, 25, C, pneumonitis, see BNF
Evorel preps, C, administration, see BNF
Evelon caps, 21, 25
Evelon solution, 21
Exemestane, 21
Exenatide, C, administration, see BNF
Exjade, 13, 22, C, administration, see BNF
Famiclovir, 9
Famvir, 9
Fasigyn, 4, 9, 21, 25
Faverin, C, driving, see BNF
Fefol, 25
Felbinac foam, 15
Feldene caps, 21
Feldene Melto, 10, patient information leaflet, 21
Felodipine m/r, 25
Fematrix, C, administration, see BNF
Femapak, C, administration, see BNF
FemSeven, C, administration, see BNF
FemSeven, C, administration, see BNF
Appendix 9: Cautionary and advisory labels

Fentanyl sublingual tablets, 2, 26
Fentazin, 2
Feospan, 25
Ferriprox, 14, C, blood disorders
Ferrograd, 25
Ferrograd C, 25
Ferrograd F, 25
Ferrous m/r, see preps
Fosampravnir susp, C, administration, see BNF
Fosavance, C, administration, see BNF
Fosrenol, 21, C, to be chewed
Fosmon SR, 21, C, administration
Fortilast SR, 24, 25
Fortral caps and tabs, 2, 21
Fosarsen SR, 21, C, driving
Fosphenytoin, C, to be chewed
Fosphenyle, 2, C, administration, see BNF
Fosphenyl, 21
Fosrenol, 25
Fosvar, 2, C, administration
Fosatrine SR, 21, C, driving
Fosavance, C, administration, see BNF
Fosipiron, 21, C, administration
Fospide, 21, C, administration
Forsolid, 21
Fosphenytin, C, to be chewed
Fosudas, 21, C, administration
Fosphenytoin, C, to be chewed
BNF 61

Appendix 9: Cautionary and advisory labels for dispensed medicines

965

Li-Liquid, 10, lithium card, C,
fluid and salt intake, see BNF
Linezolid susp and tabs, 9, 10,
patient information leaflet
Lioresal, 2, 8, 21
Lipantil, 21
Lipitor, C, muscle effects, see
BNF
Lipostat, C, muscle effects, see
BNF
Liquid paraffin, C, administration, see BNF
Liraglutide, C, administration
Liskonum, 10, lithium card, 25, C,
fluid and salt intake, see BNF
Lithium carbonate, 10, lithium
card, C, fluid and salt intake,
see BNF
Lithium carbonate m/r, 10, lithium card, 25, C, fluid and salt
intake, see BNF
Lithium citrate liq, 10, lithium
card, C, fluid and salt intake,
see BNF
Lithonate, 10, lithium card, 25, C,
fluid and salt intake, see BNF
Loceryl, 10, patient information
leaflet
Labetalol, 8, 21
Locoid cream, oint, and topical
Lacosamide tabs and syrup, 8, C,
emulsion, 28, C, application,
driving, see BNF
see BNF
Lamictal dispersible tabs, 8, 13,
Locoid scalp lotion, 15, 28, C,
C, driving, skin reactions, see
application, see BNF
BNF
Lodotra, 10, steroid card, 21, 25
Lamictal tabs, 8, C, driving, skin
Lofepramine, 2
reactions, see BNF
Lofexidine, 2
Lamisil, 9
Lopid, 22
Lamotrigine dispersible tabs, 8,
Loprazolam, 19
13, C, driving, skin reactions,
Lopresor, 8
see BNF
Lopresor SR, 8, 25
Lamotrigine tabs, 8, C, driving,
Loramyc C, 10, C, administration,
skin reactions, see BNF
see BNF
Lanoxin-PG elixir, C, use of pipLoratadine, C, driving
ette
Lorazepam, 2 or 19
Lansoprazole caps, 5, 22, 25
Lormetazepam, 19
Lansoprazole oro-dispersible
Loron tabs, 10, patient informatabs, 5, 22, C, administration,
tion leaflet, C, food and calsee BNF
cium, see BNF
Lanthanum, 21, C, to be chewed
Losec, C, administration, see BNF
Lapatinib, C, see BNF
Lotriderm, 28, C, application, see
Larapam SR, 2, 25
BNF
Largactil, 2, 11
Lugol’s solution, 27
Lariam, 21, 25, 27, C, driving,
Lustral, C, driving, see BNF
malaria prophylaxis, see BNF
Lyclear Dermal cream, 10, patient
Laxido, 13
Janumet, 21
information leaflet
Ledermycin, 7, 9, 11, 23
Joy-Rides, 2, 24
Lymecycline, 6, 9
Leflunomide, 4
Lyrica, 3, 8, C, driving
Lenalidomide, 25, C, symptoms
Lysodren, 2, 10, 21, C, driving,
Kaletra solution, 21
of thromboembolism, neutroadrenal suppression
Kaletra tabs, 25
penia, or thrombocytopenia,
Lysovir, C, driving
Kalspare, 14, (urine blue in some
patient information leaflet
lights), 21
Lercanidipine, 22
Kalten, 8
Lescol, C, muscle effects, see BNF Mabron, 2, 25
Kapake caps and tabs, 2, 29, 30
Lescol XL, 25, C, muscle effects, Macrobid, 9, 14, (urine yellow or
Kay-Cee-L, 21
brown), 21, 25
see BNF
Keflex, 9
Macrodantin, 9, 14, (urine yellow
Levetiracetam, 8
Kemadrin, C, driving
or brown), 21
Levocetirizine, C, driving
Kenalog (systemic), 10, steroid
Levofloxacin, 6, 9, 25, C, driving Macrogols, 13
card
Levomepromazine, 2
Kentera, 3, C, administration, see
BNF
Keppra, 8
Keral, 22
Ketek, 9, C, driving, hepatic disorders
Ketoconazole tabs, 5, 9, 21, C,
hepatotoxicity
Ketoprofen caps, 21
Ketoprofen m/r caps, 21, 25
Ketotifen, 2, 21
Ketorolac tabs, 17, 21
Ketovail, 21, 25
Kineret, C, blood disorder symptoms
Kivexa, C, hypersensitivity reactions, see BNF
Klaricid, 9
Klaricid sachets, 9, 13
Klaricid XL, 9, 21, 25
Klean-Prep, 10, patient information leaflet, 13, C, administration
Kuvan, 13, 21, C, administration,
see BNF
Kwells, 2

Appendix 9: Cautionary and advisory labels

Indometacin m/r, see preps
Indometacin supps, C, driving
Indoramin, 2
Industrial methylated spirit, 15
Inegy, C, muscle effects, see BNF
Infacol, C, use of dropper
Infliximab, 10, Alert card, C,
tuberculosis and hypersensitivity reactions
Inosine pranobex, 9
Inovelon, 21, C, driving, see BNF
Instanyl, 2, C, administration, see
BNF
Insulin, C, see BNF
Intal, 8, C, administration
Intelence, 21, C, rash, and
hypersensitivity reactions
Invega, 2, 25
Invirase, 21, C, arrhythmias
Iodine Solution, Aqueous, 27
Ipocol, 5, 25, C, blood disorder
symptoms, see BNF
Ipratropium inhalations, C,
administration
Isentress, 25
Isib 60XL, 25
Ismo Retard, 25
Ismo tabs, 25
Isocarboxazid, 3, 10, patient
information leaflet
Isodur XL, 25
Isogel, 13, C, administration, see
BNF
Isoket Retard, 25
Isoniazid elixir and tabs, 8, 22
Isosorbide dinitrate m/r, 25
Isosorbide mononitrate, 25
Isosorbide mononitrate m/r, 25
Isotard XL, 25
Isotretinoin, 10, patient information leaflet, 11, 21
Isotretinoin gel, 11
Isotrex, 11
Isotrexin, 11
Ispagel, 13, C, administration,
see BNF
Ispaghula, 13, C, administration,
see BNF
Itraconazole caps, 5, 9, 21, 25, C,
hepatotoxicity
Itraconazole liq, 9, 23, C,
hepatotoxicity


BNF 61

Appendix 9: Cautionary and advisory labels for dispensed medicines
Nu-Seals Aspirin, 5, 25, 32
Nystaform-HC, 28, C, application,
see BNF
Nystan susp (mouth), 9, C, use of
pipette, hold in mouth, after
food
Nystatin susp (mouth), 9, C, use
of pipette, hold in mouth, after
food
Occlusal, 15
Octim, C, fluid intake, see BNF
Oestrogel, C, administration, see
BNF
Ofloxacin, 6, 9, 11, C, driving
Olanzapine tabs, 2
Olanzapine orodispersible tabs,
2, C, administration, see BNF
Olbetam, 21
Olsalazine, 21, C, blood disorder
symptoms, see BNF
Omacor, 21
Omega-3-acid ethyl esters, 21
Omeprazole caps, C, administration, see BNF
Omeprazole tabs, 25
Onbrez Breezhaler, C, administration
Ondansetron oral lyophilisates,
C, administration, see BNF
Onsenal, 21
Opilon, 21
Optimax, 3
Oramorph preps, 2
Oramorph SR, 2, 25
Orap, 2
Orelox, 5, 9, 21
Orphenadrine, C, driving
Orudis caps, 21
Oruvail, 21, 25
Oseltamivir, 9
OsmoPrep, 10, patient information leaflet, C, administration
Osvaren, C, do not crush or chew,
with meals, avoid other drugs
at the same time, see BNF
Oxazepam, 2
Oxcarbazepine, 3, 8, C, see BNF
Oxis, C, administration
Oxprenolol, 8
Oxprenolol m/r, 8, 25
Oxybutynin tabs and elixir, 3
Oxybutynin patch, 3, C, administration, see BNF
Oxycodone caps and liq, 2
Oxycodone m/r, 2, 25
OxyContin, 2, 25
OxyNorm, 2
Oxytetracycline, 7, 9, 23
Paliperidone, 2, 25
Palladone, 2, C, administration,
see BNF
Palladone SR, 2, C, administration, see BNF
Paludrine, 21, C, malaria
prophylaxis, see BNF
Panadol caps, 29, 30

Panadol tabs, 29, 30
Panadol OA tabs, 30
Panadol Soluble, 13, 29, 30
Panadol susp, 30
Pancrease preps, C, administration, see BNF
Pancreatin, C, administration,
see BNF
Pancrex gran, 25, C, dose, see
BNF
Pancrex V Forte tabs, 5, 25, C,
dose, see BNF
Pancrex V caps, 125 caps and pdr,
C, administration, see BNF
Pancrex V tabs, 5, 25, C, dose,
see BNF
Pantoprazole, 25
Paracetamol liq and supps, 30
Paracetamol tabs and caps, 29,
30
Paracetamol tabs, soluble, 13,
29, 30
Paracodol caps, 29, 30
Paracodol effervescent tabs, 13,
29, 30
Paradote, 29, 30
Paramax sachets, 13, 17, 30
Paramax tabs, 17, 30
Pariet, 25
Parlodel, 10, 21, C, driving, see
BNF
Paroxetine tabs, 21, C, driving
Paroxetine susp, 5, 21, C, driving
Pazopanib, 23, 25
PecFent, 2, C, administration, see
BNF
Penbritin, 9, 23
Penicillamine, 6, 22, C, blood
disorder symptoms, see BNF
Pentasa tabs and gran, C,
administration, blood disorder
symptoms, see BNF
Pentasa enema and supps, C,
blood disorder symptoms, see
BNF
Pentazocine caps and tabs, 2, 21
Pentoxifylline m/r, 21, 25
Peppermint oil caps, 5, 22, 25
Percutol, C, administration, see
BNF
Pergolide, 10, C, driving, see BNF
Periactin, 2
Pericyazine, 2
Perindopril, 22
Periostat, 6, 11, 27, C, posture,
see BNF
Permethrin dermal cream, 10,
patient information leaflet
Perphenazine, 2
Persantin, 22
Persantin Retard, 21, 25
Pethidine, 2
Phenelzine, 3, 10, patient information leaflet
Phenergan, 2
Phenindione, 10, anticoagulant
card, 14, (urine pink or orange)
Phenobarbital elixir and tabs, 2,
8, C, driving, see BNF

Appendix 9: Cautionary and advisory labels

Nedocromil sodium inhalation, 8,
C, administration
Nefopam, 2, 14, (urine pink)
Nelfinavir tabs, 21
Neoclarityn, C, driving
Neo-Mercazole, C, blood disorder
symptoms, see BNF
Neo-NaClex-K, 25, 27, C, posture,
see BNF
Neoral, C, administration, see
BNF
Neotigason, 10, patient information leaflet, 11, 21
Nerisone, 28, C, application, see
BNF
Nerisone Forte, 28, application,
see BNF
Neulactil, 2
Neupro, 10, C, driving
Neurontin, 3, 5, 8, C, driving, see
BNF
Nevirapine, C, hypersensitivity
reactions, see BNF
Nexavar, 23
Nexium granules, 25, C, administration
Nexium tabs, C, administration
Niaspan, 21, 25
Nicardipine m/r, 25
Nicorette Inhalator, C, administration, see BNF
Nicorette Microtab, 26
Nicotine (inhaled), C, administration, see BNF
Nicotine (sublingual), 26
Nicotinell lozenges, 24
Nicotinic acid m/r, see preps
Nifedipine m/r, see preps
Nifedipress MR, 25
Niferex elixir, C, infants, use of
dropper
Nilotinib, 23, 25, 27
NiQuitin lozenges, 24
Nitrazepam, 19, (infantile
spasms 1, 8)
Nitrofurantoin, 9, 14, (urine yellow or brown), 21
Nitrofurantoin m/r, 9, 14, (urine
yellow or brown), 21, 25
Nivaquine, 5, C, malaria prophylaxis, see BNF
Nizoral, 5, 9, 21, C, hepatotoxicity
Nootropil, 3
Norfloxacin, 7, 9, 23, C, driving
Normacol preps, 25, 27, C,
administration, see BNF
Normax, 14, (urine red)
Norprolac, 10, 21, C, driving, see
BNF
Nortriptyline, 2
Norvir oral solution, 21, C,
administration, see BNF
Norvir tabs, 21, 25
Noxafil, 3, 9, 21
Nozinan, 2
Nplate, C, driving
Nuelin SA preps, 21, 25
Nurofen for children, 21

967


Appendix 9: Cautionary and advisory labels

968

Appendix 9: Cautionary and advisory labels for dispensed medicines

Phenoxymethylpenicillin, 9, 23
Phenytoin caps and tabs, 8, C,
administration, blood or skin
disorder symptoms, driving,
see BNF
Phenytoin chewable tabs, 8, 24,
C, blood or skin disorder
symptoms, driving, see BNF
Phenytoin susp, 8, C, administration, blood or skin disorder
symptoms, driving, see BNF
Phosex, C, do not chew, with
meals
PhosLo, C, with meals
Phosphate-Sandoz, 13
Phyllocontin Continus, 25
Physeptone, 2
Physiotens, 3
Picolax, 10, patient information
leaflet, 13, C, solution, see BNF
Pilocarpine tabs, 21, 27, C, driving
Pimecrolimus, 4, 28
Pimozide, 2
Pindolol, 8
Piperazine powder, 13
Piracetam, 3
Piriton, 2
Piroxicam caps and tabs, 21
Piroxicam dispersible tabs, 13,
21
Pivmecillinam, 9, 21, 27, C, posture, see BNF
Pizotifen, 2
Plaquenil, 5, 21
Plendil, 25
Podophyllin paint cpd, 15, C,
application, see BNF
Ponstan, 21
Posaconazole, 3, 9, 21
Potaba caps, 21
Potaba Envules, 13, 21
Potassium chloride m/r, see
preps
Potassium citrate mixt, 27
Potassium effervescent tabs, 13,
21
Pradaxa, 25
Pramipexole, 10, C, driving, see
BNF
Pramipexole m/r, 10, 25, C, driving, see BNF
Pravastatin, C, muscle effects,
see BNF
Praxilene, 25, 27
Prazosin, C, initial dose, driving,
see BNF
Prednisolone inj, 10, steroid card
Prednisolone tabs, 10, steroid
card, 21
Prednisolone e/c, 5, 10, steroid
card, 25
Prednisone m/r, 10, steroid card,
21, 25
Pregabalin, 3, 8, C, driving
Preservex, 21
Prestim, 8
Prezista, 21, C, missed dose, see
BNF

BNF 61

Relifex, 21
Relifex susp, 21
Relpax, 3
Remedeine, 2, 29, 30
Remicade, 10, Alert card, C,
tuberculosis and hypersensitivity reactions
Reminyl, 3, 21
Reminyl XL, 3, 21, 25
Renagel, 25, C, with meals
Renvela sachets, 13, C, with
meals
Renvela tabs, 25, C, with meals
Requip, 10, 21, C, driving, see
BNF
Requip XL, 10, 25, C, driving, see
BNF
Resonium A, 13
Restandol, 21, 25
Retapamulin, 28
Retin A, 11
Retrovir oral solution, C, use of
oral syringe
Revlimid, 25, C, symptoms of
thromboembolism, neutropenia, or thrombocytopenia,
patient information leaflet
Revolade, C, other drugs, see BNF
Reyataz, 5, 21
Rhumalgan, 5, 25
Riamet, 21, C, driving
Ribavirin caps, tabs, and solution, 21
Rifabutin, 8, 14, (urine orangered), C, soft lenses
Rifadin, 8, 14, (urine orange-red),
22, C, soft lenses
Rifampicin caps and syrup, 8, 14,
(urine orange-red), 22, C, soft
lenses
Rifater, 8, 14, (urine orange-red),
22, C, soft lenses
Rifinah, 8, 14, (urine orange-red),
22, C, soft lenses
Rilutek, C, blood disorders, drivQuestran preps, 13, C, avoid
ing
other drugs at same time, see
Rimactane, 8, 14, (urine orangeBNF
red), 22, C, soft lenses
Quetiapine, 2
Risedronate sodium, C, adminisQuetiapine m/r, 2, 23, 25
tration, food and calcium, see
Quinagolide, 10, 21, C, driving,
BNF
see BNF
Risperdal liquid, 2, C, use of dose
Qvar preps, 8, C, administration;
syringe
with high doses, 10, steroid
Risperdal orodispersible tabs, 2,
card
C, administration, see BNF
Risperdal tabs, 2
Risperidone liquid, 2, C, use of
Rabeprazole, 25
dose syringe
Raltegravir, 25
Risperidone orodispersible tabs,
Ranexa, 25, patient alert card
2, C, administration, see BNF
Ranitidine effervescent tabs, 13
Ranolazine, 25, patient alert card Risperidone tabs, 2
Ritonavir oral solution, 21, C,
Rapamune, C, administration
administration, see BNF
Rasilez, 21
Ritonavir tabs, 21, 25
Rebetol, 21
Rivastigmine, 21, 25
Reboxetine, C, driving
Regulan, 13, C, administration, Rivotril, 2, 8, C, driving, see BNF
Rizatriptan tabs, 3
see BNF
Rizatriptan wafers, 3, C, adminRegurin, 23
istration
Regurin XL, 23, 25
Priadel liq, 10, lithium card, C,
fluid and salt intake, see BNF
Priadel tabs, 10, lithium card, 25,
C, fluid and salt intake, see BNF
Primidone, 2, 8, C, driving, see
BNF
Pripsen, 13
Pro-Banthine, 23
Probenecid, 12, 21, 27
Procarbazine, 4
Prochlorperazine, 2
Prochlorperazine buccal tabs, 2,
C, administration, see BNF
Procyclidine, C, driving
Progesterone (micronised), C,
administration, see BNF
Prograf, 23, C, driving, see BNF
Proguanil, 21, C, malaria
prophylaxis, see BNF
Progynova TS preps, C, administration, see BNF
Promazine, 2
Promethazine, 2
Propafenone, 21, 25, C, driving
Propantheline, 23
Propiverine hydrochloride, 3
Propiverine hydrochloride m/r, 3,
25
Propranolol oral solution and
tabs, 8
Propranolol m/r, 8, 25
Protelos, 5, 13, C, administration, see BNF
Prothiaden, 2
Protopic, 4, 11, 28
Prozac, C, driving, see BNF
Psorin, 28
Pulmicort, 8, C, administration;
with high doses, 10, steroid
card
Pulmicort Respules, 8, 10, steroid card, C, dose
Pyrazinamide, 8


Sabril sachets, 3, 8, 13, C, driving, see BNF
Sabril tabs, 3, 8, C, driving, see BNF
Salactol, 15
Salagen, 27, C, driving
Salazopyrin EN-tabs, 5, 14, (urine orange-yellow), 25, C, blood disorder symptoms and soft lenses, see BNF
Salazopyrin EA-tabs, 5, 14, (urine orange-yellow), 25, C, blood disorder symptoms and soft lenses, see BNF
Salbutamol inhalations, C, administration
Salicylic acid collodion, 15
Salicylic acid m/r, 25
Salbutamol m/r, 25
Salmeterol, C, administration
Salbutamol syrup, 8, C, blood disorder symptoms, see BNF
Salbutamol tablets, 5, 25, C, blood disorder symptoms, see BNF
Sandrena, C, administration, see BNF
Sando-K, 13, 21
Sandoval, 13
Sandoval +0 preps, 13
Sanofrigo, 2
Sapropotin, 13, 21, C, administration, see BNF
Saquinavir, 21, C, arrhythmias
Sapropterin, 13, 21, C, administration
Sanomigran, 13
Sandocal +D preps, 13
Sandocal, 13
Rupafin, C, driving
Rupatadine, C, driving
Rythmodan Retard, 25
Sabril sachets, 3, 8, 13, C, driving, see BNF
Sabril tabs, 3, 8, C, driving, see BNF
Salactol, 15
Salagen, 21, 27, C, driving
Salamol Easy-Breathe, C, administration
Salaza, 15
Salazopyrin, 14, (urine orange-yellow), C, blood disorder symptoms and soft lenses, see BNF
Salazopyrin EN-tabs, 5, 14, (urine orange-yellow), 25, C, blood disorder symptoms and soft lenses, see BNF
Salbutamol inhalations, C, administration
Salicylic acid collodion, 15
Salicylic acid m/r, 25
Salbutamol m/r, 25
Salmeterol, C, administration
Salbutamol syrup, 8, C, blood disorder symptoms, see BNF
Salbutamol tablets, 5, 25, C, blood disorder symptoms, see BNF
Sandrena, C, administration, see BNF
Sando-K, 13, 21
Sandoval, 13
Sandoval +0 preps, 13
Sanofrigo, 2
Sapropotin, 13, 21, C, administration, see BNF
Saquinavir, 21, C, arrhythmias
Sativex, C, driving, see BNF
Scopoderm TTS, 19, C, administration, see BNF
Sebivo, C, muscle effects
Sodium picosulfate pdr, 10, patient information leaflet, 13, C, see BNF
Sodium valproate e/c, 5, 8, 25, C, blood or hepatic disorder symptoms, driving, see BNF
Sodium valproate m/r and granules, 8, 21, 25, C, blood or hepatic disorder symptoms, driving, see BNF
Sodium valproate crushable tablets, liquid and syrup, 8, 21, C, blood or hepatic disorder symptoms, driving, see BNF
Solian, 2
Solfenacin, 3
Soloris, C, meningococcal infection
Solpadol caps and caplets, 2, 29, 30
Solpadol Effervescent, 2, 13, 29, 30
Solu-Cortef, 10, steroid card
Solu-Medrone, 10, steroid card
Solvazine, 13, 21
Somnите, 19
Sonato, 2
Sorafenib, 23
Sotalol, 8
Spiriva inhalations, C, administration
Spironolactone, 21
Sporanox caps, 5, 9, 21, 25, C, hepatotoxicity
Sporanox liq, 9, 23, C, administration, hepatotoxicity
Sprycel, 25
Stalevo, 10, 14, (urine reddish-brown), C, driving, see BNF
Stavudine, 23
Stelara, 10, C, tuberculosis, see BNF
Stelazine syrup and tabs, 2
Stemetil, 2
Sterculia, C, administration, see BNF
Stilnox, 19
Strattera, 3
Striant SR, C, administration, see BNF
Strontium, 5, 13, C, administration, see BNF
Stugeron, 2
Suboxone, 2, 26
Subutex, 2, 26
Sucralfate, 5
Sulfadiazine, 9, 27
Sulfasalazine, 14, (urine orange-yellow), C, blood disorder symptoms and soft lenses, see BNF
Sulfasalazine e/c, 5, 14, (urine orange-yellow), 25, C, blood disorder symptoms and soft lenses, see BNF
Sulfipyrazone, 12, 21
Sulindac, 21
Sulpiride, 2
Selenium, 2
Selenium, 2
Appendix 9: Cautionary and advisory labels for dispensed medicines

Sulpor, 2
Sumatriptan, 3, 10, patient information leaflet
Sunitinib, 14
Suprax, 9
Supralip, 21
Suprecur, C, nasal decongestants, see BNF
Superfect nasal spray, C, nasal decongestants, see BNF
Surfac tabs, 21
Surgical spirit, 15
Surmontil, 2
Sustiva caps and tabs, 23
Sutent, 14
Symbicort, 8, C, administration; with high doses, 10, steroid card
Symetrel, C, driving
Symalar external preps, 28, C, application, see BNF
Synarel, 10, patient information leaflet, C, nasal decongestants, see BNF
Synflex, 21
Tacrolimus caps, 23, C, driving, see BNF
Tacrolimus granules, 13, 23, C, driving, see BNF
Tacrolimus topical, 4, 11, 28
Tambocor XL, 25
Tamiflu, 9
Tamsulosin m/r, 25, C, driving, see BNF
Tareva, 23
Targionact, 2, 25
Tarivid, 6, 9, 11, C, driving
Tarka, 25
Tasigna, 23, 25, 27
Tasmar, 14, 25
Tavanic, 6, 9, 25, C, driving
Tavegil, 2
Tegretol Chewtabs, 3, 8, 21, 24, C, blood, hepatic or skin disorder symptoms, driving, see BNF
Tegretol liq, supps and tabs, 3, 8, C, blood, hepatic or skin disorder symptoms, driving, see BNF
Tegretol Retard, 3, 8, 25, C, blood, hepatic or skin disorder symptoms, driving, see BNF
Telbivudine, C, muscle effects
Telbivudine, C, see BNF
Telbivudine liq, 14, 25
Teobromine, C, see BNF
Telbivudine tabs, 3, 8, C, see BNF
Temodal, 21
Temgesic, 26
Temodar, 23, 25
Temozolomide, 23, 25
Tenif, 8, 25
Tenafort, 21, C, administration, see BNF
Tenoret 50, 8
Tenoretic, 8
Tenorin, 8
Tenoxicam tabs, 21
Tensipine MR, 21, 25
Terazosin, C, initial dose, driving, see BNF
Terbinafine, 9
Tertubaline inhalations, C, administration
Terbutaline m/r, 25
Testim, C, administration, see BNF
Testogel, C, administration, see BNF
Testosterone buccal tablets, C, administration, see BNF
Testosterone gel, C, administration, see BNF
Testosterone patch, C, administration, see BNF
Testosterone undecanoate caps, 21, 25
Tetrafenazine, 2
Tetraycline, 7, 9, 23, C, posture
Tetrasal preps, 6, 9
Teveten, 21
Thalidomide, 2, C, symptoms of peripheral neuropathy and thromboembolism, see BNF
Thalidomide Pharmorin, 2, C, symptoms of peripheral neuropathy and thromboembolism, see BNF
Theophylline m/r, see preps
Tiagabine, 21
Tiapenac acid tabs, 21
Tilade, 8, C, administration
Tildiem preps, 25
Tiludronic acid, C, food and calcium
Timodine, 28, C, application, see BNF
Timolol, 8
Timolol tabs, 4, 9, 21, 25
Tiotropium inhalations, C, administration
Tiranavir caps, 5, 21
Tiranavir oral solution, 5, 21, C, crystallisation
Tizanidine, 2, 8
Tocilizumab, alert card, C, diverticular perforation, infection, see BNF
Toctino, 10, patient information leaflet, 11, 21
Tolcapone, 13, 29,
Tolcarone, 21
Tolterodine, 3
Tolterodine m/r, 3, 25
Topamax Sprinkle, 3, 8, C, administration, driving, see BNF
Topiramate Sprinkle caps, 3, 8, C, administration, driving, see BNF
Topiramate tabs, 3, 8, C, driving, see BNF
Topotecan, 25
Toradol tabs, 17, 21
Tostran, C, administration
Tracid, 2, 25
Tredaptive, 21, 25
Trental m/r, 21, 25
Tresosulfan, 25
Tretinoin caps, 21, 25
Tretinoin external preps, 11
Triamcinolone inj, 10, steroid card
Triamterene, 14, (urine blue in some lights), 21
Triapin preps, 25
Trientine, 6, 22
Trifluoperazone, 2
Trihexyphenidyl syrup, C, driving, see BNF
Trihexyphenidyl tabs, C, with or after food, driving, see BNF
Trileptal, 3, 8, C, see BNF
Trilostane, 21
Trimethoprim susb and tabs, 9
Trimipramine, 2
Trimopan, 9
Trinovate, 28, C, application, see BNF
Tripotassium dicitratobismuthate, C, administration, see BNF
Triptafen, 2
Trizivir, C, hypersensitivity reactions, see BNF
Tropsium chloride, 23
Trosplum chloride m/r, 23, 25
Truvada, 21, C, administration, see BNF
Tryptophan, 3
Tylex caps, 2, 29, 30
Tylex effervescent tabs, 2, 13, 29, 30
Typhoid vaccine, oral, 23, 25, C, administration, see BNF
Tyverb, 2
Ubretid, 22
Ucerax, 2
Ultralanum Plain, 28, C, application, see BNF
Uniphyltin Continus, 25
Univer, 25
Urdox, 21
Appendix 9: Cautionary and advisory labels for dispensed medicines

Urispas, 3
Ursodeoxycholic acid, 21
Ursogal, 21
Ursodiol, 21
Ustekinumab, 10, C, tuberculosis, see BNF
Utinor, 7, 9, 23, C, driving
Utrogestan, C, administration, see BNF
Valaciclovir, 9
Valcyte, 21
Valganciclovir, 21
Vallergan, 2
Valoid, 2
Valni XL, 25
Valproic acid, see individual preparations
Valtrex, 9
Vancocin caps, 9
Vancomycin caps, 9
Varenicline, 3
Vasran XL, 21, 25, C, initial dose, driving, see BNF
Venlafaxine, 3, C, driving
Venlafaxine m/r, 3, 25, C, driving
Ventmax SR, 25
Ventolin inhalations, C, administration
Vepesid caps, 23
Verapamil m/r, 25
Verapress, 25
Vertab SR, 25
Vesanoid, 21, 25
Vesicare, 3
Vfend, 9, 11, 23
Viazem XL, 25
Vibramycin-D, 6, 9, 11, 13
Victoria, C, administration
Videx e/c caps, 25, C, administration, see BNF
Videx tabs, 23, C, administration, see BNF
Vigabatrin sachets, 3, 8, 13, C, driving, see BNF
Vigabatrin tabs, 3, 8, C, driving, see BNF
Vimovo, 22, 25
Vimpat tabs and syrup, 8, C, driving, see BNF
Vinorelbine caps, 21, 25
Viread, 21, C, administration, see BNF
Vistalix, 5, 22, 25
Visken, 8
Vivotif, 23, 25, C, administration, see BNF
Voltarol dispersible tabs, 13, 21
Voltarol Rapid, 21
Voltarol 75 mg SR and Retard, 21, 25
Voltarol tabs, 5, 25
Voriconazole, 9, 11, 23
Votrient, 23, 25
Warfarin, 10, anticoagulant card
Warticon, 15
Welldorm, 19, 27
Wellvone, 21
Wilzin, 23
Xagrid, C, driving
Xamol, 28
Xanax, 2
Xatral, C, initial dose, driving, see BNF
Xatral XL, 21, 25, C, initial dose, driving, see BNF
Xeloda, 21
Xepin, 2, 10, patient information leaflet
Xismox XL, 25
Xyzal, C, driving
Yentreve, 2
Zaditen, 2, 21
Zafirlukast, 23
Zaleplon, 2
Zamadol, 2
Zamadol 24hr, 2, 25
Zamadol SR, 2, C, administration, see BNF
Zanaflex, 2, 8
Zanidip, 22
Zanocort, 2, 10, patient information leaflet
Zarontin, 8, C, blood disorder symptoms, driving, see BNF
Zavedos caps, 25
Zebinix, 8, C, driving
Zelapar, C, administration, see BNF
Zemcon XL, 25
Zemtard XL, 25
Zerit, 23
Ziagen, C, hypersensitivity reactions, see BNF
Zidovudine oral solution, C, use of oral syringe
Zimbacol XL, 21, 25
Zimovane, 19
Zinc acetate, 23
Zinc sulphate, see preps
Zinnat susp, 9, 21
Zinnat tabs, 9, 21, 25
Zispin SolTab, 2
Zithromax caps, 5, 9, 23
Zithromax susp, 5, 9
Zocor, C, muscle effects, see BNF
Zofran Melt, C, administration, see BNF
Zolmitriptan orodispersible tabs, C, administration, see BNF
Zolpidem, 19
Zomig Rapimelt, C, administration, see BNF
Zomorph, 2, C, administration, see BNF
Zonegran, 3
Zonisamide, 3
Zopiclone, 19
Zoton FosTab, 5, 22, C, administration, see BNF
Zovirax susp and tabs, 9
Zucloventhikol, 2
Zyban, 25, C, driving
Zydo, 2
Zydo soluble tabs, 2, 13
Zydo SR, 2, 25
Zydo XL, 2, 25
Zylolet, 8, 21, 27
Zyprexa tabs, 2
Zyprexa Velotab, 2, C, administration, see BNF
Zyvox susp and tabs, 9, 10, patient information leaflet
## Dental Practitioners’ Formulary

### List of Dental Preparations

The following list has been approved by the appropriate Secretaries of State, and the preparations therein may be prescribed by dental practitioners on form FP10D (GP14 in Scotland, WP10D in Wales).

**Sugar-free** versions, where available, are preferred.

<table>
<thead>
<tr>
<th>Preparation</th>
<th>BP / DPF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir Cream, BP</td>
<td></td>
</tr>
<tr>
<td>Aciclovir Oral Suspension, BP, 200 mg</td>
<td></td>
</tr>
<tr>
<td>Aciclovir Tablets, BP, 200 mg</td>
<td></td>
</tr>
<tr>
<td>Aciclovir Tablets, BP, 800 mg</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin Oral Powder, DPF</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Ampicillin Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Ampicillin Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Artificial Saliva Oral Spray, DPF</td>
<td></td>
</tr>
<tr>
<td>Artificial Saliva Substitutes - AS Saliva Orthana</td>
<td></td>
</tr>
<tr>
<td>Glandosane</td>
<td></td>
</tr>
<tr>
<td>Biotene Oralbalance</td>
<td></td>
</tr>
<tr>
<td>BioXtra</td>
<td></td>
</tr>
<tr>
<td>Saliveze</td>
<td></td>
</tr>
<tr>
<td>Salivix</td>
<td></td>
</tr>
<tr>
<td>Aspirin Tablets, Dispersible, BP</td>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral Suspension, 200 mg/5 mL, DPF</td>
<td></td>
</tr>
<tr>
<td>Beclometasone Pressurised Inhalation, BP, 50 micrograms/metered inhalation, CFC-free, as: Clenil Modulite®</td>
<td></td>
</tr>
<tr>
<td>Benzydamine Mouthwash, BP 0.15%</td>
<td></td>
</tr>
<tr>
<td>Benzydamine Oromucosal Spray, BP 0.15%</td>
<td></td>
</tr>
<tr>
<td>Betamethasone Soluble Tablets, 500 micrograms, DPF</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Carmellose Gelatin Paste, DPF</td>
<td></td>
</tr>
<tr>
<td>Cefalexin Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Cefalexin Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Cefalexin Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Cefradine Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Cetirizine Hydrochloride Tablets, 10 mg, DPF</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Gluconate Gel, BP</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Mouthwash, BP</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Oral Spray, DPF</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Oromucosal Solution, Alcohol-free, 0.2%, DPF</td>
<td></td>
</tr>
<tr>
<td>Chlorphenamine Oral Solution, BP</td>
<td></td>
</tr>
<tr>
<td>Chlorphenamine Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Chlorprothixide Dental Gel, BP</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin Oral Suspension, 125 mg/5 mL, DPF</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin Oral Suspension, 250 mg/5 mL, DPF</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Clindamycin Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Co-amoxiclav Tablets, BP, 250/125 (amoxicillin 250 mg as trihydrate, clavulanic acid 125 mg as potassium salt)</td>
<td>Co-amoxiclav Oral Suspension, BP, 125/31 (amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL</td>
</tr>
<tr>
<td>Co-amoxiclav Oral Suspension, BP, 250/62 (amoxicillin 250 mg as trihydrate, clavulanic acid 6.25 mg as potassium salt)/5 mL</td>
<td>Diazepam Oral Solution, BP, 2 mg/5 mL</td>
</tr>
<tr>
<td>Diazepam Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Diclofenac Sodium Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Dihydrocodeine Tablets, BP, 30 mg</td>
<td></td>
</tr>
<tr>
<td>Dispersible Doxycycline Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Doxycycline Capsules, BP</td>
<td></td>
</tr>
<tr>
<td>Doxycycline Oral Suspension, BP, 20 mg, DPF</td>
<td></td>
</tr>
<tr>
<td>Ephedrine Nasal Drops, BP</td>
<td></td>
</tr>
<tr>
<td>Erythromycin Ethyl Succinate Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Erythromycin Ethyl Succinate Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Erythromycin Stearate Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Erythromycin Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Flucanazole Capsules, 50 mg, DPF</td>
<td></td>
</tr>
<tr>
<td>Flucanazole Oral Suspension, 50 mg/5 mL, DPF</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone Cream, BP, 1%</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone Oromucosal Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Hydrogen Peroxide Mouthwash, BP</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen Oral Suspension, BP, sugar-free</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Lansoprazole Capsules, DPF</td>
<td></td>
</tr>
<tr>
<td>Lidoaine 5% Ointment, DPF</td>
<td></td>
</tr>
<tr>
<td>Lidoaine Spray 10%, DPF</td>
<td></td>
</tr>
<tr>
<td>Loratadine Tablets, 10 mg, DPF</td>
<td></td>
</tr>
<tr>
<td>Menthol and Eucalyptus Inhalation, BP 1980</td>
<td></td>
</tr>
<tr>
<td>Metronidazole Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Metronidazole Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Miconazole Cream, BP</td>
<td></td>
</tr>
<tr>
<td>Miconazole Oromucosal Gel, BP</td>
<td></td>
</tr>
<tr>
<td>Miconazole and Hydrocortisone Cream, BP</td>
<td></td>
</tr>
<tr>
<td>Miconazole and Hydrocortisone Ointment, BP</td>
<td></td>
</tr>
<tr>
<td>Mouthwash Solution-tablets, DPF</td>
<td></td>
</tr>
<tr>
<td>Nitrazeepam Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Nystatin Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Paracetamol Oral Suspension, BP</td>
<td></td>
</tr>
<tr>
<td>Paracetamol Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Paracetamol Tablets, Soluble, BP</td>
<td></td>
</tr>
<tr>
<td>Penciliclov Cream, DPF</td>
<td></td>
</tr>
<tr>
<td>Phenoxymethylpenicillin Oral Solution, BP</td>
<td></td>
</tr>
<tr>
<td>Phenoxymethylpenicillin Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Promethazine Hydrochloride Tablets, BP</td>
<td></td>
</tr>
<tr>
<td>Promethazine Oral Solution, BP</td>
<td></td>
</tr>
<tr>
<td>Saliva Stimulating Tablets, DPF</td>
<td></td>
</tr>
</tbody>
</table>

1. Indications approved by the ACBS are: patients suffering from dry mouth as a result of having (or having undergone) radiotherapy or sicca syndrome
2. The BP directs that when soluble aspirin tablets are prescribed, dispersible aspirin tablets should be dispensed
3. This preparation does not appear in subsequent editions of the BP
4. The BP directs that when Paediatric Paracetamol Oral Suspension or Paediatric Paracetamol Mixture is prescribed and no strength stated Paracetamol Oral Suspension 120 mg/5 mL should be dispensed
Sodium Chloride Mouthwash, Compound, BP
Sodium Fluoride Mouthwash, BP
Sodium Fluoride Oral Drops, BP
Sodium Fluoride Tablets, BP
Sodium Fluoride Toothpaste 0.619%, DPF
Sodium Fluoride Toothpaste 1.1%, DPF
Sodium Fusidate Ointment, BP
Temazepam Oral Solution, BP
Temazepam Tablets, BP
Tetracycline Tablets, BP

Preparations in this list which are not included in the BP or BFC are described under Details of DPF preparations, below

Details of DPF preparations
Preparations on the List of Dental Preparations which are specified as DPF are described as follows in the DPF.
Although brand names have sometimes been included for identification purposes preparations on the list should be prescribed by non-proprietary name.

Amoxicillin Oral Powder (proprietary product: Amoxil) amoxicillin (as trihydrate) 3 g sachet

Artificial Saliva Oral Spray (proprietary product: Xerine) consists of water, sorbitol, carmellose (carboxymethylcellulose), potassium chloride, sodium chloride, potassium phosphate, magnesium chloride, calcium chloride and other ingredients, pH neutral

Azithromycin Oral Suspension 200 mg/5 mL (proprietary product: Zithromax) azithromycin 200 mg/5 mL when reconstituted with water

Betamethasone Soluble Tablets 500 micrograms (proprietary product: Betnesol Soluble Tablets), betamethasone (as sodium phosphate) 500 micrograms

Carmellose Gelatin Paste (proprietary product: Orabase Oral Paste), gelatin, pectin, carmellose sodium, 16.58% of each in a suitable basis

Cetirizine Hydrochloride Tablets cetirizine hydrochloride 10 mg

Chlorhexidine Oral Spray (proprietary product: Corsodyl Oral Spray), chlorhexidine gluconate 0.2%

Chlorhexidine Oromucosal Solution, Alcohol-free, 0.2% (proprietary product: Periogard Oromucosal Solution), chlorhexidine gluconate 0.2%

Clarithromycin Oral Suspension 125 mg/5 mL (proprietary product: Biaxin) clarithromycin 125 mg/5 mL when reconstituted with water

Clarithromycin Oral Suspension 250 mg/5 mL (proprietary product: Biaxin) clarithromycin 250 mg/5 mL when reconstituted with water

Doxycycline Tablets 20 mg (proprietary product: Periostat), doxycycline (as hyclate) 20 mg

Fluconazole Capsules 50 mg (proprietary product: Diflucan) fluconazole 50 mg

Fluconazole Oral Suspension 50 mg/5 mL (proprietary product: Diflucan) fluconazole 50 mg/5 mL when reconstituted with water

Lansoprazole Capsules (proprietary product: Prevacid) lansoprazole 15 mg and 30 mg capsules, enclosing e/c granules

Lidocaine 5% Ointment lidocaine 5% in a suitable basis

Lidocaine Spray 10% (proprietary product: Xylocaine Spray), lidocaine 10% supplying 10 mg lidocaine/spray

Loratadine Tablets loratadine 10 mg

Mouthwash Solution-tablets consist of tablets which may contain antimicrobial, colouring and flavouring agents in a suitable soluble effervescent basis to make a mouthwash suitable for dental purposes

Penciclovir Cream (proprietary product: Vectavir Cream), penciclovir 1%

Saliva Stimulating Tablets (proprietary product: SST), citric acid, malic acid and other ingredients in a sorbitol base

Sodium Fluoride Toothpaste 0.619% (proprietary product: Duraphat ‘2800 ppm’ Toothpaste), sodium fluoride 0.619%

Sodium Fluoride Toothpaste 1.1% (proprietary product: Duraphat ‘5000 ppm’ Toothpaste), sodium fluoride 1.1%

Changes to Dental Practitioners’ Formulary since September 2010

Deletions
Artificial Saliva Liquid, DPF

Changes of title

<table>
<thead>
<tr>
<th>Old</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-amoxiclav Oral Suspension, 125/31</td>
<td>Co-amoxiclav Oral Suspension, BP, 125/31</td>
</tr>
<tr>
<td>(amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL, DPF</td>
<td>(amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL</td>
</tr>
<tr>
<td>Co-amoxiclav Oral Suspension, 250/62</td>
<td>Co-amoxiclav Oral Suspension, BP, 250/62</td>
</tr>
<tr>
<td>(amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL, DPF</td>
<td>(amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL</td>
</tr>
</tbody>
</table>
Nurse Prescribers’ Formulary for Community Practitioners

Nurse Prescribers’ Formulary Appendix (Appendix NPF). List of preparations approved by the Secretary of State which may be prescribed on form FP10P (form HS21(N) in Northern Ireland, form GP10(N) in Scotland, forms WP10CN and WP10PN in Wales) by Nurses for National Health Service patients.

Community practitioners who have completed the necessary training may only prescribe items appearing in the nurse prescribers’ list set out below. Community Practitioner Nurse Prescribers are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved generic name.

Medicinal Preparations

Preparations on this list which are not included in the BP or BPC are described on p. 975

Almond Oil Ear Drops, BP
Arachis Oil Enema, NPF
1 Aspirin Tablets, Dispersible, 300 mg, BP
Bisacodyl Suppositories, BP (includes 5-mg and 10-mg strengths)
Bisacodyl Tablets, BP
Catheter Maintenance Solution, Chlorhexidine, NPF
Catheter Maintenance Solution, Sodium Chloride, NPF
Catheter Maintenance Solution, ‘Solution G’, NPF
Catheter Maintenance Solution, ‘Solution R’, NPF
Chlorhexidine Gluconate Alcoholic Solutions containing at least 0.05%
Chlorhexidine Gluconate Aqueous Solutions containing at least 0.05%
Choline Salicylate Dental Gel, BP
Clotrimazole Cream 1%, BP
Co-danthramer Capsules, NPF
Co-danthramer Capsules, Strong, NPF
Co-danthramer Oral Suspension, NPF
Co-danthramer Oral Suspension, Strong, NPF
Co-danthrusate Capsules, BP
Co-danthrusate Oral Suspension, NPF
Crotamiton Cream, BP
Crotamiton Lotion, BP
Dimeticone barrier creams containing at least 10%
Dimeticone Lotion, NPF
Docusate Capsules, BP
Docusate Enema, NPF
Docusate Oral Solution, BP
Docusate Oral Solution, Paediatric, BP
Econazole Cream 1%, BP

1 Max. 96 tablets; max. pack size 32 tablets

Emollients as listed below:

Aquadrate® 10% w/w Cream
Aqueous Cream, BP
Arachis Oil, BP
Balneum® Plus Cream
Cetraben® Emollient Cream
Dermamist®
Diprobase® Cream
Diprobase® Ointment
Doublebase®
E45® Cream
E45® Itch Relief Cream
Emulsifying Ointment, BP
Eucerin® Intensive 10% w/w Urea Treatment Cream
Eucerin® Intensive 10% w/w Urea Treatment Lotion
Hydromol® Cream
Hydromol® Intensive
2Hydromol® Ointment
Hydrous Ointment, BP
Lipobase®
Liquid and White Soft Paraffin Ointment, NPF
Neutrogena® Norwegian Formula Dermatological Cream
Nutraplus® Cream
Olatum® Cream
Olatum® Junior Cream
Paraffin, White Soft, BP
Paraffin, Yellow Soft, BP
2 QV® Cream
2 QV® Lotion
QV® Wash
Ultrabase®
Unguentum M®
2Zerobase® Cream
2Zerocream®
2Zeroguent® Cream

Emollient Bath Additives as listed below:

1 Balneum®
1 Balneum Plus® Bath Oil
Cetraben® Emollient Bath Additive
Dermalo® Bath Emollient
Diprobase®
Doublebase® Emollient Bath Additive
Doublebase® Emollient Shower Gel
Doublebase® Emollient Wash Gel
Hydromol® Bath and Shower Emollient
Olatum® Emollient
Olatum® Junior Bath Additive
Olatum® Gel
2 QV® Bath Oil
Zerolatum® Emollient Medicinal Bath Oil
2 Zeroneum® Bath Oil
Zeroule® Bath Oil

2 Included in the Drug Tariff (Part IXA)
3 Except pack sizes that are not to be prescribed under the NHS (see Part XVIIIA of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff)
<table>
<thead>
<tr>
<th>BNF 61 Nurse Prescribers’ Formulary</th>
<th>975</th>
</tr>
</thead>
</table>

### Appliances and Reagents (including Wound Management Products)

Community Practitioner Nurse Prescribers in England, Wales and Northern Ireland can prescribe any appliance or reagent in the relevant Drug Tariff. In the Scottish Drug Tariff, Appliances and Reagents which may not be prescribed by Nurses are annotated Nx.

**Appliances** (including Contraceptive Devices) as listed in Part IXA of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 3 (Appliances) and Part 2 (Dressings) of the Scottish Drug Tariff)

**Incontinence Appliances** as listed in Part IXB of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 5 of the Scottish Drug Tariff)

**Stoma Appliances and Associated Products** as listed in Part IXC of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 6 of the Scottish Drug Tariff)

**Chemical Reagents** as listed in Part IXR of the Drug Tariff

Details of NPF preparations

Preparations on the Nurse Prescribers’ Formulary which are not included in the BP or BPC are described as follows in the Nurse Prescribers’ Formulary.

Although brand names have sometimes been included for identification purposes, it is recommended that non-proprietary names should be used for prescribing medicinal preparations in the NPF except where a non-proprietary name is not available.

### Arachis Oil Enema
- arachis oil 100%

### Catheter Maintenance Solution, Chlorhexidine
- proprietary product: *Uro-Tainer Chlorhexidine*, chlorhexidine 0.02%

### Catheter Maintenance Solution, Sodium Chloride
- proprietary products: *Optiflo S*, *Uro-Tainer Sodium Chloride*, *Urifax-S*, sodium chloride 0.9%

### Catheter Maintenance Solution, ‘Solution G’
- proprietary products: *Optiflo G*, *Uro-Tainer Suby G*, *Urifax G*, citric acid 3.23%, magnesium oxide 0.38%, sodium bicarbonate 0.7%, disodium edetate 0.01%

---

1. Except for indications and doses that are
2. Max. 96 tablets; max. pack size 32 tablets

---

**Nurse Prescribers’ Formulary**

**Details of NPF preparations**

Preparations on the Nurse Prescribers’ Formulary which are not included in the BP or BPC are described as follows in the Nurse Prescribers’ Formulary.

Although brand names have sometimes been included for identification purposes, it is recommended that non-proprietary names should be used for prescribing medicinal preparations in the NPF except where a non-proprietary name is not available.

### Arachis Oil Enema
- arachis oil 100%

### Catheter Maintenance Solution, Chlorhexidine
- proprietary product: *Uro-Tainer Chlorhexidine*, chlorhexidine 0.02%

### Catheter Maintenance Solution, Sodium Chloride
- proprietary products: *Optiflo S*, *Uro-Tainer Sodium Chloride*, *Urifax-S*, sodium chloride 0.9%

### Catheter Maintenance Solution, ‘Solution G’
- proprietary products: *Optiflo G*, *Uro-Tainer Suby G*, *Urifax G*, citric acid 3.23%, magnesium oxide 0.38%, sodium bicarbonate 0.7%, disodium edetate 0.01%

---

1. Except for indications and doses that are
2. Max. 96 tablets; max. pack size 32 tablets
Catheter Maintenance Solution, ‘Solution R’
(proprietary products: OptiFlo R; Uro-Tainer Solution R; Ureflex R), citric acid 6%, glucoconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%

Chlorhexidine gluconate alcoholic solutions
(proprietary products: Chloraprep; Hydrex Solution; Hydrex spray), chlorhexidine gluconate in alcoholic solution

Chlorhexidine gluconate aqueous solutions
(proprietary product: Unisept) chlorhexidine gluconate in aqueous solution

Co-danthramer Capsules
co-danthramer 25/200 (dantron 25 mg, poloxamer ‘188’ 200 mg)

Co-danthramer Capsules, Strong
co-danthramer 37.5/500 (dantron 37.5 mg, poloxamer ‘188’ 500 mg)

Co-danthramer Oral Suspension
(proprietary product: Codalax), co-danthramer 25/200 in 5 mL (dantron 25 mg, poloxamer ‘188’ 200 mg/5 mL)

Co-danthramer Oral Suspension, Strong
(proprietary product: Codalax Forte), co-danthramer 75/1000 in 5 mL (dantron 75 mg, poloxamer ‘188’ 1 g/5 mL)

Co-danthrusate Oral Suspension
(proprietary product: Normax), co-danthrusate 50/60 (dantron 50 mg, docusate sodium 60 mg/5 mL)

Dimeticone barrier creams
(proprietary products: Conotrane Cream, dimeticone ‘350’ 22%; Siopel Barrier Cream, dimeticone ‘1000’ 10%; Vasogen Barrier Cream, dimeticone 20%), dimeticone 10–22%

Dimeticone Lotion
(proprietary product: Hedrin), dimeticone 4%

Docusate Enema
(proprietary product: Norgalax Micro-enema) docusate sodium 120 mg in 10 g

Folic Acid Oral Solution 400 micrograms/5 mL
(proprietary product: Folicare), folic acid 400 micrograms/5 mL

Liquid and White Soft Paraffin Ointment
liquid paraffin 50%, white soft paraffin 50%

Macrogol Oral Powder, Compound
macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 g, potassium chloride 46.6 mg/sachet (proprietary products: Movicol, Laxido)

Note Amount of potassium chloride varies according to flavour of Movicol® as follows: plain-flavour (sugar-free) = 50.2 mg/sachet, lime and lemon flavour = 46.6 mg/sachet, chocolate flavour = 31.7 mg/sachet. 1 sachet when reconstituted with 125 mL water provides K+ 5.4 mmol/litre

Macrogol Oral Powder, Compound, Half-strength
(proprietary product: Movicol-Half), macrogol ‘3350’ (polyethylene glycol ‘3350’) 6.563 g, sodium bicarbonate 89.3 g, sodium chloride 175.4 mg, potassium chloride 23.3 mg/sachet

Malathion aqueous lotions
(proprietary products: Derbac-M Liquid), malathion 0.5% in an aqueous basis

Mebendazole Oral Suspension
(proprietary product: Vermox), mebendazole 100 mg/5 mL

Mebendazole Tablets
(proprietary products: Over, Vermox), mebendazole 100 mg

Mouthwash Solution-tablets
consist of tablets which may contain antimicrobial, colouring and flavouring agents in a suitable soluble effervescent basis to make a mouthwash

Nicolotine Inhalation Cartridge for Oro-mucosal Use
(proprietary products: Nicorette Inhalator), nicotine 10 mg

Nicolotine Lozenge
nicotine (as bitartrate) 1 mg or 2 mg (proprietary product: Nicotinell Mint Lozenge) or nicotine (as polacrilax) 2 mg or 4 mg (proprietary product: NiQuitin Lozenges), or nicotine (as resinate complex) 1.5 mg (proprietary product: Nicopass Lozenge)

Nicolotine Medicated Chewing Gum
(proprietary products: Nicorette Gum, Nicotinell Gum, NiQuitin Gum), nicotine 2 mg or 4 mg

Nicolotine Nasal Spray
(proprietary product: Nicorette Nasal Spray), nicotine 500 micrograms/metered spray

Nicolotine Sublingual Tablets
(proprietary product: Nicorette Microtab), nicotine (as a cyclodextrin complex) 2 mg

Nicolotine Transdermal Patches
releasing in each 12 hours, nicotine approx. 5 mg, 10 mg, or 15 mg (proprietary product: Boots NicAssist Patch, Nicorette Patch) or releasing in each 24 hours nicotine approx. 7 mg, 14 mg, or 21 mg (proprietary products: Nicopatch, Nicotinell TTS, NiQuitin)

Permethrin Cream
(proprietary product: Lyclear Dermal Cream), permethrin 5%

Phosphate Suppositories
(proprietary product: Carbalax), sodium acid phosphate (anhydrous) 1.3 g, sodium bicarbonate 1.08 g

Piperazine and Senna Powder
(proprietary product: Prispen Oral Powder), piperazine phosphate 4 g, sennosides 15.3 mg/sachet

Senna Oral Solution
(proprietary product: Senokot Syrup), sennosides 7.5 mg/5 mL

Senna and Ispaghula Granules
(proprietary product: Manevac Granules), senna fruit 12.4%, ispaghula 54.2%

1. For exemption, see p. 415
2. For use with inhalation mouthpiece; to be prescribed as either a starter pack (6 cartridges with inhalator device and holder) or refill pack (42 cartridges with inhalator device)
3. To be prescribed as either a starter pack (2 x 15-tablet discs with dispenser) or refill pack (7 x 15-tablet discs)
4. Prescriber should specify the brand to be dispensed
Sodium Citrate Compound Enema  
(proprietary products: Micolette Micro-enema; Micralax Micro-enema; Relaxit Micro-enema), sodium citrate 450 mg with glycerol, sorbitol and an anionic surfactant.

Sodium Picosulfate Capsules  
(proprietary products: Dulcolax Perles), sodium picosulfate 2.5 mg.

Sodium Picosulfate Elixir  
(proprietary products: Dulcolax Liquid), sodium picosulfate 5 mg/5 mL.

Sterculia Granules  
(proprietary product: Normacol Granules), sterculia 62%.

Sterculia and Frangula Granules  
(proprietary product: Normacol Plus Granules), sterculia 62%, frangula (standardised) 8%.

Zinc Oxide and Dimeticone Spray  
(proprietary product: Sprilon), dimeticone 1.04%, zinc oxide 12.5% in a pressurised aerosol unit.

Zinc Oxide Impregnated Medicated Bandage  
(proprietary product: Steripaste), sterile cotton bandage impregnated with paste containing zinc oxide 15%.

Zinc Oxide Impregnated Medicated Stocking  
(proprietary product: Zipzoc), sterile rayon stocking impregnated with ointment containing zinc oxide 20%.

### Nurse Independent Prescribing

Nurse Independent Prescribers (formerly known as Extended Formulary Nurse Prescribers) are able to prescribe any medicine for any medical condition, including some Controlled Drugs (see below).

Nurse Independent Prescribers must work within their own level of professional competence and expertise. They are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved non-proprietary name.

Nurse Independent Prescribers are also able to prescribe independently the Controlled Drugs in the table below, solely for the medical conditions indicated.

For information on the mixing of medicines by Nurse Independent Prescribers, see Mixing of medicines prior to administration in clinical practice—responding to legislative changes, National Prescribing Centre, May 2010 (available at www.npc.co.uk/policy/mixing/mixing_medicines.htm).

Up-to-date information and guidance on nurse independent prescribing is available on the Department of Health website at www.dh.gov.uk/nonmedicalprescribing.

#### Controlled drugs prescribable by Nurse Independent Prescribers solely for the medical conditions indicated

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine</td>
<td>Transdermal use in palliative care</td>
<td>Transdermal</td>
</tr>
<tr>
<td>Chlordiazepoxide hydrochloride</td>
<td>Treatment of initial or acute withdrawal symptoms caused by the withdrawal of alcohol from persons habituated to it</td>
<td>Oral</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>–</td>
<td>Oral</td>
</tr>
<tr>
<td>Co-phenotrope</td>
<td>–</td>
<td>Oral</td>
</tr>
<tr>
<td>Diamorphine hydrochloride</td>
<td>Use in palliative care, pain relief in respect of suspected myocardial infarction or for relief of acute or severe pain after trauma, including in either case postoperative pain relief</td>
<td>Oral, parenteral, rectal</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Use in palliative care, treatment of initial or acute withdrawal symptoms caused by the withdrawal of alcohol from persons habituated to it, tonic-clonic seizures</td>
<td>Oral, parenteral, rectal</td>
</tr>
<tr>
<td>Dihydrocodeine tartrate</td>
<td>–</td>
<td>Oral</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Transdermal use in palliative care</td>
<td>Transdermal</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>Use in palliative care, tonic-clonic seizures</td>
<td>Oral, parenteral</td>
</tr>
<tr>
<td>Midazolam</td>
<td>Use in palliative care, tonic-clonic seizures</td>
<td>Parenteral, buccal</td>
</tr>
<tr>
<td>Morphine hydrochloride</td>
<td>Use in palliative care, pain relief in respect of suspected myocardial infarction or for relief of acute or severe pain after trauma, including in either case postoperative pain relief</td>
<td>Rectal</td>
</tr>
<tr>
<td>Morphine sulphate</td>
<td>Use in palliative care, pain relief in respect of suspected myocardial infarction or for relief of acute or severe pain after trauma, including in either case postoperative pain relief</td>
<td>Oral, parenteral, rectal</td>
</tr>
<tr>
<td>Oxycodone hydrochloride</td>
<td>Use in palliative care</td>
<td>Oral, parenteral</td>
</tr>
</tbody>
</table>

**Note:** For the purposes of nurse independent prescribing, palliative care means the care of patients with advanced, progressive illness.
Non-medical prescribing

A range of non-medical healthcare professionals can prescribe medicines for patients as either Independent or Supplementary Prescribers.

Independent prescribers are practitioners responsible and accountable for the assessment of patients with previously undiagnosed or diagnosed conditions and for decisions about the clinical management required, including prescribing. They are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved non-proprietary name.

Supplementary prescribing is a partnership between an independent prescriber (a doctor or a dentist) and a supplementary prescriber to implement an agreed Clinical Management Plan for an individual patient with that patient’s agreement.

Independent and Supplementary Prescribers are identified by an annotation next to their name in the relevant professional register.

Up-to-date information and guidance on non-medical prescribing is available on the Department of Health website at www.dh.gov.uk/nonmedicalprescribing.

For information on the mixing of medicines by Independent and Supplementary Prescribers, see Mixing of medicines prior to administration in clinical practice—responding to legislative changes, National Prescribing Centre, May 2010 (available at www.npc.co.uk/policy/mixing/mixing_medicines.htm).

For information on the supply and administration of medicines to groups of patients using Patient Group Directions, see p. 4.

Nurses

For further information on Nurse Independent Prescribing, see Nurse Prescribers’ Formulary, p. 977.

Optometrists

Optometrist Independent Prescribers can prescribe any licensed medicine for ocular conditions affecting the eye and the tissues surrounding the eye, except Controlled Drugs or medicines for parenteral administration. Optometrist Independent Prescribers must work within their own level of professional competence and expertise.

Pharmacists

Pharmacist Independent Prescribers can prescribe any medicine, except Controlled Drugs, for any medical condition. Pharmacist Independent Prescribers must work within their own level of professional competence and expertise.
### Index of manufacturers

The following is an alphabetical list of manufacturers and other companies referenced in the BNF, with their medicines information or general contact details. For information on ‘special-order’ manufacturers and specialist importing companies see p. 988.

#### 3M
- **3M Health Care Ltd**
  - tel: (01509) 611 611

#### A&H
- Allen & Hanburys Ltd
  - See GSK

#### A1 Pharmaceuticals
- A1 Pharmaceuticals Plc
  - tel: (01708) 528 900
  - sales@a1plc.co.uk

#### Abbott
- Abbott Laboratories Ltd
  - tel: (01628) 773 355
  - ukmedinfo@abbott.com
- Abbott Healthcare Products Ltd
  - tel: (023) 8046 7000
  - medinfo.shl@solvay.com

#### Abbott Healthcare
- Abbott Healthcare Products Ltd
  - tel: (023) 8046 7000
  - medinfo.shl@solvay.com

#### Abraxis
- Abraxis BioScience Ltd
  - tel: (020) 7081 0850
  - abraxismedical@idispharma.com

#### ABT Healthcare
- ABT Healthcare UK Ltd
  - tel: (01565) 757 783

#### Acorus
- Acorus Therapeutics Ltd
  - tel: (01244) 625 152
  - enquiries@acorus-therapeutics.com

#### Actavis
- Actavis UK Ltd
  - tel: (01271) 311 257
  - medinfo@actavis.co.uk

#### Actelion Pharmaceuticals UK Ltd
- Actelion Pharmaceuticals UK Ltd
  - tel: (020) 8987 3333
  - medinfo@actelion.com

#### Activa
- Activa Healthcare
  - tel: 0845 060 6707
  - advice@activahealthcare.co.uk

#### ADI Medical
- ADI Medical Ltd
  - tel: (01494) 882 666
  - info@adimedical.co.uk

#### Advancis
- Advancis Medical Ltd
  - tel: (01623) 751 500
  - info@advancis.co.uk

#### Agepha
- Agepha GmbH
  - tel: (020) 3239 6241
  - uk@agepha.com

#### Air Products
- Air Products plc
  - tel: 0800 373 580

#### Alan Pharmaceuticals
- Alan Pharmaceuticals
  - tel: 020 7284 2887

#### Alcon
- Alcon Laboratories (UK) Ltd
  - tel: (01442) 341 234

#### Alexion
- Alexion Pharma UK Ltd
  - tel: (01932) 359 220
  - alexion.uk@alxn.com

#### ALK-Abelló
- ALK-Abelló (UK) Ltd
  - tel: (01488) 686 016
  - info@uk.alk-abellol.com

#### Allergan
- Allergan Laboratories (UK) Ltd
  - tel: (01442) 341 234

#### Allergy Therapeutics
- Allergy Therapeutics Ltd
  - tel: (01903) 844 702

#### Alliance Pharmaceuticals
- Alliance Pharmaceuticals
  - tel: (01248) 466 966
  - info@alliancepharma.co.uk

#### Almirall
- Almirall Ltd
  - tel: 0870 066 4117
  - info@aspenmedical.com

#### Alphashow
- Alphashow Ltd
  - tel: 0870 066 4117
  - info@alphashow.co.uk

#### Altacor
- Altacor Ltd
  - tel: (01223) 421 411
  - info@altacor-pharma.com

#### Amdipharm
- Amdipharm plc
  - tel: 0870 777 7675
  - medinfo@amdipharm.com

#### Archimedes
- Archimedes Pharma UK Ltd
  - tel: (0118) 931 5060
  - medicalinformation@archimedespharma.com

#### Ardana
- Ardana Bioscience Ltd
  - tel: (0131) 226 8550
  - info@ardana.co.uk

#### Ark Therapeutics
- Ark Therapeutics Group Plc
  - tel: (020) 7388 7722
  - info@arktherapeutics.com

#### Aspen
- Aspen Europe GmbH
  - tel: 0049 (4531) 8940 2301
  - medinfoenquiries@pharsafer.com

#### Aspen Medical
- Aspen Medical Europe Ltd
  - tel: (01527) 587 728
  - customers@aspenmedical-europe.com

#### AS Pharma
- AS Pharma Ltd
  - tel: 0870 066 4117
  - info@aspharma.co.uk

#### Aspire
- Aspire Pharma Ltd
  - tel: (01730) 234 327
  - info@aspirepharma.co.uk

#### Astellas
- Astellas Pharma Ltd
  - tel: (01784) 419 615
<table>
<thead>
<tr>
<th>Company</th>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>AstraZeneca UK Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0800 783 0033</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medical.informationuk@astrazeneca.com">medical.informationuk@astrazeneca.com</a></td>
</tr>
<tr>
<td>Auden McKenzie</td>
<td>Auden McKenzie (Pharma Division) Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01895) 627 420</td>
</tr>
<tr>
<td>Axcan</td>
<td>Axcan Pharma SA</td>
</tr>
<tr>
<td></td>
<td>tel: (0033) 130 461 900</td>
</tr>
<tr>
<td>Ayerton Saunders</td>
<td>Ayerton Saunders Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0151) 709 2074</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@ayrtons.com">info@ayrtons.com</a></td>
</tr>
<tr>
<td>Bard</td>
<td>Bard Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01293) 527 888</td>
</tr>
<tr>
<td>Basilea</td>
<td>Basilea Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01483) 790 023</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:ukmedinfo@basilea.com">ukmedinfo@basilea.com</a></td>
</tr>
<tr>
<td>Bausch &amp; Lomb</td>
<td>Bausch &amp; Lomb Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01748) 828 864</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medicalinformationUK@bausch.com">medicalinformationUK@bausch.com</a></td>
</tr>
<tr>
<td>Baxter</td>
<td>Baxter Healthcare Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01635) 206 345</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:surecall@baxter.com">surecall@baxter.com</a></td>
</tr>
<tr>
<td>Bayer Consumer Care</td>
<td>See Bayer Schering</td>
</tr>
<tr>
<td>Bayer Diabetes Care</td>
<td>See Bayer Schering</td>
</tr>
<tr>
<td>Bayer Diagnostics</td>
<td>See Bayer Schering</td>
</tr>
<tr>
<td>Bayer Schering</td>
<td>Bayer Schering Pharma</td>
</tr>
<tr>
<td></td>
<td>tel: (01792) 229 333</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medical.information@bayer.co.uk">medical.information@bayer.co.uk</a></td>
</tr>
<tr>
<td>BBI Healthcare</td>
<td>BBI Healthcare</td>
</tr>
<tr>
<td></td>
<td>tel: (01635) 563 116</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@bbihealthcare.com">info@bbihealthcare.com</a></td>
</tr>
<tr>
<td>Beacon</td>
<td>Beacon Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01892) 600 930</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@beaconpharma.co.uk">info@beaconpharma.co.uk</a></td>
</tr>
<tr>
<td>Beiersdorf</td>
<td>Beiersdorf UK Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0121) 329 8800</td>
</tr>
<tr>
<td>BHR</td>
<td>BHR Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (024) 7635 3742</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@bhr.co.uk">info@bhr.co.uk</a></td>
</tr>
<tr>
<td>Bioenvision</td>
<td>Bioenvision Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0131) 248 3555</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@bioenvision.com">info@bioenvision.com</a></td>
</tr>
<tr>
<td>Biogen</td>
<td>Biogen Idec Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0800 008 7401</td>
</tr>
<tr>
<td>Biolitec</td>
<td>Biolitec Pharma Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (00353) 1463 7415</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medical.info@biolitec.com">medical.info@biolitec.com</a></td>
</tr>
<tr>
<td>BioMarin</td>
<td>BioMarin Europe Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (020) 7420 0800</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:biomarin-europe@bmm.com">biomarin-europe@bmm.com</a></td>
</tr>
<tr>
<td>Biotest UK</td>
<td>Biotest (UK) Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0121) 733 3393</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medicinesinformation@biotestuk.com">medicinesinformation@biotestuk.com</a></td>
</tr>
<tr>
<td>Blackwell</td>
<td>Blackwell Supplies Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01634) 877 620</td>
</tr>
<tr>
<td>BOC</td>
<td>BOC Medical</td>
</tr>
<tr>
<td></td>
<td>tel: 0800 111 333</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Boehringer Ingelheim Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01344) 424 600</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medinfo@bra.boehringer-ingelheim.com">medinfo@bra.boehringer-ingelheim.com</a></td>
</tr>
<tr>
<td>Boots</td>
<td>Boots the Chemists</td>
</tr>
<tr>
<td></td>
<td>tel: (0115) 959 5165</td>
</tr>
<tr>
<td>BPC 100</td>
<td>The Bolton Pharmaceutical 100 Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0845 602 3907</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@bpc100.com">info@bpc100.com</a></td>
</tr>
<tr>
<td>BPL</td>
<td>Bio Products Laboratory</td>
</tr>
<tr>
<td></td>
<td>tel: (020) 8957 2622</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medinfo@bpl.co.uk">medinfo@bpl.co.uk</a></td>
</tr>
<tr>
<td>Braun</td>
<td>B Braun (Medical) Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0114) 225 9000</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info.bbrun@babrun.co.uk">info.bbrun@babrun.co.uk</a></td>
</tr>
<tr>
<td>Bray</td>
<td>Bray Healthcare</td>
</tr>
<tr>
<td></td>
<td>tel: (01367) 240 736</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@bray-healthcare.com">info@bray-healthcare.com</a></td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Bristol-Myers Squibb Pharmaceuticals Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01895) 523 000</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medical.information@bms.com">medical.information@bms.com</a></td>
</tr>
<tr>
<td>Britannia</td>
<td>Britannia Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>tel: 0870 851 0207</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:enquiries@medinformation.co.uk">enquiries@medinformation.co.uk</a></td>
</tr>
<tr>
<td>BSN Medical</td>
<td>BSN Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0845 122 3600</td>
</tr>
<tr>
<td>Casen-Fleet</td>
<td>Casen-Fleet</td>
</tr>
<tr>
<td></td>
<td>tel: (0034) 913 518 800</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:su@casenfleet.com">su@casenfleet.com</a></td>
</tr>
<tr>
<td>C D Medical</td>
<td>C D Medical Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01942) 816 184</td>
</tr>
<tr>
<td>Celgene</td>
<td>Celgene Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0844 801 0045</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medinfo.uk.ire@celgene.com">medinfo.uk.ire@celgene.com</a></td>
</tr>
<tr>
<td>Cephalon</td>
<td>Cephalon Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: 0800 783 4869</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:ukmedinfo@cepalon.com">ukmedinfo@cepalon.com</a></td>
</tr>
<tr>
<td>Chattem UK</td>
<td>Chattem UK Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01256) 844 144</td>
</tr>
<tr>
<td>Chefaro UK</td>
<td>Chefaro UK Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01480) 421 800</td>
</tr>
<tr>
<td>Chemidex</td>
<td>Chemidex Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01784) 477 167</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@chemidex.co.uk">info@chemidex.co.uk</a></td>
</tr>
<tr>
<td>Chiesi</td>
<td>Chiesi Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (0161) 488 5555</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:medinfo@chiesi.uk">medinfo@chiesi.uk</a></td>
</tr>
<tr>
<td>CHS</td>
<td>Cambridge Healthcare Supplies Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01603) 735 200</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:customerservices@typharm.com">customerservices@typharm.com</a></td>
</tr>
<tr>
<td>Chugai</td>
<td>Chugai Pharma UK Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (020) 8867 5680</td>
</tr>
<tr>
<td>Clement Clarke</td>
<td>Clement Clarke International Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01279) 414 969</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:resp@clement-clarke.com">resp@clement-clarke.com</a></td>
</tr>
<tr>
<td>Clinigen</td>
<td>Clinigen Healthcare Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01748) 820 805</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:clinigenuk@professionalinformation.co.uk">clinigenuk@professionalinformation.co.uk</a></td>
</tr>
<tr>
<td>CliniMed</td>
<td>CliniMed Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01628) 535 250</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:enquires@cliniimed.co.uk">enquires@cliniimed.co.uk</a></td>
</tr>
<tr>
<td>Clinisupplies</td>
<td>Clinisupplies Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (020) 8863 4168</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:info@clinisupplies.co.uk">info@clinisupplies.co.uk</a></td>
</tr>
<tr>
<td>Colgate-Palmolive</td>
<td>Colgate-Palmolive Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01483) 392 222</td>
</tr>
<tr>
<td>Coloplast</td>
<td>Coloplast Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (01733) 392 000</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:gbcareteam@coloplast.com">gbcareteam@coloplast.com</a></td>
</tr>
<tr>
<td>Community</td>
<td>Community Foods Ltd</td>
</tr>
<tr>
<td></td>
<td>tel: (020) 8450 9411</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:email@communityfoods.co.uk">email@communityfoods.co.uk</a></td>
</tr>
</tbody>
</table>
Complan Foods
Complan Foods Ltd
tel: (020) 7395 7565

Consilient
Consilient Health UK Ltd
tel: (020) 8956 2310
drugssafety@consilienthealth.com

Convatec
Convatec Ltd
tel: (01895) 628 400

Co-Pharma
Co-Pharma Ltd
tel: 0870 851 0207
copharma@medinformation.co.uk

Covidien
Covidien UK Commercial Ltd
tel: (01329) 224 226

Cow & Gate
Cow & Gate
tel: 0845 762 3624
careline@inpractice.co.uk

Cranage
Cranage Healthcare Ltd
tel: (01477) 549 392
db@cranagehealth.com

Crawford
Crawford Pharmaceuticals
tel: (01565) 654 920

Crucell
Crucell (UK) Ltd
tel: 0844 800 3908
info@crucell.co.uk

CSL Behring
CSL Behring UK Ltd
tel: (01444) 447 400
medinfo@cslbehring.com

Daichi Sankyo
Daichi Sankyo UK Ltd
tel: (01753) 482 771
medinfo@daichisankyo.co.uk

Danetre
Danetre Health Products Ltd
tel: (01327) 310 909
enquiries@danetrehealthproducts.com

DDD
DDD Ltd
tel: (01923) 229 251

Dee
Dee Pharmaceuticals Ltd
tel: (01978) 661953
enquiries@deepharmaceuticals.co.uk

Dental Health
Dental Health Products Ltd
tel: (01622) 749 222

Dentsply
Dentsply Ltd
tel: (01932) 837 279

Dermal
Dermal Laboratories Ltd
tel: (01462) 458 866

Dermatronics
Dermatronics Ltd
tel: (01480) 462 910
sales@dermatronics.co.uk

Derma UK
Derma UK Ltd
tel: (01462) 733 500
info@dermauk.co.uk

DeVilbiss
DeVilbiss Healthcare UK Ltd
tel: (01384) 446 688

Dexcel
Dexcel-Pharma Ltd
tel: (01327) 312 266
office@dexcelpharma.co.uk

DHP Healthcare
DHP Healthcare Ltd
tel: (01622) 749 222
sales@dphhealthcare.co.uk

Dreamskin
Dreamskin Health Ltd
tel: (01727) 668 288
medinfo@dreamskinhealth.co.uk

Dr Falk
Dr Falk Pharma UK Ltd
tel: (01628) 536 600

Drossa
Drossa Ltd
tel: (020) 3393 0859
info@drossa.co.uk

Dubin
Dubin plc
tel: (020) 8869 288
info@dubin.co.uk

Eakin
T G Eakin
tel: (028) 9187 1000
mail@eakin.co.uk

Easigrip
Easigrip Ltd
tel: (01926) 497 108
enquiry@easigrip.co.uk

Ecolab
Ecolab UK
tel: (0113) 232 0066
info.healthcare@ecolab.co.uk

Egis
Egis Pharmaceuticals UK Ltd
tel: (020) 7266 2668
enquiries@medimpexuk.com

Eisai
Eisai Ltd
tel: (020) 8600 1400
lmedinfo@eisai.net

Encysive
Encysive (UK) Ltd
tel: (01895) 876 168
enquiries@encysive.co.uk

Enturia
Enturia Ltd
tel: 0800 043 7546
enquiries@enturia.co.uk

Espere
Espere Healthcare Ltd
tel: (01234) 834 614
info@sperehealth.co.uk

Ethicon
Ethicon Ltd
tel: (01506) 594 500

Eumedica
Eumedica S.A.
tel: (020) 8444 3377
enquiries@eumedica.com

EUSA Pharma
EUSA Pharma (Europe) Ltd
tel: (01438) 740 720
medinfo-uk@eusapharma.com

Everfresh
Everfresh Natural Foods
tel: (01296) 425 333

Fabe
Faber plc
 tel: (01962) 874 435
medicalinformation@pierre-fabre.co.uk

Fenton
Fenton Pharmaceuticals Ltd
tel: (020) 7224 1388
mail@Fent-Pharm.co.uk

Ferdnade
Ferdnade Pharmaceuticals Ltd
tel: (01937) 541 122
info@ferndalepharma.co.uk

Ferring
Ferring Pharmaceuticals (UK)
tel: (01753) 214 800

Firstplay Dietary
Firstplay Dietary Foods Ltd
tel: (0161) 474 7576

Flynn
Flynn Pharma Ltd
tel: (01438) 727 822
medinfo@flynnpharma.com
Index of manufacturers

BNF 61

Insight
Insight Medical Products Ltd
tel: (01666) 500 055
info@insightmedical.net

Intrapharm
Intrapharm Laboratories Ltd
tel: (01622) 749 222
sales@intraphamlabs.com

Ipsen
Ipsen Ltd
tel: (01753) 627 777
medical.information.uk@ipsen.com

Iroko
Iroko Cardio LLC
tel: (001) 267 546 3182

IS Pharmaceuticals
IS Pharmaceuticals Ltd
tel: (01244) 625 152
enquiries@ispharma.plc.uk

IVAX
See TEVA UK

J&J
Johnson & Johnson Ltd
tel: (01628) 822 222
medinfo@congb.jnj.com

Janssen-Cilag
Janssen-Cilag Ltd
tel: (01494) 567 444
medinfo@janssen-cilag.com

Jobskin
Jobskin Ltd
tel: (0115) 973 4300
dw@jobskin.co.uk

Juvela
Juvela (Hero UK) Ltd
tel: (0151) 432 5300
info@juvela.co.uk

K/L
K/L Pharmaceuticals Ltd
tel: (01294) 215 951

Kappin
Kappin Ltd
tel: (020) 8961 8511
orbispv@orbisplc.com

KCI Medical
KCI Medical Ltd
tel: (01865) 840 600

Kestrel Ophthalmics
Kestrel Ophthalmics Ltd
tel: (0202) 658 444
info@kestrolphthalnics.co.uk

King
King Pharmaceuticals Ltd
tel: (01438) 356 924

KoRa
KoRa Healthcare Ltd
tel: 0845 303 8631
info@korael.co.uk

Kyowa Hakko
Kyowa Hakko UK Ltd
tel: (01753) 566 020

Lantor
Lantor UK Ltd
tel: (01204) 855 000
help@lantor.co.uk

LEO
LEO Laboratories Ltd
tel: (01844) 347 333
medical.info.uk@leo-pharma.com

LifeScan
LifeScan
tel: (01494) 658 750

Lilly
Eli Lilly & Co Ltd
tel: (01256) 315 000
ukmedinfo@lilly.com

Lincoln Medical
Lincoln Medical Ltd
tel: (01748) 828 785
info@lincolnmedical.co.uk

Linderma
Linderma Ltd
tel: (01942) 816 184
linderma@virgin.net

Lipomed
Lipomed GmbH
tel: (0049) 776 155 9222
lipomed@lipomed.com

Livwell
Livwell Ltd
tel: 0845 120 0038
info@livwell.eu

Lornamexd
Lornamexd UK Ltd
tel: (01276) 674000
lornamexd@ahl.com

LPC
LPC Pharmaceuticals Ltd
tel: (01582) 580 393
info@lpctpharma.com

Lundbeck
Lundbeck Ltd
tel: (01908) 638 972
ukmedicalinformation@lundbeck.com

M & A Pharmachem
M & A Pharmachem Ltd
tel: (01942) 816 184
buy@mapharmachem.co.uk

Manuka Medical
Manuka Medical Ltd
tel: (01623) 600 669

Index of manufacturers 983

Manx
Manx Healthcare
tel: (01928) 482 511
info@manxhealthcare.com

Marborough
Marborough Pharmaceuticals
tel: (01672) 514 187
info@marborough-pharma.co.uk

Martindale
Martindale Pharma
tel: (01708) 382 793
GMB-Medinfo@martindalepharma.co.uk

MASTA
MASTA
tel: (0113) 238 7500
medical@masta.org

McNeil
McNeil Products Ltd
tel: (01628) 822 222

MDE
Medical Diagnostics Europe Ltd
tel: 0845 370 8077
info@mdediagnostic.co.uk

Mead Johnson
Mead Johnson Nutritionals
tel: (01895) 523 764

Meadow
Meadow Laboratories Ltd
tel: (020) 8597 1203
enquiries@meadowlabs.fsnet.co.uk

Meda
Meda Pharmaceuticals Ltd
tel: (01748) 828 810
meda@professionalinformation.co.uk

Medac
Medac (UK)
tel: (01786) 458 086
info@medac-uk.co.uk

Medicare
Medicare Plus International Ltd
tel: (020) 8810 8811
info@medicare-plus.com

Medicom
Medicom Healthcare Ltd
tel: (01489) 574 119
info@medicomhealthcare.com

Medihoney
Medihoney (Europe) Ltd
tel: 0800 071 3912

Medlock
Medlock Medical Ltd
tel: (0161) 621 2100
medical.information@medlockmedical.com
984 Index of manufacturers

MedLogic
MedLogic Global Ltd
tel: (01752) 209 955
enquiries@mlgl.co.uk

Menarini
A. Menarini Pharma UK SRL
tel: (01628) 856 400
menarini@medinformation.co.uk

Menarini Diagnostics
A. Menarini Diagnostics
tel: (0118) 944 4100

Merck Serono
Merck Serono Ltd
tel: (020) 8818 7200
medinfo.uk@merckserono.net

Merz
Merz Pharma UK Ltd
tel: (020) 8236 0000
info@merzpharma.co.uk

Micro Medical
Micro Medical Ltd
tel: (01634) 893 500
sales@micromedical.co.uk

Milupa
Milupa Aptamil
tel: 0845 762 3676
careline@aptamil4hcps.co.uk

Mölndlycke
Mölndlycke Health Care Ltd
tel: (0161) 777 2628
info.uk@molnlycke.net

Moorfields
Moorfields Pharmaceuticals
tel: (020) 7684 9090

Morningside
Morningside Healthcare Ltd
tel: (0116) 204 5950

Movetis
Movetis
tel: 08000 6683 8470
medical.information@movetis.com

Movianto
Movianto UK
tel: (01234) 248 500
movianto.uk@movianto.com

MSD
Merck Sharp & Dohme Ltd
tel: (01992) 467 272
medicalinformationuk@merck.com

Mylan
Mylan
tel: (01707) 853 000
info@mylan.co.uk

Nagor
Nagor Ltd
tel: (01624) 625 556
enquiries@nagor.com

Napp
Napp Pharmaceuticals Ltd
tel: (01223) 424 444

Neocuticals
Neocuticals Ltd
tel: (01748) 828 865

Neolab
Neolab Ltd
tel: (01256) 704 110
info@neolab.co.uk

Neomedic
Neomedic Ltd
tel: (01923) 836 379
marketing@neomedic.co.uk

Nestlé
Nestlé Nutrition
tel: 08000 6887 4846
nestlehealthcarenutrition@uk.nestle.com

Newport
Newport Pharmaceuticals Ltd
tel: (00353) 1890 3011

Nordic
Nordic Pharma UK Ltd
tel: (0118) 928 8233
info@nordicpharma.co.uk

Norgine
Norgine Pharmaceuticals Ltd
tel: (01895) 826 650

Novartis
Novartis Consumer Health
tel: (01403) 210 211
medicalaffairs.uk@novartis.com

Novartis Vaccines
Novartis Vaccines Ltd
tel: 0845 745 1500
service.uk@novartis.com

Novo Nordisk
Novo Nordisk Ltd
tel: (01293) 613 555
customercareuk@novonordisk.com

nSPIRE Health
nSPIRE Health Ltd
tel: (01992) 526 300
info@nspirehealth.com

Nutricia Clinical
Nutricia Clinical Care
tel: (01225) 711 688
resourcecentre@nutricia.com

Nutrinovo
Nutrinovo Ltd
tel: (01304) 829 068
info@nutrinovo.com

Nutrition Point
Nutrition Point Ltd
tel: (07041) 544 044
nutritionpoint.co.uk

Nycomed
Nycomed UK Ltd
tel: 0800 633 5797
medinfo@nycomed.com

OakMed
OakMed Ltd
tel: 0800 592 786
orders@oakmed.co.uk

Octapharma
Octapharma Ltd
tel: (0161) 837 3770/octapharma@octapharma.co.uk

Omon
Omon Health Care (UK) Ltd
tel: 0870 750 2771
info.omonhealthcare.uk@eu.omon.com

Organon
See MSD

Orion
Orion Pharma (UK) Ltd
tel: (01635) 520 300
medicalinformation@orionpharma.com

Orphan Europe
Orphan Europe (UK) Ltd
tel: (01491) 414 333
infouk@orphan-europe.com

Otsuka
Otsuka Pharmaceutical (UK) Ltd
tel: (020) 8756 3100
medinfo@otsuka.co.uk

Ovation
Ovation Healthcare International Ltd
tel: (00353) 1613 9707

Owen Mumford
Owen Mumford Ltd
tel: (01993) 812 021
customerservices@owenmumford.co.uk

Oxford Nutrition
Oxford Nutrition Ltd
tel: (01628) 832 067
info@nutrinox.com

Paines & Byrne
Paines & Byrne Ltd
tel: (01784) 419 620

Parkside
Parkside Healthcare
tel: (0161) 795 2792

Peckforton
Peckforton Pharmaceuticals Ltd
tel: (01270) 582 255
info@peckforton.com

Penn
Penn Pharmaceuticals Services Ltd
tel: (01495) 711 222
penn@pennpharm.co.uk

Pfizer
Pfizer Ltd
tel: (01304) 616 161
EUMEDINFO@pfizer.com
<table>
<thead>
<tr>
<th>Index of manufacturers</th>
<th>985</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Contact Information</th>
</tr>
</thead>
</table>
| PGR Health Foods | PGR Health Foods Ltd  
  tel: (01992) 581 715  
  info@pgrhealthfoods.co.uk |
| Pharmacia | See Pfizer |
| Pharma-Global | Pharma-Global Ltd  
  tel: (00353) 1280 1104  
  eyecare@pharmaglobal.ie |
| Pharma Mar | See IDS |
| Pharma Nord | Pharma Nord (UK) Ltd  
  tel: (01670) 519 989  
  uksales@pharmanord.co.uk |
| Pharmasure | Pharmasure Ltd  
  tel: (01923) 233 466  
  info@pharmasure.co.uk |
| Pinewood | Pinewood Healthcare  
  tel: (00353) 523 6253  
  info@pinewood.ie |
| Potters | Potters Herbal Medicines  
  tel: (01942) 219 960  
  info@pottersherbals.co.uk |
| Procel | Procel  
  tel: (01226) 713 044  
  admin@procel.co.uk |
| Procter & Gamble | Procter & Gamble (Health and Beauty Care) Ltd  
  tel: (0191) 297 5000 |
| Profile | Profile Pharma Ltd  
  tel: 0800 1300 855  
  info@profiplharma.com |
| ProStrakan | ProStrakan Ltd  
  tel: (01896) 664 000  
  medinfo@prostrakan.com |
| Protes | Protes Healthcare (UK) Ltd  
  tel: 0870 011 4112  
  orders@proteshealthcare.co.uk |
| Ranbaxy | Ranbaxy UK Ltd  
  tel: (020) 8280 1986  
  medinfoeurope@ranbaxy.com |
| Ransom | Ransom Consumer Healthcare  
  tel: (01462) 437 615  
  info@williamransom.com |
| Ratiopharm UK | Ratiopharm UK Ltd  
  tel: (023) 9231 3592  
  info@ratiopharm.co.uk |
| Reckitt Benckiser | Reckitt Benckiser Healthcare  
  tel: (01482) 326 151  
  info.MIU@reckittbenckiser.com |
| Recordati | Recordati Pharmaceuticals Ltd  
  tel: (01491) 576 336  
  medinfo@recordati.co.uk |
| ReSource Medical | ReSource Medical UK Ltd  
  tel: (01484) 531 489  
  info@resourcemedical.co.uk |
| Respironics | Philips Respironics (UK) Ltd  
  tel: 0800 130 0840  
  rukmarketing@respironics.com |
| Richardson | Richardson Healthcare Ltd  
  tel: 0870 011 1126  
  info@richardsonhealthcare.com |
| Riemser | Riemser Arzneimittel AG  
  tel: (0049) 383 517 6679  
  info@RIEMSER.de |
| RIS Products | RIS Products Ltd  
  tel: (01438) 840 135  
  info@risproducts.co.uk |
| Robinsons | Robinsons Healthcare Ltd  
  tel: (01909) 735 064  
  enquiry@robinsonhealthcare.com |
| Roche | Roche Products Ltd  
  tel: 0800 328 1629  
  medinfo.uk@roche.com |
| Roche Diagnostics | Roche Diagnostics Ltd  
  tel: (01444) 256 000  
  burgesshill.accu-chek@roche.com |
| Rosemont | Rosemont Pharmaceuticals Ltd  
  tel: 0800 919 312  
  infodesk@rosemontpharma.com |
| Rosea | Rosea Pharmaceuticals Ltd  
  tel: (00353) 275 0077  
  rosea@rosea-pharma.ie |
| S&N Hlth. | Smith & Nephew Healthcare Ltd  
  tel: (01482) 222 200  
  advice@smith-nephew.com |
| Sallis | Sallis Healthcare Ltd  
  tel: (0115) 978 7841 |
| Sandoz | Sandox Ltd  
  tel: (01275) 698 020  
  sandox@professionalinformation.co.uk |
| Sanofi-Aventis | Sanofi-Aventis Ltd  
  tel: (01483) 555 515  
  uk-medicalinformation@sanofi-aventis.com |
| Sanofi Pasteur | Sanofi Pasteur MSD Ltd  
  tel: (01628) 785 291 |
| Schering-Plough | See MSD |
| Schuco | Schuco International Ltd  
  tel: (020) 8368 1642  
  sales@schuco.co.uk |
| Schülke | Schülke UK  
  tel: (0114) 254 3500  
  mail.uk@schuelke.com |
| Scope Ophthalmics | Scope Ophthalmics Ltd  
  tel: (0161) 266 1011  
  info@scopeophthalmics.com |
| SD Healthcare | SD Healthcare  
  tel: (0161) 776 7626  
  sales@sdhealthcare.com |
| Septodont | Septodont Ltd  
  tel: (01622) 695 520 |
| Servier | Servier Laboratories Ltd  
  tel: (01753) 666 409  
  medical.information@uk.netgrs.com |
| Seven Seas | Seven Seas Ltd  
  tel: (01482) 375 234 |
| Shire | Shire Pharmaceuticals Ltd  
  tel: 0800 055 6614  
  medinfoglobal@shire.com |

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Contact Information</th>
</tr>
</thead>
</table>
| Sallis | Sallis Healthcare Ltd  
  tel: (0115) 978 7841 |
| Sandox | Sandox Ltd  
  tel: (01275) 698 020  
  sandox@professionalinformation.co.uk |
| Sanofi-Aventis | Sanofi-Aventis Ltd  
  tel: (01483) 555 515  
  uk-medicalinformation@sanofi-aventis.com |
| Sanofi Pasteur | Sanofi Pasteur MSD Ltd  
  tel: (01628) 785 291 |
| Schering-Plough | See MSD |
| Schuco | Schuco International Ltd  
  tel: (020) 8368 1642  
  sales@schuco.co.uk |
| Schülke | Schülke UK  
  tel: (0114) 254 3500  
  mail.uk@schuelke.com |
| Scope Ophthalmics | Scope Ophthalmics Ltd  
  tel: (0161) 266 1011  
  info@scopeophthalmics.com |
| SD Healthcare | SD Healthcare  
  tel: (0161) 776 7626  
  sales@sdhealthcare.com |
| Septodont | Septodont Ltd  
  tel: (01622) 695 520 |
| Servier | Servier Laboratories Ltd  
  tel: (01753) 666 409  
  medical.information@uk.netgrs.com |
| Seven Seas | Seven Seas Ltd  
  tel: (01482) 375 234 |
| Shire | Shire Pharmaceuticals Ltd  
  tel: 0800 055 6614  
  medinfoglobal@shire.com |
<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>Telephone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgo</td>
<td>Urgo Ltd</td>
<td>(01509) 502 051</td>
<td><a href="mailto:medical@parema.com">medical@parema.com</a></td>
</tr>
<tr>
<td>Vegenat</td>
<td>c/o Archaelis Ltd</td>
<td>0870 803 2484</td>
<td><a href="mailto:info@vegenat.co.uk">info@vegenat.co.uk</a></td>
</tr>
<tr>
<td>ViV</td>
<td>ViV Healthcare UK Ltd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viridian</td>
<td>Viridian Pharma Ltd</td>
<td>(01633) 400 335</td>
<td><a href="mailto:info@viridianpharma.co.uk">info@viridianpharma.co.uk</a></td>
</tr>
<tr>
<td>Vitaflo</td>
<td>Vitaflo International Ltd</td>
<td>(0151) 709 9020</td>
<td><a href="mailto:vitaflo@vitaflo.co.uk">vitaflo@vitaflo.co.uk</a></td>
</tr>
<tr>
<td>Vitaline</td>
<td>Vitaline Pharmaceuticals UK Ltd</td>
<td>(01844) 269 007</td>
<td><a href="mailto:vitalineinfo@aol.com">vitalineinfo@aol.com</a></td>
</tr>
<tr>
<td>Vitalograph</td>
<td>Vitalograph Ltd</td>
<td>(01280) 827 110</td>
<td><a href="mailto:sales@vitalograph.co.uk">sales@vitalograph.co.uk</a></td>
</tr>
<tr>
<td>Wallace Cameron</td>
<td>Wallace Cameron Ltd</td>
<td>(01698) 354 600</td>
<td><a href="mailto:sales@wallacecameron.com">sales@wallacecameron.com</a></td>
</tr>
<tr>
<td>Wallace Mfg</td>
<td>Wallace Manufacturing Chemists Ltd</td>
<td>(01235) 538 700</td>
<td><a href="mailto:info@alinter.co.uk">info@alinter.co.uk</a></td>
</tr>
<tr>
<td>Warner Chilcott</td>
<td>Warner Chilcott UK Ltd</td>
<td>(01932) 824 700</td>
<td></td>
</tr>
<tr>
<td>WaveSense</td>
<td>WaveSense Europe Ltd</td>
<td>(01235) 838 639</td>
<td><a href="mailto:enquiries@wavesense.co.uk">enquiries@wavesense.co.uk</a></td>
</tr>
<tr>
<td>Wellfoods</td>
<td>Wellfoods Ltd</td>
<td>(01226) 381 712</td>
<td><a href="mailto:wellfoods@talk21.com">wellfoods@talk21.com</a></td>
</tr>
<tr>
<td>Williams</td>
<td>Williams Medical Supplies Ltd</td>
<td>(01665) 844 739</td>
<td></td>
</tr>
<tr>
<td>Winthrop</td>
<td>Winthrop Pharmaceuticals UK Ltd</td>
<td>(01483) 554 101</td>
<td><a href="mailto:winthrop@professionalinformation.co.uk">winthrop@professionalinformation.co.uk</a></td>
</tr>
<tr>
<td>Wallace Mfg</td>
<td>Wallace Manufacturing Chemists Ltd</td>
<td>(01235) 538 700</td>
<td><a href="mailto:info@alinter.co.uk">info@alinter.co.uk</a></td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth Pharmaceuticals</td>
<td>(01628) 604 377</td>
<td><a href="mailto:EUMEDINFO@pfizer.com">EUMEDINFO@pfizer.com</a></td>
</tr>
<tr>
<td>Wynlit</td>
<td>Wynlit Laboratories</td>
<td>(07903) 370 130</td>
<td></td>
</tr>
<tr>
<td>Wyvern</td>
<td>Wyvern Medical Ltd</td>
<td>(01531) 631 105</td>
<td></td>
</tr>
<tr>
<td>Zeroderma</td>
<td>Zeroderma Ltd</td>
<td>(01858) 525 643</td>
<td><a href="mailto:info@ixlpharma.com">info@ixlpharma.com</a></td>
</tr>
<tr>
<td>ZooBiotic</td>
<td>ZooBiotic Ltd</td>
<td>0845 230 1810</td>
<td><a href="mailto:enquiries@zoobiotic.co.uk">enquiries@zoobiotic.co.uk</a></td>
</tr>
</tbody>
</table>
Unlicensed medicines are available from ‘special-order’ manufacturers and specialist-importing companies; the MHRA maintains a register of these companies at http://tinyurl.com/cdslke.

Licensed hospital manufacturing units also manufacture ‘special-order’ products as unlicensed medicines, the principal NHS units are listed below. A database (Pro-File; www.pro-file.nhs.uk) provides information on medicines manufactured in the NHS; access is restricted to NHS pharmacy staff.

The Association of Commercial Specials Manufacturers may also be able to provide further information about commercial companies (www.acsm.uk.com).

The MHRA recommends that an unlicensed medicine should only be used when a patient has special requirements that cannot be met by use of a licensed medicine.

### England

#### London

**Barts and the London NHS Trust**

Mr J. Singh
Production Manager

Barts and the London NHS Trust
Pathology and Pharmacy Building
Royal London Hospital
80 Newark St
Whitechapel
London, E1 2ES.

tel: (020) 3246 0274 (order)
tel: (020) 3246 0399 (enquiry)
jasdeep.singh@bartsandthelondon.nhs.uk

**Guy’s and St. Thomas’ NHS Foundation Trust**

Mr P. Forsey
Associate Chief Pharmacist

Guy’s and St. Thomas’ NHS Foundation Trust
Pharmacy Department
Great Maze Pond
London, SE1 9RT.

tel: (020) 7188 4992 (order)
tel: (020) 7188 5063 (enquiry)
fax: (020) 7188 5013

paul.forsey@gstt.nhs.uk

---

**Moorfields Pharmaceuticals**

Mr N. Precious
Technical Director

Moorfields Pharmaceuticals
34 Nile St
London, N1 7TP.

tel: (020) 7684 9090 (order)
tel: (020) 7684 8574 (enquiry)
fax: (020) 7502 2332
nick.precious@moorfields.nhs.uk

**North West London Hospitals NHS Trust**

Dr K. Middleton
North West London Hospitals NHS Trust
Northwick Park Hospital
Watford Rd
Harrow
Middlesex, HA1 3UJ.

tel: (020) 8869 2295 (order)
tel: (020) 8869 2204/2223 (enquiry)
keith.middleton@nwlh.nhs.uk

**Royal Free Hampstead NHS Trust**

Ms C. Trehan
Production Manager

Royal Free
Pond St
London, NW3 2QG.

tel: (020) 7830 2424 (order)
tel: (020) 7830 2282 (enquiry)
fax: (020) 7794 1875
christine.trehane@nhs.net

**St George’s Healthcare NHS Trust**

Mr V. Kumar
Assistant Chief Pharmacist

ST George’s Hospital
Blackshaw Rd
Tooting
London, SW17 0QT.

tel: (020) 8723 1770/1768
fax: (020) 8723 3947
vinodh.kumar@stgeorges.nhs.uk

**University College Hospital NHS Foundation Trust**

Mr T. Murphy
Production Manager

University College Hospital
235 Euston Rd
London, NW1 2BU.

tel: (020) 7388 9722 (order)
tel: (020) 7388 9472 (enquiry)
fax: (020) 7380 9726
tony.murphy@uclh.nhs.uk

---

**Midlands and Eastern**

**Burton Hospitals NHS Trust**

Mr P. Williams
Pharmacy Technical and Support Services Manager

Pharmacy Manufacturing Unit

Queens Hospital
Burton Hospitals NHS Trust
Belvedere Rd
Burton-on-Trent, DE13 ORB.

tel: (01283) 511 511 (or 566 333) ext: 5115 (order) 5138 (enquiry)
fax: (01283) 593 036
paul.williams@burton-tr.wmids.nhs.uk

**Colchester Hospital University NHS Foundation Trust**

Ms N. Rhodes
Production Manager

Colchester Hospital University NHS Foundation Trust

Turner Rd
Colchester, CO4 5JL.

tel: (01206) 745 962 (order)
tel: (01206) 742 949 (enquiry)
fax: (01206) 841 249
n.nicola.rhodes@colchester.nhs.uk

**Ipswich Hospital NHS Trust**

Dr J. Harwood
Production Manager

Pharmacy Manufacturing Unit

Ipswich Hospital NHS Trust
Heath Rd
Ipswich, IP4 5PD.

tel: (01473) 703 440 (order)
tel: (01473) 703 603 (enquiry)
fax: (01473) 703 698
john.harwood@ipswichhospital.nhs.uk

**Nottingham University Hospitals NHS Trust**

Ms J. Kendall
Assistant Head of Pharmacy, Technical and Logistical Services

Pharmacy Production Units

Nottingham University Hospitals NHS Trust
Queens Medical Centre Campus
Nottingham, NG7 2UH.

tel: (0115) 875 4521 (order)
tel: (0115) 924 9924 ext: 64177 (enquiry)
fax: (0115) 970 9780
jeanette.kendall@nuh.nhs.uk
University Hospital of North Staffordshire NHS Trust
Ms K. Ferguson
Chief Technician
Pharmacy Technical Services
University Hospital of North Staffordshire NHS Trust
City General Site
Stoke-on-Trent, ST4 6QG.
tel: (01782) 552 289 (order)
tel: (01782) 552 290 (enquiry)
fax: (01782) 552 916
caroline.ferguson@uhns.nhs.uk

North East
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Mr Y. Hunter-Blair
Production Manager
Newcastle Specials
Pharmacy Production Unit
Royal Victoria Infirmary
Queen Victoria Rd
Newcastle-upon-Tyne, NE1 4LP.
tel: (0191) 282 0395 (order)
tel: (0191) 282 0389 (enquiry)
fax: (0191) 282 0469
yan.hunter-blair@nuth.nhs.uk

North West
Preston Pharmaceuticals
Ms A. Nutman
Assistant Director of Pharmacy
Preston Pharmaceuticals
Royal Preston Hospital
Fulwood
Preston, PR2 9HT.
tel: (01772) 523 617 (order)
tel: (01772) 522 593 (enquiry)
fax: (01772) 523 645
angela.nutman@lthtr.nhs.uk

Stockport Pharmaceuticals
Mr M. Booth
Principal Pharmacist/Deputy Chief Pharmacist
Stockport Pharmaceuticals
Pharmacy Department
Stepping Hill Hospital
Stockport
Cheshire, SK2 7JE.
tel: (0161) 419 5666 (order)
tel: (0161) 419 5677 (enquiry)
fax: (0161) 419 5426
mike.booth@stockport.nhs.uk

South
Portsmouth Hospitals NHS Trust
Mr R. Lucas
Product Development Manager
Pharmacy Manufacturing Unit
Portsmouth Hospitals NHS Trust
Unit D2, Railway Triangle Industrial Estate
Walton Road
Farlington, Portsmouth
Hampshire, PO6 1TF.
tel: (02392) 389 078 (order)
tel: (02392) 316 312 (enquiry)
fax: (02392) 316 316
robert.lucas@northosp.nhs.uk

North East
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Mr Y. Hunter-Blair
Production Manager
Newcastle Specials
Pharmacy Production Unit
Royal Victoria Infirmary
Queen Victoria Rd
Newcastle-upon-Tyne, NE1 4LP.
tel: (0191) 282 0395 (order)
tel: (0191) 282 0389 (enquiry)
fax: (0191) 282 0469
yan.hunter-blair@nuth.nhs.uk

South East
East Sussex Hospitals NHS Trust
Mr P. Keen
Business Manager
Eastbourne DGH Pharmaceuticals
Eastbourne District General Hospital
East Sussex Hospitals NHS Trust
Kings Drive, Eastbourne
East Sussex, BN21 2UD.
tel: (01323) 414 906 (order)
tel: (01323) 417 400 ext: 3076 (enquiry)
fax: (01323) 414 931
paul.keen@esht.nhs.uk

South West
Torbay PMU
Mr P. Bendell
Pharmacy Manufacturing Services Manager
Torbay PMU
South Devon Healthcare NHS Foundation Trust
Kemmings Close, Long Rd
Paignton
Devon, TQ4 7TW.
tel: (01803) 664 707 (order)
tel: (01803) 664 354 (enquiry)
phil.bendell@nhs.net

Yorkshire
Calderdale and Huddersfield NHS Foundation Trust
Dr S. Langford
Pharmacy Production Director
Pharmacy Manufacturing Unit
Huddersfield Royal Infirmary
Gate 2-Acre Mills, School St
Lindley
Huddersfield, HD3 3ET.
tel: (01484) 355 386 (order)
tel: (01484) 355 371 (enquiry)
fax: (01484) 355 377
stephen.langford@cht.nhs.uk

Northern Ireland
Victoria Pharmaceuticals
Ms C. McBride
Victoria Pharmaceuticals
Belfast Health and Social Care Trust
77 Boucher Crescent
Belfast, BT12 6JU.
tel: (028) 9063 3310 (sterile)
tel: (028) 9055 3407 (non-sterile)
fax: (028) 9032 8972 (sterile)
fax: (028) 9055 3498 (non-sterile)
colettemcbride@belfasttrust.hscni.net

Scotland
NHS Greater Glasgow and Clyde
Mr G. Conkie
Production Manager
Western Infirmary
Dumbarton Rd
Glasgow, G11 6NT.
tel: (0141) 211 2754 (order)
tel: (0141) 211 2882 (enquiry)
fax: (0141) 211 1967
graham.conkie@ggc.scot.nhs.uk

Wales
Cardiff and Vale University Health Board
Mr P. Spark
Principal Pharmacist (Production)
Cardiff and Vale University Health Board
20 Fieldway
Cardiff, CF14 4HY.
tel: (029) 2074 8120
fax: (029) 2074 8130
paul.spark@wales.nhs.uk

BNF 61
Special-order Manufacturers 989
Antibacterials

Antibacterials—Arachis 993

Antidepressants

Antiepileptics

Antimarial drugs

Antineoplastic drugs

Antiviral drugs

Antipsychotics

Antihyperlipidaemics

Antihypertensives

Anticoagulant treatment

Anticoagulants

Anticoagulant treatment

Anticholinesterases

Anticholinergic drugs

Antibiotics

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment

Antibacterial treatment
Aripiprazole

Aspergillosis, 373

5-ASA, 61

Arthritis

Arteritis, giant cell (temporal),

Artemether

Aspart, insulin

Ascorbic acid,

Asmanex

Asmabec

products

Asilone

Ascensia

preparations, 62

AS Saliva Orthana

Arzip

Arythmol

(naproxen), 639

preparations, 635

(ibuprofen), 636

Arthrofen

Aromatase inhibitors, 568

Asthma, 170

acute (table), 173

beta, agonists, 175

chronic (table), 172

emergency treatment, 171

dental practice, 27

exercise-induced, 175

toomial, 175, 176

prophylaxis, 189

Astringents
ear, 685

skin, 742

AT-10, 620

Atarax, 194

Atazanavir, 382, 386

Atevonol, 100

cardiovascular disease

chloraldehyde with, 100

co-amidolaze with, 100

rifampicin with, 100

infusion table, 895

migraine, 277

see also Beta-adrenoceptor

blocking drugs

Athlete's foot, 736

Atinos Modulate, 177

Ativan (lorazepam), 214

Atomoxetine, 245, 246

Atorvastatin

table 162, 163

Atosiban, 489, 490

infusion table, 895

Atovaquone

malaria, 403, 409

pneumocystis pneumonia, 413, 414

progauan with, 410

Atracurium, 788, 789

infusion table, 895

Atracurium products, 937

silver with, 945

Atrial fibrillation, 81, 90, 146

Atrial flutter, 61, 91

Atrazine, 534

Atriplex, 385

Atropine sulphate

anaesthesia, 781, 782

bradycardia, 781

anthoclinesterases and, 791

antispasmodic, 47

beta-blocker poisoning, 37

bradycardia, 91

cardiospulmonary resuscitation, 139

eye, 673

myocardial infarction, 91

organophosphorus poisoning, 41

Aurovent preparations, 180

Attention deficit hyperactivity disorder, 245

Atypical antipsychotics, 222

poisoning by, 38

prolactin elevation, 222

Augmentin preparations, 338

Aureocort, 714

Aurothiomalate, 642

Autoopen, 426

Avanex, 691

Avandamet, 431

Avandia, 431

Avastin, 538

Avaxim, 754

Aveeno preparations, 702, 704

Avelox, 370

Aviva, 438

Aviloxor, 408

Avoca, 730

Avodart, 460

Avoxine, 251

Avonex, 562

Avid, 52

Axorid, 637

Axsain, 665

Azacitidine, 531

Azactam, 346

Azamune (azathioprine), 554

Azarga, 678

Azathioprine, 553

eczema, 721

immunosuppression, 554

inflammatory bowel disease, 60, 65

infusion table, 895

myasthenia gravis, 659

rheumatic disease, 645

thiopurine methyltransferase

testing, 553

transplant rejection, 554

Azelaic acid, 725

Azelastine

eye, 671, 672

nose, 689

Azidothymidine see Zidovudine

Azilect, 304

Azithromycin, 352

trachoma, 667

Azopt, 677

AZT see Zidovudine

Aztreonam, 346

infusion table, 895

Azzalure, 309
Bevacizumab, 537, 538
Bezafibrate, 166, 167
Bezalip preparations, 166, 167
BiaAlimenta products, 927
Biaitan products, 942
silver with, 946
Bicalutamide, 537, 538, 539
Bosantan, 107, 108
Botulinum antitoxin, 751
hyperhidrosis, 745
toxin type A, 309
migraine, 277
toxin type B, 309
Botulism antitoxin, 751
Bowel cleansing preparations, 73
irrigation, 33
sterilisation, 350, 359
Bradycardia, 91
anaesthesia, 781
Bramitob, 351
Bran, 67
Brand names, symbol, 1
Bralisol, 726
Breast cancer, 568
bone metastases, 471
trastuzumab, 552
pain, 482
Breast-feeding
milk, drugs in, 19
prescribing during, 19
Breeze products, 438
Brevibloc, 102
Brevinor, 213
Brezidol, 639
Briconyl preparations, 179
Bridion, 792
Brimodine, 676, 677
timolol with, 677
Brinzanolide, 677
timolol with, 678
BritLofex, 317
Broflex, 307
Brolene, 669
Bromocriptine, 477, 478
acromegaly, 477
galactorrhoea, 677
hypogonadism, 478
lactation suppression, 478
neuroleptic malignant syndrome, 217
Parkinson’s disease, 298, 299
prolactinoma, 478
Bromochlacis, 202
Bronsitis, 202, 324
bronchodilators, 171
Bronchodilators
adrenoceptor agonist, 175
antimuscarinic, 179
surgery, 776
symptomimetic, 175
theophylline, 181
Bromosepam, 175
Brucellosis, 346, 365
Brufen preparations, 636
Brugia malayi, 416
Bruxism, 257
Brymont (brimonidine), 677
BSA, 16
Buccastem, 252
Bucizpine, 261
Buddin Novolizer, 187
Budenofoal, 64
Budesonide
asthma, 184, 187
chronic, 172
formoterol with, 188
autoimmune hepatitis, 64
chronic obstructive airways disease, formoterol with, 188
Cohren’s, 59, 64
croup, 174
inflammatory bowel disease, 59, 64
nasal allergy, 690
polyps, 690
Bug Baster kit, 740
Bumetamide, 86, 87
aminolide with, 89
infusion table, 895
Bupivacaine, 794, 795
adrenaline with, 795
Buprenorphine
intra-operative analgesia, 263
opioid dependence, 314, 315, 316
breast-feeding, 316
naloxone with, 316
pregnancy, 315
pain, 262, 263, 264
palliative care, 21
premedication, 263
supervised consumption, 9
Bupropion, 311
Burinex, 87
Burns, infected, 734
Bucoglan preparations (hyoscine butylbromide), 48
Buserelin
diendrothiosis, 481
in vitro fertilisation, 481
prostate cancer, 571
Buslhex, 524
Buspirone, 215
Busulfan, 523, 524
Busulphan see Busulfan, 523, 524
BuTrans, 264
Butyrophenones, 432
Ciclosporin—Co-fluampicil

999

Ciclosporin

aplastic anaemia, 582
eczma, 721
immunosuppression, 555, 556, 557
infusion table, 895
nephrotic syndrome, 556
psoriasis, 721
rheumatic disease, 645, 646
ulcerative colitis, 59, 65
Cidofovir, 395
infusion table, 895
Cidoxyacin, 351
Cigarette smoking, 311
Cilastatin, imipenem with, 344, 345
infusion table, 898
Clazapril, 117
see also ACE inhibitors
Cilest, 498
Clocostazol, 135, 136
Ciloxan, 668
Citech products, 947
Cimetidine, 51, 52
Cimexia, 852
Cincalacet, 470, 610
Cinchocaine [ingredient], 76
Cinnarizine, 250
dimethyldithizone with, 250
nausea and vertigo, 250
Ciproflox, 241
Ciprofloxacin, 166, 167
Ciprofloxacin, 368, 369
Crohn’s disease, 60
ear, 688
eye, 667, 668
travellers’ diarrhoea, 57
Ciproflox, 369
Circadin, 212
Cisatracurium, 788, 789
infusion table, 895
Cisplatin, 542, 543
Citrapam, 239, 240
Citanest, 798
with Octapressin, 798
CitraFleet, 74
Citramag, 74
Citrabine, 530, 532
Clairette, 727
Clarelux, 711
Clarithromycin, 352, 353
infusion table, 896
Classification changes, xvii
Clasteon, 475
Clavulanic acid, 336
amoxicillin with, 336, 337
infusion table (co-amoxiclav), 896
ticarcillin with, 339, 340
infusion table, 901
Cleanlet Fine, 426
Cleansers, skin, 742
Clearpore, 939
Clemastine, 194
Clenil Modulate, 186
Clexane preparations, 143
CliskSTAR, 426
Climatest, 452

Climanor, 457
Climaval, 454
Climesse, 452
Climadynin, 354, 355
acne, 725
benzoyl peroxide with, 725
infusion table, 896
malaria treatment, 402, 403
oral infections, 354
pneumocystis pneumonia, 413
vaginal infections, 493
ClimiFast, 952
ClimiLite, 953
Clinimix preparations, 603
Clinipak syringe, 427
CliniPlus, 953
Clitipore, 950
Clinsorbid, 944
Clinistat, 437
Clinitox preparations, 680, 681
Clinitek Microalbumin, 437
Clinicest, 437
ClinOleic, 603
Clinorette, 452
Clinuten preparations
nutritional supplement, 913
Clioquinol
ear, 685, 686, 687
skin
betamethasone with, 711
flucinolone with, 713
Clipper, 64
CLL see Leukaemia, chronic lymphocytic, 529
Clobazam
anxiety, 213, 293
epilepsy, 280, 293
Clotobasol propionate, 711, 712
neomycin and nystatin with, 712
Clotobasone butyrate, 712
tetracycline with, 712
Clodronate sodium see Sodium clodronate, 475
Clolarabine, 530, 532
Clolafazine, 366, 367
Clomethasone, 211
alcohol withdrawal, 310
Clomid, 462
Clomifene, 461, 462
Clomiphene see Clomifene, 461, 462
Clomipramine, 234, 235
Clonazepam
epilepsy, 281, 293, 294
status epilepticus, 294, 295
infusion table, 896
Clonidine
hypertension, 110, 111
injection, 288
menopausal flushing, 278, 449
migraine, 277, 278
Tourette syndrome, 307
Clonapamide, 84
pindolol with, 104
Clorpipogrel, 149, 152, 153, 155
Clorazolox, 222, 229
Cloroxol Acuphase, 222
Cloroxol Conc., 229
Cloral betaine, 211
Clostridium botulinum, 751
Clostridium difficile, 60
antibacterial therapy, 323
metronidazole in, 367
vancomycin in, 356
Clostrapid, 274
Clotrimazole
anogenital, 492
ear, 687
skin, 736, 737
betamethasone with, 711
hydrocortisone with, 709
Clozapine, 222, 223, 224
Clozartil, 224
Cluster headache, 278
CMV see Cytomegalovirus
Coal tar, 714, 716, 718, 719
calamine with, 718
dithranol and salicylic acid with, 719
hydrocortisone with, 719
salicylic acid with, 718
scalp, 718, 732, 733
zinc with, 718
Co-amilofruse, 69
Co-amilozide, 89
atenolol with, 100
Co-amoxiclav, 336, 337, 338
infusion table, 896
urinary tract infection, 371
CoAprovel, 122
Cobalin-H (hydroxocobalamin), 581
Coban products, 954, 955
Co-beneldopa, 302, 303
COC see Contraception, oral, combined, 494
Cocaine
poisoning by, 38
Co-careldopa, 303, 304
entacapone with, 304
Cockcroft and Gault formula, 18
Co-codamol preparations, 260, 261
Co-codaprin preparations, 259
Cocuss, 718
Co-cyprindiol, 727
Cod liver oil
zinc oxide with, 706
Codalax preparations, 69
Co-danthramer preparations, 69
Co-danthrusate preparations, 69
Codeine
cough suppressant, 204
diabetic neuropathy, 436
diarrhoea, 58
pain, 263, 264
aspirin with, 259
bucindilene with, 261
palliative care, 20
paracetamol with, 260, 261
Co-Diovan, 124
Codipar, 260
Co-dydroxamol, 261
Coeliac disease, 607
ACBS, 925
Co-fluampicil, 336, 338, 339
infusion table, 896
Cutiplast Steril products, 937
Cutisorb products, 937
Cutivate, 713
C-View, 939
CX Antiseptic Dusting Powder, 743
Cyanides, poisoning by, 39
Cyanocobalamin, 581
Cyanokit, 39
Cyclomorph, 269
Cyclazine, 250, 251
ergotamine and caffeine with, 277
palliative care, 22, 23
Cyclocaps
beclometasone, 186
budesonide, 187
salbutamol, 178
Cyclogest, 458
Cyclohaler
beclometasone, 186
budesonide, 187
salbutamol, 178
Cyclophosphamide, 523, 525
Cyclopenia see Cycloserine, 363
Cycrobin, 458
Crisantaspase, 46
[ingredient], 46
Cromoglicate (Crohn’s disease, 59
Creatinine clearance, dosage and,
Creams
Cramps, nocturnal, 662
Crab lice, 740
Co-zidocapt, 117
Co-covering creams, 732
Co-tenidone, 100
Co-triamterzide, 89
Co-trimoxazole, 359, 360
infusion table, 896
neuromyocystis pneumonia, 413
Cotton
absorbent, 948
gauze, 948
Cough
palliative care, 22
suppressants, 204
Coumarins, 146
Counter-irritants, 664
Coverflex, 952
Covering creams, 732
Covermark preparations, 732
Coversyl preparations, 732
Co-zidocept, 117
Crab lice, 740
Cradle cap, 732
Cramps, nocturnal, 662
Creams
definition, 700
suitable quantities, 701
Creatinine clearance, dosage and, 18
Creon preparations, 79, 80
Crestor, 164
Cretinism see Hypothyroidism, neonatal, 439
Crinone, 458
Crisanatsapase, 540
Crixivan, 387
Crohn’s disease, 59
fistulating, 60
Crohn’s disease, 59
fistulating, 60
Cromoglicate (or cromoglycate) see Sodium cromoglicate
Crotamiton, 706, 707
corticosteroid-induced, 446
Cutaneous larva migrans, 417
Cuticell Classic, 937
Cutimed products
foam, 942
hydrogel, 938
Siltec, 940
Sorbact, 946, 947
Cutinova products, 941
Cytokine modulators
Crohn’s disease, 66
psoriasis, 721
rheumatoid arthritis, 647
ulcerative colitis, 66
Cytomegalovirus infections, 395, 669
Cytotec, 54
Cytotoxic drugs, 518
alopecia, 520
bladder instillation, 513
bone-marrow suppression, 520
dosage, 519
extravasation, 519
handling guidelines, 518
hyperuricaemia, 520
nausea and vomiting, 520
pregnancy, 520
regimens, 518
thromboembolism, 521

D
Didanosine, 382, 384, 385
Darbeperin, 148
Dacarbazine, 540
Daclizumab, 527
Daktacort, 709
Daktarin
oral gel, 696
skin, 738
Dalacin, 355
acne, 725
bacterial vaginosis, 493
Dalivit, 621
Dalmine, 209
Dalfopristin, 141, 142
Dapagliflozin, 143, 144
infusion table, 896
Dapsonex, 480
Dandrazol (ketoconazole), 732
Dandron, 732
Danol, 69
Dantron, 68, 69
Dantron see Dantron, 68, 69
Dantronium, 661
Intravenous, 793
Dantrolene
malignant hyperthermia, 793
muscle spasm, 660, 661
neuroleptic malignant syndrome, 217
Dantron, 68, 69
Dapsone
dermatitis herpetiformis, 366
leprosy, 366
pneumocystis pneumonia, 413
poisoning, elimination, 33
pyrimethamine with, 405
Dapsonex, 357, 358
infusion table, 896
Daraprim, 410
Darbeperin, 582, 583
Darier’s disease, 716
Daripenem, 509
Darunavir, 382, 386, 387
Dasatinib, 544, 546
Daunorubicin, 527, 528
DaunoXome, 528
Daxas, 191
DDAVP preparations, 467, 468
DDI see Didanosine, 382, 383, 384
Deco-Durabolin, 461
Decan, 607
Decapeptyl SR, 482, 572
Dentinox colic drops, 46
Dentomycin, 695
Denture stomatitis, 695
Dentazine, 224
Depakote, 230
Depex XL (venlafaxine), 245
Depolarising muscle relaxants
Depo-Medrone, 448, 641
with Lidocaine, 641
Deporon, 126
Depo-Provera, 501, 502
Depression, 232
antineoplastics, 216
manic, 229
Desloratadine, 191, 780
Depsiphylline, 249
Dexamethasone, 447
Dexamethasone sodium phosphate, 447
Dexametomidine, 245, 246
Dexamethasone see Dexameta- 
mime, 245, 246
Dexedrine—discontinued
Dexfenfluramine, 249
Dexibuprofen, 630, 633
Deximune, 557
Dexketoprofen, 630, 633
Dexmon (diclofenac sodium), 634
Dexrazoxane, 521
infusion table, 896
Dexsol (dexamethasone), 447
Dextran
intravenous infusion, 600, 601
Dextrogel, 28, 435
Dextromethorphan, 204
Dextropropoxyphene, poisoning by, 36
Dextrose monohydrate see Glu-
cose
DFI18 Forte, 265
D-Gam, 773
DHC Continus, 265
diabact UBT, 50
Diabetes insipidus, 466
diagnosis, 466
Diabetes mellitus, 419
diagnosis, 439
monitoring, 421, 437
meters, 438, 439
test strips, 438, 439
Diabetic ketoacidosis, 435, 597, 598
nephropathy, 436
neuropathy, 436
skin ulcers, 745
Diabur Test-5000, 437
Diaconiq, 281
DIAGLYK (gliclazide), 426
Diamicron preparations, 428
Foods for special diets, 607 ACBS, 903
vitamin supplements, 621, 622
Foradil, 177
Forfen (fenfenflaxine), 245 Forceval, 621 Formaldehyde, 729 Formoterol, 176, 177 beclometasone with, 187 budesonide with, 188 Formulary Dental, 972 Nurse, 974 Forsteo, 471 Forticare, 916 Forticreme, 914 Fortijuce, 911 Fortimel, 913 Fortral (pentazocine), 271 Fortum, 343 Fosamax preparations, 472 Fosaprepitant, 249, 255 infusion table, 897 Fosavance, 472 Foscarn, 543 Foscarnet, 392, 395, 396 infusion table, 897 Foscariz, 396 Fosinopril, 118 see also ACE inhibitors Fosphenytoin, 295, 296 infusion table, 897 Status epilepticus, 294 Fosrenol, 612 Fostair, 187 Fosamax preparations, 382, 387 Fosphenytoin, 249, 255 infusion table, 897 Fosamucol, 472 Foscarnet, 392, 395, 396 infusion table, 897 Foscavir, 396 Fosinopril, 118 see also ACE inhibitors Fortimel, 913 Freedom products, 949 Fexofenadine, 426, 438 Fresh frozen plasma, 161 Furaiubin preparations enteral feed, 904, 906, 907, 908 soya formula, 905 nutritional supplement, 912, 915 thickeners, 913 Friars' Balsam, 204 Fristim (clozabam), 293 Frobien preparations, 636 Frova, 274, 275 Fructose, 602, 925 presence of, 2 Frumil (co-amiflurase), 89 Frusol (furmeside), 89 Frusol (furmeside), 86 FSH see Follicle-stimulating hormone, 462 FTC see Entricitabine FTU see Fingertip unit, 708 Lucib, 711
Fucidin, 356 skin, 736 Fucidin H, 710 Fucithalmic, 688 Full Marks solution, 740 Fusidic acid, 356 Fuspin, 412 Furosemide, 66 amiloride with, 89 infusion table, 897 potassium with, 90 spiranolactone with, 89 triamterene with, 89 Fusidic acid, 356 angular cheilitis, 695 eye, 667, 668 infusion table, 897 skin, 734, 736 betaamethasone with, 711 hydrocortisone with, 710 Fusone, 391 Frybogel, 68 Frybogel Mebeverine, 49
Gingivitis, 697
across necrotising ulcerative antibacterial treatment, 328, 367
mouthwashes, 697
Glamin, 603
Glandosane, 698
Glarginine, insulin, see Insulin glargine
Glatiramer, 564
Glucagon, 435, 436
Glycine, 598
Glucose, 598
Glucostat, 603
Glucosamine, 657
Glutafin, 572
Glutamic acid, 23
Glutaarylglycerol, 729
Glutamic aciduria, 929
Glutaric aciduria, 929
Glutarol, 679
Glutaraldehyde, 729
Glutaryl-CoA dehydrogenase, 328
Glutathione, 121, 127
Gluten-sensitive enteropathies, 925
Gluten-free foods, ACBS, 925, 926, 927
bread, 926
flour mixes, 926
Gluten-sensitive enteropathies, 925
Glycerin suppositories, 70
Glycerol
constipation, 69, 70
glaucoma, 677
Glycerol trinitrate
anal fissure, 77
angina, 125, 126
infusion table, 898
Glycine irritation solution, 513
Glycogen storage disease, dietary supplement, 929
Glycopeptide antibiotics, 356
Glycophorin, 607
Glycoprotein IIb/IIIa inhibitors, 547
Glycopyrronium bromide
palliative care, 21, 23
premedication, 781, 782
Glycopyrronium bromide
palliative care, 21, 23
premedication, 781, 782
Glycylcycline antibiotic, 349
Glycoside, 929
Glycylcysteine antibiotic, 349
Glycine
irrigation solution, 671
infusion table, 898
supplement, 929
Griseofulvin, 374, 379
Growth factor, platelet derived, 745
Growth hormone, 464
receptor antagonists, 465
GTN 300-mcg, 126
Guanethidine, 112
Guillain-Barré syndrome, 769
Gygel, 503
GyneFix, 503, 504
Gynest, 491
Gyno-Daktarin preparations, 492, 493
Gyno-Pevaryl preparations, 493, 494
Gynoxin preparations, 493

H
Haem arginate, 627
infusion table, 898
Haemate P (factor VIII fraction), 160
Haemocytin (factor VIII fraction), 160
Haemodialysis, 33
Haemolytic anaemia, 582
G6PD deficiency, 591
Haemolytic disease of newborn, prevention, 772
Haemophilia
blood products, 160
desmopressin, in, 466
Haemophilus influenzae type b (Hib)
immunisation, 753
prophylaxis, 330
vaccines, 753
combined, 752
meningitis with, 754
Haemorrhage, 159
abortion, 486
gastro-intestinal, 51
intracerebral, 151
postpartum, 486
Haemorrhoids, 75
Haemostatics, 159
HAES-steril, 601
Halodol, 219
depot injection, 228
Haleraid, 183
Half-Beta-Propranolol (propranolol), 99
Half-Inderal LA, 99
Half-Securon SR, 134
Half-Stenem CR, 304
HalIBUT-liver oil capsules, 615

Glucophage products, 438
GlucoMen, 439
GlucoGel, 439
Glucobay, 439
GlucaGen HypoKit, 440
Glivec, 441
Gliadel products, 927
Glebe Farm, 928
Glandosane, 698
Glamin, 603
Gingivitis, 697
across necrotising ulcerative antibacterial treatment, 328, 367
mouthwashes, 697
Glamin, 603
Glandosane, 698
Glarginine, insulin, see Insulin glarginine
Glatiramer, 564
Glucagon, 435, 436
Glycine, 598
Glucose, 598
Glucostat, 603
Glucosamine, 657
Glucose
hypoglycaemia, 435
infusion, 598
potassium and, 599
sodium and, 598
intravenous nutrition, 602
oral hydration, 596
presence of, 2
special diets, 929
tests
blood, 437
tolerance, 439
urine, 437
Glucose 6-phosphate dehydrogenase deficiency see G6PD deficiency
Glucose syrup, hydrogenated, presence of, 2
Gluconic acid, 688
Glutamic acid, insulin see Insulin glutamine
Glusarol, 679
Glycosylated haemoglobin, 698

Index
Hydrochlorothiazide—Hypoxaemia

1011

Hydrochlorothiazide, 84
amiloride and timolol with, 104
amiloride with, 89
captopril with, 117
enalapril with, 118
ibresartan with, 122
lisinopril with, 119
losartan with, 123
olmesartan with, 124
valsartan with, 124

Hydrocolloid dressings, 940, 941

Hydrocortisone, 443

Hydrocolloid preparations, 939

Hydrocolloid solutions, 680

Hydrofilm

Hydrocortistab

Hydrocoll

Hydrochlorothiazide, 84
BNF 61

Hydrochlorothiazide—Hypoxaemia

1011

Hydroxyzine, see Hypersensitivity

Hyperphosphataemia, 612

Hyperparathyroidism, 610

Hyperosmolar hyperglycaemic state, 435

Hyperreflexia, 164

Hyperlipidaemia, 161, 162

Hyperkalaemia, 595

Hyperglycaemia, 419

Hypergammaglobulinaemia, 769

Hypoglycaemia, 421, 435

Hypogammaglobulinaemia, 769

Hypothyroidism, 439

Hypothalamic hormones, 462

Hypopituitarism

Hyperparathyroidism, 618

Hyperparathyroidism, see Thyrotoxicosis

Hyperpertensive crises, 106

Hyperthermia

malignant, 793

poisoning and, 33

Hyperthyroidism, see Thyrotoxicosis

Hyperthermia

malignant, 793

poisoning and, 33

Hyperthyroidism, see Thyrotoxicosis

Hyperactive children, 245

Hyperadrenocorticalism, 104

ACE inhibitors, 115

beta-blockers, 98

calcium-channel blockers, 128

crises, 106

diabetes, 106

diuretics, 84

elderly, 105

poisoning and, 32

pregnancy, 106

pulmonary, 107, 145

renal disease, 106

systolic, 105

Hypertensive crises, 106

Hyperventilation, dental practice, 28

Hypomagnesaemia, 610

Hypocalcaemia, 608

Hypodermoclysis, 597

Hypodermoclysis

Starch, 435

Hypoglycaemia

oral, 448

oral and lactacid with, 709

urea with, 709

urea and lactic acid with,

Hypodermic equipment, insulin, 426

Hypodermoclysis, 597

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,

Hypodermic equipment, insulin, 426

Hypoglycaemia

oral, 448

oral and lactacid with,
<table>
<thead>
<tr>
<th>Insulin—analogues, 422</th>
</tr>
</thead>
<tbody>
<tr>
<td>aspart, 422</td>
</tr>
<tr>
<td>biphasic, 423, 425</td>
</tr>
<tr>
<td>detemir, 423, 424</td>
</tr>
<tr>
<td>glargine, 423, 424</td>
</tr>
<tr>
<td>glulisine, 423, 423</td>
</tr>
<tr>
<td>human, 419</td>
</tr>
<tr>
<td>hypodermic equipment, 426</td>
</tr>
<tr>
<td>infusion table, 898</td>
</tr>
<tr>
<td>injection devices, 426</td>
</tr>
<tr>
<td>isophane, 423, 424, 425</td>
</tr>
<tr>
<td>biphasic, 423, 425, 426</td>
</tr>
<tr>
<td>lispro, 422, 423</td>
</tr>
<tr>
<td>biphasic, 423, 425</td>
</tr>
<tr>
<td>protamine zinc, 423, 425</td>
</tr>
<tr>
<td>soluble, 422</td>
</tr>
<tr>
<td>subcutaneous infusion, 420</td>
</tr>
<tr>
<td>zinc suspension, 423, 424</td>
</tr>
<tr>
<td>mixed, 424</td>
</tr>
<tr>
<td>Insulin-like growth factor, 483</td>
</tr>
<tr>
<td>Insulin Basal, 425</td>
</tr>
<tr>
<td>Insulin Comb preparations, 426</td>
</tr>
<tr>
<td>Insulin Rapid, 422</td>
</tr>
<tr>
<td>Insupak, 427</td>
</tr>
<tr>
<td>Intal, 190</td>
</tr>
<tr>
<td>Intanza, 759</td>
</tr>
<tr>
<td>Integril, 153</td>
</tr>
<tr>
<td>Intellece, 390</td>
</tr>
<tr>
<td>Interactions, 800</td>
</tr>
<tr>
<td>Interferon</td>
</tr>
<tr>
<td>alfalfa, 560, 561</td>
</tr>
<tr>
<td>chronic hepatitis B, 397</td>
</tr>
<tr>
<td>chronic hepatitis C, 397</td>
</tr>
<tr>
<td>beta, 561, 562</td>
</tr>
<tr>
<td>gamma, 563</td>
</tr>
<tr>
<td>pegferferon alfalfa, 561</td>
</tr>
<tr>
<td>chronic hepatitis C, 397</td>
</tr>
<tr>
<td>Interferon gamma release assay, 751</td>
</tr>
<tr>
<td>Interleukin-2 see Aldesleukin, 563</td>
</tr>
<tr>
<td>Intermittent claudication, 135</td>
</tr>
<tr>
<td>International nomenclature, cosmetic ingredients see INCI synonyms, 731</td>
</tr>
<tr>
<td>International travel, immunisation for, 773</td>
</tr>
<tr>
<td>Intepose, 937</td>
</tr>
<tr>
<td>Intracerebral haemorrhage, 151</td>
</tr>
<tr>
<td>Intracranial pressure, raised corticosteroids, 443</td>
</tr>
<tr>
<td>palliative care, 22</td>
</tr>
<tr>
<td>thiopteral, 779</td>
</tr>
<tr>
<td>Intralipid preparations, 603</td>
</tr>
<tr>
<td>Intrazite products, 938</td>
</tr>
<tr>
<td>Intratect, 770</td>
</tr>
<tr>
<td>Intra-uterine devices, 503</td>
</tr>
<tr>
<td>copper-bearing, 503, 504, 505</td>
</tr>
<tr>
<td>progestogen-releasing, 502</td>
</tr>
<tr>
<td>Intravenous infusions, 597</td>
</tr>
<tr>
<td>addition to, 892</td>
</tr>
<tr>
<td>Intravenous nutrition, 602</td>
</tr>
<tr>
<td>Intrinis, 459</td>
</tr>
<tr>
<td>Introna, 561</td>
</tr>
<tr>
<td>Invane, 345</td>
</tr>
<tr>
<td>Invega, 225</td>
</tr>
<tr>
<td>Invisrare, 389</td>
</tr>
<tr>
<td>Iocare, 681</td>
</tr>
<tr>
<td>Iodine</td>
</tr>
<tr>
<td>dressings, with, 945</td>
</tr>
<tr>
<td>radioactive, 441</td>
</tr>
<tr>
<td>thyrotoxicosis, 441</td>
</tr>
<tr>
<td>topical, 744</td>
</tr>
<tr>
<td>Iodoflox, 945</td>
</tr>
<tr>
<td>Iodosorb products, 945</td>
</tr>
<tr>
<td>Iodosyme, 945</td>
</tr>
<tr>
<td>topidine, 682</td>
</tr>
<tr>
<td>lpecacuana, poisoning in, 33</td>
</tr>
<tr>
<td>Ipocol, 62</td>
</tr>
<tr>
<td>Isomol (isopropylam with salbutamol), 182</td>
</tr>
<tr>
<td>Isopropylam</td>
</tr>
<tr>
<td>bronchodilation, 180</td>
</tr>
<tr>
<td>fenoterol with, 182</td>
</tr>
<tr>
<td>salbutamol with, 182</td>
</tr>
<tr>
<td>rhinorrhoea, 691, 692</td>
</tr>
<tr>
<td>Isosartan, 121, 122</td>
</tr>
<tr>
<td>hydrochlorothiazide with, 122</td>
</tr>
<tr>
<td>Iressa, 547</td>
</tr>
<tr>
<td>Irinotecan, 550, 551</td>
</tr>
<tr>
<td>Iron</td>
</tr>
<tr>
<td>deficiency, 576</td>
</tr>
<tr>
<td>folic acid and, 577</td>
</tr>
<tr>
<td>overload, 587</td>
</tr>
<tr>
<td>poisoning by, 588</td>
</tr>
<tr>
<td>therapy</td>
</tr>
<tr>
<td>oral, 576, 577, 578</td>
</tr>
<tr>
<td>parenteral, 578, 579, 580</td>
</tr>
<tr>
<td>Iron dextran, 578, 579</td>
</tr>
<tr>
<td>infusion table, 898</td>
</tr>
<tr>
<td>Iron isomaltoside 1000, 578, 579</td>
</tr>
<tr>
<td>infusion table, 898</td>
</tr>
<tr>
<td>Iron sucrrose, 578, 580</td>
</tr>
<tr>
<td>infusion table, 898</td>
</tr>
<tr>
<td>Ionorm, 577</td>
</tr>
<tr>
<td>Irriclen, 743</td>
</tr>
<tr>
<td>Irippod, 743</td>
</tr>
<tr>
<td>Irritable bowel syndrome, 47, 61</td>
</tr>
<tr>
<td>Ischaemic stroke, 151</td>
</tr>
<tr>
<td>Isentress, 592</td>
</tr>
<tr>
<td>Iob 600XL, 127</td>
</tr>
<tr>
<td>Imselin, 112</td>
</tr>
<tr>
<td>Ismo preparations, 127</td>
</tr>
<tr>
<td>Isocarboxazid, 237, 238</td>
</tr>
<tr>
<td>Isodur preparations, 127</td>
</tr>
<tr>
<td>Isoluran, 779, 780</td>
</tr>
<tr>
<td>Isogel, 68</td>
</tr>
<tr>
<td>Isoket preparations, 127</td>
</tr>
<tr>
<td>Isoleucine amino acid supplement, 930</td>
</tr>
<tr>
<td>Isomethyphene, 261</td>
</tr>
<tr>
<td>paracetamol with, 261</td>
</tr>
<tr>
<td>Isoniazid, 361, 362, 364</td>
</tr>
<tr>
<td>Isophane protamine insulin see Insulin, isophane</td>
</tr>
<tr>
<td>Isoplex, 601</td>
</tr>
<tr>
<td>Isoprenaline, 137</td>
</tr>
<tr>
<td>Isopto</td>
</tr>
<tr>
<td>Alkaline, 680</td>
</tr>
<tr>
<td>Plain, 680</td>
</tr>
<tr>
<td>Iosorbide dinitrate, 125, 126, 127</td>
</tr>
<tr>
<td>infusion table, 899</td>
</tr>
<tr>
<td>Iosorbide mononitrate, 125, 127, 128</td>
</tr>
<tr>
<td>Iosource preparations, 904, 907, 910</td>
</tr>
<tr>
<td>Iotard preparations, 127</td>
</tr>
</tbody>
</table>

**Insulin—Kaltostat 1013**

- Isotretinoin
  - acne
    - oral, 724, 728
    - topical, 725, 726
    - erythromycin with, 726
    - rosacea, 724
  - Isetrex, 726
  - Isotrexin, 726
  - Isovarin, 522
  - Isopagel Orange, 68
  - Ispaghula constipation, 68
  - diarrhoea, 58
  - mebeverine with, 49

- Isradipine, 128, 131
  - see also Calcium-channel blockers

- Istin, 129
- Israconazole, 373, 374, 375, 376
  - infusion table, 899
- IUDs see Intra-uterine devices
- IV3000, 939
- IVA Anamix preparations, 930
- Ivabradine, 134
- Ivermectin larva migrans, 417
  - onchocerciasis, 416
  - scabies, 740
  - strongyloidiasis, 417
- Ixaro, 759
- IZS see Insulin, zinc suspension

**J**

- Janumet, 343
- Januvia, 343
- Japanese encephalitis
  - immunisation, 759
  - vaccine, 759
- Javel, 536
- Jelonet, 937
- Jet nebulisers, 184
- Jevity preparations, 904, 907, 908, 909
- Joint prostheses
  - endocarditis prophylaxis, 332
- Joy Rides, 256

**K**

- Kabiven preparations, 603
- Kala-azar, 412
- Kalso, 388
- Kalspare, 89
- Kalten, 100
- Kaltostat products, 943
Leptospirosis—Luteinising 1015

Leptospirosis, 333, 346
Lercanidipine, 128, 131
see also Calcium-channel blockers
Leocol preparations, 163
Letrozole, 568, 570
Leucine amino acid supplement, 931
Leucovorin see Calcium folinate, 521, 522, 580
Leukaemia acute, 526, 530
lymphoblastic, 529, 540, 555
chronic lymphocytic, 529
chronic myeloid, 523, 541, 561
CNS, prophyaxis, 529
haery cell, 561
lymphoid, 582
Leukeran, 525
Leukofax, 950
Leukomed preparations, 927, 939
Leukophor, 950
Leukosil, 950
Leukostrat, 951
Leukotriene receptor antagonists, 190
Leuprolrelin endometriosis, 481
prostate cancer, 571, 572
uterine fibroids, 480
Leuotir, 532
Levacet, 524
Levamisole, 416
Levemir preparations, 424
Levext, 498
Levetracetam epilepsy, 280, 287
infusion table, 899
Levitra, 517
Levobunolol, 674
Levobupivacaine, 795, 796
Levocetirizine, 191, 193
Levodopa, 302
benserazide with, 302, 303
carbidopa with, 302, 303, 304
and entacapone with, 304
Levofloxacine, 368, 370
eye, 667, 668
Levofolinic acid, 522
Levomenthol cream, 707
Levomepromazine, 220
nausea and vertigo, 249
palliative care, 21, 22, 23
psychosis, 520
Levone 1500, 505
Levonelle One Step, 505
Levonorgestrel, 502, 505
contraception, 501
emergency, 505
ethinylestradiol with, 498, 499
intra-uterine, 503
HRT estradiol with, 453
Levohydroxyine, 439, 440
Loper (folic acid), 581
LH see Luteinising hormone, 462
LH-RH see Gonadotropin, 466
Librium (chloridiazepoxide), 214
Lice, 740
Lidocaine
arrhythmias, 96, 97
local anaesthesia, 796, 797
adrenaline with, 796
dental, 794, 796
eye, fluorescein with, 679
haemorrhoids, 76, 77
mouth, 694, 695
neuropathic pain, 273
5% ointment—discontinued
phenylephrine with, 797
postherpetic neuralgia, 797
prilocaine with, 797
rectal, 75
Lifestyle products, 926
Lignocaine see Lidocaine
Lignospan Special, 796
Li-Liquid, 232
Linezolid, 358, 359
Linola Gamma—discontinued
Lint, absorbent, 948
Lioresal, 660
Lothrynine, 440
Lipamit preparations, 167
Lipidem preparations, 603
Lipid-regulating drugs, 161
Lipitor, 163
Lipobase, 703
Lipodystrophy syndrome, 382
Lipofundin preparations, 603
Lipopeptide antibiotic, 357
Liposic, 680
Lipostat, 164
Liquibond, 742
Liquid and White Soft Paraffin Ointment, 702
Liquid paraffin constipation, 70, 71
emulsion, 71
magnesium hydroxide and, 72
eye, lubricant, 680
Liquifilm Tears, 681
Liquigen, 921
Liquivis, 680
Liraglutide, 431, 433
Liscostad preparations, 119
Lisinopril, 118, 119
hydrochlorothiazide with, 119
see also ACE inhibitors
Liskonom, 231
Lispro, insulin see Insulin lispro
Litok, 532
Lithium
cluster headache, 278
mania, 230
poisoning by, 38
resistant depression, 230, 233
surgery, 776
Lithium carbonate, 231
Lithium citrate, 232
Lithobon (lithium carbonate), 231
Liver disease, prescribing in, 17
Livial, 455
Lowell products, 926
LMX 4, 796
Loo loa, 416
Load 375, 504
Local anaesthetics see Anaesthesia, local
Loceryl, 737
cream—discontinued
Locorin preparations, 710
Locorin-Vioform, 686
Lodine, 635
Lodota, 448
Lodoxamide, 671, 672
Loestrin preparations, 496
Lofepramine, 234, 236
Lofexidine, 317
Lognon preparations, 499
Lomont (lofepramine), 236
Lomitol, 58
Lomustine, 524, 525, 526
Lontien, 109
Loop diuretics see Diuretics, loop, 86
Loperamide, 58, 59
palliative care, 21
Lophlex preparations, 931, 932
Lopid, 168
Lopinavir, 382, 387
ritonavir with, 388
Loprazolam, 206, 209
Lopresor preparations, 102, 103
Loprofin products, 928
PKU drink, 931
Loramyc, 696
Loratadine, 191, 193
Lorazepam
anaesthesia, 783, 784
anxiety, 213, 214
nausea and vomiting, 520
status epilepticus, 294, 296
Lormetazepam, 208, 209
Loron, 475
Losartan, 121, 122, 123
hydrochlorothiazide with, 123
Losec, 56
Lotemax, 671
Lopetrednol, 671
Lotions
definition, 701
eye, 666
suitable quantities, 701
Lotrimex, 711
Low sodium content (antacids), 44
Low-protein foods, 928
Low-protein foods, ACBS, 928
Lp-drink, 931
LSD see Lysergide, 9
Lucanthone, 416
Lucents, 683
Lugol’s solution see Aqueous iodine oral solution, 441
Lumecare preparations, 680
Lumefantrine, 403, 407
artemether with, 407
Lumigan, 675
Lupus erythematosus discoid, 642
systemic, 443, 641, 642, 645
Lustral, 242
Luteinising hormone, 462
Memantine—Micolette 1017

Memantine, 318, 319
Menadione sodium phosphate, 621
Mendelson’s syndrome, 51, 776
Meniere’s disease, 250
Meningeal carcinoma, 529
Meningitec, 762
Meningitis cryptococcal, 373
haemophilus, 325
immunisation, 761
Hib with, 754
vaccine, 762
initial therapy, 325
lateral, 325
meningococcal, 325
prophylaxis, 330
travel, 761, 774
pneumococcal, 325
Meningococcal see Meningitis
Menitorix, 754
Menjugate, 762
Menopausal symptoms, 278, 449
Menopur, 464
Mepore preparations, 48
Meptid products, 940
silver with, 946
Meptazinol, 263, 267
Mepacrine, 267, 268
cough, 205
linctus, 205
opiod dependence, 314, 315, 316
breast-feeding, 316
pregnancy, 315
oral solutions, 316
pain, 263, 267
palliative care, 20
parenteral, 316
poisoning by, 36
supervised consumption, 9
Methodone, 316
Methaemoglobinemia, treatment of, 797
Methanol, poisoning by, 40
Methadone products, 940
Mepivacaine, 794, 797
Mepore products, 937, 939
Mepradec (omeprazole), 56
Meprobamate, 215
muscle spasm, 662
Meptal, 263, 267
Meptid, 267
Merbentyl preparations, 48
Mercaptamine (cysteamine), 625
Mercaptopurine
inflammatory bowel disease, 59, 60, 65
malignant disease, 531, 533
6-Mercaptopurine see Mercapto-
urine
Mercuron, 498
Merional, 463
Meronem, 346
Meropenem, 344, 346
infusion table, 899
Mesalazine, 59, 61, 62
Mesitran products, 944, 945
Mesna, 523
Mesorbo, 937
Mevor MR, 62
Mesterolone, 460
Mestinon, 659
Mestranol, norethisterone with, 498
Metabet SR, 430
Metabolic acidosis, 599
Metabolic Mineral Mixture, 924
Metals, poisoning by, 40
Metalyse, 158
Metanil, 706
Metaraminol, 138
infusion table, 899
Metatrauron (strontium), 20
Methadose
Metanil
Metabolism clonidine, 281
Mecysteine, 203
Methyl alcohol, 40
Mecysteine, 203
Methyl alcohol poisoning by, 40
Methadone (methadone), 316
Methacetate, 368
Crohn’s disease, 59, 65
malignant disease, 529, 533, 534
psoriasis, 721, 722
rheumatic disease, 642, 645, 647
Methotrimeneprazime see Levome-
pramine
Methoxy polyethylene glycol-
epoetin beta, 582, 586
Methyl alcohol see Methanol, 40
Methyl alcohol see Methanol, 40
Methyl cysteine see Mecysteine, 203
Methyl salicylate, 743
dithranol and salicylic acid
with, 719
Methyl-s-aminolevulinate, 731
Methylated spirit, industrial, 742
Methylcellulose
constipation, 68
diarrhoea, 58
obesity, 248
Methyldopa, 110, 111
Methylene blue see Methylthioni-
urn chloride, 797
Methylenedioxyethamfetamine
controlled drug, 8
poisoning by, 39
Methylprednisolone, 448
lidocaine with, 641
rheumatic disease, 641
Methylprednisolone acetate, 448
Methylprednisolone sodium succinate, 448
infusion table, 899
Methylthioninium chloride, 797
Methyserydine, 277, 278
cluster headache, 278
Meticillin-resistant Staphylococ-
cus aureus see MRSA
Metipranol, 674, 675
Metirosine, 113
Metoclopramide
diabetic neuropathy, 436
gastro-intestinal, 49
hiccup, palliative care, 22
infusion table, 899
migraine, 277
aspirin with, 259
paracetamol with, 261
nausea and vomiting, 249, 253, 254
cytotoxic drugs, 520
palliative care, 22, 23
pregnancy, 250
Metoject, 647
Metolazone, 84, 85
Metopirone, 483
Metoprolol, 102, 103
migraine, 277
see also Beta-adrenoceptor blocking drugs
Metrosyn, 713
Metrogel, 736
Metrol, 368
Metronidazole, 367, 368
amoebiasis, 411
Crohn’s disease, 60
giardiasis, 412
protozoal infections, 412
skin, 735, 736
fungating tumours, 22
trichomoniasis, 412
ulcerative gingivitis, 367, 695
vaginal infections, 493
Metrosa, 736
Metrotrop, 736
Metsol (metformin), 430
Metvix, 731
Metyrapone, 482, 483
Mexiletine, 94, 97
Mezavant XL, 62
Mezolar (fentanyl), 267
Miucalcic, 471
Mianserin, 234, 237
Micafungin, 374, 378, 379
infusion table, 899
Micanol, 719
Miconard preparations, 123, 124
Micolette Micro-enema, 72
Miconazole
mouth, 695, 696
palliative care, 22
skin, 736, 737, 738
hydrocortisone and, 709
vaginal, 492
Microlax
Micron—mouthwashes BNF 61

Minims
Artificial Tears, 880
Atropine Sulphate, 673
Chloramphenicol, 668
Cyclopentolate, 673
Dexamethasone, 670
Fluorescein Sodium, 681
Lidocaine and Fluorescein, 679
Metipranolol, 675
Oxybuprocaine, 679
Phenylephrine, 674
Pilocarpine Nitrate, 679
Prednisolone, 671
Proxymetacaine, 679
Proxymetacaine and Fluorescein, 679
Saline, 681
Tetracaine, 679
Tropicamide, 673

MintQuick, 465
Minitrans, 126
Minivert, 743

Minocin, 349
Minocycline, 347, 348
acne, 727
preparations, 348, 349

Minoxidil
androgenetic alopecia, 734
hypertension, 107, 109
scalp, 733

Mintec, 49
Mibetol, 682
Miphel, 682
Miraexpin preparations, 300
Mircera, 586
Mirena, 502, 503
Mirtazapine, 242, 243, 244
Macariage, recurrent, 456
Misoprostol, 54
diclofenac with, 635
naproxen with, 639
obstetrics, 485

Misuse of drugs
Act, 8
Regulations 2001, 8
Mibromitol, 524
Mitomycin, 527, 528
bladder, 513

Mitomycin C Kyowa, 528
Mitotan, 541
Mitoxyantrone, 527, 529
Mitoxyantrone see Mitoxantrone, 527, 529
Mivacron, 789
Mivacurium, 788, 789
infusion table, 899

Mixtard 30—discontinued
Mizolastine, 191, 193

Mizollen, 193
MMA/FPA Anamix preparations, 921
MMR vaccine, 759, 761
MMRwaxPro, 761
Mobic, 638
Mobiflex, 640
Mobigel, 664
Mobile, 438
Moclobemide, 239
Modafinil, 245, 247, 248
Modafinil—discontinued
Modoxon preparations, 228
Modification of Diet in Renal Disease study (‘MDRD formula’), 18
Modigraf, 558
Modisal LA—discontinued
Modisal XL, 127
Modiflavour System, 925
Modrasone, 710
Modrenal, 483
Modulen IBD, 917
Moduret-25 (co-amilozide), 89
Moderetic (co-amilozide), 89
Moexipril, 119
see also ACE inhibitors
Mogadon (nitrazepam), 209
Molaxole, 71
Molcor, 688
Molipaxin, 237
Mollelast products, 951
Momentasone
asthma, 184, 189
chronic, 172
nasal allergy, 691
skin, 713
Monoamine-oxidase inhibitors
depression, 237
surgery, 776
type A (reversible), 239
Parkinson’s disease, 304
Monoethanolamine olate see Ethanolamine olate, 169
Monofer, 579
Monofluorooxypophosphate, 613
Monoject products, 426, 427
Monoct, 426
Monomax preparations, 128
Monomil XL, 128
Mononine (factor IX fraction), 169
Monosorb XL, 128
Montelukast, 190
Morhumil, 706
Morococog alfa, 160
Morphpic SR, 268
palliative care, 20

Morphine, 263
analgesia, 262, 268, 269
cyclizine with, 269
diamorphine equivalence, 24
fentanyl equivalence, 21
neuropathic pain, 273
palliative care, 20, 21
cough, 205
palliative care, 22
diarrhoea
kaolin with, 59

Motens, 131
Motifene, 634
Motilium, 253
Motion sickness, 250
Motor neurone disease, amyotrophic lateral sclerosis, 308
Mountain sickness, 90
Mouth ulceration, 693
Mouthwash solution-tablets, 698
Mouthwashes, 697
Movement disorders, 307
Movicol preparations, 71, 72
Moviprep, 73
Moxifloxacin, 368, 370
eye, 667, 668
Moxisylyte, 136
Moxidig, 668
Moxonidine, 110, 111
Moxobil, 593
MFD Ultra Thin, 426
MRSA, 334
nasal, 692
MST Continus, 269
palliative care, 20
MSUD preparations, 930
Mucolite, 203
Mucolog, 203
Mucogel, 45
Mucolytics, 202
Mucosa, oral, side-effects on, 13
Mucositis, oral, 519
Multaq, 93
Multiclix, 426
Multiload
Movement disorders, 307
Musculoskeletal disorders, 183
Muscle spasm, 659
Muscle relaxants
anaesthesia, 788
depolarising, 790
non-depolarising, 788
skeletal, 659
Muscle relaxants, 660
baclofen, 660
tizanidine, 662
Multi-Safe devices, 504
Multivitamin preparations, 621
Mumps, vaccines, combined,
N
N-A products, 937
Nabumetone, 630, 638
Nadolol, 103
cardiovascular, 103
migraine, 277
see also Beta-adrenoceptor
blocking drugs
myeloma, multiple see Multiple
myeloma, 538, 561, 582
Nafarelin, 482
Nalidixic acid, 368, 370
Naloxone
anaesthesia, 792
analgesia
oxycodone with, 270
infusion table, 899
opioid dependence, 317
buprenorphine with, 316
poisoning, 36
Naltrexone, 317
Nandrolone decanoate, 461
Naproxen
gout, 654
pain, 630
rheumatic disease, 630, 638, 639
esomeprazole with, 639
misoprostol with, 639
Naronig, 275
Naratriptan, 274, 275
Narcolepsy, 247
Narcotic analgesics see Anal-
gesics, opioid
Narcotic antagonists see Opioid
antagonists
Nardil, 238
Naropin, 798
Niasacort, 691
Nasal
allergy, 689
congestion, 688, 691
decongestants
 systemic, 191, 205
topical, 691
infection, 692
gout, 654
Nasacort
Nebusal
Nebivolol, 97, 103
see also Beta-adrenoceptor
blocking drugs
Nebucambur, 183
Nebulisers, 184
Nebusal, 203
Necatoriasis, 416
Nedocromil
asthma, 189, 190
eye, 671, 672
Needles, insulin, 426, 427
clicking device, 427
Nefopam, 258, 261, 262
Nefopam, 258
Nefopam, 258
Index
Oral hypoglycaemic drugs
Oral glucose tolerance test, 439
Osteonecrosis of the jaw, 472, 537
Osteomyelitis, 327, 354, 356
Osteoarthritis, 629, 630
Organophosphorus insecticides, 248
Orlistat, 537
Oral rehydration therapy, 596
Oral rehydration salts, 596
Ostenil preparations, 905, 908
Osmanil (fentanyl), 267
Oruvail preparations, 637
Orudis, 637
Oravil preparations, 637
dressings, 781
Orthopaedic surgery
Oral contraceptives
Oseltamivir, 400
Osmanil (tensamyl), 267
Osmolite preparations, 905, 908, 909
OsmoPrep, 74
Ostenil, 630
Osteoarthritis, 629, 630
Osteomyelitis, 327, 354, 356
Osteonecrosis of the jaw, 472, 537
Osteoporosis, 469
anabolic steroids, 461
bisphosphonates, 469, 471
calcitonin, 469
calcitriol, 469, 618
calcium, 469, 608
corticosteroid-induced, 470
HRT, 469
parathyroid hormone, 469
postmenopausal, 469
raloxifene, 469
strontium ranelate, 469
teriparatide, 469
Ovaren, 612
Oct, 688
Otitis externa, 685
systemic treatment, 328
topical treatment, 685
Ortis media, 687
systemic treatment, 329
with effusion, 688
Otomize, 686
Otosporin, 687
Otralogs (xylometazoline), 692
Otrivine (xylometazoline), 692
Otrivine-Antistin, 671
Oxel, 491
Oxetrel, 463
Oxanet, 498
Oxysmen, 498
Oxacin (fluoxetine), 241
Oxalaplatin, 542, 543
Oxamnique, 416
Oxazepam, 213, 215
Oxazolidinone antibacterials, 358
Oxcarbazepine
epilepsy, 280, 281, 283
Oxerutins, 136
Oxidising agents
Oxybutynin, 508, 510
Oxycodeone
analgesia, 263, 269, 270
naloxone with, 270
neuropathic pain, 273
infusion table, 900
palliative care, 20, 21
morphine equivalence, 20
OxyContin, 270
Oxygen
acute asthma, 201
alert card, 174
anaphylaxis, 197
chronic obstructive pulmonary disease, 201
cluster headache, 278
equipment, 202
myocardial infarction, 156
nitrous oxide with, 781
supply arrangements, 202
Oxytetracycline, 349
acne, 727
clobetasone butyrate with, 712
oral infections, 347
rosacea, 724
Oxytocin, 486, 488
ergometrine with, 487
infusion table, 900
Oxyzyme, 945
Ozurdex, 671
Oxyamphetamine, 582
Oxymycin (oxytetracycline), 349
OxyNorm, 270
Oxytetracycline, 349
acne, 727
clobetasone butyrate with, 712
oral infections, 347
rosacea, 724
P
Paralielinum—Phenol

Paraffin, 541, 542
Panoxyl preparations, 724
Panthenol, 616
Pantoprazole, 57
infusion table, 900
Pantothenic acid, 616
Papaveretum, 270
anaesthesia, 270
hyoscine with, 270
Papaverine, impotence, 517

Paracetamol
febrile convulsions, 297
infusion table, 900
migraine, 273
bucalazine with, 261
metoclopramide with, 261
pain, 257, 259, 260
codeine with, 260, 261
dihydrocodeine with, 261
isomethnephtine with, 261
methionine with, 261
palliative care, 20
postoperative, 785
tramadol with, 261
poisoning by, 34
post-immunisation pyrexia, 747

Paracetamol Seltzer (paracetamol), 259
Paracodol (co-codamol 8/500), 260
Paradone, 261
Paraffin
eye lubricant, 680, 681
gauze dressing, 937
liquid and white soft, 702
oral emulsion, 71
white soft, 702
yellow soft, 681, 702

Paraglise, 937
Paraldehyde, 294, 296
Paramax, 261
Paracetamol, 937
Paraproteinaemias, 582
Parasiticidal preparations, 740
suitable quantities, 740
Parasympathomimetics
anaesthesia, 791
eye, 678
laxatives, 69
myasthenia gravis, 658
urinary retention, 508

Parathyroid hormone, 469, 470, 471
Pardelprin (indometacin), 637
Parecoxib, 785, 786
Parenteral nutrition, 602
preparations, 607

PARI
Vortex Spacer, 183
Paricalcitol, 618, 620
Pariat, 57
Parkinsonism
drug-induced, 217, 306
Parkinson’s disease, 297
idiopathic, 297

Parlodel, 478
Parmid XL (felodipine), 130
Paromomycin, 413
Parozen, 136

Paroxetine, 239, 241, 242
Paroxysmal nocturnal haemoglobinuria, 589
Partial seizures see Focal seizures, 280
Partobulin SDF, 773
Parvolex, 36
Pastes, definition, 701
Pastically products, 926, 927
Patents, 3
Patient group direction, 4
Pavaco-D (pholcodine), 205
Pazopanib, 545, 548
Peak flow meters, 182
Peanut oil see Arachis oil
PEC high compression bandage, 954
PeFent, 266
Pedital, 752
Pediculosis, 740
Peditrace, 607
Pegaptanib, 683
Pegasys, 561
Pegfilgrastim, 591, 593
Regitriteron alfa, 397, 561
Pegvisomant, 465, 466
Peha-haft products, 951
Pelvic inflammatory disease, 326
Pemetrexed, 530, 534
Pemphigus, 443
Penbritin, 337
Penciclovir, 392, 739
Penfite, 427
Penicillamine, 643
autoimmune hepatitis, 622
cystinuria, 622
rheumatic disease, 642, 643
Wilson’s disease, 622
Penicillin G see Benzylpenicillin sodium
Penicillin V see Phenoxy methyl penicillin, 333, 334
Penicillin VK see Phenoxy methyl penicillin, 333, 334
Penicillinases, 334
Penicillins, 332

taupe-sudomonal, 339
broad spectrum, 335
penicillines-resistant, 334
penicillines-sensitive, 333

Pentacarinat, 414
Pentamidine isethionate, 414
infusion table, 900
leishmaniasis, 413
Pentax, 62
Pentastarch, 600, 601
Pentazocine, 263, 270, 271
Pentostam, 413
Pentostatin, 542
Pentoxifylline, 136, 954
Pentrax, 733
Pepcid (famotidine) preparations, 52
Peppermint oil, 48, 49
Peptac, 46
Peptamen preparations, 905, 909
Pepitord, 909
Perazine, 909
Percutol, 126
Perlix, 119
Perfalgan, 260
Perfan, 83
Pergolide, 298, 299, 300
Pergoveris, 463
Periactin, 194
Pericoronitis, 328
Pericyazine, 220
Percodan, 76
Perindopril ariners, 119, 120
indapamide with, 120
see also ACE inhibitors
Perindopril erbumine, 119
see also ACE inhibitors
Perindopril, 573
Periactin, 183

Peritoneal dialysis, 693
antibacterial treatment, 328
Periogard, 697
Periostat, 693, 694
Peripheral vascular disease, 135
Pentonitri, 323
PermaFoam products, 942
Permevair, 740, 741
Permitabs, 744
Peroxyll, 698
Perphenazine
depression
amitriptyline with, 235
nausea, 249, 252
psychosis, 220
Persantin preparations, 153
Personal Best, 182
Perutosis
immunisation, 762
prophylaxis, 530
vaccines, combined, 752, 753
Pethidine, 271
analgesia, 263
postoperative, 263
promethazine with, 271
Petroleum jelly, 702
Petroleum products, poisoning by, 33
Pevaryl, 737
Peyronie’s disease, 617

PGD see Patient group direction, 4
Phaeochromocytoma, 98, 113
Pharmacist independent prescribing, 978

Pharmac-Ject Morfine Sulphate, 263
Pharmagen, 196
Pharmacope-PU products, 939
Pharmacorbin, 528
Pharyngitis see Throat infections
Pharynx see Oropharynx
Phenelzine, 237, 238
Phenergan preparations, 195
Phenindione, 146, 148
Phenobarbital, 288, 296
convulsions, palliative care, 22
epilepsy, 287
status epilepticus, 296
poisoning, elimination, 33
Phenobarbitone see Phenobarbital
Phenol
haemorrhoids, 77
injection, oily, 77
Polyurethane foam dressing, 941, 942
silver with, 946
Polyvinyl alcohol, 681
Pompe disease, 625
Ponstan preparations, 638
POP see Progestogens, contraceptives, oral, 494, 500
Poractant alfa, 200
Poriferan sodium, 543
Porphyrins, acute, 627
drugs to be avoided in, 627, 628
Portal hypertension, 99
Posaconazole, 373, 374, 300
Potassium chlorhexidine, 648
Potassium chloride, 599, 598, 599
concentrate, sterile, 599
infusion
sodium chloride and, 599
Potassium bicarbonate, 596, 597
Potassium aminobenzoate, 617
potable water, 3
Prescription forms
controlled drugs, 8
dental, 6
nurses, 974
security, 4
Prescription only medicines see preparations identified by throughout BNF
Prescription writing, 5
Preservex, 632
Presinex (desmopressin), 467
Prestige products, 439
Prestim, 104
Prevenar 13, 763, 764
Prezista, 387
Priadel, 231, 232
Priorit, 258
Priapism, 514
Prices, xiv
Prilocaine, 797, 798
felypressin with, 794, 798
lidocaine with, 797
Prilofekal, 798
Primacine (erythromycin), 353
Primacor, 83
Primafax, 950
Primplan, 937
Primamone, 403, 409
neumocystis pneumonia, 413
Primina, 345
infusion table, 898
Primene, 606
Primidone, 287, 288
Primolut N, 458
Priorix, 761
Pripen, 415
Privigen, 771
Pro-Banthine, 48
Probeneicid, 655, 656
Procainamide, 93, 94, 96
Pro-Cal preparations, 923
Procarbazine, 544
Procyclidine, 306, 307
Proceed with caution
controlled drugs, 9
dental practice, 6
drug misusers, 10
elderly, 24
generic, 1
independent, 978
instalments, 9
liver disease, 17
non-proprietary, 1
palliative care, 20
pregnancy, 19
renal impairment, 17
supplementary, 978
Process, 252
Psychosis, 221
Promethazine, 492
Progestogens, contraceptives, oral, 494, 500
Pramocaine, 76
Pramipexole, 298
Pralidoxime chloride,
948
PremierBand products, 951, 953
PremierPad, 948
PremierPore products, 937, 939
Premique preparations, 452
Cycle—discontinued
Prempak-C, 452
Preoact, 471
Presca, 131
Prednisone, 443, 448
asthma, acute severe, 171
cluster headache, 278
Crohn’s disease, 64
ear, 687
neomycin with, 687
eye, 671
haemorrhoids, 76
lepra reactions, 366
malignant disease, 555
myasthenia gravis, 659
palliative care, 21
neumocystis pneumonia, 413
rectal, 65
rheumatic disease, 640, 641
ulcerative colitis, 64
withdrawal of, 444
Prednisolone, 443, 448
ear, 687
eye, 671
Pred-N
rectal, 65
Pre-eclampsia, 106
Pre-eclampsia, 106
Pre-emplasia, 106
magnesium in, 611
Preface, iii
Pregabalin
diabetic neuropathy, 436
epilepsy, 280, 284, 285
generalised anxiety disorder, 284
neuropathic pain, 272, 284
palliative care, 21
Pregady, 578
Pregnancy
anticoagulants, 147
asthma, 170
epilepsy and, 280
folate supplements, 577, 580
hypertension in, 106
iron, 576
folic acid and, 577
nausea and vomiting, 250
prescribing in, 19
termination, 465
Pregnyl, 462
Premarin
oral, 454
genuine—discontinued
Premarina, 489
Premedication, 781
children, 783
dental procedures, 208, 783
Premenstrual syndrome, 456, 616
PremierBand products, 951, 953
PremierPad, 948
PremierPore products, 937, 939
Premique preparations, 452
Premira
Cycle—discontinued
Premira, 452
Presca, 131
Prescription writing, 5
Preservation
controlled drugs, 8
dental, 6
nurses, 974
security, 4
Prescription only medicines see preparations identified by throughout BNF
Prescription writing, 5
Preservex, 632
Presinex (desmopressin), 467
Prestige products, 439
Prestim, 104
Prevenar 13, 763, 764
Prezista, 387
Priadel, 231, 232
Priorit, 258
Priapism, 514
Prices, xiv
Prilocaine, 797, 798
felypressin with, 794, 798
lidocaine with, 797
Priloyekal, 798
Primacine (erythromycin), 353
Primacor, 83
Primafax, 950
Primplan, 937
Primamone, 403, 409
neumocystis pneumonia, 413
Primina, 345
infusion table, 898
Primene, 606
Primidone, 287, 288
Primolut N, 458
Priorix, 761
Pripen, 415
Privigen, 771
Pro-Banthine, 48
Probeneicid, 655, 656
Procainamide, 93, 94, 96
Pro-Cal preparations, 923
Procarbazine, 544
Procyclidine, 306, 307
Propylene glycol, presence of, 3
Propylthiouracil, 442
Proscar, 461
ProSource, 922
Prostacyclin see Epoprostenol
Prostaglandins
anticoagulant, 145
eye, 674, 675
gastro-intestinal, 54
obstetrics, 485, 486, 487
Prostap preparations, 572
Prostate cancer
estramustine, 524
gonadorelin analogues, 571
gonadotrophin-releasing hormone antagonists, 574
Prostatic hyperplasia, benign
alpha-blockers, 506
anti-androgens, 460, 461
Prostatitis, 326, 372
Prostin E2 preparations, 487
ProSure, 918
Promazine, 218, 408, 409
Promazine teoclate, 251
Promazine—discontinued
Protiram, 922
Prolactin, 538
Protease inhibitors, 381, 382,
Protamine sulphate, 141,
Protamino, 927
Prohormone see Fraxonamide, 363
Prothrombin complex, dried, 147,
Prothrombin complex, human, 161
Psoriasis, 719
Psoriasis vulgaris, 695
Psoriderm preparations, 719
Psorin preparations, 723
Psychoses, 215
Psychoactive, 222
Psychoses, 225
Psychoactive, 233
Pyelonephritis, 326, 372
Pyridoxine, 616,
Pyrimethamine
malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyridoxine hydrochloride, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Psorin preparations, 723
Psorin, 472
Psoriasis vulgaris, 695
Psoriasis, 719
Psoriderm preparations, 719
Pyelonephritis, 326, 372
Pyridoxine, 616,
Pyrimethamine
malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Psorin preparations, 723
Psorin, 472
Psoriasis vulgaris, 695
Psoriasis, 719
Psoriderm preparations, 719
Pyelonephritis, 326, 372
Pyridoxine, 616,
Pyrimethamine
malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Psorin preparations, 723
Psorin, 472
Psoriasis vulgaris, 695
Psoriasis, 719
Psoriderm preparations, 719
Pyelonephritis, 326, 372
Pyridoxine, 616,
Pyrimethamine
malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Psorin preparations, 723
Psorin, 472
Psoriasis vulgaris, 695
Psoriasis, 719
Psoriderm preparations, 719
Pyelonephritis, 326, 372
Pyridoxine, 616,
Pyrimethamine
malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Pyridoxine, 472
Pyrimethamine malaria, 410
sulfadoxine with, 402, 410
toxoplasmosis, 413
Psorin preparations, 723
Quinil (quinapril), 120
Quinine, 411
infusion table, 900
malaria, 402, 403, 404, 411
nocturnal cramps, 662
poisoning, 145
Renal failure, 199
Rhabdomyolysis, 361, 364
Rice, 63
Rifamycins, 361, 362, 363, 364, 365
ribavirin, 401
Rifater, 459
Rifabutin, 363
Rickets, hypophosphataemic, 611
Riboflavin, 616
Rheumatic diseases, 629, 640
rhinocytitis, 381
Rhinocort Aqua, 75
Rhuamatac Retard, 330
Rhumin (diclofenac sodium), 634
Rheumatoid arthritis, 443, 629
Rhinitis allergic, 191, 688
medicamentosa, 691
vasonomotor, 191, 691
Rhinocestoma, 498
Rhinoscopy, 75
Rifampicin, 365
compound preparations, 365
infusion table, 900
leprosy, 366
tuberculosis, 361, 362
Rifamycins, 361, 362, 363, 364, 365
Rifater, 361, 365
Rifinah, 361, 365
Rigavidon, 498
Rilutek, 398
Rihuzole, 308

Rabies
immunisation, 764
travel, 774
immunoglobulin, 771, 772
vaccine, 764, 765
Rabipur, 765
Raloxifene, 456, 469
Raltegravir, 382, 391, 392
Ralitrexed, 531, 534
Ramipril, 120, 121
felodipine with, 121
see also ACE inhibitors
Ranexa, 135
Ronafaxine XL (venlafaxine), 245
Ranibizumab, 683
Ranitidine, 53
infusion table, 900
Ranolazine, 134, 135
Tapamune, 557
Rapifen, 235
infusion table, 900
Rashes, urticarial, 191
Rasilez, 124
Ratiograstim, 593
Raynaud's syndrome, 113, 132, 135
Rebetol, 402
RebiDose, 562
Rebif, 562
RebiSmart, 562
Reboxetine, 242, 244
Recombinant activated protein C, 160
Rectogesic, 77
Red eye, 667, 670
Redoxon (ascorbic acid), 617
ReFacto AF (factor VIII fraction), 160
Reflexions diaphragm, 505
Redfluran, 145
Reflux oesophagitis see Gastro-oesophageal reflux disease, 44
Refolithin (calcium folinate), 522
Regaine, 734
Regaine for Men Regular Strength—discontinued
Regal, 950
Regranex, 745
Regular, 68
Regulose (lactulose), 71
Regurin preparations, 512
Rehydration
oral, 596
parenteral, 597
Relactagel, 493
Relaxin, 73
Release, 957
Relena, 400
Reletal, 672
Reliflex, 638
Relitor, 75
Relpax, 274
Remedelina, 261
Remicaide, 653
Remifentanil, 263, 786, 787
infusion table, 900
Remirel preparations, 319
Renagel, 613
Renal colic see Ureteric colic, 512
Renal excretion, interactions affecting, 800
Renal impairment, prescribing in, 17
Renamil, 918
Renaprox, 918
Renastart, 918
Renasy products, 949
Renilon 7.5, 915
Renin inhibitors, 124
Renvela, 613
RexPro, 152
Replaglide, 430, 433, 434
Repepx, 753
Replagal, 623
Repleni-VF (factor IX fraction), 160
Replens, 491
Requip preparations, 301
RescueFlow, 601
Resolvent, 75
Resonim A, 595
Resource preparations
enteral feed, 908
fibre supplement, 924
nutritional supplement, 911, 914, 915
thickened, 925
Respiror, 918
Respiratory depression
poisoning, 32
postoperative, 792
distress syndrome, 200
failure, 199
secretions, excessive, palliative care, 21
stimulants, 199
syncytial virus infections, 400
Respontin, 180
Resprin, 259
Restandol, 459
Restless legs syndrome
pramipexole, 300
ropinirole, 301
rotigotine, 301
Restlessness, palliative care, 22, 23
Resuscitation
cardiopulmonary, 139
dental practice, 776
Retacrit, 586
Retapamulin, 734, 735
Reteplase, 157, 158
Retin-A, 726
Retinoids
acne
oral, 728
topical, 725
eczema, 715
leukaemia, 552
psoriasis, 716, 720
Retinol see Vitamin A
Retovir, 386
Revatio, 109
Revaxis, 753
Revlimg, 565
Revolade, 590
Rexocaine, 796
Reyataz, 386
Rye’s syndrome, aspirin and, 258
Rhusus incompatibility, 772
Rheumatoc Retard (diclofenac sodium), 634
Rheumatic diseases, 629, 640
corticosteroid injections, 641
rubefacients, 664
Rheumatic fever prophylaxis, 330
Rheumatism, palindromic, 642
Rheumatoid arthritis, 443, 629
Rhinitis allergic, 191, 688
medicamentosa, 691
vasonomotor, 191, 691
Rhinocort Aqua, 690
Rhinalast preparations, 689
Rhophyllac, 773
Rhumalgon (diclofenac sodium), 634
Riamet, 402, 407
Ribavirin, 401, 402
chronic hepatitis C, 397, 400
respiratory syncytial virus, 400
Riboffavin, 616
Rickets, hypophosphataemic, 611
Rickettsia, 346
Rifabutin, 363
Rilutek, 398
Rihuzole, 308
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rima, see Monoamine-oxidase inhibitors, type A (reversible)</td>
</tr>
<tr>
<td>Rimacid (indometacin), 637</td>
</tr>
<tr>
<td>Rimacidil (ampicillin), 337</td>
</tr>
<tr>
<td>Rimactane, 385</td>
</tr>
<tr>
<td>Rimafen (ibuprofen), 636</td>
</tr>
<tr>
<td>Rimapam (diazepam), 214</td>
</tr>
<tr>
<td>Rimapurinol (allopurinol), 656</td>
</tr>
<tr>
<td>Rimexolone, 671</td>
</tr>
<tr>
<td>Rimexillin (amoxicillin), 336</td>
</tr>
<tr>
<td>Rimflo-50, 513</td>
</tr>
<tr>
<td>Rinacet, 692</td>
</tr>
<tr>
<td>Ringer's solution, 598</td>
</tr>
<tr>
<td>Ringer-Lactate solution, 598</td>
</tr>
<tr>
<td>Ringworm infection see Dermatophyte infection, 373</td>
</tr>
<tr>
<td>Risodronate sodium, 469, 474</td>
</tr>
<tr>
<td>Calcium carbonate and colecalciferol with, 474</td>
</tr>
<tr>
<td>Risperdal preparations, 227, 229</td>
</tr>
<tr>
<td>Risperidone</td>
</tr>
<tr>
<td>aggression, 226</td>
</tr>
<tr>
<td>psychosis, 222, 226, 227</td>
</tr>
<tr>
<td>depot injection, 229</td>
</tr>
<tr>
<td>resistant depression, 233</td>
</tr>
<tr>
<td>Ritalin, 247</td>
</tr>
<tr>
<td>Ritodrine, 490</td>
</tr>
<tr>
<td>Ritonavir, 382, 386</td>
</tr>
<tr>
<td>Lopinavir with, 388</td>
</tr>
<tr>
<td>see also Kaletra</td>
</tr>
<tr>
<td>Rituximab</td>
</tr>
<tr>
<td>infusion table, 900</td>
</tr>
<tr>
<td>Malignant diseases, 559, 560</td>
</tr>
<tr>
<td>Rheumatic diseases, 648, 653</td>
</tr>
<tr>
<td>Rivaroxaban, 148, 149</td>
</tr>
<tr>
<td>Rivastigmine, 318, 319</td>
</tr>
<tr>
<td>Rivottir, 294, 295</td>
</tr>
<tr>
<td>Rizatriptan, 274, 275</td>
</tr>
<tr>
<td>Rizapiprazole products, 927</td>
</tr>
<tr>
<td>Roaccutane, 728</td>
</tr>
<tr>
<td>RoActemra, 654</td>
</tr>
<tr>
<td>Robaxin, 662</td>
</tr>
<tr>
<td>Robinul powder, 745</td>
</tr>
<tr>
<td>Rocaltol, 619</td>
</tr>
<tr>
<td>Rocephin, 544</td>
</tr>
<tr>
<td>Rocuronium, 788, 790</td>
</tr>
<tr>
<td>infusion table, 900</td>
</tr>
<tr>
<td>Roferon-A, 561</td>
</tr>
<tr>
<td>Rofiglumastil, 174, 191</td>
</tr>
<tr>
<td>Rognite, 114</td>
</tr>
<tr>
<td>Romiplostin, 590</td>
</tr>
<tr>
<td>Ropinirole, 298, 301</td>
</tr>
<tr>
<td>Ropivacaine, 798</td>
</tr>
<tr>
<td>Rosacea, 724</td>
</tr>
<tr>
<td>Rosacid, 736</td>
</tr>
<tr>
<td>Rosidal K, 954</td>
</tr>
<tr>
<td>Rosiglitazone, 431</td>
</tr>
<tr>
<td>Rosuvastatin, 162, 164</td>
</tr>
<tr>
<td>Rotarix, 765</td>
</tr>
<tr>
<td>Rotavirus vaccine, 765</td>
</tr>
<tr>
<td>Rotigotine, 298, 301</td>
</tr>
<tr>
<td>Roundworm infections, 416</td>
</tr>
<tr>
<td>Rowachol, 78</td>
</tr>
<tr>
<td>Rowatrine, 513</td>
</tr>
<tr>
<td>Roxel, 736</td>
</tr>
<tr>
<td>rt-PA see Alteplase</td>
</tr>
<tr>
<td>Rubefacients, 664</td>
</tr>
<tr>
<td>Rubella</td>
</tr>
<tr>
<td>Immunisation, 759, 765</td>
</tr>
<tr>
<td>Immunoglobulin, normal, 770</td>
</tr>
<tr>
<td>Vaccines, combined, 761</td>
</tr>
<tr>
<td>Rufinamide, 281, 289</td>
</tr>
<tr>
<td>Rupafin, 193</td>
</tr>
<tr>
<td>Rupatadine, 191, 193</td>
</tr>
<tr>
<td>Rusyde (furosemide), 86</td>
</tr>
<tr>
<td>Rutidosides, 136</td>
</tr>
<tr>
<td>Rynacrom, 691</td>
</tr>
<tr>
<td>Rythmodan preparations, 95</td>
</tr>
<tr>
<td>S</td>
</tr>
<tr>
<td>St John's Wort, 232</td>
</tr>
<tr>
<td>S.O.S. preparations, 920</td>
</tr>
<tr>
<td>Sabril, 293</td>
</tr>
<tr>
<td>Saflutan, 676</td>
</tr>
<tr>
<td>Saizen, 465</td>
</tr>
<tr>
<td>Salactol, 729</td>
</tr>
<tr>
<td>Salagen, 699</td>
</tr>
<tr>
<td>Salamol (salmeterol) preparations, 178</td>
</tr>
<tr>
<td>Salapir (salmeterol), 178</td>
</tr>
<tr>
<td>Salatec, 729</td>
</tr>
<tr>
<td>Salazopyrin, 63, 654</td>
</tr>
<tr>
<td>Salbutin Novolizer, 178</td>
</tr>
<tr>
<td>Salbutamol, 177, 178</td>
</tr>
<tr>
<td>Asthma, 175</td>
</tr>
<tr>
<td>IPratropium with, 182</td>
</tr>
<tr>
<td>Infusion table, 901</td>
</tr>
<tr>
<td>Premature labour, 490</td>
</tr>
<tr>
<td>Salbutamol see Calcium</td>
</tr>
<tr>
<td>Salicylates</td>
</tr>
<tr>
<td>Aphthous ulcers, 695</td>
</tr>
<tr>
<td>Salicylic acid, 719</td>
</tr>
<tr>
<td>Acne, 726, 727</td>
</tr>
<tr>
<td>Fungal infections, 738</td>
</tr>
<tr>
<td>Hyperkeratoses, 729</td>
</tr>
<tr>
<td>Psoriasis, 716</td>
</tr>
<tr>
<td>Betamethasone with, 711</td>
</tr>
<tr>
<td>Coal tar and dithranol with, 719</td>
</tr>
<tr>
<td>Dithranol and zinc with, 719</td>
</tr>
<tr>
<td>Sulphur with, 733</td>
</tr>
<tr>
<td>Zinc with, 720</td>
</tr>
<tr>
<td>Scalp, 732</td>
</tr>
<tr>
<td>Warts and calluses, 729</td>
</tr>
<tr>
<td>Podophyllum with, 729</td>
</tr>
<tr>
<td>Saline see Sodium chloride</td>
</tr>
<tr>
<td>Salipropanol (propripranol with salbutamol), 182</td>
</tr>
<tr>
<td>Saliva, artificial, 698</td>
</tr>
<tr>
<td>Salivaze, 699</td>
</tr>
<tr>
<td>Salivix, 699</td>
</tr>
<tr>
<td>Salmeterol, 175, 178, 179</td>
</tr>
<tr>
<td>Fluticasone with, 189</td>
</tr>
<tr>
<td>Salmonella, 323</td>
</tr>
<tr>
<td>Salofalk preparations, 62</td>
</tr>
<tr>
<td>Salpingitis, 346</td>
</tr>
<tr>
<td>Salt substitutes, 594</td>
</tr>
<tr>
<td>Samnca, 469</td>
</tr>
<tr>
<td>Sandimmun, 557</td>
</tr>
<tr>
<td>Sandokan preparations, 609</td>
</tr>
<tr>
<td>Colecalciferol with, 619</td>
</tr>
<tr>
<td>Sando-K, 595</td>
</tr>
<tr>
<td>Sandostatin, 575</td>
</tr>
<tr>
<td>Sandostatin LAR, 575</td>
</tr>
<tr>
<td>Sandrena, 455</td>
</tr>
<tr>
<td>Sanomigmon, 278</td>
</tr>
<tr>
<td>Sapropterin, 607, 608</td>
</tr>
<tr>
<td>Saquinavir, 382, 389</td>
</tr>
<tr>
<td>Salivex, 661</td>
</tr>
<tr>
<td>Savene, 521</td>
</tr>
<tr>
<td>Savlon Dry powder, 744</td>
</tr>
<tr>
<td>Saxagliptin, 431, 434</td>
</tr>
<tr>
<td>Scabies, 740</td>
</tr>
<tr>
<td>Scandishake, 923</td>
</tr>
<tr>
<td>Scandonest preparations, 797</td>
</tr>
<tr>
<td>Scanpor, 950</td>
</tr>
<tr>
<td>Scar FX, 947</td>
</tr>
<tr>
<td>Scaril, 947</td>
</tr>
<tr>
<td>Scheriproct, 76</td>
</tr>
<tr>
<td>Schizotomas, 416</td>
</tr>
<tr>
<td>Schistosomicides, 416</td>
</tr>
<tr>
<td>Schizophrenia, 216</td>
</tr>
<tr>
<td>Scleroderma, 617</td>
</tr>
<tr>
<td>Sclerosants, 169</td>
</tr>
<tr>
<td>Scopoderm preparations, 256</td>
</tr>
<tr>
<td>Scopolamine see Hyoscine hydrobromide</td>
</tr>
<tr>
<td>Scottish Medicines Consortium, 4</td>
</tr>
<tr>
<td>Scurvy, 617</td>
</tr>
<tr>
<td>SeaSorb products, 943</td>
</tr>
<tr>
<td>Silver with, 946</td>
</tr>
<tr>
<td>Sebco, 719</td>
</tr>
<tr>
<td>Sebivo, 399</td>
</tr>
<tr>
<td>Sebomin, 349</td>
</tr>
<tr>
<td>Seborrhoic dermatitis, 714</td>
</tr>
<tr>
<td>Seborrhoeic eczema, 714</td>
</tr>
<tr>
<td>Sectral, 100</td>
</tr>
<tr>
<td>Securon preparations, 134</td>
</tr>
<tr>
<td>Sedation, anaesthesia, 782</td>
</tr>
<tr>
<td>Sedatives, 307</td>
</tr>
<tr>
<td>see also Anxiolytics</td>
</tr>
<tr>
<td>Select-A-Jet Dopamine—continued</td>
</tr>
<tr>
<td>Selegeline, 304, 305</td>
</tr>
<tr>
<td>Selenase, 615</td>
</tr>
<tr>
<td>Selenium, 615</td>
</tr>
<tr>
<td>Selenium sulphide, 732, 733, 736</td>
</tr>
<tr>
<td>Sectaxid, 340</td>
</tr>
<tr>
<td>Selsun, 733</td>
</tr>
<tr>
<td>Semi-permeable adhesive film, 938</td>
</tr>
<tr>
<td>Semisodium valproate see Valproic acid</td>
</tr>
<tr>
<td>Senna, 70</td>
</tr>
<tr>
<td>Senokot, 70</td>
</tr>
<tr>
<td>Septanest, 794</td>
</tr>
<tr>
<td>Septic arthritis, 327</td>
</tr>
<tr>
<td>Septicaemia, 327</td>
</tr>
<tr>
<td>Catheter-related, 327</td>
</tr>
<tr>
<td>Community-acquired, 327</td>
</tr>
<tr>
<td>Hospital-acquired, 327</td>
</tr>
<tr>
<td>Meningococcal, 327</td>
</tr>
<tr>
<td>Seprin, 360</td>
</tr>
<tr>
<td>Sercatil, 633</td>
</tr>
<tr>
<td>Seratix, Paediatric, 924</td>
</tr>
<tr>
<td>Serc, 256</td>
</tr>
<tr>
<td>Seroxat, 220</td>
</tr>
<tr>
<td>Seretide, 189</td>
</tr>
</tbody>
</table>
Sodium picosulphate, 70
magnesium citrate with, 74
Sodium picosulphate see Sodium picosulphate
Sodium pidolate, 703
Sodium polystyrene sulphonate, 595
Sodium risedronate see Risedronate sodium
Sodium stibocaprate, 416
Sodium stibogluconate, 412, 413
Sodium tetradeyl sulphate, 169
Sodium thiosulphate, 39, 40
Sodium valproate see Sodium valproate
Soft tissue disorders, 629
Soft polymer dressings, 939, 940
Sorbsan products, 940
Sorbion products, 943
Sorbalgon
Sonata (nitrazepam), 209
Somavert preparations, 574
Solvazinc
Solvaline N
Solu-Medrone
Solu-Cortef (tamoxifen), 571
Solu-Medrone, 448
Sollipal, 615
Solvents, ear wax removal, 688
Somatomedins, 483
Somatostatin analogues, 574
Somatotrophin
Somatropin, 464, 465
Somatostatin preparations, 574
Somavet, 466
Somnite (nitrazepam), 209
Sonata, 210
Sorafenib, 548
Sorbital, 692
Sorban products, 943
Sorbin, 940
Sorbus, presence of, 2
Sorboan products, 943
charcoal with, 944
silver with, 946
Sotorac, 104
Sotaval, 104
cardiovascular, 98
see also Beta-adrenoceptor blocking drugs
Soya oil, 704
Spa devices, 183
Spasmonal preparations, 48
Sparticity, 859
Special Importing companies, 894
Special order
dermatological preparations, 700
manufacturers, 894
Spermicides, 503
SPF see Sun protection factor, 731
Spiramycin, 352, 413
Spirit
industrial methylated, 742
surgical, 743
Spiriva preparations, 180
Spirinolactone, 88
furosemide with, 89
heart failure, 114
hydroflumethiazide with, 89
nephrotic syndrome, 88
Spleenectomy see Asplenia
Sporanox preparations, 376
Sports card, 31
Sprycel, 546
SSRIs see Antidepressants, seroton re-uptake inhibitor, 239
StS, 699
Stalevo, 304
Stamavit, 786
Stannous fluoride, 614
Starch, etherified, 600, 601, 602
Stericlens
Sterifix
Steri-Neb
Steristrip, 951
Sterile larvae, 744
Steri-Neb, 951
ipratropium, 180
Salamol, 178
sodium chloride, 184
Steripaste, 955
Steripod (sodium chloride), 743
Steripoule (sodium chloride), 743
Steripaste see Sodium stibocaprate, 416
Stiemycin, 725
Sterile larvae, 744
Still’s disease see Arthritis, juvenile idiopathic, 642
Stilnox, 210
Stimulants
central nervous system, 245
respiratory, 199
Stings, 42
Strep, 281
Stocknettes, 951, 952
Stoma, drugs and, 77
Stomatitis
denture, 695
herpetic, 696
Strappal, 950
Strattera, 246
Stefren, 694
Streptase, 158
Streptococcal infection
antibacterial prophylaxis, 330
Streptokinase, 157, 158
infusion table, 901
Streptomycin, 361, 363, 365, 366
Striant SR, 459
Strode
intracerebral haemorrhage, 151
ischaemic, 151
transient ischaemic attack, 151
Stronazon MR (tamoxifen), 571
Strongyloidiasis, 417
Strontium ranelate, 469, 476, 477
StructoKabiven preparations, 606
Structolipid, 606
Stugeron, 250
Subcutaneous, 770
Subgum, 770
Subilmaze, 787
Suboxone, 316
Subutex, 316
Succimer, 40
Succinylcholine see Suxamethonium, 790, 791
Sucralfate, 53, 54
Sucrose, presence of, 2
Sulfadiazine, 206
Sudocrem, 706
Sulgamadex, 791, 792
Sugar-free liquid medicines see preparations identified by ‘sugar-free’ throughout BNF
Sugar-free, definition, 2
Sulphazine EC (sulfasalazine), 63, 654
Sulfa... see also Sulpha...
Sulfadiazine, 360
toxoplasmosis, 413
Sulfadiazine, silver, 735
Sulfadoxine, pyrimethamine with, 402, 410
Sulfamethoxazole, trimethoprim with, see Co-trimoxazole
Sulfasalazine, 59
Crohn’s disease, 63
inflammatory bowel disease, 61, 63
rheumatic disease, 642, 654
ulcerative colitis, 61, 63
Sulfapyrazine, 655, 656, 657
Sulfonamides, 359
Sulfonyleureas, 427
Sulindac, 631, 639, 640
gout, 654
Sulpha... see also Sulfa...
Sulphadiazine see Sulfadiazine
Sulphasalazine see Sulfasalazine
Sulphinpyrazine see Sulfapyrazine, 655, 656, 657
Sulfides, presence of, 2
Sulphonamides see sulfonamides, 359
Sulphonylureas see Sulfonyleureas, 427
BNF 61

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Surgical
- Surgery
- Superinfection, 322
- Swine influenza, 758, 759
- Swabs, 950
- Suxamethonium, 790
- Suxi, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

T

Tabophyn MR (tamulosin), 507
- Tacalcitol, 716, 717, 718
- Tachycardias see Arrhythmias

Tar
- 719
- see also Coal tar

Targenex, 270
- Tarceva, 546
- Tardive dyskinesia, 217
- Tarceva, 546
- Targocid, 357
- Targetin, 538
- Tariquidar, 371
- Tarixa, 121
- Targretin, presence of, 2
- Tasigna, 548
- Tasmor, 306
- Tavanic, 370
- Tavegil, 194
- Taxanes, 549
- Taxol, 550
- Taxotere, 550
- Tazaronet, 716, 718
- Tazobactam
- piperacillin with, 339
- infusion table, 900
- Tazocin, 339
- 3TC see Lamivudine
- Tear deficiency, 679
- Tear gas, 40
- Teas Natural preparations, 680
- Tears, artificial, 679
- Tegaderm products
- alginates, 943
- silver with, 946
- antimicrobial, 947
- bio-cellulose, 940
- film dressing, 939
- foam dressings, 941, 942
- protease-modulating, 947
- Tegraz, 342
- Supercue, 418
- Suprecue, 571
- Suramin, 416
- SurePres, 954
- Surfactants, pulmonary, 200
- Surgam preparations, 640
- Surgery
- antibacterial prophylaxis, 330, 331
- diabetes and, 421
- long-term medication and, 775
tetanus vaccine, 766
- Surgical
- absorbent dressings, 948
- adhesive tapes, 950
- spirit, 743
- Surgipad, 948
- Surmontol, 237
- Survanta, 200
- Survined OPD, 905
- Susscar, 126
- Sustanon 250, 459
- Sustiva, 390
- Sutent, 549
- Suxamethonium, 790, 791
- Swabs, 950
- Swine influenza, 758, 759
- Syk, 491
- Symbocto, 185, 188
- Symbols, inside back cover
- Symmetrel, 396

Sympathomimetics
- asthma, 175
- decongestants, 691
- eye, 673, 674, 676
- inotropic, 137
- premature labour, 489
- vasoconstrictor, 138
- Synacthen preparations, 462
- Synagis, 401
- Synalar preparations, 712, 713
- Synarex, 482
- Synastone (methadone), 268, 316
- Syncope, dental practice, 28
- Syner-KINASE, 159
- Synflex, 639
- Synflorix, 763, 764
- Synocrom, 630
- Synpaque, 499
- Systant, 690
- Synthamin preparations, 606
- Syntocinon, 486, 488
- Syntometrine, 486, 487
- Synvisc, 630
- Syphilis, 326
- Syprol (propranolol), 99
- Syringe drivers, palliative care, 23
- mixing and compatibility, 23
- problems, 24
- Syringes
- insulin, 427
- blind patients, 427
- oral, 2
- System 4 products, 955
- Systemic sclerosis, 107
- Sysyron, 578

Tamsulosin, 506, 507
- Tamiflu, 400
- Tamsulosin, 506, 507
- Tandec with, 507
- Tannin, 118
- Tapes, surgical adhesive, 950
- Tapeworm infections, 416

Tazocin, 531, 534, 535
- Tegaderm products
- Telofox, 356, 357
- Telofox, see also Coal tar
- Telbivudine, 397, 398, 399
- Telgaser products
- alginates, 943
- silver with, 946
- film dressing, 939, 940
- foam dressing, 942
- hydrocolloid, 941
- protease-modulating, 947
- Telgafur, 531, 534, 535
- uracil with, 535
- Tegretol preparations, 282
- Telcoform, 356, 357
- infusion table, 901
- Telangiecstasia, hereditary
- haemorrhagic, 456
- Telbivudine, 397, 398, 399
- Telgaser products
- Telsar, 264
- Temocillin, 334, 335
- infusion table, 901
- Temodal, 541
- Temozolomide (temozolomide), 540
- Temoporfin, 543
- Temozolomide, 540, 541
- Temporary mandibular dysfunction, 257
- Temsirolimus, 545, 549
- Tendinitis, 641
- Tenecteplase, 157, 158
- Tenf, 100
- Tennis elbow, 641
Tenofovir—Toltenamic

Tenofovir

chronic hepatitis B, 385, 397
HIV infection, 382, 385
efavirenz and emtricitabine with, 385
efavirenz with, 385
Tenoret-50, 100
Tenoretic, 100
Tenormin, 100
Tenoxicam, 631, 640
TENS see Transcutaneous electrical nerve stimulation, 21
Tensipine MR, 133
Tensium (diazepam), 214
Tensopress, 954
Tentopic, 674
Tepadina, 526
Teratogenesis, 19
Tetralysal-300

Teriparatide, 469, 470,

Thalassaemia, 587
Thalidomide, 565, 566
lepra reactions, 366
Thalidomide Cellgene, 566
Thelin, 110
Theophylline, 181

poisoning, 39
elimination, 33
see also Aminophylline
Thiamine, 616
alcohol dependence, 310
deficiency, 616
status epilepticus, 294
Thiazides, 84
diabetes insipidus, 466
see also Diuretics
Thiazolidinediones, 430

Thick and Easy, 925
Thioguanine see Tioguanine, 531, 535
Thiopental, 777, 779
Thiopentone see Thiopental, 777, 779
Thiopurine methyltransferase, 553
Thiotepa, 513, 524, 526
Thioxanthenes, 217
Thixo-D, 925
Threadworm infections, 415
Throat infections, 328
gonorrhoea, 326
Thrombocythaemia, 590
Thrombocytopenia, 582
Thrombocytopenic purpura, 589
Thrombomembolism, 146
pulmonary, 140, 157, 201
Thrombolytics, 157
Thrombosis
antiplatelet drugs, 149
dee-vein, 140, 146
prophylaxis, 140
venous, 157

Thrush see Candidiasis
Thymoglobin, 556
Thymol, 698
Thymoxamine see Moxisylyte, 136
Thyrogen, 466

Thyroid

antagonists, 440
carcinoma, 439
hormones, 439
stimulating hormone, 466
storm, 441
Thyroidectomy, 440
Thyrotoxic crisis, 441
Thyrotoxicosis, 440

beta-blockers, 99, 441
Thyrotropin alfa, 466
Thyroxine see Levothyroxine, 439, 440
Tiagabine, 280, 289, 290
Tiapronentic acid, 630, 640
Tilbutol, 449, 455
Ticarcillin, 339
clavulanic acid with, 339, 340
infusion table, 901
Ticlopidine, 104

amiloride and hydrochlorothiazide with, 104
bendrofluamide with, 104
eye, 674, 675
bimatropost with, 673
brimonidine with, 677
brinzolamide with, 678
dorzolamide with, 678
latanoprost with, 676
trovoprost with, 676
migraine, 277
see also Beta-adrenoceptor blocking drugs

Timoptol preparations, 675
Tinea infections, 373, 736
Tinidazole, 367, 368
amoebiasis, 411
giardiasis, 412
protozoal infections, 412
trichomoniasis, 412
Tinzaparin, 141, 143
Tioconazole, 736, 738, 739
Tioguanine, 531, 535
Tiotropium, 180
Tilbutol, 150, 154, 155
infusion table, 901
Tisme, 743
Tissue adhesive, 742
Tissue-type plasminogen activator see Alteplase
Titanium dioxide, 706
Tizanidine, 660, 662
Tobi, 352
Tobia products, 927
Tobradex, 670
Tobramycin, 350, 351, 352
eye, 667, 669, 670
infusion table, 901
Tobramycin, 669
Tocilizumab, 650, 654
infusion table, 901
Tocopherol, 620
Tocopheryl, 620
Toctino, 715
Toilet preparations, ACBS, 934
Tolbutamide, 427, 429
Tolcapone, 305, 306
Toltenamic acid, 273, 274, 631
Ulceraive—Venlafaxine

Valproate
epilepsy, 280, 290, 291, 292
infusion table, 901
migraine, 277, 291
Valproic acid
bipolar disorder, 230
epilepsy, 292
migraine, 230
Valsartan, 121, 124
amiodipine with, 129
hydrochlorothiazide with, 124
Valtrex, 395
Vamin preparations, 606
Vaminoact, 606
Vancocin, 357
Vancomycin, 356, 357
eye, 679
infusion table, 901
Vancomycin-resistant enterococci, 349, 358
Vaniq, 733
Vantas, 572
Vapour-permeable adhesive film, 938
Vaqta, 754
Vardenafil, 517, 516, 517
Varenicline, 314
Varicai bleeding, 467, 574
Varicella zoster, 392
corticosteroids, caution in, 444
immunisation
vaccine, 767, 768, 772
immunoglobulin, 772
Varicose veins, 169, 745
Varibix, 768
Varirax, 768
Vascoc, 117
Vasalapha (felodipine), 130
Vascular surgery
antibacterial prophylaxis, 331
Vasoconstrictors
local anaesthesia, 793
dental practice, 794
sympathomimetic, 138
Vasodilators
antihypertensive, 107
peripheral, 135
Vasogen, 706
Vasopressin, 468
diabetes insipidus, 466
varicai bleeding, 467
infusion table, 901
Vasran XL, 507
V.C.E high compression bandage, 954
Vectavir, 739
Vectibix, 542
Vecuronium, 788, 790
infusion table, 901
Vedrop, 620
Vegent-med preparations, 915
Veil preparations, 732
Veglucose alfa, 624
infusion table, 901
Velband, 954
Velbe, 536
Velcade, 539
Venax XL (venlafaxine), 245
Venlafaxine, 242, 244, 245

Ultraviolet radiation, 730
Ultrasonic nebulisers, 184
Urine tests, 437
Uristix, 437
Urofolitropin see Urofolitropin, 462, 464
Urofolitropin, 462, 464
Urokinase, 157, 158, 159
infusion table, 901
Urological procedures
antibacterial prophylaxis, 331
Uro-Trainer preparations, 514
Urethral toxicity, 523
Urodox, 396
Ursosuric drugs, 655
Urticaria, 191
Ureteric colic, 512
Urethritis, non-gonococcal, 326,
Urethritis, non-gonococcal, 371
Vaginosis, bacterial, 327
Vaginyl (metronidazole), 371
Vaginal infections, 326, 371
Vaginology (diazepam), 214
Valcon, 214
Valcyte, 397
Valdaxan, 243
Valganclclovir, 395, 396, 397
Valine amino acid supplement, 930
Valni XL, 133
Valoid, 251
Valproate
epilepsy, 280, 290, 291, 292
infusion table, 901
migraine, 277, 291
Valproic acid
bipolar disorder, 230
epilepsy, 292
migraine, 230
Valsartan, 121, 124
amiodipine with, 129
hydrochlorothiazide with, 124
Valtrex, 395
Vamin preparations, 606
Vaminoact, 606
Vancocin, 357
Vancomycin, 356, 357
eye, 679
infusion table, 901
Vancomycin-resistant enterococci, 349, 358
Vaniq, 733
Vantas, 572
Vapour-permeable adhesive film, 938
Vaqta, 754
Vardenafil, 516, 517
Varenicline, 314
Varicai bleeding, 467, 574
Variclea zoster, 392
corticosteroids, caution in, 444
immunisation
vaccine, 767, 768, 772
immunoglobulin, 772
Varicose veins, 169, 745
Varibix, 768
Varirax, 768
Vascoc, 117
Vasalapha (felodipine), 130
Vascular surgery
antibacterial prophylaxis, 331
Vasoconstrictors
local anaesthesia, 793
dental practice, 794
sympathomimetic, 138
Vasodilators
antihypertensive, 107
peripheral, 135
Vasogen, 706
Vasopressin, 468
diabetes insipidus, 466
varicai bleeding, 467
infusion table, 901
Vasran XL, 507
V.C.E high compression bandage, 954
Vectavir, 739
Vectibix, 542
Vecuronium, 788, 790
infusion table, 901
Vedrop, 620
Vegent-med preparations, 915
Veil preparations, 732
Veglucose alfa, 624
infusion table, 901
Velband, 954
Velbe, 536
Velcade, 539
Venax XL (venlafaxine), 245
Venlafaxine, 242, 244, 245

Valproate
epilepsy, 280, 290, 291, 292
infusion table, 901
migraine, 277, 291
Valproic acid
bipolar disorder, 230
epilepsy, 292
migraine, 230
Valsartan, 121, 124
amiodipine with, 129
hydrochlorothiazide with, 124
Valtrex, 395
Vamin preparations, 606
Vaminoact, 606
Vancocin, 357
Vancomycin, 356, 357
eye, 679
infusion table, 901
Vancomycin-resistant enterococci, 349, 358
Vaniq, 733
Vantas, 572
Vapour-permeable adhesive film, 938
Vaqta, 754
Vardenafil, 516, 517
Varenicline, 314
Varicai bleeding, 467, 574
Varicila zoster, 392
corticosteroids, caution in, 444
immunisation
vaccine, 767, 768, 772
immunoglobulin, 772
Varicose veins, 169, 745
Varibix, 768
Varirax, 768
Vascoc, 117
Vasalapha (felodipine), 130
Vascular surgery
antibacterial prophylaxis, 331
Vasoconstrictors
local anaesthesia, 793
dental practice, 794
sympathomimetic, 138
Vasodilators
antihypertensive, 107
peripheral, 135
Vasogen, 706
Vasopressin, 468
diabetes insipidus, 466
varicai bleeding, 467
infusion table, 901
Vasran XL, 507
V.C.E high compression bandage, 954
Vectavir, 739
Vectibix, 542
Vecuronium, 788, 790
infusion table, 901
Vedrop, 620
Vegent-med preparations, 915
Veil preparations, 732
Veglucose alfa, 624
infusion table, 901
Velband, 954
Velbe, 536
Velcade, 539
Venax XL (venlafaxine), 245
Venlafaxine, 242, 244, 245
Xanthine bronchodilators see Theophylline
Xanthine-oxidase inhibitor, 655
Xarelto, 149
Xarelto preparations, 507
Xelma, 947
Xeloda, 532
Xenazine, 308
Xenical, 249
Xeomin, 309
Xepin, 707
Xerostomia, 522, 698
XACBS, 934
Xerotin, 699
Xigle (drotrecogin alfa (activated)), 160
Zipamide, 84, 85
Xismax 60XL (isosorbide mononitrate), 127
XLEU preparations, 930
XLYS Low TRY preparations, 929
XLYS preparations, 930
XLYS TRY preparations, 929
XMET preparations, 929
XMTVI preparations, 931
Xolair, 197
Xomolix, 252
XP preparations, 933
XPHEN TYR preparations, 933
XFTM preparations, 933
Xupad, 948
Xylitol, presence of, 2
Xylocaine, 695, 796, 797
Xylometazoline eye, 671
nose, 691, 692
Xyloproct, 77
Xyrem, 212
Xyzal, 193

Zamadol preparations, 272
Zanaflex, 662
Zanamivir, 399, 400
Zanidip, 131
Zantrac, 53
Zapin (co-codamol 30/500), 280
Zaponex, 224
Zarontin, 283
Zarzio, 593
Zavedos, 528
Zavesca, 627
ZeaSORB, 745
Zeblinix, 283
Zefix, 384
Zelapar, 305
Zemon preparations, 128
Zemplar, 620
Zemtard preparations, 130
Zenalb (albumin) preparations, 800
Zeridame SR, 272
Zerit, 385
Zerobase, 703
Zerocream, 703
Zeroguen, 703
Zerolatum preparations, 705
Zeroneum, 705
Zerole, 705
Zestoretic preparations, 119
Zestril, 119
Zetuvit products, 937
Ziagen, 383
Zibor, 142
Ziconotide, 258
Zidovudin, 493
Zidovudine, 385, 386
abacavir and lamivudine with, 383
infusion table, 902
lamivudine with, 386
Zimbacol XL (bezafibrate), 166
Zimovane, 211
Zinc, 344
Zinc bandages, 955
ichthammol and, 714, 955
stocking, 955
deficiency, 614, 615
skin benzyl benzoate with, 706
caster oil and, 705
coil tar with, 718
cod liver oil with, 706
cream, 705
dimeticone with, 706
ichthammol with, 715
ointment, 705
salicylic acid with, 720
tape, adhesive, 950
Wilson’s disease (zinc acetate), 622, 623
Zinc sulphate eye drops—discontinued
Zindacin, 725
Zinrey, 725
Zinnat, 344
Zipoc, 955
Zipin preparations, 244
Zithromax, 352
Zocor preparations, 164
Zofran, 255
Zoladex preparations, 572
endometriosis, 481
IFV, 481
Zoledronic acid, 475, 476
infusion table, 902
Zoleptil—discontinued
Zollinger-Ellison syndrome, 55
Zolmitriptan
cluster headache, 276, 278
migraine, 274, 276
Zolpidem, 210
Zolvera (verapamil), 134
Zonacton, 465
Zoneta, 476
Zomig preparations, 276
Zomorph, 269
palliative care, 20
Zonegran, 293
Zonisamide, 280, 293
Zopiclone, 210, 211
Zorac, 718
Zoster see Herpes infections
Zotepine—discontinued
Zotren, 56
Zovirax preparations
cream, 739
eye ointment, 669
injection, 393
tablets, 393
Zuclopenthixol, 217, 229
depot injections, 227, 229
injection, 222
tablets, 222
Zuclopenthixol acetate, 222
Zuclopenthixol decanoate, 229
Zuclopenthixol dihydrochloride, 222
Zumenon, 455
Zutectra, 771
Zuvogen, 739
Zyban, 311
Zydo preparations, 272
Zylopic, 656
Zyomet, 736
ZypAdhera, 229
Zypexa, 225
Zyvox, 359
**BNF**  
*In Confidence*

**Yellowcard**  
COMMISSION ON HUMAN MEDICINES (CHM)

**It’s easiest to report online at www.yellowcard.gov.uk**

**SUSPECTED ADVERSE DRUG REACTIONS**

If you suspect an adverse reaction may be related to one or more drugs/vaccines/complementary remedies, please complete this Yellow Card. See ‘Adverse reactions to drugs’ section in BNF or www.yellowcard.gov.uk for guidance. Do not be put off reporting because some details are not known.

**PATIENT DETAILS**

- Patient Initials: ________
- Sex: M / F
- Ethnicity: ________________
- Weight if known (kg): ________
- Age (at time of reaction): ________________
- Identification number (e.g. Your Practice or Hospital Ref): ________________

**SUSPECTED DRUG(S)/VACCINE(S)**

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUSPECTED REACTION(S)**

Please describe the reaction(s) and any treatment given:

Outcome:  
- Recovered: [ ]  
- Recovering: [ ]  
- Continuing: [ ]  
- Other: [ ]

Date reaction(s) started: ________________  
Date reaction(s) stopped: ________________

Do you consider the reactions to be serious?  
Yes / No

If yes, please indicate why the reaction is considered to be serious (please tick all that apply):
- [ ] Patient died due to reaction
- [ ] Life threatening
- [ ] Congenital abnormality
- [ ] Involved or prolonged inpatient hospitalisation
- [ ] Involved persistent or significant disability or incapacity
- [ ] Medically significant; please give details: ____________________________
It's easiest to report online at www.yellowcard.gov.uk

OTHER DRUG(S) (including self-medication and complementary remedies)

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional relevant information e.g. medical history, test results, known allergies, rechallenge (if performed), suspect drug interactions. For congenital abnormalities please state all other drugs taken during pregnancy and the last menstrual period.

Please list any medicines obtained from the internet:

REPORTER DETAILS
Name and Professional Address: ____________________________
Postcode: _______________ Tel No: _______________________
Email: __________________ Speciality: _________________
Signature: ______________ Date: ________________

CLINICIAN (if not the reporter)
Name and Professional Address: ____________________________
Postcode: _______________ Tel No: _______________________
Email: __________________ Speciality: _________________
Date: ________________

Information on adverse drug reactions received by the MHRA can be downloaded at www.mhra.gov.uk/daps
Stay up-to-date on the latest advice for the safe use of medicines with our monthly bulletin Drug Safety Update, at www.mhra.gov.uk/drugsafetyupdate

Please attach additional pages if necessary. Send to: FREEPOST YELLOW CARD (no other address details required)
How to use the Cardiovascular Risk Prediction Charts for Primary Prevention

These charts are for estimating cardiovascular disease (CVD) risk (non-fatal myocardial infarction and stroke, coronary and stroke death and new angina pectoris) for individuals who have not already developed coronary heart disease (CHD) or other major atherosclerotic disease. They are an aid to making clinical decisions about how intensively to intervene on lifestyle and whether to use antihypertensive, lipid lowering and anti-platelet medication, but should not replace clinical judgment.

- The use of these charts is not appropriate for patients who have existing diseases which already put them at high risk such as:
  - coronary heart disease or other major atherosclerotic disease;
  - familial hypercholesterolaemia or other inherited dyslipidaemias;
  - renal dysfunction including diabetic nephropathy;
  - type 1 and 2 diabetes mellitus.

- The charts should not be used to decide whether to introduce antihypertensive medication when blood pressure is persistently at or above 160/100 mmHg or when target organ damage due to hypertension is present. In both cases antihypertensive medication is recommended regardless of CVD risk. Similarly the charts should not be used to decide whether to introduce lipid-lowering medication when the ratio of serum total to HDL cholesterol exceeds 6. Such medication is generally then indicated regardless of estimated CVD risk.

- To estimate an individual's absolute 10-year risk of developing CVD choose the chart for his or her sex, lifetime smoking status and age. Within this square identify the level of risk according to the point where the coordinates for systolic blood pressure and the ratio of total cholesterol to high density lipoprotein (HDL) cholesterol meet. If no HDL cholesterol result is available, then assume this is 1.0 mmol/litre and the lipid scale can be used for total cholesterol alone.

- Higher risk individuals (red areas) are defined as those whose 10-year CVD risk exceeds 20%, which is approximately equivalent to the coronary heart disease risk of > 15% over the same period.

- The chart also assists in identifying individuals whose 10-year CVD risk is moderately increased in the range 10–20% (orange areas) and those in whom risk is lower than 10% over 10 years (green areas).

- Smoking status should reflect lifetime exposure to tobacco and not simply tobacco use at the time of assessment. For example, those who have given up smoking within 5 years should be regarded as current smokers for the purposes of the charts.

- The initial blood pressure and the first random (non-fasting) total cholesterol and HDL cholesterol can be used to estimate an individual's risk. However, the decision on using drug therapy should generally be based on repeat risk factor measurements over a period of time.

- Men and women do not reach the level of risk predicted by the charts for the three age bands until they reach the ages 49, 59, and 69 years respectively. The charts will overestimate current risk most in the under 40s. Clinical judgement must be exercised in deciding on treatment in younger patients. However, it should be recognised that blood pressure and cholesterol tend to rise most and HDL cholesterol to decline most in younger people already with adverse levels. Left untreated, their risk at the age of 49 years is likely to be higher than the projected risk shown on the age-under-50-years chart. From age 70 years the CVD risk, especially for men, is usually ≥ 20% over 10 years and the charts will underestimate true total CVD risk.

- These charts (and all other currently available methods of CVD risk prediction) are based on groups of people with untreated levels of blood pressure, total cholesterol and HDL cholesterol. In patients already receiving antihypertensive therapy in whom the decision is to be made about whether to introduce lipid-lowering medication, or vice versa, the charts can only act as a guide. Unless recent pre-treatment risk factor values are available it is generally safest to assume that CVD risk is higher than that predicted by current levels of blood pressure or lipids on treatment.

- CVD risk is also higher than indicated in the charts for:
  - those with a family history of premature CVD (male first-degree relatives aged < 55 years and female first-degree relatives aged < 65 years) which increases the risk by a factor of approximately 1.5;
  - men with HDL cholesterol < 1 mmol/litre or women with HDL cholesterol < 1.2 mmol/litre;
  - those with raised triglyceride levels (> 1.7 mmol/litre);
  - those with BMI ≥ 30 kg/m²;
  - women with premature menopause;
  - those who are not yet diabetic, but have impaired fasting glycaemia (6.1–6.9 mmol/ litre) or impaired glucose tolerance (2 hour glucose ≥ 7.8 mmol/litre but < 11.1 mmol/litre in an oral glucose tolerance test).

- The charts have not been validated in ethnic minorities and in some may underestimate CVD risk. For example, in people originating from the Indian subcontinent it is safest to assume that the CVD risk is higher than predicted from the charts (1.4 times).
An individual can be shown on the chart the direction in which his or her risk of CVD can be reduced by changing smoking status, blood pressure, or cholesterol, but it should be borne in mind that the estimate of risk is for a group of people with similar risk factors and that within that group there will be considerable variation in risk. It should also be pointed out in younger people that the estimated risk will generally not be reached before the age of 50, if their current blood pressure and lipid levels remain unchanged. The charts are primarily to assist in directing intervention to those who typically stand to benefit most.

The estimation of CVD risk in NICE clinical guideline 67 (May 2008): Lipid modification–Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (available at www.nice.org.uk) differs from that shown here as follows:

- estimated CVD risk increases by a factor of 1.5 in those with a family history of premature CHD (male first-degree relatives aged < 55 years and female first-degree relatives aged < 65 years)
- estimated CVD risk increases by a factor of 1.5–2 if more than one first-degree relative has a history of premature CHD
- estimated CVD risk for South Asian men is increased by a factor of 1.4
- CVD risk is higher than estimated in those with BMI > 40 kg/m²

The NICE guideline does not include the recommendation to treat all patients with a serum total to HDL cholesterol ratio of greater than 6 with lipid-lowering drugs.

The NICE guideline advises that the following factor is also taken into account when calculating CVD risk:

- presence of left ventricular hypertrophy

In addition, NICE advises that all patients over the age of 75 years should be considered at increased risk of CVD, and are likely to benefit from treatment.

In February 2010, NICE withdrew the recommendation that the Framingham risk equation should be the equation of choice for assessment of CVD risk, but agreed that it should be considered as one of the possible equations to use.
CVD risk 10–20% over next 10 years
CVD risk <10% over next 10 years
CVD risk >20% over next 10 years

SBP = systolic blood pressure mmHg
TC : HDL = serum total cholesterol to HDL cholesterol ratio

Nondiabetic Men

(Continued over)
Nondiabetic Women

Non-smoker

Age under 50 years

Age 50–59 years

Age 60 years and over

Smoker

SBP = systolic blood pressure mmHg
TC : HDL = serum total cholesterol to HDL cholesterol ratio

CVD risk over next 10 years

© Central Manchester and Manchester Children’s University Hospitals NHS Trust
ADULT ADVANCED LIFE SUPPORT ALGORITHM

Unresponsive? Not breathing or only occasional gasps

Call Resuscitation Team

CPR 30:2
Attach defibrillator/monitor
Minimise interruptions

Assess rhythm

Shockable (VF/pulseless VT)

Non-shockable (PEA/Asystole)

1 Shock
Immediately resume CPR for 2 min
Minimise interruptions

Return of spontaneous circulation
Immediate post cardiac arrest treatment
• Use ABCDE approach
• Controlled oxygenation and ventilation
• 12-lead ECG
• Treat precipitating cause
• Temperature control / therapeutic hypothermia

Immediately resume CPR for 2 min
Minimise interruptions

During CPR
• Ensure high-quality CPR: rate, depth, recoil
• Plan actions before interrupting CPR
• Give oxygen
• Consider advanced airway and capnography
• Continuous chest compressions when advanced airway in place
• Vascular access (intravenous, intraosseous)
• Give adrenaline every 3-5 min
• Correct reversible causes

Reversible causes
• Hypoxia
• Hypovolaemia
• Hypo- / hyperkalaemia / metabolic
• Hypothermia
• Thrombosis - coronary or pulmonary
• Tamponade - cardiac
• Toxins
• Tension pneumothorax

Reproduced with the kind permission of the Resuscitation Council (UK) from Resuscitation Guidelines, October 2010
Medical emergencies in the community

Drug treatment outlined below is intended for use by community healthcare professionals. Only drugs that are used for immediate relief are shown; advice on supporting care is not given. Where the patient’s condition requires investigation and further treatment, the patient should be transferred to hospital promptly.

Anaphylaxis (section 3.4.3)

Adrenaline injection (1 mg/mL (1 in 1000))
- By intramuscular injection
  CHILD UNDER 6 YEARS 150 micrograms (0.15 mL), repeated every 5 minutes if necessary
  CHILD 6–12 YEARS 300 micrograms (0.3 mL), repeated every 5 minutes if necessary
  CHILD 12–18 YEARS 500 micrograms (0.5 mL), repeated every 5 minutes if necessary
  ADULT 500 micrograms (0.5 mL), repeated every 5 minutes if necessary

High-flow oxygen (section 3.6) and intravenous fluids should be given as soon as available.

Chlorphenamine injection by intramuscular or intravenous injection (section 3.4.1) may help counter histamine-mediated vasodilation and bronchoconstriction.

Hydrocortisone (preferably as sodium succinate) by intravenous injection (section 6.3.2) has delayed action but should be given to severely affected patients to prevent further deterioration.

Angina: unstable (section 2.10.1)
Aspirin dispersible tablets (75 mg, 300 mg)
- By mouth (dispersed in water or chewed)
  ADULT 300 mg

Plus
- either Gliceryl trinitrate aerosol spray (400 micrograms/metered dose)
  Sublingually
  ADULT 1–2 sprays, repeated as required
- or Gliceryl trinitrate tablets (300 micrograms, 500 micrograms, 600 micrograms)
  Sublingually
  ADULT 0.3–1 mg, repeated as required

Asthma: acute (section 3.1)

Regard each emergency consultation as being for severe acute asthma until shown otherwise; failure to respond adequately at any time requires immediate transfer to hospital

Either salbutamol aerosol inhaler (100 micrograms/metered inhalation)
- By aerosol inhalation via large-volume spacer (and a close-fitting face mask if child under 3 years)
  ADULT and CHILD 2–10 puffs each inhaled separately, repeated every 10–20 minutes or as necessary
  or salbutamol nebuliser solution (1 mg/mL, 2 mg/mL)
- By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
  CHILD UNDER 5 YEARS 2.5 mg every 20–30 minutes or as necessary
  CHILD 5–12 YEARS 2.5–5 mg every 20–30 minutes or as necessary
  ADULT 5 mg every 20–30 minutes or as necessary

or terbutaline nebuliser solution (2.5 mg/mL)
- By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
  CHILD UNDER 5 YEARS 5 mg every 20–30 minutes or as necessary
  CHILD 5–12 YEARS 5–10 mg every 20–30 minutes or as necessary
  ADULT 10 mg every 20–30 minutes or as necessary

Plus (in all cases)
either prednisolone tablets (or prednisolone soluble tablets) (5 mg)
- By mouth
  CHILD UNDER 12 YEARS 1–2 mg/kg (max. 40 mg) once daily for up to 3 days or longer if necessary; if child has been taking an oral corticosteroid for more than a few days, give prednisolone 2 mg/kg (max. 60 mg) once daily
  ADULT 40–50 mg once daily for 5 days

or hydrocortisone (preferably as sodium succinate)
- By intravenous injection
  CHILD UNDER 12 YEARS 4 mg/kg every 6 hours until conversion to oral prednisolone is possible; CHILD UNDER 2 YEARS max. 25 mg, 2–5 YEARS max. 50 mg, 6–12 YEARS max. 100 mg
  ADULT 100 mg every 6 hours until conversion to oral prednisolone is possible

High-flow oxygen (section 3.6) if available (via face mask in children)

Monitor response 15 to 30 minutes after nebulisation; if any signs of acute asthma persist, arrange hospital admission. While awaiting ambulance, repeat nebulised beta, agonist (as above) and give with

ipratropium nebuliser solution (250 micrograms/mL)
- By inhalation of nebulised solution (via oxygen-driven nebuliser if available)
  CHILD UNDER 12 YEARS 250 micrograms, repeated every 20–30 minutes for the first 2 hours, then every 4–6 hours as necessary
  ADULT 500 micrograms every 4–6 hours as necessary
**Convulsive (including febrile) seizures lasting longer than 5 minutes**  
(section 4.8.2 and section 4.8.3)  
*Either diazepam rectal solution (2 mg/mL, 4 mg/mL)*  
- By rectum  
  - **NEONATE** 1.25–2.5 mg, repeated once after 10–15 minutes if necessary  
  - **CHILD 1 MONTH–2 YEARS** 5 mg, repeated once after 10–15 minutes if necessary  
  - **CHILD 2–12 YEARS** 5–10 mg, repeated once after 10–15 minutes if necessary  
  - **ADULT** and **CHILD OVER 12 YEARS** 10–20 mg  
  - **ELDERLY** 10 mg, repeated once after 10–15 minutes if necessary  
*or midazolam buccal liquid (10 mg/mL) or injection solution given by buccal route*  
- By buccal administration, repeated once if necessary  
  - **NEONATE** 300 micrograms/kg  
  - **CHILD 1–6 MONTHS** 300 micrograms/kg (max. 2.5 mg)  
  - **CHILD 6 MONTHS–1 YEAR** 2.5 mg  
  - **CHILD 1–5 YEARS** 5 mg  
  - **CHILD 5–10 YEARS** 7.5 mg  
  - **ADULT** and **CHILD OVER 10 YEARS** 10 mg

**Glucose intravenous infusion (20%)**  
- By intravenous injection into large vein  
  - **ADULT** 50 mL

**Meningococcal disease**  
(Table 1, section 5.1)  
*Benzylpenicillin sodium injection (600 mg, 1.2 g)*  
- By intravenous injection (or by intramuscular injection if venous access not available)  
  - **NEONATE** 300 mg  
  - **CHILD 1 MONTH–1 YEAR** 300 mg  
  - **CHILD 1–10 YEARS** 600 mg  
  - **CHILD 10–18 YEARS** 1.2 g  
  - **ADULT** 1.2 g  
  - **Note** A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer  
*or if history of allergy to penicillin*  
*Cefotaxime injection (1 g)*  
- By intravenous injection (or by intramuscular injection if venous access not available)  
  - **NEONATE** 50 mg/kg  
  - **CHILD 1 MONTH–12 YEARS** 50 mg/kg (max. 1 g)  
  - **CHILD 12–18 YEARS** 1 g  
  - **ADULT** 1 g  
  - **Note** A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer  
*or if history of immediate hypersensitivity reaction (including anaphylaxis, angioedema, or urticarial reaction) to penicillin or to cephalosporins*  
*Chloramphenicol injection (1 g)*  
- By intravenous injection  
  - **CHILD 1 MONTH–18 YEARS** 12.5–25 mg/kg  
  - **ADULT** 12.5–25 mg/kg  
  - **Note** A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer

**Diabetic hypoglycaemia**  
(section 6.1.4)  
**Glucose or sucrose**  
- By mouth  
  - **CHILD 1 MONTH–2 YEARS** 150 micrograms/kg as a single dose  
*or if hypoglycaemia unresponsive or if oral route cannot be used*  
*Glucagon injection (1 mg/mL)*  
- By subcutaneous, intramuscular, or intravenous injection  
  - **CHILD BODY-WEIGHT UNDER 25 KG** 500 micrograms (0.5 mL)  
  - **CHILD BODY-WEIGHT OVER 25 KG** 1 mg (1 mL)  
  - **ADULT** 1 mg (1 mL)  
*or if hypoglycaemia prolonged or unresponsive to glucagon after 10 minutes*  
*Glucose intravenous infusion (10%)*  
- By intravenous injection into large vein  
  - **CHILD 1 MONTH–18 YEARS** 5 mL/kg (glucose 500 mg/kg)  

**Myocardial infarction: ST-segment elevation**  
(section 2.10.1)  
*Aspirin dispersible tablets (75 mg, 300 mg)*  
- By mouth (dispersed in water or chewed)  
  - **ADULT** 300 mg  
*Glyceryl trinitrate aerosol spray (400 micrograms/metered dose)*  
- Sublingually  
  - **ADULT** 1–2 sprays, repeated as required  
*or Glyceryl trinitrate tablets (300 micrograms, 500 micrograms, 600 micrograms)*  
- Sublingually  
  - **ADULT** 0.3–1 mg, repeated as required  
*Metoclopramide injection (5 mg/mL)*  
- By intravenous injection  
  - **ADULT UNDER 60 KG** 18–19 YEARS 5 mg  
  - **ADULT OVER 60 KG** 18–19 YEARS 10 mg  
  - **ADULT OVER 19 YEARS** 10 mg
Diamorphine injection (5 mg powder for reconstitution)

- By slow intravenous injection (1–2 mg/minute)
  - **ADULT** 5 mg followed by a further 2.5–5 mg if necessary; **ELDERLY** or **FRAIL** patients, reduce dose by half

or Morphine sulphate injection (10 mg/mL)

- By slow intravenous injection (1–2 mg/minute)
  - **ADULT** 5–10 mg followed by a further 5–10 mg if necessary; **ELDERLY** or **FRAIL** patients, reduce dose by half

Oxygen, if appropriate

---

**Myocardial infarction: non-ST-segment elevation**

Treat as for **Angina: unstable**, above
Approximate conversions and units

<table>
<thead>
<tr>
<th>lb</th>
<th>kg</th>
<th>stones</th>
<th>kg</th>
<th>mL</th>
<th>fl oz</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.45</td>
<td>1</td>
<td>6.35</td>
<td>50</td>
<td>1.8</td>
</tr>
<tr>
<td>2</td>
<td>0.91</td>
<td>2</td>
<td>12.70</td>
<td>100</td>
<td>3.5</td>
</tr>
<tr>
<td>3</td>
<td>1.36</td>
<td>3</td>
<td>19.05</td>
<td>150</td>
<td>5.3</td>
</tr>
<tr>
<td>4</td>
<td>1.81</td>
<td>4</td>
<td>25.40</td>
<td>200</td>
<td>7.0</td>
</tr>
<tr>
<td>5</td>
<td>2.27</td>
<td>5</td>
<td>31.75</td>
<td>500</td>
<td>17.6</td>
</tr>
<tr>
<td>6</td>
<td>2.72</td>
<td>6</td>
<td>38.10</td>
<td>1000</td>
<td>35.2</td>
</tr>
<tr>
<td>7</td>
<td>3.18</td>
<td>7</td>
<td>44.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>3.63</td>
<td>8</td>
<td>50.80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>4.08</td>
<td>9</td>
<td>57.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>4.54</td>
<td>10</td>
<td>63.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>4.99</td>
<td>11</td>
<td>69.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>5.44</td>
<td>12</td>
<td>76.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>5.90</td>
<td>13</td>
<td>82.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>6.35</td>
<td>14</td>
<td>88.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>6.81</td>
<td>15</td>
<td>95.25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Length

1 metre (m) = 1000 millimetres (mm)
1 centimetre (cm) = 10 mm
1 inch (in) = 25.4 mm
1 foot (ft) = 12 inches
12 inches = 304.8 mm

Mass

1 kilogram (kg) = 1000 grams (g)
1 gram (g) = 1000 milligrams (mg)
1 milligram (mg) = 1000 micrograms
1 microgram = 1000 nanograms
1 nanogram = 1000 picograms

Volume

1 litre = 1000 millilitres (mL)
1 millilitre (1 mL) = 1000 microlitres
1 pint ≈ 568 mL

Other units

1 kilocalorie (kcal) = 4186.8 joules (J)
1000 kilocalories (kcal) = 4.186 megajoules (MJ)
1 megajoule (MJ) = 238.8 kilocalories (kcal)
1 millimetre of mercury (mmHg) = 133.3 pascals (Pa)
1 kilopascal (kPa) = 7.5 mmHg (pressure)

Plasma-drug concentrations in the BNF are expressed in mass units per litre (e.g. mg/litre). The approximate equivalent in terms of amount of substance units (e.g. micromol/litre) is given in brackets.

Prescribing for children

Weight, height, and gender

The table below shows the mean values for weight, height, and gender by age; these values have been derived from the UK-WHO growth charts 2009 and UK1990 standard centile charts, by extrapolating the 50th centile, and may be used to calculate doses in the absence of measurements. However, an individual’s weight and height might vary considerably from the values in the table and it is important to ensure that the value chosen is appropriate. In most cases the actual measurement should be obtained as soon as possible and the dose re-calculated.

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight</th>
<th>Height</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>kg</td>
<td>cm</td>
</tr>
<tr>
<td>Full-term neonate</td>
<td>3.5</td>
<td>51</td>
</tr>
<tr>
<td>1 month</td>
<td>4.3</td>
<td>55</td>
</tr>
<tr>
<td>2 months</td>
<td>5.4</td>
<td>58</td>
</tr>
<tr>
<td>3 months</td>
<td>6.1</td>
<td>61</td>
</tr>
<tr>
<td>4 months</td>
<td>6.7</td>
<td>63</td>
</tr>
<tr>
<td>6 months</td>
<td>7.6</td>
<td>67</td>
</tr>
<tr>
<td>1 year</td>
<td>9</td>
<td>75</td>
</tr>
<tr>
<td>3 years</td>
<td>14</td>
<td>96</td>
</tr>
<tr>
<td>5 years</td>
<td>18</td>
<td>109</td>
</tr>
<tr>
<td>7 years</td>
<td>23</td>
<td>122</td>
</tr>
<tr>
<td>10 years</td>
<td>32</td>
<td>138</td>
</tr>
<tr>
<td>12 years</td>
<td>39</td>
<td>149</td>
</tr>
<tr>
<td>14 year-old boy</td>
<td>49</td>
<td>163</td>
</tr>
<tr>
<td>14 year-old girl</td>
<td>50</td>
<td>159</td>
</tr>
<tr>
<td>Adult male</td>
<td>68</td>
<td>176</td>
</tr>
<tr>
<td>Adult female</td>
<td>58</td>
<td>164</td>
</tr>
</tbody>
</table>

Weight, height, and gender

The table below shows the mean values for weight, height, and gender by age; these values have been derived from the UK-WHO growth charts 2009 and UK1990 standard centile charts, by extrapolating the 50th centile, and may be used to calculate doses in the absence of measurements. However, an individual’s weight and height might vary considerably from the values in the table and it is important to ensure that the value chosen is appropriate. In most cases the actual measurement should be obtained as soon as possible and the dose re-calculated.

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight</th>
<th>Height</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>kg</td>
<td>cm</td>
</tr>
<tr>
<td>Full-term neonate</td>
<td>3.5</td>
<td>51</td>
</tr>
<tr>
<td>1 month</td>
<td>4.3</td>
<td>55</td>
</tr>
<tr>
<td>2 months</td>
<td>5.4</td>
<td>58</td>
</tr>
<tr>
<td>3 months</td>
<td>6.1</td>
<td>61</td>
</tr>
<tr>
<td>4 months</td>
<td>6.7</td>
<td>63</td>
</tr>
<tr>
<td>6 months</td>
<td>7.6</td>
<td>67</td>
</tr>
<tr>
<td>1 year</td>
<td>9</td>
<td>75</td>
</tr>
<tr>
<td>3 years</td>
<td>14</td>
<td>96</td>
</tr>
<tr>
<td>5 years</td>
<td>18</td>
<td>109</td>
</tr>
<tr>
<td>7 years</td>
<td>23</td>
<td>122</td>
</tr>
<tr>
<td>10 years</td>
<td>32</td>
<td>138</td>
</tr>
<tr>
<td>12 years</td>
<td>39</td>
<td>149</td>
</tr>
<tr>
<td>14 year-old boy</td>
<td>49</td>
<td>163</td>
</tr>
<tr>
<td>14 year-old girl</td>
<td>50</td>
<td>159</td>
</tr>
<tr>
<td>Adult male</td>
<td>68</td>
<td>176</td>
</tr>
<tr>
<td>Adult female</td>
<td>58</td>
<td>164</td>
</tr>
</tbody>
</table>
Recommended wording of cautionary and advisory labels

For details see Appendix 9

1. Warning: This medicine may make you sleepy
2. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol
3. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines
4. Warning: Do not drink alcohol while taking this medicine
5. Do not take indigestion remedies 2 hours before or after you take this medicine
6. Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
7. Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
8. Warning: Do not stop taking this medicine unless your doctor tells you to stop
9. Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop
10. Warning: Read the additional information given with this medicine
11. Protect your skin from sunlight—even on a bright but cloudy day. Do not use sunbeds
12. Do not take anything containing aspirin while taking this medicine
13. Dissolve or mix with water before taking
14. This medicine may colour your urine. This is harmless
15. Caution: flammable. Keep your body away from fire or flames after you have put on the medicine
16. Dissolve the tablet under your tongue—do not swallow. Store the tablets in this bottle with the cap tightly closed. Get a new supply 8 weeks after opening
17. Do not take more than... in 24 hours
18. Do not take more than... in 24 hours. Also, do not take more than... in any one week
19. Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol
20. Take with or just after food, or a meal
21. Take 30 to 60 minutes before food
22. Take this medicine when your stomach is empty. This means an hour before food or 2 hours after food
23. Suck or chew this medicine
24. Swallow this medicine whole. Do not chew or break
25. Dissolve this medicine under your tongue
26. Take with a full glass of water
27. Spread thinly on the affected skin only
28. Do not take more than 2 at any one time. Do not take more than 8 in 24 hours
29. Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine
30. Contains aspirin. Do not take anything else containing aspirin while taking this medicine
Abbreviations and symbols
Internationally recognised units and symbols are used in the BNF where possible.

ACBS Advisory Committee on Borderline Substances, see Appendix 7

ACE Angiotensin-converting enzyme

ADHD Attention deficit hyperactivity disorder

AIDS Acquired immunodeficiency syndrome

approx. approximately

AV atrioventricular

BAN British Approved Name

BMI body mass index

BP British Pharmacopoeia 2010, unless otherwise stated

BPC British Pharmaceutical Codex 1973 and Supplement 1976, unless otherwise stated

CAPD Continuous ambulatory peritoneal dialysis

CHM Commission on Human Medicines

CHMP Committee for Medicinal Products for Human Use

CNS central nervous system

CPMP Committee on Proprietary Medicinal Products

CRM Committee on the Review of Medicines

CSM Committee on Safety of Medicines (now subsumed under Commission on Human Medicines)

d. c. direct current

dMARD Disease-modifying antirheumatic drug

DPF Dental Practitioners’ Formulary

e/c enteric-coated (termed gastro-resistant in BP)

ECG electrocardiogram

EEG electro-encephalogram

eGFR estimated glomerular filtration rate, see Prescribing in renal impairment

f/c film-coated

G6PD glucose 6-phosphate dehydrogenase

HIV Human immunodeficiency virus

HRT Hormone replacement therapy

INR international normalised ratio

MAOI Monoamine-oxidase inhibitor

max. maximum

MCA Medicines Control Agency, now MHRA

MHRA Medicines and Healthcare products Regulatory Agency

m/r modified-release

NCL no cautionary labels, see Appendix 9

NHS National Health Service

NICE National Institute for Health and Clinical Excellence

NPF Nurse Prescribers’ Formulary

NSAID Non-steroidal anti-inflammatory drug

NSTEMI non-ST-segment elevation myocardial infarction

PGD patient group direction

rINN Recommended International Non-proprietary Name

RSV respiratory syncytial virus

s/c sugar-coated

SLS Selected List Scheme

SMAC Standing Medical Advisory Committee

SMC Scottish Medicines Consortium

SPC Summary of Product Characteristics

spp. species

SSRI Selective serotonin reuptake inhibitor

STEMI ST-segment elevation myocardial infarction

UK United Kingdom

Units for SI units see Prescription Writing, p. 5

WHO World Health Organization

preparation subject to prescription requirements under The Misuse of Drugs Act. For regulations see p. 8

t. d. s. = ter die sumendum (to be taken three times daily)

t.i.d. = ter in die (three times daily)

Latin abbreviations
Directions should be in English without abbreviation. However, Latin abbreviations have been used when prescribing.

The following is a list of appropriate abbreviations. It should be noted that the English version is not always an exact translation.

a. c. = ante cibum (before food)

b. d. = bis die (twice daily)

o. d. = omni die (every day)

o. m. = omni mane (every morning)

o. n. = omni nocte (every night)

p. c. = post cibum (after food)

p. r. n. = pro re nata (when required)

q. d. s. = quater die sumendum (to be taken four times daily)

q. q. h. = quarta quaque hora (every four hours)

stat = immediately

t. d. s. = ter die sumendum (to be taken three times daily)

t.i.d. = ter in die (three times daily)

E numbers
The following is a list of common E numbers and the inactive ingredients to which they correspond.

E102 Tartrazine
E104 Quinoline Yellow
E110 Sunset Yellow FCF
E123 Amaranth
E124 Ponceau 4R
E127 Erythrosine BS
E132 Indigo Carmine
E142 Green S
E171 Titanium Dioxide
E172 Iron oxides, iron hydroxides
E200 Sorbic Acid
E211 Sodium Benzoate

E223 Sodium Metabisulphite
E320 Butylated Hydroxyanisole
E321 Butylated Hydroxytoluene
E322 Lecithins
E420 Sorbitol
E421 Mannitol
E422 Glycerol
E509 Beeswax (white and yellow)